1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O

1	Flurazepam	O
2	thus	O
3	appears	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	hypnotic	O
9	drug	O
10	with	O
11	the	O
12	optimum	O
13	dose	O
14	for	O
15	use	O
16	in	O
17	general	O
18	practice	O
19	being	O
20	15	O
21	mg	O
22	at	O
23	night	O
24	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O

1	Intravenous	O
2	administration	O
3	(	O
4	25	O
5	mg	O
6	/	O
7	kg	O
8	)	O
9	of	O
10	carbonic	B
11	anhydrase	I
12	inhibitors	O
13	(	O
14	acetazolamide	O
15	,	O
16	methazolamide	O
17	,	O
18	dichlorphenamide	O
19	,	O
20	sulthiame	O
21	)	O
22	induced	O
23	an	O
24	early	O
25	important	O
26	rise	O
27	of	O
28	cortical	O
29	p	O
30	O2	O
31	,	O
32	which	O
33	is	O
34	not	O
35	dependent	O
36	on	O
37	increase	O
38	of	O
39	p	O
40	O2	O
41	and	O
42	p	O
43	CO2	O
44	and	O
45	decrease	O
46	of	O
47	pH	O
48	in	O
49	arterial	O
50	blood	O
51	.	O

1	Teratological	O
2	study	O
3	of	O
4	etoperidone	O
5	in	O
6	the	O
7	rat	O
8	and	O
9	rabbit	O
10	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	The	O
2	variable	O
3	HMG	B
4	dosage	O
5	regimen	O
6	was	O
7	found	O
8	to	O
9	offer	O
10	no	O
11	advantages	O
12	when	O
13	compared	O
14	with	O
15	our	O
16	standard	O
17	daily	O
18	dosage	O
19	regimen	O
20	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	B
5	HI	I
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	B
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	Anti	O
2	-	O
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O

1	Abstracts	O
2	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	An	O
2	IgG	B
3	monoclonal	O
4	gammopathy	O
5	was	O
6	present	O
7	in	O
8	the	O
9	serum	O
10	of	O
11	4	O
12	patients	O
13	and	O
14	Bence	O
15	-	O
16	Joanes	O
17	proteinuria	O
18	was	O
19	found	O
20	in	O
21	1	O
22	patient	O
23	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	Peroxydase	B
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	B
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	acquisition	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	0acteriuria	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	figure	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O

1	Late	O
2	complications	O
3	of	O
4	catheterisation	O
5	for	O
6	intravenous	O
7	nutrition	O
8	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O

1	False	O
2	positive	O
3	amniotic	B
4	fluid	I
5	alpha	I
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	Serum	O
2	-	O
3	ferritin	B
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O

1	In	O
2	2	O
3	subjects	O
4	the	O
5	phytomitogen	O
6	reactivity	O
7	of	O
8	the	O
9	lymphocytes	O
10	was	O
11	improved	O
12	after	O
13	treatment	O
14	.	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Preface	O
2	.	O

1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	factor	B
6	IX	I
7	activity	O
8	is	O
9	decreased	O
10	in	O
11	coumarin	O
12	treatment	O
13	with	O
14	factor	B
15	IX	I
16	antigen	O
17	remaining	O
18	normal	O
19	.	O

1	The	O
2	concentration	O
3	of	O
4	alpha	B
5	2	I
6	-	I
7	macroglobulin	I
8	,	O
9	alpha	B
10	1	I
11	-	I
12	antitrypsin	I
13	,	O
14	plasminogen	B
15	,	O
16	C3	B
17	-	I
18	complement	I
19	,	O
20	fibrinogen	B
21	degradation	I
22	products	I
23	(	O
24	FDP	B
25	)	O
26	and	O
27	fibrinolytic	O
28	activity	O
29	,	O
30	were	O
31	studied	O
32	in	O
33	the	O
34	aqueous	O
35	humour	O
36	and	O
37	serum	O
38	from	O
39	nine	O
40	patients	O
41	with	O
42	Fuchs	O
43	'	O
44	endothelial	O
45	dystrophy	O
46	,	O
47	17	O
48	patients	O
49	with	O
50	uncomplicated	O
51	senile	O
52	cataract	O
53	and	O
54	in	O
55	the	O
56	secondary	O
57	aqueous	O
58	from	O
59	six	O
60	cataract	O
61	patients	O
62	.	O

1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O

1	Prazosin	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	59	O
2	cases	O
3	of	O
4	surgically	O
5	resectable	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	N0	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	followup	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O

1	The	O
2	effect	O
3	of	O
4	CBZ	O
5	and	O
6	DPH	O
7	can	O
8	be	O
9	explained	O
10	by	O
11	interference	O
12	with	O
13	thyroid	O
14	hormone	O
15	binding	O
16	to	O
17	TBG	B
18	combined	O
19	with	O
20	enzyme	O
21	-	O
22	induced	O
23	increased	O
24	metabolic	O
25	clearance	O
26	rate	O
27	of	O
28	thyroid	O
29	hormones	O
30	without	O
31	homeostatic	O
32	maintenance	O
33	of	O
34	premedication	O
35	levels	O
36	of	O
37	FT4	O
38	and	O
39	FT3	O
40	.	O

1	The	O
2	present	O
3	research	O
4	evaluated	O
5	the	O
6	possibility	O
7	that	O
8	polyethylene	O
9	glycol	O
10	400	O
11	(	O
12	PEG	O
13	400	O
14	)	O
15	might	O
16	be	O
17	efficacious	O
18	,	O
19	toxic	O
20	,	O
21	or	O
22	both	O
23	.	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	O
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	Pentobarbital	O
2	(	O
3	1	O
4	,	O
5	3	O
6	,	O
7	10	O
8	,	O
9	and	O
10	17	O
11	.	O
12	5	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	was	O
18	also	O
19	tested	O
20	in	O
21	combination	O
22	with	O
23	rate	O
24	-	O
25	decreasing	O
26	doses	O
27	of	O
28	normeperidine	O
29	(	O
30	17	O
31	.	O
32	5	O
33	mg	O
34	/	O
35	kg	O
36	),	O
37	anileridine	O
38	(	O
39	10	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	alphaprodine	O
45	(	O
46	10	O
47	mg	O
48	/	O
49	kg	O
50	),	O
51	and	O
52	fentanyl	O
53	(	O
54	0	O
55	.	O
56	3	O
57	mg	O
58	/	O
59	kg	O
60	).	O

1	Pb	O
2	foil	O
3	(	O
4	0	O
5	.	O
6	55	O
7	gcm	O
8	-	O
9	2	O
10	)	O
11	provided	O
12	the	O
13	best	O
14	overall	O
15	improvement	O
16	.	O

1	An	O
2	anatomical	O
3	and	O
4	histochemical	O
5	study	O
6	has	O
7	been	O
8	undertaken	O
9	and	O
10	as	O
11	a	O
12	result	O
13	emphasis	O
14	is	O
15	given	O
16	to	O
17	recent	O
18	hypotheses	O
19	that	O
20	suggest	O
21	there	O
22	are	O
23	similarities	O
24	with	O
25	Type	O
26	IV	O
27	glycogen	O
28	storage	O
29	disease	O
30	(	O
31	Andersen	O
32	'	O
33	s	O
34	disease	O
35	)	O
36	which	O
37	,	O
38	although	O
39	clinically	O
40	distinct	O
41	,	O
42	has	O
43	the	O
44	same	O
45	enzyme	O
46	defect	O
47	.	O

1	All	O
2	groups	O
3	were	O
4	tested	O
5	in	O
6	a	O
7	Hebb	O
8	-	O
9	Williams	O
10	maze	O
11	at	O
12	100	O
13	approximately	O
14	10	O
15	days	O
16	of	O
17	age	O
18	.	O

1	Erythromycin	O
2	and	O
3	clindamycin	O
4	resistance	O
5	in	O
6	Corynebacterium	O
7	diphtheriae	O
8	from	O
9	skin	O
10	lesions	O
11	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	O
6	'	O
7	s	O
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	O
16	terms	O
17	M1	O
18	,	O
19	M2	O
20	,	O
21	and	O
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O

1	In	O
2	this	O
3	animal	O
4	,	O
5	infected	O
6	with	O
7	what	O
8	was	O
9	judged	O
10	previously	O
11	to	O
12	be	O
13	the	O
14	less	O
15	virulent	O
16	of	O
17	the	O
18	two	O
19	T	O
20	.	O
21	cruzi	O
22	stocks	O
23	used	O
24	('	O
25	strain	O
26	7	O
27	'),	O
28	there	O
29	was	O
30	severe	O
31	myocarditis	O
32	,	O
33	with	O
34	myofibre	O
35	degeneration	O
36	,	O
37	and	O
38	lesions	O
39	of	O
40	the	O
41	oesophagus	O
42	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	Variability	O
2	within	O
3	Down	O
4	'	O
5	s	O
6	syndrome	O
7	(	O
8	trisomy	O
9	-	O
10	21	O
11	):	O
12	empirically	O
13	observed	O
14	sex	O
15	differences	O
16	in	O
17	IQs	O
18	.	O

1	VII	O
2	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	indicator	O
19	of	O
20	intravascular	O
21	coagulation	O
22	.	O

1	Eight	O
2	hours	O
3	after	O
4	the	O
5	administration	O
6	of	O
7	colchicine	O
8	,	O
9	the	O
10	serum	B
11	ceruloplasmin	I
12	level	O
13	began	O
14	to	O
15	rise	O
16	again	O
17	in	O
18	female	O
19	rats	O
20	,	O
21	but	O
22	not	O
23	in	O
24	male	O
25	rats	O
26	.	O

1	Radioimmunoassays	O
2	of	O
3	pregnenolone	O
4	,	O
5	progesterone	O
6	,	O
7	dehydroepiandrosterone	O
8	(	O
9	DHA	O
10	)	O
11	16	O
12	alpha	O
13	-	O
14	hydroxy	O
15	-	O
16	DHA	O
17	,	O
18	estriol	O
19	,	O
20	and	O
21	cortisol	O
22	were	O
23	performed	O
24	on	O
25	a	O
26	total	O
27	of	O
28	0	O
29	;	O
30	1	O
31	ml	O
32	;	O
33	of	O
34	fetal	O
35	plasma	O
36	,	O
37	collected	O
38	during	O
39	the	O
40	course	O
41	of	O
42	normal	O
43	vaginal	O
44	delivery	O
45	.	O

1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O

1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	No	O
2	post	O
3	-	O
4	operative	O
5	haemorrhages	O
6	from	O
7	the	O
8	prostheses	O
9	were	O
10	observed	O
11	.	O

1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	O
23	EcoRI	B
24	fragment	O
25	.	O

1	Accepting	O
2	arbitrarily	O
3	chosen	O
4	limits	O
5	of	O
6	maximized	O
7	errors	O
8	of	O
9	+/-	O
10	10	O
11	%,	O
12	it	O
13	could	O
14	be	O
15	shown	O
16	that	O
17	the	O
18	system	O
19	did	O
20	not	O
21	work	O
22	acceptably	O
23	when	O
24	the	O
25	mean	O
26	carbon	O
27	dioxide	O
28	concentration	O
29	was	O
30	below	O
31	1	O
32	.	O
33	5	O
34	vol	O
35	.%	O
36	within	O
37	the	O
38	fresh	O
39	gas	O
40	flow	O
41	rates	O
42	(	O
43	2	O
44	.	O
45	2	O
46	--	O
47	7	O
48	.	O
49	7	O
50	1	O
51	min	O
52	-	O
53	1	O
54	)	O
55	and	O
56	the	O
57	range	O
58	of	O
59	minute	O
60	ventilation	O
61	(	O
62	4	O
63	--	O
64	10	O
65	1	O
66	min	O
67	-	O
68	1	O
69	)	O
70	employed	O
71	.	O

1	SV	O
2	increased	O
3	less	O
4	in	O
5	SHR	O
6	,	O
7	mainly	O
8	reflecting	O
9	the	O
10	reduced	O
11	diastolic	O
12	compliance	O
13	of	O
14	the	O
15	hypertrophied	O
16	SHR	O
17	left	O
18	ventricle	O
19	and	O
20	the	O
21	consequent	O
22	rightward	O
23	shift	O
24	of	O
25	its	O
26	Frank	O
27	-	O
28	Starling	O
29	curve	O
30	.	O

1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Patulin	O
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	The	O
2	matrix	O
3	surrounding	O
4	the	O
5	clusters	O
6	either	O
7	showed	O
8	a	O
9	normal	O
10	morphology	O
11	or	O
12	a	O
13	homogeneous	O
14	appearance	O
15	,	O
16	within	O
17	which	O
18	faint	O
19	cross	O
20	striations	O
21	but	O
22	no	O
23	distinctly	O
24	fibrillar	O
25	outlines	O
26	could	O
27	be	O
28	identified	O
29	.	O

1	Riboflavin	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	aflatoxin	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	disturbances	O
26	in	O
27	elimination	O
28	of	O
29	kynurenic	O
30	and	O
31	xanthurenic	O
32	acids	O
33	.	O

1	Polyglactin	O
2	910	O
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	The	O
2	incidence	O
3	of	O
4	DNCB	O
5	reactions	O
6	was	O
7	78	O
8	per	O
9	cent	O
10	for	O
11	Stage	O
12	I	O
13	and	O
14	II	O
15	cancers	O
16	(	O
17	37	O
18	patinets	O
19	),	O
20	73	O
21	per	O
22	cent	O
23	for	O
24	resectable	O
25	Stage	O
26	III	O
27	cancer	O
28	(	O
29	22	O
30	patients	O
31	),	O
32	and	O
33	66	O
34	per	O
35	cent	O
36	in	O
37	patients	O
38	with	O
39	unresectable	O
40	or	O
41	inoperable	O
42	Stage	O
43	III	O
44	cancer	O
45	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	Sixteen	O
2	other	O
3	normal	O
4	subjects	O
5	with	O
6	2	O
7	g	O
8	of	O
9	Metyrapone	O
10	are	O
11	best	O
12	responses	O
13	.	O

1	EEG	O
2	theta	O
3	waves	O
4	and	O
5	psychological	O
6	phenomena	O
7	:	O
8	a	O
9	review	O
10	and	O
11	analysis	O
12	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	O
6	for	O
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	O
37	,	O
38	spatial	O
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	Ectopic	O
2	ACTH	B
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	B
18	contents	O
19	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	serum	B
7	LH	I
8	and	O
9	chronological	O
10	or	O
11	bone	O
12	age	O
13	in	O
14	this	O
15	age	O
16	group	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	the	O
22	correlation	O
23	found	O
24	is	O
25	not	O
26	due	O
27	to	O
28	age	O
29	-	O
30	related	O
31	parallel	O
32	phenomena	O
33	.	O

1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O

1	Efforts	O
2	were	O
3	made	O
4	to	O
5	determine	O
6	the	O
7	amount	O
8	of	O
9	time	O
10	required	O
11	for	O
12	kidney	O
13	lesions	O
14	to	O
15	develop	O
16	and	O
17	,	O
18	if	O
19	possible	O
20	,	O
21	to	O
22	delineate	O
23	the	O
24	potential	O
25	site	O
26	of	O
27	action	O
28	of	O
29	PBB	O
30	.	O

1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O

1	Distribution	O
2	and	O
3	correlations	O
4	of	O
5	serum	O
6	uric	O
7	-	O
8	acid	O
9	in	O
10	two	O
11	French	O
12	adult	O
13	populations	O
14	:	O
15	13	O
16	,	O
17	885	O
18	men	O
19	and	O
20	6	O
21	,	O
22	861	O
23	women	O

1	The	O
2	incidence	O
3	of	O
4	hepatitis	B
5	B	I
6	antigen	I
7	following	O
8	transfusion	O
9	was	O
10	about	O
11	2	O
12	.	O
13	8	O
14	per	O
15	cent	O
16	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	Treatment	O
2	of	O
3	2	O
4	patients	O
5	with	O
6	pseudohypoparathyroidism	O
7	type	O
8	I	O
9	with	O
10	vitamin	O
11	-	O
12	D	O
13	-	O
14	3	O
15	and	O
16	1	O
17	alpha	O
18	-	O
19	Hydroxycholecalciferol	O
20	consecutively	O
21	resulted	O
22	in	O
23	a	O
24	nonuniform	O
25	response	O
26	with	O
27	regard	O
28	to	O
29	the	O
30	normalisation	O
31	of	O
32	serum	O
33	-	O
34	calcium	O
35	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	O
19	-	O
20	block	O
21	group	O
22	.	O
23	beta	O
24	-	O
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	O
78	played	O
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	O
21	vitro	O
22	.	O

1	Modulation	O
2	of	O
3	25	B
4	-	I
5	hydroxyvitamin	I
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	I
18	450	I
19	monooxygenase	I
20	system	O
21	.	O

1	In	O
2	both	O
3	these	O
4	respects	O
5	,	O
6	however	O
7	,	O
8	the	O
9	DBP	B
10	mRNA	I
11	resembles	O
12	the	O
13	late	O
14	messengers	O
15	of	O
16	SV40	O
17	and	O
18	polyoma	O
19	viruses	O
20	.	O

1	Effect	O
2	of	O
3	corticosteroid	O
4	-	O
5	containing	O
6	antirheumatic	O
7	combination	O
8	drugs	O
9	on	O
10	endogenous	O
11	ACTH	B
12	and	O
13	cortisol	O
14	production	O
15	.	O

1	Serum	B
2	ACTH	I
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	metyrapone	O
10	.	O

1	Anatomy	O
2	of	O
3	the	O
4	RNA	O
5	and	O
6	gene	O
7	products	O
8	of	O
9	MC29	O
10	and	O
11	MH2	O
12	,	O
13	two	O
14	defective	O
15	avian	O
16	tumor	O
17	viruses	O
18	causing	O
19	acute	O
20	leukemia	O
21	and	O
22	carcinoma	O
23	:	O
24	evidence	O
25	for	O
26	a	O
27	new	O
28	class	O
29	of	O
30	transforming	O
31	genes	O
32	.	O

1	Bertioga	O
2	(	O
3	Guama	O
4	group	O
5	)	O
6	and	O
7	Anhembi	O
8	(	O
9	Bunyamwera	O
10	group	O
11	),	O
12	two	O
13	new	O
14	arboviruses	O
15	isolated	O
16	in	O
17	Sao	O
18	Paulo	O
19	,	O
20	Brazil	O
21	.	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	activity	O
5	was	O
6	increased	O
7	up	O
8	to	O
9	15	O
10	times	O
11	above	O
12	the	O
13	upper	O
14	normal	O
15	limit	O
16	in	O
17	children	O
18	,	O
19	who	O
20	received	O
21	aminopyrine	O
22	for	O
23	two	O
24	weeks	O
25	or	O
26	longer	O
27	.	O

1	XXI	O
2	.	O

1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O

1	Dopamine	B
2	receptor	I
3	blockade	O
4	and	O
5	the	O
6	neuroleptics	O
7	,	O
8	a	O
9	crystallographic	O
10	study	O
11	.	O

1	V	O
2	.	O

1	A	O
2	rapid	O
3	fluorimetric	O
4	procedure	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	the	O
10	fungicide	O
11	5	O
12	-	O
13	fluorocytosine	O
14	in	O
15	serum	O
16	is	O
17	described	O
18	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	Similarly	O
2	,	O
3	maternal	B
4	serum	I
5	somatomedin	I
6	A	I
7	was	O
8	significantly	O
9	reduced	O
10	in	O
11	rats	O
12	nursing	O
13	large	O
14	litters	O
15	.	O

1	The	O
2	sequences	O
3	following	O
4	the	O
5	X	O
6	.	O
7	borealis	O
8	oocyte	O
9	and	O
10	somatic	O
11	5S	B
12	genes	I
13	are	O
14	identical	O
15	in	O
16	12	O
17	of	O
18	the	O
19	first	O
20	14	O
21	residues	O
22	and	O
23	contain	O
24	two	O
25	or	O
26	more	O
27	T	O
28	clusters	O
29	,	O
30	as	O
31	does	O
32	the	O
33	corresponding	O
34	region	O
35	of	O
36	X	B
37	.	I
38	laevis	I
39	oocyte	I
40	5S	I
41	DNA	I
42	.	O

1	This	O
2	mechanism	O
3	is	O
4	not	O
5	due	O
6	to	O
7	the	O
8	observed	O
9	grain	O
10	boundary	O
11	precipitates	O
12	.	O

1	This	O
2	report	O
3	has	O
4	reviewed	O
5	some	O
6	of	O
7	the	O
8	reasons	O
9	for	O
10	treatment	O
11	failures	O
12	and	O
13	has	O
14	presented	O
15	a	O
16	philosophy	O
17	for	O
18	their	O
19	management	O
20	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	planning	O
5	in	O
6	Class	O
7	II	O
8	,	O
9	division	O
10	2	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	It	O
2	seems	O
3	that	O
4	the	O
5	way	O
6	in	O
7	which	O
8	drugs	O
9	modify	O
10	a	O
11	patient	O
12	'	O
13	s	O
14	serum	O
15	chemistry	O
16	may	O
17	be	O
18	used	O
19	to	O
20	assess	O
21	the	O
22	efficacy	O
23	with	O
24	which	O
25	they	O
26	control	O
27	the	O
28	inflammatory	O
29	process	O
30	.	O

1	Here	O
2	the	O
3	conventional	O
4	tests	O
5	clearly	O
6	pointed	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	retrocochlear	O
12	disease	O
13	.	O

1	The	O
2	end	O
3	-	O
4	stage	O
5	or	O
6	involutional	O
7	phase	O
8	of	O
9	proliferative	O
10	diabetic	O
11	retinopathy	O
12	may	O
13	result	O
14	in	O
15	stabilization	O
16	of	O
17	vision	O
18	for	O
19	long	O
20	periods	O
21	of	O
22	time	O
23	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	B
6	alpha1AT	I
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	In	O
2	patients	O
3	who	O
4	were	O
5	not	O
6	vented	O
7	,	O
8	there	O
9	was	O
10	overall	O
11	significant	O
12	depression	O
13	of	O
14	function	O
15	(	O
16	67	O
17	+/-	O
18	5	O
19	%	O
20	of	O
21	control	O
22	;	O
23	range	O
24	,	O
25	91	O
26	--	O
27	45	O
28	%,	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	).	O

1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	A	O
2	total	O
3	of	O
4	26	O
5	BCG	O
6	strains	O
7	,	O
8	out	O
9	of	O
10	them	O
11	10	O
12	Czechoslovak	O
13	strains	O
14	(	O
15	2	O
16	lyophilized	O
17	cultures	O
18	of	O
19	BCG	O
20	of	O
21	different	O
22	batch	O
23	,	O
24	6	O
25	strains	O
26	isolated	O
27	from	O
28	abscesses	O
29	of	O
30	children	O
31	after	O
32	BCG	O
33	-	O
34	vaccination	O
35	and	O
36	2	O
37	strains	O
38	from	O
39	fatal	O
40	cases	O
41	after	O
42	BCG	O
43	-	O
44	vaccination	O
45	)	O
46	and	O
47	16	O
48	strains	O
49	obtained	O
50	from	O
51	foreign	O
52	laboratories	O
53	,	O
54	were	O
55	used	O
56	.	O

1	High	O
2	levels	O
3	of	O
4	serum	O
5	calcitonin	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O

1	Detection	O
2	of	O
3	anti	O
4	-	O
5	lymphocyte	O
6	antibodies	O
7	using	O
8	the	O
9	immunoperoxidase	B
10	antiglobulin	I
11	technic	O
12	.	O

1	The	O
2	response	O
3	of	O
4	serum	B
5	GH	I
6	to	O
7	arginine	O
8	infusion	O
9	was	O
10	normal	O
11	,	O
12	while	O
13	that	O
14	to	O
15	insulin	B
16	-	O
17	induced	O
18	hypoglycemia	O
19	was	O
20	poor	O
21	.	O

1	The	O
2	mortality	O
3	rate	O
4	and	O
5	histopathological	O
6	features	O
7	of	O
8	Nocardia	O
9	asteroides	O
10	and	O
11	Nocardia	O
12	brasiliensis	O
13	infections	O
14	in	O
15	congenitally	O
16	athymic	O
17	(	O
18	nude	O
19	)	O
20	mice	O
21	of	O
22	ICR	O
23	and	O
24	C3H	O
25	/	O
26	eB	O
27	origins	O
28	were	O
29	quite	O
30	different	O
31	from	O
32	what	O
33	we	O
34	found	O
35	for	O
36	Swiss	O
37	white	O
38	mice	O
39	and	O
40	other	O
41	inbred	O
42	mouse	O
43	strains	O
44	(	O
45	namely	O
46	,	O
47	C57	O
48	/	O
49	BL	O
50	/	O
51	6J	O
52	,	O
53	New	O
54	Zealand	O
55	Black	O
56	,	O
57	BALB	O
58	/	O
59	c	O
60	,	O
61	CBA	O
62	/	O
63	LAC	O
64	,	O
65	and	O
66	C3H	O
67	/	O
68	eB	O
69	).	O

1	Williams	O
2	,	O
3	2	O
4	August	O
5	1977	O
6	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Disrupted	O
2	vaccines	O
3	and	O
4	whole	O
5	-	O
6	virus	O
7	vaccines	O
8	containing	O
9	type	B
10	B	I
11	antigen	I
12	only	O
13	did	O
14	not	O
15	cause	O
16	significant	O
17	reactivity	O
18	.	O

1	255	O
2	-	O
3	61	O
4	.	O

1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O

1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	B
22	coli	I
23	endotoxin	I
24	intraperitoneally	O
25	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	The	O
2	maximum	O
3	period	O
4	of	O
5	treatment	O
6	was	O
7	73	O
8	(	O
9	oral	O
10	),	O
11	73	O
12	(	O
13	intraperitoneal	O
14	)	O
15	or	O
16	75	O
17	(	O
18	dermal	O
19	)	O
20	weeks	O
21	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	comparative	O
6	efficacy	O
7	of	O
8	diflucortolone	O
9	valerate	O
10	0	O
11	.	O
12	3	O
13	%	O
14	ointment	O
15	and	O
16	clobetasol	O
17	propionate	O
18	0	O
19	.	O
20	05	O
21	%	O
22	ointment	O
23	.	O

1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O

1	Basal	O
2	FSH	B
3	and	O
4	LH	B
5	levels	O
6	were	O
7	significantly	O
8	lower	O
9	in	O
10	addicts	O
11	;	O
12	after	O
13	GnRH	B
14	stimulation	O
15	the	O
16	addicts	O
17	'	O
18	FSH	B
19	and	O
20	LH	B
21	values	O
22	increased	O
23	but	O
24	not	O
25	significantly	O
26	compared	O
27	to	O
28	controls	O
29	.	O

1	Adriamycin	O
2	:	O
3	comparison	O
4	of	O
5	a	O
6	5	O
7	-	O
8	week	O
9	schedule	O
10	with	O
11	a	O
12	3	O
13	-	O
14	week	O
15	schedule	O
16	in	O
17	the	O
18	treatment	O
19	of	O
20	breast	O
21	cancer	O
22	.	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	O
9	LH	B
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	B
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	A	O
2	randomized	O
3	clinical	O
4	trial	O
5	in	O
6	sixty	O
7	-	O
8	two	O
9	adult	O
10	patients	O
11	suffering	O
12	from	O
13	typhoid	O
14	fever	O
15	,	O
16	proved	O
17	by	O
18	blood	O
19	and	O
20	marrow	O
21	culture	O
22	,	O
23	showed	O
24	that	O
25	amoxycillin	O
26	in	O
27	a	O
28	dosage	O
29	schedule	O
30	of	O
31	1	O
32	g	O
33	8	O
34	-	O
35	hourly	O
36	orally	O
37	for	O
38	fourteen	O
39	days	O
40	was	O
41	better	O
42	than	O
43	chloramphenicol	O
44	with	O
45	regard	O
46	to	O
47	clinical	O
48	and	O
49	temperature	O
50	response	O
51	and	O
52	in	O
53	respect	O
54	of	O
55	carriers	O
56	and	O
57	relapse	O
58	rates	O
59	.	O

1	202	O
2	-	O
3	8	O
4	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	actions	O
8	of	O
9	the	O
10	principal	O
11	dopamine	B
12	receptor	I
13	stimulating	O
14	agents	O
15	(	O
16	apomorphine	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	piribedil	O
22	,	O
23	rye	O
24	-	O
25	ergot	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	pharmacological	O
38	properties	O
39	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	Thus	O
2	,	O
3	the	O
4	inhibition	O
5	of	O
6	pepsin	B
7	in	O
8	human	O
9	gastric	O
10	juice	O
11	does	O
12	not	O
13	appear	O
14	to	O
15	have	O
16	a	O
17	major	O
18	influence	O
19	on	O
20	the	O
21	healing	O
22	of	O
23	duodenal	O
24	ulcer	O
25	.	O

1	The	O
2	IDF	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	penicillin	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	sulphonamide	O
20	residues	O
21	in	O
22	milk	O
23	.	O

1	Capsular	O
2	antigens	O
3	of	O
4	Staphylococcus	O
5	aureus	O

1	The	O
2	course	O
3	of	O
4	endotoxin	O
5	fever	O
6	remained	O
7	uninfluenced	O
8	by	O
9	ALS	O
10	.	O

1	2	O
2	new	O
3	Algerian	O
4	cases	O

1	Seventy	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	patients	O
7	treated	O
8	with	O
9	ticarcillin	O
10	alone	O
11	responded	O
12	favorably	O
13	.	O

1	Accurate	O
2	pathologic	O
3	staging	O
4	identifies	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	curable	O
10	with	O
11	radiotherapy	O
12	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	Neomycin	O
2	is	O
3	fairly	O
4	effective	O
5	against	O
6	staphylococci	O
7	,	O
8	less	O
9	effective	O
10	against	O
11	streptococci	O
12	,	O
13	and	O
14	fairly	O
15	effective	O
16	against	O
17	gram	O
18	-	O
19	negative	O
20	intestinal	O
21	organisms	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O

1	2	O
2	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	Ultrasonic	O
2	evaluation	O
3	of	O
4	renal	O
5	calculi	O
6	.	O

1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O

1	Isolation	O
2	of	O
3	T	O
4	.	O
5	gambiense	O
6	strains	O
7	in	O
8	Zaire	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Intestinal	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	B
14	renin	I
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	40	O
2	patients	O
3	with	O
4	chronic	O
5	osteomyelitis	O
6	were	O
7	treated	O
8	per	O
9	os	O
10	with	O
11	the	O
12	bactericidal	O
13	beta	O
14	-	O
15	lactam	O
16	-	O
17	antibiotic	O
18	cephalexin	O
19	during	O
20	3	O
21	to	O
22	60	O
23	weeks	O
24	.	O

1	A	O
2	total	O
3	of	O
4	57	O
5	patients	O
6	with	O
7	Hodgkin	O
8	'	O
9	s	O
10	disease	O
11	limited	O
12	to	O
13	above	O
14	the	O
15	diaphragm	O
16	(	O
17	Stages	O
18	I	O
19	and	O
20	II	O
21	,	O
22	A	O
23	and	O
24	B	O
25	)	O
26	were	O
27	treated	O
28	with	O
29	radiation	O
30	therapy	O
31	alone	O
32	at	O
33	the	O
34	University	O
35	of	O
36	Florida	O
37	between	O
38	1964	O
39	and	O
40	1974	O
41	.	O

1	Year	O
2	one	O
3	of	O
4	the	O
5	first	O
6	general	O
7	practitioner	O
8	medical	O
9	unit	O
10	in	O
11	the	O
12	greater	O
13	Glasgow	O
14	area	O
15	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	As	O
2	authorized	O
3	by	O
4	the	O
5	World	O
6	Health	O
7	Organization	O
8	29th	O
9	Expert	O
10	Committee	O
11	on	O
12	Biological	O
13	Standardization	O
14	,	O
15	the	O
16	preparation	O
17	of	O
18	human	B
19	prolactin	I
20	in	O
21	ampoules	O
22	coded	O
23	75	O
24	/	O
25	504	O
26	has	O
27	been	O
28	established	O
29	as	O
30	the	O
31	International	O
32	Reference	O
33	Preparation	O
34	(	O
35	IRP	O
36	)	O
37	of	O
38	human	B
39	prolactin	I
40	for	O
41	immunoassay	O
42	.	O

1	i	O
2	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Such	O
2	marked	O
3	differences	O
4	are	O
5	found	O
6	occasionally	O
7	in	O
8	the	O
9	literature	O
10	:	O
11	heterophile	O
12	antibodies	O
13	against	O
14	bovine	B
15	gammaglobulin	I
16	are	O
17	regarded	O
18	as	O
19	responsible	O
20	for	O
21	the	O
22	interference	O
23	in	O
24	the	O
25	Sephadex	O
26	system	O
27	of	O
28	RIST	O
29	.	O

1	"	O
2	Let	O
3	the	O
4	hundred	O
5	flowers	O
6	bloom	O
7	".	O

1	Various	O
2	treatment	O
3	modalities	O
4	are	O
5	reviewed	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	psychology	O
12	as	O
13	well	O
14	as	O
15	the	O
16	physiology	O
17	of	O
18	severe	O
19	intractable	O
20	pain	O
21	.	O

1	Lethal	O
2	Tachmalcor	O
3	(	O
4	4	O
5	-(	O
6	3	O
7	'-	O
8	diethylamino	O
9	-	O
10	2	O
11	'-	O
12	hydroxypropyl	O
13	)-	O
14	ajmaline	O
15	)	O
16	poisoning	O
17	in	O
18	childhood	O

1	Ophthalmosonographic	O
2	evaluation	O
3	of	O
4	blood	O
5	flow	O
6	velocity	O
7	in	O
8	arteriocavernous	O
9	fistula	O

1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	The	O
2	systolic	O
3	pressure	O
4	gradient	O
5	(	O
6	SPG	O
7	)	O
8	between	O
9	the	O
10	left	O
11	ventricle	O
12	(	O
13	LV	O
14	)	O
15	and	O
16	left	O
17	atrium	O
18	(	O
19	LA	O
20	)	O
21	was	O
22	obtained	O
23	from	O
24	high	O
25	-	O
26	fidelity	O
27	pressure	O
28	transducers	O
29	.	O

1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O

1	The	O
2	preferential	O
3	serum	B
4	IgA	I
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	The	O
2	effects	O
3	of	O
4	intracisternal	O
5	injection	O
6	(	O
7	i	O
8	.	O
9	c	O
10	.	O
11	i	O
12	.)	O
13	of	O
14	clonidine	O
15	(	O
16	1	O
17	microgram	O
18	kg	O
19	-	O
20	1	O
21	)	O
22	on	O
23	blood	O
24	pressure	O
25	and	O
26	heart	O
27	rate	O
28	were	O
29	studied	O
30	in	O
31	conscious	O
32	rabbits	O
33	with	O
34	an	O
35	implanted	O
36	catheter	O
37	in	O
38	the	O
39	cisterna	O
40	magna	O
41	.	O

1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	O
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O

1	A	O
2	rise	O
3	of	O
4	hemoglobin	B
5	concentration	O
6	accompanied	O
7	by	O
8	an	O
9	increase	O
10	of	O
11	the	O
12	total	O
13	iron	O
14	in	O
15	the	O
16	blood	O
17	serum	O
18	of	O
19	white	O
20	mice	O
21	was	O
22	found	O
23	under	O
24	oxygen	O
25	pressure	O
26	of	O
27	4	O
28	atm	O
29	for	O
30	an	O
31	hour	O
32	(	O
33	preconvulsive	O
34	state	O
35	)	O
36	and	O
37	6	O
38	atm	O
39	(	O
40	convulsive	O
41	state	O
42	).	O

1	Nernst	O
2	--	O
3	Planck	O
4	analog	O
5	equations	O
6	and	O
7	stationary	O
8	state	O
9	membrane	O
10	electric	O
11	potentials	O
12	.	O

1	Effects	O
2	of	O
3	methylene	O
4	chloride	O
5	,	O
6	trichloroethane	O
7	,	O
8	trichloroethylene	O
9	,	O
10	tetrachloroethylene	O
11	and	O
12	toluene	O
13	on	O
14	the	O
15	development	O
16	of	O
17	chick	O
18	embryos	O
19	.	O

1	Effect	O
2	of	O
3	intraventricular	O
4	administration	O
5	of	O
6	streptolysin	B
7	O	I
8	on	O
9	the	O
10	electroencephalogram	O
11	of	O
12	rabbits	O
13	.	O

1	In	O
2	this	O
3	situation	O
4	the	O
5	convlusion	O
6	threshold	O
7	for	O
8	the	O
9	8	O
10	substances	O
11	is	O
12	as	O
13	follows	O
14	:	O
15	pethidine	O
16	20	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	I	O
23	.	O
24	V	O
25	.,	O
26	piritramide	O
27	30	O
28	,	O
29	morphine	O
30	180	O
31	,	O
32	phenoperidine	O
33	4	O
34	,	O
35	R	O
36	39	O
37	209	O
38	5	O
39	,	O
40	fentanyl	O
41	4	O
42	,	O
43	sufentanil	O
44	4	O
45	and	O
46	R	O
47	34	O
48	995	O
49	10	O
50	mg	O
51	.	O
52	kg	O
53	-	O
54	1	O
55	I	O
56	.	O
57	V	O
58	.	O

1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Resistance	O
2	to	O
3	the	O
4	simulated	O
5	physiologic	O
6	environment	O
7	was	O
8	tested	O
9	by	O
10	measured	O
11	retention	O
12	of	O
13	mechanical	O
14	properties	O
15	after	O
16	immersion	O
17	times	O
18	in	O
19	pseudo	O
20	-	O
21	extracellular	O
22	fluid	O
23	(	O
24	PECF	O
25	)	O
26	at	O
27	37	O
28	degrees	O
29	C	O
30	for	O
31	as	O
32	long	O
33	as	O
34	three	O
35	years	O
36	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	B
6	receptors	I
7	bordering	O
8	the	O
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	O
18	of	O
19	fentanyl	O
20	.	O

1	In	O
2	case	O
3	of	O
4	a	O
5	pathologically	O
6	convoluted	O
7	internal	O
8	carotid	O
9	the	O
10	common	O
11	carotid	O
12	artery	O
13	was	O
14	resected	O
15	with	O
16	an	O
17	end	O
18	-	O
19	to	O
20	-	O
21	end	O
22	anastomosis	O
23	.	O

1	This	O
2	expression	O
3	assumes	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	laminar	O
10	flow	O
11	regimen	O
12	during	O
13	expiration	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	The	O
2	failures	O
3	frequently	O
4	were	O
5	related	O
6	to	O
7	patient	O
8	intolerance	O
9	or	O
10	poor	O
11	mechanical	O
12	fit	O
13	and	O
14	occurred	O
15	in	O
16	the	O
17	first	O
18	few	O
19	days	O
20	or	O
21	first	O
22	few	O
23	months	O
24	after	O
25	insertion	O
26	.	O

1	The	O
2	major	O
3	urinary	O
4	metabolites	O
5	were	O
6	3	O
7	-(	O
8	3	O
9	-	O
10	carboxyphenyl	O
11	)-	O
12	5	O
13	-	O
14	hydroxymethyl	O
15	-	O
16	2	O
17	-	O
18	oxazolidinone	O
19	and	O
20	a	O
21	glucuronide	O
22	of	O
23	toloxatone	O
24	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	The	O
2	ventilation	O
3	did	O
4	not	O
5	increase	O
6	when	O
7	PACO2	O
8	was	O
9	increased	O
10	.	O

1	Carbohydrate	O
2	metabolism	O
3	and	O
4	the	O
5	semen	O
6	profile	O
7	:	O
8	glucose	O
9	,	O
10	insulin	B
11	,	O
12	and	O
13	sperm	O
14	studies	O
15	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	The	O
2	sub	O
3	-	O
4	acute	O
5	inhalation	O
6	toxicity	O
7	of	O
8	furfural	O
9	was	O
10	studied	O
11	in	O
12	Syrian	O
13	golden	O
14	hamsters	O
15	.	O

1	Changes	O
2	of	O
3	thirtynine	O
4	serum	O
5	protein	O
6	components	O
7	following	O
8	surgical	O
9	stress	O
10	.	O

1	These	O
2	differences	O
3	are	O
4	smaller	O
5	than	O
6	those	O
7	described	O
8	in	O
9	standard	O
10	textbooks	O
11	.	O

1	A	O
2	study	O
3	of	O
4	the	O
5	E	O
6	.	O
7	O	O
8	.	O
9	R	O
10	.	O
11	T	O
12	.	O
13	C	O
14	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	dependence	O
7	of	O
8	difference	O
9	tone	O
10	level	O
11	[	O
12	L	O
13	(	O
14	f2	O
15	-	O
16	f1	O
17	)]	O
18	on	O
19	the	O
20	following	O
21	parameters	O
22	of	O
23	the	O
24	two	O
25	-	O
26	tone	O
27	input	O
28	:	O
29	f1	O
30	,	O
31	f2	O
32	/	O
33	f1	O
34	(	O
35	f2	O
36	greater	O
37	than	O
38	f1	O
39	),	O
40	L1	O
41	,	O
42	L2	O
43	,	O
44	and	O
45	L1	O
46	=	O
47	L2	O
48	.	O

1	An	O
2	intravenous	O
3	preparation	O
4	of	O
5	doxycycline	O
6	(	O
7	DOTC	O
8	,	O
9	Vibramycin	O
10	'	O
11	Pfizer	O
12	'),	O
13	a	O
14	long	O
15	-	O
16	lasting	O
17	tetracycline	O
18	,	O
19	was	O
20	administered	O
21	mainly	O
22	by	O
23	drip	O
24	infusion	O
25	for	O
26	a	O
27	series	O
28	of	O
29	study	O
30	in	O
31	the	O
32	pediatrics	O
33	field	O
34	,	O
35	and	O
36	the	O
37	results	O
38	were	O
39	as	O
40	follows	O
41	:	O
42	1	O
43	)	O
44	DOTC	O
45	(	O
46	100	O
47	mg	O
48	)	O
49	was	O
50	dissolved	O
51	in	O
52	a	O
53	100	O
54	ml	O
55	of	O
56	glucose	O
57	solution	O
58	and	O
59	2	O
60	--	O
61	3	O
62	mg	O
63	/	O
64	kg	O
65	was	O
66	administered	O
67	intravenously	O
68	.	O

1	5	O
2	)	O
3	Before	O
4	and	O
5	ten	O
6	days	O
7	after	O
8	DOTC	O
9	infusion	O
10	,	O
11	laboratory	O
12	tests	O
13	for	O
14	liver	O
15	and	O
16	renal	O
17	functions	O
18	and	O
19	blood	O
20	were	O
21	performed	O
22	.	O

1	Structural	O
2	characteristics	O
3	of	O
4	the	O
5	erythrocyte	O
6	membrane	O
7	,	O
8	peroxidation	O
9	processes	O
10	and	O
11	antioxidant	O
12	function	O
13	in	O
14	children	O
15	with	O
16	diffuse	O
17	glomerulonephritis	O

1	The	O
2	enteric	O
3	route	O
4	is	O
5	the	O
6	principal	O
7	mode	O
8	of	O
9	transmission	O
10	for	O
11	hepatitis	O
12	A	O
13	,	O
14	but	O
15	maximal	O
16	levels	O
17	of	O
18	hepatitis	O
19	A	O
20	virus	O
21	excretion	O
22	occur	O
23	before	O
24	the	O
25	onset	O
26	of	O
27	jaundice	O
28	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	B
17	sulphatase	I
18	deficiency	O
19	.	O

1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O

1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	gallium	O
11	by	O
12	tumor	O
13	cells	O
14	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O

1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O

1	Following	O
2	the	O
3	satisfactory	O
4	results	O
5	and	O
6	taking	O
7	into	O
8	account	O
9	that	O
10	the	O
11	complications	O
12	had	O
13	reduced	O
14	to	O
15	a	O
16	very	O
17	low	O
18	rate	O
19	(	O
20	in	O
21	2	O
22	cases	O
23	lead	O
24	tip	O
25	displacement	O
26	and	O
27	pouch	O
28	haematoma	O
29	occurred	O
30	respectively	O
31	),	O
32	the	O
33	Authors	O
34	consider	O
35	the	O
36	adopted	O
37	method	O
38	an	O
39	useful	O
40	approach	O
41	for	O
42	PMK	O
43	implantation	O
44	particularly	O
45	when	O
46	the	O
47	use	O
48	of	O
49	the	O
50	vena	O
51	cephalica	O
52	is	O
53	deemed	O
54	impossible	O
55	.	O

1	When	O
2	two	O
3	determinations	O
4	were	O
5	performed	O
6	on	O
7	12	O
8	samples	O
9	of	O
10	plasma	O
11	taken	O
12	from	O
13	normal	O
14	adults	O
15	in	O
16	October	O
17	,	O
18	the	O
19	values	O
20	were	O
21	22	O
22	.	O
23	6	O
24	+/-	O
25	4	O
26	.	O
27	8	O
28	and	O
29	21	O
30	.	O
31	0	O
32	+/-	O
33	3	O
34	.	O
35	6	O
36	(	O
37	mean	O
38	+/-	O
39	SD	O
40	)	O
41	ng	O
42	/	O
43	ml	O
44	,	O
45	respectively	O
46	.	O

1	The	O
2	six	O
3	commonest	O
4	causes	O
5	of	O
6	death	O
7	varied	O
8	in	O
9	the	O
10	three	O
11	ethnic	O
12	groups	O
13	.	O

1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	"	O
42	classical	O
43	"	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Study	O
2	on	O
3	re	O
4	-	O
5	establishment	O
6	of	O
7	ovulation	O
8	after	O
9	termination	O
10	of	O
11	sex	O
12	-	O
13	steroidal	O
14	treatment	O
15	--	O
16	compared	O
17	with	O
18	re	O
19	-	O
20	appearance	O
21	of	O
22	ovulation	O
23	after	O
24	abortion	O
25	and	O
26	premature	O
27	delivery	O
28	.	O

1	Pharmacokinetics	O
2	of	O
3	Carbamazepine	O
4	in	O
5	man	O
6	:	O
7	a	O
8	review	O
9	.	O

1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	Delayed	O
2	mortality	O
3	of	O
4	mice	O
5	following	O
6	inhalation	O
7	of	O
8	acute	O
9	doses	O
10	of	O
11	CH2O	O
12	,	O
13	SO2Cl2	O
14	,	O
15	and	O
16	Br2	O
17	.	O

1	Guinea	O
2	pigs	O
3	weighing	O
4	300	O
5	approximately	O
6	350	O
7	g	O
8	were	O
9	used	O
10	.	O

1	Under	O
2	halothane	O
3	anesthesia	O
4	,	O
5	the	O
6	flow	O
7	pneumocardiogram	O
8	(	O
9	PnCG	O
10	)	O
11	and	O
12	its	O
13	time	O
14	derivative	O
15	(	O
16	acceleration	O
17	pneumocardiogram	O
18	or	O
19	dPn	O
20	/	O
21	dt	O
22	)	O
23	were	O
24	transduced	O
25	during	O
26	apnea	O
27	by	O
28	a	O
29	small	O
30	high	O
31	-	O
32	gain	O
33	pneumotachograph	O
34	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	stereotypy	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	striatal	O
16	dopaminergic	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	striatal	O
32	cholinergic	O
33	-	O
34	dopaminergic	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	shifted	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	manifestation	O
53	.	O

1	None	O
2	of	O
3	the	O
4	cystometrograms	O
5	showed	O
6	uninhibited	O
7	detrusor	O
8	contractions	O
9	.	O

1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	O
17	-	O
18	acetyldigoxin	O
19	.	O

1	Functional	O
2	effects	O
3	following	O
4	subacute	O
5	administration	O
6	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Contrary	O
2	to	O
3	1	O
4	,	O
5	8	O
6	-	O
7	dihydroxy	O
8	-	O
9	9	O
10	-	O
11	anthrone	O
12	,	O
13	1	O
14	,	O
15	8	O
16	,	O
17	9	O
18	-	O
19	triacetoxyanthracene	O
20	and	O
21	1	O
22	,	O
23	8	O
24	-	O
25	diacetoxy	O
26	-	O
27	9	O
28	-	O
29	anthrone	O
30	are	O
31	effective	O
32	against	O
33	psoriatic	O
34	lesions	O
35	without	O
36	accompanying	O
37	inflammations	O
38	of	O
39	the	O
40	skin	O
41	.	O

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Nursing	O
2	of	O
3	patients	O
4	with	O
5	gynecological	O
6	diseases	O

1	We	O
2	measured	O
3	basal	O
4	plasma	O
5	prolactin	B
6	concentrations	O
7	(	O
8	in	O
9	samples	O
10	obtained	O
11	during	O
12	the	O
13	early	O
14	follicular	O
15	phase	O
16	)	O
17	in	O
18	25	O
19	normal	O
20	(	O
21	control	O
22	)	O
23	women	O
24	and	O
25	in	O
26	a	O
27	similar	O
28	group	O
29	of	O
30	40	O
31	patients	O
32	with	O
33	a	O
34	long	O
35	-	O
36	standing	O
37	history	O
38	of	O
39	infertility	O
40	.	O

1	Ovarian	O
2	allotransplantation	O
3	in	O
4	human	O
5	.	O

1	Allergic	O
2	reaction	O
3	to	O
4	Patent	O
5	Blue	O
6	Violet	O
7	during	O
8	lymphography	O
9	.	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	O
8	papio	O
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	B
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O

1	In	O
2	girls	O
3	prolactin	B
4	levels	O
5	rise	O
6	at	O
7	stage	O
8	2	O
9	,	O
10	and	O
11	are	O
12	higher	O
13	after	O
14	menarche	O
15	;	O
16	in	O
17	boys	O
18	there	O
19	is	O
20	no	O
21	change	O
22	in	O
23	prolactin	B
24	levels	O
25	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	both	O
6	of	O
7	these	O
8	surgical	O
9	procedures	O
10	were	O
11	as	O
12	effective	O
13	as	O
14	pinealectomy	O
15	in	O
16	reversing	O
17	the	O
18	pineal	O
19	-	O
20	induced	O
21	alterations	O
22	in	O
23	the	O
24	reproductive	O
25	physiology	O
26	of	O
27	the	O
28	blind	O
29	-	O
30	anosmic	O
31	female	O
32	rat	O
33	.	O

1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O

1	Such	O
2	an	O
3	hemoglobin	B
4	solution	O
5	was	O
6	shown	O
7	to	O
8	exhibit	O
9	a	O
10	high	O
11	affinity	O
12	for	O
13	oxygen	O
14	and	O
15	a	O
16	low	O
17	Bohr	O
18	effect	O
19	(	O
20	assessed	O
21	from	O
22	the	O
23	delta	O
24	log	O
25	Po2	O
26	/	O
27	delta	O
28	pH	O
29	ratio	O
30	).	O

1	A	O
2	one	O
3	-	O
4	week	O
5	ulcer	O
6	therapy	O
7	with	O
8	atropine	O
9	and	O
10	Vikalin	O
11	(	O
12	Roter	O
13	)	O
14	led	O
15	to	O
16	a	O
17	significant	O
18	(	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	01	O
25	)	O
26	reduction	O
27	of	O
28	the	O
29	nocturnal	O
30	proteolytic	O
31	activity	O
32	.	O

1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	diarrhea	O
7	the	O
8	estriol	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	normalised	O
19	and	O
20	the	O
21	estriol	O
22	concentration	O
23	went	O
24	up	O
25	exactly	O
26	when	O
27	the	O
28	diarrhea	O
29	stopped	O
30	.	O

1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	contrary	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	observers	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O

1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O

1	Vitrectomy	O
2	in	O
3	ocular	O
4	traumatology	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	No	O
2	systematic	O
3	L	O
4	-	O
5	R	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	B
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	Deep	O
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Stress	O
2	effects	O
3	on	O
4	affiliation	O
5	preferences	O
6	among	O
7	subjects	O
8	possessing	O
9	the	O
10	type	O
11	A	O
12	coronary	O
13	-	O
14	prone	O
15	behavior	O
16	pattern	O
17	.	O

1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O

1	Smoking	O
2	was	O
3	regarded	O
4	as	O
5	the	O
6	major	O
7	contribution	O
8	to	O
9	pulmonary	O
10	dysfunction	O
11	.	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	I
33	and	I
34	beta	I
35	-	I
36	adrenoceptors	I
37	.	O

1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O

1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O

1	Evaluation	O
2	of	O
3	the	O
4	Du	O
5	Pont	O
6	aca	O
7	ammonia	O
8	procedure	O
9	.	O

1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O

1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O

1	Kodak	O
2	XV	O
3	-	O
4	2	O
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	O
6	renin	B
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	Cortisone	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	clearing	O
11	agents	O
12	.	O

1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	sharing	O
7	principle	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	Delayed	O
2	hypersensitivity	O
3	in	O
4	man	O
5	:	O
6	effects	O
7	of	O
8	systemic	O
9	anticoagulation	O
10	.	O

1	In	O
2	three	O
3	of	O
4	the	O
5	seven	O
6	,	O
7	inhalation	O
8	of	O
9	2	O
10	ml	O
11	normal	O
12	saline	O
13	produced	O
14	FEV1	O
15	falls	O
16	of	O
17	25	O
18	%	O
19	to	O
20	30	O
21	%,	O
22	but	O
23	these	O
24	falls	O
25	were	O
26	not	O
27	as	O
28	great	O
29	as	O
30	each	O
31	subject	O
32	'	O
33	s	O
34	reactions	O
35	to	O
36	the	O
37	test	O
38	solutions	O
39	.	O

1	Experimental	O
2	studies	O
3	on	O
4	virus	O
5	excretion	O
6	and	O
7	non	O
8	-	O
9	arthropod	O
10	transmission	O
11	.	O

1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	O
9	superoxide	B
10	dismutase	I
11	.	O

1	Measurement	O
2	of	O
3	magnesium	O
4	absorption	O
5	in	O
6	man	O
7	using	O
8	stable	O
9	26Mg	O
10	as	O
11	a	O
12	tracer	O
13	.	O

1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O

1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O

1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O

1	Escherichia	O
2	of	O
3	a	O
4	single	O
5	sero	O
6	-	O
7	anzymatic	O
8	type	O
9	(	O
10	06a6b	O
11	:	O
12	K13	O
13	:	O
14	H1	O
15	)	O
16	were	O
17	isolated	O
18	in	O
19	a	O
20	group	O
21	affection	O
22	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Analysis	O
2	of	O
3	liver	O
4	biopsy	O
5	specimens	O
6	from	O
7	patients	O
8	with	O
9	hepatitis	O
10	showed	O
11	a	O
12	large	O
13	variation	O
14	in	O
15	the	O
16	mean	O
17	iron	O
18	content	O
19	of	O
20	the	O
21	liver	O
22	ferritin	B
23	molecules	O
24	.	O

1	Female	O
2	mice	O
3	were	O
4	significantly	O
5	more	O
6	resistant	O
7	to	O
8	infection	O
9	than	O
10	males	O
11	.	O

1	During	O
2	the	O
3	following	O
4	9	O
5	1	O
6	/	O
7	2	O
8	years	O
9	three	O
10	sequential	O
11	liver	O
12	biopsies	O
13	were	O
14	performed	O
15	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O

1	Silicosis	O
2	mortality	O

1	These	O
2	consisted	O
3	of	O
4	beading	O
5	and	O
6	strictures	O
7	mainly	O
8	of	O
9	the	O
10	intrahepatic	O
11	biliary	O
12	tree	O
13	(	O
14	IHB	O
15	).	O

1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O

1	Thromboplastic	O
2	and	O
3	fibrynolytic	O
4	activity	O
5	of	O
6	the	O
7	blood	O
8	after	O
9	administration	O
10	of	O
11	intralipid	O
12	in	O
13	men	O
14	with	O
15	history	O
16	of	O
17	myocardial	O
18	infarction	O
19	up	O
20	to	O
21	45	O
22	year	O
23	of	O
24	life	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	clinicopathologic	O
6	findings	O
7	in	O
8	four	O
9	cases	O
10	of	O
11	adult	O
12	women	O
13	with	O
14	rhabdomyosarcomas	O
15	that	O
16	originated	O
17	in	O
18	the	O
19	endometrium	O
20	or	O
21	cervix	O
22	,	O
23	or	O
24	both	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	pure	O
5	natural	O
6	porcine	B
7	secretin	I
8	on	O
9	endocrine	O
10	and	O
11	exocrine	O
12	pancreatic	O
13	secretion	O
14	was	O
15	studied	O
16	in	O
17	the	O
18	totally	O
19	isolated	O
20	perfused	O
21	porcine	O
22	pancreas	O
23	.	O

1	Biometric	O
2	analysis	O
3	of	O
4	intraocular	O
5	lens	O
6	power	O
7	required	O
8	to	O
9	produce	O
10	emmetropia	O
11	:	O
12	results	O
13	of	O
14	450	O
15	implants	O
16	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O

1	99mTc	O
2	phytate	O
3	,	O
4	198Au	O
5	colloid	O
6	,	O
7	and	O
8	99mTc	O
9	antimony	O
10	sulfide	O
11	have	O
12	been	O
13	used	O
14	;	O
15	the	O
16	last	O
17	appears	O
18	to	O
19	have	O
20	been	O
21	the	O
22	most	O
23	satisfactory	O
24	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	A	O
2	suspected	O
3	hypothalamic	O
4	dysfunction	O
5	and	O
6	a	O
7	slightly	O
8	impaired	O
9	pituitary	O
10	function	O
11	manifested	O
12	as	O
13	GH	B
14	deficiency	O
15	were	O
16	their	O
17	common	O
18	endocrinological	O
19	features	O
20	.	O

1	A	O
2	sharp	O
3	outbreak	O
4	of	O
5	influenza	O
6	A	O
7	occurred	O
8	on	O
9	the	O
10	base	O
11	during	O
12	February	O
13	that	O
14	was	O
15	due	O
16	to	O
17	an	O
18	A	O
19	/	O
20	Texas	O
21	/	O
22	1	O
23	/	O
24	77	O
25	-	O
26	like	O
27	virus	O
28	,	O
29	a	O
30	variant	O
31	of	O
32	the	O
33	A	O
34	/	O
35	Victoria	O
36	/	O
37	3	O
38	/	O
39	75	O
40	prototpye	O
41	.	O

1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O

1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	A	O
2	one	O
3	-	O
4	way	O
5	analysis	O
6	of	O
7	variance	O
8	,	O
9	performed	O
10	separately	O
11	for	O
12	men	O
13	and	O
14	women	O
15	for	O
16	differences	O
17	among	O
18	the	O
19	three	O
20	phobic	O
21	groups	O
22	on	O
23	field	O
24	dependence	O
25	,	O
26	showed	O
27	significance	O
28	(	O
29	rho	O
30	less	O
31	than	O
32	.	O
33	05	O
34	)	O
35	for	O
36	the	O
37	females	O
38	,	O
39	with	O
40	the	O
41	famale	O
42	agoraphobic	O
43	being	O
44	more	O
45	field	O
46	dependent	O
47	than	O
48	the	O
49	female	O
50	simple	O
51	phobic	O
52	groups	O
53	,	O
54	but	O
55	not	O
56	for	O
57	the	O
58	males	O
59	.	O

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	O
13	11	O
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	The	O
2	calculated	O
3	pD2	O
4	values	O
5	were	O
6	8	O
7	.	O
8	8	O
9	for	O
10	E	O
11	,	O
12	8	O
13	.	O
14	6	O
15	for	O
16	DHE	O
17	and	O
18	6	O
19	.	O
20	6	O
21	for	O
22	M	O
23	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	Treatment	O
2	of	O
3	hypertension	O
4	with	O
5	a	O
6	combination	O
7	of	O
8	the	O
9	adrenergic	B
10	beta	I
11	receptor	I
12	blockader	O
13	,	O
14	obsidan	O
15	,	O
16	and	O
17	the	O
18	vasodilator	O
19	,	O
20	apressin	O

1	Orthop	O
2	.	O

1	Thyroid	O
2	disease	O
3	and	O
4	pregnancy	O
5	.	O

1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O

1	To	O
2	minimize	O
3	reflux	O
4	into	O
5	the	O
6	blind	O
7	loop	O
8	,	O
9	a	O
10	number	O
11	of	O
12	technical	O
13	steps	O
14	are	O
15	considered	O
16	indispensable	O
17	:	O
18	1	O
19	)	O
20	fluted	O
21	section	O
22	of	O
23	the	O
24	jejunal	O
25	stump	O
26	;	O
27	2	O
28	)	O
29	isoperistaltic	O
30	construction	O
31	of	O
32	the	O
33	anastomosis	O
34	and	O
35	,	O
36	particularly	O
37	,	O
38	3	O
39	)	O
40	the	O
41	creation	O
42	of	O
43	a	O
44	single	O
45	or	O
46	double	O
47	valve	O
48	system	O
49	upstream	O
50	from	O
51	the	O
52	anastomosis	O
53	by	O
54	spiral	O
55	introflexion	O
56	of	O
57	the	O
58	mucosa	O
59	using	O
60	seroserous	O
61	stitches	O
62	parallel	O
63	and	O
64	perpendicular	O
65	to	O
66	the	O
67	ileal	O
68	lumen	O
69	.	O

1	At	O
2	this	O
3	stage	O
4	,	O
5	the	O
6	eventual	O
7	high	O
8	mortality	O
9	of	O
10	acute	O
11	ischemia	O
12	is	O
13	established	O
14	whatever	O
15	the	O
16	urgency	O
17	of	O
18	the	O
19	operation	O
20	or	O
21	the	O
22	skill	O
23	with	O
24	which	O
25	it	O
26	is	O
27	performed	O
28	.	O

1	Pathogens	O
2	(	O
3	Staphylococcus	O
4	aureus	O
5	or	O
6	Gram	O
7	-	O
8	negative	O
9	bacilli	O
10	)	O
11	were	O
12	isolated	O
13	from	O
14	only	O
15	one	O
16	member	O
17	of	O
18	staff	O
19	in	O
20	small	O
21	numbers	O
22	and	O
23	irregularly	O
24	and	O
25	rarely	O
26	in	O
27	large	O
28	numbers	O
29	from	O
30	patients	O
31	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	A	O
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O

1	The	O
2	data	O
3	indicate	O
4	a	O
5	three	O
6	-	O
7	phase	O
8	reaction	O
9	after	O
10	B1	O
11	injection	O
12	:	O
13	Phase	O
14	1	O
15	--	O
16	shortly	O
17	after	O
18	injection	O
19	there	O
20	is	O
21	a	O
22	drop	O
23	of	O
24	all	O
25	parameters	O
26	lasting	O
27	for	O
28	30	O
29	sec	O
30	.	O

1	Serum	B
2	relaxin	I
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O

1	Effect	O
2	of	O
3	indoramin	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	vasomotor	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	chloralose	O
17	anesthetized	O
18	cats	O
19	by	O
20	localizing	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O

1	Contingency	O
2	contracting	O
3	between	O
4	clients	O
5	and	O
6	their	O
7	parents	O
8	/	O
9	caregivers	O
10	was	O
11	used	O
12	to	O
13	specify	O
14	consequences	O
15	for	O
16	daily	O
17	self	O
18	-	O
19	monitoring	O
20	,	O
21	reduced	O
22	caloric	O
23	intake	O
24	,	O
25	weight	O
26	loss	O
27	,	O
28	and	O
29	exercise	O
30	.	O

1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O

1	The	O
2	results	O
3	of	O
4	a	O
5	quantitative	O
6	study	O
7	of	O
8	vasculosyncytial	O
9	membranes	O
10	in	O
11	123	O
12	placentas	O
13	are	O
14	presented	O
15	.	O

1	The	O
2	micromethod	O
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	O
15	.	O

1	Platelet	O
2	serotonin	O
3	(	O
4	5	O
5	-	O
6	HT	O
7	)	O
8	and	O
9	5	B
10	-	I
11	HT	I
12	releasing	I
13	factor	I
14	in	O
15	plasma	O
16	of	O
17	migrainous	O
18	patients	O
19	.	O

1	The	O
2	overall	O
3	incidence	O
4	of	O
5	SIDS	O
6	was	O
7	1	O
8	.	O
9	43	O
10	per	O
11	1	O
12	,	O
13	000	O
14	live	O
15	births	O
16	.	O

1	The	O
2	vigilance	O
3	task	O
4	and	O
5	the	O
6	measurement	O
7	of	O
8	attentional	O
9	deficits	O
10	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O

1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O

1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	Carcinoembryonic	B
2	antigen	I
3	(	O
4	CEA	B
5	)	O
6	procedures	O
7	and	O
8	clinical	O
9	evaluation	O
10	.	O

1	We	O
2	remain	O
3	convinced	O
4	that	O
5	antilymphocyte	B
6	globulin	I
7	(	O
8	ALG	B
9	)	O
10	is	O
11	a	O
12	potent	O
13	immunosuppressive	O
14	agent	O
15	in	O
16	humans	O
17	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	global	O
7	assessment	O
8	patients	O
9	showed	O
10	a	O
11	highly	O
12	significant	O
13	preference	O
14	for	O
15	imipramine	O
16	compared	O
17	with	O
18	placebo	O
19	as	O
20	adjunctive	O
21	therapy	O
22	.	O

1	39	O
2	-	O
3	47	O
4	.	O

1	Patients	O
2	were	O
3	subclassified	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	"	O
23	cured	O
24	"	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	Advances	O
2	in	O
3	the	O
4	management	O
5	of	O
6	gynecologic	O
7	cancer	O
8	--	O
9	radiation	O
10	therapy	O
11	.	O

1	The	O
2	clinico	O
3	-	O
4	pathological	O
5	data	O
6	from	O
7	a	O
8	patient	O
9	with	O
10	irreversible	O
11	post	O
12	-	O
13	partum	O
14	renal	O
15	failure	O
16	(	O
17	IPRF	O
18	)	O
19	are	O
20	presented	O
21	.	O

1	Personal	O
2	satisfaction	O
3	in	O
4	nursing	O
5	:	O
6	an	O
7	encounter	O
8	with	O
9	extremely	O
10	hostile	O
11	patients	O

1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O

1	19	O
2	-	O
3	32	O
4	.	O

1	Rheumatoid	B
2	factor	I
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	The	O
2	effect	O
3	of	O
4	hydrostatic	O
5	pressure	O
6	on	O
7	the	O
8	swimming	O
9	activity	O
10	of	O
11	three	O
12	hyponeustonic	O
13	crustacea	O
14	,	O
15	Anomalocera	O
16	patersoni	O
17	,	O
18	Pontella	O
19	mediterranea	O
20	,	O
21	Labidocera	O
22	wollastoni	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Deflunia	O
2	was	O
3	well	O
4	tolerated	O
5	by	O
6	25	O
7	patients	O
8	,	O
9	very	O
10	well	O
11	tolerated	O
12	by	O
13	2	O
14	.	O

1	III	O
2	.	O

1	A	O
2	new	O
3	instrument	O
4	has	O
5	been	O
6	designed	O
7	for	O
8	freeze	O
9	-	O
10	fracturing	O
11	of	O
12	biological	O
13	material	O
14	in	O
15	ultra	O
16	high	O
17	vacuum	O
18	.	O

1	Pancreatic	O
2	and	O
3	biliary	O
4	secretion	O
5	and	O
6	gastric	O
7	emptying	O
8	rates	O
9	of	O
10	a	O
11	liquid	O
12	test	O
13	meal	O
14	(	O
15	LTM	O
16	)	O
17	were	O
18	determined	O
19	in	O
20	normal	O
21	persons	O
22	,	O
23	in	O
24	patients	O
25	with	O
26	subtotal	O
27	gastrectomy	O
28	with	O
29	gastroduodenostomy	O
30	(	O
31	STG	O
32	-	O
33	BI	O
34	)	O
35	or	O
36	with	O
37	gastrojejunostomy	O
38	(	O
39	STG	O
40	-	O
41	BII	O
42	),	O
43	and	O
44	in	O
45	patients	O
46	with	O
47	truncal	O
48	vagotomy	O
49	and	O
50	pyloroplasty	O
51	(	O
52	V	O
53	&	O
54	P	O
55	).	O

1	Abnormal	O
2	calcium	O
3	metabolism	O
4	in	O
5	normocalcaemic	O
6	sarcoidosis	O
7	.	O

1	Also	O
2	,	O
3	except	O
4	in	O
5	one	O
6	patient	O
7	who	O
8	developed	O
9	gallstones	O
10	following	O
11	institution	O
12	of	O
13	colestipol	O
14	,	O
15	saturation	O
16	of	O
17	gallbladder	O
18	bile	O
19	with	O
20	cholesterol	O
21	was	O
22	not	O
23	markedly	O
24	increased	O
25	by	O
26	this	O
27	drug	O
28	alone	O
29	.	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	"	O
21	ON	O
22	"	O
23	or	O
24	"	O
25	OFF	O
26	"	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	If	O
2	,	O
3	however	O
4	,	O
5	the	O
6	mean	O
7	temperature	O
8	rise	O
9	was	O
10	higher	O
11	(	O
12	0	O
13	.	O
14	57	O
15	degrees	O
16	C	O
17	or	O
18	0	O
19	.	O
20	69	O
21	degrees	O
22	C	O
23	),	O
24	such	O
25	a	O
26	selection	O
27	practically	O
28	resulted	O
29	in	O
30	the	O
31	disappearance	O
32	of	O
33	'	O
34	passable	O
35	'	O
36	qualifications	O
37	in	O
38	the	O
39	triplet	O
40	groups	O
41	and	O
42	a	O
43	great	O
44	predominance	O
45	of	O
46	'	O
47	to	O
48	be	O
49	rejected	O
50	'	O
51	qualifications	O
52	in	O
53	the	O
54	large	O
55	groups	O
56	.	O

1	The	O
2	elevated	O
3	Viso	O
4	V	O
5	in	O
6	the	O
7	RDS	O
8	group	O
9	suggests	O
10	an	O
11	increase	O
12	in	O
13	small	O
14	airway	O
15	resistance	O
16	secondary	O
17	to	O
18	the	O
19	disease	O
20	or	O
21	to	O
22	its	O
23	therapy	O
24	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	Selective	O
2	bronchial	O
3	intubation	O
4	in	O
5	the	O
6	management	O
7	of	O
8	unilateral	O
9	pulmonary	O
10	interstitial	O
11	emphysema	O
12	.	O

1	The	O
2	background	O
3	processes	O
4	depending	O
5	on	O
6	the	O
7	etiological	O
8	factor	O
9	and	O
10	the	O
11	character	O
12	of	O
13	lesion	O
14	of	O
15	the	O
16	epithelium	O
17	are	O
18	divided	O
19	into	O
20	dyshormonal	O
21	,	O
22	inflammatory	O
23	,	O
24	and	O
25	posttraumatic	O
26	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Eleven	O
2	strains	O
3	of	O
4	Fusarium	O
5	poae	O
6	and	O
7	F	O
8	.	O
9	sporotrichioides	O
10	from	O
11	the	O
12	U	O
13	.	O
14	S	O
15	.	O
16	S	O
17	.	O
18	R	O
19	.	O
20	and	O
21	7	O
22	strains	O
23	of	O
24	these	O
25	species	O
26	and	O
27	one	O
28	of	O
29	F	O
30	.	O
31	sporotrichioides	O
32	var	O
33	.	O
34	tricinctum	O
35	from	O
36	U	O
37	.	O
38	S	O
39	.	O
40	A	O
41	.	O
42	and	O
43	France	O
44	have	O
45	been	O
46	compared	O
47	as	O
48	to	O
49	their	O
50	capacity	O
51	to	O
52	yield	O
53	T	B
54	-	I
55	2	I
56	toxin	I
57	.	O

1	Current	O
2	diagnostic	O
3	uses	O
4	of	O
5	computerized	O
6	tomography	O
7	in	O
8	clinical	O
9	medicine	O
10	.	O

1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	Recurrence	O
2	of	O
3	bladder	O
4	tumors	O
5	among	O
6	the	O
7	original	O
8	9	O
9	cases	O
10	has	O
11	occurred	O
12	only	O
13	among	O
14	the	O
15	5	O
16	whose	O
17	properdin	B
18	levels	O
19	remained	O
20	below	O
21	the	O
22	median	O
23	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	Dangers	O
2	in	O
3	use	O
4	of	O
5	live	O
6	-	O
7	virus	O
8	vaccines	O
9	.	O

1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	B
6	activators	O
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O

1	In	O
2	diethyl	O
3	ether	O
4	solution	O
5	the	O
6	main	O
7	peak	O
8	is	O
9	that	O
10	of	O
11	2	O
12	-	O
13	benzylidenamio	O
14	-	O
15	1	O
16	-	O
17	phenylpropane	O
18	,	O
19	which	O
20	has	O
21	a	O
22	retention	O
23	time	O
24	of	O
25	23	O
26	,	O
27	2	O
28	minutes	O
29	under	O
30	the	O
31	condition	O
32	delineated	O
33	.	O

1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O

1	The	O
2	data	O
3	normally	O
4	available	O
5	are	O
6	insufficient	O
7	and	O
8	take	O
9	no	O
10	account	O
11	of	O
12	the	O
13	direction	O
14	of	O
15	recirculation	O
16	,	O
17	which	O
18	may	O
19	be	O
20	a	O
21	determining	O
22	factor	O
23	.	O

1	During	O
2	activity	O
3	III	O
4	,	O
5	one	O
6	patient	O
7	developed	O
8	angina	O
9	.	O

1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	O
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O

1	The	O
2	acids	O
3	were	O
4	obtained	O
5	by	O
6	hydrolysis	O
7	of	O
8	the	O
9	corresponding	O
10	esters	O
11	,	O
12	and	O
13	their	O
14	anti	O
15	-	O
16	inflammatory	O
17	activity	O
18	was	O
19	tested	O
20	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Bacterial	O
2	meningitis	O
3	secondary	O
4	to	O
5	abscess	O
6	of	O
7	the	O
8	nasal	O
9	septum	O
10	.	O

1	Serum	B
2	amylase	I
3	became	O
4	markedly	O
5	elevated	O
6	(	O
7	2	O
8	,	O
9	624	O
10	CU	O
11	/	O
12	100	O
13	ml	O
14	),	O
15	as	O
16	did	O
17	the	O
18	serum	O
19	FFA	O
20	(	O
21	29	O
22	.	O
23	19	O
24	mEq	O
25	/	O
26	liter	O
27	).	O

1	In	O
2	the	O
3	control	O
4	preparation	O
5	before	O
6	weight	O
7	was	O
8	allowed	O
9	to	O
10	increase	O
11	,	O
12	isogravimetric	O
13	capillary	O
14	pressure	O
15	(	O
16	Pci	O
17	)	O
18	averaged	O
19	8	O
20	mmHg	O
21	lower	O
22	than	O
23	colloid	O
24	osmotic	O
25	pressure	O
26	of	O
27	the	O
28	plasma	O
29	(	O
30	IIp	O
31	).	O

1	Infants	O
2	who	O
3	died	O
4	in	O
5	the	O
6	first	O
7	12	O
8	hours	O
9	from	O
10	'	O
11	IVH	O
12	only	O
13	'	O
14	had	O
15	suffered	O
16	severe	O
17	birth	O
18	asphyxia	O
19	but	O
20	in	O
21	those	O
22	who	O
23	died	O
24	later	O
25	the	O
26	main	O
27	symptom	O
28	was	O
29	recurrent	O
30	apnoea	O
31	.	O

1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	B
21	Lytic	I
22	Factor	I
23	and	O
24	Phospholipase	B
25	-	I
26	A	I
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O

1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	The	O
2	length	O
3	scales	O
4	of	O
5	the	O
6	turbulence	O
7	were	O
8	also	O
9	estimated	O
10	:	O
11	at	O
12	a	O
13	Reynolds	O
14	number	O
15	near	O
16	4	O
17	,	O
18	000	O
19	the	O
20	macroscale	O
21	is	O
22	about	O
23	1	O
24	.	O
25	25	O
26	mm	O
27	,	O
28	the	O
29	Taylor	O
30	microscale	O
31	is	O
32	about	O
33	0	O
34	.	O
35	85	O
36	mm	O
37	,	O
38	and	O
39	the	O
40	Kolmogoroff	O
41	scale	O
42	is	O
43	near	O
44	0	O
45	.	O
46	075	O
47	mm	O
48	.	O

1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	No	O
2	hypotension	O
3	was	O
4	noted	O
5	in	O
6	patients	O
7	with	O
8	toxemia	O
9	and	O
10	only	O
11	2	O
12	ran	O
13	a	O
14	fever	O
15	above	O
16	37	O
17	.	O
18	5	O
19	degrees	O
20	C	O
21	.	O

1	The	O
2	sera	O
3	and	O
4	nasal	O
5	secretions	O
6	of	O
7	142	O
8	patients	O
9	,	O
10	who	O
11	were	O
12	positive	O
13	in	O
14	HD	O
15	or	O
16	mites	O
17	skin	O
18	test	O
19	,	O
20	were	O
21	subjected	O
22	to	O
23	a	O
24	radioallergosorbent	O
25	test	O
26	(	O
27	RAST	O
28	)	O
29	for	O
30	estimating	O
31	the	O
32	specific	O
33	IgE	B
34	antibody	I
35	activity	O
36	to	O
37	mites	O
38	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	Diallylnitrosamine	O
2	(	O
3	DAN	O
4	),	O
5	one	O
6	of	O
7	the	O
8	few	O
9	nitrosamines	O
10	tested	O
11	thus	O
12	far	O
13	that	O
14	has	O
15	not	O
16	induced	O
17	neoplasms	O
18	in	O
19	rats	O
20	,	O
21	caused	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	respiratory	O
27	tract	O
28	tumors	O
29	in	O
30	Syrian	O
31	golden	O
32	hamsters	O
33	treated	O
34	sc	O
35	with	O
36	single	O
37	or	O
38	weekly	O
39	doses	O
40	of	O
41	the	O
42	compound	O
43	.	O

1	Near	O
2	term	O
3	,	O
4	under	O
5	experimental	O
6	conditions	O
7	,	O
8	maternal	O
9	and	O
10	fetal	O
11	blood	O
12	gases	O
13	,	O
14	pH	O
15	,	O
16	uterine	O
17	and	O
18	umbilical	O
19	blood	O
20	flows	O
21	were	O
22	measured	O
23	or	O
24	calculated	O
25	.	O

1	Haemodynamic	O
2	responses	O
3	to	O
4	antagonism	O
5	of	O
6	bocurarine	O
7	block	O
8	with	O
9	atropine	O
10	-	O
11	neostigmine	O
12	mixture	O
13	in	O
14	children	O
15	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	large	O
6	molecules	O
7	,	O
8	such	O
9	as	O
10	the	O
11	diphosphonate	O
12	99mTc	O
13	-	O
14	labeled	O
15	EHDP	O
16	or	O
17	99mTc	O
18	-	O
19	labeled	O
20	pyrophosphate	O
21	,	O
22	pass	O
23	through	O
24	capillaries	O
25	in	O
26	bone	O
27	is	O
28	by	O
29	passive	O
30	diffusion	O
31	.	O

1	Twenty	O
2	-	O
3	nine	O
4	days	O
5	after	O
6	injection	O
7	of	O
8	5	O
9	.	O
10	8	O
11	mCi	O
12	of	O
13	Tc	O
14	-	O
15	99m	O
16	,	O
17	which	O
18	gives	O
19	28	O
20	rads	O
21	to	O
22	the	O
23	testis	O
24	,	O
25	the	O
26	number	O
27	of	O
28	sperm	O
29	hads	O
30	decreased	O
31	to	O
32	70	O
33	%	O
34	of	O
35	control	O
36	.	O

1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O

1	Possibility	O
2	of	O
3	a	O
4	TSH	B
5	-	O
6	Screening	O
7	method	O
8	for	O
9	detection	O
10	of	O
11	hypothyroidism	O
12	in	O
13	the	O
14	newborn	O

1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	O
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	B
5	B	I
6	surface	I
7	antigen	I
8	(	O
9	HBsAg	B
10	)	O
11	and	O
12	anti	B
13	-	I
14	HBs	I
15	was	O
16	determined	O
17	by	O
18	a	O
19	sensitive	O
20	double	O
21	-	O
22	antibody	O
23	radio	O
24	-	O
25	immunoassay	O
26	technique	O
27	in	O
28	a	O
29	series	O
30	of	O
31	patients	O
32	with	O
33	chronic	O
34	liver	O
35	diseases	O
36	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	patients	O
6	with	O
7	acute	O
8	respiratory	O
9	failure	O
10	requiring	O
11	artificial	O
12	ventilation	O
13	have	O
14	two	O
15	componenents	O
16	of	O
17	the	O
18	pulmonary	O
19	shunt	O
20	,	O
21	one	O
22	parallel	O
23	with	O
24	and	O
25	the	O
26	other	O
27	inversely	O
28	related	O
29	with	O
30	the	O
31	PAO2	O
32	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	Biological	O
2	evaluation	O
3	of	O
4	mibolerone	O
5	in	O
6	the	O
7	female	O
8	Beagle	O
9	.	O

1	Levels	O
2	of	O
3	both	O
4	PGF	O
5	and	O
6	PGFM	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	labour	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	dilatation	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	labour	O
31	.	O

1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O

1	Propranolol	O
2	(	O
3	Inderal	O
4	)	O
5	administered	O
6	in	O
7	a	O
8	dose	O
9	which	O
10	blocks	O
11	the	O
12	beta	O
13	-	O
14	adrenergic	O
15	apparatus	O
16	of	O
17	the	O
18	heart	O
19	prevents	O
20	the	O
21	development	O
22	of	O
23	the	O
24	positive	O
25	inotropic	O
26	effect	O
27	of	O
28	therapeutic	O
29	doses	O
30	of	O
31	strophanthin	O
32	K	O
33	on	O
34	a	O
35	hypodynamic	O
36	left	O
37	ventricular	O
38	myocardium	O
39	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O

1	Scanning	O
2	electron	O
3	microscopic	O
4	investigations	O
5	on	O
6	the	O
7	formation	O
8	of	O
9	Reissner	O
10	'	O
11	s	O
12	fiber	O
13	in	O
14	Rattus	O
15	rattus	O

1	Feeding	O
2	behavior	O
3	,	O
4	circannual	O
5	body	O
6	weight	O
7	and	O
8	hibernation	O
9	rhythms	O
10	in	O
11	European	O
12	hamsters	O
13	lesioned	O
14	in	O
15	the	O
16	noradrenergic	O
17	ascending	O
18	bundles	O

1	Role	O
2	of	O
3	the	O
4	infectious	O
5	-	O
6	disease	O
7	specialist	O
8	of	O
9	a	O
10	polyclinic	O
11	in	O
12	reducing	O
13	the	O
14	incidence	O
15	of	O
16	communicable	O
17	diseases	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	Circulatory	O
2	arrest	O
3	in	O
4	the	O
5	operating	O
6	room	O
7	.	O

1	At	O
2	a	O
3	systolic	O
4	blood	O
5	pressure	O
6	(	O
7	BP	O
8	)	O
9	of	O
10	60	O
11	mmHg	O
12	,	O
13	C02	O
14	responsiveness	O
15	was	O
16	abolished	O
17	,	O
18	but	O
19	was	O
20	maintained	O
21	at	O
22	higher	O
23	levels	O
24	of	O
25	BP	O
26	.	O

1	Iodine	O
2	-	O
3	123	O
4	was	O
5	satisfactorily	O
6	imaged	O
7	only	O
8	with	O
9	the	O
10	MEC	O
11	and	O
12	pinhole	O
13	collimators	O
14	,	O
15	which	O
16	in	O
17	turn	O
18	yielded	O
19	MTF	O
20	values	O
21	comparable	O
22	to	O
23	those	O
24	measured	O
25	for	O
26	99mTc	O
27	.	O

1	Petrous	O
2	meningioma	O
3	en	O
4	plaque	O
5	presenting	O
6	as	O
7	a	O
8	right	O
9	middle	O
10	ear	O
11	tumor	O
12	.	O

1	The	O
2	difficulties	O
3	to	O
4	analyse	O
5	prostaglandins	O
6	(	O
7	PG	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	chromatograph	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	packed	O
42	columns	O
43	.	O

1	On	O
2	cessation	O
3	of	O
4	steroid	O
5	therapy	O
6	the	O
7	patient	O
8	was	O
9	noted	O
10	to	O
11	have	O
12	radiologic	O
13	manifestations	O
14	of	O
15	hypertrophic	O
16	osteoarthropathy	O
17	(	O
18	HOA	O
19	)	O
20	as	O
21	well	O
22	as	O
23	clinical	O
24	and	O
25	laboratory	O
26	features	O
27	of	O
28	rheumatoid	O
29	arthritis	O
30	(	O
31	RA	O
32	).	O

1	The	O
2	effect	O
3	of	O
4	food	O
5	on	O
6	procainamide	O
7	absorption	O
8	.	O

1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	O
61	-	O
62	2	O
63	-	O
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O

1	RESULTS	O
2	:	O
3	Total	O
4	IgE	B
5	levels	O
6	showed	O
7	a	O
8	tendency	O
9	to	O
10	diminish	O
11	.	O

1	Does	O
2	afferent	O
3	loop	O
4	syndrome	O
5	exist	O
6	?]	O
7	It	O
8	is	O
9	the	O
10	author	O
11	'	O
12	s	O
13	opinion	O
14	that	O
15	diagnosis	O
16	of	O
17	the	O
18	"	O
19	adducent	O
20	loop	O
21	syndrome	O
22	"	O
23	is	O
24	unlikely	O
25	to	O
26	be	O
27	correct	O
28	in	O
29	patients	O
30	subjected	O
31	to	O
32	Billroth	O
33	-	O
34	II	O
35	gastrectomy	O
36	.	O

1	Letter	O
2	:	O
3	Is	O
4	actinic	O
5	(	O
6	solar	O
7	)	O
8	damage	O
9	the	O
10	provoking	O
11	cause	O
12	of	O
13	'	O
14	post	O
15	-	O
16	inflammatory	O
17	elastolysis	O
18	and	O
19	cutis	O
20	laxa	O
21	(	O
22	PECL	O
23	)'?	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	O
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O

1	Batch	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	mutans	O
7	serotype	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	MSB	O
14	agar	O
15	.	O

1	Also	O
2	,	O
3	samples	O
4	of	O
5	serum	O
6	were	O
7	absorbed	O
8	with	O
9	the	O
10	various	O
11	solid	O
12	-	O
13	phase	O
14	allergens	O
15	and	O
16	the	O
17	reactivity	O
18	of	O
19	the	O
20	remaining	O
21	IgE	B
22	antibodies	I
23	was	O
24	determined	O
25	.	O

1	Crisis	O
2	of	O
3	the	O
4	therapeutic	O
5	community	O
6	in	O
7	Great	O
8	Britain	O

1	Pregnant	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	lowest	O
8	levels	O
9	of	O
10	antithrombin	B
11	III	I
12	.	O

1	Hematology	O
2	problem	O
3	of	O
4	the	O
5	month	O
6	:	O
7	band	O
8	or	O
9	seg	O
10	?	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O

1	I	O
2	.	O

1	The	O
2	recovered	O
3	calves	O
4	were	O
5	tested	O
6	for	O
7	immunity	O
8	to	O
9	homologous	O
10	severe	O
11	challenge	O
12	,	O
13	50	O
14	or	O
15	73	O
16	days	O
17	after	O
18	the	O
19	first	O
20	infection	O
21	.	O

1	The	O
2	performance	O
3	of	O
4	three	O
5	commonly	O
6	used	O
7	chemical	O
8	cartridge	O
9	respirators	O
10	for	O
11	SO2	O
12	was	O
13	measured	O
14	under	O
15	working	O
16	conditions	O
17	in	O
18	a	O
19	copper	O
20	smelter	O
21	.	O

1	The	O
2	neuroleptic	O
3	-	O
4	induced	O
5	increase	O
6	in	O
7	central	O
8	DA	O
9	turnover	O
10	(	O
11	an	O
12	indicator	O
13	for	O
14	the	O
15	degree	O
16	of	O
17	DA	B
18	receptor	I
19	blocking	O
20	)	O
21	was	O
22	found	O
23	to	O
24	be	O
25	positively	O
26	correlated	O
27	with	O
28	the	O
29	therapeutic	O
30	effect	O
31	of	O
32	neuroleptics	O
33	and	O
34	the	O
35	development	O
36	of	O
37	hypokinetic	O
38	-	O
39	rigid	O
40	symptoms	O
41	.	O

1	Rainbow	O
2	trout	O
3	were	O
4	obtained	O
5	from	O
6	a	O
7	commercial	O
8	trout	O
9	farm	O
10	,	O
11	kept	O
12	in	O
13	running	O
14	water	O
15	and	O
16	feeding	O
17	in	O
18	experimental	O
19	pellets	O
20	for	O
21	4	O
22	to	O
23	8	O
24	weeks	O
25	.	O

1	Stimulation	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	killed	O
7	Bordetella	O
8	pertussis	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	beneficial	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O

1	Primary	O
2	amenorrhoea	O
3	in	O
4	a	O
5	phenotypically	O
6	female	O
7	individual	O
8	with	O
9	a	O
10	karyotype	O
11	46	O
12	,	O
13	xy	O
14	and	O
15	bilateral	O
16	gonadoblastoma	O

1	Toward	O
2	absolute	O
3	methods	O
4	in	O
5	clinical	O
6	chemistry	O
7	:	O
8	application	O
9	of	O
10	mass	O
11	fragmentography	O
12	to	O
13	high	O
14	-	O
15	accuracy	O
16	analyses	O
17	.	O

1	Application	O
2	of	O
3	the	O
4	2	O
5	-	O
6	deoxy	O
7	-	O
8	D	O
9	-	O
10	glucose	O
11	method	O
12	to	O
13	the	O
14	coupling	O
15	of	O
16	cerebral	O
17	metabolism	O
18	and	O
19	blood	O
20	flow	O
21	.	O

1	Serum	O
2	gastrin	B
3	levels	O
4	did	O
5	not	O
6	change	O
7	in	O
8	either	O
9	group	O
10	;	O
11	however	O
12	,	O
13	background	O
14	serum	O
15	gastrin	B
16	concentrations	O
17	were	O
18	significantly	O
19	greater	O
20	for	O
21	V	O
22	&	O
23	P	O
24	patients	O
25	than	O
26	V	O
27	&	O
28	A	O
29	patients	O
30	throughout	O
31	the	O
32	study	O
33	.	O

1	Efferent	O
2	projections	O
3	of	O
4	the	O
5	ventral	O
6	portion	O
7	of	O
8	the	O
9	putamen	O
10	to	O
11	the	O
12	frontal	O
13	,	O
14	parietal	O
15	and	O
16	temporal	O
17	regions	O
18	of	O
19	the	O
20	cat	O
21	cerebral	O
22	cortex	O

1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	O
33	long	O
34	-	O
35	term	O
36	weightlessness	O
37	.	O

1	Mean	O
2	corpuscular	B
3	hemoglobin	I
4	concentrations	O
5	remained	O
6	normal	O
7	for	O
8	48	O
9	h	O
10	and	O
11	then	O
12	decreased	O
13	in	O
14	both	O
15	groups	O
16	,	O
17	the	O
18	CO2	O
19	group	O
20	showing	O
21	the	O
22	larger	O
23	decrease	O
24	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	calcitonin	B
5	,	O
6	a	O
7	large	O
8	amount	O
9	of	O
10	calcium	O
11	given	O
12	orally	O
13	,	O
14	pentagastrin	O
15	and	O
16	glucagon	B
17	on	O
18	plasma	O
19	47Ca	O
20	radioactivity	O
21	curves	O
22	in	O
23	subjects	O
24	pretreated	O
25	with	O
26	47Ca	O
27	was	O
28	examined	O
29	.	O

1	State	O
2	of	O
3	the	O
4	body	O
5	in	O
6	disorders	O
7	of	O
8	diurnal	O
9	physiological	O
10	rhythms	O
11	and	O
12	long	O
13	-	O
14	term	O
15	hypokinesia	O

1	Oxygen	O
2	tension	O
3	of	O
4	the	O
5	small	O
6	lymph	O
7	vessels	O
8	(	O
9	PLO2	O
10	)	O
11	of	O
12	the	O
13	rabbit	O
14	hind	O
15	limb	O
16	was	O
17	measured	O
18	with	O
19	both	O
20	a	O
21	flow	O
22	-	O
23	through	O
24	micro	O
25	chamber	O
26	and	O
27	a	O
28	polarographic	O
29	catheter	O
30	-	O
31	tip	O
32	oxygen	O
33	electrode	O
34	to	O
35	obtain	O
36	experimental	O
37	data	O
38	on	O
39	the	O
40	source	O
41	of	O
42	oxygen	O
43	in	O
44	the	O
45	lymph	O
46	.	O

1	The	O
2	response	O
3	of	O
4	the	O
5	plasma	B
6	fibrinogen	I
7	level	O
8	to	O
9	the	O
10	subucutaneous	O
11	injection	O
12	of	O
13	turpentine	O
14	and	O
15	to	O
16	the	O
17	intravenous	O
18	injection	O
19	of	O
20	endotoxin	O
21	was	O
22	measured	O
23	in	O
24	normal	O
25	rabbits	O
26	and	O
27	in	O
28	rabbits	O
29	made	O
30	granulocytopenic	O
31	and	O
32	thrombocytopenic	O
33	with	O
34	busulfan	O
35	.	O

1	Constantly	O
2	rectilinear	O
3	pressure	O
4	curves	O
5	without	O
6	uterine	O
7	activities	O
8	are	O
9	interpreted	O
10	as	O
11	characteristic	O
12	tocographic	O
13	criteria	O
14	of	O
15	an	O
16	advanced	O
17	ectopic	O
18	gravidity	O
19	.	O

1	Since	O
2	myoglobin	B
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	E	O
2	50	O
3	,	O
4	843	O
5	(	O
6	1994	O
7	)].	O

1	Six	O
2	patients	O
3	with	O
4	the	O
5	diagnosis	O
6	of	O
7	acute	O
8	mania	O
9	were	O
10	treated	O
11	with	O
12	high	O
13	doses	O
14	of	O
15	the	O
16	beta	O
17	-	O
18	adrenergic	O
19	blocking	O
20	agent	O
21	propranolol	O
22	.	O

1	Effect	O
2	of	O
3	trauma	O
4	on	O
5	plasma	B
6	glucagon	I
7	and	O
8	insulin	B
9	concentrations	O
10	in	O
11	sheep	O
12	.	O

1	With	O
2	the	O
3	help	O
4	of	O
5	a	O
6	nomogram	O
7	one	O
8	can	O
9	read	O
10	off	O
11	the	O
12	refraction	O
13	,	O
14	when	O
15	axis	O
16	length	O
17	and	O
18	corneal	O
19	curvature	O
20	are	O
21	known	O
22	.	O

1	This	O
2	up	O
3	-	O
4	grading	O
5	of	O
6	the	O
7	final	O
8	score	O
9	by	O
10	the	O
11	CA	O
12	component	O
13	is	O
14	greater	O
15	(	O
16	3	O
17	-	O
18	8	O
19	%)	O
20	in	O
21	the	O
22	less	O
23	able	O
24	students	O
25	with	O
26	scores	O
27	below	O
28	the	O
29	mean	O
30	level	O
31	.	O

1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	O
11	tracing	O

1	Dual	O
2	innervation	O
3	of	O
4	fast	O
5	fibers	O
6	in	O
7	trunk	O
8	muscles	O
9	of	O
10	lamprey	O
11	larvae	O

1	The	O
2	feed	O
3	consumed	O
4	which	O
5	was	O
6	lowered	O
7	by	O
8	25	O
9	%	O
10	initially	O
11	,	O
12	did	O
13	not	O
14	alter	O
15	later	O
16	.	O

1	Certain	O
2	characteristics	O
3	of	O
4	eye	O
5	changes	O
6	in	O
7	patients	O
8	with	O
9	pheochromocytoma	O
10	including	O
11	Sipple	O
12	'	O
13	s	O
14	syndrome	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	B
18	--	I
19	phenylalanine	I
20	-	I
21	8	I
22	-	I
23	lysine	I
24	vasopressin	I
25	(	O
26	Octapressin	B
27	).	O

1	Potscoital	O
2	test	O

1	I	O
2	.	O

1	When	O
2	a	O
3	tumour	O
4	is	O
5	present	O
6	nipple	O
7	discharge	O
8	is	O
9	of	O
10	little	O
11	importance	O
12	for	O
13	the	O
14	diagnosis	O
15	and	O
16	treatment	O
17	.	O

1	Studies	O
2	of	O
3	biochemical	O
4	and	O
5	morphological	O
6	changes	O
7	(	O
8	between	O
9	normal	O
10	and	O
11	treated	O
12	animals	O
13	)	O
14	show	O
15	that	O
16	chrysotile	O
17	induces	O
18	an	O
19	increase	O
20	in	O
21	the	O
22	lung	O
23	free	O
24	cell	O
25	population	O
26	and	O
27	pulmonary	O
28	surfactant	O
29	levels	O
30	.	O

1	Infrared	O
2	measurements	O
3	of	O
4	temperature	O
5	changes	O
6	and	O
7	estimates	O
8	of	O
9	the	O
10	heating	O
11	produced	O
12	at	O
13	the	O
14	mical	O
15	.	O

1	Who	O
2	says	O
3	'	O
4	National	O
5	Health	O
6	Dis	O
7	-	O
8	service	O
9	'.	O

1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	O
7	and	O
8	does	O
9	it	O
10	have	O
11	educational	O
12	value	O
13	?	O
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	O
19	improved	O
20	patient	O
21	care	O

1	Critique	O
2	of	O
3	"	O
4	Interactive	O
5	Effects	O
6	of	O
7	Test	O
8	Anxiety	O
9	and	O
10	Credit	O
11	/	O
12	No	O
13	Credit	O
14	or	O
15	A	O
16	-	O
17	F	O
18	Grade	O
19	Condition	O
20	upon	O
21	Short	O
22	-	O
23	term	O
24	and	O
25	Long	O
26	-	O
27	term	O
28	Recall	O
29	of	O
30	Course	O
31	Information	O
32	.	O

1	These	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	majority	O
8	of	O
9	tested	O
10	staphylococci	O
11	were	O
12	resistant	O
13	to	O
14	penicillin	O
15	G	O
16	,	O
17	erythromycin	O
18	,	O
19	and	O
20	produced	O
21	beta	B
22	-	I
23	lactamase	I
24	.	O

1	Since	O
2	1968	O
3	,	O
4	a	O
5	steep	O
6	decrease	O
7	in	O
8	the	O
9	number	O
10	of	O
11	strains	O
12	resistant	O
13	to	O
14	three	O
15	or	O
16	more	O
17	antibiotics	O
18	(	O
19	multiple	O
20	-	O
21	resistant	O
22	)	O
23	and	O
24	in	O
25	strains	O
26	of	O
27	the	O
28	83A	O
29	complex	O
30	was	O
31	noticed	O
32	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O

1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O

1	The	O
2	contraceptive	O
3	pattern	O
4	of	O
5	157	O
6	women	O
7	was	O
8	analysed	O
9	and	O
10	13	O
11	.	O
12	8	O
13	percent	O
14	were	O
15	using	O
16	inefficient	O
17	methods	O
18	.	O

1	Plethysmographic	O
2	technique	O
3	and	O
4	indirect	O
5	blood	O
6	pressure	O
7	recordings	O
8	were	O
9	used	O
10	.	O

1	I	O
2	.	O

1	The	O
2	second	O
3	and	O
4	third	O
5	responded	O
6	similarly	O
7	to	O
8	either	O
9	a	O
10	combined	O
11	cyclophosphamide	O
12	+	O
13	antilymphocyte	B
14	globulin	I
15	(	O
16	ALG	B
17	)	O
18	treatment	O
19	or	O
20	to	O
21	ALG	B
22	administration	O
23	preceded	O
24	by	O
25	a	O
26	small	O
27	dosage	O
28	of	O
29	cyclophosphamide	O
30	,	O
31	which	O
32	had	O
33	proved	O
34	ineffective	O
35	when	O
36	administered	O
37	alone	O
38	.	O

1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O

1	Fibrin	B
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	mobile	O
6	pupil	O
7	on	O
8	the	O
9	response	O
10	in	O
11	the	O
12	DC	O
13	-	O
14	ERG	O
15	is	O
16	demonstrated	O
17	.	O

1	A	O
2	newly	O
3	synthesized	O
4	anti	O
5	-	O
6	inflammatory	O
7	agent	O
8	,	O
9	Y	O
10	-	O
11	8004	O
12	demonstrated	O
13	a	O
14	greater	O
15	inhibition	O
16	than	O
17	did	O
18	indomethacin	O
19	(	O
20	IM	O
21	).	O
22	on	O
23	inflammatory	O
24	response	O
25	such	O
26	as	O
27	ultraviolet	O
28	erythema	O
29	in	O
30	guinea	O
31	pigs	O
32	,	O
33	carrageenin	O
34	edema	O
35	,	O
36	evans	O
37	blue	O
38	and	O
39	carrageenin	O
40	-	O
41	induced	O
42	pleuritis	O
43	and	O
44	acetic	O
45	acid	O
46	-	O
47	induced	O
48	peritonitis	O
49	in	O
50	rats	O
51	.	O

1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O

1	Alpha	B
2	-	I
3	1	I
4	antitrypsin	I
5	and	O
6	Indian	O
7	childhood	O
8	cirrhosis	O
9	.	O

1	Lymphocyte	O
2	subpopulations	O
3	,	O
4	serum	B
5	IgE	I
6	and	O
7	total	O
8	eosinophil	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O

1	A	O
2	range	O
3	of	O
4	normal	O
5	ventricular	O
6	measurements	O
7	for	O
8	the	O
9	EMI	O
10	scan	O
11	is	O
12	suggested	O
13	.	O

1	A	O
2	comparison	O
3	of	O
4	physical	O
5	and	O
6	cytogenetic	O
7	estimates	O
8	of	O
9	radiation	O
10	dose	O
11	in	O
12	patients	O
13	treated	O
14	with	O
15	iodine	O
16	-	O
17	131	O
18	for	O
19	thyroid	O
20	carcinoma	O
21	.	O

1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O

1	Mean	O
2	total	O
3	lung	O
4	capacity	O
5	,	O
6	functional	O
7	residual	O
8	capacity	O
9	,	O
10	and	O
11	residual	O
12	volume	O
13	increased	O
14	significantly	O
15	,	O
16	and	O
17	the	O
18	mean	O
19	closing	O
20	volume	O
21	,	O
22	the	O
23	lung	O
24	volume	O
25	above	O
26	residual	O
27	volume	O
28	at	O
29	which	O
30	phase	O
31	IV	O
32	begins	O
33	,	O
34	decreased	O
35	significantly	O
36	with	O
37	11	O
38	cm	O
39	H20	O
40	continuous	O
41	positive	O
42	airway	O
43	pressure	O
44	;	O
45	differences	O
46	at	O
47	5	O
48	cm	O
49	H20	O
50	were	O
51	not	O
52	significant	O
53	.	O

1	Current	O
2	status	O
3	of	O
4	zinc	O
5	deficiency	O
6	in	O
7	the	O
8	pathogenesis	O
9	of	O
10	neurological	O
11	,	O
12	dermatological	O
13	and	O
14	musculoskeletal	O
15	disorders	O
16	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	Modern	O
2	studies	O
3	,	O
4	conducted	O
5	with	O
6	Delta	O
7	-	O
8	9	O
9	-	O
10	THC	O
11	,	O
12	in	O
13	healthy	O
14	voluntaries	O
15	,	O
16	again	O
17	suggest	O
18	the	O
19	comparison	O
20	or	O
21	even	O
22	the	O
23	identity	O
24	of	O
25	the	O
26	modifications	O
27	caused	O
28	by	O
29	cannabis	O
30	with	O
31	sleep	O
32	and	O
33	dream	O
34	.	O

1	The	O
2	correcting	O
3	action	O
4	of	O
5	tropatepine	O
6	hydrochloride	O
7	upon	O
8	the	O
9	extrapyramidal	O
10	effects	O
11	induced	O
12	by	O
13	neuroleptics	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	psychotic	O
21	states	O
22	.	O

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O

1	Results	O
2	obtained	O
3	for	O
4	chloramphenicol	O
5	-	O
6	containing	O
7	preparations	O
8	are	O
9	presented	O
10	,	O
11	and	O
12	both	O
13	dissolution	O
14	curves	O
15	and	O
16	cup	O
17	-	O
18	plate	O
19	assays	O
20	demonstrate	O
21	that	O
22	chloramphenicol	O
23	has	O
24	far	O
25	superior	O
26	release	O
27	(	O
28	and	O
29	hence	O
30	activity	O
31	)	O
32	from	O
33	creams	O
34	than	O
35	from	O
36	ophthalmic	O
37	ointments	O
38	.	O

1	IgG	B
2	levels	O
3	of	O
4	1	O
5	/	O
6	100	O
7	were	O
8	present	O
9	in	O
10	only	O
11	four	O
12	out	O
13	of	O
14	ten	O
15	samples	O
16	obtained	O
17	150	O
18	days	O
19	after	O
20	the	O
21	clinical	O
22	onset	O
23	.	O

1	Letter	O
2	:	O
3	Perspectives	O
4	in	O
5	bone	O
6	marrow	O
7	transplantation	O
8	.	O

1	Assessment	O
2	of	O
3	the	O
4	carcinogenicity	O
5	of	O
6	non	O
7	-	O
8	nutritive	O
9	sweetners	O
10	II	O
11	:	O
12	Cyclamates	O
13	and	O
14	cyclohexylamine	O
15	.	O

1	The	O
2	discordant	O
3	behaviour	O
4	in	O
5	weakly	O
6	infected	O
7	mice	O
8	was	O
9	due	O
10	to	O
11	the	O
12	occurrence	O
13	in	O
14	some	O
15	animals	O
16	of	O
17	a	O
18	second	O
19	phase	O
20	of	O
21	more	O
22	rapid	O
23	increase	O
24	of	O
25	the	O
26	parasitemia	O
27	.	O

1	Residual	O
2	amphotericin	O
3	B	O
4	was	O
5	detected	O
6	in	O
7	the	O
8	feces	O
9	of	O
10	the	O
11	mice	O
12	only	O
13	while	O
14	they	O
15	were	O
16	receiving	O
17	the	O
18	0	O
19	.	O
20	3	O
21	mg	O
22	/	O
23	ml	O
24	dose	O
25	level	O
26	.	O

1	There	O
2	was	O
3	a	O
4	slight	O
5	increase	O
6	in	O
7	total	O
8	transferrin	B
9	2	O
10	hr	O
11	after	O
12	1	O
13	tablet	O
14	and	O
15	values	O
16	remained	O
17	high	O
18	throughout	O
19	the	O
20	experiment	O
21	.	O

1	Following	O
2	intravenous	O
3	administration	O
4	,	O
5	the	O
6	myocardial	O
7	concentration	O
8	of	O
9	tracer	O
10	thallium	O
11	-	O
12	201	O
13	,	O
14	potassium	O
15	-	O
16	43	O
17	,	O
18	and	O
19	rubidium	O
20	-	O
21	81	O
22	were	O
23	determined	O
24	in	O
25	mice	O
26	;	O
27	thallium	O
28	was	O
29	present	O
30	in	O
31	the	O
32	greatest	O
33	concentration	O
34	in	O
35	the	O
36	myocardium	O
37	(	O
38	2	O
39	.	O
40	08	O
41	%	O
42	compared	O
43	1	O
44	.	O
45	25	O
46	%	O
47	for	O
48	potassium	O
49	and	O
50	1	O
51	.	O
52	15	O
53	%	O
54	for	O
55	rubidium	O
56	at	O
57	10	O
58	minutes	O
59	).	O

1	Thromboplastin	B
2	time	O
3	,	O
4	partial	O
5	thromboplastin	B
6	time	O
7	,	O
8	thrombin	B
9	time	O
10	,	O
11	heat	O
12	-	O
13	dependent	O
14	fibrin	B
15	,	O
16	clot	O
17	retraction	O
18	,	O
19	and	O
20	clotting	B
21	factors	I
22	II	I
23	,	I
24	V	I
25	,	I
26	VIII	I
27	,	I
28	IX	I
29	,	I
30	X	I
31	,	O
32	and	O
33	the	O
34	platelet	O
35	count	O
36	were	O
37	determined	O
38	.	O

1	The	O
2	data	O
3	support	O
4	the	O
5	notion	O
6	that	O
7	suppression	O
8	of	O
9	images	O
10	during	O
11	binocular	O
12	rivalry	O
13	is	O
14	independent	O
15	in	O
16	both	O
17	eyes	O
18	.	O

1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	O
11	phosphate	O
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O

1	The	O
2	records	O
3	from	O
4	1948	O
5	through	O
6	1967	O
7	of	O
8	344	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	squamous	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	oropharynx	O
22	,	O
23	supraglottic	O
24	larynx	O
25	and	O
26	hypopharynx	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	metastases	O
35	staged	O
36	N1	O
37	,	O
38	N2A	O
39	,	O
40	or	O
41	N2B	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O

1	With	O
2	0	O
3	.	O
4	5	O
5	vol	O
6	.-%,	O
7	the	O
8	corresponding	O
9	values	O
10	were	O
11	345	O
12	mumol	O
13	/	O
14	1	O
15	(	O
16	5	O
17	.	O
18	72	O
19	mg	O
20	/	O
21	100	O
22	ml	O
23	)	O
24	and	O
25	137	O
26	mumol	O
27	/	O
28	1	O
29	(	O
30	2	O
31	.	O
32	25	O
33	mg	O
34	/	O
35	100	O
36	ml	O
37	)	O
38	respectively	O
39	.	O

1	The	O
2	authors	O
3	describe	O
4	the	O
5	technique	O
6	of	O
7	transverse	O
8	axial	O
9	tomography	O
10	of	O
11	the	O
12	spine	O
13	and	O
14	give	O
15	a	O
16	detailed	O
17	description	O
18	of	O
19	the	O
20	axial	O
21	anatomy	O
22	of	O
23	the	O
24	normal	O
25	lumbar	O
26	spine	O
27	from	O
28	L	O
29	-	O
30	4	O
31	to	O
32	the	O
33	sacrum	O
34	.	O

1	Owing	O
2	to	O
3	parental	O
4	attitude	O
5	,	O
6	a	O
7	low	O
8	protein	O
9	diet	O
10	(	O
11	1	O
12	-	O
13	5	O
14	g	O
15	/	O
16	kg	O
17	)	O
18	was	O
19	introduced	O
20	only	O
21	late	O
22	.	O

1	In	O
2	none	O
3	of	O
4	the	O
5	44	O
6	type	O
7	I	O
8	attacks	O
9	and	O
10	29	O
11	type	O
12	II	O
13	attacks	O
14	which	O
15	were	O
16	recorded	O
17	did	O
18	circulatory	O
19	changes	O
20	;	O
21	the	O
22	latter	O
23	were	O
24	different	O
25	in	O
26	the	O
27	two	O
28	groups	O
29	.	O

1	A	O
2	clinically	O
3	useful	O
4	diagnostic	O
5	method	O
6	has	O
7	been	O
8	developed	O
9	for	O
10	detecting	O
11	and	O
12	quantitating	O
13	periods	O
14	of	O
15	apnea	O
16	in	O
17	pediatric	O
18	patients	O
19	.	O

1	The	O
2	other	O
3	hypoglycaemic	O
4	patient	O
5	showed	O
6	an	O
7	exaggerated	O
8	insulin	B
9	release	O
10	in	O
11	response	O
12	to	O
13	tolbutamide	O
14	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	Effect	O
2	of	O
3	ingestion	O
4	of	O
5	Norbiogest	O
6	during	O
7	the	O
8	quiescent	O
9	period	O
10	of	O
11	the	O
12	genital	O
13	organs	O

1	Risk	O
2	of	O
3	infection	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	fractures	O

1	Bulbar	O
2	pouches	O
3	were	O
4	perfused	O
5	with	O
6	solutions	O
7	of	O
8	0	O
9	.	O
10	9	O
11	%	O
12	Na	O
13	C1	O
14	,	O
15	0	O
16	.	O
17	1	O
18	N	O
19	HC1	O
20	,	O
21	40	O
22	%	O
23	glucose	O
24	,	O
25	40	O
26	%	O
27	NaC1	O
28	,	O
29	and	O
30	40	O
31	%	O
32	peptone	O
33	or	O
34	with	O
35	0	O
36	.	O
37	1	O
38	%	O
39	solutions	O
40	of	O
41	acetylcholine	O
42	chloride	O
43	.	O

1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	B
14	hydrase	I
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O

1	Prolonged	O
2	heavy	O
3	work	O
4	effected	O
5	an	O
6	increase	O
7	of	O
8	10	O
9	.	O
10	3	O
11	plus	O
12	or	O
13	minus	O
14	0	O
15	.	O
16	9	O
17	mmHg	O
18	in	O
19	in	O
20	vivo	O
21	P50	O
22	(	O
23	7	O
24	.	O
25	30	O
26	PH	O
27	-	O
28	v	O
29	,	O
30	41	O
31	degrees	O
32	C	O
33	-	O
34	v	O
35	,	O
36	and	O
37	45	O
38	Pv	O
39	-	O
40	CO2	O
41	);	O
42	due	O
43	entirely	O
44	to	O
45	the	O
46	additive	O
47	effects	O
48	of	O
49	increased	O
50	venous	O
51	temperature	O
52	and	O
53	[	O
54	H	O
55	+].	O

1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O

1	The	O
2	American	O
3	Burkitt	O
4	Lymphoma	O
5	Registry	O
6	:	O
7	a	O
8	progress	O
9	report	O
10	.	O

1	Vitrectomy	O
2	with	O
3	an	O
4	alternative	O
5	instrument	O
6	system	O
7	.	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	B
10	luteinizing	I
11	hormone	I
12	(	O
13	Sairam	O
14	,	O
15	M	O
16	.	O

1	The	O
2	mean	O
3	plasma	O
4	sodium	O
5	concentration	O
6	which	O
7	was	O
8	135	O
9	.	O
10	95	O
11	(+/-	O
12	SD	O
13	4	O
14	.	O
15	14	O
16	)	O
17	mEq	O
18	/	O
19	kg	O
20	before	O
21	diuretic	O
22	treatment	O
23	was	O
24	significantly	O
25	decreased	O
26	during	O
27	treatment	O
28	to	O
29	129	O
30	.	O
31	19	O
32	(+/-	O
33	SD	O
34	2	O
35	.	O
36	77	O
37	)	O
38	mEq	O
39	/	O
40	kg	O
41	,	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	.	O

1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O

1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O

1	Effects	O
2	of	O
3	perceptual	O
4	salience	O
5	on	O
6	the	O
7	matrix	O
8	task	O
9	performance	O
10	of	O
11	four	O
12	-	O
13	and	O
14	six	O
15	-	O
16	year	O
17	-	O
18	old	O
19	children	O
20	.	O

1	Glucose	B
2	-	I
3	6	I
4	-	I
5	phosphate	I
6	dehydrogenase	I
7	(	O
8	G	B
9	-	I
10	6	I
11	-	I
12	PD	I
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O

1	The	O
2	eluting	O
3	solvent	O
4	was	O
5	methanol	O
6	-	O
7	chloroform	O
8	(	O
9	10	O
10	+	O
11	90	O
12	)	O
13	at	O
14	a	O
15	flow	O
16	rate	O
17	of	O
18	2	O
19	.	O
20	0	O
21	ml	O
22	/	O
23	min	O
24	.	O

1	The	O
2	bronchial	O
3	epithelia	O
4	of	O
5	all	O
6	smoke	O
7	-	O
8	exposed	O
9	animals	O
10	were	O
11	hyperplastic	O
12	,	O
13	and	O
14	their	O
15	ultrastructure	O
16	showed	O
17	invaginations	O
18	,	O
19	tilt	O
20	of	O
21	nuclear	O
22	axes	O
23	,	O
24	an	O
25	increase	O
26	in	O
27	the	O
28	number	O
29	and	O
30	size	O
31	of	O
32	lysosomes	O
33	and	O
34	multivesiculated	O
35	bodies	O
36	,	O
37	and	O
38	increased	O
39	numbers	O
40	of	O
41	enlarged	O
42	intramitochondrial	O
43	granules	O
44	.	O

1	The	O
2	routine	O
3	administration	O
4	of	O
5	fat	O
6	-	O
7	soluble	O
8	vitamins	O
9	appears	O
10	unnecessary	O
11	but	O
12	it	O
13	is	O
14	prudent	O
15	to	O
16	measure	O
17	prothrombin	B
18	time	O
19	and	O
20	serum	O
21	vitamins	O
22	A	O
23	and	O
24	E	O
25	at	O
26	intervals	O
27	.	O

1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O

1	Before	O
2	this	O
3	date	O
4	,	O
5	the	O
6	drug	O
7	directly	O
8	inhibits	O
9	fetal	O
10	weight	O
11	gain	O
12	,	O
13	whereas	O
14	the	O
15	sensitivity	O
16	of	O
17	the	O
18	placenta	O
19	is	O
20	only	O
21	transient	O
22	at	O
23	day	O
24	16	O
25	resulting	O
26	in	O
27	maximum	O
28	weight	O
29	decrease	O
30	of	O
31	this	O
32	organ	O
33	24	O
34	h	O
35	later	O
36	.	O

1	Groups	O
2	of	O
3	ten	O
4	dependent	O
5	and	O
6	ten	O
7	saline	O
8	mice	O
9	were	O
10	singly	O
11	tested	O
12	in	O
13	both	O
14	light	O
15	and	O
16	dark	O
17	conditions	O
18	in	O
19	each	O
20	of	O
21	five	O
22	covered	O
23	cylinders	O
24	(	O
25	2	O
26	-	O
27	23	O
28	in	O
29	high	O
30	).	O

1	The	O
2	effects	O
3	initiated	O
4	from	O
5	the	O
6	nucleus	O
7	accumbens	O
8	septi	O
9	were	O
10	most	O
11	marked	O
12	.	O

1	The	O
2	appearance	O
3	of	O
4	dyskinetic	O
5	movement	O
6	disorders	O
7	in	O
8	humans	O
9	following	O
10	the	O
11	chronic	O
12	use	O
13	of	O
14	levodopa	O
15	or	O
16	amphetamine	O
17	may	O
18	be	O
19	a	O
20	manifestation	O
21	of	O
22	similarly	O
23	increased	O
24	dopamine	B
25	receptor	I
26	site	I
27	sensitivity	O
28	within	O
29	the	O
30	striatum	O
31	.	O

1	Association	O
2	with	O
3	HL	B
4	-	I
5	A	I
6	W	I
7	-	I
8	27	I
9	.	O

1	Letter	O
2	:	O
3	Lactose	O
4	tolerance	O
5	tests	O
6	as	O
7	a	O
8	predictor	O
9	of	O
10	milk	O
11	tolerance	O
12	.	O

1	Retinoblastoma	O
2	:	O
3	a	O
4	study	O
5	of	O
6	natural	O
7	history	O
8	and	O
9	prognosis	O
10	of	O
11	268	O
12	cases	O
13	.	O

1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O

1	D	O
2	.	O

1	Atherosclerosis	O

1	The	O
2	authors	O
3	concluded	O
4	that	O
5	ultrasonic	O
6	Doppler	O
7	-	O
8	cardiography	O
9	can	O
10	be	O
11	used	O
12	for	O
13	measuring	O
14	the	O
15	relative	O
16	changes	O
17	in	O
18	the	O
19	stroke	O
20	volume	O
21	.	O

1	The	O
2	attainment	O
3	of	O
4	sexual	O
5	maturity	O
6	in	O
7	terms	O
8	of	O
9	secondary	O
10	sexual	O
11	characteristics	O
12	,	O
13	the	O
14	production	O
15	of	O
16	spermatozoa	O
17	in	O
18	the	O
19	male	O
20	,	O
21	and	O
22	the	O
23	cyclical	O
24	female	O
25	pattern	O
26	with	O
27	release	O
28	of	O
29	ova	O
30	are	O
31	end	O
32	-	O
33	points	O
34	of	O
35	the	O
36	developmental	O
37	process	O
38	.	O

1	However	O
2	,	O
3	a	O
4	10	O
5	--	O
6	15	O
7	%	O
8	lengthening	O
9	of	O
10	the	O
11	partial	O
12	thromboplastin	B
13	time	O
14	is	O
15	evident	O
16	after	O
17	24	O
18	hours	O
19	of	O
20	storage	O
21	.	O

1	Caution	O
2	should	O
3	be	O
4	exercised	O
5	in	O
6	the	O
7	use	O
8	of	O
9	these	O
10	dyes	O
11	for	O
12	lymphograms	O
13	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Three	O
2	groups	O
3	of	O
4	patients	O
5	who	O
6	had	O
7	undergone	O
8	subtotal	O
9	thyroidectomy	O
10	for	O
11	Graves	O
12	'	O
13	s	O
14	disease	O
15	,	O
16	toxic	O
17	multinodular	O
18	goitre	O
19	,	O
20	or	O
21	euthyroid	O
22	multinodular	O
23	goitre	O
24	12	O
25	to	O
26	15	O
27	years	O
28	before	O
29	and	O
30	in	O
31	whom	O
32	a	O
33	normal	O
34	serum	O
35	thyroxine	O
36	(	O
37	T	O
38	-	O
39	4	O
40	)	O
41	level	O
42	was	O
43	found	O
44	were	O
45	each	O
46	divided	O
47	into	O
48	two	O
49	subgroups	O
50	on	O
51	the	O
52	basis	O
53	of	O
54	a	O
55	normal	O
56	or	O
57	a	O
58	raised	O
59	serum	O
60	thyrotrophin	B
61	concentration	O
62	.	O

1	Routine	O
2	isotope	O
3	cystography	O
4	using	O
5	99M	O
6	Tc	O
7	sulfur	O
8	colloid	O
9	for	O
10	detection	O
11	and	O
12	follow	O
13	-	O
14	up	O
15	of	O
16	vesico	O
17	-	O
18	ureteral	O
19	reflux	O

1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O

1	No	O
2	evidence	O
3	of	O
4	either	O
5	positive	O
6	or	O
7	negative	O
8	chemography	O
9	was	O
10	found	O
11	.	O

1	The	O
2	interpretation	O
3	of	O
4	antibiotic	O
5	disc	O
6	sensitivities	O
7	.	O

1	Following	O
2	retransfusion	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	lining	O
8	appeared	O
9	greatly	O
10	distended	O
11	over	O
12	the	O
13	oedematous	O
14	lamina	O
15	propria	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	detail	O
24	.	O

1	A	O
2	study	O
3	of	O
4	chromosomes	O
5	of	O
6	lymphocytes	O
7	from	O
8	patients	O
9	treated	O
10	with	O
11	hycanthone	O
12	.	O

1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	Tobramycin	O
2	60	O
3	mg	O
4	did	O
5	not	O
6	show	O
7	any	O
8	remarkable	O
9	effect	O
10	,	O
11	but	O
12	dibecacin	O
13	100	O
14	mg	O
15	produced	O
16	a	O
17	slight	O
18	potentiating	O
19	effect	O
20	on	O
21	the	O
22	action	O
23	of	O
24	d	O
25	-	O
26	tubocurarine	O
27	.	O

1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O

1	The	O
2	specific	O
3	electrical	O
4	resistance	O
5	of	O
6	the	O
7	cerebrospinal	O
8	fluid	O
9	was	O
10	measured	O
11	by	O
12	means	O
13	of	O
14	conductometry	O
15	in	O
16	14	O
17	cases	O
18	of	O
19	meningitis	O
20	purulenta	O
21	,	O
22	17	O
23	cases	O
24	of	O
25	meningitis	O
26	serosa	O
27	,	O
28	10	O
29	cases	O
30	of	O
31	encephalitis	O
32	and	O
33	in	O
34	32	O
35	control	O
36	subjects	O
37	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	Besides	O
2	,	O
3	we	O
4	found	O
5	in	O
6	3	O
7	patients	O
8	increased	O
9	serum	B
10	immunoglobulins	I
11	,	O
12	chiefly	O
13	IgG	B
14	,	O
15	as	O
16	first	O
17	Russe	O
18	,	O
19	Busey	O
20	and	O
21	Barbeau	O
22	demonstrated	O
23	in	O
24	a	O
25	large	O
26	French	O
27	-	O
28	Canadian	O
29	family	O
30	.	O

1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O

1	Streptococcal	O
2	preparation	O
3	(	O
4	OK	O
5	-	O
6	432	O
7	),	O
8	a	O
9	new	O
10	type	O
11	of	O
12	anti	O
13	-	O
14	cancer	O
15	agent	O
16	,	O
17	was	O
18	given	O
19	to	O
20	the	O
21	patients	O
22	with	O
23	advanced	O
24	cancer	O
25	in	O
26	combination	O
27	with	O
28	Mitomycin	O
29	-	O
30	C	O
31	,	O
32	5	O
33	-	O
34	FU	O
35	and	O
36	Cytosine	O
37	arabinoside	O
38	.	O

1	Generally	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	highest	O
9	concentrations	O
10	of	O
11	CSF	B
12	immunoglobulins	I
13	and	O
14	degree	O
15	of	O
16	meningeal	O
17	inflammatory	O
18	response	O
19	,	O
20	even	O
21	if	O
22	this	O
23	was	O
24	a	O
25	component	O
26	of	O
27	other	O
28	neurological	O
29	diseases	O
30	.	O

1	Maternal	O
2	lactation	O

1	Experimental	O
2	cardiotoxicity	O
3	of	O
4	adriamycin	O

1	Muscular	O
2	pathology	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	NLA	O
10	II	O
11	with	O
12	or	O
13	without	O
14	nalorphine	O
15	,	O
16	morphine	O
17	or	O
18	Micoren	O
19	.	O

1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O

1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O

1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	B
15	carboxyhemoglobin	I
16	(	O
17	COHb	B
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O

1	Reduction	O
2	in	O
3	dosage	O
4	restored	O
5	normal	O
6	taste	O
7	sense	O
8	in	O
9	all	O
10	three	O
11	,	O
12	but	O
13	in	O
14	two	O
15	the	O
16	drug	O
17	had	O
18	to	O
19	be	O
20	discontinued	O
21	because	O
22	of	O
23	persisting	O
24	high	O
25	transaminase	O
26	levels	O
27	.	O

1	The	O
2	calcium	O
3	ratio	O
4	(	O
5	mean	O
6	ratio	O
7	of	O
8	the	O
9	predicted	O
10	to	O
11	measured	O
12	TBCa	O
13	)	O
14	in	O
15	men	O
16	was	O
17	1	O
18	.	O
19	000	O
20	+/-	O
21	7	O
22	.	O
23	8	O
24	%	O
25	and	O
26	in	O
27	women	O
28	0	O
29	.	O
30	996	O
31	+/-	O
32	7	O
33	.	O
34	1	O
35	%.	O

1	A	O
2	late	O
3	diagnosis	O
4	of	O
5	retinoblastoma	O
6	is	O
7	an	O
8	unquestionable	O
9	fact	O
10	that	O
11	allows	O
12	its	O
13	growth	O
14	and	O
15	leads	O
16	to	O
17	a	O
18	deterioration	O
19	in	O
20	the	O
21	outlook	O
22	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	measured	O
5	in	O
6	amniotic	O
7	fluids	O
8	collected	O
9	at	O
10	different	O
11	stages	O
12	of	O
13	gestation	O
14	.	O

1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O

1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	fear	O
8	and	O
9	pugnacity	O
10	all	O
11	husband	O
12	-	O
13	wife	O
14	trait	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	Winch	O
23	'	O
24	s	O
25	principle	O
26	of	O
27	type	O
28	I	O
29	complementarity	O
30	.	O

1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O

1	3	O
2	activities	O
3	of	O
4	the	O
5	factor	B
6	II	I
7	molecule	O
8	in	O
9	the	O
10	newborn	O
11	infant	O
12	at	O
13	term	O

1	The	O
2	concept	O
3	of	O
4	"	O
5	structural	O
6	identifiability	O
7	"	O
8	is	O
9	employed	O
10	in	O
11	this	O
12	analysis	O
13	to	O
14	determine	O
15	which	O
16	model	O
17	parameters	O
18	can	O
19	be	O
20	and	O
21	which	O
22	cannot	O
23	be	O
24	determined	O
25	"	O
26	uniquely	O
27	"	O
28	from	O
29	given	O
30	input	O
31	-	O
32	output	O
33	data	O
34	;	O
35	a	O
36	step	O
37	-	O
38	by	O
39	-	O
40	step	O
41	procedure	O
42	based	O
43	on	O
44	an	O
45	extension	O
46	of	O
47	this	O
48	concept	O
49	is	O
50	presented	O
51	for	O
52	adapting	O
53	the	O
54	overall	O
55	approach	O
56	to	O
57	the	O
58	experimental	O
59	design	O
60	problem	O
61	.	O

1	However	O
2	,	O
3	we	O
4	did	O
5	detect	O
6	lot	O
7	-	O
8	to	O
9	-	O
10	lot	O
11	variation	O
12	and	O
13	differences	O
14	in	O
15	performance	O
16	between	O
17	narrow	O
18	bandpass	O
19	and	O
20	wide	O
21	bandpass	O
22	spectrophotometers	O
23	.	O

1	The	O
2	cochlear	O
3	compromise	O
4	.	O

1	A	O
2	case	O
3	observed	O
4	in	O
5	Saigon	O

1	Hypertonic	O
2	glucose	O
3	administered	O
4	intrajejunally	O
5	in	O
6	Heidenhain	O
7	pouch	O
8	dogs	O
9	resulted	O
10	in	O
11	an	O
12	equal	O
13	inhibition	O
14	of	O
15	pentagastrin	O
16	-	O
17	induced	O
18	acid	O
19	secretion	O
20	from	O
21	the	O
22	pouch	O
23	and	O
24	the	O
25	main	O
26	stomach	O
27	,	O
28	whereas	O
29	hypertonic	O
30	saline	O
31	had	O
32	no	O
33	effect	O
34	.	O

1	Acquired	O
2	factor	B
3	VIII	I
4	inhibitor	O
5	in	O
6	non	O
7	-	O
8	hemophilic	O
9	patients	O

1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O

1	The	O
2	study	O
3	of	O
4	calcium	O
5	metabolism	O
6	in	O
7	ten	O
8	thalassaemic	O
9	children	O
10	comperatively	O
11	with	O
12	controls	O
13	after	O
14	oral	O
15	administration	O
16	of	O
17	47Ca	O
18	has	O
19	shown	O
20	diminished	O
21	intestinal	O
22	absorption	O
23	.	O

1	Chlamydial	O
2	agents	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	semen	O
8	near	O
9	the	O
10	end	O
11	of	O
12	the	O
13	chlamydemic	O
14	phase	O
15	.	O

1	Because	O
2	of	O
3	the	O
4	increased	O
5	CPK	B
6	activity	O
7	found	O
8	in	O
9	normal	O
10	newborns	O
11	,	O
12	screening	O
13	for	O
14	Duchenne	O
15	-	O
16	type	O
17	muscular	O
18	dystrophy	O
19	should	O
20	be	O
21	postponed	O
22	for	O
23	a	O
24	few	O
25	weeks	O
26	after	O
27	delivery	O
28	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	insulin	B
6	response	O
7	had	O
8	returned	O
9	to	O
10	the	O
11	non	O
12	-	O
13	pregnant	O
14	value	O
15	by	O
16	the	O
17	second	O
18	day	O
19	of	O
20	the	O
21	puerperium	O
22	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	toxicological	O
11	tests	O
12	conducted	O
13	on	O
14	plastic	O
15	materials	O
16	(	O
17	polyethylene	O
18	)	O
19	activated	O
20	with	O
21	tetraphenylbutadiene	O
22	(	O
23	TPB	O
24	)	O
25	an	O
26	additive	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	sensitizer	O
32	capable	O
33	of	O
34	photodegrading	O
35	plastic	O
36	materials	O
37	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	major	O
6	homology	O
7	region	O
8	of	O
9	Mason	O
10	-	O
11	Pfizer	O
12	monkey	O
13	virus	O
14	by	O
15	use	O
16	of	O
17	saturation	O
18	mutagenesis	O
19	.	O

1	One	O
2	site	O
3	,	O
4	PAL	B
5	,	O
6	occurs	O
7	within	O
8	the	O
9	10	O
10	bp	O
11	sequence	O
12	GGGGAGGAGG	O
13	.	O

1	Nuclear	O
2	extracts	O
3	prepared	O
4	from	O
5	both	O
6	neural	O
7	and	O
8	non	O
9	-	O
10	neural	O
11	cell	O
12	lines	O
13	,	O
14	mouse	O
15	brain	O
16	,	O
17	and	O
18	mouse	O
19	liver	O
20	contain	O
21	proteins	O
22	that	O
23	recognize	O
24	and	O
25	bind	O
26	to	O
27	the	O
28	PROX	O
29	and	O
30	PAL	O
31	sequences	O
32	indicating	O
33	that	O
34	proteins	O
35	which	O
36	bind	O
37	to	O
38	these	O
39	target	O
40	sequences	O
41	are	O
42	widespread	O
43	.	O

1	To	O
2	determine	O
3	if	O
4	the	O
5	NF	B
6	(	I
7	H	I
8	)	I
9	promoter	I
10	can	O
11	be	O
12	activated	O
13	in	O
14	a	O
15	tissue	O
16	specific	O
17	manner	O
18	during	O
19	development	O
20	transgenic	O
21	mice	O
22	containing	O
23	the	O
24	promoter	O
25	region	O
26	linked	O
27	to	O
28	a	O
29	beta	B
30	-	I
31	galactosidase	I
32	reporter	I
33	gene	I
34	were	O
35	generated	O
36	.	O

1	Here	O
2	we	O
3	describe	O
4	and	O
5	map	O
6	two	O
7	more	O
8	new	O
9	genes	O
10	identified	O
11	as	O
12	allele	O
13	-	O
14	specific	O
15	suppressors	O
16	that	O
17	compensate	O
18	for	O
19	carboxy	O
20	-	O
21	terminal	O
22	truncation	O
23	of	O
24	PET122	B
25	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	[	O
6	Hisanaga	O
7	,	O
8	S	O
9	.,	O
10	Kusubata	O
11	,	O
12	M	O
13	.,	O
14	Okumura	O
15	,	O
16	E	O
17	.	O
18	&	O
19	Kishimoto	O
20	,	O
21	T	O
22	.	O

1	Treatment	O
2	and	O
3	staining	O
4	of	O
5	smears	O
6	and	O
7	sections	O
8	for	O
9	detection	O
10	of	O
11	microorganisms	O

1	The	O
2	apparent	O
3	Kd	O
4	of	O
5	the	O
6	MetRS	B
7	/	I
8	CAU	I
9	operator	I
10	complex	I
11	is	O
12	one	O
13	order	O
14	magnitude	O
15	higher	O
16	than	O
17	that	O
18	of	O
19	the	O
20	ThrRS	B
21	/	I
22	CGU	I
23	operator	I
24	complex	I
25	.	O

1	A	O
2	significant	O
3	direct	O
4	relationship	O
5	was	O
6	observed	O
7	between	O
8	the	O
9	percent	O
10	area	O
11	density	O
12	of	O
13	smooth	O
14	muscle	O
15	and	O
16	the	O
17	percent	O
18	change	O
19	in	O
20	peak	O
21	urinary	O
22	flow	O
23	rate	O
24	.	O

1	Rabbit	B
2	skeletal	I
3	muscle	I
4	glycogenin	I
5	.	O

1	Characterization	O
2	of	O
3	the	O
4	human	B
5	gene	I
6	encoding	I
7	cytokeratin	I
8	17	I
9	and	O
10	its	O
11	expression	O
12	pattern	O
13	.	O

1	Animals	O
2	that	O
3	received	O
4	DSP	O
5	-	O
6	4	O
7	were	O
8	significantly	O
9	retarded	O
10	in	O
11	motor	O
12	recovery	O
13	compared	O
14	with	O
15	the	O
16	saline	O
17	group	O
18	.	O

1	The	O
2	prophylactic	O
3	use	O
4	of	O
5	new	O
6	medication	O
7	for	O
8	patients	O
9	between	O
10	the	O
11	first	O
12	and	O
13	second	O
14	cycle	O
15	of	O
16	chemotherapy	O
17	,	O
18	in	O
19	agreement	O
20	with	O
21	the	O
22	estimates	O
23	calculated	O
24	,	O
25	does	O
26	not	O
27	save	O
28	health	O
29	care	O
30	costs	O
31	but	O
32	may	O
33	improve	O
34	the	O
35	quality	O
36	of	O
37	life	O
38	in	O
39	these	O
40	patients	O
41	and	O
42	permit	O
43	the	O
44	continuation	O
45	of	O
46	a	O
47	therapeutic	O
48	schedule	O
49	without	O
50	interruption	O
51	which	O
52	may	O
53	improve	O
54	the	O
55	life	O
56	expectancy	O
57	of	O
58	the	O
59	patient	O
60	.	O

1	AP	O
2	was	O
3	induced	O
4	by	O
5	intraductal	O
6	infusion	O
7	of	O
8	two	O
9	different	O
10	concentrations	O
11	of	O
12	glycodeoxycholic	O
13	acid	O
14	(	O
15	GDOC	O
16	17	O
17	mmol	O
18	and	O
19	34	O
20	mmol	O
21	).	O

1	The	O
2	isolation	O
3	of	O
4	this	O
5	gene	O
6	was	O
7	based	O
8	on	O
9	the	O
10	identification	O
11	of	O
12	the	O
13	Y	O
14	-	O
15	231	O
16	cosmid	O
17	that	O
18	contains	O
19	CpG	O
20	rich	O
21	sequences	O
22	(	O
23	HTF	O
24	islands	O
25	)	O
26	in	O
27	its	O
28	human	O
29	insert	O
30	.	O

1	Tissue	B
2	plasminogen	I
3	activator	I
4	,	O
5	its	O
6	inhibitor	O
7	and	O
8	other	O
9	parameters	O
10	of	O
11	fibrinolysis	O
12	in	O
13	blood	O
14	of	O
15	patients	O
16	operated	O
17	for	O
18	mild	O
19	hypertrophy	O
20	of	O
21	the	O
22	prostate	O

1	Gene	O
2	constructs	O
3	consisting	O
4	of	O
5	human	B
6	growth	I
7	hormone	I
8	(	O
9	hGH	B
10	)	O
11	gene	O
12	driven	O
13	by	O
14	promoter	O
15	/	O
16	regulatory	O
17	sequence	O
18	of	O
19	mouse	B
20	metallothionein	I
21	(	O
22	mMT	B
23	),	O
24	viral	B
25	thymidine	I
26	kinase	I
27	(	O
28	vTK	B
29	),	O
30	rat	B
31	cholecystokinin	I
32	(	O
33	rCCK	B
34	),	O
35	or	O
36	chicken	B
37	beta	I
38	-	I
39	actin	I
40	(	O
41	cBA	B
42	)	O
43	gene	O
44	were	O
45	injected	O
46	into	O
47	the	O
48	cytoplasm	O
49	of	O
50	fertilized	O
51	medaka	O
52	eggs	O
53	via	O
54	the	O
55	micropyle	O
56	.	O

1	Serum	O
2	gastrin	B
3	and	O
4	AFP	B
5	levels	O
6	had	O
7	the	O
8	same	O
9	evolution	O
10	and	O
11	appear	O
12	to	O
13	have	O
14	the	O
15	same	O
16	interest	O
17	to	O
18	follow	O
19	the	O
20	course	O
21	of	O
22	the	O
23	disease	O
24	.	O

1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O

1	The	O
2	mean	O
3	(+/-	O
4	SD	O
5	)	O
6	PaO2	O
7	increased	O
8	from	O
9	80	O
10	.	O
11	8	O
12	+/-	O
13	26	O
14	.	O
15	9	O
16	mmHg	O
17	before	O
18	to	O
19	89	O
20	.	O
21	8	O
22	+/-	O
23	27	O
24	.	O
25	3	O
26	mmHg	O
27	after	O
28	the	O
29	infusion	O
30	(	O
31	P	O
32	<	O
33	0	O
34	.	O
35	05	O
36	)	O
37	and	O
38	the	O
39	PaCO2	O
40	decreased	O
41	from	O
42	42	O
43	.	O
44	4	O
45	+/-	O
46	8	O
47	.	O
48	3	O
49	to	O
50	39	O
51	.	O
52	6	O
53	+/-	O
54	7	O
55	.	O
56	9	O
57	mmHg	O
58	(	O
59	P	O
60	<	O
61	0	O
62	.	O
63	05	O
64	).	O

1	Though	O
2	hepatomegaly	O
3	and	O
4	mild	O
5	elevation	O
6	of	O
7	enzymes	O
8	can	O
9	be	O
10	observed	O
11	in	O
12	a	O
13	significant	O
14	proportion	O
15	of	O
16	patients	O
17	,	O
18	involvement	O
19	of	O
20	liver	O
21	leading	O
22	to	O
23	acute	O
24	hepatitis	O
25	or	O
26	liver	O
27	cell	O
28	necrosis	O
29	is	O
30	a	O
31	relatively	O
32	uncommon	O
33	complication	O
34	in	O
35	P	O
36	.	O
37	falciparum	O
38	malaria	O
39	.	O

1	For	O
2	the	O
3	first	O
4	group	O
5	,	O
6	the	O
7	maximal	O
8	decrease	O
9	in	O
10	plasma	O
11	potassium	O
12	elicited	O
13	by	O
14	salbutamol	O
15	was	O
16	0	O
17	.	O
18	80	O
19	+/-	O
20	0	O
21	.	O
22	19	O
23	,	O
24	0	O
25	.	O
26	48	O
27	+/-	O
28	0	O
29	.	O
30	22	O
31	,	O
32	and	O
33	0	O
34	.	O
35	78	O
36	+/-	O
37	0	O
38	.	O
39	46	O
40	mmol	O
41	/	O
42	l	O
43	,	O
44	and	O
45	for	O
46	the	O
47	second	O
48	group	O
49	,	O
50	maximal	O
51	decrement	O
52	was	O
53	1	O
54	.	O
55	31	O
56	+/-	O
57	0	O
58	.	O
59	37	O
60	,	O
61	0	O
62	.	O
63	70	O
64	+/-	O
65	0	O
66	.	O
67	24	O
68	,	O
69	and	O
70	0	O
71	.	O
72	84	O
73	+/-	O
74	0	O
75	.	O
76	17	O
77	mmol	O
78	/	O
79	l	O
80	for	O
81	the	O
82	iv	O
83	,	O
84	po	O
85	,	O
86	and	O
87	it	O
88	routes	O
89	,	O
90	respectively	O
91	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	O
20	prolactin	B
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O

1	The	O
2	magnitude	O
3	of	O
4	the	O
5	early	O
6	response	O
7	was	O
8	241	O
9	+/-	O
10	51	O
11	%	O
12	in	O
13	A	O
14	(%	O
15	baseline	O
16	RL	O
17	;	O
18	mean	O
19	+/-	O
20	SE	O
21	),	O
22	and	O
23	significantly	O
24	less	O
25	in	O
26	B	O
27	(	O
28	119	O
29	+/-	O
30	7	O
31	%)	O
32	and	O
33	C	O
34	(	O
35	131	O
36	+/-	O
37	16	O
38	%)	O
39	(	O
40	p	O
41	<	O
42	0	O
43	.	O
44	01	O
45	).	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	presented	O
6	with	O
7	Transient	O
8	Ischemic	O
9	Attacks	O
10	(	O
11	64	O
12	%)	O
13	or	O
14	Reversible	O
15	Ischemic	O
16	Neurologic	O
17	Deficits	O
18	(	O
19	19	O
20	%).	O

1	We	O
2	cloned	O
3	the	O
4	third	O
5	human	O
6	gene	O
7	for	O
8	the	O
9	LD78	B
10	,	O
11	termed	O
12	LD78	B
13	gamma	I
14	and	O
15	the	O
16	sequence	O
17	analysis	O
18	showed	O
19	that	O
20	it	O
21	is	O
22	a	O
23	5	O
24	'-	O
25	truncated	O
26	pseudogene	O
27	.	O

1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	consideration	O
8	of	O
9	the	O
10	SCBs	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	SWI4	B
16	,	I
17	6	I
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	proposal	O
26	of	O
27	a	O
28	revised	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	a	O
5	DNA	O
6	sequence	O
7	involved	O
8	in	O
9	linking	O
10	gene	O
11	expression	O
12	to	O
13	the	O
14	cell	O
15	cycle	O
16	.	O

1	The	O
2	natural	O
3	history	O
4	of	O
5	these	O
6	lesions	O
7	,	O
8	locoregional	O
9	efficiency	O
10	of	O
11	the	O
12	different	O
13	treatments	O
14	used	O
15	,	O
16	the	O
17	part	O
18	played	O
19	by	O
20	chemotherapy	O
21	,	O
22	survival	O
23	,	O
24	causes	O
25	of	O
26	death	O
27	and	O
28	therapeutic	O
29	modalities	O
30	used	O
31	as	O
32	a	O
33	last	O
34	measure	O
35	,	O
36	have	O
37	been	O
38	analysed	O
39	.	O

1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	histological	O
6	criteria	O
7	,	O
8	which	O
9	it	O
10	is	O
11	difficult	O
12	to	O
13	demand	O
14	in	O
15	view	O
16	of	O
17	the	O
18	variability	O
19	of	O
20	results	O
21	and	O
22	potential	O
23	dangers	O
24	of	O
25	endomyocardial	O
26	biopsy	O
27	involving	O
28	such	O
29	thin	O
30	and	O
31	fragile	O
32	ventricular	O
33	walls	O
34	,	O
35	the	O
36	diagnosis	O
37	of	O
38	ACRV	O
39	is	O
40	based	O
41	upon	O
42	the	O
43	concomitant	O
44	existence	O
45	of	O
46	:	O
47	(	O
48	1	O
49	)	O
50	electrophysiological	O
51	criteria	O
52	:	O
53	ventricular	O
54	arrhythmias	O
55	,	O
56	in	O
57	particular	O
58	sustained	O
59	monomorphous	O
60	VT	O
61	,	O
62	with	O
63	the	O
64	particular	O
65	feature	O
66	of	O
67	a	O
68	very	O
69	high	O
70	degree	O
71	of	O
72	sensitivity	O
73	to	O
74	adrenergic	O
75	stimulation	O
76	(	O
77	exercise	O
78	),	O
79	the	O
80	existence	O
81	of	O
82	late	O
83	potentials	O
84	on	O
85	the	O
86	high	O
87	amplification	O
88	ECG	O
89	,	O
90	a	O
91	highly	O
92	specific	O
93	sign	O
94	,	O
95	though	O
96	unfortunately	O
97	of	O
98	poor	O
99	sensitivity	O
100	in	O
101	localized	O
102	froms	O
103	,	O
104	those	O
105	which	O
106	are	O
107	most	O
108	difficult	O
109	to	O
110	identify	O
111	(	O
112	2	O
113	);	O
114	segmentary	O
115	morphological	O
116	and	O
117	kinetic	O
118	RV	O
119	abnormalities	O
120	,	O
121	most	O
122	often	O
123	resulting	O
124	in	O
125	localized	O
126	akinetic	O
127	or	O
128	dyskinetic	O
129	parietal	O
130	vaulting	O
131	,	O
132	with	O
133	stasis	O
134	"	O
135	in	O
136	situ	O
137	".	O

1	In	O
2	7	O
3	of	O
4	9	O
5	cases	O
6	,	O
7	the	O
8	enhancer	O
9	is	O
10	fused	O
11	to	O
12	the	O
13	c	B
14	-	I
15	myc	I
16	bearing	I
17	sequences	I
18	of	O
19	chromosome	O
20	8	O
21	.	O

1	These	O
2	components	O
3	both	O
4	had	O
5	a	O
6	median	O
7	R2	O
8	of	O
9	0	O
10	.	O
11	84	O
12	,	O
13	compared	O
14	to	O
15	median	O
16	R2s	O
17	ranging	O
18	from	O
19	0	O
20	.	O
21	37	O
22	to	O
23	0	O
24	.	O
25	83	O
26	for	O
27	five	O
28	commonly	O
29	used	O
30	ad	O
31	hoc	O
32	EEG	O
33	components	O
34	.	O

1	The	O
2	obtained	O
3	results	O
4	were	O
5	compared	O
6	with	O
7	control	O
8	group	O
9	(	O
10	10	O
11	female	O
12	volunteers	O
13	).	O

1	100	O
2	years	O
3	of	O
4	dentistry	O
5	at	O
6	the	O
7	Friedrich	O
8	Schiller	O
9	University	O
10	in	O
11	Jena	O

1	The	O
2	target	O
3	contained	O
4	between	O
5	positions	O
6	-	O
7	403	O
8	and	O
9	-	O
10	125	O
11	acts	O
12	independently	O
13	of	O
14	orientation	O
15	,	O
16	in	O
17	different	O
18	cell	O
19	types	O
20	and	O
21	species	O
22	,	O
23	and	O
24	in	O
25	the	O
26	context	O
27	of	O
28	a	O
29	heterologous	O
30	promoter	O
31	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	Synergistic	O
2	transactivation	O
3	of	O
4	the	O
5	BMRF1	B
6	promoter	I
7	by	O
8	the	O
9	Z	B
10	/	O
11	c	B
12	-	I
13	myb	I
14	combination	O
15	appears	O
16	to	O
17	involve	O
18	direct	O
19	binding	O
20	by	O
21	the	O
22	Z	B
23	protein	I
24	but	O
25	not	O
26	the	O
27	c	B
28	-	I
29	myb	I
30	protein	I
31	.	O

1	The	O
2	UCR	O
3	core	O
4	sequence	O
5	,	O
6	CGCCATTTT	O
7	,	O
8	binds	O
9	a	O
10	ubiquitous	O
11	nuclear	O
12	factor	O
13	and	O
14	mediates	O
15	negative	O
16	regulation	O
17	of	O
18	MuLV	O
19	promoter	O
20	activity	O
21	.	O

1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	B
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	B
21	-	I
22	associated	I
23	virus	I
24	P5	I
25	promoter	I
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	B
31	light	I
32	-	I
33	and	I
34	heavy	I
35	-	I
36	chain	I
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	B
45	protein	I
46	genes	I
47	.	O

1	Possibly	O
2	,	O
3	the	O
4	scr1	B
5	-	I
6	1	I
7	mutation	I
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	B
26	synthesis	O
27	.	O

1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O

1	Both	O
2	Rep78	B
3	and	O
4	Rep68	B
5	cut	O
6	the	O
7	terminal	O
8	AAV	O
9	sequence	O
10	at	O
11	the	O
12	same	O
13	site	O
14	(	O
15	nucleotide	O
16	124	O
17	).	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	TAR	B
7	-	I
8	binding	I
9	protein	I
10	is	O
11	very	O
12	similar	O
13	to	O
14	the	O
15	CREB2	B
16	protein	I
17	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	B
20	protein	I
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	B
36	protein	I
37	.	O

1	The	O
2	JS78	O
3	mutation	O
4	changes	O
5	Gln243	O
6	in	O
7	gp0	O
8	.	O
9	7	O
10	to	O
11	an	O
12	amber	O
13	codon	O
14	,	O
15	which	O
16	explains	O
17	the	O
18	production	O
19	of	O
20	the	O
21	truncated	O
22	,	O
23	30	B
24	-	I
25	kDa	I
26	gp0	I
27	.	I
28	7	I
29	-	I
30	related	I
31	polypeptide	I
32	,	O
33	and	O
34	implicates	O
35	the	O
36	11	O
37	-	O
38	kDa	O
39	C	O
40	-	O
41	terminal	O
42	domain	O
43	in	O
44	host	O
45	transcription	O
46	shut	O
47	-	O
48	off	O
49	.	O

1	A	O
2	patient	O
3	suffering	O
4	from	O
5	heparin	O
6	-	O
7	associated	O
8	thrombocytopenia	O
9	(	O
10	HAT	O
11	),	O
12	recurrent	O
13	arteriothromboses	O
14	,	O
15	and	O
16	acute	O
17	renal	O
18	failure	O
19	after	O
20	treatment	O
21	with	O
22	standard	O
23	heparin	O
24	is	O
25	described	O
26	.	O

1	The	O
2	predicted	O
3	receptor	O
4	structure	O
5	includes	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	extracellular	O
11	domain	O
12	,	O
13	a	O
14	single	O
15	hydrophobic	O
16	transmembrane	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	predicted	O
22	cytoplasmic	B
23	serine	I
24	/	I
25	threonine	I
26	kinase	I
27	domain	I
28	.	O

1	Drosophila	B
2	UbcD1	I
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	B
8	-	O
9	conjugating	O
10	enzyme	O
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O

1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O

1	The	O
2	goal	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	determine	O
10	the	O
11	feasibility	O
12	of	O
13	retrovirus	O
14	mediated	O
15	expression	O
16	of	O
17	rp47phox	B
18	in	O
19	the	O
20	HL60	O
21	and	O
22	U937	O
23	human	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	,	O
28	and	O
29	in	O
30	an	O
31	Epstein	O
32	-	O
33	Barr	O
34	virus	O
35	transformed	O
36	B	O
37	-	O
38	lymphocyte	O
39	cell	O
40	line	O
41	(	O
42	EBV	O
43	-	O
44	BCL	O
45	)	O
46	derived	O
47	from	O
48	a	O
49	p47phox	B
50	-	O
51	deficient	O
52	CGD	O
53	patient	O
54	.	O

1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	B
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	I
16	superfamily	I
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	B
22	amalgam	I
23	,	O
24	the	O
25	melanoma	B
26	Ag	I
27	MUC	I
28	-	I
29	18	I
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	B
35	Ag	I
36	family	I
37	,	O
38	the	O
39	poliovirus	B
40	receptor	I
41	,	O
42	and	O
43	the	O
44	neural	B
45	cell	I
46	adhesion	I
47	molecule	I
48	.	O

1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	B
13	mRNA	I
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	B
25	-	I
26	coding	I
27	sequence	I
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O

1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O

1	In	O
2	contrast	O
3	,	O
4	gel	O
5	mobility	O
6	shift	O
7	experiments	O
8	have	O
9	failed	O
10	to	O
11	reveal	O
12	that	O
13	HAP2	B
14	or	O
15	HAP3	B
16	binds	O
17	to	O
18	domain	O
19	1	O
20	or	O
21	that	O
22	hap3	B
23	mutations	O
24	affect	O
25	the	O
26	complexes	O
27	bound	O
28	to	O
29	it	O
30	.	O

1	Myogenic	O
2	differentiation	O
3	can	O
4	be	O
5	inhibited	O
6	by	O
7	the	O
8	adenovirus	O
9	E1a	B
10	protein	I
11	in	O
12	the	O
13	rat	O
14	L6	O
15	muscle	O
16	cell	O
17	line	O
18	.	O

1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O

1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O

1	Acad	O
2	.	O

1	Both	O
2	in	O
3	vitro	O
4	-	O
5	synthesized	O
6	S2	B
7	protein	I
8	and	O
9	synthetic	O
10	peptides	O
11	corresponding	O
12	to	O
13	S2	B
14	are	O
15	shown	O
16	to	O
17	react	O
18	positively	O
19	with	O
20	sera	O
21	obtained	O
22	from	O
23	EIAV	O
24	-	O
25	infected	O
26	horses	O
27	,	O
28	providing	O
29	the	O
30	first	O
31	direct	O
32	evidence	O
33	of	O
34	expression	O
35	of	O
36	this	O
37	protein	O
38	in	O
39	infected	O
40	animals	O
41	.	O

1	Many	O
2	canonical	O
3	TATA	O
4	sequences	O
5	are	O
6	present	O
7	upstream	O
8	from	O
9	these	O
10	VZV	O
11	transcriptional	O
12	start	O
13	sites	O
14	but	O
15	,	O
16	apparently	O
17	,	O
18	are	O
19	not	O
20	used	O
21	.	O

1	The	O
2	ORF	O
3	4	O
4	gene	O
5	was	O
6	minimally	O
7	active	O
8	,	O
9	whereas	O
10	the	O
11	ORF	O
12	62	O
13	gene	O
14	gave	O
15	twofold	O
16	induction	O
17	;	O
18	both	O
19	genes	O
20	,	O
21	acting	O
22	together	O
23	,	O
24	gave	O
25	fivefold	O
26	induction	O
27	.	O

1	Interestingly	O
2	,	O
3	the	O
4	IR5	B
5	ORF	I
6	of	O
7	EHV	O
8	-	O
9	1	O
10	possesses	O
11	a	O
12	sequence	O
13	of	O
14	13	O
15	amino	O
16	acids	O
17	(	O
18	CAYWCCLGHAFAC	O
19	)	O
20	that	O
21	is	O
22	a	O
23	perfect	O
24	match	O
25	to	O
26	the	O
27	consensus	O
28	zinc	O
29	finger	O
30	motif	O
31	(	O
32	C	O
33	-	O
34	X2	O
35	-	O
36	4	O
37	-	O
38	C	O
39	-	O
40	X2	O
41	-	O
42	15	O
43	-	O
44	C	O
45	/	O
46	H	O
47	-	O
48	X2	O
49	-	O
50	4	O
51	-	O
52	C	O
53	/	O
54	H	O
55	).	O

1	The	O
2	DNA	O
3	sequence	O
4	of	O
5	the	O
6	sulfate	B
7	activation	I
8	locus	I
9	from	O
10	Escherichia	O
11	coli	O
12	K	O
13	-	O
14	12	O
15	has	O
16	been	O
17	determined	O
18	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O

1	Plasma	O
2	membranes	O
3	of	O
4	cultured	O
5	cells	O
6	contain	O
7	high	O
8	affinity	O
9	receptors	O
10	for	O
11	high	B
12	density	I
13	lipoprotein	I
14	(	O
15	HDL	B
16	)	O
17	that	O
18	appear	O
19	to	O
20	mediate	O
21	removal	O
22	of	O
23	excess	O
24	intracellular	O
25	cholesterol	O
26	.	O

1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	an	O
6	internal	O
7	short	O
8	element	O
9	located	O
10	at	O
11	the	O
12	very	O
13	5	O
14	'	O
15	terminal	O
16	of	O
17	L1	B
18	sequence	I
19	and	O
20	the	O
21	nuclear	O
22	factor	O
23	binding	O
24	to	O
25	the	O
26	element	O
27	play	O
28	a	O
29	crucial	O
30	role	O
31	in	O
32	the	O
33	transcription	O
34	of	O
35	human	B
36	L1	I
37	.	O

1	Tumor	O
2	cells	O
3	were	O
4	focally	O
5	immunoreactive	O
6	for	O
7	neuron	B
8	-	I
9	specific	I
10	enolase	I
11	,	O
12	insulin	B
13	,	O
14	glucagon	B
15	and	O
16	VIP	B
17	.	O

1	A	O
2	recombinant	O
3	with	O
4	a	O
5	5	O
6	'	O
7	end	O
8	from	O
9	src	B
10	and	O
11	a	O
12	3	O
13	'	O
14	end	O
15	from	O
16	ros	B
17	,	O
18	called	O
19	SRC	B
20	x	O
21	ROS	B
22	,	O
23	transformed	O
24	chicken	O
25	embryo	O
26	fibroblasts	O
27	(	O
28	CEF	O
29	)	O
30	to	O
31	a	O
32	spindle	O
33	shape	O
34	morphology	O
35	,	O
36	mimicking	O
37	that	O
38	of	O
39	UR2	B
40	.	O

1	ROS	B
2	x	O
3	SRC	B
4	(	O
5	R	B
6	)	O
7	contains	O
8	a	O
9	16	O
10	-	O
11	amino	O
12	-	O
13	acid	O
14	deletion	O
15	that	O
16	includes	O
17	the	O
18	3	O
19	'	O
20	half	O
21	of	O
22	the	O
23	transmembrane	O
24	domain	O
25	of	O
26	ros	B
27	.	O

1	To	O
2	define	O
3	the	O
4	number	O
5	and	O
6	nature	O
7	of	O
8	the	O
9	E6	B
10	and	O
11	E7	B
12	gene	I
13	products	O
14	expressed	O
15	in	O
16	BPV	O
17	-	O
18	1	O
19	-	O
20	transformed	O
21	cells	O
22	,	O
23	we	O
24	performed	O
25	immunoprecipitation	O
26	experiments	O
27	with	O
28	antisera	O
29	raised	O
30	to	O
31	bacterially	O
32	expressed	O
33	BPV	B
34	-	I
35	1	I
36	E6	I
37	and	O
38	E7	B
39	fusion	I
40	proteins	I
41	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	showed	O
5	that	O
6	site	O
7	A	O
8	is	O
9	necessary	O
10	and	O
11	sufficient	O
12	for	O
13	RXR	B
14	alpha	I
15	-	O
16	mediated	O
17	transactivation	O
18	of	O
19	the	O
20	apoAI	B
21	gene	I
22	basal	I
23	promoter	I
24	in	O
25	human	O
26	hepatoma	O
27	HepG2	O
28	cells	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	RA	O
34	and	O
35	that	O
36	this	O
37	transactivation	O
38	is	O
39	abolished	O
40	by	O
41	increasing	O
42	amounts	O
43	of	O
44	cotransfected	O
45	ARP	B
46	-	I
47	1	I
48	.	O

1	The	O
2	enhancer	O
3	region	O
4	of	O
5	Akv	O
6	murine	O
7	leukemia	O
8	virus	O
9	contains	O
10	the	O
11	sequence	O
12	motif	O
13	ACAGATGG	O
14	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	B
6	cDNA	I
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	A	O
2	third	O
3	prominent	O
4	component	O
5	of	O
6	apparent	O
7	molecular	O
8	mass	O
9	16	O
10	kDa	O
11	displayed	O
12	several	O
13	properties	O
14	,	O
15	including	O
16	ability	O
17	to	O
18	bind	O
19	45Ca2	O
20	+,	O
21	that	O
22	are	O
23	characteristic	O
24	of	O
25	the	O
26	regulatory	O
27	(	O
28	B	O
29	)	O
30	subunit	O
31	of	O
32	mammalian	B
33	calcineurin	I
34	and	O
35	was	O
36	recognized	O
37	by	O
38	an	O
39	antiserum	O
40	raised	O
41	against	O
42	bovine	B
43	calcineurin	I
44	.	O

1	As	O
2	was	O
3	observed	O
4	previously	O
5	for	O
6	MATa	B
7	cna1	I
8	cna2	I
9	double	O
10	mutants	O
11	,	O
12	MATa	B
13	cnb1	I
14	mutants	I
15	were	O
16	defective	O
17	in	O
18	their	O
19	ability	O
20	to	O
21	recover	O
22	from	O
23	alpha	B
24	-	I
25	factor	I
26	-	O
27	induced	O
28	growth	O
29	arrest	O
30	.	O

1	Antibodies	O
2	against	O
3	this	O
4	purified	O
5	protein	O
6	localize	O
7	RIM1	B
8	to	O
9	mitochondria	O
10	.	O

1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	O
6	HHV	O
7	-	O
8	6	O
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	HNF	B
2	-	I
3	3	I
4	beta	I
5	amino	I
6	-	I
7	terminal	I
8	sequences	I
9	defined	O
10	by	O
11	conserved	O
12	region	O
13	IV	O
14	also	O
15	contributed	O
16	to	O
17	transactivation	O
18	,	O
19	but	O
20	region	O
21	IV	O
22	activity	O
23	required	O
24	the	O
25	participation	O
26	of	O
27	the	O
28	region	O
29	II	O
30	-	O
31	III	O
32	domain	O
33	.	O

1	Possible	O
2	roles	O
3	of	O
4	RAD5	B
5	putative	O
6	ATPase	B
7	/	O
8	DNA	B
9	helicase	I
10	activity	O
11	in	O
12	DNA	O
13	repair	O
14	and	O
15	in	O
16	the	O
17	maintenance	O
18	of	O
19	wild	O
20	-	O
21	type	O
22	rates	O
23	of	O
24	instability	O
25	of	O
26	simple	O
27	repetitive	O
28	sequences	O
29	are	O
30	discussed	O
31	.	O

1	Susceptibilities	O
2	of	O
3	540	O
4	anaerobic	O
5	gram	O
6	-	O
7	negative	O
8	bacilli	O
9	to	O
10	amoxicillin	O
11	,	O
12	amoxicillin	O
13	-	O
14	BRL	O
15	42715	O
16	,	O
17	amoxicillin	O
18	-	O
19	clavulanate	O
20	,	O
21	temafloxacin	O
22	,	O
23	and	O
24	clindamycin	O
25	.	O

1	Nocodazole	O
2	arrest	O
3	of	O
4	DU249	O
5	cells	O
6	was	O
7	exploited	O
8	for	O
9	the	O
10	detection	O
11	of	O
12	an	O
13	M	O
14	-	O
15	phase	O
16	-	O
17	activated	O
18	MBP	B
19	kinase	I
20	that	O
21	was	O
22	resolved	O
23	from	O
24	p41	B
25	MAP	I
26	kinase	I
27	by	O
28	phenyl	O
29	-	O
30	Superose	O
31	chromatography	O
32	.	O

1	The	O
2	hit1	B
3	-	I
4	1	I
5	mutation	O
6	caused	O
7	a	O
8	defect	O
9	in	O
10	synthesis	O
11	of	O
12	a	O
13	74	B
14	-	I
15	kD	I
16	heat	I
17	shock	I
18	protein	I
19	.	O

1	The	O
2	319	O
3	base	O
4	pair	O
5	region	O
6	immediately	O
7	upstream	O
8	of	O
9	the	O
10	CAP	O
11	site	O
12	is	O
13	characterized	O
14	by	O
15	the	O
16	lack	O
17	of	O
18	a	O
19	proximal	O
20	TATA	O
21	box	O
22	and	O
23	the	O
24	presence	O
25	of	O
26	sequences	O
27	similar	O
28	to	O
29	GC	O
30	boxes	O
31	,	O
32	CACCC	O
33	boxes	O
34	,	O
35	CCAAT	O
36	boxes	O
37	,	O
38	activator	B
39	protein	I
40	2	I
41	(	O
42	Ap	B
43	-	I
44	2	I
45	)	O
46	sites	O
47	,	O
48	partial	O
49	glucocorticoid	O
50	response	O
51	elements	O
52	(	O
53	GREs	O
54	),	O
55	and	O
56	partial	O
57	cyclic	O
58	AMP	O
59	response	O
60	elements	O
61	(	O
62	CREs	O
63	).	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	O
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	In	O
2	rats	O
3	anaesthetized	O
4	with	O
5	+-	O
6	chloralose	O
7	the	O
8	changes	O
9	in	O
10	extracellular	O
11	pH	O
12	and	O
13	K	O
14	+	O
15	in	O
16	spinal	O
17	cord	O
18	dorsal	O
19	horn	O
20	were	O
21	studied	O
22	using	O
23	pH	O
24	and	O
25	K	O
26	+	O
27	ion	O
28	-	O
29	selective	O
30	electrodes	O
31	.	O

1	Replication	O
2	of	O
3	bovine	O
4	papillomavirus	O
5	-	O
6	1	O
7	(	O
8	BPV	O
9	-	O
10	1	O
11	)	O
12	DNA	O
13	requires	O
14	two	O
15	viral	O
16	gene	O
17	products	O
18	,	O
19	the	O
20	E1	B
21	protein	I
22	and	O
23	the	O
24	full	B
25	-	I
26	length	I
27	E2	I
28	protein	I
29	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	B
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	MAP	B
7	kinase	I
8	activator	I
9	/	O
10	MAP	B
11	kinase	I
12	system	O
13	may	O
14	be	O
15	the	O
16	downstream	O
17	components	O
18	of	O
19	ras	B
20	signal	O
21	transduction	O
22	pathways	O
23	.	O

1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O

1	Labile	O
2	LTR	B
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	B
27	-	I
28	binding	I
29	proteins	I
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	Ruddell	O
2	,	O
3	M	O
4	.	O

1	A	O
2	single	O
3	MEF	B
4	-	I
5	2	I
6	site	I
7	is	O
8	a	O
9	major	O
10	positive	O
11	regulatory	O
12	element	O
13	required	O
14	for	O
15	transcription	O
16	of	O
17	the	O
18	muscle	O
19	-	O
20	specific	O
21	subunit	O
22	of	O
23	the	O
24	human	B
25	phosphoglycerate	I
26	mutase	I
27	gene	I
28	in	O
29	skeletal	O
30	and	O
31	cardiac	O
32	muscle	O
33	cells	O
34	.	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	B
29	proteins	I
30	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	T	B
2	-	I
3	cell	I
4	receptor	I
5	beta	I
6	(	O
7	TCR	B
8	beta	I
9	)	O
10	gene	O
11	rearrangements	O
12	occur	O
13	in	O
14	a	O
15	third	O
16	of	O
17	early	O
18	B	O
19	-	O
20	cell	O
21	acute	O
22	lymphoblastic	O
23	leukemias	O
24	(	O
25	ALLs	O
26	).	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Peripheral	O
2	polyneuropathy	O
3	associated	O
4	with	O
5	multiple	O
6	myeloma	O
7	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	B
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	B
13	VIb	I
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	calcineurin	B
6	A	I
7	gene	I
8	was	O
9	determined	O
10	by	O
11	comparison	O
12	of	O
13	the	O
14	genomic	O
15	and	O
16	cDNA	O
17	sequences	O
18	.	O

1	The	O
2	basal	O
3	promoter	O
4	elements	O
5	of	O
6	murine	B
7	cytochrome	I
8	c	I
9	oxidase	I
10	subunit	I
11	IV	I
12	gene	I
13	consist	O
14	of	O
15	tandemly	O
16	duplicated	O
17	ets	B
18	motifs	O
19	that	O
20	bind	O
21	to	O
22	GABP	B
23	-	I
24	related	I
25	transcription	I
26	factors	I
27	.	O

1	Lastly	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	instances	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	flank	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	variola	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	short	O
6	synthetic	O
7	peptides	O
8	containing	O
9	the	O
10	pRB	B
11	-	I
12	binding	I
13	sequences	I
14	of	O
15	E1A	B
16	are	O
17	sufficient	O
18	for	O
19	interaction	O
20	with	O
21	p107	B
22	,	O
23	cyclin	B
24	A	I
25	,	O
26	and	O
27	p130	B
28	.	O

1	These	O
2	mutants	O
3	grow	O
4	normally	O
5	in	O
6	3T6	O
7	mouse	O
8	fibroblast	O
9	cells	O
10	,	O
11	and	O
12	they	O
13	do	O
14	not	O
15	complement	O
16	the	O
17	wild	O
18	-	O
19	type	O
20	virus	O
21	in	O
22	coinfection	O
23	experiments	O
24	of	O
25	C2	O
26	myoblasts	O
27	.	O

1	The	O
2	MICs	O
3	of	O
4	this	O
5	compound	O
6	against	O
7	90	O
8	%	O
9	of	O
10	these	O
11	organisms	O
12	,	O
13	except	O
14	for	O
15	methicillin	O
16	-	O
17	resistant	O
18	S	O
19	.	O
20	aureus	O
21	,	O
22	ranged	O
23	from	O
24	less	O
25	than	O
26	or	O
27	equal	O
28	to	O
29	0	O
30	.	O
31	006	O
32	to	O
33	3	O
34	.	O
35	13	O
36	micrograms	O
37	/	O
38	ml	O
39	.	O

1	The	O
2	minimal	O
3	promoter	O
4	of	O
5	the	O
6	RII	B
7	beta	I
8	gene	I
9	was	O
10	composed	O
11	of	O
12	two	O
13	adjacent	O
14	functional	O
15	elements	O
16	.	O

1	Mapping	O
2	the	O
3	cAMP	B
4	receptor	I
5	protein	I
6	contact	I
7	site	I
8	on	O
9	the	O
10	alpha	O
11	subunit	O
12	of	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	epidermal	B
6	growth	I
7	factor	I
8	or	O
9	platelet	B
10	-	I
11	derived	I
12	growth	I
13	factor	I
14	stimulation	O
15	of	O
16	intact	O
17	human	O
18	or	O
19	murine	O
20	cells	O
21	leads	O
22	to	O
23	phosphorylation	O
24	of	O
25	Nck	B
26	protein	I
27	on	O
28	tyrosine	O
29	,	O
30	serine	O
31	,	O
32	and	O
33	threonine	O
34	residues	O
35	.	O

1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O

1	A	O
2	combination	O
3	of	O
4	comparative	O
5	sequence	O
6	analysis	O
7	and	O
8	thermodynamic	O
9	methods	O
10	reveals	O
11	the	O
12	conservation	O
13	of	O
14	tertiary	O
15	structure	O
16	elements	O
17	in	O
18	the	O
19	5	O
20	'	O
21	untranslated	O
22	region	O
23	(	O
24	UTR	O
25	)	O
26	of	O
27	human	O
28	enteroviruses	O
29	and	O
30	rhinoviruses	O
31	.	O

1	The	O
2	-	O
3	64	O
4	/-	O
5	37	O
6	region	O
7	interacted	O
8	with	O
9	purified	O
10	Sp1	B
11	and	O
12	an	O
13	unidentified	O
14	protein	O
15	(	O
16	s	O
17	),	O
18	proximal	B
19	regulatory	I
20	factor	I
21	(	I
22	s	I
23	)	I
24	I	I
25	(	O
26	PRF	B
27	-	I
28	I	I
29	).	O

1	Km	O
2	and	O
3	Vmax	O
4	for	O
5	two	O
6	substrates	O
7	,	O
8	src	B
9	-	I
10	related	I
11	peptide	I
12	and	O
13	poly	O
14	(	O
15	Glu	O
16	,	O
17	Tyr	O
18	)	O
19	(	O
20	4	O
21	:	O
22	1	O
23	),	O
24	were	O
25	2	O
26	.	O
27	4	O
28	mM	O
29	and	O
30	2	O
31	.	O
32	5	O
33	mumol	O
34	min	O
35	-	O
36	1	O
37	mg	O
38	-	O
39	1	O
40	and	O
41	0	O
42	.	O
43	26	O
44	mM	O
45	and	O
46	1	O
47	.	O
48	2	O
49	mumol	O
50	min	O
51	-	O
52	1	O
53	mg	O
54	-	O
55	1	O
56	,	O
57	respectively	O
58	.	O

1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	HGFr	B
7	(	O
8	sHGFr	B
9	)	O
10	bound	O
11	HGF	B
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	authentic	O
21	,	O
22	membrane	O
23	-	O
24	associated	O
25	receptor	O
26	.	O

1	Strategies	O
2	for	O
3	blood	O
4	screening	O
5	for	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	and	O
11	for	O
12	the	O
13	human	O
14	immunodeficiency	O
15	virus	O
16	in	O
17	high	O
18	risk	O
19	groups	O
20	.	O

1	Also	O
2	,	O
3	the	O
4	human	B
5	glycoprotein	I
6	alpha	I
7	-	I
8	subunit	I
9	promoter	I
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	FSK	B
17	in	O
18	GH4	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	gene	O
7	from	O
8	Arabidopsis	O
9	thaliana	O
10	encoding	O
11	a	O
12	protein	O
13	related	O
14	to	O
15	SNF1	B
16	protein	O
17	kinase	O
18	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	characterized	O
6	a	O
7	55	O
8	-	O
9	kb	O
10	region	O
11	of	O
12	DNA	O
13	surrounding	O
14	HRAS1	B
15	.	O

1	The	O
2	ORF1	O
3	protein	O
4	was	O
5	found	O
6	to	O
7	be	O
8	highly	O
9	homologous	O
10	to	O
11	the	O
12	putative	O
13	potexvirus	B
14	RNA	I
15	replicases	I
16	;	O
17	ORF2	O
18	,	O
19	-	O
20	3	O
21	,	O
22	-	O
23	5	O
24	and	O
25	-	O
26	6	O
27	proteins	O
28	also	O
29	have	O
30	analogues	O
31	among	O
32	the	O
33	potex	O
34	-	O
35	and	O
36	/	O
37	or	O
38	carlavirus	O
39	-	O
40	encoded	O
41	proteins	O
42	.	O

1	A	O
2	total	O
3	of	O
4	281	O
5	patients	O
6	were	O
7	divided	O
8	into	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	clinical	O
14	diagnosis	O
15	and	O
16	were	O
17	examined	O
18	using	O
19	capnography	O
20	,	O
21	spirometry	O
22	and	O
23	blood	O
24	-	O
25	gas	O
26	analysis	O
27	.	O

1	The	O
2	relationships	O
3	between	O
4	the	O
5	partial	O
6	pressures	O
7	of	O
8	O2	O
9	and	O
10	CO2	O
11	as	O
12	well	O
13	as	O
14	between	O
15	their	O
16	gradients	O
17	,	O
18	become	O
19	stronger	O
20	with	O
21	the	O
22	increase	O
23	of	O
24	the	O
25	ventilation	O
26	-	O
27	perfusion	O
28	ratio	O
29	.	O

1	No	O
2	significant	O
3	correlations	O
4	of	O
5	peak	O
6	VO2	O
7	were	O
8	observed	O
9	between	O
10	the	O
11	3	O
12	tests	O
13	.	O

1	An	O
2	RNA	B
3	-	I
4	binding	I
5	protein	I
6	gene	I
7	(	O
8	rbp1	B
9	)	O
10	from	O
11	Drosophila	O
12	melanogaster	O
13	,	O
14	encoding	O
15	an	O
16	RNA	O
17	recognition	O
18	motif	O
19	and	O
20	an	O
21	Arg	O
22	-	O
23	Ser	O
24	rich	O
25	(	O
26	RS	O
27	)	O
28	domain	O
29	,	O
30	has	O
31	been	O
32	characterized	O
33	.	O

1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	total	O
7	protein	O
8	profiles	O
9	of	O
10	wild	O
11	-	O
12	type	O
13	S	O
14	.	O
15	entomophila	O
16	UC9	O
17	and	O
18	mutant	O
19	UC21	O
20	revealed	O
21	that	O
22	the	O
23	mutant	O
24	lacked	O
25	an	O
26	approximately	O
27	44	O
28	-	O
29	kDa	O
30	protein	O
31	and	O
32	overexpressed	O
33	an	O
34	approximately	O
35	20	O
36	-	O
37	kDa	O
38	protein	O
39	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulon	O
5	controlled	O
6	by	O
7	the	O
8	leucine	B
9	-	I
10	responsive	I
11	regulatory	I
12	protein	I
13	in	O
14	Escherichia	O
15	coli	O
16	.	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	B
5	ornithine	I
6	decarboxylase	I
7	-	I
8	related	I
9	sequence	I
10	family	I
11	.	O

1	This	O
2	mutation	O
3	also	O
4	results	O
5	in	O
6	markedly	O
7	decreased	O
8	levels	O
9	of	O
10	CAD	B
11	mRNA	I
12	and	O
13	protein	O
14	in	O
15	the	O
16	mutant	O
17	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	I
10	site	I
11	II	I
12	sequence	I
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	O
7	primase	B
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	Interestingly	O
2	,	O
3	the	O
4	positions	O
5	of	O
6	these	O
7	introns	O
8	have	O
9	been	O
10	conserved	O
11	in	O
12	comparison	O
13	with	O
14	the	O
15	genes	O
16	of	O
17	two	O
18	other	O
19	transglutaminase	O
20	-	O
21	like	O
22	activities	O
23	described	O
24	in	O
25	the	O
26	literature	O
27	,	O
28	but	O
29	the	O
30	TGM1	B
31	gene	I
32	is	O
33	by	O
34	far	O
35	the	O
36	smallest	O
37	characterized	O
38	to	O
39	date	O
40	because	O
41	its	O
42	introns	O
43	are	O
44	relatively	O
45	smaller	O
46	.	O

1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	data	O
7	from	O
8	35	O
9	cases	O
10	with	O
11	malignant	O
12	lymphoma	O
13	from	O
14	a	O
15	cohort	O
16	of	O
17	2017	O
18	HIV	O
19	-	O
20	infected	O
21	patients	O
22	,	O
23	the	O
24	stage	O
25	of	O
26	HIV	O
27	-	O
28	disease	O
29	,	O
30	the	O
31	CD4	B
32	counts	O
33	at	O
34	the	O
35	time	O
36	of	O
37	diagnosis	O
38	,	O
39	and	O
40	the	O
41	use	O
42	of	O
43	antineoplastic	O
44	agents	O
45	or	O
46	radiotherapy	O
47	were	O
48	correlated	O
49	with	O
50	outcome	O
51	.	O

1	1	O
2	.	O

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	cDNA	O
2	clones	O
3	encoding	O
4	Arabidopsis	O
5	thaliana	O
6	and	O
7	Zea	B
8	mays	I
9	mitochondrial	I
10	chaperonin	I
11	HSP60	I
12	and	O
13	gene	O
14	expression	O
15	during	O
16	seed	O
17	germination	O
18	and	O
19	heat	O
20	shock	O
21	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	B
11	and	I
12	Escherichia	I
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	The	O
2	single	O
3	site	O
4	of	O
5	glycosylation	O
6	is	O
7	located	O
8	near	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	in	O
14	the	O
15	N	O
16	-	O
17	glycosylation	O
18	sequon	O
19	-	O
20	Asn	O
21	-	O
22	Cys	O
23	-	O
24	Ser	O
25	-	O
26	in	O
27	which	O
28	Cys	O
29	forms	O
30	part	O
31	of	O
32	a	O
33	disulphide	O
34	bridge	O
35	.	O

1	The	O
2	pulmonary	O
3	toxic	O
4	events	O
5	induced	O
6	by	O
7	acute	O
8	nitrogen	O
9	dioxide	O
10	(	O
11	NO	O
12	)	O
13	2	O
14	exposure	O
15	were	O
16	studied	O
17	in	O
18	the	O
19	rat	O
20	to	O
21	develop	O
22	an	O
23	inhalation	O
24	model	O
25	to	O
26	investigate	O
27	therapeutic	O
28	measures	O
29	.	O

1	The	O
2	pulmonary	O
3	effects	O
4	observed	O
5	,	O
6	became	O
7	more	O
8	pronounced	O
9	with	O
10	increasing	O
11	NO2	O
12	concentrations	O
13	(	O
14	0	O
15	,	O
16	25	O
17	,	O
18	75	O
19	,	O
20	125	O
21	,	O
22	175	O
23	or	O
24	200	O
25	ppm	O
26	,	O
27	1	O
28	ppm	O
29	NO2	O
30	=	O
31	1	O
32	.	O
33	88	O
34	mg	O
35	m	O
36	-	O
37	3	O
38	NO2	O
39	)	O
40	and	O
41	exposure	O
42	times	O
43	(	O
44	5	O
45	,	O
46	10	O
47	,	O
48	20	O
49	or	O
50	30	O
51	min	O
52	).	O

1	Interaction	O
2	of	O
3	H	B
4	-	I
5	2Eb	I
6	with	O
7	an	O
8	IAP	B
9	retrotransposon	I
10	in	O
11	the	O
12	A20	O
13	/	O
14	2J	O
15	B	O
16	cell	O
17	lymphoma	O
18	.	O

1	Gestational	O
2	trophoblastic	O
3	diseases	O
4	:	O
5	recent	O
6	advances	O
7	in	O
8	the	O
9	understanding	O
10	of	O
11	cytogenetics	O
12	,	O
13	histopathology	O
14	,	O
15	and	O
16	natural	O
17	history	O
18	.	O

1	With	O
2	the	O
3	exception	O
4	of	O
5	mutants	O
6	that	O
7	remove	O
8	the	O
9	membrane	O
10	anchor	O
11	domain	O
12	,	O
13	all	O
14	of	O
15	the	O
16	mutant	O
17	glycoproteins	O
18	retained	O
19	the	O
20	ability	O
21	to	O
22	cause	O
23	fusion	O
24	of	O
25	CD4	B
26	-	O
27	bearing	O
28	cells	O
29	.	O

1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	B
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	B
15	-	I
16	17	I
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O

1	Substitution	O
2	of	O
3	the	O
4	DR1	B
5	beta	I
6	chain	I
7	with	O
8	H	B
9	-	I
10	2E	I
11	beta	I
12	k	I
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	O
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O

1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O

1	The	O
2	distal	O
3	portion	O
4	of	O
5	the	O
6	rat	B
7	insulin	I
8	I	I
9	gene	I
10	5	I
11	'-	I
12	flanking	I
13	DNA	I
14	contains	O
15	two	O
16	sequence	O
17	elements	O
18	,	O
19	the	O
20	Far	O
21	and	O
22	FLAT	O
23	elements	O
24	,	O
25	that	O
26	can	O
27	function	O
28	in	O
29	combination	O
30	,	O
31	but	O
32	not	O
33	separately	O
34	,	O
35	as	O
36	a	O
37	beta	O
38	-	O
39	cell	O
40	-	O
41	specific	O
42	transcriptional	O
43	enhancer	O
44	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	98	O
8	%	O
9	identity	O
10	to	O
11	the	O
12	human	O
13	cellular	O
14	transglutaminase	O
15	sequence	O
16	.	O

1	This	O
2	computation	O
3	is	O
4	performed	O
5	by	O
6	a	O
7	parallel	O
8	network	O
9	of	O
10	locally	O
11	connected	O
12	neuron	O
13	-	O
14	like	O
15	elements	O
16	.	O

1	Repeated	O
2	efforts	O
3	to	O
4	isolate	O
5	recombinant	O
6	baculoviruses	O
7	containing	O
8	a	O
9	wild	O
10	-	O
11	type	O
12	kinase	O
13	failed	O
14	,	O
15	whereas	O
16	recombinants	O
17	expressing	O
18	a	O
19	nonfunctional	O
20	kinase	O
21	with	O
22	a	O
23	catalytic	O
24	domain	O
25	II	O
26	mutation	O
27	were	O
28	readily	O
29	isolated	O
30	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	P68	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	dsRNA	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	dsRNA	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O

1	From	O
2	August	O
3	1989	O
4	to	O
5	October	O
6	1990	O
7	,	O
8	83	O
9	pregnant	O
10	Chinese	O
11	women	O
12	were	O
13	the	O
14	subjects	O
15	for	O
16	measuring	O
17	the	O
18	levels	O
19	of	O
20	plasma	O
21	functional	O
22	antithrombin	B
23	III	I
24	(	O
25	AT	B
26	III	I
27	)	O
28	activity	O
29	.	O

1	Visual	O
2	acuity	O
3	may	O
4	be	O
5	decreased	O
6	by	O
7	transient	O
8	changes	O
9	in	O
10	refractive	O
11	error	O
12	caused	O
13	by	O
14	sulfonamides	O
15	,	O
16	the	O
17	antifungal	O
18	agent	O
19	metronidazole	O
20	,	O
21	thiazide	O
22	diuretics	O
23	,	O
24	and	O
25	carbonic	B
26	anhydrase	I
27	inhibitors	O
28	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	21	O
6	-	O
7	mer	O
8	subrepeat	O
9	structure	O
10	is	O
11	also	O
12	present	O
13	in	O
14	each	O
15	unit	O
16	.	O

1	Sequencing	O
2	revealed	O
3	one	O
4	large	O
5	open	O
6	reading	O
7	frame	O
8	encoding	O
9	a	O
10	39	O
11	-	O
12	kDa	O
13	protein	O
14	.	O

1	These	O
2	sites	O
3	are	O
4	also	O
5	potential	O
6	keratan	O
7	sulfate	O
8	attachment	O
9	sites	O
10	.	O

1	We	O
2	propose	O
3	that	O
4	plasmids	O
5	of	O
6	the	O
7	pLS1	O
8	family	O
9	(	O
10	pE194	O
11	,	O
12	pADB201	O
13	,	O
14	and	O
15	pLB4	O
16	)	O
17	share	O
18	functional	O
19	and	O
20	structural	O
21	characteristics	O
22	for	O
23	the	O
24	regulation	O
25	of	O
26	their	O
27	copy	O
28	numbers	O
29	.	O

1	Perturbation	O
2	of	O
3	dNTP	O
4	pools	O
5	also	O
6	affected	O
7	the	O
8	frameshift	O
9	fidelity	O
10	of	O
11	the	O
12	replicative	O
13	yeast	B
14	DNA	I
15	polymerase	I
16	alpha	I
17	.	O

1	Differential	O
2	expression	O
3	of	O
4	the	O
5	"	O
6	B	O
7	"	O
8	subunit	O
9	of	O
10	the	O
11	vacuolar	B
12	H	I
13	(+)-	I
14	ATPase	I
15	in	O
16	bovine	O
17	tissues	O
18	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	B
6	gene	I
7	was	O
8	chromosomally	O
9	localized	O
10	by	O
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	O
17	pattern	O
18	in	O
19	a	O
20	panel	O
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O

1	At	O
2	some	O
3	sites	O
4	,	O
5	%	O
6	T	O
7	is	O
8	greatly	O
9	increased	O
10	by	O
11	Cl	O
12	-	O
13	concentrations	O
14	up	O
15	to	O
16	1	O
17	M	O
18	,	O
19	while	O
20	at	O
21	other	O
22	sites	O
23	%	O
24	T	O
25	is	O
26	reduced	O
27	or	O
28	unaffected	O
29	by	O
30	these	O
31	conditions	O
32	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	segments	O
6	of	O
7	C3	B
8	represented	O
9	by	O
10	amino	O
11	acid	O
12	residues	O
13	1082	O
14	-	O
15	1118	O
16	,	O
17	1117	O
18	-	O
19	1155	O
20	,	O
21	1234	O
22	-	O
23	1294	O
24	and	O
25	1312	O
26	-	O
27	1404	O
28	accommodate	O
29	C3	B
30	(	I
31	D	I
32	)	I
33	epitopes	I
34	that	O
35	are	O
36	expressed	O
37	by	O
38	erythrocyte	O
39	-	O
40	bound	O
41	C3	B
42	fragments	I
43	,	O
44	but	O
45	not	O
46	by	O
47	the	O
48	corresponding	O
49	fluid	O
50	-	O
51	phase	O
52	fragment	O
53	,	O
54	whereas	O
55	the	O
56	segments	O
57	spanning	O
58	residues	O
59	973	O
60	-	O
61	1026	O
62	and	O
63	1477	O
64	-	O
65	1510	O
66	contain	O
67	C3	B
68	(	I
69	D	I
70	)	I
71	epitopes	I
72	that	O
73	are	O
74	exposed	O
75	exclusively	O
76	in	O
77	denatured	O
78	C3	B
79	and	O
80	therefore	O
81	hidden	O
82	in	O
83	physiological	O
84	fragments	O
85	of	O
86	the	O
87	protein	O
88	.	O

1	These	O
2	exons	O
3	,	O
4	further	O
5	identified	O
6	as	O
7	exons	O
8	9	O
9	,	O
10	10	O
11	,	O
12	and	O
13	11	O
14	,	O
15	together	O
16	encode	O
17	the	O
18	37	O
19	amino	O
20	acid	O
21	residues	O
22	present	O
23	in	O
24	alpha	B
25	s1	I
26	-	I
27	casein	I
28	variant	I
29	A	I
30	but	O
31	missing	O
32	in	O
33	variant	O
34	F	O
35	.	O

1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O

1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	O
12	motif	O
13	,	O
14	with	O
15	GBF1	B
16	and	O
17	GBF3	B
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O

1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	B
13	S1	I
14	analysis	O
15	.	O

1	The	O
2	hydrophobicity	O
3	plot	O
4	of	O
5	NHE	B
6	-	I
7	3	I
8	is	O
9	very	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	NHE	B
15	-	I
16	1	I
17	and	O
18	NHE	B
19	-	I
20	2	I
21	.	O

1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O

1	Each	O
2	group	O
3	received	O
4	15	O
5	ml	O
6	/	O
7	kg	O
8	of	O
9	either	O
10	6	O
11	%	O
12	pentafraction	O
13	,	O
14	6	O
15	%	O
16	pentastarch	O
17	,	O
18	or	O
19	plasma	O
20	followed	O
21	two	O
22	hours	O
23	later	O
24	by	O
25	1	O
26	.	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	/	O
32	0	O
33	.	O
34	5	O
35	hr	O
36	E	O
37	.	O

1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	B
8	-	I
9	Crk	I
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	influencing	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O

1	We	O
2	have	O
3	constructed	O
4	,	O
5	using	O
6	synthetic	O
7	DNA	O
8	oligonucleotides	O
9	,	O
10	a	O
11	U14	B
12	snRNA	I
13	gene	I
14	which	O
15	has	O
16	been	O
17	positioned	O
18	behind	O
19	a	O
20	T7	B
21	RNA	I
22	polymerase	I
23	promoter	I
24	site	I
25	and	O
26	then	O
27	inserted	O
28	into	O
29	a	O
30	plasmid	O
31	.	O

1	Gene	O
2	and	O
3	pseudogene	O
4	of	O
5	the	O
6	mouse	O
7	cation	O
8	-	O
9	dependent	O
10	mannose	B
11	6	I
12	-	I
13	phosphate	I
14	receptor	I
15	.	O

1	The	O
2	chick	O
3	axon	O
4	-	O
5	associated	O
6	surface	O
7	glycoprotein	O
8	neurofascin	B
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O

1	The	O
2	carcinoma	O
3	was	O
4	restricted	O
5	within	O
6	the	O
7	epithelium	O
8	in	O
9	one	O
10	,	O
11	the	O
12	mucosal	O
13	layer	O
14	in	O
15	five	O
16	,	O
17	and	O
18	the	O
19	submucosal	O
20	layer	O
21	in	O
22	two	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	C	B
5	/	I
6	EBP	I
7	beta	I
8	and	O
9	C	B
10	/	I
11	EBP	I
12	gamma	I
13	readily	O
14	heterodimerize	O
15	with	O
16	each	O
17	other	O
18	as	O
19	well	O
20	as	O
21	with	O
22	C	B
23	/	I
24	EBP	I
25	alpha	I
26	.	O

1	In	O
2	contrast	O
3	,	O
4	tobacco	B
5	GS	I
6	-	I
7	2	I
8	is	O
9	composed	O
10	of	O
11	subunits	O
12	of	O
13	identical	O
14	size	O
15	in	O
16	all	O
17	organs	O
18	examined	O
19	.	O

1	Between	O
2	acoR	B
3	and	O
4	acoXABC	B
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	O
29	)-	O
30	ACA	O
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	B
41	and	O
42	NifA	B
43	upstream	I
44	activator	I
45	sequences	I
46	,	O
47	respectively	O
48	.	O

1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O

1	C	O
2	.,	O
3	Sun	O
4	,	O
5	J	O
6	.,	O
7	Hsu	O
8	,	O
9	M	O
10	.-	O
11	Y	O
12	.,	O
13	Vallejo	O
14	-	O
15	Ramirez	O
16	,	O
17	J	O
18	.,	O
19	Inouye	O
20	,	O
21	S	O
22	.,	O
23	and	O
24	Inouye	O
25	,	O
26	M	O
27	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	NC	B
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	tapered	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	prednisone	O
29	per	O
30	day	O
31	.	O

1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O

1	T	B
2	antigen	I
3	contains	O
4	four	O
5	H	O
6	-	O
7	2Db	O
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	O
25	-	O
26	1	O
27	,	O
28	Y	O
29	-	O
30	2	O
31	,	O
32	Y	O
33	-	O
34	3	O
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	The	O
2	method	O
3	requires	O
4	a	O
5	reversed	O
6	-	O
7	phase	O
8	column	O
9	and	O
10	a	O
11	paired	O
12	-	O
13	ion	O
14	technique	O
15	to	O
16	separate	O
17	docusate	O
18	sodium	O
19	from	O
20	other	O
21	components	O
22	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	protein	O
7	product	O
8	of	O
9	the	O
10	ref	B
11	-	I
12	1	I
13	gene	I
14	stimulates	O
15	the	O
16	DNA	O
17	binding	O
18	activity	O
19	of	O
20	Fos	B
21	-	O
22	Jun	B
23	heterodimers	O
24	,	O
25	Jun	B
26	-	O
27	Jun	B
28	homodimers	O
29	and	O
30	Hela	O
31	cell	O
32	AP	B
33	-	I
34	1	I
35	proteins	I
36	as	O
37	well	O
38	as	O
39	that	O
40	of	O
41	several	O
42	other	O
43	transcription	O
44	factors	O
45	including	O
46	NF	B
47	-	I
48	kappa	I
49	B	I
50	,	O
51	Myb	B
52	and	O
53	members	O
54	of	O
55	the	O
56	ATF	B
57	/	O
58	CREB	B
59	family	O
60	.	O

1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O

1	Northern	O
2	blot	O
3	analyses	O
4	demonstrate	O
5	that	O
6	3	O
7	.	O
8	9	O
9	-	O
10	and	O
11	5	O
12	-	O
13	kilobase	O
14	mRNAs	O
15	corresponding	O
16	to	O
17	the	O
18	cDNA	O
19	were	O
20	present	O
21	in	O
22	all	O
23	tissues	O
24	examined	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	protein	O
30	it	O
31	encodes	O
32	performs	O
33	a	O
34	housekeeping	O
35	function	O
36	.	O

1	The	O
2	ARG	B
3	SH2	I
4	domain	I
5	exhibited	O
6	relatively	O
7	weak	O
8	affinity	O
9	for	O
10	BCR	B
11	and	O
12	was	O
13	determined	O
14	to	O
15	bind	O
16	about	O
17	10	O
18	-	O
19	fold	O
20	less	O
21	strongly	O
22	than	O
23	the	O
24	ABL	B
25	SH2	I
26	domain	I
27	.	O

1	We	O
2	analyzed	O
3	an	O
4	EBV	O
5	B	O
6	-	O
7	cell	O
8	clone	O
9	,	O
10	E29	O
11	.	O
12	1	O
13	,	O
14	derived	O
15	from	O
16	an	O
17	11	O
18	week	O
19	-	O
20	old	O
21	embryo	O
22	,	O
23	and	O
24	secreting	O
25	both	O
26	IgM	B
27	kappa	I
28	and	O
29	IgM	B
30	lambda	I
31	.	O

1	Interestingly	O
2	,	O
3	this	O
4	activation	O
5	occurred	O
6	only	O
7	when	O
8	the	O
9	regions	O
10	were	O
11	cloned	O
12	in	O
13	the	O
14	same	O
15	relative	O
16	orientation	O
17	in	O
18	which	O
19	they	O
20	exist	O
21	on	O
22	wild	O
23	-	O
24	type	O
25	pCF10	O
26	.	O

1	In	O
2	rats	O
3	,	O
4	we	O
5	examined	O
6	the	O
7	effect	O
8	of	O
9	an	O
10	omentum	O
11	wrapping	O
12	on	O
13	the	O
14	vascularization	O
15	of	O
16	the	O
17	trachea	O
18	and	O
19	on	O
20	regeneration	O
21	of	O
22	the	O
23	mucosal	O
24	epithelium	O
25	in	O
26	the	O
27	very	O
28	early	O
29	stage	O
30	after	O
31	free	O
32	tracheal	O
33	grafting	O
34	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	B
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	B
53	).	O

1	In	O
2	general	O
3	,	O
4	two	O
5	separate	O
6	high	O
7	-	O
8	performance	O
9	liquid	O
10	chromatographic	O
11	runs	O
12	were	O
13	performed	O
14	,	O
15	one	O
16	for	O
17	the	O
18	gamma	O
19	-	O
20	aminobutyric	O
21	acid	O
22	determination	O
23	and	O
24	one	O
25	for	O
26	the	O
27	determination	O
28	of	O
29	the	O
30	monoamines	O
31	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	Entry	O
2	of	O
3	yeast	O
4	cells	O
5	into	O
6	the	O
7	mitotic	O
8	cell	O
9	cycle	O
10	(	O
11	Start	O
12	)	O
13	involves	O
14	a	O
15	form	O
16	of	O
17	the	O
18	CDC28	B
19	kinase	I
20	that	O
21	associates	O
22	with	O
23	G1	O
24	-	O
25	specific	O
26	cyclins	B
27	encoded	O
28	by	O
29	CLN1	B
30	and	O
31	CLN2	B
32	(	O
33	ref	O
34	.	O

1	Through	O
2	Southern	O
3	blot	O
4	analyses	O
5	of	O
6	DNA	O
7	from	O
8	backcross	O
9	and	O
10	cogenic	O
11	mice	O
12	,	O
13	recombinant	O
14	inbred	O
15	strains	O
16	,	O
17	and	O
18	somatic	O
19	cell	O
20	hybrids	O
21	,	O
22	the	O
23	genetic	O
24	loci	O
25	that	O
26	produce	O
27	the	O
28	cyclin	B
29	B1	I
30	-	I
31	related	I
32	sequences	I
33	(	O
34	designated	O
35	loci	B
36	Cycb1	I
37	-	I
38	rs1	I
39	to	O
40	Cycb1	B
41	-	I
42	rs9	I
43	)	O
44	were	O
45	mapped	O
46	on	O
47	mouse	O
48	chromosomes	O
49	5	O
50	,	O
51	1	O
52	,	O
53	17	O
54	,	O
55	4	O
56	,	O
57	14	O
58	,	O
59	13	O
60	,	O
61	7	O
62	,	O
63	X	O
64	,	O
65	and	O
66	8	O
67	,	O
68	respectively	O
69	.	O

1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	O
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	O
20	be	O
21	identified	O
22	,	O
23	but	O
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	O
39	,	O
40	or	O
41	Ser	O
42	-	O
43	108	O
44	.	O

1	Porcelain	O
2	to	O
3	dentin	O
4	bond	O
5	strength	O
6	with	O
7	a	O
8	dentin	O
9	adhesive	O
10	.	O

1	TBPf	O
2	is	O
3	defined	O
4	as	O
5	a	O
6	quotient	O
7	of	O
8	the	O
9	difference	O
10	of	O
11	the	O
12	first	O
13	and	O
14	the	O
15	second	O
16	measurement	O
17	:	O
18	TBPf	O
19	=	O
20	(	O
21	P1	O
22	-	O
23	P2	O
24	)/(	O
25	A1	O
26	-	O
27	A2	O
28	).	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	Scotchbond	O
6	2	O
7	and	O
8	Prisma	O
9	Universal	O
10	Bond	O
11	2	O
12	are	O
13	effective	O
14	and	O
15	are	O
16	the	O
17	dentine	O
18	bonding	O
19	agents	O
20	of	O
21	choice	O
22	.	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	The	O
2	neurohypophysial	O
3	vasopressin	B
4	and	O
5	oxytocin	B
6	content	O
7	was	O
8	bioassayed	O
9	by	O
10	pressor	O
11	effect	O
12	following	O
13	Dekanski	O
14	or	O
15	milk	O
16	-	O
17	ejection	O
18	activity	O
19	in	O
20	vitro	O
21	following	O
22	van	O
23	Dongen	O
24	and	O
25	Hays	O
26	,	O
27	respectively	O
28	.	O

1	Comments	O
2	are	O
3	given	O
4	on	O
5	the	O
6	present	O
7	status	O
8	of	O
9	regulations	O
10	concerning	O
11	water	O
12	in	O
13	swimming	O
14	pools	O
15	and	O
16	baths	O
17	--	O
18	1991	O
19	--(	O
20	in	O
21	connection	O
22	with	O
23	the	O
24	KOK	O
25	regulations	O
26	--	O
27	1972	O
28	--	O
29	and	O
30	the	O
31	Federal	O
32	German	O
33	standard	O
34	[	O
35	DIN	O
36	]	O
37	No	O
38	.	O

1	If	O
2	no	O
3	reply	O
4	was	O
5	received	O
6	,	O
7	telephone	O
8	contact	O
9	or	O
10	home	O
11	visits	O
12	were	O
13	made	O
14	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	B
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	B
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O

1	Consequently	O
2	,	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	measured	O
8	and	O
9	calculated	O
10	methods	O
11	were	O
12	noted	O
13	in	O
14	oxygen	O
15	uptake	O
16	(	O
17	213	O
18	+/-	O
19	41	O
20	ml	O
21	/	O
22	min	O
23	vs	O
24	193	O
25	+/-	O
26	25	O
27	ml	O
28	/	O
29	min	O
30	,	O
31	p	O
32	<	O
33	0	O
34	.	O
35	001	O
36	),	O
37	oxygen	O
38	delivery	O
39	(	O
40	780	O
41	+/-	O
42	297	O
43	ml	O
44	/	O
45	min	O
46	vs	O
47	716	O
48	+/-	O
49	296	O
50	ml	O
51	/	O
52	min	O
53	,	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	),	O
60	and	O
61	cardiac	O
62	output	O
63	(	O
64	5	O
65	.	O
66	8	O
67	+/-	O
68	2	O
69	.	O
70	2	O
71	L	O
72	/	O
73	min	O
74	vs	O
75	5	O
76	.	O
77	3	O
78	+/-	O
79	1	O
80	.	O
81	8	O
82	L	O
83	/	O
84	min	O
85	,	O
86	p	O
87	<	O
88	0	O
89	.	O
90	001	O
91	).	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	Negatively	O
2	supercoiled	O
3	plasmid	O
4	pUC19	O
5	did	O
6	not	O
7	compete	O
8	,	O
9	whereas	O
10	an	O
11	otherwise	O
12	identical	O
13	plasmid	O
14	pUC19	O
15	(	O
16	CG	O
17	),	O
18	which	O
19	contained	O
20	a	O
21	(	O
22	dG	O
23	-	O
24	dC	O
25	)	O
26	7	O
27	segment	O
28	in	O
29	the	O
30	Z	O
31	-	O
32	form	O
33	was	O
34	an	O
35	excellent	O
36	competitor	O
37	.	O

1	A	O
2	cDNA	O
3	library	O
4	of	O
5	tumour	O
6	cells	O
7	was	O
8	screened	O
9	with	O
10	an	O
11	interleukin	B
12	2	I
13	gene	O
14	-	O
15	specific	O
16	probe	O
17	.	O

1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	B
7	gene	I
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	B
15	transcription	I
16	factor	I
17	GATA	I
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	lumenal	O
6	domains	O
7	of	O
8	Sec12p	B
9	,	O
10	Stl1p	B
11	and	O
12	Stl2p	B
13	are	O
14	very	O
15	different	O
16	in	O
17	size	O
18	and	O
19	do	O
20	not	O
21	show	O
22	any	O
23	appreciable	O
24	homology	O
25	.	O

1	Complexes	O
2	containing	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	either	O
8	his175	B
9	or	I
10	his273	I
11	mutant	I
12	p53	I
13	proteins	I
14	are	O
15	completely	O
16	unable	O
17	to	O
18	bind	O
19	to	O
20	the	O
21	RGC	B
22	DNA	I
23	sequence	I
24	.	O

1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	B
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	B
26	polymerases	I
27	I	I
28	,	I
29	II	I
30	,	I
31	and	I
32	III	I
33	in	O
34	vitro	O
35	.	O

1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	I
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O

1	The	O
2	gene	O
3	sequence	O
4	also	O
5	identified	O
6	a	O
7	340	O
8	-	O
9	nucleotide	O
10	RNA	O
11	in	O
12	total	O
13	yeast	O
14	RNA	O
15	and	O
16	in	O
17	purified	O
18	RNase	B
19	MRP	I
20	enzyme	I
21	preparations	O
22	.	O

1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O

1	Clone	O
2	pSRc200	O
3	hybrid	O
4	selected	O
5	an	O
6	mRNA	O
7	that	O
8	on	O
9	cell	O
10	-	O
11	free	O
12	translation	O
13	produced	O
14	a	O
15	38	O
16	-	O
17	kDa	O
18	polypeptide	O
19	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	Cleavage	O
2	by	O
3	the	O
4	intron	O
5	-	O
6	encoded	O
7	enzyme	O
8	(	O
9	I	B
10	-	I
11	CreI	I
12	)	O
13	occurs	O
14	5	O
15	bp	O
16	and	O
17	1	O
18	bp	O
19	3	O
20	'	O
21	to	O
22	the	O
23	intron	O
24	insertion	O
25	site	O
26	(	O
27	in	O
28	the	O
29	3	O
30	'-	O
31	exon	O
32	)	O
33	in	O
34	the	O
35	top	O
36	(/)	O
37	and	O
38	bottom	O
39	(,)	O
40	strands	O
41	,	O
42	respectively	O
43	,	O
44	resulting	O
45	in	O
46	4	O
47	-	O
48	nt	O
49	single	O
50	-	O
51	stranded	O
52	overhangs	O
53	with	O
54	3	O
55	'-	O
56	OH	O
57	termini	O
58	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	Xenopus	B
5	U7	I
6	gene	I
7	contains	O
8	two	O
9	adjacent	O
10	octamer	O
11	-	O
12	binding	O
13	motifs	O
14	located	O
15	only	O
16	12	O
17	and	O
18	24	O
19	bp	O
20	upstream	O
21	from	O
22	the	O
23	PSE	B
24	,	O
25	instead	O
26	of	O
27	the	O
28	usual	O
29	location	O
30	around	O
31	150	O
32	-	O
33	200	O
34	bp	O
35	upstream	O
36	.	O

1	The	O
2	results	O
3	support	O
4	earlier	O
5	reports	O
6	that	O
7	collagenase	B
8	inhibitors	O
9	are	O
10	useful	O
11	in	O
12	controlling	O
13	blister	O
14	formation	O
15	in	O
16	recessive	O
17	dystrophic	O
18	epidermolysis	O
19	bullosa	O
20	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	essential	O
5	IncP	O
6	alpha	O
7	plasmid	O
8	transfer	O
9	genes	O
10	traF	B
11	and	O
12	traG	B
13	and	O
14	involvement	O
15	of	O
16	traF	B
17	in	O
18	phage	O
19	sensitivity	O
20	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	B
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	B
11	(	O
12	muscle	O
13	),	O
14	L	B
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	I
7	E	I
8	-	O
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	B
24	AMPD3	I
25	cDNA	I
26	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	salsolinol	O
11	into	O
12	N	O
13	-	O
14	methylsalsolinol	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O

1	DR1	B
2	molecules	I
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O

1	This	O
2	article	O
3	describes	O
4	the	O
5	collaborative	O
6	care	O
7	of	O
8	the	O
9	woman	O
10	participating	O
11	in	O
12	maternal	O
13	blood	O
14	donation	O
15	for	O
16	intrauterine	O
17	transfusion	O
18	.	O

1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O

1	Behind	O
2	the	O
3	ATPase	B
4	cluster	I
5	,	O
6	two	O
7	open	O
8	reading	O
9	frames	O
10	were	O
11	detected	O
12	that	O
13	are	O
14	not	O
15	homologous	O
16	to	O
17	any	O
18	known	O
19	chloroplast	O
20	gene	O
21	.	O

1	Therefore	O
2	,	O
3	recombinant	O
4	human	O
5	Ads	O
6	that	O
7	express	O
8	noninfectious	O
9	HIV	O
10	or	O
11	other	O
12	microbial	O
13	proteins	O
14	are	O
15	attractive	O
16	vaccine	O
17	candidates	O
18	.	O

1	Alignment	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	predict	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	homodimeric	O
19	Rel	B
20	-	I
21	related	I
22	proteins	I
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O

1	Using	O
2	either	O
3	a	O
4	p50	B
5	-	O
6	or	O
7	p65	B
8	-	I
9	selected	I
10	kappa	I
11	B	I
12	motif	I
13	,	O
14	which	O
15	displayed	O
16	differential	O
17	binding	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	other	O
23	protein	O
24	,	O
25	little	O
26	to	O
27	no	O
28	binding	O
29	was	O
30	observed	O
31	with	O
32	the	O
33	heterodimeric	B
34	NF	I
35	-	I
36	kappa	I
37	B	I
38	complex	I
39	.	O

1	However	O
2	,	O
3	a	O
4	cosmid	O
5	clone	O
6	containing	O
7	the	O
8	entire	O
9	mouse	B
10	alpha	I
11	1	I
12	(	I
13	I	I
14	)	I
15	gene	I
16	,	O
17	including	O
18	3	O
19	.	O
20	7	O
21	kb	O
22	of	O
23	5	O
24	'-	O
25	and	O
26	4	O
27	kb	O
28	of	O
29	3	O
30	'-	O
31	flanking	O
32	DNA	O
33	,	O
34	was	O
35	expressed	O
36	at	O
37	reduced	O
38	levels	O
39	in	O
40	fibroblasts	O
41	overexpressing	O
42	oncogenic	B
43	ras	I
44	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O

1	Sequencing	O
2	analysis	O
3	has	O
4	shown	O
5	that	O
6	each	O
7	rap1t	B
8	allele	I
9	contains	O
10	a	O
11	nonsense	O
12	mutation	O
13	within	O
14	a	O
15	discrete	O
16	region	O
17	between	O
18	amino	O
19	acids	O
20	663	O
21	and	O
22	684	O
23	.	O

1	By	O
2	screening	O
3	a	O
4	Y1	O
5	cell	O
6	cDNA	O
7	library	O
8	with	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	region	O
14	of	O
15	the	O
16	H	B
17	-	I
18	2RIIBP	I
19	nuclear	I
20	hormone	I
21	receptor	I
22	cDNA	I
23	,	O
24	we	O
25	isolated	O
26	a	O
27	cDNA	O
28	that	O
29	is	O
30	selectively	O
31	expressed	O
32	in	O
33	steroidogenic	O
34	cells	O
35	.	O

1	Autopsy	O
2	demonstrated	O
3	good	O
4	survival	O
5	of	O
6	the	O
7	transplanted	O
8	cells	O
9	with	O
10	good	O
11	integration	O
12	with	O
13	the	O
14	brain	O
15	of	O
16	the	O
17	recipient	O
18	and	O
19	traces	O
20	of	O
21	positive	O
22	immunocytochemical	O
23	reaction	O
24	for	O
25	tyrosine	B
26	hydroxylase	I
27	.	O

1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O

1	The	O
2	sequence	O
3	of	O
4	this	O
5	region	O
6	shows	O
7	high	O
8	G	O
9	+	O
10	C	O
11	content	O
12	(	O
13	62	O
14	%),	O
15	which	O
16	is	O
17	particularly	O
18	emphasized	O
19	in	O
20	the	O
21	200	O
22	bp	O
23	upstream	O
24	from	O
25	the	O
26	mRNA	O
27	start	O
28	(	O
29	80	O
30	%	O
31	G	O
32	+	O
33	C	O
34	).	O

1	In	O
2	the	O
3	eight	O
4	patients	O
5	with	O
6	persistent	O
7	generalized	O
8	lymph	O
9	-	O
10	adenopathy	O
11	(	O
12	PGL	O
13	)	O
14	and	O
15	nontender	O
16	,	O
17	nonenlarging	O
18	nodes	O
19	,	O
20	pathologic	O
21	analysis	O
22	revealed	O
23	lymphoid	O
24	hyperplasia	O
25	.	O

1	PaO2	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	indwelling	O
8	O2	O
9	sensor	O
10	catheter	O
11	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	By	O
2	using	O
3	lambda	O
4	gt11	O
5	expression	O
6	cloning	O
7	with	O
8	oligonucleotides	O
9	corresponding	O
10	to	O
11	the	O
12	human	O
13	immunodeficiency	O
14	virus	O
15	1	O
16	TATA	O
17	element	O
18	,	O
19	we	O
20	report	O
21	the	O
22	identification	O
23	of	O
24	a	O
25	cellular	O
26	protein	O
27	with	O
28	a	O
29	calculated	O
30	molecular	O
31	mass	O
32	of	O
33	123	O
34	kDa	O
35	that	O
36	we	O
37	designate	O
38	TATA	B
39	element	I
40	modulatory	I
41	factor	I
42	(	O
43	TMF	B
44	).	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	We	O
2	couldn	O
3	'	O
4	t	O
5	detect	O
6	any	O
7	effect	O
8	of	O
9	n	O
10	-	O
11	3	O
12	FA	O
13	supplementation	O
14	on	O
15	total	O
16	cholesterol	O
17	,	O
18	HDL	B
19	cholesterol	I
20	,	O
21	LDL	B
22	cholesterol	I
23	,	O
24	apo	B
25	A1	I
26	,	O
27	Lp	O
28	(	O
29	a	O
30	),	O
31	HbA1C	B
32	,	O
33	glucose	O
34	,	O
35	fibrinogen	B
36	,	O
37	factor	B
38	VIII	I
39	,	O
40	antithrombin	B
41	III	I
42	,	O
43	plasminogen	B
44	activator	I
45	inhibitor	I
46	,	O
47	tissue	B
48	plasminogen	I
49	activator	I
50	and	O
51	von	B
52	Willebrand	I
53	factor	I
54	concentration	O
55	,	O
56	on	O
57	bleeding	O
58	time	O
59	or	O
60	on	O
61	systolic	O
62	or	O
63	diastolic	O
64	blood	O
65	pressure	O
66	.	O

1	In	O
2	8	O
3	healthy	O
4	volunteers	O
5	there	O
6	were	O
7	no	O
8	significant	O
9	differences	O
10	in	O
11	AUC	O
12	,	O
13	peak	O
14	plasma	O
15	concentrations	O
16	or	O
17	time	O
18	to	O
19	peak	O
20	concentration	O
21	when	O
22	OXC	O
23	was	O
24	administered	O
25	either	O
26	with	O
27	or	O
28	without	O
29	ERY	O
30	.	O

1	Using	O
2	5	O
3	ng	O
4	/	O
5	mL	O
6	as	O
7	the	O
8	cutoff	O
9	,	O
10	the	O
11	sensitivity	O
12	of	O
13	CEA	B
14	was	O
15	68	O
16	%.	O

1	Rolandic	O
2	spikes	O
3	and	O
4	cognitive	O
5	function	O
6	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	18	O
6	beta	O
7	-	O
8	glycyrrhetate	O
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O

1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O

1	The	O
2	effects	O
3	of	O
4	diltiazem	O
5	were	O
6	stereoselective	O
7	,	O
8	thus	O
9	the	O
10	potentiation	O
11	induced	O
12	by	O
13	d	O
14	-	O
15	cis	O
16	diltiazem	O
17	was	O
18	significantly	O
19	greater	O
20	in	O
21	all	O
22	cases	O
23	than	O
24	that	O
25	induced	O
26	by	O
27	l	O
28	-	O
29	cis	O
30	diltiazem	O
31	,	O
32	which	O
33	suggests	O
34	that	O
35	calcium	O
36	channel	O
37	blockade	O
38	plays	O
39	a	O
40	role	O
41	in	O
42	these	O
43	interactions	O
44	.	O

1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	O
9	stimulator	O
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O

1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	O
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	O
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O

1	Significance	O
2	of	O
3	the	O
4	biopsy	O
5	site	O
6	of	O
7	the	O
8	latissimus	O
9	dorsi	O
10	muscle	O
11	for	O
12	fiber	O
13	typing	O
14	.	O

1	The	O
2	TIMP	B
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	O
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	B
13	tissue	I
14	inhibitor	I
15	of	I
16	metalloproteinases	I
17	-	I
18	1	I
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	Of	O
2	the	O
3	serum	B
4	neutralizing	I
5	(	I
6	SN	I
7	)	I
8	antibody	I
9	negative	O
10	calves	O
11	89	O
12	.	O
13	7	O
14	%	O
15	(	O
16	26	O
17	/	O
18	29	O
19	)	O
20	and	O
21	92	O
22	.	O
23	8	O
24	%	O
25	(	O
26	90	O
27	/	O
28	97	O
29	)	O
30	developed	O
31	SN	B
32	antibody	I
33	1	O
34	month	O
35	after	O
36	intranasal	O
37	and	O
38	intramuscular	O
39	vaccination	O
40	,	O
41	respectively	O
42	.	O

1	Fractionation	O
2	of	O
3	crude	O
4	nuclear	O
5	extracts	O
6	by	O
7	heparin	O
8	-	O
9	agarose	O
10	chromatography	O
11	indicates	O
12	that	O
13	PCAT	B
14	-	I
15	1	I
16	is	O
17	more	O
18	prevalent	O
19	in	O
20	extracts	O
21	prepared	O
22	from	O
23	salt	O
24	-	O
25	stressed	O
26	leaf	O
27	tissue	O
28	.	O

1	A	O
2	controlled	O
3	trial	O
4	of	O
5	recombinant	B
6	human	I
7	granulocyte	I
8	-	I
9	macrophage	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	after	O
15	total	O
16	body	O
17	irradiation	O
18	,	O
19	high	O
20	-	O
21	dose	O
22	chemotherapy	O
23	,	O
24	and	O
25	autologous	O
26	bone	O
27	marrow	O
28	transplantation	O
29	for	O
30	acute	O
31	lymphoblastic	O
32	leukemia	O
33	or	O
34	malignant	O
35	lymphoma	O
36	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	DMVA	O
6	does	O
7	not	O
8	cause	O
9	more	O
10	myocardial	O
11	trauma	O
12	than	O
13	CPB	O
14	when	O
15	used	O
16	to	O
17	provide	O
18	resuscitative	O
19	circulatory	O
20	support	O
21	.	O

1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	B
21	approximately	O
22	IgG2	B
23	>	O
24	IgG3	B
25	>	O
26	IgG4	B
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O

1	Examination	O
2	of	O
3	ANCA	B
4	is	O
5	not	O
6	only	O
7	a	O
8	significant	O
9	contribution	O
10	towards	O
11	a	O
12	more	O
13	accurate	O
14	diagnosis	O
15	of	O
16	renal	O
17	vasculitis	O
18	,	O
19	but	O
20	also	O
21	an	O
22	indicator	O
23	of	O
24	the	O
25	activity	O
26	of	O
27	the	O
28	disease	O
29	and	O
30	thus	O
31	of	O
32	the	O
33	effectiveness	O
34	of	O
35	immunosuppressive	O
36	treatment	O
37	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	total	O
7	pinealectomy	O
8	in	O
9	these	O
10	already	O
11	sympathectomized	O
12	blinded	O
13	rabbits	O
14	always	O
15	resulted	O
16	in	O
17	a	O
18	substantial	O
19	deceleration	O
20	of	O
21	the	O
22	rhythms	O
23	(	O
24	mean	O
25	delta	O
26	tau	O
27	=	O
28	+	O
29	0	O
30	.	O
31	23	O
32	h	O
33	).	O

1	Cicatricial	O
2	pemphigoid	O
3	is	O
4	an	O
5	autoimmune	O
6	systemic	O
7	disease	O
8	characterized	O
9	by	O
10	chronic	O
11	conjunctival	O
12	cicatrization	O
13	.	O

1	The	O
2	effects	O
3	of	O
4	two	O
5	levels	O
6	of	O
7	caffeine	O
8	ingestion	O
9	on	O
10	excess	O
11	postexercise	O
12	oxygen	O
13	consumption	O
14	in	O
15	untrained	O
16	women	O
17	.	O

1	The	O
2	distinguishing	O
3	features	O
4	involved	O
5	eight	O
6	amino	O
7	acid	O
8	changes	O
9	,	O
10	including	O
11	a	O
12	single	O
13	lysine	O
14	deletion	O
15	relative	O
16	to	O
17	a	O
18	primate	O
19	consensus	O
20	sequence	O
21	in	O
22	the	O
23	first	O
24	complementary	O
25	-	O
26	determing	O
27	region	O
28	of	O
29	V1J1	B
30	.	O

1	4	O
2	.	O

1	The	O
2	in	O
3	vivo	O
4	profile	O
5	of	O
6	ZFH	B
7	-	I
8	2	I
9	in	O
10	the	O
11	larval	O
12	CNS	O
13	shows	O
14	intriguing	O
15	overlap	O
16	with	O
17	DDC	B
18	in	O
19	specific	O
20	serotonin	O
21	and	O
22	dopamine	O
23	neurons	O
24	.	O

1	Unlike	O
2	the	O
3	introns	O
4	of	O
5	other	O
6	duplicated	O
7	ribosomal	B
8	protein	I
9	genes	I
10	which	O
11	are	O
12	highly	O
13	diverged	O
14	,	O
15	the	O
16	duplicated	O
17	S13	B
18	genes	I
19	have	O
20	two	O
21	nearly	O
22	identical	O
23	DNA	O
24	sequences	O
25	of	O
26	25	O
27	and	O
28	31	O
29	bp	O
30	in	O
31	length	O
32	within	O
33	their	O
34	introns	O
35	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	Therefore	O
2	,	O
3	it	O
4	would	O
5	be	O
6	advantageous	O
7	to	O
8	identify	O
9	such	O
10	persons	O
11	and	O
12	treat	O
13	them	O
14	preferentially	O
15	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	unique	O
7	properties	O
8	,	O
9	the	O
10	newly	O
11	characterized	O
12	hemagglutinin	B
13	has	O
14	been	O
15	termed	O
16	Limulus	B
17	18K	I
18	agglutination	I
19	-	I
20	aggregation	I
21	factor	I
22	(	O
23	18K	B
24	-	I
25	LAF	I
26	).	O

1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	O
13	guanyl	O
14	nucleotide	O
15	-	O
16	dependent	O
17	activity	O
18	of	O
19	adenylylcyclase	B
20	in	O
21	vitro	O
22	.	O

1	Clin	O
2	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	B
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O

1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	presequence	O
8	and	O
9	the	O
10	lipoyl	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	O
25	E2	B
26	gene	I
27	.	O

1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O

1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	B
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O

1	A	O
2	mutant	O
3	form	O
4	of	O
5	Vps1p	B
6	lacking	O
7	the	O
8	entire	O
9	GTP	O
10	-	O
11	binding	O
12	domain	O
13	interfered	O
14	with	O
15	vacuolar	O
16	protein	O
17	sorting	O
18	in	O
19	wild	O
20	-	O
21	type	O
22	cells	O
23	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	B
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	B
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	"	O
7	macro	O
8	"	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	polyhedrin	B
9	gene	I
10	of	O
11	Spodoptera	O
12	exigua	O
13	nuclear	O
14	polyhedrosis	O
15	virus	O
16	.	O

1	Validation	O
2	of	O
3	automated	O
4	systems	O
5	--	O
6	system	O
7	definition	O
8	.	O

1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O

1	Subcutaneous	O
2	administration	O
3	of	O
4	the	O
5	somatostatin	B
6	analogue	O
7	,	O
8	octreotide	O
9	,	O
10	100	O
11	micrograms	O
12	thrice	O
13	daily	O
14	,	O
15	resulted	O
16	in	O
17	a	O
18	sustained	O
19	improvement	O
20	in	O
21	diarrhoea	O
22	and	O
23	disappearance	O
24	of	O
25	faecal	O
26	incontinence	O
27	without	O
28	reducing	O
29	calcitonin	B
30	levels	O
31	.	O

1	Anti	B
2	-	I
3	CRK	I
4	antibodies	I
5	detect	O
6	a	O
7	53kDa	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	fasciculata	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O

1	205	O
2	,	O
3	285	O
4	-	O
5	290	O
6	]	O
7	and	O
8	was	O
9	subsequently	O
10	cloned	O
11	and	O
12	sequenced	O
13	[	O
14	J	O
15	.	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	Use	O
2	of	O
3	free	O
4	-	O
5	access	O
6	minerals	O
7	.	O

1	Interferon	B
2	type	I
3	I	I
4	in	O
5	protective	O
6	body	O
7	reactions	O
8	in	O
9	an	O
10	experimental	O
11	Klebsiella	O
12	infection	O

1	No	O
2	other	O
3	changes	O
4	in	O
5	hematopoietic	O
6	differentiation	O
7	status	O
8	were	O
9	observed	O
10	in	O
11	association	O
12	with	O
13	Id	B
14	-	I
15	SCL	I
16	expression	O
17	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	One	O
2	air	O
3	embolism	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	retrieval	O
14	-	O
15	related	O
16	complication	O
17	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	B
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	O
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	I
37	.	O

1	V	O
2	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	RNK	B
6	-	I
7	Met	I
8	-	I
9	1	I
10	is	O
11	a	O
12	serine	B
13	protease	I
14	with	O
15	unique	O
16	activity	O
17	that	O
18	is	O
19	expressed	O
20	in	O
21	the	O
22	granules	O
23	of	O
24	large	O
25	granular	O
26	lymphocytes	O
27	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	We	O
2	describe	O
3	here	O
4	17	O
5	dominant	B
6	GCN2	I
7	mutations	I
8	that	O
9	lead	O
10	to	O
11	derepression	O
12	of	O
13	GCN4	B
14	expression	O
15	in	O
16	the	O
17	absence	O
18	of	O
19	amino	O
20	acid	O
21	starvation	O
22	.	O

1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	B
26	clover	I
27	mottle	I
28	virus	I
29	RNA	I
30	1	I
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	B
50	presumed	I
51	helicase	I
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	B
68	presumed	I
69	polymerase	I
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O

1	Rice	B
2	dwarf	I
3	phytoreovirus	I
4	segment	I
5	S12	I
6	transcript	I
7	is	O
8	tricistronic	O
9	in	O
10	vitro	O
11	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	Cold	O
2	cardioplegia	O
3	was	O
4	administered	O
5	at	O
6	45	O
7	mm	O
8	Hg	O
9	every	O
10	20	O
11	minutes	O
12	for	O
13	2	O
14	hours	O
15	.	O

1	The	O
2	addition	O
3	of	O
4	diatrizoate	O
5	to	O
6	the	O
7	IPRK	O
8	led	O
9	to	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	biphasic	O
15	change	O
16	in	O
17	RPF	O
18	and	O
19	GFR	O
20	characterized	O
21	by	O
22	an	O
23	initial	O
24	transient	O
25	increase	O
26	followed	O
27	by	O
28	a	O
29	marked	O
30	and	O
31	sustained	O
32	decrease	O
33	.	O

1	To	O
2	prepare	O
3	for	O
4	analyses	O
5	with	O
6	the	O
7	family	O
8	variables	O
9	,	O
10	we	O
11	next	O
12	present	O
13	descriptive	O
14	data	O
15	based	O
16	on	O
17	separate	O
18	principal	O
19	components	O
20	analysis	O
21	(	O
22	PCA	O
23	)	O
24	and	O
25	multidimensional	O
26	scaling	O
27	analysis	O
28	(	O
29	MDS	O
30	)	O
31	of	O
32	14	O
33	self	O
34	-	O
35	reported	O
36	health	O
37	scores	O
38	for	O
39	husbands	O
40	and	O
41	for	O
42	wives	O
43	.	O

1	The	O
2	structural	O
3	genes	O
4	encoding	O
5	glyceraldehyde	B
6	-	I
7	3	I
8	-	I
9	phosphate	I
10	dehydrogenase	I
11	(	O
12	GAPDH	B
13	),	O
14	3	B
15	-	I
16	phosphoglycerate	I
17	kinase	I
18	(	O
19	PGK	B
20	)	O
21	and	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	triosephosphate	B
29	isomerase	I
30	(	O
31	TIM	B
32	)	O
33	from	O
34	mesophilic	O
35	Bacillus	O
36	megaterium	O
37	DSM319	O
38	have	O
39	been	O
40	cloned	O
41	as	O
42	a	O
43	gene	O
44	cluster	O
45	(	O
46	gap	B
47	operon	I
48	)	O
49	by	O
50	complementation	O
51	of	O
52	an	O
53	Escherichia	O
54	coli	O
55	gap	B
56	amber	I
57	mutant	I
58	.	O

1	Pseudomonas	B
2	aeruginosa	I
3	exotoxin	I
4	A	I
5	:	O
6	its	O
7	role	O
8	in	O
9	retardation	O
10	of	O
11	wound	O
12	healing	O
13	:	O
14	the	O
15	1992	O
16	Lindberg	O
17	Award	O
18	.	O

1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O

1	To	O
2	study	O
3	the	O
4	significance	O
5	of	O
6	these	O
7	domains	O
8	and	O
9	the	O
10	overall	O
11	evolutionary	O
12	conservation	O
13	of	O
14	the	O
15	gene	O
16	,	O
17	the	O
18	homolog	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	was	O
23	isolated	O
24	by	O
25	low	O
26	stringency	O
27	hybridizations	O
28	using	O
29	two	O
30	flanking	O
31	probes	O
32	of	O
33	the	O
34	human	B
35	ERCC3	I
36	cDNA	I
37	.	O

1	Mono	O
2	-	O
3	ADP	O
4	-	O
5	ribosylation	O
6	is	O
7	a	O
8	reversible	O
9	modification	O
10	of	O
11	proteins	O
12	,	O
13	with	O
14	NAD	O
15	:	O
16	arginine	B
17	ADP	I
18	-	I
19	ribosyltransferases	I
20	(	O
21	EC	B
22	2	I
23	.	I
24	4	I
25	.	I
26	2	I
27	.	I
28	31	I
29	)	O
30	and	O
31	ADP	B
32	-	I
33	ribosylarginine	I
34	hydrolases	I
35	(	O
36	EC	B
37	3	I
38	.	I
39	2	I
40	.	I
41	2	I
42	.	I
43	19	I
44	)	O
45	catalyzing	O
46	the	O
47	opposing	O
48	reactions	O
49	in	O
50	an	O
51	ADP	O
52	-	O
53	ribosylation	O
54	cycle	O
55	.	O

1	For	O
2	this	O
3	reason	O
4	,	O
5	the	O
6	particle	O
7	forming	O
8	capacity	O
9	of	O
10	derivatives	O
11	of	O
12	the	O
13	HIV	B
14	-	I
15	1	I
16	group	I
17	specific	I
18	core	I
19	antigen	I
20	p55	I
21	gag	I
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	O
30	systems	O
31	:	O
32	recombinant	O
33	bacteria	O
34	,	O
35	vaccinia	O
36	-	O
37	and	O
38	baculoviruses	O
39	were	O
40	established	O
41	encoding	O
42	the	O
43	entire	O
44	core	B
45	protein	I
46	p55	I
47	either	O
48	in	O
49	its	O
50	authentic	O
51	sequence	O
52	or	O
53	lacking	O
54	the	O
55	myristylation	O
56	consensus	O
57	signal	O
58	.	O

1	The	O
2	tramtrack	B
3	(	O
4	ttk	B
5	)	O
6	gene	O
7	of	O
8	Drosophila	O
9	encodes	O
10	69	O
11	-	O
12	kDa	O
13	and	O
14	88	O
15	-	O
16	kDa	O
17	proteins	O
18	through	O
19	alternative	O
20	splicing	O
21	of	O
22	the	O
23	primary	O
24	ttk	B
25	transcript	I
26	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	Adapromine	O
2	was	O
3	established	O
4	to	O
5	evoke	O
6	a	O
7	decrease	O
8	of	O
9	the	O
10	amplitude	O
11	of	O
12	the	O
13	dominant	O
14	peak	O
15	and	O
16	dominant	O
17	theta	O
18	-	O
19	activity	O
20	in	O
21	power	O
22	spectra	O
23	of	O
24	the	O
25	EEG	O
26	in	O
27	the	O
28	cortex	O
29	and	O
30	hippocamp	O
31	,	O
32	with	O
33	an	O
34	increase	O
35	of	O
36	rapid	O
37	wave	O
38	activity	O
39	in	O
40	the	O
41	beta	O
42	2	O
43	range	O
44	in	O
45	the	O
46	right	O
47	cortex	O
48	and	O
49	hippocamp	O
50	.	O

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	Four	O
2	ruminally	O
3	and	O
4	duodenally	O
5	cannulated	O
6	Hampshire	O
7	wethers	O
8	were	O
9	used	O
10	in	O
11	a	O
12	4	O
13	x	O
14	4	O
15	Latin	O
16	square	O
17	experiment	O
18	to	O
19	determine	O
20	whether	O
21	linoleoyl	O
22	methionine	O
23	and	O
24	calcium	O
25	linoleate	O
26	would	O
27	increase	O
28	duodenal	O
29	flow	O
30	of	O
31	unsaturated	O
32	fatty	O
33	acids	O
34	(	O
35	C18	O
36	:	O
37	2	O
38	+	O
39	cis	O
40	C18	O
41	:	O
42	1	O
43	).	O

1	Truncated	B
2	ICSBP	I
3	lacking	O
4	the	O
5	first	O
6	33	O
7	amino	O
8	-	O
9	terminal	O
10	amino	O
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	B
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	Therefore	O
2	,	O
3	ICSBP	B
4	may	O
5	be	O
6	involved	O
7	in	O
8	maintaining	O
9	submaximal	O
10	transcriptional	O
11	activity	O
12	of	O
13	IFN	B
14	-	O
15	inducible	O
16	genes	O
17	in	O
18	hematopoietic	O
19	cells	O
20	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	Dynamic	O
2	decision	O
3	making	O
4	:	O
5	human	O
6	control	O
7	of	O
8	complex	O
9	systems	O
10	.	O

1	A	O
2	coiled	B
3	-	I
4	coil	I
5	related	I
6	protein	I
7	specific	O
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	Comparable	O
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	O
23	-	O
24	binding	O
25	fragment	O
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Abstracts	O
2	.	O

1	These	O
2	results	O
3	indicate	O
4	a	O
5	possible	O
6	involvement	O
7	of	O
8	endogenous	O
9	opioid	O
10	peptides	O
11	in	O
12	the	O
13	cardiac	O
14	effects	O
15	due	O
16	to	O
17	myocardial	O
18	ischaemia	O
19	and	O
20	reperfusion	O
21	,	O
22	mediated	O
23	by	O
24	opiate	B
25	receptors	I
26	through	O
27	opiate	O
28	antagonism	O
29	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	B
6	and	O
7	HIS3	B
8	cDNAs	O
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	Among	O
2	these	O
3	,	O
4	ACT1	B
5	was	O
6	isolated	O
7	four	O
8	times	O
9	,	O
10	and	O
11	NSR1	B
12	three	O
13	times	O
14	.	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	B
41	acid	I
42	decarboxylase	I
43	.	O

1	However	O
2	,	O
3	in	O
4	the	O
5	subgroup	O
6	with	O
7	normal	O
8	Ht	O
9	(<	O
10	0	O
11	.	O
12	45	O
13	l	O
14	/	O
15	l	O
16	;	O
17	n	O
18	=	O
19	201	O
20	)	O
21	there	O
22	was	O
23	a	O
24	significant	O
25	reduction	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	05	O
32	)	O
33	of	O
34	the	O
35	mortality	O
36	after	O
37	3	O
38	months	O
39	(	O
40	27	O
41	%	O
42	and	O
43	16	O
44	%,	O
45	respectively	O
46	)	O
47	and	O
48	an	O
49	increase	O
50	of	O
51	independence	O
52	at	O
53	home	O
54	(	O
55	35	O
56	%	O
57	and	O
58	48	O
59	%,	O
60	respectively	O
61	)	O
62	due	O
63	to	O
64	a	O
65	reduction	O
66	of	O
67	the	O
68	viscosity	O
69	by	O
70	means	O
71	of	O
72	haemodilution	O
73	with	O
74	albumin	B
75	(	O
76	a	O
77	specific	O
78	viscosity	O
79	effect	O
80	in	O
81	the	O
82	normovolaemic	O
83	group	O
84	).	O

1	Distribution	O
2	and	O
3	changing	O
4	morphological	O
5	course	O

1	The	O
2	appropriate	O
3	use	O
4	and	O
5	benefits	O
6	of	O
7	bile	O
8	acid	O
9	sequestrants	O
10	,	O
11	nicotinic	O
12	acid	O
13	,	O
14	fibric	O
15	acids	O
16	,	O
17	3	B
18	-	I
19	hydroxy	I
20	-	I
21	3	I
22	-	I
23	methylglutaryl	I
24	coenzyme	I
25	A	I
26	(	I
27	HMG	I
28	-	I
29	CoA	I
30	)	I
31	reductase	I
32	inhibitors	O
33	,	O
34	and	O
35	probucol	O
36	are	O
37	individually	O
38	discussed	O
39	,	O
40	whereas	O
41	nonpharmacologic	O
42	approaches	O
43	used	O
44	in	O
45	conjunction	O
46	with	O
47	the	O
48	drugs	O
49	are	O
50	recommended	O
51	emphatically	O
52	.	O

1	This	O
2	may	O
3	result	O
4	in	O
5	more	O
6	reabsorption	O
7	and	O
8	hence	O
9	reduced	O
10	renal	O
11	clearance	O
12	.	O

1	The	O
2	major	O
3	pathological	O
4	findings	O
5	of	O
6	the	O
7	placenta	O
8	were	O
9	prematuration	O
10	and	O
11	hypoplasia	O
12	.	O

1	Green	O
2	pepper	O
3	significantly	O
4	inhibited	O
5	N	O
6	-	O
7	nitrosothiazolidine	O
8	-	O
9	carboxylic	O
10	acid	O
11	formation	O
12	relative	O
13	to	O
14	ascorbic	O
15	acid	O
16	alone	O
17	.	O

1	A	O
2	genomic	O
3	clone	O
4	,	O
5	pTt21	O
6	,	O
7	containing	O
8	DNA	O
9	apparently	O
10	transcribed	O
11	specifically	O
12	in	O
13	Trypanosoma	O
14	cruzi	O
15	trypomastigotes	O
16	,	O
17	was	O
18	obtained	O
19	by	O
20	differentially	O
21	screening	O
22	a	O
23	genomic	O
24	library	O
25	with	O
26	trypomastigote	O
27	and	O
28	epimastigote	O
29	cDNA	O
30	.	O

1	Brucellosis	O
2	--	O
3	1990	O

1	Assay	O
2	of	O
3	urea	O
4	by	O
5	immobilized	O
6	urease	B
7	coupled	O
8	to	O
9	a	O
10	differential	O
11	pH	O
12	-	O
13	meter	O
14	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	One	O
2	phage	O
3	clone	O
4	contains	O
5	a	O
6	junction	O
7	between	O
8	alpha	O
9	satellite	O
10	DNA	O
11	and	O
12	a	O
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	human	B
9	lactoferrin	I
10	gene	I
11	was	O
12	isolated	O
13	from	O
14	a	O
15	human	O
16	placental	O
17	genomic	O
18	library	O
19	.	O

1	Therefore	O
2	,	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	the	O
8	estrogen	O
9	action	O
10	that	O
11	govern	O
12	the	O
13	lactoferrin	B
14	gene	I
15	expression	O
16	differ	O
17	between	O
18	mouse	O
19	and	O
20	human	O
21	.	O

1	BiP670	B
2	retains	O
3	basal	O
4	and	O
5	Ca2	O
6	+	O
7	ionophore	O
8	A23187	O
9	-	O
10	inducible	O
11	activities	O
12	.	O

1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	O
16	via	O
17	an	O
18	interface	O
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O

1	Magnetic	O
2	resonance	O
3	spectroscopy	O
4	(	O
5	MRS	O
6	)	O
7	and	O
8	imaging	O
9	(	O
10	MRI	O
11	)	O
12	are	O
13	now	O
14	well	O
15	established	O
16	techniques	O
17	for	O
18	the	O
19	study	O
20	of	O
21	cellular	O
22	metabolism	O
23	and	O
24	gross	O
25	structure	O
26	of	O
27	muscle	O
28	.	O

1	Simultaneously	O
2	a	O
3	greater	O
4	NA	O
5	was	O
6	found	O
7	with	O
8	no	O
9	change	O
10	in	O
11	plasma	O
12	epinephrine	O
13	response	O
14	.	O

1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	B
31	-	I
32	specific	I
33	IgE	I
34	antibodies	I
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O

1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	gene	O
6	segment	O
7	containing	O
8	the	O
9	mu	O
10	m	O
11	poly	O
12	(	O
13	A	O
14	)	O
15	signals	O
16	,	O
17	along	O
18	with	O
19	536	O
20	bp	O
21	of	O
22	downstream	O
23	flanking	O
24	sequence	O
25	,	O
26	acted	O
27	as	O
28	a	O
29	transcription	O
30	terminator	O
31	in	O
32	both	O
33	myeloma	O
34	cells	O
35	and	O
36	L	O
37	cell	O
38	fibroblasts	O
39	.	O

1	As	O
2	a	O
3	part	O
4	of	O
5	a	O
6	large	O
7	examination	O
8	,	O
9	total	O
10	and	O
11	free	O
12	serum	O
13	cholesterol	O
14	,	O
15	total	O
16	lipid	O
17	and	O
18	triglyceride	O
19	levels	O
20	were	O
21	determined	O
22	.	O

1	Alena	O
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	O

1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O

1	DIBA	O
2	was	O
3	more	O
4	sensitive	O
5	and	O
6	had	O
7	a	O
8	better	O
9	negative	O
10	predictive	O
11	value	O
12	and	O
13	a	O
14	lower	O
15	false	O
16	negative	O
17	percentage	O
18	than	O
19	DFAT	O
20	.	O

1	Caries	O
2	and	O
3	parodontitis	O
4	have	O
5	been	O
6	one	O
7	of	O
8	the	O
9	most	O
10	spread	O
11	diseases	O
12	of	O
13	mankind	O
14	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O

1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	mother	O
18	without	O
19	pathogens	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O

1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	parsley	B
19	chalcone	I
20	synthase	I
21	promoter	I
22	.	O

1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O

1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O

1	ME1a1	B
2	,	O
3	a	O
4	16	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	nuclear	O
10	factor	O
11	binding	O
12	site	O
13	residing	O
14	between	O
15	the	O
16	c	B
17	-	I
18	MYC	I
19	P1	I
20	and	I
21	P2	I
22	transcription	I
23	initiation	I
24	sites	I
25	,	O
26	is	O
27	required	O
28	for	O
29	P2	O
30	activity	O
31	.	O

1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	O
6	prevention	O
7	in	O
8	Indian	O
9	country	O
10	:	O
11	visionary	O
12	,	O
13	complex	O
14	,	O
15	and	O
16	practical	O
17	.	O

1	Exogenous	O
2	LHRH	B
3	is	O
4	also	O
5	known	O
6	to	O
7	facilitate	O
8	mating	O
9	behavior	O
10	in	O
11	several	O
12	species	O
13	.	O

1	The	O
2	first	O
3	146	O
4	consecutive	O
5	patients	O
6	treated	O
7	with	O
8	EVL	O
9	during	O
10	the	O
11	period	O
12	from	O
13	August	O
14	,	O
15	1986	O
16	to	O
17	July	O
18	,	O
19	1989	O
20	are	O
21	reported	O
22	.	O

1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	O
6	a	O
7	lysine	O
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O

1	During	O
2	V	O
3	-	O
4	A	O
5	bypass	O
6	,	O
7	hemodynamics	O
8	were	O
9	stable	O
10	.	O

1	Greater	O
2	rupture	O
3	force	O
4	was	O
5	required	O
6	in	O
7	the	O
8	adult	O
9	pigs	O
10	than	O
11	in	O
12	the	O
13	young	O
14	pigs	O
15	.	O

1	At	O
2	rest	O
3	AFF	O
4	was	O
5	significantly	O
6	higher	O
7	in	O
8	UT	O
9	(	O
10	29	O
11	%)	O
12	as	O
13	compared	O
14	to	O
15	AT	O
16	(	O
17	25	O
18	%)	O
19	and	O
20	UEA	O
21	(	O
22	25	O
23	%).	O

1	We	O
2	investigated	O
3	the	O
4	smoking	O
5	habits	O
6	of	O
7	relapsers	O
8	1	O
9	year	O
10	after	O
11	quitting	O
12	in	O
13	a	O
14	smoking	O
15	cessation	O
16	trial	O
17	using	O
18	nicotine	O
19	or	O
20	placebo	O
21	patches	O
22	.	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	O
7	the	O
8	general	O
9	population	O
10	of	O
11	Hisayama	O
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	B
21	B	I
22	surface	I
23	antigen	I
24	in	O
25	general	O
26	population	O
27	.	O

1	Because	O
2	of	O
3	this	O
4	latter	O
5	phenomenon	O
6	,	O
7	we	O
8	were	O
9	able	O
10	to	O
11	identify	O
12	a	O
13	particular	O
14	cysteine	O
15	motif	O
16	that	O
17	was	O
18	repeated	O
19	multiple	O
20	times	O
21	in	O
22	Dfurin2	B
23	but	O
24	present	O
25	only	O
26	twice	O
27	in	O
28	mammalian	B
29	furin	I
30	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	neither	O
7	phosphate	O
8	buffered	O
9	saline	O
10	injection	O
11	into	O
12	the	O
13	ES	O
14	nor	O
15	primary	O
16	KLH	B
17	challenges	O
18	of	O
19	the	O
20	ES	O
21	were	O
22	capable	O
23	of	O
24	elevating	O
25	the	O
26	threshold	O
27	level	O
28	and	O
29	changing	O
30	the	O
31	latency	O
32	.	O

1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	The	O
2	mean	O
3	serum	O
4	creatinine	O
5	levels	O
6	were	O
7	similar	O
8	at	O
9	one	O
10	year	O
11	(	O
12	SPK	O
13	1	O
14	.	O
15	8	O
16	,	O
17	KTA	O
18	1	O
19	.	O
20	9	O
21	mg	O
22	/	O
23	d	O
24	).(	O
25	ABSTRACT	O
26	TRUNCATED	O
27	AT	O
28	250	O
29	WORDS	O
30	)	O

1	Model	O
2	predictions	O
3	were	O
4	in	O
5	accord	O
6	with	O
7	the	O
8	nine	O
9	-	O
10	year	O
11	survival	O
12	experience	O
13	of	O
14	women	O
15	in	O
16	the	O
17	HIP	O
18	trial	O
19	,	O
20	and	O
21	,	O
22	with	O
23	the	O
24	exception	O
25	of	O
26	women	O
27	40	O
28	-	O
29	44	O
30	years	O
31	old	O
32	,	O
33	with	O
34	HIP	O
35	data	O
36	on	O
37	18	O
38	-	O
39	year	O
40	survival	O
41	.	O

1	High	O
2	-	O
3	resolution	O
4	computed	O
5	tomography	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	miliary	O
11	tuberculosis	O
12	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	SNF2	B
7	,	O
8	SNF5	B
9	,	O
10	and	O
11	SNF6	B
12	function	O
13	interdependently	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	heteromeric	O
22	complex	O
23	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	O
6	GAL4	B
7	and	O
8	LexA	B
9	-	O
10	Bicoid	B
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O

1	George	O
2	T	O
3	.	O

1	A	O
2	lambda	O
3	gt10	O
4	cDNA	O
5	library	O
6	was	O
7	constructed	O
8	from	O
9	poly	O
10	(	O
11	A	O
12	)+	O
13	RNA	O
14	of	O
15	young	O
16	green	O
17	leaves	O
18	of	O
19	spinach	O
20	.	O

1	NE	B
2	and	O
3	PR3	B
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	B
16	-	I
17	tissue	I
18	protein	I
19	elastin	I
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	I
29	-	I
30	proteinase	I
31	inhibitor	I
32	complexes	I
33	and	O
34	elastin	B
35	peptides	I
36	.	O

1	Selected	O
2	topics	O
3	in	O
4	pediatric	O
5	ultrasonography	O
6	--	O
7	1992	O
8	.	O

1	Methods	O
2	included	O
3	24	O
4	-	O
5	hour	O
6	dietary	O
7	recall	O
8	,	O
9	menu	O
10	weights	O
11	,	O
12	and	O
13	recipe	O
14	analysis	O
15	.	O

1	Factors	O
2	associated	O
3	with	O
4	afterdrop	O
5	included	O
6	age	O
7	,	O
8	end	O
9	-	O
10	of	O
11	-	O
12	surgery	O
13	temperature	O
14	(	O
15	both	O
16	positively	O
17	)	O
18	and	O
19	body	O
20	mass	O
21	(	O
22	negatively	O
23	).	O

1	Both	O
2	GH	B
3	deficiency	O
4	and	O
5	impaired	O
6	spinal	O
7	growth	O
8	may	O
9	result	O
10	in	O
11	short	O
12	stature	O
13	,	O
14	whereas	O
15	the	O
16	occurrence	O
17	of	O
18	early	O
19	puberty	O
20	in	O
21	association	O
22	with	O
23	GH	B
24	deficiency	O
25	reduces	O
26	the	O
27	time	O
28	available	O
29	for	O
30	GH	B
31	therapy	O
32	.	O

1	By	O
2	contrast	O
3	,	O
4	d	B
5	(	I
6	T2AG3T	I
7	)	I
8	and	O
9	d	B
10	(	I
11	T2G4T	I
12	)	I
13	form	O
14	only	O
15	the	O
16	G	O
17	-	O
18	quadruplex	O
19	monomer	O
20	structures	O
21	independent	O
22	of	O
23	K	O
24	cation	O
25	concentration	O
26	as	O
27	reported	O
28	previously	O
29	[	O
30	Sen	O
31	,	O
32	D	O
33	.,	O
34	&	O
35	Gilbert	O
36	,	O
37	W	O
38	.	O

1	Differentiating	O
2	among	O
3	renal	O
4	stones	O
5	.	O

1	IFI	B
2	16	I
3	mRNA	I
4	was	O
5	found	O
6	to	O
7	be	O
8	constitutively	O
9	expressed	O
10	in	O
11	lymphoid	O
12	cells	O
13	and	O
14	in	O
15	cell	O
16	lines	O
17	of	O
18	both	O
19	the	O
20	T	O
21	and	O
22	B	O
23	lineages	O
24	.	O

1	Mitochondria	O
2	-	O
3	lytic	O
4	action	O
5	of	O
6	warfarin	O
7	in	O
8	lymphocytes	O
9	.	O

1	Exon	O
2	-	O
3	intron	O
4	junctions	O
5	in	O
6	the	O
7	human	O
8	and	O
9	rat	B
10	AdoMet	I
11	decarboxylase	I
12	genes	I
13	were	O
14	in	O
15	identical	O
16	positions	O
17	except	O
18	that	O
19	exons	O
20	6	O
21	and	O
22	7	O
23	of	O
24	the	O
25	human	O
26	gene	O
27	formed	O
28	a	O
29	single	O
30	exon	O
31	in	O
32	the	O
33	rat	O
34	gene	O
35	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	-	O
5	induced	O
6	gene	O
7	expression	O
8	:	O
9	evidence	O
10	for	O
11	a	O
12	selective	O
13	effect	O
14	of	O
15	ouabain	O
16	on	O
17	activation	O
18	of	O
19	the	O
20	ISGF3	B
21	transcription	I
22	complex	I
23	.	O

1	The	O
2	cDNA	O
3	has	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	900	O
10	amino	O
11	acids	O
12	capable	O
13	of	O
14	encoding	O
15	a	O
16	97	O
17	-	O
18	kDa	O
19	protein	O
20	.	O

1	Moreover	O
2	,	O
3	LD50	O
4	in	O
5	mice	O
6	of	O
7	RP	O
8	-	O
9	170	O
10	(	O
11	4	O
12	.	O
13	3	O
14	g	O
15	/	O
16	kg	O
17	on	O
18	i	O
19	.	O
20	v	O
21	.)	O
22	was	O
23	increased	O
24	to	O
25	5	O
26	.	O
27	2	O
28	g	O
29	/	O
30	kg	O
31	by	O
32	oral	O
33	administration	O
34	.	O

1	Among	O
2	the	O
3	few	O
4	proteins	O
5	of	O
6	the	O
7	eukaryotic	O
8	nucleolus	O
9	that	O
10	have	O
11	been	O
12	characterized	O
13	,	O
14	four	O
15	proteins	O
16	,	O
17	nucleolin	B
18	,	O
19	fibrillarin	B
20	,	O
21	SSB1	B
22	and	O
23	NSR1	B
24	,	O
25	possess	O
26	a	O
27	common	O
28	structural	O
29	motif	O
30	,	O
31	the	O
32	GAR	O
33	domain	O
34	,	O
35	which	O
36	is	O
37	rich	O
38	in	O
39	glycine	O
40	and	O
41	arginine	O
42	residues	O
43	.	O

1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O

1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	B
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O

1	Expense	O
2	limits	O
3	the	O
4	use	O
5	of	O
6	hepatitis	O
7	B	O
8	vaccines	O
9	,	O
10	but	O
11	low	O
12	-	O
13	dose	O
14	intradermal	O
15	immunization	O
16	has	O
17	been	O
18	evaluated	O
19	as	O
20	a	O
21	cost	O
22	-	O
23	saving	O
24	strategy	O
25	in	O
26	numerous	O
27	studies	O
28	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	I
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	house	O
27	dust	O
28	or	O
29	to	O
30	fish	O
31	flour	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	O
39	IgE	B
40	(	O
41	except	O
42	for	O
43	dyspnea	O
44	).	O

1	An	O
2	unexpected	O
3	finding	O
4	was	O
5	the	O
6	presence	O
7	at	O
8	position	O
9	-	O
10	403	O
11	to	O
12	-	O
13	385	O
14	of	O
15	a	O
16	putative	O
17	dioxin	O
18	responsive	O
19	element	O
20	,	O
21	a	O
22	sequence	O
23	found	O
24	to	O
25	be	O
26	responsible	O
27	for	O
28	the	O
29	induction	O
30	of	O
31	transcription	O
32	of	O
33	the	O
34	cytochrome	B
35	P450IA1	I
36	gene	I
37	(	O
38	CYPIA1	B
39	)	O
40	and	O
41	other	O
42	genes	O
43	involved	O
44	in	O
45	detoxification	O
46	/	O
47	activation	O
48	of	O
49	polycyclic	O
50	aromatic	O
51	hydrocarbons	O
52	.	O

1	The	O
2	gene	O
3	encoding	O
4	TRP	B
5	-	I
6	2	I
7	maps	O
8	to	O
9	mouse	O
10	chromosome	O
11	14	O
12	,	O
13	in	O
14	the	O
15	region	O
16	of	O
17	the	O
18	coat	B
19	colour	I
20	mutation	I
21	slaty	I
22	.	O

1	Using	O
2	bovine	B
3	and	I
4	murine	I
5	c	I
6	-	I
7	myb	I
8	clones	O
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O

1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O

1	Moreover	O
2	,	O
3	the	O
4	reconstitution	O
5	of	O
6	eUSF	B
7	and	O
8	TFIID	B
9	-	O
10	depleted	O
11	transcription	O
12	complexes	O
13	with	O
14	purified	O
15	protein	O
16	fractions	O
17	demonstrate	O
18	that	O
19	not	O
20	only	O
21	TFIID	B
22	but	O
23	also	O
24	eUSF	B
25	essentially	O
26	participates	O
27	in	O
28	complex	O
29	formation	O
30	even	O
31	on	O
32	H5	B
33	promoter	I
34	mutations	O
35	lacking	O
36	the	O
37	TATA	O
38	-	O
39	box	O
40	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O

1	Radiolabelled	O
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O

1	17	O
2	volunteer	O
3	deaf	O
4	Ss	O
5	were	O
6	compared	O
7	with	O
8	18	O
9	volunteer	O
10	hearing	O
11	Ss	O
12	on	O
13	the	O
14	Stanford	O
15	Hypnotic	O
16	Clinical	O
17	Scale	O
18	(	O
19	SHCS	O
20	)	O
21	of	O
22	Morgan	O
23	and	O
24	J	O
25	.	O

1	Mature	B
2	tobacco	I
3	L12	I
4	protein	I
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	O
13	protein	O
14	L7	B
15	/	O
16	L12	B
17	of	O
18	Escherichia	O
19	coli	O
20	.	O

1	Nuclear	B
2	-	I
3	encoded	I
4	chloroplast	I
5	ribosomal	I
6	protein	I
7	L12	I
8	of	I
9	Nicotiana	I
10	tabacum	I
11	:	O
12	characterization	O
13	of	O
14	mature	O
15	protein	O
16	and	O
17	isolation	O
18	and	O
19	sequence	O
20	analysis	O
21	of	O
22	cDNA	O
23	clones	O
24	encoding	O
25	its	O
26	cytoplasmic	O
27	precursor	O
28	.	O

1	The	O
2	gene	O
3	encoding	O
4	IFN	B
5	-	I
6	gamma	I
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	B
34	-	I
35	gamma	I
36	-	I
37	encoding	I
38	gene	I
39	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	polypeptide	O
6	component	O
7	of	O
8	the	O
9	Rel	B
10	-	I
11	related	I
12	human	I
13	p75	I
14	nucleoprotein	I
15	complex	I
16	has	O
17	revealed	O
18	its	O
19	identity	O
20	with	O
21	the	O
22	65	O
23	-	O
24	kDa	O
25	(	O
26	p65	B
27	)	O
28	subunit	O
29	of	O
30	NF	B
31	-	I
32	kappa	I
33	B	I
34	.	O

1	Because	O
2	single	O
3	-	O
4	chamber	O
5	rate	O
6	-	O
7	adaptive	O
8	atrial	O
9	pacing	O
10	leaves	O
11	the	O
12	patient	O
13	exposed	O
14	to	O
15	the	O
16	risk	O
17	of	O
18	future	O
19	development	O
20	of	O
21	AV	O
22	block	O
23	and	O
24	DDD	O
25	pacing	O
26	does	O
27	not	O
28	provide	O
29	chronotropic	O
30	support	O
31	,	O
32	it	O
33	is	O
34	likely	O
35	that	O
36	the	O
37	new	O
38	rate	O
39	-	O
40	adaptive	O
41	dual	O
42	-	O
43	chamber	O
44	(	O
45	DDDR	O
46	)	O
47	devices	O
48	will	O
49	be	O
50	used	O
51	in	O
52	a	O
53	significant	O
54	number	O
55	of	O
56	these	O
57	patients	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	When	O
2	transiently	O
3	transfected	O
4	into	O
5	K562	O
6	cells	O
7	,	O
8	this	O
9	Lg	B
10	genomic	O
11	clone	O
12	is	O
13	actively	O
14	transcribed	O
15	,	O
16	suggesting	O
17	that	O
18	,	O
19	although	O
20	it	O
21	possesses	O
22	the	O
23	characteristics	O
24	of	O
25	a	O
26	processed	O
27	pseudogene	O
28	,	O
29	it	O
30	is	O
31	likely	O
32	to	O
33	correspond	O
34	to	O
35	the	O
36	gene	O
37	encoding	O
38	this	O
39	new	O
40	ferritin	B
41	subunit	I
42	.	O

1	Of	O
2	the	O
3	drugs	O
4	orally	O
5	administered	O
6	,	O
7	WR	O
8	-	O
9	168643	O
10	was	O
11	the	O
12	best	O
13	protector	O
14	with	O
15	a	O
16	DMF	O
17	of	O
18	1	O
19	.	O
20	51	O
21	.	O

1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	azido	O
11	-	O
12	cAMP	O
13	photoaffinity	O
14	labeling	O
15	and	O
16	immunoreactivity	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	dodecyl	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	PAGE	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	RII	B
46	beta	I
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	RII	B
54	alpha	I
55	dephosphoform	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	RI	B
63	alpha	I
64	(	O
65	49	O
66	kDa	O
67	).	O

1	Comparison	O
2	of	O
3	the	O
4	genomic	O
5	DNA	O
6	sequence	O
7	with	O
8	that	O
9	of	O
10	the	O
11	four	O
12	different	O
13	mRNAs	O
14	indicates	O
15	that	O
16	these	O
17	transcripts	O
18	are	O
19	produced	O
20	by	O
21	alternative	O
22	splicing	O
23	of	O
24	the	O
25	murine	O
26	pre	O
27	-	O
28	mRNA	O
29	according	O
30	to	O
31	a	O
32	cassette	O
33	model	O
34	.	O

1	During	O
2	the	O
3	1980	O
4	'	O
5	s	O
6	,	O
7	quantifications	O
8	of	O
9	immunoserological	O
10	testings	O
11	,	O
12	especially	O
13	C	B
14	reactive	I
15	protein	I
16	,	O
17	rheumatoid	B
18	factor	I
19	and	O
20	antistreptolysin	B
21	O	I
22	,	O
23	progressed	O
24	rapidly	O
25	.	O

1	Within	O
2	the	O
3	human	O
4	enhancer	O
5	,	O
6	these	O
7	two	O
8	sites	O
9	are	O
10	located	O
11	within	O
12	the	O
13	previously	O
14	defined	O
15	DNase	B
16	I	I
17	footprints	I
18	,	O
19	NFAT	B
20	-	I
21	1	I
22	and	O
23	NFIL	B
24	-	I
25	2B	I
26	,	O
27	respectively	O
28	.	O

1	The	O
2	cardiac	B
3	myosin	I
4	light	I
5	chain	I
6	-	I
7	2	I
8	(	O
9	MLC	B
10	-	I
11	2	I
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	B
16	-	I
17	2	I
18	gene	I
19	transcription	O
20	.	O

1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	B
9	gene	I
10	.	O
11	slk1	B
12	null	I
13	mutants	I
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O

1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	B
8	early	I
9	meiotic	I
10	recombination	I
11	genes	I
12	REC102	I
13	and	O
14	REC107	B
15	/	O
16	MER2	B
17	.	O

1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	O
6	-	O
7	phosphorylated	O
8	proteins	O
9	that	O
10	complexed	O
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	O
28	transformed	O
29	Rat	O
30	-	O
31	2	O
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	O
47	.	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	O
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O

1	Proprotein	O
2	processing	O
3	occurs	O
4	intracellularly	O
5	.	O

1	A	O
2	32P	O
3	-	O
4	labeled	O
5	LAP	B
6	DNA	O
7	-	O
8	binding	O
9	and	O
10	dimerization	O
11	domain	O
12	"	O
13	zipper	O
14	probe	O
15	"	O
16	was	O
17	used	O
18	to	O
19	isolate	O
20	a	O
21	clone	O
22	that	O
23	encodes	O
24	a	O
25	new	O
26	C	B
27	/	I
28	EBP	I
29	-	I
30	homologous	I
31	protein	I
32	:	O
33	CHOP	B
34	-	I
35	10	I
36	.	O

1	Using	O
2	a	O
3	degenerate	O
4	oligodeoxyribonucleotide	O
5	(	O
6	oligo	O
7	)	O
8	based	O
9	on	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	aa	O
15	sequence	O
16	,	O
17	plus	O
18	an	O
19	internal	O
20	oligo	O
21	homologous	O
22	to	O
23	a	O
24	conserved	O
25	region	O
26	within	O
27	the	O
28	portion	O
29	of	O
30	CYP1	B
31	and	O
32	CYP2	B
33	that	O
34	had	O
35	been	O
36	deleted	O
37	in	O
38	the	O
39	genome	O
40	,	O
41	a	O
42	CYP3	B
43	-	I
44	specific	I
45	DNA	I
46	fragment	I
47	was	O
48	generated	O
49	by	O
50	the	O
51	polymerase	O
52	chain	O
53	reaction	O
54	(	O
55	PCR	O
56	)	O
57	using	O
58	GL81	O
59	genomic	O
60	DNA	O
61	as	O
62	a	O
63	substrate	O
64	.	O

1	Stringent	O
2	hybridization	O
3	of	O
4	EHS	B
5	-	I
6	1	I
7	back	O
8	to	O
9	primate	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	EHS	B
16	-	I
17	1	I
18	loci	I
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	chimpanzee	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	rhesus	O
38	monkey	O
39	DNA	O
40	.	O

1	The	O
2	level	O
3	of	O
4	carboxyl	B
5	-	I
6	terminal	I
7	parathyroid	I
8	hormone	I
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O

1	The	O
2	Caenorhabditis	B
3	elegans	I
4	vitellogenin	I
5	genes	I
6	are	O
7	subject	O
8	to	O
9	sex	O
10	-,	O
11	stage	O
12	-,	O
13	and	O
14	tissue	O
15	-	O
16	specific	O
17	regulation	O
18	:	O
19	they	O
20	are	O
21	expressed	O
22	solely	O
23	in	O
24	the	O
25	adult	O
26	hermaphrodite	O
27	intestine	O
28	.	O

1	The	O
2	MET4	B
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	B
23	transcriptional	I
24	activators	I
25	.	O

1	The	O
2	functions	O
3	of	O
4	isolated	O
5	portions	O
6	of	O
7	the	O
8	insulin	B
9	,	O
10	IAPP	B
11	,	O
12	and	O
13	beta	B
14	GK	I
15	promoters	I
16	were	O
17	studied	O
18	by	O
19	using	O
20	transient	O
21	expression	O
22	and	O
23	DNA	O
24	binding	O
25	assays	O
26	.	O

1	It	O
2	is	O
3	believed	O
4	that	O
5	these	O
6	domains	O
7	are	O
8	important	O
9	for	O
10	directing	O
11	specific	O
12	protein	O
13	-	O
14	protein	O
15	interactions	O
16	necessary	O
17	for	O
18	the	O
19	proper	O
20	functioning	O
21	of	O
22	Src	B
23	.	O

1	The	O
2	c	B
3	-	I
4	Ets	I
5	-	I
6	1	I
7	oncoprotein	I
8	is	O
9	a	O
10	transcription	O
11	activator	O
12	that	O
13	specifically	O
14	binds	O
15	to	O
16	DNA	O
17	.	O

1	Previous	O
2	transactivation	O
3	experiments	O
4	indicated	O
5	that	O
6	three	O
7	amino	O
8	acids	O
9	residing	O
10	in	O
11	this	O
12	region	O
13	,	O
14	Gly	O
15	,	O
16	Ser	O
17	and	O
18	Val	O
19	,	O
20	appear	O
21	to	O
22	be	O
23	critical	O
24	for	O
25	target	O
26	-	O
27	site	O
28	discrimination	O
29	.	O

1	GR63178A	O
2	is	O
3	a	O
4	water	O
5	-	O
6	soluble	O
7	analogue	O
8	of	O
9	mitoquidone	O
10	,	O
11	a	O
12	pentacyclic	O
13	pyrroloquinone	O
14	.	O

1	Marker	O
2	rescue	O
3	analysis	O
4	has	O
5	localized	O
6	ts8	B
7	to	O
8	a	O
9	910	O
10	-	O
11	bp	O
12	internal	O
13	segment	O
14	of	O
15	rpoB	B
16	that	O
17	encodes	O
18	the	O
19	Rif	B
20	domain	I
21	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	Competition	O
2	analysis	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	electrophoresis	O
8	indicates	O
9	that	O
10	this	O
11	DNA	O
12	-	O
13	protein	O
14	interaction	O
15	is	O
16	novel	O
17	and	O
18	not	O
19	related	O
20	to	O
21	many	O
22	transcription	O
23	factors	O
24	previously	O
25	reported	O
26	.	O

1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	O
8	-	O
9	binding	O
10	sequence	O
11	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	investigate	O
9	the	O
10	frequency	O
11	of	O
12	alterations	O
13	in	O
14	serum	O
15	creatinine	O
16	in	O
17	patients	O
18	with	O
19	psoriasis	O
20	receiving	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	/	O
26	day	O
27	of	O
28	cyclosporine	O
29	.	O

1	Intrapocket	O
2	chemotherapy	O
3	in	O
4	adult	O
5	periodontitis	O
6	using	O
7	a	O
8	new	O
9	controlled	O
10	-	O
11	release	O
12	insert	O
13	containing	O
14	ofloxacin	O
15	(	O
16	PT	O
17	-	O
18	01	O
19	).	O

1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O

1	Hence	O
2	temperature	O
3	and	O
4	virF	B
5	are	O
6	both	O
7	required	O
8	for	O
9	the	O
10	induction	O
11	of	O
12	the	O
13	yop	B
14	regulon	I
15	.	O

1	Problems	O
2	remain	O
3	to	O
4	be	O
5	resolved	O
6	in	O
7	the	O
8	area	O
9	of	O
10	quantitative	O
11	risk	O
12	assessment	O
13	.	O

1	The	O
2	recently	O
3	developed	O
4	gamma	B
5	-	I
6	interferon	I
7	(	O
8	IFN	B
9	-	I
10	gamma	I
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	accredited	O
25	by	O
26	the	O
27	Standing	O
28	Committee	O
29	on	O
30	Agriculture	O
31	for	O
32	use	O
33	in	O
34	Australia	O
35	.	O

1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O

1	The	O
2	Klebsiella	B
3	aerogenes	I
4	gene	I
5	maoA	I
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	B
15	oxidase	I
16	,	O
17	was	O
18	induced	O
19	by	O
20	tyramine	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	catabolite	O
29	and	O
30	ammonium	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O

1	However	O
2	,	O
3	other	O
4	regions	O
5	of	O
6	the	O
7	plasmid	O
8	are	O
9	also	O
10	efficiently	O
11	repaired	O
12	.	O

1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O

1	Thus	O
2	,	O
3	the	O
4	human	B
5	D1A	I
6	gene	I
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O

1	Similar	O
2	observations	O
3	have	O
4	been	O
5	made	O
6	previously	O
7	for	O
8	other	O
9	genes	O
10	.	O

1	Preceptorship	O
2	of	O
3	CNS	O
4	students	O
5	:	O
6	an	O
7	exploratory	O
8	study	O
9	.	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O

1	The	O
2	1	O
3	.	O
4	7	O
5	kb	O
6	cloned	O
7	fragment	O
8	was	O
9	sequenced	O
10	and	O
11	shown	O
12	to	O
13	contain	O
14	the	O
15	entire	O
16	fliA	B
17	gene	I
18	.	O

1	Institution	O
2	of	O
3	both	O
4	intravenous	O
5	and	O
6	intracisternal	O
7	administration	O
8	of	O
9	amphotericin	O
10	B	O
11	and	O
12	possibly	O
13	concomitant	O
14	intravenous	O
15	administration	O
16	of	O
17	dexamethasone	O
18	may	O
19	be	O
20	warranted	O
21	in	O
22	situations	O
23	in	O
24	which	O
25	the	O
26	association	O
27	of	O
28	C	O
29	.	O
30	immitis	O
31	with	O
32	CNS	O
33	vasculitis	O
34	or	O
35	encephalitis	O
36	appears	O
37	likely	O
38	before	O
39	serologic	O
40	or	O
41	cultural	O
42	confirmation	O
43	of	O
44	C	O
45	.	O
46	immitis	O
47	infection	O
48	involving	O
49	the	O
50	CNS	O
51	is	O
52	available	O
53	.	O

1	Lac	B
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	B
11	promoter	I
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O

1	Overproduction	O
2	,	O
3	purification	O
4	and	O
5	characterization	O
6	of	O
7	M	B
8	.	I
9	HinfI	I
10	methyltransferase	I
11	and	O
12	its	O
13	deletion	O
14	mutant	O
15	.	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	From	O
2	March	O
3	5	O
4	through	O
5	October	O
6	26	O
7	,	O
8	1991	O
9	,	O
10	eight	O
11	persons	O
12	were	O
13	diagnosed	O
14	with	O
15	elevated	O
16	blood	O
17	lead	O
18	levels	O
19	(	O
20	BLLs	O
21	)	O
22	at	O
23	a	O
24	local	O
25	hospital	O
26	and	O
27	were	O
28	reported	O
29	to	O
30	the	O
31	notifiable	O
32	disease	O
33	surveillance	O
34	system	O
35	maintained	O
36	by	O
37	the	O
38	Alabama	O
39	Department	O
40	of	O
41	Public	O
42	Health	O
43	(	O
44	ADPH	O
45	).	O

1	According	O
2	to	O
3	the	O
4	changes	O
5	of	O
6	perfusion	O
7	defects	O
8	between	O
9	Ex	O
10	,	O
11	RD	O
12	and	O
13	ReI	O
14	images	O
15	,	O
16	they	O
17	were	O
18	classified	O
19	into	O
20	3	O
21	types	O
22	:	O
23	Type	O
24	I	O
25	;	O
26	perfusion	O
27	defect	O
28	on	O
29	the	O
30	RD	O
31	image	O
32	was	O
33	identical	O
34	to	O
35	ReI	O
36	image	O
37	(	O
38	75	O
39	%)	O
40	Type	O
41	I	O
42	was	O
43	divided	O
44	into	O
45	2	O
46	subgroups	O
47	whether	O
48	perfusion	O
49	defect	O
50	at	O
51	Ex	O
52	was	O
53	unchanged	O
54	(	O
55	Ia	O
56	,	O
57	42	O
58	%)	O
59	or	O
60	improved	O
61	(	O
62	Ib	O
63	,	O
64	33	O
65	%)	O
66	on	O
67	the	O
68	RD	O
69	image	O
70	.	O

1	Keck	O
2	,	O
3	C	O
4	.	O
5	J	O
6	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	Domain	O
2	II	O
3	is	O
4	highly	O
5	homologous	O
6	to	O
7	the	O
8	LDL	B
9	receptor	I
10	and	O
11	contains	O
12	four	O
13	repeats	O
14	with	O
15	perfect	O
16	conservation	O
17	of	O
18	all	O
19	6	O
20	consecutive	O
21	cysteines	O
22	.	O

1	In	O
2	both	O
3	cities	O
4	,	O
5	HTLV	O
6	-	O
7	I	O
8	/	O
9	II	O
10	prevalence	O
11	increased	O
12	significantly	O
13	with	O
14	age	O
15	,	O
16	and	O
17	the	O
18	New	O
19	Orleans	O
20	age	O
21	-	O
22	and	O
23	sex	O
24	-	O
25	adjusted	O
26	HTLV	O
27	-	O
28	I	O
29	/	O
30	II	O
31	prevalence	O
32	was	O
33	significantly	O
34	higher	O
35	than	O
36	that	O
37	of	O
38	Baltimore	O
39	(	O
40	P	O
41	less	O
42	than	O
43	.	O
44	001	O
45	).	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O

1	Hybridization	O
2	data	O
3	indicate	O
4	that	O
5	6F6	B
6	.	I
7	2	I
8	corresponds	O
9	to	O
10	the	O
11	previously	O
12	characterized	O
13	m6F6	B
14	cDNA	I
15	clone	I
16	and	O
17	that	O
18	6F6	B
19	.	I
20	1	I
21	and	O
22	6F6	B
23	.	I
24	3	I
25	,	O
26	but	O
27	not	O
28	6F6	B
29	.	I
30	2	I
31	,	O
32	are	O
33	adjacent	O
34	to	O
35	alpha	B
36	-	I
37	type	I
38	genes	I
39	.	O

1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O

1	Protein	B
2	tyrosine	I
3	kinases	I
4	(	O
5	PTKs	B
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	virtue	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	transducers	O
31	,	O
32	and	O
33	as	O
34	growth	B
35	factor	I
36	receptors	I
37	or	O
38	components	O
39	thereof	O
40	.	O

1	The	O
2	IA4	B
3	mAb	I
4	was	O
5	identified	O
6	among	O
7	a	O
8	series	O
9	of	O
10	antibodies	O
11	raised	O
12	in	O
13	BALB	O
14	/	O
15	c	O
16	mice	O
17	after	O
18	immunization	O
19	against	O
20	a	O
21	HLA	B
22	class	O
23	I	O
24	-	O
25	deficient	O
26	,	O
27	lymphokine	O
28	-	O
29	activated	O
30	killer	O
31	(	O
32	LAK	O
33	)-	O
34	susceptible	O
35	EBV	O
36	-	O
37	B	O
38	lymphocyte	O
39	line	O
40	.	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	O
12	the	O
13	subjects	O
14	received	O
15	theophylline	O
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	O
48	7	O
49	days	O
50	.	O

1	Primer	O
2	extension	O
3	and	O
4	mung	B
5	bean	I
6	and	I
7	S1	I
8	nuclease	I
9	mapping	O
10	indicated	O
11	multiple	O
12	transcription	O
13	initiation	O
14	sites	O
15	and	O
16	were	O
17	consistent	O
18	with	O
19	Northern	O
20	analyses	O
21	.	O

1	Two	O
2	variant	O
3	PRP	B
4	-	I
5	precursor	I
6	alleles	I
7	occur	O
8	which	O
9	slightly	O
10	differ	O
11	in	O
12	the	O
13	number	O
14	of	O
15	repeats	O
16	in	O
17	domain	O
18	C	O
19	.	O

1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	In	O
2	the	O
3	last	O
4	20	O
5	years	O
6	,	O
7	the	O
8	therapeutic	O
9	uses	O
10	of	O
11	botulinum	B
12	toxin	I
13	,	O
14	a	O
15	potent	O
16	neurotoxin	O
17	,	O
18	have	O
19	been	O
20	investigated	O
21	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	Sensitivity	O
2	and	O
3	specificity	O
4	was	O
5	established	O
6	for	O
7	the	O
8	Pharmacia	O
9	CAP	O
10	System	O
11	and	O
12	the	O
13	DPC	O
14	AlaSTAT	O
15	System	O
16	by	O
17	comparison	O
18	with	O
19	results	O
20	of	O
21	the	O
22	skin	O
23	prick	O
24	test	O
25	.	O

1	PSI	B
2	-	I
3	G	I
4	and	O
5	PSI	B
6	-	I
7	K	I
8	probably	O
9	have	O
10	evolved	O
11	from	O
12	a	O
13	gene	O
14	duplication	O
15	of	O
16	an	O
17	ancestral	O
18	gene	O
19	.	O

1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	B
29	-	I
30	chimerin	I
31	,	O
32	and	O
33	rho	B
34	GAP	I
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	B
46	activity	O
47	on	O
48	small	B
49	GTPases	I
50	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O

1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O

1	An	O
2	experiment	O
3	examined	O
4	the	O
5	effects	O
6	of	O
7	treatment	O
8	with	O
9	gonadotrophin	B
10	releasing	I
11	hormone	I
12	(	O
13	100	O
14	micrograms	O
15	GnRH	B
16	injected	O
17	24	O
18	h	O
19	after	O
20	progestagen	O
21	sponge	O
22	removal	O
23	),	O
24	season	O
25	of	O
26	treatment	O
27	(	O
28	autumn	O
29	v	O
30	.	O
31	spring	O
32	),	O
33	the	O
34	effect	O
35	of	O
36	supplementary	O
37	feeding	O
38	with	O
39	lupin	O
40	grain	O
41	(	O
42	in	O
43	autumn	O
44	only	O
45	,	O
46	from	O
47	12	O
48	days	O
49	before	O
50	until	O
51	8	O
52	days	O
53	after	O
54	sponge	O
55	removal	O
56	)	O
57	on	O
58	the	O
59	time	O
60	of	O
61	ovulation	O
62	in	O
63	182	O
64	mature	O
65	Merino	O
66	ewes	O
67	superovulated	O
68	with	O
69	a	O
70	combination	O
71	of	O
72	400	O
73	I	O
74	.	O
75	U	O
76	.	O
77	pregnant	B
78	mare	I
79	serum	I
80	gonadotrophin	I
81	(	O
82	PMSG	B
83	)	O
84	and	O
85	12	O
86	mg	O
87	follicle	B
88	stimulating	I
89	hormone	I
90	(	O
91	FSH	B
92	-	I
93	P	I
94	).	O

1	Drug	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	medications	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	narrow	O
22	therapeutic	O
23	window	O
24	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	Total	O
2	body	O
3	irradiation	O
4	was	O
5	delivered	O
6	according	O
7	to	O
8	a	O
9	hyperfractionated	O
10	scheme	O
11	of	O
12	12	O
13	fractions	O
14	given	O
15	three	O
16	per	O
17	day	O
18	5	O
19	hr	O
20	apart	O
21	for	O
22	4	O
23	days	O
24	.	O

1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	O
8	observed	O
9	at	O
10	the	O
11	end	O
12	of	O
13	the	O
14	study	O
15	,	O
16	from	O
17	142	O
18	+/-	O
19	17	O
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	for	O
49	DBP	O
50	).	O

1	AgMNPV	O
2	and	O
3	Orgyia	O
4	pseudotsugata	O
5	MNPV	O
6	(	O
7	OpMNPV	O
8	)	O
9	are	O
10	similar	O
11	in	O
12	terms	O
13	of	O
14	promoter	O
15	structure	O
16	and	O
17	polyhedrin	B
18	primary	I
19	sequence	I
20	,	O
21	and	O
22	the	O
23	polyhedrin	B
24	gene	I
25	of	O
26	both	O
27	viruses	O
28	is	O
29	transcribed	O
30	in	O
31	the	O
32	anti	O
33	-	O
34	clockwise	O
35	direction	O
36	in	O
37	relation	O
38	to	O
39	their	O
40	physical	O
41	maps	O
42	.	O

1	A	O
2	gene	O
3	homologous	O
4	to	O
5	the	O
6	Escherichia	B
7	coli	I
8	dnaA	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	Pseudomonas	O
14	putida	O
15	and	O
16	its	O
17	transcription	O
18	was	O
19	investigated	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	as	O
25	well	O
26	as	O
27	in	O
28	P	O
29	.	O
30	putida	O
31	.	O

1	STP1	B
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O

1	Using	O
2	these	O
3	antibodies	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	define	O
10	the	O
11	conditions	O
12	to	O
13	completely	O
14	solubilize	O
15	the	O
16	Cdc25	B
17	protein	I
18	.	O

1	GCR1	B
2	gene	I
3	function	O
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	level	O
10	glycolytic	O
11	gene	O
12	expression	O
13	in	O
14	Saccharomyces	O
15	cerevisiae	O
16	.	O

1	The	O
2	decay	O
3	curves	O
4	of	O
5	chlorophyll	O
6	fluorescence	O
7	showed	O
8	a	O
9	superposition	O
10	of	O
11	three	O
12	exponentially	O
13	decaying	O
14	components	O
15	with	O
16	time	O
17	constants	O
18	of	O
19	T1	O
20	=	O
21	100	O
22	-	O
23	200	O
24	ps	O
25	,	O
26	T2	O
27	=	O
28	300	O
29	-	O
30	500	O
31	ps	O
32	and	O
33	T3	O
34	=	O
35	2	O
36	.	O
37	0	O
38	-	O
39	3	O
40	.	O
41	5	O
42	ns	O
43	.	O

1	After	O
2	tilting	O
3	,	O
4	systolic	O
5	blood	O
6	pressure	O
7	fell	O
8	an	O
9	average	O
10	of	O
11	17	O
12	%	O
13	in	O
14	patients	O
15	who	O
16	cramped	O
17	infrequently	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0031	O
24	)	O
25	but	O
26	only	O
27	10	O
28	%	O
29	in	O
30	frequently	O
31	cramping	O
32	patients	O
33	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	roles	O
8	that	O
9	CCK	B
10	and	O
11	trypsin	B
12	inhibitors	O
13	are	O
14	believed	O
15	to	O
16	play	O
17	in	O
18	the	O
19	negative	O
20	feedback	O
21	control	O
22	of	O
23	pancreatic	O
24	exocrine	O
25	function	O
26	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	Eight	O
2	rabbits	O
3	were	O
4	exposed	O
5	to	O
6	0	O
7	.	O
8	7	O
9	+/-	O
10	0	O
11	.	O
12	4	O
13	mg	O
14	/	O
15	m3	O
16	Co2	O
17	+	O
18	as	O
19	CoCl2	O
20	and	O
21	1	O
22	.	O
23	2	O
24	+/-	O
25	0	O
26	.	O
27	7	O
28	mg	O
29	/	O
30	m3	O
31	Cr3	O
32	+	O
33	as	O
34	Cr	O
35	(	O
36	NO3	O
37	)	O
38	3	O
39	(	O
40	group	O
41	Co	O
42	+	O
43	Cr	O
44	),	O
45	eight	O
46	to	O
47	0	O
48	.	O
49	6	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	mg	O
55	/	O
56	m3	O
57	Co2	O
58	+	O
59	(	O
60	group	O
61	Co	O
62	),	O
63	and	O
64	eight	O
65	to	O
66	filtered	O
67	air	O
68	(	O
69	control	O
70	group	O
71	),	O
72	for	O
73	4	O
74	months	O
75	,	O
76	5	O
77	days	O
78	/	O
79	week	O
80	,	O
81	and	O
82	6	O
83	hr	O
84	/	O
85	day	O
86	.	O

1	16	O
2	women	O
3	were	O
4	treated	O
5	with	O
6	methadone	O
7	to	O
8	prevent	O
9	withdrawal	O
10	symptoms	O
11	.	O

1	Disruption	O
2	demonstrates	O
3	that	O
4	CDC14	B
5	is	O
6	an	O
7	essential	O
8	gene	O
9	.	O

1	Coronary	O
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O

1	The	O
2	60A	B
3	transcripts	I
4	and	O
5	protein	O
6	are	O
7	first	O
8	detected	O
9	at	O
10	the	O
11	onset	O
12	of	O
13	gastrulation	O
14	,	O
15	primarily	O
16	in	O
17	the	O
18	mesoderm	O
19	of	O
20	the	O
21	extending	O
22	germ	O
23	band	O
24	.	O

1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O

1	Influence	O
2	of	O
3	neural	O
4	regulation	O
5	on	O
6	anti	O
7	-	O
8	arrhythmic	O
9	effects	O
10	of	O
11	GABA	O
12	in	O
13	rats	O

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O

1	And	O
2	the	O
3	natural	O
4	barriers	O
5	?	O

1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	O
16	..	O

1	The	O
2	serum	O
3	erythropoietin	B
4	(	O
5	EPO	B
6	)	O
7	concentrations	O
8	of	O
9	15	O
10	male	O
11	triathletes	O
12	(	O
13	26	O
14	.	O
15	3	O
16	U	O
17	.	O
18	ml	O
19	-	O
20	1	O
21	)	O
22	were	O
23	significantly	O
24	lower	O
25	than	O
26	those	O
27	of	O
28	45	O
29	male	O
30	distance	O
31	runners	O
32	(	O
33	31	O
34	.	O
35	6	O
36	U	O
37	.	O
38	ml	O
39	-	O
40	1	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	).	O

1	The	O
2	coating	O
3	materials	O
4	were	O
5	poloxamine	O
6	904	O
7	,	O
8	poloxamine	O
9	908	O
10	,	O
11	poloxamine	O
12	1508	O
13	,	O
14	poloxamer	O
15	338	O
16	,	O
17	and	O
18	Brij	O
19	35	O
20	.	O

1	The	O
2	eating	O
3	and	O
4	drinking	O
5	patterns	O
6	of	O
7	pygmy	O
8	goats	O
9	fed	O
10	ad	O
11	lib	O
12	and	O
13	kept	O
14	on	O
15	a	O
16	12	O
17	h	O
18	light	O
19	/	O
20	12	O
21	h	O
22	dark	O
23	cycle	O
24	were	O
25	recorded	O
26	and	O
27	analyzed	O
28	.	O

1	The	O
2	present	O
3	study	O
4	highlights	O
5	the	O
6	improvement	O
7	in	O
8	sputum	O
9	amoxycillin	O
10	(	O
11	amoxy	O
12	)	O
13	levels	O
14	when	O
15	a	O
16	combination	O
17	tablet	O
18	,	O
19	amoxy	O
20	500	O
21	mg	O
22	plus	O
23	bromhexeine	O
24	8	O
25	mg	O
26	,	O
27	is	O
28	administered	O
29	as	O
30	compared	O
31	to	O
32	plain	O
33	amoxy	O
34	500	O
35	mg	O
36	.	O

1	His	O
2	HC	B
3	II	I
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	daughter	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O

1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	B
9	II	I
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O

1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O

1	Because	O
2	the	O
3	adrenergic	O
4	nervous	O
5	system	O
6	influences	O
7	cardiac	O
8	arrhythmias	O
9	and	O
10	myocardial	O
11	infarction	O
12	can	O
13	directly	O
14	affect	O
15	sympathetic	O
16	innervation	O
17	in	O
18	the	O
19	heart	O
20	,	O
21	we	O
22	investigated	O
23	the	O
24	role	O
25	of	O
26	the	O
27	sympathetic	O
28	nervous	O
29	system	O
30	on	O
31	reentry	O
32	in	O
33	the	O
34	canine	O
35	heart	O
36	4	O
37	days	O
38	after	O
39	infarction	O
40	.	O

1	DESIGN	O
2	:	O
3	Serum	O
4	aldosterone	O
5	and	O
6	plasma	B
7	renin	I
8	activity	O
9	were	O
10	measured	O
11	supine	O
12	prior	O
13	to	O
14	and	O
15	60	O
16	,	O
17	90	O
18	,	O
19	120	O
20	minutes	O
21	after	O
22	oral	O
23	captopril	O
24	,	O
25	25	O
26	mg	O
27	.	O

1	Furthermore	O
2	,	O
3	no	O
4	transcripts	O
5	of	O
6	the	O
7	same	O
8	size	O
9	and	O
10	having	O
11	the	O
12	same	O
13	developmental	O
14	profile	O
15	as	O
16	those	O
17	generated	O
18	by	O
19	the	O
20	wild	B
21	-	I
22	type	I
23	E10	I
24	fragment	I
25	were	O
26	identified	O
27	by	O
28	probes	O
29	covering	O
30	the	O
31	remainder	O
32	of	O
33	the	O
34	cloned	O
35	region	O
36	.	O

1	Intravenous	O
2	amine	O
3	pressor	O
4	tests	O
5	in	O
6	healthy	O
7	volunteers	O
8	.	O

1	The	O
2	mean	O
3	minimum	O
4	steady	O
5	-	O
6	state	O
7	concentration	O
8	after	O
9	the	O
10	oral	O
11	regimen	O
12	(	O
13	23	O
14	micrograms	O
15	.	O
16	l	O
17	-	O
18	1	O
19	)	O
20	was	O
21	78	O
22	%	O
23	of	O
24	that	O
25	after	O
26	the	O
27	intramuscular	O
28	regime	O
29	(	O
30	29	O
31	micrograms	O
32	.	O
33	l	O
34	-	O
35	1	O
36	).	O

1	In	O
2	an	O
3	ongoing	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	SMSP	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	Mini	O
18	Speech	O
19	Processor	O
20	(	O
21	MSP	O
22	).	O

1	Both	O
2	parents	O
3	are	O
4	clinically	O
5	normal	O
6	and	O
7	unrelated	O
8	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	The	O
2	sequence	O
3	-	O
4	specific	O
5	interaction	O
6	of	O
7	nuclear	B
8	factor	I
9	HiNF	I
10	-	I
11	D	I
12	with	O
13	this	O
14	key	O
15	proximal	O
16	promoter	O
17	element	O
18	of	O
19	the	O
20	H4	B
21	-	I
22	FO108	I
23	gene	I
24	is	O
25	cell	O
26	cycle	O
27	regulated	O
28	in	O
29	normal	O
30	diploid	O
31	cells	O
32	(	O
33	J	O
34	.	O

1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O

1	Four	O
2	of	O
3	these	O
4	five	O
5	subjects	O
6	also	O
7	performed	O
8	mixed	O
9	sequences	O
10	under	O
11	conditional	O
12	control	O
13	of	O
14	the	O
15	words	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	A1	O
22	----	O
23	B2	O
24	----	O
25	A3	O
26	----	O
27	B4	O
28	----	O
29	A5	O
30	and	O
31	its	O
32	reversal	O
33	),	O
34	verifying	O
35	that	O
36	the	O
37	stimuli	O
38	which	O
39	occupied	O
40	the	O
41	same	O
42	position	O
43	in	O
44	each	O
45	sequence	O
46	were	O
47	members	O
48	of	O
49	the	O
50	same	O
51	class	O
52	.	O

1	UF	O
2	-	O
3	021	O
4	ophthalmic	O
5	solution	O
6	(	O
7	0	O
8	.	O
9	03	O
10	to	O
11	0	O
12	.	O
13	24	O
14	%),	O
15	when	O
16	topically	O
17	applied	O
18	to	O
19	the	O
20	eyes	O
21	of	O
22	rabbits	O
23	,	O
24	caused	O
25	dose	O
26	-	O
27	dependent	O
28	IOP	O
29	reduction	O
30	(	O
31	2	O
32	.	O
33	8	O
34	to	O
35	5	O
36	.	O
37	2	O
38	mmHg	O
39	),	O
40	without	O
41	transient	O
42	IOP	O
43	rise	O
44	.	O

1	While	O
2	blood	O
3	pressure	O
4	and	O
5	noradrenergic	O
6	activity	O
7	,	O
8	assessed	O
9	as	O
10	changes	O
11	in	O
12	the	O
13	plasma	O
14	levels	O
15	and	O
16	urinary	O
17	excretion	O
18	of	O
19	norepinephrine	O
20	,	O
21	remained	O
22	unaffected	O
23	in	O
24	the	O
25	Pl	O
26	group	O
27	,	O
28	a	O
29	significant	O
30	drop	O
31	in	O
32	the	O
33	supine	O
34	systolic	O
35	and	O
36	diastolic	O
37	blood	O
38	pressures	O
39	,	O
40	as	O
41	well	O
42	as	O
43	in	O
44	the	O
45	resting	O
46	venous	O
47	norepinephrine	O
48	level	O
49	and	O
50	in	O
51	urinary	O
52	norepinephrine	O
53	excretion	O
54	was	O
55	found	O
56	after	O
57	the	O
58	first	O
59	month	O
60	of	O
61	dF	O
62	administration	O
63	.	O

1	Wild	O
2	-	O
3	type	O
4	protein	O
5	bound	O
6	azido	O
7	-	O
8	ATP	O
9	well	O
10	,	O
11	but	O
12	mutants	O
13	with	O
14	substitutions	O
15	in	O
16	the	O
17	consensus	O
18	amino	O
19	acids	O
20	were	O
21	unable	O
22	to	O
23	bind	O
24	azido	O
25	-	O
26	ATP	O
27	.	O

1	Therefore	O
2	,	O
3	with	O
4	a	O
5	biopsy	O
6	from	O
7	the	O
8	stoma	O
9	site	O
10	there	O
11	is	O
12	a	O
13	risk	O
14	of	O
15	missing	O
16	early	O
17	rejection	O
18	.	O

1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	O
11	(	O
12	n	O
13	=	O
14	35	O
15	)	O
16	and	O
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	O
25	(	O
26	n	O
27	=	O
28	127	O
29	)	O
30	on	O
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	O
55	transplantation	O
56	(	O
57	n	O
58	=	O
59	53	O
60	).	O

1	Tissues	O
2	and	O
3	exudates	O
4	contain	O
5	sufficient	O
6	thymidine	O
7	for	O
8	growth	O
9	of	O
10	anaerobic	O
11	bacteria	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	inhibitory	O
17	levels	O
18	of	O
19	trimethoprim	O
20	-	O
21	sulfamethoxazole	O
22	.	O

1	The	O
2	homologies	O
3	between	O
4	RAD16	B
5	,	O
6	RAD54	B
7	and	O
8	SNF2	B
9	are	O
10	also	O
11	shared	O
12	by	O
13	several	O
14	additional	O
15	,	O
16	recently	O
17	isolated	O
18	yeast	O
19	and	O
20	Drosophila	O
21	genes	O
22	.	O

1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O

1	In	O
2	the	O
3	Rett	O
4	syndrome	O
5	we	O
6	,	O
7	therefore	O
8	,	O
9	suspect	O
10	there	O
11	are	O
12	disturbances	O
13	in	O
14	the	O
15	brain	O
16	stem	O
17	functions	O
18	especially	O
19	in	O
20	the	O
21	ascending	O
22	reticular	O
23	activating	O
24	system	O
25	which	O
26	is	O
27	related	O
28	to	O
29	elevation	O
30	of	O
31	the	O
32	conscious	O
33	level	O
34	.	O

1	In	O
2	a	O
3	similar	O
4	experiment	O
5	,	O
6	simultaneous	O
7	nitrofurazone	O
8	administration	O
9	and	O
10	S	O
11	.	O
12	enteritidis	O
13	challenge	O
14	resulted	O
15	in	O
16	no	O
17	significant	O
18	differences	O
19	in	O
20	S	O
21	.	O
22	enteritidis	O
23	isolation	O
24	frequency	O
25	.	O

1	In	O
2	agreement	O
3	with	O
4	this	O
5	southern	O
6	blotting	O
7	of	O
8	mouse	O
9	DNA	O
10	with	O
11	SmN	B
12	probes	O
13	reveals	O
14	bands	O
15	,	O
16	additional	O
17	to	O
18	those	O
19	derived	O
20	from	O
21	the	O
22	pseudogene	O
23	,	O
24	which	O
25	are	O
26	characteristic	O
27	of	O
28	an	O
29	intron	O
30	-	O
31	containing	O
32	SmN	B
33	gene	I
34	.	O

1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	B
5	kinase	I
6	-	I
7	1	I
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	CKI1	B
19	and	O
20	CKI2	B
21	.	O

1	Incidence	O
2	rate	O
3	ranging	O
4	between	O
5	122	O
6	/	O
7	100	O
8	,	O
9	000	O
10	/	O
11	year	O
12	and	O
13	190	O
14	/	O
15	100	O
16	,	O
17	000	O
18	/	O
19	year	O
20	were	O
21	found	O
22	(	O
23	minimum	O
24	,	O
25	estimated	O
26	and	O
27	raw	O
28	datasets	O
29	).	O

1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	B
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	B
24	region	I
25	is	O
26	unaffected	O
27	.	O

1	The	O
2	final	O
3	screening	O
4	yielded	O
5	a	O
6	clone	O
7	containing	O
8	a	O
9	2	O
10	kilobase	O
11	(	O
12	kb	O
13	)	O
14	insert	O
15	.	O

1	Lesions	O
2	were	O
3	made	O
4	by	O
5	pressure	O
6	injection	O
7	of	O
8	kainic	O
9	acid	O
10	into	O
11	the	O
12	SOC	O
13	through	O
14	a	O
15	stereotaxically	O
16	positioned	O
17	glass	O
18	micropipette	O
19	.	O

1	A	O
2	38	O
3	-	O
4	bp	O
5	poly	O
6	(	O
7	dA	O
8	-	O
9	dT	O
10	)	O
11	region	O
12	was	O
13	found	O
14	to	O
15	be	O
16	a	O
17	positive	O
18	regulator	O
19	of	O
20	Act1	B
21	promoter	I
22	activity	O
23	.	O

1	We	O
2	identified	O
3	a	O
4	protein	O
5	,	O
6	termed	O
7	NFIL	B
8	-	I
9	1	I
10	beta	I
11	A	I
12	(	O
13	NF	B
14	beta	I
15	A	I
16	),	O
17	that	O
18	binds	O
19	to	O
20	a	O
21	highly	O
22	conserved	O
23	12	O
24	-	O
25	bp	O
26	DNA	O
27	sequence	O
28	(-	O
29	49	O
30	to	O
31	-	O
32	38	O
33	)	O
34	located	O
35	upstream	O
36	of	O
37	the	O
38	TATA	O
39	box	O
40	motif	O
41	in	O
42	both	O
43	the	O
44	human	B
45	and	I
46	murine	I
47	IL	I
48	-	I
49	1	I
50	beta	I
51	genes	I
52	.	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	O
10	of	O
11	the	O
12	tumor	O
13	was	O
14	obtained	O
15	.	O

1	Cutis	O
2	aplasia	O
3	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	B
9	-	I
10	kb	I
11	EcoRI	I
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	B
32	gene	I
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	were	O
5	measured	O
6	by	O
7	standardized	O
8	techniques	O
9	.	O

1	Production	O
2	costs	O
3	included	O
4	feed	O
5	,	O
6	non	O
7	-	O
8	feed	O
9	operating	O
10	,	O
11	fixed	O
12	,	O
13	and	O
14	replacement	O
15	stock	O
16	costs	O
17	.	O

1	We	O
2	report	O
3	a	O
4	patient	O
5	developing	O
6	factor	B
7	VII	I
8	inhibitor	I
9	possibly	O
10	as	O
11	a	O
12	reaction	O
13	to	O
14	penicillin	O
15	administration	O
16	;	O
17	it	O
18	gave	O
19	rise	O
20	to	O
21	fatal	O
22	haemorrhage	O
23	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	with	O
6	the	O
7	classical	O
8	'	O
9	oxygen	O
10	debt	O
11	hypothesis	O
12	',	O
13	which	O
14	states	O
15	that	O
16	the	O
17	oxygen	O
18	debt	O
19	and	O
20	lactate	O
21	clearance	O
22	are	O
23	linked	O
24	.	O

1	Account	O
2	was	O
3	taken	O
4	of	O
5	noncellular	O
6	and	O
7	nonhuman	O
8	elements	O
9	in	O
10	the	O
11	smears	O
12	;	O
13	they	O
14	included	O
15	mucus	O
16	,	O
17	Charcot	O
18	-	O
19	Layden	O
20	crystals	O
21	,	O
22	pollen	O
23	grains	O
24	,	O
25	vegetal	O
26	fragments	O
27	and	O
28	fungi	O
29	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	carbon	O
7	-	O
8	perfused	O
9	areas	O
10	and	O
11	MBF	O
12	in	O
13	the	O
14	liver	O
15	,	O
16	renal	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	and	O
22	small	O
23	intestinal	O
24	serosa	O
25	(	O
26	only	O
27	MBF	O
28	)	O
29	increased	O
30	significantly	O
31	5	O
32	h	O
33	after	O
34	CLP	O
35	.	O

1	In	O
2	addition	O
3	a	O
4	greater	O
5	proportion	O
6	of	O
7	women	O
8	in	O
9	the	O
10	sweeping	O
11	group	O
12	had	O
13	a	O
14	cervical	O
15	dilatation	O
16	of	O
17	4	O
18	cm	O
19	or	O
20	more	O
21	at	O
22	the	O
23	first	O
24	vaginal	O
25	examination	O
26	in	O
27	the	O
28	labour	O
29	ward	O
30	(	O
31	16	O
32	/	O
33	33	O
34	(	O
35	49	O
36	%)	O
37	vs	O
38	5	O
39	/	O
40	32	O
41	(	O
42	16	O
43	%);	O
44	OR	O
45	4	O
46	.	O
47	39	O
48	;	O
49	95	O
50	%	O
51	CI	O
52	1	O
53	.	O
54	56	O
55	to	O
56	12	O
57	.	O
58	32	O
59	;	O
60	P	O
61	=	O
62	0	O
63	.	O
64	005	O
65	).	O

1	Lewis	O
2	,	O
3	N	O
4	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	O
8	age	O
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	This	O
2	accurate	O
3	and	O
4	rapid	O
5	method	O
6	makes	O
7	the	O
8	MLPA	O
9	test	O
10	logistically	O
11	feasible	O
12	for	O
13	large	O
14	-	O
15	scale	O
16	screening	O
17	.	O

1	The	O
2	modalities	O
3	for	O
4	using	O
5	reference	O
6	values	O
7	for	O
8	individual	O
9	subjects	O
10	as	O
11	well	O
12	as	O
13	for	O
14	groups	O
15	are	O
16	then	O
17	discussed	O
18	and	O
19	the	O
20	main	O
21	points	O
22	of	O
23	research	O
24	which	O
25	must	O
26	be	O
27	faced	O
28	in	O
29	the	O
30	near	O
31	future	O
32	regarding	O
33	reference	O
34	values	O
35	are	O
36	highlighted	O
37	.	O

1	The	O
2	clinical	O
3	application	O
4	of	O
5	the	O
6	antibody	O
7	-	O
8	targeted	O
9	Phthalocyanine	O
10	was	O
11	performed	O
12	in	O
13	3	O
14	patients	O
15	suffering	O
16	from	O
17	an	O
18	advanced	O
19	ovarian	O
20	carcinoma	O
21	(	O
22	FIGO	O
23	III	O
24	).	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	This	O
2	open	O
3	reading	O
4	frame	O
5	was	O
6	confirmed	O
7	the	O
8	correct	O
9	one	O
10	by	O
11	direct	O
12	amino	O
13	-	O
14	terminal	O
15	sequence	O
16	analysis	O
17	of	O
18	the	O
19	overproduced	O
20	msgB	B
21	gene	I
22	product	I
23	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	purified	O
7	and	O
8	characterized	O
9	the	O
10	recombinant	B
11	furin	I
12	from	O
13	the	O
14	conditioned	O
15	medium	O
16	of	O
17	these	O
18	cells	O
19	.	O

1	The	O
2	virus	O
3	encodes	O
4	a	O
5	40	O
6	-	O
7	kDa	O
8	protein	O
9	,	O
10	tax	B
11	,	O
12	that	O
13	is	O
14	important	O
15	for	O
16	the	O
17	immortalization	O
18	of	O
19	T	O
20	cells	O
21	.	O

1	However	O
2	,	O
3	butyrate	O
4	was	O
5	at	O
6	least	O
7	2	O
8	-	O
9	fold	O
10	more	O
11	effective	O
12	in	O
13	stimulating	O
14	CAT	B
15	activity	O
16	of	O
17	fusion	O
18	genes	O
19	containing	O
20	upstream	O
21	sequences	O
22	(-	O
23	834	O
24	to	O
25	-	O
26	576	O
27	)	O
28	than	O
29	those	O
30	containing	O
31	proximal	O
32	sequences	O
33	(-	O
34	456	O
35	to	O
36	-	O
37	172	O
38	),	O
39	suggesting	O
40	two	O
41	regions	O
42	in	O
43	the	O
44	PSG1	B
45	-	I
46	I	I
47	gene	I
48	that	O
49	mediate	O
50	the	O
51	butyrate	O
52	response	O
53	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	role	O
6	of	O
7	the	O
8	carboxyl	O
9	terminus	O
10	in	O
11	regulating	O
12	NGFI	B
13	-	I
14	B	I
15	transcriptional	O
16	activity	O
17	revealed	O
18	that	O
19	,	O
20	in	O
21	accordance	O
22	with	O
23	other	O
24	nuclear	O
25	receptors	O
26	,	O
27	mutants	O
28	lacking	O
29	portions	O
30	of	O
31	the	O
32	carboxyl	O
33	terminus	O
34	had	O
35	greatly	O
36	decreased	O
37	activity	O
38	.	O

1	Altogether	O
2	these	O
3	results	O
4	indicate	O
5	that	O
6	the	O
7	Syn	B
8	5	I
9	locus	I
10	segregates	O
11	from	O
12	the	O
13	gene	O
14	specifying	O
15	gH	B
16	,	O
17	to	O
18	a	O
19	region	O
20	encompassing	O
21	portions	O
22	of	O
23	the	O
24	TK	B
25	and	O
26	UL	B
27	24	I
28	genes	I
29	,	O
30	and	O
31	that	O
32	the	O
33	syn	B
34	mutation	I
35	does	O
36	not	O
37	affect	O
38	the	O
39	expression	O
40	or	O
41	activity	O
42	of	O
43	TK	B
44	.	O

1	Nucleoprotein	O
2	(	O
3	N	O
4	)	O
5	expressed	O
6	by	O
7	both	O
8	recombinant	O
9	vaccinia	O
10	virus	O
11	and	O
12	TGEV	O
13	had	O
14	a	O
15	relative	O
16	molecular	O
17	mass	O
18	(	O
19	Mr	O
20	)	O
21	of	O
22	47	O
23	,	O
24	000	O
25	and	O
26	was	O
27	susceptible	O
28	to	O
29	degradation	O
30	at	O
31	the	O
32	C	O
33	-	O
34	terminus	O
35	yielding	O
36	discrete	O
37	breakdown	O
38	products	O
39	.	O

1	Recently	O
2	,	O
3	the	O
4	3	B
5	.	I
6	6	I
7	-	I
8	kb	I
9	full	I
10	-	I
11	length	I
12	alpha	I
13	-	I
14	GalNAc	I
15	cDNA	I
16	sequence	I
17	was	O
18	isolated	O
19	and	O
20	found	O
21	to	O
22	have	O
23	remarkable	O
24	nucleotide	O
25	and	O
26	predicted	O
27	amino	O
28	acid	O
29	homology	O
30	(	O
31	55	O
32	.	O
33	8	O
34	and	O
35	46	O
36	.	O
37	9	O
38	%,	O
39	respectively	O
40	)	O
41	with	O
42	the	O
43	human	B
44	alpha	I
45	-	I
46	galactosidase	I
47	A	I
48	(	O
49	alpha	B
50	-	I
51	Gal	I
52	A	I
53	)	O
54	cDNA	O
55	.	O

1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O

1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O

1	All	O
2	mutant	B
3	JCV	I
4	T	I
5	antigens	I
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O

1	The	O
2	relation	O
3	between	O
4	myocardial	B
5	beta	I
6	-	I
7	adrenergic	I
8	receptor	I
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O

1	Since	O
2	each	O
3	transcript	O
4	appears	O
5	to	O
6	encode	O
7	the	O
8	same	O
9	protein	O
10	,	O
11	this	O
12	complexity	O
13	may	O
14	reflect	O
15	the	O
16	need	O
17	for	O
18	lineage	O
19	-	O
20	specific	O
21	or	O
22	differentiation	O
23	-	O
24	dependent	O
25	control	O
26	of	O
27	expression	O
28	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	We	O
2	identify	O
3	the	O
4	"	O
5	M	O
6	region	O
7	"	O
8	of	O
9	the	O
10	muscle	B
11	-	I
12	specific	I
13	Xenopus	I
14	cardiac	I
15	actin	I
16	gene	I
17	promoter	I
18	from	O
19	-	O
20	282	O
21	to	O
22	-	O
23	348	O
24	as	O
25	necessary	O
26	for	O
27	the	O
28	embryonic	O
29	expression	O
30	of	O
31	a	O
32	cardiac	O
33	actin	B
34	-	O
35	beta	B
36	-	I
37	globin	I
38	reporter	O
39	gene	O
40	injected	O
41	into	O
42	fertilized	O
43	eggs	O
44	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	attenuator	B
10	1	I
11	situated	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	attenuator	O
26	,	O
27	attenuator	B
28	2	I
29	,	O
30	situated	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O

1	EBNA	B
2	-	I
3	2	I
4	and	O
5	the	O
6	cis	O
7	-	O
8	acting	O
9	CD23	B
10	element	I
11	increased	O
12	TK	B
13	-	O
14	promoted	O
15	mRNA	O
16	and	O
17	did	O
18	not	O
19	alter	O
20	the	O
21	herpes	B
22	simplex	I
23	virus	I
24	TK	I
25	promoter	I
26	transcription	I
27	start	I
28	site	I
29	.	O

1	These	O
2	experiments	O
3	delineate	O
4	a	O
5	186	O
6	-	O
7	bp	O
8	,	O
9	EBNA	B
10	-	I
11	2	I
12	-	O
13	responsive	O
14	cell	O
15	DNA	O
16	fragment	O
17	and	O
18	provide	O
19	firm	O
20	evidence	O
21	that	O
22	EBNA	B
23	-	I
24	2	I
25	transactivates	O
26	transcription	O
27	of	O
28	cell	O
29	genes	O
30	.	O

1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	B
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O

1	Transfecting	O
2	the	O
3	cloned	O
4	bovine	O
5	PBR	B
6	/	O
7	IBP	B
8	cDNA	O
9	into	O
10	COS	O
11	-	O
12	7	O
13	cells	O
14	resulted	O
15	in	O
16	an	O
17	11	O
18	-	O
19	fold	O
20	increase	O
21	in	O
22	the	O
23	density	O
24	of	O
25	high	O
26	affinity	O
27	[	O
28	3H	O
29	]	O
30	PK	O
31	11195	O
32	binding	O
33	sites	O
34	which	O
35	had	O
36	only	O
37	low	O
38	affinity	O
39	for	O
40	Ro5	O
41	-	O
42	4864	O
43	.	O

1	The	O
2	initial	O
3	phase	O
4	of	O
5	increased	O
6	vascular	O
7	permeability	O
8	in	O
9	the	O
10	peritoneal	O
11	cavity	O
12	and	O
13	LTB4	O
14	production	O
15	was	O
16	dose	O
17	dependently	O
18	inhibited	O
19	by	O
20	the	O
21	5	O
22	-	O
23	LO	O
24	inhibitors	O
25	phenidone	O
26	,	O
27	BW	O
28	A4C	O
29	,	O
30	A63162	O
31	,	O
32	and	O
33	ICI	O
34	207	O
35	968	O
36	but	O
37	not	O
38	by	O
39	dexamethasone	O
40	or	O
41	colchicine	O
42	.	O

1	Discrepant	O
2	results	O
3	with	O
4	a	O
5	latex	O
6	agglutination	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	cytomegalovirus	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O

1	Each	O
2	mRNA	O
3	contained	O
4	five	O
5	or	O
6	six	O
7	internal	O
8	uridine	O
9	residues	O
10	,	O
11	which	O
12	were	O
13	transcribed	O
14	using	O
15	a	O
16	mixture	O
17	of	O
18	UTP	O
19	and	O
20	thio	O
21	-	O
22	UTP	O
23	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	two	O
7	overlapping	O
8	cDNA	O
9	fragments	O
10	which	O
11	could	O
12	encode	O
13	the	O
14	complete	O
15	amino	O
16	acid	O
17	sequence	O
18	of	O
19	rat	B
20	testis	I
21	fructose	I
22	-	I
23	6	I
24	-	I
25	phosphate	I
26	,	I
27	2	I
28	-	I
29	kinase	I
30	:	O
31	fructose	B
32	-	I
33	2	I
34	,	I
35	6	I
36	-	I
37	bisphosphatase	I
38	.	O

1	We	O
2	have	O
3	identified	O
4	SWI5	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	NLS	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O

1	In	O
2	contrast	O
3	to	O
4	behavioral	O
5	deviation	O
6	(	O
7	the	O
8	avoidance	O
9	conditioning	O
10	lost	O
11	),	O
12	the	O
13	haloperidol	O
14	intrastriatal	O
15	microinjections	O
16	did	O
17	not	O
18	affect	O
19	the	O
20	DA	O
21	synaptic	O
22	level	O
23	in	O
24	rostral	O
25	neostriatum	O
26	.	O

1	In	O
2	similar	O
3	transient	O
4	transfection	O
5	experiments	O
6	in	O
7	HeLa	O
8	cells	O
9	,	O
10	overexpression	O
11	of	O
12	the	O
13	wt	B
14	human	I
15	retinoblastoma	I
16	susceptibility	I
17	gene	I
18	product	I
19	,	O
20	RB	B
21	,	O
22	was	O
23	found	O
24	to	O
25	repress	O
26	the	O
27	serum	O
28	-	O
29	induced	O
30	IL	B
31	-	I
32	6	I
33	(-	O
34	225	O
35	to	O
36	+	O
37	13	O
38	),	O
39	c	B
40	-	I
41	fos	I
42	(-	O
43	711	O
44	to	O
45	+	O
46	42	O
47	),	O
48	and	O
49	beta	B
50	-	I
51	actin	I
52	(-	O
53	3400	O
54	to	O
55	+	O
56	912	O
57	)	O
58	promoters	O
59	but	O
60	not	O
61	the	O
62	PRV	O
63	-	O
64	induced	O
65	IL	B
66	-	I
67	6	I
68	(-	O
69	110	O
70	to	O
71	+	O
72	13	O
73	)	O
74	or	O
75	the	O
76	serum	O
77	-	O
78	induced	O
79	MHC	B
80	(-	O
81	528	O
82	to	O
83	-	O
84	38	O
85	)	O
86	promoters	O
87	.	O

1	This	O
2	repression	O
3	was	O
4	mediated	O
5	through	O
6	binding	O
7	to	O
8	the	O
9	E2	B
10	DNA	I
11	-	I
12	binding	I
13	site	I
14	immediately	O
15	upstream	O
16	of	O
17	the	O
18	P105	B
19	promoter	O
20	TATA	O
21	box	O
22	and	O
23	could	O
24	be	O
25	abrogated	O
26	by	O
27	preincubation	O
28	of	O
29	the	O
30	HPV	B
31	-	I
32	18	I
33	P105	I
34	promoter	I
35	template	O
36	with	O
37	the	O
38	nuclear	O
39	extract	O
40	allowing	O
41	the	O
42	formation	O
43	of	O
44	the	O
45	preinitiation	O
46	complex	O
47	.	O

1	We	O
2	did	O
3	not	O
4	detect	O
5	p50	B
6	in	O
7	association	O
8	with	O
9	native	B
10	glucocorticoid	I
11	receptor	I
12	in	O
13	L	O
14	cells	O
15	or	O
16	with	O
17	the	O
18	overexpressed	O
19	glucocorticoid	B
20	receptor	I
21	in	O
22	Chinese	O
23	hamster	O
24	ovary	O
25	cells	O
26	.	O

1	Two	O
2	putative	O
3	12	O
4	-	O
5	O	O
6	-	O
7	tetradecanoyl	O
8	-	O
9	phorbol	O
10	-	O
11	13	O
12	-	O
13	acetate	O
14	(	O
15	TPA	O
16	)	O
17	response	O
18	elements	O
19	,	O
20	that	O
21	might	O
22	serve	O
23	as	O
24	binding	O
25	sites	O
26	for	O
27	the	O
28	transcription	B
29	factor	I
30	AP	I
31	-	I
32	1	I
33	and	O
34	a	O
35	consensus	O
36	sequence	O
37	of	O
38	a	O
39	transforming	B
40	growth	I
41	factor	I
42	beta	I
43	1	I
44	(	O
45	TGF	B
46	-	I
47	beta	I
48	1	I
49	)	O
50	inhibitory	O
51	element	O
52	were	O
53	found	O
54	in	O
55	the	O
56	promoter	O
57	region	O
58	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	Feed	O
2	intake	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	dietary	O
8	KCl	O
9	or	O
10	NaHCO3	O
11	supplementation	O
12	,	O
13	but	O
14	average	O
15	daily	O
16	gain	O
17	increased	O
18	with	O
19	increased	O
20	K	O
21	and	O
22	tended	O
23	to	O
24	be	O
25	reduced	O
26	by	O
27	dietary	O
28	NaHCO3	O
29	.	O

1	Extraction	O
2	procedure	O
3	for	O
4	the	O
5	measurement	O
6	of	O
7	butyltin	O
8	compounds	O
9	in	O
10	biological	O
11	tissues	O
12	using	O
13	toluene	O
14	,	O
15	HBr	O
16	,	O
17	and	O
18	tropolone	O
19	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	a	O
9	region	O
10	that	O
11	complements	O
12	the	O
13	exoenzyme	B
14	S	I
15	-	O
16	deficient	O
17	phenotype	O
18	of	O
19	strain	O
20	388	O
21	exs1	B
22	::	O
23	Tn1	B
24	,	O
25	a	O
26	chromosomal	B
27	Tn1	I
28	insertional	I
29	mutation	I
30	.	O

1	axl	O
2	,	O
3	a	O
4	transforming	O
5	gene	O
6	isolated	O
7	from	O
8	primary	O
9	human	O
10	myeloid	O
11	leukemia	O
12	cells	O
13	,	O
14	encodes	O
15	a	O
16	novel	O
17	receptor	B
18	tyrosine	I
19	kinase	I
20	.	O

1	Alignment	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	surrounding	O
8	Tyr	O
9	-	O
10	766	O
11	with	O
12	corresponding	O
13	regions	O
14	of	O
15	other	O
16	FGFRs	B
17	revealed	O
18	conserved	O
19	tyrosine	O
20	residues	O
21	in	O
22	all	O
23	known	O
24	members	O
25	of	O
26	the	O
27	FGFR	B
28	family	I
29	.	O

1	The	O
2	single	O
3	most	O
4	important	O
5	element	O
6	,	O
7	by	O
8	linker	O
9	-	O
10	scanning	O
11	analysis	O
12	,	O
13	is	O
14	a	O
15	10	O
16	-	O
17	bp	O
18	region	O
19	that	O
20	contains	O
21	a	O
22	CCAAT	O
23	motif	O
24	.	O

1	Capnography	O
2	curves	O
3	of	O
4	40	O
5	HVS	O
6	patients	O
7	,	O
8	40	O
9	non	O
10	-	O
11	HVS	O
12	patients	O
13	with	O
14	psycho	O
15	-	O
16	somatic	O
17	complaints	O
18	and	O
19	26	O
20	healthy	O
21	controls	O
22	were	O
23	analyzed	O
24	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O

1	All	O
2	anti	B
3	-	I
4	I	I
5	and	O
6	anti	B
7	-	I
8	i	I
9	CA	I
10	were	O
11	shown	O
12	to	O
13	express	O
14	VH4	B
15	heavy	I
16	chains	I
17	,	O
18	and	O
19	14	O
20	of	O
21	17	O
22	CA	B
23	expressed	O
24	a	O
25	previously	O
26	described	O
27	VH4	B
28	second	O
29	hypervariable	O
30	region	O
31	determinant	O
32	,	O
33	termed	O
34	VH4	B
35	-	I
36	HV2a	I
37	.	O

1	Intron	O
2	K1	B
3	cox1	I
4	.	I
5	2	I
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	the	O
6	mutants	O
7	define	O
8	two	O
9	complementation	O
10	groups	O
11	,	O
12	designated	O
13	cgs1	B
14	+	I
15	and	O
16	cgs2	B
17	+	I
18	(	O
19	continues	O
20	to	O
21	grow	O
22	in	O
23	stationary	O
24	).	O

1	However	O
2	,	O
3	alterations	O
4	in	O
5	electrostatic	O
6	and	O
7	hydrophobic	O
8	interactions	O
9	created	O
10	by	O
11	the	O
12	three	O
13	amino	O
14	acid	O
15	substitutions	O
16	prevent	O
17	the	O
18	conformational	O
19	change	O
20	in	O
21	the	O
22	enzyme	O
23	usually	O
24	produced	O
25	by	O
26	calmodulin	B
27	binding	O
28	.	O

1	The	O
2	results	O
3	of	O
4	induced	O
5	coexpression	O
6	were	O
7	also	O
8	supported	O
9	by	O
10	rapid	O
11	generation	O
12	of	O
13	FeLV	O
14	recombinants	O
15	when	O
16	FeLV	O
17	-	O
18	C	O
19	was	O
20	used	O
21	to	O
22	infect	O
23	the	O
24	feline	O
25	3201B	O
26	cell	O
27	line	O
28	that	O
29	constitutively	O
30	expresses	O
31	high	O
32	levels	O
33	of	O
34	endogenous	O
35	FeLV	O
36	-	O
37	specific	O
38	mRNAs	O
39	.	O

1	Recombination	O
2	between	O
3	feline	O
4	leukemia	O
5	virus	O
6	subgroup	O
7	B	O
8	or	O
9	C	O
10	and	O
11	endogenous	O
12	env	B
13	elements	O
14	alters	O
15	the	O
16	in	O
17	vitro	O
18	biological	O
19	activities	O
20	of	O
21	the	O
22	viruses	O
23	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	at	O
5	the	O
6	5	O
7	'	O
8	and	O
9	3	O
10	'	O
11	ends	O
12	of	O
13	these	O
14	introns	O
15	are	O
16	characteristic	O
17	of	O
18	spliced	O
19	transcripts	O
20	from	O
21	eukaryotic	O
22	protein	O
23	-	O
24	encoding	O
25	genes	O
26	,	O
27	with	O
28	one	O
29	significant	O
30	difference	O
31	;	O
32	i	O
33	.	O
34	e	O
35	.,	O
36	the	O
37	5	O
38	'	O
39	end	O
40	of	O
41	the	O
42	LAT	B
43	intron	I
44	is	O
45	GC	O
46	instead	O
47	of	O
48	the	O
49	consensus	O
50	sequence	O
51	GT	O
52	.	O

1	At	O
2	1	O
3	,	O
4	5	O
5	,	O
6	and	O
7	9	O
8	months	O
9	after	O
10	initial	O
11	isolation	O
12	of	O
13	C	O
14	.	O
15	kutscheri	O
16	from	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	hamsters	O
22	were	O
23	euthanatized	O
24	,	O
25	and	O
26	attempts	O
27	were	O
28	made	O
29	to	O
30	culture	O
31	C	O
32	.	O
33	kutscheri	O
34	from	O
35	13	O
36	additional	O
37	sites	O
38	.	O

1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	B
18	cerevisiae	I
19	ADE	I
20	1	I
21	locus	I
22	.	O

1	Two	O
2	independent	O
3	promoters	O
4	as	O
5	well	O
6	as	O
7	5	O
8	'	O
9	untranslated	O
10	regions	O
11	regulate	O
12	Dd	B
13	ras	I
14	expression	O
15	in	O
16	Dictyostelium	O
17	.	O

1	The	O
2	results	O
3	suggested	O
4	that	O
5	,	O
6	depending	O
7	upon	O
8	the	O
9	cell	O
10	type	O
11	,	O
12	gene	O
13	cotransfer	O
14	using	O
15	aminoglycoside	O
16	resistance	O
17	as	O
18	a	O
19	selectable	O
20	marker	O
21	may	O
22	seriously	O
23	perturb	O
24	important	O
25	cellular	O
26	control	O
27	mechanisms	O
28	such	O
29	as	O
30	the	O
31	PKC	B
32	pathway	O
33	leading	O
34	to	O
35	activation	O
36	of	O
37	gene	O
38	expression	O
39	.	O

1	Transfer	O
2	RNA	O
3	genes	O
4	from	O
5	Dictyostelium	O
6	discoideum	O
7	are	O
8	frequently	O
9	associated	O
10	with	O
11	repetitive	O
12	elements	O
13	and	O
14	contain	O
15	consensus	O
16	boxes	O
17	in	O
18	their	O
19	5	O
20	'	O
21	and	O
22	3	O
23	'-	O
24	flanking	O
25	regions	O
26	.	O

1	Therefore	O
2	,	O
3	the	O
4	strD	B
5	and	O
6	strE	B
7	genes	I
8	could	O
9	serve	O
10	as	O
11	universal	O
12	probes	O
13	indicative	O
14	of	O
15	the	O
16	presence	O
17	of	O
18	biosynthetic	O
19	capacity	O
20	for	O
21	6	O
22	-	O
23	deoxyhexose	O
24	moieties	O
25	.	O

1	The	O
2	two	O
3	genes	O
4	code	O
5	for	O
6	polypeptides	B
7	of	I
8	420	I
9	amino	I
10	acids	I
11	(	I
12	M	I
13	.	I
14	HgiCI	I
15	)	I
16	and	O
17	345	O
18	amino	O
19	acids	O
20	(	O
21	R	O
22	.	O
23	HgiCI	O
24	).	O

1	Expression	O
2	of	O
3	the	O
4	wt1	B
5	gene	I
6	via	O
7	transient	O
8	transfection	O
9	in	O
10	COS	O
11	-	O
12	1	O
13	cells	O
14	revealed	O
15	a	O
16	52	O
17	kDa	O
18	protein	O
19	which	O
20	was	O
21	immunoprecipitated	O
22	by	O
23	both	O
24	the	O
25	N	O
26	-	O
27	terminal	O
28	-	O
29	and	O
30	C	O
31	-	O
32	terminal	O
33	-	O
34	specific	O
35	antisera	O
36	.	O

1	The	O
2	factor	O
3	which	O
4	binds	O
5	to	O
6	the	O
7	TR	B
8	promoter	I
9	co	O
10	-	O
11	sedimented	O
12	with	O
13	SV40	O
14	chromosomes	O
15	extracted	O
16	late	O
17	in	O
18	infection	O
19	.	O

1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O

1	Its	O
2	neuromuscular	O
3	effects	O
4	are	O
5	similar	O
6	to	O
7	a	O
8	single	O
9	ED90	O
10	dose	O
11	of	O
12	vecuronium	O
13	.	O

1	The	O
2	patient	O
3	with	O
4	a	O
5	prolonged	O
6	fever	O
7	caused	O
8	by	O
9	dissecting	O
10	aneurysm	O
11	of	O
12	the	O
13	aorta	O
14	in	O
15	whom	O
16	pleuropneumonia	O
17	masked	O
18	the	O
19	real	O
20	diseases	O
21	has	O
22	been	O
23	presented	O
24	.	O

1	The	O
2	resulting	O
3	clone	O
4	pKB11	B
5	,	O
6	which	O
7	has	O
8	a	O
9	1369	O
10	-	O
11	base	O
12	pair	O
13	(	O
14	bp	O
15	)	O
16	cDNA	O
17	insert	O
18	,	O
19	overlapping	O
20	pCAD142	B
21	by	O
22	781	O
23	bp	O
24	,	O
25	was	O
26	identified	O
27	by	O
28	hybridization	O
29	methods	O
30	and	O
31	sequence	O
32	analysis	O
33	and	O
34	found	O
35	to	O
36	contain	O
37	the	O
38	entire	O
39	cDNA	O
40	sequence	O
41	for	O
42	the	O
43	amino	O
44	end	O
45	of	O
46	the	O
47	CAD	B
48	polypeptide	I
49	.	O

1	This	O
2	conclusion	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blotting	O
8	analysis	O
9	of	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	of	O
16	CAD	B
17	gene	I
18	.	O

1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	genomic	O
7	and	O
8	cDNA	O
9	clones	O
10	of	O
11	the	O
12	light	O
13	-	O
14	independent	O
15	Sn	B
16	:	I
17	bol3	I
18	allele	I
19	.	O

1	Histamine	O
2	-	O
3	2	O
4	blockade	O
5	in	O
6	psoriasis	O

1	Its	O
2	clearance	O
3	has	O
4	been	O
5	found	O
6	to	O
7	be	O
8	decreased	O
9	(	O
10	typically	O
11	by	O
12	around	O
13	25	O
14	%,	O
15	but	O
16	often	O
17	by	O
18	far	O
19	more	O
20	)	O
21	by	O
22	erythromycin	O
23	,	O
24	troleandomycin	O
25	(	O
26	triacetyloleandomycin	O
27	),	O
28	roxithromycin	O
29	,	O
30	enoxacin	O
31	,	O
32	ciprofloxacin	O
33	,	O
34	pefloxacin	O
35	,	O
36	norfloxacin	O
37	,	O
38	ofloxacin	O
39	,	O
40	fluoroquinolone	O
41	T	O
42	-	O
43	3262	O
44	,	O
45	pipemidic	O
46	acid	O
47	,	O
48	cimetidine	O
49	,	O
50	etintidine	O
51	,	O
52	propranolol	O
53	,	O
54	verapamil	O
55	,	O
56	diltiazem	O
57	,	O
58	nifedipine	O
59	,	O
60	furosemide	O
61	(	O
62	frusemide	O
63	),	O
64	at	O
65	least	O
66	some	O
67	anovulent	O
68	agents	O
69	,	O
70	viloxazine	O
71	,	O
72	allopurinol	O
73	,	O
74	ticlopidine	O
75	,	O
76	idrocilamide	O
77	,	O
78	thiabendazole	O
79	,	O
80	disulfiram	O
81	,	O
82	influenza	O
83	-	O
84	and	O
85	BCG	O
86	-	O
87	vaccination	O
88	,	O
89	interferon	B
90	,	O
91	and	O
92	caffeine	O
93	(	O
94	half	O
95	-	O
96	life	O
97	increase	O
98	).	O

1	A	O
2	third	O
3	is	O
4	a	O
5	partial	O
6	element	O
7	terminating	O
8	at	O
9	a	O
10	probable	O
11	internal	O
12	restriction	O
13	site	O
14	used	O
15	for	O
16	cloning	O
17	.	O

1	We	O
2	enrolled	O
3	253	O
4	HIV	B
5	-	I
6	antibody	I
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	O
12	-	O
13	related	O
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	RNA14	B
7	and	O
8	RNA15	B
9	or	O
10	between	O
11	RNA14	B
12	and	O
13	other	O
14	proteins	O
15	contained	O
16	in	O
17	data	O
18	banks	O
19	.	O

1	Mutations	O
2	in	O
3	the	O
4	yeast	B
5	RNA14	I
6	and	O
7	RNA15	B
8	genes	I
9	result	O
10	in	O
11	an	O
12	abnormal	O
13	mRNA	O
14	decay	O
15	rate	O
16	;	O
17	sequence	O
18	analysis	O
19	reveals	O
20	an	O
21	RNA	O
22	-	O
23	binding	O
24	domain	O
25	in	O
26	the	O
27	RNA15	B
28	protein	I
29	.	O

1	Myocardial	O
2	infarction	O
3	in	O
4	patients	O
5	with	O
6	previous	O
7	bypass	O
8	surgery	O
9	.	O

1	The	O
2	most	O
3	striking	O
4	difference	O
5	in	O
6	the	O
7	birch	B
8	NAD	I
9	(	I
10	P	I
11	)	I
12	H	I
13	-	I
14	NR	I
15	sequence	I
16	in	O
17	comparison	O
18	to	O
19	NADH	B
20	-	I
21	NR	I
22	sequences	I
23	was	O
24	found	O
25	at	O
26	the	O
27	putative	O
28	pyridine	O
29	nucleotide	O
30	binding	O
31	site	O
32	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	difference	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	region	O
12	influences	O
13	dominant	O
14	negative	O
15	activity	O
16	and	O
17	receptor	O
18	dimer	O
19	formation	O
20	.	O

1	No	O
2	such	O
3	benefits	O
4	were	O
5	seen	O
6	for	O
7	children	O
8	with	O
9	CD4	B
10	+	I
11	counts	O
12	below	O
13	0	O
14	.	O
15	2	O
16	x	O
17	10	O
18	(	O
19	9	O
20	)	O
21	per	O
22	liter	O
23	at	O
24	entry	O
25	.	O

1	Because	O
2	the	O
3	human	B
4	Antp	I
5	TATAA	I
6	binding	I
7	protein	I
8	is	O
9	expressed	O
10	in	O
11	both	O
12	lymphoid	O
13	and	O
14	non	O
15	-	O
16	lymphoid	O
17	cells	O
18	,	O
19	we	O
20	suggest	O
21	that	O
22	this	O
23	homeobox	B
24	gene	I
25	has	O
26	evolved	O
27	a	O
28	more	O
29	general	O
30	transcriptional	O
31	regulatory	O
32	function	O
33	in	O
34	higher	O
35	eukaryotic	O
36	cells	O
37	.	O

1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O

1	Among	O
2	953	O
3	infants	O
4	in	O
5	22	O
6	neonatal	O
7	care	O
8	units	O
9	studied	O
10	,	O
11	23	O
12	%	O
13	(	O
14	median	O
15	value	O
16	,	O
17	range	O
18	0	O
19	-	O
20	78	O
21	)	O
22	were	O
23	found	O
24	to	O
25	be	O
26	faecally	O
27	colonized	O
28	with	O
29	one	O
30	of	O
31	21	O
32	distinct	O
33	nosocomial	O
34	strains	O
35	of	O
36	Escherichia	O
37	coli	O
38	,	O
39	Klebsiella	O
40	or	O
41	Enterobacter	O
42	spp	O
43	.	O

1	Biochemical	O
2	studies	O
3	revealed	O
4	the	O
5	expected	O
6	loss	O
7	of	O
8	ChAT	B
9	activity	O
10	in	O
11	the	O
12	dorsal	O
13	and	O
14	ventral	O
15	hippocampi	O
16	of	O
17	lesioned	O
18	animals	O
19	along	O
20	with	O
21	elevated	O
22	levels	O
23	of	O
24	norepinephrine	O
25	(	O
26	NE	O
27	)	O
28	in	O
29	the	O
30	dorsal	O
31	hippocampus	O
32	of	O
33	MS	O
34	/	O
35	HSI	O
36	animals	O
37	.(	O
38	ABSTRACT	O
39	TRUNCATED	O
40	AT	O
41	250	O
42	WORDS	O
43	)	O

1	The	O
2	localization	O
3	of	O
4	this	O
5	proteoglycan	O
6	locus	O
7	in	O
8	the	O
9	human	O
10	genome	O
11	and	O
12	the	O
13	availability	O
14	of	O
15	new	O
16	RFLPs	O
17	provide	O
18	the	O
19	tools	O
20	for	O
21	future	O
22	studies	O
23	of	O
24	human	O
25	diseases	O
26	where	O
27	the	O
28	HSPG2	B
29	proteoglycan	I
30	gene	I
31	is	O
32	suspected	O
33	to	O
34	be	O
35	involved	O
36	.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	During	O
2	coronary	O
3	stenosis	O
4	,	O
5	on	O
6	the	O
7	contrary	O
8	,	O
9	intracoronary	O
10	procaterol	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	deteriorated	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	LCX	O
23	flow	O
24	,	O
25	global	O
26	hemodynamics	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	major	B
7	IE	I
8	proteins	I
9	IE86	I
10	,	O
11	IE72	B
12	,	O
13	and	O
14	IE55	B
15	are	O
16	capable	O
17	of	O
18	trans	O
19	-	O
20	activating	O
21	the	O
22	HIV	B
23	LTR	I
24	in	O
25	a	O
26	T	O
27	-	O
28	cell	O
29	line	O
30	,	O
31	HUT	O
32	-	O
33	78	O
34	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	mediating	O
7	glucocorticoid	O
8	inducibility	O
9	of	O
10	the	O
11	chicken	B
12	glutamine	I
13	synthetase	I
14	gene	I
15	has	O
16	been	O
17	identified	O
18	.	O

1	However	O
2	,	O
3	the	O
4	increase	O
5	in	O
6	biliary	O
7	excretion	O
8	did	O
9	not	O
10	compensate	O
11	for	O
12	the	O
13	reduced	O
14	elimination	O
15	of	O
16	bretylium	O
17	and	O
18	hexylsalicylic	O
19	acid	O
20	via	O
21	the	O
22	kidney	O
23	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	cerebrospinal	B
5	fluid	I
6	immunoglobulin	I
7	G	I
8	(	O
9	IgG	B
10	)	O
11	in	O
12	pediatric	O
13	neurological	O
14	diseases	O
15	.	O

1	Expression	O
2	of	O
3	six	O
4	genes	O
5	,	O
6	ipaB	B
7	,	O
8	ipaC	B
9	,	O
10	invE	B
11	,	O
12	invG	B
13	,	O
14	invJ	B
15	,	O
16	and	O
17	invK	B
18	,	O
19	was	O
20	apparently	O
21	regulated	O
22	by	O
23	the	O
24	positive	O
25	regulator	O
26	virF	B
27	.	O

1	Inducible	O
2	VT	O
3	was	O
4	suppressed	O
5	entirely	O
6	in	O
7	one	O
8	patient	O
9	.	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	corresponding	O
6	mature	O
7	mRNA	O
8	transcripts	O
9	(	O
10	3	O
11	.	O
12	2	O
13	-	O
14	3	O
15	.	O
16	5	O
17	kilobase	O
18	pairs	O
19	(	O
20	kb	O
21	]	O
22	in	O
23	human	O
24	fibroblasts	O
25	was	O
26	shown	O
27	by	O
28	Northern	O
29	blot	O
30	hybridization	O
31	,	O
32	S1	B
33	nuclease	I
34	protection	O
35	assay	O
36	,	O
37	and	O
38	the	O
39	polymerase	O
40	chain	O
41	reaction	O
42	.	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	ribosomal	O
7	DNA	O
8	(	O
9	rDNA	O
10	)	O
11	units	O
12	of	O
13	Drosophila	O
14	melanogaster	O
15	are	O
16	inactivated	O
17	by	O
18	two	O
19	different	O
20	28	B
21	S	I
22	RNA	I
23	ribosomal	I
24	gene	I
25	insertions	O
26	(	O
27	type	O
28	I	O
29	and	O
30	type	O
31	II	O
32	).	O

1	Gap	B
2	b3	I
3	consists	O
4	of	O
5	two	O
6	polypeptide	O
7	chains	O
8	(	O
9	Mr	O
10	=	O
11	110	O
12	,	O
13	000	O
14	and	O
15	30	O
16	,	O
17	000	O
18	),	O
19	which	O
20	seem	O
21	to	O
22	be	O
23	proteolytic	O
24	cleavage	O
25	products	O
26	connected	O
27	by	O
28	disulfide	O
29	bonds	O
30	from	O
31	a	O
32	precursor	O
33	protein	O
34	.	O

1	However	O
2	,	O
3	the	O
4	rtFc	B
5	gamma	I
6	R	I
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	complementary	O
12	to	O
13	at	O
14	least	O
15	two	O
16	different	O
17	-	O
18	sized	O
19	mRNAs	O
20	expressed	O
21	by	O
22	CRNK	O
23	-	O
24	16	O
25	cells	O
26	,	O
27	contrasting	O
28	the	O
29	single	O
30	Fc	B
31	gamma	I
32	R	I
33	-	I
34	related	I
35	mRNA	I
36	species	O
37	expressed	O
38	by	O
39	human	O
40	and	O
41	mouse	O
42	natural	O
43	killer	O
44	cells	O
45	.	O

1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O

1	Stable	O
2	expression	O
3	of	O
4	the	O
5	chimeric	O
6	alpha	B
7	i	I
8	(	I
9	54	I
10	)/	I
11	s	I
12	polypeptide	O
13	in	O
14	Chinese	O
15	hamster	O
16	ovary	O
17	(	O
18	CHO	O
19	)	O
20	cells	O
21	constitutively	O
22	increased	O
23	both	O
24	cAMP	O
25	synthesis	O
26	and	O
27	cAMP	B
28	-	I
29	dependent	I
30	protein	I
31	kinase	I
32	activity	O
33	.	O

1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O

1	Treatment	O
2	of	O
3	human	O
4	myeloid	O
5	cell	O
6	lines	O
7	HL	O
8	-	O
9	60	O
10	and	O
11	U937	O
12	with	O
13	phorbol	O
14	12	O
15	-	O
16	myristate	O
17	13	O
18	-	O
19	acetate	O
20	(	O
21	PMA	O
22	)	O
23	increased	O
24	within	O
25	2	O
26	h	O
27	cellular	O
28	levels	O
29	of	O
30	the	O
31	RNA	O
32	hybridizable	O
33	to	O
34	LD78	B
35	cDNA	I
36	.	O

1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O

1	Isopenicillin	B
2	N	I
3	isomerase	I
4	(	O
5	epimerase	B
6	)	O
7	has	O
8	been	O
9	purified	O
10	from	O
11	Streptomyces	O
12	clavuligerus	O
13	,	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	sequence	O
19	of	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	has	O
25	been	O
26	determined	O
27	.	O

1	Serum	O
2	IgG	B
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	O
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	157	O
2	+/-	O
3	16	O
4	mg	O
5	/	O
6	dl	O
7	;	O
8	NS	O
9	),	O
10	glucose	O
11	levels	O
12	,	O
13	and	O
14	basal	O
15	(	O
16	17	O
17	+/-	O
18	4	O
19	vs	O
20	.	O

1	Platelet	O
2	aggregation	O
3	and	O
4	metabolic	O
5	control	O
6	are	O
7	not	O
8	affected	O
9	by	O
10	calcium	O
11	antagonist	O
12	treatment	O
13	in	O
14	type	O
15	II	O
16	diabetes	O
17	mellitus	O
18	.	O

1	Wnt	B
2	-	I
3	1	I
4	(	O
5	int	B
6	-	I
7	1	I
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O

1	Induction	O
2	of	O
3	Jurkat	O
4	leukemic	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	ionomycin	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	FKBP	B
24	mRNA	I
25	.	O

1	GLUT5	B
2	mRNA	I
3	is	O
4	expressed	O
5	at	O
6	highest	O
7	levels	O
8	in	O
9	small	O
10	intestine	O
11	and	O
12	at	O
13	much	O
14	lower	O
15	levels	O
16	in	O
17	kidney	O
18	,	O
19	skeletal	O
20	muscle	O
21	,	O
22	and	O
23	adipose	O
24	tissue	O
25	.	O

1	e	O
2	.	O

1	We	O
2	speculate	O
3	that	O
4	these	O
5	tumors	O
6	may	O
7	represent	O
8	congenital	O
9	hamartomatous	O
10	growths	O
11	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	B
10	gene	I
11	.	O

1	Surprisingly	O
2	,	O
3	there	O
4	is	O
5	no	O
6	sequence	O
7	homology	O
8	between	O
9	this	O
10	region	O
11	of	O
12	Ly	B
13	-	I
14	6E	I
15	and	O
16	the	O
17	established	O
18	consensus	O
19	for	O
20	the	O
21	interferon	B
22	-	I
23	stimulated	I
24	response	I
25	element	I
26	,	O
27	which	O
28	has	O
29	been	O
30	shown	O
31	functionally	O
32	important	O
33	to	O
34	all	O
35	previously	O
36	characterized	O
37	alpha	B
38	/	I
39	beta	I
40	interferon	I
41	-	O
42	inducible	O
43	promoters	O
44	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	O
15	-	O
16	terminal	O
17	histone	B
18	H1	I
19	-	I
20	like	I
21	structure	O
22	of	O
23	AlgP	B
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O

1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	O
10	identical	O
11	,	O
12	the	O
13	CArG	B
14	box	I
15	binding	I
16	proteins	I
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	B
27	,	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	,	O
33	and	O
34	c	B
35	-	I
36	fos	I
37	genes	I
38	.	O

1	Polyadenylation	O
2	of	O
3	B4	B
4	RNA	I
5	,	O
6	which	O
7	occurs	O
8	very	O
9	early	O
10	during	O
11	maturation	O
12	,	O
13	is	O
14	limited	O
15	to	O
16	150	O
17	residues	O
18	,	O
19	and	O
20	it	O
21	is	O
22	this	O
23	number	O
24	that	O
25	is	O
26	required	O
27	for	O
28	polysomal	O
29	recruitment	O
30	.	O

1	Co	O
2	-	O
3	existence	O
4	of	O
5	these	O
6	regulatory	O
7	elements	O
8	with	O
9	other	O
10	elements	O
11	,	O
12	such	O
13	as	O
14	the	O
15	AP	B
16	-	I
17	2	I
18	element	I
19	or	O
20	CCAAT	O
21	box	O
22	,	O
23	was	O
24	also	O
25	found	O
26	.	O

1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	disrupt	O
8	collagen	B
9	synthesis	O
10	and	O
11	deposition	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	angiogenesis	O
17	inhibitors	O
18	.	O

1	Since	O
2	the	O
3	5	O
4	'-	O
5	flanking	O
6	region	O
7	of	O
8	this	O
9	gene	O
10	is	O
11	likely	O
12	involved	O
13	in	O
14	hormonal	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	,	O
20	we	O
21	have	O
22	isolated	O
23	and	O
24	partially	O
25	characterized	O
26	an	O
27	avian	O
28	fatty	B
29	acid	I
30	synthase	I
31	gene	O
32	.	O

1	A	O
2	new	O
3	set	O
4	of	O
5	cDNA	O
6	clones	O
7	spanning	O
8	approximately	O
9	3	O
10	.	O
11	2	O
12	kb	O
13	was	O
14	isolated	O
15	from	O
16	a	O
17	lambda	O
18	-	O
19	ZAP	O
20	goose	O
21	liver	O
22	cDNA	O
23	library	O
24	using	O
25	the	O
26	5	O
27	'-	O
28	most	O
29	exon	O
30	-	O
31	containing	O
32	fragment	O
33	of	O
34	the	O
35	5	O
36	'-	O
37	most	O
38	genomic	O
39	DNA	O
40	clone	O
41	.	O

1	Northern	O
2	blotting	O
3	analysis	O
4	indicates	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	genes	O
10	corresponding	O
11	to	O
12	these	O
13	clones	O
14	is	O
15	confined	O
16	to	O
17	pollen	O
18	tissue	O
19	.	O

1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	B
14	genes	I
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	B
27	cDNA	I
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O

1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O

1	The	O
2	Drosophila	B
3	suppressor	I
4	of	I
5	sable	I
6	gene	I
7	encodes	O
8	a	O
9	polypeptide	O
10	with	O
11	regions	O
12	similar	O
13	to	O
14	those	O
15	of	O
16	RNA	O
17	-	O
18	binding	O
19	proteins	O
20	.	O

1	2	O
2	:	O
3	121	O
4	-	O
5	133	O
6	,	O
7	1988	O
8	).	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O

1	Although	O
2	the	O
3	N13	O
4	-	O
5	N20	O
6	interpeak	O
7	interval	O
8	remained	O
9	stable	O
10	because	O
11	of	O
12	the	O
13	parallel	O
14	shift	O
15	of	O
16	the	O
17	2	O
18	peaks	O
19	,	O
20	the	O
21	central	O
22	conduction	O
23	time	O
24	measured	O
25	from	O
26	onset	O
27	latencies	O
28	of	O
29	N11	O
30	and	O
31	N20	O
32	significantly	O
33	increased	O
34	.	O

1	Using	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	O
6	DNA	O
7	binding	O
8	assays	O
9	,	O
10	a	O
11	series	O
12	of	O
13	overlapping	O
14	alpha	B
15	promoter	I
16	DNA	I
17	sequences	I
18	between	O
19	-	O
20	170	O
21	to	O
22	29	O
23	basepairs	O
24	were	O
25	tested	O
26	,	O
27	but	O
28	each	O
29	failed	O
30	to	O
31	bind	O
32	GR	B
33	,	O
34	whereas	O
35	a	O
36	control	O
37	GRE	O
38	avidly	O
39	bound	O
40	receptor	O
41	.	O

1	Sequence	O
2	determination	O
3	of	O
4	isolated	O
5	peptides	O
6	suggested	O
7	that	O
8	Asn120	O
9	is	O
10	glycosylated	O
11	,	O
12	Asn65	O
13	and	O
14	Asn109	O
15	glycosylated	O
16	in	O
17	some	O
18	molecules	O
19	but	O
20	not	O
21	in	O
22	others	O
23	,	O
24	and	O
25	Asn72	O
26	not	O
27	glycosylated	O
28	.	O

1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O

1	The	O
2	murine	B
3	mutation	I
4	dominant	I
5	white	I
6	spotting	I
7	(	O
8	W	B
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	O
14	-	O
15	oncogene	O
16	,	O
17	c	B
18	-	I
19	kit	I
20	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	rat	O
7	chromosomal	O
8	gene	O
9	for	O
10	a	O
11	polypeptide	O
12	(	O
13	pS1	B
14	)	O
15	antigenically	O
16	related	O
17	to	O
18	statin	B
19	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	Our	O
2	results	O
3	also	O
4	indicate	O
5	the	O
6	existence	O
7	of	O
8	sequences	O
9	downstream	O
10	of	O
11	-	O
12	0	O
13	.	O
14	11	O
15	kb	O
16	which	O
17	can	O
18	influence	O
19	the	O
20	pattern	O
21	of	O
22	tissue	O
23	-	O
24	specific	O
25	expression	O
26	of	O
27	the	O
28	HLA	B
29	-	I
30	B7	I
31	gene	I
32	and	O
33	the	O
34	ability	O
35	of	O
36	this	O
37	gene	O
38	to	O
39	respond	O
40	to	O
41	gamma	B
42	interferon	I
43	.	O

1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	I
6	of	O
7	pp60src	B
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	p110	B
18	.	O

1	Chem	O
2	.	O

1	These	O
2	clones	O
3	overlapped	O
4	and	O
5	contained	O
6	the	O
7	structural	O
8	gene	O
9	encoding	O
10	the	O
11	complete	O
12	C5	B
13	alpha	I
14	-	I
15	chain	I
16	and	O
17	90	O
18	%	O
19	of	O
20	the	O
21	beta	O
22	-	O
23	chain	O
24	.	O

1	The	O
2	C5	B
3	alpha	I
4	-	I
5	chain	I
6	was	O
7	encoded	O
8	by	O
9	49	O
10	kilobases	O
11	containing	O
12	26	O
13	exons	O
14	;	O
15	the	O
16	beta	O
17	-	O
18	chain	O
19	was	O
20	encoded	O
21	by	O
22	29	O
23	kilobases	O
24	containing	O
25	16	O
26	exons	O
27	.	O

1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	B
15	-	I
16	alpha	I
17	2	I
18	(	I
19	I	I
20	)	I
21	gene	I
22	(	O
23	COL1A2	B
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	these	O
6	genes	O
7	differ	O
8	at	O
9	only	O
10	nine	O
11	positions	O
12	,	O
13	resulting	O
14	in	O
15	three	O
16	amino	O
17	acid	O
18	differences	O
19	.	O

1	The	O
2	protein	O
3	predicted	O
4	by	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	human	B
10	pim	I
11	-	I
12	1	I
13	proto	I
14	-	I
15	oncogene	I
16	shares	O
17	extensive	O
18	homology	O
19	with	O
20	known	O
21	serine	B
22	/	I
23	threonine	I
24	protein	I
25	kinases	I
26	,	O
27	and	O
28	yet	O
29	the	O
30	human	B
31	Pim	I
32	-	I
33	1	I
34	enzyme	I
35	has	O
36	previously	O
37	been	O
38	reported	O
39	to	O
40	exhibit	O
41	protein	B
42	tyrosine	I
43	kinase	I
44	activity	O
45	both	O
46	in	O
47	vitro	O
48	and	O
49	in	O
50	vivo	O
51	.	O

1	A	O
2	full	B
3	-	I
4	length	I
5	human	I
6	pim	I
7	-	I
8	1	I
9	cDNA	I
10	was	O
11	subcloned	O
12	into	O
13	the	O
14	bacterial	O
15	vector	O
16	pGEX	O
17	-	O
18	2T	O
19	and	O
20	the	O
21	Pim	B
22	-	I
23	1	I
24	protein	I
25	expressed	O
26	as	O
27	a	O
28	fusion	O
29	product	O
30	with	O
31	bacterial	B
32	glutathione	I
33	S	I
34	-	I
35	transferase	I
36	(	O
37	GST	B
38	).	O

1	This	O
2	report	O
3	substantiates	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	hsps	B
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O

1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O

1	Homology	O
2	with	O
3	the	O
4	human	O
5	protein	O
6	is	O
7	only	O
8	34	O
9	%	O
10	in	O
11	the	O
12	tandem	O
13	repeat	O
14	domain	O
15	,	O
16	mainly	O
17	showing	O
18	conservation	O
19	of	O
20	serines	O
21	and	O
22	threonines	O
23	,	O
24	presumed	O
25	sites	O
26	of	O
27	O	O
28	-	O
29	linked	O
30	carbohydrate	O
31	attachment	O
32	.	O

1	In	O
2	addition	O
3	to	O
4	targeting	O
5	partially	O
6	assembled	O
7	Ti	B
8	alpha	I
9	-	I
10	beta	I
11	CD3	I
12	gamma	I
13	delta	I
14	epsilon	I
15	TCR	I
16	complexes	I
17	to	O
18	the	O
19	cell	O
20	surface	O
21	,	O
22	CD3	B
23	zeta	I
24	appears	O
25	to	O
26	be	O
27	essential	O
28	for	O
29	interleukin	B
30	-	I
31	2	I
32	production	O
33	after	O
34	TCR	B
35	stimulation	O
36	with	O
37	antigen	B
38	/	I
39	major	I
40	histocompatibility	I
41	complex	I
42	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	Opposite	O
2	effects	O
3	of	O
4	CYP1	B
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O

1	A	O
2	segmental	O
3	analysis	O
4	of	O
5	the	O
6	key	O
7	regions	O
8	of	O
9	HLA	B
10	-	I
11	DR1	I
12	that	O
13	control	O
14	T	O
15	cell	O
16	allorecognition	O
17	was	O
18	performed	O
19	by	O
20	using	O
21	a	O
22	series	O
23	of	O
24	transfected	O
25	cell	O
26	lines	O
27	expressing	O
28	the	O
29	products	O
30	of	O
31	recombinant	O
32	DRB	B
33	/	O
34	H	B
35	-	I
36	2Eb	I
37	genes	O
38	,	O
39	paired	O
40	with	O
41	either	O
42	DR	B
43	alpha	I
44	or	O
45	H	B
46	-	I
47	2E	I
48	alpha	I
49	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O

1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	O
8	Gag	B
9	-	O
10	Pol	B
11	PR	O
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	B
17	in	O
18	trans	O
19	by	O
20	a	O
21	wild	O
22	-	O
23	type	O
24	PR	B
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	O
33	PR	B
34	domain	O
35	in	O
36	Gag	B
37	-	O
38	Pol	B
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	B
45	.	O

1	The	O
2	alpha	B
3	inhibin	I
4	promoter	I
5	containing	O
6	a	O
7	mutated	O
8	CRE	O
9	was	O
10	not	O
11	regulated	O
12	by	O
13	forskolin	O
14	in	O
15	granulosa	O
16	cells	O
17	and	O
18	did	O
19	not	O
20	bind	O
21	the	O
22	CREB	B
23	protein	I
24	.	O

1	Regulation	O
2	of	O
3	the	O
4	alpha	B
5	inhibin	I
6	gene	I
7	by	O
8	cyclic	O
9	adenosine	O
10	3	O
11	',	O
12	5	O
13	'-	O
14	monophosphate	O
15	after	O
16	transfection	O
17	into	O
18	rat	O
19	granulosa	O
20	cells	O
21	.	O

1	Comparison	O
2	of	O
3	the	O
4	nucleotide	O
5	sequences	O
6	between	O
7	the	O
8	human	O
9	and	O
10	bovine	O
11	DNA	O
12	showed	O
13	that	O
14	the	O
15	sequence	O
16	similarity	O
17	extended	O
18	2400	O
19	bp	O
20	downstream	O
21	from	O
22	the	O
23	coding	O
24	region	O
25	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O

1	In	O
2	patients	O
3	with	O
4	osteomyelitis	O
5	and	O
6	joint	O
7	empyema	O
8	(	O
9	n	O
10	=	O
11	48	O
12	)	O
13	PMN	B
14	elastase	I
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	exceeded	O
25	by	O
26	that	O
27	of	O
28	the	O
29	unspecific	O
30	erythrocyte	O
31	sedimentation	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O

1	E	O
2	.,	O
3	Hession	O
4	,	O
5	C	O
6	.,	O
7	Goff	O
8	,	O
9	D	O
10	.,	O
11	Griffiths	O
12	,	O
13	B	O
14	.,	O
15	Tizard	O
16	,	O
17	R	O
18	.,	O
19	Newman	O
20	,	O
21	B	O
22	.,	O
23	Chi	O
24	-	O
25	Rosso	O
26	,	O
27	G	O
28	.,	O
29	and	O
30	Lobb	O
31	,	O
32	R	O
33	.,	O
34	(	O
35	1990	O
36	)	O
37	Cell	O
38	63	O
39	,	O
40	1349	O
41	-	O
42	1356	O
43	).	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	An	O
2	approximately	O
3	2	B
4	-	I
5	kilobase	I
6	B2	I
7	transcript	I
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	B
23	.	O

1	Pharmacokinetics	O
2	of	O
3	FK	O
4	506	O
5	in	O
6	transplant	O
7	patients	O
8	.	O

1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	B
18	ribonuclease	I
19	H	I
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	O
52	O	O
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	O
67	structure	O
68	,	O
69	respectively	O
70	.	O

1	Analysis	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	suggests	O
9	that	O
10	CHIP28	B
11	protein	I
12	contains	O
13	six	O
14	bilayer	O
15	-	O
16	spanning	O
17	domains	O
18	,	O
19	two	O
20	exofacial	O
21	potential	O
22	N	O
23	-	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	intracellular	O
29	N	O
30	and	O
31	C	O
32	termini	O
33	.	O

1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O

1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O

1	The	O
2	activity	O
3	of	O
4	serum	B
5	lipase	I
6	and	O
7	amylase	B
8	distinctly	O
9	increased	O
10	at	O
11	3	O
12	h	O
13	and	O
14	went	O
15	up	O
16	to	O
17	the	O
18	maximum	O
19	at	O
20	12	O
21	h	O
22	after	O
23	injection	O
24	of	O
25	Na	O
26	-	O
27	Tc	O
28	.	O

1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	B
6	-	I
7	HCV	I
8	(	O
9	anti	B
10	-	I
11	C100	I
12	-	I
13	3	I
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O

1	Diltiazem	O
2	resulted	O
3	in	O
4	a	O
5	significant	O
6	increase	O
7	in	O
8	epicardial	O
9	diameter	O
10	(+	O
11	10	O
12	%;	O
13	p	O
14	=	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	in	O
21	coronary	O
22	blood	O
23	flow	O
24	(	O
25	CBF	O
26	)	O
27	(+	O
28	30	O
29	%;	O
30	p	O
31	=	O
32	0	O
33	.	O
34	0001	O
35	).	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	These	O
2	risk	O
3	factors	O
4	can	O
5	be	O
6	divided	O
7	into	O
8	2	O
9	groups	O
10	:	O
11	local	O
12	vessel	O
13	wall	O
14	-	O
15	related	O
16	factors	O
17	,	O
18	and	O
19	local	O
20	(	O
21	focal	O
22	action	O
23	)	O
24	systemic	O
25	factors	O
26	.	O

1	Epidemiology	O
2	and	O
3	prevention	O
4	of	O
5	hospital	O
6	infections	O
7	in	O
8	the	O
9	Local	O
10	Health	O
11	Unit	O
12	of	O
13	Sassari	O
14	:	O
15	profile	O
16	of	O
17	bacterial	O
18	resistance	O
19	and	O
20	antimicrobial	O
21	agents	O
22	of	O
23	large	O
24	usage	O
25	.	O

1	PRDII	B
2	-	I
3	BF1	I
4	-	I
5	derived	I
6	cDNAs	I
7	did	O
8	not	O
9	result	O
10	in	O
11	stimulation	O
12	of	O
13	either	O
14	basal	O
15	or	O
16	tat	B
17	-	O
18	induced	O
19	activated	O
20	gene	O
21	expression	O
22	.	O

1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	O
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O

1	Max	B
2	:	O
3	functional	O
4	domains	O
5	and	O
6	interaction	O
7	with	O
8	c	B
9	-	I
10	Myc	I
11	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	Substitutions	O
2	introduced	O
3	at	O
4	bases	O
5	surrounding	O
6	the	O
7	ICR2	B
8	motif	I
9	yielded	O
10	levels	O
11	of	O
12	pRNA	O
13	replication	O
14	that	O
15	differed	O
16	,	O
17	depending	O
18	on	O
19	the	O
20	maintenance	O
21	of	O
22	a	O
23	putative	O
24	5	O
25	'	O
26	stem	O
27	-	O
28	loop	O
29	structure	O
30	in	O
31	the	O
32	positive	O
33	strand	O
34	of	O
35	the	O
36	viral	O
37	genome	O
38	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	B
11	32	I
12	protein	O
13	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	B
10	gene	I
11	32	I
12	protein	I
13	.	O

1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O

1	The	O
2	pathophysiology	O
3	and	O
4	clinical	O
5	management	O
6	of	O
7	acute	O
8	brain	O
9	injury	O
10	in	O
11	infancy	O
12	and	O
13	childhood	O
14	are	O
15	presented	O
16	using	O
17	acute	O
18	traumatic	O
19	brain	O
20	injury	O
21	as	O
22	a	O
23	model	O
24	.	O

1	Transcripts	O
2	from	O
3	a	O
4	second	O
5	POU	B
6	-	I
7	domain	I
8	gene	I
9	,	O
10	Oct	B
11	-	I
12	25	I
13	,	O
14	were	O
15	present	O
16	at	O
17	low	O
18	levels	O
19	in	O
20	oocytes	O
21	and	O
22	early	O
23	embryos	O
24	and	O
25	were	O
26	dramatically	O
27	upregulated	O
28	during	O
29	early	O
30	gastrulation	O
31	.	O

1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	Abelson	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	LT	B
21	mRNA	I
22	is	O
23	constitutively	O
24	expressed	O
25	.	O

1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O

1	These	O
2	tumors	O
3	were	O
4	classified	O
5	into	O
6	three	O
7	broad	O
8	groups	O
9	:	O
10	I	O
11	,	O
12	cystadenoma	O
13	;	O
14	II	O
15	,	O
16	cystadenocarcinoma	O
17	;	O
18	and	O
19	III	O
20	,	O
21	adenocarcinoma	O
22	with	O
23	mucin	B
24	production	O
25	or	O
26	an	O
27	associated	O
28	cyst	O
29	.	O

1	Immunostaining	O
2	of	O
3	cells	O
4	transfected	O
5	with	O
6	these	O
7	constructs	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	myristoylated	O
13	and	O
14	nonmyristoylated	O
15	mutants	O
16	were	O
17	localized	O
18	in	O
19	nuclei	O
20	,	O
21	whereas	O
22	wild	B
23	-	I
24	type	I
25	PKC	I
26	alpha	I
27	was	O
28	primarily	O
29	cytoplasmic	O
30	and	O
31	perinuclear	O
32	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	Effects	O
2	of	O
3	thromboxane	B
4	synthetase	I
5	inhibition	O
6	on	O
7	postburn	O
8	mesenteric	O
9	vascular	O
10	resistance	O
11	and	O
12	the	O
13	rate	O
14	of	O
15	bacterial	O
16	translocation	O
17	in	O
18	a	O
19	chronic	O
20	porcine	O
21	model	O
22	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	B
19	lipase	I
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	mutant	O
6	molecule	O
7	corresponds	O
8	to	O
9	the	O
10	unprocessed	O
11	cytoplasmic	O
12	precursor	O
13	(	O
14	pre	B
15	-	I
16	super	I
17	-	I
18	pro	I
19	-	I
20	PrB	I
21	),	O
22	as	O
23	detected	O
24	in	O
25	sec61	B
26	mutants	I
27	,	O
28	when	O
29	translocation	O
30	into	O
31	the	O
32	endoplasmic	O
33	reticulum	O
34	is	O
35	blocked	O
36	.	O

1	Thus	O
2	,	O
3	the	O
4	active	O
5	-	O
6	site	O
7	mutation	O
8	prevents	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	processing	O
14	of	O
15	the	O
16	N	O
17	-	O
18	glycosylated	O
19	73	O
20	-	O
21	kDa	O
22	precursor	O
23	of	O
24	PrB	B
25	to	O
26	the	O
27	41	B
28	.	I
29	5	I
30	kDa	I
31	pro	I
32	-	I
33	PrB	I
34	in	O
35	the	O
36	endoplasmic	O
37	reticulum	O
38	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	70	O
8	%	O
9	identity	O
10	to	O
11	that	O
12	of	O
13	Bacillus	B
14	stearothermophilus	I
15	TyrTS	I
16	and	O
17	55	O
18	%	O
19	identity	O
20	to	O
21	that	O
22	of	O
23	E	B
24	.	I
25	coli	I
26	TyrTS	I
27	,	O
28	while	O
29	identity	O
30	to	O
31	a	O
32	second	O
33	cryptic	O
34	B	B
35	.	I
36	subtilis	I
37	TyrTS	I
38	gene	I
39	,	O
40	designated	O
41	tyrZ	B
42	,	O
43	was	O
44	only	O
45	27	O
46	%.	O

1	Heat	O
2	-	O
3	inducible	O
4	CAT	B
5	activity	O
6	was	O
7	detectable	O
8	when	O
9	additional	O
10	sequences	O
11	from	O
12	the	O
13	native	O
14	promoter	O
15	containing	O
16	three	O
17	CCAAT	O
18	boxes	O
19	and	O
20	a	O
21	single	O
22	HSE	O
23	were	O
24	present	O
25	in	O
26	the	O
27	constructions	O
28	.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	Testosterone	O
2	,	O
3	free	O
4	testosterone	O
5	,	O
6	non	B
7	-	I
8	sex	I
9	hormone	I
10	-	I
11	binding	I
12	globulin	I
13	-	O
14	bound	O
15	testosterone	O
16	,	O
17	and	O
18	free	O
19	androgen	O
20	index	O
21	:	O
22	which	O
23	testosterone	O
24	measurement	O
25	is	O
26	most	O
27	relevant	O
28	to	O
29	reproductive	O
30	and	O
31	sexual	O
32	function	O
33	in	O
34	men	O
35	with	O
36	epilepsy	O
37	?	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	The	O
2	upstream	O
3	delta	O
4	-	O
5	alpha	O
6	breakpoint	O
7	is	O
8	flanked	O
9	by	O
10	the	O
11	direct	O
12	repeats	O
13	of	O
14	the	O
15	acceptor	O
16	splice	O
17	site	O
18	,	O
19	whereas	O
20	the	O
21	down	O
22	-	O
23	stream	O
24	alpha	O
25	-	O
26	delta	O
27	breakpoint	O
28	is	O
29	located	O
30	in	O
31	the	O
32	adjacent	O
33	intron	O
34	.	O

1	Patients	O
2	with	O
3	moderate	O
4	PDDAT	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O

1	Bone	O
2	and	O
3	bones	O
4	.	O

1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O

1	Complex	O
2	repetitive	O
3	discharges	O
4	were	O
5	observed	O
6	in	O
7	muscles	O
8	of	O
9	mdx	O
10	mice	O
11	but	O
12	no	O
13	complex	O
14	repetitive	O
15	discharges	O
16	or	O
17	other	O
18	abnormalities	O
19	were	O
20	observed	O
21	in	O
22	muscles	O
23	of	O
24	normal	O
25	control	O
26	mice	O
27	.	O

1	Management	O
2	often	O
3	involves	O
4	beta	O
5	-	O
6	and	O
7	calcium	O
8	channel	O
9	blocking	O
10	drugs	O
11	or	O
12	type	O
13	IC	O
14	antiarrhythmic	O
15	drugs	O
16	.	O

1	To	O
2	overcome	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	Kex2p	B
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O

1	J	O
2	.	O

1	The	O
2	major	B
3	49	I
4	-	I
5	kDa	I
6	core	I
7	protein	I
8	in	O
9	the	O
10	liver	O
11	HSPG	B
12	preparation	O
13	was	O
14	found	O
15	to	O
16	be	O
17	reactive	O
18	to	O
19	an	O
20	antibody	O
21	that	O
22	specifically	O
23	recognizes	O
24	the	O
25	cytoplasmic	O
26	domain	O
27	of	O
28	fibroglycan	B
29	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	Toxicity	O
2	was	O
3	mild	O
4	,	O
5	mainly	O
6	consisting	O
7	of	O
8	emesis	O
9	(	O
10	81	O
11	%	O
12	of	O
13	the	O
14	patients	O
15	;	O
16	66	O
17	%	O
18	of	O
19	the	O
20	courses	O
21	),	O
22	leukopenia	O
23	of	O
24	World	O
25	Health	O
26	Organization	O
27	(	O
28	WHO	O
29	)	O
30	grade	O
31	1	O
32	to	O
33	2	O
34	(	O
35	47	O
36	%	O
37	of	O
38	the	O
39	patients	O
40	;	O
41	18	O
42	%	O
43	of	O
44	the	O
45	courses	O
46	),	O
47	and	O
48	thrombocytopenia	O
49	(	O
50	12	O
51	%	O
52	of	O
53	the	O
54	patients	O
55	;	O
56	3	O
57	%	O
58	of	O
59	the	O
60	courses	O
61	).	O

1	W	O
2	.	O
3	G	O
4	.	O

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O

1	A	O
2	mouse	B
3	brain	I
4	beta	I
5	-	I
6	spectrin	I
7	of	O
8	cDNA	O
9	was	O
10	identified	O
11	within	O
12	a	O
13	lambda	O
14	Gt11	O
15	expression	O
16	library	O
17	using	O
18	an	O
19	antibody	O
20	which	O
21	specifically	O
22	binds	O
23	with	O
24	the	O
25	235	B
26	kDa	I
27	spectrin	I
28	beta	I
29	-	I
30	subunit	I
31	.	O

1	RESULTS	O
2	:	O
3	Plasma	B
4	AVP	I
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O

1	The	O
2	fragments	O
3	of	O
4	each	O
5	region	O
6	were	O
7	amplified	O
8	by	O
9	polymerase	O
10	chain	O
11	reaction	O
12	and	O
13	analyzed	O
14	by	O
15	gel	O
16	electrophoresis	O
17	to	O
18	detect	O
19	single	O
20	-	O
21	strand	O
22	conformation	O
23	polymorphism	O
24	.	O

1	The	O
2	csbA	B
3	fusion	I
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	The	O
2	constraints	O
3	of	O
4	primase	B
5	recognition	I
6	sequences	I
7	,	O
8	nucleotide	O
9	substrate	O
10	requirements	O
11	,	O
12	and	O
13	the	O
14	effects	O
15	of	O
16	additional	O
17	proteins	O
18	on	O
19	oligoribonucleotide	O
20	synthesis	O
21	by	O
22	the	O
23	63	B
24	-	I
25	kDa	I
26	gene	I
27	4	I
28	protein	I
29	have	O
30	been	O
31	examined	O
32	using	O
33	templates	O
34	of	O
35	defined	O
36	sequence	O
37	.	O

1	Thrombolytic	O
2	therapy	O
3	in	O
4	spontaneous	O
5	coronary	O
6	artery	O
7	dissection	O
8	.	O

1	A	O
2	prospective	O
3	trial	O
4	was	O
5	carried	O
6	out	O
7	in	O
8	156	O
9	unselected	O
10	patients	O
11	(	O
12	41	O
13	men	O
14	,	O
15	mean	O
16	age	O
17	67	O
18	.	O
19	5	O
20	years	O
21	,	O
22	115	O
23	women	O
24	,	O
25	mean	O
26	age	O
27	71	O
28	.	O
29	4	O
30	years	O
31	)	O
32	who	O
33	had	O
34	undergone	O
35	total	O
36	hip	O
37	joint	O
38	replacement	O
39	because	O
40	of	O
41	degenerative	O
42	or	O
43	inflammatory	O
44	arthritis	O
45	or	O
46	fracture	O
47	of	O
48	the	O
49	neck	O
50	of	O
51	the	O
52	femur	O
53	.	O

1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	O
14	recovery	O
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O

1	Human	O
2	SRF	B
3	-	I
4	related	I
5	proteins	I
6	:	O
7	DNA	O
8	-	O
9	binding	O
10	properties	O
11	and	O
12	potential	O
13	regulatory	O
14	targets	O
15	.	O

1	We	O
2	have	O
3	isolated	O
4	cDNAs	O
5	for	O
6	a	O
7	gene	O
8	coding	O
9	for	O
10	a	O
11	G	B
12	protein	I
13	alpha	I
14	subunit	I
15	from	I
16	tomato	I
17	(	O
18	Lycopersicon	O
19	esculentum	O
20	,	O
21	cv	O
22	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	I
15	activation	I
16	domain	I
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	The	O
2	authors	O
3	evaluated	O
4	the	O
5	potential	O
6	for	O
7	thrombotic	O
8	complications	O
9	arising	O
10	from	O
11	implantation	O
12	of	O
13	a	O
14	ventricular	O
15	assist	O
16	device	O
17	(	O
18	Sarns	O
19	/	O
20	3M	O
21	-	O
22	VAD	O
23	)	O
24	in	O
25	four	O
26	calves	O
27	.	O

1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O

1	Amino	O
2	acid	O
3	residues	O
4	147	O
5	-	O
6	167	O
7	of	O
8	the	O
9	previously	O
10	reported	O
11	sequence	O
12	are	O
13	replaced	O
14	by	O
15	new	O
16	residues	O
17	147	O
18	to	O
19	150	O
20	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	Tat	I
9	protein	I
10	requires	O
11	specific	O
12	residues	O
13	in	O
14	the	O
15	hexanucleotide	O
16	loop	O
17	and	O
18	trinucleotide	O
19	bulge	O
20	of	O
21	the	O
22	TAR	B
23	RNA	O
24	stem	O
25	-	O
26	loop	O
27	structure	O
28	found	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	untranslated	O
34	leader	O
35	of	O
36	all	O
37	viral	O
38	transcripts	O
39	.	O

1	We	O
2	obtained	O
3	quantitative	O
4	evidence	O
5	on	O
6	the	O
7	coding	O
8	of	O
9	interaural	O
10	time	O
11	differences	O
12	(	O
13	ITDs	O
14	)	O
15	of	O
16	click	O
17	stimuli	O
18	by	O
19	40	O
20	single	O
21	neurons	O
22	in	O
23	the	O
24	auditory	O
25	cortex	O
26	of	O
27	anesthetized	O
28	albino	O
29	rats	O
30	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	As	O
2	an	O
3	initial	O
4	step	O
5	towards	O
6	the	O
7	characterization	O
8	of	O
9	replicative	O
10	DNA	B
11	polymerases	I
12	of	I
13	trypanosomes	I
14	,	O
15	we	O
16	have	O
17	cloned	O
18	,	O
19	sequenced	O
20	and	O
21	examined	O
22	the	O
23	expression	O
24	of	O
25	the	O
26	Trypanosoma	O
27	(	O
28	Trypanozoon	O
29	)	O
30	brucei	O
31	brucei	O
32	gene	O
33	that	O
34	encodes	O
35	the	O
36	DNA	B
37	polymerase	I
38	alpha	I
39	catalytic	I
40	core	I
41	(	O
42	pol	B
43	alpha	I
44	).	O

1	In	O
2	addition	O
3	,	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	increase	O
9	in	O
10	postdexamethasone	O
11	cortical	O
12	concentrations	O
13	with	O
14	age	O
15	(	O
16	p	O
17	less	O
18	than	O
19	0	O
20	.	O
21	01	O
22	;	O
23	r	O
24	=	O
25	0	O
26	.	O
27	31	O
28	).	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	The	O
2	volume	O
3	fraction	O
4	(	O
5	Vv	O
6	)	O
7	and	O
8	number	O
9	/	O
10	mm2	O
11	(	O
12	Na	O
13	)	O
14	of	O
15	all	O
16	capillaries	O
17	(	O
18	perfused	O
19	and	O
20	nonperfused	O
21	)	O
22	in	O
23	a	O
24	given	O
25	area	O
26	of	O
27	brain	O
28	were	O
29	determined	O
30	after	O
31	staining	O
32	for	O
33	alkaline	B
34	phosphatase	I
35	.	O

1	Airway	O
2	pressure	O
3	and	O
4	air	O
5	flow	O
6	were	O
7	measured	O
8	at	O
9	the	O
10	endotracheal	O
11	tube	O
12	in	O
13	13	O
14	children	O
15	on	O
16	a	O
17	variety	O
18	of	O
19	ventilators	O
20	.	O

1	Appl	O
2	.	O

1	Issues	O
2	of	O
3	distribution	O
4	of	O
5	kinetic	O
6	energy	O
7	of	O
8	traumatizing	O
9	object	O
10	in	O
11	direct	O
12	contact	O
13	interaction	O
14	with	O
15	head	O
16	during	O
17	impact	O
18	are	O
19	discussed	O
20	from	O
21	position	O
22	of	O
23	biomechanics	O
24	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Diltiazem	O
2	decreased	O
3	the	O
4	total	O
5	body	O
6	clearance	O
7	from	O
8	34	O
9	.	O
10	0	O
11	+/-	O
12	8	O
13	.	O
14	0	O
15	to	O
16	28	O
17	.	O
18	6	O
19	+/-	O
20	6	O
21	.	O
22	1	O
23	mL	O
24	/	O
25	min	O
26	(	O
27	P	O
28	less	O
29	than	O
30	.	O
31	01	O
32	),	O
33	and	O
34	prolonged	O
35	the	O
36	elimination	O
37	half	O
38	-	O
39	life	O
40	from	O
41	12	O
42	.	O
43	6	O
44	+/-	O
45	3	O
46	.	O
47	0	O
48	to	O
49	14	O
50	.	O
51	3	O
52	+/-	O
53	2	O
54	.	O
55	5	O
56	hours	O
57	(	O
58	P	O
59	less	O
60	than	O
61	.	O
62	01	O
63	)	O
64	of	O
65	antipyrine	O
66	without	O
67	any	O
68	changes	O
69	in	O
70	volume	O
71	of	O
72	distribution	O
73	.	O

1	The	O
2	granules	O
3	grew	O
4	as	O
5	the	O
6	melted	O
7	material	O
8	immersed	O
9	into	O
10	the	O
11	void	O
12	space	O
13	among	O
14	the	O
15	adhered	O
16	particles	O
17	.	O

1	Hence	O
2	,	O
3	the	O
4	uPA	B
5	promoter	I
6	contains	O
7	multiple	O
8	weak	O
9	cis	O
10	-	O
11	acting	O
12	elements	O
13	distributed	O
14	over	O
15	7	O
16	.	O
17	0	O
18	kb	O
19	5	O
20	'	O
21	to	O
22	the	O
23	translation	O
24	start	O
25	site	O
26	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	B
16	tetrapeptide	I
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	B
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O

1	P	O
2	.	O

1	In	O
2	one	O
3	,	O
4	exploratory	O
5	behavior	O
6	(	O
7	assessed	O
8	by	O
9	hole	O
10	pokes	O
11	)	O
12	and	O
13	locomotion	O
14	were	O
15	assessed	O
16	during	O
17	a	O
18	10	O
19	-	O
20	min	O
21	test	O
22	session	O
23	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	12	O
2	-	O
3	O	O
4	-	O
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	B
26	and	O
27	myogenin	B
28	.	O

1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	These	O
2	introns	O
3	belong	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O

1	The	O
2	mRNA	O
3	identified	O
4	in	O
5	both	O
6	human	O
7	and	O
8	rat	O
9	cells	O
10	with	O
11	the	O
12	human	B
13	clathrin	I
14	clone	O
15	revealed	O
16	transcripts	O
17	of	O
18	approximately	O
19	6	O
20	.	O
21	5	O
22	kb	O
23	,	O
24	which	O
25	is	O
26	consistent	O
27	with	O
28	the	O
29	predicted	O
30	180	O
31	kDa	O
32	molecular	O
33	weight	O
34	of	O
35	the	O
36	clathrin	B
37	heavy	I
38	chain	I
39	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	1251	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	junctions	O
33	,	O
34	and	O
35	583	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O

1	An	O
2	8	O
3	-	O
4	h	O
5	exposure	O
6	to	O
7	10	O
8	mg	O
9	DMEA	O
10	/	O
11	m3	O
12	corresponds	O
13	to	O
14	a	O
15	postexposure	O
16	plasma	O
17	concentration	O
18	and	O
19	2	O
20	-	O
21	h	O
22	postexposure	O
23	urinary	O
24	excretion	O
25	of	O
26	4	O
27	.	O
28	9	O
29	mumol	O
30	/	O
31	l	O
32	and	O
33	75	O
34	mmol	O
35	/	O
36	mol	O
37	creatinine	O
38	,	O
39	respectively	O
40	.	O

1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	B
12	heavy	I
13	chain	I
14	gene	I
15	which	O
16	relies	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	selectable	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O

1	Allergenic	O
2	activity	O
3	of	O
4	allergen	O
5	extract	O
6	Ambrosia	O
7	elatior	O
8	(	O
9	AE	O
10	)	O
11	was	O
12	tested	O
13	in	O
14	fifteen	O
15	volunteers	O
16	extremely	O
17	sensitive	O
18	to	O
19	the	O
20	allergen	O
21	.	O

1	This	O
2	study	O
3	was	O
4	aimed	O
5	at	O
6	assessing	O
7	whether	O
8	c	O
9	-	O
10	DDP	O
11	administration	O
12	immediately	O
13	before	O
14	radiotherapy	O
15	could	O
16	increase	O
17	frequency	O
18	and	O
19	duration	O
20	of	O
21	objective	O
22	responses	O
23	,	O
24	as	O
25	well	O
26	as	O
27	survival	O
28	,	O
29	in	O
30	patients	O
31	affected	O
32	with	O
33	locally	O
34	advanced	O
35	stages	O
36	of	O
37	squamous	O
38	carcinomas	O
39	of	O
40	the	O
41	head	O
42	and	O
43	neck	O
44	.	O

1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	B
22	/	O
23	HAP3	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	B
34	consensus	I
35	recognition	I
36	sequence	I
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	O
6	serum	B
7	fibrinogen	I
8	and	O
9	prolonged	O
10	prothrombin	B
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	B
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	We	O
2	exploit	O
3	the	O
4	properties	O
5	of	O
6	LexA	B
7	fusion	I
8	proteins	I
9	to	O
10	study	O
11	the	O
12	dimerization	O
13	and	O
14	DNA	O
15	-	O
16	contacting	O
17	domains	O
18	of	O
19	cRel	B
20	.	O

1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	O
6	were	O
7	compared	O
8	in	O
9	elderly	O
10	female	O
11	runners	O
12	(	O
13	RU	O
14	:	O
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	O
47	-	O
48	1	O
49	min	O
50	-	O
51	1	O
52	,	O
53	mean	O
54	+/-	O
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	O
64	UT	O
65	:	O
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	O
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	O
82	26	O
83	+/-	O
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	O
90	-	O
91	1	O
92	).	O

1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	O
30	kHz	O
31	.	O

1	Fundamental	O
2	and	O
3	clinical	O
4	evaluation	O
5	of	O
6	equilibrium	O
7	dialysis	O
8	--	O
9	radioimmunoassay	O
10	system	O
11	for	O
12	measurement	O
13	of	O
14	serum	O
15	free	O
16	thyroxine	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	thromboxane	B
11	synthetase	I
12	inhibitor	O
13	and	O
14	a	O
15	thromboxane	B
16	receptor	I
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	digoxin	O
24	intoxication	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O

1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	B
13	-	O
14	DQA1	B
15	locus	O
16	through	O
17	the	O
18	Y3	B
19	/	O
20	Ring	B
21	4	I
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	Adverse	O
2	foetal	O
3	outcome	O
4	in	O
5	specific	O
6	IgM	B
7	positive	O
8	Chlamydia	O
9	trachomatis	O
10	infection	O
11	in	O
12	pregnancy	O
13	.	O

1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O

1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O

1	If	O
2	delay	O
3	has	O
4	occurred	O
5	between	O
6	centrifugation	O
7	and	O
8	the	O
9	measurement	O
10	,	O
11	causing	O
12	substantial	O
13	loss	O
14	of	O
15	CO2	O
16	,	O
17	equilibration	O
18	of	O
19	the	O
20	sample	O
21	with	O
22	a	O
23	gas	O
24	mixture	O
25	corresponding	O
26	to	O
27	PCO2	O
28	=	O
29	5	O
30	.	O
31	3	O
32	kPa	O
33	prior	O
34	to	O
35	the	O
36	measurement	O
37	is	O
38	recommended	O
39	.	O

1	The	O
2	possible	O
3	mechanisms	O
4	underlying	O
5	differences	O
6	in	O
7	post	O
8	-	O
9	tetanic	O
10	effects	O
11	from	O
12	muscle	O
13	and	O
14	cutaneous	O
15	afferents	O
16	in	O
17	adults	O
18	and	O
19	neonates	O
20	are	O
21	discussed	O
22	.	O

1	We	O
2	examined	O
3	behavioral	O
4	alterations	O
5	in	O
6	the	O
7	brown	O
8	cockroach	O
9	,	O
10	Periplaneta	O
11	brunnea	O
12	,	O
13	infected	O
14	with	O
15	the	O
16	acanthocephalan	O
17	,	O
18	Moniliformis	O
19	moniliformis	O
20	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	O
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	I
29	unit	I
30	in	I
31	rhesus	I
32	macaque	I
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	O
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	O
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	O
70	repeat	O
71	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	repressor	O
6	locus	O
7	,	O
8	c	O
9	,	O
10	of	O
11	the	O
12	Streptomyces	O
13	temperate	O
14	phage	O
15	,	O
16	phi	O
17	C31	O
18	,	O
19	was	O
20	shown	O
21	previously	O
22	to	O
23	contain	O
24	an	O
25	open	O
26	reading	O
27	frame	O
28	encoding	O
29	a	O
30	74	O
31	kDa	O
32	protein	O
33	.	O

1	The	O
2	EPO	B
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O

1	This	O
2	differential	O
3	sensitivity	O
4	to	O
5	DB	O
6	,	O
7	as	O
8	measured	O
9	by	O
10	a	O
11	lower	O
12	concentration	O
13	of	O
14	DB	O
15	which	O
16	caused	O
17	loss	O
18	of	O
19	righting	O
20	in	O
21	LS	O
22	,	O
23	was	O
24	accompanied	O
25	by	O
26	an	O
27	equal	O
28	rate	O
29	of	O
30	water	O
31	-	O
32	soluble	O
33	barbiturate	O
34	brain	O
35	distribution	O
36	and	O
37	elimination	O
38	in	O
39	the	O
40	two	O
41	lines	O
42	.	O

1	The	O
2	existence	O
3	of	O
4	threshold	O
5	concentrations	O
6	,	O
7	above	O
8	which	O
9	certain	O
10	phenomena	O
11	may	O
12	occur	O
13	,	O
14	strengthens	O
15	the	O
16	role	O
17	of	O
18	sentinels	O
19	.	O

1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O

1	Felodipine	O
2	did	O
3	not	O
4	alter	O
5	the	O
6	baseline	O
7	FEV1	O
8	,	O
9	but	O
10	showed	O
11	a	O
12	small	O
13	significant	O
14	inhibitory	O
15	effect	O
16	upon	O
17	histamine	O
18	and	O
19	AMP	O
20	induced	O
21	bronchoconstriction	O
22	.	O

1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	O
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O

1	Our	O
2	mapping	O
3	results	O
4	did	O
5	not	O
6	suggest	O
7	involvement	O
8	of	O
9	this	O
10	gene	O
11	in	O
12	previously	O
13	mapped	O
14	genetic	O
15	disorders	O
16	or	O
17	in	O
18	known	O
19	neoplasia	O
20	-	O
21	associated	O
22	translocation	O
23	breakpoints	O
24	.	O

1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O

1	These	O
2	changes	O
3	weren	O
4	'	O
5	t	O
6	so	O
7	significant	O
8	in	O
9	the	O
10	group	O
11	of	O
12	obese	O
13	children	O
14	who	O
15	didn	O
16	'	O
17	t	O
18	lose	O
19	weight	O
20	.	O

1	Arsenic	O
2	contents	O
3	in	O
4	native	O
5	copper	O

1	In	O
2	ten	O
3	other	O
4	experiments	O
5	(	O
6	5	O
7	experimental	O
8	and	O
9	5	O
10	control	O
11	rats	O
12	)	O
13	99mTc	O
14	-	O
15	sulfur	O
16	colloid	O
17	was	O
18	injected	O
19	intravenously	O
20	.	O

1	Magnetotherapy	O
2	of	O
3	hepatitis	O
4	A	O
5	and	O
6	B	O
7	in	O
8	children	O

1	These	O
2	results	O
3	were	O
4	superior	O
5	to	O
6	those	O
7	in	O
8	24	O
9	patients	O
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	sutures	O
18	on	O
19	clinical	O
20	testing	O
21	.	O

1	Mutational	O
2	analysis	O
3	supports	O
4	a	O
5	role	O
6	for	O
7	multiple	O
8	structural	O
9	features	O
10	in	O
11	the	O
12	C	O
13	-	O
14	terminal	O
15	secretion	O
16	signal	O
17	of	O
18	Escherichia	B
19	coli	I
20	haemolysin	I
21	.	O

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	O
10	regardless	O
11	the	O
12	number	O
13	of	O
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	O
26	to	O
27	the	O
28	percentage	O
29	of	O
30	male	O
31	blood	O
32	donors	O
33	.	O

1	Extramedullary	O
2	relapse	O
3	in	O
4	childhood	O
5	leukemia	O
6	.	O

1	Mycoplasma	O
2	pneumoniae	O
3	was	O
4	isolated	O
5	from	O
6	the	O
7	pleural	O
8	fluid	O
9	of	O
10	this	O
11	patient	O
12	.	O

1	RU486	O
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O

1	The	O
2	presence	O
3	of	O
4	local	O
5	abnormalities	O
6	in	O
7	both	O
8	patients	O
9	can	O
10	support	O
11	the	O
12	hypothesis	O
13	that	O
14	the	O
15	cortex	O
16	,	O
17	especially	O
18	of	O
19	the	O
20	temporal	O
21	anterior	O
22	lobe	O
23	,	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	origin	O
29	of	O
30	the	O
31	laughing	O
32	seizures	O
33	.	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	Many	O
2	cells	O
3	were	O
4	negative	O
5	for	O
6	endothelial	O
7	-	O
8	cell	O
9	markers	O
10	,	O
11	and	O
12	they	O
13	reacted	O
14	with	O
15	a	O
16	monoclonal	O
17	antibody	O
18	against	O
19	muscle	O
20	actin	B
21	.	O

1	CT	O
2	abnormalities	O
3	noted	O
4	in	O
5	term	O
6	babies	O
7	included	O
8	hemorrhage	O
9	(	O
10	subarachnoid	O
11	5	O
12	.	O
13	8	O
14	%,	O
15	intracerebral	O
16	11	O
17	.	O
18	6	O
19	%),	O
20	hypodensity	O
21	(	O
22	mild	O
23	23	O
24	.	O
25	2	O
26	%,	O
27	moderate	O
28	11	O
29	.	O
30	6	O
31	%	O
32	severe	O
33	5	O
34	.	O
35	8	O
36	%);	O
37	hypodensity	O
38	with	O
39	hemorrhage	O
40	5	O
41	.	O
42	8	O
43	%	O
44	and	O
45	cerebral	O
46	atrophy	O
47	5	O
48	.	O
49	8	O
50	%.	O

1	The	O
2	effects	O
3	of	O
4	contrast	O
5	media	O
6	on	O
7	coagulation	B
8	factor	I
9	XII	I
10	.	O

1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O

1	In	O
2	sixteen	O
3	patients	O
4	with	O
5	moderate	O
6	essential	O
7	hypertension	O
8	the	O
9	effects	O
10	of	O
11	10	O
12	-	O
13	day	O
14	nifedipine	O
15	treatment	O
16	on	O
17	serum	O
18	uric	O
19	acid	O
20	and	O
21	renal	O
22	excretion	O
23	of	O
24	uric	O
25	acid	O
26	were	O
27	evaluated	O
28	.	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O

1	Examples	O
2	are	O
3	using	O
4	more	O
5	subjects	O
6	or	O
7	an	O
8	improved	O
9	research	O
10	design	O
11	,	O
12	developing	O
13	consensus	O
14	statements	O
15	or	O
16	using	O
17	meta	O
18	-	O
19	analysis	O
20	.	O

1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	(	O
6	rCBF	O
7	)	O
8	measurements	O
9	and	O
10	psychiatric	O
11	ratings	O
12	were	O
13	performed	O
14	on	O
15	seven	O
16	schizophrenic	O
17	patients	O
18	(	O
19	mean	O
20	age	O
21	=	O
22	41	O
23	.	O
24	4	O
25	years	O
26	)	O
27	who	O
28	had	O
29	been	O
30	examined	O
31	18	O
32	years	O
33	previously	O
34	in	O
35	a	O
36	study	O
37	that	O
38	used	O
39	similar	O
40	psychiatric	O
41	ratings	O
42	and	O
43	a	O
44	comparable	O
45	rCBF	O
46	technique	O
47	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	strong	O
10	positive	O
11	cis	O
12	-	O
13	regulatory	O
14	element	O
15	at	O
16	-	O
17	70	O
18	bp	O
19	to	O
20	-	O
21	75	O
22	bp	O
23	in	O
24	the	O
25	LpS1	B
26	beta	I
27	promoter	I
28	with	O
29	the	O
30	sequence	O
31	(	O
32	G	O
33	)	O
34	6	O
35	and	O
36	a	O
37	similar	O
38	,	O
39	more	O
40	distal	O
41	cis	O
42	-	O
43	element	O
44	at	O
45	-	O
46	721	O
47	bp	O
48	to	O
49	-	O
50	726	O
51	bp	O
52	.	O

1	The	O
2	present	O
3	study	O
4	reports	O
5	visual	O
6	evoked	O
7	potential	O
8	responses	O
9	to	O
10	pattern	O
11	reversal	O
12	(	O
13	VEP	O
14	-	O
15	P	O
16	)	O
17	in	O
18	ten	O
19	third	O
20	trimester	O
21	pregnant	O
22	women	O
23	and	O
24	changes	O
25	in	O
26	latency	O
27	of	O
28	NPN	O
29	complex	O
30	when	O
31	compared	O
32	with	O
33	these	O
34	responses	O
35	in	O
36	the	O
37	non	O
38	pregnant	O
39	state	O
40	.	O

1	No	O
2	case	O
3	of	O
4	SMF	O
5	demonstrated	O
6	expansive	O
7	tumorous	O
8	growth	O
9	.	O

1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O

1	Review	O
2	of	O
3	the	O
4	literature	O
5	and	O
6	report	O
7	of	O
8	a	O
9	case	O
10	of	O
11	a	O
12	dermoid	O
13	cyst	O
14	.	O

1	Resolution	O
2	of	O
3	thermographic	O
4	asymmetry	O
5	and	O
6	/	O
7	or	O
8	decrease	O
9	in	O
10	Delta	O
11	T	O
12	was	O
13	demonstrated	O
14	in	O
15	approximately	O
16	81	O
17	%	O
18	of	O
19	the	O
20	post	O
21	-	O
22	treatment	O
23	population	O
24	.	O

1	In	O
2	all	O
3	instances	O
4	the	O
5	apparent	O
6	alcohol	O
7	responses	O
8	were	O
9	very	O
10	small	O
11	and	O
12	never	O
13	exceeded	O
14	a	O
15	reading	O
16	of	O
17	1	O
18	microgram	O
19	/	O
20	100ml	O
21	for	O
22	breath	O
23	samples	O
24	more	O
25	than	O
26	10min	O
27	post	O
28	-	O
29	exposure	O
30	.	O

1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	B
13	rbcS	I
14	promoters	I
15	.	O

1	Measurements	O
2	were	O
3	done	O
4	with	O
5	a	O
6	commercial	O
7	haematofluorometer	O
8	Buchler	O
9	ZF	O
10	which	O
11	was	O
12	calibrated	O
13	to	O
14	the	O
15	average	O
16	haematocrit	O
17	value	O
18	of	O
19	0	O
20	.	O
21	42	O
22	.	O

1	The	O
2	relatively	O
3	scanty	O
4	number	O
5	of	O
6	examples	O
7	,	O
8	which	O
9	could	O
10	be	O
11	justified	O
12	by	O
13	the	O
14	variety	O
15	and	O
16	complexity	O
17	of	O
18	combined	O
19	exposure	O
20	,	O
21	allows	O
22	to	O
23	conclude	O
24	that	O
25	life	O
26	-	O
27	style	O
28	factors	O
29	have	O
30	considerable	O
31	influence	O
32	on	O
33	interindividual	O
34	differences	O
35	in	O
36	susceptibility	O
37	to	O
38	xenobiotics	O
39	toxicity	O
40	.	O

1	The	O
2	12S	B
3	E1A	I
4	product	I
5	does	O
6	not	O
7	activate	O
8	a	O
9	TRE	O
10	sequence	O
11	,	O
12	but	O
13	cotransfection	O
14	with	O
15	c	B
16	-	I
17	jun	I
18	circumvents	O
19	this	O
20	lack	O
21	of	O
22	stimulation	O
23	.	O

1	After	O
2	treatment	O
3	with	O
4	tunicamycin	O
5	,	O
6	the	O
7	transfectants	O
8	secreted	O
9	unglycosylated	O
10	18	O
11	-	O
12	kDa	O
13	polypeptides	O
14	which	O
15	could	O
16	also	O
17	bind	O
18	IgE	B
19	.	O

1	PAS1	B
2	,	O
3	a	O
4	yeast	O
5	gene	O
6	required	O
7	for	O
8	peroxisome	O
9	biogenesis	O
10	,	O
11	encodes	O
12	a	O
13	member	O
14	of	O
15	a	O
16	novel	O
17	family	O
18	of	O
19	putative	O
20	ATPases	B
21	.	O

1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	O
21	SIG	B
22	family	I
23	,	O
24	the	O
25	beta	B
26	TG	I
27	gene	I
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O

1	The	O
2	pp90rsk	B
3	-	I
4	protein	I
5	kinase	I
6	activity	O
7	(	O
8	referred	O
9	to	O
10	as	O
11	rsk	B
12	-	I
13	kinase	I
14	)	O
15	is	O
16	also	O
17	not	O
18	related	O
19	to	O
20	cofactor	O
21	-	O
22	dependent	O
23	signal	O
24	transducing	O
25	protein	O
26	kinases	O
27	such	O
28	as	O
29	the	O
30	cyclic	B
31	AMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinases	I
36	,	O
37	members	O
38	of	O
39	the	O
40	protein	B
41	kinase	I
42	C	I
43	family	I
44	,	O
45	or	O
46	other	O
47	Ca2	B
48	(+)-	I
49	dependent	I
50	protein	I
51	kinases	I
52	.	O

1	Human	B
2	GATA	I
3	-	I
4	3	I
5	:	O
6	a	O
7	lineage	O
8	-	O
9	restricted	O
10	transcription	O
11	factor	O
12	that	O
13	regulates	O
14	the	O
15	expression	O
16	of	O
17	the	O
18	T	B
19	cell	I
20	receptor	I
21	alpha	I
22	gene	I
23	.	O

1	Like	O
2	many	O
3	eukaryotic	O
4	transcription	O
5	factors	O
6	,	O
7	these	O
8	proteins	O
9	bind	O
10	to	O
11	DNA	O
12	as	O
13	dimers	O
14	.	O

1	Furthermore	O
2	,	O
3	the	O
4	UvrA	B
5	protein	I
6	interacts	O
7	with	O
8	the	O
9	UvrB	B
10	protein	I
11	to	O
12	modulate	O
13	its	O
14	activities	O
15	,	O
16	both	O
17	in	O
18	solution	O
19	and	O
20	in	O
21	association	O
22	with	O
23	DNA	O
24	,	O
25	where	O
26	the	O
27	UvrAB	B
28	complex	I
29	possesses	O
30	a	O
31	helicase	B
32	activity	O
33	.	O

1	The	O
2	ED30	O
3	values	O
4	were	O
5	2	O
6	.	O
7	4	O
8	and	O
9	2	O
10	.	O
11	2	O
12	mg	O
13	/	O
14	kg	O
15	and	O
16	similar	O
17	to	O
18	the	O
19	respective	O
20	values	O
21	of	O
22	nifedipine	O
23	(	O
24	ED	O
25	30	O
26	:	O
27	2	O
28	.	O
29	4	O
30	,	O
31	2	O
32	.	O
33	1	O
34	mg	O
35	/	O
36	kg	O
37	).	O

1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	B
12	B	I
13	element	I
14	directly	O
15	and	O
16	specifically	O
17	.	O

1	Thus	O
2	,	O
3	the	O
4	positive	O
5	effect	O
6	of	O
7	NS1	B
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	B
16	transcripts	I
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	O
24	number	O
25	and	O
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O

1	The	O
2	minus	O
3	-	O
4	end	O
5	-	O
6	directed	O
7	microtubule	O
8	motors	O
9	,	O
10	the	O
11	dyneins	B
12	,	O
13	may	O
14	also	O
15	constitute	O
16	a	O
17	superfamily	O
18	of	O
19	force	O
20	-	O
21	generating	O
22	proteins	O
23	with	O
24	distinct	O
25	attachment	O
26	domains	O
27	.	O

1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O

1	The	O
2	incompatibility	O
3	group	O
4	W	O
5	plasmid	O
6	pSa	O
7	suppresses	O
8	Agrobacterium	O
9	tumefaciens	O
10	oncogenicity	O
11	(	O
12	J	O
13	.	O

1	Potential	O
2	translational	O
3	start	O
4	signals	O
5	are	O
6	upstream	O
7	of	O
8	ORF1	O
9	and	O
10	ORF2	O
11	.	O

1	Imaging	O
2	of	O
3	D2	B
4	dopamine	I
5	receptor	I

1	The	O
2	Thr161Val	O
3	mutation	O
4	causes	O
5	a	O
6	lethal	O
7	phenotype	O
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	while	O
16	replacement	O
17	of	O
18	Thr161	O
19	with	O
20	glutamic	O
21	acid	O
22	,	O
23	potentially	O
24	mimicking	O
25	phosphorylation	O
26	,	O
27	causes	O
28	uncoordination	O
29	of	O
30	mitosis	O
31	and	O
32	multiple	O
33	cytokinesis	O
34	.	O

1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	I
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O

1	Deregulation	O
2	of	O
3	their	O
4	expression	O
5	may	O
6	contribute	O
7	to	O
8	malignant	O
9	transformation	O
10	associated	O
11	with	O
12	HTLV	O
13	-	O
14	1	O
15	infection	O
16	.	O

1	The	O
2	murine	B
3	Mov	I
4	-	I
5	34	I
6	gene	I
7	:	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	and	O
13	genomic	O
14	organization	O
15	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	The	O
2	spectrum	O
3	of	O
4	histologically	O
5	diagnosed	O
6	malignant	O
7	neoplasms	O
8	in	O
9	Sabah	O
10	,	O
11	1983	O
12	-	O
13	1988	O
14	.	O

1	When	O
2	transfected	O
3	into	O
4	Drosophila	O
5	SL	O
6	-	O
7	2	O
8	cells	O
9	,	O
10	pCAT	O
11	plasmid	O
12	containing	O
13	2	O
14	,	O
15	090	O
16	bp	O
17	of	O
18	5	O
19	'-	O
20	flanking	O
21	region	O
22	shows	O
23	a	O
24	3	O
25	.	O
26	0	O
27	-	O
28	to	O
29	3	O
30	.	O
31	5	O
32	-	O
33	fold	O
34	increase	O
35	in	O
36	chloramphenicol	B
37	acetyltransferase	I
38	activity	O
39	after	O
40	induction	O
41	with	O
42	retinoic	O
43	acid	O
44	and	O
45	/	O
46	or	O
47	8	O
48	-	O
49	bromo	O
50	-	O
51	cAMP	O
52	.	O

1	Two	O
2	alternatively	O
3	spliced	O
4	5	O
5	'	O
6	UTRs	O
7	,	O
8	designated	O
9	type	O
10	I	O
11	and	O
12	type	O
13	II	O
14	,	O
15	of	O
16	222	O
17	and	O
18	115	O
19	bp	O
20	,	O
21	respectively	O
22	,	O
23	were	O
24	found	O
25	associated	O
26	with	O
27	PFP	B
28	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	B
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	B
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	O
13	plants	O
14	and	O
15	have	O
16	established	O
17	that	O
18	the	O
19	nuclear	O
20	transport	O
21	machinery	O
22	is	O
23	similar	O
24	in	O
25	monocots	O
26	and	O
27	dicots	O
28	.	O

1	A	O
2	novel	O
3	cDNA	O
4	clone	O
5	termed	O
6	R2	O
7	was	O
8	isolated	O
9	by	O
10	subtractive	O
11	hybridization	O
12	of	O
13	a	O
14	cDNA	O
15	library	O
16	of	O
17	phytohemagglutinin	B
18	(	O
19	PHA	B
20	)/	O
21	phorbol	O
22	myristate	O
23	acetate	O
24	-	O
25	stimulated	O
26	Jurkat	O
27	cells	O
28	and	O
29	by	O
30	rescreening	O
31	a	O
32	cDNA	O
33	library	O
34	of	O
35	PHA	O
36	-	O
37	stimulated	O
38	peripheral	O
39	blood	O
40	lymphocytes	O
41	.	O

1	In	O
2	conclusion	O
3	,	O
4	we	O
5	observed	O
6	a	O
7	great	O
8	regeneration	O
9	ability	O
10	following	O
11	mechanical	O
12	injury	O
13	in	O
14	the	O
15	nasal	O
16	mucosa	O
17	.	O

1	There	O
2	occurred	O
3	a	O
4	linear	O
5	relationship	O
6	between	O
7	the	O
8	drop	O
9	in	O
10	glucose	B
11	-	I
12	6	I
13	-	I
14	phosphatase	I
15	dehydrogenase	I
16	activity	O
17	and	O
18	in	O
19	vitamin	O
20	E	O
21	level	O
22	,	O
23	on	O
24	one	O
25	hand	O
26	,	O
27	and	O
28	the	O
29	duration	O
30	of	O
31	poisoning	O
32	with	O
33	sodium	O
34	nitrite	O
35	.	O

1	A	O
2	vector	O
3	containing	O
4	a	O
5	transcriptionally	O
6	inactive	O
7	neomycin	B
8	phosphotransferase	I
9	II	I
10	gene	I
11	was	O
12	used	O
13	to	O
14	select	O
15	promoter	O
16	sequences	O
17	from	O
18	a	O
19	pool	O
20	of	O
21	random	O
22	genomic	O
23	DNA	O
24	fragments	O
25	.	O

1	Chagas	O
2	'	O
3	disease	O
4	,	O
5	visceral	O
6	leishmaniasis	O
7	,	O
8	anti	B
9	-	I
10	nuclear	I
11	factor	I
12	,	O
13	schistosomiasis	O
14	,	O
15	rheumatoid	B
16	factor	I
17	and	O
18	normal	O
19	controls	O
20	.	O

1	Previous	O
2	analysis	O
3	of	O
4	the	O
5	98	O
6	-	O
7	bp	O
8	sequence	O
9	has	O
10	delineated	O
11	several	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	that	O
17	are	O
18	recognized	O
19	by	O
20	nuclear	O
21	factors	O
22	present	O
23	in	O
24	human	O
25	brain	O
26	cells	O
27	.	O

1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	B
8	.	I
9	5	I
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	B
24	35	I
25	proteins	I
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	B
43	transcription	O
44	initiation	O
45	site	O
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	B
62	transcriptional	I
63	unit	I
64	.	O

1	The	O
2	adeno	B
3	-	I
4	associated	I
5	virus	I
6	(	I
7	AAV	I
8	)	I
9	rep	I
10	gene	I
11	encodes	O
12	four	O
13	proteins	O
14	(	O
15	Rep78	B
16	,	O
17	Rep68	B
18	,	O
19	Rep52	B
20	,	O
21	and	O
22	Rep40	B
23	)	O
24	required	O
25	for	O
26	AAV	O
27	DNA	O
28	replication	O
29	and	O
30	AAV	O
31	gene	O
32	regulation	O
33	.	O

1	A	O
2	larger	O
3	region	O
4	upstream	O
5	of	O
6	human	B
7	CMV	I
8	dbp	I
9	also	O
10	mediated	O
11	replication	O
12	in	O
13	transient	O
14	assays	O
15	.	O

1	It	O
2	also	O
3	contains	O
4	a	O
5	picornaviral	B
6	3C	I
7	-	I
8	like	I
9	protease	I
10	domain	I
11	and	O
12	two	O
13	papain	B
14	-	I
15	like	I
16	protease	I
17	domains	I
18	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	In	O
2	short	O
3	-	O
4	term	O
5	cotransfections	O
6	,	O
7	a	O
8	pFRTK	B
9	-	O
10	CAT	B
11	target	O
12	containing	O
13	EBNA	B
14	-	I
15	1	I
16	-	I
17	binding	I
18	sites	I
19	from	O
20	the	O
21	EBV	O
22	origin	O
23	of	O
24	plasmid	O
25	replication	O
26	,	O
27	ori	B
28	-	I
29	P	I
30	,	O
31	was	O
32	transactivated	O
33	by	O
34	a	O
35	carboxy	B
36	-	I
37	terminal	I
38	EBNA	I
39	-	I
40	1	I
41	construction	I
42	(	O
43	amino	O
44	acids	O
45	450	O
46	to	O
47	641	O
48	)	O
49	that	O
50	also	O
51	carried	O
52	a	O
53	c	B
54	-	I
55	myc	I
56	nuclear	I
57	localization	I
58	signal	I
59	.	O

1	The	O
2	findings	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	genes	O
11	encoding	O
12	PDGF	B
13	receptors	I
14	in	O
15	glioma	O
16	cells	O
17	are	O
18	regulated	O
19	in	O
20	concert	O
21	with	O
22	other	O
23	genes	O
24	,	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	may	O
30	reflect	O
31	the	O
32	developmental	O
33	program	O
34	of	O
35	normal	O
36	glia	O
37	cell	O
38	lineages	O
39	.	O

1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O

1	This	O
2	study	O
3	tested	O
4	the	O
5	hypothesis	O
6	that	O
7	sodium	O
8	channel	O
9	blocking	O
10	drugs	O
11	selectively	O
12	prolong	O
13	the	O
14	late	O
15	potential	O
16	,	O
17	or	O
18	terminal	O
19	low	O
20	amplitude	O
21	signal	O
22	,	O
23	portion	O
24	of	O
25	the	O
26	signal	O
27	-	O
28	averaged	O
29	QRS	O
30	complex	O
31	and	O
32	that	O
33	prolongation	O
34	of	O
35	the	O
36	late	O
37	potential	O
38	would	O
39	correlate	O
40	with	O
41	slowing	O
42	of	O
43	ventricular	O
44	tachycardia	O
45	.	O

1	Identification	O
2	and	O
3	nucleotide	O
4	sequence	O
5	of	O
6	Rhizobium	B
7	meliloti	I
8	insertion	I
9	sequence	I
10	ISRm3	I
11	:	O
12	similarity	O
13	between	O
14	the	O
15	putative	O
16	transposase	B
17	encoded	O
18	by	O
19	ISRm3	B
20	and	O
21	those	O
22	encoded	O
23	by	O
24	Staphylococcus	B
25	aureus	I
26	IS256	I
27	and	O
28	Thiobacillus	B
29	ferrooxidans	I
30	IST2	I
31	.	O

1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O

1	Whereas	O
2	a	O
3	PR55	B
4	beta	I
5	transcript	I
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	O
23	LA	O
24	-	O
25	N	O
26	-	O
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	Heterodimers	O
2	of	O
3	myogenin	B
4	and	O
5	E12	B
6	(	O
7	or	O
8	MyoD	B
9	and	O
10	E12	B
11	)	O
12	specifically	O
13	bound	O
14	a	O
15	restriction	O
16	fragment	O
17	extending	O
18	from	O
19	-	O
20	200	O
21	to	O
22	-	O
23	103	O
24	relative	O
25	to	O
26	the	O
27	start	O
28	of	O
29	cardiac	B
30	alpha	I
31	-	I
32	actin	I
33	transcription	O
34	.	O

1	The	O
2	effects	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	were	O
8	further	O
9	dissected	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	I
15	myc	I
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	Id	B
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O

1	Stable	O
2	association	O
3	of	O
4	U2	B
5	snRNP	I
6	with	O
7	the	O
8	branchpoint	O
9	sequence	O
10	of	O
11	mammalian	O
12	pre	O
13	-	O
14	mRNAs	O
15	requires	O
16	binding	O
17	of	O
18	a	O
19	non	O
20	-	O
21	snRNP	O
22	protein	O
23	to	O
24	the	O
25	polypyrimidine	O
26	tract	O
27	.	O

1	Naturally	O
2	acquired	O
3	antibodies	O
4	were	O
5	demonstrated	O
6	in	O
7	some	O
8	rabbits	O
9	kept	O
10	on	O
11	commercial	O
12	farms	O
13	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	O
7	(	O
8	FONICAP	O
9	).	O

1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	B
7	encoding	I
8	Alzheimer	I
9	beta	I
10	-	I
11	amyloid	I
12	precursor	I
13	protein	I
14	(	O
15	APP	B
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O

1	Biol	O
2	.	O

1	Nucleotide	O
2	sequences	O
3	between	O
4	the	O
5	env	B
6	gene	I
7	and	O
8	the	O
9	LTR	B
10	of	I
11	SFV	I
12	-	I
13	1	I
14	were	O
15	determined	O
16	.	O

1	This	O
2	element	O
3	was	O
4	used	O
5	to	O
6	screen	O
7	an	O
8	EMBL3	O
9	mouse	O
10	genomic	O
11	library	O
12	.	O

1	The	O
2	MVV	O
3	-	O
4	value	O
5	is	O
6	under	O
7	the	O
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	O
16	76	O
17	percent	O
18	.	O

1	The	O
2	rad9	B
3	.	I
4	192	I
5	DNA	I
6	repair	I
7	mutant	I
8	from	I
9	the	I
10	fission	I
11	yeast	I
12	,	I
13	Schizosaccharomyces	I
14	pombe	I
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	shows	O
6	strong	O
7	sequence	O
8	similarity	O
9	to	O
10	Escherichia	O
11	coli	O
12	consensus	O
13	promoters	O
14	and	O
15	ribosome	O
16	-	O
17	binding	O
18	sequences	O
19	and	O
20	allows	O
21	high	O
22	levels	O
23	of	O
24	expression	O
25	in	O
26	E	O
27	.	O
28	coli	O
29	.	O

1	Premature	O
2	initiation	O
3	of	O
4	mitosis	O
5	in	O
6	yeast	O
7	lacking	O
8	RCC1	B
9	or	O
10	an	O
11	interacting	O
12	GTPase	B
13	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	routinely	O
6	used	O
7	in	O
8	our	O
9	laboratory	O
10	for	O
11	1	O
12	year	O
13	and	O
14	has	O
15	proven	O
16	to	O
17	be	O
18	a	O
19	reliable	O
20	procedure	O
21	for	O
22	the	O
23	biological	O
24	control	O
25	of	O
26	occupational	O
27	exposure	O
28	to	O
29	toluene	O
30	and	O
31	/	O
32	or	O
33	xylene	O
34	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	Oculus	O
2	-	O
3	500	O
4	is	O
5	a	O
6	group	O
7	of	O
8	high	O
9	resolution	O
10	imaging	O
11	boards	O
12	for	O
13	use	O
14	with	O
15	IBM	O
16	-	O
17	AT	O
18	and	O
19	compatible	O
20	computers	O
21	.	O

1	The	O
2	human	O
3	cDNA	O
4	was	O
5	used	O
6	to	O
7	demonstrate	O
8	that	O
9	tumor	B
10	necrosis	I
11	factor	I
12	-	I
13	alpha	I
14	could	O
15	rapidly	O
16	stimulate	O
17	MARCKS	B
18	gene	I
19	transcription	O
20	in	O
21	the	O
22	human	O
23	promyelocytic	O
24	leukemia	O
25	cell	O
26	line	O
27	HL60	O
28	.	O

1	After	O
2	resection	O
3	of	O
4	the	O
5	proximal	O
6	fragment	O
7	,	O
8	all	O
9	scaphoid	O
10	contact	O
11	area	O
12	and	O
13	pressure	O
14	was	O
15	born	O
16	by	O
17	the	O
18	distal	O
19	scaphoid	O
20	fragment	O
21	.	O

1	Plate	O
2	luting	O
3	,	O
4	a	O
5	technique	O
6	that	O
7	uses	O
8	polymethylmethacrylate	O
9	(	O
10	PMMA	O
11	)	O
12	interposed	O
13	between	O
14	the	O
15	plate	O
16	and	O
17	the	O
18	bone	O
19	,	O
20	as	O
21	well	O
22	as	O
23	between	O
24	the	O
25	screw	O
26	heads	O
27	and	O
28	the	O
29	plate	O
30	,	O
31	to	O
32	improve	O
33	the	O
34	stability	O
35	of	O
36	internal	O
37	fixation	O
38	was	O
39	tested	O
40	in	O
41	vitro	O
42	using	O
43	20	O
44	paired	O
45	equine	O
46	third	O
47	metacarpal	O
48	bones	O
49	with	O
50	mid	O
51	-	O
52	diaphyseal	O
53	osteotomies	O
54	plated	O
55	with	O
56	six	O
57	-	O
58	hole	O
59	broad	O
60	ASIF	O
61	compression	O
62	plates	O
63	.	O

1	These	O
2	features	O
3	were	O
4	considered	O
5	consistent	O
6	with	O
7	a	O
8	diagnosis	O
9	of	O
10	Rothmund	O
11	-	O
12	Thomson	O
13	syndrome	O
14	.	O

1	Thyroid	O
2	lymphoma	O
3	and	O
4	its	O
5	management	O
6	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	B
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	Space	O
2	limitations	O
3	prevent	O
4	an	O
5	exhaustive	O
6	review	O
7	of	O
8	all	O
9	biologic	O
10	pharmaceuticals	O
11	,	O
12	such	O
13	as	O
14	tissue	B
15	plasminogen	I
16	activating	I
17	substance	I
18	,	O
19	hormones	O
20	(	O
21	e	O
22	.	O
23	g	O
24	.,	O
25	thyroid	O
26	,	O
27	insulin	B
28	,	O
29	growth	B
30	hormone	I
31	,	O
32	erythropoietin	B
33	),	O
34	clotting	O
35	factors	O
36	,	O
37	and	O
38	blood	O
39	products	O
40	.	O

1	Dd	B
2	PK1	I
3	RNA	I
4	decreases	O
5	after	O
6	6	O
7	h	O
8	of	O
9	starvation	O
10	to	O
11	re	O
12	-	O
13	accumulate	O
14	once	O
15	the	O
16	cells	O
17	have	O
18	aggregated	O
19	.	O

1	The	O
2	various	O
3	forms	O
4	of	O
5	sickle	O
6	cell	O
7	disease	O
8	share	O
9	the	O
10	common	O
11	feature	O
12	of	O
13	an	O
14	abnormal	O
15	globin	B
16	chain	I
17	that	O
18	,	O
19	under	O
20	certain	O
21	conditions	O
22	such	O
23	as	O
24	hypoxia	O
25	,	O
26	results	O
27	in	O
28	the	O
29	sickling	O
30	of	O
31	red	O
32	blood	O
33	cells	O
34	and	O
35	obstruction	O
36	of	O
37	blood	O
38	vessels	O
39	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	B
19	contrapsin	I
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	B
33	alpha	I
34	1	I
35	-	I
36	protease	I
37	inhibitor	O
38	.	O

1	Patterns	O
2	of	O
3	connections	O
4	underlying	O
5	cross	O
6	-	O
7	modality	O
8	integration	O
9	were	O
10	studied	O
11	by	O
12	injecting	O
13	distinguishable	O
14	,	O
15	retrograde	O
16	tracers	O
17	(	O
18	Fluoro	O
19	-	O
20	Gold	O
21	and	O
22	diamidino	O
23	yellow	O
24	)	O
25	in	O
26	pairwise	O
27	manner	O
28	into	O
29	different	O
30	sensory	O
31	representations	O
32	(	O
33	visual	O
34	,	O
35	somatosensory	O
36	,	O
37	and	O
38	auditory	O
39	)	O
40	in	O
41	the	O
42	cerebral	O
43	cortex	O
44	of	O
45	the	O
46	rat	O
47	.	O

1	Young	O
2	CD	O
3	-	O
4	1	O
5	mice	O
6	,	O
7	4	O
8	days	O
9	old	O
10	,	O
11	exposed	O
12	to	O
13	0	O
14	.	O
15	1	O
16	%	O
17	nicotine	O
18	sulfate	O
19	on	O
20	gestational	O
21	days	O
22	6	O
23	-	O
24	20	O
25	were	O
26	compared	O
27	with	O
28	untreated	O
29	pups	O
30	of	O
31	the	O
32	same	O
33	age	O
34	to	O
35	determine	O
36	its	O
37	effect	O
38	on	O
39	the	O
40	development	O
41	of	O
42	mandibular	O
43	first	O
44	molars	O
45	.	O

1	USF	B
2	synthesized	O
3	in	O
4	an	O
5	in	O
6	vitro	O
7	transcription	O
8	and	O
9	translation	O
10	system	O
11	also	O
12	binds	O
13	to	O
14	the	O
15	ADH	B
16	promoter	I
17	as	O
18	well	O
19	as	O
20	to	O
21	the	O
22	MLP	O
23	.	O

1	The	O
2	across	O
3	-	O
4	fiber	O
5	pattern	O
6	of	O
7	the	O
8	responses	O
9	to	O
10	hypotonic	O
11	NaCl	O
12	solutions	O
13	correlated	O
14	strongly	O
15	to	O
16	that	O
17	elicited	O
18	by	O
19	distilled	O
20	H2O	O
21	.(	O
22	ABSTRACT	O
23	TRUNCATED	O
24	AT	O
25	400	O
26	WORDS	O
27	)	O

1	Arterial	O
2	radioactivity	O
3	content	O
4	after	O
5	the	O
6	intravenous	O
7	administration	O
8	of	O
9	HMPAO	O
10	in	O
11	seven	O
12	human	O
13	subjects	O
14	was	O
15	analyzed	O
16	.	O

1	Linear	O
2	regression	O
3	analysis	O
4	was	O
5	performed	O
6	and	O
7	the	O
8	following	O
9	result	O
10	was	O
11	obtained	O
12	:	O
13	clearance	O
14	(	O
15	HMPAO	O
16	)	O
17	=	O
18	0	O
19	.	O
20	07	O
21	+	O
22	0	O
23	.	O
24	43	O
25	.	O
26	rCBF	O
27	with	O
28	a	O
29	high	O
30	significance	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	001	O
38	).	O

1	Human	B
2	immunodeficiency	I
3	virus	I
4	type	I
5	1	I
6	(	I
7	HIV	I
8	-	I
9	1	I
10	)	I
11	IN	I
12	,	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	,	O
18	was	O
19	purified	O
20	to	O
21	near	O
22	homogeneity	O
23	.	O

1	Thigh	O
2	girth	O
3	correlated	O
4	positively	O
5	with	O
6	HDL	B
7	and	O
8	HDL2	B
9	-	I
10	C	I
11	and	O
12	mass	O
13	,	O
14	and	O
15	with	O
16	LDL	B
17	particle	O
18	size	O
19	among	O
20	women	O
21	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	Tests	O
2	showed	O
3	that	O
4	an	O
5	overall	O
6	impression	O
7	of	O
8	the	O
9	force	O
10	applied	O
11	could	O
12	be	O
13	obtained	O
14	from	O
15	a	O
16	laboratory	O
17	simulation	O
18	,	O
19	but	O
20	that	O
21	clearing	O
22	cement	O
23	and	O
24	testing	O
25	cement	O
26	were	O
27	not	O
28	modelled	O
29	by	O
30	this	O
31	method	O
32	.	O

1	The	O
2	cDNA	O
3	contained	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1392	O
10	bp	O
11	that	O
12	predicted	O
13	a	O
14	protein	O
15	of	O
16	464	O
17	amino	O
18	acids	O
19	and	O
20	a	O
21	molecular	O
22	mass	O
23	of	O
24	52	O
25	kDa	O
26	;	O
27	this	O
28	protein	O
29	has	O
30	97	O
31	%	O
32	identity	O
33	to	O
34	rat	B
35	liver	I
36	glucokinase	I
37	.	O

1	Analysis	O
2	of	O
3	viral	O
4	mutants	O
5	in	O
6	vivo	O
7	demonstrated	O
8	that	O
9	the	O
10	NFIII	B
11	/	O
12	OCT	B
13	-	I
14	1	I
15	binding	O
16	site	O
17	and	O
18	a	O
19	conserved	O
20	ATF	B
21	motif	I
22	were	O
23	important	O
24	for	O
25	efficient	O
26	viral	O
27	growth	O
28	.	O

1	Recovery	O
2	of	O
3	radiolabelled	O
4	BA	O
5	through	O
6	urine	O
7	(	O
8	28	O
9	%)	O
10	and	O
11	faeces	O
12	(	O
13	22	O
14	%)	O
15	up	O
16	to	O
17	96	O
18	hrs	O
19	averaged	O
20	50	O
21	%,	O
22	whereas	O
23	residual	O
24	radioactivity	O
25	in	O
26	liver	O
27	and	O
28	testis	O
29	experienced	O
30	a	O
31	recovery	O
32	of	O
33	29	O
34	%	O
35	in	O
36	scorbutic	O
37	animals	O
38	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	has	O
4	been	O
5	used	O
6	widely	O
7	both	O
8	as	O
9	a	O
10	model	O
11	system	O
12	for	O
13	unraveling	O
14	the	O
15	biochemical	O
16	,	O
17	genetic	O
18	,	O
19	and	O
20	molecular	O
21	details	O
22	of	O
23	gene	O
24	expression	O
25	and	O
26	the	O
27	secretion	O
28	process	O
29	,	O
30	and	O
31	as	O
32	a	O
33	host	O
34	for	O
35	the	O
36	production	O
37	of	O
38	heterologous	O
39	proteins	O
40	of	O
41	biotechnological	O
42	interest	O
43	.	O

1	Paradoxically	O
2	,	O
3	however	O
4	,	O
5	the	O
6	GH	B
7	receptor	I
8	cloned	O
9	from	O
10	liver	O
11	exhibits	O
12	no	O
13	sequence	O
14	similarity	O
15	to	O
16	receptors	O
17	with	O
18	known	O
19	signal	O
20	transduction	O
21	mechanisms	O
22	,	O
23	including	O
24	those	O
25	exhibiting	O
26	ligand	O
27	-	O
28	activated	O
29	tyrosine	B
30	kinase	I
31	activity	O
32	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	O
10	p58	B
11	and	O
12	cdc2	B
13	/	O
14	p62	B
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	Mutation	O
2	analysis	O
3	implicated	O
4	multiple	O
5	segments	O
6	of	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	region	O
12	as	O
13	contributing	O
14	to	O
15	the	O
16	inhibitory	O
17	effect	O
18	.	O

1	Identification	O
2	of	O
3	Ets	B
4	-	O
5	and	O
6	notch	B
7	-	O
8	related	O
9	subunits	O
10	in	O
11	GA	B
12	binding	I
13	protein	I
14	.	O

1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	B
16	oxidase	I
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O

1	In	O
2	the	O
3	ileum	O
4	,	O
5	enterotoxin	O
6	increased	O
7	the	O
8	luminal	O
9	disappearance	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	)	O
18	and	O
19	peripheral	O
20	blood	O
21	appearance	O
22	(	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	)	O
30	of	O
31	chloroquine	O
32	.	O

1	Formalin	O
2	activated	O
3	both	O
4	SNO	O
5	NS	O
6	and	O
7	NnS	O
8	neurones	O
9	,	O
10	but	O
11	,	O
12	when	O
13	they	O
14	responded	O
15	,	O
16	NS	O
17	neurones	O
18	(	O
19	n	O
20	=	O
21	5	O
22	)	O
23	showed	O
24	only	O
25	the	O
26	first	O
27	phase	O
28	of	O
29	activity	O
30	while	O
31	NnS	O
32	neurones	O
33	showed	O
34	either	O
35	one	O
36	(	O
37	n	O
38	=	O
39	13	O
40	)	O
41	or	O
42	two	O
43	phases	O
44	(	O
45	n	O
46	=	O
47	6	O
48	).	O

1	Uptake	O
2	of	O
3	ofloxacin	O
4	by	O
5	Escherichia	O
6	coli	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	attention	O
6	to	O
7	these	O
8	issues	O
9	can	O
10	substantially	O
11	improve	O
12	the	O
13	quality	O
14	of	O
15	research	O
16	on	O
17	AIDS	O
18	related	O
19	behaviors	O
20	on	O
21	Black	O
22	communities	O
23	.	O

1	The	O
2	effectiveness	O
3	of	O
4	alpha	O
5	-	O
6	mercapto	O
7	-	O
8	beta	O
9	-(	O
10	2	O
11	-	O
12	furyl	O
13	)	O
14	acrylic	O
15	acid	O
16	(	O
17	MFA	O
18	)	O
19	and	O
20	N	O
21	-	O
22	benzyl	O
23	-	O
24	N	O
25	-	O
26	dithiocarboxy	O
27	-	O
28	D	O
29	-	O
30	glucamine	O
31	(	O
32	NaB	O
33	),	O
34	used	O
35	in	O
36	combination	O
37	,	O
38	in	O
39	the	O
40	mobilization	O
41	and	O
42	excretion	O
43	of	O
44	lead	O
45	was	O
46	investigated	O
47	in	O
48	rats	O
49	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	effects	O
6	of	O
7	hypovolemia	O
8	on	O
9	the	O
10	extracellular	O
11	ptO2	O
12	and	O
13	ptH	O
14	distributions	O
15	at	O
16	multiple	O
17	tissue	O
18	sites	O
19	using	O
20	a	O
21	recently	O
22	developed	O
23	multipoint	O
24	microelectrode	O
25	,	O
26	that	O
27	provides	O
28	simultaneous	O
29	measurements	O
30	of	O
31	ptO2	O
32	and	O
33	ptH	O
34	.	O

1	All	O
2	members	O
3	are	O
4	also	O
5	capable	O
6	of	O
7	activating	O
8	in	O
9	vivo	O
10	transcription	O
11	from	O
12	promoters	O
13	that	O
14	contain	O
15	a	O
16	C	B
17	/	I
18	EBP	I
19	-	I
20	binding	I
21	site	I
22	.	O

1	The	O
2	domains	O
3	involved	O
4	in	O
5	superactivation	O
6	appear	O
7	to	O
8	be	O
9	a	O
10	subset	O
11	of	O
12	those	O
13	necessary	O
14	to	O
15	achieve	O
16	synergistic	O
17	activation	O
18	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	B
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	I
21	collagen	I
22	gene	I
23	.	O

1	Chlamydia	O
2	trachomatis	O
3	and	O
4	Chlamydia	O
5	psittaci	O
6	were	O
7	not	O
8	affected	O
9	by	O
10	methanol	O
11	fixation	O
12	.	O

1	Although	O
2	human	O
3	infections	O
4	with	O
5	bacteraemia	O
6	due	O
7	to	O
8	Pasteurella	O
9	multocida	O
10	are	O
11	not	O
12	uncommon	O
13	,	O
14	endocarditis	O
15	associated	O
16	with	O
17	P	O
18	.	O
19	haemolytica	O
20	is	O
21	rare	O
22	.	O

1	For	O
2	SMX	O
3	at	O
4	pH	O
5	7	O
6	.	O
7	0	O
8	,	O
9	a	O
10	1	O
11	:	O
12	1	O
13	complex	O
14	is	O
15	formed	O
16	,	O
17	but	O
18	at	O
19	pH	O
20	7	O
21	.	O
22	5	O
23	HPCD	O
24	has	O
25	little	O
26	effect	O
27	on	O
28	the	O
29	solubility	O
30	of	O
31	the	O
32	highly	O
33	ionized	O
34	SMX	O
35	,	O
36	presumably	O
37	since	O
38	only	O
39	un	O
40	-	O
41	ionized	O
42	molecules	O
43	can	O
44	form	O
45	inclusion	O
46	complexes	O
47	with	O
48	the	O
49	HPCD	O
50	.	O

1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O

1	POU	B
2	-	O
3	specific	O
4	and	O
5	POU	B
6	-	O
7	homeo	O
8	domains	O
9	of	O
10	Oct3	B
11	were	O
12	produced	O
13	in	O
14	Echerichia	O
15	coli	O
16	for	O
17	characterization	O
18	of	O
19	DNA	O
20	binding	O
21	to	O
22	the	O
23	octamer	O
24	sequence	O
25	.	O

1	A	O
2	deletion	O
3	series	O
4	of	O
5	the	O
6	5	O
7	'	O
8	flanking	O
9	region	O
10	was	O
11	created	O
12	from	O
13	position	O
14	-	O
15	1329	O
16	to	O
17	-	O
18	74	O
19	relative	O
20	to	O
21	the	O
22	transcriptional	O
23	initiation	O
24	site	O
25	and	O
26	similarly	O
27	examined	O
28	in	O
29	transgenic	O
30	tobacco	O
31	.	O

1	The	O
2	nucleotide	O
3	(	O
4	nt	O
5	)	O
6	sequences	O
7	of	O
8	the	O
9	exons	O
10	,	O
11	exon	O
12	/	O
13	intron	O
14	boundaries	O
15	and	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	untranslated	O
22	regions	O
23	were	O
24	determined	O
25	.	O

1	Out	O
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	leprosy	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O

1	Thus	O
2	,	O
3	two	O
4	very	O
5	different	O
6	regulatory	O
7	elements	O
8	are	O
9	used	O
10	to	O
11	mediate	O
12	estrogen	O
13	induction	O
14	of	O
15	related	O
16	genes	O
17	in	O
18	chickens	O
19	and	O
20	amphibians	O
21	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	Experimentally	O
2	in	O
3	green	O
4	monkeys	O
5	,	O
6	Syrian	O
7	hamsters	O
8	and	O
9	white	O
10	mice	O
11	the	O
12	authors	O
13	studied	O
14	the	O
15	pathogenic	O
16	properties	O
17	of	O
18	a	O
19	new	O
20	virus	O
21	Issyk	O
22	-	O
23	Kul	O
24	.	O

1	Increasing	O
2	mean	O
3	arterial	O
4	pressure	O
5	by	O
6	phenylephrine	O
7	infusion	O
8	to	O
9	levels	O
10	much	O
11	greater	O
12	than	O
13	produced	O
14	by	O
15	NMA	O
16	and	O
17	NNA	O
18	caused	O
19	only	O
20	small	O
21	reductions	O
22	in	O
23	cardiac	O
24	output	O
25	.	O

1	J	O
2	.	O

1	Limits	O
2	of	O
3	energy	O
4	turnover	O
5	in	O
6	relation	O
7	to	O
8	physical	O
9	performance	O
10	were	O
11	addressed	O
12	in	O
13	terms	O
14	of	O
15	upper	O
16	and	O
17	lower	O
18	limit	O
19	,	O
20	changes	O
21	during	O
22	a	O
23	training	O
24	programme	O
25	and	O
26	how	O
27	to	O
28	regulate	O
29	energy	O
30	balance	O
31	at	O
32	a	O
33	changing	O
34	energy	O
35	turnover	O
36	.	O

1	With	O
2	stepwise	O
3	reductions	O
4	in	O
5	flow	O
6	,	O
7	the	O
8	peak	O
9	(	O
10	S	O
11	)	O
12	and	O
13	trough	O
14	(	O
15	D	O
16	)	O
17	points	O
18	of	O
19	the	O
20	maximum	O
21	shifted	O
22	-	O
23	frequency	O
24	envelope	O
25	fell	O
26	in	O
27	parallel	O
28	in	O
29	a	O
30	linear	O
31	fashion	O
32	until	O
33	D	O
34	reached	O
35	zero	O
36	.	O

1	The	O
2	IE0	B
3	gene	I
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	Evaluation	O
2	of	O
3	left	O
4	ventricular	O
5	function	O
6	using	O
7	gated	O
8	planar	O
9	myocardial	O
10	imaging	O
11	with	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	MIBI	O

1	Ivermectin	O
2	uptake	O
3	and	O
4	distribution	O
5	in	O
6	the	O
7	plasma	O
8	and	O
9	tissue	O
10	of	O
11	Sudanese	O
12	and	O
13	Mexican	O
14	patients	O
15	infected	O
16	with	O
17	Onchocerca	O
18	volvulus	O
19	.	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	O
17	.	O

1	The	O
2	currently	O
3	proposed	O
4	extended	O
5	arch	O
6	repair	O
7	should	O
8	be	O
9	reserved	O
10	for	O
11	the	O
12	small	O
13	group	O
14	of	O
15	infants	O
16	with	O
17	transverse	O
18	aortic	O
19	arch	O
20	to	O
21	ascending	O
22	aorta	O
23	diameter	O
24	ratios	O
25	(	O
26	arch	O
27	indices	O
28	)	O
29	of	O
30	less	O
31	than	O
32	0	O
33	.	O
34	25	O
35	.	O

1	DNA	O
2	hybridization	O
3	analysis	O
4	revealed	O
5	that	O
6	both	O
7	pigmented	O
8	and	O
9	nonpigmented	O
10	cells	O
11	of	O
12	Y	O
13	.	O
14	pestis	O
15	possess	O
16	a	O
17	DNA	O
18	locus	O
19	homologous	O
20	to	O
21	the	O
22	Escherichia	B
23	coli	I
24	fur	I
25	gene	I
26	.	O

1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O

1	Expression	O
2	was	O
3	cell	O
4	cycle	O
5	controlled	O
6	,	O
7	with	O
8	steady	O
9	-	O
10	state	O
11	RNA	O
12	levels	O
13	significantly	O
14	higher	O
15	in	O
16	growth	O
17	-	O
18	arrested	O
19	than	O
20	in	O
21	growth	O
22	-	O
23	stimulated	O
24	cells	O
25	.	O

1	Determinants	O
2	of	O
3	recurrent	O
4	ischaemia	O
5	and	O
6	revascularisation	O
7	procedures	O
8	after	O
9	thrombolysis	O
10	with	O
11	recombinant	O
12	tissue	B
13	plasminogen	I
14	activator	I
15	in	O
16	primary	O
17	coronary	O
18	occlusion	O
19	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	O
6	rbcS	B
7	locus	O
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	Relationship	O
2	between	O
3	mitochondrial	B
4	NADH	I
5	-	I
6	ubiquinone	I
7	reductase	I
8	and	O
9	a	O
10	bacterial	B
11	NAD	I
12	-	I
13	reducing	I
14	hydrogenase	I
15	.	O

1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	B
8	-	I
9	BP1	I
10	and	O
11	AT	B
12	-	I
13	BP2	I
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	3	O
2	cases	O

1	UDP	B
2	-	I
3	Gal	I
4	:	I
5	Gal	I
6	beta	I
7	1	I
8	----	I
9	4GlcNAc	I
10	alpha	I
11	1	I
12	----	I
13	3	I
14	-	I
15	galactosyltransferase	I
16	is	O
17	a	O
18	terminal	B
19	glycosyltransferase	I
20	that	O
21	is	O
22	widely	O
23	expressed	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	mammalian	O
29	species	O
30	,	O
31	with	O
32	the	O
33	notable	O
34	exception	O
35	of	O
36	man	O
37	,	O
38	apes	O
39	,	O
40	and	O
41	Old	O
42	World	O
43	monkeys	O
44	.	O

1	A	O
2	synthetic	O
3	oligonucleotide	O
4	containing	O
5	the	O
6	SRE	O
7	sequence	O
8	from	O
9	the	O
10	mouse	B
11	c	I
12	-	I
13	fos	I
14	gene	I
15	promoter	I
16	(-	O
17	299	O
18	to	O
19	-	O
20	322	O
21	)	O
22	was	O
23	radioactively	O
24	labeled	O
25	,	O
26	used	O
27	as	O
28	a	O
29	probe	O
30	for	O
31	the	O
32	mobility	O
33	shift	O
34	assay	O
35	and	O
36	Southwestern	O
37	(	O
38	DNA	O
39	-	O
40	protein	O
41	)	O
42	blotting	O
43	,	O
44	and	O
45	also	O
46	used	O
47	for	O
48	sequence	O
49	-	O
50	specific	O
51	affinity	O
52	chromatography	O
53	.	O

1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	B
14	c	I
15	-	I
16	fos	I
17	gene	I
18	.	O

1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O

1	One	O
2	of	O
3	its	O
4	lysine	O
5	residues	O
6	is	O
7	modified	O
8	by	O
9	spermidine	O
10	to	O
11	form	O
12	hypusine	O
13	,	O
14	a	O
15	posttranslational	O
16	modification	O
17	unique	O
18	to	O
19	eIF	B
20	-	I
21	5A	I
22	.	O

1	The	O
2	plasmid	O
3	shuffle	O
4	technique	O
5	was	O
6	used	O
7	to	O
8	replace	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	gene	O
14	with	O
15	the	O
16	mutant	O
17	form	O
18	,	O
19	resulting	O
20	in	O
21	failure	O
22	of	O
23	the	O
24	yeast	O
25	cells	O
26	to	O
27	grow	O
28	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	Transcription	O
2	of	O
3	the	O
4	metH	B
5	gene	I
6	in	I
7	Salmonella	I
8	typhimurium	I
9	and	I
10	Escherichia	I
11	coli	I
12	is	O
13	positively	O
14	regulated	O
15	by	O
16	the	O
17	metR	B
18	gene	I
19	product	I
20	,	O
21	a	O
22	DNA	O
23	binding	O
24	protein	O
25	.	O

1	Disruption	O
2	of	O
3	the	O
4	chromosomal	B
5	AAR1	I
6	gene	I
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	nonmating	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	diploids	O
25	could	O
26	not	O
27	sporulate	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	The	O
2	ORF	O
3	was	O
4	analyzed	O
5	for	O
6	secondary	O
7	structural	O
8	features	O
9	,	O
10	and	O
11	the	O
12	sequence	O
13	data	O
14	bases	O
15	were	O
16	searched	O
17	for	O
18	homologies	O
19	.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	this	O
6	dose	O
7	-	O
8	intense	O
9	regimen	O
10	can	O
11	be	O
12	safely	O
13	administered	O
14	,	O
15	even	O
16	with	O
17	the	O
18	use	O
19	of	O
20	purged	O
21	marrow	O
22	,	O
23	with	O
24	an	O
25	acceptable	O
26	toxicity	O
27	profile	O
28	.	O

1	Mitomycin	O
2	-	O
3	C	O
4	can	O
5	cause	O
6	severe	O
7	necrosis	O
8	and	O
9	ulceration	O
10	when	O
11	extravasated	O
12	inadvertently	O
13	into	O
14	skin	O
15	and	O
16	soft	O
17	tissues	O
18	following	O
19	IV	O
20	drug	O
21	administration	O
22	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	B
16	nidogen	I
17	gene	I
18	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	Consistent	O
2	with	O
3	the	O
4	in	O
5	vivo	O
6	result	O
7	,	O
8	the	O
9	pseudorevertant	O
10	endonucleases	O
11	in	O
12	the	O
13	crude	O
14	cell	O
15	extract	O
16	display	O
17	site	O
18	-	O
19	specific	O
20	partial	O
21	DNA	O
22	cleavage	O
23	activity	O
24	.	O

1	Additionally	O
2	,	O
3	I	B
4	kappa	I
5	B	I
6	beta	I
7	,	O
8	but	O
9	not	O
10	I	B
11	kappa	I
12	B	I
13	alpha	I
14	,	O
15	also	O
16	prevented	O
17	the	O
18	binding	O
19	of	O
20	Rel	B
21	to	O
22	the	O
23	kappa	B
24	B	I
25	site	I
26	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	Lengthy	O
2	and	O
3	repeated	O
4	hemodialyses	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	lithemia	O
10	to	O
11	nontoxic	O
12	ranges	O
13	.	O

1	A	O
2	single	O
3	i	O
4	.	O
5	p	O
6	.	O
7	injection	O
8	of	O
9	d	O
10	,	O
11	l	O
12	-	O
13	baclofen	O
14	10	O
15	mg	O
16	/	O
17	kg	O
18	both	O
19	reduced	O
20	noradrenaline	O
21	(	O
22	NA	O
23	)	O
24	biosynthesis	O
25	in	O
26	vivo	O
27	(	O
28	31	O
29	%)	O
30	and	O
31	the	O
32	endogenous	O
33	concentration	O
34	of	O
35	normetanephrine	O
36	(	O
37	NMN	O
38	)	O
39	(	O
40	32	O
41	%)	O
42	and	O
43	increased	O
44	NA	O
45	levels	O
46	(	O
47	28	O
48	%).	O

1	Fufang	O
2	wuzi	O
3	yanzong	O
4	pills	O
5	have	O
6	strong	O
7	leukogenic	O
8	effect	O
9	on	O
10	cyclophosphamide	O
11	induced	O
12	leukopenia	O
13	in	O
14	mice	O
15	.	O

1	Mutations	O
2	in	O
3	the	O
4	small	O
5	subunit	O
6	of	O
7	ribulosebisphosphate	B
8	carboxylase	I
9	affect	O
10	subunit	O
11	binding	O
12	and	O
13	catalysis	O
14	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	NZ	O
6	-	O
7	107	O
8	may	O
9	be	O
10	a	O
11	useful	O
12	drug	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	bronchial	O
18	asthma	O
19	by	O
20	reducing	O
21	late	O
22	-	O
23	phase	O
24	airway	O
25	responses	O
26	and	O
27	airway	O
28	hyperreactivity	O
29	.	O

1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O

1	Bronchial	O
2	mucosa	O
3	tattooing	O
4	in	O
5	persons	O
6	exposed	O
7	to	O
8	different	O
9	industrial	O
10	aerosols	O
11	did	O
12	not	O
13	depend	O
14	on	O
15	the	O
16	forms	O
17	of	O
18	PC	O
19	,	O
20	DB	O
21	and	O
22	the	O
23	diseases	O
24	'	O
25	stages	O
26	.	O

1	Anti	B
2	-	I
3	HBc	I
4	production	O
5	of	O
6	PBMC	O
7	was	O
8	enhanced	O
9	remarkably	O
10	in	O
11	this	O
12	case	O
13	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	I
7	upstream	I
8	sequences	I
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	The	O
2	cDNA	O
3	segment	O
4	is	O
5	flanked	O
6	by	O
7	the	O
8	immunoglobulin	B
9	gene	I
10	recombination	I
11	signal	I
12	sequences	I
13	so	O
14	that	O
15	the	O
16	cDNA	O
17	segment	O
18	can	O
19	invert	O
20	and	O
21	the	O
22	human	B
23	IL	I
24	-	I
25	2R	I
26	L	I
27	chain	I
28	is	O
29	subsequently	O
30	expressed	O
31	under	O
32	the	O
33	control	O
34	of	O
35	the	O
36	SV40	B
37	promoter	I
38	.	O

1	Lipoprotein	B
2	lipase	I
3	(	O
4	LPL	B
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O

1	Deletion	O
2	of	O
3	the	O
4	proximal	O
5	octanucleotide	O
6	motif	O
7	from	O
8	the	O
9	plasmid	O
10	containing	O
11	the	O
12	-	O
13	461	O
14	fragment	O
15	of	O
16	the	O
17	LPL	B
18	promoter	I
19	,	O
20	resulted	O
21	in	O
22	a	O
23	79	O
24	and	O
25	76	O
26	%	O
27	decrease	O
28	in	O
29	the	O
30	level	O
31	of	O
32	expression	O
33	in	O
34	transfected	O
35	3T3	O
36	-	O
37	L1	O
38	adipocytes	O
39	and	O
40	HepG2	O
41	hepatocytes	O
42	,	O
43	respectively	O
44	.	O

1	We	O
2	examined	O
3	the	O
4	binding	O
5	of	O
6	purified	O
7	T3	B
8	receptor	I
9	alpha	I
10	(	O
11	T3R	B
12	alpha	I
13	),	O
14	overexpressed	O
15	in	O
16	Escherichia	O
17	coli	O
18	,	O
19	to	O
20	wild	O
21	-	O
22	type	O
23	and	O
24	up	O
25	and	O
26	down	O
27	mutations	O
28	of	O
29	the	O
30	rGH	B
31	T3RE	I
32	to	O
33	evaluate	O
34	whether	O
35	transcriptional	O
36	potency	O
37	correlates	O
38	with	O
39	changes	O
40	in	O
41	T3R	B
42	binding	O
43	.	O

1	Comparison	O
2	of	O
3	the	O
4	cDNA	O
5	-	O
6	predicted	O
7	avian	B
8	TnIcardiac	I
9	amino	I
10	acid	I
11	sequences	I
12	with	O
13	known	O
14	TnI	B
15	sequences	I
16	indicated	O
17	1	O
18	)	O
19	that	O
20	the	O
21	presence	O
22	of	O
23	an	O
24	N	O
25	-	O
26	terminal	O
27	extension	O
28	sequence	O
29	carrying	O
30	a	O
31	dual	O
32	protein	B
33	kinase	I
34	A	I
35	phosphorylation	O
36	target	O
37	site	O
38	and	O
39	an	O
40	adjacent	O
41	proline	O
42	-	O
43	rich	O
44	segment	O
45	is	O
46	an	O
47	ancient	O
48	cardiac	O
49	-	O
50	specific	O
51	feature	O
52	of	O
53	TnI	B
54	which	O
55	has	O
56	been	O
57	conserved	O
58	since	O
59	the	O
60	bird	O
61	/	O
62	mammal	O
63	divergence	O
64	,	O
65	2	O
66	)	O
67	that	O
68	features	O
69	of	O
70	the	O
71	near	O
72	-	O
73	N	O
74	-	O
75	terminal	O
76	troponin	B
77	C	I
78	(	O
79	TnC	B
80	)-	O
81	binding	O
82	site	O
83	sequence	O
84	suggest	O
85	isoform	O
86	-	O
87	specific	O
88	adaptation	O
89	of	O
90	TnI	B
91	and	O
92	TnC	B
93	,	O
94	and	O
95	3	O
96	)	O
97	that	O
98	the	O
99	avian	O
100	TnIcardiac	B
101	internal	O
102	actin	B
103	/	I
104	TnC	I
105	-	I
106	binding	I
107	,	I
108	actomyosin	I
109	-	I
110	inhibitory	I
111	,	I
112	domain	I
113	shows	O
114	significant	O
115	sequence	O
116	divergence	O
117	from	O
118	mammalian	B
119	TnIcardiac	I
120	sequences	I
121	,	O
122	including	O
123	the	O
124	absence	O
125	of	O
126	a	O
127	protein	B
128	kinase	I
129	C	I
130	target	O
131	site	O
132	which	O
133	is	O
134	a	O
135	cardiac	O
136	-	O
137	specific	O
138	feature	O
139	of	O
140	TnI	B
141	in	O
142	mammals	O
143	.	O

1	Ventilatory	O
2	management	O
3	casebook	O
4	.	O

1	An	O
2	ASSEMBLER	O
3	routine	O
4	for	O
5	on	O
6	-	O
7	line	O
8	graphic	O
9	display	O
10	and	O
11	averaging	O
12	of	O
13	data	O
14	acquired	O
15	on	O
16	a	O
17	personal	O
18	microcomputer	O
19	.	O

1	Expression	O
2	of	O
3	the	O
4	mouse	B
5	TSH	I
6	beta	I
7	gene	I
8	,	O
9	therefore	O
10	,	O
11	gives	O
12	rise	O
13	to	O
14	multiple	O
15	mRNAs	O
16	,	O
17	each	O
18	with	O
19	a	O
20	unique	O
21	5	O
22	'-	O
23	untranslated	O
24	region	O
25	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	ROSP	O
7	undergoes	O
8	a	O
9	number	O
10	of	O
11	fluctuations	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	directions	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	ROSP	O
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	implanted	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	dura	O
58	mater	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	implanted	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	pia	O
72	mater	O
73	.	O

1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	DNA	O
5	using	O
6	flow	O
7	cytometry	O
8	and	O
9	immunocytochemical	O
10	findings	O
11	in	O
12	16	O
13	cases	O
14	of	O
15	cardiac	O
16	myxomas	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	the	O
9	non	O
10	-	O
11	spliced	O
12	variant	O
13	,	O
14	multiple	O
15	mRNA	O
16	species	O
17	were	O
18	generated	O
19	by	O
20	alternative	O
21	splicing	O
22	resulting	O
23	in	O
24	the	O
25	exclusion	O
26	of	O
27	92	O
28	,	O
29	166	O
30	,	O
31	170	O
32	,	O
33	174	O
34	and	O
35	263	O
36	nucleotides	O
37	(	O
38	nt	O
39	),	O
40	respectively	O
41	,	O
42	from	O
43	exon	O
44	1	O
45	.	O

1	Position	O
2	22	O
3	is	O
4	an	O
5	isoleucine	O
6	in	O
7	the	O
8	complete	B
9	SsoL12	I
10	protein	I
11	sequence	I
12	,	O
13	coded	O
14	by	O
15	an	O
16	AUA	O
17	codon	O
18	.	O

1	Symptoms	O
2	due	O
3	to	O
4	the	O
5	action	O
6	of	O
7	mastocyte	O
8	mediators	O
9	were	O
10	observed	O
11	.	O

1	In	O
2	the	O
3	yeast	O
4	Saccharomyces	O
5	cerevisiae	O
6	,	O
7	copper	O
8	levels	O
9	exert	O
10	some	O
11	control	O
12	over	O
13	the	O
14	level	O
15	of	O
16	SOD1	B
17	expression	O
18	.	O

1	Of	O
2	these	O
3	179	O
4	samples	O
5	,	O
6	Mobiluncus	O
7	SP	O
8	was	O
9	observed	O
10	in	O
11	35	O
12	(	O
13	19	O
14	.	O
15	6	O
16	%)	O
17	using	O
18	Gram	O
19	staining	O
20	and	O
21	in	O
22	18	O
23	(	O
24	10	O
25	.	O
26	1	O
27	%)	O
28	this	O
29	microorganism	O
30	was	O
31	isolated	O
32	in	O
33	agar	O
34	RLK	O
35	and	O
36	anaerobic	O
37	atmosphere	O
38	.	O

1	Previous	O
2	investigators	O
3	have	O
4	suggested	O
5	that	O
6	subretinal	O
7	blood	O
8	damages	O
9	the	O
10	retina	O
11	in	O
12	part	O
13	because	O
14	of	O
15	its	O
16	solid	O
17	fibrin	B
18	meshwork	O
19	.	O

1	Twenty	O
2	-	O
3	four	O
4	hours	O
5	later	O
6	,	O
7	the	O
8	animals	O
9	were	O
10	randomized	O
11	to	O
12	subretinal	O
13	treatment	O
14	with	O
15	2	O
16	.	O
17	5	O
18	micrograms	O
19	of	O
20	tissue	B
21	plasminogen	I
22	activator	I
23	or	O
24	a	O
25	similar	O
26	volume	O
27	of	O
28	physiologic	O
29	saline	O
30	.	O

1	Neuro	O
2	-	O
3	otological	O
4	examinations	O
5	revealed	O
6	spontaneous	O
7	downbeat	O
8	nystagmus	O
9	,	O
10	bilateral	O
11	gaze	O
12	nystagmus	O
13	and	O
14	rebound	O
15	nystagmus	O
16	.	O

1	Since	O
2	the	O
3	morphology	O
4	of	O
5	the	O
6	lesions	O
7	can	O
8	mimic	O
9	that	O
10	of	O
11	other	O
12	cutaneous	O
13	disorders	O
14	,	O
15	Bowen	O
16	'	O
17	s	O
18	disease	O
19	is	O
20	often	O
21	not	O
22	recognized	O
23	initially	O
24	.	O

1	Equine	O
2	amnion	O
3	and	O
4	live	O
5	yeast	O
6	cell	O
7	derivative	O
8	were	O
9	evaluated	O
10	as	O
11	a	O
12	biological	O
13	dressing	O
14	and	O
15	as	O
16	a	O
17	topical	O
18	wound	O
19	medicament	O
20	respectively	O
21	,	O
22	in	O
23	the	O
24	treatment	O
25	of	O
26	granulating	O
27	wounds	O
28	of	O
29	the	O
30	distal	O
31	portion	O
32	of	O
33	the	O
34	limbs	O
35	of	O
36	horses	O
37	.	O

1	To	O
2	lower	O
3	the	O
4	current	O
5	high	O
6	incidence	O
7	of	O
8	NANB	O
9	-	O
10	induced	O
11	PTH	O
12	,	O
13	in	O
14	1986	O
15	,	O
16	the	O
17	American	O
18	Association	O
19	of	O
20	Blood	O
21	Banks	O
22	(	O
23	AABB	O
24	)	O
25	recommended	O
26	testing	O
27	for	O
28	these	O
29	PTH	O
30	-	O
31	associated	O
32	"	O
33	surrogate	O
34	"	O
35	markers	O
36	on	O
37	all	O
38	donated	O
39	units	O
40	of	O
41	blood	O
42	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	O
8	IGF	B
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	Fusion	O
2	of	O
3	ubiquitin	B
4	to	O
5	pADPRP	B
6	increased	O
7	the	O
8	yield	O
9	of	O
10	pADPRP	B
11	approximately	O
12	10	O
13	-	O
14	fold	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	the	O
20	unfused	O
21	enzyme	O
22	.	O

1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	mediastinal	O
11	drainage	O
12	blood	O
13	,	O
14	shed	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	washing	O
25	in	O
26	a	O
27	MBRS	O
28	.	O

1	The	O
2	suppression	O
3	was	O
4	also	O
5	demonstrated	O
6	in	O
7	a	O
8	transient	O
9	expression	O
10	assay	O
11	in	O
12	vivo	O
13	using	O
14	isolated	O
15	barley	O
16	endosperms	O
17	.	O

1	The	O
2	effect	O
3	of	O
4	salmon	B
5	calcitonin	I
6	nasal	O
7	spray	O
8	in	O
9	women	O
10	with	O
11	established	O
12	osteoporosis	O
13	has	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	responses	O
5	are	O
6	impaired	O
7	in	O
8	heart	O
9	failure	O
10	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O

1	Evaluation	O
2	of	O
3	antiepileptic	O
4	drug	O
5	effect	O
6	on	O
7	membrane	O
8	fluidity	O
9	.	O

1	The	O
2	examinations	O
3	were	O
4	performed	O
5	on	O
6	two	O
7	groups	O
8	of	O
9	20	O
10	(	O
11	using	O
12	AmF	O
13	/	O
14	SnF2	O
15	)-,	O
16	resp	O
17	.	O

1	RNA	O
2	gel	O
3	retardation	O
4	and	O
5	competition	O
6	analyses	O
7	indicate	O
8	that	O
9	TRP	B
10	-	I
11	185	I
12	binding	O
13	is	O
14	strongly	O
15	dependent	O
16	on	O
17	the	O
18	TAR	O
19	RNA	O
20	loop	O
21	sequences	O
22	.	O

1	The	O
2	vaccine	O
3	used	O
4	was	O
5	known	O
6	to	O
7	be	O
8	immunogenic	O
9	for	O
10	older	O
11	children	O
12	and	O
13	adults	O
14	.	O

1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	hypnotic	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O

1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Recombinant	B
2	human	I
3	TFIID	I
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O

1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O

1	We	O
2	conclude	O
3	that	O
4	solidification	O
5	could	O
6	occur	O
7	in	O
8	all	O
9	feeds	O
10	containing	O
11	casein	B
12	and	O
13	that	O
14	alternative	O
15	feeds	O
16	should	O
17	be	O
18	considered	O
19	in	O
20	patients	O
21	with	O
22	increased	O
23	gastric	O
24	acidity	O
25	.	O

1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O

1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	The	O
2	effect	O
3	of	O
4	diffusion	O
5	limitation	O
6	was	O
7	quantified	O
8	in	O
9	terms	O
10	of	O
11	the	O
12	ratio	O
13	O2	O
14	uptake	O
15	/	O
16	O2	O
17	requirement	O
18	(=	O
19	fraction	O
20	of	O
21	cross	O
22	-	O
23	sectional	O
24	area	O
25	supplied	O
26	with	O
27	O2	O
28	),	O
29	assuming	O
30	local	O
31	O2	O
32	requirement	O
33	per	O
34	unit	O
35	volume	O
36	to	O
37	be	O
38	constant	O
39	and	O
40	independent	O
41	of	O
42	PO2	O
43	at	O
44	PO2	O
45	greater	O
46	than	O
47	0	O
48	.	O

1	(	O
2	2	O
3	)	O
4	Diffusion	O
5	limitation	O
6	in	O
7	the	O
8	heterogeneous	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	homogeneous	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	cylinder	O
39	diameter	O
40	.	O

1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	Estulic	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	101	O
17	hypertensive	O
18	patients	O
19	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O

1	Monitoring	O
2	patients	O
3	with	O
4	acute	O
5	leukemia	O
6	for	O
7	IL	B
8	-	I
9	1	I
10	and	O
11	TNF	B
12	levels	O
13	throughout	O
14	the	O
15	clinical	O
16	course	O
17	of	O
18	disease	O
19	may	O
20	help	O
21	clarify	O
22	the	O
23	causes	O
24	of	O
25	febrile	O
26	episodes	O
27	.	O

1	Echinococcus	O
2	granulosus	O
3	was	O
4	diagnosed	O
5	by	O
6	fine	O
7	-	O
8	needle	O
9	aspiration	O
10	cytology	O
11	of	O
12	a	O
13	lung	O
14	cyst	O
15	in	O
16	a	O
17	6	O
18	-	O
19	yr	O
20	-	O
21	old	O
22	white	O
23	female	O
24	in	O
25	central	O
26	Missouri	O
27	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	of	O
6	6493	O
7	nucleotides	O
8	encompassing	O
9	the	O
10	bet	B
11	genes	I
12	of	I
13	Escherichia	I
14	coli	I
15	which	O
16	encode	O
17	the	O
18	osmoregulatory	O
19	choline	O
20	-	O
21	glycine	O
22	betaine	O
23	pathway	O
24	.	O

1	A	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	of	O
7	amphotericin	O
8	B	O
9	(	O
10	5	O
11	mg	O
12	/	O
13	kg	O
14	/	O
15	day	O
16	i	O
17	.	O
18	p	O
19	.)	O
20	significantly	O
21	reduced	O
22	the	O
23	glomerular	O
24	filtration	O
25	rate	O
26	(	O
27	GFR	O
28	)	O
29	measured	O
30	as	O
31	inuline	O
32	clearance	O
33	and	O
34	creatinine	O
35	clearance	O
36	(	O
37	0	O
38	.	O
39	74	O
40	+/-	O
41	0	O
42	.	O
43	29	O
44	and	O
45	0	O
46	.	O
47	16	O
48	+/-	O
49	0	O
50	.	O
51	04	O
52	ml	O
53	/	O
54	min	O
55	,	O
56	respectively	O
57	)	O
58	in	O
59	comparison	O
60	to	O
61	vehicle	O
62	-	O
63	treated	O
64	rats	O
65	(	O
66	2	O
67	.	O
68	04	O
69	+/-	O
70	0	O
71	.	O
72	23	O
73	and	O
74	1	O
75	.	O
76	29	O
77	+/-	O
78	0	O
79	.	O
80	19	O
81	ml	O
82	/	O
83	min	O
84	,	O
85	respectively	O
86	).	O

1	Evolution	O
2	of	O
3	lesions	O
4	did	O
5	not	O
6	necessarily	O
7	follow	O
8	a	O
9	regular	O
10	progression	O
11	through	O
12	the	O
13	later	O
14	stages	O
15	of	O
16	the	O
17	vitelliform	O
18	classification	O
19	.	O

1	Confocal	O
2	fluorescence	O
3	microscopy	O
4	in	O
5	modern	O
6	cell	O
7	biology	O
8	.	O

1	Toluene	O
2	is	O
3	the	O
4	chemical	O
5	most	O
6	frequently	O
7	present	O
8	in	O
9	cases	O
10	involving	O
11	volatile	O
12	solvents	O
13	.	O

1	Fortunately	O
2	DDT	O
3	-,	O
4	HCH	O
5	-	O
6	and	O
7	HCB	O
8	-	O
9	levels	O
10	decreased	O
11	in	O
12	breast	O
13	milk	O
14	during	O
15	the	O
16	last	O
17	years	O
18	.	O

1	A	O
2	herpesvirus	O
3	proteinase	O
4	activity	O
5	has	O
6	been	O
7	identified	O
8	and	O
9	partially	O
10	characterized	O
11	by	O
12	using	O
13	the	O
14	cloned	O
15	enzyme	O
16	and	O
17	substrate	O
18	genes	O
19	in	O
20	transient	O
21	transfection	O
22	assays	O
23	.	O

1	Adult	O
2	H	O
3	,	O
4	but	O
5	not	O
6	R	O
7	,	O
8	manifested	O
9	the	O
10	burrowing	O
11	preference	O
12	whenever	O
13	offered	O
14	the	O
15	opportunity	O
16	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	O
12	protons	O
13	in	O
14	water	O
15	and	O
16	it	O
17	efficiently	O
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	O

1	Heterogeneous	O
2	electron	O
3	transfer	O
4	of	O
5	cytochrome	B
6	c	I
7	facilitated	O
8	by	O
9	polypyrrole	O
10	and	O
11	methylene	O
12	blue	O
13	polypyrrole	O
14	film	O
15	modified	O
16	electrodes	O
17	.	O

1	Selective	O
2	activation	O
3	of	O
4	adrenaline	O
5	secretion	O
6	by	O
7	the	O
8	rat	O
9	adrenal	O
10	in	O
11	neuroglycopenia	O
12	detected	O
13	via	O
14	microdialysis	O

1	Urine	O
2	specimens	O
3	containing	O
4	either	O
5	phencyclidine	O
6	(	O
7	PCP	O
8	)	O
9	or	O
10	11	O
11	-	O
12	nor	O
13	-	O
14	delta	O
15	9	O
16	-	O
17	tetrahydrocannabinol	O
18	-	O
19	9	O
20	-	O
21	carboxylic	O
22	acid	O
23	(	O
24	9	O
25	-	O
26	THC	O
27	-	O
28	COOH	O
29	)	O
30	were	O
31	adulterated	O
32	with	O
33	sodium	O
34	chloride	O
35	,	O
36	bleach	O
37	,	O
38	vinegar	O
39	,	O
40	potassium	O
41	hydroxide	O
42	,	O
43	liquid	O
44	soap	O
45	,	O
46	2	O
47	-	O
48	propanol	O
49	,	O
50	and	O
51	ammonia	O
52	.	O

1	The	O
2	1489	O
3	-	O
4	base	O
5	pair	O
6	EFIA	B
7	cDNA	O
8	encodes	O
9	a	O
10	322	O
11	-	O
12	amino	O
13	acid	O
14	protein	O
15	which	O
16	is	O
17	nearly	O
18	identical	O
19	to	O
20	two	O
21	previously	O
22	described	O
23	human	O
24	DNA	O
25	binding	O
26	proteins	O
27	.	O

1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	pASB	B
15	-	I
16	1	I
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	orientations	O
23	.	O

1	Sci	O
2	.	O

1	Dose	O
2	standardisation	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	The	O
2	coding	O
3	sequence	O
4	for	O
5	a	O
6	260	O
7	-	O
8	amino	O
9	-	O
10	acid	O
11	residue	O
12	polypeptide	O
13	was	O
14	interrupted	O
15	by	O
16	a	O
17	single	O
18	short	O
19	intron	O
20	of	O
21	60	O
22	base	O
23	pairs	O
24	(	O
25	bp	O
26	),	O
27	and	O
28	about	O
29	70	O
30	%	O
31	of	O
32	the	O
33	deduced	O
34	amino	O
35	acid	O
36	sequence	O
37	of	O
38	the	O
39	Drosophila	B
40	PCNA	I
41	was	O
42	identical	O
43	to	O
44	the	O
45	rat	O
46	and	O
47	human	B
48	PCNA	I
49	polypeptides	I
50	,	O
51	with	O
52	conserved	O
53	unique	O
54	repeats	O
55	of	O
56	leucine	O
57	in	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	region	O
63	.	O

1	Translational	O
2	fusions	O
3	of	O
4	the	O
5	aroF	B
6	regulatory	I
7	regions	I
8	to	O
9	lacZ	B
10	were	O
11	constructed	O
12	and	O
13	then	O
14	introduced	O
15	in	O
16	single	O
17	copy	O
18	into	O
19	the	O
20	E	O
21	.	O
22	coli	O
23	chromosome	O
24	.	O
25	beta	B
26	-	I
27	Galactosidase	I
28	assays	O
29	for	O
30	tyrR	O
31	-	O
32	mediated	O
33	regulation	O
34	of	O
35	aroF	B
36	-	O
37	lacZ	B
38	expression	O
39	revealed	O
40	that	O
41	the	O
42	E	B
43	.	I
44	coli	I
45	TyrR	I
46	repressor	I
47	apparently	O
48	recognizes	O
49	the	O
50	operators	O
51	of	O
52	both	O
53	organisms	O
54	with	O
55	about	O
56	equal	O
57	efficiency	O
58	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	B
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	O
13	+	O
14	concentration	O
15	rises	O
16	.	O

1	Following	O
2	treatment	O
3	,	O
4	serum	O
5	estradiol	O
6	levels	O
7	were	O
8	higher	O
9	in	O
10	groups	O
11	E	O
12	+	O
13	T	O
14	and	O
15	E	O
16	than	O
17	in	O
18	group	O
19	C	O
20	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	beta	O
6	-	O
7	adrenergic	O
8	agonist	O
9	,	O
10	isoproterenol	O
11	,	O
12	has	O
13	little	O
14	influence	O
15	on	O
16	vascular	O
17	capacitance	O
18	or	O
19	liver	O
20	volume	O
21	of	O
22	dogs	O
23	,	O
24	unless	O
25	the	O
26	hepatic	O
27	outflow	O
28	resistance	O
29	is	O
30	elevated	O
31	by	O
32	agents	O
33	such	O
34	as	O
35	histamine	O
36	.	O

1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	B
8	domain	I
9	of	O
10	the	O
11	Syrian	B
12	hamster	I
13	multifunctional	I
14	protein	I
15	CAD	I
16	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	these	O
6	synthetic	O
7	binding	O
8	sites	O
9	have	O
10	a	O
11	more	O
12	restricted	O
13	and	O
14	specific	O
15	ability	O
16	to	O
17	enhance	O
18	transcription	O
19	when	O
20	assayed	O
21	in	O
22	transformed	O
23	embryos	O
24	.	O

1	After	O
2	base	O
3	-	O
4	line	O
5	CBF	O
6	was	O
7	established	O
8	,	O
9	hexamethonium	O
10	bromide	O
11	(	O
12	2	O
13	mg	O
14	/	O
15	kg	O
16	iv	O
17	),	O
18	ipratropium	O
19	bromide	O
20	(	O
21	0	O
22	.	O
23	5	O
24	microgram	O
25	/	O
26	kg	O
27	iv	O
28	),	O
29	indomethacin	O
30	(	O
31	2	O
32	mg	O
33	/	O
34	kg	O
35	iv	O
36	),	O
37	or	O
38	intravenous	O
39	0	O
40	.	O
41	9	O
42	%	O
43	saline	O
44	was	O
45	administered	O
46	.	O

1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	polymorphism	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	BglII	B
22	.	O

1	The	O
2	antilog	O
3	transformation	O
4	of	O
5	pH	O
6	did	O
7	not	O
8	improve	O
9	the	O
10	results	O
11	.	O

1	Telomeres	O
2	prevent	O
3	end	O
4	-	O
5	to	O
6	-	O
7	end	O
8	fusions	O
9	and	O
10	exonucleolytic	O
11	degradation	O
12	,	O
13	enable	O
14	the	O
15	end	O
16	of	O
17	the	O
18	linear	O
19	DNA	O
20	molecule	O
21	to	O
22	replicate	O
23	,	O
24	and	O
25	function	O
26	in	O
27	cell	O
28	division	O
29	.	O

1	One	O
2	of	O
3	these	O
4	is	O
5	located	O
6	in	O
7	the	O
8	5	O
9	'-	O
10	untranslated	O
11	region	O
12	,	O
13	and	O
14	may	O
15	encode	O
16	regulatory	O
17	sequences	O
18	.	O

1	The	O
2	native	O
3	enzyme	O
4	purified	O
5	from	O
6	protease	B
7	-	I
8	B	I
9	-	O
10	deficient	O
11	URA2	B
12	-	O
13	transformed	O
14	cells	O
15	,	O
16	was	O
17	phosphorylated	O
18	in	O
19	vitro	O
20	using	O
21	catalytic	O
22	subunits	O
23	of	O
24	pure	O
25	cAMP	B
26	-	I
27	dependent	I
28	protein	I
29	kinase	I
30	.	O

1	This	O
2	study	O
3	suggests	O
4	that	O
5	BSPMs	O
6	are	O
7	useful	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	AMI	O
13	in	O
14	terms	O
15	of	O
16	diagnosis	O
17	,	O
18	location	O
19	and	O
20	extent	O
21	of	O
22	myocardial	O
23	infarct	O
24	.	O

1	A	O
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	B
18	H	I
19	,	I
20	K	I
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	Judicious	O
2	use	O
3	of	O
4	laboratory	O
5	testing	O
6	,	O
7	including	O
8	monitoring	O
9	of	O
10	CD4	B
11	cell	O
12	counts	O
13	,	O
14	is	O
15	recommended	O
16	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	growth	O
10	-	O
11	regulated	O
12	Syrian	B
13	hamster	I
14	CAD	I
15	gene	I
16	.	O

1	Early	O
2	cirrhosis	O
3	,	O
4	an	O
5	early	O
6	modality	O
7	of	O
8	the	O
9	evolution	O
10	of	O
11	acute	O
12	hepatitis	O
13	.	O

1	Examination	O
2	of	O
3	immediate	B
4	-	I
5	early	I
6	transcription	I
7	factor	I
8	expression	O
9	during	O
10	the	O
11	MDI	O
12	regimen	O
13	revealed	O
14	that	O
15	RA	O
16	mediated	O
17	an	O
18	elevated	O
19	,	O
20	prolonged	O
21	expression	O
22	of	O
23	c	B
24	-	I
25	Jun	I
26	mRNA	I
27	accompanied	O
28	by	O
29	diminished	O
30	expression	O
31	of	O
32	c	B
33	-	I
34	Fos	I
35	and	O
36	Jun	B
37	-	I
38	B	I
39	mRNAs	I
40	.	O

1	Although	O
2	heart	O
3	rate	O
4	and	O
5	diastolic	O
6	pressure	O
7	rose	O
8	in	O
9	some	O
10	degree	O
11	1	O
12	min	O
13	after	O
14	intubation	O
15	,	O
16	free	O
17	and	O
18	total	O
19	CA	O
20	concentrations	O
21	did	O
22	not	O
23	increase	O
24	during	O
25	study	O
26	period	O
27	.	O

1	Processing	O
2	,	O
3	secretion	O
4	,	O
5	and	O
6	immunoreactivity	O
7	of	O
8	carboxy	B
9	terminally	I
10	truncated	I
11	dengue	I
12	-	I
13	2	I
14	virus	I
15	envelope	I
16	proteins	I
17	expressed	O
18	in	O
19	insect	O
20	cells	O
21	by	O
22	recombinant	O
23	baculoviruses	O
24	.	O

1	Combined	O
2	therapy	O
3	with	O
4	MK	O
5	-	O
6	801	O
7	and	O
8	nimodipine	O
9	for	O
10	protection	O
11	of	O
12	ischemic	O
13	brain	O
14	damage	O
15	.	O

1	Initial	O
2	screening	O
3	of	O
4	a	O
5	rat	O
6	liver	O
7	cDNA	O
8	library	O
9	with	O
10	an	O
11	oligonucleotide	O
12	probe	O
13	derived	O
14	from	O
15	the	O
16	rat	O
17	SCP2	B
18	protein	O
19	sequence	O
20	revealed	O
21	an	O
22	825	O
23	-	O
24	base	O
25	pair	O
26	cDNA	O
27	clone	O
28	coding	O
29	for	O
30	the	O
31	complete	O
32	SCP2	B
33	protein	O
34	sequence	O
35	.	O

1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O

1	The	O
2	addition	O
3	of	O
4	an	O
5	equimolar	O
6	complex	O
7	of	O
8	the	O
9	fourth	O
10	and	O
11	seventh	O
12	largest	O
13	subunits	O
14	,	O
15	purified	O
16	from	O
17	pol	B
18	II	I
19	holoenzyme	I
20	by	O
21	ion	O
22	-	O
23	exchange	O
24	chromatography	O
25	in	O
26	the	O
27	presence	O
28	of	O
29	urea	O
30	,	O
31	restored	O
32	promoter	O
33	-	O
34	directed	O
35	initiation	O
36	activity	O
37	to	O
38	pol	B
39	II	I
40	delta	I
41	4	I
42	/	I
43	7	I
44	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	HSF	B
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	.	O

1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	a	O
7	synthetic	O
8	E6	B
9	motif	I
10	detected	O
11	a	O
12	B	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	complex	O
18	in	O
19	addition	O
20	to	O
21	a	O
22	ubiquitous	O
23	band	O
24	found	O
25	also	O
26	in	O
27	T	O
28	cells	O
29	and	O
30	HeLa	O
31	cells	O
32	.	O

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	O
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	O
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	B
32	(	I
33	2	I
34	'-	I
35	5	I
36	')	I
37	oligoadenylate	I
38	synthetase	I
39	gene	I
40	interferon	O
41	response	O
42	element	O
43	as	O
44	a	O
45	probe	O
46	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	B
12	-	I
13	bp	I
14	BAL	I
15	cDNA	I
16	structure	O
17	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	instruments	O
6	allows	O
7	occlusion	O
8	of	O
9	the	O
10	ascending	O
11	aorta	O
12	traversed	O
13	by	O
14	the	O
15	perfusion	O
16	cannula	O
17	inserted	O
18	directly	O
19	or	O
20	through	O
21	the	O
22	apex	O
23	of	O
24	the	O
25	heart	O
26	as	O
27	well	O
28	as	O
29	simultaneous	O
30	left	O
31	ventricular	O
32	venting	O
33	.	O

1	Adenylosuccinate	B
2	synthetase	I
3	(	O
4	IMP	O
5	:	O
6	L	B
7	-	I
8	aspartate	I
9	ligase	I
10	(	O
11	GDP	O
12	),	O
13	EC	B
14	6	I
15	.	I
16	3	I
17	.	I
18	4	I
19	.	I
20	4	I
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	purine	O
28	biosynthesis	O
29	catalyzing	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	IMP	O
37	to	O
38	AMP	O
39	.	O

1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O

1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	UHF	B
12	-	I
13	1	I
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	dodecyl	O
21	sulfate	O
22	-	O
23	acrylamide	O
24	gels	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O

1	The	O
2	results	O
3	strengthen	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	G4	B
13	content	O
14	of	O
15	mature	O
16	innervated	O
17	fast	O
18	muscles	O
19	.	O

1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	mRNA	O
15	(	O
16	RRE	B
17	,	O
18	the	O
19	Rev	B
20	response	I
21	element	I
22	)	O
23	and	O
24	the	O
25	virus	B
26	-	I
27	encoded	I
28	protein	I
29	Rev	I
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O

1	We	O
2	reviewed	O
3	the	O
4	records	O
5	of	O
6	151	O
7	patients	O
8	with	O
9	optic	O
10	neuritis	O
11	examined	O
12	over	O
13	an	O
14	eight	O
15	-	O
16	year	O
17	period	O
18	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O

1	All	O
2	six	O
3	ARF	B
4	cDNAs	I
5	are	O
6	more	O
7	similar	O
8	to	O
9	each	O
10	other	O
11	than	O
12	to	O
13	other	O
14	approximately	O
15	20	B
16	-	I
17	kDa	I
18	guanine	I
19	nucleotide	I
20	-	I
21	binding	I
22	proteins	I
23	.	O

1	The	O
2	long	O
3	terminal	O
4	repeat	O
5	(	O
6	LTR	O
7	)	O
8	of	O
9	the	O
10	human	O
11	immunodeficiency	O
12	virus	O
13	(	O
14	HIV	O
15	)	O
16	contains	O
17	three	O
18	binding	O
19	sites	O
20	for	O
21	the	O
22	transcriptional	O
23	factor	O
24	Sp1	B
25	.	O

1	DNA	O
2	from	O
3	PCR	O
4	was	O
5	labeled	O
6	and	O
7	used	O
8	to	O
9	isolate	O
10	several	O
11	lambda	O
12	gt11	O
13	cDNA	O
14	clones	O
15	,	O
16	including	O
17	one	O
18	full	O
19	-	O
20	length	O
21	one	O
22	(	O
23	Dd	B
24	kinase	I
25	-	I
26	2	I
27	).	O

1	Radiation	O
2	-	O
3	induced	O
4	changes	O
5	in	O
6	the	O
7	area	O
8	of	O
9	alveoli	O
10	and	O
11	septa	O
12	as	O
13	well	O
14	as	O
15	collagen	B
16	content	O
17	were	O
18	seen	O
19	11	O
20	weeks	O
21	after	O
22	irradiation	O
23	.	O

1	The	O
2	first	O
3	follow	O
4	-	O
5	up	O
6	was	O
7	at	O
8	a	O
9	nearly	O
10	constant	O
11	interval	O
12	of	O
13	5	O
14	.	O
15	1	O
16	years	O
17	in	O
18	Caerphilly	O
19	and	O
20	3	O
21	.	O
22	2	O
23	years	O
24	in	O
25	Speedwell	O
26	;	O
27	251	O
28	major	O
29	IHD	O
30	events	O
31	had	O
32	occurred	O
33	.	O

1	A	O
2	.	O

1	Perilunar	O
2	luxation	O
3	--	O
4	an	O
5	unusual	O
6	injury	O
7	demanding	O
8	immediate	O
9	and	O
10	correct	O
11	treatment	O

1	Landsberg	O
2	(	O
3	La	O
4	-	O
5	O	O
6	)	O
7	and	O
8	cv	O
9	.	O

1	In	O
2	summary	O
3	,	O
4	at	O
5	equianesthetic	O
6	concentrations	O
7	,	O
8	desflurane	O
9	and	O
10	isoflurane	O
11	produced	O
12	similar	O
13	hemodynamic	O
14	effects	O
15	;	O
16	however	O
17	,	O
18	in	O
19	the	O
20	absence	O
21	of	O
22	drugs	O
23	that	O
24	inhibit	O
25	autonomic	O
26	reflexes	O
27	,	O
28	desflurane	O
29	had	O
30	less	O
31	negative	O
32	inotropic	O
33	activity	O
34	and	O
35	produced	O
36	less	O
37	decrease	O
38	in	O
39	arterial	O
40	pressure	O
41	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	full	O
9	-	O
10	length	O
11	cDNA	O
12	clone	O
13	coding	O
14	for	O
15	a	O
16	hitherto	O
17	undiscovered	O
18	isoform	O
19	of	O
20	the	O
21	bovine	B
22	C	I
23	-	I
24	subunit	I
25	.	O

1	Isoform	B
2	C	I
3	beta	I
4	2	I
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	O
13	subunit	O
14	of	O
15	cAMP	B
16	-	I
17	dependent	I
18	protein	I
19	kinase	I
20	.	O

1	Salient	O
2	applications	O
3	of	O
4	PB	O
5	-	O
6	PK	O
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	Patients	O
2	with	O
3	apparently	O
4	minor	O
5	CT	O
6	abnormalities	O
7	may	O
8	have	O
9	significant	O
10	epidural	O
11	disease	O
12	.	O

1	The	O
2	cdr1	B
3	sequence	I
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	O
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	Armed	O
2	with	O
3	a	O
4	clear	O
5	understanding	O
6	of	O
7	the	O
8	pathophysiologic	O
9	pathways	O
10	that	O
11	may	O
12	cause	O
13	and	O
14	/	O
15	or	O
16	contribute	O
17	to	O
18	the	O
19	development	O
20	of	O
21	unconjugated	O
22	hyperbilirubinemia	O
23	and	O
24	the	O
25	associated	O
26	jaundice	O
27	,	O
28	the	O
29	practitioner	O
30	will	O
31	be	O
32	successful	O
33	in	O
34	helping	O
35	the	O
36	family	O
37	understand	O
38	their	O
39	child	O
40	'	O
41	s	O
42	illness	O
43	.	O

1	Displacement	O
2	thresholds	O
3	of	O
4	peripheral	O
5	sites	O
6	in	O
7	monocular	O
8	human	O
9	vision	O
10	were	O
11	obtained	O
12	.	O

1	The	O
2	authors	O
3	report	O
4	a	O
5	case	O
6	in	O
7	which	O
8	stereotactic	O
9	irrigation	O
10	of	O
11	a	O
12	brain	O
13	cyst	O
14	was	O
15	temporally	O
16	associated	O
17	with	O
18	respiratory	O
19	distress	O
20	.	O

1	ELISA	O
2	was	O
3	found	O
4	to	O
5	make	O
6	a	O
7	contribution	O
8	to	O
9	the	O
10	diagnosis	O
11	of	O
12	tuberculosis	O
13	similar	O
14	to	O
15	that	O
16	of	O
17	sputum	O
18	smear	O
19	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	B
29	and	O
30	pulCp	B
31	promoters	I
32	.	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	O
26	alpha	B
27	-	I
28	IFN	I
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	Paroxysmal	O
2	fluctuations	O
3	in	O
4	observed	O
5	parasitemia	O
6	in	O
7	Plasmodium	O
8	falciparum	O
9	malaria	O
10	.	O

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	Occupational	O
2	asthma	O
3	and	O
4	rhinoconjunctivitis	O
5	from	O
6	inhalation	O
7	of	O
8	crystalline	O
9	bovine	B
10	serum	I
11	albumin	I
12	powder	O
13	.	O

1	A	O
2	further	O
3	subdivision	O
4	of	O
5	Category	O
6	pN1	O
7	into	O
8	pN1a	O
9	(	O
10	metastasis	O
11	in	O
12	single	O
13	node	O
14	)	O
15	and	O
16	pN1b	O
17	(	O
18	two	O
19	or	O
20	more	O
21	nodes	O
22	)	O
23	is	O
24	recommended	O
25	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparisons	O
5	of	O
6	the	O
7	E74A	B
8	protein	I
9	reveal	O
10	a	O
11	highly	O
12	conserved	O
13	C	O
14	-	O
15	terminal	O
16	region	O
17	that	O
18	is	O
19	rich	O
20	in	O
21	basic	O
22	amino	O
23	acid	O
24	residues	O
25	and	O
26	which	O
27	has	O
28	been	O
29	proposed	O
30	to	O
31	possess	O
32	sequence	O
33	-	O
34	specific	O
35	DNA	O
36	binding	O
37	activity	O
38	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	relative	O
6	strengths	O
7	of	O
8	the	O
9	promoters	O
10	were	O
11	similar	O
12	in	O
13	different	O
14	contexts	O
15	.	O

1	Grasso	O
2	,	O
3	and	O
4	A	O
5	.	O

1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O

1	Age	O
2	at	O
3	POI	O
4	and	O
5	asymptote	O
6	were	O
7	achieved	O
8	later	O
9	for	O
10	Line	O
11	RBC2	O
12	than	O
13	for	O
14	Line	O
15	F	O
16	.	O

1	To	O
2	identify	O
3	the	O
4	DNA	O
5	sequences	O
6	that	O
7	cis	O
8	-	O
9	regulate	O
10	the	O
11	expression	O
12	of	O
13	the	O
14	rat	B
15	liver	I
16	pyruvate	I
17	kinase	I
18	(	O
19	L	B
20	-	I
21	PK	I
22	)	O
23	genes	O
24	,	O
25	a	O
26	series	O
27	of	O
28	constructs	O
29	in	O
30	which	O
31	the	O
32	chloramphenicol	B
33	acetyltransferase	I
34	reporter	I
35	genes	I
36	is	O
37	driven	O
38	by	O
39	various	O
40	deleted	O
41	fragments	O
42	of	O
43	the	O
44	3200	O
45	base	O
46	pairs	O
47	(	O
48	bp	O
49	)	O
50	upstream	O
51	of	O
52	the	O
53	L	B
54	-	I
55	PK	I
56	gene	I
57	cap	I
58	site	I
59	have	O
60	been	O
61	assayed	O
62	for	O
63	transient	O
64	expression	O
65	after	O
66	introduction	O
67	into	O
68	hepatoma	O
69	HepG2	O
70	cells	O
71	,	O
72	rat	O
73	hepatocytes	O
74	in	O
75	primary	O
76	culture	O
77	,	O
78	fibroblast	O
79	LTK	O
80	-	O
81	cells	O
82	,	O
83	myogenic	O
84	C2C12	O
85	cells	O
86	,	O
87	and	O
88	CHO	O
89	cells	O
90	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	A	O
2	dose	O
3	of	O
4	3	O
5	and	O
6	6	O
7	micrograms	O
8	/	O
9	kg	O
10	/	O
11	day	O
12	GM	B
13	-	I
14	CSF	I
15	reduces	O
16	the	O
17	severity	O
18	of	O
19	neutropenia	O
20	and	O
21	thrombocytopenia	O
22	after	O
23	carboplatin	O
24	-	O
25	cyclophosphamide	O
26	chemotherapy	O
27	,	O
28	which	O
29	may	O
30	lead	O
31	to	O
32	more	O
33	effective	O
34	chemotherapy	O
35	for	O
36	ovarian	O
37	cancer	O
38	in	O
39	the	O
40	future	O
41	.	O

1	These	O
2	differences	O
3	involve	O
4	specific	O
5	hydrogen	O
6	-	O
7	bonding	O
8	interactions	O
9	between	O
10	the	O
11	protein	O
12	and	O
13	DNA	O
14	,	O
15	including	O
16	guanine	O
17	N7	O
18	sites	O
19	in	O
20	the	O
21	major	O
22	groove	O
23	of	O
24	DNA	O
25	,	O
26	and	O
27	alterations	O
28	in	O
29	DNA	O
30	phosphodiester	O
31	conformation	O
32	induced	O
33	by	O
34	protein	O
35	binding	O
36	.	O

1	Biochemical	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	BJ1	B
7	protein	I
8	is	O
9	associated	O
10	with	O
11	nucleosomes	O
12	and	O
13	is	O
14	released	O
15	from	O
16	chromatin	O
17	by	O
18	agents	O
19	which	O
20	intercalate	O
21	into	O
22	DNA	O
23	,	O
24	as	O
25	previously	O
26	shown	O
27	for	O
28	the	O
29	high	B
30	mobility	I
31	group	I
32	proteins	I
33	(	O
34	HMGs	B
35	).	O

1	I	O
2	propose	O
3	that	O
4	their	O
5	gene	O
6	products	O
7	bind	O
8	to	O
9	the	O
10	chromatin	O
11	to	O
12	establish	O
13	or	O
14	maintain	O
15	a	O
16	proper	O
17	higher	O
18	order	O
19	structure	O
20	as	O
21	a	O
22	prerequisite	O
23	for	O
24	a	O
25	regulated	O
26	gene	O
27	expression	O
28	.	O

1	The	O
2	C4BP	B
3	alpha	I
4	gene	I
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	1	I
7	(	I
8	HIV	I
9	-	I
10	1	I
11	)	I
12	Rev	I
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	Once	O
2	the	O
3	proliferation	O
4	of	O
5	fibroblasts	O
6	and	O
7	collagen	B
8	synthesis	O
9	had	O
10	led	O
11	to	O
12	an	O
13	increase	O
14	of	O
15	mechanical	O
16	strength	O
17	,	O
18	no	O
19	negative	O
20	effect	O
21	on	O
22	wound	O
23	healing	O
24	could	O
25	be	O
26	detected	O
27	applying	O
28	the	O
29	same	O
30	chemotherapeutic	O
31	agents	O
32	.	O

1	The	O
2	CDC7	B
3	gene	I
4	has	O
5	two	O
6	in	O
7	-	O
8	frame	O
9	AUG	O
10	codons	O
11	as	O
12	possible	O
13	translation	O
14	start	O
15	sites	O
16	,	O
17	which	O
18	would	O
19	produce	O
20	58	O
21	-	O
22	and	O
23	56	O
24	-	O
25	kDa	O
26	proteins	O
27	,	O
28	respectively	O
29	.	O

1	During	O
2	the	O
3	years	O
4	1980	O
5	-	O
6	87	O
7	a	O
8	total	O
9	of	O
10	287	O
11	persons	O
12	received	O
13	disability	O
14	pensions	O
15	in	O
16	the	O
17	municipality	O
18	of	O
19	Nordreisa	O
20	in	O
21	northern	O
22	Norway	O
23	.	O

1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	B
9	gene	I
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	B
18	-	I
19	1	I
20	LTR	I
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O

1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	The	O
7	two	O
8	groups	O
9	were	O
10	similar	O
11	on	O
12	entry	O
13	into	O
14	the	O
15	study	O
16	,	O
17	including	O
18	mean	O
19	FEV1	O
20	measurements	O
21	(	O
22	0	O
23	.	O
24	70	O
25	L	O
26	atropine	O
27	/	O
28	0	O
29	.	O
30	60	O
31	L	O
32	metaproterenol	O
33	,	O
34	P	O
35	greater	O
36	than	O
37	.	O
38	05	O
39	).	O

1	Using	O
2	an	O
3	ELISA	O
4	,	O
5	we	O
6	found	O
7	that	O
8	surfactant	B
9	protein	I
10	A	I
11	(	O
12	SP	B
13	-	I
14	A	I
15	)	O
16	was	O
17	markedly	O
18	elevated	O
19	in	O
20	the	O
21	pneumonia	O
22	patients	O
23	.	O

1	In	O
2	view	O
3	of	O
4	the	O
5	short	O
6	t1	O
7	/	O
8	2	O
9	,	O
10	we	O
11	used	O
12	three	O
13	doses	O
14	/	O
15	day	O
16	.	O

1	Temporal	O
2	control	O
3	of	O
4	GUS	B
5	expression	O
6	was	O
7	found	O
8	to	O
9	involve	O
10	two	O
11	negative	O
12	regulatory	O
13	sequences	O
14	,	O
15	NRS1	O
16	(-	O
17	391	O
18	to	O
19	-	O
20	295	O
21	)	O
22	and	O
23	NRS2	O
24	(-	O
25	518	O
26	to	O
27	-	O
28	418	O
29	),	O
30	as	O
31	well	O
32	as	O
33	the	O
34	positive	O
35	domain	O
36	UAS1	O
37	.	O

1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O

1	In	O
2	most	O
3	cases	O
4	,	O
5	DR4	B
6	-	O
7	homozygous	O
8	,	O
9	DRB1	B
10	-	O
11	heterozygous	O
12	individuals	O
13	could	O
14	be	O
15	genotyped	O
16	with	O
17	the	O
18	panel	O
19	of	O
20	probes	O
21	.	O

1	Two	O
2	patients	O
3	had	O
4	immediate	O
5	adverse	O
6	effects	O
7	from	O
8	NMF	O
9	;	O
10	one	O
11	had	O
12	a	O
13	grand	O
14	mal	O
15	seizure	O
16	and	O
17	the	O
18	other	O
19	developed	O
20	severe	O
21	abdominal	O
22	pain	O
23	.	O

1	The	O
2	muscles	O
3	from	O
4	the	O
5	ischemic	O
6	group	O
7	had	O
8	significantly	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	.	O
15	05	O
16	)	O
17	values	O
18	for	O
19	capillary	O
20	density	O
21	and	O
22	capillary	O
23	to	O
24	fiber	O
25	ratio	O
26	and	O
27	significantly	O
28	higher	O
29	intercapillary	O
30	distance	O
31	than	O
32	those	O
33	from	O
34	the	O
35	normal	O
36	group	O
37	.	O

1	The	O
2	prevalence	O
3	of	O
4	opportunistic	O
5	infection	O
6	among	O
7	surviving	O
8	AIDS	O
9	patients	O
10	and	O
11	the	O
12	probability	O
13	of	O
14	being	O
15	in	O
16	tumour	O
17	response	O
18	following	O
19	cancer	O
20	therapy	O
21	conditional	O
22	on	O
23	being	O
24	alive	O
25	are	O
26	two	O
27	examples	O
28	of	O
29	such	O
30	functions	O
31	.	O

1	Serum	B
2	TNF	I
3	concentrations	O
4	were	O
5	elevated	O
6	at	O
7	diagnosis	O
8	and	O
9	gradually	O
10	decreased	O
11	toward	O
12	the	O
13	reference	O
14	limits	O
15	by	O
16	week	O
17	16	O
18	.	O

1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O

1	Polymerase	O
2	chain	O
3	reaction	O
4	analysis	O
5	of	O
6	ETS1	B
7	cDNA	I
8	identified	O
9	several	O
10	amplified	O
11	products	O
12	,	O
13	indicating	O
14	alternative	O
15	splicing	O
16	.	O

1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O

1	To	O
2	test	O
3	promotor	O
4	function	O
5	,	O
6	chimeric	O
7	genes	O
8	were	O
9	constructed	O
10	linking	O
11	fragments	O
12	of	O
13	chicken	O
14	IGF	B
15	-	I
16	I	I
17	5	O
18	'-	O
19	flanking	O
20	DNA	O
21	to	O
22	a	O
23	promoterless	O
24	reporter	O
25	plasmid	O
26	.	O

1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O

1	Characterization	O
2	of	O
3	the	O
4	alpha	B
5	4	I
6	integrin	I
7	gene	I
8	promoter	I
9	.	O

1	Only	O
2	the	O
3	3	O
4	.	O
5	0	O
6	-	O
7	kb	O
8	transcript	O
9	was	O
10	detected	O
11	in	O
12	adult	O
13	tissues	O
14	,	O
15	where	O
16	its	O
17	expression	O
18	was	O
19	restricted	O
20	almost	O
21	exclusively	O
22	to	O
23	the	O
24	central	O
25	nervous	O
26	system	O
27	.	O

1	Two	O
2	homologues	O
3	of	O
4	the	O
5	rhombotin	B
6	gene	I
7	have	O
8	now	O
9	been	O
10	isolated	O
11	.	O

1	Angina	O
2	haemorrhagica	O
3	bullosa	O
4	causing	O
5	respiratory	O
6	obstruction	O
7	postoperatively	O
8	.	O

1	We	O
2	examined	O
3	the	O
4	effects	O
5	of	O
6	long	O
7	-	O
8	term	O
9	perfusion	O
10	with	O
11	pyridoxalated	O
12	hemoglobin	B
13	polyoxyethylene	O
14	conjugate	O
15	(	O
16	PHP	O
17	)	O
18	solution	O
19	on	O
20	cardiac	O
21	function	O
22	of	O
23	isolated	O
24	rat	O
25	hearts	O
26	.	O

1	Conclusion	O
2	:	O
3	inlet	O
4	type	O
5	VSD	O
6	and	O
7	perimembranous	O
8	type	O
9	TOF	O
10	have	O
11	anatomic	O
12	features	O
13	in	O
14	which	O
15	the	O
16	proximal	O
17	His	O
18	bundle	O
19	tends	O
20	to	O
21	be	O
22	jeopardized	O
23	by	O
24	suturing	O
25	for	O
26	VSD	O
27	closure	O
28	.	O

1	The	O
2	gcd2	B
3	-	I
4	503	I
5	mutation	O
6	also	O
7	results	O
8	in	O
9	polysome	O
10	runoff	O
11	,	O
12	accumulation	O
13	of	O
14	inactive	O
15	80S	B
16	ribosomal	I
17	couples	I
18	,	O
19	and	O
20	accumulation	O
21	of	O
22	at	O
23	least	O
24	one	O
25	of	O
26	the	O
27	subunits	O
28	of	O
29	the	O
30	general	B
31	translation	I
32	initiation	I
33	factor	I
34	2	I
35	(	O
36	eIF	B
37	-	I
38	2	I
39	alpha	I
40	)	O
41	in	O
42	43S	B
43	-	O
44	48S	B
45	particles	O
46	following	O
47	a	O
48	shift	O
49	to	O
50	the	O
51	restrictive	O
52	temperature	O
53	.	O

1	Eight	O
2	patients	O
3	with	O
4	ARC	O
5	and	O
6	renal	O
7	failure	O
8	were	O
9	recently	O
10	evaluated	O
11	.	O

1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	B
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	B
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O

1	A	O
2	single	O
3	case	O
4	of	O
5	an	O
6	adenocarcinoma	O
7	,	O
8	arising	O
9	in	O
10	a	O
11	retroperitoneal	O
12	enterogenous	O
13	cyst	O
14	and	O
15	which	O
16	presented	O
17	as	O
18	a	O
19	left	O
20	renal	O
21	cyst	O
22	,	O
23	is	O
24	reported	O
25	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	we	O
8	analyzed	O
9	the	O
10	U6	B
11	RNA	I
12	genes	I
13	of	O
14	52	O
15	organisms	O
16	.	O

1	Both	O
2	tear	O
3	volume	O
4	and	O
5	tear	O
6	flow	O
7	were	O
8	found	O
9	to	O
10	be	O
11	significantly	O
12	(	O
13	P	O
14	less	O
15	than	O
16	0	O
17	.	O
18	001	O
19	)	O
20	decreased	O
21	up	O
22	to	O
23	6	O
24	h	O
25	after	O
26	instillation	O
27	,	O
28	reaching	O
29	a	O
30	minimum	O
31	90	O
32	min	O
33	after	O
34	application	O
35	(	O
36	tear	O
37	volume	O
38	:	O
39	-	O
40	63	O
41	%;	O
42	tear	O
43	flow	O
44	:	O
45	-	O
46	71	O
47	%).	O

1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O

1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	Food	O
13	and	O
14	Drug	O
15	Administration	O
16	(	O
17	FDA	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	1970s	O
24	began	O
25	assigning	O
26	therapeutic	O
27	ratings	O
28	to	O
29	investigational	O
30	new	O
31	drugs	O
32	and	O
33	holding	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	conferences	O
41	with	O
42	drug	O
43	sponsors	O
44	.	O

1	In	O
2	contrast	O
3	,	O
4	similar	O
5	rates	O
6	of	O
7	B	O
8	.	O
9	sphaericus	O
10	products	O
11	,	O
12	ABG	O
13	-	O
14	6184	O
15	technical	O
16	powder	O
17	and	O
18	BSP	O
19	-	O
20	2	O
21	flowable	O
22	concentrate	O
23	,	O
24	produced	O
25	no	O
26	significant	O
27	reduction	O
28	.	O

1	The	O
2	remainder	O
3	(	O
4	18	O
5	.	O
6	4	O
7	%)	O
8	was	O
9	with	O
10	IgA	B
11	nephropathy	O
12	,	O
13	which	O
14	was	O
15	histologically	O
16	mild	O
17	.	O

1	Grossly	O
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O

1	3	O
2	.	O

1	Furthermore	O
2	,	O
3	the	O
4	DNA	B
5	polymerase	I
6	II	I
7	complex	I
8	was	O
9	difficult	O
10	to	O
11	obtain	O
12	from	O
13	dpb2	B
14	-	I
15	1	I
16	mutant	O
17	cells	O
18	,	O
19	suggesting	O
20	that	O
21	a	O
22	stable	O
23	DNA	B
24	polymerase	I
25	II	I
26	complex	I
27	requires	O
28	DPB2	B
29	and	O
30	is	O
31	essential	O
32	for	O
33	chromosomal	O
34	replication	O
35	.	O

1	To	O
2	determine	O
3	whether	O
4	mononuclear	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	O
20	postmenopausal	O
21	osteoporosis	O
22	,	O
23	we	O
24	evaluated	O
25	the	O
26	effects	O
27	of	O
28	oophorectomy	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	O
33	on	O
34	the	O
35	spontaneous	O
36	secretion	O
37	of	O
38	interleukin	B
39	1	I
40	(	O
41	IL	B
42	-	I
43	1	I
44	)	O
45	and	O
46	tumor	B
47	necrosis	I
48	factor	I
49	alpha	I
50	(	O
51	TNF	B
52	-	I
53	alpha	I
54	)	O
55	and	O
56	on	O
57	the	O
58	phytohemagglutinin	B
59	A	I
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	B
65	-	I
66	macrophage	I
67	colony	I
68	-	I
69	stimulating	I
70	factor	I
71	(	O
72	GM	B
73	-	I
74	CSF	I
75	)	O
76	from	O
77	peripheral	O
78	blood	O
79	mononuclear	O
80	cells	O
81	.	O

1	There	O
2	were	O
3	45	O
4	to	O
5	56	O
6	nt	O
7	differences	O
8	between	O
9	the	O
10	virulent	O
11	and	O
12	avirulent	O
13	groups	O
14	while	O
15	there	O
16	were	O
17	6	O
18	to	O
19	14	O
20	nt	O
21	differences	O
22	among	O
23	four	O
24	avirulent	O
25	strains	O
26	.	O

1	The	O
2	standard	O
3	principles	O
4	of	O
5	surgical	O
6	management	O
7	must	O
8	be	O
9	adhered	O
10	to	O
11	when	O
12	using	O
13	Sandostatin	O
14	to	O
15	treat	O
16	patients	O
17	with	O
18	these	O
19	disorders	O
20	.	O

1	Some	O
2	of	O
3	the	O
4	PCR	O
5	products	O
6	contained	O
7	mutations	O
8	in	O
9	ATG1	B
10	and	O
11	/	O
12	or	O
13	ATG2	B
14	.	O

1	Hemorrhagic	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	swine	O
9	model	O
10	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	levels	O
7	of	O
8	oxygen	O
9	free	O
10	radicals	O
11	were	O
12	increased	O
13	in	O
14	hepatocytes	O
15	and	O
16	mitochondria	O
17	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	pMxL1	O
6	plasmid	O
7	containing	O
8	the	O
9	invertible	O
10	region	O
11	contains	O
12	a	O
13	perfect	O
14	tandem	O
15	repeat	O
16	of	O
17	19	O
18	bp	O
19	in	O
20	the	O
21	orientation	O
22	1	O
23	nonexpressed	O
24	pilin	B
25	gene	I
26	at	O
27	the	O
28	middle	O
29	of	O
30	the	O
31	recombination	O
32	junction	O
33	site	O
34	.	O

1	No	O
2	evidence	O
3	for	O
4	the	O
5	presence	O
6	of	O
7	introns	O
8	within	O
9	the	O
10	acvA	B
11	gene	I
12	has	O
13	been	O
14	found	O
15	.	O

1	These	O
2	observations	O
3	,	O
4	together	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	putative	O
10	4	O
11	'-	O
12	phosphopantetheine	O
13	-	O
14	attachment	O
15	sites	O
16	and	O
17	a	O
18	putative	O
19	thioesterase	B
20	site	I
21	,	O
22	are	O
23	discussed	O
24	with	O
25	reference	O
26	to	O
27	the	O
28	reaction	O
29	sequence	O
30	leading	O
31	to	O
32	production	O
33	of	O
34	the	O
35	ACV	B
36	tripeptide	I
37	.	O

1	Pargyline	O
2	,	O
3	a	O
4	monoamine	B
5	oxidase	I
6	inhibitor	O
7	,	O
8	reduces	O
9	peak	O
10	3	O
11	transiently	O
12	(	O
13	max	O
14	.	O

1	When	O
2	given	O
3	the	O
4	choice	O
5	between	O
6	an	O
7	estrous	O
8	female	O
9	and	O
10	a	O
11	sexually	O
12	active	O
13	male	O
14	in	O
15	the	O
16	AOF	O
17	,	O
18	flutamide	O
19	females	O
20	,	O
21	as	O
22	well	O
23	as	O
24	controls	O
25	,	O
26	preferred	O
27	the	O
28	male	O
29	partner	O
30	.	O

1	Hypoxic	O
2	ventilatory	O
3	responses	O
4	were	O
5	-	O
6	1	O
7	.	O
8	99	O
9	+/-	O
10	0	O
11	.	O
12	37	O
13	L	O
14	/	O
15	min	O
16	/%	O
17	SaO2	O
18	in	O
19	the	O
20	relatives	O
21	and	O
22	-	O
23	1	O
24	.	O
25	54	O
26	+/-	O
27	0	O
28	.	O
29	25	O
30	L	O
31	/	O
32	min	O
33	/%	O
34	SaO2	O
35	in	O
36	the	O
37	control	O
38	subjects	O
39	.(	O
40	ABSTRACT	O
41	TRUNCATED	O
42	AT	O
43	250	O
44	WORDS	O
45	)	O

1	Very	O
2	small	O
3	deletions	O
4	within	O
5	the	O
6	conserved	O
7	region	O
8	completely	O
9	abolished	O
10	transforming	O
11	activity	O
12	of	O
13	dbl	B
14	,	O
15	while	O
16	extensive	O
17	deletion	O
18	outside	O
19	of	O
20	this	O
21	region	O
22	had	O
23	no	O
24	effect	O
25	.	O

1	This	O
2	computerized	O
3	list	O
4	was	O
5	linked	O
6	to	O
7	the	O
8	central	O
9	files	O
10	of	O
11	the	O
12	Massachusetts	O
13	Cancer	O
14	Registry	O
15	and	O
16	cases	O
17	diagnosed	O
18	between	O
19	1982	O
20	and	O
21	1988	O
22	were	O
23	identified	O
24	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	for	O
6	a	O
7	negative	O
8	regulatory	O
9	element	O
10	in	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	Mlu	B
19	I	I
20	upstream	I
21	activation	I
22	sequence	I
23	.	O

1	A	O
2	method	O
3	for	O
4	establishing	O
5	stimulus	O
6	control	O
7	of	O
8	ethanol	O
9	responding	O
10	was	O
11	developed	O
12	.	O

1	Mechanism	O
2	of	O
3	activation	O
4	of	O
5	the	O
6	vav	B
7	protooncogene	I
8	.	O
9	vav	B
10	is	O
11	a	O
12	human	O
13	locus	O
14	that	O
15	appears	O
16	to	O
17	be	O
18	specifically	O
19	expressed	O
20	in	O
21	cells	O
22	of	O
23	hematopoietic	O
24	origin	O
25	regardless	O
26	of	O
27	their	O
28	differentiation	O
29	lineage	O
30	.	O

1	Endothelial	O
2	cell	O
3	seeding	O
4	.	O

1	Menetrier	O
2	disease	O
3	in	O
4	a	O
5	child	O
6	.	O

1	After	O
2	hemodynamic	O
3	stabilization	O
4	,	O
5	the	O
6	goal	O
7	of	O
8	therapy	O
9	is	O
10	to	O
11	diminish	O
12	the	O
13	chance	O
14	that	O
15	an	O
16	ulcer	O
17	will	O
18	continue	O
19	to	O
20	bleed	O
21	or	O
22	will	O
23	rebleed	O
24	.	O

1	Thirty	O
2	seven	O
3	patients	O
4	(	O
5	amitriptyline	O
6	n	O
7	=	O
8	16	O
9	,	O
10	moclobemide	O
11	n	O
12	=	O
13	21	O
14	)	O
15	completed	O
16	the	O
17	six	O
18	week	O
19	protocol	O
20	,	O
21	which	O
22	was	O
23	conducted	O
24	under	O
25	double	O
26	blind	O
27	conditions	O
28	.	O

1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O

1	Analysis	O
2	of	O
3	electrically	O
4	evoked	O
5	response	O
6	(	O
7	EER	O
8	)	O
9	in	O
10	relation	O
11	to	O
12	the	O
13	central	O
14	visual	O
15	pathway	O
16	of	O
17	the	O
18	cat	O
19	(	O
20	1	O
21	).	O

1	Furthermore	O
2	,	O
3	plasma	O
4	fibrinogen	B
5	levels	O
6	increased	O
7	by	O
8	a	O
9	mean	O
10	of	O
11	17	O
12	.	O
13	6	O
14	%,	O
15	a	O
16	potentially	O
17	adverse	O
18	effect	O
19	of	O
20	gemfibrozil	O
21	that	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	.	O

1	Gemfibrozil	O
2	in	O
3	hyperlipidaemic	O
4	patients	O
5	with	O
6	peripheral	O
7	arterial	O
8	disease	O
9	:	O
10	some	O
11	undiscovered	O
12	actions	O
13	.	O

1	An	O
2	RME1	B
3	-	O
4	independent	O
5	pathway	O
6	for	O
7	sporulation	O
8	control	O
9	in	O
10	Saccharomyces	O
11	cerevisiae	O
12	acts	O
13	through	O
14	IME1	B
15	transcript	I
16	accumulation	O
17	.	O

1	The	O
2	role	O
3	of	O
4	pharmacological	O
5	profiling	O
6	in	O
7	safety	O
8	assessment	O
9	.	O

1	Its	O
2	application	O
3	in	O
4	Madagascar	O
5	:	O
6	advantages	O
7	and	O
8	disadvantages	O

1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	B
12	avian	I
13	integrins	I
14	was	O
15	obtained	O
16	.	O

1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O

1	In	O
2	adulthood	O
3	these	O
4	rats	O
5	were	O
6	hyperactive	O
7	and	O
8	learned	O
9	the	O
10	active	O
11	avoidance	O
12	response	O
13	later	O
14	than	O
15	the	O
16	controls	O
17	.	O

1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	Spec	B
7	gene	I
8	activity	O
9	,	O
10	the	O
11	region	O
12	around	O
13	the	O
14	Spec1	B
15	transcriptional	I
16	initiation	I
17	site	I
18	was	O
19	analyzed	O
20	for	O
21	sites	O
22	of	O
23	protein	O
24	-	O
25	DNA	O
26	interaction	O
27	.	O

1	Phosphopeptide	O
2	mapping	O
3	revealed	O
4	the	O
5	same	O
6	autophosphorylation	O
7	sites	O
8	utilized	O
9	by	O
10	EGFR	B
11	-	I
12	IC	I
13	as	O
14	those	O
15	identified	O
16	in	O
17	wild	B
18	-	I
19	type	I
20	EGFR	I
21	.	O

1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O

1	The	O
2	TCF	B
3	-	I
4	1	I
5	alpha	I
6	binding	I
7	site	I
8	was	O
9	also	O
10	required	O
11	for	O
12	TCR	B
13	alpha	I
14	enhancer	I
15	activity	O
16	in	O
17	transcriptionally	O
18	active	O
19	extracts	O
20	from	O
21	Jurkat	O
22	but	O
23	not	O
24	HeLa	O
25	cells	O
26	,	O
27	confirming	O
28	that	O
29	TCF	B
30	-	I
31	1	I
32	alpha	I
33	is	O
34	a	O
35	T	B
36	-	I
37	cell	I
38	-	I
39	specific	I
40	transcription	I
41	factor	I
42	.	O

1	A	O
2	new	O
3	semi	O
4	-	O
5	automatic	O
6	method	O
7	for	O
8	quantifying	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	technetium	O
15	-	O
16	hexamethylpropylene	O
17	amine	O
18	oxime	O
19	(	O
20	99mTc	O
21	-	O
22	HMPAO	O
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	photon	O
30	emission	O
31	tomograms	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	Alzheimer	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	dementia	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	dementia	O
58	with	O
59	motor	O
60	neurone	O
61	disease	O
62	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	fog	O
6	,	O
7	up	O
8	to	O
9	a	O
10	level	O
11	of	O
12	base	O
13	plus	O
14	fog	O
15	of	O
16	0	O
17	.	O
18	6	O
19	optical	O
20	density	O
21	units	O
22	,	O
23	had	O
24	no	O
25	influence	O
26	on	O
27	the	O
28	diagnostic	O
29	accuracy	O
30	in	O
31	the	O
32	absence	O
33	of	O
34	any	O
35	compensation	O
36	.	O

1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O

1	In	O
2	this	O
3	model	O
4	,	O
5	eltoprazine	O
6	has	O
7	a	O
8	very	O
9	specific	O
10	anti	O
11	-	O
12	aggressive	O
13	(	O
14	serenic	O
15	)	O
16	profile	O
17	,	O
18	inhibiting	O
19	aggression	O
20	while	O
21	social	O
22	interaction	O
23	and	O
24	exploration	O
25	are	O
26	not	O
27	decreased	O
28	but	O
29	even	O
30	enhanced	O
31	;	O
32	inactivity	O
33	,	O
34	a	O
35	measure	O
36	for	O
37	sedation	O
38	,	O
39	is	O
40	not	O
41	affected	O
42	.	O

1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	in	O
7	vitro	O
8	transfer	O
9	of	O
10	delayed	O
11	hypersensitivity	O
12	by	O
13	dialysed	O
14	transfer	B
15	factor	I
16	.	O

1	Effect	O
2	of	O
3	separate	O
4	and	O
5	combined	O
6	effects	O
7	of	O
8	plutonium	O
9	-	O
10	239	O
11	,	O
12	hexachlorobutadiene	O
13	and	O
14	tributyl	O
15	phosphate	O
16	on	O
17	the	O
18	thymus	O
19	gland	O
20	of	O
21	rats	O

1	Data	O
2	collection	O
3	was	O
4	made	O
5	with	O
6	a	O
7	query	O
8	language	O
9	,	O
10	and	O
11	data	O
12	analysis	O
13	performed	O
14	with	O
15	an	O
16	interactive	O
17	knowledge	O
18	-	O
19	based	O
20	statistical	O
21	tool	O
22	,	O
23	MAXITAB	O
24	,	O
25	employing	O
26	a	O
27	multivariate	O
28	tabular	O
29	analysis	O
30	technique	O
31	.	O

1	ARPIA	O
2	has	O
3	been	O
4	implemented	O
5	by	O
6	using	O
7	a	O
8	relational	O
9	DBMS	O
10	,	O
11	very	O
12	cheap	O
13	and	O
14	highly	O
15	diffused	O
16	on	O
17	personal	O
18	computers	O
19	.	O

1	Diuresis	O
2	was	O
3	induced	O
4	by	O
5	scheduled	O
6	drinking	O
7	of	O
8	tea	O
9	(	O
10	150	O
11	ml	O
12	/	O
13	h	O
14	).	O

1	Diagnostic	O
2	value	O
3	of	O
4	adenosine	B
5	deaminase	I
6	activity	O
7	in	O
8	tuberculous	O
9	effusions	O
10	.	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Immuno	O
2	-	O
3	cytochemistry	O
4	,	O
5	using	O
6	antisera	O
7	against	O
8	Campylobacter	O
9	jejuni	O
10	,	O
11	showed	O
12	that	O
13	the	O
14	positive	O
15	staining	O
16	in	O
17	altered	O
18	epithelial	O
19	cells	O
20	were	O
21	restricted	O
22	to	O
23	intracellular	O
24	organisms	O
25	having	O
26	a	O
27	structure	O
28	resembling	O
29	Campylobacter	O
30	spp	O
31	.	O

1	Promoter	O
2	activities	O
3	were	O
4	estimated	O
5	using	O
6	beta	B
7	-	I
8	glucuronidase	I
9	and	O
10	neomycin	B
11	phosphotransferase	I
12	II	I
13	reporter	I
14	gene	I
15	systems	I
16	.	O

1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	B
9	actin	I
10	genes	I
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	O
25	-	O
26	rich	O
27	DNA	O
28	.	O

1	All	O
2	8	O
3	(	O
4	100	O
5	%)	O
6	patients	O
7	with	O
8	fulminant	O
9	hepatic	O
10	failure	O
11	who	O
12	received	O
13	grafts	O
14	survived	O
15	,	O
16	including	O
17	3	O
18	who	O
19	received	O
20	ABO	O
21	-	O
22	incompatible	O
23	grafts	O
24	,	O
25	though	O
26	2	O
27	of	O
28	these	O
29	subsequently	O
30	required	O
31	retransplantation	O
32	.	O

1	No	O
2	patient	O
3	had	O
4	a	O
5	history	O
6	of	O
7	excess	O
8	alcohol	O
9	intake	O
10	,	O
11	or	O
12	prolonged	O
13	intake	O
14	of	O
15	hepatotoxic	O
16	drugs	O
17	and	O
18	steroids	O
19	,	O
20	and	O
21	were	O
22	not	O
23	obese	O
24	or	O
25	malnourished	O
26	.	O

1	An	O
2	evolutionary	O
3	comparison	O
4	of	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	34	O
10	HSP70	B
11	proteins	I
12	from	O
13	17	O
14	species	O
15	suggests	O
16	that	O
17	BiP	B
18	genes	I
19	share	O
20	a	O
21	common	O
22	ancestor	O
23	,	O
24	which	O
25	diverged	O
26	from	O
27	other	O
28	HSP70	B
29	genes	I
30	near	O
31	the	O
32	time	O
33	when	O
34	eukaryotes	O
35	first	O
36	appeared	O
37	.	O

1	Spore	O
2	inocula	O
3	(	O
4	approximately	O
5	10	O
6	(	O
7	6	O
8	)/	O
9	coupon	O
10	)	O
11	were	O
12	dried	O
13	onto	O
14	0	O
15	.	O
16	5	O
17	-	O
18	in	O
19	.	O

1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	B
8	and	O
9	STE18	B
10	proteins	I
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	B
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	B
32	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	was	O
6	then	O
7	used	O
8	to	O
9	clone	O
10	from	O
11	human	O
12	poly	O
13	(	O
14	A	O
15	)+	O
16	RNA	O
17	the	O
18	cDNA	O
19	corresponding	O
20	to	O
21	the	O
22	expressed	O
23	homolog	O
24	of	O
25	psi	B
26	ARF	I
27	4	I
28	,	O
29	referred	O
30	to	O
31	as	O
32	human	B
33	ARF	I
34	4	I
35	.	O

1	To	O
2	evaluate	O
3	the	O
4	cost	O
5	and	O
6	benefits	O
7	of	O
8	screening	O
9	tests	O
10	for	O
11	Chlamydia	O
12	trachomatis	O
13	in	O
14	adolescent	O
15	males	O
16	,	O
17	we	O
18	developed	O
19	a	O
20	decision	O
21	analysis	O
22	model	O
23	and	O
24	compared	O
25	the	O
26	leukocyte	B
27	esterase	I
28	urine	O
29	dipstick	O
30	test	O
31	with	O
32	culture	O
33	,	O
34	with	O
35	direct	O
36	-	O
37	smear	O
38	fluorescent	O
39	antibody	O
40	(	O
41	DFA	O
42	),	O
43	and	O
44	with	O
45	the	O
46	option	O
47	of	O
48	no	O
49	screening	O
50	(	O
51	no	O
52	treatment	O
53	).	O

1	Sequencing	O
2	the	O
3	gene	O
4	for	O
5	an	O
6	imipenem	O
7	-	O
8	cefoxitin	O
9	-	O
10	hydrolyzing	O
11	enzyme	O
12	(	O
13	CfiA	B
14	)	O
15	from	O
16	Bacteroides	O
17	fragilis	O
18	TAL2480	O
19	reveals	O
20	strong	O
21	similarity	O
22	between	O
23	CfiA	B
24	and	O
25	Bacillus	B
26	cereus	I
27	beta	I
28	-	I
29	lactamase	I
30	II	I
31	.	O

1	The	O
2	cloned	O
3	HindIII	B
4	fragment	I
5	,	O
6	which	O
7	was	O
8	shown	O
9	by	O
10	DNA	O
11	sequence	O
12	analysis	O
13	to	O
14	encode	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	half	O
20	of	O
21	the	O
22	B	B
23	.	I
24	subtilis	I
25	IF2	I
26	protein	I
27	and	O
28	0	O
29	.	O
30	2	O
31	kb	O
32	of	O
33	upstream	O
34	flanking	O
35	sequence	O
36	,	O
37	was	O
38	utilized	O
39	as	O
40	a	O
41	homologous	O
42	probe	O
43	to	O
44	clone	O
45	an	O
46	overlapping	O
47	2	B
48	.	I
49	76	I
50	-	I
51	kb	I
52	ClaI	I
53	chromosomal	I
54	fragment	I
55	containing	O
56	the	O
57	entire	B
58	IF2	I
59	structural	I
60	gene	I
61	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	115	O
6	amino	O
7	acids	O
8	correspond	O
9	to	O
10	a	O
11	putative	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	and	O
17	show	O
18	significant	O
19	sequence	O
20	similarity	O
21	with	O
22	other	O
23	cloned	O
24	IFN	B
25	response	I
26	factors	I
27	(	O
28	IRF	B
29	-	I
30	1	I
31	and	O
32	IRF	B
33	-	I
34	2	I
35	).	O

1	Maternal	O
2	seizures	O
3	had	O
4	occurred	O
5	during	O
6	pregnancy	O
7	in	O
8	52	O
9	per	O
10	cent	O
11	.	O

1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	B
15	factor	I
16	Sp1	I
17	.	O

1	Krox	B
2	-	I
3	24	I
4	is	O
5	therefore	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcriptional	O
11	activator	O
12	.	O

1	The	O
2	interindividual	O
3	variability	O
4	of	O
5	the	O
6	parameters	O
7	is	O
8	taken	O
9	into	O
10	consideration	O
11	by	O
12	interactively	O
13	determining	O
14	the	O
15	threshold	O
16	levels	O
17	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	3	O
7	subgroups	O
8	:	O
9	1	O
10	)	O
11	13	O
12	N	O
13	+	O
14	patients	O
15	with	O
16	multiple	O
17	hot	O
18	spots	O
19	(	O
20	greater	O
21	than	O
22	2	O
23	)	O
24	(	O
25	N	O
26	+	O
27	IM	O
28	);	O
29	2	O
30	)	O
31	24	O
32	N	O
33	+	O
34	patients	O
35	with	O
36	single	O
37	hot	O
38	spots	O
39	(	O
40	less	O
41	than	O
42	or	O
43	equal	O
44	to	O
45	2	O
46	)	O
47	(	O
48	N	O
49	+	O
50	IS	O
51	);	O
52	3	O
53	)	O
54	12	O
55	N	O
56	-	O
57	patients	O
58	with	O
59	single	O
60	hot	O
61	spots	O
62	(	O
63	less	O
64	than	O
65	or	O
66	equal	O
67	to	O
68	2	O
69	)	O
70	(	O
71	N	O
72	-	O
73	IS	O
74	).	O

1	Inspired	O
2	CO2	O
3	causing	O
4	changes	O
5	from	O
6	hypo	O
7	-	O
8	to	O
9	normocapnia	O
10	has	O
11	previously	O
12	been	O
13	shown	O
14	to	O
15	improve	O
16	arterial	O
17	O2	O
18	tension	O
19	(	O
20	PaO2	O
21	)	O
22	and	O
23	to	O
24	reduce	O
25	alveolar	O
26	-	O
27	arterial	O
28	O2	O
29	difference	O
30	.	O

1	Expression	O
2	,	O
3	nucleotide	O
4	sequence	O
5	and	O
6	mutational	O
7	analysis	O
8	of	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	in	O
14	the	O
15	nif	B
16	gene	I
17	region	I
18	of	I
19	Anabaena	I
20	sp	I
21	.	I
22	strain	I
23	PCC7120	I
24	.	O

1	Further	O
2	,	O
3	they	O
4	are	O
5	consistent	O
6	with	O
7	the	O
8	suggestion	O
9	that	O
10	sites	O
11	homologous	O
12	to	O
13	the	O
14	CAR1	B
15	URS	I
16	may	O
17	be	O
18	situated	O
19	in	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	regions	O
25	of	O
26	multiple	O
27	unrelated	O
28	yeast	O
29	genes	O
30	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	a	O
6	sequence	O
7	match	O
8	between	O
9	enhancers	O
10	and	O
11	certain	O
12	promoter	O
13	elements	O
14	is	O
15	critical	O
16	.	O

1	This	O
2	Mr	O
3	is	O
4	similar	O
5	to	O
6	those	O
7	of	O
8	the	O
9	purified	B
10	smg	I
11	p25A	I
12	GDI	I
13	estimated	O
14	by	O
15	sodium	O
16	dodecyl	O
17	sulfate	O
18	-	O
19	polyacrylamide	O
20	gel	O
21	electrophoresis	O
22	and	O
23	sucrose	O
24	density	O
25	gradient	O
26	ultracentrifugation	O
27	,	O
28	which	O
29	are	O
30	about	O
31	54	O
32	,	O
33	000	O
34	and	O
35	65	O
36	,	O
37	000	O
38	,	O
39	respectively	O
40	.	O

1	Yeast	O
2	mutants	O
3	assigned	O
4	to	O
5	the	O
6	pet	B
7	complementation	O
8	group	O
9	G104	O
10	were	O
11	found	O
12	to	O
13	lack	O
14	alpha	B
15	-	I
16	ketoglutarate	I
17	dehydrogenase	I
18	activity	O
19	as	O
20	a	O
21	result	O
22	of	O
23	mutations	O
24	in	O
25	the	O
26	dihydrolipoyl	B
27	transsuccinylase	I
28	(	O
29	KE2	B
30	)	O
31	component	O
32	of	O
33	the	O
34	complex	O
35	.	O

1	Critical	O
2	residues	O
3	required	O
4	for	O
5	repression	O
6	are	O
7	located	O
8	within	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	27	O
14	amino	O
15	acids	O
16	of	O
17	c	B
18	-	I
19	Fos	I
20	,	O
21	since	O
22	v	B
23	-	I
24	Fos	I
25	and	O
26	C	O
27	-	O
28	terminal	O
29	truncations	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	did	O
35	not	O
36	down	O
37	regulate	O
38	.	O

1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	B
6	lambda	I
7	pseudogene	I
8	,	O
9	called	O
10	psi	B
11	V	I
12	lambda	I
13	1	I
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	B
21	lambda	I
22	gene	I
23	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	have	O
7	analyzed	O
8	the	O
9	structure	O
10	of	O
11	human	O
12	gene	O
13	for	O
14	Gx	B
15	alpha	I
16	,	O
17	which	O
18	spans	O
19	more	O
20	than	O
21	60	O
22	kilobases	O
23	.	O

1	A	O
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	O
20	type	O
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	O
27	antigen	O
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	B
35	specific	I
36	IgE	I
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	O
57	antigen	O
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	B
72	specific	I
73	IgG	I
74	.	O

1	But	O
2	no	O
3	influence	O
4	was	O
5	observed	O
6	at	O
7	lower	O
8	concentrations	O
9	than	O
10	1	O
11	/	O
12	4	O
13	MIC	O
14	of	O
15	AMK	O
16	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	B
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	O
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	Furthermore	O
2	,	O
3	we	O
4	notice	O
5	two	O
6	potential	O
7	consensus	O
8	motifs	O
9	which	O
10	are	O
11	also	O
12	found	O
13	in	O
14	corresponding	O
15	positions	O
16	in	O
17	the	O
18	genes	O
19	for	O
20	the	O
21	nerve	B
22	growth	I
23	factor	I
24	receptor	I
25	and	O
26	the	O
27	68	B
28	-	I
29	kDa	I
30	neurofilament	I
31	protein	I
32	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	-	O
6	119	O
7	to	O
8	-	O
9	81	O
10	fragment	O
11	of	O
12	the	O
13	CCK	B
14	promoter	I
15	contains	O
16	a	O
17	transcriptional	O
18	enhancer	O
19	that	O
20	potentiates	O
21	the	O
22	transcription	O
23	from	O
24	the	O
25	herpes	O
26	simplex	O
27	virus	O
28	thymidine	B
29	kinase	I
30	promoter	I
31	in	O
32	a	O
33	position	O
34	-	O
35	and	O
36	orientation	O
37	-	O
38	independent	O
39	manner	O
40	.	O

1	Thirty	O
2	minutes	O
3	of	O
4	supine	O
5	restraint	O
6	decreased	O
7	DOPAC	O
8	concentrations	O
9	in	O
10	the	O
11	median	O
12	eminence	O
13	of	O
14	female	O
15	rats	O
16	that	O
17	were	O
18	not	O
19	exposed	O
20	to	O
21	ether	O
22	,	O
23	and	O
24	brief	O
25	exposure	O
26	to	O
27	ether	O
28	enhanced	O
29	this	O
30	effect	O
31	.	O

1	Influence	O
2	of	O
3	metoprolol	O
4	treatment	O
5	on	O
6	sympatho	O
7	-	O
8	adrenal	O
9	activation	O
10	of	O
11	fibrinolysis	O
12	.	O

1	Five	O
2	of	O
3	10	O
4	scars	O
5	studied	O
6	decreased	O
7	at	O
8	least	O
9	50	O
10	%	O
11	in	O
12	linear	O
13	dimensions	O
14	.	O

1	Managing	O
2	dysphagia	O
3	in	O
4	a	O
5	chronic	O
6	care	O
7	setting	O
8	:	O
9	an	O
10	introduction	O
11	.	O

1	Gel	O
2	-	O
3	mobility	O
4	-	O
5	shift	O
6	assays	O
7	confirmed	O
8	that	O
9	the	O
10	Raji	O
11	nuclear	O
12	proteins	O
13	that	O
14	bound	O
15	to	O
16	W	O
17	and	O
18	V	O
19	elements	O
20	were	O
21	competed	O
22	with	O
23	by	O
24	an	O
25	HLA	B
26	-	I
27	DRA	I
28	X	I
29	-	I
30	box	I
31	oligonucleotide	I
32	.	O

1	In	O
2	Denmark	O
3	only	O
4	1	O
5	-	O
6	3	O
7	cases	O
8	of	O
9	transfusion	O
10	-	O
11	associated	O
12	hepatitis	O
13	NANB	O
14	(	O
15	TAH	O
16	-	O
17	NANB	O
18	)	O
19	are	O
20	registered	O
21	annually	O
22	or	O
23	about	O
24	1	O
25	case	O
26	per	O
27	100	O
28	,	O
29	000	O
30	units	O
31	transfused	O
32	.	O

1	The	O
2	NF1	B
3	locus	I
4	encodes	O
5	a	O
6	protein	O
7	functionally	O
8	related	O
9	to	O
10	mammalian	B
11	GAP	I
12	and	O
13	yeast	B
14	IRA	I
15	proteins	I
16	.	O

1	Hence	O
2	,	O
3	the	O
4	replacement	O
5	of	O
6	Phe	O
7	-	O
8	62	O
9	with	O
10	Ser	O
11	specifically	O
12	affects	O
13	a	O
14	determinant	O
15	on	O
16	the	O
17	lambda	B
18	I	I
19	light	I
20	chain	I
21	that	O
22	is	O
23	necessary	O
24	for	O
25	the	O
26	intracellular	O
27	transport	O
28	of	O
29	this	O
30	molecule	O
31	.	O

1	A	O
2	second	O
3	isotype	O
4	of	O
5	Raja	B
6	immunoglobulin	I
7	heavy	I
8	chain	I
9	genes	I
10	has	O
11	been	O
12	detected	O
13	by	O
14	screening	O
15	a	O
16	spleen	O
17	cDNA	O
18	library	O
19	with	O
20	homologous	O
21	Raja	B
22	VH	I
23	-	O
24	and	O
25	CH1	B
26	-	O
27	specific	O
28	probes	O
29	complementing	O
30	the	O
31	respective	O
32	regions	O
33	of	O
34	the	O
35	mu	B
36	-	I
37	like	I
38	isotype	I
39	.	O

1	Petko	O
2	,	O
3	and	O
4	S	O
5	.	O

1	Disruption	O
2	of	O
3	ARF2	B
4	causes	O
5	no	O
6	detectable	O
7	phenotype	O
8	.	O

1	Human	O
2	recombinant	O
3	DNA	O
4	-	O
5	derived	O
6	antihemophilic	B
7	factor	I
8	(	O
9	factor	B
10	VIII	I
11	)	O
12	in	O
13	the	O
14	treatment	O
15	of	O
16	hemophilia	O
17	A	O
18	.	O
19	recombinant	O
20	Factor	B
21	VIII	I
22	Study	O
23	Group	O
24	.	O

1	Like	O
2	other	O
3	members	O
4	of	O
5	this	O
6	family	O
7	,	O
8	the	O
9	AP	B
10	-	I
11	4	I
12	HLH	O
13	motif	O
14	and	O
15	the	O
16	adjacent	O
17	basic	O
18	domain	O
19	are	O
20	necessary	O
21	and	O
22	sufficient	O
23	to	O
24	confer	O
25	site	O
26	-	O
27	specific	O
28	DNA	O
29	binding	O
30	.	O

1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	O
8	embryonic	O
9	Drosophila	O
10	melanogaster	O
11	cells	O
12	that	O
13	lack	O
14	MyoD1	B
15	and	O
16	Sp1	B
17	is	O
18	strictly	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	exogenously	O
32	supplied	O
33	Sp1	B
34	and	O
35	MyoD1	B
36	.	O

1	Effects	O
2	of	O
3	a	O
4	selective	O
5	monoamine	B
6	oxidase	I
7	(	I
8	MAO	I
9	)--	I
10	A	I
11	inhibitor	O
12	,	O
13	clorgyline	O
14	,	O
15	a	O
16	selective	O
17	MAO	B
18	-	I
19	B	I
20	inhibitor	O
21	,	O
22	deprenyl	O
23	,	O
24	and	O
25	a	O
26	non	O
27	-	O
28	selective	O
29	MAO	B
30	inhibitor	O
31	,	O
32	nialamide	O
33	,	O
34	were	O
35	investigated	O
36	on	O
37	footshock	O
38	-	O
39	induced	O
40	aggression	O
41	(	O
42	FIA	O
43	)	O
44	in	O
45	paired	O
46	rats	O
47	.	O

1	To	O
2	identify	O
3	structural	O
4	features	O
5	of	O
6	residues	O
7	flanking	O
8	the	O
9	c	O
10	-	O
11	region	O
12	that	O
13	influence	O
14	the	O
15	fidelity	O
16	and	O
17	efficiency	O
18	of	O
19	signal	O
20	peptidase	O
21	cleavage	O
22	as	O
23	well	O
24	as	O
25	co	O
26	-	O
27	translational	O
28	translocation	O
29	,	O
30	we	O
31	introduced	O
32	six	O
33	amino	O
34	acid	O
35	substitutions	O
36	into	O
37	the	O
38	COOH	O
39	terminus	O
40	of	O
41	the	O
42	hydrophobic	O
43	core	O
44	and	O
45	seven	O
46	substitutions	O
47	at	O
48	the	O
49	NH2	O
50	terminus	O
51	of	O
52	the	O
53	mature	O
54	region	O
55	(	O
56	the	O
57	+	O
58	1	O
59	position	O
60	)	O
61	of	O
62	a	O
63	model	O
64	eukaryotic	B
65	preprotein	I
66	-	I
67	human	I
68	pre	I
69	(	I
70	delta	I
71	pro	I
72	)	I
73	apoA	I
74	-	I
75	II	I
76	.	O

1	Additionally	O
2	,	O
3	although	O
4	c	B
5	-	I
6	fos	I
7	and	O
8	egr	B
9	-	I
10	1	I
11	mRNAs	I
12	are	O
13	expressed	O
14	at	O
15	elevated	O
16	levels	O
17	in	O
18	stimulated	O
19	liver	O
20	cells	O
21	,	O
22	fos	B
23	-	I
24	B	I
25	,	O
26	fra	B
27	-	I
28	1	I
29	,	O
30	and	O
31	egr	B
32	-	I
33	2	I
34	are	O
35	not	O
36	,	O
37	which	O
38	suggests	O
39	that	O
40	factors	O
41	in	O
42	addition	O
43	to	O
44	the	O
45	serum	B
46	response	I
47	factor	I
48	participate	O
49	in	O
50	the	O
51	regulation	O
52	of	O
53	immediate	B
54	-	I
55	early	I
56	gene	I
57	induction	O
58	.	O

1	Of	O
2	848	O
3	patients	O
4	,	O
5	819	O
6	cases	O
7	with	O
8	complete	O
9	description	O
10	of	O
11	patient	O
12	'	O
13	s	O
14	background	O
15	were	O
16	evaluable	O
17	:	O
18	Group	O
19	A	O
20	(	O
21	surgery	O
22	+	O
23	MMC	O
24	+	O
25	5	O
26	-	O
27	FU	O
28	:	O
29	chemotherapy	O
30	)	O
31	253	O
32	cases	O
33	,	O
34	group	O
35	B	O
36	(	O
37	surgery	O
38	+	O
39	MMC	O
40	+	O
41	5	O
42	-	O
43	FU	O
44	+	O
45	OK	O
46	-	O
47	432	O
48	or	O
49	PSK	O
50	:	O
51	immunochemotherapy	O
52	)	O
53	282	O
54	and	O
55	group	O
56	C	O
57	(	O
58	surgery	O
59	alone	O
60	)	O
61	284	O
62	.	O

1	The	O
2	nuclear	O
3	proteins	O
4	encoded	O
5	by	O
6	the	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	c	B
12	-	I
13	jun	I
14	protooncogenes	I
15	are	O
16	expressed	O
17	during	O
18	the	O
19	proliferation	O
20	period	O
21	of	O
22	osteoblast	O
23	phenotype	O
24	development	O
25	.	O

1	This	O
2	model	O
3	is	O
4	further	O
5	supported	O
6	by	O
7	binding	O
8	of	O
9	the	O
10	Fos	B
11	-	O
12	Jun	B
13	complex	O
14	at	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	in	O
21	the	O
22	type	B
23	alpha	I
24	I	I
25	collagen	I
26	promoter	I
27	that	O
28	is	O
29	contiguous	O
30	with	O
31	,	O
32	but	O
33	not	O
34	overlapping	O
35	,	O
36	the	O
37	VDRE	O
38	.	O

1	PBSX	B
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	O
10	response	O
11	.	O

1	A	O
2	bacteriological	O
3	relapse	O
4	requiring	O
5	treatment	O
6	occurred	O
7	by	O
8	5	O
9	years	O
10	in	O
11	16	O
12	.	O
13	8	O
14	%	O
15	of	O
16	113	O
17	R3	O
18	,	O
19	5	O
20	.	O
21	2	O
22	%	O
23	of	O
24	97	O
25	R5	O
26	,	O
27	and	O
28	20	O
29	.	O
30	0	O
31	%	O
32	of	O
33	115	O
34	Z5	O
35	patients	O
36	with	O
37	organisms	O
38	sensitive	O
39	to	O
40	streptomycin	O
41	and	O
42	isoniazid	O
43	initially	O
44	.	O

1	In	O
2	the	O
3	controls	O
4	,	O
5	it	O
6	was	O
7	found	O
8	that	O
9	all	O
10	right	O
11	-	O
12	handed	O
13	and	O
14	10	O
15	out	O
16	of	O
17	14	O
18	left	O
19	-	O
20	handed	O
21	control	O
22	subjects	O
23	showed	O
24	a	O
25	right	O
26	VHF	O
27	(	O
28	i	O
29	.	O
30	e	O
31	.,	O
32	left	O
33	hemisphere	O
34	)	O
35	advantage	O
36	.	O

1	Although	O
2	no	O
3	Rh	B
4	-	I
5	antibodies	I
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	B
16	alga	I
17	Scenedemus	I
18	obliquus	I
19	plastocyanin	I
20	.	O

1	Higher	O
2	fasting	O
3	serum	O
4	gastrin	B
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	O
16	.	O
17	3	O
18	+/-	O
19	8	O
20	.	O
21	3	O
22	ng	O
23	.	O
24	l	O
25	-	O
26	1	O
27	),	O
28	and	O
29	greater	O
30	postprandial	O
31	gastrin	B
32	release	O
33	(	O
34	AUC0	O
35	-	O
36	120	O
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	O
63	.	O

1	The	O
2	experimental	O
3	group	O
4	consisted	O
5	of	O
6	61	O
7	examinees	O
8	class	O
9	II	O
10	/	O
11	2	O
12	orthodontic	O
13	anomalies	O
14	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	clarify	O
7	the	O
8	location	O
9	of	O
10	a	O
11	transesophageal	O
12	echocardiographic	O
13	(	O
14	TEE	O
15	)	O
16	transducer	O
17	when	O
18	obtaining	O
19	the	O
20	short	O
21	-	O
22	axis	O
23	view	O
24	of	O
25	the	O
26	left	O
27	ventricle	O
28	(	O
29	S	O
30	-	O
31	LV	O
32	).	O

1	Subjects	O
2	were	O
3	16	O
4	male	O
5	chronic	O
6	schizophrenics	O
7	consisting	O
8	of	O
9	8	O
10	DST	O
11	suppressors	O
12	and	O
13	8	O
14	nonsuppressors	O
15	.	O

1	From	O
2	S3	O
3	(	O
4	CBF	O
5	:	O
6	79	O
7	-	O
8	60	O
9	%)	O
10	to	O
11	S5	O
12	(	O
13	CBF	O
14	:	O
15	39	O
16	-	O
17	0	O
18	%),	O
19	%	O
20	WTh	O
21	,	O
22	1	O
23	/	O
24	TPC	O
25	and	O
26	1	O
27	/	O
28	T	O
29	were	O
30	significantly	O
31	decreased	O
32	from	O
33	those	O
34	of	O
35	the	O
36	control	O
37	levels	O
38	(	O
39	all	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	01	O
46	).	O

1	In	O
2	this	O
3	article	O
4	we	O
5	propose	O
6	to	O
7	find	O
8	out	O
9	the	O
10	percentage	O
11	of	O
12	normal	O
13	occlusion	O
14	and	O
15	the	O
16	distribution	O
17	of	O
18	maloclusions	O
19	,	O
20	according	O
21	to	O
22	the	O
23	anteroposterior	O
24	relationship	O
25	between	O
26	the	O
27	dental	O
28	archs	O
29	(	O
30	following	O
31	the	O
32	ANGLE3	O
33	classification	O
34	).	O

1	In	O
2	that	O
3	case	O
4	,	O
5	the	O
6	ratio	O
7	of	O
8	brush	O
9	abrasion	O
10	was	O
11	0	O
12	.	O
13	268	O
14	,	O
15	compressive	O
16	and	O
17	transverse	O
18	strength	O
19	,	O
20	124	O
21	.	O
22	3	O
23	and	O
24	86	O
25	.	O
26	3	O
27	MPa	O
28	respectively	O
29	,	O
30	hardness	O
31	,	O
32	43	O
33	.	O
34	2	O
35	Hk	O
36	,	O
37	water	O
38	absorption	O
39	14	O
40	.	O
41	2	O
42	micrograms	O
43	/	O
44	mm3	O
45	and	O
46	thermal	O
47	expansion	O
48	coefficient	O
49	,	O
50	47	O
51	.	O
52	4	O
53	x	O
54	10	O
55	(-	O
56	6	O
57	)/	O
58	degrees	O
59	C	O
60	.	O

1	9	O
2	,	O
3	1498	O
4	-	O
5	1506	O
6	).	O

1	In	O
2	a	O
3	highly	O
4	select	O
5	group	O
6	of	O
7	stable	O
8	hypertensive	O
9	patients	O
10	,	O
11	we	O
12	have	O
13	assessed	O
14	the	O
15	strength	O
16	of	O
17	association	O
18	between	O
19	various	O
20	blood	O
21	pressure	O
22	measurements	O
23	(	O
24	24	O
25	h	O
26	average	O
27	automated	O
28	ambulatory	O
29	blood	O
30	pressure	O
31	,	O
32	4	O
33	h	O
34	automated	O
35	ambulatory	O
36	morning	O
37	average	O
38	blood	O
39	pressure	O
40	,	O
41	multiple	O
42	office	O
43	visit	O
44	average	O
45	blood	O
46	pressure	O
47	,	O
48	and	O
49	a	O
50	single	O
51	office	O
52	visit	O
53	average	O
54	blood	O
55	pressure	O
56	)	O
57	and	O
58	various	O
59	echocardiographic	O
60	indices	O
61	of	O
62	hypertensive	O
63	cardiac	O
64	target	O
65	organ	O
66	damage	O
67	(	O
68	left	O
69	atrial	O
70	diameter	O
71	,	O
72	left	O
73	ventricular	O
74	end	O
75	diastolic	O
76	diameter	O
77	,	O
78	posterior	O
79	wall	O
80	thickness	O
81	,	O
82	combined	O
83	wall	O
84	thickness	O
85	,	O
86	relative	O
87	wall	O
88	thickness	O
89	,	O
90	left	O
91	ventricular	O
92	mass	O
93	and	O
94	mass	O
95	index	O
96	,	O
97	and	O
98	combined	O
99	wall	O
100	thickness	O
101	/	O
102	left	O
103	ventricular	O
104	diastolic	O
105	diameter	O
106	ratio	O
107	).	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	,	O
6	by	O
7	screening	O
8	a	O
9	lambda	O
10	gt11	O
11	expression	O
12	library	O
13	,	O
14	murine	B
15	protein	I
16	mXBP	I
17	,	O
18	which	O
19	binds	O
20	to	O
21	a	O
22	sequence	O
23	which	O
24	overlaps	O
25	the	O
26	3	O
27	'	O
28	end	O
29	of	O
30	the	O
31	murine	B
32	class	I
33	II	I
34	major	I
35	histocompatibility	I
36	complex	I
37	A	I
38	alpha	I
39	gene	I
40	X	I
41	box	I
42	,	O
43	a	O
44	conserved	O
45	transcription	O
46	element	O
47	found	O
48	upstream	O
49	of	O
50	all	O
51	class	O
52	II	O
53	genes	O
54	.	O

1	The	O
2	p36	B
3	gene	I
4	is	O
5	at	O
6	least	O
7	22	O
8	kb	O
9	in	O
10	length	O
11	and	O
12	has	O
13	a	O
14	coding	O
15	sequence	O
16	of	O
17	approximately	O
18	1	O
19	kb	O
20	,	O
21	representing	O
22	only	O
23	4	O
24	.	O
25	5	O
26	%	O
27	of	O
28	the	O
29	gene	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	This	O
2	multimodality	O
3	treatment	O
4	for	O
5	locally	O
6	advanced	O
7	gynecologic	O
8	tumors	O
9	appears	O
10	feasible	O
11	with	O
12	modification	O
13	,	O
14	and	O
15	continued	O
16	work	O
17	exploring	O
18	this	O
19	approach	O
20	is	O
21	encouraged	O
22	.	O

1	A	O
2	contiguous	O
3	and	O
4	sequentially	O
5	occupied	O
6	secondary	O
7	Fur	B
8	-	I
9	binding	I
10	site	I
11	in	O
12	entC	B
13	was	O
14	protected	O
15	at	O
16	higher	O
17	Fur	B
18	concentrations	O
19	,	O
20	extending	O
21	the	O
22	protected	O
23	region	O
24	to	O
25	+	O
26	49	O
27	,	O
28	and	O
29	sequestering	O
30	the	O
31	putative	O
32	Shine	O
33	-	O
34	Dalgarno	O
35	sequence	O
36	.	O

1	The	O
2	major	O
3	promoter	O
4	responds	O
5	strongly	O
6	to	O
7	virus	O
8	-	O
9	encoded	O
10	trans	O
11	activators	O
12	EIA	B
13	and	O
14	EIV	B
15	and	O
16	contains	O
17	four	O
18	elements	O
19	:	O
20	a	O
21	TAGA	O
22	motif	O
23	analogous	O
24	to	O
25	the	O
26	TATA	O
27	box	O
28	,	O
29	two	O
30	EIIF	B
31	sites	I
32	present	O
33	in	O
34	an	O
35	inverted	O
36	orientation	O
37	,	O
38	and	O
39	an	O
40	ATF	B
41	/	O
42	CREB	B
43	site	O
44	.	O

1	With	O
2	the	O
3	modified	O
4	fingertip	O
5	-	O
6	to	O
7	-	O
8	floor	O
9	(	O
10	MFTF	O
11	)	O
12	method	O
13	,	O
14	patients	O
15	stand	O
16	on	O
17	a	O
18	stool	O
19	and	O
20	forward	O
21	bend	O
22	so	O
23	that	O
24	measurements	O
25	can	O
26	be	O
27	taken	O
28	on	O
29	patients	O
30	who	O
31	are	O
32	able	O
33	to	O
34	touch	O
35	the	O
36	floor	O
37	or	O
38	reach	O
39	beyond	O
40	the	O
41	level	O
42	of	O
43	the	O
44	floor	O
45	.	O

1	No	O
2	significant	O
3	differences	O
4	could	O
5	be	O
6	seen	O
7	in	O
8	response	O
9	rates	O
10	according	O
11	to	O
12	the	O
13	concentration	O
14	of	O
15	estrogen	B
16	receptors	I
17	or	O
18	presence	O
19	of	O
20	progesteron	B
21	receptors	I
22	in	O
23	this	O
24	group	O
25	of	O
26	patients	O
27	.	O

1	Teicoplanin	O
2	was	O
3	given	O
4	most	O
5	often	O
6	because	O
7	of	O
8	persistent	O
9	fever	O
10	or	O
11	initial	O
12	Gram	O
13	-	O
14	positive	O
15	bacteraemia	O
16	and	O
17	only	O
18	one	O
19	-	O
20	third	O
21	of	O
22	these	O
23	cases	O
24	responded	O
25	.	O

1	Luteinizing	B
2	hormone	I
3	-	I
4	releasing	I
5	hormone	I
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	O
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O

1	In	O
2	Experiments	O
3	1	O
4	and	O
5	2	O
6	,	O
7	infants	O
8	,	O
9	like	O
10	adults	O
11	,	O
12	initially	O
13	categorized	O
14	novel	O
15	objects	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	physical	O
21	appearance	O
22	,	O
23	but	O
24	only	O
25	if	O
26	trained	O
27	with	O
28	multiple	O
29	exemplars	O
30	,	O
31	after	O
32	delays	O
33	of	O
34	1	O
35	and	O
36	7	O
37	days	O
38	.	O

1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O

1	Although	O
2	there	O
3	are	O
4	no	O
5	octamer	O
6	elements	O
7	in	O
8	the	O
9	adenovirus	O
10	genome	O
11	that	O
12	are	O
13	known	O
14	to	O
15	be	O
16	important	O
17	for	O
18	transcription	O
19	,	O
20	there	O
21	are	O
22	octamer	O
23	elements	O
24	in	O
25	the	O
26	viral	O
27	terminal	O
28	repeat	O
29	sequences	O
30	.	O

1	In	O
2	comparison	O
3	with	O
4	the	O
5	16	O
6	introns	O
7	reported	O
8	in	O
9	AHA3	B
10	,	O
11	AHA2	B
12	is	O
13	missing	O
14	one	O
15	intron	O
16	in	O
17	the	O
18	5	O
19	'-	O
20	untranslated	O
21	region	O
22	and	O
23	a	O
24	second	O
25	intron	O
26	in	O
27	the	O
28	C	O
29	-	O
30	terminal	O
31	coding	O
32	region	O
33	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	indicates	O
5	that	O
6	AHA2	B
7	mRNA	I
8	relative	O
9	to	O
10	total	O
11	cellular	O
12	RNA	O
13	is	O
14	expressed	O
15	at	O
16	significantly	O
17	higher	O
18	levels	O
19	in	O
20	root	O
21	tissue	O
22	as	O
23	compared	O
24	with	O
25	shoot	O
26	tissue	O
27	.	O

1	Impaction	O
2	of	O
3	gastrostomy	O
4	tube	O
5	in	O
6	the	O
7	abdominal	O
8	wall	O
9	.	O

1	Both	O
2	antidepressants	O
3	elevated	O
4	the	O
5	pain	O
6	threshold	O
7	acutely	O
8	,	O
9	while	O
10	pretreatment	O
11	with	O
12	pCPA	O
13	largely	O
14	blocked	O
15	the	O
16	analgesia	O
17	.	O

1	Sci	O
2	.	O

1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O

1	TCR	B
2	alpha	I
3	and	I
4	beta	I
5	gene	I
6	expression	O
7	may	O
8	be	O
9	regulated	O
10	by	O
11	a	O
12	common	O
13	set	O
14	of	O
15	T	B
16	-	I
17	cell	I
18	nuclear	I
19	proteins	I
20	in	O
21	that	O
22	the	O
23	T	B
24	beta	I
25	2	I
26	element	I
27	binding	O
28	a	O
29	set	O
30	of	O
31	cyclic	B
32	AMP	I
33	response	I
34	element	I
35	-	I
36	binding	I
37	proteins	I
38	that	O
39	are	O
40	also	O
41	bound	O
42	by	O
43	the	O
44	T	B
45	alpha	I
46	1	I
47	element	I
48	of	O
49	the	O
50	human	O
51	TCR	B
52	alpha	I
53	enhancer	O
54	and	O
55	the	O
56	decamer	O
57	element	O
58	present	O
59	in	O
60	a	O
61	large	O
62	number	O
63	of	O
64	human	O
65	and	O
66	murine	O
67	TCR	B
68	beta	I
69	promoters	O
70	.	O

1	The	O
2	3	O
3	'	O
4	stem	O
5	-	O
6	loop	O
7	is	O
8	highly	O
9	divergent	O
10	in	O
11	structure	O
12	among	O
13	species	O
14	and	O
15	lies	O
16	immediately	O
17	upstream	O
18	of	O
19	the	O
20	binding	O
21	site	O
22	for	O
23	Sm	B
24	proteins	I
25	.	O

1	The	O
2	deleted	O
3	nucleotide	O
4	sequence	O
5	corresponded	O
6	to	O
7	sequences	O
8	that	O
9	,	O
10	by	O
11	analogy	O
12	to	O
13	the	O
14	organization	O
15	of	O
16	the	O
17	type	B
18	I	I
19	collagen	I
20	genes	I
21	,	O
22	should	O
23	be	O
24	precisely	O
25	encoded	O
26	by	O
27	exon	O
28	41	O
29	of	O
30	the	O
31	COL3A1	B
32	gene	I
33	.	O

1	These	O
2	losses	O
3	account	O
4	for	O
5	the	O
6	resistance	O
7	of	O
8	EDS	O
9	-	O
10	IV	O
11	collagen	B
12	to	O
13	cyanogen	O
14	bromide	O
15	and	O
16	mammalian	B
17	collagenase	I
18	digestion	O
19	.	O

1	A	O
2	4	O
3	.	O
4	8	O
5	-	O
6	kilobase	O
7	BamHI	B
8	-	O
9	HindIII	B
10	fragment	O
11	encoding	O
12	the	O
13	entire	B
14	Neurospora	I
15	crassa	I
16	CuZn	I
17	superoxide	I
18	dismutase	I
19	gene	I
20	(	O
21	herein	O
22	designated	O
23	sod	B
24	-	I
25	1	I
26	)	O
27	was	O
28	isolated	O
29	from	O
30	a	O
31	genomic	O
32	library	O
33	using	O
34	two	O
35	60	O
36	-	O
37	base	O
38	deoxyoligonucleotide	O
39	probes	O
40	corresponding	O
41	to	O
42	the	O
43	published	O
44	N	O
45	.	O
46	crassa	O
47	amino	O
48	acid	O
49	sequence	O
50	.	O

1	Two	O
2	other	O
3	peptides	O
4	,	O
5	either	O
6	partially	O
7	or	O
8	totally	O
9	lacking	O
10	the	O
11	basic	O
12	region	O
13	,	O
14	but	O
15	containing	O
16	the	O
17	intact	O
18	leucine	O
19	zipper	O
20	domain	O
21	,	O
22	readily	O
23	form	O
24	dimers	O
25	but	O
26	do	O
27	not	O
28	bind	O
29	to	O
30	the	O
31	CRE	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	CRE	O
6	of	O
7	the	O
8	human	B
9	c	I
10	-	I
11	fos	I
12	promoter	I
13	located	O
14	at	O
15	-	O
16	60	O
17	was	O
18	weakly	O
19	induced	O
20	by	O
21	cAMP	O
22	and	O
23	E1a	B
24	in	O
25	both	O
26	HeLa	O
27	and	O
28	PC12	O
29	cells	O
30	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O

1	Although	O
2	popular	O
3	this	O
4	hypothesis	O
5	is	O
6	far	O
7	from	O
8	explaining	O
9	all	O
10	the	O
11	clinical	O
12	facts	O
13	,	O
14	namely	O
15	that	O
16	rigidity	O
17	is	O
18	equal	O
19	in	O
20	extensor	O
21	and	O
22	flexor	O
23	,	O
24	proximal	O
25	and	O
26	distal	O
27	muscles	O
28	.	O

1	Using	O
2	appropriate	O
3	synthetic	O
4	HSE	O
5	oligonucleotides	O
6	,	O
7	three	O
8	types	O
9	of	O
10	clones	O
11	with	O
12	potential	O
13	HSE	O
14	binding	O
15	domains	O
16	were	O
17	isolated	O
18	from	O
19	a	O
20	tomato	O
21	lambda	O
22	gt11	O
23	expression	O
24	library	O
25	by	O
26	DNA	O
27	-	O
28	ligand	O
29	screening	O
30	.	O

1	Fluid	O
2	(	O
3	AVLF	O
4	)	O
5	31	O
6	.	O

1	The	O
2	results	O
3	supported	O
4	the	O
5	therapeutic	O
6	principle	O
7	of	O
8	TCM	O
9	:	O
10	Treating	O
11	patients	O
12	according	O
13	to	O
14	their	O
15	pathophysiological	O
16	patterns	O
17	.	O

1	The	O
2	nmr	B
3	gene	I
4	is	O
5	the	O
6	major	O
7	negative	O
8	regulatory	O
9	gene	O
10	in	O
11	the	O
12	nitrogen	O
13	control	O
14	circuit	O
15	of	O
16	Neurospora	O
17	crassa	O
18	,	O
19	which	O
20	,	O
21	together	O
22	with	O
23	positive	O
24	regulatory	O
25	genes	O
26	,	O
27	governs	O
28	the	O
29	expression	O
30	of	O
31	multiple	O
32	unlinked	O
33	structural	O
34	genes	O
35	of	O
36	the	O
37	circuit	O
38	.	O

1	The	O
2	4	O
3	days	O
4	dexamethasone	O
5	suppression	O
6	test	O
7	showed	O
8	more	O
9	than	O
10	80	O
11	%	O
12	suppression	O
13	of	O
14	dehydroepiandrosterone	O
15	-	O
16	sulphate	O
17	and	O
18	a	O
19	variable	O
20	(	O
21	40	O
22	-	O
23	60	O
24	%)	O
25	reduction	O
26	of	O
27	testosterone	O
28	and	O
29	androstenedione	O
30	levels	O
31	.	O

1	The	O
2	ratio	O
3	of	O
4	P	O
5	-	O
6	31	O
7	NMR	O
8	-	O
9	S	O
10	derived	O
11	inorganic	O
12	phosphates	O
13	[	O
14	Pi	O
15	]	O
16	to	O
17	phosphocreatine	O
18	[	O
19	PCr	O
20	]	O
21	was	O
22	significantly	O
23	greater	O
24	at	O
25	rest	O
26	in	O
27	LVH	O
28	baboons	O
29	[	O
30	0	O
31	.	O
32	53	O
33	+/-	O
34	0	O
35	.	O
36	06	O
37	versus	O
38	controls	O
39	=	O
40	0	O
41	.	O
42	41	O
43	+/-	O
44	0	O
45	.	O
46	17	O
47	;	O
48	P	O
49	less	O
50	than	O
51	0	O
52	.	O
53	05	O
54	].	O

1	Cutaneous	O
2	necrosis	O
3	associated	O
4	with	O
5	protein	B
6	S	I
7	deficiency	O
8	.	O

1	Critical	O
2	study	O

1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	was	O
6	measured	O
7	using	O
8	N	O
9	-	O
10	isopropyl	O
11	-	O
12	123I	O
13	-	O
14	iodoamphetamine	O
15	with	O
16	single	O
17	-	O
18	photon	O
19	emission	O
20	computed	O
21	tomography	O
22	(	O
23	CT	O
24	)	O
25	in	O
26	16	O
27	aged	O
28	patients	O
29	with	O
30	noninsulin	O
31	-	O
32	dependent	O
33	diabetes	O
34	mellitus	O
35	(	O
36	NIDDM	O
37	,	O
38	average	O
39	age	O
40	72	O
41	.	O
42	8	O
43	years	O
44	,	O
45	average	O
46	fasting	O
47	plasma	O
48	glucose	O
49	7	O
50	.	O
51	7	O
52	mmol	O
53	/	O
54	L	O
55	),	O
56	and	O
57	12	O
58	nondiabetic	O
59	subjects	O
60	(	O
61	71	O
62	.	O
63	6	O
64	years	O
65	,	O
66	5	O
67	.	O
68	3	O
69	mmol	O
70	/	O
71	L	O
72	).	O

1	Mean	O
2	ROI	O
3	-	O
4	A	O
5	/	O
6	B	O
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O

1	These	O
2	data	O
3	strongly	O
4	implicate	O
5	the	O
6	normal	O
7	product	O
8	of	O
9	the	O
10	int	B
11	-	I
12	2	I
13	gene	I
14	,	O
15	which	O
16	is	O
17	related	O
18	to	O
19	the	O
20	fibroblast	B
21	growth	I
22	factor	I
23	family	I
24	,	O
25	as	O
26	a	O
27	contributory	O
28	factor	O
29	in	O
30	virally	O
31	induced	O
32	mammary	O
33	tumors	O
34	.	O

1	This	O
2	result	O
3	indicates	O
4	that	O
5	separate	O
6	complexes	O
7	exist	O
8	containing	O
9	ankyrin	B
10	and	O
11	fodrin	B
12	with	O
13	either	O
14	uvomorulin	B
15	or	O
16	Na	B
17	+,	I
18	K	I
19	+-	I
20	ATPase	I
21	.	O

1	These	O
2	genes	O
3	are	O
4	expressed	O
5	within	O
6	a	O
7	few	O
8	hours	O
9	of	O
10	the	O
11	initiation	O
12	of	O
13	development	O
14	;	O
15	their	O
16	mRNAs	O
17	accumulate	O
18	to	O
19	a	O
20	peak	O
21	at	O
22	12	O
23	hr	O
24	and	O
25	persist	O
26	until	O
27	culmination	O
28	.	O

1	The	O
2	PC2	B
3	protein	I
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	B
18	furin	I
19	gene	I
20	product	I
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	O
28	-	O
29	like	O
30	molecule	O
31	.	O

1	Whether	O
2	or	O
3	not	O
4	there	O
5	are	O
6	sequences	O
7	conferring	O
8	cAMP	O
9	responsiveness	O
10	which	O
11	are	O
12	common	O
13	both	O
14	to	O
15	P	B
16	-	I
17	450scc	I
18	and	O
19	the	O
20	other	O
21	steroidogenic	O
22	P	B
23	-	I
24	450	I
25	genes	I
26	remains	O
27	to	O
28	be	O
29	established	O
30	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	used	O
7	footprinting	O
8	and	O
9	gel	O
10	mobility	O
11	retardation	O
12	assays	O
13	to	O
14	reveal	O
15	that	O
16	bacterially	O
17	synthesized	O
18	Zta	B
19	fusion	I
20	proteins	I
21	bound	O
22	directly	O
23	to	O
24	six	O
25	TGTGCAA	O
26	-	O
27	like	O
28	motifs	O
29	within	O
30	DSL	B
31	.	O

1	The	O
2	zta	B
3	transactivator	I
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	-	O
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	B
24	-	I
25	1	I
26	and	O
27	ZRE	B
28	sites	I
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O

1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	B
9	Mx	I
10	protein	I
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O

1	Fragments	O
2	containing	O
3	the	O
4	21	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	repeat	O
10	region	O
11	,	O
12	the	O
13	enhancer	B
14	of	I
15	simian	I
16	virus	I
17	40	I
18	or	O
19	both	O
20	strongly	O
21	stimulated	O
22	beta	B
23	-	I
24	galactosidase	I
25	synthesis	O
26	,	O
27	and	O
28	three	O
29	fragments	O
30	from	O
31	the	O
32	polyomavirus	B
33	enhancer	I
34	region	I
35	stimulated	O
36	moderate	O
37	levels	O
38	.	O

1	The	O
2	sites	O
3	targeted	O
4	for	O
5	mutagenesis	O
6	,	O
7	residues	O
8	60	O
9	,	O
10	61	O
11	,	O
12	and	O
13	66	O
14	,	O
15	are	O
16	located	O
17	within	O
18	a	O
19	putative	O
20	helical	O
21	loop	O
22	structure	O
23	which	O
24	may	O
25	be	O
26	involved	O
27	in	O
28	substrate	O
29	recognition	O
30	by	O
31	the	O
32	enzyme	O
33	.	O

1	The	O
2	possible	O
3	benefits	O
4	of	O
5	LMW	O
6	heparin	O
7	(	O
8	reduced	O
9	frequency	O
10	of	O
11	bleeding	O
12	,	O
13	alleviation	O
14	of	O
15	hypertriglyceridemia	O
16	)	O
17	were	O
18	not	O
19	,	O
20	however	O
21	,	O
22	apparent	O
23	,	O
24	possibly	O
25	because	O
26	of	O
27	the	O
28	short	O
29	observation	O
30	period	O
31	and	O
32	the	O
33	low	O
34	incidence	O
35	of	O
36	hemorrhagic	O
37	complications	O
38	in	O
39	routine	O
40	dialyses	O
41	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	destrin	B
8	is	O
9	165	O
10	residues	O
11	long	O
12	and	O
13	is	O
14	very	O
15	similar	O
16	(	O
17	71	O
18	%	O
19	identical	O
20	)	O
21	to	O
22	that	O
23	of	O
24	cofilin	B
25	,	O
26	a	O
27	widely	O
28	distributed	O
29	,	O
30	pH	O
31	-	O
32	sensitive	O
33	actin	B
34	-	O
35	modulating	O
36	protein	O
37	.	O

1	Summers	O
2	,	O
3	Virology	O
4	89	O
5	:	O
6	517	O
7	-	O
8	527	O
9	,	O
10	1978	O
11	).	O

1	With	O
2	only	O
3	purified	O
4	T	B
5	antigen	I
6	in	O
7	the	O
8	presence	O
9	of	O
10	topoisomerase	B
11	I	I
12	to	O
13	unwind	O
14	purified	O
15	DNA	O
16	,	O
17	ori	O
18	-	O
19	auxiliary	O
20	sequences	O
21	strongly	O
22	facilitated	O
23	T	B
24	-	I
25	antigen	I
26	-	O
27	dependent	O
28	DNA	O
29	conformational	O
30	changes	O
31	consistent	O
32	with	O
33	melting	O
34	the	O
35	first	O
36	50	O
37	base	O
38	pairs	O
39	.	O

1	A	O
2	rabbit	O
3	antiserum	O
4	was	O
5	raised	O
6	against	O
7	a	O
8	synthetic	O
9	peptide	O
10	corresponding	O
11	to	O
12	a	O
13	hydrophilic	O
14	portion	O
15	of	O
16	the	O
17	translated	O
18	murine	O
19	cDNA	O
20	sequence	O
21	.	O

1	Conservation	O
2	of	O
3	function	O
4	of	O
5	Drosophila	B
6	melanogaster	I
7	abl	I
8	and	O
9	murine	B
10	v	I
11	-	I
12	abl	I
13	proteins	I
14	in	O
15	transformation	O
16	of	O
17	mammalian	O
18	cells	O
19	.	O

1	In	O
2	transient	O
3	cotransfection	O
4	assays	O
5	using	O
6	Chang	O
7	liver	O
8	cells	O
9	(	O
10	CCL	O
11	13	O
12	),	O
13	pM1	O
14	DNA	O
15	exerts	O
16	a	O
17	6	O
18	-	O
19	to	O
20	10	O
21	-	O
22	fold	O
23	trans	O
24	-	O
25	activating	O
26	effect	O
27	on	O
28	the	O
29	expression	O
30	of	O
31	the	O
32	pSV2CAT	O
33	reporter	O
34	plasmid	O
35	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	B
13	.	I
14	5	I
15	-	I
16	kb	I
17	COR	I
18	segment	I
19	that	O
20	encompasses	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	B
28	,	O
29	UTR1	B
30	,	O
31	UTR3	B
32	,	O
33	OSM1	B
34	,	O
35	tRNA	B
36	(	I
37	Gly	I
38	)	I
39	and	O
40	RAD7	B
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O

1	Specific	O
2	binding	O
3	of	O
4	the	O
5	protein	O
6	factors	O
7	to	O
8	the	O
9	sites	O
10	,	O
11	possibly	O
12	to	O
13	the	O
14	three	O
15	Mt	O
16	sequences	O
17	,	O
18	may	O
19	play	O
20	an	O
21	important	O
22	role	O
23	in	O
24	the	O
25	coordinate	O
26	regulation	O
27	of	O
28	the	O
29	transcription	O
30	of	O
31	nuclear	O
32	genes	O
33	encoding	O
34	subunits	O
35	responsible	O
36	for	O
37	mitochondrial	O
38	oxidative	O
39	phosphorylation	O
40	.	O

1	This	O
2	points	O
3	to	O
4	a	O
5	specific	O
6	interference	O
7	with	O
8	HSV	O
9	-	O
10	induced	O
11	DNA	O
12	amplification	O
13	.	O

1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O

1	The	O
2	antinociceptive	O
3	properties	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	tail	O
10	-	O
11	flick	O
12	and	O
13	hot	O
14	-	O
15	plate	O
16	tests	O
17	,	O
18	and	O
19	the	O
20	motor	O
21	effects	O
22	of	O
23	an	O
24	intrathecally	O
25	-	O
26	administered	O
27	benzodiazepine	O
28	agonist	O
29	midazolam	O
30	,	O
31	alone	O
32	,	O
33	and	O
34	in	O
35	combination	O
36	with	O
37	morphine	O
38	,	O
39	was	O
40	examined	O
41	in	O
42	rats	O
43	.	O

1	Constructs	O
2	were	O
3	made	O
4	in	O
5	which	O
6	an	O
7	AATAAA	O
8	and	O
9	the	O
10	GT	O
11	-	O
12	rich	O
13	region	O
14	were	O
15	separated	O
16	by	O
17	various	O
18	distances	O
19	ranging	O
20	from	O
21	7	O
22	to	O
23	43	O
24	bp	O
25	.	O

1	To	O
2	address	O
3	this	O
4	issue	O
5	,	O
6	the	O
7	gene	O
8	for	O
9	factor	B
10	Y	I
11	has	O
12	been	O
13	cloned	O
14	molecularly	O
15	and	O
16	its	O
17	DNA	O
18	sequence	O
19	has	O
20	been	O
21	determined	O
22	.	O

1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	B
14	(	I
15	P	I
16	)	I
17	of	O
18	human	O
19	parainfluenza	O
20	type	O
21	2	O
22	virus	O
23	(	O
24	PIV	O
25	-	O
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O

1	We	O
2	show	O
3	that	O
4	cytR	B
5	expression	O
6	is	O
7	negatively	O
8	controlled	O
9	by	O
10	the	O
11	CytR	B
12	protein	I
13	and	O
14	positively	O
15	affected	O
16	by	O
17	the	O
18	cAMP	B
19	/	I
20	CAP	I
21	complex	I
22	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	O
14	-	O
15	L1	O
16	adipocyte	B
17	insulin	I
18	receptor	I
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	B
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	O
28	-	O
29	transport	O
30	system	O
31	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	the	O
6	sequence	O
7	similarities	O
8	reflect	O
9	a	O
10	common	O
11	molecular	O
12	architecture	O
13	of	O
14	the	O
15	two	O
16	heme	O
17	binding	O
18	sites	O
19	and	O
20	of	O
21	a	O
22	copper	O
23	binding	O
24	site	O
25	in	O
26	these	O
27	enzymes	O
28	.	O

1	The	O
2	cDNA	O
3	sequence	O
4	has	O
5	an	O
6	813	O
7	-	O
8	bp	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	whose	O
16	predicted	O
17	amino	O
18	acid	O
19	sequence	O
20	is	O
21	97	O
22	.	O
23	6	O
24	%	O
25	identical	O
26	to	O
27	the	O
28	272	O
29	carboxy	O
30	-	O
31	terminal	O
32	amino	O
33	acids	O
34	of	O
35	the	O
36	human	B
37	ets	I
38	-	I
39	1	I
40	protein	I
41	.	O

1	To	O
2	characterize	O
3	the	O
4	O7	B
5	-	I
6	LPS	I
7	region	I
8	,	O
9	the	O
10	recombinant	O
11	cosmids	O
12	pJHCV31	O
13	and	O
14	pJHCV32	O
15	were	O
16	mutagenized	O
17	by	O
18	transposon	O
19	mutagenesis	O
20	with	O
21	Tn3HoHo1	B
22	,	O
23	which	O
24	carries	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	and	O
30	can	O
31	therefore	O
32	generate	O
33	lacZ	B
34	transcriptional	O
35	fusions	O
36	with	O
37	target	O
38	DNA	O
39	sequences	O
40	.	O

1	The	O
2	sacT	B
3	gene	I
4	regulating	O
5	the	O
6	sacPA	B
7	operon	I
8	in	I
9	Bacillus	I
10	subtilis	I
11	shares	O
12	strong	O
13	homology	O
14	with	O
15	transcriptional	O
16	antiterminators	O
17	.	O

1	The	O
2	TraD	B
3	protein	I
4	(	I
5	83	I
6	,	I
7	899	I
8	Da	I
9	)	I
10	contains	O
11	three	O
12	hydrophobic	O
13	regions	O
14	,	O
15	of	O
16	which	O
17	two	O
18	are	O
19	located	O
20	near	O
21	the	O
22	amino	O
23	-	O
24	terminal	O
25	region	O
26	.	O

1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	B
13	gene	I
14	(	O
15	named	O
16	traX	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O

1	Various	O
2	mutant	B
3	HN	I
4	genes	I
5	were	O
6	constructed	O
7	to	O
8	examine	O
9	the	O
10	role	O
11	of	O
12	residues	O
13	flanking	O
14	the	O
15	signal	O
16	-	O
17	anchor	O
18	domain	O
19	,	O
20	including	O
21	the	O
22	cytoplasmic	O
23	tail	O
24	,	O
25	on	O
26	assembly	O
27	and	O
28	intracellular	O
29	transport	O
30	of	O
31	the	O
32	HN	B
33	glycoprotein	I
34	.	O

1	Our	O
2	studies	O
3	extend	O
4	these	O
5	findings	O
6	and	O
7	show	O
8	that	O
9	the	O
10	E2	B
11	transactivation	I
12	gene	I
13	is	O
14	expressed	O
15	from	O
16	multiple	O
17	promoters	O
18	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	the	O
6	E2	B
7	proteins	I
8	present	O
9	in	O
10	various	O
11	cell	O
12	lines	O
13	harboring	O
14	specific	O
15	BPV	O
16	-	O
17	1	O
18	mutants	O
19	,	O
20	including	O
21	the	O
22	2558	O
23	acceptor	O
24	mutant	O
25	,	O
26	proves	O
27	that	O
28	alternate	O
29	modes	O
30	of	O
31	E2	B
32	expression	O
33	exist	O
34	.	O

1	Disruption	O
2	of	O
3	the	O
4	IRA2	B
5	gene	I
6	resulted	O
7	in	O
8	(	O
9	i	O
10	)	O
11	increased	O
12	sensitivity	O
13	to	O
14	heat	O
15	shock	O
16	and	O
17	nitrogen	O
18	starvation	O
19	,	O
20	(	O
21	ii	O
22	)	O
23	sporulation	O
24	defects	O
25	,	O
26	and	O
27	(	O
28	iii	O
29	)	O
30	suppression	O
31	of	O
32	the	O
33	lethality	O
34	of	O
35	the	O
36	cdc25	B
37	mutant	I
38	.	O

1	This	O
2	cohort	O
3	of	O
4	patients	O
5	was	O
6	selected	O
7	on	O
8	the	O
9	basis	O
10	of	O
11	clinical	O
12	stage	O
13	.	O

1	A	O
2	gene	O
3	in	O
4	Drosophila	O
5	melanogaster	O
6	that	O
7	maps	O
8	cytologically	O
9	to	O
10	2C1	O
11	-	O
12	3	O
13	on	O
14	the	O
15	distal	O
16	portion	O
17	of	O
18	the	O
19	X	O
20	-	O
21	chromosome	O
22	encodes	O
23	a	O
24	member	O
25	of	O
26	the	O
27	steroid	B
28	/	I
29	thyroid	I
30	hormone	I
31	receptor	I
32	superfamily	I
33	.	O

1	A	O
2	portion	O
3	of	O
4	Region	O
5	II	O
6	also	O
7	resembles	O
8	part	O
9	of	O
10	the	O
11	human	O
12	c	B
13	-	I
14	jun	I
15	oncoprotein	O
16	'	O
17	s	O
18	leucine	O
19	zipper	O
20	,	O
21	which	O
22	in	O
23	turn	O
24	,	O
25	has	O
26	been	O
27	demonstrated	O
28	to	O
29	be	O
30	the	O
31	heterodimerization	O
32	site	O
33	between	O
34	the	O
35	jun	B
36	and	O
37	fos	B
38	oncoproteins	I
39	.	O

1	To	O
2	determine	O
3	whether	O
4	vanadate	O
5	could	O
6	inhibit	O
7	PEPCK	B
8	gene	I
9	transcription	O
10	,	O
11	a	O
12	series	O
13	of	O
14	chimeric	O
15	genes	O
16	containing	O
17	several	O
18	deletions	O
19	in	O
20	the	O
21	P	B
22	-	I
23	enolypyruvate	I
24	carboxykinase	I
25	promoter	I
26	between	O
27	-	O
28	550	O
29	and	O
30	-	O
31	68	O
32	was	O
33	linked	O
34	to	O
35	the	O
36	structural	O
37	genes	O
38	for	O
39	either	O
40	amino	B
41	-	I
42	3	I
43	-	I
44	glycosyl	I
45	phosphotransferase	I
46	(	O
47	neo	B
48	)	O
49	or	O
50	chloramphenicol	B
51	acetyltransferase	I
52	and	O
53	introduced	O
54	into	O
55	hepatoma	O
56	cells	O
57	using	O
58	three	O
59	methods	O
60	:	O
61	(	O
62	a	O
63	)	O
64	infection	O
65	with	O
66	a	O
67	Moloney	O
68	murine	O
69	leukemia	O
70	virus	O
71	-	O
72	based	O
73	retrovirus	O
74	,	O
75	(	O
76	b	O
77	)	O
78	transfection	O
79	and	O
80	stable	O
81	selection	O
82	for	O
83	neo	B
84	expression	O
85	,	O
86	or	O
87	(	O
88	c	O
89	)	O
90	transient	O
91	expression	O
92	of	O
93	chloroamphenicol	B
94	acetyltransferase	I
95	.	O

1	The	O
2	diagnosis	O
3	of	O
4	miliary	O
5	tuberculosis	O
6	should	O
7	be	O
8	systematically	O
9	considered	O
10	in	O
11	ARDS	O
12	of	O
13	unknown	O
14	origin	O
15	.	O

1	In	O
2	order	O
3	to	O
4	characterize	O
5	the	O
6	functional	O
7	elements	O
8	of	O
9	the	O
10	promoter	O
11	that	O
12	in	O
13	some	O
14	way	O
15	must	O
16	respond	O
17	to	O
18	these	O
19	regulatory	O
20	signals	O
21	,	O
22	a	O
23	number	O
24	of	O
25	promoter	O
26	mutations	O
27	were	O
28	constructed	O
29	,	O
30	including	O
31	a	O
32	set	O
33	of	O
34	linker	O
35	-	O
36	scanning	O
37	mutations	O
38	across	O
39	the	O
40	entire	O
41	promoter	O
42	region	O
43	.	O

1	A	O
2	DNA	O
3	motif	O
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	B
14	-	I
15	located	I
16	activator	I
17	protein	I
18	-	I
19	2	I
20	binding	I
21	site	I
22	in	O
23	the	O
24	human	B
25	tissue	I
26	-	I
27	type	I
28	plasminogen	I
29	activator	I
30	gene	I
31	promoter	I
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O

1	The	O
2	26S	B
3	rRNA	I
4	binding	I
5	ribosomal	I
6	protein	I
7	equivalent	O
8	to	O
9	bacterial	B
10	protein	I
11	L11	I
12	is	O
13	encoded	O
14	by	O
15	unspliced	O
16	duplicated	O
17	genes	O
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O

1	Five	O
2	healthy	O
3	male	O
4	subjects	O
5	inspired	O
6	air	O
7	for	O
8	20	O
9	min	O
10	and	O
11	then	O
12	5	O
13	%	O
14	CO2	O
15	/	O
16	95	O
17	%	O
18	O2	O
19	for	O
20	30	O
21	min	O
22	,	O
23	of	O
24	which	O
25	the	O
26	first	O
27	10	O
28	min	O
29	was	O
30	used	O
31	to	O
32	achieve	O
33	a	O
34	steady	O
35	-	O
36	state	O
37	end	O
38	-	O
39	tidal	O
40	CO2	O
41	measurement	O
42	.	O

1	Significant	O
2	correlations	O
3	were	O
4	obtained	O
5	between	O
6	changes	O
7	in	O
8	SSEP	O
9	in	O
10	response	O
11	to	O
12	AS	O
13	and	O
14	the	O
15	presence	O
16	of	O
17	not	O
18	deep	O
19	residual	O
20	-	O
21	organic	O
22	disturbances	O
23	,	O
24	so	O
25	-	O
26	called	O
27	"	O
28	ground	O
29	"	O
30	in	O
31	psychogenic	O
32	disorders	O
33	.	O

1	The	O
2	transcripts	O
3	were	O
4	equally	O
5	active	O
6	with	O
7	or	O
8	without	O
9	a	O
10	5	O
11	'	O
12	methylated	O
13	capstructure	O
14	as	O
15	expected	O
16	,	O
17	since	O
18	EMCV	O
19	-	O
20	RNA	O
21	is	O
22	one	O
23	of	O
24	the	O
25	mRNAs	O
26	capable	O
27	of	O
28	internal	O
29	initiation	O
30	.	O

1	The	O
2	E6	B
3	/	O
4	E7	B
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	papillomaviruses	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O

1	A	O
2	case	O
3	of	O
4	Goodpasture	O
5	'	O
6	s	O
7	syndrome	O
8	.	O

1	Seventy	O
2	-	O
3	two	O
4	of	O
5	73	O
6	negative	O
7	controls	O
8	and	O
9	all	O
10	positive	O
11	blocks	O
12	as	O
13	seen	O
14	on	O
15	soft	O
16	tissue	O
17	radiographs	O
18	(	O
19	STRs	O
20	)	O
21	were	O
22	correctly	O
23	coded	O
24	(	O
25	specificity	O
26	98	O
27	.	O
28	6	O
29	%,	O
30	sensitivity	O
31	100	O
32	%).	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O

1	Both	O
2	strains	O
3	grew	O
4	very	O
5	poorly	O
6	,	O
7	or	O
8	not	O
9	at	O
10	all	O
11	,	O
12	on	O
13	nonfermentable	O
14	carbon	O
15	sources	O
16	and	O
17	exhibited	O
18	,	O
19	at	O
20	most	O
21	,	O
22	only	O
23	5	O
24	%	O
25	of	O
26	wild	B
27	-	I
28	type	I
29	ubiquinol	I
30	-	I
31	cytochrome	I
32	c	I
33	oxidoreductase	I
34	activity	O
35	.	O

1	Regulation	O
2	of	O
3	irgA	B
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	O
12	the	O
13	transcriptional	O
14	level	O
15	,	O
16	and	O
17	there	O
18	is	O
19	an	O
20	interrupted	O
21	dyad	O
22	symmetric	O
23	sequence	O
24	in	O
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	O
34	Fur	B
35	binding	I
36	sites	I
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O

1	Transcription	O
2	of	O
3	the	O
4	first	O
5	operon	O
6	coding	O
7	for	O
8	m	O
9	-	O
10	xylene	O
11	-	O
12	degrading	O
13	enzymes	O
14	on	O
15	the	O
16	TOL	O
17	plasmid	O
18	of	O
19	Pseudomonas	O
20	putida	O
21	is	O
22	activated	O
23	by	O
24	the	O
25	xylR	B
26	gene	I
27	product	I
28	in	O
29	the	O
30	presence	O
31	of	O
32	m	O
33	-	O
34	xylene	O
35	.	O

1	The	O
2	recombinant	O
3	contains	O
4	the	O
5	normal	O
6	beta	B
7	A	I
8	-	I
9	globin	I
10	gene	I
11	,	O
12	the	O
13	mutant	O
14	gene	O
15	and	O
16	Ylp	O
17	vector	O
18	sequences	O
19	between	O
20	the	O
21	two	O
22	copies	O
23	.	O

1	Some	O
2	of	O
3	the	O
4	mutations	O
5	obtained	O
6	do	O
7	not	O
8	contain	O
9	a	O
10	copy	O
11	of	O
12	the	O
13	Ulysses	B
14	element	I
15	at	O
16	the	O
17	mutant	O
18	locus	O
19	,	O
20	suggesting	O
21	that	O
22	a	O
23	different	O
24	transposable	O
25	element	O
26	may	O
27	be	O
28	responsible	O
29	for	O
30	the	O
31	mutation	O
32	.	O

1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O

1	We	O
2	show	O
3	also	O
4	that	O
5	RA	O
6	represses	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	a	O
12	reporter	O
13	gene	O
14	containing	O
15	a	O
16	TPA	O
17	responding	O
18	AP1	B
19	binding	I
20	site	I
21	driving	O
22	the	O
23	HSV	B
24	tk	I
25	promoter	I
26	.	O

1	Moreover	O
2	,	O
3	radiolabeled	O
4	EFI	B
5	,	O
6	NF	B
7	-	I
8	Y	I
9	,	O
10	or	O
11	CBF	B
12	DNAs	I
13	give	O
14	rise	O
15	to	O
16	identical	O
17	gel	O
18	retardation	O
19	patterns	O
20	in	O
21	extracts	O
22	from	O
23	a	O
24	variety	O
25	of	O
26	different	O
27	cell	O
28	types	O
29	.	O

1	Risk	O
2	factors	O
3	influencing	O
4	lymph	O
5	nodes	O
6	metastasis	O
7	in	O
8	lung	O
9	cancer	O
10	with	O
11	stage	O
12	I	O
13	,	O
14	II	O
15	or	O
16	IIIA	O

1	Multifunctional	B
2	protein	I
3	kinase	I
4	(	O
5	MFPK	B
6	)	O
7	phosphorylates	O
8	ATP	B
9	-	I
10	citrate	I
11	lyase	I
12	on	O
13	peptide	B
14	B	I
15	on	O
16	two	O
17	sites	O
18	,	O
19	BT	O
20	and	O
21	BS	O
22	,	O
23	on	O
24	threonine	O
25	and	O
26	serine	O
27	,	O
28	respectively	O
29	,	O
30	inhibitor	B
31	2	I
32	on	O
33	a	O
34	threonyl	O
35	residue	O
36	,	O
37	and	O
38	glycogen	B
39	synthase	I
40	at	O
41	sites	O
42	2	O
43	and	O
44	3	O
45	.	O

1	The	O
2	characterized	O
3	Y	B
4	'	I
5	repeated	I
6	sequence	I
7	families	I
8	provide	O
9	an	O
10	experimental	O
11	system	O
12	in	O
13	which	O
14	repeated	O
15	sequence	O
16	interactions	O
17	and	O
18	subsequent	O
19	evolution	O
20	can	O
21	be	O
22	studied	O
23	.	O

1	The	O
2	electrically	O
3	induced	O
4	motile	O
5	responses	O
6	were	O
7	not	O
8	suppressed	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	dinitrophenol	O
14	or	O
15	cytochalasin	O
16	B	O
17	.	O

1	Unlike	O
2	p59v	B
3	-	O
4	rel	B
5	,	O
6	which	O
7	is	O
8	a	O
9	nuclear	O
10	protein	O
11	in	O
12	CEF	O
13	,	O
14	indirect	O
15	immunofluorescence	O
16	showed	O
17	that	O
18	p68c	B
19	-	O
20	rel	B
21	in	O
22	JD214c	O
23	-	O
24	rel	O
25	infected	O
26	CEF	O
27	is	O
28	located	O
29	exclusively	O
30	in	O
31	the	O
32	cytoplasm	O
33	of	O
34	these	O
35	cells	O
36	,	O
37	even	O
38	though	O
39	the	O
40	sequence	O
41	of	O
42	p68c	B
43	-	O
44	rel	B
45	showed	O
46	that	O
47	it	O
48	contains	O
49	a	O
50	nuclear	O
51	localizing	O
52	sequence	O
53	identical	O
54	to	O
55	the	O
56	one	O
57	previously	O
58	identified	O
59	in	O
60	p59v	B
61	-	O
62	rel	B
63	.	O

1	Kinetic	O
2	experiments	O
3	revealed	O
4	that	O
5	within	O
6	10	O
7	min	O
8	this	O
9	radiolabeled	O
10	precursor	O
11	protein	O
12	was	O
13	converted	O
14	in	O
15	HL	O
16	-	O
17	60	O
18	cells	O
19	into	O
20	an	O
21	Mr	O
22	approximately	O
23	150	O
24	,	O
25	000	O
26	chondroitin	O
27	sulfate	O
28	proteoglycan	O
29	intermediate	O
30	.	O

1	Blood	O
2	flow	O
3	and	O
4	velocity	O
5	(	O
6	measured	O
7	using	O
8	Doppler	O
9	ultrasound	O
10	)	O
11	gradually	O
12	decreased	O
13	during	O
14	diastole	O
15	and	O
16	ultimately	O
17	reversed	O
18	in	O
19	direction	O
20	as	O
21	cotyledon	O
22	resistance	O
23	was	O
24	increased	O
25	up	O
26	to	O
27	14	O
28	fold	O
29	.	O

1	A	O
2	total	O
3	of	O
4	112	O
5	patients	O
6	received	O
7	anistreplase	O
8	and	O
9	119	O
10	received	O
11	heparin	O
12	within	O
13	a	O
14	mean	O
15	period	O
16	of	O
17	188	O
18	+/-	O
19	62	O
20	min	O
21	following	O
22	the	O
23	onset	O
24	of	O
25	symptoms	O
26	.	O

1	However	O
2	,	O
3	primary	O
4	transcripts	O
5	of	O
6	a	O
7	variant	B
8	tRNA	I
9	(	I
10	Val	I
11	)(	I
12	UAC	I
13	)	I
14	gene	I
15	are	O
16	processing	O
17	deficient	O
18	under	O
19	standard	O
20	growth	O
21	conditions	O
22	(	O
23	30	O
24	degrees	O
25	C	O
26	),	O
27	due	O
28	to	O
29	a	O
30	slightly	O
31	altered	O
32	5	O
33	'	O
34	flanking	O
35	region	O
36	.	O

1	The	O
2	promoter	O
3	activity	O
4	was	O
5	measured	O
6	by	O
7	a	O
8	transient	O
9	expression	O
10	of	O
11	a	O
12	chloramphenicol	B
13	acetyltransferase	I
14	(	O
15	CAT	B
16	)	O
17	gene	O
18	connected	O
19	with	O
20	various	O
21	5	O
22	'-	O
23	deletion	O
24	mutants	O
25	of	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	.	O

1	Three	O
2	of	O
3	the	O
4	short	O
5	ORFs	O
6	in	O
7	the	O
8	central	O
9	region	O
10	of	O
11	BIV	O
12	have	O
13	been	O
14	identified	O
15	by	O
16	location	O
17	and	O
18	structural	O
19	similarity	O
20	to	O
21	the	O
22	nonstructural	O
23	/	O
24	regulatory	O
25	genes	O
26	(	O
27	vif	B
28	,	O
29	tat	B
30	,	O
31	and	O
32	rev	B
33	)	O
34	of	O
35	other	O
36	lentiviruses	O
37	;	O
38	we	O
39	also	O
40	discovered	O
41	two	O
42	unique	O
43	ORFs	O
44	,	O
45	termed	O
46	W	O
47	and	O
48	Y	O
49	,	O
50	which	O
51	may	O
52	serve	O
53	as	O
54	exons	O
55	for	O
56	novel	O
57	genes	O
58	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	14DM	I
5	gene	I
6	,	O
7	encoding	O
8	cytochrome	B
9	P450	I
10	lanosterol	I
11	14	I
12	alpha	I
13	-	I
14	demethylase	I
15	(	O
16	14DM	B
17	),	O
18	was	O
19	overexpressed	O
20	in	O
21	various	O
22	S	O
23	.	O
24	cerevisiae	O
25	strains	O
26	under	O
27	the	O
28	control	O
29	of	O
30	three	O
31	strong	O
32	heterologous	O
33	yeast	O
34	transcription	O
35	promoters	O
36	(	O
37	pADC1	B
38	,	O
39	pGPD	B
40	,	O
41	pPHO5	B
42	)	O
43	and	O
44	under	O
45	the	O
46	control	O
47	of	O
48	its	O
49	own	O
50	promoter	O
51	.	O

1	Truncations	O
2	composed	O
3	of	O
4	78	O
5	and	O
6	64	O
7	amino	O
8	acids	O
9	were	O
10	translocated	O
11	across	O
12	the	O
13	endoplasmic	O
14	reticulum	O
15	membrane	O
16	,	O
17	and	O
18	translocation	O
19	was	O
20	found	O
21	to	O
22	be	O
23	strictly	O
24	co	O
25	-	O
26	translational	O
27	and	O
28	SRP	B
29	-	O
30	dependent	O
31	.	O

1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	The	O
2	ANB1	B
3	locus	I
4	of	O
5	Saccharomyces	O
6	cerevisiae	O
7	encodes	O
8	the	O
9	protein	B
10	synthesis	I
11	initiation	I
12	factor	I
13	eIF	I
14	-	I
15	4D	I
16	.	O

1	The	O
2	contribution	O
3	that	O
4	alternative	O
5	splicing	O
6	events	O
7	in	O
8	c	B
9	-	I
10	myb	I
11	expression	O
12	may	O
13	make	O
14	on	O
15	c	B
16	-	I
17	myb	I
18	function	O
19	remains	O
20	to	O
21	be	O
22	elucidated	O
23	.	O

1	Serum	B
2	beta	I
3	2	I
4	-	I
5	microglobulin	I
6	levels	O
7	(	O
8	beta	B
9	-	I
10	2	I
11	-	I
12	M	I
13	)	O
14	were	O
15	studied	O
16	in	O
17	150	O
18	drug	O
19	addicts	O
20	,	O
21	50	O
22	of	O
23	them	O
24	asymptomatic	O
25	carriers	O
26	of	O
27	anti	B
28	HIV	I
29	-	I
30	1	I
31	antibodies	I
32	,	O
33	50	O
34	symptomatic	O
35	carriers	O
36	with	O
37	persistent	O
38	generalized	O
39	lymphadenopathy	O
40	(	O
41	P	O
42	.	O
43	G	O
44	.	O
45	L	O
46	.)	O
47	and	O
48	50	O
49	serum	O
50	negative	O
51	patients	O
52	who	O
53	had	O
54	been	O
55	living	O
56	in	O
57	a	O
58	closed	O
59	community	O
60	for	O
61	at	O
62	least	O
63	2	O
64	years	O
65	.	O

1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O

1	No	O
2	therapy	O
3	exists	O
4	for	O
5	halting	O
6	the	O
7	progression	O
8	of	O
9	the	O
10	disease	O
11	with	O
12	the	O
13	possible	O
14	exception	O
15	of	O
16	laser	O
17	photocoagulation	O
18	treatment	O
19	used	O
20	to	O
21	ablate	O
22	subretinal	O
23	neovascular	O
24	membranes	O
25	in	O
26	an	O
27	attempt	O
28	to	O
29	avoid	O
30	complications	O
31	of	O
32	subretinal	O
33	hemorrhages	O
34	.	O

1	R	O
2	.	O

1	Specific	O
2	hyperimmune	B
3	globulins	I
4	to	O
5	pathogens	O
6	such	O
7	as	O
8	Haemophilus	O
9	influenzae	O
10	and	O
11	Streptococcus	O
12	pneumoniae	O
13	have	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Therapeutic	O
2	effects	O
3	of	O
4	cefpirome	O
5	(	O
6	HR	O
7	810	O
8	)	O
9	on	O
10	experimental	O
11	mixed	O
12	infections	O
13	with	O
14	Enterococcus	O
15	faecalis	O
16	and	O
17	Escherichia	O
18	coli	O
19	in	O
20	mice	O
21	.	O

1	Regulation	O
2	of	O
3	yeast	B
4	LEU2	I
5	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	O
11	protein	B
12	C	I
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O

1	Ischemic	O
2	stroke	O
3	due	O
4	to	O
5	protein	B
6	C	I
7	deficiency	O
8	.	O

1	TREB7	B
2	and	O
3	TREB36	B
4	protected	O
5	all	O
6	three	O
7	repeats	O
8	of	O
9	the	O
10	21	O
11	bp	O
12	,	O
13	but	O
14	TREB5	B
15	protected	O
16	only	O
17	the	O
18	second	O
19	repeat	O
20	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	5	O
6	KE	O
7	X	O
8	3	O
9	/	O
10	W	O
11	may	O
12	be	O
13	the	O
14	optimal	O
15	regimen	O
16	to	O
17	augment	O
18	the	O
19	antitumor	O
20	immunity	O
21	of	O
22	RNL	O
23	.	O

1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	B
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	B
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O

1	Since	O
2	general	B
3	regulatory	I
4	factor	I
5	I	I
6	(	O
7	GRFI	B
8	)/	O
9	repressor	B
10	/	I
11	activator	I
12	site	I
13	binding	I
14	protein	I
15	1	I
16	(	O
17	RAP1	B
18	)/	O
19	translation	B
20	upstream	I
21	factor	I
22	(	O
23	TUF	B
24	)	O
25	is	O
26	believed	O
27	to	O
28	be	O
29	an	O
30	activator	O
31	of	O
32	MAT	B
33	alpha	I
34	expression	O
35	,	O
36	we	O
37	examined	O
38	whether	O
39	PYK1	B
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	regulated	O
47	by	O
48	GRFI	B
49	/	O
50	RAP1	B
51	/	O
52	TUF	B
53	,	O
54	is	O
55	also	O
56	affected	O
57	by	O
58	the	O
59	gal11	B
60	mutation	I
61	.	O

1	Yeast	B
2	Gal11	I
3	protein	I
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	O
22	repressor	B
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	I
30	translation	I
31	upstream	I
32	factor	I
33	.	O

1	Deletion	O
2	from	O
3	either	O
4	the	O
5	N	O
6	-	O
7	or	O
8	C	O
9	-	O
10	terminal	O
11	ends	O
12	of	O
13	repA	B
14	(	O
15	28	O
16	and	O
17	69	O
18	codons	O
19	,	O
20	respectively	O
21	,	O
22	out	O
23	of	O
24	the	O
25	286	O
26	-	O
27	codon	O
28	open	O
29	reading	O
30	frame	O
31	)	O
32	affected	O
33	the	O
34	initiator	O
35	but	O
36	not	O
37	the	O
38	inhibitory	O
39	activity	O
40	.	O

1	The	O
2	two	O
3	larger	O
4	peptides	O
5	,	O
6	one	O
7	containing	O
8	amino	O
9	acids	O
10	1	O
11	-	O
12	228	O
13	and	O
14	the	O
15	other	O
16	containing	O
17	amino	O
18	acids	O
19	85	O
20	-	O
21	228	O
22	,	O
23	formed	O
24	dimers	O
25	in	O
26	solution	O
27	and	O
28	bound	O
29	DNA	O
30	specifically	O
31	as	O
32	a	O
33	dimer	O
34	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	B
7	-	I
8	1	I
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	B
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O

1	Guiding	O
2	patients	O
3	in	O
4	the	O
5	decision	O
6	should	O
7	involve	O
8	a	O
9	multidisciplinary	O
10	team	O
11	composed	O
12	of	O
13	a	O
14	surgical	O
15	oncologist	O
16	,	O
17	geneticist	O
18	,	O
19	pathologist	O
20	,	O
21	psychotherapist	O
22	and	O
23	plastic	O
24	surgeon	O
25	.	O

1	IgG	B
2	and	O
3	IgM	B
4	antibody	O
5	activity	O
6	was	O
7	determined	O
8	by	O
9	adding	O
10	a	O
11	1	O
12	:	O
13	100	O
14	dilution	O
15	of	O
16	serum	O
17	to	O
18	plates	O
19	coated	O
20	with	O
21	A60	B
22	antigen	I
23	.	O

1	These	O
2	factors	O
3	belong	O
4	to	O
5	a	O
6	set	O
7	of	O
8	genetically	O
9	distinct	O
10	molecules	O
11	,	O
12	including	O
13	AP	B
14	-	I
15	4	I
16	and	O
17	MLTF	B
18	,	O
19	that	O
20	bind	O
21	to	O
22	the	O
23	CACCTGTC	O
24	motif	O
25	or	O
26	related	O
27	sequences	O
28	.	O

1	Among	O
2	known	O
3	flea	O
4	larvae	O
5	,	O
6	the	O
7	genus	O
8	Anomiopsyllus	O
9	(	O
10	Anomiopsyllinae	O
11	,	O
12	Anomiopsyllini	O
13	)	O
14	is	O
15	as	O
16	distinctive	O
17	in	O
18	larval	O
19	form	O
20	as	O
21	are	O
22	the	O
23	adults	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	have	O
5	used	O
6	specific	O
7	antibody	O
8	to	O
9	identify	O
10	and	O
11	characterize	O
12	the	O
13	SSN6	B
14	protein	I
15	.	O

1	These	O
2	latter	O
3	results	O
4	showed	O
5	that	O
6	the	O
7	ABFI	B
8	protein	I
9	,	O
10	like	O
11	the	O
12	RAP1	B
13	protein	I
14	,	O
15	bound	O
16	sequences	O
17	required	O
18	for	O
19	positive	O
20	as	O
21	well	O
22	as	O
23	negative	O
24	regulation	O
25	of	O
26	gene	O
27	expression	O
28	.	O

1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O

1	The	O
2	computer	O
3	-	O
4	programmed	O
5	cytocentrifuge	O
6	is	O
7	currently	O
8	most	O
9	popular	O
10	.	O

1	RNase	B
2	protection	O
3	assays	O
4	reveal	O
5	that	O
6	this	O
7	gene	O
8	,	O
9	unr	B
10	,	O
11	is	O
12	transcribed	O
13	in	O
14	the	O
15	same	O
16	direction	O
17	as	O
18	N	B
19	-	I
20	ras	I
21	and	O
22	that	O
23	its	O
24	3	O
25	'	O
26	end	O
27	is	O
28	located	O
29	just	O
30	130	O
31	base	O
32	pairs	O
33	away	O
34	from	O
35	the	O
36	point	O
37	at	O
38	which	O
39	N	B
40	-	I
41	ras	I
42	transcription	O
43	begins	O
44	.	O

1	Isolation	O
2	of	O
3	a	O
4	temperature	O
5	-	O
6	sensitive	O
7	mutant	O
8	with	O
9	an	O
10	altered	O
11	tRNA	B
12	nucleotidyltransferase	I
13	and	O
14	cloning	O
15	of	O
16	the	O
17	gene	B
18	encoding	I
19	tRNA	I
20	nucleotidyltransferase	I
21	in	I
22	the	I
23	yeast	I
24	Saccharomyces	I
25	cerevisiae	I
26	.	O

1	The	O
2	juxtamembrane	O
3	region	O
4	of	O
5	the	O
6	insulin	B
7	receptor	I
8	(	I
9	IR	I
10	)	I
11	beta	I
12	-	I
13	subunit	I
14	contains	O
15	an	O
16	unphosphorylated	O
17	tyrosyl	O
18	residue	O
19	(	O
20	Tyr960	O
21	)	O
22	that	O
23	is	O
24	essential	O
25	for	O
26	insulin	B
27	-	O
28	stimulated	O
29	tyrosyl	O
30	phosphorylation	O
31	of	O
32	some	O
33	endogenous	O
34	substrates	O
35	and	O
36	certain	O
37	biological	O
38	responses	O
39	(	O
40	White	O
41	,	O
42	M	O
43	.	O
44	F	O
45	.,	O
46	Livingston	O
47	,	O
48	J	O
49	.	O
50	N	O
51	.,	O
52	Backer	O
53	,	O
54	J	O
55	.	O
56	M	O
57	.,	O
58	Lauris	O
59	,	O
60	V	O
61	.,	O
62	Dull	O
63	,	O
64	T	O
65	.	O
66	J	O
67	.,	O
68	Ullrich	O
69	,	O
70	A	O
71	.,	O
72	and	O
73	Kahn	O
74	,	O
75	C	O
76	.	O
77	R	O
78	.	O

1	This	O
2	gene	O
3	joins	O
4	the	O
5	group	O
6	of	O
7	genes	O
8	whose	O
9	members	O
10	are	O
11	rapidly	O
12	transcribed	O
13	in	O
14	response	O
15	to	O
16	insulin	B
17	and	O
18	other	O
19	mitogens	O
20	.	O

1	The	O
2	3	O
3	'	O
4	region	O
5	,	O
6	GA2	B
7	,	O
8	is	O
9	necessary	O
10	for	O
11	maximal	O
12	expression	O
13	.	O

1	1	O
2	,	O
3	among	O
4	which	O
5	nine	O
6	have	O
7	been	O
8	cloned	O
9	and	O
10	two	O
11	(	O
12	potentially	O
13	functional	O
14	)	O
15	sequenced	O
16	.	O

1	Pups	O
2	placed	O
3	into	O
4	the	O
5	novel	O
6	environment	O
7	with	O
8	their	O
9	mothers	O
10	exhibited	O
11	an	O
12	intermediate	O
13	level	O
14	of	O
15	DA	O
16	turnover	O
17	.	O

1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O

1	Homozygous	O
2	protein	B
3	C	I
4	(	O
5	PC	B
6	)	O
7	deficiency	O
8	is	O
9	reported	O
10	in	O
11	two	O
12	siblings	O
13	(	O
14	girl	O
15	and	O
16	boy	O
17	)	O
18	who	O
19	received	O
20	their	O
21	proper	O
22	diagnoses	O
23	at	O
24	the	O
25	ages	O
26	of	O
27	7	O
28	4	O
29	/	O
30	12	O
31	and	O
32	1	O
33	3	O
34	/	O
35	12	O
36	years	O
37	respectively	O
38	.	O

1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O

1	Abnormal	O
2	intrapulmonary	O
3	shunting	O
4	(	O
5	IPS	O
6	),	O
7	which	O
8	was	O
9	proved	O
10	in	O
11	4	O
12	cases	O
13	by	O
14	whole	O
15	-	O
16	body	O
17	radionuclide	O
18	scanning	O
19	with	O
20	99mTc	O
21	-	O
22	MAA	O
23	,	O
24	is	O
25	suggested	O
26	as	O
27	the	O
28	major	O
29	cause	O
30	of	O
31	cyanosis	O
32	in	O
33	liver	O
34	cirrhosis	O
35	.	O

1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	B
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O

1	More	O
2	generally	O
3	,	O
4	Ets1	B
5	and	O
6	Ets2	B
7	could	O
8	regulate	O
9	transcription	O
10	of	O
11	cellular	O
12	genes	O
13	.	O

1	Within	O
2	this	O
3	sequence	O
4	the	O
5	MSAS	B
6	gene	I
7	was	O
8	identified	O
9	as	O
10	a	O
11	5322	O
12	-	O
13	bp	O
14	-	O
15	long	O
16	open	O
17	reading	O
18	frame	O
19	coding	O
20	for	O
21	a	O
22	protein	O
23	of	O
24	1774	O
25	amino	O
26	acids	O
27	and	O
28	190	O
29	,	O
30	731	O
31	Da	O
32	molecular	O
33	mass	O
34	.	O

1	Horseradish	B
2	peroxidase	I
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O

1	Standardized	O
2	gastric	O
3	wall	O
4	specimens	O
5	from	O
6	the	O
7	area	O
8	of	O
9	grossly	O
10	healed	O
11	ulcers	O
12	were	O
13	obtained	O
14	,	O
15	processed	O
16	,	O
17	and	O
18	evaluated	O
19	by	O
20	light	O
21	microscopy	O
22	and	O
23	by	O
24	transmission	O
25	electron	O
26	microscopy	O
27	.	O

1	2	O
2	.	O

1	The	O
2	effects	O
3	of	O
4	coenzyme	O
5	Q10	O
6	(	O
7	CoQ	O
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O

1	Evidence	O
2	that	O
3	therapeutic	O
4	alterations	O
5	of	O
6	a	O
7	circadian	O
8	rhythm	O
9	for	O
10	gastric	O
11	emptying	O
12	response	O
13	may	O
14	be	O
15	possible	O
16	.	O

1	The	O
2	interrelation	O
3	of	O
4	the	O
5	levels	O
6	of	O
7	glucocorticoids	O
8	and	O
9	insulin	B
10	in	O
11	the	O
12	blood	O
13	of	O
14	irradiated	O
15	animals	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	Foveating	O
2	saccades	O
3	,	O
4	therefore	O
5	,	O
6	can	O
7	be	O
8	distinguished	O
9	from	O
10	other	O
11	FEMs	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	speed	O
17	.	O

1	Incidence	O
2	correlated	O
3	with	O
4	the	O
5	grade	O
6	of	O
7	oral	O
8	hygiene	O
9	und	O
10	periodontal	O
11	disease	O
12	.	O

1	Our	O
2	study	O
3	shows	O
4	that	O
5	the	O
6	area	O
7	of	O
8	Alcoy	O
9	is	O
10	a	O
11	medium	O
12	MS	O
13	risk	O
14	region	O
15	according	O
16	to	O
17	the	O
18	thesis	O
19	of	O
20	Kurzke	O
21	,	O
22	although	O
23	high	O
24	MS	O
25	areas	O
26	may	O
27	be	O
28	found	O
29	,	O
30	thus	O
31	confirming	O
32	that	O
33	MS	O
34	distribution	O
35	in	O
36	southern	O
37	Europe	O
38	is	O
39	not	O
40	uniform	O
41	.	O

1	On	O
2	an	O
3	antithrombin	B
4	unit	O
5	basis	O
6	,	O
7	CY	O
8	216	O
9	and	O
10	CY	O
11	222	O
12	were	O
13	equivalent	O
14	and	O
15	more	O
16	potent	O
17	than	O
18	UH	O
19	.	O

1	Chick	B
2	brain	I
3	actin	I
4	depolymerizing	I
5	factor	I
6	(	O
7	ADF	B
8	)	O
9	is	O
10	a	O
11	19	O
12	-	O
13	kDa	O
14	protein	O
15	that	O
16	severs	O
17	actin	B
18	filaments	I
19	and	O
20	binds	O
21	actin	B
22	monomers	I
23	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	Comprehensive	O
2	care	O
3	of	O
4	the	O
5	patient	O
6	exposed	O
7	to	O
8	a	O
9	human	O
10	teratogen	O
11	may	O
12	also	O
13	include	O
14	discussion	O
15	of	O
16	prenatal	O
17	diagnostic	O
18	procedures	O
19	and	O
20	other	O
21	pregnancy	O
22	management	O
23	options	O
24	.	O

1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	B
15	ODC	I
16	mRNA	I
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O

1	For	O
2	85Sr	O
3	,	O
4	larger	O
5	-	O
6	than	O
7	-	O
8	expected	O
9	distribution	O
10	coefficients	O
11	were	O
12	obtained	O
13	in	O
14	the	O
15	desorption	O
16	experiments	O
17	,	O
18	an	O
19	indication	O
20	of	O
21	the	O
22	irreversible	O
23	formation	O
24	of	O
25	metal	O
26	-	O
27	oxyhydroxides	O
28	during	O
29	a	O
30	slow	O
31	reaction	O
32	.	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	B
6	tat	I
7	,	O
8	rev	B
9	(	O
10	tat	B
11	+	I
12	rev	O
13	+)	O
14	and	O
15	env	B
16	genes	I
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	B
27	SU	I
28	-	I
29	TM	I
30	(	O
31	gp160	B
32	),	O
33	SU	B
34	.	I
35	TM	I
36	(	O
37	gp120	B
38	x	I
39	41	I
40	),	O
41	and	O
42	nucleolar	B
43	rev	I
44	protein	I
45	.	O

1	This	O
2	growth	O
3	arrest	O
4	is	O
5	partly	O
6	suppressed	O
7	on	O
8	minimal	O
9	medium	O
10	or	O
11	under	O
12	conditions	O
13	in	O
14	which	O
15	the	O
16	cells	O
17	are	O
18	less	O
19	dependent	O
20	on	O
21	mitochondrial	O
22	metabolism	O
23	.	O

1	Patients	O
2	with	O
3	detectable	O
4	serum	O
5	TNF	B
6	levels	O
7	had	O
8	significantly	O
9	lower	O
10	serum	O
11	T3	O
12	concentrations	O
13	compared	O
14	to	O
15	those	O
16	with	O
17	undetectable	O
18	levels	O
19	[	O
20	1	O
21	.	O
22	072	O
23	+/-	O
24	0	O
25	.	O
26	588	O
27	vs	O
28	.	O

1	Giant	O
2	pilomatrix	O
3	carcinoma	O
4	:	O
5	report	O
6	and	O
7	review	O
8	of	O
9	the	O
10	literature	O
11	.	O

1	Further	O
2	studies	O
3	of	O
4	mandibular	O
5	movement	O
6	at	O
7	initial	O
8	tooth	O
9	contact	O
10	.	O

1	Each	O
2	parent	O
3	interacted	O
4	with	O
5	their	O
6	4	O
7	-	O
8	or	O
9	5	O
10	-	O
11	year	O
12	-	O
13	old	O
14	son	O
15	or	O
16	daughter	O
17	in	O
18	each	O
19	of	O
20	two	O
21	conversations	O
22	--	O
23	unstructured	O
24	(	O
25	social	O
26	conversation	O
27	)	O
28	and	O
29	structured	O
30	(	O
31	task	O
32	activity	O
33	).	O

1	Droperidol	O
2	-	O
3	induced	O
4	extrapyramidal	O
5	symptoms	O
6	in	O
7	an	O
8	adolescent	O
9	following	O
10	strabismus	O
11	surgery	O
12	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	cis	O
7	-	O
8	regulatory	O
9	elements	O
10	required	O
11	for	O
12	developmental	O
13	control	O
14	of	O
15	the	O
16	HaG3	B
17	-	I
18	A	I
19	helianthinin	I
20	gene	I
21	are	O
22	located	O
23	in	O
24	a	O
25	2	O
26	.	O
27	4	O
28	kb	O
29	upstream	O
30	region	O
31	of	O
32	this	O
33	gene	O
34	.	O

1	The	O
2	induction	O
3	by	O
4	pseudorabies	O
5	virus	O
6	of	O
7	an	O
8	IL	B
9	-	I
10	6	I
11	construct	I
12	containing	O
13	the	O
14	IL	B
15	-	I
16	6	I
17	TATA	I
18	box	I
19	and	O
20	the	O
21	RNA	O
22	start	O
23	site	O
24	("	O
25	initiator	O
26	"	O
27	or	O
28	Inr	O
29	element	O
30	)	O
31	but	O
32	not	O
33	the	O
34	MRE	O
35	region	O
36	was	O
37	also	O
38	repressed	O
39	by	O
40	Dex	O
41	in	O
42	the	O
43	presence	O
44	of	O
45	wild	B
46	-	I
47	type	I
48	GR	I
49	.	O

1	Some	O
2	mutations	O
3	affected	O
4	Dhfr	B
5	in	O
6	a	O
7	qualitative	O
8	manner	O
9	,	O
10	such	O
11	as	O
12	by	O
13	changing	O
14	the	O
15	startpoint	O
16	of	O
17	one	O
18	of	O
19	the	O
20	major	O
21	Dhfr	B
22	transcripts	I
23	or	O
24	changing	O
25	the	O
26	relative	O
27	abundance	O
28	of	O
29	the	O
30	two	O
31	major	O
32	Dhfr	B
33	transcripts	I
34	.	O

1	The	O
2	glial	O
3	cyst	O
4	wall	O
5	was	O
6	lined	O
7	in	O
8	part	O
9	by	O
10	flattened	O
11	or	O
12	cuboidal	O
13	epithelium	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O

1	As	O
2	in	O
3	mammals	O
4	,	O
5	considerable	O
6	nucleotide	O
7	diversity	O
8	was	O
9	observed	O
10	at	O
11	the	O
12	junctions	O
13	of	O
14	the	O
15	variable	O
16	,	O
17	diversity	O
18	,	O
19	and	O
20	joining	O
21	elements	O
22	in	O
23	chicken	B
24	TCR	I
25	beta	I
26	cDNAs	I
27	.	O

1	The	O
2	protooncogene	O
3	c	B
4	-	I
5	myb	I
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O

1	Modification	O
2	by	O
3	this	O
4	latter	O
5	compound	O
6	was	O
7	so	O
8	extensive	O
9	that	O
10	the	O
11	amount	O
12	of	O
13	membrane	O
14	-	O
15	associated	O
16	N	O
17	-	O
18	myristoylated	O
19	protein	O
20	was	O
21	decreased	O
22	.	O

1	S6	B
2	kinase	I
3	activation	O
4	requires	O
5	displacement	O
6	of	O
7	this	O
8	inhibitory	O
9	segment	O
10	,	O
11	which	O
12	is	O
13	proposed	O
14	to	O
15	occur	O
16	consequent	O
17	to	O
18	its	O
19	multiple	O
20	phosphorylation	O
21	.	O

1	Rats	O
2	with	O
3	one	O
4	olfactory	O
5	bulb	O
6	removed	O
7	and	O
8	the	O
9	contralateral	O
10	naris	O
11	closed	O
12	can	O
13	detect	O
14	odors	O
15	.	O

1	Expression	O
2	of	O
3	the	O
4	human	O
5	T	B
6	cell	I
7	receptor	I
8	(	I
9	TCR	I
10	)	I
11	alpha	I
12	gene	I
13	is	O
14	regulated	O
15	by	O
16	a	O
17	T	O
18	cell	O
19	-	O
20	specific	O
21	transcriptional	O
22	enhancer	O
23	that	O
24	is	O
25	located	O
26	4	O
27	.	O
28	5	O
29	kilobases	O
30	(	O
31	kb	O
32	)	O
33	3	O
34	'	O
35	to	O
36	the	O
37	C	B
38	alpha	I
39	gene	I
40	segment	I
41	.	O

1	The	O
2	Ets	B
3	-	I
4	1	I
5	binding	I
6	site	I
7	was	O
8	localized	O
9	to	O
10	a	O
11	17	O
12	-	O
13	base	O
14	pair	O
15	(	O
16	bp	O
17	)	O
18	region	O
19	from	O
20	the	O
21	3	O
22	'	O
23	end	O
24	of	O
25	T	B
26	alpha	I
27	2	I
28	.	O

1	Cerebral	O
2	flow	O
3	and	O
4	resistance	O
5	showed	O
6	minor	O
7	reductions	O
8	with	O
9	HD	O
10	.	O

1	Utilization	O
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	B
13	mRNAs	I
14	of	I
15	1	I
16	.	I
17	9	I
18	and	I
19	4	I
20	.	I
21	3	I
22	kb	I
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	Presidential	O
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	encodes	O
15	a	O
16	40	O
17	-	O
18	kDa	O
19	nuclear	O
20	protein	O
21	,	O
22	Tax	B
23	,	O
24	which	O
25	stimulates	O
26	transcription	O
27	from	O
28	three	O
29	21	O
30	-	O
31	base	O
32	pair	O
33	(	O
34	bp	O
35	)	O
36	repeats	O
37	in	O
38	its	O
39	U3	O
40	region	O
41	.	O

1	We	O
2	have	O
3	now	O
4	identified	O
5	,	O
6	after	O
7	21	O
8	serial	O
9	undiluted	O
10	passages	O
11	of	O
12	MHV	O
13	,	O
14	a	O
15	small	B
16	DI	I
17	RNA	I
18	,	O
19	DIssF	B
20	,	O
21	which	O
22	is	O
23	efficiently	O
24	packaged	O
25	into	O
26	virions	O
27	.	O

1	The	O
2	Jenkins	O
3	Activity	O
4	Survey	O
5	and	O
6	the	O
7	CPI	O
8	-	O
9	revised	O
10	:	O
11	further	O
12	evidence	O
13	of	O
14	adaptive	O
15	and	O
16	maladaptive	O
17	type	O
18	A	O
19	traits	O
20	.	O

1	There	O
2	was	O
3	evidence	O
4	of	O
5	attenuated	O
6	regression	O
7	slopes	O
8	relating	O
9	recalled	O
10	to	O
11	observed	O
12	portion	O
13	sizes	O
14	for	O
15	4	O
16	of	O
17	the	O
18	10	O
19	food	O
20	groups	O
21	;	O
22	adjusted	O
23	r2	O
24	values	O
25	for	O
26	the	O
27	recalled	O
28	portion	O
29	sizes	O
30	ranged	O
31	from	O
32	0	O
33	.	O
34	02	O
35	to	O
36	0	O
37	.	O
38	94	O
39	.	O

1	The	O
2	result	O
3	suggests	O
4	that	O
5	this	O
6	non	O
7	-	O
8	invasive	O
9	TTD	O
10	method	O
11	is	O
12	easily	O
13	available	O
14	and	O
15	useful	O
16	in	O
17	monitoring	O
18	the	O
19	intraoperative	O
20	cardiac	O
21	output	O
22	.	O

1	The	O
2	TUP1	B
3	gene	I
4	was	O
5	isolated	O
6	in	O
7	a	O
8	screen	O
9	for	O
10	genes	O
11	that	O
12	regulate	O
13	mating	O
14	type	O
15	(	O
16	V	O
17	.	O
18	L	O
19	.	O

1	The	O
2	SUP44	B
3	suppressor	I
4	mutation	I
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	B
22	.	I
23	coli	I
24	S5	I
25	ram	I
26	mutations	I
27	.	O

1	Interestingly	O
2	,	O
3	disruption	O
4	of	O
5	the	O
6	VPS34	B
7	locus	I
8	resulted	O
9	in	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	growth	O
15	defect	O
16	,	O
17	indicating	O
18	that	O
19	the	O
20	VPS34	B
21	gene	I
22	is	O
23	essential	O
24	for	O
25	vegetative	O
26	growth	O
27	only	O
28	at	O
29	elevated	O
30	growth	O
31	temperatures	O
32	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	a	O
7	perinephric	O
8	abscess	O
9	treated	O
10	with	O
11	amphotericin	O
12	B	O
13	and	O
14	nephrectomy	O
15	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	This	O
2	interaction	O
3	occurs	O
4	over	O
5	a	O
6	wide	O
7	range	O
8	of	O
9	both	O
10	parameters	O
11	;	O
12	for	O
13	charge	O
14	density	O
15	from	O
16	at	O
17	least	O
18	10	O
19	to	O
20	800	O
21	microC	O
22	/	O
23	cm2	O
24	and	O
25	,	O
26	for	O
27	charge	O
28	per	O
29	phase	O
30	,	O
31	from	O
32	at	O
33	least	O
34	0	O
35	.	O
36	05	O
37	to	O
38	5	O
39	.	O
40	0	O
41	microC	O
42	per	O
43	phase	O
44	.	O

1	Perceptions	O
2	of	O
3	illness	O
4	intrusiveness	O
5	were	O
6	significantly	O
7	higher	O
8	when	O
9	both	O
10	muscle	O
11	cramp	O
12	and	O
13	headache	O
14	symptoms	O
15	occurred	O
16	during	O
17	one	O
18	or	O
19	more	O
20	assessment	O
21	intervals	O
22	as	O
23	compared	O
24	to	O
25	when	O
26	muscle	O
27	cramps	O
28	or	O
29	headaches	O
30	,	O
31	only	O
32	,	O
33	occurred	O
34	.	O

1	Results	O
2	have	O
3	surprisingly	O
4	revealed	O
5	the	O
6	presence	O
7	of	O
8	three	O
9	U14	B
10	snRNA	I
11	-	I
12	homologous	I
13	regions	I
14	positioned	O
15	within	O
16	introns	O
17	5	O
18	,	O
19	6	O
20	,	O
21	and	O
22	8	O
23	of	O
24	the	O
25	mouse	O
26	cognate	O
27	hsc70	B
28	heat	O
29	shock	O
30	gene	O
31	.	O

1	65	O
2	-	O
3	kilodalton	O
4	protein	O
5	phosphorylated	O
6	by	O
7	interleukin	B
8	2	I
9	stimulation	O
10	bears	O
11	two	O
12	putative	O
13	actin	B
14	-	I
15	binding	I
16	sites	I
17	and	O
18	two	O
19	calcium	O
20	-	O
21	binding	O
22	sites	O
23	.	O

1	The	O
2	highly	O
3	restrained	O
4	girls	O
5	had	O
6	a	O
7	significantly	O
8	higher	O
9	EAT	O
10	score	O
11	than	O
12	the	O
13	low	O
14	-	O
15	restrained	O
16	girls	O
17	,	O
18	and	O
19	shared	O
20	with	O
21	their	O
22	mothers	O
23	a	O
24	susceptibility	O
25	to	O
26	the	O
27	disinhibitory	O
28	effects	O
29	of	O
30	negative	O
31	mood	O
32	states	O
33	on	O
34	their	O
35	eating	O
36	behaviour	O
37	.	O

1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	O
16	3	O
17	.	O
18	6	O
19	and	O
20	3	O
21	.	O
22	7	O
23	kb	O
24	,	O
25	respectively	O
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	O
32	introns	O
33	and	O
34	retroid	O
35	elements	O
36	.	O

1	The	O
2	circadian	O
3	rhythm	O
4	,	O
5	however	O
6	,	O
7	was	O
8	not	O
9	affected	O
10	and	O
11	the	O
12	difference	O
13	between	O
14	minimum	O
15	(	O
16	12	O
17	.	O
18	00	O
19	h	O
20	)	O
21	and	O
22	maximum	O
23	(	O
24	18	O
25	.	O
26	50	O
27	h	O
28	)	O
29	serum	O
30	concentrations	O
31	was	O
32	31	O
33	.	O
34	3	O
35	%.	O

1	Sequence	O
2	and	O
3	genetic	O
4	organization	O
5	of	O
6	a	O
7	Zymomonas	O
8	mobilis	O
9	gene	O
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O

1	Most	O
2	strains	O
3	(	O
4	95	O
5	%)	O
6	of	O
7	S	O
8	.	O
9	lugdunensis	O
10	produced	O
11	a	O
12	delta	B
13	hemolysin	I
14	like	O
15	that	O
16	seen	O
17	with	O
18	nine	O
19	other	O
20	species	O
21	of	O
22	CNS	O
23	.	O

1	For	O
2	this	O
3	,	O
4	cDNAs	O
5	containing	O
6	the	O
7	60K	O
8	,	O
9	87K	O
10	,	O
11	110K	O
12	and	O
13	170K	O
14	protein	O
15	coding	O
16	sequences	O
17	were	O
18	each	O
19	provided	O
20	with	O
21	an	O
22	ATG	O
23	start	O
24	codon	O
25	and	O
26	the	O
27	cDNA	O
28	containing	O
29	the	O
30	60K	O
31	coding	O
32	sequence	O
33	with	O
34	a	O
35	TAA	O
36	stop	O
37	codon	O
38	immediately	O
39	downstream	O
40	of	O
41	the	O
42	coding	O
43	sequence	O
44	.	O

1	Finally	O
2	,	O
3	a	O
4	complementary	O
5	footprinting	O
6	analysis	O
7	of	O
8	the	O
9	upstream	O
10	region	O
11	of	O
12	the	O
13	constitutively	O
14	expressed	O
15	HSC82	B
16	gene	I
17	reveals	O
18	the	O
19	presence	O
20	of	O
21	three	O
22	discrete	O
23	protein	O
24	complexes	O
25	.	O

1	Pathophysiology	O
2	of	O
3	bone	O
4	loss	O
5	in	O
6	castrated	O
7	animals	O
8	.	O

1	Auditory	O
2	-	O
3	visual	O
4	interaction	O
5	in	O
6	the	O
7	generation	O
8	of	O
9	saccades	O
10	in	O
11	man	O
12	.	O

1	First	O
2	,	O
3	each	O
4	lung	O
5	was	O
6	cut	O
7	into	O
8	slices	O
9	,	O
10	from	O
11	which	O
12	primary	O
13	disectors	O
14	were	O
15	sampled	O
16	systematically	O
17	with	O
18	a	O
19	known	O
20	sampling	O
21	fraction	O
22	.	O

1	The	O
2	upstream	O
3	promoter	O
4	is	O
5	located	O
6	within	O
7	the	O
8	coding	O
9	sequence	O
10	of	O
11	a	O
12	divergent	O
13	gene	O
14	expressing	O
15	a	O
16	protein	O
17	of	O
18	Mr	O
19	39	O
20	kDa	O
21	of	O
22	unknown	O
23	function	O
24	.	O

1	Assuming	O
2	O2	O
3	consumption	O
4	of	O
5	the	O
6	isolated	O
7	skin	O
8	to	O
9	be	O
10	same	O
11	as	O
12	in	O
13	situ	O
14	,	O
15	calculations	O
16	showed	O
17	that	O
18	when	O
19	water	O
20	PO2	O
21	was	O
22	high	O
23	(	O
24	150	O
25	mm	O
26	Hg	O
27	),	O
28	about	O
29	40	O
30	%	O
31	of	O
32	total	O
33	cutaneous	O
34	O2	O
35	uptake	O
36	was	O
37	consumed	O
38	by	O
39	the	O
40	skin	O
41	.	O

1	Experiments	O
2	showed	O
3	that	O
4	temporary	O
5	arrest	O
6	of	O
7	pulmonary	O
8	circulation	O
9	under	O
10	conditions	O
11	of	O
12	extracorporeal	O
13	circulation	O
14	is	O
15	attended	O
16	by	O
17	the	O
18	development	O
19	of	O
20	ischemia	O
21	of	O
22	the	O
23	respiratory	O
24	pulmonary	O
25	tissue	O
26	.	O

1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O

1	Taste	O
2	reactivity	O
3	tests	O
4	were	O
5	used	O
6	to	O
7	examine	O
8	the	O
9	orofacial	O
10	responses	O
11	of	O
12	alcohol	O
13	preferring	O
14	(	O
15	P	O
16	)	O
17	rats	O
18	and	O
19	alcohol	O
20	nonpreferring	O
21	(	O
22	NP	O
23	)	O
24	rats	O
25	to	O
26	the	O
27	taste	O
28	of	O
29	alcohol	O
30	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	atracurium	O
5	and	O
6	laudanosine	O
7	were	O
8	0	O
9	.	O
10	73	O
11	-	O
12	3	O
13	.	O
14	11	O
15	micrograms	O
16	ml	O
17	-	O
18	1	O
19	and	O
20	0	O
21	.	O
22	48	O
23	-	O
24	8	O
25	.	O
26	65	O
27	micrograms	O
28	ml	O
29	-	O
30	1	O
31	,	O
32	respectively	O
33	;	O
34	CSF	O
35	concentration	O
36	of	O
37	laudanosine	O
38	was	O
39	70	O
40	-	O
41	440	O
42	ng	O
43	ml	O
44	-	O
45	1	O
46	.	O

1	Plasma	O
2	Al	O
3	was	O
4	obtained	O
5	during	O
6	each	O
7	baseline	O
8	and	O
9	drug	O
10	course	O
11	.	O

1	The	O
2	survival	O
3	in	O
4	the	O
5	case	O
6	of	O
7	these	O
8	patients	O
9	was	O
10	studied	O
11	five	O
12	years	O
13	later	O
14	.	O

1	The	O
2	occurrence	O
3	,	O
4	maintenance	O
5	and	O
6	possible	O
7	involvement	O
8	of	O
9	these	O
10	repeated	O
11	sequences	O
12	,	O
13	capable	O
14	of	O
15	forming	O
16	stable	O
17	secondary	O
18	structures	O
19	,	O
20	are	O
21	discussed	O
22	in	O
23	relation	O
24	to	O
25	their	O
26	location	O
27	in	O
28	the	O
29	region	O
30	of	O
31	control	O
32	signals	O
33	.	O

1	IST	B
2	is	O
3	not	O
4	the	O
5	RNA	O
6	target	O
7	(	O
8	TAR	O
9	)	O
10	for	O
11	Tat	B
12	trans	O
13	-	O
14	activation	O
15	;	O
16	however	O
17	,	O
18	because	O
19	it	O
20	relies	O
21	entirely	O
22	on	O
23	cellular	O
24	factors	O
25	for	O
26	activity	O
27	,	O
28	IST	B
29	may	O
30	serve	O
31	to	O
32	provide	O
33	abundant	O
34	RNA	O
35	targets	O
36	for	O
37	Tat	B
38	trans	O
39	-	O
40	activation	O
41	without	O
42	a	O
43	requirement	O
44	for	O
45	full	O
46	-	O
47	length	O
48	viral	O
49	mRNA	O
50	expression	O
51	.	O

1	Genotoxic	O
2	activity	O
3	of	O
4	a	O
5	tobacco	O
6	-	O
7	specific	O
8	nitrosamine	O
9	.	O

1	The	O
2	endodontal	O
3	treatment	O
4	need	O
5	has	O
6	been	O
7	forming	O
8	a	O
9	clinical	O
10	order	O
11	of	O
12	magnitude	O
13	.	O

1	1	O
2	("	O
3	long	O
4	method	O
5	")	O
6	and	O
7	the	O
8	HML	O
9	method	O
10	.	O

1	These	O
2	results	O
3	may	O
4	suggest	O
5	involvement	O
6	of	O
7	peripheral	O
8	enkephalins	O
9	in	O
10	pain	O
11	modulation	O
12	in	O
13	patients	O
14	with	O
15	episodic	O
16	cluster	O
17	headache	O
18	.	O

1	Effects	O
2	of	O
3	cisapride	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	digestive	O
11	hormones	O

1	Common	O
2	foot	O
3	pathologies	O
4	are	O
5	heel	O
6	pain	O
7	,	O
8	metatarsalgia	O
9	,	O
10	hammertoes	O
11	and	O
12	clawtoes	O
13	,	O
14	bunions	O
15	,	O
16	hallux	O
17	rigidus	O
18	,	O
19	corns	O
20	and	O
21	calluses	O
22	,	O
23	nail	O
24	pathologies	O
25	,	O
26	arthritis	O
27	,	O
28	and	O
29	neuropathies	O
30	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	Coenzyme	O
2	Q10	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	demand	O
9	.	O

1	The	O
2	CT	O
3	characteristics	O
4	are	O
5	discussed	O
6	and	O
7	the	O
8	recent	O
9	literature	O
10	is	O
11	reviewed	O
12	.	O

1	Unfortunately	O
2	,	O
3	these	O
4	preservatives	O
5	may	O
6	also	O
7	interfere	O
8	with	O
9	microbiological	O
10	assays	O
11	used	O
12	to	O
13	determine	O
14	product	O
15	sterility	O
16	or	O
17	bioburden	O
18	levels	O
19	.	O

1	In	O
2	26	O
3	patients	O
4	with	O
5	angina	O
6	pectoris	O
7	,	O
8	the	O
9	changes	O
10	of	O
11	LVEF	O
12	,	O
13	LVESV	O
14	and	O
15	PSP	O
16	/	O
17	LVESV	O
18	were	O
19	more	O
20	sensitive	O
21	for	O
22	the	O
23	detection	O
24	of	O
25	exercise	O
26	-	O
27	induced	O
28	ischemia	O
29	than	O
30	the	O
31	appearance	O
32	of	O
33	chest	O
34	pain	O
35	and	O
36	the	O
37	changes	O
38	of	O
39	ECG	O
40	.	O

1	In	O
2	both	O
3	groups	O
4	there	O
5	were	O
6	5	O
7	management	O
8	failure	O
9	of	O
10	therapy	O
11	,	O
12	so	O
13	that	O
14	alternative	O
15	medication	O
16	or	O
17	a	O
18	cesarean	O
19	section	O
20	lead	O
21	to	O
22	delivery	O
23	.	O

1	Serum	O
2	Fibrin	B
3	Degradation	I
4	Products	I
5	(	O
6	FDP	B
7	)	O
8	were	O
9	determined	O
10	in	O
11	50	O
12	oral	O
13	cancer	O
14	patients	O
15	and	O
16	50	O
17	normal	O
18	individuals	O
19	prior	O
20	to	O
21	any	O
22	kind	O
23	of	O
24	treatment	O
25	.	O

1	The	O
2	uteroglobin	B
3	promoter	I
4	contains	O
5	a	O
6	noncanonical	O
7	estrogen	O
8	responsive	O
9	element	O
10	.	O

1	Prostaglandin	O
2	synthesis	O
3	inhibitors	O
4	have	O
5	been	O
6	shown	O
7	to	O
8	delay	O
9	healing	O
10	of	O
11	bone	O
12	and	O
13	this	O
14	has	O
15	led	O
16	to	O
17	limitations	O
18	on	O
19	their	O
20	use	O
21	clinically	O
22	in	O
23	some	O
24	situations	O
25	.	O

1	The	O
2	inspiratory	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	FiO2	O
8	)	O
9	and	O
10	the	O
11	Horowitz	O
12	quotient	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	1st	O
23	day	O
24	after	O
25	trauma	O
26	.	O

1	The	O
2	corn	O
3	and	O
4	mineral	O
5	oil	O
6	emulsions	O
7	were	O
8	almost	O
9	as	O
10	effective	O
11	as	O
12	milk	O
13	but	O
14	less	O
15	effective	O
16	than	O
17	sucrose	O
18	(	O
19	0	O
20	.	O
21	3M	O
22	)	O
23	in	O
24	stimulating	O
25	ingestion	O
26	.	O

1	Significance	O
2	of	O
3	thin	O
4	glomerular	O
5	basement	O
6	membranes	O
7	in	O
8	hematuric	O
9	children	O
10	.	O

1	Significance	O
2	of	O
3	cytokine	O
4	production	O
5	and	O
6	adhesion	O
7	molecules	O
8	in	O
9	malarial	O
10	immunopathology	O
11	.	O

1	The	O
2	former	O
3	procedure	O
4	is	O
5	economical	O
6	but	O
7	complicated	O
8	,	O
9	whereas	O
10	the	O
11	latter	O
12	is	O
13	simple	O
14	and	O
15	labour	O
16	-	O
17	saving	O
18	,	O
19	but	O
20	a	O
21	special	O
22	ultrafiltration	O
23	tube	O
24	is	O
25	required	O
26	.	O

1	Simple	O
2	method	O
3	for	O
4	determination	O
5	of	O
6	the	O
7	cephalosporin	O
8	DQ	O
9	-	O
10	2556	O
11	in	O
12	biological	O
13	fluids	O
14	by	O
15	high	O
16	-	O
17	performance	O
18	liquid	O
19	chromatography	O
20	.	O

1	Since	O
2	one	O
3	group	O
4	of	O
5	adolescents	O
6	more	O
7	difficult	O
8	to	O
9	influence	O
10	are	O
11	those	O
12	whose	O
13	parents	O
14	smoke	O
15	,	O
16	parental	O
17	involvement	O
18	in	O
19	smoking	O
20	prevention	O
21	may	O
22	be	O
23	a	O
24	powerful	O
25	enhancer	O
26	.	O

1	Further	O
2	research	O
3	is	O
4	recommended	O
5	to	O
6	identify	O
7	the	O
8	coping	O
9	styles	O
10	associated	O
11	with	O
12	the	O
13	high	O
14	EE	O
15	/	O
16	low	O
17	EE	O
18	research	O
19	classification	O
20	.	O

1	Staining	O
2	with	O
3	IF	O
4	MoAB	O
5	alone	O
6	of	O
7	BAL	O
8	fluid	O
9	only	O
10	seemed	O
11	to	O
12	be	O
13	even	O
14	more	O
15	sensitive	O
16	than	O
17	silver	O
18	methenamine	O
19	staining	O
20	of	O
21	BAL	O
22	,	O
23	TBB	O
24	and	O
25	brushing	O
26	material	O
27	.	O

1	Ultrastructural	O
2	and	O
3	morphometric	O
4	study	O
5	of	O
6	the	O
7	myeloid	O
8	parenchyma	O
9	cells	O
10	of	O
11	mice	O
12	prior	O
13	and	O
14	after	O
15	X	O
16	-	O
17	ray	O
18	exposure	O

1	Using	O
2	an	O
3	audiotape	O
4	cassette	O
5	and	O
6	headphones	O
7	the	O
8	duration	O
9	of	O
10	the	O
11	hallucinations	O
12	decreased	O
13	significantly	O
14	.	O

1	The	O
2	mean	O
3	change	O
4	in	O
5	HbA1	B
6	,	O
7	adjusted	O
8	for	O
9	the	O
10	initial	O
11	value	O
12	,	O
13	was	O
14	-	O
15	0	O
16	.	O
17	4	O
18	%	O
19	in	O
20	the	O
21	experimental	O
22	and	O
23	+	O
24	0	O
25	.	O
26	5	O
27	%	O
28	in	O
29	the	O
30	control	O
31	group	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Effect	O
2	of	O
3	biliary	O
4	obstruction	O
5	and	O
6	cholangitis	O
7	on	O
8	serum	B
9	SPan	I
10	-	I
11	1	I
12	level	O

1	Very	O
2	good	O
3	accuracy	O
4	(	O
5	r	O
6	greater	O
7	than	O
8	0	O
9	.	O
10	9	O
11	)	O
12	was	O
13	found	O
14	when	O
15	except	O
16	comparing	O
17	H	O
18	*	O
19	2	O
20	with	O
21	the	O
22	other	O
23	machine	O
24	and	O
25	the	O
26	reference	O
27	methods	O
28	,	O
29	except	O
30	for	O
31	MCHCH	O
32	and	O
33	basophil	O
34	count	O
35	.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	Antileukoproteinase	B
2	(	O
3	ALP	B
4	)	O
5	is	O
6	a	O
7	low	O
8	mol	O
9	wt	O
10	mucosal	O
11	secretory	O
12	protein	O
13	which	O
14	,	O
15	in	O
16	human	O
17	tissues	O
18	,	O
19	inhibits	O
20	the	O
21	activities	O
22	of	O
23	the	O
24	neutral	O
25	serine	B
26	lysosomal	I
27	proteinases	I
28	elastase	I
29	and	O
30	cathepsin	B
31	-	I
32	G	I
33	.	O

1	By	O
2	introducing	O
3	a	O
4	series	O
5	of	O
6	deletions	O
7	in	O
8	the	O
9	vimentin	B
10	promoter	O
11	,	O
12	we	O
13	further	O
14	restrict	O
15	these	O
16	sequences	O
17	to	O
18	30	O
19	base	O
20	pairs	O
21	,	O
22	located	O
23	between	O
24	241	O
25	and	O
26	210	O
27	base	O
28	pairs	O
29	upstream	O
30	of	O
31	the	O
32	mRNA	O
33	cap	O
34	site	O
35	.	O

1	In	O
2	particular	O
3	,	O
4	71	O
5	and	O
6	69	O
7	%	O
8	amino	O
9	acid	O
10	sequence	O
11	similarities	O
12	were	O
13	identified	O
14	with	O
15	hsp70	B
16	of	I
17	Escherichia	I
18	coli	I
19	and	I
20	Bacillus	I
21	megaterium	I
22	,	O
23	respectively	O
24	.	O

1	No	O
2	causal	O
3	relations	O
4	may	O
5	be	O
6	inferred	O
7	from	O
8	the	O
9	correlation	O
10	between	O
11	the	O
12	level	O
13	of	O
14	trapezius	O
15	activity	O
16	and	O
17	complaints	O
18	,	O
19	though	O
20	it	O
21	indicates	O
22	that	O
23	individual	O
24	,	O
25	inexpedient	O
26	muscle	O
27	activity	O
28	patterns	O
29	may	O
30	constitute	O
31	an	O
32	important	O
33	risk	O
34	factor	O
35	for	O
36	development	O
37	of	O
38	musculo	O
39	-	O
40	skeletal	O
41	complaints	O
42	.	O

1	All	O
2	89	O
3	participating	O
4	household	O
5	members	O
6	were	O
7	anti	B
8	-	I
9	HIV	I
10	seronegative	O
11	,	O
12	and	O
13	78	O
14	who	O
15	were	O
16	tested	O
17	were	O
18	serum	B
19	p24	I
20	antigen	I
21	negative	O
22	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	O
5	-	O
6	peptide	O
7	antibodies	O
8	specific	O
9	for	O
10	alpha	B
11	,	I
12	beta	I
13	,	I
14	or	I
15	gamma	I
16	PKC	I
17	indicated	O
18	that	O
19	all	O
20	three	O
21	types	O
22	of	O
23	PKC	B
24	are	O
25	expressed	O
26	in	O
27	JK	O
28	cells	O
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	B
46	-	I
47	PKC	I
48	alpha	I
49	antibody	I
50	.	O

1	To	O
2	those	O
3	of	O
4	us	O
5	who	O
6	are	O
7	not	O
8	satisfied	O
9	with	O
10	the	O
11	present	O
12	outlook	O
13	there	O
14	is	O
15	much	O
16	to	O
17	be	O
18	investigated	O
19	and	O
20	much	O
21	to	O
22	be	O
23	contributed	O
24	.	O

1	To	O
2	determine	O
3	the	O
4	effects	O
5	on	O
6	the	O
7	pulmonary	O
8	barrier	O
9	of	O
10	several	O
11	surface	O
12	active	O
13	agents	O
14	,	O
15	a	O
16	series	O
17	of	O
18	metered	O
19	dose	O
20	inhalers	O
21	(	O
22	MDIs	O
23	)	O
24	was	O
25	prepared	O
26	and	O
27	used	O
28	to	O
29	dose	O
30	aerosolized	O
31	surfactant	O
32	to	O
33	the	O
34	airways	O
35	of	O
36	isolated	O
37	perfused	O
38	rat	O
39	lungs	O
40	.	O

1	The	O
2	beta	O
3	chain	O
4	contains	O
5	five	O
6	potential	O
7	N	O
8	-	O
9	linked	O
10	glycosylation	O
11	sites	O
12	,	O
13	and	O
14	endoglycosidase	B
15	digestion	O
16	suggested	O
17	that	O
18	the	O
19	beta	O
20	chain	O
21	contained	O
22	multiple	O
23	complex	O
24	carbohydrate	O
25	side	O
26	chains	O
27	.	O

1	The	O
2	therapeutic	O
3	protocole	O
4	used	O
5	at	O
6	the	O
7	Gustave	O
8	Roussy	O
9	Institute	O
10	for	O
11	invasive	O
12	epithelioma	O
13	of	O
14	the	O
15	uterine	O
16	cervix	O
17	rests	O
18	,	O
19	for	O
20	limited	O
21	forms	O
22	(	O
23	T1B	O
24	-	O
25	T2	O
26	proximal	O
27	),	O
28	on	O
29	combined	O
30	radiology	O
31	and	O
32	surgery	O
33	.	O

1	Thyrotropin	B
2	-	O
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	B
11	protein	I
12	related	O
13	to	O
14	the	O
15	trk	B
16	oncogene	I
17	.	O

1	The	O
2	introns	O
3	are	O
4	1	O
5	.	O
6	6	O
7	-	O
8	1	O
9	.	O
10	9	O
11	kbp	O
12	long	O
13	.	O

1	After	O
2	an	O
3	initial	O
4	titration	O
5	period	O
6	and	O
7	adjustment	O
8	of	O
9	the	O
10	therapeutic	O
11	dose	O
12	,	O
13	the	O
14	individual	O
15	doses	O
16	were	O
17	from	O
18	21	O
19	to	O
20	500	O
21	micrograms	O
22	/	O
23	24	O
24	hrs	O
25	(	O
26	mean	O
27	160	O
28	micrograms	O
29	/	O
30	24	O
31	hrs	O
32	).	O

1	In	O
2	the	O
3	first	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	Sprague	O
9	-	O
10	Dawley	O
11	male	O
12	rats	O
13	were	O
14	implanted	O
15	unilaterally	O
16	with	O
17	guide	O
18	cannulas	O
19	aimed	O
20	at	O
21	the	O
22	lateral	O
23	ventricle	O
24	.	O

1	Use	O
2	of	O
3	Selenastrum	O
4	capricornutum	O
5	and	O
6	Microfeast	O
7	as	O
8	food	O
9	for	O
10	Daphnia	O
11	pulex	O
12	.	O

1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	O
8	families	O
9	Tydeidae	O
10	,	O
11	Nanorchestidae	O
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	O
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	O
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	Crry	B
7	gene	I
8	encompass	O
9	over	O
10	25	O
11	kb	O
12	of	O
13	DNA	O
14	,	O
15	whereas	O
16	the	O
17	Crry	B
18	-	O
19	ps	B
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	B
27	.	I
28	6	I
29	-	I
30	kb	I
31	Eco	I
32	-	I
33	R1	I
34	fragment	I
35	.	O

1	The	O
2	genomic	O
3	and	O
4	transcriptional	O
5	complexity	O
6	of	O
7	the	O
8	Crry	B
9	and	O
10	Crry	B
11	-	O
12	ps	B
13	genes	O
14	.	O

1	From	O
2	an	O
3	RNK	O
4	-	O
5	16	O
6	lambda	O
7	-	O
8	gt11	O
9	library	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	and	O
15	sequenced	O
16	a	O
17	novel	O
18	cDNA	O
19	rat	B
20	NK	I
21	cell	I
22	protease	I
23	1	I
24	(	O
25	RNKP	B
26	-	I
27	1	I
28	)	O
29	that	O
30	has	O
31	characteristics	O
32	unique	O
33	to	O
34	serine	B
35	proteases	I
36	.	O

1	The	O
2	induction	O
3	of	O
4	RNKP	B
5	-	I
6	1	I
7	expression	O
8	in	O
9	the	O
10	Con	B
11	A	I
12	-	O
13	cultured	O
14	spleen	O
15	cells	O
16	is	O
17	accompanied	O
18	by	O
19	increases	O
20	in	O
21	both	O
22	NK	O
23	and	O
24	lymphokine	O
25	-	O
26	activated	O
27	killer	O
28	lymphocyte	O
29	activities	O
30	.	O

1	The	O
2	paper	O
3	is	O
4	concerned	O
5	with	O
6	the	O
7	data	O
8	on	O
9	change	O
10	in	O
11	the	O
12	blood	O
13	level	O
14	of	O
15	ACTH	B
16	,	O
17	STH	B
18	,	O
19	TSH	B
20	,	O
21	cortisol	O
22	,	O
23	T3	O
24	,	O
25	insulin	B
26	,	O
27	C	B
28	-	I
29	peptide	I
30	during	O
31	a	O
32	25	O
33	-	O
34	minute	O
35	session	O
36	of	O
37	respiration	O
38	using	O
39	a	O
40	gaseous	O
41	hypoxic	O
42	mixture	O
43	with	O
44	10	O
45	%	O
46	oxygen	O
47	(	O
48	GHM	O
49	-	O
50	10	O
51	).	O

1	The	O
2	abscess	O
3	was	O
4	debrided	O
5	and	O
6	the	O
7	septum	O
8	was	O
9	patched	O
10	with	O
11	a	O
12	single	O
13	layer	O
14	of	O
15	autologous	O
16	pericardium	O
17	.	O

1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O

1	The	O
2	present	O
3	study	O
4	examined	O
5	the	O
6	effect	O
7	of	O
8	intensity	O
9	,	O
10	rate	O
11	,	O
12	and	O
13	polarity	O
14	on	O
15	the	O
16	spectral	O
17	content	O
18	of	O
19	ABRs	O
20	of	O
21	15	O
22	normal	O
23	-	O
24	hearing	O
25	subjects	O
26	.	O

1	Similar	O
2	memory	O
3	impairments	O
4	found	O
5	in	O
6	medial	O
7	septal	O
8	-	O
9	vertical	O
10	diagonal	O
11	band	O
12	of	O
13	Broca	O
14	and	O
15	nucleus	O
16	basalis	O
17	lesioned	O
18	rats	O
19	:	O
20	are	O
21	memory	O
22	defects	O
23	induced	O
24	by	O
25	nucleus	O
26	basalis	O
27	lesions	O
28	related	O
29	to	O
30	the	O
31	degree	O
32	of	O
33	non	O
34	-	O
35	specific	O
36	subcortical	O
37	cell	O
38	loss	O
39	?	O
40	The	O
41	function	O
42	of	O
43	nucleus	O
44	basalis	O
45	(	O
46	NB	O
47	)	O
48	and	O
49	medial	O
50	septal	O
51	-	O
52	vertical	O
53	diagonal	O
54	band	O
55	of	O
56	Broca	O
57	(	O
58	MS	O
59	-	O
60	VDBB	O
61	)	O
62	in	O
63	a	O
64	place	O
65	navigation	O
66	task	O
67	requiring	O
68	reference	O
69	memory	O
70	was	O
71	investigated	O
72	.	O

1	Studies	O
2	also	O
3	have	O
4	alluded	O
5	to	O
6	a	O
7	relationship	O
8	between	O
9	the	O
10	MSMR	O
11	cyst	O
12	and	O
13	certain	O
14	signs	O
15	or	O
16	symptoms	O
17	of	O
18	disease	O
19	.	O

1	The	O
2	BAL	O
3	-	O
4	to	O
5	-	O
6	plasma	O
7	specific	O
8	activity	O
9	of	O
10	urea	O
11	was	O
12	about	O
13	twice	O
14	that	O
15	of	O
16	Na	O
17	+,	O
18	indicating	O
19	that	O
20	urea	O
21	diffused	O
22	into	O
23	the	O
24	ELF	O
25	more	O
26	rapidly	O
27	than	O
28	Na	O
29	+	O
30	during	O
31	the	O
32	70	O
33	s	O
34	that	O
35	elapsed	O
36	between	O
37	the	O
38	time	O
39	the	O
40	radioactive	O
41	urea	O
42	and	O
43	Na	O
44	+	O
45	were	O
46	injected	O
47	into	O
48	the	O
49	circulation	O
50	and	O
51	the	O
52	time	O
53	when	O
54	lavage	O
55	was	O
56	complete	O
57	.	O

1	The	O
2	kappa	O
3	coefficient	O
4	of	O
5	agreement	O
6	between	O
7	the	O
8	Patho	O
9	Dx	O
10	Kit	O
11	and	O
12	the	O
13	standard	O
14	method	O
15	was	O
16	0	O
17	.	O
18	958	O
19	.	O

1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O

1	When	O
2	normalized	O
3	for	O
4	imaging	O
5	time	O
6	,	O
7	all	O
8	parameters	O
9	are	O
10	significantly	O
11	higher	O
12	with	O
13	RASE	O
14	,	O
15	with	O
16	a	O
17	C	O
18	/	O
19	A	O
20	per	O
21	unit	O
22	time	O
23	that	O
24	was	O
25	338	O
26	%	O
27	higher	O
28	.	O

1	Patients	O
2	with	O
3	acute	O
4	myocardial	O
5	infarction	O
6	had	O
7	higher	O
8	plasma	O
9	concentrations	O
10	of	O
11	neutrophil	B
12	elastase	I
13	and	O
14	the	O
15	non	O
16	-	O
17	peroxide	O
18	diene	O
19	conjugated	O
20	isomer	O
21	of	O
22	linoleic	O
23	acid	O
24	than	O
25	normal	O
26	volunteers	O
27	or	O
28	patients	O
29	with	O
30	stable	O
31	ischaemic	O
32	heart	O
33	disease	O
34	.	O

1	Determination	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	imaging	O
7	properties	O
8	of	O
9	a	O
10	light	O
11	microscope	O
12	system	O
13	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	identified	O
8	as	O
9	CACGTGACCCG	O
10	,	O
11	is	O
12	located	O
13	34	O
14	bp	O
15	upstream	O
16	from	O
17	the	O
18	transcription	O
19	initiation	O
20	site	O
21	,	O
22	and	O
23	contains	O
24	the	O
25	core	O
26	sequence	O
27	of	O
28	the	O
29	upstream	O
30	promoter	O
31	sequence	O
32	of	O
33	Ad2MLP	B
34	.	O

1	The	O
2	clinical	O
3	relevance	O
4	of	O
5	these	O
6	findings	O
7	is	O
8	strengthened	O
9	by	O
10	the	O
11	observation	O
12	that	O
13	similar	O
14	results	O
15	were	O
16	obtained	O
17	when	O
18	P	O
19	.	O
20	HCl	O
21	was	O
22	given	O
23	by	O
24	the	O
25	intravenous	O
26	route	O
27	.	O

1	TMBr	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	striated	B
8	muscle	I
9	alpha	I
10	-	I
11	tropomyosin	I
12	from	O
13	amino	O
14	acids	O
15	1	O
16	through	O
17	258	O
18	but	O
19	contains	O
20	a	O
21	novel	O
22	COOH	O
23	-	O
24	terminal	O
25	region	O
26	from	O
27	amino	O
28	acids	O
29	259	O
30	through	O
31	281	O
32	.	O

1	The	O
2	procedure	O
3	has	O
4	been	O
5	applied	O
6	to	O
7	three	O
8	materials	O
9	:	O
10	particle	O
11	board	O
12	with	O
13	carpet	O
14	;	O
15	gypsum	O
16	board	O
17	with	O
18	wallpaper	O
19	;	O
20	and	O
21	plywood	O
22	with	O
23	polyurethane	O
24	lacquer	O
25	,	O
26	for	O
27	which	O
28	the	O
29	steady	O
30	-	O
31	state	O
32	emission	O
33	factors	O
34	(	O
35	mg	O
36	m	O
37	-	O
38	2	O
39	h	O
40	-	O
41	1	O
42	)	O
43	of	O
44	several	O
45	compounds	O
46	are	O
47	given	O
48	.	O

1	Intron	O
2	1	O
3	is	O
4	6	O
5	.	O
6	5	O
7	kb	O
8	long	O
9	,	O
10	and	O
11	the	O
12	minimal	O
13	sizes	O
14	of	O
15	introns	O
16	2	O
17	and	O
18	3	O
19	are	O
20	estimated	O
21	to	O
22	be	O
23	32	O
24	kb	O
25	each	O
26	.	O

1	After	O
2	4	O
3	h	O
4	,	O
5	lesions	O
6	in	O
7	the	O
8	secretory	O
9	part	O
10	of	O
11	the	O
12	stomach	O
13	were	O
14	scored	O
15	and	O
16	mucosal	O
17	prostaglandin	O
18	E2	O
19	synthesis	O
20	was	O
21	determined	O
22	by	O
23	the	O
24	ex	O
25	vivo	O
26	prostaglandin	O
27	generation	O
28	technique	O
29	.	O

1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	B
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	O
42	.	O

1	Approximately	O
2	65	O
3	%	O
4	of	O
5	the	O
6	total	O
7	cAMP	B
8	-	I
9	dependent	I
10	phosphotransferase	I
11	activity	O
12	is	O
13	recovered	O
14	in	O
15	particulate	O
16	fractions	O
17	of	O
18	homogenates	O
19	prepared	O
20	from	O
21	asynchronous	O
22	populations	O
23	of	O
24	C	O
25	.	O
26	elegans	O
27	.	O

1	High	O
2	levels	O
3	of	O
4	C	B
5	subunits	I
6	are	O
7	observed	O
8	in	O
9	several	O
10	subsequent	O
11	larval	O
12	and	O
13	adult	O
14	stages	O
15	of	O
16	development	O
17	.	O

1	A	O
2	second	O
3	,	O
4	novel	O
5	C	O
6	subunit	O
7	(	O
8	CeCAT	O
9	alpha	O
10	',	O
11	374	O
12	residues	O
13	)	O
14	has	O
15	a	O
16	unique	O
17	56	O
18	-	O
19	residue	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	that	O
25	is	O
26	generated	O
27	by	O
28	the	O
29	alternative	O
30	splicing	O
31	of	O
32	the	O
33	C	B
34	pre	I
35	-	I
36	mRNA	I
37	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	B
30	alpha	I
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	French	O
2	,	O
3	M	O
4	.	O

1	Slowly	O
2	adapting	O
3	type	O
4	I	O
5	mechanoreceptor	O
6	discharge	O
7	as	O
8	a	O
9	function	O
10	of	O
11	dynamic	O
12	force	O
13	versus	O
14	dynamic	O
15	displacement	O
16	of	O
17	glabrous	O
18	skin	O
19	of	O
20	raccoon	O
21	and	O
22	squirrel	O
23	monkey	O
24	hand	O
25	.	O

1	Methods	O
2	used	O
3	include	O
4	Cobb	O
5	angle	O
6	and	O
7	a	O
8	segmental	O
9	evaluation	O
10	(	O
11	T7	O
12	-	O
13	T12	O
14	)	O
15	of	O
16	each	O
17	of	O
18	convex	O
19	and	O
20	concave	O
21	rib	O
22	-	O
23	vertebra	O
24	angles	O
25	(	O
26	RVAs	O
27	),	O
28	rib	O
29	-	O
30	vertebra	O
31	angle	O
32	differences	O
33	(	O
34	RVADs	O
35	),	O
36	vertebral	O
37	rotation	O
38	,	O
39	tilt	O
40	and	O
41	displacement	O
42	.	O

1	Plasma	O
2	lecithin	B
3	/	I
4	cholesterol	I
5	acyltransferase	I
6	(	O
7	LCAT	B
8	)	O
9	activity	O
10	in	O
11	multiple	O
12	-	O
13	organ	O
14	donors	O
15	:	O
16	a	O
17	predictor	O
18	of	O
19	allograft	O
20	viability	O
21	in	O
22	clinical	O
23	liver	O
24	transplantation	O
25	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	Axillary	O
2	nodal	O
3	status	O
4	,	O
5	tumour	O
6	progesterone	B
7	receptor	I
8	status	O
9	,	O
10	and	O
11	season	O
12	of	O
13	tumour	O
14	detection	O
15	significantly	O
16	influenced	O
17	survival	O
18	in	O
19	both	O
20	older	O
21	(	O
22	greater	O
23	than	O
24	50	O
25	yrs	O
26	)	O
27	and	O
28	younger	O
29	(	O
30	less	O
31	than	O
32	50	O
33	yrs	O
34	)	O
35	patients	O
36	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	microelectrodes	O
6	to	O
7	the	O
8	measurement	O
9	of	O
10	rapid	O
11	,	O
12	transient	O
13	changes	O
14	in	O
15	retinal	O
16	[	O
17	K	O
18	+]	O
19	o	O
20	is	O
21	presented	O
22	.	O

1	Expression	O
2	,	O
3	cellular	O
4	localization	O
5	and	O
6	in	O
7	vitro	O
8	transcription	O
9	studies	O
10	establish	O
11	that	O
12	cloned	B
13	hUBF	I
14	encodes	O
15	a	O
16	nucleolar	O
17	factor	O
18	that	O
19	binds	O
20	specifically	O
21	to	O
22	the	O
23	upstream	O
24	control	O
25	element	O
26	and	O
27	core	O
28	of	O
29	the	O
30	rRNA	O
31	gene	O
32	promoter	O
33	to	O
34	activate	O
35	transcription	O
36	in	O
37	a	O
38	binding	O
39	site	O
40	-	O
41	dependent	O
42	manner	O
43	.	O

1	Combining	O
2	multiple	O
3	laboratory	O
4	studies	O
5	may	O
6	be	O
7	of	O
8	value	O
9	in	O
10	predetermining	O
11	the	O
12	eventual	O
13	outcome	O
14	in	O
15	near	O
16	-	O
17	drowning	O
18	.	O

1	Accumulations	O
2	of	O
3	Tl	O
4	+	O
5	1	O
6	(	O
7	202Tl	O
8	label	O
9	)	O
10	were	O
11	6	O
12	times	O
13	those	O
14	for	O
15	Ga	O
16	or	O
17	In	O
18	in	O
19	the	O
20	brain	O
21	and	O
22	muscles	O
23	,	O
24	and	O
25	.	O
26	1	O
27	times	O
28	in	O
29	plasma	O
30	.	O

1	There	O
2	was	O
3	a	O
4	gradual	O
5	increase	O
6	in	O
7	the	O
8	myocyte	O
9	diameter	O
10	according	O
11	to	O
12	age	O
13	in	O
14	the	O
15	biopsy	O
16	and	O
17	autopsy	O
18	specimens	O
19	.	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	O
9	(	O
10	EIA	O
11	)	O
12	while	O
13	breathing	O
14	WH	O
15	air	O
16	,	O
17	asthmatic	O
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	O
24	GH	O
25	increments	O
26	than	O
27	normal	O
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	O
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	The	O
2	afferents	O
3	'	O
4	phase	O
5	of	O
6	response	O
7	was	O
8	unmodified	O
9	by	O
10	electrical	O
11	EVS	O
12	stimulation	O
13	.	O

1	Solving	O
2	an	O
3	age	O
4	old	O
5	problem	O
6	.	O

1	The	O
2	distribution	O
3	of	O
4	their	O
5	fibrinogen	B
6	levels	O
7	was	O
8	Gaussian	O
9	,	O
10	but	O
11	more	O
12	wide	O
13	-	O
14	based	O
15	than	O
16	the	O
17	distribution	O
18	of	O
19	our	O
20	normal	O
21	controls	O
22	.	O

1	In	O
2	a	O
3	stepwise	O
4	logistic	O
5	regression	O
6	analysis	O
7	of	O
8	SPT	O
9	and	O
10	RAST	O
11	data	O
12	,	O
13	the	O
14	occurrence	O
15	of	O
16	serum	B
17	IgE	I
18	antibodies	I
19	to	I
20	P	I
21	.	I
22	orbiculare	I
23	had	O
24	the	O
25	highest	O
26	explanatory	O
27	value	O
28	for	O
29	current	O
30	eczema	O
31	.	O

1	The	O
2	examination	O
3	was	O
4	focused	O
5	on	O
6	assessment	O
7	of	O
8	different	O
9	types	O
10	of	O
11	drusen	O
12	,	O
13	on	O
14	evaluation	O
15	of	O
16	the	O
17	development	O
18	and	O
19	incidence	O
20	of	O
21	risk	O
22	factors	O
23	leading	O
24	to	O
25	complications	O
26	and	O
27	loss	O
28	of	O
29	central	O
30	vision	O
31	.	O

1	They	O
2	were	O
3	then	O
4	subjected	O
5	to	O
6	whole	O
7	-	O
8	body	O
9	heat	O
10	stress	O
11	(	O
12	water	O
13	-	O
14	perfused	O
15	suits	O
16	),	O
17	and	O
18	the	O
19	3	O
20	minutes	O
21	of	O
22	LBNP	O
23	was	O
24	repeated	O
25	.	O

1	An	O
2	NF1	B
3	-	I
4	related	I
5	vitellogenin	I
6	activator	I
7	element	I
8	mediates	O
9	transcription	O
10	from	O
11	the	O
12	estrogen	O
13	-	O
14	regulated	O
15	Xenopus	B
16	laevis	I
17	vitellogenin	I
18	promoter	I
19	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	also	O
6	observed	O
7	between	O
8	PbB	O
9	and	O
10	ALAD	B
11	activity	O
12	of	O
13	the	O
14	stearate	O
15	workers	O
16	.	O

1	At	O
2	the	O
3	carboxyl	O
4	terminus	O
5	,	O
6	deletion	O
7	as	O
8	far	O
9	as	O
10	residue	O
11	388	O
12	did	O
13	not	O
14	affect	O
15	in	O
16	vitro	O
17	TRF	B
18	.	I
19	C	I
20	assembly	O
21	,	O
22	although	O
23	trans	O
24	-	O
25	activating	O
26	activity	O
27	was	O
28	abolished	O
29	.	O

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	Effect	O
2	of	O
3	hyperglycemia	O
4	on	O
5	pain	O
6	threshold	O
7	in	O
8	alloxan	O
9	-	O
10	diabetic	O
11	rats	O
12	.	O

1	We	O
2	have	O
3	synthesized	O
4	[	O
5	7	O
6	,	O
7	7	O
8	-	O
9	2H2	O
10	]-	O
11	19	O
12	-	O
13	OHA	O
14	with	O
15	high	O
16	deuterium	O
17	content	O
18	and	O
19	,	O
20	together	O
21	with	O
22	[	O
23	7	O
24	,	O
25	7	O
26	-	O
27	2H2	O
28	]	O
29	A	O
30	and	O
31	[	O
32	9	O
33	,	O
34	11	O
35	-	O
36	2H2	O
37	]	O
38	estrone	O
39	(	O
40	E1	O
41	),	O
42	have	O
43	developed	O
44	a	O
45	quantitative	O
46	assay	O
47	of	O
48	serum	O
49	level	O
50	19	O
51	-	O
52	OHA	O
53	,	O
54	A	O
55	,	O
56	and	O
57	E1	O
58	using	O
59	the	O
60	gas	O
61	chromatography	O
62	/	O
63	mass	O
64	spectrometry	O
65	-	O
66	mass	O
67	fragmentography	O
68	method	O
69	to	O
70	monitor	O
71	individual	O
72	subjects	O
73	throughout	O
74	pregnancy	O
75	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	these	O
5	genes	O
6	and	O
7	their	O
8	surrounding	O
9	sequences	O
10	are	O
11	presented	O
12	and	O
13	compared	O
14	with	O
15	other	O
16	known	O
17	tRNA	O
18	genes	O
19	from	O
20	plant	O
21	mitochondria	O
22	.	O

1	Experiments	O
2	were	O
3	performed	O
4	in	O
5	which	O
6	brain	O
7	-	O
8	stem	O
9	auditory	O
10	-	O
11	evoked	O
12	responses	O
13	(	O
14	BAERs	O
15	)	O
16	were	O
17	elicited	O
18	by	O
19	two	O
20	types	O
21	of	O
22	pseudorandom	O
23	pulse	O
24	trains	O
25	:	O
26	maximum	O
27	length	O
28	sequences	O
29	(	O
30	MLS	O
31	)	O
32	and	O
33	Legendre	O
34	sequences	O
35	(	O
36	LGS	O
37	).	O

1	Since	O
2	the	O
3	UfAP	B
4	and	O
5	UTMP	B
6	share	O
7	many	O
8	biosynthetic	O
9	and	O
10	structural	O
11	features	O
12	that	O
13	include	O
14	site	O
15	of	O
16	biosynthesis	O
17	in	O
18	the	O
19	endometrium	O
20	,	O
21	P4	O
22	-	O
23	responsiveness	O
24	,	O
25	the	O
26	presence	O
27	of	O
28	the	O
29	mannose	O
30	6	O
31	-	O
32	phosphate	O
33	lysosomal	O
34	recognition	O
35	marker	O
36	,	O
37	and	O
38	considerable	O
39	sequence	O
40	similarity	O
41	,	O
42	the	O
43	UfAP	B
44	and	O
45	the	O
46	UTMP	B
47	may	O
48	have	O
49	homologous	O
50	function	O
51	which	O
52	for	O
53	both	O
54	still	O
55	remains	O
56	obscure	O
57	.	O

1	Fifteen	O
2	light	O
3	for	O
4	dates	O
5	infants	O
6	and	O
7	their	O
8	placentae	O
9	were	O
10	compared	O
11	to	O
12	15	O
13	well	O
14	-	O
15	grown	O
16	infants	O
17	and	O
18	their	O
19	placentae	O
20	.	O

1	Treating	O
2	renal	O
3	anaemia	O
4	with	O
5	recombinant	O
6	human	O
7	erythropoietin	B
8	.	O

1	The	O
2	pseudolymphoma	O
3	syndrome	O
4	is	O
5	a	O
6	reversible	O
7	reactive	O
8	condition	O
9	consisting	O
10	of	O
11	fever	O
12	,	O
13	lymphadenopathy	O
14	and	O
15	generalized	O
16	rash	O
17	.	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	In	O
2	the	O
3	artificial	O
4	lung	O
5	,	O
6	like	O
7	in	O
8	the	O
9	natural	O
10	lung	O
11	and	O
12	peripheral	O
13	tissues	O
14	,	O
15	gas	O
16	exchanges	O
17	depend	O
18	on	O
19	several	O
20	parameters	O
21	:	O
22	blood	O
23	inlet	O
24	conditions	O
25	,	O
26	blood	O
27	flow	O
28	rate	O
29	,	O
30	temperature	O
31	,	O
32	composition	O
33	of	O
34	the	O
35	gas	O
36	mixture	O
37	used	O
38	for	O
39	ventilation	O
40	,	O
41	blood	O
42	tissue	O
43	perfusion	O
44	,	O
45	O2	O
46	consumption	O
47	,	O
48	etc	O
49	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	Attitudes	O
2	were	O
3	found	O
4	to	O
5	be	O
6	multidimensional	O
7	,	O
8	with	O
9	similar	O
10	dimensions	O
11	being	O
12	identified	O
13	in	O
14	both	O
15	samples	O
16	.	O

1	We	O
2	conclude	O
3	that	O
4	DNA	O
5	ploidy	O
6	is	O
7	a	O
8	major	O
9	objective	O
10	prognostic	O
11	factor	O
12	and	O
13	therapeutic	O
14	determinant	O
15	for	O
16	endometrial	O
17	carcinoma	O
18	.	O

1	A	O
2	semiautomatic	O
3	digital	O
4	system	O
5	(	O
6	Videoplan	O
7	2	O
8	)	O
9	was	O
10	used	O
11	.	O

1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O

1	Dopamine	O
2	SERS	O
3	spectra	O
4	from	O
5	these	O
6	electrodes	O
7	are	O
8	similar	O
9	to	O
10	those	O
11	obtained	O
12	at	O
13	uncoated	O
14	electrodes	O
15	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	B
25	HDC	I
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O

1	Basing	O
2	on	O
3	experimental	O
4	toxicity	O
5	research	O
6	it	O
7	was	O
8	established	O
9	that	O
10	,	O
11	out	O
12	of	O
13	50	O
14	atmosphere	O
15	metal	O
16	corrosion	O
17	inhibitors	O
18	,	O
19	some	O
20	14	O
21	per	O
22	cent	O
23	were	O
24	found	O
25	extremely	O
26	hazardous	O
27	,	O
28	42	O
29	per	O
30	cent	O
31	--	O
32	of	O
33	high	O
34	level	O
35	hazardous	O
36	,	O
37	33	O
38	percent	O
39	--	O
40	of	O
41	moderate	O
42	and	O
43	11	O
44	per	O
45	cent	O
46	--	O
47	of	O
48	low	O
49	hazardous	O
50	.	O

1	The	O
2	order	O
3	of	O
4	the	O
5	helicase	B
6	motif	I
7	and	O
8	the	O
9	nsP3	B
10	homology	I
11	region	I
12	in	O
13	the	O
14	RUB	O
15	genome	O
16	is	O
17	reversed	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	alphavirus	O
23	genome	O
24	indicating	O
25	that	O
26	a	O
27	genetic	O
28	rearrangement	O
29	has	O
30	occurred	O
31	during	O
32	the	O
33	evolution	O
34	of	O
35	these	O
36	viruses	O
37	.	O

1	The	O
2	results	O
3	suggest	O
4	followings	O
5	--	O
6	1	O
7	)	O
8	both	O
9	eosinophils	O
10	and	O
11	neutrophils	O
12	participate	O
13	in	O
14	hypersecretion	O
15	of	O
16	type	O
17	Ib	O
18	in	O
19	atopic	O
20	cases	O
21	,	O
22	and	O
23	only	O
24	eosinophils	O
25	in	O
26	non	O
27	-	O
28	atopic	O
29	cases	O
30	.	O

1	There	O
2	were	O
3	5	O
4	treatments	O
5	:	O
6	control	O
7	(	O
8	C	O
9	);	O
10	a	O
11	wooden	O
12	surround	O
13	in	O
14	one	O
15	rear	O
16	corner	O
17	of	O
18	the	O
19	cage	O
20	(	O
21	S	O
22	);	O
23	a	O
24	fiberglass	O
25	rollaway	O
26	hollow	O
27	in	O
28	one	O
29	rear	O
30	corner	O
31	of	O
32	the	O
33	cage	O
34	(	O
35	H	O
36	);	O
37	a	O
38	hollow	O
39	and	O
40	a	O
41	surround	O
42	(	O
43	H	O
44	/	O
45	S	O
46	);	O
47	a	O
48	nest	O
49	box	O
50	attached	O
51	to	O
52	the	O
53	back	O
54	of	O
55	the	O
56	cage	O
57	,	O
58	containing	O
59	a	O
60	hollow	O
61	(	O
62	N	O
63	).	O

1	While	O
2	no	O
3	significant	O
4	differences	O
5	in	O
6	the	O
7	tensile	O
8	responses	O
9	or	O
10	failure	O
11	characteristics	O
12	were	O
13	noted	O
14	for	O
15	irradiated	O
16	and	O
17	nonirradiated	O
18	grafts	O
19	in	O
20	the	O
21	drip	O
22	,	O
23	in	O
24	the	O
25	bath	O
26	environment	O
27	the	O
28	nonirradiated	O
29	tissues	O
30	had	O
31	greater	O
32	strength	O
33	and	O
34	modulus	O
35	.	O

1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O

1	A	O
2	consensus	O
3	binding	O
4	site	O
5	for	O
6	the	O
7	transcription	O
8	factor	O
9	SP1	B
10	was	O
11	identified	O
12	in	O
13	intron	O
14	As	O
15	downstream	O
16	of	O
17	the	O
18	proenkephalin	B
19	germ	I
20	cell	I
21	cap	I
22	site	I
23	region	I
24	.	O

1	This	O
2	proposed	O
3	method	O
4	is	O
5	similar	O
6	in	O
7	principle	O
8	to	O
9	the	O
10	sets	O
11	technique	O
12	but	O
13	is	O
14	shown	O
15	to	O
16	have	O
17	much	O
18	better	O
19	expected	O
20	time	O
21	to	O
22	alarm	O
23	properties	O
24	.	O

1	The	O
2	effects	O
3	on	O
4	reflex	O
5	latencies	O
6	but	O
7	not	O
8	on	O
9	paCO2	O
10	or	O
11	pHa	O
12	were	O
13	blocked	O
14	by	O
15	naloxone	O
16	(	O
17	2	O
18	mg	O
19	/	O
20	kg	O
21	),	O
22	and	O
23	were	O
24	not	O
25	present	O
26	in	O
27	morphine	O
28	-	O
29	tolerant	O
30	animals	O
31	.	O

1	Of	O
2	the	O
3	remaining	O
4	seven	O
5	,	O
6	five	O
7	reacted	O
8	either	O
9	with	O
10	immediate	O
11	and	O
12	strong	O
13	symptoms	O
14	or	O
15	had	O
16	spontaneously	O
17	reduced	O
18	gluten	B
19	intake	O
20	,	O
21	or	O
22	had	O
23	an	O
24	acquired	O
25	IgA	B
26	deficiency	O
27	.	O

1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	vials	O
26	.	O

1	Changes	O
2	in	O
3	prognosis	O
4	of	O
5	twin	O
6	births	O
7	over	O
8	20	O
9	years	O
10	.	O

1	Dermal	O
2	toxicity	O
3	and	O
4	carcinogenicity	O
5	of	O
6	4	O
7	-	O
8	vinyl	O
9	-	O
10	1	O
11	-	O
12	cyclohexene	O
13	diepoxide	O
14	in	O
15	Fischer	O
16	rats	O
17	and	O
18	B6C3F1	O
19	mice	O
20	.	O

1	Per	O
2	kg	O
3	FFM	O
4	SMR	O
5	was	O
6	almost	O
7	restored	O
8	to	O
9	baseline	O
10	values	O
11	for	O
12	the	O
13	EX	O
14	group	O
15	,	O
16	whereas	O
17	the	O
18	non	O
19	-	O
20	exercising	O
21	subjects	O
22	still	O
23	showed	O
24	depressed	O
25	values	O
26	(	O
27	EX	O
28	3	O
29	.	O
30	7	O
31	per	O
32	cent	O
33	and	O
34	D	O
35	+	O
36	DE	O
37	15	O
38	.	O
39	8	O
40	per	O
41	cent	O
42	lower	O
43	than	O
44	before	O
45	treatment	O
46	;	O
47	P	O
48	less	O
49	than	O
50	0	O
51	.	O
52	05	O
53	).	O

1	MK	O
2	-	O
3	927	O
4	:	O
5	a	O
6	topically	O
7	active	O
8	ocular	O
9	hypotensive	O
10	carbonic	B
11	anhydrase	I
12	inhibitor	O
13	.	O

1	PCR	O
2	-	O
3	derived	O
4	fragments	O
5	were	O
6	used	O
7	as	O
8	probes	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	the	O
14	U3	B
15	snRNA	I
16	genes	I
17	from	O
18	a	O
19	genomic	O
20	library	O
21	of	O
22	Arabidopsis	O
23	.	O

1	In	O
2	addition	O
3	serum	B
4	IgE	I
5	concentrations	O
6	were	O
7	not	O
8	statistically	O
9	different	O
10	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O

1	The	O
2	transcriptional	O
3	unit	O
4	spans	O
5	a	O
6	chromosomal	O
7	region	O
8	of	O
9	about	O
10	55	O
11	kilobase	O
12	pairs	O
13	(	O
14	kbp	O
15	).	O

1	100	O
2	of	O
3	the	O
4	patients	O
5	who	O
6	would	O
7	have	O
8	died	O
9	survive	O
10	.	O

1	Co	O
2	-	O
3	administration	O
4	of	O
5	5FU	O
6	,	O
7	angiotensin	B
8	II	I
9	and	O
10	microspheres	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	compartment	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	5FU	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O

1	The	O
2	effects	O
3	of	O
4	tap	O
5	(	O
6	TW	O
7	)	O
8	or	O
9	carbonated	O
10	(	O
11	CW	O
12	)	O
13	water	O
14	on	O
15	arterial	O
16	pH	O
17	,	O
18	partial	O
19	pressure	O
20	of	O
21	carbon	O
22	dioxide	O
23	(	O
24	PCO2	O
25	)	O
26	and	O
27	plasma	O
28	lactate	O
29	were	O
30	determined	O
31	in	O
32	heat	O
33	-	O
34	stressed	O
35	broilers	O
36	.	O

1	Transient	O
2	expression	O
3	of	O
4	human	B
5	and	I
6	chicken	I
7	progesterone	I
8	receptors	I
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	2	O
5	,	O
6	397	O
7	(	O
8	74	O
9	%)	O
10	had	O
11	one	O
12	or	O
13	more	O
14	risk	O
15	factors	O
16	(	O
17	not	O
18	low	O
19	risk	O
20	);	O
21	of	O
22	these	O
23	,	O
24	5	O
25	.	O
26	3	O
27	%	O
28	died	O
29	in	O
30	6	O
31	weeks	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	001	O
39	).	O

1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O

1	However	O
2	,	O
3	at	O
4	18	O
5	months	O
6	of	O
7	age	O
8	,	O
9	significantly	O
10	higher	O
11	levels	O
12	of	O
13	IgG1	B
14	(	O
15	P	O
16	less	O
17	than	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	of	O
24	IgG4	B
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	01	O
32	)	O
33	were	O
34	found	O
35	in	O
36	infants	O
37	with	O
38	an	O
39	elevated	O
40	IgE	B
41	(	O
42	greater	O
43	than	O
44	or	O
45	equal	O
46	to	O
47	8	O
48	.	O
49	0	O
50	kU	O
51	/	O
52	l	O
53	)	O
54	than	O
55	in	O
56	those	O
57	with	O
58	a	O
59	lower	O
60	level	O
61	.	O

1	The	O
2	protein	O
3	sequence	O
4	contains	O
5	seven	O
6	potential	O
7	N	O
8	-	O
9	linked	O
10	glycosylation	O
11	sites	O
12	and	O
13	a	O
14	threonine	O
15	/	O
16	serine	O
17	-	O
18	rich	O
19	region	O
20	which	O
21	is	O
22	a	O
23	potential	O
24	site	O
25	for	O
26	attachment	O
27	of	O
28	O	O
29	-	O
30	linked	O
31	carbohydrate	O
32	.	O

1	Thus	O
2	adaptation	O
3	to	O
4	continuous	O
5	mild	O
6	stress	O
7	has	O
8	a	O
9	potent	O
10	antiarrhythmic	O
11	effect	O
12	which	O
13	occurs	O
14	due	O
15	to	O
16	the	O
17	increased	O
18	vagal	O
19	tone	O
20	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	On	O
2	histologic	O
3	examination	O
4	the	O
5	cuboidal	O
6	epithelium	O
7	of	O
8	the	O
9	mucous	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	columnar	O
18	epithelium	O
19	,	O
20	with	O
21	uneven	O
22	distribution	O
23	of	O
24	enlarged	O
25	nuclei	O
26	in	O
27	the	O
28	vacuolized	O
29	cytoplasm	O
30	.	O

1	These	O
2	results	O
3	suggest	O
4	an	O
5	increased	O
6	risk	O
7	of	O
8	developing	O
9	cancer	O
10	among	O
11	polyp	O
12	patients	O
13	and	O
14	the	O
15	possibility	O
16	of	O
17	prophylactic	O
18	effect	O
19	of	O
20	polypectomy	O
21	against	O
22	subsequent	O
23	cancer	O
24	.	O

1	The	O
2	same	O
3	trend	O
4	was	O
5	noted	O
6	between	O
7	YG	O
8	4	O
9	.	O
10	5	O
11	heifers	O
12	and	O
13	YG	O
14	5	O
15	.	O
16	5	O
17	steers	O
18	,	O
19	indicating	O
20	a	O
21	sex	O
22	-	O
23	related	O
24	deposition	O
25	of	O
26	seam	O
27	fat	O
28	in	O
29	fed	O
30	cattle	O
31	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	consists	O
5	of	O
6	48	O
7	bp	O
8	of	O
9	5	O
10	'-	O
11	end	O
12	non	O
13	-	O
14	coding	O
15	region	O
16	,	O
17	1695	O
18	bp	O
19	of	O
20	coding	O
21	region	O
22	and	O
23	212	O
24	bp	O
25	of	O
26	3	O
27	'-	O
28	end	O
29	non	O
30	-	O
31	coding	O
32	region	O
33	including	O
34	a	O
35	20	O
36	bp	O
37	poly	O
38	(	O
39	A	O
40	)	O
41	tail	O
42	.	O

1	Toxicities	O
2	included	O
3	:	O
4	nausea	O
5	/	O
6	vomiting	O
7	(	O
8	69	O
9	%),	O
10	headache	O
11	(	O
12	25	O
13	%),	O
14	chills	O
15	(	O
16	69	O
17	%),	O
18	pain	O
19	at	O
20	tumor	O
21	sites	O
22	(	O
23	63	O
24	%),	O
25	hypotension	O
26	(	O
27	31	O
28	%),	O
29	and	O
30	hypertension	O
31	(	O
32	38	O
33	%).	O

1	The	O
2	results	O
3	also	O
4	showed	O
5	that	O
6	although	O
7	oyster	O
8	shell	O
9	supplementation	O
10	generally	O
11	increased	O
12	alkaline	B
13	phosphatase	I
14	activity	O
15	,	O
16	bone	O
17	mineralization	O
18	was	O
19	relatively	O
20	uninfluenced	O
21	as	O
22	judged	O
23	by	O
24	the	O
25	low	O
26	coefficients	O
27	of	O
28	variation	O
29	(	O
30	CV	O
31	)	O
32	of	O
33	3	O
34	.	O
35	14	O
36	-	O
37	3	O
38	.	O
39	51	O
40	%	O
41	and	O
42	3	O
43	.	O
44	39	O
45	-	O
46	4	O
47	.	O
48	82	O
49	%	O
50	for	O
51	calcium	O
52	and	O
53	phosphorus	O
54	content	O
55	in	O
56	the	O
57	femur	O
58	and	O
59	tibia	O
60	respectively	O
61	.	O

1	In	O
2	6	O
3	of	O
4	24	O
5	infants	O
6	studied	O
7	(	O
8	27th	O
9	-	O
10	40th	O
11	weeks	O
12	of	O
13	gestation	O
14	),	O
15	acquired	O
16	and	O
17	congenital	O
18	structural	O
19	anomalies	O
20	of	O
21	the	O
22	airways	O
23	were	O
24	detected	O
25	with	O
26	an	O
27	ultrathin	O
28	flexible	O
29	fiberscope	O
30	(	O
31	Olympus	O
32	PF18	O
33	S	O
34	,	O
35	1	O
36	.	O
37	8	O
38	mm	O
39	).	O

1	Fatal	O
2	encephalitis	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O

1	Compared	O
2	to	O
3	its	O
4	counterpart	O
5	in	O
6	the	O
7	GPB	B
8	gene	I
9	,	O
10	exon	O
11	3	O
12	of	O
13	the	O
14	GPE	B
15	gene	I
16	contains	O
17	several	O
18	point	O
19	mutations	O
20	,	O
21	an	O
22	insertion	O
23	of	O
24	24	O
25	bp	O
26	,	O
27	and	O
28	a	O
29	stop	O
30	codon	O
31	which	O
32	shortens	O
33	the	O
34	reading	O
35	frame	O
36	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	cDNA	O
6	encoding	O
7	rat	B
8	NADH	I
9	-	I
10	cytochrome	I
11	b5	I
12	reductase	I
13	and	O
14	the	O
15	corresponding	O
16	gene	O
17	.	O

1	The	O
2	results	O
3	corroborate	O
4	the	O
5	idea	O
6	that	O
7	the	O
8	structure	O
9	of	O
10	relaxation	O
11	curves	O
12	contains	O
13	information	O
14	on	O
15	the	O
16	distance	O
17	scale	O
18	and	O
19	on	O
20	the	O
21	architecture	O
22	of	O
23	the	O
24	pore	O
25	space	O
26	,	O
27	even	O
28	if	O
29	it	O
30	is	O
31	difficult	O
32	to	O
33	extract	O
34	it	O
35	without	O
36	ambiguities	O
37	.	O

1	Serotonin	B
2	5	I
3	-	I
4	HT2	I
5	receptor	I
6	binding	O
7	on	O
8	blood	O
9	platelets	O
10	as	O
11	a	O
12	state	O
13	dependent	O
14	marker	O
15	in	O
16	major	O
17	affective	O
18	disorder	O
19	.	O

1	Although	O
2	%	O
3	BF	O
4	was	O
5	correlated	O
6	with	O
7	all	O
8	the	O
9	BMIs	O
10	(	O
11	r	O
12	=	O
13	0	O
14	.	O
15	60	O
16	-	O
17	0	O
18	.	O
19	82	O
20	),	O
21	applying	O
22	objective	O
23	definitions	O
24	of	O
25	obesity	O
26	based	O
27	on	O
28	BMIs	O
29	or	O
30	%	O
31	BF	O
32	by	O
33	densitometry	O
34	often	O
35	produced	O
36	conflicting	O
37	results	O
38	.	O

1	The	O
2	RF	O
3	values	O
4	correlated	O
5	well	O
6	with	O
7	the	O
8	angiographic	O
9	semiquantitative	O
10	scale	O
11	of	O
12	severity	O
13	of	O
14	aortal	O
15	insufficiency	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	805	O
22	;	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	),	O
30	although	O
31	they	O
32	enabled	O
33	the	O
34	authors	O
35	only	O
36	to	O
37	make	O
38	a	O
39	partial	O
40	differentiation	O
41	of	O
42	haemodynamically	O
43	severe	O
44	regurgitations	O
45	and	O
46	mild	O
47	or	O
48	insignificant	O
49	ones	O
50	.	O

1	Promoter	O
2	elements	O
3	include	O
4	an	O
5	atypical	O
6	TATA	O
7	box	O
8	(	O
9	GTTA	O
10	),	O
11	one	O
12	CCAAT	O
13	box	O
14	much	O
15	further	O
16	from	O
17	the	O
18	initiation	O
19	site	O
20	,	O
21	three	O
22	reverse	O
23	compliments	O
24	of	O
25	CCAAT	O
26	(	O
27	ATTGG	O
28	),	O
29	and	O
30	two	O
31	pyrimidine	O
32	-	O
33	rich	O
34	nucleotide	O
35	stretches	O
36	.	O

1	The	O
2	cloned	O
3	genes	O
4	were	O
5	identified	O
6	in	O
7	genetic	O
8	libraries	O
9	by	O
10	hybridization	O
11	screening	O
12	using	O
13	four	O
14	deoxyoligonucleotide	O
15	probes	O
16	which	O
17	corresponded	O
18	to	O
19	the	O
20	partial	O
21	amino	O
22	acid	O
23	sequence	O
24	of	O
25	the	O
26	purified	O
27	enzyme	O
28	.	O

1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O

1	Results	O
2	of	O
3	the	O
4	long	O
5	-	O
6	term	O
7	observation	O
8	and	O
9	treatment	O
10	of	O
11	patients	O
12	with	O
13	arterial	O
14	hypertension	O

1	Eucaryotic	O
2	transcription	O
3	factors	O
4	that	O
5	stimulate	O
6	RNA	B
7	polymerase	I
8	II	I
9	by	O
10	increasing	O
11	the	O
12	efficiency	O
13	of	O
14	elongation	O
15	of	O
16	specifically	O
17	or	O
18	randomly	O
19	initiated	O
20	RNA	O
21	chains	O
22	have	O
23	been	O
24	isolated	O
25	and	O
26	characterized	O
27	.	O

1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O

1	The	O
2	Lm	O
3	increased	O
4	and	O
5	the	O
6	alveoli	O
7	/	O
8	mm2	O
9	and	O
10	elastic	O
11	recoil	O
12	pressure	O
13	decreased	O
14	.	O

1	Comparison	O
2	of	O
3	propofol	O
4	and	O
5	thiopentone	O
6	as	O
7	anaesthetic	O
8	agents	O
9	for	O
10	electroconvulsive	O
11	therapy	O
12	.	O

1	In	O
2	Experiment	O
3	II	O
4	,	O
5	as	O
6	performing	O
7	moderate	O
8	supine	O
9	cycling	O
10	(	O
11	55	O
12	%	O
13	VO2	O
14	max	O
15	)	O
16	for	O
17	50	O
18	minutes	O
19	under	O
20	several	O
21	LBNP	O
22	conditions	O
23	in	O
24	5	O
25	sedentary	O
26	women	O
27	,	O
28	there	O
29	were	O
30	correspondingly	O
31	similar	O
32	changing	O
33	manners	O
34	of	O
35	the	O
36	cardiovascular	O
37	adjustments	O
38	to	O
39	each	O
40	of	O
41	the	O
42	phases	O
43	given	O
44	in	O
45	Experiment	O
46	I	O
47	.	O

1	Commercially	O
2	available	O
3	formulations	O
4	of	O
5	2	O
6	.	O
7	5	O
8	%	O
9	and	O
10	5	O
11	%	O
12	lambdacyhalothrin	O
13	can	O
14	be	O
15	diluted	O
16	either	O
17	with	O
18	water	O
19	for	O
20	ULV	O
21	cold	O
22	aerosol	O
23	space	O
24	-	O
25	spraying	O
26	or	O
27	with	O
28	diesel	O
29	/	O
30	kerosene	O
31	for	O
32	thermal	O
33	fogging	O
34	at	O
35	recommended	O
36	application	O
37	rates	O
38	of	O
39	0	O
40	.	O
41	5	O
42	-	O
43	1	O
44	g	O
45	ai	O
46	/	O
47	ha	O
48	for	O
49	mosquito	O
50	control	O
51	and	O
52	2	O
53	g	O
54	ai	O
55	/	O
56	ha	O
57	for	O
58	housefly	O
59	control	O
60	.	O

1	Thus	O
2	,	O
3	this	O
4	reading	O
5	frame	O
6	was	O
7	concluded	O
8	to	O
9	encode	O
10	the	O
11	precursor	O
12	of	O
13	mitochondrial	B
14	fumarase	I
15	.	O

1	Sequence	O
2	analysis	O
3	indicates	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	an	O
9	ATA	O
10	and	O
11	GC	O
12	box	O
13	,	O
14	this	O
15	region	O
16	contains	O
17	domains	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	the	O
24	regulation	O
25	of	O
26	other	O
27	muscle	O
28	-	O
29	specific	O
30	genes	O
31	:	O
32	a	O
33	CArG	O
34	box	O
35	at	O
36	-	O
37	91	O
38	bp	O
39	;	O
40	myocyte	B
41	-	I
42	specific	I
43	enhancer	I
44	-	I
45	binding	I
46	nuclear	I
47	factor	I
48	1	I
49	binding	I
50	site	I
51	homologies	O
52	at	O
53	-	O
54	58	O
55	,	O
56	-	O
57	535	O
58	,	O
59	and	O
60	-	O
61	583	O
62	bp	O
63	;	O
64	and	O
65	a	O
66	muscle	O
67	-	O
68	CAAT	O
69	consensus	O
70	sequence	O
71	at	O
72	-	O
73	394	O
74	bp	O
75	relative	O
76	to	O
77	the	O
78	cap	O
79	site	O
80	.	O

1	The	O
2	trk	B
3	-	I
4	2h	I
5	oncogene	I
6	,	O
7	isolated	O
8	from	O
9	the	O
10	human	O
11	breast	O
12	carcinoma	O
13	cell	O
14	line	O
15	MDA	O
16	-	O
17	MB	O
18	231	O
19	by	O
20	genomic	O
21	DNA	O
22	-	O
23	transfection	O
24	into	O
25	NIH3T3	O
26	cells	O
27	,	O
28	consists	O
29	of	O
30	the	O
31	trk	B
32	proto	I
33	-	I
34	oncogene	I
35	receptor	I
36	kinase	I
37	domain	I
38	fused	O
39	to	O
40	a	O
41	N	O
42	-	O
43	terminal	O
44	41	O
45	amino	O
46	acid	O
47	activating	O
48	sequence	O
49	(	O
50	Kozma	O
51	,	O
52	S	O
53	.	O
54	C	O
55	.,	O
56	Redmond	O
57	,	O
58	S	O
59	.	O
60	M	O
61	.	O
62	S	O
63	.,	O
64	Xiao	O
65	-	O
66	Chang	O
67	,	O
68	F	O
69	.,	O
70	Saurer	O
71	,	O
72	S	O
73	.	O
74	M	O
75	.,	O
76	Groner	O
77	,	O
78	B	O
79	.	O
80	and	O
81	Hynes	O
82	,	O
83	N	O
84	.	O
85	E	O
86	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	bacterially	O
6	produced	O
7	beta	B
8	gal	I
9	-	O
10	trk	B
11	receptor	O
12	kinase	O
13	fusion	O
14	protein	O
15	recognized	O
16	a	O
17	44	O
18	kd	O
19	phosphoprotein	O
20	phosphorylated	O
21	on	O
22	serine	O
23	,	O
24	threonine	O
25	and	O
26	tyrosine	O
27	in	O
28	extracts	O
29	of	O
30	trk	B
31	-	I
32	2h	I
33	transformed	O
34	NIH3T3	O
35	cells	O
36	.	O

1	Since	O
2	very	O
3	recent	O
4	scanning	O
5	-	O
6	deletion	O
7	analysis	O
8	indicates	O
9	that	O
10	there	O
11	is	O
12	a	O
13	critical	O
14	region	O
15	for	O
16	activity	O
17	near	O
18	Cys	O
19	-	O
20	118	O
21	and	O
22	that	O
23	Cys	O
24	-	O
25	118	O
26	is	O
27	necessary	O
28	for	O
29	maximal	O
30	activity	O
31	,	O
32	we	O
33	conclude	O
34	that	O
35	the	O
36	Cys	O
37	-	O
38	118	O
39	residue	O
40	is	O
41	necessary	O
42	for	O
43	proper	O
44	glycosylation	O
45	and	O
46	maximal	O
47	biologic	O
48	activity	O
49	of	O
50	GM	B
51	-	I
52	CSF	I
53	.	O

1	Molecular	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	ETS2	B
10	,	O
11	the	O
12	human	O
13	c	B
14	-	I
15	ets	I
16	-	I
17	2	I
18	gene	O
19	.	O

1	Information	O
2	about	O
3	immunologic	O
4	drug	O
5	interactions	O
6	is	O
7	needed	O
8	by	O
9	pharmacists	O
10	to	O
11	make	O
12	rational	O
13	drug	O
14	-	O
15	use	O
16	decisions	O
17	.	O

1	Branch	O
2	occlusion	O
3	of	O
4	Heubner	O
5	'	O
6	s	O
7	artery	O
8	,	O
9	or	O
10	perforators	O
11	from	O
12	the	O
13	proximal	O
14	anterior	O
15	or	O
16	middle	O
17	cerebral	O
18	arteries	O
19	were	O
20	the	O
21	posited	O
22	mechanism	O
23	of	O
24	infarction	O
25	.	O

1	All	O
2	ABFI	B
3	-	I
4	binding	I
5	sites	I
6	,	O
7	regardless	O
8	of	O
9	origin	O
10	,	O
11	provided	O
12	weak	O
13	UAS	O
14	function	O
15	in	O
16	vivo	O
17	when	O
18	examined	O
19	in	O
20	test	O
21	plasmids	O
22	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	properties	O
6	of	O
7	sequences	O
8	surrounding	O
9	ARS1	O
10	left	O
11	open	O
12	the	O
13	possibility	O
14	that	O
15	ABFI	B
16	enhances	O
17	the	O
18	initiation	O
19	of	O
20	DNA	O
21	replication	O
22	at	O
23	ARS1	O
24	by	O
25	transcriptional	O
26	activation	O
27	.	O

1	Nonvascular	O
2	ophthalmic	O
3	and	O
4	neurologic	O
5	disorders	O
6	that	O
7	can	O
8	be	O
9	confused	O
10	with	O
11	amaurosis	O
12	fugax	O
13	are	O
14	listed	O
15	,	O
16	and	O
17	an	O
18	algorithm	O
19	for	O
20	evaluation	O
21	(	O
22	which	O
23	includes	O
24	ophthalmic	O
25	examination	O
26	,	O
27	laboratory	O
28	studies	O
29	,	O
30	and	O
31	noninvasive	O
32	carotid	O
33	artery	O
34	studies	O
35	)	O
36	is	O
37	given	O
38	.	O

1	Likewise	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	the	O
7	hypotensive	O
8	action	O
9	of	O
10	converting	O
11	enzyme	O
12	inhibitors	O
13	is	O
14	age	O
15	-	O
16	related	O
17	is	O
18	as	O
19	yet	O
20	unknown	O
21	.	O

1	Polyclonal	O
2	antiserum	O
3	generated	O
4	to	O
5	the	O
6	fusion	O
7	protein	O
8	was	O
9	capable	O
10	of	O
11	detecting	O
12	42	O
13	-	O
14	and	O
15	46	O
16	-	O
17	kilodalton	O
18	polypeptides	O
19	from	O
20	virus	O
21	particles	O
22	;	O
23	both	O
24	polypeptides	O
25	were	O
26	also	O
27	shown	O
28	to	O
29	contain	O
30	HBsAg	B
31	determinants	I
32	.	O

1	These	O
2	characteristics	O
3	of	O
4	N22	O
5	/	O
6	P22	O
7	indicate	O
8	that	O
9	it	O
10	is	O
11	a	O
12	localized	O
13	synaptically	O
14	dependent	O
15	event	O
16	conforming	O
17	to	O
18	a	O
19	transverse	O
20	dipole	O
21	with	O
22	dorsal	O
23	negativity	O
24	and	O
25	a	O
26	simultaneous	O
27	anterior	O
28	positivity	O
29	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	At	O
2	maximum	O
3	photosensitivity	O
4	the	O
5	inhibitory	O
6	amino	O
7	acids	O
8	gamma	O
9	-	O
10	aminobutyric	O
11	acid	O
12	and	O
13	taurine	O
14	were	O
15	lower	O
16	,	O
17	and	O
18	those	O
19	of	O
20	asparagine	O
21	(	O
22	metabolite	O
23	of	O
24	the	O
25	excitatory	O
26	amino	O
27	acid	O
28	aspartate	O
29	)	O
30	were	O
31	higher	O
32	,	O
33	than	O
34	when	O
35	the	O
36	animals	O
37	were	O
38	not	O
39	photosensitive	O
40	.	O

1	We	O
2	evaluated	O
3	the	O
4	likelihood	O
5	of	O
6	tissues	O
7	to	O
8	be	O
9	positive	O
10	for	O
11	carcinoembryonic	B
12	antigen	I
13	and	O
14	the	O
15	intensity	O
16	of	O
17	carcinoembryonic	B
18	antigen	I
19	staining	O
20	in	O
21	specimens	O
22	of	O
23	villous	O
24	adenomas	O
25	,	O
26	mixed	O
27	polypoid	O
28	villous	O
29	adenomas	O
30	,	O
31	polypoid	O
32	adenomas	O
33	,	O
34	and	O
35	diverticulitis	O
36	using	O
37	the	O
38	peroxidase	B
39	-	O
40	antiperoxidase	B
41	technique	O
42	.	O

1	The	O
2	priming	O
3	activity	O
4	of	O
5	DNA	O
6	incised	O
7	by	O
8	either	O
9	of	O
10	the	O
11	Drosophila	O
12	enzymes	O
13	can	O
14	be	O
15	enhanced	O
16	,	O
17	however	O
18	,	O
19	by	O
20	an	O
21	additional	O
22	incubation	O
23	with	O
24	E	B
25	.	I
26	coli	I
27	endonuclease	I
28	IV	I
29	,	O
30	which	O
31	is	O
32	known	O
33	to	O
34	cleave	O
35	depurinated	O
36	DNA	O
37	on	O
38	the	O
39	5	O
40	'-	O
41	side	O
42	of	O
43	an	O
44	apurinic	O
45	site	O
46	.	O

1	A	O
2	.	O

1	Therefore	O
2	,	O
3	in	O
4	conjunction	O
5	with	O
6	a	O
7	positive	O
8	pregnancy	O
9	test	O
10	and	O
11	the	O
12	patient	O
13	'	O
14	s	O
15	clinical	O
16	history	O
17	,	O
18	a	O
19	severely	O
20	depressed	O
21	or	O
22	absent	O
23	serum	O
24	PAPP	B
25	-	I
26	A	I
27	level	O
28	may	O
29	aid	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	extrauterine	O
35	pregnancy	O
36	.	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	B
6	-	I
7	specific	I
8	and	I
9	MAP2	I
10	-	I
11	specific	I
12	mRNAs	I
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O

1	The	O
2	cDNAs	O
3	cross	O
4	-	O
5	hybridize	O
6	with	O
7	genomic	O
8	sequences	O
9	in	O
10	rat	O
11	,	O
12	human	O
13	,	O
14	and	O
15	chicken	O
16	DNA	O
17	,	O
18	but	O
19	not	O
20	with	O
21	DNA	O
22	from	O
23	frog	O
24	,	O
25	Drosophila	O
26	,	O
27	or	O
28	sea	O
29	urchin	O
30	.	O

1	Colorimetric	O
2	method	O
3	of	O
4	determining	O
5	glycerin	O
6	in	O
7	the	O
8	blood	O

1	Deletion	O
2	analysis	O
3	was	O
4	carried	O
5	out	O
6	within	O
7	a	O
8	part	O
9	of	O
10	the	O
11	5	O
12	'-	O
13	flanking	O
14	region	O
15	showing	O
16	homology	O
17	to	O
18	the	O
19	upstream	O
20	region	O
21	of	O
22	the	O
23	yeast	B
24	CYC1	I
25	gene	I
26	.	O

1	The	O
2	N1	O
3	and	O
4	P2	O
5	were	O
6	comparable	O
7	in	O
8	amplitude	O
9	and	O
10	both	O
11	had	O
12	prolonged	O
13	refractory	O
14	periods	O
15	.	O

1	Tolerance	O
2	to	O
3	fenfluramine	O
4	anorexia	O
5	:	O
6	fact	O
7	or	O
8	fiction	O
9	?	O
10	Recent	O
11	findings	O
12	in	O
13	this	O
14	laboratory	O
15	with	O
16	regard	O
17	to	O
18	tolerance	O
19	to	O
20	fenfluramine	O
21	anorexia	O
22	are	O
23	reviewed	O
24	with	O
25	respect	O
26	to	O
27	generality	O
28	of	O
29	the	O
30	behavioural	O
31	phenomenon	O
32	.	O

1	In	O
2	30	O
3	dogs	O
4	the	O
5	left	O
6	limb	O
7	(	O
8	tail	O
9	)	O
10	of	O
11	the	O
12	pancreas	O
13	was	O
14	removed	O
15	but	O
16	left	O
17	in	O
18	the	O
19	abdominal	O
20	cavity	O
21	after	O
22	cessation	O
23	of	O
24	blood	O
25	flow	O
26	to	O
27	produce	O
28	warm	O
29	ischemia	O
30	for	O
31	30	O
32	,	O
33	60	O
34	,	O
35	and	O
36	120	O
37	min	O
38	(	O
39	10	O
40	dogs	O
41	at	O
42	each	O
43	time	O
44	point	O
45	),	O
46	and	O
47	then	O
48	was	O
49	flushed	O
50	with	O
51	cold	O
52	Ringers	O
53	'	O
54	lactate	O
55	and	O
56	transplanted	O
57	to	O
58	the	O
59	iliac	O
60	vessels	O
61	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	view	O
6	that	O
7	clonidine	O
8	and	O
9	6	O
10	-	O
11	OHDA	O
12	,	O
13	but	O
14	not	O
15	alpha	O
16	-	O
17	MD	O
18	,	O
19	have	O
20	central	O
21	pressor	O
22	actions	O
23	in	O
24	the	O
25	rat	O
26	that	O
27	oppose	O
28	their	O
29	antihypertensive	O
30	action	O
31	.	O

1	Furthermore	O
2	,	O
3	beta	B
4	2	I
5	-	I
6	adrenoceptor	I
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	Hansel	O
5	'	O
6	s	O
7	stain	O
8	substantially	O
9	improves	O
10	the	O
11	recognition	O
12	of	O
13	eosinophiluria	O
14	as	O
15	compared	O
16	with	O
17	Wright	O
18	'	O
19	s	O
20	stain	O
21	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	negative	O
7	inotropic	O
8	action	O
9	of	O
10	nicorandil	O
11	is	O
12	caused	O
13	by	O
14	inhibition	O
15	of	O
16	Ca	O
17	influx	O
18	and	O
19	intracellular	O
20	mobilization	O
21	of	O
22	Ca	O
23	.	O

1	The	O
2	study	O
3	included	O
4	139	O
5	eyes	O
6	with	O
7	presumed	O
8	ocular	O
9	histoplasmosis	O
10	syndrome	O
11	(	O
12	POHS	O
13	)	O
14	and	O
15	age	O
16	-	O
17	related	O
18	macular	O
19	degeneration	O
20	(	O
21	AMD	O
22	).	O

1	Comparison	O
2	of	O
3	elastase	B
4	-	I
5	1	I
6	with	O
7	amylase	B
8	,	O
9	lipase	B
10	,	O
11	and	O
12	trypsin	B
13	-	O
14	like	O
15	immunoreactivity	O
16	in	O
17	the	O
18	diagnosis	O
19	of	O
20	acute	O
21	pancreatitis	O
22	.	O

1	A	O
2	probe	O
3	evoked	O
4	potentials	O
5	procedure	O
6	was	O
7	used	O
8	to	O
9	assess	O
10	the	O
11	relative	O
12	engagement	O
13	of	O
14	both	O
15	cerebral	O
16	hemispheres	O
17	during	O
18	a	O
19	language	O
20	task	O
21	in	O
22	the	O
23	following	O
24	four	O
25	groups	O
26	of	O
27	dextral	O
28	adults	O
29	:	O
30	left	O
31	hemisphere	O
32	(	O
33	LH	O
34	)-	O
35	damaged	O
36	aphasics	O
37	recovering	O
38	from	O
39	stroke	O
40	,	O
41	dysarthrics	O
42	,	O
43	right	O
44	hemisphere	O
45	(	O
46	RH	O
47	)-	O
48	damaged	O
49	nonaphasic	O
50	patients	O
51	,	O
52	and	O
53	normal	O
54	control	O
55	subjects	O
56	.	O

1	Mucolipidosis	O
2	type	O
3	IV	O
4	:	O
5	clinical	O
6	spectrum	O
7	and	O
8	natural	O
9	history	O
10	.	O

1	Two	O
2	of	O
3	the	O
4	three	O
5	groups	O
6	were	O
7	administered	O
8	dauricine	O
9	,	O
10	as	O
11	a	O
12	new	O
13	calcium	O
14	channel	O
15	blocker	O
16	,	O
17	and	O
18	verapamil	O
19	,	O
20	as	O
21	a	O
22	generally	O
23	recognized	O
24	calcium	O
25	channel	O
26	blocker	O
27	,	O
28	respectively	O
29	,	O
30	from	O
31	15	O
32	minutes	O
33	pre	O
34	-	O
35	bypass	O
36	to	O
37	the	O
38	end	O
39	of	O
40	the	O
41	bypass	O
42	procedure	O
43	(	O
44	a	O
45	period	O
46	of	O
47	95	O
48	minutes	O
49	).	O

1	No	O
2	reflow	O
3	occurred	O
4	in	O
5	approximately	O
6	30	O
7	percent	O
8	of	O
9	the	O
10	muscle	O
11	microvasculature	O
12	upon	O
13	reperfusion	O
14	.	O

1	Rarely	O
2	,	O
3	patients	O
4	with	O
5	locally	O
6	advanced	O
7	,	O
8	uncontrollable	O
9	,	O
10	non	O
11	-	O
12	metastatic	O
13	prostatic	O
14	cancer	O
15	enjoy	O
16	prolonged	O
17	survival	O
18	.	O

1	Lysozyme	B
2	activity	O
3	was	O
4	evidently	O
5	increased	O
6	as	O
7	well	O
8	in	O
9	undiluted	O
10	as	O
11	in	O
12	diluted	O
13	sera	O
14	in	O
15	all	O
16	our	O
17	tested	O
18	patients	O
19	.	O

1	The	O
2	first	O
3	involved	O
4	measurements	O
5	of	O
6	the	O
7	steady	O
8	state	O
9	levels	O
10	of	O
11	mRNAs	O
12	for	O
13	subunit	O
14	5	O
15	of	O
16	cytochrome	B
17	oxidase	I
18	and	O
19	the	O
20	beta	O
21	subunit	O
22	of	O
23	F1	B
24	ATPase	I
25	in	O
26	wild	O
27	type	O
28	and	O
29	in	O
30	a	O
31	hem2	B
32	mutant	I
33	.	O

1	A	O
2	5	B
3	.	I
4	8S	I
5	-	I
6	like	I
7	structure	I
8	is	O
9	present	O
10	within	O
11	the	O
12	5	O
13	'-	O
14	terminal	O
15	region	O
16	of	O
17	all	O
18	three	O
19	fungal	B
20	mitochondrial	I
21	LSU	I
22	rRNAs	I
23	;	O
24	in	O
25	contrast	O
26	,	O
27	no	O
28	4	B
29	.	I
30	5S	I
31	-	I
32	like	I
33	structure	I
34	is	O
35	evident	O
36	at	O
37	the	O
38	3	O
39	'	O
40	end	O
41	of	O
42	these	O
43	molecules	O
44	.	O

1	ATP	O
2	gamma	O
3	S	O
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	dATP	O
15	,	O
16	araATP	O
17	,	O
18	or	O
19	ddATP	O
20	.	O

1	The	O
2	recovery	O
3	of	O
4	labelled	O
5	methoxydextrane	O
6	is	O
7	98	O
8	+/-	O
9	7	O
10	%.	O

1	ASL	O
2	-	O
3	8123	O
4	demonstrated	O
5	weak	O
6	competitive	O
7	beta	B
8	-	I
9	adrenoreceptor	I
10	blocking	O
11	activity	O
12	in	O
13	isolated	O
14	guinea	O
15	pig	O
16	right	O
17	atria	O
18	with	O
19	a	O
20	pA2	O
21	of	O
22	3	O
23	.	O
24	73	O
25	+/-	O
26	0	O
27	.	O
28	07	O
29	;	O
30	no	O
31	agonist	O
32	-	O
33	like	O
34	activity	O
35	was	O
36	observed	O
37	in	O
38	this	O
39	tissue	O
40	at	O
41	concentrations	O
42	of	O
43	ASL	O
44	-	O
45	8123	O
46	from	O
47	3	O
48	X	O
49	10	O
50	(-	O
51	5	O
52	)	O
53	to	O
54	1	O
55	X	O
56	10	O
57	(-	O
58	2	O
59	)	O
60	M	O
61	.	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	We	O
2	discuss	O
3	the	O
4	results	O
5	in	O
6	relation	O
7	to	O
8	previous	O
9	systems	O
10	for	O
11	parcellating	O
12	the	O
13	posterior	O
14	ectosylvian	O
15	gyrus	O
16	of	O
17	the	O
18	cat	O
19	and	O
20	consider	O
21	the	O
22	possibility	O
23	that	O
24	divisions	O
25	of	O
26	the	O
27	feline	O
28	posterior	O
29	ectosylvian	O
30	gyrus	O
31	correspond	O
32	directly	O
33	to	O
34	areas	O
35	making	O
36	up	O
37	the	O
38	superior	O
39	temporal	O
40	gyrus	O
41	in	O
42	primates	O
43	.	O

1	The	O
2	gene	O
3	is	O
4	contained	O
5	within	O
6	a	O
7	1	O
8	.	O
9	8	O
10	-	O
11	kilobase	O
12	AccI	B
13	-	O
14	EcoRI	B
15	restriction	O
16	fragment	O
17	mapping	O
18	at	O
19	map	O
20	coordinates	O
21	0	O
22	.	O
23	136	O
24	to	O
25	0	O
26	.	O
27	148	O
28	in	O
29	the	O
30	UL	O
31	region	O
32	of	O
33	the	O
34	EHV	O
35	-	O
36	1	O
37	genome	O
38	and	O
39	is	O
40	transcribed	O
41	from	O
42	right	O
43	to	O
44	left	O
45	.	O

1	The	O
2	4	O
3	-	O
4	AP	O
5	(	O
6	4	O
7	-	O
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	TEA	O
27	or	O
28	Ba2	O
29	+.	O

1	Hybridization	O
2	of	O
3	a	O
4	probe	O
5	from	O
6	this	O
7	region	O
8	to	O
9	electrophoretic	O
10	blots	O
11	of	O
12	RNAs	O
13	from	O
14	different	O
15	human	O
16	tissues	O
17	showed	O
18	a	O
19	predominant	O
20	2	O
21	.	O
22	8	O
23	-	O
24	kilobase	O
25	(	O
26	kb	O
27	)	O
28	message	O
29	accompanied	O
30	by	O
31	weaker	O
32	bands	O
33	4	O
34	.	O
35	1	O
36	and	O
37	2	O
38	.	O
39	1	O
40	kb	O
41	in	O
42	size	O
43	.	O

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	sleep	O
10	spindles	O
11	during	O
12	continuous	O
13	overnight	O
14	EEG	O
15	recordings	O
16	.	O

1	Svensson	O
2	et	O
3	al	O
4	.	O

1	Endogenous	O
2	release	O
3	of	O
4	neuronal	O
5	serotonin	O
6	and	O
7	5	O
8	-	O
9	hydroxyindoleacetic	O
10	acid	O
11	in	O
12	the	O
13	caudate	O
14	-	O
15	putamen	O
16	of	O
17	the	O
18	rat	O
19	as	O
20	revealed	O
21	by	O
22	intracerebral	O
23	dialysis	O
24	coupled	O
25	to	O
26	high	O
27	-	O
28	performance	O
29	liquid	O
30	chromatography	O
31	with	O
32	fluorimetric	O
33	detection	O
34	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O

1	Viable	O
2	flap	O
3	areas	O
4	were	O
5	established	O
6	following	O
7	vascular	O
8	pedicle	O
9	ligation	O
10	(	O
11	both	O
12	vessels	O
13	or	O
14	only	O
15	artery	O
16	or	O
17	vein	O
18	),	O
19	on	O
20	the	O
21	third	O
22	day	O
23	after	O
24	flap	O
25	replantation	O
26	in	O
27	both	O
28	island	O
29	and	O
30	free	O
31	flaps	O
32	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	B
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	A	O
2	9	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	KpnI	B
8	-	O
9	SalI	B
10	fragment	O
11	,	O
12	where	O
13	all	O
14	the	O
15	DNA	O
16	changes	O
17	associated	O
18	with	O
19	su	B
20	(	I
21	Hw	I
22	)	I
23	mutations	I
24	were	O
25	mapped	O
26	,	O
27	was	O
28	able	O
29	to	O
30	rescue	O
31	the	O
32	su	B
33	(	I
34	Hw	I
35	)	I
36	mutant	I
37	phenotype	O
38	after	O
39	P	O
40	-	O
41	element	O
42	-	O
43	mediated	O
44	germ	O
45	-	O
46	line	O
47	transformation	O
48	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	The	O
2	effects	O
3	of	O
4	L655	O
5	,	O
6	240	O
7	,	O
8	a	O
9	selective	O
10	thromboxane	O
11	and	O
12	prostaglandin	O
13	endoperoxide	O
14	antagonist	O
15	,	O
16	on	O
17	ischemia	O
18	-	O
19	and	O
20	reperfusion	O
21	-	O
22	induced	O
23	cardiac	O
24	arrhythmias	O
25	.	O

1	In	O
2	10	O
3	pentobarbitalized	O
4	dogs	O
5	,	O
6	plasma	O
7	viscosity	O
8	(	O
9	Ep	O
10	)	O
11	was	O
12	raised	O
13	fourfold	O
14	while	O
15	apparent	O
16	blood	O
17	viscosity	O
18	(	O
19	Ea	O
20	)	O
21	increased	O
22	about	O
23	twofold	O
24	by	O
25	two	O
26	steps	O
27	of	O
28	exchange	O
29	transfusion	O
30	of	O
31	200	O
32	ml	O
33	of	O
34	plasma	O
35	with	O
36	plasma	O
37	containing	O
38	high	O
39	molecular	O
40	weight	O
41	dextran	O
42	(	O
43	mol	O
44	wt	O
45	500	O
46	,	O
47	000	O
48	,	O
49	20	O
50	%	O
51	wt	O
52	/	O
53	vol	O
54	).	O

1	The	O
2	small	B
3	IGF	I
4	-	I
5	binding	I
6	protein	I
7	is	O
8	abundant	O
9	in	O
10	human	O
11	amniotic	O
12	fluid	O
13	.	O

1	Serum	O
2	prostatic	B
3	acid	I
4	phosphatase	I
5	levels	O
6	showed	O
7	a	O
8	significantly	O
9	weaker	O
10	correlation	O
11	with	O
12	cancer	O
13	volume	O
14	(	O
15	r	O
16	equals	O
17	0	O
18	.	O
19	51	O
20	)	O
21	and	O
22	every	O
23	other	O
24	pathological	O
25	parameter	O
26	.	O

1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	O
17	of	O
18	the	O
19	MAO	B
20	-	I
21	B	I
22	inhibitor	O
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O

1	Their	O
2	studies	O
3	have	O
4	revealed	O
5	a	O
6	considerable	O
7	increase	O
8	of	O
9	CSF	B
10	AP	I
11	activity	O
12	in	O
13	purulent	O
14	meningitides	O
15	whereas	O
16	in	O
17	serous	O
18	meningitides	O
19	it	O
20	grows	O
21	negligibly	O
22	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	new	O
6	human	O
7	lymphocyte	O
8	cell	O
9	surface	O
10	molecule	O
11	has	O
12	been	O
13	isolated	O
14	and	O
15	shown	O
16	to	O
17	identify	O
18	a	O
19	fourth	O
20	member	O
21	of	O
22	a	O
23	recently	O
24	discovered	O
25	family	O
26	of	O
27	adhesion	O
28	proteins	O
29	.	O

1	Dopamine	O
2	caused	O
3	a	O
4	prominent	O
5	potassium	O
6	efflux	O
7	measured	O
8	as	O
9	86Rb	O
10	+	O
11	efflux	O
12	from	O
13	control	O
14	glands	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	denervated	O
22	glands	O
23	.	O

1	Spontaneous	O
2	sensitization	O
3	to	O
4	cross	O
5	-	O
6	reacting	O
7	chemicals	O
8	in	O
9	a	O
10	proportion	O
11	of	O
12	control	O
13	animals	O
14	is	O
15	strongly	O
16	suggested	O
17	,	O
18	somewhat	O
19	akin	O
20	to	O
21	spontaneous	O
22	sensitization	O
23	in	O
24	patients	O
25	with	O
26	anaphylactoid	O
27	reactions	O
28	to	O
29	neuromuscular	O
30	blockers	O
31	on	O
32	first	O
33	exposure	O
34	,	O
35	and	O
36	in	O
37	whom	O
38	IgE	B
39	antibodies	I
40	are	O
41	detected	O
42	.	O

1	This	O
2	approach	O
3	was	O
4	examined	O
5	utilizing	O
6	the	O
7	fetal	O
8	protein	O
9	,	O
10	HGB	B
11	F	I
12	.	O

1	The	O
2	investigation	O
3	was	O
4	apt	O
5	at	O
6	studying	O
7	the	O
8	relationship	O
9	between	O
10	urinary	O
11	metabolites	O
12	of	O
13	serotonin	O
14	and	O
15	catecholamine	O
16	(	O
17	5	O
18	-	O
19	HIAA	O
20	and	O
21	VMA	O
22	),	O
23	T	O
24	-	O
25	cells	O
26	(	O
27	OKT3	O
28	+),	O
29	T	O
30	-	O
31	helper	O
32	(	O
33	OKT4	O
34	+),	O
35	T	O
36	-	O
37	suppressor	O
38	(	O
39	OKT8	O
40	+)	O
41	and	O
42	B	O
43	-	O
44	cells	O
45	(	O
46	EAC	O
47	-	O
48	rosette	O
49	forming	O
50	cells	O
51	)	O
52	in	O
53	normal	O
54	(	O
55	10	O
56	subjects	O
57	,	O
58	1	O
59	female	O
60	,	O
61	9	O
62	male	O
63	,	O
64	age	O
65	21	O
66	+/-	O
67	5	O
68	years	O
69	)	O
70	and	O
71	stress	O
72	administered	O
73	subjects	O
74	(	O
75	20	O
76	subjects	O
77	,	O
78	3	O
79	female	O
80	,	O
81	17	O
82	male	O
83	,	O
84	age	O
85	20	O
86	+/-	O
87	4	O
88	years	O
89	).	O

1	The	O
2	84	B
3	.	I
4	1C	I
5	mAb	I
6	recognizes	O
7	a	O
8	site	O
9	on	O
10	IgE	B
11	which	O
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	B
20	epsilon	I
21	R	I
22	binding	I
23	site	I
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	B
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	B
44	epsilon	I
45	R	I
46	binding	I
47	site	I
48	.	O

1	Their	O
2	hydropathic	O
3	plots	O
4	are	O
5	very	O
6	similar	O
7	and	O
8	both	O
9	possess	O
10	three	O
11	hydrophobic	O
12	segments	O
13	that	O
14	are	O
15	likely	O
16	alpha	O
17	-	O
18	helical	O
19	transmembrane	O
20	segments	O
21	.	O

1	Angiotensin	B
2	converting	I
3	enzyme	I
4	inhibitors	O
5	enhance	O
6	the	O
7	antihypertensive	O
8	efficacy	O
9	of	O
10	diuretics	O
11	and	O
12	blunt	O
13	or	O
14	prevent	O
15	adverse	O
16	metabolic	O
17	effects	O
18	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	significant	O
6	reduction	O
7	in	O
8	blood	O
9	pressure	O
10	,	O
11	the	O
12	angiotensin	B
13	converting	I
14	enzyme	I
15	(	O
16	ACE	B
17	)	O
18	inhibitor	O
19	ramipril	O
20	caused	O
21	a	O
22	significant	O
23	regression	O
24	of	O
25	pathologic	O
26	left	O
27	ventricular	O
28	hypertrophy	O
29	demonstrated	O
30	by	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	and	O
35	echocardiography	O
36	.	O

1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	B
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O

1	The	O
2	ratio	O
3	of	O
4	radioactivity	O
5	in	O
6	tumour	O
7	compared	O
8	with	O
9	normal	O
10	tissue	O
11	(	O
12	T	O
13	:	O
14	N	O
15	ratio	O
16	)	O
17	was	O
18	determined	O
19	after	O
20	simultaneously	O
21	injecting	O
22	microspheres	O
23	into	O
24	the	O
25	portal	O
26	and	O
27	arterial	O
28	circulation	O
29	of	O
30	each	O
31	animal	O
32	.	O

1	The	O
2	mRNA	O
3	was	O
4	converted	O
5	to	O
6	cDNA	O
7	and	O
8	amplified	O
9	by	O
10	the	O
11	polymerase	O
12	chain	O
13	reaction	O
14	technique	O
15	.	O

1	Tissue	O
2	necrosis	O
3	was	O
4	evaluated	O
5	using	O
6	triphenyltetrazolium	O
7	staining	O
8	and	O
9	was	O
10	related	O
11	to	O
12	two	O
13	major	O
14	baseline	O
15	predictors	O
16	of	O
17	infarct	O
18	size	O
19	:	O
20	anatomic	O
21	risk	O
22	zone	O
23	size	O
24	and	O
25	coronary	O
26	collateral	O
27	flow	O
28	.	O

1	To	O
2	study	O
3	the	O
4	retinal	O
5	surface	O
6	in	O
7	the	O
8	human	O
9	eye	O
10	in	O
11	normal	O
12	and	O
13	diseased	O
14	states	O
15	we	O
16	used	O
17	laser	O
18	scanning	O
19	tomography	O
20	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	the	O
6	sequence	O
7	of	O
8	the	O
9	gene	B
10	encoding	I
11	human	I
12	K14	I
13	(	O
14	D	O
15	.	O

1	A	O
2	potential	O
3	TATA	O
4	box	O
5	is	O
6	located	O
7	29	O
8	base	O
9	pairs	O
10	upstream	O
11	of	O
12	the	O
13	first	O
14	transcription	O
15	initiation	O
16	site	O
17	.	O

1	Cotransfection	O
2	of	O
3	either	O
4	construct	O
5	with	O
6	plasmids	O
7	encoding	O
8	PKI	B
9	(	I
10	1	I
11	-	I
12	31	I
13	)	I
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	but	O
19	not	O
20	basal	O
21	-	O
22	or	O
23	phorbol	O
24	ester	O
25	-	O
26	stimulated	O
27	expression	O
28	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	region	O
9	revealed	O
10	several	O
11	GC	O
12	boxes	O
13	but	O
14	no	O
15	identifiable	O
16	TATA	O
17	box	O
18	.	O

1	The	O
2	underlying	O
3	cirrhosis	O
4	was	O
5	alcoholic	O
6	in	O
7	11	O
8	(	O
9	53	O
10	.	O
11	3	O
12	%),	O
13	cryptogenic	O
14	in	O
15	5	O
16	(	O
17	23	O
18	.	O
19	8	O
20	%),	O
21	and	O
22	hepatitis	O
23	B	O
24	chronic	O
25	infection	O
26	related	O
27	in	O
28	5	O
29	(	O
30	23	O
31	.	O
32	8	O
33	%).	O

1	Once	O
2	P	B
3	-	I
4	450scc	I
5	mRNA	I
6	is	O
7	induced	O
8	as	O
9	a	O
10	consequence	O
11	of	O
12	the	O
13	LH	B
14	/	O
15	hCG	B
16	surge	O
17	it	O
18	is	O
19	constitutively	O
20	maintained	O
21	by	O
22	luteinized	O
23	cells	O
24	in	O
25	vivo	O
26	(	O
27	0	O
28	-	O
29	4	O
30	days	O
31	)	O
32	and	O
33	in	O
34	vitro	O
35	(	O
36	0	O
37	-	O
38	9	O
39	days	O
40	)	O
41	in	O
42	the	O
43	absence	O
44	of	O
45	gonadotropins	B
46	,	O
47	is	O
48	susceptible	O
49	to	O
50	modulation	O
51	by	O
52	prolactin	B
53	and	O
54	is	O
55	no	O
56	longer	O
57	regulated	O
58	by	O
59	cAMP	O
60	.	O

1	Similarly	O
2	,	O
3	a	O
4	human	O
5	but	O
6	not	O
7	a	O
8	bovine	B
9	alpha	I
10	transgene	I
11	was	O
12	expressed	O
13	in	O
14	placenta	O
15	in	O
16	transgenic	O
17	mice	O
18	.	O

1	A	O
2	rapid	O
3	staining	O
4	technique	O
5	for	O
6	Leishmania	O
7	parasites	O
8	in	O
9	splenic	O
10	aspirate	O
11	smears	O
12	.	O

1	NIK	O
2	-	O
3	244	O
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O

1	In	O
2	TNF	B
3	-	O
4	resistant	O
5	T24	O
6	bladder	O
7	carcinoma	O
8	cells	O
9	,	O
10	TNF	B
11	failed	O
12	to	O
13	alter	O
14	EGF	B
15	-	I
16	R	I
17	tyrosine	I
18	protein	I
19	kinase	I
20	activity	O
21	although	O
22	both	O
23	EGF	B
24	and	O
25	phorbol	O
26	ester	O
27	were	O
28	shown	O
29	to	O
30	modulate	O
31	the	O
32	enzymatic	O
33	activity	O
34	of	O
35	the	O
36	receptor	O
37	in	O
38	these	O
39	cells	O
40	.	O

1	Thus	O
2	,	O
3	phosphodiesterase	O
4	inhibitors	O
5	that	O
6	produce	O
7	an	O
8	opiate	O
9	quasi	O
10	-	O
11	withdrawal	O
12	syndrome	O
13	potentiate	O
14	interoceptive	O
15	stimuli	O
16	and	O
17	weight	O
18	loss	O
19	associated	O
20	with	O
21	the	O
22	withdrawal	O
23	syndrome	O
24	precipitated	O
25	by	O
26	naltrexone	O
27	in	O
28	morphine	O
29	-	O
30	dependent	O
31	rats	O
32	.	O

1	The	O
2	diagnostic	O
3	value	O
4	of	O
5	blood	O
6	serum	O
7	and	O
8	urinary	B
9	amylase	I
10	,	O
11	lipase	B
12	,	O
13	and	O
14	trypsin	B
15	in	O
16	exacerbations	O
17	of	O
18	chronic	O
19	relapsing	O
20	pancreatitis	O
21	is	O
22	discussed	O
23	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	O
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	O

1	Intravenous	O
2	gamma	B
3	globulins	I

1	Following	O
2	chondroitinase	B
3	AC	I
4	and	I
5	ABC	I
6	digestion	O
7	,	O
8	staining	O
9	reactions	O
10	suggested	O
11	that	O
12	the	O
13	highest	O
14	levels	O
15	of	O
16	dermatan	O
17	sulfate	O
18	were	O
19	in	O
20	the	O
21	diabetes	O
22	resistant	O
23	group	O
24	(	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	compared	O
32	to	O
33	diabetic	O
34	,	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	001	O
41	compared	O
42	to	O
43	diabetes	O
44	prone	O
45	)	O
46	and	O
47	the	O
48	highest	O
49	levels	O
50	of	O
51	chondroitin	O
52	sulfates	O
53	were	O
54	in	O
55	the	O
56	diabetes	O
57	prone	O
58	group	O
59	(	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	001	O
66	).	O

1	Myocardial	O
2	perfusion	O
3	was	O
4	evaluated	O
5	using	O
6	the	O
7	enhanced	O
8	gray	O
9	level	O
10	after	O
11	contrast	O
12	injection	O
13	,	O
14	and	O
15	the	O
16	level	O
17	was	O
18	compared	O
19	with	O
20	the	O
21	morphology	O
22	and	O
23	degree	O
24	of	O
25	collateral	O
26	development	O
27	.	O

1	Once	O
2	NGF	B
3	administration	O
4	is	O
5	proven	O
6	effective	O
7	it	O
8	will	O
9	be	O
10	possible	O
11	to	O
12	develop	O
13	alternative	O
14	ways	O
15	of	O
16	NGF	B
17	administration	O
18	.	O

1	During	O
2	the	O
3	program	O
4	'	O
5	s	O
6	use	O
7	at	O
8	the	O
9	RSNA	O
10	meeting	O
11	,	O
12	the	O
13	program	O
14	selected	O
15	the	O
16	correct	O
17	diagnosis	O
18	in	O
19	the	O
20	top	O
21	five	O
22	22	O
23	%	O
24	of	O
25	the	O
26	time	O
27	.	O

1	Immunoglobulin	B
2	light	I
3	chain	I
4	(	O
5	IgL	B
6	)	O
7	diversity	O
8	is	O
9	generated	O
10	in	O
11	the	O
12	chicken	O
13	by	O
14	recombination	O
15	between	O
16	the	O
17	single	O
18	functional	O
19	variable	O
20	(	O
21	VL	B
22	)	O
23	and	O
24	joining	O
25	(	O
26	JL	B
27	)	O
28	gene	O
29	segments	O
30	and	O
31	subsequent	O
32	somatic	O
33	diversification	O
34	of	O
35	the	O
36	rearranged	O
37	VL	B
38	region	O
39	.	O

1	The	O
2	results	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	1	O
8	)	O
9	Total	O
10	integrated	O
11	EMG	O
12	activity	O
13	of	O
14	FB	O
15	group	O
16	was	O
17	approximately	O
18	equal	O
19	in	O
20	any	O
21	occluded	O
22	position	O
23	,	O
24	whereas	O
25	that	O
26	of	O
27	CG	O
28	and	O
29	GF	O
30	group	O
31	varied	O
32	from	O
33	position	O
34	to	O
35	position	O
36	.	O

1	Muscle	O
2	action	O
3	potential	O
4	and	O
5	masticatory	O
6	rhythm	O
7	of	O
8	anterior	O
9	temporal	O
10	and	O
11	masseter	O
12	muscles	O
13	in	O
14	children	O
15	and	O
16	adults	O

1	In	O
2	76	O
3	%	O
4	of	O
5	59	O
6	lead	O
7	-	O
8	toxic	O
9	children	O
10	,	O
11	bone	O
12	lead	O
13	values	O
14	measured	O
15	by	O
16	LXRF	O
17	were	O
18	equal	O
19	to	O
20	or	O
21	greater	O
22	than	O
23	those	O
24	measured	O
25	in	O
26	normal	O
27	and	O
28	industrially	O
29	exposed	O
30	adults	O
31	.	O

1	When	O
2	considered	O
3	with	O
4	the	O
5	known	O
6	neurotoxic	O
7	effects	O
8	on	O
9	children	O
10	of	O
11	"	O
12	low	O
13	levels	O
14	"	O
15	of	O
16	exposure	O
17	to	O
18	lead	O
19	,	O
20	these	O
21	results	O
22	also	O
23	suggest	O
24	that	O
25	either	O
26	an	O
27	excessively	O
28	narrow	O
29	margin	O
30	of	O
31	safety	O
32	or	O
33	insufficient	O
34	safety	O
35	is	O
36	provided	O
37	by	O
38	present	O
39	U	O
40	.	O
41	S	O
42	.	O
43	guidelines	O
44	,	O
45	which	O
46	classify	O
47	an	O
48	elevated	O
49	blood	O
50	lead	O
51	concentration	O
52	as	O
53	25	O
54	micrograms	O
55	/	O
56	dl	O
57	or	O
58	greater	O
59	.	O

1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	I
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	jun	B
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O

1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O

1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O

1	Enzyme	O
2	-	O
3	linked	O
4	immunosorbent	O
5	assay	O
6	for	O
7	screening	O
8	aflatoxin	O
9	B1	O
10	in	O
11	cottonseed	O
12	products	O
13	and	O
14	mixed	O
15	feed	O
16	:	O
17	collaborative	O
18	study	O
19	.	O

1	However	O
2	,	O
3	experiments	O
4	with	O
5	S1	B
6	mapping	O
7	of	O
8	in	O
9	vivo	O
10	transcripts	O
11	,	O
12	gene	O
13	disruptions	O
14	in	O
15	the	O
16	alpha	O
17	region	O
18	,	O
19	and	O
20	a	O
21	single	O
22	-	O
23	copy	O
24	transcriptional	O
25	fusion	O
26	vector	O
27	all	O
28	suggested	O
29	that	O
30	these	O
31	possible	O
32	promoters	O
33	were	O
34	largely	O
35	inactive	O
36	during	O
37	logarithmic	O
38	growth	O
39	,	O
40	that	O
41	the	O
42	major	O
43	promoter	O
44	for	O
45	the	O
46	alpha	O
47	operon	O
48	lay	O
49	upstream	O
50	from	O
51	the	O
52	region	O
53	cloned	O
54	,	O
55	and	O
56	that	O
57	the	O
58	genes	O
59	in	O
60	the	O
61	IF1	B
62	to	O
63	L17	B
64	interval	O
65	were	O
66	cotranscribed	O
67	.	O

1	Functional	O
2	rearranged	O
3	antibody	O
4	genes	O
5	were	O
6	detected	O
7	with	O
8	JH	B
9	and	O
10	VH	B
11	heavy	I
12	chain	I
13	probes	O
14	and	O
15	with	O
16	Jk	B
17	and	O
18	Vk	B
19	light	I
20	chain	I
21	probes	O
22	.	O

1	Two	O
2	specific	O
3	DNA	O
4	-	O
5	protein	O
6	complexes	O
7	were	O
8	identified	O
9	in	O
10	gel	O
11	retardation	O
12	assays	O
13	using	O
14	HeLa	O
15	cell	O
16	nuclear	O
17	extracts	O
18	and	O
19	an	O
20	oligonucleotide	O
21	probe	O
22	spanning	O
23	the	O
24	footprinted	O
25	region	O
26	.	O

1	After	O
2	transfection	O
3	,	O
4	specific	O
5	TSH	B
6	beta	I
7	promoter	I
8	activity	O
9	was	O
10	evident	O
11	in	O
12	both	O
13	TRH	B
14	-	O
15	responsive	O
16	pituitary	O
17	-	O
18	derived	O
19	GH3	O
20	and	O
21	primary	O
22	pituitary	O
23	cell	O
24	cultures	O
25	.	O

1	In	O
2	transformed	O
3	E	O
4	.	O
5	coli	O
6	,	O
7	constitutive	B
8	CAT	I
9	expression	O
10	is	O
11	maintained	O
12	when	O
13	as	O
14	little	O
15	as	O
16	0	O
17	.	O
18	3	O
19	kilobase	O
20	of	O
21	DNA	O
22	from	O
23	the	O
24	3	O
25	'	O
26	end	O
27	of	O
28	the	O
29	1	O
30	.	O
31	6	O
32	-	O
33	kilobase	O
34	segment	O
35	is	O
36	inserted	O
37	in	O
38	the	O
39	correct	O
40	orientation	O
41	in	O
42	front	O
43	of	O
44	the	O
45	CAT	B
46	gene	I
47	.	O

1	Lowering	O
2	of	O
3	the	O
4	renal	O
5	blood	O
6	flow	O
7	alters	O
8	the	O
9	glomerular	O
10	and	O
11	tubular	O
12	excretion	O
13	processes	O
14	.	O

1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	B
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	O
29	.	O

1	100	O
2	and	O
3	14	O
4	p	O
5	.	O

1	Isolation	O
2	of	O
3	Weeksella	O
4	virosa	O
5	(	O
6	formerly	O
7	CDC	O
8	group	O
9	IIf	O
10	)	O
11	from	O
12	a	O
13	vaginal	O
14	sample	O
15	.	O

1	Here	O
2	,	O
3	we	O
4	alter	O
5	the	O
6	dimerization	O
7	specificity	O
8	of	O
9	Fos	B
10	by	O
11	precisely	O
12	replacing	O
13	its	O
14	leucine	O
15	zipper	O
16	with	O
17	that	O
18	from	O
19	GCN4	B
20	.	O

1	Growth	O
2	of	O
3	tracheal	O
4	anastomoses	O
5	in	O
6	growing	O
7	animals	O

1	Fourth	O
2	,	O
3	sometime	O
4	between	O
5	4	O
6	and	O
7	24	O
8	hours	O
9	of	O
10	recovery	O
11	is	O
12	necessary	O
13	to	O
14	reverse	O
15	the	O
16	effect	O
17	of	O
18	chronic	O
19	hypoxia	O
20	on	O
21	cerebral	O
22	blood	O
23	flow	O
24	.	O

1	The	O
2	ORF1	O
3	product	O
4	was	O
5	required	O
6	for	O
7	competence	O
8	,	O
9	while	O
10	ORF2	O
11	,	O
12	which	O
13	was	O
14	cotranscribed	O
15	with	O
16	ORF1	O
17	and	O
18	encoded	O
19	a	O
20	predicted	O
21	protein	O
22	of	O
23	126	O
24	amino	O
25	acids	O
26	,	O
27	was	O
28	not	O
29	.	O

1	Kindling	O
2	of	O
3	the	O
4	primary	O
5	visual	O
6	cortex	O
7	(	O
8	VC	O
9	)	O
10	was	O
11	compared	O
12	with	O
13	that	O
14	of	O
15	the	O
16	amygdala	O
17	in	O
18	cats	O
19	.	O

1	Abundant	O
2	infiltration	O
3	of	O
4	lymphocytes	O
5	and	O
6	plasma	O
7	cells	O
8	was	O
9	also	O
10	wide	O
11	-	O
12	spread	O
13	beneath	O
14	the	O
15	carcinoma	O
16	in	O
17	situ	O
18	,	O
19	together	O
20	with	O
21	the	O
22	lymphoid	O
23	follicles	O
24	.	O

1	These	O
2	case	O
3	reports	O
4	provide	O
5	further	O
6	evidence	O
7	that	O
8	LiCO3	O
9	can	O
10	be	O
11	a	O
12	useful	O
13	medication	O
14	in	O
15	the	O
16	treatment	O
17	of	O
18	aggressive	O
19	behavior	O
20	and	O
21	affective	O
22	instability	O
23	after	O
24	brain	O
25	injury	O
26	,	O
27	but	O
28	that	O
29	it	O
30	has	O
31	significant	O
32	potential	O
33	for	O
34	neurotoxicity	O
35	in	O
36	this	O
37	population	O
38	,	O
39	particularly	O
40	when	O
41	used	O
42	in	O
43	conjunction	O
44	with	O
45	neuroleptic	O
46	agents	O
47	.	O

1	In	O
2	all	O
3	sessions	O
4	under	O
5	IFN	B
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	P100	O
12	component	O
13	of	O
14	the	O
15	VEP	O
16	was	O
17	shortened	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O

1	Among	O
2	100	O
3	cases	O
4	of	O
5	post	O
6	-	O
7	transfusion	O
8	hepatitis	O
9	,	O
10	10	O
11	are	O
12	due	O
13	to	O
14	the	O
15	hepatitis	O
16	B	O
17	virus	O
18	(	O
19	despite	O
20	systematic	O
21	search	O
22	for	O
23	HBs	B
24	Ag	I
25	),	O
26	89	O
27	are	O
28	due	O
29	to	O
30	one	O
31	of	O
32	the	O
33	non	O
34	-	O
35	A	O
36	non	O
37	-	O
38	B	O
39	viruses	O
40	(	O
41	not	O
42	detectable	O
43	by	O
44	specific	O
45	serological	O
46	tests	O
47	)	O
48	and	O
49	1	O
50	to	O
51	several	O
52	viruses	O
53	,	O
54	specially	O
55	CMV	O
56	.	O

1	Recessive	O
2	lethal	O
3	mutations	O
4	were	O
5	isolated	O
6	based	O
7	upon	O
8	failure	O
9	to	O
10	complement	O
11	the	O
12	recessive	O
13	lethality	O
14	of	O
15	Df	O
16	(	O
17	3L	O
18	)	O
19	RR2	O
20	,	O
21	a	O
22	deletion	O
23	of	O
24	the	O
25	DRE	O
26	region	O
27	that	O
28	removes	O
29	16	O
30	-	O
31	18	O
32	polytene	O
33	chromosome	O
34	bands	O
35	.	O

1	Current	O
2	status	O
3	and	O
4	future	O
5	perspectives	O

1	K	O
2	.	O

1	A	O
2	215	O
3	-	O
4	base	O
5	-	O
6	pair	O
7	(	O
8	bp	O
9	)	O
10	region	O
11	of	O
12	the	O
13	mouse	B
14	MOPC	I
15	41	I
16	kappa	I
17	light	I
18	-	I
19	chain	I
20	immunoglobulin	I
21	gene	I
22	enhancer	I
23	has	O
24	been	O
25	analyzed	O
26	for	O
27	specific	O
28	binding	O
29	of	O
30	lymphoid	O
31	and	O
32	nonlymphoid	O
33	nuclear	O
34	factors	O
35	.	O

1	This	O
2	paper	O
3	presents	O
4	the	O
5	reasons	O
6	why	O
7	countries	O
8	to	O
9	which	O
10	Chagas	O
11	disease	O
12	is	O
13	endemic	O
14	should	O
15	carry	O
16	out	O
17	the	O
18	relevant	O
19	research	O
20	themselves	O
21	.	O

1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O

1	Gastric	O
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O

1	Follow	O
2	-	O
3	up	O
4	study	O
5	showed	O
6	85	O
7	%	O
8	of	O
9	these	O
10	patients	O
11	with	O
12	effectiveness	O
13	.	O

1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O

1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O

1	Using	O
2	mutated	B
3	IL2R	I
4	alpha	I
5	promoter	I
6	constructs	I
7	in	O
8	transient	O
9	transfection	O
10	and	O
11	DNA	O
12	binding	O
13	assays	O
14	,	O
15	we	O
16	now	O
17	demonstrate	O
18	that	O
19	sequences	O
20	located	O
21	immediately	O
22	upstream	O
23	and	O
24	downstream	O
25	of	O
26	the	O
27	kappa	B
28	B	I
29	enhancer	I
30	also	O
31	contribute	O
32	to	O
33	the	O
34	regulation	O
35	of	O
36	IL2R	B
37	alpha	I
38	gene	I
39	expression	O
40	.	O

1	Palindromic	O
2	rheumatism	O

1	Inefficacy	O
2	of	O
3	phosphine	O
4	fumigation	O
5	against	O
6	ticks	O
7	.	O

1	Forty	O
2	patients	O
3	,	O
4	divided	O
5	according	O
6	to	O
7	their	O
8	initial	O
9	total	O
10	gastrointestinal	O
11	transit	O
12	times	O
13	and	O
14	presenting	O
15	symptoms	O
16	,	O
17	were	O
18	treated	O
19	with	O
20	cimetropium	O
21	bromide	O
22	50	O
23	mg	O
24	t	O
25	.	O
26	d	O
27	.	O
28	s	O
29	.	O
30	or	O
31	placebo	O
32	for	O
33	1	O
34	month	O
35	according	O
36	to	O
37	a	O
38	double	O
39	-	O
40	blind	O
41	,	O
42	parallel	O
43	group	O
44	design	O
45	.	O

1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	Mapping	O
2	of	O
3	RNA	O
4	-	O
5	temperature	B
6	-	I
7	sensitive	I
8	mutants	I
9	of	I
10	Sindbis	I
11	virus	I
12	:	I
13	complementation	I
14	group	I
15	F	I
16	mutants	I
17	have	O
18	lesions	O
19	in	O
20	nsP4	B
21	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	thromboxane	B
6	A2	I
7	(	I
8	TXA2	I
9	)/	I
10	prostaglandin	I
11	endoperoxide	I
12	receptor	I
13	antagonist	O
14	,	O
15	SQ	O
16	29	O
17	,	O
18	548	O
19	on	O
20	pacing	O
21	-	O
22	induced	O
23	ischemia	O
24	was	O
25	determined	O
26	in	O
27	anesthetized	O
28	open	O
29	-	O
30	chest	O
31	dogs	O
32	.	O

1	According	O
2	to	O
3	the	O
4	published	O
5	sequence	O
6	of	O
7	the	O
8	CHS1	B
9	gene	I
10	,	O
11	this	O
12	fragment	O
13	contains	O
14	four	O
15	repeats	O
16	of	O
17	a	O
18	TGAAACA	O
19	consensus	O
20	sequence	O
21	previously	O
22	identified	O
23	in	O
24	the	O
25	alpha	B
26	-	I
27	factor	I
28	-	O
29	inducible	O
30	BAR1	B
31	promoter	I
32	[	O
33	Kronstad	O
34	,	O
35	J	O
36	.	O

1	The	O
2	recovery	O
3	index	O
4	(	O
5	T25	O
6	-	O
7	T75	O
8	)	O
9	after	O
10	the	O
11	infusion	O
12	stopped	O
13	was	O
14	similar	O
15	in	O
16	patients	O
17	who	O
18	received	O
19	mivacurium	O
20	and	O
21	those	O
22	who	O
23	received	O
24	suxamethonium	O
25	.	O

1	The	O
2	sign	O
3	of	O
4	Leser	O
5	-	O
6	Trelat	O
7	:	O
8	does	O
9	it	O
10	exist	O
11	?	O
12	The	O
13	sign	O
14	of	O
15	Leser	O
16	-	O
17	Trelat	O
18	is	O
19	usually	O
20	regarded	O
21	as	O
22	a	O
23	reliable	O
24	cutaneous	O
25	marker	O
26	of	O
27	internal	O
28	malignancy	O
29	.	O

1	Xenopus	B
2	homolog	I
3	of	I
4	the	I
5	mos	I
6	protooncogene	I
7	transforms	O
8	mammalian	O
9	fibroblasts	O
10	and	O
11	induces	O
12	maturation	O
13	of	O
14	Xenopus	O
15	oocytes	O
16	.	O

1	Southern	O
2	blot	O
3	analyses	O
4	demonstrated	O
5	a	O
6	low	O
7	,	O
8	if	O
9	not	O
10	single	O
11	,	O
12	copy	O
13	number	O
14	for	O
15	this	O
16	gene	O
17	and	O
18	conservation	O
19	of	O
20	this	O
21	domain	O
22	in	O
23	other	O
24	vertebrates	O
25	.	O

1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	B
27	(	I
28	subunit	I
29	a	I
30	)	I
31	gene	I
32	.	O

1	Moreover	O
2	,	O
3	exons	O
4	2a	O
5	and	O
6	2b	O
7	share	O
8	the	O
9	same	O
10	5	O
11	'	O
12	sequence	O
13	but	O
14	differ	O
15	from	O
16	each	O
17	other	O
18	by	O
19	the	O
20	use	O
21	of	O
22	two	O
23	distinct	O
24	donor	O
25	splice	O
26	sites	O
27	171	O
28	bp	O
29	apart	O
30	in	O
31	the	O
32	gene	O
33	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	O
19	-	O
20	type	O
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	O
27	SP1	B
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	O
45	E1A	B
46	/	O
47	E1B	B
48	-	O
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	B
54	LTR	I
55	.	O

1	In	O
2	supine	O
3	position	O
4	,	O
5	plasma	O
6	ANP	B
7	levels	O
8	ranged	O
9	from	O
10	12	O
11	pg	O
12	/	O
13	ml	O
14	to	O
15	51	O
16	.	O
17	5	O
18	pg	O
19	/	O
20	ml	O
21	,	O
22	with	O
23	an	O
24	average	O
25	level	O
26	of	O
27	35	O
28	.	O
29	3	O
30	+/-	O
31	11	O
32	.	O
33	5	O
34	pg	O
35	/	O
36	ml	O
37	.	O

1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	HBV	O
6	markers	O
7	was	O
8	higher	O
9	among	O
10	staff	O
11	members	O
12	than	O
13	in	O
14	the	O
15	blood	O
16	donors	O
17	of	O
18	our	O
19	area	O
20	.	O

1	Quantitative	O
2	predictions	O
3	are	O
4	confirmed	O
5	for	O
6	the	O
7	positive	O
8	responses	O
9	,	O
10	but	O
11	not	O
12	for	O
13	the	O
14	negatives	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	SSTS	O
20	model	O
21	is	O
22	incorrect	O
23	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	B
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	B
12	early	I
13	genes	I
14	.	O

1	Administration	O
2	of	O
3	dexamethasone	O
4	was	O
5	associated	O
6	with	O
7	progressive	O
8	rises	O
9	in	O
10	plasma	O
11	17	O
12	alpha	O
13	OH	O
14	progesterone	O
15	,	O
16	11	O
17	beta	O
18	-	O
19	desoxycortisol	O
20	,	O
21	DHEA	O
22	sulphate	O
23	,	O
24	androstenedione	O
25	and	O
26	testosterone	O
27	,	O
28	together	O
29	with	O
30	increased	O
31	urinary	O
32	excretion	O
33	of	O
34	androsterone	O
35	,	O
36	11	O
37	beta	O
38	OH	O
39	androsterone	O
40	,	O
41	etiocholanolone	O
42	,	O
43	DHEA	O
44	,	O
45	and	O
46	16	O
47	alpha	O
48	OH	O
49	DHEA	O
50	.	O

1	RNA	O
2	transcripts	O
3	that	O
4	hybridize	O
5	to	O
6	the	O
7	introduced	O
8	foreign	O
9	gene	O
10	have	O
11	been	O
12	identified	O
13	.	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	it	O
6	activated	O
7	transcription	O
8	from	O
9	the	O
10	herpes	B
11	simplex	I
12	virus	I
13	type	I
14	1	I
15	thymidine	I
16	kinase	I
17	promoter	I
18	linked	O
19	to	O
20	the	O
21	chloramphenicol	B
22	acetyltransferase	I
23	gene	I
24	when	O
25	located	O
26	in	O
27	inverted	O
28	orientation	O
29	upstream	O
30	of	O
31	the	O
32	thymidine	B
33	kinase	I
34	promoter	I
35	or	O
36	downstream	O
37	of	O
38	the	O
39	chloramphenicol	B
40	acetyltransferase	I
41	gene	I
42	coding	I
43	sequence	I
44	.	O

1	At	O
2	the	O
3	basal	O
4	unstimulated	O
5	condition	O
6	,	O
7	Ren1d	B
8	5	I
9	'	I
10	flanking	I
11	sequence	I
12	in	O
13	the	O
14	sense	O
15	orientation	O
16	inhibited	O
17	basal	O
18	CAT	B
19	expression	O
20	from	O
21	the	O
22	TK	B
23	promoter	I
24	of	O
25	pUTKAT1	O
26	,	O
27	whereas	O
28	the	O
29	same	O
30	sequence	O
31	in	O
32	the	O
33	antisense	O
34	orientation	O
35	did	O
36	not	O
37	.	O

1	None	O
2	were	O
3	restricted	O
4	from	O
5	clinical	O
6	duties	O
7	,	O
8	were	O
9	given	O
10	varicella	B
11	-	I
12	zoster	I
13	immune	I
14	globulin	I
15	,	O
16	or	O
17	developed	O
18	disease	O
19	.	O

1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O

1	We	O
2	have	O
3	isolated	O
4	cDNA	O
5	clones	O
6	from	O
7	rat	O
8	brain	O
9	and	O
10	human	O
11	liver	O
12	encoding	O
13	a	O
14	putative	O
15	isoform	O
16	of	O
17	the	O
18	Na	B
19	,	I
20	K	I
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	several	O
6	E1	B
7	mutants	I
8	mapping	O
9	in	O
10	both	O
11	the	O
12	M	O
13	and	O
14	R	O
15	regions	O
16	and	O
17	a	O
18	single	O
19	mutant	O
20	of	O
21	the	O
22	upstream	O
23	regulatory	O
24	region	O
25	have	O
26	a	O
27	higher	O
28	transforming	O
29	activity	O
30	on	O
31	mouse	O
32	C127	O
33	cells	O
34	than	O
35	the	O
36	wild	O
37	-	O
38	type	O
39	genome	O
40	does	O
41	.	O

1	UbiA	B
2	is	O
3	also	O
4	unique	O
5	among	O
6	known	O
7	polyubiquitin	B
8	genes	I
9	in	O
10	containing	O
11	four	O
12	cis	O
13	-	O
14	spliced	O
15	introns	O
16	within	O
17	its	O
18	coding	O
19	sequence	O
20	.	O

1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	B
42	T1	I
43	gene	I
44	.	O

1	Radiation	O
2	therapy	O
3	was	O
4	effective	O
5	in	O
6	controlling	O
7	symptomatic	O
8	metastasis	O
9	in	O
10	all	O
11	three	O
12	patients	O
13	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	patients	O
6	who	O
7	undergo	O
8	postoperative	O
9	irradiation	O
10	for	O
11	low	O
12	grade	O
13	spinal	O
14	astrocytomas	O
15	and	O
16	localized	O
17	spinal	O
18	ependymomas	O
19	achieve	O
20	excellent	O
21	survival	O
22	.	O

1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	B
20	photosynthesis	I
21	genes	I
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	from	O
7	chemically	O
8	induced	O
9	B95	O
10	-	O
11	8	O
12	cells	O
13	and	O
14	from	O
15	Vero	O
16	cells	O
17	cotransfected	O
18	with	O
19	NotI	B
20	repeat	I
21	promoter	I
22	-	O
23	CAT	B
24	and	O
25	Z	B
26	showed	O
27	that	O
28	Z	B
29	transactivation	O
30	increased	O
31	the	O
32	level	O
33	of	O
34	correctly	O
35	initiated	O
36	,	O
37	stable	O
38	RNA	O
39	transcripts	O
40	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	a	O
6	)	O
7	the	O
8	likelihood	O
9	of	O
10	detecting	O
11	carcinoma	O
12	or	O
13	atypical	O
14	hyperplasia	O
15	exclusively	O
16	in	O
17	the	O
18	adipose	O
19	tissue	O
20	component	O
21	of	O
22	grossly	O
23	benign	O
24	breast	O
25	biopsies	O
26	is	O
27	extremely	O
28	low	O
29	,	O
30	and	O
31	(	O
32	b	O
33	)	O
34	a	O
35	possible	O
36	cost	O
37	-	O
38	effective	O
39	method	O
40	of	O
41	sampling	O
42	grossly	O
43	benign	O
44	breast	O
45	biopsies	O
46	consists	O
47	of	O
48	initially	O
49	submitting	O
50	a	O
51	maximum	O
52	of	O
53	10	O
54	blocks	O
55	of	O
56	fibrous	O
57	parenchyma	O
58	for	O
59	each	O
60	case	O
61	,	O
62	then	O
63	examining	O
64	the	O
65	remaining	O
66	tissue	O
67	histologically	O
68	only	O
69	if	O
70	carcinoma	O
71	or	O
72	atypical	O
73	hyperplasia	O
74	is	O
75	found	O
76	among	O
77	these	O
78	blocks	O
79	.	O

1	Analysis	O
2	of	O
3	the	O
4	DNA	O
5	from	O
6	15	O
7	cases	O
8	of	O
9	sporadic	O
10	and	O
11	familial	O
12	Wilms	O
13	'	O
14	tumor	O
15	did	O
16	not	O
17	reveal	O
18	any	O
19	changes	O
20	,	O
21	indicating	O
22	that	O
23	the	O
24	translocation	O
25	breakpoint	O
26	does	O
27	not	O
28	reside	O
29	in	O
30	this	O
31	gene	O
32	.	O

1	We	O
2	also	O
3	provide	O
4	evidence	O
5	that	O
6	neither	O
7	the	O
8	lambda	B
9	O	I
10	and	O
11	P	B
12	initiators	I
13	nor	O
14	the	O
15	E	B
16	.	I
17	coli	I
18	DnaJ	I
19	and	O
20	DnaK	B
21	heat	O
22	shock	O
23	proteins	O
24	play	O
25	a	O
26	direct	O
27	role	O
28	in	O
29	the	O
30	propagation	O
31	of	O
32	lambda	O
33	replication	O
34	forks	O
35	in	O
36	vitro	O
37	.	O

1	Synthetic	O
2	oligonucleotides	O
3	representing	O
4	the	O
5	19	O
6	bp	O
7	repeat	O
8	unit	O
9	strongly	O
10	reduced	O
11	the	O
12	activity	O
13	of	O
14	the	O
15	IE1	B
16	/	I
17	2	I
18	enhancer	I
19	/	I
20	promoter	I
21	in	O
22	cotransfection	O
23	assays	O
24	after	O
25	transient	O
26	expression	O
27	.	O

1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O

1	The	O
2	mustard	B
3	chloroplast	I
4	gene	I
5	rps16	I
6	is	O
7	split	O
8	by	O
9	an	O
10	887	O
11	bp	O
12	group	O
13	II	O
14	(	O
15	or	O
16	III	O
17	)	O
18	intron	O
19	.	O

1	Antibodies	O
2	raised	O
3	to	O
4	the	O
5	expressed	O
6	NS3	B
7	by	O
8	immunization	O
9	of	O
10	mice	O
11	detected	O
12	both	O
13	NS3	B
14	and	O
15	NS3A	B
16	in	O
17	BTV	O
18	-	O
19	10	O
20	-	O
21	infected	O
22	BHK	O
23	cells	O
24	but	O
25	not	O
26	in	O
27	purified	O
28	BTV	O
29	-	O
30	10	O
31	virus	O
32	particles	O
33	.	O

1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	The	O
2	negative	O
3	calcium	O
4	balance	O
5	with	O
6	hyperparathyroidemia	O
7	occurred	O
8	after	O
9	continuous	O
10	oral	O
11	administration	O
12	of	O
13	Cd	O
14	and	O
15	developed	O
16	via	O
17	increased	O
18	urinary	O
19	excretion	O
20	of	O
21	calcium	O
22	.	O

1	Clone	O
2	4c	O
3	(	O
4	2681	O
5	bp	O
6	)	O
7	had	O
8	a	O
9	coding	O
10	region	O
11	identical	O
12	to	O
13	that	O
14	of	O
15	clone	O
16	22c	O
17	but	O
18	it	O
19	included	O
20	a	O
21	putative	O
22	intron	O
23	of	O
24	959	O
25	bp	O
26	.	O

1	The	O
2	application	O
3	of	O
4	ISH	O
5	and	O
6	IHC	O
7	did	O
8	not	O
9	change	O
10	significantly	O
11	the	O
12	routine	O
13	histologic	O
14	classification	O
15	of	O
16	pneumonias	O
17	into	O
18	CMV	O
19	-	O
20	IP	O
21	and	O
22	IIP	O
23	.	O

1	Validity	O
2	of	O
3	immunohistology	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	in	O
9	the	O
10	differential	O
11	diagnosis	O
12	of	O
13	cytomegalovirus	O
14	pneumonia	O
15	and	O
16	idiopathic	O
17	interstitial	O
18	pneumonia	O
19	after	O
20	allogenic	O
21	bone	O
22	marrow	O
23	transplantation	O

1	The	O
2	unique	O
3	nature	O
4	and	O
5	arrangement	O
6	of	O
7	the	O
8	ANT1	B
9	transcriptional	I
10	control	I
11	elements	I
12	may	O
13	account	O
14	for	O
15	this	O
16	differential	O
17	expression	O
18	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	The	O
2	Bacillus	B
3	subtilis	I
4	phage	I
5	phi	I
6	105	I
7	repressor	I
8	,	O
9	a	O
10	lambda	B
11	repressor	I
12	-	O
13	like	O
14	transcriptional	O
15	regulatory	O
16	protein	O
17	,	O
18	was	O
19	overproduced	O
20	in	O
21	Escherichia	O
22	coli	O
23	and	O
24	purified	O
25	to	O
26	near	O
27	homogeneity	O
28	in	O
29	order	O
30	to	O
31	examine	O
32	its	O
33	in	O
34	vitro	O
35	DNA	O
36	-	O
37	binding	O
38	properties	O
39	.	O

1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	B
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	O
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	B
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O

1	Erythrocytic	O
2	stages	O
3	of	O
4	mammalian	O
5	malarial	O
6	parasites	O
7	contain	O
8	acristate	O
9	mitochondria	O
10	whose	O
11	functions	O
12	are	O
13	not	O
14	well	O
15	understood	O
16	.	O

1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O

1	Grossly	O
2	,	O
3	the	O
4	incidence	O
5	of	O
6	a	O
7	type	O
8	IIc	O
9	carcinoma	O
10	was	O
11	46	O
12	.	O
13	5	O
14	%	O
15	and	O
16	that	O
17	of	O
18	a	O
19	IIc	O
20	+	O
21	III	O
22	type	O
23	was	O
24	20	O
25	.	O
26	5	O
27	%,	O
28	respectively	O
29	.	O

1	Restriction	O
2	maps	O
3	of	O
4	the	O
5	cloned	O
6	plasmids	O
7	revealed	O
8	that	O
9	their	O
10	chromosomal	O
11	inserts	O
12	consisted	O
13	of	O
14	overlapping	O
15	fragments	O
16	.	O

1	VP5	B
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	B
7	capsid	I
8	protein	I
9	,	O
10	each	O
11	fused	O
12	to	O
13	the	O
14	chloramphenicol	B
15	acetyltransferase	I
16	gene	I
17	.	O

1	Of	O
2	202	O
3	initially	O
4	seronegative	O
5	caretakers	O
6	(	O
7	observed	O
8	for	O
9	an	O
10	average	O
11	of	O
12	305	O
13	days	O
14	per	O
15	woman	O
16	),	O
17	19	O
18	seroconverted	O
19	,	O
20	for	O
21	an	O
22	annual	O
23	seroconversion	O
24	rate	O
25	of	O
26	11	O
27	percent	O
28	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	similar	O
6	fragment	O
7	lacking	O
8	the	O
9	38	O
10	-	O
11	base	O
12	-	O
13	pair	O
14	region	O
15	had	O
16	no	O
17	such	O
18	stabilizing	O
19	effect	O
20	.	O

1	First	O
2	,	O
3	a	O
4	pet54	B
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	B
19	introns	I
20	aI5	I
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	B
7	-	O
8	related	O
9	sequences	O
10	and	O
11	a	O
12	small	B
13	Ig	I
14	-	I
15	related	I
16	sequence	I
17	.	O

1	Since	O
2	considerable	O
3	variations	O
4	in	O
5	length	O
6	and	O
7	primary	O
8	sequence	O
9	in	O
10	the	O
11	CDR3	B
12	(	O
13	complementarity	B
14	determining	I
15	region	I
16	)	O
17	peptides	O
18	of	O
19	all	O
20	the	O
21	H	B
22	-	I
23	chains	I
24	are	O
25	evident	O
26	,	O
27	conservation	O
28	of	O
29	the	O
30	D	B
31	-	I
32	region	I
33	structure	O
34	does	O
35	not	O
36	appear	O
37	to	O
38	be	O
39	necessary	O
40	for	O
41	effective	O
42	hapten	O
43	binding	O
44	.	O

1	Tyrosine	B
2	kinase	I
3	oncogenes	O
4	abrogate	O
5	interleukin	B
6	-	I
7	3	I
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	B
18	-	I
19	myc	I
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	B
25	-	I
26	myc	I
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	B
33	-	I
34	abl	I
35	.	O

1	This	O
2	TC	B
3	-	I
4	II	I
5	enhanson	I
6	,	O
7	which	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	kappa	B
13	B	I
14	motif	I
15	from	O
16	the	O
17	kappa	B
18	chain	I
19	enhancer	I
20	,	O
21	was	O
22	active	O
23	in	O
24	both	O
25	lymphoid	O
26	and	O
27	non	O
28	-	O
29	lymphoid	O
30	cells	O
31	,	O
32	which	O
33	contrasts	O
34	with	O
35	the	O
36	previously	O
37	reported	O
38	lymphoid	O
39	cell	O
40	specificity	O
41	of	O
42	the	O
43	kappa	B
44	B	I
45	motif	I
46	.	O

1	The	O
2	DNA	O
3	helix	O
4	at	O
5	the	O
6	tandemly	O
7	repeated	O
8	,	O
9	13mer	O
10	sequence	O
11	is	O
12	thermodynamically	O
13	unstable	O
14	,	O
15	as	O
16	evidenced	O
17	by	O
18	hypersensitivity	O
19	to	O
20	single	B
21	-	I
22	strand	I
23	-	I
24	specific	I
25	nuclease	I
26	in	O
27	a	O
28	negatively	O
29	supercoiled	O
30	plasmid	O
31	,	O
32	and	O
33	demonstrated	O
34	by	O
35	stable	O
36	DNA	O
37	unwinding	O
38	seen	O
39	after	O
40	two	O
41	-	O
42	dimensional	O
43	gel	O
44	electrophoresis	O
45	of	O
46	topoisomers	O
47	.	O

1	There	O
2	has	O
3	been	O
4	similar	O
5	improvement	O
6	in	O
7	treating	O
8	ampullary	O
9	and	O
10	periampullary	O
11	cancer	O
12	,	O
13	gallbladder	O
14	cancer	O
15	,	O
16	or	O
17	extrahepatic	O
18	bile	O
19	duct	O
20	cancer	O
21	.	O

1	Beta	B
2	-	I
3	endorphin	I
4	,	O
5	ACTH	B
6	and	O
7	cortisol	O
8	secretion	O
9	were	O
10	measured	O
11	in	O
12	twelve	O
13	healthy	O
14	adult	O
15	males	O
16	after	O
17	nasal	O
18	spray	O
19	administration	O
20	200	O
21	IU	O
22	salmon	B
23	calcitonin	I
24	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	O
17	cortisol	O
18	release	O
19	.	O

1	The	O
2	DNA	O
3	sequences	O
4	predict	O
5	proteins	O
6	for	O
7	SRP54sc	B
8	and	O
9	SRP54sp	B
10	that	O
11	are	O
12	47	O
13	%	O
14	and	O
15	52	O
16	%	O
17	identical	O
18	to	O
19	SRP54mam	B
20	,	O
21	respectively	O
22	.	O

1	Other	O
2	hemostatic	O
3	values	O
4	evaluated	O
5	were	O
6	activated	O
7	partial	O
8	thromboplastin	B
9	times	O
10	,	O
11	prothrombin	B
12	times	O
13	,	O
14	thrombin	B
15	times	O
16	,	O
17	fibrinogen	B
18	,	O
19	platelet	O
20	counts	O
21	,	O
22	and	O
23	fibrin	B
24	/	O
25	fibrinogen	B
26	degradation	O
27	products	O
28	.	O

1	Rare	O
2	neurogenic	O
3	tumor	O
4	with	O
5	metastasis	O
6	to	O
7	mouth	O
8	,	O
9	jaw	O
10	and	O
11	face	O
12	regions	O

1	We	O
2	have	O
3	designated	O
4	the	O
5	protein	O
6	"	B
7	cellular	I
8	NBP	I
9	"	I
10	(	O
11	CNBP	B
12	).	O

1	Responsiveness	O
2	to	O
3	beta	O
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O

1	Drug	O
2	use	O
3	in	O
4	trauma	O
5	victims	O
6	.	O

1	A	O
2	critical	O
3	heart	O
4	rate	O
5	and	O
6	/	O
7	or	O
8	appropriate	O
9	sympathetic	O
10	state	O
11	was	O
12	found	O
13	to	O
14	provoke	O
15	all	O
16	instances	O
17	of	O
18	reentrant	O
19	or	O
20	automatic	O
21	atrial	O
22	tachycardia	O
23	and	O
24	atypical	O
25	junctional	O
26	tachycardia	O
27	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	neu	B
6	proto	I
7	-	I
8	oncogene	I
9	did	O
10	not	O
11	show	O
12	kinase	O
13	activity	O
14	or	O
15	transforming	O
16	properties	O
17	when	O
18	expressed	O
19	at	O
20	similar	O
21	levels	O
22	in	O
23	NIH	O
24	3T3	O
25	cells	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	The	O
2	65	O
3	-	O
4	bp	O
5	sequence	O
6	contains	O
7	the	O
8	octameric	O
9	cAMP	O
10	-	O
11	responsive	O
12	enhancer	O
13	(	O
14	CRE	O
15	)	O
16	TGACGTCA	O
17	(	O
18	nucleotides	O
19	-	O
20	48	O
21	to	O
22	-	O
23	41	O
24	).	O

1	Somatostatin	B
2	gene	I
3	expression	O
4	in	O
5	pancreatic	O
6	islet	O
7	cells	O
8	is	O
9	directed	O
10	by	O
11	cell	O
12	-	O
13	specific	O
14	DNA	O
15	control	O
16	elements	O
17	and	O
18	DNA	O
19	-	O
20	binding	O
21	proteins	O
22	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	full	O
6	mu	O
7	-	O
8	opioid	O
9	agonists	O
10	fentanyl	O
11	,	O
12	morphine	O
13	,	O
14	I	O
15	-	O
16	methadone	O
17	and	O
18	levorphanol	O
19	produced	O
20	50	O
21	%	O
22	fentanyl	O
23	-	O
24	appropriate	O
25	responding	O
26	at	O
27	doses	O
28	only	O
29	1	O
30	.	O
31	3	O
32	to	O
33	10	O
34	.	O
35	9	O
36	times	O
37	smaller	O
38	than	O
39	those	O
40	required	O
41	to	O
42	decrease	O
43	response	O
44	rates	O
45	by	O
46	50	O
47	%.	O

1	After	O
2	overtraining	O
3	on	O
4	the	O
5	original	O
6	discrimination	O
7	,	O
8	the	O
9	controls	O
10	showed	O
11	the	O
12	normal	O
13	difficulty	O
14	in	O
15	learning	O
16	the	O
17	first	O
18	reversal	O
19	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	putative	O
10	cytokine	O
11	which	O
12	is	O
13	induced	O
14	by	O
15	stimulation	O
16	via	O
17	the	O
18	CD2	B
19	structure	I
20	on	O
21	human	O
22	T	O
23	lymphocytes	O
24	.	O

1	After	O
2	termination	O
3	of	O
4	medication	O
5	the	O
6	animals	O
7	were	O
8	kindled	O
9	electrically	O
10	in	O
11	the	O
12	nucleus	O
13	amygdala	O
14	.	O

1	Haploid	O
2	cells	O
3	of	O
4	mating	O
5	type	O
6	A	O
7	of	O
8	the	O
9	basidiomycetous	O
10	yeast	O
11	Rhodosporidium	O
12	toruloides	O
13	secrete	O
14	a	O
15	mating	O
16	pheromone	O
17	,	O
18	rhodotorucine	B
19	A	I
20	,	O
21	which	O
22	is	O
23	an	O
24	undecapeptide	O
25	containing	O
26	S	O
27	-	O
28	farnesyl	O
29	cysteine	O
30	at	O
31	its	O
32	carboxy	O
33	terminus	O
34	.	O

1	Tumour	B
2	necrosis	I
3	factor	I
4	and	O
5	adult	O
6	respiratory	O
7	distress	O
8	syndrome	O
9	.	O

1	Monitoring	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	.	O

1	The	O
2	decrease	O
3	in	O
4	left	O
5	ventricular	O
6	(	O
7	LV	O
8	)	O
9	stroke	O
10	volume	O
11	during	O
12	positive	O
13	end	O
14	-	O
15	expiratory	O
16	pressure	O
17	(	O
18	PEEP	O
19	)	O
20	has	O
21	been	O
22	attributed	O
23	to	O
24	reduced	O
25	LV	O
26	filling	O
27	and	O
28	a	O
29	decreased	O
30	contractile	O
31	state	O
32	.	O

1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O

1	Evolutionary	O
2	conservation	O
3	of	O
4	homeodomain	B
5	-	O
6	binding	O
7	sites	O
8	and	O
9	other	O
10	sequences	O
11	upstream	O
12	and	O
13	within	O
14	the	O
15	major	O
16	transcription	O
17	unit	O
18	of	O
19	the	O
20	Drosophila	B
21	segmentation	I
22	gene	I
23	engrailed	I
24	.	O

1	To	O
2	assess	O
3	the	O
4	functional	O
5	importance	O
6	of	O
7	these	O
8	NBS	O
9	in	O
10	the	O
11	overall	O
12	drug	O
13	resistance	O
14	phenotype	O
15	conferred	O
16	by	O
17	mdr1	B
18	,	O
19	we	O
20	introduced	O
21	amino	O
22	acid	O
23	substitutions	O
24	in	O
25	the	O
26	core	O
27	consensus	O
28	sequence	O
29	for	O
30	nucleotide	O
31	binding	O
32	,	O
33	GXGKST	O
34	.	O

1	When	O
2	the	O
3	first	O
4	twitch	O
5	of	O
6	TOF	O
7	spontaneously	O
8	recovered	O
9	to	O
10	10	O
11	%	O
12	of	O
13	control	O
14	value	O
15	,	O
16	neostigmine	O
17	was	O
18	injected	O
19	(	O
20	40	O
21	micrograms	O
22	/	O
23	kg	O
24	in	O
25	adults	O
26	,	O
27	30	O
28	micrograms	O
29	/	O
30	kg	O
31	in	O
32	infants	O
33	and	O
34	children	O
35	).	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	in	O
7	relation	O
8	to	O
9	Type	O
10	A	O
11	behaviour	O
12	and	O
13	beta	B
14	-	I
15	adrenoceptor	I
16	blockade	O
17	.	O

1	Selection	O
2	of	O
3	the	O
4	22	O
5	items	O
6	of	O
7	the	O
8	Clinical	O
9	Institute	O
10	Withdrawal	O
11	Assessment	O
12	-	O
13	Benzodiazepines	O
14	(	O
15	CIWA	O
16	-	O
17	B	O
18	)	O
19	was	O
20	based	O
21	on	O
22	statistically	O
23	significant	O
24	differences	O
25	between	O
26	baseline	O
27	and	O
28	critical	O
29	withdrawal	O
30	periods	O
31	in	O
32	high	O
33	-	O
34	dose	O
35	subjects	O
36	and	O
37	between	O
38	symptoms	O
39	associated	O
40	with	O
41	placebo	O
42	and	O
43	diazepam	O
44	in	O
45	low	O
46	-	O
47	dose	O
48	subjects	O
49	,	O
50	using	O
51	contingency	O
52	tables	O
53	and	O
54	logistic	O
55	regression	O
56	analysis	O
57	.	O

1	Antihistamines	O
2	in	O
3	asthma	O
4	.	O

1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	doxazosin	O
11	,	O
12	a	O
13	new	O
14	orally	O
15	active	O
16	selective	O
17	alpha	B
18	1	I
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	airflow	O
29	limitation	O
30	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	multiple	O
6	oIGF	B
7	-	I
8	I	I
9	transcripts	I
10	in	O
11	a	O
12	broad	O
13	band	O
14	at	O
15	800	O
16	-	O
17	1	O
18	,	O
19	100	O
20	nucleotides	O
21	and	O
22	other	O
23	transcripts	O
24	of	O
25	higher	O
26	molecular	O
27	weight	O
28	in	O
29	liver	O
30	.	O

1	Materials	O
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	The	O
2	latency	O
3	time	O
4	for	O
5	the	O
6	lactate	O
7	concentration	O
8	to	O
9	reach	O
10	the	O
11	top	O
12	values	O
13	was	O
14	reduced	O
15	by	O
16	aerobic	O
17	training	O
18	(	O
19	T2	O
20	).	O

1	In	O
2	patients	O
3	resistant	O
4	to	O
5	VAD	O
6	,	O
7	high	O
8	-	O
9	dose	O
10	therapies	O
11	with	O
12	intravenous	O
13	melphalan	O
14	,	O
15	a	O
16	CBV	O
17	combination	O
18	(	O
19	cyclophosphamide	O
20	-	O
21	BCNU	O
22	-	O
23	VP	O
24	-	O
25	16	O
26	)	O
27	or	O
28	an	O
29	EDAP	O
30	regimen	O
31	(	O
32	VP	O
33	-	O
34	16	O
35	-	O
36	platinum	O
37	)	O
38	produced	O
39	responses	O
40	in	O
41	about	O
42	40	O
43	%	O
44	of	O
45	patients	O
46	.	O

1	The	O
2	discussion	O
3	focuses	O
4	primarily	O
5	on	O
6	the	O
7	newer	O
8	drugs	O
9	like	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	,	O
15	alpha	B
16	-	I
17	adrenergic	I
18	receptor	I
19	blockers	O
20	,	O
21	and	O
22	calcium	O
23	antagonists	O
24	.	O

1	The	O
2	avian	O
3	cellular	O
4	homolog	O
5	of	O
6	the	O
7	oncogene	B
8	jun	I
9	.	O

1	A	O
2	736	O
3	-	O
4	bp	O
5	sequence	O
6	of	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	adjacent	O
13	to	O
14	the	O
15	cap	O
16	site	O
17	of	O
18	the	O
19	human	B
20	AFP	I
21	gene	I
22	shows	O
23	a	O
24	61	O
25	%	O
26	similarity	O
27	with	O
28	the	O
29	corresponding	O
30	region	O
31	of	O
32	the	O
33	mouse	B
34	AFP	I
35	gene	I
36	.	O

1	High	O
2	ATP	O
3	/	O
4	GTP	O
5	ratios	O
6	promoted	O
7	initiation	O
8	of	O
9	RNA	O
10	primer	O
11	synthesis	O
12	at	O
13	3	O
14	'-	O
15	dCTTT	O
16	sites	O
17	,	O
18	whereas	O
19	low	O
20	ATP	O
21	/	O
22	GTP	O
23	ratios	O
24	promoted	O
25	initiation	O
26	at	O
27	3	O
28	'-	O
29	dCCC	O
30	sites	O
31	.	O

1	After	O
2	hepatitis	O
3	B	O
4	vaccine	O
5	immunization	O
6	,	O
7	serum	O
8	antibody	O
9	response	O
10	was	O
11	of	O
12	primary	O
13	type	O
14	in	O
15	33	O
16	cases	O
17	with	O
18	anti	B
19	-	I
20	HBs	I
21	less	O
22	than	O
23	2	O
24	.	O
25	1	O
26	S	O
27	/	O
28	N	O
29	(	O
30	S	O
31	/	O
32	N	O
33	Ratio	O
34	Unit	O
35	)	O
36	at	O
37	T0	O
38	,	O
39	the	O
40	anti	B
41	-	I
42	HBs	I
43	positive	O
44	rate	O
45	was	O
46	39	O
47	.	O
48	4	O
49	%,	O
50	84	O
51	.	O
52	8	O
53	%,	O
54	96	O
55	.	O
56	7	O
57	%	O
58	and	O
59	96	O
60	.	O
61	7	O
62	%	O
63	in	O
64	T1	O
65	,	O
66	T2	O
67	,	O
68	T0	O
69	and	O
70	T12	O
71	respectively	O
72	.	O

1	The	O
2	experimental	O
3	design	O
4	incorporated	O
5	a	O
6	multiple	O
7	regression	O
8	model	O
9	,	O
10	sequential	O
11	treatments	O
12	and	O
13	a	O
14	proportional	O
15	end	O
16	point	O
17	(	O
18	95	O
19	%)	O
20	for	O
21	protection	O
22	time	O
23	.	O

1	Interspecific	O
2	complementation	O
3	tests	O
4	showed	O
5	that	O
6	the	O
7	P7	B
8	proteins	I
9	are	O
10	unable	O
11	to	O
12	complement	O
13	P1	B
14	parA	I
15	or	O
16	parB	B
17	mutants	I
18	,	O
19	and	O
20	the	O
21	P1	B
22	proteins	I
23	fail	O
24	to	O
25	complement	O
26	the	O
27	P7	B
28	mutations	I
29	.	O

1	GN101	O
2	,	O
3	YC819	O
4	-	O
5	9	O
6	,	O
7	and	O
8	SB3	O
9	.	O

1	Analysis	O
2	of	O
3	the	O
4	inferred	O
5	1	B
6	,	I
7	859	I
8	-	I
9	residue	I
10	ama	I
11	-	I
12	1	I
13	product	I
14	showed	O
15	considerable	O
16	identity	O
17	with	O
18	the	O
19	largest	O
20	subunit	O
21	of	O
22	RNAP	B
23	II	I
24	from	O
25	other	O
26	organisms	O
27	,	O
28	including	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	zinc	O
34	finger	O
35	motif	O
36	near	O
37	the	O
38	amino	O
39	terminus	O
40	,	O
41	and	O
42	a	O
43	carboxyl	O
44	-	O
45	terminal	O
46	domain	O
47	of	O
48	42	O
49	tandemly	O
50	reiterated	O
51	heptamers	O
52	with	O
53	the	O
54	consensus	O
55	Tyr	O
56	Ser	O
57	Pro	O
58	Thr	O
59	Ser	O
60	Pro	O
61	Ser	O
62	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	I
28	Type	I
29	Kappa	I
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	5	O
2	.	O

1	None	O
2	of	O
3	the	O
4	measured	O
5	parameters	O
6	(	O
7	heart	O
8	contents	O
9	of	O
10	neutral	O
11	lipids	O
12	,	O
13	total	O
14	phospholipids	O
15	,	O
16	phosphatidylcholine	O
17	,	O
18	phosphatidylethanolamine	O
19	,	O
20	diphosphatidylglycerol	O
21	,	O
22	sphingomyelin	O
23	and	O
24	fatty	O
25	acid	O
26	composition	O
27	of	O
28	each	O
29	phospholipid	O
30	class	O
31	)	O
32	appeared	O
33	to	O
34	be	O
35	related	O
36	with	O
37	the	O
38	grading	O
39	of	O
40	the	O
41	lesions	O
42	.	O

1	Of	O
2	165	O
3	women	O
4	with	O
5	non	O
6	-	O
7	malignant	O
8	diagnoses	O
9	26	O
10	(	O
11	16	O
12	%)	O
13	had	O
14	CA	B
15	125	I
16	levels	O
17	in	O
18	excess	O
19	of	O
20	35	O
21	U	O
22	/	O
23	ml	O
24	and	O
25	8	O
26	(	O
27	5	O
28	%)	O
29	greater	O
30	than	O
31	65	O
32	U	O
33	/	O
34	ml	O
35	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	steady	O
6	state	O
7	the	O
8	timing	O
9	of	O
10	a	O
11	light	O
12	meal	O
13	is	O
14	unlikely	O
15	to	O
16	alter	O
17	in	O
18	any	O
19	clinically	O
20	important	O
21	manner	O
22	the	O
23	pharmacokinetics	O
24	of	O
25	nifedipine	O
26	released	O
27	from	O
28	'	O
29	biphasic	O
30	'	O
31	tablets	O
32	.	O

1	The	O
2	GALT	O
3	-	O
4	primed	O
5	calves	O
6	had	O
7	increased	O
8	serum	O
9	IgG	B
10	,	O
11	lavage	O
12	IgG	B
13	and	O
14	IgA	B
15	and	O
16	increased	O
17	LNA	B
18	titers	O
19	in	O
20	both	O
21	lavage	O
22	fluids	O
23	and	O
24	serum	O
25	following	O
26	the	O
27	SC	O
28	dose	O
29	of	O
30	killed	O
31	bacteria	O
32	.	O

1	Recent	O
2	investigations	O
3	have	O
4	shown	O
5	that	O
6	Grenz	O
7	rays	O
8	can	O
9	suppress	O
10	the	O
11	allergic	O
12	contact	O
13	dermatitis	O
14	reaction	O
15	completely	O
16	and	O
17	that	O
18	Langerhans	O
19	cells	O
20	,	O
21	identified	O
22	by	O
23	OKT6	B
24	antibodies	I
25	and	O
26	electron	O
27	microscopy	O
28	,	O
29	disappear	O
30	from	O
31	the	O
32	epidermis	O
33	at	O
34	the	O
35	same	O
36	time	O
37	.	O

1	The	O
2	elements	O
3	responsible	O
4	for	O
5	glucocorticoid	O
6	stimulation	O
7	of	O
8	ADH	B
9	gene	I
10	transcription	O
11	appear	O
12	to	O
13	reside	O
14	outside	O
15	of	O
16	this	O
17	region	O
18	.	O

1	1	O
2	.	O

1	The	O
2	present	O
3	studies	O
4	compare	O
5	the	O
6	biochemical	O
7	characteristics	O
8	,	O
9	Kanagawa	O
10	hemolysin	B
11	reactions	O
12	,	O
13	and	O
14	plasmid	O
15	profiles	O
16	of	O
17	13	O
18	patient	O
19	and	O
20	221	O
21	environmental	O
22	isolates	O
23	of	O
24	the	O
25	organism	O
26	.	O

1	High	O
2	values	O
3	of	O
4	both	O
5	retinol	O
6	and	O
7	beta	O
8	-	O
9	carotene	O
10	were	O
11	found	O
12	in	O
13	full	O
14	fat	O
15	cheeses	O
16	and	O
17	whipping	O
18	cream	O
19	:	O
20	from	O
21	179	O
22	.	O
23	0	O
24	(	O
25	cheese	O
26	,	O
27	Edam	O
28	-	O
29	type	O
30	)	O
31	to	O
32	318	O
33	.	O
34	7	O
35	micrograms	O
36	/	O
37	100	O
38	g	O
39	(	O
40	whipping	O
41	cream	O
42	)	O
43	and	O
44	from	O
45	86	O
46	.	O
47	7	O
48	(	O
49	cheese	O
50	,	O
51	Edam	O
52	-	O
53	type	O
54	)	O
55	to	O
56	186	O
57	.	O
58	5	O
59	micrograms	O
60	/	O
61	100	O
62	g	O
63	(	O
64	whipping	O
65	cream	O
66	)	O
67	for	O
68	all	O
69	-	O
70	trans	O
71	retinol	O
72	and	O
73	total	O
74	beta	O
75	-	O
76	carotene	O
77	,	O
78	respectively	O
79	.	O

1	COGLAB	O
2	includes	O
3	measures	O
4	of	O
5	preattentional	O
6	,	O
7	attentional	O
8	,	O
9	conceptual	O
10	,	O
11	and	O
12	psychomotor	O
13	performance	O
14	.	O

1	These	O
2	data	O
3	locate	O
4	the	O
5	aniridia	B
6	gene	I
7	(	O
8	AN2	B
9	)	O
10	and	O
11	a	O
12	recurrent	O
13	T	B
14	-	I
15	cell	I
16	leukemia	I
17	breakpoint	I
18	(	O
19	TCL2	B
20	)	O
21	in	O
22	the	O
23	marker	O
24	sequence	O
25	,	O
26	on	O
27	opposite	O
28	sides	O
29	of	O
30	MIC1	B
31	.	O

1	A	O
2	fine	O
3	-	O
4	structure	O
5	deletion	O
6	map	O
7	of	O
8	human	O
9	chromosome	O
10	11p	O
11	:	O
12	analysis	O
13	of	O
14	J1	O
15	series	O
16	hybrids	O
17	.	O

1	With	O
2	respect	O
3	to	O
4	effective	O
5	diffusivity	O
6	of	O
7	platelets	O
8	(	O
9	De	O
10	)	O
11	and	O
12	the	O
13	surface	O
14	reactivity	O
15	constant	O
16	(	O
17	K	O
18	),	O
19	less	O
20	significant	O
21	differences	O
22	were	O
23	found	O
24	among	O
25	artificial	O
26	materials	O
27	.	O

1	The	O
2	two	O
3	most	O
4	recent	O
5	patients	O
6	(	O
7	35	O
8	and	O
9	132	O
10	days	O
11	)	O
12	received	O
13	only	O
14	oral	O
15	dipyridamole	O
16	(	O
17	75	O
18	mg	O
19	X	O
20	3	O
21	/	O
22	day	O
23	)	O
24	and	O
25	aspirin	O
26	(	O
27	80	O
28	mg	O
29	/	O
30	day	O
31	)	O
32	after	O
33	the	O
34	early	O
35	recovery	O
36	period	O
37	(	O
38	four	O
39	-	O
40	six	O
41	days	O
42	),	O
43	resulting	O
44	in	O
45	normal	O
46	prothrombin	B
47	and	O
48	partial	O
49	thromboplastin	B
50	times	O
51	.	O

1	Middle	O
2	-	O
3	latency	O
4	auditory	O
5	evoked	O
6	potentials	O
7	(	O
8	MAEPs	O
9	)	O
10	were	O
11	recorded	O
12	in	O
13	controls	O
14	and	O
15	patients	O
16	with	O
17	focal	O
18	lesions	O
19	in	O
20	dorsolateral	O
21	prefrontal	O
22	cortex	O
23	.	O

1	Most	O
2	of	O
3	them	O
4	were	O
5	situated	O
6	at	O
7	Sylvius	O
8	fissure	O
9	(	O
10	13	O
11	cases	O
12	).	O

1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O

1	Specifically	O
2	,	O
3	they	O
4	were	O
5	performed	O
6	to	O
7	determine	O
8	whether	O
9	detection	O
10	of	O
11	envelope	O
12	phase	O
13	disparity	O
14	was	O
15	consistent	O
16	with	O
17	processing	O
18	within	O
19	a	O
20	single	O
21	channel	O
22	in	O
23	which	O
24	the	O
25	AM	O
26	tones	O
27	were	O
28	simply	O
29	added	O
30	.	O

1	Gel	O
2	retardation	O
3	assays	O
4	combined	O
5	with	O
6	DNase	B
7	I	I
8	footprinting	O
9	and	O
10	diethyl	O
11	pyrocarbonate	O
12	interference	O
13	showed	O
14	that	O
15	a	O
16	nuclear	O
17	factor	O
18	from	O
19	differentiated	O
20	C2	O
21	myotubes	O
22	and	O
23	BC3H1	O
24	myocytes	O
25	recognized	O
26	a	O
27	conserved	O
28	A	O
29	+	O
30	T	O
31	-	O
32	rich	O
33	sequence	O
34	within	O
35	the	O
36	peripheral	O
37	activating	O
38	region	O
39	.	O

1	Such	O
2	transgenic	O
3	plants	O
4	should	O
5	enable	O
6	not	O
7	only	O
8	the	O
9	mutational	O
10	analysis	O
11	of	O
12	sequence	O
13	elements	O
14	within	O
15	the	O
16	replication	O
17	origin	O
18	region	O
19	,	O
20	but	O
21	also	O
22	the	O
23	construction	O
24	of	O
25	a	O
26	new	O
27	generation	O
28	of	O
29	vectors	O
30	for	O
31	gene	O
32	amplification	O
33	in	O
34	plants	O
35	,	O
36	based	O
37	on	O
38	a	O
39	minimal	O
40	virus	O
41	replicon	O
42	.	O

1	Ventral	O
2	rhinotomy	O
3	is	O
4	no	O
5	more	O
6	difficult	O
7	than	O
8	dorsal	O
9	rhinotomy	O
10	,	O
11	has	O
12	less	O
13	patient	O
14	morbidity	O
15	and	O
16	fewer	O
17	postoperative	O
18	complications	O
19	,	O
20	and	O
21	is	O
22	more	O
23	cosmetically	O
24	acceptable	O
25	.	O

1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	incisions	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	O
28	epidermal	B
29	growth	I
30	factor	I
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	Ringer	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O

1	During	O
2	challenge	O
3	,	O
4	rebiopsy	O
5	was	O
6	done	O
7	when	O
8	reticulin	B
9	antibodies	I
10	turned	O
11	positive	O
12	(	O
13	mean	O
14	0	O
15	.	O
16	6	O
17	years	O
18	,	O
19	range	O
20	0	O
21	.	O
22	2	O
23	-	O
24	2	O
25	.	O
26	0	O
27	)	O
28	or	O
29	at	O
30	the	O
31	end	O
32	of	O
33	the	O
34	two	O
35	year	O
36	study	O
37	.	O

1	The	O
2	effect	O
3	of	O
4	iron	O
5	intake	O
6	on	O
7	59Fe	O
8	absorption	O
9	throughout	O
10	pregnancy	O
11	,	O
12	and	O
13	on	O
14	maternal	O
15	and	O
16	fetal	O
17	Fe	O
18	status	O
19	towards	O
20	the	O
21	end	O
22	of	O
23	pregnancy	O
24	,	O
25	was	O
26	investigated	O
27	in	O
28	rats	O
29	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	is	O
6	characterized	O
7	by	O
8	a	O
9	putative	O
10	16	O
11	-	O
12	residue	O
13	amino	O
14	-	O
15	terminal	O
16	signal	O
17	peptide	O
18	that	O
19	is	O
20	cleaved	O
21	,	O
22	resulting	O
23	in	O
24	a	O
25	239	O
26	-	O
27	residue	O
28	polypeptide	O
29	.	O

1	Analysis	O
2	of	O
3	the	O
4	rate	O
5	constants	O
6	indicated	O
7	that	O
8	the	O
9	isomerization	O
10	rate	O
11	k12	O
12	was	O
13	approximately	O
14	equal	O
15	to	O
16	the	O
17	apparent	O
18	degradation	O
19	rate	O
20	of	O
21	the	O
22	delta	O
23	3	O
24	ester	O
25	kdeg	O
26	,	O
27	and	O
28	slower	O
29	than	O
30	the	O
31	hydrolysis	O
32	rate	O
33	of	O
34	the	O
35	delta	O
36	2	O
37	ester	O
38	k24	O
39	.	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	Reagent	O
2	strips	O
3	are	O
4	frequently	O
5	used	O
6	in	O
7	the	O
8	practice	O
9	of	O
10	laboratory	O
11	medicine	O
12	as	O
13	well	O
14	as	O
15	outside	O
16	the	O
17	professional	O
18	laboratories	O
19	.	O

1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O

1	Precipitating	O
2	antibodies	O
3	for	O
4	Thermophilic	O
5	actinomycetes	O
6	and	O
7	M	O
8	.	O
9	f	O
10	.	O
11	were	O
12	negative	O
13	.	O

1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	O
9	-	O
10	73	O
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	O
22	-	O
23	10	O
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O

1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O

1	Significance	O
2	of	O
3	delta	O
4	-	O
5	aminolevulinic	O
6	acid	O
7	analysis	O
8	in	O
9	clinical	O
10	tests	O

1	No	O
2	changes	O
3	were	O
4	evident	O
5	in	O
6	the	O
7	FR	O
8	-	O
9	task	O
10	performance	O
11	of	O
12	controls	O
13	that	O
14	received	O
15	daily	O
16	saline	O
17	injections	O
18	.	O

1	The	O
2	antigen	B
3	-	I
4	specific	I
5	IgG4	I
6	antibody	I
7	seems	O
8	to	O
9	be	O
10	an	O
11	index	O
12	in	O
13	evaluating	O
14	immunotherapy	O
15	objectively	O
16	.	O

1	Although	O
2	the	O
3	fertility	O
4	decline	O
5	in	O
6	the	O
7	black	O
8	population	O
9	in	O
10	the	O
11	Mississippi	O
12	Delta	O
13	between	O
14	the	O
15	late	O
16	1870	O
17	'	O
18	s	O
19	and	O
20	early	O
21	1930	O
22	'	O
23	s	O
24	closely	O
25	paralleled	O
26	that	O
27	of	O
28	the	O
29	national	O
30	black	O
31	population	O
32	,	O
33	it	O
34	rose	O
35	much	O
36	more	O
37	dramatically	O
38	in	O
39	the	O
40	1940	O
41	'	O
42	s	O
43	and	O
44	1950	O
45	'	O
46	s	O
47	to	O
48	almost	O
49	1880	O
50	levels	O
51	.	O

1	According	O
2	to	O
3	their	O
4	staining	O
5	affinity	O
6	for	O
7	anti	B
8	-	I
9	T	I
10	antibodies	I
11	,	O
12	the	O
13	glandular	O
14	tissue	O
15	cells	O
16	were	O
17	classified	O
18	as	O
19	T	B
20	-,	O
21	T	B
22	+,	O
23	T	B
24	++,	O
25	and	O
26	T	B
27	and	O
28	the	O
29	annual	O
30	changes	O
31	in	O
32	the	O
33	numbers	O
34	of	O
35	these	O
36	cell	O
37	populations	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	volume	O
45	occupied	O
46	by	O
47	the	O
48	glandular	O
49	tissue	O
50	,	O
51	were	O
52	calculated	O
53	.	O

1	Ampicillin	O
2	(	O
3	AMP	O
4	)	O
5	alone	O
6	or	O
7	with	O
8	an	O
9	aminoglycoside	O
10	(	O
11	AMI	O
12	)	O
13	was	O
14	the	O
15	treatment	O
16	in	O
17	9	O
18	and	O
19	16	O
20	cases	O
21	,	O
22	respectively	O
23	.	O

1	Alkoxymetgyl	O
2	-	O
3	3	O
4	,	O
5	4	O
6	-	O
7	dimethylpyridinium	O
8	chlorides	O
9	were	O
10	synthetized	O
11	by	O
12	reacting	O
13	3	O
14	,	O
15	4	O
16	-	O
17	dimethylpyridine	O
18	with	O
19	chloromethyl	O
20	alkyl	O
21	ethers	O
22	,	O
23	while	O
24	1	O
25	-	O
26	ethyloxymethyl	O
27	-	O
28	3	O
29	-	O
30	alkylthiomethylimidazolium	O
31	chlorides	O
32	were	O
33	obtained	O
34	in	O
35	reactions	O
36	of	O
37	1	O
38	-	O
39	ethyloxymethylimidazol	O
40	with	O
41	chloromethyl	O
42	alkyl	O
43	sulfides	O
44	.	O

1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	O
16	-	O
17	R	O
18	-	O
19	R	O
20	pseudoisochromatic	O
21	plates	O
22	.	O

1	Eighty	O
2	patients	O
3	presenting	O
4	to	O
5	HGGM	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O

1	The	O
2	relation	O
3	between	O
4	VE	O
5	/	O
6	VO2	O
7	and	O
8	Q	O
9	/	O
10	VO2	O
11	showed	O
12	a	O
13	significant	O
14	negative	O
15	correlation	O
16	(	O
17	r	O
18	=	O
19	-	O
20	0	O
21	.	O
22	93	O
23	,	O
24	p	O
25	less	O
26	than	O
27	0	O
28	.	O
29	01	O
30	).	O

1	The	O
2	differential	O
3	diagnosis	O
4	of	O
5	both	O
6	affections	O
7	is	O
8	based	O
9	on	O
10	the	O
11	clinical	O
12	course	O
13	,	O
14	sialography	O
15	and	O
16	CT	O
17	examination	O
18	which	O
19	along	O
20	with	O
21	modern	O
22	ATB	O
23	treatment	O
24	significantly	O
25	modify	O
26	hitherto	O
27	used	O
28	surgical	O
29	therapy	O
30	.	O

1	Retrograde	O
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O

1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O

1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	B
14	ANA	I
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O

1	The	O
2	maximum	O
3	stress	O
4	due	O
5	to	O
6	the	O
7	hygroscopic	O
8	examination	O
9	of	O
10	the	O
11	composite	O
12	was	O
13	0	O
14	.	O
15	74	O
16	kg	O
17	/	O
18	mm2	O
19	at	O
20	equilibrium	O
21	of	O
22	the	O
23	water	O
24	absorbed	O
25	of	O
26	the	O
27	composite	O
28	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	B
6	-	I
7	kilodalton	I
8	major	I
9	integral	I
10	membrane	I
11	immunogen	I
12	of	I
13	Treponema	I
14	pallidum	I
15	.	O

1	Potential	O
2	consensus	O
3	sequences	O
4	for	O
5	early	O
6	and	O
7	late	O
8	regulatory	O
9	elements	O
10	were	O
11	identified	O
12	.	O

1	An	O
2	FP	B
3	mutant	I
4	,	O
5	AcFP875	B
6	-	I
7	2	I
8	,	O
9	had	O
10	a	O
11	1	O
12	.	O
13	6	O
14	-	O
15	kbp	O
16	insertion	O
17	of	O
18	S	O
19	.	O
20	frugiperda	O
21	DNA	O
22	near	O
23	the	O
24	5	O
25	'	O
26	end	O
27	of	O
28	these	O
29	transcripts	O
30	which	O
31	by	O
32	S1	B
33	analysis	O
34	were	O
35	shown	O
36	to	O
37	initiate	O
38	within	O
39	the	O
40	host	O
41	cell	O
42	sequence	O
43	.	O

1	Construction	O
2	of	O
3	a	O
4	RIP1	B
5	deletion	O
6	strain	O
7	and	O
8	isolation	O
9	of	O
10	temperature	O
11	-	O
12	sensitive	O
13	mutants	O
14	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	hypocitraturia	O
6	in	O
7	type	O
8	I	O
9	renal	O
10	tubular	O
11	acidosis	O
12	may	O
13	be	O
14	due	O
15	to	O
16	a	O
17	defect	O
18	in	O
19	proximal	O
20	tubule	O
21	function	O
22	.	O

1	Concomitant	O
2	chronic	O
3	lymphocytic	O
4	leukemia	O
5	,	O
6	acute	O
7	myeloid	O
8	leukemia	O
9	,	O
10	and	O
11	thrombosis	O
12	with	O
13	protein	B
14	C	I
15	deficiency	O
16	.	O

1	Vivid	O
2	visual	O
3	hallucinations	O
4	without	O
5	other	O
6	psychopathology	O
7	have	O
8	been	O
9	reported	O
10	for	O
11	several	O
12	hundred	O
13	years	O
14	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	,	O
6	basal	O
7	GH	B
8	and	O
9	somatomedin	B
10	-	I
11	C	I
12	levels	O
13	decreased	O
14	from	O
15	a	O
16	mean	O
17	(+/-	O
18	standard	O
19	error	O
20	of	O
21	the	O
22	mean	O
23	)	O
24	of	O
25	52	O
26	.	O
27	3	O
28	+/-	O
29	12	O
30	.	O
31	7	O
32	to	O
33	11	O
34	.	O
35	1	O
36	+/-	O
37	6	O
38	.	O
39	3	O
40	ng	O
41	/	O
42	ml	O
43	and	O
44	from	O
45	7	O
46	.	O
47	6	O
48	+/-	O
49	0	O
50	.	O
51	7	O
52	to	O
53	2	O
54	.	O
55	5	O
56	+/-	O
57	0	O
58	.	O
59	5	O
60	U	O
61	/	O
62	ml	O
63	,	O
64	respectively	O
65	.	O

1	Application	O
2	of	O
3	different	O
4	criteria	O
5	of	O
6	cure	O
7	revealed	O
8	that	O
9	19	O
10	patients	O
11	(	O
12	66	O
13	%)	O
14	had	O
15	basal	O
16	GH	B
17	levels	O
18	below	O
19	5	O
20	ng	O
21	/	O
22	ml	O
23	,	O
24	17	O
25	patients	O
26	(	O
27	59	O
28	%)	O
29	had	O
30	normal	O
31	somatomedin	B
32	-	I
33	C	I
34	values	O
35	,	O
36	16	O
37	patients	O
38	(	O
39	55	O
40	%)	O
41	had	O
42	complete	O
43	GH	B
44	suppression	O
45	(	O
46	less	O
47	than	O
48	1	O
49	ng	O
50	/	O
51	ml	O
52	)	O
53	during	O
54	OGTT	O
55	,	O
56	and	O
57	13	O
58	patients	O
59	(	O
60	45	O
61	%)	O
62	met	O
63	the	O
64	above	O
65	-	O
66	mentioned	O
67	criteria	O
68	with	O
69	disappearance	O
70	of	O
71	the	O
72	paradoxical	O
73	GH	B
74	response	O
75	to	O
76	TRH	B
77	/	O
78	GnRH	B
79	test	O
80	.	O

1	It	O
2	suggests	O
3	a	O
4	sequence	O
5	of	O
6	surgical	O
7	planning	O
8	that	O
9	can	O
10	prevent	O
11	them	O
12	and	O
13	also	O
14	offers	O
15	ways	O
16	of	O
17	dealing	O
18	with	O
19	the	O
20	problems	O
21	should	O
22	they	O
23	occur	O
24	.	O

1	In	O
2	Rat	O
3	-	O
4	1a	O
5	cells	O
6	the	O
7	expression	O
8	of	O
9	human	B
10	c	I
11	-	I
12	jun	I
13	mRNA	I
14	was	O
15	associated	O
16	with	O
17	the	O
18	ability	O
19	to	O
20	clone	O
21	in	O
22	soft	O
23	agarose	O
24	and	O
25	form	O
26	tumors	O
27	in	O
28	nude	O
29	mice	O
30	.	O

1	Furthermore	O
2	,	O
3	formation	O
4	of	O
5	foci	O
6	of	O
7	transformed	O
8	RECs	O
9	by	O
10	the	O
11	c	B
12	-	I
13	jun	I
14	/	O
15	ras	B
16	combination	O
17	was	O
18	augmented	O
19	3	O
20	-	O
21	fold	O
22	by	O
23	the	O
24	tumor	O
25	promoter	O
26	phorbol	O
27	12	O
28	-	O
29	tetradecanoate	O
30	13	O
31	-	O
32	acetate	O
33	.	O

1	Platelet	B
2	activating	I
3	factor	I
4	was	O
5	given	O
6	in	O
7	six	O
8	doses	O
9	at	O
10	15	O
11	minute	O
12	intervals	O
13	and	O
14	airway	O
15	response	O
16	measured	O
17	as	O
18	change	O
19	in	O
20	partial	O
21	expiratory	O
22	flow	O
23	at	O
24	30	O
25	%	O
26	of	O
27	vital	O
28	capacity	O
29	(	O
30	Vp30	O
31	).	O

1	There	O
2	was	O
3	no	O
4	significant	O
5	correlation	O
6	between	O
7	baseline	O
8	PC40	O
9	methacholine	O
10	and	O
11	the	O
12	maximal	O
13	fall	O
14	in	O
15	Vp30	O
16	after	O
17	either	O
18	the	O
19	first	O
20	(	O
21	12	O
22	micrograms	O
23	)	O
24	or	O
25	the	O
26	second	O
27	dose	O
28	(	O
29	24	O
30	micrograms	O
31	)	O
32	of	O
33	platelet	B
34	activating	I
35	factor	I
36	.	O

1	Both	O
2	BG	O
3	and	O
4	IRI	B
5	concentrations	O
6	during	O
7	the	O
8	OGTT	O
9	were	O
10	the	O
11	lowest	O
12	in	O
13	body	O
14	builders	O
15	,	O
16	medium	O
17	in	O
18	controls	O
19	,	O
20	and	O
21	the	O
22	highest	O
23	in	O
24	obese	O
25	men	O
26	.	O

1	Postcoital	O
2	contraception	O
3	:	O
4	a	O
5	family	O
6	planning	O
7	study	O
8	.	O

1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O

1	An	O
2	implant	O
3	may	O
4	release	O
5	a	O
6	drug	O
7	either	O
8	by	O
9	diffusion	O
10	concurrent	O
11	with	O
12	dissolution	O
13	of	O
14	the	O
15	polymeric	O
16	implant	O
17	material	O
18	without	O
19	depolymerization	O
20	(	O
21	Type	O
22	A	O
23	)	O
24	or	O
25	by	O
26	bioerosion	O
27	involving	O
28	depolymerization	O
29	(	O
30	Type	O
31	B	O
32	).	O

1	Although	O
2	it	O
3	is	O
4	well	O
5	known	O
6	that	O
7	calcium	O
8	channel	O
9	blockers	O
10	can	O
11	influence	O
12	contraction	O
13	of	O
14	vascular	O
15	smooth	O
16	muscle	O
17	,	O
18	there	O
19	is	O
20	less	O
21	knowledge	O
22	on	O
23	its	O
24	effect	O
25	on	O
26	excitation	O
27	contraction	O
28	coupling	O
29	in	O
30	the	O
31	endocrine	O
32	glands	O
33	and	O
34	more	O
35	specifically	O
36	on	O
37	insulin	B
38	and	O
39	glucagon	B
40	release	O
41	.	O

1	Many	O
2	studies	O
3	have	O
4	pointed	O
5	out	O
6	the	O
7	possibility	O
8	of	O
9	"	O
10	masked	O
11	"	O
12	organic	O
13	factors	O
14	in	O
15	erectile	O
16	impotence	O
17	,	O
18	detectable	O
19	only	O
20	by	O
21	means	O
22	of	O
23	laboratory	O
24	investigations	O
25	:	O
26	mild	O
27	hypogonadism	O
28	,	O
29	hyperprolactinemia	O
30	,	O
31	occlusions	O
32	selectively	O
33	located	O
34	at	O
35	the	O
36	site	O
37	of	O
38	the	O
39	sexual	O
40	arteries	O
41	,	O
42	venous	O
43	incompetence	O
44	,	O
45	subclinical	O
46	neuropathies	O
47	.	O

1	The	O
2	site	O
3	-	O
4	specific	O
5	DNA	O
6	inversion	O
7	system	O
8	Cin	B
9	encoded	O
10	by	O
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	B
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O

1	The	O
2	terminator	O
3	region	O
4	supported	O
5	termination	O
6	of	O
7	transcripts	O
8	initiated	O
9	by	O
10	RNA	B
11	polymerase	I
12	I	I
13	in	O
14	vivo	O
15	.	O

1	US	O
2	-	O
3	Doppler	O
4	has	O
5	recently	O
6	gained	O
7	attention	O
8	as	O
9	a	O
10	noninvasive	O
11	method	O
12	for	O
13	the	O
14	functional	O
15	evaluation	O
16	of	O
17	arteriovenous	O
18	fistulas	O
19	(	O
20	FAV	O
21	).	O

1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O

1	Improved	O
2	cosmesis	O
3	,	O
4	extension	O
5	of	O
6	the	O
7	scope	O
8	of	O
9	the	O
10	problems	O
11	that	O
12	can	O
13	be	O
14	addressed	O
15	with	O
16	this	O
17	repair	O
18	(	O
19	including	O
20	treatment	O
21	of	O
22	a	O
23	distal	O
24	urethrocutaneous	O
25	fistula	O
26	)	O
27	and	O
28	the	O
29	ease	O
30	with	O
31	which	O
32	the	O
33	Arap	O
34	procedure	O
35	can	O
36	be	O
37	performed	O
38	are	O
39	the	O
40	advantages	O
41	that	O
42	this	O
43	operation	O
44	has	O
45	over	O
46	other	O
47	1	O
48	-	O
49	stage	O
50	distal	O
51	hypospadias	O
52	repairs	O
53	.	O

1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O

1	The	O
2	galactose	B
3	transporter	I
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	B
15	transporters	I
16	which	O
17	includes	O
18	the	O
19	human	B
20	HepG2	I
21	-	I
22	erythrocyte	I
23	and	I
24	fetal	I
25	muscle	I
26	glucose	I
27	transporters	I
28	,	O
29	the	O
30	rat	B
31	brain	I
32	and	I
33	liver	I
34	glucose	I
35	transporters	I
36	,	O
37	the	O
38	Escherichia	B
39	coli	I
40	xylose	I
41	and	I
42	arabinose	I
43	permeases	I
44	,	O
45	and	O
46	the	O
47	S	B
48	.	I
49	cerevisiae	I
50	glucose	I
51	,	I
52	maltose	I
53	,	I
54	and	I
55	galactose	I
56	transporters	I
57	.	O

1	Of	O
2	110	O
3	previously	O
4	untreated	O
5	patients	O
6	who	O
7	had	O
8	entered	O
9	the	O
10	study	O
11	of	O
12	protocol	O
13	TCL821	O
14	,	O
15	96	O
16	were	O
17	evaluable	O
18	.	O

1	There	O
2	were	O
3	3	O
4	/	O
5	32	O
6	(	O
7	9	O
8	.	O
9	4	O
10	per	O
11	cent	O
12	)	O
13	adverse	O
14	reactions	O
15	(	O
16	ADRs	O
17	),	O
18	and	O
19	one	O
20	case	O
21	each	O
22	of	O
23	nausea	O
24	,	O
25	dizziness	O
26	and	O
27	increased	O
28	menstrual	O
29	flow	O
30	.	O

1	More	O
2	mRNA	O
3	corresponding	O
4	to	O
5	nagB	B
6	and	O
7	nagA	B
8	is	O
9	detected	O
10	than	O
11	that	O
12	corresponding	O
13	to	O
14	the	O
15	distal	O
16	genes	O
17	,	O
18	nagC	B
19	and	O
20	nagD	B
21	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	(	O
5	TNF	B
6	)	O
7	is	O
8	reported	O
9	to	O
10	cause	O
11	a	O
12	shock	O
13	syndrome	O
14	similar	O
15	to	O
16	that	O
17	produced	O
18	by	O
19	endotoxin	O
20	(	O
21	LPS	O
22	).	O

1	The	O
2	calcium	O
3	requirement	O
4	for	O
5	hypothermic	O
6	storage	O
7	of	O
8	the	O
9	cardiac	O
10	explant	O
11	.	O

1	The	O
2	seventh	O
3	cysteine	O
4	residue	O
5	of	O
6	CTSE	B
7	is	O
8	located	O
9	within	O
10	the	O
11	activation	O
12	peptide	O
13	region	O
14	of	O
15	the	O
16	proenzyme	O
17	.	O

1	The	O
2	p34	B
3	.	I
4	8	I
5	gene	I
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	bias	O
12	which	O
13	is	O
14	strikingly	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	polyhedrin	B
21	gene	I
22	.	O

1	Of	O
2	the	O
3	single	O
4	-	O
5	stranded	O
6	DNA	O
7	transformants	O
8	,	O
9	65	O
10	%	O
11	resulted	O
12	from	O
13	replacement	O
14	of	O
15	the	O
16	resident	O
17	met2	B
18	mutation	I
19	by	O
20	the	O
21	exogenous	O
22	wild	O
23	-	O
24	type	O
25	allele	O
26	.	O

1	The	O
2	results	O
3	strongly	O
4	support	O
5	the	O
6	notion	O
7	that	O
8	the	O
9	OBF1	B
10	-	I
11	binding	I
12	sites	I
13	and	O
14	the	O
15	OBF1	B
16	protein	I
17	are	O
18	important	O
19	for	O
20	normal	O
21	ARS	O
22	function	O
23	as	O
24	an	O
25	origin	O
26	of	O
27	replication	O
28	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	S1	B
6	nuclease	I
7	protection	O
8	analysis	O
9	of	O
10	RNA	O
11	preparations	O
12	from	O
13	several	O
14	mouse	O
15	tissues	O
16	,	O
17	both	O
18	dhfr	B
19	and	O
20	divergent	O
21	genes	O
22	showed	O
23	similar	O
24	levels	O
25	of	O
26	expression	O
27	but	O
28	did	O
29	show	O
30	some	O
31	specificity	O
32	in	O
33	start	O
34	site	O
35	utilization	O
36	.	O

1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	O

1	62	O
2	:	O
3	2491	O
4	-	O
5	2499	O
6	,	O
7	1987	O
8	).	O

1	With	O
2	both	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	the	O
8	mutant	O
9	enzymes	O
10	,	O
11	ATP	O
12	activates	O
13	both	O
14	[	O
15	14C	O
16	]	O
17	Asp	O
18	in	O
19	equilibrium	O
20	N	O
21	-	O
22	carbamyl	O
23	-	O
24	L	O
25	-	O
26	aspartate	O
27	(	O
28	C	O
29	-	O
30	Asp	O
31	)	O
32	and	O
33	the	O
34	[	O
35	32P	O
36	]	O
37	carbamyl	O
38	phosphate	O
39	(	O
40	C	O
41	-	O
42	P	O
43	)	O
44	in	O
45	equilibrium	O
46	Pi	O
47	exchanges	O
48	.	O

1	Survival	O
2	rates	O
3	for	O
4	the	O
5	original	O
6	treatment	O
7	group	O
8	were	O
9	84	O
10	.	O
11	5	O
12	%	O
13	and	O
14	57	O
15	.	O
16	6	O
17	%	O
18	at	O
19	12	O
20	and	O
21	21	O
22	months	O
23	,	O
24	respectively	O
25	;	O
26	for	O
27	the	O
28	delayed	O
29	treatment	O
30	group	O
31	,	O
32	78	O
33	.	O
34	8	O
35	%	O
36	and	O
37	64	O
38	.	O
39	6	O
40	%	O
41	at	O
42	12	O
43	and	O
44	21	O
45	months	O
46	,	O
47	respectively	O
48	,	O
49	and	O
50	78	O
51	.	O
52	8	O
53	%	O
54	and	O
55	47	O
56	.	O
57	5	O
58	%	O
59	at	O
60	12	O
61	and	O
62	21	O
63	months	O
64	,	O
65	respectively	O
66	,	O
67	for	O
68	77	O
69	subjects	O
70	with	O
71	AIDS	O
72	and	O
73	93	O
74	.	O
75	0	O
76	%	O
77	and	O
78	71	O
79	.	O
80	8	O
81	%,	O
82	respectively	O
83	,	O
84	for	O
85	50	O
86	subjects	O
87	with	O
88	AIDS	O
89	-	O
90	related	O
91	complex	O
92	in	O
93	the	O
94	original	O
95	treatment	O
96	group	O
97	.	O

1	Mapping	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	allelic	O
14	to	O
15	the	O
16	ag	B
17	alpha	I
18	1	I
19	mutation	O
20	identified	O
21	previously	O
22	.	O

1	The	O
2	products	O
3	of	O
4	genes	O
5	ura10	B
6	and	O
7	ura3	B
8	are	O
9	proposed	O
10	to	O
11	participate	O
12	in	O
13	the	O
14	channeling	O
15	of	O
16	orotidine	O
17	monophosphate	O
18	.	O

1	After	O
2	the	O
3	application	O
4	of	O
5	RS	O
6	86	O
7	,	O
8	REM	O
9	latency	O
10	was	O
11	shortened	O
12	in	O
13	all	O
14	groups	O
15	under	O
16	investigation	O
17	.	O

1	Hybridization	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O

1	Agranulocytosis	O
2	treatment	O
3	with	O
4	rhGM	B
5	-	I
6	CSF	I

1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	Major	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	O
9	in	O
10	this	O
11	group	O
12	of	O
13	patients	O
14	.	O

1	Recently	O
2	,	O
3	an	O
4	alternatively	O
5	spliced	O
6	form	O
7	of	O
8	c	B
9	-	I
10	myb	I
11	-	I
12	encoded	I
13	mRNA	I
14	has	O
15	been	O
16	identified	O
17	in	O
18	murine	O
19	cells	O
20	containing	O
21	either	O
22	normal	O
23	or	O
24	rearranged	O
25	c	B
26	-	I
27	myb	I
28	genes	I
29	.	O

1	Routine	O
2	clinical	O
3	analysis	O
4	revealed	O
5	lower	O
6	hematocrit	O
7	and	O
8	hemoglobin	B
9	,	O
10	and	O
11	elevated	O
12	BUN	O
13	and	O
14	alkaline	B
15	phosphatase	I
16	in	O
17	the	O
18	treated	O
19	group	O
20	.	O

1	To	O
2	assess	O
3	the	O
4	health	O
5	significance	O
6	of	O
7	the	O
8	early	O
9	renal	O
10	changes	O
11	after	O
12	chronic	O
13	exposure	O
14	to	O
15	cadmium	O
16	,	O
17	23	O
18	workers	O
19	removed	O
20	from	O
21	exposure	O
22	because	O
23	of	O
24	the	O
25	discovery	O
26	of	O
27	an	O
28	increased	O
29	urinary	O
30	excretion	O
31	of	O
32	beta	B
33	2	I
34	-	I
35	microglobulin	I
36	or	O
37	retinol	B
38	binding	I
39	protein	I
40	,	O
41	or	O
42	both	O
43	,	O
44	have	O
45	been	O
46	examined	O
47	once	O
48	a	O
49	year	O
50	for	O
51	five	O
52	years	O
53	.	O

1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	structural	O
7	and	O
8	functional	O
9	organization	O
10	of	O
11	the	O
12	eukaryotic	O
13	nucleolus	O
14	,	O
15	we	O
16	have	O
17	started	O
18	to	O
19	isolate	O
20	and	O
21	characterize	O
22	nucleolar	O
23	components	O
24	of	O
25	the	O
26	yeast	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O

1	A	O
2	transcription	O
3	factor	O
4	exclusion	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	PCF1	B
13	mutation	I
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O

1	Psychiatry	O
2	and	O
3	the	O
4	skin	O
5	.	O

1	These	O
2	adverse	O
3	effects	O
4	usually	O
5	abate	O
6	with	O
7	time	O
8	.	O

1	The	O
2	cytosolic	O
3	glutathione	B
4	S	I
5	-	I
6	transferases	I
7	(	O
8	GSTs	B
9	,	O
10	EC	B
11	2	I
12	.	I
13	5	I
14	.	I
15	1	I
16	.	I
17	18	I
18	)	O
19	are	O
20	a	O
21	superfamily	O
22	of	O
23	dimeric	O
24	isoenzymes	O
25	which	O
26	catalyze	O
27	the	O
28	conjugation	O
29	of	O
30	electrophilic	O
31	substrates	O
32	with	O
33	glutathione	O
34	.	O

1	Furthermore	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	untranslated	O
7	regions	O
8	of	O
9	pmGT10	B
10	display	O
11	a	O
12	marked	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	3	O
19	'	O
20	region	O
21	of	O
22	the	O
23	rat	B
24	Yb1	I
25	gene	I
26	,	O
27	while	O
28	this	O
29	region	O
30	of	O
31	pmGT2	B
32	displays	O
33	marked	O
34	homology	O
35	to	O
36	the	O
37	corresponding	O
38	region	O
39	of	O
40	the	O
41	rat	B
42	Yb2	I
43	gene	I
44	.	O

1	Model	O
2	IV	O
3	:	O
4	primary	O
5	abutments	O
6	with	O
7	the	O
8	lateral	O
9	incisor	O
10	and	O
11	the	O
12	second	O
13	molar	O
14	as	O
15	secondary	O
16	abutments	O
17	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	suggest	O
6	that	O
7	when	O
8	compared	O
9	to	O
10	the	O
11	systemic	O
12	vascular	O
13	bed	O
14	,	O
15	the	O
16	pulmonary	O
17	vascular	O
18	bed	O
19	is	O
20	less	O
21	responsive	O
22	to	O
23	bolus	O
24	administration	O
25	of	O
26	ET	B
27	-	I
28	1	I
29	.	O

1	In	O
2	comparison	O
3	with	O
4	normal	O
5	pregnant	O
6	women	O
7	and	O
8	normal	O
9	non	O
10	-	O
11	pregnant	O
12	women	O
13	,	O
14	women	O
15	with	O
16	PIH	O
17	showed	O
18	an	O
19	increase	O
20	in	O
21	heart	O
22	rate	O
23	,	O
24	suggesting	O
25	an	O
26	increased	O
27	peripheral	O
28	sympathetic	O
29	tone	O
30	,	O
31	and	O
32	an	O
33	initial	O
34	derangement	O
35	in	O
36	renal	O
37	function	O
38	as	O
39	shown	O
40	by	O
41	the	O
42	increase	O
43	in	O
44	serum	O
45	uric	O
46	acid	O
47	and	O
48	reduction	O
49	in	O
50	sodium	O
51	excretion	O
52	and	O
53	total	O
54	and	O
55	fractional	O
56	calcium	O
57	excretion	O
58	at	O
59	any	O
60	given	O
61	level	O
62	of	O
63	sodium	O
64	excretion	O
65	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	role	O
6	of	O
7	two	O
8	recombination	O
9	-	O
10	and	O
11	repair	O
12	-	O
13	defective	O
14	mutations	O
15	,	O
16	rad1	B
17	and	O
18	rad52	B
19	,	O
20	on	O
21	direct	O
22	repeat	O
23	recombination	O
24	in	O
25	transcriptionally	O
26	active	O
27	and	O
28	inactive	O
29	sequences	O
30	.	O

1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	knowledge	O
7	of	O
8	the	O
9	epidemiology	O
10	of	O
11	Parkinson	O
12	'	O
13	s	O
14	disease	O
15	is	O
16	necessary	O
17	in	O
18	creating	O
19	etiological	O
20	hypotheses	O
21	,	O
22	since	O
23	only	O
24	hypotheses	O
25	consistent	O
26	with	O
27	the	O
28	epidemiological	O
29	profile	O
30	deserve	O
31	careful	O
32	testing	O
33	.	O

1	The	O
2	stereoselectivity	O
3	of	O
4	drug	O
5	action	O
6	.	O

1	Scotchbond	O
2	2	O
3	showed	O
4	the	O
5	least	O
6	dye	O
7	penetration	O
8	but	O
9	not	O
10	statistically	O
11	less	O
12	than	O
13	the	O
14	XR	O
15	bond	O
16	/	O
17	Silus	O
18	Plus	O
19	combination	O
20	.	O

1	A	O
2	combination	O
3	of	O
4	cisplatin	O
5	and	O
6	5	O
7	-	O
8	fluorouracil	O
9	,	O
10	both	O
11	administered	O
12	4	O
13	days	O
14	continuously	O
15	as	O
16	infusion	O
17	,	O
18	was	O
19	assessed	O
20	in	O
21	advanced	O
22	head	O
23	and	O
24	neck	O
25	cancer	O
26	.	O

1	Metformin	O
2	plasma	O
3	concentrations	O
4	remained	O
5	unchanged	O
6	except	O
7	for	O
8	patients	O
9	transferred	O
10	from	O
11	1	O
12	.	O
13	5	O
14	to	O
15	2	O
16	.	O
17	0	O
18	g	O
19	daily	O
20	to	O
21	850	O
22	mg	O
23	twice	O
24	daily	O
25	;	O
26	in	O
27	these	O
28	patients	O
29	plasma	O
30	concentrations	O
31	increased	O
32	from	O
33	1	O
34	.	O
35	83	O
36	+/-	O
37	0	O
38	.	O
39	87	O
40	to	O
41	2	O
42	.	O
43	50	O
44	+/-	O
45	0	O
46	.	O
47	89	O
48	micrograms	O
49	/	O
50	l	O
51	(	O
52	p	O
53	less	O
54	than	O
55	0	O
56	.	O
57	01	O
58	).	O

1	Diagnosis	O
2	of	O
3	primary	O
4	sclerosing	O
5	cholangitis	O
6	in	O
7	a	O
8	blood	O
9	donor	O
10	with	O
11	elevated	O
12	serum	B
13	alanine	I
14	aminotransferase	I
15	.	O

1	When	O
2	statistically	O
3	analyzed	O
4	in	O
5	various	O
6	subgroupings	O
7	,	O
8	the	O
9	obtained	O
10	average	O
11	sedimentation	O
12	coefficients	O
13	and	O
14	polydispersity	O
15	profiles	O
16	supported	O
17	the	O
18	following	O
19	conclusions	O
20	:	O
21	(	O
22	a	O
23	)	O
24	loss	O
25	of	O
26	proteoglycan	O
27	aggregation	O
28	and	O
29	sedimentability	O
30	is	O
31	confirmed	O
32	to	O
33	be	O
34	a	O
35	primary	O
36	sign	O
37	of	O
38	cartilage	O
39	matrix	O
40	degradation	O
41	;	O
42	(	O
43	b	O
44	)	O
45	higher	O
46	S	O
47	values	O
48	for	O
49	proteoglycans	O
50	of	O
51	the	O
52	high	O
53	weight	O
54	(	O
55	HW	O
56	)-	O
57	bearing	O
58	areas	O
59	and	O
60	lower	O
61	values	O
62	for	O
63	those	O
64	of	O
65	the	O
66	low	O
67	weight	O
68	(	O
69	LW	O
70	)-	O
71	bearing	O
72	areas	O
73	were	O
74	a	O
75	typical	O
76	finding	O
77	in	O
78	normal	O
79	cartilage	O
80	samples	O
81	;	O
82	(	O
83	c	O
84	)	O
85	inversion	O
86	of	O
87	this	O
88	pattern	O
89	was	O
90	indicative	O
91	of	O
92	matrix	O
93	degradation	O
94	,	O
95	suggesting	O
96	that	O
97	the	O
98	HW	O
99	regions	O
100	are	O
101	more	O
102	affected	O
103	than	O
104	the	O
105	LW	O
106	-	O
107	bearing	O
108	areas	O
109	;	O
110	(	O
111	d	O
112	)	O
113	the	O
114	average	O
115	S	O
116	value	O
117	distribution	O
118	across	O
119	cartilage	O
120	thickness	O
121	tended	O
122	to	O
123	resemble	O
124	the	O
125	corresponding	O
126	proteoglycan	O
127	content	O
128	versus	O
129	distance	O
130	from	O
131	articular	O
132	surface	O
133	;	O
134	and	O
135	(	O
136	e	O
137	)	O
138	the	O
139	deepest	O
140	cartilage	O
141	layer	O
142	had	O
143	,	O
144	in	O
145	most	O
146	cases	O
147	,	O
148	the	O
149	smallest	O
150	amount	O
151	of	O
152	aggregates	O
153	while	O
154	the	O
155	highest	O
156	average	O
157	sedimentability	O
158	was	O
159	observed	O
160	at	O
161	the	O
162	middle	O
163	zone	O
164	of	O
165	the	O
166	normal	O
167	samples	O
168	.	O

1	A	O
2	significant	O
3	relationship	O
4	existed	O
5	during	O
6	the	O
7	evolution	O
8	of	O
9	the	O
10	disease	O
11	between	O
12	CRS	O
13	/	O
14	BW	O
15	and	O
16	gas	O
17	exchange	O
18	parameters	O
19	(	O
20	FIO2	O
21	and	O
22	a	O
23	/	O
24	AO2	O
25	ratio	O
26	)	O
27	(	O
28	P	O
29	less	O
30	than	O
31	0	O
32	.	O
33	01	O
34	),	O
35	but	O
36	gas	O
37	exchange	O
38	improved	O
39	earlier	O
40	than	O
41	lung	O
42	mechanics	O
43	.	O

1	End	O
2	points	O
3	measured	O
4	were	O
5	perioperative	O
6	(	O
7	30	O
8	-	O
9	day	O
10	)	O
11	myocardial	O
12	infarction	O
13	(	O
14	MI	O
15	)	O
16	rate	O
17	and	O
18	death	O
19	.	O

1	The	O
2	predicted	O
3	molecular	O
4	weight	O
5	of	O
6	the	O
7	polyprotein	O
8	encoded	O
9	by	O
10	ORF1	O
11	is	O
12	33	O
13	kilodaltons	O
14	(	O
15	kDa	O
16	).	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	An	O
2	alternative	O
3	method	O
4	of	O
5	UKM	O
6	is	O
7	proposed	O
8	based	O
9	on	O
10	collecting	O
11	a	O
12	small	O
13	fraction	O
14	of	O
15	spent	O
16	dialysate	O
17	flow	O
18	for	O
19	3	O
20	consecutive	O
21	dialyses	O
22	.	O

1	Liquid	O
2	chromatography	O
3	with	O
4	amperometric	O
5	detection	O
6	(	O
7	LC	O
8	/	O
9	AD	O
10	)	O
11	is	O
12	used	O
13	to	O
14	determine	O
15	fluazifop	O
16	acid	O
17	produced	O
18	from	O
19	the	O
20	metabolism	O
21	or	O
22	base	O
23	hydrolysis	O
24	of	O
25	fluazifop	O
26	-	O
27	butyl	O
28	in	O
29	soybeans	O
30	and	O
31	soybean	O
32	oil	O
33	.	O

1	The	O
2	dichloromethane	O
3	is	O
4	removed	O
5	,	O
6	mobile	O
7	phase	O
8	solvent	O
9	is	O
10	added	O
11	,	O
12	and	O
13	aliquots	O
14	are	O
15	injected	O
16	onto	O
17	a	O
18	PRP	O
19	-	O
20	1	O
21	liquid	O
22	chromatographic	O
23	column	O
24	;	O
25	fluazifop	O
26	acid	O
27	is	O
28	separated	O
29	from	O
30	coextracted	O
31	compounds	O
32	and	O
33	detected	O
34	at	O
35	an	O
36	applied	O
37	potential	O
38	of	O
39	+	O
40	1	O
41	.	O
42	25	O
43	V	O
44	,	O
45	using	O
46	an	O
47	amperometric	O
48	electrochemical	O
49	detector	O
50	in	O
51	the	O
52	oxidation	O
53	mode	O
54	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	B
16	IV	I
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O

1	Significantly	O
2	,	O
3	the	O
4	polymerase	O
5	chain	O
6	reaction	O
7	results	O
8	demonstrated	O
9	that	O
10	gene	B
11	IV	I
12	transcripts	I
13	were	O
14	associated	O
15	with	O
16	hepatic	O
17	polysome	O
18	fractions	O
19	,	O
20	indicating	O
21	their	O
22	active	O
23	utilization	O
24	in	O
25	this	O
26	tissue	O
27	.	O

1	Validation	O
2	of	O
3	the	O
4	survey	O
5	of	O
6	work	O
7	styles	O
8	:	O
9	a	O
10	profile	O
11	measure	O
12	of	O
13	the	O
14	type	O
15	A	O
16	behaviour	O
17	pattern	O
18	.	O

1	Only	O
2	one	O
3	ADR	O
4	was	O
5	related	O
6	definitely	O
7	to	O
8	ciprofloxacin	O
9	therapy	O
10	.	O

1	HIV	O
2	infectiousness	O
3	and	O
4	the	O
5	AIDS	O
6	epidemic	O
7	.	O

1	From	O
2	day	O
3	30	O
4	after	O
5	turnout	O
6	,	O
7	the	O
8	PFB	O
9	-	O
10	group	O
11	had	O
12	significantly	O
13	lower	O
14	serum	B
15	pepsinogen	I
16	levels	O
17	,	O
18	which	O
19	reflects	O
20	the	O
21	low	O
22	degree	O
23	of	O
24	abomasal	O
25	damage	O
26	in	O
27	these	O
28	animals	O
29	.	O

1	The	O
2	corresponding	O
3	inhibition	O
4	of	O
5	acid	B
6	phosphatase	I
7	activity	O
8	in	O
9	control	O
10	male	O
11	and	O
12	female	O
13	guinea	O
14	pigs	O
15	was	O
16	15	O
17	.	O
18	91	O
19	%	O
20	and	O
21	20	O
22	.	O
23	33	O
24	%	O
25	respectively	O
26	.	O

1	Its	O
2	clinical	O
3	and	O
4	histopathologic	O
5	characteristics	O
6	.	O

1	Normocapnic	O
2	(	O
3	PACO2	O
4	=	O
5	40	O
6	mm	O
7	Hg	O
8	)	O
9	ventilatory	O
10	drive	O
11	increased	O
12	significantly	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	)	O
21	in	O
22	six	O
23	subjects	O
24	(	O
25	Type	O
26	1	O
27	response	O
28	)	O
29	and	O
30	decreased	O
31	substantially	O
32	in	O
33	the	O
34	others	O
35	(	O
36	Type	O
37	2	O
38	response	O
39	);	O
40	with	O
41	hypercapnia	O
42	,	O
43	the	O
44	changes	O
45	in	O
46	drive	O
47	were	O
48	attenuated	O
49	in	O
50	both	O
51	groups	O
52	.	O

1	Fundus	O
2	changes	O
3	in	O
4	(	O
5	type	O
6	II	O
7	)	O
8	mesangiocapillary	O
9	glomerulonephritis	O
10	simulating	O
11	drusen	O
12	:	O
13	a	O
14	histopathological	O
15	report	O
16	.	O

1	Chronic	O
2	dose	O
3	effects	O
4	of	O
5	methyl	O
6	parathion	O
7	on	O
8	nuthatches	O
9	:	O
10	cholinesterase	B
11	and	O
12	ptilochronology	O
13	.	O

1	The	O
2	titer	O
3	of	O
4	anti	B
5	HSV	I
6	type	I
7	1	I
8	and	O
9	anti	B
10	HSV	I
11	type	I
12	2	I
13	antibodies	I
14	in	O
15	the	O
16	mothers	O
17	'	O
18	and	O
19	cord	O
20	blood	O
21	was	O
22	determined	O
23	and	O
24	compared	O
25	.	O

1	Kidney	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O

1	Allelic	O
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	I
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	optimal	O
6	development	O
7	conditions	O
8	by	O
9	summary	O
10	oxygen	O
11	consumption	O

1	Men	O
2	were	O
3	more	O
4	positive	O
5	about	O
6	their	O
7	physical	O
8	fitness	O
9	than	O
10	women	O
11	.	O

1	Handgrip	O
2	dynamometry	O
3	was	O
4	also	O
5	carried	O
6	out	O
7	in	O
8	249	O
9	of	O
10	the	O
11	patients	O
12	.	O

1	In	O
2	cerebrospinal	O
3	fluid	O
4	,	O
5	an	O
6	ADA	B
7	catalytic	O
8	concentration	O
9	above	O
10	0	O
11	.	O
12	15	O
13	mu	O
14	kat	O
15	/	O
16	L	O
17	strongly	O
18	suggests	O
19	tuberculous	O
20	meningitis	O
21	in	O
22	patients	O
23	older	O
24	than	O
25	7	O
26	years	O
27	(	O
28	sensitivity	O
29	1	O
30	.	O
31	00	O
32	,	O
33	specificity	O
34	0	O
35	.	O
36	99	O
37	and	O
38	efficiency	O
39	0	O
40	.	O
41	99	O
42	).	O

1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O

1	Swim	O
2	-	O
3	over	O
4	:	O
5	an	O
6	alternative	O
7	method	O
8	for	O
9	harvesting	O
10	motile	O
11	spermatozoa	O
12	.	O

1	Perfusion	O
2	washout	O
3	:	O
4	increasing	O
5	a	O
6	microvascular	O
7	free	O
8	flap	O
9	tolerance	O
10	to	O
11	ischemia	O
12	.	O

1	Similarly	O
2	,	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	U2	B
8	RNA	I
9	region	I
10	shown	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	pre	O
16	-	O
17	mRNA	O
18	branchpoint	O
19	recognition	O
20	in	O
21	yeast	O
22	,	O
23	and	O
24	exactly	O
25	conserved	O
26	in	O
27	metazoan	B
28	U2	I
29	RNAs	I
30	,	O
31	was	O
32	totally	O
33	divergent	O
34	in	O
35	trypanosomes	O
36	.	O

1	It	O
2	is	O
3	striking	O
4	that	O
5	the	O
6	active	O
7	CHO	O
8	spacer	O
9	promoter	O
10	violated	O
11	the	O
12	otherwise	O
13	universal	O
14	rule	O
15	that	O
16	metazoan	B
17	RNA	I
18	polymerase	I
19	I	I
20	promoters	I
21	all	O
22	have	O
23	a	O
24	G	O
25	residue	O
26	at	O
27	position	O
28	-	O
29	16	O
30	.	O

1	A	O
2	raised	O
3	amplitude	O
4	of	O
5	the	O
6	aggregation	O
7	of	O
8	plates	O
9	and	O
10	a	O
11	decrease	O
12	in	O
13	the	O
14	threshold	O
15	of	O
16	their	O
17	sensitivity	O
18	to	O
19	ADP	O
20	were	O
21	established	O
22	in	O
23	the	O
24	persons	O
25	with	O
26	types	O
27	IIa	O
28	and	O
29	IIb	O
30	HLP	O
31	and	O
32	in	O
33	CHD	O
34	without	O
35	HLP	O
36	.	O

1	Significant	O
2	intergroup	O
3	differences	O
4	are	O
5	highlighted	O
6	for	O
7	both	O
8	selected	O
9	dentoskeletal	O
10	and	O
11	soft	O
12	tissue	O
13	profile	O
14	variables	O
15	.	O

1	The	O
2	author	O
3	provides	O
4	a	O
5	rationale	O
6	for	O
7	an	O
8	interactional	O
9	view	O
10	and	O
11	presents	O
12	a	O
13	case	O
14	in	O
15	which	O
16	post	O
17	-	O
18	surgical	O
19	hiccups	O
20	were	O
21	successfully	O
22	treated	O
23	,	O
24	using	O
25	principles	O
26	developed	O
27	by	O
28	the	O
29	Mental	O
30	Research	O
31	Institute	O
32	.	O

1	The	O
2	relative	O
3	toxicity	O
4	of	O
5	nickel	O
6	oxide	O
7	(	O
8	NiO	O
9	),	O
10	nickel	O
11	sulfate	O
12	hexahydrate	O
13	(	O
14	NiSO4	O
15	.	O
16	6H2O	O
17	),	O
18	and	O
19	nickel	O
20	subsulfide	O
21	(	O
22	Ni3S2	O
23	)	O
24	was	O
25	studied	O
26	in	O
27	F344	O
28	/	O
29	N	O
30	rats	O
31	and	O
32	B6C3F1	O
33	mice	O
34	after	O
35	inhalation	O
36	exposure	O
37	for	O
38	6	O
39	hr	O
40	/	O
41	day	O
42	,	O
43	5	O
44	days	O
45	/	O
46	week	O
47	,	O
48	for	O
49	13	O
50	weeks	O
51	.	O

1	Light	O
2	microscopical	O
3	and	O
4	routine	O
5	immunohistochemical	O
6	studies	O
7	of	O
8	a	O
9	cervical	O
10	neoplasm	O
11	in	O
12	a	O
13	32	O
14	year	O
15	old	O
16	woman	O
17	initially	O
18	suggested	O
19	a	O
20	histiocytic	O
21	lymphoma	O
22	,	O
23	but	O
24	histochemical	O
25	staining	O
26	for	O
27	chloroacetate	B
28	esterase	I
29	established	O
30	the	O
31	correct	O
32	diagnosis	O
33	.	O

1	From	O
2	the	O
3	National	O
4	Institutes	O
5	of	O
6	Health	O
7	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterisation	O
5	of	O
6	the	O
7	two	O
8	homologous	O
9	genes	O
10	coding	O
11	for	O
12	nitrate	B
13	reductase	I
14	in	I
15	tobacco	I
16	.	O

1	In	O
2	the	O
3	final	O
4	model	O
5	,	O
6	grade	O
7	(	O
8	p	O
9	=	O
10	0	O
11	.	O
12	0002	O
13	),	O
14	peritoneal	O
15	cytologic	O
16	results	O
17	(	O
18	p	O
19	=	O
20	0	O
21	.	O
22	0002	O
23	),	O
24	progesterone	B
25	receptor	I
26	status	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	004	O
33	),	O
34	and	O
35	age	O
36	as	O
37	a	O
38	continuous	O
39	variable	O
40	(	O
41	p	O
42	=	O
43	0	O
44	.	O
45	008	O
46	)	O
47	were	O
48	most	O
49	closely	O
50	associated	O
51	with	O
52	disease	O
53	-	O
54	free	O
55	survival	O
56	.	O

1	In	O
2	contrast	O
3	,	O
4	despite	O
5	external	O
6	radiation	O
7	therapy	O
8	,	O
9	brain	O
10	metastases	O
11	proved	O
12	fatal	O
13	.	O

1	COUP	B
2	transcription	I
3	factor	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	steroid	B
10	receptor	I
11	superfamily	I
12	.	O

1	In	O
2	Experiment	O
3	2	O
4	,	O
5	we	O
6	again	O
7	used	O
8	classification	O
9	,	O
10	but	O
11	the	O
12	fixed	O
13	standard	O
14	75	O
15	was	O
16	not	O
17	at	O
18	the	O
19	center	O
20	of	O
21	the	O
22	range	O
23	of	O
24	target	O
25	numbers	O
26	(	O
27	20	O
28	,	O
29	21	O
30	,	O
31	...	O

1	Cosmid	O
2	clones	O
3	containing	O
4	both	O
5	VNTR	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	apart	O
22	.	O

1	The	O
2	oxygen	O
3	uptake	O
4	(	O
5	VO2	O
6	),	O
7	carbon	O
8	dioxide	O
9	output	O
10	(	O
11	VCO2	O
12	),	O
13	respiratory	O
14	rate	O
15	(	O
16	fR	O
17	),	O
18	minute	O
19	ventilation	O
20	(	O
21	VE	O
22	),	O
23	alveolar	O
24	ventilation	O
25	(	O
26	VA	O
27	),	O
28	alveolar	O
29	oxygen	O
30	pressure	O
31	(	O
32	PAO2	O
33	),	O
34	and	O
35	VE	O
36	/	O
37	VO2	O
38	ratio	O
39	were	O
40	higher	O
41	in	O
42	the	O
43	cows	O
44	,	O
45	while	O
46	the	O
47	tidal	O
48	volume	O
49	(	O
50	VT	O
51	)	O
52	and	O
53	physiological	O
54	dead	O
55	space	O
56	(	O
57	VD	O
58	)	O
59	were	O
60	larger	O
61	in	O
62	the	O
63	horses	O
64	.	O

1	Epithelial	O
2	damage	O
3	was	O
4	not	O
5	observed	O
6	in	O
7	any	O
8	controls	O
9	but	O
10	was	O
11	in	O
12	all	O
13	tissues	O
14	exposed	O
15	to	O
16	SO2	O
17	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	The	O
2	present	O
3	study	O
4	investigates	O
5	whether	O
6	prostaglandins	O
7	"	O
8	cytoprotect	O
9	"	O
10	the	O
11	gastric	O
12	mucosa	O
13	against	O
14	hemorrhage	O
15	-	O
16	induced	O
17	stress	O
18	ulceration	O
19	by	O
20	assessing	O
21	the	O
22	influence	O
23	of	O
24	16	O
25	,	O
26	16	O
27	-	O
28	dimethyl	O
29	prostaglandin	O
30	E2	O
31	(	O
32	16	O
33	,	O
34	16	O
35	-	O
36	dm	O
37	PGE2	O
38	)	O
39	on	O
40	gross	O
41	and	O
42	microscopic	O
43	lesion	O
44	formation	O
45	,	O
46	intramucosal	O
47	tissue	O
48	pH	O
49	,	O
50	H	O
51	+	O
52	back	O
53	-	O
54	diffusion	O
55	,	O
56	and	O
57	mucosal	O
58	blood	O
59	flow	O
60	in	O
61	rat	O
62	gastric	O
63	mucosa	O
64	exposed	O
65	to	O
66	luminal	O
67	acid	O
68	(	O
69	100	O
70	mM	O
71	HCl	O
72	)	O
73	during	O
74	hemorrhagic	O
75	shock	O
76	(	O
77	13	O
78	ml	O
79	/	O
80	kg	O
81	for	O
82	20	O
83	min	O
84	).	O

1	Transcripts	O
2	characterized	O
3	include	O
4	(	O
5	i	O
6	)	O
7	abundant	O
8	monocistronic	O
9	L11e	B
10	and	O
11	tricistronic	O
12	L1e	B
13	-	O
14	L10e	B
15	-	O
16	L12e	B
17	transcripts	O
18	;	O
19	(	O
20	ii	O
21	)	O
22	less	O
23	abundant	O
24	bicistronic	O
25	NAB	B
26	-	O
27	L11e	B
28	and	O
29	monocistronic	O
30	NAB	B
31	transcripts	I
32	and	O
33	(	O
34	iii	O
35	)	O
36	a	O
37	very	O
38	rare	O
39	ORF	O
40	monocistronic	O
41	transcript	O
42	.	O

1	Qualitatively	O
2	,	O
3	the	O
4	results	O
5	are	O
6	similar	O
7	for	O
8	the	O
9	two	O
10	species	O
11	:	O
12	Both	O
13	rhesus	O
14	monkey	O
15	and	O
16	man	O
17	have	O
18	photopic	O
19	and	O
20	scotopic	O
21	branches	O
22	,	O
23	which	O
24	cross	O
25	at	O
26	approximately	O
27	the	O
28	same	O
29	time	O
30	in	O
31	the	O
32	dark	O
33	and	O
34	at	O
35	approximately	O
36	the	O
37	same	O
38	background	O
39	luminance	O
40	.	O

1	Evidence	O
2	from	O
3	the	O
4	structure	O
5	of	O
6	a	O
7	number	O
8	of	O
9	cDNA	O
10	clones	O
11	,	O
12	as	O
13	well	O
14	as	O
15	S1	B
16	nuclease	I
17	and	O
18	primer	O
19	extension	O
20	studies	O
21	supports	O
22	the	O
23	hypothesis	O
24	that	O
25	the	O
26	PTHrP	B
27	gene	I
28	contains	O
29	at	O
30	least	O
31	two	O
32	mRNA	O
33	transcription	O
34	start	O
35	points	O
36	that	O
37	define	O
38	two	O
39	putative	O
40	regulatory	O
41	domains	O
42	.	O

1	At	O
2	each	O
3	level	O
4	of	O
5	PaO2	O
6	we	O
7	obtained	O
8	simultaneous	O
9	measures	O
10	of	O
11	arterial	O
12	and	O
13	venous	O
14	blood	O
15	gases	O
16	,	O
17	venous	O
18	lactate	O
19	concentration	O
20	,	O
21	and	O
22	changes	O
23	in	O
24	the	O
25	relative	O
26	concentrations	O
27	of	O
28	inorganic	O
29	phosphate	O
30	,	O
31	phosphocreatine	O
32	,	O
33	and	O
34	ATP	O
35	measured	O
36	with	O
37	31P	O
38	magnetic	O
39	resonance	O
40	spectroscopy	O
41	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O

1	Endometrial	O
2	biopsies	O
3	and	O
4	plasma	O
5	oestradiol	O
6	(	O
7	E2	O
8	)	O
9	and	O
10	progesterone	O
11	(	O
12	P4	O
13	)	O
14	levels	O
15	in	O
16	23	O
17	patients	O
18	were	O
19	evaluated	O
20	during	O
21	26	O
22	replacement	O
23	therapy	O
24	cycles	O
25	for	O
26	premature	O
27	ovarian	O
28	failure	O
29	.	O

1	The	O
2	mobility	O
3	of	O
4	the	O
5	upper	O
6	and	O
7	lower	O
8	premolars	O
9	under	O
10	load	O
11	was	O
12	investigated	O
13	in	O
14	relation	O
15	to	O
16	the	O
17	interproximal	O
18	contact	O
19	and	O
20	occlusal	O
21	facets	O
22	.	O

1	A	O
2	larval	B
3	albumin	I
4	-	I
5	like	I
6	protein	I
7	was	O
8	not	O
9	detectable	O
10	by	O
11	silver	O
12	staining	O
13	in	O
14	serum	O
15	of	O
16	tadpoles	O
17	before	O
18	the	O
19	beginning	O
20	of	O
21	metamorphosis	O
22	at	O
23	stage	O
24	48	O
25	.	O

1	Behaviorally	O
2	,	O
3	a	O
4	pain	O
5	-	O
6	tolerant	O
7	group	O
8	(	O
9	PT	O
10	=	O
11	29	O
12	Ss	O
13	)	O
14	tolerated	O
15	the	O
16	entire	O
17	3	O
18	-	O
19	min	O
20	test	O
21	(	O
22	means	O
23	=	O
24	180	O
25	+/-	O
26	0	O
27	sec	O
28	),	O
29	while	O
30	a	O
31	pain	O
32	-	O
33	sensitive	O
34	group	O
35	(	O
36	PS	O
37	=	O
38	13	O
39	Ss	O
40	)	O
41	averaged	O
42	only	O
43	50	O
44	.	O
45	31	O
46	+/-	O
47	20	O
48	.	O
49	81	O
50	sec	O
51	of	O
52	the	O
53	cold	O
54	-	O
55	pressor	O
56	test	O
57	(	O
58	t	O
59	=	O
60	16	O
61	.	O
62	75	O
63	,	O
64	P	O
65	less	O
66	than	O
67	0	O
68	.	O
69	0001	O
70	),	O
71	replicating	O
72	our	O
73	earlier	O
74	studies	O
75	.	O

1	This	O
2	suggested	O
3	that	O
4	baboon	B
5	liver	I
6	class	I
7	I	I
8	ADH	I
9	is	O
10	of	O
11	the	O
12	same	O
13	ancestral	O
14	lineage	O
15	as	O
16	the	O
17	human	B
18	ADH	I
19	-	I
20	beta	I
21	.	O

1	Isolated	O
2	proteinuria	O
3	(	O
4	i	O
5	.	O
6	e	O
7	.	O
8	without	O
9	hematuria	O
10	and	O
11	/	O
12	or	O
13	pyuria	O
14	)	O
15	is	O
16	a	O
17	frequent	O
18	finding	O
19	.	O

1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O

1	Lithium	O
2	delays	O
3	the	O
4	circadian	O
5	rhythm	O
6	of	O
7	wheel	O
8	-	O
9	running	O
10	in	O
11	Syrian	O
12	hamsters	O
13	at	O
14	plasma	O
15	concentrations	O
16	(	O
17	0	O
18	.	O
19	59	O
20	-	O
21	0	O
22	.	O
23	74	O
24	mM	O
25	)	O
26	that	O
27	also	O
28	cause	O
29	toxic	O
30	weight	O
31	loss	O
32	.	O

1	Dynamic	O
2	and	O
3	static	O
4	scintigrams	O
5	,	O
6	using	O
7	99mtechnetium	O
8	methylene	O
9	diphosphonate	O
10	,	O
11	were	O
12	obtained	O
13	at	O
14	zero	O
15	,	O
16	six	O
17	,	O
18	and	O
19	12	O
20	weeks	O
21	after	O
22	fracture	O
23	.	O

1	On	O
2	admission	O
3	to	O
4	our	O
5	department	O
6	in	O
7	September	O
8	,	O
9	1987	O
10	,	O
11	the	O
12	patient	O
13	was	O
14	alert	O
15	and	O
16	had	O
17	spastic	O
18	paraparesis	O
19	,	O
20	the	O
21	impairment	O
22	of	O
23	all	O
24	sensory	O
25	modalities	O
26	below	O
27	the	O
28	level	O
29	of	O
30	Th	O
31	10	O
32	and	O
33	urinary	O
34	disturbance	O
35	.	O

1	Prostaglandins	O
2	and	O
3	gallstones	O

1	The	O
2	nature	O
3	of	O
4	the	O
5	process	O
6	formed	O
7	by	O
8	the	O
9	successive	O
10	occurrences	O
11	of	O
12	this	O
13	arrhythmia	O
14	was	O
15	studied	O
16	in	O
17	8	O
18	patients	O
19	with	O
20	a	O
21	history	O
22	of	O
23	symptomatic	O
24	paroxysmal	O
25	AF	O
26	.	O

1	This	O
2	would	O
3	have	O
4	had	O
5	the	O
6	effect	O
7	of	O
8	positioning	O
9	the	O
10	genes	O
11	currently	O
12	on	O
13	the	O
14	long	O
15	arm	O
16	adjacent	O
17	to	O
18	the	O
19	centromeric	O
20	heterochromatin	O
21	,	O
22	perhaps	O
23	resulting	O
24	in	O
25	a	O
26	"	O
27	position	O
28	effect	O
29	"	O
30	on	O
31	transcription	O
32	of	O
33	these	O
34	genes	O
35	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	microprocessor	O
6	controlled	O
7	current	O
8	based	O
9	defibrillator	O
10	.	O

1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	B
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	O
22	sex	B
23	hormone	I
24	binding	I
25	globulin	I
26	(	O
27	SHBG	B
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	O
34	SHBG	B
35	-	O
36	bound	O
37	estradiol	O
38	.	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	(	I
5	hnRNP	I
6	)	I
7	core	I
8	protein	I
9	A1	I
10	is	O
11	a	O
12	major	O
13	component	O
14	of	O
15	mammalian	B
16	hnRNP	I
17	40	I
18	S	I
19	particles	I
20	.	O

1	Brain	B
2	cholinesterase	I
3	activity	O
4	of	O
5	nestling	O
6	great	O
7	egrets	O
8	,	O
9	snowy	O
10	egrets	O
11	and	O
12	black	O
13	-	O
14	crowned	O
15	night	O
16	-	O
17	herons	O
18	.	O
19	inhibition	O
20	of	O
21	brain	B
22	cholinesterase	I
23	(	O
24	ChE	B
25	)	O
26	activity	O
27	in	O
28	birds	O
29	is	O
30	often	O
31	used	O
32	to	O
33	diagnose	O
34	exposure	O
35	or	O
36	death	O
37	from	O
38	organophosphorus	O
39	or	O
40	carbamate	O
41	pesticides	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	zinc	O
5	deficiency	O
6	on	O
7	trace	O
8	metals	O
9	in	O
10	the	O
11	liver	O
12	,	O
13	spleen	O
14	,	O
15	kidney	O
16	,	O
17	pancreas	O
18	and	O
19	duodenum	O
20	was	O
21	investigated	O
22	in	O
23	the	O
24	control	O
25	and	O
26	zinc	O
27	-	O
28	deficient	O
29	rats	O
30	at	O
31	17	O
32	days	O
33	and	O
34	20	O
35	days	O
36	of	O
37	pregnancy	O
38	.	O

1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O

1	Heating	O
2	cells	O
3	to	O
4	43	O
5	degrees	O
6	C	O
7	decreased	O
8	the	O
9	amount	O
10	of	O
11	newly	O
12	synthesized	O
13	rRNA	O
14	to	O
15	less	O
16	than	O
17	5	O
18	%	O
19	of	O
20	the	O
21	control	O
22	level	O
23	and	O
24	led	O
25	to	O
26	greater	O
27	than	O
28	95	O
29	%	O
30	inhibition	O
31	of	O
32	transcription	O
33	termination	O
34	at	O
35	a	O
36	region	O
37	355	O
38	to	O
39	362	O
40	nucleotides	O
41	downstream	O
42	of	O
43	the	O
44	3	O
45	'	O
46	end	O
47	of	O
48	28S	B
49	rRNA	I
50	,	O
51	with	O
52	readthrough	O
53	continuing	O
54	into	O
55	the	O
56	next	O
57	transcription	O
58	unit	O
59	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	I
9	,	O
10	NF	B
11	-	I
12	4FB	I
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	O
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O

1	Cord	O
2	swelling	O
3	was	O
4	observed	O
5	in	O
6	2	O
7	patients	O
8	who	O
9	developed	O
10	complete	O
11	lesions	O
12	.	O

1	Reye	O
2	'	O
3	s	O
4	syndrome	O
5	:	O
6	reports	O
7	of	O
8	7	O
9	cases	O
10	in	O
11	the	O
12	period	O
13	1982	O
14	-	O
15	1987	O

1	When	O
2	two	O
3	-	O
4	dimensional	O
5	polyacrylamide	O
6	gel	O
7	electrophoretic	O
8	patterns	O
9	of	O
10	[	O
11	35S	O
12	]	O
13	methionine	O
14	-	O
15	labeled	O
16	proteins	O
17	secreted	O
18	from	O
19	cells	O
20	infected	O
21	with	O
22	parental	O
23	and	O
24	recombinant	O
25	viruses	O
26	were	O
27	compared	O
28	,	O
29	a	O
30	spot	O
31	missing	O
32	from	O
33	the	O
34	latter	O
35	corresponded	O
36	in	O
37	molecular	O
38	weigh	O
39	and	O
40	isoelectric	O
41	point	O
42	with	O
43	that	O
44	predicted	O
45	from	O
46	the	O
47	N1L	B
48	ORF	I
49	.	O

1	PULSE	O
2	is	O
3	used	O
4	to	O
5	set	O
6	such	O
7	NMR	O
8	spectroscopic	O
9	parameters	O
10	as	O
11	the	O
12	delay	O
13	and	O
14	duration	O
15	of	O
16	rf	O
17	transmit	O
18	and	O
19	receive	O
20	gates	O
21	,	O
22	rf	O
23	phase	O
24	,	O
25	sampling	O
26	times	O
27	,	O
28	and	O
29	such	O
30	imaging	O
31	parameters	O
32	as	O
33	rf	O
34	pulse	O
35	shape	O
36	and	O
37	gradient	O
38	waveforms	O
39	.	O

1	Definite	O
2	JPsA	O
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	O
16	coincident	O
17	,	O
18	with	O
19	a	O
20	typical	O
21	psoriatic	O
22	rash	O
23	,	O
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O

1	Hence	O
2	follows	O
3	Kurti	O
4	'	O
5	s	O
6	demand	O
7	to	O
8	mete	O
9	out	O
10	appropriate	O
11	importance	O
12	to	O
13	the	O
14	arguments	O
15	.	O

1	The	O
2	author	O
3	gives	O
4	an	O
5	account	O
6	of	O
7	antipsychotic	O
8	,	O
9	analgetic	O
10	,	O
11	myorelaxing	O
12	and	O
13	vasodilatating	O
14	effects	O
15	of	O
16	some	O
17	calcium	O
18	antagonists	O
19	,	O
20	and	O
21	their	O
22	clinical	O
23	application	O
24	is	O
25	discussed	O
26	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O

1	This	O
2	indicates	O
3	that	O
4	lipid	O
5	peroxidation	O
6	may	O
7	be	O
8	involved	O
9	in	O
10	the	O
11	development	O
12	of	O
13	senile	O
14	cataract	O
15	and	O
16	,	O
17	as	O
18	a	O
19	direct	O
20	consequence	O
21	of	O
22	retinal	O
23	damage	O
24	,	O
25	also	O
26	in	O
27	the	O
28	pathogenesis	O
29	of	O
30	cataract	O
31	in	O
32	diabetes	O
33	and	O
34	in	O
35	severe	O
36	myopia	O
37	.	O

1	The	O
2	histological	O
3	grading	O
4	was	O
5	certified	O
6	in	O
7	68	O
8	cases	O
9	:	O
10	12	O
11	G1	O
12	,	O
13	39	O
14	G2	O
15	,	O
16	17	O
17	G3	O
18	;	O
19	extracapsular	O
20	spread	O
21	was	O
22	found	O
23	in	O
24	20	O
25	/	O
26	54	O
27	cases	O
28	(	O
29	37	O
30	%).	O

1	Asthma	O
2	was	O
3	significantly	O
4	more	O
5	often	O
6	associated	O
7	with	O
8	ASA	O
9	group	O
10	(	O
11	91	O
12	%)	O
13	vs	O
14	46	O
15	%	O
16	at	O
17	AT	O
18	and	O
19	in	O
20	only	O
21	16	O
22	%	O
23	at	O
24	INTR	O
25	group	O
26	.	O

1	A	O
2	value	O
3	of	O
4	1	O
5	.	O
6	1	O
7	l	O
8	/	O
9	kg	O
10	was	O
11	used	O
12	for	O
13	V	O
14	in	O
15	calculating	O
16	all	O
17	single	O
18	sample	O
19	estimates	O
20	of	O
21	clearance	O
22	(	O
23	CL	O
24	),	O
25	and	O
26	a	O
27	value	O
28	of	O
29	4	O
30	.	O
31	3	O
32	l	O
33	/	O
34	kg	O
35	was	O
36	used	O
37	to	O
38	calculate	O
39	single	O
40	sample	O
41	estimates	O
42	of	O
43	clearance	O
44	of	O
45	plasma	O
46	unbound	O
47	drug	O
48	(	O
49	CLunb	O
50	).	O

1	The	O
2	solitary	O
3	kidney	O
4	:	O
5	a	O
6	model	O
7	of	O
8	chronic	O
9	hyperfiltration	O
10	in	O
11	humans	O
12	.	O

1	Halothane	O
2	is	O
3	metabolized	O
4	by	O
5	an	O
6	oxidative	O
7	pathway	O
8	to	O
9	stable	O
10	,	O
11	nonvolatile	O
12	end	O
13	products	O
14	,	O
15	trifluoroacetic	O
16	acid	O
17	(	O
18	TFAA	O
19	)	O
20	and	O
21	bromide	O
22	(	O
23	Br	O
24	-),	O
25	and	O
26	by	O
27	reductive	O
28	pathways	O
29	to	O
30	Br	O
31	-	O
32	and	O
33	inorganic	O
34	fluoride	O
35	(	O
36	F	O
37	-).	O

1	The	O
2	values	O
3	were	O
4	consistently	O
5	lower	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	01	O
13	)	O
14	during	O
15	summer	O
16	(	O
17	3	O
18	.	O
19	79	O
20	+/-	O
21	0	O
22	.	O
23	13	O
24	micrograms	O
25	/	O
26	100	O
27	ml	O
28	),	O
29	as	O
30	compared	O
31	to	O
32	winter	O
33	(	O
34	5	O
35	.	O
36	06	O
37	+/-	O
38	0	O
39	.	O
40	27	O
41	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAPE	O
6	-	O
7	S	O
8	-	O
9	S	O
10	are	O
11	prone	O
12	to	O
13	irregular	O
14	nocturnal	O
15	breathing	O
16	patterns	O
17	at	O
18	high	O
19	altitude	O
20	,	O
21	which	O
22	is	O
23	associated	O
24	with	O
25	the	O
26	development	O
27	of	O
28	AMS	O
29	,	O
30	but	O
31	it	O
32	was	O
33	not	O
34	possible	O
35	to	O
36	determine	O
37	whether	O
38	these	O
39	abnormal	O
40	breathing	O
41	patterns	O
42	are	O
43	a	O
44	cause	O
45	or	O
46	an	O
47	effect	O
48	of	O
49	AMS	O
50	.	O

1	Buflomedil	O
2	(	O
3	i	O
4	.	O
5	v	O
6	.)	O
7	induced	O
8	a	O
9	dose	O
10	-	O
11	dependent	O
12	increase	O
13	of	O
14	cardiac	O
15	output	O
16	at	O
17	0	O
18	.	O
19	16	O
20	-	O
21	0	O
22	.	O
23	64	O
24	mg	O
25	/	O
26	kg	O
27	,	O
28	biphasic	O
29	changes	O
30	at	O
31	1	O
32	.	O
33	28	O
34	and	O
35	2	O
36	.	O
37	56	O
38	mg	O
39	/	O
40	kg	O
41	and	O
42	a	O
43	marked	O
44	decrease	O
45	and	O
46	subsequent	O
47	slight	O
48	increase	O
49	at	O
50	a	O
51	large	O
52	dose	O
53	of	O
54	5	O
55	.	O
56	12	O
57	mg	O
58	/	O
59	kg	O
60	.	O

1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O

1	Heart	O
2	rate	O
3	(	O
4	HR	O
5	),	O
6	rectal	O
7	temperature	O
8	(	O
9	Tre	O
10	),	O
11	blood	O
12	pressure	O
13	,	O
14	temperature	O
15	and	O
16	relative	O
17	humidity	O
18	changes	O
19	inside	O
20	clothing	O
21	were	O
22	measured	O
23	on	O
24	18	O
25	professional	O
26	firemen	O
27	(	O
28	mean	O
29	age	O
30	29	O
31	.	O
32	4	O
33	+/-	O
34	7	O
35	.	O
36	4	O
37	yr	O
38	,	O
39	VO2	O
40	max	O
41	41	O
42	.	O
43	4	O
44	+	O
45	8	O
46	.	O
47	8	O
48	ml	O
49	kg	O
50	-	O
51	1	O
52	min	O
53	-	O
54	1	O
55	)	O
56	wearing	O
57	fire	O
58	fighter	O
59	'	O
60	s	O
61	uniforms	O
62	(	O
63	SU	O
64	)	O
65	or	O
66	aluminized	O
67	,	O
68	fire	O
69	resistant	O
70	,	O
71	impermeable	O
72	clothing	O
73	with	O
74	self	O
75	contained	O
76	breathing	O
77	apparatus	O
78	(	O
79	FE	O
80	).	O

1	The	O
2	clinical	O
3	tolerance	O
4	and	O
5	pharmacokinetics	O
6	of	O
7	FCE	O
8	22101	O
9	(	O
10	sodium	O
11	(	O
12	5R	O
13	,	O
14	6S	O
15	)-	O
16	6	O
17	-[(	O
18	1R	O
19	)-	O
20	hydroxyethyl	O
21	]-	O
22	2	O
23	-	O
24	carbamoyloxymethyl	O
25	-	O
26	2	O
27	-	O
28	penem	O
29	-	O
30	3	O
31	-	O
32	carboxylate	O
33	),	O
34	a	O
35	new	O
36	penem	O
37	antibiotic	O
38	,	O
39	have	O
40	been	O
41	studied	O
42	after	O
43	giving	O
44	a	O
45	single	O
46	i	O
47	.	O
48	v	O
49	.	O
50	dose	O
51	of	O
52	4	O
53	mg	O
54	.	O
55	kg	O
56	-	O
57	1	O
58	to	O
59	ten	O
60	healthy	O
61	male	O
62	volunteers	O
63	.	O

1	DNA	O
2	blot	O
3	hybridization	O
4	suggests	O
5	that	O
6	the	O
7	rat	O
8	genome	O
9	may	O
10	contain	O
11	more	O
12	than	O
13	one	O
14	gene	O
15	encoding	O
16	PtdIns	B
17	transfer	I
18	protein	I
19	.	O

1	We	O
2	use	O
3	the	O
4	term	O
5	corticosteroid	O
6	-	O
7	dependent	O
8	IA	O
9	to	O
10	refer	O
11	to	O
12	the	O
13	serious	O
14	problem	O
15	of	O
16	chronic	O
17	IA	O
18	requiring	O
19	maintenance	O
20	prednisone	O
21	therapy	O
22	.	O

1	Another	O
2	segment	O
3	of	O
4	CRL3	B
5	(-	O
6	296	O
7	to	O
8	-	O
9	184	O
10	),	O
11	also	O
12	displaying	O
13	enhancer	O
14	function	O
15	,	O
16	contained	O
17	tandem	O
18	repeated	O
19	sequences	O
20	(	O
21	DR	O
22	-	O
23	A1	O
24	and	O
25	DR	O
26	-	O
27	A2	O
28	).	O

1	1	O
2	-(	O
3	1	O
4	-	O
5	Naphthyl	O
6	)	O
7	piperazine	O
8	(	O
9	1	O
10	-	O
11	NP	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	B
24	-	I
25	HT2	I
26	subtype	I
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	actions	O
41	at	O
42	the	O
43	5	B
44	-	I
45	HT1	I
46	site	I
47	.	O

1	1	O
2	-(	O
3	m	O
4	-	O
5	Chlorophenyl	O
6	)	O
7	piperazine	O
8	(	O
9	mCPP	O
10	,	O
11	0	O
12	.	O
13	1	O
14	-	O
15	3	O
16	.	O
17	0	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	1	O
24	-(	O
25	m	O
26	-	O
27	trifluoromethylphenyl	O
28	)	O
29	piperazine	O
30	(	O
31	TFMPP	O
32	,	O
33	0	O
34	.	O
35	1	O
36	-	O
37	3	O
38	.	O
39	0	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	both	O
45	thought	O
46	to	O
47	act	O
48	primarily	O
49	at	O
50	5	B
51	-	I
52	HT1	I
53	sites	I
54	,	O
55	also	O
56	decreased	O
57	responding	O
58	and	O
59	this	O
60	effect	O
61	was	O
62	blocked	O
63	by	O
64	methysergide	O
65	and	O
66	by	O
67	1	O
68	-	O
69	NP	O
70	,	O
71	but	O
72	not	O
73	by	O
74	ketanserin	O
75	.	O

1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	B
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	B
57	.	O

1	Changes	O
2	in	O
3	xanthine	B
4	oxidase	I
5	activity	O
6	in	O
7	patients	O
8	with	O
9	circulatory	O
10	failure	O

1	A	O
2	soap	O
3	and	O
4	water	O
5	(	O
6	1	O
7	:	O
8	1	O
9	,	O
10	v	O
11	/	O
12	v	O
13	)	O
14	solution	O
15	effectively	O
16	decontaminated	O
17	powdered	O
18	stratum	O
19	corneum	O
20	.	O

1	The	O
2	cytoprotective	O
3	and	O
4	antiulcer	O
5	activities	O
6	of	O
7	the	O
8	antacid	O
9	magaldrate	O
10	(	O
11	ES	O
12	Riopan	O
13	)	O
14	as	O
15	well	O
16	as	O
17	its	O
18	effects	O
19	on	O
20	gastric	O
21	mucosal	O
22	blood	O
23	flow	O
24	and	O
25	mucus	O
26	secretions	O
27	,	O
28	were	O
29	determined	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	The	O
2	human	O
3	immunodeficiency	O
4	virus	O
5	type	O
6	1	O
7	(	O
8	HIV	O
9	-	O
10	1	O
11	)	O
12	preferentially	O
13	infects	O
14	CD4	B
15	+	I
16	T	O
17	lymphocytes	O
18	and	O
19	may	O
20	exist	O
21	as	O
22	a	O
23	latent	O
24	provirus	O
25	within	O
26	these	O
27	cells	O
28	for	O
29	extended	O
30	periods	O
31	.	O

1	Histiocytic	O
2	panniculitis	O
3	was	O
4	observed	O
5	in	O
6	biopsy	O
7	specimens	O
8	with	O
9	cytophagocytosis	O
10	.	O

1	We	O
2	have	O
3	utilized	O
4	the	O
5	human	B
6	4F2	I
7	heavy	I
8	chain	I
9	(	O
10	4F2HC	B
11	)	O
12	gene	O
13	as	O
14	a	O
15	model	O
16	system	O
17	in	O
18	studies	O
19	designed	O
20	to	O
21	elucidate	O
22	the	O
23	molecular	O
24	events	O
25	involved	O
26	in	O
27	regulating	O
28	inducible	O
29	gene	O
30	expression	O
31	during	O
32	normal	O
33	human	O
34	T	O
35	-	O
36	cell	O
37	activation	O
38	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	the	O
5	NF	B
6	-	I
7	4FB	I
8	enhancer	I
9	binding	I
10	protein	I
11	has	O
12	been	O
13	cloned	O
14	by	O
15	screening	O
16	a	O
17	lambda	O
18	gt11	O
19	cDNA	O
20	library	O
21	with	O
22	a	O
23	rabiolabelled	O
24	oligonucleotide	O
25	corresponding	O
26	to	O
27	the	O
28	NF	B
29	-	I
30	4FB	I
31	recognition	I
32	sequence	I
33	.	O

1	Electrocardiographic	O
2	right	O
3	ventricular	O
4	hypertrophy	O
5	was	O
6	seen	O
7	in	O
8	4	O
9	,	O
10	and	O
11	biventricular	O
12	hypertrophy	O
13	in	O
14	5	O
15	patients	O
16	.	O

1	The	O
2	two	O
3	IL6	B
4	mRNA	I
5	species	O
6	are	O
7	generated	O
8	by	O
9	alternative	O
10	polyadenylation	O
11	at	O
12	sites	O
13	separated	O
14	by	O
15	a	O
16	distance	O
17	of	O
18	1	O
19	.	O
20	2	O
21	kilobases	O
22	.	O

1	Sequencing	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	0	O
7	.	O
8	54	O
9	-	O
10	and	O
11	0	O
12	.	O
13	4	O
14	-	O
15	kb	O
16	fragments	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	150	O
22	nucleotides	O
23	missing	O
24	at	O
25	the	O
26	5	O
27	'	O
28	region	O
29	of	O
30	the	O
31	0	O
32	.	O
33	4	O
34	-	O
35	kb	O
36	fragment	O
37	.	O

1	The	O
2	mature	O
3	protein	O
4	also	O
5	contains	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	,	O
11	highly	O
12	hydrophilic	O
13	region	O
14	homologous	O
15	to	O
16	the	O
17	ovomucoid	B
18	serine	I
19	protease	I
20	inhibitors	I
21	(	O
22	residues	O
23	76	O
24	-	O
25	132	O
26	).	O

1	Oligosynaptic	O
2	EPSP	O
3	components	O
4	were	O
5	consistently	O
6	modulated	O
7	only	O
8	in	O
9	the	O
10	superficial	O
11	peroneal	O
12	responses	O
13	in	O
14	flexor	O
15	motoneurons	O
16	,	O
17	which	O
18	exhibited	O
19	enhanced	O
20	amplitude	O
21	during	O
22	the	O
23	flexion	O
24	phase	O
25	.	O

1	Experiments	O
2	on	O
3	23	O
4	white	O
5	rats	O
6	and	O
7	10	O
8	guinea	O
9	pigs	O
10	have	O
11	shown	O
12	that	O
13	preliminarily	O
14	indomethacin	O
15	-	O
16	induced	O
17	inhibition	O
18	of	O
19	prostaglandins	O
20	synthesis	O
21	prevented	O
22	development	O
23	of	O
24	pulmonary	O
25	oedema	O
26	,	O
27	evoked	O
28	by	O
29	heterologous	O
30	serum	O
31	in	O
32	rats	O
33	and	O
34	by	O
35	vagotomy	O
36	in	O
37	guinea	O
38	pigs	O
39	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	lack	O
7	of	O
8	conservation	O
9	of	O
10	the	O
11	membrane	O
12	attachment	O
13	sequence	O
14	arginine	O
15	-	O
16	glycine	O
17	-	O
18	aspartic	O
19	acid	O
20	argues	O
21	against	O
22	its	O
23	functional	O
24	importance	O
25	in	O
26	CgA	B
27	.	O

1	Third	O
2	-	O
3	and	O
4	later	O
5	-	O
6	parity	O
7	cows	O
8	were	O
9	randomly	O
10	assigned	O
11	after	O
12	each	O
13	parturition	O
14	to	O
15	Charolais	O
16	and	O
17	Red	O
18	Poll	O
19	bulls	O
20	in	O
21	multiple	O
22	-	O
23	sire	O
24	pastures	O
25	.	O

1	Within	O
2	each	O
3	lobe	O
4	,	O
5	the	O
6	PA	O
7	dispersion	O
8	was	O
9	up	O
10	to	O
11	10	O
12	cmH2O	O
13	at	O
14	CFV	O
15	of	O
16	90	O
17	l	O
18	/	O
19	min	O
20	;	O
21	when	O
22	flow	O
23	decreased	O
24	,	O
25	PA	O
26	at	O
27	all	O
28	sites	O
29	decreased	O
30	,	O
31	as	O
32	did	O
33	the	O
34	intralobar	O
35	dispersion	O
36	.	O

1	The	O
2	system	O
3	consisted	O
4	of	O
5	the	O
6	intact	O
7	canine	O
8	heart	O
9	connected	O
10	to	O
11	a	O
12	microcomputer	O
13	that	O
14	operated	O
15	as	O
16	the	O
17	modulated	O
18	parasystolic	O
19	pacemaker	O
20	.	O

1	In	O
2	order	O
3	to	O
4	identify	O
5	and	O
6	classify	O
7	the	O
8	basic	O
9	CT	O
10	appearances	O
11	of	O
12	interstitial	O
13	pneumonia	O
14	,	O
15	radiologic	O
16	-	O
17	pathologic	O
18	correlative	O
19	study	O
20	was	O
21	performed	O
22	using	O
23	inflated	O
24	and	O
25	fixed	O
26	lungs	O
27	from	O
28	autopsy	O
29	and	O
30	surgery	O
31	.	O

1	The	O
2	disease	O
3	ran	O
4	an	O
5	atypical	O
6	course	O
7	;	O
8	with	O
9	early	O
10	jaundice	O
11	syndrome	O
12	,	O
13	severe	O
14	enterorrhagia	O
15	and	O
16	late	O
17	appearance	O
18	of	O
19	roseola	O
20	.	O

1	The	O
2	transcription	O
3	factor	O
4	Sp1	B
5	bound	O
6	to	O
7	eight	O
8	sites	O
9	,	O
10	as	O
11	demonstrated	O
12	by	O
13	footprinting	O
14	assays	O
15	and	O
16	gel	O
17	shift	O
18	analysis	O
19	with	O
20	purified	O
21	Sp1	B
22	.	O

1	The	O
2	combination	O
3	PIP	O
4	64	O
5	micrograms	O
6	-	O
7	PEF	O
8	4	O
9	micrograms	O
10	prevents	O
11	the	O
12	frequent	O
13	secondary	O
14	regrowth	O
15	seen	O
16	after	O
17	6	O
18	hours	O
19	with	O
20	the	O
21	antibiotics	O
22	used	O
23	alone	O
24	.	O

1	With	O
2	a	O
3	sample	O
4	of	O
5	mothers	O
6	of	O
7	healthy	O
8	infants	O
9	,	O
10	all	O
11	three	O
12	subscales	O
13	of	O
14	the	O
15	revised	O
16	instrument	O
17	,	O
18	WPL	O
19	-	O
20	R	O
21	,	O
22	had	O
23	acceptable	O
24	levels	O
25	of	O
26	internal	O
27	consistency	O
28	at	O
29	7	O
30	,	O
31	30	O
32	,	O
33	and	O
34	90	O
35	days	O
36	postpartum	O
37	,	O
38	and	O
39	stability	O
40	across	O
41	administrations	O
42	.	O

1	Since	O
2	1948	O
3	,	O
4	the	O
5	use	O
6	of	O
7	saline	O
8	-	O
9	washed	O
10	red	O
11	cells	O
12	(	O
13	WRBCs	O
14	)	O
15	has	O
16	been	O
17	advocated	O
18	to	O
19	minimize	O
20	hemolysis	O
21	after	O
22	transfusion	O
23	to	O
24	patients	O
25	with	O
26	PNH	O
27	.	O

1	In	O
2	the	O
3	group	O
4	of	O
5	asthmatics	O
6	statistically	O
7	significant	O
8	correlation	O
9	was	O
10	found	O
11	between	O
12	PC20	O
13	PGF2	O
14	alpha	O
15	and	O
16	histamine	O
17	values	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	538	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	05	O
31	).	O

1	Acute	O
2	experiments	O
3	on	O
4	nembutal	O
5	-	O
6	anesthetized	O
7	cats	O
8	(	O
9	50	O
10	mg	O
11	/	O
12	kg	O
13	)	O
14	were	O
15	employed	O
16	to	O
17	investigate	O
18	the	O
19	effect	O
20	of	O
21	1	O
22	T	O
23	pulsating	O
24	magnetic	O
25	field	O
26	(	O
27	PMF	O
28	)	O
29	on	O
30	neuromuscular	O
31	system	O
32	of	O
33	the	O
34	leg	O
35	.	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	between	O
7	the	O
8	TS	O
9	and	O
10	the	O
11	PTS	O
12	.	O

1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	O
23	trochoidea	O
24	Stein	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	O
53	(	O
54	25	O
55	microEin	O
56	m	O
57	-	O
58	2	O
59	s	O
60	-	O
61	1	O
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O

1	A	O
2	genomic	O
3	DNA	O
4	clone	O
5	encoding	O
6	oryzacystatin	B
7	(	O
8	Oc	B
9	),	O
10	a	O
11	cysteine	B
12	proteinase	I
13	inhibitor	O
14	(	O
15	cystatin	B
16	)	O
17	of	O
18	rice	O
19	,	O
20	was	O
21	isolated	O
22	from	O
23	a	O
24	lambda	O
25	EMBL3	O
26	phage	O
27	library	O
28	constructed	O
29	with	O
30	Sau3AI	B
31	partial	O
32	digests	O
33	of	O
34	rice	O
35	chromosomal	O
36	DNA	O
37	,	O
38	by	O
39	screening	O
40	with	O
41	an	O
42	oc	B
43	cDNA	I
44	as	O
45	a	O
46	probe	O
47	.	O

1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O

1	Lower	O
2	limits	O
3	(	O
4	to	O
5	10	O
6	micrograms	O
7	/	O
8	kg	O
9	)	O
10	were	O
11	detectable	O
12	,	O
13	but	O
14	with	O
15	lower	O
16	reliability	O
17	(	O
18	60	O
19	%).	O

1	Instead	O
2	,	O
3	some	O
4	small	O
5	negative	O
6	effects	O
7	are	O
8	observed	O
9	,	O
10	particularly	O
11	involving	O
12	effects	O
13	of	O
14	husbands	O
15	'	O
16	retirement	O
17	on	O
18	the	O
19	marital	O
20	satisfaction	O
21	of	O
22	employed	O
23	wives	O
24	.	O

1	This	O
2	in	O
3	turn	O
4	will	O
5	further	O
6	enhance	O
7	the	O
8	role	O
9	of	O
10	meta	O
11	-	O
12	analysis	O
13	in	O
14	helping	O
15	clinicians	O
16	and	O
17	policy	O
18	makers	O
19	answer	O
20	clinical	O
21	questions	O
22	.	O

1	In	O
2	one	O
3	acromegalic	O
4	patient	O
5	visual	O
6	improvement	O
7	was	O
8	obtained	O
9	while	O
10	the	O
11	abnormal	O
12	GH	B
13	secretion	O
14	remained	O
15	unaltered	O
16	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	PPSF	O
6	+	O
7	DBP	O
8	side	O
9	showed	O
10	large	O
11	amounts	O
12	of	O
13	bone	O
14	formation	O
15	,	O
16	and	O
17	bone	O
18	almost	O
19	covered	O
20	the	O
21	implant	O
22	.	O

1	The	O
2	accuracies	O
3	of	O
4	presence	O
5	or	O
6	absence	O
7	of	O
8	neuroblastoma	O
9	were	O
10	compared	O
11	between	O
12	131I	O
13	-	O
14	MIBG	O
15	imaging	O
16	and	O
17	several	O
18	tumor	O
19	markers	O
20	.	O

1	The	O
2	congenital	O
3	forms	O
4	(	O
5	7	O
6	cases	O
7	)	O
8	all	O
9	occurred	O
10	in	O
11	female	O
12	infants	O
13	and	O
14	involved	O
15	the	O
16	mucosa	O
17	overlying	O
18	either	O
19	the	O
20	anterior	O
21	ridge	O
22	of	O
23	the	O
24	maxilla	O
25	or	O
26	the	O
27	mandible	O
28	.	O

1	Immunohistochemical	O
2	studies	O
3	revealed	O
4	positive	O
5	staining	O
6	for	O
7	S100	B
8	protein	I
9	in	O
10	all	O
11	the	O
12	granular	O
13	cell	O
14	tumors	O
15	of	O
16	the	O
17	adult	O
18	but	O
19	in	O
20	none	O
21	of	O
22	the	O
23	congenital	O
24	granular	O
25	cell	O
26	epulides	O
27	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	the	O
6	same	O
7	males	O
8	,	O
9	breeding	O
10	in	O
11	different	O
12	years	O
13	on	O
14	the	O
15	same	O
16	territories	O
17	,	O
18	had	O
19	significantly	O
20	larger	O
21	harems	O
22	in	O
23	the	O
24	years	O
25	they	O
26	had	O
27	familiar	O
28	neighbors	O
29	.	O

1	Male	B
2	-	I
3	enhanced	I
4	antigen	I
5	gene	I
6	is	O
7	phylogenetically	O
8	conserved	O
9	and	O
10	expressed	O
11	at	O
12	late	O
13	stages	O
14	of	O
15	spermatogenesis	O
16	.	O

1	In	O
2	rats	O
3	bearing	O
4	Walker	O
5	-	O
6	256	O
7	-	O
8	carcinosarcoma	O
9	4	O
10	-	O
11	EPI	O
12	was	O
13	effective	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	Pacing	O
2	the	O
3	Roux	O
4	limb	O
5	abolished	O
6	the	O
7	ectopic	O
8	pacemakers	O
9	,	O
10	restored	O
11	the	O
12	slow	O
13	emptying	O
14	of	O
15	liquids	O
16	to	O
17	the	O
18	more	O
19	rapid	O
20	rate	O
21	found	O
22	in	O
23	the	O
24	Billroth	O
25	dogs	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	:	O
31	paced	O
32	Roux	O
33	,	O
34	72	O
35	+/-	O
36	15	O
37	minutes	O
38	;	O
39	Billroth	O
40	,	O
41	43	O
42	+/-	O
43	9	O
44	minutes	O
45	;	O
46	p	O
47	greater	O
48	than	O
49	0	O
50	.	O
51	05	O
52	)	O
53	and	O
54	did	O
55	not	O
56	change	O
57	emptying	O
58	of	O
59	solids	O
60	.	O

1	The	O
2	treatments	O
3	were	O
4	60	O
5	mg	O
6	t	O
7	.	O
8	i	O
9	.	O
10	d	O
11	.	O
12	and	O
13	120	O
14	mg	O
15	t	O
16	.	O
17	i	O
18	.	O
19	d	O
20	.	O
21	during	O
22	14	O
23	days	O
24	'	O
25	treatment	O
26	,	O
27	with	O
28	the	O
29	last	O
30	dose	O
31	pulsed	O
32	with	O
33	1	O
34	.	O
35	85	O
36	MBq	O
37	[	O
38	14C	O
39	]	O
40	diltiazem	O
41	.	O

1	The	O
2	subepicardial	O
3	lymphatic	O
4	capillaries	O
5	were	O
6	ramified	O
7	and	O
8	anastomosed	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	dense	O
17	network	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	ventricles	O
27	.	O

1	The	O
2	examination	O
3	must	O
4	include	O
5	T1	O
6	and	O
7	T2	O
8	sequences	O
9	and	O
10	scans	O
11	in	O
12	three	O
13	planes	O
14	.	O

1	A	O
2	great	O
3	deal	O
4	of	O
5	information	O
6	is	O
7	available	O
8	on	O
9	the	O
10	morphology	O
11	of	O
12	the	O
13	claustrum	O
14	in	O
15	various	O
16	animal	O
17	species	O
18	,	O
19	as	O
20	well	O
21	as	O
22	on	O
23	its	O
24	neuronal	O
25	distribution	O
26	and	O
27	relationships	O
28	with	O
29	the	O
30	cerebral	O
31	cortex	O
32	and	O
33	other	O
34	nuclei	O
35	.	O

1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O

1	In	O
2	terms	O
3	of	O
4	sequence	O
5	repetitions	O
6	,	O
7	seven	O
8	tandemly	O
9	repeated	O
10	copies	O
11	of	O
12	the	O
13	hexanucleotide	O
14	ATTGTT	O
15	and	O
16	three	O
17	flanking	O
18	regions	O
19	of	O
20	dyad	O
21	symmetry	O
22	were	O
23	detected	O
24	,	O
25	all	O
26	in	O
27	ORF	O
28	T3C	O
29	.	O

1	The	O
2	significance	O
3	of	O
4	these	O
5	palindromic	O
6	domains	O
7	in	O
8	this	O
9	ORF	O
10	is	O
11	unclear	O
12	but	O
13	the	O
14	coincidence	O
15	of	O
16	the	O
17	end	O
18	of	O
19	one	O
20	larger	O
21	palindrome	O
22	with	O
23	the	O
24	end	O
25	of	O
26	the	O
27	translated	O
28	protein	O
29	sequence	O
30	that	O
31	has	O
32	homology	O
33	with	O
34	the	O
35	B	O
36	chain	O
37	of	O
38	insulin	B
39	suggests	O
40	that	O
41	the	O
42	palindromes	O
43	may	O
44	divide	O
45	the	O
46	T2	B
47	protein	I
48	into	O
49	several	O
50	functional	O
51	units	O
52	.	O

1	During	O
2	sub	O
3	-	O
4	maximal	O
5	exercise	O
6	,	O
7	DCR	O
8	in	O
9	the	O
10	UT	O
11	dogs	O
12	decreased	O
13	from	O
14	a	O
15	resting	O
16	value	O
17	of	O
18	4	O
19	.	O
20	08	O
21	+/-	O
22	0	O
23	.	O
24	18	O
25	mm	O
26	Hg	O
27	X	O
28	ml	O
29	-	O
30	1	O
31	X	O
32	min	O
33	-	O
34	1	O
35	to	O
36	1	O
37	.	O
38	91	O
39	+/-	O
40	0	O
41	.	O
42	17	O
43	mm	O
44	Hg	O
45	X	O
46	ml	O
47	-	O
48	1	O
49	X	O
50	min	O
51	-	O
52	1	O
53	at	O
54	a	O
55	workload	O
56	of	O
57	6	O
58	.	O
59	4	O
60	kph	O
61	(	O
62	speed	O
63	)/	O
64	16	O
65	%	O
66	(	O
67	grade	O
68	).	O

1	7	O
2	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	G	B
7	-	I
8	protein	I
9	gene	I
10	family	I
11	may	O
12	be	O
13	distributed	O
14	over	O
15	at	O
16	least	O
17	two	O
18	human	O
19	chromosomes	O
20	.	O

1	The	O
2	major	O
3	inserted	O
4	DNA	O
5	has	O
6	no	O
7	significant	O
8	homology	O
9	to	O
10	published	O
11	human	O
12	nucleic	O
13	acid	O
14	sequences	O
15	.	O

1	In	O
2	44	O
3	evaluable	O
4	patients	O
5	the	O
6	response	O
7	rate	O
8	was	O
9	50	O
10	%,	O
11	with	O
12	one	O
13	complete	O
14	response	O
15	.	O

1	We	O
2	have	O
3	also	O
4	found	O
5	that	O
6	the	O
7	in	O
8	vitro	O
9	interaction	O
10	between	O
11	the	O
12	SV40	O
13	octamer	O
14	motif	O
15	and	O
16	the	O
17	lymphoid	B
18	cell	I
19	-	I
20	specific	I
21	protein	I
22	oct	I
23	-	I
24	B2	I
25	was	O
26	negatively	O
27	modulated	O
28	by	O
29	a	O
30	component	O
31	present	O
32	in	O
33	the	O
34	nuclear	O
35	extracts	O
36	from	O
37	several	O
38	lymphoid	O
39	cell	O
40	lines	O
41	.	O

1	Anoxia	O
2	was	O
3	introduced	O
4	by	O
5	perfusing	O
6	the	O
7	gill	O
8	with	O
9	water	O
10	deprived	O
11	of	O
12	oxygen	O
13	or	O
14	by	O
15	halting	O
16	the	O
17	water	O
18	flow	O
19	to	O
20	the	O
21	gill	O
22	.	O

1	Growth	O
2	,	O
3	4	O
4	-	O
5	PA	O
6	and	O
7	14C	O
8	turnover	O
9	data	O
10	indicated	O
11	that	O
12	WB	O
13	contributed	O
14	to	O
15	B	O
16	-	O
17	6	O
18	intake	O
19	of	O
20	these	O
21	rats	O
22	.	O

1	Thus	O
2	,	O
3	multiple	O
4	myogenic	O
5	factors	O
6	that	O
7	vary	O
8	qualitatively	O
9	and	O
10	quantitatively	O
11	may	O
12	be	O
13	responsible	O
14	for	O
15	the	O
16	different	O
17	and	O
18	complex	O
19	modulatory	O
20	programs	O
21	of	O
22	actin	B
23	gene	I
24	expression	O
25	observed	O
26	during	O
27	in	O
28	vivo	O
29	muscle	O
30	differentiation	O
31	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	these	O
7	clones	O
8	encode	O
9	two	O
10	distinct	O
11	forms	O
12	of	O
13	translocase	B
14	.	O

1	The	O
2	effect	O
3	of	O
4	acetazolamide	O
5	(	O
6	ACZ	O
7	)	O
8	on	O
9	HCO3	O
10	-	O
11	and	O
12	Cl	O
13	-	O
14	activities	O
15	in	O
16	inner	O
17	ear	O
18	fluid	O
19	was	O
20	investigated	O
21	by	O
22	ion	O
23	-	O
24	selective	O
25	microelectrode	O
26	methods	O
27	.	O

1	RPA190	B
2	encodes	O
3	a	O
4	polypeptide	O
5	chain	O
6	of	O
7	186	O
8	,	O
9	270	O
10	daltons	O
11	in	O
12	a	O
13	large	O
14	uninterrupted	O
15	reading	O
16	frame	O
17	.	O

1	Both	O
2	the	O
3	intact	B
4	A1	I
5	protein	I
6	and	O
7	its	O
8	proteolytic	O
9	fragment	O
10	,	O
11	the	O
12	UP1	B
13	protein	I
14	,	O
15	can	O
16	be	O
17	cleaved	O
18	by	O
19	Staphylococcus	B
20	aureus	I
21	V	I
22	-	I
23	8	I
24	protease	I
25	to	O
26	produce	O
27	two	O
28	polypeptides	O
29	of	O
30	92	O
31	amino	O
32	acids	O
33	.	O

1	Irmiere	O
2	,	O
3	and	O
4	W	O
5	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	Simian	O
2	immunodeficiency	O
3	virus	O
4	(	O
5	SIV	O
6	)	O
7	is	O
8	a	O
9	lentivirus	O
10	with	O
11	morphological	O
12	and	O
13	antigenic	O
14	similarities	O
15	to	O
16	human	O
17	immunodeficiency	O
18	virus	O
19	,	O
20	the	O
21	causative	O
22	agent	O
23	of	O
24	acquired	O
25	immunodeficiency	O
26	syndrome	O
27	(	O
28	AIDS	O
29	)	O
30	of	O
31	humans	O
32	.	O

1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	B
21	'-	I
22	rearranged	I
23	myb	I
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O

1	The	O
2	use	O
3	of	O
4	CRF	B
5	-	I
6	41	I
7	in	O
8	the	O
9	differential	O
10	diagnosis	O
11	of	O
12	Cushing	O
13	'	O
14	s	O
15	syndrome	O
16	and	O
17	obesity	O
18	.	O

1	We	O
2	detected	O
3	mos	B
4	transcripts	I
5	by	O
6	Northern	O
7	(	O
8	RNA	O
9	)	O
10	analyses	O
11	in	O
12	RNA	O
13	prepared	O
14	from	O
15	chicken	O
16	and	O
17	quail	O
18	ovaries	O
19	and	O
20	testes	O
21	.	O

1	The	O
2	predicted	O
3	L	B
4	mRNA	I
5	was	O
6	6398	O
7	nucleotides	O
8	long	O
9	and	O
10	contained	O
11	a	O
12	single	O
13	open	O
14	reading	O
15	frame	O
16	corresponding	O
17	to	O
18	an	O
19	L	B
20	protein	I
21	encompassing	I
22	2109	I
23	amino	I
24	acids	I
25	with	O
26	a	O
27	MW	O
28	of	O
29	241	O
30	,	O
31	546	O
32	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	organization	O
7	of	O
8	functional	O
9	units	O
10	of	O
11	the	O
12	72	O
13	-	O
14	bp	O
15	repeat	O
16	required	O
17	for	O
18	transcriptional	O
19	enhancement	O
20	of	O
21	the	O
22	early	O
23	promoter	O
24	is	O
25	different	O
26	from	O
27	that	O
28	required	O
29	for	O
30	late	O
31	promoter	O
32	function	O
33	.	O

1	Variations	O
2	in	O
3	the	O
4	5	O
5	'	O
6	half	O
7	of	O
8	U3	O
9	were	O
10	primarily	O
11	due	O
12	to	O
13	insertions	O
14	and	O
15	deletions	O
16	.	O

1	An	O
2	analysis	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	RNA	O
8	levels	O
9	in	O
10	T	O
11	-	O
12	lymphoid	O
13	cell	O
14	lines	O
15	showed	O
16	that	O
17	at	O
18	least	O
19	three	O
20	different	O
21	incomplete	O
22	proviral	O
23	transcripts	O
24	and	O
25	their	O
26	spliced	O
27	products	O
28	made	O
29	up	O
30	the	O
31	majority	O
32	of	O
33	expressed	O
34	RD	B
35	-	I
36	114	I
37	mRNA	I
38	,	O
39	and	O
40	further	O
41	demonstrated	O
42	that	O
43	partially	O
44	deleted	O
45	proviral	O
46	loci	O
47	have	O
48	the	O
49	potential	O
50	to	O
51	be	O
52	transcriptionally	O
53	vigorous	O
54	in	O
55	certain	O
56	feline	O
57	cell	O
58	types	O
59	.	O

1	Aplastic	O
2	crisis	O
3	in	O
4	sickle	O
5	cell	O
6	disorders	O
7	:	O
8	bone	O
9	marrow	O
10	necrosis	O
11	and	O
12	human	O
13	parvovirus	O
14	infection	O
15	.	O

1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	The	O
2	bactericidal	O
3	activity	O
4	of	O
5	six	O
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	O
15	22250	O
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	O
32	)	O
33	and	O
34	CGP	O
35	27557	O
36	(	O
37	C27	O
38	)	O
39	and	O
40	rifampicin	O
41	(	O
42	RMP	O
43	)--	O
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	O
52	as	O
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	O

1	Mo	O
2	+	O
3	SV	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	inoculated	O
9	animals	O
10	became	O
11	moribund	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	postinoculation	O
18	,	O
19	whereas	O
20	delta	O
21	Mo	O
22	+	O
23	SV	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	inoculated	O
29	animals	O
30	became	O
31	moribund	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	postinoculation	O
38	.	O

1	Sodium	O
2	dodecyl	O
3	sulphate	O
4	-	O
5	induced	O
6	cleavage	O
7	by	O
8	eukaryotic	B
9	topoisomerase	I
10	I	I
11	is	O
12	known	O
13	to	O
14	yield	O
15	enzyme	O
16	covalently	O
17	attached	O
18	to	O
19	the	O
20	3	O
21	'	O
22	cut	O
23	end	O
24	of	O
25	the	O
26	DNA	O
27	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	of	O
5	one	O
6	human	O
7	liver	O
8	clone	O
9	(	O
10	HL	O
11	-	O
12	14	O
13	)	O
14	was	O
15	identical	O
16	to	O
17	the	O
18	rabbit	B
19	skeletal	I
20	muscle	I
21	phosphatase	I
22	2A	I
23	cDNA	I
24	(	O
25	with	O
26	97	O
27	%	O
28	nucleotide	O
29	identity	O
30	).	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	RVEF	O
2	and	O
3	LVEF	O
4	both	O
5	increased	O
6	by	O
7	about	O
8	14	O
9	%	O
10	(	O
11	p	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	and	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	01	O
24	).	O

1	The	O
2	levels	O
3	of	O
4	NPY	B
5	-	O
6	ir	O
7	in	O
8	the	O
9	rat	O
10	vas	O
11	deferens	O
12	were	O
13	not	O
14	affected	O
15	by	O
16	either	O
17	surgical	O
18	or	O
19	pharmacological	O
20	treatment	O
21	.	O

1	Quantitative	O
2	assays	O
3	in	O
4	which	O
5	the	O
6	activity	O
7	of	O
8	the	O
9	synthetic	B
10	alpha	I
11	s	I
12	-	I
13	1	I
14	was	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	native	O
20	purified	O
21	human	B
22	erythrocyte	I
23	type	I
24	-	I
25	1	I
26	Gs	I
27	,	O
28	indicated	O
29	that	O
30	the	O
31	two	O
32	products	O
33	are	O
34	equipotent	O
35	within	O
36	a	O
37	2	O
38	-	O
39	fold	O
40	margin	O
41	of	O
42	error	O
43	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	E2	B
6	proteins	I
7	had	O
8	little	O
9	or	O
10	no	O
11	stimulatory	O
12	effect	O
13	on	O
14	the	O
15	transcriptional	O
16	activity	O
17	of	O
18	the	O
19	HPV	B
20	-	I
21	11	I
22	enhancer	I
23	-	O
24	SV40	B
25	promoter	I
26	.	O

1	The	O
2	mechanism	O
3	by	O
4	which	O
5	E2	B
6	-	I
7	C	I
8	represses	O
9	E2	B
10	-	I
11	dependent	I
12	enhancer	I
13	activity	O
14	most	O
15	likely	O
16	involves	O
17	competition	O
18	with	O
19	E2	B
20	for	O
21	binding	O
22	to	O
23	a	O
24	common	O
25	transcriptional	O
26	regulatory	O
27	site	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	Accurate	O
2	evaluation	O
3	of	O
4	the	O
5	treatment	O
6	results	O
7	in	O
8	unresectable	O
9	lung	O
10	cancer	O
11	patients	O
12	must	O
13	take	O
14	the	O
15	strong	O
16	prognostic	O
17	factors	O
18	into	O
19	account	O
20	.	O

1	(	O
2	anti	B
3	-	I
4	IIa	I
5	)	O
6	and	O
7	Holmer	O
8	et	O
9	al	O
10	.	O

1	Introduction	O
2	of	O
3	v	B
4	-	I
5	fms	I
6	into	O
7	a	O
8	CSF	B
9	-	I
10	1	I
11	dependent	O
12	murine	O
13	macrophage	O
14	cell	O
15	line	O
16	induced	O
17	factor	O
18	independence	O
19	and	O
20	tumorigenicity	O
21	by	O
22	a	O
23	nonautocrine	O
24	mechanism	O
25	.	O

1	Chronic	O
2	E	O
3	-	O
4	B	O
5	virus	O
6	infection	O
7	terminated	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O

1	The	O
2	primary	O
3	structure	O
4	and	O
5	cotranscription	O
6	of	O
7	the	O
8	petCA	B
9	genes	I
10	encoding	O
11	the	O
12	Rieske	B
13	-	I
14	FeS	I
15	(	O
16	nuclear	B
17	encoded	I
18	in	I
19	plants	I
20	)	O
21	and	O
22	apocytochrome	B
23	f	I
24	proteins	I
25	has	O
26	been	O
27	described	O
28	previously	O
29	(	O
30	Kallas	O
31	,	O
32	T	O
33	.,	O
34	Spiller	O
35	,	O
36	S	O
37	.,	O
38	and	O
39	Malkin	O
40	,	O
41	R	O
42	.	O

1	The	O
2	Nostoc	O
3	petBD	B
4	genes	I
5	are	O
6	not	O
7	closely	O
8	linked	O
9	to	O
10	the	O
11	psbB	B
12	gene	I
13	(	O
14	encoding	O
15	the	O
16	51	O
17	-	O
18	kDa	O
19	photosystem	B
20	II	I
21	polypeptide	I
22	)	O
23	and	O
24	do	O
25	not	O
26	contain	O
27	introns	O
28	as	O
29	do	O
30	the	O
31	closely	O
32	related	O
33	chloroplast	O
34	genes	O
35	.	O

1	RNA	O
2	blot	O
3	hybridizations	O
4	identified	O
5	an	O
6	1	O
7	.	O
8	8	O
9	-	O
10	kb	O
11	mRNA	O
12	common	O
13	to	O
14	cytochrome	B
15	b6	I
16	and	O
17	subunit	O
18	IV	O
19	,	O
20	and	O
21	an	O
22	intensely	O
23	hybridizing	O
24	0	O
25	.	O
26	8	O
27	-	O
28	kb	O
29	mRNA	O
30	specific	O
31	to	O
32	the	O
33	subunit	O
34	IV	O
35	gene	O
36	probe	O
37	.	O

1	Whereas	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	997	O
8	amino	O
9	acids	O
10	and	O
11	terminates	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	Ile	O
18	-	O
19	Leu	O
20	-	O
21	Glu	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	1043	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O

1	Substitution	O
2	of	O
3	a	O
4	threonine	O
5	residue	O
6	by	O
7	an	O
8	alanine	O
9	residue	O
10	at	O
11	position	O
12	-	O
13	2	O
14	(	O
15	P2	O
16	)	O
17	of	O
18	this	O
19	cleavage	O
20	site	O
21	abolished	O
22	cleavage	O
23	,	O
24	whereas	O
25	substitution	O
26	of	O
27	a	O
28	tyrosine	O
29	residue	O
30	by	O
31	a	O
32	phenylalanine	O
33	residue	O
34	at	O
35	amino	O
36	acid	O
37	position	O
38	-	O
39	1	O
40	(	O
41	P1	O
42	)	O
43	of	O
44	the	O
45	cleavage	O
46	site	O
47	did	O
48	not	O
49	influence	O
50	processing	O
51	.	O

1	All	O
2	of	O
3	the	O
4	indigo	O
5	-	O
6	producing	O
7	bacteria	O
8	had	O
9	an	O
10	indoxyl	B
11	phosphatase	I
12	with	O
13	a	O
14	pI	O
15	of	O
16	6	O
17	.	O
18	4	O
19	.	O

1	The	O
2	number	O
3	of	O
4	polymerases	O
5	active	O
6	in	O
7	vitro	O
8	at	O
9	the	O
10	E	O
11	strand	O
12	promoter	O
13	was	O
14	similar	O
15	to	O
16	the	O
17	number	O
18	of	O
19	polymerases	O
20	at	O
21	the	O
22	L	O
23	strand	O
24	promoter	O
25	.	O

1	A	O
2	family	O
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O

1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	extremity	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	constitutes	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O

1	The	O
2	SV40	B
3	enhancer	I
4	augmented	O
5	replication	O
6	1	O
7	.	O
8	5	O
9	-	O
10	10	O
11	fold	O
12	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	the	O
6	origin	O
7	core	O
8	,	O
9	is	O
10	required	O
11	only	O
12	for	O
13	DNA	O
14	replication	O
15	.	O

1	Induction	O
2	of	O
3	proto	B
4	-	I
5	oncogene	I
6	fos	I
7	transcription	O
8	through	O
9	the	O
10	adenylate	B
11	cyclase	I
12	pathway	O
13	:	O
14	characterization	O
15	of	O
16	a	O
17	cAMP	O
18	-	O
19	responsive	O
20	element	O
21	.	O

1	A	O
2	17	O
3	-	O
4	mer	O
5	oligodeoxynucleotide	O
6	,	O
7	corresponding	O
8	to	O
9	a	O
10	region	O
11	of	O
12	the	O
13	VtHb	B
14	amino	I
15	acid	I
16	sequence	I
17	was	O
18	used	O
19	as	O
20	a	O
21	hybridization	O
22	probe	O
23	to	O
24	screen	O
25	a	O
26	Vitreoscilla	O
27	genomic	O
28	library	O
29	constructed	O
30	in	O
31	broad	O
32	-	O
33	host	O
34	-	O
35	range	O
36	cosmid	O
37	vector	O
38	pVK102	O
39	.	O

1	(	O
2	total	O
3	soluble	O
4	solids	O
5	)	O
6	and	O
7	organoleptic	O
8	characteristics	O
9	under	O
10	the	O
11	influence	O
12	of	O
13	different	O
14	treatments	O
15	.	O

1	Causes	O
2	of	O
3	death	O
4	found	O
5	in	O
6	an	O
7	epidemiological	O
8	study	O
9	of	O
10	native	O
11	chickens	O
12	in	O
13	Thai	O
14	villages	O
15	.	O

1	The	O
2	progression	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	to	O
13	chronic	O
14	diseases	O
15	,	O
16	and	O
17	the	O
18	transformation	O
19	to	O
20	hepatocellular	O
21	carcinoma	O

1	Elevated	O
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O

1	Use	O
2	of	O
3	serum	O
4	thyroglobulin	B
5	determination	O
6	in	O
7	the	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	differentiated	O
13	carcinomas	O
14	of	O
15	the	O
16	thyroid	O

1	Poor	O
2	response	O
3	when	O
4	laboratory	O
5	recommended	O
6	range	O
7	for	O
8	serum	O
9	lithium	O
10	is	O
11	changed	O
12	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	effects	O
11	of	O
12	nebulized	O
13	ipratropium	O
14	in	O
15	patients	O
16	with	O
17	acute	O
18	asthma	O
19	in	O
20	order	O
21	to	O
22	determine	O
23	whether	O
24	it	O
25	augments	O
26	the	O
27	bronchodilator	O
28	effect	O
29	of	O
30	a	O
31	beta	O
32	agonist	O
33	drug	O
34	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	DNA	O
6	fragment	O
7	showed	O
8	that	O
9	four	O
10	genes	O
11	are	O
12	present	O
13	encoding	O
14	proteins	O
15	of	O
16	16	O
17	,	O
18	18	O
19	.	O
20	5	O
21	,	O
22	21	O
23	and	O
24	89	O
25	kDal	O
26	.	O

1	Hantaan	O
2	virus	O
3	.	O

1	Changes	O
2	in	O
3	dopamine	B
4	receptor	I
5	sensitivity	O
6	in	O
7	humans	O
8	after	O
9	heavy	O
10	alcohol	O
11	intake	O
12	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	two	O
7	treatment	O
8	groups	O
9	were	O
10	found	O
11	,	O
12	but	O
13	rapid	O
14	responders	O
15	had	O
16	a	O
17	smaller	O
18	mean	O
19	initial	O
20	platelet	B
21	-	I
22	associated	I
23	IgG	I
24	index	O
25	which	O
26	returned	O
27	more	O
28	rapidly	O
29	and	O
30	more	O
31	permanently	O
32	to	O
33	normal	O
34	than	O
35	that	O
36	of	O
37	slow	O
38	responders	O
39	.	O

1	Replacement	B
2	variant	I
3	histone	I
4	genes	I
5	contain	O
6	intervening	O
7	sequences	O
8	.	O

1	Double	O
2	-	O
3	blind	O
4	randomised	O
5	trial	O
6	of	O
7	intravenous	O
8	tissue	B
9	-	I
10	type	I
11	plasminogen	I
12	activator	I
13	versus	O
14	placebo	O
15	in	O
16	acute	O
17	myocardial	O
18	infarction	O
19	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	domains	O
6	(	O
7	CTDs	O
8	)	O
9	of	O
10	the	O
11	RPase	B
12	beta	I
13	subunit	I
14	and	O
15	DNA	B
16	primase	I
17	(	O
18	dnaG	B
19	protein	I
20	)	O
21	were	O
22	not	O
23	only	O
24	strongly	O
25	homologous	O
26	to	O
27	each	O
28	other	O
29	but	O
30	also	O
31	considerably	O
32	homologous	O
33	to	O
34	the	O
35	RPase	B
36	alpha	I
37	,	O
38	suggesting	O
39	that	O
40	an	O
41	alpha	O
42	subunit	O
43	-	O
44	like	O
45	enzyme	O
46	must	O
47	have	O
48	been	O
49	commonly	O
50	ancestral	O
51	to	O
52	core	B
53	enzyme	I
54	subunits	I
55	and	O
56	primase	B
57	.	O

1	However	O
2	,	O
3	vancomycin	O
4	and	O
5	fosfomycin	O
6	,	O
7	which	O
8	revealed	O
9	suboptimal	O
10	in	O
11	vitro	O
12	bactericidal	O
13	activity	O
14	,	O
15	proved	O
16	as	O
17	efficacious	O
18	as	O
19	penicillin	O
20	G	O
21	and	O
22	imipenem	O
23	in	O
24	an	O
25	experimental	O
26	mode	O
27	of	O
28	murine	O
29	gas	O
30	gangrene	O
31	.	O

1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	B
6	-	I
7	opiate	I
8	receptor	I
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O

1	Intravesical	O
2	chemotherapy	O
3	.	O

1	Bisoprolol	O
2	was	O
3	found	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	beta	B
9	-	I
10	adrenoceptor	I
11	antagonist	O
12	,	O
13	the	O
14	pA2	O
15	values	O
16	determined	O
17	against	O
18	isoprenaline	O
19	in	O
20	guinea	O
21	pig	O
22	atria	O
23	and	O
24	tracheal	O
25	muscle	O
26	being	O
27	7	O
28	.	O
29	45	O
30	and	O
31	6	O
32	.	O
33	41	O
34	,	O
35	respectively	O
36	.	O

1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O

1	The	O
2	Hagen	O
3	-	O
4	Poiseuille	O
5	equation	O
6	is	O
7	used	O
8	to	O
9	assess	O
10	the	O
11	effects	O
12	of	O
13	attached	O
14	parasites	O
15	in	O
16	the	O
17	foregut	O
18	of	O
19	Leishmania	O
20	-	O
21	infected	O
22	sandflies	O
23	on	O
24	blood	O
25	flow	O
26	.	O

1	Moreover	O
2	,	O
3	in	O
4	rats	O
5	allowed	O
6	to	O
7	choose	O
8	in	O
9	a	O
10	T	O
11	-	O
12	maze	O
13	between	O
14	immediate	O
15	-	O
16	but	O
17	-	O
18	small	O
19	vs	O
20	.	O
21	delayed	O
22	-	O
23	but	O
24	-	O
25	large	O
26	reward	O
27	,	O
28	BZP	O
29	significantly	O
30	decreased	O
31	the	O
32	frequency	O
33	with	O
34	which	O
35	the	O
36	delayed	O
37	reward	O
38	was	O
39	chosen	O
40	,	O
41	with	O
42	5	O
43	-	O
44	HT	O
45	uptake	O
46	blockers	O
47	producing	O
48	opposite	O
49	effects	O
50	.	O

1	An	O
2	endometrial	O
3	luteal	O
4	phase	O
5	deficiency	O
6	was	O
7	detected	O
8	in	O
9	15	O
10	(	O
11	30	O
12	%)	O
13	of	O
14	aborting	O
15	patients	O
16	.	O

1	Prenatal	O
2	exposure	O
3	to	O
4	the	O
5	fungicide	O
6	dinocap	O
7	causes	O
8	behavioral	O
9	torticollis	O
10	,	O
11	ballooning	O
12	and	O
13	cleft	O
14	palate	O
15	in	O
16	mice	O
17	,	O
18	but	O
19	not	O
20	rats	O
21	or	O
22	hamsters	O
23	.	O

1	Reperfusion	O
2	with	O
3	normal	O
4	blood	O
5	in	O
6	the	O
7	beating	O
8	,	O
9	working	O
10	hearts	O
11	caused	O
12	extensive	O
13	structural	O
14	damage	O
15	,	O
16	reduced	O
17	reflow	O
18	,	O
19	and	O
20	failed	O
21	to	O
22	restore	O
23	contractility	O
24	in	O
25	any	O
26	instance	O
27	(-	O
28	27	O
29	%	O
30	systolic	O
31	shortening	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	The	O
2	sensitivity	O
3	of	O
4	the	O
5	vas	O
6	deferens	O
7	to	O
8	adrenaline	O
9	was	O
10	also	O
11	reduced	O
12	in	O
13	scorbutic	O
14	guinea	O
15	pigs	O
16	,	O
17	thus	O
18	decreasing	O
19	their	O
20	fertility	O
21	rate	O
22	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	On	O
2	Days	O
3	1	O
4	and	O
5	14	O
6	,	O
7	most	O
8	young	O
9	and	O
10	elderly	O
11	subjects	O
12	exhibited	O
13	monoexponential	O
14	decline	O
15	in	O
16	bevantolol	O
17	plasma	O
18	concentrations	O
19	after	O
20	absorption	O
21	phase	O
22	.	O

1	Mature	O
2	and	O
3	old	O
4	B6AF1	O
5	and	O
6	B6D2F1	O
7	mice	O
8	were	O
9	given	O
10	acidified	O
11	tap	O
12	water	O
13	or	O
14	promethazine	O
15	HCl	O
16	(	O
17	a	O
18	phenothiazine	O
19	with	O
20	H1	B
21	receptor	I
22	blocking	O
23	activity	O
24	),	O
25	chlorpheniramine	O
26	(	O
27	an	O
28	H1	B
29	blocker	O
30	)	O
31	or	O
32	trifluoperazine	O
33	(	O
34	a	O
35	phenothiazine	O
36	with	O
37	no	O
38	H1	B
39	blocking	O
40	activity	O
41	)	O
42	in	O
43	their	O
44	drinking	O
45	water	O
46	,	O
47	and	O
48	the	O
49	effects	O
50	of	O
51	these	O
52	agents	O
53	on	O
54	bone	O
55	mineral	O
56	content	O
57	were	O
58	assessed	O
59	by	O
60	intermittently	O
61	measuring	O
62	the	O
63	24	O
64	-	O
65	h	O
66	whole	O
67	body	O
68	retention	O
69	of	O
70	Tc	O
71	99m	O
72	methylene	O
73	diphosphonate	O
74	(	O
75	Tc	O
76	99m	O
77	MDP	O
78	,	O
79	an	O
80	indicator	O
81	of	O
82	bone	O
83	metabolism	O
84	)	O
85	and	O
86	at	O
87	the	O
88	end	O
89	of	O
90	the	O
91	studies	O
92	by	O
93	determining	O
94	ash	O
95	weights	O
96	of	O
97	femur	O
98	,	O
99	ilium	O
100	and	O
101	sacrum	O
102	.	O

1	Present	O
2	results	O
3	reveal	O
4	a	O
5	frequency	O
6	-	O
7	dependent	O
8	inhibition	O
9	of	O
10	ganglionic	O
11	transmission	O
12	by	O
13	diltiazem	O
14	,	O
15	and	O
16	suggest	O
17	that	O
18	diltiazem	O
19	may	O
20	depress	O
21	excessive	O
22	sympathetic	O
23	activity	O
24	without	O
25	affecting	O
26	normal	O
27	ganglionic	O
28	transmission	O
29	.	O

1	Studies	O
2	were	O
3	performed	O
4	on	O
5	several	O
6	superficial	O
7	veins	O
8	from	O
9	the	O
10	rabbit	O
11	face	O
12	to	O
13	examine	O
14	the	O
15	relationship	O
16	between	O
17	beta	B
18	adrenoceptor	I
19	subtype	I
20	distribution	O
21	,	O
22	intrinsic	O
23	myogenic	O
24	tone	O
25	and	O
26	sympathetic	O
27	nerve	O
28	innervation	O
29	.	O

1	Effects	O
2	of	O
3	a	O
4	new	O
5	antihypertensive	O
6	agent	O
7	,	O
8	SGB	O
9	-	O
10	1534	O
11	,	O
12	on	O
13	rat	O
14	platelet	O
15	aggregation	O
16	.	O

1	Since	O
2	the	O
3	stability	O
4	of	O
5	TF1	B
6	resides	O
7	in	O
8	its	O
9	primary	O
10	structure	O
11	,	O
12	we	O
13	cloned	O
14	a	O
15	gene	O
16	coding	O
17	for	O
18	TF1	B
19	,	O
20	and	O
21	the	O
22	primary	O
23	structure	O
24	of	O
25	the	O
26	beta	O
27	subunit	O
28	was	O
29	deduced	O
30	from	O
31	the	O
32	nucleotide	O
33	sequence	O
34	of	O
35	the	O
36	gene	O
37	to	O
38	compare	O
39	the	O
40	sequence	O
41	with	O
42	those	O
43	of	O
44	beta	O
45	'	O
46	s	O
47	of	O
48	three	O
49	major	O
50	categories	O
51	of	O
52	F1	B
53	'	O
54	s	O
55	;	O
56	prokaryotic	O
57	membranes	O
58	,	O
59	chloroplasts	O
60	,	O
61	and	O
62	mitochondria	O
63	.	O

1	Body	O
2	temperature	O
3	and	O
4	overall	O
5	conductance	O
6	in	O
7	the	O
8	cold	O
9	appear	O
10	to	O
11	be	O
12	more	O
13	variable	O
14	in	O
15	P	O
16	.	O
17	s	O
18	.	O
19	campbelli	O
20	than	O
21	in	O
22	nominative	O
23	sp	O
24	.	O

1	Two	O
2	polyadenylation	O
3	sites	O
4	were	O
5	used	O
6	,	O
7	one	O
8	at	O
9	the	O
10	end	O
11	of	O
12	the	O
13	early	B
14	(	I
15	E	I
16	)	I
17	region	I
18	of	O
19	the	O
20	viral	O
21	DNA	O
22	,	O
23	the	O
24	other	O
25	at	O
26	the	O
27	end	O
28	of	O
29	the	O
30	late	B
31	(	I
32	L	I
33	)	I
34	region	I
35	.	O

1	A	O
2	drug	O
3	with	O
4	ISA	O
5	"	O
6	down	O
7	regulates	O
8	"	O
9	beta	B
10	receptors	I
11	;	O
12	thus	O
13	,	O
14	when	O
15	the	O
16	drug	O
17	is	O
18	withdrawn	O
19	there	O
20	is	O
21	no	O
22	post	O
23	-	O
24	beta	O
25	-	O
26	blocking	O
27	drug	O
28	hypersensitivity	O
29	in	O
30	contrast	O
31	to	O
32	agents	O
33	without	O
34	ISA	O
35	.	O

1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	lymphotropic	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	myelopathy	O
19	(	O
20	HAM	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	electrophysiologic	O
26	methods	O
27	.	O

1	Terazosin	O
2	,	O
3	a	O
4	structural	O
5	analog	O
6	of	O
7	prazosin	O
8	,	O
9	also	O
10	inhibits	O
11	alpha	B
12	1	I
13	adrenoceptors	I
14	and	O
15	is	O
16	recommended	O
17	as	O
18	once	O
19	or	O
20	twice	O
21	-	O
22	daily	O
23	therapy	O
24	.	O

1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O

1	Most	O
2	patients	O
3	with	O
4	high	O
5	blood	O
6	pressure	O
7	(	O
8	BP	O
9	)	O
10	can	O
11	be	O
12	managed	O
13	by	O
14	using	O
15	one	O
16	of	O
17	4	O
18	classes	O
19	of	O
20	compounds	O
21	:	O
22	a	O
23	diuretic	O
24	,	O
25	beta	O
26	blocker	O
27	,	O
28	converting	O
29	enzyme	O
30	inhibitor	O
31	or	O
32	calcium	O
33	antagonist	O
34	.	O

1	In	O
2	a	O
3	randomised	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	episode	O
12	schizophrenics	O
13	were	O
14	given	O
15	pimozide	O
16	or	O
17	flupenthixol	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	pimozide	O
37	and	O
38	20	O
39	mg	O
40	flupenthixol	O
41	.	O

1	Somatostatin	B
2	-	O
3	producing	O
4	endocrine	O
5	pancreatic	O
6	tumor	O
7	in	O
8	Recklinghausen	O
9	'	O
10	s	O
11	neurofibromatosis	O
12	.	O

1	Direct	O
2	and	O
3	inverted	O
4	repeat	O
5	elements	O
6	of	O
7	10	O
8	,	O
9	11	O
10	,	O
11	16	O
12	,	O
13	19	O
14	,	O
15	and	O
16	22	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	flank	O
22	the	O
23	promoter	O
24	site	O
25	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O

1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O

1	DPA	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O

1	Topical	O
2	1	O
3	percent	O
4	isoproterenol	O
5	in	O
6	the	O
7	presence	O
8	of	O
9	the	O
10	phosphodiesterase	O
11	inhibitor	O
12	theophylline	O
13	was	O
14	tested	O
15	for	O
16	its	O
17	ability	O
18	to	O
19	stimulate	O
20	the	O
21	rate	O
22	of	O
23	aqueous	O
24	humor	O
25	flow	O
26	through	O
27	the	O
28	anterior	O
29	chamber	O
30	of	O
31	the	O
32	normal	O
33	and	O
34	the	O
35	partially	O
36	adrenergically	O
37	denervated	O
38	human	O
39	eye	O
40	(	O
41	Horner	O
42	'	O
43	s	O
44	syndrome	O
45	).	O

1	Hyperthyroidism	O
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O

1	A	O
2	strong	O
3	correlation	O
4	exists	O
5	between	O
6	the	O
7	numbers	O
8	of	O
9	CFU	O
10	-	O
11	GM	O
12	transfused	O
13	and	O
14	the	O
15	rate	O
16	of	O
17	granulocytes	O
18	and	O
19	platelets	O
20	recovery	O
21	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	technique	O
6	of	O
7	low	O
8	-	O
9	frequency	O
10	kindling	O
11	is	O
12	a	O
13	useful	O
14	experimental	O
15	model	O
16	in	O
17	assessing	O
18	the	O
19	effects	O
20	of	O
21	antipsychotic	O
22	or	O
23	antiepileptic	O
24	drugs	O
25	on	O
26	the	O
27	excitability	O
28	of	O
29	the	O
30	limbic	O
31	regions	O
32	.	O

1	Oestrogen	O
2	implant	O
3	overdose	O
4	.	O

1	Three	O
2	sequence	O
3	elements	O
4	are	O
5	shown	O
6	to	O
7	be	O
8	required	O
9	for	O
10	accurate	O
11	and	O
12	efficient	O
13	transcription	O
14	termination	O
15	by	O
16	RNA	B
17	polymerase	I
18	I	I
19	(	O
20	pol	B
21	I	I
22	)	O
23	assayed	O
24	both	O
25	in	O
26	a	O
27	cell	O
28	-	O
29	free	O
30	transcription	O
31	system	O
32	and	O
33	in	O
34	vivo	O
35	after	O
36	transfection	O
37	of	O
38	rDNA	O
39	minigene	O
40	constructs	O
41	into	O
42	3T6	O
43	cells	O
44	.	O

1	The	O
2	biosynthesis	O
3	and	O
4	stability	O
5	of	O
6	the	O
7	three	O
8	mutant	O
9	proteins	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	the	O
16	wild	B
17	-	I
18	type	I
19	erbB	I
20	protein	I
21	,	O
22	and	O
23	all	O
24	three	O
25	retained	O
26	the	O
27	ability	O
28	to	O
29	transform	O
30	chicken	O
31	embryo	O
32	fibroblasts	O
33	.	O

1	Codon	O
2	usage	O
3	in	O
4	C	O
5	.	O
6	reinhardtii	O
7	mitochondria	O
8	is	O
9	highly	O
10	biased	O
11	,	O
12	with	O
13	eight	O
14	codons	O
15	entirely	O
16	absent	O
17	from	O
18	all	O
19	protein	O
20	-	O
21	coding	O
22	genes	O
23	;	O
24	however	O
25	,	O
26	even	O
27	though	O
28	codon	O
29	usage	O
30	is	O
31	restricted	O
32	,	O
33	it	O
34	appears	O
35	that	O
36	C	O
37	.	O
38	reinhardtii	O
39	mtDNA	O
40	cannot	O
41	encode	O
42	the	O
43	minimum	O
44	number	O
45	of	O
46	tRNAs	O
47	needed	O
48	to	O
49	support	O
50	mitochondrial	O
51	protein	O
52	synthesis	O
53	.	O

1	A	O
2	new	O
3	physiopathological	O
4	treatment	O
5	of	O
6	HBV	O
7	-	O
8	related	O
9	polyarteritis	O
10	inspired	O
11	by	O
12	advances	O
13	in	O
14	the	O
15	treatment	O
16	of	O
17	chronic	O
18	active	O
19	hepatitis	O
20	B	O
21	was	O
22	tested	O
23	in	O
24	7	O
25	patients	O
26	.	O

1	Like	O
2	scrotal	O
3	testes	O
4	,	O
5	undescended	O
6	testes	O
7	were	O
8	hypointense	O
9	to	O
10	fat	O
11	on	O
12	sequences	O
13	with	O
14	a	O
15	short	O
16	repetition	O
17	time	O
18	(	O
19	TR	O
20	)	O
21	and	O
22	echo	O
23	time	O
24	(	O
25	TE	O
26	)	O
27	in	O
28	all	O
29	cases	O
30	,	O
31	and	O
32	hyperintense	O
33	or	O
34	isointense	O
35	to	O
36	fat	O
37	on	O
38	long	O
39	TR	O
40	/	O
41	TE	O
42	sequences	O
43	in	O
44	all	O
45	but	O
46	two	O
47	cases	O
48	.	O

1	The	O
2	subunit	B
3	-	I
4	a	I
5	gene	I
6	is	O
7	preceded	O
8	by	O
9	a	O
10	gene	O
11	coding	O
12	for	O
13	a	O
14	small	O
15	hydrophobic	O
16	protein	O
17	,	O
18	as	O
19	has	O
20	been	O
21	observed	O
22	previously	O
23	in	O
24	the	O
25	atp	B
26	operons	I
27	in	O
28	E	O
29	.	O
30	coli	O
31	,	O
32	bacterium	O
33	PS3	O
34	and	O
35	cyanobacteria	O
36	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	bovine	B
9	and	I
10	rat	I
11	GHF	I
12	-	I
13	1	I
14	cDNA	I
15	clones	O
16	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	B
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	O
19	joins	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	B
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	B
32	heavy	I
33	chain	I
34	.	O

1	The	O
2	East	O
3	African	O
4	dik	O
5	-	O
6	dik	O
7	antelope	O
8	represents	O
9	a	O
10	miniature	O
11	model	O
12	ruminant	O
13	for	O
14	comparative	O
15	studies	O
16	.	O

1	By	O
2	sequence	O
3	comparison	O
4	,	O
5	42	O
6	blocks	O
7	of	O
8	homology	O
9	are	O
10	defined	O
11	in	O
12	the	O
13	5	O
14	'-	O
15	terminal	O
16	region	O
17	,	O
18	of	O
19	which	O
20	36	O
21	appear	O
22	in	O
23	the	O
24	CpG	O
25	island	O
26	and	O
27	contain	O
28	numerous	O
29	conserved	O
30	CpG	O
31	dinucleotides	O
32	.	O

1	Among	O
2	unusual	O
3	features	O
4	,	O
5	we	O
6	report	O
7	numerous	O
8	large	O
9	G	O
10	+	O
11	C	O
12	-	O
13	rich	O
14	conserved	O
15	sequences	O
16	located	O
17	in	O
18	the	O
19	first	O
20	intron	O
21	.	O

1	In	O
2	the	O
3	first	O
4	group	O
5	,	O
6	0	O
7	.	O
8	02	O
9	%	O
10	Prazosin	O
11	(	O
12	0	O
13	.	O
14	5	O
15	mg	O
16	/	O
17	kg	O
18	)	O
19	was	O
20	administered	O
21	intravenously	O
22	for	O
23	1	O
24	.	O
25	5	O
26	hours	O
27	before	O
28	the	O
29	application	O
30	of	O
31	Oxy	O
32	-	O
33	Hb	O
34	or	O
35	PGF2	O
36	alpha	O
37	.	O

1	Efficacy	O
2	and	O
3	field	O
4	evaluation	O
5	of	O
6	Bacillus	O
7	thuringiensis	O
8	(	O
9	H	O
10	-	O
11	14	O
12	)	O
13	and	O
14	B	O
15	.	O
16	sphaericus	O
17	against	O
18	floodwater	O
19	mosquitoes	O
20	in	O
21	California	O
22	.	O

1	2	O
2	cases	O
3	of	O
4	type	O
5	II	O
6	tyrosinosis	O
7	(	O
8	Richner	O
9	-	O
10	Hanhart	O
11	syndrome	O
12	)	O

1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	calculate	O
16	the	O
17	true	O
18	free	O
19	diazepam	O
20	concentration	O
21	.	O

1	Effects	O
2	of	O
3	a	O
4	perfluorochemical	O
5	blood	O
6	substitute	O
7	on	O
8	diazepam	O
9	binding	O
10	by	O
11	human	B
12	albumin	I
13	.	O

1	A	O
2	second	O
3	promoter	O
4	activity	O
5	was	O
6	identified	O
7	in	O
8	the	O
9	region	O
10	between	O
11	the	O
12	two	O
13	major	O
14	transcriptional	O
15	start	O
16	sites	O
17	.	O

1	A	O
2	decamer	O
3	sequence	O
4	,	O
5	5	O
6	'-	O
7	CGA	O
8	-	O
9	CCCCUCC	O
10	-	O
11	3	O
12	',	O
13	complementary	O
14	to	O
15	a	O
16	conserved	O
17	sequence	O
18	adjacent	O
19	to	O
20	the	O
21	enzymatic	O
22	cleavage	O
23	site	O
24	on	O
25	the	O
26	mitochondrial	O
27	RNA	O
28	substrate	O
29	,	O
30	is	O
31	present	O
32	in	O
33	the	O
34	RNAase	B
35	MRP	I
36	RNA	I
37	.	O

1	Effects	O
2	of	O
3	aging	O
4	and	O
5	beta	O
6	-	O
7	adrenergic	O
8	-	O
9	blockade	O
10	on	O
11	standing	O
12	-	O
13	induced	O
14	QT	O
15	/	O
16	QS2	O
17	changes	O
18	.	O

1	A	O
2	patient	O
3	with	O
4	an	O
5	infected	O
6	wound	O
7	or	O
8	one	O
9	on	O
10	a	O
11	primary	O
12	area	O
13	(	O
14	hands	O
15	,	O
16	feet	O
17	,	O
18	face	O
19	,	O
20	or	O
21	perineum	O
22	)	O
23	may	O
24	have	O
25	to	O
26	be	O
27	hospitalized	O
28	to	O
29	ensure	O
30	proper	O
31	care	O
32	.	O

1	Pharmacology	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	acetylcholine	O
8	suggest	O
9	that	O
10	raveron	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	influx	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O

1	Computer	O
2	analysis	O
3	included	O
4	digital	O
5	averaging	O
6	,	O
7	followed	O
8	by	O
9	digital	O
10	filtering	O
11	in	O
12	different	O
13	frequency	O
14	bands	O
15	in	O
16	order	O
17	to	O
18	determine	O
19	the	O
20	frequency	O
21	range	O
22	corresponding	O
23	to	O
24	notches	O
25	and	O
26	slurs	O
27	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	The	O
2	risk	O
3	factors	O
4	studied	O
5	were	O
6	male	O
7	sex	O
8	,	O
9	hypertension	O
10	,	O
11	diabetes	O
12	mellitus	O
13	,	O
14	hypercholesterolemia	O
15	,	O
16	cigarette	O
17	smoking	O
18	,	O
19	sedentary	O
20	life	O
21	-	O
22	style	O
23	,	O
24	and	O
25	family	O
26	history	O
27	.	O

1	Neither	O
2	verapamil	O
3	nor	O
4	nifedipine	O
5	changed	O
6	collateral	O
7	myocardial	O
8	blood	O
9	flow	O
10	from	O
11	0	O
12	.	O
13	10	O
14	+/-	O
15	0	O
16	.	O
17	02	O
18	in	O
19	the	O
20	subendocardium	O
21	and	O
22	0	O
23	.	O
24	17	O
25	+/-	O
26	0	O
27	.	O
28	03	O
29	ml	O
30	/	O
31	min	O
32	/	O
33	g	O
34	in	O
35	the	O
36	subepicardium	O
37	.	O

1	There	O
2	were	O
3	35	O
4	boys	O
5	and	O
6	15	O
7	girls	O
8	,	O
9	with	O
10	a	O
11	mean	O
12	age	O
13	of	O
14	five	O
15	and	O
16	a	O
17	half	O
18	years	O
19	.	O

1	Controlled	O
2	versus	O
3	uncontrolled	O
4	reperfusion	O
5	of	O
6	ischemic	O
7	myocardium	O
8	after	O
9	experimental	O
10	coronary	O
11	artery	O
12	occlusion	O
13	was	O
14	studied	O
15	to	O
16	determine	O
17	the	O
18	effect	O
19	on	O
20	regional	O
21	ventricular	O
22	wall	O
23	motion	O
24	and	O
25	associated	O
26	biochemical	O
27	alterations	O
28	.	O

1	Cardiac	O
2	disease	O
3	was	O
4	not	O
5	detected	O
6	with	O
7	M	O
8	-	O
9	mode	O
10	,	O
11	2	O
12	-	O
13	dimensional	O
14	real	O
15	-	O
16	time	O
17	or	O
18	pulsed	O
19	-	O
20	wave	O
21	Doppler	O
22	echocardiography	O
23	.	O

1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	relationship	O
6	between	O
7	the	O
8	side	O
9	of	O
10	sinusitis	O
11	and	O
12	the	O
13	cleft	O
14	side	O
15	in	O
16	patients	O
17	with	O
18	unilateral	O
19	cleft	O
20	palate	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	these	O
6	low	O
7	levels	O
8	studied	O
9	,	O
10	aluminum	O
11	accumulates	O
12	in	O
13	intestinal	O
14	tissue	O
15	,	O
16	and	O
17	that	O
18	this	O
19	accumulation	O
20	is	O
21	enhanced	O
22	by	O
23	citrate	O
24	ligand	O
25	.	O

1	Thus	O
2	,	O
3	the	O
4	effects	O
5	of	O
6	father	O
7	absence	O
8	under	O
9	routine	O
10	conditions	O
11	in	O
12	relatively	O
13	healthy	O
14	samples	O
15	may	O
16	exert	O
17	no	O
18	significant	O
19	effects	O
20	independent	O
21	of	O
22	intervening	O
23	family	O
24	stressors	O
25	or	O
26	maternal	O
27	psychopathology	O
28	.	O

1	Recently	O
2	,	O
3	an	O
4	electrical	O
5	-	O
6	mechanical	O
7	analog	O
8	model	O
9	of	O
10	heat	O
11	flow	O
12	within	O
13	the	O
14	brain	O
15	has	O
16	been	O
17	developed	O
18	from	O
19	which	O
20	an	O
21	expression	O
22	for	O
23	CBF	O
24	has	O
25	been	O
26	derived	O
27	:	O
28	CBF	O
29	=	O
30	Cb	O
31	/(	O
32	tau	O
33	rho	O
34	c	O
35	)	O
36	where	O
37	tau	O
38	is	O
39	the	O
40	thermal	O
41	decay	O
42	constant	O
43	,	O
44	rho	O
45	is	O
46	the	O
47	density	O
48	of	O
49	blood	O
50	,	O
51	and	O
52	c	O
53	is	O
54	its	O
55	specific	O
56	heat	O
57	.	O

1	All	O
2	of	O
3	the	O
4	newly	O
5	acquired	O
6	proviruses	O
7	identified	O
8	in	O
9	mosaic	O
10	founder	O
11	SWR	O
12	/	O
13	J	O
14	-	O
15	RF	O
16	/	O
17	J	O
18	mice	O
19	that	O
20	could	O
21	be	O
22	transmitted	O
23	through	O
24	the	O
25	germ	O
26	line	O
27	were	O
28	also	O
29	present	O
30	in	O
31	somatic	O
32	tissues	O
33	,	O
34	demonstrating	O
35	that	O
36	viral	O
37	integration	O
38	occurred	O
39	before	O
40	the	O
41	germ	O
42	line	O
43	was	O
44	set	O
45	aside	O
46	from	O
47	the	O
48	somatic	O
49	lineages	O
50	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	cDNA	O
6	for	O
7	the	O
8	human	B
9	U2	I
10	snRNA	I
11	-	I
12	specific	I
13	A	I
14	'	I
15	protein	I
16	.	O

1	For	O
2	the	O
3	present	O
4	work	O
5	we	O
6	used	O
7	water	O
8	saturated	O
9	with	O
10	a	O
11	50	O
12	/	O
13	50	O
14	mixture	O
15	of	O
16	H2	O
17	and	O
18	O2	O
19	gases	O
20	,	O
21	for	O
22	which	O
23	the	O
24	heat	O
25	defect	O
26	is	O
27	calculated	O
28	to	O
29	be	O
30	-	O
31	2	O
32	.	O
33	1	O
34	%.	O

1	Successful	O
2	use	O
3	of	O
4	transureteroureterostomy	O
5	to	O
6	salvage	O
7	ureterosigmoidostomy	O
8	after	O
9	anastomotic	O
10	failure	O
11	.	O

1	During	O
2	flexion	O
3	whiplash	O
4	,	O
5	the	O
6	torque	O
7	at	O
8	the	O
9	occipital	O
10	condyle	O
11	reverses	O
12	its	O
13	direction	O
14	at	O
15	about	O
16	25	O
17	ms	O
18	after	O
19	impact	O
20	.	O

1	The	O
2	data	O
3	indicates	O
4	the	O
5	presence	O
6	of	O
7	5	B
8	-	I
9	HT2	I
10	serotonergic	I
11	receptors	I
12	in	O
13	the	O
14	bronchial	O
15	artery	O
16	of	O
17	these	O
18	species	O
19	.	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	By	O
2	adapting	O
3	a	O
4	method	O
5	for	O
6	DNA	O
7	-	O
8	footprinting	O
9	using	O
10	impure	O
11	extracts	O
12	of	O
13	ner	B
14	overproducing	O
15	cells	O
16	,	O
17	we	O
18	were	O
19	able	O
20	to	O
21	determine	O
22	that	O
23	the	O
24	ner	B
25	-	I
26	binding	I
27	sites	I
28	are	O
29	located	O
30	between	O
31	nucleotides	O
32	1026	O
33	and	O
34	1058	O
35	from	O
36	the	O
37	Mu	O
38	left	O
39	end	O
40	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	the	O
7	structure	O
8	of	O
9	the	O
10	Spec1	B
11	gene	I
12	in	O
13	the	O
14	sea	O
15	urchin	O
16	Strongylocentrotus	O
17	purpuratus	O
18	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	B
15	lipoxygenase	I
16	activity	O
17	.	O

1	Spontaneous	O
2	degradation	O
3	of	O
4	atracurium	O
5	in	O
6	plasma	O
7	is	O
8	the	O
9	major	O
10	route	O
11	of	O
12	elimination	O
13	in	O
14	man	O
15	and	O
16	contributes	O
17	to	O
18	a	O
19	short	O
20	elimination	O
21	half	O
22	-	O
23	life	O
24	(	O
25	approximatively	O
26	20	O
27	min	O
28	).	O

1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	B
7	or	O
8	E1a	B
9	and	O
10	E1b	B
11	gene	I
12	products	I
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O

1	Partial	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	analysis	O
9	showed	O
10	that	O
11	the	O
12	43K	B
13	and	I
14	42K	I
15	T	I
16	antigens	I
17	contain	O
18	methionine	O
19	at	O
20	residues	O
21	1	O
22	and	O
23	5	O
24	,	O
25	as	O
26	predicted	O
27	from	O
28	the	O
29	DNA	O
30	sequence	O
31	,	O
32	whereas	O
33	no	O
34	methionine	O
35	was	O
36	released	O
37	from	O
38	the	O
39	39K	B
40	T	I
41	antigen	I
42	during	O
43	the	O
44	first	O
45	six	O
46	cycles	O
47	of	O
48	Edman	O
49	degradation	O
50	.	O

1	Group	O
2	A	O
3	was	O
4	treated	O
5	with	O
6	three	O
7	or	O
8	four	O
9	doses	O
10	of	O
11	hepatitis	B
12	B	I
13	immune	I
14	globulin	I
15	(	O
16	HBIG	B
17	)	O
18	in	O
19	one	O
20	of	O
21	three	O
22	different	O
23	schedules	O
24	.	O

1	In	O
2	the	O
3	former	O
4	instance	O
5	,	O
6	in	O
7	addition	O
8	to	O
9	serum	O
10	calcium	O
11	and	O
12	phosphorous	O
13	ion	O
14	concentrations	O
15	,	O
16	tissue	O
17	pH	O
18	,	O
19	blood	O
20	supply	O
21	,	O
22	hormones	O
23	,	O
24	i	O
25	.	O
26	e	O
27	.,	O
28	vitamin	O
29	D	O
30	,	O
31	vitamin	O
32	A	O
33	,	O
34	and	O
35	various	O
36	enzymes	O
37	(	O
38	e	O
39	.	O
40	g	O
41	.,	O
42	alkaline	B
43	phosphatase	I
44	and	O
45	pyrophosphatase	B
46	)	O
47	may	O
48	all	O
49	play	O
50	significant	O
51	,	O
52	ancillary	O
53	,	O
54	time	O
55	-	O
56	dependent	O
57	,	O
58	but	O
59	as	O
60	yet	O
61	undetermined	O
62	roles	O
63	.	O

1	Penicillinase	B
2	production	O
3	in	O
4	Staphylococcus	O
5	aureus	O
6	strains	O
7	of	O
8	clinical	O
9	importance	O
10	.	O

1	Thus	O
2	,	O
3	quantitative	O
4	analysis	O
5	of	O
6	thallium	O
7	-	O
8	201	O
9	uptake	O
10	and	O
11	washout	O
12	provided	O
13	objective	O
14	evidence	O
15	for	O
16	improved	O
17	myocardial	O
18	perfusion	O
19	after	O
20	coronary	O
21	angioplasty	O
22	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	effects	O
6	of	O
7	a	O
8	preparation	O
9	with	O
10	50	O
11	micrograms	O
12	ethinyl	O
13	estradiol	O
14	and	O
15	2	O
16	mg	O
17	cyproterone	O
18	acetate	O
19	on	O
20	gonadotropins	B
21	,	O
22	prolactin	B
23	,	O
24	testosterone	O
25	,	O
26	sex	B
27	hormone	I
28	binding	I
29	globulin	I
30	(	O
31	SHBG	B
32	),	O
33	androstenedione	O
34	,	O
35	and	O
36	calculated	O
37	free	O
38	testosterone	O
39	index	O
40	before	O
41	and	O
42	after	O
43	six	O
44	months	O
45	of	O
46	treatment	O
47	.	O

1	Functional	O
2	flow	O
3	was	O
4	evaluated	O
5	using	O
6	laser	O
7	Doppler	O
8	flowmetry	O
9	(	O
10	LDF	O
11	),	O
12	for	O
13	which	O
14	the	O
15	output	O
16	signal	O
17	,	O
18	blood	O
19	cell	O
20	flux	O
21	(	O
22	BCF	O
23	),	O
24	is	O
25	expressed	O
26	in	O
27	terms	O
28	of	O
29	volts	O
30	.	O

1	In	O
2	nine	O
3	patients	O
4	with	O
5	renal	O
6	failure	O
7	routine	O
8	haemodialysis	O
9	was	O
10	accompanied	O
11	by	O
12	a	O
13	30	O
14	per	O
15	cent	O
16	reduction	O
17	in	O
18	plasma	O
19	ANP	B
20	concentration	O
21	.	O

1	To	O
2	investigate	O
3	the	O
4	effects	O
5	of	O
6	isotretinoin	O
7	on	O
8	HDL	B
9	,	O
10	we	O
11	measured	O
12	HDL	B
13	-	I
14	C	I
15	,	O
16	HDL	B
17	phospholipids	O
18	(	O
19	HDL	B
20	-	I
21	PL	I
22	),	O
23	apoprotein	B
24	A1	I
25	(	O
26	apo	B
27	A	I
28	-	I
29	1	I
30	),	O
31	and	O
32	HDL	B
33	-	I
34	C	I
35	subfractions	O
36	(	O
37	HDL2	B
38	-	I
39	C	I
40	and	O
41	HDL3	B
42	-	I
43	C	I
44	)	O
45	in	O
46	24	O
47	healthy	O
48	,	O
49	male	O
50	patients	O
51	receiving	O
52	a	O
53	16	O
54	-	O
55	week	O
56	course	O
57	of	O
58	isotretinoin	O
59	(	O
60	1	O
61	.	O
62	0	O
63	mg	O
64	/	O
65	kg	O
66	/	O
67	day	O
68	)	O
69	for	O
70	treatment	O
71	of	O
72	severe	O
73	acne	O
74	vulgaris	O
75	.	O

1	The	O
2	clinical	O
3	picture	O
4	and	O
5	laboratory	O
6	parameters	O
7	were	O
8	consistent	O
9	with	O
10	a	O
11	serum	O
12	sickness	O
13	reaction	O
14	.	O

1	Our	O
2	data	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	suggest	O
9	the	O
10	existence	O
11	of	O
12	a	O
13	conversion	O
14	factor	O
15	for	O
16	LDF	O
17	signal	O
18	to	O
19	absolute	O
20	flow	O
21	values	O
22	from	O
23	experiment	O
24	to	O
25	experiment	O
26	.	O

1	Preventive	O
2	effect	O
3	of	O
4	ONO	O
5	-	O
6	3708	O
7	on	O
8	thrombosis	O
9	and	O
10	vasospasms	O
11	in	O
12	vitro	O
13	and	O
14	in	O
15	vivo	O
16	.	O

1	The	O
2	frequency	O
3	of	O
4	PPNG	O
5	strains	O
6	increased	O
7	from	O
8	1	O
9	.	O
10	7	O
11	%	O
12	in	O
13	1981	O
14	to	O
15	6	O
16	.	O
17	7	O
18	%	O
19	in	O
20	1985	O
21	.	O

1	Monospecific	O
2	antibodies	O
3	,	O
4	eluted	O
5	from	O
6	the	O
7	beta	B
8	-	I
9	galactosidase	I
10	fusion	O
11	protein	O
12	of	O
13	either	O
14	clone	O
15	reacted	O
16	with	O
17	the	O
18	U1	B
19	snRNP	I
20	-	O
21	specific	O
22	A	B
23	antigen	I
24	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	the	O
5	coronary	O
6	stenosis	O
7	was	O
8	assessed	O
9	before	O
10	and	O
11	after	O
12	PTCA	O
13	,	O
14	and	O
15	the	O
16	dilatation	O
17	resulted	O
18	in	O
19	an	O
20	increase	O
21	in	O
22	minimal	O
23	luminal	O
24	cross	O
25	-	O
26	sectional	O
27	area	O
28	from	O
29	1	O
30	.	O
31	1	O
32	+/-	O
33	0	O
34	.	O
35	8	O
36	to	O
37	2	O
38	.	O
39	7	O
40	+/-	O
41	1	O
42	.	O
43	2	O
44	mm2	O
45	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Limited	O
5	Joint	O
6	Mobility	O
7	(	O
8	LJM	O
9	)	O
10	in	O
11	diabetes	O
12	is	O
13	unknown	O
14	,	O
15	but	O
16	the	O
17	abnormality	O
18	is	O
19	said	O
20	to	O
21	be	O
22	associated	O
23	with	O
24	an	O
25	increased	O
26	incidence	O
27	of	O
28	microangiopathy	O
29	.	O

1	In	O
2	a	O
3	previous	O
4	study	O
5	(	O
6	Brandl	O
7	,	O
8	C	O
9	.	O

1	The	O
2	experimental	O
3	end	O
4	points	O
5	were	O
6	the	O
7	time	O
8	required	O
9	for	O
10	treated	O
11	tumors	O
12	to	O
13	reach	O
14	3	O
15	times	O
16	their	O
17	treatment	O
18	size	O
19	,	O
20	the	O
21	survival	O
22	of	O
23	stem	O
24	cells	O
25	in	O
26	the	O
27	duodenal	O
28	crypts	O
29	,	O
30	and	O
31	the	O
32	breathing	O
33	rate	O
34	measured	O
35	early	O
36	(	O
37	19	O
38	-	O
39	23	O
40	weeks	O
41	)	O
42	and	O
43	late	O
44	(	O
45	41	O
46	-	O
47	46	O
48	weeks	O
49	)	O
50	after	O
51	treatment	O
52	.	O

1	Schedule	O
2	2	O
3	,	O
4	in	O
5	which	O
6	2	O
7	.	O
8	4	O
9	mg	O
10	/	O
11	kg	O
12	c	O
13	-	O
14	DDP	O
15	was	O
16	administered	O
17	immediately	O
18	before	O
19	X	O
20	-	O
21	ray	O
22	on	O
23	5	O
24	consecutive	O
25	days	O
26	produced	O
27	the	O
28	highest	O
29	degree	O
30	of	O
31	enhancement	O
32	of	O
33	radiation	O
34	effect	O
35	(	O
36	expressed	O
37	as	O
38	dose	O
39	-	O
40	effect	O
41	factor	O
42	);	O
43	and	O
44	the	O
45	next	O
46	greatest	O
47	enhancement	O
48	was	O
49	produced	O
50	by	O
51	12	O
52	mg	O
53	/	O
54	kg	O
55	c	O
56	-	O
57	DDP	O
58	administered	O
59	24	O
60	h	O
61	before	O
62	the	O
63	start	O
64	of	O
65	fractionated	O
66	daily	O
67	radiotherapy	O
68	.	O

1	The	O
2	cpc	B
3	-	I
4	1	I
5	-	I
6	encoded	I
7	transcript	I
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	720	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	preceding	O
27	the	O
28	cpc	B
29	-	I
30	1	I
31	coding	I
32	region	I
33	.	O

1	The	O
2	seco	O
3	-	O
4	steroid	O
5	hormone	O
6	1	O
7	,	O
8	25	O
9	-	O
10	dihydroxyvitamin	O
11	D3	O
12	is	O
13	known	O
14	to	O
15	induce	O
16	the	O
17	expression	O
18	of	O
19	a	O
20	calcium	O
21	binding	O
22	protein	O
23	termed	O
24	calbindin	B
25	-	I
26	D28K	I
27	in	O
28	a	O
29	variety	O
30	of	O
31	target	O
32	tissues	O
33	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	calbindin	B
6	-	I
7	D28K	I
8	promoter	I
9	is	O
10	composed	O
11	of	O
12	a	O
13	variety	O
14	of	O
15	simple	O
16	repeated	O
17	sequences	O
18	,	O
19	some	O
20	of	O
21	which	O
22	are	O
23	components	O
24	of	O
25	putative	O
26	regulatory	O
27	signals	O
28	.	O

1	The	O
2	HOI	O
3	induced	O
4	a	O
5	nearly	O
6	fourfold	O
7	increase	O
8	in	O
9	ANF	B
10	in	O
11	the	O
12	elderly	O
13	,	O
14	whereas	O
15	that	O
16	for	O
17	the	O
18	young	O
19	was	O
20	threefold	O
21	.	O

1	To	O
2	assess	O
3	the	O
4	ability	O
5	of	O
6	the	O
7	atria	O
8	to	O
9	maintain	O
10	elevated	O
11	plasma	O
12	concentrations	O
13	of	O
14	atrial	B
15	natriuretic	I
16	peptide	I
17	(	O
18	ANP	B
19	),	O
20	the	O
21	temporal	O
22	changes	O
23	in	O
24	plasma	B
25	ANP	I
26	concentrations	O
27	were	O
28	studied	O
29	in	O
30	seven	O
31	chloralose	O
32	-	O
33	anaesthetized	O
34	dogs	O
35	during	O
36	4	O
37	h	O
38	of	O
39	sustained	O
40	rapid	O
41	cardiac	O
42	pacing	O
43	.	O

1	Ig	B
2	D	I
3	-	O
4	JH	B
5	recombinations	O
6	may	O
7	precede	O
8	TcR	B
9	gene	I
10	recombination	O
11	in	O
12	these	O
13	early	O
14	T	O
15	cell	O
16	lines	O
17	,	O
18	and	O
19	some	O
20	but	O
21	not	O
22	all	O
23	express	O
24	sterile	O
25	Cmu	B
26	transcripts	I
27	.	O

1	The	O
2	RAD18	B
3	gene	I
4	open	I
5	reading	I
6	frame	I
7	encodes	O
8	a	O
9	protein	O
10	of	O
11	487	O
12	amino	O
13	acids	O
14	,	O
15	with	O
16	a	O
17	calculated	O
18	molecular	O
19	weight	O
20	of	O
21	55	O
22	,	O
23	512	O
24	.	O

1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	B
9	proteins	I
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O

1	Most	O
2	patients	O
3	preferred	O
4	tablets	O
5	to	O
6	injection	O
7	both	O
8	on	O
9	day	O
10	1	O
11	(	O
12	313	O
13	v	O
14	200	O
15	)	O
16	and	O
17	at	O
18	follow	O
19	up	O
20	(	O
21	373	O
22	v	O
23	104	O
24	).	O

1	Plots	O
2	of	O
3	RV	O
4	,	O
5	LV	O
6	+	O
7	S	O
8	and	O
9	2A	O
10	weight	O
11	vs	O
12	real	O
13	hematocrit	O
14	showed	O
15	sharp	O
16	upward	O
17	inflections	O
18	at	O
19	real	O
20	hematocrit	O
21	65	O
22	%,	O
23	suggesting	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	increased	O
29	viscosity	O
30	in	O
31	CO	O
32	cardiomegaly	O
33	at	O
34	the	O
35	higher	O
36	hematocrit	O
37	.	O

1	The	O
2	absorbable	O
3	perisplenic	O
4	mesh	O
5	is	O
6	an	O
7	important	O
8	improvement	O
9	,	O
10	and	O
11	in	O
12	some	O
13	cases	O
14	it	O
15	may	O
16	replace	O
17	other	O
18	techniques	O
19	for	O
20	arresting	O
21	splenic	O
22	bleeding	O
23	.	O

1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O

1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O

1	Oligonucleotide	O
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	The	O
2	concentration	O
3	of	O
4	PGI2	O
5	on	O
6	the	O
7	newly	O
8	-	O
9	formed	O
10	luminal	O
11	surface	O
12	remained	O
13	low	O
14	.	O

1	Organ	O
2	transplantation	O
3	in	O
4	Denmark	O
5	.	O

1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O

1	D	O
2	.	O

1	A	O
2	114	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	of	O
8	predominantly	O
9	repeating	O
10	purine	O
11	-	O
12	pyrimidine	O
13	nucleotides	O
14	separates	O
15	these	O
16	two	O
17	d	O
18	(	O
19	AC	O
20	)	O
21	repeats	O
22	.	O

1	Phase	O
2	II	O
3	study	O
4	of	O
5	VP	O
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O

1	When	O
2	the	O
3	coding	O
4	segments	O
5	,	O
6	including	O
7	both	O
8	framework	O
9	and	O
10	complementarity	O
11	-	O
12	determining	O
13	regions	O
14	,	O
15	of	O
16	these	O
17	genes	O
18	and	O
19	the	O
20	murine	O
21	probe	O
22	sequences	O
23	are	O
24	compared	O
25	by	O
26	metric	O
27	analysis	O
28	,	O
29	it	O
30	is	O
31	apparent	O
32	that	O
33	the	O
34	caiman	O
35	genes	O
36	are	O
37	only	O
38	slightly	O
39	more	O
40	related	O
41	to	O
42	each	O
43	other	O
44	than	O
45	to	O
46	the	O
47	mammalian	O
48	sequence	O
49	,	O
50	consistent	O
51	with	O
52	significant	O
53	preservation	O
54	of	O
55	nucleotide	O
56	sequence	O
57	over	O
58	an	O
59	extended	O
60	period	O
61	of	O
62	phylogenetic	O
63	time	O
64	.	O

1	Evidence	O
2	for	O
3	a	O
4	role	O
5	of	O
6	endogenous	B
7	corticotropin	I
8	-	I
9	releasing	I
10	factor	I
11	in	O
12	cold	O
13	,	O
14	ether	O
15	,	O
16	immobilization	O
17	,	O
18	and	O
19	traumatic	O
20	stress	O
21	.	O

1	An	O
2	unusual	O
3	feature	O
4	of	O
5	these	O
6	replicative	O
7	genes	O
8	is	O
9	that	O
10	the	O
11	smaller	O
12	mRNA	O
13	begins	O
14	within	O
15	a	O
16	long	O
17	open	O
18	reading	O
19	frame	O
20	of	O
21	the	O
22	larger	O
23	mRNA	O
24	.	O

1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	I
13	myc	I
14	gene	I
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O

1	81	O
2	milk	O
3	samples	O
4	collected	O
5	from	O
6	35	O
7	donors	O
8	3	O
9	days	O
10	to	O
11	7	O
12	months	O
13	after	O
14	delivery	O
15	were	O
16	examined	O
17	for	O
18	the	O
19	occurrence	O
20	of	O
21	cytomegalovirus	O
22	(	O
23	CMV	O
24	).	O

1	Subcloning	O
2	of	O
3	DNA	O
4	fragments	O
5	from	O
6	the	O
7	8	O
8	.	O
9	5	O
10	-	O
11	kilobase	O
12	(	O
13	kb	O
14	)	O
15	insert	O
16	of	O
17	pAVO4	O
18	defined	O
19	a	O
20	4	O
21	-	O
22	kb	O
23	DNA	O
24	fragment	O
25	which	O
26	contained	O
27	the	O
28	functional	B
29	FBP	I
30	+	I
31	gene	I
32	and	O
33	its	O
34	regulatory	O
35	region	O
36	.	O

1	Three	O
2	cases	O
3	of	O
4	primary	O
5	signet	O
6	-	O
7	ring	O
8	cell	O
9	carcinoma	O
10	of	O
11	the	O
12	rectum	O
13	are	O
14	described	O
15	.	O

1	The	O
2	data	O
3	obtained	O
4	up	O
5	to	O
6	now	O
7	only	O
8	suggest	O
9	the	O
10	future	O
11	potentiality	O
12	of	O
13	Bestatin	O
14	treatment	O
15	for	O
16	these	O
17	types	O
18	of	O
19	malignancy	O
20	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	dopaminergic	O
6	regulation	O
7	of	O
8	adrenal	O
9	zona	O
10	glomerulosa	O
11	corticosteroid	O
12	and	O
13	renal	B
14	renin	I
15	secretion	O
16	is	O
17	absent	O
18	in	O
19	patients	O
20	with	O
21	high	O
22	spinal	O
23	cord	O
24	transections	O
25	,	O
26	suggesting	O
27	that	O
28	intact	O
29	neural	O
30	pathways	O
31	from	O
32	the	O
33	central	O
34	nervous	O
35	system	O
36	are	O
37	necessary	O
38	for	O
39	metoclopramide	O
40	stimulation	O
41	of	O
42	aldosterone	O
43	and	O
44	renin	B
45	secretion	O
46	in	O
47	men	O
48	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	enhancer	O
6	sequences	O
7	,	O
8	the	O
9	adenovirus	B
10	E1A	I
11	gene	I
12	can	O
13	not	O
14	stimulate	O
15	CATase	B
16	synthesis	O
17	.	O

1	These	O
2	IgG	B
3	antibodies	I
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O

1	Fine	O
2	analysis	O
3	at	O
4	the	O
5	nucleotide	O
6	level	O
7	of	O
8	the	O
9	early	O
10	events	O
11	in	O
12	the	O
13	digestion	O
14	with	O
15	nuclease	B
16	S1	I
17	shows	O
18	that	O
19	the	O
20	enzyme	O
21	attacks	O
22	preferentially	O
23	the	O
24	sequence	O
25	(	O
26	G	O
27	-	O
28	A	O
29	)	O
30	12	O
31	on	O
32	the	O
33	message	O
34	complementary	O
35	strand	O
36	.	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	B
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	FK	O
2	33	O
3	-	O
4	824	O
5	,	O
6	a	O
7	methionine	O
8	-	O
9	enkephalin	B
10	analogue	O
11	,	O
12	suppressed	O
13	plasma	O
14	ACTH	B
15	to	O
16	85	O
17	%	O
18	of	O
19	basal	O
20	level	O
21	,	O
22	while	O
23	bromocriptine	O
24	(	O
25	CB	O
26	-	O
27	154	O
28	)	O
29	caused	O
30	no	O
31	significant	O
32	change	O
33	.	O

1	A	O
2	v	B
3	-	I
4	erbB	I
5	-	I
6	related	I
7	protooncogene	I
8	,	O
9	c	B
10	-	I
11	erbB	I
12	-	I
13	2	I
14	,	O
15	is	O
16	distinct	O
17	from	O
18	the	O
19	c	B
20	-	I
21	erbB	I
22	-	I
23	1	I
24	/	O
25	epidermal	B
26	growth	I
27	factor	I
28	-	I
29	receptor	I
30	gene	O
31	and	O
32	is	O
33	amplified	O
34	in	O
35	a	O
36	human	O
37	salivary	O
38	gland	O
39	adenocarcinoma	O
40	.	O

1	The	O
2	sequence	O
3	analysis	O
4	of	O
5	both	O
6	products	O
7	of	O
8	individual	O
9	phi	O
10	80	O
11	site	O
12	-	O
13	specific	O
14	recombination	O
15	events	O
16	in	O
17	vivo	O
18	shows	O
19	that	O
20	recombination	O
21	with	O
22	a	O
23	secondary	O
24	attachment	O
25	(	O
26	att	O
27	)	O
28	site	O
29	generates	O
30	several	O
31	different	O
32	novel	O
33	joints	O
34	at	O
35	the	O
36	mismatched	O
37	position	O
38	:	O
39	one	O
40	recombination	O
41	event	O
42	resulted	O
43	in	O
44	a	O
45	single	O
46	base	O
47	-	O
48	pair	O
49	deletion	O
50	and	O
51	two	O
52	other	O
53	recombination	O
54	events	O
55	resulted	O
56	in	O
57	two	O
58	different	O
59	single	O
60	base	O
61	-	O
62	pair	O
63	substitutions	O
64	.	O

1	This	O
2	L	B
3	-	I
4	myc	I
5	sequence	I
6	is	O
7	amplified	O
8	10	O
9	-	O
10	20	O
11	-	O
12	fold	O
13	in	O
14	four	O
15	SCLC	O
16	cell	O
17	line	O
18	DNAs	O
19	and	O
20	in	O
21	one	O
22	SCLC	O
23	tumour	O
24	specimen	O
25	taken	O
26	directly	O
27	from	O
28	a	O
29	patient	O
30	.	O

1	Temperature	O
2	-	O
3	shift	O
4	experiments	O
5	using	O
6	synchronously	O
7	grown	O
8	cells	O
9	of	O
10	a	O
11	delta	B
12	top1	I
13	top2	I
14	temperature	I
15	-	I
16	sensitive	I
17	(	I
18	ts	I
19	)	I
20	double	I
21	mutant	I
22	and	O
23	its	O
24	isogenic	O
25	top2	B
26	ts	O
27	strain	O
28	show	O
29	that	O
30	,	O
31	whereas	O
32	mitotic	O
33	blocks	O
34	can	O
35	prevent	O
36	killing	O
37	of	O
38	the	O
39	top2	B
40	ts	I
41	mutant	I
42	at	O
43	a	O
44	nonpermissive	O
45	temperature	O
46	,	O
47	the	O
48	same	O
49	treatments	O
50	are	O
51	ineffective	O
52	in	O
53	preventing	O
54	cell	O
55	death	O
56	of	O
57	the	O
58	delta	B
59	top1	I
60	top2	I
61	ts	I
62	double	I
63	mutant	I
64	.	O

1	The	O
2	homology	O
3	to	O
4	v	B
5	-	I
6	mil	I
7	starts	O
8	within	O
9	the	O
10	coding	O
11	sequence	O
12	of	O
13	exon	O
14	1	O
15	and	O
16	ends	O
17	within	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	exon	O
25	11	O
26	,	O
27	12	O
28	nucleotides	O
29	downstream	O
30	from	O
31	the	O
32	nonsense	O
33	codon	O
34	terminating	O
35	the	O
36	large	O
37	open	O
38	reading	O
39	frame	O
40	shared	O
41	between	O
42	c	B
43	-	I
44	mil	I
45	and	O
46	v	B
47	-	I
48	mil	I
49	.	O

1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	Punta	B
8	Toro	I
9	M	I
10	gene	I
11	product	I
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O

1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O

1	The	O
2	intensity	O
3	of	O
4	myocardial	O
5	uptake	O
6	of	O
7	Tc	O
8	-	O
9	99m	O
10	-	O
11	PYP	O
12	in	O
13	patients	O
14	with	O
15	echocardiographic	O
16	left	O
17	ventricular	O
18	hypertrophy	O
19	and	O
20	/	O
21	or	O
22	highly	O
23	refractile	O
24	myocardial	O
25	echoes	O
26	,	O
27	so	O
28	-	O
29	called	O
30	granular	O
31	sparkling	O
32	appearance	O
33	(	O
34	GS	O
35	)	O
36	was	O
37	slightly	O
38	greater	O
39	than	O
40	that	O
41	in	O
42	patients	O
43	with	O
44	neither	O
45	myocardial	O
46	hypertrophy	O
47	nor	O
48	GS	O
49	.	O

1	The	O
2	210	O
3	kDa	O
4	precursor	O
5	is	O
6	converted	O
7	slowly	O
8	(	O
9	t	O
10	1	O
11	/	O
12	2	O
13	=	O
14	2	O
15	h	O
16	)	O
17	by	O
18	proteolytic	O
19	processing	O
20	into	O
21	a	O
22	125	O
23	kDa	O
24	(	O
25	alpha	O
26	')	O
27	and	O
28	83	O
29	kDa	O
30	(	O
31	beta	O
32	')	O
33	species	O
34	.	O

1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O

1	We	O
2	have	O
3	determined	O
4	that	O
5	these	O
6	nicks	O
7	occur	O
8	in	O
9	both	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	the	O
16	mutant	O
17	sites	O
18	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	B
13	hsp70	I
14	,	O
15	trout	B
16	hsp70	I
17	,	O
18	Xenopus	B
19	hsp70	I
20	,	O
21	yeast	B
22	hsp70	I
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	B
30	-	I
31	inducible	I
32	dnaK	I
33	gene	I
34	product	I
35	of	O
36	Escherichia	O
37	coli	O
38	.	O

1	When	O
2	phosphorylation	O
3	of	O
4	exogenous	O
5	peptide	O
6	substrates	O
7	was	O
8	measured	O
9	as	O
10	a	O
11	function	O
12	of	O
13	receptor	O
14	self	O
15	-	O
16	phosphorylation	O
17	,	O
18	tyrosine	B
19	kinase	I
20	activity	O
21	was	O
22	found	O
23	to	O
24	be	O
25	enhanced	O
26	two	O
27	to	O
28	threefold	O
29	at	O
30	1	O
31	-	O
32	2	O
33	mol	O
34	of	O
35	phosphate	O
36	per	O
37	mol	O
38	of	O
39	receptor	O
40	.	O

1	At	O
2	temperatures	O
3	permissive	O
4	for	O
5	transformation	O
6	,	O
7	6m2	O
8	cells	O
9	contain	O
10	P58gag	B
11	produced	O
12	from	O
13	the	O
14	4	O
15	.	O
16	0	O
17	-	O
18	kilobase	O
19	(	O
20	kb	O
21	)	O
22	viral	O
23	RNA	O
24	genome	O
25	and	O
26	P85gag	B
27	-	O
28	mos	B
29	translated	O
30	from	O
31	a	O
32	3	O
33	.	O
34	5	O
35	-	O
36	kb	O
37	spliced	O
38	mRNA	O
39	.	O

1	The	O
2	pet56	B
3	and	O
4	his3	B
5	genes	I
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O

1	Multistep	O
2	transformation	O
3	by	O
4	defined	O
5	fragments	O
6	of	O
7	herpes	O
8	simplex	O
9	virus	O
10	type	O
11	2	O
12	DNA	O
13	:	O
14	oncogenic	O
15	region	O
16	and	O
17	its	O
18	gene	O
19	product	O
20	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	in	O
6	patients	O
7	with	O
8	first	O
9	-	O
10	attack	O
11	genital	O
12	herpes	O
13	,	O
14	the	O
15	type	O
16	of	O
17	HSV	O
18	is	O
19	the	O
20	most	O
21	important	O
22	determinant	O
23	of	O
24	subsequent	O
25	recurrences	O
26	and	O
27	that	O
28	intravenous	O
29	acyclovir	O
30	has	O
31	little	O
32	effect	O
33	on	O
34	subsequent	O
35	recurrences	O
36	.	O

1	Comparison	O
2	of	O
3	sequences	O
4	of	O
5	ovine	O
6	and	O
7	bovine	O
8	,	O
9	rat	O
10	and	O
11	guinea	B
12	-	I
13	pig	I
14	alpha	I
15	s1	I
16	-	I
17	casein	I
18	mRNAs	I
19	has	O
20	revealed	O
21	a	O
22	greater	O
23	homology	O
24	in	O
25	the	O
26	3	O
27	'	O
28	and	O
29	especially	O
30	5	O
31	'	O
32	non	O
33	coding	O
34	regions	O
35	.	O

1	One	O
2	group	O
3	(	O
4	n	O
5	=	O
6	9	O
7	)	O
8	was	O
9	premedicated	O
10	with	O
11	midazolam	O
12	,	O
13	0	O
14	.	O
15	1	O
16	mg	O
17	kg	O
18	-	O
19	1	O
20	,	O
21	and	O
22	atropine	O
23	0	O
24	.	O
25	2	O
26	-	O
27	0	O
28	.	O
29	4	O
30	mg	O
31	i	O
32	.	O
33	m	O
34	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	It	O
2	was	O
3	also	O
4	suggested	O
5	that	O
6	the	O
7	biological	O
8	activities	O
9	of	O
10	5	O
11	-	O
12	FU	O
13	,	O
14	ADM	O
15	and	O
16	MMC	O
17	in	O
18	FAMLIP	O
19	were	O
20	stable	O
21	in	O
22	FULIP	O
23	,	O
24	ADRLIP	O
25	and	O
26	MMCLIP	O
27	.	O

1	Surprisingly	O
2	,	O
3	a	O
4	C	O
5	to	O
6	G	O
7	transversion	O
8	at	O
9	the	O
10	first	O
11	residue	O
12	of	O
13	the	O
14	CAT	B
15	pentanucleotide	I
16	,	O
17	which	O
18	severely	O
19	impairs	O
20	the	O
21	activity	O
22	of	O
23	both	O
24	promoters	O
25	,	O
26	appears	O
27	to	O
28	increase	O
29	affinity	O
30	of	O
31	the	O
32	CAT	B
33	binding	I
34	protein	I
35	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	3874	O
6	bp	O
7	of	O
8	cloned	O
9	R	O
10	.	O
11	sphaeroides	O
12	chromosomal	O
13	DNA	O
14	,	O
15	including	O
16	the	O
17	three	O
18	structural	O
19	genes	O
20	fbcF	B
21	,	O
22	fbcB	B
23	and	O
24	fbcC	B
25	has	O
26	been	O
27	determined	O
28	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	sequence	O
6	of	O
7	one	O
8	hydrophilic	O
9	peptide	O
10	of	O
11	the	O
12	FeS	B
13	protein	I
14	has	O
15	been	O
16	also	O
17	obtained	O
18	confirming	O
19	the	O
20	fbcF	B
21	reading	O
22	frame	O
23	.	O

1	The	O
2	5	O
3	'	O
4	and	O
5	3	O
6	'	O
7	untranslated	O
8	sequences	O
9	contain	O
10	characteristic	O
11	sequences	O
12	that	O
13	are	O
14	involved	O
15	in	O
16	the	O
17	initiation	O
18	and	O
19	termination	O
20	of	O
21	transcription	O
22	,	O
23	including	O
24	two	O
25	possible	O
26	promoters	O
27	,	O
28	one	O
29	of	O
30	which	O
31	may	O
32	contain	O
33	two	O
34	overlapping	O
35	-	O
36	10	O
37	sequences	O
38	.	O

1	Unlike	O
2	P135gag	B
3	-	O
4	myb	B
5	-	O
6	ets	B
7	and	O
8	the	O
9	Mr	O
10	75	O
11	,	O
12	000	O
13	translation	O
14	product	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	(	O
20	P75c	B
21	-	I
22	myb	I
23	),	O
24	which	O
25	are	O
26	nuclear	O
27	proteins	O
28	,	O
29	P54c	B
30	-	I
31	ets	I
32	was	O
33	found	O
34	to	O
35	be	O
36	predominantly	O
37	cytoplasmic	O
38	.	O

1	The	O
2	Dox	B
3	-	I
4	A2	I
5	locus	I
6	is	O
7	within	O
8	3	O
9	.	O
10	4	O
11	to	O
12	4	O
13	.	O
14	4	O
15	kb	O
16	of	O
17	the	O
18	Df	B
19	(	I
20	2L	I
21	)	I
22	OD15	I
23	breakpoint	I
24	,	O
25	placing	O
26	four	O
27	of	O
28	the	O
29	vital	O
30	loci	O
31	within	O
32	a	O
33	maximum	O
34	of	O
35	15	O
36	.	O
37	5	O
38	kb	O
39	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	end	O
6	of	O
7	this	O
8	polypeptide	O
9	harbors	O
10	three	O
11	types	O
12	of	O
13	repeated	O
14	sequences	O
15	.	O

1	Further	O
2	outbreaks	O
3	of	O
4	ocular	O
5	disease	O
6	in	O
7	farmed	O
8	red	O
9	deer	O
10	calves	O
11	caused	O
12	by	O
13	HVC	O
14	-	O
15	1	O
16	were	O
17	investigated	O
18	.	O

1	From	O
2	our	O
3	ultrastructural	O
4	and	O
5	biochemical	O
6	studies	O
7	,	O
8	it	O
9	is	O
10	evident	O
11	that	O
12	Type	O
13	II	O
14	pneumocytes	O
15	are	O
16	an	O
17	early	O
18	target	O
19	of	O
20	radiation	O
21	and	O
22	the	O
23	release	O
24	of	O
25	surfactant	O
26	into	O
27	the	O
28	alveolus	O
29	shortly	O
30	after	O
31	exposure	O
32	persists	O
33	for	O
34	days	O
35	and	O
36	weeks	O
37	.	O

1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O

1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	The	O
2	open	O
3	reading	O
4	frames	O
5	of	O
6	rbsD	B
7	,	O
8	rbsA	B
9	,	O
10	and	O
11	rbsC	B
12	encode	O
13	proteins	O
14	of	O
15	139	O
16	,	O
17	501	O
18	,	O
19	and	O
20	321	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	respectively	O
26	.	O

1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	influence	O
7	of	O
8	iron	O
9	overload	O
10	on	O
11	the	O
12	polymorphonuclear	O
13	leucocyte	O
14	(	O
15	PMN	O
16	)	O
17	metabolism	O
18	of	O
19	patients	O
20	on	O
21	chronic	O
22	hemodialysis	O
23	,	O
24	generation	O
25	of	O
26	superoxide	O
27	anion	O
28	(	O
29	O2	O
30	-)	O
31	by	O
32	PMN	O
33	in	O
34	whole	O
35	blood	O
36	was	O
37	compared	O
38	in	O
39	two	O
40	groups	O
41	of	O
42	hemodialyzed	O
43	patients	O
44	:	O
45	group	O
46	A	O
47	consisted	O
48	of	O
49	twenty	O
50	-	O
51	one	O
52	individuals	O
53	with	O
54	serum	O
55	ferritin	B
56	levels	O
57	above	O
58	1000	O
59	ng	O
60	/	O
61	ml	O
62	and	O
63	group	O
64	B	O
65	of	O
66	nineteen	O
67	individuals	O
68	with	O
69	serum	O
70	ferritin	B
71	levels	O
72	below	O
73	1000	O
74	ng	O
75	/	O
76	ml	O
77	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	Human	B
2	alpha	I
3	-	I
4	galactosidase	I
5	A	I
6	:	O
7	nucleotide	O
8	sequence	O
9	of	O
10	a	O
11	cDNA	O
12	clone	O
13	encoding	O
14	the	O
15	mature	O
16	enzyme	O
17	.	O

1	Diazepam	O
2	(	O
3	3	O
4	mg	O
5	/	O
6	kg	O
7	)	O
8	generalized	O
9	to	O
10	Ro	O
11	11	O
12	-	O
13	6896	O
14	whereas	O
15	the	O
16	structurally	O
17	related	O
18	Ro	O
19	5	O
20	-	O
21	4864	O
22	(	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	and	O
28	30	O
29	mg	O
30	/	O
31	kg	O
32	)	O
33	did	O
34	not	O
35	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	was	O
6	determined	O
7	to	O
8	be	O
9	residues	O
10	716	O
11	-	O
12	724	O
13	and	O
14	hence	O
15	lysine	O
16	residue	O
17	721	O
18	is	O
19	located	O
20	within	O
21	the	O
22	ATP	O
23	-	O
24	binding	O
25	site	O
26	.	O

1	Osteocalcin	B
2	(	O
3	and	O
4	urinary	O
5	hydroxyproline	O
6	)	O
7	were	O
8	not	O
9	elevated	O
10	in	O
11	isolated	O
12	hyperphosphatasaemia	O
13	,	O
14	indicating	O
15	that	O
16	mechanisms	O
17	other	O
18	than	O
19	increased	O
20	bone	O
21	turnover	O
22	may	O
23	account	O
24	for	O
25	the	O
26	markedly	O
27	elevated	O
28	serum	B
29	alkaline	I
30	phosphatase	I
31	activity	O
32	in	O
33	these	O
34	subjects	O
35	.	O

1	Analysis	O
2	of	O
3	glucocorticoid	O
4	unresponsive	O
5	cell	O
6	variants	O
7	using	O
8	a	O
9	mouse	B
10	glucocorticoid	I
11	receptor	I
12	complementary	O
13	DNA	O
14	clone	O
15	.	O

1	Among	O
2	the	O
3	v	B
4	-	I
5	myc	I
6	codons	O
7	,	O
8	the	O
9	first	O
10	5	O
11	are	O
12	derived	O
13	from	O
14	the	O
15	noncoding	O
16	5	O
17	'	O
18	terminus	O
19	of	O
20	the	O
21	second	O
22	c	B
23	-	I
24	myc	I
25	exon	O
26	,	O
27	and	O
28	412	O
29	codons	O
30	correspond	O
31	to	O
32	the	O
33	c	B
34	-	I
35	myc	I
36	coding	O
37	region	O
38	.	O

1	A	O
2	recombinant	O
3	vector	O
4	,	O
5	p410	O
6	+,	O
7	was	O
8	constructed	O
9	which	O
10	carried	O
11	the	O
12	BamHI	B
13	-	I
14	K	I
15	fragment	I
16	(	O
17	nucleotides	O
18	107565	O
19	to	O
20	112625	O
21	of	O
22	the	O
23	B95	O
24	-	O
25	8	O
26	strain	O
27	,	O
28	encoding	O
29	the	O
30	EBV	O
31	-	O
32	associated	O
33	nuclear	O
34	antigen	O
35	EBNA	B
36	-	I
37	1	I
38	),	O
39	the	O
40	cis	O
41	-	O
42	acting	O
43	sequence	O
44	from	O
45	the	O
46	BamHI	B
47	-	I
48	C	I
49	fragment	I
50	,	O
51	and	O
52	a	O
53	dominant	O
54	selectable	O
55	marker	O
56	gene	O
57	encoding	O
58	G	O
59	-	O
60	418	O
61	resistance	O
62	in	O
63	animal	O
64	cells	O
65	.	O

1	13	O
2	men	O
3	with	O
4	a	O
5	history	O
6	of	O
7	recurrent	O
8	genital	O
9	herpes	O
10	simplex	O
11	virus	O
12	type	O
13	2	O
14	(	O
15	HSV	O
16	-	O
17	2	O
18	)	O
19	infection	O
20	were	O
21	followed	O
22	daily	O
23	for	O
24	4	O
25	weeks	O
26	with	O
27	samples	O
28	taken	O
29	from	O
30	the	O
31	urethra	O
32	for	O
33	virus	O
34	isolation	O
35	.	O

1	Next	O
2	,	O
3	with	O
4	carcinoma	O
5	presenting	O
6	a	O
7	leather	O
8	bottle	O
9	(	O
10	linitis	O
11	plastica	O
12	type	O
13	)	O
14	of	O
15	the	O
16	stomach	O
17	itself	O
18	,	O
19	the	O
20	II	O
21	c	O
22	portion	O
23	of	O
24	the	O
25	stomach	O
26	consisted	O
27	of	O
28	fundic	O
29	glands	O
30	(	O
31	undifferentiated	O
32	carcinoma	O
33	)	O
34	shall	O
35	become	O
36	the	O
37	primary	O
38	focus	O
39	supporting	O
40	Nakamura	O
41	'	O
42	s	O
43	theory	O
44	.	O

1	During	O
2	the	O
3	biosynthesis	O
4	of	O
5	all	O
6	three	O
7	mutant	O
8	polypeptides	O
9	,	O
10	the	O
11	signal	O
12	peptide	O
13	is	O
14	efficiently	O
15	and	O
16	accurately	O
17	cleaved	O
18	from	O
19	the	O
20	nascent	O
21	protein	O
22	,	O
23	even	O
24	though	O
25	in	O
26	mutants	O
27	X2	O
28	and	O
29	X3	O
30	the	O
31	cleavage	O
32	site	O
33	itself	O
34	has	O
35	been	O
36	altered	O
37	.	O

1	The	O
2	hexanucleotide	O
3	5	O
4	'-	O
5	TGTCCT	O
6	-	O
7	3	O
8	',	O
9	thought	O
10	to	O
11	be	O
12	important	O
13	for	O
14	GRE	O
15	activity	O
16	,	O
17	not	O
18	only	O
19	was	O
20	found	O
21	in	O
22	this	O
23	sequence	O
24	and	O
25	in	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	,	O
32	but	O
33	also	O
34	was	O
35	present	O
36	twice	O
37	in	O
38	the	O
39	3	O
40	'	O
41	end	O
42	of	O
43	the	O
44	gene	O
45	that	O
46	did	O
47	not	O
48	show	O
49	specific	O
50	receptor	O
51	binding	O
52	.	O

1	Five	O
2	patients	O
3	developed	O
4	metastatic	O
5	spread	O
6	,	O
7	and	O
8	all	O
9	of	O
10	them	O
11	died	O
12	of	O
13	tumor	O
14	.	O

1	The	O
2	smallest	O
3	of	O
4	the	O
5	mini	O
6	-	O
7	Mu	O
8	elements	O
9	is	O
10	only	O
11	7	O
12	.	O
13	9	O
14	kilobase	O
15	pairs	O
16	long	O
17	,	O
18	allowing	O
19	the	O
20	cloning	O
21	of	O
22	DNA	O
23	fragments	O
24	of	O
25	up	O
26	to	O
27	31	O
28	.	O
29	1	O
30	kilobase	O
31	pairs	O
32	,	O
33	and	O
34	the	O
35	largest	O
36	of	O
37	them	O
38	is	O
39	21	O
40	.	O
41	7	O
42	kilobase	O
43	pairs	O
44	,	O
45	requiring	O
46	that	O
47	clones	O
48	carry	O
49	insertions	O
50	of	O
51	less	O
52	than	O
53	17	O
54	.	O
55	3	O
56	kilobase	O
57	pairs	O
58	.	O

1	The	O
2	52	O
3	-	O
4	protein	O
5	subunit	O
6	of	O
7	T4	B
8	DNA	I
9	topoisomerase	I
10	is	O
11	homologous	O
12	to	O
13	the	O
14	gyrA	B
15	-	I
16	protein	I
17	of	O
18	gyrase	B
19	.	O

1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O

1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O

1	The	O
2	nucleosomal	O
3	arrays	O
4	detected	O
5	by	O
6	MPE	O
7	X	O
8	Fe	O
9	(	O
10	II	O
11	)	O
12	were	O
13	characterized	O
14	by	O
15	a	O
16	considerable	O
17	loss	O
18	of	O
19	detail	O
20	and	O
21	significantly	O
22	enhanced	O
23	accessibility	O
24	,	O
25	the	O
26	extent	O
27	of	O
28	which	O
29	probably	O
30	reflected	O
31	the	O
32	relative	O
33	transcription	O
34	rate	O
35	of	O
36	each	O
37	gene	O
38	.	O

1	Translation	O
2	of	O
3	specific	O
4	cellular	O
5	genes	O
6	from	O
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	unlikely	O
17	.	O

1	The	O
2	molecular	O
3	weight	O
4	of	O
5	in	O
6	vivo	O
7	-	O
8	labeled	O
9	proteins	O
10	was	O
11	increased	O
12	relative	O
13	to	O
14	that	O
15	of	O
16	in	O
17	vitro	O
18	-	O
19	translated	O
20	proteins	O
21	,	O
22	indicating	O
23	that	O
24	a	O
25	posttranslational	O
26	modification	O
27	had	O
28	occurred	O
29	.	O

1	Insertion	O
2	of	O
3	4	O
4	bp	O
5	reduced	O
6	SV40	B
7	early	I
8	promoter	I
9	-	O
10	dependent	O
11	chloramphenicol	B
12	acetyltransferase	I
13	(	O
14	CAT	B
15	)	O
16	expression	O
17	by	O
18	six	O
19	-	O
20	to	O
21	eightfold	O
22	.	O

1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	O
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	O
25	chromosome	O
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	B
36	(	O
37	breakpoint	B
38	cluster	I
39	region	I
40	).	O

1	Nuclease	O
2	footprinting	O
3	revealed	O
4	that	O
5	purified	O
6	glucocorticoid	B
7	receptor	I
8	bound	O
9	at	O
10	multiple	O
11	discrete	O
12	sites	O
13	within	O
14	and	O
15	at	O
16	the	O
17	borders	O
18	of	O
19	the	O
20	tandemly	O
21	repeated	O
22	sequence	O
23	motif	O
24	that	O
25	defines	O
26	Sa	B
27	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	B
26	product	I
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	All	O
2	tumors	O
3	proved	O
4	histologically	O
5	to	O
6	be	O
7	neuroendocrine	O
8	in	O
9	origin	O
10	.	O

1	The	O
2	coding	O
3	region	O
4	of	O
5	2385	O
6	nucleotides	O
7	corresponds	O
8	to	O
9	a	O
10	polypeptide	O
11	chain	O
12	of	O
13	795	O
14	amino	O
15	acids	O
16	,	O
17	giving	O
18	a	O
19	molecular	O
20	weight	O
21	of	O
22	91	O
23	,	O
24	555	O
25	for	O
26	the	O
27	hsp108	B
28	protein	I
29	.	O

1	Transcriptional	O
2	control	O
3	signals	O
4	of	O
5	a	O
6	herpes	B
7	simplex	I
8	virus	I
9	type	I
10	1	I
11	late	I
12	(	I
13	gamma	I
14	2	I
15	)	I
16	gene	I
17	lie	O
18	within	O
19	bases	O
20	-	O
21	34	O
22	to	O
23	+	O
24	124	O
25	relative	O
26	to	O
27	the	O
28	5	O
29	'	O
30	terminus	O
31	of	O
32	the	O
33	mRNA	O
34	.	O

1	A	O
2	noncatalytic	O
3	domain	O
4	conserved	O
5	among	O
6	cytoplasmic	B
7	protein	I
8	-	I
9	tyrosine	I
10	kinases	I
11	modifies	O
12	the	O
13	kinase	O
14	function	O
15	and	O
16	transforming	O
17	activity	O
18	of	O
19	Fujinami	B
20	sarcoma	I
21	virus	I
22	P130gag	I
23	-	O
24	fps	B
25	.	O

1	Gluzman	O
2	,	O
3	EMBO	O
4	J	O
5	.	O

1	A	O
2	single	O
3	exon	O
4	encodes	O
5	the	O
6	carboxyl	O
7	-	O
8	terminal	O
9	26	O
10	amino	O
11	acids	O
12	of	O
13	the	O
14	ssd	B
15	chain	I
16	and	O
17	the	O
18	3	O
19	'	O
20	untranslated	O
21	region	O
22	of	O
23	its	O
24	mRNA	O
25	,	O
26	ending	O
27	with	O
28	a	O
29	poly	O
30	(	O
31	A	O
32	)-	O
33	addition	O
34	site	O
35	.	O

1	The	O
2	5	O
3	'-	O
4	nontranslated	O
5	sequences	O
6	and	O
7	parts	O
8	of	O
9	the	O
10	coding	O
11	sequences	O
12	of	O
13	various	O
14	yeast	O
15	genes	O
16	have	O
17	been	O
18	cloned	O
19	into	O
20	representative	O
21	lacZ	B
22	fusion	O
23	vectors	O
24	.	O

1	Two	O
2	activities	O
3	of	O
4	the	O
5	D	B
6	protein	I
7	of	O
8	the	O
9	miniF	O
10	plasmid	O
11	have	O
12	been	O
13	found	O
14	.	O

1	SPECT	O
2	examination	O
3	of	O
4	the	O
5	TMJ	O
6	using	O
7	99m	O
8	Tc	O
9	-	O
10	MDP	O
11	was	O
12	performed	O
13	in	O
14	43	O
15	patients	O
16	with	O
17	arthrographically	O
18	proven	O
19	anterior	O
20	dislocation	O
21	of	O
22	the	O
23	disc	O
24	and	O
25	in	O
26	30	O
27	normals	O
28	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	rose	O
5	and	O
6	the	O
7	plasma	O
8	aldosterone	O
9	level	O
10	fell	O
11	after	O
12	taking	O
13	lisinopril	O
14	.	O

1	Two	O
2	mutants	O
3	,	O
4	each	O
5	representative	O
6	of	O
7	a	O
8	separate	O
9	pet	B
10	complementation	O
11	group	O
12	,	O
13	have	O
14	been	O
15	analyzed	O
16	.	O

1	The	O
2	second	O
3	group	O
4	of	O
5	homologous	O
6	elements	O
7	is	O
8	present	O
9	in	O
10	the	O
11	upstream	O
12	region	O
13	of	O
14	both	O
15	genes	O
16	.	O

1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O

1	Constitutive	O
2	function	O
3	of	O
4	a	O
5	positively	O
6	regulated	O
7	promoter	O
8	reveals	O
9	new	O
10	sequences	O
11	essential	O
12	for	O
13	activity	O
14	.	O

1	Two	O
2	separate	O
3	NF1	B
4	-	I
5	binding	I
6	loci	I
7	were	O
8	also	O
9	found	O
10	in	O
11	the	O
12	equivalent	O
13	IE68	B
14	gene	I
15	of	O
16	HCMV	O
17	(	O
18	Towne	O
19	)	O
20	DNA	O
21	,	O
22	but	O
23	in	O
24	this	O
25	case	O
26	the	O
27	DNA	O
28	sequence	O
29	and	O
30	competition	O
31	filter	O
32	binding	O
33	experiments	O
34	indicated	O
35	a	O
36	maximum	O
37	of	O
38	only	O
39	four	O
40	to	O
41	five	O
42	consensus	O
43	binding	O
44	sites	O
45	encompassing	O
46	the	O
47	promoter	O
48	-	O
49	enhancer	O
50	region	O
51	.	O

1	The	O
2	previously	O
3	described	O
4	four	O
5	sets	O
6	of	O
7	13	O
8	-	O
9	to	O
10	18	O
11	-	O
12	base	O
13	-	O
14	pair	O
15	interspersed	O
16	repeat	O
17	elements	O
18	between	O
19	-	O
20	55	O
21	and	O
22	-	O
23	580	O
24	provide	O
25	most	O
26	of	O
27	the	O
28	high	O
29	basal	O
30	transcriptional	O
31	strength	O
32	,	O
33	whereas	O
34	the	O
35	arrangement	O
36	of	O
37	further	O
38	upstream	O
39	tandemly	O
40	repeated	O
41	NF1	B
42	-	I
43	binding	I
44	sites	I
45	may	O
46	contribute	O
47	significantly	O
48	to	O
49	the	O
50	expanded	O
51	biological	O
52	host	O
53	range	O
54	for	O
55	expression	O
56	of	O
57	SCMV	B
58	IE94	I
59	compared	O
60	with	O
61	HCMV	B
62	IE68	I
63	.	O

1	We	O
2	inserted	O
3	genes	O
4	or	O
5	gene	O
6	segments	O
7	,	O
8	that	O
9	code	O
10	for	O
11	the	O
12	bacterial	B
13	chloramphenicol	I
14	acetyltransferase	I
15	,	O
16	the	O
17	bacterial	O
18	gene	O
19	conferring	O
20	resistance	O
21	against	O
22	hygromycin	O
23	,	O
24	and	O
25	the	O
26	ORF	O
27	E7	B
28	of	O
29	the	O
30	human	O
31	papillomavirus	O
32	type	O
33	18	O
34	into	O
35	these	O
36	vectors	O
37	.	O

1	By	O
2	contrast	O
3	,	O
4	their	O
5	basal	O
6	adrenal	O
7	androgen	O
8	levels	O
9	were	O
10	significantly	O
11	decreased	O
12	compared	O
13	to	O
14	those	O
15	in	O
16	normal	O
17	subjects	O
18	on	O
19	both	O
20	the	O
21	day	O
22	on	O
23	and	O
24	the	O
25	day	O
26	off	O
27	prednisone	O
28	(	O
29	P	O
30	less	O
31	than	O
32	0	O
33	.	O
34	05	O
35	).	O

1	Active	O
2	lambda	B
3	and	I
4	kappa	I
5	antibody	I
6	gene	I
7	rearrangement	O
8	in	O
9	Abelson	O
10	murine	O
11	leukemia	O
12	virus	O
13	-	O
14	transformed	O
15	pre	O
16	-	O
17	B	O
18	cell	O
19	lines	O
20	.	O

1	Identification	O
2	of	O
3	p40x	O
4	-	O
5	responsive	O
6	regulatory	O
7	sequences	O
8	within	O
9	the	O
10	human	O
11	T	O
12	-	O
13	cell	O
14	leukemia	O
15	virus	O
16	type	O
17	I	O
18	long	O
19	terminal	O
20	repeat	O
21	.	O

1	During	O
2	pentobarbital	O
3	anesthesia	O
4	,	O
5	the	O
6	basal	O
7	VO2	O
8	was	O
9	5	O
10	.	O
11	26	O
12	ml	O
13	/	O
14	kg	O
15	/	O
16	min	O
17	and	O
18	was	O
19	increased	O
20	by	O
21	epinephrine	O
22	in	O
23	a	O
24	dose	O
25	dependent	O
26	manner	O
27	at	O
28	plasma	O
29	concentrations	O
30	between	O
31	3	O
32	.	O
33	9	O
34	ng	O
35	/	O
36	ml	O
37	(	O
38	VO2	O
39	=	O
40	5	O
41	.	O
42	68	O
43	ml	O
44	/	O
45	kg	O
46	/	O
47	min	O
48	)	O
49	and	O
50	36	O
51	.	O
52	5	O
53	ng	O
54	/	O
55	ml	O
56	(	O
57	VO2	O
58	=	O
59	6	O
60	.	O
61	47	O
62	ml	O
63	/	O
64	kg	O
65	/	O
66	min	O
67	).	O

1	Influence	O
2	of	O
3	cyclo	B
4	-	I
5	oxygenase	I
6	inhibition	O
7	and	O
8	of	O
9	leukotriene	B
10	receptor	I
11	blockade	O
12	on	O
13	pulmonary	O
14	vascular	O
15	pressure	O
16	/	O
17	cardiac	O
18	index	O
19	relationships	O
20	in	O
21	hyperoxic	O
22	and	O
23	in	O
24	hypoxic	O
25	dogs	O
26	.	O

1	Oligonucleotide	O
2	-	O
3	directed	O
4	mutagenesis	O
5	was	O
6	used	O
7	to	O
8	create	O
9	an	O
10	NdeI	B
11	restriction	I
12	site	I
13	at	O
14	the	O
15	natural	O
16	ATG	O
17	of	O
18	the	O
19	yeast	O
20	R	O
21	.	O

1	ACTH	B
2	release	O
3	is	O
4	transiently	O
5	suppressed	O
6	in	O
7	some	O
8	children	O
9	after	O
10	exogenous	O
11	ACTH	B
12	treatment	O
13	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	B
12	RP39A	I
13	gene	I
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	mammalian	O
6	erythroid	O
7	alpha	B
8	-	I
9	spectrin	I
10	evolved	O
11	by	O
12	duplication	O
13	and	O
14	rapid	O
15	divergence	O
16	from	O
17	an	O
18	ancestral	O
19	alpha	B
20	-	I
21	fodrin	I
22	-	I
23	like	I
24	gene	I
25	.	O

1	Northern	O
2	analyses	O
3	of	O
4	RNAs	O
5	from	O
6	mouse	O
7	tissues	O
8	and	O
9	cell	O
10	lines	O
11	indicated	O
12	that	O
13	p11	B
14	mRNA	I
15	levels	O
16	vary	O
17	widely	O
18	.	O

1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	IR2	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	polymorphism	O
29	for	O
30	the	O
31	enzyme	B
32	SmaI	I
33	.	O

1	Combined	O
2	immunochemotherapy	O
3	with	O
4	cyclophosphamide	O
5	plus	O
6	BCG	O
7	gave	O
8	a	O
9	better	O
10	enhancement	O
11	of	O
12	the	O
13	antitumor	O
14	effect	O
15	of	O
16	the	O
17	cytostatic	O
18	than	O
19	that	O
20	of	O
21	the	O
22	combination	O
23	of	O
24	methotrexate	O
25	plus	O
26	BCG	O
27	and	O
28	cyclophosphamide	O
29	plus	O
30	levamisole	O
31	.	O

1	Morphine	O
2	produced	O
3	a	O
4	dose	O
5	-	O
6	dependent	O
7	bradycardia	O
8	followed	O
9	by	O
10	tachycardia	O
11	.	O

1	The	O
2	PSS	B
3	gene	I
4	was	O
5	subcloned	O
6	into	O
7	a	O
8	1	O
9	.	O
10	1	O
11	-	O
12	kb	O
13	fragment	O
14	of	O
15	the	O
16	yeast	O
17	DNA	O
18	on	O
19	the	O
20	YEp13	O
21	vector	O
22	.	O

1	Indeed	O
2	,	O
3	A	O
4	-	O
5	MuLV	O
6	pseudotyped	O
7	with	O
8	some	O
9	viruses	O
10	,	O
11	such	O
12	as	O
13	the	O
14	Moloney	O
15	MuLV	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	be	O
22	highly	O
23	lymphogenic	O
24	,	O
25	whereas	O
26	A	O
27	-	O
28	MuLV	O
29	pseudotyped	O
30	with	O
31	other	O
32	viruses	O
33	,	O
34	such	O
35	as	O
36	the	O
37	BALB	O
38	/	O
39	c	O
40	endogenous	O
41	N	O
42	-	O
43	tropic	O
44	MuLV	O
45	,	O
46	has	O
47	been	O
48	shown	O
49	to	O
50	be	O
51	devoid	O
52	of	O
53	lymphogenic	O
54	potential	O
55	(	O
56	N	O
57	.	O

1	The	O
2	presence	O
3	of	O
4	circulating	O
5	platelet	O
6	aggregates	O
7	and	O
8	elevated	O
9	levels	O
10	of	O
11	fibrinopeptide	B
12	A	I
13	(	O
14	a	O
15	cleavage	O
16	product	O
17	of	O
18	fibrin	B
19	)	O
20	suggests	O
21	that	O
22	platelet	O
23	activation	O
24	and	O
25	fibrin	B
26	deposition	O
27	may	O
28	play	O
29	a	O
30	role	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	this	O
36	disorder	O
37	.	O

1	The	O
2	gene	O
3	is	O
4	essential	O
5	for	O
6	yeast	O
7	vegetative	O
8	growth	O
9	.	O

1	4	O
2	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	values	O
6	obtained	O
7	by	O
8	the	O
9	two	O
10	methods	O
11	were	O
12	in	O
13	agreement	O
14	for	O
15	each	O
16	species	O
17	of	O
18	epidermal	B
19	growth	I
20	factor	I
21	and	O
22	followed	O
23	the	O
24	order	O
25	:	O
26	wild	O
27	type	O
28	greater	O
29	than	O
30	Glu24	O
31	----	O
32	Gly	O
33	greater	O
34	than	O
35	Asp27	O
36	----	O
37	Gly	O
38	much	O
39	greater	O
40	than	O
41	Pro7	O
42	----	O
43	Thr	O
44	greater	O
45	than	O
46	Tyr29	O
47	----	O
48	Gly	O
49	greater	O
50	than	O
51	Leu47	O
52	----	O
53	His	O
54	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	suppression	O
6	of	O
7	elevated	O
8	prolactin	B
9	levels	O
10	in	O
11	progressive	O
12	metastatic	O
13	breast	O
14	cancer	O
15	patients	O
16	is	O
17	not	O
18	effective	O
19	in	O
20	restoring	O
21	tumor	O
22	sensitivity	O
23	to	O
24	chemotherapy	O
25	.	O

1	We	O
2	report	O
3	a	O
4	prevalence	O
5	study	O
6	of	O
7	the	O
8	best	O
9	visual	O
10	acuity	O
11	in	O
12	the	O
13	affected	O
14	eye	O
15	of	O
16	100	O
17	selected	O
18	patients	O
19	with	O
20	herpetic	O
21	keratitis	O
22	seen	O
23	during	O
24	a	O
25	two	O
26	-	O
27	year	O
28	period	O
29	.	O

1	We	O
2	also	O
3	found	O
4	an	O
5	eIF	B
6	-	I
7	4A	I
8	intronless	O
9	retroposon	O
10	which	O
11	,	O
12	when	O
13	compared	O
14	to	O
15	the	O
16	cDNA	O
17	,	O
18	contains	O
19	a	O
20	single	O
21	nucleotide	O
22	difference	O
23	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	These	O
2	similarities	O
3	suggest	O
4	that	O
5	these	O
6	E2	B
7	proteins	I
8	are	O
9	structurally	O
10	and	O
11	evolutionarily	O
12	related	O
13	.	O

1	After	O
2	infection	O
3	of	O
4	293	O
5	cells	O
6	(	O
7	which	O
8	provide	O
9	complementary	O
10	E1a	B
11	-	O
12	E1b	B
13	functions	O
14	),	O
15	both	O
16	viruses	O
17	directed	O
18	equal	O
19	amounts	O
20	of	O
21	P	B
22	/	I
23	C	I
24	-	I
25	specific	I
26	mRNA	I
27	transcription	O
28	.	O

1	This	O
2	observation	O
3	cannot	O
4	be	O
5	explained	O
6	by	O
7	the	O
8	scanning	O
9	model	O
10	for	O
11	ribosomal	O
12	initiation	O
13	and	O
14	suggests	O
15	that	O
16	ribosomes	O
17	may	O
18	be	O
19	binding	O
20	directly	O
21	at	O
22	an	O
23	internal	O
24	mRNA	O
25	site	O
26	at	O
27	or	O
28	near	O
29	the	O
30	initiator	O
31	AUG	O
32	codon	O
33	for	O
34	the	O
35	C	B
36	protein	I
37	.	O

1	In	O
2	view	O
3	of	O
4	these	O
5	results	O
6	,	O
7	simultaneous	O
8	pancreas	O
9	-	O
10	kidney	O
11	transplantation	O
12	appears	O
13	to	O
14	be	O
15	the	O
16	treatment	O
17	of	O
18	choice	O
19	for	O
20	Type	O
21	I	O
22	diabetic	O
23	patients	O
24	.	O

1	This	O
2	makes	O
3	these	O
4	compounds	O
5	attractive	O
6	as	O
7	vehicles	O
8	for	O
9	these	O
10	and	O
11	other	O
12	gases	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O

1	DNA	O
2	sequencing	O
3	of	O
4	the	O
5	DPM1	B
6	gene	I
7	revealed	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	of	O
13	801	O
14	bases	O
15	.	O

1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O

1	Administration	O
2	of	O
3	anticoagulants	O
4	,	O
5	i	O
6	.	O
7	e	O
8	.,	O
9	heparin	O
10	,	O
11	prostaglandin	O
12	E1	O
13	and	O
14	ticlopidine	O
15	seems	O
16	to	O
17	be	O
18	effective	O
19	in	O
20	alleviating	O
21	symptoms	O
22	and	O
23	might	O
24	prevent	O
25	further	O
26	deterioration	O
27	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	L1	B
6	binding	I
7	site	I
8	of	O
9	23S	B
10	rRNA	I
11	in	I
12	Escherichia	I
13	coli	I
14	.	O

1	Animals	O
2	may	O
3	be	O
4	immunized	O
5	by	O
6	oral	O
7	vaccination	O
8	,	O
9	but	O
10	natural	O
11	mechanisms	O
12	that	O
13	also	O
14	can	O
15	terminate	O
16	outbreaks	O
17	are	O
18	discussed	O
19	.	O

1	Prostacyclin	O
2	formation	O
3	,	O
4	reflected	O
5	by	O
6	the	O
7	excretion	O
8	rate	O
9	of	O
10	its	O
11	stable	O
12	metabolite	O
13	6	O
14	-	O
15	keto	O
16	-	O
17	prostaglandin	O
18	F1	O
19	alpha	O
20	,	O
21	was	O
22	measured	O
23	by	O
24	means	O
25	of	O
26	radioimmunoassay	O
27	in	O
28	4	O
29	-	O
30	hour	O
31	urine	O
32	specimens	O
33	obtained	O
34	during	O
35	a	O
36	smoking	O
37	-	O
38	free	O
39	period	O
40	and	O
41	after	O
42	participants	O
43	had	O
44	inhaled	O
45	smoke	O
46	from	O
47	four	O
48	high	O
49	-	O
50	nicotine	O
51	cigarettes	O
52	.	O

1	However	O
2	,	O
3	excretion	O
4	of	O
5	6	O
6	-	O
7	keto	O
8	-	O
9	prostaglandin	O
10	F1	O
11	alpha	O
12	was	O
13	further	O
14	reduced	O
15	in	O
16	the	O
17	smokers	O
18	who	O
19	used	O
20	oral	O
21	contraceptives	O
22	(	O
23	133	O
24	+/-	O
25	20	O
26	to	O
27	86	O
28	+/-	O
29	9	O
30	ng	O
31	/	O
32	gm	O
33	of	O
34	creatinine	O
35	,	O
36	p	O
37	less	O
38	than	O
39	0	O
40	.	O
41	05	O
42	).	O

1	The	O
2	in	O
3	vitro	O
4	activity	O
5	of	O
6	mecillinam	O
7	and	O
8	amoxicillin	O
9	/	O
10	clavulanic	O
11	acid	O
12	against	O
13	Escherichia	O
14	coli	O
15	strains	O
16	producing	O
17	beta	B
18	-	I
19	lactamases	I
20	of	O
21	the	O
22	TEM	B
23	-	I
24	1	I
25	,	O
26	Oxa	B
27	-	I
28	1	I
29	and	O
30	chromosomal	O
31	type	O
32	were	O
33	studied	O
34	using	O
35	the	O
36	broth	O
37	and	O
38	agar	O
39	dilution	O
40	technique	O
41	.	O

1	GCN4	B
2	encodes	O
3	a	O
4	transcriptional	O
5	activator	O
6	of	O
7	amino	O
8	acid	O
9	biosynthetic	O
10	genes	O
11	in	O
12	Saccharomyces	O
13	cerevisiae	O
14	.	O

1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	B
7	product	I
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	B
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O

1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	S	O
8	.	O
9	aureus	O
10	peptide	O
11	carrying	O
12	the	O
13	phosphoryl	O
14	group	O
15	was	O
16	found	O
17	to	O
18	be	O
19	Gln	O
20	-	O
21	Val	O
22	-	O
23	Val	O
24	-	O
25	Ser	O
26	-	O
27	Thr	O
28	-	O
29	Phe	O
30	-	O
31	Met	O
32	-	O
33	Gly	O
34	-	O
35	Asn	O
36	-	O
37	Gly	O
38	-	O
39	Leu	O
40	-	O
41	Ala	O
42	-	O
43	Ile	O
44	-	O
45	Pro	O
46	-	O
47	His	O
48	-	O
49	Gly	O
50	-	O
51	Thr	O
52	-	O
53	Asp	O
54	-	O
55	Asp	O
56	.	O

1	These	O
2	mutations	O
3	alter	O
4	two	O
5	regions	O
6	of	O
7	GAL4	B
8	protein	I
9	:	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	,	O
15	and	O
16	the	O
17	transcription	O
18	activation	O
19	domain	O
20	.	O

1	The	O
2	results	O
3	indicated	O
4	that	O
5	two	O
6	genes	O
7	(	O
8	citA	B
9	and	O
10	citB	B
11	)	O
12	have	O
13	separate	O
14	promoters	O
15	,	O
16	and	O
17	the	O
18	location	O
19	of	O
20	the	O
21	promoter	O
22	for	O
23	the	O
24	citB	B
25	gene	I
26	in	O
27	the	O
28	Tn3411	B
29	nucleotide	O
30	sequence	O
31	was	O
32	different	O
33	from	O
34	that	O
35	in	O
36	pMS185	O
37	.	O

1	The	O
2	rci	B
3	gene	I
4	was	O
5	fused	O
6	with	O
7	lacZ	B
8	and	O
9	its	O
10	gene	O
11	product	O
12	was	O
13	identified	O
14	by	O
15	Western	O
16	blot	O
17	analysis	O
18	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	a	O
6	nuclear	O
7	gene	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	that	O
12	specifies	O
13	MRP13	B
14	,	O
15	a	O
16	protein	O
17	of	O
18	the	O
19	small	O
20	subunit	O
21	of	O
22	the	O
23	mitochondrial	O
24	ribosome	O
25	.	O

1	After	O
2	a	O
3	survey	O
4	of	O
5	the	O
6	anatomical	O
7	and	O
8	physiological	O
9	basis	O
10	of	O
11	operative	O
12	treatment	O
13	of	O
14	behaviour	O
15	disorders	O
16	by	O
17	stereotactic	O
18	lesions	O
19	in	O
20	the	O
21	amygdala	O
22	and	O
23	the	O
24	posterior	O
25	medial	O
26	hypothalamus	O
27	the	O
28	author	O
29	describes	O
30	his	O
31	own	O
32	experiences	O
33	with	O
34	603	O
35	operations	O
36	for	O
37	control	O
38	of	O
39	conservatively	O
40	untreatable	O
41	aggressiveness	O
42	.	O

1	Histological	O
2	examination	O
3	revealed	O
4	a	O
5	small	O
6	simple	O
7	renal	O
8	cyst	O
9	associated	O
10	with	O
11	renal	O
12	cell	O
13	carcinoma	O
14	.	O

1	Although	O
2	large	O
3	epidemiologic	O
4	studies	O
5	are	O
6	best	O
7	able	O
8	to	O
9	identify	O
10	the	O
11	relative	O
12	contributions	O
13	of	O
14	specific	O
15	risk	O
16	factors	O
17	while	O
18	controlling	O
19	for	O
20	other	O
21	risk	O
22	factors	O
23	,	O
24	new	O
25	studies	O
26	need	O
27	to	O
28	focus	O
29	on	O
30	important	O
31	unresolved	O
32	questions	O
33	.	O

1	Thus	O
2	,	O
3	prostacyclin	O
4	enhanced	O
5	the	O
6	autoregulative	O
7	property	O
8	of	O
9	the	O
10	inner	O
11	ear	O
12	vessels	O
13	.	O

1	The	O
2	method	O
3	is	O
4	accurate	O
5	,	O
6	with	O
7	good	O
8	precision	O
9	and	O
10	adequate	O
11	sensitivity	O
12	.	O

1	Factors	O
2	influencing	O
3	the	O
4	bond	O
5	strength	O
6	between	O
7	glass	O
8	polyalkenoate	O
9	(	O
10	ionomer	O
11	)	O
12	cements	O
13	and	O
14	dentine	O
15	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	yeast	O
8	and	O
9	mammalian	O
10	mitochondrial	O
11	targeting	O
12	sequences	O
13	are	O
14	similar	O
15	but	O
16	less	O
17	related	O
18	than	O
19	the	O
20	mature	O
21	polypeptides	O
22	.	O

1	Van	O
2	der	O
3	Ende	O
4	,	O
5	R	O
6	.	O

1	During	O
2	insulin	B
3	infusion	O
4	,	O
5	a	O
6	20	O
7	%	O
8	dextrose	O
9	solution	O
10	was	O
11	infused	O
12	by	O
13	a	O
14	Biostator	O
15	in	O
16	order	O
17	to	O
18	maintain	O
19	the	O
20	patient	O
21	'	O
22	s	O
23	glycemia	O
24	at	O
25	90	O
26	mg	O
27	/	O
28	dl	O
29	.	O

1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	B
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O

1	Mycobacterium	O
2	avium	O
3	-	O
4	intracellulare	O
5	complex	O
6	infections	O
7	in	O
8	the	O
9	acquired	O
10	immunodeficiency	O
11	syndrome	O
12	.	O

1	Recurrence	O
2	of	O
3	oxalate	O
4	deposition	O
5	in	O
6	a	O
7	renal	O
8	transplant	O
9	during	O
10	ciclosporin	O
11	A	O
12	therapy	O
13	.	O

1	The	O
2	bile	O
3	acid	O
4	sequestrants	O
5	(	O
6	cholestyramine	O
7	and	O
8	colestipol	O
9	),	O
10	nicotinic	O
11	acid	O
12	,	O
13	fenofibrate	O
14	and	O
15	inhibitors	O
16	of	O
17	hydroxymethylglutaryl	B
18	coenzyme	I
19	A	I
20	(	I
21	HMG	I
22	CoA	I
23	)	I
24	reductase	I
25	(	O
26	e	O
27	.	O
28	g	O
29	.	O
30	lovastatin	O
31	or	O
32	simvastatin	O
33	)	O
34	are	O
35	the	O
36	most	O
37	effective	O
38	drugs	O
39	for	O
40	use	O
41	in	O
42	patients	O
43	with	O
44	primary	O
45	hypercholesterolaemia	O
46	;	O
47	these	O
48	agents	O
49	reduce	O
50	plasma	O
51	concentrations	O
52	of	O
53	total	O
54	and	O
55	LDL	B
56	-	I
57	cholesterol	I
58	by	O
59	15	O
60	to	O
61	45	O
62	%.	O

1	Finally	O
2	,	O
3	the	O
4	pathophysiological	O
5	aspects	O
6	of	O
7	urinary	O
8	acidification	O
9	are	O
10	discussed	O
11	,	O
12	focusing	O
13	on	O
14	renal	O
15	tubular	O
16	acidosis	O
17	models	O
18	(	O
19	induced	O
20	by	O
21	maleate	O
22	and	O
23	amphotericin	O
24	B	O
25	treatment	O
26	)	O
27	and	O
28	their	O
29	cellular	O
30	mechanisms	O
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	role	O
37	of	O
38	adrenal	O
39	steroids	O
40	in	O
41	urinary	O
42	acidification	O
43	.	O

1	Analysis	O
2	in	O
3	3	O
4	groups	O
5	of	O
6	patients	O
7	suffering	O
8	from	O
9	simple	O
10	acute	O
11	and	O
12	pernicious	O
13	malarial	O
14	flare	O
15	-	O
16	ups	O

1	Statement	O
2	on	O
3	the	O
4	development	O
5	of	O
6	guidelines	O
7	for	O
8	the	O
9	prevention	O
10	of	O
11	AIDS	O
12	transmission	O
13	in	O
14	the	O
15	workplace	O
16	.	O

1	Modifications	O
2	of	O
3	the	O
4	involuntary	O
5	postcontraction	O
6	in	O
7	diseased	O
8	people	O
9	.	O

1	Cocaine	O
2	-	O
3	treated	O
4	rats	O
5	acquired	O
6	a	O
7	preference	O
8	for	O
9	cocaine	O
10	-	O
11	associated	O
12	contextual	O
13	stimuli	O
14	(	O
15	CS	O
16	)	O
17	relative	O
18	to	O
19	saline	O
20	-	O
21	injected	O
22	control	O
23	rats	O
24	.	O

1	Under	O
2	these	O
3	schedules	O
4	,	O
5	a	O
6	reinforced	O
7	response	O
8	run	O
9	consisted	O
10	of	O
11	responding	O
12	between	O
13	eight	O
14	and	O
15	12	O
16	times	O
17	on	O
18	one	O
19	response	O
20	key	O
21	(	O
22	work	O
23	key	O
24	)	O
25	and	O
26	then	O
27	responding	O
28	once	O
29	on	O
30	a	O
31	second	O
32	response	O
33	key	O
34	(	O
35	reinforced	O
36	key	O
37	).	O

1	Intravenous	O
2	glucose	O
3	tolerance	O
4	tests	O
5	were	O
6	performed	O
7	before	O
8	operation	O
9	,	O
10	before	O
11	starting	O
12	CyA	O
13	and	O
14	after	O
15	3	O
16	weeks	O
17	.	O

1	The	O
2	effects	O
3	of	O
4	glutaraldehyde	O
5	on	O
6	dimensions	O
7	and	O
8	ultrastructure	O
9	of	O
10	microvascular	O
11	beds	O
12	in	O
13	rat	O
14	mesentery	O
15	were	O
16	studied	O
17	in	O
18	two	O
19	kinds	O
20	of	O
21	experiment	O
22	,	O
23	administering	O
24	the	O
25	fixative	O
26	by	O
27	intra	O
28	-	O
29	arterial	O
30	perfusion	O
31	at	O
32	a	O
33	pressure	O
34	of	O
35	80	O
36	mm	O
37	Hg	O
38	and	O
39	by	O
40	superfusion	O
41	of	O
42	the	O
43	exteriorized	O
44	mesenteric	O
45	membrane	O
46	.	O

1	This	O
2	gave	O
3	rise	O
4	to	O
5	RNA	O
6	molecules	O
7	with	O
8	3	O
9	'-	O
10	untranslated	O
11	regions	O
12	of	O
13	roughly	O
14	375	O
15	,	O
16	655	O
17	,	O
18	and	O
19	945	O
20	base	O
21	pairs	O
22	.	O

1	Also	O
2	,	O
3	the	O
4	BALB	B
5	/	I
6	c	I
7	gene	I
8	contains	O
9	a	O
10	single	O
11	substitution	O
12	in	O
13	a	O
14	conserved	O
15	octamer	O
16	sequence	O
17	approximately	O
18	equal	O
19	to	O
20	100	O
21	nucleotides	O
22	upstream	O
23	of	O
24	the	O
25	coding	O
26	region	O
27	,	O
28	which	O
29	could	O
30	affect	O
31	its	O
32	expression	O
33	.	O

1	Clinical	O
2	findings	O
3	were	O
4	:	O
5	height	O
6	183	O
7	cm	O
8	,	O
9	weight	O
10	62	O
11	kg	O
12	,	O
13	increased	O
14	length	O
15	of	O
16	lower	O
17	limbs	O
18	,	O
19	P2	O
20	-	O
21	A2	O
22	pilosity	O
23	and	O
24	micropenis	O
25	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	it	O
6	may	O
7	be	O
8	possible	O
9	to	O
10	individualize	O
11	hCG	B
12	administration	O
13	at	O
14	midcycle	O
15	by	O
16	determining	O
17	the	O
18	number	O
19	of	O
20	follicles	O
21	greater	O
22	than	O
23	1	O
24	cm	O
25	by	O
26	ultrasound	O
27	on	O
28	cycle	O
29	day	O
30	12	O
31	or	O
32	13	O
33	and	O
34	giving	O
35	hCG	B
36	when	O
37	serum	O
38	E2	O
39	levels	O
40	reach	O
41	1100	O
42	to	O
43	1200	O
44	pmol	O
45	/	O
46	l	O
47	per	O
48	follicle	O
49	.	O

1	The	O
2	8	O
3	patients	O
4	receiving	O
5	Ir192	O
6	implant	O
7	in	O
8	addition	O
9	to	O
10	external	O
11	radiation	O
12	showed	O
13	improved	O
14	(	O
15	p	O
16	=	O
17	0	O
18	.	O
19	06	O
20	)	O
21	survival	O
22	compared	O
23	to	O
24	the	O
25	9	O
26	receiving	O
27	external	O
28	only	O
29	:	O
30	median	O
31	15	O
32	months	O
33	(	O
34	range	O
35	1	O
36	.	O
37	5	O
38	-	O
39	34	O
40	+	O
41	months	O
42	)	O
43	versus	O
44	7	O
45	months	O
46	(	O
47	range	O
48	2	O
49	.	O
50	5	O
51	-	O
52	21	O
53	months	O
54	).	O

1	Within	O
2	Stage	O
3	IA	O
4	,	O
5	141	O
6	patients	O
7	had	O
8	well	O
9	differentiated	O
10	tumor	O
11	(	O
12	G1	O
13	),	O
14	20	O
15	had	O
16	moderately	O
17	well	O
18	differentiated	O
19	tumor	O
20	(	O
21	G2	O
22	),	O
23	and	O
24	12	O
25	patients	O
26	had	O
27	poorly	O
28	differentiated	O
29	(	O
30	G3	O
31	).	O

1	Mechanism	O
2	of	O
3	the	O
4	t	O
5	(	O
6	14	O
7	;	O
8	18	O
9	)	O
10	chromosomal	O
11	translocation	O
12	:	O
13	structural	O
14	analysis	O
15	of	O
16	both	O
17	derivative	O
18	14	O
19	and	O
20	18	O
21	reciprocal	O
22	partners	O
23	.	O

1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	B
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O

1	Ritanserin	O
2	is	O
3	a	O
4	new	O
5	substance	O
6	with	O
7	highly	O
8	selective	O
9	blocking	O
10	activity	O
11	on	O
12	S2	B
13	receptors	I
14	for	O
15	5	O
16	-	O
17	HT	O
18	in	O
19	the	O
20	central	O
21	nervous	O
22	system	O
23	.	O

1	Ethylene	O
2	glycol	O
3	and	O
4	diethylene	O
5	glycol	O
6	were	O
7	each	O
8	administered	O
9	once	O
10	weekly	O
11	subcutaneously	O
12	to	O
13	groups	O
14	of	O
15	100	O
16	female	O
17	NMRI	O
18	mice	O
19	at	O
20	3	O
21	dosages	O
22	(	O
23	30	O
24	;	O
25	10	O
26	und	O
27	3	O
28	mg	O
29	single	O
30	dose	O
31	per	O
32	mouse	O
33	).	O

1	Research	O
2	on	O
3	ethylene	O
4	glycol	O
5	and	O
6	diethylene	O
7	glycol	O
8	for	O
9	carcinogenic	O
10	effects	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	greater	O
7	estrogenic	O
8	influence	O
9	associated	O
10	with	O
11	the	O
12	ethinyl	O
13	estradiol	O
14	-	O
15	containing	O
16	OC	O
17	resulted	O
18	in	O
19	inhibition	O
20	of	O
21	coronary	O
22	artery	O
23	atherosclerosis	O
24	despite	O
25	a	O
26	pronounced	O
27	progestin	O
28	-	O
29	induced	O
30	lowering	O
31	of	O
32	plasma	O
33	HDL	B
34	cholesterol	I
35	concentration	O
36	and	O
37	,	O
38	further	O
39	,	O
40	that	O
41	hormonal	O
42	balance	O
43	may	O
44	have	O
45	a	O
46	marked	O
47	influence	O
48	on	O
49	the	O
50	relationship	O
51	between	O
52	plasma	O
53	lipids	O
54	and	O
55	atherogenesis	O
56	.	O

1	During	O
2	BH	O
3	the	O
4	ventilator	O
5	was	O
6	disconnected	O
7	and	O
8	a	O
9	bias	O
10	flow	O
11	of	O
12	50	O
13	%	O
14	O2	O
15	at	O
16	4	O
17	-	O
18	5	O
19	l	O
20	/	O
21	min	O
22	was	O
23	delivered	O
24	through	O
25	the	O
26	side	O
27	ports	O
28	of	O
29	a	O
30	small	O
31	catheter	O
32	whose	O
33	tip	O
34	was	O
35	positioned	O
36	1	O
37	cm	O
38	cephalad	O
39	of	O
40	the	O
41	carina	O
42	.	O

1	Comparison	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	removal	O
8	using	O
9	the	O
10	same	O
11	polysulphone	O
12	membrane	O
13	for	O
14	haemodialysis	O
15	and	O
16	haemofiltration	O
17	shows	O
18	that	O
19	beta	B
20	2	I
21	-	I
22	microglobulin	I
23	is	O
24	more	O
25	effectively	O
26	removed	O
27	by	O
28	convection	O
29	than	O
30	by	O
31	diffusion	O
32	when	O
33	both	O
34	treatment	O
35	modes	O
36	are	O
37	matched	O
38	for	O
39	blood	O
40	flow	O
41	and	O
42	urea	O
43	clearance	O
44	.	O

1	40	O
2	.	O
3	3	O
4	+/-	O
5	10	O
6	.	O
7	1	O
8	mg	O
9	/	O
10	l	O
11	(	O
12	SD	O
13	)	O
14	vs	O
15	31	O
16	.	O
17	2	O
18	+/-	O
19	8	O
20	.	O
21	0	O
22	,	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	).	O
30	beta	B
31	2m	I
32	was	O
33	not	O
34	significantly	O
35	higher	O
36	in	O
37	patients	O
38	with	O
39	bone	O
40	cysts	O
41	(	O
42	37	O
43	.	O
44	7	O
45	+/-	O
46	11	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	l	O
52	vs	O
53	37	O
54	.	O
55	0	O
56	+/-	O
57	10	O
58	.	O
59	0	O
60	),	O
61	but	O
62	median	O
63	duration	O
64	of	O
65	dialysis	O
66	was	O
67	significantly	O
68	(	O
69	P	O
70	less	O
71	than	O
72	0	O
73	.	O
74	01	O
75	)	O
76	longer	O
77	in	O
78	patients	O
79	with	O
80	bone	O
81	cysts	O
82	(	O
83	90	O
84	vs	O
85	57	O
86	months	O
87	).	O
88	beta	B
89	2m	I
90	was	O
91	lower	O
92	in	O
93	patients	O
94	maintained	O
95	on	O
96	dialysis	O
97	for	O
98	less	O
99	than	O
100	1	O
101	year	O
102	and	O
103	whose	O
104	residual	O
105	urine	O
106	volume	O
107	was	O
108	greater	O
109	than	O
110	0	O
111	.	O
112	1	O
113	litre	O
114	per	O
115	day	O
116	.	O

1	The	O
2	mean	O
3	percentage	O
4	of	O
5	linoleic	O
6	acid	O
7	in	O
8	the	O
9	triglycerides	O
10	of	O
11	the	O
12	subcutaneous	O
13	adipose	O
14	tissue	O
15	(	O
16	PLASAT	O
17	)	O
18	of	O
19	these	O
20	subjects	O
21	was	O
22	substantially	O
23	higher	O
24	than	O
25	that	O
26	in	O
27	a	O
28	similar	O
29	group	O
30	examined	O
31	in	O
32	1975	O
33	-	O
34	1976	O
35	.	O

1	In	O
2	overdoses	O
3	up	O
4	to	O
5	2	O
6	g	O
7	fluvoxamine	O
8	no	O
9	lasting	O
10	toxic	O
11	effects	O
12	were	O
13	observed	O
14	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	plasma	B
7	prolactin	I
8	response	O
9	to	O
10	12	O
11	.	O
12	5	O
13	micrograms	O
14	i	O
15	.	O
16	v	O
17	.	O

1	No	O
2	effect	O
3	was	O
4	found	O
5	on	O
6	grooming	O
7	behavior	O
8	.	O

1	The	O
2	remaining	O
3	six	O
4	patients	O
5	had	O
6	slightly	O
7	decreased	O
8	(	O
9	n	O
10	=	O
11	3	O
12	)	O
13	or	O
14	normal	O
15	(	O
16	n	O
17	=	O
18	3	O
19	)	O
20	seminal	O
21	parameters	O
22	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	wild	O
6	-	O
7	type	O
8	strain	O
9	containing	O
10	a	O
11	temperature	B
12	-	I
13	sensitive	I
14	threonyl	I
15	-	I
16	tRNA	I
17	synthetase	I
18	mutation	I
19	showed	O
20	increased	O
21	thr	B
22	operon	I
23	expression	O
24	at	O
25	the	O
26	non	O
27	-	O
28	permissive	O
29	temperature	O
30	,	O
31	whereas	O
32	none	O
33	of	O
34	the	O
35	mutants	O
36	showed	O
37	any	O
38	change	O
39	.	O

1	Significant	O
2	treatment	O
3	-	O
4	related	O
5	problems	O
6	appeared	O
7	during	O
8	the	O
9	second	O
10	decade	O
11	in	O
12	5	O
13	patients	O
14	,	O
15	including	O
16	one	O
17	chest	O
18	wall	O
19	sarcoma	O
20	;	O
21	all	O
22	of	O
23	these	O
24	patients	O
25	had	O
26	received	O
27	at	O
28	least	O
29	60	O
30	Gy	O
31	to	O
32	breast	O
33	and	O
34	regional	O
35	nodal	O
36	areas	O
37	.	O

1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	panic	O
7	states	O
8	.	O

1	Effects	O
2	of	O
3	long	O
4	-	O
5	term	O
6	parenteral	O
7	nutrition	O
8	on	O
9	gastrin	B
10	release	O
11	in	O
12	dogs	O
13	.	O

1	The	O
2	mean	O
3	weight	O
4	and	O
5	height	O
6	velocities	O
7	were	O
8	148	O
9	%	O
10	and	O
11	122	O
12	%	O
13	of	O
14	the	O
15	standard	O
16	,	O
17	respectively	O
18	.	O

1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	vinculin	B
7	cDNA	I
8	from	I
9	chick	I
10	-	I
11	embryo	I
12	fibroblasts	I
13	.	O

1	A	O
2	complementary	O
3	study	O
4	,	O
5	showing	O
6	a	O
7	good	O
8	agreement	O
9	between	O
10	surface	O
11	and	O
12	oesophageal	O
13	EMGd	O
14	seems	O
15	to	O
16	confirm	O
17	that	O
18	surface	O
19	EMGd	O
20	is	O
21	a	O
22	useful	O
23	and	O
24	promising	O
25	tool	O
26	for	O
27	clinical	O
28	investigation	O
29	.	O

1	No	O
2	differences	O
3	in	O
4	fixation	O
5	quality	O
6	were	O
7	observed	O
8	between	O
9	cochleas	O
10	fixed	O
11	by	O
12	intravascular	O
13	perfusion	O
14	and	O
15	cochleas	O
16	fixed	O
17	by	O
18	intralabyrinthine	O
19	perfusion	O
20	.	O

1	The	O
2	DNA	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	1520	O
9	amino	O
10	acids	O
11	with	O
12	sequence	O
13	homology	O
14	to	O
15	the	O
16	human	B
17	c	I
18	-	I
19	abl	I
20	proto	I
21	-	I
22	oncogene	I
23	product	I
24	,	O
25	beginning	O
26	at	O
27	the	O
28	amino	O
29	terminus	O
30	and	O
31	extending	O
32	656	O
33	amino	O
34	acids	O
35	through	O
36	the	O
37	region	O
38	essential	O
39	for	O
40	tyrosine	B
41	kinase	I
42	activity	O
43	.	O

1	The	O
2	requirement	O
3	of	O
4	different	O
5	essential	O
6	fatty	O
7	acids	O
8	in	O
9	patients	O
10	with	O
11	total	O
12	parenteral	O
13	nutrition	O
14	after	O
15	heavy	O
16	injury	O
17	is	O
18	of	O
19	special	O
20	interest	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	development	O
26	and	O
27	prognosis	O
28	of	O
29	shock	O
30	,	O
31	sepsis	O
32	or	O
33	adult	O
34	respiratory	O
35	distress	O
36	syndrome	O
37	.	O

1	In	O
2	64	O
3	%	O
4	a	O
5	small	O
6	cardiac	O
7	vein	O
8	does	O
9	not	O
10	exist	O
11	,	O
12	but	O
13	its	O
14	origin	O
15	,	O
16	the	O
17	right	O
18	marginal	O
19	vein	O
20	,	O
21	joins	O
22	the	O
23	system	O
24	of	O
25	anterior	O
26	cardiac	O
27	veins	O
28	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	Gart	I
5	gene	I
6	encodes	O
7	three	O
8	enzymatic	O
9	activities	O
10	in	O
11	the	O
12	pathway	O
13	for	O
14	purine	O
15	de	O
16	novo	O
17	synthesis	O
18	.	O

1	The	O
2	role	O
3	of	O
4	neuroplasticity	O
5	in	O
6	the	O
7	response	O
8	to	O
9	drugs	O
10	.	O

1	Biol	O
2	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	experiments	O
6	indicate	O
7	that	O
8	at	O
9	least	O
10	two	O
11	upstream	O
12	activator	O
13	sequences	O
14	(	O
15	UAS	O
16	)	O
17	mediate	O
18	maximum	O
19	induction	O
20	by	O
21	galactose	O
22	.	O

1	Reversal	O
2	of	O
3	the	O
4	increase	O
5	in	O
6	apomorphine	O
7	-	O
8	induced	O
9	stereotypy	O
10	and	O
11	aggression	O
12	in	O
13	REM	O
14	sleep	O
15	deprived	O
16	rats	O
17	by	O
18	dopamine	O
19	agonist	O
20	pretreatments	O
21	.	O

1	The	O
2	heart	O
3	rate	O
4	,	O
5	respiratory	O
6	rate	O
7	,	O
8	arterial	O
9	O2	O
10	and	O
11	systemic	O
12	vascular	O
13	resistance	O
14	were	O
15	not	O
16	significantly	O
17	altered	O
18	.	O

1	Human	B
2	rIL	I
3	-	I
4	3	I
5	expressed	O
6	in	O
7	COS7	O
8	cells	O
9	has	O
10	multipotential	O
11	CSF	B
12	activity	O
13	in	O
14	semisolid	O
15	cultures	O
16	of	O
17	bone	O
18	marrow	O
19	cells	O
20	,	O
21	and	O
22	selectively	O
23	induced	O
24	the	O
25	proliferation	O
26	of	O
27	My	O
28	-	O
29	10	O
30	+	O
31	marrow	O
32	or	O
33	cord	O
34	blood	O
35	cells	O
36	in	O
37	liquid	O
38	cultures	O
39	.	O

1	In	O
2	14	O
3	patients	O
4	whose	O
5	PaCO2	O
6	was	O
7	greater	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	39	O
13	torr	O
14	(	O
15	range	O
16	39	O
17	to	O
18	58	O
19	torr	O
20	)	O
21	and	O
22	clinical	O
23	asthma	O
24	score	O
25	was	O
26	6	O
27	or	O
28	greater	O
29	,	O
30	PaCO2	O
31	decreased	O
32	a	O
33	mean	O
34	of	O
35	11	O
36	.	O
37	7	O
38	torr	O
39	during	O
40	a	O
41	mean	O
42	of	O
43	8	O
44	.	O
45	1	O
46	hours	O
47	.	O

1	A	O
2	randomized	O
3	,	O
4	prospective	O
5	study	O
6	was	O
7	conducted	O
8	to	O
9	compare	O
10	ovarian	O
11	stimulation	O
12	with	O
13	human	B
14	menopausal	I
15	gonadotropin	I
16	(	O
17	hMG	B
18	)	O
19	and	O
20	human	B
21	follicle	I
22	-	I
23	stimulating	I
24	hormone	I
25	(	O
26	hFSH	B
27	)	O
28	in	O
29	an	O
30	in	O
31	vitro	O
32	fertilization	O
33	and	O
34	embryo	O
35	transfer	O
36	(	O
37	IVF	O
38	-	O
39	ET	O
40	)	O
41	program	O
42	.	O

1	Our	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	mtr	B
7	product	I
8	causes	O
9	both	O
10	transcription	O
11	attenuation	O
12	and	O
13	inhibition	O
14	of	O
15	translation	O
16	of	O
17	trpE	B
18	mRNA	I
19	.	O

1	Apropos	O
2	of	O
3	a	O
4	case	O

1	A	O
2	prostaglandin	O
3	analogue	O
4	given	O
5	in	O
6	early	O
7	pregnancy	O
8	and	O
9	human	B
10	chorionic	I
11	gonadotropin	I
12	given	O
13	near	O
14	the	O
15	end	O
16	of	O
17	the	O
18	ensuing	O
19	follicular	O
20	phase	O
21	were	O
22	used	O
23	for	O
24	controlling	O
25	the	O
26	reproductive	O
27	cycle	O
28	,	O
29	timing	O
30	oocyte	O
31	collection	O
32	,	O
33	and	O
34	synchronizing	O
35	the	O
36	cycles	O
37	of	O
38	oocyte	O
39	donors	O
40	and	O
41	embryo	O
42	recipients	O
43	.	O

1	The	O
2	nucleolin	B
3	gene	I
4	extends	O
5	over	O
6	9000	O
7	base	O
8	-	O
9	pairs	O
10	and	O
11	is	O
12	split	O
13	into	O
14	14	O
15	exons	O
16	that	O
17	encode	O
18	the	O
19	706	O
20	amino	O
21	acid	O
22	residues	O
23	of	O
24	the	O
25	protein	O
26	.	O

1	Although	O
2	L	O
3	-	O
4	threo	O
5	-	O
6	dihydroxyphenylserine	O
7	(	O
8	DOPS	O
9	),	O
10	an	O
11	artificial	O
12	norepinephrine	O
13	(	O
14	NE	O
15	)	O
16	precursor	O
17	,	O
18	did	O
19	not	O
20	change	O
21	immobility	O
22	in	O
23	intact	O
24	mice	O
25	,	O
26	DOPS	O
27	significantly	O
28	reduced	O
29	immobility	O
30	in	O
31	mice	O
32	pretreated	O
33	with	O
34	the	O
35	selective	O
36	NE	O
37	neurotoxin	O
38	DSP4	O
39	.	O

1	Substantial	O
2	amounts	O
3	of	O
4	liposomal	O
5	ampicillin	O
6	were	O
7	recovered	O
8	from	O
9	isolated	O
10	Kupffer	O
11	cells	O
12	,	O
13	the	O
14	target	O
15	cells	O
16	of	O
17	L	O
18	.	O
19	monocytogenes	O
20	after	O
21	intravenous	O
22	inoculation	O
23	.	O

1	This	O
2	suggested	O
3	that	O
4	delta	O
5	6	O
6	and	O
7	delta	O
8	5	O
9	desaturation	O
10	activities	O
11	are	O
12	normal	O
13	in	O
14	these	O
15	conditions	O
16	with	O
17	this	O
18	C18	O
19	:	O
20	2w6	O
21	supply	O
22	.	O

1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	B
11	allotype	I
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	complete	O
6	6	O
7	-	O
8	kilobase	O
9	cDNA	O
10	sequence	O
11	coding	O
12	for	O
13	a	O
14	chain	O
15	of	O
16	1775	O
17	amino	O
18	acids	O
19	,	O
20	as	O
21	well	O
22	as	O
23	the	O
24	genomic	O
25	structure	O
26	.	O

1	HDL	B
2	-	I
3	cholesterol	I
4	(+	O
5	6	O
6	%,	O
7	P	O
8	less	O
9	than	O
10	.	O
11	01	O
12	)	O
13	and	O
14	apolipoprotein	B
15	A	I
16	-	I
17	I	I
18	(+	O
19	6	O
20	%,	O
21	P	O
22	less	O
23	than	O
24	.	O
25	01	O
26	)	O
27	concentrations	O
28	increased	O
29	significantly	O
30	only	O
31	in	O
32	the	O
33	young	O
34	.	O

1	The	O
2	Euglena	B
3	ribosomal	I
4	protein	I
5	gene	I
6	cluster	I
7	resembles	O
8	the	O
9	S	B
10	-	I
11	10	I
12	ribosomal	I
13	protein	I
14	operon	I
15	of	I
16	Escherichia	I
17	coli	I
18	in	O
19	gene	O
20	organization	O
21	and	O
22	follows	O
23	the	O
24	exact	O
25	linear	O
26	order	O
27	of	O
28	the	O
29	analogous	O
30	genes	O
31	in	O
32	the	O
33	tobacco	O
34	and	O
35	liverwort	O
36	chloroplast	O
37	genomes	O
38	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	sites	O
6	of	O
7	recombinational	O
8	resolution	O
9	is	O
10	inversely	O
11	correlated	O
12	with	O
13	that	O
14	of	O
15	the	O
16	gradient	O
17	of	O
18	sequence	O
19	divergence	O
20	,	O
21	with	O
22	only	O
23	approximately	O
24	7	O
25	%	O
26	of	O
27	the	O
28	X	O
29	recombinants	O
30	resolved	O
31	within	O
32	the	O
33	3	O
34	'	O
35	third	O
36	of	O
37	the	O
38	X	O
39	blocks	O
40	where	O
41	two	O
42	diverged	O
43	Alu	B
44	family	O
45	repeats	O
46	reside	O
47	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	region	O
7	upstream	O
8	from	O
9	M	B
10	.	I
11	voltae	I
12	ORFtrpA	I
13	was	O
14	determined	O
15	and	O
16	revealed	O
17	the	O
18	presence	O
19	of	O
20	an	O
21	ORF	O
22	of	O
23	1227	O
24	nucleotides	O
25	(	O
26	ORFtrpB	B
27	)	O
28	encoding	O
29	a	O
30	409	O
31	amino	O
32	acid	O
33	polypeptide	O
34	of	O
35	mol	O
36	.	O
37	wt	O
38	.	O

1	Potentiation	O
2	of	O
3	the	O
4	thrombolytic	O
5	efficacy	O
6	of	O
7	single	B
8	-	I
9	chain	I
10	urokinase	I
11	(	O
12	Pro	B
13	-	I
14	urokinase	I
15	)	O
16	by	O
17	heparin	O
18	.	O

1	Of	O
2	49	O
3	receptors	O
4	which	O
5	fired	O
6	in	O
7	phase	O
8	with	O
9	ventilation	O
10	,	O
11	13	O
12	behaved	O
13	like	O
14	mammalian	O
15	rapidly	O
16	adapting	O
17	pulmonary	O
18	stretch	O
19	receptors	O
20	,	O
21	19	O
22	like	O
23	mammalian	O
24	slowly	O
25	adapting	O
26	pulmonary	O
27	stretch	O
28	receptors	O
29	(	O
30	PSR	O
31	),	O
32	and	O
33	17	O
34	like	O
35	avian	O
36	intrapulmonary	O
37	CO2	O
38	-	O
39	sensitive	O
40	chemoreceptors	O
41	(	O
42	IPC	O
43	).	O

1	Symptomatic	O
2	hyperventilators	O
3	had	O
4	a	O
5	larger	O
6	number	O
7	of	O
8	sighs	O
9	and	O
10	abnormally	O
11	wide	O
12	fluctuations	O
13	in	O
14	baseline	O
15	for	O
16	inspiratory	O
17	time	O
18	,	O
19	expiratory	O
20	time	O
21	,	O
22	and	O
23	PETCO2	O
24	.	O

1	In	O
2	the	O
3	IA	O
4	task	O
5	,	O
6	post	O
7	-	O
8	training	O
9	intraperitoneal	O
10	injections	O
11	of	O
12	picrotoxin	O
13	and	O
14	bicuculline	O
15	induced	O
16	a	O
17	dose	O
18	-	O
19	dependent	O
20	enhancement	O
21	of	O
22	retention	O
23	measured	O
24	24	O
25	h	O
26	after	O
27	the	O
28	training	O
29	,	O
30	while	O
31	retention	O
32	was	O
33	not	O
34	affected	O
35	by	O
36	bicuculline	O
37	methiodide	O
38	(	O
39	a	O
40	GABA	B
41	receptor	I
42	antagonist	O
43	that	O
44	does	O
45	not	O
46	readily	O
47	cross	O
48	the	O
49	blood	O
50	-	O
51	brain	O
52	barrier	O
53	).	O

1	Clinical	O
2	research	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	post	O
12	-	O
13	transfusion	O
14	hepatitis	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	use	O
7	of	O
8	endogenous	O
9	creatinine	O
10	clearance	O
11	to	O
12	estimate	O
13	the	O
14	glomerular	O
15	filtration	O
16	rate	O
17	(	O
18	GFR	O
19	)	O
20	requires	O
21	caution	O
22	and	O
23	the	O
24	recognition	O
25	of	O
26	the	O
27	limitations	O
28	of	O
29	the	O
30	method	O
31	,	O
32	and	O
33	that	O
34	simpler	O
35	techniques	O
36	(	O
37	serum	O
38	creatinine	O
39	or	O
40	estimated	O
41	endogenous	O
42	creatinine	O
43	clearance	O
44	)	O
45	are	O
46	preferable	O
47	in	O
48	routine	O
49	practice	O
50	.	O

1	The	O
2	protein	O
3	mixtures	O
4	of	O
5	sesame	O
6	flour	O
7	and	O
8	soybean	O
9	flour	O
10	were	O
11	well	O
12	accepted	O
13	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	coding	O
8	region	O
9	was	O
10	located	O
11	precisely	O
12	by	O
13	comparing	O
14	the	O
15	deduced	O
16	amino	O
17	acid	O
18	sequence	O
19	to	O
20	the	O
21	actual	O
22	N	O
23	-	O
24	terminal	O
25	amino	O
26	acid	O
27	sequence	O
28	of	O
29	IHF	B
30	.	O

1	A	O
2	protein	O
3	footprint	O
4	also	O
5	was	O
6	identified	O
7	for	O
8	a	O
9	GC	O
10	box	O
11	element	O
12	at	O
13	nucleotides	O
14	-	O
15	59	O
16	to	O
17	-	O
18	45	O
19	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	II	I
7	(	O
8	IGFII	B
9	)	O
10	is	O
11	a	O
12	mitogenic	O
13	polypeptide	O
14	,	O
15	the	O
16	mRNAs	O
17	of	O
18	which	O
19	are	O
20	present	O
21	in	O
22	multiple	O
23	forms	O
24	,	O
25	despite	O
26	derivation	O
27	from	O
28	a	O
29	single	O
30	gene	O
31	.	O

1	The	O
2	central	O
3	visual	O
4	fields	O
5	of	O
6	2165	O
7	normal	O
8	and	O
9	106	O
10	glaucoma	O
11	eyes	O
12	were	O
13	measured	O
14	using	O
15	a	O
16	threshold	O
17	related	O
18	suprathreshold	O
19	strategy	O
20	.	O

1	The	O
2	variability	O
3	is	O
4	most	O
5	likely	O
6	a	O
7	result	O
8	of	O
9	alternative	O
10	splicing	O
11	of	O
12	exons	O
13	from	O
14	the	O
15	primary	O
16	elastin	B
17	transcripts	I
18	.	O

1	This	O
2	led	O
3	to	O
4	the	O
5	conclusion	O
6	that	O
7	the	O
8	metatarsal	O
9	artery	O
10	should	O
11	be	O
12	used	O
13	for	O
14	toe	O
15	MP	O
16	joint	O
17	grafts	O
18	,	O
19	while	O
20	the	O
21	unilateral	O
22	proper	O
23	digital	O
24	artery	O
25	is	O
26	suitable	O
27	for	O
28	toe	O
29	PIP	O
30	joint	O
31	grafts	O
32	,	O
33	together	O
34	with	O
35	concomitant	O
36	or	O
37	dorsal	O
38	cutaneous	O
39	vein	O
40	.	O

1	Effect	O
2	of	O
3	chronic	O
4	undernutrition	O
5	on	O
6	susceptibility	O
7	to	O
8	cold	O
9	stress	O
10	in	O
11	young	O
12	adult	O
13	and	O
14	aged	O
15	rats	O
16	.	O

1	This	O
2	effect	O
3	and	O
4	the	O
5	fact	O
6	that	O
7	all	O
8	three	O
9	doses	O
10	were	O
11	toxic	O
12	to	O
13	the	O
14	dams	O
15	dictated	O
16	that	O
17	a	O
18	second	O
19	experiment	O
20	be	O
21	carried	O
22	out	O
23	at	O
24	lower	O
25	doses	O
26	.	O

1	The	O
2	CHARGE	O
3	association	O
4	is	O
5	a	O
6	collection	O
7	of	O
8	multisystem	O
9	congenital	O
10	anomalies	O
11	including	O
12	choanal	O
13	atresia	O
14	.	O

1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	O
26	from	O
27	adults	O
28	at	O
29	risk	O
30	for	O
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	O

1	Aviators	O
2	from	O
3	the	O
4	Light	O
5	Attack	O
6	Wing	O
7	,	O
8	Pacific	O
9	were	O
10	surveyed	O
11	and	O
12	the	O
13	results	O
14	were	O
15	categorized	O
16	by	O
17	aircraft	O
18	type	O
19	.	O

1	Evaluation	O
2	of	O
3	human	O
4	and	O
5	bovine	O
6	modified	O
7	-	O
8	hemoglobin	B
9	solution	O
10	as	O
11	oxygen	O
12	-	O
13	carrying	O
14	fluid	O
15	for	O
16	blood	O
17	volume	O
18	replacement	O
19	.	O

1	Delayed	O
2	gallbladder	O
3	visualization	O
4	and	O
5	reduction	O
6	in	O
7	ejection	O
8	fraction	O
9	were	O
10	sensitive	O
11	but	O
12	nonspecific	O
13	indicators	O
14	of	O
15	biliary	O
16	disease	O
17	.	O

1	26	O
2	micrograms	O
3	PAF	B
4	or	O
5	placebo	O
6	was	O
7	sprayed	O
8	into	O
9	each	O
10	nasal	O
11	cavity	O
12	8	O
13	h	O
14	and	O
15	1	O
16	h	O
17	before	O
18	a	O
19	nasal	O
20	allergen	O
21	challenge	O
22	.	O

1	Sci	O
2	.	O

1	Chem	O
2	.	O

1	Sequential	O
2	MR	O
3	examinations	O
4	of	O
5	the	O
6	nasal	O
7	cavity	O
8	and	O
9	paranasal	O
10	sinuses	O
11	were	O
12	performed	O
13	within	O
14	a	O
15	6	O
16	-	O
17	8	O
18	h	O
19	period	O
20	in	O
21	five	O
22	normal	O
23	volunteers	O
24	.	O

1	Comparison	O
2	was	O
3	made	O
4	with	O
5	other	O
6	neuroradiological	O
7	imaging	O
8	modalities	O
9	including	O
10	CT	O
11	,	O
12	myelography	O
13	,	O
14	CT	O
15	ventriculography	O
16	,	O
17	and	O
18	CT	O
19	myelocisternography	O
20	.	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	a	O
8	mildly	O
9	-	O
10	atypical	O
11	(	O
12	inflammatory	O
13	)	O
14	cytological	O
15	result	O
16	(	O
17	class	O
18	2	O
19	)	O
20	and	O
21	a	O
22	benign	O
23	histological	O
24	diagnosis	O
25	:	O
26	48	O
27	%	O
28	of	O
29	class	O
30	-	O
31	2	O
32	smears	O
33	were	O
34	diagnosed	O
35	histologically	O
36	as	O
37	dysplasia	O
38	or	O
39	worse	O
40	.	O

1	Factors	O
2	involved	O
3	in	O
4	specific	O
5	transcription	O
6	by	O
7	mammalian	O
8	RNA	B
9	polymerase	I
10	II	I
11	:	O
12	purification	O
13	,	O
14	genetic	O
15	specificity	O
16	,	O
17	and	O
18	TATA	O
19	box	O
20	-	O
21	promoter	O
22	interactions	O
23	of	O
24	TFIID	B
25	.	O

1	Change	O
2	in	O
3	plasma	B
4	cystyl	I
5	aminopeptidase	I
6	(	O
7	oxytocinase	B
8	)	O
9	between	O
10	30	O
11	-	O
12	34	O
13	weeks	O
14	'	O
15	gestation	O
16	as	O
17	a	O
18	predictor	O
19	of	O
20	pregnancy	O
21	-	O
22	induced	O
23	hypertension	O
24	.	O

1	You	O
2	make	O
3	the	O
4	diagnosis	O
5	.	O

1	The	O
2	test	O
3	for	O
4	alpha	B
5	-	I
6	naphthyl	I
7	esterase	I
8	and	O
9	quantitation	O
10	of	O
11	macrophages	O
12	(	O
13	absolute	O
14	number	O
15	)	O
16	per	O
17	infiltration	O
18	area	O
19	unit	O
20	adjacent	O
21	to	O
22	the	O
23	abscess	O
24	suggest	O
25	a	O
26	direct	O
27	correlation	O
28	between	O
29	the	O
30	absolute	O
31	number	O
32	of	O
33	macrophages	O
34	and	O
35	the	O
36	width	O
37	of	O
38	the	O
39	capsule	O
40	.	O

1	Determined	O
2	as	O
3	migration	O
4	differentials	O
5	,	O
6	chemotactic	O
7	and	O
8	chemokinetic	O
9	responsiveness	O
10	tended	O
11	to	O
12	be	O
13	higher	O
14	in	O
15	the	O
16	neutropenic	O
17	group	O
18	.	O

1	The	O
2	deduced	O
3	96	O
4	-	O
5	residue	O
6	amino	O
7	acid	O
8	coding	O
9	sequence	O
10	of	O
11	the	O
12	murine	O
13	HMG	B
14	-	I
15	I	I
16	(	I
17	Y	I
18	)	I
19	cDNA	O
20	is	O
21	very	O
22	similar	O
23	to	O
24	the	O
25	reported	O
26	amino	O
27	acid	O
28	sequence	O
29	of	O
30	human	O
31	HMG	B
32	-	I
33	I	I
34	,	O
35	except	O
36	that	O
37	it	O
38	lacks	O
39	11	O
40	internal	O
41	amino	O
42	acids	O
43	reported	O
44	in	O
45	the	O
46	human	O
47	protein	O
48	.	O

1	Interpersonal	O
2	style	O
3	differences	O
4	among	O
5	drug	O
6	abusers	O
7	were	O
8	explored	O
9	using	O
10	Ryan	O
11	'	O
12	s	O
13	(	O
14	1977	O
15	)	O
16	typological	O
17	system	O
18	of	O
19	FIRO	O
20	-	O
21	B	O
22	interpretation	O
23	.	O

1	Statement	O
2	of	O
3	the	O
4	American	O
5	Academy	O
6	of	O
7	Implant	O
8	Dentistry	O
9	.	O

1	Sera	O
2	from	O
3	euthyroid	O
4	post	O
5	-	O
6	menopausal	O
7	or	O
8	pregnant	O
9	women	O
10	yielded	O
11	TSH	B
12	levels	O
13	within	O
14	the	O
15	normal	O
16	range	O
17	.	O

1	No	O
2	UOxase	B
3	mRNA	I
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	O
17	expression	O
18	of	O
19	this	O
20	UOxase	B
21	gene	I
22	.	O

1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	layers	O
8	were	O
9	tested	O
10	concerning	O
11	the	O
12	valuation	O
13	of	O
14	the	O
15	haemocompatibility	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	polymers	O
21	polyurethane	O
22	(	O
23	PUR	O
24	),	O
25	polyvinylchloride	O
26	(	O
27	PVC	O
28	),	O
29	and	O
30	polystyrene	O
31	(	O
32	PS	O
33	)	O
34	in	O
35	two	O
36	different	O
37	worked	O
38	test	O
39	chambers	O
40	.	O

1	Conservative	O
2	treatment	O
3	of	O
4	bladder	O
5	carcinoma	O
6	by	O
7	partial	O
8	cystectomy	O
9	and	O
10	interstitial	O
11	iridium	O
12	192	O
13	.	O

1	In	O
2	a	O
3	112	O
4	-	O
5	d	O
6	feedlot	O
7	trial	O
8	,	O
9	105	O
10	heifers	O
11	were	O
12	assigned	O
13	to	O
14	light	O
15	,	O
16	medium	O
17	and	O
18	heavy	O
19	weight	O
20	blocks	O
21	on	O
22	five	O
23	treatments	O
24	:	O
25	dietary	O
26	MGA	O
27	(.	O
28	5	O
29	mg	O
30	.	O
31	hd	O
32	-	O
33	1	O
34	.	O
35	d	O
36	-	O
37	1	O
38	),	O
39	control	O
40	(	O
41	no	O
42	MGA	O
43	)	O
44	or	O
45	DEPO	O
46	-	O
47	MGA	O
48	on	O
49	d	O
50	1	O
51	at	O
52	.	O
53	5	O
54	,	O
55	1	O
56	.	O
57	0	O
58	or	O
59	1	O
60	.	O
61	5	O
62	ml	O
63	/	O
64	hd	O
65	(	O
66	30	O
67	,	O
68	60	O
69	or	O
70	90	O
71	mg	O
72	MGA	O
73	/	O
74	hd	O
75	,	O
76	respectively	O
77	).	O

1	Existence	O
2	and	O
3	uniqueness	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	permeability	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O

1	There	O
2	were	O
3	gene	O
4	clusters	O
5	encoding	O
6	photosynthesis	O
7	components	O
8	such	O
9	as	O
10	the	O
11	psbB	B
12	-	O
13	psbH	B
14	-	O
15	petB	B
16	-	O
17	petD	B
18	and	O
19	the	O
20	psbE	O
21	-	O
22	psbF	O
23	clusters	O
24	.	O

1	The	O
2	results	O
3	presented	O
4	suggest	O
5	that	O
6	TIQ	O
7	reduces	O
8	the	O
9	turnover	O
10	rate	O
11	of	O
12	the	O
13	nigrostriatal	O
14	dopamine	O
15	neurons	O
16	after	O
17	repeated	O
18	administration	O
19	for	O
20	a	O
21	long	O
22	period	O
23	in	O
24	mice	O
25	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	B
7	-	I
8	kDa	I
9	nuclear	I
10	pore	I
11	glycoprotein	I
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	B
31	pore	I
32	glycoproteins	I
33	.	O

1	Seventy	O
2	-	O
3	two	O
4	hours	O
5	after	O
6	administration	O
7	of	O
8	vitamin	O
9	K1	O
10	,	O
11	plasma	O
12	concentrations	O
13	of	O
14	the	O
15	vitamin	O
16	were	O
17	not	O
18	different	O
19	from	O
20	normal	O
21	.	O

1	The	O
2	glomerular	O
3	filtration	O
4	rate	O
5	did	O
6	not	O
7	change	O
8	but	O
9	lithium	O
10	clearance	O
11	fell	O
12	by	O
13	30	O
14	%.	O

1	During	O
2	a	O
3	28	O
4	-	O
5	week	O
6	promotion	O
7	bioassay	O
8	,	O
9	groups	O
10	of	O
11	30	O
12	male	O
13	CD	O
14	-	O
15	1	O
16	mice	O
17	were	O
18	treated	O
19	once	O
20	with	O
21	50	O
22	microliter	O
23	of	O
24	either	O
25	DMBA	O
26	(	O
27	1	O
28	.	O
29	0	O
30	mg	O
31	/	O
32	ml	O
33	)	O
34	or	O
35	acetone	O
36	,	O
37	rested	O
38	for	O
39	2	O
40	weeks	O
41	,	O
42	and	O
43	then	O
44	treated	O
45	twice	O
46	per	O
47	week	O
48	with	O
49	test	O
50	material	O
51	for	O
52	the	O
53	remaining	O
54	25	O
55	weeks	O
56	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Dupuytren	O
5	'	O
6	s	O
7	contracture	O

1	An	O
2	ELISA	O
3	procedure	O
4	was	O
5	developed	O
6	for	O
7	monitoring	O
8	the	O
9	specific	O
10	IgE	B
11	response	O
12	in	O
13	dogs	O
14	to	O
15	Dirofilaria	O
16	immitis	O
17	infection	O
18	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	The	O
2	only	O
3	isolate	O
4	of	O
5	Aeromonas	O
6	hydrophila	O
7	produced	O
8	cytotoxic	O
9	enterotoxin	O
10	and	O
11	was	O
12	invasive	O
13	.	O

1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O

1	The	O
2	incidence	O
3	of	O
4	early	O
5	neonatal	O
6	convulsions	O
7	for	O
8	inborn	O
9	babies	O
10	was	O
11	3	O
12	.	O
13	0	O
14	/	O
15	1000	O
16	live	O
17	births	O
18	.	O

1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O

1	Critical	O
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	maturity	O
12	in	O
13	amniotic	O
14	fluid	O

1	Of	O
2	the	O
3	43	O
4	infants	O
5	with	O
6	a	O
7	(	O
8	probable	O
9	)	O
10	loss	O
11	18	O
12	were	O
13	examined	O
14	again	O
15	at	O
16	3	O
17	months	O
18	corrected	O
19	age	O
20	.	O

1	Variety	O
2	of	O
3	cows	O
4	and	O
5	sires	O
6	according	O
7	to	O
8	types	O
9	of	O
10	dermatoglyphics	O
11	(	O
12	patterns	O
13	)	O
14	of	O
15	the	O
16	nose	O
17	-	O
18	labial	O
19	mirror	O
20	of	O
21	cattle	O

1	Although	O
2	not	O
3	consistently	O
4	identified	O
5	in	O
6	all	O
7	samples	O
8	,	O
9	secondary	O
10	Academic	O
11	,	O
12	Personal	O
13	Responsibility	O
14	,	O
15	and	O
16	Community	O
17	/	O
18	Vocational	O
19	dimensions	O
20	were	O
21	also	O
22	identified	O
23	.	O

1	Recovery	O
2	was	O
3	characterized	O
4	by	O
5	rapid	O
6	improvement	O
7	such	O
8	that	O
9	all	O
10	measured	O
11	parameters	O
12	normalized	O
13	by	O
14	1	O
15	week	O
16	,	O
17	except	O
18	for	O
19	cross	O
20	-	O
21	sectional	O
22	cardiac	O
23	area	O
24	which	O
25	remained	O
26	dilated	O
27	up	O
28	to	O
29	4	O
30	weeks	O
31	(	O
32	14	O
33	+/-	O
34	3	O
35	cm2	O
36	,	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	05	O
43	versus	O
44	control	O
45	).(	O
46	ABSTRACT	O
47	TRUNCATED	O
48	AT	O
49	250	O
50	WORDS	O
51	)	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	It	O
2	has	O
3	been	O
4	calculated	O
5	that	O
6	600	O
7	,	O
8	000	O
9	new	O
10	cases	O
11	of	O
12	lung	O
13	cancer	O
14	occur	O
15	worldwide	O
16	every	O
17	year	O
18	,	O
19	most	O
20	of	O
21	them	O
22	due	O
23	to	O
24	smoking	O
25	.	O

1	Neuromyelitis	O
2	optica	O
3	(	O
4	Devic	O
5	'	O
6	s	O
7	syndrome	O
8	):	O
9	not	O
10	always	O
11	multiple	O
12	sclerosis	O
13	.	O

1	Effect	O
2	of	O
3	the	O
4	methods	O
5	of	O
6	cutaneous	O
7	administration	O
8	of	O
9	methyl	O
10	isobutyl	O
11	ketone	O
12	on	O
13	its	O
14	toxicity	O

1	Incorporation	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O

1	None	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	opportunistic	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	lymphopenia	O
15	.	O

1	Increasing	O
2	the	O
3	phosphorus	O
4	content	O
5	of	O
6	the	O
7	diet	O
8	improved	O
9	the	O
10	reabsorption	O
11	of	O
12	calcium	O
13	and	O
14	magnesium	O
15	.	O

1	Post	O
2	-	O
3	transcriptional	O
4	regulation	O
5	of	O
6	ribosomal	B
7	protein	I
8	gene	I
9	expression	O
10	during	O
11	development	O
12	in	O
13	Dictyostelium	O
14	discoideum	O
15	.	O

1	The	O
2	temporal	O
3	and	O
4	static	O
5	plasma	O
6	concentration	O
7	-	O
8	effect	O
9	relationships	O
10	were	O
11	evaluated	O
12	by	O
13	pharmacodynamic	O
14	modeling	O
15	and	O
16	linear	O
17	regression	O
18	.	O

1	The	O
2	increase	O
3	in	O
4	amplitudes	O
5	of	O
6	the	O
7	b	O
8	-	O
9	wave	O
10	during	O
11	the	O
12	adaptation	O
13	period	O
14	was	O
15	more	O
16	prominent	O
17	in	O
18	lead	O
19	-	O
20	exposed	O
21	subjects	O
22	than	O
23	in	O
24	controls	O
25	.	O

1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O

1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O

1	Many	O
2	children	O
3	with	O
4	BGC	O
5	are	O
6	delayed	O
7	in	O
8	their	O
9	development	O
10	,	O
11	but	O
12	calcifications	O
13	are	O
14	not	O
15	directly	O
16	related	O
17	to	O
18	specific	O
19	forms	O
20	of	O
21	neurologic	O
22	dysfunction	O
23	.	O

1	R	O
2	-	O
3	wave	O
4	voltage	O
5	in	O
6	the	O
7	right	O
8	precordial	O
9	leads	O
10	in	O
11	anthracycline	O
12	cardiomyopathy	O
13	:	O
14	a	O
15	clinical	O
16	study	O
17	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	pooling	O
7	requirements	O
8	are	O
9	task	O
10	dependent	O
11	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	CSFHU	B
6	can	O
7	increase	O
8	neutrophil	O
9	counts	O
10	by	O
11	increasing	O
12	the	O
13	number	O
14	and	O
15	maturity	O
16	of	O
17	the	O
18	marrow	O
19	neutrophil	O
20	precursors	O
21	in	O
22	some	O
23	types	O
24	of	O
25	childhood	O
26	chronic	O
27	neutropenia	O
28	.	O

1	The	O
2	purposes	O
3	of	O
4	this	O
5	study	O
6	were	O
7	1	O
8	)	O
9	to	O
10	examine	O
11	the	O
12	effect	O
13	of	O
14	high	O
15	intensity	O
16	,	O
17	low	O
18	frequency	O
19	transcutaneous	O
20	electrical	O
21	nerve	O
22	stimulation	O
23	at	O
24	auricular	O
25	acupuncture	O
26	points	O
27	on	O
28	experimental	O
29	pain	O
30	threshold	O
31	measured	O
32	at	O
33	the	O
34	wrist	O
35	and	O
36	2	O
37	)	O
38	to	O
39	determine	O
40	the	O
41	changes	O
42	in	O
43	effect	O
44	over	O
45	time	O
46	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	O
6	alpha	B
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	Records	O
2	of	O
3	31	O
4	children	O
5	with	O
6	AIDS	O
7	or	O
8	AIDS	O
9	-	O
10	related	O
11	complex	O
12	admitted	O
13	to	O
14	the	O
15	pediatric	O
16	intensive	O
17	care	O
18	unit	O
19	for	O
20	acute	O
21	respiratory	O
22	failure	O
23	throughout	O
24	a	O
25	46	O
26	-	O
27	month	O
28	period	O
29	were	O
30	reviewed	O
31	.	O

1	Fourteen	O
2	patients	O
3	were	O
4	in	O
5	the	O
6	multifocal	O
7	disease	O
8	group	O
9	;	O
10	13	O
11	were	O
12	detected	O
13	by	O
14	SPECT	O
15	and	O
16	10	O
17	by	O
18	TCT	O
19	.	O

1	SPECT	O
2	is	O
3	an	O
4	important	O
5	aid	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	AIDS	O
11	dementia	O
12	complex	O
13	and	O
14	contributes	O
15	to	O
16	the	O
17	understanding	O
18	of	O
19	the	O
20	pathophysiological	O
21	mechanisms	O
22	of	O
23	this	O
24	disorder	O
25	.	O

1	We	O
2	were	O
3	interested	O
4	in	O
5	studying	O
6	the	O
7	relationship	O
8	between	O
9	the	O
10	circadian	O
11	rhythm	O
12	in	O
13	body	O
14	temperature	O
15	and	O
16	24	O
17	-	O
18	h	O
19	variations	O
20	in	O
21	plasma	O
22	concentrations	O
23	of	O
24	iron	O
25	,	O
26	zinc	O
27	,	O
28	circulating	O
29	leukocyte	O
30	counts	O
31	,	O
32	and	O
33	plasma	O
34	interleukin	B
35	1	I
36	(	O
37	IL	B
38	-	I
39	1	I
40	)	O
41	activity	O
42	.	O

1	The	O
2	murine	B
3	MHC	I
4	class	I
5	I	I
6	genes	I
7	,	O
8	H	B
9	-	I
10	2Dq	I
11	and	O
12	H	B
13	-	I
14	2Lq	I
15	,	O
16	are	O
17	strikingly	O
18	homologous	O
19	to	O
20	each	O
21	other	O
22	,	O
23	H	B
24	-	I
25	2Ld	I
26	,	O
27	and	O
28	two	O
29	genes	O
30	reported	O
31	to	O
32	encode	O
33	tumor	O
34	-	O
35	specific	O
36	antigens	O
37	.	O

1	The	O
2	active	O
3	derivatives	O
4	of	O
5	the	O
6	present	O
7	series	O
8	were	O
9	also	O
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	In	O
2	untreated	O
3	mice	O
4	,	O
5	bactericidal	O
6	activity	O
7	of	O
8	peritoneal	O
9	macrophages	O
10	decreased	O
11	from	O
12	one	O
13	day	O
14	to	O
15	3	O
16	days	O
17	after	O
18	ip	O
19	injection	O
20	of	O
21	killed	O
22	L	O
23	.	O
24	monocytogenes	O
25	.	O

1	Among	O
2	a	O
3	population	O
4	of	O
5	18	O
6	,	O
7	175	O
8	children	O
9	below	O
10	7	O
11	years	O
12	of	O
13	age	O
14	in	O
15	medium	O
16	sized	O
17	towns	O
18	and	O
19	rural	O
20	areas	O
21	in	O
22	south	O
23	-	O
24	western	O
25	Germany	O
26	552	O
27	(	O
28	3	O
29	.	O
30	03	O
31	%)	O
32	cases	O
33	of	O
34	croup	O
35	were	O
36	registered	O
37	during	O
38	a	O
39	12	O
40	months	O
41	period	O
42	in	O
43	1984	O
44	-	O
45	85	O
46	by	O
47	their	O
48	physicians	O
49	.	O

1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O

1	In	O
2	vitro	O
3	assessment	O
4	of	O
5	the	O
6	biocompatibility	O
7	of	O
8	dental	O
9	materials	O
10	--	O
11	the	O
12	millipore	O
13	filter	O
14	method	O
15	.	O

1	Hypomagnesemia	O
2	was	O
3	due	O
4	to	O
5	magnesium	O
6	wasting	O
7	by	O
8	the	O
9	kidney	O
10	.	O

1	Dentalplaque	O
2	was	O
3	controlled	O
4	by	O
5	the	O
6	oral	O
7	higienic	O
8	index	O
9	of	O
10	the	O
11	whole	O
12	dentition	O
13	daily	O
14	,	O
15	after	O
16	staining	O
17	with	O
18	1	O
19	per	O
20	cent	O
21	alkaline	O
22	fuxin	O
23	.	O

1	GRFI	B
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	B
16	mating	I
17	type	I
18	loci	I
19	HML	I
20	E	I
21	and	O
22	HMR	B
23	E	I
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	RNA	B
8	polymerase	I
9	II	I
10	activity	O
11	were	O
12	assayed	O
13	by	O
14	measuring	O
15	the	O
16	ability	O
17	of	O
18	mutant	O
19	genes	O
20	to	O
21	confer	O
22	alpha	B
23	-	I
24	amanitin	I
25	resistance	O
26	after	O
27	transfection	O
28	of	O
29	susceptible	O
30	rodent	O
31	cells	O
32	.	O

1	We	O
2	report	O
3	the	O
4	use	O
5	of	O
6	a	O
7	new	O
8	technetium	O
9	-	O
10	99m	O
11	-	O
12	albumin	B
13	colloid	O
14	white	O
15	blood	O
16	cell	O
17	(	O
18	TAC	O
19	-	O
20	WBC	O
21	)	O
22	scan	O
23	in	O
24	the	O
25	evaluation	O
26	of	O
27	appendicitis	O
28	.	O

1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	rearrangement	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	MoMuLV	O
19	provirus	O
20	.	O

1	The	O
2	indications	O
3	for	O
4	its	O
5	use	O
6	include	O
7	every	O
8	primary	O
9	and	O
10	secondary	O
11	rhinoplasty	O
12	candidate	O
13	unless	O
14	tip	O
15	grafts	O
16	are	O
17	going	O
18	to	O
19	be	O
20	under	O
21	tension	O
22	or	O
23	if	O
24	the	O
25	deformity	O
26	is	O
27	minor	O
28	.	O

1	The	O
2	SSB	B
3	-	O
4	poly	O
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O

1	The	O
2	behavior	O
3	of	O
4	suf12	B
5	-	I
6	null	I
7	/	I
8	SUF12	I
9	+	I
10	heterozygotes	I
11	indicates	O
12	that	O
13	suf12	B
14	is	O
15	co	O
16	-	O
17	dominantly	O
18	expressed	O
19	and	O
20	suggests	O
21	that	O
22	suf12	B
23	allele	O
24	-	O
25	specific	O
26	suppression	O
27	may	O
28	result	O
29	from	O
30	functionally	O
31	distinct	O
32	mutant	O
33	proteins	O
34	rather	O
35	than	O
36	variation	O
37	in	O
38	residual	O
39	wild	B
40	-	I
41	type	I
42	SUF12	I
43	+	I
44	activity	O
45	.	O

1	Antituberculosis	O
2	agents	O
3	.	O

1	The	O
2	putative	O
3	immunity	O
4	protein	O
5	was	O
6	detected	O
7	among	O
8	the	O
9	[	O
10	35S	O
11	]	O
12	methionine	O
13	-	O
14	labelled	O
15	proteins	O
16	produced	O
17	by	O
18	minicells	O
19	carrying	O
20	cni	B
21	cloned	O
22	under	O
23	lac	B
24	promoter	I
25	control	O
26	,	O
27	and	O
28	when	O
29	the	O
30	gene	O
31	was	O
32	subcloned	O
33	into	O
34	expression	O
35	vectors	O
36	under	O
37	the	O
38	control	O
39	of	O
40	a	O
41	bacteriophage	O
42	T7	O
43	promoter	O
44	.	O

1	Antibodies	O
2	made	O
3	against	O
4	fusion	O
5	protein	O
6	produced	O
7	by	O
8	the	O
9	DP1A	B
10	clone	O
11	reacted	O
12	specifically	O
13	with	O
14	DP	B
15	-	I
16	I	I
17	and	I
18	-	I
19	II	I
20	on	O
21	immunoblots	O
22	.	O

1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	QO2	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	ARDS	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	ARDS	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	slope	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	slope	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O

1	Stable	O
2	patients	O
3	have	O
4	mucous	O
5	hypersecretion	O
6	and	O
7	little	O
8	evidence	O
9	of	O
10	acute	O
11	inflammation	O
12	.	O

1	Hyperprolactinaemia	O
2	,	O
3	moderate	O
4	hypogonadism	O
5	,	O
6	infraclinical	O
7	neuropathies	O
8	,	O
9	arterial	O
10	stenoses	O
11	and	O
12	moderate	O
13	venous	O
14	leakages	O
15	seem	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	starter	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	psychological	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	failures	O
45	.	O

1	Yang	O
2	and	O
3	H	O
4	.	O

1	Secretory	O
2	function	O
3	of	O
4	the	O
5	prostate	O
6	gland	O
7	.	O

1	Chronic	O
2	endotoxemia	O
3	appears	O
4	to	O
5	be	O
6	associated	O
7	with	O
8	an	O
9	elevated	O
10	pulmonary	O
11	microvascular	O
12	permeability	O
13	and	O
14	a	O
15	tendency	O
16	toward	O
17	a	O
18	hyperdynamic	O
19	circulation	O
20	but	O
21	with	O
22	an	O
23	appreciable	O
24	degree	O
25	of	O
26	refractoriness	O
27	associated	O
28	with	O
29	regional	O
30	hemodynamics	O
31	and	O
32	eicosanoid	O
33	biosynthesis	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	meningioma	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	glioblastoma	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	neurinoma	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O

1	Diet	O
2	and	O
3	atopic	O
4	eczema	O
5	.	O

1	Time	O
2	delay	O
3	effects	O
4	on	O
5	the	O
6	tensile	O
7	bond	O
8	strength	O
9	developed	O
10	by	O
11	the	O
12	Silicoater	O
13	.	O

1	The	O
2	future	O
3	of	O
4	research	O
5	with	O
6	interferon	B
7	may	O
8	be	O
9	divided	O
10	into	O
11	three	O
12	areas	O
13	:	O
14	Efforts	O
15	must	O
16	be	O
17	made	O
18	to	O
19	determine	O
20	how	O
21	best	O
22	to	O
23	translate	O
24	the	O
25	in	O
26	vitro	O
27	synergy	O
28	into	O
29	clinically	O
30	meaningful	O
31	terms	O
32	;	O
33	in	O
34	order	O
35	to	O
36	exploit	O
37	the	O
38	fullest	O
39	potential	O
40	of	O
41	IFN	B
42	,	O
43	research	O
44	is	O
45	moving	O
46	toward	O
47	using	O
48	this	O
49	agent	O
50	earlier	O
51	in	O
52	disease	O
53	either	O
54	as	O
55	an	O
56	adjuvant	O
57	after	O
58	tumor	O
59	debulking	O
60	or	O
61	after	O
62	initial	O
63	diagnosis	O
64	;	O
65	the	O
66	medical	O
67	community	O
68	must	O
69	rethink	O
70	the	O
71	natural	O
72	history	O
73	of	O
74	some	O
75	diseases	O
76	,	O
77	because	O
78	the	O
79	fullest	O
80	potential	O
81	of	O
82	the	O
83	biologic	O
84	agents	O
85	will	O
86	most	O
87	likely	O
88	manifest	O
89	itself	O
90	when	O
91	these	O
92	agents	O
93	are	O
94	used	O
95	together	O
96	.	O

1	Minor	O
2	differences	O
3	were	O
4	noted	O
5	with	O
6	latamoxef	O
7	producing	O
8	mild	O
9	persistant	O
10	elevation	O
11	of	O
12	prothrombin	B
13	time	O
14	(	O
15	0	O
16	.	O
17	7	O
18	second	O
19	)	O
20	associated	O
21	with	O
22	depression	O
23	of	O
24	factor	B
25	II	I
26	and	O
27	factor	B
28	VII	I
29	.	O

1	Six	O
2	healthy	O
3	male	O
4	subjects	O
5	received	O
6	single	O
7	oral	O
8	doses	O
9	of	O
10	regular	O
11	release	O
12	(	O
13	RR	O
14	)	O
15	quinidine	O
16	sulfate	O
17	,	O
18	sustained	O
19	release	O
20	(	O
21	SR	O
22	)	O
23	quinidine	O
24	bisulfate	O
25	and	O
26	the	O
27	same	O
28	dose	O
29	of	O
30	the	O
31	SR	O
32	product	O
33	with	O
34	food	O
35	(	O
36	SR	O
37	-	O
38	F	O
39	).	O

1	This	O
2	report	O
3	expands	O
4	on	O
5	previous	O
6	work	O
7	with	O
8	interferon	B
9	alfa	I
10	-	I
11	2b	I
12	(	I
13	Intron	I
14	A	I
15	;	I
16	Schering	I
17	-	I
18	Plough	I
19	)	I
20	in	O
21	the	O
22	treatment	O
23	of	O
24	hairy	O
25	cell	O
26	leukemia	O
27	(	O
28	HCL	O
29	).	O

1	Oxygen	O
2	delivery	O
3	and	O
4	base	O
5	excess	O
6	decreased	O
7	significantly	O
8	and	O
9	four	O
10	pigs	O
11	died	O
12	.	O

1	Clinical	O
2	chemistry	O
3	.	O

1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	Static	O
2	orthoses	O
3	for	O
4	the	O
5	management	O
6	of	O
7	microstomia	O
8	.	O

1	The	O
2	intrapancreatic	O
3	spread	O
4	of	O
5	the	O
6	carcinoma	O
7	correlated	O
8	with	O
9	portal	O
10	invasion	O
11	of	O
12	carcinoma	O
13	,	O
14	hardness	O
15	of	O
16	the	O
17	body	O
18	and	O
19	tail	O
20	,	O
21	obstruction	O
22	of	O
23	main	O
24	pancreatic	O
25	duct	O
26	and	O
27	irregular	O
28	pancreaticogram	O
29	.	O

1	Lysosomal	O
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O

1	Contrary	O
2	to	O
3	the	O
4	observation	O
5	made	O
6	with	O
7	other	O
8	S	O
9	.	O
10	pombe	O
11	genes	O
12	transcribed	O
13	in	O
14	the	O
15	budding	O
16	yeast	O
17	,	O
18	the	O
19	heterologous	O
20	actin	B
21	gene	I
22	transcript	I
23	is	O
24	initiated	O
25	39	O
26	nucleotides	O
27	upstream	O
28	of	O
29	the	O
30	initiation	O
31	start	O
32	site	O
33	used	O
34	in	O
35	the	O
36	homologous	O
37	yeast	O
38	.	O

1	A	O
2	multicentre	O
3	study	O
4	involving	O
5	9	O
6	Italian	O
7	institutions	O
8	was	O
9	carried	O
10	out	O
11	to	O
12	compare	O
13	the	O
14	efficacy	O
15	and	O
16	safety	O
17	of	O
18	ranitidine	O
19	150	O
20	mg	O
21	b	O
22	.	O
23	i	O
24	.	O
25	d	O
26	.	O
27	and	O
28	ranitidine	O
29	300	O
30	mg	O
31	nocte	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	reflux	O
37	oesophagitis	O
38	.	O

1	Monotherapy	O
2	with	O
3	ceftazidime	O
4	was	O
5	clinically	O
6	and	O
7	bacteriologically	O
8	as	O
9	effective	O
10	as	O
11	a	O
12	combination	O
13	therapy	O
14	with	O
15	cefazolin	O
16	and	O
17	tobramycin	O
18	.	O

1	The	O
2	N3	O
3	wave	O
4	of	O
5	the	O
6	SSEP	O
7	'	O
8	s	O
9	,	O
10	which	O
11	has	O
12	been	O
13	found	O
14	to	O
15	correlate	O
16	best	O
17	with	O
18	neurological	O
19	recovery	O
20	,	O
21	returned	O
22	to	O
23	65	O
24	%	O
25	+/-	O
26	48	O
27	%	O
28	of	O
29	the	O
30	preischemia	O
31	amplitude	O
32	in	O
33	the	O
34	insulin	B
35	-	O
36	treated	O
37	animals	O
38	,	O
39	compared	O
40	to	O
41	40	O
42	%	O
43	+/-	O
44	34	O
45	%	O
46	in	O
47	the	O
48	fasted	O
49	group	O
50	and	O
51	26	O
52	%	O
53	+/-	O
54	24	O
55	%	O
56	in	O
57	the	O
58	control	O
59	animals	O
60	.	O

1	Proctoscopy	O
2	and	O
3	roentgenographic	O
4	studies	O
5	may	O
6	be	O
7	an	O
8	important	O
9	part	O
10	of	O
11	evaluation	O
12	,	O
13	especially	O
14	in	O
15	patients	O
16	who	O
17	present	O
18	with	O
19	perianal	O
20	suppuration	O
21	,	O
22	masses	O
23	,	O
24	or	O
25	anal	O
26	fissures	O
27	.	O

1	In	O
2	the	O
3	control	O
4	group	O
5	the	O
6	histological	O
7	picture	O
8	resembled	O
9	osteoarthritis	O
10	.	O

1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	B
11	and	I
12	beta	I
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	does	O
5	not	O
6	predict	O
7	the	O
8	antihypertensive	O
9	efficacy	O
10	of	O
11	chlorthalidone	O
12	.	O

1	Cephradine	O
2	250	O
3	mg	O
4	at	O
5	night	O
6	for	O
7	12	O
8	months	O
9	was	O
10	given	O
11	as	O
12	a	O
13	prophylactic	O
14	measure	O
15	to	O
16	33	O
17	female	O
18	patients	O
19	of	O
20	mean	O
21	age	O
22	41	O
23	.	O
24	6	O
25	years	O
26	,	O
27	who	O
28	had	O
29	a	O
30	history	O
31	in	O
32	the	O
33	preceding	O
34	12	O
35	months	O
36	of	O
37	between	O
38	three	O
39	and	O
40	24	O
41	(	O
42	median	O
43	=	O
44	7	O
45	)	O
46	episodes	O
47	of	O
48	frequency	O
49	and	O
50	/	O
51	or	O
52	dysuria	O
53	.	O

1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	group	O
6	allocated	O
7	to	O
8	the	O
9	good	O
10	compliance	O
11	category	O
12	by	O
13	the	O
14	use	O
15	of	O
16	the	O
17	digoxin	O
18	marker	O
19	was	O
20	equivalent	O
21	in	O
22	size	O
23	to	O
24	a	O
25	group	O
26	of	O
27	patients	O
28	who	O
29	had	O
30	returned	O
31	less	O
32	than	O
33	15	O
34	%	O
35	of	O
36	their	O
37	prescribed	O
38	dose	O
39	or	O
40	reported	O
41	a	O
42	deviation	O
43	of	O
44	less	O
45	than	O
46	6	O
47	%	O
48	from	O
49	their	O
50	prescription	O
51	.	O

1	Bullous	O
2	keratopathy	O
3	was	O
4	usually	O
5	aphakic	O
6	in	O
7	origin	O
8	in	O
9	1982	O
10	,	O
11	but	O
12	after	O
13	1983	O
14	pseudophakic	O
15	bullous	O
16	keratopathy	O
17	(	O
18	PBK	O
19	)	O
20	was	O
21	the	O
22	most	O
23	common	O
24	cause	O
25	of	O
26	bullous	O
27	keratopathy	O
28	.	O

1	The	O
2	ultrastructural	O
3	findings	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	urinary	O
10	C	B
11	-	I
12	peptide	I
13	excretion	O
14	,	O
15	confirmed	O
16	that	O
17	the	O
18	glycemic	O
19	effects	O
20	should	O
21	not	O
22	be	O
23	thought	O
24	to	O
25	be	O
26	due	O
27	to	O
28	a	O
29	direct	O
30	action	O
31	of	O
32	the	O
33	drugs	O
34	used	O
35	on	O
36	the	O
37	endocrine	O
38	pancreas	O
39	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	EGF	B
6	receptor	I
7	promoter	I
8	can	O
9	be	O
10	modulated	O
11	by	O
12	E1A	B
13	protein	I
14	and	O
15	receptor	O
16	RNA	O
17	levels	O
18	increased	O
19	by	O
20	stimulation	O
21	with	O
22	phorbol	O
23	ester	O
24	or	O
25	fetal	O
26	calf	O
27	serum	O
28	.	O

1	In	O
2	vitro	O
3	antimalarial	O
4	activity	O
5	of	O
6	neem	O
7	(	O
8	Azadirachta	O
9	indica	O
10	A	O
11	.	O

1	"	O
2	In	O
3	vitro	O
4	"	O
5	study	O
6	of	O
7	dentin	O
8	adhesion	O
9	to	O
10	adhesives	O
11	made	O
12	from	O
13	urethane	O
14	molecules	O
15	with	O
16	free	O
17	groups	O
18	of	O
19	isocyanate	O

1	By	O
2	Felix	O
3	Lagrange	O
4	,	O
5	1918	O
6	.	O

1	There	O
2	is	O
3	a	O
4	cysteine	O
5	clustering	O
6	region	O
7	in	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	region	O
13	of	O
14	the	O
15	c	B
16	-	I
17	raf	I
18	(-	I
19	1	I
20	)	I
21	product	I
22	deduced	O
23	from	O
24	the	O
25	nucleotide	O
26	sequence	O
27	,	O
28	and	O
29	this	O
30	cysteine	O
31	clustering	O
32	region	O
33	was	O
34	found	O
35	to	O
36	be	O
37	highly	O
38	homologous	O
39	to	O
40	that	O
41	present	O
42	in	O
43	an	O
44	N	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	protein	B
50	kinase	I
51	C	I
52	,	O
53	although	O
54	,	O
55	in	O
56	the	O
57	latter	O
58	cysteine	O
59	clusters	O
60	are	O
61	present	O
62	in	O
63	duplicate	O
64	.	O

1	Hand	O
2	-	O
3	held	O
4	,	O
5	continuous	O
6	-	O
7	wave	O
8	Doppler	O
9	probes	O
10	,	O
11	coupled	O
12	with	O
13	sound	O
14	spectral	O
15	analysis	O
16	,	O
17	can	O
18	successfully	O
19	predict	O
20	carotid	O
21	artery	O
22	stenosis	O
23	.	O

1	The	O
2	German	O
3	Society	O
4	of	O
5	Pediatric	O
6	Oncology	O
7	in	O
8	1981	O
9	initiated	O
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O

1	The	O
2	program	O
3	has	O
4	been	O
5	written	O
6	in	O
7	a	O
8	generic	O
9	BASIC	O
10	in	O
11	order	O
12	to	O
13	make	O
14	the	O
15	procedure	O
16	user	O
17	-	O
18	friendly	O
19	.	O

1	Since	O
2	high	O
3	levels	O
4	of	O
5	immunoglobulin	B
6	G	I
7	were	O
8	demonstrated	O
9	against	O
10	the	O
11	surface	O
12	of	O
13	the	O
14	NVS	O
15	after	O
16	immunization	O
17	,	O
18	passive	O
19	transfer	O
20	experiments	O
21	were	O
22	initiated	O
23	.	O

1	A	O
2	study	O
3	was	O
4	conducted	O
5	of	O
6	a	O
7	human	O
8	male	O
9	who	O
10	had	O
11	inhaled	O
12	a	O
13	mixture	O
14	of	O
15	241Am	O
16	and	O
17	Pu	O
18	.	O

1	An	O
2	analytic	O
3	method	O
4	for	O
5	comparative	O
6	parameter	O
7	weighting	O
8	in	O
9	magnetic	O
10	resonance	O
11	(	O
12	MR	O
13	)	O
14	imaging	O
15	has	O
16	been	O
17	developed	O
18	using	O
19	the	O
20	concept	O
21	of	O
22	"	O
23	fractional	O
24	sensitivity	O
25	."	O
26	This	O
27	new	O
28	approach	O
29	results	O
30	in	O
31	easily	O
32	calculated	O
33	indexes	O
34	for	O
35	T1	O
36	,	O
37	T2	O
38	,	O
39	and	O
40	hydrogen	O
41	weighting	O
42	.	O

1	Fifty	O
2	-	O
3	four	O
4	patients	O
5	were	O
6	divided	O
7	into	O
8	groups	O
9	according	O
10	to	O
11	their	O
12	clinical	O
13	presentation	O
14	;	O
15	seven	O
16	asymptomatic	O
17	volunteers	O
18	,	O
19	20	O
20	patients	O
21	with	O
22	duodenal	O
23	-	O
24	gastric	O
25	reflux	O
26	gastropathy	O
27	(	O
28	DRG	O
29	),	O
30	16	O
31	patients	O
32	with	O
33	recurrent	O
34	ulcers	O
35	of	O
36	the	O
37	duodenal	O
38	bulb	O
39	(	O
40	RUD	O
41	),	O
42	and	O
43	11	O
44	patients	O
45	with	O
46	Moynihan	O
47	'	O
48	s	O
49	disease	O
50	.	O

1	No	O
2	previous	O
3	studies	O
4	have	O
5	determined	O
6	the	O
7	pharmaco	O
8	-	O
9	dynamics	O
10	of	O
11	intravenous	O
12	procainamide	O
13	when	O
14	administered	O
15	in	O
16	a	O
17	dose	O
18	of	O
19	15	O
20	mg	O
21	/	O
22	kg	O
23	and	O
24	at	O
25	a	O
26	rate	O
27	of	O
28	50	O
29	mg	O
30	/	O
31	min	O
32	,	O
33	as	O
34	is	O
35	common	O
36	practice	O
37	during	O
38	electropharmacologic	O
39	testing	O
40	.	O

1	High	O
2	concentrations	O
3	of	O
4	tumor	O
5	-	O
6	associated	O
7	trypsin	B
8	inhibitor	O
9	in	O
10	hemodialyzed	O
11	patients	O
12	.	O

1	In	O
2	the	O
3	chicken	O
4	liver	O
5	,	O
6	levels	O
7	of	O
8	chicken	B
9	MT	I
10	mRNA	I
11	were	O
12	rapidly	O
13	induced	O
14	by	O
15	metals	O
16	(	O
17	Cd2	O
18	+,	O
19	Zn2	O
20	+,	O
21	Cu2	O
22	+),	O
23	glucocorticoids	O
24	and	O
25	lipopolysaccharide	O
26	.	O

1	With	O
2	histology	O
3	and	O
4	Evans	O
5	blue	O
6	injections	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	alterations	O
13	were	O
14	seen	O
15	as	O
16	early	O
17	as	O
18	4	O
19	days	O
20	after	O
21	a	O
22	dose	O
23	of	O
24	50	O
25	Gy	O
26	.	O

1	Dosimetric	O
2	estimates	O
3	for	O
4	these	O
5	organs	O
6	were	O
7	2	O
8	.	O
9	3	O
10	+/-	O
11	1	O
12	.	O
13	1	O
14	and	O
15	2	O
16	.	O
17	3	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	rad	O
23	(.	O
24	02	O
25	+/-	O
26	.	O
27	01	O
28	Gy	O
29	),	O
30	respectively	O
31	,	O
32	with	O
33	a	O
34	whole	O
35	-	O
36	body	O
37	estimate	O
38	of	O
39	0	O
40	.	O
41	28	O
42	rad	O
43	(.	O
44	003	O
45	Gy	O
46	).	O

1	A	O
2	significant	O
3	association	O
4	between	O
5	a	O
6	family	O
7	history	O
8	and	O
9	a	O
10	higher	O
11	urinary	O
12	pH	O
13	was	O
14	observed	O
15	among	O
16	the	O
17	female	O
18	calcium	O
19	stone	O
20	patients	O
21	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	Thus	O
2	the	O
3	present	O
4	data	O
5	also	O
6	suggest	O
7	that	O
8	BP	O
9	and	O
10	HR	O
11	measurements	O
12	are	O
13	influenced	O
14	not	O
15	only	O
16	by	O
17	state	O
18	-	O
19	dependent	O
20	factors	O
21	but	O
22	also	O
23	by	O
24	at	O
25	least	O
26	three	O
27	different	O
28	factors	O
29	that	O
30	are	O
31	each	O
32	independent	O
33	of	O
34	the	O
35	state	O
36	:	O
37	one	O
38	leads	O
39	to	O
40	BP	O
41	and	O
42	HR	O
43	values	O
44	that	O
45	are	O
46	influenced	O
47	by	O
48	the	O
49	cycle	O
50	the	O
51	animal	O
52	is	O
53	in	O
54	and	O
55	the	O
56	other	O
57	two	O
58	influence	O
59	,	O
60	respectively	O
61	,	O
62	the	O
63	ranking	O
64	of	O
65	the	O
66	individual	O
67	'	O
68	s	O
69	BP	O
70	and	O
71	HR	O
72	levels	O
73	within	O
74	the	O
75	population	O
76	.	O

1	The	O
2	correlation	O
3	between	O
4	PaCO2	O
5	and	O
6	PtcO2	O
7	in	O
8	RDS	O
9	was	O
10	insufficient	O
11	to	O
12	make	O
13	clinical	O
14	judgement	O
15	.	O

1	Since	O
2	1967	O
3	at	O
4	the	O
5	times	O
6	of	O
7	their	O
8	biennial	O
9	ABCC	O
10	/	O
11	RERF	O
12	radiological	O
13	examinations	O
14	,	O
15	all	O
16	Adult	O
17	Health	O
18	Study	O
19	(	O
20	AHS	O
21	)	O
22	subjects	O
23	have	O
24	been	O
25	interviewed	O
26	to	O
27	determine	O
28	the	O
29	exposures	O
30	to	O
31	medical	O
32	x	O
33	-	O
34	rays	O
35	they	O
36	experienced	O
37	in	O
38	institutions	O
39	other	O
40	than	O
41	RERF	O
42	in	O
43	order	O
44	to	O
45	estimate	O
46	the	O
47	numbers	O
48	of	O
49	examinations	O
50	and	O
51	corresponding	O
52	doses	O
53	which	O
54	they	O
55	received	O
56	.	O

1	The	O
2	epidermal	B
3	growth	I
4	factor	I
5	(	I
6	EGF	I
7	)	I
8	receptor	I
9	,	O
10	which	O
11	exhibits	O
12	intrinsic	O
13	protein	B
14	tyrosine	I
15	kinase	I
16	activity	O
17	,	O
18	undergoes	O
19	a	O
20	rapid	O
21	,	O
22	intramolecular	O
23	self	O
24	-	O
25	phosphorylation	O
26	reaction	O
27	following	O
28	EGF	B
29	activation	O
30	.	O

1	One	O
2	millimolar	O
3	ouabain	O
4	completely	O
5	inhibited	O
6	net	O
7	HCO3	O
8	-	O
9	secretion	O
10	.	O

1	There	O
2	are	O
3	regions	O
4	with	O
5	long	O
6	runs	O
7	of	O
8	up	O
9	to	O
10	45	O
11	%	O
12	C	O
13	or	O
14	35	O
15	%	O
16	G	O
17	residues	O
18	.	O

1	The	O
2	same	O
3	rhythmic	O
4	structure	O
5	enables	O
6	a	O
7	prediction	O
8	to	O
9	be	O
10	made	O
11	concerning	O
12	when	O
13	vowels	O
14	of	O
15	stressed	O
16	syllables	O
17	will	O
18	be	O
19	auditorily	O
20	perceived	O
21	.	O

1	Vocal	O
2	cord	O
3	abduction	O
4	rehabilitation	O
5	by	O
6	nervous	O
7	selective	O
8	anastomosis	O
9	.	O

1	UK	O
2	'	O
3	s	O
4	biotechnology	O
5	lacking	O
6	specialists	O
7	.	O

1	A	O
2	case	O
3	of	O
4	AIDS	O
5	-	O
6	related	O
7	complex	O
8	(	O
9	ARC	O
10	/	O
11	LAS	O
12	)	O
13	in	O
14	a	O
15	health	O
16	worker	O

1	Distant	O
2	spread	O
3	was	O
4	found	O
5	in	O
6	46	O
7	patients	O
8	(	O
9	34	O
10	%),	O
11	42	O
12	of	O
13	whom	O
14	had	O
15	serum	O
16	Tg	B
17	greater	O
18	than	O
19	10	O
20	micrograms	O
21	/	O
22	l	O
23	.	O

1	The	O
2	glomerular	O
3	filtration	O
4	rate	O
5	and	O
6	effective	O
7	renal	O
8	plasma	O
9	flow	O
10	were	O
11	determined	O
12	by	O
13	a	O
14	standard	O
15	clearance	O
16	method	O
17	,	O
18	employing	O
19	continuous	O
20	infusion	O
21	of	O
22	inulin	O
23	and	O
24	para	O
25	-	O
26	aminohippuric	O
27	acid	O
28	.	O

1	After	O
2	the	O
3	meal	O
4	containing	O
5	potato	O
6	,	O
7	plasma	O
8	glucose	O
9	levels	O
10	rose	O
11	sharply	O
12	,	O
13	peaked	O
14	at	O
15	30	O
16	-	O
17	45	O
18	min	O
19	and	O
20	fell	O
21	below	O
22	initial	O
23	levels	O
24	2	O
25	to	O
26	3	O
27	h	O
28	later	O
29	.	O

1	The	O
2	relations	O
3	among	O
4	various	O
5	negative	O
6	emotional	O
7	and	O
8	behavioral	O
9	characteristics	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.,	O
15	aggression	O
16	,	O
17	anxiety	O
18	,	O
19	undercompliance	O
20	,	O
21	depressive	O
22	mood	O
23	)	O
24	and	O
25	adjustment	O
26	were	O
27	examined	O
28	through	O
29	use	O
30	of	O
31	data	O
32	from	O
33	the	O
34	31	O
35	-	O
36	year	O
37	-	O
38	old	O
39	New	O
40	York	O
41	Longitudinal	O
42	Study	O
43	.	O

1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	O
7	on	O
8	adolescent	O
9	growth	O
10	and	O
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	O
24	socioeconomic	O
25	status	O
26	and	O
27	ethnic	O
28	grouping	O
29	who	O
30	resided	O
31	at	O
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	O
46	1743	O
47	subjects	O
48	),	O
49	and	O
50	high	O
51	altitude	O
52	(	O
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	O
60	.	O

1	Because	O
2	the	O
3	CAP	O
4	measures	O
5	variables	O
6	predictive	O
7	of	O
8	abusive	O
9	behavior	O
10	,	O
11	a	O
12	substantial	O
13	relationship	O
14	was	O
15	expected	O
16	between	O
17	the	O
18	CAP	O
19	and	O
20	the	O
21	MHI	O
22	Loss	O
23	of	O
24	Behavioral	O
25	/	O
26	Emotional	O
27	Control	O
28	scale	O
29	.	O

1	We	O
2	have	O
3	improved	O
4	our	O
5	system	O
6	for	O
7	nuclear	O
8	contour	O
9	digitization	O
10	and	O
11	determined	O
12	its	O
13	theoretical	O
14	limitations	O
15	by	O
16	digitizing	O
17	standardized	O
18	objects	O
19	.	O

1	Such	O
2	a	O
3	change	O
4	may	O
5	involve	O
6	increased	O
7	mammary	O
8	utilization	O
9	of	O
10	pre	O
11	-	O
12	formed	O
13	long	O
14	-	O
15	chain	O
16	fatty	O
17	acid	O
18	and	O
19	increased	O
20	metabolism	O
21	of	O
22	glucose	O
23	via	O
24	glycolysis	O
25	.	O

1	The	O
2	skin	O
3	site	O
4	,	O
5	6	O
6	-	O
7	cm	O
8	-	O
9	distal	O
10	and	O
11	-	O
12	proximal	O
13	subcutaneous	O
14	segments	O
15	of	O
16	the	O
17	catheter	O
18	,	O
19	exudates	O
20	,	O
21	and	O
22	blood	O
23	were	O
24	cultured	O
25	.	O

1	Because	O
2	of	O
3	its	O
4	great	O
5	reliability	O
6	,	O
7	conventional	O
8	arteriography	O
9	occupies	O
10	a	O
11	place	O
12	of	O
13	choice	O
14	among	O
15	the	O
16	medical	O
17	imaging	O
18	techniques	O
19	.	O

1	Rapid	O
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O

1	The	O
2	former	O
3	group	O
4	did	O
5	excrete	O
6	less	O
7	dry	O
8	fecal	O
9	material	O
10	compared	O
11	to	O
12	both	O
13	other	O
14	groups	O
15	.	O

1	Electronic	O
2	data	O
3	processing	O
4	(	O
5	EDP	O
6	)	O
7	latex	O
8	immunoassay	O
9	using	O
10	anti	B
11	-	I
12	human	I
13	seminal	I
14	acid	I
15	phosphatase	I
16	(	O
17	anti	B
18	-	I
19	HSAP	I
20	)	O
21	immune	O
22	serum	O
23	was	O
24	applied	O
25	for	O
26	the	O
27	species	O
28	and	O
29	organ	O
30	identification	O
31	of	O
32	human	O
33	seminal	O
34	stains	O
35	.	O

1	Vimentin	B
2	positivity	O
3	was	O
4	noted	O
5	in	O
6	the	O
7	undifferentiated	O
8	and	O
9	fibroblastic	O
10	components	O
11	.	O

1	The	O
2	maximum	O
3	deflections	O
4	of	O
5	phase	O
6	IV	O
7	for	O
8	Ar	O
9	and	O
10	N2	O
11	from	O
12	extrapolated	O
13	phase	O
14	III	O
15	slopes	O
16	were	O
17	smaller	O
18	in	O
19	the	O
20	prone	O
21	position	O
22	,	O
23	suggesting	O
24	more	O
25	uniform	O
26	tracer	O
27	gas	O
28	concentrations	O
29	across	O
30	the	O
31	lungs	O
32	.	O

1	Recent	O
2	developments	O
3	in	O
4	drugs	O
5	antagonistic	O
6	to	O
7	factors	O
8	causing	O
9	peptic	O
10	ulcer	O
11	--	O
12	clinical	O
13	efficacy	O
14	and	O
15	problems	O
16	;	O
17	gastrin	B
18	receptor	I
19	blockaders	O

1	The	O
2	spermicide	O
3	nonoxynol	O
4	-	O
5	9	O
6	is	O
7	a	O
8	member	O
9	of	O
10	a	O
11	homologous	O
12	series	O
13	of	O
14	alkylphenol	O
15	-	O
16	ethoxylates	O
17	(	O
18	polyethoxyethanols	O
19	)	O
20	of	O
21	general	O
22	formula	O
23	C9H19	O
24	-	O
25	C6H6	O
26	-	O
27	O	O
28	-(	O
29	CH2CH2O	O
30	)	O
31	n	O
32	-	O
33	1	O
34	CH2CH2OH	O
35	.	O

1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O

1	Psychological	O
2	disturbance	O
3	was	O
4	greater	O
5	in	O
6	the	O
7	high	O
8	life	O
9	stress	O
10	group	O
11	as	O
12	indicated	O
13	by	O
14	significant	O
15	elevations	O
16	on	O
17	the	O
18	global	O
19	severity	O
20	index	O
21	of	O
22	the	O
23	Symptom	O
24	Checklist	O
25	-	O
26	90	O
27	and	O
28	elevations	O
29	on	O
30	somatization	O
31	,	O
32	obsessive	O
33	compulsive	O
34	,	O
35	interpersonal	O
36	sensitivity	O
37	,	O
38	depression	O
39	,	O
40	anxiety	O
41	and	O
42	psychoticism	O
43	subscales	O
44	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Nucleotide	O
2	sequencing	O
3	indicates	O
4	that	O
5	this	O
6	E1	B
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	1821	O
12	base	O
13	pairs	O
14	(	O
15	bp	O
16	)	O
17	in	O
18	length	O
19	with	O
20	an	O
21	open	O
22	reading	O
23	frame	O
24	of	O
25	1365	O
26	bp	O
27	and	O
28	a	O
29	3	O
30	'-	O
31	untranslated	O
32	region	O
33	of	O
34	356	O
35	bp	O
36	.	O

1	SPA	O
2	from	O
3	PAG	O
4	sites	O
5	was	O
6	associated	O
7	with	O
8	aversion	O
9	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	MAN	O
6	showed	O
7	a	O
8	unimodal	O
9	,	O
10	skewed	O
11	distribution	O
12	,	O
13	with	O
14	a	O
15	range	O
16	from	O
17	approximately	O
18	1	O
19	to	O
20	14	O
21	micron	O
22	and	O
23	a	O
24	maximum	O
25	at	O
26	3	O
27	-	O
28	4	O
29	micron	O
30	.	O

1	Abnormal	O
2	technetium	O
3	Tc	O
4	99m	O
5	medronate	O
6	scans	O
7	in	O
8	patients	O
9	with	O
10	previously	O
11	undiagnosed	O
12	polyarthralgias	O
13	suggested	O
14	inflammatory	O
15	arthropathy	O
16	and	O
17	influenced	O
18	management	O
19	decisions	O
20	with	O
21	favorable	O
22	therapeutic	O
23	outcomes	O
24	.	O

1	Practical	O
2	interest	O
3	of	O
4	such	O
5	studies	O
6	is	O
7	limited	O
8	since	O
9	the	O
10	pharmacokinetic	O
11	parameters	O
12	are	O
13	systematically	O
14	evaluated	O
15	in	O
16	man	O
17	during	O
18	phase	O
19	I	O
20	trials	O
21	.	O

1	The	O
2	artery	O
3	cuff	O
4	was	O
5	slightly	O
6	superior	O
7	to	O
8	the	O
9	fat	O
10	wrap	O
11	,	O
12	particularly	O
13	in	O
14	having	O
15	fewer	O
16	adhesions	O
17	and	O
18	a	O
19	better	O
20	histological	O
21	picture	O
22	.	O

1	Lithium	O
2	-	O
3	carbonate	O
4	action	O
5	during	O
6	radiation	O
7	therapy	O
8	has	O
9	been	O
10	studied	O
11	,	O
12	valuing	O
13	the	O
14	positive	O
15	effect	O
16	on	O
17	leukopoiesis	O
18	and	O
19	the	O
20	consequent	O
21	better	O
22	clinical	O
23	conditions	O
24	of	O
25	the	O
26	patients	O
27	in	O
28	course	O
29	of	O
30	treatment	O
31	.	O

1	Of	O
2	the	O
3	53	O
4	units	O
5	tested	O
6	during	O
7	sinusoidal	O
8	motion	O
9	at	O
10	0	O
11	.	O
12	05	O
13	Hz	O
14	(	O
15	9	O
16	.	O
17	1	O
18	cm	O
19	/	O
20	s	O
21	),	O
22	1	O
23	(	O
24	1	O
25	.	O
26	9	O
27	%)	O
28	was	O
29	responsive	O
30	to	O
31	the	O
32	otolith	O
33	input	O
34	only	O
35	,	O
36	13	O
37	(	O
38	24	O
39	.	O
40	5	O
41	%)	O
42	were	O
43	influenced	O
44	by	O
45	the	O
46	visual	O
47	input	O
48	only	O
49	and	O
50	23	O
51	(	O
52	43	O
53	.	O
54	4	O
55	%)	O
56	responded	O
57	to	O
58	both	O
59	modalities	O
60	.	O

1	Depending	O
2	on	O
3	the	O
4	location	O
5	and	O
6	size	O
7	of	O
8	the	O
9	mass	O
10	,	O
11	a	O
12	wide	O
13	range	O
14	of	O
15	clinical	O
16	presentations	O
17	is	O
18	associated	O
19	with	O
20	the	O
21	lesion	O
22	.	O

1	The	O
2	development	O
3	and	O
4	distribution	O
5	of	O
6	Trypanosoma	O
7	congolense	O
8	,	O
9	T	O
10	vivax	O
11	and	O
12	T	O
13	brucei	O
14	in	O
15	the	O
16	skin	O
17	of	O
18	goats	O
19	was	O
20	examined	O
21	after	O
22	the	O
23	animals	O
24	were	O
25	bitten	O
26	by	O
27	infected	O
28	Glossina	O
29	morsitans	O
30	centralis	O
31	.	O

1	Electroglottography	O
2	is	O
3	a	O
4	useful	O
5	,	O
6	non	O
7	-	O
8	invasive	O
9	technique	O
10	that	O
11	can	O
12	assist	O
13	in	O
14	the	O
15	assessment	O
16	of	O
17	vocal	O
18	fold	O
19	dysfunction	O
20	.	O

1	Statistical	O
2	analysis	O
3	of	O
4	the	O
5	degrees	O
6	of	O
7	secondary	O
8	spinal	O
9	cord	O
10	compression	O
11	was	O
12	performed	O
13	in	O
14	group	O
15	-	O
16	1	O
17	dogs	O
18	by	O
19	measuring	O
20	and	O
21	comparing	O
22	ratios	O
23	of	O
24	the	O
25	vertical	O
26	to	O
27	the	O
28	horizontal	O
29	diameters	O
30	of	O
31	the	O
32	transverse	O
33	spinal	O
34	cord	O
35	sections	O
36	from	O
37	locations	O
38	within	O
39	(	O
40	T12	O
41	to	O
42	L1	O
43	)	O
44	and	O
45	out	O
46	of	O
47	(	O
48	T11	O
49	,	O
50	T11	O
51	-	O
52	12	O
53	,	O
54	L1	O
55	-	O
56	2	O
57	,	O
58	and	O
59	L2	O
60	)	O
61	the	O
62	region	O
63	of	O
64	surgical	O
65	intervention	O
66	.	O

1	The	O
2	pharmacological	O
3	effects	O
4	of	O
5	the	O
6	novel	O
7	compound	O
8	WEB	O
9	1881	O
10	FU	O
11	(	O
12	4	O
13	-	O
14	amino	O
15	-	O
16	methyl	O
17	-	O
18	1	O
19	-	O
20	benzyl	O
21	-	O
22	pyrrolidine	O
23	-	O
24	2	O
25	-	O
26	one	O
27	-	O
28	fumarate	O
29	)	O
30	were	O
31	investigated	O
32	.	O

1	Histopathological	O
2	examination	O
3	revealed	O
4	dose	O
5	-	O
6	related	O
7	proliferation	O
8	of	O
9	type	O
10	II	O
11	pneumocytes	O
12	in	O
13	dams	O
14	and	O
15	proliferation	O
16	of	O
17	interstitial	O
18	cells	O
19	and	O
20	delayed	O
21	septal	O
22	/	O
23	capillary	O
24	development	O
25	in	O
26	neonates	O
27	.(	O
28	ABSTRACT	O
29	TRUNCATED	O
30	AT	O
31	250	O
32	WORDS	O
33	)	O

1	So	O
2	far	O
3	no	O
4	problems	O
5	with	O
6	multiply	O
7	resistant	O
8	strains	O
9	have	O
10	developed	O
11	.	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	O
9	-	O
10	30	O
11	weeks	O
12	,	O
13	cardiac	O
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	O
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	The	O
2	state	O
3	of	O
4	the	O
5	liver	O
6	in	O
7	generalized	O
8	forms	O
9	of	O
10	meningococcal	O
11	infection	O

1	Increasing	O
2	the	O
3	RH	O
4	beyond	O
5	32	O
6	%	O
7	resulted	O
8	in	O
9	solvation	O
10	of	O
11	the	O
12	peroxy	O
13	radical	O
14	,	O
15	sterically	O
16	hindering	O
17	the	O
18	radical	O
19	from	O
20	entering	O
21	the	O
22	propagation	O
23	transition	O
24	state	O
25	.	O

1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O

1	PATIENTS	O
2	and	O
3	METHODS	O
4	:	O
5	Thallium	O
6	-	O
7	201	O
8	myocardial	O
9	scintigraphy	O
10	was	O
11	performed	O
12	at	O
13	rest	O
14	and	O
15	after	O
16	0	O
17	.	O
18	56	O
19	mg	O
20	/	O
21	kg	O
22	intravenous	O
23	dipyridamole	O
24	during	O
25	four	O
26	minutes	O
27	in	O
28	16	O
29	patients	O
30	with	O
31	sarcoidosis	O
32	.	O

1	Thin	O
2	melanomas	O
3	can	O
4	metastasize	O
5	and	O
6	be	O
7	lethal	O
8	.	O

1	The	O
2	TA	O
3	muscle	O
4	was	O
5	fatigued	O
6	by	O
7	four	O
8	forms	O
9	of	O
10	repeated	O
11	isometric	O
12	contractions	O
13	:	O
14	(	O
15	1	O
16	)	O
17	maximal	O
18	voluntary	O
19	contractions	O
20	(	O
21	MVC	O
22	),	O
23	(	O
24	2	O
25	)	O
26	MVC	O
27	with	O
28	circulation	O
29	occluded	O
30	,	O
31	(	O
32	3	O
33	)	O
34	electrically	O
35	evoked	O
36	contractions	O
37	with	O
38	20	O
39	Hz	O
40	supramaximal	O
41	voltage	O
42	stimulation	O
43	and	O
44	(	O
45	4	O
46	)	O
47	electrically	O
48	evoked	O
49	contractions	O
50	with	O
51	circulation	O
52	occluded	O
53	.	O

1	The	O
2	actuarial	O
3	local	O
4	control	O
5	rates	O
6	at	O
7	10	O
8	years	O
9	for	O
10	the	O
11	three	O
12	treatment	O
13	groups	O
14	were	O
15	as	O
16	follows	O
17	:	O
18	subtotal	O
19	excision	O
20	alone	O
21	,	O
22	18	O
23	%;	O
24	subtotal	O
25	excision	O
26	plus	O
27	postoperative	O
28	radiation	O
29	therapy	O
30	,	O
31	82	O
32	%;	O
33	and	O
34	total	O
35	excision	O
36	alone	O
37	,	O
38	77	O
39	%.	O

1	The	O
2	effects	O
3	of	O
4	anabolic	O
5	implants	O
6	on	O
7	rate	O
8	,	O
9	composition	O
10	and	O
11	energetic	O
12	efficiency	O
13	of	O
14	growth	O
15	were	O
16	determined	O
17	in	O
18	steers	O
19	fed	O
20	diets	O
21	varying	O
22	in	O
23	forage	O
24	and	O
25	grain	O
26	content	O
27	.	O

1	Prolonged	O
2	suspension	O
3	induced	O
4	a	O
5	significant	O
6	change	O
7	in	O
8	the	O
9	geometric	O
10	configuration	O
11	of	O
12	the	O
13	femur	O
14	middiaphysis	O
15	by	O
16	increasing	O
17	the	O
18	minimum	O
19	diameter	O
20	(	O
21	12	O
22	%)	O
23	without	O
24	any	O
25	significant	O
26	alterations	O
27	in	O
28	cortical	O
29	area	O
30	,	O
31	density	O
32	,	O
33	mineral	O
34	,	O
35	and	O
36	collagen	B
37	concentrations	O
38	.	O

1	Which	O
2	cineangiographically	O
3	assessed	O
4	anatomic	O
5	variable	O
6	correlates	O
7	best	O
8	with	O
9	functional	O
10	measurements	O
11	of	O
12	stenosis	O
13	severity	O
14	?	O
15	A	O
16	comparison	O
17	of	O
18	quantitative	O
19	analysis	O
20	of	O
21	the	O
22	coronary	O
23	cineangiogram	O
24	with	O
25	measured	O
26	coronary	O
27	flow	O
28	reserve	O
29	and	O
30	exercise	O
31	/	O
32	redistribution	O
33	thallium	O
34	-	O
35	201	O
36	scintigraphy	O
37	.	O

1	Water	O
2	content	O
3	and	O
4	equilibrium	O
5	water	O
6	partition	O
7	in	O
8	immature	O
9	cartilage	O
10	.	O

1	Thyroid	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	admissions	O
9	,	O
10	leaving	O
11	707	O
12	untested	O
13	.	O

1	Data	O
2	on	O
3	the	O
4	line	O
5	spread	O
6	function	O
7	(	O
8	LSF	O
9	)	O
10	were	O
11	obtained	O
12	from	O
13	the	O
14	image	O
15	of	O
16	a	O
17	0	O
18	.	O
19	2	O
20	mm	O
21	wide	O
22	slit	O
23	between	O
24	tungsten	O
25	blocks	O
26	that	O
27	were	O
28	positioned	O
29	at	O
30	the	O
31	isocentre	O
32	in	O
33	front	O
34	of	O
35	a	O
36	polystyrene	O
37	phantom	O
38	.	O

1	Primary	O
2	infection	O
3	is	O
4	usually	O
5	managed	O
6	conservatively	O
7	.	O

1	Papers	O
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O

1	Prognosis	O
2	in	O
3	Bowen	O
4	'	O
5	s	O
6	disease	O
7	localized	O
8	to	O
9	the	O
10	ano	O
11	-	O
12	genital	O
13	region	O
14	.	O

1	Taken	O
2	together	O
3	,	O
4	the	O
5	results	O
6	suggest	O
7	that	O
8	chlorphentermine	O
9	may	O
10	be	O
11	capable	O
12	of	O
13	producing	O
14	dual	O
15	stimulus	O
16	effects	O
17	in	O
18	animals	O
19	.	O

1	Liquid	O
2	chromatographic	O
3	method	O
4	for	O
5	determination	O
6	of	O
7	citreoviridin	O
8	in	O
9	corn	O
10	and	O
11	rice	O
12	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	autophosphorylation	O
6	of	O
7	Thr286	O
8	(	O
9	alpha	O
10	subunit	O
11	)	O
12	and	O
13	Thr287	O
14	(	O
15	beta	O
16	subunit	O
17	)	O
18	is	O
19	responsible	O
20	for	O
21	transition	O
22	of	O
23	CaM	B
24	-	I
25	kinase	I
26	II	I
27	to	O
28	the	O
29	Ca2	O
30	+-	O
31	independent	O
32	form	O
33	.	O

1	This	O
2	rapid	O
3	and	O
4	extensive	O
5	penetration	O
6	of	O
7	intrathecally	O
8	administered	O
9	chemotherapy	O
10	may	O
11	offer	O
12	insight	O
13	into	O
14	the	O
15	myelopathy	O
16	observed	O
17	with	O
18	these	O
19	treatments	O
20	.	O

1	The	O
2	interaction	O
3	of	O
4	radiation	O
5	and	O
6	hyperthermia	O
7	was	O
8	systematically	O
9	studied	O
10	in	O
11	the	O
12	Dunning	O
13	R3327G	O
14	prostatic	O
15	adenocarcinoma	O
16	,	O
17	the	O
18	preeminent	O
19	animal	O
20	model	O
21	for	O
22	human	O
23	prostatic	O
24	cancer	O
25	.	O

1	Pregnant	O
2	rats	O
3	were	O
4	exposed	O
5	to	O
6	one	O
7	of	O
8	the	O
9	following	O
10	:	O
11	(	O
12	1	O
13	)	O
14	10	O
15	%	O
16	O2	O
17	in	O
18	N2	O
19	or	O
20	100	O
21	%	O
22	O2	O
23	for	O
24	2	O
25	days	O
26	beginning	O
27	at	O
28	day	O
29	7	O
30	,	O
31	11	O
32	,	O
33	14	O
34	,	O
35	or	O
36	18	O
37	of	O
38	pregnancy	O
39	;	O
40	(	O
41	2	O
42	)	O
43	10	O
44	%	O
45	O2	O
46	in	O
47	N2	O
48	or	O
49	100	O
50	%	O
51	O2	O
52	for	O
53	10	O
54	h	O
55	/	O
56	day	O
57	beginning	O
58	at	O
59	day	O
60	7	O
61	;	O
62	or	O
63	(	O
64	3	O
65	)	O
66	14	O
67	-	O
68	11	O
69	%	O
70	O2	O
71	in	O
72	N2	O
73	continuously	O
74	beginning	O
75	at	O
76	day	O
77	14	O
78	till	O
79	day	O
80	21	O
81	when	O
82	they	O
83	were	O
84	sacrificed	O
85	.	O

1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O

1	Seven	O
2	patients	O
3	(	O
4	8	O
5	.	O
6	3	O
7	percent	O
8	)	O
9	had	O
10	latent	O
11	hypothyroidism	O
12	only	O
13	discovered	O
14	by	O
15	hormonal	O
16	determinations	O
17	.	O

1	Addition	O
2	of	O
3	sucralfate	O
4	or	O
5	De	O
6	-	O
7	Nol	O
8	resulted	O
9	in	O
10	increments	O
11	of	O
12	gastric	O
13	HCO3	O
14	secretion	O
15	,	O
16	reaching	O
17	about	O
18	45	O
19	%	O
20	and	O
21	59	O
22	%,	O
23	respectively	O
24	,	O
25	of	O
26	the	O
27	maximal	O
28	HCO3	O
29	response	O
30	to	O
31	16	O
32	,	O
33	16	O
34	-	O
35	dimethyl	O
36	PGE2	O
37	(	O
38	dmPGE2	O
39	).	O

1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O

1	In	O
2	Salmo	O
3	gairdneri	O
4	,	O
5	no	O
6	specialized	O
7	system	O
8	of	O
9	portal	O
10	vessels	O
11	appears	O
12	to	O
13	exist	O
14	between	O
15	the	O
16	pineal	O
17	organ	O
18	and	O
19	other	O
20	portions	O
21	of	O
22	the	O
23	brain	O
24	.	O

1	The	O
2	4	O
3	degrees	O
4	stimuli	O
5	were	O
6	found	O
7	to	O
8	elicit	O
9	scalp	O
10	distributions	O
11	for	O
12	the	O
13	pattern	O
14	reversal	O
15	P100	O
16	and	O
17	the	O
18	pattern	O
19	onset	O
20	C1	O
21	consistent	O
22	with	O
23	striate	O
24	and	O
25	extrastriate	O
26	visual	O
27	cortical	O
28	origins	O
29	respectively	O
30	.	O

1	Nuclear	B
2	factor	I
3	III	I
4	(	O
5	NFIII	B
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	O
19	type	O
20	2	O
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	O
38	to	O
39	the	O
40	nuclear	B
41	factor	I
42	I	I
43	recognition	I
44	site	I
45	.	O

1	A	O
2	Golgi	O
3	study	O
4	of	O
5	the	O
6	sixth	O
7	layer	O
8	of	O
9	the	O
10	cerebral	O
11	cortex	O
12	.	O

1	We	O
2	conclude	O
3	that	O
4	cephalothin	O
5	clearance	O
6	of	O
7	S	O
8	.	O
9	aureus	O
10	from	O
11	a	O
12	site	O
13	accessible	O
14	to	O
15	phagocytes	O
16	was	O
17	delayed	O
18	when	O
19	compared	O
20	to	O
21	a	O
22	phagocyte	O
23	-	O
24	inaccessible	O
25	site	O
26	.	O

1	The	O
2	findings	O
3	are	O
4	discussed	O
5	in	O
6	the	O
7	context	O
8	of	O
9	known	O
10	properties	O
11	of	O
12	cortical	O
13	-	O
14	bar	O
15	detectors	O
16	.	O

1	Mean	O
2	rCBF	O
3	increased	O
4	in	O
5	some	O
6	patients	O
7	4	O
8	-	O
9	8	O
10	weeks	O
11	after	O
12	surgery	O
13	on	O
14	the	O
15	ipsilateral	O
16	side	O
17	.	O

1	Quantitative	O
2	computed	O
3	tomography	O
4	for	O
5	measuring	O
6	vertebral	O
7	bone	O
8	mineral	O
9	content	O
10	offers	O
11	high	O
12	sensitivity	O
13	and	O
14	reproducibility	O
15	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	enhancer	O
6	was	O
7	also	O
8	probed	O
9	by	O
10	inserting	O
11	a	O
12	pair	O
13	of	O
14	complementary	O
15	synthetic	O
16	oligodeoxynucleotides	O
17	which	O
18	represented	O
19	the	O
20	region	O
21	between	O
22	nt	O
23	positions	O
24	-	O
25	235	O
26	and	O
27	-	O
28	215	O
29	into	O
30	a	O
31	truncated	O
32	template	O
33	which	O
34	lacked	O
35	the	O
36	enhancer	O
37	.	O

1	Kf	O
2	,	O
3	c	O
4	and	O
5	CT	O
6	(	O
7	referenced	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	linearly	O
16	with	O
17	reductions	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	Kf	O
24	,	O
25	c	O
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O

1	Two	O
2	scintigraphic	O
3	methods	O
4	,	O
5	resting	O
6	dipyridamole	O
7	and	O
8	exercise	O
9	thallium	O
10	-	O
11	201	O
12	myocardial	O
13	perfusion	O
14	imaging	O
15	,	O
16	to	O
17	detect	O
18	and	O
19	localize	O
20	coronary	O
21	artery	O
22	stenosis	O
23	were	O
24	compared	O
25	in	O
26	32	O
27	patients	O
28	suffering	O
29	from	O
30	coronary	O
31	artery	O
32	disease	O
33	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	EDLF	O
10	has	O
11	clear	O
12	vasoconstrictor	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	O
29	in	O
30	the	O
31	vasoconstrictor	O
32	effects	O
33	of	O
34	EDLFs	O
35	with	O
36	respect	O
37	to	O
38	different	O
39	vascular	O
40	beds	O
41	.	O

1	Research	O
2	was	O
3	carried	O
4	out	O
5	on	O
6	the	O
7	rheumatoid	B
8	factors	I
9	in	O
10	the	O
11	serum	O
12	of	O
13	917	O
14	patients	O
15	by	O
16	means	O
17	of	O
18	two	O
19	tests	O
20	(	O
21	one	O
22	using	O
23	polystyrene	O
24	and	O
25	one	O
26	with	O
27	erythrocytes	O
28	)	O
29	and	O
30	the	O
31	results	O
32	obtained	O
33	were	O
34	compared	O
35	using	O
36	a	O
37	method	O
38	of	O
39	reference	O
40	.	O

1	A	O
2	low	O
3	aspirin	B
4	esterase	I
5	activity	O
6	may	O
7	be	O
8	a	O
9	contributory	O
10	factor	O
11	in	O
12	precipitating	O
13	these	O
14	aspirin	O
15	sensitive	O
16	reactions	O
17	.	O

1	In	O
2	both	O
3	experiments	O
4	,	O
5	average	O
6	daily	O
7	gain	O
8	and	O
9	gain	O
10	-	O
11	to	O
12	-	O
13	feed	O
14	ratio	O
15	were	O
16	similar	O
17	for	O
18	TR	O
19	and	O
20	CR	O
21	.	O

1	Overall	O
2	least	O
3	-	O
4	squares	O
5	means	O
6	for	O
7	uncooked	O
8	and	O
9	cooked	O
10	longissimus	O
11	muscle	O
12	and	O
13	subcutaneous	O
14	fat	O
15	were	O
16	63	O
17	.	O
18	32	O
19	,	O
20	80	O
21	.	O
22	27	O
23	and	O
24	98	O
25	.	O
26	90	O
27	mg	O
28	of	O
29	cholesterol	O
30	/	O
31	100	O
32	g	O
33	of	O
34	tissue	O
35	,	O
36	respectively	O
37	.	O

1	The	O
2	role	O
3	of	O
4	supercritical	O
5	fluid	O
6	chromatography	O
7	(	O
8	SFC	O
9	)	O
10	as	O
11	a	O
12	viable	O
13	technique	O
14	for	O
15	analyzing	O
16	agricultural	O
17	products	O
18	has	O
19	been	O
20	investigated	O
21	using	O
22	packed	O
23	and	O
24	capillary	O
25	column	O
26	methodology	O
27	.	O

1	Nitrofurazone	O
2	significantly	O
3	reduced	O
4	the	O
5	rise	O
6	in	O
7	LH	B
8	induced	O
9	by	O
10	LHRH	B
11	.	O

1	Ovarian	O
2	tumors	O
3	in	O
4	pregnancy	O
5	.	O

1	Ultrastructural	O
2	study	O
3	of	O
4	polyarteritis	O

1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O

1	After	O
2	a	O
3	baseline	O
4	study	O
5	,	O
6	WPW	O
7	syndrome	O
8	was	O
9	simulated	O
10	by	O
11	stimulation	O
12	at	O
13	seven	O
14	different	O
15	sites	O
16	around	O
17	the	O
18	base	O
19	of	O
20	the	O
21	ventricles	O
22	,	O
23	and	O
24	RNV	O
25	'	O
26	s	O
27	were	O
28	obtained	O
29	.	O

1	Man	O
2	and	O
3	insect	O
4	,	O
5	past	O
6	,	O
7	present	O
8	,	O
9	future	O

1	All	O
2	patients	O
3	had	O
4	the	O
5	CA	B
6	125	I
7	assay	O
8	performed	O
9	within	O
10	one	O
11	week	O
12	before	O
13	their	O
14	second	O
15	-	O
16	look	O
17	operation	O
18	.	O

1	Allergy	O
2	and	O
3	Tourette	O
4	'	O
5	s	O
6	syndrome	O
7	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	Clinical	O
2	method	O
3	for	O
4	the	O
5	treatment	O
6	of	O
7	Class	O
8	II	O
9	occlusal	O
10	anomalies	O
11	with	O
12	open	O
13	bite	O

1	Enoxacin	O
2	appears	O
3	to	O
4	be	O
5	well	O
6	suited	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	complicated	O
12	UTI	O
13	.	O

1	Mean	O
2	fluorosis	O
3	scores	O
4	,	O
5	however	O
6	,	O
7	were	O
8	similar	O
9	.	O

1	Autonomic	O
2	dysfunctions	O
3	were	O
4	restricted	O
5	to	O
6	tonic	O
7	pupils	O
8	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	The	O
2	diagnosis	O
3	of	O
4	amyloidosis	O
5	was	O
6	determined	O
7	from	O
8	a	O
9	labial	O
10	salivary	O
11	gland	O
12	biopsy	O
13	.	O

1	Hair	O
2	and	O
3	blood	O
4	samples	O
5	were	O
6	taken	O
7	before	O
8	vitamin	O
9	C	O
10	or	O
11	placebo	O
12	supplementation	O
13	was	O
14	started	O
15	and	O
16	at	O
17	monthly	O
18	intervals	O
19	thereafter	O
20	for	O
21	three	O
22	months	O
23	.	O

1	In	O
2	treated	O
3	herds	O
4	,	O
5	cows	O
6	more	O
7	than	O
8	40	O
9	d	O
10	postpartum	O
11	with	O
12	a	O
13	corpus	O
14	luteum	O
15	received	O
16	prostaglandin	O
17	F2	O
18	alpha	O
19	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	if	O
7	the	O
8	measured	O
9	angle	O
10	ANB	O
11	is	O
12	smaller	O
13	than	O
14	the	O
15	calculated	O
16	angle	O
17	,	O
18	the	O
19	skeletal	O
20	relation	O
21	is	O
22	Class	O
23	III	O
24	.	O

1	Emergency	O
2	treatment	O
3	of	O
4	facial	O
5	and	O
6	maxillary	O
7	/	O
8	mandibular	O
9	injuries	O

1	In	O
2	14	O
3	cases	O
4	,	O
5	isolates	O
6	were	O
7	biotyped	O
8	yielding	O
9	eight	O
10	with	O
11	biotype	O
12	II	O
13	,	O
14	four	O
15	with	O
16	biotype	O
17	III	O
18	,	O
19	and	O
20	one	O
21	each	O
22	with	O
23	biotypes	O
24	IV	O
25	and	O
26	V	O
27	.	O

1	A	O
2	total	O
3	of	O
4	117	O
5	EVS	O
6	treatments	O
7	were	O
8	performed	O
9	on	O
10	34	O
11	patients	O
12	.	O

1	Most	O
2	of	O
3	the	O
4	prepeptide	O
5	portion	O
6	of	O
7	the	O
8	precursor	O
9	polypeptide	O
10	is	O
11	encoded	O
12	by	O
13	the	O
14	next	O
15	three	O
16	exons	O
17	,	O
18	and	O
19	the	O
20	mature	O
21	form	O
22	of	O
23	IL	B
24	-	I
25	1	I
26	alpha	I
27	is	O
28	encoded	O
29	by	O
30	the	O
31	remaining	O
32	three	O
33	exons	O
34	.	O

1	A	O
2	stochastic	O
3	version	O
4	of	O
5	Kernell	O
6	'	O
7	s	O
8	(	O
9	1968	O
10	,	O
11	1972	O
12	)	O
13	model	O
14	with	O
15	cumulative	O
16	afterhyperpolarization	O
17	(	O
18	AHP	O
19	)	O
20	was	O
21	simulated	O
22	.	O

1	In	O
2	a	O
3	previous	O
4	interim	O
5	report	O
6	we	O
7	noted	O
8	more	O
9	prompt	O
10	resolution	O
11	of	O
12	dermatomal	O
13	signs	O
14	and	O
15	symptoms	O
16	with	O
17	acyclovir	O
18	treatment	O
19	.	O

1	The	O
2	detectability	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	RCA	O
8	or	O
9	LAD	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O

1	Pharmacologic	O
2	properties	O
3	of	O
4	serotonergic	O
5	agents	O
6	and	O
7	antidepressant	O
8	drugs	O
9	.	O

1	This	O
2	brief	O
3	hypercapnic	O
4	challenge	O
5	induced	O
6	a	O
7	rapid	O
8	increase	O
9	in	O
10	CBF	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	any	O
16	change	O
17	in	O
18	MABP	O
19	.	O

1	These	O
2	data	O
3	should	O
4	be	O
5	useful	O
6	in	O
7	developing	O
8	reagents	O
9	for	O
10	heterozygote	O
11	detection	O
12	and	O
13	prenatal	O
14	diagnosis	O
15	of	O
16	11	B
17	beta	I
18	-	I
19	hydroxylase	I
20	deficiency	O
21	,	O
22	the	O
23	second	O
24	most	O
25	frequent	O
26	cause	O
27	of	O
28	congenital	O
29	adrenal	O
30	hyperplasia	O
31	.	O

1	Osteocalcin	B
2	(	O
3	serum	B
4	bone	I
5	-	I
6	Gla	I
7	protein	I
8	,	O
9	sBGP	B
10	),	O
11	serum	B
12	alkaline	I
13	phosphatase	I
14	(	O
15	sAP	B
16	)	O
17	and	O
18	urinary	O
19	hydroxyproline	O
20	/	O
21	creatinine	O
22	ratio	O
23	(	O
24	uOH	O
25	-	O
26	Prol	O
27	/	O
28	creatinine	O
29	)	O
30	have	O
31	been	O
32	measured	O
33	in	O
34	21	O
35	patients	O
36	with	O
37	primary	O
38	hyperparathyroidism	O
39	(	O
40	PHPT	O
41	)	O
42	and	O
43	in	O
44	nine	O
45	patients	O
46	with	O
47	hypercalcaemia	O
48	of	O
49	malignancy	O
50	(	O
51	HM	O
52	).	O

1	Multivariate	O
2	logistic	O
3	regression	O
4	analysis	O
5	indicated	O
6	that	O
7	seropositivity	O
8	was	O
9	strongly	O
10	associated	O
11	with	O
12	the	O
13	prevalence	O
14	of	O
15	hepatitis	O
16	B	O
17	in	O
18	an	O
19	employee	O
20	'	O
21	s	O
22	country	O
23	of	O
24	birth	O
25	and	O
26	with	O
27	age	O
28	.	O

1	Hexsyn	O
2	is	O
3	the	O
4	Goodyear	O
5	Tire	O
6	and	O
7	Rubber	O
8	Company	O
9	tradename	O
10	for	O
11	a	O
12	polyolefin	O
13	rubber	O
14	synthesized	O
15	from	O
16	1	O
17	-	O
18	hexene	O
19	with	O
20	3	O
21	-	O
22	5	O
23	%	O
24	methylhexadiene	O
25	as	O
26	the	O
27	source	O
28	of	O
29	residual	O
30	double	O
31	bonds	O
32	for	O
33	vulcanization	O
34	.	O

1	Chimeric	O
2	phage	O
3	-	O
4	plasmid	O
5	expression	O
6	vectors	O
7	were	O
8	constructed	O
9	from	O
10	pUC18	O
11	/	O
12	19	O
13	plasmids	O
14	by	O
15	cloning	O
16	a	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	(	O
22	ssDNA	O
23	)	O
24	origin	O
25	of	O
26	replication	O
27	from	O
28	bacteriophage	O
29	f1	O
30	and	O
31	inserting	O
32	a	O
33	bacteriophage	O
34	T7	O
35	promoter	O
36	within	O
37	the	O
38	beta	B
39	-	I
40	galactosidase	I
41	gene	I
42	.	O

1	By	O
2	order	O
3	of	O
4	decreasing	O
5	rate	O
6	,	O
7	finger	O
8	flexors	O
9	,	O
10	jaw	O
11	,	O
12	crossed	O
13	adductors	O
14	,	O
15	and	O
16	triceps	O
17	reflexes	O
18	were	O
19	less	O
20	frequently	O
21	elicited	O
22	in	O
23	both	O
24	groups	O
25	.	O

1	Natl	O
2	.	O

1	Neither	O
2	ethanol	O
3	nor	O
4	estrogen	O
5	has	O
6	been	O
7	shown	O
8	to	O
9	cause	O
10	UROD	B
11	-	O
12	deficiency	O
13	in	O
14	animals	O
15	.	O

1	Although	O
2	not	O
3	common	O
4	,	O
5	the	O
6	disorder	O
7	is	O
8	the	O
9	most	O
10	frequently	O
11	diagnosed	O
12	disturbance	O
13	of	O
14	porphyrin	O
15	metabolism	O
16	in	O
17	many	O
18	countries	O
19	,	O
20	and	O
21	further	O
22	insight	O
23	into	O
24	its	O
25	unusual	O
26	pathogenesis	O
27	may	O
28	clarify	O
29	the	O
30	hepatotoxic	O
31	effects	O
32	of	O
33	the	O
34	4	O
35	etiologic	O
36	agents	O
37	.	O

1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O

1	The	O
2	highest	O
3	postoperative	O
4	CK	B
5	-	I
6	MB	I
7	level	O
8	was	O
9	less	O
10	after	O
11	BC	O
12	(	O
13	BC	O
14	,	O
15	31	O
16	+/-	O
17	17	O
18	U	O
19	/	O
20	L	O
21	;	O
22	CC	O
23	,	O
24	56	O
25	+/-	O
26	13	O
27	U	O
28	/	O
29	L	O
30	;	O
31	p	O
32	less	O
33	than	O
34	0	O
35	.	O
36	05	O
37	).	O

1	No	O
2	relevant	O
3	changes	O
4	in	O
5	heart	O
6	rate	O
7	,	O
8	body	O
9	weight	O
10	,	O
11	and	O
12	plasma	O
13	levels	O
14	of	O
15	renin	B
16	activity	O
17	and	O
18	aldosterone	O
19	concentration	O
20	were	O
21	observed	O
22	.	O

1	High	O
2	trough	O
3	serum	O
4	TOB	O
5	concentrations	O
6	were	O
7	associated	O
8	with	O
9	death	O
10	and	O
11	very	O
12	low	O
13	levels	O
14	with	O
15	recovery	O
16	.	O

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	R	O
8	.	O
9	N	O
10	.	O

1	In	O
2	a	O
3	maxicell	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	approximate	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O

1	This	O
2	means	O
3	that	O
4	the	O
5	loss	O
6	of	O
7	recessives	O
8	must	O
9	be	O
10	calculated	O
11	by	O
12	using	O
13	a	O
14	hypergeometric	O
15	and	O
16	not	O
17	a	O
18	binomial	O
19	model	O
20	as	O
21	Fisher	O
22	did	O
23	.	O

1	The	O
2	incidence	O
3	of	O
4	second	O
5	malignant	O
6	neoplasms	O
7	was	O
8	lower	O
9	(	O
10	1	O
11	.	O
12	3	O
13	%)	O
14	in	O
15	the	O
16	group	O
17	treated	O
18	with	O
19	5	O
20	-	O
21	fluorouracil	O
22	,	O
23	doxorubicin	O
24	,	O
25	and	O
26	cyclophosphamide	O
27	than	O
28	in	O
29	the	O
30	historical	O
31	control	O
32	group	O
33	(	O
34	4	O
35	.	O
36	8	O
37	%).	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	In	O
2	previous	O
3	work	O
4	(	O
5	E	O
6	.	O

1	The	O
2	small	O
3	size	O
4	and	O
5	placement	O
6	of	O
7	the	O
8	mutagenesis	O
9	marker	O
10	(	O
11	the	O
12	supF	B
13	suppressor	I
14	tRNA	I
15	gene	I
16	from	I
17	Escherichia	I
18	coli	I
19	)	O
20	within	O
21	the	O
22	vector	O
23	substantially	O
24	reduced	O
25	the	O
26	frequency	O
27	of	O
28	spontaneous	O
29	mutations	O
30	normally	O
31	observed	O
32	after	O
33	transfection	O
34	of	O
35	mammalian	O
36	cells	O
37	with	O
38	plasmid	O
39	DNA	O
40	;	O
41	hence	O
42	,	O
43	UV	O
44	-	O
45	induced	O
46	mutations	O
47	were	O
48	easily	O
49	identified	O
50	above	O
51	the	O
52	spontaneous	O
53	background	O
54	.	O

1	W	O
2	.	O

1	Tetrad	O
2	analysis	O
3	and	O
4	mitotic	O
5	recombination	O
6	experiments	O
7	localized	O
8	the	O
9	PEP4	B
10	gene	I
11	proximal	O
12	to	O
13	GAL4	B
14	on	O
15	chromosome	O
16	XVI	O
17	.	O

1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	B
18	gene	I
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	B
31	hydrolases	I
32	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	RNA	O
6	synthesized	O
7	from	O
8	the	O
9	cloned	O
10	cDNAs	O
11	predicts	O
12	that	O
13	P0	B
14	transcripts	I
15	are	O
16	translated	O
17	into	O
18	a	O
19	novel	O
20	12	O
21	.	O
22	5	O
23	-	O
24	kilodalton	O
25	protein	O
26	corresponding	O
27	to	O
28	the	O
29	first	O
30	open	O
31	reading	O
32	frame	O
33	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	Mop	B
10	has	O
11	sequence	O
12	homology	O
13	with	O
14	DNA	O
15	binding	O
16	proteins	O
17	.	O

1	Several	O
2	new	O
3	techniques	O
4	are	O
5	available	O
6	for	O
7	monitoring	O
8	control	O
9	of	O
10	diabetes	O
11	.	O

1	Ciprofloxacin	O
2	:	O
3	an	O
4	overview	O
5	of	O
6	adverse	O
7	experiences	O
8	.	O

1	Possible	O
2	pathogenetic	O
3	mechanisms	O
4	of	O
5	hemopoietic	O
6	changes	O
7	in	O
8	response	O
9	to	O
10	space	O
11	flight	O
12	effects	O
13	are	O
14	described	O
15	.	O

1	The	O
2	rho	B
3	genes	I
4	comprise	O
5	an	O
6	evolutionarily	O
7	conserved	O
8	family	O
9	with	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	ras	B
15	oncogene	I
16	family	I
17	.	O

1	Also	O
2	,	O
3	component	O
4	I	O
5	significantly	O
6	correlated	O
7	with	O
8	fasting	O
9	insulin	B
10	and	O
11	VO2	O
12	max	O
13	for	O
14	both	O
15	sexes	O
16	and	O
17	with	O
18	basal	O
19	metabolism	O
20	and	O
21	HDL	B
22	-	I
23	cholesterol	I
24	for	O
25	females	O
26	and	O
27	males	O
28	,	O
29	respectively	O
30	.	O

1	The	O
2	glucose	O
3	areas	O
4	following	O
5	the	O
6	ingestion	O
7	of	O
8	the	O
9	foods	O
10	were	O
11	:	O
12	Study	O
13	1	O
14	:	O
15	glucose	O
16	11	O
17	.	O
18	7	O
19	,	O
20	orange	O
21	juice	O
22	7	O
23	.	O
24	3	O
25	,	O
26	sucrose	O
27	5	O
28	.	O
29	2	O
30	,	O
31	glucose	O
32	+	O
33	fructose	O
34	6	O
35	.	O
36	3	O
37	,	O
38	and	O
39	fructose	O
40	0	O
41	.	O
42	7	O
43	mmol	O
44	X	O
45	h	O
46	/	O
47	l	O
48	;	O
49	Study	O
50	2	O
51	:	O
52	glucose	O
53	14	O
54	.	O
55	6	O
56	,	O
57	orange	O
58	juice	O
59	7	O
60	.	O
61	3	O
62	,	O
63	apples	O
64	5	O
65	.	O
66	5	O
67	,	O
68	and	O
69	apple	O
70	juice	O
71	4	O
72	.	O
73	7	O
74	mmol	O
75	X	O
76	h	O
77	/	O
78	l	O
79	;	O
80	Study	O
81	3	O
82	:	O
83	glucose	O
84	12	O
85	.	O
86	6	O
87	,	O
88	ice	O
89	cream	O
90	8	O
91	.	O
92	1	O
93	,	O
94	milk	O
95	3	O
96	.	O
97	7	O
98	,	O
99	and	O
100	lactose	O
101	4	O
102	.	O
103	1	O
104	mmol	O
105	X	O
106	h	O
107	/	O
108	l	O
109	.	O

1	The	O
2	serum	B
3	insulin	I
4	response	O
5	cannot	O
6	.	O

1	SCL	O
2	prolonged	O
3	promptly	O
4	after	O
5	verapamil	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O

1	Development	O
2	of	O
3	a	O
4	yeast	O
5	system	O
6	to	O
7	assay	O
8	mutational	O
9	specificity	O
10	.	O

1	Postglucose	O
2	serum	B
3	insulin	I
4	levels	O
5	showed	O
6	no	O
7	significant	O
8	correlations	O
9	with	O
10	systolic	O
11	or	O
12	diastolic	O
13	blood	O
14	pressure	O
15	levels	O
16	in	O
17	men	O
18	,	O
19	but	O
20	in	O
21	female	O
22	diabetic	O
23	and	O
24	non	O
25	-	O
26	diabetic	O
27	subjects	O
28	significant	O
29	correlations	O
30	were	O
31	found	O
32	in	O
33	particular	O
34	with	O
35	systolic	O
36	blood	O
37	pressure	O
38	level	O
39	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	B
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	B
23	.	O

1	The	O
2	latter	O
3	was	O
4	determined	O
5	as	O
6	follows	O
7	:	O
8	Type	O
9	I	O
10	-	O
11	solid	O
12	tumor	O
13	tissue	O
14	without	O
15	significant	O
16	peripheral	O
17	isolated	O
18	tumor	O
19	cells	O
20	;	O
21	Type	O
22	II	O
23	-	O
24	solid	O
25	tumor	O
26	tissue	O
27	associated	O
28	with	O
29	peripheral	O
30	isolated	O
31	tumor	O
32	cells	O
33	;	O
34	Type	O
35	III	O
36	-	O
37	isolated	O
38	tumor	O
39	cells	O
40	only	O
41	.	O

1	The	O
2	pharmacology	O
3	of	O
4	carnitine	O
5	.	O

1	Acute	O
2	inhalation	O
3	toxicity	O
4	of	O
5	T	O
6	-	O
7	2	O
8	mycotoxin	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	present	O
3	investigation	O
4	sought	O
5	to	O
6	identify	O
7	the	O
8	principal	O
9	dimensions	O
10	of	O
11	the	O
12	Framingham	O
13	Type	O
14	A	O
15	scale	O
16	(	O
17	FTAS	O
18	)	O
19	and	O
20	then	O
21	to	O
22	examine	O
23	their	O
24	physiological	O
25	and	O
26	psychological	O
27	correlates	O
28	.	O

1	A	O
2	preliminary	O
3	study	O
4	on	O
5	pyogenic	O
6	arthritis	O
7	.	O

1	Legionella	O
2	,	O
3	microbial	O
4	ecology	O
5	,	O
6	and	O
7	inconspicuous	O
8	consumption	O
9	.	O

1	Lymphatics	O
2	in	O
3	the	O
4	aorta	O
5	of	O
6	rats	O
7	treated	O
8	with	O
9	a	O
10	soy	O
11	-	O
12	bean	O
13	oil	O
14	extract	O
15	(	O
16	lipofundin	O
17	).	O

1	As	O
2	a	O
3	last	O
4	resort	O
5	,	O
6	it	O
7	may	O
8	be	O
9	possible	O
10	to	O
11	maintain	O
12	a	O
13	patient	O
14	on	O
15	dialysis	O
16	in	O
17	reasonable	O
18	health	O
19	with	O
20	a	O
21	DiaTAP	O
22	button	O
23	graft	O
24	complex	O
25	infected	O
26	with	O
27	Staphylococcus	O
28	epidermidis	O
29	and	O
30	intermittent	O
31	positive	O
32	blood	O
33	cultures	O
34	using	O
35	long	O
36	term	O
37	vancomycin	O
38	therapy	O
39	.	O

1	For	O
2	signal	O
3	durations	O
4	less	O
5	than	O
6	10	O
7	ms	O
8	,	O
9	however	O
10	,	O
11	the	O
12	SoNo	O
13	and	O
14	S	O
15	pi	O
16	No	O
17	threshold	O
18	functions	O
19	converged	O
20	and	O
21	the	O
22	masking	O
23	-	O
24	level	O
25	difference	O
26	decreased	O
27	.	O

1	The	O
2	spleen	O
3	rate	O
4	of	O
5	about	O
6	600	O
7	villagers	O
8	of	O
9	RK	O
10	I	O
11	examined	O
12	was	O
13	54	O
14	.	O
15	3	O
16	%	O
17	and	O
18	the	O
19	parasite	O
20	rate	O
21	13	O
22	.	O
23	2	O
24	%	O
25	before	O
26	the	O
27	drug	O
28	intervention	O
29	.	O

1	Multiple	O
2	dosing	O
3	four	O
4	times	O
5	daily	O
6	for	O
7	7	O
8	days	O
9	of	O
10	indoprofen	O
11	200	O
12	mg	O
13	,	O
14	a	O
15	non	O
16	-	O
17	steroidal	O
18	anti	O
19	-	O
20	inflammatory	O
21	drug	O
22	with	O
23	a	O
24	short	O
25	half	O
26	-	O
27	life	O
28	(	O
29	t1	O
30	/	O
31	2	O
32	),	O
33	revealed	O
34	drug	O
35	accumulation	O
36	in	O
37	eight	O
38	elderly	O
39	subjects	O
40	.	O

1	In	O
2	10	O
3	patients	O
4	with	O
5	subacute	O
6	cardiac	O
7	tamponade	O
8	,	O
9	pulmonary	O
10	wedge	O
11	pressure	O
12	(	O
13	PWP	O
14	),	O
15	RAP	O
16	,	O
17	and	O
18	IPP	O
19	were	O
20	measured	O
21	along	O
22	with	O
23	indexes	O
24	of	O
25	systolic	O
26	function	O
27	.	O

1	Encompassing	O
2	tamponade	O
3	and	O
4	pericardiocentesis	O
5	data	O
6	,	O
7	left	O
8	ventricular	O
9	stroke	O
10	work	O
11	index	O
12	showed	O
13	positive	O
14	correlation	O
15	with	O
16	TMFP1	O
17	(	O
18	r	O
19	=	O
20	.	O
21	59	O
22	)	O
23	and	O
24	TMFP2	O
25	(	O
26	r	O
27	=	O
28	.	O
29	52	O
30	)	O
31	but	O
32	not	O
33	with	O
34	TMFP3	O
35	.	O

1	Rabbits	O
2	developed	O
3	profound	O
4	hypocalcemia	O
5	,	O
6	with	O
7	levels	O
8	falling	O
9	from	O
10	15	O
11	.	O
12	5	O
13	+/-	O
14	0	O
15	.	O
16	2	O
17	to	O
18	7	O
19	.	O
20	6	O
21	+/-	O
22	0	O
23	.	O
24	4	O
25	mg	O
26	/	O
27	dl	O
28	under	O
29	the	O
30	influence	O
31	of	O
32	TSST	B
33	-	I
34	1	I
35	.	O

1	Reward	O
2	value	O
3	of	O
4	prosodic	O
5	features	O
6	of	O
7	language	O
8	for	O
9	autistic	O
10	,	O
11	mentally	O
12	retarded	O
13	,	O
14	and	O
15	normal	O
16	children	O
17	.	O

1	Similarly	O
2	,	O
3	actuarial	O
4	interpretations	O
5	for	O
6	the	O
7	second	O
8	protocols	O
9	were	O
10	not	O
11	more	O
12	frequently	O
13	selected	O
14	by	O
15	therapists	O
16	as	O
17	more	O
18	valid	O
19	,	O
20	regardless	O
21	of	O
22	treatment	O
23	condition	O
24	and	O
25	elevation	O
26	of	O
27	the	O
28	F	O
29	and	O
30	F	O
31	-	O
32	K	O
33	indices	O
34	on	O
35	the	O
36	first	O
37	MMPI	O
38	profile	O
39	.	O

1	Due	O
2	to	O
3	its	O
4	relatively	O
5	soluble	O
6	chemical	O
7	form	O
8	,	O
9	90Sr	O
10	was	O
11	rapidly	O
12	translocated	O
13	from	O
14	lung	O
15	to	O
16	bone	O
17	where	O
18	a	O
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	O
27	of	O
28	time	O
29	.	O

1	The	O
2	study	O
3	disclosed	O
4	generalized	O
5	atrophy	O
6	and	O
7	diffuse	O
8	symmetric	O
9	white	O
10	matter	O
11	hypodensities	O
12	.	O

1	The	O
2	diagnosis	O
3	of	O
4	metachromatic	O
5	leukodystrophy	O
6	(	O
7	MLD	O
8	)	O
9	was	O
10	confirmed	O
11	by	O
12	the	O
13	finding	O
14	of	O
15	low	O
16	arylsulfatase	B
17	A	I
18	(	O
19	ASA	B
20	)	O
21	levels	O
22	in	O
23	cultured	O
24	fibroblasts	O
25	in	O
26	both	O
27	sisters	O
28	.	O

1	Artificial	O
2	ventilation	O
3	was	O
4	conducted	O
5	using	O
6	a	O
7	tidal	O
8	volume	O
9	of	O
10	10	O
11	ml	O
12	X	O
13	kg	O
14	-	O
15	1	O
16	and	O
17	a	O
18	rate	O
19	of	O
20	10	O
21	to	O
22	12	O
23	c	O
24	X	O
25	min	O
26	-	O
27	1	O
28	.	O

1	Significantly	O
2	lower	O
3	heart	O
4	rate	O
5	reactivity	O
6	and	O
7	significantly	O
8	less	O
9	pronounced	O
10	left	O
11	temporal	O
12	artery	O
13	pulse	O
14	amplitude	O
15	responses	O
16	were	O
17	found	O
18	in	O
19	non	O
20	-	O
21	medicated	O
22	TH	O
23	subjects	O
24	than	O
25	in	O
26	controls	O
27	.	O

1	An	O
2	epidemiological	O
3	survey	O
4	of	O
5	rheumatic	O
6	valve	O
7	disease	O
8	and	O
9	rheumatic	O
10	fever	O
11	in	O
12	primary	O
13	and	O
14	secondary	O
15	school	O
16	students	O
17	in	O
18	Jiangxi	O
19	Province	O

1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O

1	A	O
2	study	O
3	of	O
4	human	O
5	genes	O
6	coding	O
7	for	O
8	U4	B
9	small	I
10	nuclear	I
11	RNA	I
12	is	O
13	presented	O
14	.	O

1	Using	O
2	the	O
3	balloon	O
4	-	O
5	gas	O
6	procedure	O
7	with	O
8	a	O
9	single	O
10	gas	O
11	injection	O
12	,	O
13	a	O
14	bubble	O
15	was	O
16	obtained	O
17	that	O
18	was	O
19	large	O
20	enough	O
21	to	O
22	tamponade	O
23	a	O
24	giant	O
25	tear	O
26	without	O
27	prior	O
28	drainage	O
29	of	O
30	subretinal	O
31	fluid	O
32	or	O
33	vitrectomy	O
34	.	O

1	Heat	O
2	-	O
3	labile	O
4	-	O
5	like	O
6	enterotoxin	O
7	(	O
8	LT	B
9	)	O
10	was	O
11	produced	O
12	by	O
13	26	O
14	of	O
15	42	O
16	stool	O
17	isolates	O
18	(	O
19	62	O
20	%),	O
21	while	O
22	only	O
23	1	O
24	of	O
25	the	O
26	42	O
27	isolates	O
28	(	O
29	2	O
30	%)	O
31	produced	O
32	enterotoxinlike	O
33	activity	O
34	in	O
35	suckling	O
36	mice	O
37	;	O
38	65	O
39	%	O
40	of	O
41	the	O
42	cytotoxin	O
43	-	O
44	producing	O
45	strains	O
46	also	O
47	produced	O
48	an	O
49	LT	B
50	-	I
51	like	I
52	material	O
53	.	O

1	Development	O
2	of	O
3	a	O
4	provisional	O
5	information	O
6	-	O
7	retrieval	O
8	descriptor	O
9	language	O
10	for	O
11	"	O
12	Roentgenology	O
13	and	O
14	Medical	O
15	Radiology	O
16	"	O
17	for	O
18	use	O
19	in	O
20	the	O
21	Medinform	O
22	system	O

1	Persistent	O
2	acantholytic	O
3	dermatosis	O
4	with	O
5	increased	O
6	light	O
7	sensitivity	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Dorsal	O
2	foot	O
3	TcpO2	O
4	was	O
5	measured	O
6	by	O
7	using	O
8	oxygen	O
9	-	O
10	sensing	O
11	electrodes	O
12	with	O
13	surface	O
14	temperatures	O
15	of	O
16	42	O
17	degrees	O
18	C	O
19	and	O
20	45	O
21	degrees	O
22	C	O
23	;	O
24	in	O
25	theory	O
26	,	O
27	changes	O
28	in	O
29	sympathetic	O
30	activity	O
31	should	O
32	affect	O
33	vasomotor	O
34	tone	O
35	and	O
36	TcpO2	O
37	in	O
38	skin	O
39	beneath	O
40	an	O
41	electrode	O
42	at	O
43	42	O
44	degrees	O
45	C	O
46	(	O
47	submaximal	O
48	vasodilation	O
49	),	O
50	but	O
51	not	O
52	at	O
53	45	O
54	degrees	O
55	C	O
56	(	O
57	maximal	O
58	vasodilation	O
59	).	O

1	In	O
2	subjects	O
3	(	O
4	n	O
5	=	O
6	5	O
7	)	O
8	with	O
9	quadriplegia	O
10	and	O
11	reduced	O
12	sympathetic	O
13	tone	O
14	secondary	O
15	to	O
16	cervical	O
17	cord	O
18	trauma	O
19	,	O
20	TcpO2	O
21	at	O
22	42	O
23	degrees	O
24	C	O
25	and	O
26	vasodilation	O
27	index	O
28	were	O
29	increased	O
30	(	O
31	45	O
32	.	O
33	0	O
34	mmHg	O
35	and	O
36	0	O
37	.	O
38	61	O
39	);	O
40	TcpO2	O
41	at	O
42	45	O
43	degrees	O
44	C	O
45	did	O
46	not	O
47	change	O
48	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	the	O
6	human	B
7	and	I
8	murine	I
9	ornithine	I
10	decarboxylase	I
11	mRNAs	I
12	share	O
13	an	O
14	85	O
15	%	O
16	homology	O
17	,	O
18	even	O
19	in	O
20	their	O
21	3	O
22	'-	O
23	noncoding	O
24	regions	O
25	.	O

1	The	O
2	absolute	O
3	concentrations	O
4	of	O
5	alpha	B
6	2	I
7	-	I
8	plasmin	I
9	inhibitor	O
10	,	O
11	alpha	B
12	2	I
13	-	I
14	macroglobulin	I
15	,	O
16	and	O
17	antithrombin	B
18	III	I
19	increased	O
20	with	O
21	exercise	O
22	(	O
23	all	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	005	O
30	),	O
31	but	O
32	when	O
33	concentrations	O
34	were	O
35	corrected	O
36	for	O
37	acute	O
38	shifts	O
39	of	O
40	plasma	O
41	water	O
42	during	O
43	exercise	O
44	,	O
45	the	O
46	quantity	O
47	of	O
48	these	O
49	inhibitors	O
50	actually	O
51	decreased	O
52	(	O
53	all	O
54	P	O
55	less	O
56	than	O
57	0	O
58	.	O
59	005	O
60	).	O

1	The	O
2	other	O
3	model	O
4	was	O
5	a	O
6	continuous	O
7	exponential	O
8	plus	O
9	constant	O
10	of	O
11	the	O
12	form	O
13	La	O
14	-	O
15	=	O
16	a	O
17	+	O
18	b	O
19	[	O
20	exp	O
21	(	O
22	cVO2	O
23	)].	O

1	Cell	O
2	.	O

1	Timing	O
2	of	O
3	symptoms	O
4	and	O
5	oocyst	O
6	excretion	O
7	in	O
8	human	O
9	cryptosporidiosis	O
10	.	O

1	After	O
2	dopamine	O
3	infusion	O
4	in	O
5	women	O
6	with	O
7	polycystic	O
8	ovary	O
9	syndrome	O
10	and	O
11	in	O
12	matched	O
13	controls	O
14	,	O
15	steady	O
16	state	O
17	levels	O
18	of	O
19	plasma	O
20	dopamine	O
21	,	O
22	norepinephrine	O
23	,	O
24	and	O
25	the	O
26	ratio	O
27	of	O
28	dopamine	O
29	/	O
30	norepinephrine	O
31	were	O
32	similar	O
33	in	O
34	the	O
35	two	O
36	groups	O
37	.	O

1	Diagnostic	O
2	importance	O
3	of	O
4	determining	O
5	the	O
6	complement	O
7	constituents	O
8	in	O
9	children	O
10	with	O
11	autoimmune	O
12	thyroiditis	O

1	In	O
2	the	O
3	normal	O
4	,	O
5	basal	O
6	(	O
7	unstimulated	O
8	)	O
9	condition	O
10	there	O
11	were	O
12	no	O
13	significant	O
14	correlations	O
15	(	O
16	p	O
17	greater	O
18	than	O
19	0	O
20	.	O
21	05	O
22	)	O
23	between	O
24	the	O
25	systolic	O
26	blood	O
27	pressure	O
28	and	O
29	dopamine	O
30	(	O
31	r	O
32	=	O
33	0	O
34	.	O
35	09	O
36	),	O
37	norepinephrine	O
38	(	O
39	r	O
40	=	O
41	0	O
42	.	O
43	26	O
44	),	O
45	or	O
46	epinephrine	O
47	(	O
48	r	O
49	=	O
50	0	O
51	.	O
52	27	O
53	),	O
54	nor	O
55	were	O
56	there	O
57	significant	O
58	correlations	O
59	between	O
60	melatonin	O
61	and	O
62	dopamine	O
63	(	O
64	r	O
65	=	O
66	-	O
67	0	O
68	.	O
69	01	O
70	),	O
71	norepinephrine	O
72	(	O
73	r	O
74	=	O
75	-	O
76	0	O
77	.	O
78	26	O
79	),	O
80	or	O
81	growth	B
82	hormone	I
83	(	O
84	r	O
85	=	O
86	0	O
87	.	O
88	17	O
89	).	O

1	The	O
2	4	O
3	patients	O
4	with	O
5	carboxyhemoglobin	B
6	levels	O
7	in	O
8	excess	O
9	of	O
10	10	O
11	%	O
12	may	O
13	represent	O
14	occult	O
15	carbon	O
16	monoxide	O
17	poisoning	O
18	in	O
19	this	O
20	population	O
21	.	O

1	All	O
2	these	O
3	processes	O
4	were	O
5	fully	O
6	developed	O
7	during	O
8	the	O
9	last	O
10	month	O
11	of	O
12	pregnancy	O
13	,	O
14	offering	O
15	the	O
16	same	O
17	picture	O
18	as	O
19	the	O
20	controls	O
21	.	O

1	Hypoglycemic	O
2	action	O
3	of	O
4	"	O
5	he	O
6	xiang	O
7	zhuang	O
8	qi	O
9	gong	O
10	"	O
11	and	O
12	its	O
13	mechanism	O
14	on	O
15	diabetes	O
16	mellitus	O

1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O

1	This	O
2	region	O
3	of	O
4	60	O
5	amino	O
6	acids	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	coiled	O
12	-	O
13	coil	O
14	interactions	O
15	similar	O
16	to	O
17	those	O
18	that	O
19	facilitate	O
20	the	O
21	filament	O
22	formation	O
23	in	O
24	the	O
25	rod	O
26	region	O
27	.	O

1	This	O
2	approach	O
3	enables	O
4	the	O
5	sources	O
6	of	O
7	error	O
8	in	O
9	the	O
10	calculation	O
11	of	O
12	nutrient	O
13	utilization	O
14	to	O
15	be	O
16	readily	O
17	identified	O
18	,	O
19	and	O
20	their	O
21	effect	O
22	on	O
23	precision	O
24	to	O
25	be	O
26	assessed	O
27	in	O
28	different	O
29	nutritional	O
30	and	O
31	metabolic	O
32	states	O
33	.	O

1	The	O
2	effect	O
3	of	O
4	dietary	O
5	zinc	O
6	deficiency	O
7	on	O
8	the	O
9	mossy	O
10	fiber	O
11	zinc	O
12	content	O
13	of	O
14	the	O
15	rat	O
16	hippocampus	O
17	.	O

1	Weaned	O
2	rats	O
3	were	O
4	fed	O
5	a	O
6	normal	O
7	diet	O
8	or	O
9	a	O
10	low	O
11	-	O
12	protein	O
13	,	O
14	low	O
15	-	O
16	energy	O
17	diet	O
18	,	O
19	and	O
20	injected	O
21	with	O
22	saline	O
23	or	O
24	thyroxine	O
25	(	O
26	5	O
27	micrograms	O
28	/	O
29	100	O
30	g	O
31	BW	O
32	)	O
33	for	O
34	22	O
35	days	O
36	.	O

1	It	O
2	is	O
3	largely	O
4	predicted	O
5	by	O
6	lupus	O
7	anticoagulant	O
8	(	O
9	estimated	O
10	by	O
11	activated	O
12	partial	O
13	thromboplastin	B
14	time	O
15	)	O
16	and	O
17	/	O
18	or	O
19	antibody	O
20	to	O
21	cardiolipin	O
22	.	O

1	The	O
2	effects	O
3	of	O
4	several	O
5	opioid	O
6	agonists	O
7	and	O
8	the	O
9	opioid	O
10	antagonist	O
11	naloxone	O
12	were	O
13	examined	O
14	in	O
15	rats	O
16	responding	O
17	under	O
18	a	O
19	fixed	O
20	-	O
21	consecutive	O
22	-	O
23	number	O
24	(	O
25	FCN	O
26	)	O
27	schedule	O
28	.	O

1	The	O
2	rate	O
3	-	O
4	decreasing	O
5	effects	O
6	of	O
7	morphine	O
8	and	O
9	U50488	O
10	were	O
11	reversed	O
12	completely	O
13	by	O
14	a	O
15	0	O
16	.	O
17	01	O
18	and	O
19	1	O
20	.	O
21	0	O
22	mg	O
23	/	O
24	kg	O
25	dose	O
26	of	O
27	naloxone	O
28	,	O
29	respectively	O
30	.	O

1	Data	O
2	from	O
3	119	O
4	men	O
5	and	O
6	40	O
7	women	O
8	undergoing	O
9	coronary	O
10	angiography	O
11	provide	O
12	an	O
13	opportunity	O
14	to	O
15	compare	O
16	these	O
17	associations	O
18	in	O
19	relation	O
20	to	O
21	a	O
22	direct	O
23	and	O
24	continuous	O
25	measure	O
26	of	O
27	atherosclerosis	O
28	while	O
29	controlling	O
30	for	O
31	age	O
32	,	O
33	sex	O
34	,	O
35	income	O
36	,	O
37	hypertension	O
38	,	O
39	serum	O
40	cholesterol	O
41	,	O
42	smoking	O
43	,	O
44	angina	O
45	,	O
46	diabetes	O
47	,	O
48	family	O
49	history	O
50	of	O
51	heart	O
52	disease	O
53	,	O
54	Type	O
55	A	O
56	behavior	O
57	pattern	O
58	,	O
59	and	O
60	hostility	O
61	.	O

1	An	O
2	intralobar	O
3	change	O
4	in	O
5	temperature	O
6	above	O
7	or	O
8	below	O
9	36	O
10	degrees	O
11	C	O
12	decreases	O
13	only	O
14	the	O
15	lobar	O
16	bronchial	O
17	blood	O
18	flow	O
19	and	O
20	does	O
21	not	O
22	influence	O
23	blood	O
24	flow	O
25	to	O
26	other	O
27	nearby	O
28	tissues	O
29	including	O
30	those	O
31	vascularized	O
32	by	O
33	the	O
34	bronchial	O
35	circulation	O
36	.	O

1	Convulsive	O
2	status	O
3	epilepticus	O
4	after	O
5	infusion	O
6	of	O
7	cisplatin	O

1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	adrenaline	O
10	and	O
11	noradrenaline	O
12	is	O
13	indicative	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	catecholamine	O
19	biotransformation	O
20	.	O

1	The	O
2	following	O
3	markers	O
4	were	O
5	looked	O
6	for	O
7	in	O
8	the	O
9	serum	O
10	,	O
11	skin	O
12	and	O
13	liver	O
14	of	O
15	all	O
16	patients	O
17	with	O
18	chronic	O
19	hepatitis	O
20	:	O
21	HBV	O
22	(	O
23	HBs	B
24	Ag	I
25	and	O
26	HBe	B
27	Ag	I
28	,	O
29	anti	B
30	-	I
31	HBs	I
32	,	O
33	anti	B
34	-	I
35	HBe	I
36	and	O
37	anti	B
38	-	I
39	HBc	I
40	in	O
41	the	O
42	serum	O
43	,	O
44	HBs	B
45	and	I
46	HBc	I
47	Ag	I
48	in	O
49	the	O
50	liver	O
51	);	O
52	non	B
53	-	I
54	A	I
55	non	I
56	-	I
57	B	I
58	(	O
59	non	B
60	-	I
61	A	I
62	,	I
63	non	I
64	-	I
65	B	I
66	Ag	I
67	and	I
68	antibody	I
69	,	O
70	anti	B
71	non	I
72	-	I
73	A	I
74	non	I
75	-	I
76	Bc	I
77	in	O
78	the	O
79	serum	O
80	,	O
81	non	B
82	-	I
83	A	I
84	,	I
85	non	I
86	-	I
87	Bc	I
88	Ag	I
89	in	O
90	the	O
91	liver	O
92	).	O

1	Groups	O
2	of	O
3	male	O
4	and	O
5	female	O
6	Fischer	O
7	344	O
8	rats	O
9	,	O
10	B6C3F1	O
11	mice	O
12	,	O
13	and	O
14	Hartley	O
15	guinea	O
16	pigs	O
17	were	O
18	exposed	O
19	once	O
20	for	O
21	6	O
22	hr	O
23	to	O
24	mean	O
25	concentrations	O
26	of	O
27	10	O
28	.	O
29	5	O
30	,	O
31	5	O
32	.	O
33	4	O
34	,	O
35	2	O
36	.	O
37	4	O
38	,	O
39	1	O
40	.	O
41	0	O
42	,	O
43	or	O
44	0	O
45	(	O
46	control	O
47	)	O
48	ppm	O
49	of	O
50	methyl	O
51	isocyanate	O
52	(	O
53	MIC	O
54	)	O
55	vapor	O
56	.	O

1	Radionuclide	O
2	study	O
3	and	O
4	endomyocardial	O
5	biopsy	O
6	revealed	O
7	remarkable	O
8	degeneration	O
9	of	O
10	myocardium	O
11	.	O

1	Immobilization	O
2	of	O
3	the	O
4	fracture	O
5	in	O
6	a	O
7	collar	O
8	and	O
9	cuff	O
10	sling	O
11	was	O
12	as	O
13	effective	O
14	as	O
15	more	O
16	elaborate	O
17	methods	O
18	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O

1	Typical	O
2	and	O
3	atypical	O
4	clinical	O
5	features	O
6	of	O
7	this	O
8	lacrimal	O
9	sac	O
10	cyst	O
11	are	O
12	emphasized	O
13	.	O

1	The	O
2	role	O
3	of	O
4	saliva	O
5	in	O
6	sour	O
7	taste	O
8	perception	O
9	was	O
10	investigated	O
11	in	O
12	a	O
13	series	O
14	of	O
15	4	O
16	experiments	O
17	.	O

1	Samples	O
2	from	O
3	1415	O
4	neurological	O
5	patients	O
6	were	O
7	used	O
8	to	O
9	study	O
10	the	O
11	diagnostic	O
12	value	O
13	of	O
14	acid	B
15	alpha	I
16	1	I
17	-	I
18	glycoprotein	I
19	in	O
20	the	O
21	lumbar	O
22	cerebrospinal	O
23	fluid	O
24	.	O

1	Separate	O
2	experiments	O
3	measured	O
4	AIB	O
5	and	O
6	86RbCl	O
7	uptake	O
8	in	O
9	36B	O
10	-	O
11	10	O
12	cells	O
13	in	O
14	vitro	O
15	1	O
16	and	O
17	2	O
18	days	O
19	following	O
20	20	O
21	Gy	O
22	irradiation	O
23	to	O
24	assess	O
25	whether	O
26	this	O
27	radiation	O
28	dose	O
29	reduced	O
30	the	O
31	capacity	O
32	of	O
33	tumor	O
34	cells	O
35	to	O
36	trap	O
37	AIB	O
38	or	O
39	Rb	O
40	+.	O

1	For	O
2	patients	O
3	with	O
4	recurrent	O
5	or	O
6	metastatic	O
7	disease	O
8	,	O
9	the	O
10	data	O
11	suggest	O
12	that	O
13	I	O
14	-	O
15	131	O
16	MIBG	O
17	scintigraphy	O
18	is	O
19	the	O
20	examination	O
21	of	O
22	choice	O
23	.	O

1	W	O
2	.	O

1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequence	O
7	of	O
8	the	O
9	M	B
10	RNA	I
11	product	I
12	of	I
13	Uukuniemi	I
14	virus	I
15	with	O
16	that	O
17	of	O
18	Punta	O
19	Toro	O
20	and	O
21	Rift	O
22	Valley	O
23	fever	O
24	viruses	O
25	showed	O
26	in	O
27	both	O
28	cases	O
29	a	O
30	weak	O
31	homology	O
32	that	O
33	was	O
34	more	O
35	pronounced	O
36	for	O
37	the	O
38	proteins	O
39	located	O
40	at	O
41	the	O
42	COOH	O
43	-	O
44	terminal	O
45	end	O
46	of	O
47	the	O
48	precursor	O
49	.	O

1	Cyclosporine	O
2	treatment	O
3	for	O
4	intractable	O
5	polymyositis	O
6	.	O

1	In	O
2	addition	O
3	,	O
4	on	O
5	the	O
6	Cohler	O
7	'	O
8	s	O
9	maternal	O
10	scale	O
11	,	O
12	Korean	O
13	mothers	O
14	were	O
15	found	O
16	to	O
17	view	O
18	their	O
19	infants	O
20	as	O
21	more	O
22	passive	O
23	and	O
24	dependent	O
25	than	O
26	American	O
27	mothers	O
28	did	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	00	O
36	).	O

1	A	O
2	preoperative	O
3	teaching	O
4	booklet	O
5	for	O
6	pediatric	O
7	patients	O
8	.	O

1	Hyperthyroidism	O

1	We	O
2	conclude	O
3	that	O
4	for	O
5	mono	O
6	-	O
7	intronic	O
8	precursors	O
9	in	O
10	which	O
11	there	O
12	is	O
13	only	O
14	one	O
15	choice	O
16	of	O
17	splice	O
18	sites	O
19	,	O
20	most	O
21	of	O
22	the	O
23	exon	O
24	sequences	O
25	are	O
26	not	O
27	mechanistically	O
28	involved	O
29	in	O
30	the	O
31	splicing	O
32	process	O
33	.	O

1	UVA	O
2	-	O
3	induced	O
4	melanocytic	O
5	lesions	O
6	.	O

1	Ex	O
2	vivo	O
3	MAO	B
4	inhibition	O
5	data	O
6	indicated	O
7	DPGPEA	O
8	to	O
9	be	O
10	an	O
11	inhibitor	O
12	of	O
13	MAO	B
14	-	I
15	B	I
16	,	O
17	although	O
18	the	O
19	effect	O
20	was	O
21	much	O
22	weaker	O
23	than	O
24	seen	O
25	with	O
26	tranylcypromine	O
27	or	O
28	pargyline	O
29	.	O

1	Thus	O
2	in	O
3	this	O
4	region	O
5	of	O
6	the	O
7	vessel	O
8	pyridinoline	O
9	represents	O
10	the	O
11	major	O
12	stabilising	O
13	crosslink	O
14	of	O
15	collagen	B
16	.	O

1	A	O
2	careful	O
3	,	O
4	radiolabelled	O
5	tissue	O
6	-	O
7	distribution	O
8	study	O
9	is	O
10	warranted	O
11	to	O
12	elucidate	O
13	the	O
14	complicated	O
15	metabolic	O
16	fate	O
17	of	O
18	perhexiline	O
19	.	O

1	Systemic	O
2	lupus	O
3	erythematosus	O
4	was	O
5	diagnosed	O
6	.	O

1	In	O
2	the	O
3	evening	O
4	,	O
5	the	O
6	amplitude	O
7	of	O
8	the	O
9	responses	O
10	to	O
11	both	O
12	O2	O
13	and	O
14	CO2	O
15	increased	O
16	but	O
17	the	O
18	increase	O
19	in	O
20	CO2	O
21	sensitivity	O
22	was	O
23	proportionally	O
24	more	O
25	important	O
26	.	O

1	The	O
2	statistical	O
3	significance	O
4	of	O
5	the	O
6	prognosis	O
7	factors	O
8	was	O
9	studied	O
10	by	O
11	uni	O
12	-	O
13	and	O
14	multivariative	O
15	methods	O
16	,	O
17	according	O
18	to	O
19	the	O
20	model	O
21	of	O
22	Cox	O
23	,	O
24	with	O
25	the	O
26	help	O
27	of	O
28	an	O
29	IMB	O
30	computer	O
31	.	O

1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	less	O
6	antidopaminergic	O
7	activity	O
8	of	O
9	RHAL	O
10	in	O
11	this	O
12	neuroleptic	O
13	test	O
14	might	O
15	be	O
16	explained	O
17	by	O
18	the	O
19	lesser	O
20	conversion	O
21	of	O
22	RHAL	O
23	to	O
24	HAL	O
25	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	is	O
7	twofold	O
8	:	O
9	(	O
10	1	O
11	)	O
12	to	O
13	present	O
14	a	O
15	parallel	O
16	form	O
17	of	O
18	the	O
19	Gudjonsson	O
20	Suggestibility	O
21	Scale	O
22	(	O
23	GSS	O
24	,	O
25	Form	O
26	1	O
27	);	O
28	(	O
29	2	O
30	)	O
31	to	O
32	study	O
33	test	O
34	-	O
35	retest	O
36	reliabilities	O
37	of	O
38	interrogative	O
39	suggestibility	O
40	.	O

1	Organisms	O
2	were	O
3	recovered	O
4	from	O
5	the	O
6	conjunctiva	O
7	for	O
8	several	O
9	weeks	O
10	,	O
11	and	O
12	persistent	O
13	genital	O
14	and	O
15	gastrointestinal	O
16	infection	O
17	also	O
18	resulted	O
19	from	O
20	the	O
21	ocular	O
22	infection	O
23	in	O
24	some	O
25	cats	O
26	.	O

1	In	O
2	vivo	O
3	epiluminescence	O
4	microscopy	O
5	of	O
6	pigmented	O
7	skin	O
8	lesions	O
9	.	O

1	These	O
2	equilibrium	O
3	solutions	O
4	are	O
5	then	O
6	shown	O
7	to	O
8	arise	O
9	from	O
10	the	O
11	vertices	O
12	of	O
13	a	O
14	particular	O
15	convex	O
16	polyhedron	O
17	.	O

1	The	O
2	average	O
3	deviations	O
4	in	O
5	the	O
6	X	O
7	-	O
8	ray	O
9	counts	O
10	of	O
11	the	O
12	constant	O
13	elements	O
14	from	O
15	the	O
16	series	O
17	means	O
18	were	O
19	used	O
20	to	O
21	correct	O
22	the	O
23	recorded	O
24	count	O
25	of	O
26	the	O
27	variable	O
28	element	O
29	in	O
30	each	O
31	block	O
32	.	O

1	Statistically	O
2	significant	O
3	effects	O
4	were	O
5	noted	O
6	at	O
7	doses	O
8	which	O
9	did	O
10	not	O
11	appear	O
12	to	O
13	be	O
14	maternally	O
15	toxic	O
16	.	O

1	Low	O
2	MAO	B
3	subjects	O
4	showed	O
5	a	O
6	pattern	O
7	of	O
8	higher	O
9	scores	O
10	in	O
11	KSP	O
12	Impulsiveness	O
13	,	O
14	EPQ	O
15	Neuroticism	O
16	,	O
17	and	O
18	KSP	O
19	Somatic	O
20	Anxiety	O
21	and	O
22	Irritability	O
23	and	O
24	lower	O
25	scores	O
26	in	O
27	KSP	O
28	Socialization	O
29	,	O
30	in	O
31	line	O
32	with	O
33	personality	O
34	profiles	O
35	found	O
36	in	O
37	alcoholics	O
38	,	O
39	psychopaths	O
40	,	O
41	and	O
42	suicide	O
43	attempters	O
44	who	O
45	also	O
46	tend	O
47	to	O
48	have	O
49	low	O
50	platelet	O
51	MAO	B
52	activity	O
53	.	O

1	To	O
2	evaluate	O
3	the	O
4	relative	O
5	accuracy	O
6	of	O
7	continuous	O
8	wave	O
9	(	O
10	CW	O
11	)	O
12	and	O
13	high	O
14	pulse	O
15	repetition	O
16	frequency	O
17	(	O
18	HPRF	O
19	)	O
20	Doppler	O
21	for	O
22	estimating	O
23	aortic	O
24	transvalvular	O
25	pressure	O
26	gradients	O
27	,	O
28	Doppler	O
29	examinations	O
30	with	O
31	both	O
32	devices	O
33	were	O
34	obtained	O
35	in	O
36	87	O
37	consecutive	O
38	patients	O
39	with	O
40	aortic	O
41	valve	O
42	disease	O
43	.	O

1	In	O
2	group	O
3	I	O
4	,	O
5	Paw	O
6	,	O
7	delta	O
8	V	O
9	,	O
10	PaO2	O
11	,	O
12	Vinj	O
13	and	O
14	VT	O
15	significantly	O
16	decreased	O
17	whereas	O
18	operating	O
19	pressure	O
20	and	O
21	E	O
22	significantly	O
23	increased	O
24	when	O
25	the	O
26	internal	O
27	diameter	O
28	of	O
29	the	O
30	injector	O
31	cannula	O
32	was	O
33	reduced	O
34	.	O

1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O

1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O

1	The	O
2	number	O
3	of	O
4	fecal	O
5	pellets	O
6	ingested	O
7	peaked	O
8	at	O
9	5	O
10	to	O
11	6	O
12	weeks	O
13	old	O
14	(	O
15	13	O
16	pellets	O
17	/	O
18	day	O
19	)	O
20	and	O
21	gradually	O
22	decreased	O
23	,	O
24	thereafter	O
25	(	O
26	2	O
27	.	O
28	1	O
29	pellets	O
30	at	O
31	78	O
32	weeks	O
33	old	O
34	,	O
35	1	O
36	.	O
37	5	O
38	pellets	O
39	at	O
40	104	O
41	weeks	O
42	old	O
43	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	N	O
6	-	O
7	nitroso	O
8	compounds	O
9	can	O
10	be	O
11	formed	O
12	in	O
13	vivo	O
14	in	O
15	the	O
16	infected	O
17	bladder	O
18	,	O
19	which	O
20	could	O
21	explain	O
22	the	O
23	association	O
24	between	O
25	urinary	O
26	-	O
27	tract	O
28	infections	O
29	and	O
30	increased	O
31	risk	O
32	for	O
33	bladder	O
34	cancer	O
35	.	O

1	Epithelial	O
2	nerve	O
3	fiber	O
4	defects	O
5	included	O
6	absence	O
7	or	O
8	distorted	O
9	architecture	O
10	of	O
11	the	O
12	basal	O
13	epithelial	O
14	plexus	O
15	and	O
16	intra	O
17	-	O
18	epithelial	O
19	terminals	O
20	.	O

1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O

1	Serum	O
2	levels	O
3	of	O
4	albumin	B
5	,	O
6	globulin	B
7	,	O
8	and	O
9	coagulation	B
10	protein	I
11	activity	O
12	were	O
13	measured	O
14	preshock	O
15	,	O
16	postshock	O
17	,	O
18	and	O
19	daily	O
20	for	O
21	3	O
22	days	O
23	;	O
24	skin	O
25	lymph	O
26	levels	O
27	were	O
28	measured	O
29	on	O
30	Day	O
31	3	O
32	.	O

1	For	O
2	colostral	O
3	milk	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	correlation	O
9	of	O
10	vitamin	O
11	K1	O
12	to	O
13	cholesterol	O
14	(	O
15	r	O
16	=	O
17	0	O
18	.	O
19	62	O
20	)	O
21	but	O
22	not	O
23	to	O
24	total	O
25	lipid	O
26	or	O
27	phospholipid	O
28	suggesting	O
29	a	O
30	role	O
31	for	O
32	cholesterol	O
33	in	O
34	the	O
35	secretion	O
36	of	O
37	vitamin	O
38	K1	O
39	into	O
40	colostral	O
41	milk	O
42	.	O

1	Endurance	O
2	training	O
3	resulted	O
4	in	O
5	an	O
6	increase	O
7	of	O
8	stiffness	O
9	associated	O
10	with	O
11	a	O
12	decrease	O
13	of	O
14	type	O
15	II	O
16	fibers	O
17	.	O

1	A	O
2	rate	O
3	-	O
4	decreasing	O
5	dose	O
6	of	O
7	physostigmine	O
8	,	O
9	an	O
10	acetylcholinesterase	B
11	inhibitor	O
12	,	O
13	was	O
14	studied	O
15	in	O
16	combination	O
17	with	O
18	the	O
19	range	O
20	of	O
21	atropine	O
22	doses	O
23	.	O

1	References	O
2	for	O
3	occupational	O
4	fitness	O
5	of	O
6	adolescents	O
7	with	O
8	diseases	O
9	of	O
10	the	O
11	respiratory	O
12	tract	O
13	and	O
14	lungs	O

1	Salzburg	O
2	,	O
3	9	O
4	-	O
5	12	O
6	September	O
7	1987	O
8	.	O

1	Two	O
2	new	O
3	glucosidase	B
4	inhibitors	O
5	(	O
6	BAY	O
7	m	O
8	1099	O
9	and	O
10	BAY	O
11	o	O
12	1248	O
13	)	O
14	were	O
15	studied	O
16	in	O
17	volunteers	O
18	and	O
19	type	O
20	II	O
21	diabetics	O
22	under	O
23	various	O
24	conditions	O
25	.	O

1	The	O
2	models	O
3	accurately	O
4	localized	O
5	the	O
6	common	O
7	boundaries	O
8	between	O
9	the	O
10	PBB	O
11	and	O
12	CN	O
13	.	O

1	Two	O
2	of	O
3	these	O
4	six	O
5	cases	O
6	showed	O
7	mucosal	O
8	spread	O
9	without	O
10	stromal	O
11	invasion	O
12	(	O
13	type	O
14	A	O
15	);	O
16	the	O
17	remaining	O
18	four	O
19	cases	O
20	presented	O
21	a	O
22	direct	O
23	extension	O
24	(	O
25	type	O
26	B	O
27	)	O
28	from	O
29	muscle	O
30	-	O
31	invasive	O
32	carcinomas	O
33	of	O
34	the	O
35	bladder	O
36	.	O

1	However	O
2	,	O
3	conversions	O
4	of	O
5	12	O
6	mm	O
7	or	O
8	more	O
9	from	O
10	a	O
11	documented	O
12	negative	O
13	result	O
14	indicated	O
15	spread	O
16	of	O
17	infection	O
18	.	O

1	The	O
2	maximum	O
3	amplitude	O
4	of	O
5	evoked	O
6	responses	O
7	in	O
8	the	O
9	cervical	O
10	sympathetic	O
11	trunk	O
12	was	O
13	obtained	O
14	when	O
15	the	O
16	T2	O
17	white	O
18	ramus	O
19	was	O
20	stimulated	O
21	and	O
22	decreased	O
23	gradually	O
24	when	O
25	followed	O
26	by	O
27	the	O
28	stimulation	O
29	of	O
30	T1	O
31	,	O
32	T3	O
33	,	O
34	T4	O
35	and	O
36	T5	O
37	white	O
38	rami	O
39	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	contact	O
6	allergy	O
7	to	O
8	K	O
9	-	O
10	CG	O
11	is	O
12	common	O
13	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	beta	B
6	-	I
7	adrenoceptor	I
8	antagonist	O
9	,	O
10	pindolol	O
11	,	O
12	on	O
13	uterine	O
14	smooth	O
15	muscle	O
16	in	O
17	term	O
18	pregnant	O
19	women	O
20	was	O
21	studied	O
22	in	O
23	vitro	O
24	and	O
25	in	O
26	vivo	O
27	(	O
28	in	O
29	hypertensive	O
30	women	O
31	).	O

1	The	O
2	less	O
3	-	O
4	polar	O
5	mycolic	O
6	acid	O
7	-	O
8	containing	O
9	Rhodococcus	O
10	species	O
11	showed	O
12	chromatographic	O
13	patterns	O
14	that	O
15	partially	O
16	overlapped	O
17	(	O
18	in	O
19	elution	O
20	times	O
21	)	O
22	the	O
23	patterns	O
24	of	O
25	Nocardia	O
26	asteroides	O
27	,	O
28	N	O
29	.	O
30	otitidiscaviarum	O
31	,	O
32	and	O
33	N	O
34	.	O
35	brasiliensis	O
36	,	O
37	but	O
38	the	O
39	larger	O
40	number	O
41	of	O
42	peaks	O
43	in	O
44	the	O
45	last	O
46	species	O
47	made	O
48	separation	O
49	between	O
50	the	O
51	genera	O
52	possible	O
53	.	O

1	The	O
2	development	O
3	of	O
4	a	O
5	data	O
6	base	O
7	is	O
8	described	O
9	which	O
10	can	O
11	be	O
12	used	O
13	as	O
14	common	O
15	reference	O
16	for	O
17	ECG	O
18	computer	O
19	programs	O
20	analyzing	O
21	12	O
22	or	O
23	15	O
24	simultaneously	O
25	recorded	O
26	leads	O
27	.	O

1	Blood	B
2	serum	I
3	erythropoietin	I
4	level	O
5	and	O
6	basic	O
7	hematological	O
8	indices	O
9	during	O
10	the	O
11	adaptation	O
12	of	O
13	healthy	O
14	newborn	O
15	infants	O

1	49	O
2	,	O
3	XXXXY	O
4	chromosome	O
5	anomaly	O
6	:	O
7	an	O
8	unusual	O
9	variant	O
10	of	O
11	Klinefelter	O
12	'	O
13	s	O
14	syndrome	O
15	.	O

1	Contraction	O
2	of	O
3	the	O
4	tracheal	O
5	muscle	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	stretch	O
11	receptors	O
12	in	O
13	the	O
14	trachea	O

1	The	O
2	selenium	O
3	level	O
4	and	O
5	glutathione	B
6	peroxidase	I
7	activity	O
8	in	O
9	the	O
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	Oxygen	O
2	delivery	O
3	and	O
4	consumption	O
5	and	O
6	P50	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	myocardial	O
12	infarction	O
13	.	O

1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	O
7	PL	O
8	visual	O
9	acuities	O
10	similar	O
11	to	O
12	those	O
13	established	O
14	by	O
15	McDonald	O
16	et	O
17	al	O
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	effect	O
7	of	O
8	the	O
9	isomers	O
10	of	O
11	pentobarbital	O
12	and	O
13	secobarbital	O
14	on	O
15	mult	O
16	FR30	O
17	FI600	O
18	responding	O
19	and	O
20	on	O
21	suppressed	O
22	responding	O
23	are	O
24	qualitatively	O
25	similar	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	The	O
2	number	O
3	of	O
4	crystalline	O
5	deposits	O
6	is	O
7	less	O
8	in	O
9	the	O
10	advanced	O
11	atrophic	O
12	areas	O
13	of	O
14	the	O
15	RPE	O
16	-	O
17	choriocapillaris	O
18	complex	O
19	.	O

1	All	O
2	33	O
3	subjects	O
4	were	O
5	given	O
6	psychometric	O
7	instruments	O
8	for	O
9	measuring	O
10	various	O
11	components	O
12	of	O
13	anger	O
14	and	O
15	anxiety	O
16	:	O
17	Spielberger	O
18	'	O
19	s	O
20	State	O
21	-	O
22	Trait	O
23	Personality	O
24	Inventory	O
25	,	O
26	the	O
27	Anger	O
28	Expression	O
29	Scale	O
30	,	O
31	and	O
32	the	O
33	State	O
34	Anger	O
35	Reaction	O
36	Scale	O
37	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	primary	O
7	visual	O
8	cortex	O
9	of	O
10	the	O
11	rat	O
12	is	O
13	asymmetrical	O
14	in	O
15	volume	O
16	,	O
17	and	O
18	that	O
19	the	O
20	asymmetry	O
21	reflects	O
22	side	O
23	differences	O
24	in	O
25	the	O
26	number	O
27	of	O
28	neurons	O
29	.	O

1	The	O
2	subjects	O
3	received	O
4	a	O
5	single	O
6	500	O
7	mg	O
8	dose	O
9	of	O
10	acetaminophen	O
11	i	O
12	.	O
13	v	O
14	.	O
15	and	O
16	concentrations	O
17	in	O
18	plasma	O
19	were	O
20	measured	O
21	for	O
22	360	O
23	minutes	O
24	and	O
25	in	O
26	urine	O
27	for	O
28	24	O
29	h	O
30	in	O
31	order	O
32	to	O
33	estimate	O
34	the	O
35	production	O
36	of	O
37	metabolites	O
38	.	O

1	Mean	O
2	weighted	O
3	skin	O
4	temperature	O
5	(	O
6	Tsk	O
7	)	O
8	was	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	01	O
17	)	O
18	following	O
19	acclimation	O
20	than	O
21	before	O
22	,	O
23	and	O
24	acclimation	O
25	resulted	O
26	in	O
27	a	O
28	larger	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	02	O
36	)	O
37	Tre	O
38	-	O
39	to	O
40	-	O
41	Tsk	O
42	gradient	O
43	.	O

1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O

1	The	O
2	effect	O
3	of	O
4	L	O
5	-	O
6	methionine	O
7	supplementation	O
8	on	O
9	the	O
10	utilization	O
11	of	O
12	a	O
13	soy	O
14	protein	O
15	isolate	O
16	(	O
17	SPI	O
18	)	O
19	was	O
20	evaluated	O
21	by	O
22	short	O
23	-	O
24	term	O
25	nitrogen	O
26	balance	O
27	studies	O
28	in	O
29	young	O
30	women	O
31	.	O

1	Primary	O
2	invasive	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	disease	O
8	:	O
9	a	O
10	population	O
11	-	O
12	based	O
13	assessment	O
14	of	O
15	risk	O
16	factors	O
17	.	O

1	Overall	O
2	,	O
3	lesions	O
4	infiltrating	O
5	the	O
6	deep	O
7	lamina	O
8	propria	O
9	do	O
10	not	O
11	exhibit	O
12	a	O
13	reduced	O
14	frequency	O
15	of	O
16	occurrence	O
17	compared	O
18	to	O
19	lesions	O
20	infiltrating	O
21	the	O
22	skeletal	O
23	muscle	O
24	;	O
25	however	O
26	,	O
27	carcinomas	O
28	affecting	O
29	other	O
30	oral	O
31	sites	O
32	showed	O
33	a	O
34	reduced	O
35	frequency	O
36	of	O
37	deeply	O
38	infiltrating	O
39	lesions	O
40	in	O
41	comparison	O
42	to	O
43	more	O
44	superficial	O
45	lesions	O
46	.	O

1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	B
39	IgG	I
40	.	O

1	Induction	O
2	of	O
3	both	O
4	potential	O
5	transcripts	O
6	follows	O
7	heat	O
8	shock	O
9	in	O
10	vivo	O
11	.	O

1	New	O
2	and	O
3	successful	O
4	steps	O
5	have	O
6	been	O
7	made	O
8	in	O
9	immunodiagnostics	O
10	,	O
11	immunotherapy	O
12	,	O
13	and	O
14	immunoprophylaxis	O
15	of	O
16	immunologically	O
17	conditioned	O
18	infertility	O
19	.	O

1	Amikacin	O
2	was	O
3	the	O
4	most	O
5	stable	O
6	and	O
7	tobramycin	O
8	was	O
9	the	O
10	least	O
11	stable	O
12	aminoglycoside	O
13	under	O
14	the	O
15	conditions	O
16	tested	O
17	.	O

1	This	O
2	may	O
3	explain	O
4	in	O
5	part	O
6	a	O
7	secular	O
8	trend	O
9	towards	O
10	reduced	O
11	birthweight	O
12	for	O
13	gestation	O
14	in	O
15	preterm	O
16	infants	O
17	.	O

1	Estimated	O
2	nucleic	O
3	acid	O
4	N	O
5	absorption	O
6	is	O
7	7	O
8	-	O
9	8	O
10	%	O
11	of	O
12	N	O
13	intake	O
14	.	O

1	Adhesion	O
2	,	O
3	phagocytosis	O
4	,	O
5	chemotactic	O
6	and	O
7	random	O
8	migration	O
9	,	O
10	nitroblue	O
11	tetrazolium	O
12	dye	O
13	reduction	O
14	of	O
15	peritoneal	O
16	exudate	O
17	neutrophils	O
18	and	O
19	macrophages	O
20	,	O
21	fibrinogen	B
22	level	O
23	,	O
24	gelation	O
25	of	O
26	soluble	O
27	fibrin	B
28	and	O
29	serial	O
30	dilution	O
31	protamine	O
32	sulfate	O
33	test	O
34	were	O
35	investigated	O
36	in	O
37	115	O
38	New	O
39	Zealand	O
40	white	O
41	rabbits	O
42	with	O
43	experimentally	O
44	induced	O
45	Shwartzman	O
46	phenomenon	O
47	in	O
48	the	O
49	colon	O
50	,	O
51	and	O
52	in	O
53	control	O
54	animals	O
55	.	O

1	Nickel	O
2	is	O
3	the	O
4	most	O
5	common	O
6	cause	O
7	of	O
8	allergic	O
9	contact	O
10	dermatitis	O
11	in	O
12	Singapore	O
13	,	O
14	resulting	O
15	in	O
16	positive	O
17	reactions	O
18	in	O
19	patch	O
20	tests	O
21	between	O
22	7	O
23	and	O
24	14	O
25	%.	O

1	The	O
2	FFA	O
3	levels	O
4	were	O
5	not	O
6	affected	O
7	(	O
8	P	O
9	greater	O
10	than	O
11	.	O
12	1	O
13	)	O
14	by	O
15	meal	O
16	interval	O
17	.	O

1	He	O
2	visited	O
3	our	O
4	hospital	O
5	and	O
6	left	O
7	solitary	O
8	renal	O
9	cyst	O
10	was	O
11	suspected	O
12	.	O

1	However	O
2	,	O
3	further	O
4	analyses	O
5	of	O
6	the	O
7	data	O
8	indicate	O
9	that	O
10	increasing	O
11	VO2	O
12	AT	O
13	(	O
14	r	O
15	=	O
16	-	O
17	0	O
18	.	O
19	63	O
20	,	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	rather	O
29	than	O
30	VO2max	O
31	(	O
32	r	O
33	=	O
34	-	O
35	0	O
36	.	O
37	15	O
38	)	O
39	could	O
40	result	O
41	in	O
42	improving	O
43	the	O
44	10	O
45	,	O
46	000	O
47	m	O
48	race	O
49	performance	O
50	to	O
51	a	O
52	larger	O
53	extent	O
54	,	O
55	and	O
56	that	O
57	the	O
58	absolute	O
59	amount	O
60	of	O
61	change	O
62	(	O
63	delta	O
64	)	O
65	in	O
66	the	O
67	10	O
68	,	O
69	000	O
70	m	O
71	run	O
72	time	O
73	is	O
74	best	O
75	accounted	O
76	for	O
77	by	O
78	a	O
79	combination	O
80	of	O
81	delta	O
82	VO2	O
83	AT	O
84	and	O
85	delta	O
86	5	O
87	,	O
88	000	O
89	m	O
90	run	O
91	time	O
92	.	O

1	A	O
2	significant	O
3	herd	O
4	X	O
5	period	O
6	interaction	O
7	existed	O
8	for	O
9	liver	O
10	TG	O
11	and	O
12	serum	O
13	dextran	O
14	precipitable	O
15	cholesterol	O
16	concentrations	O
17	.	O

1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	nerve	O
6	and	O
7	roots	O
8	differ	O
9	considerably	O
10	both	O
11	in	O
12	the	O
13	force	O
14	they	O
15	sustain	O
16	before	O
17	failure	O
18	and	O
19	in	O
20	the	O
21	other	O
22	biomechanics	O
23	they	O
24	exhibit	O
25	.	O

1	When	O
2	the	O
3	coronary	O
4	sinus	O
5	pressure	O
6	reached	O
7	15	O
8	torr	O
9	,	O
10	there	O
11	was	O
12	a	O
13	significant	O
14	decrease	O
15	in	O
16	cardiac	O
17	index	O
18	(	O
19	3	O
20	.	O
21	60	O
22	+/-	O
23	0	O
24	.	O
25	5	O
26	to	O
27	2	O
28	.	O
29	70	O
30	+/-	O
31	0	O
32	.	O
33	6	O
34	L	O
35	/	O
36	min	O
37	/	O
38	m2	O
39	,	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	001	O
46	),	O
47	coronary	O
48	blood	O
49	flow	O
50	(	O
51	13	O
52	.	O
53	7	O
54	+/-	O
55	3	O
56	.	O
57	1	O
58	to	O
59	7	O
60	.	O
61	0	O
62	+/-	O
63	2	O
64	.	O
65	1	O
66	ml	O
67	/	O
68	min	O
69	,	O
70	p	O
71	less	O
72	than	O
73	0	O
74	.	O
75	001	O
76	),	O
77	rate	O
78	of	O
79	rise	O
80	of	O
81	left	O
82	ventricular	O
83	pressure	O
84	(	O
85	1	O
86	,	O
87	567	O
88	+/-	O
89	275	O
90	to	O
91	1	O
92	,	O
93	331	O
94	+/-	O
95	314	O
96	,	O
97	p	O
98	less	O
99	than	O
100	0	O
101	.	O
102	05	O
103	),	O
104	and	O
105	an	O
106	increase	O
107	in	O
108	coronary	O
109	arteriovenous	O
110	difference	O
111	(	O
112	62	O
113	.	O
114	8	O
115	%	O
116	+/-	O
117	9	O
118	.	O
119	3	O
120	%	O
121	to	O
122	70	O
123	.	O
124	5	O
125	%	O
126	+/-	O
127	5	O
128	.	O
129	4	O
130	%	O
131	saturation	O
132	,	O
133	p	O
134	less	O
135	than	O
136	0	O
137	.	O
138	03	O
139	).	O

1	Calcifications	O
2	in	O
3	the	O
4	thoracic	O
5	aorta	O
6	at	O
7	the	O
8	level	O
9	of	O
10	the	O
11	11th	O
12	and	O
13	the	O
14	12th	O
15	thoracic	O
16	vertebrae	O
17	in	O
18	592	O
19	men	O
20	and	O
21	333	O
22	women	O
23	were	O
24	studied	O
25	using	O
26	computed	O
27	tomography	O
28	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	402	O
6	consecutive	O
7	autopsies	O
8	,	O
9	parietal	O
10	pleural	O
11	plaques	O
12	(	O
13	PP	O
14	)	O
15	were	O
16	found	O
17	in	O
18	68	O
19	individuals	O
20	above	O
21	40	O
22	years	O
23	of	O
24	age	O
25	.	O

1	Approximately	O
2	60	O
3	%	O
4	of	O
5	cell	O
6	bodies	O
7	of	O
8	primary	O
9	neurons	O
10	innervating	O
11	the	O
12	intra	O
13	and	O
14	perioral	O
15	structures	O
16	through	O
17	the	O
18	inferior	O
19	alveolar	O
20	,	O
21	lingual	O
22	,	O
23	mental	O
24	,	O
25	and	O
26	buccal	O
27	nerves	O
28	were	O
29	in	O
30	the	O
31	range	O
32	between	O
33	300	O
34	and	O
35	600	O
36	micron	O
37	2	O
38	in	O
39	cross	O
40	-	O
41	sectional	O
42	area	O
43	:	O
44	mean	O
45	+/-	O
46	SD	O
47	509	O
48	+/-	O
49	243	O
50	micron	O
51	2	O
52	,	O
53	420	O
54	+/-	O
55	181	O
56	micron	O
57	2	O
58	,	O
59	469	O
60	+/-	O
61	200	O
62	micron	O
63	2	O
64	,	O
65	and	O
66	444	O
67	+/-	O
68	186	O
69	micron	O
70	2	O
71	,	O
72	respectively	O
73	.	O

1	Pharmacological	O
2	action	O
3	of	O
4	eptazocine	O
5	(	O
6	l	O
7	-	O
8	1	O
9	,	O
10	4	O
11	-	O
12	dimethyl	O
13	-	O
14	10	O
15	-	O
16	hydroxy	O
17	-	O
18	2	O
19	,	O
20	3	O
21	,	O
22	4	O
23	,	O
24	5	O
25	,	O
26	6	O
27	,	O
28	7	O
29	-	O
30	hexahydro	O
31	-	O
32	1	O
33	,	O
34	6	O
35	-	O
36	methano	O
37	-	O
38	1H	O
39	-	O
40	4	O
41	-	O
42	benz	O
43	azonine	O
44	).	O

1	On	O
2	transition	O
3	from	O
4	high	O
5	to	O
6	low	O
7	voltage	O
8	there	O
9	was	O
10	a	O
11	significant	O
12	fall	O
13	in	O
14	arterial	O
15	pressure	O
16	(	O
17	7	O
18	%)	O
19	and	O
20	an	O
21	increase	O
22	in	O
23	flow	O
24	(	O
25	19	O
26	-	O
27	38	O
28	%)	O
29	to	O
30	areas	O
31	of	O
32	the	O
33	brain	O
34	corresponding	O
35	to	O
36	the	O
37	arborization	O
38	of	O
39	the	O
40	reticular	O
41	formation	O
42	,	O
43	i	O
44	.	O
45	e	O
46	.	O
47	excluding	O
48	the	O
49	cerebrum	O
50	and	O
51	cerebellum	O
52	.	O

1	Findings	O
2	of	O
3	positive	O
4	potentials	O
5	showed	O
6	that	O
7	N1	O
8	originated	O
9	in	O
10	the	O
11	area	O
12	of	O
13	ventral	O
14	gray	O
15	matter	O
16	through	O
17	the	O
18	ventro	O
19	-	O
20	lateral	O
21	column	O
22	and	O
23	N2	O
24	through	O
25	the	O
26	dorsal	O
27	column	O
28	.	O

1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O

1	Failures	O
2	of	O
3	colorimetric	O
4	additivity	O
5	under	O
6	these	O
7	experimental	O
8	conditions	O
9	are	O
10	discussed	O
11	.	O

1	There	O
2	have	O
3	been	O
4	five	O
5	problems	O
6	(	O
7	extravasation	O
8	2	O
9	,	O
10	suspected	O
11	sepsis	O
12	1	O
13	,	O
14	and	O
15	hematoma	O
16	2	O
17	)	O
18	during	O
19	a	O
20	total	O
21	of	O
22	2	O
23	,	O
24	927	O
25	days	O
26	of	O
27	exposure	O
28	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O

1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O

1	Splenectomized	O
2	patients	O
3	are	O
4	predisposed	O
5	toward	O
6	developing	O
7	overwhelming	O
8	bacterial	O
9	infections	O
10	.	O

1	When	O
2	phencyclidine	O
3	was	O
4	administered	O
5	alone	O
6	,	O
7	overall	O
8	response	O
9	rate	O
10	decreased	O
11	and	O
12	percent	O
13	errors	O
14	increased	O
15	with	O
16	increasing	O
17	doses	O
18	.	O

1	Possibilities	O
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	O

1	Study	O
2	of	O
3	the	O
4	energy	O
5	metabolism	O
6	of	O
7	the	O
8	sensomotor	O
9	cortex	O
10	and	O
11	hippocampus	O
12	by	O
13	the	O
14	(	O
15	14C	O
16	)	O
17	2	O
18	-	O
19	deoxyglucose	O
20	method	O
21	during	O
22	the	O
23	development	O
24	of	O
25	dissociated	O
26	states	O

1	Malignant	O
2	lymphoma	O
3	is	O
4	very	O
5	heterogeneous	O
6	in	O
7	terms	O
8	of	O
9	its	O
10	biological	O
11	behavior	O
12	.	O

1	Further	O
2	investigations	O
3	are	O
4	necessary	O
5	to	O
6	elucidate	O
7	the	O
8	biochemical	O
9	and	O
10	physiological	O
11	properties	O
12	of	O
13	DLIS	O
14	.	O

1	Among	O
2	them	O
3	,	O
4	26	O
5	cases	O
6	were	O
7	benign	O
8	and	O
9	34	O
10	malignant	O
11	.	O

1	Of	O
2	the	O
3	cases	O
4	with	O
5	PLD	O
6	,	O
7	50	O
8	%	O
9	had	O
10	associated	O
11	renal	O
12	cysts	O
13	and	O
14	10	O
15	%	O
16	of	O
17	the	O
18	cases	O
19	with	O
20	APCD	O
21	had	O
22	associated	O
23	liver	O
24	cysts	O
25	.	O

1	Fast	O
2	goal	O
3	-	O
4	directed	O
5	voluntary	O
6	movements	O
7	of	O
8	the	O
9	human	O
10	upper	O
11	extremity	O
12	are	O
13	known	O
14	to	O
15	be	O
16	associated	O
17	with	O
18	three	O
19	distinct	O
20	bursts	O
21	of	O
22	EMG	O
23	activity	O
24	in	O
25	antagonistic	O
26	muscles	O
27	.	O

1	The	O
2	combination	O
3	of	O
4	F1	O
5	and	O
6	F2	O
7	which	O
8	was	O
9	the	O
10	best	O
11	predictor	O
12	of	O
13	CHD	O
14	in	O
15	this	O
16	population	O
17	(	O
18	G1	O
19	)	O
20	might	O
21	be	O
22	interpreted	O
23	as	O
24	reflecting	O
25	trunk	O
26	adiposity	O
27	mainly	O
28	abdominal	O
29	.	O

1	Renal	O
2	clearance	O
3	fell	O
4	from	O
5	19	O
6	.	O
7	0	O
8	+/-	O
9	4	O
10	.	O
11	9	O
12	ml	O
13	/	O
14	min	O
15	/	O
16	1	O
17	.	O
18	73	O
19	m2	O
20	(	O
21	group	O
22	I	O
23	)	O
24	to	O
25	1	O
26	.	O
27	0	O
28	+/-	O
29	0	O
30	.	O
31	4	O
32	ml	O
33	/	O
34	min	O
35	/	O
36	1	O
37	.	O
38	73	O
39	m2	O
40	(	O
41	group	O
42	IV	O
43	).	O

1	The	O
2	relations	O
3	between	O
4	type	O
5	A	O
6	behavior	O
7	,	O
8	clinically	O
9	relevant	O
10	behavior	O
11	,	O
12	academic	O
13	achievement	O
14	,	O
15	and	O
16	IQ	O
17	in	O
18	children	O
19	.	O

1	The	O
2	rats	O
3	were	O
4	used	O
5	for	O
6	the	O
7	study	O
8	of	O
9	the	O
10	effects	O
11	of	O
12	sepsis	O
13	on	O
14	the	O
15	utilization	O
16	of	O
17	exogenous	O
18	fat	O
19	emulsion	O
20	.	O

1	She	O
2	also	O
3	had	O
4	slight	O
5	weakness	O
6	of	O
7	the	O
8	upper	O
9	extremities	O
10	.	O

1	Results	O
2	of	O
3	electron	O
4	therapy	O
5	of	O
6	tumors	O
7	in	O
8	different	O
9	sites	O

1	The	O
2	mechanism	O
3	of	O
4	action	O
5	is	O
6	explored	O
7	in	O
8	some	O
9	detail	O
10	,	O
11	specifically	O
12	as	O
13	it	O
14	relates	O
15	to	O
16	reticuloendothelial	O
17	system	O
18	(	O
19	RES	O
20	)	O
21	Fc	B
22	receptor	I
23	blockade	O
24	and	O
25	suppression	O
26	of	O
27	antiplatelet	O
28	antibody	O
29	synthesis	O
30	.	O

1	Incidences	O
2	of	O
3	nonfatal	O
4	stroke	O
5	,	O
6	myocardial	O
7	infarction	O
8	,	O
9	angina	O
10	pectoris	O
11	und	O
12	left	O
13	ventricular	O
14	hypertrophy	O
15	could	O
16	also	O
17	be	O
18	lowered	O
19	.	O

1	High	O
2	radial	O
3	r	O
4	values	O
5	with	O
6	small	O
7	standard	O
8	deviations	O
9	were	O
10	observed	O
11	in	O
12	normal	O
13	LV	O
14	(	O
15	0	O
16	.	O
17	972	O
18	+/-	O
19	0	O
20	.	O
21	016	O
22	)	O
23	and	O
24	in	O
25	non	O
26	-	O
27	MI	O
28	regions	O
29	(	O
30	0	O
31	.	O
32	964	O
33	+/-	O
34	0	O
35	.	O
36	018	O
37	),	O
38	indicating	O
39	temporally	O
40	homogeneous	O
41	radial	O
42	shortening	O
43	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	contributing	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O

1	We	O
2	analyzed	O
3	data	O
4	from	O
5	56	O
6	patients	O
7	with	O
8	Systemic	O
9	Lupus	O
10	Erythematosus	O
11	(	O
12	SLE	O
13	)	O
14	in	O
15	whom	O
16	renal	O
17	biopsies	O
18	were	O
19	done	O
20	systematically	O
21	.	O

1	The	O
2	possibility	O
3	of	O
4	a	O
5	hereditary	O
6	disorder	O
7	leading	O
8	to	O
9	a	O
10	minor	O
11	defect	O
12	in	O
13	elastic	O
14	fibre	O
15	structure	O
16	which	O
17	could	O
18	be	O
19	responsible	O
20	for	O
21	the	O
22	spontaneous	O
23	lesions	O
24	is	O
25	discussed	O
26	.	O

1	Prevention	O
2	by	O
3	a	O
4	heparin	O
5	-	O
6	antithrombin	B
7	III	I
8	combination	O

1	N	O
2	-	O
3	Substituted	O
4	trimethylsilylcarbamates	O
5	were	O
6	tested	O
7	as	O
8	derivatizing	O
9	reagents	O
10	for	O
11	gas	O
12	chromatographic	O
13	analysis	O
14	.	O

1	MICs	O
2	of	O
3	four	O
4	antifungal	O
5	agents	O
6	(	O
7	5	O
8	-	O
9	fluorocytosine	O
10	,	O
11	miconazole	O
12	,	O
13	ketoconazole	O
14	,	O
15	and	O
16	amphotericin	O
17	B	O
18	)	O
19	for	O
20	84	O
21	clinical	O
22	isolates	O
23	of	O
24	various	O
25	Candida	O
26	species	O
27	were	O
28	then	O
29	determined	O
30	with	O
31	both	O
32	media	O
33	in	O
34	agar	O
35	dilution	O
36	and	O
37	microtiter	O
38	broth	O
39	dilution	O
40	systems	O
41	.	O

1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	attempted	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O

1	Evidence	O
2	that	O
3	opiate	O
4	addiction	O
5	is	O
6	in	O
7	part	O
8	an	O
9	immune	O
10	response	O
11	.	O

1	Parasitological	O
2	post	O
3	-	O
4	mortem	O
5	examination	O
6	of	O
7	all	O
8	seropositive	O
9	animals	O
10	showed	O
11	five	O
12	and	O
13	seven	O
14	false	O
15	-	O
16	positive	O
17	animals	O
18	when	O
19	E	B
20	/	I
21	S	I
22	and	I
23	CWE	I
24	antigens	I
25	were	O
26	used	O
27	,	O
28	respectively	O
29	.	O

1	Glucocorticoid	O
2	induced	O
3	hypertension	O
4	has	O
5	been	O
6	regarded	O
7	as	O
8	independent	O
9	of	O
10	sodium	O
11	(	O
12	Na	O
13	),	O
14	in	O
15	contrast	O
16	to	O
17	mineralocorticoid	O
18	induced	O
19	hypertension	O
20	,	O
21	which	O
22	is	O
23	Na	O
24	+-	O
25	dependent	O
26	.	O

1	Seventeen	O
2	of	O
3	them	O
4	were	O
5	on	O
6	treatment	O
7	with	O
8	systemic	O
9	steroids	O
10	.	O

1	Examples	O
2	of	O
3	its	O
4	use	O
5	in	O
6	the	O
7	intensive	O
8	therapy	O
9	unit	O
10	are	O
11	described	O
12	.	O

1	The	O
2	growing	O
3	drug	O
4	problem	O
5	is	O
6	also	O
7	reflected	O
8	in	O
9	the	O
10	increasing	O
11	number	O
12	of	O
13	cases	O
14	of	O
15	hepatitis	O
16	B	O
17	and	O
18	of	O
19	drug	O
20	-	O
21	related	O
22	deaths	O
23	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	Although	O
2	differences	O
3	were	O
4	not	O
5	significant	O
6	,	O
7	infants	O
8	in	O
9	the	O
10	experimental	O
11	group	O
12	had	O
13	more	O
14	changes	O
15	in	O
16	the	O
17	intermittent	O
18	mandatory	O
19	ventilation	O
20	(	O
21	IMV	O
22	)	O
23	settings	O
24	during	O
25	transport	O
26	,	O
27	and	O
28	more	O
29	such	O
30	infants	O
31	arrived	O
32	at	O
33	the	O
34	receiving	O
35	hospital	O
36	with	O
37	acceptable	O
38	pH	O
39	and	O
40	PCO2	O
41	values	O
42	.	O

1	Repetitive	O
2	sequences	O
3	are	O
4	present	O
5	in	O
6	at	O
7	least	O
8	three	O
9	introns	O
10	of	O
11	the	O
12	cytochrome	B
13	P	I
14	-	I
15	450PBc2	I
16	gene	I
17	,	O
18	but	O
19	not	O
20	in	O
21	exons	O
22	or	O
23	the	O
24	5	O
25	'-	O
26	flanking	O
27	region	O
28	.	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	Respiratory	O
2	adaptation	O
3	to	O
4	chronic	O
5	hypoxia	O
6	in	O
7	newborn	O
8	rats	O
9	.	O

1	Compound	O
2	1	O
3	is	O
4	either	O
5	21	O
6	-	O
7	O	O
8	-	O
9	angeloyl	O
10	,	O
11	22	O
12	-	O
13	O	O
14	-	O
15	tigloyl	O
16	R1	O
17	-	O
18	barrigenol	O
19	,	O
20	or	O
21	21	O
22	-	O
23	O	O
24	-	O
25	tigloyl	O
26	,	O
27	22	O
28	-	O
29	O	O
30	-	O
31	angeloyl	O
32	R1	O
33	-	O
34	barrigenol	O
35	.	O

1	Human	O
2	and	O
3	Chinese	B
4	hamster	I
5	S14	I
6	protein	I
7	sequences	I
8	deduced	O
9	from	O
10	the	O
11	cDNAs	O
12	are	O
13	identical	O
14	.	O

1	RPS14	B
2	introns	O
3	3	O
4	and	O
5	4	O
6	both	O
7	contain	O
8	Alu	B
9	sequences	O
10	.	O

1	One	O
2	of	O
3	the	O
4	most	O
5	relevant	O
6	aspects	O
7	in	O
8	achieving	O
9	the	O
10	consistent	O
11	survival	O
12	of	O
13	an	O
14	animal	O
15	undergoing	O
16	the	O
17	experimental	O
18	implantation	O
19	of	O
20	a	O
21	total	O
22	artificial	O
23	heart	O
24	is	O
25	obviously	O
26	related	O
27	to	O
28	the	O
29	correct	O
30	anatomic	O
31	placement	O
32	of	O
33	prosthetic	O
34	ventricles	O
35	inside	O
36	the	O
37	chest	O
38	.	O

1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	there	O
6	may	O
7	be	O
8	a	O
9	relationship	O
10	between	O
11	the	O
12	pathogenesis	O
13	of	O
14	MAL	O
15	,	O
16	narcolepsy	O
17	,	O
18	and	O
19	OSA	O
20	.	O

1	Among	O
2	82	O
3	superficial	O
4	lesions	O
5	34	O
6	were	O
7	classified	O
8	as	O
9	showing	O
10	CR	O
11	and	O
12	another	O
13	23	O
14	as	O
15	showing	O
16	PR	O
17	,	O
18	with	O
19	a	O
20	response	O
21	rate	O
22	of	O
23	69	O
24	.	O
25	5	O
26	%.	O

1	Under	O
2	the	O
3	same	O
4	hematocrit	O
5	and	O
6	flow	O
7	conditions	O
8	,	O
9	the	O
10	rate	O
11	of	O
12	oxygen	O
13	saturation	O
14	decrease	O
15	was	O
16	significantly	O
17	higher	O
18	for	O
19	the	O
20	sickle	O
21	cells	O
22	than	O
23	for	O
24	normal	O
25	cells	O
26	.	O

1	While	O
2	the	O
3	examiner	O
4	observed	O
5	the	O
6	interior	O
7	of	O
8	the	O
9	eye	O
10	with	O
11	indirect	O
12	ophthalmoscopy	O
13	,	O
14	the	O
15	point	O
16	source	O
17	of	O
18	light	O
19	from	O
20	the	O
21	fiberoptic	O
22	light	O
23	pipe	O
24	was	O
25	moved	O
26	along	O
27	the	O
28	margins	O
29	of	O
30	the	O
31	episcleral	O
32	plaque	O
33	.	O

1	These	O
2	fusion	O
3	proteins	O
4	also	O
5	allowed	O
6	the	O
7	localization	O
8	of	O
9	the	O
10	transcriptional	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	domains	O
16	of	O
17	the	O
18	ToxR	B
19	protein	I
20	to	O
21	its	O
22	cytoplasmically	O
23	located	O
24	N	O
25	-	O
26	terminal	O
27	portion	O
28	.	O

1	From	O
2	life	O
3	-	O
4	table	O
5	analyses	O
6	of	O
7	these	O
8	patients	O
9	,	O
10	we	O
11	estimated	O
12	that	O
13	the	O
14	incidence	O
15	of	O
16	secondary	O
17	chondrosarcoma	O
18	in	O
19	patients	O
20	who	O
21	have	O
22	Ollier	O
23	disease	O
24	is	O
25	about	O
26	25	O
27	per	O
28	cent	O
29	at	O
30	the	O
31	age	O
32	of	O
33	forty	O
34	years	O
35	,	O
36	and	O
37	that	O
38	malignant	O
39	degeneration	O
40	is	O
41	almost	O
42	a	O
43	certainty	O
44	in	O
45	patients	O
46	who	O
47	have	O
48	Maffucci	O
49	syndrome	O
50	.	O

1	The	O
2	lethal	O
3	toxicity	O
4	of	O
5	inorganic	O
6	(	O
7	HgCl2	O
8	)	O
9	and	O
10	organic	O
11	(	O
12	CH3HgCl	O
13	)	O
14	mercury	O
15	chloride	O
16	was	O
17	compared	O
18	for	O
19	Coturnix	O
20	(	O
21	Japanese	O
22	quail	O
23	,	O
24	Coturnix	O
25	japonica	O
26	)	O
27	of	O
28	different	O
29	ages	O
30	from	O
31	hatch	O
32	through	O
33	adulthood	O
34	by	O
35	single	O
36	-	O
37	dose	O
38	acute	O
39	oral	O
40	and	O
41	intramuscular	O
42	injections	O
43	and	O
44	by	O
45	a	O
46	5	O
47	-	O
48	d	O
49	dietary	O
50	trial	O
51	.	O

1	Since	O
2	the	O
3	integrated	O
4	13h00	O
5	-	O
6	16h00	O
7	plasma	O
8	cortisol	O
9	estimation	O
10	is	O
11	cheaper	O
12	and	O
13	simpler	O
14	than	O
15	the	O
16	mean	O
17	13h00	O
18	-	O
19	16h00	O
20	plasma	O
21	cortisol	O
22	estimation	O
23	,	O
24	we	O
25	recommend	O
26	it	O
27	as	O
28	an	O
29	adjunct	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	Cushing	O
35	'	O
36	s	O
37	syndrome	O
38	.	O

1	Most	O
2	of	O
3	the	O
4	patients	O
5	had	O
6	locally	O
7	advanced	O
8	lesions	O
9	(	O
10	63	O
11	T3	O
12	-	O
13	4	O
14	:	O
15	91	O
16	.	O
17	5	O
18	%)	O
19	according	O
20	to	O
21	the	O
22	adopted	O
23	TNM	O
24	system	O
25	(	O
26	Lederman	O
27	-	O
28	Gadeberg	O
29	,	O
30	Sisson	O
31	-	O
32	Jesse	O
33	).	O

1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	O
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O

1	Chlorambucil	O
2	and	O
3	interferon	B
4	for	O
5	low	O
6	grade	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphoma	O
13	.	O

1	Selenium	O
2	(.	O
3	1	O
4	ppm	O
5	)	O
6	and	O
7	E	O
8	(	O
9	50	O
10	IU	O
11	/	O
12	kg	O
13	)	O
14	supplementation	O
15	of	O
16	the	O
17	diet	O
18	of	O
19	the	O
20	sow	O
21	increased	O
22	plasma	O
23	tocopherol	O
24	and	O
25	Se	O
26	concentrations	O
27	,	O
28	but	O
29	did	O
30	not	O
31	increase	O
32	plasma	B
33	glutathione	I
34	peroxidase	I
35	(	O
36	GSH	B
37	-	I
38	Px	I
39	)	O
40	activity	O
41	.	O

1	Framingham	O
2	Type	O
3	A	O
4	behavior	O
5	was	O
6	positively	O
7	associated	O
8	with	O
9	diastolic	O
10	blood	O
11	pressure	O
12	(	O
13	r	O
14	=	O
15	0	O
16	.	O
17	17	O
18	,	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	05	O
25	)	O
26	among	O
27	the	O
28	women	O
29	.	O

1	The	O
2	in	O
3	vitro	O
4	antibacterial	O
5	potency	O
6	is	O
7	greatest	O
8	when	O
9	the	O
10	1	O
11	-	O
12	substituent	O
13	is	O
14	2	O
15	,	O
16	4	O
17	-	O
18	difluorophenyl	O
19	and	O
20	the	O
21	7	O
22	-	O
23	substituent	O
24	is	O
25	a	O
26	3	O
27	-	O
28	amino	O
29	-	O
30	1	O
31	-	O
32	pyrrolidinyl	O
33	group	O
34	.	O

1	The	O
2	M	B
3	reading	I
4	frame	I
5	differed	O
6	from	O
7	the	O
8	reported	O
9	sequence	O
10	by	O
11	a	O
12	single	O
13	nucleotide	O
14	corresponding	O
15	to	O
16	a	O
17	conservative	O
18	lysine	O
19	to	O
20	arginine	O
21	amino	O
22	acid	O
23	substitution	O
24	near	O
25	the	O
26	carboxy	O
27	-	O
28	terminus	O
29	conserved	O
30	among	O
31	the	O
32	M	B
33	proteins	I
34	of	O
35	paramyxoviruses	O
36	.	O

1	An	O
2	ion	O
3	chromatographic	O
4	method	O
5	was	O
6	used	O
7	to	O
8	determine	O
9	Br	O
10	ion	O
11	in	O
12	the	O
13	urine	O
14	of	O
15	Greyhounds	O
16	.	O

1	II	O
2	.	O

1	Laryngographic	O
2	changes	O
3	following	O
4	endotracheal	O
5	intubation	O
6	in	O
7	adults	O
8	.	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O

1	The	O
2	relationships	O
3	among	O
4	four	O
5	descriptors	O
6	of	O
7	lactate	O
8	increase	O
9	:	O
10	lactate	O
11	threshold	O
12	(	O
13	LT	O
14	)	O
15	(	O
16	the	O
17	VO2	O
18	at	O
19	which	O
20	blood	O
21	lactate	O
22	concentration	O
23	begins	O
24	to	O
25	increase	O
26	above	O
27	the	O
28	resting	O
29	level	O
30	during	O
31	an	O
32	incremental	O
33	exercise	O
34	test	O
35	),	O
36	LT1	O
37	(	O
38	the	O
39	VO2	O
40	at	O
41	which	O
42	blood	O
43	lactate	O
44	increases	O
45	1	O
46	mM	O
47	above	O
48	the	O
49	resting	O
50	level	O
51	),	O
52	LT2	O
53	(	O
54	the	O
55	VO2	O
56	at	O
57	which	O
58	blood	O
59	lactate	O
60	concentration	O
61	reaches	O
62	a	O
63	fixed	O
64	value	O
65	of	O
66	2	O
67	mM	O
68	),	O
69	onset	O
70	of	O
71	blood	O
72	lactate	O
73	accumulation	O
74	(	O
75	OBLA	O
76	;	O
77	the	O
78	VO2	O
79	at	O
80	which	O
81	blood	O
82	lactate	O
83	reaches	O
84	a	O
85	concentration	O
86	of	O
87	4	O
88	mM	O
89	),	O
90	were	O
91	compared	O
92	with	O
93	aerobic	O
94	capacity	O
95	(	O
96	VO2max	O
97	)	O
98	and	O
99	12	O
100	min	O
101	running	O
102	performance	O
103	in	O
104	19	O
105	untrained	O
106	female	O
107	students	O
108	.	O

1	This	O
2	is	O
3	based	O
4	on	O
5	partitioning	O
6	an	O
7	underlying	O
8	multivariate	O
9	normal	O
10	distribution	O
11	.	O

1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O

1	Practical	O
2	use	O
3	and	O
4	interpretation	O
5	of	O
6	viral	O
7	hepatitis	O
8	B	O
9	markers	O
10	and	O
11	hepatic	O
12	biopsy	O
13	in	O
14	HBs	B
15	Ag	I
16	carriers	O
17	and	O
18	at	O
19	the	O
20	chronic	O
21	hepatitis	O
22	stage	O

1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O

1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	Northern	O
2	blotting	O
3	with	O
4	a	O
5	unique	O
6	17	O
7	-	O
8	mer	O
9	oligonucleotide	O
10	demonstrated	O
11	the	O
12	absence	O
13	of	O
14	the	O
15	mutant	O
16	sequence	O
17	in	O
18	the	O
19	mRNA	O
20	from	O
21	which	O
22	the	O
23	cDNA	O
24	library	O
25	giving	O
26	rise	O
27	to	O
28	the	O
29	mutant	O
30	cDNA	O
31	was	O
32	constructed	O
33	.	O

1	Novel	O
2	multigene	O
3	families	O
4	encoding	O
5	highly	O
6	repetitive	O
7	peptide	O
8	sequences	O
9	.	O

1	Chemotherapy	O
2	of	O
3	metastasizing	O
4	breast	O
5	cancer	O

1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O

1	Linear	O
2	extrapolation	O
3	is	O
4	used	O
5	below	O
6	the	O
7	experimental	O
8	data	O
9	range	O
10	to	O
11	establish	O
12	an	O
13	upper	O
14	bound	O
15	on	O
16	carcinogenic	O
17	risk	O
18	at	O
19	low	O
20	doses	O
21	.	O

1	Hisako	O
2	Minowa	O
3	who	O
4	has	O
5	worked	O
6	as	O
7	a	O
8	psychiatric	O
9	counsellor	O
10	in	O
11	industry	O
12	for	O
13	the	O
14	past	O
15	20	O
16	years	O

1	Deletion	O
2	mapping	O
3	studies	O
4	revealed	O
5	that	O
6	the	O
7	upstream	O
8	DNA	O
9	sequences	O
10	up	O
11	to	O
12	-	O
13	86	O
14	were	O
15	sufficient	O
16	for	O
17	the	O
18	optimal	O
19	basal	O
20	level	O
21	transcription	O
22	in	O
23	HeLa	O
24	cells	O
25	and	O
26	also	O
27	for	O
28	the	O
29	EIA	B
30	-	O
31	induced	O
32	transcription	O
33	.	O

1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O

1	Eleven	O
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O

1	Serum	B
2	IgM	I
3	and	O
4	IgE	B
5	concentrations	O
6	,	O
7	allergen	B
8	-	I
9	specific	I
10	IgE	I
11	scores	O
12	,	O
13	and	O
14	the	O
15	tumor	O
16	E2R	B
17	status	O
18	were	O
19	combined	O
20	to	O
21	construct	O
22	a	O
23	three	O
24	-	O
25	level	O
26	risk	O
27	classification	O
28	that	O
29	was	O
30	more	O
31	prognostic	O
32	than	O
33	any	O
34	of	O
35	the	O
36	individual	O
37	components	O
38	.	O

1	The	O
2	M	O
3	-	O
4	3	O
5	subtype	O
6	was	O
7	an	O
8	adverse	O
9	prognostic	O
10	factor	O
11	.	O

1	Within	O
2	the	O
3	Strep	O
4	.	O
5	mutans	O
6	group	O
7	there	O
8	was	O
9	a	O
10	highly	O
11	-	O
12	significant	O
13	difference	O
14	between	O
15	Strep	O
16	.	O
17	mutans	O
18	/	O
19	Strep	O
20	.	O
21	cricetus	O
22	(	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	)	O
30	with	O
31	respect	O
32	to	O
33	mean	O
34	clump	O
35	size	O
36	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	I
11	C	I
12	.,	O
13	HDL	B
14	-	I
15	C	I
16	.,	O
17	HDL2	B
18	-	I
19	C	I
20	.,	O
21	apo	B
22	B	I
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	I
29	B	I
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	I
37	B	I
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	unique	O
7	suppository	O
8	formulation	O
9	of	O
10	CZX	O
11	-	O
12	S	O
13	is	O
14	useful	O
15	in	O
16	the	O
17	treatment	O
18	of	O
19	infections	O
20	in	O
21	children	O
22	with	O
23	heavy	O
24	psychophysiologic	O
25	disorders	O
26	and	O
27	in	O
28	children	O
29	who	O
30	cannot	O
31	take	O
32	oral	O
33	drugs	O
34	because	O
35	of	O
36	severe	O
37	vomiting	O
38	.	O

1	In	O
2	addition	O
3	,	O
4	marked	O
5	hypertension	O
6	accompanied	O
7	this	O
8	disorder	O
9	and	O
10	all	O
11	abnormalities	O
12	,	O
13	including	O
14	the	O
15	hypertension	O
16	,	O
17	responded	O
18	to	O
19	1	B
20	-	I
21	desamino	I
22	-	I
23	8	I
24	-	I
25	D	I
26	-	I
27	arginine	I
28	vasopressin	I
29	therapy	O
30	.	O

1	Single	O
2	photon	O
3	emission	O
4	computerized	O
5	tomography	O
6	(	O
7	SPECT	O
8	),	O
9	by	O
10	providing	O
11	three	O
12	-	O
13	dimensional	O
14	representation	O
15	of	O
16	myocardial	O
17	Tl	O
18	-	O
19	201	O
20	,	O
21	offers	O
22	promise	O
23	for	O
24	improved	O
25	localization	O
26	of	O
27	CAD	O
28	.	O

1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O

1	In	O
2	19	O
3	patients	O
4	vagotomy	O
5	not	O
6	only	O
7	curbed	O
8	the	O
9	bleeding	O
10	but	O
11	provided	O
12	definitive	O
13	therapy	O
14	(	O
15	Visick	O
16	I	O
17	-	O
18	II	O
19	);	O
20	4	O
21	patients	O
22	died	O
23	(	O
24	mortality	O
25	rate	O
26	16	O
27	%).	O

1	Documentation	O
2	of	O
3	a	O
4	successful	O
5	intrauterine	O
6	fertilization	O
7	with	O
8	delivery	O
9	of	O
10	a	O
11	term	O
12	baby	O
13	supports	O
14	the	O
15	theoretical	O
16	feasibility	O
17	of	O
18	the	O
19	EP	O
20	;	O
21	however	O
22	,	O
23	anovulation	O
24	incurred	O
25	by	O
26	our	O
27	procedure	O
28	appears	O
29	to	O
30	be	O
31	the	O
32	major	O
33	drawback	O
34	.	O

1	MRI	O
2	disclosed	O
3	one	O
4	or	O
5	more	O
6	of	O
7	the	O
8	following	O
9	abnormalities	O
10	in	O
11	24	O
12	(	O
13	63	O
14	%)	O
15	of	O
16	38	O
17	treated	O
18	kidneys	O
19	:	O
20	(	O
21	1	O
22	)	O
23	loss	O
24	of	O
25	corticomedullary	O
26	differentiation	O
27	,	O
28	(	O
29	2	O
30	)	O
31	perirenal	O
32	fluid	O
33	,	O
34	(	O
35	3	O
36	)	O
37	subcapsular	O
38	hematoma	O
39	,	O
40	(	O
41	4	O
42	)	O
43	hemorrhage	O
44	into	O
45	a	O
46	renal	O
47	cyst	O
48	,	O
49	and	O
50	(	O
51	5	O
52	)	O
53	unexplained	O
54	abnormalities	O
55	.	O

1	The	O
2	results	O
3	obtained	O
4	are	O
5	similar	O
6	to	O
7	those	O
8	described	O
9	with	O
10	the	O
11	previous	O
12	Cremophor	O
13	formulation	O
14	although	O
15	greater	O
16	variability	O
17	in	O
18	induction	O
19	and	O
20	recovery	O
21	times	O
22	was	O
23	noted	O
24	with	O
25	the	O
26	emulsion	O
27	formulation	O
28	.	O

1	The	O
2	percentage	O
3	RFR	O
4	reduction	O
5	at	O
6	the	O
7	end	O
8	of	O
9	CPB	O
10	showed	O
11	significant	O
12	correlation	O
13	with	O
14	1	O
15	)	O
16	CPB	O
17	duration	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	49	O
24	),	O
25	2	O
26	)	O
27	oxygen	O
28	flow	O
29	rate	O
30	index	O
31	(	O
32	OFRI	O
33	),	O
34	i	O
35	.	O
36	e	O
37	.	O
38	flow	O
39	/	O
40	min	O
41	in	O
42	the	O
43	bubble	O
44	oxygenator	O
45	/	O
46	m2	O
47	bsa	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	38	O
54	),	O
55	and	O
56	3	O
57	)	O
58	blood	O
59	flow	O
60	rate	O
61	index	O
62	(	O
63	BFRI	O
64	),	O
65	i	O
66	.	O
67	e	O
68	.	O
69	average	O
70	volume	O
71	of	O
72	blood	O
73	pumped	O
74	through	O
75	the	O
76	heart	O
77	-	O
78	lung	O
79	machine	O
80	/	O
81	min	O
82	CPB	O
83	time	O
84	/	O
85	m2	O
86	bsa	O
87	(	O
88	r	O
89	=	O
90	0	O
91	.	O
92	51	O
93	).	O

1	Diagnosis	O
2	of	O
3	unilateral	O
4	renal	O
5	artery	O
6	lesions	O
7	after	O
8	captopril	O
9	administration	O
10	.	O

1	A	O
2	yeast	O
3	DNA	O
4	fragment	O
5	carrying	O
6	the	O
7	gene	B
8	CP	I
9	A1	I
10	encoding	O
11	the	O
12	small	O
13	subunit	O
14	of	O
15	the	O
16	arginine	O
17	pathway	O
18	carbamoyl	B
19	-	I
20	phosphate	I
21	synthetase	I
22	has	O
23	been	O
24	sequenced	O
25	.	O

1	A	O
2	retrospective	O
3	study	O
4	of	O
5	banked	O
6	sera	O
7	from	O
8	19	O
9	cats	O
10	with	O
11	the	O
12	eosinophilic	O
13	granuloma	O
14	complex	O
15	revealed	O
16	that	O
17	68	O
18	%	O
19	of	O
20	affected	O
21	cats	O
22	had	O
23	circulating	O
24	antibodies	O
25	to	O
26	components	O
27	of	O
28	normal	O
29	cat	O
30	epithelium	O
31	.	O

1	In	O
2	memory	O
3	of	O
4	Magdelaine	O
5	Comtesse	O

1	The	O
2	H2	B
3	receptor	I
4	antagonists	O
5	and	O
6	sucralfate	O
7	cost	O
8	about	O
9	the	O
10	same	O
11	and	O
12	have	O
13	few	O
14	side	O
15	effects	O
16	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	indoramin	O
6	may	O
7	have	O
8	Class	O
9	III	O
10	antiarrhythmic	O
11	activity	O
12	.	O

1	A	O
2	high	O
3	efficacy	O
4	of	O
5	the	O
6	combined	O
7	use	O
8	of	O
9	nontoxic	O
10	doses	O
11	of	O
12	two	O
13	pharmaceuticals	O
14	:	O
15	cystamine	O
16	(	O
17	50	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	mexamine	O
24	(	O
25	25	O
26	mg	O
27	/	O
28	kg	O
29	)	O
30	under	O
31	the	O
32	conditions	O
33	of	O
34	short	O
35	-	O
36	term	O
37	exogenous	O
38	hypoxia	O
39	(	O
40	7	O
41	.	O
42	5	O
43	%	O
44	O2	O
45	)	O
46	was	O
47	found	O
48	in	O
49	(	O
50	CBA	O
51	X	O
52	C57Bl	O
53	)	O
54	F1	O
55	mice	O
56	.	O

1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	Cr	O
16	,	O
17	the	O
18	Median	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	Cr	O
25	.	O

1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	hydrogenase	B
6	encodes	O
7	a	O
8	protein	O
9	product	O
10	of	O
11	molecular	O
12	mass	O
13	45820	O
14	Da	O
15	.	O

1	Pancreaticoduodenal	O
2	lymph	O
3	node	O
4	enlargement	O
5	,	O
6	regardless	O
7	of	O
8	cause	O
9	,	O
10	has	O
11	been	O
12	a	O
13	source	O
14	of	O
15	imaging	O
16	confusion	O
17	because	O
18	of	O
19	its	O
20	propensity	O
21	to	O
22	mimic	O
23	pancreatic	O
24	malignancy	O
25	yet	O
26	not	O
27	cause	O
28	biliary	O
29	obstruction	O
30	.	O

1	Interference	O
2	with	O
3	rheumatoid	B
4	factor	I
5	was	O
6	only	O
7	observed	O
8	in	O
9	the	O
10	ELISA	O
11	enzygnost	O
12	if	O
13	sera	O
14	were	O
15	not	O
16	pretreated	O
17	with	O
18	latex	O
19	adsorbents	O
20	.	O

1	All	O
2	patients	O
3	had	O
4	elevated	O
5	levels	O
6	of	O
7	serum	B
8	IgE	I
9	antibodies	I
10	to	O
11	the	O
12	crude	O
13	soybean	O
14	extract	O
15	;	O
16	binding	O
17	values	O
18	ranged	O
19	from	O
20	2	O
21	.	O
22	3	O
23	to	O
24	28	O
25	.	O
26	1	O
27	times	O
28	that	O
29	of	O
30	a	O
31	negative	O
32	control	O
33	serum	O
34	.	O

1	New	O
2	techniques	O
3	for	O
4	the	O
5	mass	O
6	spectrometry	O
7	of	O
8	natural	O
9	products	O
10	.	O

1	Dual	O
2	radionuclide	O
3	subtraction	O
4	imaging	O
5	of	O
6	the	O
7	spleen	O
8	using	O
9	67Ga	O
10	citrate	O
11	and	O
12	99mTc	O
13	is	O
14	useful	O
15	in	O
16	further	O
17	delineating	O
18	lesions	O
19	that	O
20	are	O
21	identified	O
22	on	O
23	either	O
24	a	O
25	routine	O
26	radiogallium	O
27	survey	O
28	or	O
29	on	O
30	a	O
31	conventional	O
32	sulfur	O
33	colloid	O
34	liver	O
35	-	O
36	spleen	O
37	image	O
38	.	O

1	Such	O
2	studied	O
3	acquired	O
4	with	O
5	low	O
6	energy	O
7	or	O
8	medium	O
9	energy	O
10	collimation	O
11	and	O
12	a	O
13	window	O
14	centered	O
15	on	O
16	the	O
17	159	O
18	keV	O
19	123I	O
20	photopeak	O
21	contain	O
22	appreciable	O
23	septal	O
24	breakthrough	O
25	signals	O
26	originating	O
27	from	O
28	Compton	O
29	scatter	O
30	of	O
31	high	O
32	energy	O
33	photons	O
34	primarily	O
35	from	O
36	124I	O
37	.	O

1	Nursing	O
2	education	O
3	--	O
4	the	O
5	computer	O
6	obligation	O
7	.	O

1	Shear	O
2	bond	O
3	strength	O
4	of	O
5	a	O
6	composite	O
7	resin	O
8	to	O
9	an	O
10	etched	O
11	glass	O
12	ionomer	O
13	.	O

1	An	O
2	additional	O
3	advantage	O
4	is	O
5	that	O
6	the	O
7	resin	O
8	can	O
9	be	O
10	removed	O
11	and	O
12	the	O
13	immunoperoxidase	B
14	technique	O
15	carried	O
16	out	O
17	on	O
18	thin	O
19	sections	O
20	.	O

1	Such	O
2	a	O
3	concept	O
4	is	O
5	crucial	O
6	to	O
7	our	O
8	understanding	O
9	of	O
10	the	O
11	pathology	O
12	of	O
13	ageing	O
14	in	O
15	general	O
16	.	O

1	We	O
2	consider	O
3	that	O
4	DIL	O
5	-	O
6	CP	O
7	is	O
8	a	O
9	safe	O
10	and	O
11	excellent	O
12	CP	O
13	in	O
14	CABG	O
15	surgery	O
16	and	O
17	we	O
18	are	O
19	now	O
20	utilizing	O
21	this	O
22	CP	O
23	in	O
24	all	O
25	patients	O
26	requiring	O
27	CABG	O
28	surgery	O
29	.	O

1	We	O
2	have	O
3	earlier	O
4	evolved	O
5	an	O
6	experimental	O
7	model	O
8	by	O
9	means	O
10	of	O
11	which	O
12	changes	O
13	identical	O
14	to	O
15	the	O
16	microembolism	O
17	syndrome	O
18	can	O
19	be	O
20	induced	O
21	from	O
22	a	O
23	reproducible	O
24	musculo	O
25	-	O
26	skeletal	O
27	trauma	O
28	in	O
29	pigs	O
30	observed	O
31	under	O
32	long	O
33	-	O
34	term	O
35	anesthesia	O
36	under	O
37	standardized	O
38	conditions	O
39	.	O

1	Although	O
2	no	O
3	statistical	O
4	significance	O
5	was	O
6	achieved	O
7	,	O
8	it	O
9	is	O
10	remarkable	O
11	that	O
12	there	O
13	was	O
14	a	O
15	clear	O
16	trend	O
17	for	O
18	the	O
19	superiority	O
20	of	O
21	Galphimia	O
22	D6	O
23	while	O
24	the	O
25	Galphimia	O
26	dilution	O
27	10	O
28	(-	O
29	6	O
30	)	O
31	was	O
32	about	O
33	equally	O
34	effective	O
35	compared	O
36	with	O
37	placebo	O
38	.	O

1	The	O
2	volume	O
3	of	O
4	blood	O
5	to	O
6	the	O
7	flap	O
8	ranges	O
9	from	O
10	1	O
11	to	O
12	2	O
13	ml	O
14	/	O
15	min	O
16	,	O
17	collateral	O
18	circulation	O
19	to	O
20	the	O
21	flap	O
22	exists	O
23	,	O
24	but	O
25	is	O
26	negligible	O
27	,	O
28	and	O
29	there	O
30	is	O
31	little	O
32	change	O
33	in	O
34	the	O
35	capillary	O
36	blood	O
37	flow	O
38	as	O
39	the	O
40	flap	O
41	ages	O
42	.	O

1	With	O
2	aging	O
3	,	O
4	many	O
5	aspects	O
6	of	O
7	immune	O
8	function	O
9	change	O
10	.	O

1	Oral	O
2	candidiasis	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	gcd1	B
6	-	I
7	101	I
8	mutation	I
9	suppressed	O
10	the	O
11	low	O
12	translational	O
13	efficiency	O
14	of	O
15	GCN4	B
16	-	O
17	lacZ	B
18	mRNA	O
19	observed	O
20	in	O
21	gcn2	B
22	-	I
23	and	O
24	gcn3	B
25	-	I
26	cells	O
27	.	O

1	This	O
2	suggests	O
3	that	O
4	alaproclate	O
5	acutely	O
6	increases	O
7	the	O
8	responsiveness	O
9	of	O
10	postsynaptic	O
11	muscarinic	B
12	and	I
13	alpha	I
14	1	I
15	adrenoceptors	I
16	.	O

1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O

1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O

1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O

1	Thrombophlebitis	O
2	and	O
3	pulmonary	O
4	embolism	O
5	in	O
6	congenital	O
7	factor	B
8	XII	I
9	deficiency	O

1	Biopsies	O
2	of	O
3	the	O
4	jejunal	O
5	mucosa	O
6	have	O
7	shown	O
8	abnormal	O
9	enzyme	O
10	activity	O
11	or	O
12	deficiencies	O
13	in	O
14	transport	O
15	mechanisms	O
16	.	O

1	Laboratory	O
2	pyrolyses	O
3	have	O
4	indeed	O
5	shown	O
6	that	O
7	PCBs	O
8	give	O
9	significant	O
10	yields	O
11	of	O
12	PCDFs	O
13	,	O
14	and	O
15	chlorobenzenes	O
16	give	O
17	both	O
18	PCDFs	O
19	and	O
20	PCDDs	O
21	.	O

1	A	O
2	significant	O
3	degree	O
4	of	O
5	homology	O
6	was	O
7	also	O
8	found	O
9	among	O
10	these	O
11	genes	O
12	and	O
13	the	O
14	Mtase	B
15	gene	I
16	of	O
17	related	O
18	phage	O
19	SPR	O
20	,	O
21	which	O
22	codes	O
23	for	O
24	an	O
25	enzyme	O
26	with	O
27	different	O
28	modification	O
29	specificity	O
30	.	O

1	Thyrotropin	B
2	-	I
3	releasing	I
4	hormone	I
5	-	O
6	induced	O
7	contraction	O
8	of	O
9	urethral	O
10	and	O
11	vaginal	O
12	muscle	O
13	.	O

1	In	O
2	a	O
3	blind	O
4	controlled	O
5	trial	O
6	,	O
7	15	O
8	patients	O
9	with	O
10	COCM	O
11	(	O
12	NYHA	O
13	II	O
14	-	O
15	III	O
16	)	O
17	with	O
18	sinus	O
19	rhythm	O
20	and	O
21	a	O
22	left	O
23	ventricular	O
24	ejection	O
25	fraction	O
26	(	O
27	LV	O
28	-	O
29	EF	O
30	)	O
31	of	O
32	34	O
33	.	O
34	5	O
35	+/-	O
36	2	O
37	.	O
38	6	O
39	%	O
40	received	O
41	consecutively	O
42	D	O
43	(	O
44	0	O
45	.	O
46	25	O
47	-	O
48	0	O
49	.	O
50	5	O
51	mg	O
52	/	O
53	d	O
54	),	O
55	placebo	O
56	(	O
57	PLAC	O
58	),	O
59	P	O
60	(	O
61	slow	O
62	releases	O
63	=	O
64	SR	O
65	)	O
66	(	O
67	80	O
68	mg	O
69	/	O
70	d	O
71	SR	O
72	)	O
73	and	O
74	both	O
75	drugs	O
76	combined	O
77	in	O
78	respective	O
79	doses	O
80	.	O

1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O

1	The	O
2	sample	O
3	is	O
4	deproteinized	O
5	and	O
6	after	O
7	centrifugation	O
8	valproic	O
9	acid	O
10	in	O
11	the	O
12	supernatant	O
13	is	O
14	measured	O
15	in	O
16	the	O
17	free	O
18	form	O
19	by	O
20	direct	O
21	injection	O
22	into	O
23	the	O
24	gas	O
25	chromatograph	O
26	.	O

1	Changes	O
2	in	O
3	muscarinic	B
4	acetylcholine	I
5	receptors	I
6	in	O
7	guinea	O
8	-	O
9	pig	O
10	lung	O
11	:	O
12	effects	O
13	of	O
14	aging	O
15	,	O
16	inhalation	O
17	of	O
18	an	O
19	allergen	O
20	,	O
21	administration	O
22	of	O
23	drugs	O
24	,	O
25	and	O
26	vagotomy	O
27	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	other	O
6	stabilizers	O
7	,	O
8	increased	O
9	sucrose	O
10	can	O
11	provide	O
12	increased	O
13	thermoresistance	O
14	to	O
15	the	O
16	virus	O
17	in	O
18	2	O
19	.	O
20	5	O
21	%	O
22	albumin	B
23	.	O

1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	psoriasis	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O

1	Greek	O
2	classicism	O
3	in	O
4	living	O
5	structure	O
6	?	O
7	Some	O
8	deductive	O
9	pathways	O
10	in	O
11	animal	O
12	morphology	O
13	.	O

1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O

1	Three	O
2	chromosomal	B
3	crsA	I
4	mutations	I
5	,	O
6	crsA1	B
7	,	O
8	crsA4	B
9	,	O
10	and	O
11	crsA47	B
12	,	O
13	were	O
14	transferred	O
15	by	O
16	the	O
17	"	O
18	gene	O
19	conversion	O
20	"	O
21	process	O
22	to	O
23	B	O
24	.	O
25	subtilis	O
26	plasmid	O
27	pRPD11	O
28	,	O
29	which	O
30	consists	O
31	of	O
32	the	O
33	entire	O
34	wild	B
35	-	I
36	type	I
37	rpoD	I
38	coding	I
39	sequence	I
40	,	O
41	encoding	O
42	the	O
43	major	B
44	sigma	I
45	43	I
46	factor	I
47	of	I
48	B	I
49	.	I
50	subtilis	I
51	RNA	I
52	polymerase	I
53	,	O
54	and	O
55	pUB110	O
56	.	O

1	Selective	O
2	effect	O
3	of	O
4	pulmonary	O
5	oedema	O
6	on	O
7	prostaglandin	O
8	E2	O
9	pharmacokinetics	O
10	in	O
11	rat	O
12	lung	O
13	.	O

1	This	O
2	article	O
3	will	O
4	briefly	O
5	review	O
6	the	O
7	published	O
8	data	O
9	on	O
10	the	O
11	morphology	O
12	,	O
13	function	O
14	,	O
15	and	O
16	biochemistry	O
17	of	O
18	the	O
19	normal	O
20	renal	O
21	medulla	O
22	and	O
23	the	O
24	pathology	O
25	associated	O
26	with	O
27	RPN	O
28	,	O
29	together	O
30	with	O
31	the	O
32	secondary	O
33	changes	O
34	which	O
35	give	O
36	rise	O
37	to	O
38	cortical	O
39	degeneration	O
40	or	O
41	epithelial	O
42	carcinoma	O
43	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	five	O
7	different	O
8	(	O
9	and	O
10	partially	O
11	overlapping	O
12	)	O
13	sry	B
14	messenger	I
15	RNAs	I
16	detectable	O
17	in	O
18	early	O
19	embryos	O
20	are	O
21	initiated	O
22	at	O
23	three	O
24	separate	O
25	sites	O
26	,	O
27	each	O
28	directly	O
29	upstream	O
30	from	O
31	one	O
32	of	O
33	the	O
34	three	O
35	protein	O
36	-	O
37	coding	O
38	regions	O
39	,	O
40	designated	O
41	(	O
42	in	O
43	5	O
44	'	O
45	to	O
46	3	O
47	'	O
48	order	O
49	)	O
50	beta	O
51	,	O
52	alpha	O
53	and	O
54	delta	O
55	.	O

1	Chronic	O
2	thyroiditis	O
3	as	O
4	a	O
5	risk	O
6	factor	O
7	of	O
8	B	O
9	-	O
10	cell	O
11	lymphoma	O
12	in	O
13	the	O
14	thyroid	O
15	gland	O
16	.	O

1	Plasma	B
2	secretin	I
3	levels	O
4	also	O
5	augmented	O
6	after	O
7	the	O
8	administration	O
9	of	O
10	ethanol	O
11	solutions	O
12	,	O
13	with	O
14	a	O
15	delay	O
16	of	O
17	about	O
18	one	O
19	hour	O
20	after	O
21	the	O
22	onset	O
23	of	O
24	acid	O
25	secretion	O
26	.	O

1	Spectrophotometric	O
2	microanalysis	O
3	of	O
4	ethylenediaminotetracetic	O
5	acid	O
6	in	O
7	pharmaceutical	O
8	preparations	O

1	A	O
2	comparison	O
3	among	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	regions	O
9	encompassing	O
10	the	O
11	presumptive	O
12	HS	B
13	promoter	I
14	of	O
15	the	O
16	soybean	B
17	HS	I
18	-	I
19	protein	I
20	genes	I
21	demonstrated	O
22	this	O
23	region	O
24	to	O
25	be	O
26	extremely	O
27	homologous	O
28	.	O

1	Results	O
2	of	O
3	this	O
4	study	O
5	indicate	O
6	that	O
7	GLC	O
8	of	O
9	short	O
10	chain	O
11	fatty	O
12	acids	O
13	produced	O
14	on	O
15	agar	O
16	medium	O
17	by	O
18	anaerobes	O
19	,	O
20	combined	O
21	with	O
22	simple	O
23	tests	O
24	such	O
25	as	O
26	Gram	O
27	'	O
28	s	O
29	stain	O
30	and	O
31	colonial	O
32	morphology	O
33	,	O
34	may	O
35	allow	O
36	fir	O
37	direct	O
38	presumptive	O
39	genus	O
40	identification	O
41	from	O
42	an	O
43	initial	O
44	pure	O
45	agar	O
46	culture	O
47	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	measured	O
7	absorption	O
8	of	O
9	low	O
10	doses	O
11	of	O
12	vitamin	O
13	A	O
14	,	O
15	which	O
16	may	O
17	provide	O
18	a	O
19	more	O
20	physiological	O
21	approach	O
22	to	O
23	assessment	O
24	of	O
25	fat	O
26	malabsorption	O
27	.	O

1	Fulminant	O
2	hepatitis	O
3	A	O
4	in	O
5	chronic	O
6	HBV	O
7	carrier	O
8	.	O

1	Tissue	O
2	pressure	O
3	,	O
4	rCBF	O
5	,	O
6	and	O
7	water	O
8	content	O
9	were	O
10	measured	O
11	from	O
12	gray	O
13	matter	O
14	in	O
15	the	O
16	central	O
17	core	O
18	and	O
19	the	O
20	peripheral	O
21	margin	O
22	of	O
23	the	O
24	MCA	O
25	territory	O
26	over	O
27	6	O
28	h	O
29	after	O
30	MCAO	O
31	.	O

1	During	O
2	this	O
3	time	O
4	,	O
5	the	O
6	patients	O
7	all	O
8	had	O
9	the	O
10	characteristic	O
11	plasma	O
12	thyroid	O
13	hormone	O
14	changes	O
15	associated	O
16	with	O
17	amiodarone	O
18	therapy	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	increased	O
25	T4	O
26	,	O
27	free	O
28	T4	O
29	,	O
30	and	O
31	rT3	O
32	and	O
33	decreased	O
34	T3	O
35	,	O
36	while	O
37	remaining	O
38	clinically	O
39	euthyroid	O
40	.	O

1	Drug	O
2	and	O
3	nutrient	O
4	interactions	O
5	.	O

1	In	O
2	each	O
3	compartment	O
4	O2	O
5	is	O
6	removed	O
7	by	O
8	the	O
9	tissues	O
10	as	O
11	a	O
12	chemical	O
13	reaction	O
14	takes	O
15	place	O
16	between	O
17	O2	O
18	and	O
19	oxyhemoglobin	B
20	(	O
21	HbO2	B
22	).	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	propranolol	O
7	on	O
8	myocardial	O
9	metabolism	O
10	after	O
11	coronary	O
12	reperfusion	O
13	,	O
14	serial	O
15	measurements	O
16	of	O
17	myocardial	B
18	creatine	I
19	kinase	I
20	(	O
21	CK	B
22	)	O
23	and	O
24	calcium	O
25	(	O
26	Ca	O
27	)	O
28	contents	O
29	and	O
30	CK	B
31	and	O
32	lactic	O
33	acid	O
34	(	O
35	LA	O
36	)	O
37	concentrations	O
38	in	O
39	coronary	O
40	sinus	O
41	blood	O
42	were	O
43	carried	O
44	out	O
45	in	O
46	33	O
47	open	O
48	-	O
49	chest	O
50	dogs	O
51	.	O

1	Dissolution	O
2	of	O
3	the	O
4	Pt	O
5	-	O
6	30	O
7	%	O
8	Ir	O
9	microelectrode	O
10	tip	O
11	was	O
12	observed	O
13	by	O
14	scanning	O
15	electron	O
16	microscopy	O
17	at	O
18	charge	O
19	densities	O
20	as	O
21	low	O
22	as	O
23	200	O
24	microC	O
25	/	O
26	cm2	O
27	X	O
28	ph	O
29	(	O
30	1	O
31	A	O
32	/	O
33	cm2	O
34	),	O
35	whereas	O
36	erosion	O
37	of	O
38	activated	O
39	iridium	O
40	microelectrodes	O
41	occurred	O
42	only	O
43	at	O
44	the	O
45	highest	O
46	charge	O
47	and	O
48	current	O
49	densities	O
50	(	O
51	3200	O
52	microC	O
53	/	O
54	cm2	O
55	X	O
56	ph	O
57	,	O
58	16	O
59	A	O
60	/	O
61	cm2	O
62	).	O

1	Cortisol	O
2	excretion	O
3	,	O
4	appeared	O
5	to	O
6	be	O
7	markedly	O
8	affected	O
9	by	O
10	the	O
11	season	O
12	although	O
13	other	O
14	factors	O
15	such	O
16	as	O
17	social	O
18	and	O
19	environmental	O
20	stress	O
21	cannot	O
22	be	O
23	discounted	O
24	.	O

1	Two	O
2	studies	O
3	on	O
4	the	O
5	relationship	O
6	between	O
7	taking	O
8	a	O
9	commercial	O
10	coaching	O
11	course	O
12	and	O
13	performance	O
14	on	O
15	the	O
16	Medical	O
17	College	O
18	Admission	O
19	Test	O
20	(	O
21	MCAT	O
22	)	O
23	are	O
24	reported	O
25	.	O

1	A	O
2	total	O
3	of	O
4	90	O
5	patients	O
6	were	O
7	randomly	O
8	allocated	O
9	either	O
10	to	O
11	an	O
12	MY	O
13	-	O
14	1	O
15	treated	O
16	or	O
17	an	O
18	untreated	O
19	group	O
20	.	O

1	Below	O
2	50	O
3	%	O
4	decrease	O
5	of	O
6	PaO2	O
7	,	O
8	NADH	O
9	was	O
10	reduced	O
11	largely	O
12	.	O

1	Angiography	O
2	was	O
3	performed	O
4	following	O
5	the	O
6	rCBF	O
7	study	O
8	and	O
9	the	O
10	degree	O
11	of	O
12	vasospasm	O
13	was	O
14	measured	O
15	on	O
16	the	O
17	angiograms	O
18	.	O

1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O

1	The	O
2	financial	O
3	impact	O
4	of	O
5	childhood	O
6	asthma	O
7	has	O
8	not	O
9	been	O
10	assessed	O
11	since	O
12	Vance	O
13	and	O
14	Taylor	O
15	reported	O
16	their	O
17	data	O
18	in	O
19	Annals	O
20	of	O
21	Allergy	O
22	13	O
23	years	O
24	ago	O
25	.	O

1	Hypersplenism	O

1	Electrical	O
2	activity	O
3	was	O
4	evaluated	O
5	by	O
6	monitoring	O
7	the	O
8	general	O
9	electrocorticogram	O
10	(	O
11	ECoG	O
12	)	O
13	as	O
14	well	O
15	as	O
16	local	O
17	DC	O
18	steady	O
19	potential	O
20	(	O
21	two	O
22	sites	O
23	).	O

1	The	O
2	topography	O
3	and	O
4	trajectories	O
5	of	O
6	the	O
7	commissural	O
8	fibers	O
9	of	O
10	the	O
11	superior	O
12	temporal	O
13	region	O
14	(	O
15	STR	O
16	)	O
17	are	O
18	studied	O
19	using	O
20	the	O
21	autoradiographic	O
22	technique	O
23	.	O

1	The	O
2	diabetic	O
3	state	O
4	was	O
5	characterized	O
6	by	O
7	mild	O
8	insulin	B
9	deficiency	O
10	,	O
11	plasma	O
12	levels	O
13	being	O
14	73	O
15	%	O
16	of	O
17	controls	O
18	,	O
19	and	O
20	mild	O
21	hyperglycemia	O
22	,	O
23	with	O
24	nonfasting	O
25	plasma	O
26	glucose	O
27	levels	O
28	of	O
29	1	O
30	.	O
31	5	O
32	times	O
33	normal	O
34	.	O

1	The	O
2	primary	O
3	CT	O
4	findings	O
5	were	O
6	misinterpreted	O
7	as	O
8	a	O
9	brain	O
10	infarct	O
11	or	O
12	possibly	O
13	a	O
14	tumour	O
15	.	O

1	No	O
2	consistent	O
3	correlation	O
4	between	O
5	blood	O
6	pressure	O
7	change	O
8	and	O
9	SCR	O
10	-	O
11	change	O
12	was	O
13	seen	O
14	.	O

1	Shoulder	O
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	Piroxicam	O
2	produced	O
3	a	O
4	lower	O
5	incidence	O
6	of	O
7	gastric	O
8	ulcers	O
9	than	O
10	equivalent	O
11	doses	O
12	of	O
13	indomethacin	O
14	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	O
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O

1	In	O
2	MCCP	O
3	functions	O
4	of	O
5	the	O
6	source	O
7	emission	O
8	,	O
9	surface	O
10	reflection	O
11	,	O
12	photoacceptor	O
13	sensitivity	O
14	are	O
15	approximated	O
16	by	O
17	the	O
18	normal	O
19	distribution	O
20	curves	O
21	.	O

1	However	O
2	,	O
3	kidneys	O
4	perfused	O
5	for	O
6	72	O
7	hr	O
8	demonstrated	O
9	more	O
10	similar	O
11	renal	O
12	functions	O
13	when	O
14	tested	O
15	by	O
16	either	O
17	IMPK	O
18	or	O
19	IBPK	O
20	.	O

1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	O
9	angiotensin	B
10	II	I
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	mechanically	O
28	ventilated	O
29	lambs	O
30	.	O

1	A	O
2	flow	O
3	rate	O
4	of	O
5	at	O
6	least	O
7	5	O
8	mL	O
9	/	O
10	h	O
11	is	O
12	required	O
13	through	O
14	the	O
15	receptor	O
16	(	O
17	volume	O
18	,	O
19	0	O
20	.	O
21	4	O
22	mL	O
23	)	O
24	for	O
25	accurate	O
26	results	O
27	.	O

1	We	O
2	have	O
3	now	O
4	located	O
5	the	O
6	5	O
7	'	O
8	ends	O
9	of	O
10	the	O
11	two	O
12	remaining	O
13	late	O
14	mRNAs	O
15	.	O

1	The	O
2	efficacy	O
3	of	O
4	quantitative	O
5	and	O
6	qualitative	O
7	chloride	O
8	titrators	O
9	in	O
10	the	O
11	estimation	O
12	of	O
13	human	O
14	salt	O
15	intake	O
16	.	O

1	Doctor	O
2	Berglund	O
3	warns	O
4	members	O
5	of	O
6	union	O
7	pitfalls	O
8	.	O

1	Acute	O
2	appearance	O
3	of	O
4	hemiparesis	O
5	or	O
6	hemiplegia	O
7	with	O
8	initial	O
9	marked	O
10	spasticity	O
11	was	O
12	observed	O
13	in	O
14	8	O
15	stroke	O
16	patients	O
17	.	O

1	Recurrent	O
2	acute	O
3	rhinosinusitis	O
4	was	O
5	common	O
6	in	O
7	both	O
8	groups	O
9	of	O
10	patients	O
11	,	O
12	but	O
13	the	O
14	development	O
15	of	O
16	chronic	O
17	rhinosinusitis	O
18	was	O
19	only	O
20	found	O
21	in	O
22	patients	O
23	with	O
24	CVID	O
25	,	O
26	indicating	O
27	the	O
28	more	O
29	severe	O
30	nature	O
31	of	O
32	this	O
33	condition	O
34	compared	O
35	with	O
36	selective	O
37	IgA	B
38	deficiency	O
39	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	AP	B
6	-	I
7	A	I
8	may	O
9	be	O
10	potentially	O
11	useful	O
12	in	O
13	the	O
14	management	O
15	of	O
16	heart	O
17	failure	O
18	.	O

1	The	O
2	various	O
3	muscles	O
4	of	O
5	the	O
6	pelvic	O
7	floor	O
8	region	O
9	could	O
10	be	O
11	reflexly	O
12	activated	O
13	either	O
14	individually	O
15	or	O
16	as	O
17	a	O
18	mass	O
19	unit	O
20	depending	O
21	on	O
22	the	O
23	intensity	O
24	of	O
25	stimulation	O
26	.	O

1	It	O
2	has	O
3	been	O
4	reported	O
5	that	O
6	rat	O
7	blood	O
8	chloroform	O
9	levels	O
10	were	O
11	significantly	O
12	decreased	O
13	after	O
14	treatment	O
15	with	O
16	ClO2	O
17	.	O

1	The	O
2	frequency	O
3	of	O
4	lactase	B
5	phenotypes	I
6	in	O
7	Aymara	O
8	children	O
9	.	O

1	Activities	O
2	of	O
3	hepatic	O
4	cytochrome	B
5	P	I
6	-	I
7	450	I
8	-	O
9	dependent	O
10	metabolizing	O
11	enzymes	O
12	such	O
13	as	O
14	aminopyrine	B
15	-	I
16	and	I
17	TMO	I
18	N	I
19	-	I
20	demethylase	I
21	and	O
22	aniline	B
23	hydroxylase	I
24	activity	O
25	were	O
26	decreased	O
27	by	O
28	pretreatment	O
29	of	O
30	rats	O
31	with	O
32	cimetidine	O
33	,	O
34	whereas	O
35	in	O
36	the	O
37	rats	O
38	pretreated	O
39	with	O
40	ranitidine	O
41	,	O
42	these	O
43	enzyme	O
44	activities	O
45	were	O
46	not	O
47	changed	O
48	.	O

1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	opiate	O
6	antagonist	O
7	naloxone	O
8	was	O
9	evaluated	O
10	in	O
11	11	O
12	unselected	O
13	patients	O
14	with	O
15	cerebral	O
16	ischemia	O
17	.	O

1	Electrochemical	O
2	detection	O
3	of	O
4	depressed	O
5	circulating	O
6	levels	O
7	of	O
8	vitamin	O
9	K1	O
10	in	O
11	osteoporosis	O
12	.	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	Ultrastructure	O
2	of	O
3	the	O
4	tumor	O
5	in	O
6	1	O
7	patient	O
8	in	O
9	whom	O
10	transurethral	O
11	resection	O
12	was	O
13	performed	O
14	2	O
15	weeks	O
16	after	O
17	alum	O
18	irrigation	O
19	revealed	O
20	well	O
21	preserved	O
22	nuclear	O
23	chromatin	O
24	,	O
25	thus	O
26	,	O
27	suggesting	O
28	that	O
29	whatever	O
30	changes	O
31	occur	O
32	after	O
33	alum	O
34	irrigation	O
35	are	O
36	short	O
37	-	O
38	lived	O
39	.	O

1	The	O
2	generally	O
3	adopted	O
4	criteria	O
5	enabling	O
6	to	O
7	classify	O
8	the	O
9	examined	O
10	persons	O
11	into	O
12	the	O
13	following	O
14	3	O
15	groups	O
16	have	O
17	been	O
18	used	O
19	:	O
20	(	O
21	a	O
22	)	O
23	diseased	O
24	of	O
25	BEN	O
26	;	O
27	(	O
28	b	O
29	)	O
30	suspect	O
31	to	O
32	be	O
33	diseased	O
34	of	O
35	BEN	O
36	,	O
37	and	O
38	(	O
39	c	O
40	)	O
41	individuals	O
42	without	O
43	signs	O
44	of	O
45	a	O
46	renal	O
47	disease	O
48	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	simple	O
7	respiration	O
8	-	O
9	control	O
10	device	O
11	has	O
12	been	O
13	developed	O
14	that	O
15	enables	O
16	the	O
17	patient	O
18	to	O
19	monitor	O
20	breath	O
21	-	O
22	holding	O
23	during	O
24	successive	O
25	scans	O
26	.	O

1	The	O
2	POEMS	O
3	syndrome	O
4	(	O
5	Polyneuropathy	O
6	,	O
7	Organomegaly	O
8	,	O
9	Endocrinopathy	O
10	,	O
11	Monoclonal	O
12	component	O
13	,	O
14	Skin	O
15	).	O

1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	Two	O
2	siblings	O
3	with	O
4	hemolytic	O
5	anemia	O
6	caused	O
7	by	O
8	triosephosphate	B
9	isomerase	I
10	deficiency	O
11	developed	O
12	a	O
13	progressive	O
14	neurological	O
15	syndrome	O
16	featuring	O
17	dystonic	O
18	movements	O
19	,	O
20	tremor	O
21	,	O
22	pyramidal	O
23	tract	O
24	signs	O
25	,	O
26	and	O
27	evidence	O
28	of	O
29	spinal	O
30	motor	O
31	neuron	O
32	involvement	O
33	.	O

1	One	O
2	extract	O
3	with	O
4	the	O
5	lowest	O
6	PCA	O
7	content	O
8	was	O
9	non	O
10	-	O
11	carcinogenic	O
12	.	O

1	In	O
2	the	O
3	10	O
4	patients	O
5	with	O
6	a	O
7	more	O
8	severe	O
9	degree	O
10	of	O
11	steatorrhea	O
12	the	O
13	decrease	O
14	in	O
15	fat	O
16	loss	O
17	approached	O
18	20	O
19	%	O
20	and	O
21	a	O
22	close	O
23	relationship	O
24	was	O
25	found	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	84	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	)	O
40	between	O
41	the	O
42	extent	O
43	of	O
44	the	O
45	fatty	O
46	acid	O
47	loss	O
48	on	O
49	placebo	O
50	and	O
51	the	O
52	decrease	O
53	of	O
54	this	O
55	loss	O
56	on	O
57	taurine	O
58	.	O

1	Aortic	O
2	diameters	O
3	in	O
4	infants	O
5	and	O
6	young	O
7	children	O
8	:	O
9	normative	O
10	angiographic	O
11	data	O
12	.	O

1	The	O
2	present	O
3	investigation	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	distribution	O
9	of	O
10	the	O
11	main	O
12	fatty	O
13	acids	O
14	in	O
15	Leptospira	O
16	phospholipids	O
17	is	O
18	similar	O
19	to	O
20	their	O
21	distribution	O
22	in	O
23	Leptospira	O
24	neutral	O
25	lipids	O
26	with	O
27	the	O
28	exception	O
29	of	O
30	unsaturated	O
31	fatty	O
32	acid	O
33	with	O
34	14	O
35	carbon	O
36	atoms	O
37	,	O
38	occurring	O
39	mainly	O
40	in	O
41	phospholipids	O
42	.	O

1	Since	O
2	1970	O
3	the	O
4	frequency	O
5	of	O
6	potassium	O
7	-	O
8	induced	O
9	ulceration	O
10	has	O
11	been	O
12	low	O
13	--	O
14	3	O
15	cases	O
16	per	O
17	100	O
18	000	O
19	patient	O
20	-	O
21	years	O
22	of	O
23	slow	O
24	-	O
25	release	O
26	tablet	O
27	use	O
28	.	O

1	Hydrocortisone	O
2	caused	O
3	lymphopenia	O
4	and	O
5	inhibited	O
6	the	O
7	blastogenic	O
8	response	O
9	of	O
10	peripheral	O
11	blood	O
12	lymphocytes	O
13	to	O
14	phytohemagglutinin	B
15	and	O
16	concanavalin	B
17	A	I
18	mitogens	O
19	.	O

1	To	O
2	test	O
3	the	O
4	feasibility	O
5	of	O
6	using	O
7	liposomes	O
8	to	O
9	deliver	O
10	therapeutic	O
11	agents	O
12	to	O
13	the	O
14	lungs	O
15	,	O
16	the	O
17	effect	O
18	of	O
19	liposome	O
20	-	O
21	encapsulated	O
22	superoxide	B
23	dismutase	I
24	(	O
25	SOD	B
26	)	O
27	or	O
28	catalase	B
29	on	O
30	pulmonary	O
31	oxygen	O
32	toxicity	O
33	was	O
34	studied	O
35	in	O
36	rats	O
37	.	O

1	Marrow	O
2	cell	O
3	necrosis	O
4	in	O
5	anorexia	O
6	nervosa	O
7	and	O
8	involuntary	O
9	starvation	O
10	.	O

1	For	O
2	comparison	O
3	conventional	O
4	heparin	O
5	was	O
6	used	O
7	during	O
8	18	O
9	dialyses	O
10	in	O
11	the	O
12	same	O
13	patients	O
14	.	O

1	Chenodeoxycholic	O
2	acid	O
3	(	O
4	cheno	O
5	)	O
6	and	O
7	ursodeoxycholic	O
8	acid	O
9	(	O
10	urso	O
11	)	O
12	dissolve	O
13	cholesterol	O
14	gallstones	O
15	in	O
16	man	O
17	.	O

1	Sensory	O
2	evoked	O
3	field	O
4	potentials	O
5	were	O
6	recorded	O
7	from	O
8	the	O
9	mesencephalic	O
10	reticular	O
11	formation	O
12	(	O
13	MRF	O
14	),	O
15	central	O
16	gray	O
17	(	O
18	CG	O
19	)	O
20	and	O
21	somatosensory	O
22	cortex	O
23	(	O
24	SCX	O
25	),	O
26	following	O
27	incremental	O
28	doses	O
29	of	O
30	halothane	O
31	in	O
32	freely	O
33	-	O
34	moving	O
35	rats	O
36	.	O

1	Ultrastructure	O
2	of	O
3	the	O
4	heart	O
5	muscle	O
6	in	O
7	experimental	O
8	myocardial	O
9	infarct	O
10	following	O
11	physical	O
12	training	O

1	Pharmacological	O
2	desympathization	O
3	leads	O
4	to	O
5	the	O
6	development	O
7	of	O
8	hyper	O
9	-	O
10	reactivity	O
11	of	O
12	the	O
13	true	O
14	pacemakers	O
15	to	O
16	noradrenaline	O
17	and	O
18	dopamine	O
19	and	O
20	triggers	O
21	off	O
22	changes	O
23	in	O
24	the	O
25	regulation	O
26	of	O
27	the	O
28	electric	O
29	activity	O
30	of	O
31	these	O
32	cells	O
33	by	O
34	catecholamines	O
35	.	O

1	OODG	O
2	is	O
3	a	O
4	diagnostic	O
5	method	O
6	permitting	O
7	assessment	O
8	of	O
9	ocular	O
10	pulse	O
11	curves	O
12	and	O
13	objective	O
14	determination	O
15	of	O
16	blood	O
17	pressures	O
18	in	O
19	the	O
20	ophthalmic	O
21	circulatory	O
22	system	O
23	(	O
24	retinal	O
25	and	O
26	ciliary	O
27	arterial	O
28	blood	O
29	pressures	O
30	)	O
31	simultaneously	O
32	for	O
33	both	O
34	eyes	O
35	,	O
36	without	O
37	dilatation	O
38	of	O
39	the	O
40	pupils	O
41	.	O

1	Viral	O
2	infections	O
3	have	O
4	long	O
5	been	O
6	suspected	O
7	to	O
8	be	O
9	causative	O
10	agents	O
11	in	O
12	a	O
13	number	O
14	of	O
15	inner	O
16	ear	O
17	dysfunctions	O
18	.	O

1	55	O
2	+/-	O
3	11	O
4	%),	O
5	all	O
6	other	O
7	parameters	O
8	showed	O
9	a	O
10	significant	O
11	increase	O
12	:	O
13	RS	O
14	index	O
15	5	O
16	.	O
17	4	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	mVolt	O
23	to	O
24	6	O
25	.	O
26	0	O
27	+/-	O
28	1	O
29	.	O
30	7	O
31	mVolt	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	);	O
40	EDD	O
41	6	O
42	.	O
43	3	O
44	+/-	O
45	0	O
46	.	O
47	7	O
48	to	O
49	6	O
50	.	O
51	8	O
52	+/-	O
53	0	O
54	.	O
55	9	O
56	cm	O
57	(	O
58	p	O
59	less	O
60	than	O
61	0	O
62	.	O
63	001	O
64	);	O
65	HV	O
66	1017	O
67	+/-	O
68	151	O
69	ml	O
70	to	O
71	1099	O
72	+/-	O
73	261	O
74	ml	O
75	(	O
76	p	O
77	less	O
78	than	O
79	0	O
80	.	O
81	01	O
82	);	O
83	EDV	O
84	371	O
85	+/-	O
86	131	O
87	ml	O
88	to	O
89	441	O
90	+/-	O
91	175	O
92	ml	O
93	(	O
94	p	O
95	less	O
96	than	O
97	0	O
98	.	O
99	001	O
100	);	O
101	RBV	O
102	117	O
103	+/-	O
104	57	O
105	ml	O
106	to	O
107	151	O
108	+/-	O
109	77	O
110	ml	O
111	(	O
112	p	O
113	less	O
114	than	O
115	0	O
116	.	O
117	001	O
118	).	O

1	Retrospective	O
2	analyses	O
3	of	O
4	this	O
5	death	O
6	revealed	O
7	a	O
8	significant	O
9	decrease	O
10	of	O
11	the	O
12	left	O
13	ventricular	O
14	(	O
15	LV	O
16	)	O
17	end	O
18	-	O
19	diastolic	O
20	volume	O
21	index	O
22	(	O
23	EDVI	O
24	)	O
25	of	O
26	21	O
27	ml	O
28	/	O
29	m2	O
30	(	O
31	36	O
32	%	O
33	of	O
34	normal	O
35	).	O

1	In	O
2	group	O
3	I	O
4	adults	O
5	both	O
6	of	O
7	these	O
8	variables	O
9	increased	O
10	.	O

1	Polysorbate	O
2	80	O
3	did	O
4	not	O
5	have	O
6	a	O
7	direct	O
8	stimulant	O
9	or	O
10	relaxant	O
11	effect	O
12	on	O
13	either	O
14	guinea	O
15	pig	O
16	ileum	O
17	or	O
18	rat	O
19	uterus	O
20	,	O
21	however	O
22	,	O
23	it	O
24	antagonised	O
25	the	O
26	contractions	O
27	induced	O
28	by	O
29	acetylcholine	O
30	,	O
31	histamine	O
32	,	O
33	barium	O
34	,	O
35	5	O
36	-	O
37	hydroxytryptamine	O
38	and	O
39	carbachol	O
40	in	O
41	a	O
42	dose	O
43	-	O
44	dependent	O
45	manner	O
46	.	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	Vitiligo	O
2	in	O
3	diabetes	O
4	mellitus	O
5	.	O

1	The	O
2	pharmacokinetics	O
3	of	O
4	each	O
5	tetracycline	O
6	in	O
7	serum	O
8	and	O
9	dermal	O
10	,	O
11	suction	O
12	blister	O
13	fluid	O
14	were	O
15	determined	O
16	after	O
17	oral	O
18	doses	O
19	of	O
20	300	O
21	mg	O
22	lymecycline	O
23	or	O
24	100	O
25	mg	O
26	doxycycline	O
27	on	O
28	the	O
29	3rd	O
30	day	O
31	.	O

1	A	O
2	high	O
3	degree	O
4	of	O
5	correlation	O
6	in	O
7	the	O
8	sense	O
9	of	O
10	the	O
11	classic	O
12	conception	O
13	of	O
14	brain	O
15	localization	O
16	of	O
17	neuropsychological	O
18	syndromes	O
19	was	O
20	found	O
21	.	O

1	Either	O
2	a	O
3	UV	O
4	detector	O
5	set	O
6	at	O
7	268	O
8	nm	O
9	or	O
10	an	O
11	electrochemical	O
12	(	O
13	EC	O
14	)	O
15	detector	O
16	set	O
17	at	O
18	a	O
19	potential	O
20	of	O
21	+	O
22	0	O
23	.	O
24	9	O
25	V	O
26	(	O
27	versus	O
28	Ag	O
29	/	O
30	AgCl	O
31	/	O
32	3	O
33	M	O
34	NaCl	O
35	)	O
36	was	O
37	used	O
38	to	O
39	monitor	O
40	the	O
41	drug	O
42	.	O

1	35	O
2	patients	O
3	with	O
4	acute	O
5	arterial	O
6	occlusions	O
7	[	O
8	27	O
9	]	O
10	and	O
11	graft	O
12	thromboses	O
13	[	O
14	8	O
15	],	O
16	responsible	O
17	for	O
18	severe	O
19	and	O
20	recent	O
21	ischemia	O
22	,	O
23	were	O
24	treated	O
25	by	O
26	fibrinolytic	O
27	therapy	O
28	(	O
29	Urokinase	B
30	:	O
31	1	O
32	000	O
33	units	O
34	/	O
35	kg	O
36	/	O
37	hour	O
38	,	O
39	and	O
40	Lys	O
41	Plasminogen	B
42	).	O

1	The	O
2	mean	O
3	transfer	O
4	ratios	O
5	of	O
6	the	O
7	drug	O
8	into	O
9	the	O
10	genital	O
11	tissues	O
12	to	O
13	the	O
14	concentration	O
15	in	O
16	the	O
17	uterine	O
18	arterial	O
19	blood	O
20	were	O
21	such	O
22	that	O
23	the	O
24	transfer	O
25	ratio	O
26	into	O
27	the	O
28	portio	O
29	vaginalis	O
30	was	O
31	the	O
32	highest	O
33	,	O
34	followed	O
35	by	O
36	the	O
37	uterine	O
38	cervix	O
39	and	O
40	the	O
41	myometrium	O
42	,	O
43	and	O
44	that	O
45	into	O
46	the	O
47	oviduct	O
48	was	O
49	the	O
50	lowest	O
51	with	O
52	about	O
53	1	O
54	/	O
55	2	O
56	that	O
57	into	O
58	the	O
59	portio	O
60	vaginalis	O
61	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	B
22	triglyceride	I
23	lipase	I
24	activity	O
25	.	O

1	Because	O
2	of	O
3	its	O
4	wide	O
5	spectrum	O
6	of	O
7	activity	O
8	particularly	O
9	against	O
10	ampicillin	O
11	resistant	O
12	strains	O
13	of	O
14	H	O
15	.	O
16	influenzae	O
17	and	O
18	because	O
19	of	O
20	its	O
21	good	O
22	tolerance	O
23	Cefaclor	O
24	is	O
25	very	O
26	useful	O
27	in	O
28	treatment	O
29	of	O
30	respiratory	O
31	tract	O
32	infections	O
33	in	O
34	children	O
35	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	Shape	O
2	factor	O
3	correlated	O
4	well	O
5	with	O
6	hemodynamic	O
7	data	O
8	for	O
9	RV	O
10	/	O
11	LV	O
12	systolic	O
13	pressure	O
14	ratios	O
15	(	O
16	r	O
17	=	O
18	0	O
19	.	O
20	93	O
21	,	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	001	O
28	)	O
29	for	O
30	normalized	O
31	interventricular	O
32	pressure	O
33	differences	O
34	(	O
35	r	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	,	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	).	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	O
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	Furthermore	O
2	,	O
3	the	O
4	initial	O
5	plasma	O
6	retinol	O
7	level	O
8	in	O
9	conjunction	O
10	with	O
11	RBP	B
12	was	O
13	found	O
14	to	O
15	be	O
16	even	O
17	lower	O
18	in	O
19	12	O
20	patients	O
21	(	O
22	35	O
23	.	O
24	1	O
25	micrograms	O
26	dl	O
27	-	O
28	1	O
29	,	O
30	3	O
31	.	O
32	7	O
33	mg	O
34	dl	O
35	-	O
36	1	O
37	)	O
38	who	O
39	subsequently	O
40	had	O
41	cancer	O
42	recurrence	O
43	than	O
44	in	O
45	those	O
46	who	O
47	remained	O
48	free	O
49	of	O
50	apparent	O
51	cancer	O
52	(	O
53	44	O
54	.	O
55	5	O
56	micrograms	O
57	dl	O
58	-	O
59	1	O
60	,	O
61	4	O
62	.	O
63	6	O
64	mg	O
65	dl	O
66	-	O
67	1	O
68	).	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	:	O
6	1	O
7	)	O
8	the	O
9	initial	O
10	response	O
11	to	O
12	tethering	O
13	varies	O
14	according	O
15	to	O
16	previous	O
17	penning	O
18	and	O
19	handling	O
20	experience	O
21	,	O
22	2	O
23	)	O
24	although	O
25	the	O
26	circadian	O
27	rhythm	O
28	of	O
29	cortisol	O
30	was	O
31	either	O
32	altered	O
33	or	O
34	disrupted	O
35	during	O
36	estrus	O
37	,	O
38	such	O
39	disruptions	O
40	were	O
41	not	O
42	influenced	O
43	by	O
44	type	O
45	of	O
46	penning	O
47	and	O
48	3	O
49	)	O
50	tether	O
51	stalls	O
52	may	O
53	chronically	O
54	increase	O
55	cortisol	O
56	concentrations	O
57	in	O
58	gilts	O
59	.	O

1	This	O
2	laser	O
3	provided	O
4	sufficient	O
5	power	O
6	in	O
7	an	O
8	amniotic	O
9	fluid	O
10	medium	O
11	to	O
12	occlude	O
13	placental	O
14	vessels	O
15	as	O
16	large	O
17	as	O
18	7	O
19	mm	O
20	in	O
21	diameter	O
22	within	O
23	6	O
24	seconds	O
25	at	O
26	a	O
27	power	O
28	density	O
29	of	O
30	2000	O
31	W	O
32	/	O
33	cm2	O
34	.	O

1	On	O
2	d	O
3	112	O
4	,	O
5	progesterone	O
6	was	O
7	higher	O
8	(	O
9	P	O
10	less	O
11	than	O
12	.	O
13	05	O
14	)	O
15	in	O
16	hysterectomized	O
17	heifers	O
18	than	O
19	in	O
20	other	O
21	treatment	O
22	groups	O
23	.	O

1	Male	O
2	Japanese	O
3	quail	O
4	were	O
5	chronically	O
6	exposed	O
7	to	O
8	5000	O
9	ppm	O
10	manganese	O
11	(	O
12	Mn	O
13	)	O
14	as	O
15	particulate	O
16	manganese	O
17	oxide	O
18	(	O
19	Mn3O4	O
20	)	O
21	in	O
22	their	O
23	diet	O
24	from	O
25	hatching	O
26	to	O
27	75	O
28	days	O
29	of	O
30	age	O
31	.	O

1	This	O
2	study	O
3	indicated	O
4	that	O
5	the	O
6	Japanese	O
7	quail	O
8	was	O
9	less	O
10	sensitive	O
11	to	O
12	particulate	O
13	Mn3O4	O
14	exposure	O
15	than	O
16	rodents	O
17	treated	O
18	comparably	O
19	.	O

1	Plasma	O
2	and	O
3	bladder	O
4	platinum	O
5	concentration	O
6	were	O
7	measured	O
8	following	O
9	intravesical	O
10	DDP	O
11	,	O
12	and	O
13	also	O
14	histopathological	O
15	examination	O
16	,	O
17	urinalysis	O
18	,	O
19	complete	O
20	blood	O
21	count	O
22	and	O
23	blood	O
24	chemistry	O
25	were	O
26	performed	O
27	in	O
28	order	O
29	to	O
30	know	O
31	the	O
32	toxicity	O
33	of	O
34	intravesical	O
35	DDP	O
36	.	O

1	Scintigraphic	O
2	visualisation	O
3	of	O
4	Walker	O
5	carcinoma	O
6	-	O
7	256	O
8	in	O
9	Sprague	O
10	-	O
11	Dawley	O
12	rats	O
13	by	O
14	means	O
15	of	O
16	99mTc	O
17	-	O
18	labelled	O
19	monocytes	O
20	.	O

1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	those	O
7	obtained	O
8	in	O
9	-	O
10	D	O
11	mothers	O
12	and	O
13	pups	O
14	,	O
15	after	O
16	giving	O
17	the	O
18	mothers	O
19	an	O
20	oral	O
21	supplement	O
22	(	O
23	10	O
24	i	O
25	.	O
26	u	O
27	.	O
28	vitamin	O
29	D3	O
30	/	O
31	day	O
32	)	O
33	during	O
34	the	O
35	period	O
36	of	O
37	lactation	O
38	(	O
39	20	O
40	days	O
41	).	O

1	Rabbit	O
2	eyes	O
3	were	O
4	removed	O
5	and	O
6	held	O
7	in	O
8	temperature	O
9	-	O
10	regulated	O
11	chambers	O
12	and	O
13	irrigated	O
14	with	O
15	saline	O
16	.	O

1	Before	O
2	birth	O
3	,	O
4	there	O
5	were	O
6	a	O
7	few	O
8	perivascular	O
9	adrenergic	O
10	nerves	O
11	and	O
12	correspondingly	O
13	low	O
14	ovarian	O
15	NE	O
16	levels	O
17	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	O
5	heart	O
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	O
20	Pre	O
21	-	O
22	par	O

1	Since	O
2	September	O
3	1980	O
4	to	O
5	June	O
6	1983	O
7	we	O
8	have	O
9	treated	O
10	32	O
11	patients	O
12	with	O
13	ovarian	O
14	cancer	O
15	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	calcium	O
7	antagonist	O
8	,	O
9	diltiazem	O
10	,	O
11	may	O
12	modify	O
13	the	O
14	effects	O
15	of	O
16	isoflurane	O
17	on	O
18	myocardial	O
19	function	O
20	.	O

1	Supraventricular	O
2	arrhythmias	O
3	--	O
4	digoxin	O
5	and	O
6	quinidine	O
7	revisited	O
8	.	O

1	Visidex	O
2	I	O
3	is	O
4	unsuitable	O
5	for	O
6	storage	O
7	and	O
8	re	O
9	-	O
10	reading	O
11	.	O

1	Treatment	O
2	with	O
3	oxyphenylbutazone	O
4	and	O
5	hydrocortisone	O
6	failed	O
7	to	O
8	inhibit	O
9	the	O
10	raised	O
11	serum	B
12	CPN	I
13	levels	O
14	.	O

1	40	O
2	,	O
3	000	O
4	).	O

1	The	O
2	Cox	O
3	proportional	O
4	hazards	O
5	model	O
6	was	O
7	applied	O
8	to	O
9	the	O
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	O
23	.	O

1	This	O
2	suggests	O
3	that	O
4	mechanisms	O
5	other	O
6	than	O
7	an	O
8	excessive	O
9	increase	O
10	in	O
11	myocardial	O
12	oxygen	O
13	demand	O
14	may	O
15	be	O
16	responsible	O
17	for	O
18	the	O
19	many	O
20	episodes	O
21	occurring	O
22	outside	O
23	the	O
24	hospital	O
25	.	O

1	Duration	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	sequential	O
12	dose	O
13	of	O
14	MTX	O
15	and	O
16	5	O
17	-	O
18	FU	O

1	These	O
2	data	O
3	showed	O
4	:	O
5	that	O
6	progesterone	O
7	secretion	O
8	is	O
9	pulsatile	O
10	throughout	O
11	the	O
12	human	O
13	luteal	O
14	phase	O
15	,	O
16	with	O
17	maximum	O
18	frequency	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	luteal	O
24	phase	O
25	;	O
26	that	O
27	during	O
28	the	O
29	mid	O
30	-	O
31	luteal	O
32	phase	O
33	most	O
34	subjects	O
35	had	O
36	progesterone	O
37	levels	O
38	both	O
39	above	O
40	and	O
41	below	O
42	currently	O
43	accepted	O
44	ovulatory	O
45	thresholds	O
46	;	O
47	the	O
48	use	O
49	of	O
50	a	O
51	single	O
52	measurement	O
53	of	O
54	progesterone	O
55	in	O
56	the	O
57	mid	O
58	-	O
59	luteal	O
60	phase	O
61	is	O
62	not	O
63	always	O
64	a	O
65	reliable	O
66	indicator	O
67	of	O
68	ovulation	O
69	;	O
70	a	O
71	threshold	O
72	greater	O
73	than	O
74	20	O
75	nmol	O
76	/	O
77	l	O
78	may	O
79	yield	O
80	an	O
81	unacceptable	O
82	number	O
83	of	O
84	false	O
85	negative	O
86	results	O
87	.	O

1	The	O
2	fast	O
3	real	O
4	-	O
5	time	O
6	digital	O
7	processing	O
8	of	O
9	the	O
10	N2	O
11	and	O
12	flow	O
13	signals	O
14	incorporated	O
15	filtering	O
16	,	O
17	delay	O
18	compensation	O
19	,	O
20	and	O
21	corrections	O
22	for	O
23	the	O
24	effects	O
25	of	O
26	changes	O
27	in	O
28	gas	O
29	composition	O
30	and	O
31	temperature	O
32	.	O

1	This	O
2	slope	O
3	tended	O
4	to	O
5	be	O
6	higher	O
7	(	O
8	approximately	O
9	1	O
10	.	O
11	6	O
12	dB	O
13	/	O
14	dB	O
15	)	O
16	for	O
17	L1	O
18	=	O
19	L2	O
20	greater	O
21	than	O
22	80	O
23	dB	O
24	.	O

1	Histamine	O
2	reactivity	O
3	was	O
4	significantly	O
5	reduced	O
6	after	O
7	the	O
8	nifedipine	O
9	aerosol	O
10	,	O
11	the	O
12	geometric	O
13	mean	O
14	provocative	O
15	concentration	O
16	causing	O
17	a	O
18	35	O
19	%	O
20	fall	O
21	in	O
22	specific	O
23	airway	O
24	conductance	O
25	,	O
26	rising	O
27	from	O
28	5	O
29	.	O
30	0	O
31	to	O
32	10	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	ml	O
38	of	O
39	histamine	O
40	(	O
41	p	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	Pharmacologic	O
2	doses	O
3	of	O
4	vitamin	O
5	B6	O
6	administered	O
7	to	O
8	lactating	O
9	women	O
10	have	O
11	been	O
12	reported	O
13	to	O
14	suppress	O
15	plasma	B
16	prolactin	I
17	.	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	but	O
6	similar	O
7	elevation	O
8	of	O
9	mean	O
10	O2	O
11	uptake	O
12	during	O
13	40	O
14	min	O
15	postexercise	O
16	by	O
17	13	O
18	.	O
19	6	O
20	%	O
21	in	O
22	both	O
23	the	O
24	fasted	O
25	(	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	)	O
33	and	O
34	fed	O
35	state	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	National	O
2	Institutes	O
3	of	O
4	Health	O
5	Consensus	O
6	Development	O
7	Conference	O
8	Statement	O
9	.	O

1	In	O
2	controls	O
3	,	O
4	most	O
5	of	O
6	the	O
7	output	O
8	from	O
9	the	O
10	conduit	O
11	occurred	O
12	during	O
13	type	O
14	I	O
15	activity	O
16	(	O
17	73	O
18	+/-	O
19	14	O
20	%).	O

1	Greater	O
2	attenuation	O
3	of	O
4	the	O
5	N1	O
6	-	O
7	P2	O
8	and	O
9	baseline	O
10	-	O
11	P2	O
12	amplitude	O
13	of	O
14	the	O
15	probe	O
16	EPs	O
17	was	O
18	observed	O
19	when	O
20	the	O
21	probe	O
22	stimulus	O
23	was	O
24	presented	O
25	to	O
26	the	O
27	right	O
28	ear	O
29	and	O
30	the	O
31	verbal	O
32	material	O
33	presented	O
34	to	O
35	the	O
36	left	O
37	ear	O
38	than	O
39	when	O
40	the	O
41	opposite	O
42	stimulation	O
43	arrangement	O
44	was	O
45	used	O
46	.	O

1	Twenty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	80	O
7	,	O
8	6	O
9	%)	O
10	with	O
11	mixed	O
12	neoplasms	O
13	were	O
14	operated	O
15	on	O
16	by	O
17	total	O
18	conservative	O
19	parotidectomy	O
20	(	O
21	T	O
22	.	O
23	C	O
24	.	O
25	P	O
26	.),	O
27	3	O
28	(	O
29	9	O
30	,	O
31	7	O
32	%)	O
33	by	O
34	S	O
35	.	O
36	P	O
37	.	O
38	and	O
39	3	O
40	(	O
41	9	O
42	,	O
43	7	O
44	%)	O
45	by	O
46	En	O
47	.	O

1	The	O
2	comparisons	O
3	revealed	O
4	that	O
5	female	O
6	homicide	O
7	-	O
8	suicide	O
9	perpetrators	O
10	were	O
11	more	O
12	likely	O
13	than	O
14	female	O
15	homicide	O
16	-	O
17	suicide	O
18	victims	O
19	to	O
20	live	O
21	in	O
22	mobile	O
23	homes	O
24	,	O
25	kill	O
26	their	O
27	lover	O
28	or	O
29	ex	O
30	-	O
31	lover	O
32	,	O
33	have	O
34	their	O
35	crime	O
36	accidentally	O
37	discovered	O
38	,	O
39	leave	O
40	a	O
41	suicide	O
42	note	O
43	,	O
44	kill	O
45	on	O
46	a	O
47	weekend	O
48	,	O
49	and	O
50	be	O
51	depressed	O
52	,	O
53	but	O
54	are	O
55	less	O
56	likely	O
57	than	O
58	female	O
59	homicide	O
60	-	O
61	suicide	O
62	victims	O
63	to	O
64	live	O
65	with	O
66	a	O
67	spouse	O
68	.	O

1	Germ	O
2	-	O
3	free	O
4	rabbits	O
5	given	O
6	mouse	O
7	CRF	O
8	-	O
9	flora	O
10	showed	O
11	values	O
12	quite	O
13	different	O
14	from	O
15	control	O
16	animals	O
17	for	O
18	most	O
19	parameters	O
20	,	O
21	indicating	O
22	unsuitability	O
23	of	O
24	mouse	O
25	CRF	O
26	flora	O
27	to	O
28	'	O
29	normalize	O
30	'	O
31	rabbits	O
32	.	O

1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	O
6	and	O
7	Zn	O
8	to	O
9	Mg	O
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O

1	L3	O
2	-	O
3	L4	O
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O

1	Component	O
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O

1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	O
6	in	O
7	the	O
8	decrease	O
9	in	O
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	O
19	and	O
20	alpha	B
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	B
31	-	O
32	treated	O
33	group	O
34	.	O

1	Failure	O
2	of	O
3	stapedius	O
4	reflexometry	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	myasthenia	O
10	gravis	O
11	.	O

1	Factors	O
2	influencing	O
3	semen	O
4	characteristics	O
5	in	O
6	young	O
7	boars	O
8	reared	O
9	in	O
10	a	O
11	subtropical	O
12	environment	O
13	were	O
14	studied	O
15	.	O

1	[	O
2	14C	O
3	]-	O
4	beta	O
5	-	O
6	phenethylamine	O
7	,	O
8	its	O
9	distribution	O
10	after	O
11	administration	O
12	by	O
13	various	O
14	routes	O
15	to	O
16	cats	O
17	,	O
18	and	O
19	the	O
20	effects	O
21	of	O
22	monoamine	B
23	oxidase	I
24	inhibitors	O
25	.	O

1	All	O
2	runners	O
3	drank	O
4	a	O
5	total	O
6	of	O
7	1	O
8	.	O
9	4	O
10	L	O
11	of	O
12	water	O
13	during	O
14	the	O
15	race	O
16	.	O

1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	Following	O
2	seven	O
3	days	O
4	'	O
5	incubation	O
6	both	O
7	at	O
8	20	O
9	degrees	O
10	C	O
11	and	O
12	28	O
13	degrees	O
14	C	O
15	,	O
16	Ae	O
17	.	O
18	vexans	O
19	nip	O
20	.	O
21	was	O
22	capable	O
23	of	O
24	transmitting	O
25	the	O
26	virus	O
27	.	O

1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	O
7	saginata	O
8	taeniasis	O
9	.	O

1	The	O
2	imino	O
3	proton	O
4	of	O
5	T3	O
6	in	O
7	the	O
8	O6meG	O
9	.	O
10	T	O
11	12	O
12	-	O
13	mer	O
14	and	O
15	G3	O
16	in	O
17	the	O
18	O6meG	O
19	.	O
20	N	O
21	12	O
22	-	O
23	mer	O
24	helix	O
25	,	O
26	which	O
27	are	O
28	associated	O
29	with	O
30	the	O
31	modification	O
32	site	O
33	,	O
34	resonate	O
35	at	O
36	unusually	O
37	high	O
38	field	O
39	(	O
40	8	O
41	.	O
42	5	O
43	to	O
44	9	O
45	.	O
46	0	O
47	ppm	O
48	)	O
49	compared	O
50	to	O
51	imino	O
52	protons	O
53	in	O
54	Watson	O
55	-	O
56	Crick	O
57	base	O
58	pairs	O
59	(	O
60	12	O
61	.	O
62	5	O
63	to	O
64	14	O
65	.	O
66	5	O
67	ppm	O
68	).	O

1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	B
16	and	I
17	serum	I
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	O
16	and	O
17	serum	B
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	Gains	O
2	increased	O
3	3	O
4	.	O
5	5	O
6	%	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	10	O
13	)	O
14	and	O
15	feed	O
16	conversion	O
17	improved	O
18	5	O
19	.	O
20	9	O
21	%	O
22	(	O
23	P	O
24	less	O
25	than	O
26	.	O
27	07	O
28	)	O
29	in	O
30	steers	O
31	fed	O
32	.	O
33	28	O
34	%	O
35	AS	O
36	-	O
37	VFA	O
38	compared	O
39	with	O
40	gain	O
41	and	O
42	feed	O
43	conversion	O
44	of	O
45	the	O
46	control	O
47	steers	O
48	.	O

1	Postnatal	O
2	volumetric	O
3	development	O
4	of	O
5	the	O
6	prefrontal	O
7	cortex	O
8	in	O
9	the	O
10	rat	O
11	.	O

1	Daily	O
2	and	O
3	seasonal	O
4	rhythmicity	O
5	in	O
6	the	O
7	methylation	O
8	of	O
9	pineal	O
10	indolic	O
11	compounds	O
12	in	O
13	adult	O
14	male	O
15	golden	O
16	hamsters	O
17	,	O
18	kept	O
19	under	O
20	natural	O
21	conditions	O
22	.	O

1	The	O
2	transit	O
3	time	O
4	was	O
5	significantly	O
6	shortened	O
7	.	O

1	Among	O
2	the	O
3	patients	O
4	grades	O
5	1	O
6	-	O
7	2	O
8	-	O
9	3	O
10	,	O
11	81	O
12	%	O
13	had	O
14	a	O
15	good	O
16	out	O
17	come	O
18	without	O
19	any	O
20	neurological	O
21	abnormality	O
22	,	O
23	among	O
24	the	O
25	patients	O
26	graded	O
27	4	O
28	-	O
29	5	O
30	,	O
31	only	O
32	27	O
33	%	O
34	had	O
35	a	O
36	fair	O
37	out	O
38	come	O
39	.	O

1	Activity	O
2	of	O
3	acid	B
4	hydrolases	I
5	of	O
6	peripheral	O
7	blood	O
8	leukocytes	O
9	in	O
10	focal	O
11	and	O
12	segmental	O
13	pneumonia	O
14	in	O
15	children	O

1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	the	O
6	predictive	O
7	ability	O
8	of	O
9	the	O
10	selected	O
11	attitudes	O
12	and	O
13	orientations	O
14	increased	O
15	considerably	O
16	from	O
17	1975	O
18	to	O
19	1982	O
20	.	O

1	Relations	O
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	O
7	cardiac	O
8	mechanical	O
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O

1	Treatment	O
2	of	O
3	Paget	O
4	'	O
5	s	O
6	disease	O
7	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	O
9	subjects	O
10	.	O

1	Experiences	O
2	with	O
3	the	O
4	clinical	O
5	and	O
6	experimental	O
7	use	O
8	of	O
9	Urat	O
10	-	O
11	I	O
12	lithotriptor	O
13	.	O

1	Formation	O
2	of	O
3	hyphae	O
4	and	O
5	chlamydospores	O
6	by	O
7	Cryptococcus	O
8	laurentii	O
9	.	O

1	Evaluation	O
2	of	O
3	thyroid	O
4	function	O
5	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	tissue	O
6	emulsion	O
7	,	O
8	vitamin	O
9	A	O
10	and	O
11	nonspecific	O
12	gamma	B
13	-	I
14	globulin	I
15	on	O
16	the	O
17	blood	O
18	clearance	O
19	in	O
20	rabbits	O

1	HL	B
2	-	I
3	A	I
4	antibodies	I
5	in	O
6	polytransfused	O
7	patients	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	O
7	guinea	O
8	pig	O
9	organ	O
10	of	O
11	Corti	O
12	after	O
13	electron	O
14	microscopic	O
15	silver	O
16	staining	O

1	Histamine	O
2	metabolism	O
3	in	O
4	hemorrhagic	O
5	-	O
6	hypotensive	O
7	shock	O

1	They	O
2	also	O
3	discuss	O
4	the	O
5	existing	O
6	nomenclature	O
7	.	O

1	Relaxation	O
2	of	O
3	catch	O
4	in	O
5	a	O
6	molluscan	O
7	smooth	O
8	muscle	O
9	.	O

1	Studies	O
2	on	O
3	alcoholic	O
4	liver	O
5	injury	O
6	.	O

1	Hypothalamic	O
2	control	O
3	of	O
4	coronary	O
5	circulation	O
6	in	O
7	the	O
8	dog	O
9	.	O

1	Evidence	O
2	for	O
3	two	O
4	distinctive	O
5	clinical	O
6	,	O
7	epidemiological	O
8	,	O
9	and	O
10	immunological	O
11	types	O
12	of	O
13	infection	O
14	.	O

1	Ultraviolet	O
2	light	O
3	-	O
4	induced	O
5	kinin	B
6	formation	O
7	in	O
8	human	O
9	skin	O
10	.	O

1	Poliomyelitis	O
2	from	O
3	a	O
4	vaccine	O
5	.	O

1	To	O
2	the	O
3	problem	O
4	of	O
5	the	O
6	stimulation	O
7	of	O
8	the	O
9	growth	O
10	of	O
11	transplantable	O
12	tumors	O
13	of	O
14	animals	O
15	previously	O
16	treated	O
17	with	O
18	antineoplastic	O
19	antibiotics	O

1	Assessment	O
2	of	O
3	nutrient	O
4	media	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	diptheria	O

1	Aluminium	O
2	resin	O
3	for	O
4	the	O
5	treatment	O
6	of	O
7	the	O
8	hyperkalamia	O
9	of	O
10	renal	O
11	failure	O
12	.	O

1	Value	O
2	of	O
3	the	O
4	EMG	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	a	O
10	cardiomyopathy	O
11	associated	O
12	with	O
13	a	O
14	myotonic	O
15	myopathy	O
16	.	O

1	D	O
2	.	O

1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	B
8	-	I
9	Rh	I
10	immune	I
11	globulin	I
12	.	O

1	Serotonin	O
2	levels	O
3	in	O
4	infant	O
5	hypothyroidism	O
6	.	O

1	Cerebrospinal	O
2	fluid	O
3	transferrin	B
4	II	I
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	High	O
2	dosages	O
3	of	O
4	D	O
5	-	O
6	penicillamine	O
7	in	O
8	pulmonary	O
9	fibroses	O

1	Inverse	O
2	relation	O
3	between	O
4	serum	O
5	IgG	B
6	concentration	O
7	and	O
8	glucose	O
9	and	O
10	xylose	O
11	absorption	O
12	in	O
13	Zambian	O
14	African	O
15	adults	O
16	.	O

1	Disorders	O
2	of	O
3	platelet	O
4	function	O
5	in	O
6	chronic	O
7	myeloid	O
8	leukemias	O

1	The	O
2	effect	O
3	of	O
4	anticonvulsants	O
5	on	O
6	sodium	B
7	-	I
8	potassium	I
9	-	I
10	activated	I
11	ATPase	I
12	,	O
13	sodium	O
14	,	O
15	and	O
16	potassim	O
17	in	O
18	cortex	O
19	.	O

1	Effect	O
2	of	O
3	immune	O
4	lymphocytes	O
5	and	O
6	of	O
7	rabbit	B
8	-	I
9	anti	I
10	-	I
11	lymphocyte	I
12	globulin	I
13	(	O
14	RAMLG	B
15	)	O
16	on	O
17	infected	O
18	macrophages	O
19	exposed	O
20	to	O
21	increased	O
22	incubation	O
23	temperature	O
24	in	O
25	vitro	O
26	.	O

1	Estral	O
2	cycle	O
3	in	O
4	white	O
5	rats	O
6	in	O
7	the	O
8	low	O
9	and	O
10	high	O
11	mountains	O
12	of	O
13	Kirghizia	O

1	Lactation	O
2	of	O
3	baboons	O
4	fed	O
5	a	O
6	low	O
7	protein	O
8	maintenance	O
9	diet	O
10	.	O

1	Studies	O
2	on	O
3	the	O
4	organic	O
5	matrix	O
6	of	O
7	human	O
8	ear	O
9	ossicles	O

1	A	O
2	medical	O
3	-	O
4	geographical	O
5	review	O

1	Age	O
2	and	O
3	sex	O
4	structure	O
5	of	O
6	the	O
7	natural	O
8	population	O
9	of	O
10	Ornithodoros	O
11	tatarovski	O
12	Ol	O
13	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	Vitamin	O
2	D3	O
3	and	O
4	calcium	O
5	absorption	O
6	in	O
7	the	O
8	chick	O
9	.	O

1	The	O
2	incidence	O
3	of	O
4	tumours	O
5	in	O
6	young	O
7	chickens	O
8	.	O

1	Laboratory	O
2	aspects	O
3	with	O
4	particular	O
5	reference	O
6	to	O
7	chemotherapy	O
8	and	O
9	control	O
10	.	O

1	Their	O
2	effect	O
3	on	O
4	the	O
5	guinea	O
6	pig	O
7	vas	O
8	deferens	O
9	.	O

1	Androgens	O
2	and	O
3	growth	O
4	.	O

1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O

1	Therapeutic	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	corticoid	O
9	association	O
10	used	O
11	for	O
12	instillations	O
13	in	O
14	otology	O

1	Clinico	O
2	-	O
3	physiological	O
4	experiment	O

1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	O

1	Familial	O
2	glutathione	B
3	reductase	I
4	deficiency	O
5	and	O
6	disorder	O
7	of	O
8	glutathione	O
9	synthesis	O
10	in	O
11	the	O
12	erythrocyte	O

1	Studies	O
2	on	O
3	swine	O
4	enteroviruses	O
5	.	O

1	Serodiagnosis	O
2	of	O
3	ectromelia	O
4	in	O
5	laboratory	O
6	mice	O

1	Ultrasound	O
2	effect	O
3	on	O
4	the	O
5	cytochrome	B
6	oxidase	I
7	activity	O

1	Metastasis	O
2	of	O
3	colon	O
4	carcinoma	O
5	to	O
6	the	O
7	lip	O
8	.	O

1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O

1	Pre	B
2	-	I
3	beta	I
4	-	I
5	1	I
6	lipoprotein	I
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O

1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	B
7	-	I
8	stimulating	I
9	factor	I
10	(	O
11	CSF	B
12	).	O

1	Absence	O
2	of	O
3	action	O
4	potentials	O
5	in	O
6	frog	O
7	slow	O
8	muscle	O
9	fibres	O
10	paralysed	O
11	by	O
12	botulinum	B
13	toxin	I
14	.	O

1	An	O
2	automated	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	the	O
10	polyamines	O
11	putrescine	O
12	,	O
13	spermidine	O
14	and	O
15	spermine	O
16	in	O
17	cerebrospinal	O
18	fluid	O
19	(	O
20	CSF	O
21	)	O
22	was	O
23	used	O
24	to	O
25	analyze	O
26	CSF	O
27	samples	O
28	from	O
29	37	O
30	patients	O
31	with	O
32	central	O
33	nervous	O
34	system	O
35	(	O
36	CNS	O
37	)	O
38	tumors	O
39	and	O
40	from	O
41	13	O
42	patients	O
43	without	O
44	tumors	O
45	.	O

1	I	O
2	.	O

1	Disulfiram	O
2	and	O
3	the	O
4	drug	O
5	-	O
6	induced	O
7	effects	O
8	on	O
9	motility	O
10	.	O

1	Particles	O
2	resembling	O
3	microbodies	O
4	in	O
5	normal	O
6	and	O
7	neoplastic	O
8	perianal	O
9	glands	O
10	of	O
11	dogs	O
12	.	O

1	Natural	O
2	and	O
3	induced	O
4	malarias	O
5	in	O
6	western	O
7	hemisphere	O
8	monkeys	O
9	.	O

1	A	O
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	B
7	receptors	I
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O

1	Intracranial	O
2	arachnoid	O
3	cyst	O
4	of	O
5	the	O
6	middle	O
7	fossa	O
8	demonstrated	O
9	by	O
10	positive	O
11	99mTc	O
12	brainscintigraphy	O
13	.	O

1	Effects	O
2	of	O
3	estrogen	O
4	and	O
5	glucocorticoids	O
6	on	O
7	the	O
8	adrenal	O
9	development	O
10	of	O
11	the	O
12	fetus	O
13	.	O

1	Copper	O
2	and	O
3	ceruloplasmin	B
4	content	O
5	in	O
6	pregnant	O
7	women	O
8	and	O
9	in	O
10	women	O
11	with	O
12	certain	O
13	gynecological	O
14	diseases	O

1	Effect	O
2	of	O
3	noise	O
4	on	O
5	CO	O
6	-	O
7	induced	O
8	increases	O
9	of	O
10	LAP	B
11	and	O
12	GPT	B
13	activity	O
14	in	O
15	the	O
16	plasma	O
17	of	O
18	rats	O

1	Kinetics	O
2	of	O
3	calcium	O
4	metabolism	O
5	.	O

1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O

1	A	O
2	hydrodynamic	O
3	description	O
4	of	O
5	the	O
6	osmotic	O
7	reflection	O
8	coefficient	O
9	with	O
10	application	O
11	to	O
12	the	O
13	pore	O
14	theory	O
15	of	O
16	transcapillary	O
17	exchange	O
18	.	O

1	Pathology	O
2	of	O
3	neuritis	O
4	caudae	O
5	equinae	O
6	in	O
7	the	O
8	horse	O

1	Abnormal	O
2	characteristics	O
3	and	O
4	verticillation	O
5	in	O
6	Platynothrus	O
7	peltifer	O

1	Selected	O
2	topics	O
3	in	O
4	laboratory	O
5	animal	O
6	medicine	O
7	.	O

1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	O

1	Clinical	O
2	course	O
3	and	O
4	nursing	O
5	care	O
6	of	O
7	patients	O
8	with	O
9	decubitus	O
10	ulcer	O
11	--	O
12	use	O
13	of	O
14	pillows	O
15	stuffed	O
16	with	O
17	buckwheat	O
18	chaff	O

1	On	O
2	parents	O

1	From	O
2	the	O
3	Icelandic	O
4	Red	O
5	Cross	O
6	activities	O

1	Effects	O
2	of	O
3	alcoholism	O
4	on	O
5	the	O
6	family	O

1	Treatment	O
2	and	O
3	care	O
4	of	O
5	adult	O
6	diabetes	O
7	mellitus	O
8	without	O
9	coma	O

1	Re	O
2	-	O
3	examining	O
4	methylbenzene	O
5	(	O
6	toluene	O
7	)	O
8	as	O
9	a	O
10	treatment	O
11	for	O
12	Ancylostomum	O
13	caninum	O
14	.	O

1	Junctions	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O

1	Electrocardiograms	O
2	of	O
3	the	O
4	month	O
5	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	Hodgkin	O
2	'	O
3	s	O
4	disease	O
5	.	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	I
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	Glutathione	B
2	peroxidase	I
3	in	O
4	human	O
5	red	O
6	cells	O
7	in	O
8	health	O
9	and	O
10	disease	O
11	.	O

1	Histopathologic	O
2	response	O
3	of	O
4	gingival	O
5	tissues	O
6	to	O
7	hemodent	O
8	and	O
9	aluminum	O
10	chloride	O
11	solutions	O
12	as	O
13	tissue	O
14	displacement	O
15	materials	O
16	.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	Intracellular	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	flux	O
7	and	O
8	H	O
9	ion	O
10	permeability	O
11	coefficient	O
12	in	O
13	bullfrog	O
14	toe	O
15	muscle	O
16	.	O

1	Teratological	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	837	O
7	.	O

1	Directives	O
2	concerning	O
3	medical	O
4	care	O

1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O

1	Method	O
2	of	O
3	synthesis	O
4	of	O
5	the	O
6	rheumatoid	B
7	factor	I
8	in	O
9	clinico	O
10	-	O
11	immunological	O
12	studies	O

1	Variations	O
2	of	O
3	the	O
4	timing	O
5	of	O
6	deflections	O
7	in	O
8	the	O
9	His	O
10	bundle	O
11	recordings	O
12	.	O

1	Extracellular	O
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	Blood	O
2	platelets	O
3	,	O
4	coagulation	O
5	factors	O
6	and	O
7	morphologic	O
8	organ	O
9	changes	O
10	following	O
11	scalding	O
12	shock	O
13	in	O
14	rhesus	O
15	monkeys	O

1	Cell	O
2	viability	O
3	and	O
4	lysosomal	B
5	enzymes	I

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	--	O
8	R	O
9	.	O
10	N	O
11	.,	O
12	1972	O
13	.	O

1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	B
9	hormone	I
10	on	O
11	lymphocytes	O

1	1	O
2	,	O
3	3	O
4	-	O
5	bis	O
6	(	O
7	2	O
8	-	O
9	chloroethyl	O
10	)-	O
11	1	O
12	-	O
13	nitrosourea	O
14	(	O
15	bcnu	O
16	)	O
17	and	O
18	other	O
19	nitrosoureas	O
20	in	O
21	cancer	O
22	treatment	O
23	:	O
24	a	O
25	review	O
26	.	O

1	Pneumothorax	O
2	following	O
3	lung	O
4	abscess	O
5	in	O
6	the	O
7	renal	O
8	transplant	O
9	patient	O
10	.	O

1	Taxonomically	O
2	significant	O
3	colour	O
4	changes	O
5	in	O
6	Brevibacterium	O
7	linens	O
8	probably	O
9	associated	O
10	with	O
11	a	O
12	carotenoid	O
13	-	O
14	like	O
15	pigment	O
16	.	O

1	Temporal	O
2	relationships	O
3	and	O
4	the	O
5	development	O
6	phase	O
7	affected	O
8	.	O

1	A	O
2	short	O
3	history	O
4	of	O
5	dermatology	O
6	in	O
7	Lagos	O
8	,	O
9	Nigeria	O
10	.	O

1	Local	O
2	graft	O
3	irradiation	O
4	as	O
5	an	O
6	adjunct	O
7	to	O
8	pharmacologic	O
9	immunosuppression	O
10	.	O

1	Letter	O
2	:	O
3	Salmonella	O
4	detection	O

1	Role	O
2	of	O
3	biocenosis	O
4	in	O
5	the	O
6	manifestation	O
7	of	O
8	Shigella	O
9	virulence	O

1	The	O
2	effect	O
3	of	O
4	antilymphocyte	O
5	sera	O
6	on	O
7	formation	O
8	of	O
9	transplantation	O
10	and	O
11	anti	O
12	-	O
13	infection	O
14	immunity	O
15	in	O
16	mice	O

1	60th	O
2	birthday	O
3	of	O
4	colonel	O
5	prof	O
6	.	O
7	e	O
8	.	O
9	cerny	O
10	m	O
11	.	O
12	d	O
13	.	O

1	Morphology	O
2	of	O
3	bacteriophages	O
4	of	O
5	Klebsiella	O
6	bacilli	O
7	.	O

1	Cortical	O
2	afferents	O
3	to	O
4	the	O
5	entorhinal	O
6	cortex	O
7	of	O
8	the	O
9	Rhesus	O
10	monkey	O
11	.	O

1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O

1	Resistance	O
2	pattern	O
3	of	O
4	Mycobacterium	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	Rv	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	lividomycin	O

1	Pulmonary	O
2	arterial	O
3	pressure	O
4	and	O
5	structure	O
6	in	O
7	the	O
8	patas	O
9	monkey	O
10	after	O
11	prolonged	O
12	administration	O
13	of	O
14	aminorex	O
15	fumarate	O
16	.	O

1	Effect	O
2	of	O
3	triftazin	O
4	and	O
5	aminazin	O
6	on	O
7	hippocampal	O
8	bioelectric	O
9	activity	O

1	Sex	O
2	ratio	O
3	at	O
4	birth	O
5	.	O

1	Pathological	O
2	processes	O
3	in	O
4	the	O
5	cervix	O
6	uteri	O

1	Benign	O
2	intramural	O
3	tumors	O
4	of	O
5	the	O
6	esophagus	O

1	General	O
2	formulae	O
3	for	O
4	estimating	O
5	heritability	O
6	in	O
7	a	O
8	population	O
9	with	O
10	related	O
11	parents	O
12	.	O

1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O

1	Glucose	O
2	disappearance	O
3	rate	O
4	and	O
5	changes	O
6	in	O
7	plasma	O
8	nutrients	O
9	after	O
10	intravenouly	O
11	injected	O
12	glucose	O
13	in	O
14	normoglycaemic	O
15	and	O
16	hypoglycaemic	O
17	underweight	O
18	newborns	O
19	.	O

1	Normal	O
2	values	O
3	for	O
4	the	O
5	peripheral	O
6	blood	O
7	and	O
8	bone	O
9	marrow	O
10	of	O
11	the	O
12	grey	O
13	(	O
14	Armenian	O
15	)	O
16	hamster	O

1	The	O
2	relationship	O
3	of	O
4	human	O
5	umbilical	O
6	arterial	O
7	and	O
8	venous	O
9	plasma	O
10	levels	O
11	of	O
12	corticosteroids	O
13	to	O
14	gestational	O
15	age	O
16	.	O

1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	O

1	Sulfuric	O
2	acid	O
3	concentration	O
4	in	O
5	the	O
6	catalyzed	O
7	breathalyzer	O
8	ampules	O
9	.	O

1	Role	O
2	of	O
3	histoclinical	O
4	studies	O
5	in	O
6	the	O
7	prophylaxis	O
8	of	O
9	spontaneous	O
10	abortions	O

1	Range	O
2	behavior	O
3	of	O
4	Hereford	O
5	,	O
6	Hereford	O
7	x	O
8	Holstein	O
9	and	O
10	Holstein	O
11	non	O
12	-	O
13	lactating	O
14	heifers	O
15	.	O

1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O

1	Methyl	O
2	mercury	O
3	intoxication	O
4	in	O
5	rat	O
6	kidneys	O
7	.	O

1	Microdetermination	O
2	of	O
3	adrenocortical	O
4	steroids	O
5	by	O
6	double	O
7	isotope	O
8	method	O
9	.	O

1	Compensative	O
2	justice	O
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	Effects	O
2	of	O
3	cortisone	O
4	,	O
5	starvation	O
6	,	O
7	and	O
8	rickets	O
9	on	O
10	oxidative	O
11	enzyme	O
12	activities	O
13	of	O
14	epiphyseal	O
15	cartilage	O
16	from	O
17	rats	O
18	.	O

1	Metal	O
2	coordination	O
3	compounds	O
4	of	O
5	thiabendazole	O
6	.	O

1	Estimation	O
2	of	O
3	renin	B
4	secretion	O
5	rate	O
6	and	O
7	renal	O
8	plasma	O
9	flow	O
10	from	O
11	peripheral	O
12	and	O
13	renal	B
14	vein	I
15	renin	I
16	levels	O
17	.	O

1	Disability	O
2	insurance	O
3	under	O
4	social	O
5	security	O
6	.	O

1	Choice	O
2	of	O
3	vessel	O
4	.	O

1	Suppression	O
2	of	O
3	food	O
4	intake	O
5	in	O
6	the	O
7	rat	O
8	by	O
9	tung	O
10	oil	O
11	.	O

1	Studies	O
2	of	O
3	lipoprotein	B
4	-	I
5	X	I
6	(	O
7	LP	B
8	-	I
9	X	I
10	)	O
11	and	O
12	bile	O
13	acids	O
14	in	O
15	familial	O
16	LCAT	B
17	deficiency	O
18	.	O

1	Pneumothorax	O
2	complicated	O
3	by	O
4	chronic	O
5	steroid	O
6	treatment	O
7	.	O

1	Polycythemia	O
2	-	O
3	1973	O
4	.	O

1	Manifest	O
2	anxiety	O
3	of	O
4	Vietnam	O
5	returnees	O
6	and	O
7	undergraduates	O
8	.	O

1	Familial	O
2	juvenile	O
3	nephronophthisis	O

1	Early	O
2	heparin	O
3	therapy	O
4	in	O
5	60	O
6	children	O
7	with	O
8	acute	O
9	meningococcemia	O
10	.	O

1	9	O
2	,	O
3	11	O
4	-	O
5	Seco	O
6	steroids	O
7	derived	O
8	from	O
9	estradiol	O
10	3	O
11	-	O
12	methyl	O
13	ether	O
14	.	O

1	Psychological	O
2	examinations	O
3	in	O
4	patients	O
5	with	O
6	chronic	O
7	kidney	O
8	insufficiency	O

1	Possibilities	O
2	of	O
3	needleless	O
4	administration	O
5	of	O
6	various	O
7	substances	O
8	to	O
9	animals	O

1	Change	O
2	in	O
3	the	O
4	makeup	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	permanent	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O

1	Observations	O
2	on	O
3	the	O
4	flight	O
5	activities	O
6	of	O
7	Chrysops	O
8	caecutiens	O
9	L	O
10	.	O

1	Combination	O
2	of	O
3	3	O
4	multiple	O
5	primary	O
6	malignant	O
7	and	O
8	benign	O
9	tumors	O
10	of	O
11	the	O
12	breasts	O
13	and	O
14	uterus	O

1	Analysis	O
2	of	O
3	clearance	O
4	curve	O
5	of	O
6	rose	O
7	bengal	O
8	-	O
9	I	O
10	-	O
11	131	O

1	Proceedings	O
2	:	O
3	Barrels	O
4	and	O
5	somatotopy	O
6	in	O
7	S	O
8	I	O
9	neocortex	O
10	of	O
11	the	O
12	brush	O
13	-	O
14	tailed	O
15	possum	O
16	.	O

1	Antivitamin	O
2	K	O
3	agents	O

1	Canine	O
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O

1	3	O
2	.	O

1	Hypoglycemic	O
2	and	O
3	antidiabetic	O
4	properties	O

1	Hematopoietic	O
2	system	O
3	in	O
4	streptococcal	O
5	allergy	O
6	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	Evaluation	O
2	of	O
3	1	O
4	,	O
5	10	O
6	-	O
7	phenanthroline	O
8	as	O
9	a	O
10	reagent	O
11	for	O
12	sialic	O
13	acid	O
14	determinations	O
15	.	O

1	Delta	O
2	-	O
3	aminolevulinic	O
4	acid	O
5	in	O
6	physiological	O
7	conditions	O
8	and	O
9	some	O
10	diseases	O
11	in	O
12	children	O

1	Nonteratogenicity	O
2	in	O
3	rats	O
4	of	O
5	blighted	O
6	potatoes	O
7	and	O
8	compounds	O
9	contained	O
10	in	O
11	them	O
12	.	O

1	VII	O
2	.	O

1	Isolation	O
2	of	O
3	tha	O
4	avian	O
5	reticuloendothelial	O
6	virus	O
7	(	O
8	strain	O
9	T	O
10	).	O

1	Observations	O
2	on	O
3	saccules	O
4	of	O
5	rats	O
6	exposed	O
7	to	O
8	long	O
9	-	O
10	term	O
11	hypergravity	O
12	.	O

1	Effect	O
2	of	O
3	a	O
4	high	O
5	-	O
6	intensity	O
7	SHF	O
8	field	O
9	on	O
10	the	O
11	blood	O
12	coagulation	O
13	system	O

1	The	O
2	levels	O
3	of	O
4	galactosyltransferase	B
5	activity	O
6	in	O
7	sera	O
8	from	O
9	normal	O
10	children	O
11	and	O
12	patients	O
13	with	O
14	cystic	O
15	fibrosis	O
16	.	O

1	Lack	O
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	O
11	105	O
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O

1	Relationship	O
2	between	O
3	gross	O
4	lesions	O
5	and	O
6	Escherichia	O
7	coli	O
8	serotypes	O
9	in	O
10	chronic	O
11	respiratory	O
12	disease	O
13	(	O
14	CRD	O
15	)	O
16	of	O
17	poultry	O
18	.	O

1	Plastic	O
2	solution	O
3	of	O
4	elbow	O
5	joint	O
6	ankylosis	O
7	with	O
8	a	O
9	decorticated	O
10	cylindrical	O
11	flap	O

1	Effects	O
2	of	O
3	ionizing	O
4	radiation	O
5	in	O
6	the	O
7	human	O
8	oral	O
9	cavity	O
10	and	O
11	oropharynx	O
12	:	O
13	results	O
14	of	O
15	a	O
16	survey	O
17	.	O

1	The	O
2	Twentieth	O
3	Anniversary	O
4	of	O
5	the	O
6	Pomeranian	O
7	Medical	O
8	Academy	O
9	.	O

1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	B
14	and	O
15	FTA	B
16	antibodies	I

1	Motile	O
2	nocardoid	O
3	Actinomycetales	O
4	.	O

1	Electrocardiographic	O
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	Study	O
2	of	O
3	antinuclear	O
4	autoantibodies	O
5	by	O
6	immunofluorescence	O
7	technic	O
8	in	O
9	collagen	B
10	diseases	O

1	Cardiac	O
2	preservation	O
3	.	O

1	Labial	O
2	bar	O
3	.	O

1	Yusuf	O
2	Dawood	O
3	Docrat	O
4	L	O
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O

1	Dr	O
2	.	O

1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O

1	Spleen	O
2	weight	O
3	in	O
4	rats	O
5	during	O
6	tumour	O
7	growth	O
8	and	O
9	in	O
10	homograft	O
11	rejection	O
12	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	Human	O
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O

1	Effects	O
2	of	O
3	temperature	O
4	and	O
5	moulting	O
6	cycle	O
7	on	O
8	melanin	O
9	synthesis	O
10	in	O
11	the	O
12	newt	O
13	,	O
14	Triturus	O
15	cristatus	O
16	.	O

1	Some	O
2	reflexions	O
3	apropos	O
4	of	O
5	a	O
6	personal	O
7	statistical	O
8	study	O
9	of	O
10	513	O
11	arterial	O
12	embolisms	O

1	LA	O
2	-	O
3	3848	O
4	-	O
5	MS	O
6	.	O

1	Immunochemical	O
2	studies	O
3	with	O
4	filarial	O
5	antigens	O
6	.	O

1	Morphological	O
2	and	O
3	functional	O
4	alterations	O
5	noted	O
6	after	O
7	baboon	O
8	renal	O
9	allotransplantation	O
10	.	O

1	Heterogeneity	O
2	of	O
3	human	B
4	serum	I
5	albumin	I
6	.	O

1	Analysis	O
2	of	O
3	corticosteroids	O
4	.	O

1	Reactivities	O
2	to	O
3	horse	B
4	anti	I
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O

1	Plasma	B
2	histaminase	I
3	in	O
4	patients	O
5	of	O
6	bronchial	O
7	asthma	O
8	and	O
9	the	O
10	effect	O
11	of	O
12	prednisolone	O
13	administration	O
14	on	O
15	it	O
16	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	cortical	O
7	end	O
8	of	O
9	the	O
10	auditory	O
11	analyzer	O
12	during	O
13	postnatal	O
14	ontogenesis	O
15	in	O
16	lower	O
17	monkeys	O
18	and	O
19	man	O

1	The	O
2	effect	O
3	of	O
4	osmotic	O
5	flow	O
6	on	O
7	the	O
8	distribution	O
9	of	O
10	horseradish	B
11	peroxidase	I
12	within	O
13	the	O
14	intercellular	O
15	spaces	O
16	of	O
17	toad	O
18	bladder	O
19	epithelium	O
20	.	O

1	Immunogenicity	O
2	of	O
3	various	O
4	mycobacteria	O
5	and	O
6	the	O
7	corresponding	O
8	levels	O
9	of	O
10	cross	O
11	-	O
12	protection	O
13	developed	O
14	between	O
15	species	O
16	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	Nitrogen	O
2	-	O
3	hydrogen	O
4	tautomerism	O
5	in	O
6	porphyrins	O
7	and	O
8	chlorins	O
9	.	O

1	Factors	O
2	affecting	O
3	the	O
4	inhibition	O
5	of	O
6	phagocytosis	O
7	by	O
8	chlorpromazine	O
9	.	O

1	Photopic	O
2	spectral	O
3	sensitivity	O
4	determined	O
5	electroretinographically	O
6	for	O
7	the	O
8	pigeon	O
9	eye	O
10	.	O

1	Angiography	O
2	of	O
3	aneurysmal	O
4	bone	O
5	cyst	O
6	.	O

1	Cholinesterase	B

1	Sodium	O
2	restriction	O
3	in	O
4	cardiac	O
5	failure	O
6	.	O

1	Clinical	O
2	and	O
3	angiographic	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O

1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	Successful	O
2	treatment	O
3	of	O
4	candidiasis	O
5	with	O
6	transfer	B
7	factor	I
8	.	O

1	A	O
2	possible	O
3	role	O
4	for	O
5	the	O
6	mixed	O
7	function	O
8	oxidase	B
9	enzyme	O
10	system	O
11	in	O
12	the	O
13	requirement	O
14	for	O
15	selenium	O
16	in	O
17	the	O
18	rat	O
19	.	O

1	Periodic	O
2	breathing	O
3	and	O
4	apnea	O
5	in	O
6	preterm	O
7	infants	O
8	.	O

1	Working	O
2	session	O
3	report	O
4	:	O
5	in	O
6	vivo	O
7	-	O
8	in	O
9	vitro	O
10	screening	O
11	.	O

1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	On	O
2	the	O
3	constituents	O
4	of	O
5	Dryopteris	O
6	polylepis	O

1	Relation	O
2	between	O
3	mixing	O
4	ratio	O
5	of	O
6	raw	O
7	materials	O
8	and	O
9	composition	O
10	of	O
11	products	O
12	in	O
13	the	O
14	synthesis	O
15	of	O
16	aluminosilicates	O

1	Influence	O
2	of	O
3	diet	O
4	on	O
5	urinary	O
6	VMA	O
7	excretion	O
8	.	O

1	Oscilloscope	O
2	triggering	O
3	circuit	O
4	for	O
5	recording	O
6	long	O
7	transients	O
8	at	O
9	fast	O
10	sweep	O
11	speeds	O
12	.	O

1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O

1	The	O
2	status	O
3	of	O
4	education	O
5	and	O
6	training	O
7	programs	O
8	in	O
9	speech	O
10	pathology	O
11	and	O
12	audiology	O
13	--	O
14	1971	O
15	-	O
16	72	O
17	.	O

1	Coronary	O
2	arteries	O
3	--	O
4	old	O
5	and	O
6	new	O
7	.	O

1	Antiviral	O
2	agents	O
3	.	O

1	Separation	O
2	of	O
3	ninhydrin	O
4	-	O
5	positive	O
6	compounds	O
7	in	O
8	urine	O
9	by	O
10	the	O
11	combined	O
12	methods	O
13	of	O
14	medium	O
15	-	O
16	tension	O
17	intophoresis	O
18	and	O
19	partition	O
20	chromatography	O

1	Conservative	O
2	treatment	O
3	of	O
4	central	O
5	nervous	O
6	system	O
7	injuries	O

1	Spasmus	O
2	nutans	O
3	:	O
4	a	O
5	syndrome	O
6	of	O
7	auto	O
8	-	O
9	arousal	O
10	.	O

1	6	O
2	.	O

1	1st	O
2	data	O
3	on	O
4	the	O
5	immunosuppressive	O
6	therapy	O
7	of	O
8	scleroderma	O

1	Slowed	O
2	lysosomal	B
3	enzyme	I
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	Treatment	O
2	of	O
3	ovarian	O
4	neoplasms	O

1	Experimental	O
2	pancreatitis	O
3	in	O
4	pigs	O
5	.	O

1	Bacterial	O
2	metabolism	O
3	of	O
4	4	O
5	-	O
6	chlorophenoxyacetate	O
7	.	O

1	Dynamics	O
2	of	O
3	hospital	O
4	stay	O
5	in	O
6	peptic	O
7	ulcer	O
8	patients	O

1	I	O
2	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pathologic	O
5	scars	O
6	of	O
7	myocardial	O
8	infarct	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	B
11	oxidase	I
12	inhibitors	O
13	.	O

1	Effect	O
2	of	O
3	phenformin	O
4	on	O
5	gluconeogenesis	O
6	in	O
7	perfused	O
8	rat	O
9	liver	O
10	.	O

1	New	O
2	alkaloids	O
3	from	O
4	bark	O
5	of	O
6	Erythrophleum	O
7	ivorense	O
8	.	O

1	A	O
2	case	O
3	of	O
4	M	O
5	hemoglobinosis	O

1	Radiosensitive	O
2	nature	O
3	of	O
4	paravascular	O
5	infiltrate	O
6	-	O
7	producing	O
8	potential	O
9	of	O
10	parental	O
11	spleen	O
12	cells	O
13	.	O

1	Sinusoidal	O
2	oscillations	O
3	of	O
4	a	O
5	gas	O
6	dilution	O
7	indicator	O

1	The	O
2	value	O
3	of	O
4	different	O
5	sources	O
6	of	O
7	nitrogen	O
8	in	O
9	diets	O
10	for	O
11	the	O
12	early	O
13	-	O
14	weaned	O
15	calf	O
16	.	O

1	1	O
2	.	O

1	Abdominal	O
2	tumors	O
3	in	O
4	childhood	O
5	.	O

1	Results	O
2	of	O
3	the	O
4	official	O
5	inspection	O
6	of	O
7	the	O
8	commercial	O
9	anti	O
10	-	O
11	inflammatory	O
12	enzyme	O
13	preparations	O
14	containing	O
15	chymotrypsin	B
16	and	O
17	trypsin	B
18	by	O
19	means	O
20	of	O
21	modified	O
22	NF	O
23	13	O
24	methods	O

1	Studies	O
2	on	O
3	the	O
4	hereditary	O
5	nature	O
6	of	O
7	sole	O
8	prints	O
9	--	O
10	with	O
11	special	O
12	reference	O
13	to	O
14	interdigital	O
15	and	O
16	triradii	O

1	The	O
2	problem	O
3	of	O
4	disablement	O
5	due	O
6	to	O
7	pulmonary	O
8	tuberculosis	O
9	,	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	an	O
15	analysis	O
16	of	O
17	the	O
18	history	O
19	of	O
20	395	O
21	cases	O
22	as	O
23	observed	O
24	in	O
25	Gdansk	O
26	in	O
27	the	O
28	years	O
29	1946	O
30	-	O
31	1965	O

1	Cleidocranial	O
2	dysostosis	O

1	Proposals	O
2	on	O
3	authorization	O
4	;	O
5	by	O
6	a	O
7	group	O
8	of	O
9	nurses	O
10	from	O
11	psychiatric	O
12	hospitals	O

1	Successive	O
2	abdominal	O
3	scintillation	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	BSP	O
11	--	O
12	description	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	O
29	)	O

1	Pneumonia	O
2	in	O
3	children	O

1	Osteosarcoma	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	benzopyrene	O

1	The	O
2	content	O
3	of	O
4	glucosamine	O
5	and	O
6	galactosamine	O
7	in	O
8	tartar	O

1	Relapse	O
2	of	O
3	leukemia	O
4	after	O
5	prolonged	O
6	remission	O
7	.	O

1	Influence	O
2	of	O
3	cigarette	O
4	smoking	O
5	on	O
6	some	O
7	blood	O
8	coagulation	O
9	tests	O
10	.	O

1	The	O
2	non	O
3	-	O
4	role	O
5	of	O
6	fluoride	O
7	in	O
8	the	O
9	control	O
10	of	O
11	plasma	O
12	calcium	O
13	in	O
14	the	O
15	parathyroidectomized	O
16	rat	O
17	.	O

1	Second	O
2	report	O
3	of	O
4	the	O
5	Norwegian	O
6	Cancer	O
7	Society	O
8	.	O

1	Modification	O
2	of	O
3	the	O
4	growth	O
5	of	O
6	Tetrahymena	O
7	by	O
8	compounds	O
9	which	O
10	affect	O
11	the	O
12	adrenergic	O
13	mechanism	O
14	.	O

1	SAM	O
2	-	O
3	TR	O
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O

1	A	O
2	brief	O
3	discussion	O
4	of	O
5	color	O
6	deficiencies	O
7	.	O

1	BIM	O
2	130	O
3	.	O

1	Problems	O
2	in	O
3	the	O
4	determination	O
5	of	O
6	the	O
7	antigenic	O
8	content	O
9	of	O
10	influenza	O
11	vaccines	O
12	.	O

1	Aedes	O
2	aegypti	O
3	(	O
4	L	O
5	.)	O
6	and	O
7	Aedes	O
8	albopictus	O
9	(	O
10	Skuse	O
11	)	O
12	in	O
13	Singapore	O
14	City	O
15	.	O

1	Homograft	O
2	response	O
3	and	O
4	hemagglutinin	B
5	production	O
6	by	O
7	sensitized	O
8	thymectomized	O
9	irradiated	O
10	adult	O
11	mice	O
12	.	O

1	Comparative	O
2	study	O
3	on	O
4	acute	O
5	oral	O
6	overload	O
7	using	O
8	tolbutamide	O
9	and	O
10	tolazamide	O
11	in	O
12	normal	O
13	and	O
14	diabetic	O
15	subjects	O
16	.	O

1	Mycotoxins	O
2	in	O
3	feeds	O
4	and	O
5	foods	O
6	.	O

1	Factors	O
2	influencing	O
3	in	O
4	vitro	O
5	skin	B
6	permeability	I
7	factor	I
8	production	O
9	by	O
10	Vibrio	O
11	cholerae	O
12	.	O

1	Spinal	O
2	cord	O
3	representation	O
4	of	O
5	the	O
6	micturition	O
7	reflex	O
8	.	O

1	Biological	O
2	action	O
3	and	O
4	kinetics	O
5	of	O
6	the	O
7	elimination	O
8	of	O
9	tritium	O
10	oxide	O
11	in	O
12	dogs	O

1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O

1	IX	O
2	.	O

1	Pitfalls	O
2	in	O
3	the	O
4	use	O
5	of	O
6	chromosome	O
7	aberration	O
8	analysis	O
9	for	O
10	biological	O
11	radiation	O
12	dosimetry	O
13	.	O

1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O

1	The	O
2	need	O
3	for	O
4	including	O
5	forensic	O
6	medical	O
7	expertise	O
8	in	O
9	the	O
10	list	O
11	of	O
12	urgent	O
13	criminal	O
14	investigative	O
15	actions	O

1	Histopathology	O
2	and	O
3	pathogenesis	O
4	of	O
5	exanthematous	O
6	viroses	O

1	CNS	O
2	effects	O
3	of	O
4	local	O
5	anesthetics	O
6	only	O
7	partially	O
8	dependent	O
9	on	O
10	biogenic	O
11	amine	O
12	mechanisms	O
13	.	O

1	Diethylene	O
2	benzene	O

1	Midge	O
2	control	O
3	in	O
4	flood	O
5	channels	O
6	.	O

1	The	O
2	effects	O
3	of	O
4	taloximine	O
5	and	O
6	aminophylline	O
7	on	O
8	isolated	O
9	human	O
10	smooth	O
11	muscle	O
12	.	O

1	The	O
2	exploratory	O
3	behaviour	O
4	in	O
5	normal	O
6	and	O
7	aggressive	O
8	mice	O
9	.	O

1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O

1	Tolerance	O
2	test	O
3	of	O
4	HB	O
5	419	O
6	in	O
7	animal	O
8	experiments	O

1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O

1	The	O
2	"	O
3	28	O
4	percent	O
5	"	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O

1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	O
11	-	O
12	phenyl	O
13	derivatives	O
14	of	O
15	5	O
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	O
24	-	O
25	benzomorphans	O
26	.	O

1	Antidromic	O
2	invasion	O
3	of	O
4	impulses	O
5	and	O
6	recurrent	O
7	collateral	O
8	inhibition	O
9	in	O
10	pyramidal	O
11	tract	O
12	neurones	O
13	.	O

1	The	O
2	distribution	O
3	of	O
4	body	O
5	fluids	O
6	following	O
7	hemorrhage	O
8	and	O
9	resuscitation	O
10	in	O
11	combat	O
12	casualties	O
13	.	O

1	Once	O
2	more	O
3	Hong	O
4	Kong	O
5	influenza	O
6	in	O
7	the	O
8	Netherlands	O

1	Early	O
2	disagnosis	O
3	of	O
4	cancer	O
5	--	O
6	50	O
7	per	O
8	cent	O
9	of	O
10	all	O
11	patients	O
12	could	O
13	be	O
14	cured	O

1	Difficulties	O
2	bound	O
3	to	O
4	measuring	O
5	of	O
6	sputum	O
7	viscosity	O

1	Lipid	O
2	concentration	O
3	and	O
4	lipase	B
5	activity	O
6	in	O
7	the	O
8	epiphysis	O
9	of	O
10	adrenalectomized	O
11	rats	O
12	consuming	O
13	food	O
14	with	O
15	different	O
16	sodium	O
17	content	O

1	Behavior	O
2	of	O
3	aspartate	B
4	aminotransferase	I
5	(	O
6	EC	B
7	2	I
8	.	I
9	6	I
10	.	I
11	1	I
12	.	I
13	1	I
14	)	O
15	and	O
16	alanine	B
17	aminotransferase	I
18	(	O
19	EC	B
20	2	I
21	.	I
22	6	I
23	.	I
24	1	I
25	.	I
26	2	I
27	)	O
28	in	O
29	rat	O
30	serum	O
31	during	O
32	the	O
33	course	O
34	of	O
35	acute	O
36	radiation	O
37	syndrome	O
38	following	O
39	whole	O
40	body	O
41	X	O
42	-	O
43	irradiation	O

1	Diminished	O
2	forearm	O
3	arteriolar	O
4	dilator	O
5	capacity	O
6	produced	O
7	by	O
8	mineralocorticoid	O
9	-	O
10	induced	O
11	salt	O
12	retention	O
13	in	O
14	man	O
15	.	O

1	Studies	O
2	on	O
3	the	O
4	pathogenicity	O
5	of	O
6	ECHO	O
7	9	O
8	(	O
9	HILL	O
10	)	O
11	virus	O
12	and	O
13	its	O
14	mutants	O
15	for	O
16	suckling	O
17	mice	O

1	Counter	O
2	-	O
3	current	O
4	heat	O
5	exchange	O
6	in	O
7	the	O
8	respiratory	O
9	passages	O
10	:	O
11	effect	O
12	on	O
13	water	O
14	and	O
15	heat	O
16	balance	O
17	.	O

1	Calibration	O
2	and	O
3	a	O
4	correction	O
5	of	O
6	blood	O
7	O2	O
8	content	O
9	measured	O
10	by	O
11	Po2	O
12	and	O
13	CO	O
14	saturation	O
15	.	O

1	Mae	O
2	West	O
3	and	O
4	the	O
5	doctor	O
6	shortage	O
7	.	O

1	Elimination	O
2	of	O
3	gamma	O
4	-	O
5	irradiation	O
6	induced	O
7	oxidation	O
8	in	O
9	aqueous	O
10	drug	O
11	preparations	O

1	The	O
2	absolute	O
3	configuration	O
4	at	O
5	C	O
6	-	O
7	2	O
8	in	O
9	monocrotalic	O
10	acid	O
11	.	O

1	Teratogenic	O
2	effects	O
3	of	O
4	actinomycin	O
5	D	O
6	in	O
7	rats	O

1	The	O
2	plasma	B
3	growth	I
4	hormone	I
5	concentration	O
6	of	O
7	the	O
8	foetal	O
9	lamb	O
10	.	O

1	Bimodal	O
2	cochlear	O
3	response	O
4	curves	O
5	in	O
6	rodents	O
7	.	O

1	A	O
2	new	O
3	hemagglutination	O
4	test	O
5	for	O
6	the	O
7	on	O
8	-	O
9	slide	O
10	assay	O
11	of	O
12	rheumatoid	B
13	factor	I

1	CO2	O
2	assimilation	O
3	by	O
4	chloroplasts	O
5	illuminated	O
6	on	O
7	filter	O
8	paper	O
9	.	O

1	The	O
2	biology	O
3	of	O
4	Hyostrongylus	O
5	ruidus	O
6	.	O

1	Foreign	O
2	profiles	O
3	in	O
4	air	O
5	pollution	O
6	control	O
7	activities	O
8	.	O

1	Effects	O
2	of	O
3	chronic	O
4	metaraminol	O
5	treatment	O
6	on	O
7	the	O
8	sympathetic	O
9	activity	O
10	of	O
11	intact	O
12	and	O
13	adrenal	O
14	demedullated	O
15	rats	O
16	kept	O
17	in	O
18	warm	O
19	or	O
20	cold	O
21	environments	O
22	.	O

1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	dosage	O
6	radiation	O
7	on	O
8	metabolism	O
9	and	O
10	function	O
11	of	O
12	the	O
13	rat	O
14	kidney	O
15	damaged	O
16	by	O
17	ischemia	O

1	Leukemia	O
2	in	O
3	twins	O
4	:	O
5	world	O
6	-	O
7	wide	O
8	review	O
9	of	O
10	clinical	O
11	cases	O
12	.	O

1	Preliminary	O
2	report	O
3	.	O

1	Quantitation	O
2	of	O
3	exocrine	B
4	IgA	I
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	Iodine	O
2	metabolism	O
3	in	O
4	chronic	O
5	thyroiditis	O
6	.	O

1	Total	O
2	body	O
3	water	O
4	,	O
5	rhodanide	O
6	space	O
7	and	O
8	I	B
9	-	I
10	131	I
11	-	I
12	albumin	I
13	space	O
14	under	O
15	the	O
16	acute	O
17	effect	O
18	of	O
19	furosemide	O

1	V	O
2	.	O

1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O

1	Propagation	O
2	and	O
3	hormone	O
4	production	O
5	by	O
6	human	O
7	normal	O
8	and	O
9	malignant	O
10	trophoblast	O
11	in	O
12	rats	O
13	.	O

1	Health	O
2	:	O
3	an	O
4	integrative	O
5	reticulum	O
6	.	O

1	Sensitive	O
2	fluorometric	O
3	method	O
4	of	O
5	determining	O
6	SH	O
7	-	O
8	and	O
9	S	O
10	-	O
11	S	O
12	-	O
13	groups	O
14	when	O
15	jointly	O
16	present	O

1	Morphogenesis	O
2	of	O
3	the	O
4	trochanter	O
5	produced	O
6	by	O
7	femoral	O
8	regeneration	O
9	in	O
10	the	O
11	phasmid	O
12	Carausius	O
13	morosus	O
14	Br	O

1	Behavioral	O
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	O

1	Sensitivities	O
2	of	O
3	thromboplastins	B
4	to	O
5	factor	B
6	VII	I
7	deficiency	O
8	.	O

1	3	O
2	.	O

1	Central	O
2	venous	O
3	catheter	O
4	used	O
5	for	O
6	recording	O
7	intracardiac	O
8	electrocardiogram	O
9	.	O

1	Two	O
2	Lab	O
3	8	O
4	computer	O
5	programmes	O
6	for	O
7	use	O
8	in	O
9	the	O
10	study	O
11	of	O
12	the	O
13	isometric	O
14	and	O
15	isotonic	O
16	contractile	O
17	characteristics	O
18	of	O
19	skeletal	O
20	muscle	O
21	.	O

1	Open	O
2	head	O
3	-	O
4	brain	O
5	injuries	O

1	The	O
2	modification	O
3	of	O
4	P32	O
5	uptake	O
6	into	O
7	the	O
8	Jensen	O
9	sarcoma	O
10	in	O
11	vitro	O
12	by	O
13	adding	O
14	of	O
15	peroxide	O
16	to	O
17	the	O
18	nutritive	O
19	medium	O

1	Students	O
2	,	O
3	parents	O
4	,	O
5	teachers	O
6	and	O
7	hearing	O
8	disorders	O

1	Changing	O
2	and	O
3	predicting	O
4	doses	O
5	of	O
6	Cs137	O
7	irradiation	O

1	Positive	O
2	shifts	O
3	of	O
4	basal	O
5	skin	O
6	potentials	O
7	during	O
8	human	O
9	sleep	O
10	.	O

1	Evaluating	O
2	dietary	O
3	department	O
4	management	O
5	.	O

1	5	O
2	-(	O
3	Dimethylaminopropyl	O
4	)-	O
5	19	O
6	,	O
7	11	O
8	-	O
9	dihydro	O
10	-	O
11	5H	O
12	-	O
13	benzo	O
14	[	O
15	2	O
16	,	O
17	3	O
18	]	O
19	pyrido	O
20	[	O
21	6	O
22	,	O
23	7	O
24	-	O
25	b	O
26	]	O
27	azepine	O
28	.	O

1	Osteogenesis	O
2	imperfecta	O

1	Investigation	O
2	on	O
3	the	O
4	exchange	O
5	of	O
6	Ca45	O
7	in	O
8	intact	O
9	and	O
10	burned	O
11	rats	O
12	by	O
13	the	O
14	kinetic	O
15	analysis	O
16	method	O

1	Effect	O
2	of	O
3	thrombotic	O
4	and	O
5	antithrombotic	O
6	drugs	O
7	on	O
8	the	O
9	surface	O
10	charge	O
11	characteristics	O
12	of	O
13	canine	O
14	blood	O
15	vessels	O
16	:	O
17	in	O
18	vivo	O
19	and	O
20	in	O
21	vitro	O
22	studies	O
23	.	O

1	Measurements	O
2	of	O
3	activity	O
4	with	O
5	the	O
6	radioprotective	O
7	chamber	O
8	VA	O
9	-	O
10	K	O
11	-	O
12	254	O
13	of	O
14	the	O
15	osimeter	O
16	VA	O
17	-	O
18	J18	O

1	3	O
2	-(	O
3	N	O
4	-	O
5	Alkyl	O
6	-	O
7	N	O
8	-	O
9	2	O
10	-	O
11	chloroethylaminomethyl	O
12	)-	O
13	5	O
14	-	O
15	or	O
16	7	O
17	-	O
18	halogenobenzo	O
19	[	O
20	b	O
21	]	O
22	thiophen	O
23	hydrochlorides	O
24	.	O

1	Nephrectomy	O
2	applied	O
3	to	O
4	cattle	O

1	Evaluation	O
2	of	O
3	automatic	O
4	blood	O
5	cell	O
6	counters	O
7	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	Sterols	O
2	in	O
3	pollen	O
4	.	O

1	Dermoid	O
2	cyst	O
3	in	O
4	a	O
5	free	O
6	skin	O
7	flap	O
8	as	O
9	the	O
10	complication	O
11	after	O
12	treatment	O
13	of	O
14	recurring	O
15	hernia	O

1	Histological	O
2	observations	O
3	on	O
4	the	O
5	decidua	O
6	in	O
7	the	O
8	second	O
9	half	O
10	of	O
11	pregnancy	O

1	Endocardial	O
2	fibro	O
3	-	O
4	elastosis	O
5	,	O
6	mitral	O
7	incompetence	O
8	,	O
9	and	O
10	coarctation	O
11	of	O
12	abdominal	O
13	aorta	O
14	.	O

1	Studies	O
2	on	O
3	the	O
4	method	O
5	of	O
6	size	O
7	reduction	O
8	of	O
9	medicinal	O
10	compounds	O
11	.	O

1	Children	O
2	with	O
3	defective	O
4	vision	O

1	Identification	O
2	and	O
3	estimation	O
4	of	O
5	monosaccharides	O
6	and	O
7	disaccharides	O
8	in	O
9	urine	O
10	by	O
11	gas	O
12	-	O
13	liquid	O
14	chromatography	O
15	.	O

1	Steroids	O
2	in	O
3	germfree	O
4	and	O
5	conventional	O
6	rats	O
7	.	O

1	The	O
2	effects	O
3	of	O
4	loading	O
5	the	O
6	respiratory	O
7	pumps	O
8	on	O
9	the	O
10	oxygen	O
11	consumption	O
12	of	O
13	Callionymus	O
14	lyra	O
15	.	O

1	Trials	O
2	of	O
3	sevine	O
4	activity	O
5	against	O
6	mosquito	O
7	larvae	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	constant	O
6	magnetic	O
7	field	O
8	on	O
9	the	O
10	phagocytic	O
11	activity	O
12	of	O
13	Paramecia	O

1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O

1	Relations	O
2	between	O
3	adrenergic	O
4	mechanisms	O
5	and	O
6	analgesic	O
7	effects	O

1	Transformations	O
2	in	O
3	the	O
4	morphine	O
5	series	O
6	.	O

1	Dissociative	O
2	anesthetics	O
3	2	O
4	-(	O
5	o	O
6	-	O
7	chlorophenyl	O
8	)-	O
9	2	O
10	-	O
11	methyl	O
12	-	O
13	amino	O
14	cyclohexane	O
15	HCL	O
16	(	O
17	CI	O
18	-	O
19	581	O
20	)	O

1	Estrus	O
2	and	O
3	copulative	O
4	abilities	O
5	of	O
6	androgen	O
7	-	O
8	sterilized	O
9	rats	O

1	The	O
2	bearing	O
3	of	O
4	season	O
5	and	O
6	sequence	O
7	of	O
8	calving	O
9	on	O
10	frequency	O
11	of	O
12	male	O
13	,	O
14	female	O
15	and	O
16	total	O
17	calvings	O
18	in	O
19	Hariana	O
20	cows	O
21	.	O

1	Hemodynamics	O
2	changes	O
3	in	O
4	man	O
5	during	O
6	flight	O

1	Caries	O
2	prevention	O
3	in	O
4	the	O
5	dental	O
6	office	O
7	.	O

1	I	O
2	.	O

1	Clinical	O
2	applications	O
3	of	O
4	inhibition	O
5	of	O
6	beta	B
7	-	I
8	adrenergic	I
9	receptors	I
10	with	O
11	propranolol	O
12	.	O

1	Automatic	O
2	view	O
3	box	O
4	.	O

1	Measurement	O
2	of	O
3	gastric	O
4	acid	O
5	secretion	O
6	by	O
7	conductivity	O
8	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	B
6	and	I
7	serum	I
8	LH	I
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	The	O
2	significance	O
3	of	O
4	the	O
5	phenolphthalein	B
6	sulphatase	I
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	Nocardia	O
15	species	O
16	.	O

1	Relationship	O
2	of	O
3	mast	O
4	cells	O
5	to	O
6	sarcoidosis	O
7	granuloma	O
8	of	O
9	the	O
10	skin	O

1	Long	O
2	-	O
3	term	O
4	effects	O
5	of	O
6	clofibrate	O
7	(	O
8	Atromid	O
9	-	O
10	S	O
11	)	O
12	on	O
13	serum	O
14	lipids	O
15	in	O
16	man	O
17	.	O

1	Phosphate	B
2	glucose	I
3	dehydrogenase	I
4	deficiency	O
5	causing	O
6	hyperbilirubinemia	O
7	in	O
8	the	O
9	newborn	O

1	Evidence	O
2	forthe	O
3	electroosmosis	O
4	theory	O
5	of	O
6	transport	O
7	in	O
8	the	O
9	phloem	O
10	.	O

1	Effects	O
2	of	O
3	beta	B
4	-	I
5	adrenergic	I
6	receptor	I
7	blockade	O
8	on	O
9	airway	O
10	conductance	O
11	and	O
12	lung	O
13	volume	O
14	in	O
15	normal	O
16	and	O
17	asthmatic	O
18	subjects	O
19	.	O

1	Effect	O
2	of	O
3	heparin	O
4	on	O
5	the	O
6	inactivation	O
7	of	O
8	serum	B
9	lipoprotein	I
10	lipase	I
11	by	O
12	the	O
13	liver	O
14	in	O
15	unanesthetized	O
16	dogs	O
17	.	O

1	Experimental	O
2	chlorpromazine	O
3	cataracts	O
4	.	O

1	I	O
2	.	O

1	Specialist	O
2	in	O
3	family	O
4	practice	O
5	--	O
6	prototype	O
7	of	O
8	a	O
9	doctor	O
10	.	O

1	The	O
2	possibility	O
3	of	O
4	selective	O
5	chemotherapy	O
6	of	O
7	progressive	O
8	recurring	O
9	ovarian	O
10	carcinoma	O
11	with	O
12	the	O
13	aid	O
14	of	O
15	cytodiagnosis	O
16	and	O
17	incorporation	O
18	of	O
19	tagged	O
20	idoxuridine	O

1	Variation	O
2	in	O
3	the	O
4	temporal	O
5	-	O
6	spatial	O
7	distribution	O
8	of	O
9	228Ra	O
10	and	O
11	224Ra	O
12	in	O
13	the	O
14	RES	O
15	and	O
16	marrow	O
17	-	O
18	free	O
19	skeleton	O
20	after	O
21	incorporation	O
22	of	O
23	colloidal	O
24	ThO2	O

1	Oxidative	O
2	degradation	O
3	of	O
4	adrenaline	O
5	solutions	O
6	:	O
7	study	O
8	of	O
9	the	O
10	intermediate	O
11	stages	O
12	and	O
13	their	O
14	analytic	O
15	value	O
16	for	O
17	the	O
18	control	O
19	of	O
20	this	O
21	solute	O

1	Absorption	O
2	of	O
3	electrolytes	O
4	from	O
5	the	O
6	colon	O
7	in	O
8	cases	O
9	of	O
10	ulcerative	O
11	colitis	O
12	and	O
13	in	O
14	control	O
15	subjects	O
16	.	O

1	Ion	O
2	injection	O
3	.	O

1	Polyvinyl	O
2	alcohol	O
3	as	O
4	a	O
5	solution	O
6	mediator	O

1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O

1	The	O
2	structure	O
3	of	O
4	digiprogenin	O
5	.	O

1	The	O
2	need	O
3	in	O
4	the	O
5	small	O
6	hospital	O
7	.	O

1	I	O
2	.	O

1	On	O
2	the	O
3	character	O
4	of	O
5	changes	O
6	in	O
7	the	O
8	enzyme	O
9	activity	O
10	in	O
11	the	O
12	brain	O
13	tissue	O
14	during	O
15	reflex	O
16	epilepsy	O

1	A	O
2	malignant	O
3	true	O
4	teratoma	O
5	of	O
6	liver	O
7	in	O
8	childhood	O
9	.	O

1	Methoxyflurane	O
2	and	O
3	renal	O
4	function	O

1	Histochemistry	O
2	and	O
3	electron	O
4	microscopy	O
5	of	O
6	acute	O
7	liver	O
8	lesions	O
9	induced	O
10	by	O
11	Aflatoxin	O
12	B1	O
13	in	O
14	ducklings	O
15	.	O

1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	ureter	O
6	following	O
7	gynecologic	O
8	surgery	O

1	Study	O
2	of	O
3	the	O
4	alterations	O
5	of	O
6	intestinal	O
7	absorption	O
8	,	O
9	by	O
10	means	O
11	of	O
12	I	O
13	-	O
14	131	O
15	-	O
16	triolein	O
17	,	O
18	in	O
19	the	O
20	whole	O
21	body	O
22	irradiated	O
23	rat	O

1	Chemical	O
2	histologic	O
3	and	O
4	immunologic	O
5	responses	O
6	in	O
7	rats	O
8	to	O
9	CC1	O
10	-	O
11	4	O
12	by	O
13	different	O
14	routes	O
15	of	O
16	administration	O
17	.	O

1	Clinical	O
2	trials	O
3	with	O
4	1	O
5	,	O
6	3	O
7	-	O
8	bis	O
9	(	O
10	2	O
11	-	O
12	chloroethyl	O
13	)-	O
14	1	O
15	-	O
16	nitrosourea	O
17	,	O
18	NSC	O
19	-	O
20	409962	O
21	.	O

1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	O
11	for	O
12	electron	O
13	microscopy	O
14	.	O

1	Statistics	O
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O

1	On	O
2	the	O
3	diagnosis	O
4	of	O
5	bovine	O
6	leucosis	O
7	and	O
8	its	O
9	control	O
10	in	O
11	southern	O
12	Lower	O
13	Saxony	O

1	Experience	O
2	with	O
3	the	O
4	restoration	O
5	of	O
6	agglutination	O
7	properties	O
8	of	O
9	non	O
10	-	O
11	agglutinating	O
12	dysenterial	O
13	cultures	O
14	with	O
15	the	O
16	use	O
17	of	O
18	Rzhaninov	O
19	'	O
20	s	O
21	method	O

1	Study	O
2	on	O
3	micromelias	O
4	in	O
5	the	O
6	mouse	O
7	fetus	O
8	caused	O
9	by	O
10	x	O
11	-	O
12	radiation	O
13	,	O
14	hypoxia	O
15	,	O
16	trypan	O
17	blue	O
18	injection	O
19	of	O
20	hypervitaminosis	O
21	-	O
22	A	O
23	upon	O
24	mother	O
25	animals	O
26	during	O
27	pregnancy	O
28	.	O

1	Human	O
2	antitetanus	O
3	serum	O
4	:	O
5	an	O
6	unused	O
7	wealth	O

1	(	O
2	3	O
3	).	O

1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O

1	On	O
2	catabolism	O
3	of	O
4	aminoketones	O
5	in	O
6	climacteric	O
7	age	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O

1	IV	O
2	.	O

1	Studies	O
2	on	O
3	powdered	O
4	preparations	O
5	.	O

1	A	O
2	case	O
3	report	O
4	with	O
5	angiographic	O
6	follow	O
7	-	O
8	up	O
9	study	O
10	.	O

1	Interactions	O
2	between	O
3	adrenergics	O
4	,	O
5	adrenolytics	O
6	and	O
7	monoamine	B
8	oxidase	I
9	inhibitors	O

1	Further	O
2	studies	O
3	on	O
4	a	O
5	"	O
6	new	O
7	"	O
8	human	O
9	isoprecipitin	B
10	system	O
11	(	O
12	Australia	O
13	antigen	O
14	).	O

1	Pigmentary	O
2	rhythms	O
3	as	O
4	indicators	O
5	of	O
6	neurosecretion	O
7	.	O

1	Story	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	filmed	O
7	its	O
8	employee	O
9	orientation	O
10	program	O
11	.	O

1	When	O
2	the	O
3	cervical	O
4	Pap	O
5	smear	O
6	is	O
7	positive	O
8	.	O

1	I	O
2	.	O

1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O

1	Persistence	O
2	of	O
3	toxaphene	O
4	in	O
5	treated	O
6	lakes	O
7	.	O

1	Studies	O
2	on	O
3	Coxsackie	O
4	B	O
5	Type	O
6	5	O
7	virus	O
8	infections	O
9	.	O

1	Value	O
2	of	O
3	the	O
4	method	O
5	of	O
6	passive	O
7	hemagglutination	O
8	with	O
9	polysaccharide	O
10	C	O
11	in	O
12	detecting	O
13	C	B
14	-	I
15	reactive	I
16	protein	I
17	as	O
18	compared	O
19	to	O
20	precipitation	O
21	in	O
22	capillaries	O
23	and	O
24	slide	O
25	latex	O
26	test	O
27	with	O
28	anti	B
29	-	I
30	CRP	I
31	serum	O

1	Adrenergic	O
2	nerve	O
3	function	O
4	,	O
5	noradrenaline	O
6	level	O
7	and	O
8	noradrenaline	O
9	uptake	O
10	in	O
11	cat	O
12	nictitating	O
13	membrane	O
14	after	O
15	reserpine	O
16	treatment	O
17	.	O

1	Concussion	O
2	of	O
3	the	O
4	spinal	O
5	cord	O

1	Study	O
2	on	O
3	the	O
4	evagination	O
5	of	O
6	Cysticercus	O
7	pisiformis	O
8	.	O

1	Antimicrobial	O
2	substance	O
3	isolated	O
4	from	O
5	an	O
6	acorn	O
7	extract	O
8	.	O

1	The	O
2	pathogenicity	O
3	of	O
4	Achromobacter	O
5	puntatum	O
6	for	O
7	cold	O
8	blooded	O
9	and	O
10	warm	O
11	blooded	O
12	animals	O

1	Consanguinity	O
2	and	O
3	migration	O
4	in	O
5	the	O
6	marriages	O
7	of	O
8	the	O
9	region	O
10	of	O
11	Nunoa	O
12	,	O
13	Santiago	O
14	,	O
15	1850	O
16	-	O
17	1960	O

1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O

1	Studies	O
2	of	O
3	lipogenesis	O
4	by	O
5	labelled	O
6	precursors	O
7	in	O
8	the	O
9	pregnant	O
10	rat	O
11	.	O

1	Pharmacodynamic	O
2	studies	O
3	on	O
4	the	O
5	cardiovascular	O
6	system	O
7	of	O
8	spontaneously	O
9	hypertensive	O
10	rats	O
11	.	O

1	Nuclear	O
2	spin	O
3	of	O
4	249Bk	O
5	from	O
6	the	O
7	hyperfine	O
8	structure	O
9	in	O
10	its	O
11	emission	O
12	spectrum	O
13	.	O

1	Further	O
2	observations	O
3	on	O
4	resorption	O
5	in	O
6	guinea	O
7	pigs	O
8	following	O
9	injections	O
10	of	O
11	trypan	O
12	blue	O
13	.	O

1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O

1	Note	O
2	on	O
3	Slot	O
4	'	O
5	s	O
6	method	O
7	for	O
8	the	O
9	specific	O
10	determination	O
11	of	O
12	creatinine	O
13	.	O

1	Retention	O
2	behavior	O
3	of	O
4	steroids	O
5	in	O
6	gas	O
7	chromatography	O
8	with	O
9	a	O
10	series	O
11	of	O
12	combination	O
13	columns	O
14	.	O

1	Compensatory	O
2	renal	O
3	hypertrophy	O
4	in	O
5	parabiotic	O
6	rats	O
7	.	O

1	(	O
2	3	O
3	).	O

1	XXI	O
2	.	O

1	In	O
2	vitro	O
3	evaluation	O
4	of	O
5	the	O
6	mucolytic	O
7	action	O
8	of	O
9	urea	O
10	.	O

1	Electrophoretic	O
2	characteriaztion	O
3	of	O
4	virus	O
5	-	O
6	induced	O
7	interferon	B
8	of	O
9	the	O
10	blood	O
11	and	O
12	urine	O
13	in	O
14	rabbits	O

1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O

1	Symposium	O
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	Twenty	O
2	-	O
3	two	O
4	of	O
5	the	O
6	24	O
7	patients	O
8	had	O
9	a	O
10	rise	O
11	in	O
12	the	O
13	total	O
14	serum	O
15	amylase	B
16	following	O
17	ERCP	O
18	.	O

1	The	O
2	immuno	O
3	-	O
4	purified	O
5	mRNA	O
6	in	O
7	the	O
8	polysome	O
9	complex	O
10	was	O
11	used	O
12	to	O
13	prepare	O
14	cDNA	O
15	with	O
16	which	O
17	to	O
18	probe	O
19	a	O
20	D	O
21	.	O
22	melanogaster	O
23	genomic	O
24	library	O
25	.	O

1	Elevated	O
2	maternal	B
3	alpha	I
4	fetoproteins	I
5	and	O
6	oligoamnios	O
7	:	O
8	fetal	O
9	prognosis	O

1	Also	O
2	discussed	O
3	is	O
4	the	O
5	possibility	O
6	of	O
7	a	O
8	combined	O
9	genetic	O
10	and	O
11	environmental	O
12	etiology	O
13	.	O

1	Courses	O
2	were	O
3	repeated	O
4	monthly	O
5	upon	O
6	recovery	O
7	of	O
8	myelosuppression	O
9	.	O

1	Stimulation	O
2	with	O
3	MCh	O
4	produced	O
5	a	O
6	Ca	O
7	-	O
8	dependent	O
9	transient	O
10	elevation	O
11	of	O
12	cGMP	O
13	level	O
14	from	O
15	10	O
16	to	O
17	80	O
18	fmol	O
19	/	O
20	gland	O
21	,	O
22	peaking	O
23	at	O
24	1	O
25	-	O
26	2	O
27	min	O
28	but	O
29	returning	O
30	to	O
31	the	O
32	basal	O
33	level	O
34	by	O
35	5	O
36	min	O
37	.	O

1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O

1	The	O
2	PEPCK	B
3	promoter	O
4	fragment	O
5	was	O
6	introduced	O
7	either	O
8	in	O
9	the	O
10	proper	O
11	orientation	O
12	for	O
13	transcription	O
14	of	O
15	the	O
16	TK	B
17	gene	I
18	or	O
19	in	O
20	the	O
21	opposite	O
22	orientation	O
23	.	O

1	Many	O
2	mammary	O
3	tumors	O
4	induced	O
5	by	O
6	mouse	O
7	mammary	O
8	tumor	O
9	virus	O
10	(	O
11	MMTV	O
12	)	O
13	contain	O
14	a	O
15	provirus	O
16	in	O
17	the	O
18	same	O
19	region	O
20	of	O
21	the	O
22	host	O
23	-	O
24	cell	O
25	genome	O
26	,	O
27	leading	O
28	to	O
29	expression	O
30	of	O
31	a	O
32	putative	O
33	cellular	O
34	oncogene	O
35	called	O
36	int	B
37	-	I
38	1	I
39	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	asbestos	O
6	or	O
7	erionite	O
8	-	O
9	tissue	O
10	burden	O
11	followed	O
12	by	O
13	fibrosis	O
14	was	O
15	frequently	O
16	observed	O
17	.	O

1	Hepatitis	O
2	B	O
3	virus	O
4	and	O
5	hepatoma	O
6	.	O

1	Eight	O
2	recombinant	O
3	DNA	O
4	clones	O
5	of	O
6	endogenous	O
7	murine	O
8	leukemia	O
9	virus	O
10	(	O
11	MuLV	O
12	)-	O
13	related	O
14	DNA	O
15	sequences	O
16	have	O
17	been	O
18	isolated	O
19	from	O
20	a	O
21	lambdaphage	O
22	genomic	O
23	library	O
24	of	O
25	Balb	O
26	/	O
27	c	O
28	mouse	O
29	DNA	O
30	.	O

1	USA	O
2	80	O
3	,	O
4	3618	O
5	-	O
6	3622	O
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	The	O
2	envelope	O
3	glycoproteins	O
4	of	O
5	Rous	O
6	sarcoma	O
7	virus	O
8	(	O
9	RSV	O
10	),	O
11	gp85	B
12	and	O
13	gp37	B
14	,	O
15	are	O
16	anchored	O
17	in	O
18	the	O
19	membrane	O
20	by	O
21	a	O
22	27	O
23	-	O
24	amino	O
25	acid	O
26	,	O
27	hydrophobic	O
28	domain	O
29	that	O
30	lies	O
31	adjacent	O
32	to	O
33	a	O
34	22	O
35	-	O
36	amino	O
37	acid	O
38	,	O
39	cytoplasmic	O
40	domain	O
41	at	O
42	the	O
43	carboxy	O
44	terminus	O
45	of	O
46	gp37	B
47	.	O

1	The	O
2	drug	O
3	was	O
4	given	O
5	in	O
6	a	O
7	daily	O
8	oral	O
9	dose	O
10	of	O
11	0	O
12	.	O
13	5	O
14	g	O
15	/	O
16	m2	O
17	,	O
18	3	O
19	.	O
20	5	O
21	h	O
22	prior	O
23	to	O
24	each	O
25	radiation	O
26	treatment	O
27	.	O

1	Histogenetic	O
2	aspects	O
3	of	O
4	mesoblastic	O
5	nephroma	O
6	.	O

1	Effect	O
2	of	O
3	acute	O
4	and	O
5	chronic	O
6	psychogenic	O
7	stress	O
8	on	O
9	corticoadrenal	O
10	and	O
11	pituitary	B
12	-	I
13	thyroid	I
14	hormones	I
15	in	O
16	male	O
17	rats	O
18	.	O

1	Mature	O
2	mRNA	O
3	for	O
4	cytosolic	B
5	phosphoenolpyruvate	I
6	carboxykinase	I
7	of	I
8	the	I
9	chicken	I
10	is	O
11	2	O
12	.	O
13	8	O
14	kilobases	O
15	in	O
16	length	O
17	,	O
18	similar	O
19	to	O
20	that	O
21	previously	O
22	noted	O
23	for	O
24	mRNA	O
25	coding	O
26	for	O
27	the	O
28	same	O
29	enzyme	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	Upstream	O
2	activation	O
3	sites	O
4	of	O
5	the	O
6	CYC1	B
7	gene	I
8	of	O
9	Saccharomyces	O
10	cerevisiae	O
11	are	O
12	active	O
13	when	O
14	inverted	O
15	but	O
16	not	O
17	when	O
18	placed	O
19	downstream	O
20	of	O
21	the	O
22	"	O
23	TATA	O
24	box	O
25	".	O

1	An	O
2	intact	O
3	5	O
4	.	O
5	7	O
6	-	O
7	kb	O
8	provirus	O
9	of	O
10	the	O
11	avian	O
12	erythroblastosis	O
13	virus	O
14	E26	O
15	has	O
16	been	O
17	molecularly	O
18	cloned	O
19	for	O
20	comparisons	O
21	with	O
22	avian	O
23	myeloblastosis	O
24	virus	O
25	(	O
26	AMV	O
27	)	O
28	and	O
29	other	O
30	avian	O
31	tumor	O
32	viruses	O
33	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	haloperidol	O
6	selectively	O
7	reduced	O
8	the	O
9	animal	O
10	'	O
11	s	O
12	capacity	O
13	to	O
14	'	O
15	programme	O
16	non	O
17	-	O
18	stimulus	O
19	directed	O
20	motor	O
21	behaviour	O
22	'.	O

1	Neither	O
2	side	O
3	effect	O
4	nor	O
5	abnormal	O
6	laboratory	O
7	findings	O
8	due	O
9	to	O
10	this	O
11	drug	O
12	were	O
13	observed	O
14	.	O

1	The	O
2	results	O
3	presented	O
4	in	O
5	this	O
6	report	O
7	suggest	O
8	that	O
9	the	O
10	SV40	O
11	G	O
12	-	O
13	C	O
14	-	O
15	rich	O
16	sequences	O
17	can	O
18	function	O
19	as	O
20	independent	O
21	RNA	B
22	polymerase	I
23	II	I
24	transcriptional	O
25	-	O
26	control	O
27	elements	O
28	.	O

1	Construction	O
2	of	O
3	human	O
4	cell	O
5	lines	O
6	which	O
7	contain	O
8	and	O
9	express	O
10	the	O
11	adenovirus	O
12	DNA	O
13	binding	O
14	protein	O
15	gene	O
16	by	O
17	cotransformation	O
18	with	O
19	the	O
20	HSV	B
21	-	I
22	1	I
23	tk	I
24	gene	I
25	.	O

1	Diagnosis	O
2	and	O
3	treatment	O
4	of	O
5	insulin	B
6	-	O
7	secreting	O
8	tumours	O
9	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	The	O
2	effects	O
3	of	O
4	cardioselective	O
5	beta	O
6	-	O
7	1	O
8	adrenergic	O
9	agonist	O
10	,	O
11	1	O
12	-(	O
13	4	O
14	-	O
15	hydroxyphenoxy	O
16	)-	O
17	isopropylamino	O
18	-	O
19	2	O
20	-	O
21	propanol	O
22	),	O
23	i	O
24	.	O
25	e	O
26	.,	O
27	prenalterol	O
28	,	O
29	were	O
30	examined	O
31	on	O
32	direct	O
33	and	O
34	continuous	O
35	measurements	O
36	of	O
37	left	O
38	ventricular	O
39	(	O
40	LV	O
41	)	O
42	pressure	O
43	,	O
44	diameter	O
45	,	O
46	dP	O
47	/	O
48	dt	O
49	,	O
50	velocity	O
51	of	O
52	shortening	O
53	,	O
54	arterial	O
55	pressure	O
56	,	O
57	iliac	O
58	blood	O
59	flow	O
60	and	O
61	heart	O
62	rate	O
63	in	O
64	10	O
65	conscious	O
66	dogs	O
67	.	O

1	Endorphins	B
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O

1	Trial	O
2	treatment	O
3	of	O
4	schizophrenia	O
5	with	O
6	des	B
7	-	I
8	Tyr	I
9	-	I
10	gamma	I
11	-	I
12	endorphin	I

1	Cardiac	O
2	taurine	O
3	levels	O
4	and	O
5	sarcolemmal	O
6	calcium	O
7	binding	O
8	activity	O
9	in	O
10	furazolidone	O
11	-	O
12	induced	O
13	cardiomyopathy	O
14	.	O

1	Separation	O
2	of	O
3	malaria	O
4	-	O
5	infected	O
6	erythrocytes	O
7	from	O
8	whole	O
9	blood	O
10	:	O
11	use	O
12	of	O
13	a	O
14	selective	O
15	high	O
16	-	O
17	gradient	O
18	magnetic	O
19	separation	O
20	technique	O
21	.	O

1	The	O
2	roll	O
3	-	O
4	over	O
5	test	O
6	to	O
7	predict	O
8	toxemia	O
9	in	O
10	pregnancy	O
11	.	O

1	Can	O
2	thyroglobulin	B
3	assay	O
4	really	O
5	supplant	O
6	radioiodine	O
7	scans	O
8	in	O
9	patients	O
10	with	O
11	differentiated	O
12	thyroid	O
13	cancer	O
14	?	O

1	3	O
2	Significant	O
3	reductions	O
4	in	O
5	lying	O
6	mean	O
7	arterial	O
8	blood	O
9	pressure	O
10	were	O
11	observed	O
12	with	O
13	daily	O
14	doses	O
15	of	O
16	200	O
17	mg	O
18	(-	O
19	9	O
20	%),	O
21	400	O
22	mg	O
23	(-	O
24	10	O
25	%)	O
26	and	O
27	800	O
28	mg	O
29	(-	O
30	14	O
31	%),	O
32	and	O
33	were	O
34	associated	O
35	with	O
36	significant	O
37	decreases	O
38	in	O
39	heart	O
40	rate	O
41	and	O
42	plasma	B
43	renin	I
44	activity	O
45	.	O

1	Isolation	O
2	of	O
3	Aeromonas	O
4	from	O
5	faeces	O
6	.	O

1	Plasma	O
2	and	O
3	erthrocyte	O
4	lipid	O
5	profile	O
6	and	O
7	lipoprotein	B
8	lipase	I
9	activity	O
10	in	O
11	postheparin	O
12	plasma	O
13	on	O
14	vasectomized	O
15	rabbits	O
16	were	O
17	studied	O
18	and	O
19	also	O
20	the	O
21	incidence	O
22	of	O
23	atherosclerosis	O
24	in	O
25	different	O
26	arterial	O
27	beds	O
28	.	O

1	(	O
2	iii	O
3	)	O
4	The	O
5	mRNA	O
6	is	O
7	not	O
8	efficiently	O
9	polyadenylated	O
10	at	O
11	sequences	O
12	in	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	the	O
19	DHFR	B
20	cDNA	I
21	but	O
22	rather	O
23	uses	O
24	polyadenylation	O
25	signals	O
26	downstream	O
27	from	O
28	the	O
29	DHFR	B
30	cDNA	I
31	.	O

1	At	O
2	both	O
3	water	O
4	temperatures	O
5	,	O
6	VO2	O
7	increased	O
8	linearly	O
9	with	O
10	increasing	O
11	swimming	O
12	velocity	O
13	.	O

1	Propranolol	O
2	also	O
3	effectively	O
4	controlled	O
5	her	O
6	familial	O
7	tremor	O
8	.	O

1	Brief	O
2	report	O
3	.	O

1	The	O
2	distribution	O
3	phase	O
4	is	O
5	followed	O
6	by	O
7	an	O
8	elimination	O
9	phase	O
10	with	O
11	a	O
12	much	O
13	longer	O
14	half	O
15	-	O
16	life	O
17	(	O
18	mean	O
19	value	O
20	375	O
21	min	O
22	)	O
23	and	O
24	a	O
25	volume	O
26	of	O
27	distribution	O
28	of	O
29	approximately	O
30	200	O
31	-	O
32	400	O
33	l	O
34	.	O

1	Hybrid	O
2	-	O
3	selection	O
4	experiments	O
5	against	O
6	total	O
7	PB	O
8	-	O
9	inducible	O
10	RNA	O
11	were	O
12	performed	O
13	with	O
14	plasmid	O
15	DNA	O
16	derived	O
17	from	O
18	clones	O
19	enriched	O
20	in	O
21	PB	O
22	-	O
23	inducible	O
24	information	O
25	.	O

1	Risk	O
2	of	O
3	HTLV	O
4	infection	O
5	in	O
6	patients	O
7	on	O
8	haemodialysis	O
9	.	O

1	In	O
2	vitro	O
3	metabolism	O
4	of	O
5	progesterone	O
6	by	O
7	the	O
8	human	O
9	undescended	O
10	testis	O
11	.	O

1	Two	O
2	patients	O
3	withdrew	O
4	from	O
5	therapy	O
6	,	O
7	one	O
8	for	O
9	personal	O
10	reasons	O
11	and	O
12	one	O
13	because	O
14	a	O
15	paraspinal	O
16	mass	O
17	developed	O
18	.	O

1	All	O
2	patients	O
3	received	O
4	VCR	O
5	1	O
6	.	O
7	0	O
8	mg	O
9	/	O
10	m2	O
11	weekly	O
12	for	O
13	6	O
14	weeks	O
15	with	O
16	dose	O
17	modification	O
18	for	O
19	neurotoxicity	O
20	.	O

1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O

1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	Plasma	B
2	secretin	I
3	,	O
4	pancreozymin	B
5	,	O
6	and	O
7	somatostatin	B
8	-	I
9	like	I
10	hormone	I
11	in	O
12	chronic	O
13	renal	O
14	failure	O
15	patients	O
16	.	O

1	Effect	O
2	of	O
3	bromazepam	O
4	on	O
5	growth	B
6	hormone	I
7	and	O
8	prolactin	B
9	secretion	O
10	in	O
11	normal	O
12	subjects	O
13	.	O

1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O

1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O

1	Thalamotomy	O
2	aiming	O
3	at	O
4	the	O
5	CM	O
6	-	O
7	Pf	O
8	complex	O
9	and	O
10	using	O
11	stereotactic	O
12	gamma	O
13	irradiation	O
14	has	O
15	been	O
16	performed	O
17	in	O
18	a	O
19	series	O
20	of	O
21	52	O
22	patients	O
23	with	O
24	severe	O
25	pain	O
26	due	O
27	to	O
28	malignancy	O
29	.	O

1	2	O
2	Silastic	O
3	capsules	O
4	,	O
5	each	O
6	containing	O
7	22	O
8	-	O
9	23	O
10	mg	O
11	of	O
12	ethinyl	O
13	estradiol	O
14	,	O
15	were	O
16	inserted	O
17	subcutaneously	O
18	in	O
19	5	O
20	men	O
21	with	O
22	benign	O
23	prostatic	O
24	hypertrophy	O
25	.	O

1	When	O
2	used	O
3	subcutaneously	O
4	or	O
5	intravenously	O
6	in	O
7	maximum	O
8	tolerated	O
9	doses	O
10	the	O
11	antibiotic	O
12	inhibited	O
13	the	O
14	development	O
15	of	O
16	lymphadenosis	O
17	NK	O
18	/	O
19	Li	O
20	by	O
21	90	O
22	and	O
23	70	O
24	per	O
25	cent	O
26	respectively	O
27	.	O

1	Effect	O
2	of	O
3	2	O
4	-(	O
5	p	O
6	-	O
7	chlorophenyl	O
8	)	O
9	cyclopropylamine	O
10	on	O
11	5	O
12	-	O
13	hydroxyindole	O
14	concentration	O
15	and	O
16	monoamine	B
17	oxidase	I
18	activity	O
19	in	O
20	rat	O
21	brain	O
22	.	O

1	Then	O
2	,	O
3	pure	O
4	pancreatic	O
5	juice	O
6	was	O
7	infused	O
8	into	O
9	the	O
10	duodenum	O
11	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	O
13	4	O
14	industrial	O
15	farms	O
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	(	O
2	2	O
3	)	O
4	The	O
5	inappropriateness	O
6	of	O
7	adaptive	O
8	segmentation	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	spikes	O
14	and	O
15	sharp	O
16	waves	O
17	,	O
18	which	O
19	had	O
20	been	O
21	anticipated	O
22	in	O
23	view	O
24	of	O
25	the	O
26	short	O
27	duration	O
28	of	O
29	such	O
30	transients	O
31	in	O
32	relation	O
33	to	O
34	the	O
35	length	O
36	of	O
37	the	O
38	window	O
39	(	O
40	1	O
41	.	O
42	2	O
43	sec	O
44	)	O
45	used	O
46	for	O
47	the	O
48	autocorrelation	O
49	functions	O
50	employed	O
51	in	O
52	the	O
53	segmentation	O
54	algorithm	O
55	,	O
56	was	O
57	confirmed	O
58	.	O

1	The	O
2	ability	O
3	of	O
4	chronic	O
5	UM	O
6	-	O
7	272	O
8	(	O
9	dimethylpropranolol	O
10	)	O
11	treatment	O
12	to	O
13	prevent	O
14	the	O
15	induction	O
16	of	O
17	reentrant	O
18	ventricular	O
19	tachyarrhythmias	O
20	was	O
21	assessed	O
22	in	O
23	the	O
24	conscious	O
25	dog	O
26	subjected	O
27	to	O
28	serial	O
29	programmed	O
30	electrical	O
31	stimulation	O
32	on	O
33	days	O
34	3	O
35	--	O
36	5	O
37	after	O
38	myocardial	O
39	infarction	O
40	.	O

1	The	O
2	effect	O
3	of	O
4	echothiophate	O
5	on	O
6	the	O
7	biphasic	O
8	response	O
9	of	O
10	rabbit	O
11	ocular	O
12	pressure	O
13	to	O
14	dipivefrin	O
15	.	O

1	In	O
2	most	O
3	cases	O
4	of	O
5	acute	O
6	transmural	O
7	infarction	O
8	,	O
9	the	O
10	reciprocal	O
11	ST	O
12	segment	O
13	depressions	O
14	observed	O
15	in	O
16	contralateral	O
17	leads	O
18	are	O
19	less	O
20	marked	O
21	than	O
22	the	O
23	primary	O
24	ST	O
25	segment	O
26	elevations	O
27	.	O

1	Bacillus	O
2	cereus	O
3	cross	O
4	-	O
5	infection	O
6	in	O
7	a	O
8	maternity	O
9	-	O
10	unit	O
11	.	O

1	We	O
2	have	O
3	followed	O
4	37	O
5	phenytoin	O
6	-	O
7	treated	O
8	patients	O
9	with	O
10	reduced	O
11	serum	B
12	IgA	I
13	concentrations	O
14	for	O
15	2	O
16	-	O
17	7	O
18	years	O
19	.	O

1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	O
22	.	O

1	Unusual	O
2	course	O
3	of	O
4	plasmocytosis	O
5	.	O

1	Late	O
2	mRNA	O
3	selected	O
4	by	O
5	a	O
6	cDNA	O
7	homologous	O
8	to	O
9	the	O
10	HindIII	B
11	-	I
12	P	I
13	/	O
14	EcoRI	B
15	-	I
16	B	I
17	region	O
18	of	O
19	the	O
20	AcNPV	O
21	map	O
22	directed	O
23	the	O
24	synthesis	O
25	of	O
26	31K	O
27	and	O
28	30K	O
29	proteins	O
30	which	O
31	comigrated	O
32	with	O
33	the	O
34	31K	O
35	and	O
36	30K	O
37	proteins	O
38	translated	O
39	from	O
40	RNA	O
41	selected	O
42	by	O
43	the	O
44	HindIII	B
45	-	I
46	A	I
47	/	O
48	EcoRI	B
49	-	I
50	C	I
51	/	O
52	SstI	B
53	-	I
54	G	I
55	cDNA	O
56	.	O

1	Intraoperatively	O
2	the	O
3	complement	B
4	factor	I
5	C3c	I
6	decreased	O
7	by	O
8	20	O
9	%,	O
10	while	O
11	alpha	B
12	1	I
13	-	I
14	antitrypsin	I
15	showed	O
16	postoperatively	O
17	an	O
18	increase	O
19	by	O
20	30	O
21	%.	O

1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	resembles	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	ADP	O
22	binding	O
23	site	O
24	of	O
25	bovine	B
26	muscle	I
27	pyruvate	I
28	kinase	I
29	.	O

1	The	O
2	P165	O
3	component	O
4	,	O
5	however	O
6	,	O
7	could	O
8	be	O
9	differentiated	O
10	from	O
11	the	O
12	two	O
13	later	O
14	components	O
15	since	O
16	it	O
17	increased	O
18	in	O
19	amplitude	O
20	with	O
21	increased	O
22	task	O
23	demands	O
24	while	O
25	the	O
26	N2	O
27	and	O
28	P3	O
29	amplitudes	O
30	remained	O
31	constant	O
32	.	O

1	Differential	O
2	drawing	O
3	size	O
4	associated	O
5	with	O
6	unilateral	O
7	brain	O
8	damage	O
9	.	O

1	The	O
2	intracoronary	O
3	administration	O
4	of	O
5	both	O
6	drugs	O
7	markedly	O
8	reduced	O
9	the	O
10	incidence	O
11	of	O
12	VF	O
13	induced	O
14	by	O
15	the	O
16	release	O
17	of	O
18	a	O
19	40	O
20	-	O
21	min	O
22	coronary	O
23	artery	O
24	occlusion	O
25	.	O

1	These	O
2	fusions	O
3	are	O
4	contained	O
5	on	O
6	plasmids	O
7	which	O
8	have	O
9	both	O
10	yeast	O
11	and	O
12	E	O
13	.	O
14	coli	O
15	replication	O
16	origins	O
17	and	O
18	selectable	O
19	markers	O
20	and	O
21	,	O
22	therefore	O
23	,	O
24	can	O
25	be	O
26	used	O
27	to	O
28	transform	O
29	either	O
30	yeast	O
31	or	O
32	E	O
33	.	O
34	coli	O
35	cells	O
36	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	Toxicity	O
2	was	O
3	significant	O
4	in	O
5	selected	O
6	cases	O
7	;	O
8	three	O
9	patients	O
10	developed	O
11	WBC	O
12	counts	O
13	less	O
14	than	O
15	1	O
16	,	O
17	000	O
18	/	O
19	mm3	O
20	and	O
21	one	O
22	of	O
23	these	O
24	patients	O
25	died	O
26	with	O
27	sepsis	O
28	.	O

1	Subdural	O
2	electrodes	O
3	may	O
4	yield	O
5	larger	O
6	VEP	O
7	amplitudes	O
8	than	O
9	skull	O
10	or	O
11	scalp	O
12	electrodes	O
13	.	O

1	Products	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	B
8	factor	I
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O

1	Use	O
2	of	O
3	the	O
4	immunofluorescence	O
5	method	O
6	for	O
7	identification	O
8	of	O
9	enteroviruses	O
10	in	O
11	cell	O
12	cultures	O

1	This	O
2	fraction	O
3	is	O
4	resistant	O
5	to	O
6	digestions	O
7	by	O
8	DNase	B
9	I	I
10	and	O
11	RNase	B
12	T1	I
13	and	O
14	disappears	O
15	completely	O
16	upon	O
17	alkali	O
18	hydrolysis	O
19	.	O

1	The	O
2	construction	O
3	of	O
4	a	O
5	small	O
6	library	O
7	of	O
8	mouse	O
9	repetitive	O
10	DNA	O
11	has	O
12	been	O
13	previously	O
14	reported	O
15	(	O
16	Pietras	O
17	et	O
18	al	O
19	.,	O
20	Nucleic	O
21	Acids	O
22	Res	O
23	.	O

1	No	O
2	direct	O
3	repeats	O
4	flank	O
5	the	O
6	pseudogene	O
7	in	O
8	the	O
9	U2	B
10	/	I
11	4	I
12	locus	I
13	.	O

1	The	O
2	direct	O
3	effects	O
4	of	O
5	transmitter	O
6	release	O
7	were	O
8	(	O
9	a	O
10	)	O
11	an	O
12	early	O
13	fall	O
14	in	O
15	MAP	O
16	followed	O
17	by	O
18	a	O
19	late	O
20	pressor	O
21	effect	O
22	;	O
23	and	O
24	(	O
25	b	O
26	)	O
27	an	O
28	early	O
29	bradycardia	O
30	followed	O
31	by	O
32	a	O
33	late	O
34	tachycardia	O
35	.	O

1	At	O
2	Cabras	O
3	(	O
4	Oristano	O
5	),	O
6	a	O
7	town	O
8	characterized	O
9	by	O
10	a	O
11	high	O
12	incidence	O
13	of	O
14	thalassaemia	O
15	and	O
16	G6PD	B
17	deficiency	O
18	less	O
19	than	O
20	half	O
21	the	O
22	people	O
23	between	O
24	18	O
25	and	O
26	35	O
27	have	O
28	a	O
29	fair	O
30	knowledge	O
31	of	O
32	genetic	O
33	diseases	O
34	and	O
35	of	O
36	their	O
37	prevention	O
38	.	O

1	The	O
2	number	O
3	of	O
4	elements	O
5	and	O
6	their	O
7	sizes	O
8	relative	O
9	to	O
10	the	O
11	configuration	O
12	were	O
13	varied	O
14	in	O
15	a	O
16	series	O
17	of	O
18	five	O
19	experiments	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	overall	O
6	chance	O
7	that	O
8	a	O
9	patient	O
10	would	O
11	undergo	O
12	ET	O
13	was	O
14	greater	O
15	in	O
16	a	O
17	cycle	O
18	in	O
19	which	O
20	more	O
21	than	O
22	one	O
23	follicle	O
24	20	O
25	mm	O
26	or	O
27	larger	O
28	was	O
29	developing	O
30	than	O
31	in	O
32	a	O
33	cycle	O
34	in	O
35	which	O
36	a	O
37	single	O
38	large	O
39	follicle	O
40	was	O
41	developing	O
42	.	O

1	Experience	O
2	with	O
3	the	O
4	tensor	O
5	fasciae	O
6	latae	O
7	free	O
8	flap	O
9	.	O

1	Five	O
2	of	O
3	the	O
4	patients	O
5	with	O
6	increased	O
7	L	O
8	-	O
9	L	O
10	size	O
11	had	O
12	a	O
13	normal	O
14	A	O
15	-	O
16	P	O
17	diameter	O
18	.	O

1	Immunochemotherapy	O
2	with	O
3	schizophyllan	O
4	(	O
5	SPG	O
6	)	O
7	combined	O
8	with	O
9	chemotherapeutic	O
10	agents	O
11	was	O
12	evaluated	O
13	in	O
14	two	O
15	syngeneic	O
16	tumor	O
17	-	O
18	C3H	O
19	/	O
20	He	O
21	mouse	O
22	systems	O
23	.	O

1	However	O
2	,	O
3	when	O
4	combined	O
5	with	O
6	mitomycin	O
7	C	O
8	given	O
9	with	O
10	1	O
11	to	O
12	5	O
13	-	O
14	days	O
15	interval	O
16	,	O
17	the	O
18	concurrent	O
19	administration	O
20	of	O
21	SPG	O
22	prolonged	O
23	significantly	O
24	the	O
25	life	O
26	-	O
27	span	O
28	of	O
29	the	O
30	tumor	O
31	-	O
32	bearing	O
33	mice	O
34	.	O

1	Data	O
2	are	O
3	presented	O
4	hinting	O
5	that	O
6	the	O
7	15	O
8	beta	O
9	-	O
10	hydroxy	O
11	-,	O
12	metabolite	O
13	of	O
14	CPA	O
15	may	O
16	actually	O
17	be	O
18	the	O
19	biologically	O
20	active	O
21	agent	O
22	.	O

1	The	O
2	abluminal	O
3	surface	O
4	is	O
5	often	O
6	almost	O
7	entirely	O
8	encircled	O
9	by	O
10	a	O
11	thick	O
12	layer	O
13	of	O
14	fibrillary	O
15	connective	O
16	tissue	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	in	O
5	LL	O
6	patients	O
7	during	O
8	ENL	O
9	the	O
10	ConA	B
11	-	O
12	induced	O
13	suppressor	O
14	response	O
15	was	O
16	markedly	O
17	reduced	O
18	.	O

1	Functional	O
2	characterization	O
3	of	O
4	a	O
5	fraction	O
6	identified	O
7	by	O
8	its	O
9	activity	O
10	in	O
11	a	O
12	second	O
13	template	O
14	rescue	O
15	assay	O
16	.	O

1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O

1	Fibrin	B
2	gels	O
3	and	O
4	their	O
5	possible	O
6	implication	O
7	for	O
8	surface	O
9	hemorheology	O
10	in	O
11	health	O
12	and	O
13	disease	O
14	.	O

1	Hepatitis	O
2	-	O
3	B	O
4	vaccination	O
5	in	O
6	the	O
7	elderly	O
8	.	O

1	Radiogallium	O
2	imaging	O
3	is	O
4	thus	O
5	of	O
6	limited	O
7	use	O
8	in	O
9	evaluation	O
10	of	O
11	suspected	O
12	giant	O
13	cell	O
14	tumors	O
15	of	O
16	bone	O
17	.	O

1	The	O
2	customary	O
3	coupling	O
4	reagent	O
5	sulfanilic	O
6	acid	O
7	has	O
8	been	O
9	replaced	O
10	by	O
11	1	O
12	,	O
13	3	O
14	-	O
15	dimethylbarbituric	O
16	acid	O
17	;	O
18	CNCl	O
19	is	O
20	produced	O
21	in	O
22	the	O
23	flow	O
24	through	O
25	system	O
26	directly	O
27	from	O
28	KCN	O
29	and	O
30	chloramine	O
31	T	O
32	.	O

1	Ventricular	O
2	volume	O
3	stiffness	O
4	vs	O
5	.	O
6	the	O
7	mean	O
8	wall	O
9	stress	O
10	relationship	O
11	of	O
12	LVH	O
13	shifted	O
14	upward	O
15	,	O
16	whereas	O
17	the	O
18	normalized	O
19	wall	O
20	muscle	O
21	stiffness	O
22	vs	O
23	.	O
24	the	O
25	mean	O
26	wall	O
27	stress	O
28	relationship	O
29	of	O
30	LVH	O
31	showed	O
32	a	O
33	smaller	O
34	slope	O
35	.	O

1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O

1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O

1	The	O
2	effect	O
3	of	O
4	treatment	O
5	may	O
6	thus	O
7	be	O
8	divided	O
9	into	O
10	two	O
11	main	O
12	phases	O
13	--	O
14	an	O
15	initial	O
16	phase	O
17	with	O
18	a	O
19	reduction	O
20	in	O
21	LV	O
22	mass	O
23	and	O
24	a	O
25	reduction	O
26	in	O
27	cardiac	O
28	output	O
29	and	O
30	no	O
31	change	O
32	in	O
33	total	O
34	peripheral	O
35	resistance	O
36	--	O
37	and	O
38	a	O
39	second	O
40	phase	O
41	with	O
42	a	O
43	constant	O
44	LV	O
45	mass	O
46	but	O
47	an	O
48	increase	O
49	in	O
50	cardiac	O
51	output	O
52	to	O
53	the	O
54	pretreatment	O
55	level	O
56	again	O
57	and	O
58	a	O
59	concomitant	O
60	decrease	O
61	in	O
62	total	O
63	peripheral	O
64	resistance	O
65	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	assess	O
7	the	O
8	effects	O
9	of	O
10	hypothermia	O
11	and	O
12	chemical	O
13	cardioplegia	O
14	on	O
15	the	O
16	functional	O
17	recovery	O
18	of	O
19	hypertrophied	O
20	non	O
21	-	O
22	failing	O
23	rat	O
24	hearts	O
25	subjected	O
26	to	O
27	an	O
28	extended	O
29	period	O
30	of	O
31	global	O
32	ischaemia	O
33	.	O

1	Oxygen	O
2	profiles	O
3	calculated	O
4	for	O
5	the	O
6	Krogh	O
7	model	O
8	with	O
9	excentric	O
10	diffusion	O
11	were	O
12	similar	O
13	to	O
14	those	O
15	derived	O
16	for	O
17	the	O
18	two	O
19	models	O
20	of	O
21	concentric	O
22	diffusion	O
23	.	O

1	Cultivation	O
2	technics	O
3	for	O
4	Codonopsis	O
5	pilosula	O

1	Radioimmunoassay	O
2	of	O
3	serum	O
4	creatine	B
5	kinase	I
6	B	I
7	isoenzyme	I
8	in	O
9	the	O
10	diagnosis	O
11	of	O
12	acute	O
13	myocardial	O
14	infarction	O
15	.	O

1	Selective	O
2	macrophage	O
3	inhibition	O
4	abolishes	O
5	warfarin	O
6	-	O
7	induced	O
8	reduction	O
9	of	O
10	metastasis	O
11	.	O

1	Restriction	O
2	enzyme	O
3	and	O
4	heteroduplex	O
5	analyses	O
6	confirmed	O
7	that	O
8	sequences	O
9	unique	O
10	to	O
11	FeSV	O
12	(	O
13	src	B
14	sequences	I
15	)	O
16	are	O
17	located	O
18	at	O
19	the	O
20	center	O
21	of	O
22	the	O
23	FeSV	O
24	genome	O
25	and	O
26	are	O
27	approximately	O
28	1	O
29	.	O
30	5	O
31	kilobase	O
32	pairs	O
33	in	O
34	length	O
35	.	O

1	Among	O
2	six	O
3	different	O
4	library	O
5	isolates	O
6	containing	O
7	6	B
8	.	I
9	5	I
10	-	I
11	to	I
12	7	I
13	-	I
14	kb	I
15	IAP	I
16	units	I
17	,	O
18	some	O
19	restriction	O
20	sites	O
21	were	O
22	highly	O
23	conserved	O
24	whereas	O
25	others	O
26	varied	O
27	in	O
28	both	O
29	occurrence	O
30	and	O
31	position	O
32	.	O

1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O

1	A	O
2	haemolytic	O
3	enterotoxigenic	O
4	strain	O
5	of	O
6	E	O
7	.	O
8	coli	O
9	(	O
10	O149	O
11	:	O
12	K88	O
13	:	O
14	H10	O
15	)	O
16	was	O
17	regularly	O
18	recovered	O
19	from	O
20	piglets	O
21	with	O
22	PWD	O
23	while	O
24	rotavirus	O
25	was	O
26	demonstrated	O
27	on	O
28	a	O
29	number	O
30	of	O
31	occasions	O
32	.	O

1	The	O
2	antibody	O
3	titer	O
4	of	O
5	202	O
6	chickens	O
7	to	O
8	SA	O
9	-	O
10	11	O
11	rotavirus	O
12	was	O
13	determined	O
14	by	O
15	enzyme	O
16	-	O
17	linked	O
18	immunosorbent	O
19	blocking	O
20	assay	O
21	.	O

1	Poly	O
2	(	O
3	dT	O
4	)	O
5	and	O
6	denatured	O
7	calf	O
8	thymus	O
9	DNA	O
10	were	O
11	more	O
12	effective	O
13	than	O
14	were	O
15	other	O
16	polynucleotides	O
17	tested	O
18	in	O
19	promoting	O
20	accumulation	O
21	of	O
22	19	O
23	HDP	O
24	*;	O
25	(	O
26	dT	O
27	)	O
28	8	O
29	was	O
30	as	O
31	effective	O
32	as	O
33	were	O
34	longer	O
35	molecules	O
36	of	O
37	(	O
38	dT	O
39	)	O
40	n	O
41	,	O
42	but	O
43	(	O
44	dT	O
45	)	O
46	4	O
47	and	O
48	(	O
49	dT	O
50	)	O
51	6	O
52	were	O
53	much	O
54	less	O
55	effective	O
56	,	O
57	indicating	O
58	that	O
59	the	O
60	binding	O
61	site	O
62	involved	O
63	in	O
64	19	O
65	HDP	B
66	*	I
67	accumulation	O
68	covered	O
69	between	O
70	6	O
71	and	O
72	8	O
73	residues	O
74	of	O
75	(	O
76	dT	O
77	)	O
78	n	O
79	.	O

1	A	O
2	double	O
3	-	O
4	blind	O
5	trial	O
6	of	O
7	half	O
8	-	O
9	strength	O
10	Polybactrin	O
11	Soluble	O
12	GU	O
13	bladder	O
14	irrigation	O
15	in	O
16	cystoscopy	O
17	.	O

1	Thus	O
2	it	O
3	appears	O
4	that	O
5	insertion	O
6	of	O
7	a	O
8	transposable	O
9	element	O
10	near	O
11	the	O
12	5	O
13	'	O
14	terminus	O
15	of	O
16	the	O
17	structural	O
18	gene	O
19	can	O
20	produce	O
21	constitutive	O
22	expression	O
23	of	O
24	a	O
25	normally	O
26	glucose	O
27	-	O
28	repressed	O
29	enzyme	O
30	.	O

1	Five	O
2	experiments	O
3	examined	O
4	the	O
5	influence	O
6	of	O
7	opiate	O
8	antagonists	O
9	on	O
10	both	O
11	the	O
12	short	O
13	-	O
14	term	O
15	analgesic	O
16	reaction	O
17	resulting	O
18	30	O
19	min	O
20	after	O
21	exposure	O
22	to	O
23	inescapable	O
24	shock	O
25	and	O
26	the	O
27	long	O
28	-	O
29	term	O
30	analgesic	O
31	reaction	O
32	resulting	O
33	after	O
34	reexposure	O
35	to	O
36	shock	O
37	24	O
38	hr	O
39	after	O
40	inescapable	O
41	shock	O
42	exposure	O
43	.	O

1	Experiment	O
2	3	O
3	showed	O
4	that	O
5	the	O
6	long	O
7	-	O
8	term	O
9	analgesic	O
10	reaction	O
11	could	O
12	also	O
13	be	O
14	reduced	O
15	by	O
16	administration	O
17	of	O
18	naltrexone	O
19	prior	O
20	to	O
21	reexposure	O
22	to	O
23	shock	O
24	.	O

1	During	O
2	the	O
3	period	O
4	from	O
5	May	O
6	to	O
7	August	O
8	,	O
9	1978	O
10	,	O
11	an	O
12	epidemic	O
13	of	O
14	hand	O
15	,	O
16	foot	O
17	and	O
18	mouth	O
19	disease	O
20	(	O
21	HFMD	O
22	)	O
23	occurred	O
24	in	O
25	Gifu	O
26	prefecture	O
27	.	O

1	A	O
2	22K	O
3	polypeptide	O
4	was	O
5	detected	O
6	as	O
7	a	O
8	translation	O
9	product	O
10	of	O
11	late	O
12	RNA	O
13	that	O
14	hybridized	O
15	to	O
16	this	O
17	DNA	O
18	fragment	O
19	.	O

1	Replicating	O
2	simian	O
3	virus	O
4	40	O
5	(	O
6	SV40	O
7	)	O
8	chromosomes	O
9	were	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	to	O
15	other	O
16	eukaryotic	O
17	chromosomes	O
18	in	O
19	that	O
20	the	O
21	rate	O
22	and	O
23	extent	O
24	of	O
25	micrococcal	B
26	nuclease	I
27	(	O
28	MNase	B
29	)	O
30	digestion	O
31	were	O
32	greater	O
33	with	O
34	replicating	O
35	than	O
36	with	O
37	nonreplicating	O
38	mature	O
39	SV40	O
40	chromatin	O
41	.	O

1	A	O
2	hypothesis	O
3	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	requirements	O
6	of	O
7	the	O
8	CH	B
9	gene	I
10	switch	O
11	by	O
12	characterizing	O
13	two	O
14	rearranged	B
15	gamma	I
16	2b	I
17	genes	I
18	from	O
19	a	O
20	gamma	B
21	2b	I
22	producing	O
23	mouse	O
24	myeloma	O
25	(	O
26	MPC	O
27	-	O
28	11	O
29	).	O

1	Physiology	O
2	and	O
3	Physiopathology	O

1	The	O
2	genome	O
3	of	O
4	avian	O
5	erythroblastosis	O
6	virus	O
7	contains	O
8	two	O
9	independently	O
10	expressed	O
11	genetic	O
12	loci	O
13	(	O
14	v	B
15	-	I
16	erbA	I
17	and	O
18	v	B
19	-	I
20	erbB	I
21	)	O
22	whose	O
23	activities	O
24	are	O
25	probably	O
26	responsible	O
27	for	O
28	oncogenesis	O
29	by	O
30	the	O
31	virus	O
32	.	O

1	Because	O
2	RNase	B
3	III	I
4	host	I
5	mutants	I
6	are	O
7	defective	O
8	in	O
9	sib	B
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	B
16	mRNA	I
17	at	O
18	sib	B
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	B
25	mRNA	I
26	decay	O
27	and	O
28	decrease	O
29	int	B
30	synthesis	O
31	.	O

1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	O
7	HHG	O
8	41	O
9	,	O
10	contains	O
11	,	O
12	in	O
13	addition	O
14	to	O
15	the	O
16	histone	B
17	genes	I
18	,	O
19	a	O
20	region	O
21	that	O
22	hybridizes	O
23	with	O
24	a	O
25	cytoplasmic	O
26	RNA	O
27	approximately	O
28	330	O
29	nucleotides	O
30	in	O
31	length	O
32	.	O

1	Both	O
2	neural	O
3	and	O
4	hormonal	O
5	pathways	O
6	and	O
7	both	O
8	opiate	O
9	and	O
10	nonopiate	O
11	substances	O
12	play	O
13	roles	O
14	in	O
15	the	O
16	complex	O
17	modulation	O
18	of	O
19	pain	O
20	transmission	O
21	.	O

1	Restoration	O
2	of	O
3	impaired	O
4	immune	O
5	functions	O
6	in	O
7	aging	O
8	animals	O
9	.	O

1	Postoperative	O
2	serum	O
3	ACTH	B
4	levels	O
5	were	O
6	normal	O
7	.	O

1	WR	O
2	-	O
3	2721	O
4	(	O
5	S	O
6	-	O
7	2	O
8	-(	O
9	3	O
10	aminopropylamino	O
11	)	O
12	ethylphosphorothioic	O
13	acid	O
14	)	O
15	has	O
16	been	O
17	investigated	O
18	for	O
19	its	O
20	ability	O
21	to	O
22	protect	O
23	gut	O
24	,	O
25	lung	O
26	,	O
27	and	O
28	testis	O
29	,	O
30	as	O
31	well	O
32	as	O
33	fibrosarcoma	O
34	(	O
35	FSa	O
36	)	O
37	tumor	O
38	nodules	O
39	,	O
40	in	O
41	the	O
42	lungs	O
43	of	O
44	mice	O
45	from	O
46	gamma	O
47	-	O
48	radiation	O
49	injury	O
50	.	O

1	In	O
2	fact	O
3	,	O
4	families	O
5	of	O
6	polypeptides	O
7	were	O
8	produced	O
9	by	O
10	initiation	O
11	of	O
12	translation	O
13	at	O
14	AUG	O
15	codons	O
16	within	O
17	sequences	O
18	coding	O
19	for	O
20	VP1	B
21	and	O
22	T	B
23	,	O
24	presumably	O
25	as	O
26	a	O
27	result	O
28	of	O
29	transcription	O
30	initiation	O
31	events	O
32	that	O
33	generated	O
34	5	O
35	'	O
36	ends	O
37	immediately	O
38	upstream	O
39	from	O
40	these	O
41	AUGs	O
42	.	O

1	In	O
2	addition	O
3	,	O
4	TRP1	B
5	RI	O
6	Circle	O
7	DNA	O
8	is	O
9	organized	O
10	into	O
11	nucleosomes	O
12	whose	O
13	size	O
14	and	O
15	spacing	O
16	are	O
17	indistinguishable	O
18	from	O
19	that	O
20	of	O
21	bulk	O
22	yeast	O
23	chromatin	O
24	.	O

1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O

1	Of	O
2	115	O
3	hepatitis	O
4	B	O
5	patients	O
6	seen	O
7	at	O
8	12	O
9	months	O
10	,	O
11	6	O
12	%	O
13	had	O
14	chronic	O
15	hepatitis	O
16	Bs	O
17	antigenaemia	O
18	,	O
19	60	O
20	%	O
21	had	O
22	developed	O
23	anti	B
24	-	I
25	HBs	I
26	antibodies	I
27	,	O
28	and	O
29	7	O
30	.	O
31	3	O
32	%	O
33	still	O
34	had	O
35	abnormal	O
36	liver	O
37	function	O
38	.	O

1	Survey	O
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O

1	In	O
2	49	O
3	patients	O
4	in	O
5	whom	O
6	gated	O
7	equilibrium	O
8	ventriculography	O
9	and	O
10	cardiac	O
11	catheterization	O
12	were	O
13	performed	O
14	within	O
15	a	O
16	6	O
17	day	O
18	interval	O
19	,	O
20	total	O
21	and	O
22	fractional	O
23	portions	O
24	of	O
25	global	O
26	and	O
27	regional	O
28	right	O
29	ventricular	O
30	ejection	O
31	fraction	O
32	(	O
33	RVEF	O
34	)	O
35	were	O
36	correlated	O
37	with	O
38	pulmonary	O
39	arterial	O
40	systolic	O
41	pressure	O
42	.	O

1	74	O
2	,	O
3	193	O
4	-	O
5	197	O
6	).	O

1	The	O
2	combination	O
3	of	O
4	MISO	O
5	and	O
6	WR	O
7	-	O
8	2721	O
9	gave	O
10	an	O
11	intermediate	O
12	response	O
13	compared	O
14	with	O
15	either	O
16	drug	O
17	used	O
18	alone	O
19	,	O
20	resulting	O
21	in	O
22	some	O
23	sensitization	O
24	with	O
25	single	O
26	doses	O
27	and	O
28	an	O
29	overall	O
30	protection	O
31	with	O
32	repeated	O
33	small	O
34	doses	O
35	.	O

1	Two	O
2	mutations	O
3	that	O
4	affect	O
5	larval	B
6	cuticle	I
7	protein	I
8	gene	I
9	expression	O
10	in	O
11	the	O
12	2	O
13	/	O
14	3	O
15	variant	O
16	Drosophila	O
17	melanogaster	O
18	strain	O
19	were	O
20	investigated	O
21	.	O

1	The	O
2	ensembles	O
3	are	O
4	considered	O
5	to	O
6	be	O
7	one	O
8	of	O
9	the	O
10	forms	O
11	of	O
12	activity	O
13	of	O
14	the	O
15	structured	O
16	morphofunctional	O
17	cortical	O
18	units	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	columns	O
26	.	O

1	The	O
2	strong	O
3	conservation	O
4	of	O
5	the	O
6	inverted	O
7	terminal	O
8	repeat	O
9	sequence	O
10	may	O
11	reflect	O
12	a	O
13	common	O
14	integration	O
15	mechanism	O
16	for	O
17	VL30	B
18	elements	I
19	and	O
20	MuLV	O
21	proviruses	O
22	.	O

1	A	O
2	cDNA	O
3	cloning	O
4	vector	O
5	that	O
6	permits	O
7	expression	O
8	of	O
9	cDNA	O
10	inserts	O
11	in	O
12	mammalian	O
13	cells	O
14	.	O

1	Hybridization	O
2	of	O
3	plasmid	O
4	-	O
5	transformed	O
6	Escherichia	O
7	coli	O
8	RR1	O
9	colonies	O
10	with	O
11	32P	O
12	-	O
13	labeled	O
14	viral	O
15	genome	O
16	RNAs	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	DNA	O
22	clones	O
23	representative	O
24	of	O
25	each	O
26	of	O
27	the	O
28	10	O
29	reovirus	O
30	RNAs	O
31	and	O
32	10	O
33	of	O
34	the	O
35	11	O
36	constituent	O
37	segments	O
38	of	O
39	the	O
40	rotavirus	O
41	genome	O
42	.	O

1	Another	O
2	sequence	O
3	,	O
4	GGGXGGAG	O
5	,	O
6	which	O
7	is	O
8	repeated	O
9	several	O
10	times	O
11	in	O
12	many	O
13	polyomaviruses	O
14	and	O
15	adenoviruses	O
16	,	O
17	and	O
18	which	O
19	is	O
20	thought	O
21	to	O
22	play	O
23	a	O
24	role	O
25	in	O
26	DNA	O
27	replication	O
28	and	O
29	/	O
30	or	O
31	transcription	O
32	,	O
33	is	O
34	not	O
35	found	O
36	in	O
37	the	O
38	JCV	O
39	sequence	O
40	presented	O
41	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	studies	O
6	indicate	O
7	that	O
8	LiCl	O
9	(	O
10	1	O
11	)	O
12	decreases	O
13	histamine	O
14	-	O
15	stimulated	O
16	gastric	O
17	acid	O
18	secretion	O
19	,	O
20	and	O
21	(	O
22	2	O
23	)	O
24	diminishes	O
25	bile	O
26	-	O
27	induced	O
28	disruption	O
29	of	O
30	the	O
31	gastric	O
32	mucosal	O
33	barrier	O
34	in	O
35	the	O
36	canine	O
37	Heidenhain	O
38	pouch	O
39	.	O

1	Lung	O
2	density	O
3	increased	O
4	in	O
5	quartz	O
6	-	O
7	exposed	O
8	,	O
9	but	O
10	not	O
11	in	O
12	volcanic	O
13	-	O
14	ash	O
15	-	O
16	exposed	O
17	animals	O
18	.	O

1	The	O
2	hepatitis	B
3	A	I
4	virus	I
5	antibody	I
6	(	O
7	anti	B
8	-	I
9	HAV	I
10	)	O
11	in	O
12	chronic	O
13	diffuse	O
14	liver	O
15	diseases	O

1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	B
21	sequence	I
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O

1	Naloxone	O
2	(	O
3	2	O
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	X	O
16	h	O
17	-	O
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O

1	Gel	O
2	route	O
3	preparation	O
4	of	O
5	low	O
6	fusing	O
7	dental	O
8	porcelain	O
9	frit	O
10	.	O

1	I	O
2	.	O

1	Viral	O
2	RNA	O
3	,	O
4	molecularly	O
5	cloned	O
6	proviral	O
7	DNA	O
8	,	O
9	and	O
10	virus	O
11	-	O
12	specific	O
13	protein	O
14	of	O
15	avian	O
16	retrovirus	O
17	MH2	O
18	were	O
19	analyzed	O
20	.	O

1	Intracellular	O
2	recordings	O
3	were	O
4	performed	O
5	on	O
6	the	O
7	optic	O
8	tectum	O
9	of	O
10	the	O
11	carp	O
12	in	O
13	vitro	O
14	.	O

1	Molecular	O
2	structure	O
3	and	O
4	evolutionary	O
5	origin	O
6	of	O
7	human	B
8	cardiac	I
9	muscle	I
10	actin	I
11	gene	I
12	.	O

1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O

1	Plasmids	O
2	for	O
3	the	O
4	cloning	O
5	and	O
6	expression	O
7	of	O
8	full	O
9	-	O
10	length	O
11	double	O
12	-	O
13	stranded	O
14	cDNAs	O
15	under	O
16	control	O
17	of	O
18	the	O
19	SV40	B
20	early	I
21	or	O
22	late	B
23	gene	I
24	promoter	O
25	.	O

1	Supplementing	O
2	a	O
3	soybean	O
4	protein	O
5	and	O
6	sucrose	O
7	-	O
8	based	O
9	diet	O
10	with	O
11	levels	O
12	of	O
13	2	O
14	.	O
15	2	O
16	,	O
17	11	O
18	,	O
19	and	O
20	55	O
21	ppm	O
22	of	O
23	the	O
24	antibiotic	O
25	,	O
26	from	O
27	the	O
28	two	O
29	sources	O
30	each	O
31	with	O
32	two	O
33	different	O
34	purities	O
35	,	O
36	improved	O
37	weight	O
38	gain	O
39	of	O
40	chicks	O
41	an	O
42	average	O
43	of	O
44	23	O
45	%	O
46	and	O
47	improved	O
48	feed	O
49	efficiency	O
50	an	O
51	average	O
52	of	O
53	13	O
54	%	O
55	at	O
56	the	O
57	higher	O
58	levels	O
59	(	O
60	all	O
61	P	O
62	less	O
63	than	O
64	.	O
65	01	O
66	).	O

1	The	O
2	dnaQ	B
3	-	O
4	lacZ	B
5	and	O
6	the	O
7	rnh	B
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O

1	Overall	O
2	prevalences	O
3	of	O
4	antibody	O
5	were	O
6	70	O
7	per	O
8	cent	O
9	in	O
10	cattle	O
11	,	O
12	67	O
13	per	O
14	cent	O
15	in	O
16	sheep	O
17	and	O
18	76	O
19	per	O
20	cent	O
21	in	O
22	goats	O
23	as	O
24	assessed	O
25	by	O
26	an	O
27	immunodiffusion	O
28	test	O
29	.	O

1	Expression	O
2	of	O
3	herpes	O
4	simplex	O
5	virus	O
6	beta	O
7	and	O
8	gamma	O
9	genes	O
10	integrated	O
11	in	O
12	mammalian	O
13	cells	O
14	and	O
15	their	O
16	induction	O
17	by	O
18	an	O
19	alpha	O
20	gene	O
21	product	O
22	.	O

1	The	O
2	splice	O
3	acceptor	O
4	site	O
5	is	O
6	ca	O
7	.	O

1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	O
20	sarcoma	O
21	associated	O
22	virus	O
23	and	O
24	proto	B
25	-	I
26	sis	I
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	B
38	-	I
39	sis	I
40	messenger	I
41	RNA	I
42	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	with	O
6	autonomic	O
7	nervous	O
8	system	O
9	activity	O
10	intact	O
11	,	O
12	carotid	O
13	chemoreceptor	O
14	reflex	O
15	activation	O
16	can	O
17	elicit	O
18	an	O
19	absolute	O
20	reflexly	O
21	mediated	O
22	reduction	O
23	in	O
24	coronary	O
25	blood	O
26	flow	O
27	in	O
28	the	O
29	normal	O
30	,	O
31	conscious	O
32	dog	O
33	,	O
34	despite	O
35	an	O
36	increase	O
37	in	O
38	arterial	O
39	pressure	O
40	.	O

1	Female	O
2	subjects	O
3	,	O
4	including	O
5	both	O
6	normal	O
7	subjects	O
8	and	O
9	idiopathic	O
10	calcium	O
11	stone	O
12	-	O
13	formers	O
14	,	O
15	have	O
16	higher	O
17	urinary	O
18	cyclic	O
19	AMP	O
20	levels	O
21	than	O
22	their	O
23	male	O
24	counterparts	O
25	,	O
26	and	O
27	this	O
28	difference	O
29	is	O
30	significant	O
31	when	O
32	urinary	O
33	cyclic	O
34	AMP	O
35	is	O
36	expressed	O
37	in	O
38	the	O
39	units	O
40	mumol	O
41	/	O
42	g	O
43	of	O
44	creatinine	O
45	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	'	O
6	morning	O
7	dip	O
8	'	O
9	observed	O
10	in	O
11	asthmatic	O
12	patients	O
13	cannot	O
14	simply	O
15	be	O
16	explained	O
17	by	O
18	changes	O
19	in	O
20	cell	O
21	receptor	O
22	number	O
23	or	O
24	affinity	O
25	,	O
26	as	O
27	our	O
28	results	O
29	suggest	O
30	that	O
31	both	O
32	groups	O
33	have	O
34	intact	O
35	beta	B
36	-	I
37	adrenoceptor	I
38	function	O
39	.	O

1	The	O
2	effect	O
3	of	O
4	desipramine	O
5	probably	O
6	represents	O
7	inhibition	O
8	of	O
9	neuronal	O
10	uptake	O
11	and	O
12	that	O
13	of	O
14	amitriptyline	O
15	and	O
16	mianserin	O
17	blockade	O
18	of	O
19	neuronal	O
20	uptake	O
21	and	O
22	prejunctional	O
23	alpha	B
24	2	I
25	-	I
26	adrenoreceptors	I
27	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	gp54	B
6	structural	I
7	gene	I
8	is	O
9	required	O
10	for	O
11	initiation	O
12	or	O
13	amplification	O
14	of	O
15	the	O
16	splenic	O
17	erythroblast	O
18	hyperplasia	O
19	which	O
20	characterizes	O
21	the	O
22	preleukemic	O
23	phase	O
24	of	O
25	Rauscher	O
26	disease	O
27	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pulmonary	O
5	metastases	O
6	.	O

1	A	O
2	promoter	O
3	sequence	O
4	(	O
5	Goldberg	O
6	-	O
7	Hogness	O
8	or	O
9	TATA	O
10	box	O
11	)	O
12	is	O
13	situated	O
14	28	O
15	base	O
16	pairs	O
17	upstream	O
18	from	O
19	the	O
20	point	O
21	of	O
22	initiation	O
23	of	O
24	transcription	O
25	which	O
26	was	O
27	found	O
28	by	O
29	S1	B
30	nuclease	I
31	mapping	O
32	and	O
33	by	O
34	oligonucleotide	O
35	-	O
36	primed	O
37	reverse	O
38	transcription	O
39	of	O
40	rat	B
41	PTH	I
42	mRNA	I
43	.	O

1	Each	O
2	of	O
3	these	O
4	spliced	O
5	mRNAs	O
6	has	O
7	an	O
8	untranslated	O
9	leader	O
10	sequence	O
11	of	O
12	249	O
13	bases	O
14	and	O
15	a	O
16	single	O
17	intron	O
18	of	O
19	approximately	O
20	540	O
21	bases	O
22	which	O
23	are	O
24	contained	O
25	entirely	O
26	within	O
27	TRs	O
28	/	O
29	IRs	O
30	sequences	O
31	.	O

1	The	O
2	expression	O
3	of	O
4	chloramphenicol	B
5	acetyltransferase	I
6	was	O
7	detected	O
8	within	O
9	1	O
10	h	O
11	after	O
12	infection	O
13	of	O
14	cells	O
15	with	O
16	recombinant	O
17	virus	O
18	,	O
19	reflecting	O
20	the	O
21	early	O
22	nature	O
23	of	O
24	the	O
25	promoters	O
26	used	O
27	.	O

1	NPT	B
2	II	I
3	synthesis	O
4	,	O
5	measured	O
6	by	O
7	agar	O
8	plate	O
9	assays	O
10	of	O
11	kanamycin	O
12	resistance	O
13	and	O
14	by	O
15	immunoprecipitation	O
16	of	O
17	the	O
18	NPT	B
19	II	I
20	protein	I
21	,	O
22	was	O
23	repressed	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	cysteine	O
29	and	O
30	derepressed	O
31	in	O
32	its	O
33	absence	O
34	.	O

1	A	O
2	computed	O
3	tomographic	O
4	scan	O
5	obtained	O
6	after	O
7	EOE	O
8	-	O
9	13	O
10	infusion	O
11	accurately	O
12	showed	O
13	the	O
14	perfusion	O
15	pattern	O
16	of	O
17	the	O
18	implanted	O
19	catheter	O
20	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	the	O
6	GAL7	B
7	5	I
8	'	I
9	flanking	I
10	region	I
11	has	O
12	many	O
13	features	O
14	common	O
15	to	O
16	those	O
17	of	O
18	multicellular	O
19	eukaryotic	O
20	genes	O
21	.	O

1	The	O
2	12	B
3	,	I
4	000	I
5	MW	I
6	(	I
7	12K	I
8	)	I
9	IE	I
10	polypeptide	I
11	encoded	O
12	by	O
13	IEmRNA	B
14	-	I
15	5	I
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	The	O
2	greatest	O
3	difference	O
4	between	O
5	the	O
6	Ad7	B
7	and	I
8	Ad5	I
9	DBPs	I
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	Ad7	O
17	protein	O
18	,	O
19	of	O
20	12	O
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	O
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	Ad5	O
32	protein	O
33	(	O
34	amino	O
35	acids	O
36	151	O
37	-	O
38	162	O
39	).	O

1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O

1	Furthermore	O
2	,	O
3	no	O
4	Shine	O
5	-	O
6	Dalgarno	O
7	sequences	O
8	are	O
9	present	O
10	upstream	O
11	of	O
12	the	O
13	presumed	O
14	translational	O
15	start	O
16	codons	O
17	.	O

1	The	O
2	gene	B
3	cat	I
4	-	I
5	86	I
6	,	O
7	specifying	O
8	chloramphenicol	B
9	-	I
10	inducible	I
11	chloramphenicol	I
12	acetyltransferase	I
13	,	O
14	is	O
15	located	O
16	on	O
17	the	O
18	1	O
19	.	O
20	1	O
21	-	O
22	kilobase	O
23	cloned	O
24	DNA	O
25	.	O

1	The	O
2	myeloproliferative	O
3	sarcoma	O
4	virus	O
5	(	O
6	MPSV	O
7	)	O
8	was	O
9	derived	O
10	by	O
11	passage	O
12	of	O
13	Moloney	O
14	sarcoma	O
15	virus	O
16	(	O
17	Mo	O
18	-	O
19	MuSV	O
20	)	O
21	in	O
22	adult	O
23	mice	O
24	.	O

1	The	O
2	same	O
3	-	O
4	sized	O
5	EBNA	B
6	protein	I
7	(	I
8	approximately	I
9	78	I
10	,	I
11	000	I
12	)	I
13	was	O
14	made	O
15	after	O
16	transfection	O
17	with	O
18	BamHI	B
19	-	I
20	K	I
21	(	I
22	5	I
23	.	I
24	2	I
25	kilobase	I
26	pairs	I
27	[	I
28	kbp	I
29	])	I
30	or	O
31	the	O
32	I1f	O
33	subfragment	O
34	(	O
35	2	O
36	.	O
37	9	O
38	kbp	O
39	).	O

1	They	O
2	generated	O
3	ca	O
4	.	O

1	Here	O
2	we	O
3	have	O
4	determined	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	3	O
10	.	O
11	5	O
12	kb	O
13	from	O
14	the	O
15	3	O
16	'	O
17	end	O
18	of	O
19	delta	B
20	gag	I
21	to	O
22	the	O
23	3	O
24	'	O
25	end	O
26	of	O
27	molecularly	O
28	cloned	O
29	proviral	O
30	MH2	O
31	DNA	O
32	,	O
33	in	O
34	order	O
35	to	O
36	elucidate	O
37	the	O
38	genetic	O
39	structure	O
40	of	O
41	the	O
42	virus	O
43	and	O
44	to	O
45	compare	O
46	it	O
47	with	O
48	other	O
49	mht	B
50	-	O
51	and	O
52	myc	B
53	-	O
54	containing	O
55	oncogenic	O
56	viruses	O
57	as	O
58	well	O
59	as	O
60	with	O
61	the	O
62	chicken	B
63	proto	I
64	-	I
65	myc	I
66	gene	I
67	.	O

1	USA	O
2	80	O
3	,	O
4	802	O
5	-	O
6	806	O
7	]	O
8	was	O
9	used	O
10	to	O
11	isolate	O
12	a	O
13	genomic	O
14	clone	O
15	lambda	O
16	PGK	B
17	-	I
18	1	I
19	containing	O
20	a	O
21	portion	O
22	of	O
23	an	O
24	autosomal	O
25	locus	O
26	for	O
27	phosphoglycerate	B
28	kinase	I
29	(	O
30	PGK	B
31	).	O

1	A	O
2	.	O

1	188	O
2	patients	O
3	received	O
4	cimetidine	O
5	400	O
6	mg	O
7	q	O
8	.	O
9	i	O
10	.	O
11	d	O
12	.	O
13	intravenously	O
14	and	O
15	1	O
16	,	O
17	000	O
18	mg	O
19	daily	O
20	orally	O
21	in	O
22	divided	O
23	doses	O
24	.	O

1	An	O
2	immunologic	O
3	test	O
4	using	O
5	stomach	O
6	and	O
7	tumor	O
8	antigens	O
9	for	O
10	screening	O
11	of	O
12	those	O
13	at	O
14	high	O
15	risk	O
16	for	O
17	stomach	O
18	cancer	O
19	is	O
20	suggested	O
21	.	O

1	Thirty	O
2	isolates	O
3	of	O
4	Haemophilus	O
5	influenzae	O
6	type	O
7	b	O
8	were	O
9	obtained	O
10	during	O
11	an	O
12	outbreak	O
13	of	O
14	invasive	O
15	H	O
16	.	O
17	influenzae	O
18	type	O
19	b	O
20	disease	O
21	and	O
22	were	O
23	classified	O
24	by	O
25	the	O
26	electrophoretic	O
27	profile	O
28	of	O
29	their	O
30	lipopolysaccharide	O
31	(	O
32	LPS	O
33	).	O

1	Tiaprofenic	O
2	acid	O
3	overdose	O
4	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	DMCM	O
2	also	O
3	permits	O
4	extension	O
5	of	O
6	the	O
7	possibilities	O
8	of	O
9	obtaining	O
10	and	O
11	transplanting	O
12	donor	O
13	organs	O
14	.	O

1	Grimelius	O
2	stain	O
3	was	O
4	positive	O
5	,	O
6	Masson	O
7	Fontana	O
8	stain	O
9	negative	O
10	.	O

1	Blood	O
2	glucose	O
3	and	O
4	plasma	O
5	insulin	B
6	were	O
7	measured	O
8	at	O
9	zero	O
10	time	O
11	and	O
12	then	O
13	at	O
14	15	O
15	,	O
16	30	O
17	,	O
18	60	O
19	,	O
20	90	O
21	and	O
22	120	O
23	min	O
24	after	O
25	ingestion	O
26	of	O
27	25	O
28	g	O
29	glucose	O
30	,	O
31	fructose	O
32	or	O
33	lactose	O
34	,	O
35	or	O
36	30	O
37	g	O
38	honey	O
39	,	O
40	50	O
41	g	O
42	white	O
43	bread	O
44	,	O
45	125	O
46	g	O
47	white	O
48	rice	O
49	or	O
50	potatoes	O
51	,	O
52	150	O
53	g	O
54	apples	O
55	or	O
56	260	O
57	g	O
58	carrots	O
59	.	O

1	Clinical	O
2	use	O
3	of	O
4	absorbable	O
5	polyglycolic	O
6	acid	O
7	suture	O
8	in	O
9	Blalock	O
10	-	O
11	Taussig	O
12	'	O
13	s	O
14	operation	O

1	Among	O
2	these	O
3	are	O
4	:	O
5	(	O
6	1	O
7	)	O
8	Is	O
9	there	O
10	sufficient	O
11	understanding	O
12	of	O
13	family	O
14	pathophysiology	O
15	,	O
16	of	O
17	the	O
18	sensitivity	O
19	and	O
20	specificity	O
21	of	O
22	diagnostic	O
23	techniques	O
24	and	O
25	of	O
26	the	O
27	safety	O
28	and	O
29	efficacy	O
30	of	O
31	therapeutic	O
32	modalities	O
33	to	O
34	make	O
35	true	O
36	family	O
37	health	O
38	care	O
39	possible	O
40	?	O
41	(	O
42	2	O
43	)	O
44	If	O
45	this	O
46	type	O
47	of	O
48	care	O
49	is	O
50	possible	O
51	,	O
52	how	O
53	are	O
54	the	O
55	needs	O
56	of	O
57	the	O
58	family	O
59	and	O
60	its	O
61	individual	O
62	members	O
63	met	O
64	,	O
65	or	O
66	value	O
67	judgements	O
68	made	O
69	about	O
70	their	O
71	relative	O
72	importance	O
73	?	O
74	and	O
75	(	O
76	3	O
77	)	O
78	What	O
79	are	O
80	the	O
81	consequences	O
82	for	O
83	the	O
84	health	O
85	care	O
86	delivery	O
87	system	O
88	of	O
89	this	O
90	type	O
91	of	O
92	care	O
93	?	O
94	An	O
95	extensive	O
96	literature	O
97	review	O
98	is	O
99	used	O
100	in	O
101	an	O
102	attempt	O
103	to	O
104	answer	O
105	these	O
106	queries	O
107	,	O
108	from	O
109	which	O
110	questions	O
111	for	O
112	further	O
113	study	O
114	are	O
115	posed	O
116	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	Immunologically	O
2	reactive	O
3	insulin	B
4	levels	O
5	were	O
6	determined	O
7	in	O
8	freely	O
9	-	O
10	moving	O
11	normal	O
12	rats	O
13	offered	O
14	three	O
15	different	O
16	test	O
17	-	O
18	meals	O
19	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	naturally	O
7	acquired	O
8	and	O
9	passive	O
10	(	O
11	modified	O
12	immune	B
13	serum	I
14	globulin	I
15	)	O
16	antibodies	O
17	to	O
18	type	B
19	III	I
20	group	I
21	B	I
22	Streptococcus	I
23	antigen	I
24	are	O
25	partially	O
26	protective	O
27	against	O
28	intra	O
29	-	O
30	amniotic	O
31	infection	O
32	.	O

1	In	O
2	the	O
3	posthospital	O
4	phase	O
5	of	O
6	AMI	O
7	,	O
8	as	O
9	well	O
10	as	O
11	in	O
12	CCHD	O
13	,	O
14	the	O
15	occurrence	O
16	of	O
17	high	O
18	-	O
19	grade	O
20	VPBs	O
21	usually	O
22	indicates	O
23	more	O
24	advanced	O
25	degrees	O
26	of	O
27	both	O
28	coronary	O
29	and	O
30	left	O
31	ventricular	O
32	disease	O
33	as	O
34	well	O
35	as	O
36	the	O
37	possibility	O
38	of	O
39	cardiac	O
40	and	O
41	/	O
42	or	O
43	sudden	O
44	death	O
45	.	O

1	Sweet	O
2	oranges	O
3	,	O
4	mandarin	O
5	,	O
6	grapefruit	O
7	,	O
8	lemon	O
9	,	O
10	and	O
11	lime	O
12	are	O
13	generally	O
14	used	O
15	for	O
16	processing	O
17	.	O

1	The	O
2	genes	O
3	at	O
4	each	O
5	locus	O
6	are	O
7	divergently	O
8	transcribed	O
9	and	O
10	the	O
11	coding	O
12	sequences	O
13	are	O
14	separated	O
15	by	O
16	646	O
17	base	O
18	-	O
19	pairs	O
20	at	O
21	one	O
22	locus	O
23	and	O
24	676	O
25	base	O
26	-	O
27	pairs	O
28	at	O
29	the	O
30	other	O
31	.	O

1	The	O
2	enzymic	O
3	hydrolysis	O
4	of	O
5	urea	O
6	produces	O
7	ammonia	O
8	which	O
9	causes	O
10	a	O
11	vivid	O
12	yellow	O
13	to	O
14	purple	O
15	colour	O
16	change	O
17	in	O
18	the	O
19	pH	O
20	indicator	O
21	.	O

1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	O
11	-	O
12	R1	O
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	O
38	-	O
39	R1	O
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O

1	Side	O
2	effect	O
3	including	O
4	subjective	O
5	and	O
6	objective	O
7	symptoms	O
8	were	O
9	strictly	O
10	evaluated	O
11	in	O
12	163	O
13	cases	O
14	(	O
15	KS	O
16	-	O
17	R1	O
18	group	O
19	in	O
20	83	O
21	cases	O
22	,	O
23	oral	O
24	group	O
25	in	O
26	80	O
27	cases	O
28	),	O
29	but	O
30	the	O
31	incidence	O
32	rate	O
33	which	O
34	was	O
35	22	O
36	.	O
37	9	O
38	%	O
39	for	O
40	the	O
41	KS	O
42	-	O
43	R1	O
44	group	O
45	and	O
46	23	O
47	.	O
48	8	O
49	%	O
50	for	O
51	the	O
52	oral	O
53	group	O
54	showed	O
55	no	O
56	significant	O
57	difference	O
58	.	O

1	Plasma	O
2	renin	B
3	activity	O
4	did	O
5	not	O
6	change	O
7	in	O
8	response	O
9	to	O
10	head	O
11	-	O
12	up	O
13	tilt	O
14	or	O
15	isoprenaline	O
16	infusion	O
17	in	O
18	the	O
19	patients	O
20	.	O

1	Martin	O
2	Luther	O
3	and	O
4	his	O
5	physicians	O
6	.	O

1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O

1	Induced	O
2	gamma	O
3	-	O
4	ray	O
5	spectroscopy	O

1	Bepridil	O
2	,	O
3	a	O
4	calcium	O
5	antagonist	O
6	with	O
7	a	O
8	half	O
9	-	O
10	life	O
11	of	O
12	approximately	O
13	42	O
14	hours	O
15	,	O
16	was	O
17	compared	O
18	with	O
19	placebo	O
20	in	O
21	a	O
22	double	O
23	-	O
24	blind	O
25	,	O
26	randomized	O
27	,	O
28	crossover	O
29	trial	O
30	.	O

1	Analysis	O
2	of	O
3	proteins	O
4	synthesized	O
5	by	O
6	plasmids	O
7	containing	O
8	deleted	O
9	forms	O
10	of	O
11	the	O
12	trfA	B
13	region	I
14	indicates	O
15	that	O
16	the	O
17	A2	B
18	protein	I
19	is	O
20	the	O
21	essential	O
22	trfA	B
23	-	I
24	encoded	I
25	replication	I
26	protein	I
27	of	O
28	plasmid	O
29	RK2	O
30	.	O

1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O

1	Resting	O
2	plasma	O
3	norepinephrine	O
4	(	O
5	NE	O
6	)	O
7	and	O
8	epinephrine	O
9	(	O
10	E	O
11	)	O
12	levels	O
13	were	O
14	lower	O
15	during	O
16	active	O
17	therapy	O
18	than	O
19	2	O
20	wk	O
21	after	O
22	withdrawal	O
23	(	O
24	guanfacine	O
25	and	O
26	control	O
27	:	O
28	plasma	O
29	NE	O
30	,	O
31	0	O
32	.	O
33	27	O
34	+/-	O
35	0	O
36	.	O
37	03	O
38	/	O
39	0	O
40	.	O
41	64	O
42	+/-	O
43	0	O
44	.	O
45	13	O
46	ng	O
47	/	O
48	ml	O
49	;	O
50	plasma	O
51	E	O
52	,	O
53	0	O
54	.	O
55	09	O
56	+/-	O
57	0	O
58	.	O
59	02	O
60	/	O
61	0	O
62	.	O
63	17	O
64	+/-	O
65	0	O
66	.	O
67	05	O
68	ng	O
69	/	O
70	ml	O
71	).	O

1	Renal	O
2	response	O
3	to	O
4	captopril	O
5	in	O
6	severe	O
7	heart	O
8	failure	O
9	:	O
10	role	O
11	of	O
12	furosemide	O
13	in	O
14	natriuresis	O
15	and	O
16	reversal	O
17	of	O
18	hyponatremia	O
19	.	O

1	Lauciello	O
2	describes	O
3	a	O
4	technique	O
5	for	O
6	the	O
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O

1	Eleven	O
2	biopsy	O
3	specimens	O
4	(	O
5	five	O
6	papules	O
7	and	O
8	six	O
9	dusky	O
10	or	O
11	crusted	O
12	lesions	O
13	)	O
14	from	O
15	four	O
16	patients	O
17	with	O
18	pityriasis	O
19	lichenoides	O
20	et	O
21	varioliformis	O
22	acuta	O
23	(	O
24	PLEVA	O
25	)	O
26	were	O
27	studied	O
28	by	O
29	direct	O
30	immunofluorescence	O
31	and	O
32	immunoperoxidase	B
33	technics	O
34	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	a	O
6	major	O
7	part	O
8	of	O
9	the	O
10	reduction	O
11	in	O
12	food	O
13	intake	O
14	in	O
15	hyperphagic	O
16	rats	O
17	eating	O
18	a	O
19	quinine	O
20	-	O
21	adulterated	O
22	diet	O
23	is	O
24	due	O
25	to	O
26	postingestional	O
27	events	O
28	.	O

1	The	O
2	aspirate	O
3	from	O
4	a	O
5	parathyroid	O
6	cyst	O
7	was	O
8	watery	O
9	clear	O
10	and	O
11	contained	O
12	high	O
13	amount	O
14	of	O
15	parathyroid	B
16	hormone	I
17	.	O

1	EGV	O
2	had	O
3	no	O
4	detectable	O
5	effect	O
6	on	O
7	PP	B
8	secretion	O
9	under	O
10	basal	O
11	or	O
12	stimulated	O
13	conditions	O
14	.	O

1	The	O
2	numerous	O
3	tests	O
4	demonstrate	O
5	that	O
6	the	O
7	HDL	O
8	-	O
9	2M	O
10	can	O
11	be	O
12	extensively	O
13	and	O
14	successfully	O
15	used	O
16	for	O
17	therapy	O
18	of	O
19	insulin	B
20	-	O
21	dependent	O
22	diabetes	O
23	mellitus	O
24	in	O
25	clinical	O
26	practice	O
27	.	O

1	Lung	O
2	prostacyclin	O
3	production	O
4	may	O
5	be	O
6	related	O
7	to	O
8	flow	O
9	.	O

1	For	O
2	the	O
3	first	O
4	30	O
5	min	O
6	following	O
7	insulin	B
8	administration	O
9	,	O
10	the	O
11	rate	O
12	of	O
13	change	O
14	in	O
15	glucose	O
16	levels	O
17	was	O
18	significantly	O
19	less	O
20	among	O
21	the	O
22	patients	O
23	with	O
24	major	O
25	depressive	O
26	disorder	O
27	than	O
28	among	O
29	either	O
30	the	O
31	patients	O
32	with	O
33	dysthymic	O
34	disorder	O
35	or	O
36	the	O
37	normal	O
38	control	O
39	subjects	O
40	.	O

1	Management	O
2	of	O
3	hypertension	O
4	in	O
5	the	O
6	elderly	O
7	.	O

1	Climatic	O
2	treatment	O
3	of	O
4	children	O
5	with	O
6	respiratory	O
7	allergy	O

1	Transplantation	O
2	of	O
3	kidneys	O
4	of	O
5	juvenile	O
6	donors	O
7	in	O
8	adult	O
9	recipients	O
10	.	O

1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O

1	Effect	O
2	of	O
3	proteolytic	O
4	enzymes	O
5	and	O
6	polypeptides	O
7	on	O
8	the	O
9	antacid	O
10	activity	O
11	of	O
12	almagate	O
13	and	O
14	other	O
15	antacids	O
16	.	O

1	Results	O
2	of	O
3	a	O
4	controlled	O
5	study	O

1	Hydrallazine	O
2	also	O
3	caused	O
4	a	O
5	slight	O
6	increase	O
7	in	O
8	plasma	B
9	renin	I
10	activity	O
11	and	O
12	urinary	O
13	excretion	O
14	of	O
15	noradrenaline	O
16	.	O

1	Urease	B
2	activity	O
3	of	O
4	97	O
5	%	O
6	of	O
7	these	O
8	organisms	O
9	became	O
10	evident	O
11	within	O
12	30	O
13	min	O
14	.	O

1	After	O
2	description	O
3	of	O
4	his	O
5	short	O
6	life	O
7	and	O
8	an	O
9	explanation	O
10	of	O
11	the	O
12	light	O
13	conductor	O
14	Bozzini	O
15	'	O
16	s	O
17	merit	O
18	is	O
19	emphasized	O
20	,	O
21	by	O
22	his	O
23	invention	O
24	as	O
25	first	O
26	physician	O
27	to	O
28	have	O
29	made	O
30	accessible	O
31	to	O
32	medicine	O
33	endoscopic	O
34	diagnostic	O
35	possibilities	O
36	.	O

1	The	O
2	effect	O
3	of	O
4	lithium	O
5	on	O
6	the	O
7	osmoregulation	O
8	of	O
9	arginine	B
10	vasopressin	I
11	secretion	O
12	.	O

1	The	O
2	susceptibility	O
3	of	O
4	the	O
5	PPNG	O
6	strains	O
7	to	O
8	clinically	O
9	relevant	O
10	antibiotics	O
11	varied	O
12	with	O
13	the	O
14	plasmid	O
15	pattern	O
16	;	O
17	this	O
18	stresses	O
19	the	O
20	necessity	O
21	of	O
22	permanent	O
23	surveillance	O
24	of	O
25	gonococcal	O
26	infections	O
27	and	O
28	of	O
29	regular	O
30	evaluation	O
31	of	O
32	the	O
33	recommendations	O
34	for	O
35	antimicrobial	O
36	treatment	O
37	.	O

1	Antithrombin	B
2	III	I
3	(	O
4	AT	B
5	III	I
6	)	O
7	is	O
8	a	O
9	plasma	O
10	protein	O
11	which	O
12	acts	O
13	as	O
14	the	O
15	principal	O
16	inhibitor	O
17	of	O
18	thrombin	B
19	and	O
20	is	O
21	a	O
22	major	O
23	modulator	O
24	of	O
25	intravascular	O
26	coagulation	O
27	.	O

1	Eighteen	O
2	patients	O
3	were	O
4	untreated	O
5	,	O
6	and	O
7	8	O
8	had	O
9	been	O
10	given	O
11	previous	O
12	treatment	O
13	with	O
14	depot	O
15	testosterone	O
16	100	O
17	mg	O
18	intramuscularly	O
19	every	O
20	2	O
21	-	O
22	3	O
23	weeks	O
24	for	O
25	an	O
26	average	O
27	duration	O
28	of	O
29	4	O
30	.	O
31	7	O
32	years	O
33	.	O

1	195mPt	O
2	-	O
3	labeled	O
4	cisplatin	O
5	was	O
6	administered	O
7	iv	O
8	and	O
9	ip	O
10	to	O
11	control	O
12	mice	O
13	and	O
14	to	O
15	mice	O
16	bearing	O
17	Sarcoma	O
18	180	O
19	.	O

1	New	O
2	beta	O
3	-	O
4	blocking	O
5	drugs	O
6	have	O
7	been	O
8	introduced	O
9	which	O
10	may	O
11	prove	O
12	beneficial	O
13	in	O
14	certain	O
15	clinical	O
16	situations	O
17	since	O
18	they	O
19	exert	O
20	more	O
21	selective	O
22	blockade	O
23	of	O
24	the	O
25	cardiac	B
26	receptors	I
27	(	O
28	beta1	B
29	)	O
30	as	O
31	opposed	O
32	to	O
33	smooth	B
34	muscle	I
35	receptors	I
36	(	O
37	beta2	B
38	).	O

1	If	O
2	facilities	O
3	for	O
4	measurements	O
5	of	O
6	O2	O
7	consumption	O
8	and	O
9	hence	O
10	metabolic	O
11	rate	O
12	are	O
13	available	O
14	,	O
15	these	O
16	should	O
17	be	O
18	utilized	O
19	.	O

1	This	O
2	generally	O
3	means	O
4	an	O
5	energy	O
6	intake	O
7	of	O
8	1	O
9	.	O
10	4	O
11	to	O
12	1	O
13	.	O
14	6	O
15	times	O
16	the	O
17	energy	O
18	expenditure	O
19	,	O
20	with	O
21	a	O
22	N	O
23	intake	O
24	of	O
25	250	O
26	to	O
27	400	O
28	mg	O
29	/	O
30	kg	O
31	/	O
32	day	O
33	.	O

1	In	O
2	the	O
3	37	O
4	patients	O
5	without	O
6	lung	O
7	disease	O
8	respiratory	O
9	muscle	O
10	weakness	O
11	was	O
12	accompanied	O
13	by	O
14	significant	O
15	decreases	O
16	in	O
17	vital	O
18	capacity	O
19	,	O
20	total	O
21	lung	O
22	capacity	O
23	,	O
24	and	O
25	maximum	O
26	voluntary	O
27	ventilation	O
28	;	O
29	by	O
30	significant	O
31	increases	O
32	in	O
33	residual	O
34	volume	O
35	and	O
36	arterial	O
37	carbon	O
38	dioxide	O
39	tension	O
40	(	O
41	PaCO2	O
42	);	O
43	and	O
44	greater	O
45	likelihood	O
46	of	O
47	dependence	O
48	on	O
49	ventilators	O
50	,	O
51	atelectasis	O
52	,	O
53	and	O
54	pneumonia	O
55	.	O

1	Commun	O
2	.	O

1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	B
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O

1	Total	O
2	cumulative	O
3	doses	O
4	of	O
5	doxorubicin	O
6	ranged	O
7	from	O
8	145	O
9	to	O
10	625	O
11	mg	O
12	./	O
13	m	O
14	.	O
15	2	O
16	.	O

1	Movement	O
2	programming	O
3	depends	O
4	on	O
5	understanding	O
6	of	O
7	behavioral	O
8	requirements	O
9	.	O

1	Following	O
2	20	O
3	min	O
4	of	O
5	steady	O
6	state	O
7	anaesthesia	O
8	during	O
9	which	O
10	measurements	O
11	of	O
12	IOP	O
13	,	O
14	arterial	O
15	pressure	O
16	,	O
17	heart	O
18	rate	O
19	,	O
20	FIO2	O
21	,	O
22	FE	O
23	'	O
24	CO2	O
25	and	O
26	CVP	O
27	were	O
28	recorded	O
29	,	O
30	one	O
31	group	O
32	of	O
33	patients	O
34	received	O
35	atracurium	O
36	0	O
37	.	O
38	45	O
39	mg	O
40	kg	O
41	-	O
42	1	O
43	and	O
44	the	O
45	other	O
46	pancuronium	O
47	0	O
48	.	O
49	1	O
50	mg	O
51	kg	O
52	-	O
53	1	O
54	.	O

1	Transitory	O
2	subclinical	O
3	and	O
4	permanent	O
5	hypothyroidism	O
6	in	O
7	the	O
8	course	O
9	of	O
10	subacute	O
11	thyroiditis	O
12	(	O
13	de	O
14	Quervain	O
15	).	O

1	Gonadotropin	B
2	levels	O
3	in	O
4	mothers	O
5	who	O
6	have	O
7	had	O
8	two	O
9	sets	O
10	of	O
11	DZ	O
12	twins	O
13	.	O

1	Freezing	O
2	of	O
3	plasma	O
4	to	O
5	obtain	O
6	better	O
7	yield	O
8	of	O
9	factor	B
10	VIII	I
11	:	O
12	C	O
13	.	O

1	These	O
2	children	O
3	were	O
4	grouped	O
5	into	O
6	four	O
7	diagnostic	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	idiopathic	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	hypopituitarism	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	intrauterine	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	constitutional	O
43	delay	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	familial	O
50	short	O
51	stature	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	pharmacological	O
65	tests	O
66	of	O
67	GH	B
68	reserve	O
69	.	O

1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	B
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	B
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	B
23	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	O
61	-	O
62	2	O
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	Cimetidine	O
2	800	O
3	mg	O
4	given	O
5	at	O
6	night	O
7	is	O
8	as	O
9	effective	O
10	as	O
11	400	O
12	mg	O
13	twice	O
14	daily	O
15	;	O
16	the	O
17	single	O
18	dose	O
19	regimen	O
20	may	O
21	improve	O
22	patient	O
23	compliance	O
24	,	O
25	thus	O
26	facilitating	O
27	treatment	O
28	.	O

1	Ceftazidime	O
2	shows	O
3	promise	O
4	as	O
5	single	O
6	-	O
7	agent	O
8	therapy	O
9	for	O
10	serious	O
11	gram	O
12	-	O
13	negative	O
14	bacillary	O
15	infections	O
16	.	O

1	Regional	O
2	CBF	O
3	was	O
4	determined	O
5	by	O
6	clearance	O
7	of	O
8	xenon	O
9	133	O
10	in	O
11	67	O
12	patients	O
13	undergoing	O
14	coronary	O
15	bypass	O
16	grafting	O
17	procedures	O
18	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	serum	B
6	BGP	I
7	is	O
8	a	O
9	valuable	O
10	measurement	O
11	of	O
12	bone	O
13	metabolism	O
14	.	O

1	The	O
2	management	O
3	of	O
4	the	O
5	"	O
6	chronic	O
7	"	O
8	patient	O
9	.	O

1	Study	O
2	of	O
3	bacterial	O
4	motility	O
5	and	O
6	rate	O
7	of	O
8	movement	O
9	using	O
10	a	O
11	closed	O
12	circuit	O
13	television	O

1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O

1	Each	O
2	causative	O
3	organism	O
4	has	O
5	a	O
6	species	O
7	-	O
8	specific	O
9	preference	O
10	and	O
11	requirement	O
12	for	O
13	temperature	O
14	,	O
15	salinity	O
16	,	O
17	pH	O
18	,	O
19	the	O
20	basic	O
21	nutrients	O
22	,	O
23	and	O
24	growth	O
25	factors	O
26	,	O
27	and	O
28	the	O
29	toxin	O
30	formation	O
31	is	O
32	affected	O
33	by	O
34	these	O
35	environmental	O
36	factors	O
37	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	axillo	O
6	-	O
7	axillary	O
8	by	O
9	-	O
10	pass	O
11	is	O
12	a	O
13	simple	O
14	solution	O
15	for	O
16	a	O
17	complex	O
18	haemodynamic	O
19	,	O
20	clinical	O
21	and	O
22	therapeutic	O
23	problem	O
24	.	O

1	Deformities	O
2	of	O
3	the	O
4	tip	O
5	of	O
6	the	O
7	olecranon	O
8	and	O
9	of	O
10	the	O
11	coronoid	O
12	process	O
13	are	O
14	also	O
15	described	O
16	(	O
17	De	O
18	Palma	O
19	1956	O
20	,	O
21	Jordan	O
22	1958	O
23	,	O
24	Ahlberg	O
25	1965	O
26	,	O
27	Weseloh	O
28	1973	O
29	).	O

1	There	O
2	was	O
3	significant	O
4	correlation	O
5	of	O
6	LVM	O
7	/	O
8	M2	O
9	and	O
10	PWVn	O
11	for	O
12	pre	O
13	-	O
14	AVR	O
15	and	O
16	post	O
17	AVR	O
18	studies	O
19	.	O

1	Statokinesimetric	O
2	recording	O
3	in	O
4	Huntington	O
5	choreas	O

1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O

1	It	O
2	has	O
3	been	O
4	shown	O
5	in	O
6	an	O
7	animal	O
8	experiment	O
9	that	O
10	alterations	O
11	of	O
12	the	O
13	renal	O
14	vasculature	O
15	and	O
16	parenchyma	O
17	after	O
18	hemostasis	O
19	performed	O
20	by	O
21	Infrared	O
22	-	O
23	Contact	O
24	-	O
25	Coagulation	O
26	are	O
27	best	O
28	shown	O
29	by	O
30	intravital	O
31	magnification	O
32	angiography	O
33	(	O
34	magnification	O
35	factor	O
36	2	O
37	.	O
38	22	O
39	).	O

1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O

1	Intravenous	O
2	injections	O
3	of	O
4	SG	O
5	-	O
6	75	O
7	(	O
8	0	O
9	.	O
10	03	O
11	-	O
12	1	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	decreased	O
18	systemic	O
19	blood	O
20	pressure	O
21	(	O
22	SBP	O
23	)	O
24	and	O
25	increased	O
26	peripheral	O
27	(	O
28	coronary	O
29	,	O
30	renal	O
31	,	O
32	mesenteric	O
33	and	O
34	femoral	O
35	)	O
36	blood	O
37	flow	O
38	(	O
39	PBF	O
40	)	O
41	dose	O
42	-	O
43	dependently	O
44	.	O

1	In	O
2	doses	O
3	of	O
4	0	O
5	.	O
6	03	O
7	-	O
8	0	O
9	.	O
10	3	O
11	mg	O
12	/	O
13	kg	O
14	i	O
15	.	O
16	v	O
17	.,	O
18	SG	O
19	-	O
20	75	O
21	did	O
22	not	O
23	significantly	O
24	affect	O
25	pulse	O
26	pressure	O
27	,	O
28	heart	O
29	rate	O
30	,	O
31	aortic	O
32	blood	O
33	flow	O
34	,	O
35	left	O
36	ventricular	O
37	pressure	O
38	(	O
39	LVP	O
40	)	O
41	and	O
42	LVdP	O
43	/	O
44	dt	O
45	max	O
46	.	O

1	Resting	O
2	VE	O
3	in	O
4	the	O
5	luteal	O
6	phase	O
7	was	O
8	7	O
9	.	O
10	8	O
11	%	O
12	greater	O
13	than	O
14	that	O
15	in	O
16	the	O
17	follicular	O
18	phase	O
19	.	O

1	Exposure	O
2	of	O
3	endothelium	O
4	to	O
5	pulsatile	O
6	shear	O
7	stresses	O
8	that	O
9	followed	O
10	a	O
11	tape	O
12	recording	O
13	of	O
14	physiological	O
15	flow	O
16	waveforms	O
17	(	O
18	electromagnetic	O
19	flowmeter	O
20	)	O
21	did	O
22	not	O
23	cause	O
24	gross	O
25	injury	O
26	or	O
27	denudation	O
28	even	O
29	when	O
30	peak	O
31	shear	O
32	exceeded	O
33	1500	O
34	dyne	O
35	/	O
36	cm2	O
37	.	O

1	Modern	O
2	cancer	O
3	therapy	O
4	has	O
5	included	O
6	surgery	O
7	,	O
8	radiotherapy	O
9	,	O
10	chemotherapy	O
11	,	O
12	and	O
13	most	O
14	recently	O
15	,	O
16	immunotherapy	O
17	and	O
18	hyperthermia	O
19	.	O

1	There	O
2	was	O
3	a	O
4	close	O
5	correlation	O
6	between	O
7	plasma	O
8	clearance	O
9	of	O
10	NT	O
11	by	O
12	10	O
13	-	O
14	hydroxylation	O
15	and	O
16	the	O
17	D	O
18	metabolic	O
19	ratio	O
20	(	O
21	D	O
22	/	O
23	4	O
24	-	O
25	OH	O
26	-	O
27	D	O
28	in	O
29	urine	O
30	)	O
31	in	O
32	the	O
33	Ghanaians	O
34	(	O
35	rs	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	01	O
48	)	O
49	and	O
50	Swedes	O
51	(	O
52	rs	O
53	=	O
54	-	O
55	0	O
56	.	O
57	84	O
58	;	O
59	P	O
60	less	O
61	than	O
62	0	O
63	.	O
64	01	O
65	).	O

1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O

1	Endothelium	O
2	of	O
3	the	O
4	central	O
5	ear	O
6	artery	O
7	of	O
8	an	O
9	anesthetized	O
10	rabbit	O
11	is	O
12	damaged	O
13	by	O
14	placing	O
15	artery	O
16	forceps	O
17	on	O
18	the	O
19	ear	O
20	directly	O
21	over	O
22	the	O
23	vessel	O
24	.	O

1	Despite	O
2	supraphysiologic	O
3	E2	O
4	concentrations	O
5	,	O
6	however	O
7	,	O
8	cervical	O
9	mucus	O
10	scores	O
11	were	O
12	significantly	O
13	reduced	O
14	in	O
15	the	O
16	CC	O
17	-	O
18	treated	O
19	group	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	01	O
27	).	O

1	Stimulation	O
2	of	O
3	the	O
4	caudate	O
5	nucleus	O
6	'	O
7	dophamine	O
8	-	O
9	reactive	O
10	system	O
11	in	O
12	dogs	O
13	by	O
14	means	O
15	of	O
16	administration	O
17	of	O
18	dophamine	O
19	(	O
20	60	O
21	micrograms	O
22	)	O
23	and	O
24	phenamine	O
25	led	O
26	to	O
27	deterioration	O
28	of	O
29	conditioned	O
30	and	O
31	unconditioned	O
32	components	O
33	of	O
34	feeding	O
35	behaviour	O
36	.	O

1	Value	O
2	of	O
3	urine	O
4	glucose	O
5	tests	O
6	in	O
7	the	O
8	management	O
9	of	O
10	type	O
11	II	O
12	diabetes	O
13	mellitus	O
14	.	O

1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O

1	Hydrocortisone	O
2	seems	O
3	to	O
4	be	O
5	unable	O
6	to	O
7	hinder	O
8	the	O
9	postdenervation	O
10	changes	O
11	in	O
12	the	O
13	muscle	O
14	membrane	O
15	whereas	O
16	high	O
17	doses	O
18	of	O
19	the	O
20	hormone	O
21	are	O
22	able	O
23	to	O
24	induce	O
25	changes	O
26	in	O
27	the	O
28	muscle	O
29	membrane	O
30	.	O

1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	O
12	were	O
13	longer	O
14	survival	O
15	time	O
16	following	O
17	diagnosis	O
18	of	O
19	illness	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O

1	A	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	apalcillin	O
6	was	O
7	performed	O
8	in	O
9	12	O
10	patients	O
11	in	O
12	an	O
13	intensive	O
14	-	O
15	care	O
16	unit	O
17	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	was	O
6	observed	O
7	only	O
8	for	O
9	a	O
10	12	O
11	-	O
12	month	O
13	period	O
14	in	O
15	4	O
16	children	O
17	with	O
18	a	O
19	bone	O
20	age	O
21	of	O
22	7	O
23	to	O
24	8	O
25	years	O
26	.	O

1	Thrombocyte	O
2	function	O
3	was	O
4	impaired	O
5	in	O
6	all	O
7	patients	O
8	,	O
9	characterized	O
10	by	O
11	a	O
12	diminished	O
13	platelet	O
14	shape	O
15	change	O
16	.	O

1	The	O
2	findings	O
3	demonstrate	O
4	that	O
5	AMPH	O
6	administration	O
7	induces	O
8	a	O
9	significant	O
10	increase	O
11	in	O
12	the	O
13	height	O
14	of	O
15	a	O
16	major	O
17	electroactive	O
18	peak	O
19	in	O
20	the	O
21	caudate	O
22	nucleus	O
23	of	O
24	pigtail	O
25	monkeys	O
26	,	O
27	and	O
28	further	O
29	that	O
30	such	O
31	amphetamine	O
32	-	O
33	induced	O
34	increases	O
35	can	O
36	be	O
37	manipulated	O
38	by	O
39	altering	O
40	the	O
41	affective	O
42	and	O
43	/	O
44	or	O
45	emotional	O
46	state	O
47	of	O
48	the	O
49	animal	O
50	.	O

1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	O
24	-	O
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O

1	For	O
2	228	O
3	of	O
4	425	O
5	deaths	O
6	(	O
7	54	O
8	%)	O
9	occurring	O
10	among	O
11	26	O
12	100	O
13	people	O
14	of	O
15	known	O
16	age	O
17	in	O
18	the	O
19	Malumfashi	O
20	area	O
21	of	O
22	northern	O
23	Nigeria	O
24	,	O
25	data	O
26	were	O
27	collected	O
28	on	O
29	symptoms	O
30	present	O
31	prior	O
32	to	O
33	death	O
34	.	O

1	Salivary	O
2	estradiol	O
3	17	O
4	beta	O
5	(	O
6	E2	O
7	-	O
8	17	O
9	beta	O
10	)	O
11	and	O
12	progesterone	O
13	(	O
14	P	O
15	)	O
16	were	O
17	determined	O
18	by	O
19	using	O
20	radioimmunoassay	O
21	techniques	O
22	in	O
23	30	O
24	pregnant	O
25	females	O
26	in	O
27	the	O
28	first	O
29	,	O
30	second	O
31	and	O
32	third	O
33	trimesters	O
34	as	O
35	well	O
36	as	O
37	in	O
38	10	O
39	non	O
40	-	O
41	pregnant	O
42	controls	O
43	during	O
44	the	O
45	luteal	O
46	phase	O
47	of	O
48	the	O
49	menstrual	O
50	cycle	O
51	.	O

1	Other	O
2	than	O
3	d	O
4	7	O
5	,	O
6	there	O
7	was	O
8	no	O
9	significant	O
10	effect	O
11	on	O
12	the	O
13	number	O
14	of	O
15	implants	O
16	.	O

1	Variable	O
2	FHR	O
3	decelerations	O
4	or	O
5	bradycardias	O
6	were	O
7	encountered	O
8	on	O
9	95	O
10	nonstress	O
11	tests	O
12	(	O
13	18	O
14	.	O
15	8	O
16	%)	O
17	in	O
18	80	O
19	(	O
20	33	O
21	.	O
22	5	O
23	%)	O
24	postdate	O
25	patients	O
26	.	O

1	The	O
2	response	O
3	chain	O
4	in	O
5	each	O
6	component	O
7	was	O
8	maintained	O
9	by	O
10	food	O
11	presentation	O
12	under	O
13	a	O
14	fixed	O
15	-	O
16	ratio	O
17	schedule	O
18	.	O

1	The	O
2	results	O
3	imply	O
4	that	O
5	kindling	O
6	does	O
7	not	O
8	produce	O
9	its	O
10	facilitating	O
11	effect	O
12	on	O
13	acquisition	O
14	of	O
15	HPC	O
16	SS	O
17	by	O
18	removing	O
19	a	O
20	disruptive	O
21	effect	O
22	of	O
23	the	O
24	stimulation	O
25	.	O

1	The	O
2	persistent	O
3	fetal	O
4	dispersion	O
5	of	O
6	nodal	O
7	and	O
8	Hiss	O
9	bundle	O
10	fragments	O
11	within	O
12	the	O
13	ventricular	O
14	septum	O
15	is	O
16	proposed	O
17	as	O
18	a	O
19	possible	O
20	explanation	O
21	.	O

1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O

1	Changes	O
2	of	O
3	plasma	O
4	cortisol	O
5	level	O
6	in	O
7	late	O
8	asthmatic	O
9	responses	O

1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	vasectomized	O
6	rats	O
7	from	O
8	sham	O
9	rats	O
10	included	O
11	:	O
12	testicular	O
13	and	O
14	epididymal	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	pathologic	O
20	vas	O
21	deferens	O
22	granulomas	O
23	,	O
24	decreased	O
25	total	O
26	serum	O
27	protein	O
28	,	O
29	lowered	O
30	alpha	B
31	-	I
32	globulin	I
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	agglutinin	B
44	antibody	O
45	titers	O
46	.	O

1	SFP	O
2	was	O
3	significantly	O
4	elevated	O
5	in	O
6	Hn	O
7	(	O
8	s	O
9	).	O

1	The	O
2	average	O
3	birth	O
4	mass	O
5	of	O
6	these	O
7	newborns	O
8	was	O
9	3491	O
10	.	O
11	9	O
12	+/-	O
13	2	O
14	SD	O
15	780	O
16	.	O
17	5	O
18	g	O
19	and	O
20	that	O
21	in	O
22	the	O
23	control	O
24	group	O
25	3	O
26	,	O
27	767	O
28	.	O
29	5	O
30	+/-	O
31	2	O
32	SD	O
33	824	O
34	.	O
35	2	O
36	g	O
37	(	O
38	P	O
39	less	O
40	than	O
41	0	O
42	.	O
43	05	O
44	).	O

1	This	O
2	machine	O
3	drift	O
4	,	O
5	which	O
6	was	O
7	not	O
8	associated	O
9	with	O
10	a	O
11	rise	O
12	in	O
13	water	O
14	phantom	O
15	temperature	O
16	and	O
17	did	O
18	not	O
19	consistently	O
20	correlate	O
21	with	O
22	estimated	O
23	x	O
24	-	O
25	ray	O
26	tube	O
27	heat	O
28	,	O
29	could	O
30	result	O
31	in	O
32	a	O
33	significant	O
34	overestimation	O
35	of	O
36	regional	O
37	cerebral	O
38	blood	O
39	flow	O
40	(	O
41	rCBF	O
42	)	O
43	for	O
44	a	O
45	xenon	O
46	/	O
47	CT	O
48	rCBF	O
49	protocol	O
50	involving	O
51	5	O
52	-	O
53	7	O
54	sequential	O
55	scans	O
56	obtained	O
57	at	O
58	1	O
59	-	O
60	min	O
61	interscan	O
62	intervals	O
63	.	O

1	Other	O
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	O
9	12	O
10	and	O
11	Vinca	O
12	are	O
13	unaltered	O
14	.	O

1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	2X	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	8X	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O

1	By	O
2	contrast	O
3	,	O
4	kidneys	O
5	from	O
6	rats	O
7	with	O
8	chronic	O
9	metabolic	O
10	acidosis	O
11	produced	O
12	significantly	O
13	more	O
14	NH3	O
15	than	O
16	both	O
17	these	O
18	groups	O
19	(	O
20	2	O
21	.	O
22	73	O
23	+/-	O
24	0	O
25	.	O
26	29	O
27	mumol	O
28	X	O
29	min	O
30	-	O
31	1	O
32	X	O
33	g	O
34	-	O
35	1	O
36	).	O

1	Serodiagnosis	O
2	of	O
3	trypanosomiasis	O
4	in	O
5	dromedary	O
6	camels	O
7	using	O
8	a	O
9	card	O
10	agglutination	O
11	test	O
12	set	O
13	(	O
14	Testryp	O
15	CATT	O
16	).	O

1	Adenyl	B
2	cyclase	I
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O

1	Proteinuria	O
2	--	O
3	selected	O
4	physiopathological	O
5	and	O
6	clinical	O
7	problems	O

1	However	O
2	,	O
3	subcutaneously	O
4	administered	O
5	pneumococci	O
6	gave	O
7	a	O
8	lower	O
9	mortality	O
10	than	O
11	pneumococci	O
12	given	O
13	intravenously	O
14	or	O
15	intraperitoneally	O
16	.	O

1	Reaction	O
2	of	O
3	human	O
4	organism	O
5	to	O
6	exercise	O
7	.	O

1	HA	O
2	resulted	O
3	in	O
4	decreased	O
5	(	O
6	p	O
7	less	O
8	than	O
9	0	O
10	.	O
11	05	O
12	)	O
13	Tre	O
14	(	O
15	0	O
16	.	O
17	4	O
18	degrees	O
19	C	O
20	)	O
21	and	O
22	HR	O
23	(	O
24	17	O
25	b	O
26	X	O
27	min	O
28	-	O
29	1	O
30	),	O
31	and	O
32	increased	O
33	(	O
34	p	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	)	O
41	Msw	O
42	(	O
43	16	O
44	g	O
45	X	O
46	m	O
47	-	O
48	2	O
49	X	O
50	h	O
51	-	O
52	1	O
53	)	O
54	during	O
55	the	O
56	saline	O
57	experiments	O
58	.	O

1	The	O
2	results	O
3	obtained	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	The	O
9	mitral	O
10	valve	O
11	orifice	O
12	area	O
13	(	O
14	MVA	O
15	)	O
16	was	O
17	significantly	O
18	smaller	O
19	in	O
20	patients	O
21	with	O
22	type	O
23	III	O
24	of	O
25	the	O
26	LVIT	O
27	flow	O
28	velocity	O
29	pattern	O
30	than	O
31	in	O
32	patients	O
33	with	O
34	type	O
35	I	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Scientific	O
2	cooperation	O
3	of	O
4	CMEA	O
5	member	O
6	countries	O
7	has	O
8	been	O
9	carried	O
10	out	O
11	since	O
12	1974	O
13	under	O
14	the	O
15	sponsorship	O
16	of	O
17	the	O
18	Cancer	O
19	Research	O
20	Institute	O
21	,	O
22	Slovak	O
23	Academy	O
24	of	O
25	Sciences	O
26	(	O
27	Czechoslovakia	O
28	)	O
29	within	O
30	the	O
31	framework	O
32	of	O
33	CMEA	O
34	.	O

1	This	O
2	compares	O
3	favorably	O
4	to	O
5	results	O
6	of	O
7	similarly	O
8	sized	O
9	melanomas	O
10	treated	O
11	by	O
12	enucleation	O
13	.	O

1	A	O
2	new	O
3	variant	O
4	of	O
5	the	O
6	EMG	O
7	-	O
8	BFB	O
9	method	O
10	(	O
11	multichannel	O
12	)	O
13	is	O
14	offered	O
15	which	O
16	has	O
17	made	O
18	it	O
19	possible	O
20	to	O
21	use	O
22	the	O
23	method	O
24	not	O
25	only	O
26	for	O
27	training	O
28	weakened	O
29	muscles	O
30	and	O
31	reducing	O
32	spasticity	O
33	in	O
34	their	O
35	antagonists	O
36	but	O
37	also	O
38	for	O
39	improving	O
40	motor	O
41	coordination	O
42	.	O

1	Lymphocytes	O
2	from	O
3	all	O
4	3	O
5	species	O
6	yielded	O
7	maximum	O
8	responses	O
9	with	O
10	a	O
11	48	O
12	-	O
13	hour	O
14	prelabel	O
15	and	O
16	12	O
17	-	O
18	to	O
19	-	O
20	16	O
21	hour	O
22	postlabel	O
23	incubation	O
24	period	O
25	at	O
26	41	O
27	C	O
28	and	O
29	1	O
30	:	O
31	20	O
32	blood	O
33	dilution	O
34	.	O

1	However	O
2	,	O
3	there	O
4	was	O
5	a	O
6	difference	O
7	in	O
8	the	O
9	quality	O
10	of	O
11	immunity	O
12	:	O
13	fever	O
14	and	O
15	body	O
16	weight	O
17	loss	O
18	were	O
19	seen	O
20	in	O
21	hamsters	O
22	vaccinated	O
23	with	O
24	the	O
25	killed	O
26	-	O
27	toxoplasma	O
28	vaccine	O
29	after	O
30	they	O
31	were	O
32	challenge	O
33	exposed	O
34	with	O
35	T	O
36	-	O
37	1	O
38	strain	O
39	,	O
40	whereas	O
41	these	O
42	changes	O
43	were	O
44	rarely	O
45	seen	O
46	in	O
47	hamsters	O
48	given	O
49	the	O
50	live	O
51	-	O
52	toxoplasma	O
53	vaccine	O
54	and	O
55	then	O
56	challenge	O
57	exposed	O
58	with	O
59	RH	O
60	strain	O
61	.	O

1	Alternating	O
2	proline	O
3	/	O
4	alanine	O
5	sequence	O
6	of	O
7	beta	B
8	B1	I
9	subunit	I
10	originates	O
11	from	O
12	a	O
13	repetitive	O
14	DNA	O
15	sequence	O
16	.	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	B
34	phosphatase	I
35	(	O
36	ACP	B
37	)	O
38	method	O
39	.	O

1	Removal	O
2	of	O
3	lipid	O
4	fractions	O
5	of	O
6	plant	O
7	extractions	O
8	with	O
9	hexane	O
10	is	O
11	recommended	O
12	to	O
13	avoid	O
14	damage	O
15	to	O
16	the	O
17	HPLC	O
18	column	O
19	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	The	O
2	toxicological	O
3	evaluation	O
4	of	O
5	chlorofluorocarbon	O
6	22	O
7	(	O
8	CFC	O
9	22	O
10	).	O

1	All	O
2	patients	O
3	were	O
4	evaluable	O
5	for	O
6	toxicity	O
7	and	O
8	9	O
9	for	O
10	response	O
11	.	O

1	Methods	O
2	of	O
3	clinical	O
4	and	O
5	experimental	O
6	algesimetry	O
7	are	O
8	described	O
9	that	O
10	have	O
11	been	O
12	used	O
13	to	O
14	evaluate	O
15	effects	O
16	of	O
17	peripherally	O
18	and	O
19	centrally	O
20	acting	O
21	analgesics	O
22	.	O

1	The	O
2	present	O
3	paper	O
4	elucidates	O
5	the	O
6	existing	O
7	discrepancies	O
8	,	O
9	and	O
10	offers	O
11	a	O
12	consistent	O
13	terminology	O
14	incorporating	O
15	also	O
16	such	O
17	terms	O
18	as	O
19	"	O
20	additivity	O
21	",	O
22	"	O
23	potentiation	O
24	",	O
25	and	O
26	"	O
27	simple	O
28	similarity	O
29	".	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	ambiguous	O
6	discrimination	O
7	required	O
8	a	O
9	greater	O
10	time	O
11	for	O
12	simulus	O
13	evaluation	O
14	and	O
15	that	O
16	this	O
17	was	O
18	reflected	O
19	in	O
20	the	O
21	delayed	O
22	P3	O
23	latencies	O
24	.	O

1	Ammonia	O
2	concentration	O
3	dropped	O
4	significantly	O
5	in	O
6	all	O
7	treatments	O
8	,	O
9	a	O
10	finding	O
11	which	O
12	suggests	O
13	a	O
14	protective	O
15	effect	O
16	on	O
17	protein	O
18	nitrogen	O
19	degradation	O
20	to	O
21	non	O
22	-	O
23	protein	O
24	nitrogen	O
25	(	O
26	NH3	O
27	).	O

1	In	O
2	this	O
3	respect	O
4	C	B
5	reactive	I
6	protein	I
7	concentrations	O
8	are	O
9	superior	O
10	to	O
11	white	O
12	cell	O
13	count	O
14	,	O
15	erythrocyte	O
16	sedimentation	O
17	rate	O
18	,	O
19	and	O
20	temperature	O
21	and	O
22	the	O
23	concentrations	O
24	of	O
25	antiproteases	O
26	.	O

1	Human	B
2	thyroid	I
3	stimulator	I
4	(	O
5	HTS	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O

1	We	O
2	conclude	O
3	that	O
4	administration	O
5	of	O
6	the	O
7	calcium	O
8	antagonist	O
9	Verapamil	O
10	is	O
11	of	O
12	no	O
13	additional	O
14	value	O
15	in	O
16	tocolytic	O
17	treatment	O
18	with	O
19	beta	O
20	-	O
21	mimetics	O
22	.	O

1	Brainstem	O
2	auditory	O
3	evoked	O
4	responses	O
5	(	O
6	BAERs	O
7	)	O
8	and	O
9	quantitative	O
10	saccadic	O
11	eye	O
12	movement	O
13	studies	O
14	provide	O
15	information	O
16	on	O
17	the	O
18	integrity	O
19	of	O
20	pathways	O
21	traversing	O
22	the	O
23	brainstem	O
24	.	O

1	Effects	O
2	of	O
3	ketamine	O
4	on	O
5	the	O
6	circulatory	O
7	functions	O
8	and	O
9	body	O
10	tissue	O
11	oxygenation	O
12	in	O
13	dogs	O
14	under	O
15	normal	O
16	and	O
17	hypovolemic	O
18	conditions	O
19	.	O

1	The	O
2	salient	O
3	clinical	O
4	features	O
5	,	O
6	the	O
7	problems	O
8	of	O
9	management	O
10	and	O
11	the	O
12	modern	O
13	approaches	O
14	to	O
15	the	O
16	reconstruction	O
17	of	O
18	facial	O
19	deformities	O
20	seen	O
21	in	O
22	this	O
23	disease	O
24	are	O
25	described	O
26	.	O

1	Besides	O
2	,	O
3	it	O
4	was	O
5	considered	O
6	that	O
7	the	O
8	NPF	O
9	was	O
10	a	O
11	useful	O
12	tool	O
13	for	O
14	activation	O
15	of	O
16	velopharyngeal	O
17	activity	O
18	by	O
19	way	O
20	of	O
21	visual	O
22	feed	O
23	-	O
24	back	O
25	control	O
26	.	O

1	To	O
2	evaluate	O
3	the	O
4	comparative	O
5	safety	O
6	of	O
7	U	O
8	-	O
9	P	O
10	and	O
11	D	O
12	&	O
13	E	O
14	,	O
15	we	O
16	analyzed	O
17	2	O
18	,	O
19	805	O
20	U	O
21	-	O
22	P	O
23	and	O
24	9	O
25	,	O
26	572	O
27	D	O
28	&	O
29	E	O
30	abortions	O
31	at	O
32	13	O
33	to	O
34	24	O
35	menstrual	O
36	weeks	O
37	'	O
38	gestation	O
39	.	O

1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	O
20	.	O

1	In	O
2	a	O
3	man	O
4	with	O
5	myelomonocytic	O
6	leukemia	O
7	,	O
8	the	O
9	association	O
10	of	O
11	increased	O
12	prostatic	B
13	acid	I
14	phosphatase	I
15	activity	O
16	in	O
17	serum	O
18	and	O
19	the	O
20	presence	O
21	of	O
22	typical	O
23	bone	O
24	lesions	O
25	on	O
26	roentgenography	O
27	suggested	O
28	the	O
29	existence	O
30	of	O
31	disseminated	O
32	prostatic	O
33	carcinoma	O
34	.	O

1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O

1	An	O
2	experimental	O
3	long	O
4	-	O
5	term	O
6	study	O
7	.	O

1	No	O
2	anisotropism	O
3	was	O
4	recorded	O
5	in	O
6	a	O
7	tetrahydrofuran	O
8	solution	O
9	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O

1	The	O
2	calculated	O
3	values	O
4	of	O
5	lambda	O
6	tb	O
7	at	O
8	37	O
9	degrees	O
10	C	O
11	and	O
12	50	O
13	per	O
14	cent	O
15	haematocrit	O
16	were	O
17	0	O
18	.	O
19	650	O
20	for	O
21	the	O
22	pulp	O
23	,	O
24	0	O
25	.	O
26	674	O
27	for	O
28	the	O
29	tongue	O
30	,	O
31	0	O
32	.	O
33	828	O
34	for	O
35	the	O
36	submandibular	O
37	gland	O
38	and	O
39	0	O
40	.	O
41	881	O
42	for	O
43	the	O
44	gingiva	O
45	of	O
46	the	O
47	dog	O
48	.	O
49	lambda	O
50	cp	O
51	increased	O
52	and	O
53	lambda	O
54	tp	O
55	decreased	O
56	as	O
57	the	O
58	temperature	O
59	was	O
60	reduced	O
61	from	O
62	37	O
63	to	O
64	4	O
65	degrees	O
66	C	O
67	.	O

1	As	O
2	pleural	O
3	thickening	O
4	is	O
5	seen	O
6	commonly	O
7	in	O
8	asbestosis	O
9	and	O
10	may	O
11	influence	O
12	lung	O
13	volumes	O
14	and	O
15	the	O
16	ratio	O
17	of	O
18	transfer	B
19	factor	I
20	to	O
21	effective	O
22	alveolar	O
23	volume	O
24	,	O
25	the	O
26	results	O
27	of	O
28	these	O
29	measurements	O
30	were	O
31	compared	O
32	only	O
33	in	O
34	the	O
35	cases	O
36	showing	O
37	absent	O
38	or	O
39	minimal	O
40	pleural	O
41	thickening	O
42	.	O

1	The	O
2	invasive	O
3	pattern	O
4	of	O
5	squamous	O
6	cell	O
7	carcinoma	O
8	in	O
9	the	O
10	mandibular	O
11	gingiva	O

1	Azygos	O
2	vein	O
3	abutting	O
4	the	O
5	posterior	O
6	wall	O
7	of	O
8	the	O
9	right	O
10	main	O
11	and	O
12	upper	O
13	lobe	O
14	bronchi	O
15	:	O
16	a	O
17	normal	O
18	CT	O
19	variant	O
20	.	O

1	However	O
2	,	O
3	the	O
4	history	O
5	of	O
6	acute	O
7	severe	O
8	complications	O
9	from	O
10	otitis	O
11	media	O
12	revealed	O
13	a	O
14	higher	O
15	frequency	O
16	in	O
17	those	O
18	individuals	O
19	with	O
20	alpha	B
21	1	I
22	-	I
23	antitrypsin	I
24	deficiency	O
25	as	O
26	compared	O
27	to	O
28	normals	O
29	.	O

1	The	O
2	Sarns	O
3	51F	O
4	cavoatrial	O
5	cannula	O
6	decompressed	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	caval	O
16	cannulas	O
17	.	O

1	All	O
2	other	O
3	changes	O
4	at	O
5	the	O
6	3	O
7	-,	O
8	5	O
9	-,	O
10	and	O
11	6	O
12	-	O
13	positions	O
14	,	O
15	as	O
16	well	O
17	as	O
18	the	O
19	replacement	O
20	of	O
21	the	O
22	phenyl	O
23	group	O
24	at	O
25	position	O
26	2	O
27	,	O
28	caused	O
29	a	O
30	marked	O
31	decrease	O
32	of	O
33	activity	O
34	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	Limb	O
2	allografts	O
3	in	O
4	rats	O
5	immunosuppressed	O
6	with	O
7	cyclosporin	O
8	A	O
9	.	O

1	The	O
2	method	O
3	involved	O
4	deproteinizing	O
5	samples	O
6	with	O
7	two	O
8	volumes	O
9	of	O
10	acetonitrile	O
11	followed	O
12	by	O
13	injection	O
14	of	O
15	5	O
16	microliters	O
17	of	O
18	deproteinized	O
19	supernatant	O
20	onto	O
21	a	O
22	C18	O
23	reversed	O
24	-	O
25	phase	O
26	column	O
27	.	O

1	Refractory	O
2	periods	O
3	of	O
4	the	O
5	AV	O
6	junction	O
7	were	O
8	altered	O
9	in	O
10	a	O
11	comparable	O
12	fashion	O
13	to	O
14	conduction	O
15	through	O
16	the	O
17	AV	O
18	node	O
19	.	O

1	This	O
2	paper	O
3	brings	O
4	together	O
5	data	O
6	,	O
7	obtained	O
8	from	O
9	a	O
10	variety	O
11	of	O
12	sources	O
13	,	O
14	on	O
15	the	O
16	extent	O
17	of	O
18	prescription	O
19	and	O
20	use	O
21	of	O
22	psychotropic	O
23	drugs	O
24	in	O
25	the	O
26	late	O
27	1960s	O
28	and	O
29	early	O
30	1970s	O
31	.	O

1	Sixteen	O
2	patients	O
3	were	O
4	studied	O
5	within	O
6	24	O
7	hours	O
8	of	O
9	resuscitation	O
10	and	O
11	all	O
12	showed	O
13	depressed	O
14	right	O
15	ventricular	O
16	ejection	O
17	(	O
18	RVEF	O
19	)	O
20	and	O
21	/	O
22	or	O
23	an	O
24	increased	O
25	end	O
26	-	O
27	diastolic	O
28	volume	O
29	(	O
30	RVEDVI	O
31	).	O

1	During	O
2	a	O
3	single	O
4	LAD	O
5	occlusion	O
6	lasting	O
7	35	O
8	minutes	O
9	(	O
10	series	O
11	I	O
12	,	O
13	n	O
14	=	O
15	10	O
16	)	O
17	9	O
18	microns	O
19	TMs	O
20	were	O
21	infused	O
22	immediately	O
23	and	O
24	30	O
25	minutes	O
26	after	O
27	ligation	O
28	,	O
29	15	O
30	microns	O
31	TMs	O
32	being	O
33	infused	O
34	after	O
35	15	O
36	-	O
37	20	O
38	minutes	O
39	.	O

1	The	O
2	population	O
3	of	O
4	between	O
5	75	O
6	,	O
7	000	O
8	and	O
9	100	O
10	,	O
11	000	O
12	was	O
13	largely	O
14	unstable	O
15	,	O
16	and	O
17	cost	O
18	per	O
19	capita	O
20	was	O
21	$	O
22	0	O
23	.	O
24	95	O
25	to	O
26	$	O
27	1	O
28	.	O
29	21	O
30	.	O

1	Female	O
2	Wistar	O
3	rats	O
4	were	O
5	fed	O
6	a	O
7	liquid	O
8	diet	O
9	,	O
10	Sustacal	O
11	,	O
12	which	O
13	contained	O
14	ethanol	O
15	(	O
16	40	O
17	%	O
18	of	O
19	calories	O
20	)	O
21	or	O
22	isocaloric	O
23	sucrose	O
24	.	O

1	HL	O
2	02	O
3	type	O
4	oculomotor	O
5	stimulator	O
6	.	O

1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O

1	Brain	O
2	pH	O
3	following	O
4	3	O
5	h	O
6	of	O
7	cerebral	O
8	focal	O
9	ischemia	O
10	changed	O
11	from	O
12	a	O
13	normal	O
14	value	O
15	of	O
16	7	O
17	.	O
18	0	O
19	to	O
20	6	O
21	.	O
22	5	O
23	and	O
24	6	O
25	.	O
26	2	O
27	in	O
28	animals	O
29	studied	O
30	under	O
31	barbiturate	O
32	and	O
33	halothane	O
34	anesthesia	O
35	,	O
36	respectively	O
37	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	the	O
5	importance	O
6	of	O
7	phosphate	O
8	and	O
9	calcium	O
10	in	O
11	influencing	O
12	the	O
13	secretion	O
14	of	O
15	PTH	B
16	and	O
17	CT	B
18	in	O
19	uremia	O
20	.	O

1	Thin	O
2	-	O
3	layer	O
4	chromatographic	O
5	methods	O
6	were	O
7	up	O
8	-	O
9	dated	O
10	for	O
11	pharmacokinetic	O
12	studies	O
13	of	O
14	imipramine	O
15	in	O
16	plasma	O
17	and	O
18	urine	O
19	.	O

1	Introductory	O
2	remarks	O
3	.	O

1	Increasing	O
2	the	O
3	cut	O
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O

1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	O
18	levels	O
19	.	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	Combination	O
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	O
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O

1	A	O
2	combined	O
3	series	O
4	of	O
5	patients	O
6	experienced	O
7	a	O
8	TOL	O
9	after	O
10	two	O
11	or	O
12	more	O
13	previous	O
14	cesarean	O
15	deliveries	O
16	;	O
17	the	O
18	rate	O
19	of	O
20	vaginal	O
21	delivery	O
22	was	O
23	66	O
24	%,	O
25	and	O
26	there	O
27	was	O
28	virtually	O
29	no	O
30	morbidity	O
31	.	O

1	Nursing	O
2	home	O
3	discharges	O
4	in	O
5	clinical	O
6	practice	O
7	.	O

1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	O
24	of	O
25	feed	O
26	for	O
27	2	O
28	.	O
29	5	O
30	hr	O
31	and	O
32	then	O
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O

1	The	O
2	carcinogen	O
3	bioassay	O
4	therefore	O
5	is	O
6	a	O
7	very	O
8	important	O
9	component	O
10	of	O
11	the	O
12	battery	O
13	of	O
14	toxicological	O
15	tests	O
16	used	O
17	in	O
18	hazard	O
19	evaluation	O
20	.	O

1	Harmful	O
2	effects	O
3	in	O
4	animals	O
5	and	O
6	man	O
7	may	O
8	result	O
9	from	O
10	both	O
11	deficient	O
12	or	O
13	excessive	O
14	amounts	O
15	of	O
16	intake	O
17	.	O

1	Angionephroscintigraphy	O
2	in	O
3	the	O
4	diagnosis	O
5	of	O
6	diseases	O
7	of	O
8	the	O
9	kidney	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	sleep	O
9	period	O
10	as	O
11	a	O
12	whole	O
13	reveals	O
14	that	O
15	with	O
16	increasing	O
17	of	O
18	the	O
19	age	O
20	the	O
21	delta	O
22	-	O
23	wave	O
24	stage	O
25	(	O
26	DS	O
27	)	O
28	of	O
29	the	O
30	QS	O
31	(	O
32	determined	O
33	by	O
34	defined	O
35	polygraphic	O
36	parameters	O
37	)	O
38	increases	O
39	,	O
40	while	O
41	the	O
42	paradoxical	O
43	phase	O
44	of	O
45	sleep	O
46	(	O
47	PS	O
48	)	O
49	decreases	O
50	,	O
51	this	O
52	change	O
53	being	O
54	more	O
55	pronounced	O
56	during	O
57	the	O
58	first	O
59	six	O
60	months	O
61	than	O
62	during	O
63	the	O
64	second	O
65	ones	O
66	of	O
67	the	O
68	first	O
69	year	O
70	of	O
71	the	O
72	life	O
73	.	O

1	[	O
2	82Br	O
3	]	O
4	MISO	O
5	was	O
6	prepared	O
7	by	O
8	irradiating	O
9	samples	O
10	of	O
11	Br	O
12	-	O
13	MISO	O
14	in	O
15	a	O
16	SLOWPOKE	O
17	reactor	O
18	for	O
19	2	O
20	h	O
21	at	O
22	a	O
23	thermal	O
24	neutron	O
25	flux	O
26	of	O
27	10	O
28	(	O
29	12	O
30	)	O
31	n	O
32	cm	O
33	-	O
34	2	O
35	s	O
36	-	O
37	1	O
38	.	O

1	While	O
2	these	O
3	findings	O
4	may	O
5	reflect	O
6	the	O
7	sensitivity	O
8	of	O
9	a	O
10	thick	O
11	myocardial	O
12	wall	O
13	to	O
14	ischaemia	O
15	during	O
16	surgery	O
17	,	O
18	the	O
19	postoperative	O
20	recovery	O
21	was	O
22	not	O
23	related	O
24	to	O
25	the	O
26	serum	B
27	CK	I
28	-	I
29	MB	I
30	level	O
31	.	O

1	Morphofunctional	O
2	status	O
3	of	O
4	the	O
5	formed	O
6	elements	O
7	of	O
8	the	O
9	blood	O
10	in	O
11	rats	O
12	subjected	O
13	to	O
14	different	O
15	variants	O
16	of	O
17	combined	O
18	and	O
19	isolated	O
20	exposure	O
21	to	O
22	BR	O
23	-	O
24	1	O
25	benzene	O

1	Using	O
2	a	O
3	MOS	O
4	-	O
5	Hypersil	O
6	reversed	O
7	-	O
8	phase	O
9	column	O
10	with	O
11	a	O
12	phosphate	O
13	buffer	O
14	--	O
15	acetonitrile	O
16	mobile	O
17	phase	O
18	,	O
19	baseline	O
20	separation	O
21	of	O
22	antipyrine	O
23	,	O
24	its	O
25	metabolites	O
26	3	O
27	-	O
28	hydroxymethylantipyrine	O
29	,	O
30	norantipyrine	O
31	and	O
32	4	O
33	-	O
34	hydroxyantipyrine	O
35	,	O
36	and	O
37	the	O
38	internal	O
39	standard	O
40	,	O
41	phenacetin	O
42	,	O
43	was	O
44	achieved	O
45	within	O
46	6	O
47	min	O
48	.	O

1	The	O
2	liver	O
3	in	O
4	the	O
5	severely	O
6	ill	O

1	In	O
2	a	O
3	randomized	O
4	study	O
5	on	O
6	150	O
7	patients	O
8	(	O
9	ASA	O
10	1	O
11	)	O
12	undergoing	O
13	induction	O
14	of	O
15	anaesthesia	O
16	,	O
17	the	O
18	effects	O
19	of	O
20	Fentanyl	O
21	(	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	),	O
27	the	O
28	combination	O
29	of	O
30	Fentanyl	O
31	(	O
32	0	O
33	.	O
34	1	O
35	mg	O
36	)	O
37	and	O
38	Droperidol	O
39	(	O
40	5	O
41	mg	O
42	)	O
43	(	O
44	Innovar	O
45	,	O
46	Thalamonal	O
47	)	O
48	and	O
49	Atropine	O
50	(	O
51	0	O
52	.	O
53	01	O
54	mg	O
55	/	O
56	kg	O
57	b	O
58	.	O
59	w	O
60	.)	O
61	alone	O
62	on	O
63	cardiocirculatory	O
64	parameters	O
65	were	O
66	studied	O
67	.	O

1	These	O
2	results	O
3	confirming	O
4	the	O
5	high	O
6	validity	O
7	of	O
8	NOM	O
9	inhibiting	O
10	test	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	tumoural	O
16	hyperprolactinemic	O
17	states	O
18	,	O
19	reveal	O
20	contradictory	O
21	responses	O
22	to	O
23	CD	O
24	/	O
25	LD	O
26	,	O
27	LD	O
28	and	O
29	DOM	O
30	,	O
31	with	O
32	sustain	O
33	the	O
34	existence	O
35	of	O
36	2	O
37	sub	O
38	-	O
39	group	O
40	of	O
41	Prolactinomas	O
42	:	O
43	with	O
44	or	O
45	without	O
46	a	O
47	maintained	O
48	DA	O
49	central	O
50	tonus	O
51	supporting	O
52	the	O
53	possibility	O
54	of	O
55	different	O
56	etiopathogenetical	O
57	factors	O
58	in	O
59	inducing	O
60	a	O
61	tumoural	O
62	hyperprolactinemic	O
63	states	O
64	.	O

1	Serum	O
2	lipids	O
3	and	O
4	lipoproteins	O
5	of	O
6	29	O
7	insulin	B
8	dependent	O
9	diabetic	O
10	children	O
11	have	O
12	been	O
13	determined	O
14	and	O
15	related	O
16	to	O
17	the	O
18	metabolic	O
19	status	O
20	of	O
21	the	O
22	patients	O
23	.	O

1	Low	O
2	NA	O
3	and	O
4	A	O
5	may	O
6	participate	O
7	in	O
8	lowering	O
9	the	O
10	plasma	B
11	renin	I
12	activity	O
13	which	O
14	in	O
15	PA	O
16	in	O
17	suppressed	O
18	,	O
19	sometimes	O
20	disproportionately	O
21	to	O
22	the	O
23	actual	O
24	body	O
25	sodium	O
26	content	O
27	.	O

1	Amikacin	O
2	concentrations	O
3	in	O
4	serum	O
5	and	O
6	blister	O
7	fluid	O
8	in	O
9	healthy	O
10	volunteers	O
11	and	O
12	in	O
13	patients	O
14	with	O
15	renal	O
16	impairment	O
17	.	O

1	The	O
2	subgroup	O
3	innervating	O
4	the	O
5	medial	O
6	rectus	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	oculomotor	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	longitudinal	O
26	fasciculus	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O

1	Hepatitis	O
2	B	O
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	O
15	hepatitis	O
16	B	O
17	endemicity	O
18	.	O

1	An	O
2	intravenous	O
3	drip	O
4	infusion	O
5	of	O
6	AMK	O
7	in	O
8	adequate	O
9	dosage	O
10	would	O
11	be	O
12	beneficial	O
13	to	O
14	use	O
15	against	O
16	some	O
17	infectious	O
18	diseases	O
19	of	O
20	otorhinolaryngologic	O
21	field	O
22	.	O

1	Out	O
2	of	O
3	these	O
4	families	O
5	74	O
6	,	O
7	3	O
8	%	O
9	planned	O
10	next	O
11	pregnancy	O
12	(	O
13	table	O
14	IX	O
15	),	O
16	57	O
17	,	O
18	6	O
19	%	O
20	wanted	O
21	to	O
22	have	O
23	prenatal	O
24	diagnosis	O
25	(	O
26	table	O
27	VI	O
28	).	O

1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	O
9	hemoglobin	B
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	Berthelot	O
16	classic	O
17	and	O
18	Berthelot	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	plasmatic	O
26	urea	O
27	.	O

1	Parkinsonian	O
2	patients	O
3	had	O
4	a	O
5	significantly	O
6	lower	O
7	prevalence	O
8	of	O
9	alcohol	O
10	use	O
11	.	O

1	These	O
2	cells	O
3	averaged	O
4	17	O
5	microns	O
6	in	O
7	diameter	O
8	and	O
9	reproduced	O
10	by	O
11	fission	O
12	,	O
13	forming	O
14	clusters	O
15	of	O
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	Female	O
2	but	O
3	not	O
4	male	O
5	mortalities	O
6	were	O
7	significantly	O
8	higher	O
9	for	O
10	cake	O
11	-	O
12	fed	O
13	rats	O
14	than	O
15	for	O
16	those	O
17	fed	O
18	diet	O
19	41B	O
20	.	O

1	Urinary	B
2	N	I
3	-	I
4	acetylglucosaminidase	I
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O

1	The	O
2	associations	O
3	between	O
4	sex	B
5	-	I
6	hormone	I
7	-	I
8	binding	I
9	globulin	I
10	capacity	O
11	(	O
12	SHBG	B
13	),	O
14	age	O
15	,	O
16	body	O
17	mass	O
18	index	O
19	(	O
20	BMI	O
21	),	O
22	and	O
23	physical	O
24	fitness	O
25	have	O
26	been	O
27	studied	O
28	in	O
29	34	O
30	men	O
31	and	O
32	36	O
33	women	O
34	.	O

1	Dipetalonema	O
2	(	O
3	Alafilaria	O
4	)	O
5	hydrochoerus	O
6	subgen	O
7	.	O
8	et	O
9	sp	O
10	.	O
11	n	O
12	.	O

1	After	O
2	1	O
3	.	O
4	5	O
5	years	O
6	of	O
7	such	O
8	photoperiodic	O
9	control	O
10	,	O
11	all	O
12	ewes	O
13	were	O
14	blinded	O
15	by	O
16	bilateral	O
17	orbital	O
18	enucleation	O
19	.	O

1	The	O
2	concentrations	O
3	of	O
4	C4	B
5	and	O
6	C1	B
7	-	I
8	INH	I
9	increased	O
10	with	O
11	advancing	O
12	stage	O
13	of	O
14	disease	O
15	and	O
16	were	O
17	above	O
18	normal	O
19	mean	O
20	values	O
21	in	O
22	all	O
23	stages	O
24	.	O

1	Less	O
2	antibacterial	O
3	activity	O
4	was	O
5	shown	O
6	toward	O
7	the	O
8	Gram	O
9	-	O
10	negative	O
11	bacilli	O
12	,	O
13	i	O
14	.	O
15	e	O
16	.,	O
17	Pseudomonas	O
18	,	O
19	Klebsiella	O
20	-	O
21	Enterobacter	O
22	,	O
23	Shigella	O
24	,	O
25	Escherichia	O
26	coli	O
27	,	O
28	Serratia	O
29	marcescens	O
30	and	O
31	Proteus	O
32	.	O

1	The	O
2	mucosal	O
3	defence	O
4	capacity	O
5	against	O
6	proteolytic	O
7	leukocyte	O
8	enzymes	O
9	.	O

1	The	O
2	apparatus	O
3	consists	O
4	of	O
5	an	O
6	Am	O
7	-	O
8	241	O
9	exciting	O
10	source	O
11	(	O
12	300	O
13	mCi	O
14	)	O
15	and	O
16	pure	O
17	Ge	O
18	detector	O
19	(	O
20	50	O
21	mm2	O
22	X	O
23	5	O
24	mm	O
25	)	O
26	for	O
27	measuring	O
28	K	O
29	alpha	O
30	fluorescent	O
31	x	O
32	-	O
33	rays	O
34	(	O
35	28	O
36	.	O
37	3	O
38	and	O
39	28	O
40	.	O
41	6	O
42	KeV	O
43	)	O
44	emitted	O
45	from	O
46	exited	O
47	iodine	O
48	.	O

1	Ultrastructural	O
2	studies	O
3	of	O
4	retinopathy	O
5	of	O
6	premature	O
7	infants	O

1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	deviations	O
16	for	O
17	each	O
18	analyte	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	O
30	(	O
31	25	O
32	-	O
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O

1	The	O
2	effects	O
3	of	O
4	antithrombotic	O
5	drugs	O
6	in	O
7	patients	O
8	with	O
9	left	O
10	ventricular	O
11	thrombi	O
12	:	O
13	assessment	O
14	with	O
15	indium	O
16	-	O
17	111	O
18	platelet	O
19	imaging	O
20	and	O
21	two	O
22	-	O
23	dimensional	O
24	echocardiography	O
25	.	O

1	A	O
2	stable	O
3	interface	O
4	depends	O
5	on	O
6	overall	O
7	stress	O
8	and	O
9	microstress	O
10	distribution	O
11	on	O
12	the	O
13	bone	O
14	,	O
15	particularly	O
16	trabecular	O
17	bone	O
18	.	O

1	Plasma	O
2	NE	O
3	was	O
4	also	O
5	low	O
6	in	O
7	the	O
8	anephric	O
9	group	O
10	(	O
11	289	O
12	mg	O
13	/	O
14	liter	O
15	+/-	O
16	126	O
17	(	O
18	1	O
19	SD	O
20	)	O
21	vs	O
22	612	O
23	+/-	O
24	189	O
25	,	O
26	P	O
27	=	O
28	0	O
29	.	O
30	033	O
31	,	O
32	resting	O
33	).(	O
34	ABSTRACT	O
35	TRUNCATED	O
36	AT	O
37	250	O
38	WORDS	O
39	)	O

1	10	O
2	long	O
3	-	O
4	term	O
5	hemodialysis	O
6	patients	O
7	had	O
8	immediate	O
9	and	O
10	redistribution	O
11	thallium	O
12	-	O
13	201	O
14	myocardial	O
15	imaging	O
16	performed	O
17	after	O
18	a	O
19	course	O
20	of	O
21	hemodialysis	O
22	.	O

1	The	O
2	Prolactin	B
3	levels	O
4	were	O
5	within	O
6	the	O
7	physiological	O
8	norms	O
9	;	O
10	the	O
11	responses	O
12	to	O
13	TRH	B
14	were	O
15	normal	O
16	,	O
17	and	O
18	elevated	O
19	only	O
20	in	O
21	a	O
22	few	O
23	cases	O
24	.	O

1	Despite	O
2	total	O
3	tumor	O
4	resection	O
5	,	O
6	multiple	O
7	intraperitoneal	O
8	tumor	O
9	nodules	O
10	of	O
11	varying	O
12	sizes	O
13	were	O
14	found	O
15	and	O
16	resected	O
17	six	O
18	months	O
19	and	O
20	one	O
21	year	O
22	later	O
23	.	O

1	Private	O
2	hospital	O
3	accreditation	O
4	.	O

1	Antithrombin	B
2	III	I
3	in	O
4	hip	O
5	surgery	O

1	In	O
2	14	O
3	of	O
4	21	O
5	infant	O
6	hearts	O
7	(	O
8	66	O
9	%)	O
10	with	O
11	aortic	O
12	arch	O
13	interruption	O
14	between	O
15	the	O
16	left	O
17	common	O
18	carotid	O
19	and	O
20	left	O
21	subclavian	O
22	arteries	O
23	(	O
24	type	O
25	B	O
26	of	O
27	Celoria	O
28	and	O
29	Patton	O
30	),	O
31	the	O
32	right	O
33	subclavian	O
34	artery	O
35	(	O
36	SA	O
37	)	O
38	arose	O
39	anomalously	O
40	.	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	O
7	in	O
8	pallid	O
9	bats	O
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O

1	Additionally	O
2	,	O
3	observations	O
4	that	O
5	patients	O
6	with	O
7	mitral	O
8	versus	O
9	aortic	O
10	regurgitation	O
11	respond	O
12	differently	O
13	to	O
14	valve	O
15	replacement	O
16	suggest	O
17	that	O
18	differences	O
19	exist	O
20	preoperatively	O
21	between	O
22	these	O
23	two	O
24	types	O
25	of	O
26	volume	O
27	overload	O
28	.	O

1	A	O
2	case	O
3	of	O
4	manifest	O
5	latent	O
6	nystagmus	O
7	of	O
8	late	O
9	onset	O
10	in	O
11	a	O
12	13	O
13	-	O
14	year	O
15	-	O
16	old	O
17	girl	O
18	is	O
19	reported	O
20	.	O

1	Within	O
2	the	O
3	compartment	O
4	or	O
5	dimension	O
6	of	O
7	severity	O
8	of	O
9	depression	O
10	a	O
11	subscale	O
12	of	O
13	the	O
14	Hamilton	O
15	Depression	O
16	Scale	O
17	(	O
18	or	O
19	the	O
20	Melancholia	O
21	Scale	O
22	)	O
23	was	O
24	shown	O
25	to	O
26	have	O
27	reached	O
28	an	O
29	instrumental	O
30	perfection	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.	O
36	as	O
37	an	O
38	outcome	O
39	measure	O
40	of	O
41	antidepressant	O
42	treatment	O
43	.	O

1	Significant	O
2	immunoglobulinuria	O
3	developed	O
4	prior	O
5	to	O
6	the	O
7	development	O
8	of	O
9	azotemia	O
10	,	O
11	significantly	O
12	decreased	O
13	creatinine	O
14	clearance	O
15	,	O
16	significant	O
17	proteinuria	O
18	(	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	3	O
25	+	O
26	dipstick	O
27	or	O
28	greater	O
29	than	O
30	or	O
31	equal	O
32	to	O
33	5	O
34	gm	O
35	per	O
36	24	O
37	-	O
38	hour	O
39	urine	O
40	collection	O
41	),	O
42	or	O
43	oliguria	O
44	.	O

1	A	O
2	total	O
3	number	O
4	of	O
5	1628	O
6	cases	O
7	were	O
8	collected	O
9	from	O
10	135	O
11	medical	O
12	institutions	O
13	.	O

1	Epileptiform	O
2	activity	O
3	recorded	O
4	from	O
5	superficial	O
6	laminae	O
7	bordering	O
8	layer	O
9	4	O
10	,	O
11	and	O
12	into	O
13	which	O
14	layer	O
15	4	O
16	'	O
17	s	O
18	primary	O
19	projections	O
20	terminate	O
21	,	O
22	is	O
23	suppressed	O
24	preferentially	O
25	by	O
26	phenytoin	O
27	.	O

1	The	O
2	AD	O
3	components	O
4	were	O
5	markedly	O
6	more	O
7	dependent	O
8	on	O
9	the	O
10	affective	O
11	state	O
12	of	O
13	the	O
14	rat	O
15	then	O
16	was	O
17	the	O
18	V1	O
19	component	O
20	.	O

1	Is	O
2	nisoldipine	O
3	capable	O
4	of	O
5	reducing	O
6	left	O
7	ventricular	O
8	preload	O
9	?	O
10	In	O
11	ten	O
12	anesthetized	O
13	pigs	O
14	,	O
15	nisoldipine	O
16	(	O
17	2	O
18	-	O
19	4	O
20	micrograms	O
21	X	O
22	kg	O
23	-	O
24	1	O
25	X	O
26	min	O
27	-	O
28	1	O
29	),	O
30	a	O
31	calcium	O
32	channel	O
33	blocker	O
34	structurally	O
35	related	O
36	to	O
37	nifedipine	O
38	,	O
39	reduced	O
40	left	O
41	ventricular	O
42	systolic	O
43	pressure	O
44	(	O
45	40	O
46	%)	O
47	and	O
48	systemic	O
49	vascular	O
50	resistance	O
51	(	O
52	35	O
53	%),	O
54	whereas	O
55	maxLVdP	O
56	/	O
57	dt	O
58	decreased	O
59	by	O
60	20	O
61	%	O
62	and	O
63	cardiac	O
64	output	O
65	was	O
66	unchanged	O
67	.	O

1	Monkeys	O
2	were	O
3	evaluated	O
4	before	O
5	and	O
6	after	O
7	unilateral	O
8	and	O
9	serial	O
10	bilateral	O
11	removal	O
12	of	O
13	superior	O
14	temporal	O
15	cortex	O
16	.	O

1	HBB	O
2	concentration	O
3	in	O
4	the	O
5	fetuses	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O

1	All	O
2	samples	O
3	exhibited	O
4	a	O
5	decline	O
6	in	O
7	ethanol	O
8	concentration	O
9	,	O
10	with	O
11	most	O
12	losses	O
13	falling	O
14	within	O
15	the	O
16	expected	O
17	20	O
18	to	O
19	40	O
20	mg	O
21	%	O
22	range	O
23	.	O

1	Plasma	B
2	lactoferrin	I
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O

1	The	O
2	importance	O
3	of	O
4	selective	O
5	renal	O
6	vein	O
7	phlebography	O
8	in	O
9	the	O
10	evaluation	O
11	of	O
12	unexplained	O
13	hematuria	O
14	and	O
15	filing	O
16	defects	O
17	in	O
18	the	O
19	excretory	O
20	urogram	O
21	is	O
22	illustrated	O
23	.	O

1	Pilot	O
2	study	O
3	of	O
4	blood	O
5	coagulation	O
6	in	O
7	gout	O
8	patients	O
9	.	O

1	The	O
2	statistical	O
3	analysis	O
4	consist	O
5	of	O
6	the	O
7	F	O
8	test	O
9	followed	O
10	by	O
11	Snedecor	O
12	'	O
13	s	O
14	contrast	O
15	test	O
16	.	O

1	The	O
2	pyramidal	O
3	tract	O
4	and	O
5	Mesencephalic	O
6	Reticular	O
7	Formation	O
8	(	O
9	MRF	O
10	)	O
11	were	O
12	stimulated	O
13	before	O
14	and	O
15	after	O
16	the	O
17	transection	O
18	.	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	O
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	Effects	O
2	of	O
3	methiothepin	O
4	and	O
5	lysergic	O
6	acid	O
7	diethylamide	O
8	on	O
9	serotonin	O
10	release	O
11	in	O
12	vitro	O
13	and	O
14	serotonin	O
15	synthesis	O
16	in	O
17	vivo	O
18	:	O
19	possible	O
20	relation	O
21	to	O
22	serotonin	B
23	autoreceptor	I
24	function	O
25	.	O

1	In	O
2	a	O
3	recent	O
4	measles	O
5	epidemic	O
6	in	O
7	El	O
8	Paso	O
9	,	O
10	TX	O
11	,	O
12	120	O
13	,	O
14	000	O
15	records	O
16	were	O
17	screened	O
18	using	O
19	these	O
20	criteria	O
21	,	O
22	and	O
23	as	O
24	a	O
25	result	O
26	13	O
27	,	O
28	000	O
29	students	O
30	were	O
31	vaccinated	O
32	.	O

1	No	O
2	patient	O
3	with	O
4	bradyarrhythmia	O
5	-	O
6	related	O
7	SCD	O
8	had	O
9	manifest	O
10	atrioventricular	O
11	block	O
12	or	O
13	bundle	O
14	branch	O
15	block	O
16	.	O

1	The	O
2	measurement	O
3	of	O
4	the	O
5	areas	O
6	of	O
7	fibrin	B
8	,	O
9	of	O
10	tissue	O
11	and	O
12	fibrinolysis	O
13	,	O
14	at	O
15	the	O
16	above	O
17	mentioned	O
18	times	O
19	,	O
20	has	O
21	been	O
22	effected	O
23	at	O
24	standard	O
25	magnification	O
26	(	O
27	15	O
28	X	O
29	)	O
30	by	O
31	an	O
32	image	O
33	analyser	O
34	(	O
35	Videoplan	O
36	)	O
37	scale	O
38	1	O
39	:	O
40	8	O
41	.	O

1	Diclofenac	O
2	sodium	O
3	-	O
4	chlormezanone	O
5	poisoning	O
6	.	O

1	Postprandial	O
2	plasma	B
3	enteroglucagon	I
4	concentration	O
5	after	O
6	90	O
7	minutes	O
8	in	O
9	untreated	O
10	patients	O
11	correlated	O
12	positively	O
13	to	O
14	the	O
15	faecal	O
16	fat	O
17	excretion	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	58	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	02	O
31	).	O

1	Blood	O
2	pressure	O
3	in	O
4	children	O
5	.	O

1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	the	O
6	sensitivity	O
7	of	O
8	the	O
9	3	O
10	given	O
11	guinea	O
12	pig	O
13	strains	O
14	was	O
15	comparable	O
16	.	O

1	Adult	O
2	Amblyomma	O
3	lepidum	O
4	ticks	O
5	fed	O
6	as	O
7	nymphs	O
8	on	O
9	this	O
10	goat	O
11	transmitted	O
12	heartwater	O
13	to	O
14	a	O
15	Friesian	O
16	(	O
17	Bos	O
18	taurus	O
19	)	O
20	calf	O
21	.	O

1	Twenty	O
2	-	O
3	one	O
4	percent	O
5	of	O
6	these	O
7	patients	O
8	had	O
9	neurologic	O
10	disease	O
11	that	O
12	appeared	O
13	to	O
14	be	O
15	responsible	O
16	for	O
17	the	O
18	tinnitus	O
19	.	O

1	Morphine	O
2	injected	O
3	into	O
4	the	O
5	lateral	O
6	ventricle	O
7	of	O
8	the	O
9	rat	O
10	produced	O
11	unilateral	O
12	analgesia	O
13	in	O
14	the	O
15	formalin	O
16	test	O
17	,	O
18	which	O
19	involves	O
20	continuous	O
21	,	O
22	moderate	O
23	pain	O
24	.	O

1	The	O
2	maps	O
3	of	O
4	Case	O
5	2	O
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	moved	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	thorax	O
28	.	O

1	Urinary	O
2	urate	O
3	excretion	O
4	,	O
5	urate	O
6	clearance	O
7	,	O
8	and	O
9	fractional	O
10	excretion	O
11	of	O
12	urate	O
13	all	O
14	increased	O
15	significantly	O
16	during	O
17	water	O
18	immersion	O
19	,	O
20	and	O
21	decreased	O
22	in	O
23	the	O
24	hour	O
25	following	O
26	water	O
27	immersion	O
28	.	O

1	Mutations	O
2	in	O
3	seven	O
4	other	O
5	lts	B
6	genes	I
7	do	O
8	not	O
9	result	O
10	in	O
11	the	O
12	mak	B
13	-	I
14	phenotype	I
15	.	O

1	Twenty	O
2	-	O
3	eight	O
4	were	O
5	excluded	O
6	as	O
7	gallstones	O
8	were	O
9	not	O
10	proved	O
11	:	O
12	of	O
13	the	O
14	remainder	O
15	,	O
16	21	O
17	patients	O
18	received	O
19	glucagon	B
20	and	O
21	22	O
22	placebo	O
23	.	O

1	4	O
2	Five	O
3	patients	O
4	died	O
5	within	O
6	one	O
7	month	O
8	of	O
9	captopril	O
10	and	O
11	five	O
12	between	O
13	four	O
14	and	O
15	seven	O
16	months	O
17	,	O
18	three	O
19	of	O
20	whom	O
21	had	O
22	improved	O
23	to	O
24	class	O
25	IIM	O
26	and	O
27	one	O
28	to	O
29	IIS	O
30	before	O
31	death	O
32	.	O

1	Bullous	O
2	angiolymphoid	O
3	hyperplasia	O
4	with	O
5	eosinophilia	O

1	Regions	O
2	of	O
3	the	O
4	translated	O
5	open	O
6	reading	O
7	frames	O
8	of	O
9	cobA	B
10	and	O
11	the	O
12	third	O
13	intron	O
14	of	O
15	the	O
16	cob	B
17	gene	I
18	in	I
19	yeast	I
20	show	O
21	high	O
22	amino	O
23	acid	O
24	homology	O
25	.	O

1	Multiresistant	O
2	strains	O
3	isolated	O
4	from	O
5	humans	O
6	in	O
7	enteral	O
8	toxico	O
9	-	O
10	infections	O
11	kill	O
12	orally	O
13	infected	O
14	mice	O
15	more	O
16	frequently	O
17	than	O
18	strains	O
19	isolated	O
20	in	O
21	hospital	O
22	infections	O
23	.	O

1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O

1	The	O
2	13	O
3	,	O
4	14	O
5	-	O
6	dihydro	O
7	-	O
8	15	O
9	-	O
10	keto	O
11	-	O
12	metabolites	O
13	of	O
14	PGE2	O
15	and	O
16	PGF2	O
17	alpha	O
18	had	O
19	no	O
20	statistically	O
21	significant	O
22	antiarrhythmic	O
23	effect	O
24	.	O

1	Nucleotide	O
2	sequence	O
3	of	O
4	DNA	O
5	controlling	O
6	expression	O
7	of	O
8	genes	O
9	for	O
10	maltosaccharide	O
11	utilization	O
12	in	O
13	Streptococcus	O
14	pneumoniae	O
15	.	O

1	The	O
2	hypertension	O
3	with	O
4	elevated	O
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	O
13	angiotensin	B
14	II	I
15	(	O
16	AII	B
17	)	O
18	analog	O
19	[	O
20	Sar1	O
21	,	O
22	Ile8	O
23	]	O
24	ALL	O
25	.	O

1	Colorimetric	O
2	determination	O
3	of	O
4	urinary	O
5	iron	O
6	,	O
7	chelated	O
8	with	O
9	deferoxamine	O
10	B	O
11	,	O
12	using	O
13	a	O
14	single	O
15	reagent	O

1	Measurements	O
2	of	O
3	perfusion	O
4	also	O
5	showed	O
6	significantly	O
7	higher	O
8	values	O
9	under	O
10	active	O
11	therapy	O
12	.	O

1	Volume	O
2	of	O
3	distribution	O
4	of	O
5	total	O
6	DMDZ	O
7	(	O
8	range	O
9	,	O
10	1	O
11	.	O
12	33	O
13	to	O
14	6	O
15	.	O
16	30	O
17	l	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	of	O
23	unbound	O
24	DMDZ	O
25	after	O
26	correction	O
27	for	O
28	protein	O
29	binding	O
30	(	O
31	range	O
32	,	O
33	43	O
34	to	O
35	243	O
36	l	O
37	/	O
38	kg	O
39	)	O
40	was	O
41	larger	O
42	in	O
43	women	O
44	than	O
45	in	O
46	men	O
47	of	O
48	all	O
49	ages	O
50	,	O
51	and	O
52	in	O
53	the	O
54	elderly	O
55	as	O
56	opposed	O
57	to	O
58	the	O
59	young	O
60	.	O

1	Effects	O
2	of	O
3	dopamine	O
4	and	O
5	of	O
6	a	O
7	dopaminergic	O
8	blocker	O
9	,	O
10	haloperidol	O
11	,	O
12	on	O
13	the	O
14	responses	O
15	of	O
16	carotid	O
17	body	O
18	chemoreceptors	O
19	to	O
20	hypoxia	O
21	and	O
22	hypercapnia	O
23	were	O
24	investigated	O
25	in	O
26	16	O
27	anesthetized	O
28	cats	O
29	.	O

1	HLA	B
2	-	I
3	A	I
4	and	I
5	B	I
6	phenotypes	O
7	of	O
8	105	O
9	patients	O
10	suffering	O
11	from	O
12	malignant	O
13	melanomas	O
14	were	O
15	determined	O
16	,	O
17	with	O
18	special	O
19	regard	O
20	for	O
21	metastatic	O
22	form	O
23	or	O
24	relapse	O
25	.	O

1	Trypanosoma	O
2	cruzi	O
3	.	O

1	The	O
2	subjects	O
3	of	O
4	the	O
5	study	O
6	were	O
7	10	O
8	normal	O
9	subjects	O
10	and	O
11	64	O
12	patients	O
13	with	O
14	gastroduodenal	O
15	disease	O
16	.	O

1	1	O
2	.	O

1	This	O
2	study	O
3	represents	O
4	the	O
5	first	O
6	published	O
7	long	O
8	-	O
9	term	O
10	follow	O
11	-	O
12	up	O
13	regarding	O
14	this	O
15	mode	O
16	of	O
17	treatment	O
18	in	O
19	patients	O
20	with	O
21	alveolar	O
22	hypoventilation	O
23	.	O

1	The	O
2	alterations	O
3	in	O
4	differentiation	O
5	of	O
6	osteoprogenitor	O
7	cells	O
8	,	O
9	together	O
10	with	O
11	the	O
12	failure	O
13	of	O
14	mineralization	O
15	,	O
16	resulted	O
17	in	O
18	significantly	O
19	lower	O
20	rates	O
21	of	O
22	bone	O
23	formation	O
24	(	O
25	as	O
26	measured	O
27	by	O
28	fluorochrome	O
29	labeling	O
30	)	O
31	in	O
32	the	O
33	magnesium	O
34	-	O
35	deficient	O
36	rats	O
37	.	O

1	A	O
2	convenient	O
3	measure	O
4	of	O
5	this	O
6	impairment	O
7	may	O
8	be	O
9	obtained	O
10	using	O
11	the	O
12	ratio	O
13	of	O
14	urine	O
15	volume	O
16	(	O
17	V	O
18	)	O
19	divided	O
20	by	O
21	lithium	O
22	clearance	O
23	(	O
24	CLi	O
25	).	O

1	Nitrogen	O
2	balance	O
3	was	O
4	compared	O
5	,	O
6	and	O
7	metabolic	O
8	complications	O
9	were	O
10	monitored	O
11	by	O
12	evaluating	O
13	BUN	O
14	,	O
15	serum	O
16	creatinine	O
17	,	O
18	creatinine	O
19	clearance	O
20	,	O
21	serum	O
22	CO2	O
23	,	O
24	SGOT	B
25	,	O
26	SGPT	B
27	,	O
28	serum	B
29	LDH	I
30	,	O
31	and	O
32	serum	B
33	alkaline	I
34	phosphatase	I
35	.	O

1	Production	O
2	of	O
3	C	B
4	mu	I
5	RNAs	I
6	,	O
7	unlike	O
8	mu	B
9	mRNAs	I
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	B
18	region	I
19	(	O
20	JH	B
21	)	O
22	locus	O
23	.	O

1	The	O
2	1	O
3	.	O
4	9	O
5	-	O
6	kb	O
7	C	B
8	mu	I
9	RNA	O
10	contains	O
11	the	O
12	3	O
13	'	O
14	sequence	O
15	characteristic	O
16	of	O
17	secreted	O
18	mu	B
19	chain	I
20	,	O
21	whereas	O
22	the	O
23	longer	O
24	species	O
25	bear	O
26	that	O
27	of	O
28	membrane	O
29	-	O
30	bound	O
31	mu	B
32	chin	O
33	.	O

1	Transcripts	O
2	of	O
3	the	O
4	immunoglobulin	B
5	C	I
6	mu	I
7	gene	I
8	vary	O
9	in	O
10	structure	O
11	and	O
12	splicing	O
13	during	O
14	lymphoid	O
15	development	O
16	.	O

1	Non	O
2	-	O
3	complement	O
4	-	O
5	dependent	O
6	sperm	O
7	-	O
8	immobilizing	O
9	activity	O
10	was	O
11	also	O
12	detected	O
13	in	O
14	the	O
15	cervical	O
16	mucus	O
17	of	O
18	several	O
19	patients	O
20	.	O

1	The	O
2	role	O
3	of	O
4	DNA	O
5	rearrangement	O
6	and	O
7	alternative	O
8	RNA	O
9	processing	O
10	in	O
11	the	O
12	expression	O
13	of	O
14	immunoglobulin	B
15	delta	I
16	genes	I
17	.	O

1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	ICRF	O
8	-	O
9	159	O
10	and	O
11	187	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	preclinical	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	The	O
2	evaluation	O
3	of	O
4	amniotic	O
5	fluid	O
6	delta	O
7	OD450	O
8	is	O
9	considered	O
10	to	O
11	be	O
12	the	O
13	cornerstone	O
14	of	O
15	clinical	O
16	management	O
17	.	O

1	Host	O
2	lipids	O
3	in	O
4	tuberculous	O
5	infection	O
6	.	O

1	There	O
2	is	O
3	now	O
4	a	O
5	significative	O
6	difference	O
7	between	O
8	age	O
9	group	O
10	1	O
11	-	O
12	5	O
13	and	O
14	the	O
15	others	O
16	(	O
17	p	O
18	Less	O
19	Than	O
20	0	O
21	,	O
22	02	O
23	).	O

1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O

1	Lens	B
2	aldose	I
3	reductase	I
4	in	O
5	diabetic	O
6	and	O
7	galactosemic	O
8	cataracts	O
9	.	O

1	Fenfluramine	O
2	(	O
3	in	O
4	doses	O
5	ranging	O
6	from	O
7	0	O
8	.	O
9	0625	O
10	-	O
11	4	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	infusion	O
19	)	O
20	did	O
21	not	O
22	maintain	O
23	self	O
24	-	O
25	administration	O
26	behavior	O
27	at	O
28	or	O
29	above	O
30	the	O
31	minimum	O
32	requirement	O
33	(	O
34	FR	O
35	30	O
36	).	O

1	In	O
2	the	O
3	course	O
4	of	O
5	Hepatitis	B
6	A	I
7	HBs	I
8	-	I
9	and	I
10	HBe	I
11	-	I
12	antigen	I
13	as	O
14	well	O
15	as	O
16	HBc	B
17	(	I
18	IgM	I
19	and	I
20	IgG	I
21	)-,	I
22	HBs	I
23	-	I
24	and	I
25	HBe	I
26	-	I
27	antibodies	I
28	can	O
29	be	O
30	detected	O
31	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	fatty	B
6	acid	I
7	cyclo	I
8	-	I
9	oxygenase	I
10	inhibitor	O
11	indomethacin	O
12	on	O
13	cerebral	O
14	blood	O
15	flow	O
16	(	O
17	CBF	O
18	)	O
19	and	O
20	the	O
21	metabolic	O
22	rate	O
23	for	O
24	oxygen	O
25	(	O
26	CMRO2	O
27	)	O
28	was	O
29	studied	O
30	in	O
31	paralyzed	O
32	and	O
33	artificially	O
34	ventilated	O
35	rats	O
36	.	O

1	The	O
2	rat	O
3	incisor	O
4	is	O
5	an	O
6	excellent	O
7	model	O
8	system	O
9	in	O
10	which	O
11	to	O
12	study	O
13	amelgenesis	O
14	.	O

1	The	O
2	already	O
3	elevated	O
4	prolactin	B
5	levels	O
6	in	O
7	nursing	O
8	women	O
9	were	O
10	not	O
11	influenced	O
12	by	O
13	chronic	O
14	oestradiol	O
15	administration	O
16	.	O

1	Factor	B
2	VIII	I
3	procoagulant	O
4	activity	O
5	,	O
6	antigen	O
7	concentration	O
8	and	O
9	von	B
10	Willebrand	I
11	activity	O
12	as	O
13	ristocetin	B
14	cofactor	I
15	were	O
16	determined	O
17	several	O
18	times	O
19	in	O
20	10	O
21	patients	O
22	with	O
23	DIC	O
24	.	O

1	Morphine	O
2	-	O
3	dependent	O
4	and	O
5	control	O
6	rats	O
7	in	O
8	an	O
9	oral	O
10	free	O
11	-	O
12	choice	O
13	protocol	O
14	were	O
15	treated	O
16	with	O
17	gamma	O
18	-	O
19	vinyl	O
20	GABA	O
21	(	O
22	GVG	O
23	),	O
24	60	O
25	,	O
26	120	O
27	and	O
28	240	O
29	mg	O
30	/	O
31	kg	O
32	IP	O
33	,	O
34	for	O
35	3	O
36	days	O
37	over	O
38	three	O
39	successive	O
40	periods	O
41	.	O

1	Significance	O
2	of	O
3	the	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	reaction	O
8	to	O
9	physical	O
10	loading	O
11	in	O
12	evaluating	O
13	the	O
14	effectiveness	O
15	of	O
16	mitral	O
17	commissurotomy	O

1	Thyreoliberin	B
2	VUFB	O
3	in	O
4	thyroid	O
5	gammagraphy	O

1	In	O
2	silicosis	O
3	,	O
4	significant	O
5	relationships	O
6	between	O
7	patients	O
8	and	O
9	sons	O
10	were	O
11	not	O
12	seen	O
13	with	O
14	respect	O
15	to	O
16	arterial	O
17	blood	O
18	gas	O
19	determinations	O
20	and	O
21	ventilatory	O
22	responses	O
23	except	O
24	for	O
25	Paco2	O
26	of	O
27	patients	O
28	and	O
29	hypercapnic	O
30	ventilatory	O
31	responses	O
32	of	O
33	sons	O
34	.	O

1	For	O
2	steers	O
3	the	O
4	urinary	O
5	N	O
6	values	O
7	were	O
8	403	O
9	and	O
10	295	O
11	mg	O
12	/	O
13	kg	O
14	W0	O
15	.	O
16	75	O
17	at	O
18	200	O
19	and	O
20	350	O
21	kg	O
22	live	O
23	weight	O
24	respectively	O
25	and	O
26	total	O
27	N	O
28	excretion	O
29	including	O
30	faecal	O
31	N	O
32	was	O
33	408	O
34	and	O
35	320	O
36	mg	O
37	/	O
38	kg	O
39	W0	O
40	.	O
41	75	O
42	.	O

1	Advances	O
2	in	O
3	hemophilia	O
4	treatment	O
5	:	O
6	a	O
7	hepatitis	O
8	-	O
9	safe	O
10	factor	B
11	VIII	I
12	concentrate	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	O
17	to	O
18	block	O
19	EIB	O
20	.	O

1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O

1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O

1	Phagocytosis	O
2	of	O
3	tubercle	O
4	bacilli	O
5	by	O
6	macrophages	O
7	.	O

1	Detection	O
2	of	O
3	hemophilia	O
4	A	O
5	carriers	O
6	.	O

1	The	O
2	stability	O
3	of	O
4	isoniazid	O
5	solutions	O
6	increases	O
7	markedly	O
8	with	O
9	increasing	O
10	NTA	O
11	or	O
12	EDTA	O
13	concentration	O
14	up	O
15	to	O
16	1	O
17	mmol	O
18	/	O
19	l	O
20	.	O

1	Bile	O
2	bilirubin	O
3	did	O
4	not	O
5	rise	O
6	within	O
7	12	O
8	h	O
9	after	O
10	haem	O
11	infusion	O
12	a	O
13	finding	O
14	which	O
15	warrants	O
16	further	O
17	investigation	O
18	.	O

1	Autoimmune	O
2	manipulation	O
3	aids	O
4	juvenile	O
5	diabetes	O
6	management	O
7	.	O

1	Other	O
2	properties	O
3	of	O
4	Hg	O
5	-	O
6	and	O
7	Cd	O
8	-	O
9	spores	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	control	O
16	spores	O
17	.	O

1	The	O
2	decrease	O
3	in	O
4	HDL	B
5	-	I
6	cholesterol	I
7	with	O
8	increasing	O
9	VLDL	B
10	-	I
11	triglycerides	I
12	was	O
13	relatively	O
14	much	O
15	larger	O
16	than	O
17	the	O
18	concomitant	O
19	decrease	O
20	in	O
21	apo	B
22	A	I
23	-	I
24	I	I
25	.	O

1	Apo	B
2	A	I
3	-	I
4	I	I
5	level	O
6	was	O
7	unrelated	O
8	to	O
9	age	O
10	,	O
11	but	O
12	increased	O
13	with	O
14	ethanol	O
15	consumption	O
16	and	O
17	decreased	O
18	with	O
19	adiposity	O
20	.	O

1	TEMTU	O
2	and	O
3	DPTU	O
4	were	O
5	the	O
6	most	O
7	potent	O
8	teratogens	O
9	.	O

1	The	O
2	osmotic	O
3	diuretic	O
4	mannitol	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O

1	Of	O
2	270	O
3	patients	O
4	with	O
5	well	O
6	-	O
7	defined	O
8	drug	O
9	reactions	O
10	,	O
11	190	O
12	(	O
13	70	O
14	per	O
15	cent	O
16	)	O
17	gave	O
18	a	O
19	positive	O
20	response	O
21	to	O
22	the	O
23	mast	O
24	cell	O
25	test	O
26	.	O

1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	O
7	glutathione	B
8	peroxidase	I
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	serum	B
5	myoglobin	I
6	in	O
7	cases	O
8	of	O
9	neuromuscular	O
10	disease	O

1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	Asthmatic	O
2	patients	O
3	showed	O
4	greater	O
5	responses	O
6	of	O
7	both	O
8	parameters	O
9	to	O
10	adrenaline	O
11	than	O
12	controls	O
13	indicating	O
14	that	O
15	long	O
16	-	O
17	term	O
18	corticosteroid	O
19	treatment	O
20	enhances	O
21	the	O
22	acute	O
23	responses	O
24	of	O
25	plasminogen	B
26	activator	I
27	and	O
28	clotting	B
29	factor	I
30	VIII	I
31	to	O
32	adrenaline	O
33	infusion	O
34	.	O

1	Sulphur	O
2	amino	O
3	acids	O
4	(	O
5	g	O
6	/	O
7	16	O
8	g	O
9	N	O
10	)	O
11	were	O
12	higher	O
13	in	O
14	the	O
15	isolates	O
16	than	O
17	in	O
18	the	O
19	flours	O
20	.	O

1	Time	O
2	shifts	O
3	increase	O
4	growth	B
5	hormone	I
6	release	O
7	.	O

1	It	O
2	then	O
3	merged	O
4	with	O
5	right	O
6	ventricular	O
7	wavefronts	O
8	ending	O
9	along	O
10	the	O
11	right	O
12	ventricular	O
13	anterior	O
14	atrioventricular	O
15	groove	O
16	and	O
17	outflow	O
18	tract	O
19	.	O

1	Many	O
2	of	O
3	these	O
4	landfill	O
5	operations	O
6	were	O
7	undertaken	O
8	in	O
9	the	O
10	early	O
11	1950s	O
12	and	O
13	1960s	O
14	,	O
15	when	O
16	knowledge	O
17	regarding	O
18	the	O
19	safe	O
20	and	O
21	prolonged	O
22	containment	O
23	of	O
24	the	O
25	waste	O
26	buried	O
27	was	O
28	nonexistent	O
29	or	O
30	minimal	O
31	at	O
32	best	O
33	.	O

1	Vesicles	O
2	could	O
3	be	O
4	induced	O
5	only	O
6	with	O
7	multiple	O
8	exposures	O
9	to	O
10	UVA	O
11	.	O

1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O

1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	B
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	hypothermia	O
47	.	O

1	Similar	O
2	observations	O
3	were	O
4	made	O
5	with	O
6	unilateral	O
7	pneumothorax	O
8	of	O
9	15	O
10	cmH2O	O
11	for	O
12	30	O
13	min	O
14	.	O

1	According	O
2	to	O
3	Sugiura	O
4	'	O
5	s	O
6	classification	O
7	,	O
8	they	O
9	consisted	O
10	of	O
11	Type	O
12	Ia	O
13	in	O
14	63	O
15	%,	O
16	Type	O
17	Ib	O
18	in	O
19	11	O
20	%,	O
21	Type	O
22	II	O
23	in	O
24	11	O
25	%,	O
26	and	O
27	Type	O
28	III	O
29	in	O
30	16	O
31	%.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	define	O
7	the	O
8	mechanism	O
9	for	O
10	the	O
11	respiratory	O
12	inhibition	O
13	observed	O
14	during	O
15	high	O
16	-	O
17	frequency	O
18	oscillatory	O
19	ventilation	O
20	(	O
21	HFOV	O
22	).	O

1	Determination	O
2	of	O
3	20	O
4	alpha	O
5	-	O
6	hydroxy	O
7	-	O
8	9	O
9	beta	O
10	,	O
11	10	O
12	alpha	O
13	-	O
14	pregna	O
15	-	O
16	4	O
17	,	O
18	6	O
19	-	O
20	dien	O
21	-	O
22	3	O
23	-	O
24	one	O
25	in	O
26	plasma	O
27	by	O
28	selected	O
29	ion	O
30	monitoring	O
31	.	O

1	A	O
2	case	O
3	of	O
4	a	O
5	dense	O
6	epidermoid	O
7	cyst	O
8	of	O
9	the	O
10	suprasellar	O
11	cistern	O
12	is	O
13	presented	O
14	.	O

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	Fibromuscular	O
2	intimal	O
3	thickening	O
4	was	O
5	seen	O
6	in	O
7	the	O
8	ascending	O
9	and	O
10	thoracic	O
11	aorta	O
12	of	O
13	the	O
14	swine	O
15	fed	O
16	62	O
17	,	O
18	500	O
19	IU	O
20	of	O
21	vitamin	O
22	D3	O
23	/	O
24	kg	O
25	of	O
26	diet	O
27	for	O
28	three	O
29	months	O
30	duration	O
31	;	O
32	and	O
33	after	O
34	3	O
35	months	O
36	of	O
37	vitamin	O
38	D3	O
39	withdrawal	O
40	,	O
41	atherosclerotic	O
42	lesions	O
43	were	O
44	found	O
45	.	O

1	Because	O
2	of	O
3	a	O
4	rapid	O
5	development	O
6	of	O
7	the	O
8	connective	O
9	tissue	O
10	scars	O
11	,	O
12	however	O
13	,	O
14	at	O
15	the	O
16	place	O
17	of	O
18	the	O
19	destroyed	O
20	glandular	O
21	parenchyma	O
22	areas	O
23	,	O
24	there	O
25	is	O
26	no	O
27	normalization	O
28	of	O
29	the	O
30	organ	O
31	'	O
32	s	O
33	structure	O
34	and	O
35	function	O
36	by	O
37	the	O
38	42d	O
39	day	O
40	.	O

1	Histological	O
2	signs	O
3	of	O
4	the	O
5	flare	O
6	-	O
7	up	O
8	reaction	O
9	were	O
10	already	O
11	present	O
12	at	O
13	6	O
14	hr	O
15	after	O
16	i	O
17	.	O
18	v	O
19	.	O
20	challenge	O
21	and	O
22	lasted	O
23	for	O
24	at	O
25	least	O
26	4	O
27	days	O
28	.	O

1	Significant	O
2	GMBF	O
3	reductions	O
4	occurred	O
5	in	O
6	early	O
7	shock	O
8	in	O
9	both	O
10	treatment	O
11	groups	O
12	.	O

1	Of	O
2	254	O
3	children	O
4	with	O
5	neuroblastoma	O
6	treated	O
7	at	O
8	St	O
9	.	O

1	Penicillin	O
2	-	O
3	G	O
4	degradation	O
5	products	O
6	inhibit	O
7	in	O
8	vitro	O
9	granulopoiesis	O
10	.	O

1	Plasma	O
2	fibrinogen	B
3	was	O
4	measured	O
5	by	O
6	the	O
7	turbidimetric	O
8	method	O
9	in	O
10	timol	O
11	turbidimetric	O
12	units	O
13	.	O

1	Five	O
2	patients	O
3	with	O
4	type	O
5	III	O
6	musculoskeletal	O
7	infection	O
8	from	O
9	nongonococcal	O
10	Neisseria	O
11	species	O
12	were	O
13	examined	O
14	during	O
15	a	O
16	13	O
17	-	O
18	month	O
19	period	O
20	.	O

1	Distal	O
2	tubular	O
3	acidification	O
4	and	O
5	the	O
6	threshold	O
7	for	O
8	proximal	O
9	tubular	O
10	bicarbonate	O
11	reabsorption	O
12	were	O
13	normal	O
14	,	O
15	as	O
16	was	O
17	urine	O
18	concentrating	O
19	capacity	O
20	.	O

1	Detection	O
2	of	O
3	exercise	O
4	-	O
5	induced	O
6	asynergy	O
7	by	O
8	M	O
9	-	O
10	mode	O
11	echocardiography	O
12	.	O

1	The	O
2	Tullio	O
3	phenomenon	O
4	,	O
5	fistula	O
6	test	O
7	,	O
8	and	O
9	Hennebert	O
10	'	O
11	s	O
12	sign	O
13	:	O
14	clinical	O
15	significance	O
16	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	significant	O
6	pulmonary	O
7	metabolism	O
8	of	O
9	5	O
10	-	O
11	HT	O
12	followed	O
13	by	O
14	efflux	O
15	of	O
16	5	O
17	-	O
18	HIAA	O
19	into	O
20	venous	O
21	output	O
22	occurs	O
23	during	O
24	single	O
25	-	O
26	pass	O
27	circulation	O
28	.	O

1	Disturbances	O
2	of	O
3	placental	O
4	maturation	O
5	,	O
6	2	O
7	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	histopathological	O
6	findings	O
7	,	O
8	the	O
9	origin	O
10	of	O
11	amyloid	O
12	appeared	O
13	to	O
14	be	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	fibroblasts	O
20	.	O

1	Both	O
2	groups	O
3	were	O
4	subjected	O
5	to	O
6	tests	O
7	of	O
8	delayed	O
9	hypersensitivity	O
10	with	O
11	Candidin	B
12	,	O
13	Trycophytin	B
14	and	O
15	Tuberculin	B
16	.	O

1	Serum	O
2	lactate	B
3	dehydrogenase	I
4	and	O
5	haptoglobin	B
6	levels	O
7	were	O
8	normal	O
9	,	O
10	and	O
11	total	O
12	bilirubin	O
13	was	O
14	only	O
15	slightly	O
16	elevated	O
17	.	O

1	Low	O
2	-	O
3	dose	O
4	D	O
5	(	O
6	0	O
7	.	O
8	4	O
9	-	O
10	0	O
11	.	O
12	8	O
13	mg	O
14	)	O
15	and	O
16	DB	O
17	(	O
18	1	O
19	.	O
20	0	O
21	-	O
22	5	O
23	.	O
24	0	O
25	mg	O
26	)	O
27	did	O
28	not	O
29	significantly	O
30	alter	O
31	any	O
32	parameter	O
33	from	O
34	control	O
35	.	O

1	Efficacy	O
2	of	O
3	cervical	O
4	spine	O
5	immobilization	O
6	methods	O
7	.	O

1	Leads	O
2	from	O
3	the	O
4	MMWR	O
5	.	O

1	The	O
2	presence	O
3	of	O
4	visna	O
5	-	O
6	maedi	O
7	in	O
8	Italy	O
9	is	O
10	reported	O
11	for	O
12	the	O
13	first	O
14	time	O
15	.	O

1	High	O
2	levels	O
3	of	O
4	IC	O
5	coincided	O
6	with	O
7	relative	O
8	hypocomplementemia	O
9	.	O

1	Circulating	O
2	platelets	O
3	may	O
4	be	O
5	activated	O
6	by	O
7	exposed	O
8	triple	O
9	-	O
10	helical	O
11	collagen	B
12	in	O
13	atherosclerotic	O
14	lesions	O
15	in	O
16	Mg	O
17	-	O
18	deficient	O
19	ruminants	O
20	.	O

1	Acute	O
2	type	O
3	A	O
4	hepatitis	O
5	in	O
6	three	O
7	patients	O
8	with	O
9	chronic	O
10	HBV	O
11	infection	O
12	.	O

1	Pathogenetic	O
2	relationships	O
3	between	O
4	renal	O
5	tubular	O
6	acidosis	O
7	and	O
8	sodium	O
9	metabolism	O
10	alterations	O
11	in	O
12	liver	O
13	cirrhosis	O
14	.	O

1	5	O
2	microU	O
3	/	O
4	l	O
5	thyrotropin	B
6	:	O
7	75	O
8	%	O
9	(	O
10	1974	O
11	),	O
12	45	O
13	%	O
14	(	O
15	1977	O
16	)	O
17	and	O
18	20	O
19	%	O
20	(	O
21	1980	O
22	).	O

1	Echosismography	O
2	enables	O
3	to	O
4	improve	O
5	the	O
6	diagnosis	O
7	when	O
8	compared	O
9	with	O
10	classical	O
11	sonography	O
12	in	O
13	about	O
14	20	O
15	%	O
16	of	O
17	cases	O
18	.	O

1	Relationships	O
2	with	O
3	the	O
4	acquired	O
5	immune	O
6	deficiency	O
7	syndrome	O
8	.	O

1	The	O
2	prevalence	O
3	of	O
4	CPAF	O
5	was	O
6	similar	O
7	in	O
8	type	O
9	1	O
10	and	O
11	type	O
12	2	O
13	diabetes	O
14	,	O
15	was	O
16	greater	O
17	in	O
18	women	O
19	than	O
20	in	O
21	men	O
22	,	O
23	and	O
24	was	O
25	significantly	O
26	greater	O
27	after	O
28	repeated	O
29	administrations	O
30	than	O
31	after	O
32	one	O
33	single	O
34	administration	O
35	of	O
36	chlorpropamide	O
37	.	O

1	A	O
2	reassessment	O
3	of	O
4	the	O
5	prevalence	O
6	data	O
7	was	O
8	carried	O
9	out	O
10	in	O
11	the	O
12	southern	O
13	province	O
14	of	O
15	Uusimaa	O
16	and	O
17	in	O
18	the	O
19	western	O
20	province	O
21	of	O
22	Vaasa	O
23	,	O
24	the	O
25	prevalence	O
26	day	O
27	being	O
28	January	O
29	1	O
30	,	O
31	1979	O
32	.	O

1	The	O
2	results	O
3	confirm	O
4	and	O
5	extend	O
6	previous	O
7	work	O
8	by	O
9	other	O
10	researchers	O
11	.	O

1	In	O
2	the	O
3	ultramarathon	O
4	runner	O
5	the	O
6	testosterone	O
7	levels	O
8	sharply	O
9	rose	O
10	at	O
11	the	O
12	beginning	O
13	of	O
14	the	O
15	training	O
16	session	O
17	(	O
18	from	O
19	the	O
20	7	O
21	,	O
22	20	O
23	ng	O
24	/	O
25	ml	O
26	to	O
27	11	O
28	,	O
29	50	O
30	ng	O
31	/	O
32	ml	O
33	after	O
34	20	O
35	'	O
36	training	O
37	),	O
38	and	O
39	subsequently	O
40	decrease	O
41	after	O
42	3	O
43	hours	O
44	(	O
45	9	O
46	,	O
47	20	O
48	ng	O
49	/	O
50	ml	O
51	)	O
52	and	O
53	at	O
54	the	O
55	end	O
56	of	O
57	the	O
58	6	O
59	hours	O
60	training	O
61	(	O
62	4	O
63	,	O
64	60	O
65	ng	O
66	/	O
67	ml	O
68	).	O

1	In	O
2	patients	O
3	with	O
4	complete	O
5	or	O
6	partial	O
7	remission	O
8	of	O
9	the	O
10	tumor	O
11	,	O
12	the	O
13	neopterine	O
14	excretion	O
15	dropped	O
16	to	O
17	normal	O
18	values	O
19	.	O

1	In	O
2	visible	O
3	tumours	O
4	the	O
5	best	O
6	results	O
7	were	O
8	obtained	O
9	with	O
10	FB	O
11	(	O
12	85	O
13	%)	O
14	while	O
15	TBN	O
16	was	O
17	positive	O
18	in	O
19	65	O
20	%.	O

1	Total	O
2	PGE	O
3	levels	O
4	in	O
5	synovial	O
6	fluid	O
7	remained	O
8	significantly	O
9	depressed	O
10	in	O
11	the	O
12	patient	O
13	group	O
14	for	O
15	24	O
16	hours	O
17	after	O
18	the	O
19	400	O
20	-	O
21	mg	O
22	test	O
23	dose	O
24	of	O
25	tolmetin	O
26	on	O
27	day	O
28	8	O
29	.	O

1	Normal	O
2	rates	O
3	of	O
4	weight	O
5	gain	O
6	were	O
7	seen	O
8	once	O
9	absorbed	O
10	energy	O
11	intakes	O
12	reached	O
13	100	O
14	-	O
15	110	O
16	%	O
17	of	O
18	requirements	O
19	.	O

1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O

1	Behcet	O
2	'	O
3	s	O
4	syndrome	O

1	Survival	O
2	of	O
3	111	O
4	Indium	O
5	-	O
6	labelled	O
7	autologous	O
8	platelets	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	shortened	O
24	.	O

1	The	O
2	effect	O
3	of	O
4	emotional	O
5	-	O
6	painful	O
7	stress	O
8	(	O
9	EPS	O
10	)	O
11	on	O
12	myocardial	O
13	extensibility	O
14	and	O
15	contractility	O
16	was	O
17	studied	O
18	on	O
19	an	O
20	isolated	O
21	rat	O
22	atrium	O
23	.	O

1	Terbutaline	O
2	;	O
3	a	O
4	beta2	O
5	-	O
6	adrenergic	O
7	agonist	O
8	,	O
9	and	O
10	aminophyllin	O
11	,	O
12	a	O
13	phosphodiesterase	O
14	inhibitor	O
15	,	O
16	were	O
17	given	O
18	separately	O
19	,	O
20	or	O
21	in	O
22	combination	O
23	,	O
24	to	O
25	rabbit	O
26	fetuses	O
27	on	O
28	the	O
29	28th	O
30	day	O
31	of	O
32	gestation	O
33	.	O

1	When	O
2	O2	O
3	therapy	O
4	was	O
5	controlled	O
6	for	O
7	,	O
8	the	O
9	association	O
10	between	O
11	RBT	O
12	and	O
13	RLF	O
14	did	O
15	not	O
16	achieve	O
17	statistical	O
18	significance	O
19	(	O
20	P	O
21	=	O
22	.	O
23	07	O
24	).	O

1	This	O
2	two	O
3	-	O
4	helix	O
5	motif	O
6	is	O
7	thought	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	specific	O
13	DNA	O
14	sequence	O
15	recognition	O
16	by	O
17	CAP	B
18	.	O

1	The	O
2	hyperacute	O
3	phase	O
4	of	O
5	posterolateral	O
6	myocardial	O
7	infarction	O
8	.	O

1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O

1	The	O
2	infection	O
3	rate	O
4	was	O
5	five	O
6	times	O
7	greater	O
8	in	O
9	patients	O
10	with	O
11	Hickman	O
12	catheters	O
13	than	O
14	in	O
15	those	O
16	with	O
17	Broviac	O
18	catheters	O
19	(	O
20	p	O
21	=	O
22	0	O
23	.	O
24	01	O
25	).	O

1	After	O
2	a	O
3	year	O
4	of	O
5	planning	O
6	in	O
7	the	O
8	Laboratory	O
9	Assistants	O
10	'	O
11	School	O
12	in	O
13	Stockholm	O
14	:	O
15	new	O
16	education	O
17	for	O
18	laboratory	O
19	assistants	O
20	is	O
21	now	O
22	arranged	O

1	The	O
2	electrocardiogram	O
3	.	O

1	Setting	O
2	takes	O
3	place	O
4	through	O
5	complex	O
6	formation	O
7	of	O
8	(	O
9	NH4Mg	O
10	PO4	O
11	.	O
12	6H2O	O
13	)	O
14	n	O
15	,	O
16	excess	O
17	reactants	O
18	,	O
19	and	O
20	water	O
21	.	O

1	The	O
2	Authors	O
3	have	O
4	proposed	O
5	to	O
6	develop	O
7	this	O
8	research	O
9	employing	O
10	a	O
11	preparation	O
12	containing	O
13	exclusively	O
14	a	O
15	cortisonic	O
16	,	O
17	the	O
18	desametazone	O
19	,	O
20	in	O
21	order	O
22	to	O
23	evaluate	O
24	the	O
25	alterations	O
26	of	O
27	the	O
28	dentinogenesis	O
29	to	O
30	be	O
31	attributed	O
32	to	O
33	such	O
34	component	O
35	.	O

1	Secretory	B
2	IgA	I
3	and	O
4	serum	B
5	immunoglobulins	I
6	as	O
7	indices	O
8	of	O
9	the	O
10	local	O
11	immunity	O
12	of	O
13	the	O
14	intestinal	O
15	mucosa	O
16	in	O
17	acute	O
18	leukemias	O

1	Serum	B
2	IgE	I
3	levels	O
4	in	O
5	Tauranga	O
6	children	O
7	.	O

1	Use	O
2	of	O
3	prostaglandin	O
4	F2	O
5	alpha	O
6	(	O
7	PGF2	O
8	alpha	O
9	)	O
10	in	O
11	cattle	O
12	breeding	O
13	.	O

1	Thus	O
2	it	O
3	appears	O
4	that	O
5	the	O
6	management	O
7	of	O
8	blood	O
9	,	O
10	including	O
11	washing	O
12	is	O
13	of	O
14	great	O
15	importance	O
16	.	O

1	Range	O
2	,	O
3	variations	O
4	and	O
5	neoplastic	O
6	potential	O
7	.	O

1	The	O
2	scores	O
3	are	O
4	dependent	O
5	in	O
6	part	O
7	on	O
8	the	O
9	reliability	O
10	of	O
11	faculty	O
12	evaluations	O
13	.	O

1	Study	O
2	on	O
3	distribution	O
4	of	O
5	metal	O
6	in	O
7	the	O
8	teeth	O
9	treated	O
10	by	O
11	iontophoresis	O
12	with	O
13	transparent	O
14	specimens	O

1	Whereas	O
2	creatine	B
3	kinase	I
4	activity	O
5	declined	O
6	exponentially	O
7	from	O
8	a	O
9	single	O
10	peak	O
11	,	O
12	myoglobin	B
13	appeared	O
14	in	O
15	multiple	O
16	episodes	O
17	inadequately	O
18	represented	O
19	by	O
20	a	O
21	single	O
22	peak	O
23	value	O
24	and	O
25	having	O
26	no	O
27	clear	O
28	clinical	O
29	correlation	O
30	.	O

1	Utero	O
2	-	O
3	placental	O
4	blood	O
5	flow	O
6	and	O
7	the	O
8	effect	O
9	of	O
10	beta	B
11	2	I
12	-	I
13	adrenoceptor	I
14	stimulating	O
15	drugs	O
16	.	O

1	Development	O
2	of	O
3	basophilic	O
4	leukemia	O
5	with	O
6	trisomy	O
7	8	O
8	and	O
9	atypical	O
10	erythroblastosis	O
11	in	O
12	a	O
13	patient	O
14	with	O
15	a	O
16	history	O
17	of	O
18	aplastic	O
19	anemia	O
20	22	O
21	years	O
22	earlier	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	B
17	IXa	I
18	by	O
19	factor	B
20	XIa	I
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	Alveolar	O
2	growth	O
3	,	O
4	contemporary	O
5	with	O
6	dental	O
7	eruption	O
8	,	O
9	is	O
10	sufficient	O
11	to	O
12	compensate	O
13	possible	O
14	hypotrophy	O
15	of	O
16	maxillary	O
17	bone	O
18	bases	O
19	.	O

1	Fluorometric	O
2	methods	O
3	can	O
4	also	O
5	provide	O
6	information	O
7	about	O
8	porphyrin	O
9	binding	O
10	sites	O
11	that	O
12	is	O
13	useful	O
14	in	O
15	understanding	O
16	porphyrin	O
17	transport	O
18	and	O
19	clearance	O
20	.	O

1	Renal	O
2	and	O
3	extrarenal	O
4	arterial	O
5	fibromuscular	O
6	hyperplasia	O
7	with	O
8	hypertension	O
9	.	O

1	The	O
2	monoexponential	O
3	rate	O
4	of	O
5	clearance	O
6	of	O
7	tracer	O
8	--	O
9	obtained	O
10	from	O
11	the	O
12	portion	O
13	of	O
14	the	O
15	residue	O
16	-	O
17	detection	O
18	curve	O
19	reflecting	O
20	metabolism	O
21	of	O
22	fatty	O
23	acid	O
24	incorporated	O
25	into	O
26	neutral	O
27	lipids	O
28	--	O
29	correlated	O
30	directly	O
31	with	O
32	induced	O
33	changes	O
34	in	O
35	tension	O
36	-	O
37	time	O
38	index	O
39	after	O
40	injections	O
41	into	O
42	the	O
43	left	O
44	atrium	O
45	(	O
46	r	O
47	=	O
48	0	O
49	.	O
50	96	O
51	,	O
52	n	O
53	=	O
54	12	O
55	),	O
56	right	O
57	atrium	O
58	(	O
59	r	O
60	=	O
61	0	O
62	.	O
63	86	O
64	,	O
65	n	O
66	=	O
67	14	O
68	),	O
69	and	O
70	ear	O
71	vein	O
72	(	O
73	r	O
74	=	O
75	0	O
76	.	O
77	93	O
78	,	O
79	n	O
80	=	O
81	14	O
82	).	O

1	Both	O
2	examinations	O
3	are	O
4	sensitive	O
5	indicators	O
6	of	O
7	CNS	O
8	abnormalities	O
9	associated	O
10	with	O
11	bacterial	O
12	meningeal	O
13	infections	O
14	and	O
15	are	O
16	important	O
17	determinants	O
18	of	O
19	the	O
20	therapy	O
21	and	O
22	ultimate	O
23	prognosis	O
24	of	O
25	such	O
26	complications	O
27	.	O

1	Specific	O
2	IgE	B
3	levels	O
4	decreased	O
5	slightly	O
6	,	O
7	but	O
8	always	O
9	remained	O
10	within	O
11	the	O
12	pathological	O
13	range	O
14	.	O

1	Similar	O
2	clinical	O
3	evaluation	O
4	of	O
5	an	O
6	obligate	O
7	carrier	O
8	revealed	O
9	no	O
10	ocular	O
11	abnormalities	O
12	.	O

1	Correlation	O
2	between	O
3	intraocular	O
4	involvement	O
5	and	O
6	systemic	O
7	outcome	O
8	was	O
9	poor	O
10	.	O

1	A	O
2	case	O
3	of	O
4	anterior	O
5	cleavage	O
6	syndrome	O
7	in	O
8	a	O
9	27	O
10	-	O
11	year	O
12	-	O
13	old	O
14	female	O
15	patient	O
16	is	O
17	described	O
18	.	O

1	The	O
2	daily	O
3	administration	O
4	of	O
5	betamethasone	O
6	for	O
7	three	O
8	weeks	O
9	markedly	O
10	reduced	O
11	the	O
12	absorption	O
13	of	O
14	calcium	O
15	and	O
16	phosphate	O
17	as	O
18	well	O
19	as	O
20	the	O
21	growth	O
22	rate	O
23	.	O

1	Endorphins	B
2	and	O
3	legal	O
4	issues	O
5	.	O

1	At	O
2	necropsy	O
3	28	O
4	days	O
5	post	O
6	-	O
7	inoculation	O
8	,	O
9	F344	O
10	rats	O
11	had	O
12	no	O
13	gross	O
14	lung	O
15	lesions	O
16	,	O
17	even	O
18	those	O
19	given	O
20	the	O
21	maximum	O
22	dose	O
23	of	O
24	1	O
25	.	O
26	4	O
27	X	O
28	10	O
29	(	O
30	9	O
31	)	O
32	colony	O
33	-	O
34	forming	O
35	units	O
36	of	O
37	M	O
38	.	O
39	pulmonis	O
40	.	O

1	Aneurysmectomy	O
2	and	O
3	the	O
4	performance	O
5	of	O
6	CABG	O
7	were	O
8	not	O
9	significantly	O
10	associated	O
11	with	O
12	postoperative	O
13	ECG	O
14	changes	O
15	,	O
16	but	O
17	more	O
18	bypass	O
19	grafts	O
20	per	O
21	patient	O
22	grafted	O
23	appeared	O
24	in	O
25	the	O
26	group	O
27	with	O
28	postoperative	O
29	ECG	O
30	changes	O
31	,	O
32	suggesting	O
33	that	O
34	coronary	O
35	artery	O
36	disease	O
37	may	O
38	be	O
39	more	O
40	severe	O
41	in	O
42	that	O
43	group	O
44	.	O

1	REV	O
2	I	O
3	:	O
4	All	O
5	vessels	O
6	up	O
7	to	O
8	50	O
9	%	O
10	stenosed	O
11	have	O
12	a	O
13	patent	O
14	graft	O
15	.	O

1	Complete	O
2	sequences	O
3	were	O
4	obtained	O
5	for	O
6	the	O
7	three	O
8	large	O
9	thrombic	O
10	peptides	O
11	,	O
12	and	O
13	these	O
14	were	O
15	aligned	O
16	by	O
17	using	O
18	peptides	O
19	from	O
20	the	O
21	V8	B
22	protease	I
23	digest	O
24	.	O

1	The	O
2	extraction	O
3	measurements	O
4	were	O
5	used	O
6	to	O
7	test	O
8	for	O
9	extracerebral	O
10	contamination	O
11	of	O
12	venous	O
13	outflow	O
14	.	O

1	Contractile	O
2	responses	O
3	to	O
4	norepinephrine	O
5	,	O
6	serotonin	O
7	and	O
8	potassium	O
9	(	O
10	K	O
11	+)	O
12	and	O
13	relaxant	O
14	responses	O
15	to	O
16	isoproterenol	O
17	and	O
18	papaverine	O
19	were	O
20	studied	O
21	in	O
22	vitro	O
23	with	O
24	spirally	O
25	cut	O
26	thoracic	O
27	aortic	O
28	strips	O
29	from	O
30	aortic	O
31	coarcted	O
32	hypertensive	O
33	rats	O
34	(	O
35	AHR	O
36	)	O
37	2	O
38	,	O
39	6	O
40	,	O
41	14	O
42	and	O
43	28	O
44	days	O
45	postoperatively	O
46	and	O
47	compared	O
48	to	O
49	time	O
50	-	O
51	matched	O
52	,	O
53	sham	O
54	-	O
55	operated	O
56	normotensive	O
57	controls	O
58	.	O

1	On	O
2	line	O
3	calculation	O
4	of	O
5	steroid	O
6	concentrations	O
7	by	O
8	radioimmunoassay	O

1	Detection	O
2	of	O
3	congenital	O
4	hypothyroidism	O
5	in	O
6	26	O
7	,	O
8	282	O
9	newborn	O
10	infants	O

1	In	O
2	rubella	O
3	patients	O
4	with	O
5	serologic	O
6	confirmation	O
7	by	O
8	HI	O
9	,	O
10	the	O
11	IF	O
12	test	O
13	detected	O
14	significant	O
15	rises	O
16	in	O
17	219	O
18	(	O
19	99	O
20	.	O
21	1	O
22	%)	O
23	of	O
24	221	O
25	patients	O
26	and	O
27	the	O
28	PHA	B
29	test	O
30	detected	O
31	antibody	O
32	conversion	O
33	in	O
34	68	O
35	(	O
36	93	O
37	%)	O
38	of	O
39	73	O
40	patients	O
41	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	folate	O
6	compounds	O
7	decrease	O
8	formate	O
9	accumulation	O
10	after	O
11	methanol	O
12	by	O
13	stimulating	O
14	formate	O
15	oxidation	O
16	or	O
17	utilization	O
18	and	O
19	suggest	O
20	a	O
21	possible	O
22	use	O
23	for	O
24	folates	O
25	in	O
26	the	O
27	treatment	O
28	of	O
29	certain	O
30	cases	O
31	of	O
32	human	O
33	methanol	O
34	poisoning	O
35	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	saccharin	O
6	in	O
7	the	O
8	diet	O
9	on	O
10	caecal	O
11	microflora	O
12	.	O

1	The	O
2	residue	O
3	functions	O
4	,	O
5	R	O
6	(	O
7	t	O
8	),	O
9	for	O
10	C	O
11	-	O
12	11	O
13	CPZ	O
14	and	O
15	In	O
16	-	O
17	113m	O
18	transferrin	B
19	were	O
20	plotted	O
21	against	O
22	time	O
23	for	O
24	selected	O
25	areas	O
26	of	O
27	interest	O
28	,	O
29	and	O
30	the	O
31	CPZ	O
32	area	O
33	-	O
34	weighted	O
35	extraction	O
36	,	O
37	E	O
38	(	O
39	t	O
40	),	O
41	was	O
42	computed	O
43	for	O
44	the	O
45	same	O
46	areas	O
47	every	O
48	250	O
49	msec	O
50	using	O
51	the	O
52	formula	O
53	:	O
54	E	O
55	(	O
56	t	O
57	)	O
58	=	O
59	[	O
60	RT	O
61	(	O
62	t	O
63	)	O
64	-	O
65	RR	O
66	(	O
67	t	O
68	)]/[	O
69	1	O
70	-	O
71	RR	O
72	(	O
73	t	O
74	)],	O
75	where	O
76	RT	O
77	and	O
78	RR	O
79	are	O
80	the	O
81	normalized	O
82	residue	O
83	functions	O
84	for	O
85	CPZ	O
86	and	O
87	transferrin	B
88	,	O
89	respectively	O
90	.	O

1	Synchronous	O
2	extracts	O
3	showed	O
4	no	O
5	significant	O
6	migration	O
7	inhibition	O
8	in	O
9	allogeneic	O
10	assays	O
11	.	O

1	Ten	O
2	days	O
3	of	O
4	cefadroxil	O
5	therapy	O
6	was	O
7	used	O
8	to	O
9	treat	O
10	44	O
11	children	O
12	with	O
13	urinary	O
14	tract	O
15	infection	O
16	and	O
17	CRP	B
18	values	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	28	O
25	microgram	O
26	/	O
27	ml	O
28	(	O
29	CRP	B
30	-	O
31	positive	O
32	group	O
33	).	O

1	Both	O
2	resting	O
3	blood	O
4	flow	O
5	(	O
6	RBF	O
7	)	O
8	and	O
9	maximal	O
10	blood	O
11	flow	O
12	(	O
13	NBF	O
14	)	O
15	were	O
16	studied	O
17	by	O
18	Xenon	O
19	133	O
20	clearance	O
21	.	O

1	Plasma	B
2	renin	I
3	concentration	O
4	is	O
5	significantly	O
6	higher	O
7	in	O
8	the	O
9	subcapsular	O
10	venous	O
11	outflow	O
12	,	O
13	which	O
14	drains	O
15	the	O
16	superficial	O
17	cortex	O
18	,	O
19	than	O
20	in	O
21	the	O
22	deep	O
23	venous	O
24	outflow	O
25	,	O
26	which	O
27	drains	O
28	the	O
29	inner	O
30	half	O
31	of	O
32	the	O
33	cortex	O
34	and	O
35	medulla	O
36	of	O
37	the	O
38	cat	O
39	kidney	O
40	.	O

1	After	O
2	acclimation	O
3	,	O
4	resting	O
5	supine	O
6	and	O
7	sitting	O
8	DPB	O
9	decreased	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	)	O
18	by	O
19	6	O
20	and	O
21	9	O
22	mmHg	O
23	,	O
24	respectively	O
25	.	O

1	In	O
2	the	O
3	diabetics	O
4	,	O
5	Ca2	O
6	+	O
7	infusions	O
8	induced	O
9	a	O
10	rise	O
11	of	O
12	plasma	O
13	Ca2	O
14	+	O
15	up	O
16	to	O
17	3	O
18	.	O
19	2	O
20	+/-	O
21	0	O
22	.	O
23	1	O
24	mmol	O
25	/	O
26	1	O
27	and	O
28	a	O
29	fall	O
30	of	O
31	circulating	O
32	glucagon	B
33	(-	O
34	26	O
35	.	O
36	4	O
37	+/-	O
38	5	O
39	.	O
40	7	O
41	%;	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	)	O
49	and	O
50	glucose	O
51	(-	O
52	23	O
53	.	O
54	3	O
55	+/-	O
56	3	O
57	.	O
58	6	O
59	%;	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	05	O
66	).	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	The	O
2	foregoing	O
3	results	O
4	show	O
5	that	O
6	CXD	O
7	has	O
8	high	O
9	efficacy	O
10	and	O
11	safety	O
12	and	O
13	it	O
14	can	O
15	be	O
16	said	O
17	that	O
18	it	O
19	is	O
20	a	O
21	drug	O
22	required	O
23	in	O
24	the	O
25	pediatric	O
26	field	O
27	.	O

1	Based	O
2	on	O
3	peptide	O
4	map	O
5	similarities	O
6	,	O
7	partial	O
8	amino	O
9	-	O
10	terminal	O
11	sequence	O
12	data	O
13	,	O
14	and	O
15	common	O
16	genetic	O
17	origin	O
18	,	O
19	it	O
20	is	O
21	suggested	O
22	that	O
23	p60	B
24	and	O
25	p62	B
26	have	O
27	identical	O
28	amino	O
29	acid	O
30	sequences	O
31	carboxy	O
32	-	O
33	terminal	O
34	to	O
35	the	O
36	p60	B
37	initiator	O
38	methionine	O
39	(	O
40	residue	O
41	21	O
42	of	O
43	p62	B
44	).	O

1	All	O
2	patients	O
3	in	O
4	the	O
5	control	O
6	group	O
7	showed	O
8	a	O
9	significant	O
10	improvement	O
11	in	O
12	their	O
13	PEFR	O
14	while	O
15	only	O
16	3	O
17	patients	O
18	in	O
19	the	O
20	treated	O
21	group	O
22	showed	O
23	an	O
24	improvement	O
25	.	O

1	Facts	O
2	on	O
3	the	O
4	Economic	O
5	Recovery	O
6	Tax	O
7	Act	O
8	of	O
9	1981	O
10	for	O
11	speech	O
12	-	O
13	language	O
14	pathologists	O
15	and	O
16	audiologists	O
17	.	O

1	From	O
2	Pap	O
3	to	O
4	ApUp	O
5	.	O

1	The	O
2	relationship	O
3	between	O
4	the	O
5	rare	O
6	complications	O
7	mentioned	O
8	above	O
9	and	O
10	the	O
11	pathophysiology	O
12	of	O
13	Bartter	O
14	'	O
15	s	O
16	syndrome	O
17	is	O
18	still	O
19	obscure	O
20	.	O

1	Using	O
2	an	O
3	opsonophagocytic	O
4	bacterial	O
5	assay	O
6	and	O
7	a	O
8	suckling	O
9	rat	O
10	model	O
11	of	O
12	GBS	O
13	sepsis	O
14	,	O
15	we	O
16	analyzed	O
17	a	O
18	modified	O
19	human	B
20	immunoglobulin	I
21	for	O
22	opsonic	O
23	and	O
24	protective	O
25	antibody	O
26	.	O

1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	Commonly	O
2	observed	O
3	systemic	O
4	toxic	O
5	effects	O
6	(	O
7	bone	O
8	marrow	O
9	,	O
10	gastrointestinal	O
11	tract	O
12	,	O
13	and	O
14	heart	O
15	)	O
16	were	O
17	not	O
18	seen	O
19	in	O
20	this	O
21	study	O
22	.	O

1	2	O
2	.	O

1	When	O
2	vascular	O
3	pressure	O
4	(	O
5	Pvas	O
6	)	O
7	was	O
8	raised	O
9	abruptly	O
10	from	O
11	-	O
12	5	O
13	to	O
14	+	O
15	25	O
16	cmH2O	O
17	by	O
18	air	O
19	inflation	O
20	for	O
21	60	O
22	min	O
23	,	O
24	Px	O
25	(	O
26	f	O
27	)	O
28	became	O
29	abruptly	O
30	less	O
31	negative	O
32	,	O
33	then	O
34	remained	O
35	stable	O
36	.	O

1	(	O
2	1980	O
3	):	O
4	Science	O
5	210	O
6	,	O
7	77	O
8	-	O
9	72	O
10	)	O
11	that	O
12	stimulating	O
13	the	O
14	crossed	O
15	olivocochlear	O
16	bundle	O
17	(	O
18	COCB	O
19	)	O
20	can	O
21	change	O
22	the	O
23	magnitude	O
24	of	O
25	the	O
26	distortion	O
27	product	O
28	(	O
29	f2	O
30	-	O
31	f1	O
32	)	O
33	in	O
34	the	O
35	ear	O
36	-	O
37	canal	O
38	sound	O
39	pressure	O
40	.	O

1	Rats	O
2	underwent	O
3	either	O
4	a	O
5	90	O
6	-	O
7	95	O
8	%	O
9	JIB	O
10	or	O
11	a	O
12	sham	O
13	operation	O
14	.	O

1	When	O
2	the	O
3	l	O
4	-	O
5	methadone	O
6	-	O
7	sensitive	O
8	,	O
9	opioid	B
10	receptor	I
11	is	O
12	blocked	O
13	by	O
14	naloxone	O
15	or	O
16	tolerance	O
17	has	O
18	developed	O
19	,	O
20	than	O
21	l	O
22	-	O
23	methadone	O
24	can	O
25	produce	O
26	behavioral	O
27	effects	O
28	by	O
29	a	O
30	nonopioid	O
31	mechanism	O
32	.	O

1	Microwave	O
2	hyperthermia	O
3	-	O
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	Large	O
2	and	O
3	small	O
4	medullary	O
5	lesions	O
6	inhibited	O
7	the	O
8	occurrence	O
9	of	O
10	target	O
11	fibres	O
12	in	O
13	the	O
14	tenotomized	O
15	muscles	O
16	,	O
17	the	O
18	smallest	O
19	one	O
20	being	O
21	neurolysis	O
22	of	O
23	the	O
24	dorsal	O
25	roots	O
26	.	O

1	Diagnosis	O
2	of	O
3	phenylalanine	B
4	hydroxylase	I
5	deficiency	O
6	(	O
7	phenylketonuria	O
8	).	O

1	In	O
2	10	O
3	control	O
4	sheep	O
5	mean	O
6	plasma	O
7	TXB2	O
8	concentration	O
9	increased	O
10	from	O
11	0	O
12	.	O
13	39	O
14	ng	O
15	/	O
16	ml	O
17	prebypass	O
18	to	O
19	about	O
20	1	O
21	.	O
22	1	O
23	ng	O
24	/	O
25	ml	O
26	at	O
27	8	O
28	and	O
29	16	O
30	min	O
31	of	O
32	bypass	O
33	.	O

1	The	O
2	respiratory	O
3	rate	O
4	was	O
5	13	O
6	+/-	O
7	1	O
8	breaths	O
9	/	O
10	min	O
11	with	O
12	52	O
13	+/-	O
14	4	O
15	%	O
16	of	O
17	the	O
18	respiratory	O
19	cycle	O
20	spent	O
21	in	O
22	inspiration	O
23	;	O
24	end	O
25	-	O
26	tidal	O
27	CO2	O
28	pressure	O
29	increased	O
30	by	O
31	3	O
32	.	O
33	3	O
34	+/-	O
35	1	O
36	.	O
37	0	O
38	Torr	O
39	during	O
40	runs	O
41	at	O
42	SIP	O
43	.	O

1	There	O
2	was	O
3	no	O
4	further	O
5	increase	O
6	in	O
7	oxygen	O
8	consumption	O
9	when	O
10	these	O
11	subjects	O
12	breathed	O
13	with	O
14	inspiratory	O
15	pressures	O
16	above	O
17	SIP	O
18	.	O

1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	extravascular	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	sucrose	O
17	indicators	O
18	in	O
19	8	O
20	normal	O
21	and	O
22	11	O
23	edematous	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O

1	Investigated	O
2	the	O
3	reliability	O
4	,	O
5	validity	O
6	and	O
7	dimensionality	O
8	of	O
9	scores	O
10	obtained	O
11	by	O
12	acute	O
13	psychiatric	O
14	inpatients	O
15	(	O
16	N	O
17	=	O
18	120	O
19	)	O
20	on	O
21	the	O
22	Michigan	O
23	Alcoholism	O
24	Screening	O
25	Test	O
26	adapted	O
27	to	O
28	assess	O
29	lifetime	O
30	and	O
31	current	O
32	symptomatology	O
33	.	O

1	A	O
2	simple	O
3	method	O
4	for	O
5	measuring	O
6	urinary	O
7	iron	O
8	following	O
9	the	O
10	administration	O
11	of	O
12	desferrioxamine	O
13	(	O
14	DF	O
15	)	O
16	is	O
17	described	O
18	.	O

1	During	O
2	conventional	O
3	hemofiltration	O
4	using	O
5	substitution	O
6	fluid	O
7	with	O
8	a	O
9	Na	O
10	+	O
11	concentration	O
12	of	O
13	140	O
14	mEq	O
15	/	O
16	L	O
17	,	O
18	a	O
19	decrease	O
20	in	O
21	extracellular	O
22	fluid	O
23	volume	O
24	was	O
25	noted	O
26	whereas	O
27	the	O
28	intracellular	O
29	fluid	O
30	volume	O
31	was	O
32	unaltered	O
33	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	Transvenous	O
2	serial	O
3	xeroradiography	O
4	.	O

1	Recommendations	O
2	to	O
3	deal	O
4	with	O
5	these	O
6	and	O
7	related	O
8	issues	O
9	are	O
10	presented	O
11	.	O

1	Use	O
2	of	O
3	subcutaneous	O
4	deferoxamine	O
5	in	O
6	a	O
7	child	O
8	with	O
9	hemochromatosis	O
10	associated	O
11	with	O
12	congenital	O
13	dyserythropoietic	O
14	anemia	O
15	,	O
16	type	O
17	I	O
18	.	O

1	There	O
2	was	O
3	a	O
4	significant	O
5	correlation	O
6	between	O
7	tubular	O
8	diameter	O
9	and	O
10	spg	O
11	(	O
12	r	O
13	=	O
14	0	O
15	.	O
16	68	O
17	,	O
18	P	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	)	O
25	suggesting	O
26	that	O
27	tubular	O
28	diameter	O
29	measurements	O
30	in	O
31	histological	O
32	sections	O
33	could	O
34	be	O
35	used	O
36	to	O
37	predict	O
38	sperm	O
39	production	O
40	.	O

1	The	O
2	differential	O
3	investigation	O
4	of	O
5	lipoproteins	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	B
13	-	I
14	density	I
15	lipoprotein	I
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	absolutely	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	B
29	-	I
30	density	I
31	lipoproteins	I
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	infarcts	O
38	and	O
39	in	O
40	transient	O
41	ischaemic	O
42	attacks	O
43	.	O

1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O

1	Selenium	O
2	status	O
3	of	O
4	thoroughbreds	O
5	in	O
6	the	O
7	United	O
8	Kingdom	O
9	.	O

1	During	O
2	an	O
3	8	O
4	-	O
5	wk	O
6	follow	O
7	-	O
8	up	O
9	,	O
10	parasites	O
11	reappeared	O
12	in	O
13	10	O
14	patients	O
15	,	O
16	5	O
17	after	O
18	each	O
19	drug	O
20	,	O
21	between	O
22	1	O
23	and	O
24	7	O
25	wk	O
26	after	O
27	treatment	O
28	.	O

1	Preparation	O
2	of	O
3	a	O
4	stable	O
5	phospholipid	O
6	reagent	O
7	for	O
8	coagulation	O
9	assays	O
10	.	O

1	A	O
2	note	O
3	on	O
4	some	O
5	consequences	O
6	of	O
7	UV	O
8	vision	O
9	in	O
10	birds	O
11	.	O

1	Before	O
2	turnout	O
3	,	O
4	a	O
5	morantel	O
6	sustained	O
7	release	O
8	bolus	O
9	(	O
10	MSRB	O
11	)	O
12	was	O
13	administered	O
14	to	O
15	each	O
16	animal	O
17	in	O
18	the	O
19	"	O
20	treated	O
21	"	O
22	category	O
23	.	O

1	In	O
2	a	O
3	longitudinal	O
4	study	O
5	,	O
6	14	O
7	low	O
8	-	O
9	risk	O
10	fetuses	O
11	were	O
12	studied	O
13	at	O
14	2	O
15	-	O
16	week	O
17	intervals	O
18	from	O
19	32	O
20	weeks	O
21	of	O
22	gestation	O
23	onward	O
24	.	O

1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O

1	Seventeen	O
2	of	O
3	the	O
4	35	O
5	patients	O
6	were	O
7	randomly	O
8	chosen	O
9	to	O
10	receive	O
11	a	O
12	training	O
13	program	O
14	(	O
15	lasting	O
16	approximately	O
17	1	O
18	month	O
19	)	O
20	designed	O
21	to	O
22	establish	O
23	a	O
24	systematic	O
25	strategy	O
26	of	O
27	organizing	O
28	complex	O
29	visual	O
30	material	O
31	.	O

1	The	O
2	duration	O
3	and	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	negative	O
9	potential	O
10	were	O
11	greatest	O
12	for	O
13	completely	O
14	regenerating	O
15	ears	O
16	with	O
17	overgrowth	O
18	,	O
19	smaller	O
20	for	O
21	partially	O
22	regenerating	O
23	ears	O
24	,	O
25	and	O
26	smallest	O
27	for	O
28	the	O
29	nonregenerating	O
30	ears	O
31	.	O

1	Samples	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O

1	These	O
2	results	O
3	suggested	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	fetus	O
9	played	O
10	some	O
11	role	O
12	in	O
13	the	O
14	production	O
15	of	O
16	E3	O
17	-	O
18	16	O
19	-	O
20	G	O
21	in	O
22	early	O
23	pregnancy	O
24	.	O

1	In	O
2	this	O
3	way	O
4	it	O
5	is	O
6	possible	O
7	to	O
8	simulate	O
9	the	O
10	growth	O
11	function	O
12	of	O
13	the	O
14	embryofetal	O
15	curve	O
16	of	O
17	the	O
18	length	O
19	'	O
20	increase	O
21	of	O
22	man	O
23	and	O
24	the	O
25	curve	O
26	of	O
27	the	O
28	mass	O
29	'	O
30	increase	O
31	of	O
32	rat	O
33	.	O

1	The	O
2	highest	O
3	doses	O
4	were	O
5	found	O
6	for	O
7	drivers	O
8	who	O
9	transported	O
10	large	O
11	numbers	O
12	of	O
13	99Mo	O
14	generators	O
15	.	O

1	The	O
2	steepness	O
3	of	O
4	the	O
5	standard	O
6	O2	O
7	dissociation	O
8	curve	O
9	becomes	O
10	greater	O
11	during	O
12	the	O
13	training	O
14	period	O
15	(	O
16	increase	O
17	in	O
18	Hill	O
19	'	O
20	s	O
21	n	O
22	from	O
23	2	O
24	.	O
25	68	O
26	+/-	O
27	0	O
28	.	O
29	10	O
30	to	O
31	2	O
32	.	O
33	96	O
34	+/-	O
35	0	O
36	.	O
37	15	O
38	).	O

1	Conjugated	O
2	and	O
3	unconjugated	O
4	phenylacetic	O
5	acid	O
6	and	O
7	m	O
8	-	O
9	and	O
10	p	O
11	-	O
12	hydroxyphenylacetic	O
13	acid	O
14	have	O
15	been	O
16	determined	O
17	in	O
18	the	O
19	plasma	O
20	of	O
21	normal	O
22	,	O
23	healthy	O
24	subjects	O
25	after	O
26	fasting	O
27	,	O
28	consumption	O
29	of	O
30	a	O
31	meal	O
32	and	O
33	ingestion	O
34	of	O
35	deuterium	O
36	labelled	O
37	amine	O
38	precursors	O
39	,	O
40	by	O
41	high	O
42	-	O
43	resolution	O
44	gas	O
45	chromatography	O
46	--	O
47	high	O
48	resolution	O
49	mass	O
50	spectrometry	O
51	with	O
52	selected	O
53	ion	O
54	monitoring	O
55	of	O
56	their	O
57	trifluoroethyl	O
58	-	O
59	pentafluoropropionyl	O
60	derivatives	O
61	.	O

1	In	O
2	concept	O
3	II	O
4	62	O
5	patients	O
6	were	O
7	treated	O
8	with	O
9	selective	O
10	vagotomy	O
11	and	O
12	pyloroplasty	O
13	.	O

1	They	O
2	consisted	O
3	of	O
4	behavioural	O
5	disorders	O
6	,	O
7	tetraparesis	O
8	,	O
9	incontinence	O
10	and	O
11	oculomotor	O
12	paralysis	O
13	.	O

1	CSF	O
2	adenosine	B
3	deaminase	I
4	activity	O
5	(	O
6	ADA	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O

1	Histamine	O
2	reactivity	O
3	had	O
4	returned	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	factories	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	worker	O
23	who	O
24	had	O
25	moved	O
26	within	O
27	her	O
28	original	O
29	factory	O
30	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	EF	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	NS	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	NS	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O

1	After	O
2	MOPP	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	normalization	O
16	of	O
17	the	O
18	glucocerebrosidase	B
19	level	O
20	and	O
21	disappearance	O
22	of	O
23	Gaucher	O
24	'	O
25	s	O
26	cells	O
27	.	O

1	Specifically	O
2	,	O
3	by	O
4	the	O
5	type	O
6	of	O
7	adjuvant	O
8	therapy	O
9	,	O
10	the	O
11	median	O
12	disease	O
13	-	O
14	free	O
15	interval	O
16	and	O
17	survival	O
18	from	O
19	stage	O
20	IVA	O
21	for	O
22	23	O
23	patients	O
24	receiving	O
25	Corynebacterium	O
26	parvum	O
27	were	O
28	6	O
29	.	O
30	9	O
31	and	O
32	19	O
33	months	O
34	;	O
35	for	O
36	39	O
37	patients	O
38	receiving	O
39	BCG	O
40	,	O
41	eight	O
42	months	O
43	and	O
44	26	O
45	months	O
46	;	O
47	for	O
48	24	O
49	patients	O
50	receiving	O
51	BCG	O
52	+	O
53	DTIC	O
54	,	O
55	eight	O
56	and	O
57	17	O
58	.	O
59	4	O
60	months	O
61	;	O
62	and	O
63	for	O
64	all	O
65	51	O
66	DTIC	O
67	treated	O
68	patients	O
69	6	O
70	.	O
71	3	O
72	and	O
73	17	O
74	.	O
75	8	O
76	months	O
77	,	O
78	respectively	O
79	.	O

1	The	O
2	COP	O
3	-	O
4	PAWP	O
5	gradient	O
6	was	O
7	markedly	O
8	decreased	O
9	in	O
10	both	O
11	shock	O
12	and	O
13	non	O
14	-	O
15	shock	O
16	patients	O
17	with	O
18	pulmonary	O
19	edema	O
20	.	O

1	Re	O
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O

1	A	O
2	limited	O
3	study	O
4	in	O
5	a	O
6	glassware	O
7	factory	O
8	(	O
9	As2O3	O
10	exposure	O
11	)	O
12	involving	O
13	the	O
14	measurement	O
15	of	O
16	total	O
17	airborne	O
18	arsenic	O
19	,	O
20	the	O
21	determination	O
22	of	O
23	urinary	O
24	arsenic	O
25	,	O
26	and	O
27	the	O
28	evaluation	O
29	of	O
30	hand	O
31	and	O
32	mouth	O
33	contamination	O
34	by	O
35	arsenic	O
36	before	O
37	and	O
38	after	O
39	the	O
40	workshift	O
41	suggests	O
42	that	O
43	the	O
44	high	O
45	urinary	O
46	arsenic	O
47	levels	O
48	(	O
49	300	O
50	microgram	O
51	/	O
52	g	O
53	creatinine	O
54	)	O
55	are	O
56	likely	O
57	to	O
58	be	O
59	more	O
60	related	O
61	to	O
62	an	O
63	increased	O
64	oral	O
65	intake	O
66	from	O
67	contaminated	O
68	hands	O
69	than	O
70	to	O
71	an	O
72	increased	O
73	absorption	O
74	from	O
75	the	O
76	lungs	O
77	.	O

1	Parasitological	O
2	and	O
3	pathological	O
4	findings	O
5	in	O
6	capuchin	O
7	monkeys	O
8	infected	O
9	with	O
10	Schistosoma	O
11	japonicum	O
12	or	O
13	Schistosoma	O
14	mansoni	O
15	.	O

1	The	O
2	pia	O
3	mater	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O

1	Experimental	O
2	reproduction	O
3	of	O
4	malignant	O
5	catarrhal	O
6	fever	O
7	in	O
8	Bali	O
9	cattle	O

1	1	O
2	A	O
3	colonic	O
4	delivery	O
5	system	O
6	is	O
7	described	O
8	to	O
9	deliver	O
10	orally	O
11	ingested	O
12	drugs	O
13	to	O
14	the	O
15	colon	O
16	and	O
17	release	O
18	them	O
19	at	O
20	that	O
21	site	O
22	by	O
23	coating	O
24	with	O
25	an	O
26	acrylic	O
27	based	O
28	resin	O
29	(	O
30	Eudragit	O
31	S	O
32	).	O

1	Administration	O
2	of	O
3	the	O
4	dopamine	O
5	agonist	O
6	bromocriptine	O
7	(	O
8	2	O
9	.	O
10	5	O
11	mg	O
12	three	O
13	times	O
14	a	O
15	day	O
16	for	O
17	4	O
18	days	O
19	)	O
20	suppressed	O
21	(	O
22	P	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	mean	O
30	24	O
31	-	O
32	h	O
33	plasma	O
34	18	O
35	-	O
36	OHB	O
37	levels	O
38	from	O
39	21	O
40	.	O
41	9	O
42	+/-	O
43	2	O
44	.	O
45	0	O
46	to	O
47	14	O
48	.	O
49	8	O
50	+/-	O
51	1	O
52	.	O
53	4	O
54	ng	O
55	/	O
56	dl	O
57	.	O

1	Restarting	O
2	time	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	magnesium	O
8	cardioplegia	O
9	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	Repair	O
2	of	O
3	a	O
4	cosmetic	O
5	defect	O
6	of	O
7	the	O
8	lower	O
9	leg	O
10	with	O
11	a	O
12	myocutaneous	O
13	free	O
14	flap	O
15	.	O

1	According	O
2	to	O
3	the	O
4	literature	O
5	,	O
6	second	O
7	malignant	O
8	epithelial	O
9	tumours	O
10	are	O
11	,	O
12	in	O
13	contrast	O
14	to	O
15	mesenchymal	O
16	tumours	O
17	such	O
18	as	O
19	osteosarcoma	O
20	,	O
21	very	O
22	rare	O
23	in	O
24	retinoblastoma	O
25	survivors	O
26	.	O

1	In	O
2	Malmo	O
3	,	O
4	Sweden	O
5	,	O
6	17	O
7	,	O
8	181	O
9	school	O
10	children	O
11	born	O
12	in	O
13	the	O
14	years	O
15	1961	O
16	-	O
17	1965	O
18	were	O
19	screened	O
20	for	O
21	scoliosis	O
22	once	O
23	a	O
24	year	O
25	between	O
26	the	O
27	ages	O
28	of	O
29	7	O
30	and	O
31	16	O
32	years	O
33	,	O
34	during	O
35	1971	O
36	-	O
37	1980	O
38	.	O

1	In	O
2	the	O
3	past	O
4	,	O
5	immunology	O
6	in	O
7	Singapore	O
8	was	O
9	mainly	O
10	confined	O
11	to	O
12	serology	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	certain	O
18	infectious	O
19	diseases	O
20	.	O

1	Intra	O
2	-	O
3	articular	O
4	dislocation	O
5	of	O
6	the	O
7	patella	O
8	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	Histological	O
2	evaluation	O
3	revealed	O
4	a	O
5	more	O
6	than	O
7	twofold	O
8	increase	O
9	in	O
10	the	O
11	number	O
12	of	O
13	interepithelial	O
14	mononuclear	O
15	cells	O
16	(	O
17	p	O
18	less	O
19	than	O
20	0	O
21	.	O
22	005	O
23	),	O
24	while	O
25	the	O
26	number	O
27	of	O
28	epithelial	O
29	cells	O
30	/	O
31	100	O
32	microns	O
33	of	O
34	villous	O
35	mucosa	O
36	and	O
37	the	O
38	mean	O
39	height	O
40	of	O
41	the	O
42	epithelial	O
43	cells	O
44	were	O
45	comparable	O
46	in	O
47	both	O
48	groups	O
49	.	O

1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O

1	A	O
2	suspected	O
3	new	O
4	storage	O
5	disease	O
6	in	O
7	cattle	O
8	.	O

1	For	O
2	various	O
3	dog	O
4	vessels	O
5	in	O
6	vivo	O
7	,	O
8	Q	O
9	/	O
10	Dk	O
11	ranged	O
12	from	O
13	0	O
14	.	O
15	15	O
16	to	O
17	47	O
18	X	O
19	10	O
20	(	O
21	5	O
22	)	O
23	Torr	O
24	/	O
25	cm2	O
26	.	O

1	The	O
2	tetraphasic	O
3	action	O
4	of	O
5	lidocaine	O
6	on	O
7	CNS	O
8	electrical	O
9	activity	O
10	and	O
11	behavior	O
12	in	O
13	cats	O
14	.	O

1	Modification	O
2	of	O
3	enteral	O
4	resorption	O
5	by	O
6	cytostatic	O
7	therapy	O

1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O

1	Triumph	O
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O

1	The	O
2	application	O
3	of	O
4	ultrafiltration	O
5	to	O
6	sample	O
7	preparation	O
8	in	O
9	the	O
10	detection	O
11	and	O
12	quantification	O
13	of	O
14	ethylene	O
15	glycol	O
16	in	O
17	plasma	O
18	by	O
19	gas	O
20	chromatography	O
21	is	O
22	described	O
23	.	O

1	Mastocytosis	O
2	.	O

1	A	O
2	new	O
3	Onchocerca	O
4	species	O
5	,	O
6	a	O
7	parasite	O
8	of	O
9	domestic	O
10	cattle	O
11	,	O
12	in	O
13	Senegal	O

1	It	O
2	was	O
3	suggested	O
4	that	O
5	the	O
6	absence	O
7	of	O
8	pronounced	O
9	differences	O
10	between	O
11	conditions	O
12	may	O
13	have	O
14	been	O
15	due	O
16	to	O
17	the	O
18	complexity	O
19	of	O
20	the	O
21	task	O
22	or	O
23	the	O
24	type	O
25	of	O
26	prompts	O
27	employed	O
28	.	O

1	A	O
2	limiting	O
3	factor	O
4	were	O
5	disturbances	O
6	in	O
7	the	O
8	system	O
9	of	O
10	energy	O
11	transport	O
12	(	O
13	creatine	O
14	phosphate	O
15	,	O
16	creatine	B
17	phosphokinase	I
18	)	O
19	and	O
20	of	O
21	the	O
22	calcium	O
23	pump	O
24	(	O
25	Ca	B
26	++-	I
27	ATPase	I
28	of	O
29	the	O
30	sarcoplasmic	O
31	reticulum	O
32	,	O
33	SPR	O
34	),	O
35	which	O
36	evidently	O
37	led	O
38	to	O
39	a	O
40	decrease	O
41	of	O
42	the	O
43	inotropic	O
44	properties	O
45	of	O
46	the	O
47	myocardium	O
48	at	O
49	70	O
50	%	O
51	restriction	O
52	of	O
53	coronary	O
54	blood	O
55	flow	O
56	.	O

1	In	O
2	vitro	O
3	penetration	O
4	tests	O
5	of	O
6	human	O
7	sperm	O
8	into	O
9	cervical	O
10	mucus	O
11	were	O
12	introduced	O
13	in	O
14	order	O
15	to	O
16	study	O
17	the	O
18	interaction	O
19	between	O
20	sperm	O
21	and	O
22	cervical	O
23	mucus	O
24	.	O

1	Vibrio	O
2	fluvialis	O
3	(	O
4	group	O
5	F	O
6	vibrio	O
7	)	O
8	in	O
9	Maharashtra	O
10	.	O

1	Serum	B
2	creatine	I
3	kinase	I
4	(	O
5	SCK	B
6	)	O
7	was	O
8	measured	O
9	in	O
10	ten	O
11	subjects	O
12	in	O
13	the	O
14	laboratory	O
15	before	O
16	and	O
17	after	O
18	the	O
19	performance	O
20	of	O
21	bicycle	O
22	ergometry	O
23	and	O
24	a	O
25	lifting	O
26	task	O
27	.	O

1	Organisms	O
2	were	O
3	not	O
4	observed	O
5	in	O
6	the	O
7	5	O
8	bobcats	O
9	trapped	O
10	in	O
11	2	O
12	other	O
13	counties	O
14	.	O

1	The	O
2	cause	O
3	of	O
4	death	O
5	is	O
6	often	O
7	quite	O
8	apparent	O
9	from	O
10	the	O
11	pathological	O
12	and	O
13	toxicological	O
14	findings	O
15	;	O
16	however	O
17	,	O
18	the	O
19	manner	O
20	of	O
21	death	O
22	often	O
23	gives	O
24	the	O
25	examining	O
26	official	O
27	some	O
28	difficulty	O
29	.	O

1	The	O
2	average	O
3	annual	O
4	cost	O
5	per	O
6	head	O
7	of	O
8	population	O
9	was	O
10	US	O
11	+	O
12	0	O
13	X	O
14	46	O
15	.	O

1	It	O
2	is	O
3	postulated	O
4	that	O
5	altered	O
6	blood	O
7	flow	O
8	,	O
9	mediated	O
10	through	O
11	the	O
12	well	O
13	-	O
14	known	O
15	prostaglandin	B
16	synthetase	I
17	inhibitory	O
18	effects	O
19	of	O
20	ibuprofen	O
21	,	O
22	resulted	O
23	in	O
24	tubular	O
25	necrosis	O
26	.	O

1	Either	O
2	20	O
3	mg	O
4	mitomycin	O
5	/	O
6	20	O
7	ml	O
8	distilled	O
9	water	O
10	or	O
11	40	O
12	mg	O
13	/	O
14	40	O
15	ml	O
16	distilled	O
17	water	O
18	was	O
19	locally	O
20	instilled	O
21	into	O
22	the	O
23	bladder	O
24	with	O
25	a	O
26	catheter	O
27	after	O
28	emptying	O
29	it	O
30	and	O
31	was	O
32	left	O
33	for	O
34	about	O
35	25	O
36	-	O
37	l20	O
38	min	O
39	.	O

1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O

1	The	O
2	mean	O
3	extracted	O
4	concentration	O
5	of	O
6	flucloxacillin	O
7	obtained	O
8	at	O
9	operation	O
10	was	O
11	12	O
12	.	O
13	9	O
14	micrograms	O
15	/	O
16	ml	O
17	(	O
18	SD	O
19	5	O
20	.	O
21	25	O
22	)	O
23	in	O
24	synovial	O
25	fluid	O
26	;	O
27	2	O
28	.	O
29	9	O
30	micrograms	O
31	/	O
32	g	O
33	(	O
34	SD	O
35	3	O
36	.	O
37	59	O
38	)	O
39	in	O
40	synovium	O
41	;	O
42	2	O
43	.	O
44	0	O
45	micrograms	O
46	/	O
47	g	O
48	(	O
49	SD	O
50	1	O
51	.	O
52	48	O
53	)	O
54	in	O
55	cancellous	O
56	bone	O
57	and	O
58	1	O
59	.	O
60	3	O
61	micrograms	O
62	/	O
63	g	O
64	(	O
65	SD	O
66	1	O
67	.	O
68	25	O
69	)	O
70	in	O
71	cortical	O
72	bone	O
73	.	O

1	A	O
2	preliminary	O
3	study	O
4	of	O
5	vincristine	O
6	,	O
7	methotrexate	O
8	,	O
9	and	O
10	prednisolone	O
11	(	O
12	VM	O
13	*	O
14	P	O
15	)	O
16	combination	O
17	chemotherapy	O
18	for	O
19	advanced	O
20	adult	O
21	non	O
22	-	O
23	Hodgkin	O
24	'	O
25	s	O
26	lymphoma	O

1	Lacrimal	O
2	secretion	O
3	in	O
4	hyperthyroidism	O

1	Re	O
2	-	O
3	examination	O
4	of	O
5	the	O
6	ED01	O
7	study	O
8	.	O

1	Based	O
2	on	O
3	213	O
4	determinations	O
5	,	O
6	the	O
7	control	O
8	mean	O
9	serum	B
10	CPK	I
11	activity	O
12	was	O
13	262	O
14	+/-	O
15	113	O
16	I	O
17	.	O
18	U	O
19	./	O
20	liter	O
21	.	O

1	A	O
2	further	O
3	study	O
4	on	O
5	plasminogen	B
6	activator	I
7	release	O
8	by	O
9	vasoactive	O
10	agents	O
11	in	O
12	the	O
13	isolated	O
14	perfused	O
15	dog	O
16	leg	O
17	.	O

1	CDDP	O
2	is	O
3	active	O
4	as	O
5	a	O
6	single	O
7	agent	O
8	in	O
9	non	O
10	-	O
11	Hodgkin	O
12	'	O
13	s	O
14	lymphoma	O
15	.	O

1	Treatment	O
2	of	O
3	meat	O
4	muscle	O
5	800	O
6	V	O
7	for	O
8	45	O
9	s	O
10	reduced	O
11	weeping	O
12	but	O
13	increased	O
14	slightly	O
15	the	O
16	rate	O
17	of	O
18	autoxidation	O
19	of	O
20	lipids	O
21	.	O

1	The	O
2	hormonal	O
3	response	O
4	to	O
5	a	O
6	standardized	O
7	bicycle	O
8	exercise	O
9	test	O
10	was	O
11	studied	O
12	in	O
13	11	O
14	male	O
15	cadets	O
16	exposed	O
17	to	O
18	a	O
19	course	O
20	of	O
21	107	O
22	h	O
23	of	O
24	continuous	O
25	activity	O
26	with	O
27	less	O
28	than	O
29	2	O
30	h	O
31	sleep	O
32	.	O

1	At	O
2	an	O
3	ambient	O
4	temperature	O
5	of	O
6	25	O
7	degrees	O
8	C	O
9	,	O
10	the	O
11	responses	O
12	to	O
13	spinal	O
14	cooling	O
15	are	O
16	reduced	O
17	during	O
18	the	O
19	dark	O
20	phase	O
21	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	After	O
2	successful	O
3	subtotal	O
4	parathyroidectomy	O
5	,	O
6	evident	O
7	by	O
8	the	O
9	decrease	O
10	of	O
11	serum	O
12	iPTH	B
13	levels	O
14	,	O
15	both	O
16	the	O
17	CL	O
18	of	O
19	group	O
20	2	O
21	PMNs	O
22	and	O
23	the	O
24	ability	O
25	of	O
26	group	O
27	2	O
28	sera	O
29	to	O
30	induce	O
31	augmented	O
32	CL	O
33	in	O
34	normal	O
35	PMNs	O
36	decreased	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	025	O
43	).	O

1	TCZ	O
2	provides	O
3	quick	O
4	,	O
5	inexpensive	O
6	,	O
7	noninvasive	O
8	indication	O
9	of	O
10	tissue	O
11	necrosis	O
12	,	O
13	moderate	O
14	-	O
15	to	O
16	-	O
17	severe	O
18	intracranial	O
19	hemorrhage	O
20	,	O
21	and	O
22	delayed	O
23	brain	O
24	maturation	O
25	.	O

1	The	O
2	number	O
3	of	O
4	muricidal	O
5	rats	O
6	increased	O
7	with	O
8	increase	O
9	in	O
10	the	O
11	duration	O
12	of	O
13	Cd	O
14	administration	O
15	in	O
16	association	O
17	with	O
18	greater	O
19	accumulation	O
20	of	O
21	Cd	O
22	in	O
23	the	O
24	olfactory	O
25	bulb	O
26	than	O
27	in	O
28	any	O
29	other	O
30	region	O
31	of	O
32	the	O
33	brain	O
34	.	O

1	This	O
2	test	O
3	should	O
4	provide	O
5	another	O
6	practical	O
7	means	O
8	to	O
9	study	O
10	leprosy	O
11	.	O

1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	O
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O

1	Each	O
2	trial	O
3	consisted	O
4	of	O
5	light	O
6	and	O
7	buzzer	O
8	for	O
9	five	O
10	seconds	O
11	as	O
12	conditioned	O
13	stimuli	O
14	and	O
15	electric	O
16	shock	O
17	for	O
18	five	O
19	seconds	O
20	as	O
21	an	O
22	unconditioned	O
23	stimulus	O
24	.	O

1	Ulcer	O
2	appeared	O
3	on	O
4	the	O
5	angulus	O
6	of	O
7	the	O
8	stomach	O
9	at	O
10	the	O
11	28th	O
12	week	O
13	and	O
14	resulted	O
15	in	O
16	ulcer	O
17	scar	O
18	at	O
19	the	O
20	42nd	O
21	week	O
22	.	O

1	Family	O
2	visits	O
3	and	O
4	involvement	O
5	in	O
6	treatment	O
7	of	O
8	patients	O
9	at	O
10	a	O
11	state	O
12	hospital	O
13	.	O

1	A	O
2	transparent	O
3	overlay	O
4	for	O
5	assessing	O
6	amplitude	O
7	of	O
8	ECG	O
9	wave	O
10	forms	O
11	.	O

1	Adverse	O
2	reaction	O
3	of	O
4	the	O
5	apparently	O
6	healthy	O
7	partner	O
8	in	O
9	response	O
10	to	O
11	improvement	O
12	in	O
13	the	O
14	overtly	O
15	dysfunctional	O
16	partner	O
17	.	O

1	Brain	O
2	scan	O
3	with	O
4	99mTc	O
5	-	O
6	labelled	O
7	macroaggregated	B
8	albumin	I
9	(	O
10	MAA	B
11	brain	O
12	scan	O
13	)	O
14	and	O
15	computed	O
16	tomography	O
17	studies	O
18	(	O
19	CT	O
20	)	O
21	were	O
22	performed	O
23	on	O
24	78	O
25	patients	O
26	with	O
27	intracranial	O
28	diseases	O
29	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	The	O
2	five	O
3	-	O
4	drug	O
5	combination	O
6	of	O
7	fluorouracil	O
8	imidazole	O
9	carboxamide	O
10	dimethyl	O
11	triazeno	O
12	,	O
13	vincristine	O
14	,	O
15	bis	O
16	-	O
17	chloroethyl	O
18	nitrosourea	O
19	,	O
20	and	O
21	prednisone	O
22	(	O
23	FIVB	O
24	+	O
25	P	O
26	)	O
27	was	O
28	given	O
29	to	O
30	120	O
31	women	O
32	with	O
33	metastatic	O
34	breast	O
35	cancer	O
36	.	O

1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	the	O
7	simultaneous	O
8	determination	O
9	of	O
10	1	O
11	,	O
12	alpha	O
13	-	O
14	acetylmethadol	O
15	(	O
16	LAAM	O
17	)	O
18	and	O
19	five	O
20	active	O
21	metabolites	O
22	--	O
23	noracetylmethadol	O
24	,	O
25	dinoracetylmethadol	O
26	,	O
27	methadol	O
28	,	O
29	normethadol	O
30	,	O
31	and	O
32	dinormethadol	O
33	--	O
34	in	O
35	biofluids	O
36	by	O
37	high	O
38	-	O
39	performance	O
40	liquid	O
41	chromatography	O
42	using	O
43	a	O
44	normal	O
45	-	O
46	phase	O
47	column	O
48	and	O
49	a	O
50	UV	O
51	detector	O
52	at	O
53	218	O
54	nm	O
55	.	O

1	Results	O
2	of	O
3	the	O
4	recognition	O
5	task	O
6	revealed	O
7	significant	O
8	effects	O
9	of	O
10	consonant	O
11	voicing	O
12	,	O
13	position	O
14	and	O
15	vowel	O
16	context	O
17	on	O
18	syllable	O
19	recognition	O
20	.	O

1	Visual	O
2	response	O
3	properties	O
4	of	O
5	neurons	O
6	in	O
7	four	O
8	extrastriate	O
9	visual	O
10	areas	O
11	of	O
12	the	O
13	owl	O
14	monkey	O
15	(	O
16	Aotus	O
17	trivirgatus	O
18	):	O
19	a	O
20	quantitative	O
21	comparison	O
22	of	O
23	medial	O
24	,	O
25	dorsomedial	O
26	,	O
27	dorsolateral	O
28	,	O
29	and	O
30	middle	O
31	temporal	O
32	areas	O
33	.	O

1	A	O
2	unified	O
3	approach	O
4	to	O
5	the	O
6	standardization	O
7	of	O
8	allergens	O
9	.	O

1	Clinical	O
2	and	O
3	anatomical	O
4	considerations	O

1	A	O
2	dose	O
3	-	O
4	dependent	O
5	fall	O
6	in	O
7	GABA	O
8	content	O
9	was	O
10	observed	O
11	;	O
12	GABA	O
13	decrease	O
14	was	O
15	evident	O
16	15	O
17	min	O
18	after	O
19	the	O
20	administration	O
21	,	O
22	reached	O
23	its	O
24	nadir	O
25	at	O
26	60	O
27	min	O
28	and	O
29	disappeared	O
30	at	O
31	120	O
32	minutes	O
33	.	O

1	Theory	O
2	and	O
3	applications	O
4	of	O
5	pulse	O
6	dosing	O
7	:	O
8	a	O
9	summary	O
10	of	O
11	the	O
12	symposium	O
13	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	neonate	O
7	differs	O
8	from	O
9	the	O
10	adult	O
11	in	O
12	respect	O
13	of	O
14	both	O
15	the	O
16	nature	O
17	of	O
18	effects	O
19	of	O
20	the	O
21	drug	O
22	and	O
23	sensitivity	O
24	to	O
25	it	O
26	.	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	The	O
2	hemodynamics	O
3	of	O
4	isoproterenol	O
5	-	O
6	induced	O
7	cardiac	O
8	failure	O
9	in	O
10	the	O
11	rat	O
12	.	O

1	Several	O
2	authors	O
3	have	O
4	recently	O
5	reported	O
6	interference	O
7	in	O
8	theophylline	O
9	analysis	O
10	by	O
11	paraxanthine	O
12	(	O
13	1	O
14	,	O
15	7	O
16	-	O
17	dimethylxanthine	O
18	),	O
19	an	O
20	important	O
21	metabolite	O
22	of	O
23	caffeine	O
24	.	O

1	Multi	O
2	drug	O
3	regimens	O
4	like	O
5	C	O
6	-	O
7	MOPP	O
8	,	O
9	CHOP	O
10	and	O
11	BACOP	O
12	led	O
13	to	O
14	high	O
15	remission	O
16	rates	O
17	and	O
18	in	O
19	some	O
20	cases	O
21	probably	O
22	also	O
23	to	O
24	a	O
25	cure	O
26	of	O
27	the	O
28	disease	O
29	.	O

1	For	O
2	monocytes	O
3	,	O
4	as	O
5	measured	O
6	on	O
7	the	O
8	Hematrak	O
9	,	O
10	it	O
11	was	O
12	13	O
13	.	O
14	4	O
15	%.	O

1	Morphological	O
2	features	O
3	of	O
4	Jat	O
5	dentition	O
6	.	O

1	Clinical	O
2	accuracy	O
3	of	O
4	updated	O
5	version	O
6	of	O
7	the	O
8	Phadebas	O
9	RAST	O
10	test	O
11	.	O

1	Five	O
2	control	O
3	subjects	O
4	with	O
5	COPD	O
6	,	O
7	who	O
8	performed	O
9	the	O
10	same	O
11	sequence	O
12	of	O
13	tests	O
14	without	O
15	breathing	O
16	30	O
17	%	O
18	O2	O
19	,	O
20	showed	O
21	no	O
22	change	O
23	in	O
24	flow	O
25	rates	O
26	or	O
27	density	O
28	dependence	O
29	.	O

1	Following	O
2	extended	O
3	recovery	O
4	hippocampal	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	CA3	O
15	and	O
16	CA4	O
17	.	O

1	Evoked	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	volleys	O
11	in	O
12	the	O
13	isolated	O
14	turtle	O
15	olfactory	O
16	bulb	O
17	.	O

1	While	O
2	all	O
3	deletions	O
4	within	O
5	the	O
6	sequence	O
7	coding	O
8	for	O
9	the	O
10	mature	O
11	tRNA	O
12	led	O
13	to	O
14	inactivity	O
15	of	O
16	the	O
17	mutated	O
18	genes	O
19	,	O
20	substitution	O
21	of	O
22	the	O
23	central	O
24	portion	O
25	by	O
26	concatenated	B
27	Hind	I
28	III	I
29	linkers	I
30	produced	O
31	gene	O
32	units	O
33	active	O
34	in	O
35	transcription	O
36	.	O

1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O

1	Strontium	O
2	-	O
3	90	O
4	was	O
5	inject	O
6	i	O
7	.	O
8	v	O
9	.	O
10	into	O
11	pregnant	O
12	rats	O
13	on	O
14	day	O
15	18	O
16	post	O
17	conception	O
18	(	O
19	p	O
20	.	O
21	c	O
22	.).	O

1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O

1	Eight	O
2	hr	O
3	of	O
4	acidosis	O
5	caused	O
6	a	O
7	significant	O
8	(	O
9	P	O
10	less	O
11	than	O
12	0	O
13	.	O
14	01	O
15	)	O
16	decrease	O
17	in	O
18	P50	O
19	in	O
20	vitro	O
21	which	O
22	fell	O
23	from	O
24	29	O
25	.	O
26	0	O
27	to	O
28	24	O
29	.	O
30	4	O
31	torr	O
32	.	O

1	Catheter	O
2	transit	O
3	slows	O
4	the	O
5	response	O
6	to	O
7	a	O
8	step	O
9	increase	O
10	in	O
11	concentration	O
12	by	O
13	about	O
14	0	O
15	.	O
16	13	O
17	s	O
18	(	O
19	from	O
20	10	O
21	per	O
22	cent	O
23	-	O
24	90	O
25	per	O
26	cent	O
27	)	O
28	and	O
29	prolongs	O
30	the	O
31	transit	O
32	time	O
33	through	O
34	the	O
35	catheter	O
36	for	O
37	a	O
38	volatile	O
39	anesthetic	O
40	by	O
41	about	O
42	0	O
43	.	O
44	04	O
45	s	O
46	more	O
47	than	O
48	N2	O
49	.	O

1	These	O
2	women	O
3	should	O
4	not	O
5	be	O
6	given	O
7	the	O
8	current	O
9	estrogen	O
10	PPI	O
11	,	O
12	which	O
13	was	O
14	designed	O
15	to	O
16	warn	O
17	women	O
18	of	O
19	the	O
20	risks	O
21	of	O
22	long	O
23	-	O
24	term	O
25	estrogen	O
26	use	O
27	;	O
28	a	O
29	PPI	O
30	should	O
31	be	O
32	written	O
33	specifically	O
34	for	O
35	patients	O
36	receiving	O
37	short	O
38	courses	O
39	.	O

1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	B
8	creatine	I
9	kinase	I
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	actively	O
19	warmed	O
20	.	O

1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O

1	We	O
2	studied	O
3	the	O
4	role	O
5	of	O
6	prostaglandins	O
7	in	O
8	acid	O
9	-	O
10	induced	O
11	esophagitis	O
12	and	O
13	the	O
14	associated	O
15	LES	O
16	hypotension	O
17	by	O
18	simultaneous	O
19	treatment	O
20	of	O
21	some	O
22	animals	O
23	with	O
24	indomethacin	O
25	(	O
26	150	O
27	micrograms	O
28	/	O
29	kg	O
30	intravenous	O
31	),	O
32	a	O
33	specific	O
34	inhibitor	O
35	of	O
36	prostaglandin	O
37	synthesis	O
38	,	O
39	either	O
40	during	O
41	production	O
42	of	O
43	esophagitis	O
44	or	O
45	during	O
46	recovery	O
47	.	O

1	Since	O
2	only	O
3	58	O
4	%	O
5	of	O
6	our	O
7	sample	O
8	could	O
9	be	O
10	adequately	O
11	classified	O
12	with	O
13	one	O
14	diagnosis	O
15	,	O
16	we	O
17	expect	O
18	that	O
19	the	O
20	ASDC	O
21	nosology	O
22	will	O
23	need	O
24	to	O
25	evolve	O
26	further	O
27	.	O

1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O

1	Effects	O
2	of	O
3	prostaglandin	O
4	inhibitors	O
5	on	O
6	the	O
7	onset	O
8	of	O
9	proteinuria	O
10	and	O
11	stroke	O
12	in	O
13	stroke	O
14	-	O
15	prone	O
16	spontaneously	O
17	hypertensive	O
18	rats	O
19	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	general	O
7	clinical	O
8	criteria	O
9	for	O
10	inhalation	O
11	injury	O
12	--	O
13	presence	O
14	of	O
15	facial	O
16	or	O
17	oropharyngeal	O
18	burns	O
19	,	O
20	carboxyhemoglobin	B
21	levels	O
22	,	O
23	carbonaceous	O
24	sputum	O
25	,	O
26	or	O
27	closed	O
28	space	O
29	injury	O
30	--	O
31	did	O
32	not	O
33	differentiate	O
34	patients	O
35	with	O
36	airway	O
37	injury	O
38	only	O
39	from	O
40	those	O
41	with	O
42	parenchymal	O
43	injury	O
44	.	O

1	Survival	O
2	was	O
3	calculated	O
4	both	O
5	from	O
6	the	O
7	date	O
8	of	O
9	onset	O
10	and	O
11	from	O
12	the	O
13	date	O
14	of	O
15	diagnosis	O
16	.	O

1	Methisergide	O
2	(	O
3	0	O
4	.	O
5	5	O
6	mg	O
7	/	O
8	kg	O
9	,	O
10	i	O
11	.	O
12	p	O
13	.),	O
14	a	O
15	blocker	O
16	of	O
17	serotonin	B
18	receptors	I
19	,	O
20	prevented	O
21	the	O
22	development	O
23	of	O
24	the	O
25	antinociceptive	O
26	effect	O
27	of	O
28	serotonin	O
29	.	O

1	The	O
2	plasma	O
3	half	O
4	-	O
5	life	O
6	of	O
7	slow	O
8	disposition	O
9	phase	O
10	t1	O
11	/	O
12	2	O
13	beta	O
14	,	O
15	increases	O
16	from	O
17	0	O
18	.	O
19	26	O
20	hour	O
21	in	O
22	rabbits	O
23	with	O
24	normal	O
25	renal	O
26	function	O
27	to	O
28	5	O
29	.	O
30	41	O
31	hours	O
32	in	O
33	rabbits	O
34	with	O
35	severe	O
36	renal	O
37	impairment	O
38	.	O

1	Effects	O
2	of	O
3	early	O
4	monocular	O
5	deprivation	O
6	on	O
7	development	O
8	of	O
9	cortico	O
10	-	O
11	geniculate	O
12	projections	O
13	in	O
14	the	O
15	cat	O
16	.	O

1	Corticosteroid	O
2	therapy	O
3	is	O
4	known	O
5	to	O
6	be	O
7	hazardous	O
8	in	O
9	patients	O
10	with	O
11	occult	O
12	infection	O
13	but	O
14	the	O
15	mechanism	O
16	by	O
17	which	O
18	the	O
19	host	O
20	parasite	O
21	relationship	O
22	is	O
23	altered	O
24	by	O
25	steroids	O
26	is	O
27	not	O
28	known	O
29	.	O
30	We	O
31	have	O
32	used	O
33	an	O
34	intestinal	O
35	protozoal	O
36	parasite	O
37	,	O
38	Giardia	O
39	muris	O
40	,	O
41	to	O
42	examine	O
43	the	O
44	effects	O
45	of	O
46	corticosteroids	O
47	on	O
48	the	O
49	number	O
50	of	O
51	parasites	O
52	in	O
53	the	O
54	intestine	O
55	in	O
56	the	O
57	course	O
58	of	O
59	a	O
60	primary	O
61	infection	O
62	.	O

1	Static	O
2	lung	O
3	function	O
4	in	O
5	puppies	O
6	after	O
7	pneumonectomy	O
8	.	O

1	With	O
2	Sair	O
3	and	O
4	So2	O
5	,	O
6	mean	O
7	vital	O
8	capacity	O
9	was	O
10	reduced	O
11	by	O
12	44	O
13	%	O
14	from	O
15	control	O
16	.	O

1	Bilateral	O
2	Charnley	O
3	arthroplasty	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O

1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O

1	The	O
2	relationship	O
3	between	O
4	estrogenic	O
5	properties	O
6	of	O
7	Tamoxifen	O
8	and	O
9	breast	O
10	cancer	O
11	management	O
12	is	O
13	discussed	O
14	.	O

1	The	O
2	new	O
3	semi	O
4	-	O
5	synthetic	O
6	oral	O
7	cephalosporin	O
8	,	O
9	CGP	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	hospitalized	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O

1	A	O
2	fluoroimmunoassay	O
3	for	O
4	the	O
5	determination	O
6	of	O
7	serum	O
8	of	O
9	plasma	O
10	levels	O
11	of	O
12	propranolol	O
13	was	O
14	developed	O
15	using	O
16	antibodies	O
17	to	O
18	propranolol	O
19	coupled	O
20	to	O
21	magnetizable	O
22	solid	O
23	-	O
24	phase	O
25	particles	O
26	and	O
27	fluorescein	O
28	-	O
29	labeled	O
30	propranolol	O
31	as	O
32	tracer	O
33	.	O

1	The	O
2	syncytial	O
3	microvillous	O
4	projections	O
5	seemed	O
6	to	O
7	be	O
8	more	O
9	numerous	O
10	and	O
11	longer	O
12	in	O
13	CNF	O
14	,	O
15	otherwise	O
16	the	O
17	structure	O
18	of	O
19	the	O
20	trophoblastic	O
21	layer	O
22	of	O
23	the	O
24	villi	O
25	and	O
26	the	O
27	lining	O
28	of	O
29	the	O
30	subtrophoblastic	O
31	vessels	O
32	were	O
33	identical	O
34	in	O
35	CNF	O
36	and	O
37	controls	O
38	.	O

1	When	O
2	pollen	O
3	allergen	O
4	from	O
5	three	O
6	grass	O
7	species	O
8	were	O
9	used	O
10	,	O
11	The	O
12	RAST	O
13	-	O
14	test	O
15	results	O
16	did	O
17	not	O
18	differ	O
19	from	O
20	duplicate	O
21	values	O
22	either	O
23	.	O

1	DMI	O
2	and	O
3	2	O
4	-	O
5	OH	O
6	-	O
7	DMI	O
8	concentrations	O
9	were	O
10	determined	O
11	in	O
12	a	O
13	similar	O
14	group	O
15	of	O
16	61	O
17	DMI	O
18	-	O
19	treated	O
20	patients	O
21	.	O

1	It	O
2	has	O
3	been	O
4	shown	O
5	in	O
6	experiments	O
7	in	O
8	vitro	O
9	that	O
10	the	O
11	hepatotrophic	O
12	organic	O
13	anions	O
14	,	O
15	the	O
16	radiographic	O
17	contrast	O
18	agent	O
19	(	O
20	RCA	O
21	)	O
22	bilignost	O
23	used	O
24	in	O
25	cholecystography	O
26	and	O
27	Bengal	O
28	pink	O
29	,	O
30	have	O
31	an	O
32	affinity	O
33	,	O
34	unlike	O
35	the	O
36	urographic	O
37	RCA	O
38	triombrin	O
39	and	O
40	renotrophic	O
41	dye	O
42	indigo	O
43	-	O
44	carmine	O
45	,	O
46	for	O
47	the	O
48	plasmatic	O
49	membranes	O
50	(	O
51	PM	O
52	)	O
53	of	O
54	liver	O
55	cells	O
56	.	O

1	33	O
2	out	O
3	of	O
4	90	O
5	neurons	O
6	of	O
7	the	O
8	cat	O
9	medial	O
10	geniculate	O
11	body	O
12	revealed	O
13	the	O
14	selectivity	O
15	of	O
16	their	O
17	afterdischarges	O
18	to	O
19	movement	O
20	of	O
21	sound	O
22	when	O
23	velocity	O
24	of	O
25	the	O
26	movement	O
27	changed	O
28	from	O
29	30	O
30	to	O
31	180	O
32	deg	O
33	/	O
34	s	O
35	.	O

1	In	O
2	controls	O
3	,	O
4	only	O
5	modest	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	Assay	O
2	of	O
3	serum	B
4	immunoreactive	I
5	trypsin	I
6	in	O
7	dried	O
8	blood	O
9	spots	O
10	and	O
11	the	O
12	early	O
13	detection	O
14	of	O
15	cystic	O
16	fibrosis	O
17	.	O

1	Similar	O
2	waves	O
3	were	O
4	seen	O
5	on	O
6	cross	O
7	-	O
8	correlating	O
9	a	O
10	motor	O
11	unit	O
12	with	O
13	an	O
14	electronic	O
15	oscillator	O
16	,	O
17	confirming	O
18	that	O
19	their	O
20	occurrence	O
21	does	O
22	not	O
23	necessarily	O
24	demonstrate	O
25	the	O
26	existence	O
27	of	O
28	active	O
29	neural	O
30	interactions	O
31	.	O

1	Leukocyte	O
2	enzyme	O
3	activity	O
4	and	O
5	blood	O
6	lymphocyte	O
7	blast	O
8	transformation	O
9	in	O
10	chronic	O
11	bronchitis	O

1	Current	O
2	status	O
3	of	O
4	chemotherapy	O
5	for	O
6	Hodgkin	O
7	'	O
8	s	O
9	disease	O

1	In	O
2	literature	O
3	,	O
4	the	O
5	HBE	O
6	has	O
7	been	O
8	displayed	O
9	by	O
10	application	O
11	of	O
12	the	O
13	averaging	O
14	method	O
15	.	O

1	Forty	O
2	-	O
3	five	O
4	cases	O
5	were	O
6	surgically	O
7	by	O
8	direct	O
9	approach	O
10	to	O
11	the	O
12	tumour	O
13	,	O
14	while	O
15	two	O
16	cases	O
17	were	O
18	treated	O
19	only	O
20	with	O
21	a	O
22	shunt	O
23	.	O

1	In	O
2	Group	O
3	V	O
4	,	O
5	the	O
6	salvaged	O
7	tissue	O
8	was	O
9	primarily	O
10	subepicardial	O
11	with	O
12	virtually	O
13	no	O
14	lateral	O
15	zone	O
16	of	O
17	salvaged	O
18	tissue	O
19	(	O
20	ratio	O
21	of	O
22	salvaged	O
23	subepicardium	O
24	to	O
25	salvaged	O
26	subendocardium	O
27	14	O
28	.	O
29	8	O
30	+/-	O
31	1	O
32	.	O
33	9	O
34	to	O
35	1	O
36	).	O

1	Progressive	O
2	100	O
3	-	O
4	mmHg	O
5	stepwise	O
6	decreases	O
7	in	O
8	superfusate	O
9	oxygen	O
10	partial	O
11	pressure	O
12	(	O
13	PO2	O
14	)	O
15	from	O
16	control	O
17	(	O
18	95	O
19	%	O
20	O2	O
21	aeration	O
22	,	O
23	PO2	O
24	,	O
25	620	O
26	-	O
27	650	O
28	mmHg	O
29	)	O
30	were	O
31	produced	O
32	,	O
33	and	O
34	subsequent	O
35	changes	O
36	in	O
37	isometric	O
38	active	O
39	and	O
40	resting	O
41	tension	O
42	were	O
43	measured	O
44	.	O

1	The	O
2	known	O
3	B1	O
4	-	O
5	deficiency	O
6	reaches	O
7	excessive	O
8	high	O
9	values	O
10	with	O
11	light	O
12	exercise	O
13	.	O

1	Based	O
2	on	O
3	AUC	O
4	infinity	O
5	analyses	O
6	,	O
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	450	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O

1	Gastrin	B
2	secretion	O
3	during	O
4	food	O
5	stimulation	O
6	in	O
7	digestive	O
8	system	O
9	diseases	O

1	Fibrinogen	B
2	determination	O
3	using	O
4	the	O
5	KZM	O
6	-	O
7	1	O
8	meter	O

1	Over	O
2	a	O
3	period	O
4	of	O
5	15	O
6	days	O
7	16	O
8	%	O
9	of	O
10	the	O
11	dose	O
12	administered	O
13	was	O
14	excreted	O
15	with	O
16	faeces	O
17	and	O
18	0	O
19	.	O
20	9	O
21	%	O
22	in	O
23	the	O
24	urine	O
25	.	O

1	Delayed	O
2	or	O
3	paradoxically	O
4	emptying	O
5	regions	O
6	of	O
7	the	O
8	left	O
9	ventricle	O
10	were	O
11	detected	O
12	by	O
13	a	O
14	relatively	O
15	new	O
16	nuclear	O
17	technique	O
18	--	O
19	phase	O
20	imaging	O
21	.	O

1	Responses	O
2	to	O
3	brainstem	O
4	of	O
5	nuclei	O
6	medialis	O
7	dorsalis	O
8	,	O
9	lateralis	O
10	posterior	O
11	were	O
12	of	O
13	considerably	O
14	longer	O
15	latency	O
16	.	O

1	Nineteen	O
2	patients	O
3	with	O
4	non	O
5	-	O
6	visualized	O
7	gallbladder	O
8	with	O
9	OCG	O
10	subsequently	O
11	had	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	PyG	O
17	cholescintigraphy	O
18	performed	O
19	.	O

1	One	O
2	was	O
3	allowed	O
4	fresh	O
5	drinking	O
6	water	O
7	ad	O
8	libitum	O
9	whilst	O
10	the	O
11	other	O
12	received	O
13	Aludrox	O
14	in	O
15	their	O
16	drinking	O
17	water	O
18	.	O

1	Anamnestic	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	case	O
7	history	O
8	,	O
9	smoking	O
10	habits	O
11	were	O
12	not	O
13	known	O
14	in	O
15	collective	O
16	A	O
17	and	O
18	C	O
19	.	O

1	The	O
2	determination	O
3	of	O
4	physical	O
5	performance	O
6	capacity	O
7	was	O
8	based	O
9	on	O
10	W170	O
11	,	O
12	W85	O
13	%	O
14	and	O
15	on	O
16	predicted	O
17	VO2	O
18	max	O
19	measured	O
20	with	O
21	continuously	O
22	increasing	O
23	work	O
24	load	O
25	on	O
26	a	O
27	bicycle	O
28	ergometer	O
29	.	O

1	Determination	O
2	of	O
3	lead	O
4	in	O
5	blood	O
6	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	and	O
5	prostaglandin	O
6	F2	O
7	alpha	O
8	on	O
9	parturition	O
10	in	O
11	swine	O
12	.	O

1	LD50	O
2	values	O
3	of	O
4	terms	O
5	of	O
6	KP	O
7	were	O
8	84	O
9	mg	O
10	/	O
11	kg	O
12	in	O
13	male	O
14	rats	O
15	and	O
16	122	O
17	mg	O
18	/	O
19	kg	O
20	in	O
21	female	O
22	rats	O
23	when	O
24	KP	O
25	-	O
26	CMC	O
27	was	O
28	administered	O
29	intrarectally	O
30	,	O
31	and	O
32	117	O
33	mg	O
34	/	O
35	kg	O
36	in	O
37	male	O
38	and	O
39	92	O
40	mg	O
41	/	O
42	kg	O
43	in	O
44	female	O
45	when	O
46	KP	O
47	-	O
48	T10	O
49	was	O
50	administered	O
51	intrarectally	O
52	.,	O
53	while	O
54	peroral	O
55	administration	O
56	of	O
57	KP	O
58	-	O
59	CMC	O
60	showed	O
61	LD50	O
62	values	O
63	of	O
64	68	O
65	mg	O
66	/	O
67	kg	O
68	in	O
69	males	O
70	and	O
71	78	O
72	mg	O
73	/	O
74	kg	O
75	in	O
76	females	O
77	in	O
78	terms	O
79	of	O
80	KP	O
81	.	O

1	Autotransfusion	O
2	was	O
3	performed	O
4	as	O
5	follows	O
6	:	O
7	Heparin	O
8	-	O
9	ACD	O
10	-	O
11	B	O
12	-	O
13	Heparin	O
14	-	O
15	DPD	O
16	-	O
17	Heparin	O
18	-	O
19	ACD	O
20	-	O
21	B	O
22	etc	O
23	.	O

1	Electron	O
2	microscopic	O
3	picture	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	cooled	O
11	to	O
12	22	O
13	degrees	O
14	C	O

1	Generally	O
2	the	O
3	differences	O
4	between	O
5	short	O
6	gut	O
7	and	O
8	sham	O
9	operation	O
10	animals	O
11	disappeared	O
12	when	O
13	the	O
14	data	O
15	were	O
16	normalised	O
17	for	O
18	mucosal	O
19	weight	O
20	.	O

1	A	O
2	simplified	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	hippuric	O
10	acid	O
11	and	O
12	methylhippuric	O
13	acids	O
14	.	O

1	The	O
2	architecture	O
3	of	O
4	microvasculature	O
5	in	O
6	these	O
7	two	O
8	regions	O
9	was	O
10	also	O
11	examined	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	,	O
17	using	O
18	the	O
19	resin	O
20	casting	O
21	method	O
22	.	O

1	MSMS	O
2	Council	O
3	hears	O
4	new	O
5	public	O
6	health	O
7	director	O
8	.	O

1	Chordoma	O
2	of	O
3	the	O
4	spinal	O
5	cord	O
6	in	O
7	a	O
8	F344	O
9	rat	O
10	.	O

1	Micro	O
2	high	O
3	-	O
4	performance	O
5	liquid	O
6	chromatographic	O
7	system	O
8	with	O
9	micro	O
10	precolumn	O
11	and	O
12	dual	O
13	electrochemical	O
14	detector	O
15	for	O
16	direct	O
17	injection	O
18	analysis	O
19	of	O
20	catecholamines	O
21	in	O
22	body	O
23	fluids	O
24	.	O

1	Thirty	O
2	-	O
3	one	O
4	age	O
5	-	O
6	matched	O
7	,	O
8	conscious	O
9	,	O
10	virgin	O
11	,	O
12	male	O
13	Sprague	O
14	-	O
15	Dawley	O
16	rats	O
17	and	O
18	spontaneously	O
19	hypertensive	O
20	rats	O
21	(	O
22	SHRs	O
23	)	O
24	were	O
25	individually	O
26	injected	O
27	with	O
28	a	O
29	single	O
30	subcutaneous	O
31	dose	O
32	of	O
33	85	O
34	mg	O
35	/	O
36	kg	O
37	dl	O
38	-	O
39	isoproterenol	O
40	to	O
41	determine	O
42	the	O
43	degree	O
44	and	O
45	time	O
46	course	O
47	of	O
48	drug	O
49	-	O
50	induced	O
51	cardiac	O
52	failure	O
53	and	O
54	functional	O
55	recovery	O
56	.	O

1	A	O
2	narrow	O
3	zone	O
4	of	O
5	myelin	O
6	-	O
7	axonal	O
8	dissociation	O
9	was	O
10	also	O
11	observed	O
12	.	O

1	The	O
2	IgA	B
3	deficiency	O
4	is	O
5	combined	O
6	with	O
7	the	O
8	IgE	B
9	one	O
10	.	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	Nutritional	O
2	cataracts	O
3	in	O
4	timber	O
5	wolves	O
6	.	O

1	Prevention	O
2	of	O
3	transfusion	O
4	reactions	O
5	by	O
6	the	O
7	use	O
8	of	O
9	saline	O
10	washed	O
11	red	O
12	blood	O
13	cells	O
14	.	O

1	The	O
2	geometric	O
3	mean	O
4	hemagglutination	O
5	-	O
6	inhibition	O
7	antibody	O
8	titers	O
9	(	O
10	GMT	O
11	)	O
12	of	O
13	non	O
14	-	O
15	immunized	O
16	,	O
17	once	O
18	-	O
19	immunized	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	immunized	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O

1	The	O
2	quantitative	O
3	determination	O
4	of	O
5	HBSAG	B
6	--	O
7	a	O
8	valuable	O
9	aid	O
10	in	O
11	evaluating	O
12	the	O
13	infectiousness	O
14	of	O
15	hepatitis	O
16	B	O
17	virus	O
18	carriers	O

1	2	O
2	.	O
3	numerous	O
4	narrow	O
5	shunt	O
6	vessels	O
7	departing	O
8	continuously	O
9	from	O
10	the	O
11	primary	O
12	arteries	O
13	to	O
14	feed	O
15	a	O
16	secondary	O
17	arterial	O
18	system	O
19	which	O
20	parallels	O
21	the	O
22	primary	O
23	one	O
24	.	O

1	Urological	O
2	complications	O
3	are	O
4	frequent	O
5	during	O
6	and	O
7	after	O
8	the	O
9	treatment	O
10	of	O
11	gynecological	O
12	malignancy	O
13	.	O

1	Arachnoid	O
2	cyst	O
3	.	O

1	100	O
2	more	O
3	than	O
4	in	O
5	the	O
6	summer	O
7	coat	O
8	).	O

1	Hypotension	O
2	was	O
3	produced	O
4	by	O
5	head	O
6	up	O
7	tilt	O
8	.	O

1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O

1	Mucoepidermoid	O
2	and	O
3	acinous	O
4	cell	O
5	carcinomas	O
6	of	O
7	salivary	O
8	tissues	O
9	.	O

1	Twenty	O
2	patients	O
3	aged	O
4	45	O
5	or	O
6	older	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	endogenous	O
12	depression	O
13	were	O
14	evaluated	O
15	in	O
16	terms	O
17	of	O
18	safety	O
19	and	O
20	efficacy	O
21	in	O
22	their	O
23	response	O
24	to	O
25	multiple	O
26	monitored	O
27	electroconvulsive	O
28	therapy	O
29	(	O
30	MMECT	O
31	)	O
32	versus	O
33	single	O
34	electroconvulsive	O
35	therapy	O
36	(	O
37	SECT	O
38	).	O

1	Two	O
2	new	O
3	artifacts	O
4	in	O
5	automated	O
6	coagulation	O
7	testing	O
8	.	O

1	This	O
2	relatively	O
3	simple	O
4	and	O
5	easily	O
6	performed	O
7	technique	O
8	of	O
9	measuring	O
10	deep	O
11	muscle	O
12	temperature	O
13	appears	O
14	to	O
15	be	O
16	a	O
17	useful	O
18	adjunct	O
19	in	O
20	choosing	O
21	the	O
22	amputation	O
23	level	O
24	.	O

1	Longitudinal	O
2	force	O
3	-	O
4	length	O
5	relationships	O
6	of	O
7	guinea	O
8	pig	O
9	ureter	O
10	were	O
11	studied	O
12	in	O
13	vitro	O
14	in	O
15	animals	O
16	3	O
17	weeks	O
18	,	O
19	3	O
20	months	O
21	,	O
22	and	O
23	3	O
24	years	O
25	of	O
26	age	O
27	.	O

1	Tests	O
2	of	O
3	the	O
4	method	O
5	indicate	O
6	(	O
7	1	O
8	)	O
9	the	O
10	Mossbauer	O
11	source	O
12	can	O
13	be	O
14	placed	O
15	on	O
16	the	O
17	basilar	O
18	membrane	O
19	without	O
20	altering	O
21	the	O
22	signal	O
23	-	O
24	transmission	O
25	properties	O
26	of	O
27	the	O
28	cochlea	O
29	,	O
30	and	O
31	(	O
32	2	O
33	)	O
34	the	O
35	source	O
36	adheres	O
37	to	O
38	the	O
39	basilar	O
40	membrane	O
41	.	O

1	Angiographic	O
2	work	O
3	-	O
4	up	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	late	O
10	vaginal	O
11	metastasis	O
12	from	O
13	a	O
14	renal	O
15	carcinoma	O
16	.	O

1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	O
8	platelet	B
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	B
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O

1	Ecthyma	O
2	,	O
3	a	O
4	known	O
5	disease	O
6	,	O
7	of	O
8	which	O
9	little	O
10	is	O
11	known	O

1	Estrogen	O
2	replacement	O
3	,	O
4	either	O
5	as	O
6	17	O
7	beta	O
8	-	O
9	estradiol	O
10	or	O
11	beta	O
12	-	O
13	estradiol	O
14	-	O
15	3	O
16	-	O
17	benzoate	O
18	via	O
19	subcutaneous	O
20	Silastic	O
21	capsules	O
22	,	O
23	was	O
24	associated	O
25	with	O
26	elevated	O
27	rates	O
28	of	O
29	heat	O
30	production	O
31	and	O
32	dry	O
33	heat	O
34	loss	O
35	relative	O
36	to	O
37	untreated	O
38	ovariectomized	O
39	controls	O
40	.	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	Changes	O
2	in	O
3	immunologic	O
4	reactivity	O
5	in	O
6	subjects	O
7	receiving	O
8	transfer	B
9	factor	I
10	could	O
11	not	O
12	be	O
13	distinguished	O
14	from	O
15	those	O
16	in	O
17	subjects	O
18	receiving	O
19	placebo	O
20	.	O

1	It	O
2	was	O
3	argued	O
4	that	O
5	this	O
6	arose	O
7	from	O
8	the	O
9	possibility	O
10	that	O
11	the	O
12	nature	O
13	of	O
14	blue	O
15	collar	O
16	jobs	O
17	was	O
18	physical	O
19	,	O
20	and	O
21	that	O
22	loss	O
23	of	O
24	myocardial	O
25	tissue	O
26	might	O
27	be	O
28	expected	O
29	to	O
30	more	O
31	markedly	O
32	interfere	O
33	with	O
34	their	O
35	work	O
36	efficiency	O
37	(	O
38	on	O
39	returning	O
40	to	O
41	work	O
42	)	O
43	than	O
44	it	O
45	would	O
46	the	O
47	efficiency	O
48	of	O
49	the	O
50	more	O
51	sedentary	O
52	jobs	O
53	of	O
54	white	O
55	collar	O
56	workers	O
57	.	O

1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O

1	The	O
2	results	O
3	revealed	O
4	increased	O
5	blood	O
6	lead	O
7	level	O
8	associated	O
9	with	O
10	decreased	O
11	blood	B
12	haemoglobin	I
13	and	O
14	increased	O
15	urinary	O
16	excretion	O
17	of	O
18	delta	O
19	amino	O
20	levulinic	O
21	acid	O
22	.	O

1	Following	O
2	iv	O
3	injection	O
4	of	O
5	0	O
6	.	O
7	5	O
8	g	O
9	galactose	O
10	per	O
11	kg	O
12	body	O
13	weight	O
14	,	O
15	together	O
16	with	O
17	2	O
18	mu	O
19	Ci	O
20	generally	O
21	14C	O
22	-	O
23	labelled	O
24	galactose	O
25	,	O
26	14CO2	O
27	is	O
28	collected	O
29	in	O
30	regular	O
31	intervals	O
32	during	O
33	one	O
34	hour	O
35	.	O

1	Specific	O
2	clotting	O
3	factor	O
4	assays	O
5	showed	O
6	an	O
7	isolated	O
8	deficiency	O
9	of	O
10	factor	B
11	X	I
12	ranging	O
13	from	O
14	7	O
15	to	O
16	12	O
17	per	O
18	cent	O
19	on	O
20	three	O
21	determinations	O
22	.	O

1	Charcoal	O
2	-	O
3	facilitated	O
4	dialysis	O
5	.	O

1	Blood	O
2	variables	O
3	measured	O
4	at	O
5	eight	O
6	intervals	O
7	before	O
8	,	O
9	during	O
10	,	O
11	and	O
12	after	O
13	operation	O
14	were	O
15	as	O
16	follows	O
17	:	O
18	seven	O
19	plasma	O
20	proteins	O
21	,	O
22	free	O
23	hemoglobin	B
24	,	O
25	formed	O
26	elements	O
27	,	O
28	and	O
29	clotting	O
30	functions	O
31	.	O

1	Retinal	O
2	changes	O
3	in	O
4	pigmentary	O
5	retinopathy	O
6	in	O
7	children	O

1	As	O
2	a	O
3	result	O
4	,	O
5	beta	O
6	-	O
7	apo	O
8	-	O
9	8	O
10	'-	O
11	carotenoic	O
12	acid	O
13	ethyl	O
14	ester	O
15	(	O
16	apo	O
17	-	O
18	EE	O
19	)	O
20	was	O
21	used	O
22	as	O
23	a	O
24	reference	O
25	standard	O
26	in	O
27	Experiments	O
28	4	O
29	to	O
30	6	O
31	.	O

1	The	O
2	ability	O
3	of	O
4	sodium	O
5	phenobarbital	O
6	(	O
7	60	O
8	mg	O
9	/	O
10	kg	O
11	)	O
12	and	O
13	sodium	O
14	barbital	O
15	(	O
16	80	O
17	mg	O
18	/	O
19	kg	O
20	)	O
21	to	O
22	produce	O
23	a	O
24	taste	O
25	aversion	O
26	in	O
27	23	O
28	hr	O
29	fluid	O
30	deprived	O
31	rats	O
32	was	O
33	examined	O
34	using	O
35	a	O
36	discrimination	O
37	or	O
38	two	O
39	bottle	O
40	taste	O
41	aversion	O
42	task	O
43	(	O
44	0	O
45	.	O
46	125	O
47	%	O
48	sodium	O
49	saccharin	O
50	solution	O
51	or	O
52	water	O
53	).	O

1	It	O
2	appears	O
3	that	O
4	the	O
5	pulmonary	O
6	gas	O
7	exchange	O
8	parenchyma	O
9	of	O
10	these	O
11	smallest	O
12	mammals	O
13	is	O
14	well	O
15	suited	O
16	to	O
17	supply	O
18	the	O
19	organism	O
20	with	O
21	the	O
22	comparatively	O
23	high	O
24	levels	O
25	of	O
26	O2	O
27	required	O
28	by	O
29	the	O
30	high	O
31	metabolic	O
32	rates	O
33	,	O
34	exhibiting	O
35	a	O
36	structural	O
37	adaptation	O
38	of	O
39	the	O
40	lung	O
41	to	O
42	higher	O
43	VO2	O
44	.	O

1	Underestimations	O
2	by	O
3	as	O
4	much	O
5	as	O
6	35	O
7	%	O
8	may	O
9	occur	O
10	due	O
11	to	O
12	the	O
13	problems	O
14	in	O
15	the	O
16	existing	O
17	methodologies	O
18	.	O

1	Chemotherapy	O
2	was	O
3	administered	O
4	without	O
5	altering	O
6	the	O
7	course	O
8	of	O
9	the	O
10	disorder	O
11	.	O

1	Drug	O
2	inhibition	O
3	of	O
4	whole	O
5	blood	O
6	aspirin	B
7	esterase	I
8	.	O

1	However	O
2	,	O
3	at	O
4	lower	O
5	temperature	O
6	the	O
7	positive	O
8	staircase	O
9	was	O
10	not	O
11	clear	O
12	and	O
13	rather	O
14	negative	O
15	staircase	O
16	appeared	O
17	(	O
18	1	O
19	--	O
20	3	O
21	Hz	O
22	).	O

1	Visual	O
2	averaged	O
3	evoked	O
4	responses	O
5	and	O
6	platelet	B
7	monoamine	I
8	oxidase	I
9	in	O
10	patients	O
11	suffering	O
12	from	O
13	alcoholism	O
14	.	O

1	At	O
2	the	O
3	end	O
4	of	O
5	the	O
6	experiment	O
7	the	O
8	urinary	O
9	porphyrin	O
10	excretion	O
11	and	O
12	the	O
13	porphyrin	O
14	content	O
15	in	O
16	lijver	O
17	and	O
18	skin	O
19	were	O
20	diminished	O
21	in	O
22	HCB	O
23	-	O
24	CQ	O
25	-	O
26	treated	O
27	animals	O
28	by	O
29	about	O
30	50	O
31	%	O
32	compared	O
33	to	O
34	the	O
35	HCB	O
36	controls	O
37	.	O

1	Six	O
2	hours	O
3	after	O
4	the	O
5	last	O
6	administration	O
7	,	O
8	uterus	O
9	of	O
10	Gf	O
11	and	O
12	Cv	O
13	mice	O
14	were	O
15	weight	O
16	337	O
17	.	O
18	6	O
19	mg	O
20	%	O
21	and	O
22	423	O
23	.	O
24	5	O
25	mg	O
26	%	O
27	respectively	O
28	,	O
29	the	O
30	difference	O
31	was	O
32	statistically	O
33	significant	O
34	(	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O

1	Autoradiographic	O
2	localisation	O
3	of	O
4	its	O
5	cellular	O
6	distribution	O
7	in	O
8	the	O
9	kidney	O
10	.	O

1	Hippocampal	O
2	stimulation	O
3	overlapping	O
4	conditioned	O
5	stimulus	O
6	preexposure	O
7	produced	O
8	attenuation	O
9	of	O
10	latent	O
11	inhibition	O
12	,	O
13	as	O
14	did	O
15	stimulation	O
16	presented	O
17	during	O
18	conditioning	O
19	after	O
20	preexposure	O
21	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	Cataract	O
2	extraction	O
3	in	O
4	primary	O
5	glaucoma	O

1	Number	O
2	and	O
3	size	O
4	of	O
5	the	O
6	myelin	O
7	structures	O
8	in	O
9	the	O
10	pneumocytes	O
11	typ	O
12	II	O
13	increased	O
14	simultaneously	O
15	.	O

1	In	O
2	the	O
3	intact	O
4	animal	O
5	,	O
6	postextrasystolic	O
7	potentiation	O
8	depended	O
9	on	O
10	the	O
11	basic	O
12	pacing	O
13	interval	O
14	,	O
15	t0	O
16	,	O
17	and	O
18	the	O
19	timing	O
20	of	O
21	the	O
22	extrasystole	O
23	,	O
24	t1	O
25	:	O
26	when	O
27	t0	O
28	was	O
29	held	O
30	constant	O
31	and	O
32	t1	O
33	was	O
34	increased	O
35	,	O
36	potentiation	O
37	decreased	O
38	;	O
39	when	O
40	t1	O
41	was	O
42	held	O
43	constant	O
44	and	O
45	t0	O
46	was	O
47	increased	O
48	,	O
49	potentiation	O
50	increased	O
51	.	O

1	In	O
2	spite	O
3	of	O
4	this	O
5	and	O
6	other	O
7	complications	O
8	of	O
9	corticosteroids	O
10	,	O
11	she	O
12	made	O
13	a	O
14	full	O
15	recovery	O
16	from	O
17	the	O
18	fungal	O
19	infection	O
20	following	O
21	treatment	O
22	with	O
23	amphotericin	O
24	B	O
25	and	O
26	surgical	O
27	excision	O
28	of	O
29	the	O
30	lung	O
31	abscess	O
32	.	O

1	Implications	O
2	of	O
3	this	O
4	observation	O
5	for	O
6	pediatrics	O
7	are	O
8	discussed	O
9	.	O

1	For	O
2	the	O
3	study	O
4	of	O
5	the	O
6	transition	O
7	of	O
8	long	O
9	to	O
10	short	O
11	waves	O
12	(	O
13	deep	O
14	-	O
15	water	O
16	waves	O
17	)	O
18	a	O
19	closed	O
20	-	O
21	form	O
22	solution	O
23	is	O
24	advantageous	O
25	;	O
26	this	O
27	can	O
28	,	O
29	however	O
30	,	O
31	only	O
32	be	O
33	obtained	O
34	at	O
35	the	O
36	cost	O
37	of	O
38	further	O
39	simplification	O
40	.	O

1	Treatment	O
2	of	O
3	suppurative	O
4	peritonitis	O

1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	pheochromocytoma	O
7	manifesting	O
8	during	O
9	the	O
10	third	O
11	trimester	O
12	of	O
13	pregnancy	O
14	.	O

1	Fasting	O
2	plasma	O
3	and	O
4	lipoprotein	O
5	lipid	O
6	concentrations	O
7	,	O
8	adipose	B
9	tissue	I
10	lipoprotein	I
11	lipase	I
12	activity	O
13	,	O
14	anthropometric	O
15	data	O
16	,	O
17	alcohol	O
18	consumption	O
19	,	O
20	smoking	O
21	habits	O
22	,	O
23	weekly	O
24	mileage	O
25	run	O
26	and	O
27	performance	O
28	on	O
29	a	O
30	bicycle	O
31	ergometer	O
32	were	O
33	recorded	O
34	before	O
35	and	O
36	after	O
37	the	O
38	training	O
39	period	O
40	.	O

1	The	O
2	C18	O
3	:	O
4	1	O
5	:	O
6	C10	O
7	value	O
8	is	O
9	a	O
10	convenient	O
11	measure	O
12	of	O
13	these	O
14	changes	O
15	and	O
16	can	O
17	be	O
18	determined	O
19	more	O
20	rapidly	O
21	than	O
22	determining	O
23	all	O
24	the	O
25	lower	O
26	fatty	O
27	acids	O
28	.	O

1	A	O
2	progressive	O
3	growth	O
4	of	O
5	blood	O
6	erythrocyte	O
7	membrane	O
8	injury	O
9	has	O
10	been	O
11	demonstrated	O
12	after	O
13	rats	O
14	were	O
15	exposed	O
16	to	O
17	gamma	O
18	-	O
19	irradiaton	O
20	at	O
21	a	O
22	dose	O
23	of	O
24	100	O
25	to	O
26	500	O
27	Gy	O
28	.	O

1	Within	O
2	the	O
3	3	O
4	'	O
5	terminal	O
6	50	O
7	nucleotides	O
8	,	O
9	the	O
10	mouse	B
11	mt	I
12	12S	I
13	rRNA	I
14	contains	O
15	a	O
16	potential	O
17	10	O
18	bp	O
19	hairpin	O
20	structure	O
21	and	O
22	a	O
23	sequence	O
24	of	O
25	15	O
26	consecutive	O
27	nucleotides	O
28	common	O
29	to	O
30	the	O
31	RNA	O
32	of	O
33	the	O
34	small	O
35	ribosomal	O
36	subunit	O
37	in	O
38	all	O
39	systems	O
40	,	O
41	but	O
42	does	O
43	not	O
44	contain	O
45	the	O
46	mRNA	O
47	binding	O
48	site	O
49	(	O
50	ACCUCC	O
51	)	O
52	found	O
53	in	O
54	E	O
55	.	O
56	coli	O
57	and	O
58	corn	O
59	chloroplast	O
60	rRNAs	O
61	.	O

1	Microscopic	O
2	anatomy	O
3	and	O
4	cell	O
5	population	O
6	dynamics	O
7	.	O

1	Thirty	O
2	cadaver	O
3	brains	O
4	were	O
5	examined	O
6	under	O
7	X	O
8	6	O
9	to	O
10	16	O
11	magnification	O
12	in	O
13	order	O
14	to	O
15	define	O
16	the	O
17	microsurgical	O
18	anatomy	O
19	of	O
20	the	O
21	pineal	O
22	region	O
23	,	O
24	particularly	O
25	the	O
26	relationship	O
27	of	O
28	the	O
29	pineal	O
30	body	O
31	,	O
32	posterior	O
33	cerebral	O
34	artery	O
35	,	O
36	superior	O
37	cerebellar	O
38	artery	O
39	,	O
40	vein	O
41	of	O
42	Galen	O
43	,	O
44	basal	O
45	vein	O
46	of	O
47	Rosenthal	O
48	,	O
49	internal	O
50	cerebral	O
51	vein	O
52	,	O
53	straight	O
54	sinus	O
55	,	O
56	bridging	O
57	vein	O
58	,	O
59	the	O
60	size	O
61	of	O
62	the	O
63	tentorial	O
64	notch	O
65	,	O
66	and	O
67	the	O
68	third	O
69	and	O
70	the	O
71	fourth	O
72	cranial	O
73	nerves	O
74	.	O

1	Serum	O
2	antibody	O
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O

1	We	O
2	propose	O
3	that	O
4	refeeding	O
5	may	O
6	be	O
7	an	O
8	important	O
9	mechanism	O
10	for	O
11	activation	O
12	of	O
13	certain	O
14	viral	O
15	infections	O
16	previously	O
17	suppressed	O
18	by	O
19	famine	O
20	.	O

1	One	O
2	hundred	O
3	twenty	O
4	units	O
5	of	O
6	deglycerolized	O
7	red	O
8	blood	O
9	cells	O
10	,	O
11	some	O
12	with	O
13	glycerol	O
14	added	O
15	so	O
16	as	O
17	to	O
18	exceed	O
19	an	O
20	acceptable	O
21	1	O
22	%	O
23	glycerol	O
24	content	O
25	,	O
26	had	O
27	measurements	O
28	made	O
29	of	O
30	the	O
31	post	O
32	-	O
33	wash	O
34	supernatant	O
35	fluid	O
36	by	O
37	refractive	O
38	index	O
39	and	O
40	osmometry	O
41	.	O

1	The	O
2	symptoms	O
3	and	O
4	objective	O
5	findings	O
6	were	O
7	caused	O
8	by	O
9	a	O
10	malignant	O
11	lymphoma	O
12	,	O
13	and	O
14	the	O
15	diagnosis	O
16	was	O
17	established	O
18	from	O
19	a	O
20	drill	O
21	biopsy	O
22	.	O

1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	All	O
2	control	O
3	persons	O
4	had	O
5	a	O
6	normal	O
7	reaction	O
8	to	O
9	DNFB	O
10	.	O

1	In	O
2	a	O
3	control	O
4	group	O
5	both	O
6	common	O
7	carotid	O
8	arteries	O
9	(	O
10	CCA	O
11	)	O
12	were	O
13	ligated	O
14	.	O

1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O

1	Simultaneous	O
2	right	O
3	and	O
4	left	O
5	adrenal	O
6	and	O
7	peripheral	O
8	blood	O
9	samples	O
10	were	O
11	collected	O
12	for	O
13	determination	O
14	of	O
15	oestrone	O
16	(	O
17	E1	O
18	)	O
19	and	O
20	oestradiol	O
21	(	O
22	E2	O
23	).	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	The	O
2	same	O
3	response	O
4	occurs	O
5	whether	O
6	acrylamide	O
7	is	O
8	given	O
9	immediately	O
10	after	O
11	nerve	O
12	ligation	O
13	or	O
14	1	O
15	week	O
16	later	O
17	.	O

1	The	O
2	operation	O
3	recommended	O
4	is	O
5	excision	O
6	of	O
7	3	O
8	mm	O
9	of	O
10	central	O
11	slip	O
12	followed	O
13	by	O
14	end	O
15	-	O
16	to	O
17	-	O
18	end	O
19	repair	O
20	of	O
21	the	O
22	tendon	O
23	.	O

1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O

1	Marked	O
2	sedative	O
3	activity	O
4	was	O
5	observed	O
6	with	O
7	9	O
8	-	O
9	methoxy	O
10	-	O
11	5	O
12	-	O
13	phenylpyrrolo	O
14	[	O
15	2	O
16	,	O
17	1	O
18	-	O
19	d	O
20	][	O
21	1	O
22	,	O
23	5	O
24	]	O
25	benzothiazepin	O
26	-	O
27	6	O
28	,	O
29	6	O
30	-	O
31	dioxide	O
32	(	O
33	NF19	O
34	)	O
35	and	O
36	9	O
37	-	O
38	chloro	O
39	-	O
40	5	O
41	-	O
42	p	O
43	-	O
44	nitrophenylpyrrolo	O
45	[	O
46	2	O
47	,	O
48	1	O
49	-	O
50	d	O
51	][	O
52	1	O
53	,	O
54	5	O
55	]	O
56	benzothiazepin	O
57	-	O
58	6	O
59	,	O
60	6	O
61	-	O
62	dioxide	O
63	(	O
64	NF20	O
65	).	O

1	In	O
2	patients	O
3	,	O
4	the	O
5	effect	O
6	of	O
7	CCK	B
8	-	O
9	PZ	B
10	on	O
11	the	O
12	movement	O
13	of	O
14	the	O
15	terminal	O
16	part	O
17	of	O
18	the	O
19	bile	O
20	duct	O
21	was	O
22	measured	O
23	with	O
24	a	O
25	pressure	O
26	sensor	O
27	using	O
28	a	O
29	duodenofiberscope	O
30	.	O

1	In	O
2	11	O
3	patients	O
4	with	O
5	Horton	O
6	'	O
7	s	O
8	headache	O
9	morphological	O
10	investigations	O
11	(	O
12	differential	O
13	white	O
14	blood	O
15	cell	O
16	count	O
17	),	O
18	cytoenzymatic	O
19	determinations	O
20	(	O
21	alkaline	B
22	and	I
23	acid	I
24	phosphatase	I
25	,	O
26	non	B
27	-	I
28	specific	I
29	esterase	I
30	)	O
31	and	O
32	cytoimmunological	O
33	tests	O
34	(	O
35	IgM	B
36	and	O
37	IgG	B
38	binding	O
39	)	O
40	were	O
41	carried	O
42	out	O
43	on	O
44	capillary	O
45	blood	O
46	neutrophils	O
47	obtained	O
48	from	O
49	the	O
50	area	O
51	of	O
52	pain	O
53	,	O
54	non	O
55	-	O
56	painful	O
57	area	O
58	of	O
59	the	O
60	skin	O
61	on	O
62	the	O
63	head	O
64	on	O
65	the	O
66	contralateral	O
67	side	O
68	,	O
69	and	O
70	from	O
71	the	O
72	finger	O
73	.	O

1	As	O
2	high	O
3	-	O
4	speed	O
5	,	O
6	volumetric	O
7	imaging	O
8	,	O
9	computed	O
10	tomographic	O
11	scan	O
12	machines	O
13	such	O
14	as	O
15	the	O
16	Dynamic	O
17	Spatial	O
18	Reconstructor	O
19	become	O
20	available	O
21	with	O
22	higher	O
23	density	O
24	resolution	O
25	,	O
26	perhaps	O
27	a	O
28	single	O
29	injection	O
30	of	O
31	contrast	O
32	agent	O
33	into	O
34	the	O
35	right	O
36	atrium	O
37	or	O
38	even	O
39	a	O
40	peripheral	O
41	vein	O
42	may	O
43	be	O
44	adequate	O
45	to	O
46	obtain	O
47	all	O
48	these	O
49	measurements	O
50	.	O

1	The	O
2	ESEG	O
3	'	O
4	s	O
5	are	O
6	a	O
7	direct	O
8	result	O
9	of	O
10	the	O
11	NEXT	O
12	study	O
13	.	O

1	The	O
2	potentially	O
3	SLE	O
4	-	O
5	inducing	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O

1	A	O
2	third	O
3	series	O
4	of	O
5	mice	O
6	were	O
7	given	O
8	a	O
9	single	O
10	injection	O
11	of	O
12	5	O
13	-	O
14	OH	O
15	-	O
16	DA	O
17	,	O
18	sacrificed	O
19	,	O
20	and	O
21	prepared	O
22	for	O
23	ultrastructural	O
24	study	O
25	.	O

1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O

1	No	O
2	symptoms	O
3	other	O
4	than	O
5	hot	O
6	flush	O
7	showed	O
8	such	O
9	significant	O
10	correlation	O
11	with	O
12	plasma	O
13	epinephrine	O
14	or	O
15	norepinephrine	O
16	levels	O
17	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	concentrations	O
7	of	O
8	the	O
9	components	O
10	due	O
11	to	O
12	tobacco	O
13	smoke	O
14	are	O
15	:	O
16	CO	O
17	=	O
18	1	O
19	.	O
20	1	O
21	ppm	O
22	,	O
23	NO	O
24	=	O
25	32	O
26	ppb	O
27	,	O
28	NO2	O
29	=	O
30	24	O
31	ppb	O
32	,	O
33	nicotine	O
34	=	O
35	0	O
36	.	O
37	9	O
38	micrograms	O
39	/	O
40	m3	O
41	,	O
42	particulate	O
43	matter	O
44	=	O
45	133	O
46	micrograms	O
47	/	O
48	m3	O
49	.	O

1	The	O
2	average	O
3	backscatter	O
4	coefficient	O
5	was	O
6	six	O
7	time	O
8	larger	O
9	in	O
10	regions	O
11	of	O
12	infarct	O
13	studied	O
14	8	O
15	--	O
16	10	O
17	weeks	O
18	after	O
19	occlusion	O
20	than	O
21	that	O
22	in	O
23	regions	O
24	of	O
25	infarct	O
26	studied	O
27	5	O
28	--	O
29	6	O
30	weeks	O
31	after	O
32	occlusion	O
33	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O

1	Pentachlorophenol	O
2	accelerates	O
3	the	O
4	onset	O
5	of	O
6	HCB	O
7	porphyria	O
8	,	O
9	in	O
10	other	O
11	words	O
12	it	O
13	increases	O
14	the	O
15	total	O
16	urinary	O
17	porphyrin	O
18	excretion	O
19	and	O
20	causes	O
21	an	O
22	earlier	O
23	disturbance	O
24	of	O
25	the	O
26	porphyrin	O
27	pattern	O
28	.	O

1	Family	O
2	planning	O
3	continues	O
4	to	O
5	play	O
6	a	O
7	minor	O
8	role	O
9	,	O
10	and	O
11	only	O
12	25	O
13	.	O
14	3	O
15	per	O
16	cent	O
17	of	O
18	all	O
19	patients	O
20	reviewed	O
21	took	O
22	to	O
23	oral	O
24	contraceptives	O
25	for	O
26	shorter	O
27	or	O
28	longer	O
29	periods	O
30	of	O
31	time	O
32	.	O
33	-	O
34	The	O
35	percentages	O
36	of	O
37	primiparae	O
38	and	O
39	secundiparae	O
40	in	O
41	all	O
42	births	O
43	as	O
44	well	O
45	as	O
46	the	O
47	high	O
48	percentage	O
49	of	O
50	multigravidity	O
51	are	O
52	parameters	O
53	by	O
54	which	O
55	the	O
56	approach	O
57	to	O
58	reproduction	O
59	differs	O
60	substantively	O
61	from	O
62	behaviour	O
63	patterns	O
64	in	O
65	Europe	O
66	.	O

1	The	O
2	term	O
3	osteomesopycnosis	O
4	is	O
5	proposed	O
6	for	O
7	a	O
8	sclerosing	O
9	bone	O
10	disease	O
11	with	O
12	dominant	O
13	inheritance	O
14	that	O
15	has	O
16	been	O
17	discovered	O
18	in	O
19	five	O
20	members	O
21	of	O
22	four	O
23	different	O
24	families	O
25	.	O

1	The	O
2	87K	O
3	protein	O
4	,	O
5	together	O
6	with	O
7	proteins	O
8	of	O
9	105	O
10	,	O
11	000	O
12	and	O
13	75	O
14	,	O
15	000	O
16	daltons	O
17	,	O
18	are	O
19	translated	O
20	from	O
21	leftward	O
22	transcribed	O
23	(	O
24	1	O
25	-	O
26	strand	O
27	)	O
28	messenger	O
29	RNAs	O
30	that	O
31	are	O
32	complementary	O
33	to	O
34	the	O
35	viral	O
36	genome	O
37	between	O
38	positions	O
39	11	O
40	.	O
41	2	O
42	and	O
43	31	O
44	.	O
45	5	O
46	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	The	O
2	temporal	O
3	component	O
4	lacked	O
5	a	O
6	mandibular	O
7	fossa	O
8	as	O
9	well	O
10	as	O
11	articular	O
12	eminence	O
13	.	O

1	EUK	O
2	-	O
3	8	O
4	is	O
5	a	O
6	novel	O
7	,	O
8	synthetic	O
9	,	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	salen	O
16	-	O
17	manganese	O
18	complex	O
19	that	O
20	exhibits	O
21	both	O
22	superoxide	B
23	dismutase	I
24	and	O
25	catalase	B
26	activities	O
27	in	O
28	vitro	O
29	.	O

1	The	O
2	protein	B
3	ELT	I
4	-	I
5	1	I
6	,	O
7	encoded	O
8	by	O
9	a	O
10	single	O
11	-	O
12	copy	O
13	gene	O
14	homologous	O
15	to	O
16	the	O
17	GATA	B
18	family	I
19	of	I
20	vertebrate	I
21	transcription	I
22	factors	I
23	,	O
24	is	O
25	potentially	O
26	capable	O
27	of	O
28	interacting	O
29	with	O
30	this	O
31	element	O
32	.	O

1	However	O
2	,	O
3	in	O
4	contrast	O
5	with	O
6	previous	O
7	in	O
8	vitro	O
9	cell	O
10	-	O
11	free	O
12	integration	O
13	studies	O
14	,	O
15	alteration	O
16	of	O
17	the	O
18	highly	O
19	conserved	O
20	CA	O
21	dinucleotide	O
22	resulted	O
23	in	O
24	a	O
25	mutant	O
26	which	O
27	still	O
28	retained	O
29	40	O
30	%	O
31	of	O
32	wild	O
33	-	O
34	type	O
35	integration	O
36	activity	O
37	.	O

1	The	O
2	resulting	O
3	R	B
4	protein	I
5	terminates	O
6	five	O
7	codons	O
8	downstream	O
9	of	O
10	the	O
11	frameshift	O
12	site	O
13	at	O
14	the	O
15	V	B
16	protein	I
17	stop	O
18	codon	O
19	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	although	O
6	PI2	O
7	and	O
8	PI3	O
9	viruses	O
10	belong	O
11	to	O
12	the	O
13	same	O
14	parainfluenza	O
15	virus	O
16	genus	O
17	,	O
18	these	O
19	viruses	O
20	show	O
21	marked	O
22	differences	O
23	with	O
24	respect	O
25	to	O
26	functional	O
27	requirements	O
28	for	O
29	the	O
30	cytoplasmic	O
31	tail	O
32	of	O
33	the	O
34	F	B
35	glycoprotein	I
36	.	O

1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	I
16	amino	I
17	acid	I
18	residues	I
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O

1	Magnetic	O
2	resonance	O
3	imaging	O
4	(	O
5	MRI	O
6	)	O
7	has	O
8	enabled	O
9	us	O
10	to	O
11	see	O
12	the	O
13	spinal	O
14	intramedullary	O
15	pathology	O
16	as	O
17	differences	O
18	in	O
19	signal	O
20	intensity	O
21	.	O

1	Patients	O
2	with	O
3	psychotropic	O
4	drugs	O
5	showed	O
6	significantly	O
7	higher	O
8	PRL	B
9	levels	O
10	.	O

1	The	O
2	Laser	O
3	Scanning	O
4	Ophthalmoscope	O
5	enables	O
6	a	O
7	fundus	O
8	-	O
9	based	O
10	examination	O
11	and	O
12	therefore	O
13	allows	O
14	exact	O
15	comparison	O
16	between	O
17	morphologic	O
18	appearance	O
19	and	O
20	corresponding	O
21	function	O
22	.	O

1	Malaria	O
2	,	O
3	anaemia	O
4	,	O
5	and	O
6	HIV	O
7	-	O
8	1	O
9	transmission	O
10	in	O
11	central	O
12	Africa	O
13	.	O

1	BSE	O
2	and	O
3	farmworkers	O
4	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	-	O
6	dimensional	O
7	nuclear	O
8	magnetic	O
9	resonance	O
10	studies	O
11	with	O
12	F17A	O
13	,	O
14	K13Q	O
15	,	O
16	F15Y	O
17	and	O
18	F27Y	O
19	revealed	O
20	that	O
21	the	O
22	mutants	O
23	have	O
24	the	O
25	same	O
26	overall	O
27	structure	O
28	as	O
29	the	O
30	wild	B
31	-	I
32	type	I
33	CspB	I
34	protein	I
35	.	O

1	Considerably	O
2	high	O
3	levels	O
4	of	O
5	IgE	B
6	antibodies	I
7	was	O
8	also	O
9	established	O
10	while	O
11	other	O
12	pollens	O
13	did	O
14	not	O
15	show	O
16	such	O
17	correspondence	O
18	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPARs	B
8	)	O
9	and	O
10	retinoid	B
11	X	I
12	receptors	I
13	(	O
14	RXRs	B
15	)	O
16	are	O
17	nuclear	B
18	hormone	I
19	receptors	I
20	that	O
21	are	O
22	activated	O
23	by	O
24	fatty	O
25	acids	O
26	and	O
27	9	O
28	-	O
29	cis	O
30	-	O
31	retinoic	O
32	acid	O
33	,	O
34	respectively	O
35	.	O

1	This	O
2	is	O
3	particularly	O
4	intriguing	O
5	because	O
6	SKUT	O
7	-	O
8	1B	O
9	-	O
10	20	O
11	cells	O
12	lack	O
13	the	O
14	transcription	O
15	factor	O
16	Pit	B
17	-	I
18	1	I
19	.	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	B
27	products	I
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	Some	O
2	strains	O
3	of	O
4	A	O
5	.	O
6	parasiticus	O
7	produced	O
8	all	O
9	four	O
10	aflatoxins	O
11	B1	O
12	B2	O
13	G1	O
14	G2	O
15	,	O
16	while	O
17	the	O
18	other	O
19	ones	O
20	produced	O
21	AF	O
22	B1	O
23	+	O
24	G1	O
25	only	O
26	,	O
27	with	O
28	concentrations	O
29	of	O
30	aflatoxins	O
31	from	O
32	0	O
33	.	O
34	1	O
35	to	O
36	450	O
37	mg	O
38	/	O
39	kg	O
40	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	O
6	,	O
7	larger	O
8	rat	B
9	B	I
10	-	I
11	myc	I
12	genomic	I
13	clone	I
14	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	nine	O
6	and	O
7	51	O
8	terminal	O
9	amino	O
10	acid	O
11	forms	O
12	already	O
13	known	O
14	,	O
15	we	O
16	identified	O
17	a	O
18	third	O
19	with	O
20	43	O
21	terminal	O
22	amino	O
23	acids	O
24	predicted	O
25	to	O
26	encode	O
27	a	O
28	novel	O
29	RET	B
30	protein	I
31	isoform	I
32	.	O

1	Both	O
2	classes	O
3	of	O
4	MHBst	B
5	proteins	I
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	the	O
8	PERE	B
9	formed	O
10	three	O
11	major	O
12	complexes	O
13	(	O
14	P1	O
15	,	O
16	P2	O
17	and	O
18	P3	O
19	)	O
20	with	O
21	proteins	O
22	in	O
23	nuclear	O
24	extracts	O
25	from	O
26	HeLa	O
27	or	O
28	293	O
29	cells	O
30	.	O

1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	identified	O
6	four	O
7	open	O
8	reading	O
9	frames	O
10	(	O
11	ORFs	O
12	)	O
13	which	O
14	are	O
15	designated	O
16	UL1	B
17	,	O
18	UL2	B
19	,	O
20	UL3	B
21	,	O
22	and	O
23	UL3	B
24	.	I
25	5	I
26	based	O
27	on	O
28	their	O
29	homology	O
30	with	O
31	proteins	O
32	of	O
33	herpes	O
34	simplex	O
35	virus	O
36	-	O
37	1	O
38	(	O
39	HSV	O
40	-	O
41	1	O
42	),	O
43	pseudorabies	O
44	virus	O
45	(	O
46	PRV	O
47	),	O
48	equine	O
49	herpesvirus	O
50	-	O
51	1	O
52	,	O
53	and	O
54	varicella	O
55	-	O
56	zoster	O
57	virus	O
58	.	O

1	These	O
2	HPV16	O
3	E6	B
4	/	O
5	E7	B
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	O
44	.	O

1	Correlation	O
2	coefficients	O
3	between	O
4	the	O
5	reference	O
6	methods	O
7	and	O
8	NIT	O
9	were	O
10	>	O
11	or	O
12	=	O
13	0	O
14	.	O
15	95	O
16	for	O
17	water	O
18	,	O
19	fat	O
20	,	O
21	crude	O
22	protein	O
23	and	O
24	connective	O
25	-	O
26	tissue	O
27	-	O
28	protein	O
29	frei	O
30	meat	O
31	protein	O
32	,	O
33	and	O
34	>	O
35	or	O
36	=	O
37	0	O
38	.	O
39	86	O
40	for	O
41	connective	O
42	-	O
43	tissue	O
44	-	O
45	protein	O
46	.	O

1	The	O
2	translation	O
3	products	O
4	of	O
5	both	O
6	clones	O
7	are	O
8	highly	O
9	homologous	O
10	to	O
11	APS1	B
12	(	O
13	66	O
14	and	O
15	86	O
16	%	O
17	identity	O
18	,	O
19	respectively	O
20	)	O
21	over	O
22	their	O
23	entire	O
24	lengths	O
25	,	O
26	including	O
27	amino	O
28	terminal	O
29	sequences	O
30	resembling	O
31	transit	O
32	peptides	O
33	for	O
34	plastid	O
35	localization	O
36	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	IgE	B
6	,	O
7	and	O
8	asIgE	B
9	and	O
10	IgG	B
11	-	I
12	4	I
13	against	O
14	14	O
15	common	O
16	food	O
17	allergens	O
18	were	O
19	determined	O
20	.	O

1	Two	O
2	experiments	O
3	investigating	O
4	the	O
5	effects	O
6	of	O
7	short	O
8	-	O
9	term	O
10	spaceflight	O
11	on	O
12	cancellous	O
13	bone	O
14	turnover	O
15	were	O
16	carried	O
17	out	O
18	:	O
19	Physiological	O
20	Systems	O
21	Experiment	O
22	-	O
23	1	O
24	(	O
25	PSE	O
26	-	O
27	1	O
28	)	O
29	(	O
30	a	O
31	4	O
32	-	O
33	d	O
34	orbital	O
35	spaceflight	O
36	)	O
37	and	O
38	PSE	O
39	-	O
40	2	O
41	(	O
42	a	O
43	10	O
44	-	O
45	d	O
46	flight	O
47	).	O

1	That	O
2	sequence	O
3	strongly	O
4	promoted	O
5	the	O
6	transcription	O
7	of	O
8	the	O
9	promotorless	O
10	chloramphenicol	B
11	acetyltranferase	I
12	(	O
13	CAT	B
14	)	O
15	gene	O
16	in	O
17	cells	O
18	of	O
19	pancreatic	O
20	origin	O
21	(	O
22	AR	O
23	-	O
24	42J	O
25	)	O
26	but	O
27	not	O
28	in	O
29	cells	O
30	of	O
31	non	O
32	-	O
33	pancreatic	O
34	origin	O
35	(	O
36	Rat	O
37	2	O
38	and	O
39	IEC	O
40	6	O
41	).	O

1	Functional	O
2	analysis	O
3	of	O
4	aryl	B
5	hydrocarbon	I
6	receptor	I
7	nuclear	I
8	translocator	I
9	interactions	O
10	with	O
11	aryl	B
12	hydrocarbon	I
13	receptor	I
14	in	O
15	the	O
16	yeast	O
17	two	O
18	-	O
19	hybrid	O
20	system	O
21	.	O

1	Histopathologic	O
2	observations	O
3	showed	O
4	that	O
5	both	O
6	somatostatin	B
7	and	O
8	triamcinolone	O
9	acetonide	O
10	reduced	O
11	the	O
12	inflammatory	O
13	signs	O
14	in	O
15	the	O
16	joint	O
17	structures	O
18	,	O
19	although	O
20	triamcinolone	O
21	acetonide	O
22	appeared	O
23	to	O
24	be	O
25	more	O
26	effective	O
27	.	O

1	An	O
2	approach	O
3	to	O
4	a	O
5	biomathematical	O
6	model	O
7	of	O
8	lymphocytopoiesis	O
9	.	O

1	The	O
2	influenza	O
3	virus	O
4	NS1	B
5	protein	O
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O

1	These	O
2	are	O
3	two	O
4	regions	O
5	of	O
6	known	O
7	conserved	O
8	synteny	O
9	,	O
10	providing	O
11	further	O
12	evidence	O
13	that	O
14	the	O
15	human	B
16	STEP	I
17	is	O
18	a	O
19	true	O
20	homolog	O
21	of	O
22	the	O
23	murine	B
24	STEP	I
25	gene	I
26	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	human	O
6	homolog	O
7	of	O
8	a	O
9	striatum	B
10	-	I
11	enriched	I
12	phosphatase	I
13	(	I
14	STEP	I
15	)	I
16	gene	I
17	and	O
18	chromosomal	O
19	mapping	O
20	of	O
21	the	O
22	human	O
23	and	O
24	murine	O
25	loci	O
26	.	O

1	Carbonic	B
2	anhydrase	I
3	V	I
4	(	O
5	CA	B
6	V	I
7	)	O
8	is	O
9	expressed	O
10	in	O
11	mitochondrial	O
12	matrix	O
13	in	O
14	liver	O
15	and	O
16	several	O
17	other	O
18	tissues	O
19	.	O

1	Vitamin	O
2	D3	O
3	plus	O
4	nicotine	O
5	treatment	O
6	produced	O
7	parallel	O
8	increases	O
9	in	O
10	cardiac	O
11	mass	O
12	and	O
13	elastic	O
14	modulus	O
15	,	O
16	with	O
17	a	O
18	significant	O
19	correlation	O
20	between	O
21	the	O
22	two	O
23	.	O

1	The	O
2	latter	O
3	domain	O
4	appears	O
5	to	O
6	be	O
7	involved	O
8	in	O
9	targeting	O
10	Num1p	B
11	to	O
12	the	O
13	mother	O
14	cell	O
15	cortex	O
16	.	O

1	This	O
2	finding	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	notion	O
8	that	O
9	the	O
10	dsRNA	O
11	binding	O
12	domains	O
13	may	O
14	be	O
15	composed	O
16	of	O
17	two	O
18	separate	O
19	functional	O
20	subdomains	O
21	.	O

1	Preferential	O
2	heterodimeric	O
3	parallel	O
4	coiled	O
5	-	O
6	coil	O
7	formation	O
8	by	O
9	synthetic	B
10	Max	I
11	and	O
12	c	B
13	-	I
14	Myc	I
15	leucine	I
16	zippers	I
17	:	O
18	a	O
19	description	O
20	of	O
21	putative	O
22	electrostatic	O
23	interactions	O
24	responsible	O
25	for	O
26	the	O
27	specificity	O
28	of	O
29	heterodimerization	O
30	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	B
5	genes	I
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	B
24	coxI	I
25	intron	I
26	aI4	I
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	O
32	-	O
33	amino	O
34	-	O
35	acid	O
36	site	O
37	-	O
38	specific	O
39	DNA	B
40	endonuclease	I
41	.	O

1	We	O
2	studied	O
3	the	O
4	GR	B
5	in	O
6	DMS	O
7	-	O
8	79	O
9	cells	O
10	derived	O
11	from	O
12	a	O
13	human	O
14	ACTH	B
15	-	O
16	secreting	O
17	small	O
18	cell	O
19	lung	O
20	cancer	O
21	.	O

1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	QRS	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O

1	The	O
2	promoter	O
3	mutation	O
4	is	O
5	complemented	O
6	in	O
7	trans	O
8	by	O
9	E1A	B
10	products	O
11	of	O
12	the	O
13	heterologous	O
14	helper	O
15	adenovirus	O
16	type	O
17	5	O
18	(	O
19	Ad5	O
20	).	O

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O

1	Treatment	O
2	of	O
3	PCC4	O
4	.	O
5	aza1R	O
6	cells	O
7	with	O
8	an	O
9	RAR	B
10	-	O
11	selective	O
12	agonist	O
13	also	O
14	repressed	O
15	the	O
16	expression	O
17	of	O
18	EC	B
19	-	I
20	1	I
21	mRNA	I
22	while	O
23	treatment	O
24	with	O
25	an	O
26	RXR	B
27	-	O
28	selective	O
29	agonist	O
30	reduced	O
31	EC	B
32	-	I
33	1	I
34	expression	O
35	slightly	O
36	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	E1A243	B
6	,	O
7	YY1	B
8	represses	O
9	CRE	O
10	-	O
11	dependent	O
12	transcription	O
13	of	O
14	c	B
15	-	I
16	fos	I
17	by	O
18	physically	O
19	interacting	O
20	with	O
21	ATF	B
22	/	O
23	CREB	B
24	proteins	O
25	bound	O
26	to	O
27	the	O
28	-	O
29	67	O
30	CRE	O
31	.	O

1	Shift	O
2	-	O
3	down	O
4	experiments	O
5	indicated	O
6	that	O
7	the	O
8	10	O
9	(	O
10	4	O
11	)-	O
12	to	O
13	10	O
14	(	O
15	5	O
16	)-	O
17	fold	O
18	reduction	O
19	in	O
20	virus	O
21	yield	O
22	at	O
23	the	O
24	nonpermissive	O
25	temperature	O
26	was	O
27	due	O
28	to	O
29	the	O
30	disfunction	O
31	of	O
32	alpha	B
33	TIF	I
34	late	O
35	in	O
36	infection	O
37	,	O
38	presumably	O
39	in	O
40	virion	O
41	maturation	O
42	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	tip	B
6	acts	O
7	at	O
8	an	O
9	early	O
10	stage	O
11	of	O
12	the	O
13	T	O
14	-	O
15	cell	O
16	signal	O
17	transduction	O
18	cascade	O
19	by	O
20	associating	O
21	with	O
22	Lck	B
23	and	O
24	downregulating	O
25	Lck	O
26	-	O
27	mediated	O
28	activation	O
29	.	O

1	Human	B
2	immunodeficiency	I
3	virus	I
4	type	I
5	1	I
6	Vpr	I
7	is	O
8	a	O
9	virion	O
10	-	O
11	associated	O
12	,	O
13	regulatory	O
14	protein	O
15	that	O
16	is	O
17	required	O
18	for	O
19	efficient	O
20	viral	O
21	replication	O
22	in	O
23	monocytes	O
24	/	O
25	macrophages	O
26	.	O

1	Here	O
2	we	O
3	examine	O
4	the	O
5	potential	O
6	for	O
7	VP16	B
8	protein	O
9	-	O
10	protein	O
11	interactions	O
12	specific	O
13	to	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	show	O
20	that	O
21	VP16	B
22	copurifies	O
23	in	O
24	a	O
25	highly	O
26	enriched	O
27	fraction	O
28	with	O
29	a	O
30	single	O
31	major	O
32	polypeptide	O
33	which	O
34	we	O
35	identify	O
36	as	O
37	the	O
38	virus	O
39	-	O
40	encoded	O
41	structural	O
42	protein	O
43	VP22	B
44	.	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	O
7	,	O
8	kinase	O
9	interaction	O
10	sites	O
11	,	O
12	and	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	the	O
17	LMP2A	B
18	homologs	I
19	have	O
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	O
25	heterogeneity	O
26	in	O
27	the	O
28	preterminal	O
29	repeat	O
30	regions	O
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	Results	O
2	of	O
3	the	O
4	ECAT	O
5	Angina	O
6	Pectoris	O
7	Study	O
8	Group	O
9	.	O

1	Therefore	O
2	,	O
3	a	O
4	prospective	O
5	Phase	O
6	II	O
7	trial	O
8	was	O
9	conducted	O
10	to	O
11	determine	O
12	the	O
13	safety	O
14	and	O
15	efficacy	O
16	of	O
17	cryosurgery	O
18	following	O
19	radiation	O
20	therapy	O
21	in	O
22	men	O
23	with	O
24	local	O
25	recurrence	O
26	.	O

1	These	O
2	motifs	O
3	include	O
4	a	O
5	Chi	O
6	motif	O
7	and	O
8	a	O
9	Chi	O
10	-	O
11	like	O
12	element	O
13	previously	O
14	found	O
15	in	O
16	the	O
17	recombination	O
18	hotspot	O
19	region	O
20	of	O
21	the	O
22	Bcl	B
23	-	I
24	2	I
25	proto	I
26	-	I
27	oncogene	I
28	and	O
29	close	O
30	to	O
31	chromosomal	O
32	breakpoints	O
33	in	O
34	T	O
35	-	O
36	ALL	O
37	lines	O
38	.	O

1	Common	O
2	history	O
3	and	O
4	prospects	O
5	in	O
6	surgical	O
7	gynecology	O
8	of	O
9	the	O
10	Charite	O
11	and	O
12	the	O
13	Vienna	O
14	University	O
15	Clinic	O

1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	B
8	mRNA	I
9	(	O
10	HMGR1S	B
11	mRNA	I
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	B
27	mRNA	I
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O

1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	B
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	B
22	mutator	I
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O

1	The	O
2	second	O
3	mutation	O
4	present	O
5	in	O
6	the	O
7	original	O
8	mutant	O
9	proved	O
10	to	O
11	be	O
12	an	O
13	allele	O
14	of	O
15	a	O
16	known	O
17	gene	O
18	,	O
19	PBS2	B
20	,	O
21	which	O
22	encodes	O
23	a	O
24	putative	O
25	protein	O
26	kinase	O
27	that	O
28	functions	O
29	in	O
30	the	O
31	high	O
32	osmolarity	O
33	stress	O
34	pathway	O
35	.	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	As	O
2	hGM	B
3	-	I
4	CSF	I
5	receptor	I
6	(	O
7	hGMR	B
8	)	O
9	does	O
10	not	O
11	contain	O
12	a	O
13	consensus	O
14	sequence	O
15	for	O
16	binding	O
17	of	O
18	PI	B
19	3	I
20	-	I
21	kinase	I
22	,	O
23	hGMR	B
24	must	O
25	use	O
26	a	O
27	distinct	O
28	mechanism	O
29	for	O
30	its	O
31	association	O
32	with	O
33	and	O
34	activation	O
35	of	O
36	PI	B
37	3	I
38	-	I
39	kinase	I
40	.	O

1	J	O
2	.	O

1	The	O
2	identity	O
3	between	O
4	hnRNPs	B
5	H	I
6	and	O
7	H	B
8	'	I
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	B
14	and	O
15	F	B
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	B
21	'	I
22	and	O
23	F	B
24	75	O
25	%,	O
26	respectively	O
27	.	O

1	TPBF	B
2	has	O
3	two	O
4	potential	O
5	coiled	O
6	-	O
7	coil	O
8	regions	O
9	,	O
10	a	O
11	basic	O
12	region	O
13	,	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	region	O
19	,	O
20	a	O
21	histidine	O
22	-	O
23	rich	O
24	N	O
25	terminus	O
26	,	O
27	and	O
28	a	O
29	nuclear	O
30	targeting	O
31	sequence	O
32	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	transiently	O
8	expressed	O
9	in	O
10	primary	O
11	cultures	O
12	of	O
13	rat	O
14	hepatocytes	O
15	plasmids	O
16	consisting	O
17	of	O
18	CYP3A1	B
19	5	I
20	'-	I
21	flanking	I
22	sequences	I
23	fused	O
24	to	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	plasmid	O
30	.	O

1	We	O
2	show	O
3	that	O
4	stimulation	O
5	of	O
6	resting	O
7	splenic	O
8	B	O
9	cells	O
10	with	O
11	CD40L	B
12	-	O
13	expressing	O
14	Sf9	O
15	cells	O
16	induces	O
17	germ	O
18	-	O
19	line	O
20	gamma	O
21	1	O
22	and	O
23	epsilon	O
24	transcripts	O
25	independently	O
26	of	O
27	cytokines	O
28	.	O

1	To	O
2	confirm	O
3	the	O
4	GapIII	B
5	protein	I
6	activity	O
7	,	O
8	constructs	O
9	containing	O
10	different	O
11	GapIII	B
12	-	O
13	GRD	B
14	domains	O
15	were	O
16	transformed	O
17	into	O
18	iral	B
19	mutant	O
20	yeast	O
21	to	O
22	determine	O
23	their	O
24	relative	O
25	ability	O
26	to	O
27	replace	O
28	IRA1	B
29	functionally	O
30	.	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	latest	O
8	BPVs	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O

1	A	O
2	tobacco	O
3	homologue	O
4	(	O
5	trolC	B
6	)	O
7	of	O
8	the	O
9	rolC	B
10	gene	I
11	of	I
12	the	I
13	Agrobacterium	I
14	rhizogenes	I
15	Ri	I
16	-	I
17	plasmid	I
18	was	O
19	cloned	O
20	and	O
21	sequenced	O
22	from	O
23	Nicotiana	O
24	tabacum	O
25	L	O
26	.	O
27	cv	O
28	.	O

1	High	O
2	ADR1	B
3	gene	I
4	dosage	O
5	increased	O
6	the	O
7	transcription	O
8	of	O
9	genes	O
10	encoding	O
11	peroxisomal	O
12	proteins	O
13	as	O
14	compared	O
15	to	O
16	one	O
17	copy	O
18	of	O
19	the	O
20	ADR1	B
21	gene	I
22	.	O

1	A	O
2	water	O
3	-	O
4	vapour	O
5	giga	O
6	-	O
7	maser	O
8	in	O
9	the	O
10	active	O
11	galaxy	O
12	TXFS2226	O
13	-	O
14	184	O
15	.	O

1	Of	O
2	the	O
3	three	O
4	known	O
5	C	B
6	/	I
7	EBP	I
8	family	I
9	inhibitors	O
10	,	O
11	Ig	B
12	/	I
13	EBP	I
14	,	O
15	LIP	B
16	and	O
17	CHOP	B
18	-	I
19	10	I
20	,	O
21	only	O
22	Ig	B
23	/	I
24	EBP	I
25	is	O
26	ubiquitously	O
27	expressed	O
28	.	O

1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	monophosphoryl	O
15	lipid	O
16	A	O
17	(	O
18	MLA	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	stunning	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	occlusions	O
36	were	O
37	studied	O
38	in	O
39	barbital	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O

1	These	O
2	incisors	O
3	were	O
4	studied	O
5	by	O
6	scanning	O
7	electron	O
8	microscopy	O
9	-	O
10	energy	O
11	dispersive	O
12	spectroscopy	O
13	analysis	O
14	(	O
15	SEM	O
16	-	O
17	EDS	O
18	)	O
19	and	O
20	light	O
21	microscopy	O
22	to	O
23	examine	O
24	the	O
25	calciotraumatic	O
26	lines	O
27	of	O
28	strontium	O
29	in	O
30	the	O
31	rat	O
32	incisor	O
33	labial	O
34	dentin	O
35	.	O

1	A	O
2	platelet	B
3	-	I
4	derived	I
5	growth	I
6	factor	I
7	receptor	I
8	(	O
9	PDGF	B
10	-	I
11	R	I
12	)	O
13	phosphopeptide	O
14	containing	O
15	Tyr	O
16	-	O
17	857	O
18	does	O
19	not	O
20	bind	O
21	appreciably	O
22	to	O
23	the	O
24	Src	B
25	SH2	I
26	domain	I
27	,	O
28	suggesting	O
29	it	O
30	is	O
31	not	O
32	the	O
33	PDGF	B
34	-	I
35	R	I
36	binding	O
37	site	O
38	for	O
39	Src	B
40	as	O
41	previously	O
42	reported	O
43	.	O

1	We	O
2	have	O
3	also	O
4	tested	O
5	Src	B
6	SH2	I
7	mutants	O
8	for	O
9	their	O
10	binding	O
11	properties	O
12	and	O
13	have	O
14	interpreted	O
15	our	O
16	results	O
17	in	O
18	light	O
19	of	O
20	the	O
21	recent	O
22	crystal	O
23	structure	O
24	solution	O
25	for	O
26	the	O
27	Src	B
28	SH2	I
29	domain	O
30	.	O

1	These	O
2	observations	O
3	link	O
4	actin	B
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O

1	The	O
2	early	O
3	lethality	O
4	of	O
5	the	O
6	left	O
7	-	O
8	sided	O
9	resectio	O
10	was	O
11	0	O
12	%	O
13	and	O
14	the	O
15	postoperative	O
16	survival	O
17	--	O
18	5	O
19	-	O
20	10	O
21	months	O
22	.	O

1	There	O
2	are	O
3	two	O
4	immunogenic	O
5	sites	O
6	on	O
7	the	O
8	type	O
9	A	O
10	influenza	O
11	A	O
12	/	O
13	Japan	O
14	/	O
15	57	O
16	(	O
17	H2N2	O
18	)	O
19	hemagglutinin	B
20	(	O
21	HA	B
22	)	O
23	that	O
24	can	O
25	be	O
26	recognized	O
27	by	O
28	class	B
29	I	I
30	major	I
31	histocompatibility	I
32	complex	I
33	(	O
34	MHC	B
35	),	O
36	H	B
37	-	I
38	2Kd	I
39	-	O
40	restricted	O
41	cytolytic	O
42	T	O
43	lymphocytes	O
44	(	O
45	CTLs	O
46	).	O

1	This	O
2	enhancer	O
3	activates	O
4	both	O
5	the	O
6	K19	B
7	and	O
8	TK	B
9	basal	I
10	promoters	I
11	in	O
12	HeLa	O
13	cells	O
14	.	O

1	Mechanism	O
2	of	O
3	enhancement	O
4	of	O
5	DNA	O
6	expression	O
7	consequent	O
8	to	O
9	cointernalization	O
10	of	O
11	a	O
12	replication	O
13	-	O
14	deficient	O
15	adenovirus	O
16	and	O
17	unmodified	O
18	plasmid	O
19	DNA	O
20	.	O

1	Interestingly	O
2	,	O
3	one	O
4	IRF	B
5	binding	I
6	site	I
7	was	O
8	found	O
9	within	O
10	the	O
11	IRF	B
12	-	I
13	2	I
14	promoter	I
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	O
20	IRF	B
21	-	I
22	2	I
23	gene	I
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	O
31	IRF	B
32	-	I
33	1	I
34	expression	O
35	.	O

1	Therefore	O
2	,	O
3	we	O
4	studied	O
5	ninety	O
6	coagulopathic	O
7	patients	O
8	with	O
9	the	O
10	aim	O
11	of	O
12	determining	O
13	the	O
14	prevalence	O
15	of	O
16	hepatitis	B
17	C	I
18	virus	I
19	(	I
20	HCV	I
21	)	I
22	antibodies	I
23	using	O
24	the	O
25	ELISA	O
26	and	O
27	RIBA	O
28	methods	O
29	.	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	Hepatitis	B
2	B	I
3	surface	I
4	antigen	I
5	was	O
6	detected	O
7	in	O
8	2	O
9	patients	O
10	,	O
11	with	O
12	negative	O
13	hepatitis	B
14	C	I
15	virus	I
16	antibody	I
17	.	O

1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O

1	Antibodies	O
2	affinity	O
3	-	O
4	purified	O
5	using	O
6	the	O
7	bacterially	O
8	expressed	O
9	recombinant	O
10	protein	O
11	recognized	O
12	the	O
13	56K	B
14	autoantigen	I
15	in	O
16	a	O
17	HeLa	O
18	cell	O
19	extract	O
20	.	O
21	cDNA	O
22	sequencing	O
23	revealed	O
24	that	O
25	the	O
26	56K	B
27	cDNA	I
28	shares	O
29	a	O
30	high	O
31	degree	O
32	of	O
33	homology	O
34	in	O
35	both	O
36	nucleotide	O
37	(	O
38	87	O
39	%)	O
40	and	O
41	amino	O
42	acid	O
43	sequence	O
44	(	O
45	92	O
46	.	O
47	5	O
48	%)	O
49	with	O
50	bovine	B
51	annexin	I
52	XI	I
53	,	O
54	indicating	O
55	that	O
56	the	O
57	56K	B
58	cDNA	I
59	encodes	O
60	the	O
61	human	B
62	homologue	I
63	of	I
64	annexin	I
65	XI	I
66	,	O
67	a	O
68	member	O
69	of	O
70	the	O
71	Ca	B
72	(	I
73	2	I
74	+)-	I
75	dependent	I
76	phospholipid	I
77	binding	I
78	protein	I
79	family	I
80	.	O

1	The	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	O
8	ABC	B
9	-	I
10	P	I
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	O
31	-	O
32	Neelsen	O
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	Its	O
2	role	O
3	in	O
4	these	O
5	processes	O
6	suggests	O
7	that	O
8	the	O
9	function	O
10	of	O
11	c	B
12	-	I
13	Myb	I
14	may	O
15	be	O
16	important	O
17	early	O
18	in	O
19	the	O
20	establishment	O
21	of	O
22	the	O
23	hematopoietic	O
24	lineage	O
25	.	O

1	The	O
2	transforming	O
3	gene	O
4	of	O
5	the	O
6	avian	B
7	sarcoma	I
8	virus	I
9	CT10	I
10	encodes	O
11	a	O
12	fusion	O
13	protein	O
14	(	O
15	p47gag	B
16	-	O
17	crk	B
18	or	O
19	v	B
20	-	I
21	Crk	I
22	)	O
23	containing	O
24	viral	B
25	Gag	I
26	sequences	I
27	fused	O
28	to	O
29	cellular	O
30	sequences	O
31	consisting	O
32	primarily	O
33	of	O
34	Src	B
35	homology	I
36	regions	I
37	2	I
38	and	I
39	3	I
40	(	O
41	SH2	B
42	and	O
43	SH3	B
44	sequences	I
45	).	O

1	This	O
2	specific	O
3	methylation	O
4	pattern	O
5	caused	O
6	inactivation	O
7	of	O
8	the	O
9	HSV	B
10	tk	I
11	gene	I
12	,	O
13	while	O
14	methylation	O
15	of	O
16	the	O
17	cytosine	O
18	residues	O
19	within	O
20	the	O
21	nucleotide	O
22	sequence	O
23	from	O
24	+	O
25	811	O
26	to	O
27	+	O
28	1309	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	HSV	B
34	tk	I
35	gene	I
36	activity	O
37	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	study	O
5	documents	O
6	that	O
7	regression	O
8	of	O
9	choroidal	O
10	neovascularization	O
11	that	O
12	occurred	O
13	with	O
14	alpha	B
15	interferon	I
16	treatment	O
17	was	O
18	minimal	O
19	.	O

1	Long	O
2	-	O
3	range	O
4	mapping	O
5	of	O
6	the	O
7	11q23	O
8	region	O
9	involved	O
10	in	O
11	chromosome	O
12	aberrations	O
13	in	O
14	human	O
15	tumors	O
16	by	O
17	pulsed	O
18	-	O
19	field	O
20	gel	O
21	electrophoresis	O
22	with	O
23	a	O
24	yeast	O
25	artificial	O
26	chromosome	O
27	.	O

1	GTRE	O
2	,	O
3	TRE	O
4	,	O
5	and	O
6	CRE	O
7	oligonucleotides	O
8	all	O
9	compete	O
10	more	O
11	efficiently	O
12	for	O
13	protein	O
14	binding	O
15	to	O
16	their	O
17	labeled	O
18	congeners	O
19	than	O
20	for	O
21	protein	O
22	binding	O
23	to	O
24	either	O
25	of	O
26	the	O
27	other	O
28	labeled	O
29	oligonucleotides	O
30	,	O
31	suggesting	O
32	that	O
33	the	O
34	GTRE	O
35	,	O
36	TRE	O
37	,	O
38	and	O
39	CRE	O
40	oligonucleotides	O
41	,	O
42	suggesting	O
43	that	O
44	the	O
45	GTRE	O
46	,	O
47	TRE	O
48	,	O
49	and	O
50	CRE	O
51	oligonucleotides	O
52	each	O
53	bind	O
54	unique	O
55	as	O
56	well	O
57	as	O
58	common	O
59	proteins	O
60	,	O
61	likely	O
62	to	O
63	be	O
64	members	O
65	of	O
66	the	O
67	Jun	B
68	/	O
69	Fos	B
70	and	O
71	cAMP	B
72	-	I
73	responsive	I
74	element	I
75	-	I
76	binding	I
77	protein	I
78	/	O
79	activating	B
80	transcription	I
81	factors	I
82	(	O
83	CREB	B
84	/	O
85	ATF	B
86	)	O
87	families	O
88	of	O
89	transcription	O
90	factors	O
91	,	O
92	in	O
93	chromaffin	O
94	cells	O
95	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	One	O
2	antibody	O
3	,	O
4	mAb1C2	B
5	,	O
6	and	O
7	a	O
8	synthetic	O
9	peptide	O
10	comprising	O
11	its	O
12	epitope	O
13	selectively	O
14	inhibited	O
15	in	O
16	vitro	O
17	transcription	O
18	from	O
19	TATA	O
20	-	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	from	O
26	TATA	O
27	-	O
28	less	O
29	promoters	O
30	,	O
31	irrespective	O
32	of	O
33	whether	O
34	they	O
35	were	O
36	transcribed	O
37	by	O
38	Pol	B
39	II	I
40	or	O
41	Pol	B
42	III	I
43	.	O

1	The	O
2	lymph	O
3	nodes	O
4	from	O
5	two	O
6	of	O
7	the	O
8	patients	O
9	with	O
10	rheumatoid	O
11	arthritis	O
12	contained	O
13	numerous	O
14	sarcoid	O
15	like	O
16	granulomata	O
17	,	O
18	further	O
19	indicating	O
20	a	O
21	possible	O
22	association	O
23	between	O
24	sarcoidosis	O
25	and	O
26	rheumatoid	O
27	arthritis	O
28	.	O

1	HCV	O
2	infection	O
3	acquired	O
4	during	O
5	or	O
6	after	O
7	BMT	O
8	caused	O
9	only	O
10	mild	O
11	acute	O
12	hepatitis	O
13	C	O
14	,	O
15	which	O
16	progressed	O
17	to	O
18	chronic	O
19	hepatitis	O
20	C	O
21	in	O
22	one	O
23	patient	O
24	surviving	O
25	10	O
26	years	O
27	after	O
28	BMT	O
29	.	O

1	Hepatitis	O
2	C	O
3	virus	O
4	infection	O
5	is	O
6	a	O
7	risk	O
8	factor	O
9	for	O
10	liver	O
11	failure	O
12	from	O
13	veno	O
14	-	O
15	occlusive	O
16	disease	O
17	after	O
18	bone	O
19	marrow	O
20	transplantation	O
21	.	O

1	High	O
2	plasma	O
3	concentrations	O
4	of	O
5	soluble	O
6	E	B
7	-	I
8	selectin	I
9	were	O
10	closely	O
11	associated	O
12	with	O
13	multiple	O
14	-	O
15	organ	O
16	dysfunction	O
17	and	O
18	death	O
19	.	O

1	These	O
2	human	O
3	IFN	B
4	-	I
5	beta	I
6	-	O
7	transformed	O
8	cell	O
9	populations	O
10	have	O
11	acquired	O
12	a	O
13	low	O
14	,	O
15	constitutive	O
16	production	O
17	of	O
18	human	B
19	IFN	I
20	,	O
21	while	O
22	replicating	O
23	at	O
24	a	O
25	rate	O
26	similar	O
27	to	O
28	that	O
29	of	O
30	untransformed	O
31	cells	O
32	and	O
33	of	O
34	cells	O
35	transformed	O
36	with	O
37	the	O
38	control	O
39	vector	O
40	carrying	O
41	a	O
42	human	B
43	IFN	I
44	-	I
45	beta	I
46	sequence	I
47	encoding	O
48	an	O
49	inactive	O
50	,	O
51	mutated	O
52	protein	O
53	.	O

1	Improvement	O
2	of	O
3	the	O
4	polypyrimidine	O
5	tract	O
6	also	O
7	increased	O
8	the	O
9	splicing	O
10	efficiency	O
11	,	O
12	but	O
13	to	O
14	a	O
15	degree	O
16	slightly	O
17	less	O
18	than	O
19	that	O
20	obtained	O
21	with	O
22	the	O
23	branchpoint	O
24	mutation	O
25	.	O

1	Liver	O
2	transplantation	O
3	in	O
4	one	O
5	patient	O
6	resolved	O
7	metabolic	O
8	complications	O
9	but	O
10	did	O
11	not	O
12	improve	O
13	PMN	O
14	count	O
15	or	O
16	the	O
17	infectious	O
18	status	O
19	,	O
20	while	O
21	neutropenia	O
22	was	O
23	corrected	O
24	by	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	Joys	O
2	and	O
3	F	O
4	.	O

1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	B
12	-	I
13	PTP2	I
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O

1	Tyrosine	O
2	phosphorylation	O
3	of	O
4	cellular	O
5	proteins	O
6	is	O
7	the	O
8	earliest	O
9	identifiable	O
10	event	O
11	following	O
12	T	B
13	-	I
14	cell	I
15	antigen	I
16	receptor	I
17	(	O
18	TCR	B
19	)	O
20	stimulation	O
21	and	O
22	is	O
23	essential	O
24	for	O
25	activating	O
26	downstream	O
27	signaling	O
28	machinery	O
29	.	O

1	The	O
2	interferon	B
3	-	O
4	induced	O
5	RNA	B
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	(	O
11	PKR	B
12	)	O
13	is	O
14	considered	O
15	to	O
16	play	O
17	an	O
18	important	O
19	role	O
20	in	O
21	the	O
22	cellular	O
23	defense	O
24	against	O
25	viral	O
26	infection	O
27	and	O
28	,	O
29	in	O
30	addition	O
31	,	O
32	has	O
33	been	O
34	suggested	O
35	to	O
36	be	O
37	a	O
38	tumor	O
39	suppressor	O
40	gene	O
41	because	O
42	of	O
43	its	O
44	growth	O
45	-	O
46	suppressive	O
47	properties	O
48	.	O

1	Moreover	O
2	,	O
3	Lck	B
4	was	O
5	reversibly	O
6	co	O
7	-	O
8	immunoprecipitated	O
9	with	O
10	p95Vav	B
11	,	O
12	and	O
13	the	O
14	stoichiometry	O
15	of	O
16	binding	O
17	increased	O
18	in	O
19	anti	B
20	-	I
21	CD3	I
22	-	O
23	treated	O
24	Jurkat	O
25	cells	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	injection	O
5	of	O
6	a	O
7	plasmid	O
8	encoding	O
9	simian	B
10	virus	I
11	40	I
12	small	I
13	t	I
14	antigen	I
15	,	O
16	which	O
17	interacts	O
18	with	O
19	PP2A	B
20	to	O
21	inhibit	O
22	its	O
23	activity	O
24	towards	O
25	several	O
26	phosphoprotein	O
27	substrates	O
28	,	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	the	O
34	phosphorylation	O
35	state	O
36	of	O
37	CREB	B
38	in	O
39	stimulated	O
40	or	O
41	unstimulated	O
42	NIH	O
43	3T3	O
44	cells	O
45	.	O

1	Several	O
2	Src	B
3	SH3	I
4	-	I
5	binding	I
6	proteins	I
7	were	O
8	phosphorylated	O
9	in	O
10	Src	B
11	-	O
12	transformed	O
13	cells	O
14	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	effect	O
6	of	O
7	proteolytic	O
8	processing	O
9	in	O
10	the	O
11	MVE	O
12	nonstructural	O
13	polyprotein	O
14	segment	O
15	mediated	O
16	by	O
17	the	O
18	viral	B
19	proteinase	I
20	NS3	I
21	on	O
22	antigen	O
23	processing	O
24	and	O
25	presentation	O
26	of	O
27	the	O
28	MVE	O
29	H	O
30	-	O
31	2Kk	O
32	-	O
33	restricted	O
34	T	O
35	cell	O
36	determinant	O
37	.	O

1	A	O
2	full	B
3	-	I
4	length	I
5	PRL	I
6	receptor	I
7	(	O
8	PRLR	B
9	)	O
10	complementary	O
11	DNA	O
12	from	O
13	pigeons	O
14	was	O
15	obtained	O
16	by	O
17	screening	O
18	pigeon	O
19	crop	O
20	sac	O
21	libraries	O
22	and	O
23	by	O
24	reverse	O
25	transcription	O
26	coupled	O
27	with	O
28	polymerase	O
29	chain	O
30	reaction	O
31	.	O

1	After	O
2	7	O
3	days	O
4	,	O
5	a	O
6	spontaneous	O
7	regression	O
8	of	O
9	the	O
10	morphologic	O
11	alterations	O
12	caused	O
13	by	O
14	caerulein	O
15	-	O
16	induced	O
17	acute	O
18	pancreatitis	O
19	occurs	O
20	;	O
21	however	O
22	,	O
23	recovery	O
24	of	O
25	the	O
26	secretory	O
27	function	O
28	of	O
29	the	O
30	pancreas	O
31	was	O
32	only	O
33	reached	O
34	after	O
35	this	O
36	period	O
37	of	O
38	time	O
39	when	O
40	L	O
41	-	O
42	364	O
43	,	O
44	718	O
45	was	O
46	administered	O
47	therapeutically	O
48	(	O
49	0	O
50	.	O
51	1	O
52	mg	O
53	/	O
54	kg	O
55	/	O
56	day	O
57	).	O

1	We	O
2	observed	O
3	that	O
4	dephosphorylation	O
5	severely	O
6	inhibits	O
7	the	O
8	DNA	O
9	-	O
10	binding	O
11	ability	O
12	of	O
13	C	B
14	/	I
15	EBP	I
16	-	I
17	delta	I
18	and	O
19	its	O
20	transactivating	O
21	potential	O
22	increases	O
23	in	O
24	the	O
25	presence	O
26	of	O
27	cellular	O
28	phosphatase	O
29	inhibitors	O
30	,	O
31	such	O
32	as	O
33	okadaic	O
34	acid	O
35	and	O
36	sodium	O
37	orthovanadate	O
38	.	O

1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O

1	Interleukin	B
2	-	I
3	8	I
4	(	O
5	IL	B
6	-	I
7	8	I
8	)	O
9	is	O
10	a	O
11	potent	O
12	inflammatory	O
13	mediator	O
14	that	O
15	belongs	O
16	to	O
17	the	O
18	family	O
19	of	O
20	C	B
21	-	I
22	X	I
23	-	I
24	C	I
25	chemokines	I
26	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	cells	O
7	containing	O
8	a	O
9	PTP1C	B
10	in	O
11	which	O
12	the	O
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	O
25	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	the	O
6	p72syk	B
7	protein	I
8	tyrosine	I
9	kinase	I
10	is	O
11	physically	O
12	associated	O
13	with	O
14	the	O
15	TCR	B
16	/	O
17	CD3	B
18	complex	O
19	and	O
20	is	O
21	rapidly	O
22	tyrosine	O
23	phosphorylated	O
24	and	O
25	activated	O
26	by	O
27	receptor	O
28	triggering	O
29	also	O
30	in	O
31	T	O
32	cells	O
33	lacking	O
34	p56lck	B
35	.	O

1	The	O
2	transforming	O
3	protein	O
4	of	O
5	Rous	O
6	sarcoma	O
7	virus	O
8	,	O
9	pp60v	B
10	-	I
11	src	I
12	,	O
13	and	O
14	its	O
15	normal	O
16	cellular	O
17	homolog	O
18	,	O
19	pp60c	B
20	-	I
21	src	I
22	,	O
23	differ	O
24	not	O
25	only	O
26	in	O
27	oncogenic	O
28	potential	O
29	but	O
30	also	O
31	in	O
32	their	O
33	subcellular	O
34	localization	O
35	and	O
36	cytoskeletal	O
37	binding	O
38	ability	O
39	.	O
40	pp60v	B
41	-	I
42	src	I
43	has	O
44	been	O
45	shown	O
46	to	O
47	stably	O
48	associate	O
49	with	O
50	a	O
51	detergent	O
52	-	O
53	insoluble	O
54	cytoskeletal	O
55	matrix	O
56	,	O
57	whereas	O
58	pp60c	B
59	-	I
60	src	I
61	does	O
62	not	O
63	.	O

1	Organization	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	B
9	nitric	I
10	oxide	I
11	synthase	I
12	.	O

1	We	O
2	determined	O
3	whether	O
4	regional	O
5	myocardial	O
6	work	O
7	efficiency	O
8	(	O
9	segment	O
10	work	O
11	/	O
12	regional	O
13	O2	O
14	consumption	O
15	)	O
16	would	O
17	be	O
18	elevated	O
19	by	O
20	surgically	O
21	-	O
22	augmented	O
23	inflow	O
24	.	O

1	In	O
2	female	O
3	Sl	B
4	(	I
5	pan	I
6	)/	I
7	Sl	I
8	(	I
9	pan	I
10	)	I
11	mice	O
12	,	O
13	ovarian	O
14	follicle	O
15	development	O
16	is	O
17	arrested	O
18	at	O
19	the	O
20	one	O
21	layered	O
22	cuboidal	O
23	stage	O
24	as	O
25	a	O
26	result	O
27	of	O
28	reduced	O
29	KL	B
30	expression	O
31	in	O
32	follicle	O
33	cells	O
34	,	O
35	indicating	O
36	a	O
37	role	O
38	for	O
39	c	B
40	-	I
41	kit	I
42	in	O
43	oocyte	O
44	growth	O
45	.	O

1	Anti	B
2	-	I
3	NPROSP	I
4	-	I
5	C	I
6	also	O
7	exclusively	O
8	detected	O
9	time	O
10	-	O
11	dependent	O
12	appearances	O
13	of	O
14	5	B
15	-	I
16	10	I
17	-	I
18	kDa	I
19	proSP	I
20	-	I
21	C	I
22	forms	O
23	in	O
24	lamellar	O
25	bodies	O
26	and	O
27	homogenates	O
28	.	O

1	In	O
2	the	O
3	B6	O
4	-	O
5	derived	O
6	Db	B
7	mutant	I
8	B6	I
9	.	I
10	CH	I
11	-	I
12	2bm13	I
13	(	I
14	bm13	I
15	)	I
16	strain	O
17	,	O
18	part	O
19	of	O
20	the	O
21	class	B
22	I	I
23	Db	I
24	antigen	I
25	-	I
26	presenting	I
27	groove	I
28	is	O
29	shaped	O
30	by	O
31	a	O
32	class	B
33	I	I
34	Kb	I
35	-	I
36	encoded	I
37	sequence	I
38	.	O

1	Three	O
2	mutants	O
3	(	O
4	pms1	B
5	,	O
6	pms2	B
7	and	O
8	pms3	B
9	)	O
10	isolated	O
11	earlier	O
12	from	O
13	MW104	O
14	-	O
15	1B	O
16	were	O
17	shown	O
18	to	O
19	correct	O
20	in	O
21	vitro	O
22	constructed	O
23	plasmids	O
24	with	O
25	defined	O
26	DNA	O
27	mismatches	O
28	(	O
29	G	O
30	/	O
31	T	O
32	,	O
33	A	O
34	/	O
35	C	O
36	,	O
37	G	O
38	/	O
39	G	O
40	,	O
41	etc	O
42	.)	O
43	poorly	O
44	(	O
45	Kramer	O
46	et	O
47	al	O
48	.,	O
49	1989a	O
50	).	O

1	Our	O
2	findings	O
3	confirm	O
4	the	O
5	high	O
6	frequency	O
7	of	O
8	proximal	O
9	nerve	O
10	lesions	O
11	in	O
12	early	O
13	GBS	O
14	and	O
15	CIDP	O
16	,	O
17	not	O
18	all	O
19	of	O
20	which	O
21	are	O
22	associated	O
23	with	O
24	distal	O
25	motor	O
26	conduction	O
27	abnormalities	O
28	,	O
29	and	O
30	suggest	O
31	that	O
32	assessment	O
33	of	O
34	multiple	O
35	F	O
36	wave	O
37	parameters	O
38	,	O
39	in	O
40	particular	O
41	chronodispersion	O
42	,	O
43	mean	O
44	latency	O
45	and	O
46	mean	O
47	amplitude	O
48	(	O
49	in	O
50	addition	O
51	to	O
52	absence	O
53	and	O
54	minimum	O
55	latency	O
56	),	O
57	increases	O
58	the	O
59	yield	O
60	of	O
61	F	O
62	wave	O
63	studies	O
64	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	are	O
5	being	O
6	used	O
7	to	O
8	accelerate	O
9	the	O
10	recovery	O
11	of	O
12	myelopoiesis	O
13	following	O
14	high	O
15	-	O
16	dose	O
17	chemotherapy	O
18	in	O
19	cancer	O
20	patients	O
21	.	O

1	Effects	O
2	of	O
3	alterations	O
4	of	O
5	primer	O
6	-	O
7	binding	O
8	site	O
9	sequences	O
10	on	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	type	O
15	1	O
16	replication	O
17	.	O

1	Presentation	O
2	of	O
3	a	O
4	horse	B
5	cytochrome	I
6	c	I
7	peptide	I
8	by	O
9	multiple	O
10	H	B
11	-	I
12	2b	I
13	class	I
14	I	I
15	major	I
16	histocompatibility	I
17	complex	I
18	(	O
19	MHC	B
20	)	O
21	molecules	O
22	to	O
23	C57BL	O
24	/	O
25	6	O
26	-	O
27	and	O
28	bm1	O
29	-	O
30	derived	O
31	cytotoxic	O
32	T	O
33	lymphocytes	O
34	:	O
35	presence	O
36	of	O
37	a	O
38	single	O
39	MHC	B
40	anchor	I
41	residue	I
42	may	O
43	confer	O
44	efficient	O
45	peptide	O
46	-	O
47	specific	O
48	CTL	O
49	recognition	O
50	.	O

1	A	O
2	particularly	O
3	striking	O
4	HpaII	B
5	tiny	O
6	fragment	O
7	island	O
8	,	O
9	extending	O
10	over	O
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	surrounds	O
19	the	O
20	USF2	B
21	translation	I
22	initiation	I
23	site	I
24	.	O

1	Diagnosis	O
2	of	O
3	prostatic	O
4	carcinoma	O
5	:	O
6	the	O
7	yield	O
8	of	O
9	serum	B
10	prostate	I
11	specific	I
12	antigen	I
13	,	O
14	digital	O
15	rectal	O
16	examination	O
17	and	O
18	transrectal	O
19	ultrasonography	O
20	.	O

1	Increased	O
2	granulocyte	B
3	-	I
4	colony	I
5	stimulating	I
6	factor	I
7	(	O
8	G	B
9	-	I
10	CSF	I
11	)	O
12	levels	O
13	in	O
14	neonates	O
15	with	O
16	perinatal	O
17	complications	O
18	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	B
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O

1	When	O
2	expressed	O
3	in	O
4	and	O
5	purified	O
6	from	O
7	Escherichia	O
8	coli	O
9	,	O
10	both	O
11	full	B
12	-	I
13	length	I
14	Fpr3	I
15	and	O
16	its	O
17	isolated	O
18	COOH	O
19	-	O
20	terminal	O
21	domain	O
22	exhibit	O
23	readily	O
24	detectable	O
25	PPIase	B
26	activity	O
27	.	O

1	Dilutions	O
2	of	O
3	H	B
4	-	I
5	2b	I
6	or	I
7	H	I
8	-	I
9	2d	I
10	NP	I
11	peptides	I
12	indicated	O
13	that	O
14	3	O
15	-	O
16	4	O
17	logs	O
18	less	O
19	H	B
20	-	I
21	2b	I
22	NP	I
23	peptide	I
24	was	O
25	required	O
26	to	O
27	sensitize	O
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	O
44	-	O
45	2b	O
46	and	O
47	H	O
48	-	O
49	2d	O
50	major	B
51	histocompatibility	I
52	complex	I
53	molecules	I
54	for	O
55	their	O
56	peptides	O
57	likely	O
58	account	O
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	O
69	-	O
70	2b	O
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O

1	However	O
2	,	O
3	expression	O
4	of	O
5	sigma	B
6	3	I
7	from	O
8	S4	B
9	(	O
10	3	B
11	'	I
12	UTR	I
13	/	I
14	S1	I
15	),	O
16	which	O
17	included	O
18	the	O
19	PKR	B
20	activator	I
21	sequence	I
22	from	O
23	S1	B
24	within	O
25	the	O
26	3	B
27	'-	I
28	UTR	I
29	of	I
30	S4	I
31	,	O
32	was	O
33	comparable	O
34	to	O
35	that	O
36	from	O
37	wild	B
38	-	I
39	type	I
40	S4	I
41	.	O

1	Microvessels	O
2	were	O
3	counted	O
4	in	O
5	a	O
6	x200	O
7	field	O
8	(	O
9	0	O
10	.	O
11	754	O
12	mm2	O
13	)	O
14	in	O
15	the	O
16	area	O
17	of	O
18	maximal	O
19	angiogenesis	O
20	.	O

1	Although	O
2	both	O
3	transfected	O
4	cell	O
5	lines	O
6	contain	O
7	FGF	B
8	-	I
9	1	I
10	cell	I
11	surface	I
12	receptors	I
13	as	O
14	judged	O
15	by	O
16	crosslinking	O
17	studies	O
18	,	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	transfectants	O
24	are	O
25	refractory	O
26	to	O
27	exogenous	O
28	FGF	B
29	-	I
30	1	I
31	,	O
32	whereas	O
33	the	O
34	mutant	O
35	transfectants	O
36	respond	O
37	normally	O
38	.(	O
39	ABSTRACT	O
40	TRUNCATED	O
41	AT	O
42	250	O
43	WORDS	O
44	)	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	activated	O
8	GH	B
9	receptor	I
10	can	O
11	stimulate	O
12	Stat1	B
13	,	O
14	a	O
15	cytoplasmic	O
16	transcription	O
17	factor	O
18	that	O
19	becomes	O
20	tyrosine	O
21	phosphorylated	O
22	and	O
23	translocates	O
24	to	O
25	the	O
26	nucleus	O
27	,	O
28	where	O
29	it	O
30	can	O
31	interact	O
32	with	O
33	specific	O
34	DNA	O
35	sequences	O
36	to	O
37	modulate	O
38	gene	O
39	expression	O
40	.	O

1	In	O
2	viral	O
3	infections	O
4	,	O
5	G	B
6	-	I
7	CSF	I
8	was	O
9	correlated	O
10	with	O
11	mononuclear	O
12	cells	O
13	(	O
14	rs	O
15	=	O
16	0	O
17	.	O
18	41	O
19	,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	05	O
25	),	O
26	white	O
27	blood	O
28	cell	O
29	counts	O
30	(	O
31	rs	O
32	=	O
33	0	O
34	.	O
35	56	O
36	,	O
37	P	O
38	<	O
39	0	O
40	.	O
41	01	O
42	),	O
43	neutrophils	O
44	(	O
45	rs	O
46	=	O
47	0	O
48	.	O
49	41	O
50	,	O
51	P	O
52	<	O
53	0	O
54	.	O
55	05	O
56	)	O
57	and	O
58	CRP	B
59	(	O
60	rs	O
61	=	O
62	0	O
63	.	O
64	47	O
65	,	O
66	P	O
67	<	O
68	0	O
69	.	O
70	05	O
71	).	O

1	Minor	O
2	initiation	O
3	sites	O
4	were	O
5	found	O
6	at	O
7	positions	O
8	-	O
9	128	O
10	,	O
11	-	O
12	111	O
13	,	O
14	-	O
15	91	O
16	,	O
17	and	O
18	-	O
19	74	O
20	.	O

1	Phosphoamino	O
2	acid	O
3	analysis	O
4	of	O
5	radiolabeled	O
6	ASGPR	B
7	subunits	I
8	identified	O
9	Ser	O
10	(	O
11	P	O
12	)	O
13	as	O
14	the	O
15	predominant	O
16	(	O
17	approximately	O
18	95	O
19	%)	O
20	and	O
21	Thr	O
22	(	O
23	P	O
24	)	O
25	as	O
26	a	O
27	minor	O
28	(	O
29	approximately	O
30	5	O
31	%)	O
32	phosphoamino	O
33	acid	O
34	in	O
35	each	O
36	polypeptide	O
37	and	O
38	confirmed	O
39	the	O
40	presence	O
41	of	O
42	Tyr	O
43	(	O
44	P	O
45	)	O
46	(	O
47	approximately	O
48	1	O
49	%)	O
50	in	O
51	RHL1	B
52	.	O

1	To	O
2	further	O
3	define	O
4	the	O
5	structural	O
6	requirements	O
7	for	O
8	ZAP	B
9	-	I
10	70	I
11	interaction	O
12	with	O
13	the	O
14	TCR	B
15	,	O
16	we	O
17	developed	O
18	a	O
19	binding	O
20	assay	O
21	using	O
22	immobilized	O
23	glutathione	B
24	S	I
25	-	I
26	transferase	I
27	fusion	I
28	proteins	I
29	containing	O
30	the	O
31	NH2	O
32	-	O
33	and	O
34	/	O
35	or	O
36	COOH	B
37	-	I
38	terminal	I
39	SH2	I
40	domains	I
41	of	O
42	ZAP	B
43	-	I
44	70	I
45	,	O
46	and	O
47	soluble	O
48	synthetic	O
49	peptides	O
50	with	O
51	the	O
52	sequence	O
53	of	O
54	the	O
55	cytoplasmic	O
56	region	O
57	of	O
58	the	O
59	TCR	B
60	zeta	I
61	chain	I
62	(	O
63	TCR	B
64	zeta	I
65	cyt	I
66	)	O
67	or	O
68	individual	O
69	TCR	B
70	zeta	I
71	and	O
72	CD3	B
73	epsilon	I
74	TAM	I
75	motifs	I
76	.	O

1	All	O
2	four	O
3	doubly	O
4	tyrosine	O
5	phosphorylated	O
6	TAM	O
7	peptides	O
8	cross	O
9	-	O
10	compete	O
11	with	O
12	each	O
13	other	O
14	for	O
15	binding	O
16	to	O
17	the	O
18	tandem	O
19	SH2	B
20	domains	I
21	of	O
22	ZAP	B
23	-	I
24	70	I
25	.	O

1	The	O
2	three	O
3	-	O
4	dimensional	O
5	structure	O
6	of	O
7	RT	B
8	shows	O
9	that	O
10	it	O
11	is	O
12	a	O
13	strikingly	O
14	asymmetric	O
15	heterodimer	O
16	consisting	O
17	of	O
18	two	O
19	differently	O
20	folded	O
21	subunits	O
22	(	O
23	molecular	O
24	weights	O
25	66	O
26	kDa	O
27	and	O
28	51	O
29	kDa	O
30	)	O
31	with	O
32	identical	O
33	amino	O
34	-	O
35	terminal	O
36	amino	O
37	acid	O
38	sequences	O
39	(	O
40	residues	O
41	1	O
42	-	O
43	428	O
44	).	O

1	Pharmacological	O
2	and	O
3	pharmacokinetic	O
4	characteristics	O
5	of	O
6	the	O
7	non	O
8	-	O
9	ionic	O
10	monomeric	O
11	X	O
12	-	O
13	ray	O
14	contrast	O
15	agent	O
16	iopromide	O
17	(	O
18	Ultravist	O
19	,	O
20	CAS	O
21	73334	O
22	-	O
23	07	O
24	-	O
25	3	O
26	)	O
27	were	O
28	evaluated	O
29	in	O
30	preclinical	O
31	studies	O
32	.	O

1	All	O
2	subsequent	O
3	patients	O
4	were	O
5	treated	O
6	at	O
7	the	O
8	maximal	O
9	tolerated	O
10	dose	O
11	of	O
12	EDXR	O
13	(	O
14	35	O
15	mg	O
16	/	O
17	m2	O
18	/	O
19	day	O
20	).	O

1	The	O
2	median	O
3	post	O
4	-	O
5	treatment	O
6	,	O
7	pre	O
8	-	O
9	operative	O
10	serum	B
11	PSA	I
12	was	O
13	0	O
14	.	O
15	4	O
16	ng	O
17	/	O
18	ml	O
19	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	B
5	human	I
6	SLF	I
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	B
19	-	I
20	kit	I
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	Membrane	O
2	-	O
3	bound	O
4	Steel	B
5	factor	I
6	induces	O
7	more	O
8	persistent	O
9	tyrosine	B
10	kinase	I
11	activation	O
12	and	O
13	longer	O
14	life	O
15	span	O
16	of	O
17	c	B
18	-	I
19	kit	I
20	gene	O
21	-	O
22	encoded	O
23	protein	O
24	than	O
25	its	O
26	soluble	O
27	form	O
28	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequences	O
5	with	O
6	the	O
7	BLAST	O
8	and	O
9	GRAIL	O
10	programs	O
11	provided	O
12	additional	O
13	independent	O
14	evidence	O
15	that	O
16	15	O
17	of	O
18	these	O
19	17	O
20	clones	O
21	contain	O
22	coding	O
23	sequences	O
24	and	O
25	that	O
26	nine	O
27	other	O
28	clones	O
29	are	O
30	likely	O
31	to	O
32	contain	O
33	sequences	O
34	coding	O
35	for	O
36	portions	O
37	of	O
38	new	O
39	genes	O
40	.	O

1	Patients	O
2	with	O
3	more	O
4	than	O
5	250	O
6	PVC	O
7	/	O
8	24	O
9	hours	O
10	were	O
11	selected	O
12	for	O
13	distribution	O
14	of	O
15	PVC	O
16	and	O
17	CI	O
18	evaluation	O
19	.	O

1	Horvath	O
2	,	O
3	I	O
4	.	O

1	Cell	O
2	lines	O
3	derived	O
4	from	O
5	the	O
6	tumors	O
7	were	O
8	examined	O
9	by	O
10	fluorescent	O
11	in	O
12	situ	O
13	hybridization	O
14	for	O
15	the	O
16	status	O
17	of	O
18	the	O
19	transferred	O
20	human	O
21	chromosome	O
22	and	O
23	by	O
24	PCR	O
25	for	O
26	marker	O
27	loss	O
28	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	predicted	O
8	RfbA	B
9	and	O
10	RfbB	B
11	homologs	I
12	showed	O
13	identities	O
14	of	O
15	75	O
16	.	O
17	7	O
18	%	O
19	(	O
20	87	O
21	.	O
22	9	O
23	%	O
24	total	O
25	similarity	O
26	)	O
27	and	O
28	78	O
29	.	O
30	0	O
31	%	O
32	(	O
33	86	O
34	.	O
35	5	O
36	%	O
37	total	O
38	similarity	O
39	),	O
40	respectively	O
41	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	B
21	EFP	I
22	.	O

1	The	O
2	FinO	B
3	protein	I
4	of	O
5	IncF	O
6	plasmids	O
7	binds	O
8	FinP	B
9	antisense	I
10	RNA	I
11	and	O
12	its	O
13	target	O
14	,	O
15	traJ	B
16	mRNA	I
17	,	O
18	and	O
19	promotes	O
20	duplex	O
21	formation	O
22	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	report	O
6	that	O
7	ligand	O
8	binding	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	in	O
13	BaF3	O
14	cells	O
15	engineered	O
16	to	O
17	express	O
18	the	O
19	murine	B
20	Mpl	I
21	receptor	I
22	(	O
23	BaF3	O
24	/	O
25	mMpl	B
26	).	O

1	A	O
2	chicken	B
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O

1	We	O
2	linked	O
3	a	O
4	4	O
5	.	O
6	1	O
7	-	O
8	kilobase	O
9	pair	O
10	HindIII	B
11	DNA	I
12	fragment	I
13	from	O
14	the	O
15	region	O
16	upstream	O
17	of	O
18	the	O
19	human	B
20	AP	I
21	endonuclease	I
22	gene	I
23	(	O
24	APE	B
25	)	O
26	to	O
27	the	O
28	chloramphenicol	B
29	acetyltransferase	I
30	(	O
31	CAT	B
32	)	O
33	gene	O
34	.	O

1	The	O
2	overexpressed	O
3	His6	B
4	-	I
5	tagged	I
6	GrsA	I
7	derivatives	I
8	were	O
9	affinity	O
10	-	O
11	purified	O
12	,	O
13	and	O
14	the	O
15	catalytic	O
16	properties	O
17	of	O
18	the	O
19	deletion	O
20	mutants	O
21	were	O
22	examined	O
23	by	O
24	biochemical	O
25	studies	O
26	including	O
27	ATP	O
28	-	O
29	dependent	O
30	amino	O
31	acid	O
32	activation	O
33	,	O
34	carboxyl	O
35	thioester	O
36	formation	O
37	,	O
38	and	O
39	the	O
40	ability	O
41	to	O
42	racemize	O
43	the	O
44	covalently	O
45	bound	O
46	phenylalanine	O
47	from	O
48	L	O
49	-	O
50	to	O
51	the	O
52	D	O
53	-	O
54	isomer	O
55	.	O

1	CD7	B
2	+/	O
3	CD3	B
4	-	O
5	T	O
6	-	O
7	cell	O
8	precursors	O
9	exhibit	O
10	V	B
11	delta	I
12	2D	I
13	delta	I
14	3	I
15	rearrangements	I
16	.	O

1	HVH2	B
2	mRNA	I
3	showed	O
4	an	O
5	expression	O
6	pattern	O
7	distinct	O
8	from	O
9	CL100	B
10	(	O
11	human	B
12	homologue	I
13	of	I
14	mouse	I
15	MKP1	I
16	)	O
17	and	O
18	PAC1	B
19	,	O
20	two	O
21	previously	O
22	identified	O
23	MAP	B
24	kinase	I
25	phosphatases	I
26	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	B
17	-	I
18	3	I
19	deletion	I
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	B
41	gamma	I
42	-	I
43	globin	I
44	genes	I
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O

1	In	O
2	vivo	O
3	association	O
4	between	O
5	Shb	B
6	-	O
7	SH3	B
8	domain	O
9	proteins	O
10	v	B
11	-	I
12	Src	I
13	and	O
14	Eps8	B
15	was	O
16	detected	O
17	by	O
18	coimmunoprecipitation	O
19	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	interaction	O
6	between	O
7	Jak2	B
8	and	O
9	PRLR	B
10	requires	O
11	a	O
12	proline	O
13	-	O
14	rich	O
15	sequence	O
16	in	O
17	the	O
18	membrane	O
19	proximal	O
20	region	O
21	of	O
22	the	O
23	receptor	O
24	,	O
25	which	O
26	is	O
27	conserved	O
28	among	O
29	the	O
30	different	O
31	members	O
32	of	O
33	the	O
34	cytokine	B
35	receptor	I
36	superfamily	I
37	.	O

1	Transcription	O
2	of	O
3	the	O
4	vascular	B
5	cell	I
6	adhesion	I
7	molecule	I
8	1	I
9	(	O
10	VCAM	B
11	-	I
12	1	I
13	)	O
14	gene	O
15	in	O
16	endothelial	O
17	cells	O
18	is	O
19	induced	O
20	by	O
21	lipopolysaccharide	O
22	and	O
23	the	O
24	inflammatory	O
25	cytokines	B
26	interleukin	I
27	-	I
28	1	I
29	beta	I
30	and	O
31	tumor	B
32	necrosis	I
33	factor	I
34	alpha	I
35	(	O
36	TNF	B
37	-	I
38	alpha	I
39	).	O

1	Experiments	O
2	with	O
3	recombinant	O
4	proteins	O
5	showed	O
6	that	O
7	p50	B
8	/	O
9	p65	B
10	and	O
11	high	B
12	-	I
13	mobility	I
14	-	I
15	group	I
16	I	I
17	(	I
18	Y	I
19	)	I
20	protein	I
21	cooperatively	O
22	facilitated	O
23	the	O
24	binding	O
25	of	O
26	IRF	B
27	-	I
28	1	I
29	to	O
30	the	O
31	VCAM1	B
32	IRF	I
33	binding	I
34	site	I
35	and	O
36	that	O
37	IRF	B
38	-	I
39	1	I
40	physically	O
41	interacted	O
42	with	O
43	p50	B
44	and	O
45	with	O
46	high	B
47	-	I
48	mobility	I
49	-	I
50	group	I
51	I	I
52	(	I
53	Y	I
54	)	I
55	protein	I
56	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	the	O
6	minimal	O
7	control	O
8	element	O
9	(	O
10	AX	O
11	470	O
12	)	O
13	specifying	O
14	the	O
15	anterior	O
16	boundary	O
17	of	O
18	Hox	B
19	expression	O
20	was	O
21	designated	O
22	as	O
23	Hoxa	B
24	-	I
25	7	I
26	enhancer	I
27	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	the	O
7	isolation	O
8	of	O
9	a	O
10	Fab	B
11	fragment	I
12	(	O
13	Fab	B
14	A8	I
15	)	O
16	showing	O
17	a	O
18	high	O
19	relative	O
20	affinity	O
21	for	O
22	the	O
23	receptor	O
24	(	O
25	0	O
26	.	O
27	5	O
28	nM	O
29	).	O

1	MBP	B
2	-	O
3	Rep68	B
4	delta	I
5	-	O
6	mediated	O
7	DNA	O
8	-	O
9	RNA	O
10	helicase	O
11	activity	O
12	required	O
13	ATP	O
14	hydrolysis	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	Mg2	O
20	+	O
21	ions	O
22	and	O
23	was	O
24	inhibited	O
25	by	O
26	high	O
27	ionic	O
28	strength	O
29	.	O

1	To	O
2	identify	O
3	critical	O
4	regions	O
5	mediating	O
6	growth	O
7	signal	O
8	transduction	O
9	by	O
10	hG	B
11	-	I
12	CSFR	I
13	,	O
14	deletions	O
15	or	O
16	site	O
17	-	O
18	directed	O
19	amino	O
20	acid	O
21	substitutions	O
22	were	O
23	introduced	O
24	into	O
25	the	O
26	cytoplasmic	O
27	domain	O
28	of	O
29	hG	B
30	-	I
31	CSFR	I
32	,	O
33	and	O
34	the	O
35	mutant	O
36	cDNAs	O
37	were	O
38	transfected	O
39	into	O
40	the	O
41	murine	B
42	interleukin	I
43	-	I
44	3	I
45	(	O
46	IL	B
47	-	I
48	3	I
49	)-	O
50	dependent	O
51	Ba	O
52	/	O
53	F3	O
54	and	O
55	FDCP	O
56	cell	O
57	lines	O
58	.	O

1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	I
11	abl	I
12	kinase	I
13	domain	I
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	B
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	B
33	mutant	I
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O

1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	Abl	B
9	SH3	I
10	domain	O
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O

1	Changes	O
2	induced	O
3	in	O
4	the	O
5	gills	O
6	of	O
7	milkfish	O
8	(	O
9	Chanos	O
10	chanos	O
11	Forsskal	O
12	)	O
13	fingerlings	O
14	after	O
15	acute	O
16	exposure	O
17	to	O
18	nifurpirinol	O
19	(	O
20	Furanace	O
21	;	O
22	P	O
23	-	O
24	7138	O
25	).	O

1	Retreatment	O
2	of	O
3	these	O
4	2	O
5	dogs	O
6	resulted	O
7	in	O
8	a	O
9	similar	O
10	,	O
11	but	O
12	blunted	O
13	,	O
14	response	O
15	to	O
16	human	B
17	immunoglobulin	I
18	.	O

1	The	O
2	levels	O
3	of	O
4	NSE	B
5	and	O
6	MBP	B
7	in	O
8	the	O
9	IJVB	O
10	were	O
11	compared	O
12	to	O
13	those	O
14	in	O
15	the	O
16	PVB	O
17	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	insulin	B
6	effect	O
7	to	O
8	increase	O
9	ras	B
10	GTP	I
11	formation	O
12	and	O
13	MAP	B
14	kinase	I
15	activity	O
16	was	O
17	negligible	O
18	in	O
19	A	O
20	/	O
21	K1018	O
22	cells	O
23	but	O
24	normal	O
25	,	O
26	or	O
27	supernormal	O
28	,	O
29	in	O
30	Y	O
31	/	O
32	F2	O
33	cells	O
34	.	O

1	Morphologic	O
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	histologic	O
8	grade	O
9	,	O
10	capsular	O
11	penetration	O
12	,	O
13	seminal	O
14	vesicle	O
15	invasion	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	these	O
5	regions	O
6	showed	O
7	a	O
8	CAAT	O
9	box	O
10	upstream	O
11	of	O
12	exon	O
13	1a	O
14	and	O
15	high	O
16	G	O
17	-	O
18	C	O
19	content	O
20	regions	O
21	within	O
22	both	O
23	P1	O
24	and	O
25	P2	O
26	.	O

1	The	O
2	fusion	O
3	proteins	O
4	were	O
5	tested	O
6	by	O
7	ELISA	O
8	for	O
9	reactivity	O
10	with	O
11	a	O
12	panel	O
13	of	O
14	human	B
15	anti	I
16	-	I
17	La	I
18	sera	I
19	in	O
20	order	O
21	to	O
22	define	O
23	the	O
24	nature	O
25	of	O
26	the	O
27	epitopes	O
28	.	O

1	GCD10	B
2	was	O
3	first	O
4	identified	O
5	genetically	O
6	as	O
7	a	O
8	translational	O
9	repressor	O
10	of	O
11	GCN4	B
12	.	O

1	GCD10	B
2	binds	O
3	RNA	O
4	in	O
5	vitro	O
6	and	O
7	we	O
8	present	O
9	strong	O
10	biochemical	O
11	evidence	O
12	that	O
13	it	O
14	is	O
15	identical	O
16	to	O
17	the	O
18	RNA	O
19	-	O
20	binding	O
21	subunit	O
22	of	O
23	yeast	B
24	initiation	I
25	factor	I
26	-	I
27	3	I
28	(	O
29	eIF	B
30	-	I
31	3	I
32	).	O
33	eIF	B
34	-	I
35	3	I
36	is	O
37	a	O
38	multisubunit	O
39	complex	O
40	that	O
41	stimulates	O
42	translation	O
43	initiation	O
44	in	O
45	vitro	O
46	at	O
47	several	O
48	different	O
49	steps	O
50	.	O

1	Sources	O
2	of	O
3	noise	O
4	in	O
5	these	O
6	signals	O
7	were	O
8	evaluated	O
9	in	O
10	preparations	O
11	stained	O
12	with	O
13	the	O
14	potentiometric	O
15	probe	O
16	RH	O
17	-	O
18	414	O
19	.	O

1	1993	O
2	.	O

1	A	O
2	transformation	O
3	-	O
4	competent	O
5	mutant	O
6	,	O
7	like	O
8	the	O
9	wild	B
10	-	I
11	type	I
12	E5	I
13	protein	I
14	,	O
15	bound	O
16	the	O
17	receptor	O
18	and	O
19	induced	O
20	receptor	O
21	tyrosine	O
22	phosphorylation	O
23	and	O
24	down	O
25	-	O
26	regulation	O
27	.	O

1	We	O
2	conclude	O
3	that	O
4	cAMP	O
5	,	O
6	acting	O
7	through	O
8	PKA	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	regulator	O
14	of	O
15	basal	O
16	CFTR	B
17	gene	I
18	expression	O
19	and	O
20	may	O
21	mediate	O
22	an	O
23	induction	O
24	of	O
25	CFTR	B
26	in	O
27	responsive	O
28	cell	O
29	types	O
30	.	O

1	Appropriate	O
2	restriction	O
3	sites	O
4	allow	O
5	one	O
6	to	O
7	insert	O
8	virtually	O
9	any	O
10	desired	O
11	cDNA	O
12	fragment	O
13	directly	O
14	behind	O
15	the	O
16	epitope	O
17	-	O
18	specific	O
19	sequence	O
20	and	O
21	before	O
22	a	O
23	long	O
24	poly	O
25	(	O
26	A	O
27	)	O
28	tail	O
29	.	O

1	Both	O
2	PPC	O
3	-	O
4	1	O
5	and	O
6	ALVA	O
7	-	O
8	31	O
9	cells	O
10	display	O
11	tumorigenesis	O
12	and	O
13	invasiveness	O
14	in	O
15	nude	O
16	mice	O
17	,	O
18	whereas	O
19	LNCap	O
20	cells	O
21	exhibit	O
22	a	O
23	less	O
24	malignant	O
25	phenotype	O
26	,	O
27	suggesting	O
28	a	O
29	correlation	O
30	between	O
31	CD44	B
32	variant	I
33	(	O
34	CD44v	B
35	)	O
36	expression	O
37	and	O
38	aggressive	O
39	prostate	O
40	tumor	O
41	behavior	O
42	.	O

1	The	O
2	gene	O
3	product	O
4	of	O
5	cotS	B
6	was	O
7	confirmed	O
8	to	O
9	be	O
10	identical	O
11	to	O
12	Cot40	B
13	-	I
14	2	I
15	by	O
16	SDS	O
17	-	O
18	PAGE	O
19	and	O
20	immunoblotting	O
21	from	O
22	Escherichia	O
23	coli	O
24	transformed	O
25	with	O
26	a	O
27	plasmid	O
28	containing	O
29	the	O
30	cotS	B
31	region	I
32	.	O

1	Two	O
2	such	O
3	genes	O
4	,	O
5	designated	O
6	hsiggll150	B
7	and	O
8	hsiggll295	B
9	,	O
10	were	O
11	cloned	O
12	and	O
13	sequenced	O
14	from	O
15	genomic	O
16	DNA	O
17	.	O

1	A	O
2	retrospective	O
3	epidemiological	O
4	study	O
5	is	O
6	reported	O
7	concerning	O
8	burn	O
9	injuries	O
10	in	O
11	775	O
12	children	O
13	hospitalized	O
14	at	O
15	the	O
16	unit	O
17	of	O
18	burn	O
19	care	O
20	of	O
21	Casablanca	O
22	between	O
23	1985	O
24	and	O
25	1993	O
26	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	protein	O
6	binding	O
7	to	O
8	the	O
9	E2F	B
10	-	I
11	like	I
12	sequences	I
13	may	O
14	act	O
15	to	O
16	reduce	O
17	expression	O
18	.	O

1	The	O
2	RAD6	B
3	/	O
4	UBC2	B
5	gene	O
6	from	O
7	Saccharomyces	O
8	cerevisiae	O
9	encodes	O
10	a	O
11	ubiquitin	B
12	-	I
13	conjugating	I
14	enzyme	I
15	involved	O
16	in	O
17	DNA	O
18	repair	O
19	,	O
20	induced	O
21	mutagenesis	O
22	,	O
23	and	O
24	sporulation	O
25	.	O

1	Echocardiography	O
2	revealed	O
3	right	O
4	ventricular	O
5	diastolic	O
6	collapse	O
7	(	O
8	RVDC	O
9	)	O
10	without	O
11	physical	O
12	signs	O
13	of	O
14	cardiac	O
15	tamponade	O
16	.	O

1	In	O
2	on	O
3	-	O
4	going	O
5	screening	O
6	programmes	O
7	,	O
8	the	O
9	Haemoccult	O
10	test	O
11	consists	O
12	of	O
13	six	O
14	slides	O
15	and	O
16	a	O
17	test	O
18	is	O
19	considered	O
20	positive	O
21	if	O
22	at	O
23	least	O
24	one	O
25	slide	O
26	is	O
27	coloured	O
28	.	O

1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	p40	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O

1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	B
12	184	I
13	HNF	I
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O

1	In	O
2	4	O
3	spinalized	O
4	cats	O
5	,	O
6	the	O
7	effects	O
8	of	O
9	afferent	O
10	inputs	O
11	from	O
12	hindlimb	O
13	cutaneous	O
14	nerves	O
15	(	O
16	sural	O
17	cutaneous	O
18	nerve	O
19	:	O
20	Sur	O
21	)	O
22	on	O
23	mono	O
24	-	O
25	and	O
26	poly	O
27	-	O
28	synaptic	O
29	reflex	O
30	recorded	O
31	from	O
32	tail	O
33	muscle	O
34	motoneurons	O
35	were	O
36	studied	O
37	before	O
38	and	O
39	after	O
40	spinal	O
41	lesioning	O
42	at	O
43	S2	O
44	-	O
45	3	O
46	level	O
47	.	O

1	The	O
2	flow	O
3	rate	O
4	of	O
5	phosphate	O
6	buffered	O
7	saline	O
8	through	O
9	dermis	O
10	was	O
11	measured	O
12	as	O
13	a	O
14	function	O
15	of	O
16	applied	O
17	pressure	O
18	.	O

1	However	O
2	,	O
3	parallax	O
4	measurements	O
5	showed	O
6	that	O
7	at	O
8	150K	O
9	,	O
10	collapse	O
11	of	O
12	Epon	O
13	sections	O
14	does	O
15	not	O
16	take	O
17	place	O
18	.	O

1	Although	O
2	within	O
3	normal	O
4	limits	O
5	,	O
6	latency	O
7	was	O
8	high	O
9	.	O

1	The	O
2	outcome	O
3	of	O
4	the	O
5	optimization	O
6	of	O
7	the	O
8	seven	O
9	-	O
10	field	O
11	plan	O
12	prompted	O
13	an	O
14	investigation	O
15	into	O
16	the	O
17	best	O
18	results	O
19	that	O
20	could	O
21	be	O
22	achieved	O
23	by	O
24	an	O
25	"	O
26	ideal	O
27	"	O
28	conformal	O
29	radiotherapy	O
30	technique	O
31	.	O

1	Specific	O
2	requirements	O
3	for	O
4	branched	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	glutamine	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O

1	The	O
2	pea	B
3	rps10	I
4	intron	I
5	is	O
6	homologous	O
7	to	O
8	introns	O
9	in	O
10	rrn26	B
11	and	O
12	cox3	B
13	in	O
14	the	O
15	Marchantia	O
16	mitochondrial	O
17	genome	O
18	,	O
19	while	O
20	the	O
21	Marchantia	B
22	rps10	I
23	gene	I
24	lacks	O
25	an	O
26	intron	O
27	.	O

1	The	O
2	optimal	O
3	care	O
4	of	O
5	CHF	O
6	patient	O
7	includes	O
8	the	O
9	recognition	O
10	and	O
11	management	O
12	of	O
13	these	O
14	electrolyte	O
15	disturbances	O
16	.	O

1	Serum	O
2	magnesium	O
3	in	O
4	79	O
5	patients	O
6	of	O
7	gynecologic	O
8	neoplasms	O
9	treated	O
10	with	O
11	cisplatin	O
12	and	O
13	their	O
14	controls	O
15	was	O
16	measured	O
17	.	O

1	METHODS	O
2	:	O
3	rHb1	B
4	.	I
5	1	I
6	or	O
7	human	B
8	serum	I
9	albumin	I
10	was	O
11	administered	O
12	intravenously	O
13	to	O
14	fasting	O
15	male	O
16	volunteers	O
17	.	O

1	Alanine	B
2	aminotransferase	I
3	(	O
4	ALT	B
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	investigated	O
7	the	O
8	role	O
9	of	O
10	C	B
11	/	I
12	EBP	I
13	beta	I
14	in	O
15	initiating	O
16	the	O
17	adipogenic	O
18	program	O
19	by	O
20	overexpressing	O
21	C	B
22	/	I
23	EBP	I
24	beta	I
25	in	O
26	multipotential	O
27	NIH	O
28	-	O
29	3T3	O
30	fibroblasts	O
31	.	O

1	XYL1	B
2	was	O
3	isolated	O
4	as	O
5	a	O
6	highly	O
7	expressed	O
8	fusion	O
9	clone	O
10	from	O
11	a	O
12	'	B
13	lacZ	I
14	translational	O
15	fusion	O
16	library	O
17	.	O

1	Various	O
2	transcripts	O
3	are	O
4	generated	O
5	from	O
6	the	O
7	VCSA1	B
8	gene	I
9	by	O
10	alternative	O
11	splicing	O
12	and	O
13	poly	O
14	(	O
15	A	O
16	)	O
17	processing	O
18	in	O
19	the	O
20	rat	O
21	submandibular	O
22	gland	O
23	.	O

1	However	O
2	,	O
3	division	O
4	of	O
5	the	O
6	chest	O
7	wall	O
8	muscles	O
9	,	O
10	usually	O
11	with	O
12	diathermy	O
13	,	O
14	contributes	O
15	to	O
16	prolonged	O
17	pain	O
18	and	O
19	morbidity	O
20	.	O

1	Closure	O
2	of	O
3	an	O
4	open	O
5	high	O
6	below	O
7	-	O
8	knee	O
9	guillotine	O
10	amputation	O
11	wound	O
12	using	O
13	a	O
14	skin	O
15	-	O
16	stretching	O
17	device	O
18	.	O

1	Our	O
2	study	O
3	was	O
4	addressed	O
5	to	O
6	the	O
7	synthesis	O
8	of	O
9	some	O
10	derivatives	O
11	of	O
12	this	O
13	sequence	O
14	in	O
15	order	O
16	to	O
17	obtain	O
18	both	O
19	peptide	O
20	substrates	O
21	suitable	O
22	for	O
23	the	O
24	detection	O
25	of	O
26	the	O
27	Src	B
28	-	O
29	like	O
30	tyrosine	B
31	kinase	I
32	activity	O
33	and	O
34	active	O
35	site	O
36	-	O
37	directed	O
38	inhibitors	O
39	specific	O
40	for	O
41	this	O
42	class	O
43	of	O
44	enzymes	O
45	.	O

1	Citrate	B
2	synthase	I
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	putative	O
6	operon	O
7	bglPH	B
8	of	O
9	Bacillus	O
10	subtilis	O
11	was	O
12	studied	O
13	by	O
14	using	O
15	bglP	O
16	'-	O
17	lacZ	B
18	transcriptional	O
19	fusions	O
20	.	O

1	Although	O
2	eight	O
3	contiguous	O
4	genes	O
5	necessary	O
6	for	O
7	urease	B
8	activity	O
9	have	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	the	O
16	transcriptional	O
17	organization	O
18	and	O
19	regulation	O
20	of	O
21	specific	O
22	genes	O
23	within	O
24	the	O
25	Proteus	B
26	gene	I
27	cluster	I
28	has	O
29	not	O
30	been	O
31	investigated	O
32	in	O
33	detail	O
34	.	O

1	The	O
2	hypBFCDE	B
3	operon	I
4	from	O
5	Rhizobium	O
6	leguminosarum	O
7	biovar	O
8	viciae	O
9	is	O
10	expressed	O
11	from	O
12	an	O
13	Fnr	B
14	-	I
15	type	I
16	promoter	I
17	that	O
18	escapes	O
19	mutagenesis	O
20	of	O
21	the	O
22	fnrN	B
23	gene	I
24	.	O

1	We	O
2	demonstrate	O
3	that	O
4	a	O
5	VT	O
6	+	O
7	peptide	O
8	was	O
9	specifically	O
10	phosphorylated	O
11	by	O
12	protein	B
13	kinase	I
14	C	I
15	(	O
16	PKC	B
17	)	O
18	in	O
19	vitro	O
20	,	O
21	but	O
22	not	O
23	by	O
24	protein	B
25	kinase	I
26	A	I
27	(	O
28	PKA	B
29	).	O

1	R	O
2	.	O

1	15	O
2	,	O
3	2500	O
4	-	O
5	2508	O
6	;	O
7	O	O
8	'	O
9	Neill	O
10	,	O
11	T	O
12	.	O

1	Control	O
2	experiments	O
3	showed	O
4	that	O
5	each	O
6	fusion	O
7	protein	O
8	had	O
9	a	O
10	high	O
11	affinity	O
12	binding	O
13	site	O
14	for	O
15	estradiol	O
16	-	O
17	17	O
18	beta	O
19	and	O
20	could	O
21	transactivate	O
22	an	O
23	ERE	O
24	-	O
25	LacZ	B
26	reporter	O
27	gene	O
28	in	O
29	yeast	O
30	similar	O
31	to	O
32	the	O
33	wild	B
34	type	I
35	ER	I
36	.	O

1	Although	O
2	Micrococcus	B
3	luteus	I
4	UV	I
5	endonuclease	I
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	B
22	-	I
23	kDa	I
24	endonuclease	I
25	V	I
26	from	I
27	bacteriophage	I
28	T4	I
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O

1	Several	O
2	different	O
3	oncogenes	O
4	and	O
5	growth	O
6	factors	O
7	promote	O
8	G1	O
9	phase	O
10	progression	O
11	.	O

1	Cyclin	B
2	D1	I
3	promoter	I
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	(	O
16	p41MAPK	B
17	)	O
18	or	O
19	c	B
20	-	I
21	Ets	I
22	-	I
23	2	I
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O

1	Indeed	O
2	,	O
3	ERM	B
4	and	O
5	c	B
6	-	I
7	Jun	I
8	synergistically	O
9	activated	O
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O

1	A	O
2	mutant	O
3	(	O
4	residues	O
5	1	O
6	-	O
7	332	O
8	)	O
9	showed	O
10	complete	O
11	Ca2	O
12	+/	O
13	CaM	B
14	-	O
15	dependent	O
16	activity	O
17	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	R206S	B
6	HSF	I
7	substitution	O
8	exhibits	O
9	constitutive	O
10	transcriptional	O
11	activation	O
12	from	O
13	a	O
14	consensus	O
15	HSE	O
16	(	O
17	HSE2	O
18	).	O

1	The	O
2	two	O
3	bases	O
4	immediately	O
5	flanking	O
6	the	O
7	5	O
8	'	O
9	end	O
10	of	O
11	the	O
12	element	O
13	proved	O
14	to	O
15	be	O
16	very	O
17	important	O
18	to	O
19	its	O
20	function	O
21	as	O
22	a	O
23	UAS	O
24	element	O
25	as	O
26	did	O
27	the	O
28	two	O
29	bases	O
30	immediately	O
31	3	O
32	'	O
33	of	O
34	the	O
35	bHLH	O
36	core	O
37	motif	O
38	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	PCNA	B
7	gene	I
8	is	O
9	a	O
10	likely	O
11	target	O
12	gene	O
13	of	O
14	E2F	B
15	.	O

1	Differential	O
2	sensitivity	O
3	of	O
4	the	O
5	MMPI	O
6	-	O
7	2	O
8	depression	O
9	scales	O
10	and	O
11	subscales	O
12	.	O

1	After	O
2	recovery	O
3	,	O
4	a	O
5	hypertonic	O
6	saline	O
7	challenge	O
8	was	O
9	performed	O
10	.	O

1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	O
20	nadir	O
21	33	O
22	%).	O

1	Comparisons	O
2	of	O
3	rrnB	B
4	P1	I
5	-	O
6	lacZ	B
7	expression	O
8	at	O
9	different	O
10	ppGpp	O
11	levels	O
12	is	O
13	interpreted	O
14	for	O
15	the	O
16	rpoD	B
17	(	I
18	P504L	I
19	)	I
20	mutant	I
21	as	O
22	resulting	O
23	from	O
24	a	O
25	hypersensitivity	O
26	to	O
27	ppGpp	O
28	.	O

1	These	O
2	intron	O
3	chimeras	O
4	show	O
5	that	O
6	peripheral	O
7	sequences	O
8	and	O
9	the	O
10	elements	O
11	that	O
12	define	O
13	the	O
14	splice	O
15	sites	O
16	are	O
17	adequate	O
18	for	O
19	self	O
20	-	O
21	splicing	O
22	activity	O
23	but	O
24	that	O
25	the	O
26	central	O
27	portions	O
28	containing	O
29	the	O
30	catalytic	O
31	cores	O
32	of	O
33	ai4	B
34	and	O
35	bi4	B
36	are	O
37	deficient	O
38	;	O
39	these	O
40	cores	O
41	are	O
42	the	O
43	likely	O
44	targets	O
45	of	O
46	the	O
47	splicing	O
48	proteins	O
49	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	genetically	O
5	that	O
6	plus	O
7	-	O
8	strand	O
9	DNA	O
10	synthesis	O
11	of	O
12	the	O
13	yeast	B
14	Ty1	I
15	element	I
16	is	O
17	initiated	O
18	at	O
19	two	O
20	sites	O
21	located	O
22	at	O
23	the	O
24	5	O
25	'	O
26	boundary	O
27	of	O
28	the	O
29	3	O
30	'	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	PPT1	B
36	)	O
37	and	O
38	near	O
39	the	O
40	middle	O
41	of	O
42	the	O
43	pol	B
44	gene	I
45	in	O
46	the	O
47	integrase	B
48	coding	I
49	sequence	I
50	(	O
51	PPT2	B
52	).	O

1	Characterization	O
2	of	O
3	the	O
4	3	O
5	'	O
6	ends	O
7	of	O
8	the	O
9	plus	O
10	-	O
11	strand	O
12	DNA	O
13	fragments	O
14	reveals	O
15	(	O
16	1	O
17	)	O
18	that	O
19	the	O
20	upstream	O
21	fragment	O
22	is	O
23	elongated	O
24	beyond	O
25	PPT2	B
26	creating	O
27	a	O
28	plus	O
29	-	O
30	strand	O
31	overlap	O
32	and	O
33	(	O
34	2	O
35	)	O
36	that	O
37	the	O
38	majority	O
39	of	O
40	plus	O
41	-	O
42	strand	O
43	strong	O
44	-	O
45	stop	O
46	DNA	O
47	fragments	O
48	bear	O
49	a	O
50	copy	O
51	of	O
52	the	O
53	minus	O
54	-	O
55	strand	O
56	primer	O
57	binding	O
58	site	O
59	in	O
60	agreement	O
61	with	O
62	the	O
63	accepted	O
64	model	O
65	of	O
66	retroviral	O
67	genomic	O
68	RNA	O
69	reverse	O
70	transcription	O
71	.	O

1	The	O
2	patients	O
3	undergoing	O
4	VTLB	O
5	had	O
6	significantly	O
7	shorter	O
8	operative	O
9	times	O
10	(	O
11	VTLB	O
12	,	O
13	100	O
14	.	O
15	2	O
16	+/-	O
17	27	O
18	.	O
19	2	O
20	min	O
21	.	O
22	vs	O
23	OLB	O
24	,	O
25	119	O
26	.	O
27	8	O
28	+/-	O
29	42	O
30	.	O
31	6	O
32	min	O
33	;	O
34	p	O
35	<	O
36	0	O
37	.	O
38	01	O
39	)	O
40	and	O
41	less	O
42	blood	O
43	loss	O
44	(	O
45	VTLB	O
46	,	O
47	4	O
48	.	O
49	7	O
50	+/-	O
51	14	O
52	.	O
53	6	O
54	ml	O
55	vs	O
56	OLB	O
57	,	O
58	65	O
59	.	O
60	7	O
61	+/-	O
62	77	O
63	.	O
64	0	O
65	ml	O
66	;	O
67	p	O
68	<	O
69	0	O
70	.	O
71	001	O
72	).	O

1	By	O
2	150	O
3	minutes	O
4	after	O
5	Cr2O3	O
6	inhalation	O
7	,	O
8	FEV1	O
9	.	O
10	0	O
11	had	O
12	decreased	O
13	by	O
14	32	O
15	%.	O

1	This	O
2	combined	O
3	intravenous	O
4	anaesthetic	O
5	regimen	O
6	gave	O
7	good	O
8	anaesthesia	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O

1	Twenty	O
2	food	O
3	products	O
4	were	O
5	contaminated	O
6	with	O
7	V	O
8	.	O
9	cholerae	O
10	O1	O
11	,	O
12	Ogawa	O
13	,	O
14	toxigenic	O
15	and	O
16	not	O
17	toxigenic	O
18	strains	O
19	:	O
20	yoghurt	O
21	,	O
22	cream	O
23	cheese	O
24	,	O
25	apricot	O
26	marmelade	O
27	,	O
28	hip	O
29	rose	O
30	marmelade	O
31	,	O
32	mayonnaise	O
33	,	O
34	italian	O
35	pasta	O
36	for	O
37	"	O
38	empanadas	O
39	",	O
40	"	O
41	dulce	O
42	de	O
43	leche	O
44	",	O
45	meat	O
46	sausage	O
47	,	O
48	meat	O
49	and	O
50	spinach	O
51	ravioli	O
52	,	O
53	margarine	O
54	,	O
55	milk	O
56	dessert	O
57	(	O
58	made	O
59	with	O
60	cocoa	O
61	,	O
62	milk	O
63	confiture	O
64	,	O
65	starch	O
66	and	O
67	additives	O
68	),	O
69	lettuce	O
70	,	O
71	tuna	O
72	fish	O
73	,	O
74	ricotta	O
75	and	O
76	sterilized	O
77	milk	O
78	.	O

1	It	O
2	is	O
3	impossible	O
4	to	O
5	define	O
6	only	O
7	one	O
8	clinical	O
9	outline	O
10	because	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	infected	O
16	NB	O
17	may	O
18	be	O
19	found	O
20	with	O
21	gestational	O
22	age	O
23	at	O
24	term	O
25	and	O
26	pre	O
27	-	O
28	term	O
29	and	O
30	when	O
31	born	O
32	with	O
33	a	O
34	weight	O
35	above	O
36	or	O
37	below	O
38	2000	O
39	g	O
40	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	pilin	B
6	gene	I
7	,	O
8	tcpA	B
9	,	O
10	is	O
11	dependent	O
12	upon	O
13	ToxR	B
14	and	O
15	upon	O
16	ToxT	B
17	.	O

1	The	O
2	chloramphenicol	B
3	-	I
4	resistance	I
5	transposon	I
6	Tn4451	I
7	undergoes	O
8	precise	O
9	conjugative	O
10	deletion	O
11	from	O
12	its	O
13	parent	O
14	plasmid	O
15	plP401	O
16	in	O
17	Clostridium	O
18	perfringens	O
19	and	O
20	precise	O
21	spontaneous	O
22	excision	O
23	from	O
24	multicopy	O
25	plasmids	O
26	in	O
27	Escherichia	O
28	coli	O
29	.	O

1	Ras	B
2	p21Val	I
3	inhibits	O
4	myogenesis	O
5	without	O
6	altering	O
7	the	O
8	DNA	O
9	binding	O
10	or	O
11	transcriptional	O
12	activities	O
13	of	O
14	the	O
15	myogenic	B
16	basic	I
17	helix	I
18	-	I
19	loop	I
20	-	I
21	helix	I
22	factors	I
23	.	O

1	In	O
2	cells	O
3	limited	O
4	for	O
5	His	O
6	,	O
7	increased	O
8	expression	O
9	of	O
10	arg	B
11	-	I
12	2	I
13	and	O
14	cpc	B
15	-	I
16	1	I
17	,	O
18	and	O
19	decreased	O
20	expression	O
21	of	O
22	cox	B
23	-	I
24	5	I
25	,	O
26	also	O
27	had	O
28	translational	O
29	and	O
30	transcriptional	O
31	components	O
32	.	O

1	The	O
2	peptide	O
3	sequences	O
4	reveal	O
5	that	O
6	the	O
7	factor	O
8	consists	O
9	of	O
10	GABP	B
11	alpha	I
12	and	O
13	GABP	B
14	beta	I
15	1	I
16	with	O
17	Ets	B
18	and	O
19	Notch	B
20	motifs	I
21	,	O
22	respectively	O
23	.	O

1	Immunofluorescence	O
2	microscopy	O
3	and	O
4	cell	O
5	fractionation	O
6	analyses	O
7	showed	O
8	that	O
9	the	O
10	110	O
11	-	O
12	kDa	O
13	protein	O
14	was	O
15	exclusively	O
16	nuclear	O
17	,	O
18	whereas	O
19	the	O
20	150	O
21	-	O
22	kDa	O
23	protein	O
24	was	O
25	present	O
26	in	O
27	both	O
28	the	O
29	cytoplasm	O
30	and	O
31	nucleus	O
32	of	O
33	human	O
34	cells	O
35	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	B
9	-	I
10	stranded	I
11	-	I
12	RNA	I
13	-	I
14	specific	I
15	adenosine	I
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	O
28	.	O

1	T	O
2	-	O
3	cell	O
4	hybridomas	O
5	,	O
6	thymocytes	O
7	,	O
8	and	O
9	T	O
10	cells	O
11	can	O
12	be	O
13	induced	O
14	to	O
15	undergo	O
16	apoptotic	O
17	cell	O
18	death	O
19	by	O
20	activation	O
21	through	O
22	the	O
23	T	B
24	-	I
25	cell	I
26	receptor	I
27	.	O

1	Deletions	O
2	were	O
3	examined	O
4	in	O
5	the	O
6	LYS2	B
7	gene	I
8	,	O
9	using	O
10	a	O
11	set	O
12	of	O
13	31	O
14	-	O
15	to	O
16	156	O
17	-	O
18	bp	O
19	inserts	O
20	that	O
21	included	O
22	inserts	O
23	with	O
24	no	O
25	apparent	O
26	potential	O
27	for	O
28	secondary	O
29	structure	O
30	as	O
31	well	O
32	as	O
33	two	O
34	quasipalindromes	O
35	.	O

1	Overexpression	O
2	of	O
3	SCS1	B
4	could	O
5	not	O
6	complement	O
7	an	O
8	HSP60	B
9	-	I
10	null	I
11	allele	I
12	,	O
13	indicating	O
14	that	O
15	suppression	O
16	was	O
17	not	O
18	due	O
19	to	O
20	the	O
21	bypassing	O
22	of	O
23	Hsp60	B
24	activity	O
25	.	O

1	The	O
2	DNA	O
3	binding	O
4	domain	O
5	of	O
6	NirA	B
7	was	O
8	expressed	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	the	O
15	glutathione	B
16	S	I
17	-	I
18	transferase	I
19	of	O
20	Schistosoma	O
21	japonicum	O
22	.	O

1	The	O
2	kinase	O
3	is	O
4	essential	O
5	in	O
6	vivo	O
7	for	O
8	normal	O
9	phosphorylation	O
10	of	O
11	the	O
12	CTD	O
13	and	O
14	for	O
15	normal	O
16	growth	O
17	and	O
18	differentiation	O
19	.	O

1	A	O
2	general	O
3	model	O
4	for	O
5	ARE	O
6	-	O
7	mediated	O
8	mRNA	O
9	degradation	O
10	involving	O
11	a	O
12	potential	O
13	role	O
14	for	O
15	certain	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoproteins	O
19	and	O
20	ARE	B
21	-	I
22	binding	I
23	proteins	I
24	is	O
25	proposed	O
26	.	O

1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	alpha	I
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	B
15	-	I
16	CSF	I
17	receptor	I
18	alpha	I
19	promoter	O
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O

1	Endocytosis	O
2	and	O
3	vacuolar	O
4	degradation	O
5	of	O
6	the	O
7	plasma	O
8	membrane	O
9	-	O
10	localized	O
11	Pdr5	B
12	ATP	I
13	-	I
14	binding	I
15	cassette	I
16	multidrug	I
17	transporter	I
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O

1	Individual	O
2	mutations	O
3	in	O
4	motifs	O
5	III	O
6	,	O
7	IV	O
8	,	O
9	and	O
10	V	O
11	had	O
12	distinctive	O
13	effects	O
14	on	O
15	the	O
16	affinity	O
17	of	O
18	enzyme	O
19	for	O
20	GTP	O
21	,	O
22	the	O
23	rate	O
24	of	O
25	covalent	O
26	catalysis	O
27	(	O
28	EpG	O
29	formation	O
30	),	O
31	or	O
32	the	O
33	transfer	O
34	of	O
35	GMP	O
36	from	O
37	enzyme	O
38	to	O
39	RNA	O
40	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mRNA	B
5	capping	I
6	enzyme	I
7	identifies	O
8	amino	O
9	acids	O
10	involved	O
11	in	O
12	GTP	O
13	binding	O
14	,	O
15	enzyme	O
16	-	O
17	guanylate	O
18	formation	O
19	,	O
20	and	O
21	GMP	O
22	transfer	O
23	to	O
24	RNA	O
25	.	O

1	Disruption	O
2	of	O
3	the	O
4	HOG1	B
5	and	O
6	PBS2	B
7	genes	I
8	leads	O
9	to	O
10	a	O
11	dramatic	O
12	decrease	O
13	of	O
14	the	O
15	HSP12	B
16	inducibility	O
17	in	O
18	osmostressed	O
19	cells	O
20	,	O
21	whereas	O
22	overproduction	O
23	of	O
24	Hog1	B
25	produces	O
26	a	O
27	fivefold	O
28	increase	O
29	in	O
30	wild	O
31	-	O
32	type	O
33	induced	O
34	levels	O
35	upon	O
36	a	O
37	shift	O
38	to	O
39	a	O
40	high	O
41	salt	O
42	concentration	O
43	.	O

1	Deletion	O
2	or	O
3	inactivation	O
4	of	O
5	CRY1	B
6	leads	O
7	to	O
8	5	O
9	-	O
10	to	O
11	10	O
12	-	O
13	fold	O
14	-	O
15	increased	O
16	levels	O
17	of	O
18	CRY2	B
19	mRNA	I
20	.	O

1	(	O
2	1986	O
3	)	O
4	method	O
5	of	O
6	separation	O
7	of	O
8	Cryptosporidium	O
9	spp	O
10	.	O
11	oocysts	O
12	from	O
13	feces	O
14	by	O
15	using	O
16	a	O
17	percoll	O
18	discontinuous	O
19	density	O
20	gradient	O
21	appeared	O
22	a	O
23	method	O
24	of	O
25	choice	O
26	for	O
27	obtaining	O
28	large	O
29	numbers	O
30	of	O
31	oocysts	O
32	of	O
33	C	O
34	.	O
35	parvum	O
36	free	O
37	of	O
38	fecal	O
39	contamination	O
40	.	O

1	Staphylococcal	B
2	enterotoxin	I
3	A	I
4	involvement	O
5	in	O
6	the	O
7	illness	O
8	of	O
9	a	O
10	20	O
11	-	O
12	month	O
13	-	O
14	old	O
15	burn	O
16	patient	O
17	.	O

1	METHODS	O
2	:	O
3	We	O
4	obtained	O
5	maximal	O
6	inspiratory	O
7	and	O
8	expiratory	O
9	flow	O
10	-	O
11	volume	O
12	curves	O
13	in	O
14	41	O
15	unselected	O
16	patients	O
17	with	O
18	essential	O
19	tremor	O
20	(	O
21	14	O
22	males	O
23	,	O
24	27	O
25	females	O
26	,	O
27	age	O
28	61	O
29	.	O
30	7	O
31	+/-	O
32	2	O
33	.	O
34	14	O
35	years	O
36	).	O

1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	B
19	receptor	I
20	2	I
21	and	O
22	hERR1	B
23	.	O

1	Four	O
2	p53	B
3	DNA	I
4	-	I
5	binding	I
6	domain	I
7	peptides	I
8	bind	O
9	natural	O
10	p53	B
11	-	I
12	response	I
13	elements	I
14	and	O
15	bend	O
16	the	O
17	DNA	O
18	.	O

1	The	O
2	Stat5b	B
3	mRNA	I
4	has	O
5	a	O
6	size	O
7	of	O
8	5	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	786	O
18	amino	O
19	acids	O
20	.	O

1	The	O
2	hydropathy	O
3	plot	O
4	revealed	O
5	a	O
6	rather	O
7	hydrophilic	O
8	N	O
9	-	O
10	terminal	O
11	region	O
12	and	O
13	the	O
14	absence	O
15	of	O
16	a	O
17	hydrophobic	O
18	signal	O
19	peptide	O
20	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	G	B
6	beta	I
7	gamma	I
8	-	O
9	stimulated	O
10	Shc	B
11	phosphorylation	O
12	represents	O
13	an	O
14	early	O
15	step	O
16	in	O
17	the	O
18	pathway	O
19	leading	O
20	to	O
21	p21ras	B
22	activation	O
23	,	O
24	similar	O
25	to	O
26	the	O
27	mechanism	O
28	utilized	O
29	by	O
30	growth	B
31	factor	I
32	tyrosine	I
33	kinase	I
34	receptors	I
35	.	O

1	This	O
2	report	O
3	focused	O
4	on	O
5	the	O
6	relationship	O
7	between	O
8	Type	O
9	A	O
10	behavior	O
11	and	O
12	eight	O
13	basic	O
14	emotion	O
15	dimensions	O
16	.	O

1	All	O
2	carcasses	O
3	resulted	O
4	in	O
5	contamination	O
6	with	O
7	aerobic	O
8	mesophilic	O
9	bacteria	O
10	in	O
11	the	O
12	range	O
13	from	O
14	6	O
15	x	O
16	10	O
17	(	O
18	3	O
19	)	O
20	to	O
21	1	O
22	.	O
23	2	O
24	x	O
25	10	O
26	(	O
27	6	O
28	)	O
29	CFU	O
30	/	O
31	ml	O
32	liquid	O
33	washed	O
34	,	O
35	and	O
36	94	O
37	%	O
38	them	O
39	with	O
40	sporulate	O
41	bacteria	O
42	,	O
43	the	O
44	threshold	O
45	being	O
46	under	O
47	100	O
48	CFU	O
49	/	O
50	ml	O
51	(	O
52	Figure	O
53	1	O
54	).	O

1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	CR	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	O
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	radiography	O
38	,	O
39	CT	O
40	,	O
41	FBS	O
42	,	O
43	cytology	O
44	and	O
45	/	O
46	or	O
47	histology	O
48	.	O

1	Pediatric	O
2	medical	O
3	emergencies	O
4	in	O
5	a	O
6	regional	O
7	hospital	O
8	:	O
9	appropriate	O
10	locale	O
11	?	O

1	Protein	O
2	electrophoresis	O
3	showed	O
4	decreased	O
5	albumin	B
6	levels	O
7	in	O
8	both	O
9	groups	O
10	,	O
11	with	O
12	lower	O
13	values	O
14	in	O
15	G2	O
16	.	O

1	METHODS	O
2	:	O
3	All	O
4	these	O
5	30	O
6	non	O
7	-	O
8	responders	O
9	received	O
10	an	O
11	extra	O
12	dose	O
13	of	O
14	the	O
15	same	O
16	vaccine	O
17	2	O
18	months	O
19	after	O
20	primary	O
21	immunization	O
22	and	O
23	a	O
24	booster	O
25	dose	O
26	with	O
27	a	O
28	yeast	O
29	-	O
30	derived	O
31	vaccine	O
32	6	O
33	years	O
34	later	O
35	.	O

1	An	O
2	abnormally	O
3	high	O
4	percentage	O
5	of	O
6	hypertensive	O
7	patients	O
8	(	O
9	approximately	O
10	30	O
11	%)	O
12	undergoing	O
13	cardiac	O
14	catheterization	O
15	because	O
16	of	O
17	anginal	O
18	pain	O
19	and	O
20	/	O
21	or	O
22	exercise	O
23	-	O
24	induced	O
25	ST	O
26	-	O
27	segment	O
28	depressions	O
29	has	O
30	angiographically	O
31	normal	O
32	coronary	O
33	arteries	O
34	.	O

1	Negative	O
2	-	O
3	staining	O
4	,	O
5	refractile	O
6	mycobacteria	O
7	in	O
8	Romanowsky	O
9	-	O
10	stained	O
11	smears	O
12	.	O

1	Mibefradil	O
2	(	O
3	Ro	O
4	40	O
5	-	O
6	5967	O
7	)	O
8	is	O
9	a	O
10	novel	O
11	calcium	O
12	antagonist	O
13	from	O
14	a	O
15	new	O
16	chemical	O
17	class	O
18	and	O
19	is	O
20	the	O
21	first	O
22	that	O
23	selectively	O
24	blocks	O
25	the	O
26	T	O
27	-	O
28	type	O
29	calcium	O
30	channel	O
31	.	O

1	However	O
2	,	O
3	2	O
4	minimum	O
5	alveolar	O
6	concentration	O
7	anesthesia	O
8	did	O
9	significantly	O
10	decrease	O
11	the	O
12	calculated	O
13	VE	O
14	at	O
15	a	O
16	PCO2	O
17	of	O
18	60	O
19	mmHg	O
20	(	O
21	from	O
22	7	O
23	.	O
24	4	O
25	+/-	O
26	1	O
27	.	O
28	2	O
29	to	O
30	4	O
31	.	O
32	0	O
33	+/-	O
34	0	O
35	.	O
36	6	O
37	l	O
38	.	O
39	min	O
40	-	O
41	1	O
42	),	O
43	indicating	O
44	a	O
45	rightward	O
46	shift	O
47	in	O
48	the	O
49	response	O
50	relationship	O
51	.	O

1	cDNA	O
2	encoding	O
3	a	O
4	functional	O
5	feline	B
6	liver	I
7	/	I
8	bone	I
9	/	I
10	kidney	I
11	-	I
12	type	I
13	alkaline	I
14	phosphatase	I
15	.	O

1	Protein	B
2	kinase	I
3	C	I
4	(	O
5	PKC	B
6	),	O
7	a	O
8	widely	O
9	-	O
10	distributed	O
11	enzyme	O
12	implicated	O
13	in	O
14	the	O
15	regulation	O
16	of	O
17	many	O
18	physiological	O
19	processes	O
20	,	O
21	consists	O
22	of	O
23	a	O
24	family	O
25	of	O
26	at	O
27	least	O
28	twelve	O
29	isoenzymes	O
30	which	O
31	differ	O
32	in	O
33	tissue	O
34	distribution	O
35	,	O
36	subcellular	O
37	localization	O
38	,	O
39	regulatory	O
40	properties	O
41	,	O
42	etc	O
43	.	O

1	This	O
2	work	O
3	,	O
4	therefore	O
5	,	O
6	also	O
7	emphasizes	O
8	the	O
9	importance	O
10	of	O
11	careful	O
12	choice	O
13	of	O
14	oligonucleotide	O
15	and	O
16	cDNA	O
17	probes	O
18	to	O
19	study	O
20	PKC	B
21	zeta	I
22	mRNA	I
23	.	O

1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	factors	I
12	bound	O
13	to	O
14	the	O
15	E1	B
16	element	O
17	.	O

1	The	O
2	debate	O
3	over	O
4	electives	O
5	--	O
6	1899	O
7	.	O

1	Polypeptide	O
2	growth	O
3	factors	O
4	and	O
5	cytokines	O
6	mediate	O
7	their	O
8	biochemical	O
9	functions	O
10	through	O
11	their	O
12	responsive	O
13	receptors	O
14	.	O

1	However	O
2	,	O
3	a	O
4	strongly	O
5	increased	O
6	frequency	O
7	of	O
8	CpG	O
9	dinucleotides	O
10	was	O
11	found	O
12	.	O

1	Here	O
2	we	O
3	focused	O
4	on	O
5	the	O
6	role	O
7	of	O
8	the	O
9	5	O
10	'	O
11	proximal	O
12	regulatory	O
13	cassette	O
14	(-	O
15	190	O
16	;	O
17	+	O
18	53	O
19	bp	O
20	)	O
21	of	O
22	the	O
23	rat	B
24	enkephalin	I
25	(	O
26	rENK	B
27	)	O
28	gene	O
29	in	O
30	the	O
31	developmental	O
32	regulation	O
33	of	O
34	the	O
35	enkephalin	B
36	phenotype	O
37	.	O

1	Unexpectedly	O
2	,	O
3	all	O
4	ENK	B
5	-	I
6	specific	I
7	motifs	I
8	formed	O
9	specific	O
10	and	O
11	highly	O
12	abundant	O
13	protein	O
14	-	O
15	DNA	O
16	complexes	O
17	when	O
18	nuclear	O
19	extracts	O
20	from	O
21	the	O
22	human	O
23	tumor	O
24	cell	O
25	line	O
26	(	O
27	HeLa	O
28	),	O
29	which	O
30	does	O
31	not	O
32	express	O
33	ENK	B
34	,	O
35	were	O
36	used	O
37	.	O

1	Infant	O
2	aged	O
3	3	O
4	.	O
5	5	O
6	years	O
7	presents	O
8	persistence	O
9	of	O
10	primordial	O
11	vitreous	O
12	body	O
13	with	O
14	crystalline	O
15	dislocation	O
16	in	O
17	the	O
18	camera	O
19	aquosa	O
20	and	O
21	secondary	O
22	buphthalmos	O
23	of	O
24	the	O
25	left	O
26	eye	O
27	and	O
28	microphthalmos	O
29	with	O
30	dislocation	O
31	of	O
32	the	O
33	crystalline	O
34	in	O
35	the	O
36	vitreous	O
37	body	O
38	of	O
39	the	O
40	right	O
41	eye	O
42	.	O

1	During	O
2	the	O
3	dose	O
4	-	O
5	finding	O
6	,	O
7	two	O
8	patients	O
9	were	O
10	temporarily	O
11	withdrawn	O
12	from	O
13	medication	O
14	and	O
15	one	O
16	patient	O
17	was	O
18	excluded	O
19	because	O
20	of	O
21	elevated	O
22	levels	O
23	of	O
24	liver	O
25	enzymes	O
26	.	O

1	In	O
2	comparison	O
3	of	O
4	cDNA	O
5	and	O
6	genomic	O
7	sequences	O
8	four	O
9	RNA	O
10	editing	O
11	events	O
12	were	O
13	found	O
14	in	O
15	both	O
16	atp9	B
17	genes	I
18	.	O

1	MZF	B
2	-	I
3	1	I
4	represses	O
5	CAT	B
6	reporter	I
7	gene	I
8	expression	O
9	via	O
10	GAL4	B
11	binding	I
12	sites	I
13	in	O
14	the	O
15	nonhematopoietic	O
16	cell	O
17	lines	O
18	NIH	O
19	3T3	O
20	and	O
21	293	O
22	.	O

1	As	O
2	with	O
3	the	O
4	heterologous	O
5	DNA	O
6	binding	O
7	domain	O
8	,	O
9	MZF	B
10	-	I
11	1	I
12	represses	O
13	reporter	O
14	gene	O
15	expression	O
16	in	O
17	nonhematopoietic	O
18	cell	O
19	lines	O
20	and	O
21	activates	O
22	expression	O
23	in	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	.	O

1	Analyses	O
2	of	O
3	hGMR	B
4	beta	I
5	subunit	I
6	mutants	I
7	revealed	O
8	two	O
9	cytoplasmic	O
10	regions	O
11	involved	O
12	in	O
13	activation	O
14	of	O
15	the	O
16	c	B
17	-	I
18	myc	I
19	promoter	I
20	,	O
21	one	O
22	is	O
23	essential	O
24	and	O
25	the	O
26	other	O
27	is	O
28	dispensable	O
29	but	O
30	enhances	O
31	the	O
32	activity	O
33	.	O

1	Similarly	O
2	,	O
3	we	O
4	observed	O
5	synthetic	O
6	phenotypes	O
7	between	O
8	mutations	O
9	in	O
10	MIF2	B
11	and	O
12	trans	O
13	-	O
14	acting	O
15	mutations	O
16	in	O
17	three	O
18	known	O
19	yeast	O
20	centromere	O
21	protein	O
22	genes	O
23	-	O
24	CEP1	B
25	/	O
26	CBF1	B
27	/	O
28	CPF1	B
29	,	O
30	NDC10	B
31	/	O
32	CBF2	B
33	,	O
34	and	O
35	CEP3	B
36	/	O
37	CBF3B	B
38	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	suggest	O
7	that	O
8	the	O
9	Mif2	B
10	protein	I
11	interacts	O
12	with	O
13	Cep1p	B
14	at	O
15	the	O
16	centromere	O
17	and	O
18	that	O
19	the	O
20	yeast	O
21	centromere	O
22	indeed	O
23	exists	O
24	as	O
25	a	O
26	higher	O
27	order	O
28	protein	O
29	-	O
30	DNA	O
31	complex	O
32	.	O

1	To	O
2	accomplish	O
3	this	O
4	,	O
5	actin	B
6	cables	O
7	and	O
8	patches	O
9	are	O
10	redistributed	O
11	during	O
12	the	O
13	cell	O
14	cycle	O
15	to	O
16	direct	O
17	secretory	O
18	components	O
19	to	O
20	appropriate	O
21	sites	O
22	for	O
23	cell	O
24	growth	O
25	.	O

1	The	O
2	effects	O
3	of	O
4	Codonopsis	O
5	pilosula	O
6	oral	O
7	liquor	O
8	(	O
9	CPOL	O
10	)	O
11	on	O
12	tissue	B
13	-	I
14	type	I
15	plasminogen	I
16	activator	I
17	(	O
18	t	B
19	-	I
20	PA	I
21	)	O
22	and	O
23	plasminogen	B
24	activator	I
25	inhibitor	I
26	(	O
27	PAI	B
28	)	O
29	in	O
30	the	O
31	plasma	O
32	of	O
33	25	O
34	patients	O
35	of	O
36	coronary	O
37	heart	O
38	disease	O
39	with	O
40	blood	O
41	stasis	O
42	were	O
43	studied	O
44	.	O

1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	O
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O

1	Imaging	O
2	features	O
3	of	O
4	splenic	O
5	epidermoid	O
6	cyst	O
7	with	O
8	pathologic	O
9	correlation	O
10	.	O

1	In	O
2	two	O
3	further	O
4	cases	O
5	(	O
6	one	O
7	type	O
8	I	O
9	and	O
10	one	O
11	type	O
12	III	O
13	SMA	O
14	),	O
15	de	O
16	novo	O
17	deletions	O
18	of	O
19	only	O
20	one	O
21	copy	O
22	of	O
23	Ag1	B
24	-	I
25	CA	I
26	and	O
27	C212	B
28	were	O
29	found	O
30	.	O

1	With	O
2	each	O
3	of	O
4	the	O
5	three	O
6	pairs	O
7	of	O
8	isolates	O
9	(	O
10	case	O
11	and	O
12	suspicious	O
13	case	O
14	),	O
15	identical	O
16	IS6110	O
17	banding	O
18	patterns	O
19	were	O
20	found	O
21	suggesting	O
22	identical	O
23	MTB	O
24	strains	O
25	.	O

1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	B
27	toxin	I
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O

1	These	O
2	early	O
3	structural	O
4	processes	O
5	are	O
6	assumed	O
7	to	O
8	be	O
9	subserved	O
10	by	O
11	the	O
12	anterior	O
13	parts	O
14	of	O
15	the	O
16	left	O
17	hemisphere	O
18	,	O
19	as	O
20	event	O
21	-	O
22	related	O
23	brain	O
24	potentials	O
25	show	O
26	this	O
27	area	O
28	to	O
29	be	O
30	maximally	O
31	activated	O
32	when	O
33	phrase	O
34	structure	O
35	violations	O
36	are	O
37	processed	O
38	and	O
39	as	O
40	circumscribed	O
41	lesions	O
42	in	O
43	this	O
44	area	O
45	lead	O
46	to	O
47	an	O
48	impairment	O
49	of	O
50	the	O
51	on	O
52	-	O
53	line	O
54	structural	O
55	assignment	O
56	.	O

1	In	O
2	men	O
3	with	O
4	BMI	O
5	<	O
6	30	O
7	,	O
8	the	O
9	OR	O
10	was	O
11	1	O
12	.	O
13	83	O
14	for	O
15	postprandial	O
16	TG	O
17	(	O
18	P	O
19	=	O
20	.	O
21	041	O
22	)	O
23	and	O
24	2	O
25	.	O
26	77	O
27	for	O
28	postprandial	O
29	RP	O
30	(	O
31	P	O
32	=	O
33	.	O
34	032	O
35	)	O
36	in	O
37	models	O
38	that	O
39	included	O
40	fasting	O
41	TG	O
42	,	O
43	LDL	B
44	-	I
45	C	I
46	,	O
47	and	O
48	hypertension	O
49	.	O

1	SL1	B
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	O
20	elegans	O
21	pre	O
22	-	O
23	mRNA	O
24	.	O

1	A	O
2	pyrazolo	O
3	-	O
4	quinoline	O
5	compound	O
6	,	O
7	6	O
8	-	O
9	methoxy	O
10	-	O
11	4	O
12	-[	O
13	2	O
14	-[(	O
15	2	O
16	-	O
17	hydroxyethoxyl	O
18	)-	O
19	ethyl	O
20	]	O
21	amino	O
22	]-	O
23	3	O
24	-	O
25	methyl	O
26	-	O
27	1M	O
28	-	O
29	pyrazo	O
30	lo	O
31	[	O
32	3	O
33	,	O
34	4	O
35	-	O
36	b	O
37	]	O
38	quinoline	O
39	(	O
40	SCH	O
41	51344	O
42	),	O
43	was	O
44	identified	O
45	based	O
46	on	O
47	its	O
48	ability	O
49	to	O
50	derepress	O
51	human	O
52	smooth	O
53	muscle	O
54	alpha	B
55	-	I
56	actin	I
57	promoter	I
58	activity	O
59	in	O
60	ras	B
61	-	O
62	transformed	O
63	cells	O
64	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	relations	O
7	,	O
8	a	O
9	risk	O
10	factor	O
11	-	O
12	selection	O
13	scale	O
14	(	O
15	RFSS	O
16	)	O
17	(	O
18	range	O
19	,	O
20	0	O
21	to	O
22	10	O
23	)	O
24	was	O
25	developed	O
26	by	O
27	computing	O
28	appropriate	O
29	weights	O
30	for	O
31	each	O
32	risk	O
33	factor	O
34	.	O

1	The	O
2	Caenorhabditis	B
3	elegans	I
4	death	I
5	susceptibility	I
6	gene	I
7	,	O
8	ced	B
9	-	I
10	3	I
11	,	O
12	has	O
13	a	O
14	number	O
15	of	O
16	homologs	O
17	in	O
18	vertebrate	O
19	species	O
20	,	O
21	including	O
22	interleukin	B
23	-	I
24	1	I
25	beta	I
26	(	I
27	IL	I
28	-	I
29	1	I
30	beta	I
31	)-	I
32	converting	I
33	enzyme	I
34	(	O
35	ICE	B
36	),	O
37	Ich	B
38	-	I
39	1long	I
40	,	O
41	and	O
42	CPP32	B
43	.	O

1	Repression	O
2	of	O
3	glucocorticoid	B
4	receptor	I
5	-	O
6	mediated	O
7	transcriptional	O
8	activation	O
9	by	O
10	unliganded	O
11	thyroid	B
12	hormone	I
13	receptor	I
14	(	O
15	TR	B
16	)	O
17	is	O
18	TR	B
19	isoform	O
20	-	O
21	specific	O
22	.	O

1	The	O
2	results	O
3	indicate	O
4	considerable	O
5	flexibility	O
6	in	O
7	the	O
8	spacing	O
9	between	O
10	DH	B
11	regulatory	O
12	sites	O
13	.	O

1	Obstruction	O
2	of	O
3	the	O
4	ERF	B
5	repressor	I
6	function	O
7	by	O
8	the	O
9	transactivating	O
10	members	O
11	of	O
12	the	O
13	ets	B
14	family	I
15	of	O
16	genes	O
17	(	O
18	i	O
19	.	O
20	e	O
21	.	O
22	gag	B
23	-	O
24	myb	B
25	-	O
26	ets	B
27	)	O
28	may	O
29	be	O
30	essential	O
31	for	O
32	the	O
33	control	O
34	of	O
35	genes	O
36	involved	O
37	in	O
38	cell	O
39	proliferation	O
40	and	O
41	may	O
42	also	O
43	underlie	O
44	their	O
45	tumorigenic	O
46	effects	O
47	.	O

1	Overexpression	O
2	of	O
3	wild	B
4	-	I
5	type	I
6	p53	I
7	also	O
8	induces	O
9	apoptosis	O
10	in	O
11	an	O
12	LCL	O
13	.	O

1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	B
41	.	O

1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	B
9	-	I
10	phosphoglycerate	I
11	kinase	I
12	gene	I
13	of	O
14	Pyrococcus	O
15	woesei	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O

1	These	O
2	observations	O
3	lead	O
4	to	O
5	the	O
6	proposal	O
7	that	O
8	the	O
9	RNAP	B
10	II	I
11	CTD	I
12	might	O
13	be	O
14	an	O
15	in	O
16	vivo	O
17	target	O
18	for	O
19	the	O
20	activated	O
21	p42mapk	B
22	and	O
23	p44mapk	B
24	MAP	I
25	kinases	I
26	.	O

1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	B
10	CD6	I
11	cDNA	I
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	CD6	B
31	-	O
32	PB1	B
33	.	O

1	We	O
2	sought	O
3	to	O
4	determine	O
5	whether	O
6	such	O
7	differences	O
8	in	O
9	polyadenylation	O
10	affect	O
11	the	O
12	steady	O
13	-	O
14	state	O
15	levels	O
16	of	O
17	DHFR	B
18	and	O
19	mRNAs	O
20	expressed	O
21	from	O
22	either	O
23	allele	O
24	and	O
25	,	O
26	in	O
27	a	O
28	more	O
29	general	O
30	sense	O
31	,	O
32	to	O
33	ask	O
34	whether	O
35	differences	O
36	in	O
37	3	O
38	'	O
39	end	O
40	RNA	O
41	processing	O
42	in	O
43	a	O
44	gene	O
45	containing	O
46	multiple	O
47	poly	O
48	(	O
49	A	O
50	)	O
51	sites	O
52	affects	O
53	the	O
54	final	O
55	level	O
56	of	O
57	gene	O
58	expression	O
59	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	Drosophila	O
6	melanogaster	O
7	(	O
8	Dm	O
9	)	O
10	cDNA	O
11	encoding	O
12	a	O
13	polypeptide	O
14	that	O
15	has	O
16	extensive	O
17	sequence	O
18	similarity	O
19	to	O
20	the	O
21	mammalian	B
22	MAPKAPK	I
23	-	I
24	2	I
25	.	O

1	A	O
2	2	B
3	.	I
4	4	I
5	-	I
6	kb	I
7	MAPKAPK	I
8	-	I
9	2	I
10	message	I
11	is	O
12	expressed	O
13	throughout	O
14	development	O
15	,	O
16	while	O
17	two	O
18	shorter	O
19	transcripts	O
20	of	O
21	2	O
22	.	O
23	3	O
24	and	O
25	1	O
26	.	O
27	8	O
28	kb	O
29	appear	O
30	to	O
31	be	O
32	specifically	O
33	expressed	O
34	in	O
35	the	O
36	germline	O
37	.	O

1	The	O
2	finding	O
3	that	O
4	the	O
5	chimeric	B
6	TdT	I
7	::	O
8	Pol	B
9	beta	I
10	protein	I
11	possessed	O
12	significant	O
13	template	O
14	-	O
15	dependent	O
16	polymerase	O
17	activity	O
18	suggests	O
19	that	O
20	aa	O
21	1	O
22	-	O
23	60	O
24	of	O
25	Pol	B
26	beta	I
27	are	O
28	involved	O
29	in	O
30	template	O
31	utilization	O
32	during	O
33	the	O
34	polymerization	O
35	reaction	O
36	,	O
37	as	O
38	suggested	O
39	by	O
40	the	O
41	previous	O
42	finding	O
43	that	O
44	the	O
45	8	O
46	-	O
47	kDa	O
48	N	O
49	-	O
50	terminal	O
51	domain	O
52	of	O
53	Pol	B
54	beta	I
55	possesses	O
56	ssDNA	O
57	-	O
58	binding	O
59	activity	O
60	[	O
61	Kumar	O
62	et	O
63	al	O
64	.,	O
65	J	O
66	.	O

1	The	O
2	average	O
3	values	O
4	were	O
5	199	O
6	and	O
7	424	O
8	revertants	O
9	/	O
10	g	O
11	for	O
12	the	O
13	hamburgers	O
14	and	O
15	hot	O
16	dogs	O
17	,	O
18	respectively	O
19	.	O

1	Cholangiography	O
2	was	O
3	performed	O
4	in	O
5	all	O
6	cases	O
7	and	O
8	classified	O
9	by	O
10	a	O
11	scoring	O
12	system	O
13	specifically	O
14	developed	O
15	for	O
16	pediatric	O
17	patients	O
18	.	O

1	The	O
2	integrity	O
3	of	O
4	the	O
5	cDNA	O
6	sequence	O
7	was	O
8	confirmed	O
9	by	O
10	analysis	O
11	of	O
12	several	O
13	overlapping	O
14	genomic	O
15	clones	O
16	that	O
17	span	O
18	the	O
19	GAR1	B
20	gene	I
21	.	O

1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	O
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O

1	End	O
2	-	O
3	tidal	O
4	PO2	O
5	and	O
6	the	O
7	ratio	O
8	of	O
9	minute	O
10	ventilation	O
11	to	O
12	oxygen	O
13	consumption	O
14	(	O
15	VE	O
16	/	O
17	VO2	O
18	)	O
19	were	O
20	lower	O
21	while	O
22	PETCO2	O
23	was	O
24	higher	O
25	for	O
26	Hyp	O
27	(	O
28	P	O
29	<	O
30	or	O
31	=	O
32	0	O
33	.	O
34	01	O
35	).	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	NfxB	B
6	negatively	O
7	autoregulates	O
8	the	O
9	expression	O
10	of	O
11	nfxB	B
12	itself	O
13	.	O

1	A511	O
2	is	O
3	a	O
4	broad	O
5	-	O
6	host	O
7	-	O
8	range	O
9	,	O
10	virulent	O
11	myovirus	O
12	for	O
13	Listeria	O
14	monocytogenes	O
15	.	O

1	The	O
2	mechanism	O
3	of	O
4	peroxisome	O
5	proliferation	O
6	is	O
7	poorly	O
8	understood	O
9	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	B
38	delta	I
39	mutation	I
40	.	O

1	The	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	Pur	B
7	alpha	I
8	recognition	I
9	element	I
10	disrupts	O
11	these	O
12	complexes	O
13	.	O

1	Association	O
2	of	O
3	human	B
4	Pur	I
5	alpha	I
6	with	O
7	the	O
8	retinoblastoma	B
9	protein	I
10	,	O
11	Rb	B
12	,	O
13	regulates	O
14	binding	O
15	to	O
16	the	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	Pur	B
22	alpha	I
23	recognition	I
24	element	I
25	.	O

1	The	O
2	insulin	B
3	-	O
4	induced	O
5	DNA	O
6	-	O
7	binding	O
8	complex	O
9	was	O
10	identified	O
11	as	O
12	the	O
13	p50	B
14	/	O
15	p65	B
16	heterodimer	O
17	.	O

1	Using	O
2	varying	O
3	conditions	O
4	,	O
5	three	O
6	distinct	O
7	complexes	O
8	were	O
9	shown	O
10	to	O
11	interact	O
12	specifically	O
13	with	O
14	the	O
15	NIP	B
16	region	I
17	,	O
18	although	O
19	only	O
20	one	O
21	correlates	O
22	with	O
23	repressor	O
24	activity	O
25	.	O

1	Exchange	O
2	of	O
3	the	O
4	LPL	B
5	and	O
6	HL	B
7	lids	O
8	resulted	O
9	in	O
10	a	O
11	reversal	O
12	of	O
13	the	O
14	phospholipase	B
15	/	O
16	neutral	O
17	lipase	B
18	ratio	O
19	,	O
20	establishing	O
21	the	O
22	important	O
23	role	O
24	of	O
25	this	O
26	region	O
27	in	O
28	mediating	O
29	substrate	O
30	specificity	O
31	.	O

1	The	O
2	interferon	B
3	-	O
4	inducible	O
5	protein	B
6	kinase	I
7	PKR	I
8	modulates	O
9	the	O
10	transcriptional	O
11	activation	O
12	of	O
13	immunoglobulin	B
14	kappa	I
15	gene	I
16	.	O

1	Truncated	O
2	forms	O
3	of	O
4	a	O
5	novel	O
6	yeast	O
7	protein	O
8	suppress	O
9	the	O
10	lethality	O
11	of	O
12	a	O
13	G	B
14	protein	I
15	alpha	I
16	subunit	I
17	deficiency	O
18	by	O
19	interacting	O
20	with	O
21	the	O
22	beta	O
23	subunit	O
24	.	O

1	Another	O
2	common	O
3	mutation	O
4	involved	O
5	amino	O
6	acids	O
7	that	O
8	are	O
9	thought	O
10	to	O
11	make	O
12	specific	O
13	contacts	O
14	with	O
15	DNA	O
16	.	O

1	Phorbol	O
2	esters	O
3	stimulated	O
4	phosphorylation	O
5	of	O
6	CSK	B
7	35H	I
8	proteins	I
9	,	O
10	thus	O
11	emphasizing	O
12	that	O
13	sequences	O
14	isolated	O
15	according	O
16	to	O
17	PKC	B
18	binding	O
19	activity	O
20	in	O
21	vitro	O
22	are	O
23	also	O
24	PKC	B
25	substrates	O
26	in	O
27	vivo	O
28	.	O

1	Levels	O
2	of	O
3	TSG	B
4	-	I
5	14	I
6	protein	I
7	(	O
8	also	O
9	termed	O
10	PTX	B
11	-	I
12	3	I
13	)	O
14	become	O
15	elevated	O
16	in	O
17	the	O
18	serum	O
19	of	O
20	mice	O
21	and	O
22	humans	O
23	after	O
24	injection	O
25	with	O
26	bacterial	O
27	lipopolysaccharide	O
28	,	O
29	but	O
30	in	O
31	contrast	O
32	to	O
33	conventional	O
34	acute	O
35	phase	O
36	proteins	O
37	,	O
38	the	O
39	bulk	O
40	of	O
41	TSG	B
42	-	I
43	14	I
44	synthesis	O
45	in	O
46	the	O
47	intact	O
48	organism	O
49	occurs	O
50	outside	O
51	the	O
52	liver	O
53	.	O

1	The	O
2	mouse	B
3	beta	I
4	2	I
5	-	I
6	syntrophin	I
7	gene	I
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	B
29	1	I
30	-	I
31	syntrophin	I
32	gene	I
33	.	O

1	Altogether	O
2	our	O
3	data	O
4	indicate	O
5	that	O
6	PEDF	B
7	belongs	O
8	to	O
9	the	O
10	subgroup	O
11	of	O
12	noninhibitory	O
13	serpins	B
14	and	O
15	that	O
16	its	O
17	N	O
18	-	O
19	terminal	O
20	region	O
21	confers	O
22	a	O
23	neurite	O
24	-	O
25	promoting	O
26	activity	O
27	to	O
28	the	O
29	protein	O
30	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	B
10	MAP	I
11	kinase	I
12	(	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	1	I
19	)	O
20	gene	O
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	It	O
2	contains	O
3	three	O
4	putative	O
5	TATA	O
6	boxes	O
7	far	O
8	upstream	O
9	of	O
10	the	O
11	main	O
12	start	O
13	sites	O
14	region	O
15	,	O
16	one	O
17	AP	B
18	-	I
19	1	I
20	box	I
21	,	O
22	one	O
23	AP	B
24	-	I
25	2	I
26	box	I
27	,	O
28	one	O
29	Malt	B
30	box	I
31	,	O
32	one	O
33	GAGA	O
34	box	O
35	,	O
36	one	O
37	half	O
38	serum	O
39	-	O
40	responsive	O
41	element	O
42	,	O
43	and	O
44	putative	O
45	binding	O
46	sites	O
47	for	O
48	Sp1	B
49	(	O
50	five	O
51	),	O
52	GC	B
53	-	I
54	rich	I
55	binding	I
56	factor	I
57	(	O
58	five	O
59	),	O
60	CTF	B
61	-	I
62	NF1	I
63	(	O
64	one	O
65	),	O
66	Myb	B
67	(	O
68	one	O
69	),	O
70	p53	B
71	(	O
72	two	O
73	),	O
74	Ets	B
75	-	I
76	1	I
77	(	O
78	one	O
79	),	O
80	NF	B
81	-	I
82	IL6	I
83	(	O
84	two	O
85	),	O
86	MyoD	B
87	(	O
88	two	O
89	),	O
90	Zeste	B
91	(	O
92	one	O
93	),	O
94	and	O
95	hepatocyte	B
96	nuclear	I
97	factor	I
98	-	I
99	5	I
100	(	O
101	one	O
102	).	O

1	One	O
2	of	O
3	these	O
4	is	O
5	surrounded	O
6	by	O
7	an	O
8	adenine	O
9	-	O
10	uridine	O
11	rich	O
12	region	O
13	that	O
14	can	O
15	form	O
16	an	O
17	11	O
18	-	O
19	base	O
20	pair	O
21	stem	O
22	structure	O
23	.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	Effects	O
2	of	O
3	verapamil	O
4	and	O
5	propranolol	O
6	on	O
7	early	O
8	afterdepolarizations	O
9	and	O
10	ventricular	O
11	arrhythmias	O
12	induced	O
13	by	O
14	epinephrine	O
15	in	O
16	congenital	O
17	long	O
18	QT	O
19	syndrome	O
20	.	O

1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	I
6	IL6	I
7	beta	I
8	leucine	I
9	zipper	I
10	domain	I
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O

1	After	O
2	cells	O
3	were	O
4	stably	O
5	transfected	O
6	with	O
7	CIITA	B
8	,	O
9	endogenous	O
10	MHC	B
11	class	I
12	II	I
13	genes	I
14	were	O
15	constitutively	O
16	expressed	O
17	,	O
18	and	O
19	MHC	B
20	class	I
21	II	I
22	promoters	I
23	,	O
24	delivered	O
25	by	O
26	transfection	O
27	,	O
28	were	O
29	actively	O
30	transcribed	O
31	in	O
32	CIITA	B
33	-	O
34	expressing	O
35	cells	O
36	.	O

1	Two	O
2	domains	O
3	of	O
4	EBNA2	B
5	defined	O
6	by	O
7	deletion	O
8	of	O
9	amino	O
10	acids	O
11	247	O
12	-	O
13	337	O
14	and	O
15	437	O
16	-	O
17	476	O
18	were	O
19	found	O
20	to	O
21	be	O
22	important	O
23	for	O
24	the	O
25	activation	O
26	of	O
27	both	O
28	promoters	O
29	,	O
30	while	O
31	two	O
32	different	O
33	domains	O
34	corresponding	O
35	to	O
36	residues	O
37	4	O
38	-	O
39	18	O
40	and	O
41	118	O
42	-	O
43	198	O
44	were	O
45	required	O
46	solely	O
47	for	O
48	the	O
49	LMP1	B
50	promoter	I
51	.	O

1	The	O
2	peak	O
3	velocities	O
4	of	O
5	the	O
6	atrial	O
7	systolic	O
8	waves	O
9	of	O
10	the	O
11	transmitral	O
12	and	O
13	pulmonary	O
14	venous	O
15	flow	O
16	velocities	O
17	(	O
18	A	O
19	and	O
20	PVA	O
21	,	O
22	respectively	O
23	)	O
24	and	O
25	first	O
26	systolic	O
27	wave	O
28	(	O
29	PVS1	O
30	)	O
31	of	O
32	pulmonary	O
33	venous	O
34	flow	O
35	,	O
36	durations	O
37	of	O
38	both	O
39	atrial	O
40	systolic	O
41	waves	O
42	,	O
43	and	O
44	amplitude	O
45	of	O
46	interatrial	O
47	septal	O
48	motion	O
49	during	O
50	atrial	O
51	systole	O
52	increased	O
53	significantly	O
54	ten	O
55	days	O
56	after	O
57	cardioversion	O
58	compared	O
59	with	O
60	those	O
61	measured	O
62	within	O
63	a	O
64	day	O
65	of	O
66	cardioversion	O
67	in	O
68	all	O
69	patients	O
70	except	O
71	the	O
72	5	O
73	patients	O
74	with	O
75	dilated	O
76	cardiomyopathy	O
77	.	O

1	Additionally	O
2	,	O
3	the	O
4	enzyme	O
5	shows	O
6	activity	O
7	towards	O
8	triglycerides	O
9	such	O
10	as	O
11	olive	O
12	oil	O
13	and	O
14	tributyrin	O
15	and	O
16	towards	O
17	egg	O
18	-	O
19	yolk	O
20	emulsions	O
21	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	directly	O
5	upstream	O
6	of	O
7	fimA	B
8	contains	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	ORF5	O
15	and	O
16	ORF1	O
17	,	O
18	whose	O
19	deduced	O
20	protein	O
21	products	O
22	are	O
23	homologous	O
24	to	O
25	members	O
26	of	O
27	a	O
28	superfamily	O
29	of	O
30	ATP	B
31	-	I
32	binding	I
33	cassette	I
34	membrane	I
35	transport	I
36	proteins	I
37	,	O
38	including	O
39	both	O
40	prokaryotic	O
41	and	O
42	eukaryotic	O
43	uptake	O
44	and	O
45	export	O
46	systems	O
47	.	O

1	The	O
2	ORF3	O
3	probe	O
4	also	O
5	hybridized	O
6	to	O
7	a	O
8	540	O
9	bp	O
10	transcript	O
11	consistent	O
12	with	O
13	the	O
14	size	O
15	of	O
16	ORF3	O
17	alone	O
18	and	O
19	supportive	O
20	of	O
21	the	O
22	mutagenesis	O
23	data	O
24	of	O
25	non	O
26	-	O
27	linkage	O
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	low	O
6	concentrations	O
7	of	O
8	IL	B
9	-	I
10	1	I
11	beta	I
12	may	O
13	be	O
14	useful	O
15	for	O
16	nonsurgical	O
17	treatment	O
18	of	O
19	human	O
20	vitreous	O
21	hemorrhage	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	pancreatic	O
5	polypeptide	O
6	and	O
7	motilin	B
8	responses	O
9	to	O
10	a	O
11	meal	O
12	are	O
13	different	O
14	in	O
15	encopretic	O
16	children	O
17	than	O
18	in	O
19	children	O
20	in	O
21	the	O
22	control	O
23	group	O
24	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	,	O
7	expression	O
8	,	O
9	and	O
10	biochemical	O
11	characterization	O
12	of	O
13	the	O
14	32	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	human	O
20	(	O
21	h	O
22	)	O
23	TFIID	B
24	,	O
25	termed	O
26	hTAFII32	B
27	.	O

1	Hemolytic	O
2	jaundice	O
3	due	O
4	to	O
5	G6PD	B
6	deficiency	O
7	causing	O
8	kernicterus	O
9	in	O
10	a	O
11	female	O
12	newborn	O
13	.	O

1	Two	O
2	transcripts	O
3	of	O
4	1	O
5	.	O
6	6	O
7	kb	O
8	and	O
9	5	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	5	O
15	'	O
16	coterminal	O
17	and	O
18	may	O
19	both	O
20	encode	O
21	the	O
22	novel	O
23	glycoprotein	B
24	gene	I
25	EUS4	I
26	.	O

1	Mean	O
2	growth	O
3	changes	O
4	in	O
5	this	O
6	Class	O
7	II	O
8	sample	O
9	were	O
10	comparable	O
11	to	O
12	those	O
13	previously	O
14	reported	O
15	for	O
16	male	O
17	subjects	O
18	with	O
19	Class	O
20	I	O
21	malocclusions	O
22	over	O
23	the	O
24	same	O
25	age	O
26	period	O
27	,	O
28	suggesting	O
29	a	O
30	similarity	O
31	in	O
32	postpubertal	O
33	development	O
34	between	O
35	these	O
36	two	O
37	groups	O
38	.	O

1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	benefit	O
21	.	O

1	The	O
2	fracture	O
3	groups	O
4	were	O
5	significantly	O
6	older	O
7	and	O
8	had	O
9	more	O
10	years	O
11	since	O
12	menopause	O
13	than	O
14	the	O
15	control	O
16	groups	O
17	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	differences	O
7	in	O
8	the	O
9	binding	O
10	of	O
11	nuclear	O
12	factors	O
13	from	O
14	shoots	O
15	versus	O
16	from	O
17	roots	O
18	,	O
19	in	O
20	agreement	O
21	with	O
22	the	O
23	different	O
24	activities	O
25	of	O
26	the	O
27	promoter	O
28	in	O
29	these	O
30	two	O
31	organs	O
32	.	O

1	The	O
2	prevalence	O
3	and	O
4	incidence	O
5	of	O
6	human	O
7	immunodeficiency	O
8	virus	O
9	types	O
10	1	O
11	and	O
12	2	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	,	O
18	HIV	O
19	-	O
20	2	O
21	),	O
22	human	O
23	T	O
24	-	O
25	lymphotropic	O
26	virus	O
27	types	O
28	I	O
29	and	O
30	II	O
31	(	O
32	HTLV	O
33	-	O
34	I	O
35	/	O
36	II	O
37	),	O
38	and	O
39	syphilitic	O
40	infections	O
41	and	O
42	the	O
43	association	O
44	between	O
45	these	O
46	infections	O
47	were	O
48	determined	O
49	in	O
50	a	O
51	cohort	O
52	of	O
53	police	O
54	officers	O
55	in	O
56	Guinea	O
57	-	O
58	Bissau	O
59	.	O

1	By	O
2	in	O
3	vitro	O
4	immunoprecipitations	O
5	and	O
6	gel	O
7	shift	O
8	assays	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	classes	O
14	of	O
15	high	O
16	affinity	O
17	Engrailed	B
18	-	I
19	binding	I
20	sites	I
21	upstream	O
22	of	O
23	each	O
24	of	O
25	the	O
26	two	O
27	polyhomeotic	O
28	transcription	O
29	units	O
30	.	O

1	Subjects	O
2	with	O
3	a	O
4	short	O
5	postexposure	O
6	time	O
7	and	O
8	a	O
9	dioxin	O
10	burden	O
11	>	O
12	0	O
13	.	O
14	6	O
15	pg	O
16	/	O
17	m3	O
18	had	O
19	a	O
20	significantly	O
21	higher	O
22	risk	O
23	of	O
24	hypoergy	O
25	than	O
26	unexposed	O
27	subjects	O
28	(	O
29	hypoergy	O
30	I	O
31	:	O
32	OR	O
33	=	O
34	9	O
35	.	O
36	51	O
37	,	O
38	95	O
39	%	O
40	CI	O
41	=	O
42	1	O
43	.	O
44	96	O
45	-	O
46	42	O
47	.	O
48	02	O
49	;	O
50	hypoergy	O
51	II	O
52	:	O
53	OR	O
54	=	O
55	2	O
56	.	O
57	92	O
58	,	O
59	95	O
60	%	O
61	CI	O
62	=	O
63	1	O
64	.	O
65	14	O
66	-	O
67	7	O
68	.	O
69	5	O
70	).	O

1	Analysis	O
2	of	O
3	this	O
4	sequence	O
5	combined	O
6	with	O
7	that	O
8	previously	O
9	reported	O
10	for	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	directly	O
17	proximal	O
18	to	O
19	the	O
20	start	O
21	of	O
22	transcription	O
23	revealed	O
24	several	O
25	putative	O
26	regulatory	O
27	sequences	O
28	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	the	O
6	BAT1	B
7	translation	I
8	product	I
9	is	O
10	the	O
11	homolog	O
12	of	O
13	the	O
14	rat	B
15	p47	I
16	nuclear	I
17	protein	I
18	,	O
19	the	O
20	WM6	B
21	Drosophila	I
22	gene	I
23	product	I
24	,	O
25	and	O
26	probably	O
27	also	O
28	Ce08102	B
29	of	O
30	Caenorhabditis	O
31	elegans	O
32	,	O
33	all	O
34	members	O
35	of	O
36	the	O
37	DEAD	B
38	protein	I
39	family	I
40	of	O
41	ATP	B
42	-	I
43	dependent	I
44	RNA	I
45	helicases	I
46	.	O

1	By	O
2	using	O
3	lacZ	B
4	fusions	I
5	,	O
6	it	O
7	was	O
8	possible	O
9	to	O
10	localize	O
11	the	O
12	DNA	O
13	sequences	O
14	required	O
15	to	O
16	mediate	O
17	nitrate	O
18	repression	O
19	to	O
20	the	O
21	pfl	B
22	promoter	I
23	-	I
24	regulatory	I
25	region	I
26	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	describe	O
7	the	O
8	characterization	O
9	of	O
10	two	O
11	early	O
12	class	B
13	II	I
14	flagellar	I
15	genes	I
16	contained	O
17	in	O
18	the	O
19	orfX	O
20	-	O
21	fliP	B
22	locus	O
23	.	O

1	Vestibular	O
2	adaptation	O
3	exercises	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	acoustic	O
11	neuroma	O
12	resection	O
13	.	O

1	The	O
2	experimental	O
3	design	O
4	represents	O
5	a	O
6	2	O
7	x	O
8	3	O
9	factorial	O
10	arrangement	O
11	of	O
12	treatments	O
13	with	O
14	three	O
15	dietary	O
16	levels	O
17	of	O
18	incorporation	O
19	of	O
20	RSB	O
21	(	O
22	0	O
23	,	O
24	50	O
25	,	O
26	and	O
27	100	O
28	%),	O
29	and	O
30	chickens	O
31	either	O
32	infected	O
33	or	O
34	uninfected	O
35	.	O

1	A	O
2	cDNA	O
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	GA	B
9	20	I
10	-	O
11	oxidase	B
12	genomic	O
13	sequence	O
14	was	O
15	constructed	O
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	analyzing	O
35	the	O
36	capability	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	convert	O
47	GA53	B
48	to	O
49	GA44	B
50	and	O
51	GA19	B
52	to	O
53	GA20	B
54	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	changes	O
6	in	O
7	either	O
8	the	O
9	fatty	O
10	acid	O
11	composition	O
12	of	O
13	biliary	O
14	lecithin	O
15	or	O
16	in	O
17	the	O
18	bile	O
19	acid	O
20	composition	O
21	of	O
22	bile	O
23	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	also	O
5	reduced	O
6	at	O
7	week	O
8	12	O
9	by	O
10	17	O
11	.	O
12	0	O
13	%	O
14	(	O
15	20	O
16	mg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	15	O
22	.	O
23	7	O
24	%	O
25	(	O
26	20	O
27	-	O
28	30	O
29	mg	O
30	/	O
31	day	O
32	),	O
33	and	O
34	at	O
35	week	O
36	52	O
37	by	O
38	20	O
39	.	O
40	4	O
41	%	O
42	(<	O
43	or	O
44	=	O
45	20	O
46	mg	O
47	/	O
48	day	O
49	)	O
50	and	O
51	19	O
52	.	O
53	2	O
54	%	O
55	(>	O
56	or	O
57	=	O
58	30	O
59	mg	O
60	/	O
61	day	O
62	).	O

1	Although	O
2	further	O
3	studies	O
4	are	O
5	required	O
6	to	O
7	determine	O
8	the	O
9	precise	O
10	role	O
11	of	O
12	PEBP2	B
13	in	O
14	the	O
15	GM	B
16	-	I
17	CSF	I
18	promoter	I
19	activity	O
20	,	O
21	the	O
22	present	O
23	findings	O
24	suggested	O
25	the	O
26	importance	O
27	of	O
28	the	O
29	relative	O
30	ratio	O
31	of	O
32	different	O
33	PEBP2	B
34	isoforms	I
35	in	O
36	regulating	O
37	the	O
38	levels	O
39	of	O
40	the	O
41	promoter	O
42	activity	O
43	.	O

1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O

1	Piperacillin	O
2	-	O
3	tazobactam	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	aerobic	O
23	,	O
24	and	O
25	anaerobic	O
26	bacteria	O
27	.	O

1	Basal	O
2	plasma	O
3	renin	B
4	activity	O
5	(	O
6	PRA	O
7	)	O
8	was	O
9	slightly	O
10	raised	O
11	prior	O
12	to	O
13	training	O
14	(	O
15	P	O
16	<	O
17	0	O
18	.	O
19	07	O
20	)	O
21	compared	O
22	to	O
23	the	O
24	controls	O
25	and	O
26	post	O
27	-	O
28	training	O
29	.	O

1	This	O
2	apparently	O
3	anomalous	O
4	structure	O
5	/	O
6	activity	O
7	relationship	O
8	raises	O
9	important	O
10	issues	O
11	for	O
12	understanding	O
13	the	O
14	evolution	O
15	of	O
16	regulatory	O
17	peptides	O
18	and	O
19	the	O
20	mechanisms	O
21	that	O
22	control	O
23	their	O
24	expression	O
25	.	O

1	The	O
2	structural	O
3	gene	O
4	encoding	O
5	the	O
6	novel	O
7	lantibiotic	O
8	epilancin	B
9	K7	I
10	from	O
11	Staphylococcus	O
12	epidermidis	O
13	K7	O
14	was	O
15	cloned	O
16	and	O
17	its	O
18	nucleotide	O
19	sequence	O
20	was	O
21	determined	O
22	.	O

1	This	O
2	paper	O
3	summarises	O
4	the	O
5	experimental	O
6	evidence	O
7	upon	O
8	which	O
9	the	O
10	clinical	O
11	trials	O
12	of	O
13	aldose	B
14	reductase	I
15	inhibitors	O
16	in	O
17	diabetic	O
18	patients	O
19	have	O
20	been	O
21	initiated	O
22	and	O
23	the	O
24	results	O
25	of	O
26	published	O
27	drug	O
28	trials	O
29	in	O
30	these	O
31	patients	O
32	.	O

1	The	O
2	spectrum	O
3	of	O
4	phenotypes	O
5	caused	O
6	by	O
7	these	O
8	mutations	O
9	was	O
10	strikingly	O
11	different	O
12	than	O
13	mutations	O
14	in	O
15	the	O
16	adaptor	O
17	for	O
18	the	O
19	VP16	B
20	activation	I
21	domain	I
22	.	O

1	Increase	O
2	in	O
3	urinary	O
4	calcium	O
5	and	O
6	oxalate	O
7	after	O
8	fructose	O
9	infusion	O
10	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	is	O
7	highly	O
8	GC	O
9	rich	O
10	,	O
11	with	O
12	multiple	O
13	CpG	O
14	doublets	O
15	,	O
16	and	O
17	contains	O
18	multiple	O
19	binding	O
20	sites	O
21	for	O
22	Sp1	B
23	.	O

1	To	O
2	discern	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	melatonin	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	IGD	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	O
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	pubertal	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O

1	Increased	O
2	blood	O
3	pressure	O
4	during	O
5	CyA	O
6	treatment	O
7	was	O
8	independent	O
9	of	O
10	circulating	O
11	ET	B
12	-	I
13	1	I
14	levels	O
15	.	O

1	Analysis	O
2	of	O
3	several	O
4	Tat	B
5	mutants	I
6	indicated	O
7	that	O
8	both	O
9	the	O
10	cysteine	O
11	-	O
12	rich	O
13	and	O
14	the	O
15	core	O
16	domains	O
17	of	O
18	this	O
19	transactivator	O
20	are	O
21	necessary	O
22	and	O
23	sufficient	O
24	to	O
25	activate	O
26	transcription	O
27	when	O
28	TBP	B
29	is	O
30	overexpressed	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	I
8	1	I
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	I
17	1	I
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O

1	Transactivation	O
2	of	O
3	the	O
4	HIV	B
5	-	I
6	1	I
7	LTR	I
8	by	O
9	T3R	B
10	alpha	I
11	and	O
12	several	O
13	receptor	O
14	mutants	O
15	revealed	O
16	that	O
17	the	O
18	50	O
19	-	O
20	amino	O
21	-	O
22	acid	O
23	N	O
24	-	O
25	terminal	O
26	A	O
27	/	O
28	B	O
29	region	O
30	of	O
31	T3R	B
32	alpha	I
33	,	O
34	known	O
35	to	O
36	interact	O
37	with	O
38	the	O
39	basal	B
40	transcription	I
41	factor	I
42	TFIIB	I
43	,	O
44	is	O
45	critical	O
46	for	O
47	activation	O
48	of	O
49	both	O
50	Tat	B
51	-	O
52	dependent	O
53	and	O
54	Tat	B
55	-	O
56	independent	O
57	responsive	O
58	sequences	O
59	of	O
60	the	O
61	LTR	O
62	.	O

1	M	O
2	.	O
3	M	O
4	.	O
5	C	O
6	.	O
7	was	O
8	used	O
9	for	O
10	2	O
11	.	O
12	5	O
13	minutes	O
14	in	O
15	44	O
16	cases	O
17	(	O
18	20	O
19	HR	O
20	patients	O
21	,	O
22	24	O
23	LR	O
24	patients	O
25	),	O
26	and	O
27	for	O
28	5	O
29	minutes	O
30	in	O
31	66	O
32	cases	O
33	(	O
34	46	O
35	HR	O
36	patients	O
37	,	O
38	20	O
39	LR	O
40	patients	O
41	).	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	C25	B
11	,	O
12	C30	B
13	and	O
14	C35	B
15	complexes	I
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	SAA	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	relevance	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	functioning	O
44	of	O
45	the	O
46	rat	B
47	APP	I
48	promoter	I
49	.	O

1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	prevalence	O
6	values	O
7	shows	O
8	clearly	O
9	that	O
10	the	O
11	global	O
12	MS	O
13	-	O
14	frequency	O
15	is	O
16	closer	O
17	related	O
18	to	O
19	the	O
20	geomagnetic	O
21	than	O
22	to	O
23	the	O
24	geographic	O
25	latitude	O
26	.	O

1	Diltiazem	O
2	caused	O
3	significant	O
4	decrease	O
5	in	O
6	the	O
7	ventricular	O
8	response	O
9	without	O
10	conversion	O
11	to	O
12	sinus	O
13	rhythm	O
14	.	O

1	Subhuman	O
2	primates	O
3	appear	O
4	to	O
5	be	O
6	more	O
7	sensitive	O
8	to	O
9	reproductive	O
10	and	O
11	other	O
12	adverse	O
13	effects	O
14	of	O
15	PCBs	O
16	than	O
17	humans	O
18	.	O

1	When	O
2	excluding	O
3	children	O
4	with	O
5	ocular	O
6	and	O
7	cerebral	O
8	pathology	O
9	,	O
10	32	O
11	matched	O
12	pairs	O
13	of	O
14	premature	O
15	and	O
16	control	O
17	children	O
18	remained	O
19	.	O

1	The	O
2	cryptococcal	B
3	antigen	I
4	test	O
5	was	O
6	positive	O
7	at	O
8	1	O
9	:	O
10	125	O
11	by	O
12	latex	O
13	agglutination	O
14	.	O

1	Functional	O
2	analysis	O
3	of	O
4	DNase	B
5	-	I
6	I	I
7	hypersensitive	O
8	sites	O
9	at	O
10	the	O
11	mouse	B
12	porphobilinogen	I
13	deaminase	I
14	gene	I
15	locus	I
16	.	O

1	These	O
2	transcripts	O
3	have	O
4	a	O
5	unique	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	and	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	and	O
16	encode	O
17	a	O
18	predicted	O
19	protein	O
20	of	O
21	121	O
22	kD	O
23	.	O

1	Both	O
2	mu	B
3	and	I
4	gamma	I
5	2b	I
6	heavy	I
7	chain	I
8	genes	I
9	cause	O
10	this	O
11	feedback	O
12	inhibition	O
13	of	O
14	heavy	O
15	chain	O
16	gene	O
17	rearrangement	O
18	.	O

1	Purified	O
2	CarP	B
3	binds	O
4	in	O
5	vitro	O
6	to	O
7	the	O
8	carAB	B
9	control	I
10	region	I
11	and	O
12	protects	O
13	against	O
14	DNase	B
15	I	I
16	two	O
17	approximately	O
18	25	O
19	bp	O
20	long	O
21	stretches	O
22	,	O
23	one	O
24	of	O
25	which	O
26	is	O
27	located	O
28	just	O
29	downstream	O
30	of	O
31	the	O
32	GATC	O
33	sequence	O
34	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	B
13	to	I
14	3	I
15	),	O
16	apocytochrome	B
17	b	I
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	B
30	to	I
31	6	I
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	O
38	(	O
39	atp6	B
40	and	O
41	atp9	B
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	B
48	,	O
49	srn	B
50	and	O
51	lrn	B
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	B
61	,	O
62	rps11	B
63	,	O
64	rps12	B
65	and	O
66	rpl16	B
67	).	O

1	From	O
2	day	O
3	10	O
4	,	O
5	a	O
6	significant	O
7	increase	O
8	in	O
9	platelet	O
10	count	O
11	was	O
12	observed	O
13	in	O
14	eight	O
15	of	O
16	the	O
17	ten	O
18	patients	O
19	treated	O
20	with	O
21	heparin	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	),	O
29	with	O
30	return	O
31	to	O
32	the	O
33	initial	O
34	value	O
35	after	O
36	heparin	O
37	cessation	O
38	in	O
39	six	O
40	of	O
41	the	O
42	responders	O
43	.	O

1	These	O
2	"	O
3	nucleocapsid	O
4	-	O
5	like	O
6	"	O
7	structures	O
8	were	O
9	readily	O
10	purified	O
11	by	O
12	density	O
13	gradient	O
14	centrifugation	O
15	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	Resources	O
2	for	O
3	helping	O
4	patients	O
5	to	O
6	quit	O
7	smoking	O
8	.	O

1	The	O
2	PEBP2	B
3	alpha	I
4	proteins	I
5	contain	O
6	a	O
7	128	O
8	-	O
9	amino	O
10	-	O
11	acid	O
12	(	O
13	aa	O
14	)	O
15	region	O
16	highly	O
17	homologous	O
18	to	O
19	the	O
20	Drosophila	B
21	melanogaster	I
22	segmentation	I
23	gene	I
24	runt	I
25	.	O

1	In	O
2	human	O
3	proliferative	O
4	cells	O
5	,	O
6	the	O
7	NADP	O
8	-	O
9	dependent	O
10	ME	B
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	barely	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O

1	Based	O
2	on	O
3	previous	O
4	mapping	O
5	of	O
6	the	O
7	G	B
8	beta	I
9	gamma	I
10	binding	I
11	region	I
12	of	O
13	beta	B
14	ARK	I
15	,	O
16	and	O
17	conserved	O
18	residues	O
19	within	O
20	the	O
21	PH	B
22	domain	I
23	,	O
24	we	O
25	have	O
26	constructed	O
27	a	O
28	series	O
29	of	O
30	mutants	O
31	in	O
32	the	O
33	carboxyl	O
34	terminus	O
35	of	O
36	beta	B
37	ARK	I
38	in	O
39	order	O
40	to	O
41	determine	O
42	important	O
43	residues	O
44	involved	O
45	in	O
46	G	B
47	beta	I
48	gamma	I
49	and	O
50	PIP2	O
51	binding	O
52	.	O

1	Histopathological	O
2	features	O
3	of	O
4	relapsed	O
5	leprosy	O
6	.	O

1	To	O
2	dissect	O
3	these	O
4	mechanisms	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	and	O
10	mutant	B
11	Raf	I
12	-	I
13	1	I
14	proteins	I
15	were	O
16	studied	O
17	in	O
18	an	O
19	in	O
20	vitro	O
21	system	O
22	with	O
23	purified	O
24	plasma	O
25	membranes	O
26	from	O
27	v	B
28	-	I
29	Ras	I
30	-	O
31	and	O
32	v	B
33	-	I
34	Src	I
35	-	O
36	transformed	O
37	cells	O
38	(	O
39	transformed	O
40	membranes	O
41	).	O

1	In	O
2	CV	O
3	-	O
4	1	O
5	cells	O
6	,	O
7	cotransfection	O
8	of	O
9	the	O
10	retinoid	B
11	and	I
12	estrogen	I
13	receptors	I
14	led	O
15	to	O
16	mutual	O
17	inhibition	O
18	of	O
19	the	O
20	other	O
21	'	O
22	s	O
23	activity	O
24	,	O
25	while	O
26	an	O
27	RA	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	ER	B
33	activity	O
34	was	O
35	observed	O
36	in	O
37	breast	O
38	cancer	O
39	cells	O
40	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	HRF	B
7	-	I
8	1	I
9	,	O
10	recognizes	O
11	a	O
12	cis	O
13	element	O
14	consisting	O
15	of	O
16	an	O
17	inverted	O
18	palindromic	O
19	motif	O
20	.	O

1	Regulation	O
2	of	O
3	Gax	B
4	homeobox	I
5	gene	I
6	transcription	O
7	by	O
8	a	O
9	combination	O
10	of	O
11	positive	O
12	factors	O
13	including	O
14	myocyte	B
15	-	I
16	specific	I
17	enhancer	I
18	factor	I
19	2	I
20	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	transactivation	O
6	domain	O
7	of	O
8	heat	B
9	shock	I
10	factor	I
11	1	I
12	is	O
13	negatively	O
14	regulated	O
15	and	O
16	stress	O
17	responsive	O
18	.	O

1	D	O
2	.	O

1	It	O
2	was	O
3	proposed	O
4	that	O
5	the	O
6	synthetase	O
7	-	O
8	related	O
9	sequences	O
10	of	O
11	GCN2	B
12	stimulate	O
13	the	O
14	activity	O
15	of	O
16	the	O
17	kinase	O
18	by	O
19	interacting	O
20	directly	O
21	with	O
22	uncharged	O
23	tRNA	O
24	that	O
25	accumulates	O
26	during	O
27	amino	O
28	acid	O
29	limitation	O
30	.	O

1	However	O
2	,	O
3	unlike	O
4	Bcl	B
5	-	I
6	2	I
7	and	O
8	the	O
9	E1B	B
10	19K	I
11	proteins	I
12	,	O
13	which	O
14	completely	O
15	block	O
16	apoptosis	O
17	but	O
18	not	O
19	p53	B
20	-	O
21	dependent	O
22	growth	O
23	arrest	O
24	,	O
25	H	B
26	-	I
27	ras	I
28	expression	O
29	permitted	O
30	DNA	O
31	synthesis	O
32	and	O
33	cell	O
34	proliferation	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	high	O
40	levels	O
41	of	O
42	wild	B
43	-	I
44	type	I
45	p53	I
46	.	O

1	To	O
2	compare	O
3	the	O
4	PAX3	B
5	and	O
6	putative	O
7	PAX3	B
8	-	O
9	FKHR	B
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	O
23	GAL4	B
24	DNA	I
25	-	I
26	binding	I
27	domain	I
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O

1	All	O
2	subjects	O
3	were	O
4	submitted	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	B
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	B
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	glutamine	B
30	transaminase	I
31	,	O
32	cholesterol	O
33	and	O
34	triglycerides	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	T0	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	T30	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	washout	O
55	(	O
56	T45	O
57	).	O

1	Acute	O
2	decrease	O
3	in	O
4	body	O
5	temperature	O
6	(	O
7	TB	O
8	)	O
9	lowered	O
10	PaCO2	O
11	(	O
12	32	O
13	.	O
14	5	O
15	to	O
16	14	O
17	.	O
18	5	O
19	mmHg	O
20	)	O
21	and	O
22	[	O
23	HCO3	O
24	-]	O
25	a	O
26	(	O
27	24	O
28	.	O
29	20	O
30	mEq	O
31	/	O
32	L	O
33	to	O
34	17	O
35	.	O
36	56	O
37	mEq	O
38	/	O
39	L	O
40	),	O
41	increased	O
42	pHa	O
43	(	O
44	7	O
45	.	O
46	481	O
47	to	O
48	7	O
49	.	O
50	608	O
51	)	O
52	and	O
53	diminished	O
54	the	O
55	[	O
56	OH	O
57	-]/[	O
58	H	O
59	+]	O
60	ratio	O
61	,	O
62	but	O
63	had	O
64	no	O
65	significant	O
66	effect	O
67	on	O
68	[	O
69	SID	O
70	]	O
71	or	O
72	[	O
73	Atot	O
74	],	O
75	although	O
76	both	O
77	total	O
78	phosphorus	O
79	[	O
80	PT	O
81	]	O
82	and	O
83	inorganic	O
84	phosphate	O
85	[	O
86	Pi	O
87	]	O
88	increased	O
89	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O

1	Basal	O
2	promoter	O
3	activity	O
4	is	O
5	enhanced	O
6	by	O
7	a	O
8	functional	O
9	M1	O
10	domain	O
11	in	O
12	LHR	B
13	-	O
14	expressing	O
15	mouse	O
16	Leydig	O
17	tumor	O
18	cells	O
19	(	O
20	MLTC	O
21	)	O
22	but	O
23	not	O
24	in	O
25	non	O
26	-	O
27	expressing	O
28	CHO	O
29	cells	O
30	.	O

1	The	O
2	RAT3	B
3	gene	I
4	encodes	O
5	an	O
6	1157	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	without	O
12	similarity	O
13	to	O
14	other	O
15	known	O
16	proteins	O
17	.	O

1	For	O
2	Al	O
3	,	O
4	the	O
5	exposure	O
6	to	O
7	1	O
8	.	O
9	36	O
10	mg	O
11	/	O
12	m3	O
13	during	O
14	the	O
15	shift	O
16	corresponded	O
17	to	O
18	a	O
19	urinary	O
20	concentration	O
21	at	O
22	the	O
23	end	O
24	of	O
25	the	O
26	shift	O
27	of	O
28	200	O
29	microgram	O
30	/	O
31	g	O
32	creatinine	O
33	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	),	O
10	a	O
11	proinflammatory	O
12	cytokine	O
13	,	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	testosterone	O
19	production	O
20	in	O
21	mouse	O
22	Leydig	O
23	cells	O
24	.	O

1	The	O
2	Drosophila	B
3	insulin	I
4	receptor	I
5	homolog	I
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	RA	O
6	and	O
7	E1A	B
8	induce	O
9	phosphorylation	O
10	of	O
11	the	O
12	E1A	B
13	-	I
14	associated	I
15	300	I
16	kDa	I
17	protein	I
18	(	O
19	p300	B
20	)	O
21	during	O
22	the	O
23	differentiation	O
24	of	O
25	F9	O
26	cells	O
27	.	O

1	The	O
2	double	O
3	-	O
4	stranded	O
5	RNA	O
6	binding	O
7	domain	O
8	(	O
9	dsRBD	O
10	)	O
11	is	O
12	an	O
13	approximately	O
14	65	O
15	amino	O
16	acid	O
17	motif	O
18	that	O
19	is	O
20	found	O
21	in	O
22	a	O
23	variety	O
24	of	O
25	proteins	O
26	that	O
27	interact	O
28	with	O
29	double	O
30	-	O
31	stranded	O
32	(	O
33	ds	O
34	)	O
35	RNA	O
36	,	O
37	such	O
38	as	O
39	Escherichia	O
40	coli	O
41	RNase	B
42	III	I
43	and	O
44	the	O
45	dsRNA	B
46	-	I
47	dependent	I
48	kinase	I
49	,	O
50	PKR	B
51	.	O

1	CCAAT	B
2	/	I
3	enhancer	I
4	-	I
5	binding	I
6	protein	I
7	isoforms	I
8	beta	I
9	and	I
10	delta	I
11	are	O
12	expressed	O
13	in	O
14	mammary	O
15	epithelial	O
16	cells	O
17	and	O
18	bind	O
19	to	O
20	multiple	O
21	sites	O
22	in	O
23	the	O
24	beta	B
25	-	I
26	casein	I
27	gene	I
28	promoter	I
29	.	O

1	SCA	B
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	O
9	aspartyl	O
10	,	O
11	and	O
12	metalloproteases	B
13	,	O
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	potential	O
5	activating	O
6	phosphorylation	O
7	sites	O
8	found	O
9	in	O
10	NIMA	B
11	,	O
12	NIM	B
13	-	I
14	1	I
15	,	O
16	and	O
17	related	O
18	protein	O
19	kinases	O
20	was	O
21	performed	O
22	on	O
23	NIMA	B
24	.	O

1	However	O
2	,	O
3	a	O
4	similar	O
5	mutation	O
6	of	O
7	a	O
8	leucine	O
9	residue	O
10	to	O
11	arginine	O
12	at	O
13	position	O
14	422	O
15	showed	O
16	no	O
17	alteration	O
18	of	O
19	heterodimerization	O
20	,	O
21	DNA	O
22	binding	O
23	,	O
24	or	O
25	transcriptional	O
26	activation	O
27	.	O

1	Expression	O
2	of	O
3	the	O
4	CYP11A1	B
5	gene	I
6	is	O
7	increased	O
8	by	O
9	hormones	O
10	,	O
11	such	O
12	as	O
13	adrenocorticotropin	B
14	and	O
15	luteinizing	B
16	hormone	I
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	number	O
24	of	O
25	growth	O
26	factors	O
27	,	O
28	suggesting	O
29	that	O
30	its	O
31	promoter	O
32	may	O
33	contain	O
34	regulatory	O
35	elements	O
36	that	O
37	respond	O
38	to	O
39	multiple	O
40	signal	O
41	transduction	O
42	pathways	O
43	.	O

1	NH2	O
2	-	O
3	and	O
4	COOH	O
5	-	O
6	terminal	O
7	deletion	O
8	analysis	O
9	revealed	O
10	that	O
11	both	O
12	the	O
13	PH	B
14	and	O
15	putative	O
16	guanine	B
17	nucleotide	I
18	exchange	I
19	factor	I
20	domains	I
21	are	O
22	required	O
23	,	O
24	but	O
25	the	O
26	zinc	O
27	butterfly	O
28	is	O
29	dispensable	O
30	,	O
31	for	O
32	transformation	O
33	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	GTPase	B
9	-	O
10	deficient	O
11	mutants	O
12	of	O
13	alpha	B
14	12	I
15	(	O
16	alpha	B
17	12Q229L	I
18	)	O
19	or	O
20	alpha	B
21	13	I
22	(	O
23	alpha	B
24	13Q226L	I
25	)	O
26	leads	O
27	to	O
28	robust	O
29	activation	O
30	of	O
31	the	O
32	Jun	B
33	kinase	I
34	/	O
35	stress	B
36	-	I
37	activated	I
38	protein	I
39	kinase	I
40	(	O
41	JNK	B
42	/	O
43	SAPK	B
44	)	O
45	pathway	O
46	.	O

1	The	O
2	objective	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	age	O
11	,	O
12	sex	O
13	,	O
14	clinical	O
15	conditions	O
16	,	O
17	family	O
18	history	O
19	,	O
20	site	O
21	,	O
22	catheter	O
23	association	O
24	,	O
25	means	O
26	of	O
27	radiologic	O
28	evaluation	O
29	,	O
30	development	O
31	of	O
32	pulmonary	O
33	involvement	O
34	,	O
35	prevalence	O
36	of	O
37	antithrombin	B
38	III	I
39	,	O
40	protein	B
41	C	I
42	and	O
43	protein	B
44	S	I
45	deficiencies	O
46	,	O
47	and	O
48	lupus	O
49	anticoagulants	O
50	in	O
51	children	O
52	who	O
53	suffered	O
54	a	O
55	thrombotic	O
56	event	O
57	.	O

1	Harel	O
2	,	O
3	E	O
4	.	O
5	M	O
6	.	O

1	Radiotherapy	O
2	and	O
3	early	O
4	orchiectomy	O
5	in	O
6	stage	O
7	D1	O
8	prostatic	O
9	carcinoma	O

1	Structural	O
2	organization	O
3	and	O
4	developmental	O
5	expression	O
6	pattern	O
7	of	O
8	the	O
9	mouse	B
10	WD	I
11	-	I
12	repeat	I
13	gene	I
14	DMR	I
15	-	I
16	N9	I
17	immediately	O
18	upstream	O
19	of	O
20	the	O
21	myotonic	B
22	dystrophy	I
23	locus	I
24	.	O

1	The	O
2	ARX2	O
3	procedure	O
4	models	O
5	the	O
6	recorded	O
7	signal	O
8	as	O
9	the	O
10	sum	O
11	of	O
12	three	O
13	signals	O
14	:	O
15	(	O
16	a	O
17	)	O
18	the	O
19	background	O
20	EEG	O
21	activity	O
22	,	O
23	modelled	O
24	as	O
25	an	O
26	autoregressive	O
27	process	O
28	driven	O
29	by	O
30	a	O
31	white	O
32	noise	O
33	;	O
34	(	O
35	b	O
36	)	O
37	a	O
38	filtered	O
39	version	O
40	of	O
41	a	O
42	reference	O
43	signal	O
44	carrying	O
45	the	O
46	average	O
47	information	O
48	contained	O
49	in	O
50	each	O
51	sweep	O
52	;	O
53	(	O
54	c	O
55	)	O
56	a	O
57	signal	O
58	due	O
59	to	O
60	the	O
61	ocular	O
62	artefact	O
63	propagation	O
64	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	enzyme	O
9	(	O
10	CYP19	B
11	)	O
12	is	O
13	regulated	O
14	,	O
15	in	O
16	part	O
17	,	O
18	by	O
19	tissue	O
20	-	O
21	specific	O
22	promoters	O
23	through	O
24	the	O
25	use	O
26	of	O
27	alternative	O
28	-	O
29	splicing	O
30	mechanisms	O
31	.	O

1	Using	O
2	mutagenesis	O
3	,	O
4	we	O
5	have	O
6	identified	O
7	two	O
8	mutations	O
9	of	O
10	the	O
11	second	O
12	actin	B
13	-	I
14	binding	I
15	domain	I
16	that	O
17	can	O
18	also	O
19	suppress	O
20	the	O
21	act1	B
22	mutations	O
23	of	O
24	interest	O
25	.	O

1	CIITA	B
2	mRNA	I
3	is	O
4	normally	O
5	inducible	O
6	by	O
7	IFN	B
8	-	I
9	gamma	I
10	in	O
11	class	O
12	II	O
13	non	O
14	-	O
15	inducible	O
16	,	O
17	RB	O
18	-	O
19	defective	O
20	lines	O
21	,	O
22	and	O
23	in	O
24	one	O
25	line	O
26	,	O
27	re	O
28	-	O
29	expression	O
30	of	O
31	RB	B
32	has	O
33	no	O
34	effect	O
35	on	O
36	CIITA	B
37	mRNA	I
38	induction	O
39	levels	O
40	.	O

1	The	O
2	normal	O
3	cell	O
4	cycle	O
5	is	O
6	regulated	O
7	by	O
8	several	O
9	molecules	O
10	,	O
11	such	O
12	as	O
13	the	O
14	tumor	B
15	-	I
16	suppressor	I
17	protein	I
18	pRb	I
19	,	O
20	the	O
21	G1	B
22	cyclins	I
23	,	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinases	I
29	,	O
30	and	O
31	their	O
32	inhibitors	O
33	.	O

1	Consistent	O
2	with	O
3	the	O
4	protein	O
5	expression	O
6	data	O
7	,	O
8	V	B
9	beta	I
10	8	I
11	.	I
12	3	I
13	gene	I
14	transcripts	I
15	were	O
16	found	O
17	only	O
18	in	O
19	the	O
20	transgenic	O
21	lines	O
22	with	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	promoter	O
28	.	O

1	These	O
2	results	O
3	are	O
4	very	O
5	useful	O
6	for	O
7	deciding	O
8	on	O
9	the	O
10	doses	O
11	of	O
12	hormones	O
13	and	O
14	the	O
15	expected	O
16	serum	O
17	estradiol	O
18	level	O
19	in	O
20	HRT	O
21	for	O
22	Japanese	O
23	women	O
24	.	O

1	Comparison	O
2	of	O
3	1	O
4	.	O
5	5	O
6	Tesla	O
7	and	O
8	0	O
9	.	O
10	35	O
11	Tesla	O
12	field	O
13	strength	O
14	magnetic	O
15	resonance	O
16	imaging	O
17	scans	O
18	in	O
19	the	O
20	morphometric	O
21	evaluation	O
22	of	O
23	the	O
24	lumbar	O
25	intervertebral	O
26	foramina	O
27	.	O

1	One	O
2	month	O
3	after	O
4	the	O
5	DTaP	O
6	booster	O
7	vaccination	O
8	,	O
9	both	O
10	groups	O
11	had	O
12	6	O
13	-	O
14	to	O
15	40	O
16	-	O
17	fold	O
18	increases	O
19	in	O
20	serum	O
21	antibody	O
22	concentrations	O
23	to	O
24	all	O
25	antigens	O
26	tested	O
27	;	O
28	the	O
29	concentrations	O
30	against	O
31	the	O
32	three	O
33	pertussis	B
34	antigens	I
35	were	O
36	higher	O
37	in	O
38	the	O
39	DTaP	O
40	-	O
41	primed	O
42	children	O
43	(	O
44	p	O
45	<	O
46	0	O
47	.	O
48	05	O
49	).	O

1	Interestingly	O
2	,	O
3	this	O
4	amino	O
5	-	O
6	terminal	O
7	determinant	O
8	appears	O
9	not	O
10	to	O
11	reside	O
12	in	O
13	the	O
14	HSV	O
15	-	O
16	alpha	B
17	TIF	I
18	,	O
19	which	O
20	displays	O
21	no	O
22	independent	O
23	amino	O
24	-	O
25	terminal	O
26	activity	O
27	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	in	O
6	fusions	O
7	with	O
8	the	O
9	DNA	O
10	binding	O
11	domain	O
12	of	O
13	GAL4	B
14	,	O
15	full	O
16	activity	O
17	requires	O
18	the	O
19	entire	O
20	BHV	B
21	-	I
22	alpha	I
23	TIF	I
24	,	O
25	although	O
26	both	O
27	amino	O
28	and	O
29	carboxyl	O
30	termini	O
31	display	O
32	some	O
33	activity	O
34	on	O
35	their	O
36	own	O
37	.	O

1	To	O
2	investigate	O
3	the	O
4	potential	O
5	role	O
6	of	O
7	SP1	B
8	,	O
9	we	O
10	examined	O
11	nuclear	O
12	extracts	O
13	from	O
14	HCMV	O
15	-	O
16	infected	O
17	cells	O
18	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	messenger	O
6	RNAs	O
7	encoding	O
8	trans	O
9	-	O
10	sialidases	O
11	containing	O
12	the	O
13	repeats	O
14	are	O
15	not	O
16	present	O
17	in	O
18	epimastigotes	O
19	but	O
20	are	O
21	abundant	O
22	in	O
23	trypomastigotes	O
24	.	O

1	From	O
2	May	O
3	1985	O
4	to	O
5	May	O
6	1989	O
7	,	O
8	126	O
9	necropsies	O
10	were	O
11	performed	O
12	at	O
13	the	O
14	Sao	O
15	Paulo	O
16	City	O
17	Morgue	O
18	on	O
19	cadavers	O
20	of	O
21	individuals	O
22	AIDS	O
23	victims	O
24	whose	O
25	unnatural	O
26	deaths	O
27	had	O
28	prompted	O
29	police	O
30	investigations	O
31	.	O

1	A	O
2	model	O
3	with	O
4	age	O
5	and	O
6	weight	O
7	described	O
8	the	O
9	best	O
10	fit	O
11	for	O
12	TBBMD	O
13	,	O
14	whereas	O
15	age	O
16	,	O
17	weight	O
18	,	O
19	and	O
20	height	O
21	described	O
22	the	O
23	best	O
24	fit	O
25	for	O
26	total	O
27	body	O
28	TBBMC	O
29	.	O

1	As	O
2	retinoic	O
3	acid	O
4	and	O
5	thyroid	O
6	hormone	O
7	are	O
8	frequently	O
9	involved	O
10	in	O
11	developmental	O
12	regulatory	O
13	processes	O
14	,	O
15	it	O
16	is	O
17	possible	O
18	that	O
19	this	O
20	element	O
21	may	O
22	be	O
23	important	O
24	in	O
25	the	O
26	process	O
27	of	O
28	islet	O
29	cell	O
30	differentiation	O
31	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	peptide	O
6	sequences	O
7	of	O
8	the	O
9	human	B
10	lymphocyte	I
11	-	I
12	specific	I
13	high	I
14	mobility	I
15	group	I
16	(	I
17	HMG	I
18	)-	I
19	box	I
20	transcription	I
21	factor	I
22	TCF	I
23	-	I
24	1	I
25	are	O
26	determined	O
27	by	O
28	alternative	O
29	splice	O
30	mechanisms	O
31	affecting	O
32	the	O
33	exons	O
34	VIII	O
35	to	O
36	X	O
37	.	O

1	Thromboxane	O
2	B2	O
3	increased	O
4	(	O
5	97	O
6	+/-	O
7	105	O
8	versus	O
9	40	O
10	+/-	O
11	26	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	and	O
17	was	O
18	significantly	O
19	higher	O
20	during	O
21	heparin	O
22	free	O
23	hemodialysis	O
24	than	O
25	during	O
26	hemodialysis	O
27	with	O
28	heparin	O
29	(	O
30	p	O
31	=	O
32	0	O
33	.	O
34	01	O
35	,	O
36	Wilcoxon	O
37	matched	O
38	pairs	O
39	signed	O
40	rank	O
41	test	O
42	).	O

1	A	O
2	new	O
3	vector	O
4	,	O
5	pHBK280	O
6	,	O
7	was	O
8	designed	O
9	to	O
10	facilitate	O
11	this	O
12	analysis	O
13	.	O

1	To	O
2	explore	O
3	the	O
4	mechanism	O
5	of	O
6	RSK	B
7	activation	O
8	,	O
9	a	O
10	cloned	O
11	human	O
12	RSK	B
13	cDNA	O
14	(	O
15	RSK3	B
16	)	O
17	was	O
18	used	O
19	to	O
20	generate	O
21	and	O
22	characterize	O
23	several	O
24	site	O
25	-	O
26	directed	O
27	RSK	B
28	mutants	I
29	;	O
30	K91A	O
31	(	O
32	N	O
33	-	O
34	Lys	O
35	,	O
36	NH2	O
37	-	O
38	terminal	O
39	ATP	O
40	-	O
41	binding	O
42	mutant	O
43	),	O
44	K444A	O
45	(	O
46	C	O
47	-	O
48	Lys	O
49	,	O
50	COOH	O
51	-	O
52	terminal	O
53	ATP	O
54	-	O
55	binding	O
56	mutant	O
57	),	O
58	N	O
59	/	O
60	C	O
61	-	O
62	Lys	O
63	(	O
64	double	O
65	ATP	O
66	-	O
67	binding	O
68	mutant	O
69	)	O
70	T570A	O
71	(	O
72	C	O
73	-	O
74	Thr	O
75	,	O
76	mutant	O
77	of	O
78	the	O
79	putative	O
80	MAPK	B
81	phosphorylation	O
82	site	O
83	in	O
84	subdomain	O
85	VIII	O
86	of	O
87	the	O
88	C	O
89	-	O
90	domain	O
91	),	O
92	S218A	O
93	(	O
94	N	O
95	-	O
96	Ser	O
97	,	O
98	mutant	O
99	of	O
100	the	O
101	corresponding	O
102	NH2	O
103	-	O
104	terminal	O
105	residue	O
106	).	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	O
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O

1	Conversely	O
2	,	O
3	treatment	O
4	of	O
5	human	B
6	protein	I
7	-	I
8	tyrosine	I
9	phosphatase	I
10	alpha	I
11	-	O
12	overexpressing	O
13	cells	O
14	with	O
15	phenylarsine	O
16	oxide	O
17	led	O
18	to	O
19	a	O
20	loss	O
21	of	O
22	the	O
23	constitutive	O
24	NF	B
25	-	I
26	kappa	I
27	B	I
28	activity	O
29	.	O

1	A	O
2	TATA	O
3	-	O
4	less	O
5	promoter	O
6	containing	O
7	binding	O
8	sites	O
9	for	O
10	ubiquitous	O
11	transcription	O
12	factors	O
13	mediates	O
14	cell	O
15	type	O
16	-	O
17	specific	O
18	regulation	O
19	of	O
20	the	O
21	gene	O
22	for	O
23	transcription	B
24	enhancer	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	TEF	B
30	-	I
31	1	I
32	).	O

1	Since	O
2	electrical	O
3	stimulation	O
4	of	O
5	neurones	O
6	may	O
7	activate	O
8	not	O
9	only	O
10	cell	O
11	bodies	O
12	but	O
13	also	O
14	neuronal	O
15	fibres	O
16	,	O
17	this	O
18	study	O
19	aimed	O
20	to	O
21	test	O
22	a	O
23	selectively	O
24	cholinergic	O
25	neurochemical	O
26	stimulation	O
27	of	O
28	the	O
29	rat	O
30	substantia	O
31	innominata	O
32	(	O
33	SI	O
34	)	O
35	by	O
36	the	O
37	local	O
38	microinjection	O
39	of	O
40	carbachol	O
41	;	O
42	the	O
43	effects	O
44	of	O
45	this	O
46	acetylcholine	O
47	agonist	O
48	were	O
49	compared	O
50	with	O
51	glutamate	O
52	.	O

1	Here	O
2	we	O
3	describe	O
4	an	O
5	in	O
6	vitro	O
7	assay	O
8	where	O
9	the	O
10	NS3	B
11	-	I
12	4A	I
13	polyprotein	I
14	,	O
15	NS3	B
16	,	O
17	the	O
18	serine	O
19	proteinase	O
20	domain	O
21	(	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	181	O
27	residues	O
28	of	O
29	NS3	O
30	),	O
31	and	O
32	the	O
33	NS4A	B
34	cofactor	I
35	were	O
36	produced	O
37	by	O
38	cell	O
39	-	O
40	free	O
41	translation	O
42	and	O
43	tested	O
44	for	O
45	trans	O
46	-	O
47	processing	O
48	of	O
49	radiolabeled	O
50	substrates	O
51	.	O

1	In	O
2	contrast	O
3	,	O
4	over	O
5	-	O
6	expression	O
7	of	O
8	RAR	B
9	beta	I
10	only	O
11	poorly	O
12	restored	O
13	differentiation	O
14	,	O
15	although	O
16	it	O
17	could	O
18	replace	O
19	RAR	B
20	gamma	I
21	for	O
22	the	O
23	activation	O
24	of	O
25	target	O
26	genes	O
27	.	O

1	We	O
2	purified	O
3	both	O
4	proteins	O
5	from	O
6	human	O
7	platelet	O
8	membranes	O
9	using	O
10	DEAE	O
11	-	O
12	Sepharose	O
13	chromatography	O
14	followed	O
15	by	O
16	mAb	B
17	F11	I
18	affinity	O
19	chromatography	O
20	.	O

1	The	O
2	homeobox	B
3	gene	I
4	ATK1	I
5	of	O
6	Arabidopsis	O
7	thaliana	O
8	is	O
9	expressed	O
10	in	O
11	the	O
12	shoot	O
13	apex	O
14	of	O
15	the	O
16	seedling	O
17	and	O
18	in	O
19	flowers	O
20	and	O
21	inflorescence	O
22	stems	O
23	of	O
24	mature	O
25	plants	O
26	.	O

1	The	O
2	most	O
3	likely	O
4	explanation	O
5	for	O
6	this	O
7	is	O
8	that	O
9	gold	O
10	principally	O
11	accumulates	O
12	in	O
13	the	O
14	Kupffer	O
15	cells	O
16	and	O
17	renal	O
18	cortex	O
19	and	O
20	these	O
21	cells	O
22	do	O
23	not	O
24	express	O
25	Type	B
26	I	I
27	deiodinase	I
28	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	different	O
6	models	O
7	of	O
8	intestinal	O
9	ischemia	O
10	have	O
11	different	O
12	cytokine	O
13	profiles	O
14	and	O
15	that	O
16	the	O
17	early	O
18	TNF	B
19	response	O
20	associated	O
21	with	O
22	SMA	O
23	occlusion	O
24	model	O
25	is	O
26	primarily	O
27	due	O
28	to	O
29	the	O
30	laparotomy	O
31	.	O

1	Our	O
2	evidence	O
3	derives	O
4	from	O
5	three	O
6	principal	O
7	observations	O
8	:	O
9	1	O
10	)	O
11	a	O
12	transfection	O
13	construct	O
14	containing	O
15	only	O
16	122	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	of	O
22	promoter	O
23	1	O
24	and	O
25	328	O
26	nt	O
27	of	O
28	the	O
29	5	O
30	'-	O
31	UTR	O
32	retained	O
33	full	O
34	PGE2	O
35	-	O
36	stimulated	O
37	reporter	O
38	expression	O
39	;	O
40	2	O
41	)	O
42	maximal	O
43	PGE2	O
44	-	O
45	driven	O
46	reporter	O
47	expression	O
48	required	O
49	the	O
50	presence	O
51	of	O
52	nt	O
53	196	O
54	to	O
55	328	O
56	of	O
57	exon	O
58	1	O
59	when	O
60	tested	O
61	within	O
62	the	O
63	context	O
64	of	O
65	IGF	B
66	-	I
67	I	I
68	promoter	I
69	1	I
70	;	O
71	3	O
72	)	O
73	cotransfection	O
74	of	O
75	IGF	B
76	-	I
77	I	I
78	promoter	I
79	-	O
80	luciferase	B
81	-	O
82	reporter	O
83	constructs	O
84	with	O
85	a	O
86	plasmid	O
87	encoding	O
88	the	O
89	alpha	O
90	-	O
91	isoform	O
92	of	O
93	the	O
94	catalytic	O
95	subunit	O
96	of	O
97	murine	B
98	cAMP	I
99	-	I
100	dependent	I
101	protein	I
102	kinase	I
103	(	O
104	PKA	B
105	)	O
106	produced	O
107	results	O
108	comparable	O
109	to	O
110	those	O
111	seen	O
112	with	O
113	PGE2	O
114	treatment	O
115	,	O
116	whereas	O
117	cotransfection	O
118	with	O
119	a	O
120	plasmid	O
121	encoding	O
122	a	O
123	mutant	O
124	regulatory	O
125	subunit	O
126	of	O
127	PKA	B
128	that	O
129	cannot	O
130	bind	O
131	cAMP	O
132	blocked	O
133	PGE2	O
134	-	O
135	induced	O
136	reporter	O
137	expression	O
138	.	O

1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	chiefly	O
8	by	O
9	electromyography	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	auxiliary	O
20	indicators	O
21	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	and	O
6	DNase	B
7	I	I
8	footprinting	O
9	experiments	O
10	using	O
11	purified	O
12	42	O
13	kDa	O
14	repressor	O
15	isoform	O
16	confirmed	O
17	that	O
18	CIRs	B
19	5	I
20	and	I
21	6	I
22	were	O
23	indeed	O
24	the	O
25	targets	O
26	for	O
27	binding	O
28	of	O
29	this	O
30	protein	O
31	.	O

1	The	O
2	5	O
3	'-	O
4	terminus	O
5	of	O
6	the	O
7	p	B
8	-	I
9	gvpF	I
10	-	I
11	M	I
12	mRNA	I
13	was	O
14	located	O
15	169	O
16	nucleotides	O
17	upstream	O
18	of	O
19	p	B
20	-	I
21	gvpF	I
22	within	O
23	p	B
24	-	I
25	gvpE	I
26	.	O

1	Retransformation	O
2	of	O
3	uvsH77	B
4	mutants	I
5	with	O
6	the	O
7	rescued	O
8	cosmids	O
9	from	O
10	the	O
11	MMS	O
12	-	O
13	resistant	O
14	transformants	O
15	resulted	O
16	in	O
17	restoration	O
18	of	O
19	both	O
20	UV	O
21	and	O
22	MMS	O
23	resistance	O
24	to	O
25	wild	O
26	-	O
27	type	O
28	levels	O
29	.	O

1	Furthermore	O
2	,	O
3	this	O
4	element	O
5	confers	O
6	p53	B
7	induction	O
8	to	O
9	the	O
10	otherwise	O
11	nonresponsive	O
12	adenovirus	O
13	major	O
14	late	O
15	promoter	O
16	.	O

1	In	O
2	flies	O
3	,	O
4	the	O
5	dShc	B
6	protein	I
7	physically	O
8	associates	O
9	with	O
10	the	O
11	activated	O
12	Drosophila	B
13	epidermal	I
14	growth	I
15	factor	I
16	receptor	I
17	homolog	I
18	(	O
19	DER	B
20	)	O
21	and	O
22	is	O
23	inducibly	O
24	phosphorylated	O
25	on	O
26	tyrosine	O
27	by	O
28	DER	B
29	.	O

1	A	O
2	potential	O
3	binding	O
4	site	O
5	for	O
6	the	O
7	dShc	B
8	PTB	O
9	domain	O
10	is	O
11	located	O
12	at	O
13	Tyr	O
14	-	O
15	1228	O
16	of	O
17	DER	B
18	.	O

1	A	O
2	Drosophila	B
3	shc	I
4	gene	I
5	product	I
6	is	O
7	implicated	O
8	in	O
9	signaling	O
10	by	O
11	the	O
12	DER	B
13	receptor	I
14	tyrosine	I
15	kinase	I
16	.	O

1	This	O
2	inhibition	O
3	can	O
4	be	O
5	overcome	O
6	by	O
7	mutating	O
8	either	O
9	the	O
10	exon	O
11	'	O
12	s	O
13	5	O
14	'	O
15	or	O
16	3	O
17	'	O
18	splice	O
19	site	O
20	to	O
21	make	O
22	it	O
23	correspond	O
24	more	O
25	closely	O
26	to	O
27	the	O
28	relevant	O
29	consensus	O
30	sequence	O
31	.	O

1	Biochemical	O
2	analysis	O
3	shows	O
4	that	O
5	Ssm1p	B
6	is	O
7	a	O
8	structural	O
9	protein	O
10	that	O
11	forms	O
12	part	O
13	of	O
14	the	O
15	largest	O
16	60S	B
17	ribosomal	I
18	subunit	I
19	,	O
20	which	O
21	does	O
22	not	O
23	exist	O
24	in	O
25	a	O
26	pool	O
27	of	O
28	free	O
29	proteins	O
30	.	O

1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	B
8	transcripts	I
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	B
16	transcripts	I
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	B
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	B
29	pool	O
30	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	B
9	-	I
10	1	I
11	mRNA	I
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	B
21	-	I
22	2	I
23	mRNA	I
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	this	O
6	anatomic	O
7	concept	O
8	,	O
9	the	O
10	brachioplasty	O
11	procedure	O
12	was	O
13	modified	O
14	to	O
15	provide	O
16	secure	O
17	anchoring	O
18	of	O
19	the	O
20	arm	O
21	flap	O
22	to	O
23	the	O
24	axillary	O
25	fascia	O
26	along	O
27	with	O
28	strong	O
29	superficial	O
30	fascial	O
31	system	O
32	repair	O
33	of	O
34	incisions	O
35	,	O
36	reducing	O
37	the	O
38	risk	O
39	of	O
40	widening	O
41	or	O
42	migration	O
43	of	O
44	scars	O
45	and	O
46	unnatural	O
47	contours	O
48	.	O

1	Furthermore	O
2	,	O
3	microinjection	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	Rac	B
10	and	O
11	Cdc42	B
12	or	O
13	of	O
14	the	O
15	Rho	B
16	inhibitor	O
17	C3	B
18	transferase	I
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O

1	INF	B
2	-	I
3	alpha	I
4	therapy	O
5	has	O
6	been	O
7	a	O
8	major	O
9	development	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	CML	O
15	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	O
10	,	O
11	d20	O
12	,	O
13	d27	O
14	,	O
15	d31	O
16	,	O
17	d40	O
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	O
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	O
51	-	O
52	SR	O
53	alpha	O
54	-	O
55	296	O
56	)	O
57	in	O
58	CV	O
59	-	O
60	1	O
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	Intrathecal	O
2	acetyl	B
3	cholinesterase	I
4	inhibitors	O
5	produce	O
6	analgesia	O
7	that	O
8	is	O
9	synergistic	O
10	with	O
11	morphine	O
12	and	O
13	clonidine	O
14	in	O
15	rats	O
16	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	O
7	,	O
8	birds	O
9	were	O
10	given	O
11	a	O
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	O
21	9	O
22	)	O
23	or	O
24	a	O
25	kappa	O
26	-	O
27	opioid	O
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	Max	B
2	was	O
3	constantly	O
4	transcribed	O
5	at	O
6	a	O
7	relatively	O
8	low	O
9	level	O
10	during	O
11	cell	O
12	cycle	O
13	progression	O
14	.	O

1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O

1	Key	O
2	areas	O
3	of	O
4	the	O
5	selection	O
6	process	O
7	including	O
8	medical	O
9	and	O
10	surgical	O
11	alternatives	O
12	to	O
13	transplantation	O
14	,	O
15	the	O
16	composition	O
17	of	O
18	the	O
19	transplant	O
20	work	O
21	-	O
22	up	O
23	,	O
24	specific	O
25	inclusion	O
26	criteria	O
27	as	O
28	well	O
29	as	O
30	specific	O
31	psychosocial	O
32	factors	O
33	and	O
34	specific	O
35	disease	O
36	etiologies	O
37	and	O
38	co	O
39	-	O
40	morbidities	O
41	that	O
42	might	O
43	represent	O
44	contraindications	O
45	were	O
46	extensively	O
47	reviewed	O
48	.	O

1	The	O
2	transport	O
3	of	O
4	a	O
5	genetically	O
6	engineered	O
7	chimeric	O
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	O
29	sequence	O
30	has	O
31	been	O
32	derived	O
33	.	O

1	In	O
2	both	O
3	shoots	O
4	and	O
5	roots	O
6	,	O
7	GT	B
8	-	I
9	2	I
10	protein	I
11	is	O
12	undetectable	O
13	in	O
14	meristematic	O
15	tissue	O
16	but	O
17	becomes	O
18	expressed	O
19	at	O
20	later	O
21	stages	O
22	of	O
23	cellular	O
24	development	O
25	,	O
26	consistent	O
27	with	O
28	a	O
29	role	O
30	in	O
31	contributing	O
32	to	O
33	the	O
34	pattern	O
35	of	O
36	phytochrome	B
37	A	I
38	gene	I
39	expression	O
40	.	O

1	A	O
2	polymorphic	O
3	bipartite	O
4	motif	O
5	signals	O
6	nuclear	O
7	targeting	O
8	of	O
9	early	O
10	auxin	O
11	-	O
12	inducible	O
13	proteins	O
14	related	O
15	to	O
16	PS	O
17	-	O
18	IAA4	O
19	from	O
20	pea	O
21	(	O
22	Pisum	O
23	sativum	O
24	).	O

1	Comparative	O
2	DNA	O
3	sequence	O
4	analysis	O
5	showed	O
6	the	O
7	Genethon	O
8	microsatellite	B
9	D19S596	I
10	lies	O
11	2	O
12	.	O
13	2	O
14	kb	O
15	downstream	O
16	of	O
17	the	O
18	coding	O
19	region	O
20	of	O
21	FUT1	B
22	,	O
23	indicating	O
24	that	O
25	the	O
26	cluster	O
27	comprising	O
28	the	O
29	closely	O
30	linked	O
31	FUT1	B
32	and	O
33	FUT2	B
34	genes	I
35	is	O
36	located	O
37	4	O
38	cM	O
39	distal	O
40	to	O
41	D19S412	B
42	(	O
43	lod	O
44	score	O
45	13	O
46	.	O
47	7	O
48	)	O
49	and	O
50	9	O
51	cM	O
52	proximal	O
53	to	O
54	D19S571	B
55	(	O
56	lod	O
57	score	O
58	11	O
59	.	O
60	7	O
61	).	O

1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	B
8	-	I
9	1	I
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O

1	TH	B
2	-	O
3	SH3	B
4	binding	O
5	in	O
6	vitro	O
7	is	O
8	abolished	O
9	by	O
10	specific	O
11	,	O
12	single	O
13	amino	O
14	acid	O
15	substitutions	O
16	within	O
17	the	O
18	Btk	B
19	TH	I
20	domain	I
21	or	O
22	the	O
23	Fyn	B
24	SH3	I
25	domain	I
26	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	K	B
6	-	I
7	glypican	I
8	is	O
9	a	O
10	novel	O
11	GPI	B
12	-	I
13	anchored	I
14	HSPG	I
15	involved	O
16	in	O
17	embryonic	O
18	development	O
19	.	O

1	Protein	B
2	S	I
3	levels	O
4	were	O
5	virtually	O
6	undetectable	O
7	at	O
8	the	O
9	time	O
10	of	O
11	admission	O
12	and	O
13	failed	O
14	to	O
15	respond	O
16	to	O
17	infusions	O
18	of	O
19	fresh	O
20	frozen	O
21	plasma	O
22	,	O
23	despite	O
24	correction	O
25	of	O
26	other	O
27	procoagulant	O
28	and	O
29	anticoagulant	O
30	factors	O
31	.	O

1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	B
8	genes	I
9	.	O

1	The	O
2	test	O
3	was	O
4	not	O
5	performed	O
6	in	O
7	3923	O
8	patients	O
9	because	O
10	of	O
11	contraindications	O
12	.	O

1	The	O
2	ubiquitous	O
3	transcription	O
4	factor	O
5	Oct	B
6	-	I
7	1	I
8	forms	O
9	complexes	O
10	with	O
11	an	O
12	octamer	O
13	motif	O
14	present	O
15	within	O
16	FPIV	O
17	by	O
18	gel	O
19	shift	O
20	analysis	O
21	with	O
22	liver	O
23	and	O
24	kidney	O
25	extracts	O
26	,	O
27	making	O
28	Oct	B
29	-	I
30	1	I
31	an	O
32	intriguing	O
33	candidate	O
34	for	O
35	partnership	O
36	in	O
37	androgen	O
38	regulation	O
39	.	O

1	A	O
2	new	O
3	non	O
4	-	O
5	LTR	O
6	retrotransposon	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	O
16	in	O
17	Crithidia	O
18	fasciculata	O
19	miniexon	O
20	arrays	O
21	.	O

1	We	O
2	used	O
3	deletion	O
4	analysis	O
5	and	O
6	transfection	O
7	assays	O
8	with	O
9	reporter	O
10	gene	O
11	constructs	O
12	to	O
13	examine	O
14	the	O
15	transcription	O
16	control	O
17	elements	O
18	in	O
19	the	O
20	5	O
21	'	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	B
27	EpoR	I
28	gene	I
29	.	O

1	The	O
2	CVA16	B
3	.	I
4	4	I
5	proteolipid	I
6	transcript	I
7	is	O
8	the	O
9	most	O
10	prevalent	O
11	of	O
12	the	O
13	two	O
14	proteolipid	O
15	messages	O
16	in	O
17	expanding	O
18	ovules	O
19	harvested	O
20	10	O
21	d	O
22	post	O
23	-	O
24	anthesis	O
25	.	O

1	Incubation	O
2	of	O
3	the	O
4	purified	O
5	fusion	O
6	proteins	O
7	with	O
8	[	O
9	gamma	O
10	-	O
11	32P	O
12	]	O
13	ATP	O
14	in	O
15	an	O
16	in	O
17	vitro	O
18	assay	O
19	showed	O
20	that	O
21	both	O
22	proteins	O
23	were	O
24	capable	O
25	of	O
26	autophosphorylation	O
27	.	O

1	The	O
2	character	O
3	of	O
4	specific	O
5	immune	O
6	response	O
7	in	O
8	101	O
9	immunized	O
10	children	O
11	and	O
12	in	O
13	12	O
14	adults	O
15	belonging	O
16	to	O
17	a	O
18	high	O
19	risk	O
20	group	O
21	with	O
22	respect	O
23	to	O
24	VHB	O
25	.	O

1	After	O
2	nadolol	O
3	,	O
4	heart	O
5	rate	O
6	decreased	O
7	(-	O
8	22	O
9	+/-	O
10	8	O
11	%),	O
12	and	O
13	so	O
14	did	O
15	PBV	O
16	and	O
17	PBF	O
18	(	O
19	8	O
20	.	O
21	8	O
22	+/-	O
23	3	O
24	.	O
25	4	O
26	vs	O
27	.	O

1	The	O
2	synthetic	O
3	DNA	O
4	sequence	O
5	was	O
6	constructed	O
7	to	O
8	achieve	O
9	efficient	O
10	base	O
11	pairing	O
12	with	O
13	Escherichia	B
14	coli	I
15	16S	I
16	ribosomal	I
17	RNA	I
18	,	O
19	avoidance	O
20	of	O
21	internal	O
22	secondary	O
23	structure	O
24	,	O
25	and	O
26	optimal	O
27	codon	O
28	usage	O
29	for	O
30	high	O
31	-	O
32	level	O
33	protein	O
34	expression	O
35	in	O
36	accord	O
37	with	O
38	the	O
39	known	O
40	preferences	O
41	in	O
42	E	O
43	.	O
44	coli	O
45	.	O

1	Adrenergic	O
2	system	O
3	activation	O
4	,	O
5	indicated	O
6	by	O
7	metanephrine	O
8	/	O
9	epinephrine	O
10	ratio	O
11	,	O
12	increased	O
13	with	O
14	time	O
15	in	O
16	losing	O
17	males	O
18	,	O
19	except	O
20	that	O
21	after	O
22	one	O
23	month	O
24	of	O
25	cohabitation	O
26	,	O
27	turnover	O
28	returned	O
29	to	O
30	levels	O
31	that	O
32	equaled	O
33	those	O
34	of	O
35	control	O
36	animals	O
37	.	O

1	Transabdominal	O
2	repair	O
3	of	O
4	type	O
5	IV	O
6	thoraco	O
7	-	O
8	abdominal	O
9	aortic	O
10	aneurysms	O
11	.	O

1	A	O
2	.	O

1	Transcription	O
2	factors	O
3	containing	O
4	a	O
5	basic	O
6	helix	O
7	-	O
8	loop	O
9	-	O
10	helix	O
11	(	O
12	bHLH	O
13	)	O
14	motif	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	tissue	O
20	-	O
21	specific	O
22	genes	O
23	in	O
24	a	O
25	number	O
26	of	O
27	mammalian	O
28	and	O
29	insect	O
30	systems	O
31	.	O

1	Primer	O
2	extension	O
3	and	O
4	cDNA	O
5	cloning	O
6	were	O
7	used	O
8	to	O
9	isolate	O
10	the	O
11	complete	O
12	5	O
13	'	O
14	end	O
15	of	O
16	the	O
17	Nramp1	B
18	mRNA	I
19	.	O

1	Primer	O
2	extension	O
3	and	O
4	S1	B
5	nuclease	I
6	mapping	O
7	experiments	O
8	were	O
9	used	O
10	to	O
11	locate	O
12	the	O
13	transcription	O
14	initiation	O
15	site	O
16	of	O
17	Nramp1	B
18	and	O
19	revealed	O
20	the	O
21	presence	O
22	of	O
23	one	O
24	major	O
25	and	O
26	several	O
27	minor	O
28	initiation	O
29	sites	O
30	.	O

1	EsaR	B
2	can	O
3	repress	O
4	its	O
5	own	O
6	expression	O
7	but	O
8	seems	O
9	not	O
10	to	O
11	regulate	O
12	the	O
13	expression	O
14	of	O
15	esaI	B
16	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	B
12	gene	I
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	The	O
2	plasmin	B
3	-	I
4	derived	I
5	D	I
6	(	I
7	approximately	I
8	105	I
9	-	I
10	kDa	I
11	)	I
12	product	I
13	,	O
14	however	O
15	,	O
16	could	O
17	be	O
18	cross	O
19	-	O
20	linked	O
21	into	O
22	DD	O
23	dimers	O
24	.	O

1	All	O
2	clinical	O
3	isolates	O
4	were	O
5	concomitantly	O
6	tested	O
7	by	O
8	disk	O
9	diffusion	O
10	and	O
11	agar	O
12	dilution	O
13	procedures	O
14	as	O
15	outlined	O
16	by	O
17	the	O
18	National	O
19	Committee	O
20	for	O
21	Clinical	O
22	Laboratory	O
23	Standards	O
24	.	O

1	IgE	B
2	levels	O
3	showed	O
4	higher	O
5	values	O
6	compared	O
7	to	O
8	normal	O
9	individuals	O
10	and	O
11	IgE	B
12	levels	O
13	were	O
14	higher	O
15	in	O
16	children	O
17	groups	O
18	than	O
19	in	O
20	adults	O
21	regardless	O
22	of	O
23	the	O
24	intensity	O
25	of	O
26	infection	O
27	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	tmy	B
8	-	I
9	1	I
10	gene	I
11	was	O
12	determined	O
13	by	O
14	microinjection	O
15	of	O
16	a	O
17	promoter	B
18	/	I
19	lacZ	I
20	fusion	I
21	gene	I
22	and	O
23	with	O
24	immunohistochemistry	O
25	by	O
26	using	O
27	affinity	O
28	-	O
29	purified	O
30	tissue	B
31	-	I
32	specific	I
33	anti	I
34	-	I
35	tropomyosins	I
36	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	Investigation	O
2	of	O
3	the	O
4	control	O
5	of	O
6	coronavirus	O
7	subgenomic	O
8	mRNA	O
9	transcription	O
10	by	O
11	using	O
12	T7	O
13	-	O
14	generated	O
15	negative	O
16	-	O
17	sense	O
18	RNA	O
19	transcripts	O
20	.	O

1	Initiation	O
2	of	O
3	translation	O
4	of	O
5	the	O
6	human	O
7	hepatitis	O
8	C	O
9	virus	O
10	(	O
11	HCV	O
12	)	O
13	RNA	O
14	genome	O
15	occurs	O
16	by	O
17	internal	O
18	ribosome	O
19	entry	O
20	into	O
21	the	O
22	5	O
23	'	O
24	noncoding	O
25	region	O
26	(	O
27	5	O
28	'	O
29	NCR	O
30	)	O
31	in	O
32	a	O
33	cap	O
34	-	O
35	independent	O
36	manner	O
37	.	O

1	Mean	O
2	longitudinal	O
3	extension	O
4	of	O
5	the	O
6	epidural	O
7	lesion	O
8	was	O
9	2	O
10	.	O
11	6	O
12	vertebral	O
13	segments	O
14	.	O

1	The	O
2	association	O
3	of	O
4	p255	B
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	B
15	CC3	I
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	O
23	pre	O
24	-	O
25	messenger	O
26	RNA	O
27	and	O
28	splicing	O
29	products	O
30	.	O

1	L	O
2	-	O
3	735	O
4	,	O
5	524	O
6	free	O
7	base	O
8	or	O
9	sulfate	O
10	salt	O
11	was	O
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	O
19	in	O
20	solid	O
21	dosage	O
22	forms	O
23	to	O
24	fasted	O
25	or	O
26	fed	O
27	Beagle	O
28	dogs	O
29	.	O

1	Doppler	O
2	ultrasound	O
3	studies	O
4	of	O
5	long	O
6	-	O
7	term	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	children	O
13	with	O
14	hemolytic	O
15	-	O
16	uremic	O
17	syndrome	O

1	Thus	O
2	,	O
3	endemic	O
4	cumlations	O
5	of	O
6	hepatitis	O
7	A	O
8	diseases	O
9	are	O
10	possible	O
11	.	O

1	(	O
2	1991	O
3	).	O

1	The	O
2	properties	O
3	of	O
4	the	O
5	phi	O
6	29	O
7	SSB	B
8	-	I
9	ssDNA	I
10	complex	O
11	are	O
12	described	O
13	.	O

1	This	O
2	shows	O
3	that	O
4	the	O
5	characteristically	O
6	diffuse	O
7	banding	O
8	pattern	O
9	of	O
10	plant	O
11	nuclear	O
12	proteins	O
13	interacting	O
14	with	O
15	the	O
16	G	O
17	-	O
18	box	O
19	is	O
20	also	O
21	observed	O
22	in	O
23	a	O
24	binding	O
25	assay	O
26	using	O
27	only	O
28	one	O
29	recombinant	B
30	GBF	I
31	.	O

1	We	O
2	studied	O
3	120	O
4	male	O
5	and	O
6	42	O
7	female	O
8	patients	O
9	with	O
10	early	O
11	CAD	O
12	who	O
13	were	O
14	unrelated	O
15	to	O
16	each	O
17	other	O
18	but	O
19	were	O
20	from	O
21	families	O
22	in	O
23	which	O
24	at	O
25	least	O
26	one	O
27	other	O
28	sibling	O
29	had	O
30	early	O
31	CAD	O
32	.	O

1	The	O
2	physical	O
3	linkage	O
4	of	O
5	the	O
6	FHR2	B
7	and	O
8	the	O
9	factor	B
10	H	I
11	genes	I
12	provides	O
13	additional	O
14	evidence	O
15	for	O
16	a	O
17	close	O
18	relatedness	O
19	of	O
20	complement	B
21	factor	I
22	H	I
23	and	O
24	the	O
25	factor	B
26	H	I
27	-	I
28	related	I
29	proteins	I
30	.	O

1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	B
9	pre	I
10	-	I
11	T	I
12	-	I
13	cell	I
14	receptor	I
15	alpha	I
16	gene	I
17	.	O

1	The	O
2	third	O
3	domain	O
4	had	O
5	the	O
6	motif	O
7	of	O
8	a	O
9	cAMP	O
10	response	O
11	element	O
12	(	O
13	CRE	O
14	).	O

1	The	O
2	tyrosine	O
3	-	O
4	phosphorylated	O
5	state	O
6	of	O
7	CAK	B
8	beta	I
9	was	O
10	not	O
11	reduced	O
12	on	O
13	trypsinization	O
14	,	O
15	nor	O
16	enhanced	O
17	in	O
18	response	O
19	to	O
20	plating	O
21	3Y1	O
22	cells	O
23	onto	O
24	fibronectin	B
25	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	while	O
6	many	O
7	muscle	O
8	gene	O
9	E	O
10	-	O
11	boxes	O
12	are	O
13	capable	O
14	of	O
15	binding	O
16	the	O
17	previously	O
18	characterized	O
19	spectrum	O
20	of	O
21	MDF	B
22	/	I
23	bH	I
24	-	I
25	L	I
26	-	I
27	H	I
28	heterodimers	I
29	in	O
30	vitro	O
31	,	O
32	MCK	B
33	-	I
34	L	I
35	type	O
36	E	O
37	-	O
38	boxes	O
39	probably	O
40	bind	O
41	qualitatively	O
42	different	O
43	factors	O
44	in	O
45	vivo	O
46	.	O

1	A	O
2	single	O
3	-	O
4	case	O
5	experimental	O
6	ABAB	O
7	multiple	O
8	baseline	O
9	design	O
10	was	O
11	employed	O
12	to	O
13	test	O
14	for	O
15	treatment	O
16	effectiveness	O
17	.	O

1	These	O
2	clones	O
3	were	O
4	found	O
5	to	O
6	share	O
7	a	O
8	common	O
9	domain	O
10	encoded	O
11	by	O
12	p	O
13	(	O
14	CA	O
15	)	O
16	n	O
17	repeats	O
18	;	O
19	a	O
20	simple	O
21	sequence	O
22	length	O
23	polymorphism	O
24	(	O
25	SSLP	O
26	).	O

1	In	O
2	one	O
3	glioblastoma	O
4	cell	O
5	line	O
6	,	O
7	a	O
8	Shc	B
9	-	O
10	associated	O
11	p190	B
12	was	O
13	identified	O
14	as	O
15	the	O
16	activated	O
17	PDGFR	B
18	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	comparison	O
7	to	O
8	reports	O
9	from	O
10	other	O
11	regions	O
12	,	O
13	Scandinavian	O
14	renal	O
15	transplant	O
16	recipients	O
17	are	O
18	at	O
19	high	O
20	risk	O
21	of	O
22	dying	O
23	of	O
24	IHD	O
25	.	O

1	Veterinary	O
2	certification	O
3	for	O
4	livestock	O
5	export	O
6	.	O

1	The	O
2	serum	O
3	concentration	O
4	of	O
5	iP	O
6	before	O
7	dialysis	O
8	(	O
9	HD	O
10	)	O
11	was	O
12	on	O
13	average	O
14	3	O
15	.	O
16	06	O
17	(+/-	O
18	0	O
19	.	O
20	81	O
21	)	O
22	mmol	O
23	/	O
24	l	O
25	and	O
26	D	O
27	was	O
28	on	O
29	average	O
30	55	O
31	.	O
32	6	O
33	(+/-	O
34	10	O
35	.	O
36	0	O
37	)	O
38	mmol	O
39	.	O

1	A	O
2	significant	O
3	correlation	O
4	between	O
5	a	O
6	number	O
7	of	O
8	functional	O
9	parameters	O
10	of	O
11	gastric	O
12	secretion	O
13	,	O
14	incretion	O
15	and	O
16	histological	O
17	changes	O
18	of	O
19	gastric	O
20	mucosa	O
21	was	O
22	found	O
23	in	O
24	patients	O
25	with	O
26	chronic	O
27	gastritis	O
28	.	O

1	The	O
2	TAF	O
3	factor	O
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O

1	Diffuse	O
2	white	O
3	matter	O
4	injury	O
5	can	O
6	be	O
7	attributed	O
8	to	O
9	radiation	O
10	and	O
11	associated	O
12	with	O
13	neurological	O
14	deficits	O
15	,	O
16	but	O
17	leukoencephalopathy	O
18	is	O
19	rarely	O
20	observed	O
21	in	O
22	the	O
23	absence	O
24	of	O
25	chemotherapy	O
26	.	O

1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	B
8	-	I
9	kDa	I
10	CaM	I
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Little	O
2	or	O
3	no	O
4	protection	O
5	was	O
6	detected	O
7	using	O
8	adrenal	O
9	cortex	O
10	,	O
11	adrenal	O
12	medulla	O
13	,	O
14	liver	O
15	,	O
16	kidney	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	or	O
22	T	O
23	-	O
24	lymphocyte	O
25	total	O
26	RNA	O
27	.	O

1	The	O
2	PDGFR	B
3	mutants	I
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O

1	We	O
2	found	O
3	a	O
4	direct	O
5	correlation	O
6	between	O
7	the	O
8	levels	O
9	of	O
10	transcription	O
11	of	O
12	the	O
13	acc	B
14	genes	I
15	and	O
16	the	O
17	rate	O
18	of	O
19	cellular	O
20	growth	O
21	.	O

1	The	O
2	hybridizing	O
3	clone	O
4	of	O
5	V	O
6	.	O
7	vulnificus	O
8	chromosomal	O
9	DNA	O
10	complemented	O
11	a	O
12	V	B
13	.	I
14	cholerae	I
15	fur	I
16	mutant	I
17	.	O

1	We	O
2	generated	O
3	transformed	O
4	B	O
5	lymphoblast	O
6	cell	O
7	lines	O
8	from	O
9	controls	O
10	,	O
11	from	O
12	four	O
13	patients	O
14	with	O
15	p47	B
16	-	O
17	phox	B
18	-	O
19	deficient	O
20	chronic	O
21	granulomatous	O
22	disease	O
23	,	O
24	and	O
25	from	O
26	three	O
27	parents	O
28	.	O

1	The	O
2	ectopic	O
3	expression	O
4	of	O
5	Oct	B
6	-	I
7	3	I
8	/	I
9	4	I
10	in	O
11	hybrid	O
12	cells	O
13	under	O
14	a	O
15	constitutive	O
16	promoter	O
17	is	O
18	sufficient	O
19	for	O
20	transcriptional	O
21	activation	O
22	of	O
23	an	O
24	octamer	O
25	-	O
26	dependent	O
27	promoter	O
28	.	O

1	RNase	B
2	protection	O
3	and	O
4	primer	O
5	extension	O
6	assays	O
7	confirmed	O
8	that	O
9	the	O
10	5	O
11	'	O
12	non	O
13	-	O
14	coding	O
15	exon	O
16	is	O
17	included	O
18	in	O
19	the	O
20	DDT1	O
21	aFGF	B
22	mRNA	I
23	and	O
24	that	O
25	a	O
26	major	O
27	transcription	O
28	start	O
29	site	O
30	is	O
31	approximately	O
32	136	O
33	bp	O
34	upstream	O
35	of	O
36	the	O
37	5	O
38	'	O
39	non	O
40	-	O
41	coding	O
42	splice	O
43	junction	O
44	of	O
45	this	O
46	exon	O
47	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	FK	O
6	506	O
7	is	O
8	a	O
9	useful	O
10	immunosuppressive	O
11	agent	O
12	in	O
13	kidney	O
14	transplantation	O
15	.	O

1	The	O
2	roles	O
3	of	O
4	phorbol	O
5	esters	O
6	and	O
7	cyclic	O
8	AMP	O
9	in	O
10	mediating	O
11	the	O
12	GnRH	B
13	response	O
14	were	O
15	also	O
16	investigated	O
17	.	O

1	RT	O
2	-	O
3	PCR	O
4	using	O
5	1	O
6	.	O
7	D	O
8	-	O
9	specific	O
10	primers	O
11	showed	O
12	that	O
13	kidney	O
14	,	O
15	brain	O
16	and	O
17	prostate	O
18	do	O
19	not	O
20	express	O
21	1	O
22	.	O
23	D	O
24	mRNA	O
25	even	O
26	though	O
27	kidney	O
28	and	O
29	brain	O
30	are	O
31	the	O
32	most	O
33	abundant	O
34	source	O
35	for	O
36	aFGF	B
37	protein	I
38	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	two	O
7	genes	B
8	encoding	I
9	gp138	I
10	,	O
11	a	O
12	cell	O
13	surface	O
14	glycoprotein	O
15	involved	O
16	in	O
17	the	O
18	sexual	O
19	cell	O
20	fusion	O
21	of	O
22	Dictyostelium	O
23	discoideum	O
24	.	O

1	Two	O
2	-	O
3	dimensional	O
4	phosphotryptic	O
5	analyses	O
6	indicate	O
7	that	O
8	phosphorylation	O
9	on	O
10	Ser	O
11	-	O
12	12	O
13	and	O
14	Ser	O
15	-	O
16	48	O
17	in	O
18	unstimulated	O
19	cells	O
20	is	O
21	associated	O
22	with	O
23	the	O
24	ability	O
25	of	O
26	overexpressed	O
27	pp60c	B
28	-	I
29	src	I
30	to	O
31	potentiate	O
32	beta	O
33	-	O
34	adrenergic	O
35	signalling	O
36	.	O

1	Piroximone	O
2	is	O
3	a	O
4	new	O
5	phosphodiesterase	B
6	III	I
7	inhibitor	O
8	that	O
9	combines	O
10	inotropic	O
11	and	O
12	vasodilator	O
13	properties	O
14	.	O

1	Cytogenetic	O
2	studies	O
3	were	O
4	performed	O
5	in	O
6	lymphocytes	O
7	from	O
8	hospital	O
9	workers	O
10	exposed	O
11	to	O
12	low	O
13	doses	O
14	of	O
15	radiation	O
16	(	O
17	1	O
18	.	O
19	6	O
20	-	O
21	42	O
22	.	O
23	71	O
24	mSv	O
25	).	O

1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O

1	The	O
2	first	O
3	exon	O
4	encodes	O
5	66	O
6	bp	O
7	of	O
8	the	O
9	5	O
10	'-	O
11	untranslated	O
12	sequence	O
13	,	O
14	while	O
15	exon	O
16	2	O
17	encodes	O
18	the	O
19	coding	O
20	and	O
21	3	O
22	'-	O
23	untranslated	O
24	sequences	O
25	.	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	four	O
6	members	O
7	of	O
8	the	O
9	SRC	B
10	-	I
11	family	I
12	revealed	O
13	nearly	O
14	identical	O
15	exon	O
16	/	O
17	intron	O
18	boundaries	O
19	within	O
20	the	O
21	catalytic	O
22	domain	O
23	of	O
24	this	O
25	family	O
26	.	O

1	Since	O
2	we	O
3	have	O
4	observed	O
5	effects	O
6	of	O
7	growth	O
8	factors	O
9	and	O
10	cAMP	O
11	as	O
12	well	O
13	as	O
14	estradiol	O
15	(	O
16	E2	O
17	)	O
18	on	O
19	regulation	O
20	of	O
21	expression	O
22	of	O
23	some	O
24	genes	O
25	stimulated	O
26	by	O
27	the	O
28	estrogen	B
29	receptor	I
30	(	O
31	ER	B
32	),	O
33	we	O
34	have	O
35	undertaken	O
36	studies	O
37	to	O
38	examine	O
39	directly	O
40	whether	O
41	activators	O
42	of	O
43	protein	O
44	kinases	O
45	can	O
46	modulate	O
47	transcriptional	O
48	activity	O
49	of	O
50	the	O
51	ER	B
52	.	O

1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	Whipple	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	284	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	Whipple	O
22	bacterium	O
23	(	O
24	Tropheryma	O
25	whippelii	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O

1	RNA	B
2	polymerase	I
3	bound	O
4	to	O
5	the	O
6	+	O
7	10A	O
8	promoter	O
9	partially	O
10	protects	O
11	a	O
12	20	O
13	base	O
14	-	O
15	pair	O
16	sequence	O
17	from	O
18	DNase	B
19	I	I
20	digestion	O
21	upstream	O
22	of	O
23	the	O
24	start	O
25	site	O
26	.	O

1	Salivary	O
2	sodium	O
3	,	O
4	calcium	O
5	,	O
6	and	O
7	magnesium	O
8	concentrations	O
9	were	O
10	significantly	O
11	higher	O
12	in	O
13	the	O
14	SLE	O
15	patients	O
16	with	O
17	systemic	O
18	lupus	O
19	erythematosus	O
20	,	O
21	whereas	O
22	potassium	O
23	and	O
24	total	O
25	protein	O
26	concentrations	O
27	and	O
28	amylase	B
29	activity	O
30	did	O
31	not	O
32	differ	O
33	significantly	O
34	from	O
35	the	O
36	controls	O
37	.	O

1	Chem	O
2	.	O

1	Recombinant	O
2	plasmid	O
3	pFV100	O
4	was	O
5	subsequently	O
6	isolated	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	B	O
13	-	O
14	band	O
15	expression	O
16	in	O
17	ge6	B
18	.	O

1	We	O
2	here	O
3	demonstrate	O
4	that	O
5	a	O
6	temperature	O
7	-	O
8	sensitive	O
9	fission	O
10	yeast	O
11	mutant	O
12	which	O
13	has	O
14	a	O
15	mutation	O
16	in	O
17	a	O
18	homologous	O
19	gene	O
20	,	O
21	and	O
22	two	O
23	of	O
24	three	O
25	additional	O
26	(	O
27	mtr1	B
28	/	O
29	prp20	B
30	/	O
31	srm1	B
32	)	O
33	mutants	O
34	accumulate	O
35	nuclear	O
36	poly	O
37	(	O
38	A	O
39	)+	O
40	RNA	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	.	O

1	Since	O
2	RCC1p	B
3	acts	O
4	as	O
5	GNRP	B
6	for	O
7	Ran	B
8	,	O
9	a	O
10	small	B
11	nuclear	I
12	GTPase	I
13	of	O
14	the	O
15	ras	B
16	superfamily	I
17	,	O
18	we	O
19	have	O
20	identified	O
21	two	O
22	homologs	O
23	of	O
24	Ran	B
25	in	O
26	S	O
27	.	O
28	cerevisiae	O
29	(	O
30	CNR1	B
31	and	O
32	CNR2	B
33	).	O

1	The	O
2	immunosuppressant	O
3	FK506	O
4	inhibits	O
5	amino	O
6	acid	O
7	import	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	.	O

1	Prostate	B
2	specific	I
3	antigen	I
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	worse	O
13	]	O
14	than	O
15	prostatic	B
16	acid	I
17	phosphatase	I
18	.	O

1	Protein	O
2	phosphorylation	O
3	appears	O
4	to	O
5	play	O
6	a	O
7	critical	O
8	role	O
9	in	O
10	uPA	B
11	gene	I
12	expression	O
13	in	O
14	these	O
15	cells	O
16	;	O
17	protein	B
18	kinase	I
19	C	I
20	-	O
21	activating	O
22	phorbol	O
23	esters	O
24	cooperate	O
25	with	O
26	pp60v	B
27	-	I
28	src	I
29	to	O
30	synergistically	O
31	increase	O
32	uPA	B
33	mRNA	I
34	,	O
35	whereas	O
36	cyclic	B
37	AMP	I
38	(	I
39	cAMP	I
40	)-	I
41	dependent	I
42	protein	I
43	kinase	I
44	-	O
45	activating	O
46	agents	O
47	(	O
48	e	O
49	.	O
50	g	O
51	.,	O
52	8	O
53	-	O
54	bromo	O
55	cAMP	O
56	)	O
57	repress	O
58	uPA	B
59	mRNA	I
60	levels	O
61	.	O

1	Of	O
2	these	O
3	carriers	O
4	149	O
5	were	O
6	diagnosed	O
7	to	O
8	be	O
9	asymptomatic	O
10	clinically	O
11	,	O
12	biochemically	O
13	and	O
14	echographically	O
15	.	O

1	This	O
2	300	O
3	bp	O
4	5	O
5	'-	O
6	upstream	O
7	sequence	O
8	of	O
9	K3	B
10	keratin	I
11	gene	I
12	,	O
13	which	O
14	can	O
15	function	O
16	in	O
17	vitro	O
18	as	O
19	a	O
20	keratinocyte	O
21	-	O
22	specific	O
23	promoter	O
24	,	O
25	contains	O
26	two	O
27	clusters	O
28	of	O
29	partially	O
30	overlapping	O
31	motifs	O
32	,	O
33	one	O
34	with	O
35	an	O
36	NFkB	B
37	consensus	O
38	sequence	O
39	and	O
40	another	O
41	with	O
42	a	O
43	GC	O
44	box	O
45	.	O

1	Identification	O
2	of	O
3	mutations	O
4	in	O
5	the	O
6	coding	O
7	sequence	O
8	of	O
9	the	O
10	proto	B
11	-	I
12	oncogene	I
13	c	I
14	-	I
15	kit	I
16	in	O
17	a	O
18	human	O
19	mast	O
20	cell	O
21	leukemia	O
22	cell	O
23	line	O
24	causing	O
25	ligand	O
26	-	O
27	independent	O
28	activation	O
29	of	O
30	c	B
31	-	I
32	kit	I
33	product	I
34	.	O

1	BACKGROUND	O
2	:	O
3	Delineation	O
4	of	O
5	the	O
6	morphologic	O
7	aspects	O
8	of	O
9	age	O
10	-	O
11	related	O
12	macular	O
13	degeneration	O
14	(	O
15	ARMD	O
16	)	O
17	is	O
18	helpful	O
19	in	O
20	correlation	O
21	with	O
22	the	O
23	clinical	O
24	features	O
25	and	O
26	may	O
27	contribute	O
28	to	O
29	understanding	O
30	the	O
31	pathogenesis	O
32	.	O

1	An	O
2	abundant	O
3	1	O
4	.	O
5	1	O
6	-	O
7	kb	O
8	virion	O
9	-	O
10	sense	O
11	polyadenylated	O
12	RNA	O
13	and	O
14	four	O
15	complementary	O
16	-	O
17	sense	O
18	polyadenylated	O
19	RNAs	O
20	of	O
21	1	O
22	.	O
23	7	O
24	,	O
25	1	O
26	.	O
27	5	O
28	,	O
29	1	O
30	.	O
31	3	O
32	,	O
33	and	O
34	0	O
35	.	O
36	7	O
37	kb	O
38	have	O
39	been	O
40	identified	O
41	by	O
42	northern	O
43	blot	O
44	hybridization	O
45	,	O
46	confirming	O
47	the	O
48	bidirectional	O
49	transcription	O
50	strategy	O
51	implied	O
52	by	O
53	the	O
54	arrangement	O
55	of	O
56	ORFs	O
57	.	O

1	Risk	O
2	factors	O
3	associated	O
4	with	O
5	a	O
6	high	O
7	seroprevalence	O
8	of	O
9	hepatitis	O
10	C	O
11	virus	O
12	infection	O
13	in	O
14	Egyptian	O
15	blood	O
16	donors	O
17	.	O

1	Here	O
2	the	O
3	cloning	O
4	and	O
5	molecular	O
6	analysis	O
7	of	O
8	the	O
9	Zm	B
10	-	I
11	ERabp1	I
12	,	O
13	Zm	B
14	-	I
15	ERabp4	I
16	,	O
17	and	O
18	Zm	B
19	-	I
20	ERabp5	I
21	genes	I
22	is	O
23	presented	O
24	.	O

1	This	O
2	agent	O
3	,	O
4	isolated	O
5	from	O
6	the	O
7	fungus	O
8	Streptomyces	O
9	tsukubaensis	O
10	,	O
11	has	O
12	a	O
13	mechanism	O
14	of	O
15	action	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	cyclosporine	O
21	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O

1	Finally	O
2	,	O
3	the	O
4	stability	O
5	of	O
6	the	O
7	nucleotide	O
8	binding	O
9	function	O
10	of	O
11	the	O
12	two	O
13	proteins	O
14	is	O
15	similar	O
16	as	O
17	assessed	O
18	by	O
19	sensitivity	O
20	to	O
21	urea	O
22	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	binding	I
8	protein	I
9	-	I
10	2	I
11	(	O
12	IGF	B
13	-	I
14	BP	I
15	-	I
16	2	I
17	)	O
18	transcription	O
19	in	O
20	rat	O
21	liver	O
22	varies	O
23	with	O
24	developmental	O
25	age	O
26	and	O
27	fasting	O
28	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	RV	O
6	5	O
7	'(+)	O
8	SL	O
9	sequence	O
10	had	O
11	the	O
12	primary	O
13	enhancing	O
14	effect	O
15	on	O
16	translation	O
17	.	O

1	By	O
2	contrast	O
3	,	O
4	all	O
5	proteins	O
6	initiated	O
7	with	O
8	a	O
9	methionine	O
10	placed	O
11	one	O
12	residue	O
13	upstream	O
14	of	O
15	the	O
16	natural	O
17	N	O
18	terminus	O
19	of	O
20	PR	B
21	failed	O
22	to	O
23	show	O
24	specific	O
25	proteolysis	O
26	.	O

1	Reverse	B
2	transcriptase	I
3	and	O
4	protease	O
5	activities	O
6	of	O
7	avian	O
8	leukosis	O
9	virus	O
10	Gag	B
11	-	O
12	Pol	B
13	fusion	O
14	proteins	O
15	expressed	O
16	in	O
17	insect	O
18	cells	O
19	.	O

1	In	O
2	addition	O
3	,	O
4	an	O
5	mck1	B
6	mds1	I
7	mrk1	I
8	triple	O
9	disruptant	O
10	was	O
11	viable	O
12	.	O

1	However	O
2	,	O
3	there	O
4	were	O
5	some	O
6	properties	O
7	of	O
8	Rak	B
9	that	O
10	are	O
11	distinct	O
12	from	O
13	Src	B
14	-	I
15	like	I
16	kinases	I
17	:	O
18	(	O
19	a	O
20	)	O
21	expression	O
22	of	O
23	Rak	B
24	was	O
25	predominantly	O
26	in	O
27	epithelial	O
28	-	O
29	derived	O
30	cell	O
31	lines	O
32	and	O
33	tissues	O
34	,	O
35	especially	O
36	normal	O
37	liver	O
38	and	O
39	kidney	O
40	,	O
41	and	O
42	cell	O
43	lines	O
44	of	O
45	breast	O
46	and	O
47	colon	O
48	origin	O
49	;	O
50	(	O
51	b	O
52	)	O
53	Rak	B
54	does	O
55	not	O
56	harbor	O
57	the	O
58	NH2	O
59	-	O
60	terminal	O
61	glycine	O
62	essential	O
63	for	O
64	myristylation	O
65	and	O
66	membrane	O
67	localization	O
68	;	O
69	and	O
70	(	O
71	c	O
72	)	O
73	Rak	B
74	possesses	O
75	a	O
76	putative	O
77	bipartite	O
78	nuclear	O
79	localization	O
80	signal	O
81	in	O
82	the	O
83	SH2	B
84	domain	I
85	,	O
86	and	O
87	subcellular	O
88	fractionation	O
89	studies	O
90	revealed	O
91	that	O
92	p54rak	B
93	resides	O
94	predominantly	O
95	in	O
96	the	O
97	nucleus	O
98	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	We	O
6	report	O
7	our	O
8	experience	O
9	with	O
10	seven	O
11	children	O
12	with	O
13	active	O
14	small	O
15	bowel	O
16	Crohn	O
17	'	O
18	s	O
19	disease	O
20	given	O
21	a	O
22	casein	B
23	-	O
24	based	O
25	,	O
26	polymeric	O
27	feed	O
28	rich	O
29	in	O
30	TGF	B
31	-	I
32	beta	I
33	2	I
34	(	O
35	Specific	O
36	Polymeric	O
37	Diet	O
38	;	O
39	Nestle	O
40	-	O
41	Clintec	O
42	;	O
43	Vevey	O
44	,	O
45	Switzerland	O
46	)	O
47	as	O
48	complete	O
49	nutrition	O
50	for	O
51	8	O
52	weeks	O
53	.	O

1	The	O
2	leader	O
3	sequence	O
4	of	O
5	the	O
6	isolated	O
7	cDNA	O
8	clone	O
9	contains	O
10	several	O
11	small	O
12	open	O
13	reading	O
14	frames	O
15	upstream	O
16	of	O
17	the	O
18	initiation	O
19	codon	O
20	of	O
21	the	O
22	largest	O
23	open	O
24	reading	O
25	frame	O
26	coding	O
27	for	O
28	the	O
29	homeodomain	B
30	protein	I
31	.	O

1	A	O
2	small	O
3	amount	O
4	of	O
5	HSP81	B
6	-	I
7	1	I
8	mRNA	I
9	was	O
10	detected	O
11	only	O
12	in	O
13	roots	O
14	.	O

1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O

1	No	O
2	local	O
3	destruction	O
4	by	O
5	tumor	O
6	or	O
7	infection	O
8	could	O
9	be	O
10	demonstrated	O
11	apart	O
12	from	O
13	HIV	O
14	infection	O
15	.	O

1	Among	O
2	the	O
3	mixed	O
4	race	O
5	persons	O
6	one	O
7	Chukcha	O
8	-	O
9	Eskimo	O
10	had	O
11	AS	O
12	,	O
13	one	O
14	Eskimo	O
15	-	O
16	Russian	O
17	had	O
18	psoriatic	O
19	arthritis	O
20	(	O
21	PsA	O
22	).	O

1	Our	O
2	data	O
3	complement	O
4	other	O
5	studies	O
6	of	O
7	circumpolar	O
8	populations	O
9	and	O
10	reinforce	O
11	the	O
12	reported	O
13	high	O
14	prevalences	O
15	of	O
16	SPA	O
17	and	O
18	HLA	B
19	-	I
20	B27	I
21	among	O
22	those	O
23	populations	O
24	.	O

1	Clinical	O
2	studies	O
3	SY5555	O
4	was	O
5	administered	O
6	to	O
7	45	O
8	patients	O
9	with	O
10	various	O
11	infectious	O
12	diseases	O
13	(	O
14	2	O
15	with	O
16	acute	O
17	pharyngitis	O
18	,	O
19	8	O
20	with	O
21	acute	O
22	tonsillitis	O
23	,	O
24	4	O
25	with	O
26	lacunar	O
27	tonsillitis	O
28	,	O
29	3	O
30	each	O
31	with	O
32	acute	O
33	bronchitis	O
34	,	O
35	pneumonia	O
36	and	O
37	pertussis	O
38	,	O
39	7	O
40	with	O
41	scarlet	O
42	fever	O
43	,	O
44	3	O
45	with	O
46	impetigo	O
47	contagiosa	O
48	,	O
49	6	O
50	with	O
51	acute	O
52	urinary	O
53	tract	O
54	infections	O
55	,	O
56	2	O
57	with	O
58	balanoposthitis	O
59	and	O
60	1	O
61	each	O
62	with	O
63	cervical	O
64	lymphadenitis	O
65	,	O
66	S	O
67	.	O
68	S	O
69	.	O
70	S	O
71	.	O
72	S	O
73	.,	O
74	vulvitis	O
75	and	O
76	acute	O
77	colitis	O
78	)	O
79	at	O
80	daily	O
81	doses	O
82	between	O
83	3	O
84	.	O
85	4	O
86	-	O
87	10	O
88	mg	O
89	/	O
90	kg	O
91	,	O
92	t	O
93	.	O
94	i	O
95	.	O
96	d	O
97	.,	O
98	for	O
99	3	O
100	-	O
101	14	O
102	days	O
103	.	O

1	Although	O
2	most	O
3	SH2	B
4	-	O
5	pTyr	B
6	interactions	O
7	occur	O
8	between	O
9	two	O
10	different	O
11	types	O
12	of	O
13	molecules	O
14	,	O
15	some	O
16	appear	O
17	to	O
18	involve	O
19	only	O
20	a	O
21	single	O
22	molecular	O
23	type	O
24	.	O

1	RESULTS	O
2	:	O
3	Closure	O
4	time	O
5	of	O
6	fistulas	O
7	in	O
8	patients	O
9	receiving	O
10	TPN	O
11	+	O
12	somatostatin	B
13	was	O
14	significantly	O
15	shorter	O
16	(	O
17	13	O
18	.	O
19	86	O
20	+/-	O
21	1	O
22	.	O
23	84	O
24	versus	O
25	20	O
26	.	O
27	4	O
28	+/-	O
29	2	O
30	.	O
31	89	O
32	days	O
33	)	O
34	than	O
35	in	O
36	those	O
37	receiving	O
38	TPN	O
39	alone	O
40	.	O

1	Experimental	O
2	adhesion	O
3	prophylaxis	O
4	with	O
5	recombinant	B
6	tissue	I
7	plasminogen	I
8	activator	I
9	.	O

1	Scratching	O
2	during	O
3	sleep	O
4	in	O
5	children	O
6	with	O
7	atopic	O
8	dermatitis	O
9	is	O
10	associated	O
11	with	O
12	increased	O
13	VO2	O
14	.	O

1	To	O
2	determine	O
3	which	O
4	sequences	O
5	in	O
6	the	O
7	rat	B
8	P450c17	I
9	promoter	I
10	may	O
11	be	O
12	responsible	O
13	for	O
14	basal	O
15	and	O
16	cAMP	O
17	-	O
18	stimulated	O
19	gene	O
20	transcription	O
21	,	O
22	deletion	O
23	constructs	O
24	containing	O
25	between	O
26	-	O
27	1	O
28	,	O
29	560	O
30	and	O
31	-	O
32	53	O
33	base	O
34	pairs	O
35	of	O
36	5	O
37	'-	O
38	flanking	O
39	DNA	O
40	from	O
41	the	O
42	rat	B
43	P450c17	I
44	gene	I
45	were	O
46	ligated	O
47	to	O
48	plasmids	O
49	expressing	O
50	the	O
51	reporter	O
52	gene	O
53	luciferase	B
54	and	O
55	transfected	O
56	into	O
57	two	O
58	mouse	O
59	cell	O
60	lines	O
61	,	O
62	adrenal	O
63	Y	O
64	-	O
65	1	O
66	cells	O
67	,	O
68	and	O
69	testicular	O
70	Leydig	O
71	MA	O
72	-	O
73	10	O
74	cells	O
75	.	O

1	Within	O
2	-	O
3	subject	O
4	BP	O
5	differences	O
6	between	O
7	fish	O
8	oil	O
9	and	O
10	corn	O
11	oil	O
12	treatment	O
13	were	O
14	similar	O
15	for	O
16	Dinamap	O
17	(	O
18	3	O
19	.	O
20	2	O
21	+/-	O
22	1	O
23	.	O
24	8	O
25	/	O
26	2	O
27	.	O
28	5	O
29	+/-	O
30	1	O
31	.	O
32	0	O
33	mm	O
34	Hg	O
35	)	O
36	and	O
37	for	O
38	24	O
39	-	O
40	h	O
41	ABP	O
42	(	O
43	2	O
44	.	O
45	5	O
46	+/-	O
47	1	O
48	.	O
49	0	O
50	/	O
51	2	O
52	.	O
53	3	O
54	+/-	O
55	0	O
56	.	O
57	8	O
58	mm	O
59	Hg	O
60	),	O
61	but	O
62	were	O
63	more	O
64	significant	O
65	with	O
66	the	O
67	latter	O
68	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	the	O
7	mouse	B
8	NMO1	I
9	cDNA	I
10	,	O
11	which	O
12	encodes	O
13	the	O
14	NAD	B
15	(	I
16	P	I
17	)	I
18	H	I
19	:	I
20	menadione	I
21	oxidoreductase	I
22	[	O
23	also	O
24	called	O
25	NAD	B
26	(	I
27	P	I
28	)	I
29	H	I
30	:(	I
31	quinone	I
32	acceptor	I
33	)	I
34	oxidoreductase	I
35	;	O
36	quinone	B
37	reductase	I
38	;	O
39	azo	B
40	dye	I
41	reductase	I
42	;	O
43	DT	B
44	diaphorase	I
45	;	O
46	EC	B
47	1	I
48	.	I
49	6	I
50	.	I
51	99	I
52	.	I
53	2	I
54	].	O

1	Escherichia	O
2	coli	O
3	JRG582	O
4	is	O
5	an	O
6	ampD	B
7	ampE	I
8	deletion	O
9	derivative	O
10	of	O
11	strain	O
12	HfrH	O
13	and	O
14	accordingly	O
15	it	O
16	is	O
17	derepressed	O
18	for	O
19	expression	O
20	of	O
21	the	O
22	cloned	O
23	inducible	O
24	beta	B
25	-	I
26	lactamase	I
27	gene	I
28	of	O
29	Citrobacter	O
30	freundii	O
31	,	O
32	carried	O
33	on	O
34	plasmid	O
35	pNU305	O
36	.	O

1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O

1	Solitary	O
2	thyroid	O
3	nodule	O
4	.	O

1	Male	O
2	contraception	O
3	:	O
4	ideas	O
5	for	O
6	the	O
7	future	O
8	.	O

1	While	O
2	daily	O
3	food	O
4	intake	O
5	was	O
6	almost	O
7	constant	O
8	regardless	O
9	of	O
10	the	O
11	dietary	O
12	protein	O
13	level	O
14	,	O
15	water	O
16	intake	O
17	and	O
18	urine	O
19	volume	O
20	increased	O
21	with	O
22	increasing	O
23	the	O
24	dietary	O
25	protein	O
26	.	O

1	We	O
2	propose	O
3	that	O
4	Mad	B
5	and	O
6	Medea	B
7	encode	O
8	rate	O
9	-	O
10	limiting	O
11	components	O
12	integral	O
13	to	O
14	dpp	B
15	pathways	O
16	throughout	O
17	development	O
18	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	vacuolar	B
6	H	I
7	(+)-	I
8	ATPase	I
9	B2	I
10	subunit	I
11	gene	I
12	in	O
13	differentiating	O
14	THP	O
15	-	O
16	1	O
17	cells	O
18	.	O

1	However	O
2	,	O
3	the	O
4	inability	O
5	to	O
6	export	O
7	RNA	O
8	from	O
9	the	O
10	nucleus	O
11	to	O
12	the	O
13	cytoplasm	O
14	was	O
15	not	O
16	limited	O
17	to	O
18	a	O
19	particular	O
20	phase	O
21	of	O
22	the	O
23	cell	O
24	division	O
25	cycle	O
26	.	O

1	An	O
2	E	O
3	box	O
4	element	O
5	is	O
6	required	O
7	for	O
8	the	O
9	expression	O
10	of	O
11	the	O
12	ad4bp	B
13	gene	I
14	,	O
15	a	O
16	mammalian	B
17	homologue	I
18	of	I
19	ftz	I
20	-	I
21	f1	I
22	gene	I
23	,	O
24	which	O
25	is	O
26	essential	O
27	for	O
28	adrenal	O
29	and	O
30	gonadal	O
31	development	O
32	.	O

1	Inhibition	O
2	assays	O
3	performed	O
4	with	O
5	over	O
6	30	O
7	different	O
8	natural	O
9	and	O
10	synthetic	O
11	sialylated	O
12	and	O
13	/	O
14	or	O
15	sulfated	O
16	compounds	O
17	are	O
18	utilized	O
19	to	O
20	define	O
21	in	O
22	greater	O
23	detail	O
24	specific	O
25	structural	O
26	features	O
27	involved	O
28	in	O
29	oligosaccharide	O
30	-	O
31	protein	O
32	binding	O
33	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	protein	O
8	in	O
9	the	O
10	region	O
11	of	O
12	the	O
13	specificity	O
14	pocket	O
15	is	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	S	B
21	.	I
22	griseus	I
23	proteases	I
24	A	I
25	,	I
26	B	I
27	,	I
28	and	I
29	C	I
30	.	O

1	Mutations	O
2	in	O
3	the	O
4	VPS45	B
5	gene	I
6	,	O
7	a	O
8	SEC1	B
9	homologue	O
10	,	O
11	result	O
12	in	O
13	vacuolar	O
14	protein	O
15	sorting	O
16	defects	O
17	and	O
18	accumulation	O
19	of	O
20	membrane	O
21	vesicles	O
22	.	O

1	In	O
2	293	O
3	cells	O
4	,	O
5	expression	O
6	of	O
7	the	O
8	NF	B
9	-	I
10	kappa	I
11	B	I
12	inhibitor	O
13	,	O
14	I	B
15	kappa	I
16	B	I
17	-	I
18	alpha	I
19	,	O
20	reduced	O
21	the	O
22	stimulatory	O
23	activity	O
24	of	O
25	LMP	B
26	.	O

1	This	O
2	experimental	O
3	design	O
4	was	O
5	used	O
6	to	O
7	determine	O
8	the	O
9	effect	O
10	of	O
11	displacement	O
12	of	O
13	the	O
14	alpha	B
15	4	I
16	-	I
17	2	I
18	binding	I
19	site	I
20	on	O
21	the	O
22	repression	O
23	of	O
24	alpha	B
25	4	I
26	gene	I
27	transcription	O
28	by	O
29	ICP4	B
30	.	O

1	Immediate	O
2	-	O
3	early	O
4	transcription	O
5	from	O
6	the	O
7	channel	O
8	catfish	O
9	virus	O
10	genome	O
11	:	O
12	characterization	O
13	of	O
14	two	O
15	immediate	B
16	-	I
17	early	I
18	transcripts	I
19	.	O

1	The	O
2	GRE	O
3	at	O
4	nucleotide	O
5	7640	O
6	is	O
7	a	O
8	composite	O
9	GRE	O
10	(	O
11	cGRE	O
12	)	O
13	containing	O
14	an	O
15	overlapping	O
16	activator	B
17	protein	I
18	-	I
19	1	I
20	(	O
21	AP	B
22	-	I
23	1	I
24	)	O
25	motif	O
26	for	O
27	the	O
28	c	B
29	-	I
30	jun	I
31	homodimer	I
32	and	O
33	c	B
34	-	I
35	jun	I
36	/	O
37	c	B
38	-	I
39	fos	I
40	heterodimer	O
41	.	O

1	In	O
2	contrast	O
3	to	O
4	some	O
5	results	O
6	previously	O
7	published	O
8	for	O
9	a	O
10	very	O
11	close	O
12	sequence	O
13	variant	O
14	(	O
15	see	O
16	ref	O
17	.	O

1	Transcriptional	O
2	activation	O
3	by	O
4	thyroid	O
5	hormone	O
6	(	O
7	T3	O
8	)	O
9	requires	O
10	interactions	O
11	between	O
12	the	O
13	T3	B
14	receptor	I
15	(	O
16	TR	B
17	)	O
18	and	O
19	T3	O
20	response	O
21	elements	O
22	(	O
23	TREs	O
24	)	O
25	composed	O
26	of	O
27	two	O
28	copies	O
29	of	O
30	sequences	O
31	related	O
32	to	O
33	AGGTCA	O
34	.	O

1	A	O
2	multivariate	O
3	analysis	O
4	of	O
5	risk	O
6	factors	O
7	for	O
8	relapse	O
9	examined	O
10	age	O
11	,	O
12	WBC	O
13	at	O
14	diagnosis	O
15	,	O
16	blast	O
17	count	O
18	at	O
19	diagnosis	O
20	,	O
21	percentage	O
22	of	O
23	marrow	O
24	blasts	O
25	,	O
26	FAB	B
27	subtype	O
28	,	O
29	the	O
30	number	O
31	of	O
32	remission	O
33	induction	O
34	courses	O
35	to	O
36	achieve	O
37	a	O
38	remission	O
39	,	O
40	maintenance	O
41	therapy	O
42	,	O
43	consolidation	O
44	therapy	O
45	,	O
46	marrow	O
47	cell	O
48	dose	O
49	,	O
50	donor	O
51	-	O
52	recipient	O
53	sex	O
54	,	O
55	GVHD	O
56	prophylaxis	O
57	regimen	O
58	and	O
59	isolation	O
60	and	O
61	decontamination	O
62	in	O
63	laminar	O
64	airflow	O
65	rooms	O
66	.	O

1	Carnitine	B
2	palmitoyltransferase	I
3	(	I
4	CPT	I
5	)	I
6	II	I
7	deficiency	O
8	is	O
9	the	O
10	most	O
11	common	O
12	inherited	O
13	disorder	O
14	of	O
15	lipid	O
16	metabolism	O
17	affecting	O
18	skeletal	O
19	muscle	O
20	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	Binding	O
2	of	O
3	meAda	B
4	is	O
5	necessary	O
6	to	O
7	activate	O
8	transcription	O
9	of	O
10	the	O
11	adaptive	O
12	response	O
13	genes	O
14	;	O
15	accordingly	O
16	,	O
17	in	O
18	vitro	O
19	transcription	O
20	of	O
21	aidB	B
22	is	O
23	dependent	O
24	on	O
25	the	O
26	presence	O
27	of	O
28	meAda	B
29	.	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	identified	O
6	between	O
7	groups	O
8	for	O
9	pH	O
10	,	O
11	PaCO2	O
12	,	O
13	intracranial	O
14	pressure	O
15	,	O
16	heart	O
17	rate	O
18	,	O
19	brain	O
20	temperature	O
21	,	O
22	or	O
23	glucose	O
24	levels	O
25	.	O

1	Blood	O
2	pressure	O
3	also	O
4	was	O
5	increased	O
6	by	O
7	lidocaine	O
8	(	O
9	6	O
10	mg	O
11	kg	O
12	-	O
13	1	O
14	).	O

1	Anesthesiologists	O
2	often	O
3	use	O
4	more	O
5	than	O
6	one	O
7	drug	O
8	in	O
9	a	O
10	patient	O
11	to	O
12	achieve	O
13	a	O
14	target	O
15	response	O
16	,	O
17	such	O
18	as	O
19	a	O
20	desired	O
21	blood	O
22	pressure	O
23	.	O

1	We	O
2	suggest	O
3	that	O
4	this	O
5	gene	O
6	cluster	O
7	codes	O
8	for	O
9	(	O
10	parts	O
11	of	O
12	)	O
13	a	O
14	multisubunit	B
15	cytochrome	I
16	c	I
17	haem	I
18	lyase	I
19	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	a	O
6	comparison	O
7	between	O
8	the	O
9	number	O
10	and	O
11	shape	O
12	of	O
13	corneal	O
14	endothelial	O
15	cells	O
16	has	O
17	been	O
18	performed	O
19	in	O
20	25	O
21	patients	O
22	before	O
23	and	O
24	6	O
25	months	O
26	after	O
27	PRK	O
28	.	O

1	Standard	O
2	reference	O
3	sources	O
4	indicate	O
5	that	O
6	an	O
7	able	O
8	-	O
9	bodied	O
10	11	O
11	-	O
12	year	O
13	-	O
14	old	O
15	child	O
16	of	O
17	comparable	O
18	height	O
19	requires	O
20	1	O
21	,	O
22	493	O
23	kcal	O
24	/	O
25	d	O
26	for	O
27	support	O
28	of	O
29	basal	O
30	metabolic	O
31	functions	O
32	.	O

1	Weak	O
2	allergenicity	O
3	of	O
4	recombinant	B
5	hirudin	I
6	CGP	I
7	39393	I
8	(	O
9	REVASC	O
10	)	O
11	in	O
12	immunocompetent	O
13	volunteers	O
14	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	myoD	B
6	promoter	I
7	,	O
8	the	O
9	myoD	B
10	enhancer	I
11	shows	O
12	striking	O
13	conservation	O
14	between	O
15	humans	O
16	and	O
17	mice	O
18	both	O
19	in	O
20	its	O
21	sequence	O
22	and	O
23	its	O
24	distal	O
25	position	O
26	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	B
31	core	I
32	enhancer	I
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	B
38	enhancer	I
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	Using	O
2	Ki	B
3	-	I
4	ras	I
5	-	O
6	transformed	O
7	3T3	O
8	cells	O
9	as	O
10	a	O
11	model	O
12	system	O
13	,	O
14	we	O
15	show	O
16	that	O
17	both	O
18	RA	O
19	and	O
20	the	O
21	'	O
22	dissociating	O
23	'	O
24	retinoids	O
25	inhibit	O
26	anchorage	O
27	-	O
28	independent	O
29	cell	O
30	proliferation	O
31	,	O
32	suggesting	O
33	that	O
34	retinoid	O
35	-	O
36	induced	O
37	growth	O
38	inhibition	O
39	may	O
40	be	O
41	related	O
42	to	O
43	AP1	B
44	transrepression	O
45	.	O

1	The	O
2	Oct	B
3	and	O
4	HMG2	B
5	proteins	I
6	also	O
7	interact	O
8	in	O
9	vivo	O
10	.	O

1	Atopic	O
2	dermatitis	O
3	is	O
4	an	O
5	"	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	"	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	showed	O
5	that	O
6	there	O
7	are	O
8	two	O
9	transcription	O
10	initiation	O
11	sites	O
12	16	O
13	bp	O
14	apart	O
15	in	O
16	the	O
17	mouse	B
18	type	I
19	2	I
20	receptor	I
21	gene	I
22	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	Fc	B
7	epsilon	I
8	R1	I
9	is	O
10	a	O
11	33	O
12	-	O
13	kDa	O
14	tyrosine	O
15	phosphoprotein	O
16	,	O
17	but	O
18	the	O
19	p33	B
20	Grb2	I
21	-	I
22	binding	I
23	protein	I
24	described	O
25	in	O
26	the	O
27	present	O
28	report	O
29	is	O
30	not	O
31	the	O
32	Fc	B
33	epsilon	I
34	R1	I
35	beta	I
36	chain	I
37	and	O
38	its	O
39	identity	O
40	is	O
41	unknown	O
42	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	After	O
2	24	O
3	hour	O
4	incubation	O
5	,	O
6	total	O
7	cell	O
8	-	O
9	associated	O
10	IL	B
11	-	I
12	1Ra	I
13	and	O
14	IL	B
15	-	I
16	1	I
17	beta	I
18	were	O
19	measured	O
20	by	O
21	specific	O
22	radioimmunoassay	O
23	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	1972	O
2	.	O

1	In	O
2	contrast	O
3	,	O
4	recent	O
5	evidence	O
6	suggests	O
7	that	O
8	children	O
9	with	O
10	sickle	B
11	-	I
12	hemoglobin	I
13	C	I
14	disease	O
15	do	O
16	not	O
17	develop	O
18	functional	O
19	asplenia	O
20	before	O
21	3	O
22	to	O
23	4	O
24	years	O
25	of	O
26	age	O
27	and	O
28	thus	O
29	may	O
30	not	O
31	benefit	O
32	from	O
33	penicillin	O
34	prophylaxis	O
35	.	O

1	Deletion	O
2	analysis	O
3	indicates	O
4	that	O
5	TBP	B
6	and	O
7	hTAFII18	B
8	bind	O
9	to	O
10	distinct	O
11	domains	O
12	of	O
13	hTAFII28	B
14	.	O
15	hTAFII18	B
16	also	O
17	interacts	O
18	with	O
19	TBP	B
20	,	O
21	but	O
22	it	O
23	interacts	O
24	more	O
25	strongly	O
26	with	O
27	hTAFII28	B
28	and	O
29	hTAFII30	B
30	.	O

1	The	O
2	NarX	B
3	and	O
4	NarQ	B
5	proteins	I
6	with	O
7	amino	O
8	acid	O
9	substitutions	O
10	at	O
11	the	O
12	first	O
13	conserved	O
14	histidine	O
15	position	O
16	were	O
17	also	O
18	unable	O
19	to	O
20	dephosphorylate	O
21	NarL	B
22	-	O
23	phosphate	O
24	in	O
25	vitro	O
26	.	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	Because	O
2	ATF	B
3	-	I
4	1	I
5	and	O
6	CREM	B
7	are	O
8	known	O
9	to	O
10	bind	O
11	to	O
12	cAMP	O
13	response	O
14	elements	O
15	(	O
16	CRE	O
17	),	O
18	this	O
19	functional	O
20	sequence	O
21	was	O
22	named	O
23	the	O
24	kappa	O
25	E3	O
26	'-	O
27	CRE	O
28	.	O

1	The	O
2	Ng	B
3	/	I
4	RC3	I
5	and	O
6	PKC	B
7	-	I
8	gamma	I
9	genes	I
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	neuron	O
10	-	O
11	specific	O
12	protein	B
13	kinase	I
14	C	I
15	substrate	O
16	neurogranin	B
17	(	O
18	RC3	B
19	protein	I
20	).	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	known	O
8	largest	O
9	subunits	O
10	of	O
11	DdRPs	B
12	from	O
13	different	O
14	species	O
15	contain	O
16	highly	O
17	conserved	O
18	regions	O
19	.	O

1	The	O
2	TTG	B
3	-	I
4	2	I
5	gene	I
6	has	O
7	been	O
8	identified	O
9	at	O
10	the	O
11	site	O
12	of	O
13	chromosomal	O
14	translocations	O
15	in	O
16	acute	O
17	T	O
18	-	O
19	cell	O
20	leukemia	O
21	'	O
22	s	O
23	(	O
24	T	O
25	-	O
26	ALL	O
27	).	O

1	In	O
2	vitro	O
3	studies	O
4	with	O
5	blood	O
6	cells	O
7	incubated	O
8	with	O
9	acetate	O
10	or	O
11	bicarbonate	O
12	ions	O
13	in	O
14	concentrations	O
15	,	O
16	which	O
17	are	O
18	observed	O
19	in	O
20	vivo	O
21	during	O
22	hemodialysis	O
23	,	O
24	suggest	O
25	that	O
26	probably	O
27	these	O
28	ions	O
29	do	O
30	not	O
31	directly	O
32	affect	O
33	superoxide	O
34	anions	O
35	generation	O
36	,	O
37	erythrocyte	O
38	SOD	B
39	-	I
40	1	I
41	and	O
42	catalase	B
43	activities	O
44	and	O
45	erythrocyte	O
46	membrane	O
47	lipid	O
48	peroxidation	O
49	.	O

1	Short	O
2	therapy	O
3	with	O
4	omeprazole	O
5	20	O
6	mg	O
7	/	O
8	b	O
9	.	O
10	i	O
11	.	O
12	d	O
13	.,	O
14	clarithromycin	O
15	500	O
16	mg	O
17	/	O
18	b	O
19	.	O
20	i	O
21	.	O
22	d	O
23	.,	O
24	and	O
25	CBS	O
26	120	O
27	mg	O
28	/	O
29	q	O
30	.	O
31	i	O
32	.	O
33	d	O
34	.	O
35	is	O
36	a	O
37	safe	O
38	,	O
39	well	O
40	tolerated	O
41	combination	O
42	that	O
43	achieves	O
44	a	O
45	80	O
46	.	O
47	6	O
48	%	O
49	eradication	O
50	rate	O
51	of	O
52	H	O
53	.	O
54	pylori	O
55	and	O
56	duodenal	O
57	ulcer	O
58	healing	O
59	rates	O
60	as	O
61	good	O
62	as	O
63	those	O
64	achieved	O
65	by	O
66	omeprazole	O
67	20	O
68	mg	O
69	/	O
70	d	O
71	when	O
72	given	O
73	for	O
74	4	O
75	wk	O
76	.	O

1	The	O
2	concentration	O
3	of	O
4	mite	O
5	allergen	O
6	was	O
7	very	O
8	low	O
9	(	O
10	mean	O
11	0	O
12	.	O
13	18	O
14	micrograms	O
15	Der	O
16	p	O
17	milligrams	O
18	sieved	O
19	house	O
20	dust	O
21	),	O
22	whereas	O
23	that	O
24	of	O
25	cat	O
26	allergen	O
27	was	O
28	high	O
29	in	O
30	homes	O
31	with	O
32	a	O
33	cat	O
34	(	O
35	80	O
36	.	O
37	8	O
38	micrograms	O
39	Fel	O
40	d	O
41	milligrams	O
42	)	O
43	but	O
44	also	O
45	in	O
46	homes	O
47	with	O
48	no	O
49	cat	O
50	(	O
51	3	O
52	.	O
53	2	O
54	micrograms	O
55	Fel	O
56	d	O
57	milligrams	O
58	).	O

1	CONCLUSIONS	O
2	:	O
3	A	O
4	comparison	O
5	of	O
6	the	O
7	LysU	B
8	crystal	O
9	structure	O
10	with	O
11	the	O
12	structures	O
13	of	O
14	seryl	B
15	-	I
16	and	I
17	aspartyl	I
18	-	I
19	tRNA	I
20	synthetases	I
21	enables	O
22	a	O
23	conserved	O
24	core	O
25	to	O
26	be	O
27	identified	O
28	.	O

1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O

1	The	O
2	MPS1	B
3	open	I
4	reading	I
5	frame	I
6	has	O
7	been	O
8	fused	O
9	to	O
10	those	O
11	that	O
12	encode	O
13	the	O
14	LexA	B
15	protein	I
16	or	O
17	the	O
18	GST	B
19	protein	I
20	and	O
21	both	O
22	of	O
23	these	O
24	constructs	O
25	function	O
26	in	O
27	yeast	O
28	.	O

1	As	O
2	in	O
3	Tb	O
4	,	O
5	U6	B
6	is	O
7	a	O
8	single	O
9	-	O
10	copy	O
11	gene	O
12	and	O
13	two	O
14	tRNA	O
15	genes	O
16	,	O
17	tRNAGln	B
18	and	O
19	tRNAIle	B
20	,	O
21	are	O
22	found	O
23	upstream	O
24	to	O
25	the	O
26	gene	O
27	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	have	O
5	already	O
6	had	O
7	an	O
8	enormous	O
9	impact	O
10	on	O
11	transfusion	O
12	practice	O
13	by	O
14	eliminating	O
15	or	O
16	reducing	O
17	the	O
18	need	O
19	for	O
20	red	O
21	blood	O
22	cell	O
23	transfusions	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	anemic	O
29	states	O
30	characterized	O
31	by	O
32	an	O
33	absolute	O
34	or	O
35	relative	O
36	decrease	O
37	in	O
38	erythropoietin	B
39	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O

1	During	O
2	IC	O
3	breaths	O
4	and	O
5	following	O
6	EC	O
7	and	O
8	VC	O
9	breaths	O
10	at	O
11	rest	O
12	,	O
13	end	O
14	-	O
15	tidal	O
16	CO2	O
17	pressure	O
18	(	O
19	PET	O
20	,	O
21	CO2	O
22	)	O
23	fell	O
24	by	O
25	7	O
26	.	O
27	5	O
28	,	O
29	8	O
30	.	O
31	5	O
32	and	O
33	9	O
34	.	O
35	5	O
36	mmHg	O
37	,	O
38	respectively	O
39	.	O

1	2	O
2	.	O

1	Phylogenetic	O
2	analyses	O
3	of	O
4	19	O
5	amino	O
6	acid	O
7	sequences	O
8	of	O
9	6	O
10	related	O
11	protein	O
12	types	O
13	indicate	O
14	that	O
15	actin	B
16	-	O
17	associated	O
18	proteins	O
19	related	O
20	to	O
21	gelsolin	B
22	are	O
23	monophyletic	O
24	to	O
25	a	O
26	common	O
27	ancestor	O
28	and	O
29	include	O
30	flightless	B
31	proteins	I
32	.	O

1	No	O
2	homologs	O
3	of	O
4	other	O
5	members	O
6	of	O
7	the	O
8	Surfeit	B
9	gene	I
10	cluster	I
11	were	O
12	detected	O
13	in	O
14	close	O
15	proximity	O
16	to	O
17	the	O
18	D	O
19	.	O
20	melanogaster	O
21	Surf	B
22	-	I
23	3	I
24	/	O
25	rpL7a	B
26	gene	O
27	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SGC1	B
9	gene	I
10	product	I
11	includes	O
12	a	O
13	region	O
14	with	O
15	substantial	O
16	similarity	O
17	to	O
18	the	O
19	basic	O
20	-	O
21	helix	O
22	-	O
23	loop	O
24	-	O
25	helix	O
26	domain	O
27	of	O
28	the	O
29	Myc	B
30	family	I
31	of	O
32	DNA	O
33	-	O
34	binding	O
35	proteins	O
36	.	O

1	By	O
2	creating	O
3	Pax	B
4	-	I
5	6	I
6	-	O
7	BSAP	B
8	fusion	O
9	proteins	O
10	,	O
11	we	O
12	were	O
13	able	O
14	to	O
15	identify	O
16	a	O
17	short	O
18	amino	O
19	acid	O
20	stretch	O
21	in	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	the	O
29	paired	B
30	domain	O
31	which	O
32	is	O
33	responsible	O
34	for	O
35	these	O
36	differences	O
37	in	O
38	DNA	O
39	-	O
40	binding	O
41	specificity	O
42	.	O

1	To	O
2	establish	O
3	a	O
4	possible	O
5	association	O
6	between	O
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	O
24	the	O
25	framework	O
26	of	O
27	the	O
28	SSC	O
29	Subcommittee	O
30	on	O
31	Fibrinogen	B
32	of	O
33	the	O
34	International	O
35	Society	O
36	on	O
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O

1	Conjugated	O
2	estrogens	O
3	shorten	O
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O

1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O

1	According	O
2	to	O
3	symptoms	O
4	,	O
5	signs	O
6	,	O
7	imaging	O
8	features	O
9	,	O
10	operation	O
11	findings	O
12	,	O
13	the	O
14	original	O
15	places	O
16	and	O
17	the	O
18	expansive	O
19	directions	O
20	of	O
21	the	O
22	tumor	O
23	,	O
24	they	O
25	were	O
26	divided	O
27	into	O
28	four	O
29	clinical	O
30	types	O
31	:	O
32	sellar	O
33	,	O
34	clival	O
35	,	O
36	occipito	O
37	-	O
38	temporal	O
39	and	O
40	extent	O
41	.	O

1	Two	O
2	mammalian	O
3	enzymes	O
4	,	O
5	the	O
6	haem	B
7	-	I
8	controlled	I
9	repressor	I
10	(	O
11	HCR	B
12	)	O
13	and	O
14	the	O
15	double	B
16	-	I
17	stranded	I
18	RNA	I
19	-	I
20	activated	I
21	inhibitor	I
22	(	O
23	dsI	B
24	),	O
25	phosphorylate	O
26	Ser	O
27	-	O
28	51	O
29	of	O
30	the	O
31	alpha	O
32	subunit	O
33	,	O
34	thereby	O
35	inhibiting	O
36	the	O
37	exchange	O
38	of	O
39	bound	O
40	nucleotides	O
41	on	O
42	,	O
43	and	O
44	thus	O
45	the	O
46	recycling	O
47	of	O
48	,	O
49	eIF	B
50	-	I
51	2	I
52	.	O

1	A	O
2	triple	O
3	Ser	O
4	-->	O
5	Ala	O
6	mutant	O
7	form	O
8	of	O
9	yeast	O
10	eIF	B
11	-	I
12	2	I
13	alpha	I
14	was	O
15	found	O
16	to	O
17	be	O
18	no	O
19	longer	O
20	phosphorylated	O
21	by	O
22	either	O
23	of	O
24	the	O
25	yeast	O
26	(	O
27	or	O
28	mammalian	O
29	)	O
30	casein	B
31	kinase	I
32	activities	O
33	in	O
34	vitro	O
35	.	O

1	The	O
2	cases	O
3	included	O
4	35	O
5	de	O
6	novo	O
7	diffuse	O
8	aggressive	O
9	lymphomas	O
10	(	O
11	DAL	O
12	;	O
13	19	O
14	large	O
15	-	O
16	cell	O
17	,	O
18	4	O
19	mixed	O
20	-	O
21	cell	O
22	,	O
23	and	O
24	12	O
25	large	O
26	-	O
27	cell	O
28	immunoblastic	O
29	),	O
30	52	O
31	transformed	O
32	aggressive	O
33	lymphomas	O
34	derived	O
35	from	O
36	follicular	O
37	lymphomas	O
38	(	O
39	TFL	O
40	),	O
41	42	O
42	indolent	O
43	follicular	O
44	lymphomas	O
45	(	O
46	FL	O
47	),	O
48	14	O
49	mantle	O
50	cell	O
51	lymphomas	O
52	(	O
53	MCL	O
54	),	O
55	and	O
56	27	O
57	small	O
58	noncleaved	O
59	cell	O
60	lymphomas	O
61	(	O
62	SNCL	O
63	).	O

1	Icterus	O
2	and	O
3	beta	O
4	-	O
5	thalassemia	O
6	in	O
7	Congolese	O
8	children	O
9	in	O
10	Brazzaville	O

1	Female	O
2	patients	O
3	with	O
4	breast	O
5	cancer	O
6	diagnosed	O
7	between	O
8	1982	O
9	and	O
10	1991	O
11	at	O
12	Roswell	O
13	Park	O
14	Cancer	O
15	Institute	O
16	(	O
17	RPCI	O
18	)	O
19	in	O
20	Buffalo	O
21	,	O
22	New	O
23	York	O
24	,	O
25	who	O
26	provided	O
27	information	O
28	on	O
29	their	O
30	cigarette	O
31	smoking	O
32	history	O
33	at	O
34	the	O
35	time	O
36	of	O
37	their	O
38	diagnosis	O
39	were	O
40	included	O
41	.	O

1	Upon	O
2	analysis	O
3	of	O
4	the	O
5	tissue	O
6	distribution	O
7	of	O
8	AAMP	B
9	,	O
10	it	O
11	was	O
12	found	O
13	to	O
14	be	O
15	expressed	O
16	strongly	O
17	in	O
18	endothelial	O
19	cells	O
20	,	O
21	cytotrophoblasts	O
22	,	O
23	and	O
24	poorly	O
25	differentiated	O
26	colon	O
27	adenocarcinoma	O
28	cells	O
29	found	O
30	in	O
31	lymphatics	O
32	.	O

1	Data	O
2	from	O
3	the	O
4	V	O
5	-	O
6	HeFT	O
7	II	O
8	show	O
9	that	O
10	at	O
11	2	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	,	O
18	a	O
19	progressive	O
20	rise	O
21	of	O
22	plasma	O
23	norepinephrine	O
24	was	O
25	observed	O
26	in	O
27	both	O
28	treatment	O
29	arms	O
30	,	O
31	suggesting	O
32	that	O
33	disease	O
34	progresses	O
35	despite	O
36	treatment	O
37	with	O
38	either	O
39	an	O
40	angiotensin	B
41	-	I
42	converting	I
43	enzyme	I
44	inhibitor	O
45	,	O
46	enalapril	O
47	,	O
48	or	O
49	vasodilator	O
50	therapy	O
51	with	O
52	hydralazine	O
53	/	O
54	isosorbide	O
55	dinitrate	O
56	.	O

1	Binding	O
2	activity	O
3	in	O
4	rat	O
5	liver	O
6	nuclear	O
7	extracts	O
8	includes	O
9	these	O
10	orphan	O
11	receptors	O
12	as	O
13	judged	O
14	from	O
15	electromobility	O
16	supershift	O
17	experiments	O
18	and	O
19	from	O
20	results	O
21	obtained	O
22	with	O
23	expressed	O
24	receptors	O
25	,	O
26	although	O
27	the	O
28	element	O
29	in	O
30	CYP2C11	B
31	did	O
32	not	O
33	bind	O
34	HNF	B
35	-	I
36	4	I
37	.	O

1	Transcript	O
2	analysis	O
3	reveals	O
4	that	O
5	lethal	O
6	B	B
7	block	I
8	substitutions	O
9	reduce	O
10	U6	B
11	RNA	I
12	synthesis	O
13	at	O
14	least	O
15	10	O
16	-	O
17	fold	O
18	in	O
19	vivo	O
20	and	O
21	20	O
22	-	O
23	fold	O
24	in	O
25	vitro	O
26	.	O

1	Analysis	O
2	of	O
3	Bcl	B
4	-	I
5	2	I
6	/	O
7	Bcl	B
8	-	I
9	2	I
10	homodimerization	O
11	using	O
12	both	O
13	in	O
14	vitro	O
15	binding	O
16	assays	O
17	as	O
18	well	O
19	as	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	method	O
26	provided	O
27	evidence	O
28	in	O
29	support	O
30	of	O
31	a	O
32	head	O
33	-	O
34	to	O
35	-	O
36	tail	O
37	model	O
38	for	O
39	Bcl	B
40	-	I
41	2	I
42	/	O
43	Bcl	B
44	-	I
45	2	I
46	homodimerization	O
47	and	O
48	revealed	O
49	that	O
50	sequences	O
51	within	O
52	the	O
53	NH2	O
54	-	O
55	terminal	O
56	A	O
57	domain	O
58	interact	O
59	with	O
60	a	O
61	structure	O
62	that	O
63	requires	O
64	the	O
65	presence	O
66	of	O
67	both	O
68	the	O
69	carboxyl	O
70	B	O
71	and	O
72	C	O
73	domains	O
74	in	O
75	combination	O
76	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O

1	Radioligand	O
2	binding	O
3	was	O
4	indistinguishable	O
5	for	O
6	both	O
7	transiently	O
8	expressed	O
9	constructs	O
10	.	O

1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O

1	Human	B
2	papillomavirus	I
3	type	I
4	31b	I
5	late	I
6	gene	I
7	expression	O
8	is	O
9	regulated	O
10	through	O
11	protein	B
12	kinase	I
13	C	I
14	-	O
15	mediated	O
16	changes	O
17	in	O
18	RNA	O
19	processing	O
20	.	O

1	Interestingly	O
2	,	O
3	virions	O
4	also	O
5	contained	O
6	smaller	O
7	proteins	O
8	that	O
9	reacted	O
10	with	O
11	antibodies	O
12	specific	O
13	for	O
14	the	O
15	accessory	O
16	proteins	O
17	as	O
18	well	O
19	as	O
20	SN	B
21	and	O
22	CAT	B
23	fusion	I
24	partners	O
25	.	O

1	Studies	O
2	using	O
3	an	O
4	inhibitor	O
5	or	O
6	a	O
7	mutant	B
8	Lb	I
9	proteinase	I
10	indicated	O
11	that	O
12	stimulation	O
13	of	O
14	IRES	O
15	-	O
16	driven	O
17	translation	O
18	is	O
19	mediated	O
20	via	O
21	proteolysis	O
22	of	O
23	some	O
24	cellular	O
25	component	O
26	(	O
27	s	O
28	).	O

1	Restriction	O
2	mapping	O
3	analysis	O
4	localized	O
5	this	O
6	cDNA	O
7	to	O
8	the	O
9	HHV	B
10	-	I
11	6A	I
12	(	I
13	U1102	I
14	)	I
15	genomic	I
16	BamHI	I
17	G	I
18	fragment	I
19	,	O
20	at	O
21	the	O
22	right	O
23	end	O
24	of	O
25	the	O
26	unique	O
27	long	O
28	segment	O
29	of	O
30	the	O
31	genome	O
32	and	O
33	to	O
34	the	O
35	SalI	B
36	L	I
37	and	O
38	SalI	B
39	O	I
40	fragments	I
41	within	O
42	the	O
43	left	O
44	and	O
45	right	O
46	terminal	O
47	direct	O
48	repeat	O
49	regions	O
50	,	O
51	respectively	O
52	.	O

1	For	O
2	replication	O
3	reporter	O
4	constructs	O
5	where	O
6	E1	B
7	and	O
8	E2	B
9	are	O
10	supplied	O
11	in	O
12	trans	O
13	by	O
14	the	O
15	respective	O
16	expression	O
17	vectors	O
18	,	O
19	distance	O
20	between	O
21	the	O
22	half	O
23	sites	O
24	seems	O
25	to	O
26	play	O
27	a	O
28	major	O
29	role	O
30	,	O
31	yet	O
32	the	O
33	phasing	O
34	relationships	O
35	are	O
36	measurable	O
37	.	O

1	As	O
2	it	O
3	had	O
4	been	O
5	previously	O
6	reported	O
7	that	O
8	the	O
9	18	O
10	-	O
11	bp	O
12	palindrome	O
13	contains	O
14	sufficient	O
15	nucleotide	O
16	sequence	O
17	information	O
18	for	O
19	E1	B
20	binding	O
21	,	O
22	we	O
23	speculate	O
24	that	O
25	a	O
26	minimal	O
27	E1	B
28	recognition	O
29	motif	O
30	is	O
31	presented	O
32	in	O
33	each	O
34	half	O
35	site	O
36	.	O

1	METHODS	O
2	:	O
3	Out	O
4	of	O
5	171	O
6	patients	O
7	receiving	O
8	anticoagulation	O
9	between	O
10	July	O
11	1992	O
12	and	O
13	December	O
14	1993	O
15	,	O
16	83	O
17	patients	O
18	with	O
19	hemispheric	O
20	embolisms	O
21	received	O
22	heparin	O
23	within	O
24	72	O
25	hours	O
26	from	O
27	onset	O
28	(	O
29	activated	O
30	partial	O
31	thromboplastin	B
32	time	O
33	[	O
34	aPTT	O
35	]	O
36	1	O
37	.	O
38	5	O
39	times	O
40	control	O
41	value	O
42	).	O

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	Lung	O
2	function	O
3	tests	O
4	(	O
5	EFR	O
6	)	O
7	were	O
8	performed	O
9	on	O
10	these	O
11	patients	O
12	for	O
13	a	O
14	period	O
15	of	O
16	19	O
17	.	O
18	2	O
19	+/-	O
20	3	O
21	.	O
22	4	O
23	months	O
24	.	O

1	Sequence	O
2	comparisons	O
3	of	O
4	prokaryotic	B
5	RCR	I
6	initiators	I
7	has	O
8	revealed	O
9	a	O
10	set	O
11	of	O
12	three	O
13	common	O
14	motifs	O
15	,	O
16	two	O
17	of	O
18	which	O
19	,	O
20	a	O
21	putative	O
22	metal	O
23	coordination	O
24	site	O
25	and	O
26	a	O
27	downstream	O
28	active	O
29	-	O
30	site	O
31	tyrosine	O
32	motif	O
33	,	O
34	could	O
35	be	O
36	tentatively	O
37	identified	O
38	in	O
39	parvoviral	B
40	replicator	I
41	proteins	I
42	.	O

1	The	O
2	mean	O
3	marginal	O
4	discrepancy	O
5	of	O
6	provisional	O
7	restorations	O
8	was	O
9	compared	O
10	for	O
11	restorations	O
12	fabricated	O
13	from	O
14	stone	O
15	,	O
16	low	O
17	-	O
18	viscosity	O
19	poly	O
20	(	O
21	vinyl	O
22	siloxane	O
23	),	O
24	and	O
25	medium	O
26	-	O
27	viscosity	O
28	poly	O
29	(	O
30	vinyl	O
31	siloxane	O
32	).	O

1	The	O
2	characterized	O
3	Aplysia	B
4	Afurin2	I
5	is	O
6	a	O
7	candidate	O
8	PC	B
9	that	O
10	may	O
11	play	O
12	an	O
13	important	O
14	role	O
15	in	O
16	the	O
17	processing	O
18	of	O
19	egg	B
20	-	I
21	laying	I
22	hormone	I
23	(	O
24	ELH	B
25	)-	O
26	related	O
27	precursors	O
28	in	O
29	the	O
30	secretory	O
31	cells	O
32	of	O
33	the	O
34	atrial	O
35	gland	O
36	.	O

1	Rats	O
2	treated	O
3	with	O
4	8	O
5	-	O
6	OH	O
7	-	O
8	DPAT	O
9	were	O
10	not	O
11	impaired	O
12	in	O
13	their	O
14	ability	O
15	to	O
16	learn	O
17	a	O
18	visual	O
19	discrimination	O
20	in	O
21	a	O
22	water	O
23	maze	O
24	.	O

1	The	O
2	term	O
3	endovascular	O
4	papillary	O
5	haemangioma	O
6	is	O
7	suggested	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	internal	O
6	promoters	O
7	,	O
8	PmiaA	B
9	and	O
10	P1hfq	B
11	were	O
12	identified	O
13	and	O
14	mapped	O
15	to	O
16	201	O
17	and	O
18	837	O
19	nucleotides	O
20	upstream	O
21	from	O
22	the	O
23	respective	O
24	translation	O
25	start	O
26	sites	O
27	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	mutL	B
6	,	O
7	miaA	B
8	,	O
9	and	O
10	hfq	B
11	expression	O
12	could	O
13	be	O
14	regulated	O
15	by	O
16	multiple	O
17	mechanisms	O
18	,	O
19	including	O
20	degree	O
21	of	O
22	cotranscription	O
23	from	O
24	upstream	O
25	genes	O
26	,	O
27	modulation	O
28	of	O
29	internal	O
30	promoter	O
31	strength	O
32	,	O
33	and	O
34	by	O
35	RNase	B
36	E	I
37	activity	O
38	.	O

1	Coronary	O
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O

1	The	O
2	2	O
3	kb	O
4	of	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	and	O
10	the	O
11	1	O
12	.	O
13	1	O
14	kb	O
15	of	O
16	the	O
17	entire	O
18	sGTH	B
19	alpha	I
20	subunit	I
21	coding	O
22	region	O
23	were	O
24	sequenced	O
25	from	O
26	the	O
27	genomic	O
28	clone	O
29	,	O
30	sGTH	B
31	alpha	I
32	-	I
33	G1	I
34	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	sGTH	B
6	alpha	I
7	subunit	I
8	promoter	I
9	by	O
10	the	O
11	transient	O
12	transfection	O
13	of	O
14	several	O
15	sGTH	B
16	alpha	I
17	/	O
18	CAT	B
19	chimeric	O
20	plasmids	O
21	into	O
22	rainbow	O
23	trout	O
24	pituitary	O
25	cells	O
26	suggests	O
27	that	O
28	its	O
29	pituitary	O
30	-	O
31	specific	O
32	expression	O
33	is	O
34	GSE	B
35	-	O
36	dependent	O
37	.	O

1	Indium	O
2	-	O
3	111	O
4	OncoScint	O
5	CR	O
6	/	O
7	OV	O
8	and	O
9	F	O
10	-	O
11	18	O
12	FDG	O
13	in	O
14	colorectal	O
15	and	O
16	ovarian	O
17	carcinoma	O
18	recurrences	O
19	.	O

1	His	O
2	carnitine	B
3	palmitoyltransferase	I
4	(	I
5	CPT	I
6	)	I
7	I	I
8	and	I
9	II	I
10	activities	O
11	were	O
12	0	O
13	.	O
14	06	O
15	and	O
16	0	O
17	.	O
18	12	O
19	nmol	O
20	/	O
21	min	O
22	/	O
23	mg	O
24	protein	O
25	,	O
26	as	O
27	compared	O
28	with	O
29	a	O
30	mean	O
31	value	O
32	of	O
33	0	O
34	.	O
35	22	O
36	+/-	O
37	0	O
38	.	O
39	14	O
40	and	O
41	0	O
42	.	O
43	27	O
44	+/-	O
45	0	O
46	.	O
47	07	O
48	nmol	O
49	/	O
50	min	O
51	/	O
52	mg	O
53	protein	O
54	,	O
55	respectively	O
56	,	O
57	in	O
58	control	O
59	subjects	O
60	.	O

1	The	O
2	Myc	B
3	LZ	I
4	was	O
5	found	O
6	to	O
7	prevent	O
8	homodimeric	O
9	interactions	O
10	,	O
11	thus	O
12	explaining	O
13	Myc	B
14	inability	O
15	to	O
16	homodimerize	O
17	efficiently	O
18	.	O

1	Staphylococcus	O
2	aureus	O
3	and	O
4	CNS	O
5	showed	O
6	high	O
7	or	O
8	moderate	O
9	resistance	O
10	rates	O
11	to	O
12	methicillin	O
13	(	O
14	DMPPC	O
15	).	O

1	Thus	O
2	,	O
3	VF	O
4	resistant	O
5	to	O
6	defibrillation	O
7	is	O
8	not	O
9	necessarily	O
10	associated	O
11	with	O
12	both	O
13	toxic	O
14	plasma	O
15	drug	O
16	level	O
17	and	O
18	remarkably	O
19	decreased	O
20	conduction	O
21	.	O

1	The	O
2	smallest	O
3	active	B
4	FecR	I
5	derivative	I
6	contained	O
7	59	O
8	amino	O
9	acid	O
10	residues	O
11	as	O
12	compared	O
13	to	O
14	the	O
15	317	O
16	residues	O
17	of	O
18	wild	B
19	-	I
20	type	I
21	FecR	I
22	.	O

1	The	O
2	gene	O
3	pairs	O
4	psbB	B
5	-	O
6	psbT	B
7	and	O
8	psbH	B
9	-	O
10	psbN	B
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O

1	Hybridization	O
2	signals	O
3	were	O
4	also	O
5	detected	O
6	with	O
7	total	O
8	DNAs	O
9	of	O
10	Rhizobium	O
11	leguminosarum	O
12	bv	O
13	.	O
14	phaseoli	O
15	,	O
16	Rhodobacter	O
17	capsulatus	O
18	and	O
19	Escherichia	O
20	coli	O
21	,	O
22	but	O
23	not	O
24	those	O
25	of	O
26	Xanthomonas	O
27	campestris	O
28	pv	O
29	.	O
30	campestris	O
31	and	O
32	Pseudomonas	O
33	putida	O
34	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	contains	O
7	regions	O
8	identical	O
9	to	O
10	the	O
11	sequences	O
12	of	O
13	peptides	O
14	derived	O
15	from	O
16	bovine	B
17	liver	I
18	eIF	I
19	-	I
20	2B	I
21	alpha	I
22	subunit	I
23	.	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	B
14	eIF	I
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O

1	Six	O
2	of	O
3	them	O
4	,	O
5	NUC1	B
6	,	O
7	PRP21	B
8	(	O
9	also	O
10	called	O
11	SPP91	B
12	),	O
13	CDC6	B
14	,	O
15	CRY2	B
16	,	O
17	the	O
18	gene	O
19	encoding	O
20	the	O
21	ribosomal	B
22	protein	I
23	S24	I
24	and	O
25	the	O
26	gene	O
27	coding	O
28	for	O
29	a	O
30	hypothetical	O
31	protein	O
32	of	O
33	599	O
34	amino	O
35	acids	O
36	,	O
37	have	O
38	been	O
39	sequenced	O
40	previously	O
41	.	O

1	Intrastriatal	O
2	grafts	O
3	of	O
4	nigral	O
5	and	O
6	adrenal	O
7	tissues	O
8	have	O
9	been	O
10	found	O
11	to	O
12	be	O
13	effective	O
14	in	O
15	alleviating	O
16	many	O
17	of	O
18	the	O
19	simple	O
20	motor	O
21	and	O
22	sensorimotor	O
23	deficits	O
24	associated	O
25	with	O
26	lesions	O
27	of	O
28	the	O
29	nigrostriatal	O
30	dopamine	O
31	system	O
32	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	impact	O
7	of	O
8	the	O
9	introduction	O
10	of	O
11	clarithromycin	O
12	and	O
13	azithromycin	O
14	on	O
15	the	O
16	treatment	O
17	and	O
18	survival	O
19	of	O
20	patients	O
21	with	O
22	AIDS	O
23	and	O
24	disseminated	O
25	Mycobacterium	O
26	avium	O
27	complex	O
28	(	O
29	DMAC	O
30	).	O

1	Thereafter	O
2	,	O
3	the	O
4	aggregation	O
5	rose	O
6	to	O
7	the	O
8	initial	O
9	100	O
10	%	O
11	value	O
12	4	O
13	h	O
14	after	O
15	drug	O
16	application	O
17	and	O
18	remained	O
19	at	O
20	this	O
21	level	O
22	during	O
23	the	O
24	observation	O
25	period	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Growth	O
2	curves	O
3	indicated	O
4	that	O
5	proliferation	O
6	of	O
7	clone	O
8	CA9	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	10	O
14	%	O
15	serum	O
16	was	O
17	reduced	O
18	by	O
19	60	O
20	%	O
21	compared	O
22	with	O
23	clone	O
24	ME10	O
25	.	O

1	The	O
2	protein	O
3	coding	O
4	region	O
5	,	O
6	1	O
7	,	O
8	696	O
9	bps	O
10	long	O
11	,	O
12	is	O
13	divided	O
14	by	O
15	an	O
16	intron	O
17	into	O
18	two	O
19	exons	O
20	.	O

1	The	O
2	UAS	O
3	of	O
4	the	O
5	AAC2	B
6	gene	I
7	contains	O
8	at	O
9	least	O
10	two	O
11	distinct	O
12	motifs	O
13	for	O
14	DNA	O
15	-	O
16	binding	O
17	transcriptional	O
18	activators	O
19	,	O
20	including	O
21	one	O
22	which	O
23	is	O
24	identical	O
25	with	O
26	the	O
27	core	O
28	HAP2	B
29	/	I
30	3	I
31	/	I
32	4	I
33	binding	I
34	motif	I
35	,	O
36	and	O
37	a	O
38	second	O
39	one	O
40	with	O
41	the	O
42	ABF1	B
43	consensus	I
44	binding	I
45	sequence	I
46	.	O

1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	I
14	gene	I
15	was	O
16	emphasised	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	hybridise	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	span	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O

1	A	O
2	polymorphic	O
3	dinucleotide	O
4	(	O
5	GT	O
6	/	O
7	CA	O
8	)	O
9	n	O
10	repeat	O
11	contained	O
12	in	O
13	the	O
14	NHE5	O
15	cosmid	O
16	was	O
17	identified	O
18	and	O
19	developed	O
20	into	O
21	a	O
22	microsatellite	O
23	PCR	O
24	marker	O
25	.	O

1	The	O
2	proteins	O
3	are	O
4	more	O
5	than	O
6	90	O
7	%	O
8	identical	O
9	to	O
10	each	O
11	other	O
12	within	O
13	the	O
14	protein	O
15	kinase	O
16	domain	O
17	but	O
18	only	O
19	51	O
20	-	O
21	59	O
22	%	O
23	identical	O
24	to	O
25	other	O
26	casein	B
27	kinase	I
28	I	I
29	isoforms	I
30	within	O
31	this	O
32	region	O
33	.	O

1	We	O
2	used	O
3	two	O
4	approaches	O
5	to	O
6	ascertain	O
7	whether	O
8	CDP	B
9	/	O
10	cut	B
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	gp91	B
17	-	O
18	phox	B
19	gene	O
20	expression	O
21	.	O

1	Serum	O
2	induction	O
3	of	O
4	a	O
5	MEF2	B
6	reporter	I
7	gene	I
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	O
21	MEF2	B
22	site	I
23	binding	O
24	activity	O
25	.	O

1	Despite	O
2	the	O
3	activation	O
4	of	O
5	these	O
6	intracellular	O
7	signaling	O
8	molecules	O
9	,	O
10	PDGF	B
11	beta	I
12	receptor	I
13	activation	O
14	elicited	O
15	no	O
16	detectable	O
17	effect	O
18	on	O
19	cell	O
20	proliferation	O
21	or	O
22	differentiation	O
23	.	O

1	UAS1	O
2	is	O
3	the	O
4	binding	O
5	site	O
6	for	O
7	the	O
8	transcriptional	O
9	regulator	O
10	Adr1p	B
11	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	the	O
6	ADH2	B
7	upstream	I
8	regulatory	I
9	region	I
10	,	O
11	including	O
12	UAS1	O
13	,	O
14	working	O
15	in	O
16	concert	O
17	with	O
18	the	O
19	ADH2	B
20	basal	I
21	promoter	I
22	elements	I
23	,	O
24	UAS2	O
25	-	O
26	dependent	O
27	gene	O
28	activation	O
29	was	O
30	dependent	O
31	on	O
32	orientation	O
33	,	O
34	copy	O
35	number	O
36	,	O
37	and	O
38	helix	O
39	phase	O
40	.	O

1	Induction	O
2	in	O
3	AP	B
4	-	I
5	1	I
6	DNA	O
7	binding	O
8	correlates	O
9	with	O
10	a	O
11	concomitant	O
12	GH	B
13	trans	O
14	-	O
15	activation	O
16	of	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	c	B
22	-	I
23	fos	I
24	genes	I
25	described	O
26	previously	O
27	.	O

1	Inactivation	O
2	of	O
3	MAP	B
4	kinases	I
5	occurs	O
6	via	O
7	a	O
8	specific	O
9	phosphatase	O
10	,	O
11	MKP	B
12	-	I
13	1	I
14	.	O

1	Short	O
2	-	O
3	course	O
4	amphotericin	O
5	B	O
6	therapy	O
7	for	O
8	candidemia	O
9	in	O
10	pediatric	O
11	patients	O
12	.	O

1	Furthermore	O
2	,	O
3	45Ca	O
4	-	O
5	binding	O
6	assays	O
7	revealed	O
8	that	O
9	CCaMK	B
10	directly	O
11	binds	O
12	Ca2	O
13	+.	O

1	Since	O
2	AP	B
3	-	I
4	1	I
5	is	O
6	an	O
7	important	O
8	mediator	O
9	of	O
10	tumor	O
11	promoter	O
12	action	O
13	,	O
14	these	O
15	findings	O
16	may	O
17	explain	O
18	the	O
19	anti	O
20	-	O
21	tumor	O
22	-	O
23	promoting	O
24	activity	O
25	of	O
26	phenolic	O
27	antioxidants	O
28	.	O

1	The	O
2	second	O
3	complex	O
4	,	O
5	when	O
6	purified	O
7	,	O
8	contained	O
9	four	O
10	protein	O
11	components	O
12	including	O
13	the	O
14	36	O
15	-	O
16	kDa	O
17	protein	O
18	.	O

1	The	O
2	protein	O
3	expressed	O
4	from	O
5	the	O
6	cloned	O
7	cDNA	O
8	is	O
9	secreted	O
10	into	O
11	the	O
12	culture	O
13	medium	O
14	and	O
15	yields	O
16	of	O
17	up	O
18	to	O
19	40	O
20	mg	O
21	per	O
22	litre	O
23	have	O
24	been	O
25	obtained	O
26	.	O

1	The	O
2	study	O
3	was	O
4	repeated	O
5	after	O
6	administration	O
7	of	O
8	oral	O
9	amiodarone	O
10	,	O
11	50	O
12	mg	O
13	/	O
14	kg	O
15	/	O
16	day	O
17	for	O
18	2	O
19	days	O
20	in	O
21	8	O
22	divided	O
23	doses	O
24	(	O
25	mean	O
26	dose	O
27	6	O
28	.	O
29	9	O
30	+/-	O
31	0	O
32	.	O
33	4	O
34	g	O
35	).	O

1	Plasmids	O
2	pAMS12	O
3	,	O
4	pAMS13	O
5	and	O
6	pAMS14	O
7	were	O
8	transformed	O
9	into	O
10	a	O
11	laboratory	O
12	strain	O
13	of	O
14	Saccharomyces	O
15	cerevisiae	O
16	,	O
17	whereas	O
18	pAMS15	O
19	was	O
20	stably	O
21	introduced	O
22	into	O
23	two	O
24	commercial	O
25	wine	O
26	yeast	O
27	strains	O
28	.	O

1	The	O
2	maximum	O
3	induction	O
4	of	O
5	ACC	B
6	-	I
7	oxidase	I
8	transcripts	I
9	occurred	O
10	at	O
11	about	O
12	6	O
13	h	O
14	after	O
15	excision	O
16	,	O
17	while	O
18	the	O
19	maximum	O
20	enzyme	O
21	activity	O
22	was	O
23	observed	O
24	at	O
25	24	O
26	h	O
27	.	O

1	Within	O
2	their	O
3	polypeptide	O
4	chain	O
5	,	O
6	they	O
7	all	O
8	contain	O
9	those	O
10	conserved	O
11	features	O
12	that	O
13	define	O
14	a	O
15	plant	O
16	CDPK	B
17	;	O
18	kinase	O
19	catalytic	O
20	sequences	O
21	are	O
22	linked	O
23	to	O
24	a	O
25	calmodulin	B
26	-	I
27	like	I
28	regulatory	I
29	domain	I
30	through	O
31	a	O
32	junction	O
33	region	O
34	.	O

1	Repair	O
2	of	O
3	this	O
4	insertion	O
5	by	O
6	homologous	O
7	recombination	O
8	restores	O
9	the	O
10	activity	O
11	of	O
12	the	O
13	hprt	B
14	locus	I
15	,	O
16	thus	O
17	confirming	O
18	the	O
19	site	O
20	of	O
21	mutation	O
22	.	O

1	The	O
2	timing	O
3	of	O
4	fla	B
5	gene	I
6	expression	O
7	in	O
8	the	O
9	cell	O
10	cycle	O
11	is	O
12	determined	O
13	by	O
14	specialized	O
15	forms	O
16	of	O
17	RNA	B
18	polymerase	I
19	and	O
20	the	O
21	appearance	O
22	and	O
23	/	O
24	or	O
25	activation	O
26	of	O
27	regulatory	O
28	proteins	O
29	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Polypeptides	O
2	of	O
3	the	O
4	same	O
5	apparent	O
6	sizes	O
7	are	O
8	detected	O
9	in	O
10	spores	O
11	of	O
12	a	O
13	cotE	B
14	null	O
15	mutant	O
16	,	O
17	on	O
18	which	O
19	basis	O
20	we	O
21	infer	O
22	that	O
23	the	O
24	products	O
25	of	O
26	the	O
27	cotJ	B
28	operon	I
29	are	O
30	required	O
31	for	O
32	the	O
33	normal	O
34	formation	O
35	of	O
36	the	O
37	inner	O
38	layers	O
39	of	O
40	the	O
41	coat	O
42	or	O
43	are	O
44	themselves	O
45	structural	O
46	components	O
47	of	O
48	the	O
49	coat	O
50	.	O

1	Based	O
2	on	O
3	the	O
4	estimated	O
5	values	O
6	of	O
7	divergence	O
8	of	O
9	apobec1	B
10	sequences	I
11	in	O
12	terms	O
13	of	O
14	the	O
15	numbers	O
16	of	O
17	synonymous	O
18	and	O
19	non	O
20	-	O
21	synonymous	O
22	suhstitutions	O
23	per	O
24	site	O
25	,	O
26	we	O
27	found	O
28	that	O
29	apobec1	B
30	is	O
31	a	O
32	fairly	O
33	rapidly	O
34	evolving	O
35	protein	O
36	.	O

1	EEA1	B
2	is	O
3	a	O
4	conserved	O
5	alpha	O
6	-	O
7	helical	O
8	peripheral	O
9	membrane	O
10	protein	O
11	flanked	O
12	by	O
13	cysteine	O
14	"	O
15	fingers	O
16	"	O
17	and	O
18	contains	O
19	a	O
20	calmodulin	B
21	-	I
22	binding	I
23	IQ	I
24	motif	I
25	.	O

1	Nucleotide	O
2	sequences	O
3	of	O
4	the	O
5	clones	O
6	revealed	O
7	that	O
8	one	O
9	clone	O
10	,	O
11	cap3	B
12	,	O
13	contained	O
14	an	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	ORF	O
20	)	O
21	that	O
22	would	O
23	code	O
24	for	O
25	a	O
26	26	O
27	-	O
28	amino	O
29	acid	O
30	,	O
31	cysteine	O
32	-	O
33	rich	O
34	peptide	O
35	with	O
36	significant	O
37	homology	O
38	to	O
39	Neurospora	B
40	crassa	I
41	copper	I
42	metallothionein	I
43	.	O

1	Sensing	O
2	with	O
3	chemically	O
4	and	O
5	biologically	O
6	modified	O
7	carbon	O
8	electrodes	O
9	.	O

1	Elevation	O
2	of	O
3	the	O
4	tissues	O
5	of	O
6	the	O
7	face	O
8	is	O
9	essentially	O
10	vertical	O
11	and	O
12	acts	O
13	on	O
14	the	O
15	forehead	O
16	,	O
17	temporal	O
18	region	O
19	,	O
20	gaze	O
21	and	O
22	cheekbones	O
23	.	O

1	This	O
2	region	O
3	binds	O
4	two	O
5	ubiquitous	O
6	nuclear	O
7	factors	O
8	,	O
9	USF	B
10	/	O
11	MLTF	B
12	and	O
13	the	O
14	CAAT	B
15	-	I
16	binding	I
17	transcription	I
18	factor	I
19	/	O
20	nuclear	B
21	factor	I
22	1	I
23	(	O
24	CTF	B
25	/	O
26	NF1	B
27	).	O

1	The	O
2	potential	O
3	impact	O
4	of	O
5	using	O
6	a	O
7	rapid	O
8	diagnostic	O
9	test	O
10	(	O
11	Strep	O
12	A	O
13	OIA	O
14	)	O
15	on	O
16	detection	O
17	and	O
18	treatment	O
19	of	O
20	group	O
21	A	O
22	beta	O
23	-	O
24	hemolytic	O
25	streptococcal	O
26	(	O
27	GABHS	O
28	)	O
29	pharyngitis	O
30	in	O
31	a	O
32	large	O
33	-	O
34	volume	O
35	pediatric	O
36	and	O
37	adolescent	O
38	clinic	O
39	was	O
40	examined	O
41	.	O

1	The	O
2	bHLH	B
3	proteins	I
4	function	O
5	as	O
6	potent	O
7	transcriptional	O
8	activators	O
9	of	O
10	tissue	O
11	-	O
12	specific	O
13	genes	O
14	by	O
15	forming	O
16	heterodimers	O
17	between	O
18	ubiquitous	O
19	and	O
20	cell	O
21	-	O
22	restricted	O
23	family	O
24	members	O
25	.	O

1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	BRCA1	B
8	region	I
9	were	O
10	used	O
11	to	O
12	select	O
13	cDNA	O
14	clones	O
15	from	O
16	pools	O
17	of	O
18	cDNAs	O
19	derived	O
20	from	O
21	human	O
22	placenta	O
23	,	O
24	HeLa	O
25	cells	O
26	,	O
27	activated	O
28	T	O
29	cells	O
30	,	O
31	and	O
32	fetal	O
33	head	O
34	.	O

1	The	O
2	other	O
3	two	O
4	clones	O
5	,	O
6	Ash	B
7	-	I
8	m	I
9	and	I
10	-	I
11	s	I
12	,	O
13	had	O
14	nucleotide	O
15	sequences	O
16	identical	O
17	with	O
18	Ash	B
19	-	I
20	l	I
21	cDNA	O
22	in	O
23	the	O
24	amino	O
25	-	O
26	terminal	O
27	region	O
28	.	O

1	This	O
2	study	O
3	assesses	O
4	the	O
5	feasibility	O
6	and	O
7	toxicity	O
8	of	O
9	adoptive	O
10	immunotherapy	O
11	with	O
12	tumor	O
13	infiltrating	O
14	lymphocytes	O
15	and	O
16	recombinant	B
17	interleukin	I
18	-	I
19	2	I
20	in	O
21	29	O
22	patients	O
23	who	O
24	underwent	O
25	resection	O
26	for	O
27	stage	O
28	III	O
29	non	O
30	-	O
31	small	O
32	-	O
33	cell	O
34	lung	O
35	cancer	O
36	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	Of	O
6	the	O
7	17	O
8	men	O
9	and	O
10	17	O
11	women	O
12	,	O
13	who	O
14	were	O
15	21	O
16	to	O
17	80	O
18	years	O
19	of	O
20	age	O
21	,	O
22	27	O
23	had	O
24	hereditary	O
25	motor	O
26	and	O
27	sensory	O
28	neuropathy	O
29	type	O
30	I	O
31	and	O
32	7	O
33	had	O
34	acquired	O
35	demyelinating	O
36	polyneuropathy	O
37	.	O

1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	COUP	B
5	-	I
6	TF	I
7	alone	O
8	had	O
9	no	O
10	effect	O
11	on	O
12	repCRS2	O
13	-	O
14	dependent	O
15	reporter	O
16	gene	O
17	activity	O
18	.	O

1	DNA	O
2	sequencing	O
3	and	O
4	Southern	O
5	blot	O
6	analyses	O
7	established	O
8	that	O
9	the	O
10	cDNA	O
11	clones	O
12	are	O
13	derived	O
14	from	O
15	two	O
16	different	O
17	genes	O
18	.	O

1	Muscle	B
2	GSH	I
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	Mutation	O
2	of	O
3	the	O
4	Sp1	B
5	element	I
6	,	O
7	which	O
8	abolishes	O
9	Sp1	B
10	binding	O
11	,	O
12	results	O
13	in	O
14	a	O
15	6	O
16	-	O
17	10	O
18	-	O
19	fold	O
20	reduction	O
21	in	O
22	reporter	O
23	activity	O
24	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	gene	I
6	is	O
7	overexpressed	O
8	in	O
9	a	O
10	variety	O
11	of	O
12	tumor	O
13	types	O
14	and	O
15	appears	O
16	to	O
17	play	O
18	an	O
19	important	O
20	role	O
21	in	O
22	the	O
23	abnormal	O
24	growth	O
25	of	O
26	a	O
27	number	O
28	of	O
29	cell	O
30	types	O
31	.	O

1	We	O
2	found	O
3	that	O
4	PML	B
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O

1	Schooling	O
2	is	O
3	found	O
4	to	O
5	be	O
6	related	O
7	to	O
8	good	O
9	health	O
10	even	O
11	after	O
12	controlling	O
13	for	O
14	differences	O
15	in	O
16	observable	O
17	health	O
18	inputs	O
19	.	O

1	With	O
2	this	O
3	bisected	O
4	diastolic	O
5	driving	O
6	,	O
7	the	O
8	abnormal	O
9	echo	O
10	disappeared	O
11	completely	O
12	.	O

1	It	O
2	acts	O
3	on	O
4	Cdks	B
5	in	O
6	the	O
7	G1	O
8	and	O
9	S	O
10	phases	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	,	O
16	and	O
17	also	O
18	binds	O
19	to	O
20	proliferating	B
21	cell	I
22	nuclear	I
23	antigen	I
24	(	O
25	PCNA	B
26	),	O
27	blocking	O
28	DNA	O
29	replication	O
30	in	O
31	vitro	O
32	.	O

1	Two	O
2	major	O
3	and	O
4	one	O
5	minor	O
6	transcription	O
7	initiation	O
8	sites	O
9	were	O
10	assigned	O
11	to	O
12	positions	O
13	+	O
14	1	O
15	and	O
16	+	O
17	24	O
18	and	O
19	position	O
20	+	O
21	14	O
22	,	O
23	respectively	O
24	,	O
25	by	O
26	a	O
27	combination	O
28	of	O
29	ribonuclease	O
30	protection	O
31	,	O
32	primer	O
33	extension	O
34	,	O
35	and	O
36	5	O
37	'	O
38	RACE	O
39	analyses	O
40	.	O

1	The	O
2	roxithromycin	O
3	doses	O
4	that	O
5	were	O
6	chosen	O
7	for	O
8	these	O
9	studies	O
10	were	O
11	less	O
12	than	O
13	achievable	O
14	blood	O
15	levels	O
16	.	O

1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O

1	Further	O
2	,	O
3	the	O
4	ORFs	O
5	of	O
6	components	O
7	3	O
8	and	O
9	5	O
10	potentially	O
11	encoded	O
12	proteins	O
13	of	O
14	about	O
15	20	O
16	kDa	O
17	,	O
18	the	O
19	size	O
20	of	O
21	the	O
22	BBTV	B
23	coat	I
24	protein	I
25	.	O

1	Serial	O
2	followup	O
3	strength	O
4	data	O
5	for	O
6	2	O
7	patients	O
8	were	O
9	compared	O
10	to	O
11	change	O
12	in	O
13	creatinine	B
14	kinase	I
15	(	O
16	CK	B
17	)	O
18	levels	O
19	.	O

1	CodY	B
2	does	O
3	not	O
4	have	O
5	any	O
6	homologues	O
7	in	O
8	the	O
9	data	O
10	-	O
11	bases	O
12	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	investigate	O
5	the	O
6	incidence	O
7	and	O
8	presentation	O
9	of	O
10	acute	O
11	pernicious	O
12	or	O
13	fulminating	O
14	beriberi	O
15	in	O
16	a	O
17	general	O
18	district	O
19	hospital	O
20	.	O

1	Unlike	O
2	most	O
3	other	O
4	small	B
5	G	I
6	proteins	I
7	which	O
8	are	O
9	expressed	O
10	ubiquitously	O
11	,	O
12	TTF	B
13	was	O
14	transcribed	O
15	only	O
16	in	O
17	hemopoietic	O
18	cells	O
19	as	O
20	a	O
21	2	O
22	.	O
23	2	O
24	kb	O
25	transcript	O
26	.	O

1	An	O
2	explanation	O
3	explored	O
4	for	O
5	this	O
6	lack	O
7	of	O
8	gene	O
9	expression	O
10	was	O
11	that	O
12	increased	O
13	levels	O
14	of	O
15	RAR	B
16	alpha	I
17	or	O
18	PML	B
19	might	O
20	suppress	O
21	APL	O
22	cell	O
23	growth	O
24	.	O

1	Transfection	O
2	of	O
3	non	O
4	-	O
5	deleted	O
6	expression	O
7	vector	O
8	into	O
9	NIH3T3	O
10	cells	O
11	results	O
12	in	O
13	acquisition	O
14	of	O
15	focus	O
16	-	O
17	forming	O
18	activity	O
19	while	O
20	a	O
21	deleted	O
22	form	O
23	of	O
24	expression	O
25	vector	O
26	fails	O
27	to	O
28	show	O
29	this	O
30	activity	O
31	even	O
32	in	O
33	the	O
34	presence	O
35	of	O
36	basic	B
37	FGF	I
38	.	O

1	Cytosolic	O
2	extracts	O
3	from	O
4	a	O
5	variety	O
6	of	O
7	mammalian	O
8	cell	O
9	lines	O
10	(	O
11	monkey	O
12	Cos7	O
13	,	O
14	several	O
15	mouse	O
16	fibrosarcomas	O
17	and	O
18	human	O
19	HeLa	O
20	S3	O
21	)	O
22	demonstrated	O
23	similar	O
24	TGF	B
25	-	I
26	beta	I
27	1	I
28	dependent	O
29	RNA	O
30	-	O
31	protein	O
32	band	O
33	shifts	O
34	as	O
35	cell	O
36	extract	O
37	from	O
38	BALB	O
39	/	O
40	c	O
41	3T3	O
42	mouse	O
43	fibroblasts	O
44	.	O

1	All	O
2	ribosomal	B
3	protein	I
4	(	O
5	rp	B
6	)	O
7	gene	O
8	promoters	O
9	from	O
10	Saccharomyces	O
11	cerevisiae	O
12	studied	O
13	so	O
14	far	O
15	contain	O
16	either	O
17	(	O
18	usually	O
19	two	O
20	)	O
21	binding	O
22	sites	O
23	for	O
24	the	O
25	global	O
26	gene	O
27	regulator	O
28	Rap1p	B
29	or	O
30	one	O
31	binding	O
32	site	O
33	for	O
34	another	O
35	global	O
36	factor	O
37	,	O
38	Abf1p	B
39	.	O

1	The	O
2	provisional	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	macroscopic	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	supplementary	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	histochemistry	O
27	,	O
28	more	O
29	rarely	O
30	electron	O
31	microscopy	O
32	,	O
33	immunohistochemistry	O
34	and	O
35	/	O
36	or	O
37	microbiology	O
38	.	O

1	Circulating	O
2	thrombomodulin	B
3	:	O
4	current	O
5	knowledge	O
6	and	O
7	future	O
8	prospects	O

1	CPT	O
2	-	O
3	11	O
4	was	O
5	administered	O
6	as	O
7	a	O
8	30	O
9	-	O
10	minute	O
11	i	O
12	.	O
13	v	O
14	.	O
15	infusion	O
16	at	O
17	a	O
18	dose	O
19	of	O
20	350	O
21	mg	O
22	/	O
23	m2	O
24	diluted	O
25	in	O
26	250	O
27	ml	O
28	normal	O
29	saline	O
30	every	O
31	3	O
32	weeks	O
33	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	MTD	O
5	for	O
6	CPT	O
7	-	O
8	11	O
9	administered	O
10	in	O
11	a	O
12	3	O
13	consecutive	O
14	-	O
15	days	O
16	-	O
17	every	O
18	-	O
19	3	O
20	weeks	O
21	schedule	O
22	in	O
23	this	O
24	patient	O
25	population	O
26	is	O
27	115	O
28	mg	O
29	/	O
30	m2	O
31	/	O
32	day	O
33	.	O

1	A	O
2	73	O
3	bp	O
4	fragment	O
5	(	O
6	X1	O
7	region	O
8	)	O
9	of	O
10	the	O
11	PRB	B
12	-	I
13	1b	I
14	promoter	I
15	,	O
16	located	O
17	between	O
18	positions	O
19	-	O
20	213	O
21	and	O
22	-	O
23	141	O
24	,	O
25	was	O
26	sufficient	O
27	to	O
28	confer	O
29	ethylene	O
30	responsiveness	O
31	to	O
32	the	O
33	reporter	O
34	gene	O
35	.	O

1	To	O
2	assess	O
3	the	O
4	function	O
5	(	O
6	s	O
7	)	O
8	of	O
9	E74	B
10	during	O
11	metamorphosis	O
12	,	O
13	we	O
14	have	O
15	isolated	O
16	and	O
17	characterized	O
18	recessive	O
19	loss	O
20	-	O
21	of	O
22	-	O
23	function	O
24	mutations	O
25	specific	O
26	to	O
27	each	O
28	transcription	O
29	unit	O
30	.	O

1	Although	O
2	the	O
3	extracellular	O
4	domain	O
5	of	O
6	the	O
7	TSH	B
8	-	I
9	R	I
10	is	O
11	sufficient	O
12	for	O
13	high	O
14	affinity	O
15	binding	O
16	of	O
17	TSH	B
18	,	O
19	we	O
20	conclude	O
21	that	O
22	the	O
23	hyt	O
24	mutation	O
25	in	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	eliminates	O
31	TSH	B
32	binding	O
33	.	O

1	Lipiodol	O
2	was	O
3	covalently	O
4	conjugated	O
5	with	O
6	EDTB	O
7	.	O

1	Moreover	O
2	,	O
3	Western	O
4	blots	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	Ypt	B
12	in	O
13	both	O
14	Cr	O
15	and	O
16	Vc	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	Ypt	B
22	are	O
23	used	O
24	for	O
25	household	O
26	functions	O
27	responsible	O
28	for	O
29	vesicle	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O

1	The	O
2	absence	O
3	of	O
4	other	O
5	regions	O
6	of	O
7	hybridization	O
8	suggests	O
9	that	O
10	there	O
11	are	O
12	no	O
13	closely	O
14	related	O
15	sequences	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	reverse	O
22	transcribed	O
23	pseudogenes	O
24	)	O
25	scattered	O
26	throughout	O
27	the	O
28	genome	O
29	and	O
30	that	O
31	if	O
32	there	O
33	are	O
34	closely	O
35	related	O
36	genes	O
37	,	O
38	they	O
39	must	O
40	be	O
41	clustered	O
42	near	O
43	GSTT2	B
44	.	O

1	However	O
2	,	O
3	the	O
4	lens	O
5	dose	O
6	(	O
7	3	O
8	.	O
9	6	O
10	Gy	O
11	/	O
12	25	O
13	fractions	O
14	)	O
15	was	O
16	higher	O
17	compared	O
18	to	O
19	the	O
20	other	O
21	techniques	O
22	.	O

1	Antibodies	O
2	to	O
3	the	O
4	human	B
5	PTS1R	I
6	recognize	O
7	this	O
8	protein	O
9	in	O
10	human	O
11	,	O
12	monkey	O
13	,	O
14	rat	O
15	,	O
16	and	O
17	hamster	O
18	cells	O
19	.	O

1	There	O
2	is	O
3	a	O
4	national	O
5	effort	O
6	to	O
7	begin	O
8	to	O
9	ask	O
10	all	O
11	female	O
12	patients	O
13	about	O
14	family	O
15	violence	O
16	.	O

1	GnRH	B
2	treatment	O
3	was	O
4	found	O
5	to	O
6	increase	O
7	the	O
8	phosphorylation	O
9	of	O
10	tyrosine	O
11	residues	O
12	of	O
13	MAPK	B
14	and	O
15	to	O
16	increase	O
17	MAPK	B
18	activity	O
19	,	O
20	as	O
21	determined	O
22	by	O
23	an	O
24	immune	O
25	complex	O
26	kinase	O
27	assay	O
28	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	amphibian	B
6	insulin	I
7	receptor	I
8	substrate	I
9	1	I
10	-	I
11	like	I
12	cDNA	I
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	B
17	3	I
18	-	I
19	kinase	I
20	in	O
21	insulin	B
22	-	O
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	in	O
6	cultured	O
7	Jurkat	O
8	T	O
9	cells	O
10	,	O
11	Cbl	B
12	is	O
13	coprecipitated	O
14	with	O
15	antibody	O
16	against	O
17	the	O
18	adapter	B
19	protein	I
20	Grb2	I
21	.	O

1	The	O
2	effect	O
3	of	O
4	these	O
5	cell	O
6	cycle	O
7	regulators	O
8	is	O
9	not	O
10	specific	O
11	to	O
12	the	O
13	rap1s	B
14	or	O
15	hmr	B
16	delta	I
17	A	I
18	mutation	I
19	,	O
20	since	O
21	swi6	B
22	,	O
23	swi4	B
24	,	O
25	and	O
26	clb5	B
27	mutations	I
28	also	O
29	suppress	O
30	mutations	O
31	in	O
32	SIR1	B
33	,	O
34	another	O
35	gene	O
36	implicated	O
37	in	O
38	the	O
39	establishment	O
40	of	O
41	silencing	O
42	.	O

1	ICP4	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	form	O
7	tripartite	O
8	complexes	O
9	cooperatively	O
10	with	O
11	the	O
12	TATA	B
13	box	I
14	-	I
15	binding	I
16	protein	I
17	and	O
18	TFIIB	B
19	on	O
20	DNA	O
21	containing	O
22	an	O
23	ICP4	B
24	binding	I
25	site	I
26	and	O
27	a	O
28	TATA	O
29	box	O
30	(	O
31	C	O
32	.	O

1	Otte	O
2	,	O
3	Mol	O
4	.	O

1	Characterization	O
2	of	O
3	fus1	B
4	of	O
5	Schizosaccharomyces	O
6	pombe	O
7	:	O
8	a	O
9	developmentally	O
10	controlled	O
11	function	O
12	needed	O
13	for	O
14	conjugation	O
15	.	O

1	SRY	B
2	-	I
3	related	I
4	cDNA	I
5	encoding	O
6	a	O
7	protein	O
8	with	O
9	a	O
10	high	B
11	-	I
12	mobility	I
13	-	I
14	group	I
15	(	O
16	HMG	B
17	)	O
18	box	O
19	and	O
20	a	O
21	leucine	O
22	zipper	O
23	motif	O
24	,	O
25	which	O
26	was	O
27	designated	O
28	SOX	B
29	-	I
30	LZ	I
31	,	O
32	was	O
33	isolated	O
34	from	O
35	a	O
36	rainbow	O
37	trout	O
38	testis	O
39	cDNA	O
40	library	O
41	.	O

1	Scalp	O
2	flaps	O
3	can	O
4	be	O
5	expanded	O
6	just	O
7	to	O
8	the	O
9	point	O
10	of	O
11	becoming	O
12	noticeable	O
13	over	O
14	4	O
15	to	O
16	6	O
17	weeks	O
18	followed	O
19	by	O
20	scalp	O
21	flap	O
22	transposition	O
23	and	O
24	easy	O
25	closure	O
26	of	O
27	the	O
28	donor	O
29	site	O
30	.	O

1	In	O
2	the	O
3	Center	O
4	for	O
5	Human	O
6	Genetics	O
7	in	O
8	Leuven	O
9	,	O
10	predictive	O
11	DNA	O
12	-	O
13	testing	O
14	for	O
15	Huntington	O
16	'	O
17	s	O
18	disease	O
19	is	O
20	available	O
21	as	O
22	a	O
23	clinical	O
24	service	O
25	since	O
26	November	O
27	1987	O
28	,	O
29	initially	O
30	by	O
31	DNA	O
32	-	O
33	linkage	O
34	and	O
35	since	O
36	mid	O
37	1993	O
38	by	O
39	direct	O
40	mutation	O
41	analysis	O
42	.	O

1	Risks	O
2	of	O
3	chronicity	O
4	following	O
5	acute	O
6	hepatitis	O
7	B	O
8	virus	O
9	infection	O
10	:	O
11	a	O
12	review	O
13	.	O

1	Examination	O
2	of	O
3	neurohumoral	O
4	factors	O
5	revealed	O
6	a	O
7	hyperactive	O
8	sympathetic	O
9	nervous	O
10	system	O
11	and	O
12	an	O
13	increase	O
14	in	O
15	plasma	O
16	renin	B
17	activity	O
18	.	O

1	We	O
2	compared	O
3	the	O
4	inhibitory	O
5	effect	O
6	of	O
7	naturally	O
8	occurring	O
9	mutant	B
10	hTR	I
11	beta	I
12	1	I
13	,	O
14	artificially	O
15	created	O
16	hTR	B
17	alpha	I
18	1	I
19	mutants	I
20	,	O
21	c	B
22	-	I
23	erbA	I
24	alpha	I
25	2	I
26	and	O
27	the	O
28	human	B
29	peroxisome	I
30	proliferator	I
31	-	I
32	activated	I
33	receptor	I
34	(	O
35	hPPAR	B
36	)	O
37	on	O
38	three	O
39	prototypic	O
40	T3	O
41	-	O
42	response	O
43	elements	O
44	(	O
45	TREs	O
46	),	O
47	TRE	O
48	-	O
49	PAL	O
50	,	O
51	DR	O
52	+	O
53	4	O
54	and	O
55	TRE	O
56	-	O
57	LAP	O
58	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	DNA	O
6	-	O
7	binding	O
8	domain	O
9	of	O
10	Pip	B
11	exhibits	O
12	a	O
13	high	O
14	degree	O
15	of	O
16	homology	O
17	to	O
18	the	O
19	DNA	O
20	-	O
21	binding	O
22	domains	O
23	of	O
24	members	O
25	of	O
26	the	O
27	interferon	B
28	regulatory	I
29	factor	I
30	(	O
31	IRF	B
32	)	O
33	family	O
34	,	O
35	which	O
36	includes	O
37	IRF	B
38	-	I
39	1	I
40	,	O
41	IRF	B
42	-	I
43	2	I
44	,	O
45	ICSBP	B
46	,	O
47	and	O
48	ISGF3	B
49	gamma	I
50	.	O

1	An	O
2	outbreak	O
3	of	O
4	hepatitis	O
5	A	O
6	among	O
7	homosexual	O
8	men	O
9	in	O
10	Amsterdam	O
11	,	O
12	1991	O
13	-	O
14	1993	O
15	.	O

1	The	O
2	RAP74	B
3	subunit	I
4	of	O
5	TFIIF	B
6	alone	O
7	contained	O
8	the	O
9	stimulatory	O
10	activity	O
11	and	O
12	the	O
13	minimal	O
14	region	O
15	sufficient	O
16	for	O
17	stimulation	O
18	corresponds	O
19	to	O
20	COOH	O
21	-	O
22	terminal	O
23	residues	O
24	358	O
25	-	O
26	517	O
27	.	O

1	We	O
2	have	O
3	generated	O
4	various	O
5	base	O
6	substitutions	O
7	and	O
8	internal	O
9	deletions	O
10	in	O
11	and	O
12	around	O
13	DRE	O
14	(	O
15	nucleotide	O
16	positions	O
17	-	O
18	93	O
19	to	O
20	-	O
21	100	O
22	with	O
23	respect	O
24	to	O
25	the	O
26	transcription	O
27	initiation	O
28	site	O
29	)	O
30	of	O
31	the	O
32	PCNA	B
33	gene	I
34	in	O
35	vitro	O
36	and	O
37	subsequently	O
38	examined	O
39	their	O
40	effects	O
41	on	O
42	the	O
43	binding	O
44	to	O
45	DREF	B
46	(	O
47	DRE	B
48	-	I
49	binding	I
50	factor	I
51	)	O
52	and	O
53	PCNA	B
54	gene	I
55	promote	O
56	activity	O
57	in	O
58	cultured	O
59	Drosophila	O
60	Kc	O
61	cells	O
62	as	O
63	well	O
64	as	O
65	in	O
66	living	O
67	flies	O
68	.	O

1	The	O
2	hsp70	B
3	gene	I
4	family	I
5	of	O
6	Neurospora	O
7	crassa	O
8	:	O
9	cloning	O
10	,	O
11	sequence	O
12	analysis	O
13	,	O
14	expression	O
15	,	O
16	and	O
17	genetic	O
18	mapping	O
19	of	O
20	the	O
21	major	O
22	stress	O
23	-	O
24	inducible	O
25	member	O
26	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequences	O
6	of	O
7	each	O
8	of	O
9	the	O
10	W3A1	B
11	ETF	I
12	subunits	I
13	exhibit	O
14	only	O
15	approximately	O
16	30	O
17	%	O
18	identity	O
19	with	O
20	the	O
21	corresponding	O
22	subunits	O
23	of	O
24	the	O
25	ETF	B
26	from	O
27	human	O
28	,	O
29	rat	O
30	,	O
31	and	O
32	Paracoccus	O
33	denitrificans	O
34	,	O
35	which	O
36	as	O
37	a	O
38	group	O
39	are	O
40	greater	O
41	than	O
42	50	O
43	%	O
44	identical	O
45	.	O

1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	B
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	gene	O
18	expression	O
19	.	O

1	A	O
2	role	O
3	for	O
4	glycogen	B
5	synthase	I
6	kinase	I
7	-	I
8	3	I
9	in	O
10	the	O
11	control	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	This	O
2	last	O
3	region	O
4	contains	O
5	two	O
6	sites	O
7	that	O
8	bind	O
9	Ets	B
10	-	I
11	related	I
12	proteins	I
13	present	O
14	in	O
15	liver	O
16	nuclear	O
17	extracts	O
18	as	O
19	well	O
20	as	O
21	recombinant	B
22	purified	I
23	Ets	I
24	-	I
25	1	I
26	protein	I
27	.	O

1	Other	O
2	assays	O
3	also	O
4	distinguished	O
5	the	O
6	processive	O
7	replication	O
8	of	O
9	pNeo	O
10	.	O
11	Myc	O
12	-	O
13	2	O
14	.	O
15	4	O
16	from	O
17	the	O
18	dispersive	O
19	labeling	O
20	of	O
21	control	O
22	plasmids	O
23	.	O

1	Reconstitution	O
2	of	O
3	complexes	O
4	containing	O
5	p62	B
6	and	O
7	the	O
8	src	B
9	family	I
10	kinase	I
11	p59fyn	I
12	in	O
13	HeLa	O
14	cells	O
15	demonstrated	O
16	that	O
17	complex	O
18	formation	O
19	resulted	O
20	in	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	p62	B
25	and	O
26	was	O
27	mediated	O
28	by	O
29	both	O
30	the	O
31	SH3	B
32	and	O
33	SH2	B
34	domains	I
35	of	O
36	p59fyn	B
37	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	hoped	O
6	that	O
7	by	O
8	defining	O
9	the	O
10	transcriptional	O
11	control	O
12	of	O
13	the	O
14	L7	B
15	gene	I
16	insights	O
17	into	O
18	the	O
19	mechanisms	O
20	that	O
21	control	O
22	functional	O
23	fate	O
24	and	O
25	organization	O
26	in	O
27	the	O
28	nervous	O
29	system	O
30	can	O
31	be	O
32	gained	O
33	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	Maf	B
6	-	I
7	related	I
8	protein	I
9	,	O
10	Nrl	B
11	,	O
12	completely	O
13	mimicked	O
14	c	B
15	-	I
16	Maf	I
17	actions	O
18	.	O

1	The	O
2	27	O
3	-	O
4	base	O
5	element	O
6	interacts	O
7	with	O
8	a	O
9	PDGF	B
10	-	O
11	activated	O
12	serine	O
13	/	O
14	threonine	O
15	phosphoprotein	O
16	that	O
17	is	O
18	detected	O
19	only	O
20	within	O
21	the	O
22	nucleus	O
23	of	O
24	PDGF	O
25	-	O
26	treated	O
27	3T3	O
28	cells	O
29	.	O

1	By	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	this	O
7	Ras	B
8	-	I
9	binding	I
10	site	I
11	did	O
12	not	O
13	diminish	O
14	activation	O
15	of	O
16	Raf	B
17	-	I
18	1	I
19	kinase	I
20	by	O
21	Src	B
22	,	O
23	implying	O
24	that	O
25	Src	B
26	and	O
27	Ras	B
28	can	O
29	activate	O
30	Raf	B
31	-	I
32	1	I
33	through	O
34	independent	O
35	mechanisms	O
36	.	O

1	In	O
2	studies	O
3	of	O
4	many	O
5	different	O
6	phenotypically	O
7	distinct	O
8	cells	O
9	,	O
10	the	O
11	CRE	O
12	of	O
13	the	O
14	somatostatin	B
15	gene	I
16	promoter	I
17	is	O
18	a	O
19	prototype	O
20	of	O
21	a	O
22	highly	O
23	cAMP	O
24	-	O
25	responsive	O
26	element	O
27	regulated	O
28	by	O
29	CREB	B
30	.	O

1	The	O
2	first	O
3	gene	O
4	,	O
5	NSR1	B
6	,	O
7	a	O
8	previously	O
9	identified	O
10	gene	O
11	,	O
12	encodes	O
13	a	O
14	protein	O
15	involved	O
16	in	O
17	ribosomal	O
18	RNA	O
19	maturation	O
20	and	O
21	possibly	O
22	in	O
23	transport	O
24	of	O
25	proteins	O
26	into	O
27	the	O
28	nucleus	O
29	.	O

1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	B
8	85	I
9	kDa	I
10	cytosolic	I
11	phospholipase	I
12	A2	I
13	gene	I
14	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	advantages	O
6	and	O
7	limitations	O
8	of	O
9	the	O
10	main	O
11	study	O
12	approaches	O
13	used	O
14	.	O

1	Comparative	O
2	study	O
3	of	O
4	the	O
5	differential	O
6	white	O
7	blood	O
8	cell	O
9	count	O
10	using	O
11	three	O
12	automated	O
13	analyzers	O
14	:	O
15	Coulter	O
16	STKS	O
17	,	O
18	Sysmex	O
19	NE	O
20	8000	O
21	and	O
22	Technicon	O
23	H	O
24	-	O
25	1	O
26	.	O

1	Characterization	O
2	of	O
3	FIII	B
4	/	O
5	YY1	B
6	,	O
7	a	O
8	Xenopus	B
9	laevis	I
10	conserved	I
11	zinc	I
12	-	I
13	finger	I
14	protein	I
15	binding	O
16	to	O
17	the	O
18	first	O
19	exon	O
20	of	O
21	L1	B
22	and	O
23	L14	B
24	ribosomal	I
25	protein	I
26	genes	I
27	.	O

1	Further	O
2	studies	O
3	established	O
4	that	O
5	the	O
6	Ep	B
7	-	O
8	induced	O
9	increase	O
10	in	O
11	beta	B
12	-	I
13	globin	I
14	mRNA	I
15	could	O
16	be	O
17	inhibited	O
18	by	O
19	the	O
20	tyrosine	B
21	kinase	I
22	inhibitor	O
23	genistein	O
24	and	O
25	the	O
26	protein	B
27	kinase	I
28	C	I
29	inhibitor	O
30	Compound	O
31	3	O
32	.(	O
33	ABSTRACT	O
34	TRUNCATED	O
35	AT	O
36	250	O
37	WORDS	O
38	)	O

1	This	O
2	structure	O
3	of	O
4	cucumisin	B
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O

1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	O
6	CD3	B
7	-	O
8	TCR	B
9	complex	O
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	B
19	zeta	I
20	and	O
21	CD3	B
22	epsilon	I
23	,	O
24	autonomously	O
25	couple	O
26	antigenic	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O

1	Protein	B
2	cHMGI	I
3	binds	O
4	preferentially	O
5	to	O
6	AT	O
7	-	O
8	rich	O
9	DNA	O
10	with	O
11	a	O
12	half	O
13	-	O
14	saturation	O
15	value	O
16	of	O
17	1	O
18	.	O
19	1	O
20	nM	O
21	.	O

1	This	O
2	study	O
3	investigated	O
4	the	O
5	degree	O
6	to	O
7	which	O
8	racial	O
9	identity	O
10	influences	O
11	Mexican	O
12	-	O
13	Americans	O
14	'	O
15	performance	O
16	on	O
17	the	O
18	L	O
19	,	O
20	K	O
21	,	O
22	and	O
23	MF	O
24	scales	O
25	of	O
26	the	O
27	MMPI	O
28	-	O
29	2	O
30	.	O

1	Both	O
2	can	O
3	be	O
4	elevated	O
5	on	O
6	a	O
7	single	O
8	vascular	O
9	pedicle	O
10	based	O
11	on	O
12	the	O
13	superficial	O
14	temporal	O
15	artery	O
16	,	O
17	the	O
18	double	O
19	-	O
20	layered	O
21	temporal	O
22	fascia	O
23	flap	O
24	.	O

1	To	O
2	do	O
3	this	O
4	,	O
5	segments	O
6	of	O
7	DNA	O
8	from	O
9	the	O
10	5	O
11	'	O
12	flank	O
13	of	O
14	the	O
15	initiation	O
16	sites	O
17	for	O
18	germline	O
19	epsilon	O
20	RNA	O
21	were	O
22	ligated	O
23	to	O
24	a	O
25	luciferase	B
26	reporter	I
27	gene	I
28	and	O
29	transfected	O
30	into	O
31	two	O
32	mouse	O
33	B	O
34	cell	O
35	lines	O
36	,	O
37	one	O
38	of	O
39	which	O
40	can	O
41	be	O
42	induced	O
43	to	O
44	switch	O
45	to	O
46	IgE	B
47	.	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	O
8	vs	O
9	80	O
10	%	O
11	for	O
12	the	O
13	NCEP	O
14	I	O
15	.	O

1	Oncogenic	O
2	capacity	O
3	of	O
4	the	O
5	E2F1	B
6	gene	I
7	.	O

1	In	O
2	some	O
3	of	O
4	the	O
5	cases	O
6	of	O
7	solitary	O
8	lesion	O
9	,	O
10	serum	B
11	TSH	I
12	levels	O
13	,	O
14	serum	B
15	thyroglobulin	I
16	values	O
17	,	O
18	and	O
19	131I	O
20	protein	O
21	bounded	O
22	iodine	O
23	(	O
24	131I	O
25	-	O
26	PBI	O
27	)	O
28	were	O
29	measured	O
30	,	O
31	but	O
32	there	O
33	were	O
34	no	O
35	significant	O
36	differences	O
37	between	O
38	successful	O
39	and	O
40	unsuccessful	O
41	therapy	O
42	.	O

1	Endo16	B
2	transcripts	I
3	are	O
4	confined	O
5	to	O
6	the	O
7	definitive	O
8	vegetal	O
9	plate	O
10	in	O
11	blastula	O
12	stage	O
13	embryos	O
14	;	O
15	at	O
16	gastrula	O
17	stage	O
18	this	O
19	gene	O
20	is	O
21	expressed	O
22	throughout	O
23	the	O
24	archenteron	O
25	,	O
26	but	O
27	later	O
28	only	O
29	in	O
30	the	O
31	midgut	O
32	.	O

1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	B
20	-	I
21	1	I
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O

1	Another	O
2	full	O
3	ORF	O
4	was	O
5	found	O
6	on	O
7	the	O
8	opposite	O
9	strand	O
10	downstream	O
11	from	O
12	the	O
13	nspC	B
14	gene	I
15	.	O

1	The	O
2	U14	B
3	genes	I
4	of	O
5	mouse	O
6	as	O
7	well	O
8	as	O
9	rat	O
10	,	O
11	hamster	O
12	,	O
13	human	O
14	,	O
15	Xenopus	O
16	and	O
17	trout	O
18	are	O
19	encoded	O
20	within	O
21	introns	O
22	of	O
23	the	O
24	constitutively	O
25	expressed	O
26	70	B
27	-	I
28	kDa	I
29	-	I
30	cognate	I
31	-	I
32	heat	I
33	-	I
34	shock	I
35	protein	I
36	gene	I
37	(	O
38	hsc70	B
39	).	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O

1	Deletion	O
2	of	O
3	both	O
4	prfA	B
5	and	O
6	ponA	B
7	resulted	O
8	in	O
9	extremely	O
10	slow	O
11	growth	O
12	and	O
13	a	O
14	reduction	O
15	in	O
16	sporulation	O
17	efficiency	O
18	.	O

1	Inclusion	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	B
10	and	O
11	FliR	B
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	B
12	M6P	I
13	/	I
14	IGF	I
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	O
20	IGF	B
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	Chem	O
2	.	O

1	For	O
2	the	O
3	first	O
4	time	O
5	we	O
6	describe	O
7	deletion	O
8	and	O
9	point	O
10	mutations	O
11	within	O
12	the	O
13	plasma	B
14	membrane	I
15	family	I
16	of	I
17	guanylyl	I
18	cyclase	I
19	receptors	I
20	that	O
21	result	O
22	in	O
23	the	O
24	formation	O
25	of	O
26	effective	O
27	dominant	O
28	negative	O
29	proteins	O
30	.	O

1	Increase	O
2	in	O
3	blood	O
4	NEFA	O
5	was	O
6	further	O
7	augmented	O
8	by	O
9	fat	O
10	plus	O
11	AA	O
12	supplementation	O
13	,	O
14	but	O
15	no	O
16	changes	O
17	in	O
18	concentrations	O
19	of	O
20	Lys	O
21	or	O
22	Met	O
23	in	O
24	blood	O
25	were	O
26	found	O
27	.	O

1	Virol	O
2	.	O

1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	B
6	-	I
7	1	I
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	Comparison	O
2	of	O
3	the	O
4	deduced	O
5	amino	B
6	acid	I
7	sequence	I
8	of	I
9	gamma	I
10	-	I
11	kafirin	I
12	with	O
13	the	O
14	published	O
15	sequences	B
16	of	I
17	gamma	I
18	-	I
19	prolamins	I
20	of	I
21	maize	I
22	,	I
23	and	I
24	Coix	I
25	revealed	O
26	highly	O
27	conserved	O
28	domains	O
29	.	O

1	Atcys1	B
2	,	O
3	Athyp1	B
4	,	O
5	AKin10	B
6	and	O
7	the	O
8	ORF	O
9	are	O
10	very	O
11	close	O
12	to	O
13	each	O
14	other	O
15	and	O
16	organized	O
17	in	O
18	the	O
19	same	O
20	polarity	O
21	;	O
22	hence	O
23	,	O
24	the	O
25	intergenic	O
26	regions	O
27	probably	O
28	contain	O
29	,	O
30	within	O
31	less	O
32	than	O
33	0	O
34	.	O
35	5	O
36	kb	O
37	,	O
38	all	O
39	the	O
40	regulatory	O
41	elements	O
42	necessary	O
43	to	O
44	govern	O
45	initiation	O
46	and	O
47	termination	O
48	of	O
49	transcription	O
50	.	O

1	Southern	O
2	blot	O
3	hybridization	O
4	experiments	O
5	suggest	O
6	the	O
7	presence	O
8	of	O
9	one	O
10	copy	O
11	of	O
12	Atcys1	B
13	,	O
14	Athyp1	B
15	and	O
16	AKin10	B
17	per	O
18	haploid	O
19	genome	O
20	,	O
21	and	O
22	Northern	O
23	blot	O
24	analysis	O
25	demonstrates	O
26	that	O
27	the	O
28	three	O
29	genes	O
30	are	O
31	differentially	O
32	expressed	O
33	in	O
34	roots	O
35	,	O
36	shoots	O
37	and	O
38	leaves	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAC1	B
6	may	O
7	also	O
8	be	O
9	one	O
10	of	O
11	the	O
12	meiotic	O
13	genes	O
14	.	O

1	We	O
2	characterized	O
3	three	O
4	Arabidopsis	O
5	thaliana	O
6	cDNA	O
7	clones	O
8	that	O
9	could	O
10	rescue	O
11	the	O
12	sterile	O
13	phenotype	O
14	of	O
15	the	O
16	Schizosaccharomyces	B
17	pombe	I
18	pde1	I
19	mutant	I
20	,	O
21	which	O
22	is	O
23	defective	O
24	in	O
25	cAMP	B
26	phosphodiesterase	I
27	.	O

1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	B
8	-	I
9	like	I
10	protein	I
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	B
38	.	O

1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	O
20	BTU2	B
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	the	O
6	STR	B
7	family	I
8	of	O
9	genes	O
10	is	O
11	represented	O
12	in	O
13	a	O
14	nematode	O
15	whose	O
16	ancestor	O
17	appeared	O
18	well	O
19	before	O
20	the	O
21	branching	O
22	that	O
23	gave	O
24	rise	O
25	to	O
26	the	O
27	Arthropoda	O
28	and	O
29	Chordata	O
30	.	O

1	The	O
2	pre	O
3	-	O
4	and	O
5	postoperative	O
6	haemoglobin	B
7	concentrations	O
8	in	O
9	the	O
10	autologous	O
11	group	O
12	were	O
13	lower	O
14	by	O
15	15	O
16	and	O
17	10	O
18	g	O
19	/	O
20	L	O
21	,	O
22	respectively	O
23	,	O
24	after	O
25	primary	O
26	THR	O
27	and	O
28	by	O
29	10	O
30	g	O
31	/	O
32	L	O
33	in	O
34	both	O
35	instances	O
36	after	O
37	revision	O
38	THR	O
39	.	O

1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	alpha	I
5	,	O
6	the	O
7	cytokine	O
8	that	O
9	participates	O
10	in	O
11	the	O
12	autocrine	O
13	growth	O
14	control	O
15	of	O
16	hairy	O
17	cell	O
18	leukemia	O
19	has	O
20	strong	O
21	bone	O
22	resorptive	O
23	properties	O
24	.	O

1	(	O
2	iv	O
3	)	O
4	Although	O
5	UCRBP	B
6	has	O
7	been	O
8	previously	O
9	shown	O
10	to	O
11	act	O
12	as	O
13	a	O
14	transcriptional	O
15	repressor	O
16	,	O
17	we	O
18	show	O
19	here	O
20	that	O
21	UCRBP	B
22	can	O
23	also	O
24	act	O
25	as	O
26	a	O
27	positive	O
28	transactivator	O
29	of	O
30	a	O
31	reporter	O
32	driven	O
33	by	O
34	UCR	O
35	elements	O
36	when	O
37	used	O
38	in	O
39	co	O
40	-	O
41	transfection	O
42	assays	O
43	.	O

1	The	O
2	sequence	O
3	of	O
4	monkey	B
5	opsin	I
6	closely	O
7	resembles	O
8	the	O
9	human	O
10	sequence	O
11	at	O
12	the	O
13	nucleotide	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	levels	O
19	,	O
20	with	O
21	the	O
22	latter	O
23	having	O
24	only	O
25	7	O
26	differences	O
27	out	O
28	of	O
29	348	O
30	residues	O
31	.	O

1	One	O
2	complex	O
3	appears	O
4	to	O
5	be	O
6	ubiquitous	O
7	but	O
8	enriched	O
9	in	O
10	lymphoid	O
11	cells	O
12	and	O
13	represents	O
14	the	O
15	binding	O
16	of	O
17	a	O
18	potentially	O
19	novel	O
20	factor	O
21	with	O
22	an	O
23	apparent	O
24	molecular	O
25	mass	O
26	of	O
27	approximately	O
28	50	O
29	kDa	O
30	.	O

1	Chem	O
2	.	O

1	Conversely	O
2	,	O
3	activation	O
4	of	O
5	Oct	B
6	-	I
7	3	I
8	/	I
9	4	I
10	promoter	I
11	by	O
12	RAR	B
13	:	O
14	RXR	B
15	heterodimers	I
16	was	O
17	completely	O
18	abolished	O
19	by	O
20	EAR	B
21	-	I
22	3	I
23	/	O
24	COUP	B
25	-	I
26	TFI	I
27	and	O
28	by	O
29	ARP	B
30	-	I
31	1	I
32	/	O
33	COUP	B
34	-	I
35	TFII	I
36	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	EKLF	B
6	provides	O
7	a	O
8	crucial	O
9	transactivation	O
10	function	O
11	for	O
12	globin	B
13	expression	O
14	and	O
15	further	O
16	reinforce	O
17	the	O
18	idea	O
19	that	O
20	EKLF	B
21	is	O
22	an	O
23	important	O
24	regulator	O
25	of	O
26	CACCC	O
27	element	O
28	-	O
29	directed	O
30	transcription	O
31	in	O
32	erythroid	O
33	cells	O
34	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	O
22	I	B
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	O
34	-	O
35	terminal	O
36	region	O
37	of	O
38	I	B
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	O
47	-	O
48	protein	O
49	binding	O
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	O
94	-	O
95	like	O
96	region	O
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	The	O
2	negative	O
3	regulatory	O
4	activity	O
5	of	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	domain	O
11	was	O
12	antagonized	O
13	by	O
14	a	O
15	C	O
16	-	O
17	terminal	O
18	segment	O
19	of	O
20	Pho81p	B
21	supplied	O
22	in	O
23	trans	O
24	.	O

1	At	O
2	different	O
3	times	O
4	of	O
5	the	O
6	surgical	O
7	procedures	O
8	(	O
9	thorax	O
10	opening	O
11	and	O
12	closure	O
13	,	O
14	period	O
15	of	O
16	cardiopulmonary	O
17	bypass	O
18	)	O
19	67	O
20	to	O
21	100	O
22	%	O
23	of	O
24	the	O
25	patients	O
26	in	O
27	group	O
28	1	O
29	had	O
30	vancomycin	O
31	concentrations	O
32	in	O
33	the	O
34	studied	O
35	tissues	O
36	above	O
37	the	O
38	MIC	O
39	90	O
40	for	O
41	Staphylococcus	O
42	aureus	O
43	(	O
44	1	O
45	microgram	O
46	/	O
47	g	O
48	)	O
49	and	O
50	Staphylococcus	O
51	epidermidis	O
52	(	O
53	2	O
54	micrograms	O
55	/	O
56	g	O
57	).	O

1	On	O
2	-	O
3	line	O
4	angioscopic	O
5	images	O
6	of	O
7	tissue	O
8	flaps	O
9	floating	O
10	in	O
11	the	O
12	lumen	O
13	,	O
14	recent	O
15	or	O
16	structured	O
17	thrombi	O
18	,	O
19	artery	O
20	wall	O
21	dissections	O
22	,	O
23	plaque	O
24	ruptures	O
25	,	O
26	deep	O
27	fissurations	O
28	and	O
29	sub	O
30	-	O
31	intimal	O
32	haemorrhages	O
33	demonstrate	O
34	,	O
35	in	O
36	live	O
37	colour	O
38	,	O
39	the	O
40	pathophysiological	O
41	mechanisms	O
42	of	O
43	coronary	O
44	artery	O
45	stenosis	O
46	.	O

1	The	O
2	enhanced	O
3	cysteine	O
4	formation	O
5	in	O
6	a	O
7	pCSK4F	O
8	plant	O
9	responding	O
10	to	O
11	sulfite	O
12	was	O
13	also	O
14	observed	O
15	in	O
16	leaf	O
17	discs	O
18	.	O

1	Each	O
2	type	O
3	was	O
4	divided	O
5	into	O
6	two	O
7	subgroups	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	whether	O
13	the	O
14	body	O
15	and	O
16	tail	O
17	of	O
18	the	O
19	pancreas	O
20	showed	O
21	intense	O
22	fatty	O
23	replacement	O
24	(	O
25	type	O
26	a	O
27	=	O
28	negative	O
29	for	O
30	intense	O
31	fatty	O
32	replacement	O
33	,	O
34	type	O
35	b	O
36	=	O
37	positive	O
38	for	O
39	intense	O
40	fatty	O
41	replacement	O
42	).	O

1	Between	O
2	the	O
3	subgroups	O
4	of	O
5	dementia	O
6	disorders	O
7	there	O
8	were	O
9	no	O
10	significant	O
11	differences	O
12	in	O
13	basal	O
14	cortisol	O
15	levels	O
16	.	O

1	A	O
2	new	O
3	hypothesis	O
4	on	O
5	mechanisms	O
6	for	O
7	inhibiting	O
8	catalytic	O
9	subunits	O
10	by	O
11	gamma	O
12	-	O
13	subunits	O
14	and	O
15	activation	O
16	of	O
17	a	O
18	holoenzyme	O
19	by	O
20	transducin	B

1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	B
9	polymerase	I
10	II	I
11	,	O
12	TATA	B
13	-	I
14	binding	I
15	protein	I
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	O
28	(	O
29	CTD	O
30	)	O
31	of	O
32	RNA	B
33	polymerase	I
34	II	I
35	a	O
36	"	O
37	portable	O
38	enhancer	O
39	domain	O
40	"?	O
41	Regions	O
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	B
70	TATA	I
71	-	I
72	binding	I
73	proteins	I
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O

1	Mutagenesis	O
2	of	O
3	IM1	B
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	I
10	Fos	I
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	I
16	promoter	I
17	.	O

1	Binding	O
2	of	O
3	SSP	B
4	to	O
5	the	O
6	stage	B
7	selector	I
8	element	I
9	(	O
10	SSE	B
11	)	O
12	in	O
13	the	O
14	proximal	O
15	gamma	B
16	-	I
17	globin	I
18	promoter	I
19	is	O
20	integral	O
21	to	O
22	the	O
23	competitive	O
24	silencing	O
25	of	O
26	a	O
27	linked	O
28	beta	B
29	-	I
30	promoter	I
31	in	O
32	embryonic	O
33	/	O
34	fetal	O
35	stage	O
36	erythroleukemia	O
37	(	O
38	K562	O
39	)	O
40	cells	O
41	.	O

1	This	O
2	failure	O
3	to	O
4	execute	O
5	regulated	O
6	G1	O
7	/	O
8	S	O
9	arrest	O
10	is	O
11	correlated	O
12	with	O
13	enhanced	O
14	thermosensitivity	O
15	of	O
16	colony	O
17	-	O
18	forming	O
19	ability	O
20	.	O

1	Mutations	O
2	that	O
3	alter	O
4	photoreceptor	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	telomeres	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	O
12	.	O

1	Integrated	O
2	mapping	O
3	analysis	O
4	of	O
5	the	O
6	Werner	O
7	syndrome	O
8	region	O
9	of	O
10	chromosome	O
11	8	O
12	.	O

1	The	O
2	region	O
3	between	O
4	DXS52	B
5	and	O
6	Factor	B
7	VIII	I
8	gene	I
9	in	O
10	the	O
11	human	O
12	Xq28	O
13	chromosomal	O
14	band	O
15	contains	O
16	a	O
17	G	O
18	+	O
19	C	O
20	-	O
21	rich	O
22	isochore	O
23	to	O
24	which	O
25	many	O
26	genes	O
27	have	O
28	been	O
29	mapped	O
30	.	O

1	Haplotype	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	Nramp	B
10	gene	I
11	predict	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	parasites	O
18	.	O

1	This	O
2	utilization	O
3	of	O
4	an	O
5	intronic	O
6	polyadenylation	O
7	site	O
8	without	O
9	alternative	O
10	exon	O
11	usage	O
12	is	O
13	comparable	O
14	to	O
15	the	O
16	mechanism	O
17	whereby	O
18	both	O
19	secreted	O
20	and	O
21	membrane	O
22	-	O
23	bound	O
24	forms	O
25	of	O
26	the	O
27	immunoglobulin	B
28	mu	I
29	heavy	I
30	chain	I
31	are	O
32	made	O
33	from	O
34	a	O
35	single	O
36	genetic	O
37	locus	O
38	.	O

1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	hapten	O
15	-	O
16	syngeneic	O
17	or	O
18	allogeneic	O
19	protein	O
20	conjugates	O
21	(	O
22	corrosion	O
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	humoral	O
48	immunity	O
49	)	O
50	to	O
51	metals	O
52	was	O
53	developed	O
54	.	O

1	In	O
2	contrast	O
3	,	O
4	peak	O
5	filling	O
6	rate	O
7	(	O
8	PFR	O
9	),	O
10	normalized	O
11	to	O
12	end	O
13	diastolic	O
14	volume	O
15	(	O
16	EDV	O
17	),	O
18	or	O
19	stroke	O
20	volume	O
21	(	O
22	SV	O
23	),	O
24	or	O
25	expressed	O
26	as	O
27	the	O
28	ratio	O
29	of	O
30	PFR	O
31	-	O
32	to	O
33	-	O
34	PER	O
35	was	O
36	reduced	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	01	O
43	),	O
44	time	O
45	to	O
46	PFR	O
47	(	O
48	TPFR	O
49	)	O
50	was	O
51	prolonged	O
52	(	O
53	p	O
54	<	O
55	0	O
56	.	O
57	01	O
58	),	O
59	and	O
60	echocardiographic	O
61	left	O
62	ventricular	O
63	mass	O
64	index	O
65	was	O
66	higher	O
67	(	O
68	p	O
69	<	O
70	0	O
71	.	O
72	001	O
73	)	O
74	in	O
75	patients	O
76	with	O
77	acromegaly	O
78	compared	O
79	to	O
80	normals	O
81	.	O

1	A	O
2	genetic	O
3	complementation	O
4	system	O
5	was	O
6	developed	O
7	in	O
8	which	O
9	tobacco	B
10	etch	I
11	virus	I
12	(	I
13	TEV	I
14	)	I
15	polymerase	I
16	(	O
17	NIb	B
18	)-	O
19	expressing	O
20	transgenic	O
21	plants	O
22	or	O
23	protoplasts	O
24	were	O
25	inoculated	O
26	with	O
27	NIb	B
28	-	O
29	defective	O
30	TEV	B
31	mutants	I
32	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	DNA	B
9	polymerase	I
10	gene	I
11	of	I
12	Bombyx	I
13	mori	I
14	nuclear	I
15	polyhedrosis	I
16	virus	I
17	.	O

1	Comparison	O
2	of	O
3	the	O
4	genomes	O
5	of	O
6	PMTV	O
7	,	O
8	BNYVV	O
9	,	O
10	and	O
11	SBWMV	O
12	shows	O
13	that	O
14	furoviruses	O
15	exhibit	O
16	considerable	O
17	heterogeneity	O
18	in	O
19	genome	O
20	organization	O
21	.	O

1	The	O
2	drug	O
3	sensitivity	O
4	was	O
5	100	O
6	%	O
7	for	O
8	vancomycin	O
9	(	O
10	VCM	O
11	),	O
12	30	O
13	%	O
14	for	O
15	imipenam	O
16	(	O
17	IMP	O
18	),	O
19	31	O
20	%	O
21	for	O
22	minomycin	O
23	(	O
24	MINO	O
25	),	O
26	31	O
27	%	O
28	for	O
29	amikacin	O
30	(	O
31	AMK	O
32	),	O
33	and	O
34	7	O
35	%	O
36	for	O
37	fosfomycin	O
38	(	O
39	FOM	O
40	).	O

1	Deglycosylation	O
2	with	O
3	endoglycosidase	B
4	H	I
5	showed	O
6	that	O
7	the	O
8	mutant	O
9	receptors	O
10	had	O
11	mainly	O
12	high	O
13	-	O
14	mannose	O
15	oligosaccharide	O
16	chains	O
17	.	O

1	Dietary	O
2	supplement	O
3	with	O
4	fish	O
5	oil	O
6	and	O
7	related	O
8	n	O
9	-	O
10	3	O
11	EFAs	O
12	has	O
13	been	O
14	used	O
15	to	O
16	study	O
17	their	O
18	antihypertensive	O
19	property	O
20	in	O
21	animals	O
22	and	O
23	humans	O
24	with	O
25	borderline	O
26	and	O
27	essential	O
28	hypertension	O
29	.	O

1	The	O
2	HSD3B1	B
3	and	O
4	HSD3B2	B
5	genes	I
6	encoding	O
7	the	O
8	types	B
9	I	I
10	and	I
11	II	I
12	3	I
13	beta	I
14	-	I
15	HSD	I
16	isoenzymes	I
17	,	O
18	respectively	O
19	,	O
20	have	O
21	been	O
22	previously	O
23	assigned	O
24	by	O
25	in	O
26	situ	O
27	hybridization	O
28	to	O
29	the	O
30	chromosome	O
31	1p13	O
32	.	O
33	1	O
34	region	O
35	.	O

1	Therefore	O
2	the	O
3	prevalences	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	GDM	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O

1	Insulin	B
2	-	O
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	O
12	insulin	B
13	receptor	I
14	.	O

1	After	O
2	selection	O
3	and	O
4	conversion	O
5	to	O
6	adipocytes	O
7	,	O
8	the	O
9	level	O
10	of	O
11	EGFR	B
12	expression	O
13	was	O
14	retained	O
15	in	O
16	infectant	O
17	adipocytes	O
18	(	O
19	150	O
20	,	O
21	000	O
22	and	O
23	250	O
24	,	O
25	000	O
26	/	O
27	cell	O
28	,	O
29	respectively	O
30	),	O
31	but	O
32	not	O
33	in	O
34	the	O
35	parental	O
36	3T3	O
37	-	O
38	L1	O
39	adipocytes	O
40	(<	O
41	5000	O
42	/	O
43	cell	O
44	).	O

1	Intron	O
2	-	O
3	exon	O
4	structure	O
5	of	O
6	the	O
7	porcine	B
8	I	I
9	kappa	I
10	B	I
11	alpha	I
12	-	I
13	encoding	I
14	gene	I
15	.	O

1	Fraction	O
2	2	O
3	contains	O
4	1	O
5	,	O
6	25	O
7	(	O
8	OH	O
9	)	O
10	2	O
11	-	O
12	vitamin	O
13	D3	O
14	,	O
15	vitamin	O
16	D3	O
17	,	O
18	25	O
19	(	O
20	OH	O
21	)-	O
22	vitamin	O
23	D3	O
24	and	O
25	1	O
26	,	O
27	24	O
28	,	O
29	25	O
30	(	O
31	OH	O
32	)	O
33	3	O
34	-	O
35	vitamin	O
36	D3	O
37	.	O

1	The	O
2	kallistatin	B
3	gene	I
4	was	O
5	localized	O
6	by	O
7	in	O
8	situ	O
9	hybridization	O
10	to	O
11	human	O
12	chromosome	O
13	14q31	O
14	-	O
15	q32	O
16	.	O
17	1	O
18	,	O
19	close	O
20	to	O
21	the	O
22	serpin	B
23	genes	I
24	encoding	O
25	alpha	B
26	1	I
27	-	I
28	antichymotrypsin	I
29	,	O
30	protein	B
31	C	I
32	inhibitor	I
33	,	O
34	alpha	B
35	1	I
36	-	I
37	antitrypsin	I
38	,	O
39	and	O
40	corticosteroid	B
41	-	I
42	binding	I
43	globulin	I
44	.	O

1	The	O
2	locus	O
3	encoding	O
4	the	O
5	XD	B
6	gene	I
7	(	O
8	designated	O
9	Xd	B
10	)	O
11	was	O
12	mapped	O
13	to	O
14	the	O
15	distal	O
16	part	O
17	of	O
18	mouse	O
19	chromosome	O
20	17	O
21	by	O
22	haplotype	O
23	analysis	O
24	of	O
25	114	O
26	interspecific	O
27	backcross	O
28	mice	O
29	.	O

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	B
8	-	I
9	endorphin	I
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	B
28	-	I
29	endorphin	I
30	.	O

1	An	O
2	interatrial	O
3	communication	O
4	mitigates	O
5	the	O
6	impairment	O
7	of	O
8	LV	O
9	function	O
10	after	O
11	an	O
12	acute	O
13	and	O
14	sustained	O
15	drop	O
16	of	O
17	intrathoracic	O
18	pressure	O
19	.	O

1	Self	O
2	or	O
3	foreign	O
4	cellular	O
5	proteins	O
6	provide	O
7	peptides	O
8	for	O
9	presentation	O
10	by	O
11	major	B
12	histocompatibility	I
13	complex	I
14	(	I
15	MHC	I
16	)	I
17	class	I
18	I	I
19	molecules	I
20	on	O
21	the	O
22	surface	O
23	of	O
24	antigen	O
25	presenting	O
26	cells	O
27	(	O
28	APC	O
29	).	O

1	The	O
2	characteristics	O
3	of	O
4	the	O
5	VirD1	B
6	/	O
7	VirD2	B
8	-	O
9	mediated	O
10	cleavage	O
11	reaction	O
12	strongly	O
13	resemble	O
14	those	O
15	observed	O
16	with	O
17	relaxosomes	O
18	of	O
19	IncP	O
20	plasmids	O
21	involved	O
22	in	O
23	initiation	O
24	of	O
25	transfer	O
26	DNA	O
27	replication	O
28	during	O
29	bacterial	O
30	conjugation	O
31	.	O

1	Isoelectric	O
2	focusing	O
3	of	O
4	tryptic	O
5	peptides	O
6	generated	O
7	from	O
8	MHC	B
9	-	I
10	B	I
11	phosphorylated	O
12	with	O
13	cdc2	B
14	kinase	I
15	revealed	O
16	one	O
17	major	O
18	phosphopeptide	O
19	that	O
20	was	O
21	purified	O
22	by	O
23	reverse	O
24	-	O
25	phase	O
26	high	O
27	performance	O
28	liquid	O
29	chromatography	O
30	and	O
31	sequenced	O
32	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	was	O
6	88	O
7	%	O
8	homologous	O
9	to	O
10	that	O
11	of	O
12	hNUC	B
13	I	I
14	,	O
15	isolated	O
16	from	O
17	human	O
18	osteosarcoma	O
19	cells	O
20	.	O

1	However	O
2	,	O
3	cotransfection	O
4	studies	O
5	indicate	O
6	that	O
7	RVR	B
8	does	O
9	not	O
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	O
16	element	O
17	is	O
18	linked	O
19	to	O
20	a	O
21	reporter	O
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	B
33	alpha	I
34	function	O
35	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	O
6	glycosylasparaginase	B
7	with	O
8	a	O
9	mammalian	O
10	glycosylasparaginase	B
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	Dissociation	O
2	and	O
3	complexation	O
4	of	O
5	the	O
6	fluoroquinolone	O
7	antimicrobials	O
8	--	O
9	an	O
10	update	O
11	.	O

1	Superoxide	B
2	dismutase	I
3	(	O
4	SOD	B
5	)	O
6	activity	O
7	decreased	O
8	significantly	O
9	in	O
10	sperm	O
11	subjected	O
12	to	O
13	direct	O
14	electric	O
15	current	O
16	in	O
17	comparison	O
18	to	O
19	the	O
20	control	O
21	or	O
22	the	O
23	sample	O
24	incubated	O
25	with	O
26	electrolyzed	O
27	medium	O
28	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	electrical	O
11	stimulation	O
12	generate	O
13	reactive	O
14	oxygen	O
15	species	O
16	and	O
17	affect	O
18	SOD	B
19	activity	O
20	,	O
21	which	O
22	in	O
23	part	O
24	are	O
25	responsible	O
26	for	O
27	decreased	O
28	sperm	O
29	motion	O
30	and	O
31	viability	O
32	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	B
10	beta	I
11	revealed	O
12	that	O
13	SR	B
14	beta	I
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	O
20	,	O
21	like	O
22	SR	B
23	alpha	I
24	and	O
25	SRP54	B
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	B
33	superfamily	I
34	.	O

1	To	O
2	understand	O
3	the	O
4	function	O
5	of	O
6	receptor	B
7	-	I
8	linked	I
9	tyrosine	I
10	phosphatases	I
11	in	O
12	neural	O
13	development	O
14	,	O
15	we	O
16	sought	O
17	to	O
18	identify	O
19	LAR	B
20	isoforms	I
21	preferentially	O
22	expressed	O
23	in	O
24	the	O
25	nervous	O
26	system	O
27	and	O
28	cellular	O
29	processes	O
30	regulating	O
31	LAR	B
32	alternative	O
33	splicing	O
34	.	O

1	Sex	O
2	selection	O
3	via	O
4	albumin	B
5	columns	O
6	:	O
7	20	O
8	years	O
9	of	O
10	results	O
11	.	O

1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O

1	They	O
2	also	O
3	reported	O
4	that	O
5	E	B
6	mu	I
7	pim	I
8	-	I
9	1	I
10	transgenic	O
11	mice	O
12	show	O
13	greatly	O
14	accelerated	O
15	lymphoma	O
16	development	O
17	when	O
18	infected	O
19	with	O
20	wild	O
21	-	O
22	type	O
23	M	O
24	-	O
25	MuLV	O
26	at	O
27	birth	O
28	.	O

1	Comparison	O
2	of	O
3	human	B
4	and	I
5	murine	I
6	blk	I
7	sequences	I
8	indicated	O
9	that	O
10	they	O
11	share	O
12	86	O
13	%	O
14	amino	O
15	acid	O
16	identity	O
17	,	O
18	the	O
19	most	O
20	conserved	O
21	region	O
22	being	O
23	the	O
24	catalytic	O
25	domain	O
26	(	O
27	93	O
28	%	O
29	identity	O
30	).	O

1	Chrispeels	O
2	[	O
3	1993	O
4	]	O
5	EMBO	O
6	J	O
7	12	O
8	:	O
9	2241	O
10	-	O
11	2247	O
12	).	O

1	The	O
2	mRNAs	O
3	of	O
4	the	O
5	GRF	B
6	genes	I
7	are	O
8	encoded	O
9	by	O
10	six	O
11	exons	O
12	interrupted	O
13	by	O
14	five	O
15	introns	O
16	.	O

1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	sensorimotor	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	examining	O
13	the	O
14	acoustic	O
15	startle	O
16	response	O
17	.	O

1	Digitalis	O
2	glycosides	O
3	or	O
4	beta	B
5	-	I
6	receptor	I
7	antagonists	O
8	are	O
9	not	O
10	helpful	O
11	in	O
12	the	O
13	therapy	O
14	of	O
15	this	O
16	form	O
17	of	O
18	atrial	O
19	fibrillation	O
20	whereas	O
21	class	O
22	I	O
23	antiarrhythmic	O
24	drugs	O
25	have	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	more	O
31	effective	O
32	.	O

1	Atrial	O
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O

1	VIII	O
2	in	O
3	doses	O
4	2	O
5	-	O
6	3	O
7	times	O
8	higher	O
9	than	O
10	usually	O
11	used	O
12	in	O
13	haemophiliacs	O
14	without	O
15	inhibitor	O
16	were	O
17	successful	O
18	.	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	Thus	O
2	,	O
3	these	O
4	studies	O
5	indicate	O
6	that	O
7	the	O
8	104	O
9	-	O
10	kDa	O
11	isoform	O
12	is	O
13	required	O
14	for	O
15	normal	O
16	proliferation	O
17	of	O
18	female	O
19	germline	O
20	cells	O
21	and	O
22	perhaps	O
23	for	O
24	oocyte	O
25	differentiation	O
26	.	O

1	Physical	O
2	analysis	O
3	maps	O
4	SAL6	B
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	B
10	and	O
11	spt14	B
12	.	O

1	The	O
2	newly	O
3	devised	O
4	DCT	O
5	method	O
6	yields	O
7	reliable	O
8	data	O
9	in	O
10	measuring	O
11	TBF	O
12	.	O

1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O

1	Rho	B
2	GDP	I
3	/	I
4	GTP	I
5	exchange	I
6	inhibitor	I
7	,	O
8	Rho	B
9	GDI	I
10	,	O
11	comigrated	O
12	with	O
13	Rac2	B
14	and	O
15	RhoA	B
16	,	O
17	but	O
18	not	O
19	Rac1	B
20	.	O

1	A	O
2	major	O
3	task	O
4	for	O
5	sports	O
6	scientists	O
7	may	O
8	be	O
9	to	O
10	verify	O
11	empirically	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	O
19	the	O
20	sport	O
21	performer	O
22	.	O

1	Schnell	O
2	,	O
3	J	O
4	.	O

1	Encapsidation	O
2	of	O
3	poliovirus	O
4	replicons	O
5	encoding	O
6	the	O
7	complete	O
8	human	B
9	immunodeficiency	I
10	virus	I
11	type	I
12	1	I
13	gag	I
14	gene	I
15	by	O
16	using	O
17	a	O
18	complementation	O
19	system	O
20	which	O
21	provides	O
22	the	O
23	P1	B
24	capsid	I
25	protein	I
26	in	O
27	trans	O
28	.	O

1	Removal	O
2	of	O
3	the	O
4	GST	B
5	domain	I
6	from	O
7	GST	B
8	-	O
9	Tax	B
10	by	O
11	thrombin	B
12	restores	O
13	Tax	B
14	'	O
15	s	O
16	ability	O
17	to	O
18	assemble	O
19	a	O
20	ternary	O
21	Tax	B
22	-	O
23	CREB	B
24	-	O
25	21	O
26	-	O
27	bp	O
28	-	O
29	repeat	O
30	complex	O
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	400	O
36	WORDS	O
37	)	O

1	The	O
2	requirement	O
3	of	O
4	PilE	B
5	in	O
6	pilus	O
7	biogenesis	O
8	was	O
9	confirmed	O
10	by	O
11	demonstrating	O
12	that	O
13	chromosomal	B
14	pilE	I
15	insertion	I
16	mutants	I
17	were	O
18	pilus	O
19	-	O
20	and	O
21	twitching	O
22	-	O
23	motility	O
24	deficient	O
25	.	O

1	The	O
2	pilE	B
3	gene	I
4	product	I
5	of	I
6	Pseudomonas	I
7	aeruginosa	I
8	,	O
9	required	O
10	for	O
11	pilus	O
12	biogenesis	O
13	,	O
14	shares	O
15	amino	O
16	acid	O
17	sequence	O
18	identity	O
19	with	O
20	the	O
21	N	O
22	-	O
23	termini	O
24	of	O
25	type	B
26	4	I
27	prepilin	I
28	proteins	I
29	.	O

1	Because	O
2	of	O
3	the	O
4	functional	O
5	conservation	O
6	of	O
7	cell	O
8	cycle	O
9	control	O
10	elements	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	a	O
16	vertebrate	B
17	wee1	I
18	or	O
19	mik1	B
20	homolog	I
21	would	O
22	be	O
23	expected	O
24	to	O
25	rescue	O
26	such	O
27	lethal	O
28	mutations	O
29	in	O
30	yeast	O
31	.	O

1	The	O
2	expression	O
3	of	O
4	this	O
5	clone	O
6	in	O
7	a	O
8	wee1	B
9	/	O
10	mik1	B
11	-	O
12	deficient	O
13	mutant	O
14	causes	O
15	an	O
16	elongated	O
17	cell	O
18	phenotype	O
19	under	O
20	non	O
21	-	O
22	permissive	O
23	growth	O
24	conditions	O
25	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	B
8	protein	I
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O

1	Near	O
2	a	O
3	third	O
4	(	O
5	31	O
6	.	O
7	6	O
8	%)	O
9	of	O
10	Insulin	B
11	Dependent	O
12	and	O
13	a	O
14	third	O
15	(	O
16	33	O
17	.	O
18	41	O
19	%)	O
20	for	O
21	Non	O
22	Insulin	B
23	Dependent	O
24	were	O
25	of	O
26	D	O
27	,	O
28	F	O
29	,	O
30	H	O
31	White	O
32	'	O
33	s	O
34	Class	O
35	.	O

1	The	O
2	activity	O
3	of	O
4	6	O
5	-	O
6	fluoroquinolones	O
7	and	O
8	their	O
9	nonfluorinated	O
10	derivatives	O
11	is	O
12	compared	O
13	in	O
14	general	O
15	.	O

1	As	O
2	the	O
3	half	O
4	-	O
5	life	O
6	of	O
7	the	O
8	compound	O
9	did	O
10	never	O
11	exceed	O
12	8	O
13	-	O
14	9	O
15	h	O
16	,	O
17	the	O
18	data	O
19	do	O
20	not	O
21	support	O
22	any	O
23	change	O
24	of	O
25	pidotimod	O
26	administration	O
27	schedule	O
28	(	O
29	every	O
30	24	O
31	-	O
32	12	O
33	h	O
34	).	O

1	The	O
2	MAP	B
3	kinase	I
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O

1	A	O
2	comparative	O
3	study	O
4	by	O
5	holographic	O
6	interferometry	O
7	of	O
8	ten	O
9	porcine	O
10	bioprosthetic	O
11	valves	O
12	(	O
13	seven	O
14	Carpentier	O
15	-	O
16	Edwards	O
17	SAV	O
18	,	O
19	two	O
20	BioImplant	O
21	and	O
22	one	O
23	Valcor	O
24	)	O
25	with	O
26	five	O
27	human	O
28	aortic	O
29	valves	O
30	before	O
31	and	O
32	after	O
33	glutaraldehyde	O
34	treatment	O
35	is	O
36	presented	O
37	.	O

1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O

1	This	O
2	region	O
3	constitutes	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	domain	O
9	with	O
10	basic	O
11	-	O
12	helix	O
13	-	O
14	loop	O
15	-	O
16	helix	O
17	and	O
18	leucine	O
19	-	O
20	zipper	O
21	motifs	O
22	,	O
23	features	O
24	common	O
25	to	O
26	the	O
27	myc	B
28	-	I
29	related	I
30	transcription	I
31	factor	I
32	family	I
33	.	O

1	Specific	O
2	binding	O
3	was	O
4	not	O
5	observed	O
6	with	O
7	either	O
8	the	O
9	orthologous	O
10	rat	O
11	or	O
12	mouse	O
13	fragments	O
14	using	O
15	human	O
16	or	O
17	rodent	O
18	extracts	O
19	.	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	O
6	Cdk	B
7	complexes	O
8	in	O
9	Rb	B
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	B
19	/	O
20	MTS1	B
21	tumour	O
22	suppressor	O
23	gene	O
24	product	O
25	.	O

1	Recombinant	B
2	human	I
3	serum	I
4	albumin	I
5	(	O
6	rHSA	B
7	)	O
8	produced	O
9	by	O
10	cultured	O
11	fermentation	O
12	has	O
13	been	O
14	prepared	O
15	in	O
16	the	O
17	form	O
18	of	O
19	microcapsules	O
20	nominally	O
21	3	O
22	-	O
23	5	O
24	microns	O
25	in	O
26	diameter	O
27	and	O
28	radiolabelled	O
29	with	O
30	technetium	O
31	-	O
32	99m	O
33	following	O
34	reduction	O
35	with	O
36	stannous	O
37	chloride	O
38	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	release	O
6	of	O
7	interleukin	B
8	-	I
9	1	I
10	beta	I
11	(	O
12	IL	B
13	-	I
14	1	I
15	)	O
16	and	O
17	tumour	B
18	necrosis	I
19	factor	I
20	-	I
21	alpha	I
22	(	O
23	TNF	B
24	)	O
25	by	O
26	unstimulated	O
27	monocytes	O
28	and	O
29	monocytes	O
30	stimulated	O
31	with	O
32	lipopolysaccharide	O
33	(	O
34	LPS	O
35	)	O
36	isolated	O
37	from	O
38	the	O
39	peripheral	O
40	blood	O
41	of	O
42	two	O
43	patients	O
44	with	O
45	acute	O
46	poststreptococcal	O
47	glomerulonephritis	O
48	(	O
49	AGN	O
50	)	O
51	and	O
52	16	O
53	healthy	O
54	controls	O
55	.	O

1	Such	O
2	an	O
3	intervention	O
4	may	O
5	be	O
6	of	O
7	considerable	O
8	use	O
9	for	O
10	the	O
11	treatment	O
12	of	O
13	angiogenesis	O
14	-	O
15	dependent	O
16	diseases	O
17	involving	O
18	FGF	B
19	-	I
20	2	I
21	.	O

1	We	O
2	have	O
3	attempted	O
4	to	O
5	clone	O
6	two	O
7	recessive	O
8	extragenic	O
9	suppressors	O
10	of	O
11	such	O
12	ts	O
13	mutants	O
14	(	O
15	sdp1	B
16	for	O
17	mutation	B
18	pol3	I
19	-	I
20	14	I
21	and	O
22	sdp5	B
23	-	I
24	1	I
25	for	O
26	mutation	B
27	pol3	I
28	-	I
29	11	I
30	)	O
31	by	O
32	transforming	O
33	thermoresistant	O
34	haploid	O
35	strains	O
36	pol3	B
37	-	I
38	14	I
39	sdp1	I
40	and	O
41	pol3	B
42	-	I
43	11	I
44	sdp5	I
45	-	I
46	1	I
47	with	O
48	wild	O
49	-	O
50	type	O
51	genomic	O
52	libraries	O
53	in	O
54	singlecopy	O
55	or	O
56	multicopy	O
57	vectors	O
58	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	TEP	B
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O

1	In	O
2	acute	O
3	-	O
4	phase	O
5	livers	O
6	,	O
7	we	O
8	observed	O
9	a	O
10	dramatic	O
11	reduction	O
12	in	O
13	HNF	B
14	-	I
15	3	I
16	alpha	I
17	expression	O
18	which	O
19	correlates	O
20	with	O
21	a	O
22	decrease	O
23	in	O
24	the	O
25	expression	O
26	of	O
27	its	O
28	target	O
29	gene	O
30	,	O
31	the	O
32	TTR	B
33	gene	I
34	.	O

1	Alternatively	O
2	,	O
3	loss	O
4	-	O
5	of	O
6	-	O
7	function	O
8	alleles	O
9	of	O
10	genes	O
11	that	O
12	inhibit	O
13	cAPK	B
14	lead	O
15	to	O
16	the	O
17	inability	O
18	to	O
19	undergo	O
20	sexual	O
21	differentiation	O
22	.	O

1	One	O
2	member	O
3	of	O
4	this	O
5	family	O
6	,	O
7	RFX1	B
8	,	O
9	is	O
10	a	O
11	transcription	O
12	factor	O
13	for	O
14	a	O
15	variety	O
16	of	O
17	viral	O
18	and	O
19	cellular	O
20	genes	O
21	.	O

1	This	O
2	mutant	O
3	was	O
4	identified	O
5	by	O
6	screening	O
7	with	O
8	a	O
9	TGF	B
10	-	I
11	beta	I
12	-	O
13	inducible	O
14	vector	O
15	a	O
16	series	O
17	of	O
18	mink	O
19	lung	O
20	epithelial	O
21	cell	O
22	clones	O
23	that	O
24	have	O
25	normal	O
26	TGF	B
27	-	I
28	beta	I
29	binding	O
30	activity	O
31	but	O
32	have	O
33	lost	O
34	antiproliferative	O
35	and	O
36	transcriptional	O
37	responses	O
38	to	O
39	TGF	B
40	-	I
41	beta	I
42	.	O

1	Cloning	O
2	by	O
3	complementation	O
4	and	O
5	subsequent	O
6	physical	O
7	and	O
8	genetic	O
9	analysis	O
10	revealed	O
11	that	O
12	it	O
13	maps	O
14	to	O
15	RAF1	B
16	.	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	inositol	O
6	and	O
7	choline	O
8	(	O
9	repressing	O
10	),	O
11	the	O
12	product	O
13	of	O
14	the	O
15	OPI1	B
16	gene	I
17	represses	O
18	transcription	O
19	dictated	O
20	by	O
21	the	O
22	UASINO	O
23	element	O
24	.	O

1	By	O
2	treating	O
3	monkey	O
4	COS	O
5	cells	O
6	with	O
7	oligonucleotides	O
8	linked	O
9	to	O
10	psoralen	O
11	,	O
12	we	O
13	have	O
14	generated	O
15	targeted	O
16	mutations	O
17	in	O
18	a	O
19	simian	O
20	virus	O
21	40	O
22	(	O
23	SV40	O
24	)	O
25	vector	O
26	contained	O
27	within	O
28	the	O
29	cells	O
30	via	O
31	intracellular	O
32	triple	O
33	helix	O
34	formation	O
35	.	O

1	The	O
2	interleukin	B
3	2	I
4	receptor	I
5	alpha	I
6	-	I
7	chain	I
8	(	O
9	IL	B
10	-	I
11	2R	I
12	alpha	I
13	)	O
14	gene	O
15	is	O
16	rapidly	O
17	and	O
18	potently	O
19	induced	O
20	in	O
21	T	O
22	cells	O
23	in	O
24	response	O
25	to	O
26	mitogenic	O
27	stimuli	O
28	.	O

1	The	O
2	Wilms	B
3	'	I
4	tumour	I
5	suppressor	I
6	protein	I
7	(	O
8	WT1	B
9	)	O
10	is	O
11	a	O
12	putative	O
13	transcriptional	O
14	regulatory	O
15	protein	O
16	with	O
17	four	O
18	zinc	O
19	fingers	O
20	,	O
21	the	O
22	last	O
23	three	O
24	of	O
25	which	O
26	have	O
27	extensive	O
28	sequence	O
29	homology	O
30	to	O
31	the	O
32	early	B
33	growth	I
34	response	I
35	-	I
36	1	I
37	(	O
38	EGR	B
39	-	I
40	1	I
41	)	O
42	protein	O
43	.	O

1	OBJECTIVES	O
2	:	O
3	1	O
4	)	O
5	to	O
6	determine	O
7	serum	B
8	ACE	I
9	activity	O
10	in	O
11	patients	O
12	with	O
13	COPD	O
14	treated	O
15	with	O
16	and	O
17	without	O
18	continuous	O
19	ambulatory	O
20	oxygen	O
21	therapy	O
22	(	O
23	CAOT	O
24	);	O
25	2	O
26	)	O
27	to	O
28	verify	O
29	whether	O
30	there	O
31	is	O
32	a	O
33	correlation	O
34	between	O
35	ACE	B
36	and	O
37	any	O
38	hematological	O
39	,	O
40	spirometric	O
41	or	O
42	gasometric	O
43	parameter	O
44	.	O

1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O

1	Among	O
2	9	O
3	group	O
4	I	O
5	patients	O
6	with	O
7	a	O
8	positive	O
9	result	O
10	on	O
11	head	O
12	-	O
13	up	O
14	tilt	O
15	-	O
16	table	O
17	testing	O
18	and	O
19	no	O
20	evidence	O
21	of	O
22	structural	O
23	heart	O
24	disease	O
25	(	O
26	mean	O
27	follow	O
28	-	O
29	up	O
30	4	O
31	.	O
32	3	O
33	years	O
34	),	O
35	7	O
36	are	O
37	without	O
38	further	O
39	episodes	O
40	of	O
41	syncope	O
42	;	O
43	3	O
44	have	O
45	discontinued	O
46	medication	O
47	and	O
48	5	O
49	have	O
50	resumed	O
51	at	O
52	least	O
53	limited	O
54	exercise	O
55	.	O

1	Constructs	O
2	designed	O
3	and	O
4	expressed	O
5	were	O
6	E2L1	O
7	(	O
8	1	O
9	-	O
10	98	O
11	),	O
12	E2L1	O
13	.	O
14	H1	O
15	(	O
16	1	O
17	-	O
18	128	O
19	),	O
20	E2L2	O
21	(	O
22	120	O
23	-	O
24	233	O
25	),	O
26	E2H1	O
27	.	O
28	L2	O
29	(	O
30	98	O
31	-	O
32	233	O
33	),	O
34	and	O
35	E2L1	O
36	.	O
37	H1	O
38	.	O
39	L2	O
40	(	O
41	1	O
42	-	O
43	233	O
44	),	O
45	where	O
46	numbers	O
47	in	O
48	parentheses	O
49	give	O
50	the	O
51	amino	O
52	acid	O
53	sequence	O
54	for	O
55	the	O
56	portions	O
57	of	O
58	the	O
59	E2	B
60	component	O
61	incorporated	O
62	into	O
63	a	O
64	construct	O
65	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	produced	O
6	lipoyl	O
7	domain	O
8	constructs	O
9	that	O
10	can	O
11	be	O
12	employed	O
13	in	O
14	sorting	O
15	the	O
16	specific	O
17	roles	O
18	of	O
19	E2L1	B
20	and	O
21	E2L2	B
22	in	O
23	facilitating	O
24	catalytic	O
25	and	O
26	regulatory	O
27	processes	O
28	.	O

1	METHODS	O
2	:	O
3	Ten	O
4	influenza	O
5	A	O
6	(	O
7	H3N2	O
8	)	O
9	viruses	O
10	isolated	O
11	during	O
12	the	O
13	outbreaks	O
14	were	O
15	examined	O
16	for	O
17	resistance	O
18	to	O
19	amantadine	O
20	and	O
21	rimantadine	O
22	by	O
23	means	O
24	of	O
25	an	O
26	enzyme	O
27	immunoassay	O
28	and	O
29	by	O
30	sequencing	O
31	of	O
32	the	O
33	viral	O
34	nucleic	O
35	acid	O
36	that	O
37	encodes	O
38	the	O
39	transmembrane	O
40	domain	O
41	of	O
42	the	O
43	M2	B
44	protein	I
45	.	O

1	The	O
2	first	O
3	contains	O
4	ATF	B
5	/	O
6	CRE	O
7	and	O
8	TBP	B
9	/	O
10	TATA	O
11	sequence	O
12	motifs	O
13	within	O
14	an	O
15	87	O
16	-	O
17	bp	O
18	region	O
19	.	O

1	Gene	O
2	expression	O
3	occurs	O
4	in	O
5	a	O
6	circadian	O
7	rhythm	O
8	and	O
9	induced	O
10	by	O
11	light	O
12	in	O
13	leaves	O
14	of	O
15	dark	O
16	-	O
17	adapted	O
18	plants	O
19	.	O

1	Our	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	hexamer	O
7	and	O
8	the	O
9	octamer	O
10	motifs	O
11	may	O
12	play	O
13	important	O
14	role	O
15	(	O
16	s	O
17	)	O
18	in	O
19	regulation	O
20	of	O
21	replication	O
22	-	O
23	dependent	O
24	but	O
25	not	O
26	of	O
27	replication	O
28	-	O
29	independent	O
30	expression	O
31	of	O
32	the	O
33	wheat	B
34	histone	I
35	H3	I
36	gene	I
37	.	O

1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	I
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	B
16	/	O
17	E2F	B
18	heterodimers	O
19	that	O
20	constitute	O
21	DRTF1	B
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O

1	Similarly	O
2	,	O
3	in	O
4	mammalian	O
5	cells	O
6	PBP74	B
7	is	O
8	synthesized	O
9	as	O
10	a	O
11	pre	O
12	-	O
13	protein	O
14	that	O
15	requires	O
16	membrane	O
17	potential	O
18	-	O
19	dependent	O
20	import	O
21	into	O
22	mitochondria	O
23	for	O
24	its	O
25	maturation	O
26	.	O

1	In	O
2	a	O
3	second	O
4	experiment	O
5	involving	O
6	an	O
7	18	O
8	-	O
9	h	O
10	lung	O
11	clearance	O
12	assay	O
13	,	O
14	we	O
15	used	O
16	the	O
17	mAb	B
18	3	I
19	.	I
20	2	I
21	.	I
22	3	I
23	to	O
24	deplete	O
25	rats	O
26	of	O
27	LGL	O
28	/	O
29	NK	O
30	cells	O
31	with	O
32	the	O
33	following	O
34	rationale	O
35	:	O
36	if	O
37	LGL	O
38	/	O
39	NK	O
40	cells	O
41	are	O
42	necessary	O
43	to	O
44	mediate	O
45	an	O
46	event	O
47	,	O
48	then	O
49	in	O
50	their	O
51	absence	O
52	,	O
53	that	O
54	event	O
55	should	O
56	not	O
57	occur	O
58	.	O

1	Treatment	O
2	of	O
3	recurrent	O
4	FSGS	O
5	has	O
6	included	O
7	high	O
8	-	O
9	dose	O
10	steroids	O
11	,	O
12	high	O
13	-	O
14	dose	O
15	cyclosporine	O
16	(	O
17	CSA	O
18	),	O
19	plasmapheresis	O
20	,	O
21	and	O
22	ACE	B
23	inhibitors	O
24	with	O
25	mixed	O
26	results	O
27	.	O

1	Our	O
2	results	O
3	concluded	O
4	that	O
5	1	O
6	)	O
7	the	O
8	two	O
9	inhibin	B
10	/	O
11	activin	B
12	beta	O
13	B	O
14	-	O
15	subunit	O
16	mRNAs	O
17	were	O
18	transcribed	O
19	from	O
20	different	O
21	initiation	O
22	sites	O
23	;	O
24	2	O
25	)	O
26	both	O
27	promoters	O
28	may	O
29	be	O
30	controlled	O
31	by	O
32	up	O
33	-	O
34	stream	O
35	negative	O
36	regulatory	O
37	elements	O
38	;	O
39	and	O
40	3	O
41	)	O
42	neither	O
43	of	O
44	these	O
45	promoters	O
46	is	O
47	responsive	O
48	to	O
49	cAMP	O
50	and	O
51	/	O
52	or	O
53	phorbol	O
54	esters	O
55	under	O
56	the	O
57	conditions	O
58	employed	O
59	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	B
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	O
25	alpha	B
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	B
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	B
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	Upstream	O
2	from	O
3	the	O
4	transcription	O
5	start	O
6	point	O
7	(	O
8	tsp	O
9	),	O
10	a	O
11	nucleotide	O
12	sequence	O
13	highly	O
14	homologous	O
15	to	O
16	the	O
17	consensus	B
18	sequence	I
19	motif	I
20	for	I
21	the	I
22	sigma	I
23	35	I
24	-	I
25	recognized	I
26	promoters	I
27	was	O
28	found	O
29	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	an	O
6	analysis	O
7	of	O
8	the	O
9	dynamics	O
10	in	O
11	the	O
12	closing	O
13	phase	O
14	of	O
15	the	O
16	occluder	O
17	of	O
18	a	O
19	mechanical	O
20	monoleaflet	O
21	heart	O
22	valve	O
23	prosthesis	O
24	is	O
25	presented	O
26	.	O

1	During	O
2	ISO	O
3	+	O
4	AT	O
5	infusion	O
6	,	O
7	abdominal	O
8	fat	O
9	blood	O
10	flow	O
11	was	O
12	still	O
13	significantly	O
14	increased	O
15	as	O
16	compared	O
17	with	O
18	control	O
19	values	O
20	in	O
21	lean	O
22	and	O
23	obese	O
24	subjects	O
25	.	O

1	When	O
2	expressed	O
3	per	O
4	kilogram	O
5	body	O
6	weight	O
7	,	O
8	mean	O
9	GIT	O
10	increased	O
11	in	O
12	the	O
13	dF	O
14	group	O
15	from	O
16	0	O
17	.	O
18	14	O
19	%	O
20	to	O
21	0	O
22	.	O
23	16	O
24	%	O
25	above	O
26	RMR	O
27	,	O
28	with	O
29	a	O
30	significant	O
31	decrease	O
32	from	O
33	0	O
34	.	O
35	15	O
36	%	O
37	to	O
38	0	O
39	.	O
40	13	O
41	%	O
42	in	O
43	the	O
44	P	O
45	group	O
46	.	O

1	In	O
2	nucleus	O
3	ventralis	O
4	anterior	O
5	thalami	O
6	-	O
7	nucleus	O
8	ventralis	O
9	lateralis	O
10	thalami	O
11	neurons	O
12	with	O
13	an	O
14	inhibitory	O
15	input	O
16	from	O
17	nucleus	O
18	entopeduncularis	O
19	,	O
20	a	O
21	shortening	O
22	of	O
23	inhibition	O
24	from	O
25	17	O
26	.	O
27	5	O
28	+/-	O
29	3	O
30	.	O
31	6	O
32	to	O
33	9	O
34	.	O
35	1	O
36	+/-	O
37	1	O
38	.	O
39	8	O
40	ms	O
41	(	O
42	P	O
43	<	O
44	0	O
45	.	O
46	05	O
47	)	O
48	under	O
49	the	O
50	haloperidol	O
51	influence	O
52	was	O
53	evident	O
54	.	O

1	However	O
2	,	O
3	inclusion	O
4	of	O
5	the	O
6	neighboring	O
7	CGGAAR	O
8	motifs	O
9	from	O
10	the	O
11	ICP4	B
12	promoter	I
13	,	O
14	which	O
15	bind	O
16	factors	O
17	GABP	B
18	alpha	I
19	and	I
20	beta	I
21	,	O
22	results	O
23	in	O
24	a	O
25	strong	O
26	synergistic	O
27	activation	O
28	.	O

1	The	O
2	first	O
3	open	O
4	reading	O
5	frame	O
6	of	O
7	the	O
8	blueberry	O
9	scorch	O
10	carlavirus	O
11	(	O
12	BBScV	O
13	)	O
14	genome	O
15	encodes	O
16	a	O
17	putative	O
18	replication	O
19	-	O
20	associated	O
21	protein	O
22	of	O
23	223	O
24	kDa	O
25	(	O
26	p223	B
27	).	O

1	From	O
2	sequence	O
3	alignments	O
4	with	O
5	phylogenetically	O
6	related	O
7	viruses	O
8	,	O
9	including	O
10	tymoviruses	O
11	,	O
12	we	O
13	predicted	O
14	that	O
15	p223	B
16	contained	O
17	a	O
18	papain	B
19	-	I
20	like	I
21	proteinase	I
22	domain	I
23	with	O
24	a	O
25	putative	O
26	catalytic	O
27	cysteine994	O
28	and	O
29	histidine1075	O
30	.	O

1	This	O
2	finding	O
3	represents	O
4	both	O
5	a	O
6	potentially	O
7	important	O
8	mechanism	O
9	by	O
10	which	O
11	HPV	O
12	gene	O
13	expression	O
14	can	O
15	be	O
16	regulated	O
17	and	O
18	an	O
19	interesting	O
20	model	O
21	for	O
22	the	O
23	study	O
24	of	O
25	transcriptional	O
26	cooperativity	O
27	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	VLPs	O
6	were	O
7	obtained	O
8	in	O
9	quantities	O
10	sufficient	O
11	for	O
12	further	O
13	characterization	O
14	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	upstream	O
6	of	O
7	this	O
8	initiation	O
9	codon	O
10	reveals	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	promotor	O
16	sequence	O
17	.	O

1	SUP46	B
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	I
13	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	relationship	O
6	between	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	Rb	B
12	,	O
13	a	O
14	eukaryotic	O
15	expression	O
16	plasmid	O
17	was	O
18	constructed	O
19	containing	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	gene	I
25	under	O
26	control	O
27	of	O
28	the	O
29	SV40	B
30	promoter	I
31	complex	O
32	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	sequence	O
6	identity	O
7	(	O
8	96	O
9	%)	O
10	between	O
11	hydrolase	B
12	B	I
13	and	I
14	C	I
15	,	O
16	particularly	O
17	in	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	,	O
24	suggests	O
25	that	O
26	the	O
27	genes	O
28	encoding	O
29	these	O
30	two	O
31	carboxylesterases	B
32	evolved	O
33	by	O
34	duplication	O
35	and	O
36	divergence	O
37	of	O
38	a	O
39	common	O
40	ancestral	O
41	gene	O
42	.	O

1	The	O
2	regions	O
3	of	O
4	the	O
5	tooth	O
6	fracture	O
7	are	O
8	determined	O
9	.	O

1	Secondary	O
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O

1	The	O
2	NR2	O
3	hybrid	O
4	is	O
5	a	O
6	powerful	O
7	tool	O
8	for	O
9	the	O
10	mapping	O
11	of	O
12	new	O
13	probes	O
14	of	O
15	this	O
16	region	O
17	,	O
18	as	O
19	well	O
20	as	O
21	for	O
22	obtaining	O
23	new	O
24	informative	O
25	probes	O
26	specific	O
27	for	O
28	the	O
29	deletion	O
30	by	O
31	subtractive	O
32	cloning	O
33	of	O
34	the	O
35	region	O
36	.	O

1	TDEYA	O
2	at	O
3	doses	O
4	of	O
5	200	O
6	to	O
7	500	O
8	mg	O
9	/	O
10	kg	O
11	significantly	O
12	suppressed	O
13	xanthine	B
14	oxidase	I
15	(	O
16	XO	B
17	)	O
18	activity	O
19	in	O
20	the	O
21	stomach	O
22	tissue	O
23	following	O
24	its	O
25	oral	O
26	administration	O
27	.	O

1	Like	O
2	humans	O
3	,	O
4	the	O
5	PITSLRE	B
6	PK	I
7	genes	I
8	in	I
9	chickens	I
10	must	O
11	be	O
12	closely	O
13	linked	O
14	,	O
15	based	O
16	on	O
17	fluorescent	O
18	in	O
19	situ	O
20	hybridization	O
21	(	O
22	FISH	O
23	)	O
24	localization	O
25	of	O
26	these	O
27	genes	O
28	to	O
29	a	O
30	single	O
31	chicken	O
32	microchromosome	O
33	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	characterization	O
7	of	O
8	an	O
9	alternatively	O
10	processed	O
11	form	O
12	of	O
13	AFAP	B
14	-	I
15	110	I
16	that	O
17	encodes	O
18	an	O
19	additional	O
20	258	O
21	base	O
22	pair	O
23	(	O
24	bp	O
25	)	O
26	of	O
27	open	O
28	reading	O
29	frame	O
30	.	O

1	Expression	O
2	of	O
3	class	B
4	IV	I
5	ADH	I
6	mRNA	I
7	was	O
8	detected	O
9	in	O
10	human	O
11	stomach	O
12	but	O
13	not	O
14	liver	O
15	.	O

1	In	O
2	ICE	B
3	gamma	I
4	,	O
5	most	O
6	of	O
7	the	O
8	propeptide	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	catalyst	O
28	for	O
29	ICE	B
30	autoprocessing	O
31	in	O
32	vivo	O
33	.	O

1	Endocytosis	O
2	and	O
3	lysosomal	O
4	targeting	O
5	of	O
6	epidermal	B
7	growth	I
8	factor	I
9	receptors	I
10	are	O
11	mediated	O
12	by	O
13	distinct	O
14	sequences	O
15	independent	O
16	of	O
17	the	O
18	tyrosine	B
19	kinase	I
20	domain	I
21	.	O

1	It	O
2	is	O
3	now	O
4	recognized	O
5	that	O
6	essentially	O
7	all	O
8	eukaryotic	O
9	and	O
10	prokaryotic	O
11	genes	O
12	whose	O
13	5	O
14	'-	O
15	flanking	O
16	regions	O
17	are	O
18	known	O
19	and	O
20	that	O
21	encode	O
22	barbiturate	O
23	-	O
24	inducible	O
25	proteins	O
26	contain	O
27	the	O
28	Barbie	O
29	box	O
30	element	O
31	.	O

1	Mutation	O
2	of	O
3	the	O
4	P450BM	B
5	-	I
6	3	I
7	Barbie	I
8	box	I
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	P450BM	B
16	-	I
17	3	I
18	and	O
19	Bm3P1	B
20	(	O
21	another	O
22	small	O
23	gene	O
24	located	O
25	upstream	O
26	of	O
27	the	O
28	P450BM	B
29	-	I
30	3	I
31	gene	I
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	pentobarbital	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O

1	The	O
2	p97	B
3	-	O
4	depleted	O
5	nuclei	O
6	remained	O
7	largely	O
8	competent	O
9	for	O
10	nuclear	O
11	protein	O
12	import	O
13	.	O

1	A	O
2	potential	O
3	outcome	O
4	of	O
5	these	O
6	biochemical	O
7	effects	O
8	may	O
9	include	O
10	the	O
11	limited	O
12	responsiveness	O
13	of	O
14	infected	O
15	T	O
16	cells	O
17	to	O
18	antigenic	O
19	stimulation	O
20	observed	O
21	during	O
22	HIV	O
23	-	O
24	1	O
25	infection	O
26	.	O

1	The	O
2	full	O
3	protocol	O
4	was	O
5	completed	O
6	by	O
7	33	O
8	patients	O
9	(	O
10	45	O
11	%	O
12	of	O
13	original	O
14	cohort	O
15	).	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	that	O
7	cell	O
8	-	O
9	specific	O
10	suppression	O
11	of	O
12	RA	O
13	-	O
14	stimulated	O
15	zif268	B
16	gene	I
17	expression	O
18	can	O
19	be	O
20	attributed	O
21	to	O
22	a	O
23	29	O
24	base	O
25	pair	O
26	nucleotide	O
27	sequence	O
28	,	O
29	located	O
30	downstream	O
31	of	O
32	the	O
33	RA	O
34	-	O
35	responsive	O
36	region	O
37	in	O
38	the	O
39	zif268	B
40	gene	I
41	.	O

1	We	O
2	show	O
3	that	O
4	CBF	B
5	-	I
6	A	I
7	and	O
8	CBF	B
9	-	I
10	C	I
11	interact	O
12	with	O
13	each	O
14	other	O
15	to	O
16	form	O
17	a	O
18	CBF	B
19	-	I
20	A	I
21	-	O
22	CBF	B
23	-	I
24	C	I
25	complex	O
26	and	O
27	that	O
28	CBF	B
29	-	I
30	B	I
31	does	O
32	not	O
33	interact	O
34	with	O
35	CBF	B
36	-	I
37	A	I
38	or	O
39	CBF	B
40	-	I
41	C	I
42	individually	O
43	but	O
44	that	O
45	it	O
46	associates	O
47	with	O
48	the	O
49	CBF	B
50	-	I
51	A	I
52	-	O
53	CBF	B
54	-	I
55	C	I
56	complex	O
57	.	O

1	In	O
2	the	O
3	first	O
4	,	O
5	homologous	O
6	sequences	O
7	were	O
8	deleted	O
9	from	O
10	a	O
11	mouse	O
12	enhancer	O
13	,	O
14	resulting	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	loss	O
21	of	O
22	activity	O
23	when	O
24	assayed	O
25	in	O
26	transgenic	O
27	mice	O
28	.	O

1	OKT3	B
2	prophylaxis	O
3	improves	O
4	long	O
5	-	O
6	term	O
7	renal	O
8	graft	O
9	survival	O
10	in	O
11	high	O
12	-	O
13	risk	O
14	patients	O
15	as	O
16	compared	O
17	to	O
18	cyclosporine	O
19	:	O
20	combined	O
21	results	O
22	from	O
23	the	O
24	prospective	O
25	,	O
26	randomized	O
27	Belgian	O
28	and	O
29	US	O
30	studies	O
31	.	O

1	The	O
2	major	O
3	PKC	B
4	beta	I
5	transcription	O
6	initiation	O
7	site	O
8	was	O
9	identified	O
10	by	O
11	primer	O
12	extension	O
13	and	O
14	S1	B
15	nuclease	I
16	protection	O
17	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	a	O
6	study	O
7	of	O
8	low	O
9	dose	O
10	X	O
11	-	O
12	rays	O
13	effects	O
14	,	O
15	we	O
16	found	O
17	that	O
18	male	O
19	ICR	O
20	white	O
21	Swiss	O
22	mice	O
23	showed	O
24	remarkable	O
25	suppression	O
26	of	O
27	mounting	O
28	behavior	O
29	after	O
30	whole	O
31	body	O
32	irradiation	O
33	by	O
34	5	O
35	to	O
36	15	O
37	cGy	O
38	X	O
39	-	O
40	rays	O
41	.	O

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	Supplementary	O
2	Phase	O
3	Contraste	O
4	RSE	O
5	("	O
6	Rapid	O
7	Sequential	O
8	Excitation	O
9	")	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O

1	In	O
2	yeast	O
3	,	O
4	the	O
5	products	O
6	of	O
7	the	O
8	UPF1	B
9	and	O
10	UPF3	B
11	genes	I
12	are	O
13	required	O
14	for	O
15	this	O
16	decay	O
17	pathway	O
18	,	O
19	and	O
20	in	O
21	this	O
22	report	O
23	we	O
24	focus	O
25	on	O
26	the	O
27	identification	O
28	and	O
29	characterization	O
30	of	O
31	additional	O
32	factors	O
33	required	O
34	for	O
35	rapid	O
36	decay	O
37	of	O
38	nonsense	O
39	-	O
40	containing	O
41	mRNAs	O
42	.	O

1	Mutations	O
2	in	O
3	UPF1	B
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	A	O
2	DNA	O
3	fragment	O
4	encoding	O
5	the	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	(	O
11	amino	O
12	acids	O
13	1	O
14	-	O
15	60	O
16	)	O
17	of	O
18	the	O
19	Escherichia	B
20	coli	I
21	fru	I
22	transcriptional	I
23	regulator	I
24	was	O
25	cloned	O
26	into	O
27	the	O
28	pGEX	O
29	-	O
30	KT	O
31	vector	O
32	and	O
33	expressed	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	fused	O
39	gene	O
40	encoding	O
41	glutathione	B
42	S	I
43	-	I
44	transferase	I
45	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	0	O
2	.	O
3	61	O
4	+/-	O
5	0	O
6	.	O
7	04	O
8	).	O

1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O

1	With	O
2	a	O
3	population	O
4	of	O
5	853	O
6	million	O
7	there	O
8	should	O
9	be	O
10	51	O
11	,	O
12	204	O
13	patients	O
14	with	O
15	hemophilia	O
16	A	O
17	in	O
18	India	O
19	assuming	O
20	a	O
21	prevalence	O
22	of	O
23	6	O
24	/	O
25	100	O
26	,	O
27	000	O
28	population	O
29	.	O

1	When	O
2	combined	O
3	with	O
4	serum	O
5	ferritin	B
6	and	O
7	hemoglobin	B
8	determinations	O
9	,	O
10	the	O
11	serum	O
12	transferrin	B
13	receptor	I
14	assay	O
15	is	O
16	a	O
17	valuable	O
18	addition	O
19	in	O
20	epidemiologic	O
21	surveys	O
22	because	O
23	it	O
24	provides	O
25	a	O
26	quantitative	O
27	measure	O
28	of	O
29	functional	O
30	iron	O
31	deficiency	O
32	and	O
33	it	O
34	distinguishes	O
35	true	O
36	IDA	O
37	from	O
38	the	O
39	anemia	O
40	of	O
41	chronic	O
42	disease	O
43	.	O

1	Twenty	O
2	-	O
3	two	O
4	consecutive	O
5	patients	O
6	with	O
7	ischaemic	O
8	ulcers	O
9	had	O
10	tcPO2	O
11	measured	O
12	and	O
13	the	O
14	ankle	O
15	/	O
16	brachial	O
17	(	O
18	ABI	O
19	)	O
20	and	O
21	toe	O
22	/	O
23	brachial	O
24	(	O
25	TBI	O
26	)	O
27	indices	O
28	calculated	O
29	.	O

1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O

1	Since	O
2	1990	O
3	the	O
4	University	O
5	Hospital	O
6	of	O
7	Tromso	O
8	has	O
9	provided	O
10	local	O
11	hospitals	O
12	in	O
13	northern	O
14	Norway	O
15	with	O
16	a	O
17	remote	O
18	frozen	O
19	section	O
20	service	O
21	and	O
22	with	O
23	access	O
24	to	O
25	video	O
26	conferences	O
27	for	O
28	the	O
29	review	O
30	of	O
31	microscopic	O
32	findings	O
33	and	O
34	for	O
35	the	O
36	discussion	O
37	of	O
38	major	O
39	diagnostic	O
40	issues	O
41	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	B
19	IV	I
20	PDE	I
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	B
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O

1	PMEK1	B
2	displays	O
3	96	O
4	and	O
5	80	O
6	%	O
7	identity	O
8	respectively	O
9	with	O
10	the	O
11	tobacco	B
12	NTF3	I
13	and	O
14	Arabidopsis	B
15	ATMPK1	I
16	kinases	I
17	,	O
18	and	O
19	only	O
20	50	O
21	%	O
22	to	O
23	the	O
24	more	O
25	distantly	O
26	related	O
27	plant	O
28	MAP	O
29	kinase	O
30	MsERK1	B
31	from	O
32	alfalfa	O
33	.	O

1	Translation	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	B
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O

1	The	O
2	presence	O
3	of	O
4	type	O
5	I	O
6	hypersensitivity	O
7	in	O
8	a	O
9	subgroup	O
10	of	O
11	aspergillomas	O
12	suggests	O
13	an	O
14	immunoallergic	O
15	component	O
16	to	O
17	this	O
18	disease	O
19	which	O
20	could	O
21	contribute	O
22	to	O
23	a	O
24	chronic	O
25	inflammatory	O
26	response	O
27	to	O
28	Aspergillus	O
29	in	O
30	some	O
31	aspergillomas	O
32	.	O

1	This	O
2	concept	O
3	is	O
4	supported	O
5	by	O
6	the	O
7	identification	O
8	of	O
9	RH	B
10	-	I
11	like	I
12	genes	I
13	in	O
14	non	O
15	human	O
16	primates	O
17	.	O

1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	mouse	O
6	cDNA	O
7	library	O
8	of	O
9	an	O
10	MIN6	O
11	cell	O
12	line	O
13	,	O
14	derived	O
15	from	O
16	pancreatic	O
17	beta	O
18	cells	O
19	,	O
20	for	O
21	its	O
22	novel	O
23	isoform	O
24	and	O
25	have	O
26	identified	O
27	a	O
28	cDNA	O
29	encoding	O
30	a	O
31	593	O
32	-	O
33	amino	O
34	acid	O
35	protein	O
36	having	O
37	63	O
38	,	O
39	53	O
40	,	O
41	and	O
42	30	O
43	%	O
44	identity	O
45	with	O
46	munc	B
47	-	I
48	18	I
49	/	I
50	n	I
51	-	I
52	Sec1	I
53	/	I
54	rbSec1	I
55	,	O
56	Caenorhabditis	B
57	elegans	I
58	unc18	I
59	,	O
60	and	O
61	Saccharomyces	B
62	cerevisiae	I
63	Sec1p	I
64	,	O
65	respectively	O
66	.	O

1	The	O
2	catenins	B
3	bind	O
4	to	O
5	APC	B
6	and	O
7	E	B
8	-	I
9	cadherin	I
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	APC	B
17	and	O
18	E	B
19	-	I
20	cadherin	I
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	catenins	B
35	.	O

1	However	O
2	,	O
3	addition	O
4	of	O
5	core	B
6	DNA	I
7	polymerase	I
8	III	I
9	to	O
10	preinitiation	O
11	complex	O
12	,	O
13	fully	O
14	reconstituting	O
15	holoenzyme	O
16	resulted	O
17	in	O
18	replacement	O
19	of	O
20	gamma	O
21	by	O
22	alpha	O
23	at	O
24	the	O
25	primer	O
26	terminus	O
27	.	O

1	The	O
2	PSD2	B
3	gene	I
4	was	O
5	heterologously	O
6	expressed	O
7	by	O
8	infection	O
9	of	O
10	Sf	O
11	-	O
12	9	O
13	insect	O
14	cells	O
15	with	O
16	recombinant	O
17	baculovirus	O
18	,	O
19	resulting	O
20	in	O
21	a	O
22	10	O
23	-	O
24	fold	O
25	increase	O
26	in	O
27	PSD	B
28	activity	O
29	.	O

1	Computerized	O
2	detection	O
3	of	O
4	abnormal	O
5	asymmetry	O
6	in	O
7	digital	O
8	chest	O
9	radiographs	O
10	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	gluconeogenic	O
6	genes	O
7	are	O
8	derepressed	O
9	upon	O
10	binding	O
11	of	O
12	Cat8p	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	Cat4p	B
22	(	O
23	Mig1p	B
24	)	O
25	from	O
26	the	O
27	CAT8	B
28	promoter	I
29	.	O

1	Like	O
2	Epo	B
3	,	O
4	HNF	B
5	-	I
6	4	I
7	is	O
8	expressed	O
9	in	O
10	kidney	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	Hep3B	O
16	cells	O
17	but	O
18	not	O
19	in	O
20	HeLa	O
21	cells	O
22	.	O

1	Moreover	O
2	,	O
3	the	O
4	hypoxia	O
5	-	O
6	induced	O
7	expression	O
8	of	O
9	the	O
10	endogenous	O
11	Epo	B
12	gene	I
13	was	O
14	significantly	O
15	inhibited	O
16	in	O
17	Hep3B	O
18	cells	O
19	stably	O
20	transfected	O
21	with	O
22	HNF	B
23	-	I
24	4	I
25	delta	I
26	C	I
27	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	Small	B
2	Maf	I
3	proteins	I
4	heterodimerize	O
5	with	O
6	Fos	B
7	and	O
8	may	O
9	act	O
10	as	O
11	competitive	O
12	repressors	O
13	of	O
14	the	O
15	NF	B
16	-	I
17	E2	I
18	transcription	I
19	factor	I
20	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	B
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O

1	Survival	O
2	after	O
3	development	O
4	of	O
5	symptomatic	O
6	infection	O
7	(	O
8	P	O
9	-	O
10	2	O
11	)	O
12	did	O
13	not	O
14	differ	O
15	by	O
16	transmission	O
17	mode	O
18	.	O

1	Both	O
2	factors	O
3	demonstrated	O
4	significant	O
5	correlations	O
6	with	O
7	rCBF	O
8	in	O
9	the	O
10	medial	O
11	prefrontal	O
12	cortex	O
13	and	O
14	frontal	O
15	polar	O
16	cortex	O
17	while	O
18	for	O
19	each	O
20	factor	O
21	there	O
22	were	O
23	also	O
24	unique	O
25	patterns	O
26	of	O
27	correlations	O
28	with	O
29	posterior	O
30	brain	O
31	regions	O
32	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	function	O
7	of	O
8	the	O
9	DS2	B
10	may	O
11	be	O
12	the	O
13	protection	O
14	of	O
15	the	O
16	nuclear	O
17	DNA	O
18	from	O
19	desiccation	O
20	.	O

1	Glomerular	O
2	hemodynamics	O
3	during	O
4	abortion	O
5	induced	O
6	by	O
7	RU	O
8	486	O
9	and	O
10	sepsis	O
11	in	O
12	rats	O
13	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	retrospective	O
6	study	O
7	was	O
8	to	O
9	demonstrate	O
10	that	O
11	in	O
12	certain	O
13	cases	O
14	of	O
15	expulsive	O
16	choroidal	O
17	hemorrhage	O
18	(	O
19	ECH	O
20	)	O
21	anatomical	O
22	success	O
23	and	O
24	useful	O
25	vision	O
26	can	O
27	be	O
28	obtained	O
29	with	O
30	repeated	O
31	vitreoretinal	O
32	surgery	O
33	.	O

1	The	O
2	function	O
3	of	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	tail	O
9	in	O
10	telomere	O
11	maintenance	O
12	is	O
13	not	O
14	mediated	O
15	through	O
16	the	O
17	RAP1	B
18	interacting	I
19	factor	I
20	RIF1	I
21	:	O
22	rap1	B
23	alleles	I
24	defective	O
25	in	O
26	both	O
27	the	O
28	C	O
29	-	O
30	terminal	O
31	tail	O
32	and	O
33	RIF1	B
34	interaction	I
35	domains	I
36	have	O
37	additive	O
38	effects	O
39	on	O
40	telomere	O
41	length	O
42	.	O

1	The	O
2	resulting	O
3	integrated	O
4	physical	O
5	,	O
6	genetic	O
7	,	O
8	and	O
9	cytogenetic	O
10	map	O
11	constitutes	O
12	a	O
13	resource	O
14	for	O
15	the	O
16	characterization	O
17	of	O
18	genes	O
19	that	O
20	may	O
21	be	O
22	involved	O
23	in	O
24	the	O
25	WAGR	O
26	syndrome	O
27	.	O

1	The	O
2	contribution	O
3	of	O
4	skin	O
5	flow	O
6	to	O
7	the	O
8	changes	O
9	in	O
10	760	O
11	-	O
12	800	O
13	nm	O
14	absorption	O
15	was	O
16	investigated	O
17	by	O
18	simultaneous	O
19	measurement	O
20	of	O
21	skin	O
22	flow	O
23	by	O
24	laser	O
25	flow	O
26	Doppler	O
27	and	O
28	NIR	O
29	recordings	O
30	during	O
31	hot	O
32	water	O
33	immersion	O
34	.	O

1	Proteins	O
2	immunoprecipitated	O
3	from	O
4	lysates	O
5	of	O
6	control	O
7	-	O
8	and	O
9	VEGF	B
10	-	O
11	stimulated	O
12	BAEC	O
13	with	O
14	antisera	O
15	to	O
16	phospholipase	B
17	C	I
18	-	I
19	gamma	I
20	(	O
21	PLC	B
22	-	I
23	gamma	I
24	)	O
25	were	O
26	fractionated	O
27	by	O
28	SDS	O
29	-	O
30	polyacrylamide	O
31	gel	O
32	electrophoresis	O
33	and	O
34	transferred	O
35	to	O
36	Immobilon	O
37	-	O
38	P	O
39	.	O

1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	B
6	nucleic	I
7	acid	I
8	-	I
9	binding	I
10	protein	I
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O

1	Involvement	O
2	of	O
3	early	B
4	growth	I
5	response	I
6	factor	I
7	Egr	I
8	-	I
9	1	I
10	in	O
11	apolipoprotein	B
12	AI	I
13	gene	I
14	transcription	O
15	.	O

1	The	O
2	wild	O
3	-	O
4	type	O
5	and	O
6	altered	O
7	forms	O
8	of	O
9	the	O
10	F	B
11	protein	I
12	were	O
13	expressed	O
14	in	O
15	BHK	O
16	-	O
17	21	O
18	and	O
19	HeLa	O
20	T4	O
21	cells	O
22	by	O
23	use	O
24	of	O
25	the	O
26	recombinant	B
27	vaccinia	I
28	virus	I
29	-	I
30	encoding	I
31	T7	I
32	polymerase	I
33	system	O
34	.	O

1	Erythrocyte	B
2	delta	I
3	-	I
4	aminolevulinic	I
5	acid	I
6	dehydratase	I
7	(	O
8	ALAD	B
9	)	O
10	activity	O
11	,	O
12	erythrocyte	O
13	zinc	O
14	protoporphyrin	O
15	(	O
16	ZPP	O
17	)/	O
18	heme	O
19	ratio	O
20	,	O
21	and	O
22	urinary	O
23	coproporphyrin	O
24	(	O
25	UC	O
26	)	O
27	concentration	O
28	have	O
29	been	O
30	employed	O
31	as	O
32	biological	O
33	indicators	O
34	of	O
35	moderate	O
36	-	O
37	to	O
38	high	O
39	-	O
40	level	O
41	lead	O
42	exposure	O
43	,	O
44	corresponding	O
45	to	O
46	blood	O
47	levels	O
48	in	O
49	excess	O
50	of	O
51	50	O
52	micrograms	O
53	/	O
54	dl	O
55	,	O
56	in	O
57	human	O
58	subjects	O
59	.	O

1	The	O
2	relative	O
3	risk	O
4	of	O
5	graft	O
6	loss	O
7	after	O
8	conversion	O
9	to	O
10	azathioprine	O
11	compared	O
12	with	O
13	graft	O
14	loss	O
15	after	O
16	conversion	O
17	to	O
18	azathioprine	O
19	compared	O
20	with	O
21	cyclosporin	O
22	maintenance	O
23	was	O
24	0	O
25	.	O
26	71	O
27	(	O
28	0	O
29	.	O
30	37	O
31	-	O
32	1	O
33	.	O
34	38	O
35	)	O
36	and	O
37	the	O
38	relative	O
39	risk	O
40	of	O
41	patient	O
42	death	O
43	was	O
44	0	O
45	.	O
46	57	O
47	(	O
48	0	O
49	.	O
50	23	O
51	-	O
52	1	O
53	.	O
54	41	O
55	).	O

1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O

1	The	O
2	"	O
3	tobacco	O
4	issue	O
5	".	O

1	Pregnancy	O
2	screening	O
3	by	O
4	uterine	O
5	artery	O
6	Doppler	O
7	velocimetry	O
8	--	O
9	which	O
10	criterion	O
11	performs	O
12	best	O
13	?	O
14	OBJECTIVE	O
15	:	O
16	To	O
17	test	O
18	whether	O
19	repeating	O
20	Doppler	O
21	studies	O
22	of	O
23	the	O
24	uteroplacental	O
25	circulation	O
26	late	O
27	in	O
28	gestation	O
29	will	O
30	improve	O
31	the	O
32	test	O
33	'	O
34	s	O
35	power	O
36	for	O
37	predicting	O
38	pregnancy	O
39	-	O
40	induced	O
41	hypertension	O
42	and	O
43	fetal	O
44	growth	O
45	restriction	O
46	(	O
47	FGR	O
48	),	O
49	and	O
50	whether	O
51	analysis	O
52	based	O
53	on	O
54	a	O
55	combination	O
56	of	O
57	quantitative	O
58	and	O
59	qualitative	O
60	assessments	O
61	of	O
62	the	O
63	uterine	O
64	arterial	O
65	waveforms	O
66	will	O
67	yield	O
68	better	O
69	results	O
70	than	O
71	analysis	O
72	based	O
73	on	O
74	either	O
75	alone	O
76	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	Ca	O
6	entry	O
7	blocker	O
8	nitrendipine	O
9	,	O
10	the	O
11	antioxidant	O
12	superoxide	B
13	dismutase	I
14	(	O
15	SOD	B
16	),	O
17	and	O
18	a	O
19	combination	O
20	of	O
21	nitrendipine	O
22	and	O
23	superoxide	B
24	dismutase	I
25	on	O
26	postischemic	O
27	renal	O
28	function	O
29	was	O
30	studied	O
31	in	O
32	four	O
33	groups	O
34	(	O
35	n	O
36	=	O
37	24	O
38	)	O
39	of	O
40	rats	O
41	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	evaluate	O
11	the	O
12	bony	O
13	anchorage	O
14	of	O
15	a	O
16	new	O
17	implant	O
18	(	O
19	orderly	O
20	wired	O
21	surface	O
22	effect	O
23	with	O
24	alloy	O
25	Ti	O
26	Al	O
27	Va	O
28	and	O
29	ordered	O
30	pores	O
31	of	O
32	488	O
33	mu	O
34	).	O

1	To	O
2	determine	O
3	whether	O
4	food	O
5	and	O
6	/	O
7	or	O
8	water	O
9	in	O
10	the	O
11	gastrointestinal	O
12	tract	O
13	affects	O
14	restitution	O
15	of	O
16	blood	O
17	volume	O
18	and	O
19	plasma	O
20	protein	O
21	after	O
22	hemorrhage	O
23	,	O
24	fed	O
25	and	O
26	24	O
27	-	O
28	h	O
29	-	O
30	fasted	O
31	awake	O
32	rats	O
33	received	O
34	a	O
35	20	O
36	ml	O
37	.	O
38	kg	O
39	-	O
40	1	O
41	x	O
42	3	O
43	min	O
44	-	O
45	1	O
46	hemorrhage	O
47	,	O
48	and	O
49	restitution	O
50	of	O
51	blood	O
52	volume	O
53	was	O
54	measured	O
55	by	O
56	Evans	O
57	blue	O
58	dye	O
59	and	O
60	dilution	O
61	of	O
62	hematocrit	O
63	.	O

1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	B
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O

1	We	O
2	took	O
3	advantage	O
4	of	O
5	the	O
6	high	O
7	degree	O
8	of	O
9	aa	O
10	sequence	O
11	homology	O
12	between	O
13	DAHPSs	B
14	from	O
15	several	O
16	species	O
17	to	O
18	isolate	O
19	ARO3	B
20	homologues	I
21	from	O
22	the	O
23	pathogenic	O
24	yeast	O
25	Candida	O
26	albicans	O
27	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	BOX	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	B
15	kinase	I
16	(	O
17	TK	B
18	)	O
19	promoter	O
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O

1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	construct	O
6	revealed	O
7	that	O
8	the	O
9	transcription	O
10	of	O
11	BOXF1	B
12	gene	I
13	is	O
14	regulated	O
15	by	O
16	BOX	O
17	DNA	O
18	,	O
19	preferentially	O
20	in	O
21	undifferentiated	O
22	EC	O
23	cells	O
24	versus	O
25	differentiated	O
26	cells	O
27	.	O

1	Analysis	O
2	of	O
3	disassociation	O
4	rates	O
5	indicates	O
6	that	O
7	the	O
8	Grf10	B
9	-	O
10	Swi5	B
11	-	O
12	DNA	O
13	complex	O
14	has	O
15	a	O
16	longer	O
17	half	O
18	-	O
19	life	O
20	than	O
21	protein	O
22	-	O
23	DNA	O
24	complexes	O
25	that	O
26	contain	O
27	only	O
28	Swi5	B
29	or	O
30	Grf10	B
31	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O

1	The	O
2	mutant	O
3	allele	O
4	of	O
5	the	O
6	alpha	B
7	1	I
8	-	I
9	tubulin	I
10	gene	I
11	was	O
12	designated	O
13	tua1	B
14	-	I
15	1	I
16	.	O

1	During	O
2	chronic	O
3	treatment	O
4	,	O
5	when	O
6	plasma	O
7	concentrations	O
8	fluctuated	O
9	between	O
10	23	O
11	.	O
12	5	O
13	ng	O
14	.	O
15	ml	O
16	-	O
17	1	O
18	at	O
19	8	O
20	h	O
21	and	O
22	14	O
23	ng	O
24	.	O
25	ml	O
26	-	O
27	1	O
28	at	O
29	24	O
30	h	O
31	post	O
32	-	O
33	dosing	O
34	,	O
35	ST	O
36	segment	O
37	depression	O
38	at	O
39	an	O
40	individually	O
41	comparable	O
42	workload	O
43	was	O
44	significantly	O
45	decreased	O
46	by	O
47	28	O
48	%	O
49	compared	O
50	with	O
51	placebo	O
52	(	O
53	P	O
54	<	O
55	0	O
56	.	O
57	005	O
58	)	O
59	at	O
60	both	O
61	points	O
62	in	O
63	time	O
64	.	O

1	Results	O
2	from	O
3	in	O
4	vitro	O
5	transcription	O
6	-	O
7	translation	O
8	analysis	O
9	and	O
10	maxicell	O
11	experiments	O
12	suggested	O
13	that	O
14	the	O
15	447	O
16	-	O
17	bp	O
18	ORF	O
19	was	O
20	the	O
21	one	O
22	being	O
23	actively	O
24	expressed	O
25	.	O

1	Preliminary	O
2	experiments	O
3	demonstrated	O
4	that	O
5	it	O
6	was	O
7	possible	O
8	to	O
9	produce	O
10	fasD	B
11	mutants	I
12	,	O
13	whose	O
14	products	O
15	remain	O
16	functional	O
17	for	O
18	fimbrial	O
19	export	O
20	and	O
21	assembly	O
22	.	O

1	Evoked	O
2	electromyographic	O
3	response	O
4	to	O
5	indirect	O
6	supramaximal	O
7	stimulation	O
8	at	O
9	1	O
10	Hz	O
11	was	O
12	monitored	O
13	in	O
14	ten	O
15	adult	O
16	goats	O
17	under	O
18	thiopentone	O
19	-	O
20	halothane	O
21	anaesthesia	O
22	.	O

1	313	O
2	,	O
3	98	O
4	-	O
5	102	O
6	).	O

1	Group	O
2	6	O
3	was	O
4	given	O
5	physostigmine	O
6	,	O
7	0	O
8	.	O
9	1	O
10	mg	O
11	/	O
12	kg	O
13	i	O
14	.	O
15	v	O
16	.,	O
17	known	O
18	to	O
19	inhibit	O
20	cholinesterase	B
21	degradation	O
22	,	O
23	5	O
24	min	O
25	before	O
26	bupivacaine	O
27	administration	O
28	,	O
29	and	O
30	Group	O
31	7	O
32	received	O
33	a	O
34	combination	O
35	of	O
36	physostigmine	O
37	pretreatment	O
38	and	O
39	electrical	O
40	vagal	O
41	stimulation	O
42	.	O

1	To	O
2	examine	O
3	the	O
4	possibility	O
5	that	O
6	LNNB	O
7	performance	O
8	of	O
9	the	O
10	schizophrenic	O
11	groups	O
12	may	O
13	have	O
14	been	O
15	related	O
16	to	O
17	neuroleptic	O
18	medication	O
19	,	O
20	analyses	O
21	were	O
22	completed	O
23	on	O
24	the	O
25	relationship	O
26	between	O
27	medication	O
28	levels	O
29	and	O
30	LNNB	O
31	scores	O
32	.	O

1	ISIS	O
2	5	O
3	possibilities	O
4	.	O

1	The	O
2	use	O
3	of	O
4	specific	O
5	antibodies	O
6	allowed	O
7	the	O
8	identification	O
9	of	O
10	at	O
11	least	O
12	RAR	B
13	beta	I
14	in	O
15	some	O
16	of	O
17	the	O
18	DNA	O
19	-	O
20	protein	O
21	complexes	O
22	,	O
23	although	O
24	the	O
25	four	O
26	sequences	O
27	bind	O
28	single	O
29	RARs	B
30	transfected	O
31	in	O
32	COS	O
33	cells	O
34	much	O
35	less	O
36	efficiently	O
37	,	O
38	or	O
39	not	O
40	at	O
41	all	O
42	,	O
43	when	O
44	compared	O
45	to	O
46	a	O
47	canonical	O
48	RAR	B
49	responsive	I
50	element	I
51	.	O

1	The	O
2	present	O
3	treatment	O
4	strategy	O
5	in	O
6	progressive	O
7	disorders	O
8	is	O
9	mainly	O
10	based	O
11	on	O
12	the	O
13	complementary	O
14	effect	O
15	of	O
16	intensive	O
17	radiochemotherapy	O
18	,	O
19	autologous	O
20	stem	O
21	-	O
22	cell	O
23	transplantation	O
24	and	O
25	the	O
26	rational	O
27	use	O
28	of	O
29	cytokines	O
30	,	O
31	mostly	O
32	colony	B
33	-	I
34	stimulating	I
35	factors	I
36	.	O

1	Our	O
2	study	O
3	cohorts	O
4	consisted	O
5	of	O
6	15	O
7	patients	O
8	who	O
9	received	O
10	SC	O
11	rIL	B
12	-	I
13	2	I
14	at	O
15	doses	O
16	of	O
17	4	O
18	.	O
19	8	O
20	-	O
21	14	O
22	.	O
23	4	O
24	million	O
25	IU	O
26	/	O
27	m2	O
28	/	O
29	day	O
30	on	O
31	5	O
32	days	O
33	per	O
34	week	O
35	for	O
36	a	O
37	total	O
38	of	O
39	8	O
40	weeks	O
41	,	O
42	20	O
43	patients	O
44	who	O
45	received	O
46	rIFN	B
47	-	I
48	alpha	I
49	2b	I
50	at	O
51	3	O
52	.	O
53	0	O
54	-	O
55	6	O
56	.	O
57	0	O
58	million	O
59	U	O
60	/	O
61	m2	O
62	/	O
63	day	O
64	thrice	O
65	weekly	O
66	for	O
67	a	O
68	total	O
69	of	O
70	6	O
71	weeks	O
72	,	O
73	and	O
74	72	O
75	patients	O
76	who	O
77	were	O
78	given	O
79	SC	O
80	rIFN	B
81	-	I
82	alpha	I
83	2b	I
84	at	O
85	6	O
86	.	O
87	0	O
88	million	O
89	U	O
90	/	O
91	m2	O
92	/	O
93	day	O
94	thrice	O
95	weekly	O
96	plus	O
97	SC	O
98	rIL	B
99	-	I
100	2	I
101	at	O
102	14	O
103	.	O
104	4	O
105	-	O
106	18	O
107	.	O
108	0	O
109	million	O
110	IU	O
111	/	O
112	m2	O
113	/	O
114	day	O
115	on	O
116	days	O
117	1	O
118	and	O
119	2	O
120	,	O
121	followed	O
122	by	O
123	4	O
124	.	O
125	8	O
126	million	O
127	IU	O
128	/	O
129	m2	O
130	/	O
131	day	O
132	,	O
133	5	O
134	days	O
135	per	O
136	week	O
137	for	O
138	6	O
139	consecutive	O
140	weeks	O
141	.	O

1	Analysis	O
2	of	O
3	a	O
4	set	O
5	of	O
6	deletion	O
7	constructs	O
8	in	O
9	transient	O
10	transfection	O
11	assays	O
12	measuring	O
13	heterologous	O
14	reporter	O
15	gene	O
16	(	O
17	luciferase	B
18	)	O
19	activity	O
20	demonstrated	O
21	that	O
22	the	O
23	182	O
24	-	O
25	bp	O
26	5	O
27	'-	O
28	flanking	O
29	region	O
30	provides	O
31	full	O
32	promoter	O
33	activity	O
34	in	O
35	IL	B
36	-	I
37	2	I
38	-	O
39	stimulated	O
40	L2	O
41	cells	O
42	.	O

1	At	O
2	the	O
3	MTD	O
4	(	O
5	8	O
6	mg	O
7	/	O
8	m2	O
9	/	O
10	day	O
11	),	O
12	the	O
13	dose	O
14	-	O
15	limiting	O
16	toxicity	O
17	of	O
18	this	O
19	agent	O
20	is	O
21	myelosuppression	O
22	.	O

1	Mitogen	O
2	-	O
3	induced	O
4	lymphocyte	O
5	proliferation	O
6	was	O
7	diminished	O
8	.	O

1	A	O
2	decanucleotide	O
3	promoter	O
4	sequence	O
5	homologous	O
6	to	O
7	those	O
8	found	O
9	in	O
10	humans	O
11	and	O
12	mice	O
13	was	O
14	located	O
15	in	O
16	the	O
17	5	O
18	'	O
19	untranslated	O
20	region	O
21	of	O
22	one	O
23	horse	O
24	gene	O
25	.	O

1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	Northern	O
2	analysis	O
3	of	O
4	RNA	O
5	samples	O
6	isolated	O
7	from	O
8	ammonium	O
9	-	O
10	grown	O
11	cultures	O
12	of	O
13	the	O
14	ntcA	B
15	mutant	I
16	showed	O
17	reduced	O
18	amounts	O
19	of	O
20	glnA	B
21	message	I
22	and	O
23	the	O
24	absence	O
25	of	O
26	a	O
27	1	O
28	.	O
29	7	O
30	-	O
31	kb	O
32	transcript	O
33	.	O

1	HER2	B
2	overexpressing	O
3	cells	O
4	showed	O
5	a	O
6	single	O
7	prominent	O
8	DNase	B
9	I	I
10	hypersensitive	O
11	site	O
12	near	O
13	a	O
14	conserved	O
15	and	O
16	hitherto	O
17	unrecognized	O
18	ets	B
19	response	O
20	element	O
21	(	O
22	GAGGAA	O
23	),	O
24	located	O
25	38	O
26	bases	O
27	down	O
28	-	O
29	stream	O
30	from	O
31	the	O
32	CAAT	O
33	box	O
34	and	O
35	directly	O
36	5	O
37	'	O
38	of	O
39	the	O
40	TATA	O
41	box	O
42	in	O
43	the	O
44	human	B
45	HER2	I
46	promoter	I
47	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	with	O
6	nuclear	O
7	extracts	O
8	and	O
9	oligonucleotide	O
10	sequences	O
11	spanning	O
12	the	O
13	0	O
14	.	O
15	125	O
16	-	O
17	kb	O
18	promoter	O
19	region	O
20	detected	O
21	an	O
22	ETS	B
23	-	O
24	immunoreactive	O
25	complex	O
26	,	O
27	present	O
28	most	O
29	abundantly	O
30	in	O
31	cells	O
32	overexpressing	O
33	HER2	B
34	,	O
35	whose	O
36	high	O
37	-	O
38	affinity	O
39	binding	O
40	depended	O
41	on	O
42	the	O
43	GAGGAA	O
44	response	O
45	element	O
46	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	arise	O
12	as	O
13	a	O
14	result	O
15	of	O
16	alternate	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O

1	The	O
2	gene	O
3	for	O
4	the	O
5	RNA	B
6	-	I
7	dependent	I
8	eIF	I
9	-	I
10	2	I
11	alpha	I
12	protein	I
13	kinase	I
14	(	O
15	PKR	B
16	)	O
17	was	O
18	isolated	O
19	from	O
20	mouse	O
21	genomic	O
22	DNA	O
23	and	O
24	characterized	O
25	.	O

1	High	O
2	-	O
3	frequency	O
4	electrical	O
5	stimulation	O
6	in	O
7	the	O
8	hippocampus	O
9	leads	O
10	to	O
11	an	O
12	increase	O
13	in	O
14	synaptic	O
15	efficacy	O
16	that	O
17	lasts	O
18	for	O
19	many	O
20	hours	O
21	.	O

1	Similar	O
2	to	O
3	the	O
4	mouse	O
5	gene	O
6	,	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	of	O
13	human	B
14	CD79	I
15	alpha	I
16	lacks	O
17	a	O
18	TATA	O
19	box	O
20	;	O
21	however	O
22	,	O
23	unlike	O
24	mouse	B
25	CD79	I
26	alpha	I
27	,	O
28	a	O
29	classical	O
30	octamer	O
31	motif	O
32	could	O
33	not	O
34	be	O
35	identified	O
36	in	O
37	the	O
38	human	O
39	gene	O
40	.	O

1	Detailed	O
2	molecular	O
3	organization	O
4	of	O
5	the	O
6	coding	O
7	and	O
8	upstream	O
9	regulatory	O
10	regions	O
11	of	O
12	the	O
13	murine	O
14	homeodomain	B
15	-	I
16	containing	I
17	gene	I
18	,	O
19	Msx	B
20	-	I
21	1	I
22	,	O
23	is	O
24	reported	O
25	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	B
9	goosecoid	I
10	gene	I
11	(	O
12	GSC	B
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O

1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	inherited	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	Kruppel	B
20	-	I
21	related	I
22	sequences	I
23	to	O
24	isolate	O
25	zinc	O
26	finger	O
27	-	O
28	containing	O
29	cDNAs	O
30	.	O

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	O
16	PWV	O
17	):	O
18	the	O
19	deduced	O
20	CP	B
21	sequence	I
22	is	O
23	only	O
24	distantly	O
25	related	O
26	to	O
27	CPs	B
28	of	O
29	other	O
30	sequenced	O
31	strains	O
32	of	O
33	PWV	O
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	The	O
2	ratio	O
3	of	O
4	the	O
5	activity	O
6	of	O
7	arogenate	B
8	dehydrogenase	I
9	to	O
10	that	O
11	of	O
12	prephenate	B
13	dehydrogenase	I
14	(	O
15	approximately	O
16	3	O
17	:	O
18	1	O
19	)	O
20	remained	O
21	constant	O
22	throughout	O
23	purification	O
24	,	O
25	and	O
26	the	O
27	two	O
28	activities	O
29	were	O
30	therefore	O
31	inseparable	O
32	.	O

1	The	O
2	isolated	O
3	POT1	B
4	clones	O
5	hybridized	O
6	to	O
7	a	O
8	1	O
9	.	O
10	4	O
11	kb	O
12	RNA	O
13	species	O
14	,	O
15	which	O
16	was	O
17	induced	O
18	approximately	O
19	30	O
20	-	O
21	fold	O
22	when	O
23	oleate	O
24	was	O
25	the	O
26	carbon	O
27	source	O
28	.	O

1	The	O
2	Y	O
3	.	O
4	lipolytica	O
5	genomic	O
6	POT1	B
7	gene	O
8	was	O
9	disrupted	O
10	by	O
11	replacing	O
12	120	O
13	bp	O
14	of	O
15	its	O
16	coding	O
17	sequence	O
18	with	O
19	2	O
20	.	O
21	7	O
22	kbp	O
23	of	O
24	DNA	O
25	including	O
26	the	O
27	Y	O
28	.	O
29	lipolytica	O
30	LEU2	B
31	gene	I
32	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	B
8	of	I
9	Hairy	I
10	-	I
11	wing	I
12	protein	I
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O

1	The	O
2	predicted	O
3	DNA	O
4	-	O
5	binding	O
6	,	O
7	zinc	B
8	finger	I
9	domain	I
10	protein	I
11	sequence	O
12	was	O
13	strictly	O
14	conserved	O
15	.	O

1	60	O
2	patients	O
3	were	O
4	entered	O
5	into	O
6	a	O
7	randomised	O
8	study	O
9	comparing	O
10	vindesine	O
11	(	O
12	3	O
13	mg	O
14	/	O
15	m2	O
16	/	O
17	week	O
18	)	O
19	plus	O
20	interferon	B
21	-	I
22	alpha	I
23	2b	I
24	(	O
25	6	O
26	U	O
27	/	O
28	m2	O
29	3	O
30	times	O
31	per	O
32	week	O
33	)	O
34	to	O
35	vindesine	O
36	alone	O
37	or	O
38	to	O
39	interferon	B
40	alone	O
41	for	O
42	the	O
43	treatment	O
44	of	O
45	metastatic	O
46	malignant	O
47	melanoma	O
48	.	O

1	The	O
2	novel	O
3	Notch	B
4	homologue	I
5	mouse	I
6	Notch	I
7	3	I
8	lacks	O
9	specific	O
10	epidermal	B
11	growth	I
12	factor	I
13	-	I
14	repeats	I
15	and	O
16	is	O
17	expressed	O
18	in	O
19	proliferating	O
20	neuroepithelium	O
21	.	O

1	BACKGROUND	O
2	:	O
3	We	O
4	conducted	O
5	a	O
6	phase	O
7	I	O
8	study	O
9	with	O
10	MDL	O
11	73	O
12	,	O
13	147EF	O
14	,	O
15	a	O
16	new	O
17	5	B
18	hydroxytryptamine	I
19	3	I
20	(	I
21	5	I
22	-	I
23	HT3	I
24	)	I
25	receptor	I
26	antagonist	O
27	,	O
28	in	O
29	25	O
30	patients	O
31	requiring	O
32	emetogenic	O
33	chemotherapy	O
34	.	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	B
12	,	O
13	thioredoxin	B
14	reductase	I
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	B
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	O
9	and	O
10	exon	O
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	B
18	-	I
19	Myc	I
20	protein	I
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	B
26	/	O
27	Max	B
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O

1	Biological	O
2	activities	O
3	of	O
4	hematopoietic	B
5	growth	I
6	factors	I
7	that	O
8	lead	O
9	to	O
10	future	O
11	clinical	O
12	application	O
13	.	O

1	Expression	O
2	is	O
3	exclusively	O
4	limited	O
5	to	O
6	the	O
7	CNS	O
8	at	O
9	this	O
10	and	O
11	later	O
12	stages	O
13	.	O

1	Immunoreactive	O
2	AR	B
3	content	O
4	in	O
5	transfected	O
6	COS	O
7	-	O
8	1	O
9	cells	O
10	was	O
11	not	O
12	influenced	O
13	by	O
14	exposure	O
15	to	O
16	8	O
17	-	O
18	Br	O
19	-	O
20	cAMP	O
21	.	O

1	Disruption	O
2	of	O
3	any	O
4	one	O
5	of	O
6	the	O
7	four	O
8	genes	O
9	encoding	O
10	the	O
11	newly	O
12	identified	O
13	SRP	B
14	proteins	I
15	results	O
16	in	O
17	slow	O
18	cell	O
19	growth	O
20	and	O
21	inefficient	O
22	protein	O
23	translocation	O
24	across	O
25	the	O
26	ER	O
27	membrane	O
28	.	O

1	Genetic	O
2	alterations	O
3	in	O
4	elements	O
5	of	O
6	normal	O
7	signal	O
8	transduction	O
9	mechanisms	O
10	are	O
11	known	O
12	to	O
13	be	O
14	oncogenic	O
15	events	O
16	often	O
17	resulting	O
18	in	O
19	aberrant	O
20	activation	O
21	of	O
22	programs	O
23	of	O
24	gene	O
25	transcription	O
26	.	O

1	The	O
2	expression	O
3	pattern	O
4	of	O
5	GL2	B
6	,	O
7	as	O
8	demonstrated	O
9	by	O
10	in	O
11	situ	O
12	hybridization	O
13	,	O
14	indicated	O
15	that	O
16	the	O
17	gene	O
18	is	O
19	expressed	O
20	in	O
21	trichome	O
22	progenitor	O
23	cells	O
24	and	O
25	at	O
26	stages	O
27	associated	O
28	with	O
29	trichome	O
30	development	O
31	.	O

1	NOT4	B
2	interacts	O
3	with	O
4	NOT1	B
5	and	O
6	NOT3	B
7	in	O
8	the	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	,	O
14	and	O
15	overexpression	O
16	of	O
17	NOT3	B
18	or	O
19	NOT4	B
20	suppresses	O
21	not1	B
22	and	O
23	not2	B
24	mutations	O
25	.	O

1	Binding	O
2	site	O
3	selection	O
4	using	O
5	in	O
6	vitro	O
7	-	O
8	synthesized	O
9	proteins	O
10	reveals	O
11	that	O
12	the	O
13	ROR	B
14	alpha	I
15	1	I
16	and	O
17	ROR	B
18	alpha	I
19	2	I
20	isoforms	I
21	bind	O
22	DNA	O
23	as	O
24	monomers	O
25	to	O
26	hormone	O
27	response	O
28	elements	O
29	composed	O
30	of	O
31	a	O
32	6	O
33	-	O
34	bp	O
35	AT	O
36	-	O
37	rich	O
38	sequence	O
39	preceding	O
40	a	O
41	half	O
42	-	O
43	site	O
44	core	O
45	motif	O
46	PuGGTCA	O
47	(	O
48	RORE	B
49	).	O

1	The	O
2	p73pct1	B
3	/	O
4	p85cdc10	B
5	complex	O
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	MCB	B
15	but	O
16	not	O
17	SCB	B
18	or	O
19	E2F	B
20	sites	I
21	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	B
6	stripes	O
7	expand	O
8	anteriorly	O
9	in	O
10	slp	B
11	mutant	O
12	embryos	O
13	and	O
14	that	O
15	slp	B
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	B
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	B
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	B
37	.	O

1	The	O
2	DNA	O
3	sequence	O
4	adjacent	O
5	to	O
6	the	O
7	lacZ	B
8	gene	I
9	has	O
10	been	O
11	determined	O
12	for	O
13	91	O
14	vegetative	O
15	fusion	O
16	genes	O
17	whose	O
18	products	O
19	have	O
20	been	O
21	localized	O
22	and	O
23	for	O
24	43	O
25	meiotically	O
26	induced	O
27	fusions	O
28	.	O

1	CMV	O
2	hyperimmunoglobulin	B
3	treatment	O
4	(	O
5	Cytotect	O
6	,	O
7	Biotest	O
8	)	O
9	was	O
10	started	O
11	(	O
12	2	O
13	ml	O
14	/	O
15	kg	O
16	bw	O
17	on	O
18	day	O
19	1	O
20	and	O
21	3	O
22	,	O
23	and	O
24	1	O
25	ml	O
26	/	O
27	kg	O
28	on	O
29	days	O
30	5	O
31	,	O
32	7	O
33	and	O
34	9	O
35	),	O
36	which	O
37	led	O
38	to	O
39	the	O
40	eradication	O
41	of	O
42	the	O
43	residual	O
44	infiltrate	O
45	and	O
46	CMV	O
47	-	O
48	DNA	O
49	in	O
50	the	O
51	myocardium	O
52	.	O

1	Internal	O
2	biliary	O
3	drainage	O
4	,	O
5	unlike	O
6	external	O
7	drainage	O
8	,	O
9	does	O
10	not	O
11	suppress	O
12	the	O
13	regeneration	O
14	of	O
15	cholestatic	O
16	rat	O
17	liver	O
18	after	O
19	partial	O
20	hepatectomy	O
21	.	O

1	ORF	O
2	2	O
3	potentially	O
4	encoded	O
5	a	O
6	hydrophobic	O
7	protein	O
8	of	O
9	29	O
10	,	O
11	705	O
12	Da	O
13	with	O
14	six	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	regions	O
20	.	O

1	In	O
2	eight	O
3	groups	O
4	of	O
5	subjects	O
6	operating	O
7	various	O
8	hand	O
9	-	O
10	held	O
11	vibrating	O
12	tools	O
13	and	O
14	aged	O
15	from	O
16	30	O
17	to	O
18	59	O
19	years	O
20	,	O
21	the	O
22	prevalence	O
23	rates	O
24	of	O
25	vibration	O
26	-	O
27	induced	O
28	white	O
29	finger	O
30	(	O
31	VWF	O
32	)	O
33	and	O
34	numbness	O
35	,	O
36	pain	O
37	,	O
38	or	O
39	stiffness	O
40	in	O
41	the	O
42	upper	O
43	and	O
44	lower	O
45	extremities	O
46	were	O
47	investigated	O
48	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	gene	O
8	was	O
9	525	O
10	bp	O
11	long	O
12	and	O
13	encoded	O
14	a	O
15	175	O
16	-	O
17	amino	O
18	-	O
19	acid	O
20	protein	O
21	with	O
22	a	O
23	molecular	O
24	weight	O
25	of	O
26	19	O
27	,	O
28	094	O
29	containing	O
30	a	O
31	21	O
32	-	O
33	residue	O
34	typical	O
35	lipoprotein	O
36	signal	O
37	peptide	O
38	and	O
39	consensus	O
40	prolipoprotein	O
41	processing	O
42	site	O
43	.	O

1	DNA	O
2	sequence	O
3	and	O
4	functions	O
5	of	O
6	the	O
7	actVI	B
8	region	I
9	of	O
10	the	O
11	actinorhodin	O
12	biosynthetic	O
13	gene	O
14	cluster	O
15	of	O
16	Streptomyces	O
17	coelicolor	O
18	A3	O
19	(	O
20	2	O
21	).	O

1	(	O
2	1992	O
3	)	O
4	Genomics	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	polypeptide	O
7	sequence	O
8	of	O
9	the	O
10	Drosophila	O
11	protein	O
12	with	O
13	the	O
14	equivalent	O
15	subunits	O
16	from	O
17	mouse	O
18	and	O
19	yeast	O
20	suggests	O
21	that	O
22	they	O
23	are	O
24	closely	O
25	related	O
26	and	O
27	defines	O
28	three	O
29	conserved	O
30	regions	O
31	which	O
32	are	O
33	likely	O
34	to	O
35	be	O
36	important	O
37	for	O
38	enzyme	O
39	activity	O
40	.	O

1	Plasmids	O
2	were	O
3	constructed	O
4	with	O
5	the	O
6	mouse	O
7	promoter	O
8	region	O
9	linked	O
10	to	O
11	the	O
12	reporter	B
13	gene	I
14	chloramphenicol	I
15	acetyltransferase	I
16	(	O
17	CAT	B
18	),	O
19	and	O
20	transiently	O
21	and	O
22	stably	O
23	transfected	O
24	in	O
25	the	O
26	INS	O
27	-	O
28	1	O
29	cells	O
30	.	O

1	Cytoplasmic	B
2	dynein	I
3	is	O
4	a	O
5	multisubunit	O
6	,	O
7	microtubule	O
8	-	O
9	dependent	O
10	mechanochemical	O
11	enzyme	O
12	that	O
13	has	O
14	been	O
15	proposed	O
16	to	O
17	function	O
18	in	O
19	a	O
20	variety	O
21	of	O
22	intracellular	O
23	movements	O
24	,	O
25	including	O
26	minus	O
27	-	O
28	end	O
29	-	O
30	directed	O
31	transport	O
32	of	O
33	organelles	O
34	.	O

1	Identification	O
2	of	O
3	the	O
4	plakoglobin	B
5	-	O
6	binding	O
7	domain	O
8	in	O
9	desmoglein	B
10	and	O
11	its	O
12	role	O
13	in	O
14	plaque	O
15	assembly	O
16	and	O
17	intermediate	O
18	filament	O
19	anchorage	O
20	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	One	O
6	hundred	O
7	eighty	O
8	-	O
9	four	O
10	chemotherapy	O
11	-	O
12	naive	O
13	patients	O
14	receiving	O
15	high	O
16	-	O
17	dose	O
18	cisplatin	O
19	(	O
20	81	O
21	to	O
22	120	O
23	mg	O
24	/	O
25	m2	O
26	)	O
27	were	O
28	randomized	O
29	to	O
30	receive	O
31	one	O
32	of	O
33	four	O
34	granisetron	O
35	doses	O
36	(	O
37	5	O
38	,	O
39	10	O
40	,	O
41	20	O
42	,	O
43	or	O
44	40	O
45	micrograms	O
46	/	O
47	kg	O
48	)	O
49	administered	O
50	before	O
51	chemotherapy	O
52	.	O

1	Nine	O
2	new	O
3	naphthalene	O
4	related	O
5	compounds	O
6	(	O
7	I	O
8	,	O
9	IV	O
10	,	O
11	V	O
12	,	O
13	VII	O
14	-	O
15	XII	O
16	)	O
17	together	O
18	with	O
19	four	O
20	known	O
21	compounds	O
22	(	O
23	II	O
24	,	O
25	III	O
26	,	O
27	VI	O
28	,	O
29	XIII	O
30	)	O
31	were	O
32	isolated	O
33	from	O
34	the	O
35	root	O
36	bark	O
37	of	O
38	Oroxylum	O
39	indicum	O
40	Vent	O
41	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	Mutually	O
2	exclusive	O
3	interaction	O
4	of	O
5	the	O
6	adenovirus	B
7	E4	I
8	-	I
9	6	I
10	/	I
11	7	I
12	protein	I
13	and	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	with	O
19	internal	O
20	domains	O
21	of	O
22	E2F	B
23	-	I
24	1	I
25	and	O
26	DP	B
27	-	I
28	1	I
29	.	O

1	As	O
2	shown	O
3	previously	O
4	,	O
5	EBNA2	B
6	transactivates	O
7	the	O
8	promoters	O
9	of	O
10	the	O
11	viral	B
12	latent	I
13	membrane	I
14	proteins	I
15	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	,	O
9	the	O
10	oncoprotein	O
11	of	O
12	the	O
13	avian	O
14	retrovirus	O
15	Rev	O
16	-	O
17	T	O
18	,	O
19	can	O
20	increase	O
21	expression	O
22	from	O
23	promoters	O
24	containing	O
25	binding	O
26	sites	O
27	for	O
28	the	O
29	cellular	O
30	transcription	O
31	factor	O
32	Sp1	B
33	in	O
34	chicken	O
35	embryo	O
36	fibroblasts	O
37	(	O
38	S	O
39	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	O
16	induced	O
17	HIV	O
18	-	O
19	1	O
20	gene	O
21	expression	O
22	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	sequence	O
7	of	O
8	the	O
9	p54	B
10	gene	I
11	carried	O
12	by	O
13	two	O
14	virulent	O
15	ASFV	O
16	strains	O
17	(	O
18	E70	O
19	and	O
20	E75	O
21	)	O
22	with	O
23	that	O
24	obtained	O
25	from	O
26	virus	O
27	Ba71V	O
28	showed	O
29	100	O
30	%	O
31	similarity	O
32	.	O

1	The	O
2	p55	B
3	mRNA	I
4	is	O
5	undetectable	O
6	in	O
7	non	O
8	-	O
9	EBV	O
10	-	O
11	infected	O
12	B	O
13	-	O
14	and	O
15	T	O
16	-	O
17	cell	O
18	lines	O
19	or	O
20	in	O
21	a	O
22	myelomonocytic	O
23	cell	O
24	line	O
25	(	O
26	U937	O
27	).	O

1	A	O
2	simple	O
3	registration	O
4	as	O
5	an	O
6	incentive	O
7	for	O
8	improvement	O

1	The	O
2	transverse	O
3	magnetization	O
4	decays	O
5	mentioned	O
6	above	O
7	exhibited	O
8	two	O
9	components	O
10	,	O
11	a	O
12	T2	O
13	fast	O
14	(	O
15	T2f	O
16	)	O
17	and	O
18	a	O
19	T2	O
20	slow	O
21	(	O
22	T2s	O
23	)	O
24	component	O
25	.	O

1	RESULTS	O
2	:	O
3	The	O
4	diagnostic	O
5	quality	O
6	of	O
7	FDG	O
8	images	O
9	was	O
10	at	O
11	least	O
12	as	O
13	good	O
14	as	O
15	that	O
16	of	O
17	their	O
18	Tl	O
19	-	O
20	201	O
21	counterparts	O
22	,	O
23	with	O
24	less	O
25	liver	O
26	background	O
27	in	O
28	all	O
29	but	O
30	one	O
31	FDG	O
32	study	O
33	.	O

1	The	O
2	coordinated	O
3	expression	O
4	of	O
5	CD4	B
6	and	O
7	CD8	B
8	during	O
9	T	O
10	-	O
11	cell	O
12	development	O
13	is	O
14	tightly	O
15	coupled	O
16	with	O
17	the	O
18	maturation	O
19	state	O
20	of	O
21	the	O
22	T	O
23	cell	O
24	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	B
12	/	O
13	PGS2	B
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O

1	The	O
2	dying	O
3	tTG	B
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	-	O
6	mediated	O
7	mapping	O
8	technique	O
9	,	O
10	we	O
11	show	O
12	that	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	CstF	B
20	can	O
21	be	O
22	photo	O
23	cross	O
24	-	O
25	linked	O
26	to	O
27	pre	O
28	-	O
29	mRNAs	O
30	at	O
31	U	O
32	-	O
33	rich	O
34	regions	O
35	located	O
36	downstream	O
37	of	O
38	the	O
39	cleavage	O
40	site	O
41	of	O
42	the	O
43	simian	O
44	virus	O
45	40	O
46	late	O
47	and	O
48	adenovirus	B
49	L3	I
50	pre	I
51	-	I
52	mRNAs	I
53	.	O

1	The	O
2	protein	O
3	encoded	O
4	is	O
5	114	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	diazepam	B
8	-	I
9	binding	I
10	inhibitor	I
11	in	O
12	Drosophila	O
13	melanogaster	O
14	:	O
15	cloning	O
16	,	O
17	structure	O
18	,	O
19	and	O
20	localization	O
21	of	O
22	the	O
23	gene	O
24	.	O

1	Using	O
2	a	O
3	v	B
4	-	I
5	erbA	I
6	probe	O
7	,	O
8	we	O
9	obtained	O
10	a	O
11	cDNA	O
12	which	O
13	encodes	O
14	a	O
15	novel	O
16	445	O
17	-	O
18	amino	O
19	-	O
20	acid	O
21	protein	O
22	,	O
23	RLD	B
24	-	I
25	1	I
26	,	O
27	that	O
28	contains	O
29	the	O
30	characteristic	O
31	domains	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O

1	Only	O
2	two	O
3	of	O
4	the	O
5	isoforms	O
6	possess	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	zinc	O
12	finger	O
13	domain	O
14	that	O
15	is	O
16	necessary	O
17	and	O
18	sufficient	O
19	for	O
20	TdT	B
21	promoter	I
22	binding	O
23	.	O

1	This	O
2	study	O
3	provides	O
4	direct	O
5	evidence	O
6	that	O
7	USF	B
8	,	O
9	a	O
10	member	O
11	of	O
12	the	O
13	basic	B
14	helix	I
15	-	I
16	loop	I
17	-	I
18	helix	I
19	leucine	I
20	zipper	I
21	family	I
22	,	O
23	binds	O
24	to	O
25	MLE1	B
26	,	O
27	HF	B
28	-	I
29	1a	I
30	,	O
31	and	O
32	PRE	B
33	B	I
34	sites	I
35	and	O
36	suggests	O
37	that	O
38	it	O
39	is	O
40	a	O
41	component	O
42	of	O
43	protein	O
44	complexes	O
45	that	O
46	may	O
47	coordinately	O
48	control	O
49	the	O
50	expression	O
51	of	O
52	MLC	B
53	-	I
54	2v	I
55	and	O
56	alpha	B
57	-	I
58	myosin	I
59	heavy	I
60	-	I
61	chain	I
62	genes	I
63	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	Tax	B
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappa	I
15	B	I
16	/	O
17	Rel	B
18	involves	O
19	phosphorylation	O
20	and	O
21	degradation	O
22	of	O
23	I	B
24	kappa	I
25	B	I
26	alpha	I
27	and	O
28	RelA	O
29	(	O
30	p65	O
31	)-	O
32	mediated	O
33	induction	O
34	of	O
35	the	O
36	c	B
37	-	I
38	rel	I
39	gene	I
40	.	O

1	Activation	O
2	of	O
3	c	B
4	-	I
5	fos	I
6	gene	I
7	expression	O
8	by	O
9	a	O
10	kinase	O
11	-	O
12	deficient	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	.	O

1	Because	O
2	endogenous	O
3	HSF	B
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	is	O
9	low	O
10	and	O
11	anti	B
12	-	I
13	hHSF1	I
14	antibody	I
15	does	O
16	not	O
17	recognize	O
18	Xenopus	B
19	HSF	I
20	,	O
21	we	O
22	employed	O
23	this	O
24	system	O
25	for	O
26	mapping	O
27	regions	O
28	in	O
29	hHSF1	B
30	that	O
31	are	O
32	required	O
33	for	O
34	the	O
35	maintenance	O
36	of	O
37	the	O
38	monomeric	O
39	state	O
40	.	O

1	Enhancers	O
2	containing	O
3	disrupted	O
4	Ets	B
5	-	I
6	1	I
7	binding	I
8	sites	I
9	were	O
10	tested	O
11	in	O
12	transient	O
13	expression	O
14	assays	O
15	in	O
16	the	O
17	murine	O
18	T	O
19	-	O
20	cell	O
21	line	O
22	EL4	O
23	.	O
24	E1	O
25	;	O
26	alterations	O
27	in	O
28	the	O
29	LVb	O
30	element	O
31	affected	O
32	constitutive	O
33	enhancer	O
34	activity	O
35	,	O
36	while	O
37	mutation	O
38	of	O
39	either	O
40	the	O
41	LVb	O
42	or	O
43	LVc	O
44	element	O
45	disrupted	O
46	phorbol	O
47	ester	O
48	-	O
49	induced	O
50	enhancer	O
51	activity	O
52	.	O

1	The	O
2	predominant	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	Ets	B
8	-	I
9	1	I
10	but	O
11	rather	O
12	two	O
13	independent	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	that	O
19	comigrated	O
20	in	O
21	mobility	O
22	shift	O
23	assays	O
24	.	O

1	These	O
2	RZR	B
3	subtypes	O
4	represent	O
5	members	O
6	of	O
7	a	O
8	new	O
9	family	O
10	of	O
11	orphan	B
12	nuclear	I
13	receptors	I
14	that	O
15	most	O
16	likely	O
17	regulate	O
18	specific	O
19	gene	O
20	expression	O
21	.	O

1	Interestingly	O
2	,	O
3	these	O
4	response	O
5	elements	O
6	display	O
7	dramatically	O
8	reduced	O
9	affinity	O
10	for	O
11	retinoic	B
12	acid	I
13	receptor	I
14	-	O
15	retinoid	B
16	-	I
17	X	I
18	receptor	I
19	heterodimers	O
20	.	O

1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	B
7	(	I
8	trp	I
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	I
15	mitochondria	I
16	is	O
17	also	O
18	reported	O
19	.	O

1	The	O
2	parameters	O
3	of	O
4	nonspecific	O
5	humoral	O
6	immunity	O
7	--	O
8	serum	B
9	immunoglobulins	I
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	irradiated	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	cervix	O
24	carcinoma	O
25	(	O
26	Stages	O
27	IIB	O
28	and	O
29	IIIB	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O

1	Mutation	O
2	of	O
3	KRKR	O
4	to	O
5	NGER	O
6	retains	O
7	MO15	B
8	in	O
9	the	O
10	cytoplasmic	O
11	compartment	O
12	,	O
13	whilst	O
14	the	O
15	wild	O
16	-	O
17	type	O
18	protein	O
19	is	O
20	detected	O
21	exclusively	O
22	in	O
23	the	O
24	nucleus	O
25	.	O

1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	O
10	in	O
11	cells	O
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	B
28	alpha	I
29	promoter	I
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	O
46	levels	O
47	.	O

1	Strikingly	O
2	,	O
3	this	O
4	subdomain	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	p58c	B
19	-	I
20	ets	I
21	-	I
22	2	I
23	and	O
24	was	O
25	thus	O
26	named	O
27	BEC	B
28	for	O
29	Ets	B
30	-	I
31	1	I
32	-	I
33	beta	I
34	/	O
35	Ets	B
36	-	I
37	2	I
38	-	I
39	Conserved	I
40	sequence	I
41	.	O

1	This	O
2	work	O
3	unravels	O
4	a	O
5	new	O
6	model	O
7	for	O
8	the	O
9	ets	B
10	-	I
11	1	I
12	/	O
13	ets	B
14	-	I
15	2	I
16	gene	I
17	'	O
18	s	O
19	evolution	O
20	,	O
21	based	O
22	for	O
23	the	O
24	first	O
25	time	O
26	on	O
27	both	O
28	structural	O
29	and	O
30	functional	O
31	evidences	O
32	.	O

1	The	O
2	v	B
3	-	I
4	ets	I
5	oncogene	I
6	of	O
7	the	O
8	avian	O
9	retrovirus	O
10	E26	O
11	differs	O
12	from	O
13	its	O
14	cellular	O
15	progenitor	O
16	p68c	B
17	-	I
18	ets	I
19	-	I
20	1	I
21	by	O
22	two	O
23	amino	O
24	acid	O
25	substitutions	O
26	(	O
27	alanine	O
28	285	O
29	and	O
30	isoleucine	O
31	445	O
32	in	O
33	c	B
34	-	I
35	ets	I
36	-	I
37	1	I
38	both	O
39	substituted	O
40	by	O
41	valine	O
42	in	O
43	v	B
44	-	I
45	ets	I
46	,	O
47	mutations	O
48	A	O
49	and	O
50	B	O
51	respectively	O
52	)	O
53	and	O
54	its	O
55	carboxy	O
56	-	O
57	terminal	O
58	end	O
59	(	O
60	mutation	O
61	C	O
62	).	O

1	Consequently	O
2	functional	O
3	mRNAs	O
4	can	O
5	be	O
6	produced	O
7	by	O
8	endogenous	B
9	RNA	I
10	polymerase	I
11	I	O
12	.	O

1	The	O
2	individual	O
3	subunits	O
4	of	O
5	Ku	B
6	have	O
7	been	O
8	difficult	O
9	to	O
10	isolate	O
11	from	O
12	human	O
13	cells	O
14	without	O
15	denaturation	O
16	and	O
17	attempts	O
18	to	O
19	produce	O
20	functional	B
21	recombinant	I
22	Ku	I
23	have	O
24	been	O
25	largely	O
26	unsuccessful	O
27	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	B
19	early	I
20	regions	I
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O

1	Remarkably	O
2	,	O
3	U21	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O

1	A	O
2	genetic	O
3	system	O
4	was	O
5	devised	O
6	to	O
7	select	O
8	for	O
9	pi	B
10	protein	I
11	mutants	I
12	which	O
13	discriminate	O
14	between	O
15	IR	O
16	and	O
17	DR	O
18	(	O
19	York	O
20	et	O
21	al	O
22	.,	O
23	Gene	O
24	(	O
25	Amst	O
26	.)	O
27	116	O
28	,	O
29	7	O
30	-	O
31	12	O
32	,	O
33	1992	O
34	;	O
35	York	O
36	and	O
37	Filutowicz	O
38	,	O
39	J	O
40	.	O

1	Univariate	O
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	O
7	-	O
8	Meier	O
9	-	O
10	estimates	O
11	and	O
12	Log	O
13	-	O
14	Rank	O
15	-	O
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	B
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	O
51	alkaline	B
52	phosphatase	I
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	O
68	albumin	B
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	HBx	B
2	strongly	O
3	elevates	O
4	levels	O
5	of	O
6	GTP	O
7	-	O
8	bound	O
9	Ras	B
10	,	O
11	activated	O
12	and	O
13	phosphorylated	O
14	Raf	B
15	,	O
16	and	O
17	tyrosine	O
18	-	O
19	phosphorylated	O
20	and	O
21	activated	O
22	MAP	B
23	kinase	I
24	.	O

1	Role	O
2	of	O
3	c	B
4	-	I
5	myc	I
6	in	O
7	simian	B
8	virus	I
9	40	I
10	large	I
11	tumor	I
12	antigen	I
13	-	O
14	induced	O
15	DNA	O
16	synthesis	O
17	in	O
18	quiescent	O
19	3T3	O
20	-	O
21	L1	O
22	mouse	O
23	fibroblasts	O
24	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	Laser	O
2	therapy	O
3	of	O
4	penile	O
5	carcinoma	O

1	A	O
2	15	O
3	.	O
4	1	O
5	kb	O
6	fragment	O
7	of	O
8	the	O
9	yeast	O
10	genome	O
11	was	O
12	allocated	O
13	to	O
14	the	O
15	centromeric	O
16	region	O
17	of	O
18	chromosome	O
19	XIV	O
20	by	O
21	genetic	O
22	mapping	O
23	.	O

1	A	O
2	third	O
3	one	O
4	is	O
5	homologous	O
6	in	O
7	half	O
8	of	O
9	its	O
10	length	O
11	to	O
12	the	O
13	prokaryotic	B
14	hydantoinase	I
15	HyuA	I
16	and	O
17	in	O
18	the	O
19	other	O
20	half	O
21	to	O
22	hydatoinase	B
23	HyuB	I
24	.	O

1	It	O
2	was	O
3	shown	O
4	that	O
5	estradiol	O
6	concentrations	O
7	obtained	O
8	after	O
9	estradiol	O
10	valerate	O
11	and	O
12	micronized	O
13	estradiol	O
14	ingestion	O
15	were	O
16	dependent	O
17	on	O
18	the	O
19	patient	O
20	'	O
21	s	O
22	age	O
23	as	O
24	well	O
25	as	O
26	on	O
27	the	O
28	constitutional	O
29	type	O
30	.	O

1	There	O
2	were	O
3	9	O
4	patients	O
5	in	O
6	NYHA	O
7	class	O
8	III	O
9	and	O
10	8	O
11	in	O
12	class	O
13	IV	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	Constipation	O
2	is	O
3	not	O
4	a	O
5	risk	O
6	factor	O
7	for	O
8	hemorrhoids	O
9	:	O
10	a	O
11	case	O
12	-	O
13	control	O
14	study	O
15	of	O
16	potential	O
17	etiological	O
18	agents	O
19	.	O

1	Of	O
2	419	O
3	persons	O
4	surveyed	O
5	,	O
6	207	O
7	(	O
8	49	O
9	.	O
10	4	O
11	%)	O
12	were	O
13	antigen	O
14	-	O
15	positive	O
16	with	O
17	the	O
18	Og4C3	B
19	assay	O
20	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	Vibrio	O
2	cholerae	O
3	O139	O
4	in	O
5	Calcutta	O
6	.	O

1	Ten	O
2	volunteers	O
3	were	O
4	tested	O
5	at	O
6	18	O
7	,	O
8	000	O
9	ft	O
10	(	O
11	5	O
12	,	O
13	486	O
14	m	O
15	),	O
16	and	O
17	through	O
18	12	O
19	,	O
20	000	O
21	,	O
22	8	O
23	,	O
24	000	O
25	,	O
26	and	O
27	5	O
28	,	O
29	000	O
30	ft	O
31	(	O
32	3	O
33	,	O
34	657	O
35	,	O
36	2	O
37	,	O
38	438	O
39	,	O
40	and	O
41	1	O
42	,	O
43	524	O
44	m	O
45	)	O
46	with	O
47	directional	O
48	sounds	O
49	recorded	O
50	via	O
51	a	O
52	dummy	O
53	head	O
54	microphone	O
55	and	O
56	presented	O
57	binaurally	O
58	.	O

1	Upon	O
2	differentiation	O
3	with	O
4	retinoic	O
5	acid	O
6	(	O
7	RA	O
8	),	O
9	transcription	O
10	of	O
11	the	O
12	Rex	B
13	-	I
14	1	I
15	gene	I
16	decreases	O
17	rapidly	O
18	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	zebrafish	B
6	egr1	I
7	coding	I
8	region	I
9	revealed	O
10	a	O
11	high	O
12	level	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	mouse	O
18	,	O
19	rat	O
20	,	O
21	and	O
22	human	B
23	Egr1	I
24	genes	I
25	with	O
26	the	O
27	notable	O
28	exception	O
29	of	O
30	a	O
31	polymorphic	O
32	,	O
33	triplet	O
34	nucleotide	O
35	repeat	O
36	sequence	O
37	in	O
38	the	O
39	region	O
40	coding	O
41	for	O
42	the	O
43	amino	O
44	terminus	O
45	of	O
46	the	O
47	Egr1	B
48	protein	I
49	.	O

1	The	O
2	fibrinogen	B
3	,	O
4	serum	O
5	proteins	O
6	,	O
7	sodium	O
8	heparin	O
9	and	O
10	membrane	O
11	contributed	O
12	to	O
13	Cm	O
14	by	O
15	20	O
16	%,	O
17	14	O
18	%,	O
19	2	O
20	%	O
21	and	O
22	64	O
23	%,	O
24	respectively	O
25	.	O

1	In	O
2	these	O
3	vectors	O
4	the	O
5	chimeric	B
6	long	I
7	terminal	I
8	repeat	I
9	(	O
10	chLTR	B
11	)	O
12	drives	O
13	the	O
14	expression	O
15	of	O
16	the	O
17	chloramphenicol	B
18	acetyl	I
19	transferase	I
20	(	O
21	CAT	B
22	)	O
23	reporter	O
24	gene	O
25	that	O
26	is	O
27	followed	O
28	by	O
29	an	O
30	internal	O
31	SV40	B
32	virus	I
33	early	I
34	region	I
35	promoter	I
36	linked	O
37	to	O
38	the	O
39	neomycin	B
40	phosphotransferase	I
41	II	I
42	(	O
43	NEO	B
44	)	O
45	gene	O
46	.	O

1	Optima	O
2	)	O
3	genomic	O
4	library	O
5	by	O
6	hybridizing	O
7	with	O
8	elicitor	O
9	-	O
10	induced	O
11	stilbene	B
12	synthase	I
13	cDNA	I
14	as	O
15	a	O
16	probe	O
17	.	O

1	A	O
2	total	O
3	of	O
4	125	O
5	acute	O
6	leukemia	O
7	adult	O
8	patients	O
9	were	O
10	autografted	O
11	with	O
12	bone	O
13	marrow	O
14	(	O
15	BM	O
16	)	O
17	purged	O
18	by	O
19	mafosfamide	O
20	(	O
21	ASTA	O
22	Z	O
23	)	O
24	during	O
25	the	O
26	period	O
27	of	O
28	January	O
29	1983	O
30	to	O
31	January	O
32	1993	O
33	.	O

1	The	O
2	pretransplant	O
3	regimen	O
4	consisted	O
5	of	O
6	cyclophosphamide	O
7	(	O
8	120	O
9	mg	O
10	/	O
11	kg	O
12	)	O
13	and	O
14	total	O
15	body	O
16	irradiation	O
17	.	O

1	The	O
2	site	O
3	-	O
4	directed	O
5	mutation	O
6	of	O
7	the	O
8	kappa	B
9	B	I
10	motif	I
11	in	O
12	IL	B
13	-	I
14	6	I
15	/	O
16	CAT	B
17	plasmid	O
18	resulted	O
19	in	O
20	the	O
21	complete	O
22	abrogation	O
23	of	O
24	IL	B
25	-	I
26	6	I
27	promoter	I
28	activity	O
29	in	O
30	these	O
31	cells	O
32	.	O

1	Curiously	O
2	,	O
3	testololactone	O
4	was	O
5	earlier	O
6	and	O
7	more	O
8	widely	O
9	used	O
10	than	O
11	aminoglutethimide	O
12	in	O
13	treating	O
14	advanced	O
15	breast	O
16	carcinoma	O
17	.	O

1	Use	O
2	of	O
3	the	O
4	vena	O
5	cava	O
6	to	O
7	extend	O
8	the	O
9	right	O
10	renal	O
11	vein	O
12	for	O
13	cadaver	O
14	transplantation	O
15	is	O
16	controversial	O
17	.	O

1	Enhanced	O
2	hepatic	O
3	portal	O
4	blood	O
5	flow	O
6	induced	O
7	by	O
8	prostaglandin	O
9	E1	O
10	following	O
11	liver	O
12	transplantation	O
13	in	O
14	pigs	O
15	.	O

1	One	O
2	gene	O
3	appears	O
4	ubiquitously	O
5	expressed	O
6	while	O
7	the	O
8	other	O
9	is	O
10	prominently	O
11	expressed	O
12	in	O
13	muscle	O
14	.	O

1	For	O
2	HeLa	O
3	,	O
4	293	O
5	,	O
6	U937	O
7	,	O
8	and	O
9	A549	O
10	cells	O
11	,	O
12	participation	O
13	of	O
14	E2F	B
15	-	I
16	1	I
17	,	O
18	DP	B
19	-	I
20	1	I
21	,	O
22	cyclin	B
23	A	I
24	,	O
25	and	O
26	RB	B
27	was	O
28	involved	O
29	in	O
30	formation	O
31	of	O
32	some	O
33	complexes	O
34	only	O
35	,	O
36	assuming	O
37	participation	O
38	of	O
39	factors	O
40	different	O
41	from	O
42	E2F	B
43	-	I
44	1	I
45	or	O
46	DP	B
47	-	I
48	1	I
49	in	O
50	others	O
51	.	O

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	O

1	Cestode	O
2	invasion	O
3	in	O
4	irradiated	O
5	host	O
6	organism	O
7	increases	O
8	the	O
9	negative	O
10	effect	O
11	of	O
12	ionizing	O
13	radiation	O
14	on	O
15	the	O
16	hamster	O
17	immune	O
18	system	O
19	.	O

1	During	O
2	heat	O
3	exposure	O
4	,	O
5	chicks	O
6	that	O
7	had	O
8	been	O
9	subjected	O
10	to	O
11	early	O
12	60	O
13	%	O
14	restriction	O
15	with	O
16	non	O
17	-	O
18	metyrapone	O
19	-	O
20	treated	O
21	food	O
22	had	O
23	lower	O
24	H	O
25	/	O
26	L	O
27	ratios	O
28	and	O
29	improved	O
30	resistance	O
31	to	O
32	marble	O
33	spleen	O
34	disease	O
35	infection	O
36	.	O

1	Analyses	O
2	of	O
3	additional	O
4	tumors	O
5	induced	O
6	in	O
7	mice	O
8	from	O
9	two	O
10	reciprocal	O
11	crosses	O
12	,	O
13	A	O
14	/	O
15	J	O
16	x	O
17	C3H	O
18	/	O
19	HeJ	O
20	F1	O
21	(	O
22	hereafter	O
23	called	O
24	AC3F1	O
25	)	O
26	and	O
27	C3H	O
28	/	O
29	HeJ	O
30	x	O
31	A	O
32	/	O
33	J	O
34	F1	O
35	(	O
36	hereafter	O
37	called	O
38	C3AF1	O
39	),	O
40	provided	O
41	evidence	O
42	for	O
43	the	O
44	inactivation	O
45	of	O
46	one	O
47	allele	O
48	of	O
49	the	O
50	putative	O
51	chromosome	O
52	4	O
53	tumor	O
54	suppressor	O
55	gene	O
56	by	O
57	parental	O
58	imprinting	O
59	.	O

1	ERV1	B
2	is	O
3	involved	O
4	in	O
5	the	O
6	cell	O
7	-	O
8	division	O
9	cycle	O
10	and	O
11	the	O
12	maintenance	O
13	of	O
14	mitochondrial	O
15	genomes	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

1	Lesion	O
2	diameters	O
3	of	O
4	greater	O
5	than	O
6	20	O
7	mm	O
8	and	O
9	the	O
10	large	O
11	sessile	O
12	-	O
13	type	O
14	configurations	O
15	were	O
16	factors	O
17	that	O
18	were	O
19	associated	O
20	with	O
21	incomplete	O
22	removal	O
23	.	O

1	Routinely	O
2	collected	O
3	,	O
4	processed	O
5	and	O
6	stored	O
7	breast	O
8	cancer	O
9	tissue	O
10	blocks	O
11	recovered	O
12	from	O
13	the	O
14	archives	O
15	of	O
16	the	O
17	Pathology	O
18	laboratory	O
19	in	O
20	Dar	O
21	es	O
22	Salaam	O
23	after	O
24	storage	O
25	of	O
26	up	O
27	to	O
28	3	O
29	years	O
30	were	O
31	analysed	O
32	by	O
33	a	O
34	flow	O
35	cytometry	O
36	for	O
37	DNA	O
38	ploidy	O
39	and	O
40	S	O
41	-	O
42	phase	O
43	fraction	O
44	.	O

1	Cbf3	B
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	Cbf3a	B
7	,	O
8	Cbf3b	B
9	and	O
10	Cbf3c	B
11	.	O

1	Such	O
2	an	O
3	interaction	O
4	could	O
5	be	O
6	detected	O
7	using	O
8	a	O
9	GST	B
10	-	O
11	POU	B
12	fusion	O
13	protein	O
14	bound	O
15	to	O
16	glutathione	O
17	-	O
18	agarose	O
19	beads	O
20	.	O

1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	B
12	transactivator	I
13	VP16	I
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	B
23	contacts	O
24	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	filtration	O
6	rate	O
7	in	O
8	relevant	O
9	areas	O
10	appears	O
11	to	O
12	be	O
13	an	O
14	integrative	O
15	and	O
16	easily	O
17	determined	O
18	parameter	O
19	,	O
20	reflecting	O
21	hormonal	O
22	and	O
23	neurogenic	O
24	vascular	O
25	as	O
26	well	O
27	as	O
28	local	O
29	interstitial	O
30	control	O
31	of	O
32	the	O
33	Starling	O
34	forces	O
35	.	O

1	Notably	O
2	,	O
3	these	O
4	residues	O
5	are	O
6	located	O
7	in	O
8	different	O
9	domains	O
10	.	O

1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O

1	Intraventricular	O
2	injection	O
3	of	O
4	(	O
5	2S	O
6	,	O
7	1	O
8	'	O
9	R	O
10	,	O
11	2	O
12	'	O
13	R	O
14	,	O
15	3	O
16	'	O
17	R	O
18	)-	O
19	2	O
20	-(	O
21	2	O
22	,	O
23	3	O
24	-	O
25	dicarboxycyclopropyl	O
26	)	O
27	glycine	O
28	(	O
29	DCG	O
30	-	O
31	IV	O
32	),	O
33	a	O
34	potent	O
35	agonist	O
36	for	O
37	metabotropic	O
38	glutamate	B
39	receptors	I
40	,	O
41	to	O
42	rats	O
43	retarded	O
44	dose	O
45	-	O
46	dependently	O
47	the	O
48	recovery	O
49	from	O
50	halothane	O
51	anesthesia	O
52	at	O
53	a	O
54	dose	O
55	range	O
56	from	O
57	30	O
58	to	O
59	300	O
60	pmol	O
61	/	O
62	rat	O
63	.	O

1	The	O
2	hepatocyte	B
3	nuclear	I
4	factor	I
5	-	I
6	3	I
7	(	O
8	HNF	B
9	-	I
10	3	I
11	)/	O
12	forkhead	B
13	(	O
14	fkh	B
15	)	O
16	proteins	O
17	consist	O
18	of	O
19	an	O
20	extensive	O
21	family	O
22	of	O
23	tissue	O
24	-	O
25	specific	O
26	and	O
27	developmental	O
28	gene	O
29	regulators	O
30	which	O
31	share	O
32	homology	O
33	within	O
34	the	O
35	winged	O
36	helix	O
37	DNA	O
38	binding	O
39	motif	O
40	.	O

1	Homozygous	O
2	null	O
3	embryos	O
4	also	O
5	displayed	O
6	abnormalities	O
7	in	O
8	heart	O
9	development	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	conclusion	O
15	that	O
16	Tek	B
17	is	O
18	necessary	O
19	for	O
20	endocardial	O
21	/	O
22	myocardial	O
23	interactions	O
24	during	O
25	development	O
26	.	O

1	Interestingly	O
2	,	O
3	dTFIIA	B
4	-	I
5	L	I
6	/	I
7	S	I
8	is	O
9	also	O
10	able	O
11	to	O
12	significantly	O
13	enhance	O
14	transcriptional	O
15	activation	O
16	by	O
17	upstream	O
18	transcription	O
19	factors	O
20	including	O
21	Sp1	B
22	,	O
23	VP16	B
24	,	O
25	and	O
26	NTF	B
27	-	I
28	1	I
29	.	O

1	A	O
2	strong	O
3	trithorax	B
4	binding	I
5	site	I
6	was	O
7	found	O
8	at	O
9	the	O
10	cytological	O
11	location	O
12	of	O
13	the	O
14	fork	B
15	head	I
16	gene	I
17	,	O
18	a	O
19	region	O
20	-	O
21	specific	O
22	homeotic	B
23	gene	I
24	not	O
25	located	O
26	within	O
27	a	O
28	homeotic	B
29	complex	I
30	.	O

1	In	O
2	particular	O
3	,	O
4	changes	O
5	in	O
6	intracellular	O
7	Ca2	O
8	+	O
9	have	O
10	the	O
11	potential	O
12	to	O
13	either	O
14	inhibit	O
15	or	O
16	augment	O
17	the	O
18	ability	O
19	of	O
20	cAMP	O
21	to	O
22	stimulate	O
23	transcription	O
24	,	O
25	depending	O
26	on	O
27	the	O
28	presence	O
29	of	O
30	specific	O
31	forms	O
32	of	O
33	Ca2	B
34	+/	I
35	calmodulin	I
36	-	I
37	dependent	I
38	protein	I
39	kinases	I
40	.	O

1	Antibodies	O
2	directed	O
3	against	O
4	the	O
5	SNM1	B
6	protein	I
7	immunoprecipitated	O
8	RNase	B
9	MRP	I
10	RNA	I
11	from	O
12	whole	O
13	-	O
14	cell	O
15	extracts	O
16	without	O
17	precipitating	O
18	the	O
19	structurally	O
20	and	O
21	functionally	O
22	related	O
23	RNase	B
24	P	I
25	RNA	I
26	.	O

1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O

1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	ORF	O
7	of	O
8	hAMPK	B
9	encodes	O
10	552	O
11	amino	O
12	acids	O
13	(	O
14	aa	O
15	)	O
16	(	O
17	62	O
18	.	O
19	250	O
20	kDa	O
21	)	O
22	and	O
23	is	O
24	highly	O
25	conserved	O
26	with	O
27	rAMPK	B
28	with	O
29	identities	O
30	of	O
31	97	O
32	.	O
33	3	O
34	and	O
35	90	O
36	%	O
37	at	O
38	the	O
39	aa	O
40	and	O
41	nt	O
42	levels	O
43	,	O
44	respectively	O
45	.	O

1	In	O
2	human	O
3	brain	O
4	,	O
5	contactin	B
6	was	O
7	first	O
8	identified	O
9	by	O
10	amino	O
11	terminal	O
12	and	O
13	peptide	O
14	sequencing	O
15	of	O
16	the	O
17	lentil	B
18	-	I
19	lectin	I
20	-	I
21	binding	I
22	glycoprotein	I
23	Gp135	I
24	.	O

1	The	O
2	centromeric	O
3	YAC	O
4	contig	O
5	,	O
6	which	O
7	consists	O
8	of	O
9	23	O
10	overlapping	O
11	YACs	O
12	and	O
13	orders	O
14	19	O
15	sequence	O
16	-	O
17	tagged	O
18	sites	O
19	(	O
20	STSs	O
21	),	O
22	covers	O
23	a	O
24	minimum	O
25	of	O
26	2	O
27	.	O
28	2	O
29	Mb	O
30	and	O
31	spans	O
32	the	O
33	Ewing	O
34	sarcoma	O
35	breakpoint	O
36	.	O
37	c	B
38	-	I
39	ets	I
40	1	I
41	and	O
42	Fli	B
43	-	I
44	1	I
45	,	O
46	two	O
47	members	O
48	of	O
49	the	O
50	ets	B
51	family	I
52	,	O
53	have	O
54	been	O
55	linked	O
56	within	O
57	400	O
58	kb	O
59	of	O
60	intervening	O
61	DNA	O
62	within	O
63	this	O
64	contig	O
65	,	O
66	which	O
67	also	O
68	comprises	O
69	a	O
70	polymorphic	O
71	microsatellite	O
72	,	O
73	D11S912	B
74	(	O
75	CA	O
76	)	O
77	n	O
78	,	O
79	which	O
80	we	O
81	have	O
82	localized	O
83	within	O
84	the	O
85	Fli	B
86	-	I
87	1	I
88	gene	I
89	.	O

1	A	O
2	cDNA	O
3	for	O
4	a	O
5	newly	O
6	discovered	O
7	pseudogene	O
8	,	O
9	closely	O
10	related	O
11	to	O
12	the	O
13	mouse	B
14	mast	I
15	cell	I
16	chymases	I
17	was	O
18	isolated	O
19	by	O
20	polymerase	O
21	chain	O
22	reaction	O
23	amplification	O
24	from	O
25	a	O
26	mouse	O
27	connective	O
28	tissue	O
29	-	O
30	like	O
31	mast	O
32	cell	O
33	line	O
34	.	O

1	IFI16	B
2	consists	O
3	of	O
4	ten	O
5	exons	O
6	and	O
7	nine	O
8	intervening	O
9	introns	O
10	spanning	O
11	at	O
12	least	O
13	28	O
14	kilobases	O
15	(	O
16	kb	O
17	)	O
18	of	O
19	DNA	O
20	.	O

1	Courses	O
2	were	O
3	repeated	O
4	every	O
5	four	O
6	weeks	O
7	.	O

1	Peter	O
2	Elfer	O
3	explores	O
4	the	O
5	implications	O
6	of	O
7	the	O
8	ruling	O
9	.	O

1	Other	O
2	adverse	O
3	events	O
4	with	O
5	incidences	O
6	significantly	O
7	higher	O
8	than	O
9	with	O
10	placebo	O
11	were	O
12	dizziness	O
13	,	O
14	constipation	O
15	,	O
16	sweating	O
17	,	O
18	nervousness	O
19	,	O
20	and	O
21	abnormal	O
22	ejaculation	O
23	.	O

1	Homology	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	B
13	synthase	I
14	C	I
15	and	O
16	other	O
17	mitochondrion	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O

1	Furthermore	O
2	,	O
3	our	O
4	data	O
5	also	O
6	show	O
7	that	O
8	,	O
9	in	O
10	addition	O
11	to	O
12	TEF	B
13	-	I
14	1	I
15	,	O
16	another	O
17	HF	B
18	-	I
19	1a	I
20	-	I
21	related	I
22	factor	I
23	may	O
24	be	O
25	recognized	O
26	by	O
27	the	O
28	alpha	B
29	-	I
30	MHC	I
31	gene	I
32	EM	O
33	element	O
34	.	O

1	Rat	B
2	kidney	I
3	carboxylesterase	I
4	.	O

1	Recombinant	B
2	I	I
3	-	I
4	kappa	I
5	B	I
6	alpha	I
7	inhibited	O
8	kappa	B
9	B	I
10	motif	I
11	binding	O
12	by	O
13	nuclear	B
14	factor	I
15	-	I
16	kappa	I
17	B1	I
18	,	O
19	RelA	B
20	,	O
21	and	O
22	c	B
23	-	I
24	Rel	I
25	as	O
26	indicated	O
27	by	O
28	studies	O
29	using	O
30	UV	O
31	radiation	O
32	-	O
33	induced	O
34	covalent	O
35	cross	O
36	-	O
37	linking	O
38	to	O
39	a	O
40	bromodeoxyuridine	O
41	-	O
42	substituted	O
43	kappa	B
44	B	I
45	oligonucleotide	I
46	.	O

1	The	O
2	physical	O
3	and	O
4	chemical	O
5	stability	O
6	of	O
7	a	O
8	combination	O
9	of	O
10	drugs	O
11	commonly	O
12	administered	O
13	into	O
14	the	O
15	epidural	O
16	or	O
17	intrathecal	O
18	space	O
19	for	O
20	the	O
21	treatment	O
22	of	O
23	chronic	O
24	pain	O
25	was	O
26	investigated	O
27	.	O

1	Therefore	O
2	,	O
3	mechanisms	O
4	that	O
5	control	O
6	activation	O
7	of	O
8	the	O
9	MAP	B
10	kinase	I
11	cascade	O
12	temporally	O
13	and	O
14	spatially	O
15	may	O
16	be	O
17	important	O
18	for	O
19	specification	O
20	of	O
21	cellular	O
22	responses	O
23	.	O

1	A	O
2	candidate	O
3	gene	O
4	for	O
5	Bcg	B
6	,	O
7	designated	O
8	natural	B
9	resistance	I
10	-	I
11	associated	I
12	macrophage	I
13	protein	I
14	(	O
15	Nramp	B
16	),	O
17	has	O
18	been	O
19	isolated	O
20	and	O
21	shown	O
22	to	O
23	encode	O
24	a	O
25	novel	O
26	macrophage	O
27	-	O
28	specific	O
29	membrane	O
30	protein	O
31	,	O
32	which	O
33	is	O
34	altered	O
35	in	O
36	susceptible	O
37	animals	O
38	.	O

1	This	O
2	motif	O
3	is	O
4	similar	O
5	to	O
6	but	O
7	distinct	O
8	from	O
9	the	O
10	LIM	B
11	domain	I
12	and	O
13	the	O
14	RING	B
15	finger	I
16	family	I
17	,	O
18	and	O
19	is	O
20	reminiscent	O
21	of	O
22	known	O
23	metal	O
24	-	O
25	binding	O
26	regions	O
27	.	O

1	The	O
2	P131	O
3	ORF	O
4	is	O
5	followed	O
6	in	O
7	-	O
8	frame	O
9	by	O
10	a	O
11	second	O
12	ORF	O
13	which	O
14	is	O
15	probably	O
16	expressed	O
17	by	O
18	partial	O
19	readthrough	O
20	of	O
21	the	O
22	UGA	O
23	termination	O
24	codon	O
25	of	O
26	the	O
27	P131	O
28	ORF	O
29	to	O
30	produce	O
31	a	O
32	polypeptide	O
33	of	O
34	M	O
35	(	O
36	r	O
37	)	O
38	191044	O
39	(	O
40	P191	O
41	).	O

1	One	O
2	hundred	O
3	fifty	O
4	patients	O
5	were	O
6	reviewed	O
7	at	O
8	1	O
9	year	O
10	after	O
11	arthroplasty	O
12	.	O

1	Elementary	O
2	visual	O
3	hallucinations	O
4	in	O
5	migraine	O
6	and	O
7	epilepsy	O
8	.	O

1	The	O
2	influence	O
3	of	O
4	patient	O
5	-	O
6	related	O
7	factors	O
8	on	O
9	inter	O
10	-	O
11	observer	O
12	variability	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	neurological	O
18	signs	O
19	was	O
20	investigated	O
21	.	O

1	Segments	O
2	with	O
3	more	O
4	reduced	O
5	BMIPP	O
6	uptake	O
7	than	O
8	MIBI	O
9	uptake	O
10	(	O
11	mismatching	O
12	)	O
13	showed	O
14	either	O
15	normal	O
16	wall	O
17	motion	O
18	or	O
19	demonstrated	O
20	inotropic	O
21	reserve	O
22	during	O
23	dobutamine	O
24	stimulation	O
25	.	O

1	The	O
2	defined	O
3	length	O
4	of	O
5	the	O
6	mRNA	O
7	,	O
8	1	O
9	,	O
10	838	O
11	nucleotides	O
12	,	O
13	was	O
14	in	O
15	agreement	O
16	with	O
17	that	O
18	of	O
19	a	O
20	1	O
21	.	O
22	9	O
23	-	O
24	kb	O
25	RNA	O
26	expressed	O
27	throughout	O
28	the	O
29	replication	O
30	cycle	O
31	,	O
32	starting	O
33	at	O
34	the	O
35	early	O
36	stages	O
37	of	O
38	infection	O
39	.	O

1	Infect	O
2	.	O

1	Transient	O
2	transfections	O
3	of	O
4	a	O
5	construct	O
6	expressing	O
7	the	O
8	RNA	O
9	transcript	O
10	defined	O
11	by	O
12	clone	O
13	B1	O
14	.	O
15	1	O
16	into	O
17	D17	O
18	cells	O
19	led	O
20	to	O
21	the	O
22	expression	O
23	of	O
24	an	O
25	Env	B
26	/	O
27	Mlvi	B
28	-	I
29	4	I
30	fusion	O
31	protein	O
32	with	O
33	an	O
34	apparent	O
35	molecular	O
36	mass	O
37	of	O
38	33	O
39	kDa	O
40	.	O

1	Roizman	O
2	,	O
3	J	O
4	.	O

1	Articles	O
2	addressing	O
3	valvular	O
4	heart	O
5	disease	O
6	or	O
7	heart	O
8	failure	O
9	secondary	O
10	to	O
11	acute	O
12	myocardial	O
13	infarction	O
14	or	O
15	Chagas	O
16	'	O
17	disease	O
18	were	O
19	excluded	O
20	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	indicate	O
6	that	O
7	patients	O
8	with	O
9	TGBM	O
10	nephropathy	O
11	often	O
12	have	O
13	concomitant	O
14	IgA	B
15	nephropathy	O
16	and	O
17	mesangial	O
18	proliferative	O
19	glomerulonephritis	O
20	.	O

1	All	O
2	nuclear	O
3	receptors	O
4	have	O
5	several	O
6	well	O
7	-	O
8	characterized	O
9	structural	O
10	domains	O
11	,	O
12	including	O
13	a	O
14	conserved	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	,	O
20	and	O
21	a	O
22	ligand	O
23	binding	O
24	domain	O
25	at	O
26	the	O
27	carboxyl	O
28	terminus	O
29	of	O
30	the	O
31	receptor	O
32	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	O
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	O
27	"	O
28	Ospedale	O
29	Maggiore	O
30	"	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O

1	Using	O
2	in	O
3	organello	O
4	footprint	O
5	analysis	O
6	,	O
7	we	O
8	demonstrate	O
9	that	O
10	within	O
11	human	O
12	placental	O
13	mitochondria	O
14	there	O
15	is	O
16	a	O
17	high	O
18	level	O
19	of	O
20	protein	O
21	-	O
22	DNA	O
23	binding	O
24	at	O
25	regularly	O
26	phased	O
27	intervals	O
28	throughout	O
29	a	O
30	500	O
31	-	O
32	bp	O
33	region	O
34	encompassing	O
35	the	O
36	D	O
37	-	O
38	loop	O
39	DNA	O
40	origins	O
41	and	O
42	two	O
43	promoter	O
44	regions	O
45	.	O

1	The	O
2	Nur77	B
3	protein	I
4	can	O
5	act	O
6	as	O
7	a	O
8	potent	O
9	transcription	O
10	activator	O
11	and	O
12	may	O
13	function	O
14	to	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	downstream	O
20	genes	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	.	O

1	One	O
2	class	O
3	of	O
4	plasmids	O
5	contained	O
6	tRNA	B
7	(	I
8	His	I
9	)	I
10	genes	I
11	and	O
12	conferred	O
13	efficient	O
14	suppression	O
15	only	O
16	when	O
17	cells	O
18	were	O
19	starved	O
20	for	O
21	histidine	O
22	;	O
23	these	O
24	plasmids	O
25	suppressed	O
26	a	O
27	gcn2	B
28	deletion	O
29	much	O
30	less	O
31	efficiently	O
32	than	O
33	they	O
34	suppressed	O
35	gcn2	B
36	-	I
37	507	I
38	.	O

1	Thus	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	Cln2	B
8	PEST	I
9	domain	I
10	was	O
11	sufficient	O
12	to	O
13	destabilize	O
14	a	O
15	heterologous	O
16	protein	O
17	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	with	O
6	each	O
7	of	O
8	these	O
9	sequences	O
10	demonstrated	O
11	complexes	O
12	with	O
13	mobilities	O
14	identical	O
15	to	O
16	those	O
17	of	O
18	the	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	site	I
24	from	O
25	the	O
26	kappa	B
27	light	I
28	-	I
29	chain	I
30	gene	I
31	.	O

1	Although	O
2	a	O
3	carboxyl	O
4	-	O
5	terminal	O
6	HSF	B
7	transcriptional	O
8	activation	O
9	domain	O
10	is	O
11	critical	O
12	for	O
13	the	O
14	activation	O
15	of	O
16	CUP1	B
17	transcription	O
18	in	O
19	response	O
20	to	O
21	both	O
22	heat	O
23	shock	O
24	stress	O
25	and	O
26	glucose	O
27	starvation	O
28	,	O
29	this	O
30	region	O
31	is	O
32	dispensable	O
33	for	O
34	transient	O
35	heat	O
36	shock	O
37	activation	O
38	of	O
39	at	O
40	least	O
41	two	O
42	genes	O
43	encoding	O
44	members	O
45	of	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	hsp70	B
51	family	I
52	.	O

1	We	O
2	have	O
3	recently	O
4	detected	O
5	high	O
6	levels	O
7	of	O
8	CKB	B
9	mRNA	I
10	in	O
11	HeLa	O
12	cells	O
13	and	O
14	,	O
15	in	O
16	this	O
17	study	O
18	,	O
19	have	O
20	tested	O
21	whether	O
22	this	O
23	may	O
24	be	O
25	due	O
26	to	O
27	the	O
28	extremely	O
29	low	O
30	amounts	O
31	of	O
32	p53	B
33	protein	I
34	present	O
35	in	O
36	HeLa	O
37	cells	O
38	.	O

1	Distal	O
2	lower	O
3	motor	O
4	neuron	O
5	syndrome	O
6	with	O
7	high	O
8	-	O
9	titer	O
10	serum	B
11	IgM	I
12	anti	I
13	-	I
14	GM1	I
15	antibodies	I
16	:	O
17	improvement	O
18	following	O
19	immunotherapy	O
20	with	O
21	monthly	O
22	plasma	O
23	exchange	O
24	and	O
25	intravenous	O
26	cyclophosphamide	O
27	.	O

1	Regulators	O
2	responsible	O
3	for	O
4	the	O
5	pervasive	O
6	,	O
7	nonsex	O
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	characteristic	O
16	of	O
17	metazoans	O
18	are	O
19	almost	O
20	entirely	O
21	unknown	O
22	or	O
23	uncertain	O
24	.	O

1	A	O
2	normal	O
3	systemic	O
4	response	O
5	was	O
6	obtained	O
7	after	O
8	IF	O
9	,	O
10	indicating	O
11	that	O
12	rhG	B
13	-	I
14	CSF	I
15	retains	O
16	activity	O
17	in	O
18	the	O
19	solid	O
20	state	O
21	.	O

1	A	O
2	full	O
3	-	O
4	length	O
5	cDNA	O
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	ANP	B
35	-	I
36	receptor	I
37	kinase	I
38	-	I
39	like	I
40	domain	I
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	B
50	-	I
51	serine	I
52	phosphatase	I
53	domain	O
54	.	O

1	A	O
2	high	O
3	-	O
4	resolution	O
5	restriction	O
6	map	O
7	of	O
8	over	O
9	200	O
10	kb	O
11	of	O
12	contiguous	O
13	DNA	O
14	containing	O
15	N	B
16	-	I
17	myc	I
18	has	O
19	been	O
20	generated	O
21	by	O
22	subcloning	O
23	YACs	O
24	into	O
25	cosmids	O
26	.	O

1	PAI	B
2	-	I
3	1	I
4	levels	O
5	increased	O
6	significantly	O
7	in	O
8	patients	O
9	who	O
10	received	O
11	iohexol	O
12	but	O
13	not	O
14	in	O
15	those	O
16	who	O
17	received	O
18	ioxaglate	O
19	.	O

1	In	O
2	the	O
3	present	O
4	article	O
5	,	O
6	the	O
7	causes	O
8	of	O
9	death	O
10	or	O
11	ill	O
12	-	O
13	being	O
14	as	O
15	found	O
16	in	O
17	10	O
18	consecutive	O
19	carcinogenicity	O
20	studies	O
21	--	O
22	5	O
23	studies	O
24	with	O
25	2400	O
26	OFA	O
27	(	O
28	Sprague	O
29	-	O
30	Dawley	O
31	-	O
32	derived	O
33	)	O
34	and	O
35	Wistar	O
36	rats	O
37	and	O
38	5	O
39	studies	O
40	with	O
41	2400	O
42	OF1	O
43	and	O
44	NMRI	O
45	mice	O
46	--	O
47	were	O
48	re	O
49	-	O
50	examined	O
51	.	O

1	Determination	O
2	of	O
3	potassium	O
4	iodide	O
5	in	O
6	Polish	O
7	edible	O
8	salt	O

1	The	O
2	recovery	O
3	value	O
4	of	O
5	systolic	O
6	pressure	O
7	was	O
8	higher	O
9	than	O
10	diastolic	O
11	pressure	O
12	and	O
13	pulse	O
14	pressure	O
15	increased	O
16	.	O

1	The	O
2	importance	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	as	O
12	a	O
13	cause	O
14	of	O
15	chronic	O
16	liver	O
17	disease	O
18	has	O
19	become	O
20	clear	O
21	with	O
22	the	O
23	introduction	O
24	of	O
25	serologic	O
26	detection	O
27	methods	O
28	.	O

1	Human	O
2	adenovirus	O
3	type	O
4	41	O
5	contains	O
6	two	O
7	fibers	O
8	.	O

1	Outflow	O
2	obstruction	O
3	of	O
4	pancreatic	O
5	juice	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	"	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	papilla	O
18	,"	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	papilla	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	O
41	papilla	O
42	might	O
43	suffer	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	drainage	O
51	of	O
52	pancreatic	O
53	juice	O
54	and	O
55	excessive	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	duct	O
61	.	O

1	Sequencing	O
2	of	O
3	the	O
4	TP53	B
5	transcripts	I
6	from	O
7	exons	O
8	2	O
9	to	O
10	10	O
11	,	O
12	however	O
13	,	O
14	did	O
15	not	O
16	reveal	O
17	mutations	O
18	of	O
19	the	O
20	remaining	O
21	allele	O
22	in	O
23	any	O
24	of	O
25	these	O
26	tumors	O
27	.	O

1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O

1	In	O
2	the	O
3	ISO	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	DEX	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	166	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	hypercapnia	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	).(	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O

1	All	O
2	other	O
3	ejaculate	O
4	parameters	O
5	(	O
6	density	O
7	,	O
8	motility	O
9	,	O
10	swelling	O
11	test	O
12	,	O
13	penetration	O
14	test	O
15	)	O
16	remained	O
17	unchanged	O
18	,	O
19	and	O
20	there	O
21	was	O
22	only	O
23	one	O
24	post	O
25	-	O
26	therapeutic	O
27	pregnancy	O
28	.	O

1	KRN2391	O
2	and	O
3	cromakalim	O
4	produced	O
5	a	O
6	dose	O
7	-	O
8	dependent	O
9	increase	O
10	in	O
11	aortic	O
12	and	O
13	coronary	O
14	blood	O
15	flow	O
16	.	O

1	In	O
2	H4IIE	O
3	rat	O
4	hepatoma	O
5	cells	O
6	,	O
7	glucocorticoids	O
8	,	O
9	retinoic	O
10	acid	O
11	and	O
12	cyclic	O
13	AMP	O
14	(	O
15	cAMP	O
16	)	O
17	increase	O
18	PEPCK	B
19	gene	I
20	transcription	O
21	whereas	O
22	insulin	B
23	and	O
24	phorbol	O
25	esters	O
26	have	O
27	the	O
28	opposite	O
29	effect	O
30	.	O

1	Acta	O
2	572	O
3	,	O
4	113	O
5	-	O
6	120	O
7	].	O

1	Basal	O
2	plasma	O
3	AVP	B
4	levels	O
5	and	O
6	AVP	B
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	B
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O

1	A	O
2	stretch	O
3	of	O
4	16	O
5	nucleotides	O
6	just	O
7	upstream	O
8	of	O
9	the	O
10	IL	B
11	-	I
12	4RE	I
13	contributed	O
14	to	O
15	IL	B
16	-	I
17	4	I
18	inducibility	O
19	and	O
20	formed	O
21	nucleoprotein	O
22	complexes	O
23	with	O
24	constitutive	O
25	factors	O
26	.	O

1	Our	O
2	previous	O
3	study	O
4	suggested	O
5	that	O
6	pertussis	B
7	toxin	I
8	(	O
9	IAP	B
10	)-	O
11	sensitive	O
12	GTP	B
13	-	I
14	binding	I
15	protein	I
16	(	I
17	s	I
18	)	I
19	(	O
20	G	B
21	-	I
22	protein	I
23	)	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	process	O
29	of	O
30	differentiation	O
31	by	O
32	hormones	O
33	/	O
34	IBMX	O
35	,	O
36	accompanied	O
37	by	O
38	c	B
39	-	I
40	fos	I
41	induction	O
42	.	O

1	ATX	B
2	,	O
3	like	O
4	PC	B
5	-	I
6	1	I
7	,	O
8	was	O
9	found	O
10	to	O
11	hydrolyze	O
12	the	O
13	type	B
14	I	I
15	phosphodiesterase	I
16	substrate	O
17	p	O
18	-	O
19	nitrophenyl	O
20	thymidine	O
21	-	O
22	5	O
23	'-	O
24	monophosphate	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	site	O
5	-	O
6	specific	O
7	mutations	O
8	in	O
9	the	O
10	mouse	B
11	platelet	I
12	-	I
13	derived	I
14	growth	I
15	factor	I
16	(	I
17	PDGF	I
18	)	I
19	beta	I
20	-	I
21	receptor	I
22	on	O
23	activation	O
24	of	O
25	the	O
26	Na	B
27	+/	I
28	H	I
29	+	I
30	exchanger	I
31	was	O
32	examined	O
33	in	O
34	normal	O
35	murine	O
36	mammary	O
37	gland	O
38	epithelial	O
39	(	O
40	NMuMG	O
41	)	O
42	and	O
43	Chinese	O
44	hamster	O
45	ovary	O
46	(	O
47	CHO	O
48	)	O
49	cells	O
50	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	:	O
5	1	O
6	)	O
7	a	O
8	kinase	O
9	catalytic	O
10	domain	O
11	most	O
12	characteristic	O
13	of	O
14	serine	B
15	/	I
16	threonine	I
17	kinases	I
18	but	O
19	hybrid	O
20	between	O
21	members	O
22	of	O
23	the	O
24	family	O
25	of	O
26	microtubule	B
27	-	I
28	associated	I
29	protein	I
30	kinase	I
31	kinase	I
32	kinases	I
33	and	O
34	the	O
35	fibroblast	B
36	growth	I
37	factor	I
38	receptor	I
39	family	I
40	;	O
41	2	O
42	)	O
43	two	O
44	putative	O
45	alpha	O
46	-	O
47	helical	O
48	leucine	O
49	zipper	O
50	motifs	O
51	separated	O
52	by	O
53	a	O
54	25	O
55	-	O
56	amino	O
57	acid	O
58	charged	O
59	intermediate	O
60	segment	O
61	but	O
62	lacking	O
63	an	O
64	NH2	O
65	-	O
66	terminal	O
67	basic	O
68	domain	O
69	;	O
70	and	O
71	3	O
72	)	O
73	COOH	O
74	-	O
75	terminal	O
76	and	O
77	NH2	O
78	-	O
79	terminal	O
80	proline	O
81	-	O
82	rich	O
83	domains	O
84	suggestive	O
85	of	O
86	src	B
87	homology	I
88	3	I
89	(	O
90	SH3	B
91	)	O
92	domain	O
93	binding	O
94	regions	O
95	.	O

1	Type	O
2	2	O
3	genomes	O
4	containing	O
5	this	O
6	sequence	O
7	presumably	O
8	more	O
9	closely	O
10	reflect	O
11	the	O
12	structure	O
13	of	O
14	the	O
15	infectious	O
16	,	O
17	replication	O
18	-	O
19	competent	O
20	retrovirus	O
21	ancestors	O
22	of	O
23	the	O
24	HERV	O
25	-	O
26	K	O
27	family	O
28	than	O
29	do	O
30	type	O
31	1	O
32	genomes	O
33	that	O
34	lack	O
35	the	O
36	sequence	O
37	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	Point	O
2	mutations	O
3	that	O
4	suppressed	O
5	the	O
6	in	O
7	vitro	O
8	binding	O
9	of	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	internal	O
16	palindromic	O
17	arm	O
18	reduced	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	resident	O
24	P4	O
25	promoter	O
26	,	O
27	while	O
28	those	O
29	preventing	O
30	complex	O
31	formation	O
32	with	O
33	USF	B
34	did	O
35	not	O
36	,	O
37	as	O
38	determined	O
39	by	O
40	transient	O
41	expression	O
42	assays	O
43	using	O
44	the	O
45	luciferase	B
46	reporter	O
47	gene	O
48	.	O

1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	B
11	transcriptase	I
12	-	O
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	B
31	and	O
32	Y88L	B
33	RNAs	I
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O

1	Surprisingly	O
2	,	O
3	nuclear	O
4	forms	O
5	of	O
6	IE110	B
7	were	O
8	found	O
9	to	O
10	move	O
11	a	O
12	cytoplasmic	O
13	form	O
14	of	O
15	IE175	B
16	into	O
17	nuclear	O
18	punctate	O
19	structures	O
20	,	O
21	and	O
22	a	O
23	cytoplasmic	O
24	form	O
25	of	O
26	IE110	B
27	was	O
28	able	O
29	to	O
30	retain	O
31	nuclear	O
32	forms	O
33	of	O
34	IE175	B
35	in	O
36	cytoplasmic	O
37	punctate	O
38	structures	O
39	.	O

1	Transcription	O
2	of	O
3	the	O
4	gene	O
5	for	O
6	ivanolysin	B
7	O	I
8	and	O
9	expression	O
10	of	O
11	other	O
12	genes	O
13	of	O
14	the	O
15	virulence	B
16	gene	I
17	cluster	I
18	in	I
19	L	I
20	.	I
21	ivanovii	I
22	were	O
23	dependent	O
24	on	O
25	PrfA	B
26	.	O

1	Moreover	O
2	,	O
3	by	O
4	complementation	O
5	of	O
6	the	O
7	WA	B
8	fyuA	I
9	mutant	I
10	by	O
11	the	O
12	cloned	O
13	fyuA	B
14	gene	I
15	,	O
16	yersiniabactin	O
17	uptake	O
18	and	O
19	mouse	O
20	virulence	O
21	were	O
22	restored	O
23	.	O

1	The	O
2	ICBF	O
3	in	O
4	the	O
5	ischaemic	O
6	cortex	O
7	revealed	O
8	a	O
9	graded	O
10	reduction	O
11	from	O
12	the	O
13	ischaemic	O
14	centre	O
15	to	O
16	the	O
17	surrounding	O
18	tissues	O
19	.	O

1	The	O
2	treatment	O
3	of	O
4	hydronephrosis	O
5	in	O
6	children	O

1	The	O
2	inflation	O
3	hub	O
4	of	O
5	the	O
6	probe	O
7	is	O
8	recreated	O
9	by	O
10	modifying	O
11	a	O
12	standard	O
13	USCI	O
14	Tuohy	O
15	-	O
16	Borst	O
17	Y	O
18	adaptor	O
19	and	O
20	attaching	O
21	this	O
22	to	O
23	the	O
24	transected	O
25	probe	O
26	hypotube	O
27	.	O

1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	B
6	-	I
7	J	I
8	kappa	I
9	with	O
10	low	O
11	affinity	O
12	.	O

1	The	O
2	basal	O
3	promoter	O
4	strength	O
5	of	O
6	constructs	O
7	that	O
8	contained	O
9	deletions	O
10	in	O
11	the	O
12	U5	B
13	region	I
14	of	O
15	the	O
16	LTR	O
17	was	O
18	analyzed	O
19	by	O
20	chloramphenicol	B
21	acetyltransferase	I
22	(	O
23	CAT	B
24	)	O
25	assays	O
26	following	O
27	transfection	O
28	of	O
29	HeLa	O
30	cells	O
31	or	O
32	Jurkat	O
33	T	O
34	-	O
35	cells	O
36	in	O
37	the	O
38	presence	O
39	or	O
40	absence	O
41	of	O
42	viral	O
43	transactivator	O
44	tax	B
45	protein	O
46	.	O

1	In	O
2	reviewing	O
3	a	O
4	number	O
5	of	O
6	the	O
7	most	O
8	intensely	O
9	studied	O
10	environmentally	O
11	inducible	O
12	promoters	O
13	it	O
14	becomes	O
15	clear	O
16	that	O
17	the	O
18	presence	O
19	of	O
20	two	O
21	cis	O
22	-	O
23	acting	O
24	elements	O
25	are	O
26	critical	O
27	for	O
28	promoter	O
29	activity	O
30	,	O
31	one	O
32	of	O
33	which	O
34	is	O
35	the	O
36	G	O
37	-	O
38	box	O
39	(	O
40	CCACGTGG	O
41	).	O

1	Recently	O
2	,	O
3	a	O
4	protein	O
5	designated	O
6	GF14	B
7	has	O
8	been	O
9	isolated	O
10	that	O
11	is	O
12	associated	O
13	with	O
14	the	O
15	GBF	B
16	protein	I
17	complex	I
18	.	O

1	New	O
2	diagnostic	O
3	strategies	O
4	for	O
5	lupus	O
6	anticoagulants	O
7	and	O
8	antiphospholipid	O
9	antibodies	O
10	.	O

1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	O
7	arrest	O
8	elongation	O
9	by	O
10	polIII	B
11	at	O
12	defined	O
13	positions	O
14	within	O
15	the	O
16	tRNA	O
17	gene	O
18	transcription	O
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	B
31	polIII	I
32	ternary	I
33	complexes	I
34	.	O

1	Propafenone	O
2	is	O
3	well	O
4	tolerated	O
5	in	O
6	the	O
7	majority	O
8	of	O
9	young	O
10	patients	O
11	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	yeast	B
5	CEG1	I
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	O
12	conserved	O
13	motifs	O
14	are	O
15	essential	O
16	for	O
17	capping	B
18	enzyme	I
19	function	O
20	in	O
21	vivo	O
22	.	O

1	2	O
2	patients	O
3	(	O
4	11	O
5	%)	O
6	had	O
7	significant	O
8	morbidity	O
9	502	O
10	and	O
11	529	O
12	days	O
13	respectively	O
14	after	O
15	transplantation	O
16	.	O

1	A	O
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	O
12	(	O
13	1990	O
14	)	O
15	is	O
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	B
12	-	I
13	1	I
14	isoforms	I
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O

1	Transfer	O
2	also	O
3	correlated	O
4	inversely	O
5	with	O
6	gastric	O
7	juice	O
8	pH	O
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	619	O
16	,	O
17	P	O
18	<	O
19	0	O
20	.	O
21	02	O
22	).	O

1	This	O
2	technique	O
3	has	O
4	a	O
5	sensitivity	O
6	and	O
7	a	O
8	specificity	O
9	of	O
10	almost	O
11	100	O
12	%,	O
13	and	O
14	is	O
15	currently	O
16	the	O
17	best	O
18	way	O
19	to	O
20	diagnose	O
21	nodal	O
22	involvement	O
23	,	O
24	apart	O
25	from	O
26	laparotomy	O
27	.	O

1	The	O
2	data	O
3	show	O
4	conclusively	O
5	that	O
6	phosphorylation	O
7	of	O
8	His	O
9	-	O
10	304	O
11	is	O
12	not	O
13	essential	O
14	for	O
15	any	O
16	of	O
17	the	O
18	known	O
19	functions	O
20	of	O
21	A	B
22	.	I
23	vinelandii	I
24	NifL	I
25	.	O

1	The	O
2	role	O
3	of	O
4	HIV	B
5	tat	I
6	,	O
7	which	O
8	is	O
9	the	O
10	main	O
11	enhancing	O
12	factor	O
13	for	O
14	viral	B
15	LTR	I
16	,	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	IL	B
22	-	I
23	2	I
24	gene	I
25	transcription	O
26	has	O
27	been	O
28	studied	O
29	following	O
30	transient	O
31	expression	O
32	of	O
33	the	O
34	tat	B
35	gene	I
36	in	O
37	phorbol	O
38	ester	O
39	and	O
40	calcium	O
41	ionophore	O
42	-	O
43	activated	O
44	Jurkat	O
45	cells	O
46	transfected	O
47	with	O
48	IL	B
49	-	I
50	2	I
51	promoter	O
52	-	O
53	chloramphenicol	B
54	acetyltransferase	I
55	reporter	O
56	constructs	O
57	.	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	B
7	and	O
8	D9S5	B
9	and	O
10	between	O
11	FRDA	B
12	and	O
13	D9S15	B
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O

1	A	O
2	receptor	B
3	-	I
4	like	I
5	protein	I
6	kinase	I
7	,	O
8	OsPK10	B
9	,	O
10	has	O
11	been	O
12	cloned	O
13	from	O
14	rice	O
15	(	O
16	Oryza	O
17	sativa	O
18	).	O

1	A	O
2	sequence	O
3	representing	O
4	about	O
5	50	O
6	%	O
7	of	O
8	the	O
9	expected	O
10	complete	O
11	sequence	O
12	was	O
13	obtained	O
14	by	O
15	translation	O
16	of	O
17	the	O
18	two	O
19	open	O
20	reading	O
21	frames	O
22	present	O
23	on	O
24	a	O
25	1	O
26	.	O
27	6	O
28	kb	O
29	DNA	O
30	genomic	O
31	fragment	O
32	.	O

1	Goodpasture	O
2	'	O
3	s	O
4	-	O
5	like	O
6	syndrome	O
7	and	O
8	effect	O
9	of	O
10	extracorporeal	O
11	membrane	O
12	oxygenator	O
13	support	O
14	.	O

1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	O
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	O
12	kinase	O
13	TFIIH	B
14	/	O
15	TFIIK	B
16	.	O

1	The	O
2	git1	B
3	,	O
4	git3	B
5	,	O
6	git5	B
7	,	O
8	git7	B
9	,	O
10	git8	B
11	and	O
12	git10	B
13	genes	I
14	act	O
15	upstream	O
16	of	O
17	adenylate	B
18	cyclase	I
19	,	O
20	presumably	O
21	encoding	O
22	an	O
23	adenylate	B
24	cyclase	I
25	activation	O
26	pathway	O
27	.	O

1	These	O
2	same	O
3	regions	O
4	showed	O
5	remarkable	O
6	homology	O
7	to	O
8	two	O
9	invertebrate	O
10	proteins	O
11	,	O
12	CNC	B
13	and	O
14	skin	B
15	-	I
16	1	I
17	,	O
18	postulated	O
19	to	O
20	regulate	O
21	embryonic	O
22	development	O
23	in	O
24	Drosophila	O
25	melanogaster	O
26	and	O
27	Caenorhabditis	O
28	elegans	O
29	,	O
30	respectively	O
31	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	290	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	rpoAL290H	B
32	).	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	findings	O
5	indicate	O
6	a	O
7	physical	O
8	barrier	O
9	of	O
10	oesophageal	O
11	surfactant	O
12	which	O
13	could	O
14	offer	O
15	some	O
16	degree	O
17	of	O
18	protection	O
19	against	O
20	gastro	O
21	-	O
22	oesophageal	O
23	reflux	O
24	but	O
25	one	O
26	which	O
27	is	O
28	particularly	O
29	prone	O
30	to	O
31	attack	O
32	by	O
33	bile	O
34	.	O

1	Differential	O
2	screening	O
3	of	O
4	mitochondrial	O
5	cDNA	O
6	libraries	O
7	from	O
8	male	O
9	-	O
10	fertile	O
11	and	O
12	cytoplasmic	O
13	male	O
14	-	O
15	sterile	O
16	sugar	O
17	-	O
18	beet	O
19	reveals	O
20	genome	O
21	rearrangements	O
22	at	O
23	atp6	B
24	and	O
25	atpA	B
26	loci	I
27	.	O

1	The	O
2	effects	O
3	of	O
4	social	O
5	isolation	O
6	on	O
7	morphine	O
8	-	O
9	induced	O
10	locomotor	O
11	activity	O
12	were	O
13	compared	O
14	in	O
15	:	O
16	(	O
17	i	O
18	)	O
19	animals	O
20	with	O
21	an	O
22	intact	O
23	hypothalamo	O
24	-	O
25	pituitary	O
26	-	O
27	adrenal	O
28	(	O
29	HPA	O
30	)	O
31	axis	O
32	;	O
33	(	O
34	ii	O
35	)	O
36	animals	O
37	in	O
38	which	O
39	stress	O
40	-	O
41	induced	O
42	corticosterone	O
43	secretion	O
44	was	O
45	blocked	O
46	by	O
47	adrenalectomy	O
48	.	O

1	Using	O
2	this	O
3	reporter	O
4	gene	O
5	system	O
6	,	O
7	we	O
8	previously	O
9	showed	O
10	that	O
11	EPO	B
12	-	O
13	induced	O
14	activation	O
15	of	O
16	the	O
17	c	B
18	-	I
19	fos	I
20	promoter	I
21	can	O
22	be	O
23	detected	O
24	rapidly	O
25	and	O
26	sensitively	O
27	as	O
28	an	O
29	elevation	O
30	of	O
31	cellular	B
32	luciferase	I
33	activity	O
34	.	O

1	I	O
2	hypothesize	O
3	that	O
4	white	B
5	gene	I
6	expression	O
7	from	O
8	P	B
9	[	I
10	en	I
11	]	I
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	B
27	PS	I
28	sites	I
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O

1	SPP41	B
2	was	O
3	cloned	O
4	and	O
5	sequenced	O
6	and	O
7	found	O
8	to	O
9	be	O
10	essential	O
11	.	O
12	spp43	B
13	is	O
14	allelic	O
15	to	O
16	the	O
17	previously	O
18	identified	O
19	suppressor	B
20	srn1	I
21	,	O
22	which	O
23	encodes	O
24	a	O
25	negative	O
26	regulator	O
27	of	O
28	gene	O
29	expression	O
30	.	O

1	Standard	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	995	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	validation	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O

1	To	O
2	see	O
3	if	O
4	a	O
5	pulse	O
6	oximeter	O
7	can	O
8	monitor	O
9	the	O
10	fetus	O
11	during	O
12	labour	O
13	we	O
14	recruited	O
15	100	O
16	Caucasian	O
17	women	O
18	in	O
19	normal	O
20	uncomplicated	O
21	labour	O
22	.	O

1	There	O
2	was	O
3	no	O
4	difference	O
5	in	O
6	plasma	O
7	concentrations	O
8	of	O
9	PGI2	O
10	(	O
11	figure	O
12	4	O
13	)	O
14	and	O
15	TxA2	O
16	in	O
17	patients	O
18	with	O
19	normal	O
20	blood	O
21	pressure	O
22	,	O
23	mild	O
24	preeclampsia	O
25	and	O
26	hypotension	O
27	,	O
28	whereas	O
29	in	O
30	severe	O
31	preeclampsia	O
32	,	O
33	the	O
34	plasma	O
35	concentration	O
36	of	O
37	PGI2	O
38	was	O
39	significantly	O
40	lower	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	001	O
47	)	O
48	and	O
49	of	O
50	TxA2	O
51	significantly	O
52	higher	O
53	(	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	).	O

1	A	O
2	causal	O
3	analysis	O
4	of	O
5	secondary	O
6	variables	O
7	showed	O
8	that	O
9	the	O
10	formation	O
11	of	O
12	FB	O
13	memories	O
14	was	O
15	primarily	O
16	associated	O
17	with	O
18	the	O
19	level	O
20	of	O
21	importance	O
22	attached	O
23	to	O
24	the	O
25	event	O
26	and	O
27	level	O
28	of	O
29	affective	O
30	response	O
31	to	O
32	the	O
33	news	O
34	.	O

1	Deletion	O
2	studies	O
3	identified	O
4	a	O
5	distal	O
6	response	O
7	element	O
8	that	O
9	is	O
10	responsible	O
11	for	O
12	the	O
13	cytokine	O
14	response	O
15	and	O
16	has	O
17	properties	O
18	of	O
19	an	O
20	inducible	O
21	transcriptional	O
22	enhancer	O
23	.	O

1	The	O
2	IPL1	B
3	gene	I
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	fidelity	O
10	chromosome	O
11	segregation	O
12	in	O
13	the	O
14	budding	O
15	yeast	O
16	Saccharomyces	O
17	cerevisiae	O
18	.	O

1	2	O
2	.	O

1	No	O
2	drop	O
3	in	O
4	oxygen	O
5	saturation	O
6	(	O
7	SaO2	O
8	)	O
9	or	O
10	visual	O
11	evidence	O
12	of	O
13	transient	O
14	electroencephalographic	O
15	(	O
16	EEG	O
17	)	O
18	arousals	O
19	can	O
20	be	O
21	found	O
22	at	O
23	repeat	O
24	polysomnography	O
25	.	O

1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	O
24	chain	O
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O

1	INO2	B
2	,	O
3	a	O
4	regulatory	O
5	gene	O
6	in	O
7	yeast	O
8	phospholipid	O
9	biosynthesis	O
10	,	O
11	affects	O
12	nuclear	O
13	segregation	O
14	and	O
15	bud	O
16	pattern	O
17	formation	O
18	.	O

1	The	O
2	pentafluorobenzyl	O
3	derivative	O
4	of	O
5	clonidine	O
6	yields	O
7	an	O
8	intense	O
9	ion	O
10	fragment	O
11	at	O
12	m	O
13	/	O
14	z	O
15	354	O
16	,	O
17	and	O
18	the	O
19	lower	O
20	limit	O
21	of	O
22	detection	O
23	is	O
24	0	O
25	.	O
26	025	O
27	ng	O
28	/	O
29	ml	O
30	for	O
31	a	O
32	1	O
33	-	O
34	ml	O
35	plasma	O
36	sample	O
37	.	O

1	Mammalian	B
2	ABPs	I
3	and	O
4	SHBGs	B
5	bind	O
6	sex	O
7	steroids	O
8	with	O
9	high	O
10	affinity	O
11	,	O
12	but	O
13	some	O
14	binding	O
15	properties	O
16	differ	O
17	among	O
18	species	O
19	.	O

1	Src	B
2	homology	I
3	(	O
4	SH	B
5	)	O
6	domain	O
7	dependent	O
8	protein	O
9	-	O
10	protein	O
11	interactions	O
12	are	O
13	important	O
14	to	O
15	tyrosine	B
16	kinase	I
17	receptor	I
18	signal	O
19	transduction	O
20	.	O

1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O

1	Under	O
2	resting	O
3	conditions	O
4	,	O
5	activity	O
6	levels	O
7	of	O
8	cardiac	O
9	vagal	O
10	and	O
11	sympathetic	O
12	outflows	O
13	are	O
14	not	O
15	related	O
16	across	O
17	young	O
18	,	O
19	healthy	O
20	human	O
21	subjects	O
22	and	O
23	peripheral	O
24	interaction	O
25	is	O
26	not	O
27	manifest	O
28	between	O
29	the	O
30	autonomic	O
31	divisions	O
32	.	O

1	Both	O
2	proprioceptive	O
3	and	O
4	electroreceptive	O
5	units	O
6	showed	O
7	a	O
8	progression	O
9	of	O
10	receptive	O
11	fields	O
12	from	O
13	anterior	O
14	to	O
15	posterior	O
16	body	O
17	in	O
18	the	O
19	rostral	O
20	to	O
21	caudal	O
22	direction	O
23	along	O
24	the	O
25	length	O
26	of	O
27	DGR	O
28	.	O

1	In	O
2	control	O
3	patients	O
4	,	O
5	baseline	O
6	images	O
7	presented	O
8	Type	O
9	I	O
10	in	O
11	25	O
12	,	O
13	Type	O
14	II	O
15	in	O
16	7	O
17	,	O
18	and	O
19	the	O
20	Type	O
21	III	O
22	&	O
23	IV	O
24	in	O
25	0	O
26	,	O
27	and	O
28	the	O
29	Type	O
30	after	O
31	loading	O
32	was	O
33	the	O
34	same	O
35	as	O
36	the	O
37	Type	O
38	at	O
39	baseline	O
40	.	O

1	A	O
2	more	O
3	complete	O
4	analysis	O
5	of	O
6	dose	O
7	response	O
8	,	O
9	time	O
10	and	O
11	mode	O
12	of	O
13	Ga	O
14	administration	O
15	(	O
16	preinjury	O
17	or	O
18	postinjury	O
19	),	O
20	and	O
21	availability	O
22	of	O
23	Ga	O
24	across	O
25	the	O
26	blood	O
27	-	O
28	brain	O
29	barrier	O
30	is	O
31	needed	O
32	to	O
33	further	O
34	evaluate	O
35	the	O
36	efficacy	O
37	of	O
38	this	O
39	compound	O
40	.	O

1	The	O
2	presence	O
3	of	O
4	regulatory	O
5	sequences	O
6	for	O
7	the	O
8	binding	O
9	of	O
10	transcription	O
11	factors	O
12	such	O
13	as	O
14	NF	B
15	-	I
16	kappa	I
17	B	I
18	and	O
19	AP	B
20	-	I
21	2	I
22	,	O
23	whose	O
24	activation	O
25	is	O
26	associated	O
27	with	O
28	the	O
29	immediate	O
30	response	O
31	of	O
32	the	O
33	cell	O
34	to	O
35	an	O
36	injury	O
37	,	O
38	may	O
39	be	O
40	an	O
41	indication	O
42	of	O
43	the	O
44	important	O
45	role	O
46	which	O
47	HO	B
48	-	I
49	1	I
50	may	O
51	play	O
52	in	O
53	defense	O
54	mechanisms	O
55	against	O
56	tissue	O
57	injury	O
58	.	O

1	Granisetron	O
2	,	O
3	but	O
4	not	O
5	saline	O
6	,	O
7	abolished	O
8	vomiting	O
9	and	O
10	nausea	O
11	when	O
12	given	O
13	as	O
14	intervention	O
15	after	O
16	this	O
17	combined	O
18	emetic	O
19	regimen	O
20	.	O

1	The	O
2	femoroarterial	O
3	coronary	O
4	sinus	O
5	difference	O
6	in	O
7	lactate	O
8	turned	O
9	negative	O
10	,	O
11	and	O
12	pH	O
13	,	O
14	PCO2	O
15	and	O
16	potassium	O
17	differences	O
18	increased	O
19	in	O
20	group	O
21	2	O
22	during	O
23	pacing	O
24	.	O

1	This	O
2	was	O
3	obtained	O
4	with	O
5	the	O
6	thermal	O
7	neutron	O
8	fluency	O
9	2	O
10	.	O
11	0	O
12	x	O
13	10	O
14	(	O
15	10	O
16	)	O
17	n	O
18	/	O
19	cm2	O
20	.	O

1	Endotoxemia	O
2	induced	O
3	by	O
4	gram	O
5	-	O
6	negative	O
7	bacteria	O
8	leads	O
9	to	O
10	endotoxic	O
11	shock	O
12	pathogenetically	O
13	stemming	O
14	from	O
15	the	O
16	integral	O
17	component	O
18	of	O
19	the	O
20	bacterial	O
21	wall	O
22	--	O
23	lipid	O
24	A	O
25	.	O

1	The	O
2	study	O
3	made	O
4	to	O
5	define	O
6	the	O
7	ability	O
8	of	O
9	lipid	B
10	A	I
11	monoclonal	I
12	antibodies	I
13	to	O
14	correct	O
15	hemodynamic	O
16	disturbances	O
17	due	O
18	to	O
19	endotoxemia	O
20	in	O
21	dog	O
22	experiments	O
23	showed	O
24	the	O
25	efficacy	O
26	of	O
27	the	O
28	antibodies	O
29	administration	O
30	.	O

1	A	O
2	randomised	O
3	,	O
4	controlled	O
5	trial	O
6	was	O
7	undertaken	O
8	in	O
9	40	O
10	patients	O
11	with	O
12	active	O
13	Crohn	O
14	'	O
15	s	O
16	disease	O
17	to	O
18	evaluate	O
19	clinical	O
20	and	O
21	nutritional	O
22	outcomes	O
23	after	O
24	an	O
25	amino	O
26	acid	O
27	based	O
28	diet	O
29	containing	O
30	3	O
31	%	O
32	fat	O
33	was	O
34	given	O
35	by	O
36	a	O
37	feeding	O
38	tube	O
39	compared	O
40	with	O
41	a	O
42	peptide	O
43	based	O
44	diet	O
45	containing	O
46	33	O
47	%	O
48	fat	O
49	.	O

1	This	O
2	sequenced	O
3	region	O
4	of	O
5	the	O
6	V	O
7	beta	O
8	locus	O
9	contains	O
10	an	O
11	average	O
12	number	O
13	of	O
14	repetitive	O
15	DNA	O
16	elements	O
17	(	O
18	21	O
19	Alu	B
20	,	O
21	three	O
22	L1	B
23	,	O
24	three	O
25	MER	O
26	,	O
27	and	O
28	three	O
29	retrovirus	O
30	-	O
31	related	O
32	elements	O
33	.	O

1	The	O
2	sequenced	O
3	genomic	O
4	region	O
5	thus	O
6	accounts	O
7	for	O
8	essentially	O
9	all	O
10	of	O
11	the	O
12	longest	O
13	known	O
14	transcript	O
15	(	O
16	4	O
17	.	O
18	5	O
19	kb	O
20	),	O
21	although	O
22	the	O
23	precise	O
24	ends	O
25	of	O
26	this	O
27	transcript	O
28	have	O
29	not	O
30	been	O
31	defined	O
32	.	O

1	The	O
2	pexB	B
3	upstream	I
4	region	I
5	contained	O
6	245	O
7	nucleotides	O
8	within	O
9	which	O
10	sequences	O
11	approximating	O
12	the	O
13	consensus	O
14	for	O
15	cyclic	B
16	AMP	I
17	receptor	I
18	protein	I
19	and	O
20	integration	B
21	host	I
22	factor	I
23	binding	O
24	sites	O
25	were	O
26	discernible	O
27	.	O

1	The	O
2	fepA	B
3	-	O
4	entD	B
5	and	O
6	fes	B
7	-	O
8	entF	B
9	operons	O
10	in	O
11	the	O
12	enterobactin	O
13	synthesis	O
14	and	O
15	transport	O
16	system	O
17	are	O
18	divergently	O
19	transcribed	O
20	from	O
21	overlapping	O
22	promoters	O
23	,	O
24	and	O
25	both	O
26	are	O
27	inhibited	O
28	by	O
29	the	O
30	Fur	B
31	repressor	I
32	protein	I
33	under	O
34	iron	O
35	-	O
36	replete	O
37	conditions	O
38	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	a	O
5	6	O
6	.	O
7	3	O
8	-	O
9	kbp	O
10	genomic	O
11	EcoRI	B
12	-	O
13	fragment	O
14	of	O
15	Alcaligenes	O
16	eutrophus	O
17	,	O
18	which	O
19	was	O
20	recently	O
21	identified	O
22	by	O
23	using	O
24	a	O
25	dihydrolipoamide	B
26	dehydrogenase	I
27	-	O
28	specific	O
29	DNA	O
30	probe	O
31	(	O
32	A	O
33	.	O

1	Using	O
2	a	O
3	previously	O
4	published	O
5	two	O
6	-	O
7	frequency	O
8	(	O
9	AC	O
10	excitation	O
11	)	O
12	three	O
13	-	O
14	electrode	O
15	method	O
16	,	O
17	the	O
18	admittance	O
19	locus	O
20	plot	O
21	(	O
22	ALP	O
23	)	O
24	in	O
25	the	O
26	low	O
27	-	O
28	frequency	O
29	region	O
30	(<	O
31	1000	O
32	Hz	O
33	)	O
34	has	O
35	been	O
36	shown	O
37	to	O
38	be	O
39	very	O
40	well	O
41	approximated	O
42	by	O
43	a	O
44	straight	O
45	line	O
46	and	O
47	can	O
48	be	O
49	described	O
50	with	O
51	frequency	O
52	-	O
53	independent	O
54	parameters	O
55	;	O
56	phase	O
57	angle	O
58	alpha	O
59	pi	O
60	/	O
61	2	O
62	,	O
63	conductance	O
64	at	O
65	extrapolated	O
66	zero	O
67	frequency	O
68	G0	O
69	=	O
70	1	O
71	/	O
72	R0	O
73	,	O
74	and	O
75	ion	O
76	relaxation	O
77	time	O
78	tau	O
79	.	O

1	Intraoperative	O
2	measurement	O
3	of	O
4	activated	O
5	partial	O
6	thromboplastin	B
7	time	O
8	and	O
9	prothrombin	B
10	time	O
11	with	O
12	a	O
13	new	O
14	compact	O
15	monitor	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	sought	O
6	to	O
7	test	O
8	the	O
9	hypothesis	O
10	that	O
11	,	O
12	when	O
13	equal	O
14	volumes	O
15	are	O
16	administered	O
17	intrathecally	O
18	,	O
19	significant	O
20	differences	O
21	exist	O
22	in	O
23	the	O
24	potential	O
25	to	O
26	three	O
27	commonly	O
28	used	O
29	anesthetic	O
30	solutions	O
31	to	O
32	induce	O
33	sensory	O
34	impairment	O
35	.	O

1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	B
9	-	I
10	CBP	I
11	antiserum	I
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O

1	Cloning	O
2	of	O
3	higher	B
4	plant	I
5	omega	I
6	-	I
7	3	I
8	fatty	I
9	acid	I
10	desaturases	I
11	.	O

1	65	O
2	,	O
3	3829	O
4	-	O
5	3838	O
6	,	O
7	1991	O
8	),	O
9	a	O
10	truncated	O
11	form	O
12	of	O
13	the	O
14	IE	B
15	polypeptide	I
16	lacking	O
17	IE	B
18	amino	I
19	acid	I
20	residues	I
21	1	I
22	-	I
23	322	I
24	(	O
25	and	O
26	,	O
27	therefore	O
28	lacks	O
29	the	O
30	deduced	O
31	transcriptional	O
32	activation	O
33	domain	O
34	),	O
35	fails	O
36	to	O
37	transactivate	O
38	the	O
39	EHV	B
40	-	I
41	1	I
42	tk	I
43	promoter	I
44	,	O
45	but	O
46	retains	O
47	the	O
48	ability	O
49	to	O
50	down	O
51	-	O
52	regulate	O
53	the	O
54	EHV	B
55	-	I
56	1	I
57	IE	I
58	promoter	I
59	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	B
6	-	I
7	specific	I
8	RNA	I
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	B
27	.	O

1	CONCLUSION	O
2	:	O
3	Human	O
4	preterm	O
5	birth	O
6	is	O
7	associated	O
8	with	O
9	significantly	O
10	lower	O
11	progesterone	O
12	/	O
13	17	O
14	beta	O
15	-	O
16	estradiol	O
17	ratios	O
18	than	O
19	those	O
20	of	O
21	women	O
22	with	O
23	preterm	O
24	labor	O
25	delivered	O
26	at	O
27	term	O
28	.	O

1	Ketamine	O
2	in	O
3	the	O
4	treatment	O
5	of	O
6	bronchospasm	O
7	during	O
8	mechanical	O
9	ventilation	O
10	.	O

1	In	O
2	conclusion	O
3	,	O
4	the	O
5	disposition	O
6	of	O
7	venlafaxine	O
8	and	O
9	O	O
10	-	O
11	desmethylvenlafaxine	O
12	is	O
13	markedly	O
14	altered	O
15	in	O
16	renal	O
17	disease	O
18	;	O
19	therefore	O
20	dosage	O
21	adjustment	O
22	is	O
23	warranted	O
24	for	O
25	patients	O
26	with	O
27	creatinine	O
28	clearance	O
29	values	O
30	below	O
31	30	O
32	ml	O
33	/	O
34	min	O
35	.	O

1	The	O
2	availability	O
3	of	O
4	sequence	O
5	from	O
6	multiple	O
7	species	O
8	has	O
9	permitted	O
10	us	O
11	to	O
12	determine	O
13	that	O
14	the	O
15	UBE	O
16	site	O
17	has	O
18	close	O
19	similarity	O
20	to	O
21	motifs	O
22	that	O
23	bind	O
24	members	O
25	of	O
26	the	O
27	NF	B
28	-	I
29	1	I
30	family	I
31	of	I
32	transcription	I
33	factors	I
34	.	O

1	The	O
2	incidence	O
3	of	O
4	HSV	O
5	-	O
6	2	O
7	positive	O
8	subjects	O
9	(	O
10	HSV	B
11	-	I
12	2	I
13	/	I
14	HSV	I
15	-	I
16	1	I
17	antibody	I
18	ratio	O
19	>	O
20	or	O
21	=	O
22	1	O
23	)	O
24	was	O
25	low	O
26	in	O
27	the	O
28	Jewish	O
29	Israeli	O
30	population	O
31	,	O
32	compared	O
33	to	O
34	other	O
35	demographic	O
36	areas	O
37	.	O

1	The	O
2	mechanism	O
3	whereby	O
4	zeta	B
5	PKC	I
6	regulates	O
7	NF	B
8	-	I
9	kappa	I
10	B	I
11	most	O
12	probably	O
13	involves	O
14	the	O
15	activation	O
16	of	O
17	a	O
18	putative	O
19	I	B
20	kappa	I
21	B	I
22	kinase	I
23	of	O
24	molecular	O
25	mass	O
26	approximately	O
27	50	O
28	kDa	O
29	,	O
30	which	O
31	phosphorylates	O
32	and	O
33	inactivates	O
34	I	B
35	kappa	I
36	B	I
37	.	O

1	Stable	O
2	expression	O
3	of	O
4	truncated	B
5	inositol	I
6	1	I
7	,	I
8	4	I
9	,	I
10	5	I
11	-	I
12	trisphosphate	I
13	receptor	I
14	subunits	I
15	in	O
16	3T3	O
17	fibroblasts	O
18	.	O

1	The	O
2	molecular	O
3	basis	O
4	for	O
5	commitment	O
6	of	O
7	progenitors	O
8	to	O
9	the	O
10	eosinophil	O
11	lineage	O
12	and	O
13	mechanisms	O
14	by	O
15	which	O
16	eosinophil	O
17	-	O
18	specific	O
19	genes	O
20	are	O
21	expressed	O
22	and	O
23	regulated	O
24	during	O
25	differentiation	O
26	is	O
27	unknown	O
28	.	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	B
9	4	I
10	(	O
11	myosin	B
12	from	I
13	rat	I
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	O
28	myosin	B
29	I	I
30	.	O

1	M	O
2	.,	O
3	and	O
4	D	O
5	.	O

1	In	O
2	addition	O
3	,	O
4	computer	O
5	analysis	O
6	suggests	O
7	that	O
8	sequences	O
9	similar	O
10	to	O
11	the	O
12	A	O
13	stem	O
14	element	O
15	are	O
16	present	O
17	within	O
18	the	O
19	three	O
20	AAV	B
21	promoter	I
22	regions	O
23	.	O

1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	kinds	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	dissociation	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	fourfold	O
38	faster	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O

1	Processing	O
2	of	O
3	the	O
4	NS3	O
5	'-	O
6	5B	B
7	polyprotein	O
8	was	O
9	complex	O
10	and	O
11	occurred	O
12	rapidly	O
13	.	O

1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	B
16	.	O

1	32Pi	O
2	labeling	O
3	or	O
4	isoelectric	O
5	focusing	O
6	analysis	O
7	of	O
8	eIF	B
9	-	I
10	2	I
11	alpha	I
12	from	O
13	conditional	O
14	casein	B
15	kinase	I
16	II	I
17	mutants	I
18	indicated	O
19	that	O
20	phosphorylation	O
21	of	O
22	eIF	B
23	-	I
24	2	I
25	alpha	I
26	is	O
27	abolished	O
28	or	O
29	dephosphorylated	O
30	forms	O
31	of	O
32	eIF	B
33	-	I
34	2	I
35	alpha	I
36	are	O
37	detected	O
38	when	O
39	these	O
40	strains	O
41	are	O
42	grown	O
43	at	O
44	the	O
45	restrictive	O
46	growth	O
47	conditions	O
48	.	O

1	Thus	O
2	,	O
3	YMIP	B
4	is	O
5	a	O
6	functional	O
7	homolog	O
8	of	O
9	RMIP	B
10	and	O
11	represents	O
12	a	O
13	new	O
14	component	O
15	of	O
16	the	O
17	yeast	O
18	mitochondrial	O
19	import	O
20	machinery	O
21	.	O

1	The	O
2	R2	O
3	region	O
4	within	O
5	the	O
6	class	O
7	I	O
8	enhancer	O
9	acts	O
10	as	O
11	a	O
12	negative	O
13	element	O
14	in	O
15	Ad12	O
16	-	O
17	transformed	O
18	cells	O
19	and	O
20	exhibits	O
21	a	O
22	stronger	O
23	binding	O
24	activity	O
25	than	O
26	is	O
27	observed	O
28	in	O
29	nontumorigenic	O
30	Ad5	O
31	-	O
32	transformed	O
33	cells	O
34	,	O
35	which	O
36	are	O
37	not	O
38	reduced	O
39	in	O
40	class	O
41	I	O
42	expression	O
43	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	kinetics	O
7	of	O
8	erythropoietin	B
9	(	O
10	EPO	B
11	)	O
12	production	O
13	and	O
14	address	O
15	the	O
16	pathogenesis	O
17	of	O
18	anemia	O
19	of	O
20	prematurity	O
21	,	O
22	we	O
23	measured	O
24	EPO	B
25	levels	O
26	in	O
27	infants	O
28	during	O
29	the	O
30	first	O
31	year	O
32	of	O
33	life	O
34	.	O

1	The	O
2	nerve	B
3	growth	I
4	factor	I
5	beta	I
6	gene	I
7	(	O
8	NGFB	B
9	)	O
10	belongs	O
11	to	O
12	a	O
13	conserved	O
14	syntenic	O
15	group	O
16	on	O
17	human	O
18	chromosome	O
19	1	O
20	and	O
21	mouse	O
22	Chromosome	O
23	3	O
24	.	O

1	Furthermore	O
2	,	O
3	an	O
4	upstream	O
5	element	O
6	,	O
7	collagen	O
8	element	O
9	I	O
10	(-	O
11	370	O
12	/-	O
13	344	O
14	),	O
15	which	O
16	shares	O
17	homology	O
18	with	O
19	the	O
20	LAP	B
21	binding	O
22	cis	O
23	-	O
24	element	O
25	of	O
26	the	O
27	albumin	B
28	promoter	I
29	(	O
30	9	O
31	of	O
32	13	O
33	bp	O
34	)	O
35	is	O
36	described	O
37	.	O

1	Number	O
2	and	O
3	size	O
4	of	O
5	silver	O
6	-	O
7	stained	O
8	nucleoli	O
9	(	O
10	Ag	O
11	-	O
12	NOR	O
13	clusters	O
14	)	O
15	in	O
16	canine	O
17	seminomas	O
18	:	O
19	correlation	O
20	with	O
21	histological	O
22	features	O
23	and	O
24	tumour	O
25	behaviour	O
26	.	O

1	We	O
2	speculate	O
3	that	O
4	mast	O
5	cell	O
6	degranulation	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	the	O
12	pathogenesis	O
13	of	O
14	necrobiosis	O
15	by	O
16	altering	O
17	fibroblast	O
18	enzyme	O
19	activity	O
20	and	O
21	/	O
22	or	O
23	producing	O
24	prolonged	O
25	inflammatory	O
26	reactions	O
27	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	cysteine	B
6	synthase	I
7	cDNA	I
8	from	O
9	Citrullus	O
10	vulgaris	O
11	(	O
12	watermelon	O
13	)	O
14	by	O
15	genetic	O
16	complementation	O
17	in	O
18	an	O
19	Escherichia	O
20	coli	O
21	Cys	O
22	-	O
23	auxotroph	O
24	.	O

1	In	O
2	earlier	O
3	studies	O
4	we	O
5	identified	O
6	several	O
7	regulatory	O
8	elements	O
9	that	O
10	control	O
11	transcriptional	O
12	activation	O
13	and	O
14	aerobic	O
15	repression	O
16	of	O
17	one	O
18	of	O
19	these	O
20	genes	O
21	,	O
22	COX5b	B
23	.	O

1	Although	O
2	elevated	O
3	serum	O
4	levels	O
5	of	O
6	antibodies	O
7	to	O
8	the	O
9	nicotinic	B
10	acetylcholine	I
11	receptor	I
12	(	O
13	nAChR	B
14	)	O
15	have	O
16	been	O
17	reported	O
18	in	O
19	neuroleptic	O
20	treated	O
21	patients	O
22	with	O
23	tardive	O
24	dyskinesia	O
25	,	O
26	such	O
27	antibodies	O
28	have	O
29	not	O
30	been	O
31	determined	O
32	in	O
33	comparable	O
34	nondyskinetic	O
35	patients	O
36	.	O

1	The	O
2	tumor	O
3	suppressor	O
4	and	O
5	transcriptional	O
6	factor	O
7	p53	B
8	is	O
9	a	O
10	phosphorylated	O
11	protein	O
12	.	O

1	This	O
2	DNA	O
3	containing	O
4	promoter	O
5	activity	O
6	has	O
7	been	O
8	sequenced	O
9	in	O
10	its	O
11	entirety	O
12	and	O
13	found	O
14	to	O
15	contain	O
16	multiple	O
17	putative	O
18	regulatory	O
19	sites	O
20	.	O

1	However	O
2	,	O
3	Southern	O
4	blot	O
5	and	O
6	karyotype	O
7	analyses	O
8	did	O
9	not	O
10	reveal	O
11	any	O
12	significant	O
13	changes	O
14	in	O
15	copy	O
16	number	O
17	or	O
18	gross	O
19	rearrangements	O
20	of	O
21	the	O
22	p53	B
23	gene	I
24	in	O
25	any	O
26	of	O
27	the	O
28	p53	B
29	-	I
30	cell	O
31	lines	O
32	.	O

1	HupI	B
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	rubredoxin	B
7	and	O
8	rubredoxin	B
9	-	I
10	like	I
11	proteins	I
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O

1	The	O
2	PCr	O
3	resynthesis	O
4	rate	O
5	(	O
6	P	O
7	<	O
8	0	O
9	.	O
10	01	O
11	)	O
12	and	O
13	the	O
14	effective	O
15	maximal	O
16	rate	O
17	of	O
18	mitochondrial	O
19	ATP	O
20	synthesis	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	)	O
28	also	O
29	improved	O
30	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	However	O
2	,	O
3	regional	O
4	MVO2	O
5	increased	O
6	to	O
7	about	O
8	the	O
9	same	O
10	extent	O
11	in	O
12	the	O
13	CFX	O
14	(	O
15	from	O
16	6	O
17	.	O
18	0	O
19	+/-	O
20	0	O
21	.	O
22	7	O
23	to	O
24	12	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	9	O
31	ml	O
32	O2	O
33	.	O
34	min	O
35	-	O
36	1	O
37	times	O
38	100	O
39	g	O
40	-	O
41	1	O
42	)	O
43	and	O
44	the	O
45	LAD	O
46	region	O
47	(	O
48	from	O
49	7	O
50	.	O
51	0	O
52	+/-	O
53	0	O
54	.	O
55	6	O
56	to	O
57	14	O
58	.	O
59	5	O
60	+/-	O
61	1	O
62	.	O
63	3	O
64	ml	O
65	O2	O
66	.	O
67	min	O
68	-	O
69	1	O
70	times	O
71	100	O
72	g	O
73	-	O
74	1	O
75	).	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	Immunodepression	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	registered	O
23	.	O

1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	B
23	A	I
24	-	I
25	T	I
26	-	I
27	rich	I
28	binding	I
29	protein	I
30	1	I
31	(	O
32	SATB1	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	O
49	/	O
50	SARs	O
51	).	O

1	Aberrant	O
2	protein	O
3	phosphorylation	O
4	at	O
5	tyrosine	O
6	is	O
7	responsible	O
8	for	O
9	the	O
10	growth	O
11	-	O
12	inhibitory	O
13	action	O
14	of	O
15	pp60v	B
16	-	I
17	src	I
18	expressed	O
19	in	O
20	the	O
21	yeast	O
22	Saccharomyces	O
23	cerevisiae	O
24	.	O

1	Acute	O
2	pancreatitis	O
3	:	O
4	a	O
5	multisystem	O
6	disease	O
7	.	O

1	Alginate	O
2	biosynthesis	O
3	is	O
4	controlled	O
5	by	O
6	a	O
7	complex	O
8	regulatory	O
9	mechanism	O
10	.	O

1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	B
7	promoter	I
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	B
20	regulator	I
21	.	O

1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	I
33	digestion	O
34	in	O
35	vivo	O
36	.	O

1	Heparin	O
2	had	O
3	no	O
4	effect	O
5	on	O
6	rAC	B
7	-	I
8	st	I
9	myosin	I
10	light	I
11	chain	I
12	phosphatase	I
13	activity	O
14	,	O
15	while	O
16	the	O
17	B	O
18	subunit	O
19	-	O
20	containing	O
21	forms	O
22	were	O
23	stimulated	O
24	2	O
25	-	O
26	3	O
27	-	O
28	fold	O
29	.	O

1	The	O
2	relative	O
3	abundance	O
4	of	O
5	each	O
6	alternatively	O
7	spliced	O
8	mRNA	O
9	was	O
10	determined	O
11	by	O
12	reverse	O
13	transcription	O
14	-	O
15	polymerase	O
16	chain	O
17	reaction	O
18	in	O
19	various	O
20	human	O
21	tissues	O
22	and	O
23	cell	O
24	lines	O
25	.	O

1	BACKGROUND	O
2	AND	O
3	DESIGN	O
4	:	O
5	Fifty	O
6	-	O
7	nine	O
8	melanocytic	O
9	nevi	O
10	with	O
11	eccentric	O
12	foci	O
13	of	O
14	hyperpigmentation	O
15	("	O
16	small	O
17	dark	O
18	dots	O
19	")	O
20	that	O
21	measured	O
22	primarily	O
23	1	O
24	to	O
25	2	O
26	mm	O
27	in	O
28	diameter	O
29	were	O
30	prospectively	O
31	examined	O
32	to	O
33	determine	O
34	the	O
35	histologic	O
36	correlates	O
37	of	O
38	the	O
39	dark	O
40	dots	O
41	.	O

1	The	O
2	retention	O
3	index	O
4	of	O
5	201Tl	O
6	SPECT	O
7	is	O
8	a	O
9	useful	O
10	indicator	O
11	of	O
12	metastatic	O
13	potential	O
14	,	O
15	thereby	O
16	facilitating	O
17	the	O
18	prediction	O
19	of	O
20	prognosis	O
21	,	O
22	and	O
23	provides	O
24	insight	O
25	into	O
26	the	O
27	relationship	O
28	between	O
29	201Tl	O
30	uptake	O
31	and	O
32	malignancy	O
33	.	O

1	The	O
2	central	O
3	globular	O
4	domain	O
5	is	O
6	highly	O
7	similar	O
8	to	O
9	those	O
10	regions	O
11	from	O
12	other	O
13	H1	B
14	molecules	I
15	,	O
16	and	O
17	the	O
18	carboxyl	O
19	-	O
20	terminal	O
21	domain	O
22	contains	O
23	a	O
24	repeating	O
25	hexapeptide	O
26	motif	O
27	,	O
28	variants	O
29	of	O
30	which	O
31	are	O
32	conserved	O
33	among	O
34	H1	B
35	molecules	I
36	.	O

1	The	O
2	location	O
3	and	O
4	approximate	O
5	length	O
6	of	O
7	the	O
8	intron	O
9	are	O
10	conserved	O
11	in	O
12	both	O
13	the	O
14	tomato	O
15	and	O
16	Arabidopsis	O
17	genes	O
18	,	O
19	with	O
20	the	O
21	intron	O
22	separating	O
23	the	O
24	'	O
25	nose	O
26	'	O
27	region	O
28	(	O
29	encoded	O
30	by	O
31	exon	O
32	1	O
33	)	O
34	from	O
35	the	O
36	central	O
37	globular	O
38	domain	O
39	(	O
40	exon	O
41	2	O
42	).	O

1	The	O
2	topology	O
3	and	O
4	chain	O
5	folding	O
6	of	O
7	the	O
8	beta	O
9	subunits	O
10	in	O
11	the	O
12	artifactual	O
13	beta	O
14	60	O
15	capsid	O
16	are	O
17	similar	O
18	to	O
19	the	O
20	native	B
21	alpha	I
22	3	I
23	beta	I
24	60	I
25	enzyme	I
26	.	O

1	A	O
2	single	O
3	NMSC	O
4	was	O
5	present	O
6	in	O
7	69	O
8	.	O
9	4	O
10	%,	O
11	two	O
12	in	O
13	16	O
14	%,	O
15	three	O
16	in	O
17	6	O
18	.	O
19	4	O
20	%,	O
21	four	O
22	in	O
23	3	O
24	.	O
25	5	O
26	%,	O
27	five	O
28	to	O
29	nine	O
30	in	O
31	4	O
32	.	O
33	2	O
34	%,	O
35	and	O
36	0	O
37	.	O
38	5	O
39	%	O
40	had	O
41	ten	O
42	or	O
43	more	O
44	.	O

1	A	O
2	constitutive	O
3	mutant	O
4	form	O
5	with	O
6	a	O
7	single	O
8	substitution	O
9	(	O
10	V88A	O
11	)	O
12	in	O
13	the	O
14	amino	O
15	-	O
16	terminal	O
17	(	O
18	response	O
19	regulator	O
20	)	O
21	region	O
22	was	O
23	used	O
24	.	O

1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	O
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	B
13	heptamers	I
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O

1	Direct	O
2	binding	O
3	and	O
4	competition	O
5	assays	O
6	using	O
7	30	O
8	-	O
9	mer	O
10	oligonucleotide	O
11	probes	O
12	representing	O
13	the	O
14	individual	O
15	CBF1	B
16	binding	I
17	sites	I
18	indicated	O
19	that	O
20	CBF1	B
21	bound	O
22	less	O
23	efficiently	O
24	to	O
25	the	O
26	CD23	B
27	promoter	I
28	and	O
29	the	O
30	EBV	B
31	LMP	I
32	-	I
33	1	I
34	promoter	I
35	sites	I
36	than	O
37	to	O
38	the	O
39	Cp	B
40	site	I
41	.	O

1	We	O
2	have	O
3	found	O
4	a	O
5	satisfactory	O
6	reproducibility	O
7	in	O
8	vitro	O
9	(	O
10	T1	O
11	:	O
12	1	O
13	.	O
14	9	O
15	%;	O
16	T2	O
17	:	O
18	6	O
19	.	O
20	2	O
21	%),	O
22	while	O
23	the	O
24	reproducibility	O
25	was	O
26	less	O
27	satisfactory	O
28	in	O
29	vivo	O
30	(	O
31	T1	O
32	:	O
33	16	O
34	.	O
35	4	O
36	%;	O
37	T2	O
38	:	O
39	13	O
40	.	O
41	4	O
42	%).	O

1	The	O
2	two	O
3	ParA	B
4	proteins	I
5	that	O
6	are	O
7	produced	O
8	as	O
9	a	O
10	result	O
11	of	O
12	independent	O
13	translation	O
14	initiation	O
15	at	O
16	two	O
17	different	O
18	start	O
19	codons	O
20	within	O
21	the	O
22	same	O
23	open	O
24	reading	O
25	frame	O
26	were	O
27	overexpressed	O
28	in	O
29	Escherichia	O
30	coli	O
31	and	O
32	partially	O
33	purified	O
34	.	O

1	To	O
2	get	O
3	further	O
4	insights	O
5	into	O
6	the	O
7	molecular	O
8	mechanisms	O
9	that	O
10	control	O
11	tal	B
12	-	I
13	1	I
14	expression	O
15	,	O
16	we	O
17	have	O
18	isolated	O
19	5	O
20	'	O
21	sequences	O
22	of	O
23	the	O
24	murine	O
25	gene	O
26	and	O
27	compared	O
28	them	O
29	to	O
30	their	O
31	human	O
32	counterparts	O
33	.	O

1	CONCLUSION	O
2	:	O
3	Sonographic	O
4	angiography	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	nodules	O
15	in	O
16	patients	O
17	with	O
18	CRF	O
19	.	O

1	Each	O
2	expressed	O
3	domain	O
4	,	O
5	as	O
6	well	O
7	as	O
8	FKBP	B
9	-	I
10	33	I
11	itself	O
12	,	O
13	possesses	O
14	peptidyl	B
15	-	I
16	prolyl	I
17	cis	I
18	-	I
19	trans	I
20	isomerase	I
21	activity	O
22	,	O
23	though	O
24	with	O
25	much	O
26	lower	O
27	specific	O
28	activities	O
29	than	O
30	FKBP	B
31	-	I
32	12	I
33	.	O

1	The	O
2	first	O
3	85	O
4	nt	O
5	upstream	O
6	of	O
7	the	O
8	transcription	O
9	initiation	O
10	site	O
11	of	O
12	the	O
13	mouse	B
14	desmin	I
15	gene	I
16	,	O
17	which	O
18	contain	O
19	an	O
20	E	O
21	box	O
22	(	O
23	E1	O
24	),	O
25	the	O
26	binding	O
27	site	O
28	of	O
29	the	O
30	helix	B
31	-	I
32	loop	I
33	-	I
34	helix	I
35	myogenic	I
36	regulators	I
37	,	O
38	are	O
39	sufficient	O
40	to	O
41	confer	O
42	low	O
43	level	O
44	muscle	O
45	-	O
46	specific	O
47	expression	O
48	.	O

1	The	O
2	acfD	B
3	gene	I
4	encompasses	O
5	254	O
6	nt	O
7	that	O
8	are	O
9	predicted	O
10	to	O
11	encode	O
12	an	O
13	88	O
14	-	O
15	amino	O
16	-	O
17	acid	O
18	(	O
19	aa	O
20	)	O
21	protein	O
22	.	O

1	We	O
2	find	O
3	that	O
4	beta	B
5	II	I
6	PKC	I
7	phosphorylates	O
8	nuclear	B
9	envelope	I
10	lamin	I
11	B	I
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	B
21	PKC	I
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	B
28	lamin	I
29	B	I
30	at	O
31	similar	O
32	rates	O
33	.	O

1	Regulation	O
2	of	O
3	parathyroid	B
4	hormone	I
5	-	I
6	related	I
7	protein	I
8	(	O
9	PTHrP	B
10	)	O
11	gene	O
12	expression	O
13	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	diverse	O
7	set	O
8	of	O
9	carboxyl	O
10	-	O
11	terminal	O
12	sequence	O
13	motifs	O
14	and	O
15	posttranslational	O
16	modifications	O
17	lead	O
18	to	O
19	functional	O
20	Ras	B
21	proteins	I
22	in	O
23	yeast	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Abl	I
7	activates	O
8	c	B
9	-	I
10	myc	I
11	transcription	O
12	indirectly	O
13	with	O
14	no	O
15	requirement	O
16	for	O
17	DNA	O
18	binding	O
19	by	O
20	c	B
21	-	I
22	Abl	I
23	.	O

1	Long	O
2	-	O
3	latency	O
4	:	O
5	locked	O
6	units	O
7	responded	O
8	to	O
9	shocks	O
10	with	O
11	little	O
12	jitter	O
13	and	O
14	long	O
15	latency	O
16	(	O
17	4	O
18	-	O
19	11	O
20	ms	O
21	).	O

1	The	O
2	highly	O
3	conserved	O
4	ninth	O
5	heptad	O
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	heterodimerization	O
12	,	O
13	appears	O
14	to	O
15	participate	O
16	in	O
17	the	O
18	receptor	O
19	-	O
20	inhibitor	O
21	interaction	O
22	,	O
23	suggesting	O
24	that	O
25	the	O
26	inhibitor	O
27	is	O
28	a	O
29	related	O
30	member	O
31	of	O
32	the	O
33	receptor	O
34	gene	O
35	family	O
36	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	for	O
6	expression	O
7	of	O
8	snRNA	O
9	genes	O
10	in	O
11	maize	O
12	,	O
13	a	O
14	monocotyledonous	O
15	plant	O
16	,	O
17	the	O
18	USE	O
19	and	O
20	TATA	O
21	elements	O
22	are	O
23	essential	O
24	,	O
25	but	O
26	not	O
27	sufficient	O
28	,	O
29	for	O
30	transcription	O
31	.	O

1	Extensive	O
2	DNA	O
3	rearrangement	O
4	occurs	O
5	during	O
6	the	O
7	development	O
8	of	O
9	the	O
10	somatic	O
11	macronucleus	O
12	from	O
13	the	O
14	germ	O
15	line	O
16	micronucleus	O
17	in	O
18	ciliated	O
19	protozoans	O
20	.	O

1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	B
18	-	I
19	type	I
20	HLF	I
21	and	O
22	chimeric	O
23	E2A	B
24	-	O
25	HLF	B
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O

1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	(	O
8	snRNP	O
9	)	O
10	to	O
11	the	O
12	pre	O
13	-	O
14	mRNA	O
15	is	O
16	an	O
17	early	O
18	and	O
19	important	O
20	step	O
21	in	O
22	spliceosome	O
23	assembly	O
24	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Dbf8p	B
9	plays	O
10	an	O
11	essential	O
12	role	O
13	in	O
14	chromosome	O
15	segregation	O
16	.	O

1	Ariga	O
2	,	O
3	Biochem	O
4	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	KRAB	B
7	domain	I
8	present	O
9	in	O
10	the	O
11	non	O
12	-	O
13	finger	O
14	region	O
15	of	O
16	many	O
17	ZFP	B
18	genes	I
19	quenches	O
20	transcription	O
21	possibly	O
22	due	O
23	to	O
24	specific	O
25	protein	O
26	-	O
27	protein	O
28	interactions	O
29	between	O
30	the	O
31	KRAB	B
32	-	I
33	A	I
34	domain	I
35	and	O
36	components	O
37	of	O
38	the	O
39	proximal	O
40	transcriptional	O
41	apparatus	O
42	.	O

1	Marine	O
2	oils	O
3	and	O
4	cardiovascular	O
5	reactivity	O
6	.	O

1	The	O
2	diagnostic	O
3	significance	O
4	of	O
5	creatine	B
6	phosphokinase	I
7	antibodies	O
8	in	O
9	the	O
10	cardiac	O
11	muscle	O
12	in	O
13	non	O
14	-	O
15	coronarogenic	O
16	myocardial	O
17	diseases	O

1	According	O
2	to	O
3	the	O
4	results	O
5	of	O
6	assays	O
7	obtained	O
8	with	O
9	the	O
10	use	O
11	of	O
12	assay	O
13	systems	O
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	O
18	HCV	O
19	EIA	O
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	B
28	-	I
29	HCV	I
30	-	I
31	C100	I
32	-	I
33	3	I
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	B
53	carriers	O
54	(	O
55	1	O
56	.	O
57	8	O
58	%)	O
59	and	O
60	among	O
61	donors	O
62	with	O
63	anti	B
64	-	I
65	HCV	I
66	-	I
67	C100	I
68	-	I
69	3	I
70	in	O
71	the	O
72	blood	O
73	(	O
74	1	O
75	.	O
76	6	O
77	%)	O
78	(	O
79	p	O
80	<	O
81	0	O
82	.	O
83	01	O
84	).	O

1	We	O
2	examined	O
3	the	O
4	hypothesis	O
5	that	O
6	the	O
7	coronary	O
8	vasomotor	O
9	responses	O
10	to	O
11	etomidate	O
12	(	O
13	ETO	O
14	),	O
15	propofol	O
16	(	O
17	PRO	O
18	),	O
19	and	O
20	sodium	O
21	thiopental	O
22	(	O
23	STP	O
24	)	O
25	are	O
26	mediated	O
27	through	O
28	contrasting	O
29	effects	O
30	on	O
31	the	O
32	resting	O
33	nitric	O
34	oxide	O
35	(	O
36	NO	O
37	)-	O
38	dependent	O
39	vasodilator	O
40	tone	O
41	that	O
42	opposes	O
43	adrenergic	O
44	vasoconstrictor	O
45	activity	O
46	in	O
47	the	O
48	intact	O
49	dog	O
50	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	O
7	serum	B
8	CRP	I
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	These	O
2	alternative	O
3	splice	O
4	variants	O
5	were	O
6	detected	O
7	in	O
8	RNA	O
9	isolated	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	primary	O
16	leptomeningeal	O
17	tissue	O
18	and	O
19	an	O
20	established	O
21	line	O
22	of	O
23	leptomeningeal	O
24	cells	O
25	(	O
26	LMC	O
27	).	O

1	Roux	O
2	-	O
3	en	O
4	-	O
5	Y	O
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O

1	Surface	O
2	-	O
3	coil	O
4	experiments	O
5	on	O
6	phantoms	O
7	and	O
8	on	O
9	human	O
10	calf	O
11	muscles	O
12	in	O
13	vivo	O
14	are	O
15	presented	O
16	.	O

1	Large	O
2	interpatient	O
3	variation	O
4	in	O
5	peak	O
6	PCZ	O
7	plasma	O
8	levels	O
9	(	O
10	91	O
11	-	O
12	3215	O
13	ng	O
14	/	O
15	ml	O
16	)	O
17	was	O
18	seen	O
19	,	O
20	with	O
21	the	O
22	plasma	O
23	half	O
24	-	O
25	life	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	alpha	O
31	)	O
32	being	O
33	approximately	O
34	57	O
35	min	O
36	in	O
37	patients	O
38	given	O
39	135	O
40	-	O
41	180	O
42	mg	O
43	/	O
44	m2	O
45	PCZ	O
46	.	O

1	The	O
2	maximal	O
3	effect	O
4	was	O
5	seen	O
6	at	O
7	100	O
8	ng	O
9	/	O
10	ml	O
11	EGF	B
12	,	O
13	with	O
14	a	O
15	time	O
16	lag	O
17	of	O
18	about	O
19	5	O
20	h	O
21	.	O

1	KAR1	B
2	encodes	O
3	an	O
4	essential	O
5	component	O
6	of	O
7	the	O
8	yeast	O
9	spindle	O
10	pole	O
11	body	O
12	(	O
13	SPB	O
14	)	O
15	that	O
16	is	O
17	required	O
18	for	O
19	karyogamy	O
20	and	O
21	SPB	O
22	duplication	O
23	.	O

1	CDC31	B
2	is	O
3	required	O
4	for	O
5	SPB	O
6	duplication	O
7	and	O
8	encodes	O
9	a	O
10	calmodulin	B
11	-	I
12	like	I
13	protein	I
14	that	O
15	is	O
16	most	O
17	closely	O
18	related	O
19	to	O
20	caltractin	B
21	/	O
22	centrin	B
23	,	O
24	a	O
25	protein	O
26	associated	O
27	with	O
28	the	O
29	Chlamydomonas	O
30	basal	O
31	body	O
32	.	O

1	During	O
2	transcript	O
3	elongation	O
4	,	O
5	the	O
6	sizes	O
7	of	O
8	the	O
9	DNA	O
10	footprint	O
11	and	O
12	the	O
13	single	O
14	-	O
15	stranded	O
16	transcription	O
17	bubble	O
18	vary	O
19	markedly	O
20	among	O
21	transcription	O
22	complexes	O
23	halted	O
24	at	O
25	different	O
26	template	O
27	positions	O
28	.	O

1	The	O
2	newly	O
3	recognised	O
4	skeletogenital	O
5	syndrome	O
6	.	O

1	All	O
2	our	O
3	patients	O
4	had	O
5	polyps	O
6	,	O
7	23	O
8	(	O
9	54	O
10	%)	O
11	had	O
12	asthma	O
13	,	O
14	12	O
15	(	O
16	27	O
17	%)	O
18	had	O
19	aspirin	O
20	sensitivity	O
21	,	O
22	20	O
23	(	O
24	65	O
25	%)	O
26	had	O
27	eosinophilia	O
28	,	O
29	and	O
30	9	O
31	(	O
32	69	O
33	%)	O
34	had	O
35	increased	O
36	total	O
37	IgE	B
38	levels	O
39	.	O

1	Ras	B
2	-	I
3	and	I
4	ultra	I
5	-	I
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	I
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	A	O
2	short	O
3	sequence	O
4	surrounding	O
5	the	O
6	major	O
7	JNK	B
8	phosphorylation	O
9	site	O
10	of	O
11	c	B
12	-	I
13	Jun	I
14	is	O
15	conserved	O
16	in	O
17	c	B
18	-	I
19	Fos	I
20	and	O
21	is	O
22	part	O
23	of	O
24	its	O
25	activation	O
26	domain	O
27	,	O
28	suggesting	O
29	that	O
30	c	B
31	-	I
32	Fos	I
33	may	O
34	be	O
35	similarly	O
36	regulated	O
37	.	O

1	c	B
2	-	I
3	Fos	I
4	transcriptional	O
5	activity	O
6	stimulated	O
7	by	O
8	H	B
9	-	I
10	Ras	I
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	distinct	O
16	from	O
17	JNK	B
18	and	O
19	ERK	B
20	.	O

1	A	O
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	O
16	WWW	O
17	server	O
18	.	O

1	Essential	O
2	features	O
3	of	O
4	this	O
5	model	O
6	are	O
7	bending	O
8	of	O
9	the	O
10	DNA	O
11	double	O
12	helix	O
13	and	O
14	contact	O
15	of	O
16	operator	O
17	sites	O
18	with	O
19	repressor	O
20	domains	O
21	bearing	O
22	sequence	O
23	homologies	O
24	with	O
25	the	O
26	helix	O
27	-	O
28	turn	O
29	-	O
30	helix	O
31	(	O
32	HTH	O
33	)	O
34	motifs	O
35	of	O
36	other	O
37	DNA	O
38	-	O
39	binding	O
40	proteins	O
41	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	binding	O
3	of	O
4	transcription	O
5	factor	O
6	AP	B
7	-	I
8	1	I
9	and	O
10	vitamin	B
11	D	I
12	receptor	I
13	(	O
14	VDR	B
15	)	O
16	to	O
17	the	O
18	composite	O
19	AP	B
20	-	I
21	1	I
22	plus	I
23	vitamin	I
24	-	I
25	D	I
26	-	I
27	responsive	I
28	promoter	I
29	region	O
30	(	O
31	AP	B
32	-	I
33	1	I
34	+	I
35	VDRE	I
36	)	O
37	of	O
38	the	O
39	human	B
40	osteocalcin	I
41	gene	I
42	was	O
43	characterized	O
44	in	O
45	osteocalcin	B
46	-	O
47	producing	O
48	(	O
49	MG	O
50	-	O
51	63	O
52	)	O
53	and	O
54	non	O
55	-	O
56	producing	O
57	(	O
58	U2	O
59	-	O
60	Os	O
61	,	O
62	SaOs	O
63	-	O
64	2	O
65	)	O
66	human	O
67	osteosarcoma	O
68	cell	O
69	lines	O
70	.	O

1	Rapid	O
2	detection	O
3	of	O
4	this	O
5	mutation	O
6	is	O
7	achieved	O
8	by	O
9	restriction	O
10	digestion	O
11	of	O
12	PCR	O
13	-	O
14	amplified	O
15	genomic	O
16	DNA	O
17	;	O
18	a	O
19	mismatch	O
20	primer	O
21	combined	O
22	with	O
23	the	O
24	point	O
25	mutation	O
26	creates	O
27	a	O
28	Tru9I	B
29	restriction	I
30	site	I
31	.	O

1	Wild	B
2	type	I
3	and	I
4	mutant	I
5	Epo	I
6	cDNAs	I
7	were	O
8	transiently	O
9	expressed	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	COS1	O
15	and	O
16	COS7	O
17	cells	O
18	.	O

1	OBJECTIVE	O
2	--	O
3	To	O
4	assess	O
5	the	O
6	risk	O
7	of	O
8	hepatitis	O
9	A	O
10	in	O
11	international	O
12	travelers	O
13	and	O
14	to	O
15	recommend	O
16	preventive	O
17	measures	O
18	.	O

1	The	O
2	bactericidal	O
3	effect	O
4	of	O
5	disinfectants	O
6	against	O
7	biofilm	O
8	cells	O
9	was	O
10	found	O
11	to	O
12	be	O
13	considerably	O
14	enhanced	O
15	by	O
16	increasing	O
17	the	O
18	concentrations	O
19	of	O
20	the	O
21	disinfectants	O
22	.	O

1	Expression	O
2	of	O
3	ME31B	B
4	cDNA	I
5	in	O
6	S	O
7	.	O
8	pombe	O
9	suppresses	O
10	the	O
11	ste13	B
12	mutation	O
13	.	O

1	Use	O
2	of	O
3	Medi	O
4	-	O
5	Jector	O
6	EZ	O
7	dermojet	O
8	for	O
9	anesthesia	O
10	in	O
11	minor	O
12	surgery	O

1	2	O
2	.	O

1	The	O
2	immune	O
3	response	O
4	of	O
5	past	O
6	-	O
7	infection	O
8	of	O
9	cytomegalovirus	O
10	in	O
11	the	O
12	patients	O
13	of	O
14	RTID	O
15	is	O
16	rather	O
17	remarkable	O
18	.	O

1	Acupuncture	O
2	effect	O
3	on	O
4	deep	O
5	receptors	O
6	was	O
7	not	O
8	limited	O
9	to	O
10	one	O
11	point	O
12	but	O
13	within	O
14	a	O
15	certain	O
16	area	O
17	,	O
18	namely	O
19	distant	O
20	effect	O
21	existed	O
22	.	O

1	Reduced	O
2	NK	O
3	activity	O
4	correlates	O
5	with	O
6	active	O
7	disease	O
8	in	O
9	HIV	O
10	-	O
11	patients	O
12	with	O
13	multidrug	O
14	-	O
15	resistant	O
16	pulmonary	O
17	tuberculosis	O
18	.	O

1	Smoking	O
2	history	O
3	and	O
4	awake	O
5	oxygen	O
6	saturation	O
7	(	O
8	SaO2	O
9	)	O
10	was	O
11	recorded	O
12	in	O
13	all	O
14	of	O
15	them	O
16	.	O

1	(	O
2	LH	B
3	P	O
4	<	O
5	0	O
6	.	O
7	05	O
8	,	O
9	LH	B
10	/	O
11	FSH	B
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	).	O

1	The	O
2	relative	O
3	R	O
4	-	O
5	and	O
6	L	O
7	-	O
8	brain	O
9	weights	O
10	were	O
11	found	O
12	to	O
13	be	O
14	inversely	O
15	related	O
16	to	O
17	the	O
18	relative	O
19	R	O
20	-	O
21	L	O
22	brain	O
23	weight	O
24	only	O
25	in	O
26	the	O
27	RH	O
28	female	O
29	cats	O
30	with	O
31	R	O
32	-	O
33	L	O
34	brain	O
35	weight	O
36	smaller	O
37	than	O
38	zero	O
39	(	O
40	testosterone	O
41	in	O
42	males	O
43	,	O
44	estrogen	O
45	in	O
46	females	O
47	).	O

1	This	O
2	mode	O
3	of	O
4	ternary	O
5	complex	O
6	formation	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	the	O
12	one	O
13	seen	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	the	O
19	c	B
20	-	I
21	fos	I
22	protooncogene	I
23	,	O
24	where	O
25	formation	O
26	of	O
27	the	O
28	ternary	O
29	complex	O
30	is	O
31	dependent	O
32	on	O
33	the	O
34	prior	O
35	assembly	O
36	of	O
37	the	O
38	serum	B
39	response	I
40	factor	I
41	-	I
42	DNA	I
43	binary	I
44	complex	I
45	.	O

1	The	O
2	LTR	O
3	-	O
4	binding	O
5	activities	O
6	of	O
7	VBP	B
8	,	O
9	a1	B
10	/	I
11	EBP	I
12	,	O
13	and	O
14	B	B
15	-	I
16	cell	I
17	nuclear	I
18	extract	I
19	protein	I
20	were	O
21	compared	O
22	and	O
23	mapped	O
24	by	O
25	gel	O
26	shift	O
27	,	O
28	DNase	B
29	I	I
30	footprinting	O
31	,	O
32	and	O
33	methylation	O
34	interference	O
35	assays	O
36	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	Vaccinia	O
2	virus	O
3	-	O
4	expressed	O
5	,	O
6	purified	O
7	full	B
8	-	I
9	length	I
10	HPV	I
11	-	I
12	16	I
13	and	I
14	BPV	I
15	-	I
16	1	I
17	E2	I
18	proteins	I
19	bound	O
20	a	O
21	consensus	O
22	E2	B
23	site	I
24	with	O
25	high	O
26	specific	O
27	affinities	O
28	(	O
29	Kd	O
30	=	O
31	approximately	O
32	10	O
33	(-	O
34	9	O
35	)	O
36	M	O
37	)	O
38	and	O
39	stimulated	O
40	in	O
41	vitro	O
42	transcription	O
43	up	O
44	to	O
45	six	O
46	-	O
47	to	O
48	eightfold	O
49	.	O

1	This	O
2	alternatively	O
3	spliced	O
4	transcript	O
5	contained	O
6	an	O
7	open	O
8	reading	O
9	frame	O
10	extending	O
11	from	O
12	the	O
13	upstream	O
14	J	O
15	alpha	O
16	11	O
17	-	O
18	2	O
19	region	O
20	to	O
21	82	O
22	nucleotides	O
23	downstream	O
24	of	O
25	the	O
26	beginning	O
27	of	O
28	the	O
29	TCR	B
30	C	I
31	alpha	I
32	region	I
33	,	O
34	and	O
35	potentially	O
36	encoded	O
37	a	O
38	36	O
39	amino	O
40	acid	O
41	polypeptide	O
42	.	O

1	In	O
2	HeLa	O
3	x	O
4	fibroblast	O
5	cell	O
6	hybrids	O
7	its	O
8	expression	O
9	correlates	O
10	with	O
11	tumorigenicity	O
12	.	O

1	Demographic	O
2	characteristics	O
3	and	O
4	risk	O
5	factor	O
6	data	O
7	for	O
8	76	O
9	,	O
10	672	O
11	clients	O
12	were	O
13	studied	O
14	to	O
15	characterize	O
16	the	O
17	distribution	O
18	of	O
19	infection	O
20	with	O
21	human	O
22	immunodeficiency	O
23	virus	O
24	(	O
25	HIV	O
26	)	O
27	and	O
28	the	O
29	use	O
30	of	O
31	counseling	O
32	and	O
33	testing	O
34	facilities	O
35	in	O
36	Houston	O
37	,	O
38	Tex	O
39	.	O

1	Results	O
2	indicate	O
3	that	O
4	KNM	O
5	-	O
6	LU	O
7	335	O
8	differs	O
9	from	O
10	both	O
11	human	O
12	and	O
13	chimpanzee	O
14	M1s	O
15	in	O
16	relative	O
17	distances	O
18	(	O
19	measured	O
20	in	O
21	three	O
22	dimensions	O
23	)	O
24	between	O
25	crown	O
26	fissure	O
27	termini	O
28	.	O

1	We	O
2	describe	O
3	49	O
4	cases	O
5	with	O
6	papillary	O
7	tumor	O
8	<	O
9	1	O
10	cm	O
11	.	O

1	Comparison	O
2	with	O
3	the	O
4	bovine	O
5	gene	O
6	showed	O
7	that	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	hATP1	B
16	gene	I
17	has	O
18	an	O
19	unconserved	O
20	guanine	O
21	-	O
22	cytosine	O
23	(	O
24	GC	O
25	)	O
26	rich	O
27	region	O
28	,	O
29	including	O
30	several	O
31	binding	O
32	motifs	O
33	of	O
34	transcriptional	O
35	factors	O
36	,	O
37	such	O
38	as	O
39	Sp1	B
40	,	O
41	AP	B
42	-	I
43	2	I
44	,	O
45	and	O
46	GCF	B
47	.	O

1	Structure	O
2	,	O
3	promoter	O
4	analysis	O
5	and	O
6	chromosomal	O
7	assignment	O
8	of	O
9	the	O
10	human	B
11	APEX	I
12	gene	I
13	.	O

1	The	O
2	polyubiquitin	B
3	gene	I
4	was	O
5	transcribed	O
6	throughout	O
7	the	O
8	Volvox	O
9	life	O
10	cycle	O
11	with	O
12	peaks	O
13	in	O
14	the	O
15	1	O
16	.	O
17	6	O
18	-	O
19	kb	O
20	mRNA	O
21	levels	O
22	during	O
23	pre	O
24	-	O
25	cleavage	O
26	,	O
27	cleavage	O
28	,	O
29	and	O
30	post	O
31	-	O
32	inversion	O
33	.	O

1	Thus	O
2	,	O
3	in	O
4	stress	O
5	-	O
6	induced	O
7	arrhythmic	O
8	disease	O
9	as	O
10	well	O
11	as	O
12	in	O
13	ischemic	O
14	heart	O
15	disease	O
16	,	O
17	the	O
18	main	O
19	pathogenetic	O
20	links	O
21	are	O
22	outside	O
23	the	O
24	heart	O
25	,	O
26	but	O
27	they	O
28	differ	O
29	from	O
30	those	O
31	observed	O
32	in	O
33	ischemia	O
34	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	genetic	O
6	evidence	O
7	in	O
8	Saccharomyces	O
9	cerevisiae	O
10	for	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	the	O
16	DEAH	B
17	protein	I
18	Prp16	I
19	,	O
20	and	O
21	the	O
22	U6	B
23	and	O
24	U2	B
25	spliceosomal	I
26	snRNAs	I
27	.	O

1	The	O
2	consensus	O
3	gene	O
4	order	O
5	deduced	O
6	by	O
7	combining	O
8	data	O
9	from	O
10	both	O
11	crosses	O
12	is	O
13	D2Mit1	B
14	-(	O
15	Dbh	B
16	,	O
17	Notch1	B
18	)-(	O
19	Col5a1	B
20	,	O
21	Rxra	B
22	)-	O
23	Spna2	B
24	-	O
25	Ab	B
26	l	I
27	-(	O
28	Ak1	B
29	,	O
30	Fpgs	B
31	)-	O
32	(	O
33	Grp78	B
34	,	O
35	Pbx3	B
36	)-(	O
37	Epb7	B
38	.	I
39	2	I
40	,	I
41	Hc	I
42	,	I
43	Gsn	I
44	)-	O
45	Acra	B
46	.	O

1	The	O
2	high	O
3	level	O
4	of	O
5	transformation	O
6	-	O
7	associated	O
8	deletions	O
9	in	O
10	the	O
11	human	O
12	YACs	O
13	was	O
14	reduced	O
15	over	O
16	10	O
17	-	O
18	fold	O
19	when	O
20	the	O
21	host	O
22	was	O
23	a	O
24	recombination	O
25	-	O
26	deficient	O
27	strain	O
28	deleted	O
29	for	O
30	the	O
31	RAD52	B
32	gene	I
33	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	megabase	O
6	region	O
7	surrounding	O
8	the	O
9	dagA	B
10	locus	I
11	was	O
12	mapped	O
13	.	O

1	These	O
2	mutants	O
3	had	O
4	deletions	O
5	of	O
6	the	O
7	extreme	O
8	amino	O
9	-	O
10	terminal	O
11	residues	O
12	as	O
13	far	O
14	as	O
15	amino	O
16	acid	O
17	residue	O
18	30	O
19	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	Elimination	O
2	of	O
3	natural	O
4	antibodies	O
5	in	O
6	discordant	O
7	xenografts	O

1	An	O
2	8	O
3	-	O
4	bp	O
5	sequence	O
6	(	O
7	ATTTCAAA	O
8	)	O
9	within	O
10	the	O
11	protected	O
12	region	O
13	shares	O
14	significant	O
15	homology	O
16	with	O
17	promoter	O
18	sequences	O
19	required	O
20	for	O
21	ethylene	O
22	responsiveness	O
23	from	O
24	the	O
25	tomato	O
26	fruit	O
27	-	O
28	ripening	O
29	E4	B
30	gene	I
31	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	DNA	B
6	polymerase	I
7	delta	I
8	of	I
9	Saccharomyces	I
10	cerevisiae	I
11	,	O
12	an	O
13	enzyme	O
14	that	O
15	is	O
16	essential	O
17	for	O
18	viability	O
19	and	O
20	chromosomal	O
21	replication	O
22	,	O
23	is	O
24	also	O
25	required	O
26	for	O
27	base	O
28	excision	O
29	repair	O
30	of	O
31	exogenous	O
32	DNA	O
33	methylation	O
34	damage	O
35	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	Marek	O
6	'	O
7	s	O
8	Disease	O
9	Virus	O
10	(	O
11	MDV	O
12	)	O
13	genes	O
14	within	O
15	the	O
16	EcoRI	B
17	-	I
18	B	I
19	fragment	I
20	of	O
21	MDV	O
22	-	O
23	GA	O
24	genomic	O
25	DNA	O
26	.	O

1	Cowpox	O
2	virus	O
3	contains	O
4	two	O
5	copies	O
6	of	O
7	an	O
8	early	B
9	gene	I
10	encoding	O
11	a	O
12	soluble	O
13	secreted	O
14	form	O
15	of	O
16	the	O
17	type	B
18	II	I
19	TNF	I
20	receptor	I
21	.	O

1	To	O
2	determine	O
3	whether	O
4	P35	B
5	could	O
6	activate	O
7	the	O
8	39k	O
9	promoter	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	IE1	B
15	,	O
16	the	O
17	p35	B
18	open	O
19	reading	O
20	frame	O
21	was	O
22	cloned	O
23	under	O
24	the	O
25	control	O
26	of	O
27	the	O
28	ie1	B
29	promoter	I
30	.	O

1	Mutagenesis	O
2	of	O
3	each	O
4	NRF	B
5	-	I
6	1	I
7	motif	I
8	in	O
9	the	O
10	ALAS	B
11	promoter	I
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	NRF	B
26	-	I
27	1	I
28	motifs	I
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	analysis	O
5	indicated	O
6	that	O
7	DREF	B
8	binds	O
9	to	O
10	the	O
11	24	O
12	-	O
13	bp	O
14	DRE	O
15	region	O
16	of	O
17	the	O
18	DNA	B
19	polymerase	I
20	alpha	I
21	gene	I
22	in	O
23	which	O
24	8	O
25	-	O
26	bp	O
27	palindromic	O
28	sequences	O
29	are	O
30	centered	O
31	.	O

1	Novel	O
2	8	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	(	O
8	Drosophila	O
9	DNA	O
10	replication	O
11	-	O
12	related	O
13	element	O
14	)	O
15	and	O
16	specific	O
17	binding	O
18	factor	O
19	involved	O
20	in	O
21	the	O
22	expression	O
23	of	O
24	Drosophila	O
25	genes	O
26	for	O
27	DNA	B
28	polymerase	I
29	alpha	I
30	and	O
31	proliferating	B
32	cell	I
33	nuclear	I
34	antigen	I
35	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	B
38	locus	I
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O

1	However	O
2	,	O
3	tyrA	B
4	can	O
5	be	O
6	expressed	O
7	efficiently	O
8	from	O
9	an	O
10	internal	O
11	promoter	O
12	which	O
13	appears	O
14	to	O
15	lie	O
16	within	O
17	the	O
18	3	O
19	'	O
20	portion	O
21	of	O
22	aroF	B
23	.	O

1	Within	O
2	the	O
3	span	O
4	of	O
5	attenuator	O
6	region	O
7	encoding	O
8	the	O
9	three	O
10	stem	O
11	-	O
12	loop	O
13	structures	O
14	of	O
15	mRNA	O
16	secondary	O
17	configuration	O
18	,	O
19	hot	O
20	spots	O
21	of	O
22	base	O
23	-	O
24	residue	O
25	divergence	O
26	were	O
27	localized	O
28	to	O
29	looped	O
30	-	O
31	out	O
32	regions	O
33	.	O

1	Most	O
2	,	O
3	however	O
4	,	O
5	would	O
6	tell	O
7	the	O
8	spouse	O
9	the	O
10	full	O
11	truth	O
12	about	O
13	both	O
14	diagnosis	O
15	and	O
16	prognosis	O
17	.	O

1	Previous	O
2	studies	O
3	showed	O
4	that	O
5	mutations	O
6	in	O
7	the	O
8	6K	O
9	protein	O
10	led	O
11	to	O
12	the	O
13	slow	O
14	release	O
15	of	O
16	aberrant	O
17	,	O
18	multi	O
19	-	O
20	cored	O
21	infectious	O
22	virions	O
23	.	O

1	Metabolism	O
2	of	O
3	calcium	O
4	and	O
5	vitamin	O
6	D3	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	tubulointerstitial	O
12	nephritis	O
13	:	O
14	a	O
15	study	O
16	of	O
17	41	O
18	patients	O
19	with	O
20	nephropathia	O
21	epidemica	O
22	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	demonstrates	O
6	that	O
7	reduced	O
8	inotropy	O
9	with	O
10	timolol	O
11	helped	O
12	uniform	O
13	local	O
14	contraction	O
15	as	O
16	estimated	O
17	by	O
18	the	O
19	increased	O
20	LONG	O
21	/	O
22	CIRC	O
23	ratio	O
24	,	O
25	a	O
26	transition	O
27	that	O
28	could	O
29	improve	O
30	contraction	O
31	efficacy	O
32	.	O

1	Effects	O
2	of	O
3	moderate	O
4	hypercapnia	O
5	on	O
6	hypothermia	O
7	induced	O
8	by	O
9	cold	O
10	He	O
11	-	O
12	O2	O
13	in	O
14	rats	O
15	.	O

1	The	O
2	RFLP	O
3	patterns	O
4	of	O
5	the	O
6	isolates	O
7	from	O
8	six	O
9	of	O
10	these	O
11	patients	O
12	remained	O
13	essentially	O
14	unchanged	O
15	(	O
16	two	O
17	strains	O
18	showed	O
19	one	O
20	additional	O
21	band	O
22	)	O
23	despite	O
24	the	O
25	development	O
26	of	O
27	drug	O
28	resistance	O
29	.	O

1	We	O
2	recommend	O
3	that	O
4	ovarian	O
5	stimulation	O
6	is	O
7	done	O
8	only	O
9	if	O
10	there	O
11	is	O
12	a	O
13	valid	O
14	indication	O
15	after	O
16	proper	O
17	assessment	O
18	of	O
19	the	O
20	ovaries	O
21	,	O
22	and	O
23	that	O
24	women	O
25	who	O
26	have	O
27	had	O
28	ovarian	O
29	stimulation	O
30	are	O
31	followed	O
32	for	O
33	longer	O
34	than	O
35	at	O
36	present	O
37	.	O

1	A23187	O
2	did	O
3	not	O
4	induce	O
5	any	O
6	modifications	O
7	of	O
8	the	O
9	endolymphatic	O
10	potential	O
11	,	O
12	the	O
13	ampullar	O
14	direct	O
15	current	O
16	or	O
17	the	O
18	frequency	O
19	of	O
20	the	O
21	evoked	O
22	afferent	O
23	spikes	O
24	.	O

1	Activation	O
2	of	O
3	the	O
4	aboral	O
5	ectoderm	B
6	-	I
7	specific	I
8	Spec2a	I
9	gene	I
10	in	O
11	blastula	O
12	-	O
13	stage	O
14	sea	O
15	urchin	O
16	embryos	O
17	requires	O
18	an	O
19	upstream	O
20	regulatory	O
21	region	O
22	that	O
23	is	O
24	part	O
25	of	O
26	a	O
27	repetitive	O
28	sequence	O
29	element	O
30	(	O
31	RSR	O
32	)	O
33	associated	O
34	with	O
35	all	O
36	Spec1	B
37	/	O
38	Spec2	B
39	genes	O
40	.	O

1	A	O
2	transcript	O
3	of	O
4	about	O
5	2	O
6	kb	O
7	is	O
8	expected	O
9	for	O
10	each	O
11	PPO	B
12	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	Salazopyrine	O
2	desensitization	O

1	During	O
2	exercise	O
3	,	O
4	the	O
5	Pes	O
6	-	O
7	Ves	O
8	relation	O
9	was	O
10	shifted	O
11	toward	O
12	the	O
13	left	O
14	and	O
15	the	O
16	slope	O
17	[	O
18	end	O
19	-	O
20	systolic	O
21	elastance	O
22	(	O
23	Ees	O
24	)]	O
25	increased	O
26	from	O
27	7	O
28	.	O
29	7	O
30	+/-	O
31	2	O
32	.	O
33	8	O
34	to	O
35	12	O
36	.	O
37	7	O
38	+/-	O
39	4	O
40	.	O
41	2	O
42	(	O
43	SD	O
44	)	O
45	mmHg	O
46	/	O
47	ml	O
48	(	O
49	P	O
50	<	O
51	0	O
52	.	O
53	05	O
54	).	O

1	We	O
2	show	O
3	that	O
4	HRI	B
5	and	O
6	dsRNA	B
7	-	I
8	PK	I
9	phosphorylate	O
10	yeast	B
11	eIF	I
12	-	I
13	2	I
14	alpha	I
15	in	O
16	vitro	O
17	and	O
18	in	O
19	vivo	O
20	and	O
21	functionally	O
22	substitute	O
23	for	O
24	GCN2	B
25	protein	I
26	to	O
27	stimulate	O
28	GCN4	B
29	translation	O
30	in	O
31	yeast	O
32	.	O

1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	B
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	B
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O

1	Interestingly	O
2	,	O
3	in	O
4	the	O
5	adult	O
6	,	O
7	transgene	O
8	expression	O
9	patterns	O
10	within	O
11	the	O
12	cerebellum	O
13	in	O
14	two	O
15	lines	O
16	appeared	O
17	to	O
18	mark	O
19	distinct	O
20	anterior	O
21	-	O
22	posterior	O
23	compartments	O
24	.	O

1	Southern	O
2	analysis	O
3	on	O
4	genomic	O
5	DNA	O
6	isolated	O
7	from	O
8	tissues	O
9	and	O
10	cell	O
11	lines	O
12	from	O
13	several	O
14	mouse	O
15	strains	O
16	using	O
17	mCD22	B
18	cDNA	I
19	demonstrated	O
20	that	O
21	the	O
22	Cd22	B
23	locus	I
24	encoding	O
25	mCD22	B
26	is	O
27	a	O
28	single	O
29	copy	O
30	gene	O
31	of	O
32	<	O
33	or	O
34	=	O
35	30	O
36	kb	O
37	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	Instead	O
2	,	O
3	the	O
4	results	O
5	support	O
6	the	O
7	idea	O
8	that	O
9	Pc	B
10	group	I
11	products	I
12	provide	O
13	stable	O
14	memory	O
15	or	O
16	imprinting	O
17	of	O
18	boundaries	O
19	which	O
20	are	O
21	initially	O
22	specified	O
23	by	O
24	gap	O
25	and	O
26	pair	O
27	-	O
28	rule	O
29	regulators	O
30	.	O

1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	expression	O
7	of	O
8	the	O
9	human	B
10	mdr1	I
11	gene	I
12	,	O
13	the	O
14	response	O
15	of	O
16	the	O
17	mdr1	B
18	promoter	I
19	to	O
20	signals	O
21	involved	O
22	in	O
23	cell	O
24	proliferation	O
25	was	O
26	examined	O
27	.	O

1	The	O
2	tyrosine	B
3	hydroxylase	I
4	gene	I
5	(	O
6	TH	B
7	)	O
8	contains	O
9	a	O
10	single	O
11	copy	O
12	of	O
13	a	O
14	consensus	O
15	CRE	O
16	at	O
17	-	O
18	45	O
19	to	O
20	-	O
21	38	O
22	base	O
23	pair	O
24	(	O
25	bp	O
26	)	O
27	upstream	O
28	of	O
29	the	O
30	transcription	O
31	initiation	O
32	site	O
33	.	O

1	Tobacco	O
2	mosaic	O
3	virus	O
4	-	O
5	infected	O
6	tobacco	O
7	(	O
8	Nicotiana	O
9	tabacum	O
10	var	O
11	.	O

1	Through	O
2	a	O
3	stretch	O
4	of	O
5	56	O
6	amino	O
7	acids	O
8	,	O
9	constituting	O
10	the	O
11	MADS	B
12	domain	I
13	,	O
14	the	O
15	two	O
16	proteins	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	two	O
22	conservative	O
23	amino	O
24	acid	O
25	substitutions	O
26	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	SRF	B
6	accessory	I
7	proteins	I
8	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	:	O
6	(	O
7	a	O
8	)	O
9	proSRIF	B
10	cleavage	O
11	is	O
12	initiated	O
13	in	O
14	the	O
15	TGN	O
16	,	O
17	and	O
18	(	O
19	b	O
20	)	O
21	this	O
22	reaction	O
23	requires	O
24	an	O
25	acidic	O
26	pH	O
27	which	O
28	is	O
29	facilitated	O
30	by	O
31	a	O
32	Golgi	B
33	-	I
34	associated	I
35	vacuolar	I
36	-	I
37	type	I
38	ATPase	I
39	.	O

1	Fenoldopam	O
2	,	O
3	a	O
4	dopamine	B
5	receptor	I
6	agonist	O
7	,	O
8	has	O
9	been	O
10	shown	O
11	,	O
12	in	O
13	animal	O
14	experiments	O
15	,	O
16	to	O
17	improve	O
18	renal	O
19	perfusion	O
20	.	O

1	Clinical	O
2	aspects	O
3	of	O
4	early	O
5	increase	O
6	in	O
7	serum	O
8	gamma	B
9	-	I
10	glutamyl	I
11	transferase	I
12	in	O
13	cerebral	O
14	infarction	O
15	.	O

1	In	O
2	the	O
3	3	O
4	'	O
5	flanking	O
6	region	O
7	of	O
8	the	O
9	27	B
10	kDa	I
11	zein	I
12	gene	I
13	,	O
14	several	O
15	AATAAA	O
16	-	O
17	like	O
18	sequences	O
19	and	O
20	a	O
21	sequence	O
22	resembling	O
23	the	O
24	mammalian	O
25	GT	O
26	-	O
27	rich	O
28	sequence	O
29	are	O
30	present	O
31	around	O
32	the	O
33	polyadenylation	O
34	sites	O
35	.	O

1	The	O
2	indoor	O
3	radon	O
4	concentration	O
5	in	O
6	the	O
7	summer	O
8	(	O
9	1990	O
10	)	O
11	period	O
12	ranged	O
13	between	O
14	8	O
15	and	O
16	81	O
17	Bq	O
18	m	O
19	-	O
20	3	O
21	,	O
22	while	O
23	in	O
24	the	O
25	winter	O
26	(	O
27	1989	O
28	-	O
29	1990	O
30	)	O
31	it	O
32	ranged	O
33	between	O
34	20	O
35	and	O
36	143	O
37	Bq	O
38	m	O
39	-	O
40	3	O
41	for	O
42	the	O
43	first	O
44	year	O
45	of	O
46	measurements	O
47	or	O
48	between	O
49	8	O
50	and	O
51	92	O
52	Bq	O
53	m	O
54	-	O
55	3	O
56	in	O
57	the	O
58	summer	O
59	(	O
60	1991	O
61	)	O
62	period	O
63	and	O
64	between	O
65	12	O
66	and	O
67	119	O
68	Bq	O
69	m	O
70	-	O
71	3	O
72	in	O
73	the	O
74	winter	O
75	(	O
76	1990	O
77	-	O
78	1991	O
79	)	O
80	for	O
81	the	O
82	second	O
83	year	O
84	of	O
85	measurements	O
86	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	hrpRS	B
6	and	O
7	hrpL	B
8	are	O
9	part	O
10	of	O
11	a	O
12	regulatory	O
13	cascade	O
14	in	O
15	which	O
16	HrpR	B
17	and	O
18	HrpS	B
19	activate	O
20	expression	O
21	of	O
22	hrpL	B
23	and	O
24	HrpL	B
25	,	O
26	a	O
27	putative	O
28	sigma	B
29	factor	I
30	,	O
31	induces	O
32	expression	O
33	of	O
34	HrpL	B
35	-	I
36	responsive	I
37	genes	I
38	.	O

1	DtxR	B
2	is	O
3	an	O
4	iron	O
5	-	O
6	dependent	O
7	sequence	O
8	-	O
9	specific	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	the	O
18	tox	B
19	operator	I
20	,	O
21	an	O
22	inverted	O
23	-	O
24	repeat	O
25	nucleotide	O
26	sequence	O
27	located	O
28	upstream	O
29	from	O
30	the	O
31	diphtheria	B
32	toxin	I
33	gene	I
34	.	O

1	Vasopressin	B
2	(	O
3	AVP	B
4	),	O
5	the	O
6	antidiuretic	O
7	hormone	O
8	,	O
9	is	O
10	a	O
11	cyclic	O
12	nonapeptide	O
13	that	O
14	acts	O
15	through	O
16	binding	O
17	to	O
18	G	B
19	protein	I
20	-	I
21	coupled	I
22	specific	I
23	membrane	I
24	receptors	I
25	pharmacologically	O
26	divided	O
27	into	O
28	three	O
29	subtypes	O
30	(	O
31	V1a	B
32	,	O
33	V1b	B
34	,	O
35	and	O
36	V2	B
37	)	O
38	linked	O
39	to	O
40	distinct	O
41	second	O
42	messengers	O
43	.	O

1	These	O
2	results	O
3	confirmed	O
4	that	O
5	cleavage	O
6	of	O
7	the	O
8	leader	O
9	peptide	O
10	is	O
11	the	O
12	last	O
13	step	O
14	in	O
15	nisin	B
16	maturation	O
17	and	O
18	is	O
19	necessary	O
20	to	O
21	generate	O
22	a	O
23	biologically	O
24	active	O
25	peptide	O
26	.	O

1	When	O
2	the	O
3	promoter	O
4	region	O
5	was	O
6	linked	O
7	with	O
8	a	O
9	heterologous	O
10	reporter	O
11	gene	O
12	,	O
13	we	O
14	found	O
15	that	O
16	the	O
17	promoter	O
18	region	O
19	is	O
20	inducible	O
21	by	O
22	both	O
23	interferons	B
24	(	O
25	interferon	B
26	-	I
27	alpha	I
28	and	I
29	-	I
30	gamma	I
31	)	O
32	and	O
33	interferon	B
34	regulatory	I
35	factor	I
36	1	I
37	.	O

1	Anti	B
2	-	I
3	B	I
4	.	I
5	burgdorferi	I
6	,	O
7	anti	B
8	-	I
9	B	I
10	.	I
11	turicatae	I
12	and	O
13	anti	B
14	-	I
15	B	I
16	.	I
17	parkeri	I
18	antibodies	I
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	immunofluorescent	O
25	assay	O
26	(	O
27	IFA	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	IFA	O
54	-	O
55	ABS	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O

1	The	O
2	approach	O
3	derives	O
4	from	O
5	a	O
6	recently	O
7	described	O
8	strategy	O
9	for	O
10	making	O
11	recombinants	O
12	from	O
13	five	O
14	overlapping	O
15	EBV	O
16	cosmid	O
17	-	O
18	cloned	O
19	DNAs	O
20	(	O
21	B	O
22	.	O

1	Evaluation	O
2	of	O
3	desmopressin	O
4	for	O
5	dental	O
6	extractions	O
7	in	O
8	patients	O
9	with	O
10	hemostatic	O
11	disorders	O
12	.	O

1	Comparative	O
2	analysis	O
3	with	O
4	an	O
5	antiandrogen	O
6	niftolid	O
7	and	O
8	synthetic	B
9	GnRH	I
10	was	O
11	carried	O
12	out	O
13	in	O
14	22	O
15	normal	O
16	subjects	O
17	,	O
18	14	O
19	patients	O
20	with	O
21	primary	O
22	and	O
23	20	O
24	ones	O
25	with	O
26	secondary	O
27	hypogonadism	O
28	,	O
29	and	O
30	in	O
31	5	O
32	patients	O
33	with	O
34	clinical	O
35	signs	O
36	of	O
37	gonadal	O
38	insufficiency	O
39	and	O
40	obscure	O
41	diagnosis	O
42	in	O
43	order	O
44	to	O
45	elucidate	O
46	the	O
47	pituitary	B
48	gonadotropin	I
49	reserves	O
50	.	O

1	All	O
2	other	O
3	normal	O
4	and	O
5	transformed	O
6	lymphoid	O
7	and	O
8	nonlymphoid	O
9	cell	O
10	lines	O
11	and	O
12	normal	O
13	tissues	O
14	were	O
15	negative	O
16	for	O
17	PANG	B
18	expression	O
19	except	O
20	for	O
21	the	O
22	brain	O
23	,	O
24	wherein	O
25	unique	O
26	4	O
27	.	O
28	0	O
29	-	O
30	and	O
31	6	O
32	.	O
33	1	O
34	-	O
35	kb	O
36	transcripts	O
37	were	O
38	detected	O
39	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	regulatory	O
6	properties	O
7	of	O
8	an	O
9	872	O
10	bp	O
11	promoter	O
12	fragment	O
13	of	O
14	a	O
15	B	O
16	.	O
17	napus	O
18	oleosin	B
19	gene	I
20	were	O
21	examined	O
22	by	O
23	analysis	O
24	of	O
25	beta	B
26	-	I
27	glucuronidase	I
28	(	O
29	GUS	B
30	)	O
31	expression	O
32	in	O
33	transgenic	O
34	tobacco	O
35	plants	O
36	containing	O
37	an	O
38	oleosin	B
39	promoter	I
40	-	O
41	GUS	B
42	transcriptional	O
43	fusion	O
44	.	O

1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	CX	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	tubulin	B
14	mRNA	I
15	in	O
16	vivo	O
17	is	O
18	not	O
19	simply	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O

1	L	O
2	.,	O
3	Greer	O
4	,	O
5	J	O
6	.	O
7	&	O
8	Carter	O
9	,	O
10	G	O
11	.	O

1	Increasing	O
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O

1	Structural	O
2	organization	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	human	B
9	lipocalin	I
10	tear	I
11	prealbumin	I
12	and	O
13	synthesis	O
14	of	O
15	the	O
16	recombinant	O
17	protein	O
18	in	O
19	Escherichia	O
20	coli	O
21	.	O

1	The	O
2	sequence	O
3	has	O
4	a	O
5	1092	O
6	-	O
7	bp	O
8	open	O
9	reading	O
10	frame	O
11	encoding	O
12	a	O
13	protein	O
14	of	O
15	364	O
16	amino	O
17	acids	O
18	.	O

1	Western	O
2	blotting	O
3	(	O
4	immunoblotting	O
5	)	O
6	with	O
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	SOD	B
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	masses	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O

1	The	O
2	gene	O
3	organization	O
4	of	O
5	CRSV	B
6	RNA	I
7	-	I
8	1	I
9	is	O
10	similar	O
11	to	O
12	those	O
13	of	O
14	red	O
15	clover	O
16	necrotic	O
17	mosaic	O
18	(	O
19	RCNMV	O
20	)	O
21	and	O
22	sweet	O
23	clover	O
24	necrotic	O
25	mosaic	O
26	(	O
27	SCNMV	O
28	)	O
29	dianthoviruses	O
30	with	O
31	the	O
32	exception	O
33	that	O
34	CRSV	B
35	RNA	I
36	-	I
37	1	I
38	contains	O
39	the	O
40	additional	O
41	3	O
42	'-	O
43	terminal	O
44	ORF	O
45	.	O

1	Members	O
2	of	O
3	the	O
4	myocyte	B
5	-	I
6	specific	I
7	enhancer	I
8	-	I
9	binding	I
10	factor	I
11	2	I
12	(	O
13	MEF2	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	B
7	-	I
8	1	I
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	B
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O

1	These	O
2	results	O
3	illustrate	O
4	an	O
5	important	O
6	role	O
7	for	O
8	La	B
9	in	O
10	RNA	O
11	production	O
12	by	O
13	demonstrating	O
14	its	O
15	ability	O
16	to	O
17	clear	O
18	the	O
19	termination	O
20	sites	O
21	of	O
22	class	O
23	III	O
24	templates	O
25	,	O
26	thereby	O
27	promoting	O
28	efficient	O
29	use	O
30	of	O
31	transcription	O
32	complexes	O
33	by	O
34	pol	B
35	III	I
36	.	O

1	The	O
2	films	O
3	were	O
4	analyzed	O
5	using	O
6	a	O
7	scanning	O
8	helium	O
9	-	O
10	neon	O
11	laser	O
12	densitometer	O
13	with	O
14	a	O
15	small	O
16	aperture	O
17	of	O
18	5	O
19	-	O
20	10	O
21	microns	O
22	.	O

1	The	O
2	GafChromic	O
3	method	O
4	has	O
5	proven	O
6	to	O
7	be	O
8	an	O
9	accurate	O
10	and	O
11	rapid	O
12	method	O
13	of	O
14	analysis	O
15	and	O
16	could	O
17	be	O
18	easily	O
19	incorporated	O
20	into	O
21	a	O
22	quality	O
23	assurance	O
24	program	O
25	.	O

1	Viral	O
2	genomic	O
3	RNA	O
4	for	O
5	these	O
6	reactions	O
7	was	O
8	obtained	O
9	directly	O
10	from	O
11	fecal	O
12	specimens	O
13	of	O
14	infected	O
15	infant	O
16	rats	O
17	.	O

1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	-	I
5	alpha	I
6	(	O
7	TNF	B
8	alpha	I
9	)	O
10	is	O
11	one	O
12	of	O
13	several	O
14	autocrine	O
15	/	O
16	paracrine	O
17	factors	O
18	known	O
19	to	O
20	exert	O
21	potent	O
22	inhibitory	O
23	effects	O
24	on	O
25	bone	O
26	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	role	O
6	of	O
7	cellular	B
8	p21ras	I
9	protein	I
10	in	O
11	insulin	B
12	and	O
13	insulin	B
14	-	I
15	like	I
16	growth	I
17	factor	I
18	-	I
19	I	I
20	(	O
21	IGF	B
22	-	I
23	I	I
24	)	O
25	signaling	O
26	pathways	O
27	.	O

1	The	O
2	lack	O
3	of	O
4	the	O
5	C2	B
6	domain	O
7	of	O
8	the	O
9	Ca	B
10	(	I
11	2	I
12	+)-	I
13	dependent	I
14	PKCs	I
15	and	O
16	the	O
17	presence	O
18	of	O
19	a	O
20	unique	O
21	NH2	O
22	-	O
23	terminal	O
24	sequence	O
25	with	O
26	a	O
27	potential	O
28	signal	O
29	peptide	O
30	and	O
31	a	O
32	transmembrane	O
33	domain	O
34	suggest	O
35	that	O
36	PKC	B
37	mu	I
38	is	O
39	a	O
40	novel	O
41	member	O
42	of	O
43	the	O
44	subgroup	O
45	of	O
46	atypical	O
47	PKCs	B
48	.	O

1	Moreover	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	the	O
7	function	O
8	of	O
9	T3R	B
10	-	O
11	RXR	B
12	heterodimers	O
13	on	O
14	response	O
15	elements	O
16	composed	O
17	of	O
18	two	O
19	half	O
20	-	O
21	sites	O
22	in	O
23	a	O
24	directly	O
25	repeated	O
26	orientation	O
27	spaced	O
28	by	O
29	4	O
30	nucleotides	O
31	is	O
32	determined	O
33	in	O
34	major	O
35	parts	O
36	by	O
37	the	O
38	5	O
39	'-	O
40	flanking	O
41	sequence	O
42	of	O
43	the	O
44	upstream	O
45	half	O
46	-	O
47	site	O
48	.	O

1	However	O
2	,	O
3	three	O
4	Hm1	B
5	mutants	I
6	that	O
7	were	O
8	moderately	O
9	deficient	O
10	in	O
11	stimulating	O
12	PI	O
13	turnover	O
14	displayed	O
15	normal	O
16	sequestration	O
17	,	O
18	suggesting	O
19	distinct	O
20	mechanisms	O
21	.	O

1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	B
22	message	I
23	.	O

1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	pCD41	B
6	ORF	I
7	-	I
8	A	I
9	and	O
10	the	O
11	use	O
12	of	O
13	promoter	O
14	constructs	O
15	further	O
16	mapped	O
17	an	O
18	internal	O
19	functional	O
20	promoter	O
21	within	O
22	the	O
23	pCD41	B
24	sequence	I
25	that	O
26	can	O
27	direct	O
28	the	O
29	synthesis	O
30	of	O
31	the	O
32	trans	O
33	-	O
34	activating	O
35	protein	O
36	.	O

1	Seven	O
2	of	O
3	these	O
4	had	O
5	counterparts	O
6	in	O
7	the	O
8	US	O
9	of	O
10	herpes	O
11	simplex	O
12	type	O
13	1	O
14	(	O
15	HSV	O
16	-	O
17	1	O
18	),	O
19	pseudorabies	O
20	virus	O
21	(	O
22	PRV	O
23	),	O
24	and	O
25	equine	O
26	herpesvirus	O
27	type	O
28	1	O
29	(	O
30	EHV	O
31	-	O
32	1	O
33	).	O

1	The	O
2	inferred	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	cyanobacterial	B
9	HemB	I
10	protein	I
11	indicates	O
12	a	O
13	significant	O
14	difference	O
15	in	O
16	the	O
17	metal	O
18	cofactor	O
19	requirement	O
20	from	O
21	the	O
22	higher	O
23	-	O
24	plant	O
25	enzymes	O
26	,	O
27	which	O
28	was	O
29	confirmed	O
30	by	O
31	overexpression	O
32	and	O
33	biochemical	O
34	analysis	O
35	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	In	O
6	25	O
7	open	O
8	-	O
9	chest	O
10	,	O
11	anesthetized	O
12	dogs	O
13	,	O
14	progressive	O
15	circumflex	O
16	artery	O
17	stenosis	O
18	led	O
19	to	O
20	a	O
21	concordant	O
22	decrease	O
23	of	O
24	circumflex	O
25	artery	O
26	resting	O
27	and	O
28	hyperemic	O
29	flow	O
30	,	O
31	coronary	O
32	flow	O
33	reserve	O
34	,	O
35	and	O
36	inverse	O
37	angiographic	O
38	mean	O
39	transit	O
40	time	O
41	Tmicro	O
42	-	O
43	1	O
44	(	O
45	P	O
46	<	O
47	.	O
48	01	O
49	).	O

1	However	O
2	,	O
3	a	O
4	correlation	O
5	was	O
6	observed	O
7	between	O
8	SF	O
9	levels	O
10	of	O
11	IL	B
12	-	I
13	8	I
14	with	O
15	those	O
16	of	O
17	lactate	O
18	,	O
19	LDH	B
20	,	O
21	beta	B
22	2	I
23	-	I
24	microglobulin	I
25	and	O
26	glucose	O
27	.	O

1	Sodium	O
2	-	O
3	taurocholate	O
4	-	O
5	induced	O
6	acute	O
7	necrotizing	O
8	pancreatitis	O
9	does	O
10	not	O
11	affect	O
12	jejunal	O
13	oxygenation	O
14	in	O
15	pigs	O
16	.	O

1	Although	O
2	inactive	O
3	in	O
4	cells	O
5	under	O
6	normal	O
7	conditions	O
8	,	O
9	the	O
10	CHOP	B
11	gene	I
12	is	O
13	markedly	O
14	induced	O
15	by	O
16	a	O
17	variety	O
18	of	O
19	cellular	O
20	stresses	O
21	,	O
22	including	O
23	nutrient	O
24	deprivation	O
25	and	O
26	metabolic	O
27	perturbations	O
28	.	O

1	The	O
2	ipiO	B
3	genes	I
4	code	O
5	for	O
6	two	O
7	almost	O
8	identical	O
9	152	O
10	-	O
11	aa	O
12	proteins	O
13	which	O
14	do	O
15	not	O
16	have	O
17	any	O
18	homology	O
19	with	O
20	sequences	O
21	present	O
22	in	O
23	data	O
24	libraries	O
25	.	O

1	Sterol	O
2	analysis	O
3	of	O
4	the	O
5	disrupted	O
6	mutant	O
7	demonstrated	O
8	the	O
9	accumulation	O
10	of	O
11	ignosterol	O
12	,	O
13	indicating	O
14	a	O
15	loss	O
16	of	O
17	Erg24p	B
18	activity	O
19	.	O

1	The	O
2	previously	O
3	described	O
4	enhanced	O
5	translation	O
6	of	O
7	spinach	O
8	L12	B
9	mRNA	I
10	from	O
11	its	O
12	two	O
13	tandem	O
14	AUG	O
15	codons	O
16	and	O
17	the	O
18	two	O
19	functional	O
20	rpl12	B
21	genes	I
22	in	O
23	Arabidopsis	O
24	probably	O
25	provide	O
26	two	O
27	mechanisms	O
28	for	O
29	generating	O
30	the	O
31	four	O
32	copies	O
33	of	O
34	L12	B
35	/	I
36	chloroplast	I
37	ribosome	I
38	,	O
39	qualitatively	O
40	different	O
41	from	O
42	those	O
43	attempted	O
44	in	O
45	eubacteria	O
46	.	O

1	In	O
2	these	O
3	experiments	O
4	we	O
5	begin	O
6	to	O
7	study	O
8	the	O
9	potential	O
10	functions	O
11	of	O
12	the	O
13	alpha	B
14	7	I
15	cytoplasmic	I
16	domain	I
17	by	O
18	analyzing	O
19	homologies	O
20	between	O
21	the	O
22	rat	O
23	and	O
24	human	O
25	sequences	O
26	,	O
27	by	O
28	immunologic	O
29	studies	O
30	using	O
31	an	O
32	anti	O
33	-	O
34	cytoplasmic	O
35	domain	O
36	antiserum	O
37	,	O
38	and	O
39	by	O
40	identifying	O
41	two	O
42	alternate	O
43	forms	O
44	.	O

1	The	O
2	alpha	O
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O

1	In	O
2	order	O
3	to	O
4	evaluate	O
5	the	O
6	function	O
7	of	O
8	the	O
9	hypothalamic	O
10	-	O
11	pituitary	O
12	-	O
13	thyroid	O
14	(	O
15	HPT	O
16	)-	O
17	axis	O
18	in	O
19	unipolar	O
20	depression	O
21	,	O
22	the	O
23	authors	O
24	measured	O
25	basal	O
26	0800h	O
27	plasma	O
28	levels	O
29	of	O
30	free	O
31	thyroxine	O
32	(	O
33	FT4	O
34	),	O
35	free	O
36	triiodothyronine	O
37	(	O
38	FT3	O
39	),	O
40	and	O
41	thyroid	B
42	stimulating	I
43	hormone	I
44	(	O
45	TSH	B
46	)	O
47	by	O
48	means	O
49	of	O
50	the	O
51	new	O
52	,	O
53	ultrasensitive	O
54	assays	O
55	(	O
56	TSH	O
57	-	O
58	IRMA	O
59	)	O
60	in	O
61	69	O
62	healthy	O
63	controls	O
64	,	O
65	62	O
66	minor	O
67	,	O
68	101	O
69	simple	O
70	major	O
71	,	O
72	and	O
73	57	O
74	melancholic	O
75	depressed	O
76	subjects	O
77	.	O

1	CRS	B
2	function	O
3	in	O
4	a	O
5	5	O
6	'	O
7	LTR	O
8	-	O
9	linked	O
10	gene	O
11	expression	O
12	assay	O
13	correlates	O
14	with	O
15	the	O
16	ability	O
17	of	O
18	both	O
19	p60CRS	B
20	and	O
21	p40CRS	B
22	to	O
23	interact	O
24	with	O
25	5	O
26	'	O
27	LTR	O
28	RNA	O
29	in	O
30	vitro	O
31	.	O

1	Serial	O
2	levels	O
3	of	O
4	troponin	B
5	T	I
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	B
11	-	I
12	MB	I
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	unclamping	O
26	.	O

1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O

1	The	O
2	epidemic	O
3	occurred	O
4	in	O
5	a	O
6	group	O
7	of	O
8	26	O
9	community	O
10	members	O
11	(	O
12	23	O
13	men	O
14	and	O
15	3	O
16	women	O
17	,	O
18	mean	O
19	age	O
20	,	O
21	28	O
22	.	O
23	9	O
24	--	O
25	3	O
26	years	O
27	)	O
28	living	O
29	and	O
30	working	O
31	together	O
32	,	O
33	who	O
34	underwent	O
35	acute	O
36	and	O
37	convalescent	O
38	serologic	O
39	tests	O
40	for	O
41	Mycoplasma	O
42	pneumoniae	O
43	,	O
44	Legionella	O
45	pneumophila	O
46	,	O
47	cytomegalovirus	O
48	,	O
49	adenovirus	O
50	,	O
51	Coxiella	O
52	burnetii	O
53	,	O
54	and	O
55	Chlamydia	O
56	pneumoniae	O
57	.	O

1	MEK	B
2	itself	O
3	is	O
4	activated	O
5	via	O
6	serine	O
7	phosphorylation	O
8	by	O
9	upstream	B
10	activator	I
11	kinases	I
12	,	O
13	including	O
14	c	B
15	-	I
16	raf	I
17	,	O
18	mos	B
19	and	O
20	MEK	B
21	kinase	I
22	.	O

1	Genomic	O
2	DNA	O
3	clones	O
4	containing	O
5	the	O
6	T	B
7	-	I
8	cell	I
9	-	I
10	specific	I
11	human	I
12	MAL	I
13	gene	I
14	were	O
15	isolated	O
16	.	O

1	Members	O
2	of	O
3	SVA	B
4	are	O
5	also	O
6	present	O
7	in	O
8	the	O
9	complement	B
10	C2	I
11	gene	I
12	located	O
13	about	O
14	20	O
15	kilobases	O
16	upstream	O
17	of	O
18	RP1	B
19	in	O
20	the	O
21	HLA	B
22	and	O
23	in	O
24	the	O
25	cytochrome	B
26	CYP1A1	I
27	gene	I
28	.	O

1	Expression	O
2	of	O
3	the	O
4	dibasic	O
5	proprotein	O
6	processing	O
7	enzyme	O
8	furin	B
9	is	O
10	directed	O
11	by	O
12	multiple	O
13	promoters	O
14	.	O

1	European	O
2	Community	O
3	Huntington	O
4	'	O
5	s	O
6	Disease	O
7	Collaborative	O
8	Study	O
9	Group	O
10	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	and	O
6	skeletal	B
7	alpha	I
8	-	I
9	actin	I
10	gene	I
11	promoters	I
12	contain	O
13	YY1	B
14	binding	I
15	sites	I
16	thought	O
17	to	O
18	act	O
19	either	O
20	as	O
21	positive	O
22	or	O
23	negative	O
24	cis	O
25	-	O
26	acting	O
27	elements	O
28	.	O

1	MSSP	B
2	-	I
3	1	I
4	produced	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	GST	B
15	specifically	O
16	interacted	O
17	with	O
18	single	O
19	-	O
20	stranded	O
21	TCTTAT	O
22	(	O
23	plus	O
24	myc	B
25	(	O
26	H	O
27	-	O
28	P	O
29	)	O
30	21	O
31	)	O
32	and	O
33	ACT	O
34	-	O
35	ATT	O
36	(	O
37	in	O
38	minus	O
39	myc	B
40	(	O
41	H	O
42	-	O
43	P	O
44	)	O
45	21	O
46	),	O
47	the	O
48	consensus	O
49	of	O
50	which	O
51	can	O
52	be	O
53	referred	O
54	to	O
55	as	O
56	A	O
57	/	O
58	TCTA	O
59	/	O
60	TA	O
61	/	O
62	TT	O
63	.	O

1	Within	O
2	12	O
3	hours	O
4	after	O
5	MR	O
6	tomography	O
7	the	O
8	patients	O
9	were	O
10	surgically	O
11	explored	O
12	,	O
13	biopsied	O
14	and	O
15	if	O
16	necessary	O
17	orchiectomised	O
18	.	O

1	Certain	O
2	spt10	B
3	spontaneous	O
4	alleles	O
5	are	O
6	good	O
7	suppressors	O
8	but	O
9	have	O
10	a	O
11	normal	O
12	growth	O
13	rate	O
14	,	O
15	suggesting	O
16	that	O
17	the	O
18	SPT10	B
19	protein	I
20	may	O
21	have	O
22	two	O
23	distinct	O
24	functions	O
25	.	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O

1	The	O
2	3	O
3	'	O
4	UTR	O
5	has	O
6	several	O
7	stable	O
8	hairpins	O
9	that	O
10	are	O
11	flanked	O
12	by	O
13	single	O
14	-	O
15	stranded	O
16	(	O
17	A	O
18	/	O
19	U	O
20	)	O
21	UGC	O
22	sequences	O
23	.	O

1	Moreover	O
2	,	O
3	the	O
4	major	O
5	site	O
6	of	O
7	transcriptional	O
8	initiation	O
9	,	O
10	which	O
11	was	O
12	localized	O
13	by	O
14	primer	O
15	extension	O
16	250	O
17	bp	O
18	upstream	O
19	of	O
20	the	O
21	5	O
22	'	O
23	end	O
24	of	O
25	the	O
26	Ets	B
27	-	I
28	1	I
29	cDNA	I
30	clone	I
31	,	O
32	was	O
33	shown	O
34	to	O
35	be	O
36	identical	O
37	in	O
38	normal	O
39	cells	O
40	and	O
41	tumors	O
42	carrying	O
43	a	O
44	provirus	O
45	in	O
46	the	O
47	Tpl	B
48	-	I
49	1	I
50	locus	I
51	.	O

1	Specifically	O
2	,	O
3	by	O
4	oligonucleotide	O
5	-	O
6	directed	O
7	site	O
8	-	O
9	specific	O
10	mutagenesis	O
11	,	O
12	we	O
13	demonstrate	O
14	that	O
15	of	O
16	10	O
17	cysteine	O
18	residues	O
19	in	O
20	the	O
21	ORF4	O
22	polypeptide	O
23	,	O
24	only	O
25	C	O
26	-	O
27	421	O
28	and	O
29	C	O
30	-	O
31	426	O
32	are	O
33	essential	O
34	for	O
35	transactivator	O
36	function	O
37	and	O
38	suggest	O
39	that	O
40	these	O
41	cysteine	O
42	residues	O
43	may	O
44	participate	O
45	in	O
46	critical	O
47	protein	O
48	-	O
49	protein	O
50	interactions	O
51	rather	O
52	than	O
53	protein	O
54	-	O
55	nucleic	O
56	acid	O
57	interactions	O
58	to	O
59	mediate	O
60	ORF4	O
61	inducibility	O
62	.	O

1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	B
7	stimulation	O
8	of	O
9	phospholipase	B
10	C	I
11	beta	I
12	and	O
13	the	O
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	activation	O
31	of	O
32	protein	B
33	kinase	I
34	A	I
35	.	O

1	The	O
2	mutations	O
3	did	O
4	not	O
5	affect	O
6	the	O
7	repression	O
8	of	O
9	CPA1	B
10	by	O
11	arginine	O
12	.	O

1	A	O
2	segment	O
3	of	O
4	mRNA	O
5	encoding	O
6	the	O
7	leader	O
8	peptide	O
9	of	O
10	the	O
11	CPA1	B
12	gene	I
13	confers	O
14	repression	O
15	by	O
16	arginine	O
17	on	O
18	a	O
19	heterologous	O
20	yeast	O
21	gene	O
22	transcript	O
23	.	O

1	To	O
2	search	O
3	for	O
4	genes	O
5	that	O
6	interact	O
7	with	O
8	the	O
9	SLK1	B
10	-	O
11	SLT2	B
12	pathway	O
13	,	O
14	a	O
15	synthetic	O
16	lethal	O
17	suppression	O
18	screen	O
19	was	O
20	carried	O
21	out	O
22	.	O

1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	O
7	NHP6A	B
8	and	O
9	NHP6B	B
10	function	O
11	downstream	O
12	of	O
13	SLT2	B
14	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	present	O
7	two	O
8	lines	O
9	of	O
10	evidence	O
11	that	O
12	all	O
13	ribosomes	O
14	which	O
15	synthesize	O
16	GCN4	B
17	have	O
18	previously	O
19	translated	O
20	uORF1	O
21	,	O
22	resumed	O
23	scanning	O
24	,	O
25	and	O
26	reinitiated	O
27	at	O
28	the	O
29	GCN4	B
30	start	O
31	site	O
32	.	O

1	Identical	O
2	components	O
3	of	O
4	yeast	O
5	transcription	B
6	factor	I
7	IIIB	I
8	are	O
9	required	O
10	and	O
11	sufficient	O
12	for	O
13	transcription	O
14	of	O
15	TATA	O
16	box	O
17	-	O
18	containing	O
19	and	O
20	TATA	O
21	-	O
22	less	O
23	genes	O
24	.	O

1	Concordantly	O
2	,	O
3	it	O
4	was	O
5	shown	O
6	that	O
7	the	O
8	dnHLH	B
9	protein	I
10	Id1	I
11	inhibits	O
12	differentiation	O
13	of	O
14	muscle	O
15	and	O
16	myeloid	O
17	cells	O
18	in	O
19	vitro	O
20	.	O

1	RNP1	B
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	O
12	protein	O
13	-	O
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	To	O
2	achieve	O
3	complete	O
4	dissection	O
5	of	O
6	the	O
7	anterior	O
8	vitreous	O
9	,	O
10	we	O
11	remove	O
12	even	O
13	a	O
14	clear	O
15	lens	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	intervention	O
21	in	O
22	selected	O
23	cases	O
24	.	O

1	Restoration	O
2	of	O
3	opponens	O
4	function	O
5	with	O
6	transplantation	O
7	of	O
8	free	O
9	composites	O
10	dorsal	O
11	pedal	O
12	skin	O
13	flap	O
14	containing	O
15	m	O
16	.	O
17	extensor	O
18	hallucis	O
19	brevis	O

1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O

1	The	O
2	mean	O
3	(+/-	O
4	sd	O
5	)	O
6	intra	O
7	-	O
8	vesicular	O
9	pressure	O
10	(	O
11	IVP	O
12	)	O
13	and	O
14	maximal	O
15	urethral	O
16	closure	O
17	pressures	O
18	(	O
19	MUCP	O
20	)	O
21	were	O
22	10	O
23	.	O
24	3	O
25	(+/-	O
26	1	O
27	.	O
28	7	O
29	)	O
30	and	O
31	129	O
32	.	O
33	8	O
34	(+/-	O
35	19	O
36	.	O
37	6	O
38	)	O
39	cmH2O	O
40	,	O
41	respectively	O
42	,	O
43	and	O
44	the	O
45	ratio	O
46	between	O
47	MUCP	O
48	and	O
49	IVP	O
50	was	O
51	13	O
52	.	O
53	2	O
54	(+/-	O
55	2	O
56	.	O
57	5	O
58	).	O

1	Several	O
2	highly	O
3	conserved	O
4	regions	O
5	were	O
6	identified	O
7	at	O
8	the	O
9	near	O
10	N	O
11	terminus	O
12	,	O
13	middle	O
14	and	O
15	C	O
16	terminus	O
17	.	O

1	Thioredoxin	B
2	(	O
3	TR	B
4	)	O
5	is	O
6	a	O
7	small	O
8	ubiquitous	O
9	dithiol	B
10	-	I
11	reductase	I
12	enzyme	I
13	first	O
14	identified	O
15	in	O
16	bacteria	O
17	and	O
18	plants	O
19	.	O

1	The	O
2	mutation	O
3	within	O
4	the	O
5	asgB480	B
6	allele	I
7	was	O
8	identified	O
9	as	O
10	an	O
11	A	O
12	-	O
13	to	O
14	-	O
15	G	O
16	transition	O
17	that	O
18	results	O
19	in	O
20	a	O
21	threonine	O
22	-	O
23	to	O
24	-	O
25	alanine	O
26	substitution	O
27	in	O
28	the	O
29	predicted	O
30	protein	O
31	product	O
32	.	O

1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	B
8	-	I
9	1	I
10	kinase	I
11	contains	O
12	zinc	O
13	,	O
14	translocates	O
15	to	O
16	liposomes	O
17	,	O
18	and	O
19	is	O
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	O
25	binds	O
26	GTP	B
27	-	I
28	ras	I
29	.	O

1	Kinetic	O
2	coupling	O
3	and	O
4	requirement	O
5	for	O
6	ATP	O
7	hydrolysis	O
8	.	O

1	ATP	O
2	by	O
3	itself	O
4	also	O
5	reduced	O
6	polypeptide	O
7	binding	O
8	to	O
9	Ssb1	B
10	/	I
11	2p	I
12	to	O
13	a	O
14	level	O
15	that	O
16	was	O
17	intermediate	O
18	between	O
19	that	O
20	observed	O
21	for	O
22	the	O
23	Ssa	B
24	Hsp70	I
25	proteins	I
26	tested	O
27	and	O
28	BiP	B
29	and	O
30	DnaK	B
31	.	O

1	Digestion	O
2	of	O
3	NF	B
4	-	I
5	IL6	I
6	with	O
7	endoprotease	B
8	Asp	I
9	-	I
10	N	I
11	produced	O
12	a	O
13	domain	O
14	smaller	O
15	than	O
16	the	O
17	TCD	B
18	(	O
19	NF	B
20	-	I
21	IL6	I
22	bZIP	I
23	domains	I
24	(	O
25	NFBD	B
26	)	O
27	(	O
28	272	O
29	-	O
30	345	O
31	)),	O
32	a	O
33	domain	O
34	identified	O
35	either	O
36	in	O
37	the	O
38	absence	O
39	or	O
40	the	O
41	presence	O
42	of	O
43	DNA	O
44	.	O

1	Signaling	O
2	by	O
3	tyrosine	B
4	kinases	I
5	involves	O
6	direct	O
7	associations	O
8	between	O
9	proteins	O
10	with	O
11	Src	B
12	homology	I
13	2	I
14	(	O
15	SH2	B
16	)	O
17	domains	O
18	and	O
19	sites	O
20	of	O
21	tyrosine	O
22	phosphorylation	O
23	.	O

1	Rather	O
2	,	O
3	complete	O
4	skipping	O
5	of	O
6	exon	O
7	V	O
8	and	O
9	subsequent	O
10	joining	O
11	of	O
12	exon	O
13	IV	O
14	to	O
15	exon	O
16	VI	O
17	caused	O
18	a	O
19	shift	O
20	in	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	which	O
27	remodeled	O
28	GPHe	B
29	(	I
30	P2	I
31	)	I
32	with	O
33	an	O
34	elongated	O
35	new	O
36	hydrophobic	O
37	sequence	O
38	for	O
39	membrane	O
40	anchoring	O
41	.	O

1	The	O
2	responses	O
3	of	O
4	the	O
5	"	O
6	stress	O
7	hormones	O
8	"	O
9	cortisol	O
10	,	O
11	11	O
12	-	O
13	deoxycortisol	O
14	,	O
15	ACTH	B
16	,	O
17	vasopressin	B
18	(	O
19	AVP	B
20	),	O
21	and	O
22	corticotropin	B
23	releasing	I
24	factor	I
25	(	O
26	CRF	B
27	)	O
28	were	O
29	studied	O
30	in	O
31	6	O
32	normal	O
33	males	O
34	in	O
35	response	O
36	to	O
37	acute	O
38	cortisol	O
39	deficiency	O
40	induced	O
41	by	O
42	the	O
43	11	B
44	-	I
45	beta	I
46	-	I
47	hydroxylase	I
48	inhibitor	O
49	,	O
50	metyrapone	O
51	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	O
7	sigma	B
8	factor	I
9	,	O
10	RpoN	B
11	,	O
12	in	O
13	Rhodobacter	O
14	capsulatus	O
15	;	O
16	physiological	O
17	relevance	O
18	of	O
19	an	O
20	autoactivated	O
21	nifU2	B
22	-	O
23	rpoN	B
24	superoperon	O
25	.	O

1	Thus	O
2	our	O
3	observations	O
4	establish	O
5	a	O
6	functional	O
7	link	O
8	between	O
9	the	O
10	PKC	B
11	and	O
12	retinoid	O
13	pathways	O
14	,	O
15	which	O
16	are	O
17	generally	O
18	considered	O
19	to	O
20	have	O
21	antagonistic	O
22	activities	O
23	on	O
24	differentiation	O
25	processes	O
26	.	O

1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	B
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	O
27	macrophage	B
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	O
34	sometimes	O
35	called	O
36	multi	B
37	-	I
38	CSF	I
39	).	O

1	The	O
2	degree	O
3	of	O
4	lung	O
5	destruction	O
6	,	O
7	reflected	O
8	by	O
9	interstitial	O
10	hemorrhage	O
11	was	O
12	assessed	O
13	by	O
14	measuring	O
15	hemoglobin	B
16	content	O
17	in	O
18	the	O
19	fluid	O
20	of	O
21	the	O
22	lavaged	O
23	lungs	O
24	.	O

1	Expression	O
2	plasmids	O
3	harboring	O
4	full	O
5	-	O
6	length	O
7	or	O
8	kinase	O
9	domain	O
10	of	O
11	PKC	B
12	alpha	I
13	and	O
14	PKC	B
15	delta	I
16	(	O
17	PKC	B
18	alpha	I
19	K	I
20	and	O
21	PKC	B
22	delta	I
23	K	I
24	)	O
25	were	O
26	constructed	O
27	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	PKC	B
7	alpha	I
8	(	O
9	calcium	O
10	dependent	O
11	)	O
12	and	O
13	PKC	B
14	delta	I
15	(	O
16	calcium	O
17	independent	O
18	)	O
19	may	O
20	mediate	O
21	the	O
22	transcription	O
23	of	O
24	TPA	O
25	-	O
26	inducible	O
27	genes	O
28	through	O
29	both	O
30	AP	B
31	-	I
32	1	I
33	and	O
34	non	O
35	-	O
36	AP	B
37	-	I
38	1	I
39	sequences	O
40	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	Insertion	O
2	of	O
3	short	O
4	oligonucleotides	O
5	encoding	O
6	the	O
7	basic	O
8	amino	O
9	acid	O
10	motifs	O
11	726	O
12	-	O
13	GRKRKSP	O
14	-	O
15	732	O
16	from	O
17	IE175	B
18	and	O
19	500	O
20	-	O
21	VRPRKRR	O
22	-	O
23	506	O
24	from	O
25	IE110	B
26	into	O
27	deleted	O
28	cytoplasmic	O
29	forms	O
30	of	O
31	the	O
32	two	O
33	proteins	O
34	restored	O
35	the	O
36	karyophilic	O
37	phenotype	O
38	and	O
39	confirmed	O
40	that	O
41	these	O
42	motifs	O
43	are	O
44	both	O
45	necessary	O
46	and	O
47	sufficient	O
48	for	O
49	proper	O
50	nuclear	O
51	localization	O
52	.	O

1	Mapping	O
2	of	O
3	intracellular	O
4	localization	O
5	domains	O
6	and	O
7	evidence	O
8	for	O
9	colocalization	O
10	interactions	O
11	between	O
12	the	O
13	IE110	B
14	and	O
15	IE175	B
16	nuclear	O
17	transactivator	O
18	proteins	O
19	of	O
20	herpes	O
21	simplex	O
22	virus	O
23	.	O

1	The	O
2	revertant	O
3	TATA	O
4	boxes	O
5	accelerated	O
6	the	O
7	kinetics	O
8	of	O
9	HIV	O
10	replication	O
11	when	O
12	present	O
13	in	O
14	the	O
15	context	O
16	of	O
17	an	O
18	LTR	O
19	containing	O
20	a	O
21	Sp1	B
22	mutation	O
23	(	O
24	deletion	O
25	or	O
26	site	O
27	specific	O
28	);	O
29	no	O
30	effect	O
31	was	O
32	observed	O
33	on	O
34	the	O
35	infectivity	O
36	of	O
37	wild	O
38	-	O
39	type	O
40	HIV	O
41	.	O

1	Panlobular	O
2	emphysema	O

1	Since	O
2	the	O
3	ETS	B
4	domain	I
5	,	O
6	which	O
7	is	O
8	localized	O
9	in	O
10	the	O
11	carboxy	O
12	terminal	O
13	region	O
14	of	O
15	the	O
16	encoded	O
17	protein	O
18	,	O
19	is	O
20	95	O
21	%	O
22	and	O
23	96	O
24	%	O
25	identical	O
26	to	O
27	that	O
28	of	O
29	PEA3	B
30	and	O
31	ER81	B
32	,	O
33	respectively	O
34	,	O
35	we	O
36	named	O
37	this	O
38	new	O
39	member	O
40	'	B
41	Ets	I
42	Related	I
43	Molecule	I
44	PEA3	I
45	-	I
46	like	I
47	'	I
48	(	O
49	ERM	B
50	).	O

1	Gel	O
2	shift	O
3	analysis	O
4	indicates	O
5	that	O
6	the	O
7	full	B
8	-	I
9	length	I
10	ERM	I
11	protein	I
12	is	O
13	able	O
14	to	O
15	bind	O
16	specifically	O
17	to	O
18	an	O
19	oligonucleotide	O
20	containing	O
21	the	O
22	consensus	O
23	nucleotide	O
24	core	O
25	sequence	O
26	GGAA	O
27	recognized	O
28	by	O
29	the	O
30	Ets	B
31	proteins	O
32	.	O

1	Effects	O
2	of	O
3	estradiol	O
4	on	O
5	worm	O
6	burden	O
7	and	O
8	peripheral	O
9	leukocytes	O
10	in	O
11	Parastrongylus	O
12	malaysiensis	O
13	-	O
14	infected	O
15	rats	O
16	.	O

1	Dotarizine	O
2	produced	O
3	arterial	O
4	dilation	O
5	in	O
6	both	O
7	systemic	O
8	and	O
9	pulmonary	O
10	circulation	O
11	:	O
12	the	O
13	total	O
14	peripheral	O
15	resistance	O
16	dropped	O
17	,	O
18	and	O
19	femoral	O
20	artery	O
21	flow	O
22	rose	O
23	;	O
24	aortic	O
25	and	O
26	pulmonary	O
27	artery	O
28	mean	O
29	and	O
30	diastolic	O
31	pressures	O
32	declined	O
33	,	O
34	and	O
35	systolic	O
36	pressures	O
37	remained	O
38	almost	O
39	stable	O
40	.	O

1	These	O
2	issues	O
3	include	O
4	the	O
5	use	O
6	of	O
7	LMWHs	O
8	in	O
9	patients	O
10	with	O
11	arterial	O
12	thrombosis	O
13	or	O
14	myocardial	O
15	infarction	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.	O
21	in	O
22	conjunction	O
23	with	O
24	thrombolytic	O
25	treatment	O
26	),	O
27	and	O
28	in	O
29	patients	O
30	with	O
31	pulmonary	O
32	embolism	O
33	.	O

1	The	O
2	usefulness	O
3	of	O
4	the	O
5	lambda	O
6	PG15	O
7	and	O
8	the	O
9	lambda	O
10	AD5	O
11	cloning	O
12	vectors	O
13	was	O
14	demonstrated	O
15	by	O
16	constructing	O
17	large	O
18	Neurospora	O
19	crassa	O
20	cDNA	O
21	libraries	O
22	.	O

1	Endoscopic	O
2	transthoracic	O
3	sympathectomy	O
4	as	O
5	adjuvant	O
6	treatment	O
7	for	O
8	critical	O
9	upper	O
10	-	O
11	limb	O
12	ischaemia	O
13	.	O

1	Sequence	O
2	comparisons	O
3	have	O
4	shown	O
5	that	O
6	Aps1p	B
7	is	O
8	more	O
9	similar	O
10	to	O
11	the	O
12	sigma	O
13	subunit	O
14	of	O
15	the	O
16	Golgi	O
17	-	O
18	localized	O
19	mammalian	O
20	AP	B
21	-	I
22	1	I
23	complex	I
24	than	O
25	Aps2p	B
26	,	O
27	which	O
28	is	O
29	more	O
30	related	O
31	to	O
32	the	O
33	plasma	O
34	membrane	O
35	AP	B
36	-	I
37	2	I
38	sigma	I
39	subunit	O
40	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	APS1	I
5	gene	I
6	encodes	O
7	a	O
8	homolog	O
9	of	O
10	the	O
11	small	O
12	subunit	O
13	of	O
14	the	O
15	mammalian	B
16	clathrin	I
17	AP	I
18	-	I
19	1	I
20	complex	I
21	:	O
22	evidence	O
23	for	O
24	functional	O
25	interaction	O
26	with	O
27	clathrin	B
28	at	O
29	the	O
30	Golgi	O
31	complex	O
32	.	O

1	These	O
2	results	O
3	are	O
4	the	O
5	first	O
6	to	O
7	demonstrate	O
8	the	O
9	structural	O
10	organization	O
11	of	O
12	a	O
13	vertebrate	O
14	gene	O
15	encoding	O
16	an	O
17	integral	O
18	membrane	O
19	protein	O
20	of	O
21	the	O
22	nuclear	O
23	envelope	O
24	that	O
25	may	O
26	be	O
27	a	O
28	member	O
29	of	O
30	a	O
31	family	O
32	of	O
33	polypeptides	O
34	conserved	O
35	in	O
36	evolution	O
37	.	O

1	Biochemical	O
2	characterization	O
3	of	O
4	valosin	B
5	-	I
6	containing	I
7	protein	I
8	,	O
9	a	O
10	protein	B
11	tyrosine	I
12	kinase	I
13	substrate	O
14	in	O
15	hematopoietic	O
16	cells	O
17	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O

1	All	O
2	patients	O
3	with	O
4	deterioriation	O
5	in	O
6	mental	O
7	status	O
8	showed	O
9	a	O
10	marked	O
11	increase	O
12	in	O
13	liver	O
14	enzymes	O
15	(	O
16	aspartate	B
17	and	I
18	alanine	I
19	aminotransaminases	I
20	)	O
21	and	O
22	severe	O
23	coagulopathy	O
24	.	O

1	Functional	O
2	postnatal	O
3	development	O
4	of	O
5	the	O
6	rat	O
7	primary	O
8	visual	O
9	cortex	O
10	and	O
11	the	O
12	role	O
13	of	O
14	visual	O
15	experience	O
16	:	O
17	dark	O
18	rearing	O
19	and	O
20	monocular	O
21	deprivation	O
22	.	O

1	Eleven	O
2	patients	O
3	tested	O
4	positive	O
5	for	O
6	the	O
7	hepatitis	B
8	B	I
9	surface	I
10	antigen	I
11	(	O
12	HBsAg	B
13	).	O

1	The	O
2	xylose	B
3	isomerase	I
4	-	I
5	encoding	I
6	gene	I
7	(	O
8	xylA	B
9	)	O
10	of	O
11	Clostridium	O
12	thermosaccharolyticum	O
13	:	O
14	cloning	O
15	,	O
16	sequencing	O
17	and	O
18	phylogeny	O
19	of	O
20	XylA	B
21	enzymes	I
22	.	O

1	Two	O
2	phosphopeptides	O
3	,	O
4	identified	O
5	as	O
6	RS	O
7	-[	O
8	32P	O
9	]	O
10	SGASGLLTSEHHSR	O
11	and	O
12	S	O
13	-[	O
14	32P	O
15	]	O
16	SGASGLLTSEHHSR	O
17	,	O
18	were	O
19	obtained	O
20	after	O
21	stoichiometric	O
22	phosphorylation	O
23	and	O
24	trypsinization	O
25	of	O
26	the	O
27	peptide	O
28	.	O

1	Mitochondrial	B
2	Mas70p	I
3	signal	I
4	anchor	I
5	sequence	I
6	.	O

1	Altogether	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	Ypt51p	B
8	,	O
9	Ypt52p	B
10	,	O
11	and	O
12	Ypt53p	B
13	are	O
14	required	O
15	for	O
16	transport	O
17	in	O
18	the	O
19	endocytic	O
20	pathway	O
21	and	O
22	for	O
23	correct	O
24	sorting	O
25	of	O
26	vacuolar	B
27	hydrolases	I
28	suggesting	O
29	a	O
30	possible	O
31	intersection	O
32	of	O
33	the	O
34	endocytic	O
35	with	O
36	the	O
37	vacuolar	O
38	sorting	O
39	pathway	O
40	.	O

1	All	O
2	of	O
3	the	O
4	basal	O
5	TPN	O
6	solutions	O
7	were	O
8	isonitrogenous	O
9	and	O
10	identical	O
11	in	O
12	nutrient	O
13	composition	O
14	,	O
15	except	O
16	for	O
17	the	O
18	difference	O
19	in	O
20	energy	O
21	level	O
22	,	O
23	which	O
24	was	O
25	adjusted	O
26	with	O
27	glucose	O
28	.	O

1	Surprisingly	O
2	,	O
3	TFIIIC	B
4	alpha	I
5	has	O
6	no	O
7	homology	O
8	to	O
9	any	O
10	of	O
11	the	O
12	yeast	B
13	TFIIIC	I
14	subunits	I
15	already	O
16	cloned	O
17	,	O
18	suggesting	O
19	a	O
20	significant	O
21	degree	O
22	of	O
23	evolutionary	O
24	divergence	O
25	for	O
26	RNA	B
27	polymerase	I
28	III	I
29	factors	I
30	.	O

1	Transactivation	O
2	domain	O
3	is	O
4	located	O
5	downstream	O
6	of	O
7	the	O
8	128	B
9	-	I
10	amino	I
11	-	I
12	acid	I
13	runt	I
14	homology	I
15	region	I
16	,	O
17	referred	O
18	to	O
19	as	O
20	the	O
21	Runt	B
22	domain	I
23	.	O

1	We	O
2	estimate	O
3	that	O
4	the	O
5	protease	O
6	activity	O
7	is	O
8	at	O
9	least	O
10	35	O
11	-	O
12	fold	O
13	greater	O
14	in	O
15	mature	O
16	B	O
17	cells	O
18	than	O
19	in	O
20	pre	O
21	-	O
22	B	O
23	cells	O
24	.	O

1	The	O
2	ligand	O
3	for	O
4	RXR	B
5	,	O
6	9	O
7	-	O
8	cis	O
9	retinoic	O
10	acid	O
11	,	O
12	has	O
13	the	O
14	opposite	O
15	effect	O
16	of	O
17	destabilizing	O
18	the	O
19	heterodimeric	O
20	-	O
21	DNA	O
22	complex	O
23	.	O

1	Cerebral125	B
2	albumin	I
3	was	O
4	increased	O
5	to	O
6	similar	O
7	proportions	O
8	in	O
9	those	O
10	groups	O
11	submitted	O
12	to	O
13	hyperosmolality	O
14	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	Response	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	heavily	O
21	pretreated	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Therefore	O
2	,	O
3	the	O
4	amino	O
5	-	O
6	terminal	O
7	sequence	O
8	of	O
9	the	O
10	purified	O
11	carA	B
12	product	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	derived	O
18	from	O
19	the	O
20	nucleotide	O
21	sequence	O
22	in	O
23	both	O
24	organisms	O
25	,	O
26	P	O
27	.	O
28	stutzeri	O
29	having	O
30	four	O
31	additional	O
32	amino	O
33	acids	O
34	.	O

1	Aneurysmal	O
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	O
11	coli	O
12	transcription	O
13	factor	O
14	,	O
15	FNR	B
16	.	O

1	Moxidectin	O
2	(	O
3	at	O
4	3	O
5	times	O
6	the	O
7	therapeutic	O
8	dose	O
9	)	O
10	did	O
11	not	O
12	have	O
13	deleterious	O
14	effects	O
15	on	O
16	cow	O
17	reproductive	O
18	performance	O
19	as	O
20	examined	O
21	(	O
22	eg	O
23	,	O
24	at	O
25	folliculogenesis	O
26	,	O
27	ovulation	O
28	,	O
29	and	O
30	the	O
31	early	O
32	embryonic	O
33	phase	O
34	of	O
35	development	O
36	).	O

1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	Avicel	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	patriciarum	O
14	showed	O
15	that	O
16	xynB	B
17	hybridized	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O

1	The	O
2	variable	O
3	regions	O
4	of	O
5	vertebrate	O
6	striated	O
7	TnT	B
8	isoforms	I
9	reflect	O
10	the	O
11	subsequent	O
12	addition	O
13	and	O
14	modification	O
15	of	O
16	genomic	O
17	sequences	O
18	to	O
19	give	O
20	rise	O
21	to	O
22	members	O
23	of	O
24	the	O
25	TnT	B
26	multigene	I
27	family	I
28	.	O

1	The	O
2	class	B
3	II	I
4	Escherichia	I
5	coli	I
6	alanine	I
7	tRNA	I
8	synthetase	I
9	aminoacylates	I
10	RNA	I
11	miniduplexes	I
12	,	O
13	which	O
14	reconstruct	O
15	the	O
16	acceptor	O
17	end	O
18	of	O
19	alanine	B
20	tRNA	I
21	with	O
22	the	O
23	critical	O
24	G3	O
25	:	O
26	U70	O
27	base	O
28	pair	O
29	.	O

1	Simple	O
2	reaction	O
3	time	O
4	(	O
5	RT	O
6	)	O
7	to	O
8	a	O
9	peripheral	O
10	visual	O
11	target	O
12	(	O
13	S2	O
14	)	O
15	is	O
16	shortened	O
17	when	O
18	a	O
19	non	O
20	-	O
21	informative	O
22	cue	O
23	(	O
24	S1	O
25	)	O
26	is	O
27	flashed	O
28	at	O
29	the	O
30	S2	O
31	location	O
32	100	O
33	-	O
34	150	O
35	ms	O
36	before	O
37	target	O
38	onset	O
39	(	O
40	early	O
41	facilitation	O
42	).	O

1	A	O
2	second	O
3	study	O
4	group	O
5	,	O
6	with	O
7	intact	O
8	cardiac	O
9	innervation	O
10	,	O
11	consisted	O
12	of	O
13	19	O
14	patients	O
15	with	O
16	stable	O
17	angina	O
18	pectoris	O
19	class	O
20	I	O
21	to	O
22	III	O
23	.	O

1	These	O
2	viruses	O
3	depend	O
4	on	O
5	the	O
6	host	O
7	cell	O
8	machinery	O
9	for	O
10	their	O
11	existence	O
12	,	O
13	and	O
14	interference	O
15	with	O
16	these	O
17	processes	O
18	typically	O
19	interferes	O
20	with	O
21	other	O
22	important	O
23	host	O
24	physiology	O
25	.	O

1	Treatment	O
2	was	O
3	well	O
4	-	O
5	tolerated	O
6	.	O

1	A	O
2	concentration	O
3	of	O
4	12	O
5	.	O
6	5	O
7	ppm	O
8	SO2	O
9	induced	O
10	a	O
11	decrease	O
12	from	O
13	baseline	O
14	values	O
15	of	O
16	approximately	O
17	80	O
18	%	O
19	in	O
20	mean	O
21	MCA	O
22	and	O
23	of	O
24	roughly	O
25	70	O
26	%	O
27	in	O
28	mean	O
29	CBF	O
30	.	O

1	We	O
2	have	O
3	used	O
4	these	O
5	modified	O
6	assay	O
7	conditions	O
8	to	O
9	extend	O
10	studies	O
11	on	O
12	the	O
13	transposition	O
14	pathway	O
15	.	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	B
6	constitutively	O
7	increases	O
8	ras	B
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	separated	O
6	the	O
7	signal	O
8	function	O
9	from	O
10	the	O
11	anchor	O
12	function	O
13	of	O
14	the	O
15	6	O
16	.	O
17	7K	O
18	SA	O
19	domain	O
20	.	O

1	Five	O
2	concensus	O
3	poly	O
4	A	O
5	addition	O
6	sites	O
7	are	O
8	located	O
9	in	O
10	the	O
11	350	O
12	base	O
13	pairs	O
14	immediately	O
15	following	O
16	the	O
17	protein	B
18	IX	I
19	coding	O
20	region	O
21	.	O

1	Factors	O
2	associated	O
3	with	O
4	intrafamilial	O
5	transmission	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	infection	O
11	in	O
12	Korea	O
13	.	O

1	Exposure	O
2	to	O
3	higher	O
4	TPA	O
5	concentrations	O
6	decreased	O
7	the	O
8	content	O
9	of	O
10	these	O
11	transcripts	O
12	.	O

1	Northern	O
2	analysis	O
3	,	O
4	to	O
5	search	O
6	for	O
7	a	O
8	pcbAB	B
9	transcript	I
10	,	O
11	showed	O
12	no	O
13	distinct	O
14	transcript	O
15	and	O
16	indicated	O
17	severely	O
18	degraded	O
19	mRNA	O
20	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	requirements	O
8	for	O
9	induction	O
10	of	O
11	PEPCK	B
12	by	O
13	PKA	B
14	and	O
15	inhibition	O
16	by	O
17	insulin	B
18	include	O
19	:	O
20	1	O
21	)	O
22	the	O
23	CREB	B
24	activation	I
25	domain	I
26	,	O
27	2	O
28	)	O
29	the	O
30	PEPCK	B
31	TATA	I
32	sequence	I
33	,	O
34	and	O
35	3	O
36	)	O
37	insulin	B
38	-	O
39	responsive	O
40	hepatoma	O
41	cells	O
42	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	B
8	and	O
9	NQO1	B
10	gene	I
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	B
17	gene	I
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O

1	The	O
2	efficacy	O
3	of	O
4	a	O
5	Propionibacterium	O
6	acnes	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	coliform	O
12	mastitis	O
13	was	O
14	evaluated	O
15	following	O
16	intramammary	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O

1	The	O
2	gene	O
3	encoding	O
4	the	O
5	105	B
6	-	I
7	kDa	I
8	protein	I
9	(	I
10	p105	I
11	)	I
12	precursor	I
13	of	O
14	the	O
15	p50	B
16	subunit	I
17	of	O
18	transcription	O
19	factor	O
20	NF	B
21	-	I
22	kappa	I
23	B	I
24	also	O
25	encodes	O
26	a	O
27	p70	B
28	I	I
29	kappa	I
30	B	I
31	protein	I
32	,	O
33	I	B
34	kappa	I
35	B	I
36	gamma	I
37	,	O
38	which	O
39	is	O
40	identical	O
41	to	O
42	the	O
43	C	O
44	-	O
45	terminal	O
46	607	O
47	amino	O
48	acids	O
49	of	O
50	p105	B
51	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O

1	Topical	O
2	L	O
3	-	O
4	NNA	O
5	attenuated	O
6	the	O
7	hypercapnic	O
8	increase	O
9	of	O
10	CoBF	O
11	by	O
12	52	O
13	+/-	O
14	6	O
15	%	O
16	and	O
17	CeBF	O
18	by	O
19	29	O
20	+/-	O
21	5	O
22	%	O
23	after	O
24	45	O
25	-	O
26	min	O
27	exposure	O
28	.	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	B
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	change	O
6	in	O
7	the	O
8	CPY	B
9	vacuolar	I
10	sorting	I
11	signal	I
12	prevents	O
13	this	O
14	interaction	O
15	.	O

1	Glutamyl	B
2	-	I
3	tRNA	I
4	synthetase	I
5	and	O
6	prolyl	B
7	-	I
8	tRNA	I
9	synthetase	I
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	B
16	-	I
17	tRNA	I
18	synthetases	I
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O

1	Using	O
2	the	O
3	sequence	O
4	data	O
5	obtained	O
6	from	O
7	the	O
8	human	O
9	TCRAC	B
10	/	O
11	TCRDC	B
12	region	O
13	,	O
14	we	O
15	have	O
16	extended	O
17	a	O
18	polymerase	O
19	chain	O
20	reaction	O
21	-	O
22	based	O
23	assay	O
24	to	O
25	test	O
26	for	O
27	the	O
28	expression	O
29	of	O
30	the	O
31	individual	O
32	TCRAJ	B
33	gene	I
34	segments	I
35	.	O

1	This	O
2	analysis	O
3	revealed	O
4	an	O
5	intact	O
6	gene	O
7	(	O
8	arg4	B
9	)	O
10	showing	O
11	a	O
12	high	O
13	degree	O
14	of	O
15	homology	O
16	with	O
17	the	O
18	Saccharomyces	B
19	cerevisiae	I
20	CPA2	I
21	gene	I
22	encoding	O
23	the	O
24	large	O
25	subunit	O
26	of	O
27	carbamoyl	B
28	-	I
29	phosphate	I
30	synthetase	I
31	(	O
32	CPS	B
33	-	I
34	A	I
35	).	O

1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	B
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O

1	The	O
2	baroreflex	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	MSNA	O
15	burst	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	synchronicity	O
34	was	O
35	maintained	O
36	.	O

1	DESIGN	O
2	--	O
3	A	O
4	randomised	O
5	study	O
6	was	O
7	conducted	O
8	in	O
9	all	O
10	women	O
11	aged	O
12	50	O
13	-	O
14	70	O
15	years	O
16	who	O
17	were	O
18	eligible	O
19	for	O
20	breast	O
21	cancer	O
22	screening	O
23	and	O
24	living	O
25	in	O
26	the	O
27	city	O
28	of	O
29	Utrecht	O
30	.	O

1	Identification	O
2	of	O
3	an	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	in	O
9	the	O
10	Marek	O
11	'	O
12	s	O
13	disease	O
14	virus	O
15	long	O
16	internal	O
17	repeat	O
18	region	O
19	which	O
20	encodes	O
21	a	O
22	unique	O
23	14	O
24	-	O
25	kilodalton	O
26	polypeptide	O
27	.	O

1	We	O
2	have	O
3	used	O
4	a	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	clone	O
10	of	O
11	a	O
12	mouse	O
13	hepatitis	O
14	virus	O
15	strain	O
16	A59	O
17	defective	O
18	interfering	O
19	(	O
20	DI	O
21	)	O
22	RNA	O
23	,	O
24	pMIDI	B
25	-	I
26	C	I
27	,	O
28	and	O
29	cassette	O
30	mutagenesis	O
31	to	O
32	study	O
33	the	O
34	mechanism	O
35	of	O
36	coronavirus	O
37	subgenomic	O
38	mRNA	O
39	synthesis	O
40	.	O

1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	B
10	5	I
11	product	I
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	B
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	O
39	-	O
40	3	O
41	)	O
42	expression	O
43	system	O
44	.	O

1	Gel	O
2	electrophoresis	O
3	and	O
4	Western	O
5	immunoblot	O
6	analyses	O
7	of	O
8	intracellular	O
9	fractions	O
10	derived	O
11	from	O
12	infected	O
13	cells	O
14	revealed	O
15	that	O
16	large	O
17	amounts	O
18	of	O
19	NS53	B
20	were	O
21	present	O
22	in	O
23	the	O
24	cytosol	O
25	and	O
26	in	O
27	association	O
28	with	O
29	the	O
30	cytoskeletal	O
31	matrix	O
32	.	O

1	The	O
2	transcription	B
3	factor	I
4	AP	I
5	-	I
6	2	I
7	is	O
8	encoded	O
9	by	O
10	a	O
11	gene	O
12	located	O
13	on	O
14	chromosome	O
15	6	O
16	near	O
17	the	O
18	HLA	B
19	locus	I
20	.	O

1	The	O
2	mature	O
3	AP	B
4	-	I
5	2	I
6	mRNA	I
7	is	O
8	spliced	O
9	from	O
10	7	O
11	exons	O
12	distributed	O
13	over	O
14	a	O
15	region	O
16	of	O
17	18	O
18	kb	O
19	genomic	O
20	DNA	O
21	.	O

1	San	O
2	Martin	O
3	'	O
4	s	O
5	psychological	O
6	traits	O
7	coupled	O
8	to	O
9	his	O
10	work	O
11	with	O
12	masonic	O
13	lodges	O
14	that	O
15	allowed	O
16	him	O
17	to	O
18	display	O
19	his	O
20	abilities	O
21	as	O
22	strategist	O
23	and	O
24	political	O
25	ruler	O
26	.	O

1	The	O
2	participants	O
3	were	O
4	homosexual	O
5	men	O
6	in	O
7	hepatitis	O
8	B	O
9	vaccine	O
10	trials	O
11	in	O
12	Amsterdam	O
13	(	O
14	n	O
15	=	O
16	74	O
17	),	O
18	New	O
19	York	O
20	City	O
21	(	O
22	n	O
23	=	O
24	120	O
25	),	O
26	and	O
27	San	O
28	Francisco	O
29	(	O
30	n	O
31	=	O
32	168	O
33	).	O

1	The	O
2	7	O
3	-	O
4	day	O
5	treatment	O
6	resulted	O
7	in	O
8	a	O
9	decrease	O
10	in	O
11	mitochondrial	O
12	uptake	O
13	of	O
14	Rh123	O
15	and	O
16	an	O
17	increase	O
18	in	O
19	NAO	O
20	uptake	O
21	.	O

1	Thrombotic	O
2	thrombocytopenic	O
3	purpura	O
4	in	O
5	systemic	O
6	lupus	O
7	erythematosus	O
8	.	O

1	Comparison	O
2	with	O
3	the	O
4	crystal	O
5	structure	O
6	of	O
7	Desulfovibrio	O
8	gigas	O
9	,	O
10	Dg	O
11	,	O
12	Fd	B
13	(	O
14	Kissinger	O
15	et	O
16	al	O
17	.,	O
18	1991	O
19	)	O
20	reveals	O
21	a	O
22	very	O
23	similar	O
24	folding	O
25	topology	O
26	,	O
27	although	O
28	several	O
29	secondary	O
30	structural	O
31	elements	O
32	are	O
33	extended	O
34	in	O
35	Pf	O
36	relative	O
37	to	O
38	Dg	O
39	Fd	B
40	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	B
4	prolactin	I
5	concentrations	O
6	show	O
7	age	O
8	related	O
9	variations	O
10	in	O
11	presumably	O
12	fertile	O
13	men	O
14	.	O

1	Eight	O
2	highly	O
3	trained	O
4	male	O
5	kayakers	O
6	were	O
7	studied	O
8	to	O
9	determine	O
10	the	O
11	relationship	O
12	between	O
13	critical	O
14	power	O
15	(	O
16	CP	O
17	)	O
18	and	O
19	the	O
20	onset	O
21	of	O
22	blood	O
23	lactate	O
24	accumulation	O
25	(	O
26	OBLA	O
27	).	O

1	As	O
2	in	O
3	S	O
4	.	O
5	cerevisiae	O
6	,	O
7	the	O
8	sequence	O
9	of	O
10	rhp51	B
11	+	I
12	showed	O
13	two	O
14	MluI	B
15	cell	I
16	-	I
17	cycle	I
18	boxes	I
19	and	O
20	a	O
21	putative	O
22	DNA	O
23	damage	O
24	-	O
25	responsive	O
26	element	O
27	in	O
28	its	O
29	upstream	O
30	region	O
31	.	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	O
15	Tea	B
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	B
27	retrovirus	I
28	receptor	I
29	/	O
30	cationic	B
31	amino	I
32	acid	I
33	transporter	I
34	(	O
35	ecoR	B
36	/	O
37	CAT1	B
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	B
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O

1	Furthermore	O
2	,	O
3	unlike	O
4	the	O
5	case	O
6	for	O
7	HIS3	B
8	where	O
9	only	O
10	a	O
11	limited	O
12	subset	O
13	of	O
14	TATA	O
15	-	O
16	like	O
17	sequences	O
18	can	O
19	activate	O
20	transcription	O
21	in	O
22	conjunction	O
23	with	O
24	GCN4p	B
25	,	O
26	many	O
27	divergent	O
28	TATA	O
29	-	O
30	like	O
31	sequences	O
32	allowed	O
33	GCN4p	B
34	activation	O
35	of	O
36	TRP3	B
37	.	O

1	Bacterially	O
2	expressed	O
3	protein	O
4	,	O
5	as	O
6	well	O
7	as	O
8	the	O
9	in	O
10	vitro	O
11	reticulocyte	O
12	lysate	O
13	translation	O
14	product	O
15	,	O
16	comigrated	O
17	with	O
18	the	O
19	purified	O
20	37	O
21	-	O
22	kDa	O
23	protein	O
24	on	O
25	sodium	O
26	dodecyl	O
27	sulfate	O
28	-	O
29	polyacrylamide	O
30	gels	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	this	O
5	kinase	O
6	is	O
7	well	O
8	conserved	O
9	evolutionarily	O
10	,	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	and	O
15	its	O
16	genes	O
17	map	O
18	to	O
19	a	O
20	position	O
21	on	O
22	human	O
23	chromosome	O
24	1	O
25	frequently	O
26	deleted	O
27	in	O
28	the	O
29	late	O
30	stages	O
31	of	O
32	tumorigenesis	O
33	.	O

1	Deletion	O
2	analysis	O
3	of	O
4	the	O
5	ICL1	B
6	promoter	I
7	led	O
8	to	O
9	the	O
10	identification	O
11	of	O
12	an	O
13	upstream	O
14	activating	O
15	sequence	O
16	element	O
17	,	O
18	UASICL1	O
19	(	O
20	5	O
21	'	O
22	CATTCATCCG	O
23	3	O
24	'),	O
25	necessary	O
26	and	O
27	sufficient	O
28	for	O
29	conferring	O
30	carbon	O
31	source	O
32	-	O
33	dependent	O
34	regulation	O
35	on	O
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O

1	Interestingly	O
2	,	O
3	the	O
4	interaction	O
5	of	O
6	ZAP	B
7	-	I
8	70	I
9	with	O
10	the	O
11	motif	O
12	was	O
13	dependent	O
14	on	O
15	the	O
16	presence	O
17	of	O
18	both	O
19	ZAP	B
20	-	I
21	70	I
22	SH2	I
23	domains	I
24	and	O
25	both	O
26	of	O
27	the	O
28	tyrosine	O
29	residues	O
30	in	O
31	the	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	ZAP	B
37	-	I
38	70	I
39	interacts	O
40	with	O
41	two	O
42	phosphotyrosine	O
43	residues	O
44	and	O
45	that	O
46	the	O
47	binding	O
48	of	O
49	the	O
50	two	O
51	SH2	B
52	domains	I
53	is	O
54	cooperative	O
55	.	O

1	PRL	B
2	-	I
3	1	I
4	is	O
5	able	O
6	to	O
7	dephosphorylate	O
8	phosphotyrosine	O
9	substrates	O
10	,	O
11	and	O
12	mutation	O
13	of	O
14	the	O
15	active	O
16	-	O
17	site	O
18	cysteine	O
19	residue	O
20	abolishes	O
21	this	O
22	activity	O
23	.	O

1	In	O
2	Mv1Lu	O
3	lung	O
4	epithelial	O
5	cells	O
6	,	O
7	ActR	B
8	-	I
9	IB	I
10	and	O
11	T	B
12	beta	I
13	R	I
14	-	I
15	I	I
16	signal	O
17	a	O
18	common	O
19	set	O
20	of	O
21	growth	O
22	-	O
23	inhibitory	O
24	and	O
25	transcriptional	O
26	responses	O
27	in	O
28	association	O
29	with	O
30	their	O
31	corresponding	O
32	ligands	O
33	and	O
34	type	B
35	II	I
36	receptors	I
37	.	O

1	50	O
2	kDa	O
3	and	O
4	130	O
5	-	O
6	170	O
7	kDa	O
8	were	O
9	detected	O
10	.	O

1	H	O
2	-	O
3	7	O
4	,	O
5	which	O
6	specifically	O
7	,	O
8	although	O
9	weakly	O
10	,	O
11	inhibited	O
12	PKC	B
13	activation	O
14	,	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	tyrosine	O
20	phosphorylation	O
21	and	O
22	PtdIns	O
23	(	O
24	3	O
25	,	O
26	4	O
27	)	O
28	P2	O
29	production	O
30	.	O

1	The	O
2	effects	O
3	of	O
4	systemic	O
5	glucose	O
6	concentration	O
7	on	O
8	brain	O
9	metabolism	O
10	following	O
11	repeated	O
12	brain	O
13	ischemia	O
14	.	O

1	This	O
2	strategy	O
3	was	O
4	used	O
5	to	O
6	place	O
7	both	O
8	the	O
9	Tn903	B
10	neo	I
11	gene	I
12	and	O
13	the	O
14	Rhodosporidium	B
15	toruloides	I
16	phenylalanine	I
17	ammonia	I
18	lyase	I
19	(	O
20	PAL	B
21	)-	O
22	encoding	O
23	gene	O
24	under	O
25	the	O
26	transcriptional	O
27	control	O
28	of	O
29	pPGK	B
30	::	O
31	REP2	B
32	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	B
7	C	I
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	started	O
16	cautiously	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O

1	A	O
2	-	O
3	69	O
4	-	O
5	year	O
6	-	O
7	old	O
8	patient	O
9	with	O
10	postoperative	O
11	small	O
12	-	O
13	bowel	O
14	obstruction	O
15	underwent	O
16	laparotomy	O
17	three	O
18	times	O
19	.	O

1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	the	O
8	hUBF	B
9	-	I
10	promoter	I
11	interaction	O
12	is	O
13	highly	O
14	sensitive	O
15	to	O
16	the	O
17	antagonistic	O
18	effects	O
19	of	O
20	cisplatin	O
21	-	O
22	DNA	O
23	adducts	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	SIMV	O
6	is	O
7	useful	O
8	in	O
9	weaning	O
10	neonates	O
11	from	O
12	the	O
13	ventilator	O
14	.	O

1	VP	O
2	-	O
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O

1	A	O
2	total	O
3	of	O
4	7	O
5	(	O
6	4	O
7	males	O
8	and	O
9	3	O
10	females	O
11	)	O
12	patients	O
13	were	O
14	included	O
15	in	O
16	this	O
17	retrospective	O
18	study	O
19	to	O
20	determine	O
21	the	O
22	sensitivity	O
23	of	O
24	radioimmunoscintigraphy	O
25	with	O
26	I	O
27	-	O
28	131	O
29	labeled	O
30	anti	B
31	CEA	I
32	/	O
33	CA	B
34	19	I
35	-	I
36	9	I
37	monoclonal	O
38	antibodies	O
39	.	O

1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O

1	A	O
2	genomic	O
3	clone	O
4	for	O
5	the	O
6	cyc07	B
7	gene	I
8	,	O
9	which	O
10	is	O
11	expressed	O
12	specifically	O
13	at	O
14	the	O
15	S	O
16	phase	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	in	O
22	synchronous	O
23	cultures	O
24	of	O
25	periwinkle	O
26	(	O
27	Catharanthus	O
28	roseus	O
29	)	O
30	cells	O
31	,	O
32	was	O
33	isolated	O
34	.	O

1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O

1	The	O
2	pyrR	B
3	and	O
4	pyrP	B
5	genes	I
6	encoded	O
7	polypeptides	O
8	with	O
9	calculated	O
10	molecular	O
11	masses	O
12	of	O
13	19	O
14	.	O
15	9	O
16	and	O
17	45	O
18	.	O
19	2	O
20	kDa	O
21	,	O
22	respectively	O
23	.	O

1	Southern	O
2	blotting	O
3	analysis	O
4	implied	O
5	the	O
6	occurrence	O
7	of	O
8	multiple	O
9	COXVb	B
10	genes	I
11	in	O
12	the	O
13	rat	O
14	genome	O
15	.	O

1	Acylation	O
2	with	O
3	the	O
4	palmitate	O
5	analog	O
6	was	O
7	prevented	O
8	when	O
9	Gly	O
10	-	O
11	2	O
12	was	O
13	mutated	O
14	to	O
15	alanine	O
16	,	O
17	implying	O
18	that	O
19	N	O
20	-	O
21	myristylation	O
22	is	O
23	required	O
24	for	O
25	palmitylation	O
26	,	O
27	and	O
28	when	O
29	either	O
30	Cys	O
31	-	O
32	3	O
33	or	O
34	Cys	O
35	-	O
36	6	O
37	was	O
38	mutated	O
39	to	O
40	serine	O
41	.	O

1	Subunit	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	Spo0A	B
9	sporulation	I
10	transcription	I
11	factor	I
12	of	I
13	Bacillus	I
14	subtilis	I
15	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	analysis	O
5	indicates	O
6	that	O
7	NF	B
8	-	I
9	IL	I
10	-	I
11	6	I
12	,	O
13	as	O
14	well	O
15	as	O
16	other	O
17	related	O
18	members	O
19	of	O
20	this	O
21	family	O
22	,	O
23	bind	O
24	specifically	O
25	to	O
26	the	O
27	NF	B
28	-	I
29	IL	I
30	-	I
31	6	I
32	site	O
33	in	O
34	the	O
35	IL	B
36	-	I
37	8	I
38	promoter	I
39	.	O

1	BYV	O
2	,	O
3	citrus	O
4	tristeza	O
5	virus	O
6	(	O
7	CTV	O
8	),	O
9	beet	O
10	yellow	O
11	stunt	O
12	virus	O
13	(	O
14	BYSV	O
15	)	O
16	and	O
17	carnation	O
18	necrotic	O
19	fleck	O
20	virus	O
21	templates	O
22	produced	O
23	1	O
24	kb	O
25	amplification	O
26	products	O
27	,	O
28	which	O
29	were	O
30	shown	O
31	by	O
32	sequencing	O
33	to	O
34	represent	O
35	fragments	O
36	of	O
37	the	O
38	respective	O
39	HSP70	B
40	genes	I
41	.	O

1	To	O
2	identify	O
3	the	O
4	precise	O
5	location	O
6	of	O
7	the	O
8	phosphorylation	O
9	site	O
10	on	O
11	the	O
12	64	O
13	-	O
14	kDa	O
15	protein	O
16	,	O
17	a	O
18	step	O
19	-	O
20	by	O
21	-	O
22	step	O
23	mutagenesis	O
24	procedures	O
25	was	O
26	followed	O
27	.	O

1	The	O
2	p53	B
3	tumor	I
4	suppressor	I
5	gene	I
6	product	I
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	B
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	O

1	Rearrangements	O
2	of	O
3	the	O
4	NFKB2	B
5	gene	I
6	are	O
7	associated	O
8	with	O
9	lymphoid	O
10	malignancies	O
11	,	O
12	but	O
13	the	O
14	functional	O
15	significance	O
16	of	O
17	these	O
18	alterations	O
19	is	O
20	not	O
21	known	O
22	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	corresponding	O
7	cDNAs	O
8	indicates	O
9	that	O
10	,	O
11	via	O
12	alternative	O
13	splicing	O
14	,	O
15	the	O
16	rearranged	O
17	gene	O
18	codes	O
19	for	O
20	two	O
21	proteins	O
22	of	O
23	84	O
24	and	O
25	85	O
26	kD	O
27	(	O
28	p84	B
29	/	I
30	85	I
31	)	O
32	which	O
33	retain	O
34	the	O
35	DNA	O
36	-	O
37	binding	O
38	rel	B
39	domain	I
40	and	O
41	the	O
42	first	O
43	five	O
44	ankyrin	B
45	repeats	O
46	,	O
47	but	O
48	have	O
49	lost	O
50	their	O
51	carboxy	O
52	-	O
53	terminus	O
54	including	O
55	the	O
56	seventh	O
57	ankyrin	B
58	repeat	O
59	.	O

1	Transient	O
2	co	O
3	-	O
4	transfection	O
5	assays	O
6	involving	O
7	NFKB2	B
8	expression	O
9	vectors	O
10	and	O
11	kappa	B
12	B	I
13	-	O
14	driven	O
15	reporter	O
16	plasmids	O
17	indicate	O
18	that	O
19	NFKB2	B
20	p85	I
21	has	O
22	lost	O
23	the	O
24	transcriptional	O
25	repressor	O
26	functions	O
27	typical	O
28	of	O
29	normal	O
30	NFKB2	B
31	p52	I
32	.	O

1	Also	O
2	,	O
3	HR21ap	B
4	as	O
5	well	O
6	as	O
7	HR21Xap	B
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O

1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O

1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	B
11	-	I
12	1	I
13	BamHI	I
14	-	I
15	D	I
16	DNA	I
17	fragment	I
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O

1	The	O
2	ns2	B
3	gene	I
4	comprises	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	(	O
10	ORF	O
11	)	O
12	encoding	O
13	a	O
14	putative	O
15	nonstructural	O
16	(	O
17	ns	O
18	)	O
19	protein	O
20	of	O
21	279	O
22	amino	O
23	acids	O
24	with	O
25	a	O
26	predicted	O
27	molecular	O
28	mass	O
29	of	O
30	32	O
31	-	O
32	kDa	O
33	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	a	O
6	tat	B
7	expressing	O
8	plasmid	O
9	with	O
10	these	O
11	viruses	O
12	containing	O
13	the	O
14	tat	B
15	ORF	I
16	mutations	O
17	resulted	O
18	in	O
19	higher	O
20	levels	O
21	of	O
22	virus	O
23	production	O
24	demonstrating	O
25	that	O
26	the	O
27	effects	O
28	of	O
29	both	O
30	mutants	O
31	are	O
32	tat	B
33	specific	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	gag	B
5	and	O
6	rev	B
7	proteins	I
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	O
19	in	O
20	cells	O
21	transfected	O
22	with	O
23	the	O
24	tat	B
25	mutants	I
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	O
36	in	O
37	trans	O
38	with	O
39	a	O
40	tat	B
41	expression	O
42	vector	O
43	.	O

1	The	O
2	hydrophobicity	O
3	profile	O
4	of	O
5	the	O
6	methyltransferase	O
7	reveals	O
8	the	O
9	presence	O
10	of	O
11	at	O
12	least	O
13	five	O
14	potential	O
15	transmembrane	O
16	domains	O
17	.	O

1	Measurement	O
2	of	O
3	SaO2	O
4	at	O
5	moderate	O
6	altitude	O
7	can	O
8	be	O
9	helpful	O
10	in	O
11	the	O
12	care	O
13	of	O
14	both	O
15	healthy	O
16	and	O
17	ill	O
18	newborns	O
19	or	O
20	infants	O
21	.	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	excess	O
6	prevalence	O
7	of	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	)	O
18	infection	O
19	in	O
20	US	O
21	black	O
22	and	O
23	Hispanic	O
24	homosexual	O
25	men	O
26	relative	O
27	to	O
28	white	O
29	men	O
30	can	O
31	be	O
32	explained	O
33	by	O
34	differences	O
35	in	O
36	sociodemographic	O
37	factors	O
38	,	O
39	history	O
40	of	O
41	sexually	O
42	transmitted	O
43	diseases	O
44	,	O
45	or	O
46	sexual	O
47	and	O
48	drug	O
49	-	O
50	use	O
51	behaviors	O
52	,	O
53	the	O
54	authors	O
55	conducted	O
56	a	O
57	cross	O
58	-	O
59	sectional	O
60	analysis	O
61	of	O
62	baseline	O
63	HIV	O
64	-	O
65	1	O
66	seroprevalence	O
67	and	O
68	HIV	O
69	-	O
70	1	O
71	risk	O
72	factors	O
73	among	O
74	4	O
75	,	O
76	475	O
77	non	O
78	-	O
79	Hispanic	O
80	white	O
81	,	O
82	234	O
83	Hispanic	O
84	white	O
85	,	O
86	and	O
87	194	O
88	black	O
89	homosexual	O
90	men	O
91	from	O
92	four	O
93	centers	O
94	in	O
95	the	O
96	United	O
97	States	O
98	(	O
99	Baltimore	O
100	/	O
101	Washington	O
102	,	O
103	DC	O
104	,	O
105	Pittsburgh	O
106	,	O
107	Chicago	O
108	,	O
109	and	O
110	Los	O
111	Angeles	O
112	).	O

1	The	O
2	patients	O
3	in	O
4	one	O
5	group	O
6	had	O
7	intrauterine	O
8	catheters	O
9	inserted	O
10	and	O
11	oxytocin	B
12	was	O
13	titrated	O
14	to	O
15	achieve	O
16	the	O
17	75th	O
18	percentile	O
19	of	O
20	uterine	O
21	activity	O
22	observed	O
23	in	O
24	spontaneous	O
25	normal	O
26	labour	O
27	according	O
28	to	O
29	parity	O
30	.	O

1	Continued	O
2	development	O
3	of	O
4	the	O
5	rat	O
6	conditioning	O
7	paradigm	O
8	is	O
9	especially	O
10	warranted	O
11	because	O
12	of	O
13	the	O
14	ability	O
15	to	O
16	record	O
17	sympathetic	O
18	nerve	O
19	activity	O
20	in	O
21	intact	O
22	,	O
23	awake	O
24	subjects	O
25	and	O
26	the	O
27	large	O
28	number	O
29	of	O
30	readily	O
31	available	O
32	genetic	O
33	strains	O
34	,	O
35	which	O
36	model	O
37	human	O
38	pathological	O
39	states	O
40	.	O

1	The	O
2	ultrastructure	O
3	of	O
4	retinal	O
5	vessels	O
6	was	O
7	examined	O
8	in	O
9	three	O
10	eyes	O
11	from	O
12	diabetic	O
13	patients	O
14	and	O
15	two	O
16	eyes	O
17	from	O
18	control	O
19	subjects	O
20	.	O

1	The	O
2	regulatory	O
3	region	O
4	also	O
5	has	O
6	a	O
7	sequence	O
8	similar	O
9	to	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	a	O
15	liver	O
16	-	O
17	specific	O
18	transcription	O
19	factor	O
20	,	O
21	hepatocyte	B
22	nuclear	I
23	factor	I
24	1	I
25	(	O
26	HNF	B
27	-	I
28	1	I
29	),	O
30	at	O
31	positions	O
32	-	O
33	120	O
34	to	O
35	-	O
36	132	O
37	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	GRE	O
8	sufficient	O
9	to	O
10	account	O
11	for	O
12	full	O
13	glucocorticoid	O
14	inducibility	O
15	and	O
16	an	O
17	HNF	B
18	-	I
19	1	I
20	site	I
21	close	O
22	to	O
23	the	O
24	promoter	O
25	that	O
26	are	O
27	major	O
28	determinants	O
29	of	O
30	transcriptional	O
31	control	O
32	of	O
33	the	O
34	Xenopus	B
35	fibrinogen	I
36	B	I
37	beta	I
38	subunit	I
39	gene	I
40	in	O
41	cells	O
42	from	O
43	normal	O
44	liver	O
45	tissue	O
46	.	O

1	Acad	O
2	.	O

1	The	O
2	PRB	B
3	-	I
4	1b	I
5	gene	I
6	encodes	O
7	for	O
8	a	O
9	basic	O
10	-	O
11	type	O
12	component	O
13	of	O
14	the	O
15	pathogenesis	O
16	-	O
17	related	O
18	PR	B
19	-	I
20	1	I
21	protein	I
22	family	I
23	.	O

1	Replacement	O
2	of	O
3	the	O
4	CRE	O
5	with	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	the	O
11	AP	B
12	-	I
13	1	I
14	site	I
15	results	O
16	in	O
17	a	O
18	level	O
19	of	O
20	transcriptional	O
21	activity	O
22	comparable	O
23	with	O
24	that	O
25	of	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	sequence	O
31	,	O
32	but	O
33	replacement	O
34	of	O
35	the	O
36	AP	B
37	-	I
38	1	I
39	site	I
40	with	O
41	a	O
42	CRE	O
43	abolishes	O
44	activity	O
45	.	O

1	The	O
2	T	B
3	-	I
4	cyt	I
5	promoter	I
6	,	O
7	although	O
8	of	O
9	bacterial	O
10	origin	O
11	is	O
12	active	O
13	in	O
14	planta	O
15	and	O
16	the	O
17	30	B
18	bp	I
19	cyt	I
20	-	I
21	1	I
22	element	I
23	is	O
24	located	O
25	within	O
26	a	O
27	region	O
28	that	O
29	is	O
30	essential	O
31	for	O
32	T	B
33	-	I
34	cyt	I
35	promotor	I
36	activity	O
37	in	O
38	leaf	O
39	,	O
40	stem	O
41	and	O
42	root	O
43	cells	O
44	of	O
45	tobacco	O
46	plants	O
47	.	O

1	Reviewing	O
2	manuscripts	O
3	:	O
4	developing	O
5	an	O
6	efficient	O
7	system	O
8	.	O

1	We	O
2	suggest	O
3	that	O
4	CT	O
5	scan	O
6	be	O
7	preferable	O
8	in	O
9	diagnosis	O
10	of	O
11	tumors	O
12	in	O
13	that	O
14	area	O
15	.	O

1	SIN	O
2	-	O
3	1	O
4	had	O
5	no	O
6	influence	O
7	on	O
8	either	O
9	the	O
10	ischemic	O
11	parameters	O
12	in	O
13	the	O
14	surface	O
15	electrocardiogram	O
16	(	O
17	ECG	O
18	)	O
19	or	O
20	the	O
21	intracoronary	O
22	ECG	O
23	.	O

1	Effect	O
2	of	O
3	aging	O
4	on	O
5	respiratory	O
6	skeletal	O
7	muscles	O
8	.	O

1	Two	O
2	BASIC	O
3	computer	O
4	programs	O
5	using	O
6	logit	O
7	transformation	O
8	for	O
9	the	O
10	analysis	O
11	of	O
12	S	O
13	-	O
14	shaped	O
15	curves	O
16	are	O
17	presented	O
18	.	O

1	The	O
2	yeast	B
3	SSS1	I
4	gene	I
5	is	O
6	essential	O
7	for	O
8	secretory	O
9	protein	O
10	translocation	O
11	and	O
12	encodes	O
13	a	O
14	conserved	O
15	protein	O
16	of	O
17	the	O
18	endoplasmic	O
19	reticulum	O
20	.	O

1	The	O
2	lengths	O
3	of	O
4	the	O
5	complete	O
6	polypeptide	O
7	chain	O
8	of	O
9	the	O
10	recombinant	O
11	enzyme	O
12	and	O
13	its	O
14	transit	O
15	peptide	O
16	are	O
17	388	O
18	and	O
19	53	O
20	residues	O
21	,	O
22	respectively	O
23	.	O

1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	B
9	protein	I
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	B
24	protein	I
25	.	O

1	TATA	O
2	and	O
3	CCAAT	O
4	boxes	O
5	are	O
6	located	O
7	34	O
8	-	O
9	bp	O
10	and	O
11	68	O
12	-	O
13	bp	O
14	,	O
15	respectively	O
16	,	O
17	upstream	O
18	of	O
19	the	O
20	transcription	O
21	start	O
22	site	O
23	,	O
24	the	O
25	5	O
26	'-	O
27	untranslated	O
28	leader	O
29	is	O
30	78	O
31	nucleotides	O
32	long	O
33	,	O
34	and	O
35	the	O
36	intronless	O
37	gene	O
38	has	O
39	at	O
40	least	O
41	two	O
42	different	O
43	polyadenylation	O
44	sites	O
45	.	O

1	GGS1	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	TPS1	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	trehalose	B
18	-	I
19	6	I
20	-	I
21	phosphate	I
22	synthase	I
23	/	I
24	phosphatase	I
25	complex	I
26	and	O
27	it	O
28	is	O
29	allelic	O
30	to	O
31	the	O
32	fdp1	B
33	,	O
34	byp1	B
35	,	O
36	glc6	B
37	and	O
38	cif1	O
39	mutations	O
40	.	O

1	We	O
2	also	O
3	compared	O
4	the	O
5	sequence	O
6	with	O
7	the	O
8	partly	O
9	homologous	O
10	products	O
11	of	O
12	the	O
13	S	O
14	.	O
15	cerevisiae	O
16	genes	O
17	TPS2	B
18	and	O
19	TSL1	B
20	which	O
21	code	O
22	for	O
23	the	O
24	larger	O
25	subunits	O
26	of	O
27	the	O
28	trehalose	B
29	synthase	I
30	complex	I
31	and	O
32	with	O
33	a	O
34	TSL1	B
35	homologue	I
36	,	O
37	TPS3	B
38	,	O
39	of	O
40	unknown	O
41	function	O
42	.	O

1	Stroop	O
2	interference	O
3	:	O
4	aging	O
5	effects	O
6	assessed	O
7	with	O
8	the	O
9	Stroop	O
10	Color	O
11	-	O
12	Word	O
13	Test	O
14	.	O

1	Stimulation	O
2	of	O
3	[	O
4	3H	O
5	]	O
6	PA	O
7	production	O
8	upon	O
9	CD3	B
10	cross	O
11	-	O
12	linking	O
13	was	O
14	77	O
15	%	O
16	lower	O
17	in	O
18	permeabilized	O
19	CD45	B
20	-	I
21	cells	O
22	than	O
23	in	O
24	CD45	B
25	+	I
26	cells	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	reduced	O
32	activity	O
33	of	O
34	p59fyn	B
35	in	O
36	CD45	B
37	-	I
38	cells	O
39	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	study	O
5	demonstrates	O
6	that	O
7	transvaginal	O
8	ultrasonography	O
9	has	O
10	an	O
11	efficiency	O
12	of	O
13	88	O
14	%	O
15	in	O
16	differentiating	O
17	endometriomas	O
18	from	O
19	other	O
20	ovarian	O
21	masses	O
22	with	O
23	a	O
24	specificity	O
25	of	O
26	90	O
27	%.	O

1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	of	O
6	rat	B
7	EFIA	I
8	(	O
9	gene	O
10	encoding	O
11	enhancer	B
12	factor	I
13	I	I
14	subunit	I
15	A	I
16	)	O
17	reveals	O
18	a	O
19	complex	O
20	band	O
21	pattern	O
22	when	O
23	cDNA	O
24	subfragment	O
25	probes	O
26	are	O
27	used	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	ibopamine	O
5	and	O
6	furosemide	O
7	in	O
8	130	O
9	patients	O
10	with	O
11	NYHA	O
12	Class	O
13	I	O
14	and	O
15	II	O
16	heart	O
17	failure	O
18	were	O
19	studied	O
20	in	O
21	a	O
22	parallel	O
23	,	O
24	double	O
25	-	O
26	blind	O
27	,	O
28	randomized	O
29	placebo	O
30	-	O
31	controlled	O
32	multi	O
33	-	O
34	centre	O
35	trial	O
36	.	O

1	The	O
2	nit	B
3	-	I
4	3	I
5	gene	I
6	of	I
7	the	I
8	filamentous	I
9	fungus	I
10	Neurospora	I
11	crassa	I
12	encodes	O
13	nitrate	B
14	reductase	I
15	,	O
16	the	O
17	enzyme	O
18	which	O
19	catalyzes	O
20	the	O
21	first	O
22	step	O
23	in	O
24	nitrate	O
25	assimilation	O
26	.	O

1	Unfolding	O
2	can	O
3	be	O
4	described	O
5	by	O
6	a	O
7	two	O
8	-	O
9	state	O
10	process	O
11	since	O
12	a	O
13	ratio	O
14	of	O
15	delta	O
16	Hcalorimetric	O
17	to	O
18	delta	O
19	Hvan	O
20	'	O
21	t	O
22	Hoff	O
23	equals	O
24	0	O
25	.	O
26	96	O
27	.	O

1	A	O
2	Dictyostelium	O
3	transformant	O
4	overexpressing	O
5	DdPTPa	B
6	does	O
7	not	O
8	develop	O
9	normally	O
10	.	O

1	This	O
2	motif	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	mediate	O
8	protein	O
9	interactions	O
10	in	O
11	the	O
12	case	O
13	of	O
14	ankyrin	B
15	as	O
16	well	O
17	as	O
18	several	O
19	other	O
20	repeat	O
21	-	O
22	bearing	O
23	proteins	O
24	.	O

1	[	B
2	Ala85	I
3	]	I
4	Dk	I
5	(	I
6	69	I
7	-	I
8	85	I
9	)	I
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	We	O
2	postulate	O
3	that	O
4	CaM	B
5	binding	O
6	by	O
7	HIV	B
8	envelope	I
9	proteins	I
10	is	O
11	likely	O
12	to	O
13	exert	O
14	diverse	O
15	modulatory	O
16	effects	O
17	,	O
18	and	O
19	the	O
20	mechanism	O
21	for	O
22	HIV	O
23	-	O
24	induced	O
25	cytotoxicity	O
26	may	O
27	involve	O
28	,	O
29	in	O
30	part	O
31	,	O
32	inhibition	O
33	of	O
34	CaM	B
35	-	O
36	regulated	O
37	cellular	O
38	functions	O
39	.	O

1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	fad7	B
17	mRNA	I
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O

1	The	O
2	major	O
3	myosin	B
4	-	I
5	binding	I
6	domain	I
7	of	O
8	skeletal	B
9	muscle	I
10	MyBP	I
11	-	I
12	C	I
13	(	O
14	C	B
15	protein	I
16	)	O
17	resides	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	,	O
24	immunoglobulin	B
25	C2	I
26	motif	I
27	.	O

1	A	O
2	second	O
3	important	O
4	molecule	O
5	in	O
6	TCR	B
7	signal	O
8	transduction	O
9	is	O
10	the	O
11	guanine	B
12	nucleotide	I
13	binding	I
14	protein	I
15	,	O
16	p21ras	B
17	,	O
18	which	O
19	is	O
20	coupled	O
21	to	O
22	the	O
23	TCR	B
24	by	O
25	a	O
26	protein	B
27	tyrosine	I
28	kinase	I
29	dependent	O
30	mechanism	O
31	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	periseizure	O
6	lipid	O
7	accumulation	O
8	is	O
9	related	O
10	to	O
11	cortical	O
12	oxygenation	O
13	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	QLMI	O
6	questionnaire	O
7	has	O
8	good	O
9	potential	O
10	as	O
11	an	O
12	instrument	O
13	for	O
14	assessing	O
15	QL	O
16	in	O
17	post	O
18	-	O
19	AMI	O
20	patients	O
21	and	O
22	that	O
23	it	O
24	can	O
25	be	O
26	successfully	O
27	self	O
28	-	O
29	administered	O
30	.	O

1	Most	O
2	smokers	O
3	would	O
4	prefer	O
5	to	O
6	quit	O
7	smoking	O
8	on	O
9	their	O
10	own	O
11	.	O

1	The	O
2	inhibitory	O
3	response	O
4	to	O
5	taps	O
6	is	O
7	essentially	O
8	a	O
9	protective	O
10	reflex	O
11	which	O
12	probably	O
13	serves	O
14	to	O
15	reduce	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	jaw	O
21	-	O
22	closing	O
23	muscles	O
24	when	O
25	one	O
26	bites	O
27	unexpectedly	O
28	on	O
29	hard	O
30	objects	O
31	.	O

1	The	O
2	action	O
3	of	O
4	nef	B
5	was	O
6	specific	O
7	to	O
8	the	O
9	LTR	O
10	,	O
11	as	O
12	expression	O
13	of	O
14	nef	B
15	had	O
16	no	O
17	effect	O
18	on	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	simian	O
24	virus	O
25	40	O
26	,	O
27	c	B
28	-	I
29	fms	I
30	,	O
31	urokinase	B
32	plasminogen	I
33	activator	I
34	,	O
35	or	O
36	type	B
37	5	I
38	acid	I
39	phosphatase	I
40	promoter	I
41	.	O
42	trans	O
43	-	O
44	activating	O
45	activity	O
46	was	O
47	also	O
48	manifested	O
49	by	O
50	a	O
51	frameshift	O
52	mutant	O
53	expressing	O
54	only	O
55	the	O
56	first	O
57	35	O
58	amino	O
59	acids	O
60	of	O
61	the	O
62	protein	O
63	.	O

1	The	O
2	product	O
3	of	O
4	the	O
5	vpr	B
6	open	I
7	reading	I
8	frame	I
9	of	I
10	human	I
11	immunodeficiency	I
12	virus	I
13	type	I
14	1	I
15	(	I
16	HIV	I
17	-	I
18	1	I
19	)	I
20	is	O
21	a	O
22	15	O
23	-	O
24	kDa	O
25	,	O
26	arginine	O
27	-	O
28	rich	O
29	protein	O
30	that	O
31	is	O
32	present	O
33	in	O
34	virions	O
35	in	O
36	molar	O
37	quantities	O
38	equivalent	O
39	to	O
40	that	O
41	of	O
42	Gag	B
43	.	O

1	The	O
2	recombinant	B
3	vaccinia	I
4	virus	I
5	-	I
6	expressed	I
7	mutant	I
8	P1	I
9	polyproteins	I
10	were	O
11	analyzed	O
12	for	O
13	proteolytic	O
14	processing	O
15	defects	O
16	in	O
17	cells	O
18	coinfected	O
19	with	O
20	a	O
21	recombinant	O
22	vaccinia	O
23	virus	O
24	(	O
25	VVP3	O
26	)	O
27	that	O
28	expresses	O
29	the	O
30	poliovirus	B
31	3CD	I
32	protease	I
33	and	O
34	for	O
35	processing	O
36	and	O
37	assembly	O
38	defects	O
39	by	O
40	using	O
41	a	O
42	trans	O
43	complementation	O
44	system	O
45	in	O
46	which	O
47	P1	B
48	-	O
49	expressing	O
50	recombinant	O
51	vaccinia	O
52	viruses	O
53	provide	O
54	capsid	B
55	precursor	I
56	to	O
57	a	O
58	defective	O
59	poliovirus	O
60	genome	O
61	that	O
62	does	O
63	not	O
64	express	O
65	functional	O
66	capsid	B
67	proteins	I
68	(	O
69	D	O
70	.	O

1	In	O
2	contrast	O
3	,	O
4	capsid	B
5	proteins	I
6	derived	O
7	from	O
8	the	O
9	P1	B
10	precursor	I
11	with	O
12	a	O
13	valine	O
14	substitution	O
15	at	O
16	the	O
17	amino	O
18	terminus	O
19	of	O
20	VP1	B
21	(	O
22	VP1	B
23	-	I
24	G001V	I
25	)	O
26	assembled	O
27	empty	O
28	capsid	O
29	particles	O
30	but	O
31	were	O
32	deficient	O
33	in	O
34	assembling	O
35	RNA	O
36	-	O
37	containing	O
38	virions	O
39	.	O

1	RESULTS	O
2	:	O
3	In	O
4	an	O
5	18	O
6	moth	O
7	period	O
8	and	O
9	out	O
10	of	O
11	a	O
12	total	O
13	of	O
14	284	O
15	positive	O
16	blood	O
17	cultures	O
18	(	O
19	154	O
20	significant	O
21	isolations	O
22	)	O
23	14	O
24	episodes	O
25	of	O
26	bacteremia	O
27	by	O
28	M	O
29	.	O
30	tuberculosis	O
31	were	O
32	studied	O
33	in	O
34	12	O
35	prison	O
36	patients	O
37	coinfected	O
38	by	O
39	the	O
40	human	O
41	immunodeficiency	O
42	virus	O
43	with	O
44	associated	O
45	severe	O
46	immunosuppression	O
47	(	O
48	mean	O
49	of	O
50	CD4	B
51	=	O
52	0	O
53	.	O
54	068	O
55	x	O
56	10	O
57	(	O
58	9	O
59	)/	O
60	l	O
61	).	O

1	Acid	O
2	instilled	O
3	on	O
4	the	O
5	larynx	O
6	of	O
7	maturing	O
8	rabbits	O
9	resulted	O
10	in	O
11	significant	O
12	obstructive	O
13	,	O
14	central	O
15	,	O
16	and	O
17	mixed	O
18	apnea	O
19	.	O

1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	B
39	tsp	I
40	).	O

1	A	O
2	series	O
3	of	O
4	5	O
5	'-	O
6	deletions	O
7	revealed	O
8	that	O
9	the	O
10	fragment	O
11	-	O
12	218	O
13	to	O
14	+	O
15	4	O
16	from	O
17	the	O
18	TSS	O
19	had	O
20	the	O
21	highest	O
22	promoter	O
23	activity	O
24	,	O
25	nearly	O
26	1000	O
27	-	O
28	fold	O
29	greater	O
30	than	O
31	the	O
32	promoterless	O
33	chloramphenicol	B
34	acetyltransferase	I
35	construct	I
36	.	O

1	The	O
2	lemdr1	B
3	gene	I
4	was	O
5	cloned	O
6	in	O
7	the	O
8	expression	O
9	vector	O
10	pALTNEO	O
11	and	O
12	transfected	O
13	into	O
14	wild	O
15	-	O
16	type	O
17	L	O
18	.	O
19	enriettii	O
20	and	O
21	the	O
22	resulting	O
23	transfected	O
24	cells	O
25	were	O
26	resistant	O
27	to	O
28	vinblastine	O
29	but	O
30	at	O
31	lower	O
32	levels	O
33	than	O
34	in	O
35	the	O
36	selected	O
37	mutant	O
38	cells	O
39	.	O

1	The	O
2	bioavailability	O
3	of	O
4	etodolac	O
5	from	O
6	capsules	O
7	exposed	O
8	to	O
9	stressed	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	capsules	O
20	stored	O
21	at	O
22	RT	O
23	conditions	O
24	.	O

1	Similar	O
2	synergistic	O
3	activation	O
4	was	O
5	observed	O
6	in	O
7	the	O
8	IL	B
9	-	I
10	8	I
11	promoter	I
12	,	O
13	which	O
14	also	O
15	contains	O
16	both	O
17	NF	B
18	-	I
19	IL6	I
20	and	O
21	NF	B
22	-	I
23	kappa	I
24	B	I
25	binding	I
26	sites	I
27	.	O

1	Notice	O
2	of	O
3	retraction	O
4	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O

1	We	O
2	report	O
3	an	O
4	odd	O
5	case	O
6	of	O
7	marked	O
8	enlargement	O
9	of	O
10	suprapineal	O
11	recess	O
12	in	O
13	a	O
14	patient	O
15	with	O
16	triventricular	O
17	hydrocephalus	O
18	.	O

1	As	O
2	regards	O
3	lipid	O
4	metabolism	O
5	,	O
6	the	O
7	mean	O
8	values	O
9	for	O
10	total	O
11	triglycerides	O
12	,	O
13	cholesterol	O
14	,	O
15	LDL	B
16	-	I
17	cholesterol	I
18	and	O
19	HDL	B
20	-	I
21	cholesterol	I
22	seen	O
23	at	O
24	the	O
25	end	O
26	of	O
27	five	O
28	years	O
29	of	O
30	Norplant	O
31	-	O
32	2	O
33	rod	O
34	use	O
35	and	O
36	six	O
37	months	O
38	postremoval	O
39	were	O
40	similar	O
41	to	O
42	the	O
43	preinsertion	O
44	mean	O
45	.	O

1	At	O
2	a	O
3	PaCO2	O
4	of	O
5	40	O
6	mmHg	O
7	,	O
8	baseline	O
9	brain	O
10	pHi	O
11	measured	O
12	7	O
13	.	O
14	03	O
15	+/-	O
16	0	O
17	.	O
18	04	O
19	,	O
20	while	O
21	regional	O
22	cortical	O
23	blood	O
24	flow	O
25	was	O
26	47	O
27	.	O
28	0	O
29	+/-	O
30	4	O
31	.	O
32	3	O
33	ml	O
34	.	O
35	100	O
36	g	O
37	-	O
38	1	O
39	.	O
40	min	O
41	-	O
42	1	O
43	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	Effects	O
2	of	O
3	diltiazem	O
4	on	O
5	netilmicin	O
6	-	O
7	induced	O
8	nephrotoxicity	O
9	in	O
10	rabbits	O
11	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	About	O
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O

1	To	O
2	our	O
3	knowledge	O
4	this	O
5	is	O
6	the	O
7	first	O
8	case	O
9	in	O
10	which	O
11	a	O
12	probable	O
13	association	O
14	between	O
15	cholelithiasis	O
16	and	O
17	Wildervanck	O
18	'	O
19	s	O
20	syndrome	O
21	has	O
22	been	O
23	recorded	O
24	.	O

1	Both	O
2	4	O
3	,	O
4	8	O
5	-	O
6	DiMeIQx	O
7	and	O
8	A	O
9	alpha	O
10	C	O
11	were	O
12	found	O
13	at	O
14	<	O
15	1	O
16	p	O
17	.	O
18	p	O
19	.	O
20	b	O
21	.	O

1	Three	O
2	cysteine	O
3	and	O
4	four	O
5	tryptophan	O
6	residues	O
7	,	O
8	previously	O
9	identified	O
10	as	O
11	conserved	O
12	amongst	O
13	nitrous	B
14	-	I
15	oxide	I
16	reductases	I
17	,	O
18	are	O
19	found	O
20	in	O
21	the	O
22	Paracoccus	O
23	enzyme	O
24	.	O

1	Recombinant	B
2	Leishmania	I
3	surface	I
4	glycoprotein	I
5	GP63	I
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	B
17	.	O

1	Delineating	O
2	the	O
3	molecular	O
4	basis	O
5	for	O
6	agonist	O
7	-	O
8	induced	O
9	destabilization	O
10	of	O
11	mRNA	O
12	of	O
13	G	B
14	-	I
15	protein	I
16	-	I
17	linked	I
18	receptors	I
19	that	O
20	contributes	O
21	to	O
22	receptor	O
23	down	O
24	-	O
25	regulation	O
26	is	O
27	fundamental	O
28	to	O
29	our	O
30	understanding	O
31	of	O
32	long	O
33	-	O
34	term	O
35	regulation	O
36	of	O
37	receptors	O
38	by	O
39	agonist	O
40	.	O

1	Addition	O
2	of	O
3	phalloidin	O
4	-	O
5	stabilized	O
6	F	B
7	-	I
8	actin	I
9	nuclei	O
10	and	O
11	phalloidin	O
12	restored	O
13	L266D	O
14	actin	B
15	'	O
16	s	O
17	ability	O
18	to	O
19	polymerize	O
20	at	O
21	4	O
22	degrees	O
23	C	O
24	.	O

1	These	O
2	cells	O
3	produce	O
4	a	O
5	low	O
6	level	O
7	of	O
8	IL	B
9	-	I
10	5	I
11	when	O
12	stimulated	O
13	with	O
14	PMA	O
15	alone	O
16	;	O
17	however	O
18	,	O
19	N6	O
20	,	O
21	O2	O
22	-	O
23	dibutyryl	O
24	cAMP	O
25	(	O
26	Bt2cAMP	O
27	),	O
28	in	O
29	combination	O
30	with	O
31	PMA	O
32	,	O
33	augmented	O
34	by	O
35	more	O
36	than	O
37	tenfold	O
38	the	O
39	IL	B
40	-	I
41	5	I
42	production	O
43	at	O
44	the	O
45	mRNA	O
46	and	O
47	the	O
48	protein	O
49	levels	O
50	.	O

1	Hu	B
2	-	I
3	Met	I
4	-	I
5	1	I
6	mRNA	I
7	expression	O
8	in	O
9	a	O
10	small	O
11	number	O
12	of	O
13	human	O
14	T	O
15	cell	O
16	tumor	O
17	lines	O
18	did	O
19	not	O
20	correlate	O
21	with	O
22	any	O
23	particular	O
24	phenotype	O
25	or	O
26	stage	O
27	of	O
28	development	O
29	.	O

1	Partial	O
2	engorgement	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	analysis	O
6	demonstrated	O
7	expression	O
8	of	O
9	human	O
10	PI	B
11	3	I
12	-	I
13	kinase	I
14	in	O
15	all	O
16	tissues	O
17	and	O
18	cell	O
19	lines	O
20	tested	O
21	.	O

1	These	O
2	results	O
3	demonstrate	O
4	the	O
5	existence	O
6	of	O
7	different	O
8	PI	B
9	3	I
10	-	I
11	kinase	I
12	isoforms	I
13	and	O
14	define	O
15	a	O
16	family	O
17	of	O
18	genes	O
19	encoding	O
20	distinct	O
21	PI	B
22	3	I
23	-	I
24	kinase	I
25	catalytic	I
26	subunits	I
27	that	O
28	can	O
29	associate	O
30	with	O
31	p85	B
32	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	protein	B
6	-	I
7	tyrosine	I
8	kinase	I
9	domain	I
10	,	O
11	p56lck	B
12	possesses	O
13	Src	B
14	homology	I
15	2	I
16	and	I
17	3	I
18	(	O
19	SH2	B
20	and	O
21	SH3	B
22	)	O
23	domains	O
24	as	O
25	well	O
26	as	O
27	a	O
28	unique	O
29	N	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	Strains	O
2	bearing	O
3	the	O
4	drs2	B
5	mutation	I
6	process	O
7	the	O
8	20S	B
9	precursor	I
10	of	O
11	the	O
12	mature	B
13	18S	I
14	rRNA	I
15	slowly	O
16	and	O
17	are	O
18	deficient	O
19	in	O
20	40S	B
21	ribosomal	I
22	subunits	I
23	.	O

1	Hepatitis	O
2	B	O
3	and	O
4	liver	O
5	transplantation	O
6	.	O

1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	B
31	gene	I
32	expression	O
33	.	O

1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O

1	The	O
2	rate	O
3	of	O
4	enzymic	O
5	stimulation	O
6	induced	O
7	by	O
8	a	O
9	given	O
10	nitrate	O
11	correlates	O
12	closely	O
13	with	O
14	the	O
15	rate	O
16	of	O
17	measured	O
18	NO	O
19	production	O
20	from	O
21	the	O
22	nitrate	O
23	molecule	O
24	.	O

1	Clipping	O
2	resulted	O
3	in	O
4	a	O
5	serious	O
6	mislocalization	O
7	of	O
8	the	O
9	position	O
10	of	O
11	the	O
12	peak	O
13	of	O
14	the	O
15	epicortical	O
16	potential	O
17	field	O
18	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	The	O
2	247	O
3	-	O
4	kDa	O
5	complex	O
6	appears	O
7	to	O
8	contain	O
9	two	O
10	distinct	O
11	protein	O
12	-	O
13	DNA	O
14	complexes	O
15	of	O
16	approximately	O
17	232	O
18	and	O
19	256	O
20	kDa	O
21	and	O
22	represents	O
23	two	O
24	proteins	O
25	covalently	O
26	cross	O
27	-	O
28	linked	O
29	to	O
30	a	O
31	single	O
32	DRE	O
33	oligonucleotide	O
34	,	O
35	while	O
36	the	O
37	97	O
38	,	O
39	105	O
40	,	O
41	and	O
42	115	O
43	-	O
44	kDa	O
45	complexes	O
46	represent	O
47	single	O
48	protein	O
49	-	O
50	DRE	O
51	cross	O
52	-	O
53	links	O
54	.	O

1	The	O
2	promoter	O
3	and	O
4	upstream	O
5	region	O
6	of	O
7	the	O
8	Brassica	B
9	napus	I
10	2S	I
11	storage	I
12	protein	I
13	napA	I
14	gene	I
15	were	O
16	studied	O
17	to	O
18	identify	O
19	cis	O
20	-	O
21	acting	O
22	sequences	O
23	involved	O
24	in	O
25	developmental	O
26	seed	O
27	-	O
28	specific	O
29	expression	O
30	.	O

1	However	O
2	,	O
3	limited	O
4	comparisons	O
5	reveal	O
6	domains	O
7	in	O
8	the	O
9	NH2	O
10	and	O
11	COOH	O
12	termini	O
13	that	O
14	have	O
15	a	O
16	high	O
17	degree	O
18	of	O
19	similarity	O
20	suggesting	O
21	functional	O
22	conservation	O
23	.	O

1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	O
18	.	O

1	We	O
2	have	O
3	explored	O
4	the	O
5	mechanism	O
6	of	O
7	action	O
8	of	O
9	the	O
10	fibronectin	B
11	splicing	I
12	enhancer	I
13	and	O
14	found	O
15	that	O
16	the	O
17	SE	O
18	element	O
19	is	O
20	required	O
21	for	O
22	efficient	O
23	assembly	O
24	of	O
25	early	O
26	splicing	O
27	complexes	O
28	,	O
29	allowing	O
30	a	O
31	more	O
32	efficient	O
33	interaction	O
34	of	O
35	the	O
36	U2	B
37	snRNP	I
38	with	O
39	branch	O
40	site	O
41	sequences	O
42	.	O

1	Inspection	O
2	of	O
3	enhancer	O
4	mutants	O
5	suggests	O
6	that	O
7	trans	O
8	-	O
9	activation	O
10	by	O
11	hLEF	B
12	/	O
13	GAL4	B
14	is	O
15	especially	O
16	dependent	O
17	on	O
18	TCF	B
19	-	I
20	2	I
21	,	O
22	a	O
23	distinct	O
24	T	O
25	-	O
26	cell	O
27	-	O
28	enriched	O
29	protein	O
30	that	O
31	binds	O
32	to	O
33	sequences	O
34	flanking	O
35	the	O
36	hLEF	B
37	-	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	enhancer	O
43	.	O

1	We	O
2	conclude	O
3	that	O
4	sequences	O
5	outside	O
6	of	O
7	the	O
8	hLEF	B
9	HMG	I
10	box	I
11	mediate	O
12	cell	O
13	-	O
14	and	O
15	context	O
16	-	O
17	specific	O
18	activation	O
19	of	O
20	the	O
21	TCR	B
22	alpha	I
23	enhancer	I
24	and	O
25	may	O
26	facilitate	O
27	interactions	O
28	between	O
29	hLEF	B
30	and	O
31	other	O
32	T	O
33	-	O
34	cell	O
35	-	O
36	specific	O
37	factors	O
38	recruited	O
39	to	O
40	the	O
41	enhancer	O
42	.	O

1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	B
25	.	I
26	5	I
27	gene	I
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O

1	A	O
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	B
16	G	I
17	(	O
18	IgG	B
19	)	O
20	are	O
21	now	O
22	commercially	O
23	available	O
24	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	B
6	T	I
7	antigens	I
8	expressed	O
9	by	O
10	recombinant	O
11	baculoviruses	O
12	in	O
13	Sf9	O
14	cells	O
15	,	O
16	we	O
17	find	O
18	that	O
19	the	O
20	origin	O
21	unwinding	O
22	activities	O
23	of	O
24	both	O
25	TS677	O
26	-->	O
27	A	O
28	and	O
29	TS677	O
30	,	O
31	679	O
32	-->	O
33	A	O
34	are	O
35	inhibited	O
36	by	O
37	the	O
38	T	B
39	-	I
40	antigen	I
41	kinase	I
42	,	O
43	as	O
44	is	O
45	wild	B
46	-	I
47	type	I
48	T	I
49	antigen	I
50	.	O

1	The	O
2	degree	O
3	of	O
4	hypoperfusion	O
5	was	O
6	slightly	O
7	related	O
8	to	O
9	decrease	O
10	in	O
11	FEV1	O
12	.	O
13	0	O
14	%,	O
15	V25	O
16	and	O
17	PaO2	O
18	and	O
19	increase	O
20	in	O
21	circulating	O
22	blood	O
23	volume	O
24	and	O
25	peripheral	O
26	red	O
27	blood	O
28	cell	O
29	counts	O
30	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	successfully	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	metronidazole	O
11	(	O
12	a	O
13	tissue	O
14	amoebicide	O
15	)	O
16	and	O
17	diloxanide	O
18	(	O
19	a	O
20	lumenal	O
21	amoebicide	O
22	).	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	B
13	copia	I
14	retrotransposon	I
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	O
21	LTR	O
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	O
29	homeoproteins	O
30	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	lesions	O
7	of	O
8	the	O
9	OPT	O
10	complex	O
11	(	O
12	the	O
13	thalamic	O
14	source	O
15	of	O
16	afferents	O
17	to	O
18	IHA	O
19	and	O
20	HD	O
21	)	O
22	were	O
23	found	O
24	to	O
25	have	O
26	no	O
27	effect	O
28	on	O
29	color	O
30	-	O
31	reversal	O
32	learning	O
33	performance	O
34	.	O

1	The	O
2	fourth	O
3	dose	O
4	produced	O
5	favorable	O
6	results	O
7	(	O
8	66	O
9	.	O
10	7	O
11	%)	O
12	in	O
13	individuals	O
14	with	O
15	HB	B
16	antibodies	I
17	between	O
18	10	O
19	and	O
20	100	O
21	IU	O
22	/	O
23	ml	O
24	and	O
25	unfavorable	O
26	ones	O
27	(	O
28	3	O
29	.	O
30	8	O
31	%)	O
32	where	O
33	the	O
34	HB	B
35	antibodies	I
36	were	O
37	below	O
38	10	O
39	IU	O
40	/	O
41	ml	O
42	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	our	O
5	patients	O
6	and	O
7	within	O
8	the	O
9	range	O
10	of	O
11	treatment	O
12	variables	O
13	studied	O
14	,	O
15	age	O
16	,	O
17	Karnofsky	O
18	index	O
19	,	O
20	and	O
21	graft	O
22	-	O
23	versus	O
24	-	O
25	host	O
26	disease	O
27	are	O
28	the	O
29	most	O
30	important	O
31	factors	O
32	related	O
33	with	O
34	early	O
35	mortality	O
36	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	B
7	gene	I
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	B
15	-	I
16	phenotype	O
17	.	O

1	This	O
2	intron	O
3	occupies	O
4	a	O
5	conserved	O
6	position	O
7	corresponding	O
8	to	O
9	that	O
10	of	O
11	intron	O
12	1	O
13	in	O
14	the	O
15	transit	O
16	peptide	O
17	region	O
18	of	O
19	chloroplast	B
20	GAPDH	I
21	genes	I
22	(	O
23	GapA	B
24	and	O
25	GapB	B
26	)	O
27	of	O
28	higher	O
29	plants	O
30	.	O

1	The	O
2	drug	O
3	-	O
4	resistant	O
5	cell	O
6	lines	O
7	P388	O
8	/	O
9	ADR	O
10	/	O
11	3	O
12	and	O
13	P388	O
14	/	O
15	ADR	O
16	/	O
17	7	O
18	express	O
19	a	O
20	shortened	O
21	topo	B
22	II	I
23	alpha	I
24	mRNA	I
25	transcript	I
26	in	O
27	addition	O
28	to	O
29	the	O
30	native	O
31	transcript	O
32	present	O
33	in	O
34	the	O
35	drug	O
36	-	O
37	sensitive	O
38	P388	O
39	/	O
40	4	O
41	cell	O
42	line	O
43	.	O

1	Using	O
2	a	O
3	3	O
4	'-	O
5	rapid	O
6	amplification	O
7	of	O
8	cDNA	O
9	ends	O
10	strategy	O
11	,	O
12	we	O
13	have	O
14	cloned	O
15	cDNAs	O
16	representing	O
17	the	O
18	3	O
19	'-	O
20	termini	O
21	of	O
22	both	O
23	the	O
24	native	O
25	and	O
26	mutant	O
27	transcripts	O
28	from	O
29	both	O
30	P388	O
31	/	O
32	ADR	O
33	/	O
34	3	O
35	and	O
36	P388	O
37	/	O
38	ADR	O
39	/	O
40	7	O
41	cells	O
42	.	O

1	The	O
2	phi	B
3	AP3	I
4	factor	I
5	is	O
6	a	O
7	nuclear	O
8	phosphoprotein	O
9	;	O
10	the	O
11	extent	O
12	of	O
13	its	O
14	phosphorylation	O
15	is	O
16	regulated	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	.	O

1	Similarly	O
2	,	O
3	the	O
4	N	O
5	-	O
6	terminal	O
7	cytoplasmic	O
8	domain	O
9	of	O
10	the	O
11	latent	B
12	membrane	I
13	protein	I
14	2A	I
15	(	O
16	LMP2A	B
17	)	O
18	of	O
19	the	O
20	Epstein	O
21	-	O
22	Barr	O
23	virus	O
24	(	O
25	EBV	O
26	)	O
27	contains	O
28	a	O
29	single	O
30	copy	O
31	of	O
32	the	O
33	Tyr	O
34	-	O
35	X	O
36	-	O
37	X	O
38	-	O
39	Leu	O
40	/	O
41	Ile	O
42	-	O
43	containing	O
44	motif	O
45	which	O
46	could	O
47	play	O
48	a	O
49	critical	O
50	role	O
51	in	O
52	B	O
53	cell	O
54	transformation	O
55	.	O

1	The	O
2	functional	O
3	homology	O
4	of	O
5	Cwg2	B
6	with	O
7	Cdc43	B
8	,	O
9	which	O
10	has	O
11	been	O
12	implicated	O
13	in	O
14	the	O
15	control	O
16	of	O
17	cell	O
18	polarity	O
19	,	O
20	suggests	O
21	a	O
22	link	O
23	between	O
24	two	O
25	morphogenetic	O
26	events	O
27	such	O
28	as	O
29	establishment	O
30	of	O
31	cell	O
32	polarity	O
33	and	O
34	cell	O
35	wall	O
36	biosynthesis	O
37	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	P	B
6	-	I
7	type	I
8	ATPase	I
9	gene	I
10	from	O
11	the	O
12	cyanobacterium	O
13	Synechocystis	O
14	sp	O
15	.	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	B
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	O
17	peptide	O
18	transport	O
19	gene	O
20	.	O

1	By	O
2	using	O
3	the	O
4	full	O
5	-	O
6	length	O
7	cytoplasmic	O
8	domain	O
9	and	O
10	mutants	O
11	with	O
12	progressive	O
13	carboxy	O
14	-	O
15	terminal	O
16	deletions	O
17	,	O
18	internal	O
19	deletions	O
20	,	O
21	or	O
22	point	O
23	mutations	O
24	,	O
25	we	O
26	identified	O
27	the	O
28	first	O
29	150	O
30	amino	O
31	acid	O
32	residues	O
33	of	O
34	LIFR	B
35	as	O
36	the	O
37	minimal	O
38	region	O
39	necessary	O
40	for	O
41	signaling	O
42	.	O

1	To	O
2	examine	O
3	the	O
4	biochemical	O
5	basis	O
6	of	O
7	the	O
8	end	O
9	joining	O
10	,	O
11	nuclear	O
12	extracts	O
13	were	O
14	prepared	O
15	from	O
16	a	O
17	wide	O
18	variety	O
19	of	O
20	mammalian	O
21	cell	O
22	lines	O
23	and	O
24	tested	O
25	for	O
26	their	O
27	ability	O
28	to	O
29	join	O
30	test	O
31	plasmid	O
32	substrates	O
33	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	largest	O
7	subunit	O
8	of	O
9	RNA	B
10	polymerase	I
11	II	I
12	and	O
13	TFIIB	B
14	are	O
15	important	O
16	determinants	O
17	of	O
18	transcription	O
19	start	O
20	site	O
21	selection	O
22	in	O
23	S	O
24	.	O
25	cerevisiae	O
26	and	O
27	suggest	O
28	that	O
29	this	O
30	function	O
31	might	O
32	be	O
33	conferred	O
34	by	O
35	interaction	O
36	between	O
37	these	O
38	two	O
39	proteins	O
40	.	O

1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	EGFR	B
7	/	O
8	ErbB	B
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	I
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O

1	Oligonucleotide	O
2	competitors	O
3	were	O
4	used	O
5	to	O
6	evaluate	O
7	the	O
8	accessibility	O
9	of	O
10	the	O
11	TATA	O
12	-	O
13	binding	O
14	site	O
15	in	O
16	TIF	B
17	-	I
18	IB	I
19	,	O
20	TFIID	B
21	,	O
22	and	O
23	TFIIIB	B
24	.	O

1	The	O
2	227	O
3	-	O
4	to	O
5	-	O
6	239	O
7	region	O
8	blocked	O
9	ADR1	B
10	activity	O
11	independently	O
12	of	O
13	the	O
14	TAD	B
15	present	O
16	on	O
17	ADR1	B
18	,	O
19	ADR1	B
20	DNA	O
21	binding	O
22	,	O
23	and	O
24	specific	O
25	ADH2	B
26	promoter	I
27	sequences	I
28	.	O

1	Analysis	O
2	of	O
3	strains	O
4	harboring	O
5	an	O
6	mds1	B
7	null	I
8	mutation	I
9	demonstrates	O
10	that	O
11	MDS1	B
12	is	O
13	not	O
14	essential	O
15	during	O
16	normal	O
17	vegetative	O
18	growth	O
19	but	O
20	appears	O
21	to	O
22	be	O
23	required	O
24	for	O
25	meiosis	O
26	.	O

1	TGF	B
2	beta	I
3	1	I
4	expression	O
5	is	O
6	largely	O
7	governed	O
8	by	O
9	three	O
10	AP	B
11	-	I
12	1	I
13	binding	I
14	sites	I
15	located	O
16	in	O
17	two	O
18	different	O
19	promoters	O
20	of	O
21	this	O
22	gene	O
23	.	O

1	Val	O
2	-->	O
3	Ala	O
4	mutations	O
5	selectively	O
6	alter	O
7	helix	O
8	-	O
9	helix	O
10	packing	O
11	in	O
12	the	O
13	transmembrane	O
14	segment	O
15	of	O
16	phage	B
17	M13	I
18	coat	I
19	protein	I
20	.	O

1	Strategic	O
2	change	O
3	in	O
4	the	O
5	NHS	O
6	.	O

1	A	O
2	much	O
3	less	O
4	expensive	O
5	solution	O
6	than	O
7	UW	O
8	,	O
9	containing	O
10	only	O
11	K	O
12	(+)-	O
13	lactobionate	O
14	,	O
15	KH2PO4	O
16	,	O
17	MgSO4	O
18	and	O
19	raffinose	O
20	,	O
21	can	O
22	be	O
23	used	O
24	successfully	O
25	for	O
26	preservation	O
27	of	O
28	rat	O
29	hepatocytes	O
30	for	O
31	24	O
32	hr	O
33	for	O
34	drug	O
35	transport	O
36	studies	O
37	.	O

1	Repeated	O
2	administration	O
3	of	O
4	GRg2	O
5	20	O
6	mg	O
7	/	O
8	kg	O
9	i	O
10	.	O
11	p	O
12	.	O
13	significantly	O
14	improved	O
15	the	O
16	CYP	O
17	-	O
18	induced	O
19	recognitional	O
20	deficits	O
21	by	O
22	increasing	O
23	the	O
24	CYP	O
25	-	O
26	decreased	O
27	rate	O
28	from	O
29	55	O
30	.	O
31	8	O
32	+/-	O
33	9	O
34	.	O
35	6	O
36	to	O
37	80	O
38	.	O
39	8	O
40	+/-	O
41	4	O
42	.	O
43	2	O
44	in	O
45	d	O
46	3	O
47	learning	O
48	acquisition	O
49	(	O
50	F	O
51	(	O
52	1	O
53	,	O
54	14	O
55	)	O
56	=	O
57	5	O
58	.	O
59	6	O
60	,	O
61	p	O
62	<	O
63	0	O
64	.	O
65	05	O
66	),	O
67	from	O
68	53	O
69	.	O
70	4	O
71	+/-	O
72	8	O
73	.	O
74	4	O
75	to	O
76	60	O
77	.	O
78	0	O
79	+/-	O
80	8	O
81	.	O
82	2	O
83	in	O
84	48	O
85	h	O
86	memory	O
87	acquisition	O
88	(	O
89	F	O
90	(	O
91	1	O
92	,	O
93	14	O
94	)	O
95	=	O
96	7	O
97	.	O
98	5	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	05	O
105	)	O
106	and	O
107	from	O
108	55	O
109	.	O
110	0	O
111	+/-	O
112	5	O
113	.	O
114	5	O
115	to	O
116	88	O
117	.	O
118	3	O
119	+/-	O
120	2	O
121	.	O
122	5	O
123	in	O
124	24	O
125	h	O
126	memory	O
127	retention	O
128	(	O
129	F	O
130	(	O
131	1	O
132	,	O
133	12	O
134	)	O
135	27	O
136	.	O
137	5	O
138	,	O
139	p	O
140	<	O
141	0	O
142	.	O
143	01	O
144	)	O
145	as	O
146	well	O
147	as	O
148	from	O
149	60	O
150	.	O
151	0	O
152	+/-	O
153	6	O
154	.	O
155	8	O
156	to	O
157	85	O
158	.	O
159	6	O
160	+/-	O
161	6	O
162	.	O
163	9	O
164	in	O
165	48	O
166	h	O
167	memory	O
168	retrieval	O
169	(	O
170	F	O
171	(	O
172	1	O
173	,	O
174	12	O
175	)	O
176	=	O
177	5	O
178	.	O
179	2	O
180	,	O
181	p	O
182	<	O
183	0	O
184	.	O
185	05	O
186	),	O
187	respectively	O
188	.	O

1	Human	B
2	bcl3	I
3	protein	I
4	specifically	O
5	displaces	O
6	(	B
7	p50	I
8	)	I
9	2	I
10	-	I
11	DNA	I
12	complexes	I
13	.	O

1	The	O
2	therapeutic	O
3	action	O
4	of	O
5	cyclosporin	O
6	A	O
7	(	O
8	Sandimmun	O
9	):	O
10	its	O
11	application	O
12	in	O
13	rheumatoid	O
14	arthritis	O
15	.	O

1	In	O
2	vitro	O
3	translation	O
4	experiments	O
5	show	O
6	that	O
7	human	O
8	cDNA	O
9	derived	O
10	RNA	O
11	translates	O
12	into	O
13	a	O
14	protein	O
15	with	O
16	a	O
17	mobility	O
18	of	O
19	44	O
20	-	O
21	46	O
22	kD	O
23	on	O
24	SDS	O
25	polyacrylamide	O
26	gels	O
27	.	O

1	After	O
2	peripheral	O
3	administration	O
4	of	O
5	both	O
6	CRF	B
7	and	O
8	TRH	B
9	,	O
10	ACTH	B
11	levels	O
12	were	O
13	significantly	O
14	higher	O
15	on	O
16	the	O
17	tumor	O
18	side	O
19	in	O
20	all	O
21	patients	O
22	.	O

1	Pentazocine	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	niche	O
8	for	O
9	Talwin	O
10	Nx	O
11	?	O
12	Pentazocine	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	analgesic	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O

1	A	O
2	sequence	O
3	homology	O
4	analysis	O
5	between	O
6	human	B
7	nm23	I
8	-	I
9	H1	I
10	and	O
11	the	O
12	homolog	O
13	gene	O
14	of	O
15	the	O
16	rat	O
17	(	O
18	NDP	B
19	-	I
20	K	I
21	beta	I
22	)	O
23	shows	O
24	that	O
25	exon	O
26	-	O
27	intron	O
28	boundaries	O
29	are	O
30	well	O
31	conserved	O
32	between	O
33	these	O
34	two	O
35	species	O
36	.	O

1	A	O
2	favourable	O
3	response	O
4	was	O
5	achieved	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	amphotericin	O
11	B	O
12	and	O
13	cotrimoxazole	O
14	.	O

1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O

1	RESULTS	O
2	:	O
3	At	O
4	the	O
5	beginning	O
6	of	O
7	the	O
8	QA	O
9	/	O
10	QI	O
11	process	O
12	,	O
13	monitoring	O
14	of	O
15	blood	O
16	administration	O
17	practices	O
18	revealed	O
19	that	O
20	a	O
21	variance	O
22	from	O
23	institutional	O
24	blood	O
25	administration	O
26	policy	O
27	occurred	O
28	during	O
29	50	O
30	percent	O
31	of	O
32	blood	O
33	and	O
34	component	O
35	transfusions	O
36	.	O

1	In	O
2	addition	O
3	,	O
4	REP21	O
5	plants	O
6	were	O
7	resistant	O
8	to	O
9	an	O
10	unusually	O
11	broad	O
12	range	O
13	of	O
14	tobamoviruses	O
15	including	O
16	tomato	O
17	mosaic	O
18	virus	O
19	,	O
20	tobacco	O
21	mild	O
22	green	O
23	mosaic	O
24	virus	O
25	,	O
26	TMV	O
27	-	O
28	U5	O
29	,	O
30	green	O
31	tomato	O
32	atypical	O
33	mosaic	O
34	virus	O
35	,	O
36	and	O
37	ribgrass	O
38	mosaic	O
39	virus	O
40	.	O

1	Drug	O
2	effect	O
3	,	O
4	measured	O
5	as	O
6	postural	O
7	sway	O
8	,	O
9	was	O
10	also	O
11	similar	O
12	in	O
13	the	O
14	patients	O
15	with	O
16	cirrhosis	O
17	and	O
18	control	O
19	subjects	O
20	;	O
21	therefore	O
22	the	O
23	ratio	O
24	of	O
25	effect	O
26	area	O
27	under	O
28	the	O
29	curve	O
30	to	O
31	concentration	O
32	area	O
33	under	O
34	the	O
35	curve	O
36	,	O
37	a	O
38	measure	O
39	of	O
40	sensitivity	O
41	,	O
42	did	O
43	not	O
44	differ	O
45	significantly	O
46	between	O
47	the	O
48	patients	O
49	with	O
50	cirrhosis	O
51	and	O
52	the	O
53	control	O
54	subjects	O
55	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	YY1	B
6	,	O
7	a	O
8	ubiquitously	O
9	expressed	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	regulates	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	c	B
21	-	I
22	fos	I
23	promoter	I
24	primarily	O
25	through	O
26	an	O
27	effect	O
28	on	O
29	DNA	O
30	structure	O
31	.	O

1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	first	O
7	-	O
8	time	O
9	total	O
10	colonoscopies	O
11	in	O
12	685	O
13	patients	O
14	,	O
15	we	O
16	investigated	O
17	the	O
18	relationship	O
19	between	O
20	hyperplastic	O
21	and	O
22	adenomatous	O
23	polyps	O
24	.	O

1	The	O
2	rate	O
3	of	O
4	decrement	O
5	in	O
6	DPOAE	O
7	amplitude	O
8	over	O
9	a	O
10	prescribed	O
11	time	O
12	period	O
13	was	O
14	utilized	O
15	as	O
16	a	O
17	measure	O
18	of	O
19	susceptibility	O
20	to	O
21	the	O
22	acoustic	O
23	trauma	O
24	.	O

1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O

1	The	O
2	predicted	O
3	Pay4p	B
4	sequence	I
5	contains	O
6	two	O
7	putative	O
8	ATP	O
9	-	O
10	binding	O
11	domains	O
12	and	O
13	shows	O
14	structural	O
15	relationships	O
16	to	O
17	other	O
18	potential	O
19	ATP	B
20	-	I
21	binding	I
22	proteins	I
23	involved	O
24	in	O
25	biological	O
26	processes	O
27	as	O
28	diverse	O
29	as	O
30	peroxisome	O
31	biogenesis	O
32	,	O
33	vesicle	O
34	-	O
35	mediated	O
36	protein	O
37	transport	O
38	,	O
39	cell	O
40	cycle	O
41	control	O
42	,	O
43	and	O
44	transcriptional	O
45	regulation	O
46	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	the	O
6	structure	O
7	of	O
8	the	O
9	decorin	B
10	gene	I
11	promoter	I
12	is	O
13	different	O
14	from	O
15	that	O
16	of	O
17	any	O
18	other	O
19	proteoglycan	O
20	promoter	O
21	characterized	O
22	so	O
23	far	O
24	and	O
25	indicate	O
26	that	O
27	the	O
28	pur	O
29	/	O
30	pyr	O
31	segment	O
32	plays	O
33	a	O
34	role	O
35	in	O
36	the	O
37	regulation	O
38	of	O
39	gene	O
40	transcription	O
41	.	O

1	The	O
2	kinase	O
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	O
17	growth	O
18	factor	O
19	-	O
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	O
26	MAP	B
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	O
33	protein	O
34	kinase	O
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O

1	267	O
2	,	O
3	4870	O
4	-	O
5	4877	O
6	))	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O

1	Mothers	O
2	with	O
3	severe	O
4	anatomical	O
5	abnormalities	O
6	,	O
7	who	O
8	are	O
9	HIV	O
10	positive	O
11	,	O
12	have	O
13	active	O
14	TB	O
15	or	O
16	whose	O
17	children	O
18	have	O
19	inherited	O
20	mono	O
21	-	O
22	or	O
23	disaccharide	O
24	intolerances	O
25	should	O
26	not	O
27	breastfeed	O
28	.	O

1	G	O
2	.	O

1	The	O
2	psaD	B
3	,	O
4	psaF	B
5	,	O
6	psaH	B
7	,	O
8	and	O
9	psaL	B
10	products	I
11	have	O
12	two	O
13	isoforms	O
14	each	O
15	that	O
16	are	O
17	distinguished	O
18	by	O
19	different	O
20	mobilities	O
21	in	O
22	polyacrylamide	O
23	gel	O
24	electrophoresis	O
25	,	O
26	and	O
27	the	O
28	psaE	B
29	product	I
30	has	O
31	four	O
32	isoforms	O
33	.	O

1	When	O
2	Hy	O
3	-	O
4	Vac	O
5	SPF	O
6	type	O
7	V	O
8	embryos	O
9	were	O
10	exposed	O
11	to	O
12	either	O
13	0	O
14	.	O
15	20	O
16	ml	O
17	50	O
18	%	O
19	ethanol	O
20	in	O
21	CRS	O
22	or	O
23	to	O
24	0	O
25	.	O
26	20	O
27	ml	O
28	CRS	O
29	(	O
30	controls	O
31	),	O
32	ethanol	O
33	-	O
34	treated	O
35	embryos	O
36	showed	O
37	a	O
38	VSD	O
39	incidence	O
40	of	O
41	34	O
42	.	O
43	1	O
44	%	O
45	compared	O
46	with	O
47	a	O
48	3	O
49	.	O
50	6	O
51	%	O
52	incidence	O
53	in	O
54	the	O
55	controls	O
56	(	O
57	P	O
58	=	O
59	0	O
60	.	O
61	0017	O
62	).	O

1	Peripheral	O
2	vitreochorioretinal	O
3	dystrophies	O
4	in	O
5	myopia	O
6	patients	O

1	In	O
2	our	O
3	studies	O
4	,	O
5	we	O
6	utilized	O
7	HIV	O
8	-	O
9	1	O
10	HXB2	B
11	and	O
12	HIV	O
13	-	O
14	1	O
15	Z2Z6	B
16	core	I
17	enhancers	I
18	because	O
19	the	O
20	Z2Z6	B
21	strain	O
22	has	O
23	a	O
24	single	O
25	point	O
26	mutation	O
27	flanking	O
28	the	O
29	right	O
30	ETS	B
31	-	I
32	binding	I
33	site	I
34	.	O

1	The	O
2	secondary	O
3	,	O
4	but	O
5	not	O
6	the	O
7	primary	O
8	,	O
9	antibody	O
10	responses	O
11	of	O
12	male	O
13	C57Bl	O
14	/	O
15	6	O
16	mice	O
17	were	O
18	higher	O
19	among	O
20	mice	O
21	housed	O
22	alone	O
23	compared	O
24	to	O
25	mice	O
26	housed	O
27	in	O
28	groups	O
29	;	O
30	differences	O
31	were	O
32	observed	O
33	for	O
34	both	O
35	IgM	B
36	and	O
37	IgG	B
38	anti	I
39	-	I
40	KLH	I
41	antibodies	I
42	.	O

1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O

1	Interleukin	B
2	-	I
3	6	I
4	may	O
5	possibly	O
6	potentiate	O
7	metastasis	O
8	of	O
9	cardiac	O
10	myxoma	O
11	.	O

1	Other	O
2	parameters	O
3	of	O
4	iron	O
5	metabolism	O
6	,	O
7	including	O
8	ferritin	B
9	,	O
10	were	O
11	not	O
12	found	O
13	to	O
14	contribute	O
15	to	O
16	the	O
17	risk	O
18	.	O

1	Responses	O
2	to	O
3	the	O
4	Plowright	O
5	Rinderpest	O
6	vaccine	O
7	by	O
8	43	O
9	calves	O
10	and	O
11	70	O
12	adult	O
13	cattle	O
14	in	O
15	Uganda	O
16	in	O
17	1990	O
18	,	O
19	through	O
20	the	O
21	production	O
22	of	O
23	IgG	B
24	antibodies	I
25	,	O
26	were	O
27	monitored	O
28	for	O
29	4	O
30	weeks	O
31	using	O
32	the	O
33	ELISA	O
34	assay	O
35	.	O

1	Because	O
2	of	O
3	the	O
4	small	O
5	number	O
6	of	O
7	visceral	O
8	angiography	O
9	procedures	O
10	performed	O
11	(	O
12	38	O
13	),	O
14	no	O
15	definitive	O
16	conclusions	O
17	could	O
18	be	O
19	drawn	O
20	as	O
21	to	O
22	the	O
23	differences	O
24	between	O
25	ionic	O
26	and	O
27	nonionic	O
28	agents	O
29	regarding	O
30	grade	O
31	-	O
32	2	O
33	and	O
34	grade	O
35	-	O
36	3	O
37	adverse	O
38	events	O
39	.	O

1	Tumours	O
2	of	O
3	the	O
4	cavum	O
5	oris	O
6	and	O
7	oropharynx	O
8	of	O
9	T1	O
10	-	O
11	stage	O
12	are	O
13	possible	O
14	only	O
15	in	O
16	1	O
17	of	O
18	3	O
19	cases	O
20	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	O
28	safe	O
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	hyperlipidemic	O
13	control	O
14	than	O
15	the	O
16	nonhyperlipidemic	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	diets	O
25	containing	O
26	pectin	B
27	or	O
28	prune	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	hyperlipidemic	O
34	control	O
35	group	O
36	.	O

1	The	O
2	Stryker	O
3	frame	O
4	modification	O
5	to	O
6	the	O
7	standard	O
8	Dornier	O
9	HM3	O
10	lithotriptor	O
11	allows	O
12	for	O
13	improved	O
14	visualization	O
15	and	O
16	easier	O
17	localization	O
18	of	O
19	distal	O
20	ureteral	O
21	calculi	O
22	compared	O
23	to	O
24	the	O
25	standard	O
26	gantry	O
27	.	O

1	Glomerular	O
2	mesangial	O
3	cells	O
4	expressed	O
5	an	O
6	abundant	O
7	1	O
8	.	O
9	1	O
10	kb	O
11	mRNA	O
12	transcript	O
13	for	O
14	Id1	B
15	,	O
16	but	O
17	in	O
18	contrast	O
19	to	O
20	other	O
21	cell	O
22	types	O
23	Id1	B
24	mRNA	I
25	was	O
26	expressed	O
27	in	O
28	both	O
29	randomly	O
30	cycling	O
31	cells	O
32	and	O
33	in	O
34	serum	O
35	-	O
36	deprived	O
37	,	O
38	quiescent	O
39	cultures	O
40	.	O

1	Routine	O
2	psychometric	O
3	screening	O
4	of	O
5	IHD	O
6	patients	O
7	may	O
8	provide	O
9	a	O
10	cost	O
11	-	O
12	effective	O
13	means	O
14	of	O
15	alerting	O
16	cardiologists	O
17	and	O
18	internists	O
19	to	O
20	the	O
21	relatively	O
22	high	O
23	levels	O
24	of	O
25	distress	O
26	among	O
27	their	O
28	patients	O
29	.	O

1	A	O
2	single	O
3	1	O
4	.	O
5	8	O
6	-	O
7	kb	O
8	transcript	O
9	mRNA	O
10	was	O
11	detected	O
12	by	O
13	Northern	O
14	(	O
15	RNA	O
16	)	O
17	blot	O
18	analysis	O
19	,	O
20	and	O
21	its	O
22	5	O
23	'	O
24	end	O
25	maps	O
26	to	O
27	a	O
28	position	O
29	51	O
30	bp	O
31	upstream	O
32	from	O
33	the	O
34	site	O
35	of	O
36	initiation	O
37	of	O
38	protein	O
39	synthesis	O
40	.	O

1	Employing	O
2	this	O
3	sequence	O
4	information	O
5	from	O
6	c11	O
7	/	O
8	1	O
9	,	O
10	the	O
11	c11	O
12	/	O
13	1	O
14	-	O
15	specific	O
16	cDNA	O
17	was	O
18	generated	O
19	from	O
20	poly	O
21	(	O
22	A	O
23	)+	O
24	RNA	O
25	of	O
26	bovine	O
27	PMNLs	O
28	by	O
29	reverse	O
30	transcription	O
31	and	O
32	a	O
33	combination	O
34	of	O
35	polymerase	O
36	chain	O
37	reaction	O
38	(	O
39	PCR	O
40	)	O
41	methods	O
42	.	O

1	The	O
2	sequence	O
3	similarity	O
4	has	O
5	suggested	O
6	that	O
7	SCG10	B
8	and	O
9	stathmin	B
10	have	O
11	been	O
12	derived	O
13	from	O
14	structurally	O
15	and	O
16	evolutionarily	O
17	related	O
18	genes	O
19	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	neuron	B
11	-	I
12	specific	I
13	SCG10	I
14	gene	I
15	evolved	O
16	by	O
17	duplication	O
18	and	O
19	modification	O
20	of	O
21	the	O
22	more	O
23	broadly	O
24	expressed	O
25	stathmin	B
26	/	O
27	Lap18	B
28	gene	O
29	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	mouse	B
9	HO	I
10	-	I
11	1	I
12	gene	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	of	O
18	p32	B
19	,	O
20	initially	O
21	identified	O
22	as	O
23	a	O
24	stress	O
25	-	O
26	induced	O
27	protein	O
28	in	O
29	mouse	O
30	BALBc	O
31	/	O
32	3T3	O
33	cells	O
34	.	O

1	We	O
2	found	O
3	that	O
4	T3	O
5	(	O
6	10	O
7	(-	O
8	8	O
9	)	O
10	M	O
11	)	O
12	selectively	O
13	stimulates	O
14	transcription	O
15	from	O
16	rGH	B
17	-	O
18	TRE	O
19	-	O
20	and	O
21	TREpal	O
22	-,	O
23	but	O
24	not	O
25	ME	O
26	-	O
27	TRE	O
28	-	O
29	and	O
30	F2	O
31	-	O
32	TRE	O
33	-,	O
34	containing	O
35	templates	O
36	in	O
37	which	O
38	these	O
39	TREs	O
40	are	O
41	linked	O
42	in	O
43	front	O
44	of	O
45	the	O
46	rGH	B
47	minimal	I
48	promoter	I
49	containing	O
50	only	O
51	the	O
52	TATA	B
53	box	I
54	binding	I
55	protein	I
56	,	O
57	but	O
58	not	O
59	any	O
60	other	O
61	proximal	O
62	binding	O
63	protein	O
64	,	O
65	sequence	O
66	.	O

1	Using	O
2	a	O
3	polymerase	O
4	chain	O
5	reaction	O
6	-	O
7	based	O
8	approach	O
9	,	O
10	we	O
11	cloned	O
12	a	O
13	150	O
14	-	O
15	base	O
16	pair	O
17	fragment	O
18	of	O
19	a	O
20	new	O
21	sialymotif	O
22	from	O
23	human	O
24	placenta	O
25	mRNA	O
26	,	O
27	which	O
28	was	O
29	then	O
30	used	O
31	as	O
32	a	O
33	probe	O
34	to	O
35	clone	O
36	the	O
37	complete	O
38	coding	O
39	sequence	O
40	of	O
41	the	O
42	corresponding	O
43	gene	O
44	from	O
45	a	O
46	cDNA	O
47	library	O
48	.	O

1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	B
12	mRNA	I
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	O
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O

1	A	O
2	complementary	O
3	DNA	O
4	was	O
5	isolated	O
6	from	O
7	Caenorhabditis	O
8	elegans	O
9	that	O
10	encoded	O
11	a	O
12	polypeptide	O
13	of	O
14	1438	O
15	amino	O
16	acid	O
17	residues	O
18	,	O
19	CeGAP	B
20	,	O
21	which	O
22	contains	O
23	a	O
24	domain	O
25	with	O
26	sequence	O
27	similarity	O
28	to	O
29	the	O
30	COOH	B
31	-	I
32	terminal	I
33	segment	I
34	(	I
35	GTPase	I
36	-	I
37	activating	I
38	protein	I
39	region	I
40	)	I
41	of	O
42	Bcr	B
43	and	O
44	other	O
45	known	O
46	GTPase	B
47	-	I
48	activating	I
49	proteins	I
50	of	O
51	the	O
52	Rho	B
53	subfamily	I
54	.	O

1	Additional	O
2	exonuclease	B
3	III	I
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	B
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	Repression	O
2	is	O
3	alleviated	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	B
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	B
16	-	I
17	C	I
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	B
25	-	O
26	RS	O
27	are	O
28	mutated	O
29	.	O

1	A	O
2	mutant	O
3	in	O
4	the	O
5	AAV	O
6	terminal	O
7	resolution	O
8	site	O
9	(	O
10	trs	O
11	)	O
12	was	O
13	defective	O
14	for	O
15	DNA	O
16	replication	O
17	in	O
18	the	O
19	in	O
20	vitro	O
21	assay	O
22	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	rep	B
6	strongly	O
7	enhances	O
8	the	O
9	function	O
10	of	O
11	negative	O
12	regulatory	O
13	elements	O
14	of	O
15	the	O
16	LTR	O
17	.	O

1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O

1	The	O
2	Oct	B
3	-	I
4	3	I
5	/	I
6	4	I
7	gene	I
8	product	I
9	,	O
10	which	O
11	belongs	O
12	to	O
13	the	O
14	POU	B
15	family	I
16	of	I
17	transcription	I
18	factors	I
19	,	O
20	is	O
21	a	O
22	good	O
23	candidate	O
24	for	O
25	regulating	O
26	initial	O
27	differentiation	O
28	decisions	O
29	.	O

1	Using	O
2	site	O
3	-	O
4	directed	O
5	mutagenesis	O
6	,	O
7	we	O
8	show	O
9	that	O
10	the	O
11	RAREoct	B
12	contributes	O
13	to	O
14	the	O
15	transcriptional	O
16	activation	O
17	of	O
18	Oct	B
19	-	I
20	3	I
21	/	I
22	4	I
23	promoter	I
24	in	O
25	P19	O
26	cells	O
27	and	O
28	,	O
29	most	O
30	interestingly	O
31	,	O
32	mediates	O
33	the	O
34	RA	O
35	-	O
36	induced	O
37	repression	O
38	in	O
39	RA	O
40	-	O
41	differentiated	O
42	EC	O
43	cells	O
44	.	O

1	176	O
2	:	O
3	787	O
4	-	O
5	792	O
6	,	O
7	1992	O
8	;	O
9	M	O
10	.	O

1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	I
10	TFs	I
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	B
20	embryonic	I
21	stem	I
22	cell	I
23	-	I
24	specific	I
25	enhancer	I
26	.	O

1	Analysis	O
2	of	O
3	mig	B
4	/	O
5	CAT	B
6	chimeric	O
7	constructs	O
8	transiently	O
9	transfected	O
10	into	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	mouse	O
17	monocytic	O
18	cell	O
19	line	O
20	revealed	O
21	a	O
22	unique	O
23	IFN	B
24	-	I
25	gamma	I
26	-	I
27	responsive	I
28	element	I
29	(	O
30	gamma	B
31	RE	I
32	-	I
33	1	I
34	).	O

1	When	O
2	expressed	O
3	alone	O
4	in	O
5	test	O
6	cells	O
7	,	O
8	Atr	B
9	-	I
10	I	I
11	is	O
12	unable	O
13	to	O
14	bind	O
15	TGF	B
16	-	I
17	beta	I
18	,	O
19	activin	B
20	,	O
21	or	O
22	bone	B
23	morphogenetic	I
24	protein	I
25	2	I
26	.	O

1	Therefore	O
2	,	O
3	Mxi1	B
4	and	O
5	Mad	B
6	might	O
7	antagonize	O
8	Myc	B
9	function	O
10	and	O
11	are	O
12	candidate	O
13	tumor	O
14	suppressor	O
15	genes	O
16	.	O

1	To	O
2	our	O
3	knowledge	O
4	,	O
5	type	O
6	IV	O
7	renal	O
8	tubular	O
9	acidosis	O
10	has	O
11	not	O
12	been	O
13	reported	O
14	previously	O
15	in	O
16	association	O
17	with	O
18	Alport	O
19	'	O
20	s	O
21	syndrome	O
22	in	O
23	an	O
24	adult	O
25	patient	O
26	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	isolated	O
6	from	O
7	a	O
8	chicken	O
9	embryo	O
10	cDNA	O
11	library	O
12	employing	O
13	a	O
14	PCR	O
15	-	O
16	generated	O
17	radiolabeled	O
18	probe	O
19	specific	O
20	for	O
21	the	O
22	U3	B
23	region	I
24	of	O
25	the	O
26	Rous	B
27	sarcoma	I
28	virus	I
29	LTR	I
30	.	O

1	Two	O
2	basic	O
3	patterns	O
4	of	O
5	locomotor	O
6	behavior	O
7	and	O
8	corresponding	O
9	torso	O
10	morphology	O
11	exist	O
12	among	O
13	extant	O
14	anthropoids	O
15	.	O

1	Animal	O
2	age	O
3	and	O
4	sex	O
5	had	O
6	no	O
7	significant	O
8	effects	O
9	on	O
10	CSF	O
11	composition	O
12	,	O
13	but	O
14	serum	O
15	IgG	B
16	concentration	O
17	increased	O
18	with	O
19	age	O
20	.	O

1	Fast	O
2	continuous	O
3	expansion	O
4	.	O

1	A	O
2	randomized	O
3	,	O
4	multicenter	O
5	study	O
6	comparing	O
7	the	O
8	efficacy	O
9	and	O
10	tolerability	O
11	of	O
12	tropisetron	O
13	,	O
14	a	O
15	new	O
16	5	B
17	-	I
18	HT3	I
19	receptor	I
20	antagonist	O
21	,	O
22	with	O
23	a	O
24	metoclopramide	O
25	-	O
26	containing	O
27	antiemetic	O
28	cocktail	O
29	in	O
30	the	O
31	prevention	O
32	of	O
33	cisplatin	O
34	-	O
35	induced	O
36	emesis	O
37	.	O

1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O

1	ENV	B
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	B
12	.	I
13	cerevisiae	I
14	alpha	I
15	-	I
16	factor	I
17	prepro	I
18	secretion	I
19	leader	I
20	and	O
21	the	O
22	S	B
23	.	I
24	cerevisiae	I
25	invertase	I
26	signal	I
27	sequence	I
28	.	O

1	BACKGROUND	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	predictors	O
7	of	O
8	desipramine	O
9	-	O
10	refractory	O
11	depression	O
12	,	O
13	the	O
14	authors	O
15	examined	O
16	the	O
17	outcome	O
18	in	O
19	patients	O
20	with	O
21	major	O
22	depression	O
23	who	O
24	were	O
25	admitted	O
26	to	O
27	a	O
28	general	O
29	hospital	O
30	and	O
31	treated	O
32	with	O
33	desipramine	O
34	adjusted	O
35	to	O
36	an	O
37	adequate	O
38	blood	O
39	level	O
40	.	O

1	Analysis	O
2	of	O
3	the	O
4	intact	O
5	hGH	B
6	gene	I
7	or	O
8	hGH	B
9	5	I
10	'-	I
11	flanking	I
12	DNA	I
13	(	I
14	5	I
15	'-	I
16	FR	I
17	)	I
18	coupled	O
19	to	O
20	the	O
21	hGh	B
22	cDNA	I
23	or	O
24	chloramphenicol	B
25	acetyltransferase	I
26	or	O
27	luciferase	B
28	genes	I
29	,	O
30	indicated	O
31	that	O
32	cAMP	O
33	primarily	O
34	stimulated	O
35	hGH	B
36	promoter	I
37	activity	O
38	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SAP	B
9	-	I
10	1	I
11	cDNA	I
12	showed	O
13	that	O
14	mature	B
15	SAP	I
16	-	I
17	1	I
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	B
26	-	I
27	type	I
28	PTP	I
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	B
35	-	I
36	conserved	I
37	domain	I
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O

1	The	O
2	following	O
3	evidence	O
4	indicates	O
5	that	O
6	the	O
7	69	O
8	-	O
9	kD	O
10	protein	O
11	is	O
12	a	O
13	common	O
14	,	O
15	rather	O
16	than	O
17	a	O
18	U1	B
19	-	O
20	specific	O
21	,	O
22	protein	O
23	,	O
24	possibly	O
25	associating	O
26	with	O
27	the	O
28	snRNP	O
29	core	O
30	particles	O
31	by	O
32	protein	O
33	-	O
34	protein	O
35	interaction	O
36	.	O

1	Several	O
2	features	O
3	of	O
4	10	O
5	.	O
6	24	O
7	.	O
8	6	O
9	cells	O
10	suggest	O
11	that	O
12	the	O
13	mutation	O
14	disrupts	O
15	normal	O
16	intracellular	O
17	formation	O
18	of	O
19	peptide	B
20	/	I
21	DR	I
22	complexes	I
23	.	O

1	This	O
2	distribution	O
3	parallels	O
4	that	O
5	of	O
6	the	O
7	neurotransmitters	O
8	glutamate	O
9	and	O
10	aspartate	O
11	;	O
12	however	O
13	,	O
14	neither	O
15	of	O
16	these	O
17	excitatory	O
18	amino	O
19	acids	O
20	is	O
21	a	O
22	substrate	O
23	for	O
24	transport	O
25	.	O

1	The	O
2	Harleco	O
3	apparatus	O
4	is	O
5	a	O
6	simple	O
7	,	O
8	useful	O
9	,	O
10	cost	O
11	-	O
12	effective	O
13	adjunct	O
14	to	O
15	the	O
16	diagnosis	O
17	and	O
18	treatment	O
19	of	O
20	this	O
21	life	O
22	-	O
23	threatening	O
24	condition	O
25	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	expression	O
6	vectors	O
7	for	O
8	CCAAT	B
9	/	I
10	enhancer	I
11	binding	I
12	protein	I
13	(	I
14	C	I
15	/	I
16	EBP	I
17	)	I
18	alpha	I
19	and	O
20	C	B
21	/	I
22	EBP	I
23	beta	I
24	trans	O
25	-	O
26	activated	O
27	the	O
28	rat	B
29	uncoupling	I
30	protein	I
31	gene	I
32	promoter	I
33	due	O
34	to	O
35	sequences	O
36	in	O
37	the	O
38	5	O
39	'	O
40	proximal	O
41	region	O
42	.	O

1	It	O
2	was	O
3	not	O
4	possible	O
5	to	O
6	study	O
7	the	O
8	basis	O
9	for	O
10	tissue	O
11	-	O
12	specific	O
13	expression	O
14	of	O
15	this	O
16	gene	O
17	,	O
18	because	O
19	the	O
20	beta	B
21	3	I
22	gene	I
23	promoter	I
24	had	O
25	not	O
26	been	O
27	isolated	O
28	previously	O
29	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	TATA	O
7	-	O
8	less	O
9	promoter	O
10	for	O
11	the	O
12	human	B
13	beta	I
14	3	I
15	integrin	I
16	gene	I
17	.	O

1	Subretinal	O
2	fluid	O
3	was	O
4	punctured	O
5	on	O
6	the	O
7	poorer	O
8	eye	O
9	in	O
10	19	O
11	eyes	O
12	(	O
13	52	O
14	.	O
15	7	O
16	%)	O
17	and	O
18	on	O
19	the	O
20	better	O
21	eye	O
22	in	O
23	7	O
24	eyes	O
25	(	O
26	19	O
27	.	O
28	4	O
29	%).	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O

1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	"	O
25	readthrough	O
26	"	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O

1	Concordance	O
2	of	O
3	IBDQ	O
4	scores	O
5	was	O
6	tested	O
7	in	O
8	280	O
9	stable	O
10	subjects	O
11	.	O

1	Regression	O
2	line	O
3	slopes	O
4	of	O
5	IBDQ	O
6	scores	O
7	were	O
8	significantly	O
9	different	O
10	in	O
11	patients	O
12	who	O
13	deteriorated	O
14	from	O
15	those	O
16	who	O
17	remained	O
18	stable	O
19	([	O
20	b	O
21	]	O
22	<	O
23	0	O
24	.	O
25	15	O
26	;	O
27	P	O
28	<	O
29	0	O
30	.	O
31	0001	O
32	).	O

1	Praziquantel	O
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	neurocysticercosis	O
12	,	O
13	but	O
14	because	O
15	of	O
16	serious	O
17	side	O
18	effects	O
19	encountered	O
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O

1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	I
15	in	O
16	Saccharopolyspora	O
17	erythraea	O
18	.	O

1	This	O
2	region	O
3	is	O
4	required	O
5	for	O
6	activation	O
7	of	O
8	DNA	O
9	binding	O
10	of	O
11	MyoD	B
12	and	O
13	E12	B
14	homodimers	I
15	and	O
16	E12	B
17	/	O
18	MyoD	B
19	heterodimers	O
20	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	One	O
2	of	O
3	these	O
4	elements	O
5	,	O
6	the	O
7	homeodomain	B
8	-	I
9	binding	I
10	element	I
11	,	O
12	was	O
13	identified	O
14	to	O
15	mediate	O
16	negative	O
17	regulation	O
18	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	traI	B
8	structural	I
9	gene	I
10	and	O
11	application	O
12	of	O
13	purified	O
14	mutant	O
15	TraI	B
16	proteins	I
17	for	O
18	in	O
19	vitro	O
20	assays	O
21	served	O
22	to	O
23	evaluate	O
24	the	O
25	functional	O
26	importance	O
27	of	O
28	conserved	O
29	amino	O
30	acid	O
31	residues	O
32	.	O

1	Concerted	O
2	action	O
3	of	O
4	three	O
5	distinct	O
6	domains	O
7	in	O
8	the	O
9	DNA	O
10	cleaving	O
11	-	O
12	joining	O
13	reaction	O
14	catalyzed	O
15	by	O
16	relaxase	B
17	(	O
18	TraI	B
19	)	O
20	of	O
21	conjugative	O
22	plasmid	O
23	RP4	O
24	.	O

1	The	O
2	COOH	O
3	-	O
4	terminal	O
5	46	O
6	codons	O
7	of	O
8	slyD	B
9	encode	O
10	a	O
11	remarkable	O
12	histidine	O
13	-	O
14	rich	O
15	peptide	O
16	sequence	O
17	which	O
18	is	O
19	at	O
20	least	O
21	partly	O
22	dispensable	O
23	for	O
24	slyD	B
25	function	O
26	in	O
27	E	B
28	-	O
29	mediated	O
30	lysis	O
31	.	O

1	Monospecific	O
2	antibodies	O
3	raised	O
4	against	O
5	rat	B
6	cytochrome	I
7	P	I
8	-	I
9	450	I
10	1A1	I
11	recognized	O
12	a	O
13	protein	O
14	in	O
15	the	O
16	hepatic	O
17	microsomes	O
18	of	O
19	the	O
20	double	O
21	-	O
22	crested	O
23	cormorant	O
24	,	O
25	and	O
26	also	O
27	in	O
28	those	O
29	of	O
30	the	O
31	great	O
32	blue	O
33	heron	O
34	(	O
35	Ardea	O
36	herodias	O
37	),	O
38	using	O
39	immunoblotting	O
40	.	O

1	We	O
2	studied	O
3	GSH	O
4	-	O
5	Px	O
6	enzyme	O
7	activity	O
8	in	O
9	serum	O
10	after	O
11	acute	O
12	myocardial	O
13	infarction	O
14	(	O
15	AMI	O
16	)	O
17	and	O
18	unstable	O
19	angina	O
20	pectoris	O
21	(	O
22	UAP	O
23	).	O

1	The	O
2	HGF	B
3	-	O
4	induced	O
5	cell	O
6	motility	O
7	was	O
8	mimicked	O
9	by	O
10	12	O
11	-	O
12	0	O
13	-	O
14	tetradecanoyl	O
15	-	O
16	phorbol	O
17	-	O
18	13	O
19	-	O
20	acetate	O
21	,	O
22	a	O
23	protein	B
24	kinase	I
25	C	I
26	-	O
27	activating	O
28	phorbol	O
29	ester	O
30	,	O
31	but	O
32	not	O
33	by	O
34	Ca2	O
35	+	O
36	ionophore	O
37	.	O

1	In	O
2	addition	O
3	,	O
4	lexical	O
5	priming	O
6	was	O
7	examined	O
8	by	O
9	presenting	O
10	an	O
11	identity	O
12	prime	O
13	earlier	O
14	in	O
15	the	O
16	text	O
17	.	O

1	METHODS	O
2	:	O
3	Forty	O
4	-	O
5	nine	O
6	cases	O
7	with	O
8	intrahepatic	O
9	multiple	O
10	nodules	O
11	of	O
12	HCC	O
13	,	O
14	by	O
15	gross	O
16	examination	O
17	,	O
18	among	O
19	184	O
20	consecutive	O
21	resected	O
22	HCCs	O
23	were	O
24	examined	O
25	clinicopathologically	O
26	.	O

1	In	O
2	the	O
3	present	O
4	report	O
5	,	O
6	66	O
7	hemochromatosis	O
8	families	O
9	yielding	O
10	151	O
11	hemochromatosis	O
12	chromosomes	O
13	and	O
14	182	O
15	normal	O
16	chromosomes	O
17	were	O
18	RFLP	O
19	-	O
20	typed	O
21	with	O
22	a	O
23	battery	O
24	of	O
25	probes	O
26	,	O
27	including	O
28	two	O
29	newly	O
30	derived	O
31	polymorphic	O
32	markers	O
33	from	O
34	the	O
35	6	O
36	.	O
37	7	O
38	and	O
39	HLA	B
40	-	I
41	F	I
42	loci	I
43	located	O
44	150	O
45	and	O
46	250	O
47	kb	O
48	telomeric	O
49	to	O
50	HLA	B
51	-	I
52	A	I
53	,	O
54	respectively	O
55	.	O

1	Pneumothorax	O
2	during	O
3	laparoscopic	O
4	dissection	O
5	of	O
6	the	O
7	diaphragmatic	O
8	hiatus	O
9	.	O

1	Different	O
2	cortical	O
3	malformations	O
4	were	O
5	produced	O
6	in	O
7	rats	O
8	by	O
9	a	O
10	single	O
11	dose	O
12	of	O
13	X	O
14	-	O
15	rays	O
16	(	O
17	200	O
18	cGy	O
19	)	O
20	given	O
21	on	O
22	different	O
23	days	O
24	during	O
25	gestation	O
26	.	O

1	T2	O
2	cancers	O
3	should	O
4	not	O
5	be	O
6	excluded	O
7	from	O
8	the	O
9	benefit	O
10	of	O
11	preoperative	O
12	irradiation	O
13	.	O

1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	I
26	site	I
27	(	O
28	GAS	B
29	).	O

1	Mutations	O
2	in	O
3	the	O
4	nuclear	B
5	gene	I
6	CBP1	I
7	of	I
8	Saccharomyces	I
9	cerevisiae	I
10	result	O
11	in	O
12	degradation	O
13	of	O
14	mitochondrially	B
15	encoded	I
16	cytochrome	I
17	b	I
18	(	O
19	cob	B
20	)	O
21	RNA	O
22	;	O
23	thus	O
24	,	O
25	the	O
26	cells	O
27	are	O
28	unable	O
29	to	O
30	respire	O
31	.	O

1	Twenty	O
2	-	O
3	three	O
4	sequence	O
5	-	O
6	tagged	O
7	sites	O
8	(	O
9	STSs	O
10	)	O
11	were	O
12	mapped	O
13	within	O
14	the	O
15	contig	O
16	,	O
17	a	O
18	density	O
19	of	O
20	approximately	O
21	1	O
22	per	O
23	200	O
24	kb	O
25	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	binding	O
9	of	O
10	the	O
11	GA	B
12	-	I
13	binding	I
14	protein	I
15	(	O
16	GABP	B
17	)	O
18	to	O
19	ets	B
20	sequence	I
21	motifs	I
22	within	O
23	each	O
24	repeated	O
25	unit	O
26	is	O
27	required	O
28	for	O
29	transcriptional	O
30	activation	O
31	of	O
32	the	O
33	COXIV	B
34	promoter	I
35	.	O

1	To	O
2	gain	O
3	further	O
4	insight	O
5	into	O
6	the	O
7	pathogenesis	O
8	of	O
9	the	O
10	adult	O
11	respiratory	O
12	distress	O
13	syndrome	O
14	(	O
15	ARDS	O
16	),	O
17	the	O
18	authors	O
19	studied	O
20	possible	O
21	relationships	O
22	among	O
23	the	O
24	activation	O
25	status	O
26	of	O
27	circulating	O
28	polymorphonuclear	O
29	neutrophils	O
30	(	O
31	PMN	O
32	),	O
33	cytokine	O
34	levels	O
35	,	O
36	and	O
37	the	O
38	severity	O
39	of	O
40	lung	O
41	injury	O
42	in	O
43	31	O
44	patients	O
45	:	O
46	15	O
47	with	O
48	ARDS	O
49	,	O
50	9	O
51	with	O
52	severe	O
53	pneumonia	O
54	uncomplicated	O
55	by	O
56	ARDS	O
57	,	O
58	and	O
59	7	O
60	mechanically	O
61	ventilated	O
62	patients	O
63	with	O
64	neither	O
65	ARDS	O
66	nor	O
67	pneumonia	O
68	.	O

1	Amiodarone	O
2	,	O
3	seldom	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	dopamine	B
6	receptor	I
7	stimulation	O
8	by	O
9	different	O
10	dopamine	O
11	agonists	O
12	produces	O
13	a	O
14	different	O
15	pattern	O
16	of	O
17	effects	O
18	on	O
19	the	O
20	characteristics	O
21	of	O
22	the	O
23	reaction	O
24	time	O
25	response	O
26	.	O

1	Two	O
2	experiments	O
3	were	O
4	conducted	O
5	to	O
6	study	O
7	the	O
8	vacuous	O
9	jaw	O
10	movements	O
11	induced	O
12	in	O
13	rats	O
14	by	O
15	acute	O
16	administration	O
17	of	O
18	the	O
19	monoamine	O
20	-	O
21	depleting	O
22	agent	O
23	reserpine	O
24	.	O

1	Depletion	O
2	of	O
3	dopamine	O
4	in	O
5	the	O
6	nucleus	O
7	accumbens	O
8	led	O
9	to	O
10	a	O
11	dramatic	O
12	shift	O
13	in	O
14	behavior	O
15	in	O
16	which	O
17	there	O
18	was	O
19	a	O
20	significant	O
21	decrease	O
22	in	O
23	lever	O
24	pressing	O
25	but	O
26	a	O
27	significant	O
28	increase	O
29	in	O
30	consumption	O
31	of	O
32	lab	O
33	chow	O
34	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	influence	O
6	of	O
7	NaFe3	O
8	+	O
9	EDTA	O
10	,	O
11	and	O
12	of	O
13	increasing	O
14	dietary	O
15	levels	O
16	of	O
17	Na2EDTA	O
18	,	O
19	on	O
20	Zn	O
21	,	O
22	Cu	O
23	and	O
24	Ca	O
25	metabolism	O
26	in	O
27	rats	O
28	fed	O
29	on	O
30	Zn	O
31	-	O
32	sufficient	O
33	and	O
34	Zn	O
35	-	O
36	deficient	O
37	soya	O
38	-	O
39	bean	O
40	-	O
41	isolate	O
42	-	O
43	based	O
44	diets	O
45	.	O

1	Recovery	O
2	of	O
3	carbimazole	O
4	-	O
5	induced	O
6	agranulocytosis	O
7	following	O
8	recombinant	B
9	granulocyte	I
10	-	I
11	macrophage	I
12	colony	I
13	stimulating	I
14	factor	I
15	(	O
16	rhGM	B
17	-	I
18	CSF	I
19	)	O
20	administration	O
21	.	O

1	Thus	O
2	,	O
3	the	O
4	system	O
5	can	O
6	be	O
7	used	O
8	to	O
9	detect	O
10	and	O
11	study	O
12	dynamic	O
13	perfusion	O
14	changes	O
15	from	O
16	the	O
17	brain	O
18	surface	O
19	with	O
20	minimal	O
21	tissue	O
22	damage	O
23	.	O

1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	B
11	,	O
12	of	O
13	Neurospora	O
14	crassa	O
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	Analysis	O
2	of	O
3	the	O
4	upstream	O
5	untranslated	O
6	region	O
7	of	O
8	CHL15	B
9	revealed	O
10	the	O
11	presence	O
12	of	O
13	the	O
14	hexamer	O
15	element	O
16	,	O
17	ACGCGT	O
18	(	O
19	an	O
20	MluI	B
21	restriction	I
22	site	I
23	)	O
24	controlling	O
25	both	O
26	the	O
27	periodic	O
28	expression	O
29	and	O
30	coordinate	O
31	regulation	O
32	of	O
33	the	O
34	DNA	O
35	synthesis	O
36	genes	O
37	in	O
38	budding	O
39	yeast	O
40	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	the	O
8	150	O
9	-	O
10	kDa	O
11	protein	O
12	contains	O
13	an	O
14	NTP	O
15	-	O
16	binding	O
17	helicase	B
18	motif	I
19	and	O
20	the	O
21	readthrough	O
22	region	O
23	,	O
24	an	O
25	RNA	B
26	polymerase	I
27	motif	I
28	,	O
29	indicating	O
30	that	O
31	these	O
32	two	O
33	overlapping	O
34	proteins	O
35	may	O
36	form	O
37	an	O
38	RNA	O
39	replication	O
40	complex	O
41	similar	O
42	to	O
43	those	O
44	of	O
45	tobamo	O
46	-	O
47	and	O
48	tobraviruses	O
49	.	O

1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	F3R	B
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	TAAAG	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O

1	On	O
2	T2	O
3	weighted	O
4	images	O
5	,	O
6	low	O
7	intensity	O
8	areas	O
9	in	O
10	the	O
11	thalamus	O
12	,	O
13	the	O
14	striatum	O
15	,	O
16	the	O
17	anterior	O
18	limb	O
19	of	O
20	the	O
21	internal	O
22	capsule	O
23	,	O
24	the	O
25	tegmentum	O
26	of	O
27	midbrain	O
28	,	O
29	high	O
30	intensity	O
31	areas	O
32	in	O
33	middle	O
34	cerebellar	O
35	peduncle	O
36	,	O
37	the	O
38	posterior	O
39	limb	O
40	of	O
41	the	O
42	internal	O
43	capsule	O
44	,	O
45	the	O
46	lateral	O
47	part	O
48	of	O
49	the	O
50	cerebral	O
51	peduncle	O
52	,	O
53	and	O
54	the	O
55	cerebral	O
56	white	O
57	matter	O
58	were	O
59	noted	O
60	.	O

1	Using	O
2	the	O
3	rap1t	B
4	alleles	I
5	to	O
6	generate	O
7	wild	O
8	-	O
9	type	O
10	cells	O
11	differing	O
12	only	O
13	in	O
14	telomere	O
15	tract	O
16	lengths	O
17	,	O
18	we	O
19	also	O
20	show	O
21	that	O
22	telomere	O
23	position	O
24	effects	O
25	are	O
26	highly	O
27	sensitive	O
28	to	O
29	changes	O
30	in	O
31	the	O
32	size	O
33	(	O
34	or	O
35	structure	O
36	)	O
37	of	O
38	the	O
39	telomeric	O
40	tract	O
41	.	O

1	Pronounced	O
2	microangiopathy	O
3	characterized	O
4	by	O
5	avascular	O
6	fields	O
7	,	O
8	enlarged	O
9	and	O
10	tortuous	O
11	capillaries	O
12	and	O
13	increased	O
14	transcapillary	O
15	diffusion	O
16	of	O
17	sodium	O
18	fluorescein	O
19	,	O
20	was	O
21	clearly	O
22	demonstrable	O
23	in	O
24	the	O
25	area	O
26	of	O
27	the	O
28	nodules	O
29	.	O

1	Epigenetic	O
2	switching	O
3	of	O
4	transcriptional	O
5	states	O
6	:	O
7	cis	O
8	-	O
9	and	O
10	trans	O
11	-	O
12	acting	O
13	factors	O
14	affecting	O
15	establishment	O
16	of	O
17	silencing	O
18	at	O
19	the	O
20	HMR	B
21	locus	I
22	in	O
23	Saccharomyces	O
24	cerevisiae	O
25	.	O

1	NF	B
2	-	I
3	kappa	I
4	B	I
5	p65	I
6	,	O
7	p50	B
8	,	O
9	and	O
10	Rel	B
11	functionally	O
12	synergize	O
13	with	O
14	C	B
15	/	I
16	EBP	I
17	alpha	I
18	,	O
19	C	B
20	/	I
21	EBP	I
22	beta	I
23	,	O
24	and	O
25	C	B
26	/	I
27	EBP	I
28	delta	I
29	.	O

1	It	O
2	could	O
3	be	O
4	detected	O
5	exclusively	O
6	in	O
7	the	O
8	culture	O
9	medium	O
10	of	O
11	cDNA	O
12	-	O
13	transfected	O
14	COS	O
15	cells	O
16	.	O

1	The	O
2	first	O
3	group	O
4	of	O
5	sequential	O
6	BMB	O
7	showed	O
8	a	O
9	significant	O
10	progress	O
11	to	O
12	myelofibrosis	O
13	in	O
14	so	O
15	-	O
16	called	O
17	"	O
18	Chronic	O
19	Megakaryocytic	O
20	-	O
21	Granulocytic	O
22	Myelosis	O
23	"--	O
24	CMGM	O
25	-,	O
26	which	O
27	corresponds	O
28	to	O
29	Agnogenic	O
30	Myeloid	O
31	Metaplasia	O
32	-	O
33	AMM	O
34	-	O
35	in	O
36	72	O
37	.	O
38	4	O
39	%	O
40	(	O
41	21	O
42	/	O
43	29	O
44	patients	O
45	),	O
46	as	O
47	well	O
48	as	O
49	in	O
50	CML	O
51	with	O
52	megakaryocytic	O
53	increase	O
54	-	O
55	CML	O
56	.	O
57	MI	O
58	-	O
59	in	O
60	39	O
61	.	O
62	2	O
63	%	O
64	(	O
65	20	O
66	/	O
67	51	O
68	).	O

1	The	O
2	two	O
3	methods	O
4	identify	O
5	the	O
6	same	O
7	patients	O
8	only	O
9	if	O
10	micturitional	O
11	pressures	O
12	are	O
13	normal	O
14	(	O
15	40	O
16	to	O
17	60	O
18	cmH2O	O
19	)	O
20	to	O
21	high	O
22	(	O
23	over	O
24	60	O
25	cmH2O	O
26	)	O
27	and	O
28	the	O
29	Sussett	O
30	formula	O
31	is	O
32	used	O
33	with	O
34	a	O
35	higher	O
36	(	O
37	95th	O
38	centile	O
39	)	O
40	cutoff	O
41	.	O

1	There	O
2	was	O
3	no	O
4	clear	O
5	correlation	O
6	between	O
7	the	O
8	MFA	O
9	and	O
10	the	O
11	severity	O
12	of	O
13	the	O
14	UTS	O
15	phenotype	O
16	.	O

1	Chicken	O
2	sterol	B
3	carrier	I
4	protein	I
5	2	I
6	/	O
7	sterol	B
8	carrier	I
9	protein	I
10	x	I
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O

1	The	O
2	plasmatic	B
3	albumin	I
4	concentration	O
5	(	O
6	3	O
7	.	O
8	5	O
9	-	O
10	4	O
11	.	O
12	5	O
13	g	O
14	/	O
15	dl	O
16	)	O
17	represents	O
18	about	O
19	60	O
20	%	O
21	of	O
22	the	O
23	total	O
24	plasma	O
25	protein	O
26	.	O

1	These	O
2	lesions	O
3	were	O
4	asymptomatic	O
5	,	O
6	but	O
7	both	O
8	were	O
9	characterized	O
10	clinically	O
11	by	O
12	central	O
13	ulceration	O
14	.	O

1	A	O
2	single	O
3	five	O
4	minute	O
5	period	O
6	of	O
7	rapid	O
8	atrial	O
9	pacing	O
10	fails	O
11	to	O
12	limit	O
13	infarct	O
14	size	O
15	in	O
16	the	O
17	in	O
18	situ	O
19	rabbit	O
20	heart	O
21	.	O

1	Neither	O
2	RD19	B
3	nor	O
4	RD21	B
5	mRNA	I
6	synthesis	O
7	was	O
8	responsive	O
9	to	O
10	cold	O
11	or	O
12	to	O
13	heat	O
14	stress	O
15	.	O

1	Previous	O
2	studies	O
3	indicated	O
4	that	O
5	the	O
6	20S	B
7	proteasome	I
8	is	O
9	a	O
10	catalytic	O
11	core	O
12	of	O
13	the	O
14	26S	B
15	proteolytic	I
16	complex	I
17	that	O
18	possesses	O
19	a	O
20	latent	O
21	multicatalytic	O
22	proteinase	O
23	activity	O
24	and	O
25	catalyzes	O
26	an	O
27	ATP	O
28	-	O
29	dependent	O
30	,	O
31	selective	O
32	breakdown	O
33	of	O
34	proteins	O
35	ligated	O
36	to	O
37	ubiquitin	B
38	.	O

1	The	O
2	O2	O
3	deficit	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	submaximal	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	citrate	B
19	synthase	I
20	,	O
21	3	B
22	-	I
23	hydroxyacyl	I
24	-	I
25	CoA	I
26	-	I
27	dehydrogenase	I
28	,	O
29	lactate	B
30	dehydrogenase	I
31	),	O
32	number	O
33	of	O
34	muscle	O
35	capillaries	O
36	,	O
37	%	O
38	ST	O
39	fibres	O
40	or	O
41	muscle	O
42	buffer	O
43	capacity	O
44	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	putative	O
6	RBP1	B
7	protein	I
8	contains	O
9	two	O
10	copies	O
11	of	O
12	an	O
13	RNA	O
14	recognition	O
15	motif	O
16	,	O
17	two	O
18	glutamine	O
19	stretches	O
20	,	O
21	an	O
22	asparagine	O
23	-	O
24	rich	O
25	region	O
26	,	O
27	a	O
28	methionine	O
29	-	O
30	rich	O
31	region	O
32	,	O
33	and	O
34	two	O
35	long	O
36	potential	O
37	alpha	O
38	-	O
39	helixes	O
40	.	O

1	One	O
2	defective	O
3	RNA	O
4	with	O
5	a	O
6	large	O
7	deletion	O
8	in	O
9	the	O
10	p70	B
11	coding	I
12	region	I
13	was	O
14	able	O
15	to	O
16	replicate	O
17	efficiently	O
18	,	O
19	both	O
20	when	O
21	inoculated	O
22	with	O
23	the	O
24	helper	O
25	genome	O
26	and	O
27	when	O
28	inoculated	O
29	with	O
30	a	O
31	second	O
32	complementing	O
33	defective	O
34	RNA	O
35	that	O
36	supplied	O
37	a	O
38	wild	B
39	-	I
40	type	I
41	p70	I
42	.	O

1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	B
7	K1F	I
8	tail	I
9	gene	I
10	encoding	O
11	endo	B
12	-	I
13	N	I
14	-	I
15	acylneuraminidase	I
16	(	O
17	endo	B
18	-	I
19	N	I
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	B
26	-	I
27	N	I
28	homolog	I
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	was	O
8	partially	O
9	inhibited	O
10	.	O

1	Morphometrical	O
2	quantification	O
3	of	O
4	brain	O
5	edema	O
6	related	O
7	to	O
8	experimental	O
9	multiple	O
10	micro	O
11	-	O
12	infarcts	O
13	in	O
14	mice	O
15	:	O
16	assessment	O
17	of	O
18	neurotropin	B
19	effect	O
20	.	O

1	One	O
2	member	O
3	of	O
4	this	O
5	multigene	O
6	family	O
7	,	O
8	GATA	B
9	-	I
10	3	I
11	,	O
12	is	O
13	most	O
14	abundantly	O
15	expressed	O
16	in	O
17	T	O
18	lymphocytes	O
19	,	O
20	a	O
21	cellular	O
22	target	O
23	for	O
24	human	O
25	immunodeficiency	O
26	virus	O
27	type	O
28	1	O
29	(	O
30	HIV	O
31	-	O
32	1	O
33	)	O
34	infection	O
35	and	O
36	replication	O
37	.	O

1	Indeed	O
2	,	O
3	significant	O
4	level	O
5	of	O
6	CAT	B
7	activity	O
8	was	O
9	observed	O
10	in	O
11	human	O
12	lung	O
13	adenocarcinoma	O
14	(	O
15	A549	O
16	-	O
17	1	O
18	)	O
19	cells	O
20	which	O
21	had	O
22	been	O
23	incubated	O
24	with	O
25	a	O
26	complex	O
27	of	O
28	T7	B
29	RNA	I
30	polymerase	I
31	,	O
32	pT7	B
33	-	I
34	EMC	I
35	-	I
36	CAT	I
37	DNA	I
38	and	O
39	DC	O
40	-	O
41	chol	O
42	cationic	O
43	liposomes	O
44	.	O

1	Pneumoscrotum	O
2	is	O
3	a	O
4	rare	O
5	condition	O
6	that	O
7	receives	O
8	little	O
9	discussion	O
10	in	O
11	standard	O
12	texts	O
13	of	O
14	urology	O
15	.	O

1	The	O
2	first	O
3	gene	O
4	codes	O
5	for	O
6	a	O
7	protein	O
8	containing	O
9	11	O
10	cystein	O
11	residues	O
12	in	O
13	an	O
14	arrangement	O
15	typical	O
16	for	O
17	Fe	B
18	/	I
19	S	I
20	proteins	I
21	.	O

1	Triton	O
2	-	O
3	disrupted	O
4	cells	O
5	retained	O
6	capacity	O
7	for	O
8	activation	O
9	of	O
10	the	O
11	pathway	O
12	by	O
13	both	O
14	peptide	O
15	growth	O
16	factors	O
17	and	O
18	by	O
19	addition	O
20	of	O
21	GTP	O
22	-	O
23	loaded	O
24	p21	B
25	rasVal12	I
26	.	O

1	To	O
2	begin	O
3	to	O
4	examine	O
5	the	O
6	mechanism	O
7	controlling	O
8	expression	O
9	of	O
10	this	O
11	gene	O
12	during	O
13	the	O
14	cell	O
15	-	O
16	cycle	O
17	,	O
18	a	O
19	mouse	B
20	B	I
21	-	I
22	myb	I
23	5	I
24	'	I
25	flanking	I
26	sequence	I
27	was	O
28	isolated	O
29	from	O
30	a	O
31	cosmid	O
32	library	O
33	and	O
34	shown	O
35	to	O
36	promote	O
37	efficiently	O
38	the	O
39	transcription	O
40	of	O
41	a	O
42	luciferase	B
43	reporter	I
44	gene	I
45	when	O
46	transfected	O
47	into	O
48	NIH3T3	O
49	fibroblasts	O
50	.	O

1	The	O
2	influence	O
3	of	O
4	a	O
5	high	O
6	ionic	O
7	strength	O
8	on	O
9	the	O
10	resolution	O
11	was	O
12	clearly	O
13	shown	O
14	.	O

1	The	O
2	number	O
3	of	O
4	bacteria	O
5	in	O
6	the	O
7	lung	O
8	,	O
9	peripheral	O
10	white	O
11	blood	O
12	cell	O
13	and	O
14	BAL	O
15	fluid	O
16	cell	O
17	also	O
18	decreased	O
19	by	O
20	the	O
21	administration	O
22	of	O
23	FN	B
24	.	O

1	In	O
2	mice	O
3	,	O
4	three	O
5	major	O
6	families	O
7	of	O
8	L1	O
9	elements	O
10	,	O
11	termed	O
12	"	O
13	A	O
14	,"	O
15	"	O
16	F	O
17	,"	O
18	and	O
19	"	O
20	V	O
21	,"	O
22	have	O
23	been	O
24	defined	O
25	on	O
26	the	O
27	basis	O
28	of	O
29	the	O
30	sequence	O
31	found	O
32	at	O
33	the	O
34	5	O
35	'	O
36	terminus	O
37	.	O

1	TFEC	B
2	,	O
3	a	O
4	basic	B
5	helix	I
6	-	I
7	loop	I
8	-	I
9	helix	I
10	protein	I
11	,	O
12	forms	O
13	heterodimers	O
14	with	O
15	TFE3	B
16	and	O
17	inhibits	O
18	TFE3	B
19	-	O
20	dependent	O
21	transcription	O
22	activation	O
23	.	O

1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O

1	Similar	O
2	results	O
3	were	O
4	seen	O
5	on	O
6	Western	O
7	blots	O
8	of	O
9	Autographa	O
10	californica	O
11	MNPV	O
12	(	O
13	AcMNPV	O
14	)-	O
15	infected	O
16	Spodoptera	O
17	frugiperda	O
18	cells	O
19	.	O

1	In	O
2	infected	O
3	mammalian	O
4	cells	O
5	,	O
6	the	O
7	ARV	B
8	G	I
9	and	O
10	GNS	B
11	genes	I
12	are	O
13	transcribed	O
14	primarily	O
15	as	O
16	a	O
17	polycistronic	O
18	mRNA	O
19	which	O
20	appears	O
21	to	O
22	extend	O
23	from	O
24	the	O
25	consensus	O
26	sequence	O
27	(	O
28	AACAG	O
29	)	O
30	at	O
31	the	O
32	start	O
33	of	O
34	the	O
35	G	B
36	gene	I
37	to	O
38	the	O
39	next	O
40	recognized	O
41	polyadenylation	O
42	signal	O
43	(	O
44	CATG	O
45	[	O
46	A	O
47	]	O
48	7	O
49	)	O
50	located	O
51	697	O
52	nucleotides	O
53	downstream	O
54	of	O
55	the	O
56	GNS	B
57	protein	I
58	termination	O
59	codon	O
60	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	RPE65	B
7	,	O
8	a	O
9	novel	O
10	retinal	O
11	pigment	O
12	epithelium	O
13	-	O
14	specific	O
15	microsomal	O
16	protein	O
17	that	O
18	is	O
19	post	O
20	-	O
21	transcriptionally	O
22	regulated	O
23	in	O
24	vitro	O
25	.	O

1	The	O
2	mean	O
3	power	O
4	(	O
5	in	O
6	mu	O
7	W	O
8	)	O
9	required	O
10	to	O
11	produce	O
12	the	O
13	observed	O
14	flow	O
15	rate	O
16	was	O
17	estimated	O
18	at	O
19	each	O
20	outflow	O
21	pressure	O
22	as	O
23	the	O
24	product	O
25	of	O
26	the	O
27	flow	O
28	rate	O
29	and	O
30	the	O
31	pressure	O
32	across	O
33	the	O
34	lymphatic	O
35	vessel	O
36	.	O

1	Although	O
2	antisperm	O
3	antibodies	O
4	are	O
5	associated	O
6	with	O
7	infertility	O
8	,	O
9	many	O
10	hospital	O
11	laboratories	O
12	do	O
13	not	O
14	test	O
15	for	O
16	these	O
17	antibodies	O
18	.	O

1	PPD	B
2	-	O
3	specific	O
4	IgG	B
5	subclass	O
6	responses	O
7	were	O
8	evident	O
9	to	O
10	all	O
11	four	O
12	IgG	B
13	subclasses	O
14	.	O

1	Anterior	O
2	body	O
3	pattern	O
4	in	O
5	Drosophila	O
6	is	O
7	specified	O
8	by	O
9	the	O
10	graded	O
11	distribution	O
12	of	O
13	the	O
14	bicoid	B
15	protein	I
16	(	O
17	bcd	B
18	),	O
19	which	O
20	activates	O
21	subordinate	O
22	genes	O
23	in	O
24	distinct	O
25	anterior	O
26	domains	O
27	.	O

1	GAP	B
2	-	I
3	N	I
4	bound	O
5	constitutively	O
6	to	O
7	p190	B
8	in	O
9	both	O
10	serum	O
11	-	O
12	deprived	O
13	and	O
14	growth	O
15	factor	O
16	-	O
17	stimulated	O
18	cells	O
19	.	O

1	The	O
2	peptide	O
3	sequence	O
4	contains	O
5	a	O
6	region	O
7	of	O
8	80	O
9	amino	O
10	acids	O
11	that	O
12	shows	O
13	similarity	O
14	to	O
15	bcl	B
16	-	I
17	2	I
18	and	O
19	to	O
20	the	O
21	recently	O
22	described	O
23	bcl	B
24	-	I
25	2	I
26	-	I
27	related	I
28	gene	I
29	,	O
30	MCL1	B
31	.	O

1	The	O
2	phosphorylation	O
3	efficiency	O
4	is	O
5	improved	O
6	by	O
7	increasing	O
8	the	O
9	number	O
10	of	O
11	N	O
12	-	O
13	terminal	O
14	arginine	O
15	residues	O
16	and	O
17	by	O
18	moving	O
19	the	O
20	arginyl	O
21	cluster	O
22	one	O
23	residue	O
24	further	O
25	away	O
26	from	O
27	the	O
28	serine	O
29	,	O
30	the	O
31	nonapeptide	O
32	(	O
33	Arg	O
34	)	O
35	4	O
36	-	O
37	Ala	O
38	-	O
39	Ala	O
40	-	O
41	Ser	O
42	-	O
43	Val	O
44	-	O
45	Ala	O
46	being	O
47	the	O
48	best	O
49	substrate	O
50	among	O
51	all	O
52	the	O
53	short	O
54	peptides	O
55	tested	O
56	(	O
57	Km	O
58	=	O
59	15	O
60	microM	O
61	).	O

1	Botulinum	B
2	toxin	I
3	:	O
4	preferred	O
5	treatment	O
6	for	O
7	hemifacial	O
8	spasm	O
9	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	GAL1	I
5	and	O
6	GAL10	B
7	genes	I
8	are	O
9	controlled	O
10	in	O
11	response	O
12	to	O
13	the	O
14	availability	O
15	of	O
16	galactose	O
17	and	O
18	glucose	O
19	by	O
20	multiple	O
21	activating	O
22	and	O
23	repressing	O
24	proteins	O
25	bound	O
26	at	O
27	adjacent	O
28	or	O
29	overlapping	O
30	sites	O
31	in	O
32	UASG	O
33	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	results	O
5	of	O
6	several	O
7	experiments	O
8	suggest	O
9	that	O
10	the	O
11	TSF	B
12	genes	I
13	encode	O
14	global	O
15	regulatory	O
16	factors	O
17	.	O
18	tsf1	B
19	to	O
20	tsf6	B
21	mutations	O
22	derepressed	O
23	expression	O
24	from	O
25	yeast	O
26	CYC	B
27	-	O
28	GAL	B
29	hybrid	O
30	promoters	O
31	(	O
32	fused	O
33	to	O
34	lacZ	B
35	)	O
36	that	O
37	harbor	O
38	a	O
39	variety	O
40	of	O
41	operator	O
42	sequences	O
43	,	O
44	and	O
45	caused	O
46	pleiotropic	O
47	defects	O
48	in	O
49	cell	O
50	growth	O
51	,	O
52	mating	O
53	,	O
54	and	O
55	sporulation	O
56	.	O

1	Sex	O
2	of	O
3	calf	O
4	(	O
5	variate	O
6	2	O
7	)	O
8	was	O
9	associated	O
10	most	O
11	closely	O
12	with	O
13	width	O
14	of	O
15	muzzle	O
16	and	O
17	head	O
18	.	O

1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	B
15	and	O
16	PSG12	B
17	psi	I
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	B
33	psi	I
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O

1	The	O
2	mechanisms	O
3	that	O
4	govern	O
5	the	O
6	activation	O
7	or	O
8	suppression	O
9	of	O
10	the	O
11	CD8	B
12	gene	I
13	are	O
14	likely	O
15	to	O
16	be	O
17	central	O
18	to	O
19	the	O
20	T	O
21	cell	O
22	development	O
23	program	O
24	.	O

1	We	O
2	suggest	O
3	that	O
4	the	O
5	ER	O
6	lumenal	O
7	variable	O
8	domain	O
9	of	O
10	gp19K	B
11	has	O
12	a	O
13	specific	O
14	tertiary	O
15	structure	O
16	that	O
17	is	O
18	important	O
19	for	O
20	binding	O
21	to	O
22	the	O
23	polymorphic	O
24	alpha	O
25	1	O
26	and	O
27	alpha	O
28	2	O
29	domains	O
30	of	O
31	class	B
32	I	I
33	heavy	I
34	(	I
35	alpha	I
36	)	I
37	chains	I
38	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	Recombinant	B
2	human	I
3	erythropoietin	I
4	(	O
5	epoetin	B
6	)	O
7	is	O
8	approved	O
9	to	O
10	be	O
11	administered	O
12	by	O
13	the	O
14	intravenous	O
15	(	O
16	i	O
17	.	O
18	v	O
19	.)	O
20	or	O
21	subcutaneous	O
22	(	O
23	SC	O
24	)	O
25	route	O
26	.	O

1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O

1	2	O
2	-	O
3	AP	O
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	O
19	-	O
20	1	O
21	constructs	O
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	B
31	-	I
32	actin	I
33	or	O
34	glucose	B
35	6	I
36	-	I
37	phosphate	I
38	dehydrogenase	I
39	.	O

1	The	O
2	UV	O
3	induction	O
4	of	O
5	c	B
6	-	I
7	jun	I
8	is	O
9	mediated	O
10	by	O
11	two	O
12	UV	O
13	response	O
14	elements	O
15	consisting	O
16	of	O
17	AP	B
18	-	I
19	1	I
20	-	I
21	like	I
22	sequences	I
23	within	O
24	its	O
25	5	O
26	'	O
27	control	O
28	region	O
29	.	O

1	Protein	B
2	tyrosine	I
3	phosphatases	I
4	(	O
5	PTPs	B
6	),	O
7	together	O
8	with	O
9	protein	B
10	tyrosine	I
11	kinases	I
12	(	O
13	PTKs	B
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	cell	O
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O

1	ST	O
2	elevation	O
3	occurs	O
4	in	O
5	5	O
6	patients	O
7	(	O
8	55	O
9	.	O
10	5	O
11	%)	O
12	of	O
13	subgroup	O
14	A	O
15	and	O
16	in	O
17	no	O
18	patient	O
19	of	O
20	the	O
21	subgroup	O
22	B	O
23	.	O

1	Furthermore	O
2	,	O
3	a	O
4	p21X	B
5	protein	I
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O

1	HTLV	O
2	-	O
3	1	O
4	gene	O
5	expression	O
6	by	O
7	defective	O
8	proviruses	O
9	in	O
10	an	O
11	infected	O
12	T	O
13	-	O
14	cell	O
15	line	O
16	.	O

1	Thus	O
2	,	O
3	it	O
4	was	O
5	confirmed	O
6	that	O
7	the	O
8	sodium	O
9	lauryl	O
10	sulfate	O
11	method	O
12	of	O
13	estimating	O
14	hemoglobin	B
15	concentration	O
16	is	O
17	an	O
18	appropriate	O
19	alternative	O
20	to	O
21	the	O
22	cyanmethemoglobin	B
23	method	O
24	and	O
25	avoids	O
26	the	O
27	generation	O
28	of	O
29	toxic	O
30	wastes	O
31	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	amino	O
7	acid	O
8	sequences	O
9	of	O
10	the	O
11	two	O
12	human	B
13	PKC	I
14	-	I
15	delta	I
16	clones	O
17	with	O
18	the	O
19	rat	O
20	and	O
21	mouse	O
22	homologues	O
23	indicated	O
24	a	O
25	greater	O
26	degree	O
27	of	O
28	sequence	O
29	divergence	O
30	(	O
31	89	O
32	-	O
33	90	O
34	%	O
35	homology	O
36	)	O
37	compared	O
38	to	O
39	the	O
40	high	O
41	degree	O
42	of	O
43	sequence	O
44	conservation	O
45	observed	O
46	with	O
47	other	O
48	human	B
49	PKC	I
50	family	I
51	members	I
52	and	O
53	their	O
54	mammalian	O
55	counterparts	O
56	.	O

1	XII	O
2	.	O

1	When	O
2	comparing	O
3	the	O
4	barley	B
5	PSI	I
6	-	I
7	K	I
8	and	O
9	PSI	B
10	-	I
11	G	I
12	with	O
13	the	O
14	reported	O
15	PSI	B
16	-	I
17	K	I
18	sequence	I
19	from	I
20	Synechococcus	I
21	vulcanus	I
22	,	O
23	the	O
24	degree	O
25	of	O
26	similarity	O
27	is	O
28	equal	O
29	,	O
30	suggesting	O
31	that	O
32	an	O
33	ancestral	O
34	gene	O
35	has	O
36	been	O
37	duplicated	O
38	in	O
39	a	O
40	chloroplast	O
41	progenitor	O
42	but	O
43	not	O
44	in	O
45	a	O
46	cyanobacterial	O
47	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	O
8	of	O
9	the	O
10	b	O
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	B
20	-	I
21	related	I
22	proteins	I
23	.	O

1	Under	O
2	these	O
3	conditions	O
4	,	O
5	transfections	O
6	with	O
7	cDNAs	O
8	of	O
9	the	O
10	NF	B
11	-	I
12	kappa	I
13	B	I
14	p50	I
15	and	O
16	serum	B
17	response	I
18	factor	I
19	(	O
20	SRF	B
21	)	O
22	produced	O
23	a	O
24	factor	O
25	(	O
26	s	O
27	)	O
28	that	O
29	mediated	O
30	Tax	B
31	binding	O
32	to	O
33	the	O
34	NF	B
35	-	I
36	kappa	I
37	B	I
38	site	I
39	and	O
40	the	O
41	CArG	O
42	box	O
43	respectively	O
44	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	specifically	O
9	increased	O
10	expression	O
11	from	O
12	a	O
13	reporter	O
14	plasmid	O
15	containing	O
16	multiple	O
17	Sp1	B
18	binding	I
19	sites	I
20	approximately	O
21	sixfold	O
22	in	O
23	chicken	O
24	embryo	O
25	fibroblasts	O
26	(	O
27	CEFs	O
28	),	O
29	even	O
30	though	O
31	v	B
32	-	I
33	Rel	I
34	did	O
35	not	O
36	bind	O
37	directly	O
38	to	O
39	these	O
40	sites	O
41	.	O
42	v	B
43	-	I
44	Rel	I
45	also	O
46	increased	O
47	expression	O
48	from	O
49	a	O
50	reporter	O
51	plasmid	O
52	containing	O
53	a	O
54	human	B
55	immunodeficiency	I
56	virus	I
57	type	I
58	1	I
59	(	I
60	HIV	I
61	-	I
62	1	I
63	)	I
64	long	I
65	terminal	I
66	repeat	I
67	(	O
68	LTR	O
69	)	O
70	in	O
71	which	O
72	the	O
73	kappa	B
74	B	I
75	binding	I
76	sites	I
77	were	O
78	mutated	O
79	but	O
80	which	O
81	still	O
82	contained	O
83	intact	O
84	Sp1	B
85	binding	I
86	sites	I
87	.	O

1	The	O
2	simultaneous	O
3	recording	O
4	of	O
5	electrical	O
6	activity	O
7	from	O
8	the	O
9	surface	O
10	electrocardiogram	O
11	,	O
12	right	O
13	ventricular	O
14	apex	O
15	,	O
16	His	O
17	bundle	O
18	,	O
19	high	O
20	right	O
21	atrium	O
22	,	O
23	coronary	O
24	sinus	O
25	,	O
26	with	O
27	or	O
28	without	O
29	a	O
30	roving	O
31	mapping	O
32	catheter	O
33	,	O
34	enables	O
35	us	O
36	to	O
37	precisely	O
38	map	O
39	the	O
40	electrical	O
41	activation	O
42	sequence	O
43	in	O
44	the	O
45	heart	O
46	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	retrospective	O
5	analysis	O
6	does	O
7	not	O
8	confirm	O
9	the	O
10	efficacy	O
11	of	O
12	one	O
13	course	O
14	of	O
15	simultaneous	O
16	Mitomycin	O
17	-	O
18	C	O
19	and	O
20	5	O
21	-	O
22	fluorouracil	O
23	,	O
24	at	O
25	least	O
26	in	O
27	association	O
28	with	O
29	full	O
30	-	O
31	dose	O
32	radiotherapy	O
33	incorporating	O
34	Iridium	O
35	-	O
36	192	O
37	boost	O
38	.	O

1	Despite	O
2	the	O
3	existence	O
4	of	O
5	30	O
6	cysteine	O
7	residues	O
8	,	O
9	carboxymethylation	O
10	prevented	O
11	the	O
12	formation	O
13	of	O
14	most	O
15	if	O
16	not	O
17	all	O
18	disulfide	O
19	bonds	O
20	that	O
21	otherwise	O
22	occurred	O
23	when	O
24	the	O
25	cells	O
26	were	O
27	sonicated	O
28	.	O

1	Cerebro	O
2	-	O
3	oculo	O
4	-	O
5	facioskeletal	O
6	syndrome	O
7	(	O
8	Pena	O
9	-	O
10	Shokeir	O
11	syndrome	O
12	II	O
13	)	O

1	Most	O
2	importantly	O
3	,	O
4	the	O
5	addition	O
6	of	O
7	purified	O
8	17S	B
9	U2	I
10	snRNPs	I
11	,	O
12	but	O
13	not	O
14	of	O
15	12S	B
16	U2	I
17	snRNPs	I
18	,	O
19	to	O
20	HeLa	O
21	splicing	O
22	extracts	O
23	in	O
24	which	O
25	the	O
26	endogeneous	B
27	U2	I
28	snRNPs	I
29	have	O
30	been	O
31	functionally	O
32	neutralized	O
33	with	O
34	anti	B
35	-	I
36	PRP9	I
37	antibodies	I
38	fully	O
39	restores	O
40	the	O
41	mRNA	O
42	-	O
43	splicing	O
44	activity	O
45	of	O
46	the	O
47	extracts	O
48	.	O

1	Differences	O
2	in	O
3	profiles	O
4	of	O
5	viscosity	O
6	variables	O
7	between	O
8	subgroups	O
9	of	O
10	EAD	O
11	in	O
12	RA	O
13	patients	O
14	were	O
15	observed	O
16	.	O

1	These	O
2	contain	O
3	a	O
4	single	O
5	1977	O
6	-	O
7	bp	O
8	exon	O
9	that	O
10	encodes	O
11	900	O
12	bp	O
13	of	O
14	the	O
15	5	O
16	'	O
17	and	O
18	3	O
19	'	O
20	untranslated	O
21	sequences	O
22	in	O
23	addition	O
24	to	O
25	a	O
26	1077	O
27	-	O
28	bp	O
29	open	O
30	reading	O
31	frame	O
32	identical	O
33	to	O
34	that	O
35	found	O
36	in	O
37	vascular	B
38	smooth	I
39	muscle	I
40	cell	I
41	AT1a	I
42	receptor	I
43	cDNAs	I
44	.	O

1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O

1	One	O
2	chimpanzee	O
3	reliably	O
4	selected	O
5	the	O
6	larger	O
7	numeral	O
8	4	O
9	during	O
10	testing	O
11	with	O
12	a	O
13	nonadjacent	O
14	pair	O
15	(	O
16	2	O
17	-	O
18	4	O
19	),	O
20	and	O
21	2	O
22	chimps	O
23	showed	O
24	no	O
25	preference	O
26	.	O

1	Dissipation	O
2	of	O
3	claudication	O
4	pain	O
5	after	O
6	walking	O
7	:	O
8	implications	O
9	for	O
10	endurance	O
11	training	O
12	.	O

1	Alternative	O
2	transcript	O
3	of	O
4	the	O
5	nonselective	O
6	-	O
7	type	O
8	endothelin	B
9	receptor	I
10	from	O
11	rat	O
12	brain	O
13	.	O

1	The	O
2	Functional	O
3	Independence	O
4	Measure	O
5	:	O
6	a	O
7	comparative	O
8	study	O
9	of	O
10	clinician	O
11	and	O
12	self	O
13	ratings	O
14	.	O

1	Polymyxin	O
2	B	O
3	was	O
4	given	O
5	intravenously	O
6	for	O
7	1	O
8	week	O
9	postburn	O
10	in	O
11	doses	O
12	designed	O
13	to	O
14	neutralize	O
15	circulating	O
16	endotoxemia	O
17	.	O

1	SvO2	O
2	can	O
3	be	O
4	determined	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	.	O

1	The	O
2	transverse	O
3	relaxation	O
4	time	O
5	(	O
6	T2	O
7	)	O
8	and	O
9	apparent	O
10	diffusion	O
11	coefficient	O
12	of	O
13	water	O
14	were	O
15	determined	O
16	.	O

1	The	O
2	Drosophila	O
3	clathrin	B
4	heavy	I
5	chain	I
6	gene	O
7	:	O
8	clathrin	B
9	function	O
10	is	O
11	essential	O
12	in	O
13	a	O
14	multicellular	O
15	organism	O
16	.	O

1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	B
13	E2F	I
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	B
19	E2F	I
20	sites	I
21	as	O
22	competitors	O
23	.	O

1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	IgG1	B
26	and	O
27	two	O
28	IgG3	B
29	)	O
30	mAb	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	patch	O
7	determines	O
8	the	O
9	proper	O
10	conformation	O
11	of	O
12	the	O
13	site	O
14	and	O
15	thereby	O
16	contributes	O
17	to	O
18	recognition	O
19	indirectly	O
20	.	O

1	These	O
2	findings	O
3	suggest	O
4	a	O
5	functional	O
6	cross	O
7	-	O
8	talk	O
9	between	O
10	RB	B
11	protein	I
12	and	O
13	p21ras	B
14	,	O
15	which	O
16	balances	O
17	the	O
18	cell	O
19	phenotype	O
20	between	O
21	normal	O
22	and	O
23	transformed	O
24	states	O
25	.	O

1	The	O
2	7	O
3	-	O
4	kb	O
5	mRNA	O
6	differs	O
7	by	O
8	alternative	O
9	splicing	O
10	such	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	with	O
17	a	O
18	distinct	O
19	amino	O
20	terminus	O
21	.	O

1	Kinetics	O
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	The	O
2	other	O
3	transmembrane	O
4	regions	O
5	as	O
6	well	O
7	as	O
8	the	O
9	nucleoplasmic	O
10	domain	O
11	are	O
12	not	O
13	required	O
14	for	O
15	sorting	O
16	.	O

1	3	O
2	.	O

1	McCann	O
2	III	O
3	,	O
4	F	O
5	.	O

1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	B
19	mutant	I
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	B
26	and	O
27	VP23	B
28	null	O
29	mutants	O
30	.	O

1	The	O
2	E1	B
3	nuclear	I
4	transport	I
5	motif	I
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	B
26	genes	I
27	.	O

1	The	O
2	E1	B
3	replication	I
4	protein	I
5	of	O
6	bovine	O
7	papillomavirus	O
8	type	O
9	1	O
10	contains	O
11	an	O
12	extended	O
13	nuclear	O
14	localization	O
15	signal	O
16	that	O
17	includes	O
18	a	O
19	p34cdc2	B
20	phosphorylation	O
21	site	O
22	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	to	O
6	what	O
7	extent	O
8	this	O
9	interaction	O
10	might	O
11	contribute	O
12	to	O
13	tumor	O
14	induction	O
15	by	O
16	the	O
17	virus	O
18	,	O
19	we	O
20	have	O
21	introduced	O
22	two	O
23	different	O
24	point	O
25	mutations	O
26	within	O
27	the	O
28	putative	O
29	pRb	B
30	-	I
31	binding	I
32	sequence	I
33	of	O
34	large	B
35	T	I
36	antigen	I
37	,	O
38	and	O
39	as	O
40	a	O
41	preliminary	O
42	to	O
43	in	O
44	vivo	O
45	experiments	O
46	we	O
47	have	O
48	studied	O
49	their	O
50	effects	O
51	in	O
52	vitro	O
53	on	O
54	some	O
55	biological	O
56	activities	O
57	relevant	O
58	to	O
59	tumor	O
60	induction	O
61	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	conservation	O
6	of	O
7	nucleotides	O
8	154	O
9	to	O
10	156	O
11	is	O
12	likely	O
13	to	O
14	be	O
15	a	O
16	consequence	O
17	of	O
18	their	O
19	role	O
20	as	O
21	a	O
22	sequence	O
23	-	O
24	specific	O
25	recognition	O
26	element	O
27	for	O
28	the	O
29	SRP54	B
30	protein	I
31	.	O

1	A	O
2	region	O
3	of	O
4	the	O
5	deduced	O
6	protein	O
7	shares	O
8	extensive	O
9	homology	O
10	with	O
11	a	O
12	catalytic	O
13	region	O
14	of	O
15	Raf	B
16	kinases	I
17	,	O
18	a	O
19	feature	O
20	shared	O
21	only	O
22	with	O
23	TFIIE	B
24	among	O
25	transcription	O
26	factors	O
27	.	O

1	The	O
2	low	O
3	molecular	O
4	mass	O
5	polypeptide	O
6	complex	O
7	is	O
8	assumed	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	antigen	O
14	presentation	O
15	,	O
16	generating	O
17	peptides	O
18	from	O
19	cytosolic	O
20	protein	O
21	antigens	O
22	,	O
23	which	O
24	are	O
25	subsequently	O
26	presented	O
27	to	O
28	cytotoxic	O
29	T	O
30	-	O
31	lymphocytes	O
32	on	O
33	the	O
34	cell	O
35	surface	O
36	.	O

1	Secondary	O
2	cleavage	O
3	of	O
4	RT	B
5	at	O
6	Trp	O
7	-	O
8	595	O
9	-	O
10	Tyr	O
11	-	O
12	596	O
13	of	O
14	Pol	B
15	yields	O
16	a	O
17	truncated	O
18	form	O
19	lacking	O
20	the	O
21	C	B
22	-	I
23	terminal	I
24	RNase	I
25	H	I
26	domain	I
27	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	approximately	O
6	50	O
7	amino	O
8	acids	O
9	of	O
10	Bel	B
11	-	I
12	1	I
13	are	O
14	shown	O
15	to	O
16	be	O
17	essential	O
18	for	O
19	Bel	B
20	-	I
21	1	I
22	activity	O
23	but	O
24	can	O
25	be	O
26	effectively	O
27	substituted	O
28	by	O
29	the	O
30	C	O
31	-	O
32	terminal	O
33	activation	O
34	domain	O
35	of	O
36	VP16	B
37	.	O

1	Since	O
2	the	O
3	-	O
4	172	O
5	/-	O
6	148	O
7	element	O
8	also	O
9	conferred	O
10	estrogen	O
11	and	O
12	thyroid	O
13	hormone	O
14	responsiveness	O
15	,	O
16	it	O
17	can	O
18	be	O
19	considered	O
20	a	O
21	composite	O
22	hormone	O
23	response	O
24	element	O
25	.	O

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O

1	Together	O
2	with	O
3	a	O
4	considerably	O
5	shortened	O
6	and	O
7	interrupted	O
8	aromatic	O
9	aa	O
10	stretch	O
11	in	O
12	this	O
13	region	O
14	,	O
15	these	O
16	differences	O
17	are	O
18	discussed	O
19	in	O
20	terms	O
21	of	O
22	the	O
23	peculiar	O
24	affinity	O
25	of	O
26	cyanobacterial	B
27	cytochrome	I
28	oxidases	I
29	for	O
30	acidic	O
31	c	B
32	-	I
33	type	I
34	cytochromes	I
35	.	O

1	All	O
2	four	O
3	of	O
4	the	O
5	genes	O
6	have	O
7	a	O
8	similar	O
9	structure	O
10	,	O
11	with	O
12	the	O
13	receptor	O
14	protein	O
15	encoded	O
16	in	O
17	a	O
18	single	O
19	exon	O
20	.	O

1	Identity	O
2	of	O
3	GABP	B
4	with	O
5	NRF	B
6	-	I
7	2	I
8	,	O
9	a	O
10	multisubunit	O
11	activator	O
12	of	O
13	cytochrome	B
14	oxidase	I
15	expression	O
16	,	O
17	reveals	O
18	a	O
19	cellular	O
20	role	O
21	for	O
22	an	O
23	ETS	B
24	domain	I
25	activator	O
26	of	O
27	viral	O
28	promoters	O
29	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	beta	O
7	-	O
8	funaltrexamine	O
9	(	O
10	beta	O
11	-	O
12	FNA	O
13	)	O
14	and	O
15	naltrindole	O
16	(	O
17	NTI	O
18	)	O
19	(	O
20	nonequilibrium	O
21	mu	O
22	-	O
23	and	O
24	delta	O
25	-	O
26	antagonist	O
27	,	O
28	respectively	O
29	)	O
30	were	O
31	used	O
32	to	O
33	precipitate	O
34	withdrawal	O
35	in	O
36	butorphanol	O
37	-	O
38	dependent	O
39	rats	O
40	.	O

1	The	O
2	intracellular	O
3	basic	B
4	region	I
5	/	I
6	helix	I
7	-	I
8	loop	I
9	-	I
10	helix	I
11	(	I
12	bHLH	I
13	)	I
14	dioxin	I
15	receptor	I
16	mediates	O
17	signal	O
18	transduction	O
19	by	O
20	dioxin	O
21	(	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	)	O
36	and	O
37	functions	O
38	as	O
39	a	O
40	ligand	O
41	-	O
42	activated	O
43	DNA	O
44	binding	O
45	protein	O
46	directly	O
47	interacting	O
48	with	O
49	target	O
50	genes	O
51	by	O
52	binding	O
53	to	O
54	dioxin	O
55	response	O
56	elements	O
57	.	O

1	The	O
2	alpha	B
3	2A	I
4	-	I
5	adrenergic	I
6	receptor	I
7	(	O
8	alpha	B
9	2AAR	I
10	)	O
11	is	O
12	coupled	O
13	to	O
14	a	O
15	variety	O
16	of	O
17	effectors	O
18	via	O
19	pertussis	B
20	toxin	I
21	-	O
22	sensitive	O
23	GTP	B
24	-	I
25	binding	I
26	proteins	I
27	.	O

1	A	O
2	sequence	O
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	B
7	/	I
8	enhancer	I
9	binding	I
10	protein	I
11	(	O
12	C	B
13	/	I
14	EBP	I
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	zippers	O
26	1	O
27	and	O
28	2	O
29	(	O
30	bZIP1	O
31	and	O
32	bZIP2	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O

1	One	O
2	of	O
3	these	O
4	genes	O
5	,	O
6	REC114	B
7	,	O
8	is	O
9	described	O
10	here	O
11	,	O
12	and	O
13	the	O
14	data	O
15	confirm	O
16	that	O
17	REC114	B
18	is	O
19	a	O
20	meiosis	O
21	-	O
22	specific	O
23	recombination	O
24	gene	O
25	with	O
26	no	O
27	detectable	O
28	function	O
29	in	O
30	mitosis	O
31	.	O

1	The	O
2	transactivation	O
3	function	O
4	of	O
5	EBNA2	B
6	was	O
7	also	O
8	observed	O
9	in	O
10	the	O
11	HeLa	O
12	epithelial	O
13	cell	O
14	line	O
15	,	O
16	which	O
17	suggests	O
18	that	O
19	EBV	O
20	and	O
21	HIV	O
22	-	O
23	1	O
24	infection	O
25	of	O
26	non	O
27	-	O
28	B	O
29	cells	O
30	may	O
31	result	O
32	in	O
33	HIV	B
34	-	I
35	1	I
36	promoter	I
37	activation	O
38	.	O

1	Mutation	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	binding	I
8	sites	I
9	in	O
10	the	O
11	Rous	B
12	sarcoma	I
13	virus	I
14	long	I
15	terminal	I
16	repeat	I
17	and	O
18	gag	B
19	enhancers	I
20	.	O

1	Nuclear	B
2	protein	I
3	phosphatase	I
4	2A	I
5	dephosphorylates	O
6	protein	B
7	kinase	I
8	A	I
9	-	O
10	phosphorylated	O
11	CREB	B
12	and	O
13	regulates	O
14	CREB	B
15	transcriptional	O
16	stimulation	O
17	.	O

1	We	O
2	show	O
3	that	O
4	IL	B
5	-	I
6	6	I
7	activates	O
8	JRE	B
9	-	I
10	IL6	I
11	through	O
12	an	O
13	H7	O
14	-	O
15	sensitive	O
16	pathway	O
17	that	O
18	does	O
19	not	O
20	involve	O
21	protein	B
22	kinase	I
23	C	I
24	,	O
25	cyclic	B
26	AMP	I
27	-	I
28	dependent	I
29	kinase	I
30	,	O
31	Ca	B
32	(	I
33	2	I
34	+)-	I
35	or	I
36	calmodulin	I
37	-	I
38	dependent	I
39	kinases	I
40	,	O
41	Ras	B
42	,	O
43	Raf	B
44	-	I
45	1	I
46	,	O
47	or	O
48	NF	B
49	-	I
50	IL6	I
51	(	O
52	C	B
53	/	I
54	EBP	I
55	beta	I
56	).	O

1	Mutation	O
2	of	O
3	the	O
4	presumptive	O
5	phosphorylated	O
6	tyrosine	O
7	and	O
8	threonine	O
9	residues	O
10	of	O
11	Mpk1p	B
12	individually	O
13	to	O
14	phenylalanine	O
15	and	O
16	alanine	O
17	,	O
18	respectively	O
19	,	O
20	severely	O
21	impaired	O
22	Mpk1p	B
23	function	O
24	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	I
30	region	I
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	B
38	kd	I
39	cellular	I
40	Elk	I
41	-	I
42	1	I
43	kinase	I
44	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	situation	O
6	in	O
7	mammalian	O
8	cells	O
9	,	O
10	prolonged	O
11	exposure	O
12	of	O
13	the	O
14	agonist	O
15	(	O
16	24	O
17	h	O
18	)	O
19	does	O
20	not	O
21	result	O
22	in	O
23	down	O
24	regulation	O
25	of	O
26	the	O
27	remaining	O
28	70	O
29	%	O
30	of	O
31	the	O
32	receptors	O
33	.	O

1	This	O
2	stimulatory	O
3	effect	O
4	could	O
5	also	O
6	be	O
7	elicited	O
8	by	O
9	c	B
10	-	I
11	Jun	I
12	,	O
13	which	O
14	interacts	O
15	with	O
16	topo	B
17	II	I
18	,	O
19	but	O
20	not	O
21	by	O
22	c	B
23	-	I
24	Fos	I
25	,	O
26	which	O
27	does	O
28	not	O
29	bind	O
30	topo	B
31	II	I
32	in	O
33	our	O
34	in	O
35	vitro	O
36	assay	O
37	.	O

1	The	O
2	regulation	O
3	of	O
4	Myf	B
5	-	I
6	5	I
7	and	O
8	MyoD	B
9	function	O
10	by	O
11	a	O
12	cAMP	O
13	-	O
14	dependent	O
15	pathway	O
16	may	O
17	partly	O
18	explain	O
19	how	O
20	external	O
21	signals	O
22	generated	O
23	by	O
24	serum	O
25	and	O
26	certain	O
27	peptide	O
28	growth	O
29	factors	O
30	can	O
31	be	O
32	transduced	O
33	to	O
34	the	O
35	nucleus	O
36	and	O
37	inhibit	O
38	dominant	O
39	-	O
40	acting	O
41	factors	O
42	that	O
43	are	O
44	responsible	O
45	for	O
46	myoblast	O
47	differentiation	O
48	.	O

1	16	O
2	,	O
3	99	O
4	-	O
5	104	O
6	).	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	high	O
7	level	O
8	human	B
9	desmin	I
10	expression	O
11	depends	O
12	on	O
13	a	O
14	280	O
15	-	O
16	base	O
17	pair	O
18	muscle	O
19	-	O
20	specific	O
21	enhancer	O
22	which	O
23	can	O
24	function	O
25	not	O
26	only	O
27	in	O
28	myotubes	O
29	,	O
30	but	O
31	can	O
32	also	O
33	activate	O
34	gene	O
35	expression	O
36	in	O
37	myoblasts	O
38	.	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	Replacement	O
2	of	O
3	the	O
4	wild	O
5	-	O
6	type	O
7	5	O
8	'-	O
9	regulatory	O
10	region	O
11	with	O
12	either	O
13	of	O
14	the	O
15	mutants	O
16	'	O
17	cis	O
18	-	O
19	acting	O
20	regulatory	O
21	element	O
22	resulted	O
23	in	O
24	the	O
25	anaerobic	O
26	expression	O
27	of	O
28	active	B
29	Mn	I
30	-	I
31	superoxide	I
32	dismutase	I
33	.	O

1	The	O
2	orf61	B
3	gene	I
4	product	I
5	,	O
6	when	O
7	expressed	O
8	from	O
9	an	O
10	exogenous	O
11	promoter	O
12	,	O
13	inhibited	O
14	int	B
15	-	O
16	mediated	O
17	integration	O
18	at	O
19	the	O
20	chromosomal	B
21	attB	I
22	site	I
23	.	O

1	Expression	O
2	in	O
3	established	O
4	LCLs	O
5	,	O
6	occurring	O
7	irrespective	O
8	of	O
9	virus	O
10	producer	O
11	status	O
12	,	O
13	was	O
14	not	O
15	a	O
16	consequence	O
17	of	O
18	continued	O
19	in	O
20	vitro	O
21	passage	O
22	;	O
23	thus	O
24	,	O
25	appropriately	O
26	spliced	O
27	BamHI	B
28	-	I
29	A	I
30	transcripts	I
31	could	O
32	be	O
33	amplified	O
34	from	O
35	normal	O
36	B	O
37	cells	O
38	within	O
39	1	O
40	day	O
41	of	O
42	their	O
43	experimental	O
44	infection	O
45	in	O
46	vitro	O
47	,	O
48	along	O
49	with	O
50	BamHI	B
51	-	I
52	C	I
53	/	I
54	W	I
55	promoter	O
56	-	O
57	initiated	O
58	but	O
59	not	O
60	BamHI	B
61	-	I
62	F	I
63	promoter	I
64	-	I
65	initiated	I
66	mRNAs	I
67	.	O

1	Analysis	O
2	by	O
3	cell	O
4	surface	O
5	immunofluorescence	O
6	showed	O
7	that	O
8	the	O
9	UL28	B
10	gene	I
11	is	O
12	not	O
13	required	O
14	for	O
15	expression	O
16	of	O
17	viral	O
18	glycoproteins	O
19	on	O
20	the	O
21	surface	O
22	of	O
23	infected	O
24	cells	O
25	.	O

1	Furthermore	O
2	,	O
3	a	O
4	mutant	O
5	receptor	O
6	(	O
7	Y977F	O
8	/	O
9	Y989F	O
10	[	O
11	PLC	B
12	gamma	I
13	-	O
14	binding	O
15	sites	O
16	])	O
17	could	O
18	fully	O
19	activate	O
20	Ras	B
21	,	O
22	and	O
23	the	O
24	direct	O
25	activation	O
26	of	O
27	protein	B
28	kinase	I
29	C	I
30	and	O
31	calcium	O
32	mobilization	O
33	had	O
34	almost	O
35	no	O
36	effect	O
37	on	O
38	the	O
39	GDP	O
40	/	O
41	GTP	O
42	state	O
43	of	O
44	Ras	B
45	in	O
46	this	O
47	cell	O
48	line	O
49	.	O

1	Estrogen	O
2	treatment	O
3	in	O
4	high	O
5	doses	O
6	is	O
7	effective	O
8	in	O
9	reducing	O
10	adult	O
11	stature	O
12	in	O
13	constitutionally	O
14	tall	O
15	girls	O
16	.	O

1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	B
10	Tat	I
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O

1	This	O
2	observation	O
3	suggests	O
4	that	O
5	the	O
6	methyl	O
7	-	O
8	directed	O
9	repair	O
10	system	O
11	utilizes	O
12	the	O
13	proximal	O
14	d	O
15	(	O
16	GATC	O
17	)	O
18	sequence	O
19	to	O
20	direct	O
21	correction	O
22	.	O

1	Uracil	B
2	DNA	I
3	glycosylase	I
4	catalyzes	O
5	the	O
6	initial	O
7	step	O
8	in	O
9	the	O
10	repair	O
11	pathway	O
12	that	O
13	removes	O
14	potentially	O
15	mutagenic	O
16	uracil	O
17	from	O
18	duplex	O
19	DNA	O
20	.	O

1	Current	O
2	clinical	O
3	trials	O
4	should	O
5	answer	O
6	the	O
7	question	O
8	of	O
9	which	O
10	of	O
11	the	O
12	therapeutic	O
13	options	O
14	impairs	O
15	quality	O
16	of	O
17	life	O
18	less	O
19	.	O

1	Lithium	O
2	phthalocyanine	O
3	(	O
4	LiPc	O
5	)	O
6	is	O
7	a	O
8	prototype	O
9	of	O
10	another	O
11	generation	O
12	of	O
13	synthetic	O
14	,	O
15	metallic	O
16	-	O
17	organic	O
18	,	O
19	paramagnetic	O
20	crystallites	O
21	that	O
22	appear	O
23	very	O
24	useful	O
25	for	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	electron	O
32	paramagnetic	O
33	resonance	O
34	oximetry	O
35	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	focus	O
7	on	O
8	the	O
9	genetics	O
10	of	O
11	the	O
12	region	O
13	of	O
14	the	O
15	17	B
16	hep	I
17	syn	I
18	gB	I
19	gene	I
20	that	O
21	conferred	O
22	both	O
23	the	O
24	syncytial	O
25	and	O
26	pathogenic	O
27	phenotypes	O
28	to	O
29	17	O
30	syn	O
31	+.	O

1	Recipients	O
2	with	O
3	acute	O
4	leukaemia	O
5	in	O
6	first	O
7	remission	O
8	or	O
9	chronic	O
10	myeloid	O
11	leukaemia	O
12	in	O
13	first	O
14	chronic	O
15	phase	O
16	were	O
17	analysed	O
18	as	O
19	good	O
20	risk	O
21	,	O
22	and	O
23	those	O
24	beyond	O
25	these	O
26	stages	O
27	,	O
28	as	O
29	poor	O
30	risk	O
31	patients	O
32	.	O

1	Elledge	O
2	,	O
3	P	O
4	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	Losses	O
2	during	O
3	the	O
4	complete	O
5	procedure	O
6	are	O
7	corrected	O
8	for	O
9	using	O
10	radioactive	O
11	estrogen	O
12	conjugates	O
13	during	O
14	the	O
15	first	O
16	steps	O
17	and	O
18	later	O
19	by	O
20	adding	O
21	deuterated	O
22	internal	O
23	standards	O
24	of	O
25	all	O
26	compounds	O
27	measured	O
28	(	O
29	matairesinol	O
30	,	O
31	enterodiol	O
32	,	O
33	enterolactone	O
34	,	O
35	daidzein	O
36	,	O
37	O	O
38	-	O
39	desmethylangolensin	O
40	,	O
41	equol	O
42	,	O
43	and	O
44	genistein	O
45	).	O

1	IE2	B
2	-	O
3	IE2	B
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	The	O
2	Sp1	B
3	region	I
4	,	O
5	however	O
6	,	O
7	is	O
8	converted	O
9	to	O
10	a	O
11	functionally	O
12	strong	O
13	TRE	O
14	by	O
15	the	O
16	viral	B
17	tat	I
18	factor	I
19	.	O

1	Precipitation	O
2	using	O
3	GST	B
4	fusion	I
5	proteins	I
6	containing	O
7	Fyn	B
8	SH2	I
9	,	O
10	SH3	B
11	,	O
12	and	O
13	SH2	B
14	/	O
15	SH3	B
16	domains	O
17	revealed	O
18	that	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	bound	O
24	principally	O
25	to	O
26	the	O
27	SH3	B
28	domain	I
29	of	O
30	Fyn	B
31	.	O

1	A	O
2	sheep	O
3	testicular	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	pcDNA1	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	B
35	luteinizing	I
36	hormone	I
37	receptor	I
38	cDNA	I
39	.	O

1	Two	O
2	putative	O
3	Rev	B
4	proteins	I
5	with	O
6	apparent	O
7	molecular	O
8	masses	O
9	of	O
10	18	O
11	and	O
12	16	O
13	kDa	O
14	were	O
15	expressed	O
16	by	O
17	p2	B
18	/	I
19	2	I
20	and	O
21	p176	B
22	,	O
23	while	O
24	p20	B
25	expressed	O
26	only	O
27	a	O
28	16	O
29	-	O
30	kDa	O
31	species	O
32	.	O

1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O

1	The	O
2	ability	O
3	of	O
4	spt2	B
5	mutations	I
6	to	O
7	suppress	O
8	the	O
9	transcriptional	O
10	interference	O
11	caused	O
12	by	O
13	the	O
14	delta	B
15	promoter	I
16	insertion	I
17	his	I
18	-	I
19	4	I
20	-	I
21	912	I
22	delta	I
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	B
29	-	I
30	type	I
31	HIS4	I
32	mRNA	I
33	levels	O
34	.	O

1	Nuclear	O
2	localization	O
3	and	O
4	protein	O
5	sequence	O
6	similarities	O
7	suggested	O
8	that	O
9	the	O
10	SPT2	B
11	/	O
12	SIN1	B
13	protein	O
14	may	O
15	be	O
16	related	O
17	to	O
18	the	O
19	nonhistone	B
20	chromosomal	I
21	protein	I
22	HMG1	I
23	.	O

1	The	O
2	conserved	O
3	ninth	O
4	C	O
5	-	O
6	terminal	O
7	heptad	O
8	in	O
9	thyroid	O
10	hormone	O
11	and	O
12	retinoic	B
13	acid	I
14	receptors	I
15	mediates	O
16	diverse	O
17	responses	O
18	by	O
19	affecting	O
20	heterodimer	O
21	but	O
22	not	O
23	homodimer	O
24	formation	O
25	.	O

1	Genetic	O
2	interactions	O
3	between	O
4	BCK2	B
5	and	O
6	other	O
7	pathway	O
8	components	O
9	suggested	O
10	that	O
11	BCK2	B
12	functions	O
13	on	O
14	a	O
15	common	O
16	pathway	O
17	branch	O
18	with	O
19	PPZ1	B
20	and	O
21	PPZ2	B
22	.	O

1	Steroidogenic	B
2	factor	I
3	1	I
4	,	O
5	an	O
6	orphan	B
7	nuclear	I
8	receptor	I
9	,	O
10	regulates	O
11	the	O
12	expression	O
13	of	O
14	the	O
15	rat	B
16	aromatase	I
17	gene	I
18	in	O
19	gonadal	O
20	tissues	O
21	.	O

1	To	O
2	study	O
3	the	O
4	functional	O
5	differences	O
6	between	O
7	cutaneous	O
8	HPV5	O
9	and	O
10	HPV8	O
11	E7s	B
12	and	O
13	genital	B
14	HPV16	I
15	E7	I
16	,	O
17	we	O
18	cloned	O
19	each	O
20	of	O
21	the	O
22	E7	B
23	open	O
24	reading	O
25	frames	O
26	and	O
27	tested	O
28	their	O
29	immortalizing	O
30	and	O
31	transforming	O
32	activities	O
33	,	O
34	the	O
35	binding	O
36	ability	O
37	of	O
38	their	O
39	products	O
40	with	O
41	retinoblastoma	B
42	protein	I
43	(	O
44	RB	B
45	)	O
46	and	O
47	their	O
48	complementation	O
49	activity	O
50	of	O
51	a	O
52	RB	B
53	-	I
54	nonbinding	I
55	adenovirus	I
56	E1A	I
57	mutant	I
58	.	O

1	The	O
2	rhaB	B
3	transcription	I
4	start	I
5	site	I
6	was	O
7	mapped	O
8	to	O
9	-	O
10	24	O
11	relative	O
12	to	O
13	the	O
14	start	O
15	of	O
16	translation	O
17	.	O

1	Several	O
2	lines	O
3	of	O
4	evidence	O
5	demonstrate	O
6	that	O
7	this	O
8	growth	O
9	inhibition	O
10	requires	O
11	active	O
12	PKA	B
13	subunits	I
14	and	O
15	cAMP	O
16	:	O
17	(	O
18	i	O
19	)	O
20	this	O
21	phenotype	O
22	is	O
23	dependent	O
24	on	O
25	cAMP	O
26	since	O
27	it	O
28	is	O
29	not	O
30	seen	O
31	in	O
32	a	O
33	strain	O
34	lacking	O
35	adenylyl	B
36	cyclase	I
37	activity	O
38	,	O
39	but	O
40	the	O
41	growth	O
42	rate	O
43	of	O
44	these	O
45	transformants	O
46	is	O
47	slower	O
48	when	O
49	exogenous	O
50	cAMP	O
51	is	O
52	added	O
53	;	O
54	(	O
55	ii	O
56	)	O
57	normal	O
58	growth	O
59	occurs	O
60	when	O
61	wild	O
62	-	O
63	type	O
64	RI	B
65	cDNA	O
66	is	O
67	replaced	O
68	by	O
69	a	O
70	mutant	B
71	RI	I
72	cDNA	I
73	encoding	O
74	a	O
75	RI	B
76	protein	I
77	with	O
78	reduced	O
79	cAMP	O
80	binding	O
81	;	O
82	and	O
83	(	O
84	iii	O
85	)	O
86	the	O
87	growth	O
88	-	O
89	inhibited	O
90	phenotype	O
91	of	O
92	the	O
93	transformed	O
94	BL21	O
95	(	O
96	DE3	O
97	)	O
98	cells	O
99	requires	O
100	soluble	O
101	,	O
102	active	O
103	C	B
104	alpha	I
105	protein	I
106	.	O

1	Liu	O
2	,	O
3	B	O
4	.	O

1	BCR	B
2	-	O
3	ABL	B
4	and	O
5	v	B
6	-	I
7	abl	I
8	oncogenes	I
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	thymic	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	subsets	O
19	.	O

1	These	O
2	experiments	O
3	confirm	O
4	that	O
5	the	O
6	6	O
7	-	O
8	S	O
9	liganded	O
10	form	O
11	of	O
12	the	O
13	receptor	O
14	identified	O
15	in	O
16	nuclear	O
17	extracts	O
18	of	O
19	cells	O
20	treated	O
21	with	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	(	O
36	TCDD	O
37	)	O
38	contains	O
39	the	O
40	Ah	B
41	receptor	I
42	protein	I
43	and	O
44	ARNT	B
45	but	O
46	not	O
47	the	O
48	90	B
49	-	I
50	kDa	I
51	heat	I
52	shock	I
53	protein	I
54	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	This	O
2	negative	O
3	element	O
4	may	O
5	,	O
6	at	O
7	least	O
8	in	O
9	part	O
10	,	O
11	be	O
12	responsible	O
13	for	O
14	the	O
15	cell	O
16	type	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	the	O
22	DGK	B
23	gene	I
24	.	O

1	Regulated	O
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	B
13	corticotropin	I
14	-	I
15	releasing	I
16	hormone	I
17	gene	I
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	O
24	(	O
25	A	O
26	gamma	O
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	O
39	gamma	B
40	-	I
41	globin	I
42	mRNA	O
43	.	O

1	INTERVENTIONS	O
2	--	O
3	Patients	O
4	allocated	O
5	to	O
6	treatment	O
7	with	O
8	levodopa	B
9	/	I
10	dopa	I
11	decarboxylase	I
12	inhibitor	O
13	alone	O
14	(	O
15	arm	O
16	1	O
17	),	O
18	levodopa	B
19	/	I
20	decarboxylase	I
21	inhibitor	O
22	/	O
23	selegiline	O
24	in	O
25	combination	O
26	(	O
27	arm	O
28	2	O
29	),	O
30	or	O
31	bromocriptine	O
32	(	O
33	arm	O
34	3	O
35	).	O

1	It	O
2	contains	O
3	three	O
4	putative	O
5	binding	O
6	sites	O
7	for	O
8	transcription	B
9	factor	I
10	Sp1	I
11	as	O
12	well	O
13	as	O
14	several	O
15	short	O
16	sequences	O
17	that	O
18	are	O
19	similar	O
20	to	O
21	known	O
22	cis	O
23	-	O
24	acting	O
25	enhancers	O
26	or	O
27	binding	O
28	sites	O
29	for	O
30	transcription	O
31	factors	O
32	.	O

1	French	O
2	bean	O
3	contains	O
4	a	O
5	small	O
6	family	O
7	of	O
8	genes	B
9	encoding	I
10	PAL	I
11	and	O
12	two	O
13	of	O
14	these	O
15	genes	O
16	,	O
17	PAL2	B
18	and	O
19	PAL3	B
20	,	O
21	have	O
22	been	O
23	shown	O
24	to	O
25	be	O
26	differentially	O
27	expressed	O
28	at	O
29	the	O
30	mRNA	O
31	level	O
32	in	O
33	bean	O
34	tissues	O
35	.	O

1	Plasma	O
2	thromboxane	O
3	B2	O
4	levels	O
5	in	O
6	the	O
7	older	O
8	group	O
9	were	O
10	about	O
11	double	O
12	those	O
13	in	O
14	younger	O
15	piglets	O
16	.	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	The	O
2	human	B
3	insulin	I
4	-	I
5	like	I
6	growth	I
7	factor	I
8	II	I
9	(	O
10	IGF	B
11	-	I
12	II	I
13	)	O
14	gene	O
15	contains	O
16	four	O
17	promoters	O
18	(	O
19	P1	O
20	,	O
21	P2	O
22	,	O
23	P3	O
24	and	O
25	P4	O
26	).	O

1	Moreover	O
2	,	O
3	in	O
4	transient	O
5	transfection	O
6	assays	O
7	,	O
8	PU	B
9	.	I
10	1	I
11	alone	O
12	activated	O
13	reporter	O
14	constructs	O
15	containing	O
16	the	O
17	JB	O
18	cis	O
19	-	O
20	element	O
21	,	O
22	and	O
23	the	O
24	activation	O
25	was	O
26	shown	O
27	to	O
28	be	O
29	dependent	O
30	on	O
31	a	O
32	glutamine	O
33	-	O
34	rich	O
35	sequence	O
36	in	O
37	the	O
38	amino	O
39	-	O
40	terminal	O
41	portion	O
42	of	O
43	PU	B
44	.	I
45	1	I
46	.	O

1	Army	O
2	veterans	O
3	given	O
4	yellow	O
5	fever	O
6	vaccine	O
7	contaminated	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	1942	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	veterans	O
27	with	O
28	hepatocellular	O
29	carcinoma	O
30	in	O
31	Veterans	O
32	Affairs	O
33	hospitals	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	receipt	O
41	of	O
42	contaminated	O
43	vaccine	O
44	in	O
45	1942	O
46	.	O

1	They	O
2	were	O
3	found	O
4	to	O
5	be	O
6	seropositive	O
7	for	O
8	antibodies	O
9	to	O
10	hepatitis	O
11	C	O
12	virus	O
13	by	O
14	second	O
15	-	O
16	generation	O
17	testing	O
18	(	O
19	RIBA	O
20	2	O
21	,	O
22	Ortho	O
23	Diagnostic	O
24	Systems	O
25	Inc	O
26	,	O
27	Westwood	O
28	,	O
29	MA	O
30	).	O

1	Defects	O
2	of	O
3	fibrillin	B
4	(	O
5	FBN1	B
6	),	O
7	a	O
8	glycoprotein	O
9	component	O
10	of	O
11	the	O
12	extracellular	O
13	microfibril	O
14	,	O
15	cause	O
16	Marfan	O
17	syndrome	O
18	.	O

1	When	O
2	introduced	O
3	into	O
4	recJ	B
5	+	I
6	strains	O
7	,	O
8	srjA	B
9	mutations	O
10	conferred	O
11	hyperrecombinational	O
12	and	O
13	hyper	B
14	-	I
15	UVr	I
16	phenotypes	O
17	.	O

1	Distinguishing	O
2	roles	O
3	of	O
4	the	O
5	membrane	O
6	-	O
7	cytoskeleton	O
8	and	O
9	cadherin	B
10	mediated	O
11	cell	O
12	-	O
13	cell	O
14	adhesion	O
15	in	O
16	generating	O
17	different	O
18	Na	B
19	+,	I
20	K	I
21	(+)-	I
22	ATPase	I
23	distributions	O
24	in	O
25	polarized	O
26	epithelia	O
27	.	O

1	Neonatal	O
2	lupus	O
3	erythematosus	O
4	is	O
5	most	O
6	often	O
7	associated	O
8	with	O
9	autoantibodies	O
10	against	O
11	Ro	B
12	and	O
13	La	B
14	antigens	O
15	.	O

1	Genetic	O
2	abnormalities	O
3	that	O
4	could	O
5	lead	O
6	to	O
7	mutagenesis	O
8	include	O
9	chromosomal	O
10	abnormalities	O
11	and	O
12	single	O
13	-	O
14	gene	O
15	mutations	O
16	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	Continued	O
2	absorption	O
3	of	O
4	amino	O
5	acids	O
6	by	O
7	the	O
8	NBB	O
9	carrier	O
10	(	O
11	for	O
12	neutral	O
13	amino	O
14	acids	O
15	),	O
16	the	O
17	Y	O
18	+	O
19	system	O
20	(	O
21	for	O
22	dibasic	O
23	amino	O
24	acids	O
25	),	O
26	and	O
27	the	O
28	PHE	O
29	carrier	O
30	were	O
31	operative	O
32	even	O
33	during	O
34	the	O
35	actively	O
36	purging	O
37	stage	O
38	of	O
39	watery	O
40	diarrhoea	O
41	due	O
42	to	O
43	cholera	O
44	.	O

1	1	O
2	)	O
3	CFDN	O
4	,	O
5	AMPC	O
6	and	O
7	MNZ	O
8	showed	O
9	a	O
10	potent	O
11	antimicrobial	O
12	activity	O
13	against	O
14	H	O
15	.	O
16	pylori	O
17	,	O
18	and	O
19	especially	O
20	,	O
21	AMPC	O
22	showed	O
23	a	O
24	marked	O
25	bactericidal	O
26	activity	O
27	in	O
28	a	O
29	short	O
30	time	O
31	.	O

1	Creutzfeldt	O
2	-	O
3	Jakob	O
4	disease	O
5	and	O
6	lyophilised	O
7	dura	O
8	mater	O
9	grafts	O
10	:	O
11	report	O
12	of	O
13	two	O
14	cases	O
15	.	O

1	A	O
2	high	O
3	mean	O
4	intensity	O
5	of	O
6	CLTPA	O
7	(	O
8	standardized	O
9	multivariate	O
10	regression	O
11	coefficient	O
12	beta	O
13	-	O
14	0	O
15	.	O
16	059	O
17	,	O
18	p	O
19	=	O
20	0	O
21	.	O
22	020	O
23	)	O
24	and	O
25	a	O
26	high	O
27	maximal	O
28	oxygen	O
29	uptake	O
30	(	O
31	beta	O
32	-	O
33	0	O
34	.	O
35	163	O
36	,	O
37	p	O
38	<	O
39	0	O
40	.	O
41	001	O
42	)	O
43	were	O
44	associated	O
45	with	O
46	reduced	O
47	plasma	B
48	fibrinogen	I
49	when	O
50	adjusting	O
51	for	O
52	the	O
53	strongest	O
54	covariates	O
55	.	O

1	What	O
2	young	O
3	people	O
4	think	O
5	and	O
6	do	O
7	when	O
8	the	O
9	option	O
10	for	O
11	cystic	O
12	fibrosis	O
13	carrier	O
14	testing	O
15	is	O
16	available	O
17	.	O

1	A	O
2	patient	O
3	matches	O
4	a	O
5	PIC	O
6	patient	O
7	if	O
8	both	O
9	have	O
10	the	O
11	same	O
12	mechanism	O
13	of	O
14	injury	O
15	,	O
16	the	O
17	same	O
18	coding	O
19	of	O
20	Revised	O
21	Trauma	O
22	Score	O
23	variables	O
24	(	O
25	Glascow	O
26	Coma	O
27	Scale	O
28	score	O
29	,	O
30	systolic	O
31	blood	O
32	pressure	O
33	,	O
34	respiratory	O
35	rate	O
36	),	O
37	the	O
38	same	O
39	coded	O
40	age	O
41	per	O
42	A	O
43	Severity	O
44	Characterization	O
45	of	O
46	Trauma	O
47	)	O
48	(	O
49	ASCOT	O
50	),	O
51	and	O
52	if	O
53	they	O
54	differ	O
55	by	O
56	no	O
57	more	O
58	than	O
59	0	O
60	.	O
61	5	O
62	for	O
63	A	O
64	,	O
65	B	O
66	,	O
67	and	O
68	C	O
69	(	O
70	the	O
71	ASCOT	O
72	components	O
73	for	O
74	serious	O
75	injuries	O
76	).	O

1	Skin	O
2	and	O
3	bowel	O
4	TPO2	O
5	varied	O
6	with	O
7	DO2	O
8	and	O
9	each	O
10	other	O
11	(	O
12	P	O
13	<	O
14	0	O
15	.	O
16	05	O
17	).	O

1	A	O
2	region	O
3	approximately	O
4	100	O
5	bp	O
6	upstream	O
7	from	O
8	the	O
9	transcription	O
10	start	O
11	point	O
12	of	O
13	virB	B
14	was	O
15	identified	O
16	as	O
17	being	O
18	necessary	O
19	for	O
20	full	O
21	activation	O
22	of	O
23	this	O
24	promoter	O
25	by	O
26	VirF	B
27	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	cosmid	O
6	containing	O
7	DNA	O
8	that	O
9	corresponds	O
10	to	O
11	the	O
12	site	O
13	of	O
14	transposon	O
15	insertion	O
16	in	O
17	257DH4	O
18	and	O
19	have	O
20	localized	O
21	Tn5	B
22	on	O
23	an	O
24	8	B
25	.	I
26	0	I
27	kb	I
28	EcoRI	I
29	fragment	I
30	.	O

1	The	O
2	scr	B
3	regulon	I
4	of	O
5	pUR400	O
6	and	O
7	the	O
8	chromosomally	B
9	encoded	I
10	scr	I
11	regulon	I
12	of	I
13	Klebsiella	I
14	pneumoniae	I
15	KAY2026	I
16	are	O
17	both	O
18	negatively	O
19	controlled	O
20	by	O
21	a	O
22	specific	O
23	repressor	O
24	(	O
25	ScrR	B
26	).	O

1	Although	O
2	the	O
3	molecular	O
4	mechanisms	O
5	involved	O
6	in	O
7	this	O
8	regulation	O
9	are	O
10	currently	O
11	being	O
12	elucidated	O
13	,	O
14	very	O
15	little	O
16	is	O
17	known	O
18	about	O
19	the	O
20	trans	O
21	-	O
22	acting	O
23	factors	O
24	that	O
25	allow	O
26	expression	O
27	of	O
28	the	O
29	nitrate	B
30	and	I
31	nitrite	I
32	reductase	I
33	genes	I
34	which	O
35	code	O
36	for	O
37	the	O
38	first	O
39	enzymes	O
40	in	O
41	the	O
42	pathway	O
43	.	O

1	The	O
2	Ntl1	B
3	gene	I
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O

1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	I
10	a	I
11	and	I
12	b	I
13	,	O
14	but	O
15	not	O
16	c	O
17	and	O
18	d	O
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	B
32	-	I
33	domain	I
34	recognition	I
35	sequence	I
36	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	third	O
6	of	O
7	the	O
8	protein	O
9	contains	O
10	a	O
11	high	B
12	-	I
13	mobility	I
14	-	I
15	group	I
16	motif	I
17	characteristic	O
18	of	O
19	DNA	O
20	-	O
21	binding	O
22	proteins	O
23	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	ability	O
6	of	O
7	various	O
8	NF	B
9	-	I
10	kappa	I
11	B	I
12	subunits	I
13	to	O
14	bind	O
15	to	O
16	,	O
17	and	O
18	activate	O
19	transcription	O
20	from	O
21	,	O
22	the	O
23	IL	B
24	-	I
25	8	I
26	promoter	I
27	.	O

1	When	O
2	multiple	O
3	copies	O
4	of	O
5	the	O
6	IL	B
7	-	I
8	1	I
9	beta	I
10	NF	I
11	-	I
12	kappa	I
13	B	I
14	site	I
15	were	O
16	linked	O
17	to	O
18	an	O
19	enhancerless	O
20	simian	B
21	virus	I
22	40	I
23	promoter	I
24	,	O
25	this	O
26	element	O
27	was	O
28	able	O
29	to	O
30	mediate	O
31	phorbol	O
32	ester	O
33	-	O
34	or	O
35	lipopolysaccharide	O
36	-	O
37	inducible	O
38	gene	O
39	expression	O
40	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	3	O
6	'-	O
7	end	O
8	-	O
9	adjacent	O
10	sequence	O
11	CA	O
12	(	O
13	N	O
14	)	O
15	3	O
16	-	O
17	10AGTNNAA	O
18	,	O
19	conserved	O
20	in	O
21	plant	O
22	Pol	B
23	II	I
24	-	O
25	specific	O
26	U	B
27	snRNA	I
28	genes	I
29	,	O
30	is	O
31	essential	O
32	for	O
33	the	O
34	3	O
35	'-	O
36	end	O
37	formation	O
38	of	O
39	U2	B
40	transcripts	I
41	and	O
42	,	O
43	similar	O
44	to	O
45	the	O
46	vertebrate	O
47	3	O
48	'	O
49	box	O
50	,	O
51	is	O
52	highly	O
53	tolerant	O
54	to	O
55	mutation	O
56	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	Rb	B
6	protein	I
7	is	O
8	interacting	O
9	with	O
10	some	O
11	component	O
12	(	O
13	s	O
14	)	O
15	of	O
16	the	O
17	cell	O
18	cycle	O
19	-	O
20	regulatory	O
21	machinery	O
22	during	O
23	G2	O
24	phase	O
25	.	O

1	MDBP	B
2	from	O
3	HeLa	O
4	and	O
5	Raji	O
6	cells	O
7	formed	O
8	DNA	O
9	-	O
10	protein	O
11	complexes	O
12	with	O
13	X	O
14	-	O
15	box	O
16	oligonucleotides	O
17	that	O
18	coelectrophoresed	O
19	with	O
20	those	O
21	containing	O
22	standard	O
23	MDBP	B
24	sites	I
25	.	O

1	Transgenic	O
2	mice	O
3	harboring	O
4	the	O
5	rat	O
6	TnI	B
7	-	O
8	CAT	B
9	fusion	O
10	gene	O
11	expressed	O
12	the	O
13	reporter	O
14	specifically	O
15	in	O
16	the	O
17	skeletal	O
18	muscle	O
19	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	169	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	fields	O
17	,	O
18	and	O
19	132	O
20	glaucomatous	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	qualitative	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	optic	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O

1	Consistent	O
2	with	O
3	the	O
4	hypothesis	O
5	that	O
6	it	O
7	acts	O
8	as	O
9	transcriptional	O
10	regulator	O
11	,	O
12	wild	B
13	-	I
14	type	I
15	p53	I
16	protein	I
17	binds	O
18	DNA	O
19	and	O
20	activates	O
21	transcription	O
22	of	O
23	several	O
24	promoters	O
25	.	O

1	The	O
2	ADP	B
3	-	I
4	ribosylation	I
5	factor	I
6	(	O
7	ARF	B
8	)	O
9	family	O
10	is	O
11	one	O
12	of	O
13	four	O
14	subfamilies	O
15	of	O
16	the	O
17	RAS	B
18	superfamily	I
19	of	O
20	low	B
21	molecular	I
22	weight	I
23	GTP	I
24	-	I
25	binding	I
26	proteins	I
27	(	O
28	G	B
29	proteins	I
30	).	O

1	The	O
2	E1	B
3	gene	I
4	is	O
5	located	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	gene	O
13	for	O
14	RCC1	B
15	,	O
16	a	O
17	protein	O
18	that	O
19	regulates	O
20	onset	O
21	of	O
22	mitosis	O
23	.	O

1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	and	O
6	chromosome	O
7	mapping	O
8	showed	O
9	that	O
10	GPRK6	B
11	hybridizes	O
12	to	O
13	two	O
14	closely	O
15	related	O
16	genes	O
17	located	O
18	on	O
19	chromosomes	O
20	5	O
21	and	O
22	13	O
23	and	O
24	are	O
25	,	O
26	therefore	O
27	,	O
28	distinct	O
29	from	O
30	the	O
31	GPRK	B
32	located	O
33	near	O
34	the	O
35	Huntington	B
36	disease	I
37	locus	I
38	on	O
39	chromosome	O
40	4	O
41	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	B
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	B
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	These	O
2	CTD	B
3	kinases	I
4	,	O
5	designated	O
6	CTDK1	B
7	and	O
8	CTDK2	B
9	,	O
10	are	O
11	fractionated	O
12	by	O
13	chromatography	O
14	on	O
15	Mono	O
16	Q	O
17	.	O

1	Instead	O
2	,	O
3	mRNA	O
4	of	O
5	2	O
6	.	O
7	0	O
8	and	O
9	2	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	detected	O
15	in	O
16	varying	O
17	abundance	O
18	.	O

1	Previously	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	51	O
7	-	O
8	bp	O
9	promoter	O
10	fragment	O
11	,	O
12	oligo31	O
13	/	O
14	32	O
15	,	O
16	which	O
17	conferred	O
18	heat	O
19	shock	O
20	inducibility	O
21	on	O
22	the	O
23	heterologous	O
24	CYC1	B
25	-	O
26	lacZ	B
27	reporter	O
28	gene	O
29	in	O
30	S	O
31	.	O
32	cerevisiae	O
33	(	O
34	N	O
35	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	HIR1	B
6	gene	I
7	predicts	O
8	an	O
9	88	O
10	-	O
11	kDa	O
12	protein	O
13	with	O
14	three	O
15	repeats	O
16	of	O
17	a	O
18	motif	O
19	found	O
20	in	O
21	the	O
22	G	B
23	beta	I
24	subunit	I
25	of	O
26	retinal	B
27	transducin	I
28	and	O
29	in	O
30	a	O
31	yeast	O
32	transcriptional	O
33	repressor	O
34	,	O
35	Tup1	B
36	.	O

1	All	O
2	of	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	replication	O
8	of	O
9	UV	O
10	-	O
11	damaged	O
12	templates	O
13	occurs	O
14	in	O
15	vitro	O
16	as	O
17	it	O
18	does	O
19	in	O
20	vivo	O
21	and	O
22	that	O
23	this	O
24	replication	O
25	results	O
26	in	O
27	mutation	O
28	fixation	O
29	.	O

1	To	O
2	identify	O
3	factors	O
4	that	O
5	may	O
6	modify	O
7	the	O
8	heterosexual	O
9	transmission	O
10	of	O
11	human	O
12	T	O
13	cell	O
14	leukemia	O
15	/	O
16	lymphoma	O
17	virus	O
18	type	O
19	I	O
20	(	O
21	HTLV	O
22	-	O
23	I	O
24	),	O
25	534	O
26	married	O
27	couples	O
28	enrolled	O
29	in	O
30	the	O
31	Miyazaki	O
32	Cohort	O
33	Study	O
34	between	O
35	November	O
36	1984	O
37	and	O
38	April	O
39	1989	O
40	were	O
41	studied	O
42	:	O
43	95	O
44	husband	O
45	HTLV	O
46	-	O
47	I	O
48	-	O
49	seropositive	O
50	(	O
51	H	O
52	+)/	O
53	wife	O
54	seropositive	O
55	(	O
56	W	O
57	+),	O
58	33	O
59	H	O
60	+/	O
61	W	O
62	-,	O
63	64	O
64	H	O
65	-/	O
66	W	O
67	+,	O
68	and	O
69	342	O
70	H	O
71	-/	O
72	W	O
73	-.	O

1	Biol	O
2	.	O

1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	B
8	repair	I
9	enzyme	I
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O

1	L	O
2	.,	O
3	Stange	O
4	,	O
5	G	O
6	.,	O
7	Markovich	O
8	,	O
9	D	O
10	.,	O
11	Biber	O
12	,	O
13	J	O
14	.,	O
15	Testar	O
16	,	O
17	X	O
18	.,	O
19	Zorzano	O
20	,	O
21	A	O
22	.,	O
23	Palacin	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	Murer	O
29	,	O
30	H	O
31	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	gene	O
7	predicts	O
8	a	O
9	polypeptide	O
10	of	O
11	215	O
12	amino	O
13	acids	O
14	(	O
15	25	O
16	.	O
17	2	O
18	kDa	O
19	)	O
20	with	O
21	two	O
22	putative	O
23	membrane	O
24	-	O
25	spanning	O
26	domains	O
27	.	O

1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O

1	They	O
2	were	O
3	called	O
4	PACE4	B
5	and	O
6	PC4	B
7	.	O

1	265	O
2	,	O
3	1102	O
4	-	O
5	1110	O
6	).	O

1	Both	O
2	fusion	O
3	proteins	O
4	form	O
5	stable	O
6	specific	O
7	complexes	O
8	with	O
9	a	O
10	short	O
11	DNA	O
12	duplex	O
13	harboring	O
14	the	O
15	CTGT	O
16	(	O
17	at	O
18	)	O
19	4ACAG	O
20	consensus	O
21	sequence	O
22	of	O
23	the	O
24	LexA	B
25	repressor	I
26	.	O

1	Ten	O
2	selenocysteine	O
3	residues	O
4	(	O
5	deduced	O
6	)	O
7	are	O
8	present	O
9	.	O

1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	B
5	S	I
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O

1	During	O
2	the	O
3	past	O
4	decade	O
5	,	O
6	different	O
7	types	O
8	of	O
9	endogenous	O
10	retroviral	O
11	sequences	O
12	have	O
13	been	O
14	defined	O
15	in	O
16	the	O
17	human	O
18	genome	O
19	usually	O
20	by	O
21	low	O
22	stringency	O
23	hybridization	O
24	employing	O
25	DNA	O
26	probes	O
27	of	O
28	evolutionary	O
29	conserved	O
30	animal	O
31	retrovirus	O
32	genes	O
33	.	O

1	As	O
2	the	O
3	components	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	at	O
9	least	O
10	five	O
11	TRBPs	B
12	(	O
13	p30	B
14	,	O
15	p37	B
16	,	O
17	p46	B
18	,	O
19	p50	B
20	,	O
21	and	O
22	p56	B
23	)	O
24	showing	O
25	specific	O
26	binding	O
27	to	O
28	the	O
29	TAR	O
30	RNA	O
31	were	O
32	detected	O
33	in	O
34	the	O
35	uv	O
36	cross	O
37	-	O
38	linking	O
39	assay	O
40	.	O

1	The	O
2	obvious	O
3	functional	O
4	necessity	O
5	for	O
6	editing	O
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	O
12	formation	O
13	of	O
14	translatable	O
15	mRNAs	O
16	.	O

1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	investigating	O
8	pathophysiologically	O
9	significant	O
10	issues	O
11	in	O
12	denervating	O
13	diseases	O
14	is	O
15	illustrated	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O

1	An	O
2	extensive	O
3	inverted	O
4	repeat	O
5	is	O
6	present	O
7	3	O
8	'	O
9	of	O
10	rpeA	B
11	;	O
12	inverted	O
13	repeats	O
14	are	O
15	found	O
16	downstream	O
17	of	O
18	all	O
19	PE	B
20	operons	I
21	sequenced	O
22	to	O
23	date	O
24	,	O
25	although	O
26	the	O
27	sequence	O
28	is	O
29	not	O
30	conserved	O
31	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	cytoplasmic	B
6	tyrosine	I
7	kinase	I
8	,	O
9	termed	O
10	BPK	B
11	(	O
12	B	B
13	cell	I
14	progenitor	I
15	kinase	I
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	all	O
22	stages	O
23	of	O
24	the	O
25	B	O
26	lineage	O
27	and	O
28	in	O
29	myeloid	O
30	cells	O
31	.	O

1	Large	O
2	differences	O
3	between	O
4	the	O
5	groups	O
6	were	O
7	not	O
8	observed	O
9	in	O
10	HA	B
11	-	I
12	synthesizing	I
13	enzyme	I
14	activity	O
15	,	O
16	but	O
17	degradative	O
18	enzyme	O
19	activity	O
20	was	O
21	much	O
22	higher	O
23	in	O
24	aspirin	O
25	-	O
26	induced	O
27	asthma	O
28	-	O
29	related	O
30	polyps	O
31	than	O
32	in	O
33	other	O
34	types	O
35	of	O
36	nasal	O
37	polyps	O
38	tested	O
39	.	O

1	In	O
2	the	O
3	multivariate	O
4	analysis	O
5	,	O
6	six	O
7	variables	O
8	were	O
9	independently	O
10	correlated	O
11	with	O
12	survival	O
13	:	O
14	blood	O
15	urea	O
16	nitrogen	O
17	level	O
18	,	O
19	serum	B
20	aspartate	I
21	aminotransferase	I
22	level	O
23	,	O
24	community	O
25	-	O
26	acquired	O
27	vs	O
28	.	O
29	hospital	O
30	-	O
31	acquired	O
32	peritonitis	O
33	,	O
34	age	O
35	,	O
36	Child	O
37	-	O
38	Pugh	O
39	score	O
40	and	O
41	ileus	O
42	.	O

1	Localization	O
2	of	O
3	the	O
4	intronless	O
5	gene	O
6	coding	O
7	for	O
8	calmodulin	B
9	-	I
10	like	I
11	protein	I
12	CLP	I
13	to	O
14	human	O
15	chromosome	O
16	10p13	O
17	-	O
18	ter	O
19	.	O

1	In	O
2	wandering	O
3	stage	O
4	larvae	O
5	,	O
6	the	O
7	OBP	B
8	transcript	I
9	appeared	O
10	to	O
11	be	O
12	at	O
13	least	O
14	250	O
15	-	O
16	fold	O
17	less	O
18	abundant	O
19	than	O
20	ribosomal	O
21	RNA	O
22	.	O

1	One	O
2	such	O
3	mutant	O
4	also	O
5	affects	O
6	the	O
7	overlapping	O
8	-	O
9	10	O
10	hexamer	O
11	of	O
12	PR	O
13	and	O
14	results	O
15	in	O
16	reduced	O
17	occupancy	O
18	by	O
19	both	O
20	MerR	B
21	and	O
22	RNA	B
23	polymerase	I
24	,	O
25	likely	O
26	as	O
27	a	O
28	result	O
29	of	O
30	inefficient	O
31	transcriptional	O
32	initiation	O
33	of	O
34	merR	B
35	mRNA	I
36	.	O

1	However	O
2	,	O
3	L	B
4	-	I
5	plastin	I
6	has	O
7	been	O
8	found	O
9	in	O
10	many	O
11	types	O
12	of	O
13	malignant	O
14	human	O
15	cells	O
16	of	O
17	non	O
18	-	O
19	hemopoietic	O
20	origin	O
21	suggesting	O
22	that	O
23	its	O
24	expression	O
25	is	O
26	induced	O
27	accompanying	O
28	tumorigenesis	O
29	in	O
30	solid	O
31	tissues	O
32	.	O

1	Finally	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	fimbrin	B
8	is	O
9	a	O
10	third	O
11	distinct	O
12	plastin	B
13	isoform	I
14	which	O
15	is	O
16	specifically	O
17	expressed	O
18	at	O
19	high	O
20	levels	O
21	in	O
22	the	O
23	small	O
24	intestine	O
25	.	O

1	This	O
2	promoter	O
3	could	O
4	direct	O
5	the	O
6	constitutive	O
7	expression	O
8	of	O
9	the	O
10	reporter	O
11	beta	B
12	-	I
13	galactosidase	I
14	at	O
15	high	O
16	frequency	O
17	in	O
18	transfected	O
19	colonies	O
20	of	O
21	transformed	O
22	cells	O
23	that	O
24	express	O
25	L	B
26	-	I
27	plastin	I
28	constitutively	O
29	;	O
30	by	O
31	contrast	O
32	,	O
33	this	O
34	promoter	O
35	was	O
36	virtually	O
37	inactive	O
38	in	O
39	transfected	O
40	colonies	O
41	of	O
42	normal	O
43	fibroblasts	O
44	and	O
45	it	O
46	exhibited	O
47	a	O
48	low	O
49	frequency	O
50	of	O
51	constitutive	O
52	activation	O
53	in	O
54	transfected	O
55	colonies	O
56	of	O
57	in	O
58	vitro	O
59	SV40	O
60	-	O
61	transformed	O
62	fibroblasts	O
63	which	O
64	did	O
65	not	O
66	exhibit	O
67	L	B
68	-	I
69	plastin	I
70	expression	O
71	.	O

1	The	O
2	half	O
3	-	O
4	life	O
5	of	O
6	the	O
7	serum	O
8	-	O
9	induced	O
10	CBP	B
11	/	O
12	tk	B
13	binding	O
14	activity	O
15	was	O
16	estimated	O
17	to	O
18	be	O
19	less	O
20	than	O
21	1	O
22	h	O
23	.(	O
24	ABSTRACT	O
25	TRUNCATED	O
26	AT	O
27	400	O
28	WORDS	O
29	)	O

1	The	O
2	DNase	B
3	I	I
4	footprint	O
5	extended	O
6	5	O
7	'	O
8	in	O
9	the	O
10	silencer	O
11	region	O
12	to	O
13	include	O
14	an	O
15	inverted	O
16	repeat	O
17	of	O
18	a	O
19	six	O
20	-	O
21	nucleotide	O
22	motif	O
23	(	O
24	epsilon	O
25	-	O
26	267	O
27	to	O
28	-	O
29	278	O
30	bp	O
31	)	O
32	which	O
33	shares	O
34	5	O
35	of	O
36	6	O
37	bases	O
38	with	O
39	the	O
40	GATA	B
41	-	I
42	1	I
43	consensus	I
44	sequence	I
45	.	O

1	Furthermore	O
2	,	O
3	competitor	O
4	containing	O
5	the	O
6	YY1	B
7	consensus	I
8	sequence	I
9	competed	O
10	for	O
11	protein	B
12	B	I
13	binding	O
14	,	O
15	whereas	O
16	competitor	O
17	containing	O
18	a	O
19	perfect	O
20	yeast	B
21	ABF	I
22	-	I
23	1	I
24	consensus	I
25	sequence	I
26	did	O
27	not	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O

1	The	O
2	gene	O
3	includes	O
4	three	O
5	exons	O
6	and	O
7	two	O
8	introns	O
9	within	O
10	1	O
11	.	O
12	6	O
13	kilobases	O
14	of	O
15	DNA	O
16	,	O
17	and	O
18	the	O
19	entire	O
20	open	O
21	reading	O
22	frame	O
23	for	O
24	glycoprotein	B
25	IX	I
26	is	O
27	included	O
28	within	O
29	the	O
30	third	O
31	exon	O
32	.	O

1	Rhizobium	O
2	meliloti	O
3	large	O
4	plasmid	O
5	pRmeGR4b	O
6	carries	O
7	the	O
8	nodulation	O
9	competitiveness	O
10	locus	O
11	nfe	B
12	responsible	O
13	for	O
14	the	O
15	nodulation	O
16	efficiency	O
17	and	O
18	competitive	O
19	ability	O
20	of	O
21	strain	O
22	GR4	O
23	on	O
24	alfalfa	O
25	roots	O
26	.	O

1	Further	O
2	,	O
3	the	O
4	ability	O
5	of	O
6	recombinant	O
7	beta	O
8	and	O
9	/	O
10	or	O
11	gamma	O
12	chains	O
13	to	O
14	function	O
15	in	O
16	defined	O
17	biochemical	O
18	assays	O
19	of	O
20	beta	O
21	gamma	O
22	activity	O
23	was	O
24	assessed	O
25	for	O
26	membrane	O
27	extracts	O
28	and	O
29	supernatant	O
30	fractions	O
31	from	O
32	infected	O
33	Sf9	O
34	cells	O
35	.	O

1	This	O
2	report	O
3	describes	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	gene	O
9	of	O
10	related	O
11	function	O
12	,	O
13	SMD1	B
14	,	O
15	located	O
16	immediately	O
17	3	O
18	'	O
19	to	O
20	PRP38	B
21	.	O

1	These	O
2	data	O
3	establish	O
4	Smd1p	B
5	as	O
6	a	O
7	required	O
8	component	O
9	of	O
10	the	O
11	cellular	O
12	splicing	O
13	apparatus	O
14	and	O
15	a	O
16	factor	O
17	in	O
18	snRNA	O
19	maturation	O
20	and	O
21	stability	O
22	.	O

1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	fine	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	traumatically	O
13	brain	O
14	-	O
15	injured	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	consciousness	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O

1	We	O
2	compared	O
3	the	O
4	parameters	O
5	pleural	B
6	adenosine	I
7	deaminase	I
8	(	O
9	PADA	B
10	,	O
11	determined	O
12	in	O
13	405	O
14	patients	O
15	),	O
16	the	O
17	PADA	B
18	/	O
19	serum	B
20	ADA	I
21	ratio	O
22	(	O
23	P	B
24	/	O
25	SADA	B
26	;	O
27	276	O
28	cases	O
29	),	O
30	pleural	B
31	lysozyme	I
32	(	O
33	PLYS	B
34	,	O
35	276	O
36	cases	O
37	),	O
38	the	O
39	PLYS	B
40	/	O
41	serum	B
42	LYS	I
43	ratio	O
44	(	O
45	P	B
46	/	O
47	SLYS	B
48	;	O
49	276	O
50	cases	O
51	),	O
52	and	O
53	pleural	B
54	interferon	I
55	gamma	I
56	(	O
57	IFN	B
58	,	O
59	145	O
60	cases	O
61	)	O
62	regarding	O
63	their	O
64	ability	O
65	to	O
66	differentiate	O
67	tuberculous	O
68	pleural	O
69	effusions	O
70	from	O
71	others	O
72	.	O

1	These	O
2	exons	O
3	were	O
4	identified	O
5	by	O
6	cloning	O
7	and	O
8	sequencing	O
9	cDNAs	O
10	obtained	O
11	by	O
12	polymerase	O
13	chain	O
14	reaction	O
15	amplification	O
16	of	O
17	a	O
18	fibroblast	O
19	cDNA	O
20	library	O
21	.	O

1	Deletion	O
2	of	O
3	the	O
4	apeA	B
5	gene	I
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	O
15	(	O
16	protease	B
17	IV	I
18	and	O
19	aminopeptidase	B
20	N	I
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O

1	In	O
2	Experiment	O
3	2	O
4	scopolamine	O
5	hydrobromide	O
6	,	O
7	0	O
8	.	O
9	5	O
10	and	O
11	1	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	i	O
18	.	O
19	p	O
20	.,	O
21	was	O
22	administered	O
23	1	O
24	h	O
25	before	O
26	each	O
27	electrical	O
28	stimulation	O
29	until	O
30	each	O
31	rat	O
32	showed	O
33	the	O
34	stage	O
35	-	O
36	3	O
37	seizure	O
38	.	O

1	PNT	O
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O

1	CONCLUSIONS	O
2	.	O

1	There	O
2	was	O
3	a	O
4	positive	O
5	correlation	O
6	between	O
7	pyridinium	O
8	cross	O
9	-	O
10	link	O
11	excretion	O
12	and	O
13	thyroid	O
14	hormone	O
15	concentrations	O
16	.	O

1	Mutations	O
2	truncating	O
3	as	O
4	many	O
5	as	O
6	143	O
7	C	O
8	-	O
9	terminal	O
10	residues	O
11	from	O
12	the	O
13	transcriptional	O
14	activator	O
15	encoded	O
16	by	O
17	the	O
18	areA	B
19	gene	I
20	,	O
21	mediating	O
22	nitrogen	O
23	metabolite	O
24	repression	O
25	in	O
26	Aspergillus	O
27	nidulans	O
28	,	O
29	do	O
30	not	O
31	significantly	O
32	reduce	O
33	the	O
34	ability	O
35	of	O
36	the	O
37	areA	B
38	product	I
39	to	O
40	activate	O
41	expression	O
42	of	O
43	most	O
44	genes	O
45	under	O
46	areA	B
47	control	O
48	.	O

1	Naval	O
2	personnel	O
3	who	O
4	exceed	O
5	standards	O
6	for	O
7	%	O
8	BF	O
9	can	O
10	be	O
11	separated	O
12	from	O
13	active	O
14	duty	O
15	.	O

1	Weak	O
2	promoter	O
3	activity	O
4	was	O
5	observed	O
6	for	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	C1	B
12	and	O
13	C2	B
14	ORFs	O
15	(	O
16	C1	B
17	-	O
18	C2	B
19	gene	O
20	)	O
21	and	O
22	for	O
23	the	O
24	promoter	O
25	of	O
26	the	O
27	V1	B
28	ORF	I
29	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	coat	B
6	protein	I
7	promoter	I
8	of	O
9	chloris	O
10	striate	O
11	mosaic	O
12	virus	O
13	is	O
14	enhanced	O
15	by	O
16	its	O
17	own	O
18	and	O
19	C1	B
20	-	O
21	C2	B
22	gene	O
23	products	O
24	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	alignment	O
6	of	O
7	TC	B
8	II	I
9	with	O
10	that	O
11	of	O
12	other	O
13	Cbl	B
14	binding	I
15	proteins	I
16	(	O
17	rat	B
18	intrinsic	I
19	factor	I
20	,	O
21	human	B
22	transcobalamin	I
23	I	I
24	and	O
25	porcine	B
26	haptocorrin	I
27	)	O
28	revealed	O
29	only	O
30	33	O
31	%	O
32	overall	O
33	homology	O
34	.	O

1	This	O
2	short	O
3	communication	O
4	compares	O
5	a	O
6	novel	O
7	fluorimetric	O
8	microplate	O
9	enzyme	O
10	immunoassay	O
11	(	O
12	FEIA	O
13	)	O
14	with	O
15	a	O
16	commercial	O
17	time	O
18	-	O
19	resolved	O
20	fluoroimmunoassay	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	thyrotropin	B
26	in	O
27	dried	O
28	blood	O
29	spots	O
30	.	O

1	The	O
2	evaluation	O
3	was	O
4	performed	O
5	using	O
6	a	O
7	retrospective	O
8	study	O
9	design	O
10	with	O
11	newborn	O
12	blood	O
13	samples	O
14	from	O
15	three	O
16	screening	O
17	centres	O
18	.	O

1	A	O
2	region	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	adenovirus	B
10	2	I
11	/	I
12	5	I
13	E1a	I
14	protein	I
15	is	O
16	required	O
17	for	O
18	association	O
19	with	O
20	a	O
21	cellular	O
22	phosphoprotein	O
23	and	O
24	important	O
25	for	O
26	the	O
27	negative	O
28	modulation	O
29	of	O
30	T24	O
31	-	O
32	ras	B
33	mediated	O
34	transformation	O
35	,	O
36	tumorigenesis	O
37	and	O
38	metastasis	O
39	.	O

1	These	O
2	studies	O
3	demonstrate	O
4	that	O
5	both	O
6	G	B
7	alpha	I
8	i	I
9	genes	I
10	are	O
11	dynamically	O
12	regulated	O
13	in	O
14	LLC	O
15	-	O
16	PK1	O
17	cells	O
18	by	O
19	both	O
20	growth	O
21	,	O
22	differentiation	O
23	,	O
24	and	O
25	hormone	O
26	signals	O
27	.	O

1	Constructs	O
2	containing	O
3	the	O
4	full	B
5	-	I
6	length	I
7	PfCPK	I
8	cDNA	I
9	have	O
10	been	O
11	expressed	O
12	in	O
13	Escherichia	O
14	coli	O
15	at	O
16	a	O
17	high	O
18	level	O
19	to	O
20	generate	O
21	a	O
22	60	O
23	-	O
24	kDa	O
25	recombinant	O
26	protein	O
27	.	O

1	When	O
2	ligated	O
3	to	O
4	the	O
5	proIL	B
6	-	I
7	1	I
8	beta	I
9	cap	I
10	site	I
11	-	I
12	proximal	I
13	region	I
14	(	O
15	located	O
16	between	O
17	-	O
18	131	O
19	to	O
20	+	O
21	12	O
22	),	O
23	both	O
24	the	O
25	proIL	B
26	-	I
27	1	I
28	beta	I
29	and	O
30	the	O
31	simian	B
32	virus	I
33	40	I
34	enhancer	I
35	elements	I
36	functioned	O
37	more	O
38	efficiently	O
39	in	O
40	monocytes	O
41	than	O
42	in	O
43	HeLa	O
44	cells	O
45	,	O
46	which	O
47	are	O
48	not	O
49	normally	O
50	competent	O
51	for	O
52	IL	B
53	-	I
54	1	I
55	beta	I
56	expression	O
57	.	O

1	Therefore	O
2	,	O
3	PC	B
4	-	I
5	PLC	I
6	is	O
7	a	O
8	component	O
9	of	O
10	a	O
11	signal	O
12	transduction	O
13	pathway	O
14	leading	O
15	to	O
16	transcription	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	and	O
22	junB	B
23	that	O
24	collaborates	O
25	with	O
26	c	B
27	-	I
28	myc	I
29	and	O
30	is	O
31	independent	O
32	of	O
33	PKC	B
34	-	I
35	delta	I
36	and	O
37	Ras	B
38	activation	O
39	.	O

1	In	O
2	mitogen	O
3	-	O
4	stimulated	O
5	splenocytes	O
6	,	O
7	Gfi	B
8	-	I
9	1	I
10	expression	O
11	begins	O
12	to	O
13	rise	O
14	at	O
15	12	O
16	h	O
17	after	O
18	stimulation	O
19	and	O
20	reaches	O
21	very	O
22	high	O
23	levels	O
24	after	O
25	50	O
26	h	O
27	,	O
28	suggesting	O
29	that	O
30	it	O
31	may	O
32	be	O
33	functionally	O
34	involved	O
35	in	O
36	events	O
37	occurring	O
38	after	O
39	the	O
40	interaction	O
41	of	O
42	IL	B
43	-	I
44	2	I
45	with	O
46	its	O
47	receptor	O
48	,	O
49	perhaps	O
50	during	O
51	the	O
52	transition	O
53	from	O
54	the	O
55	G1	O
56	to	O
57	the	O
58	S	O
59	phase	O
60	of	O
61	the	O
62	cell	O
63	cycle	O
64	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterized	O
6	the	O
7	GCD6	B
8	and	O
9	GCD7	B
10	genes	I
11	and	O
12	shown	O
13	that	O
14	their	O
15	products	O
16	are	O
17	required	O
18	to	O
19	repress	O
20	GCN4	B
21	translation	O
22	under	O
23	nonstarvation	O
24	conditions	O
25	.	O

1	The	O
2	plateau	O
3	MO2	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	allometric	O
10	relation	O
11	.	O

1	While	O
2	the	O
3	latter	O
4	corresponded	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	824	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	uORF	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O

1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	I
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	B
10	gene	I
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	Histochemical	O
2	localization	O
3	of	O
4	GUS	B
5	revealed	O
6	promoter	O
7	function	O
8	in	O
9	leaf	O
10	epidermis	O
11	,	O
12	mesophyll	O
13	and	O
14	vascular	O
15	bundles	O
16	,	O
17	in	O
18	the	O
19	cortex	O
20	and	O
21	vascular	O
22	cylinder	O
23	of	O
24	the	O
25	root	O
26	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	B
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O

1	Southern	O
2	blot	O
3	analysis	O
4	using	O
5	probes	O
6	from	O
7	the	O
8	3	O
9	'	O
10	portions	O
11	of	O
12	the	O
13	genomic	O
14	and	O
15	B	B
16	.	I
17	napus	I
18	MA	I
19	and	O
20	MB	B
21	cDNA	I
22	clones	O
23	showed	O
24	that	O
25	MA	B
26	type	I
27	myrosinases	I
28	are	O
29	encoded	O
30	by	O
31	approximately	O
32	4	O
33	genes	O
34	,	O
35	while	O
36	MB	B
37	type	I
38	myrosinases	I
39	are	O
40	encoded	O
41	by	O
42	more	O
43	than	O
44	10	O
45	genes	O
46	in	O
47	B	O
48	.	O
49	napus	O
50	.	O

1	Sudomoina	O
2	,	O
3	A	O
4	.	O

1	Zinc	O
2	fingers	O
3	(	O
4	Zf	O
5	)	O
6	are	O
7	a	O
8	common	O
9	structural	O
10	motif	O
11	found	O
12	in	O
13	many	O
14	nucleic	O
15	acid	O
16	-	O
17	binding	O
18	proteins	O
19	.	O

1	The	O
2	deduced	O
3	bovine	O
4	EFIA	B
5	#	I
6	1	I
7	amino	O
8	acid	O
9	(	O
10	aa	O
11	)	O
12	sequence	O
13	is	O
14	98	O
15	%	O
16	identical	O
17	to	O
18	rat	O
19	EFIA	B
20	and	O
21	100	O
22	%	O
23	identical	O
24	to	O
25	human	O
26	EFIA	B
27	/	O
28	DbpB	B
29	/	O
30	YB	B
31	-	I
32	1	I
33	family	O
34	member	O
35	DNA	B
36	-	I
37	binding	I
38	protein	I
39	B	I
40	(	O
41	DbpB	B
42	).	O

1	Effect	O
2	of	O
3	tracheal	O
4	insufflation	O
5	of	O
6	deferoxamine	O
7	on	O
8	acute	O
9	ozone	O
10	toxicity	O
11	in	O
12	rats	O
13	.	O

1	Localization	O
2	of	O
3	the	O
4	insertion	O
5	locus	O
6	in	O
7	the	O
8	yeast	O
9	genome	O
10	and	O
11	complementation	O
12	studies	O
13	with	O
14	the	O
15	temperature	O
16	-	O
17	sensitive	O
18	mutant	O
19	indicate	O
20	that	O
21	the	O
22	two	O
23	mutations	O
24	are	O
25	allelic	O
26	.	O

1	Replacement	O
2	of	O
3	the	O
4	spacer	O
5	sequence	O
6	between	O
7	the	O
8	two	O
9	ARMs	O
10	with	O
11	a	O
12	shorter	O
13	stretch	O
14	of	O
15	sequence	O
16	also	O
17	reduced	O
18	RNA	O
19	binding	O
20	in	O
21	vitro	O
22	.	O

1	Type	O
2	II	O
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	IIA	O
12	and	O
13	IIB	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	underscribed	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O

1	Second	O
2	,	O
3	the	O
4	transcription	B
5	factor	I
6	Gal	I
7	-	I
8	ER	I
9	was	O
10	rendered	O
11	more	O
12	potent	O
13	and	O
14	less	O
15	susceptible	O
16	to	O
17	cell	O
18	type	O
19	-	O
20	specific	O
21	variation	O
22	by	O
23	fusing	O
24	the	O
25	strong	O
26	activating	O
27	domain	O
28	of	O
29	the	O
30	herpesvirus	B
31	protein	I
32	VP16	I
33	onto	O
34	its	O
35	C	O
36	terminus	O
37	.	O

1	The	O
2	exogenous	O
3	fos	B
4	gene	I
5	was	O
6	rapidly	O
7	induced	O
8	to	O
9	maximal	O
10	levels	O
11	within	O
12	1	O
13	-	O
14	2	O
15	hr	O
16	of	O
17	estrogen	O
18	addition	O
19	.	O

1	Elimination	O
2	of	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	meningitis	O
8	after	O
9	introduction	O
10	of	O
11	vaccination	O

1	Endosonography	O
2	accurately	O
3	assessed	O
4	tumor	O
5	extension	O
6	in	O
7	two	O
8	T2	O
9	tumors	O
10	,	O
11	14	O
12	T3	O
13	tumors	O
14	,	O
15	and	O
16	seven	O
17	T4	O
18	tumors	O
19	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	demonstrated	O
7	a	O
8	unique	O
9	mechanism	O
10	of	O
11	action	O
12	of	O
13	8	O
14	-	O
15	Cl	O
16	-	O
17	cAMP	O
18	in	O
19	the	O
20	regulation	O
21	of	O
22	these	O
23	kinase	O
24	isozymes	O
25	in	O
26	HL	O
27	-	O
28	60	O
29	human	O
30	promyelocytic	O
31	leukemia	O
32	cells	O
33	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	regulation	O
6	in	O
7	the	O
8	budding	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	has	O
13	shown	O
14	that	O
15	a	O
16	central	O
17	regulatory	O
18	protein	O
19	kinase	O
20	,	O
21	Cdc28	B
22	,	O
23	undergoes	O
24	changes	O
25	in	O
26	activity	O
27	through	O
28	the	O
29	cell	O
30	cycle	O
31	by	O
32	associating	O
33	with	O
34	distinct	O
35	groups	O
36	of	O
37	cyclins	B
38	that	O
39	accumulate	O
40	at	O
41	different	O
42	times	O
43	.	O

1	Overlapping	O
2	clones	O
3	representing	O
4	full	O
5	-	O
6	length	O
7	cDNAs	O
8	for	O
9	MMI	B
10	alpha	I
11	were	O
12	obtained	O
13	from	O
14	mouse	O
15	brain	O
16	.	O

1	The	O
2	method	O
3	involves	O
4	preliminary	O
5	isolation	O
6	of	O
7	oxiracetam	O
8	and	O
9	internal	O
10	standard	O
11	from	O
12	plasma	O
13	by	O
14	solid	O
15	-	O
16	phase	O
17	extraction	O
18	prior	O
19	to	O
20	the	O
21	formation	O
22	of	O
23	their	O
24	n	O
25	-	O
26	propyl	O
27	carbamate	O
28	derivatives	O
29	.	O

1	There	O
2	are	O
3	,	O
4	however	O
5	,	O
6	several	O
7	differences	O
8	between	O
9	the	O
10	two	O
11	new	O
12	ars	O
13	sequences	O
14	.	O

1	Pathways	O
2	linking	O
3	the	O
4	olfactory	O
5	bulbs	O
6	with	O
7	the	O
8	medial	O
9	preoptic	O
10	anterior	O
11	hypothalamus	O
12	are	O
13	important	O
14	for	O
15	intermale	O
16	aggression	O
17	in	O
18	mice	O
19	.	O

1	Pokeweed	B
2	mitogen	I
3	(	O
4	PWM	B
5	)	O
6	or	O
7	anti	B
8	-	I
9	CD3	I
10	significantly	O
11	increases	O
12	c	B
13	-	I
14	jun	I
15	messenger	I
16	RNA	I
17	(	I
18	mRNA	I
19	)	I
20	levels	O
21	in	O
22	T	O
23	cells	O
24	.	O

1	Following	O
2	seizure	O
3	induction	O
4	,	O
5	MABP	O
6	increased	O
7	to	O
8	105	O
9	mm	O
10	Hg	O
11	and	O
12	brain	O
13	pHi	O
14	fell	O
15	to	O
16	6	O
17	.	O
18	79	O
19	+/-	O
20	0	O
21	.	O
22	03	O
23	within	O
24	15	O
25	min	O
26	and	O
27	remained	O
28	at	O
29	this	O
30	level	O
31	for	O
32	1	O
33	h	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	001	O
40	).	O

1	In	O
2	contrast	O
3	,	O
4	rats	O
5	receiving	O
6	U74500A	O
7	(	O
8	2	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	v	O
15	.	O
16	infusion	O
17	commencing	O
18	30	O
19	min	O
20	prior	O
21	to	O
22	revascularisation	O
23	)	O
24	exhibited	O
25	enhanced	O
26	GMBF	O
27	throughout	O
28	reperfusion	O
29	[	O
30	PI	O
31	10	O
32	min	O
33	:	O
34	3	O
35	.	O
36	26	O
37	(	O
38	2	O
39	.	O
40	56	O
41	-	O
42	3	O
43	.	O
44	63	O
45	);	O
46	120	O
47	min	O
48	:	O
49	2	O
50	.	O
51	03	O
52	(	O
53	1	O
54	.	O
55	73	O
56	-	O
57	2	O
58	.	O
59	25	O
60	);	O
61	240	O
62	min	O
63	:	O
64	2	O
65	.	O
66	13	O
67	(	O
68	1	O
69	.	O
70	75	O
71	-	O
72	2	O
73	.	O
74	44	O
75	),	O
76	p	O
77	<	O
78	0	O
79	.	O
80	01	O
81	vs	O
82	.	O
83	controls	O
84	and	O
85	normals	O
86	]	O
87	with	O
88	complete	O
89	muscle	O
90	salvage	O
91	[	O
92	GMV	O
93	100	O
94	%	O
95	in	O
96	all	O
97	reperfused	O
98	muscles	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	01	O
105	vs	O
106	.	O
107	controls	O
108	,	O
109	not	O
110	significant	O
111	(	O
112	NS	O
113	)	O
114	vs	O
115	.	O
116	normals	O
117	and	O
118	6	O
119	h	O
120	ischaemia	O
121	].(	O
122	ABSTRACT	O
123	TRUNCATED	O
124	AT	O
125	250	O
126	WORDS	O
127	)	O

1	Sequencing	O
2	of	O
3	a	O
4	1	O
5	.	O
6	3	O
7	-	O
8	kilobase	O
9	fragment	O
10	of	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	TSG6	B
19	gene	I
20	identified	O
21	TATA	O
22	-	O
23	like	O
24	and	O
25	CAAT	O
26	sequences	O
27	near	O
28	the	O
29	transcription	O
30	start	O
31	site	O
32	.	O

1	The	O
2	region	O
3	that	O
4	imparts	O
5	inducibility	O
6	by	O
7	IL	B
8	-	I
9	1	I
10	or	O
11	TNF	B
12	(	O
13	positions	O
14	-	O
15	165	O
16	to	O
17	-	O
18	58	O
19	)	O
20	contains	O
21	potential	O
22	binding	O
23	sites	O
24	for	O
25	IRF	B
26	-	I
27	1	I
28	and	I
29	-	I
30	2	I
31	,	O
32	AP	B
33	-	I
34	1	I
35	,	O
36	and	O
37	NF	B
38	-	I
39	IL	I
40	-	I
41	6	I
42	.	O

1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O

1	Sterile	O
2	mutants	O
3	of	O
4	Saccharomyces	O
5	cerevisiae	O
6	were	O
7	isolated	O
8	from	O
9	alpha	O
10	*	O
11	cells	O
12	having	O
13	the	O
14	a	B
15	/	I
16	alpha	I
17	aar1	I
18	-	I
19	6	I
20	genotype	O
21	(	O
22	exhibiting	O
23	alpha	O
24	mating	O
25	ability	O
26	and	O
27	weak	O
28	a	O
29	mating	O
30	ability	O
31	as	O
32	a	O
33	result	O
34	of	O
35	a	O
36	defect	O
37	in	O
38	a1	B
39	-	I
40	alpha	I
41	2	I
42	repression	O
43	).	O

1	We	O
2	studied	O
3	the	O
4	functional	O
5	interaction	O
6	between	O
7	human	O
8	embryonic	O
9	zeta	B
10	2	I
11	globin	I
12	promoter	O
13	and	O
14	the	O
15	alpha	B
16	globin	I
17	regulatory	I
18	element	I
19	(	O
20	HS	B
21	-	I
22	40	I
23	)	O
24	located	O
25	40	O
26	kb	O
27	upstream	O
28	of	O
29	the	O
30	zeta	B
31	2	I
32	globin	I
33	gene	I
34	.	O

1	It	O
2	was	O
3	shown	O
4	by	O
5	transient	O
6	expression	O
7	assay	O
8	that	O
9	HS	B
10	-	I
11	40	I
12	behaved	O
13	as	O
14	an	O
15	authentic	O
16	enhancer	O
17	for	O
18	high	O
19	-	O
20	level	O
21	zeta	B
22	2	I
23	globin	I
24	promoter	I
25	activity	O
26	in	O
27	K562	O
28	cells	O
29	,	O
30	an	O
31	erythroid	O
32	cell	O
33	line	O
34	of	O
35	embryonic	O
36	and	O
37	/	O
38	or	O
39	fetal	O
40	origin	O
41	.	O

1	Initial	O
2	results	O
3	indicate	O
4	that	O
5	this	O
6	23S	B
7	pre	I
8	-	I
9	rRNA	I
10	is	O
11	the	O
12	same	O
13	as	O
14	the	O
15	species	O
16	detected	O
17	on	O
18	depletion	O
19	of	O
20	the	O
21	small	B
22	nucleolar	I
23	RNA	I
24	-	I
25	associated	I
26	proteins	I
27	NOP1	I
28	and	O
29	GAR1	B
30	and	O
31	in	O
32	an	O
33	snr10	B
34	mutant	I
35	strain	O
36	.	O

1	Breitbart	O
2	,	O
3	L	O
4	.	O

1	This	O
2	study	O
3	evaluates	O
4	the	O
5	feasibility	O
6	of	O
7	indirect	O
8	mesenteric	O
9	lymphangiography	O
10	as	O
11	a	O
12	colonoscopic	O
13	technique	O
14	in	O
15	a	O
16	canine	O
17	model	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	Our	O
4	purpose	O
5	was	O
6	to	O
7	determine	O
8	the	O
9	simultaneous	O
10	concentrations	O
11	of	O
12	serum	O
13	cotinine	O
14	in	O
15	both	O
16	fetal	O
17	and	O
18	maternal	O
19	blood	O
20	.	O

1	Internal	O
2	amino	O
3	acid	O
4	sequence	O
5	has	O
6	now	O
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	O
12	which	O
13	shares	O
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	B
25	G	I
26	alpha	I
27	11	I
28	and	O
29	G	B
30	alpha	I
31	q	I
32	cDNAs	I
33	.	O

1	Estradiol	O
2	is	O
3	known	O
4	to	O
5	induce	O
6	expression	O
7	of	O
8	certain	O
9	proto	O
10	-	O
11	oncogenes	O
12	,	O
13	and	O
14	this	O
15	led	O
16	us	O
17	to	O
18	examine	O
19	potential	O
20	regulatory	O
21	regions	O
22	of	O
23	the	O
24	cellular	B
25	c	I
26	-	I
27	fos	I
28	oncogene	I
29	.	O

1	Air	O
2	lead	O
3	was	O
4	not	O
5	a	O
6	significant	O
7	explanatory	O
8	variable	O
9	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	regulation	O
6	of	O
7	flaN	B
8	transcription	O
9	in	O
10	vivo	O
11	depends	O
12	on	O
13	a	O
14	sigma	B
15	54	I
16	promoter	I
17	and	O
18	two	O
19	ftr	O
20	elements	O
21	located	O
22	downstream	O
23	of	O
24	the	O
25	transcription	O
26	start	O
27	site	O
28	at	O
29	+	O
30	86	O
31	(	O
32	ftr2	O
33	)	O
34	and	O
35	+	O
36	120	O
37	(	O
38	ftr3	O
39	).	O

1	5	O
2	micrograms	O
3	/	O
4	l	O
5	was	O
6	detected	O
7	in	O
8	urine	O
9	from	O
10	some	O
11	non	O
12	-	O
13	occupationally	O
14	exposed	O
15	persons	O
16	.	O

1	Fibular	O
2	dimelia	O
3	with	O
4	deficiency	O
5	of	O
6	the	O
7	tibia	O
8	.	O

1	This	O
2	prospective	O
3	study	O
4	compared	O
5	the	O
6	measured	O
7	energy	O
8	expenditures	O
9	of	O
10	30	O
11	patients	O
12	using	O
13	indirect	O
14	calorimetry	O
15	with	O
16	their	O
17	predicted	O
18	basal	O
19	energy	O
20	expenditure	O
21	according	O
22	to	O
23	the	O
24	Harris	O
25	-	O
26	Benedict	O
27	equation	O
28	,	O
29	or	O
30	their	O
31	calculated	O
32	energy	O
33	expenditure	O
34	derived	O
35	from	O
36	basal	O
37	energy	O
38	expenditure	O
39	times	O
40	,	O
41	an	O
42	activity	O
43	factor	O
44	,	O
45	and	O
46	a	O
47	stress	O
48	factor	O
49	.	O

1	However	O
2	,	O
3	after	O
4	repeated	O
5	infections	O
6	,	O
7	hypobiotic	O
8	larvae	O
9	were	O
10	numerous	O
11	.	O

1	This	O
2	was	O
3	performed	O
4	in	O
5	a	O
6	double	O
7	blinded	O
8	,	O
9	randomized	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	.	O

1	Group	O
2	I	O
3	consisted	O
4	of	O
5	six	O
6	noncholestatic	O
7	patients	O
8	;	O
9	group	O
10	II	O
11	consisted	O
12	of	O
13	nine	O
14	mildly	O
15	cholestatic	O
16	patients	O
17	with	O
18	mild	O
19	hepatic	O
20	impairment	O
21	(	O
22	conjugated	O
23	bilirubin	O
24	,	O
25	47	O
26	mumol	O
27	liter	O
28	-	O
29	1	O
30	;	O
31	alkaline	B
32	phosphatase	I
33	,	O
34	280	O
35	IU	O
36	liter	O
37	-	O
38	1	O
39	;	O
40	gamma	B
41	-	I
42	glutamyltranspeptidase	I
43	,	O
44	190	O
45	IU	O
46	liter	O
47	-	O
48	1	O
49	);	O
50	group	O
51	III	O
52	consisted	O
53	of	O
54	six	O
55	benign	O
56	intrahepatic	O
57	cholestatic	O
58	patients	O
59	with	O
60	high	O
61	isolated	O
62	conjugated	O
63	hyperbilirubinemia	O
64	(	O
65	98	O
66	.	O
67	1	O
68	mumol	O
69	liter	O
70	-	O
71	1	O
72	).	O

1	There	O
2	was	O
3	either	O
4	no	O
5	change	O
6	or	O
7	an	O
8	improvement	O
9	in	O
10	renographic	O
11	findings	O
12	(	O
13	t1	O
14	/	O
15	2	O
16	time	O
17	and	O
18	/	O
19	or	O
20	split	O
21	function	O
22	)	O
23	in	O
24	40	O
25	patients	O
26	(	O
27	93	O
28	%).	O

1	We	O
2	discuss	O
3	the	O
4	need	O
5	to	O
6	use	O
7	animals	O
8	older	O
9	than	O
10	3	O
11	months	O
12	for	O
13	the	O
14	study	O
15	of	O
16	'	O
17	adult	O
18	'	O
19	regeneration	O
20	phenomena	O
21	since	O
22	3	O
23	-	O
24	month	O
25	-	O
26	old	O
27	rats	O
28	may	O
29	be	O
30	somewhat	O
31	immature	O
32	.	O

1	Nuclear	B
2	beta	I
3	II	I
4	PKC	I
5	,	O
6	like	O
7	p34cdc2	B
8	kinase	I
9	,	O
10	may	O
11	function	O
12	to	O
13	regulate	O
14	nuclear	O
15	lamina	O
16	structural	O
17	stability	O
18	during	O
19	cell	O
20	cycle	O
21	.	O

1	In	O
2	situ	O
3	copper	O
4	-	O
5	phenanthroline	O
6	footprinting	O
7	of	O
8	individual	O
9	gel	O
10	shift	O
11	assembly	O
12	intermediates	O
13	shows	O
14	that	O
15	on	O
16	the	O
17	302	O
18	-	O
19	nucleotide	O
20	G4oric	O
21	,	O
22	the	O
23	first	O
24	two	O
25	SSB	B
26	tetramers	I
27	assemble	O
28	at	O
29	random	O
30	,	O
31	but	O
32	the	O
33	addition	O
34	of	O
35	more	O
36	SSB	B
37	tetramers	I
38	results	O
39	in	O
40	formation	O
41	of	O
42	a	O
43	unique	O
44	structure	O
45	.	O

1	Effects	O
2	of	O
3	intramammary	O
4	endotoxin	O
5	infusion	O
6	on	O
7	milking	O
8	-	O
9	induced	O
10	oxytocin	B
11	release	O
12	.	O

1	Finger	B
2	associated	I
3	box	I
4	-	I
5	zinc	I
6	finger	I
7	proteins	I
8	(	O
9	FAX	B
10	-	I
11	ZFPs	I
12	)	O
13	constitute	O
14	a	O
15	subfamily	O
16	of	O
17	the	O
18	many	O
19	C2H2	B
20	type	I
21	ZFPs	I
22	in	O
23	Xenopus	O
24	laevis	O
25	.	O

1	Further	O
2	evidence	O
3	for	O
4	a	O
5	clustered	O
6	organization	O
7	of	O
8	FAX	B
9	-	O
10	ZFP	B
11	transcription	O
12	units	O
13	is	O
14	provided	O
15	by	O
16	Southern	O
17	blot	O
18	analysis	O
19	of	O
20	large	O
21	genomic	O
22	restriction	O
23	fragments	O
24	separated	O
25	by	O
26	transverse	O
27	field	O
28	gel	O
29	electrophoresis	O
30	,	O
31	and	O
32	by	O
33	in	O
34	situ	O
35	hybridization	O
36	on	O
37	intact	O
38	chromosomes	O
39	.	O

1	A	O
2	rat	O
3	cDNA	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	has	O
10	been	O
11	isolated	O
12	and	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	to	O
18	yield	O
19	a	O
20	catalytically	O
21	active	O
22	eIF	B
23	-	I
24	5	I
25	protein	I
26	.	O

1	Mutational	O
2	analyses	O
3	have	O
4	demonstrated	O
5	the	O
6	importance	O
7	of	O
8	sequences	O
9	within	O
10	the	O
11	327	O
12	bp	O
13	segment	O
14	that	O
15	contain	O
16	a	O
17	putative	O
18	cyclic	B
19	AMP	I
20	responsive	I
21	element	I
22	binding	I
23	protein	I
24	(	O
25	CREB	B
26	)	O
27	binding	O
28	site	O
29	for	O
30	TGF	B
31	-	I
32	beta	I
33	1	I
34	and	O
35	PMA	O
36	responsiveness	O
37	and	O
38	putative	O
39	PU	B
40	-	I
41	1	I
42	and	O
43	Sp1	B
44	binding	I
45	sites	I
46	for	O
47	basal	O
48	promoter	O
49	activity	O
50	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	In	O
2	F42A	O
3	-	O
4	stimulated	O
5	internalization	O
6	assays	O
7	on	O
8	forskolin	O
9	-	O
10	induced	O
11	YT	O
12	-	O
13	1	O
14	cells	O
15	,	O
16	the	O
17	IL	B
18	-	I
19	2R	I
20	alpha	I
21	chain	I
22	is	O
23	consistently	O
24	endocytosed	O
25	together	O
26	with	O
27	the	O
28	IL	B
29	-	I
30	2R	I
31	beta	I
32	subunit	I
33	indicating	O
34	that	O
35	IL	B
36	-	I
37	2R	I
38	alpha	I
39	is	O
40	stably	O
41	associated	O
42	with	O
43	the	O
44	F42A	B
45	-	I
46	IL	I
47	-	I
48	2R	I
49	beta	I
50	complex	I
51	even	O
52	though	O
53	the	O
54	alpha	O
55	-	O
56	subunit	O
57	contributes	O
58	little	O
59	if	O
60	any	O
61	affinity	O
62	to	O
63	the	O
64	F42A	O
65	binding	O
66	reaction	O
67	.	O

1	The	O
2	microcirculatory	O
3	dynamics	O
4	of	O
5	prostaglandin	O
6	E1	O
7	and	O
8	/	O
9	or	O
10	nicardipine	O
11	and	O
12	their	O
13	different	O
14	reactions	O
15	in	O
16	the	O
17	hyper	O
18	-	O
19	and	O
20	hypodynamic	O
21	state	O
22	of	O
23	septic	O
24	shock	O
25	in	O
26	a	O
27	rat	O
28	model	O

1	We	O
2	obtained	O
3	the	O
4	prevalence	O
5	of	O
6	IgG	B
7	antibodies	I
8	against	O
9	Trypanosoma	O
10	cruzi	O
11	among	O
12	1076	O
13	blood	O
14	donors	O
15	at	O
16	the	O
17	Instituto	O
18	Nacional	O
19	de	O
20	Cardiologia	O
21	"	O
22	Ignacio	O
23	Chavez	O
24	"	O
25	in	O
26	Mexico	O
27	City	O
28	.	O

1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O

1	The	O
2	short	O
3	-	O
4	term	O
5	synthesis	O
6	and	O
7	infant	O
8	-	O
9	regulated	O
10	removal	O
11	of	O
12	milk	O
13	in	O
14	lactating	O
15	women	O
16	.	O

1	Pseudosubstrate	O
2	(	O
3	19	O
4	-	O
5	36	O
6	),	O
7	derived	O
8	from	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	of	O
14	Ca	B
15	-	I
16	dependent	I
17	PKC	I
18	isotypes	I
19	,	O
20	inhibited	O
21	beta	B
22	-	I
23	PKC	I
24	but	O
25	not	O
26	nPKC	B
27	activity	O
28	using	O
29	either	O
30	Histone	B
31	IIIS	I
32	or	O
33	peptide	O
34	(	O
35	19	O
36	-	O
37	31	O
38	)	O
39	as	O
40	substrate	O
41	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	B
14	/	O
15	fix	B
16	gene	O
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O

1	Nitric	O
2	oxide	O
3	inhalation	O
4	selectively	O
5	reduces	O
6	pulmonary	O
7	hypertension	O
8	in	O
9	porcine	O
10	endotoxin	O
11	shock	O
12	and	O
13	improves	O
14	arterial	O
15	oxygenation	O
16	and	O
17	pH	O
18	with	O
19	a	O
20	marked	O
21	attenuation	O
22	of	O
23	sympathetic	O
24	activation	O
25	.	O

1	B	O
2	cell	O
3	-	O
4	specific	O
5	mb	B
6	-	I
7	1	I
8	and	O
9	B29	B
10	genes	I
11	encode	O
12	the	O
13	alpha	O
14	/	O
15	beta	O
16	components	O
17	of	O
18	the	O
19	BCR	B
20	-	I
21	associated	I
22	complex	I
23	in	O
24	mature	O
25	sIgM	B
26	+	I
27	B	O
28	cells	O
29	.	O

1	Bipolarity	O
2	in	O
3	Jungian	O
4	type	O
5	theory	O
6	and	O
7	the	O
8	Myers	O
9	-	O
10	Briggs	O
11	Type	O
12	Indicator	O
13	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	I
37	Right	I
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	Transient	O
2	transfection	O
3	analysis	O
4	with	O
5	these	O
6	mutations	O
7	revealed	O
8	that	O
9	only	O
10	a	O
11	10	O
12	-	O
13	bp	O
14	region	O
15	,	O
16	containing	O
17	precisely	O
18	the	O
19	Ets	B
20	and	O
21	proximal	O
22	LyF	B
23	-	I
24	1	I
25	binding	I
26	sites	I
27	,	O
28	was	O
29	needed	O
30	for	O
31	D	O
32	'	O
33	activity	O
34	.	O

1	However	O
2	,	O
3	despite	O
4	its	O
5	relationship	O
6	to	O
7	the	O
8	TR	B
9	,	O
10	Rev	B
11	-	O
12	Erb	B
13	bound	O
14	poorly	O
15	to	O
16	TR	B
17	binding	I
18	sites	I
19	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	a	O
6	25	O
7	-	O
8	bp	O
9	promoter	O
10	element	O
11	previously	O
12	shown	O
13	to	O
14	be	O
15	important	O
16	for	O
17	the	O
18	G1	O
19	-	O
20	S	O
21	activation	O
22	of	O
23	the	O
24	human	B
25	thymidine	I
26	kinase	I
27	(	O
28	htk	B
29	)	O
30	promoter	O
31	in	O
32	growth	O
33	-	O
34	stimulated	O
35	cells	O
36	is	O
37	a	O
38	cellular	O
39	target	O
40	of	O
41	cyclin	B
42	A	I
43	and	O
44	the	O
45	p33cdk2	B
46	complexes	I
47	.	O

1	These	O
2	protective	O
3	influences	O
4	were	O
5	observed	O
6	throughout	O
7	the	O
8	range	O
9	of	O
10	filling	O
11	pressures	O
12	measured	O
13	,	O
14	from	O
15	0	O
16	to	O
17	30	O
18	mmHg	O
19	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	with	O
5	rat	O
6	liver	O
7	nuclear	O
8	extracts	O
9	identified	O
10	7	O
11	major	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	termed	O
17	P1	O
18	through	O
19	P7	O
20	in	O
21	a	O
22	796	O
23	base	O
24	pair	O
25	DNA	O
26	fragment	O
27	(	O
28	base	O
29	pairs	O
30	-	O
31	763	O
32	to	O
33	+	O
34	33	O
35	).	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	B
16	p53	I
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	Neither	O
2	clone	O
3	encoded	O
4	the	O
5	cognate	O
6	endonuclease	O
7	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	total	O
6	cellular	O
7	RNA	O
8	indicated	O
9	that	O
10	xylP	B
11	encodes	O
12	a	O
13	1	O
14	.	O
15	3	O
16	-	O
17	kb	O
18	transcript	O
19	which	O
20	is	O
21	induced	O
22	by	O
23	xylan	O
24	.	O

1	The	O
2	nifJ	B
3	and	O
4	nifH	B
5	promoters	I
6	of	I
7	Klebsiella	I
8	pneumoniae	I
9	are	O
10	divergently	O
11	transcribed	O
12	sigma	B
13	54	I
14	-	I
15	dependent	I
16	promoters	I
17	that	O
18	are	O
19	positively	O
20	activated	O
21	by	O
22	the	O
23	NifA	B
24	protein	I
25	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	I
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	I
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	B
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	I
51	expression	O
52	in	O
53	bone	O
54	.	O

1	Both	O
2	inhaled	O
3	and	O
4	superfused	O
5	isoflurane	O
6	dilated	O
7	the	O
8	baseline	O
9	vein	O
10	diameter	O
11	before	O
12	stimulation	O
13	.	O

1	Prevalence	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	and	O
6	rheumatoid	B
7	factor	I
8	in	O
9	women	O
10	:	O
11	evidence	O
12	for	O
13	a	O
14	secular	O
15	decline	O
16	.	O

1	Although	O
2	olfactory	O
3	associative	O
4	conditioning	O
5	in	O
6	newborn	O
7	rats	O
8	produces	O
9	marked	O
10	structural	O
11	and	O
12	functional	O
13	changes	O
14	in	O
15	the	O
16	olfactory	O
17	bulb	O
18	,	O
19	recent	O
20	evidence	O
21	suggests	O
22	that	O
23	extrabulbar	O
24	circuits	O
25	must	O
26	be	O
27	involved	O
28	in	O
29	storing	O
30	these	O
31	early	O
32	memories	O
33	.	O

1	The	O
2	fission	B
3	yeast	I
4	dsk1	I
5	+	I
6	gene	I
7	,	O
8	a	O
9	multicopy	O
10	suppressor	O
11	for	O
12	cold	O
13	-	O
14	sensitive	O
15	dis1	B
16	mutants	I
17	,	O
18	encodes	O
19	a	O
20	novel	O
21	61	O
22	-	O
23	kd	O
24	protein	O
25	kinase	O
26	.	O

1	Closure	O
2	of	O
3	the	O
4	patent	O
5	ductus	O
6	arteriosus	O
7	with	O
8	a	O
9	Ligaclip	O
10	through	O
11	a	O
12	minithoracotomy	O
13	.	O

1	Sequence	O
2	comparison	O
3	between	O
4	the	O
5	translated	O
6	ORF	O
7	and	O
8	a	O
9	protein	O
10	database	O
11	reveal	O
12	between	O
13	26	O
14	.	O
15	5	O
16	and	O
17	23	O
18	.	O
19	4	O
20	%	O
21	aa	O
22	sequence	O
23	homology	O
24	to	O
25	bacterial	B
26	transmembrane	I
27	(	I
28	TM	I
29	)	I
30	proteins	I
31	including	O
32	those	O
33	mediating	O
34	chloramphenicol	O
35	(	O
36	Cm	O
37	)	O
38	and	O
39	tetracycline	O
40	(	O
41	Tc	O
42	)	O
43	resistance	O
44	and	O
45	an	O
46	arabinose	O
47	-	O
48	proton	O
49	symport	O
50	protein	O
51	.	O

1	The	O
2	yeast	O
3	gene	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	,	O
10	designated	O
11	TIF5	B
12	,	O
13	has	O
14	been	O
15	isolated	O
16	and	O
17	expressed	O
18	in	O
19	Escherichia	O
20	coli	O
21	to	O
22	yield	O
23	a	O
24	catalytically	O
25	active	O
26	eIF	B
27	-	I
28	5	I
29	protein	I
30	.	O

1	The	O
2	strategies	O
3	by	O
4	which	O
5	hepatitis	O
6	B	O
7	and	O
8	hepatitis	O
9	D	O
10	can	O
11	be	O
12	diminished	O
13	and	O
14	eventually	O
15	eliminated	O
16	are	O
17	:	O
18	immunization	O
19	,	O
20	measures	O
21	to	O
22	prevent	O
23	exposure	O
24	to	O
25	infective	O
26	blood	O
27	or	O
28	blood	O
29	derivatives	O
30	and	O
31	education	O
32	(	O
33	in	O
34	particular	O
35	awareness	O
36	that	O
37	hepatitis	O
38	B	O
39	is	O
40	a	O
41	sexually	O
42	transmitted	O
43	disease	O
44	).	O

1	Xylose	O
2	-	O
3	and	O
4	arabinose	O
5	-	O
6	containing	O
7	polymers	O
8	were	O
9	better	O
10	digested	O
11	than	O
12	was	O
13	cellulose	O
14	for	O
15	both	O
16	breads	O
17	.	O

1	The	O
2	technical	O
3	construction	O
4	of	O
5	the	O
6	mouth	O
7	protectors	O
8	is	O
9	illustrated	O
10	,	O
11	as	O
12	is	O
13	the	O
14	need	O
15	for	O
16	instrumentation	O
17	and	O
18	its	O
19	costs	O
20	and	O
21	the	O
22	materials	O
23	required	O
24	to	O
25	manufacture	O
26	these	O
27	mouth	O
28	protectors	O
29	.	O

1	The	O
2	alpha	O
3	-	O
4	subunit	O
5	by	O
6	itself	O
7	binds	O
8	to	O
9	telomeric	O
10	DNA	O
11	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	alpha	O
6	-	O
7	subunit	O
8	of	O
9	the	O
10	telomere	B
11	-	I
12	binding	I
13	protein	I
14	,	O
15	like	O
16	many	O
17	transcription	O
18	factors	O
19	,	O
20	has	O
21	separable	O
22	DNA	O
23	-	O
24	binding	O
25	and	O
26	protein	O
27	-	O
28	protein	O
29	interaction	O
30	domains	O
31	.	O

1	Three	O
2	patients	O
3	had	O
4	well	O
5	-,	O
6	6	O
7	patients	O
8	had	O
9	moderately	O
10	-,	O
11	and	O
12	5	O
13	patients	O
14	had	O
15	poorly	O
16	-	O
17	differentiated	O
18	adenocarcinoma	O
19	of	O
20	the	O
21	prostate	O
22	.	O

1	Spontaneous	O
2	burst	O
3	firing	O
4	in	O
5	cat	O
6	primary	O
7	auditory	O
8	cortex	O
9	:	O
10	age	O
11	and	O
12	depth	O
13	dependence	O
14	and	O
15	its	O
16	effect	O
17	on	O
18	neural	O
19	interaction	O
20	measures	O
21	.	O

1	By	O
2	applying	O
3	the	O
4	potentiometric	O
5	method	O
6	,	O
7	in	O
8	aqueous	O
9	medium	O
10	of	O
11	ionic	O
12	strength	O
13	mu	O
14	=	O
15	0	O
16	.	O
17	2	O
18	,	O
19	the	O
20	stability	O
21	constants	O
22	,	O
23	log	O
24	beta	O
25	1	O
26	=	O
27	4	O
28	.	O
29	42	O
30	and	O
31	log	O
32	beta	O
33	2	O
34	=	O
35	8	O
36	.	O
37	57	O
38	were	O
39	obtained	O
40	.	O

1	Cryopreservation	O
2	straws	O
3	filled	O
4	with	O
5	media	O
6	plus	O
7	additive	O
8	are	O
9	emersed	O
10	below	O
11	the	O
12	surface	O
13	of	O
14	an	O
15	unprocessed	O
16	donor	O
17	ejaculate	O
18	.	O

1	The	O
2	bcl	B
3	-	I
4	2	I
5	gene	I
6	can	O
7	potentially	O
8	encode	O
9	26	O
10	-	O
11	and	O
12	22	O
13	-	O
14	kDa	O
15	proteins	O
16	that	O
17	differ	O
18	only	O
19	in	O
20	their	O
21	carboxyl	O
22	tails	O
23	because	O
24	of	O
25	an	O
26	alternative	O
27	splicing	O
28	mechanism	O
29	.	O

1	The	O
2	active	O
3	open	O
4	reading	O
5	frame	O
6	in	O
7	the	O
8	clone	O
9	maps	O
10	at	O
11	27	O
12	min	O
13	on	O
14	the	O
15	E	O
16	.	O
17	coli	O
18	chromosome	O
19	and	O
20	is	O
21	identical	O
22	in	O
23	sequence	O
24	to	O
25	a	O
26	wild	O
27	type	O
28	counterpart	O
29	.	O

1	Subsequent	O
2	cloning	O
3	and	O
4	nucleotide	O
5	sequence	O
6	analysis	O
7	of	O
8	the	O
9	S	B
10	.	I
11	pombe	I
12	adenylate	I
13	kinase	I
14	gene	I
15	,	O
16	adk1	B
17	,	O
18	revealed	O
19	a	O
20	coding	O
21	region	O
22	of	O
23	660	O
24	nucleotides	O
25	.	O

1	Calcification	O
2	of	O
3	a	O
4	cariogenic	O
5	Streptococcus	O
6	and	O
7	of	O
8	Corynebacterium	O
9	(	O
10	Bacterionema	O
11	)	O
12	matruchotii	O
13	.	O

1	As	O
2	a	O
3	result	O
4	of	O
5	alternative	O
6	splicing	O
7	,	O
8	the	O
9	BGP	B
10	gene	I
11	is	O
12	transcribed	O
13	into	O
14	at	O
15	least	O
16	seven	O
17	distinct	O
18	mRNA	O
19	species	O
20	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	promoters	O
6	for	O
7	muMIP	B
8	-	I
9	1	I
10	beta	I
11	and	O
12	muMIP	B
13	-	I
14	1	I
15	alpha	I
16	reveals	O
17	a	O
18	conserved	O
19	CK	O
20	-	O
21	1	O
22	element	O
23	,	O
24	but	O
25	transient	O
26	expression	O
27	studies	O
28	in	O
29	RAW	O
30	264	O
31	.	O
32	7	O
33	macrophages	O
34	with	O
35	proximal	O
36	fragments	O
37	of	O
38	either	O
39	the	O
40	muMIP	B
41	-	I
42	1	I
43	beta	I
44	or	O
45	the	O
46	muMIP	B
47	-	I
48	1	I
49	alpha	I
50	5	I
51	'	I
52	promoter	I
53	fused	O
54	to	O
55	a	O
56	human	B
57	growth	I
58	hormone	I
59	reporter	I
60	gene	I
61	link	O
62	LPS	O
63	-	O
64	inducibility	O
65	in	O
66	both	O
67	to	O
68	promoter	O
69	segments	O
70	near	O
71	to	O
72	,	O
73	but	O
74	not	O
75	identical	O
76	with	O
77	,	O
78	the	O
79	consensus	O
80	CK	O
81	-	O
82	1	O
83	sequence	O
84	.	O

1	However	O
2	,	O
3	essential	O
4	contrast	O
5	differences	O
6	existing	O
7	between	O
8	the	O
9	FSE	O
10	sequences	O
11	and	O
12	their	O
13	routine	O
14	asymmetric	O
15	dual	O
16	SE	O
17	counterpart	O
18	can	O
19	be	O
20	identified	O
21	.	O

1	Sequence	O
2	analysis	O
3	and	O
4	identification	O
5	of	O
6	two	O
7	hyp	B
8	regulatory	I
9	mutants	I
10	.	O

1	The	O
2	gene	O
3	encoding	O
4	the	O
5	receptor	O
6	for	O
7	macrophage	B
8	colony	I
9	-	I
10	stimulating	I
11	factor	I
12	1	I
13	(	O
14	CSF	B
15	-	I
16	1	I
17	),	O
18	the	O
19	c	B
20	-	I
21	fms	I
22	protooncogene	I
23	,	O
24	is	O
25	selectively	O
26	expressed	O
27	in	O
28	immature	O
29	and	O
30	mature	O
31	mononuclear	O
32	phagocytes	O
33	and	O
34	trophoblasts	O
35	.	O

1	The	O
2	level	O
3	of	O
4	the	O
5	SUP4A53T61	B
6	transcript	I
7	was	O
8	threefold	O
9	higher	O
10	in	O
11	the	O
12	tap1	B
13	-	I
14	1	I
15	mutant	I
16	than	O
17	in	O
18	the	O
19	wild	O
20	type	O
21	.	O

1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	O
8	GCN1	B
9	interacts	O
10	with	O
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	B
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O

1	NF	B
2	-	I
3	HB	I
4	(	O
5	BSAP	B
6	)	O
7	is	O
8	a	O
9	repressor	O
10	of	O
11	the	O
12	murine	B
13	immunoglobulin	I
14	heavy	I
15	-	I
16	chain	I
17	3	I
18	'	I
19	alpha	I
20	enhancer	I
21	at	O
22	early	O
23	stages	O
24	of	O
25	B	O
26	-	O
27	cell	O
28	differentiation	O
29	.	O

1	Since	O
2	the	O
3	regulation	O
4	of	O
5	SWI4	B
6	is	O
7	required	O
8	for	O
9	normal	O
10	cell	O
11	cycle	O
12	progression	O
13	,	O
14	we	O
15	have	O
16	characterized	O
17	cis	O
18	-	O
19	and	O
20	trans	O
21	-	O
22	acting	O
23	regulators	O
24	of	O
25	SWI4	B
26	transcription	O
27	.	O

1	It	O
2	also	O
3	suggests	O
4	that	O
5	there	O
6	is	O
7	another	O
8	pathway	O
9	which	O
10	can	O
11	activate	O
12	SWI4	B
13	transcription	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	SWI6	B
19	.	O

1	Multiple	O
2	SWI6	B
3	-	O
4	dependent	O
5	cis	O
6	-	O
7	acting	O
8	elements	O
9	control	O
10	SWI4	B
11	transcription	O
12	through	O
13	the	O
14	cell	O
15	cycle	O
16	.	O

1	In	O
2	conclusion	O
3	,	O
4	changes	O
5	in	O
6	carotid	O
7	sinus	O
8	stimulation	O
9	alters	O
10	blood	O
11	flow	O
12	to	O
13	the	O
14	hindlimb	O
15	through	O
16	changes	O
17	in	O
18	both	O
19	Pcrit	O
20	and	O
21	Ra	O
22	.	O

1	Multizone	O
2	PRK	O
3	has	O
4	been	O
5	suggested	O
6	to	O
7	increase	O
8	the	O
9	predictability	O
10	of	O
11	higher	O
12	myopic	O
13	corrections	O
14	.	O

1	In	O
2	17	O
3	patients	O
4	with	O
5	deletions	O
6	,	O
7	the	O
8	parental	O
9	origin	O
10	of	O
11	deletion	O
12	was	O
13	determined	O
14	.	O

1	The	O
2	COL7A1	B
3	gene	I
4	,	O
5	which	O
6	encodes	O
7	type	B
8	VII	I
9	collagen	I
10	,	O
11	has	O
12	been	O
13	implicated	O
14	as	O
15	a	O
16	candidate	O
17	gene	O
18	for	O
19	dominantly	O
20	and	O
21	recessively	O
22	inherited	O
23	forms	O
24	of	O
25	dystrophic	O
26	epidermolysis	O
27	bullosa	O
28	.	O

1	However	O
2	,	O
3	study	O
4	of	O
5	the	O
6	productive	O
7	gamma	O
8	gene	O
9	showed	O
10	that	O
11	the	O
12	skipped	O
13	variable	O
14	exon	O
15	was	O
16	bounded	O
17	by	O
18	normal	O
19	splicing	O
20	signals	O
21	and	O
22	that	O
23	the	O
24	adjacent	O
25	intron	O
26	organization	O
27	was	O
28	not	O
29	altered	O
30	.	O

1	We	O
2	conclude	O
3	that	O
4	grade	O
5	III	O
6	BGCT	O
7	can	O
8	be	O
9	treated	O
10	by	O
11	modified	O
12	intralesional	O
13	excision	O
14	provided	O
15	the	O
16	articular	O
17	surfaces	O
18	and	O
19	part	O
20	of	O
21	the	O
22	metaphysis	O
23	are	O
24	intact	O
25	.	O

1	Second	O
2	,	O
3	nitrate	O
4	induction	O
5	of	O
6	aeg	B
7	-	I
8	46	I
9	.	I
10	5	I
11	operon	I
12	expression	O
13	is	O
14	substantially	O
15	enhanced	O
16	in	O
17	narL	B
18	null	O
19	strains	O
20	(	O
21	M	O
22	.	O
23	H	O
24	.	O

1	This	O
2	new	O
3	knowledge	O
4	has	O
5	contributed	O
6	to	O
7	the	O
8	development	O
9	of	O
10	a	O
11	successful	O
12	immunoprophylactic	O
13	strategy	O
14	for	O
15	eliminating	O
16	Hib	O
17	disease	O
18	.	O

1	The	O
2	HMG	B
3	CoA	I
4	reductase	I
5	inhibitors	O
6	are	O
7	the	O
8	most	O
9	effective	O
10	cholesterol	O
11	-	O
12	lowering	O
13	agents	O
14	currently	O
15	available	O
16	.	O

1	The	O
2	etiology	O
3	,	O
4	pathology	O
5	,	O
6	brain	O
7	CT	O
8	scan	O
9	features	O
10	,	O
11	clinical	O
12	manifestations	O
13	and	O
14	treatment	O
15	of	O
16	these	O
17	accidents	O
18	were	O
19	discussed	O
20	.	O

1	Drosophila	O
2	230	O
3	-	O
4	kD	O
5	TFIID	B
6	subunit	O
7	,	O
8	a	O
9	functional	O
10	homolog	O
11	of	O
12	the	O
13	human	O
14	cell	O
15	cycle	O
16	gene	O
17	product	O
18	,	O
19	negatively	O
20	regulates	O
21	DNA	O
22	binding	O
23	of	O
24	the	O
25	TATA	B
26	box	I
27	-	I
28	binding	I
29	subunit	I
30	of	I
31	TFIID	I
32	.	O

1	One	O
2	enigmatic	O
3	aspect	O
4	of	O
5	GATA	B
6	factor	I
7	expression	O
8	is	O
9	that	O
10	several	O
11	GATA	B
12	proteins	I
13	,	O
14	which	O
15	ostensibly	O
16	share	O
17	the	O
18	same	O
19	DNA	O
20	-	O
21	binding	O
22	site	O
23	specificity	O
24	,	O
25	are	O
26	coexpressed	O
27	in	O
28	erythroid	O
29	cells	O
30	.	O

1	Pit	B
2	-	I
3	1	I
4	is	O
5	a	O
6	tissue	O
7	-	O
8	specific	O
9	POU	B
10	domain	I
11	factor	I
12	obligatory	O
13	for	O
14	the	O
15	appearance	O
16	of	O
17	three	O
18	cell	O
19	phenotypes	O
20	in	O
21	the	O
22	anterior	O
23	pituitary	O
24	gland	O
25	.	O

1	Maximum	O
2	number	O
3	of	O
4	strains	O
5	(	O
6	39	O
7	.	O
8	1	O
9	%)	O
10	were	O
11	resistant	O
12	in	O
13	S	O
14	.	O
15	bareilly	O
16	serotype	O
17	,	O
18	followed	O
19	by	O
20	S	O
21	.	O
22	typhimurium	O
23	(	O
24	21	O
25	.	O
26	7	O
27	%)	O
28	and	O
29	least	O
30	in	O
31	S	O
32	.	O
33	typhi	O
34	(	O
35	17	O
36	.	O
37	4	O
38	%).	O

1	Biol	O
2	.	O

1	Characterization	O
2	and	O
3	hormonal	O
4	regulation	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	the	O
10	rat	B
11	prostaglandin	I
12	endoperoxide	I
13	synthase	I
14	2	I
15	gene	I
16	in	O
17	granulosa	O
18	cells	O
19	.	O

1	The	O
2	retention	O
3	of	O
4	75SeHCAT	O
5	was	O
6	low	O
7	.	O

1	Patient	O
2	characteristics	O
3	associated	O
4	with	O
5	deep	O
6	wounds	O
7	as	O
8	well	O
9	as	O
10	patient	O
11	and	O
12	wound	O
13	characteristics	O
14	predictive	O
15	of	O
16	the	O
17	extent	O
18	of	O
19	healing	O
20	and	O
21	time	O
22	required	O
23	for	O
24	healing	O
25	were	O
26	identified	O
27	.	O

1	Members	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	of	O
9	basic	B
10	-	I
11	leucine	I
12	zipper	I
13	(	I
14	bZip	I
15	)	I
16	transcription	I
17	factors	I
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O

1	In	O
2	mammalian	O
3	cells	O
4	,	O
5	phosphorylation	O
6	of	O
7	eIF	B
8	-	I
9	2	I
10	alpha	I
11	inhibits	O
12	the	O
13	activity	O
14	of	O
15	eIF	B
16	-	I
17	2B	I
18	,	O
19	the	O
20	GDP	B
21	-	I
22	GTP	I
23	exchange	I
24	factor	I
25	for	O
26	eIF	B
27	-	I
28	2	I
29	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	observations	O
6	demonstrated	O
7	that	O
8	stratification	O
9	of	O
10	acute	O
11	MI	O
12	patients	O
13	by	O
14	plasma	O
15	ANF	B
16	level	O
17	is	O
18	a	O
19	useful	O
20	non	O
21	-	O
22	invasive	O
23	method	O
24	for	O
25	predicting	O
26	prognosis	O
27	and	O
28	for	O
29	identifying	O
30	individuals	O
31	at	O
32	high	O
33	risk	O
34	of	O
35	cardiac	O
36	death	O
37	.	O

1	Analysis	O
2	of	O
3	the	O
4	binding	O
5	of	O
6	Lrp	B
7	to	O
8	a	O
9	set	O
10	of	O
11	circularly	O
12	permuted	O
13	DNA	O
14	fragments	O
15	from	O
16	this	O
17	region	O
18	indicates	O
19	that	O
20	Lrp	B
21	induces	O
22	DNA	O
23	bending	O
24	.	O

1	Yeast	O
2	mutants	O
3	lacking	O
4	a	O
5	functional	O
6	NOP1	B
7	gene	I
8	can	O
9	be	O
10	complemented	O
11	by	O
12	human	B
13	fibrillarin	I
14	but	O
15	are	O
16	temperature	O
17	sensitive	O
18	for	O
19	growth	O
20	and	O
21	impaired	O
22	in	O
23	pre	O
24	-	O
25	rRNA	O
26	processing	O
27	.	O

1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	ischaemia	O
7	and	O
8	non	O
9	-	O
10	ischaemia	O
11	groups	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	the	O
17	change	O
18	in	O
19	lactate	O
20	extraction	O
21	ratio	O
22	during	O
23	balloon	O
24	inflation	O
25	.	O

1	Seven	O
2	out	O
3	of	O
4	34	O
5	patients	O
6	died	O
7	,	O
8	giving	O
9	a	O
10	mortality	O
11	rate	O
12	of	O
13	21	O
14	%.	O

1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	B
22	gene	I
23	,	O
24	confirming	O
25	that	O
26	FtsN	B
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O

1	SSG1	B
2	,	O
3	a	O
4	gene	O
5	encoding	O
6	a	O
7	sporulation	B
8	-	I
9	specific	I
10	1	I
11	,	I
12	3	I
13	-	I
14	beta	I
15	-	I
16	glucanase	I
17	in	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	B
19	cytoplasmic	I
20	TyrRS	I
21	activity	O
22	was	O
23	produced	O
24	.	O

1	The	O
2	first	O
3	involved	O
4	complementation	O
5	of	O
6	a	O
7	nonphotosynthetic	O
8	mutant	O
9	of	O
10	Chlamydomonas	O
11	,	O
12	CC	O
13	-	O
14	2341	O
15	(	O
16	ac	O
17	-	O
18	u	O
19	-	O
20	g	O
21	-	O
22	2	O
23	.	O
24	3	O
25	),	O
26	which	O
27	has	O
28	a	O
29	frameshift	O
30	mutation	O
31	in	O
32	the	O
33	psaB	B
34	gene	I
35	,	O
36	and	O
37	selection	O
38	of	O
39	photosynthetic	O
40	transformants	O
41	on	O
42	minimal	O
43	medium	O
44	.	O

1	Against	O
2	200	O
3	strains	O
4	of	O
5	methicillin	O
6	-	O
7	resistant	O
8	Staphylococcus	O
9	aureus	O
10	(	O
11	MRSA	O
12	)	O
13	isolated	O
14	from	O
15	1990	O
16	to	O
17	1991	O
18	,	O
19	minimum	O
20	inhibitory	O
21	concentrations	O
22	(	O
23	MICs	O
24	)	O
25	of	O
26	a	O
27	total	O
28	of	O
29	15	O
30	antibacterial	O
31	agents	O
32	including	O
33	arbekacin	O
34	(	O
35	ABK	O
36	)	O
37	were	O
38	determined	O
39	.	O

1	It	O
2	is	O
3	reported	O
4	that	O
5	,	O
6	at	O
7	present	O
8	,	O
9	most	O
10	of	O
11	the	O
12	MRSAs	O
13	spreading	O
14	in	O
15	Japan	O
16	are	O
17	acceleratedly	O
18	acquiring	O
19	resistance	O
20	to	O
21	many	O
22	drugs	O
23	,	O
24	and	O
25	especially	O
26	,	O
27	they	O
28	are	O
29	developing	O
30	high	O
31	resistance	O
32	against	O
33	beta	O
34	-	O
35	lactams	O
36	.	O

1	Beg2	B
2	and	O
3	Beg1	B
4	are	O
5	regulated	O
6	differently	O
7	which	O
8	may	O
9	indicate	O
10	variation	O
11	in	O
12	storage	O
13	or	O
14	utilization	O
15	properties	O
16	among	O
17	the	O
18	barley	B
19	globulins	I
20	.	O

1	Here	O
2	,	O
3	we	O
4	have	O
5	more	O
6	closely	O
7	investigated	O
8	transactivation	O
9	of	O
10	the	O
11	human	B
12	HSP70	I
13	promoter	I
14	by	O
15	Myb	B
16	proteins	I
17	.	O

1	We	O
2	have	O
3	found	O
4	out	O
5	that	O
6	one	O
7	-	O
8	year	O
9	-	O
10	old	O
11	carps	O
12	are	O
13	extremely	O
14	sensitive	O
15	to	O
16	ichthiomycin	O
17	in	O
18	concentrations	O
19	between	O
20	25	O
21	-	O
22	125	O
23	micrograms	O
24	/	O
25	dm3	O
26	.	O

1	RESULTS	O
2	:	O
3	Statistically	O
4	significant	O
5	differences	O
6	were	O
7	obtained	O
8	between	O
9	group	O
10	I	O
11	and	O
12	II	O
13	concerning	O
14	the	O
15	number	O
16	of	O
17	patients	O
18	in	O
19	whom	O
20	induced	O
21	atrial	O
22	fibrillation	O
23	with	O
24	conduction	O
25	by	O
26	the	O
27	accessory	O
28	pathway	O
29	and	O
30	RR	O
31	<	O
32	or	O
33	=	O
34	250	O
35	msec	O
36	was	O
37	found	O
38	(	O
39	0	O
40	vs	O
41	6	O
42	,	O
43	p	O
44	=	O
45	0	O
46	.	O
47	0045	O
48	).	O

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	O
8	on	O
9	the	O
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	Both	O
2	immunophilins	B
3	may	O
4	have	O
5	important	O
6	roles	O
7	in	O
8	receptor	O
9	assembly	O
10	and	O
11	may	O
12	represent	O
13	a	O
14	new	O
15	category	O
16	of	O
17	ligand	O
18	-	O
19	and	O
20	calcium	O
21	-	O
22	dependent	O
23	modulators	O
24	of	O
25	protein	O
26	function	O
27	.	O

1	The	O
2	GTPase	B
3	activity	O
4	of	O
5	CDC42Ce	B
6	is	O
7	moderately	O
8	stimulated	O
9	by	O
10	human	B
11	n	I
12	-	I
13	chimaerin	I
14	,	O
15	a	O
16	GTPase	B
17	-	I
18	activating	I
19	protein	I
20	for	O
21	the	O
22	related	O
23	p21	B
24	rac1	I
25	.	O

1	Tl	O
2	-	O
3	201	O
4	uptake	O
5	ratio	O
6	of	O
7	the	O
8	right	O
9	ventricle	O
10	,	O
11	which	O
12	represents	O
13	the	O
14	ratio	O
15	of	O
16	total	O
17	counts	O
18	of	O
19	the	O
20	right	O
21	ventricle	O
22	to	O
23	counts	O
24	of	O
25	the	O
26	administered	O
27	dose	O
28	of	O
29	Tl	O
30	-	O
31	201	O
32	,	O
33	was	O
34	higher	O
35	in	O
36	COPD	O
37	,	O
38	especially	O
39	in	O
40	pulmonary	O
41	emphysema	O
42	and	O
43	B	O
44	type	O
45	COPD	O
46	by	O
47	Burrows	O
48	classification	O
49	than	O
50	in	O
51	controls	O
52	.	O

1	A	O
2	second	O
3	hydrophobic	O
4	domain	O
5	,	O
6	bordered	O
7	by	O
8	two	O
9	hydrophilic	O
10	regions	O
11	strongly	O
12	suggests	O
13	a	O
14	transmembrane	O
15	region	O
16	.	O

1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O

1	The	O
2	remaining	O
3	RAD	B
4	+	I
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	O
12	and	O
13	primitive	O
14	neuroectodermal	O
15	tumor	O
16	results	O
17	in	O
18	a	O
19	chimeric	O
20	molecule	O
21	fusing	O
22	the	O
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	B
32	gene	I
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	B
46	gene	I
47	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	a	O
6	range	O
7	of	O
8	microenvironmental	O
9	conditions	O
10	exist	O
11	within	O
12	purified	O
13	water	O
14	systems	O
15	,	O
16	leading	O
17	to	O
18	variable	O
19	populations	O
20	of	O
21	bacteria	O
22	.	O

1	X	O
2	-	O
3	linked	O
4	liver	O
5	glycogenosis	O
6	:	O
7	localization	O
8	and	O
9	isolation	O
10	of	O
11	a	O
12	candidate	O
13	gene	O
14	.	O

1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O

1	Measurement	O
2	of	O
3	anti	B
4	-	I
5	HCV	I
6	IgM	I
7	antibodies	I
8	with	O
9	an	O
10	experimental	O
11	kit	O

1	Embryo	O
2	coculture	O
3	system	O
4	may	O
5	contribute	O
6	to	O
7	understand	O
8	the	O
9	mechanisms	O
10	underlying	O
11	the	O
12	decrease	O
13	of	O
14	fertility	O
15	with	O
16	aging	O
17	.	O

1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	B
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	O
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	O
31	beta	O
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	B
43	locus	I
44	was	O
45	not	O
46	deleted	O
47	.	O

1	An	O
2	immunoperoxidase	B
3	reaction	O
4	,	O
5	PAP	B
6	method	O
7	,	O
8	with	O
9	the	O
10	antiserum	O
11	of	O
12	Factor	B
13	VIII	I
14	as	O
15	the	O
16	primary	O
17	antibody	O
18	,	O
19	was	O
20	carried	O
21	out	O
22	in	O
23	the	O
24	endometrial	O
25	biopsies	O
26	to	O
27	detect	O
28	the	O
29	Factor	B
30	VIII	I
31	activity	O
32	in	O
33	the	O
34	endometrial	O
35	endothelium	O
36	before	O
37	and	O
38	after	O
39	insertion	O
40	of	O
41	LNG	O
42	-	O
43	IUD	O
44	-	O
45	20	O
46	.	O

1	Umweltchem	O
2	.	O

1	Egd1p	B
2	is	O
3	homologous	O
4	to	O
5	human	B
6	BTF3b	I
7	,	O
8	recently	O
9	identified	O
10	as	O
11	the	O
12	beta	O
13	subunit	O
14	of	O
15	the	O
16	heterodimeric	B
17	nascent	I
18	-	I
19	polypeptide	I
20	-	I
21	associated	I
22	complex	I
23	(	O
24	NAC	B
25	)	O
26	involved	O
27	in	O
28	ensuring	O
29	signal	O
30	-	O
31	sequence	O
32	-	O
33	specific	O
34	protein	O
35	sorting	O
36	and	O
37	translocation	O
38	[	O
39	Wiedmann	O
40	et	O
41	al	O
42	.,	O
43	Nature	O
44	370	O
45	(	O
46	1994	O
47	)	O
48	434	O
49	-	O
50	440	O
51	].	O

1	Purified	O
2	PLB	B
3	showed	O
4	optimal	O
5	lyase	B
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	pelA	B
9	and	O
10	pelB	B
11	were	O
12	translationally	O
13	fused	O
14	to	O
15	the	O
16	beta	B
17	-	I
18	glucuronidase	I
19	gene	I
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	solani	O
26	f	O
27	.	O
28	sp	O
29	.	O
30	pisi	O
31	,	O
32	and	O
33	beta	B
34	-	I
35	glucuronidase	I
36	activities	O
37	of	O
38	the	O
39	transformants	O
40	were	O
41	measured	O
42	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	O
43	were	O
44	observed	O
45	.	O

1	We	O
2	failed	O
3	to	O
4	find	O
5	these	O
6	data	O
7	to	O
8	be	O
9	useful	O
10	in	O
11	predicting	O
12	the	O
13	time	O
14	of	O
15	onset	O
16	of	O
17	initial	O
18	seizures	O
19	after	O
20	acute	O
21	ischemic	O
22	stroke	O
23	and	O
24	recurrence	O
25	.	O

1	The	O
2	human	B
3	papillomavirus	I
4	type	I
5	16	I
6	E7	I
7	protein	I
8	complements	O
9	adenovirus	B
10	type	I
11	5	I
12	E1A	I
13	amino	O
14	-	O
15	terminus	O
16	-	O
17	dependent	O
18	transactivation	O
19	of	O
20	adenovirus	B
21	type	I
22	5	I
23	early	I
24	genes	I
25	and	O
26	increases	O
27	ATF	B
28	and	O
29	Oct	B
30	-	I
31	1	I
32	DNA	O
33	binding	O
34	activity	O
35	.	O

1	A	O
2	chaotropic	O
3	detergent	O
4	,	O
5	0	O
6	.	O
7	1	O
8	%	O
9	Nonidet	O
10	P	O
11	-	O
12	40	O
13	,	O
14	also	O
15	abolished	O
16	the	O
17	interaction	O
18	,	O
19	further	O
20	supporting	O
21	the	O
22	hydrophobic	O
23	nature	O
24	of	O
25	the	O
26	interaction	O
27	.	O

1	Contrary	O
2	to	O
3	expectations	O
4	,	O
5	we	O
6	find	O
7	a	O
8	relatively	O
9	high	O
10	level	O
11	of	O
12	variation	O
13	in	O
14	the	O
15	stripe	B
16	2	I
17	enhancer	O
18	region	O
19	,	O
20	including	O
21	point	O
22	substitutions	O
23	and	O
24	insertion	O
25	/	O
26	deletions	O
27	in	O
28	binding	O
29	sites	O
30	,	O
31	and	O
32	a	O
33	comparable	O
34	level	O
35	of	O
36	variation	O
37	in	O
38	the	O
39	other	O
40	noncoding	O
41	regions	O
42	.	O

1	Degradation	O
2	of	O
3	the	O
4	soybean	B
5	ribulose	I
6	-	I
7	1	I
8	,	I
9	5	I
10	-	I
11	bisphosphate	I
12	carboxylase	I
13	small	I
14	-	I
15	subunit	I
16	mRNA	I
17	,	O
18	SRS4	B
19	,	O
20	initiates	O
21	with	O
22	endonucleolytic	O
23	cleavage	O
24	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	revealed	O
5	that	O
6	dMax	B
7	contains	O
8	a	O
9	deletion	O
10	spanning	O
11	the	O
12	basic	O
13	region	O
14	and	O
15	helix	O
16	1	O
17	and	O
18	the	O
19	loop	O
20	of	O
21	the	O
22	helix	O
23	-	O
24	loop	O
25	-	O
26	helix	O
27	region	O
28	,	O
29	presumably	O
30	as	O
31	a	O
32	result	O
33	of	O
34	alternative	O
35	splicing	O
36	of	O
37	max	B
38	RNA	I
39	.	O

1	I	O
2	report	O
3	here	O
4	that	O
5	induction	O
6	of	O
7	HSP82	B
8	is	O
9	regulated	O
10	by	O
11	the	O
12	early	O
13	meiotic	O
14	IME1	B
15	-	O
16	IME2	B
17	transcriptional	O
18	cascade	O
19	.	O

1	The	O
2	domain	O
3	structure	O
4	of	O
5	bovine	B
6	LTBP	I
7	-	I
8	2	I
9	is	O
10	very	O
11	similar	O
12	to	O
13	that	O
14	of	O
15	the	O
16	human	B
17	LTBP	I
18	-	I
19	2	I
20	,	O
21	containing	O
22	20	O
23	examples	O
24	of	O
25	6	O
26	-	O
27	cysteine	O
28	epidermal	B
29	growth	I
30	factor	I
31	-	I
32	like	I
33	repeats	I
34	,	O
35	16	O
36	of	O
37	which	O
38	have	O
39	the	O
40	consensus	O
41	sequence	O
42	for	O
43	calcium	O
44	binding	O
45	,	O
46	together	O
47	with	O
48	4	O
49	examples	O
50	of	O
51	8	O
52	-	O
53	cysteine	O
54	motifs	O
55	characteristic	O
56	of	O
57	fibrillins	B
58	and	O
59	LTBP	B
60	-	I
61	1	I
62	.	O

1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	B
9	-	I
10	type	I
11	prothymosin	I
12	alpha	I
13	gene	I
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	repertoire	O
23	of	O
24	myc	B
25	-	I
26	derived	I
27	genes	I
28	,	O
29	including	O
30	myc	B
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	recessive	O
36	negative	O
37	myc	B
38	mutants	I
39	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	alpha	B
6	/	I
7	beta	I
8	interferon	I
9	-	O
10	stimulated	O
11	Jak	B
12	/	O
13	Stat	B
14	pathway	O
15	by	O
16	the	O
17	SH2	B
18	domain	O
19	-	O
20	containing	O
21	tyrosine	B
22	phosphatase	I
23	SHPTP1	I
24	.	O

1	We	O
2	now	O
3	report	O
4	the	O
5	isolation	O
6	and	O
7	expression	O
8	of	O
9	cDNAs	O
10	encoding	O
11	PTF	B
12	gamma	I
13	and	O
14	PTF	B
15	delta	I
16	,	O
17	as	O
18	well	O
19	as	O
20	functional	O
21	studies	O
22	with	O
23	cognate	O
24	antibodies	O
25	that	O
26	recognize	O
27	the	O
28	native	O
29	PTF	B
30	complex	I
31	in	O
32	HeLa	O
33	extracts	O
34	.	O

1	Results	O
2	from	O
3	the	O
4	mechanism	O
5	study	O
6	have	O
7	revealed	O
8	that	O
9	YY1	B
10	is	O
11	able	O
12	to	O
13	inhibit	O
14	transactivation	O
15	mediated	O
16	by	O
17	either	O
18	AP1	B
19	or	O
20	the	O
21	Sp1	B
22	-	I
23	related	I
24	protein	I
25	,	O
26	and	O
27	YY1	B
28	suppressive	O
29	activity	O
30	is	O
31	DNA	O
32	binding	O
33	dependent	O
34	.	O

1	The	O
2	skp1	B
3	+	I
4	gene	I
5	is	O
6	not	O
7	essential	O
8	.	O

1	The	O
2	TEA1	B
3	(	O
4	Ty	B
5	enhancer	I
6	activator	I
7	)	O
8	gene	O
9	sequence	O
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	I
33	type	I
34	family	I
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O

1	Refugees	O
2	living	O
3	in	O
4	Lund	O
5	and	O
6	repatriated	O
7	to	O
8	Chile	O
9	considered	O
10	their	O
11	health	O
12	as	O
13	bad	O
14	in	O
15	a	O
16	higher	O
17	proportion	O
18	than	O
19	their	O
20	Swedish	O
21	counterparts	O
22	,	O
23	with	O
24	an	O
25	odds	O
26	ratio	O
27	of	O
28	3	O
29	.	O
30	48	O
31	(	O
32	2	O
33	.	O
34	03	O
35	-	O
36	5	O
37	.	O
38	66	O
39	)	O
40	and	O
41	4	O
42	.	O
43	78	O
44	(	O
45	2	O
46	.	O
47	1	O
48	-	O
49	10	O
50	.	O
51	25	O
52	)	O
53	respectively	O
54	.	O

1	This	O
2	study	O
3	underlines	O
4	the	O
5	importance	O
6	of	O
7	terminal	O
8	SC5b	B
9	-	I
10	9	I
11	complement	I
12	complex	I
13	as	O
14	a	O
15	suitable	O
16	marker	O
17	in	O
18	the	O
19	evaluation	O
20	of	O
21	complement	O
22	activation	O
23	during	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	O
17	of	O
18	patients	O
19	with	O
20	vestibular	O
21	deficits	O
22	.	O

1	The	O
2	MCA	O
3	and	O
4	UA	O
5	PI	O
6	values	O
7	showed	O
8	the	O
9	greatest	O
10	deviation	O
11	for	O
12	any	O
13	single	O
14	-	O
15	vessel	O
16	parameter	O
17	.	O

1	Striking	O
2	sequence	O
3	similarities	O
4	(	O
5	57	O
6	and	O
7	53	O
8	%)	O
9	were	O
10	observed	O
11	with	O
12	yeast	O
13	mitochondrial	O
14	proteins	O
15	,	O
16	SMF1	B
17	and	O
18	SMF2	B
19	,	O
20	especially	O
21	within	O
22	putative	O
23	functional	O
24	domains	O
25	:	O
26	exon	O
27	6	O
28	encoding	O
29	the	O
30	second	O
31	transmembrane	O
32	spanning	O
33	domain	O
34	,	O
35	site	O
36	of	O
37	the	O
38	murine	B
39	susceptibility	I
40	mutation	O
41	;	O
42	and	O
43	exon	O
44	11	O
45	encoding	O
46	a	O
47	conserved	O
48	transport	O
49	motif	O
50	.	O

1	Stems	O
2	contain	O
3	distinctly	O
4	less	O
5	P	B
6	protein	I
7	mRNA	I
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O

1	The	O
2	B	B
3	.	I
4	germanica	I
5	cyclophilin	I
6	amino	I
7	acid	I
8	sequence	I
9	shares	O
10	83	O
11	%	O
12	identity	O
13	with	O
14	the	O
15	cytosolic	B
16	cyclophilin	I
17	isoform	I
18	from	I
19	Drosophila	I
20	melanogaster	I
21	(	O
22	Cyp	B
23	-	I
24	1	I
25	).	O

1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	soluble	O
8	form	O
9	of	O
10	ERp57	B
11	/	O
12	GRP58	B
13	by	O
14	Western	O
15	blotting	O
16	and	O
17	biosynthetic	O
18	labeling	O
19	.	O

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	Consistent	O
2	with	O
3	the	O
4	hepatic	O
5	and	O
6	epidermal	O
7	expression	O
8	of	O
9	histidase	B
10	,	O
11	this	O
12	finding	O
13	suggests	O
14	that	O
15	histidase	B
16	transcription	O
17	may	O
18	be	O
19	regulated	O
20	by	O
21	these	O
22	factors	O
23	.	O

1	Comparison	O
2	of	O
3	promoters	O
4	repressed	O
5	by	O
6	c	B
7	-	I
8	myc	I
9	reveals	O
10	a	O
11	weak	O
12	consensus	O
13	sequence	O
14	of	O
15	the	O
16	initiator	O
17	(	O
18	Inr	O
19	)	O
20	element	O
21	:	O
22	TCA	O
23	(+	O
24	1	O
25	)	O
26	YYYNY	O
27	.	O

1	The	O
2	human	B
3	gp39	I
4	promoter	I
5	.	O

1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	TGACCT	O
12	motifs	O
13	or	O
14	truncation	O
15	of	O
16	the	O
17	entire	O
18	HD	B
19	PPRE	O
20	into	O
21	a	O
22	separate	O
23	DR1	O
24	and	O
25	DR2	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	B
34	PPRE	O
35	to	O
36	peroxisome	O
37	proliferators	O
38	.	O

1	The	O
2	site	O
3	of	O
4	autophosphorylation	O
5	is	O
6	Tyr397	O
7	which	O
8	corresponds	O
9	to	O
10	the	O
11	consensus	O
12	autophosphorylation	O
13	site	O
14	of	O
15	other	O
16	Src	B
17	family	I
18	tyrosine	I
19	kinases	I
20	.	O

1	This	O
2	protein	O
3	-	O
4	protein	O
5	interaction	O
6	does	O
7	not	O
8	require	O
9	the	O
10	simultaneous	O
11	binding	O
12	of	O
13	Oct	B
14	proteins	I
15	to	O
16	DNA	O
17	,	O
18	and	O
19	high	O
20	resolution	O
21	footprinting	O
22	of	O
23	the	O
24	Oct	B
25	-	I
26	DNA	I
27	interaction	O
28	reveals	O
29	that	O
30	binding	O
31	of	O
32	BOB	B
33	.	I
34	1	I
35	/	O
36	OBF	B
37	.	I
38	1	I
39	to	O
40	Oct1	B
41	or	O
42	Oct2	B
43	does	O
44	not	O
45	alter	O
46	the	O
47	interaction	O
48	with	O
49	DNA	O
50	.	O

1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	B
9	orphan	I
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	O
26	beta	O
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	proteins	O
7	,	O
8	we	O
9	have	O
10	characterized	O
11	domains	O
12	responsible	O
13	for	O
14	activation	O
15	or	O
16	repression	O
17	.	O

1	Unlike	O
2	ARF	B
3	,	O
4	the	O
5	ARP	B
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O

1	It	O
2	is	O
3	considered	O
4	that	O
5	the	O
6	recurrent	O
7	annular	O
8	erythema	O
9	is	O
10	a	O
11	specific	O
12	skin	O
13	manifestation	O
14	of	O
15	SjS	O
16	with	O
17	anti	B
18	SS	I
19	-	I
20	A	I
21	/	O
22	SS	B
23	-	I
24	B	I
25	antibodies	I
26	.	O

1	Competition	O
2	needs	O
3	to	O
4	be	O
5	better	O
6	studied	O
7	,	O
8	since	O
9	in	O
10	Central	O
11	America	O
12	and	O
13	Caribean	O
14	islands	O
15	this	O
16	kind	O
17	of	O
18	study	O
19	has	O
20	favored	O
21	the	O
22	biological	O
23	control	O
24	of	O
25	planorbid	O
26	species	O
27	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	describe	O
6	properties	O
7	of	O
8	the	O
9	cdc10	B
10	-	O
11	C4	O
12	mutant	O
13	of	O
14	the	O
15	fission	O
16	yeast	O
17	Schizosaccharomyces	O
18	pombe	O
19	.	O

1	TIEG	B
2	expression	O
3	in	O
4	hFOB	O
5	cells	O
6	was	O
7	highly	O
8	induced	O
9	by	O
10	TGF	B
11	-	I
12	beta	I
13	and	O
14	bone	B
15	morphogenetic	I
16	protein	I
17	-	I
18	2	I
19	(	O
20	BMP	B
21	-	I
22	2	I
23	),	O
24	with	O
25	a	O
26	moderate	O
27	induction	O
28	by	O
29	epidermal	B
30	growth	I
31	factor	I
32	(	O
33	EGF	B
34	),	O
35	but	O
36	no	O
37	induction	O
38	by	O
39	other	O
40	growth	O
41	factors	O
42	/	O
43	cytokines	O
44	was	O
45	observed	O
46	.	O

1	An	O
2	infectious	O
3	origin	O
4	should	O
5	always	O
6	be	O
7	excluded	O
8	since	O
9	specific	O
10	etiologic	O
11	therapy	O
12	may	O
13	be	O
14	implemented	O
15	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	B
7	N2417	I
8	and	O
9	N2403	B
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	O
22	maltosa	O
23	cycloheximide	B
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	O
30	interleukin	B
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	highly	O
6	expressed	O
7	ADH1	B
8	gene	I
9	is	O
10	represented	O
11	in	O
12	this	O
13	database	O
14	by	O
15	no	O
16	less	O
17	than	O
18	20	O
19	EST	O
20	sequences	O
21	.	O

1	Five	O
2	families	O
3	of	O
4	Ashkenazi	O
5	Jewish	O
6	descent	O
7	carried	O
8	the	O
9	185delAG	O
10	mutation	O
11	and	O
12	shared	O
13	the	O
14	same	O
15	haplotype	O
16	at	O
17	eight	O
18	polymorphic	O
19	markers	O
20	spanning	O
21	approximately	O
22	850	O
23	kb	O
24	at	O
25	BRCA1	B
26	.	O

1	The	O
2	subjects	O
3	from	O
4	the	O
5	two	O
6	regions	O
7	with	O
8	a	O
9	higher	O
10	pollution	O
11	level	O
12	had	O
13	lower	O
14	FVC	O
15	and	O
16	FEV1	O
17	values	O
18	than	O
19	those	O
20	from	O
21	the	O
22	Viskovo	O
23	region	O
24	.	O

1	PTP	B
2	-	I
3	S3	I
4	differs	O
5	from	O
6	PTP	B
7	-	I
8	S4	I
9	in	O
10	having	O
11	a	O
12	deletion	O
13	of	O
14	19	O
15	amino	O
16	acids	O
17	corresponding	O
18	to	O
19	exon	O
20	E1	O
21	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	I
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	The	O
2	Arabidopsis	B
3	FAD7	I
4	gene	I
5	encodes	O
6	a	O
7	chloroplast	B
8	omega	I
9	-	I
10	3	I
11	fatty	I
12	acid	I
13	desaturase	I
14	that	O
15	catalyzes	O
16	the	O
17	desaturation	O
18	of	O
19	lipid	O
20	-	O
21	linked	O
22	dienoic	O
23	fatty	O
24	acids	O
25	(	O
26	18	O
27	:	O
28	2	O
29	and	O
30	16	O
31	:	O
32	2	O
33	).	O

1	When	O
2	differentiated	O
3	G0	O
4	-	O
5	arrested	O
6	leaf	O
7	cells	O
8	were	O
9	induced	O
10	to	O
11	resume	O
12	cell	O
13	division	O
14	by	O
15	treatment	O
16	with	O
17	plant	O
18	hormones	O
19	,	O
20	cycMs4	B
21	transcription	O
22	was	O
23	induced	O
24	before	O
25	the	O
26	onset	O
27	of	O
28	DNA	O
29	synthesis	O
30	.	O

1	A	O
2	survey	O
3	is	O
4	given	O
5	of	O
6	the	O
7	pharmacological	O
8	backgrounds	O
9	that	O
10	are	O
11	relevant	O
12	for	O
13	the	O
14	drug	O
15	treatment	O
16	of	O
17	essential	O
18	hypertension	O
19	in	O
20	the	O
21	elderly	O
22	.	O

1	Protein	O
2	kinases	O
3	play	O
4	pivotal	O
5	roles	O
6	in	O
7	the	O
8	control	O
9	of	O
10	many	O
11	cellular	O
12	processes	O
13	.	O

1	Interestingly	O
2	,	O
3	internal	O
4	and	O
5	5	O
6	'	O
7	deletions	O
8	revealed	O
9	tha	O
10	the	O
11	distal	O
12	promoter	O
13	was	O
14	not	O
15	required	O
16	for	O
17	full	O
18	transcriptional	O
19	activity	O
20	and	O
21	that	O
22	the	O
23	first	O
24	631	O
25	base	O
26	pairs	O
27	of	O
28	WNT	B
29	-	I
30	5A	I
31	harbored	O
32	the	O
33	strongest	O
34	promoter	O
35	activity	O
36	.	O

1	The	O
2	protein	O
3	kinase	O
4	domains	O
5	of	O
6	LIMK1	B
7	and	O
8	LIMK2	B
9	are	O
10	unique	O
11	in	O
12	that	O
13	they	O
14	contain	O
15	an	O
16	unusual	O
17	sequence	O
18	motif	O
19	Asp	O
20	-	O
21	Leu	O
22	-	O
23	Asn	O
24	-	O
25	Ser	O
26	-	O
27	His	O
28	-	O
29	Asn	O
30	in	O
31	subdomain	O
32	VIB	O
33	and	O
34	a	O
35	highly	O
36	basic	O
37	insert	O
38	between	O
39	subdomains	O
40	VII	O
41	and	O
42	VIII	O
43	.	O

1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	O
19	THZif	B
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	B
62	-	I
63	hypersensitive	I
64	element	I
65	(	O
66	NHE	B
67	)	O
68	of	O
69	the	O
70	human	B
71	c	I
72	-	I
73	myc	I
74	gene	I
75	.	O

1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	O
8	supplemented	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O

1	Taking	O
2	into	O
3	consideration	O
4	weight	O
5	and	O
6	seasonal	O
7	changes	O
8	in	O
9	bone	O
10	mass	O
11	,	O
12	total	O
13	(	O
14	TBBMC	O
15	)	O
16	and	O
17	regional	O
18	body	O
19	bone	O
20	mineral	O
21	content	O
22	were	O
23	measured	O
24	in	O
25	38	O
26	women	O
27	treated	O
28	with	O
29	GnRH	B
30	agonists	O
31	for	O
32	6	O
33	months	O
34	for	O
35	endometriosis	O
36	or	O
37	leiomyomata	O
38	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	B
11	-	I
12	1	I
13	allergen	I
14	of	I
15	Ascaris	I
16	,	O
17	the	O
18	gp15	B
19	/	I
20	400	I
21	'	I
22	ladder	I
23	'	I
24	protein	I
25	of	I
26	Brugia	I
27	malayi	I
28	,	I
29	Brugia	I
30	pahangi	I
31	and	I
32	Wuchereria	I
33	bancrofti	I
34	,	O
35	and	O
36	a	O
37	15	B
38	-	I
39	kDa	I
40	antigen	I
41	of	I
42	Dirofilaria	I
43	immitis	I
44	.	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O

1	Spontaneous	O
2	recovery	O
3	occurs	O
4	within	O
5	30	O
6	min	O
7	to	O
8	2	O
9	hrs	O
10	.	O

1	DAF	B
2	is	O
3	a	O
4	70	O
5	kD	O
6	glycoprotein	O
7	containing	O
8	complement	O
9	regulatory	O
10	short	O
11	consensus	O
12	repeats	O
13	(	O
14	SCRs	O
15	);	O
16	its	O
17	gene	O
18	is	O
19	located	O
20	in	O
21	the	O
22	regulation	B
23	of	I
24	complement	I
25	activation	I
26	(	O
27	RCA	B
28	)	O
29	gene	O
30	cluster	O
31	on	O
32	chromosome	O
33	1	O
34	and	O
35	is	O
36	about	O
37	40	O
38	kb	O
39	in	O
40	size	O
41	.	O

1	The	O
2	XS2	B
3	gene	I
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	B
14	genes	I
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O

1	Diabetes	O
2	care	O
3	:	O
4	a	O
5	guideline	O
6	to	O
7	the	O
8	facilities	O
9	needed	O
10	to	O
11	support	O
12	internationally	O
13	endorsed	O
14	standards	O
15	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	around	O
7	the	O
8	transcriptional	O
9	start	O
10	points	O
11	(	O
12	tsp	O
13	),	O
14	as	O
15	determined	O
16	by	O
17	primer	O
18	extension	O
19	analysis	O
20	.	O

1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	burst	O
9	of	O
10	pseudoterranovosis	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	attributed	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	lions	O
24	,	O
25	which	O
26	proliferate	O
27	in	O
28	the	O
29	Arctic	O
30	region	O
31	,	O
32	then	O
33	migrate	O
34	to	O
35	the	O
36	northern	O
37	Japan	O
38	Sea	O
39	and	O
40	eat	O
41	the	O
42	intermediate	O
43	host	O
44	fish	O
45	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	efficacies	O
6	of	O
7	adjuvant	O
8	carboplatin	O
9	and	O
10	of	O
11	abdominal	O
12	radiotherapy	O
13	seem	O
14	to	O
15	be	O
16	identical	O
17	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	Characterization	O
2	of	O
3	an	O
4	EcR	B
5	/	O
6	USP	B
7	heterodimer	O
8	target	O
9	site	O
10	that	O
11	mediates	O
12	ecdysone	O
13	responsiveness	O
14	of	O
15	the	O
16	Drosophila	B
17	Lsp	I
18	-	I
19	2	I
20	gene	I
21	.	O

1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O

1	Transcriptional	O
2	activation	O
3	of	O
4	the	O
5	chicken	B
6	lysozyme	I
7	gene	I
8	by	O
9	NF	B
10	-	I
11	kappa	I
12	Bp65	I
13	(	O
14	RelA	B
15	)	O
16	and	O
17	c	B
18	-	I
19	Rel	I
20	,	O
21	but	O
22	not	O
23	by	O
24	NF	B
25	-	I
26	kappa	I
27	Bp50	I
28	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	In	O
2	vivo	O
3	,	O
4	selective	O
5	activation	O
6	of	O
7	SAPKs	B
8	stimulates	O
9	formation	O
10	of	O
11	the	O
12	ternary	O
13	complex	O
14	containing	O
15	Elk	B
16	-	I
17	1	I
18	,	O
19	serum	B
20	response	I
21	factor	I
22	and	O
23	the	O
24	serum	O
25	response	O
26	element	O
27	,	O
28	and	O
29	enhances	O
30	Elk	B
31	-	I
32	1	I
33	-	O
34	dependent	O
35	transcription	O
36	.	O

1	An	O
2	epidemic	O
3	of	O
4	hepatitis	O
5	B	O
6	virus	O
7	infection	O
8	among	O
9	intravenous	O
10	drug	O
11	users	O
12	in	O
13	Iceland	O
14	.	O

1	The	O
2	gene	O
3	was	O
4	uniquely	O
5	mapped	O
6	with	O
7	odds	O
8	>	O
9	1	O
10	,	O
11	000	O
12	:	O
13	1	O
14	on	O
15	chromosome	O
16	3p	O
17	in	O
18	Centre	O
19	d	O
20	'	O
21	Etude	O
22	du	O
23	Polymorphisme	O
24	Humain	O
25	pedigrees	O
26	.	O

1	Three	O
2	of	O
3	these	O
4	subunits	O
5	are	O
6	also	O
7	homologous	O
8	to	O
9	the	O
10	dimeric	O
11	POR	B
12	from	O
13	a	O
14	mesophilic	O
15	archaeon	O
16	,	O
17	Halobacterium	O
18	halobium	O
19	(	O
20	21	O
21	%	O
22	identity	O
23	).	O

1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	B
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	Upstream	O
2	of	O
3	the	O
4	dra	B
5	gene	I
6	an	O
7	open	O
8	reading	O
9	frame	O
10	of	O
11	313	O
12	amino	O
13	acids	O
14	was	O
15	identified	O
16	.	O

1	Sucrose	O
2	-	O
3	specific	O
4	regulation	O
5	of	O
6	scrB	B
7	was	O
8	also	O
9	lost	O
10	upon	O
11	deletion	O
12	of	O
13	4	O
14	bp	O
15	of	O
16	a	O
17	palindromic	O
18	sequence	O
19	(	O
20	OB	O
21	)	O
22	covering	O
23	positions	O
24	+	O
25	6	O
26	to	O
27	+	O
28	21	O
29	downstream	O
30	of	O
31	the	O
32	scrB	B
33	transcriptional	O
34	start	O
35	site	O
36	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	B
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	B
18	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	first	O
6	gene	O
7	,	O
8	epiF	B
9	,	O
10	responded	O
11	to	O
12	the	O
13	activator	B
14	protein	I
15	EpiQ	I
16	and	O
17	contained	O
18	a	O
19	palindromic	O
20	sequence	O
21	similar	O
22	to	O
23	the	O
24	EpiQ	B
25	binding	I
26	site	I
27	of	O
28	the	O
29	epiA	B
30	promoter	I
31	,	O
32	which	O
33	is	O
34	also	O
35	activated	O
36	by	O
37	EpiQ	B
38	.	O

1	CXC	O
2	chemokines	O
3	bind	O
4	to	O
5	unique	O
6	sets	O
7	of	O
8	selectivity	O
9	determinants	O
10	that	O
11	can	O
12	function	O
13	independently	O
14	and	O
15	are	O
16	broadly	O
17	distributed	O
18	on	O
19	multiple	O
20	domains	O
21	of	O
22	human	O
23	interleukin	B
24	-	I
25	8	I
26	receptor	I
27	B	I
28	.	O

1	Oligodeoxynucleotides	O
2	antisense	O
3	to	O
4	the	O
5	predicted	O
6	translation	O
7	initiation	O
8	regions	O
9	of	O
10	ICP4	B
11	and	O
12	pp38	B
13	mRNAs	I
14	inhibited	O
15	proliferation	O
16	of	O
17	MSB1	O
18	cells	O
19	but	O
20	not	O
21	MDCC	O
22	-	O
23	CU91	O
24	(	O
25	CU91	O
26	)	O
27	reticuloendotheliosis	O
28	virus	O
29	-	O
30	transformed	O
31	cells	O
32	.	O

1	Retroviral	O
2	replication	O
3	requires	O
4	that	O
5	a	O
6	portion	O
7	of	O
8	the	O
9	primary	O
10	transcripts	O
11	generated	O
12	from	O
13	proviral	O
14	DNA	O
15	be	O
16	spliced	O
17	to	O
18	serve	O
19	as	O
20	mRNA	O
21	for	O
22	the	O
23	envelope	B
24	protein	I
25	and	O
26	in	O
27	Rous	O
28	sarcoma	O
29	virus	O
30	as	O
31	src	B
32	mRNA	I
33	.	O

1	In	O
2	this	O
3	case	O
4	the	O
5	degree	O
6	of	O
7	promoter	O
8	methylation	O
9	,	O
10	which	O
11	could	O
12	extend	O
13	beyond	O
14	the	O
15	T	O
16	-	O
17	DNA	O
18	borders	O
19	,	O
20	was	O
21	not	O
22	correlated	O
23	with	O
24	the	O
25	reduction	O
26	in	O
27	steady	O
28	-	O
29	state	O
30	poly	O
31	(	O
32	A	O
33	)+	O
34	mRNA	O
35	levels	O
36	,	O
37	the	O
38	silenced	O
39	state	O
40	was	O
41	transmitted	O
42	through	O
43	meiosis	O
44	and	O
45	reactivation	O
46	lasted	O
47	several	O
48	generations	O
49	.	O

1	Thus	O
2	,	O
3	the	O
4	consensus	O
5	sequences	O
6	for	O
7	phosphatase	O
8	regulation	O
9	are	O
10	5	O
11	'-	O
12	GCACGTGGG	O
13	-	O
14	3	O
15	'	O
16	and	O
17	5	O
18	'-	O
19	GCACGTTTT	O
20	-	O
21	3	O
22	'	O
23	which	O
24	differ	O
25	from	O
26	the	O
27	binding	O
28	sequences	O
29	for	O
30	the	O
31	Cpflp	B
32	protein	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	genes	O
39	in	O
40	methionine	O
41	biosynthesis	O
42	and	O
43	for	O
44	centromere	O
45	function	O
46	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	the	O
6	proline	O
7	-	O
8	rich	O
9	region	O
10	of	O
11	CAP	B
12	is	O
13	recognized	O
14	by	O
15	the	O
16	SH3	B
17	domains	I
18	of	O
19	several	O
20	proteins	O
21	,	O
22	including	O
23	the	O
24	yeast	B
25	actin	I
26	-	I
27	associated	I
28	protein	I
29	Abp1p	I
30	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	B
41	gene	I
42	.	O

1	Differentiation	O
2	was	O
3	not	O
4	observed	O
5	after	O
6	cellular	O
7	expression	O
8	of	O
9	GTPase	B
10	-	O
11	deficient	O
12	forms	O
13	of	O
14	alpha	B
15	i2	I
16	or	O
17	alpha	B
18	0	I
19	,	O
20	indicating	O
21	selectivity	O
22	for	O
23	the	O
24	Gq	B
25	family	I
26	of	O
27	G	B
28	proteins	I
29	.	O

1	Consistent	O
2	with	O
3	a	O
4	possible	O
5	role	O
6	in	O
7	transcription	O
8	,	O
9	Paf1p	B
10	is	O
11	localized	O
12	to	O
13	the	O
14	nucleus	O
15	.	O

1	By	O
2	comparing	O
3	the	O
4	abundances	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	isogenic	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	paf1	B
16	mutant	I
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	PAF1	B
29	.	O

1	Paf1p	B
2	may	O
3	therefore	O
4	be	O
5	required	O
6	for	O
7	both	O
8	positive	O
9	and	O
10	negative	O
11	regulation	O
12	of	O
13	subsets	O
14	of	O
15	yeast	O
16	genes	O
17	.	O

1	Using	O
2	a	O
3	high	O
4	-	O
5	copy	O
6	suppression	O
7	strategy	O
8	,	O
9	we	O
10	have	O
11	identified	O
12	a	O
13	yeast	O
14	gene	O
15	(	O
16	UBS1	B
17	)	O
18	whose	O
19	elevated	O
20	expression	O
21	suppresses	O
22	the	O
23	conditional	O
24	cell	O
25	cycle	O
26	defects	O
27	associated	O
28	with	O
29	cdc34	B
30	mutations	O
31	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	malignant	O
5	melanoma	O
6	of	O
7	soft	O
8	parts	O
9	or	O
10	soft	O
11	tissue	O
12	clear	O
13	cell	O
14	sarcoma	O
15	which	O
16	shares	O
17	t	O
18	(	O
19	12	O
20	;	O
21	22	O
22	)	O
23	chromosome	O
24	translocation	O
25	revealed	O
26	fusion	O
27	of	O
28	EWS	B
29	with	O
30	a	O
31	transcriptional	O
32	factor	O
33	gene	B
34	ATF	I
35	-	I
36	1	I
37	.	O

1	Clones	O
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O

1	Abp1	B
2	preferentially	O
3	binds	O
4	to	O
5	multiple	O
6	sites	O
7	in	O
8	ARS	B
9	3002	I
10	and	O
11	to	O
12	the	O
13	DNA	O
14	polymer	O
15	poly	O
16	[	O
17	d	O
18	(	O
19	A	O
20	.	O
21	T	O
22	)].	O

1	Identification	O
2	,	O
3	purification	O
4	,	O
5	and	O
6	molecular	O
7	cloning	O
8	of	O
9	autonomously	B
10	replicating	I
11	sequence	I
12	-	I
13	binding	I
14	protein	I
15	1	I
16	from	I
17	fission	I
18	yeast	I
19	Schizosaccharomyces	I
20	pombe	I
21	.	O

1	A	O
2	short	O
3	open	O
4	reading	O
5	frame	O
6	(	O
7	ORF2	O
8	),	O
9	of	O
10	unknown	O
11	function	O
12	,	O
13	is	O
14	present	O
15	in	O
16	all	O
17	FIV	O
18	isolates	O
19	.	O

1	The	O
2	patient	O
3	was	O
4	homozygous	O
5	for	O
6	the	O
7	underlying	O
8	mutation	O
9	,	O
10	which	O
11	was	O
12	found	O
13	to	O
14	be	O
15	a	O
16	G	O
17	-->	O
18	T	O
19	transversion	O
20	within	O
21	the	O
22	acceptor	O
23	splice	O
24	site	O
25	between	O
26	intron	O
27	e	O
28	and	O
29	exon	O
30	6	O
31	,	O
32	abolishing	O
33	normal	O
34	RNA	O
35	splicing	O
36	.	O

1	These	O
2	regions	O
3	overlap	O
4	with	O
5	the	O
6	HIT	B
7	protein	I
8	similarity	I
9	regions	I
10	.	O

1	We	O
2	tested	O
3	10	O
4	rats	O
5	with	O
6	electrophysiologically	O
7	guided	O
8	,	O
9	ibotenic	O
10	acid	O
11	lesions	O
12	of	O
13	the	O
14	PBN	O
15	(	O
16	PBNx	O
17	)	O
18	to	O
19	determine	O
20	whether	O
21	they	O
22	could	O
23	acquire	O
24	a	O
25	LiCl	O
26	-	O
27	induced	O
28	CTA	O
29	to	O
30	l	O
31	-	O
32	alanine	O
33	(	O
34	0	O
35	.	O
36	3	O
37	M	O
38	)	O
39	or	O
40	demonstrate	O
41	a	O
42	sodium	O
43	appetite	O
44	following	O
45	furosemide	O
46	treatment	O
47	and	O
48	overnight	O
49	access	O
50	to	O
51	sodium	O
52	deficient	O
53	chow	O
54	.	O

1	Liposomal	O
2	Amphotericin	O
3	-	O
4	B	O
5	failed	O
6	in	O
7	6	O
8	/	O
9	7	O
10	patients	O
11	with	O
12	culture	O
13	-	O
14	proven	O
15	mycosis	O
16	who	O
17	died	O
18	from	O
19	infection	O
20	with	O
21	Aspergillus	O
22	(	O
23	n	O
24	=	O
25	2	O
26	)	O
27	and	O
28	Candida	O
29	(	O
30	n	O
31	=	O
32	4	O
33	),	O
34	respectively	O
35	.	O

1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O

1	Magnetic	O
2	storm	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	medicine	O
9	,	O
10	in	O
11	geophysics	O
12	and	O
13	for	O
14	special	O
15	purposes	O
16	.	O

1	Transgenic	O
2	tobacco	O
3	plants	O
4	(	O
5	ppa	B
6	-	I
7	1	I
8	)	O
9	constitutively	O
10	expressing	O
11	Escherichia	B
12	coli	I
13	pyrophosphatase	I
14	behind	O
15	the	O
16	35S	B
17	CaMV	I
18	promoter	I
19	accumulate	O
20	high	O
21	levels	O
22	of	O
23	soluble	O
24	sugars	O
25	in	O
26	their	O
27	leaves	O
28	[	O
29	27	O
30	].	O

1	Human	B
2	LAF	I
3	-	I
4	4	I
5	readily	O
6	hybridized	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	O
19	family	O
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O

1	Hb	B
2	levels	O
3	remained	O
4	adequate	O
5	(	O
6	Hb	B
7	=	O
8	10	O
9	.	O
10	68	O
11	+/-	O
12	0	O
13	.	O
14	77	O
15	g	O
16	/	O
17	dl	O
18	)	O
19	after	O
20	14	O
21	.	O
22	6	O
23	+/-	O
24	7	O
25	.	O
26	64	O
27	months	O
28	.	O

1	CBT	O
2	is	O
3	discussed	O
4	in	O
5	comparison	O
6	with	O
7	the	O
8	Wisconsin	O
9	Card	O
10	Sorting	O
11	Test	O
12	as	O
13	a	O
14	potential	O
15	cognitive	O
16	activation	O
17	task	O
18	for	O
19	functional	O
20	neuroimaging	O
21	of	O
22	the	O
23	frontal	O
24	lobes	O
25	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	although	O
6	218leu	O
7	retains	O
8	normal	O
9	transactivation	O
10	activity	O
11	on	O
12	a	O
13	p53	B
14	promoter	I
15	in	O
16	yeast	O
17	at	O
18	physiological	O
19	temperatures	O
20	,	O
21	it	O
22	is	O
23	not	O
24	capable	O
25	of	O
26	normal	O
27	p53	B
28	function	O
29	in	O
30	the	O
31	presence	O
32	of	O
33	a	O
34	248trp	B
35	allele	I
36	in	O
37	SNU	O
38	-	O
39	C5	O
40	cells	O
41	.	O

1	Cycles	O
2	were	O
3	repeated	O
4	every	O
5	3	O
6	weeks	O
7	.	O

1	Neither	O
2	class	O
3	II	O
4	nor	O
5	IV	O
6	infections	O
7	precluded	O
8	transplantation	O
9	.	O

1	Although	O
2	a	O
3	great	O
4	deal	O
5	is	O
6	understood	O
7	about	O
8	how	O
9	bHLH	B
10	factors	I
11	activate	O
12	gene	O
13	transcription	O
14	via	O
15	E	O
16	-	O
17	box	O
18	DNA	O
19	consensus	O
20	sequences	O
21	,	O
22	studies	O
23	of	O
24	bHLH	B
25	factor	I
26	function	O
27	in	O
28	higher	O
29	eukaryotes	O
30	often	O
31	have	O
32	been	O
33	hindered	O
34	by	O
35	the	O
36	presence	O
37	of	O
38	multiple	O
39	family	O
40	members	O
41	.	O

1	Mobility	O
2	and	O
3	supershift	O
4	assays	O
5	demonstrated	O
6	that	O
7	upstream	B
8	stimulatory	I
9	factor	I
10	(	O
11	USF	B
12	)	O
13	and	O
14	Sp1	B
15	bind	O
16	to	O
17	the	O
18	former	O
19	elements	O
20	and	O
21	competition	O
22	experiments	O
23	confirmed	O
24	that	O
25	CREB	B
26	/	O
27	ATF	B
28	and	O
29	AP	B
30	-	I
31	1	I
32	bind	O
33	to	O
34	the	O
35	CRE	O
36	/	O
37	TRE	O
38	element	O
39	.	O

1	Upstream	O
2	of	O
3	-	O
4	37	O
5	,	O
6	the	O
7	5	O
8	'	O
9	untranslated	O
10	sequences	O
11	of	O
12	the	O
13	isolates	O
14	differ	O
15	in	O
16	both	O
17	length	O
18	and	O
19	sequence	O
20	.	O

1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	hCG	B
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	B
17	levels	O
18	suggest	O
19	that	O
20	hCG	B
21	has	O
22	thyrotropic	O
23	activity	O
24	.	O

1	High	O
2	fibrinogen	B
3	levels	O
4	could	O
5	thus	O
6	be	O
7	a	O
8	risk	O
9	for	O
10	perioperative	O
11	thrombosis	O
12	.	O

1	Strontium	O
2	chloride	O
3	Sr	O
4	89	O
5	is	O
6	costly	O
7	,	O
8	but	O
9	preliminary	O
10	analysis	O
11	indicates	O
12	that	O
13	it	O
14	may	O
15	reduce	O
16	management	O
17	expenditures	O
18	overall	O
19	.(	O
20	ABSTRACT	O
21	TRUNCATED	O
22	AT	O
23	250	O
24	WORDS	O
25	)	O

1	We	O
2	propose	O
3	that	O
4	epigenetic	O
5	features	O
6	of	O
7	tissue	O
8	-	O
9	specific	O
10	control	O
11	and	O
12	of	O
13	the	O
14	control	O
15	of	O
16	allelic	O
17	expression	O
18	are	O
19	intricately	O
20	linked	O
21	.	O

1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	B
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O

1	SBF	B
2	binds	O
3	to	O
4	the	O
5	promoter	O
6	prior	O
7	to	O
8	the	O
9	activation	O
10	of	O
11	transcription	O
12	in	O
13	late	O
14	G1	O
15	,	O
16	suggesting	O
17	that	O
18	Cln	B
19	/	O
20	Cdc28	B
21	kinase	O
22	regulates	O
23	the	O
24	ability	O
25	of	O
26	previously	O
27	bound	O
28	SBF	B
29	to	O
30	activate	O
31	transcription	O
32	.	O

1	However	O
2	,	O
3	it	O
4	remains	O
5	an	O
6	open	O
7	question	O
8	whether	O
9	vertebrate	B
10	Hox	I
11	genes	I
12	expressed	O
13	under	O
14	the	O
15	control	O
16	of	O
17	Drosophila	O
18	regulatory	O
19	sequences	O
20	can	O
21	substitute	O
22	the	O
23	function	O
24	of	O
25	Drosophila	B
26	Hox	I
27	genes	I
28	.	O

1	This	O
2	approach	O
3	places	O
4	gHoxb	B
5	-	I
6	1	I
7	into	O
8	the	O
9	normal	O
10	embryonic	O
11	spatiotemporal	O
12	context	O
13	in	O
14	which	O
15	lab	O
16	acts	O
17	.	O

1	This	O
2	5	O
3	'	O
4	splice	O
5	site	O
6	sequence	O
7	was	O
8	required	O
9	for	O
10	enhanced	O
11	polyadenylation	O
12	and	O
13	was	O
14	recognized	O
15	by	O
16	both	O
17	U1	B
18	small	I
19	nuclear	I
20	ribonucleoproteins	I
21	(	O
22	snRNPs	O
23	)	O
24	and	O
25	alternative	B
26	splicing	I
27	factor	I
28	/	O
29	splicing	B
30	factor	I
31	2	I
32	(	O
33	ASF	B
34	/	O
35	SF2	B
36	).	O

1	This	O
2	analysis	O
3	revealed	O
4	that	O
5	SAP	B
6	145	I
7	,	O
8	together	O
9	with	O
10	four	O
11	other	O
12	SF3a	B
13	/	O
14	SF3b	B
15	subunits	O
16	,	O
17	UV	O
18	cross	O
19	-	O
20	links	O
21	to	O
22	pre	O
23	-	O
24	mRNA	O
25	in	O
26	a	O
27	20	O
28	-	O
29	nucleotide	O
30	region	O
31	upstream	O
32	of	O
33	the	O
34	BPS	O
35	.	O

1	We	O
2	propose	O
3	that	O
4	CTS1	B
5	and	I
6	CTS2	I
7	of	I
8	Ci	I
9	are	O
10	members	O
11	of	O
12	two	O
13	distinct	O
14	classes	O
15	of	O
16	fungal	B
17	chitinases	I
18	,	O
19	an	O
20	observation	O
21	not	O
22	previously	O
23	reported	O
24	for	O
25	a	O
26	single	O
27	fungus	O
28	.	O

1	Although	O
2	the	O
3	consumption	O
4	of	O
5	myoglobin	B
6	-	O
7	bound	O
8	O2	O
9	(	O
10	MbO2	O
11	)	O
12	stores	O
13	in	O
14	seal	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	seal	O
21	muscles	O
22	during	O
23	laboratory	O
24	simulations	O
25	of	O
26	diving	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	diving	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	profound	O
53	diving	O
54	response	O
55	induced	O
56	by	O
57	forced	O
58	immersion	O
59	.	O

1	The	O
2	human	B
3	purH	I
4	cDNA	I
5	is	O
6	1776	O
7	base	O
8	pairs	O
9	in	O
10	length	O
11	encoding	O
12	for	O
13	a	O
14	591	O
15	-	O
16	amino	O
17	acid	O
18	polypeptic	O
19	(	O
20	Mr	O
21	=	O
22	64	O
23	,	O
24	425	O
25	).	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	spindle	O
5	pole	O
6	body	O
7	duplication	O
8	gene	B
9	MPS1	I
10	is	O
11	part	O
12	of	O
13	a	O
14	mitotic	O
15	checkpoint	O
16	.	O

1	In	O
2	our	O
3	opinion	O
4	,	O
5	the	O
6	SM	O
7	-	O
8	CMA	O
9	system	O
10	is	O
11	,	O
12	despite	O
13	some	O
14	shortcomings	O
15	in	O
16	its	O
17	user	O
18	-	O
19	interface	O
20	,	O
21	a	O
22	useful	O
23	and	O
24	versatile	O
25	instrument	O
26	for	O
27	examination	O
28	of	O
29	human	O
30	semen	O
31	samples	O
32	,	O
33	with	O
34	desirable	O
35	features	O
36	.	O

1	The	O
2	purpose	O
3	of	O
4	the	O
5	study	O
6	reported	O
7	here	O
8	was	O
9	to	O
10	investigate	O
11	whether	O
12	differences	O
13	in	O
14	T1	O
15	and	O
16	T2	O
17	between	O
18	tumors	O
19	are	O
20	mainly	O
21	a	O
22	consequence	O
23	of	O
24	differences	O
25	in	O
26	the	O
27	fractional	O
28	volume	O
29	of	O
30	the	O
31	extracellular	O
32	compartment	O
33	.	O

1	A	O
2	mutant	B
3	areA	I
4	product	I
5	truncated	O
6	immediately	O
7	after	O
8	the	O
9	last	O
10	residue	O
11	of	O
12	the	O
13	highly	O
14	conserved	O
15	GATA	B
16	(	I
17	DNA	I
18	-	I
19	binding	I
20	)	I
21	domain	I
22	retains	O
23	partial	O
24	function	O
25	.	O

1	Oligonucleotides	O
2	,	O
3	designed	O
4	on	O
5	the	O
6	basis	O
7	of	O
8	conserved	O
9	flanking	O
10	amino	O
11	acid	O
12	sequence	O
13	segments	O
14	within	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	eukaryotic	B
20	protein	I
21	kinase	I
22	C	I
23	(	O
24	PKC	B
25	)	O
26	proteins	O
27	,	O
28	were	O
29	used	O
30	as	O
31	primers	O
32	for	O
33	polymerase	O
34	chain	O
35	reactions	O
36	to	O
37	amplify	O
38	a	O
39	427	O
40	-	O
41	bp	O
42	chromosomal	O
43	DNA	O
44	fragment	O
45	from	O
46	the	O
47	filamentous	O
48	fungus	O
49	Trichoderma	O
50	reesei	O
51	.	O

1	Disruption	O
2	of	O
3	RB	B
4	/	O
5	E2F	B
6	-	I
7	1	I
8	interaction	O
9	by	O
10	single	O
11	point	O
12	mutations	O
13	in	O
14	E2F	B
15	-	I
16	1	I
17	enhances	O
18	S	O
19	-	O
20	phase	O
21	entry	O
22	and	O
23	apoptosis	O
24	.	O

1	Apparent	O
2	loss	O
3	of	O
4	differentiation	O
5	markers	O
6	characterizes	O
7	advanced	O
8	malignant	O
9	neoplasms	O
10	.	O

1	This	O
2	region	O
3	contains	O
4	a	O
5	motif	O
6	with	O
7	partial	O
8	identity	O
9	with	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	the	O
15	ubiquitous	O
16	transcription	O
17	factor	O
18	upstream	B
19	stimulatory	I
20	factor	I
21	(	O
22	USF	B
23	),	O
24	which	O
25	binds	O
26	to	O
27	the	O
28	human	B
29	insulin	I
30	promoter	I
31	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	satisfactorily	O
6	applied	O
7	to	O
8	the	O
9	determination	O
10	of	O
11	paracetamol	O
12	in	O
13	pharmaceutical	O
14	formulations	O
15	and	O
16	biological	O
17	fluids	O
18	.	O

1	These	O
2	primers	O
3	yielded	O
4	a	O
5	PCR	O
6	product	O
7	of	O
8	a	O
9	characteristic	O
10	length	O
11	within	O
12	most	O
13	Xanthomonas	O
14	species	O
15	and	O
16	pathovars	O
17	tested	O
18	.	O

1	The	O
2	Clb5	B
3	kinase	I
4	,	O
5	which	O
6	promotes	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	declines	O
29	rapidly	O
30	in	O
31	sim	B
32	mutants	I
33	.	O

1	The	O
2	C	O
3	/	O
4	D	O
5	ratio	O
6	was	O
7	equal	O
8	to	O
9	or	O
10	over	O
11	0	O
12	.	O
13	6	O
14	in	O
15	9	O
16	cases	O
17	(	O
18	16	O
19	eyes	O
20	),	O
21	and	O
22	the	O
23	values	O
24	were	O
25	inconsistent	O
26	between	O
27	both	O
28	eyes	O
29	in	O
30	55	O
31	%	O
32	of	O
33	the	O
34	patients	O
35	.	O

1	Rad6	B
2	mutants	I
3	display	O
4	a	O
5	remarkably	O
6	pleiotropic	O
7	phenotype	O
8	,	O
9	implicating	O
10	the	O
11	protein	O
12	in	O
13	DNA	O
14	damage	O
15	-	O
16	induced	O
17	mutagenesis	O
18	,	O
19	postreplication	O
20	repair	O
21	,	O
22	repression	O
23	of	O
24	retrotransposition	O
25	,	O
26	and	O
27	sporulation	O
28	.	O

1	RNase	B
2	protection	O
3	assays	O
4	revealed	O
5	a	O
6	correlation	O
7	between	O
8	the	O
9	levels	O
10	of	O
11	dorsal	O
12	and	O
13	ventral	O
14	skin	O
15	expression	O
16	with	O
17	pigmentation	O
18	/	O
19	phaeomelanin	O
20	phenotypes	O
21	.	O

1	Molecular	O
2	cloning	O
3	,	O
4	expression	O
5	pattern	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	human	O
12	CDKN2D	B
13	/	O
14	INK4d	B
15	,	O
16	an	O
17	inhibitor	O
18	of	O
19	cyclin	B
20	D	I
21	-	I
22	dependent	I
23	kinases	I
24	.	O

1	Overproduction	O
2	of	O
3	HrcA	B
4	protein	I
5	from	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	hrcA	B
11	derived	O
12	from	O
13	a	O
14	plasmid	O
15	(	O
16	phrcA	B
17	+)	O
18	in	O
19	B	O
20	.	O
21	subtilis	O
22	wild	O
23	-	O
24	type	O
25	and	O
26	delta	O
27	hrcA	B
28	strains	O
29	prevented	O
30	heat	O
31	shock	O
32	induction	O
33	of	O
34	the	O
35	dnaK	B
36	and	O
37	groE	B
38	operons	I
39	at	O
40	the	O
41	level	O
42	of	O
43	transcription	O
44	almost	O
45	completely	O
46	and	O
47	strongly	O
48	reduced	O
49	the	O
50	amounts	O
51	of	O
52	mRNA	O
53	at	O
54	a	O
55	low	O
56	temperature	O
57	as	O
58	well	O
59	.	O

1	We	O
2	report	O
3	the	O
4	molecular	O
5	cloning	O
6	and	O
7	functional	O
8	characterization	O
9	of	O
10	USF2	B
11	isoforms	I
12	,	O
13	corresponding	O
14	to	O
15	a	O
16	44	O
17	-	O
18	kDa	O
19	subunit	O
20	,	O
21	USF2a	B
22	,	O
23	and	O
24	a	O
25	new	O
26	38	O
27	-	O
28	kDa	O
29	subunit	O
30	,	O
31	USF2b	B
32	,	O
33	generated	O
34	by	O
35	differential	O
36	splicing	O
37	.	O

1	The	O
2	preferential	O
3	heterodimerization	O
4	of	O
5	USF	B
6	subunits	I
7	was	O
8	reproduced	O
9	ex	O
10	vivo	O
11	,	O
12	while	O
13	the	O
14	in	O
15	vitro	O
16	association	O
17	of	O
18	cotranslated	O
19	subunits	O
20	,	O
21	or	O
22	recombinant	B
23	USF	I
24	proteins	I
25	,	O
26	appeared	O
27	to	O
28	be	O
29	random	O
30	.	O

1	Activated	O
2	PKR	B
3	may	O
4	exist	O
5	as	O
6	a	O
7	dimer	O
8	and	O
9	phosphorylates	O
10	the	O
11	eukaryotic	B
12	translation	I
13	initiation	I
14	factor	I
15	2	I
16	alpha	I
17	subunit	I
18	(	O
19	cIF	B
20	-	I
21	2	I
22	alpha	I
23	)	O
24	to	O
25	inhibit	O
26	polypeptide	O
27	chain	O
28	initiation	O
29	.	O

1	GRP78	B
2	,	O
3	a	O
4	molecular	O
5	chaperone	O
6	expressed	O
7	in	O
8	the	O
9	endoplasmic	O
10	reticulum	O
11	,	O
12	is	O
13	a	O
14	"	O
15	glucose	O
16	-	O
17	regulated	O
18	protein	O
19	"	O
20	induced	O
21	by	O
22	stress	O
23	responses	O
24	that	O
25	deplete	O
26	glucose	O
27	or	O
28	intracisternal	O
29	calcium	O
30	or	O
31	otherwise	O
32	disrupt	O
33	glycoprotein	O
34	trafficking	O
35	.	O

1	The	O
2	IL	B
3	-	I
4	8	I
5	receptor	I
6	is	O
7	a	O
8	seven	O
9	-	O
10	transmembrane	O
11	spanning	O
12	receptor	O
13	coupled	O
14	to	O
15	specific	O
16	heterotrimeric	B
17	G	I
18	proteins	I
19	including	O
20	Gi	B
21	and	O
22	G16	B
23	.	O

1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	O
12	/	O
13	HDC	O
14	Ac	O
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O

1	To	O
2	elucidate	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	Fyn	B
8	in	O
9	the	O
10	expression	O
11	of	O
12	viral	O
13	promoters	O
14	,	O
15	we	O
16	transfected	O
17	a	O
18	Fyn	B
19	-	O
20	expression	O
21	vector	O
22	together	O
23	with	O
24	a	O
25	reporter	O
26	plasmid	O
27	containing	O
28	the	O
29	chloramphenicol	B
30	acetyltransferase	I
31	gene	I
32	driven	O
33	by	O
34	HIV	B
35	LTR	I
36	into	O
37	a	O
38	human	O
39	T	O
40	cell	O
41	line	O
42	,	O
43	Jurkat	O
44	.	O

1	We	O
2	conducted	O
3	a	O
4	prospective	O
5	,	O
6	randomized	O
7	controlled	O
8	trial	O
9	of	O
10	metoprolol	O
11	,	O
12	a	O
13	selective	O
14	beta	O
15	-	O
16	blocker	O
17	for	O
18	prevention	O
19	of	O
20	gastrointestinal	O
21	bleeding	O
22	from	O
23	portal	O
24	hypertension	O
25	in	O
26	29	O
27	non	O
28	-	O
29	selected	O
30	patients	O
31	with	O
32	liver	O
33	disease	O
34	and	O
35	previous	O
36	gastrointestinal	O
37	bleeding	O
38	.	O

1	A	O
2	genetic	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	non	O
8	-	O
9	inducible	O
10	qutA	B
11	mutants	I
12	showed	O
13	that	O
14	all	O
15	23	O
16	mutations	O
17	analysed	O
18	map	O
19	within	O
20	the	O
21	N	O
22	-	O
23	terminal	O
24	half	O
25	of	O
26	the	O
27	encoded	O
28	QUTA	B
29	protein	I
30	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	B
28	-	I
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	Suppressors	O
2	of	O
3	defective	O
4	silencing	O
5	in	O
6	yeast	O
7	:	O
8	effects	O
9	on	O
10	transcriptional	O
11	repression	O
12	at	O
13	the	O
14	HMR	B
15	locus	I
16	,	O
17	cell	O
18	growth	O
19	and	O
20	telomere	O
21	structure	O
22	.	O

1	Although	O
2	ANP	B
3	induced	O
4	systemic	O
5	capillary	O
6	filtration	O
7	,	O
8	in	O
9	the	O
10	calf	O
11	,	O
12	filtration	O
13	was	O
14	reduced	O
15	with	O
16	ANP	B
17	.	O

1	Recent	O
2	literature	O
3	has	O
4	suggested	O
5	that	O
6	beta	B
7	-	I
8	2	I
9	transferrin	I
10	can	O
11	also	O
12	be	O
13	used	O
14	as	O
15	a	O
16	clinical	O
17	marker	O
18	for	O
19	perilymph	O
20	.	O

1	With	O
2	current	O
3	methodology	O
4	beta	B
5	-	I
6	2	I
7	transferrin	I
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	perilymph	O
19	in	O
20	the	O
21	operative	O
22	setting	O
23	.	O

1	The	O
2	hIGF	B
3	-	I
4	I	I
5	gene	I
6	has	O
7	two	O
8	promoters	O
9	,	O
10	P1	O
11	and	O
12	P2	O
13	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	indicated	O
6	that	O
7	at	O
8	least	O
9	four	O
10	nuclear	O
11	proteins	O
12	with	O
13	distinct	O
14	biochemical	O
15	and	O
16	binding	O
17	properties	O
18	possess	O
19	the	O
20	ability	O
21	to	O
22	bind	O
23	the	O
24	3	O
25	beta	O
26	I	O
27	-	O
28	A	O
29	element	O
30	to	O
31	produce	O
32	four	O
33	DNA	O
34	-	O
35	protein	O
36	complexes	O
37	(	O
38	R1	O
39	to	O
40	R4	O
41	).	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	Significant	O
2	correlations	O
3	existed	O
4	between	O
5	FEV1	O
6	and	O
7	the	O
8	corresponding	O
9	values	O
10	of	O
11	Raw	O
12	,	O
13	MEF50	O
14	and	O
15	MEF25	O
16	,	O
17	although	O
18	there	O
19	were	O
20	considerable	O
21	individual	O
22	differences	O
23	between	O
24	test	O
25	results	O
26	.	O

1	(	O
2	1989	O
3	),	O
4	which	O
5	is	O
6	identical	O
7	to	O
8	the	O
9	SSC1	B
10	gene	I
11	(	O
12	Smith	O
13	et	O
14	al	O
15	.,	O
16	1988	O
17	).	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	O
9	Leu	B
10	-	I
11	tRNA	I
12	precursor	I
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	O
18	tau	O
19	element	O
20	.	O

1	Occupational	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O

1	Hybrid	O
2	female	O
3	mice	O
4	(	O
5	C57BL	O
6	x	O
7	CBA	O
8	)	O
9	were	O
10	paired	O
11	with	O
12	breeder	O
13	males	O
14	(	O
15	CD	O
16	-	O
17	1	O
18	)	O
19	and	O
20	LNG	O
21	pellets	O
22	were	O
23	implanted	O
24	on	O
25	day	O
26	0	O
27	,	O
28	the	O
29	day	O
30	on	O
31	which	O
32	copulation	O
33	plugs	O
34	were	O
35	found	O
36	,	O
37	or	O
38	on	O
39	day	O
40	2	O
41	or	O
42	day	O
43	3	O
44	in	O
45	the	O
46	postcoital	O
47	period	O
48	.	O

1	This	O
2	gene	O
3	encodes	O
4	a	O
5	putative	O
6	transcription	O
7	factor	O
8	with	O
9	regions	O
10	of	O
11	homology	O
12	to	O
13	several	O
14	other	O
15	proteins	O
16	including	O
17	the	O
18	zinc	O
19	fingers	O
20	and	O
21	other	O
22	domains	O
23	of	O
24	the	O
25	Drosophila	B
26	trithorax	I
27	gene	I
28	product	I
29	,	O
30	and	O
31	the	O
32	"	O
33	AT	O
34	-	O
35	hook	O
36	"	O
37	DNA	O
38	-	O
39	binding	O
40	motif	O
41	of	O
42	high	B
43	mobility	I
44	group	I
45	proteins	I
46	.	O

1	Using	O
2	reference	O
3	probes	O
4	as	O
5	internal	O
6	standards	O
7	,	O
8	we	O
9	show	O
10	that	O
11	the	O
12	ost	B
13	transcription	I
14	unit	I
15	is	O
16	located	O
17	within	O
18	the	O
19	cytogenetic	O
20	band	O
21	interval	O
22	89A1	O
23	,	O
24	2	O
25	on	O
26	the	O
27	right	O
28	arm	O
29	of	O
30	the	O
31	third	O
32	chromosome	O
33	,	O
34	and	O
35	that	O
36	it	O
37	exerts	O
38	diagnostic	O
39	segmentation	O
40	gene	O
41	expression	O
42	patterns	O
43	in	O
44	the	O
45	embryo	O
46	.	O

1	The	O
2	purified	O
3	recombinant	O
4	enzyme	O
5	catalyzed	O
6	specific	O
7	phosphoryl	O
8	transfer	O
9	from	O
10	ATP	O
11	to	O
12	UMP	O
13	and	O
14	CMP	O
15	.	O

1	Studies	O
2	on	O
3	the	O
4	life	O
5	cycle	O
6	of	O
7	Haplorchis	O
8	pumilio	O
9	(	O
10	Looss	O
11	,	O
12	1896	O
13	)	O
14	Looss	O
15	,	O
16	1899	O
17	with	O
18	morphological	O
19	redescription	O
20	of	O
21	larval	O
22	and	O
23	adult	O
24	stages	O
25	.	O

1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O

1	During	O
2	the	O
3	following	O
4	pregnancy	O
5	ultrasonographic	O
6	studies	O
7	of	O
8	the	O
9	male	O
10	fetus	O
11	in	O
12	the	O
13	16th	O
14	week	O
15	of	O
16	gestation	O
17	revealed	O
18	severe	O
19	micrognathia	O
20	,	O
21	short	O
22	and	O
23	wide	O
24	thumbs	O
25	,	O
26	and	O
27	big	O
28	toes	O
29	,	O
30	and	O
31	bowed	O
32	tibiae	O
33	.	O

1	Despite	O
2	an	O
3	overall	O
4	survival	O
5	rate	O
6	of	O
7	43	O
8	%,	O
9	survival	O
10	to	O
11	discharge	O
12	varied	O
13	greatly	O
14	(	O
15	0	O
16	to	O
17	100	O
18	%)	O
19	among	O
20	the	O
21	24	O
22	diagnostic	O
23	groups	O
24	:	O
25	tumor	O
26	lysis	O
27	syndrome	O
28	and	O
29	systemic	O
30	lupus	O
31	erythematosus	O
32	(	O
33	3	O
34	/	O
35	3	O
36	patients	O
37	each	O
38	,	O
39	100	O
40	%),	O
41	hemolytic	O
42	uremic	O
43	syndrome	O
44	(	O
45	8	O
46	/	O
47	9	O
48	patients	O
49	,	O
50	89	O
51	%).	O

1	One	O
2	hundred	O
3	units	O
4	/	O
5	kg	O
6	of	O
7	recombinant	B
8	human	I
9	erythropoietin	I
10	(	O
11	rhEPO	B
12	)	O
13	was	O
14	given	O
15	subcutaneously	O
16	3	O
17	times	O
18	a	O
19	week	O
20	for	O
21	3	O
22	weeks	O
23	.	O

1	A	O
2	3	O
3	-	O
4	week	O
5	regimen	O
6	of	O
7	erythropoietin	B
8	may	O
9	help	O
10	prevent	O
11	the	O
12	donor	O
13	'	O
14	s	O
15	need	O
16	to	O
17	receive	O
18	allogeneic	O
19	blood	O
20	transfusion	O
21	,	O
22	when	O
23	the	O
24	initial	O
25	Hb	B
26	levels	O
27	were	O
28	below	O
29	130	O
30	milligrams	O
31	.	O

1	In	O
2	these	O
3	constructs	O
4	,	O
5	GUS	B
6	expression	O
7	was	O
8	driven	O
9	by	O
10	promoter	O
11	regions	O
12	derived	O
13	from	O
14	the	O
15	Arabidopsis	B
16	alcohol	I
17	dehydrogenase	I
18	(	O
19	Adh1	B
20	),	O
21	maize	B
22	ubiquitin	I
23	(	O
24	Ubi1	B
25	),	O
26	rice	B
27	actin	I
28	(	O
29	Act1	B
30	)	O
31	and	O
32	CaMV	B
33	35S	I
34	genes	I
35	.	O

1	Its	O
2	organization	O
3	and	O
4	regulation	O
5	indicate	O
6	that	O
7	the	O
8	S	B
9	.	I
10	pombe	I
11	URA1	I
12	gene	I
13	product	I
14	appears	O
15	very	O
16	similar	O
17	to	O
18	the	O
19	S	B
20	.	I
21	cerevisiae	I
22	URA2	I
23	gene	I
24	product	I
25	.	O

1	The	O
2	mean	O
3	body	O
4	mass	O
5	index	O
6	(	O
7	BMI	O
8	)	O
9	was	O
10	31	O
11	.	O
12	8	O
13	+/-	O
14	6	O
15	.	O
16	3	O
17	kg	O
18	/	O
19	m2	O
20	and	O
21	28	O
22	.	O
23	5	O
24	+/-	O
25	6	O
26	.	O
27	3	O
28	kg	O
29	/	O
30	m2	O
31	in	O
32	women	O
33	and	O
34	men	O
35	,	O
36	respectively	O
37	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	O
14	interferon	B
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O

1	Synthetic	O
2	enantiomers	O
3	of	O
4	drugs	O

1	Polysome	O
2	analysis	O
3	further	O
4	indicated	O
5	that	O
6	these	O
7	germ	B
8	cell	I
9	-	I
10	specific	I
11	Sp1	I
12	mRNAs	I
13	are	O
14	translated	O
15	,	O
16	albeit	O
17	with	O
18	a	O
19	lower	O
20	efficiency	O
21	than	O
22	the	O
23	somatic	O
24	transcript	O
25	.	O

1	In	O
2	nondiabetics	O
3	the	O
4	response	O
5	of	O
6	tcPO2	O
7	but	O
8	not	O
9	of	O
10	LDF	O
11	was	O
12	influenced	O
13	by	O
14	the	O
15	values	O
16	at	O
17	rest	O
18	.	O

1	This	O
2	study	O
3	proposes	O
4	an	O
5	estimator	O
6	for	O
7	such	O
8	global	O
9	synchronizing	O
10	effects	O
11	upon	O
12	unit	O
13	-	O
14	pair	O
15	correlations	O
16	based	O
17	on	O
18	local	O
19	field	O
20	potentials	O
21	(	O
22	LFPs	O
23	).	O

1	The	O
2	assembly	O
3	of	O
4	sequence	O
5	ready	O
6	,	O
7	high	O
8	-	O
9	resolution	O
10	physical	O
11	maps	O
12	and	O
13	construction	O
14	of	O
15	minimally	O
16	overlapping	O
17	contigs	O
18	for	O
19	the	O
20	human	O
21	as	O
22	well	O
23	as	O
24	model	O
25	genomes	O
26	requires	O
27	accurate	O
28	determination	O
29	of	O
30	the	O
31	extent	O
32	of	O
33	overlap	O
34	between	O
35	adjacent	O
36	clones	O
37	as	O
38	well	O
39	as	O
40	their	O
41	relative	O
42	orientation	O
43	.	O

1	(	O
2	ii	O
3	)	O
4	opening	O
5	of	O
6	KATP	O
7	attenuates	O
8	,	O
9	inhibition	O
10	of	O
11	the	O
12	channel	O
13	exacerbates	O
14	functional	O
15	consequences	O
16	of	O
17	coronary	O
18	occlusion	O
19	,	O
20	and	O
21	(	O
22	iii	O
23	)	O
24	KATP	O
25	opening	O
26	attenuates	O
27	reperfusion	O
28	-	O
29	induced	O
30	VF	O
31	,	O
32	but	O
33	it	O
34	triggers	O
35	ischemia	O
36	-	O
37	induced	O
38	VF	O
39	.	O

1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	O
12	mitochondrial	O
13	-	O
14	processing	O
15	sites	O
16	,	O
17	therefore	O
18	the	O
19	proximal	O
20	5	O
21	'	O
22	ends	O
23	are	O
24	most	O
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O

1	Curing	O
2	shrinkage	O
3	and	O
4	volumetric	O
5	changes	O
6	of	O
7	resin	O
8	-	O
9	modified	O
10	glass	O
11	ionomer	O
12	restorative	O
13	materials	O
14	.	O

1	Here	O
2	we	O
3	present	O
4	genetic	O
5	evidence	O
6	suggesting	O
7	that	O
8	PP2A	B
9	functions	O
10	downstream	O
11	of	O
12	Ras1	B
13	in	O
14	the	O
15	Sevenless	B
16	receptor	I
17	tyrosine	I
18	kinase	I
19	(	O
20	RTK	B
21	)	O
22	signal	O
23	transduction	O
24	pathway	O
25	that	O
26	specifies	O
27	R7	O
28	photoreceptor	O
29	cell	O
30	fate	O
31	in	O
32	the	O
33	developing	O
34	Drosophila	O
35	eye	O
36	.	O

1	QBMDs	O
2	for	O
3	a	O
4	5	O
5	%	O
6	change	O
7	in	O
8	response	O
9	(	O
10	QBMD05	O
11	)	O
12	were	O
13	6	O
14	-	O
15	fold	O
16	lower	O
17	,	O
18	on	O
19	average	O
20	,	O
21	than	O
22	the	O
23	corresponding	O
24	NOAEL	O
25	.	O

1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O

1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	B
6	-	I
7	binding	I
8	cassette	I
9	,	O
10	ABC	B
11	transporter	I
12	.	O

1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O

1	Molecular	O
2	analysis	O
3	of	O
4	a	O
5	novel	O
6	schizosaccharomyces	O
7	pombe	O
8	gene	O
9	containing	O
10	two	O
11	RNP	O
12	consensus	O
13	-	O
14	sequence	O
15	RNA	O
16	-	O
17	binding	O
18	domains	O
19	.	O

1	Do	O
2	overall	O
3	treatment	O
4	time	O
5	,	O
6	field	O
7	size	O
8	,	O
9	and	O
10	treatment	O
11	energy	O
12	influence	O
13	local	O
14	control	O
15	of	O
16	T1	O
17	-	O
18	T2	O
19	squamous	O
20	cell	O
21	carcinomas	O
22	of	O
23	the	O
24	glottic	O
25	larynx	O
26	?	O
27	PURPOSE	O
28	:	O
29	To	O
30	evaluate	O
31	treatment	O
32	and	O
33	patient	O
34	related	O
35	prognostic	O
36	factors	O
37	that	O
38	may	O
39	influence	O
40	local	O
41	control	O
42	in	O
43	the	O
44	treatment	O
45	of	O
46	T1	O
47	-	O
48	T2	O
49	squamous	O
50	cell	O
51	carcinoma	O
52	of	O
53	the	O
54	glottic	O
55	larynx	O
56	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	B
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	B
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	I
33	,	O
34	fyn	B
35	,	O
36	and	O
37	btk	B
38	,	O
39	or	O
40	of	O
41	vav	B
42	-	I
43	and	I
44	ras	I
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	B
5	-	I
6	amanitin	I
7	conserved	O
8	domain	O
9	of	O
10	the	O
11	largest	O
12	subunit	O
13	of	O
14	yeast	B
15	RNA	I
16	polymerase	I
17	III	I
18	affect	O
19	pausing	O
20	,	O
21	RNA	O
22	cleavage	O
23	and	O
24	transcriptional	O
25	transitions	O
26	.	O

1	The	O
2	evidence	O
3	presented	O
4	here	O
5	suggests	O
6	that	O
7	the	O
8	p40	B
9	complex	I
10	is	O
11	a	O
12	ribonucleoprotein	O
13	complex	O
14	containing	O
15	L1Hs	B
16	RNA	I
17	(	I
18	s	I
19	)	I
20	and	O
21	that	O
22	protein	O
23	-	O
24	protein	O
25	interactions	O
26	in	O
27	which	O
28	alpha	O
29	-	O
30	helix	O
31	structures	O
32	participate	O
33	,	O
34	for	O
35	example	O
36	coiled	O
37	-	O
38	coils	O
39	,	O
40	may	O
41	occur	O
42	in	O
43	the	O
44	complex	O
45	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	trans	O
6	-	O
7	activation	O
8	from	O
9	the	O
10	prothymosin	B
11	intron	I
12	enhancer	I
13	is	O
14	a	O
15	faithful	O
16	reflection	O
17	of	O
18	the	O
19	transforming	O
20	properties	O
21	of	O
22	the	O
23	Myc	B
24	protein	I
25	.	O

1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O

1	In	O
2	view	O
3	of	O
4	the	O
5	presence	O
6	of	O
7	SECIS	O
8	elements	O
9	in	O
10	the	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	)	O
17	of	O
18	bacterial	B
19	selenoproteins	I
20	,	O
21	we	O
22	examine	O
23	the	O
24	effects	O
25	in	O
26	the	O
27	type	B
28	1	I
29	deiodinase	I
30	of	O
31	extending	O
32	the	O
33	ORF	O
34	into	O
35	the	O
36	SECIS	O
37	element	O
38	,	O
39	and	O
40	find	O
41	that	O
42	this	O
43	dramatically	O
44	inhibits	O
45	SECIS	O
46	function	O
47	.	O

1	The	O
2	5	O
3	'	O
4	external	O
5	transcribed	O
6	spacer	O
7	(	O
8	ETS	O
9	)	O
10	region	O
11	of	O
12	the	O
13	pre	O
14	-	O
15	rRNA	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	contains	O
20	a	O
21	sequence	O
22	with	O
23	10	O
24	bp	O
25	of	O
26	perfect	O
27	complementarity	O
28	to	O
29	the	O
30	U3	B
31	snoRNA	I
32	.	O

1	These	O
2	animals	O
3	were	O
4	viable	O
5	and	O
6	fertile	O
7	.	O

1	This	O
2	spindle	O
3	defect	O
4	of	O
5	pds1	B
6	mutants	I
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	RPF	B
6	-	I
7	1	I
8	is	O
9	likely	O
10	to	O
11	be	O
12	involved	O
13	in	O
14	early	O
15	steps	O
16	in	O
17	the	O
18	differentiation	O
19	of	O
20	amacrine	O
21	and	O
22	ganglion	O
23	cells	O
24	.	O

1	In	O
2	the	O
3	point	O
4	mutant	O
5	we	O
6	observed	O
7	normal	O
8	repair	O
9	of	O
10	endonuclease	B
11	III	I
12	site	I
13	(	O
14	i	O
15	.	O
16	e	O
17	.	O
18	as	O
19	wild	O
20	type	O
21	),	O
22	but	O
23	no	O
24	removal	O
25	of	O
26	CPDs	O
27	at	O
28	the	O
29	MAT	B
30	alpha	I
31	and	O
32	HML	B
33	alpha	I
34	loci	I
35	.	O

1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O

1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	B
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	Both	O
2	EWS	B
3	-	O
4	FLI	B
5	-	I
6	1	I
7	and	O
8	FLI	B
9	-	I
10	1	I
11	proteins	I
12	function	O
13	as	O
14	transcription	O
15	factors	O
16	that	O
17	bind	O
18	specifically	O
19	to	O
20	ets	B
21	sequences	O
22	(	O
23	the	O
24	ets	B
25	boxes	O
26	)	O
27	present	O
28	in	O
29	promoter	O
30	elements	O
31	.	O

1	In	O
2	electromobility	O
3	shift	O
4	assays	O
5	,	O
6	EWS	B
7	-	O
8	FLI	B
9	-	I
10	1	I
11	binding	O
12	to	O
13	the	O
14	SRE	O
15	is	O
16	detectable	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	SRF	B
22	whereas	O
23	the	O
24	binding	O
25	of	O
26	FLI	B
27	-	I
28	1	I
29	is	O
30	not	O
31	,	O
32	suggesting	O
33	that	O
34	the	O
35	interaction	O
36	with	O
37	DNA	O
38	is	O
39	the	O
40	step	O
41	which	O
42	limits	O
43	ternary	O
44	complex	O
45	formation	O
46	by	O
47	FLI	B
48	-	I
49	1	I
50	.	O

1	Additional	O
2	studies	O
3	with	O
4	new	O
5	and	O
6	reprocessed	O
7	regenerated	O
8	cellulose	O
9	dialyzers	O
10	comparing	O
11	450	O
12	and	O
13	220	O
14	mL	O
15	/	O
16	min	O
17	blood	O
18	flow	O
19	rates	O
20	at	O
21	10	O
22	minutes	O
23	showed	O
24	no	O
25	change	O
26	in	O
27	BTG	O
28	.	O

1	DNA	O
2	methylation	O
3	,	O
4	especially	O
5	of	O
6	either	O
7	one	O
8	or	O
9	both	O
10	of	O
11	the	O
12	deoxyadenosines	O
13	at	O
14	the	O
15	two	O
16	GATC	O
17	motifs	O
18	(	O
19	one	O
20	in	O
21	the	O
22	first	O
23	exon	O
24	and	O
25	the	O
26	other	O
27	in	O
28	the	O
29	first	O
30	intron	O
31	of	O
32	the	O
33	rice	O
34	CatA	B
35	gene	I
36	),	O
37	appeared	O
38	to	O
39	be	O
40	responsible	O
41	for	O
42	the	O
43	CatA	B
44	promoter	I
45	activity	O
46	identified	O
47	in	O
48	the	O
49	transient	O
50	assay	O
51	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	Overlapping	O
2	cDNA	O
3	clones	O
4	were	O
5	isolated	O
6	and	O
7	sequenced	O
8	.	O

1	In	O
2	conclusion	O
3	,	O
4	IgM	B
5	class	O
6	CIC	O
7	is	O
8	the	O
9	predominant	O
10	CIC	O
11	in	O
12	acute	O
13	hepatitis	O
14	A	O
15	and	O
16	correlated	O
17	with	O
18	disease	O
19	activity	O
20	.	O

1	Epitope	O
2	mapping	O
3	revealed	O
4	that	O
5	these	O
6	three	O
7	clones	O
8	appear	O
9	to	O
10	recognize	O
11	an	O
12	identical	O
13	epitope	O
14	domain	O
15	present	O
16	on	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	RNP	O
22	motif	O
23	of	O
24	the	O
25	U1A	B
26	protein	I
27	.	O

1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O

1	As	O
2	the	O
3	length	O
4	of	O
5	the	O
6	fatty	O
7	acid	O
8	decreased	O
9	,	O
10	the	O
11	binding	O
12	affinity	O
13	was	O
14	reduced	O
15	;	O
16	myristic	O
17	acid	O
18	(	O
19	14	O
20	:	O
21	0	O
22	)	O
23	bound	O
24	with	O
25	a	O
26	K	O
27	(	O
28	d	O
29	)	O
30	of	O
31	1409	O
32	+/-	O
33	423	O
34	nM	O
35	,	O
36	but	O
37	medium	O
38	-	O
39	chain	O
40	(	O
41	decanoic	O
42	acid	O
43	,	O
44	10	O
45	:	O
46	0	O
47	)	O
48	and	O
49	short	O
50	-	O
51	chain	O
52	(	O
53	octanoic	O
54	acid	O
55	,	O
56	8	O
57	:	O
58	0	O
59	)	O
60	lipids	O
61	were	O
62	not	O
63	bound	O
64	at	O
65	all	O
66	.	O

1	The	O
2	membrane	O
3	-	O
4	distal	O
5	cytoplasmic	O
6	region	O
7	of	O
8	human	B
9	granulocyte	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	receptor	I
15	is	O
16	required	O
17	for	O
18	STAT3	B
19	but	O
20	not	O
21	STAT1	B
22	homodimer	I
23	formation	O
24	.	O

1	However	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	O
10	TPI	B
11	transcripts	I
12	takes	O
13	place	O
14	prior	O
15	to	O
16	or	O
17	after	O
18	splicing	O
19	remained	O
20	unresolved	O
21	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	B
25	.	I
26	5S	I
27	RNA	I
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	Ongoing	O
2	and	O
3	future	O
4	investigations	O
5	may	O
6	better	O
7	define	O
8	the	O
9	optimal	O
10	approach	O
11	for	O
12	local	O
13	control	O
14	,	O
15	the	O
16	optimal	O
17	duration	O
18	of	O
19	maintenance	O
20	chemotherapy	O
21	,	O
22	and	O
23	the	O
24	possible	O
25	role	O
26	of	O
27	biologic	O
28	response	O
29	modifiers	O
30	and	O
31	growth	O
32	factors	O
33	in	O
34	further	O
35	improving	O
36	the	O
37	outcome	O
38	for	O
39	patients	O
40	with	O
41	this	O
42	disease	O
43	.	O

1	SUMMARY	O
2	OF	O
3	REVIEW	O
4	:	O
5	We	O
6	discuss	O
7	the	O
8	criteria	O
9	that	O
10	make	O
11	such	O
12	studies	O
13	comparable	O
14	,	O
15	drawing	O
16	on	O
17	the	O
18	experiences	O
19	of	O
20	recent	O
21	studies	O
22	performed	O
23	around	O
24	the	O
25	world	O
26	.	O

1	Forty	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O

1	Left	O
2	atrial	O
3	volumes	O
4	were	O
5	greater	O
6	in	O
7	old	O
8	compared	O
9	with	O
10	young	O
11	subjects	O
12	(	O
13	maximal	O
14	:	O
15	31	O
16	+/-	O
17	10	O
18	cm3	O
19	/	O
20	m2	O
21	vs	O
22	24	O
23	+/-	O
24	8	O
25	cm3	O
26	/	O
27	m2	O
28	,	O
29	p	O
30	=	O
31	0	O
32	.	O
33	02	O
34	;	O
35	at	O
36	onset	O
37	of	O
38	atrial	O
39	systole	O
40	:	O
41	23	O
42	+/-	O
43	8	O
44	cm3	O
45	/	O
46	m2	O
47	vs	O
48	15	O
49	+/-	O
50	5	O
51	cm3	O
52	/	O
53	m2	O
54	,	O
55	p	O
56	=	O
57	0	O
58	.	O
59	0002	O
60	;	O
61	minimal	O
62	:	O
63	13	O
64	+/-	O
65	5	O
66	cm3	O
67	/	O
68	m2	O
69	vs	O
70	9	O
71	+/-	O
72	4	O
73	cm3	O
74	/	O
75	m2	O
76	,	O
77	p	O
78	=	O
79	0	O
80	.	O
81	001	O
82	).	O

1	RESULTS	O
2	:	O
3	Basal	O
4	plasma	B
5	IGF	I
6	-	I
7	I	I
8	levels	O
9	as	O
10	well	O
11	as	O
12	body	O
13	mass	O
14	index	O
15	(	O
16	BMI	O
17	)	O
18	were	O
19	lower	O
20	in	O
21	amenorrheic	O
22	patients	O
23	than	O
24	in	O
25	healthy	O
26	controls	O
27	.	O

1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	B
7	-	O
8	erbA	B
9	alpha	I
10	mRNA	O
11	in	O
12	dividing	O
13	C2C12	O
14	myoblasts	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	postmitotic	O
25	multinucleated	O
26	myotubes	O
27	.	O

1	We	O
2	then	O
3	demonstrated	O
4	that	O
5	1	O
6	)	O
7	GAL4	B
8	-	O
9	REV	B
10	-	O
11	erbA	B
12	alpha	I
13	chimeras	O
14	that	O
15	contain	O
16	the	O
17	'	O
18	AB	O
19	'	O
20	region	O
21	and	O
22	lack	O
23	the	O
24	'	O
25	E	O
26	'	O
27	region	O
28	activated	O
29	transcription	O
30	of	O
31	GAL4	B
32	response	I
33	elements	I
34	in	O
35	the	O
36	presence	O
37	of	O
38	8	O
39	-	O
40	Br	O
41	-	O
42	cAMP	O
43	and	O
44	2	O
45	)	O
46	the	O
47	ligand	O
48	-	O
49	binding	O
50	domain	O
51	(	O
52	LBD	O
53	)	O
54	contains	O
55	an	O
56	active	O
57	transcriptional	O
58	silencer	O
59	.	O

1	The	O
2	alpha	O
3	T3	O
4	-	O
5	1	O
6	cell	O
7	line	O
8	,	O
9	a	O
10	GnRH	B
11	-	O
12	responsive	O
13	gonadotroph	O
14	cell	O
15	line	O
16	developed	O
17	by	O
18	targeted	O
19	oncogenesis	O
20	in	O
21	transgenic	O
22	mice	O
23	,	O
24	was	O
25	used	O
26	to	O
27	study	O
28	regulation	O
29	of	O
30	the	O
31	glycoprotein	B
32	hormone	I
33	alpha	I
34	-	I
35	subunit	I
36	by	O
37	activin	B
38	.	O

1	Cotransfection	O
2	with	O
3	the	O
4	ie1	B
5	gene	I
6	resulted	O
7	in	O
8	a	O
9	dramatic	O
10	increase	O
11	in	O
12	the	O
13	amount	O
14	of	O
15	the	O
16	two	O
17	enzymes	O
18	expressed	O
19	in	O
20	the	O
21	transfected	O
22	cells	O
23	.	O

1	As	O
2	expected	O
3	,	O
4	glycosylation	O
5	of	O
6	Env	B
7	produced	O
8	from	O
9	mutants	O
10	was	O
11	affected	O
12	but	O
13	,	O
14	irrespective	O
15	of	O
16	the	O
17	glycosylation	O
18	phenotype	O
19	,	O
20	(	O
21	i	O
22	)	O
23	similar	O
24	quantities	O
25	of	O
26	Env	B
27	were	O
28	synthesized	O
29	,	O
30	(	O
31	ii	O
32	)	O
33	the	O
34	immunoreactivity	O
35	of	O
36	V3	B
37	was	O
38	similar	O
39	,	O
40	(	O
41	iii	O
42	)	O
43	gp160	B
44	was	O
45	efficiently	O
46	cleaved	O
47	into	O
48	gp120	B
49	and	O
50	gp41	B
51	,	O
52	(	O
53	vi	O
54	)	O
55	Env	B
56	was	O
57	exposed	O
58	at	O
59	the	O
60	cell	O
61	membrane	O
62	,	O
63	(	O
64	v	O
65	)	O
66	secreted	O
67	gp120	B
68	bound	O
69	CD4	B
70	,	O
71	and	O
72	(	O
73	vi	O
74	)	O
75	membrane	O
76	gp41	B
77	was	O
78	able	O
79	to	O
80	induce	O
81	membrane	O
82	fusion	O
83	with	O
84	CD4	B
85	+	I
86	cells	O
87	.	O

1	Effects	O
2	of	O
3	posteroventral	O
4	pallidotomy	O
5	on	O
6	Parkinson	O
7	'	O
8	s	O
9	disease	O
10	.	O

1	On	O
2	the	O
3	trail	O
4	of	O
5	Dr	O
6	.	O

1	However	O
2	,	O
3	only	O
4	complete	B
5	DnaJ	I
6	can	O
7	cooperate	O
8	with	O
9	DnaK	B
10	and	O
11	a	O
12	third	O
13	protein	O
14	,	O
15	GrpE	B
16	,	O
17	in	O
18	refolding	O
19	denatured	B
20	firefly	I
21	luciferase	I
22	.	O

1	The	O
2	two	O
3	different	O
4	phosphoforms	O
5	of	O
6	STAT5	B
7	have	O
8	identical	O
9	in	O
10	vitro	O
11	DNA	O
12	binding	O
13	specificity	O
14	and	O
15	reactivity	O
16	with	O
17	tyrosine	O
18	phosphopeptides	O
19	,	O
20	but	O
21	differ	O
22	in	O
23	their	O
24	cellular	O
25	localization	O
26	.	O

1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	I
44	(	O
45	hsp27	B
46	).	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	protein	O
7	from	O
8	Drosophila	O
9	nuclear	O
10	extracts	O
11	which	O
12	binds	O
13	specifically	O
14	to	O
15	a	O
16	site	O
17	in	O
18	this	O
19	second	O
20	region	O
21	.	O

1	However	O
2	,	O
3	while	O
4	the	O
5	sequence	O
6	similarity	O
7	between	O
8	the	O
9	membrane	O
10	exons	O
11	of	O
12	avian	B
13	mIgY	I
14	and	O
15	mammalian	B
16	mIgG	I
17	and	I
18	IgE	I
19	is	O
20	striking	O
21	,	O
22	the	O
23	overall	O
24	similarity	O
25	with	O
26	Xenopus	B
27	mIgY	I
28	is	O
29	very	O
30	low	O
31	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	assays	O
9	indicate	O
10	that	O
11	PBP	B
12	binds	O
13	to	O
14	the	O
15	half	O
16	-	O
17	site	O
18	of	O
19	each	O
20	palindrome	O
21	with	O
22	the	O
23	core	O
24	recognition	O
25	sequence	O
26	TGGGAG	O
27	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	sequences	O
6	in	O
7	the	O
8	SH2	B
9	/	O
10	SH3	B
11	/	O
12	SH2	B
13	region	O
14	of	O
15	p120	B
16	GAP	I
17	are	O
18	required	O
19	for	O
20	full	O
21	catalytic	O
22	activity	O
23	toward	O
24	Ras	B
25	.	O

1	The	O
2	novel	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	FLT3	I
7	ligand	I
8	(	O
9	FL	B
10	)	O
11	is	O
12	the	O
13	cognate	O
14	ligand	O
15	for	O
16	the	O
17	FLT3	B
18	,	O
19	tyrosine	B
20	kinase	I
21	receptor	I
22	(	O
23	R	B
24	),	O
25	also	O
26	referred	O
27	to	O
28	as	O
29	FLK	B
30	-	I
31	2	I
32	and	O
33	STK	B
34	-	I
35	1	I
36	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	selective	O
6	expression	O
7	of	O
8	the	O
9	receptor	O
10	,	O
11	FL	B
12	expression	O
13	was	O
14	detected	O
15	in	O
16	90	O
17	-	O
18	100	O
19	%	O
20	of	O
21	the	O
22	various	O
23	cell	O
24	types	O
25	of	O
26	leukemia	O
27	cell	O
28	lines	O
29	from	O
30	all	O
31	hematopoietic	O
32	cell	O
33	lineages	O
34	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	domain	O
6	by	O
7	in	O
8	vitro	O
9	mutagenesis	O
10	pointed	O
11	to	O
12	a	O
13	core	O
14	of	O
15	hydrophobic	O
16	and	O
17	acidic	O
18	residues	O
19	as	O
20	critical	O
21	for	O
22	the	O
23	activity	O
24	.	O

1	Analysis	O
2	of	O
3	RAR	B
4	alpha	I
5	mutants	I
6	in	O
7	transfection	O
8	studies	O
9	reveals	O
10	that	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	is	O
16	sufficient	O
17	for	O
18	inhibition	O
19	of	O
20	BZLF1	B
21	activity	O
22	.	O

1	We	O
2	measured	O
3	serum	B
4	hepatocyte	I
5	growth	I
6	factor	I
7	(	O
8	HGF	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	pectoris	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	O
8	,	O
9	i	O
10	.	O
11	e	O
12	.,	O
13	rigidity	O
14	,	O
15	tremor	O
16	and	O
17	akinesia	O
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	O
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	O
44	the	O
45	disease	O
46	in	O
47	relation	O
48	to	O
49	the	O
50	neuropathological	O
51	findings	O
52	within	O
53	the	O
54	substantia	O
55	nigra	O
56	zona	O
57	compacta	O
58	(	O
59	SNc	O
60	).	O

1	Protein	O
2	splicing	O
3	:	O
4	evidence	O
5	for	O
6	an	O
7	N	O
8	-	O
9	O	O
10	acyl	O
11	rearrangement	O
12	as	O
13	the	O
14	initial	O
15	step	O
16	in	O
17	the	O
18	splicing	O
19	process	O
20	.	O

1	In	O
2	agreement	O
3	with	O
4	these	O
5	data	O
6	,	O
7	western	O
8	blot	O
9	experiments	O
10	using	O
11	an	O
12	antibody	O
13	directed	O
14	against	O
15	the	O
16	carboxy	O
17	-	O
18	terminal	O
19	portion	O
20	of	O
21	the	O
22	mouse	O
23	c	B
24	-	I
25	kit	I
26	protein	I
27	showed	O
28	that	O
29	a	O
30	polypeptide	O
31	,	O
32	of	O
33	the	O
34	size	O
35	predicted	O
36	by	O
37	the	O
38	open	O
39	reading	O
40	frame	O
41	of	O
42	the	O
43	spermatid	B
44	-	I
45	specific	I
46	c	I
47	-	I
48	kit	I
49	cDNA	I
50	,	O
51	accumulates	O
52	in	O
53	the	O
54	latest	O
55	stages	O
56	of	O
57	spermatogenesis	O
58	and	O
59	in	O
60	epididymal	O
61	spermatozoa	O
62	.	O

1	It	O
2	is	O
3	shown	O
4	that	O
5	the	O
6	(	O
7	G	O
8	+	O
9	C	O
10	)-	O
11	rich	O
12	element	O
13	of	O
14	the	O
15	aldolase	B
16	C	I
17	promoter	I
18	directs	O
19	transcription	O
20	in	O
21	neuronal	O
22	as	O
23	well	O
24	as	O
25	in	O
26	nonneuronal	O
27	cells	O
28	.	O

1	LY290181	O
2	appears	O
3	to	O
4	inhibit	O
5	uPA	B
6	promoter	I
7	activation	O
8	by	O
9	blocking	O
10	phorbol	O
11	ester	O
12	-	O
13	stimulated	O
14	binding	O
15	of	O
16	nuclear	O
17	proteins	O
18	to	O
19	the	O
20	uPA	B
21	PEA3	I
22	/	O
23	12	O
24	-	O
25	0	O
26	-	O
27	tetradecanoylphorbol	O
28	13	O
29	-	O
30	acetate	O
31	responsive	O
32	element	O
33	(	O
34	TRE	O
35	).	O

1	Treatment	O
2	of	O
3	keratinocytes	O
4	expressing	O
5	a	O
6	normal	O
7	epidermal	B
8	growth	I
9	factor	I
10	receptor	I
11	(	O
12	EGFR	B
13	)	O
14	with	O
15	TGFalpha	B
16	or	O
17	epidermal	B
18	growth	I
19	factor	I
20	for	O
21	5	O
22	min	O
23	induced	O
24	PKCdelta	B
25	tyrosine	O
26	phosphorylation	O
27	.	O

1	Only	O
2	one	O
3	of	O
4	these	O
5	bands	O
6	was	O
7	supershifted	O
8	by	O
9	antibody	O
10	to	O
11	p50	B
12	,	O
13	whereas	O
14	antibodies	O
15	to	O
16	p65	B
17	or	O
18	other	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	had	O
24	no	O
25	effect	O
26	.	O

1	We	O
2	isolated	O
3	a	O
4	complementary	O
5	DNA	O
6	(	O
7	cDNA	O
8	)	O
9	clone	O
10	from	O
11	an	O
12	RL95	O
13	-	O
14	2	O
15	expression	O
16	library	O
17	that	O
18	encodes	O
19	the	O
20	C1	B
21	site	I
22	-	I
23	binding	I
24	protein	I
25	.	O

1	Biol	O
2	.	O

1	In	O
2	addition	O
3	,	O
4	anti	B
5	-	I
6	phosphotyrosine	I
7	antibodies	I
8	immunoprecipitated	O
9	80K	B
10	-	I
11	H	I
12	from	O
13	cell	O
14	lysates	O
15	of	O
16	FGF	B
17	-	O
18	stimulated	O
19	but	O
20	not	O
21	from	O
22	control	O
23	fibroblasts	O
24	.	O

1	The	O
2	novel	O
3	protein	O
4	kinases	O
5	,	O
6	c	B
7	-	I
8	Jun	I
9	NH2	I
10	-	I
11	terminal	I
12	kinases	I
13	(	O
14	JNKs	B
15	)/	O
16	stress	B
17	-	I
18	activated	I
19	protein	I
20	kinases	I
21	,	O
22	are	O
23	also	O
24	activated	O
25	by	O
26	TNF	B
27	-	I
28	alpha	I
29	,	O
30	IL	B
31	-	I
32	1	I
33	,	O
34	and	O
35	CD28	B
36	costimulation	O
37	.	O

1	Thus	O
2	,	O
3	hGRbeta	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	B
13	activity	O
14	.	O

1	Gas6	B
2	contains	O
3	an	O
4	NH2	O
5	-	O
6	terminal	O
7	Gla	O
8	domain	O
9	followed	O
10	by	O
11	four	O
12	epidermal	B
13	growth	I
14	factor	I
15	-	I
16	like	I
17	repeats	I
18	and	O
19	tandem	O
20	globular	O
21	(	O
22	G	O
23	)	O
24	domains	O
25	.	O

1	Both	O
2	P5CDh	B
3	cDNA	I
4	clones	O
5	detect	O
6	a	O
7	single	O
8	3	O
9	.	O
10	2	O
11	-	O
12	kb	O
13	transcript	O
14	on	O
15	Northern	O
16	blots	O
17	of	O
18	multiple	O
19	human	O
20	tissues	O
21	,	O
22	indicating	O
23	the	O
24	long	O
25	cDNA	O
26	containing	O
27	the	O
28	3	O
29	'-	O
30	untranslated	O
31	intron	O
32	represents	O
33	the	O
34	predominant	O
35	transcript	O
36	.	O

1	Polymerization	O
2	of	O
3	neurofilament	B
4	L	I
5	protein	I
6	in	O
7	vitro	O
8	was	O
9	inhibited	O
10	by	O
11	phosphorylation	O
12	of	O
13	neurofilament	B
14	L	I
15	protein	I
16	by	O
17	PKN	B
18	.	O

1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	O
8	c	B
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	I
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	B
26	cell	I
27	receptor	I
28	stimulation	O
29	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	O
20	.	O

1	An	O
2	AP	B
3	-	I
4	1	I
5	binding	I
6	sequence	I
7	is	O
8	essential	O
9	for	O
10	regulation	O
11	of	O
12	the	O
13	human	B
14	alpha2	I
15	(	I
16	I	I
17	)	I
18	collagen	I
19	(	O
20	COL1A2	B
21	)	O
22	promoter	O
23	activity	O
24	by	O
25	transforming	B
26	growth	I
27	factor	I
28	-	I
29	beta	I
30	.	O

1	No	O
2	significant	O
3	differences	O
4	existed	O
5	between	O
6	the	O
7	two	O
8	age	O
9	groups	O
10	in	O
11	baseline	O
12	characteristics	O
13	,	O
14	including	O
15	treatment	O
16	protocol	O
17	,	O
18	performance	O
19	status	O
20	,	O
21	and	O
22	serum	B
23	lactate	I
24	dehydrogenase	I
25	(	O
26	LDH	B
27	)	O
28	level	O
29	.	O

1	Only	O
2	two	O
3	patients	O
4	(	O
5	0	O
6	.	O
7	3	O
8	%)	O
9	had	O
10	a	O
11	CA	B
12	125	I
13	response	O
14	at	O
15	the	O
16	time	O
17	of	O
18	clinical	O
19	progression	O
20	.	O

1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O

1	Conversely	O
2	,	O
3	when	O
4	VDR	B
5	is	O
6	overexpressed	O
7	,	O
8	vitamin	O
9	D3	O
10	attenuates	O
11	9	O
12	-	O
13	cis	O
14	RA	O
15	induction	O
16	from	O
17	an	O
18	RXR	B
19	-	O
20	responsive	O
21	element	O
22	.	O

1	These	O
2	results	O
3	illuminate	O
4	a	O
5	hitherto	O
6	unanticipated	O
7	function	O
8	of	O
9	U6	B
10	RNA	I
11	:	O
12	the	O
13	modulation	O
14	of	O
15	a	O
16	phosphorylation	O
17	-	O
18	dephosphorylation	O
19	cycle	O
20	of	O
21	C1	B
22	hnRNP	I
23	protein	I
24	that	O
25	influences	O
26	the	O
27	binding	O
28	affinity	O
29	of	O
30	this	O
31	protein	O
32	for	O
33	pre	O
34	-	O
35	mRNA	O
36	.	O

1	Inclusion	O
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	originally	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	B
20	factor	I
21	Lef	I
22	-	I
23	1	I
24	.	O

1	Truncated	O
2	mammalian	B
3	Notch1	I
4	activates	O
5	CBF1	B
6	/	O
7	RBPJk	B
8	-	O
9	repressed	O
10	genes	O
11	by	O
12	a	O
13	mechanism	O
14	resembling	O
15	that	O
16	of	O
17	Epstein	B
18	-	I
19	Barr	I
20	virus	I
21	EBNA2	I
22	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	(	O
6	EMSAs	O
7	)	O
8	using	O
9	purified	O
10	glucocorticoid	B
11	receptor	I
12	DNA	I
13	binding	I
14	domain	I
15	(	O
16	DBD	O
17	)	O
18	demonstrated	O
19	that	O
20	both	O
21	GRE	B
22	-	I
23	2	I
24	and	I
25	-	I
26	3	I
27	motifs	I
28	interact	O
29	with	O
30	DBD	O
31	and	O
32	oligonucleotide	O
33	competition	O
34	experiments	O
35	established	O
36	that	O
37	these	O
38	have	O
39	different	O
40	affinities	O
41	for	O
42	DBD	O
43	.	O

1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	I
7	kinases	I
8	(	O
9	RTKs	B
10	)	O
11	for	O
12	which	O
13	EPH	B
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O

1	The	O
2	17	O
3	-	O
4	kDa	O
5	protein	O
6	is	O
7	required	O
8	for	O
9	the	O
10	systemic	O
11	infection	O
12	of	O
13	plants	O
14	.	O

1	We	O
2	present	O
3	here	O
4	a	O
5	detailed	O
6	genomic	O
7	sequencing	O
8	analysis	O
9	of	O
10	the	O
11	cytosine	O
12	methylation	O
13	patterns	O
14	of	O
15	the	O
16	transposase	B
17	binding	O
18	sites	O
19	within	O
20	both	O
21	Ac	B
22	ends	O
23	in	O
24	the	O
25	wx	B
26	-	I
27	m9	I
28	::	O
29	Ac	B
30	allele	I
31	,	O
32	where	O
33	Ac	B
34	is	O
35	inserted	O
36	into	O
37	the	O
38	tenth	O
39	exon	O
40	of	O
41	the	O
42	Waxy	B
43	gene	I
44	.	O

1	Krox	B
2	-	I
3	20	I
4	,	O
5	a	O
6	zinc	B
7	finger	I
8	gene	I
9	,	O
10	has	O
11	a	O
12	highly	O
13	conserved	O
14	pattern	O
15	of	O
16	expression	O
17	in	O
18	r3	O
19	and	O
20	r5	O
21	and	O
22	is	O
23	functionally	O
24	required	O
25	for	O
26	their	O
27	maintenance	O
28	in	O
29	mouse	O
30	embryos	O
31	.	O

1	Pituitary	O
2	adenylate	B
3	cyclase	I
4	-	I
5	activating	I
6	polypeptide	I
7	regulates	O
8	prolactin	B
9	promoter	I
10	activity	O
11	via	O
12	a	O
13	protein	B
14	kinase	I
15	A	I
16	-	O
17	mediated	O
18	pathway	O
19	that	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	transcriptional	O
25	pathway	O
26	employed	O
27	by	O
28	thyrotropin	B
29	-	I
30	releasing	I
31	hormone	I
32	.	O

1	Clones	O
2	33F	O
3	and	O
4	34B	O
5	encoded	O
6	identical	O
7	aromatase	B
8	proteins	I
9	of	O
10	503	O
11	amino	O
12	acids	O
13	,	O
14	but	O
15	differed	O
16	in	O
17	size	O
18	due	O
19	to	O
20	alternative	O
21	polyadenylation	O
22	signal	O
23	usage	O
24	for	O
25	the	O
26	corresponding	O
27	mRNAs	O
28	.	O

1	In	O
2	sorted	O
3	bone	O
4	marrow	O
5	cells	O
6	expression	O
7	of	O
8	both	O
9	VpreB	B
10	genes	I
11	was	O
12	detected	O
13	in	O
14	pro	O
15	-	O
16	B	O
17	/	O
18	pre	O
19	-	O
20	BI	O
21	and	O
22	large	O
23	pre	O
24	-	O
25	BII	O
26	cells	O
27	,	O
28	while	O
29	the	O
30	RNA	O
31	steady	O
32	state	O
33	levels	O
34	were	O
35	at	O
36	least	O
37	100	O
38	-	O
39	fold	O
40	lower	O
41	in	O
42	small	O
43	pre	O
44	-	O
45	BII	O
46	and	O
47	immature	O
48	/	O
49	mature	O
50	B	O
51	cells	O
52	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	3574	O
8	-	O
9	bp	O
10	Bacillus	O
11	subtilis	O
12	(	O
13	Bs	O
14	)	O
15	DNA	O
16	fragment	O
17	located	O
18	between	O
19	the	O
20	nrdA	B
21	and	O
22	citB	B
23	genes	I
24	at	O
25	about	O
26	169	O
27	degrees	O
28	on	O
29	the	O
30	chromosome	O
31	.	O

1	Aeromonas	O
2	salmonicida	O
3	possesses	O
4	two	O
5	genes	O
6	encoding	O
7	homologs	O
8	of	O
9	the	O
10	major	B
11	outer	I
12	membrane	I
13	protein	I
14	,	O
15	OmpA	B
16	.	O

1	Expression	O
2	of	O
3	Msp	B
4	was	O
5	toxic	O
6	to	O
7	E	O
8	.	O
9	coli	O
10	when	O
11	the	O
12	entire	O
13	msp	B
14	gene	I
15	was	O
16	present	O
17	.	O

1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	UmuD	B
14	and	O
15	UmuD	B
16	'	I
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	O
23	(	O
24	UmuD	B
25	-	O
26	UmuD	B
27	and	O
28	UmuD	O
29	'-	O
30	UmuD	O
31	')	O
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	UmuD	B
37	-	O
38	UmuD	O
39	').	O

1	Lyn	B
2	kinase	I
3	immunoprecipitated	O
4	from	O
5	lysates	O
6	of	O
7	irradiated	O
8	BCP	O
9	as	O
10	well	O
11	as	O
12	a	O
13	full	O
14	-	O
15	length	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	(	O
21	GST	B
22	)-	O
23	Lyn	B
24	fusion	O
25	protein	O
26	-	O
27	phosphorylated	O
28	recombinant	B
29	human	I
30	p34cdc2	I
31	on	O
32	tyrosine	O
33	15	O
34	.	O

1	Mutations	O
2	within	O
3	conserved	O
4	region	O
5	2	O
6	(	O
7	CR2	O
8	)	O
9	of	O
10	E1A	B
11	that	O
12	inhibit	O
13	the	O
14	binding	O
15	of	O
16	E1A	B
17	to	O
18	the	O
19	retinoblastoma	B
20	gene	I
21	product	I
22	(	O
23	pRb	B
24	)	O
25	further	O
26	enhanced	O
27	the	O
28	stimulation	O
29	of	O
30	transcription	O
31	from	O
32	the	O
33	PEPCK	B
34	promoter	I
35	by	O
36	2	O
37	3	O
38	-	O
39	fold	O
40	compared	O
41	with	O
42	wild	B
43	type	I
44	E1A	I
45	.	O

1	Using	O
2	autoantibodies	O
3	from	O
4	a	O
5	Sjogren	O
6	'	O
7	s	O
8	syndrome	O
9	patient	O
10	,	O
11	we	O
12	have	O
13	previously	O
14	identified	O
15	a	O
16	230	O
17	-	O
18	kDa	O
19	peripheral	O
20	membrane	O
21	protein	O
22	associated	O
23	with	O
24	the	O
25	cytosolic	O
26	face	O
27	of	O
28	the	O
29	trans	O
30	-	O
31	Golgi	O
32	(	O
33	Kooy	O
34	,	O
35	J	O
36	.,	O
37	Toh	O
38	,	O
39	B	O
40	.	O

1	Apart	O
2	from	O
3	two	O
4	proline	O
5	-	O
6	rich	O
7	regions	O
8	(	O
9	amino	O
10	acids	O
11	1	O
12	-	O
13	117	O
14	and	O
15	239	O
16	-	O
17	270	O
18	),	O
19	p230	B
20	contains	O
21	a	O
22	very	O
23	high	O
24	frequency	O
25	of	O
26	heptad	O
27	repeats	O
28	,	O
29	characteristic	O
30	of	O
31	alpha	O
32	-	O
33	helices	O
34	that	O
35	form	O
36	dimeric	O
37	coiled	O
38	-	O
39	coil	O
40	structures	O
41	.	O
42	p230	B
43	also	O
44	includes	O
45	the	O
46	sequence	O
47	ESLALEELEL	O
48	(	O
49	amino	O
50	acids	O
51	538	O
52	-	O
53	546	O
54	),	O
55	a	O
56	motif	O
57	found	O
58	in	O
59	the	O
60	granin	B
61	family	I
62	of	O
63	acidic	O
64	proteins	O
65	present	O
66	in	O
67	secretory	O
68	granules	O
69	of	O
70	neuroendocrine	O
71	cells	O
72	.	O

1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	B
8	-	I
9	I	I
10	promoter	I
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O

1	They	O
2	were	O
3	found	O
4	to	O
5	stimulate	O
6	at	O
7	nanomolar	O
8	concentrations	O
9	the	O
10	turnover	O
11	of	O
12	biosynthetically	O
13	labeled	O
14	ceramide	O
15	,	O
16	glucosylceramide	O
17	,	O
18	and	O
19	lactosylceramide	O
20	.	O

1	There	O
2	is	O
3	growing	O
4	evidence	O
5	that	O
6	mammalian	B
7	AMP	I
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	(	O
13	AMPK	B
14	)	O
15	plays	O
16	a	O
17	role	O
18	in	O
19	protecting	O
20	cells	O
21	from	O
22	stresses	O
23	that	O
24	cause	O
25	ATP	O
26	depletion	O
27	by	O
28	switching	O
29	off	O
30	ATP	O
31	-	O
32	consuming	O
33	biosynthetic	O
34	pathways	O
35	.	O

1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O

1	Am	O
2	.	O

1	EMSA	O
2	competition	O
3	experiments	O
4	showed	O
5	that	O
6	mutations	O
7	within	O
8	the	O
9	direct	O
10	repeats	O
11	failed	O
12	to	O
13	compete	O
14	for	O
15	binding	O
16	of	O
17	the	O
18	nuclear	O
19	proteins	O
20	to	O
21	labeled	O
22	wild	O
23	type	O
24	oligonucleotide	O
25	.	O

1	Transcription	O
2	from	O
3	the	O
4	promoter	O
5	containing	O
6	the	O
7	mutated	O
8	direct	O
9	repeats	O
10	was	O
11	increased	O
12	greatly	O
13	,	O
14	consistent	O
15	with	O
16	the	O
17	conclusion	O
18	that	O
19	these	O
20	motifs	O
21	functions	O
22	in	O
23	vivo	O
24	to	O
25	repress	O
26	GPT	B
27	gene	I
28	expression	O
29	.	O

1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	B
11	activity	O
12	in	O
13	each	O
14	PKC	B
15	beta	I
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	B
23	-	I
24	ERK3	I
25	monoclonal	I
26	antibody	I
27	followed	O
28	by	O
29	either	O
30	immune	O
31	complex	O
32	kinase	O
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	O
40	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	100	O
6	-	O
7	bp	O
8	Col2a1	B
9	enhancer	I
10	revealed	O
11	several	O
12	sequence	O
13	motifs	O
14	similar	O
15	to	O
16	motifs	O
17	present	O
18	within	O
19	the	O
20	regulatory	O
21	region	O
22	of	O
23	the	O
24	link	B
25	protein	I
26	gene	I
27	,	O
28	another	O
29	cartilage	O
30	gene	O
31	.	O

1	Retinoid	O
2	-	O
3	dependent	O
4	activation	O
5	of	O
6	the	O
7	tissue	B
8	transglutaminase	I
9	promoter	I
10	depends	O
11	on	O
12	both	O
13	a	O
14	proximal	O
15	regulatory	O
16	region	O
17	containing	O
18	sequences	O
19	highly	O
20	conserved	O
21	between	O
22	the	O
23	human	O
24	and	O
25	the	O
26	mouse	B
27	tissue	I
28	transglutaminase	I
29	promoters	I
30	and	O
31	a	O
32	distal	O
33	region	O
34	that	O
35	includes	O
36	a	O
37	30	O
38	-	O
39	base	O
40	pair	O
41	retinoid	O
42	response	O
43	element	O
44	(	O
45	mTGRRE1	O
46	).	O
47	mTGRRE1	O
48	contains	O
49	three	O
50	hexanucleotide	O
51	half	O
52	-	O
53	sites	O
54	(	O
55	two	O
56	canonical	O
57	and	O
58	one	O
59	non	O
60	-	O
61	canonical	O
62	)	O
63	in	O
64	a	O
65	DR7	B
66	/	O
67	DR5	B
68	motif	O
69	that	O
70	bind	O
71	both	O
72	RAR	B
73	*	O
74	RXR	B
75	heterodimers	O
76	and	O
77	RXR	B
78	homodimers	I
79	.	O

1	Significantly	O
2	,	O
3	pPKR	B
4	is	O
5	capable	O
6	of	O
7	specifically	O
8	phosphorylating	O
9	Ser51	O
10	in	O
11	a	O
12	synthetic	B
13	eIF	I
14	-	I
15	2alpha	I
16	peptide	I
17	,	O
18	a	O
19	key	O
20	characteristic	O
21	of	O
22	the	O
23	eIF	B
24	-	I
25	2alpha	I
26	kinase	I
27	family	I
28	.	O

1	Vertebrate	B
2	synapsins	I
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	crude	O
7	extracts	O
8	from	O
9	FREJ4	O
10	cells	O
11	revealed	O
12	the	O
13	binding	O
14	of	O
15	a	O
16	member	O
17	(	O
18	s	O
19	)	O
20	of	O
21	the	O
22	Ets	B
23	family	I
24	of	I
25	transcription	I
26	factors	I
27	to	O
28	the	O
29	P4	B
30	EBS	I
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	interaction	O
37	of	O
38	two	O
39	members	O
40	of	O
41	the	O
42	Sp1	B
43	family	I
44	,	O
45	Sp1	B
46	and	O
47	Sp3	B
48	,	O
49	with	O
50	the	O
51	adjacent	O
52	GC	O
53	box	O
54	.	O

1	ZEBRA	B
2	and	O
3	cellular	O
4	AP	B
5	-	I
6	1	I
7	bZip	I
8	activators	I
9	,	O
10	such	O
11	as	O
12	c	B
13	-	I
14	Fos	I
15	,	O
16	have	O
17	homologous	O
18	DNA	O
19	-	O
20	binding	O
21	domains	O
22	,	O
23	and	O
24	their	O
25	DNA	O
26	-	O
27	binding	O
28	specificities	O
29	overlap	O
30	.	O

1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	I299	O
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	B
20	-	I
21	kDa	I
22	component	I
23	of	I
24	cleavage	I
25	stimulation	I
26	factor	I
27	(	O
28	CstF	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	B
53	.	O

1	CM	B
2	-	I
3	ACO3	I
4	is	O
5	expressed	O
6	in	O
7	flowers	O
8	and	O
9	is	O
10	not	O
11	induced	O
12	by	O
13	any	O
14	of	O
15	the	O
16	stimuli	O
17	tested	O
18	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	these	O
6	Jun	B
7	/	O
8	eb1	B
9	chimeras	O
10	are	O
11	potent	O
12	transactivators	O
13	of	O
14	AP1	B
15	sites	I
16	and	O
17	that	O
18	they	O
19	can	O
20	cooperate	O
21	with	O
22	c	B
23	-	I
24	Ha	I
25	-	I
26	Ras	I
27	to	O
28	induce	O
29	foci	O
30	.	O

1	In	O
2	synchronized	O
3	HeLa	O
4	cells	O
5	,	O
6	expression	O
7	of	O
8	luciferase	B
9	activity	O
10	was	O
11	induced	O
12	at	O
13	the	O
14	beginning	O
15	of	O
16	DNA	O
17	synthesis	O
18	and	O
19	was	O
20	dependent	O
21	on	O
22	the	O
23	presence	O
24	of	O
25	an	O
26	E2F	B
27	-	I
28	binding	I
29	site	I
30	in	O
31	the	O
32	H2A	B
33	.	I
34	1	I
35	promoter	I
36	.	O

1	Utilizing	O
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	I
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	We	O
2	constructed	O
3	a	O
4	yeast	O
5	reporter	O
6	strain	O
7	containing	O
8	the	O
9	lacZ	B
10	gene	I
11	under	O
12	the	O
13	control	O
14	of	O
15	the	O
16	CYC1	B
17	promoter	I
18	associated	O
19	with	O
20	three	O
21	copies	O
22	of	O
23	TRE	B
24	-	I
25	1	I
26	.	O

1	If	O
2	hnRNP	B
3	K	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	,	O
9	then	O
10	interactions	O
11	with	O
12	the	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcription	O
17	apparatus	O
18	are	O
19	predicted	O
20	.	O

1	A	O
2	developmentally	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	blots	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	laevis	O
22	cDNA	O
23	.	O

1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	B
15	and	O
16	pol	B
17	domains	I
18	of	O
19	the	O
20	E	B
21	.	I
22	coli	I
23	DNA	I
24	polymerase	I
25	I	I
26	structure	O
27	.	O

1	Despite	O
2	the	O
3	favourable	O
4	natural	O
5	history	O
6	of	O
7	acute	O
8	BI	O
9	,	O
10	mild	O
11	,	O
12	moderate	O
13	,	O
14	and	O
15	severe	O
16	posttraumatic	O
17	changes	O
18	were	O
19	shown	O
20	to	O
21	appear	O
22	as	O
23	cicatricial	O
24	-	O
25	adhesive	O
26	and	O
27	atrophic	O
28	processes	O
29	,	O
30	intracerebral	O
31	cysts	O
32	,	O
33	porencephaly	O
34	,	O
35	which	O
36	result	O
37	in	O
38	posttraumatic	O
39	epilepsy	O
40	,	O
41	hydrocephalus	O
42	,	O
43	etc	O
44	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O

1	Several	O
2	cytokines	O
3	exhibit	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	temporal	O
9	regulation	O
10	as	O
11	well	O
12	as	O
13	somnogenic	O
14	potency	O
15	(	O
16	e	O
17	.	O
18	g	O
19	.,	O
20	interleukin	B
21	-	I
22	1	I
23	[	O
24	IL	B
25	-	I
26	1	I
27	],	O
28	tumor	B
29	necrosis	I
30	factor	I
31	-	I
32	alpha	I
33	[	O
34	TNF	B
35	-	I
36	alpha	I
37	]).	O

1	As	O
2	pH	O
3	and	O
4	Hb	B
5	can	O
6	also	O
7	affect	O
8	mixed	O
9	venous	O
10	CO2	O
11	content	O
12	,	O
13	the	O
14	effect	O
15	on	O
16	Q	O
17	was	O
18	also	O
19	assessed	O
20	.	O

1	No	O
2	difference	O
3	in	O
4	elastin	B
5	peptide	I
6	concentration	O
7	was	O
8	observed	O
9	between	O
10	emphysematous	O
11	patients	O
12	and	O
13	control	O
14	subjects	O
15	(	O
16	mean	O
17	+/-	O
18	SD	O
19	=	O
20	2	O
21	.	O
22	39	O
23	+/-	O
24	1	O
25	.	O
26	18	O
27	micrograms	O
28	/	O
29	ml	O
30	in	O
31	patients	O
32	versus	O
33	2	O
34	.	O
35	55	O
36	+/-	O
37	1	O
38	.	O
39	34	O
40	micrograms	O
41	/	O
42	ml	O
43	in	O
44	policemen	O
45	and	O
46	2	O
47	.	O
48	59	O
49	+/-	O
50	1	O
51	.	O
52	20	O
53	micrograms	O
54	/	O
55	ml	O
56	in	O
57	coal	O
58	miners	O
59	).	O

1	Identification	O
2	of	O
3	this	O
4	region	O
5	as	O
6	the	O
7	E	B
8	.	I
9	coli	I
10	tmk	I
11	gene	I
12	was	O
13	confirmed	O
14	by	O
15	functional	O
16	complementation	O
17	of	O
18	a	O
19	yeast	B
20	dTMP	I
21	kinase	I
22	temperature	O
23	-	O
24	sensitive	O
25	mutant	O
26	and	O
27	by	O
28	in	O
29	vitro	O
30	enzyme	O
31	assay	O
32	of	O
33	the	O
34	thymidylate	B
35	kinase	I
36	activity	O
37	in	O
38	cell	O
39	extracts	O
40	of	O
41	E	O
42	.	O
43	coli	O
44	by	O
45	use	O
46	of	O
47	tmk	B
48	-	O
49	overproducing	O
50	plasmids	O
51	.	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	copper	B
6	-	I
7	and	I
8	topa	I
9	quinone	I
10	-	I
11	containing	I
12	monoamine	I
13	oxidase	I
14	(	O
15	maoA	B
16	)	O
17	and	O
18	an	O
19	unknown	O
20	amine	B
21	oxidase	I
22	gene	I
23	have	O
24	been	O
25	located	O
26	at	O
27	30	O
28	.	O
29	9	O
30	min	O
31	on	O
32	the	O
33	Escherichia	O
34	coli	O
35	chromosome	O
36	.	O

1	This	O
2	interaction	O
3	is	O
4	mediated	O
5	by	O
6	the	O
7	SH2	B
8	domain	I
9	of	O
10	Crk	B
11	and	O
12	can	O
13	be	O
14	inhibited	O
15	with	O
16	a	O
17	phosphopeptide	O
18	containing	O
19	the	O
20	Crk	B
21	-	O
22	SH2	B
23	binding	O
24	motif	O
25	.	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	B
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	Identification	O
2	of	O
3	a	O
4	consensus	O
5	cyclin	B
6	-	I
7	dependent	I
8	kinase	I
9	phosphorylation	I
10	site	I
11	unique	O
12	to	O
13	the	O
14	nuclear	O
15	form	O
16	of	O
17	human	B
18	deoxyuridine	I
19	triphosphate	I
20	nucleotidohydrolase	I
21	.	O

1	The	O
2	cDNA	O
3	corresponding	O
4	to	O
5	the	O
6	FPS1	B
7	gene	I
8	was	O
9	isolated	O
10	by	O
11	functional	O
12	complementation	O
13	of	O
14	a	O
15	mutant	O
16	yeast	O
17	strain	O
18	defective	O
19	in	O
20	FPS	B
21	activity	O
22	(	O
23	Delourme	O
24	,	O
25	D	O
26	.,	O
27	Lacroute	O
28	,	O
29	F	O
30	.,	O
31	and	O
32	Karst	O
33	,	O
34	F	O
35	.	O

1	The	O
2	isolated	O
3	plasmin	B
4	fragments	O
5	of	O
6	VEGF	B
7	were	O
8	compared	O
9	with	O
10	respect	O
11	to	O
12	heparin	O
13	binding	O
14	,	O
15	interaction	O
16	with	O
17	soluble	O
18	VEGF	B
19	receptors	I
20	,	O
21	and	O
22	ability	O
23	to	O
24	promote	O
25	endothelial	O
26	cell	O
27	mitogenesis	O
28	.	O

1	VDR	B
2	/	O
3	RXR	B
4	bound	O
5	well	O
6	to	O
7	the	O
8	VDREs	O
9	and	O
10	to	O
11	DR4	O
12	and	O
13	DR5	O
14	using	O
15	the	O
16	electrophoretic	O
17	mobility	O
18	shift	O
19	assay	O
20	.	O

1	The	O
2	members	O
3	of	O
4	the	O
5	Myb	B
6	family	I
7	of	I
8	transcription	I
9	factors	I
10	are	O
11	defined	O
12	by	O
13	homology	O
14	in	O
15	the	O
16	DNA	O
17	-	O
18	binding	O
19	domain	O
20	;	O
21	all	O
22	bind	O
23	the	O
24	Myb	B
25	-	I
26	binding	I
27	site	I
28	(	O
29	MBS	B
30	)	O
31	sequence	O
32	(	O
33	YG	O
34	(	O
35	A	O
36	/	O
37	G	O
38	)	O
39	C	O
40	(	O
41	A	O
42	/	O
43	C	O
44	/	O
45	G	O
46	)	O
47	GTT	O
48	(	O
49	G	O
50	/	O
51	A	O
52	)).	O

1	In	O
2	contrast	O
3	,	O
4	when	O
5	the	O
6	isoform	O
7	containing	O
8	the	O
9	C	O
10	epsilon4	O
11	domain	O
12	joined	O
13	directly	O
14	to	O
15	the	O
16	M2	O
17	exon	O
18	(	O
19	IgE	B
20	grande	I
21	)	O
22	is	O
23	expressed	O
24	in	O
25	the	O
26	J558L	O
27	cell	O
28	line	O
29	,	O
30	it	O
31	is	O
32	degraded	O
33	intracellularly	O
34	,	O
35	suggesting	O
36	a	O
37	cell	O
38	line	O
39	-	O
40	dependent	O
41	regulation	O
42	of	O
43	secretion	O
44	.	O

1	Human	B
2	cytomegalovirus	I
3	immediate	I
4	-	I
5	early	I
6	protein	I
7	IE2	I
8	tethers	O
9	a	O
10	transcriptional	O
11	repression	O
12	domain	O
13	to	O
14	p53	B
15	.	O

1	The	O
2	specificity	O
3	of	O
4	action	O
5	of	O
6	C	B
7	/	I
8	EBP	I
9	family	I
10	members	I
11	may	O
12	be	O
13	derived	O
14	from	O
15	the	O
16	characteristics	O
17	of	O
18	each	O
19	factor	O
20	,	O
21	including	O
22	the	O
23	expression	O
24	profiles	O
25	,	O
26	the	O
27	DNA	O
28	binding	O
29	affinities	O
30	,	O
31	the	O
32	cofactors	O
33	,	O
34	and	O
35	so	O
36	on	O
37	,	O
38	in	O
39	addition	O
40	to	O
41	the	O
42	DNA	O
43	binding	O
44	specificities	O
45	.	O

1	The	O
2	antibodies	O
3	inhibited	O
4	specifically	O
5	the	O
6	transcription	O
7	of	O
8	DNA	B
9	polymerase	I
10	alpha	I
11	promoter	O
12	in	O
13	vitro	O
14	.	O

1	Immunocytochemical	O
2	analysis	O
3	demonstrated	O
4	the	O
5	presence	O
6	of	O
7	DREF	B
8	polypeptide	I
9	in	O
10	nuclei	O
11	after	O
12	the	O
13	eighth	O
14	nuclear	O
15	division	O
16	cycle	O
17	,	O
18	suggesting	O
19	that	O
20	nuclear	O
21	accumulation	O
22	of	O
23	DREF	B
24	is	O
25	important	O
26	for	O
27	the	O
28	coordinate	O
29	zygotic	O
30	expression	O
31	of	O
32	DNA	O
33	replication	O
34	-	O
35	related	O
36	genes	O
37	carrying	O
38	DRE	O
39	sequences	O
40	.	O

1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	B
19	gene	I
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O

1	This	O
2	result	O
3	supports	O
4	the	O
5	argument	O
6	that	O
7	the	O
8	beta	O
9	'	O
10	subunit	O
11	plays	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	determining	O
17	the	O
18	progress	O
19	of	O
20	transcription	O
21	elongation	O
22	.	O

1	Two	O
2	XPG	B
3	regions	I
4	with	O
5	putative	O
6	NLS	O
7	[	O
8	amino	O
9	acid	O
10	(	O
11	AA	O
12	)	O
13	coordinates	O
14	:	O
15	NLS	O
16	-	O
17	B	O
18	(	O
19	AA	O
20	1057	O
21	-	O
22	1074	O
23	)	O
24	and	O
25	NLS	O
26	-	O
27	C	O
28	(	O
29	AA	O
30	1171	O
31	-	O
32	1185	O
33	)]	O
34	were	O
35	each	O
36	shown	O
37	to	O
38	independently	O
39	localize	O
40	the	O
41	beta	B
42	-	I
43	gal	I
44	extensively	O
45	(>	O
46	80	O
47	%)	O
48	to	O
49	the	O
50	nucleus	O
51	of	O
52	HeLa	O
53	cells	O
54	.	O

1	The	O
2	lacS	B
3	gene	I
4	was	O
5	cloned	O
6	in	O
7	an	O
8	E	O
9	.	O
10	coli	O
11	-	O
12	Streptococcus	O
13	shuttle	O
14	vector	O
15	and	O
16	was	O
17	expressed	O
18	both	O
19	in	O
20	a	O
21	lacS	B
22	deletion	O
23	derivative	O
24	of	O
25	S	O
26	.	O
27	thermophilus	O
28	and	O
29	in	O
30	a	O
31	pNZ63	O
32	-	O
33	cured	O
34	strain	O
35	,	O
36	L	O
37	.	O
38	lactis	O
39	NZ6091	O
40	.	O

1	The	O
2	genome	O
3	of	O
4	all	O
5	retroviruses	O
6	consists	O
7	of	O
8	two	O
9	identical	O
10	RNAs	O
11	noncovalently	O
12	linked	O
13	near	O
14	their	O
15	5	O
16	'	O
17	end	O
18	.	O

1	The	O
2	extraction	O
3	recovery	O
4	of	O
5	Amphotericin	O
6	B	O
7	from	O
8	the	O
9	cerebrospinal	O
10	fluid	O
11	is	O
12	higher	O
13	than	O
14	90	O
15	%	O
16	over	O
17	the	O
18	entire	O
19	linear	O
20	range	O
21	.	O

1	HuEpo	B
2	-	I
3	R	I
4	Ab	I
5	inhibited	O
6	Epo	B
7	-	O
8	induced	O
9	parental	O
10	UT	O
11	-	O
12	7	O
13	cell	O
14	growth	O
15	,	O
16	but	O
17	not	O
18	that	O
19	of	O
20	cells	O
21	of	O
22	clone	O
23	12	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	muEpo	B
29	-	I
30	R	I
31	is	O
32	able	O
33	to	O
34	induce	O
35	human	O
36	UT	O
37	-	O
38	7	O
39	cell	O
40	proliferation	O
41	.	O

1	The	O
2	frequency	O
3	of	O
4	integrations	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	B
12	gene	I
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	integrations	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	downregulated	O
31	on	O
32	differentiation	O
33	of	O
34	32D	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O

1	The	O
2	sequence	O
3	and	O
4	isolated	O
5	cDNAs	O
6	will	O
7	provide	O
8	useful	O
9	reagents	O
10	for	O
11	studying	O
12	the	O
13	expression	O
14	of	O
15	Brca1	B
16	in	O
17	the	O
18	mouse	O
19	,	O
20	and	O
21	for	O
22	testing	O
23	the	O
24	importance	O
25	of	O
26	the	O
27	evolutionarily	O
28	conserved	O
29	domains	O
30	.	O

1	A	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	compare	O
7	the	O
8	ONLINE	O
9	and	O
10	EMIT	O
11	II	O
12	immunoassays	O
13	with	O
14	gas	O
15	chromatographic	O
16	/	O
17	mass	O
18	spectrometric	O
19	(	O
20	GC	O
21	/	O
22	MS	O
23	)	O
24	analysis	O
25	of	O
26	methaqualone	O
27	metabolites	O
28	on	O
29	urine	O
30	using	O
31	samples	O
32	obtained	O
33	from	O
34	a	O
35	clinical	O
36	study	O
37	.	O

1	Interaction	O
2	of	O
3	the	O
4	Fur	B
5	repressor	I
6	with	O
7	a	O
8	150	O
9	-	O
10	bp	O
11	fragment	O
12	encompassing	O
13	the	O
14	pvdS	B
15	promoter	I
16	was	O
17	demonstrated	O
18	in	O
19	vivo	O
20	by	O
21	the	O
22	Fur	B
23	titration	O
24	assay	O
25	and	O
26	confirmed	O
27	in	O
28	vitro	O
29	by	O
30	gel	O
31	retardation	O
32	experiments	O
33	with	O
34	a	O
35	partially	O
36	purified	O
37	Fur	B
38	preparation	O
39	.	O

1	This	O
2	protein	O
3	encoded	O
4	by	O
5	this	O
6	cDNA	O
7	,	O
8	which	O
9	we	O
10	have	O
11	termed	O
12	p150TSP	B
13	(	O
14	for	O
15	TPR	O
16	-	O
17	containing	O
18	,	O
19	SH2	B
20	-	I
21	binding	I
22	phosphoprotein	I
23	),	O
24	is	O
25	located	O
26	predominantly	O
27	in	O
28	the	O
29	nucleus	O
30	and	O
31	is	O
32	highly	O
33	conserved	O
34	in	O
35	evolution	O
36	.	O

1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	O
9	surface	O
10	and	O
11	bound	O
12	insulin	B
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	autophosphorylation	O
20	in	O
21	response	O
22	to	O
23	insulin	B
24	.	O

1	EMBO	O
2	J	O
3	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	thrombin	B
9	-	O
10	stimulated	O
11	vascular	O
12	smooth	O
13	muscle	O
14	proliferation	O
15	is	O
16	delayed	O
17	and	O
18	requires	O
19	the	O
20	de	O
21	novo	O
22	expression	O
23	of	O
24	one	O
25	or	O
26	more	O
27	autocrine	O
28	mitogens	O
29	.	O

1	Transcription	O
2	from	O
3	adenovirus	B
4	E2	I
5	-	I
6	early	I
7	promoter	I
8	is	O
9	controlled	O
10	by	O
11	a	O
12	unique	O
13	array	O
14	of	O
15	four	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	which	O
21	include	O
22	an	O
23	atypical	O
24	TBP	B
25	site	I
26	,	O
27	two	O
28	E2F	B
29	sites	I
30	present	O
31	in	O
32	an	O
33	inverted	O
34	orientation	O
35	relative	O
36	to	O
37	each	O
38	other	O
39	,	O
40	and	O
41	an	O
42	ATF	B
43	site	I
44	.	O

1	Furthermore	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	6	I
10	/	O
11	interferon	B
12	gamma	I
13	(	O
14	IFN	B
15	gamma	I
16	)	O
17	response	O
18	element	O
19	in	O
20	the	O
21	IRF	B
22	-	I
23	1	I
24	promoter	I
25	(	O
26	IR	B
27	/	O
28	IRF	B
29	-	I
30	1	I
31	),	O
32	which	O
33	contains	O
34	a	O
35	Stat	B
36	-	I
37	binding	I
38	site	I
39	and	O
40	an	O
41	adjacent	O
42	CRE	O
43	-	O
44	like	O
45	site	O
46	,	O
47	also	O
48	makes	O
49	IL	B
50	-	I
51	6	I
52	-	O
53	induced	O
54	binding	O
55	complexes	O
56	similar	O
57	to	O
58	JRE	O
59	-	O
60	IL6	B
61	-	O
62	BCs	O
63	.	O

1	A	O
2	second	O
3	peptide	O
4	(	O
5	amino	O
6	acids	O
7	58	O
8	-	O
9	77	O
10	)	O
11	also	O
12	antagonized	O
13	p21	B
14	-	O
15	activity	O
16	,	O
17	but	O
18	this	O
19	peptide	O
20	did	O
21	not	O
22	affect	O
23	the	O
24	ability	O
25	of	O
26	p21	B
27	to	O
28	interact	O
29	with	O
30	cyclin	B
31	E	I
32	/	O
33	Cdk2	B
34	.	O

1	A	O
2	p21	B
3	peptide	I
4	spanning	O
5	amino	O
6	acids	O
7	139	O
8	-	O
9	164	O
10	was	O
11	found	O
12	to	O
13	bind	O
14	PCNA	B
15	in	O
16	a	O
17	filter	O
18	binding	O
19	assay	O
20	and	O
21	this	O
22	peptide	O
23	suppressed	O
24	recombinant	O
25	p21	B
26	-	O
27	PCNA	B
28	interaction	O
29	.	O

1	Results	O
2	were	O
3	supported	O
4	by	O
5	the	O
6	agar	O
7	diffusion	O
8	method	O
9	for	O
10	Y	O
11	.	O
12	enterocolitica	O
13	,	O
14	whereas	O
15	inhibition	O
16	activity	O
17	was	O
18	not	O
19	found	O
20	for	O
21	A	O
22	.	O
23	hydrophila	O
24	.	O

1	OND	O
2	8	O
3	mg	O
4	tid	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	tid	O
14	prn	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	prednisolone	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	qds	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	MCP	O
34	30	O
35	mg	O
36	/	O
37	metylprednisolone	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	MCP	O
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O

1	The	O
2	dynamic	O
3	properties	O
4	of	O
5	this	O
6	protein	O
7	fragment	O
8	were	O
9	measured	O
10	and	O
11	analyzed	O
12	using	O
13	both	O
14	isotropic	O
15	and	O
16	anisotropic	O
17	models	O
18	of	O
19	molecular	O
20	motion	O
21	.	O

1	Adduction	O
2	of	O
3	the	O
4	human	B
5	N	I
6	-	I
7	ras	I
8	codon	I
9	61	I
10	sequence	I
11	with	O
12	(-)-(	O
13	7S	O
14	,	O
15	8R	O
16	,	O
17	9R	O
18	,	O
19	10S	O
20	)-	O
21	7	O
22	,	O
23	8	O
24	-	O
25	dihydroxy	O
26	-	O
27	9	O
28	,	O
29	10	O
30	-	O
31	epoxy	O
32	-	O
33	7	O
34	,	O
35	8	O
36	,	O
37	9	O
38	,	O
39	10	O
40	-	O
41	tetrahydrobenzo	O
42	[	O
43	a	O
44	]	O
45	pyrene	O
46	:	O
47	structural	O
48	refinement	O
49	of	O
50	the	O
51	intercalated	O
52	SRSR	O
53	(	O
54	61	O
55	,	O
56	2	O
57	)	O
58	(-)-(	O
59	7S	O
60	,	O
61	8R	O
62	,	O
63	9S	O
64	,	O
65	10R	O
66	)-	O
67	N6	O
68	-[	O
69	10	O
70	-(	O
71	7	O
72	,	O
73	8	O
74	,	O
75	9	O
76	,	O
77	10	O
78	-	O
79	tetrahydrobenzo	O
80	[	O
81	a	O
82	]	O
83	pyrenyl	O
84	)]-	O
85	2	O
86	'-	O
87	deoxyadenosyl	O
88	adduct	O
89	from	O
90	1H	O
91	NMR	O
92	.	O

1	Isolation	O
2	by	O
3	PCR	O
4	of	O
5	a	O
6	cDNA	O
7	clone	O
8	from	O
9	pea	O
10	petals	O
11	with	O
12	similarity	O
13	to	O
14	petunia	O
15	and	O
16	wheat	B
17	zinc	I
18	finger	I
19	proteins	I
20	.	O

1	This	O
2	fragment	O
3	can	O
4	bind	O
5	several	O
6	trans	O
7	-	O
8	acting	O
9	factors	O
10	in	O
11	vitro	O
12	,	O
13	including	O
14	GATA	B
15	-	I
16	1	I
17	and	O
18	members	O
19	of	O
20	the	O
21	Ets	B
22	family	I
23	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	B
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	These	O
2	different	O
3	observations	O
4	exclude	O
5	a	O
6	heterozygosity	O
7	of	O
8	the	O
9	A	O
10	-->	O
11	G	O
12	mutation	O
13	at	O
14	codon	O
15	beta	O
16	77	O
17	,	O
18	as	O
19	well	O
20	as	O
21	a	O
22	deletion	O
23	comparable	O
24	to	O
25	that	O
26	of	O
27	Hbs	B
28	Lepore	I
29	or	I
30	Kenya	I
31	,	O
32	or	O
33	a	O
34	beta	B
35	-	I
36	globin	I
37	gene	I
38	duplication	O
39	,	O
40	and	O
41	point	O
42	to	O
43	a	O
44	nontraditional	O
45	inheritance	O
46	of	O
47	Hb	B
48	Costa	I
49	Rica	I
50	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	description	O
6	,	O
7	to	O
8	our	O
9	knowledge	O
10	,	O
11	of	O
12	regulatory	O
13	elements	O
14	that	O
15	control	O
16	expression	O
17	of	O
18	a	O
19	gene	O
20	encoding	O
21	a	O
22	B7	B
23	costimulatory	I
24	molecule	I
25	.	O

1	DNA	B
2	-	I
3	STAT	I
4	complexes	I
5	were	O
6	detected	O
7	in	O
8	all	O
9	Bcr	B
10	/	O
11	Abl	B
12	-	O
13	transformed	O
14	cell	O
15	lines	O
16	and	O
17	they	O
18	were	O
19	supershifted	O
20	by	O
21	antibodies	O
22	against	O
23	STAT1	B
24	and	O
25	STAT5	B
26	.	O

1	When	O
2	overexpressed	O
3	in	O
4	an	O
5	appropriate	O
6	cell	O
7	line	O
8	,	O
9	TAN	B
10	-	I
11	1C	I
12	prevented	O
13	kappa	B
14	B	I
15	-	O
16	dependent	O
17	transactivation	O
18	in	O
19	transient	O
20	reporter	O
21	gene	O
22	assays	O
23	in	O
24	a	O
25	fashion	O
26	similar	O
27	to	O
28	the	O
29	structurally	O
30	related	O
31	protein	O
32	,	O
33	Bcl	B
34	-	I
35	3	I
36	.	O

1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	O
7	Notch	B
8	/	O
9	translocation	O
10	-	O
11	associated	O
12	Notch	B
13	homologue	O
14	has	O
15	I	B
16	kappa	I
17	B	I
18	-	O
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	B
26	factor	I
27	-	I
28	kappa	I
29	B	I
30	proteins	O
31	in	O
32	T	O
33	cells	O
34	.	O

1	Polyprotein	O
2	processing	O
3	in	O
4	Southampton	O
5	virus	O
6	:	O
7	identification	O
8	of	O
9	3C	B
10	-	I
11	like	I
12	protease	I
13	cleavage	O
14	sites	O
15	by	O
16	in	O
17	vitro	O
18	mutagenesis	O
19	.	O

1	The	O
2	humanized	B
3	LL2	I
4	(	O
5	hLL2	B
6	),	O
7	lacking	O
8	light	B
9	chain	I
10	variable	I
11	region	I
12	glycosylation	O
13	,	O
14	exhibited	O
15	immunoreactivities	O
16	that	O
17	were	O
18	comparable	O
19	to	O
20	that	O
21	of	O
22	chimeric	B
23	LL2	I
24	(	O
25	cLL2	B
26	),	O
27	which	O
28	was	O
29	shown	O
30	previously	O
31	to	O
32	have	O
33	antigen	O
34	-	O
35	binding	O
36	properties	O
37	similar	O
38	to	O
39	its	O
40	murine	O
41	counterpart	O
42	,	O
43	suggesting	O
44	that	O
45	the	O
46	VK	O
47	-	O
48	appended	O
49	oligosaccharides	O
50	found	O
51	in	O
52	mLL2	B
53	are	O
54	not	O
55	necessary	O
56	for	O
57	antigen	O
58	binding	O
59	.	O

1	An	O
2	apparent	O
3	N	O
4	-	O
5	terminal	O
6	transit	O
7	peptide	O
8	in	O
9	the	O
10	coding	O
11	region	O
12	and	O
13	a	O
14	3	O
15	'	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	exist	O
22	in	O
23	the	O
24	cDNA	O
25	clone	O
26	indicated	O
27	that	O
28	this	O
29	chloroplast	O
30	protein	O
31	as	O
32	nuclear	O
33	encoded	O
34	.	O

1	Deletion	O
2	analysis	O
3	of	O
4	rOC	B
5	promoter	I
6	-	O
7	chloramphenicol	B
8	acetyltransferase	I
9	constructs	O
10	demonstrates	O
11	that	O
12	an	O
13	AML	B
14	-	I
15	1	I
16	-	I
17	binding	I
18	sequence	I
19	within	O
20	the	O
21	proximal	O
22	promoter	O
23	(-	O
24	138	O
25	to	O
26	-	O
27	130	O
28	nt	O
29	)	O
30	contributes	O
31	to	O
32	75	O
33	%	O
34	of	O
35	the	O
36	level	O
37	of	O
38	osteocalcin	B
39	gene	I
40	expression	O
41	.	O

1	Thus	O
2	,	O
3	a	O
4	critical	O
5	question	O
6	is	O
7	how	O
8	HOX	B
9	proteins	I
10	select	O
11	the	O
12	correct	O
13	sets	O
14	of	O
15	target	O
16	genes	O
17	in	O
18	vivo	O
19	.	O

1	RAS2val19	B
2	,	O
3	a	O
4	dominant	O
5	activated	O
6	form	O
7	of	O
8	Saccharomyces	B
9	cerevisiae	I
10	Ras2	I
11	,	O
12	stimulates	O
13	both	O
14	filamentous	O
15	growth	O
16	and	O
17	expression	O
18	of	O
19	a	O
20	transcriptional	O
21	reporter	O
22	FG	B
23	(	O
24	TyA	B
25	)::	O
26	lacZ	B
27	but	O
28	does	O
29	not	O
30	induce	O
31	the	O
32	mating	B
33	pathway	I
34	reporter	I
35	FUS1	I
36	::	O
37	lacZ	B
38	.	O

1	Moreover	O
2	,	O
3	the	O
4	Rho	B
5	family	I
6	protein	I
7	Cdc42	I
8	,	O
9	a	O
10	conserved	O
11	morphogenetic	B
12	G	I
13	protein	I
14	,	O
15	is	O
16	also	O
17	a	O
18	potent	O
19	regulator	O
20	of	O
21	filamentous	O
22	growth	O
23	and	O
24	FG	B
25	(	O
26	TyA	B
27	)::	O
28	lacZ	B
29	expression	O
30	in	O
31	S	O
32	.	O
33	cerevisiae	O
34	.	O

1	Each	O
2	immunoprecipitate	O
3	contained	O
4	a	O
5	complex	O
6	of	O
7	N1	B
8	(	I
9	deltaEC	I
10	)	I
11	and	O
12	CBF1	B
13	.	O

1	This	O
2	region	O
3	includes	O
4	verA	B
5	,	O
6	a	O
7	structural	O
8	gene	O
9	previously	O
10	shown	O
11	to	O
12	be	O
13	required	O
14	for	O
15	ST	O
16	biosynthesis	O
17	,	O
18	and	O
19	24	O
20	additional	O
21	closely	O
22	spaced	O
23	transcripts	O
24	ranging	O
25	in	O
26	size	O
27	from	O
28	0	O
29	.	O
30	6	O
31	to	O
32	7	O
33	.	O
34	2	O
35	kb	O
36	that	O
37	are	O
38	coordinately	O
39	induced	O
40	only	O
41	under	O
42	ST	O
43	-	O
44	producing	O
45	conditions	O
46	.	O

1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	O
13	SMMHC	B
14	fusion	O
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O

1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O

1	We	O
2	report	O
3	the	O
4	isolation	O
5	of	O
6	human	O
7	cDNAs	O
8	homologous	O
9	to	O
10	the	O
11	Drosophila	B
12	dishevelled	I
13	(	O
14	dsh	B
15	)	O
16	segment	O
17	-	O
18	polarity	O
19	gene	O
20	.	O

1	Escherichia	O
2	coli	O
3	BL21	O
4	(	O
5	DE3	O
6	)	O
7	plysS	O
8	,	O
9	harbouring	O
10	a	O
11	recombinant	O
12	plasmid	O
13	containing	O
14	the	O
15	catalase	B
16	-	O
17	peroxidase	B
18	gene	O
19	,	O
20	produced	O
21	a	O
22	large	O
23	amount	O
24	of	O
25	proteins	O
26	that	O
27	co	O
28	-	O
29	migrated	O
30	on	O
31	SDS	O
32	/	O
33	PAGE	O
34	with	O
35	the	O
36	native	O
37	enzyme	O
38	.	O

1	Ca2	O
2	+	O
3	decreased	O
4	Zn2	O
5	+	O
6	binding	O
7	in	O
8	S100	B
9	beta	I
10	but	O
11	it	O
12	did	O
13	not	O
14	influence	O
15	binding	O
16	to	O
17	MRP14	B
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	Zn2	O
23	+	O
24	binding	O
25	site	O
26	was	O
27	distinct	O
28	from	O
29	and	O
30	independent	O
31	of	O
32	the	O
33	two	O
34	Ca2	O
35	+	O
36	binding	O
37	domains	O
38	.	O

1	Cdk2	B
2	formed	O
3	a	O
4	complex	O
5	with	O
6	cyclin	B
7	D1	I
8	in	O
9	this	O
10	system	O
11	.	O

1	The	O
2	Cdk2	B
3	-	O
4	cyclin	B
5	-	I
6	D1	I
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	B
18	histone	I
19	,	O
20	pRB	B
21	,	O
22	SV40	B
23	large	I
24	T	I
25	antigen	I
26	,	O
27	p53	B
28	,	O
29	E2F	B
30	-	I
31	1	I
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	B
46	-	O
47	cyclin	B
48	-	I
49	E	I
50	and	O
51	Cdk2	B
52	-	O
53	cyclin	B
54	-	I
55	A	I
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O

1	Cyclin	B
2	-	I
3	dependent	I
4	kinase	I
5	-	I
6	2	I
7	(	O
8	Cdk2	B
9	)	O
10	forms	O
11	an	O
12	inactive	O
13	complex	O
14	with	O
15	cyclin	B
16	D1	I
17	since	O
18	Cdk2	B
19	associated	O
20	with	O
21	cyclin	B
22	D1	I
23	is	O
24	not	O
25	phosphorylated	O
26	by	O
27	Cdk7	B
28	-	O
29	cyclin	B
30	-	I
31	H	I
32	.	O

1	Two	O
2	overlapping	O
3	clones	O
4	contained	O
5	the	O
6	complete	O
7	Adh	B
8	-	I
9	2	I
10	gene	I
11	composed	O
12	of	O
13	nine	O
14	exons	O
15	in	O
16	a	O
17	12	O
18	-	O
19	kb	O
20	region	O
21	,	O
22	with	O
23	the	O
24	placement	O
25	of	O
26	introns	O
27	matching	O
28	that	O
29	observed	O
30	in	O
31	other	O
32	mammalian	B
33	ADH	I
34	genes	I
35	.	O

1	Ligation	O
2	of	O
3	CD40	B
4	rescues	O
5	Ramos	O
6	-	O
7	Burkitt	O
8	lymphoma	O
9	B	O
10	cells	O
11	from	O
12	calcium	O
13	ionophore	O
14	-	O
15	and	O
16	antigen	O
17	receptor	O
18	-	O
19	triggered	O
20	apoptosis	O
21	by	O
22	inhibiting	O
23	activation	O
24	of	O
25	the	O
26	cysteine	B
27	protease	I
28	CPP32	I
29	/	O
30	Yama	B
31	and	O
32	cleavage	O
33	of	O
34	its	O
35	substrate	O
36	PARP	B
37	.	O

1	Large	B
2	T	I
3	antigen	I
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	B
13	,	O
14	endogenous	O
15	TBP	B
16	,	O
17	hTAF	B
18	(	I
19	II	I
20	)	I
21	100	I
22	,	O
23	hTAF	B
24	(	I
25	II	I
26	)	I
27	130	I
28	,	O
29	and	O
30	hTAF	B
31	(	I
32	II	I
33	)	I
34	250	I
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	B
40	-	I
41	TFIID	I
42	would	O
43	be	O
44	precipitated	O
45	.	O

1	Northern	O
2	blot	O
3	hybridization	O
4	demonstrated	O
5	that	O
6	HEP	B
7	-	O
8	COP	B
9	was	O
10	expressed	O
11	in	O
12	a	O
13	wide	O
14	range	O
15	of	O
16	human	O
17	adult	O
18	and	O
19	fetal	O
20	tissues	O
21	.	O

1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	O
8	cloned	O
9	that	O
10	possesses	O
11	the	O
12	same	O
13	structural	O
14	arrangement	O
15	of	O
16	SH3	B
17	-	O
18	SH2	B
19	-	O
20	SH3	B
21	domains	O
22	as	O
23	Grb2	B
24	.	O

1	A	O
2	direct	O
3	role	O
4	for	O
5	sterol	B
6	regulatory	I
7	element	I
8	binding	I
9	protein	I
10	in	O
11	activation	O
12	of	O
13	3	B
14	-	I
15	hydroxy	I
16	-	I
17	3	I
18	-	I
19	methylglutaryl	I
20	coenzyme	I
21	A	I
22	reductase	I
23	gene	I
24	.	O

1	E3	B
2	/	I
3	19K	I
4	resides	O
5	in	O
6	the	O
7	endoplasmic	O
8	reticulum	O
9	where	O
10	it	O
11	binds	O
12	to	O
13	MHC	B
14	class	I
15	I	I
16	molecules	I
17	,	O
18	thereby	O
19	preventing	O
20	their	O
21	transport	O
22	to	O
23	the	O
24	cell	O
25	surface	O
26	.	O

1	When	O
2	the	O
3	PHT	O
4	and	O
5	CSA	O
6	groups	O
7	were	O
8	compared	O
9	,	O
10	Hyp	O
11	levels	O
12	were	O
13	significantly	O
14	higher	O
15	in	O
16	the	O
17	PHT	O
18	-	O
19	GO	O
20	+	O
21	group	O
22	than	O
23	in	O
24	the	O
25	CSA	O
26	-	O
27	GO	O
28	+	O
29	group	O
30	.	O

1	Among	O
2	the	O
3	LE6	B
4	deletions	O
5	,	O
6	only	O
7	one	O
8	had	O
9	a	O
10	reduced	O
11	transformation	O
12	efficiency	O
13	,	O
14	while	O
15	seven	O
16	transformed	O
17	cells	O
18	at	O
19	least	O
20	as	O
21	efficiently	O
22	as	O
23	wild	B
24	-	I
25	type	I
26	LE6	I
27	.	O

1	ORF	B
2	E8	I
3	colinear	O
4	with	O
5	ORF	B
6	E6	I
7	,	O
8	which	O
9	could	O
10	generate	O
11	a	O
12	50	O
13	-	O
14	amino	O
15	-	O
16	acid	O
17	protein	O
18	with	O
19	a	O
20	hydrophobic	O
21	segment	O
22	,	O
23	did	O
24	not	O
25	transform	O
26	cells	O
27	when	O
28	cloned	O
29	into	O
30	the	O
31	pZipNeo	O
32	vector	O
33	.	O

1	Cloning	O
2	of	O
3	individual	O
4	ZI	O
5	domains	O
6	upstream	O
7	of	O
8	a	O
9	minimal	O
10	promoter	O
11	demonstrated	O
12	that	O
13	the	O
14	ZIA	O
15	,	O
16	ZIC	O
17	,	O
18	and	O
19	ZID	O
20	domains	O
21	,	O
22	but	O
23	not	O
24	the	O
25	ZIB	O
26	domain	O
27	,	O
28	are	O
29	TPA	O
30	responsive	O
31	.	O

1	Clb2	B
2	/	O
3	Cdc28	B
4	kinase	O
5	is	O
6	not	O
7	required	O
8	for	O
9	the	O
10	repression	O
11	of	O
12	MCB	B
13	-	I
14	binding	I
15	factor	I
16	transcriptional	O
17	activity	O
18	in	O
19	G2	O
20	and	O
21	M	O
22	phase	O
23	.	O

1	The	O
2	carboxy	O
3	terminus	O
4	of	O
5	Mbp1	B
6	is	O
7	sufficient	O
8	for	O
9	interaction	O
10	with	O
11	Swi6	B
12	,	O
13	and	O
14	the	O
15	carboxy	O
16	terminus	O
17	of	O
18	Swi6	B
19	is	O
20	required	O
21	for	O
22	interaction	O
23	with	O
24	Mbp1	B
25	.	O

1	Multiple	O
2	single	O
3	-	O
4	stranded	O
5	cis	O
6	elements	O
7	are	O
8	associated	O
9	with	O
10	activated	O
11	chromatin	O
12	of	O
13	the	O
14	human	B
15	c	I
16	-	I
17	myc	I
18	gene	I
19	in	O
20	vivo	O
21	.	O

1	A	O
2	new	O
3	UASH	O
4	consensus	O
5	sequence	O
6	derived	O
7	from	O
8	this	O
9	mutational	O
10	analysis	O
11	closely	O
12	matches	O
13	a	O
14	consensus	O
15	Abf1	B
16	binding	I
17	site	I
18	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	analyzed	O
6	human	B
7	CTCF	I
8	cDNA	I
9	clones	O
10	and	O
11	show	O
12	here	O
13	that	O
14	the	O
15	ubiquitously	O
16	expressed	O
17	11	B
18	-	I
19	zinc	I
20	-	I
21	finger	I
22	factor	I
23	CTCF	I
24	is	O
25	an	O
26	exceptionally	O
27	highly	O
28	conserved	O
29	protein	O
30	displaying	O
31	93	O
32	%	O
33	identity	O
34	between	O
35	avian	O
36	and	O
37	human	O
38	amino	O
39	acid	O
40	sequences	O
41	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	B
6	-	I
7	proximal	I
8	CTCF	I
9	binding	I
10	site	I
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	B
26	c	I
27	-	I
28	myc	I
29	gene	I
30	.	O

1	A	O
2	chromosome	B
3	transmission	I
4	fidelity	I
5	(	O
6	ctf	B
7	)	O
8	mutant	O
9	,	O
10	s138	O
11	,	O
12	of	O
13	Saccharomyces	O
14	cerevisiae	O
15	was	O
16	identified	O
17	by	O
18	its	O
19	centromere	O
20	(	O
21	CEN	O
22	)	O
23	transcriptional	O
24	readthrough	O
25	phenotype	O
26	,	O
27	suggesting	O
28	perturbed	O
29	kinetochore	O
30	integrity	O
31	in	O
32	vivo	O
33	.	O

1	The	O
2	growth	O
3	defect	O
4	of	O
5	a	O
6	reg1	B
7	reg2	I
8	double	I
9	mutant	I
10	is	O
11	alleviated	O
12	by	O
13	a	O
14	loss	O
15	-	O
16	of	O
17	-	O
18	function	O
19	mutation	O
20	in	O
21	the	O
22	SNF1	B
23	-	I
24	encoded	I
25	protein	I
26	kinase	I
27	.	O

1	Sp1	B
2	binds	O
3	two	O
4	sites	O
5	in	O
6	the	O
7	CD11c	B
8	promoter	I
9	in	O
10	vivo	O
11	specifically	O
12	in	O
13	myeloid	O
14	cells	O
15	and	O
16	cooperates	O
17	with	O
18	AP1	B
19	to	O
20	activate	O
21	transcription	O
22	.	O

1	Expression	O
2	of	O
3	the	O
4	phenylalanine	B
5	hydroxylase	I
6	gene	I
7	in	O
8	livers	O
9	and	O
10	kidneys	O
11	of	O
12	rodents	O
13	is	O
14	activated	O
15	at	O
16	birth	O
17	and	O
18	is	O
19	induced	O
20	by	O
21	glucocorticoids	O
22	and	O
23	cyclic	O
24	AMP	O
25	in	O
26	the	O
27	liver	O
28	.	O

1	We	O
2	found	O
3	that	O
4	120	O
5	bp	O
6	of	O
7	the	O
8	enhancer	O
9	'	O
10	s	O
11	transcriptional	O
12	core	O
13	becomes	O
14	DNase	B
15	I	I
16	hypersensitive	O
17	early	O
18	in	O
19	B	O
20	-	O
21	cell	O
22	development	O
23	.	O

1	A	O
2	developmentally	O
3	modulated	O
4	chromatin	O
5	structure	O
6	at	O
7	the	O
8	mouse	B
9	immunoglobulin	I
10	kappa	I
11	3	I
12	'	I
13	enhancer	I
14	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	identification	O
6	of	O
7	a	O
8	cDNA	O
9	that	O
10	encodes	O
11	a	O
12	new	O
13	member	O
14	of	O
15	the	O
16	GTPase	B
17	-	I
18	activating	I
19	protein	I
20	(	O
21	GAP	B
22	)	O
23	family	O
24	of	O
25	GTPase	B
26	regulators	O
27	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	further	O
7	investigated	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	synthesis	O
13	of	O
14	the	O
15	c	B
16	-	I
17	mos	I
18	oncogene	I
19	product	I
20	,	O
21	which	O
22	is	O
23	necessary	O
24	for	O
25	the	O
26	activation	O
27	of	O
28	Cdc2	B
29	.	O

1	The	O
2	heterogeneity	O
3	of	O
4	bovine	B
5	IgG2	I
6	--	I
7	VIII	I
8	.	O

1	The	O
2	ability	O
3	of	O
4	BCL	B
5	-	I
6	6	I
7	to	O
8	function	O
9	as	O
10	a	O
11	transcriptional	O
12	repressor	O
13	may	O
14	contribute	O
15	to	O
16	its	O
17	ability	O
18	to	O
19	transform	O
20	B	O
21	lymphocytes	O
22	in	O
23	diffuse	O
24	large	O
25	cell	O
26	lymphoma	O
27	.	O

1	Positioning	O
2	this	O
3	uORF	O
4	,	O
5	together	O
6	with	O
7	its	O
8	accompanying	O
9	Kozak	O
10	sequences	O
11	,	O
12	between	O
13	a	O
14	heterologous	O
15	promoter	O
16	from	O
17	SV40	O
18	and	O
19	a	O
20	CAT	B
21	reporter	I
22	gene	I
23	resulted	O
24	in	O
25	marked	O
26	inhibition	O
27	of	O
28	CAT	B
29	protein	I
30	production	O
31	without	O
32	a	O
33	decrease	O
34	in	O
35	CAT	B
36	mRNA	I
37	.	O

1	A	O
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O

1	Mesial	O
2	temporal	O
3	sclerosis	O
4	was	O
5	characterized	O
6	by	O
7	severe	O
8	neuronal	O
9	loss	O
10	accompanied	O
11	by	O
12	gliosis	O
13	occurring	O
14	in	O
15	the	O
16	CA1	O
17	/	O
18	prosubiculum	O
19	(	O
20	27	O
21	patients	O
22	,	O
23	100	O
24	%),	O
25	focally	O
26	in	O
27	the	O
28	dentate	O
29	gyrus	O
30	(	O
31	12	O
32	patients	O
33	,	O
34	44	O
35	%),	O
36	and	O
37	in	O
38	the	O
39	CA4	O
40	region	O
41	(	O
42	11	O
43	patients	O
44	,	O
45	41	O
46	%).	O

1	Mesial	O
2	temporal	O
3	sclerosis	O
4	.	O

1	More	O
2	specific	O
3	adverse	O
4	events	O
5	,	O
6	also	O
7	frequently	O
8	considered	O
9	as	O
10	dose	O
11	-	O
12	limiting	O
13	toxicities	O
14	,	O
15	include	O
16	hypotension	O
17	with	O
18	IL	B
19	-	I
20	1	I
21	,	O
22	severe	O
23	headache	O
24	or	O
25	skin	O
26	rash	O
27	with	O
28	IL	B
29	-	I
30	3	I
31	,	O
32	and	O
33	nasal	O
34	congestion	O
35	and	O
36	gastroduodenal	O
37	lesions	O
38	with	O
39	IL	B
40	-	I
41	4	I
42	.	O

1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	adolescent	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	lorazepam	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	antipyrine	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	indocyanine	O
45	green	O
46	(	O
47	ICG	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	)]	O
56	was	O
57	also	O
58	determined	O
59	.	O

1	A	O
2	mutational	O
3	analysis	O
4	has	O
5	resolved	O
6	a	O
7	region	O
8	of	O
9	seven	O
10	amino	O
11	acids	O
12	(	O
13	amino	O
14	acids	O
15	26	O
16	-	O
17	32	O
18	)	O
19	in	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	of	O
25	Bob1	B
26	that	O
27	are	O
28	important	O
29	for	O
30	contacting	O
31	the	O
32	DNA	B
33	binding	I
34	POU	I
35	domain	I
36	of	O
37	Oct	B
38	-	I
39	1	I
40	or	O
41	Oct	B
42	-	I
43	2	I
44	.	O

1	Heme	B
2	oxygenase	I
3	1	I
4	is	O
5	an	O
6	essential	O
7	enzyme	O
8	in	O
9	heme	O
10	catabolism	O
11	that	O
12	cleaves	O
13	heme	O
14	to	O
15	form	O
16	biliverdin	O
17	,	O
18	iron	O
19	,	O
20	and	O
21	carbon	O
22	monoxide	O
23	.	O

1	An	O
2	inactive	O
3	analog	O
4	of	O
5	wortmannin	O
6	,	O
7	WM12	O
8	,	O
9	did	O
10	not	O
11	affect	O
12	TCR	B
13	/	O
14	CD3	B
15	-	O
16	induced	O
17	Erk2	B
18	activation	O
19	,	O
20	and	O
21	wortmannin	O
22	had	O
23	no	O
24	effect	O
25	on	O
26	the	O
27	activity	O
28	of	O
29	Erk2	B
30	when	O
31	added	O
32	directly	O
33	to	O
34	the	O
35	in	O
36	vitro	O
37	assays	O
38	.	O

1	155	O
2	aa	O
3	,	O
4	shares	O
5	78	O
6	%	O
7	identity	O
8	with	O
9	the	O
10	analogous	O
11	region	O
12	of	O
13	Xenopus	O
14	laevis	O
15	FGF3	B
16	and	O
17	72	O
18	%	O
19	identity	O
20	with	O
21	the	O
22	product	O
23	of	O
24	the	O
25	more	O
26	distantly	O
27	related	O
28	human	O
29	gene	O
30	.	O

1	The	O
2	transcription	O
3	start	O
4	point	O
5	of	O
6	the	O
7	proximal	O
8	promoter	O
9	aligns	O
10	to	O
11	that	O
12	of	O
13	mouse	O
14	promoter	O
15	P3	O
16	and	O
17	lies	O
18	within	O
19	a	O
20	conserved	O
21	region	O
22	of	O
23	sequence	O
24	.	O

1	Defects	O
2	in	O
3	the	O
4	Schizosaccharomyces	O
5	pombe	O
6	(	O
7	Sp	O
8	)	O
9	cell	O
10	cycle	O
11	-	O
12	controlling	O
13	genes	O
14	prevent	O
15	the	O
16	cell	O
17	cycle	O
18	progression	O
19	.	O

1	To	O
2	determine	O
3	the	O
4	signal	B
5	recognition	I
6	particle	I
7	(	O
8	SRP	B
9	)-	O
10	SRP	B
11	receptor	I
12	(	O
13	Srb	B
14	)	O
15	system	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	(	O
20	Bs	O
21	),	O
22	we	O
23	cloned	O
24	the	O
25	Bs	B
26	srb	I
27	gene	I
28	,	O
29	which	O
30	encodes	O
31	a	O
32	homologue	O
33	of	O
34	the	O
35	mammalian	B
36	SRP	I
37	receptor	I
38	alpha	I
39	-	I
40	subunit	I
41	[	O
42	Oguro	O
43	et	O
44	al	O
45	.,	O
46	DNA	O
47	Res	O
48	.	O

1	A	O
2	novel	O
3	gene	O
4	designated	O
5	cmr	B
6	,	O
7	which	O
8	mapped	O
9	to	O
10	18	O
11	.	O
12	8	O
13	min	O
14	of	O
15	the	O
16	Escherichia	O
17	coli	O
18	K	O
19	-	O
20	12	O
21	genome	O
22	,	O
23	was	O
24	shown	O
25	to	O
26	mediate	O
27	resistance	O
28	to	O
29	chloramphenicol	O
30	when	O
31	it	O
32	was	O
33	expressed	O
34	from	O
35	a	O
36	multicopy	O
37	vector	O
38	.	O

1	In	O
2	addition	O
3	,	O
4	5	O
5	'	O
6	deletions	O
7	removing	O
8	all	O
9	but	O
10	34	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	transcription	O
16	start	O
17	point	O
18	retained	O
19	greater	O
20	than	O
21	90	O
22	%	O
23	promoter	O
24	activity	O
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	-	O
30	35	O
31	hexamer	O
32	was	O
33	not	O
34	essential	O
35	for	O
36	promoter	O
37	activity	O
38	.	O

1	The	O
2	DNA	O
3	sequence	O
4	immediately	O
5	upstream	O
6	from	O
7	the	O
8	-	O
9	10	O
10	hexamer	O
11	contained	O
12	the	O
13	TGn	O
14	motif	O
15	described	O
16	as	O
17	an	O
18	extended	O
19	-	O
20	10	O
21	region	O
22	in	O
23	prokaryotic	O
24	promoters	O
25	.	O

1	An	O
2	apparent	O
3	ufo	B
4	mRNA	I
5	overexpression	O
6	was	O
7	not	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	positive	O
14	leukemia	O
15	cell	O
16	lines	O
17	,	O
18	but	O
19	was	O
20	identified	O
21	in	O
22	the	O
23	drug	O
24	-	O
25	resistant	O
26	subclones	O
27	of	O
28	the	O
29	cervix	O
30	carcinoma	O
31	cell	O
32	line	O
33	HeLa	O
34	.	O

1	We	O
2	conclude	O
3	from	O
4	these	O
5	studies	O
6	that	O
7	CKII	B
8	may	O
9	act	O
10	as	O
11	a	O
12	positive	O
13	regulator	O
14	of	O
15	myogenesis	O
16	by	O
17	preventing	O
18	E	B
19	protein	I
20	homodimers	I
21	from	O
22	binding	O
23	to	O
24	muscle	O
25	gene	O
26	regulatory	O
27	elements	O
28	.	O

1	The	O
2	role	O
3	of	O
4	negative	O
5	regulators	O
6	such	O
7	as	O
8	NCE3	B
9	,	O
10	as	O
11	well	O
12	as	O
13	the	O
14	previously	O
15	described	O
16	SIN5	B
17	gene	I
18	,	O
19	in	O
20	determining	O
21	the	O
22	promoter	O
23	specificity	O
24	of	O
25	homologous	O
26	activators	O
27	is	O
28	discussed	O
29	.	O

1	Transcriptional	O
2	regulators	O
3	utilizing	O
4	the	O
5	POU	B
6	domain	I
7	DNA	I
8	-	I
9	binding	I
10	motif	I
11	have	O
12	been	O
13	shown	O
14	to	O
15	form	O
16	multi	O
17	-	O
18	protein	O
19	complexes	O
20	dependent	O
21	on	O
22	the	O
23	POU	B
24	domain	I
25	itself	O
26	and	O
27	its	O
28	flexible	O
29	recognition	O
30	of	O
31	various	O
32	octamer	O
33	sequence	O
34	elements	O
35	.	O

1	We	O
2	found	O
3	strand	O
4	selective	O
5	repair	O
6	in	O
7	DNA	O
8	fragments	O
9	within	O
10	two	O
11	active	O
12	genes	O
13	,	O
14	DHFR	B
15	and	O
16	an	O
17	unknown	O
18	gene	O
19	adjacent	O
20	to	O
21	DHFR	B
22	.	O

1	MATERIALS	O
2	AND	O
3	METHODS	O
4	:	O
5	Coronal	O
6	3D	O
7	GRE	O
8	imaging	O
9	was	O
10	used	O
11	to	O
12	study	O
13	the	O
14	volar	O
15	,	O
16	middle	O
17	,	O
18	and	O
19	dorsal	O
20	portions	O
21	of	O
22	the	O
23	SLL	O
24	in	O
25	14	O
26	patients	O
27	with	O
28	an	O
29	arthroscopically	O
30	normal	O
31	SLL	O
32	and	O
33	in	O
34	five	O
35	cadaveric	O
36	wrists	O
37	that	O
38	had	O
39	a	O
40	normal	O
41	SLL	O
42	proved	O
43	with	O
44	dissection	O
45	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	contribute	O
6	to	O
7	the	O
8	transcript	O
9	map	O
10	of	O
11	human	O
12	chromosome	O
13	21	O
14	and	O
15	the	O
16	understanding	O
17	of	O
18	the	O
19	pathophysiology	O
20	of	O
21	trisomy	O
22	21	O
23	,	O
24	we	O
25	have	O
26	used	O
27	exon	O
28	trapping	O
29	to	O
30	identify	O
31	fragments	O
32	of	O
33	chromosome	O
34	21	O
35	genes	O
36	.	O

1	Reproducing	O
2	populations	O
3	of	O
4	this	O
5	aphid	O
6	were	O
7	first	O
8	detected	O
9	in	O
10	Puerto	O
11	Rico	O
12	in	O
13	April	O
14	1992	O
15	.	O

1	The	O
2	model	O
3	captures	O
4	the	O
5	essence	O
6	of	O
7	predator	O
8	-	O
9	prey	O
10	dynamics	O
11	to	O
12	provide	O
13	reasonable	O
14	predictions	O
15	of	O
16	population	O
17	patterns	O
18	.	O

1	At	O
2	cuticular	O
3	positions	O
4	exhibiting	O
5	the	O
6	Brd	B
7	bristle	I
8	loss	I
9	phenotype	I
10	,	O
11	we	O
12	have	O
13	found	O
14	that	O
15	the	O
16	progeny	O
17	of	O
18	the	O
19	multiplied	O
20	SOPs	O
21	develop	O
22	aberrantly	O
23	,	O
24	in	O
25	that	O
26	neurons	O
27	and	O
28	thecogen	O
29	(	O
30	sheath	O
31	)	O
32	cells	O
33	appear	O
34	but	O
35	not	O
36	trichogen	O
37	(	O
38	shaft	O
39	)	O
40	and	O
41	tormogen	O
42	(	O
43	socket	O
44	)	O
45	cells	O
46	.	O

1	Transcriptional	O
2	blockade	O
3	was	O
4	reversed	O
5	by	O
6	co	O
7	-	O
8	transfections	O
9	of	O
10	a	O
11	wild	B
12	-	I
13	type	I
14	SRF	I
15	expression	O
16	vector	O
17	,	O
18	but	O
19	was	O
20	not	O
21	rescued	O
22	by	O
23	the	O
24	expression	O
25	of	O
26	other	O
27	myogenic	O
28	factors	O
29	,	O
30	such	O
31	as	O
32	MyoD	B
33	and	O
34	Mef	B
35	-	I
36	2C	I
37	.	O

1	The	O
2	mMIWC1	B
3	promoter	I
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	B
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	B
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	Human	B
2	MN	I
3	/	I
4	CA9	I
5	gene	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	carbonic	B
13	anhydrase	I
14	family	I
15	:	O
16	structure	O
17	and	O
18	exon	O
19	to	O
20	protein	O
21	domain	O
22	relationships	O
23	.	O

1	The	O
2	exon	O
3	-	O
4	intron	O
5	distribution	O
6	of	O
7	Cdebp	B
8	appears	O
9	strikingly	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	App	B
16	gene	I
17	in	O
18	the	O
19	regions	O
20	encoding	O
21	the	O
22	conserved	O
23	domains	O
24	,	O
25	with	O
26	a	O
27	divergent	O
28	structure	O
29	in	O
30	the	O
31	other	O
32	parts	O
33	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	the	O
7	gene	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	rat	B
15	CRP1	I
16	.	O

1	The	O
2	gene	O
3	was	O
4	expressed	O
5	as	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	5	O
11	-	O
12	kb	O
13	mRNA	O
14	in	O
15	most	O
16	nonlymphoid	O
17	human	O
18	cells	O
19	/	O
20	tissues	O
21	including	O
22	prostate	O
23	,	O
24	lung	O
25	,	O
26	liver	O
27	,	O
28	and	O
29	colon	O
30	.	O

1	Both	O
2	of	O
3	these	O
4	domains	O
5	have	O
6	striking	O
7	sequence	O
8	homology	O
9	with	O
10	human	O
11	SIM	B
12	and	O
13	Drosophila	O
14	SIM	B
15	proteins	O
16	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	B
15	mRNA	I
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	We	O
2	have	O
3	obtained	O
4	the	O
5	human	B
6	EP4	I
7	receptor	I
8	gene	I
9	sequence	I
10	and	O
11	determined	O
12	its	O
13	structure	O
14	relative	O
15	to	O
16	EP4R	B
17	cDNA	I
18	synthesized	O
19	from	O
20	peripheral	O
21	blood	O
22	lymphocytes	O
23	.	O

1	Some	O
2	users	O
3	will	O
4	willingly	O
5	comply	O
6	with	O
7	management	O
8	measures	O
9	,	O
10	other	O
11	users	O
12	will	O
13	comply	O
14	in	O
15	response	O
16	to	O
17	education	O
18	,	O
19	but	O
20	there	O
21	will	O
22	be	O
23	another	O
24	group	O
25	who	O
26	will	O
27	only	O
28	respond	O
29	to	O
30	enforcement	O
31	activities	O
32	.	O

1	Three	O
2	separate	O
3	activation	O
4	subdomains	O
5	,	O
6	and	O
7	one	O
8	negative	O
9	-	O
10	acting	O
11	region	O
12	,	O
13	which	O
14	function	O
15	in	O
16	yeast	O
17	were	O
18	located	O
19	in	O
20	the	O
21	carboxyl	O
22	-	O
23	terminal	O
24	region	O
25	of	O
26	NIT4	B
27	.	O

1	The	O
2	front	O
3	(	O
4	F	O
5	)	O
6	interaction	O
7	occurs	O
8	ahead	O
9	of	O
10	the	O
11	growing	O
12	end	O
13	of	O
14	RNA	O
15	.	O

1	Collectively	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	HIP	B
8	is	O
9	a	O
10	membrane	O
11	-	O
12	associated	O
13	HP	B
14	-	I
15	binding	I
16	protein	I
17	expressed	O
18	on	O
19	the	O
20	surface	O
21	of	O
22	normal	O
23	human	O
24	uterine	O
25	epithelia	O
26	and	O
27	uterine	O
28	epithelial	O
29	cell	O
30	lines	O
31	.	O

1	The	O
2	corresponding	O
3	gene	O
4	was	O
5	identified	O
6	in	O
7	the	O
8	GenBankTM	O
9	data	O
10	base	O
11	by	O
12	sequence	O
13	alignment	O
14	and	O
15	termed	O
16	RPS30A	B
17	.	O

1	The	O
2	location	O
3	of	O
4	multiple	O
5	GRK2	B
6	and	O
7	GRK5	B
8	phosphoacceptor	I
9	sites	I
10	at	O
11	the	O
12	extreme	O
13	carboxyl	O
14	terminus	O
15	of	O
16	the	O
17	beta2AR	B
18	is	O
19	highly	O
20	reminiscent	O
21	of	O
22	GRK1	B
23	-	O
24	mediated	O
25	phosphorylation	O
26	of	O
27	rhodopsin	B
28	.	O

1	This	O
2	regulation	O
3	could	O
4	not	O
5	be	O
6	appreciably	O
7	modified	O
8	by	O
9	enhanced	O
10	expression	O
11	of	O
12	STAT	B
13	proteins	I
14	.	O

1	Receptors	O
2	for	O
3	interleukin	B
4	(	I
5	IL	I
6	)-	I
7	10	I
8	and	O
9	IL	B
10	-	I
11	6	I
12	-	I
13	type	I
14	cytokines	I
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	B
24	-	I
25	6	I
26	response	O
27	elements	O
28	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	B
6	-	I
7	19	I
8	amino	I
9	acid	I
10	sequence	I
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	B
23	TEF	I
24	-	I
25	1A	I
26	,	O
27	mouse	B
28	TEF	I
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	B
34	embryonic	I
35	TEA	I
36	domain	I
37	-	I
38	containing	I
39	factor	I
40	,	O
41	respectively	O
42	.	O

1	This	O
2	phenomenon	O
3	did	O
4	not	O
5	require	O
6	DNA	O
7	binding	O
8	by	O
9	the	O
10	"	O
11	interfering	O
12	"	O
13	receptor	O
14	but	O
15	required	O
16	it	O
17	to	O
18	be	O
19	hormone	O
20	-	O
21	bound	O
22	,	O
23	indicating	O
24	that	O
25	a	O
26	transcriptionally	O
27	active	O
28	form	O
29	of	O
30	the	O
31	interfering	O
32	receptor	O
33	is	O
34	essential	O
35	for	O
36	the	O
37	interfering	O
38	effect	O
39	.	O

1	The	O
2	receptor	B
3	for	I
4	hyaluronan	I
5	mediated	I
6	motility	I
7	(	I
8	RHAMM	I
9	)	I
10	gene	I
11	expression	O
12	is	O
13	markedly	O
14	elevated	O
15	in	O
16	fibrosarcomas	O
17	exposed	O
18	to	O
19	transforming	B
20	growth	I
21	factor	I
22	-	I
23	beta1	I
24	(	O
25	TGF	B
26	-	I
27	beta1	I
28	).	O

1	Oncogenic	B
2	Raf	I
3	-	I
4	1	I
5	activates	O
6	p70	B
7	S6	I
8	kinase	I
9	via	O
10	a	O
11	mitogen	B
12	-	I
13	activated	I
14	protein	I
15	kinase	I
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	Hydropathy	O
2	analysis	O
3	of	O
4	KCC1	B
5	indicates	O
6	structural	O
7	homology	O
8	to	O
9	NKCC	B
10	,	O
11	including	O
12	12	O
13	transmembrane	O
14	domains	O
15	,	O
16	a	O
17	large	O
18	extracellular	O
19	loop	O
20	with	O
21	potential	O
22	N	O
23	-	O
24	linked	O
25	glycosylation	O
26	sites	O
27	,	O
28	and	O
29	cytoplasmic	O
30	N	O
31	-	O
32	and	O
33	C	O
34	-	O
35	terminal	O
36	regions	O
37	.	O

1	A	O
2	cis	O
3	-	O
4	acting	O
5	DNA	O
6	element	O
7	located	O
8	between	O
9	TATA	O
10	box	O
11	and	O
12	transcription	O
13	initiation	O
14	site	O
15	is	O
16	critical	O
17	in	O
18	response	O
19	to	O
20	regulatory	O
21	sequences	O
22	in	O
23	human	O
24	angiotensinogen	B
25	gene	I
26	.	O

1	This	O
2	protein	O
3	with	O
4	a	O
5	hydrophobic	O
6	amino	O
7	terminus	O
8	appears	O
9	to	O
10	be	O
11	a	O
12	secreted	O
13	protein	O
14	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	I
18	site	I
19	(	I
20	CAAT	I
21	box	I
22	)	I
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	B
31	-	I
32	2	I
33	.	O
34	CAT	B
35	reporter	O
36	gene	O
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O

1	Notably	O
2	,	O
3	SRF	B
4	has	O
5	been	O
6	found	O
7	to	O
8	be	O
9	a	O
10	key	O
11	regulator	O
12	of	O
13	members	O
14	of	O
15	a	O
16	class	O
17	of	O
18	cellular	O
19	response	O
20	genes	O
21	termed	O
22	immediate	B
23	-	I
24	early	I
25	genes	I
26	(	O
27	IEGs	B
28	),	O
29	many	O
30	of	O
31	which	O
32	are	O
33	believed	O
34	to	O
35	be	O
36	involved	O
37	in	O
38	regulating	O
39	cell	O
40	growth	O
41	and	O
42	differentiation	O
43	.	O

1	The	O
2	final	O
3	sigma54	B
4	-	I
5	dependent	I
6	DmpR	I
7	activator	I
8	regulates	O
9	transcription	O
10	of	O
11	the	O
12	dmp	B
13	operon	I
14	that	O
15	encodes	O
16	the	O
17	enzymes	O
18	for	O
19	catabolism	O
20	of	O
21	(	O
22	methyl	O
23	)	O
24	phenols	O
25	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	human	B
10	DSG3	I
11	gene	I
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O

1	Clinical	O
2	evaluation	O
3	of	O
4	the	O
5	Allergan	O
6	Humphrey	O
7	500	O
8	autorefractor	O
9	and	O
10	the	O
11	Nidek	O
12	AR	O
13	-	O
14	1000	O
15	autorefractor	O
16	.	O

1	None	O
2	of	O
3	the	O
4	five	O
5	proprotein	O
6	processing	O
7	proteases	O
8	tested	O
9	were	O
10	capable	O
11	of	O
12	cleaving	O
13	human	B
14	pro	I
15	-	I
16	LPH	I
17	,	O
18	strongly	O
19	suggesting	O
20	that	O
21	they	O
22	are	O
23	not	O
24	involved	O
25	in	O
26	the	O
27	maturation	O
28	of	O
29	this	O
30	enzyme	O
31	.	O

1	These	O
2	changes	O
3	may	O
4	be	O
5	the	O
6	result	O
7	of	O
8	,	O
9	on	O
10	the	O
11	one	O
12	hand	O
13	,	O
14	an	O
15	increased	O
16	sensitivity	O
17	of	O
18	the	O
19	neuromuscular	O
20	transmission	O
21	and	O
22	/	O
23	or	O
24	decreased	O
25	muscle	O
26	contractility	O
27	and	O
28	,	O
29	on	O
30	the	O
31	other	O
32	hand	O
33	,	O
34	the	O
35	result	O
36	of	O
37	a	O
38	reduced	O
39	plasma	O
40	clearance	O
41	during	O
42	hypothermia	O
43	.	O

1	SETTING	O
2	--	O
3	Delhi	O
4	,	O
5	urban	O
6	India	O
7	,	O
8	1985	O
9	-	O
10	6	O
11	.	O

1	By	O
2	using	O
3	interleukin	B
4	-	I
5	3	I
6	-	O
7	dependent	O
8	cells	O
9	that	O
10	ectopically	O
11	express	O
12	the	O
13	three	O
14	ErbB	B
15	proteins	I
16	or	O
17	their	O
18	combinations	O
19	,	O
20	we	O
21	found	O
22	that	O
23	ErbB	B
24	-	I
25	3	I
26	is	O
27	devoid	O
28	of	O
29	any	O
30	biological	O
31	activity	O
32	but	O
33	both	O
34	ErbB	B
35	-	I
36	1	I
37	and	O
38	ErbB	B
39	-	I
40	2	I
41	can	O
42	reconstitute	O
43	its	O
44	extremely	O
45	potent	O
46	mitogenic	O
47	activity	O
48	.	O

1	ZIOS	O
2	was	O
3	significantly	O
4	more	O
5	sensitive	O
6	than	O
7	all	O
8	subsequent	O
9	methods	O
10	,	O
11	and	O
12	Ptc	O
13	,	O
14	O2	O
15	was	O
16	significantly	O
17	more	O
18	sensitive	O
19	than	O
20	FEV1	O
21	.	O

1	Selective	O
2	translation	O
3	initiation	O
4	by	O
5	ribosome	O
6	jumping	O
7	in	O
8	adenovirus	O
9	-	O
10	infected	O
11	and	O
12	heat	O
13	-	O
14	shocked	O
15	cells	O
16	.	O

1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	43	O
8	-	O
9	bp	O
10	region	O
11	of	O
12	the	O
13	24p3	B
14	promoter	I
15	required	O
16	for	O
17	the	O
18	Dex	O
19	responsiveness	O
20	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	direct	O
6	cDNA	O
7	mapping	O
8	using	O
9	fluorescence	O
10	in	O
11	situ	O
12	hybridization	O
13	provides	O
14	an	O
15	accurate	O
16	and	O
17	rapid	O
18	approach	O
19	to	O
20	the	O
21	definition	O
22	of	O
23	a	O
24	transcribed	O
25	map	O
26	of	O
27	the	O
28	human	O
29	genome	O
30	.	O

1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	Batten	B
8	disease	I
9	(	O
10	CLN3	B
11	)	O
12	region	O
13	at	O
14	16p12	O
15	.	O
16	1	O
17	-	O
18	p11	O
19	.	O
20	2	O
21	.	O

1	Isolation	O
2	of	O
3	a	O
4	near	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	from	O
10	a	O
11	human	O
12	fetal	O
13	brain	O
14	cDNA	O
15	library	O
16	revealed	O
17	a	O
18	protein	B
19	serine	I
20	-	I
21	threonine	I
22	phosphatase	I
23	with	O
24	a	O
25	tetratricopeptide	O
26	motif	O
27	,	O
28	almost	O
29	identical	O
30	to	O
31	human	B
32	PPP5C	I
33	(	O
34	PP5	B
35	)	O
36	and	O
37	highly	O
38	homologous	O
39	to	O
40	rat	B
41	PPT	I
42	.	O

1	Ly	B
2	-	I
3	49	I
4	is	O
5	a	O
6	family	B
7	type	I
8	II	I
9	transmembrane	I
10	proteins	I
11	encoded	O
12	by	O
13	a	O
14	gene	O
15	cluster	O
16	on	O
17	murine	O
18	chromosome	O
19	6	O
20	.	O

1	The	O
2	Dox	B
3	-	I
4	A2	I
5	ORF	I
6	driven	O
7	by	O
8	the	O
9	TDH3	B
10	promoter	I
11	complemented	O
12	the	O
13	phenotype	O
14	of	O
15	a	O
16	strain	O
17	deleted	O
18	for	O
19	sun2	B
20	.	O

1	The	O
2	introduction	O
3	of	O
4	hARF4	B
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	B
18	pools	O
19	.	O

1	Our	O
2	data	O
3	demonstrate	O
4	directly	O
5	that	O
6	Rpm1r	B
7	is	O
8	transcribed	O
9	with	O
10	its	O
11	substrates	O
12	,	O
13	tRNA	B
14	met	I
15	f	I
16	and	O
17	tRNAPro	B
18	,	O
19	from	O
20	a	O
21	promoter	O
22	located	O
23	upstream	O
24	of	O
25	the	O
26	tRNA	B
27	met	I
28	f	I
29	gene	I
30	and	O
31	suggest	O
32	that	O
33	a	O
34	portion	O
35	also	O
36	originates	O
37	from	O
38	a	O
39	second	O
40	promoter	O
41	,	O
42	located	O
43	between	O
44	the	O
45	tRNA	B
46	met	I
47	f	I
48	gene	I
49	and	O
50	RPM1	B
51	.	O

1	Furthermore	O
2	,	O
3	strains	O
4	with	O
5	mutant	B
6	RPM1	I
7	genes	I
8	also	O
9	accumulate	O
10	precursor	B
11	Rpm1r	I
12	,	O
13	suggesting	O
14	that	O
15	mutations	O
16	in	O
17	either	O
18	gene	O
19	can	O
20	lead	O
21	to	O
22	similar	O
23	biogenesis	O
24	defects	O
25	.	O

1	Vacuolar	O
2	membrane	O
3	vesicles	O
4	from	O
5	hum1	B
6	mutants	I
7	lack	O
8	all	O
9	Ca2	O
10	+/	O
11	H	O
12	+	O
13	antiport	O
14	activity	O
15	,	O
16	demonstrating	O
17	that	O
18	Hum1p	B
19	catalyzes	O
20	the	O
21	exchange	O
22	of	O
23	Ca2	O
24	+	O
25	for	O
26	H	O
27	+	O
28	across	O
29	the	O
30	yeast	O
31	vacuolar	O
32	membrane	O
33	.	O

1	Detailed	O
2	mutagenesis	O
3	of	O
4	the	O
5	element	O
6	'	O
7	s	O
8	rare	O
9	-	O
10	codon	O
11	/	O
12	AU	O
13	-	O
14	rich	O
15	sequence	O
16	boundary	O
17	revealed	O
18	that	O
19	the	O
20	destabilizing	O
21	activity	O
22	of	O
23	the	O
24	MATalpha1	B
25	IE	I
26	is	O
27	observed	O
28	when	O
29	the	O
30	terminal	O
31	codon	O
32	of	O
33	the	O
34	element	O
35	'	O
36	s	O
37	rare	O
38	-	O
39	codon	O
40	interval	O
41	is	O
42	translated	O
43	.	O

1	FTF	B
2	is	O
3	also	O
4	abundantly	O
5	expressed	O
6	in	O
7	the	O
8	pancreas	O
9	and	O
10	may	O
11	exert	O
12	differentiation	O
13	functions	O
14	in	O
15	endodermal	O
16	sublineages	O
17	,	O
18	similar	O
19	to	O
20	SF	B
21	-	I
22	1	I
23	in	O
24	steroidogenic	O
25	tissues	O
26	.	O

1	Merlie	O
2	,	O
3	Cold	O
4	Spring	O
5	Harbor	O
6	Symp	O
7	.	O

1	Substantial	O
2	evidence	O
3	supports	O
4	a	O
5	critical	O
6	role	O
7	for	O
8	the	O
9	activation	O
10	of	O
11	the	O
12	Raf	B
13	-	I
14	1	I
15	/	O
16	MEK	B
17	/	O
18	mitogen	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	pathway	O
24	in	O
25	oncogenic	O
26	Ras	B
27	-	O
28	mediated	O
29	transformation	O
30	.	O

1	Stylohyoid	O
2	chain	O
3	ossification	O
4	:	O
5	choice	O
6	of	O
7	the	O
8	surgical	O
9	approach	O
10	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	63	O
2	.	O
3	3	O
4	micromol	O
5	/	O
6	1	O
7	,	O
8	p	O
9	<	O
10	0	O
11	.	O
12	01	O
13	)	O
14	and	O
15	area	O
16	under	O
17	the	O
18	plasma	O
19	concentration	O
20	-	O
21	time	O
22	curve	O
23	extrapolated	O
24	to	O
25	infinity	O
26	AUC	O
27	9	O
28	(	O
29	0	O
30	-	O
31	infinity	O
32	)(	O
33	518	O
34	.	O
35	7	O
36	vs	O
37	.	O

1	Cluster	O
2	formation	O
3	of	O
4	E	B
5	-	I
6	cadherin	I
7	on	O
8	the	O
9	cell	O
10	surface	O
11	is	O
12	believed	O
13	to	O
14	be	O
15	of	O
16	major	O
17	importance	O
18	for	O
19	cell	O
20	-	O
21	cell	O
22	adhesion	O
23	.	O

1	DNA	B
2	polymerase	I
3	E	I
4	,	O
5	DNA	B
6	ligase	I
7	III	I
8	and	O
9	a	O
10	DNA	O
11	structure	O
12	-	O
13	specific	O
14	endonuclease	O
15	co	O
16	-	O
17	purify	O
18	with	O
19	the	O
20	five	O
21	polypeptide	O
22	complex	O
23	.	O

1	By	O
2	using	O
3	reporter	O
4	gene	O
5	constructs	O
6	,	O
7	it	O
8	is	O
9	shown	O
10	that	O
11	upstream	O
12	sequences	O
13	of	O
14	the	O
15	P1	O
16	promoter	O
17	contain	O
18	several	O
19	regions	O
20	that	O
21	modulate	O
22	the	O
23	expression	O
24	either	O
25	positively	O
26	or	O
27	negatively	O
28	.	O

1	The	O
2	factor	O
3	structure	O
4	of	O
5	"	O
6	schizotypal	O
7	'	O
8	traits	O
9	:	O
10	a	O
11	large	O
12	replication	O
13	study	O
14	.	O

1	Interestingly	O
2	,	O
3	however	O
4	,	O
5	it	O
6	is	O
7	homologous	O
8	to	O
9	several	O
10	expressed	O
11	sequence	O
12	tags	O
13	(	O
14	EST	O
15	)	O
16	of	O
17	unknown	O
18	function	O
19	from	O
20	Caenorhabditis	O
21	elegans	O
22	,	O
23	Oryza	O
24	sativa	O
25	and	O
26	Homo	O
27	sapiens	O
28	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O

1	Outcome	O
2	of	O
3	severe	O
4	congenital	O
5	hypothyroidism	O
6	.	O

1	Mean	O
2	increase	O
3	of	O
4	milk	O
5	protein	O
6	yield	O
7	was	O
8	46	O
9	g	O
10	/	O
11	d	O
12	with	O
13	Met	O
14	plus	O
15	Lys	O
16	,	O
17	and	O
18	mean	O
19	increase	O
20	of	O
21	true	O
22	protein	O
23	content	O
24	was	O
25	1	O
26	.	O
27	1	O
28	g	O
29	/	O
30	kg	O
31	of	O
32	milk	O
33	.	O

1	Nonreturn	O
2	rates	O
3	can	O
4	be	O
5	used	O
6	to	O
7	derive	O
8	more	O
9	elementary	O
10	biological	O
11	measures	O
12	for	O
13	reproductive	O
14	efficiency	O
15	,	O
16	such	O
17	as	O
18	conception	O
19	rate	O
20	and	O
21	calving	O
22	rate	O
23	,	O
24	which	O
25	separately	O
26	might	O
27	be	O
28	more	O
29	reliable	O
30	than	O
31	nonreturn	O
32	rate	O
33	itself	O
34	to	O
35	evaluate	O
36	the	O
37	fertility	O
38	of	O
39	a	O
40	bull	O
41	or	O
42	the	O
43	performance	O
44	of	O
45	an	O
46	AI	O
47	technician	O
48	.	O

1	However	O
2	,	O
3	if	O
4	EMPD	O
5	involves	O
6	the	O
7	glans	O
8	penis	O
9	or	O
10	perianal	O
11	area	O
12	,	O
13	a	O
14	search	O
15	for	O
16	internal	O
17	malignancy	O
18	is	O
19	still	O
20	warranted	O
21	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O

1	Each	O
2	half	O
3	molecule	O
4	contains	O
5	four	O
6	disulfide	O
7	linkages	O
8	and	O
9	four	O
10	cis	O
11	peptides	O
12	.	O

1	Only	O
2	fully	O
3	processed	O
4	Pra	B
5	(	O
6	N0	O
7	and	O
8	Nb	O
9	)	O
10	and	O
11	ICP35	B
12	(	O
13	ICP35	B
14	e	I
15	,	I
16	f	I
17	)	O
18	are	O
19	present	O
20	in	O
21	B	O
22	capsids	O
23	,	O
24	which	O
25	are	O
26	believed	O
27	to	O
28	be	O
29	precursors	O
30	of	O
31	mature	O
32	virions	O
33	.	O

1	A	O
2	chimeric	O
3	VP16	B
4	-	O
5	Tat	B
6	construct	O
7	containing	O
8	the	O
9	leucine	O
10	mutations	O
11	showed	O
12	no	O
13	increased	O
14	AP	B
15	-	I
16	1	I
17	responsiveness	O
18	in	O
19	comparison	O
20	with	O
21	that	O
22	of	O
23	the	O
24	VP16	B
25	activation	I
26	domain	I
27	alone	O
28	.	O

1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	3225	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	BPV	O
25	-	O
26	1	O
27	pre	O
28	-	O
29	mRNAs	O
30	in	O
31	BPV	O
32	-	O
33	1	O
34	-	O
35	transformed	O
36	C127	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	productively	O
46	infected	O
47	warts	O
48	.	O

1	Here	O
2	,	O
3	the	O
4	cloning	O
5	and	O
6	characterization	O
7	of	O
8	S	B
9	-	I
10	RNase	I
11	genes	I
12	from	O
13	two	O
14	species	O
15	of	O
16	Rosaceae	O
17	,	O
18	apple	O
19	(	O
20	Malus	O
21	x	O
22	domestica	O
23	)	O
24	and	O
25	Japanese	O
26	pear	O
27	(	O
28	Pyrus	O
29	serotina	O
30	)	O
31	is	O
32	described	O
33	and	O
34	these	O
35	sequences	O
36	are	O
37	compared	O
38	with	O
39	those	O
40	of	O
41	other	O
42	T2	B
43	-	I
44	type	I
45	RNases	I
46	.	O

1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	B
9	/	I
10	S	I
11	-	I
12	RNase	I
13	superfamily	I
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O

1	In	O
2	a	O
3	Hoosier	O
4	Oncology	O
5	Group	O
6	randomized	O
7	study	O
8	involving	O
9	extensive	O
10	-	O
11	disease	O
12	SCLC	O
13	patients	O
14	,	O
15	VIP	O
16	was	O
17	superior	O
18	to	O
19	etoposide	O
20	/	O
21	cisplatin	O
22	with	O
23	regard	O
24	to	O
25	median	O
26	time	O
27	to	O
28	progression	O
29	(	O
30	6	O
31	.	O
32	6	O
33	v	O
34	5	O
35	.	O
36	8	O
37	months	O
38	),	O
39	median	O
40	survival	O
41	times	O
42	(	O
43	9	O
44	.	O
45	1	O
46	v	O
47	7	O
48	.	O
49	3	O
50	months	O
51	),	O
52	and	O
53	2	O
54	-	O
55	and	O
56	3	O
57	-	O
58	year	O
59	survival	O
60	rates	O
61	(	O
62	13	O
63	%	O
64	v	O
65	5	O
66	%	O
67	and	O
68	5	O
69	%	O
70	v	O
71	0	O
72	%,	O
73	respectively	O
74	).	O

1	It	O
2	was	O
3	shown	O
4	that	O
5	administration	O
6	of	O
7	immunomodulator	O
8	neurotropin	B
9	(	O
10	NSP	B
11	)	O
12	results	O
13	in	O
14	more	O
15	steady	O
16	consolidation	O
17	and	O
18	retention	O
19	of	O
20	feeding	O
21	and	O
22	avoidance	O
23	behavior	O
24	,	O
25	and	O
26	some	O
27	neurophysiological	O
28	mechanisms	O
29	of	O
30	that	O
31	phenomena	O
32	were	O
33	revealed	O
34	.	O

1	Sestamibi	O
2	scintigraphy	O
3	,	O
4	performed	O
5	in	O
6	70	O
7	patients	O
8	,	O
9	was	O
10	less	O
11	sensitive	O
12	than	O
13	ultrasonography	O
14	(	O
15	80	O
16	%).	O

1	Atopic	O
2	allergy	O
3	and	O
4	other	O
5	hypersensitivities	O
6	.	O

1	Despite	O
2	significant	O
3	lethality	O
4	and	O
5	cardiovascular	O
6	dysfunction	O
7	,	O
8	in	O
9	the	O
10	septic	O
11	group	O
12	on	O
13	Days	O
14	1	O
15	and	O
16	2	O
17	,	O
18	septic	O
19	versus	O
20	control	O
21	animals	O
22	had	O
23	no	O
24	significant	O
25	differences	O
26	in	O
27	mean	O
28	metabolic	O
29	cart	O
30	measured	O
31	(	O
32	Vo2DIR	O
33	,	O
34	ml	O
35	/	O
36	kg	O
37	/	O
38	min	O
39	;	O
40	Day	O
41	1	O
42	:	O
43	11	O
44	.	O
45	9	O
46	versus	O
47	12	O
48	.	O
49	4	O
50	,	O
51	p	O
52	=	O
53	0	O
54	.	O
55	81	O
56	;	O
57	Day	O
58	2	O
59	:	O
60	14	O
61	.	O
62	2	O
63	versus	O
64	13	O
65	.	O
66	5	O
67	,	O
68	p	O
69	=	O
70	0	O
71	.	O
72	72	O
73	,	O
74	respectively	O
75	)	O
76	and	O
77	intravascular	O
78	catheter	O
79	calculated	O
80	(	O
81	Vo2INDIR	O
82	,	O
83	ml	O
84	/	O
85	kg	O
86	/	O
87	min	O
88	;	O
89	Day	O
90	1	O
91	:	O
92	11	O
93	.	O
94	2	O
95	versus	O
96	11	O
97	.	O
98	2	O
99	,	O
100	p	O
101	=	O
102	0	O
103	.	O
104	99	O
105	;	O
106	Day	O
107	2	O
108	:	O
109	12	O
110	.	O
111	8	O
112	versus	O
113	15	O
114	.	O
115	4	O
116	,	O
117	p	O
118	=	O
119	0	O
120	.	O
121	49	O
122	,	O
123	respectively	O
124	).	O

1	After	O
2	6	O
3	h	O
4	of	O
5	reperfusion	O
6	,	O
7	PO2	O
8	/	O
9	FlO2	O
10	ratio	O
11	was	O
12	significantly	O
13	better	O
14	after	O
15	Combined	O
16	Therapy	O
17	(	O
18	372	O
19	+/-	O
20	52	O
21	mm	O
22	Hg	O
23	)	O
24	than	O
25	in	O
26	the	O
27	Recipient	O
28	Instilled	O
29	(	O
30	117	O
31	+/-	O
32	47	O
33	mm	O
34	Hg	O
35	)	O
36	and	O
37	Control	O
38	groups	O
39	(	O
40	87	O
41	+/-	O
42	26	O
43	mm	O
44	Hg	O
45	),	O
46	with	O
47	intermediate	O
48	values	O
49	in	O
50	Donor	O
51	Aerosol	O
52	dogs	O
53	(	O
54	232	O
55	+/-	O
56	64	O
57	mm	O
58	Hg	O
59	).	O

1	The	O
2	euglobulin	B
3	clot	O
4	lysis	O
5	time	O
6	was	O
7	slightly	O
8	longer	O
9	in	O
10	the	O
11	smokers	O
12	than	O
13	in	O
14	the	O
15	non	O
16	-	O
17	smokers	O
18	in	O
19	all	O
20	three	O
21	experimental	O
22	situations	O
23	,	O
24	but	O
25	the	O
26	differences	O
27	were	O
28	not	O
29	significant	O
30	.	O

1	HS	O
2	inducibility	O
3	required	O
4	the	O
5	HSE	O
6	which	O
7	was	O
8	bound	O
9	by	O
10	HS	B
11	transcription	I
12	factor	I
13	-	I
14	1	I
15	(	O
16	HSF	B
17	-	I
18	1	I
19	)	O
20	present	O
21	in	O
22	extracts	O
23	prepared	O
24	from	O
25	cells	O
26	exposed	O
27	to	O
28	HS	O
29	.	O

1	Although	O
2	the	O
3	DSK2	B
4	-	I
5	1	I
6	mutation	I
7	alters	O
8	a	O
9	conserved	O
10	residue	O
11	in	O
12	the	O
13	Dsk2p	B
14	ubiquitin	I
15	-	I
16	like	I
17	domain	I
18	,	O
19	we	O
20	detect	O
21	no	O
22	differences	O
23	in	O
24	Dsk2p	B
25	or	O
26	Cdc31p	B
27	stability	O
28	.	O

1	Although	O
2	IL	B
3	-	I
4	2	I
5	and	O
6	IFN	B
7	-	I
8	alpha	I
9	activated	O
10	STAT1	B
11	alpha	I
12	and	O
13	STAT5	B
14	,	O
15	IL	B
16	-	I
17	2	I
18	predominantly	O
19	activated	O
20	STAT5	B
21	,	O
22	while	O
23	IFN	B
24	-	I
25	alpha	I
26	predominantly	O
27	activated	O
28	STAT1	B
29	alpha	I
30	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	recombinant	B
7	CREB	I
8	and	O
9	activating	B
10	transcription	I
11	factor	I
12	proteins	I
13	bound	O
14	the	O
15	junB	B
16	CRE	O
17	-	O
18	like	O
19	site	O
20	,	O
21	but	O
22	did	O
23	not	O
24	interact	O
25	with	O
26	a	O
27	mutant	O
28	CRE	O
29	-	O
30	like	O
31	site	O
32	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	B
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O

1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O

1	Our	O
2	results	O
3	confirm	O
4	the	O
5	participation	O
6	of	O
7	intron	O
8	1	O
9	in	O
10	transcriptional	O
11	regulation	O
12	of	O
13	the	O
14	c	B
15	-	I
16	myb	I
17	gene	I
18	(	O
19	in	O
20	mouse	O
21	and	O
22	human	O
23	)	O
24	and	O
25	implicate	O
26	multiple	O
27	and	O
28	complex	O
29	regulatory	O
30	mechanisms	O
31	of	O
32	activation	O
33	during	O
34	myelomonocytic	O
35	differentiation	O
36	and	O
37	leukemic	O
38	cell	O
39	growth	O
40	control	O
41	.	O

1	Immunofluorescence	O
2	microscopy	O
3	revealed	O
4	extensive	O
5	deposition	O
6	of	O
7	such	O
8	extracellular	O
9	matrices	O
10	as	O
11	type	B
12	IV	I
13	collagen	I
14	and	O
15	laminin	B
16	in	O
17	the	O
18	vascular	O
19	wall	O
20	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O

1	Three	O
2	ORFs	O
3	(	O
4	9765orfR002	O
5	,	O
6	9765orfR011	O
7	and	O
8	9765orfR013	O
9	)	O
10	were	O
11	found	O
12	to	O
13	be	O
14	homologous	O
15	with	O
16	Schizosaccharomyces	O
17	pombe	O
18	polyadenylate	B
19	binding	I
20	protein	I
21	,	O
22	Escherichia	O
23	coli	O
24	hypothetical	O
25	38	O
26	.	O
27	1	O
28	-	O
29	kDa	O
30	protein	O
31	in	O
32	the	O
33	BCR	B
34	5	O
35	'	O
36	region	O
37	,	O
38	and	O
39	transcription	O
40	regulatory	O
41	protein	O
42	Swi3	B
43	,	O
44	respectively	O
45	.	O

1	Two	O
2	new	O
3	flavone	O
4	glucosides	O
5	,	O
6	nevadensin	O
7	5	O
8	-	O
9	O	O
10	-	O
11	beta	O
12	-	O
13	D	O
14	-	O
15	glucoside	O
16	and	O
17	nevadensin	O
18	5	O
19	-	O
20	O	O
21	-	O
22	beta	O
23	-	O
24	D	O
25	-	O
26	glucosyl	O
27	(	O
28	1	O
29	-->	O
30	6	O
31	)	O
32	beta	O
33	-	O
34	D	O
35	-	O
36	glucoside	O
37	,	O
38	have	O
39	been	O
40	isolated	O
41	from	O
42	the	O
43	aerial	O
44	parts	O
45	of	O
46	Lysionotus	O
47	pauciflorus	O
48	.	O

1	Recently	O
2	,	O
3	our	O
4	laboratory	O
5	developed	O
6	a	O
7	screen	O
8	that	O
9	identified	O
10	five	O
11	multicopy	O
12	suppressors	O
13	that	O
14	can	O
15	rescue	O
16	lethal	O
17	strains	O
18	of	O
19	clathrin	B
20	heavy	O
21	chain	O
22	-	O
23	deficient	O
24	yeast	O
25	(	O
26	Chc	B
27	-	O
28	scd1	B
29	-	I
30	i	I
31	)	O
32	to	O
33	viability	O
34	.	O

1	Reproductive	O
2	period	O
3	affects	O
4	water	O
5	intake	O
6	in	O
7	heat	O
8	-	O
9	stressed	O
10	dehydrated	O
11	goats	O
12	.	O

1	The	O
2	logistic	O
3	regression	O
4	analysis	O
5	of	O
6	the	O
7	manual	O
8	method	O
9	(	O
10	percentage	O
11	normal	O
12	morphology	O
13	)	O
14	and	O
15	IVOS	O
16	indicated	O
17	that	O
18	both	O
19	were	O
20	predictors	O
21	of	O
22	fertilization	O
23	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	O
19	R2LC	O
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	However	O
2	,	O
3	D8	B
4	binding	O
5	was	O
6	observed	O
7	by	O
8	nuclease	O
9	protection	O
10	with	O
11	lactotroph	B
12	-	I
13	as	I
14	well	I
15	as	I
16	somatotroph	I
17	-	I
18	like	I
19	cell	I
20	nuclear	I
21	protein	I
22	.	O

1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O

1	The	O
2	ability	O
3	of	O
4	A20	B
5	to	O
6	block	O
7	NF	B
8	-	I
9	kappaB	I
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O

1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O

1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	B
13	BCL	I
14	-	I
15	6	I
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	B
24	-	I
25	6	I
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O

1	The	O
2	predictive	O
3	value	O
4	of	O
5	a	O
6	positive	O
7	flag	O
8	was	O
9	77	O
10	.	O
11	7	O
12	%.	O

1	CONCLUSIONS	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	pre	O
8	-	O
9	treatment	O
10	with	O
11	coenzyme	O
12	Q10	O
13	may	O
14	play	O
15	a	O
16	protective	O
17	role	O
18	during	O
19	routine	O
20	vascular	O
21	procedures	O
22	requiring	O
23	abdominal	O
24	aortic	O
25	cross	O
26	clamping	O
27	by	O
28	attenuating	O
29	the	O
30	degree	O
31	of	O
32	peroxidative	O
33	damage	O
34	.	O

1	Because	O
2	chromosome	O
3	X	O
4	is	O
5	frequently	O
6	involved	O
7	in	O
8	structural	O
9	alterations	O
10	in	O
11	neoplastic	O
12	Syrian	O
13	hamster	O
14	cells	O
15	transformed	O
16	by	O
17	chemical	O
18	carcinogens	O
19	and	O
20	oncogenic	O
21	viruses	O
22	,	O
23	the	O
24	localization	O
25	of	O
26	the	O
27	cph	B
28	locus	I
29	on	O
30	this	O
31	chromosome	O
32	supports	O
33	the	O
34	notion	O
35	that	O
36	the	O
37	cph	B
38	oncogene	I
39	plays	O
40	a	O
41	role	O
42	in	O
43	the	O
44	malignant	O
45	conversion	O
46	of	O
47	chemically	O
48	transformed	O
49	hamster	O
50	fibroblasts	O
51	.	O

1	In	O
2	a	O
3	screen	O
4	for	O
5	genes	O
6	with	O
7	oncogenic	O
8	potential	O
9	expressed	O
10	by	O
11	the	O
12	murine	O
13	B6SUtA1	O
14	myeloid	O
15	progenitor	O
16	cell	O
17	line	O
18	,	O
19	we	O
20	isolated	O
21	a	O
22	2	O
23	.	O

1	Gap1	O
2	(	O
3	IP4BP	O
4	),	O
5	one	O
6	of	O
7	a	O
8	member	O
9	of	O
10	Ras	B
11	GTPase	I
12	-	I
13	activating	I
14	proteins	I
15	,	O
16	has	O
17	been	O
18	identified	O
19	as	O
20	a	O
21	specific	O
22	inositol	B
23	1	I
24	,	I
25	3	I
26	,	I
27	4	I
28	,	I
29	5	I
30	-	I
31	tetrakisphosphate	I
32	(	I
33	IP4	I
34	)-	I
35	binding	I
36	protein	I
37	(	O
38	Cullen	O
39	,	O
40	P	O
41	.	O

1	We	O
2	previously	O
3	described	O
4	the	O
5	purification	O
6	of	O
7	an	O
8	83	B
9	-	I
10	kDa	I
11	phosphatidic	I
12	acid	I
13	phosphatase	I
14	(	O
15	PAP	B
16	)	O
17	from	O
18	the	O
19	porcine	O
20	thymus	O
21	membranes	O
22	(	O
23	Kanoh	O
24	,	O
25	H	O
26	.,	O
27	Imai	O
28	,	O
29	S	O
30	.-	O
31	i	O
32	.,	O
33	Yamada	O
34	,	O
35	K	O
36	.	O
37	and	O
38	Sakane	O
39	,	O
40	F	O
41	.(	O
42	1992	O
43	)	O
44	J	O
45	.	O

1	The	O
2	mechanism	O
3	involves	O
4	Gbetagamma	B
5	subunit	O
6	-	O
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	adapter	I
16	protein	I
17	,	O
18	Shc	B
19	*	O
20	Grb2	B
21	complex	O
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	I
29	nucleotide	I
30	exchange	I
31	factor	I
32	activity	O
33	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	the	O
5	amino	O
6	-	O
7	terminal	O
8	17	O
9	%	O
10	of	O
11	apoB	B
12	(	O
13	apoB17	B
14	)	O
15	was	O
16	fused	O
17	to	O
18	a	O
19	cDNA	O
20	coding	O
21	for	O
22	the	O
23	last	O
24	37	O
25	amino	O
26	acids	O
27	of	O
28	decay	B
29	-	I
30	accelerating	I
31	factor	I
32	(	O
33	DAF	B
34	),	O
35	which	O
36	contains	O
37	the	O
38	signal	O
39	for	O
40	glycosylphosphatidylinositol	O
41	anchor	O
42	attachment	O
43	.	O

1	Next	O
2	,	O
3	we	O
4	stably	O
5	overexpressed	O
6	wild	B
7	-	I
8	type	I
9	Shc	I
10	or	O
11	Y317F	B
12	mutant	I
13	Shc	I
14	into	O
15	HIRc	O
16	cells	O
17	.	O

1	The	O
2	small	B
3	GTPase	I
4	Rho	I
5	is	O
6	implicated	O
7	in	O
8	physiological	O
9	functions	O
10	associated	O
11	with	O
12	actin	B
13	-	O
14	myosin	B
15	filaments	O
16	such	O
17	as	O
18	cytokinesis	O
19	,	O
20	cell	O
21	motility	O
22	,	O
23	and	O
24	smooth	O
25	muscle	O
26	contraction	O
27	.	O

1	Conversely	O
2	,	O
3	activation	O
4	of	O
5	this	O
6	signaling	O
7	pathway	O
8	by	O
9	expression	O
10	of	O
11	a	O
12	constitutively	O
13	active	O
14	MKK1	B
15	mutant	I
16	dramatically	O
17	increased	O
18	cyclin	B
19	D1	I
20	promoter	O
21	activity	O
22	and	O
23	cyclin	B
24	D1	I
25	protein	I
26	expression	O
27	,	O
28	in	O
29	a	O
30	growth	O
31	factor	O
32	-	O
33	independent	O
34	manner	O
35	.	O

1	Furthermore	O
2	,	O
3	upstream	O
4	insertion	O
5	of	O
6	the	O
7	GSTP1	B
8	silencer	I
9	element	I
10	failed	O
11	to	O
12	inhibit	O
13	activity	O
14	of	O
15	a	O
16	heterologous	O
17	promoter	O
18	in	O
19	MCF7	O
20	cells	O
21	.	O

1	In	O
2	order	O
3	to	O
4	delineate	O
5	structural	O
6	motifs	O
7	regulating	O
8	substrate	O
9	affinity	O
10	and	O
11	recognition	O
12	for	O
13	the	O
14	human	B
15	dopamine	I
16	transporter	I
17	(	O
18	DAT	B
19	),	O
20	we	O
21	assessed	O
22	[	O
23	3H	O
24	]	O
25	dopamine	O
26	uptake	O
27	kinetics	O
28	and	O
29	[	O
30	3H	O
31	]	O
32	CFT	O
33	binding	O
34	characteristics	O
35	of	O
36	COS	O
37	-	O
38	7	O
39	cells	O
40	transiently	O
41	expressing	O
42	mutant	B
43	DATs	I
44	in	O
45	which	O
46	the	O
47	COOH	O
48	terminus	O
49	was	O
50	truncated	O
51	or	O
52	substituted	O
53	.	O

1	An	O
2	expression	O
3	library	O
4	was	O
5	constructed	O
6	by	O
7	inserting	O
8	5	O
9	'	O
10	portion	O
11	-	O
12	enriched	O
13	cDNAs	O
14	from	O
15	phytohemagglutinin	B
16	-	O
17	stimulated	O
18	peripheral	O
19	blood	O
20	mononuclear	O
21	cells	O
22	into	O
23	upstream	O
24	of	O
25	signal	B
26	sequence	I
27	-	I
28	deleted	I
29	CD4	I
30	cDNA	I
31	in	O
32	an	O
33	Epstein	O
34	-	O
35	Barr	O
36	virus	O
37	shuttle	O
38	vector	O
39	.	O

1	Radiolabeled	O
2	recombinant	B
3	TARC	I
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	elements	O
6	that	O
7	control	O
8	promoter	O
9	activity	O
10	include	O
11	binding	O
12	sites	O
13	for	O
14	transcription	O
15	factors	O
16	Sp1	B
17	and	O
18	alphaCbf	B
19	,	O
20	a	O
21	60	B
22	-	I
23	kDa	I
24	CCAAT	I
25	box	I
26	-	I
27	binding	I
28	protein	I
29	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	O
14	E	O
15	-	O
16	box	O
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	I
24	promoter	O
25	region	O
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	B
44	-	I
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O

1	Collectively	O
2	,	O
3	our	O
4	findings	O
5	demonstrate	O
6	that	O
7	SF	B
8	-	I
9	1	I
10	plays	O
11	a	O
12	key	O
13	role	O
14	in	O
15	controlling	O
16	the	O
17	basal	O
18	and	O
19	cAMP	O
20	-	O
21	stimulated	O
22	expression	O
23	of	O
24	the	O
25	StAR	B
26	gene	I
27	.	O

1	There	O
2	was	O
3	a	O
4	general	O
5	broadening	O
6	of	O
7	proton	O
8	resonances	O
9	for	O
10	a	O
11	three	O
12	-	O
13	nucleotide	O
14	segment	O
15	centered	O
16	about	O
17	the	O
18	lesion	O
19	site	O
20	which	O
21	resulted	O
22	in	O
23	a	O
24	tentative	O
25	assignment	O
26	for	O
27	the	O
28	sugar	O
29	protons	O
30	of	O
31	the	O
32	C7	O
33	residue	O
34	in	O
35	the	O
36	spectrum	O
37	of	O
38	the	O
39	adduct	O
40	duplex	O
41	.	O

1	Using	O
2	one	O
3	of	O
4	the	O
5	six	O
6	fragments	O
7	(	O
8	CPK3	B
9	-	I
10	8	I
11	),	O
12	we	O
13	isolated	O
14	a	O
15	2022	B
16	bp	I
17	cDNA	I
18	(	I
19	VrCDPK	I
20	-	I
21	1	I
22	)	I
23	from	O
24	a	O
25	Vigna	O
26	radiata	O
27	lambda	O
28	gt11	O
29	library	O
30	.	O

1	However	O
2	,	O
3	in	O
4	TF	O
5	-	O
6	1	O
7	cells	O
8	grown	O
9	on	O
10	GM	B
11	-	I
12	CSF	I
13	before	O
14	starvation	O
15	,	O
16	CREB	B
17	phosphorylation	O
18	was	O
19	observed	O
20	10	O
21	minutes	O
22	after	O
23	PIXY321	B
24	stimulation	O
25	.	O

1	Workplace	O
2	violence	O
3	--	O
4	nurses	O
5	at	O
6	risk	O
7	.	O

1	RESULTS	O
2	:	O
3	The	O
4	LV	O
5	maximum	O
6	brightness	O
7	and	O
8	area	O
9	under	O
10	the	O
11	curve	O
12	showed	O
13	significant	O
14	negative	O
15	correlations	O
16	(	O
17	p	O
18	=	O
19	<	O
20	0	O
21	.	O
22	004	O
23	)	O
24	with	O
25	the	O
26	FIO2	O
27	,	O
28	while	O
29	the	O
30	minimum	O
31	brightness	O
32	showed	O
33	a	O
34	significant	O
35	positive	O
36	correlation	O
37	(	O
38	p	O
39	=	O
40	<	O
41	0	O
42	.	O
43	002	O
44	).	O

1	The	O
2	results	O
3	also	O
4	imply	O
5	that	O
6	the	O
7	absence	O
8	of	O
9	perforin	B
10	expression	O
11	in	O
12	non	O
13	-	O
14	cytotoxic	O
15	cells	O
16	may	O
17	be	O
18	due	O
19	to	O
20	the	O
21	suppression	O
22	of	O
23	the	O
24	induction	O
25	of	O
26	the	O
27	killer	O
28	-	O
29	cell	O
30	-	O
31	specific	O
32	trans	O
33	-	O
34	acting	O
35	factor	O
36	NF	B
37	-	I
38	P2	I
39	.	O

1	We	O
2	identify	O
3	considerable	O
4	spatio	O
5	-	O
6	temporal	O
7	similarities	O
8	between	O
9	reported	O
10	expression	O
11	patterns	O
12	of	O
13	Ypr10	B
14	genes	I
15	and	O
16	ribonuclease	O
17	genes	O
18	,	O
19	which	O
20	,	O
21	together	O
22	with	O
23	the	O
24	significant	O
25	sequence	O
26	similarity	O
27	to	O
28	the	O
29	ginseng	B
30	ribonuclease	I
31	,	O
32	support	O
33	the	O
34	hypothesis	O
35	of	O
36	a	O
37	ribonuclease	O
38	function	O
39	for	O
40	PR	B
41	-	I
42	10	I
43	proteins	I
44	and	O
45	allow	O
46	the	O
47	prediction	O
48	of	O
49	possible	O
50	biological	O
51	roles	O
52	.	O

1	The	O
2	expression	O
3	of	O
4	ERV3	B
5	env	I
6	mRNA	I
7	was	O
8	found	O
9	to	O
10	be	O
11	differentiation	O
12	-	O
13	associated	O
14	,	O
15	with	O
16	high	O
17	expression	O
18	detected	O
19	in	O
20	the	O
21	late	O
22	stages	O
23	of	O
24	monocytic	O
25	development	O
26	.	O

1	Initial	O
2	estimates	O
3	indicate	O
4	that	O
5	27	O
6	,	O
7	193	O
8	people	O
9	are	O
10	either	O
11	in	O
12	receipt	O
13	of	O
14	or	O
15	in	O
16	need	O
17	of	O
18	mental	O
19	handicap	O
20	services	O
21	.	O

1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	immunohistochemical	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	"	B
19	smoothelin	I
20	."	I
21	A	O
22	human	O
23	smooth	O
24	muscle	O
25	cDNA	O
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	B
32	antibody	I
33	R4A	I
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O

1	Using	O
2	immunogold	O
3	electron	O
4	microscopy	O
5	,	O
6	we	O
7	found	O
8	that	O
9	p58	B
10	/	O
11	p45	B
12	and	O
13	p54	B
14	are	O
15	localized	O
16	on	O
17	both	O
18	sides	O
19	of	O
20	the	O
21	nuclear	O
22	pore	O
23	complex	O
24	,	O
25	like	O
26	p62	B
27	.	O

1	Concurrent	O
2	with	O
3	ligand	O
4	-	O
5	dependent	O
6	uptake	O
7	,	O
8	we	O
9	now	O
10	show	O
11	that	O
12	the	O
13	receptor	O
14	undergoes	O
15	ligand	O
16	-	O
17	induced	O
18	ubiquitination	O
19	,	O
20	suggesting	O
21	that	O
22	receptor	O
23	ubiquitination	O
24	may	O
25	function	O
26	in	O
27	the	O
28	ligand	O
29	-	O
30	dependent	O
31	endocytosis	O
32	of	O
33	the	O
34	a	B
35	-	I
36	factor	I
37	receptor	I
38	as	O
39	well	O
40	as	O
41	in	O
42	its	O
43	constitutive	O
44	endocytosis	O
45	.	O

1	Transcription	O
2	initiation	O
3	sites	O
4	of	O
5	the	O
6	rat	O
7	II	B
8	beta	I
9	-,	I
10	III	I
11	beta	I
12	,	I
13	and	I
14	O	I
15	beta	I
16	-	I
17	globin	I
18	genes	O
19	were	O
20	determined	O
21	to	O
22	be	O
23	52	O
24	base	O
25	pairs	O
26	(	O
27	bp	O
28	)	O
29	5	O
30	'-	O
31	upstream	O
32	of	O
33	the	O
34	translation	O
35	initiation	O
36	codon	O
37	(	O
38	ATG	O
39	),	O
40	in	O
41	each	O
42	gene	O
43	by	O
44	primer	O
45	extension	O
46	analysis	O
47	.	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	nuclear	I
6	protein	I
7	2	I
8	(	O
9	EBNA2	B
10	)	O
11	binds	O
12	to	O
13	a	O
14	component	O
15	of	O
16	the	O
17	human	O
18	SNF	B
19	-	O
20	SWI	B
21	complex	O
22	,	O
23	hSNF5	B
24	/	O
25	Ini1	B
26	.	O

1	Our	O
2	studies	O
3	also	O
4	excluded	O
5	the	O
6	possibility	O
7	that	O
8	the	O
9	phosphorylation	O
10	of	O
11	Ser	O
12	-	O
13	2	O
14	,	O
15	Ser	O
16	-	O
17	123	O
18	,	O
19	or	O
20	Ser	O
21	-	O
22	210	O
23	,	O
24	had	O
25	roles	O
26	in	O
27	the	O
28	trans	O
29	-	O
30	suppression	O
31	activity	O
32	of	O
33	the	O
34	large	B
35	HDAg	I
36	,	O
37	in	O
38	the	O
39	assembly	O
40	of	O
41	empty	O
42	virus	B
43	-	I
44	like	I
45	HDAg	I
46	particle	I
47	,	O
48	and	O
49	in	O
50	the	O
51	nuclear	O
52	transport	O
53	of	O
54	HDAgs	B
55	.	O

1	Homologous	O
2	recombination	O
3	between	O
4	the	O
5	Autographa	O
6	californica	O
7	nuclear	O
8	polyhedrosis	O
9	virus	O
10	(	O
11	AcNPV	O
12	)	O
13	genome	O
14	and	O
15	a	O
16	0	O
17	.	O
18	6	O
19	-	O
20	kbp	O
21	-	O
22	long	O
23	DNA	O
24	fragment	O
25	derived	O
26	from	O
27	the	O
28	putative	O
29	DNA	B
30	helicase	I
31	gene	I
32	of	I
33	Bombyx	I
34	mori	I
35	nuclear	I
36	polyhedrosis	I
37	virus	I
38	generates	O
39	eh2	O
40	-	O
41	AcNPV	O
42	,	O
43	an	O
44	expanded	O
45	-	O
46	host	O
47	-	O
48	range	O
49	AcNPV	O
50	mutant	O
51	(	O
52	S	O
53	.	O

1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	7R	I
10	alpha	I
11	chains	I
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	JAKs	B
20	and	O
21	STATs	B
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	proliferative	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O

1	Furthermore	O
2	,	O
3	the	O
4	potency	O
5	of	O
6	Dacarbacine	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	carcinoid	O
12	tumors	O
13	seems	O
14	to	O
15	be	O
16	underestimated	O
17	up	O
18	to	O
19	now	O
20	.	O

1	5	O
2	)	O
3	We	O
4	'	O
5	ve	O
6	noticed	O
7	that	O
8	the	O
9	mean	O
10	value	O
11	of	O
12	the	O
13	cost	O
14	for	O
15	episode	O
16	of	O
17	pnx	O
18	s	O
19	.	O
20	in	O
21	class	O
22	A	O
23	was	O
24	more	O
25	than	O
26	15	O
27	%	O
28	compared	O
29	to	O
30	class	O
31	B	O
32	and	O
33	the	O
34	cost	O
35	for	O
36	patient	O
37	in	O
38	class	O
39	A	O
40	was	O
41	nearly	O
42	double	O
43	than	O
44	in	O
45	class	O
46	B	O
47	.	O

1	We	O
2	have	O
3	been	O
4	studying	O
5	the	O
6	interaction	O
7	of	O
8	the	O
9	oncogenic	O
10	human	O
11	polyomavirus	O
12	BK	O
13	(	O
14	BKV	O
15	)	O
16	with	O
17	the	O
18	tumor	B
19	-	I
20	suppressor	I
21	protein	I
22	p53	I
23	to	O
24	understand	O
25	the	O
26	biology	O
27	of	O
28	this	O
29	virus	O
30	as	O
31	well	O
32	as	O
33	to	O
34	understand	O
35	the	O
36	basic	O
37	mechanisms	O
38	of	O
39	p53	B
40	transactivation	O
41	.	O

1	Site	O
2	S	O
3	-	O
4	II	O
5	also	O
6	spans	O
7	a	O
8	23	O
9	bp	O
10	sequence	O
11	containing	O
12	two	O
13	tandem	O
14	consensus	O
15	binding	O
16	sites	O
17	with	O
18	three	O
19	base	O
20	pair	O
21	mismatches	O
22	in	O
23	each	O
24	and	O
25	a	O
26	one	O
27	base	O
28	pair	O
29	deletion	O
30	.	O

1	Cbl	B
2	constitutively	O
3	interacts	O
4	with	O
5	the	O
6	SH3	B
7	domains	I
8	of	O
9	Grb2	B
10	,	O
11	with	O
12	a	O
13	preference	O
14	for	O
15	the	O
16	amino	O
17	-	O
18	terminal	O
19	domain	O
20	,	O
21	and	O
22	is	O
23	in	O
24	this	O
25	way	O
26	recruited	O
27	to	O
28	Shc	B
29	upon	O
30	BCR	B
31	stimulation	O
32	.	O

1	Activation	O
2	mediated	O
3	by	O
4	Cat8p	B
5	was	O
6	no	O
7	longer	O
8	detectable	O
9	in	O
10	a	O
11	cat1	B
12	mutant	I
13	.	O

1	Treatment	O
2	is	O
3	instituted	O
4	with	O
5	prednisone	O
6	and	O
7	cyclophosphamide	O
8	.	O

1	Unaided	O
2	attempts	O
3	to	O
4	quit	O
5	smoking	O
6	are	O
7	generally	O
8	unsuccessful	O
9	.	O

1	Laboratory	O
2	evaluation	O
3	was	O
4	normal	O
5	,	O
6	and	O
7	neuroimaging	O
8	failed	O
9	to	O
10	confirm	O
11	obstruction	O
12	of	O
13	venous	O
14	or	O
15	lymphatic	O
16	drainage	O
17	.	O

1	Microcomputer	O
2	management	O
3	of	O
4	chronic	O
5	hepatitis	O
6	B	O
7	virus	O
8	asymptomatic	O
9	patients	O

1	While	O
2	fusion	O
3	to	O
4	the	O
5	N	O
6	-	O
7	terminus	O
8	required	O
9	a	O
10	linker	O
11	to	O
12	become	O
13	surface	O
14	accessible	O
15	,	O
16	both	O
17	fusion	O
18	to	O
19	the	O
20	N	O
21	-	O
22	terminus	O
23	and	O
24	to	O
25	the	O
26	C	O
27	-	O
28	terminus	O
29	was	O
30	compatible	O
31	with	O
32	particle	O
33	assembly	O
34	and	O
35	preserved	O
36	the	O
37	native	O
38	antigenicity	O
39	and	O
40	immunogenicity	O
41	of	O
42	HBcAg	B
43	.	O

1	The	O
2	standard	O
3	dosage	O
4	of	O
5	anti	B
6	-	I
7	D	I
8	currently	O
9	given	O
10	at	O
11	all	O
12	gestational	O
13	ages	O
14	is	O
15	1	O
16	ampoule	O
17	containing	O
18	125	O
19	micrograms	O
20	of	O
21	anti	B
22	-	I
23	D	I
24	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	putative	O
10	adhesive	O
11	molecule	O
12	from	O
13	P	O
14	.	O
15	falciparum	O
16	that	O
17	shares	O
18	both	O
19	sequence	O
20	and	O
21	structural	O
22	similarities	O
23	with	O
24	a	O
25	sporozoite	O
26	surface	O
27	molecule	O
28	from	O
29	Plasmodium	O
30	termed	O
31	the	O
32	thrombospondin	B
33	-	I
34	related	I
35	anonymous	I
36	protein	I
37	(	O
38	TRAP	B
39	)	O
40	and	O
41	,	O
42	to	O
43	a	O
44	lesser	O
45	extent	O
46	,	O
47	with	O
48	the	O
49	circumsporozoite	B
50	(	I
51	CS	I
52	)	I
53	protein	I
54	.	O

1	There	O
2	are	O
3	no	O
4	introns	O
5	within	O
6	the	O
7	gene	O
8	,	O
9	which	O
10	contains	O
11	a	O
12	9360	O
13	-	O
14	bp	O
15	open	O
16	reading	O
17	frame	O
18	and	O
19	encodes	O
20	a	O
21	377	O
22	-	O
23	kDa	O
24	protein	O
25	.	O

1	METHODS	O
2	:	O
3	DSF	O
4	was	O
5	instilled	O
6	in	O
7	one	O
8	eye	O
9	chosen	O
10	at	O
11	random	O
12	and	O
13	CF	O
14	in	O
15	the	O
16	fellow	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	KCS	O
28	.	O

1	The	O
2	experience	O
3	of	O
4	the	O
5	lateral	O
6	rhinotomy	O
7	approach	O
8	in	O
9	transsphenoidal	O
10	surgery	O
11	of	O
12	acromegaly	O
13	has	O
14	been	O
15	favourable	O
16	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	The	O
2	predominant	O
3	sensitizing	O
4	allergens	O
5	in	O
6	Swedish	O
7	asthmatic	O
8	children	O
9	are	O
10	furred	O
11	pet	O
12	animals	O
13	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	distinct	O
6	cytoplasmic	O
7	domains	O
8	of	O
9	these	O
10	cytokine	O
11	receptors	O
12	elicit	O
13	convergent	O
14	signaling	O
15	pathways	O
16	and	O
17	provide	O
18	evidence	O
19	that	O
20	beta	B
21	c	I
22	and	O
23	IL	B
24	-	I
25	2R	I
26	beta	I
27	function	O
28	as	O
29	a	O
30	complete	O
31	signal	O
32	transducer	O
33	.	O

1	In	O
2	addition	O
3	,	O
4	they	O
5	display	O
6	common	O
7	features	O
8	that	O
9	make	O
10	them	O
11	strikingly	O
12	related	O
13	to	O
14	snoRNA	B
15	U14	I
16	.	O

1	U24	B
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	B
16	rRNA	I
17	.	O

1	This	O
2	complex	O
3	interacts	O
4	at	O
5	the	O
6	GTPase	B
7	domain	I
8	in	O
9	the	O
10	large	O
11	subunit	O
12	rRNA	O
13	,	O
14	overlapping	O
15	the	O
16	binding	O
17	site	O
18	of	O
19	the	O
20	protein	B
21	L11	I
22	-	I
23	like	I
24	eukaryotic	I
25	counterpart	I
26	(	O
27	Saccharomyces	B
28	cerevisiae	I
29	protein	I
30	L15	I
31	and	O
32	mammalian	B
33	protein	I
34	L12	I
35	).	O

1	Chromatin	O
2	repression	O
3	of	O
4	these	O
5	replacement	O
6	genes	O
7	would	O
8	be	O
9	avoided	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	high	O
15	,	O
16	constitutive	O
17	expression	O
18	of	O
19	replacement	O
20	H3	B
21	histone	I
22	genes	I
23	in	O
24	plants	O
25	.	O

1	This	O
2	transition	O
3	is	O
4	regulated	O
5	positively	O
6	by	O
7	G1	B
8	-	I
9	specific	I
10	cyclin	I
11	-	I
12	dependent	I
13	kinases	I
14	(	O
15	cdks	B
16	)	O
17	and	O
18	negatively	O
19	by	O
20	the	O
21	product	O
22	of	O
23	the	O
24	retinoblastoma	B
25	tumour	I
26	suppressor	I
27	gene	I
28	,	O
29	pRb	B
30	.	O

1	Possible	O
2	relationship	O
3	between	O
4	hyperinsulinemia	O
5	and	O
6	glomerular	O
7	hypertrophy	O
8	in	O
9	nephrosclerosis	O
10	.	O

1	Blood	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	was	O
7	measured	O
8	with	O
9	a	O
10	spectrophotometer	O
11	,	O
12	using	O
13	a	O
14	modification	O
15	of	O
16	a	O
17	previously	O
18	described	O
19	assay	O
20	.	O

1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	hay	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	llamas	O
21	,	O
22	and	O
23	alfalfa	O
24	hay	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	unreliable	O
30	source	O
31	of	O
32	vitamins	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O

1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O

1	However	O
2	,	O
3	as	O
4	determined	O
5	by	O
6	PCR	O
7	with	O
8	primers	O
9	specific	O
10	for	O
11	the	O
12	26	O
13	-	O
14	kDa	O
15	product	O
16	,	O
17	the	O
18	majority	O
19	of	O
20	cats	O
21	at	O
22	2	O
23	and	O
24	4	O
25	weeks	O
26	p	O
27	.	O
28	t	O
29	.	O
30	had	O
31	gastric	O
32	fluid	O
33	samples	O
34	which	O
35	were	O
36	positive	O
37	for	O
38	H	O
39	.	O
40	pylori	O
41	and	O
42	three	O
43	of	O
44	three	O
45	cats	O
46	at	O
47	2	O
48	weeks	O
49	p	O
50	.	O
51	t	O
52	.	O
53	had	O
54	dental	O
55	plaque	O
56	which	O
57	was	O
58	positive	O
59	for	O
60	H	O
61	.	O
62	pylori	O
63	.	O

1	To	O
2	derive	O
3	quantitative	O
4	concentration	O
5	changes	O
6	from	O
7	measurements	O
8	of	O
9	light	O
10	attenuation	O
11	,	O
12	the	O
13	optical	O
14	path	O
15	length	O
16	must	O
17	be	O
18	known	O
19	.	O

1	STUDY	O
2	DESIGN	O
3	.	O

1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O

1	Differential	O
2	activation	O
3	of	O
4	the	O
5	extracellular	B
6	signal	I
7	-	I
8	regulated	I
9	kinase	I
10	,	O
11	Jun	B
12	kinase	I
13	and	O
14	Janus	B
15	kinase	I
16	-	O
17	Stat	B
18	pathways	O
19	by	O
20	oncostatin	B
21	M	I
22	and	O
23	basic	B
24	fibroblast	I
25	growth	I
26	factor	I
27	in	O
28	AIDS	O
29	-	O
30	derived	O
31	Kaposi	O
32	'	O
33	s	O
34	sarcoma	O
35	cells	O
36	.	O

1	There	O
2	is	O
3	general	O
4	agreement	O
5	that	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	is	O
11	efficiently	O
12	transmitted	O
13	parenterally	O
14	,	O
15	while	O
16	data	O
17	on	O
18	viral	O
19	transmission	O
20	from	O
21	mothers	O
22	to	O
23	babies	O
24	or	O
25	by	O
26	sexual	O
27	or	O
28	non	O
29	-	O
30	sexual	O
31	household	O
32	contact	O
33	are	O
34	conflicting	O
35	.	O

1	Ten	O
2	weeks	O
3	after	O
4	reconstruction	O
5	,	O
6	the	O
7	regenerating	O
8	nerves	O
9	already	O
10	resembled	O
11	normal	O
12	nerves	O
13	.	O

1	The	O
2	distribution	O
3	and	O
4	organization	O
5	of	O
6	projections	O
7	from	O
8	the	O
9	spinal	O
10	cervical	O
11	enlargement	O
12	to	O
13	subnucleus	O
14	reticularis	O
15	dorsalis	O
16	(	O
17	SRD	O
18	)	O
19	and	O
20	the	O
21	neighbouring	O
22	Cuneate	O
23	nucleus	O
24	(	O
25	Cu	O
26	)	O
27	area	O
28	was	O
29	studied	O
30	in	O
31	the	O
32	rat	O
33	by	O
34	using	O
35	microinjections	O
36	of	O
37	Phaseolus	B
38	vulgaris	I
39	leucoagglutinin	I
40	(	O
41	PHA	B
42	-	I
43	L	I
44	)	O
45	into	O
46	different	O
47	laminae	O
48	around	O
49	the	O
50	C7	O
51	level	O
52	.	O

1	The	O
2	levels	O
3	of	O
4	fibrinogen	B
5	as	O
6	well	O
7	as	O
8	antithrombin	B
9	III	I
10	(	O
11	ATIII	B
12	)	O
13	and	O
14	heparin	B
15	cofactor	I
16	II	I
17	(	O
18	HCII	B
19	)	O
20	activities	O
21	were	O
22	steadily	O
23	increased	O
24	in	O
25	loop	O
26	-	O
27	bearing	O
28	animals	O
29	.	O

1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	I
8	erbB	I
9	-	I
10	2	I
11	gene	I
12	in	O
13	21MT	O
14	-	O
15	2	O
16	and	O
17	21MT	O
18	-	O
19	1	O
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	B
32	-	I
33	phosphorylated	I
34	p185erbB	I
35	-	I
36	2	I
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	I
44	like	I
45	growth	I
46	factor	I
47	(	O
48	IGF	B
49	)	O
50	and	O
51	combined	O
52	IGF	B
53	/	O
54	epidermal	B
55	growth	I
56	factor	I
57	(	O
58	EGF	B
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O

1	Facioscapulohumeral	O
2	muscular	O
3	dystrophy	O
4	(	O
5	FSHD	O
6	)	O
7	is	O
8	an	O
9	autosomal	O
10	dominant	O
11	,	O
12	neuromuscular	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	weakness	O
18	of	O
19	muscles	O
20	in	O
21	the	O
22	face	O
23	,	O
24	shoulder	O
25	and	O
26	upper	O
27	arm	O
28	.	O

1	The	O
2	mature	O
3	chromosome	O
4	4	O
5	FRG1	B
6	transcript	I
7	is	O
8	1042	O
9	bp	O
10	in	O
11	length	O
12	and	O
13	contains	O
14	nine	O
15	exons	O
16	which	O
17	encode	O
18	a	O
19	putative	O
20	protein	O
21	of	O
22	258	O
23	amino	O
24	acid	O
25	residues	O
26	.	O

1	Patients	O
2	who	O
3	have	O
4	undergone	O
5	thyroidectomy	O
6	for	O
7	thyroid	O
8	carcinoma	O
9	are	O
10	frequently	O
11	subjected	O
12	to	O
13	periods	O
14	of	O
15	induced	O
16	severe	O
17	hypothyroidism	O
18	in	O
19	preparation	O
20	for	O
21	131I	O
22	whole	O
23	body	O
24	scanning	O
25	and	O
26	measurement	O
27	of	O
28	serum	O
29	TG	B
30	.	O

1	Full	O
2	thyroid	O
3	function	O
4	testing	O
5	was	O
6	performed	O
7	on	O
8	600	O
9	randomly	O
10	selected	O
11	samples	O
12	with	O
13	normal	O
14	TSH	B
15	values	O
16	and	O
17	also	O
18	on	O
19	subjects	O
20	with	O
21	abnormal	O
22	TSH	B
23	levels	O
24	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	crossover	O
7	AM	O
8	between	O
9	dissimilar	O
10	textures	O
11	was	O
12	investigated	O
13	,	O
14	and	O
15	it	O
16	was	O
17	found	O
18	that	O
19	the	O
20	more	O
21	salient	O
22	textures	O
23	carried	O
24	the	O
25	AM	O
26	.	O

1	The	O
2	relative	O
3	tumor	O
4	FDG	O
5	-	O
6	uptake	O
7	(	O
8	Q	O
9	-	O
10	MRGlu	O
11	)	O
12	(	O
13	tumor	O
14	/	O
15	contralateral	O
16	cortex	O
17	)	O
18	of	O
19	all	O
20	meningiomas	O
21	was	O
22	calculated	O
23	with	O
24	0	O
25	.	O
26	73	O
27	+/-	O
28	0	O
29	.	O
30	37	O
31	(	O
32	0	O
33	.	O
34	24	O
35	-	O
36	1	O
37	.	O
38	79	O
39	).	O

1	Zatebradine	O
2	weakly	O
3	depressed	O
4	the	O
5	ectopic	O
6	ventricular	O
7	rate	O
8	but	O
9	not	O
10	the	O
11	arrhythmic	O
12	ratio	O
13	of	O
14	the	O
15	ventricular	O
16	arrhythmias	O
17	induced	O
18	by	O
19	two	O
20	-	O
21	stage	O
22	coronary	O
23	ligation	O
24	24	O
25	h	O
26	after	O
27	the	O
28	ligation	O
29	in	O
30	conscious	O
31	dogs	O
32	.	O

1	Catha	O
2	edulis	O
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O

1	The	O
2	predicted	O
3	protein	O
4	,	O
5	Seb1p	B
6	,	O
7	consists	O
8	of	O
9	82	O
10	amino	O
11	acids	O
12	and	O
13	contains	O
14	one	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	region	O
20	at	O
21	the	O
22	C	O
23	-	O
24	terminus	O
25	but	O
26	no	O
27	N	O
28	-	O
29	terminal	O
30	signal	O
31	sequence	O
32	.	O

1	The	O
2	SEB1	B
3	homologue	O
4	thus	O
5	isolated	O
6	,	O
7	SEB2	B
8	,	O
9	encodes	O
10	a	O
11	protein	O
12	53	O
13	%	O
14	identical	O
15	to	O
16	Seb1p	B
17	.	O

1	Nonetheless	O
2	,	O
3	that	O
4	ventricular	O
5	afferents	O
6	,	O
7	in	O
8	certain	O
9	special	O
10	settings	O
11	,	O
12	are	O
13	able	O
14	to	O
15	induce	O
16	e	O
17	.	O
18	g	O
19	.	O
20	generalised	O
21	vasodilation	O
22	and	O
23	hypotension	O
24	cannot	O
25	be	O
26	excluded	O
27	.	O

1	Large	O
2	ones	O
3	were	O
4	similar	O
5	in	O
6	size	O
7	to	O
8	the	O
9	main	O
10	lobe	O
11	and	O
12	small	O
13	ones	O
14	were	O
15	approximately	O
16	1	O
17	/	O
18	4	O
19	of	O
20	the	O
21	length	O
22	of	O
23	the	O
24	main	O
25	lobe	O
26	.	O

1	Fragments	O
2	and	O
3	analogs	O
4	of	O
5	the	O
6	hormone	O
7	ACTH	B
8	were	O
9	previously	O
10	shown	O
11	to	O
12	have	O
13	beneficial	O
14	effect	O
15	on	O
16	the	O
17	outcome	O
18	of	O
19	head	O
20	injury	O
21	,	O
22	while	O
23	elevated	O
24	levels	O
25	of	O
26	corticosterone	O
27	(	O
28	CS	O
29	)	O
30	exacerbate	O
31	it	O
32	.	O

1	The	O
2	most	O
3	frequent	O
4	causes	O
5	of	O
6	the	O
7	meningitis	O
8	was	O
9	the	O
10	external	O
11	ventricular	O
12	drainage	O
13	(	O
14	14	O
15	.	O
16	8	O
17	%),	O
18	post	O
19	-	O
20	neurosurgical	O
21	(	O
22	0	O
23	.	O
24	8	O
25	%)	O
26	and	O
27	head	O
28	injury	O
29	(	O
30	0	O
31	.	O
32	0007	O
33	%).	O

1	Fifty	O
2	-	O
3	one	O
4	patients	O
5	with	O
6	primary	O
7	refractory	O
8	or	O
9	relapsed	O
10	malignant	O
11	lymphoma	O
12	(	O
13	47	O
14	non	O
15	-	O
16	Hodgkin	O
17	'	O
18	s	O
19	lymphoma	O
20	and	O
21	four	O
22	Hodgkin	O
23	'	O
24	s	O
25	disease	O
26	)	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	new	O
32	chemotherapeutic	O
33	regimen	O
34	(	O
35	cisplatinum	O
36	,	O
37	methyl	O
38	GAG	O
39	,	O
40	bleomocyin	O
41	,	O
42	methyl	O
43	prednisolon	O
44	).	O

1	With	O
2	the	O
3	increasing	O
4	use	O
5	of	O
6	ACE	B
7	inhibitors	O
8	,	O
9	the	O
10	incidence	O
11	of	O
12	rare	O
13	adverse	O
14	effects	O
15	such	O
16	as	O
17	potentially	O
18	lethal	O
19	pancreatitis	O
20	is	O
21	likely	O
22	to	O
23	increase	O
24	.	O

1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O

1	Low	O
2	-	O
3	dose	O
4	aspirin	O
5	and	O
6	recurrent	O
7	miscarriage	O
8	.	O

1	Protein	O
2	films	O
3	are	O
4	distinctly	O
5	different	O
6	in	O
7	mechanical	O
8	profiles	O
9	from	O
10	those	O
11	films	O
12	made	O
13	of	O
14	other	O
15	materials	O
16	.	O

1	Furthermore	O
2	,	O
3	cpxA	B
4	*	I
5	mutations	O
6	suppress	O
7	the	O
8	toxicity	O
9	conferred	O
10	by	O
11	the	O
12	LamB	B
13	-	O
14	LacZ	B
15	hybrid	O
16	protein	O
17	,	O
18	which	O
19	exerts	O
20	its	O
21	effects	O
22	in	O
23	the	O
24	cytoplasm	O
25	,	O
26	sequestered	O
27	from	O
28	DegP	B
29	.	O

1	The	O
2	PI3K_68D	B
3	cDNA	I
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	210	O
9	kDa	O
10	,	O
11	which	O
12	lacks	O
13	sequences	O
14	implicated	O
15	in	O
16	linking	O
17	p110	B
18	PI	I
19	3	I
20	-	I
21	kinases	I
22	to	O
23	p85	B
24	adaptor	I
25	proteins	I
26	,	O
27	but	O
28	contains	O
29	an	O
30	amino	O
31	-	O
32	terminal	O
33	proline	O
34	-	O
35	rich	O
36	sequence	O
37	,	O
38	which	O
39	could	O
40	bind	O
41	to	O
42	SH3	B
43	domains	I
44	,	O
45	and	O
46	a	O
47	carboxy	O
48	-	O
49	terminal	O
50	C2	B
51	domain	O
52	.	O

1	In	O
2	vitro	O
3	interaction	O
4	studies	O
5	,	O
6	using	O
7	proteins	O
8	fused	O
9	to	O
10	glutathione	B
11	-	I
12	S	I
13	-	I
14	transferase	I
15	,	O
16	showed	O
17	that	O
18	RBP	B
19	-	I
20	J	I
21	kappa	I
22	and	O
23	Su	B
24	(	I
25	H	I
26	)	I
27	bind	O
28	directly	O
29	to	O
30	the	O
31	RAM23	B
32	regions	I
33	of	O
34	mouse	B
35	Notch1	I
36	and	O
37	Drosophila	B
38	Notch	I
39	,	O
40	respectively	O
41	.	O

1	AIMS	O
2	/	O
3	METHODS	O
4	:	O
5	Reticuloendothelial	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	radiolabelled	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	galactosamine	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O

1	Our	O
2	laboratory	O
3	and	O
4	others	O
5	have	O
6	shown	O
7	alternative	O
8	splicing	O
9	of	O
10	up	O
11	to	O
12	ten	O
13	exons	O
14	at	O
15	a	O
16	discrete	O
17	extracellular	O
18	site	O
19	to	O
20	be	O
21	primarily	O
22	responsible	O
23	for	O
24	the	O
25	generation	O
26	of	O
27	CD44	B
28	variant	I
29	(	O
30	CD44v	B
31	)	O
32	isoforms	O
33	.	O

1	Study	O
2	groups	O
3	were	O
4	control	O
5	,	O
6	and	O
7	those	O
8	treated	O
9	with	O
10	the	O
11	alpha1	B
12	-	I
13	adrenoceptor	I
14	-	I
15	subtype	I
16	blockers	O
17	WB4101	O
18	(	O
19	0	O
20	.	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	i	O
26	.	O
27	v	O
28	.)	O
29	or	O
30	chloroethylclonidine	O
31	(	O
32	1	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	kg	O
38	i	O
39	.	O
40	v	O
41	.).	O

1	This	O
2	caused	O
3	severe	O
4	cortical	O
5	damage	O
6	and	O
7	neuronal	O
8	loss	O
9	in	O
10	hippocampus	O
11	subfields	O
12	CA1	O
13	,	O
14	CA3	O
15	,	O
16	and	O
17	hilus	O
18	.	O

1	The	O
2	occurrence	O
3	of	O
4	multiple	O
5	malignancy	O
6	was	O
7	studied	O
8	in	O
9	674	O
10	patients	O
11	with	O
12	hematologic	O
13	malignancies	O
14	who	O
15	were	O
16	admitted	O
17	to	O
18	this	O
19	department	O
20	during	O
21	the	O
22	past	O
23	10	O
24	years	O
25	.	O

1	The	O
2	upTRE	O
3	binds	O
4	more	O
5	T3R	B
6	homodimers	I
7	and	O
8	less	O
9	T3R	B
10	-	O
11	RXR	B
12	heterodimers	O
13	than	O
14	the	O
15	dnTRE	O
16	,	O
17	and	O
18	T3	O
19	more	O
20	readily	O
21	facilitates	O
22	heterodimer	O
23	binding	O
24	to	O
25	the	O
26	dn	O
27	-	O
28	than	O
29	to	O
30	the	O
31	upTRE	O
32	.	O

1	Transcriptional	O
2	control	O
3	of	O
4	a	O
5	nuclear	O
6	gene	O
7	encoding	O
8	a	O
9	mitochondrial	O
10	fatty	O
11	acid	O
12	oxidation	O
13	enzyme	O
14	in	O
15	transgenic	O
16	mice	O
17	:	O
18	role	O
19	for	O
20	nuclear	O
21	receptors	O
22	in	O
23	cardiac	O
24	and	O
25	brown	O
26	adipose	O
27	expression	O
28	.	O

1	Hoeben	O
2	,	O
3	F	O
4	.	O
5	J	O
6	.	O

1	Twelve	O
2	genomic	O
3	fragments	O
4	containing	O
5	novel	O
6	response	O
7	elements	O
8	are	O
9	described	O
10	,	O
11	and	O
12	the	O
13	transcription	O
14	unit	O
15	associated	O
16	with	O
17	one	O
18	of	O
19	them	O
20	,	O
21	NN	B
22	-	I
23	84AG	I
24	,	O
25	was	O
26	characterized	O
27	in	O
28	detail	O
29	.	O

1	Moreover	O
2	,	O
3	glucan	B
4	synthase	I
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	B
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	B
19	mutant	I
20	.	O

1	In	O
2	gel	O
3	retardation	O
4	assays	O
5	,	O
6	an	O
7	RCS	O
8	cell	O
9	-	O
10	specific	O
11	protein	O
12	and	O
13	another	O
14	closely	O
15	related	O
16	protein	O
17	expressed	O
18	only	O
19	in	O
20	RCS	O
21	cells	O
22	and	O
23	primary	O
24	chondrocytes	O
25	bound	O
26	to	O
27	a	O
28	10	O
29	-	O
30	bp	O
31	sequence	O
32	within	O
33	the	O
34	18	O
35	-	O
36	mer	O
37	.	O

1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	B
22	.	O

1	Members	O
2	of	O
3	the	O
4	Ras	B
5	subfamily	I
6	of	O
7	small	B
8	GTP	I
9	-	I
10	binding	I
11	proteins	I
12	have	O
13	been	O
14	shown	O
15	to	O
16	be	O
17	promiscuous	O
18	towards	O
19	a	O
20	variety	O
21	of	O
22	putative	O
23	effector	O
24	molecules	O
25	such	O
26	as	O
27	the	O
28	protein	B
29	kinase	I
30	c	I
31	-	I
32	Raf	I
33	and	O
34	the	O
35	Ral	B
36	-	I
37	specific	I
38	guanine	I
39	nucleotide	I
40	exchange	I
41	factor	I
42	(	O
43	Ral	B
44	-	I
45	GEF	I
46	).	O

1	Thus	O
2	,	O
3	the	O
4	characterization	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	should	O
10	help	O
11	to	O
12	define	O
13	regulatory	O
14	elements	O
15	that	O
16	control	O
17	neuron	O
18	-	O
19	specific	O
20	and	O
21	developmental	O
22	expression	O
23	of	O
24	the	O
25	MAP1B	B
26	gene	I
27	.	O

1	The	O
2	cDNA	O
3	encoded	O
4	a	O
5	mature	O
6	protein	O
7	of	O
8	240	O
9	amino	O
10	acids	O
11	,	O
12	including	O
13	a	O
14	29	O
15	-	O
16	amino	O
17	acid	O
18	signal	O
19	sequence	O
20	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	O
20	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	was	O
7	highly	O
8	conserved	O
9	across	O
10	the	O
11	wide	O
12	range	O
13	of	O
14	eukaryotes	O
15	(	O
16	vertebrates	O
17	,	O
18	invertebrates	O
19	,	O
20	fungi	O
21	,	O
22	plants	O
23	and	O
24	protozoa	O
25	)	O
26	in	O
27	which	O
28	this	O
29	gene	O
30	has	O
31	now	O
32	been	O
33	identified	O
34	.	O

1	Biol	O
2	.	O

1	Semidominant	O
2	mutations	O
3	in	O
4	the	O
5	yeast	B
6	Rad51	I
7	protein	I
8	and	O
9	their	O
10	relationships	O
11	with	O
12	the	O
13	Srs2	B
14	helicase	I
15	.	O

1	Alterations	O
2	of	O
3	the	O
4	5q23	O
5	-	O
6	q31	O
7	interval	O
8	are	O
9	frequently	O
10	observed	O
11	in	O
12	myelodysplasia	O
13	and	O
14	myeloid	O
15	leukemia	O
16	.	O

1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	the	O
7	616	O
8	amino	O
9	acid	O
10	,	O
11	70	B
12	-	I
13	kDa	I
14	subunit	I
15	of	I
16	RPA	I
17	(	O
18	RPA	B
19	70	I
20	)	O
21	is	O
22	composed	O
23	of	O
24	multiple	O
25	structural	O
26	/	O
27	functional	O
28	domains	O
29	.	O

1	Neurons	O
2	were	O
3	held	O
4	at	O
5	-	O
6	67	O
7	mV	O
8	to	O
9	equate	O
10	voltage	O
11	-	O
12	dependent	O
13	effects	O
14	.	O

1	This	O
2	site	O
3	acts	O
4	as	O
5	a	O
6	negative	O
7	element	O
8	when	O
9	transferred	O
10	to	O
11	the	O
12	thymidine	B
13	kinase	I
14	promoter	I
15	,	O
16	but	O
17	does	O
18	not	O
19	confer	O
20	inducibility	O
21	.	O

1	The	O
2	extent	O
3	of	O
4	the	O
5	fbpA	O
6	operator	O
7	sequence	O
8	(	O
9	42	O
10	bp	O
11	),	O
12	as	O
13	defined	O
14	by	O
15	our	O
16	footprinting	O
17	analysis	O
18	,	O
19	would	O
20	suggest	O
21	the	O
22	binding	O
23	of	O
24	two	O
25	Fur	B
26	repressor	I
27	dimers	I
28	.	O

1	The	O
2	structural	O
3	similarity	O
4	between	O
5	Vav	B
6	and	O
7	other	O
8	guanine	B
9	nucleotide	I
10	exchange	I
11	factors	I
12	for	O
13	small	B
14	GTP	I
15	-	I
16	binding	I
17	proteins	I
18	,	O
19	together	O
20	with	O
21	the	O
22	recent	O
23	identification	O
24	of	O
25	biochemical	O
26	routes	O
27	specific	O
28	for	O
29	members	O
30	of	O
31	the	O
32	Ras	B
33	and	O
34	Rho	B
35	family	I
36	of	O
37	GTPases	B
38	,	O
39	prompted	O
40	us	O
41	to	O
42	explore	O
43	whether	O
44	MAPK	B
45	or	O
46	JNK	B
47	are	O
48	downstream	O
49	components	O
50	of	O
51	the	O
52	Vav	B
53	signaling	O
54	pathways	O
55	.	O

1	CONCLUSION	O
2	:	O
3	Twice	O
4	daily	O
5	treatment	O
6	with	O
7	inhaled	O
8	fluticasone	O
9	propionate	O
10	50	O
11	micrograms	O
12	or	O
13	100	O
14	micrograms	O
15	was	O
16	significantly	O
17	more	O
18	effective	O
19	than	O
20	theophylline	O
21	in	O
22	the	O
23	treatment	O
24	of	O
25	mild	O
26	-	O
27	to	O
28	-	O
29	moderate	O
30	asthma	O
31	.	O

1	Our	O
2	results	O
3	support	O
4	a	O
5	model	O
6	where	O
7	both	O
8	E2F	B
9	-	O
10	and	O
11	CDE	O
12	-	O
13	mediated	O
14	repression	O
15	,	O
16	acting	O
17	at	O
18	different	O
19	stages	O
20	in	O
21	the	O
22	cell	O
23	cycle	O
24	,	O
25	are	O
26	dependent	O
27	on	O
28	promoter	O
29	-	O
30	specific	O
31	CHR	O
32	elements	O
33	.	O

1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	B
18	.	O

1	Comparison	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequences	O
8	with	O
9	protein	O
10	sequences	O
11	of	O
12	T	O
13	.	O
14	pyriformis	O
15	H2As	B
16	showed	O
17	only	O
18	two	O
19	and	O
20	three	O
21	differences	O
22	respectively	O
23	,	O
24	in	O
25	a	O
26	total	O
27	of	O
28	137	O
29	amino	O
30	acids	O
31	for	O
32	H2A1	B
33	,	O
34	and	O
35	132	O
36	amino	O
37	acids	O
38	for	O
39	H2A2	B
40	,	O
41	indicating	O
42	the	O
43	two	O
44	genes	O
45	arose	O
46	before	O
47	the	O
48	divergence	O
49	of	O
50	these	O
51	two	O
52	species	O
53	.	O

1	Cognitive	O
2	visual	O
3	dysfunction	O
4	in	O
5	a	O
6	child	O
7	with	O
8	cerebral	O
9	damage	O
10	.	O

1	Interaction	O
2	was	O
3	apparently	O
4	determined	O
5	by	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	splice	O
11	region	O
12	of	O
13	RPDE	B
14	-	I
15	6	I
16	,	O
17	as	O
18	the	O
19	PDE4A	B
20	splice	O
21	variant	O
22	RPDE	B
23	-	I
24	39	I
25	,	O
26	which	O
27	differs	O
28	from	O
29	RPDE	B
30	-	I
31	6	I
32	at	O
33	the	O
34	extreme	O
35	N	O
36	-	O
37	terminus	O
38	,	O
39	failed	O
40	to	O
41	associate	O
42	with	O
43	v	B
44	-	I
45	Src	I
46	-	O
47	SH3	B
48	;	O
49	met26RD1	B
50	(	O
51	where	O
52	RD1	B
53	is	O
54	rat	B
55	'	I
56	dunc	I
57	-	I
58	like	I
59	'	I
60	PDE	I
61	),	O
62	which	O
63	has	O
64	the	O
65	N	O
66	-	O
67	terminal	O
68	splice	O
69	region	O
70	deleted	O
71	,	O
72	failed	O
73	to	O
74	associate	O
75	with	O
76	v	B
77	-	I
78	Src	I
79	-	O
80	SH3	B
81	,	O
82	and	O
83	the	O
84	association	O
85	of	O
86	RPDE	B
87	-	I
88	6	I
89	and	O
90	v	B
91	-	I
92	Src	I
93	-	O
94	SH3	B
95	was	O
96	blocked	O
97	by	O
98	a	O
99	fusion	O
100	protein	O
101	formed	O
102	from	O
103	the	O
104	N	O
105	-	O
106	terminal	O
107	splice	O
108	region	O
109	.	O

1	Potentially	O
2	load	O
3	-	O
4	insensitive	O
5	measures	O
6	of	O
7	ventricular	O
8	performance	O
9	were	O
10	therefore	O
11	evaluated	O
12	in	O
13	10	O
14	open	O
15	-	O
16	and	O
17	closed	O
18	-	O
19	chested	O
20	,	O
21	anesthetized	O
22	rabbits	O
23	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	The	O
2	effect	O
3	of	O
4	ligustrazine	O
5	hydrochloride	O
6	(	O
7	LTH	O
8	)	O
9	on	O
10	depressing	O
11	pulmonary	O
12	artery	O
13	hypertension	O
14	has	O
15	been	O
16	proved	O
17	in	O
18	recent	O
19	studies	O
20	.	O

1	It	O
2	is	O
3	the	O
4	oxidation	O
5	peak	O
6	of	O
7	this	O
8	product	O
9	,	O
10	arising	O
11	in	O
12	acidic	O
13	media	O
14	at	O
15	0	O
16	.	O
17	42	O
18	V	O
19	,	O
20	which	O
21	was	O
22	analysed	O
23	using	O
24	DPV	O
25	,	O
26	again	O
27	following	O
28	the	O
29	accumulation	O
30	of	O
31	clenbuterol	O
32	at	O
33	the	O
34	Nafion	O
35	-	O
36	modified	O
37	CPE	O
38	.	O

1	Phenylephrine	O
2	is	O
3	a	O
4	pure	O
5	alpha	B
6	-	I
7	1	I
8	adrenoreceptor	I
9	agonist	O
10	known	O
11	to	O
12	produce	O
13	marked	O
14	systemic	O
15	vasoconstriction	O
16	and	O
17	associated	O
18	hypertension	O
19	with	O
20	occasional	O
21	profound	O
22	reflex	O
23	bradycardia	O
24	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	first	O
6	two	O
7	genes	O
8	located	O
9	in	O
10	this	O
11	unit	O
12	(	O
13	c	B
14	-	I
15	gvpD	I
16	and	O
17	c	B
18	-	I
19	gvpE	I
20	)	O
21	was	O
22	also	O
23	monitored	O
24	by	O
25	Western	O
26	blot	O
27	(	O
28	immunoblot	O
29	)	O
30	analyses	O
31	using	O
32	antisera	O
33	raised	O
34	against	O
35	these	O
36	proteins	O
37	synthesized	O
38	in	O
39	Escherichia	O
40	coli	O
41	.	O

1	One	O
2	unit	O
3	encodes	O
4	traA	B
5	,	O
6	traF	B
7	,	O
8	and	O
9	traB	B
10	,	O
11	while	O
12	the	O
13	second	O
14	encodes	O
15	traC	B
16	,	O
17	traD	B
18	,	O
19	and	O
20	traG	B
21	.	O

1	A	O
2	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O

1	In	O
2	the	O
3	same	O
4	period	O
5	we	O
6	pointed	O
7	out	O
8	an	O
9	increase	O
10	of	O
11	hematocrit	O
12	(	O
13	from	O
14	29	O
15	%	O
16	to	O
17	35	O
18	%)	O
19	and	O
20	of	O
21	the	O
22	Hb	B
23	(	O
24	from	O
25	9	O
26	.	O
27	3	O
28	to	O
29	11	O
30	.	O
31	2	O
32	g	O
33	/	O
34	dl	O
35	).	O

1	The	O
2	P	B
3	-	I
4	wr	I
5	and	O
6	P	B
7	-	I
8	rr	I
9	cDNA	I
10	sequences	I
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O

1	Because	O
2	the	O
3	hcf109	B
4	locus	I
5	was	O
6	mapped	O
7	at	O
8	a	O
9	distance	O
10	<	O
11	0	O
12	.	O
13	1	O
14	centimorgans	O
15	from	O
16	the	O
17	phytochrome	B
18	C	I
19	gene	I
20	,	O
21	its	O
22	molecular	O
23	characterization	O
24	by	O
25	positional	O
26	cloning	O
27	is	O
28	possible	O
29	.	O

1	The	O
2	human	B
3	MSH	I
4	-	I
5	2	I
6	gene	I
7	product	I
8	is	O
9	a	O
10	member	O
11	of	O
12	a	O
13	highly	O
14	conserved	O
15	family	O
16	of	O
17	proteins	O
18	which	O
19	are	O
20	involved	O
21	in	O
22	post	O
23	-	O
24	replication	O
25	mismatch	O
26	repair	O
27	.	O
28	hMSH	B
29	-	I
30	2	I
31	is	O
32	homologous	O
33	to	O
34	Escherichia	O
35	coli	O
36	(	O
37	E	O
38	.	O
39	coli	O
40	)	O
41	MutS	B
42	and	O
43	Sacchromyces	B
44	cerevisiae	I
45	MSH	I
46	-	I
47	1	I
48	and	O
49	MSH	B
50	-	I
51	2	I
52	proteins	I
53	,	O
54	which	O
55	recognise	O
56	heteroduplex	O
57	DNA	O
58	at	O
59	the	O
60	sites	O
61	of	O
62	all	O
63	single	O
64	base	O
65	mismatches	O
66	and	O
67	deletions	O
68	or	O
69	insertions	O
70	up	O
71	to	O
72	4	O
73	base	O
74	pairs	O
75	.	O
76	hMSH	B
77	-	I
78	2	I
79	is	O
80	one	O
81	of	O
82	the	O
83	hereditary	B
84	non	I
85	-	I
86	polyposis	I
87	colorectal	I
88	cancer	I
89	(	I
90	HNPCC	I
91	)	I
92	tumor	I
93	suppressor	I
94	genes	I
95	,	O
96	and	O
97	maps	O
98	to	O
99	human	O
100	chromosome	O
101	2p16	O
102	.	O

1	We	O
2	have	O
3	recently	O
4	shown	O
5	that	O
6	the	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	of	O
12	the	O
13	RAR	B
14	beta	I
15	2	I
16	gene	I
17	in	I
18	mouse	I
19	embryos	I
20	is	O
21	regulated	O
22	at	O
23	the	O
24	translational	O
25	level	O
26	by	O
27	short	O
28	upstream	O
29	open	O
30	reading	O
31	frames	O
32	(	O
33	uORFs	O
34	)	O
35	In	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	Zimmer	O
43	,	O
44	A	O
45	.,	O
46	A	O
47	.	O
48	M	O
49	.	O

1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	B
15	(	O
16	zinc	B
17	finger	I
18	homeodomain	I
19	enhancer	I
20	-	I
21	binding	I
22	protein	I
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	B
32	and	O
33	ZD2	B
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	O
44	.	O

1	The	O
2	structure	O
3	of	O
4	these	O
5	genes	O
6	suggests	O
7	a	O
8	common	O
9	ancestor	O
10	for	O
11	all	O
12	viperid	B
13	PLA2	I
14	genes	I
15	.	O

1	Increased	O
2	PTHRP	B
3	production	O
4	by	O
5	a	O
6	tyrosine	B
7	kinase	I
8	oncogene	I
9	,	O
10	Tpr	B
11	-	I
12	Met	I
13	:	O
14	role	O
15	of	O
16	the	O
17	Ras	B
18	signaling	O
19	pathway	O
20	.	O

1	Subsequent	O
2	to	O
3	their	O
4	secretion	O
5	,	O
6	the	O
7	IGF	B
8	-	I
9	II	I
10	in	O
11	xz97	O
12	and	O
13	G11	O
14	cells	O
15	accumulated	O
16	in	O
17	the	O
18	conditioned	O
19	medium	O
20	mostly	O
21	as	O
22	two	O
23	partially	O
24	processed	O
25	species	O
26	with	O
27	appMr	O
28	,	O
29	of	O
30	17K	O
31	and	O
32	14K	O
33	,	O
34	respectively	O
35	.	O

1	Paradoxically	O
2	,	O
3	coexpression	O
4	of	O
5	the	O
6	transcriptionally	O
7	inactive	O
8	,	O
9	amino	O
10	-	O
11	terminally	O
12	deleted	O
13	IDX	B
14	-	I
15	1	I
16	mutant	I
17	proteins	I
18	,	O
19	either	O
20	with	O
21	the	O
22	wild	B
23	-	I
24	type	I
25	IDX	I
26	-	I
27	1	I
28	or	O
29	with	O
30	themselves	O
31	,	O
32	results	O
33	in	O
34	a	O
35	marked	O
36	enhancement	O
37	of	O
38	transactivation	O
39	of	O
40	the	O
41	transcriptional	O
42	TAAT	B
43	-	I
44	1	I
45	element	I
46	reporter	I
47	.	O

1	All	O
2	patients	O
3	had	O
4	abnormal	O
5	von	B
6	Willebrand	I
7	factor	I
8	(	O
9	vWF	B
10	)	O
11	fragmentation	O
12	as	O
13	reflected	O
14	by	O
15	decreased	O
16	high	O
17	molecular	O
18	weight	O
19	and	O
20	increased	O
21	low	O
22	molecular	O
23	weight	O
24	vWF	B
25	multimers	I
26	in	O
27	the	O
28	circulation	O
29	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	investigate	O
6	whether	O
7	the	O
8	intergenic	O
9	region	O
10	between	O
11	the	O
12	oleosin	B
13	and	O
14	a	O
15	second	O
16	open	O
17	reading	O
18	frame	O
19	(	O
20	ORFII	O
21	)	O
22	in	O
23	Brassica	O
24	napus	O
25	(	O
26	L	O
27	.)	O
28	is	O
29	a	O
30	divergent	O
31	promoter	O
32	,	O
33	and	O
34	also	O
35	to	O
36	characterize	O
37	the	O
38	ORFII	B
39	,	O
40	cDNA	B
41	clones	I
42	homologous	I
43	to	I
44	ORFII	I
45	were	O
46	isolated	O
47	from	O
48	a	O
49	leaf	O
50	cDNA	O
51	library	O
52	.	O

1	The	O
2	ORFII	B
3	gene	I
4	product	I
5	is	O
6	targeted	O
7	to	O
8	the	O
9	chloroplast	O
10	,	O
11	which	O
12	is	O
13	consistent	O
14	with	O
15	previous	O
16	data	O
17	indicating	O
18	the	O
19	presence	O
20	of	O
21	PMSR	B
22	activity	O
23	in	O
24	the	O
25	chloroplast	O
26	.	O

1	Characterization	O
2	of	O
3	LRP	B
4	,	O
5	a	O
6	leucine	B
7	-	I
8	rich	I
9	repeat	I
10	(	I
11	LRR	I
12	)	I
13	protein	I
14	from	I
15	tomato	I
16	plants	I
17	that	O
18	is	O
19	processed	O
20	during	O
21	pathogenesis	O
22	.	O

1	To	O
2	test	O
3	whether	O
4	Sp1	B
5	and	O
6	zif268	B
7	/	O
8	egr	B
9	-	I
10	1	I
11	interact	O
12	with	O
13	this	O
14	motif	O
15	,	O
16	gel	O
17	retardation	O
18	assays	O
19	were	O
20	performed	O
21	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	O
8	was	O
9	to	O
10	analyze	O
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	Stably	O
2	transfected	O
3	human	O
4	kidney	O
5	293	O
6	cells	O
7	expressing	O
8	the	O
9	wild	B
10	type	I
11	rat	I
12	LH	I
13	/	I
14	CG	I
15	receptor	I
16	(	O
17	rLHR	B
18	)	O
19	or	O
20	receptors	O
21	with	O
22	C	O
23	-	O
24	terminal	O
25	tails	O
26	truncated	O
27	at	O
28	residues	O
29	653	O
30	,	O
31	631	O
32	,	O
33	or	O
34	628	O
35	(	O
36	designated	O
37	rLHR	B
38	-	I
39	t653	I
40	,	O
41	rLHR	B
42	-	I
43	t631	I
44	,	O
45	and	O
46	rLHR	B
47	-	I
48	t628	I
49	)	O
50	were	O
51	used	O
52	to	O
53	probe	O
54	the	O
55	importance	O
56	of	O
57	this	O
58	region	O
59	on	O
60	the	O
61	regulation	O
62	of	O
63	hormonal	O
64	responsiveness	O
65	.	O

1	Are	O
2	low	O
3	P300	O
4	amplitudes	O
5	a	O
6	marker	O
7	for	O
8	schizophrenia	O
9	.	O

1	Sleep	O
2	was	O
3	determined	O
4	again	O
5	for	O
6	an	O
7	additional	O
8	3	O
9	days	O
10	and	O
11	6	O
12	hours	O
13	.	O

1	The	O
2	patients	O
3	are	O
4	two	O
5	healthy	O
6	adult	O
7	males	O
8	.	O

1	Chloroplast	B
2	mutator	I
3	(	O
4	chm	B
5	)	O
6	of	O
7	Arabidopsis	O
8	is	O
9	a	O
10	recessive	O
11	nuclear	O
12	mutation	O
13	that	O
14	causes	O
15	green	O
16	and	O
17	white	O
18	variegation	O
19	in	O
20	leaves	O
21	and	O
22	is	O
23	inherited	O
24	in	O
25	a	O
26	non	O
27	-	O
28	Mendelian	O
29	fashion	O
30	.	O

1	Indoor	O
2	concentrations	O
3	were	O
4	only	O
5	weakly	O
6	correlated	O
7	with	O
8	outdoor	O
9	concentrations	O
10	,	O
11	however	O
12	,	O
13	and	O
14	personal	O
15	exposures	O
16	were	O
17	even	O
18	more	O
19	poorly	O
20	correlated	O
21	with	O
22	outdoor	O
23	concentrations	O
24	.	O

1	A	O
2	neuropsychological	O
3	test	O
4	battery	O
5	was	O
6	used	O
7	that	O
8	contained	O
9	the	O
10	Wisconsin	O
11	card	O
12	sorting	O
13	test	O
14	,	O
15	Street	O
16	completion	O
17	test	O
18	,	O
19	Stroop	O
20	test	O
21	,	O
22	a	O
23	dichotic	O
24	memory	O
25	listening	O
26	test	O
27	,	O
28	and	O
29	a	O
30	facial	O
31	recognition	O
32	test	O
33	.	O

1	We	O
2	present	O
3	this	O
4	case	O
5	because	O
6	of	O
7	the	O
8	rarity	O
9	of	O
10	left	O
11	ventricular	O
12	involvement	O
13	associated	O
14	with	O
15	ARVD	O
16	.	O

1	In	O
2	a	O
3	randomized	O
4	single	O
5	-	O
6	blind	O
7	3	O
8	x	O
9	3	O
10	Latin	O
11	-	O
12	square	O
13	study	O
14	with	O
15	corrections	O
16	for	O
17	any	O
18	carryover	O
19	effects	O
20	,	O
21	27	O
22	males	O
23	and	O
24	30	O
25	females	O
26	consumed	O
27	supplements	O
28	containing	O
29	glucose	O
30	or	O
31	resistant	O
32	starch	O
33	(	O
34	RS	O
35	)	O
36	from	O
37	raw	O
38	high	O
39	-	O
40	amylose	O
41	cornstarch	O
42	(	O
43	RS2	O
44	)	O
45	or	O
46	from	O
47	retrograded	O
48	high	O
49	-	O
50	amylose	O
51	cornstarch	O
52	(	O
53	RS3	O
54	).	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	mouse	B
9	Met	I
10	-	I
11	ase	I
12	-	I
13	1	I
14	gene	I
15	also	O
16	shares	O
17	considerable	O
18	regions	O
19	of	O
20	identity	O
21	with	O
22	the	O
23	5	O
24	'	O
25	flanking	O
26	region	O
27	of	O
28	the	O
29	rat	B
30	Met	I
31	-	I
32	ase	I
33	-	I
34	1	I
35	gene	I
36	.	O

1	The	O
2	[	O
3	18F	O
4	]	O
5	FMISO	O
6	TMRR	O
7	is	O
8	a	O
9	simple	O
10	and	O
11	clinically	O
12	useful	O
13	index	O
14	for	O
15	detecting	O
16	tumour	O
17	hypoxia	O
18	in	O
19	NPC	O
20	.	O

1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	reproduced	O
26	,	O
27	laboratory	O
28	setting	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	time	O
6	to	O
7	engraftment	O
8	was	O
9	significantly	O
10	shorter	O
11	in	O
12	the	O
13	amifostine	O
14	arm	O
15	in	O
16	both	O
17	cohorts	O
18	.	O

1	Also	O
2	like	O
3	the	O
4	thrombin	B
5	receptor	I
6	,	O
7	PAR2	B
8	can	O
9	be	O
10	activated	O
11	by	O
12	the	O
13	hexapeptide	O
14	corresponding	O
15	to	O
16	its	O
17	tethered	O
18	ligand	O
19	sequence	O
20	independent	O
21	of	O
22	receptor	O
23	cleavage	O
24	.	O

1	We	O
2	conclude	O
3	that	O
4	CPET	O
5	is	O
6	a	O
7	useful	O
8	investigation	O
9	in	O
10	the	O
11	management	O
12	of	O
13	patients	O
14	with	O
15	cardiopulmonary	O
16	disease	O
17	and	O
18	complements	O
19	the	O
20	various	O
21	other	O
22	investigations	O
23	offered	O
24	by	O
25	a	O
26	pulmonary	O
27	function	O
28	laboratory	O
29	.	O

1	Using	O
2	fluorescence	O
3	in	O
4	situ	O
5	hybridization	O
6	,	O
7	we	O
8	mapped	O
9	the	O
10	chromosome	O
11	-	O
12	17	O
13	breakpoint	O
14	in	O
15	a	O
16	patient	O
17	with	O
18	acampomelic	O
19	CMPD	O
20	and	O
21	sex	O
22	reversal	O
23	,	O
24	who	O
25	carries	O
26	a	O
27	de	O
28	novo	O
29	constitutional	O
30	t	O
31	(	O
32	12	O
33	;	O
34	17	O
35	)	O
36	translocation	O
37	,	O
38	between	O
39	two	O
40	known	O
41	cosmid	O
42	markers	O
43	in	O
44	the	O
45	17q24	O
46	-	O
47	q25	O
48	region	O
49	.	O

1	This	O
2	is	O
3	concluded	O
4	from	O
5	the	O
6	isolation	O
7	of	O
8	cDNAs	O
9	from	O
10	spinach	O
11	(	O
12	Spinacia	O
13	oleracea	O
14	)	O
15	and	O
16	barley	O
17	(	O
18	Hordeum	O
19	vulgare	O
20	cv	O
21	.	O

1	The	O
2	data	O
3	presented	O
4	in	O
5	this	O
6	work	O
7	indicate	O
8	that	O
9	thi1	B
10	may	O
11	also	O
12	be	O
13	involved	O
14	in	O
15	DNA	O
16	damage	O
17	tolerance	O
18	in	O
19	plant	O
20	cells	O
21	.	O

1	In	O
2	the	O
3	rat	B
4	rnu	I
5	allele	I
6	described	O
7	here	O
8	,	O
9	a	O
10	nonsense	O
11	mutation	O
12	in	O
13	exon	O
14	8	O
15	of	O
16	the	O
17	whn	B
18	gene	I
19	was	O
20	identified	O
21	.	O

1	Such	O
2	an	O
3	increase	O
4	in	O
5	the	O
6	steady	O
7	-	O
8	state	O
9	testicular	B
10	TIMP	I
11	-	I
12	2	I
13	mRNA	I
14	level	O
15	apparently	O
16	is	O
17	not	O
18	the	O
19	result	O
20	of	O
21	an	O
22	up	O
23	-	O
24	regulation	O
25	by	O
26	germ	O
27	cells	O
28	because	O
29	germ	O
30	cells	O
31	cocultured	O
32	with	O
33	Sertoli	O
34	cells	O
35	failed	O
36	to	O
37	elicit	O
38	an	O
39	increase	O
40	in	O
41	the	O
42	Sertoli	O
43	cell	O
44	steady	O
45	-	O
46	state	O
47	TIMP	B
48	-	I
49	2	I
50	mRNA	I
51	level	O
52	.	O

1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	In	O
2	the	O
3	SPK	O
4	and	O
5	PTA	O
6	category	O
7	,	O
8	anti	O
9	-	O
10	T	O
11	-	O
12	cell	O
13	therapy	O
14	significantly	O
15	lowered	O
16	the	O
17	risk	O
18	of	O
19	graft	O
20	loss	O
21	.	O

1	We	O
2	have	O
3	identified	O
4	a	O
5	strong	O
6	Tas	B
7	-	I
8	responsive	I
9	element	I
10	,	O
11	designated	O
12	TRE	B
13	(	O
14	GP	B
15	),	O
16	near	O
17	the	O
18	3	O
19	'	O
20	end	O
21	of	O
22	the	O
23	gag	B
24	gene	I
25	and	O
26	preceding	O
27	the	O
28	pol	B
29	gene	I
30	of	O
31	SFV	O
32	-	O
33	1	O
34	.	O

1	Although	O
2	the	O
3	binding	O
4	of	O
5	IE2	B
6	86	I
7	to	O
8	nonphosphorylated	O
9	full	B
10	-	I
11	length	I
12	CREB	I
13	or	O
14	deltaCREB	B
15	is	O
16	minimal	O
17	,	O
18	IE2	B
19	86	I
20	does	O
21	form	O
22	complexes	O
23	with	O
24	p300	B
25	and	O
26	the	O
27	CREB	B
28	-	I
29	binding	I
30	protein	I
31	(	O
32	CBP	B
33	),	O
34	which	O
35	in	O
36	turn	O
37	bind	O
38	to	O
39	CREB	B
40	and	O
41	can	O
42	serve	O
43	as	O
44	adaptor	O
45	proteins	O
46	for	O
47	CREB	B
48	function	O
49	.	O

1	A	O
2	transgenic	O
3	complementation	O
4	assay	O
5	was	O
6	used	O
7	to	O
8	test	O
9	whether	O
10	NIa	B
11	supplied	O
12	in	O
13	trans	O
14	could	O
15	rescue	O
16	amplification	O
17	-	O
18	defective	O
19	viral	O
20	genomes	O
21	encoding	O
22	altered	O
23	NIa	B
24	proteins	I
25	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	B
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	O
20	fos	B
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	The	O
2	rCBF	O
3	and	O
4	vasomotion	O
5	were	O
6	recorded	O
7	by	O
8	laser	O
9	-	O
10	doppler	O
11	fluxmetry	O
12	.	O

1	Although	O
2	basal	O
3	vessels	O
4	may	O
5	constrict	O
6	distal	O
7	parenchymal	O
8	vessels	O
9	tend	O
10	to	O
11	dilate	O
12	after	O
13	SAH	O
14	.	O

1	The	O
2	triple	O
3	combination	O
4	of	O
5	nizatidine	O
6	,	O
7	clarithromycin	O
8	,	O
9	and	O
10	bismuth	O
11	subcitrate	O
12	resulted	O
13	in	O
14	an	O
15	ulcer	O
16	healing	O
17	rate	O
18	of	O
19	98	O
20	%	O
21	and	O
22	an	O
23	H	O
24	.	O
25	pylori	O
26	eradication	O
27	rate	O
28	of	O
29	90	O
30	%.	O

1	Several	O
2	lines	O
3	of	O
4	evidence	O
5	presented	O
6	here	O
7	suggest	O
8	that	O
9	PKC	B
10	-	I
11	zeta	I
12	plays	O
13	a	O
14	role	O
15	in	O
16	alpha	B
17	2	I
18	integrin	I
19	gene	I
20	expression	O
21	.	O

1	Plasma	O
2	thrombomodulin	B
3	:	O
4	a	O
5	marker	O
6	for	O
7	microvascular	O
8	complications	O
9	in	O
10	diabetes	O
11	mellitus	O
12	.	O

1	Update	O
2	:	O
3	diphtheria	O
4	epidemic	O
5	in	O
6	the	O
7	newly	O
8	independent	O
9	states	O
10	of	O
11	the	O
12	former	O
13	USSR	O
14	,	O
15	January	O
16	1995	O
17	-	O
18	March	O
19	1996	O
20	.	O

1	The	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	indicated	O
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	binding	I
20	site	I
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	PRDII	B
27	/	O
28	kappaB	B
29	domain	O
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	O
40	by	O
41	pp60	B
42	(	I
43	v	I
44	-)	I
45	src	I
46	.	O

1	Serine	O
2	528	O
3	is	O
4	phosphorylated	O
5	in	O
6	vivo	O
7	in	O
8	several	O
9	cell	O
10	lines	O
11	,	O
12	and	O
13	substitution	O
14	of	O
15	serine	O
16	528	O
17	to	O
18	alanine	O
19	(	O
20	S528A	O
21	)	O
22	resulted	O
23	in	O
24	an	O
25	increased	O
26	ability	O
27	of	O
28	Myb	B
29	to	O
30	transactivate	O
31	a	O
32	synthetic	O
33	promoter	O
34	containing	O
35	five	O
36	copies	O
37	of	O
38	the	O
39	mim	B
40	-	I
41	1A	I
42	Myb	I
43	-	O
44	responsive	O
45	element	O
46	and	O
47	a	O
48	minimal	O
49	herpes	B
50	tk	I
51	promoter	I
52	.	O

1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	O
8	c	B
9	-	I
10	Myb	I
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	O
36	c	B
37	-	I
38	Myb	I
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	B
15	-	I
16	PAR	I
17	gene	I
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	PIP2	O
2	,	O
3	when	O
4	incorporated	O
5	into	O
6	phosphatidylcholine	O
7	carrier	O
8	vesicles	O
9	,	O
10	binds	O
11	tightly	O
12	to	O
13	the	O
14	guanine	O
15	nucleotide	O
16	-	O
17	depleted	O
18	form	O
19	of	O
20	Cdc42Hs	B
21	and	O
22	weakly	O
23	to	O
24	the	O
25	GDP	O
26	-	O
27	bound	O
28	form	O
29	of	O
30	the	O
31	GTP	B
32	-	I
33	binding	I
34	protein	I
35	but	O
36	does	O
37	not	O
38	bind	O
39	to	O
40	GTP	O
41	-	O
42	bound	O
43	Cdc42Hs	B
44	,	O
45	similar	O
46	to	O
47	what	O
48	was	O
49	observed	O
50	for	O
51	the	O
52	Dbl	B
53	oncoprotein	I
54	.	O

1	Purified	O
2	spleen	O
3	GAP	B
4	accelerated	O
5	hydrolysis	O
6	of	O
7	GTP	O
8	bound	O
9	to	O
10	recombinant	B
11	ARF1	I
12	,	O
13	ARF3	B
14	,	O
15	ARF5	B
16	,	O
17	and	O
18	ARF6	B
19	;	O
20	no	O
21	effect	O
22	of	O
23	NH2	O
24	-	O
25	terminal	O
26	myristoylation	O
27	was	O
28	observed	O
29	.	O

1	Biol	O
2	.	O

1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	B
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	B
22	-	I
23	70	I
24	in	O
25	T	O
26	cells	O
27	.	O

1	Cys	O
2	-	O
3	757	O
4	within	O
5	the	O
6	(	O
7	Fe4S4	O
8	)-	O
9	siroheme	O
10	-	O
11	binding	O
12	domain	O
13	was	O
14	essential	O
15	for	O
16	native	O
17	enzyme	O
18	activity	O
19	.	O

1	Its	O
2	transcription	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	induced	O
9	40	O
10	-	O
11	50	O
12	-	O
13	fold	O
14	in	O
15	response	O
16	to	O
17	oxygen	O
18	or	O
19	heme	O
20	deficiency	O
21	,	O
22	in	O
23	part	O
24	through	O
25	relief	O
26	of	O
27	repression	O
28	exerted	O
29	by	O
30	Rox1p	B
31	and	O
32	in	O
33	part	O
34	by	O
35	activation	O
36	mediated	O
37	by	O
38	an	O
39	upstream	O
40	activation	O
41	sequence	O
42	(	O
43	UAS	O
44	).	O

1	Altogether	O
2	,	O
3	our	O
4	results	O
5	indicate	O
6	that	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	Cut	B
12	proteins	I
13	is	O
14	modulated	O
15	by	O
16	PKC	B
17	.	O

1	Lck	B
2	has	O
3	been	O
4	postulated	O
5	to	O
6	dimerize	O
7	through	O
8	the	O
9	SH2	B
10	and	O
11	SH3	B
12	domains	I
13	.	O

1	Furthermore	O
2	,	O
3	freezing	O
4	in	O
5	the	O
6	presence	O
7	of	O
8	bovine	B
9	lactalbumin	I
10	resulted	O
11	in	O
12	a	O
13	good	O
14	maintenance	O
15	of	O
16	the	O
17	cellular	O
18	viability	O
19	and	O
20	of	O
21	the	O
22	CCCD	O
23	heterogeneity	O
24	in	O
25	respect	O
26	to	O
27	fresh	O
28	cells	O
29	.	O

1	Myelomatous	O
2	pleural	O
3	effusion	O
4	as	O
5	presentation	O
6	form	O
7	of	O
8	multiple	O
9	myeloma	O

1	Five	O
2	-	O
3	year	O
4	survivals	O
5	amounted	O
6	to	O
7	100	O
8	%,	O
9	86	O
10	.	O
11	2	O
12	%,	O
13	59	O
14	.	O
15	4	O
16	%,	O
17	29	O
18	.	O
19	8	O
20	%,	O
21	and	O
22	20	O
23	%	O
24	for	O
25	stages	O
26	I	O
27	,	O
28	II	O
29	,	O
30	III	O
31	,	O
32	IVA	O
33	and	O
34	IVB	O
35	respectively	O
36	.	O

1	The	O
2	presence	O
3	of	O
4	unidentified	O
5	macroscopic	O
6	or	O
7	microscopic	O
8	clusters	O
9	of	O
10	neoplastic	O
11	cells	O
12	,	O
13	lying	O
14	around	O
15	,	O
16	more	O
17	or	O
18	less	O
19	close	O
20	to	O
21	,	O
22	the	O
23	line	O
24	of	O
25	insertion	O
26	of	O
27	lesion	O
28	,	O
29	could	O
30	render	O
31	any	O
32	attempt	O
33	to	O
34	gain	O
35	a	O
36	"	O
37	radical	O
38	"	O
39	excision	O
40	useless	O
41	.	O

1	The	O
2	partial	O
3	categories	O
4	of	O
5	the	O
6	SIP	O
7	that	O
8	were	O
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	,	O
5	using	O
6	the	O
7	Ltp4	B
8	-	O
9	specific	O
10	probe	O
11	,	O
12	indicated	O
13	that	O
14	Xanthomonas	O
15	campestris	O
16	pv	O
17	.	O
18	translucens	O
19	induced	O
20	an	O
21	increase	O
22	over	O
23	basal	O
24	levels	O
25	of	O
26	Ltp4	B
27	mRNA	I
28	,	O
29	while	O
30	Pseudomonas	O
31	syringae	O
32	pv	O
33	.	O
34	japonica	O
35	caused	O
36	a	O
37	decrease	O
38	.	O

1	Targeted	O
2	disruption	O
3	of	O
4	the	O
5	OGG1	B
6	gene	I
7	in	O
8	yeast	O
9	revealed	O
10	a	O
11	second	O
12	OG	B
13	glycosylase	I
14	/	I
15	lyase	I
16	protein	I
17	,	O
18	tentatively	O
19	named	O
20	Ogg2	B
21	,	O
22	which	O
23	differs	O
24	from	O
25	Ogg1	B
26	in	O
27	that	O
28	it	O
29	preferentially	O
30	acts	O
31	on	O
32	OG	O
33	:	O
34	G	O
35	.	O

1	Furthermore	O
2	,	O
3	the	O
4	use	O
5	of	O
6	zero	O
7	-	O
8	loss	O
9	filtering	O
10	in	O
11	combination	O
12	with	O
13	exit	O
14	wavefront	O
15	reconstruction	O
16	is	O
17	considerably	O
18	more	O
19	effective	O
20	at	O
21	removing	O
22	the	O
23	effects	O
24	of	O
25	multiple	O
26	elastic	O
27	and	O
28	inelastic	O
29	scattering	O
30	and	O
31	microscope	O
32	objective	O
33	lens	O
34	aberrations	O
35	than	O
36	either	O
37	technique	O
38	by	O
39	itself	O
40	.	O

1	Transcripts	O
2	for	O
3	both	O
4	ODV	B
5	-	I
6	E18	I
7	and	O
8	ODV	B
9	-	I
10	EC27	I
11	initiate	O
12	from	O
13	conserved	O
14	TAAG	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O

1	In	O
2	order	O
3	to	O
4	determine	O
5	which	O
6	sequences	O
7	in	O
8	the	O
9	GATA	B
10	-	I
11	1	I
12	promoter	I
13	are	O
14	crucial	O
15	for	O
16	activation	O
17	by	O
18	the	O
19	ME26	B
20	viral	I
21	protein	I
22	,	O
23	we	O
24	made	O
25	deletions	O
26	of	O
27	the	O
28	promoter	O
29	,	O
30	cloned	O
31	them	O
32	into	O
33	a	O
34	luciferase	B
35	expression	O
36	vector	O
37	and	O
38	tested	O
39	their	O
40	activity	O
41	in	O
42	mouse	O
43	fibroblasts	O
44	,	O
45	which	O
46	do	O
47	not	O
48	express	O
49	GATA	B
50	-	I
51	1	I
52	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	O
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	B
24	TR2	I
25	receptor	I
26	.	O

1	Genomic	O
2	DNA	O
3	hybridization	O
4	suggests	O
5	that	O
6	SpSHR2	B
7	is	O
8	a	O
9	single	O
10	-	O
11	copy	O
12	gene	O
13	in	O
14	the	O
15	S	O
16	.	O
17	purpuratus	O
18	genome	O
19	.	O

1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O

1	Isolation	O
2	and	O
3	identification	O
4	of	O
5	genes	O
6	activating	O
7	UAS2	B
8	-	I
9	dependent	I
10	ADH2	I
11	expression	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	A	O
6	64	O
7	-	O
8	year	O
9	-	O
10	old	O
11	woman	O
12	with	O
13	confirmed	O
14	AV	O
15	nodal	O
16	reentrant	O
17	tachycardia	O
18	underwent	O
19	a	O
20	successful	O
21	"	O
22	slow	O
23	pathway	O
24	"	O
25	AV	O
26	modification	O
27	with	O
28	a	O
29	single	O
30	radiofrequency	O
31	application	O
32	.	O

1	Patients	O
2	with	O
3	low	O
4	probability	O
5	of	O
6	having	O
7	aluminum	O
8	overload	O
9	(	O
10	serum	O
11	iron	O
12	levels	O
13	<	O
14	40	O
15	micrograms	O
16	/	O
17	L	O
18	and	O
19	DAI	O
20	<	O
21	150	O
22	micrograms	O
23	/	O
24	L	O
25	)	O
26	had	O
27	significantly	O
28	higher	O
29	values	O
30	of	O
31	serum	O
32	iron	O
33	,	O
34	iron	O
35	transferrin	B
36	saturation	O
37	,	O
38	and	O
39	serum	B
40	ferritin	I
41	levels	O
42	compared	O
43	with	O
44	those	O
45	patients	O
46	with	O
47	a	O
48	high	O
49	probability	O
50	of	O
51	having	O
52	aluminum	O
53	overload	O
54	(	O
55	serum	O
56	aluminum	O
57	levels	O
58	>	O
59	40	O
60	micrograms	O
61	/	O
62	L	O
63	and	O
64	DAI	O
65	>	O
66	150	O
67	micrograms	O
68	/	O
69	L	O
70	).	O

1	Although	O
2	the	O
3	RAD23	B
4	equivalents	O
5	are	O
6	well	O
7	conserved	O
8	during	O
9	evolution	O
10	,	O
11	the	O
12	mammalian	O
13	genes	O
14	did	O
15	not	O
16	express	O
17	the	O
18	UV	O
19	-	O
20	inducible	O
21	phenotype	O
22	of	O
23	their	O
24	yeast	O
25	counterpart	O
26	.	O

1	Ha	B
2	-	I
3	RasV12	I
4	and	O
5	activated	O
6	proteins	O
7	in	O
8	both	O
9	the	O
10	extra	B
11	-	I
12	cellular	I
13	regulated	I
14	kinase	I
15	(	O
16	ERK	B
17	)	O
18	and	O
19	the	O
20	stress	B
21	-	I
22	activated	I
23	protein	I
24	kinase	I
25	(	O
26	SAPK	B
27	)	O
28	or	O
29	Jun	B
30	N	I
31	-	I
32	terminal	I
33	kinase	I
34	(	O
35	JNK	B
36	)	O
37	cascades	O
38	independently	O
39	stimulated	O
40	PEA3	B
41	-	O
42	mediated	O
43	gene	O
44	expression	O
45	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	reverse	O
5	transcribed	O
6	,	O
7	amplified	O
8	cDNA	O
9	generated	O
10	from	O
11	total	O
12	RNA	O
13	isolated	O
14	from	O
15	transfected	O
16	cells	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	abnormally	O
22	spliced	O
23	products	O
24	containing	O
25	13	O
26	and	O
27	78	O
28	additional	O
29	bases	O
30	as	O
31	well	O
32	as	O
33	the	O
34	accumulation	O
35	of	O
36	unspliced	O
37	mRNA	O
38	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	O
26	alpha	O
27	-	O
28	helix	O
29	(	O
30	L	O
31	-	O
32	61	O
33	to	O
34	F	O
35	-	O
36	97	O
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	B
49	.	O

1	A	O
2	1	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	HindIII	B
8	genomic	O
9	fragment	O
10	carrying	O
11	the	O
12	vspA	B
13	gene	O
14	from	O
15	M	O
16	.	O
17	bovis	O
18	PG45	O
19	was	O
20	cloned	O
21	and	O
22	sequenced	O
23	.	O

1	Carbon	O
2	catabolite	O
3	repression	O
4	of	O
5	the	O
6	gnt	B
7	operon	I
8	of	I
9	Bacillus	I
10	subtilis	I
11	is	O
12	mediated	O
13	by	O
14	the	O
15	catabolite	O
16	control	O
17	protein	O
18	CcpA	B
19	and	O
20	by	O
21	HPr	B
22	,	O
23	a	O
24	phosphocarrier	O
25	protein	O
26	of	O
27	the	O
28	phosphotransferase	O
29	system	O
30	.	O

1	Melatonin	O
2	and	O
3	seasonality	O
4	:	O
5	filling	O
6	the	O
7	gap	O
8	.	O

1	A	O
2	subsequent	O
3	screen	O
4	for	O
5	the	O
6	loss	O
7	of	O
8	the	O
9	positively	O
10	selectable	O
11	target	O
12	locus	O
13	marker	O
14	detects	O
15	the	O
16	desired	O
17	replacement	O
18	at	O
19	modest	O
20	frequency	O
21	(>	O
22	2	O
23	%).	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	another	O
6	cellular	O
7	protein	O
8	linked	O
9	to	O
10	BCR	B
11	/	O
12	ABL	B
13	through	O
14	the	O
15	CRKL	B
16	-	O
17	SH2	B
18	domain	O
19	is	O
20	p130	B
21	(	O
22	CAS	B
23	).	O
24	p130	B
25	(	O
26	CAS	B
27	)	O
28	was	O
29	found	O
30	to	O
31	be	O
32	tyrosine	O
33	phosphorylated	O
34	and	O
35	associated	O
36	with	O
37	CRKL	B
38	in	O
39	BCR	B
40	/	O
41	ABL	B
42	expressing	O
43	cell	O
44	lines	O
45	and	O
46	in	O
47	samples	O
48	obtained	O
49	from	O
50	CML	O
51	and	O
52	ALL	O
53	patients	O
54	,	O
55	but	O
56	not	O
57	in	O
58	samples	O
59	from	O
60	controls	O
61	.	O

1	There	O
2	are	O
3	four	O
4	polyglutamine	O
5	motifs	O
6	interspersed	O
7	with	O
8	histidine	O
9	-	O
10	rich	O
11	regions	O
12	.	O

1	The	O
2	effects	O
3	of	O
4	procedural	O
5	variations	O
6	on	O
7	lateralized	O
8	Stroop	O
9	effects	O
10	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O

1	PCNA	B
2	mRNA	I
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	yellow	O
11	crescent	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	ascidian	O
18	eggs	O
19	and	O
20	embryos	O
21	.	O

1	A	O
2	1	O
3	.	O
4	8	O
5	-	O
6	kb	O
7	cDNA	O
8	clone	O
9	(	O
10	designed	O
11	hKID	B
12	,	O
13	gene	B
14	symbol	I
15	AQP2L	I
16	)	O
17	with	O
18	homology	O
19	to	O
20	the	O
21	aquaporins	B
22	was	O
23	isolated	O
24	from	O
25	a	O
26	human	O
27	kidney	O
28	cDNA	O
29	library	O
30	.	O

1	PCR	O
2	/	O
3	Southern	O
4	blot	O
5	analysis	O
6	of	O
7	human	O
8	kidney	O
9	cDNA	O
10	using	O
11	primers	O
12	flanking	O
13	the	O
14	hKID	B
15	coding	I
16	sequence	I
17	revealed	O
18	expression	O
19	of	O
20	a	O
21	full	O
22	-	O
23	length	O
24	mRNA	O
25	and	O
26	short	O
27	transcripts	O
28	with	O
29	partial	O
30	exon	O
31	1	O
32	and	O
33	partial	O
34	exon	O
35	4	O
36	deletions	O
37	.	O

1	The	O
2	high	O
3	sequence	O
4	homology	O
5	,	O
6	similar	O
7	genomic	O
8	structure	O
9	,	O
10	and	O
11	identical	O
12	chromosomal	O
13	loci	O
14	of	O
15	hKID	B
16	,	O
17	MIP	B
18	,	O
19	and	O
20	AQP	B
21	-	I
22	2	I
23	suggest	O
24	a	O
25	MIP	B
26	family	I
27	gene	I
28	cluster	I
29	at	O
30	chromosome	O
31	locus	O
32	12q13	O
33	.	O

1	The	O
2	third	O
3	ORF	O
4	generates	O
5	a	O
6	transcript	O
7	of	O
8	1	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	382	O
18	residues	O
19	including	O
20	a	O
21	perfect	O
22	match	O
23	to	O
24	the	O
25	consensus	O
26	sequence	O
27	of	O
28	a	O
29	C2H2	O
30	zinc	O
31	finger	O
32	domain	O
33	;	O
34	it	O
35	shares	O
36	a	O
37	strong	O
38	homology	O
39	with	O
40	yeast	B
41	Mig1p	I
42	and	O
43	Cre	B
44	-	I
45	A	I
46	from	I
47	Aspergillus	I
48	,	I
49	Emericella	I
50	and	I
51	E	I
52	.	I
53	coli	I
54	.	O

1	Adding	O
2	phytase	B
3	and	O
4	nP	O
5	improved	O
6	the	O
7	orderliness	O
8	of	O
9	development	O
10	,	O
11	mineralization	O
12	and	O
13	arrangement	O
14	of	O
15	cartilage	O
16	and	O
17	bone	O
18	cells	O
19	,	O
20	and	O
21	alleviated	O
22	the	O
23	effects	O
24	of	O
25	P	O
26	deficiency	O
27	on	O
28	the	O
29	histological	O
30	and	O
31	gross	O
32	structure	O
33	of	O
34	the	O
35	tibias	O
36	.	O

1	The	O
2	importance	O
3	of	O
4	temporal	O
5	factors	O
6	on	O
7	the	O
8	presence	O
9	and	O
10	severity	O
11	of	O
12	ethanol	O
13	withdrawal	O
14	signs	O
15	in	O
16	the	O
17	rat	O
18	was	O
19	quantified	O
20	using	O
21	rating	O
22	scale	O
23	,	O
24	tremor	O
25	,	O
26	and	O
27	acoustic	O
28	startle	O
29	paradigms	O
30	.	O

1	Data	O
2	supported	O
3	the	O
4	brevity	O
5	of	O
6	the	O
7	WISC	O
8	-	O
9	III	O
10	short	O
11	form	O
12	and	O
13	the	O
14	criterion	O
15	-	O
16	related	O
17	validity	O
18	of	O
19	both	O
20	the	O
21	K	O
22	-	O
23	FAST	O
24	and	O
25	and	O
26	Kaufman	O
27	Short	O
28	Neuropsychological	O
29	Assessment	O
30	Procedure	O
31	(	O
32	K	O
33	-	O
34	SNAP	O
35	).	O

1	Quantitative	O
2	analysis	O
3	of	O
4	plasmid	O
5	loss	O
6	rates	O
7	in	O
8	cdc28	B
9	-	I
10	1N	I
11	strains	O
12	carrying	O
13	plasmids	O
14	with	O
15	multiple	O
16	replication	O
17	origins	O
18	suggests	O
19	that	O
20	a	O
21	defect	O
22	in	O
23	initiating	O
24	DNA	O
25	replication	O
26	probably	O
27	causes	O
28	this	O
29	plasmid	O
30	loss	O
31	phenotype	O
32	.	O

1	Thus	O
2	,	O
3	the	O
4	multidomained	O
5	ROK	B
6	alpha	I
7	appears	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	reorganization	O
13	of	O
14	the	O
15	cytoskeleton	O
16	,	O
17	with	O
18	the	O
19	N	O
20	and	O
21	C	O
22	termini	O
23	acting	O
24	as	O
25	positive	O
26	and	O
27	negative	O
28	regulators	O
29	,	O
30	respectively	O
31	,	O
32	of	O
33	the	O
34	kinase	O
35	domain	O
36	whose	O
37	activity	O
38	is	O
39	crucial	O
40	for	O
41	formation	O
42	of	O
43	stress	O
44	fibers	O
45	and	O
46	focal	O
47	adhesion	O
48	complexes	O
49	.	O

1	These	O
2	findings	O
3	and	O
4	the	O
5	differential	O
6	tissue	O
7	distribution	O
8	of	O
9	p54	B
10	suggest	O
11	that	O
12	this	O
13	novel	O
14	SR	B
15	protein	I
16	may	O
17	participate	O
18	in	O
19	regulation	O
20	of	O
21	alternative	O
22	splicing	O
23	in	O
24	a	O
25	tissue	O
26	-	O
27	and	O
28	substrate	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	The	O
2	elevation	O
3	of	O
4	cyclic	O
5	AMP	O
6	(	O
7	cAMP	O
8	)	O
9	levels	O
10	in	O
11	the	O
12	cell	O
13	downregulates	O
14	the	O
15	activity	O
16	of	O
17	the	O
18	Raf	B
19	-	I
20	1	I
21	kinase	I
22	.	O

1	An	O
2	interaction	O
3	screen	O
4	with	O
5	the	O
6	repression	O
7	domain	O
8	of	O
9	the	O
10	orphan	B
11	receptor	I
12	RevErb	I
13	identified	O
14	N	B
15	-	I
16	CoR	I
17	,	O
18	the	O
19	corepressor	O
20	for	O
21	thyroid	B
22	hormone	I
23	receptor	I
24	(	O
25	TR	B
26	)	O
27	and	O
28	retinoic	B
29	acid	I
30	receptor	I
31	(	O
32	RAR	B
33	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	B
8	kinase	I
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	B
23	-	I
24	2	I
25	.	O

1	Our	O
2	analysis	O
3	suggests	O
4	that	O
5	Upf1p	B
6	is	O
7	a	O
8	multifunctional	O
9	protein	O
10	with	O
11	separable	O
12	activities	O
13	that	O
14	can	O
15	affect	O
16	mRNA	O
17	turnover	O
18	and	O
19	nonsense	O
20	suppression	O
21	.	O

1	Identification	O
2	of	O
3	Ste4	B
4	as	O
5	a	O
6	potential	O
7	regulator	O
8	of	O
9	Byr2	B
10	in	O
11	the	O
12	sexual	O
13	response	O
14	pathway	O
15	of	O
16	Schizosaccharomyces	O
17	pombe	O
18	.	O

1	Two	O
2	closely	O
3	related	O
4	variants	O
5	of	O
6	Stat5	B
7	,	O
8	Stat5a	B
9	and	O
10	Stat5b	B
11	,	O
12	are	O
13	encoded	O
14	by	O
15	distinct	O
16	genes	O
17	.	O

1	Mutations	O
2	in	O
3	three	O
4	loci	O
5	(	O
6	SIC1	B
7	,	O
8	SWI5	B
9	,	O
10	and	O
11	RIC3	B
12	)	O
13	were	O
14	identified	O
15	.	O

1	The	O
2	serine	B
3	/	I
4	threonine	I
5	kinase	I
6	Raf	I
7	-	I
8	1	I
9	functions	O
10	downstream	O
11	of	O
12	Rats	B
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	transmits	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O

1	Platelet	B
2	-	I
3	derived	I
4	growth	I
5	factor	I
6	-	O
7	dependent	O
8	activation	O
9	of	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	is	O
15	regulated	O
16	by	O
17	receptor	O
18	binding	O
19	of	O
20	SH2	B
21	-	I
22	domain	I
23	-	I
24	containing	I
25	proteins	I
26	which	O
27	influence	O
28	Ras	B
29	activity	O
30	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	B
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	B
12	promoter	I
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	I
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	B
26	E1A	I
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	B
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	The	O
2	retinoid	B
3	Z	I
4	receptor	I
5	beta	I
6	(	O
7	RZR	B
8	beta	I
9	),	O
10	an	O
11	orphan	O
12	receptor	O
13	,	O
14	is	O
15	a	O
16	member	O
17	of	O
18	the	O
19	retinoic	B
20	acid	I
21	receptor	I
22	(	O
23	RAR	B
24	)/	O
25	thyroid	B
26	hormone	I
27	receptor	I
28	(	O
29	TR	B
30	)	O
31	subfamily	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O

1	DNA	B
2	-	I
3	dependent	I
4	protein	I
5	kinase	I
6	(	O
7	DNA	B
8	-	I
9	PK	I
10	)	O
11	consists	O
12	of	O
13	a	O
14	heterodimeric	O
15	protein	O
16	(	O
17	Ku	B
18	)	O
19	and	O
20	a	O
21	large	O
22	catalytic	O
23	subunit	O
24	(	O
25	DNA	B
26	-	I
27	PKcs	I
28	).	O

1	Almost	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	DXS6673E	B
15	gene	I
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	tags	O
21	(	O
22	ESTs	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	DXS6673E	B
33	gene	I
34	and	O
35	a	O
36	third	O
37	EST	O
38	.	O

1	Sequencing	O
2	of	O
3	the	O
4	16p	O
5	11	O
6	.	O
7	1	O
8	/	O
9	Xq28	O
10	duplication	O
11	breakpoints	O
12	has	O
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	repetitive	O
18	immunoglobulin	B
19	-	I
20	like	I
21	CAGGG	I
22	pentamer	I
23	sequences	I
24	at	O
25	or	O
26	near	O
27	the	O
28	paralogy	O
29	boundaries	O
30	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	multivariate	O
6	analysis	O
7	considering	O
8	age	O
9	,	O
10	gender	O
11	,	O
12	and	O
13	a	O
14	previous	O
15	history	O
16	of	O
17	cardiovascular	O
18	diseases	O
19	,	O
20	female	O
21	gender	O
22	was	O
23	not	O
24	independently	O
25	associated	O
26	with	O
27	death	O
28	.	O

1	Moreover	O
2	,	O
3	following	O
4	a	O
5	single	O
6	intravenous	O
7	injection	O
8	of	O
9	the	O
10	bicistronic	O
11	vector	O
12	complexed	O
13	to	O
14	cationic	O
15	liposomes	O
16	into	O
17	recipient	O
18	mice	O
19	,	O
20	delivery	O
21	of	O
22	MDR1	B
23	and	O
24	GC	B
25	cDNAs	I
26	was	O
27	achieved	O
28	in	O
29	all	O
30	the	O
31	organs	O
32	we	O
33	tested	O
34	.	O

1	The	O
2	limits	O
3	of	O
4	agreement	O
5	between	O
6	DBS	O
7	and	O
8	TOF	O
9	responses	O
10	were	O
11	so	O
12	wide	O
13	that	O
14	they	O
15	cannot	O
16	be	O
17	used	O
18	interchangeably	O
19	.	O

1	The	O
2	harpin	B
3	-	O
4	encoding	O
5	hrpZ	B
6	gene	I
7	is	O
8	located	O
9	in	O
10	an	O
11	operon	O
12	that	O
13	also	O
14	encodes	O
15	Hrp	B
16	secretion	I
17	pathway	I
18	components	I
19	and	O
20	is	O
21	part	O
22	of	O
23	the	O
24	functional	O
25	cluster	O
26	of	O
27	hrp	B
28	genes	I
29	carried	O
30	on	O
31	cosmid	O
32	pHIR11	O
33	that	O
34	enables	O
35	saprophytic	O
36	bacteria	O
37	like	O
38	Escherichia	O
39	coli	O
40	and	O
41	Pseudomonas	O
42	fluorescens	O
43	to	O
44	elicit	O
45	the	O
46	HR	O
47	in	O
48	tobacco	O
49	leaves	O
50	.	O

1	Despite	O
2	the	O
3	presence	O
4	of	O
5	one	O
6	additional	O
7	ribonucleotide	B
8	reductase	I
9	,	O
10	the	O
11	nrdAB	B
12	-	I
13	encoded	I
14	enzyme	I
15	is	O
16	essential	O
17	to	O
18	the	O
19	aerobic	O
20	growth	O
21	of	O
22	the	O
23	cell	O
24	because	O
25	nrdAB	B
26	-	I
27	defective	I
28	mutants	I
29	of	O
30	both	O
31	species	O
32	are	O
33	not	O
34	viable	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	oxygen	O
40	.	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	Motivational	O
2	factors	O
3	focusing	O
4	on	O
5	attitudes	O
6	,	O
7	perceived	O
8	susceptibility	O
9	to	O
10	pregnancy	O
11	,	O
12	and	O
13	normative	O
14	factors	O
15	were	O
16	also	O
17	relevant	O
18	.	O

1	High	O
2	-	O
3	resolution	O
4	structure	O
5	of	O
6	the	O
7	diphtheria	B
8	toxin	I
9	repressor	I
10	complexed	O
11	with	O
12	cobalt	O
13	and	O
14	manganese	O
15	reveals	O
16	an	O
17	SH3	B
18	-	I
19	like	I
20	third	O
21	domain	O
22	and	O
23	suggests	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	phosphate	O
29	as	O
30	co	O
31	-	O
32	corepressor	O
33	.	O

1	Titration	O
2	of	O
3	the	O
4	human	O
5	and	O
6	porcine	O
7	proteins	O
8	with	O
9	2	O
10	-	O
11	nitro	O
12	-	O
13	5	O
14	-	O
15	thiosulfabenzoate	O
16	indicates	O
17	that	O
18	membrane	B
19	dipeptidase	I
20	additionally	O
21	possesses	O
22	two	O
23	intrachain	O
24	disulfide	O
25	bonds	O
26	.	O

1	FEV1	O
2	did	O
3	not	O
4	fall	O
5	significantly	O
6	in	O
7	patients	O
8	without	O
9	acute	O
10	or	O
11	chronic	O
12	GVHD	O
13	and	O
14	recovered	O
15	earlier	O
16	than	O
17	in	O
18	patients	O
19	without	O
20	posttransplant	O
21	pulmonary	O
22	infection	O
23	.	O

1	Administration	O
2	of	O
3	adrenaline	O
4	resulted	O
5	in	O
6	a	O
7	large	O
8	overestimation	O
9	of	O
10	the	O
11	SaO2	O
12	in	O
13	6	O
14	of	O
15	the	O
16	7	O
17	measurements	O
18	.	O

1	Therapy	O
2	with	O
3	dietary	O
4	modification	O
5	and	O
6	triglyceride	O
7	lowering	O
8	drugs	O
9	resulted	O
10	in	O
11	resolution	O
12	of	O
13	symptoms	O
14	and	O
15	parotid	O
16	swelling	O
17	in	O
18	one	O
19	patient	O
20	.	O

1	Chernoff	O
2	,	O
3	submitted	O
4	for	O
5	publication	O
6	).	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	protein	O
7	kinase	O
8	,	O
9	termed	O
10	hematopoietic	B
11	progenitor	I
12	kinase	I
13	1	I
14	(	O
15	HPK1	B
16	),	O
17	that	O
18	is	O
19	expressed	O
20	predominantly	O
21	in	O
22	hematopoietic	O
23	cells	O
24	,	O
25	including	O
26	early	O
27	progenitor	O
28	cells	O
29	.	O

1	Human	O
2	ESP1	B
3	/	O
4	CRP2	B
5	protein	O
6	has	O
7	two	O
8	LIM	B
9	domains	O
10	,	O
11	and	O
12	each	O
13	shares	O
14	35	O
15	.	O
16	1	O
17	%	O
18	and	O
19	77	O
20	or	O
21	79	O
22	%	O
23	identical	O
24	residues	O
25	with	O
26	human	B
27	cysteine	I
28	-	I
29	rich	I
30	protein	I
31	(	O
32	CRP	B
33	)	O
34	and	O
35	rat	B
36	CRIP	I
37	,	O
38	respectively	O
39	.	O

1	The	O
2	fragments	O
3	are	O
4	separated	O
5	and	O
6	directly	O
7	sized	O
8	by	O
9	agarose	O
10	gel	O
11	electrophoresis	O
12	.	O

1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O

1	Linkage	O
2	studies	O
3	have	O
4	shown	O
5	locus	O
6	heterogeneity	O
7	with	O
8	one	O
9	TSC	B
10	gene	I
11	mapped	O
12	to	O
13	chromosome	O
14	9q34	O
15	and	O
16	a	O
17	second	O
18	to	O
19	16p13	O
20	.	O
21	3	O
22	.	O

1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	B
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	3213	O
7	bp	O
8	BamHI	B
9	-	O
10	ClaI	B
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O

1	The	O
2	initial	O
3	inpatient	O
4	experience	O
5	for	O
6	individuals	O
7	with	O
8	HIV	O
9	-	O
10	related	O
11	TB	O
12	may	O
13	be	O
14	pivotal	O
15	to	O
16	the	O
17	acceptance	O
18	of	O
19	and	O
20	participation	O
21	in	O
22	ongoing	O
23	TB	O
24	care	O
25	.	O

1	Tristetraprolin	B
2	(	O
3	TTP	B
4	)	O
5	is	O
6	the	O
7	prototype	O
8	of	O
9	a	O
10	group	O
11	of	O
12	potential	O
13	transcription	O
14	factors	O
15	that	O
16	contain	O
17	two	O
18	or	O
19	more	O
20	unusual	O
21	CCCH	O
22	zinc	O
23	fingers	O
24	.	O

1	This	O
2	element	O
3	,	O
4	termed	O
5	CREsp	O
6	-	O
7	a	O
8	(	O
9	TGACCTCA	O
10	),	O
11	differs	O
12	by	O
13	one	O
14	nucleotide	O
15	from	O
16	a	O
17	palindromic	O
18	CRE	O
19	(	O
20	CREpal	O
21	,	O
22	TGACGTCA	O
23	),	O
24	which	O
25	is	O
26	known	O
27	to	O
28	bind	O
29	CREB	B
30	as	O
31	a	O
32	homodimer	O
33	.	O

1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	intronless	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	B
15	G	I
16	alpha	I
17	q	I
18	cDNA	I
19	.	O

1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	structure	O
7	of	O
8	the	O
9	156	B
10	-	I
11	kb	I
12	human	I
13	gene	I
14	NFKB1	I
15	,	O
16	which	O
17	encodes	O
18	the	O
19	p105	B
20	and	O
21	p50	B
22	proteins	I
23	of	O
24	transcription	O
25	factors	O
26	NF	B
27	-	I
28	kappa	I
29	B	I
30	and	O
31	I	B
32	kappa	I
33	B	I
34	-	I
35	gamma	I
36	:	O
37	implications	O
38	for	O
39	NF	B
40	-	I
41	kappa	I
42	B	I
43	-	O
44	mediated	O
45	signal	O
46	transduction	O
47	.	O

1	An	O
2	inverted	O
3	Alu	B
4	repeat	O
5	element	O
6	,	O
7	flanked	O
8	by	O
9	nonamer	O
10	direct	O
11	repeats	O
12	,	O
13	was	O
14	identified	O
15	within	O
16	the	O
17	region	O
18	-	O
19	913	O
20	/-	O
21	620	O
22	,	O
23	relative	O
24	to	O
25	the	O
26	cap	O
27	site	O
28	.	O

1	The	O
2	ewes	O
3	were	O
4	returned	O
5	to	O
6	normoxia	O
7	,	O
8	and	O
9	monitoring	O
10	was	O
11	continued	O
12	for	O
13	1	O
14	h	O
15	.	O

1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	of	O
8	the	O
9	RPO1	B
10	polypeptides	I
11	of	I
12	IIV6	I
13	,	I
14	LCDV	I
15	,	I
16	and	I
17	MCV	I
18	-	I
19	1	I
20	with	O
21	the	O
22	corresponding	O
23	prokaryotic	O
24	,	O
25	eukaryotic	O
26	,	O
27	and	O
28	viral	O
29	proteins	O
30	revealed	O
31	differences	O
32	in	O
33	amino	O
34	acid	O
35	similarity	O
36	and	O
37	phylogenetic	O
38	relationships	O
39	.	O

1	The	O
2	RPO1	B
3	of	O
4	LCDV	O
5	shows	O
6	the	O
7	highest	O
8	similarity	O
9	to	O
10	the	O
11	RPO1	B
12	of	O
13	IIV6	O
14	and	O
15	significant	O
16	lower	O
17	similarity	O
18	to	O
19	the	O
20	eukaryotic	B
21	polymerases	I
22	II	I
23	and	I
24	III	I
25	as	O
26	well	O
27	as	O
28	to	O
29	the	O
30	archaebacteral	O
31	subunit	O
32	.	O

1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O

1	We	O
2	performed	O
3	dipole	O
4	estimation	O
5	of	O
6	spikes	O
7	and	O
8	SEP	O
9	components	O
10	in	O
11	identical	O
12	patients	O
13	.	O

1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O

1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	comparison	O
6	of	O
7	the	O
8	hCHLR	B
9	gene	I
10	sequences	I
11	with	O
12	available	O
13	databases	O
14	indicates	O
15	that	O
16	a	O
17	large	O
18	portion	O
19	of	O
20	these	O
21	genes	O
22	,	O
23	including	O
24	exons	O
25	encoding	O
26	two	O
27	functional	O
28	domains	O
29	of	O
30	the	O
31	carboxyl	O
32	-	O
33	terminal	O
34	region	O
35	of	O
36	these	O
37	proteins	O
38	,	O
39	has	O
40	been	O
41	duplicated	O
42	as	O
43	part	O
44	of	O
45	a	O
46	larger	O
47	human	O
48	telomeric	O
49	repeat	O
50	sequence	O
51	found	O
52	on	O
53	many	O
54	human	O
55	chromosomes	O
56	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	LIM	B
7	domain	I
8	homeobox	I
9	protein	I
10	isl	I
11	-	I
12	1	I
13	activates	O
14	the	O
15	rat	B
16	amylin	I
17	promoter	I
18	in	O
19	both	O
20	fibroblast	O
21	and	O
22	islet	O
23	cell	O
24	lines	O
25	.	O

1	Although	O
2	isl	B
3	-	I
4	1	I
5	binds	O
6	to	O
7	both	O
8	the	O
9	insulin	B
10	and	O
11	amylin	B
12	gene	I
13	promoter	I
14	elements	I
15	in	O
16	vitro	O
17	,	O
18	these	O
19	sequences	O
20	display	O
21	marked	O
22	differences	O
23	in	O
24	their	O
25	relative	O
26	transcriptional	O
27	properties	O
28	when	O
29	ligated	O
30	adjacent	O
31	to	O
32	a	O
33	heterologous	O
34	promoter	O
35	and	O
36	transfected	O
37	into	O
38	InR1	O
39	-	O
40	G9	O
41	islet	O
42	cells	O
43	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	other	O
6	pathways	O
7	involve	O
8	alternate	O
9	signal	O
10	transduction	O
11	events	O
12	(	O
13	e	O
14	.	O
15	g	O
16	.,	O
17	calcium	O
18	mobilization	O
19	)	O
20	and	O
21	promoter	O
22	response	O
23	elements	O
24	(	O
25	e	O
26	.	O
27	g	O
28	.,	O
29	SRE	O
30	).	O

1	The	O
2	CD4	B
3	count	O
4	at	O
5	which	O
6	remission	O
7	occurs	O
8	may	O
9	reflect	O
10	severe	O
11	immunodeficiency	O
12	such	O
13	that	O
14	risk	O
15	for	O
16	AIDS	O
17	-	O
18	related	O
19	infection	O
20	is	O
21	high	O
22	.	O

1	Although	O
2	diagnostic	O
3	laparoscopy	O
4	is	O
5	still	O
6	considered	O
7	the	O
8	standard	O
9	reference	O
10	in	O
11	the	O
12	diagnosis	O
13	of	O
14	ectopic	O
15	pregnancy	O
16	(	O
17	EP	O
18	),	O
19	use	O
20	of	O
21	high	O
22	-	O
23	resolution	O
24	endovaginal	O
25	sonography	O
26	,	O
27	in	O
28	conjunction	O
29	with	O
30	qualitative	O
31	serum	O
32	assays	O
33	of	O
34	the	O
35	beta	O
36	subunit	O
37	of	O
38	human	B
39	chorionic	I
40	gonadotropin	I
41	(	O
42	beta	B
43	-	I
44	hCG	I
45	),	O
46	allows	O
47	detection	O
48	of	O
49	earlier	O
50	and	O
51	smaller	O
52	EPs	O
53	.	O

1	Bifunctionality	O
2	of	O
3	the	O
4	AcMNPV	B
5	homologous	I
6	region	I
7	sequence	I
8	(	O
9	hr1	B
10	):	O
11	enhancer	O
12	and	O
13	ori	O
14	functions	O
15	have	O
16	different	O
17	sequence	O
18	requirements	O
19	.	O

1	RVR	B
2	'	O
3	loss	O
4	of	O
5	function	O
6	'	O
7	studies	O
8	by	O
9	constitutive	O
10	over	O
11	-	O
12	expression	O
13	of	O
14	a	O
15	dominant	O
16	negative	O
17	RVR	B
18	delta	I
19	E	I
20	resulted	O
21	in	O
22	increased	O
23	levels	O
24	of	O
25	p21Cip1	B
26	/	O
27	Waf1	B
28	and	O
29	myogenin	B
30	mRNAs	I
31	after	O
32	serum	O
33	withdrawal	O
34	.	O

1	Neither	O
2	CES1	B
3	nor	O
4	CES4	B
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O

1	These	O
2	two	O
3	repeat	O
4	motifs	O
5	are	O
6	organized	O
7	in	O
8	an	O
9	extremely	O
10	well	O
11	-	O
12	ordered	O
13	pattern	O
14	in	O
15	each	O
16	domain	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	SbHRGP3	B
22	belongs	O
23	to	O
24	a	O
25	new	O
26	group	O
27	of	O
28	proteins	O
29	having	O
30	the	O
31	repeat	O
32	motifs	O
33	of	O
34	two	O
35	distinct	O
36	groups	O
37	of	O
38	dicot	B
39	extensins	I
40	.	O

1	Their	O
2	use	O
3	established	O
4	that	O
5	the	O
6	BrAAP	O
7	activity	O
8	catalyzed	O
9	both	O
10	a	O
11	postproline	O
12	and	O
13	a	O
14	postglutamate	O
15	cleavage	O
16	and	O
17	therefore	O
18	has	O
19	a	O
20	broader	O
21	specificity	O
22	than	O
23	previously	O
24	recognized	O
25	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	these	O
8	subdomains	O
9	in	O
10	PRL	B
11	binding	O
12	and	O
13	signal	O
14	transduction	O
15	,	O
16	deletion	O
17	mutants	O
18	of	O
19	S1	O
20	or	O
21	/	O
22	and	O
23	S2	O
24	subdomains	O
25	were	O
26	constructed	O
27	.	O

1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	O
8	mouse	B
9	TRH	I
10	receptor	I
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	nonexcitable	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O

1	To	O
2	understand	O
3	further	O
4	the	O
5	expression	O
6	and	O
7	regulation	O
8	of	O
9	the	O
10	V1aR	B
11	,	O
12	we	O
13	now	O
14	describe	O
15	the	O
16	genomic	O
17	characteristics	O
18	,	O
19	tissue	O
20	expression	O
21	,	O
22	chromosomal	O
23	localization	O
24	,	O
25	and	O
26	regional	O
27	mapping	O
28	of	O
29	the	O
30	human	B
31	V1aR	I
32	gene	I
33	,	O
34	AVPR1A	B
35	.	O

1	The	O
2	final	O
3	predicted	O
4	structure	O
5	has	O
6	an	O
7	overall	O
8	backbone	O
9	deviation	O
10	of	O
11	0	O
12	.	O
13	7	O
14	A	O
15	from	O
16	that	O
17	of	O
18	ras	B
19	-	O
20	p21	B
21	.	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	B
6	beta	I
7	-	I
8	catenin	I
9	gene	I
10	(	O
11	CTNNB1	B
12	).	O

1	Furthermore	O
2	,	O
3	although	O
4	the	O
5	regional	O
6	distribution	O
7	of	O
8	lean	O
9	tissue	O
10	mass	O
11	in	O
12	the	O
13	trunk	O
14	and	O
15	legs	O
16	remained	O
17	fairly	O
18	constant	O
19	at	O
20	different	O
21	pubertal	O
22	stages	O
23	,	O
24	the	O
25	regional	O
26	distribution	O
27	of	O
28	fat	O
29	was	O
30	altered	O
31	significantly	O
32	,	O
33	becoming	O
34	more	O
35	central	O
36	and	O
37	less	O
38	peripheral	O
39	.	O

1	Thus	O
2	,	O
3	the	O
4	predicted	O
5	CD30v	B
6	protein	I
7	retains	O
8	most	O
9	of	O
10	the	O
11	cytoplasmic	O
12	region	O
13	,	O
14	but	O
15	lacks	O
16	the	O
17	extracellular	O
18	and	O
19	transmembrane	O
20	domains	O
21	.	O

1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O

1	17	O
2	.	O
3	5	O
4	%	O
5	of	O
6	cycles	O
7	).	O

1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	B
22	.	O

1	Two	O
2	of	O
3	the	O
4	ORFs	O
5	are	O
6	completely	O
7	internal	O
8	to	O
9	longer	O
10	ones	O
11	and	O
12	a	O
13	third	O
14	is	O
15	partially	O
16	embedded	O
17	in	O
18	G2850	B
19	.	O

1	MVR	O
2	typing	O
3	of	O
4	rare	O
5	-	O
6	length	O
7	alleles	O
8	indicates	O
9	that	O
10	they	O
11	are	O
12	comprised	O
13	of	O
14	disorganized	O
15	sequences	O
16	,	O
17	although	O
18	they	O
19	usually	O
20	bear	O
21	a	O
22	resemblance	O
23	to	O
24	one	O
25	of	O
26	the	O
27	common	O
28	alleles	O
29	at	O
30	the	O
31	5	O
32	'-	O
33	most	O
34	end	O
35	.	O

1	Plasmid	O
2	pAL618	O
3	contains	O
4	the	O
5	genetic	O
6	determinants	O
7	for	O
8	H2	O
9	uptake	O
10	(	O
11	hup	B
12	)	O
13	from	O
14	Rhizobium	O
15	leguminosarum	O
16	bv	O
17	.	O
18	viciae	O
19	,	O
20	including	O
21	a	O
22	cluster	O
23	of	O
24	17	O
25	genes	O
26	named	O
27	hupSLCDEFGHIJK	B
28	-	I
29	hypABFCDE	I
30	.	O

1	Two	O
2	classes	O
3	of	O
4	inactive	O
5	receptors	O
6	were	O
7	identified	O
8	:	O
9	one	O
10	in	O
11	which	O
12	both	O
13	transcriptional	O
14	activation	O
15	and	O
16	dimerization	O
17	were	O
18	compromised	O
19	and	O
20	a	O
21	second	O
22	in	O
23	which	O
24	only	O
25	transcriptional	O
26	activation	O
27	was	O
28	abolished	O
29	.	O

1	Here	O
2	we	O
3	localize	O
4	a	O
5	transferable	O
6	40	O
7	-	O
8	amino	O
9	acid	O
10	region	O
11	within	O
12	the	O
13	LBDs	B
14	of	O
15	RXR	B
16	,	O
17	RAR	B
18	,	O
19	TR	B
20	,	O
21	and	O
22	chicken	B
23	ovalbumin	I
24	upstream	I
25	promoter	I
26	transcription	I
27	factor	I
28	that	O
29	is	O
30	critical	O
31	for	O
32	determining	O
33	identity	O
34	in	O
35	the	O
36	heterodimeric	O
37	interaction	O
38	and	O
39	for	O
40	high	O
41	-	O
42	affinity	O
43	DNA	O
44	binding	O
45	.	O

1	OKA	O
2	and	O
3	calyculin	O
4	A	O
5	do	O
6	not	O
7	decrease	O
8	OCFRE	B
9	DNA	O
10	-	O
11	protein	O
12	interactions	O
13	,	O
14	suggesting	O
15	that	O
16	important	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	are	O
22	phosphatase	O
23	regulated	O
24	.	O

1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	B
41	lipase	I
42	inhibitor	O
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O

1	Tilmicosin	O
2	is	O
3	a	O
4	novel	O
5	macrolide	O
6	antibiotic	O
7	developed	O
8	for	O
9	exclusive	O
10	use	O
11	in	O
12	veterinary	O
13	medicine	O
14	.	O

1	Effect	O
2	of	O
3	nitrous	O
4	oxide	O
5	(	O
6	N2O	O
7	)	O
8	on	O
9	the	O
10	somatosympathetic	O
11	A	O
12	-	O
13	and	O
14	C	O
15	-	O
16	reflexes	O
17	was	O
18	investigated	O
19	using	O
20	artificially	O
21	ventilated	O
22	rats	O
23	anesthetized	O
24	with	O
25	alpha	O
26	-	O
27	chloralose	O
28	and	O
29	urethane	O
30	.	O

1	Restriction	O
2	enzyme	O
3	mapping	O
4	and	O
5	Southern	O
6	analysis	O
7	indicated	O
8	further	O
9	that	O
10	the	O
11	human	B
12	MZF	I
13	-	I
14	1	I
15	gene	I
16	is	O
17	a	O
18	single	O
19	-	O
20	copy	O
21	gene	O
22	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	Swi4	B
6	and	O
7	Swi6	B
8	cell	O
9	viability	O
10	is	O
11	lost	O
12	,	O
13	but	O
14	can	O
15	be	O
16	regained	O
17	by	O
18	ectopic	O
19	expression	O
20	of	O
21	the	O
22	G1	B
23	cyclin	I
24	encoding	I
25	genes	I
26	,	O
27	CLN1	B
28	or	O
29	CLN2	B
30	.	O

1	The	O
2	detection	O
3	ratio	O
4	peaked	O
5	at	O
6	ages	O
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O

1	How	O
2	many	O
3	embryos	O
4	to	O
5	transfer	O
6	in	O
7	patients	O
8	undergoing	O
9	IVF	O
10	?	O

1	IMPLICATIONS	O
2	:	O
3	Given	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	inconsistency	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	associations	O
28	,	O
29	replications	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	desirable	O
36	.	O

1	The	O
2	nonconsensus	O
3	TATA	O
4	box	O
5	in	O
6	promoter	O
7	B	O
8	plays	O
9	a	O
10	more	O
11	important	O
12	role	O
13	in	O
14	promoter	O
15	activity	O
16	than	O
17	the	O
18	TATA	O
19	box	O
20	in	O
21	promoter	O
22	A	O
23	.	O

1	These	O
2	properties	O
3	indicate	O
4	that	O
5	Gle1	B
6	is	O
7	an	O
8	RNA	O
9	-	O
10	export	O
11	factor	O
12	and	O
13	that	O
14	Rev	B
15	may	O
16	mediate	O
17	viral	O
18	RNA	O
19	export	O
20	by	O
21	mimicking	O
22	the	O
23	function	O
24	of	O
25	Gle1	B
26	.	O

1	Demispan	O
2	is	O
3	a	O
4	reliable	O
5	and	O
6	reproducible	O
7	measure	O
8	of	O
9	stature	O
10	in	O
11	the	O
12	elderly	O
13	.	O

1	Two	O
2	techniques	O
3	based	O
4	on	O
5	assay	O
6	coefficients	O
7	of	O
8	variation	O
9	were	O
10	employed	O
11	to	O
12	characterize	O
13	a	O
14	normal	O
15	circadian	O
16	pattern	O
17	of	O
18	cortisol	O
19	.	O

1	We	O
2	have	O
3	performed	O
4	toeprinting	O
5	analyses	O
6	on	O
7	repA	B
8	mRNA	I
9	of	O
10	plasmid	O
11	R1	O
12	,	O
13	both	O
14	free	O
15	and	O
16	in	O
17	duplex	O
18	with	O
19	the	O
20	antisense	O
21	RNA	O
22	,	O
23	CopA	B
24	.	O

1	Previous	O
2	work	O
3	showed	O
4	that	O
5	repA	B
6	(	O
7	initiator	O
8	protein	O
9	)	O
10	expression	O
11	requires	O
12	tap	B
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	O
18	.	O

1	A	O
2	system	O
3	is	O
4	described	O
5	in	O
6	which	O
7	the	O
8	volume	O
9	flow	O
10	rate	O
11	of	O
12	blood	O
13	in	O
14	a	O
15	vessel	O
16	is	O
17	determined	O
18	using	O
19	transverse	O
20	colour	O
21	Doppler	O
22	ultrasound	O
23	imaging	O
24	.	O

1	The	O
2	enzyme	O
3	activities	O
4	studied	O
5	are	O
6	important	O
7	elements	O
8	in	O
9	the	O
10	pathophysiology	O
11	of	O
12	dental	O
13	caries	O
14	and	O
15	may	O
16	even	O
17	be	O
18	addressed	O
19	as	O
20	virulence	O
21	factors	O
22	.	O

1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O

1	In	O
2	lean	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O

1	Pharmacokinetic	O
2	parameters	O
3	were	O
4	similar	O
5	to	O
6	values	O
7	given	O
8	in	O
9	the	O
10	literature	O
11	for	O
12	intravenous	O
13	(	O
14	IV	O
15	)	O
16	or	O
17	intraarterial	O
18	(	O
19	IA	O
20	)	O
21	bolus	O
22	MMC	O
23	injections	O
24	(	O
25	Tmax	O
26	=	O
27	7	O
28	.	O
29	0	O
30	min	O
31	following	O
32	the	O
33	beginning	O
34	of	O
35	MMC	O
36	infusion	O
37	,	O
38	Vss	O
39	=	O
40	0	O
41	.	O
42	57	O
43	1	O
44	/	O
45	kg	O
46	,	O
47	C1	O
48	=	O
49	8	O
50	.	O
51	9	O
52	ml	O
53	/	O
54	min	O
55	.	O
56	kg	O
57	,	O
58	T1	O
59	/	O
60	2	O
61	alpha	O
62	=	O
63	8	O
64	.	O
65	3	O
66	min	O
67	,	O
68	T1	O
69	/	O
70	2	O
71	beta	O
72	=	O
73	58	O
74	.	O
75	6	O
76	min	O
77	).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	four	O
8	distinct	O
9	E2F	B
10	complexes	I
11	present	O
12	in	O
13	aged	O
14	and	O
15	senescent	O
16	normal	O
17	,	O
18	human	O
19	diploid	O
20	fibroblasts	O
21	.	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	If	O
2	we	O
3	apply	O
4	the	O
5	finding	O
6	of	O
7	non	O
8	-	O
9	visualization	O
10	of	O
11	the	O
12	GB	O
13	at	O
14	4	O
15	h	O
16	post	O
17	injection	O
18	as	O
19	the	O
20	criterion	O
21	for	O
22	the	O
23	diagnosis	O
24	of	O
25	AC	O
26	,	O
27	the	O
28	diagnostic	O
29	accuracy	O
30	was	O
31	only	O
32	40	O
33	.	O
34	7	O
35	%	O
36	(	O
37	11	O
38	/	O
39	27	O
40	).	O

1	These	O
2	results	O
3	were	O
4	corroborated	O
5	in	O
6	a	O
7	subsequent	O
8	study	O
9	in	O
10	which	O
11	30	O
12	hypogonadal	O
13	men	O
14	were	O
15	supplemented	O
16	with	O
17	SLT	O
18	5	O
19	mg	O
20	three	O
21	times	O
22	daily	O
23	for	O
24	6	O
25	months	O
26	.	O

1	Alternative	O
2	processing	O
3	of	O
4	the	O
5	tryptophanyl	B
6	-	I
7	tRNA	I
8	synthetase	I
9	mRNA	I
10	from	O
11	interferon	B
12	-	O
13	treated	O
14	human	O
15	cells	O
16	.	O

1	Evidence	O
2	for	O
3	the	O
4	promoting	O
5	role	O
6	of	O
7	the	O
8	intra	B
9	-	I
10	uterine	I
11	kinin	I
12	release	O
13	in	O
14	the	O
15	development	O
16	of	O
17	late	O
18	hypertonic	O
19	saline	O
20	-	O
21	induced	O
22	abortion	O
23	.	O

1	This	O
2	GAP	B
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	O
10	adipocyte	O
11	lysates	O
12	,	O
13	and	O
14	was	O
15	able	O
16	to	O
17	accelerate	O
18	the	O
19	hydrolysis	O
20	of	O
21	the	O
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	O
27	GTP	O
28	bound	O
29	to	O
30	GST	B
31	-	O
32	Rab4	B
33	into	O
34	[	O
35	alpha	O
36	-	O
37	32P	O
38	]	O
39	GDP	O
40	.	O

1	CONCLUSION	O
2	:	O
3	During	O
4	chronic	O
5	treatment	O
6	,	O
7	the	O
8	haemodynamic	O
9	response	O
10	to	O
11	oral	O
12	cilazapril	O
13	was	O
14	attenuated	O
15	,	O
16	indicating	O
17	that	O
18	continued	O
19	clinical	O
20	improvement	O
21	in	O
22	patients	O
23	with	O
24	CHF	O
25	on	O
26	CLZ	O
27	is	O
28	independent	O
29	of	O
30	to	O
31	its	O
32	acute	O
33	haemodynamic	O
34	effects	O
35	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	AIDS	O
7	patients	O
8	with	O
9	cryptococcosis	O
10	,	O
11	tolerance	O
12	to	O
13	ILd	O
14	-	O
15	AmB	O
16	was	O
17	acceptable	O
18	when	O
19	the	O
20	daily	O
21	dosage	O
22	did	O
23	not	O
24	exceed	O
25	1	O
26	mg	O
27	/	O
28	kg	O
29	,	O
30	but	O
31	the	O
32	higher	O
33	1	O
34	.	O
35	5	O
36	mg	O
37	/	O
38	kg	O
39	daily	O
40	dosage	O
41	was	O
42	associated	O
43	with	O
44	an	O
45	unacceptable	O
46	rate	O
47	of	O
48	nephrotoxicity	O
49	.	O

1	Moreover	O
2	,	O
3	the	O
4	second	O
5	RCC1	B
6	-	I
7	like	I
8	motif	I
9	located	O
10	at	O
11	the	O
12	amino	O
13	-	O
14	terminus	O
15	of	O
16	p619	B
17	stimulates	O
18	guanine	O
19	nucleotide	O
20	exchange	O
21	on	O
22	ARF1	B
23	and	O
24	on	O
25	members	O
26	of	O
27	the	O
28	related	O
29	Rab	B
30	proteins	I
31	,	O
32	but	O
33	not	O
34	on	O
35	other	O
36	small	B
37	GTP	I
38	binding	I
39	proteins	I
40	such	O
41	as	O
42	Ran	B
43	or	O
44	R	B
45	-	I
46	Ras2	I
47	/	O
48	TC21	B
49	.	O

1	The	O
2	reconstituted	O
3	RNA	B
4	polymerases	I
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	B
20	-	I
21	CRP	I
22	and	O
23	the	O
24	rrnBP1	B
25	UP	I
26	element	I
27	.	O

1	Transcription	O
2	factor	O
3	recognition	O
4	surface	O
5	on	O
6	the	O
7	RNA	B
8	polymerase	I
9	alpha	I
10	subunit	I
11	is	O
12	involved	O
13	in	O
14	contact	O
15	with	O
16	the	O
17	DNA	O
18	enhancer	O
19	element	O
20	.	O

1	Consistent	O
2	with	O
3	this	O
4	similarity	O
5	,	O
6	the	O
7	cdc28	B
8	-	O
9	P8	O
10	mutant	O
11	accumulates	O
12	unspliced	O
13	precursors	O
14	at	O
15	the	O
16	restrictive	O
17	temperature	O
18	.	O

1	A	O
2	decrease	O
3	of	O
4	erythrocyte	O
5	Mn	O
6	with	O
7	age	O
8	,	O
9	expressed	O
10	in	O
11	nmol	O
12	/	O
13	L	O
14	,	O
15	was	O
16	noted	O
17	(	O
18	p	O
19	<	O
20	0	O
21	.	O
22	02	O
23	).	O

1	Cloning	O
2	and	O
3	sequence	O
4	analyses	O
5	revealed	O
6	a	O
7	second	O
8	cDNA	O
9	with	O
10	a	O
11	95	O
12	-	O
13	nt	O
14	deletion	O
15	in	O
16	the	O
17	region	O
18	coding	O
19	for	O
20	the	O
21	putative	O
22	second	O
23	intracellular	O
24	loop	O
25	and	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	of	O
31	the	O
32	5	B
33	-	I
34	HT2C	I
35	-	I
36	R	I
37	.	O

1	Expression	O
2	of	O
3	thymidine	B
4	kinase	I
5	gene	I
6	in	O
7	normal	O
8	human	O
9	diploid	O
10	cells	O
11	is	O
12	both	O
13	cell	O
14	cycle	O
15	-	O
16	and	O
17	age	O
18	-	O
19	dependent	O
20	and	O
21	appears	O
22	to	O
23	be	O
24	transcriptionally	O
25	regulated	O
26	.	O

1	The	O
2	minimum	O
3	inhibitory	O
4	concentrations	O
5	(	O
6	MICs	O
7	)	O
8	of	O
9	ketoconazole	O
10	,	O
11	miconazole	O
12	,	O
13	itraconazole	O
14	,	O
15	fluconazole	O
16	,	O
17	and	O
18	amphotericin	O
19	B	O
20	were	O
21	significantly	O
22	influenced	O
23	by	O
24	the	O
25	inoculum	O
26	size	O
27	,	O
28	regardless	O
29	of	O
30	the	O
31	techniques	O
32	used	O
33	.	O

1	These	O
2	bacteria	O
3	produce	O
4	and	O
5	export	O
6	proteins	O
7	capable	O
8	of	O
9	specific	O
10	interactions	O
11	with	O
12	key	O
13	mammalian	O
14	cell	O
15	regulatory	O
16	molecules	O
17	in	O
18	order	O
19	to	O
20	derail	O
21	the	O
22	normal	O
23	functions	O
24	of	O
25	the	O
26	cells	O
27	.	O

1	The	O
2	elevations	O
3	achieved	O
4	by	O
5	LDEE	O
6	given	O
7	s	O
8	.	O
9	c	O
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	lasted	O
24	for	O
25	longer	O
26	periods	O
27	.	O

1	Thus	O
2	,	O
3	although	O
4	p28	B
5	may	O
6	play	O
7	only	O
8	a	O
9	limited	O
10	role	O
11	during	O
12	the	O
13	early	O
14	embryonic	O
15	cleavages	O
16	,	O
17	it	O
18	may	O
19	function	O
20	later	O
21	in	O
22	development	O
23	to	O
24	establish	O
25	a	O
26	somatic	O
27	type	O
28	of	O
29	cell	O
30	cycle	O
31	.	O

1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O

1	Moreover	O
2	,	O
3	it	O
4	also	O
5	discusses	O
6	the	O
7	effects	O
8	of	O
9	antihypertensive	O
10	drugs	O
11	currently	O
12	regarded	O
13	as	O
14	first	O
15	-	O
16	choice	O
17	agents	O
18	,	O
19	i	O
20	.	O
21	e	O
22	.	O
23	calcium	O
24	antagonists	O
25	and	O
26	the	O
27	angiotensin	B
28	converting	I
29	enzyme	I
30	inhibitors	O
31	,	O
32	on	O
33	intrarenal	O
34	hemodynamics	O
35	.	O

1	Many	O
2	human	O
3	viruses	O
4	are	O
5	able	O
6	to	O
7	develop	O
8	suitable	O
9	strategies	O
10	for	O
11	modifying	O
12	apoptosis	O
13	in	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	in	O
20	virus	O
21	-	O
22	primed	O
23	T	O
24	cells	O
25	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	observed	O
7	clinical	O
8	phenomena	O
9	in	O
10	response	O
11	to	O
12	morphine	O
13	can	O
14	be	O
15	explained	O
16	by	O
17	differences	O
18	in	O
19	expression	O
20	and	O
21	sensitivity	O
22	of	O
23	some	O
24	opioid	B
25	receptor	I
26	subtypes	O
27	in	O
28	migraine	O
29	.	O

1	Previous	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	flavin	B
7	-	I
8	containing	I
9	monooxygenases	I
10	(	O
11	FMO	B
12	)	O
13	are	O
14	expressed	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	manner	O
21	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	24	O
13	amino	O
14	acids	O
15	are	O
16	sufficient	O
17	for	O
18	NodO	B
19	secretion	O
20	although	O
21	the	O
22	region	O
23	adjacent	O
24	to	O
25	this	O
26	domain	O
27	appears	O
28	to	O
29	affect	O
30	secretion	O
31	efficiency	O
32	.	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	I
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	B
25	gene	I
26	expression	O
27	.	O

1	MSSP	B
2	proteins	I
3	have	O
4	been	O
5	identified	O
6	by	O
7	their	O
8	binding	O
9	to	O
10	an	O
11	upstream	O
12	element	O
13	of	O
14	c	B
15	-	I
16	myc	I
17	.	O

1	Gene	B
2	1	I
3	has	O
4	been	O
5	completely	O
6	sequenced	O
7	.	O

1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	O
8	induced	O
9	apoptosis	O
10	in	O
11	the	O
12	WEHI	O
13	-	O
14	231	O
15	B	O
16	lymphoma	O
17	cell	O
18	line	O
19	can	O
20	be	O
21	prevented	O
22	by	O
23	engaging	O
24	CD40	B
25	.	O

1	Both	O
2	alleles	O
3	are	O
4	functionally	O
5	expressed	O
6	and	O
7	are	O
8	distributed	O
9	within	O
10	CD4	B
11	+/	O
12	CD8	B
13	+	O
14	T	O
15	cell	O
16	subsets	O
17	.	O

1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	LvUSF2	B
8	is	O
9	nearly	O
10	identical	O
11	to	O
12	LvUSF1	B
13	except	O
14	at	O
15	the	O
16	amino	O
17	end	O
18	,	O
19	where	O
20	they	O
21	are	O
22	sharply	O
23	divergent	O
24	.	O

1	ECM	O
2	disruption	O
3	in	O
4	Lytechinus	O
5	embryos	O
6	caused	O
7	a	O
8	relative	O
9	drop	O
10	in	O
11	USF	B
12	RNA	I
13	accumulation	O
14	levels	O
15	to	O
16	approximately	O
17	60	O
18	%	O
19	of	O
20	control	O
21	embryos	O
22	,	O
23	while	O
24	LpS1	B
25	RNA	I
26	accumulation	O
27	levels	O
28	dropped	O
29	to	O
30	less	O
31	than	O
32	5	O
33	%.	O

1	Five	O
2	of	O
3	these	O
4	eight	O
5	patients	O
6	in	O
7	group	O
8	II	O
9	also	O
10	received	O
11	8	O
12	-	O
13	in	O
14	-	O
15	1	O
16	chemotherapy	O
17	.	O

1	Sixty	O
2	days	O
3	after	O
4	the	O
5	intervention	O
6	,	O
7	twitch	O
8	and	O
9	tetanic	O
10	tensions	O
11	remained	O
12	dependent	O
13	upon	O
14	the	O
15	extracellular	O
16	Ca2	O
17	+	O
18	concentration	O
19	([	O
20	Ca	O
21	]	O
22	o	O
23	)	O
24	both	O
25	in	O
26	groups	O
27	A	O
28	and	O
29	B	O
30	.	O

1	Discrimination	O
2	between	O
3	HIV	O
4	-	O
5	1	O
6	and	O
7	HIV	O
8	-	O
9	2	O
10	showed	O
11	evidence	O
12	for	O
13	the	O
14	presence	O
15	of	O
16	HIV	O
17	-	O
18	1	O
19	only	O
20	.	O

1	However	O
2	,	O
3	an	O
4	intrinsic	O
5	DNA	O
6	-	O
7	binding	O
8	subunit	O
9	for	O
10	HiNF	B
11	-	I
12	D	I
13	was	O
14	not	O
15	identified	O
16	.	O

1	The	O
2	HiNF	B
3	-	I
4	D	I
5	(	O
6	CDP	B
7	/	O
8	cut	B
9	)	O
10	complex	O
11	with	O
12	the	O
13	H4	B
14	promoter	I
15	is	O
16	immunoreactive	O
17	with	O
18	antibodies	O
19	against	O
20	CDP	B
21	/	O
22	cut	B
23	and	O
24	pRB	B
25	but	O
26	not	O
27	p107	B
28	,	O
29	whereas	O
30	the	O
31	CDP	B
32	/	O
33	cut	B
34	complex	O
35	with	O
36	a	O
37	nonhistone	O
38	promoter	O
39	(	O
40	gp91	B
41	-	O
42	phox	B
43	)	O
44	reacts	O
45	only	O
46	with	O
47	CDP	B
48	and	O
49	p107	B
50	antibodies	O
51	.	O

1	Recently	O
2	,	O
3	a	O
4	distantly	O
5	related	O
6	UmuC	B
7	-	I
8	homolog	I
9	,	O
10	DinB	B
11	,	O
12	has	O
13	also	O
14	been	O
15	identified	O
16	in	O
17	E	O
18	.	O
19	coli	O
20	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	mdr2	B
7	expression	O
8	,	O
9	the	O
10	promoter	O
11	of	O
12	the	O
13	mdr2	B
14	gene	I
15	has	O
16	been	O
17	isolated	O
18	from	O
19	a	O
20	murine	O
21	vinblastine	O
22	-	O
23	resistant	O
24	cell	O
25	line	O
26	,	O
27	J7	O
28	.	O
29	V2	O
30	-	O
31	1	O
32	,	O
33	and	O
34	characterized	O
35	.	O

1	The	O
2	amplification	O
3	was	O
4	achieved	O
5	using	O
6	two	O
7	primers	O
8	which	O
9	correspond	O
10	to	O
11	TRH	B
12	progenitor	I
13	sequence	I
14	(	O
15	Lys	O
16	/	O
17	Arg	O
18	-	O
19	Arg	O
20	-	O
21	Gln	O
22	-	O
23	His	O
24	-	O
25	Pro	O
26	-	O
27	Gly	O
28	-	O
29	Lys	O
30	/	O
31	Arg	O
32	-	O
33	Arg	O
34	).	O

1	The	O
2	intranodal	O
3	mesothelial	O
4	cells	O
5	occupied	O
6	the	O
7	sinusoids	O
8	of	O
9	the	O
10	lymph	O
11	nodes	O
12	and	O
13	were	O
14	initially	O
15	suspected	O
16	of	O
17	being	O
18	metastatic	O
19	from	O
20	the	O
21	ovarian	O
22	tumor	O
23	in	O
24	each	O
25	case	O
26	.	O

1	The	O
2	gene	B
3	ccpA	I
4	encoding	O
5	the	O
6	catabolite	B
7	control	I
8	protein	I
9	CcpA	I
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O

1	An	O
2	InlC	B
3	deletion	I
4	mutant	I
5	shows	O
6	reduced	O
7	virulence	O
8	when	O
9	tested	O
10	in	O
11	an	O
12	intravenous	O
13	mouse	O
14	model	O
15	,	O
16	but	O
17	intracellular	O
18	replication	O
19	of	O
20	the	O
21	mutant	O
22	in	O
23	Caco	O
24	-	O
25	2	O
26	and	O
27	J774	O
28	cells	O
29	appears	O
30	to	O
31	be	O
32	comparable	O
33	with	O
34	that	O
35	of	O
36	the	O
37	wild	O
38	-	O
39	type	O
40	strain	O
41	.	O

1	Thus	O
2	,	O
3	the	O
4	N	B
5	-	O
6	Nus	B
7	complex	O
8	may	O
9	be	O
10	affected	O
11	through	O
12	contacts	O
13	with	O
14	the	O
15	CTD	O
16	of	O
17	the	O
18	alpha	O
19	subunit	O
20	of	O
21	RNA	B
22	polymerase	I
23	,	O
24	as	O
25	is	O
26	a	O
27	group	O
28	of	O
29	regulatory	O
30	proteins	O
31	that	O
32	influences	O
33	initiation	O
34	of	O
35	transcription	O
36	.	O

1	Administration	O
2	of	O
3	RIFA	O
4	at	O
5	200	O
6	mg	O
7	/	O
8	kg	O
9	/	O
10	day	O
11	in	O
12	combination	O
13	with	O
14	ATO	O
15	at	O
16	100	O
17	mg	O
18	/	O
19	kg	O
20	/	O
21	day	O
22	resulted	O
23	in	O
24	a	O
25	marked	O
26	prolongation	O
27	of	O
28	survival	O
29	compared	O
30	with	O
31	that	O
32	for	O
33	mice	O
34	that	O
35	received	O
36	ATO	O
37	or	O
38	RIFA	O
39	alone	O
40	.	O

1	Eight	O
2	-	O
3	four	O
4	ACOAs	O
5	were	O
6	tested	O
7	in	O
8	order	O
9	to	O
10	examine	O
11	the	O
12	fit	O
13	of	O
14	the	O
15	model	O
16	to	O
17	the	O
18	data	O
19	by	O
20	path	O
21	analysis	O
22	with	O
23	LISREL	O
24	VII	O
25	.	O

1	Two	O
2	of	O
3	seven	O
4	initiation	O
5	sites	O
6	were	O
7	flanked	O
8	by	O
9	a	O
10	sequence	O
11	homologous	O
12	to	O
13	the	O
14	consensus	O
15	promoter	O
16	motif	O
17	that	O
18	includes	O
19	the	O
20	CRTA	O
21	motif	O
22	(	O
23	where	O
24	R	O
25	is	O
26	A	O
27	or	O
28	G	O
29	)	O
30	of	O
31	the	O
32	rice	O
33	mitochondrion	O
34	.	O

1	Selection	O
2	using	O
3	SC	O
4	EPD	O
5	was	O
6	more	O
7	effective	O
8	than	O
9	phenotypic	O
10	selection	O
11	in	O
12	reducing	O
13	age	O
14	at	O
15	puberty	O
16	in	O
17	daughters	O
18	.	O

1	Using	O
2	anchored	O
3	PCR	O
4	,	O
5	a	O
6	VL	B
7	element	I
8	rearranged	O
9	to	O
10	CL2	B
11	was	O
12	isolated	O
13	.	O

1	Sodium	O
2	polystyrene	O
3	sulfonate	O
4	treatment	O
5	for	O
6	lithium	O
7	toxicity	O
8	:	O
9	effects	O
10	on	O
11	serum	O
12	potassium	O
13	concentrations	O
14	.	O

1	The	O
2	mammalian	B
3	homeodomain	I
4	proteins	I
5	encoded	O
6	by	O
7	Hox	B
8	genes	I
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	embryonic	O
15	development	O
16	by	O
17	providing	O
18	positional	O
19	queues	O
20	which	O
21	define	O
22	developmental	O
23	identities	O
24	along	O
25	the	O
26	anteroposterior	O
27	axis	O
28	of	O
29	developing	O
30	organisms	O
31	.	O

1	Interferon	B
2	stimulated	I
3	gene	I
4	factor	I
5	3	I
6	(	O
7	ISGF3	B
8	)	O
9	is	O
10	a	O
11	trimeric	O
12	transcription	O
13	factor	O
14	activated	O
15	on	O
16	treatment	O
17	of	O
18	cells	O
19	with	O
20	interferon	B
21	-	I
22	alpha	I
23	and	I
24	beta	I
25	(	O
26	type	B
27	I	I
28	IFNs	I
29	).	O

1	The	O
2	TYAC	O
3	/	O
4	P1	O
5	resource	O
6	,	O
7	derivative	O
8	STSs	O
9	,	O
10	and	O
11	polymorphisms	O
12	constitute	O
13	an	O
14	enabling	O
15	resource	O
16	to	O
17	further	O
18	studies	O
19	of	O
20	telomere	O
21	structure	O
22	and	O
23	function	O
24	and	O
25	a	O
26	means	O
27	for	O
28	physical	O
29	and	O
30	genetic	O
31	map	O
32	integration	O
33	and	O
34	closure	O
35	.	O

1	Confirmatory	O
2	statistics	O
3	included	O
4	item	O
5	2	O
6	of	O
7	the	O
8	Clinical	O
9	Global	O
10	Impression	O
11	(	O
12	CGI	O
13	),	O
14	the	O
15	total	O
16	score	O
17	of	O
18	the	O
19	Sandoz	O
20	Clinical	O
21	Assessment	O
22	Geriatric	O
23	(	O
24	SCAG	O
25	)	O
26	scale	O
27	,	O
28	the	O
29	subscale	O
30	'	O
31	need	O
32	for	O
33	help	O
34	'	O
35	of	O
36	the	O
37	nurse	O
38	'	O
39	s	O
40	rating	O
41	of	O
42	geriatric	O
43	patients	O
44	(	O
45	Beurteilungsskala	O
46	fur	O
47	geriatrische	O
48	Patienten	O
49	;	O
50	BGP	O
51	)	O
52	and	O
53	the	O
54	total	O
55	score	O
56	of	O
57	the	O
58	Short	O
59	Cognitive	O
60	Performance	O
61	Test	O
62	(	O
63	Syndrom	O
64	-	O
65	Kurztest	O
66	;	O
67	SKT	O
68	).	O

1	Three	O
2	mutants	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	widely	O
8	used	O
9	strain	O
10	,	O
11	PAO1	O
12	.	O

1	As	O
2	extensively	O
3	examined	O
4	with	O
5	the	O
6	myogenin	B
7	promoter	I
8	,	O
9	presence	O
10	of	O
11	one	O
12	or	O
13	multiple	O
14	copies	O
15	of	O
16	Me	B
17	in	O
18	the	O
19	vectors	O
20	elevated	O
21	the	O
22	expression	O
23	activity	O
24	in	O
25	myotubes	O
26	by	O
27	4	O
28	.	O
29	5	O
30	-	O
31	to	O
32	19	O
33	-	O
34	fold	O
35	over	O
36	those	O
37	without	O
38	Me	B
39	,	O
40	but	O
41	not	O
42	significantly	O
43	in	O
44	myoblasts	O
45	.	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	B
13	,	O
14	but	O
15	activated	O
16	TC21	B
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	O
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	Fission	B
2	yeast	I
3	mal2	I
4	+	I
5	is	O
6	required	O
7	for	O
8	chromosome	O
9	segregation	O
10	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	B
14	-	I
15	10	I
16	promoter	I
17	-	I
18	regulatory	I
19	region	I
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	B
28	-	I
29	10	I
30	open	I
31	reading	I
32	frame	I
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	B
39	hygromycin	I
40	B	I
41	phosphotransferase	I
42	structural	I
43	gene	I
44	(	O
45	con10	B
46	'-'	I
47	hph	I
48	).	O

1	Mutations	O
2	at	O
3	two	O
4	neighboring	O
5	sites	O
6	,	O
7	serine	O
8	242	O
9	and	O
10	threonine	O
11	255	O
12	,	O
13	exacerbated	O
14	the	O
15	effect	O
16	.	O

1	IRF	B
2	-	I
3	1	I
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	O
11	IRF	B
12	-	I
13	2	I
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	In	O
2	contrast	O
3	,	O
4	cotransfection	O
5	of	O
6	TFIIB	B
7	and	O
8	IRF	B
9	-	I
10	1	I
11	into	O
12	NIH	O
13	3T3	O
14	cells	O
15	resulted	O
16	in	O
17	a	O
18	dose	O
19	-	O
20	dependent	O
21	repression	O
22	of	O
23	promoter	O
24	activation	O
25	which	O
26	occurred	O
27	in	O
28	a	O
29	TATA	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	The	O
2	requirement	O
3	of	O
4	Tyr	O
5	-	O
6	19	O
7	dephosphorylation	O
8	for	O
9	spindle	O
10	assembly	O
11	is	O
12	also	O
13	observed	O
14	under	O
15	conditions	O
16	in	O
17	which	O
18	spindle	O
19	formation	O
20	is	O
21	independent	O
22	of	O
23	mitosis	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	involvement	O
29	of	O
30	Cdc28	B
31	/	O
32	Clb	B
33	kinase	O
34	in	O
35	SPB	O
36	separation	O
37	is	O
38	direct	O
39	.	O

1	A	O
2	subset	O
3	of	O
4	these	O
5	DMP1	B
6	recognition	I
7	sequences	I
8	containing	O
9	a	O
10	GGA	O
11	trinucleotide	O
12	core	O
13	can	O
14	also	O
15	function	O
16	as	O
17	Ets	B
18	-	I
19	responsive	I
20	elements	I
21	.	O

1	In	O
2	both	O
3	settings	O
4	,	O
5	it	O
6	can	O
7	be	O
8	phosphorylated	O
9	by	O
10	cyclin	B
11	D	I
12	-	I
13	dependent	I
14	kinases	I
15	,	O
16	suggesting	O
17	that	O
18	its	O
19	transcriptional	O
20	activity	O
21	may	O
22	normally	O
23	be	O
24	regulated	O
25	through	O
26	such	O
27	mechanisms	O
28	.	O

1	Expression	O
2	of	O
3	the	O
4	proapoptotic	B
5	protein	I
6	Bax	I
7	under	O
8	the	O
9	control	O
10	of	O
11	a	O
12	GAL10	B
13	promoter	I
14	in	O
15	Saccharomyces	O
16	cerevisiae	O
17	resulted	O
18	in	O
19	galactose	O
20	-	O
21	inducible	O
22	cell	O
23	death	O
24	.	O

1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O

1	Enterococcus	O
2	faecium	O
3	strains	O
4	with	O
5	vanA	O
6	-	O
7	mediated	O
8	glycopeptide	O
9	resistance	O
10	were	O
11	isolated	O
12	by	O
13	enrichment	O
14	culture	O
15	from	O
16	the	O
17	intestines	O
18	and	O
19	feces	O
20	of	O
21	several	O
22	animal	O
23	species	O
24	,	O
25	mainly	O
26	horses	O
27	and	O
28	dogs	O
29	(	O
30	8	O
31	%	O
32	positive	O
33	),	O
34	chickens	O
35	(	O
36	7	O
37	%	O
38	positive	O
39	),	O
40	and	O
41	pigs	O
42	(	O
43	6	O
44	%	O
45	positive	O
46	).	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	E1A	B
8	binds	O
9	several	O
10	high	O
11	molecular	O
12	weight	O
13	proteins	O
14	and	O
15	inhibits	O
16	the	O
17	transcriptional	O
18	coactivator	O
19	function	O
20	of	O
21	p300	B
22	and	O
23	the	O
24	homologous	O
25	cAMP	B
26	response	I
27	element	I
28	(	I
29	CRE	I
30	)-	I
31	binding	I
32	protein	I
33	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	B
14	'	I
15	mdr1b	I
16	sequences	I
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	5	O
6	'	O
7	UTR	O
8	characteristic	O
9	of	O
10	testis	B
11	-	I
12	specific	I
13	c	I
14	-	I
15	mos	I
16	mRNA	I
17	strongly	O
18	represses	O
19	translation	O
20	relative	O
21	to	O
22	the	O
23	translation	O
24	of	O
25	transcripts	O
26	that	O
27	contain	O
28	a	O
29	5	O
30	'	O
31	UTR	O
32	derived	O
33	from	O
34	beta	B
35	-	I
36	globin	I
37	mRNA	I
38	,	O
39	and	O
40	this	O
41	is	O
42	mainly	O
43	due	O
44	to	O
45	the	O
46	four	O
47	uORFs	O
48	.	O

1	To	O
2	address	O
3	the	O
4	biological	O
5	effect	O
6	of	O
7	specific	O
8	isoform	O
9	expression	O
10	,	O
11	NIH3T3	O
12	cells	O
13	were	O
14	transfected	O
15	with	O
16	a	O
17	eukaryotic	O
18	expression	O
19	vector	O
20	containing	O
21	cDNA	O
22	for	O
23	FGF8a	B
24	,	O
25	FGF8b	B
26	,	O
27	or	O
28	FGF8e	B
29	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	F	O
7	-	O
8	wave	O
9	may	O
10	be	O
11	elicited	O
12	in	O
13	motoneuron	O
14	of	O
15	different	O
16	depolarization	O
17	threshold	O
18	but	O
19	primarily	O
20	in	O
21	larger	O
22	and	O
23	faster	O
24	nerve	O
25	fibers	O
26	,	O
27	with	O
28	a	O
29	lower	O
30	threshold	O
31	of	O
32	depolarization	O
33	.	O

1	In	O
2	addition	O
3	,	O
4	carp	B
5	JAK1	I
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	B
12	JAK1	I
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	B
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	B
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	When	O
2	this	O
3	DNA	O
4	fragment	O
5	was	O
6	placed	O
7	upstream	O
8	of	O
9	the	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	and	O
18	transfected	O
19	into	O
20	a	O
21	carp	O
22	CF	O
23	cell	O
24	line	O
25	,	O
26	it	O
27	could	O
28	drive	O
29	the	O
30	synthesis	O
31	of	O
32	CAT	B
33	enzyme	I
34	16	O
35	times	O
36	more	O
37	efficiently	O
38	than	O
39	the	O
40	promoterless	O
41	pCAT	B
42	-	I
43	Basic	I
44	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	Elk	B
5	-	I
6	3	I
7	,	O
8	a	O
9	new	O
10	member	O
11	of	O
12	the	O
13	Ets	B
14	family	I
15	expressed	O
16	during	O
17	mouse	O
18	embryogenesis	O
19	and	O
20	analysis	O
21	of	O
22	its	O
23	transcriptional	O
24	repression	O
25	activity	O
26	.	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	B
24	C	I
25	-	I
26	MYB	I
27	protein	I
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	O

1	Frozen	O
2	/	O
3	thawed	O
4	extensor	O
5	digitorum	O
6	longus	O
7	muscle	O
8	tendon	O
9	units	O
10	had	O
11	significantly	O
12	lower	O
13	values	O
14	for	O
15	load	O
16	to	O
17	failure	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	01	O
24	),	O
25	energy	O
26	absorbed	O
27	to	O
28	failure	O
29	(	O
30	p	O
31	<	O
32	0	O
33	.	O
34	01	O
35	),	O
36	and	O
37	strain	O
38	at	O
39	failure	O
40	(	O
41	p	O
42	<	O
43	0	O
44	.	O
45	01	O
46	),	O
47	and	O
48	they	O
49	tended	O
50	to	O
51	fail	O
52	at	O
53	a	O
54	different	O
55	anatomic	O
56	location	O
57	(	O
58	p	O
59	<	O
60	0	O
61	.	O
62	01	O
63	)	O
64	(	O
65	broadly	O
66	at	O
67	the	O
68	fascia	O
69	-	O
70	muscle	O
71	interface	O
72	as	O
73	compared	O
74	with	O
75	horizontally	O
76	at	O
77	the	O
78	musculotendinous	O
79	junction	O
80	)	O
81	than	O
82	fresh	O
83	units	O
84	.	O

1	Northern	O
2	analysis	O
3	of	O
4	the	O
5	3	B
6	.	I
7	1	I
8	-	I
9	kb	I
10	PWP2H	I
11	cDNA	I
12	revealed	O
13	that	O
14	a	O
15	3	O
16	.	O
17	3	O
18	-	O
19	kb	O
20	major	O
21	transcript	O
22	is	O
23	ubiquitously	O
24	expressed	O
25	in	O
26	human	O
27	adult	O
28	tissues	O
29	.	O

1	Forty	O
2	-	O
3	eight	O
4	10	O
5	-	O
6	12	O
7	-	O
8	week	O
9	-	O
10	old	O
11	male	O
12	Sprague	O
13	-	O
14	Dawley	O
15	rats	O
16	were	O
17	randomized	O
18	to	O
19	receive	O
20	,	O
21	daily	O
22	for	O
23	28	O
24	days	O
25	:	O
26	(	O
27	1	O
28	)	O
29	CsA	O
30	vehicle	O
31	p	O
32	.	O
33	o	O
34	.	O
35	plus	O
36	FB	O
37	vehicle	O
38	sc	O
39	;	O
40	(	O
41	2	O
42	)	O
43	CsA	O
44	(	O
45	15	O
46	mg	O
47	/	O
48	kg	O
49	)	O
50	p	O
51	.	O
52	o	O
53	.	O
54	plus	O
55	FB	O
56	vehicle	O
57	sc	O
58	,	O
59	(	O
60	3	O
61	)	O
62	CsA	O
63	vehicle	O
64	p	O
65	.	O
66	o	O
67	.	O
68	plus	O
69	FB	O
70	(	O
71	1	O
72	.	O
73	5	O
74	mg	O
75	/	O
76	kg	O
77	)	O
78	sc	O
79	;	O
80	and	O
81	(	O
82	4	O
83	)	O
84	CsA	O
85	(	O
86	15	O
87	mg	O
88	/	O
89	kg	O
90	)	O
91	p	O
92	.	O
93	o	O
94	.	O
95	plus	O
96	FB	O
97	(	O
98	1	O
99	.	O
100	5	O
101	mg	O
102	/	O
103	kg	O
104	)	O
105	sc	O
106	.	O

1	CsA	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O

1	Individuals	O
2	attending	O
3	the	O
4	GUM	O
5	Department	O
6	in	O
7	the	O
8	Royal	O
9	Infirmary	O
10	of	O
11	Edinburgh	O
12	between	O
13	1990	O
14	and	O
15	1994	O
16	with	O
17	the	O
18	diagnosis	O
19	of	O
20	HIV	O
21	infection	O
22	,	O
23	genital	O
24	warts	O
25	,	O
26	genital	O
27	herpes	O
28	,	O
29	non	O
30	-	O
31	specific	O
32	genital	O
33	infection	O
34	(	O
35	NSGI	O
36	),	O
37	gonorrhoea	O
38	and	O
39	syphilis	O
40	were	O
41	included	O
42	in	O
43	the	O
44	study	O
45	.	O

1	Oncogenic	O
2	activation	O
3	of	O
4	the	O
5	tyrosine	B
6	kinase	I
7	domain	I
8	of	O
9	the	O
10	human	B
11	trk	I
12	proto	I
13	-	I
14	oncogene	I
15	by	O
16	fusion	O
17	to	O
18	a	O
19	cell	O
20	adhesion	O
21	molecule	O
22	.	O

1	Northern	O
2	blotting	O
3	showed	O
4	that	O
5	MDMX	B
6	,	O
7	like	O
8	MDM2	B
9	,	O
10	is	O
11	expressed	O
12	in	O
13	all	O
14	tissues	O
15	tested	O
16	,	O
17	and	O
18	that	O
19	several	O
20	mRNAs	O
21	for	O
22	MDMX	B
23	can	O
24	be	O
25	detected	O
26	.	O

1	Physiol	O
2	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	22	O
6	,	O
7	846	O
8	bp	O
9	of	O
10	the	O
11	left	O
12	arm	O
13	of	O
14	chromosome	O
15	IV	O
16	is	O
17	described	O
18	.	O

1	They	O
2	suggest	O
3	that	O
4	decreased	O
5	steady	O
6	-	O
7	state	O
8	levels	O
9	of	O
10	IME1	B
11	and	O
12	IME2	B
13	mRNA	I
14	were	O
15	not	O
16	merely	O
17	the	O
18	result	O
19	of	O
20	non	O
21	-	O
22	specific	O
23	adverse	O
24	affects	O
25	on	O
26	nucleic	O
27	acid	O
28	metabolism	O
29	caused	O
30	by	O
31	the	O
32	yvh1	B
33	disruption	O
34	.	O

1	Natural	O
2	FL	B
3	protein	I
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	stromal	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	nondisulfide	O
20	-	O
21	linked	O
22	homodimeric	O
23	glycoprotein	O
24	comprised	O
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	sugars	O
42	.	O

1	The	O
2	objective	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	examine	O
9	the	O
10	influence	O
11	of	O
12	HHCA	O
13	and	O
14	other	O
15	serological	O
16	factors	O
17	upon	O
18	the	O
19	development	O
20	of	O
21	VGS	O
22	.	O

1	Spliced	O
2	exons	O
3	of	O
4	adenovirus	O
5	late	O
6	RNAs	O
7	colocalize	O
8	with	O
9	snRNP	O
10	in	O
11	a	O
12	specific	O
13	nuclear	O
14	domain	O
15	.	O

1	Using	O
2	Spurr	O
3	'	O
4	s	O
5	resin	O
6	as	O
7	a	O
8	mounting	O
9	medium	O
10	,	O
11	we	O
12	could	O
13	observe	O
14	thick	O
15	specimens	O
16	with	O
17	oil	O
18	immersion	O
19	objective	O
20	lens	O
21	without	O
22	the	O
23	use	O
24	of	O
25	coverslips	O
26	,	O
27	then	O
28	avoid	O
29	air	O
30	bubbles	O
31	near	O
32	the	O
33	specimen	O
34	.	O

1	The	O
2	present	O
3	study	O
4	investigated	O
5	dose	O
6	dependence	O
7	and	O
8	time	O
9	course	O
10	effects	O
11	of	O
12	the	O
13	benzodiazepine	O
14	(	O
15	BDZ	O
16	)	O
17	partial	O
18	inverse	O
19	agonist	O
20	,	O
21	RO19	O
22	-	O
23	4603	O
24	(	O
25	0	O
26	.	O
27	005	O
28	-	O
29	0	O
30	.	O
31	30	O
32	mg	O
33	/	O
34	kg	O
35	)	O
36	alone	O
37	,	O
38	and	O
39	in	O
40	combination	O
41	with	O
42	the	O
43	BDZ	B
44	receptor	I
45	antagonists	O
46	flumazenil	O
47	,	O
48	ZK	O
49	93426	O
50	,	O
51	and	O
52	CGS	O
53	8216	O
54	(	O
55	20	O
56	mg	O
57	/	O
58	kg	O
59	)	O
60	in	O
61	selectively	O
62	bred	O
63	alcohol	O
64	-	O
65	preferring	O
66	(	O
67	P	O
68	)	O
69	rats	O
70	provided	O
71	a	O
72	two	O
73	-	O
74	bottle	O
75	choice	O
76	test	O
77	between	O
78	ethanol	O
79	(	O
80	EtOH	O
81	)	O
82	(	O
83	10	O
84	%	O
85	v	O
86	/	O
87	v	O
88	),	O
89	and	O
90	a	O
91	palatable	O
92	saccharin	O
93	(	O
94	0	O
95	.	O
96	0125	O
97	%	O
98	g	O
99	/	O
100	v	O
101	)	O
102	solution	O
103	.	O

1	Beyond	O
2	the	O
3	Tower	O
4	of	O
5	Babel	O
6	:	O
7	a	O
8	nomenclature	O
9	for	O
10	suicidology	O
11	.	O

1	Infection	O
2	with	O
3	Neisseria	O
4	meningitidis	O
5	group	O
6	B	O
7	has	O
8	been	O
9	difficult	O
10	to	O
11	detect	O
12	,	O
13	partly	O
14	because	O
15	this	O
16	bacterial	O
17	group	O
18	'	O
19	s	O
20	polysaccharide	O
21	is	O
22	a	O
23	weak	O
24	immunogen	O
25	.	O

1	RNase	B
2	protection	O
3	analysis	O
4	of	O
5	two	O
6	rRNA	O
7	fragments	O
8	whose	O
9	genes	O
10	are	O
11	adjacent	O
12	provided	O
13	evidence	O
14	for	O
15	a	O
16	polycistronic	O
17	transcript	O
18	containing	O
19	sequences	O
20	from	O
21	both	O
22	,	O
23	as	O
24	well	O
25	as	O
26	separate	O
27	small	O
28	RNAs	O
29	.	O

1	Rss1p	B
2	encodes	O
3	a	O
4	novel	O
5	essential	O
6	protein	O
7	of	O
8	538	O
9	amino	O
10	acids	O
11	,	O
12	which	O
13	contains	O
14	an	O
15	extended	O
16	predicted	O
17	coiled	O
18	-	O
19	coil	O
20	domain	O
21	and	O
22	is	O
23	located	O
24	both	O
25	at	O
26	nuclear	O
27	pore	O
28	complexes	O
29	(	O
30	NPCs	O
31	)	O
32	and	O
33	in	O
34	the	O
35	cytoplasm	O
36	.	O

1	To	O
2	map	O
3	this	O
4	regulatory	O
5	serine	O
6	phosphorylation	O
7	site	O
8	we	O
9	developed	O
10	a	O
11	baculovirus	O
12	-	O
13	mediated	O
14	expression	O
15	system	O
16	for	O
17	wild	B
18	-	I
19	type	I
20	annexin	I
21	II	I
22	and	O
23	for	O
24	a	O
25	series	O
26	of	O
27	annexin	B
28	II	I
29	mutants	I
30	which	O
31	contained	O
32	substitutions	O
33	in	O
34	one	O
35	or	O
36	more	O
37	serine	O
38	residues	O
39	present	O
40	in	O
41	the	O
42	N	O
43	-	O
44	terminal	O
45	domain	O
46	.	O

1	The	O
2	PAI	B
3	-	I
4	2	I
5	gene	I
6	is	O
7	one	O
8	of	O
9	the	O
10	most	O
11	TNF	B
12	-	I
13	responsive	I
14	genes	I
15	known	O
16	and	O
17	is	O
18	also	O
19	highly	O
20	induced	O
21	by	O
22	the	O
23	phorbol	O
24	ester	O
25	phorbol	O
26	12	O
27	-	O
28	myristate	O
29	13	O
30	-	O
31	acetate	O
32	(	O
33	PMA	O
34	)	O
35	and	O
36	the	O
37	phosphatase	O
38	inhibitor	O
39	,	O
40	okadaic	O
41	acid	O
42	,	O
43	in	O
44	both	O
45	HT	O
46	-	O
47	1080	O
48	fibrosarcoma	O
49	and	O
50	U	O
51	-	O
52	937	O
53	histiocytic	O
54	cells	O
55	.	O

1	220	O
2	,	O
3	263	O
4	-	O
5	273	O
6	).	O

1	These	O
2	two	O
3	contigs	O
4	contain	O
5	a	O
6	total	O
7	of	O
8	163	O
9	open	O
10	reading	O
11	frames	O
12	(	O
13	ORFs	O
14	)	O
15	in	O
16	26	O
17	-	O
18	29	O
19	putative	O
20	operons	O
21	;	O
22	56	O
23	ORFs	O
24	could	O
25	be	O
26	identified	O
27	with	O
28	reasonable	O
29	certainty	O
30	.	O

1	T	O
2	.,	O
3	Patel	O
4	,	O
5	S	O
6	.	O

1	Growth	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	B
9	early	I
10	gene	I
11	products	I
12	MAP	I
13	kinase	I
14	phosphatase	I
15	-	I
16	1	I
17	(	O
18	MKP	B
19	-	I
20	1	I
21	),	O
22	c	B
23	-	I
24	Fos	I
25	and	O
26	c	B
27	-	I
28	Jun	I
29	.	O

1	The	O
2	up	O
3	-	O
4	regulation	O
5	of	O
6	E	B
7	-	I
8	selectin	I
9	,	O
10	one	O
11	of	O
12	the	O
13	adhesion	O
14	molecules	O
15	on	O
16	the	O
17	endothelium	O
18	,	O
19	is	O
20	an	O
21	important	O
22	event	O
23	in	O
24	the	O
25	mediation	O
26	of	O
27	the	O
28	inflammatory	O
29	response	O
30	.	O

1	The	O
2	NIT2	B
3	protein	I
4	is	O
5	localised	O
6	in	O
7	nuclei	O
8	and	O
9	could	O
10	not	O
11	be	O
12	detected	O
13	in	O
14	the	O
15	cytoplasmic	O
16	fraction	O
17	of	O
18	cells	O
19	subjected	O
20	to	O
21	nitrogen	O
22	derepression	O
23	or	O
24	nitrogen	O
25	repression	O
26	,	O
27	indicating	O
28	that	O
29	the	O
30	nuclear	O
31	import	O
32	of	O
33	NIT2	B
34	is	O
35	not	O
36	regulated	O
37	.	O

1	In	O
2	spite	O
3	of	O
4	much	O
5	effort	O
6	,	O
7	no	O
8	one	O
9	has	O
10	succeeded	O
11	in	O
12	isolating	O
13	and	O
14	characterizing	O
15	the	O
16	enzyme	O
17	(	O
18	s	O
19	)	O
20	responsible	O
21	for	O
22	synthesis	O
23	of	O
24	cellulose	O
25	,	O
26	the	O
27	major	O
28	cell	O
29	wall	O
30	polymer	O
31	of	O
32	plants	O
33	.	O

1	Vascular	O
2	responses	O
3	to	O
4	reactive	O
5	hyperemia	O
6	(	O
7	with	O
8	flow	O
9	increase	O
10	leading	O
11	to	O
12	endothelium	O
13	-	O
14	dependent	O
15	dilation	O
16	)	O
17	and	O
18	to	O
19	sublingual	O
20	glyceryl	O
21	trinitrate	O
22	(	O
23	GTN	O
24	;	O
25	endothelium	O
26	-	O
27	independent	O
28	dilation	O
29	)	O
30	were	O
31	recorded	O
32	.	O

1	During	O
2	this	O
3	period	O
4	,	O
5	administration	O
6	of	O
7	additional	O
8	exogenous	B
9	PRL	I
10	did	O
11	not	O
12	stimulate	O
13	further	O
14	activation	O
15	(	O
16	binding	O
17	)	O
18	of	O
19	the	O
20	Stat	B
21	factors	I
22	.	O

1	Intraperitoneal	O
2	administration	O
3	of	O
4	L	O
5	-	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	L	O
11	-	O
12	5	O
13	-	O
14	HTP	O
15	)	O
16	at	O
17	doses	O
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O

1	In	O
2	the	O
3	VA	O
4	-	O
5	SMV	O
6	mode	O
7	,	O
8	the	O
9	connection	O
10	was	O
11	made	O
12	with	O
13	valved	O
14	conduits	O
15	from	O
16	the	O
17	LV	O
18	apex	O
19	(	O
20	inflow	O
21	)	O
22	to	O
23	the	O
24	ascending	O
25	aorta	O
26	(	O
27	outflow	O
28	)	O
29	(	O
30	n	O
31	=	O
32	11	O
33	)	O
34	or	O
35	to	O
36	the	O
37	DAo	O
38	(	O
39	n	O
40	=	O
41	12	O
42	).	O

1	The	O
2	evidence	O
3	in	O
4	support	O
5	of	O
6	this	O
7	was	O
8	derived	O
9	from	O
10	the	O
11	fact	O
12	that	O
13	the	O
14	affinity	O
15	or	O
16	interaction	O
17	between	O
18	the	O
19	two	O
20	subunits	O
21	was	O
22	impaired	O
23	as	O
24	indicated	O
25	by	O
26	the	O
27	first	O
28	order	O
29	rate	O
30	constant	O
31	of	O
32	hCG	B
33	alpha	I
34	1	I
35	beta	I
36	(	O
37	km	O
38	=	O
39	4	O
40	.	O
41	1	O
42	x	O
43	10	O
44	(-	O
45	2	O
46	)	O
47	min	O
48	-	O
49	1	O
50	)	O
51	at	O
52	pH	O
53	3	O
54	.	O
55	0	O
56	at	O
57	23	O
58	degrees	O
59	C	O
60	which	O
61	is	O
62	one	O
63	order	O
64	of	O
65	magnitude	O
66	greater	O
67	relative	O
68	to	O
69	rehCG	B
70	(	O
71	kw	O
72	=	O
73	4	O
74	.	O
75	6	O
76	x	O
77	10	O
78	(-	O
79	3	O
80	)	O
81	min	O
82	-	O
83	1	O
84	).	O

1	Factor	O
2	V	O
3	Leiden	O
4	is	O
5	a	O
6	genetic	O
7	disorder	O
8	associated	O
9	with	O
10	an	O
11	increased	O
12	risk	O
13	of	O
14	venous	O
15	thrombosis	O
16	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	determination	O
6	of	O
7	the	O
8	complete	O
9	secondary	O
10	structure	O
11	of	O
12	an	O
13	RNA	O
14	spliced	O
15	in	O
16	a	O
17	spliceosome	O
18	.	O

1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O

1	These	O
2	patients	O
3	appear	O
4	to	O
5	have	O
6	slightly	O
7	better	O
8	pulmonary	O
9	function	O
10	and	O
11	nutritional	O
12	status	O
13	;	O
14	yet	O
15	,	O
16	they	O
17	seem	O
18	to	O
19	have	O
20	a	O
21	higher	O
22	degree	O
23	of	O
24	health	O
25	care	O
26	utilization	O
27	.	O

1	This	O
2	observation	O
3	calls	O
4	for	O
5	careful	O
6	monitoring	O
7	of	O
8	calcium	O
9	and	O
10	alkaline	B
11	phosphatase	I
12	values	O
13	and	O
14	possible	O
15	adjustments	O
16	of	O
17	vitamin	O
18	D	O
19	intake	O
20	when	O
21	fortifiers	O
22	are	O
23	used	O
24	for	O
25	extended	O
26	periods	O
27	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	B
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O

1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O

1	Percent	O
2	identities	O
3	of	O
4	the	O
5	mouse	B
6	PP2	I
7	to	O
8	mouse	B
9	Y1	I
10	,	O
11	mouse	O
12	Y4	B
13	/	O
14	PP1	B
15	and	O
16	human	B
17	Y2	I
18	receptors	I
19	are	O
20	53	O
21	,	O
22	42	O
23	,	O
24	and	O
25	31	O
26	,	O
27	respectively	O
28	.	O

1	Correlating	O
2	with	O
3	the	O
4	previous	O
5	observation	O
6	that	O
7	CBF	B
8	binding	O
9	to	O
10	the	O
11	78C1	O
12	site	O
13	is	O
14	enhanced	O
15	by	O
16	EGTA	O
17	and	O
18	EDTA	O
19	,	O
20	these	O
21	divalent	O
22	cation	O
23	chelators	O
24	specifically	O
25	stimulate	O
26	78C1	O
27	-	O
28	directed	O
29	transcription	O
30	.	O

1	The	O
2	human	O
3	gene	O
4	fragment	O
5	ligated	O
6	to	O
7	the	O
8	minimal	O
9	rat	O
10	liver	O
11	glucokinase	B
12	promoter	O
13	was	O
14	shown	O
15	to	O
16	work	O
17	as	O
18	an	O
19	enhancer	O
20	in	O
21	the	O
22	hepatocyte	O
23	transfection	O
24	system	O
25	.	O

1	To	O
2	test	O
3	the	O
4	role	O
5	of	O
6	ML	O
7	in	O
8	human	O
9	reproductive	O
10	axis	O
11	,	O
12	128	O
13	healthy	O
14	children	O
15	,	O
16	68	O
17	boys	O
18	and	O
19	60	O
20	girls	O
21	,	O
22	were	O
23	studied	O
24	.	O

1	However	O
2	,	O
3	the	O
4	truncated	O
5	deer	B
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O

1	This	O
2	report	O
3	provides	O
4	further	O
5	evidence	O
6	for	O
7	the	O
8	riMLF	O
9	in	O
10	the	O
11	control	O
12	of	O
13	downgaze	O
14	,	O
15	and	O
16	a	O
17	synkinesis	O
18	is	O
19	postulated	O
20	for	O
21	the	O
22	development	O
23	of	O
24	the	O
25	convergence	O
26	retraction	O
27	nystagmus	O
28	.	O

1	Rifabutin	O
2	has	O
3	substantial	O
4	efficacy	O
5	when	O
6	combined	O
7	with	O
8	other	O
9	agents	O
10	.	O

1	Ninety	O
2	-	O
3	four	O
4	percent	O
5	of	O
6	the	O
7	EPs	O
8	were	O
9	tubal	O
10	,	O
11	and	O
12	90	O
13	%	O
14	of	O
15	the	O
16	tubes	O
17	exhibited	O
18	some	O
19	pathologic	O
20	changes	O
21	,	O
22	including	O
23	chronic	O
24	salpingitis	O
25	(	O
26	49	O
27	.	O
28	5	O
29	%)	O
30	and	O
31	follicular	O
32	salpingitis	O
33	(	O
34	10	O
35	%),	O
36	among	O
37	others	O
38	.	O

1	The	O
2	assessment	O
3	using	O
4	7	O
5	H	O
6	9	O
7	liquid	O
8	medium	O
9	by	O
10	the	O
11	former	O
12	author	O
13	demonstrated	O
14	the	O
15	potent	O
16	activities	O
17	of	O
18	both	O
19	CS	O
20	-	O
21	940	O
22	*	O
23	and	O
24	sparfloxacin	O
25	(	O
26	SPFX	O
27	),	O
28	followed	O
29	by	O
30	AM	O
31	-	O
32	1155	O
33	*,	O
34	ciprofloxacin	O
35	(	O
36	CPFX	O
37	),	O
38	levofloxacin	O
39	(	O
40	LVFX	O
41	),	O
42	OPC	O
43	-	O
44	17116	O
45	*,	O
46	NM	O
47	-	O
48	394	O
49	*	O
50	in	O
51	sequence	O
52	.	O

1	The	O
2	STE20	B
3	gene	I
4	,	O
5	encoding	O
6	a	O
7	protein	O
8	kinase	O
9	required	O
10	for	O
11	pheromone	O
12	signal	O
13	transduction	O
14	,	O
15	has	O
16	recently	O
17	been	O
18	identified	O
19	in	O
20	a	O
21	genetic	O
22	screen	O
23	for	O
24	high	O
25	-	O
26	gene	O
27	-	O
28	dosage	O
29	suppressors	O
30	of	O
31	a	O
32	partly	O
33	defective	O
34	G	B
35	beta	I
36	mutation	O
37	.	O

1	This	O
2	enzyme	O
3	is	O
4	designated	O
5	(	B
6	1	I
7	-->	I
8	4	I
9	)-	I
10	beta	I
11	-	I
12	xylan	I
13	endohydrolase	I
14	isoenzyme	I
15	X	I
16	-	I
17	I	I
18	.	O

1	Magnetic	O
2	resonance	O
3	imaging	O
4	in	O
5	coccidioidal	O
6	arthritis	O
7	.	O

1	Moloney	O
2	murine	O
3	leukemia	O
4	virus	O
5	(	O
6	MMLV	O
7	)-	O
8	derived	O
9	pUCMoTiN	O
10	-	O
11	based	O
12	retroviral	O
13	vectors	O
14	were	O
15	engineered	O
16	to	O
17	allow	O
18	constitutive	O
19	and	O
20	Tat	B
21	(	O
22	trans	B
23	-	I
24	activator	I
25	of	I
26	transcription	I
27	)-	O
28	inducible	O
29	expression	O
30	of	O
31	five	O
32	hammerhead	O
33	ribozymes	O
34	targeted	O
35	against	O
36	highly	O
37	conserved	O
38	sequences	O
39	within	O
40	the	O
41	group	B
42	antigen	I
43	(	O
44	Gag	B
45	),	O
46	protease	B
47	(	O
48	Pro	B
49	),	O
50	reverse	B
51	transcriptase	I
52	(	O
53	RT	B
54	),	O
55	tat	B
56	,	O
57	and	O
58	envelope	B
59	(	O
60	Env	B
61	)	O
62	coding	O
63	regions	O
64	of	O
65	human	O
66	immunodeficiency	O
67	virus	O
68	type	O
69	-	O
70	1	O
71	(	O
72	HIV	O
73	-	O
74	1	O
75	)	O
76	RNA	O
77	.	O

1	REM	O
2	sleep	O
3	deprivation	O
4	was	O
5	performed	O
6	using	O
7	the	O
8	platform	O
9	technique	O
10	.	O

1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	O
15	dependent	O
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	O

1	We	O
2	analyzed	O
3	serial	O
4	biopsy	O
5	specimens	O
6	from	O
7	eight	O
8	patients	O
9	with	O
10	FL	O
11	for	O
12	secondary	O
13	alterations	O
14	of	O
15	the	O
16	rearranged	B
17	bcl	I
18	-	I
19	2	I
20	gene	I
21	in	O
22	the	O
23	breakpoint	O
24	and	O
25	open	O
26	reading	O
27	frame	O
28	(	O
29	ORF	O
30	)	O
31	regions	O
32	.	O

1	In	O
2	all	O
3	eight	O
4	cases	O
5	,	O
6	neither	O
7	FL	O
8	nor	O
9	DLL	O
10	cells	O
11	showed	O
12	alterations	O
13	of	O
14	bcl	B
15	-	I
16	2	I
17	gene	I
18	sequences	I
19	in	O
20	the	O
21	breakpoint	O
22	region	O
23	,	O
24	suggesting	O
25	high	O
26	conservation	O
27	of	O
28	the	O
29	bcl	B
30	-	I
31	2	I
32	gene	I
33	during	O
34	both	O
35	t	O
36	(	O
37	14	O
38	;	O
39	18	O
40	)	O
41	translocation	O
42	and	O
43	morphologic	O
44	transformation	O
45	of	O
46	the	O
47	FL	O
48	cells	O
49	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	An	O
2	essential	O
3	role	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	and	O
9	c	B
10	-	I
11	Fos	I
12	in	O
13	basal	O
14	and	O
15	PMA	O
16	-	O
17	stimulated	O
18	transcription	O
19	of	O
20	the	O
21	PAI	B
22	-	I
23	1	I
24	gene	I
25	is	O
26	demonstrated	O
27	by	O
28	our	O
29	finding	O
30	that	O
31	antisense	O
32	c	B
33	-	I
34	jun	I
35	and	O
36	c	B
37	-	I
38	fos	I
39	oligodeoxynucleotides	O
40	both	O
41	strongly	O
42	reduced	O
43	basal	O
44	and	O
45	PMA	O
46	-	O
47	stimulated	O
48	PAI	B
49	-	I
50	1	I
51	synthesis	O
52	.	O

1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	B
7	)	O
8	is	O
9	a	O
10	neuropoietin	B
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	B
68	luciferase	I
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O

1	The	O
2	optimal	O
3	sequence	O
4	for	O
5	interaction	O
6	with	O
7	mu	B
8	2	I
9	and	O
10	with	O
11	AP	B
12	-	I
13	2	I
14	has	O
15	tyrosine	O
16	as	O
17	an	O
18	anchor	O
19	and	O
20	prefers	O
21	arginine	O
22	at	O
23	position	O
24	Y	O
25	+	O
26	2	O
27	and	O
28	leucine	O
29	at	O
30	position	O
31	Y	O
32	+	O
33	3	O
34	.	O

1	STK	B
2	/	O
3	RON	B
4	-	O
5	expressing	O
6	Ba	O
7	/	O
8	F3	O
9	pro	O
10	-	O
11	B	O
12	cells	O
13	(	O
14	BaF	O
15	/	O
16	STK	B
17	)	O
18	exhibited	O
19	MSP	B
20	-	O
21	dependent	O
22	growth	O
23	,	O
24	whereas	O
25	STK	B
26	/	O
27	RON	B
28	-	O
29	expressing	O
30	mouse	O
31	erythroleukaemia	O
32	cells	O
33	(	O
34	MEL	O
35	/	O
36	STK	B
37	)	O
38	displayed	O
39	MSP	B
40	-	O
41	induced	O
42	apoptosis	O
43	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	showed	O
7	that	O
8	OxyR	B
9	-	I
10	C199S	I
11	protected	O
12	Pmom	B
13	from	O
14	-	O
15	104	O
16	to	O
17	-	O
18	46	O
19	on	O
20	the	O
21	top	O
22	strand	O
23	and	O
24	produced	O
25	a	O
26	protection	O
27	pattern	O
28	characteristic	O
29	of	O
30	reduced	B
31	wild	I
32	-	I
33	type	I
34	OxyR	I
35	.	O

1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	In	O
2	contrast	O
3	,	O
4	dig1	B
5	dig2	I
6	cells	O
7	constitutively	O
8	invade	O
9	agar	O
10	medium	O
11	,	O
12	whereas	O
13	a	O
14	dig1	B
15	dig2	I
16	ste12	I
17	triple	O
18	mutant	O
19	does	O
20	not	O
21	,	O
22	indicating	O
23	that	O
24	Dig1	B
25	and	O
26	Dig2	B
27	share	O
28	a	O
29	role	O
30	in	O
31	negatively	O
32	regulating	O
33	the	O
34	invasive	O
35	growth	O
36	pathway	O
37	.	O

1	Paracrine	O
2	activation	O
3	of	O
4	the	O
5	HIV	B
6	-	I
7	1	I
8	LTR	I
9	promoter	I
10	by	O
11	the	O
12	viral	B
13	Tat	I
14	protein	I
15	is	O
16	mechanistically	O
17	similar	O
18	to	O
19	trans	O
20	-	O
21	activation	O
22	within	O
23	a	O
24	cell	O
25	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	the	O
7	xFxFG	O
8	repeat	O
9	regions	O
10	of	O
11	p62	B
12	and	O
13	Nsplp	B
14	indicated	O
15	that	O
16	NTF2	B
17	was	O
18	probably	O
19	interacting	O
20	with	O
21	the	O
22	phenylalanine	O
23	-	O
24	containing	O
25	core	O
26	of	O
27	these	O
28	repeats	O
29	and	O
30	not	O
31	the	O
32	intervening	O
33	hydrophilic	O
34	linkers	O
35	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	report	O
6	of	O
7	the	O
8	successful	O
9	resection	O
10	of	O
11	a	O
12	MFH	O
13	originating	O
14	in	O
15	the	O
16	renal	O
17	capsular	O
18	tissue	O
19	and	O
20	extending	O
21	into	O
22	the	O
23	inferior	O
24	vena	O
25	cava	O
26	.	O

1	Transient	O
2	expression	O
3	of	O
4	VSF	B
5	-	I
6	1	I
7	in	O
8	protoplasts	O
9	stimulated	O
10	vs	B
11	-	I
12	1	I
13	dependent	O
14	activation	O
15	of	O
16	the	O
17	-	B
18	76	I
19	/	I
20	grp1	I
21	.	I
22	8	I
23	minimal	I
24	promoter	I
25	.	O

1	Keeping	O
2	in	O
3	mind	O
4	the	O
5	limited	O
6	range	O
7	of	O
8	age	O
9	and	O
10	dosages	O
11	,	O
12	advantages	O
13	and	O
14	disadvantages	O
15	of	O
16	the	O
17	drug	O
18	are	O
19	discussed	O
20	,	O
21	comparing	O
22	the	O
23	experimental	O
24	results	O
25	with	O
26	those	O
27	derived	O
28	from	O
29	the	O
30	literature	O
31	.	O

1	Blood	O
2	sampling	O
3	procedures	O
4	were	O
5	videotaped	O
6	.	O

1	Analysis	O
2	of	O
3	one	O
4	cDNA	O
5	revealed	O
6	an	O
7	unusual	O
8	splicing	O
9	event	O
10	involving	O
11	EZH1	B
12	and	O
13	a	O
14	tandemly	O
15	linked	O
16	gene	O
17	GPR2	B
18	and	O
19	suggests	O
20	a	O
21	potential	O
22	mechanism	O
23	for	O
24	modifying	O
25	the	O
26	EZH1	B
27	protein	I
28	in	O
29	the	O
30	conserved	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	.	O

1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	Vd	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	O
23	method	O
24	were	O
25	calculated	O
26	from	O
27	the	O
28	dynamic	O
29	study	O
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O

1	They	O
2	lack	O
3	a	O
4	predicted	O
5	single	O
6	stranded	O
7	(	O
8	ss	O
9	)	O
10	DNA	O
11	binding	O
12	motif	O
13	that	O
14	is	O
15	unique	O
16	the	O
17	large	O
18	terminase	B
19	proteins	I
20	in	O
21	T4	B
22	gp17	I
23	,	O
24	and	O
25	that	O
26	has	O
27	been	O
28	implicated	O
29	in	O
30	recognizing	O
31	ssDNA	O
32	regions	O
33	in	O
34	replicating	O
35	and	O
36	recombining	O
37	T4DNA	O
38	destined	O
39	to	O
40	be	O
41	packaged	O
42	.	O

1	It	O
2	can	O
3	be	O
4	concluded	O
5	that	O
6	in	O
7	normotensive	O
8	subjects	O
9	,	O
10	uric	O
11	acid	O
12	and	O
13	xanthine	B
14	oxidase	I
15	have	O
16	significant	O
17	association	O
18	with	O
19	blood	O
20	pressure	O
21	and	O
22	thus	O
23	are	O
24	one	O
25	of	O
26	the	O
27	many	O
28	factors	O
29	which	O
30	are	O
31	involved	O
32	in	O
33	the	O
34	cause	O
35	or	O
36	effect	O
37	of	O
38	hypertension	O
39	.	O

1	Immunoblotting	O
2	of	O
3	expressed	O
4	recombinant	O
5	proteins	O
6	with	O
7	the	O
8	monoclonal	B
9	08L	I
10	antibody	I
11	localized	O
12	the	O
13	08L	B
14	epitope	O
15	to	O
16	the	O
17	carboxyl	O
18	end	O
19	of	O
20	the	O
21	protein	O
22	.	O

1	We	O
2	infer	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	galactosidase	I
18	tetramer	I
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	detour	O
25	of	O
26	the	O
27	tetramer	O
28	to	O
29	the	O
30	lysosome	O
31	.	O

1	The	O
2	current	O
3	study	O
4	defines	O
5	the	O
6	vinculin	B
7	-	O
8	and	O
9	FAK	B
10	-	I
11	interaction	I
12	domains	I
13	on	O
14	paxillin	B
15	and	O
16	identifies	O
17	the	O
18	principal	O
19	paxillin	B
20	focal	O
21	adhesion	O
22	targeting	O
23	motif	O
24	.	O

1	These	O
2	data	O
3	demonstrate	O
4	the	O
5	presence	O
6	of	O
7	a	O
8	single	O
9	binding	O
10	site	O
11	for	O
12	vinculin	B
13	,	O
14	and	O
15	at	O
16	least	O
17	two	O
18	binding	O
19	sites	O
20	for	O
21	FAK	B
22	that	O
23	are	O
24	separated	O
25	by	O
26	an	O
27	intervening	O
28	stretch	O
29	of	O
30	100	O
31	amino	O
32	acids	O
33	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	paxillin	B
6	localizes	O
7	to	O
8	focal	O
9	adhesions	O
10	independent	O
11	of	O
12	interactions	O
13	with	O
14	vinculin	B
15	and	O
16	/	O
17	or	O
18	FAK	B
19	,	O
20	and	O
21	represents	O
22	the	O
23	first	O
24	definitive	O
25	demonstration	O
26	of	O
27	LIM	B
28	domains	I
29	functioning	O
30	as	O
31	a	O
32	primary	O
33	determinant	O
34	of	O
35	protein	O
36	subcellular	O
37	localization	O
38	to	O
39	focal	O
40	adhesions	O
41	.	O

1	A	O
2	single	O
3	protease	O
4	-	O
5	resistant	O
6	structure	O
7	formed	O
8	by	O
9	the	O
10	entirety	O
11	of	O
12	both	O
13	PDZ	B
14	repeats	I
15	1	I
16	and	I
17	2	I
18	(	O
19	PDZ1	B
20	-	I
21	2	I
22	)	O
23	contains	O
24	the	O
25	protein	B
26	4	I
27	.	I
28	1	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	Several	O
2	agents	O
3	have	O
4	been	O
5	tried	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O

1	Jerseys	O
2	had	O
3	higher	O
4	hepatic	O
5	Cu	O
6	concentrations	O
7	than	O
8	did	O
9	Holsteins	O
10	on	O
11	d	O
12	60	O
13	(	O
14	346	O
15	vs	O
16	.	O

1	RUSH	B
2	-	I
3	1	I
4	beta	I
5	is	O
6	a	O
7	95	O
8	-	O
9	kDa	O
10	truncated	O
11	version	O
12	of	O
13	RUSH	B
14	-	I
15	1	I
16	alpha	I
17	that	O
18	results	O
19	from	O
20	alternative	O
21	splicing	O
22	of	O
23	a	O
24	57	O
25	-	O
26	bp	O
27	exon	O
28	as	O
29	confirmed	O
30	by	O
31	genomic	O
32	cloning	O
33	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	well	O
8	established	O
9	polarity	O
10	of	O
11	RXR	B
12	heterodimer	O
13	binding	O
14	to	O
15	bipartite	O
16	hormone	O
17	response	O
18	elements	O
19	,	O
20	with	O
21	the	O
22	VDR	B
23	recognizing	O
24	the	O
25	3	O
26	'-	O
27	half	O
28	-	O
29	element	O
30	.	O

1	PPAR	B
2	gamma	I
3	mRNA	I
4	levels	O
5	were	O
6	reduced	O
7	by	O
8	95	O
9	%	O
10	with	O
11	3	O
12	nM	O
13	TNF	B
14	alpha	I
15	treatment	O
16	for	O
17	24	O
18	h	O
19	.	O

1	Exons	O
2	III	O
3	to	O
4	VIII	O
5	,	O
6	which	O
7	cover	O
8	the	O
9	coding	O
10	region	O
11	and	O
12	the	O
13	3	O
14	'	O
15	untranslated	O
16	region	O
17	,	O
18	are	O
19	almost	O
20	identical	O
21	in	O
22	all	O
23	types	O
24	of	O
25	PST	B
26	or	O
27	AST	B
28	cDNAs	I
29	.	O

1	Growth	O
2	factor	O
3	allows	O
4	effective	O
5	dose	O
6	-	O
7	intensive	O
8	regimen	O
9	in	O
10	advanced	O
11	breast	O
12	cancer	O
13	patients	O
14	.	O

1	Recombinant	B
2	erythropoietin	I
3	(	O
4	r	B
5	-	I
6	HuEPO	I
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O

1	In	O
2	1993	O
3	and	O
4	1994	O
5	and	O
6	infection	O
7	with	O
8	body	O
9	lice	O
10	was	O
11	registered	O
12	41	O
13	times	O
14	in	O
15	31	O
16	patients	O
17	at	O
18	the	O
19	clinic	O
20	for	O
21	homeless	O
22	of	O
23	the	O
24	Community	O
25	Health	O
26	Service	O
27	of	O
28	Utrecht	O
29	.	O

1	Ki	B
2	-	I
3	ras	I
4	and	O
5	p53	B
6	mutations	I
7	in	O
8	pancreatic	O
9	ductal	O
10	adenocarcinoma	O
11	.	O

1	Epidemiological	O
2	data	O
3	are	O
4	quite	O
5	controversial	O
6	but	O
7	sudden	O
8	death	O
9	occurring	O
10	during	O
11	sporting	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O

1	However	O
2	,	O
3	the	O
4	ratio	O
5	M	O
6	/	O
7	Pc	O
8	provides	O
9	a	O
10	useful	O
11	index	O
12	that	O
13	seems	O
14	to	O
15	be	O
16	independent	O
17	of	O
18	the	O
19	metabolic	O
20	demand	O
21	.	O

1	Rat	B
2	liver	I
3	catalase	I
4	is	O
5	sorted	O
6	to	O
7	peroxisomes	O
8	by	O
9	its	O
10	C	O
11	-	O
12	terminal	O
13	tripeptide	O
14	Ala	O
15	-	O
16	Asn	O
17	-	O
18	Leu	O
19	,	O
20	not	O
21	by	O
22	the	O
23	internal	O
24	Ser	O
25	-	O
26	Lys	O
27	-	O
28	Leu	O
29	motif	O
30	.	O

1	The	O
2	mobility	O
3	shift	O
4	assay	O
5	of	O
6	the	O
7	65	O
8	bp	O
9	(-	O
10	318	O
11	/	O
12	-	O
13	254	O
14	)	O
15	fragment	O
16	with	O
17	nuclear	O
18	extract	O
19	from	O
20	the	O
21	dark	O
22	-	O
23	adapted	O
24	sample	O
25	showed	O
26	an	O
27	additional	O
28	band	O
29	,	O
30	not	O
31	seen	O
32	with	O
33	the	O
34	light	O
35	-	O
36	grown	O
37	sample	O
38	.	O

1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	B
8	or	O
9	an	O
10	E2F	B
11	-	I
12	related	I
13	transcription	I
14	factor	I
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	B
22	myosin	I
23	expression	O
24	.	O

1	When	O
2	the	O
3	E1A	B
4	N	I
5	-	I
6	terminus	I
7	is	O
8	used	O
9	as	O
10	a	O
11	competitor	O
12	in	O
13	squelshing	O
14	experiments	O
15	it	O
16	abolishes	O
17	CBP	B
18	-	O
19	induced	O
20	activation	O
21	of	O
22	E2F1	B
23	/	O
24	DP1	B
25	,	O
26	whereas	O
27	an	O
28	E1A	B
29	mutant	I
30	lacking	O
31	CBP	B
32	binding	O
33	ability	O
34	fails	O
35	to	O
36	do	O
37	so	O
38	.	O

1	Small	O
2	Maf	B
3	proteins	I
4	interact	O
5	with	O
6	the	O
7	human	O
8	transcription	O
9	factor	O
10	TCF11	B
11	/	O
12	Nrf1	B
13	/	O
14	LCR	B
15	-	I
16	F1	I
17	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O

1	The	O
2	effect	O
3	of	O
4	maternal	O
5	ingestion	O
6	of	O
7	the	O
8	reduced	O
9	energy	O
10	sweetener	O
11	erythritol	O
12	was	O
13	investigated	O
14	in	O
15	KBL	O
16	:	O
17	JW	O
18	strain	O
19	pregnant	O
20	rabbits	O
21	.	O

1	Moreover	O
2	,	O
3	the	O
4	same	O
5	mutations	O
6	alter	O
7	the	O
8	structure	O
9	of	O
10	junB	B
11	5	O
12	'	O
13	flanking	O
14	DNA	O
15	within	O
16	chromatin	O
17	.	O

1	The	O
2	nm23	B
3	-	I
4	H1	I
5	/	O
6	nm23	B
7	-	I
8	H2	I
9	gene	O
10	transcriptional	O
11	activity	O
12	ratio	O
13	varied	O
14	depending	O
15	on	O
16	the	O
17	cell	O
18	line	O
19	.	O

1	CONCLUSION	O
2	:	O
3	Intravenous	O
4	diazepam	O
5	administration	O
6	before	O
7	EGD	O
8	produces	O
9	a	O
10	significant	O
11	fall	O
12	in	O
13	SpO2	O
14	during	O
15	the	O
16	procedure	O
17	,	O
18	and	O
19	so	O
20	should	O
21	be	O
22	avoided	O
23	;	O
24	continuous	O
25	monitoring	O
26	of	O
27	SpO2	O
28	should	O
29	be	O
30	done	O
31	during	O
32	EGD	O
33	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	alignment	O
5	between	O
6	mouse	O
7	and	O
8	human	B
9	CA	I
10	IV	I
11	shows	O
12	69	O
13	%	O
14	identity	O
15	in	O
16	the	O
17	coding	O
18	region	O
19	and	O
20	all	O
21	of	O
22	the	O
23	exon	O
24	-	O
25	intron	O
26	boundaries	O
27	are	O
28	conserved	O
29	,	O
30	as	O
31	are	O
32	the	O
33	sizes	O
34	of	O
35	the	O
36	introns	O
37	.	O

1	Discordance	O
2	on	O
3	the	O
4	cost	O
5	dimension	O
6	correlated	O
7	negatively	O
8	with	O
9	G	B
10	Hb	I
11	,	O
12	suggesting	O
13	better	O
14	glycemic	O
15	control	O
16	with	O
17	greater	O
18	disagreement	O
19	.	O

1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O

1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O

1	Histological	O
2	changes	O
3	,	O
4	including	O
5	cortical	O
6	cell	O
7	involution	O
8	and	O
9	hemorrhage	O
10	occurring	O
11	during	O
12	the	O
13	neonatal	O
14	period	O
15	,	O
16	would	O
17	seem	O
18	to	O
19	have	O
20	crucial	O
21	relevance	O
22	to	O
23	the	O
24	remodeling	O
25	of	O
26	the	O
27	adrenal	O
28	vasculature	O
29	.	O

1	Furthermore	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	both	O
8	p46	B
9	and	O
10	p54	B
11	subunits	I
12	markedly	O
13	altered	O
14	the	O
15	subcellular	O
16	distribution	O
17	of	O
18	p46	B
19	;	O
20	co	O
21	-	O
22	expressed	O
23	p46	B
24	was	O
25	transported	O
26	into	O
27	the	O
28	nucleus	O
29	as	O
30	efficiently	O
31	as	O
32	p54	B
33	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	both	O
8	the	O
9	N	O
10	-	O
11	and	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	talin	B
18	bind	O
19	actin	B
20	,	O
21	the	O
22	properties	O
23	of	O
24	these	O
25	two	O
26	regions	O
27	of	O
28	the	O
29	protein	O
30	are	O
31	distinct	O
32	.	O

1	Merr	O
2	.)	O
3	embryo	O
4	library	O
5	.	O

1	The	O
2	accumulation	O
3	of	O
4	both	O
5	LHA4	B
6	and	O
7	LHA2	B
8	mRNAs	I
9	is	O
10	induced	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	exogenous	O
16	sugars	O
17	and	O
18	this	O
19	induction	O
20	appears	O
21	to	O
22	be	O
23	dependent	O
24	on	O
25	sugar	O
26	uptake	O
27	and	O
28	metabolism	O
29	,	O
30	because	O
31	mannitol	O
32	and	O
33	3	O
34	-	O
35	O	O
36	-	O
37	methylglucose	O
38	do	O
39	not	O
40	stimulate	O
41	mRNA	O
42	accumulation	O
43	.	O

1	Using	O
2	the	O
3	yeast	O
4	one	O
5	-	O
6	hybrid	O
7	screen	O
8	with	O
9	integrated	O
10	NRE	O
11	and	O
12	flanking	O
13	DNA	O
14	as	O
15	bait	O
16	,	O
17	the	O
18	predominant	O
19	clone	O
20	obtained	O
21	was	O
22	bovine	B
23	Nrl	I
24	.	O

1	As	O
2	the	O
3	rate	O
4	of	O
5	protein	O
6	synthesis	O
7	decreases	O
8	during	O
9	late	O
10	embryogenesis	O
11	,	O
12	levels	O
13	of	O
14	SEC	B
15	-	I
16	1	I
17	and	O
18	its	O
19	cognate	O
20	mRNA	O
21	decline	O
22	precipitously	O
23	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	fodrin	B
6	proteolysis	O
7	in	O
8	vivo	O
9	may	O
10	reflect	O
11	the	O
12	activity	O
13	of	O
14	multiple	O
15	ICE	B
16	/	O
17	Ced	B
18	-	I
19	3	I
20	proteases	O
21	whose	O
22	partial	O
23	sensitivity	O
24	to	O
25	DEVD	O
26	-	O
27	CHO	O
28	reflects	O
29	a	O
30	limited	O
31	contribution	O
32	from	O
33	CPP32	B
34	,	O
35	or	O
36	an	O
37	ICE	B
38	/	O
39	Ced	B
40	-	I
41	3	I
42	protease	O
43	less	O
44	sensitive	O
45	than	O
46	CPP32	B
47	to	O
48	DEVD	O
49	-	O
50	CHO	O
51	inhibition	O
52	.	O

1	In	O
2	3Y1	O
3	and	O
4	3Y1	O
5	v	B
6	-	I
7	crk	I
8	-	O
9	transformed	O
10	fibroblasts	O
11	,	O
12	almost	O
13	all	O
14	of	O
15	the	O
16	total	O
17	PTP1B	B
18	and	O
19	about	O
20	40	O
21	%	O
22	of	O
23	total	O
24	p130	B
25	(	O
26	Cas	B
27	)	O
28	co	O
29	-	O
30	sediment	O
31	with	O
32	membranes	O
33	composed	O
34	primarily	O
35	of	O
36	endoplasmic	O
37	reticulum	O
38	.	O

1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	O
11	AF	O
12	-	O
13	2	O
14	domain	O
15	from	O
16	the	O
17	vitamin	B
18	D3	I
19	receptor	I
20	or	O
21	the	O
22	estrogen	B
23	receptor	I
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O

1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	B
14	cleavage	I
15	-	I
16	activating	I
17	protein	I
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O

1	The	O
2	Escherichia	B
3	coli	I
4	tet	I
5	-	I
6	repressor	I
7	(	O
8	TetR	B
9	)	O
10	operator	O
11	system	O
12	was	O
13	used	O
14	to	O
15	develop	O
16	a	O
17	variation	O
18	of	O
19	the	O
20	yeast	O
21	two	O
22	-	O
23	hybrid	O
24	assay	O
25	in	O
26	which	O
27	disruptions	O
28	of	O
29	protein	O
30	-	O
31	protein	O
32	interactions	O
33	can	O
34	be	O
35	identified	O
36	by	O
37	a	O
38	positive	O
39	selection	O
40	.	O

1	Recent	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	SHP	B
7	-	I
8	1	I
9	regulates	O
10	the	O
11	function	O
12	of	O
13	Jak	B
14	family	O
15	tyrosine	B
16	kinases	I
17	,	O
18	as	O
19	shown	O
20	by	O
21	its	O
22	constitutive	O
23	association	O
24	with	O
25	the	O
26	Tyk2	B
27	kinase	I
28	and	O
29	the	O
30	hyperphosphorylation	O
31	of	O
32	Jak	B
33	kinases	I
34	in	O
35	the	O
36	motheaten	O
37	cells	O
38	that	O
39	lack	O
40	functional	O
41	SHP	B
42	-	I
43	1	I
44	.	O

1	Administration	O
2	of	O
3	a	O
4	second	O
5	dose	O
6	of	O
7	vaccine	O
8	during	O
9	the	O
10	outbreak	O
11	was	O
12	not	O
13	protective	O
14	.	O

1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O

1	Biol	O
2	.	O

1	Structural	O
2	basis	O
3	for	O
4	activation	O
5	of	O
6	human	B
7	lymphocyte	I
8	kinase	I
9	Lck	I
10	upon	O
11	tyrosine	O
12	phosphorylation	O
13	.	O

1	Evolutive	O
2	morphology	O
3	of	O
4	the	O
5	olfactory	O
6	bulb	O
7	in	O
8	man	O
9	and	O
10	certain	O
11	non	O
12	-	O
13	human	O
14	mammals	O

1	From	O
2	these	O
3	results	O
4	,	O
5	we	O
6	concluded	O
7	that	O
8	this	O
9	ORF	O
10	is	O
11	the	O
12	FRDS	B
13	gene	I
14	.	O

1	FK506	O
2	is	O
3	10	O
4	-	O
5	to	O
6	100	O
7	-	O
8	fold	O
9	more	O
10	potent	O
11	than	O
12	cyclosporin	O
13	A	O
14	in	O
15	preventing	O
16	organ	O
17	rejection	O
18	and	O
19	in	O
20	toxicity	O
21	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Rho1p	B
6	regulates	O
7	cytoskeletal	O
8	reorganization	O
9	at	O
10	least	O
11	through	O
12	Bni1p	B
13	and	O
14	Pkc1p	B
15	.	O

1	The	O
2	ERH	B
3	expression	O
4	profile	O
5	is	O
6	similar	O
7	,	O
8	to	O
9	that	O
10	of	O
11	An3	B
12	,	O
13	which	O
14	localizes	O
15	to	O
16	the	O
17	animal	O
18	hemisphere	O
19	of	O
20	oocytes	O
21	and	O
22	is	O
23	abundantly	O
24	expressed	O
25	in	O
26	the	O
27	embryo	O
28	.	O

1	Waves	O
2	N1	O
3	,	O
4	P3	O
5	and	O
6	CNV	O
7	were	O
8	recorded	O
9	during	O
10	a	O
11	CNV	O
12	paradigm	O
13	in	O
14	a	O
15	simple	O
16	reaction	O
17	time	O
18	task	O
19	with	O
20	a	O
21	constant	O
22	interstimulus	O
23	interval	O
24	(	O
25	ISI	O
26	)	O
27	of	O
28	1	O
29	sec	O
30	.	O

1	Therefore	O
2	,	O
3	both	O
4	the	O
5	Chilean	O
6	and	O
7	the	O
8	Japanese	O
9	samples	O
10	collected	O
11	in	O
12	high	O
13	-	O
14	risk	O
15	areas	O
16	showed	O
17	higher	O
18	mutagenic	O
19	rates	O
20	than	O
21	the	O
22	Japanese	O
23	ones	O
24	in	O
25	a	O
26	low	O
27	-	O
28	risk	O
29	area	O
30	,	O
31	with	O
32	a	O
33	statistical	O
34	significance	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	chi	O
43	-	O
44	square	O
45	test	O
46	).	O

1	Regulation	O
2	of	O
3	ASN1	B
4	and	O
5	ASN2	B
6	expression	O
7	was	O
8	studied	O
9	using	O
10	lacZ	B
11	fusions	I
12	and	O
13	both	O
14	genes	O
15	were	O
16	found	O
17	to	O
18	be	O
19	several	O
20	times	O
21	less	O
22	expressed	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	the	O
28	transcription	O
29	activator	O
30	Gcn4p	B
31	.	O

1	Several	O
2	particular	O
3	features	O
4	of	O
5	this	O
6	polypeptide	O
7	fragment	O
8	from	O
9	the	O
10	hamster	B
11	lysyl	I
12	-	I
13	tRNA	I
14	synthetase	I
15	suggest	O
16	that	O
17	it	O
18	is	O
19	implicated	O
20	in	O
21	the	O
22	assembly	O
23	of	O
24	that	O
25	enzyme	O
26	within	O
27	the	O
28	multisynthetase	O
29	complex	O
30	.	O

1	He	O
2	is	O
3	well	O
4	,	O
5	five	O
6	years	O
7	after	O
8	relapse	O
9	.	O

1	Comparison	O
2	of	O
3	the	O
4	proportion	O
5	of	O
6	nonsynonymous	O
7	(	O
8	pN	O
9	)	O
10	and	O
11	synonymous	O
12	(	O
13	pS	O
14	)	O
15	substitutions	O
16	occurring	O
17	per	O
18	site	O
19	within	O
20	tamarin	B
21	variable	I
22	region	I
23	genes	I
24	demonstrated	O
25	a	O
26	reduction	O
27	in	O
28	pN	O
29	in	O
30	the	O
31	framework	O
32	regions	O
33	compared	O
34	with	O
35	pN	O
36	in	O
37	the	O
38	presumed	O
39	MHC	B
40	contact	I
41	regions	I
42	(	O
43	CDR1	B
44	and	O
45	CDR2	B
46	).	O

1	The	O
2	effects	O
3	of	O
4	oral	O
5	vanadyl	O
6	sulfate	O
7	(	O
8	VOSO4	O
9	)	O
10	(	O
11	0	O
12	.	O
13	5	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	on	O
21	anthropometry	O
22	,	O
23	body	O
24	composition	O
25	,	O
26	and	O
27	performance	O
28	were	O
29	investigated	O
30	in	O
31	a	O
32	12	O
33	-	O
34	week	O
35	,	O
36	double	O
37	-	O
38	blind	O
39	,	O
40	placebo	O
41	-	O
42	controlled	O
43	trial	O
44	involving	O
45	weight	O
46	-	O
47	training	O
48	volunteers	O
49	.	O

1	Later	O
2	in	O
3	development	O
4	,	O
5	Tbx6	B
6	expression	O
7	is	O
8	restricted	O
9	to	O
10	presomitic	O
11	,	O
12	paraxial	O
13	mesoderm	O
14	and	O
15	to	O
16	the	O
17	tail	O
18	bud	O
19	,	O
20	which	O
21	replaces	O
22	the	O
23	streak	O
24	as	O
25	the	O
26	source	O
27	of	O
28	mesoderm	O
29	.	O

1	Disruption	O
2	of	O
3	re	O
4	-	O
5	replication	O
6	control	O
7	by	O
8	overexpression	O
9	of	O
10	human	B
11	ORC1	I
12	in	O
13	fission	O
14	yeast	O
15	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	promoter	O
7	and	O
8	enhancer	O
9	regions	O
10	identified	O
11	here	O
12	are	O
13	essential	O
14	for	O
15	maintaining	O
16	the	O
17	efficient	O
18	promoter	O
19	activity	O
20	of	O
21	the	O
22	human	B
23	activin	I
24	betaA	I
25	subunit	I
26	gene	I
27	.	O

1	Recombinant	O
2	,	O
3	bacterially	O
4	expressed	O
5	PIP5KIalpha	B
6	possessed	O
7	PIP5K	B
8	activity	O
9	and	O
10	was	O
11	immunoreactive	O
12	with	O
13	erythroid	B
14	PIP5KI	I
15	antibodies	I
16	.	O

1	Human	B
2	acid	I
3	ceramidase	I
4	((	O
5	AC	O
6	)	O
7	N	O
8	-	O
9	acylsphingosine	O
10	amidohydrolase	O
11	,	O
12	EC	B
13	3	I
14	.	I
15	5	I
16	.	O

1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	NheI	B
8	/	O
9	BglII	B
10	promoter	O
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	EGR	B
29	-	I
30	1	I
31	transcription	I
32	factors	I
33	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	blot	O
6	analyses	O
7	indicated	O
8	that	O
9	the	O
10	cdh	B
11	genes	I
12	encoding	O
13	the	O
14	five	O
15	subunits	O
16	and	O
17	an	O
18	open	O
19	reading	O
20	frame	O
21	(	O
22	ORF1	O
23	)	O
24	with	O
25	unknown	O
26	function	O
27	are	O
28	cotranscribed	O
29	during	O
30	growth	O
31	on	O
32	acetate	O
33	.	O

1	Two	O
2	classes	O
3	of	O
4	mutations	O
5	were	O
6	obtained	O
7	:	O
8	(	O
9	i	O
10	)	O
11	those	O
12	that	O
13	altered	O
14	the	O
15	coding	O
16	region	O
17	of	O
18	HOL1	B
19	,	O
20	conferring	O
21	the	O
22	ability	O
23	to	O
24	take	O
25	up	O
26	histidinol	O
27	;	O
28	and	O
29	(	O
30	ii	O
31	)	O
32	cis	O
33	-	O
34	acting	O
35	mutations	O
36	(	O
37	selected	O
38	in	O
39	a	O
40	mutant	O
41	HOL1	B
42	-	I
43	1	I
44	background	O
45	)	O
46	that	O
47	increased	O
48	expression	O
49	of	O
50	the	O
51	Hol1	B
52	protein	I
53	.	O

1	Damage	O
2	to	O
3	the	O
4	BBB	O
5	was	O
6	judged	O
7	by	O
8	extravasation	O
9	of	O
10	Evans	O
11	Blue	O
12	(	O
13	EB	O
14	)	O
15	dye	O
16	,	O
17	which	O
18	was	O
19	administered	O
20	either	O
21	2	O
22	,	O
23	3	O
24	,	O
25	24	O
26	or	O
27	48	O
28	h	O
29	after	O
30	onset	O
31	of	O
32	MCAo	O
33	.	O

1	Lipid	O
2	hydroperoxide	O
3	levels	O
4	in	O
5	plasma	O
6	and	O
7	LDL	B
8	remained	O
9	unchanged	O
10	throughout	O
11	the	O
12	study	O
13	.	O

1	When	O
2	the	O
3	degree	O
4	of	O
5	exercise	O
6	was	O
7	maximal	O
8	,	O
9	mPAP	O
10	was	O
11	maintained	O
12	,	O
13	SVI	O
14	decreased	O
15	,	O
16	HR	O
17	was	O
18	unchanged	O
19	,	O
20	and	O
21	CO	O
22	and	O
23	VO2	O
24	decreased	O
25	.	O

1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	vasculitis	O
7	(	O
8	cutaneous	O
9	and	O
10	neurologic	O
11	)	O
12	which	O
13	led	O
14	to	O
15	the	O
16	discovery	O
17	of	O
18	a	O
19	selective	O
20	immunodeficit	O
21	towards	O
22	EBV	O
23	,	O
24	similar	O
25	to	O
26	Purtilo	O
27	'	O
28	s	O
29	syndrome	O
30	.	O

1	To	O
2	elucidate	O
3	whether	O
4	potential	O
5	endocrine	O
6	changes	O
7	resulted	O
8	from	O
9	acute	O
10	hypoxaemia	O
11	alone	O
12	,	O
13	the	O
14	underlying	O
15	disease	O
16	,	O
17	or	O
18	unspecific	O
19	influences	O
20	connected	O
21	with	O
22	the	O
23	ICU	O
24	setting	O
25	,	O
26	all	O
27	measurements	O
28	were	O
29	compared	O
30	to	O
31	those	O
32	of	O
33	a	O
34	completely	O
35	healthy	O
36	reference	O
37	group	O
38	(	O
39	REF	O
40	)	O
41	with	O
42	comparable	O
43	acute	O
44	experimental	O
45	hypoxaemia	O
46	.	O

1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	graft	O
8	survival	O
9	between	O
10	groups	O
11	with	O
12	early	O
13	graft	O
14	function	O
15	(	O
16	EGF	O
17	)	O
18	and	O
19	DGF	O
20	,	O
21	either	O
22	in	O
23	first	O
24	transplantations	O
25	or	O
26	retransplantations	O
27	.	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	GG	O
7	motifs	O
8	contributed	O
9	to	O
10	the	O
11	cell	O
12	-	O
13	specific	O
14	transcription	O
15	of	O
16	the	O
17	human	B
18	insulin	I
19	gene	I
20	in	O
21	association	O
22	with	O
23	the	O
24	binding	O
25	of	O
26	the	O
27	sequence	O
28	-	O
29	specific	O
30	nuclear	O
31	factor	O
32	.	O

1	Abnormal	O
2	urinary	O
3	coproporphyrin	O
4	levels	O
5	in	O
6	patients	O
7	infected	O
8	by	O
9	hepatitis	O
10	C	O
11	virus	O
12	with	O
13	or	O
14	without	O
15	human	O
16	immunodeficiency	O
17	virus	O
18	.	O

1	The	O
2	determination	O
3	of	O
4	immunoglobulin	B
5	E	I
6	(	O
7	IgE	B
8	)	O
9	antibodies	O
10	by	O
11	one	O
12	of	O
13	several	O
14	laboratory	O
15	tests	O
16	,	O
17	by	O
18	skin	O
19	-	O
20	prick	O
21	tests	O
22	or	O
23	by	O
24	appropriate	O
25	challenge	O
26	procedures	O
27	is	O
28	useful	O
29	either	O
30	to	O
31	identify	O
32	atopic	O
33	individuals	O
34	or	O
35	as	O
36	outcome	O
37	predictors	O
38	in	O
39	wheezy	O
40	children	O
41	.	O

1	Thrombosis	O
2	of	O
3	the	O
4	renal	O
5	vein	O
6	may	O
7	be	O
8	dramatic	O
9	and	O
10	include	O
11	renal	O
12	failure	O
13	.	O

1	Filter	O
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O

1	327	O
2	and	O
3	736	O
4	protocols	O
5	of	O
6	postmortem	O
7	examinations	O
8	from	O
9	Moscow	O
10	hospitals	O
11	N	O
12	31	O
13	and	O
14	57	O
15	,	O
16	respectively	O
17	,	O
18	were	O
19	evaluated	O
20	statistically	O
21	.	O

1	The	O
2	promoter	O
3	segment	O
4	was	O
5	inactive	O
6	when	O
7	introduced	O
8	into	O
9	the	O
10	rat	O
11	glioma	O
12	cell	O
13	line	O
14	C6B4	O
15	,	O
16	the	O
17	rat	O
18	submandibular	O
19	cell	O
20	line	O
21	RSMT	O
22	-	O
23	A5	O
24	,	O
25	and	O
26	the	O
27	rat	O
28	pancreatic	O
29	beta	O
30	cell	O
31	line	O
32	RIN	O
33	-	O
34	5AH	O
35	,	O
36	all	O
37	of	O
38	which	O
39	do	O
40	not	O
41	express	O
42	the	O
43	endogenous	O
44	alpha2c	B
45	-	I
46	AR	I
47	gene	I
48	.	O

1	The	O
2	sequencing	O
3	of	O
4	the	O
5	conditional	O
6	lethal	O
7	mutation	O
8	ts	O
9	-	O
10	A13	O
11	,	O
12	localized	O
13	in	O
14	the	O
15	nrdE	B
16	cistron	I
17	,	O
18	and	O
19	the	O
20	lethality	O
21	of	O
22	insertional	O
23	mutations	O
24	targeted	O
25	in	O
26	the	O
27	internal	O
28	region	O
29	of	O
30	nrdE	B
31	and	O
32	nrdF	B
33	,	O
34	demonstrated	O
35	the	O
36	essential	O
37	role	O
38	of	O
39	this	O
40	locus	O
41	.	O

1	The	O
2	microdensitometric	O
3	scores	O
4	and	O
5	their	O
6	side	O
7	-	O
8	to	O
9	-	O
10	side	O
11	differences	O
12	in	O
13	patients	O
14	correlated	O
15	negatively	O
16	with	O
17	the	O
18	serum	O
19	25	O
20	-	O
21	OHD	O
22	concentration	O
23	and	O
24	positively	O
25	with	O
26	the	O
27	degree	O
28	of	O
29	paralysis	O
30	.	O

1	These	O
2	data	O
3	do	O
4	not	O
5	support	O
6	the	O
7	use	O
8	of	O
9	LDD	O
10	to	O
11	reduce	O
12	risk	O
13	of	O
14	progression	O
15	to	O
16	MSOF	O
17	in	O
18	sepsis	O
19	.	O

1	This	O
2	correlated	O
3	with	O
4	reduced	O
5	levels	O
6	of	O
7	secreted	O
8	hepatitis	B
9	B	I
10	e	I
11	antigen	I
12	and	O
13	increased	O
14	intracellular	O
15	levels	O
16	of	O
17	core	B
18	and	O
19	Pol	B
20	proteins	I
21	and	O
22	replicative	O
23	HBV	O
24	DNA	O
25	intermediates	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	extracts	O
5	of	O
6	the	O
7	mutant	O
8	virions	O
9	catalyze	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	level	O
15	of	O
16	transcription	O
17	from	O
18	an	O
19	exogenous	O
20	template	O
21	containing	O
22	an	O
23	early	O
24	promoter	O
25	.	O

1	The	O
2	SCMV	B
3	SNE	I
4	sites	I
5	contain	O
6	potential	O
7	overlapping	O
8	core	O
9	recognition	O
10	binding	O
11	motifs	O
12	for	O
13	SRF	B
14	,	O
15	Rel	B
16	/	O
17	NFkappaB	B
18	,	O
19	ETS	B
20	,	O
21	and	O
22	YY1	B
23	class	I
24	transcription	I
25	factors	I
26	but	O
27	fail	O
28	to	O
29	respond	O
30	to	O
31	either	O
32	serum	O
33	or	O
34	tumor	B
35	necrosis	I
36	factor	I
37	alpha	I
38	.	O

1	Upon	O
2	serum	O
3	withdrawal	O
4	at	O
5	the	O
6	permissive	O
7	temperature	O
8	,	O
9	p53	B
10	-	O
11	mediated	O
12	apoptosis	O
13	was	O
14	induced	O
15	in	O
16	50	O
17	to	O
18	60	O
19	%	O
20	of	O
21	the	O
22	cells	O
23	.	O

1	To	O
2	circumvent	O
3	this	O
4	problem	O
5	,	O
6	a	O
7	simple	O
8	two	O
9	-	O
10	step	O
11	strategy	O
12	was	O
13	devised	O
14	by	O
15	which	O
16	essential	O
17	cis	O
18	-	O
19	acting	O
20	sites	O
21	like	O
22	the	O
23	a	O
24	sequence	O
25	can	O
26	be	O
27	readily	O
28	deleted	O
29	from	O
30	their	O
31	natural	O
32	loci	O
33	in	O
34	large	O
35	viral	O
36	DNA	O
37	genomes	O
38	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serological	O
6	studies	O
7	,	O
8	the	O
9	highly	O
10	conserved	O
11	A	O
12	domain	O
13	of	O
14	HspA	B
15	was	O
16	found	O
17	to	O
18	be	O
19	the	O
20	immunodominant	O
21	domain	O
22	.	O

1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	O
7	alpha	B
8	-	I
9	MSH	I
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	BAEPs	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O

1	The	O
2	Fas	B
3	receptor	I
4	mediates	O
5	a	O
6	signalling	O
7	cascade	O
8	resulting	O
9	in	O
10	programmed	O
11	cell	O
12	death	O
13	(	O
14	apoptosis	O
15	)	O
16	within	O
17	hours	O
18	of	O
19	receptor	O
20	cross	O
21	-	O
22	linking	O
23	.	O

1	Fas	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	require	O
7	ICE	B
8	(	O
9	interleukin	B
10	-	I
11	1	I
12	beta	I
13	-	I
14	converting	I
15	enzyme	I
16	)	O
17	family	O
18	proteases	O
19	to	O
20	induce	O
21	apoptosis	O
22	from	O
23	studies	O
24	utilizing	O
25	the	O
26	cowpox	O
27	ICE	B
28	inhibitor	I
29	protein	I
30	CrmA	I
31	,	O
32	the	O
33	synthetic	O
34	tetrapeptide	O
35	ICE	B
36	inhibitor	O
37	YVAD	B
38	-	I
39	CMK	I
40	,	O
41	and	O
42	the	O
43	tripeptide	O
44	pan	O
45	-	O
46	ICE	B
47	inhibitor	O
48	Z	B
49	-	I
50	VAD	I
51	-	I
52	FMK	I
53	.	O

1	The	O
2	imprinted	O
3	expression	O
4	of	O
5	the	O
6	endogenous	O
7	gene	O
8	can	O
9	be	O
10	recapitulated	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	transgene	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	endoderm	O
42	-	O
43	specific	O
44	enhancers	O
45	,	O
46	and	O
47	an	O
48	internally	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	hGCN5	B
9	is	O
10	also	O
11	an	O
12	HAT	B
13	and	O
14	has	O
15	the	O
16	same	O
17	substrate	O
18	specificity	O
19	as	O
20	yGCN5	B
21	.	O

1	The	O
2	effect	O
3	of	O
4	six	O
5	arginine	O
6	mutations	O
7	of	O
8	oxidative	O
9	phosphorylation	O
10	and	O
11	AAC	B
12	expression	O
13	.	O

1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	I
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O

1	In	O
2	some	O
3	cases	O
4	,	O
5	factor	O
6	-	O
7	induced	O
8	Rac	B
9	activation	O
10	results	O
11	in	O
12	Rho	B
13	activation	O
14	,	O
15	and	O
16	factor	O
17	-	O
18	induced	O
19	Cdc42	B
20	activation	O
21	leads	O
22	to	O
23	Rac	B
24	activation	O
25	,	O
26	as	O
27	determined	O
28	by	O
29	specific	O
30	morphological	O
31	changes	O
32	.	O

1	Several	O
2	cDNAs	O
3	corresponding	O
4	to	O
5	the	O
6	human	B
7	PWP2	I
8	gene	I
9	were	O
10	identified	O
11	and	O
12	partially	O
13	sequenced	O
14	.	O

1	Isolation	O
2	and	O
3	genomic	O
4	structure	O
5	of	O
6	a	O
7	human	O
8	homolog	O
9	of	O
10	the	O
11	yeast	B
12	periodic	I
13	tryptophan	I
14	protein	I
15	2	I
16	(	O
17	PWP2	B
18	)	O
19	gene	O
20	mapping	O
21	to	O
22	21q22	O
23	.	O
24	3	O
25	.	O

1	Patterns	O
2	defined	O
3	by	O
4	combinations	O
5	of	O
6	normal	O
7	and	O
8	abnormal	O
9	laboratory	O
10	results	O
11	had	O
12	decreased	O
13	the	O
14	likelihood	O
15	of	O
16	PEM	O
17	from	O
18	an	O
19	all	O
20	-	O
21	2	O
22	to	O
23	all	O
24	-	O
25	0	O
26	pattern	O
27	.	O

1	To	O
2	examine	O
3	whether	O
4	thiamine	O
5	(	O
6	vitamin	O
7	B1	O
8	)	O
9	deficiency	O
10	is	O
11	associated	O
12	with	O
13	recurrent	O
14	aphthous	O
15	stomatitis	O
16	,	O
17	we	O
18	studied	O
19	vitamin	O
20	B1	O
21	levels	O
22	in	O
23	70	O
24	patients	O
25	with	O
26	recurrent	O
27	aphthous	O
28	stomatitis	O
29	and	O
30	in	O
31	50	O
32	members	O
33	of	O
34	a	O
35	control	O
36	group	O
37	.	O

1	Liver	O
2	injuries	O

1	By	O
2	screening	O
3	a	O
4	cDNA	O
5	library	O
6	with	O
7	a	O
8	probe	O
9	derived	O
10	from	O
11	sequences	O
12	downstream	O
13	of	O
14	the	O
15	p53p2	B
16	start	O
17	site	O
18	,	O
19	we	O
20	have	O
21	cloned	O
22	and	O
23	characterized	O
24	a	O
25	cDNA	O
26	that	O
27	represents	O
28	a	O
29	mRNA	O
30	that	O
31	appears	O
32	to	O
33	have	O
34	been	O
35	initiated	O
36	from	O
37	the	O
38	p53p2	B
39	promoter	I
40	.	O

1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	B
13	plasma	I
14	PSA	I
15	levels	O
16	.	O

1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O

1	G	B
2	-	I
3	CSF	I
4	activates	O
5	multiple	O
6	signaling	O
7	molecules	O
8	,	O
9	including	O
10	the	O
11	JAK1	B
12	and	O
13	JAK2	B
14	kinases	I
15	and	O
16	the	O
17	STAT	B
18	transcription	O
19	factors	O
20	.	O

1	Mutants	O
2	lacking	O
3	any	O
4	tyrosine	O
5	residues	O
6	in	O
7	the	O
8	cytoplasmic	O
9	domain	O
10	maintain	O
11	their	O
12	ability	O
13	to	O
14	activate	O
15	STAT5	B
16	and	O
17	STAT1	B
18	but	O
19	cannot	O
20	activate	O
21	STAT3	B
22	,	O
23	implying	O
24	that	O
25	STAT5	B
26	and	O
27	STAT1	B
28	activation	O
29	does	O
30	not	O
31	require	O
32	receptor	O
33	tyrosine	O
34	phosphorylation	O
35	.	O

1	The	O
2	RI	B
3	alpha	I
4	gene	I
5	is	O
6	composed	O
7	of	O
8	nine	O
9	coding	O
10	exons	O
11	of	O
12	varying	O
13	lengths	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	O
24	length	O
25	of	O
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	RI	B
38	alpha	I
39	pseudogene	I
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	O
45	region	O
46	different	O
47	from	O
48	the	O
49	previously	O
50	reported	O
51	RI	B
52	alpha	I
53	complementary	I
54	RNA	I
55	indicated	O
56	that	O
57	the	O
58	RI	B
59	alpha	I
60	gene	I
61	may	O
62	have	O
63	multiple	O
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	alternately	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O

1	This	O
2	establishes	O
3	Rad3	B
4	/	O
5	Mec1	B
6	as	O
7	the	O
8	only	O
9	conserved	O
10	protein	O
11	which	O
12	is	O
13	required	O
14	for	O
15	all	O
16	the	O
17	DNA	O
18	structure	O
19	checkpoints	O
20	in	O
21	both	O
22	yeast	O
23	model	O
24	systems	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	double	O
5	mutants	O
6	with	O
7	either	O
8	dim1	B
9	-	I
10	delta	I
11	or	O
12	dim2	B
13	-	I
14	1	I
15	and	O
16	the	O
17	endocytosis	O
18	mutants	B
19	end4	I
20	-	I
21	1	I
22	or	O
23	act1	B
24	-	I
25	1	I
26	displayed	O
27	synthetic	O
28	growth	O
29	defects	O
30	,	O
31	indicating	O
32	that	O
33	the	O
34	DIM	B
35	gene	I
36	products	I
37	function	O
38	in	O
39	a	O
40	common	O
41	or	O
42	parallel	O
43	endocytic	O
44	pathway	O
45	.	O

1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	BL	O
6	cell	O
7	line	O
8	Raji	O
9	with	O
10	constructs	O
11	containing	O
12	core	O
13	promoter	O
14	mutations	O
15	confirmed	O
16	that	O
17	the	O
18	proximal	O
19	Sp1	B
20	site	I
21	and	O
22	the	O
23	TATA	O
24	box	O
25	are	O
26	essential	O
27	for	O
28	the	O
29	activation	O
30	of	O
31	promoter	O
32	P1	O
33	by	O
34	the	O
35	Ig	B
36	kappa	I
37	enhancers	I
38	.	O

1	Such	O
2	multisensory	O
3	interactions	O
4	can	O
5	be	O
6	significant	O
7	for	O
8	behavior	O
9	.	O

1	The	O
2	P13	O
3	and	O
4	N22	O
5	of	O
6	ppSEPs	O
7	had	O
8	phase	O
9	reversal	O
10	relationship	O
11	with	O
12	the	O
13	P2	O
14	and	O
15	N2	O
16	recorded	O
17	from	O
18	the	O
19	PES	O
20	,	O
21	respectively	O
22	.	O

1	The	O
2	cDNA	O
3	of	O
4	cpm7	B
5	encodes	O
6	a	O
7	closely	O
8	related	O
9	protein	O
10	of	O
11	36	O
12	.	O
13	8	O
14	kDa	O
15	.	O

1	Finally	O
2	,	O
3	the	O
4	C	O
5	-	O
6	terminal	O
7	region	O
8	of	O
9	ENBP1	B
10	shows	O
11	strong	O
12	homology	O
13	to	O
14	a	O
15	protein	O
16	from	O
17	rat	O
18	that	O
19	is	O
20	specifically	O
21	expressed	O
22	in	O
23	testis	O
24	tissue	O
25	.	O

1	The	O
2	conservation	O
3	of	O
4	both	O
5	the	O
6	G	O
7	-	O
8	box	O
9	and	O
10	H	O
11	-	O
12	box	O
13	in	O
14	different	O
15	CHS	B
16	promoters	I
17	emphasizes	O
18	their	O
19	importance	O
20	as	O
21	regulatory	O
22	motifs	O
23	.	O

1	Mortality	O
2	on	O
3	the	O
4	last	O
5	ranch	O
6	was	O
7	particularly	O
8	severe	O
9	among	O
10	certain	O
11	segregated	O
12	groups	O
13	of	O
14	turkeys	O
15	that	O
16	included	O
17	toms	O
18	,	O
19	heavier	O
20	birds	O
21	,	O
22	and	O
23	birds	O
24	undergoing	O
25	a	O
26	stressful	O
27	event	O
28	such	O
29	as	O
30	artificial	O
31	insemination	O
32	.	O

1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O

1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O

1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O

1	The	O
2	first	O
3	identification	O
4	of	O
5	the	O
6	active	O
7	37LRP	B
8	/	O
9	p40	B
10	gene	O
11	presented	O
12	in	O
13	this	O
14	study	O
15	is	O
16	a	O
17	critical	O
18	step	O
19	toward	O
20	the	O
21	isolation	O
22	of	O
23	the	O
24	corresponding	O
25	human	O
26	gene	O
27	and	O
28	the	O
29	understanding	O
30	of	O
31	the	O
32	molecular	O
33	mechanisms	O
34	involved	O
35	in	O
36	the	O
37	up	O
38	-	O
39	regulation	O
40	of	O
41	its	O
42	expression	O
43	during	O
44	tumor	O
45	invasion	O
46	and	O
47	metastasis	O
48	.	O

1	The	O
2	promoter	O
3	region	O
4	(	O
5	P1	O
6	)	O
7	corresponding	O
8	to	O
9	the	O
10	main	O
11	group	O
12	of	O
13	transcription	O
14	initiation	O
15	sites	O
16	is	O
17	devoid	O
18	of	O
19	TATA	O
20	and	O
21	CAAT	O
22	boxes	O
23	but	O
24	has	O
25	putative	O
26	binding	O
27	sites	O
28	for	O
29	the	O
30	transcription	B
31	factor	I
32	SP1	I
33	and	O
34	is	O
35	embedded	O
36	in	O
37	a	O
38	large	O
39	G	O
40	+	O
41	C	O
42	-	O
43	rich	O
44	domain	O
45	of	O
46	a	O
47	CpG	O
48	island	O
49	,	O
50	features	O
51	shared	O
52	by	O
53	the	O
54	promoters	O
55	of	O
56	constitutively	O
57	expressed	O
58	housekeeping	O
59	genes	O
60	.	O

1	The	O
2	STAT	B
3	-	I
4	1	I
5	signaling	O
6	pathway	O
7	provides	O
8	at	O
9	least	O
10	one	O
11	mechanism	O
12	for	O
13	activation	O
14	of	O
15	the	O
16	CAEV	B
17	LTR	I
18	by	O
19	IFN	B
20	-	I
21	gamma	I
22	in	O
23	monocytes	O
24	.	O

1	Reperfusion	O
2	caused	O
3	a	O
4	transient	O
5	reduction	O
6	in	O
7	lactate	O
8	production	O
9	and	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	LDH	B
15	release	O
16	.	O

1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	regenerative	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	alcoholic	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	263	O
17	patients	O
18	with	O
19	severe	O
20	alcoholic	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	B
30	growth	I
31	factor	I
32	(	O
33	HGF	B
34	)	O
35	and	O
36	alpha	B
37	-	I
38	fetoprotein	I
39	(	O
40	AFP	B
41	).	O

1	Children	O
2	born	O
3	from	O
4	chronic	O
5	alcoholic	O
6	mothers	O
7	have	O
8	shown	O
9	behavioral	O
10	teratogenic	O
11	effects	O
12	more	O
13	frequently	O
14	than	O
15	morphological	O
16	malformations	O
17	.	O

1	INTERVENTION	O
2	(	O
3	S	O
4	):	O
5	Twenty	O
6	-	O
7	six	O
8	hemostasis	O
9	parameters	O
10	evaluated	O
11	repeatedly	O
12	in	O
13	patients	O
14	undergoing	O
15	IVF	O
16	-	O
17	ET	O
18	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	I	B
9	-	I
10	POU	I
11	/	O
12	tI	B
13	-	I
14	POU	I
15	message	O
16	is	O
17	maximal	O
18	late	O
19	in	O
20	the	O
21	embryonic	O
22	phase	O
23	of	O
24	Drosophila	O
25	development	O
26	,	O
27	and	O
28	I	B
29	-	I
30	POU	I
31	is	O
32	the	O
33	preferred	O
34	splice	O
35	variant	O
36	.	O

1	Unlike	O
2	wild	B
3	-	I
4	type	I
5	p53	I
6	,	O
7	the	O
8	delta	B
9	proAE	I
10	mutant	I
11	cDNA	I
12	can	O
13	be	O
14	stably	O
15	expressed	O
16	in	O
17	tumor	O
18	derived	O
19	cell	O
20	lines	O
21	with	O
22	few	O
23	immediate	O
24	detrimental	O
25	effects	O
26	.	O

1	The	O
2	patient	O
3	'	O
4	s	O
5	role	O
6	,	O
7	organized	O
8	by	O
9	the	O
10	prerequisites	O
11	of	O
12	expressive	O
13	freedom	O
14	,	O
15	is	O
16	counter	O
17	posed	O
18	with	O
19	the	O
20	psychoanalyst	O
21	'	O
22	s	O
23	,	O
24	which	O
25	is	O
26	structured	O
27	to	O
28	empower	O
29	listening	O
30	and	O
31	understanding	O
32	.	O

1	The	O
2	most	O
3	common	O
4	risk	O
5	factor	O
6	reported	O
7	for	O
8	both	O
9	recent	O
10	and	O
11	all	O
12	other	O
13	hepatitis	O
14	C	O
15	cases	O
16	was	O
17	a	O
18	history	O
19	of	O
20	injecting	O
21	drug	O
22	use	O
23	,	O
24	although	O
25	the	O
26	proportion	O
27	of	O
28	cases	O
29	with	O
30	that	O
31	history	O
32	was	O
33	different	O
34	in	O
35	NT	O
36	from	O
37	ACT	O
38	and	O
39	Queensland	O
40	.	O

1	Silencing	O
2	can	O
3	be	O
4	restored	O
5	by	O
6	creation	O
7	of	O
8	a	O
9	telomere	O
10	at	O
11	13	O
12	kb	O
13	from	O
14	the	O
15	reporter	O
16	construct	O
17	,	O
18	or	O
19	by	O
20	insertion	O
21	of	O
22	340	O
23	bp	O
24	of	O
25	yeast	O
26	telomeric	O
27	repeat	O
28	sequence	O
29	at	O
30	this	O
31	site	O
32	without	O
33	chromosomal	O
34	truncation	O
35	.	O

1	In	O
2	contrast	O
3	with	O
4	previous	O
5	two	O
6	-	O
7	pool	O
8	models	O
9	,	O
10	provisions	O
11	were	O
12	made	O
13	for	O
14	folate	O
15	turnover	O
16	by	O
17	urinary	O
18	folate	O
19	excretion	O
20	(	O
21	as	O
22	measured	O
23	here	O
24	)	O
25	and	O
26	by	O
27	fecal	O
28	excretion	O
29	and	O
30	catabolic	O
31	processes	O
32	.	O

1	When	O
2	voltage	O
3	-	O
4	operated	O
5	Ca2	O
6	+	O
7	channels	O
8	(	O
9	VOC	O
10	)	O
11	were	O
12	blocked	O
13	by	O
14	nifedipine	O
15	,	O
16	midazolam	O
17	,	O
18	in	O
19	concentrations	O
20	more	O
21	than	O
22	1	O
23	microM	O
24	,	O
25	attenuated	O
26	both	O
27	phasic	O
28	and	O
29	tonic	O
30	responses	O
31	.	O

1	Several	O
2	artifacts	O
3	occurred	O
4	that	O
5	interfered	O
6	with	O
7	visualization	O
8	of	O
9	the	O
10	diaphragm	O
11	.	O

1	Although	O
2	p48	B
3	gene	I
4	induction	O
5	is	O
6	dependent	O
7	on	O
8	STAT1	B
9	and	O
10	JAK1	B
11	,	O
12	activated	O
13	STAT1	B
14	does	O
15	not	O
16	bind	O
17	to	O
18	GATE	B
19	.	O

1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	B
21	thyrotropin	I
22	secretion	O
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O

1	Finally	O
2	,	O
3	nonphotosynthetic	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	tscA	B
9	-	I
10	lacking	I
11	photosystem	I
12	I	I
13	mutant	I
14	,	O
15	H13	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O

1	The	O
2	progression	O
3	of	O
4	acute	O
5	bronchitis	O
6	is	O
7	associated	O
8	with	O
9	elevated	O
10	blood	O
11	concentrations	O
12	of	O
13	acute	O
14	-	O
15	phase	O
16	proteins	O
17	,	O
18	KKS	B
19	activation	O
20	in	O
21	the	O
22	blood	O
23	and	O
24	high	O
25	serotonin	O
26	and	O
27	lactic	O
28	acid	O
29	content	O
30	in	O
31	the	O
32	humor	O
33	condensated	O
34	from	O
35	the	O
36	exhaled	O
37	air	O
38	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	Differential	O
2	signaling	O
3	and	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	activation	O
9	by	O
10	four	O
11	splice	O
12	variants	O
13	of	O
14	the	O
15	human	B
16	pituitary	I
17	adenylate	I
18	cyclase	I
19	-	I
20	activating	I
21	polypeptide	I
22	receptor	I
23	(	O
24	hPACAP	B
25	-	I
26	R	I
27	).	O

1	During	O
2	skeletal	O
3	muscle	O
4	development	O
5	,	O
6	different	O
7	types	O
8	of	O
9	muscle	O
10	fibers	O
11	are	O
12	generated	O
13	,	O
14	which	O
15	express	O
16	different	O
17	combinations	O
18	of	O
19	muscle	O
20	-	O
21	specific	O
22	gene	O
23	products	O
24	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	with	O
6	respect	O
7	to	O
8	the	O
9	transcriptional	O
10	induction	O
11	of	O
12	the	O
13	HNF	B
14	-	I
15	3	I
16	alpha	I
17	gene	I
18	in	O
19	respiratory	O
20	epithelium	O
21	during	O
22	embryogenesis	O
23	.	O

1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	B
8	(	O
9	maturation	B
10	promoting	I
11	factor	I
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	B
18	/	I
19	28	I
20	-	O
21	cyclin	B
22	B	I
23	complexes	O
24	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	Apo	B
5	-	I
6	3	I
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O

1	An	O
2	N	O
3	-	O
4	terminal	O
5	arm	O
6	from	O
7	each	O
8	subunit	O
9	wraps	O
10	around	O
11	the	O
12	dinucleotide	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	an	O
18	adjacent	O
19	subunit	O
20	,	O
21	covering	O
22	the	O
23	adenine	O
24	ring	O
25	of	O
26	NADP	O
27	.	O

1	Similarity	O
2	is	O
3	most	O
4	striking	O
5	in	O
6	the	O
7	zinc	O
8	knuckle	O
9	region	O
10	,	O
11	a	O
12	region	O
13	characteristic	O
14	of	O
15	gag	B
16	genes	I
17	of	O
18	most	O
19	replication	O
20	-	O
21	competent	O
22	retroelements	O
23	.	O

1	D	O
2	.	O
3	melanogaster	O
4	HeT	B
5	-	I
6	A	I
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	O
12	region	O
13	with	O
14	insertions	O
15	/	O
16	deletions	O
17	of	O
18	1	O
19	-	O
20	31	O
21	codons	O
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O

1	Eukaryotic	B
2	initiation	I
3	factor	I
4	3	I
5	(	O
6	eIF3	B
7	)	O
8	is	O
9	a	O
10	large	O
11	multisubunit	O
12	complex	O
13	that	O
14	stabilizes	O
15	the	O
16	ternary	O
17	complex	O
18	,	O
19	eIF2	B
20	x	O
21	GTP	O
22	x	O
23	tRNA	B
24	(	I
25	Met	I
26	)	I
27	i	I
28	and	O
29	promotes	O
30	mRNA	O
31	binding	O
32	to	O
33	the	O
34	40	B
35	S	I
36	ribosomal	I
37	subunit	I
38	.	O
39	eIF3	B
40	also	O
41	functions	O
42	as	O
43	a	O
44	ribosome	O
45	subunit	O
46	anti	O
47	-	O
48	association	O
49	factor	O
50	.	O

1	Our	O
2	data	O
3	,	O
4	combined	O
5	with	O
6	those	O
7	of	O
8	Hershey	O
9	and	O
10	co	O
11	-	O
12	workers	O
13	,	O
14	suggest	O
15	that	O
16	mammalian	B
17	eIF3	I
18	is	O
19	composed	O
20	of	O
21	at	O
22	least	O
23	10	O
24	subunits	O
25	:	O
26	p170	B
27	,	O
28	p116	B
29	(	O
30	hPrt1	B
31	),	O
32	p110	B
33	,	O
34	p66	B
35	,	O
36	p48	B
37	,	O
38	p47	B
39	,	O
40	p44	B
41	,	O
42	p40	B
43	,	O
44	p36	B
45	,	O
46	and	O
47	p35	B
48	.	O

1	Identification	O
2	of	O
3	a	O
4	cis	O
5	-	O
6	acting	O
7	element	O
8	in	O
9	the	O
10	class	B
11	I	I
12	major	I
13	histocompatibility	I
14	complex	I
15	gene	I
16	promoter	I
17	responsive	O
18	to	O
19	activation	O
20	by	O
21	retroviral	O
22	sequences	O
23	.	O

1	The	O
2	results	O
3	demonstrate	O
4	that	O
5	(	O
6	i	O
7	)	O
8	no	O
9	intact	O
10	capsids	O
11	were	O
12	assembled	O
13	when	O
14	the	O
15	full	O
16	-	O
17	length	O
18	or	O
19	a	O
20	truncated	O
21	(	O
22	missing	O
23	the	O
24	C	O
25	-	O
26	terminal	O
27	65	O
28	amino	O
29	acids	O
30	)	O
31	UL80	B
32	.	I
33	5	I
34	protein	I
35	was	O
36	tested	O
37	;	O
38	(	O
39	ii	O
40	)	O
41	when	O
42	the	O
43	C	O
44	-	O
45	terminal	O
46	65	O
47	amino	O
48	acids	O
49	of	O
50	the	O
51	UL80	B
52	.	I
53	5	I
54	protein	I
55	were	O
56	replaced	O
57	with	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	25	O
63	amino	O
64	acids	O
65	of	O
66	the	O
67	UL26	B
68	.	I
69	5	I
70	protein	I
71	,	O
72	intact	O
73	capsids	O
74	were	O
75	made	O
76	and	O
77	direct	O
78	interaction	O
79	of	O
80	the	O
81	UL80	B
82	.	I
83	5	I
84	protein	I
85	with	O
86	VP5	B
87	was	O
88	detected	O
89	;	O
90	(	O
91	iii	O
92	)	O
93	assembly	O
94	of	O
95	intact	O
96	capsids	O
97	was	O
98	demonstrated	O
99	when	O
100	the	O
101	sequence	O
102	of	O
103	the	O
104	last	O
105	12	O
106	amino	O
107	acids	O
108	of	O
109	the	O
110	UL80	B
111	.	I
112	5	I
113	protein	I
114	was	O
115	changed	O
116	from	O
117	RRIFVA	O
118	ALNKLE	O
119	to	O
120	RRIFVAAMMKLE	O
121	;	O
122	(	O
123	iv	O
124	)	O
125	self	O
126	-	O
127	interaction	O
128	of	O
129	the	O
130	scaffold	O
131	proteins	O
132	is	O
133	mediated	O
134	by	O
135	sequences	O
136	N	O
137	terminal	O
138	to	O
139	the	O
140	maturation	O
141	cleavage	O
142	site	O
143	;	O
144	and	O
145	(	O
146	v	O
147	)	O
148	the	O
149	UL26	B
150	.	I
151	5	I
152	and	O
153	UL80	B
154	.	I
155	5	I
156	proteins	I
157	will	O
158	not	O
159	coassemble	O
160	into	O
161	scaffold	O
162	structures	O
163	.	O

1	Fourth	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	region	O
7	splice	O
8	junctions	O
9	of	O
10	the	O
11	MSRs	B
12	during	O
13	latent	O
14	and	O
15	productive	O
16	infection	O
17	were	O
18	determined	O
19	by	O
20	sequencing	O
21	RNA	O
22	-	O
23	PCR	O
24	products	O
25	generated	O
26	with	O
27	primers	O
28	that	O
29	flank	O
30	the	O
31	3	O
32	'	O
33	splice	O
34	region	O
35	.	O

1	(	O
2	ii	O
3	)	O
4	ICP27	B
5	binds	O
6	preferentially	O
7	to	O
8	less	O
9	modified	O
10	forms	O
11	of	O
12	ICP4	B
13	,	O
14	a	O
15	protein	O
16	that	O
17	is	O
18	extensively	O
19	modified	O
20	posttranslationally	O
21	.	O

1	Lack	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O

1	C	B
2	/	I
3	EBP	I
4	beta	I
5	V	I
6	>	O
7	A	O
8	selectively	O
9	binds	O
10	only	O
11	the	O
12	subset	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	sites	I
18	that	O
19	are	O
20	also	O
21	DBP	B
22	sites	I
23	,	O
24	both	O
25	as	O
26	oligonucleotides	O
27	and	O
28	within	O
29	the	O
30	natural	O
31	contexts	O
32	of	O
33	the	O
34	albumin	B
35	and	O
36	cholesterol	B
37	hydroxylase	I
38	promoters	I
39	.	O

1	Specific	O
2	IgG	B
3	,	O
4	specific	O
5	IgE	B
6	and	O
7	total	O
8	IgE	B
9	immunoglobulins	I
10	against	O
11	Toxocara	B
12	canis	I
13	excretory	I
14	/	I
15	secretory	I
16	antigens	I
17	(	O
18	TES	B
19	)	O
20	were	O
21	detected	O
22	by	O
23	using	O
24	ELISA	O
25	technique	O
26	.	O

1	SUMMARY	O
2	BACKGROUND	O
3	DATA	O
4	:	O
5	Melanoma	O
6	care	O
7	has	O
8	not	O
9	changed	O
10	significantly	O
11	in	O
12	the	O
13	last	O
14	20	O
15	years	O
16	,	O
17	and	O
18	the	O
19	controversy	O
20	of	O
21	elective	O
22	lymph	O
23	node	O
24	dissections	O
25	in	O
26	this	O
27	disease	O
28	continues	O
29	to	O
30	be	O
31	discussed	O
32	.	O

1	The	O
2	differences	O
3	among	O
4	subgenera	O
5	of	O
6	the	O
7	genus	O
8	Dermacentor	O
9	are	O
10	more	O
11	significant	O
12	.	O

1	Mutating	O
2	the	O
3	E	O
4	-	O
5	box	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	B
28	(	I
29	I	I
30	)	I
31	collagen	I
32	gene	I
33	promoter	I
34	.	O

1	Expression	O
2	of	O
3	neuronal	O
4	traits	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O

1	We	O
2	propose	O
3	that	O
4	Mnt	B
5	:	O
6	Max	B
7	:	O
8	Sin3	B
9	complexes	O
10	normally	O
11	function	O
12	to	O
13	restrict	O
14	Myc	B
15	:	O
16	Max	B
17	activities	O
18	associated	O
19	with	O
20	cell	O
21	proliferation	O
22	.	O

1	Its	O
2	transcription	O
3	product	O
4	,	O
5	a	O
6	1	O
7	.	O
8	3	O
9	kb	O
10	mRNA	O
11	,	O
12	is	O
13	polyadenylated	O
14	at	O
15	a	O
16	site	O
17	containing	O
18	consensus	O
19	eukaryotic	O
20	polyadenylation	O
21	signals	O
22	and	O
23	mapping	O
24	87	O
25	bp	O
26	downstream	O
27	of	O
28	the	O
29	translation	O
30	termination	O
31	codon	O
32	for	O
33	CG30	B
34	.	O

1	Phenotypic	O
2	changes	O
3	induced	O
4	by	O
5	wild	B
6	type	I
7	and	I
8	variant	I
9	c	I
10	-	I
11	src	I
12	genes	I
13	carrying	O
14	C	O
15	-	O
16	terminal	O
17	sequence	O
18	alterations	O
19	.	O

1	The	O
2	resurgence	O
3	of	O
4	drug	O
5	-	O
6	resistant	O
7	malaria	O
8	makes	O
9	urgent	O
10	the	O
11	evaluation	O
12	of	O
13	new	O
14	antimalarial	O
15	agents	O
16	.	O

1	In	O
2	the	O
3	p51	B
4	subunit	I
5	,	O
6	the	O
7	Cys181	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O

1	The	O
2	relatively	O
3	high	O
4	level	O
5	transcription	O
6	from	O
7	this	O
8	gene	O
9	shows	O
10	that	O
11	the	O
12	polymorphic	O
13	chromosome	O
14	ends	O
15	of	O
16	P	O
17	.	O
18	falciparum	O
19	,	O
20	which	O
21	have	O
22	been	O
23	proposed	O
24	to	O
25	be	O
26	transcriptionally	O
27	silent	O
28	,	O
29	can	O
30	be	O
31	active	O
32	expression	O
33	sites	O
34	for	O
35	var	B
36	genes	I
37	.	O

1	NUP145	B
2	was	O
3	previously	O
4	identified	O
5	by	O
6	using	O
7	a	O
8	genetic	O
9	synthetic	O
10	lethal	O
11	screen	O
12	(	O
13	E	O
14	.	O

1	Prevalence	O
2	of	O
3	sleep	O
4	-	O
5	disordered	O
6	breathing	O
7	(	O
8	SDB	O
9	)	O
10	is	O
11	reported	O
12	to	O
13	increase	O
14	in	O
15	menopausal	O
16	women	O
17	.	O

1	In	O
2	all	O
3	cases	O
4	the	O
5	antigenemia	O
6	was	O
7	transient	O
8	and	O
9	cleared	O
10	by	O
11	28th	O
12	day	O
13	post	O
14	-	O
15	vaccination	O
16	.	O

1	A	O
2	total	O
3	of	O
4	1459	O
5	men	O
6	aged	O
7	48	O
8	to	O
9	84	O
10	years	O
11	,	O
12	who	O
13	were	O
14	diagnosed	O
15	for	O
16	the	O
17	first	O
18	time	O
19	by	O
20	physicians	O
21	as	O
22	having	O
23	BPH	O
24	in	O
25	1994	O
26	and	O
27	who	O
28	had	O
29	not	O
30	received	O
31	treatment	O
32	,	O
33	participated	O
34	in	O
35	the	O
36	study	O
37	.	O

1	BCL	B
2	-	I
3	2	I
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	the	O
6	mTRF1	B
7	cDNA	I
8	resulted	O
9	in	O
10	a	O
11	56	O
12	kDa	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	TTAGGG	O
18	repeat	O
19	arrays	O
20	.	O
21	mTRF1	B
22	displayed	O
23	the	O
24	same	O
25	sequence	O
26	specificity	O
27	as	O
28	hTRF1	B
29	,	O
30	preferring	O
31	arrays	O
32	of	O
33	TTAGGG	O
34	repeats	O
35	as	O
36	a	O
37	binding	O
38	substrate	O
39	over	O
40	TTAGGC	O
41	and	O
42	TTGGGG	O
43	repeats	O
44	.	O

1	The	O
2	ubiquitously	O
3	expressed	O
4	E12	B
5	bHLH	I
6	protein	I
7	dimerizes	O
8	with	O
9	numerous	O
10	cell	O
11	-	O
12	specific	O
13	bHLH	B
14	factors	I
15	.	O

1	The	O
2	E	O
3	-	O
4	box	O
5	sequence	O
6	in	O
7	the	O
8	SE2	B
9	fragment	I
10	of	O
11	the	O
12	transferrin	B
13	promoter	I
14	was	O
15	CATCTG	O
16	and	O
17	was	O
18	similar	O
19	in	O
20	gel	O
21	shifts	O
22	to	O
23	the	O
24	consensus	O
25	E	O
26	-	O
27	box	O
28	elements	O
29	(	O
30	CANNTG	O
31	)	O
32	previously	O
33	characterized	O
34	.	O

1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	B
16	gene	I
17	(	O
18	named	O
19	porCa	B
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

1	Full	B
2	-	I
3	length	I
4	AT	I
5	-	I
6	PHH1	I
7	,	O
8	and	O
9	both	O
10	AT	B
11	-	I
12	PHH1	I
13	and	O
14	AT	B
15	-	I
16	PHH1	I
17	delta	I
18	C	I
19	-	I
20	513	I
21	(	O
22	truncated	O
23	to	O
24	be	O
25	approximately	O
26	the	O
27	size	O
28	of	O
29	microbial	B
30	photolyase	I
31	genes	I
32	)	O
33	cDNAs	O
34	,	O
35	were	O
36	overexpressed	O
37	,	O
38	respectively	O
39	,	O
40	in	O
41	yeast	O
42	and	O
43	Escherichia	O
44	coli	O
45	mutants	O
46	hypersensitive	O
47	to	O
48	ultraviolet	O
49	light	O
50	.	O

1	The	O
2	human	B
3	p100	I
4	protein	I
5	was	O
6	recently	O
7	identified	O
8	as	O
9	a	O
10	coactivator	O
11	of	O
12	the	O
13	Epstein	B
14	-	I
15	Barr	I
16	virus	I
17	nuclear	I
18	antigen	I
19	2	I
20	.	O

1	However	O
2	,	O
3	five	O
4	new	O
5	mutation	O
6	sites	O
7	(	O
8	S61	B
9	,	O
10	SL1	B
11	,	O
12	S29	B
13	,	O
14	SL11	B
15	,	O
16	SL196	B
17	and	O
18	SL126	B
19	)	O
20	are	O
21	unique	O
22	to	O
23	the	O
24	nrdB	B
25	intron	O
26	and	O
27	disrupt	O
28	self	O
29	-	O
30	splicing	O
31	.	O

1	This	O
2	report	O
3	presents	O
4	the	O
5	isolation	O
6	and	O
7	characterization	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	(	O
15	1	O
16	.	O
17	2	O
18	kb	O
19	)	O
20	and	O
21	exon	O
22	1	O
23	of	O
24	the	O
25	human	B
26	RII	I
27	alpha	I
28	gene	I
29	.	O

1	A	O
2	cohort	O
3	of	O
4	Swedish	O
5	children	O
6	was	O
7	monitored	O
8	from	O
9	6	O
10	months	O
11	to	O
12	11	O
13	years	O
14	of	O
15	age	O
16	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	assess	O
9	the	O
10	reproducibility	O
11	of	O
12	a	O
13	number	O
14	of	O
15	simplified	O
16	clearance	O
17	methods	O
18	using	O
19	chromium	O
20	-	O
21	51	O
22	ethylenediamine	O
23	tetraacetic	O
24	acid	O
25	(	O
26	51Cr	O
27	-	O
28	EDTA	O
29	)	O
30	and	O
31	to	O
32	compare	O
33	these	O
34	with	O
35	the	O
36	multiple	O
37	blood	O
38	sample	O
39	technique	O
40	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	a	O
6	2671	O
7	bp	O
8	DNA	O
9	fragment	O
10	between	O
11	the	O
12	pla	B
13	gene	I
14	(	O
15	encoding	O
16	plasminogen	B
17	activator	I
18	)	O
19	and	O
20	the	O
21	origin	O
22	of	O
23	replication	O
24	of	O
25	the	O
26	wild	O
27	-	O
28	type	O
29	Yersinia	O
30	pestis	O
31	plasmid	O
32	pYP358	O
33	was	O
34	determined	O
35	.	O

1	Serotonin	O
2	concentration	O
3	in	O
4	the	O
5	blood	O
6	of	O
7	patients	O
8	with	O
9	hemorrhagic	O
10	fever	O
11	with	O
12	renal	O
13	syndrome	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Associations	O
6	of	O
7	factor	O
8	analysis	O
9	-	O
10	derived	O
11	syndromes	O
12	with	O
13	risk	O
14	factors	O
15	for	O
16	chemical	O
17	interactions	O
18	that	O
19	inhibit	O
20	butyrylcholinesterase	B
21	and	O
22	neuropathy	O
23	target	O
24	esterase	B
25	.	O

1	CONCLUSION	O
2	:	O
3	Some	O
4	Gulf	O
5	War	O
6	veterans	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	neurotoxic	O
13	syndromes	O
14	from	O
15	wartime	O
16	exposure	O
17	to	O
18	combinations	O
19	of	O
20	chemicals	O
21	that	O
22	inhibit	O
23	butyrylcholinesterase	B
24	and	O
25	neuropathy	B
26	target	I
27	esterase	I
28	.	O

1	Control	O
2	examination	O
3	was	O
4	performed	O
5	at	O
6	the	O
7	end	O
8	of	O
9	each	O
10	period	O
11	.	O

1	No	O
2	correlation	O
3	between	O
4	the	O
5	age	O
6	of	O
7	the	O
8	horses	O
9	and	O
10	the	O
11	antibody	O
12	level	O
13	could	O
14	be	O
15	found	O
16	.	O

1	The	O
2	GHR	B
3	mRNA	I
4	:	O
5	GHBP	B
6	mRNA	I
7	ratio	O
8	was	O
9	1	O
10	.	O
11	1	O
12	+/-	O
13	0	O
14	.	O
15	12	O
16	and	O
17	remained	O
18	unchanged	O
19	during	O
20	differentiation	O
21	.	O

1	The	O
2	results	O
3	demonstrate	O
4	(	O
5	i	O
6	)	O
7	that	O
8	the	O
9	selenocysteine	O
10	-	O
11	specific	O
12	UGA	O
13	codon	O
14	is	O
15	readily	O
16	suppressed	O
17	under	O
18	conditions	O
19	where	O
20	the	O
21	homologous	B
22	SelB	I
23	protein	I
24	is	O
25	absent	O
26	and	O
27	(	O
28	ii	O
29	)	O
30	that	O
31	apart	O
32	from	O
33	the	O
34	specificity	O
35	of	O
36	the	O
37	SelB	B
38	-	I
39	mRNA	I
40	interaction	O
41	,	O
42	a	O
43	structural	O
44	compatibility	O
45	of	O
46	the	O
47	quaternary	O
48	complex	O
49	with	O
50	the	O
51	ribosome	O
52	is	O
53	required	O
54	.	O

1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	B
9	C	I
10	terminus	I
11	(	I
12	amino	I
13	acid	I
14	784	I
15	)	I
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	B
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O

1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	B
9	gene	I
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	B
19	RNA	I
20	polymerase	I
21	promoter	I
22	.	O

1	PrpB	B
2	showed	O
3	homology	O
4	to	O
5	carboxyphosphonoenolpyruvate	B
6	phosphonomutase	I
7	of	I
8	Streptomyces	I
9	hygroscopicus	I
10	and	O
11	to	O
12	its	O
13	homolog	O
14	in	O
15	the	O
16	carnation	O
17	Dianthus	O
18	caryophyllus	O
19	;	O
20	PrpC	B
21	was	O
22	homologous	O
23	to	O
24	both	O
25	archaeal	B
26	and	I
27	bacterial	I
28	citrate	I
29	synthases	I
30	;	O
31	PrpD	B
32	showed	O
33	homology	O
34	to	O
35	yeast	O
36	and	O
37	Bacillus	O
38	subtilis	O
39	proteins	O
40	of	O
41	unknown	O
42	function	O
43	;	O
44	PrpE	B
45	showed	O
46	homology	O
47	to	O
48	acetyl	B
49	coenzyme	I
50	A	I
51	synthetases	I
52	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Systemic	O
6	and	O
7	pulmonary	O
8	hemodynamics	O
9	,	O
10	arterial	O
11	blood	O
12	gas	O
13	determination	O
14	,	O
15	bronchoalveolar	O
16	lavage	O
17	protein	O
18	and	O
19	neutrophil	O
20	content	O
21	,	O
22	neutrophil	O
23	oxidant	O
24	burst	O
25	,	O
26	lung	B
27	myeloperoxidase	I
28	content	O
29	,	O
30	and	O
31	scanning	O
32	electron	O
33	micrographic	O
34	studies	O
35	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	cDNA	O
6	encoding	O
7	human	B
8	MEKK3	I
9	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	O
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O

1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	I
17	JUN	I
18	and	O
19	ATF	B
20	-	I
21	2	I
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O

1	The	O
2	effects	O
3	of	O
4	dominant	O
5	interfering	O
6	forms	O
7	of	O
8	the	O
9	JNK	B
10	/	O
11	p38	B
12	signaling	O
13	pathway	O
14	demonstrate	O
15	that	O
16	activation	O
17	of	O
18	these	O
19	kinases	O
20	is	O
21	critical	O
22	for	O
23	cytokine	O
24	-	O
25	induced	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	expression	O
31	.	O

1	Sp1	B
2	binds	O
3	the	O
4	CTC	O
5	repeat	O
6	with	O
7	an	O
8	affinity	O
9	,	O
10	KD	O
11	=	O
12	0	O
13	.	O
14	37	O
15	nM	O
16	,	O
17	at	O
18	least	O
19	as	O
20	high	O
21	as	O
22	the	O
23	consensus	O
24	GC	O
25	box	O
26	.	O

1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	B
7	-	I
8	binding	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	B
18	IBalpha	I
19	.	O

1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O

1	The	O
2	primer	O
3	is	O
4	generated	O
5	by	O
6	a	O
7	cleavage	O
8	that	O
9	occurs	O
10	between	O
11	bases	O
12	11	O
13	and	O
14	12	O
15	of	O
16	the	O
17	Tf1	B
18	mRNA	I
19	.	O

1	Similarly	O
2	,	O
3	we	O
4	examined	O
5	whether	O
6	the	O
7	ELK1	B
8	,	O
9	SAP1a	B
10	,	O
11	FLI1	B
12	,	O
13	EWS	B
14	-	O
15	FLI1	B
16	,	O
17	ETS1	B
18	,	O
19	ETS2	B
20	,	O
21	PEA3	B
22	and	O
23	PU	B
24	.	I
25	1	I
26	proteins	I
27	can	O
28	form	O
29	ternary	O
30	complexes	O
31	with	O
32	SRF	B
33	on	O
34	the	O
35	Egr1	B
36	SREI	I
37	and	I
38	II	I
39	.	O

1	This	O
2	R	O
3	-	O
4	domain	O
5	may	O
6	modulate	O
7	the	O
8	interaction	O
9	with	O
10	SRF	B
11	,	O
12	providing	O
13	a	O
14	mechanism	O
15	that	O
16	would	O
17	be	O
18	unique	O
19	to	O
20	FLI1	B
21	and	O
22	EWS	B
23	-	O
24	FLI1	B
25	,	O
26	thus	O
27	implicating	O
28	a	O
29	novel	O
30	function	O
31	for	O
32	these	O
33	ETS	B
34	transcription	I
35	factors	I
36	in	O
37	the	O
38	regulation	O
39	of	O
40	the	O
41	Egr1	B
42	gene	I
43	.	O

1	The	O
2	total	O
3	number	O
4	of	O
5	specimens	O
6	was	O
7	131	O
8	with	O
9	78	O
10	nonsmokers	O
11	and	O
12	53	O
13	smokers	O
14	.	O

1	The	O
2	murine	O
3	chromosomal	O
4	locations	O
5	of	O
6	the	O
7	five	O
8	NMDA	B
9	receptor	I
10	channel	I
11	subunits	I
12	,	O
13	the	O
14	epsilon	B
15	1	I
16	(	O
17	Grin2a	B
18	),	O
19	epsilon	B
20	2	I
21	(	O
22	Grin2b	B
23	),	O
24	epsilon	B
25	3	I
26	(	O
27	Grin2c	B
28	),	O
29	epsilon	B
30	4	I
31	(	O
32	Grin2d	B
33	)	O
34	and	O
35	zeta	B
36	1	I
37	(	O
38	Grinl	B
39	)	O
40	subunits	O
41	,	O
42	were	O
43	determined	O
44	using	O
45	an	O
46	interspecific	O
47	backcross	O
48	mapping	O
49	panel	O
50	derived	O
51	from	O
52	crosses	O
53	of	O
54	[(	O
55	C57BL	O
56	/	O
57	6JxM	O
58	.	O
59	spretus	O
60	)	O
61	F1xC57BL	O
62	/	O
63	6J	O
64	]	O
65	mice	O
66	.	O

1	CDNA	O
2	cloning	O
3	of	O
4	chick	B
5	brain	I
6	alpha	I
7	-	I
8	amino	I
9	-	I
10	3	I
11	-	I
12	hydroxy	I
13	-	I
14	5	I
15	-	I
16	methyl	I
17	-	I
18	4	I
19	-	I
20	isoxazolepropionic	I
21	acid	I
22	receptors	I
23	reveals	O
24	conservation	O
25	of	O
26	structure	O
27	,	O
28	function	O
29	and	O
30	post	O
31	-	O
32	transcriptional	O
33	processes	O
34	with	O
35	mammalian	O
36	receptors	O
37	.	O

1	Remarkably	O
2	,	O
3	both	O
4	TTD	O
5	-	O
6	A	O
7	and	O
8	XP	O
9	-	O
10	D	O
11	defects	O
12	are	O
13	associated	O
14	with	O
15	subunits	O
16	of	O
17	TFIIH	B
18	,	O
19	a	O
20	basal	O
21	transcription	O
22	factor	O
23	with	O
24	a	O
25	second	O
26	function	O
27	in	O
28	DNA	O
29	repair	O
30	.	O

1	Adjustment	O
2	for	O
3	age	O
4	,	O
5	total	O
6	cholesterol	O
7	,	O
8	HDL	B
9	cholesterol	I
10	,	O
11	triglycerides	O
12	,	O
13	current	O
14	smoking	O
15	,	O
16	and	O
17	systolic	O
18	pressure	O
19	slightly	O
20	reduced	O
21	the	O
22	association	O
23	between	O
24	fibrinogen	B
25	and	O
26	atherosclerosis	O
27	.	O

1	In	O
2	Experiment	O
3	1	O
4	,	O
5	pups	O
6	that	O
7	had	O
8	received	O
9	an	O
10	injection	O
11	of	O
12	the	O
13	noncompetitive	O
14	N	B
15	-	I
16	methyl	I
17	-	I
18	D	I
19	-	I
20	aspartate	I
21	receptor	I
22	antagonist	O
23	MK	O
24	-	O
25	801	O
26	(	O
27	0	O
28	.	O
29	1	O
30	mg	O
31	/	O
32	kg	O
33	,	O
34	i	O
35	.	O
36	p	O
37	.)	O
38	either	O
39	30	O
40	min	O
41	before	O
42	or	O
43	immediately	O
44	after	O
45	conditioning	O
46	spent	O
47	less	O
48	time	O
49	over	O
50	the	O
51	conditioned	O
52	odor	O
53	than	O
54	saline	O
55	-	O
56	treated	O
57	controls	O
58	.	O

1	Cholesterol	B
2	side	I
3	-	I
4	chain	I
5	cleavage	I
6	cytochrome	I
7	P450	I
8	(	O
9	CYP11A	B
10	;	O
11	P450scc	B
12	)	O
13	gene	O
14	expression	O
15	is	O
16	regulated	O
17	by	O
18	gonadotropins	B
19	via	O
20	cAMP	O
21	in	O
22	the	O
23	ovary	O
24	and	O
25	by	O
26	ACTH	B
27	via	O
28	cAMP	O
29	in	O
30	adrenal	O
31	cortical	O
32	cells	O
33	.	O

1	One	O
2	possible	O
3	solution	O
4	is	O
5	a	O
6	thin	O
7	radial	O
8	forearm	O
9	free	O
10	flap	O
11	.	O

1	Structural	O
2	analysis	O
3	and	O
4	characterization	O
5	of	O
6	tissue	O
7	and	O
8	hormonal	O
9	responsive	O
10	expression	O
11	of	O
12	the	O
13	avian	B
14	bone	I
15	sialoprotein	I
16	(	O
17	BSP	B
18	)	O
19	gene	O
20	.	O

1	Serotonin	B
2	receptors	I
3	in	O
4	suicide	O
5	victims	O
6	with	O
7	major	O
8	depression	O
9	.	O

1	The	O
2	Y	O
3	-	O
4	type	O
5	structural	O
6	motif	O
7	is	O
8	also	O
9	conserved	O
10	among	O
11	a	O
12	number	O
13	of	O
14	divergent	O
15	BiP	B
16	mRNAs	I
17	.	O

1	A	O
2	false	O
3	positive	O
4	marker	O
5	screen	O
6	was	O
7	associated	O
8	with	O
9	the	O
10	occurrence	O
11	of	O
12	hand	O
13	-	O
14	foot	O
15	syndrome	O
16	even	O
17	when	O
18	the	O
19	effect	O
20	of	O
21	regimen	O
22	was	O
23	accounted	O
24	for	O
25	by	O
26	stratification	O
27	(	O
28	p	O
29	=	O
30	.	O
31	01	O
32	).	O

1	The	O
2	detection	O
3	of	O
4	ORF	B
5	-	I
6	1	I
7	sequences	O
8	in	O
9	human	O
10	tumors	O
11	,	O
12	while	O
13	not	O
14	proof	O
15	per	O
16	se	O
17	,	O
18	is	O
19	a	O
20	prerequisite	O
21	for	O
22	establishing	O
23	its	O
24	role	O
25	in	O
26	tumor	O
27	development	O
28	.	O

1	Phylogenetic	O
2	analysis	O
3	gave	O
4	evidence	O
5	for	O
6	a	O
7	close	O
8	evolutionary	O
9	relationship	O
10	between	O
11	PhHV	O
12	-	O
13	1	O
14	and	O
15	members	O
16	of	O
17	the	O
18	Varicellovirus	O
19	genus	O
20	of	O
21	the	O
22	alpha	O
23	-	O
24	Herpesvirinae	O
25	and	O
26	canid	O
27	herpesvirus	O
28	in	O
29	particular	O
30	.	O

1	In	O
2	this	O
3	method	O
4	,	O
5	PLP	O
6	in	O
7	plasma	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	high	O
13	sensitivity	O
14	using	O
15	derivatization	O
16	with	O
17	sodium	O
18	bisulfite	O
19	in	O
20	the	O
21	mobile	O
22	phase	O
23	.	O

1	Both	O
2	HEF1	B
3	and	O
4	Cas	B
5	were	O
6	found	O
7	to	O
8	complex	O
9	with	O
10	the	O
11	related	B
12	adhesion	I
13	focal	I
14	tyrosine	I
15	kinase	I
16	(	O
17	RAFTK	B
18	),	O
19	and	O
20	when	O
21	tyrosine	O
22	phosphorylated	O
23	,	O
24	with	O
25	the	O
26	adapter	O
27	molecule	O
28	CrkL	B
29	.	O

1	SIM1	B
2	and	O
3	SIM2	B
4	do	O
5	not	O
6	form	O
7	homodimers	O
8	,	O
9	and	O
10	they	O
11	do	O
12	not	O
13	interact	O
14	with	O
15	AHR	B
16	.	O

1	Complexes	O
2	of	O
3	qTBP42	B
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	Moreover	O
2	,	O
3	the	O
4	effect	O
5	exerted	O
6	by	O
7	TIS1	B
8	appeared	O
9	to	O
10	be	O
11	selective	O
12	for	O
13	the	O
14	MCK	B
15	promoter	I
16	.	O

1	Experimental	O
2	data	O
3	showed	O
4	that	O
5	these	O
6	abnormal	O
7	proteins	O
8	are	O
9	constitutively	O
10	localized	O
11	in	O
12	the	O
13	nucleus	O
14	,	O
15	have	O
16	lost	O
17	the	O
18	transcriptional	O
19	repressor	O
20	functions	O
21	typical	O
22	of	O
23	normal	O
24	NF	B
25	-	I
26	kappa	I
27	B2p52	I
28	and	O
29	may	O
30	be	O
31	capable	O
32	of	O
33	transactivation	O
34	activity	O
35	.	O

1	Because	O
2	L	B
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	O
52	L	B
53	-	I
54	plastin	I
55	gene	O
56	promoters	O
57	.	O

1	What	O
2	'	O
3	s	O
4	new	O
5	in	O
6	gynecologic	O
7	and	O
8	obstetrical	O
9	surgery	O
10	.	O

1	The	O
2	dnaK	B
3	operon	I
4	of	I
5	Bacillus	I
6	subtilis	I
7	is	O
8	heptacistronic	O
9	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	CBF1	B
6	in	O
7	yeast	O
8	was	O
9	found	O
10	to	O
11	activate	O
12	transcription	O
13	of	O
14	reporter	O
15	genes	O
16	containing	O
17	the	O
18	C	O
19	-	O
20	repeat	O
21	/	O
22	DRE	O
23	as	O
24	an	O
25	upstream	O
26	activator	O
27	sequence	O
28	but	O
29	not	O
30	mutant	O
31	versions	O
32	of	O
33	the	O
34	DNA	O
35	element	O
36	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	OBJECTIVE	O
2	:	O
3	Our	O
4	goal	O
5	was	O
6	to	O
7	determine	O
8	whether	O
9	chlamydia	O
10	-	O
11	infected	O
12	women	O
13	have	O
14	a	O
15	higher	O
16	rate	O
17	of	O
18	febrile	O
19	complications	O
20	after	O
21	postpartum	O
22	tubal	O
23	ligation	O
24	.	O

1	In	O
2	the	O
3	electrophoresis	O
4	mobility	O
5	shift	O
6	assay	O
7	using	O
8	nuclear	O
9	extracts	O
10	of	O
11	the	O
12	myogenic	O
13	cells	O
14	,	O
15	MyoD	B
16	and	O
17	myogenin	B
18	bound	O
19	to	O
20	the	O
21	right	O
22	E	O
23	-	O
24	box	O
25	in	O
26	the	O
27	enhancer	O
28	region	O
29	of	O
30	the	O
31	MCK	B
32	gene	I
33	even	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	BMP	B
39	-	I
40	2	I
41	.	O

1	A	O
2	heterologous	O
3	promoter	O
4	construct	O
5	containing	O
6	three	O
7	repeats	O
8	of	O
9	a	O
10	consensus	O
11	Sp1	B
12	site	I
13	,	O
14	cloned	O
15	upstream	O
16	of	O
17	a	O
18	single	O
19	copy	O
20	of	O
21	the	O
22	ZII	B
23	(	O
24	CREB	B
25	/	I
26	AP1	I
27	)	O
28	element	O
29	from	O
30	the	O
31	BZLF1	B
32	promoter	I
33	linked	O
34	to	O
35	the	O
36	beta	B
37	-	I
38	globin	I
39	TATA	O
40	box	O
41	,	O
42	exhibited	O
43	phorbol	O
44	ester	O
45	inducibility	O
46	.	O

1	Subsequent	O
2	experiments	O
3	showed	O
4	that	O
5	motoric	O
6	tasks	O
7	rather	O
8	than	O
9	cognitive	O
10	aspects	O
11	of	O
12	the	O
13	COWA	O
14	task	O
15	were	O
16	critical	O
17	in	O
18	potentiating	O
19	finger	O
20	-	O
21	tapping	O
22	performance	O
23	.	O

1	How	O
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	IIIa	O
8	on	O
9	the	O
10	hCG	B
11	-	I
12	ectodomain	I
13	complex	I
14	was	O
15	also	O
16	hindered	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	mAb	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	eighth	O
31	exon	O
32	(	O
33	pE	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	O
39	LHR	B
40	.	O

1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	B
18	eIF	I
19	-(	I
20	iso	I
21	)	I
22	4F	I
23	and	O
24	mammalian	B
25	eIF	I
26	-	I
27	4G	I
28	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	important	O
6	to	O
7	control	O
8	hypertension	O
9	and	O
10	keep	O
11	appropriate	O
12	renal	O
13	blood	O
14	flow	O
15	during	O
16	living	O
17	renal	O
18	transplantation	O
19	surgery	O
20	.	O

1	The	O
2	initial	O
3	patients	O
4	treated	O
5	with	O
6	AZQ	O
7	and	O
8	mitroxantrone	O
9	experienced	O
10	prolonged	O
11	bone	O
12	marrow	O
13	suppression	O
14	and	O
15	,	O
16	therefore	O
17	,	O
18	subsequent	O
19	cohorts	O
20	were	O
21	treated	O
22	with	O
23	G	B
24	-	I
25	CSF	I
26	,	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	,	O
32	beginning	O
33	the	O
34	day	O
35	after	O
36	completion	O
37	of	O
38	the	O
39	third	O
40	cycle	O
41	of	O
42	chemotherapy	O
43	.	O

1	Human	B
2	granulocyte	I
3	-	I
4	macrophage	I
5	colony	I
6	-	I
7	stimulating	I
8	factor	I
9	(	O
10	hGM	B
11	-	I
12	CSF	I
13	)	O
14	activates	O
15	a	O
16	set	O
17	of	O
18	genes	O
19	such	O
20	as	O
21	c	B
22	-	I
23	fos	I
24	,	O
25	jun	B
26	,	O
27	myc	B
28	,	O
29	and	O
30	early	B
31	growth	I
32	response	I
33	gene	I
34	1	I
35	(	O
36	egr	B
37	-	I
38	1	I
39	).	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	Surprisingly	O
2	,	O
3	however	O
4	,	O
5	TCR	B
6	-	O
7	mediated	O
8	tyrosine	O
9	phosphorylation	O
10	of	O
11	phospholipase	B
12	C	I
13	gamma	I
14	1	I
15	remains	O
16	intact	O
17	in	O
18	the	O
19	Jurkat	O
20	cells	O
21	expressing	O
22	the	O
23	A2	B
24	/	O
25	HCP	B
26	chimera	O
27	.	O

1	The	O
2	14	B
3	.	I
4	1	I
5	(	I
6	IGLL1	I
7	)	I
8	gene	I
9	is	O
10	expressed	O
11	in	O
12	a	O
13	lineage	O
14	-	O
15	and	O
16	stage	O
17	-	O
18	restricted	O
19	manner	O
20	.	O

1	The	O
2	interferon	B
3	(	O
4	IFN	B
5	)-	O
6	induced	O
7	double	B
8	-	I
9	stranded	I
10	RNA	I
11	(	I
12	dsRNA	I
13	)-	I
14	activated	I
15	Ser	I
16	/	I
17	Thr	I
18	protein	I
19	kinase	I
20	(	O
21	PKR	B
22	)	O
23	plays	O
24	a	O
25	role	O
26	in	O
27	the	O
28	antiviral	O
29	and	O
30	antiproliferative	O
31	effects	O
32	of	O
33	IFN	B
34	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	O
17	SF	B
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	B
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	Object	O
2	relations	O
3	,	O
4	affect	O
5	management	O
6	,	O
7	and	O
8	psychic	O
9	structure	O
10	formation	O
11	.	O

1	When	O
2	expressed	O
3	in	O
4	COS	O
5	-	O
6	7	O
7	cells	O
8	,	O
9	MKP	B
10	-	I
11	4	I
12	blocks	O
13	activation	O
14	of	O
15	MAP	B
16	kinases	I
17	with	O
18	the	O
19	selectivity	O
20	ERK	B
21	>	O
22	p38	B
23	=	O
24	JNK	B
25	/	O
26	SAPK	B
27	.	O

1	In	O
2	rlf2	B
3	mutants	I
4	,	O
5	telomeric	O
6	chromatin	O
7	is	O
8	perturbed	O
9	:	O
10	Telomeric	O
11	silencing	O
12	is	O
13	reduced	O
14	and	O
15	Rap1p	B
16	localization	O
17	is	O
18	altered	O
19	.	O

1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	O

1	Interaction	O
2	of	O
3	Ets	B
4	-	I
5	1	I
6	and	O
7	the	O
8	POU	B
9	-	I
10	homeodomain	I
11	protein	I
12	GHF	I
13	-	I
14	1	I
15	/	O
16	Pit	B
17	-	I
18	1	I
19	reconstitutes	O
20	pituitary	O
21	-	O
22	specific	O
23	gene	O
24	expression	O
25	.	O

1	Although	O
2	Pho85	B
3	is	O
4	not	O
5	essential	O
6	for	O
7	viability	O
8	,	O
9	Pcl1	B
10	,	I
11	2	I
12	-	O
13	Pho85	B
14	kinase	O
15	complexes	O
16	become	O
17	essential	O
18	for	O
19	Start	O
20	in	O
21	the	O
22	absence	O
23	of	O
24	Cln1	B
25	,	I
26	2	I
27	-	O
28	Cdc28	B
29	kinases	O
30	.	O

1	Using	O
2	the	O
3	yeast	O
4	two	O
5	-	O
6	hybrid	O
7	system	O
8	to	O
9	screen	O
10	for	O
11	proteins	O
12	which	O
13	interact	O
14	with	O
15	Tax1	B
16	,	O
17	we	O
18	isolated	O
19	the	O
20	B	O
21	subunit	O
22	of	O
23	the	O
24	CCAAT	O
25	binding	O
26	protein	O
27	NF	B
28	-	I
29	Y	I
30	from	O
31	a	O
32	HeLa	O
33	cDNA	O
34	library	O
35	.	O

1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	site	I
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O

1	Studies	O
2	using	O
3	HLA	B
4	-	I
5	DR	I
6	-	O
7	B7	B
8	-	I
9	1	I
10	-	O
11	LFA	B
12	-	I
13	3	I
14	triple	O
15	transfectants	O
16	showed	O
17	that	O
18	the	O
19	LFA	B
20	-	I
21	3	I
22	-	O
23	induced	O
24	NF	B
25	-	I
26	AT	I
27	DNA	O
28	binding	O
29	activity	O
30	was	O
31	negatively	O
32	regulated	O
33	by	O
34	B7	B
35	-	I
36	1	I
37	costimulation	O
38	.	O

1	Constitutive	O
2	activation	O
3	of	O
4	Rac1	B
5	and	O
6	RhoA	B
7	causes	O
8	tumorigenic	O
9	transformation	O
10	of	O
11	NIH	O
12	3T3	O
13	cells	O
14	,	O
15	and	O
16	their	O
17	functions	O
18	may	O
19	be	O
20	required	O
21	for	O
22	full	O
23	Ras	B
24	transformation	O
25	.	O

1	Furthermore	O
2	,	O
3	Rac1	B
4	activation	O
5	of	O
6	JNK	B
7	or	O
8	SRF	B
9	,	O
10	or	O
11	induction	O
12	of	O
13	lamellipodia	O
14	,	O
15	was	O
16	neither	O
17	necessary	O
18	nor	O
19	sufficient	O
20	for	O
21	Rac1	B
22	transforming	O
23	activity	O
24	.	O

1	Overexpression	O
2	of	O
3	the	O
4	bZip	O
5	interaction	O
6	domain	O
7	of	O
8	CBP	B
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	B
17	and	O
18	p45	B
19	/	O
20	NF	B
21	-	I
22	E2	I
23	.	O

1	This	O
2	inhibitory	O
3	domain	O
4	has	O
5	been	O
6	deleted	O
7	in	O
8	all	O
9	naturally	O
10	occurring	O
11	AHC	B
12	deletion	I
13	mutants	I
14	described	O
15	to	O
16	date	O
17	.	O

1	Identification	O
2	of	O
3	a	O
4	promoter	O
5	-	O
6	specific	O
7	transactivation	O
8	domain	O
9	in	O
10	the	O
11	herpes	B
12	simplex	I
13	virus	I
14	regulatory	I
15	protein	I
16	ICP4	I
17	.	O

1	DNA	O
2	sequencing	O
3	of	O
4	a	O
5	17	O
6	-	O
7	kb	O
8	segment	O
9	encompassing	O
10	a	O
11	gammaherpesvirus	O
12	divergent	O
13	locus	O
14	(	O
15	DL	O
16	-	O
17	B	O
18	)	O
19	between	O
20	ORF11	O
21	and	O
22	ORF17	O
23	revealed	O
24	the	O
25	presence	O
26	of	O
27	nine	O
28	viral	O
29	ORFs	O
30	with	O
31	predicted	O
32	gene	O
33	products	O
34	related	O
35	to	O
36	cellular	O
37	proteins	O
38	.	O

1	Studies	O
2	in	O
3	mammalian	O
4	cells	O
5	have	O
6	correlated	O
7	induction	O
8	of	O
9	inhibitory	O
10	tyrosine	O
11	15	O
12	(	O
13	Y15	O
14	)	O
15	phosphorylation	O
16	on	O
17	p34cdc2	B
18	with	O
19	the	O
20	response	O
21	to	O
22	DNA	O
23	damage	O
24	.	O

1	We	O
2	report	O
3	herein	O
4	the	O
5	case	O
6	of	O
7	a	O
8	30	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	in	O
15	whom	O
16	ectopic	O
17	mediastinal	O
18	parathyroid	O
19	adenoma	O
20	was	O
21	detected	O
22	by	O
23	99mTc	O
24	-	O
25	methoxyisobutylisonitrile	O
26	scintigraphy	O
27	(	O
28	99mTc	O
29	-	O
30	MIBI	O
31	).	O

1	Cardiac	B
2	endothelin	I
3	release	O
4	and	O
5	infarct	O
6	size	O
7	,	O
8	myocardial	O
9	blood	O
10	flow	O
11	,	O
12	and	O
13	ventricular	O
14	function	O
15	in	O
16	canine	O
17	infarction	O
18	and	O
19	reperfusion	O
20	.	O

1	The	O
2	workup	O
3	included	O
4	skin	O
5	tests	O
6	(	O
7	up	O
8	to	O
9	1	O
10	microgram	O
11	/	O
12	ml	O
13	,	O
14	Pharmacia	O
15	),	O
16	measurement	O
17	of	O
18	specific	O
19	serum	O
20	IgE	B
21	with	O
22	RAST	O
23	-	O
24	CAP	O
25	(	O
26	Pharmacia	O
27	),	O
28	and	O
29	CAST	O
30	with	O
31	three	O
32	concentrations	O
33	of	O
34	bee	O
35	(	O
36	Apis	O
37	mellifera	O
38	)	O
39	and	O
40	wasp	O
41	(	O
42	Vespula	O
43	spec	O
44	.)	O
45	venom	O
46	(	O
47	Aquagen	O
48	ALK	O
49	).	O

1	The	O
2	proliferation	B
3	potential	I
4	protein	I
5	-	I
6	related	I
7	(	O
8	P2P	B
9	-	I
10	R	I
11	)	O
12	gene	O
13	with	O
14	domains	O
15	encoding	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoprotein	O
19	association	O
20	and	O
21	Rb1	B
22	binding	O
23	shows	O
24	repressed	O
25	expression	O
26	during	O
27	terminal	O
28	differentiation	O
29	.	O

1	Recent	O
2	application	O
3	of	O
4	recombinant	O
5	canarypox	O
6	ALVAC	O
7	/	O
8	HIV	O
9	-	O
10	1	O
11	vectors	O
12	as	O
13	vaccine	O
14	immunogens	O
15	in	O
16	HIV	O
17	-	O
18	1	O
19	,-	O
20	noninfected	O
21	volunteers	O
22	has	O
23	produced	O
24	CTL	O
25	responses	O
26	in	O
27	a	O
28	significant	O
29	number	O
30	of	O
31	vaccinees	O
32	.	O

1	The	O
2	relevance	O
3	of	O
4	these	O
5	elements	O
6	in	O
7	conferring	O
8	anaerobic	O
9	induction	O
10	of	O
11	gpc4	B
12	gene	I
13	expression	O
14	is	O
15	discussed	O
16	.	O

1	Exons	O
2	A1a	O
3	and	O
4	A1b	O
5	are	O
6	separated	O
7	from	O
8	each	O
9	other	O
10	by	O
11	a	O
12	124	O
13	-	O
14	nucleotide	O
15	intron	O
16	.	O

1	A	O
2	MEK	B
3	-	O
4	specific	O
5	inhibitor	O
6	(	O
7	PD098059	O
8	)	O
9	(	O
10	Dudley	O
11	,	O
12	D	O
13	.	O

1	These	O
2	data	O
3	support	O
4	the	O
5	idea	O
6	that	O
7	the	O
8	repression	O
9	activity	O
10	of	O
11	NRSF	B
12	/	O
13	REST	B
14	depends	O
15	upon	O
16	the	O
17	species	O
18	of	O
19	promoter	O
20	to	O
21	which	O
22	it	O
23	is	O
24	linked	O
25	and	O
26	upon	O
27	the	O
28	proteins	O
29	that	O
30	bind	O
31	to	O
32	those	O
33	promoters	O
34	.	O

1	Enhanced	O
2	period	O
3	-	O
4	peak	O
5	analysis	O
6	of	O
7	electro	O
8	-	O
9	encephalograms	O
10	using	O
11	a	O
12	fast	O
13	sinc	O
14	function	O
15	.	O

1	In	O
2	summary	O
3	,	O
4	p56	B
5	(	O
6	lck	B
7	)	O
8	activity	O
9	stimulates	O
10	G1	O
11	/	O
12	S	O
13	transition	O
14	in	O
15	immature	O
16	thymoblasts	O
17	and	O
18	maintains	O
19	cell	O
20	viability	O
21	via	O
22	transduction	O
23	of	O
24	constitutive	O
25	activation	O
26	signals	O
27	downstream	O
28	to	O
29	components	O
30	of	O
31	the	O
32	Ras	B
33	/	O
34	Raf	B
35	/	O
36	MAPK	B
37	pathway	O
38	.	O

1	However	O
2	,	O
3	the	O
4	action	O
5	of	O
6	each	O
7	cognate	O
8	ligand	O
9	and	O
10	the	O
11	accessory	O
12	cellular	O
13	factors	O
14	that	O
15	can	O
16	differentially	O
17	regulate	O
18	the	O
19	transcriptional	O
20	responses	O
21	of	O
22	a	O
23	heterodimer	O
24	-	O
25	DNA	O
26	complex	O
27	are	O
28	not	O
29	well	O
30	understood	O
31	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	MBF	O
6	on	O
7	incisors	O
8	and	O
9	its	O
10	direction	O
11	in	O
12	three	O
13	dimensions	O
14	for	O
15	different	O
16	jaw	O
17	openings	O
18	in	O
19	ten	O
20	subjects	O
21	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	intraarterial	O
6	neoadjuvant	O
7	chemotherapy	O
8	should	O
9	be	O
10	effective	O
11	on	O
12	advanced	O
13	cervical	O
14	cancer	O
15	.	O

1	The	O
2	FBF	O
3	questionnaire	O
4	did	O
5	not	O
6	highlight	O
7	a	O
8	characteristic	O
9	basic	O
10	symptoms	O
11	profile	O
12	of	O
13	schizoaffective	O
14	disorder	O
15	,	O
16	when	O
17	compared	O
18	with	O
19	bipolar	O
20	affective	O
21	disorder	O
22	and	O
23	schizophrenia	O
24	.	O

1	The	O
2	alternative	O
3	sigma	B
4	factor	I
5	sigmaB	I
6	in	I
7	Staphylococcus	I
8	aureus	I
9	:	O
10	regulation	O
11	of	O
12	the	O
13	sigB	B
14	operon	I
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	O
21	heat	O
22	shock	O

1	Cognate	O
2	promoter	O
3	elements	O
4	implicated	O
5	in	O
6	glucocorticoid	O
7	-	O
8	and	O
9	cAMP	O
10	-	O
11	mediated	O
12	regulation	O
13	as	O
14	well	O
15	as	O
16	in	O
17	liver	O
18	-,	O
19	myeloid	O
20	-,	O
21	and	O
22	lymphocyte	O
23	-	O
24	specific	O
25	expression	O
26	are	O
27	located	O
28	within	O
29	the	O
30	5	O
31	'	O
32	flanking	O
33	sequence	O
34	.	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	We	O
2	have	O
3	studied	O
4	the	O
5	biokinetics	O
6	of	O
7	BLM	O
8	labeled	O
9	with	O
10	indium	O
11	-	O
12	111	O
13	(	O
14	In	O
15	-	O
16	111	O
17	).	O

1	CD3	B
2	cross	O
3	-	O
4	linking	O
5	induced	O
6	tyrosine	O
7	phosphorylation	O
8	of	O
9	Sam68	B
10	in	O
11	uninfected	O
12	T	O
13	cells	O
14	.	O

1	Acetoin	O
2	-	O
3	dependent	O
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	B
15	.	I
16	coli	I
17	acoK	I
18	mutants	I
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	B
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	B
5	and	I
6	sigma	I
7	-	I
8	70	I
9	subunits	I
10	of	I
11	RNA	I
12	polymerase	I
13	affect	O
14	expression	O
15	of	O
16	the	O
17	mer	B
18	operon	I
19	.	O

1	Taken	O
2	together	O
3	,	O
4	we	O
5	provide	O
6	evidence	O
7	for	O
8	the	O
9	existence	O
10	of	O
11	an	O
12	activator	O
13	,	O
14	NFE	B
15	,	O
16	which	O
17	in	O
18	combination	O
19	with	O
20	the	O
21	p50	B
22	and	O
23	c	B
24	-	I
25	Rel	I
26	proteins	I
27	,	O
28	are	O
29	part	O
30	of	O
31	the	O
32	transcription	O
33	factor	O
34	machinery	O
35	that	O
36	regulates	O
37	3	O
38	'	O
39	enhancer	O
40	activity	O
41	,	O
42	and	O
43	thus	O
44	the	O
45	control	O
46	of	O
47	the	O
48	IgH	B
49	locus	I
50	in	O
51	late	O
52	B	O
53	lymphocyte	O
54	development	O
55	.	O

1	The	O
2	neuroprotective	O
3	efficacy	O
4	of	O
5	the	O
6	selective	O
7	N	O
8	-	O
9	type	O
10	voltage	O
11	-	O
12	sensitive	O
13	calcium	O
14	channel	O
15	blocker	O
16	,	O
17	SNX	O
18	-	O
19	111	O
20	,	O
21	was	O
22	evaluated	O
23	in	O
24	spontaneously	O
25	hypertensive	O
26	rats	O
27	subjected	O
28	to	O
29	60	O
30	min	O
31	of	O
32	focal	O
33	cerebral	O
34	ischemia	O
35	by	O
36	permanent	O
37	ligation	O
38	of	O
39	the	O
40	right	O
41	common	O
42	carotid	O
43	artery	O
44	and	O
45	temporary	O
46	occlusion	O
47	of	O
48	the	O
49	right	O
50	middle	O
51	cerebral	O
52	artery	O
53	.	O

1	The	O
2	genes	O
3	encoding	O
4	the	O
5	transcription	B
6	factor	I
7	yTAFII60	I
8	,	O
9	the	O
10	G4p1	B
11	protein	I
12	and	O
13	a	O
14	putative	O
15	glucose	O
16	transporter	O
17	are	O
18	contained	O
19	in	O
20	a	O
21	12	O
22	.	O
23	3	O
24	kb	O
25	DNA	O
26	fragment	O
27	on	O
28	the	O
29	left	O
30	arm	O
31	of	O
32	Saccharomyces	O
33	cerevisiae	O
34	chromosome	O
35	VII	O
36	.	O

1	The	O
2	protector	O
3	doubled	O
4	the	O
5	estimated	O
6	fall	O
7	distance	O
8	for	O
9	fracture	O
10	of	O
11	the	O
12	trochanter	O
13	.	O

1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O

1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	eight	O
6	patients	O
7	who	O
8	underwent	O
9	a	O
10	curative	O
11	hepatic	O
12	resection	O
13	for	O
14	HCC	O
15	and	O
16	whose	O
17	preoperative	O
18	AFP	B
19	levels	O
20	were	O
21	>	O
22	100	O
23	ng	O
24	/	O
25	ml	O
26	,	O
27	were	O
28	selected	O
29	for	O
30	this	O
31	study	O
32	.	O

1	Calmodulin	B
2	-	I
3	binding	I
4	peptide	I
5	(	O
6	CBP	B
7	),	O
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	B
17	myosin	I
18	light	I
19	chain	I
20	kinase	I
21	(	O
22	MLCK	B
23	),	O
24	binds	O
25	to	O
26	calmodulin	B
27	with	O
28	nanomolar	O
29	affinity	O
30	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	the	O
6	type	O
7	of	O
8	tyrosine	B
9	kinase	I
10	receptor	I
11	stimulated	O
12	also	O
13	participates	O
14	in	O
15	the	O
16	nature	O
17	of	O
18	the	O
19	cAMP	O
20	effect	O
21	.	O

1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	possible	O
7	involvement	O
8	of	O
9	p21	B
10	in	O
11	liver	O
12	cell	O
13	growth	O
14	,	O
15	the	O
16	expression	O
17	and	O
18	regulation	O
19	of	O
20	the	O
21	p21	B
22	gene	I
23	was	O
24	evaluated	O
25	in	O
26	rodent	O
27	models	O
28	of	O
29	liver	O
30	regeneration	O
31	and	O
32	specimens	O
33	of	O
34	human	O
35	liver	O
36	diseases	O
37	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	LeMT	B
6	(	I
7	A	I
8	)	I
9	and	O
10	LeMT	B
11	(	I
12	B	I
13	)	I
14	showed	O
15	that	O
16	transcripts	O
17	of	O
18	both	O
19	MT	B
20	-	I
21	like	I
22	genes	I
23	were	O
24	more	O
25	abundant	O
26	in	O
27	leaves	O
28	than	O
29	roots	O
30	in	O
31	tomato	O
32	plants	O
33	grown	O
34	without	O
35	addition	O
36	of	O
37	extra	O
38	metal	O
39	ions	O
40	,	O
41	a	O
42	characteristic	O
43	of	O
44	type	B
45	II	I
46	MTs	I
47	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	I
10	2	I
11	but	O
12	not	O
13	an	O
14	Egr	B
15	-	I
16	1	I
17	expression	O
18	vector	O
19	activated	O
20	VPF	B
21	/	O
22	VEGF	B
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	I
30	2	I
31	protein	I
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	B
37	alpha	I
38	-	O
39	induced	O
40	VPF	B
41	/	O
42	VEGF	B
43	gene	O
44	expression	O
45	.	O

1	The	O
2	HBP	B
3	gene	I
4	is	O
5	composed	O
6	of	O
7	eight	O
8	exons	O
9	covering	O
10	19	O
11	.	O
12	5	O
13	kb	O
14	on	O
15	the	O
16	short	O
17	arm	O
18	of	O
19	chromosome	O
20	4	O
21	.	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	O
13	virally	O
14	encoded	O
15	proteases	O
16	which	O
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	B
23	factor	I
24	eIF4G	I
25	.	O

1	The	O
2	best	O
3	endometrial	O
4	ablation	O
5	was	O
6	seen	O
7	when	O
8	SnET2	O
9	was	O
10	given	O
11	by	O
12	intrauterine	O
13	administration	O
14	with	O
15	light	O
16	treatment	O
17	at	O
18	150	O
19	J	O
20	/	O
21	cm	O
22	24	O
23	hours	O
24	later	O
25	.	O

1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O

1	Cytohesin	B
2	-	I
3	1	I
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O

1	In	O
2	this	O
3	regard	O
4	,	O
5	it	O
6	differs	O
7	from	O
8	a	O
9	recently	O
10	reported	O
11	BFA	O
12	-	O
13	sensitive	O
14	ARF	B
15	-	O
16	GEP	B
17	that	O
18	contains	O
19	a	O
20	Sec7	B
21	domain	I
22	.	O

1	We	O
2	now	O
3	describe	O
4	the	O
5	identification	O
6	of	O
7	DEK	B
8	as	O
9	this	O
10	43	B
11	-	I
12	kDa	I
13	pets	I
14	factor	I
15	.	O

1	These	O
2	elements	O
3	comprise	O
4	a	O
5	binding	O
6	site	O
7	for	O
8	Krox	B
9	proteins	I
10	,	O
11	one	O
12	for	O
13	nuclear	B
14	factor	I
15	1	I
16	,	O
17	an	O
18	octamer	O
19	motif	O
20	that	O
21	binds	O
22	POU	B
23	-	I
24	homeodomain	I
25	proteins	I
26	,	O
27	and	O
28	a	O
29	novel	O
30	TN	B
31	control	I
32	element	I
33	.	O

1	Tissue	O
2	samples	O
3	were	O
4	obtained	O
5	either	O
6	from	O
7	rats	O
8	that	O
9	had	O
10	been	O
11	exposed	O
12	to	O
13	opiate	O
14	withdrawal	O
15	following	O
16	a	O
17	seven	O
18	day	O
19	morphine	O
20	infusion	O
21	or	O
22	sham	O
23	treated	O
24	control	O
25	subjects	O
26	.	O

1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	B
10	mutants	I
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	B
20	plate	I
21	inducer	I
22	shh	I
23	.	O

1	RESULTS	O
2	:	O
3	The	O
4	medians	O
5	of	O
6	average	O
7	daily	O
8	CD34	B
9	+	I
10	cell	O
11	yields	O
12	for	O
13	patients	O
14	who	O
15	received	O
16	paclitaxel	O
17	plus	O
18	CY	O
19	,	O
20	CE	O
21	,	O
22	and	O
23	CEP	O
24	with	O
25	G	B
26	-	I
27	CSF	I
28	were	O
29	12	O
30	.	O
31	9	O
32	,	O
33	11	O
34	.	O
35	03	O
36	,	O
37	and	O
38	5	O
39	.	O
40	37	O
41	x	O
42	10	O
43	(	O
44	6	O
45	)/	O
46	kg	O
47	,	O
48	respectively	O
49	,	O
50	compared	O
51	with	O
52	2	O
53	.	O
54	02	O
55	x	O
56	10	O
57	(	O
58	6	O
59	)/	O
60	kg	O
61	in	O
62	the	O
63	reference	O
64	group	O
65	that	O
66	received	O
67	CY	O
68	with	O
69	G	B
70	-	I
71	CSF	I
72	(	O
73	P	O
74	=	O
75	<	O
76	.	O
77	0001	O
78	,	O
79	.	O
80	002	O
81	,	O
82	and	O
83	.	O
84	09	O
85	,	O
86	respectively	O
87	).	O

1	Increased	O
2	p53	B
3	activity	O
4	induced	O
5	by	O
6	OP	O
7	is	O
8	not	O
9	due	O
10	to	O
11	elevated	O
12	p53	B
13	mRNA	I
14	nor	O
15	to	O
16	protein	O
17	levels	O
18	.	O

1	CONCLUSION	O
2	:	O
3	Chronic	O
4	administration	O
5	of	O
6	misoprostol	O
7	may	O
8	have	O
9	caused	O
10	a	O
11	negative	O
12	natriuretic	O
13	effect	O
14	in	O
15	cirrhotic	O
16	patients	O
17	with	O
18	ascites	O
19	.	O

1	The	O
2	intensity	O
3	of	O
4	the	O
5	SSTEs	O
6	is	O
7	an	O
8	order	O
9	of	O
10	magnitude	O
11	larger	O
12	than	O
13	that	O
14	of	O
15	the	O
16	MSEs	O
17	and	O
18	determines	O
19	the	O
20	signal	O
21	contrast	O
22	if	O
23	both	O
24	effects	O
25	are	O
26	selected	O
27	simultaneously	O
28	.	O

1	In	O
2	eukaryotic	O
3	cells	O
4	,	O
5	premature	O
6	termination	O
7	of	O
8	translation	O
9	at	O
10	nonsense	O
11	codons	O
12	has	O
13	been	O
14	implicated	O
15	as	O
16	the	O
17	cause	O
18	of	O
19	a	O
20	variety	O
21	of	O
22	posttranscriptional	O
23	events	O
24	,	O
25	including	O
26	rapid	O
27	mRNA	O
28	decay	O
29	in	O
30	the	O
31	cytoplasm	O
32	or	O
33	the	O
34	nucleus	O
35	,	O
36	altered	O
37	splice	O
38	site	O
39	selection	O
40	,	O
41	and	O
42	exon	O
43	skipping	O
44	.	O

1	The	O
2	region	O
3	of	O
4	plasmid	O
5	pCM2	O
6	encoding	O
7	the	O
8	pathogenicity	B
9	locus	I
10	pat	I
11	-	I
12	1	I
13	was	O
14	mapped	O
15	by	O
16	deletion	O
17	analysis	O
18	and	O
19	complementation	O
20	studies	O
21	to	O
22	a	O
23	1	O
24	.	O
25	5	O
26	-	O
27	kb	O
28	Bg	B
29	/	I
30	II	I
31	/	O
32	SmaI	B
33	DNA	O
34	fragment	O
35	.	O

1	Transient	O
2	cotransfection	O
3	of	O
4	tat	B
5	cDNA	I
6	in	O
7	sense	O
8	orientation	O
9	(	O
10	tat	B
11	/	I
12	S	I
13	),	O
14	together	O
15	with	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	c	B
21	-	I
22	fos	I
23	promoter	I
24	(	O
25	FC3	B
26	,	O
27	from	O
28	-	O
29	711	O
30	to	O
31	+	O
32	42	O
33	)	O
34	in	O
35	front	O
36	of	O
37	the	O
38	bacterial	B
39	chloramphenicol	I
40	acetyltransferase	I
41	(	O
42	CAT	B
43	)	O
44	gene	O
45	significantly	O
46	enhanced	O
47	CAT	B
48	activity	O
49	in	O
50	Jurkat	O
51	cells	O
52	activated	O
53	by	O
54	the	O
55	addition	O
56	of	O
57	15	O
58	%	O
59	fetal	O
60	calf	O
61	serum	O
62	(	O
63	FCS	O
64	)	O
65	or	O
66	5	O
67	micrograms	O
68	/	O
69	mL	O
70	phytohemagglutinin	B
71	plus	O
72	10	O
73	(-	O
74	7	O
75	)	O
76	mol	O
77	/	O
78	L	O
79	phorbol	O
80	myristate	O
81	acetate	O
82	(	O
83	PMA	O
84	)	O
85	and	O
86	U937	O
87	cells	O
88	activated	O
89	by	O
90	15	O
91	%	O
92	FCS	O
93	or	O
94	10	O
95	(-	O
96	7	O
97	)	O
98	mol	O
99	/	O
100	L	O
101	PMA	O
102	.	O

1	Snail	O
2	mortality	O
3	did	O
4	not	O
5	differ	O
6	among	O
7	the	O
8	various	O
9	treatment	O
10	conditions	O
11	.	O

1	The	O
2	recombinant	O
3	protein	O
4	was	O
5	purified	O
6	to	O
7	homogeneity	O
8	by	O
9	(	O
10	NH4	O
11	)	O
12	2SO4	O
13	-	O
14	precipitation	O
15	and	O
16	affinity	O
17	chromatography	O
18	on	O
19	5	O
20	'	O
21	AMP	O
22	-	O
23	Sepharose	O
24	.	O

1	Derepression	O
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	B
15	lyase	I
16	gene	I
17	of	I
18	Candida	I
19	tropicalis	I
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	Exploratory	O
2	-	O
3	motor	O
4	task	O
5	to	O
6	evaluate	O
7	right	O
8	frontal	O
9	lobe	O
10	damage	O
11	.	O

1	To	O
2	avoid	O
3	complications	O
4	,	O
5	accurate	O
6	quantitative	O
7	analysis	O
8	of	O
9	NO	O
10	and	O
11	NO2	O
12	is	O
13	necessary	O
14	during	O
15	this	O
16	therapy	O
17	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	cis	O
6	elements	O
7	positioned	O
8	between	O
9	the	O
10	alpha	B
11	3	I
12	and	O
13	beta	B
14	4	I
15	coding	O
16	regions	O
17	are	O
18	important	O
19	for	O
20	establishing	O
21	part	O
22	of	O
23	the	O
24	restricted	O
25	CNS	O
26	patterns	O
27	of	O
28	beta	B
29	4	I
30	,	O
31	alpha	B
32	3	I
33	,	O
34	and	O
35	alpha	B
36	5	I
37	gene	I
38	transcription	O
39	.	O

1	RNase	B
2	protection	O
3	experiments	O
4	confirmed	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	GHR1	B
10	-	I
11	279	I
12	variant	I
13	in	O
14	IM	O
15	-	O
16	9	O
17	cells	O
18	and	O
19	human	O
20	liver	O
21	.	O

1	Functional	O
2	tests	O
3	using	O
4	a	O
5	reporter	O
6	gene	O
7	,	O
8	containing	O
9	Stat5	B
10	-	I
11	binding	I
12	elements	I
13	,	O
14	confirmed	O
15	that	O
16	while	O
17	the	O
18	variant	O
19	form	O
20	was	O
21	inactive	O
22	by	O
23	itself	O
24	,	O
25	it	O
26	could	O
27	inhibit	O
28	the	O
29	function	O
30	of	O
31	the	O
32	full	O
33	-	O
34	length	O
35	receptor	O
36	.	O

1	Conversely	O
2	,	O
3	activated	O
4	glucocorticoid	B
5	receptors	I
6	suppressed	O
7	the	O
8	transactivation	O
9	function	O
10	of	O
11	p53	B
12	,	O
13	while	O
14	transrepression	O
15	by	O
16	p53	B
17	was	O
18	largely	O
19	unaffected	O
20	.	O

1	99mTc	O
2	-	O
3	HMPAO	O
4	was	O
5	distributed	O
6	in	O
7	the	O
8	territories	O
9	of	O
10	the	O
11	ACA	O
12	and	O
13	MCA	O
14	in	O
15	the	O
16	two	O
17	patients	O
18	who	O
19	were	O
20	treated	O
21	with	O
22	intraarterial	O
23	infusion	O
24	of	O
25	papaverine	O
26	from	O
27	the	O
28	C4	O
29	segment	O
30	,	O
31	but	O
32	was	O
33	distributed	O
34	only	O
35	to	O
36	the	O
37	territory	O
38	of	O
39	the	O
40	ACA	O
41	in	O
42	four	O
43	patients	O
44	who	O
45	were	O
46	treated	O
47	with	O
48	intraarterial	O
49	infusion	O
50	of	O
51	papaverine	O
52	from	O
53	the	O
54	C1	O
55	segment	O
56	at	O
57	1	O
58	ml	O
59	/	O
60	min	O
61	.	O

1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O

1	This	O
2	promoter	O
3	segment	O
4	could	O
5	drive	O
6	expression	O
7	of	O
8	a	O
9	luciferase	B
10	reporter	I
11	gene	I
12	,	O
13	could	O
14	confer	O
15	correct	O
16	transcriptional	O
17	initiation	O
18	to	O
19	the	O
20	reporter	O
21	and	O
22	could	O
23	confer	O
24	the	O
25	EGF	B
26	-	O
27	responsiveness	O
28	previously	O
29	observed	O
30	in	O
31	the	O
32	native	O
33	gene	O
34	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	report	O
6	that	O
7	an	O
8	in	O
9	vitro	O
10	-	O
11	synthesized	O
12	alphavirus	O
13	RNA	O
14	lacking	O
15	a	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	can	O
22	initiate	O
23	infection	O
24	and	O
25	produce	O
26	3	O
27	'	O
28	polyadenylated	O
29	viral	O
30	genome	O
31	in	O
32	vivo	O
33	.	O

1	The	O
2	human	O
3	coreceptor	O
4	was	O
5	as	O
6	active	O
7	as	O
8	the	O
9	simian	O
10	for	O
11	SIV	O
12	entry	O
13	.	O

1	These	O
2	changes	O
3	in	O
4	virus	O
5	entry	O
6	features	O
7	may	O
8	result	O
9	in	O
10	coronaviruses	O
11	with	O
12	novel	O
13	pathogenic	O
14	properties	O
15	.	O

1	RESULTS	O
2	:	O
3	Among	O
4	women	O
5	,	O
6	the	O
7	age	O
8	-	O
9	related	O
10	decline	O
11	in	O
12	BMD	O
13	at	O
14	all	O
15	non	O
16	-	O
17	spine	O
18	skeletal	O
19	sites	O
20	was	O
21	significantly	O
22	different	O
23	from	O
24	zero	O
25	,	O
26	with	O
27	the	O
28	largest	O
29	decline	O
30	seen	O
31	at	O
32	the	O
33	femoral	O
34	neck	O
35	(-.	O
36	0038	O
37	g	O
38	/	O
39	cm2	O
40	/	O
41	y	O
42	,	O
43	p	O
44	<	O
45	.	O
46	001	O
47	)	O
48	and	O
49	the	O
50	smallest	O
51	at	O
52	the	O
53	trochanter	O
54	of	O
55	the	O
56	hip	O
57	(-.	O
58	0023	O
59	g	O
60	/	O
61	cm2	O
62	/	O
63	y	O
64	,	O
65	p	O
66	=	O
67	.	O
68	03	O
69	).	O

1	Sixty	O
2	-	O
3	nine	O
4	(	O
5	44	O
6	%)	O
7	patients	O
8	were	O
9	administered	O
10	250	O
11	MBq	O
12	(	O
13	7	O
14	mCi	O
15	)	O
16	99Tcm	O
17	-	O
18	tetrofosmin	O
19	at	O
20	rest	O
21	followed	O
22	4	O
23	h	O
24	later	O
25	by	O
26	750	O
27	MBq	O
28	(	O
29	21	O
30	mCi	O
31	)	O
32	during	O
33	stress	O
34	(	O
35	the	O
36	1	O
37	day	O
38	protocol	O
39	),	O
40	whereas	O
41	88	O
42	(	O
43	56	O
44	%)	O
45	patients	O
46	had	O
47	rest	O
48	and	O
49	stress	O
50	imaging	O
51	studies	O
52	on	O
53	two	O
54	separate	O
55	days	O
56	,	O
57	receiving	O
58	a	O
59	500	O
60	MBq	O
61	(	O
62	14	O
63	mCi	O
64	)	O
65	dose	O
66	of	O
67	99Tcm	O
68	-	O
69	tetrofosmin	O
70	on	O
71	each	O
72	occasion	O
73	(	O
74	the	O
75	2	O
76	day	O
77	protocol	O
78	).	O

1	Myocardial	O
2	SPET	O
3	imaging	O
4	with	O
5	99Tcm	O
6	-	O
7	tetrofosmin	O
8	in	O
9	clinical	O
10	practice	O
11	:	O
12	comparison	O
13	of	O
14	a	O
15	1	O
16	day	O
17	and	O
18	a	O
19	2	O
20	day	O
21	imaging	O
22	protocol	O
23	.	O

1	99Tcm	O
2	-	O
3	DMP	O
4	-	O
5	HSA	O
6	showed	O
7	an	O
8	almost	O
9	identical	O
10	behaviour	O
11	to	O
12	in	O
13	vitro	O
14	labelled	O
15	red	O
16	blood	O
17	cells	O
18	(	O
19	RBCs	O
20	),	O
21	which	O
22	are	O
23	generally	O
24	considered	O
25	the	O
26	reference	O
27	standard	O
28	for	O
29	blood	O
30	pool	O
31	agents	O
32	.	O

1	Relief	O
2	from	O
3	autoinhibition	O
4	and	O
5	a	O
6	subsequent	O
7	10	O
8	-	O
9	60	O
10	-	O
11	fold	O
12	increase	O
13	in	O
14	V	O
15	(	O
16	max	O
17	)	O
18	have	O
19	been	O
20	observed	O
21	upon	O
22	N	B
23	-	I
24	SH2	I
25	domain	I
26	engagement	O
27	by	O
28	a	O
29	specific	O
30	phosphotyrosyl	O
31	ligand	O
32	or	O
33	upon	O
34	deletion	O
35	of	O
36	the	O
37	SH2	B
38	domains	I
39	to	O
40	yield	O
41	the	O
42	catalytic	O
43	PTPase	B
44	domain	I
45	.	O

1	We	O
2	have	O
3	thus	O
4	identified	O
5	the	O
6	first	O
7	mammalian	B
8	homolog	I
9	of	I
10	yeast	I
11	UPF1	I
12	,	O
13	a	O
14	protein	O
15	that	O
16	regulates	O
17	levels	O
18	of	O
19	nonsense	O
20	mRNA	O
21	,	O
22	and	O
23	we	O
24	tentatively	O
25	name	O
26	this	O
27	protein	O
28	human	B
29	HUPF1	I
30	(	O
31	for	O
32	human	B
33	homolog	I
34	of	I
35	UPF1	I
36	).	O

1	A	O
2	miracle	O
3	cure	O
4	and	O
5	its	O
6	solution	O

1	The	O
2	addition	O
3	of	O
4	zidovudine	O
5	did	O
6	not	O
7	influence	O
8	this	O
9	transfer	O
10	.	O

1	DNA	O
2	strand	O
3	exchange	O
4	catalyzed	O
5	by	O
6	Rad51	B
7	protein	I
8	is	O
9	also	O
10	greatly	O
11	stimulated	O
12	by	O
13	RPA	B
14	.	O

1	Ume6p	B
2	,	O
3	which	O
4	also	O
5	controls	O
6	the	O
7	expression	O
8	of	O
9	early	O
10	meiotic	O
11	genes	O
12	,	O
13	represses	O
14	CAR1	B
15	expression	O
16	through	O
17	a	O
18	sequence	O
19	called	O
20	URS	O
21	,	O
22	as	O
23	a	O
24	function	O
25	of	O
26	nitrogen	O
27	availability	O
28	.	O

1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	hybridized	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	O
21	mammalian	B
22	lactase	I
23	mRNA	I
24	.	O

1	In	O
2	cell	O
3	lines	O
4	transformed	O
5	by	O
6	BCR	B
7	/	O
8	ABL	B
9	,	O
10	CRKL	B
11	was	O
12	tyrosine	O
13	phosphorylated	O
14	,	O
15	while	O
16	CRK	B
17	was	O
18	not	O
19	.	O

1	In	O
2	untransformed	O
3	cells	O
4	,	O
5	three	O
6	major	O
7	proteins	O
8	coprecipitated	O
9	with	O
10	CRKL	B
11	,	O
12	identified	O
13	as	O
14	C3G	B
15	,	O
16	SOS	B
17	and	O
18	c	B
19	-	I
20	ABL	I
21	.	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	RESULTS	O
2	:	O
3	Nodular	O
4	opacities	O
5	,	O
6	mainly	O
7	centrilobular	O
8	in	O
9	distribution	O
10	,	O
11	were	O
12	the	O
13	most	O
14	common	O
15	finding	O
16	,	O
17	seen	O
18	in	O
19	21	O
20	(	O
21	72	O
22	%)	O
23	and	O
24	15	O
25	(	O
26	65	O
27	%)	O
28	of	O
29	patients	O
30	with	O
31	MTB	O
32	and	O
33	NTMB	O
34	,	O
35	respectively	O
36	.	O

1	Circulating	O
2	oxytocin	B
3	in	O
4	male	O
5	guinea	O
6	pigs	O
7	affected	O
8	by	O
9	the	O
10	female	O
11	cohabitation	O
12	and	O
13	reproductive	O
14	condition	O
15	.	O

1	In	O
2	cellular	O
3	supernatant	O
4	fraction	O
5	,	O
6	SHRSP	O
7	showed	O
8	a	O
9	decrease	O
10	of	O
11	magnesium	O
12	in	O
13	many	O
14	tissues	O
15	and	O
16	an	O
17	elevation	O
18	of	O
19	the	O
20	calcium	O
21	to	O
22	magnesium	O
23	ratio	O
24	when	O
25	compared	O
26	to	O
27	age	O
28	-	O
29	matched	O
30	WKY	O
31	and	O
32	SHRSR	O
33	.	O

1	Antisense	O
2	transcription	O
3	of	O
4	a	O
5	murine	B
6	FGFR	I
7	-	I
8	3	I
9	psuedogene	I
10	during	O
11	fetal	O
12	developement	O
13	.	O

1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	548	O
8	-	O
9	bp	O
10	BglII	B
11	-	O
12	SmaI	B
13	fragment	O
14	has	O
15	an	O
16	SSO	O
17	activity	O
18	(	O
19	ori2	O
20	;	O
21	Kataoka	O
22	et	O
23	al	O
24	.,	O
25	Mol	O
26	.	O

1	The	O
2	human	B
3	CD38	I
4	gene	I
5	consists	O
6	of	O
7	8	O
8	exons	O
9	that	O
10	extend	O
11	more	O
12	than	O
13	77	O
14	kb	O
15	on	O
16	the	O
17	human	O
18	genome	O
19	.	O

1	Type	O
2	IV	O
3	splice	O
4	pattern	O
5	,	O
6	containing	O
7	exon	O
8	U3	O
9	and	O
10	S	O
11	was	O
12	found	O
13	both	O
14	in	O
15	kidney	O
16	and	O
17	ovary	O
18	.	O

1	GH	B
2	deficiency	O
3	may	O
4	be	O
5	absolute	O
6	,	O
7	but	O
8	often	O
9	is	O
10	not	O
11	and	O
12	the	O
13	diagnosis	O
14	may	O
15	be	O
16	complicated	O
17	by	O
18	a	O
19	constellation	O
20	of	O
21	physical	O
22	and	O
23	hormonal	O
24	findings	O
25	that	O
26	are	O
27	along	O
28	a	O
29	spectrum	O
30	from	O
31	low	O
32	normal	O
33	GH	B
34	sufficiency	O
35	to	O
36	absent	O
37	GH	B
38	secretion	O
39	.	O

1	Positive	O
2	CRP	B
3	test	O
4	were	O
5	seen	O
6	.	O

1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O

1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	The	O
2	minimum	O
3	and	O
4	essential	O
5	subunits	O
6	for	O
7	RNA	O
8	synthesis	O
9	have	O
10	not	O
11	yet	O
12	been	O
13	identified	O
14	.	O

1	Syndecan	B
2	-	I
3	4	I
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	localize	O
16	PKC	B
17	and	O
18	amplify	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	adhesions	O
26	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	B
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	Members	O
2	of	O
3	the	O
4	MAPK	B
5	family	I
6	include	O
7	the	O
8	extracellular	B
9	response	I
10	kinases	I
11	(	O
12	ERKs	B
13	or	O
14	p42	B
15	/	I
16	44	I
17	(	O
18	MAPK	B
19	)),	O
20	the	O
21	c	B
22	-	I
23	Jun	I
24	amino	I
25	-	I
26	terminal	I
27	kinases	I
28	(	O
29	JNKs	B
30	),	O
31	and	O
32	the	O
33	p38	B
34	/	O
35	Hog	B
36	1	I
37	protein	O
38	kinases	O
39	.	O

1	MOP5	B
2	contained	O
3	the	O
4	characteristic	O
5	PAS	B
6	domain	O
7	and	O
8	a	O
9	variable	O
10	C	O
11	terminus	O
12	;	O
13	it	O
14	is	O
15	possible	O
16	that	O
17	the	O
18	cDNA	O
19	contains	O
20	a	O
21	bHLH	O
22	domain	O
23	,	O
24	but	O
25	the	O
26	entire	O
27	open	O
28	reading	O
29	frame	O
30	has	O
31	yet	O
32	to	O
33	be	O
34	completed	O
35	.	O

1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	B
17	NO	I
18	synthetase	I
19	.	O

1	Some	O
2	8	O
3	.	O
4	8	O
5	kb	O
6	of	O
7	the	O
8	Lactobacillus	O
9	sake	O
10	plasmid	O
11	pCIM1	O
12	was	O
13	sequenced	O
14	,	O
15	revealing	O
16	eight	O
17	tightly	O
18	clustered	O
19	open	O
20	reading	O
21	frames	O
22	(	O
23	ORFs	O
24	)	O
25	downstream	O
26	from	O
27	lasA	B
28	,	O
29	which	O
30	encodes	O
31	pre	B
32	-	I
33	lactocin	I
34	S	I
35	.	O

1	Purified	B
2	Pra	I
3	was	O
4	also	O
5	shown	O
6	to	O
7	physically	O
8	interact	O
9	with	O
10	pyruvate	B
11	kinase	I
12	(	O
13	Pk	B
14	);	O
15	Pk	B
16	and	O
17	Pra	B
18	can	O
19	form	O
20	a	O
21	complex	O
22	,	O
23	but	O
24	when	O
25	the	O
26	12	B
27	-	I
28	kDa	I
29	Ndk	I
30	,	O
31	Pk	B
32	,	O
33	and	O
34	Pra	B
35	are	O
36	all	O
37	present	O
38	,	O
39	Pk	B
40	has	O
41	a	O
42	higher	O
43	affinity	O
44	than	O
45	Pra	B
46	for	O
47	forming	O
48	a	O
49	complex	O
50	with	O
51	the	O
52	12	B
53	-	I
54	kDa	I
55	Ndk	I
56	.	O

1	Apart	O
2	from	O
3	iron	O
4	regulation	O
5	,	O
6	sodA	B
7	expression	O
8	was	O
9	affected	O
10	by	O
11	changes	O
12	in	O
13	DNA	O
14	topology	O
15	induced	O
16	by	O
17	coumermycin	O
18	A	O
19	but	O
20	not	O
21	by	O
22	the	O
23	global	O
24	virulence	O
25	regulatory	O
26	Bvg	B
27	system	I
28	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	O
6	Borrelia	O
7	burgdorferi	O
8	motility	O
9	operon	O
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	O
16	sigma70	B
17	promoter	I
18	.	O

1	M	B
2	.	I
3	leprae	I
4	OxyR	I
5	was	O
6	overproduced	O
7	and	O
8	purified	O
9	,	O
10	and	O
11	its	O
12	binding	O
13	to	O
14	the	O
15	oxyR	B
16	-	O
17	ahpC	B
18	intergenic	O
19	region	O
20	of	O
21	M	O
22	.	O
23	leprae	O
24	was	O
25	demonstrated	O
26	.	O

1	The	O
2	binding	O
3	site	O
4	for	O
5	OxyR	B
6	overlapped	O
7	P1oxyR	B
8	,	O
9	reminiscent	O
10	of	O
11	the	O
12	autoregulatory	O
13	loops	O
14	controlling	O
15	expression	O
16	of	O
17	oxyR	B
18	in	O
19	enteric	O
20	bacteria	O
21	and	O
22	characteristic	O
23	of	O
24	the	O
25	LysR	B
26	superfamily	I
27	in	O
28	general	O
29	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	O
12	p15E	B
13	cDNA	I
14	gene	I
15	fragments	I
16	amplified	O
17	by	O
18	means	O
19	of	O
20	polymerase	O
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	O
37	)	O
38	tumour	O
39	cells	O
40	.	O

1	Thirty	O
2	-	O
3	five	O
4	patients	O
5	were	O
6	included	O
7	.	O

1	Grade	O
2	3	O
3	-	O
4	4	O
5	mucositis	O
6	was	O
7	present	O
8	in	O
9	13	O
10	%	O
11	of	O
12	the	O
13	cycles	O
14	.	O

1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O

1	None	O
2	of	O
3	these	O
4	organic	O
5	manifestations	O
6	was	O
7	discovered	O
8	by	O
9	scintigraphic	O
10	means	O
11	.	O

1	While	O
2	TGF	B
3	-	I
4	beta1	I
5	does	O
6	not	O
7	alter	O
8	the	O
9	mitogen	O
10	-	O
11	induced	O
12	expression	O
13	and	O
14	abundance	O
15	of	O
16	G1	O
17	phase	O
18	cyclin	B
19	D1	I
20	and	O
21	cdks	B
22	4	I
23	and	I
24	2	I
25	in	O
26	MCs	O
27	,	O
28	it	O
29	inhibits	O
30	cyclin	B
31	E	I
32	-	O
33	cdk	B
34	2	I
35	activity	O
36	,	O
37	thus	O
38	preventing	O
39	mitogen	O
40	-	O
41	elicited	O
42	phosphorylation	O
43	and	O
44	inactivation	O
45	of	O
46	pRb	B
47	in	O
48	G1	O
49	phase	O
50	and	O
51	transition	O
52	to	O
53	S	O
54	phase	O
55	.	O

1	However	O
2	,	O
3	the	O
4	range	O
5	of	O
6	values	O
7	observed	O
8	is	O
9	suggestive	O
10	of	O
11	the	O
12	need	O
13	to	O
14	investigate	O
15	districts	O
16	with	O
17	contrasting	O
18	values	O
19	of	O
20	SYPLR	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	inter	O
26	-	O
27	relationships	O
28	between	O
29	sociodemographic	O
30	characteristics	O
31	,	O
32	duration	O
33	of	O
34	symptoms	O
35	,	O
36	clinical	O
37	presentation	O
38	and	O
39	treatment	O
40	efficacy	O
41	.	O

1	The	O
2	prominent	O
3	lesions	O
4	were	O
5	confined	O
6	to	O
7	the	O
8	cerebral	O
9	surface	O
10	layer	O
11	and	O
12	leptomeningeal	O
13	tissue	O
14	including	O
15	the	O
16	arachnoid	O
17	vessels	O
18	,	O
19	which	O
20	were	O
21	all	O
22	bathed	O
23	in	O
24	the	O
25	cerebrospinal	O
26	fluid	O
27	,	O
28	suggesting	O
29	that	O
30	some	O
31	necrotizing	O
32	toxins	O
33	had	O
34	been	O
35	secreted	O
36	into	O
37	the	O
38	fluid	O
39	by	O
40	the	O
41	B	O
42	.	O
43	cereus	O
44	.	O

1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	B
12	,	O
13	encoding	O
14	3	B
15	-	I
16	isopropylmalate	I
17	dehydrogenase	I
18	;	O
19	asd	B
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	B
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	B
41	proteins	I
42	from	I
43	Vibrio	I
44	spp	I
45	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	I
21	smegmatis	I
22	clones	O
23	.	O

1	Hovenitin	O
2	I	O
3	and	O
4	(+)-	O
5	ampelopsin	O
6	,	O
7	both	O
8	of	O
9	which	O
10	were	O
11	principal	O
12	ingredients	O
13	of	O
14	the	O
15	active	O
16	fractions	O
17	from	O
18	this	O
19	natural	O
20	medicine	O
21	,	O
22	were	O
23	found	O
24	to	O
25	show	O
26	an	O
27	inhibitory	O
28	activity	O
29	on	O
30	the	O
31	ethanol	O
32	-	O
33	induced	O
34	muscle	O
35	relaxation	O
36	in	O
37	rats	O
38	.	O

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	Areas	O
2	with	O
3	significantly	O
4	greater	O
5	rCBF	O
6	for	O
7	targeting	O
8	were	O
9	the	O
10	left	O
11	motor	O
12	cortex	O
13	,	O
14	left	O
15	intraparietal	O
16	sulcus	O
17	,	O
18	and	O
19	left	O
20	caudate	O
21	.	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	U1	B
8	snRNP	I
9	is	O
10	recruited	O
11	to	O
12	the	O
13	5	O
14	'	O
15	splice	O
16	site	O
17	by	O
18	protein	O
19	/	O
20	protein	O
21	interactions	O
22	involving	O
23	the	O
24	SR	B
25	domains	O
26	of	O
27	the	O
28	U1	B
29	-	I
30	70K	I
31	protein	I
32	and	O
33	SF2	B
34	/	O
35	ASF	B
36	.	O

1	Thus	O
2	,	O
3	the	O
4	tri	O
5	-	O
6	snRNP	O
7	-	O
8	specific	O
9	27K	O
10	protein	O
11	could	O
12	potentially	O
13	be	O
14	involved	O
15	in	O
16	SR	B
17	protein	O
18	-	O
19	mediated	O
20	protein	O
21	/	O
22	protein	O
23	interactions	O
24	and	O
25	,	O
26	additionally	O
27	,	O
28	its	O
29	phosphorylation	O
30	state	O
31	could	O
32	modulate	O
33	pre	O
34	-	O
35	mRNA	O
36	splicing	O
37	.	O

1	Purified	B
2	P7	I
3	could	O
4	be	O
5	assembled	O
6	onto	O
7	particles	O
8	lacking	O
9	P7	B
10	and	O
11	particles	O
12	lacking	O
13	both	O
14	P2	B
15	(	O
16	RNA	B
17	polymerase	I
18	)	O
19	and	O
20	P7	B
21	.	O

1	However	O
2	,	O
3	the	O
4	same	O
5	U1A	B
6	peptide	I
7	,	O
8	when	O
9	conjugated	O
10	to	O
11	BSA	B
12	,	O
13	inhibits	O
14	vertebrate	B
15	PAP	I
16	.	O

1	Plasma	O
2	levels	O
3	of	O
4	protein	B
5	C	I
6	,	O
7	protein	B
8	S	I
9	,	O
10	and	O
11	antithrombin	B
12	III	I
13	in	O
14	patients	O
15	with	O
16	subarachnoid	O
17	haemorrhage	O
18	.	O

1	Idiopathic	O
2	bilateral	O
3	recurrent	O
4	branch	O
5	retinal	O
6	arterial	O
7	occlusion	O
8	(	O
9	IBRBRAO	O
10	)	O
11	is	O
12	a	O
13	rare	O
14	syndrome	O
15	characterized	O
16	by	O
17	migraine	O
18	headaches	O
19	,	O
20	tinnitus	O
21	,	O
22	vertigo	O
23	,	O
24	hearing	O
25	loss	O
26	,	O
27	and	O
28	recurrent	O
29	branch	O
30	retinal	O
31	artery	O
32	occlusion	O
33	of	O
34	unknown	O
35	etiology	O
36	.	O

1	Epithelial	O
2	and	O
3	corneal	O
4	thickness	O
5	measurements	O
6	by	O
7	in	O
8	vivo	O
9	confocal	O
10	microscopy	O
11	through	O
12	focusing	O
13	(	O
14	CMTF	O
15	).	O

1	Sequences	O
2	downstream	O
3	of	O
4	the	O
5	two	O
6	human	B
7	CA	I
8	genes	I
9	,	O
10	possibly	O
11	containing	O
12	homologous	O
13	enhancer	O
14	elements	O
15	,	O
16	have	O
17	not	O
18	yet	O
19	been	O
20	reported	O
21	.	O

1	Recombinant	O
2	plasmids	O
3	containing	O
4	the	O
5	entire	O
6	322	O
7	nt	O
8	5	O
9	'	O
10	UTR	O
11	of	O
12	exon	O
13	1	O
14	and	O
15	a	O
16	1630	O
17	nt	O
18	segment	O
19	of	O
20	5	O
21	'	O
22	flanking	O
23	sequence	O
24	stimulated	O
25	luciferase	B
26	activity	O
27	nearly	O
28	70	O
29	times	O
30	higher	O
31	than	O
32	a	O
33	promoterless	O
34	control	O
35	plasmid	O
36	.	O

1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O

1	It	O
2	is	O
3	also	O
4	homologous	O
5	to	O
6	other	O
7	sugar	O
8	carriers	O
9	from	O
10	human	O
11	,	O
12	mouse	O
13	and	O
14	Escherichia	O
15	coli	O
16	.	O

1	Until	O
2	now	O
3	,	O
4	each	O
5	of	O
6	these	O
7	loci	O
8	was	O
9	considered	O
10	to	O
11	contain	O
12	three	O
13	genes	O
14	(	O
15	for	O
16	regulator	B
17	,	O
18	permease	B
19	and	O
20	alpha	B
21	-	I
22	glucosidase	I
23	),	O
24	but	O
25	a	O
26	fourth	O
27	gene	O
28	,	O
29	presumably	O
30	an	O
31	extra	O
32	alpha	B
33	-	I
34	glucosidase	I
35	gene	I
36	,	O
37	was	O
38	found	O
39	at	O
40	MAL1	B
41	adjacent	O
42	to	O
43	the	O
44	usual	O
45	cluster	O
46	of	O
47	three	O
48	genes	O
49	.	O

1	Although	O
2	methods	O
3	to	O
4	align	O
5	the	O
6	control	O
7	and	O
8	activation	O
9	fMR	O
10	images	O
11	may	O
12	correct	O
13	for	O
14	some	O
15	of	O
16	this	O
17	motional	O
18	error	O
19	,	O
20	they	O
21	will	O
22	be	O
23	incomplete	O
24	in	O
25	correcting	O
26	for	O
27	those	O
28	that	O
29	depend	O
30	on	O
31	spatial	O
32	orientation	O
33	.	O

1	Three	O
2	women	O
3	have	O
4	had	O
5	abnormal	O
6	endocervical	O
7	follow	O
8	up	O
9	cytology	O
10	suggestive	O
11	of	O
12	residual	O
13	disease	O
14	.	O

1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	B
13	and	I
14	acid	I
15	phosphatases	I
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O

1	Analysis	O
2	of	O
3	homologous	O
4	DNA	O
5	sequences	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	mouse	B
13	and	I
14	human	I
15	mts1	I
16	genes	I
17	:	O
18	kB	B
19	-	I
20	like	I
21	site	I
22	and	O
23	microsatellite	O
24	DNA	O

1	The	O
2	integration	O
3	at	O
4	the	O
5	VIP	B
6	CyRE	I
7	of	O
8	the	O
9	Jak	B
10	-	O
11	Stat	B
12	and	O
13	AP	B
14	-	I
15	1	I
16	signaling	O
17	pathways	O
18	with	O
19	other	O
20	pre	O
21	-	O
22	existing	O
23	proteins	O
24	provides	O
25	a	O
26	cellular	O
27	mechanism	O
28	for	O
29	cell	O
30	-	O
31	and	O
32	cytokine	O
33	-	O
34	specific	O
35	signaling	O
36	.	O

1	These	O
2	studies	O
3	point	O
4	to	O
5	the	O
6	involvement	O
7	of	O
8	the	O
9	MAP	B
10	kinase	I
11	pathway	O
12	in	O
13	the	O
14	activation	O
15	of	O
16	monocytic	O
17	cells	O
18	during	O
19	transmigration	O
20	to	O
21	inflammatory	O
22	sites	O
23	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	the	O
6	temperature	B
7	-	I
8	sensitive	I
9	rad54	I
10	-	I
11	3	I
12	allele	I
13	blocks	O
14	mitotic	O
15	recombination	O
16	between	O
17	tandemly	O
18	repeated	O
19	DYZ3	B
20	satellite	I
21	sequences	I
22	and	O
23	significantly	O
24	stabilizes	O
25	a	O
26	human	B
27	DYZ5	I
28	satellite	O
29	-	O
30	containing	O
31	YAC	O
32	clone	O
33	.	O

1	A	O
2	P22	O
3	R17	O
4	derivative	O
5	with	O
6	an	O
7	OcRNA	O
8	site	O
9	(	O
10	P22	O
11	R17	O
12	[	O
13	A	O
14	(-	O
15	10	O
16	)	O
17	U	O
18	])	O
19	develops	O
20	lytically	O
21	following	O
22	infection	O
23	of	O
24	these	O
25	strains	O
26	.	O

1	Circularized	O
2	Ac	B
3	/	O
4	Ds	B
5	transposons	O
6	:	O
7	formation	O
8	,	O
9	structure	O
10	and	O
11	fate	O
12	.	O

1	This	O
2	site	O
3	is	O
4	upstream	O
5	from	O
6	the	O
7	TATA	O
8	box	O
9	used	O
10	in	O
11	somatic	O
12	cells	O
13	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	O
18	Cdks	B
19	.	O

1	Candidate	O
2	tumor	O
3	suppressor	O
4	genes	O
5	,	O
6	Mts1	B
7	(	O
8	p16INK4a	B
9	)	O
10	and	O
11	Mts2	B
12	(	O
13	p15INK4b	B
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O

1	Excision	O
2	repair	O
3	at	O
4	the	O
5	level	O
6	of	O
7	the	O
8	nucleotide	O
9	in	O
10	the	O
11	Saccharomyces	B
12	cerevisiae	I
13	MFA2	I
14	gene	I
15	:	O
16	mapping	O
17	of	O
18	where	O
19	enhanced	O
20	repair	O
21	in	O
22	the	O
23	transcribed	O
24	strand	O
25	begins	O
26	or	O
27	ends	O
28	and	O
29	identification	O
30	of	O
31	only	O
32	a	O
33	partial	O
34	rad16	B
35	requisite	O
36	for	O
37	repairing	O
38	upstream	O
39	control	O
40	sequences	O
41	.	O

1	An	O
2	aromatic	O
3	stacking	O
4	interaction	O
5	between	O
6	subunits	O
7	helps	O
8	mediate	O
9	DNA	O
10	sequence	O
11	specificity	O
12	:	O
13	operator	O
14	site	O
15	discrimination	O
16	by	O
17	phage	B
18	lambda	I
19	cI	I
20	repressor	I
21	.	O

1	We	O
2	have	O
3	characterized	O
4	a	O
5	panel	O
6	of	O
7	6	O
8	monoclonal	O
9	antibodies	O
10	raised	O
11	against	O
12	human	B
13	platelet	I
14	talin	I
15	by	O
16	Western	O
17	blotting	O
18	,	O
19	immune	O
20	precipitation	O
21	,	O
22	and	O
23	immunofluorescence	O
24	,	O
25	and	O
26	shown	O
27	that	O
28	antibodies	B
29	TA205	I
30	and	O
31	TD77	B
32	disrupt	O
33	actin	B
34	stress	O
35	fibers	O
36	and	O
37	focal	O
38	adhesions	O
39	,	O
40	and	O
41	inhibit	O
42	cell	O
43	motility	O
44	when	O
45	microinjected	O
46	into	O
47	human	O
48	fibroblasts	O
49	.	O

1	This	O
2	locus	O
3	maps	O
4	approximately	O
5	160	O
6	kbp	O
7	from	O
8	the	O
9	genes	O
10	encoding	O
11	cytadherence	O
12	-	O
13	associated	O
14	proteins	O
15	HMW1	B
16	and	O
17	HMW3	B
18	,	O
19	and	O
20	yet	O
21	insertions	O
22	therein	O
23	result	O
24	in	O
25	loss	O
26	of	O
27	these	O
28	proteins	O
29	and	O
30	a	O
31	hemadsorption	O
32	-	O
33	negative	O
34	(	O
35	HA	O
36	-)	O
37	phenotype	O
38	,	O
39	prompting	O
40	the	O
41	designation	O
42	cytadherence	B
43	-	I
44	regulatory	I
45	locus	I
46	(	O
47	crl	B
48	).	O

1	Coliphage	B
2	186	I
3	B	I
4	is	O
5	a	O
6	72	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	belonging	O
12	to	O
13	the	O
14	Ogr	B
15	family	O
16	of	O
17	analogous	O
18	transcription	O
19	factors	O
20	present	O
21	in	O
22	P2	O
23	-	O
24	like	O
25	phage	O
26	,	O
27	which	O
28	contain	O
29	a	O
30	Cys	O
31	-	O
32	X2	O
33	-	O
34	Cys	O
35	-	O
36	X22	O
37	-	O
38	Cys	O
39	-	O
40	X4	O
41	-	O
42	Cys	O
43	presumptive	O
44	zinc	O
45	-	O
46	finger	O
47	motif	O
48	.	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	O
39	epsilon	O
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Diacylglycerol	B
2	kinase	I
3	(	O
4	DGK	B
5	)	O
6	attenuates	O
7	levels	O
8	of	O
9	second	O
10	messenger	O
11	diacylglycerol	O
12	in	O
13	cells	O
14	and	O
15	produces	O
16	another	O
17	(	O
18	putative	O
19	)	O
20	messenger	O
21	,	O
22	phosphatidic	O
23	acid	O
24	.	O

1	Recently	O
2	,	O
3	we	O
4	have	O
5	reported	O
6	the	O
7	cloning	O
8	of	O
9	the	O
10	germ	O
11	cell	O
12	-	O
13	specific	O
14	,	O
15	nuclear	O
16	orphan	O
17	receptor	O
18	germ	B
19	cell	I
20	nuclear	I
21	factor	I
22	(	O
23	GCNF	B
24	)/	O
25	RTR	B
26	.	O

1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	conRTRE	B
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	RTRE	B
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	B
19	-	I
20	RE	I
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	B
33	protamine	I
34	2	I
35	gene	I
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	spermatogenesis	O
46	as	O
47	RTR	B
48	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	purification	O
6	of	O
7	this	O
8	larger	O
9	form	O
10	as	O
11	an	O
12	approximately	O
13	320	O
14	-	O
15	kDa	O
16	particle	O
17	that	O
18	contains	O
19	mRNP3	B
20	+	I
21	4	I
22	and	O
23	nine	O
24	additional	O
25	polypeptides	O
26	,	O
27	including	O
28	mRNA	O
29	-	O
30	binding	O
31	polypeptides	O
32	of	O
33	34	O
34	and	O
35	36	O
36	kDa	O
37	and	O
38	a	O
39	doublet	O
40	of	O
41	110	O
42	/	O
43	105	O
44	kDa	O
45	that	O
46	proved	O
47	to	O
48	be	O
49	nucleolin	B
50	.	O

1	Active	O
2	complexes	O
3	eluted	O
4	at	O
5	a	O
6	higher	O
7	molecular	O
8	weight	O
9	than	O
10	inactive	O
11	complexes	O
12	,	O
13	were	O
14	relatively	O
15	deficient	O
16	in	O
17	both	O
18	p21	B
19	and	O
20	p27	B
21	,	O
22	and	O
23	contained	O
24	Cdk2	B
25	with	O
26	increased	O
27	threonine	O
28	160	O
29	phosphorylation	O
30	,	O
31	consistent	O
32	with	O
33	a	O
34	mechanism	O
35	of	O
36	activation	O
37	of	O
38	cyclin	B
39	E	I
40	-	O
41	Cdk2	B
42	involving	O
43	both	O
44	reduced	O
45	CDK	B
46	inhibitor	O
47	association	O
48	and	O
49	CDK	B
50	-	I
51	activating	I
52	kinase	I
53	-	O
54	mediated	O
55	phosphorylation	O
56	of	O
57	Cdk2	B
58	.	O

1	Thirty	O
2	Class	O
3	I	O
4	and	O
5	Class	O
6	II	O
7	recessions	O
8	in	O
9	30	O
10	patients	O
11	were	O
12	treated	O
13	with	O
14	a	O
15	modified	O
16	subepithelial	O
17	connective	O
18	tissue	O
19	graft	O
20	procedure	O
21	.	O

1	The	O
2	derivatives	O
3	of	O
4	the	O
5	latter	O
6	two	O
7	cell	O
8	lines	O
9	showed	O
10	increased	O
11	expression	O
12	of	O
13	the	O
14	p27Kip1	B
15	protein	I
16	and	O
17	inhibition	O
18	of	O
19	cell	O
20	growth	O
21	.	O

1	The	O
2	perioperative	O
3	mortality	O
4	of	O
5	all	O
6	patients	O
7	was	O
8	1	O
9	.	O
10	9	O
11	%,	O
12	the	O
13	mortality	O
14	of	O
15	patients	O
16	older	O
17	than	O
18	70	O
19	years	O
20	was	O
21	4	O
22	.	O
23	3	O
24	%.	O

1	Chronic	O
2	renal	O
3	failure	O
4	patients	O
5	essentially	O
6	die	O
7	from	O
8	cardiovascular	O
9	causes	O
10	,	O
11	and	O
12	the	O
13	frequency	O
14	of	O
15	malignant	O
16	disease	O
17	responsible	O
18	for	O
19	death	O
20	is	O
21	estimated	O
22	to	O
23	be	O
24	10	O
25	%.	O

1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	IA	O
10	:	O
11	a	O
12	critique	O
13	.	O

1	The	O
2	effect	O
3	of	O
4	Vpu	B
5	on	O
6	class	O
7	I	O
8	biogenesis	O
9	was	O
10	analyzed	O
11	in	O
12	more	O
13	detail	O
14	using	O
15	a	O
16	Vpu	B
17	-	O
18	expressing	O
19	recombinant	O
20	vaccinia	O
21	virus	O
22	(	O
23	VV	O
24	).	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	myofibrillar	O
9	disarray	O
10	seen	O
11	in	O
12	HCM	O
13	patients	O
14	which	O
15	harbor	O
16	either	O
17	of	O
18	these	O
19	two	O
20	mutations	O
21	may	O
22	not	O
23	be	O
24	directly	O
25	due	O
26	to	O
27	the	O
28	failure	O
29	of	O
30	the	O
31	mutant	B
32	myosin	I
33	heavy	I
34	chain	I
35	protein	I
36	to	O
37	assemble	O
38	and	O
39	form	O
40	normal	O
41	sarcomeres	O
42	,	O
43	but	O
44	may	O
45	rather	O
46	be	O
47	a	O
48	secondary	O
49	effect	O
50	possibly	O
51	resulting	O
52	from	O
53	the	O
54	chronic	O
55	stress	O
56	of	O
57	decreased	O
58	beta	B
59	MHC	I
60	function	O
61	.	O

1	Inductively	O
2	coupled	O
3	plasma	O
4	atomic	O
5	emission	O
6	spectroscopy	O
7	was	O
8	employed	O
9	to	O
10	obtain	O
11	the	O
12	tissue	O
13	silicon	O
14	measurements	O
15	.	O

1	An	O
2	egg	O
3	protein	O
4	,	O
5	lysozyme	B
6	,	O
7	is	O
8	a	O
9	still	O
10	unlabeled	O
11	additive	O
12	currently	O
13	used	O
14	in	O
15	cheese	O
16	preparation	O
17	.	O

1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	ethyl	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O

1	Similarly	O
2	,	O
3	the	O
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	of	O
9	activator	B
10	protein	I
11	1	I
12	(	O
13	AP	B
14	-	I
15	1	I
16	)	O
17	is	O
18	modified	O
19	by	O
20	a	O
21	DNA	B
22	repair	I
23	enzyme	I
24	,	O
25	redox	B
26	factor	I
27	1	I
28	(	O
29	Ref	B
30	-	I
31	1	I
32	),	O
33	which	O
34	is	O
35	identical	O
36	to	O
37	a	O
38	DNA	B
39	repair	I
40	enzyme	I
41	,	O
42	AP	B
43	endonuclease	I
44	.	O

1	Having	O
2	an	O
3	LRR	B
4	domain	I
5	and	O
6	an	O
7	SH3	B
8	-	I
9	binding	I
10	domain	I
11	,	O
12	Acan125	B
13	and	O
14	the	O
15	C	O
16	.	O
17	elegans	O
18	homologue	O
19	define	O
20	a	O
21	novel	O
22	family	O
23	of	O
24	bifunctional	O
25	binding	O
26	proteins	O
27	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	gagging	O
7	induced	O
8	by	O
9	oropharyngeal	O
10	irritation	O
11	is	O
12	unclear	O
13	.	O

1	The	O
2	capacity	O
3	to	O
4	repair	O
5	8	O
6	-	O
7	OxoG	O
8	has	O
9	been	O
10	measured	O
11	in	O
12	cell	O
13	-	O
14	free	O
15	extracts	O
16	of	O
17	wild	O
18	-	O
19	type	O
20	and	O
21	ogg1	B
22	strains	O
23	using	O
24	a	O
25	34mer	O
26	DNA	O
27	fragment	O
28	containing	O
29	a	O
30	single	O
31	8	O
32	-	O
33	OxoG	O
34	residue	O
35	paired	O
36	with	O
37	a	O
38	cytosine	O
39	(	O
40	8	O
41	-	O
42	OxoG	O
43	/	O
44	C	O
45	)	O
46	as	O
47	a	O
48	substrate	O
49	.	O

1	Results	O
2	from	O
3	our	O
4	and	O
5	other	O
6	laboratories	O
7	have	O
8	suggested	O
9	that	O
10	UCN	O
11	-	O
12	01	O
13	induces	O
14	preferential	O
15	G1	O
16	-	O
17	phase	O
18	accumulation	O
19	in	O
20	several	O
21	human	O
22	tumor	O
23	cell	O
24	lines	O
25	tested	O
26	.	O

1	Northern	O
2	and	O
3	RT	O
4	-	O
5	PCR	O
6	analysis	O
7	of	O
8	Ube3a	B
9	expression	O
10	in	O
11	mouse	O
12	tissues	O
13	from	O
14	animals	O
15	with	O
16	segmental	O
17	,	O
18	paternal	O
19	uniparental	O
20	disomy	O
21	failed	O
22	to	O
23	detect	O
24	substantially	O
25	reduced	O
26	or	O
27	absent	O
28	expression	O
29	compared	O
30	to	O
31	control	O
32	animals	O
33	,	O
34	failing	O
35	to	O
36	provide	O
37	any	O
38	evidence	O
39	for	O
40	maternal	O
41	-	O
42	specific	O
43	expression	O
44	from	O
45	this	O
46	locus	O
47	.	O

1	Two	O
2	predominant	O
3	effects	O
4	were	O
5	noted	O
6	:	O
7	(	O
8	i	O
9	)	O
10	the	O
11	Xaa	O
12	residue	O
13	in	O
14	the	O
15	dual	O
16	phosphorylation	O
17	motif	O
18	Thr	O
19	-	O
20	Xaa	O
21	-	O
22	Tyr	O
23	as	O
24	well	O
25	as	O
26	the	O
27	length	O
28	of	O
29	L12	O
30	influence	O
31	p38	B
32	substrate	O
33	specificity	O
34	,	O
35	and	O
36	(	O
37	ii	O
38	)	O
39	the	O
40	length	O
41	of	O
42	L12	O
43	plays	O
44	a	O
45	major	O
46	role	O
47	in	O
48	controlling	O
49	autophosphorylation	O
50	.	O

1	A	O
2	novel	O
3	,	O
4	testis	B
5	-	I
6	specific	I
7	mRNA	I
8	transcript	I
9	encoding	O
10	an	O
11	NH2	B
12	-	I
13	terminal	I
14	truncated	I
15	nitric	I
16	-	I
17	oxide	I
18	synthase	I
19	.	O
20	mRNA	O
21	diversity	O
22	represents	O
23	a	O
24	major	O
25	theme	O
26	of	O
27	neuronal	B
28	nitric	I
29	-	I
30	oxide	I
31	synthase	I
32	(	O
33	nNOS	B
34	)	O
35	gene	O
36	expression	O
37	in	O
38	somatic	O
39	cells	O
40	/	O
41	tissues	O
42	.	O

1	Unlike	O
2	the	O
3	MAR	O
4	-	O
5	binding	O
6	domain	O
7	,	O
8	the	O
9	homeodomain	B
10	when	O
11	isolated	O
12	binds	O
13	poorly	O
14	and	O
15	with	O
16	low	O
17	specificity	O
18	to	O
19	DNA	O
20	.	O

1	Cotransfection	O
2	of	O
3	Ets	B
4	-	I
5	2	I
6	and	O
7	p44	B
8	mitogen	I
9	-	I
10	activated	I
11	protein	I
12	(	I
13	MAP	I
14	)	I
15	kinase	I
16	expression	O
17	vectors	O
18	strongly	O
19	potentiated	O
20	HB	B
21	-	O
22	EGF	B
23	promoter	O
24	activation	O
25	in	O
26	response	O
27	to	O
28	deltaRaf	B
29	-	I
30	1	I
31	:	O
32	ER	B
33	.	O

1	Cyclin	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	displaced	O
7	from	O
8	cdk4	B
9	in	O
10	the	O
11	resistant	O
12	184A1L5R	O
13	cell	O
14	lysates	O
15	.	O

1	The	O
2	importance	O
3	of	O
4	posttranslational	O
5	regulation	O
6	of	O
7	p15INK4B	B
8	by	O
9	TGF	B
10	-	I
11	beta	I
12	is	O
13	underlined	O
14	by	O
15	the	O
16	observation	O
17	that	O
18	in	O
19	TGF	B
20	-	I
21	beta	I
22	-	O
23	resistant	O
24	184A1L5R	O
25	,	O
26	although	O
27	the	O
28	p15	B
29	transcript	I
30	increased	O
31	,	O
32	p15INK4B	B
33	protein	I
34	was	O
35	not	O
36	stabilized	O
37	and	O
38	did	O
39	not	O
40	accumulate	O
41	,	O
42	and	O
43	cyclin	B
44	D1	I
45	-	O
46	cdk	B
47	association	O
48	and	O
49	kinase	O
50	activation	O
51	were	O
52	not	O
53	inhibited	O
54	.	O

1	The	O
2	Rlm1	B
3	protein	I
4	,	O
5	a	O
6	member	O
7	of	O
8	the	O
9	MADS	B
10	box	I
11	family	I
12	of	O
13	transcription	O
14	factors	O
15	,	O
16	functions	O
17	downstream	O
18	of	O
19	Mpk1	B
20	in	O
21	the	O
22	pathway	O
23	.	O

1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	I
11	myc	I
12	mRNA	I
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	B
25	myc	I
26	genes	I
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	B
34	sequences	I
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	B
40	beta	I
41	-	I
42	globin	I
43	gene	I
44	or	O
45	to	O
46	the	O
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	O
51	CAT	B
52	)	O
53	gene	O
54	.	O

1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	32D	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	B
15	-	I
16	1	I
17	expression	O
18	at	O
19	the	O
20	permissive	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	proliferative	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	B
41	-	I
42	1	I
43	proliferative	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	checkpoints	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	I
64	myc	I
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	B
70	-	I
71	1	I
72	mutant	I
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	B
78	-	I
79	1	I
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	heterodimerization	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	B
97	-	I
98	terminally	I
99	truncated	I
100	tal	I
101	-	I
102	1	I
103	variant	I
104	(	O
105	M3	B
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	ALL	O
112	malignant	O
113	cells	O
114	mimics	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O

1	The	O
2	likelihood	O
3	that	O
4	a	O
5	common	O
6	region	O
7	of	O
8	deletions	O
9	would	O
10	contain	O
11	a	O
12	tumor	O
13	suppressor	O
14	is	O
15	strongly	O
16	enhanced	O
17	by	O
18	coincidence	O
19	of	O
20	that	O
21	region	O
22	with	O
23	a	O
24	chromosome	O
25	fragment	O
26	suppressing	O
27	tumorigenicity	O
28	upon	O
29	introduction	O
30	in	O
31	tumor	O
32	cells	O
33	.	O

1	DNA	O
2	-	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	increased	O
8	by	O
9	the	O
10	addition	O
11	of	O
12	forskolin	O
13	to	O
14	thecal	O
15	or	O
16	luteal	O
17	cells	O
18	.	O

1	However	O
2	,	O
3	in	O
4	some	O
5	of	O
6	them	O
7	either	O
8	pattern	O
9	may	O
10	predominate	O
11	or	O
12	be	O
13	exclusively	O
14	present	O
15	.	O

1	Upon	O
2	induction	O
3	of	O
4	SOS	O
5	,	O
6	viability	O
7	increased	O
8	2	O
9	-	O
10	6	O
11	-	O
12	fold	O
13	.	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	11	O
2	-	O
3	Aminoundecanoyl	O
4	-	O
5	SK	O
6	-	O
7	NH2	O
8	and	O
9	11	O
10	-	O
11	aminoundecanoyl	O
12	-	O
13	SH	O
14	-	O
15	NH2	O
16	establish	O
17	that	O
18	a	O
19	simple	O
20	alkyl	O
21	backbone	O
22	can	O
23	maintain	O
24	an	O
25	appropriate	O
26	distance	O
27	between	O
28	three	O
29	elements	O
30	critical	O
31	for	O
32	recognition	O
33	by	O
34	the	O
35	fungal	O
36	enzyme	O
37	'	O
38	s	O
39	peptide	O
40	-	O
41	binding	O
42	site	O
43	:	O
44	a	O
45	simple	O
46	omega	O
47	-	O
48	terminal	O
49	amino	O
50	group	O
51	,	O
52	a	O
53	beta	O
54	-	O
55	hydroxyl	O
56	,	O
57	and	O
58	an	O
59	epsilon	O
60	-	O
61	amino	O
62	group	O
63	or	O
64	an	O
65	imidazole	O
66	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	O
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	B
19	transcription	I
20	factor	I
21	GATA	I
22	-	I
23	1	I
24	.	O

1	Cdc2	B
2	co	O
3	-	O
4	precipitates	O
5	with	O
6	Pch1	B
7	in	O
8	S	O
9	.	O
10	pombe	O
11	cell	O
12	lysates	O
13	,	O
14	although	O
15	Cdc2	B
16	may	O
17	not	O
18	be	O
19	the	O
20	major	O
21	catalytic	O
22	partner	O
23	of	O
24	a	O
25	Pch1	B
26	kinase	I
27	in	O
28	vivo	O
29	.	O

1	Little	O
2	is	O
3	known	O
4	about	O
5	the	O
6	mechanism	O
7	,	O
8	but	O
9	the	O
10	availability	O
11	of	O
12	rapid	O
13	facile	O
14	assays	O
15	for	O
16	monitoring	O
17	immunoglobulin	B
18	hypermutation	O
19	would	O
20	greatly	O
21	aid	O
22	the	O
23	development	O
24	of	O
25	culture	O
26	systems	O
27	for	O
28	hypermutating	O
29	B	O
30	cells	O
31	as	O
32	well	O
33	as	O
34	the	O
35	screening	O
36	for	O
37	individuals	O
38	deficient	O
39	in	O
40	the	O
41	process	O
42	.	O

1	Expression	O
2	of	O
3	the	O
4	human	B
5	heat	I
6	shock	I
7	protein	I
8	70	I
9	gene	I
10	(	O
11	hsp70	B
12	)	O
13	is	O
14	induced	O
15	by	O
16	various	O
17	kinds	O
18	of	O
19	stress	O
20	and	O
21	by	O
22	oncogenes	O
23	.	O

1	Of	O
2	these	O
3	proteins	O
4	,	O
5	five	O
6	have	O
7	previously	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	phosphorylated	O
13	during	O
14	mitosis	O
15	(	O
16	epithelial	B
17	-	I
18	microtubule	I
19	associated	I
20	protein	I
21	-	I
22	115	I
23	,	O
24	Oct91	B
25	,	O
26	Elongation	B
27	factor	I
28	1gamma	I
29	,	O
30	BRG1	B
31	and	O
32	Ribosomal	B
33	protein	I
34	L18A	I
35	),	O
36	five	O
37	are	O
38	related	O
39	to	O
40	proteins	O
41	postulated	O
42	to	O
43	have	O
44	roles	O
45	in	O
46	mitosis	O
47	(	O
48	epithelial	B
49	-	I
50	microtubule	I
51	associated	I
52	protein	I
53	-	I
54	115	I
55	,	O
56	Schizosaccharomyces	B
57	pombe	I
58	Cdc5	I
59	,	O
60	innercentrosome	B
61	protein	I
62	,	O
63	BRG1	B
64	and	O
65	the	O
66	RNA	B
67	helicase	I
68	WM6	I
69	),	O
70	and	O
71	nine	O
72	are	O
73	related	O
74	to	O
75	transcription	O
76	factors	O
77	(	O
78	BRG1	B
79	,	O
80	negative	B
81	co	I
82	-	I
83	factor	I
84	2alpha	I
85	,	O
86	Oct91	B
87	,	O
88	S	O
89	.	O
90	pombe	O
91	Cdc5	B
92	,	O
93	HoxD1	B
94	,	O
95	Sox3	B
96	,	O
97	Vent2	B
98	,	O
99	and	O
100	two	O
101	isoforms	O
102	of	O
103	Xbr1b	B
104	).	O

1	Thus	O
2	,	O
3	depending	O
4	on	O
5	their	O
6	location	O
7	,	O
8	psoralen	O
9	cross	O
10	-	O
11	links	O
12	affected	O
13	different	O
14	steps	O
15	in	O
16	the	O
17	initiation	O
18	process	O
19	.	O

1	Activation	O
2	of	O
3	alpha	B
4	4	I
5	beta	I
6	1	I
7	with	O
8	TS2	B
9	/	I
10	16	I
11	inhibited	O
12	the	O
13	cytoplasmic	O
14	protrusions	O
15	and	O
16	cell	O
17	migration	O
18	but	O
19	did	O
20	not	O
21	affect	O
22	the	O
23	pattern	O
24	of	O
25	phosphorylation	O
26	.	O

1	Performance	O
2	on	O
3	two	O
4	verbal	O
5	measures	O
6	-	O
7	the	O
8	National	O
9	Adult	O
10	Reading	O
11	Test	O
12	-	O
13	Revised	O
14	(	O
15	NART	O
16	-	O
17	R	O
18	)	O
19	and	O
20	the	O
21	Vocabulary	O
22	subtest	O
23	from	O
24	the	O
25	Wechsler	O
26	Adult	O
27	Intelligence	O
28	Scale	O
29	-	O
30	Revised	O
31	(	O
32	WAIS	O
33	-	O
34	R	O
35	)-	O
36	showed	O
37	strong	O
38	correlations	O
39	with	O
40	level	O
41	of	O
42	education	O
43	.	O

1	L	O
2	-	O
3	canavanine	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	O
11	nitric	B
12	oxide	I
13	synthase	I
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	improving	O
24	venous	O
25	return	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	O
12	G	B
13	-	I
14	CSF	I
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	The	O
2	different	O
3	holoenzyme	B
4	RNA	I
5	polymerases	I
6	generated	O
7	upon	O
8	reconstituting	O
9	these	O
10	mutants	O
11	independently	O
12	with	O
13	core	B
14	RNA	I
15	polymerase	I
16	(	O
17	alpha2beta	O
18	beta	O
19	')	O
20	have	O
21	shown	O
22	reduced	O
23	transcriptional	O
24	activity	O
25	in	O
26	comparison	O
27	to	O
28	the	O
29	enzyme	O
30	containing	O
31	wild	B
32	-	I
33	type	I
34	sigma	I
35	factor	I
36	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	a	O
7	model	O
8	in	O
9	which	O
10	GATA	B
11	-	I
12	5	I
13	performs	O
14	a	O
15	unique	O
16	temporally	O
17	and	O
18	spatially	O
19	restricted	O
20	function	O
21	in	O
22	the	O
23	embryonic	O
24	heart	O
25	and	O
26	lung	O
27	.	O

1	The	O
2	exonic	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	495	O
9	amino	O
10	acids	O
11	that	O
12	is	O
13	nearly	O
14	identical	O
15	to	O
16	the	O
17	previously	O
18	reported	O
19	protein	O
20	sequence	O
21	of	O
22	human	B
23	GPT	I
24	-	I
25	1	I
26	.	O

1	Here	O
2	we	O
3	characterize	O
4	an	O
5	S	B
6	.	I
7	cerevisiae	I
8	Swi3	I
9	homolog	I
10	(	O
11	Swh3	B
12	)	O
13	and	O
14	present	O
15	evidence	O
16	that	O
17	it	O
18	associates	O
19	in	O
20	a	O
21	complex	O
22	with	O
23	a	O
24	Snf2	B
25	homolog	I
26	,	O
27	Sthl	B
28	.	O

1	Shc	B
2	stimulates	O
3	Ras	B
4	/	O
5	mitogen	B
6	-	I
7	activated	I
8	protein	I
9	kinase	I
10	(	O
11	MAPK	B
12	)	O
13	through	O
14	forming	O
15	a	O
16	complex	O
17	with	O
18	Grb2	B
19	at	O
20	the	O
21	phosphorylated	O
22	tyrosine	O
23	(	O
24	Y	O
25	)	O
26	residue	O
27	317	O
28	.	O

1	In	O
2	contrast	O
3	,	O
4	Y239	B
5	/	I
6	240F	I
7	Shc	I
8	,	O
9	but	O
10	not	O
11	Y317F	B
12	Shc	I
13	,	O
14	reduced	O
15	the	O
16	EGF	B
17	-	O
18	induced	O
19	c	B
20	-	I
21	myc	I
22	message	O
23	.	O

1	The	O
2	Ras	B
3	guanine	I
4	nucleotide	I
5	-	I
6	binding	I
7	protein	I
8	functions	O
9	as	O
10	a	O
11	molecular	O
12	switch	O
13	in	O
14	signalling	O
15	downstream	O
16	of	O
17	protein	B
18	-	I
19	tyrosine	I
20	kinases	I
21	.	O

1	We	O
2	show	O
3	that	O
4	Rlm1	B
5	and	O
6	Smp1	B
7	have	O
8	MEF2	B
9	-	O
10	related	O
11	DNA	O
12	-	O
13	binding	O
14	specificities	O
15	:	O
16	Rlm1	B
17	binds	O
18	with	O
19	the	O
20	same	O
21	specificity	O
22	as	O
23	MEF2	B
24	,	O
25	CTA	B
26	(	I
27	T	I
28	/	I
29	A	I
30	)	I
31	4TAG	I
32	,	O
33	while	O
34	SMP1	B
35	binds	O
36	a	O
37	more	O
38	extended	O
39	consensus	O
40	sequence	O
41	,	O
42	ACTACTA	O
43	(	O
44	T	O
45	/	O
46	A	O
47	)	O
48	4TAG	O
49	.	O

1	Domains	O
2	I	O
3	and	O
4	II	O
5	of	O
6	B	B
7	"	I
8	are	O
9	buried	O
10	upon	O
11	assembly	O
12	of	O
13	the	O
14	TFIIIB	B
15	-	I
16	DNA	I
17	complex	I
18	,	O
19	as	O
20	determined	O
21	by	O
22	protein	O
23	footprinting	O
24	.	O

1	Domain	O
2	switch	O
3	experiments	O
4	reveal	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	beta	I
10	proteins	I
11	containing	O
12	either	O
13	the	O
14	leucine	O
15	zipper	O
16	or	O
17	the	O
18	activation	O
19	domain	O
20	of	O
21	C	B
22	/	I
23	EBP	I
24	alpha	I
25	are	O
26	unable	O
27	to	O
28	stimulate	O
29	the	O
30	2D5	B
31	promoter	I
32	yet	O
33	are	O
34	fully	O
35	capable	O
36	of	O
37	transactivating	O
38	an	O
39	artificial	O
40	promoter	O
41	bearing	O
42	a	O
43	high	O
44	-	O
45	affinity	O
46	C	B
47	/	I
48	EBP	I
49	site	I
50	.	O

1	The	O
2	similar	O
3	phenotypes	O
4	of	O
5	bur6	B
6	and	O
7	bur3	B
8	(	O
9	mot1	B
10	)	O
11	mutations	O
12	suggest	O
13	that	O
14	Bur6p	B
15	and	O
16	Mot1p	B
17	have	O
18	related	O
19	,	O
20	but	O
21	not	O
22	identical	O
23	,	O
24	functions	O
25	in	O
26	modulating	O
27	the	O
28	activity	O
29	of	O
30	the	O
31	general	O
32	transcription	O
33	machinery	O
34	in	O
35	vivo	O
36	.	O

1	PRH75	B
2	,	O
3	a	O
4	new	O
5	nucleus	O
6	-	O
7	localized	O
8	member	O
9	of	O
10	the	O
11	DEAD	B
12	-	I
13	box	I
14	protein	I
15	family	I
16	from	O
17	higher	O
18	plants	O
19	.	O

1	These	O
2	activities	O
3	are	O
4	all	O
5	required	O
6	for	O
7	stimulation	O
8	of	O
9	cell	O
10	growth	O
11	by	O
12	middle	B
13	-	I
14	T	I
15	and	O
16	activate	O
17	members	O
18	of	O
19	the	O
20	MAP	B
21	kinase	I
22	family	I
23	.	O

1	A	O
2	role	O
3	for	O
4	the	O
5	small	B
6	GTPase	I
7	Rac	I
8	in	O
9	polyomavirus	B
10	middle	I
11	-	I
12	T	I
13	antigen	I
14	-	O
15	mediated	O
16	activation	O
17	of	O
18	the	O
19	serum	O
20	response	O
21	element	O
22	and	O
23	in	O
24	cell	O
25	transformation	O
26	.	O

1	Time	O
2	-	O
3	activity	O
4	curves	O
5	from	O
6	the	O
7	gastric	O
8	region	O
9	of	O
10	interest	O
11	were	O
12	used	O
13	,	O
14	after	O
15	subjection	O
16	to	O
17	appropriate	O
18	corrective	O
19	procedures	O
20	,	O
21	to	O
22	calculate	O
23	the	O
24	mean	O
25	gastric	O
26	transit	O
27	time	O
28	(	O
29	MTT	O
30	90	O
31	)	O
32	and	O
33	the	O
34	fraction	O
35	of	O
36	the	O
37	test	O
38	meal	O
39	retained	O
40	in	O
41	the	O
42	stomach	O
43	after	O
44	90	O
45	min	O
46	(	O
47	F90	O
48	).	O

1	This	O
2	study	O
3	provides	O
4	a	O
5	direct	O
6	demonstration	O
7	of	O
8	a	O
9	role	O
10	for	O
11	G	B
12	betagamma	I
13	in	O
14	mediating	O
15	the	O
16	agonist	O
17	-	O
18	stimulated	O
19	translocation	O
20	of	O
21	GRK2	B
22	and	O
23	GRK3	B
24	in	O
25	an	O
26	intact	O
27	cellular	O
28	system	O
29	and	O
30	demonstrates	O
31	isoform	O
32	specificity	O
33	in	O
34	the	O
35	interaction	O
36	of	O
37	these	O
38	components	O
39	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	RA	O
6	-	O
7	mediated	O
8	repression	O
9	of	O
10	the	O
11	hMGP	B
12	gene	I
13	is	O
14	due	O
15	to	O
16	binding	O
17	of	O
18	liganded	O
19	RAR	B
20	/	O
21	RXR	B
22	to	O
23	a	O
24	novel	O
25	negative	O
26	RA	O
27	response	O
28	element	O
29	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	five	O
6	tyrosine	O
7	residues	O
8	in	O
9	the	O
10	cytoplasmic	O
11	domain	O
12	of	O
13	the	O
14	receptor	O
15	were	O
16	subsequently	O
17	used	O
18	to	O
19	confirm	O
20	our	O
21	conclusions	O
22	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	method	O
6	using	O
7	Saccharomyces	O
8	cerevisiae	O
9	for	O
10	detecting	O
11	protein	O
12	-	O
13	truncating	O
14	mutations	O
15	in	O
16	any	O
17	gene	O
18	of	O
19	interest	O
20	.	O

1	Hepatocellular	O
2	injury	O
3	during	O
4	preservation	O
5	of	O
6	human	O
7	livers	O
8	with	O
9	UW	O
10	and	O
11	HTK	O
12	solution	O
13	.	O

1	The	O
2	electromyographically	O
3	recorded	O
4	responses	O
5	consisted	O
6	of	O
7	an	O
8	early	O
9	R1	O
10	response	O
11	in	O
12	the	O
13	orbicularis	O
14	oculi	O
15	muscle	O
16	ipsilateral	O
17	to	O
18	the	O
19	side	O
20	of	O
21	stimulation	O
22	,	O
23	a	O
24	bilateral	O
25	late	O
26	response	O
27	(	O
28	ipsilateral	O
29	R2	O
30	and	O
31	contralateral	O
32	Rc	O
33	)	O
34	and	O
35	a	O
36	third	O
37	,	O
38	R3	O
39	response	O
40	,	O
41	in	O
42	the	O
43	ipsilateral	O
44	orbicularis	O
45	oculi	O
46	muscle	O
47	.	O

1	The	O
2	prognosis	O
3	of	O
4	seven	O
5	patients	O
6	who	O
7	received	O
8	ABSCT	O
9	was	O
10	significantly	O
11	better	O
12	than	O
13	that	O
14	of	O
15	13	O
16	patients	O
17	who	O
18	received	O
19	conventional	O
20	therapy	O
21	alone	O
22	.	O

1	(	O
2	1994	O
3	,	O
4	Hum	O
5	.	O

1	The	O
2	pigment	O
3	intensity	O
4	of	O
5	both	O
6	melanized	O
7	colonies	O
8	and	O
9	appressoria	O
10	of	O
11	CAL	O
12	transformants	O
13	was	O
14	weaker	O
15	than	O
16	that	O
17	of	O
18	the	O
19	wild	O
20	type	O
21	.	O

1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	B
11	-	I
12	S	I
13	-[	I
14	acyl	I
15	-	I
16	carrier	I
17	protein	I
18	]	I
19	from	O
20	acetyl	B
21	-	I
22	S	I
23	-[	I
24	acyl	I
25	-	I
26	carrier	I
27	protein	I
28	]	I
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	B
36	protein	I
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O

1	The	O
2	Jem	B
3	peptide	O
4	sequence	O
5	shows	O
6	a	O
7	'	O
8	leucine	O
9	-	O
10	zipper	O
11	'	O
12	dimerisation	O
13	motif	O
14	with	O
15	limited	O
16	homology	O
17	to	O
18	Fos	B
19	/	O
20	Jun	B
21	and	O
22	ATF	B
23	/	O
24	CREB	B
25	proteins	O
26	and	O
27	several	O
28	putative	O
29	phosphorylation	O
30	sites	O
31	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	protein	O
9	that	O
10	binds	O
11	to	O
12	enhancer	O
13	site	O
14	III	O
15	.	O

1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	B
9	,	O
10	Spc98p	B
11	and	O
12	Spc97p	B
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	B
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	B
30	or	O
31	SPC98	B
32	.	O

1	Sequences	O
2	needed	O
3	for	O
4	iron	O
5	-	O
6	regulated	O
7	expression	O
8	of	O
9	sid1	B
10	were	O
11	localized	O
12	to	O
13	a	O
14	306	O
15	bp	O
16	region	O
17	mapping	O
18	2	O
19	.	O
20	3	O
21	and	O
22	2	O
23	.	O
24	6	O
25	kb	O
26	upstream	O
27	of	O
28	the	O
29	ATG	O
30	.	O

1	A	O
2	genetic	O
3	screen	O
4	applied	O
5	to	O
6	mutants	O
7	in	O
8	the	O
9	branch	O
10	site	O
11	region	O
12	shows	O
13	that	O
14	all	O
15	positions	O
16	in	O
17	the	O
18	conserved	O
19	TACTAAC	O
20	sequence	O
21	are	O
22	important	O
23	for	O
24	intron	O
25	recognition	O
26	.	O

1	Implication	O
2	of	O
3	PAF	B
4	and	O
5	acetylhydrolase	B
6	(	O
7	PAF	B
8	-	I
9	AH	I
10	)	O
11	activity	O
12	in	O
13	periodontal	O
14	disease	O
15	.	O

1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	I
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	O
17	-	O
18	binding	O
19	protein	O
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	B
26	cell	I
27	cycle	I
28	control	I
29	protein	I
30	(	I
31	cdc	I
32	)	I
33	37	O
34	.	O

1	A	O
2	polypeptide	O
3	encoded	O
4	by	O
5	the	O
6	NTS	O
7	16	O
8	open	O
9	reading	O
10	frame	O
11	has	O
12	sequence	O
13	similarity	O
14	to	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	several	O
20	receptor	B
21	protein	I
22	kinases	I
23	from	I
24	plants	I
25	including	O
26	the	O
27	S	B
28	-	I
29	receptor	I
30	kinases	I
31	implicated	O
32	in	O
33	the	O
34	rejection	O
35	of	O
36	self	O
37	-	O
38	pollen	O
39	in	O
40	Brassica	O
41	species	O
42	and	O
43	the	O
44	Pto	B
45	gene	I
46	product	I
47	of	I
48	tomato	I
49	which	O
50	confers	O
51	resistance	O
52	to	O
53	a	O
54	bacterial	O
55	pathogen	O
56	.	O

1	The	O
2	atp	B
3	1	I
4	and	O
5	atp	B
6	2	I
7	types	O
8	of	O
9	cDNA	O
10	sequences	O
11	were	O
12	the	O
13	most	O
14	redundant	O
15	among	O
16	the	O
17	28	O
18	different	O
19	isoperoxidases	B
20	identified	O
21	among	O
22	about	O
23	200	O
24	peroxidase	B
25	encoding	I
26	ESTs	I
27	.	O

1	Additional	O
2	information	O
3	including	O
4	echocardiographic	O
5	sequences	O
6	,	O
7	perioperative	O
8	video	O
9	sequences	O
10	,	O
11	x	O
12	-	O
13	ray	O
14	analysis	O
15	,	O
16	angiograms	O
17	,	O
18	etc	O
19	.	O
20	is	O
21	represented	O
22	in	O
23	the	O
24	program	O
25	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	B
8	could	O
9	activate	O
10	p96h2bk	B
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	B
16	Ras	I
17	.	O

1	In	O
2	Schizosaccharomyces	O
3	pombe	O
4	,	O
5	the	O
6	activity	O
7	of	O
8	the	O
9	M	O
10	-	O
11	phase	O
12	-	O
13	inducing	O
14	Cdc2	B
15	/	O
16	Cdc13	B
17	cyclin	O
18	-	O
19	dependent	O
20	kinase	O
21	is	O
22	inhibited	O
23	by	O
24	Wee1	B
25	and	O
26	Mik1	B
27	tyrosine	I
28	kinases	I
29	,	O
30	and	O
31	activated	O
32	by	O
33	Cdc25	B
34	and	O
35	Pyp3	B
36	tyrosine	I
37	phosphatases	I
38	.	O

1	Glycemic	O
2	response	O
3	to	O
4	malted	O
5	,	O
6	popped	O
7	and	O
8	roller	O
9	dried	O
10	wheat	O
11	-	O
12	legume	O
13	based	O
14	foods	O
15	in	O
16	normal	O
17	subjects	O
18	.	O

1	4	O
2	.	O
3	26	O
4	+/-	O
5	1	O
6	.	O
7	54	O
8	mmol	O
9	/	O
10	l	O
11	,	O
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	),	O
18	and	O
19	systolic	O
20	BP	O
21	responses	O
22	to	O
23	intravenous	O
24	norepinephrine	O
25	and	O
26	angiotensin	B
27	II	I
28	were	O
29	significantly	O
30	higher	O
31	on	O
32	glibenclamide	O
33	than	O
34	on	O
35	metformin	O
36	(	O
37	P	O
38	<	O
39	0	O
40	.	O
41	02	O
42	and	O
43	P	O
44	<	O
45	0	O
46	.	O
47	05	O
48	,	O
49	respectively	O
50	).	O

1	The	O
2	sequencing	O
3	of	O
4	Stellate	B
5	copies	O
6	located	O
7	along	O
8	the	O
9	discontinuous	O
10	cluster	O
11	revealed	O
12	a	O
13	complex	O
14	pattern	O
15	of	O
16	diversification	O
17	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	DNA	O
6	methylation	O
7	,	O
8	chromatin	O
9	structure	O
10	,	O
11	and	O
12	transactivation	O
13	at	O
14	an	O
15	Sp1	B
16	site	I
17	contribute	O
18	to	O
19	the	O
20	highly	O
21	restricted	O
22	expression	O
23	of	O
24	this	O
25	myelomonocytic	O
26	lineage	O
27	specific	O
28	gene	O
29	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	factors	O
8	present	O
9	in	O
10	nuclear	O
11	extracts	O
12	derived	O
13	from	O
14	differentiated	O
15	osteoblast	O
16	bound	O
17	to	O
18	oligonucleotide	O
19	probes	O
20	containing	O
21	the	O
22	E	O
23	-	O
24	box	O
25	1	O
26	and	O
27	E	O
28	-	O
29	box	O
30	2	O
31	elements	O
32	.	O

1	Laboratory	O
2	exam	O
3	:	O
4	IDR	O
5	of	O
6	the	O
7	tuberculin	B
8	was	O
9	high	O
10	positive	O
11	,	O
12	chest	O
13	radiography	O
14	shows	O
15	hilar	O
16	bilateral	O
17	calcifications	O
18	,	O
19	ORL	O
20	exam	O
21	shows	O
22	a	O
23	tumor	O
24	at	O
25	the	O
26	foot	O
27	of	O
28	the	O
29	epiglottis	O
30	and	O
31	anatomopathological	O
32	exam	O
33	shows	O
34	low	O
35	differentiated	O
36	epidermoid	O
37	carcinoma	O
38	.	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	PhLP	B
7	complexes	O
8	,	O
9	at	O
10	least	O
11	partially	O
12	,	O
13	with	O
14	Gbetagamma	B
15	in	O
16	vivo	O
17	.	O

1	CTF1alpha	B
2	,	O
3	expressed	O
4	in	O
5	Escherichia	O
6	coli	O
7	,	O
8	showed	O
9	specific	O
10	binding	O
11	to	O
12	the	O
13	palindrome	O
14	2	O
15	DNA	O
16	fragment	O
17	but	O
18	not	O
19	to	O
20	palindrome	O
21	1	O
22	or	O
23	mutant	O
24	palindrome	O
25	2	O
26	DNA	O
27	fragments	O
28	,	O
29	suggesting	O
30	specific	O
31	binding	O
32	of	O
33	CTF1alpha	B
34	to	O
35	palindrome	O
36	2	O
37	.	O

1	Cyclin	B
2	G2	I
3	is	O
4	highly	O
5	expressed	O
6	in	O
7	the	O
8	immune	O
9	system	O
10	where	O
11	immunologic	O
12	tolerance	O
13	subjects	O
14	self	O
15	-	O
16	reactive	O
17	lymphocytes	O
18	to	O
19	negative	O
20	selection	O
21	and	O
22	clonal	O
23	deletion	O
24	via	O
25	apoptosis	O
26	.	O

1	A	O
2	sterol	O
3	-	O
4	regulated	O
5	protease	O
6	initiates	O
7	release	O
8	of	O
9	the	O
10	NH2	O
11	-	O
12	terminal	O
13	segments	O
14	of	O
15	sterol	B
16	regulatory	I
17	element	I
18	-	I
19	binding	I
20	proteins	I
21	(	O
22	SREBPs	B
23	)	O
24	from	O
25	cell	O
26	membranes	O
27	,	O
28	thereby	O
29	allowing	O
30	them	O
31	to	O
32	enter	O
33	the	O
34	nucleus	O
35	and	O
36	to	O
37	stimulate	O
38	transcription	O
39	of	O
40	genes	O
41	involved	O
42	in	O
43	the	O
44	uptake	O
45	and	O
46	synthesis	O
47	of	O
48	cholesterol	O
49	and	O
50	fatty	O
51	acids	O
52	.	O

1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	B
10	promoters	I
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	O
34	crp	B
35	promoters	I
36	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	cloned	O
5	PCR	O
6	products	O
7	confirmed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	different	O
13	nifV	B
14	-	I
15	like	I
16	DNA	I
17	fragments	I
18	,	O
19	which	O
20	were	O
21	subsequently	O
22	used	O
23	as	O
24	nifV	B
25	-	O
26	and	O
27	leuA	B
28	-	I
29	specific	I
30	probes	I
31	,	O
32	respectively	O
33	,	O
34	to	O
35	clone	O
36	XbaI	B
37	fragments	I
38	of	O
39	2	O
40	.	O
41	1	O
42	kbp	O
43	(	O
44	pOST4	O
45	)	O
46	and	O
47	2	O
48	.	O
49	6	O
50	kbp	O
51	(	O
52	pOST2	O
53	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	O
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	B
10	from	O
11	the	O
12	TRE	O
13	.	O

1	Is	O
2	leishmaniasis	O
3	endemic	O
4	on	O
5	the	O
6	island	O
7	of	O
8	Minorca	O
9	(	O
10	Spain	O
11	)?	O
12	A	O
13	human	O
14	visceral	O
15	case	O
16	after	O
17	living	O
18	13	O
19	years	O
20	in	O
21	Minorca	O
22	.	O

1	RESULTS	O
2	:	O
3	Surprisingly	O
4	,	O
5	PAF	B
6	blockade	O
7	increased	O
8	mortality	O
9	after	O
10	trauma	O
11	(	O
12	5	O
13	of	O
14	11	O
15	WEB	O
16	-	O
17	2086	O
18	animals	O
19	versus	O
20	1	O
21	of	O
22	9	O
23	vehicle	O
24	animals	O
25	;	O
26	p	O
27	=	O
28	0	O
29	.	O
30	15	O
31	)	O
32	and	O
33	depressed	O
34	cardiac	O
35	index	O
36	and	O
37	O2	O
38	delivery	O
39	at	O
40	72	O
41	hours	O
42	(	O
43	p	O
44	<	O
45	0	O
46	.	O
47	05	O
48	).	O

1	This	O
2	finding	O
3	is	O
4	the	O
5	first	O
6	example	O
7	of	O
8	utilization	O
9	of	O
10	noncomplementary	O
11	dinucleotide	O
12	primer	O
13	by	O
14	an	O
15	RNA	B
16	polymerase	I
17	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	NFAT	B
13	nearest	O
14	AP	B
15	-	I
16	1	I
17	is	O
18	the	O
19	Rel	B
20	insert	O
21	region	O
22	(	O
23	RIR	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	notable	O
30	for	O
31	its	O
32	hypervariability	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	amongst	O
39	members	O
40	of	O
41	the	O
42	Rel	B
43	transcription	I
44	factor	I
45	family	I
46	.	O

1	We	O
2	thus	O
3	conclude	O
4	that	O
5	the	O
6	NFAT	B
7	RIR	I
8	plays	O
9	an	O
10	essential	O
11	dual	O
12	role	O
13	in	O
14	DNA	O
15	recognition	O
16	and	O
17	cooperative	O
18	binding	O
19	to	O
20	AP	B
21	-	I
22	1	I
23	family	I
24	transcription	I
25	factors	I
26	.	O

1	Thus	O
2	,	O
3	the	O
4	association	O
5	of	O
6	PS1	B
7	fragments	I
8	may	O
9	be	O
10	maintained	O
11	during	O
12	cycles	O
13	of	O
14	phosphorylation	O
15	/	O
16	dephosphorylation	O
17	of	O
18	the	O
19	PS1	B
20	CTF	I
21	.	O

1	This	O
2	conformer	O
3	features	O
4	a	O
5	Type	O
6	I	O
7	beta	O
8	-	O
9	turn	O
10	and	O
11	has	O
12	extensive	O
13	hydrophobic	O
14	contacts	O
15	with	O
16	the	O
17	FKBP12	B
18	binding	O
19	surface	O
20	.	O

1	This	O
2	protein	O
3	can	O
4	bind	O
5	to	O
6	a	O
7	region	O
8	of	O
9	the	O
10	promoter	O
11	of	O
12	an	O
13	Arabidopsis	B
14	light	I
15	-	I
16	harvesting	I
17	chlorophyll	I
18	a	I
19	/	I
20	b	I
21	protein	I
22	gene	I
23	,	O
24	Lhcb1	B
25	*	I
26	3	I
27	,	O
28	which	O
29	is	O
30	necessary	O
31	for	O
32	its	O
33	regulation	O
34	by	O
35	phytochrome	B
36	.	O

1	A	O
2	patient	O
3	of	O
4	Group	O
5	B	O
6	had	O
7	severe	O
8	athetoid	O
9	CP	O
10	with	O
11	spasticity	O
12	,	O
13	being	O
14	unable	O
15	to	O
16	right	O
17	his	O
18	trunk	O
19	and	O
20	neck	O
21	.	O

1	Dystonic	O
2	movement	O
3	of	O
4	the	O
5	left	O
6	upper	O
7	limb	O
8	in	O
9	a	O
10	case	O
11	of	O
12	the	O
13	right	O
14	pontine	O
15	hemorrhage	O

1	It	O
2	has	O
3	repeatedly	O
4	been	O
5	shown	O
6	that	O
7	HCMV	O
8	IE1	B
9	/	O
10	IE2	B
11	can	O
12	independently	O
13	transactivate	O
14	HIV	B
15	-	I
16	1	I
17	LTR	I
18	.	O

1	TAR	B
2	and	O
3	Sp1	B
4	-	O
5	independent	O
6	transactivation	O
7	of	O
8	HIV	B
9	long	I
10	terminal	I
11	repeat	I
12	by	O
13	the	O
14	Tat	B
15	protein	I
16	in	O
17	the	O
18	presence	O
19	of	O
20	human	O
21	cytomegalovirus	O
22	IE1	B
23	/	O
24	IE2	B
25	.	O

1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	Cellular	B
2	Csk	I
3	was	O
4	associated	O
5	with	O
6	several	O
7	phosphoproteins	O
8	,	O
9	some	O
10	of	O
11	which	O
12	were	O
13	interacting	O
14	with	O
15	the	O
16	Csk	B
17	SH2	I
18	domain	I
19	.	O

1	Thus	O
2	,	O
3	our	O
4	studies	O
5	suggest	O
6	that	O
7	pV	O
8	-	O
9	mediated	O
10	activation	O
11	of	O
12	HIV	B
13	-	I
14	1	I
15	LTR	I
16	activity	O
17	is	O
18	controlled	O
19	by	O
20	the	O
21	nuclear	O
22	translocation	O
23	of	O
24	the	O
25	NF	B
26	-	I
27	kappaB	I
28	transcription	I
29	factor	I
30	,	O
31	which	O
32	is	O
33	mediated	O
34	by	O
35	IkappaBalpha	B
36	serine	O
37	phosphorylation	O
38	and	O
39	degradation	O
40	,	O
41	but	O
42	also	O
43	by	O
44	a	O
45	still	O
46	undefined	O
47	NF	B
48	-	I
49	kappaB	I
50	-	O
51	independent	O
52	pathway	O
53	.	O

1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	subclones	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	Ctpct	B
23	gene	I
24	.	O

1	FN	B
2	-	O
3	stimulated	O
4	c	B
5	-	I
6	Src	I
7	PTK	I
8	activity	O
9	was	O
10	enhanced	O
11	by	O
12	wild	O
13	type	O
14	FAK	B
15	expression	O
16	,	O
17	whereas	O
18	FN	B
19	-	O
20	stimulated	O
21	activation	O
22	of	O
23	ERK2	B
24	was	O
25	blocked	O
26	by	O
27	expression	O
28	of	O
29	the	O
30	c	B
31	-	I
32	Src	I
33	binding	I
34	site	I
35	Phe	I
36	-	I
37	397	I
38	mutant	I
39	of	O
40	FAK	B
41	.	O

1	A	O
2	promising	O
3	new	O
4	cement	O
5	,	O
6	4	O
7	-	O
8	META	O
9	/	O
10	MMA	O
11	-	O
12	TBB	O
13	opaque	O
14	resin	O
15	,	O
16	has	O
17	shown	O
18	remarkable	O
19	adhesive	O
20	properties	O
21	as	O
22	a	O
23	bone	O
24	cement	O
25	in	O
26	vivo	O
27	.	O

1	Congruent	O
2	with	O
3	empirical	O
4	predictions	O
5	,	O
6	the	O
7	most	O
8	homesick	O
9	children	O
10	perceived	O
11	low	O
12	control	O
13	over	O
14	homesickness	O
15	and	O
16	separation	O
17	,	O
18	and	O
19	coped	O
20	by	O
21	relinquishing	O
22	control	O
23	.	O

1	Each	O
2	sample	O
3	was	O
4	analysed	O
5	as	O
6	soon	O
7	as	O
8	possible	O
9	,	O
10	and	O
11	repeated	O
12	15	O
13	,	O
14	30	O
15	,	O
16	60	O
17	and	O
18	120	O
19	min	O
20	after	O
21	sampling	O
22	.	O

1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	grains	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	interstellar	O
16	molecular	O
17	clouds	O
18	.	O

1	Like	O
2	the	O
3	elicitors	O
4	of	O
5	the	O
6	hypersensitive	O
7	reaction	O
8	(	O
9	HR	O
10	)	O
11	produced	O
12	by	O
13	E	O
14	.	O
15	chrysanthemi	O
16	(	O
17	HarpinEch	O
18	)	O
19	and	O
20	E	O
21	.	O
22	amylovora	O
23	(	O
24	HarpinEa	O
25	),	O
26	the	O
27	deduced	O
28	36	O
29	-	O
30	kDa	O
31	protein	O
32	does	O
33	not	O
34	possess	O
35	a	O
36	typical	O
37	signal	O
38	sequence	O
39	,	O
40	but	O
41	it	O
42	contains	O
43	a	O
44	putative	O
45	membrane	O
46	-	O
47	spanning	O
48	domain	O
49	.	O

1	Molecular	O
2	characterization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	Erwinia	B
8	carotovora	I
9	hrpNEcc	I
10	gene	I
11	,	O
12	which	O
13	encodes	O
14	an	O
15	elicitor	O
16	of	O
17	the	O
18	hypersensitive	O
19	reaction	O
20	.	O

1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	HES1	B
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O

1	Anesthesia	O
2	was	O
3	maintained	O
4	with	O
5	isoflurane	O
6	(	O
7	ISO	O
8	)/	O
9	N2O	O
10	/	O
11	O2	O
12	inhalation	O
13	.	O

1	They	O
2	observed	O
3	depressed	O
4	protein	B
5	C	I
6	activity	O
7	that	O
8	significantly	O
9	(	O
10	p	O
11	<	O
12	0	O
13	.	O
14	005	O
15	)	O
16	increased	O
17	and	O
18	became	O
19	normal	O
20	immediately	O
21	after	O
22	hemodialysis	O
23	while	O
24	factor	B
25	X	I
26	and	O
27	factor	B
28	VII	I
29	increased	O
30	(	O
31	p	O
32	<	O
33	0	O
34	.	O
35	01	O
36	;	O
37	p	O
38	<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	despite	O
44	heparinization	O
45	together	O
46	with	O
47	amount	O
48	of	O
49	serum	O
50	lipoprotein	O
51	(	O
52	a	O
53	).	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	type	O
7	II	O
8	hyperbetalipoproteinemia	O
9	in	O
10	a	O
11	patient	O
12	whose	O
13	diagnosis	O
14	had	O
15	been	O
16	previously	O
17	unrecognized	O
18	,	O
19	and	O
20	who	O
21	had	O
22	previously	O
23	been	O
24	misdiagnosed	O
25	with	O
26	rheumatoid	O
27	arthritis	O
28	and	O
29	later	O
30	gout	O
31	.	O

1	These	O
2	data	O
3	provide	O
4	evidence	O
5	that	O
6	the	O
7	2	B
8	.	I
9	0	I
10	-	I
11	kb	I
12	LAT	I
13	is	O
14	an	O
15	intron	O
16	of	O
17	the	O
18	mLAT	B
19	pre	I
20	-	I
21	mRNA	I
22	with	O
23	a	O
24	unique	O
25	branch	O
26	point	O
27	.	O

1	The	O
2	altered	O
3	amino	O
4	acid	O
5	residues	O
6	of	O
7	the	O
8	seven	O
9	mutant	B
10	9ORF1	I
11	polypeptides	I
12	clustered	O
13	within	O
14	three	O
15	separate	O
16	regions	O
17	referred	O
18	to	O
19	as	O
20	region	O
21	I	O
22	(	O
23	residues	O
24	34	O
25	to	O
26	41	O
27	),	O
28	region	O
29	II	O
30	(	O
31	residues	O
32	89	O
33	to	O
34	91	O
35	),	O
36	and	O
37	C	O
38	-	O
39	terminal	O
40	region	O
41	III	O
42	(	O
43	residues	O
44	122	O
45	to	O
46	125	O
47	).	O

1	Rep	B
2	-	O
3	Rep	B
4	protein	O
5	interaction	O
6	was	O
7	confirmed	O
8	in	O
9	vitro	O
10	through	O
11	coimmunoprecipitation	O
12	experiments	O
13	with	O
14	a	O
15	bacterially	O
16	expressed	O
17	maltose	B
18	-	I
19	binding	I
20	protein	I
21	-	O
22	Rep78	B
23	fusion	O
24	protein	O
25	in	O
26	combination	O
27	with	O
28	[	O
29	35S	O
30	]	O
31	methionine	O
32	-	O
33	labeled	O
34	Rep78	B
35	synthesized	O
36	in	O
37	a	O
38	coupled	O
39	in	O
40	vitro	O
41	transcription	O
42	-	O
43	translation	O
44	system	O
45	.	O

1	The	O
2	C	O
3	-	O
4	LIP	O
5	also	O
6	was	O
7	compared	O
8	with	O
9	transcather	O
10	arterial	O
11	embolization	O
12	(	O
13	TAE	O
14	;	O
15	C	O
16	-	O
17	LIP	O
18	followed	O
19	by	O
20	gelatin	O
21	sponge	O
22	)	O
23	and	O
24	percutaneous	O
25	ethanol	O
26	injection	O
27	therapy	O
28	(	O
29	PEIT	O
30	).	O

1	Fourteen	O
2	patients	O
3	with	O
4	New	O
5	York	O
6	Heart	O
7	Association	O
8	class	O
9	II	O
10	congestive	O
11	heart	O
12	failure	O
13	were	O
14	enrolled	O
15	in	O
16	a	O
17	double	O
18	-	O
19	blind	O
20	,	O
21	cross	O
22	-	O
23	over	O
24	study	O
25	.	O

1	The	O
2	main	O
3	advantages	O
4	of	O
5	Multi	O
6	-	O
7	MUP	O
8	analysis	O
9	are	O
10	:	O
11	(	O
12	1	O
13	)	O
14	quick	O
15	acquisition	O
16	of	O
17	many	O
18	MUPs	O
19	;	O
20	(	O
21	2	O
22	)	O
23	simultaneous	O
24	collection	O
25	of	O
26	several	O
27	MUPs	O
28	at	O
29	one	O
30	recording	O
31	site	O
32	;	O
33	(	O
34	3	O
35	)	O
36	possibility	O
37	to	O
38	analyze	O
39	not	O
40	only	O
41	low	O
42	threshold	O
43	MUPs	O
44	;	O
45	(	O
46	4	O
47	)	O
48	less	O
49	bias	O
50	in	O
51	the	O
52	selection	O
53	of	O
54	MUPs	O
55	and	O
56	(	O
57	5	O
58	)	O
59	the	O
60	reproducibility	O
61	of	O
62	the	O
63	results	O
64	that	O
65	allow	O
66	the	O
67	same	O
68	reference	O
69	values	O
70	to	O
71	be	O
72	used	O
73	in	O
74	different	O
75	laboratories	O
76	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	preformed	O
6	triplexes	O
7	are	O
8	quite	O
9	stable	O
10	when	O
11	precipitated	O
12	with	O
13	ethanol	O
14	and	O
15	resuspended	O
16	in	O
17	water	O
18	.	O

1	Transfection	O
2	experiments	O
3	using	O
4	preformed	O
5	triplexes	O
6	with	O
7	a	O
8	reporter	O
9	plasmid	O
10	containing	O
11	the	O
12	collagen	B
13	promoter	I
14	sequence	I
15	showed	O
16	significant	O
17	inhibition	O
18	of	O
19	transcription	O
20	when	O
21	compared	O
22	with	O
23	a	O
24	control	O
25	phosphorothioate	O
26	ODN	O
27	.	O

1	Thus	O
2	,	O
3	an	O
4	increase	O
5	in	O
6	plasma	B
7	TBG	I
8	and	O
9	a	O
10	shift	O
11	from	O
12	adrenal	O
13	androgen	O
14	and	O
15	mineralocorticoid	O
16	steroid	O
17	secretion	O
18	towards	O
19	cortisol	O
20	secretion	O
21	may	O
22	be	O
23	endocrine	O
24	markers	O
25	for	O
26	progression	O
27	of	O
28	the	O
29	disease	O
30	in	O
31	patients	O
32	with	O
33	HIV	O
34	-	O
35	infection	O
36	.	O

1	In	O
2	several	O
3	studies	O
4	the	O
5	RDFS	O
6	has	O
7	shown	O
8	evidence	O
9	of	O
10	reliability	O
11	and	O
12	validity	O
13	.	O

1	Latanoprost	O
2	produces	O
3	an	O
4	additional	O
5	reduction	O
6	of	O
7	intraocular	O
8	pressure	O
9	(	O
10	IOP	O
11	)	O
12	when	O
13	used	O
14	in	O
15	combination	O
16	with	O
17	timolol	O
18	,	O
19	pilocarpine	O
20	,	O
21	acetazolamide	O
22	and	O
23	dipivefrin	O
24	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	dietary	O
6	safflower	O
7	phospholipids	O
8	may	O
9	be	O
10	a	O
11	valuable	O
12	ingredient	O
13	to	O
14	layers	O
15	for	O
16	reducing	O
17	liver	O
18	triglycerides	O
19	and	O
20	serum	O
21	cholesterol	O
22	without	O
23	any	O
24	adverse	O
25	effects	O
26	.	O

1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	B
18	DNA	I
19	polymerase	I
20	beta	I
21	(	O
22	beta	B
23	-	I
24	pol	I
25	)	O
26	gene	O
27	promoter	O
28	.	O

1	Saturable	O
2	spermidine	O
3	transport	O
4	in	O
5	stk2	B
6	::	O
7	lacZ	B
8	mutants	I
9	had	O
10	an	O
11	approximately	O
12	fivefold	O
13	-	O
14	lower	O
15	affinity	O
16	and	O
17	twofold	O
18	-	O
19	lower	O
20	Vmax	O
21	than	O
22	in	O
23	the	O
24	parental	O
25	strain	O
26	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	induced	O
8	tenascin	B
9	-	I
10	C	I
11	expression	O
12	in	O
13	primary	O
14	REF	O
15	and	O
16	in	O
17	FR3T3	O
18	,	O
19	an	O
20	established	O
21	fibroblast	O
22	cell	O
23	line	O
24	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Raf	B
5	-	I
6	1	I
7	kinase	I
8	by	O
9	cyclic	O
10	AMP	O
11	agonists	O
12	causes	O
13	apoptosis	O
14	of	O
15	v	B
16	-	I
17	abl	I
18	-	O
19	transformed	O
20	cells	O
21	.	O

1	Previous	O
2	studies	O
3	have	O
4	indicated	O
5	that	O
6	a	O
7	hamster	O
8	cell	O
9	line	O
10	(	O
11	ts13	O
12	)	O
13	with	O
14	a	O
15	point	O
16	mutation	O
17	in	O
18	the	O
19	TAF	B
20	(	I
21	II	I
22	)	I
23	250	I
24	/	O
25	CCG1	B
26	(	O
27	TAF	B
28	(	I
29	II	I
30	)	I
31	250	I
32	)	O
33	gene	O
34	shows	O
35	temperature	O
36	-	O
37	sensitive	O
38	expression	O
39	of	O
40	a	O
41	subset	O
42	of	O
43	genes	O
44	and	O
45	arrests	O
46	in	O
47	late	O
48	G1	O
49	at	O
50	39	O
51	.	O
52	5	O
53	degrees	O
54	C	O
55	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	protein	O
7	kinase	O
8	MEKK1	B
9	can	O
10	induce	O
11	reporter	O
12	gene	O
13	expression	O
14	from	O
15	the	O
16	atrial	B
17	natriuretic	I
18	factor	I
19	(	O
20	ANF	B
21	)	O
22	promoter	O
23	,	O
24	a	O
25	genetic	O
26	marker	O
27	that	O
28	is	O
29	activated	O
30	during	O
31	in	O
32	vivo	O
33	hypertrophy	O
34	.	O

1	Overexpression	O
2	of	O
3	EFG1	B
4	in	O
5	C	O
6	.	O
7	albicans	O
8	leads	O
9	to	O
10	enhanced	O
11	filamentous	O
12	growth	O
13	in	O
14	the	O
15	form	O
16	of	O
17	extended	O
18	pseudohyphae	O
19	in	O
20	liquid	O
21	and	O
22	on	O
23	solid	O
24	media	O
25	.	O

1	Selected	O
2	parameters	O
3	:	O
4	heart	O
5	rate	O
6	(	O
7	HR	O
8	),	O
9	arterial	O
10	blood	O
11	pressure	O
12	(	O
13	ABP	O
14	)	O
15	and	O
16	arterial	O
17	O2	O
18	saturation	O
19	(	O
20	SaO2	O
21	)	O
22	monitored	O
23	by	O
24	pulsoximetry	O
25	were	O
26	measured	O
27	during	O
28	the	O
29	procedure	O
30	.	O

1	To	O
2	determine	O
3	if	O
4	signing	O
5	,	O
6	when	O
7	established	O
8	,	O
9	would	O
10	compete	O
11	with	O
12	SIB	O
13	when	O
14	both	O
15	were	O
16	reinforced	O
17	,	O
18	extinction	O
19	was	O
20	then	O
21	withdrawn	O
22	.	O

1	The	O
2	husband	O
3	in	O
4	one	O
5	of	O
6	the	O
7	married	O
8	couples	O
9	was	O
10	treated	O
11	for	O
12	hepatitis	O
13	of	O
14	unidentified	O
15	etiology	O
16	in	O
17	an	O
18	Infectology	O
19	Department	O
20	four	O
21	years	O
22	ago	O
23	.	O

1	Both	O
2	quantitative	O
3	and	O
4	qualitative	O
5	analysis	O
6	of	O
7	individual	O
8	cytoarchitectonic	O
9	peculiarities	O
10	of	O
11	Meynart	O
12	'	O
13	s	O
14	nucleus	O
15	as	O
16	well	O
17	as	O
18	of	O
19	external	O
20	part	O
21	of	O
22	dorsomedial	O
23	nucleus	O
24	of	O
25	thalamus	O
26	was	O
27	performed	O
28	in	O
29	mentally	O
30	normal	O
31	individuals	O
32	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	proposal	O
6	by	O
7	carrying	O
8	out	O
9	circular	O
10	dichroism	O
11	(	O
12	CD	O
13	)	O
14	and	O
15	NMR	O
16	experiments	O
17	on	O
18	the	O
19	Skn	B
20	domain	I
21	and	O
22	five	O
23	truncated	O
24	proteins	O
25	.	O

1	Positional	O
2	cloning	O
3	has	O
4	already	O
5	produced	O
6	the	O
7	sequences	O
8	of	O
9	more	O
10	than	O
11	70	O
12	human	O
13	genes	O
14	associated	O
15	with	O
16	specific	O
17	diseases	O
18	.	O

1	Genes	O
2	for	O
3	ocs	B
4	element	I
5	binding	I
6	factors	I
7	(	O
8	OBFs	B
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	The	O
2	30	O
3	-	O
4	day	O
5	mortality	O
6	in	O
7	the	O
8	CPB	O
9	group	O
10	and	O
11	the	O
12	non	O
13	-	O
14	CPB	O
15	group	O
16	were	O
17	20	O
18	%	O
19	and	O
20	4	O
21	.	O
22	6	O
23	%,	O
24	respectively	O
25	which	O
26	was	O
27	not	O
28	statistically	O
29	significant	O
30	(	O
31	p	O
32	=	O
33	0	O
34	.	O
35	06	O
36	).	O

1	As	O
2	opposed	O
3	to	O
4	in	O
5	vitro	O
6	co	O
7	-	O
8	precipitation	O
9	studies	O
10	,	O
11	the	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screen	O
17	reveals	O
18	in	O
19	vivo	O
20	protein	O
21	-	O
22	protein	O
23	interactions	O
24	.	O

1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	B
9	-	O
10	SH2	B
11	domain	O
12	,	O
13	because	O
14	PECAM	B
15	-	I
16	1	I
17	can	O
18	be	O
19	precipitated	O
20	by	O
21	a	O
22	GST	B
23	-	O
24	Src	B
25	-	O
26	SH2	B
27	affinity	O
28	matrix	O
29	.	O

1	MKK3	B
2	autophosphorylation	O
3	and	O
4	activation	O
5	of	O
6	p38	B
7	was	O
8	also	O
9	observed	O
10	following	O
11	coexpression	O
12	of	O
13	MKK3	B
14	with	O
15	MEKK3	B
16	,	O
17	but	O
18	not	O
19	with	O
20	MEKK2	B
21	.	O

1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	B
5	-	I
6	1	I
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	B
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	B
26	-	I
27	1	I
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	B
36	-	I
37	selectin	I
38	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	data	O
6	establish	O
7	that	O
8	the	O
9	previously	O
10	reported	O
11	human	B
12	MAdCAM	I
13	-	I
14	1	I
15	cDNA	I
16	does	O
17	indeed	O
18	encode	O
19	the	O
20	human	O
21	homologue	O
22	of	O
23	mouse	B
24	MAdCAM	I
25	-	I
26	1	I
27	,	O
28	despite	O
29	gross	O
30	dissimilarities	O
31	in	O
32	the	O
33	MAdCAM	B
34	-	I
35	1	I
36	C	O
37	-	O
38	terminal	O
39	structures	O
40	.	O

1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	Xaa	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	sequons	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	The	O
6	authors	O
7	analyzed	O
8	41	O
9	persons	O
10	formerly	O
11	submitted	O
12	to	O
13	surgery	O
14	(	O
15	after	O
16	8	O
17	years	O
18	and	O
19	4	O
20	months	O
21	,	O
22	as	O
23	a	O
24	mean	O
25	),	O
26	31	O
27	to	O
28	highly	O
29	selective	O
30	vagotomy	O
31	,	O
32	and	O
33	10	O
34	to	O
35	truncal	O
36	or	O
37	selective	O
38	vagotomy	O
39	plus	O
40	gastroduodenal	O
41	drainage	O
42	.	O

1	This	O
2	region	O
3	does	O
4	not	O
5	contain	O
6	an	O
7	identifiable	O
8	TATA	O
9	element	O
10	,	O
11	indicating	O
12	that	O
13	transcription	O
14	of	O
15	the	O
16	glutaminase	B
17	gene	I
18	is	O
19	driven	O
20	by	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	.	O

1	SRE	O
2	activity	O
3	is	O
4	dependent	O
5	upon	O
6	the	O
7	activation	O
8	by	O
9	phosphorylation	O
10	of	O
11	a	O
12	ternary	O
13	complex	O
14	factor	O
15	;	O
16	included	O
17	among	O
18	the	O
19	ternary	O
20	complex	O
21	factors	O
22	is	O
23	Elk	B
24	-	I
25	1	I
26	.	O

1	Serum	B
2	alkaline	I
3	phosphatase	I
4	activity	O
5	,	O
6	bone	O
7	mass	O
8	measurements	O
9	,	O
10	dual	O
11	energy	O
12	x	O
13	-	O
14	ray	O
15	absortiometric	O
16	analysis	O
17	of	O
18	mineral	O
19	density	O
20	,	O
21	and	O
22	mechanical	O
23	testing	O
24	values	O
25	in	O
26	vertebrae	O
27	and	O
28	femora	O
29	of	O
30	the	O
31	-	O
32	D	O
33	Sal	O
34	animals	O
35	did	O
36	not	O
37	significantly	O
38	differ	O
39	from	O
40	those	O
41	in	O
42	+	O
43	D	O
44	Sal	O
45	animals	O
46	.	O

1	The	O
2	monkey	B
3	LHR	I
4	cDNA	I
5	displayed	O
6	83	O
7	-	O
8	94	O
9	%	O
10	overall	O
11	sequence	O
12	homology	O
13	with	O
14	the	O
15	other	O
16	mammalian	B
17	LHR	I
18	cDNAs	I
19	.	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	B
5	monkey	I
6	LHR	I
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	B
19	gene	I
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	In	O
2	unc	B
3	-	I
4	4	I
5	mutants	I
6	,	O
7	VA	O
8	motor	O
9	neurons	O
10	assume	O
11	the	O
12	pattern	O
13	of	O
14	synaptic	O
15	input	O
16	normally	O
17	reserved	O
18	for	O
19	their	O
20	lineal	O
21	sister	O
22	cells	O
23	,	O
24	the	O
25	VB	O
26	motor	O
27	neurons	O
28	;	O
29	the	O
30	loss	O
31	of	O
32	normal	O
33	input	O
34	to	O
35	the	O
36	VAs	O
37	produces	O
38	a	O
39	distinctive	O
40	backward	O
41	movement	O
42	defect	O
43	.	O

1	Intracavitary	O
2	irradiation	O
3	was	O
4	carried	O
5	out	O
6	with	O
7	a	O
8	microSelectron	O
9	HDR	O
10	afterloading	O
11	device	O
12	and	O
13	usually	O
14	22	O
15	.	O
16	5	O
17	Gy	O
18	was	O
19	given	O
20	in	O
21	three	O
22	fractions	O
23	repeated	O
24	weekly	O
25	.	O

1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	HAT	O
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	006	O
14	versus	O
15	group	O
16	1	O
17	).	O

1	Sequence	O
2	comparison	O
3	of	O
4	the	O
5	0	O
6	.	O
7	38	O
8	kb	O
9	promoter	O
10	sequence	O
11	with	O
12	the	O
13	promoters	O
14	of	O
15	the	O
16	Sm	B
17	-	I
18	E	I
19	gene	O
20	and	O
21	U1	B
22	snRNA	I
23	genes	I
24	revealed	O
25	several	O
26	homologous	O
27	motifs	O
28	,	O
29	suggesting	O
30	that	O
31	genes	O
32	encoding	O
33	the	O
34	snRNP	O
35	components	O
36	may	O
37	be	O
38	coordinately	O
39	regulated	O
40	.	O

1	METHODS	O
2	:	O
3	The	O
4	responses	O
5	of	O
6	a	O
7	31	O
8	-	O
9	year	O
10	-	O
11	old	O
12	woman	O
13	with	O
14	complex	O
15	regional	O
16	pain	O
17	syndrome	O
18	type	O
19	I	O
20	(	O
21	reflex	O
22	sympathetic	O
23	dystrophy	O
24	)	O
25	to	O
26	a	O
27	thermal	O
28	grill	O
29	were	O
30	evaluated	O
31	before	O
32	and	O
33	after	O
34	stellate	O
35	ganglion	O
36	block	O
37	.	O

1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	O
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O

1	A	O
2	xylE	B
3	transcriptional	I
4	fusion	I
5	to	O
6	the	O
7	putative	O
8	mxbD	B
9	promoter	I
10	showed	O
11	low	O
12	-	O
13	level	O
14	expression	O
15	in	O
16	wild	O
17	-	O
18	type	O
19	cells	O
20	grown	O
21	on	O
22	one	O
23	-	O
24	carbon	O
25	(	O
26	C1	O
27	)	O
28	compounds	O
29	and	O
30	no	O
31	detectable	O
32	expression	O
33	in	O
34	cells	O
35	grown	O
36	on	O
37	succinate	O
38	.	O

1	In	O
2	AcMNPV	O
3	-	O
4	infected	O
5	Sf9	O
6	cells	O
7	,	O
8	late	O
9	transcription	O
10	initiation	O
11	is	O
12	detected	O
13	from	O
14	only	O
15	two	O
16	upstream	O
17	TAAG	O
18	sites	O
19	and	O
20	not	O
21	from	O
22	three	O
23	downstream	O
24	TAAG	O
25	sites	O
26	.	O

1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	O
7	AP	B
8	-	I
9	1	I
10	cis	I
11	-	I
12	response	I
13	elements	I
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O

1	The	O
2	close	O
3	proximity	O
4	of	O
5	the	O
6	two	O
7	neuropeptide	B
8	Y	I
9	receptor	I
10	genes	I
11	suggests	O
12	that	O
13	they	O
14	have	O
15	evolved	O
16	from	O
17	a	O
18	gene	O
19	duplication	O
20	event	O
21	with	O
22	the	O
23	small	O
24	intron	O
25	interrupting	O
26	the	O
27	coding	O
28	sequence	O
29	of	O
30	the	O
31	y1	B
32	gene	I
33	being	O
34	converted	O
35	into	O
36	a	O
37	functional	O
38	sequence	O
39	within	O
40	the	O
41	y5	B
42	gene	I
43	,	O
44	while	O
45	the	O
46	reverse	O
47	complementary	O
48	sequence	O
49	was	O
50	utilized	O
51	as	O
52	an	O
53	alternatively	O
54	spliced	O
55	5	O
56	'	O
57	exon	O
58	for	O
59	the	O
60	y1	B
61	gene	I
62	.	O

1	The	O
2	mammalian	B
3	phosphoinositide	I
4	3	I
5	-	I
6	kinases	I
7	(	O
8	PI3Ks	B
9	)	O
10	p110alpha	B
11	,	I
12	beta	I
13	,	I
14	and	I
15	delta	I
16	form	O
17	heterodimers	O
18	with	O
19	Src	B
20	homology	I
21	2	I
22	(	O
23	SH2	B
24	)	O
25	domain	O
26	-	O
27	containing	O
28	adaptors	O
29	such	O
30	as	O
31	p85alpha	B
32	or	O
33	p55	B
34	(	O
35	PIK	B
36	).	O

1	In	O
2	the	O
3	studies	O
4	reported	O
5	here	O
6	,	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	the	O
14	human	B
15	gp130	I
16	gene	I
17	was	O
18	isolated	O
19	and	O
20	the	O
21	transcription	O
22	initiation	O
23	sites	O
24	were	O
25	mapped	O
26	.	O

1	Localization	O
2	of	O
3	the	O
4	cytokine	O
5	response	O
6	element	O
7	by	O
8	5	O
9	'-	O
10	deletion	O
11	analysis	O
12	and	O
13	site	O
14	-	O
15	directed	O
16	mutagenesis	O
17	revealed	O
18	a	O
19	cis	O
20	-	O
21	acting	O
22	binding	O
23	site	O
24	for	O
25	activated	O
26	STAT	B
27	complexes	O
28	.	O

1	Insulin	B
2	regulation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	kinase	I
9	kinase	I
10	(	O
11	MEK	B
12	),	O
13	mitogen	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	and	O
19	casein	B
20	kinase	I
21	in	O
22	the	O
23	cell	O
24	nucleus	O
25	:	O
26	a	O
27	possible	O
28	role	O
29	in	O
30	the	O
31	regulation	O
32	of	O
33	gene	O
34	expression	O
35	.	O

1	Sequencing	O
2	of	O
3	the	O
4	three	O
5	pag	B
6	-	I
7	3	I
8	alleles	I
9	showed	O
10	that	O
11	two	O
12	apparent	O
13	null	O
14	alleles	O
15	encode	O
16	a	O
17	nonsense	O
18	mutation	O
19	before	O
20	the	O
21	zinc	O
22	fingers	O
23	and	O
24	a	O
25	missense	O
26	mutation	O
27	in	O
28	the	O
29	fourth	O
30	zinc	O
31	finger	O
32	that	O
33	changes	O
34	a	O
35	coordinating	O
36	histidine	O
37	to	O
38	a	O
39	tyrosine	O
40	.	O

1	Pax	B
2	-	I
3	3	I
4	is	O
5	a	O
6	paired	B
7	-	I
8	type	I
9	homeobox	I
10	gene	I
11	that	O
12	is	O
13	specifically	O
14	expressed	O
15	in	O
16	the	O
17	dorsal	O
18	and	O
19	posterior	O
20	neural	O
21	tube	O
22	.	O

1	Instead	O
2	,	O
3	they	O
4	contained	O
5	dendritic	O
6	cells	O
7	that	O
8	express	O
9	melanogenic	O
10	marker	O
11	proteins	O
12	such	O
13	as	O
14	tyrosinase	B
15	and	O
16	tyrosinase	B
17	-	I
18	related	I
19	protein	I
20	1	I
21	.	O

1	These	O
2	mutations	O
3	create	O
4	stop	O
5	codons	O
6	in	O
7	exon	O
8	7	O
9	and	O
10	8	O
11	,	O
12	respectively	O
13	,	O
14	and	O
15	probably	O
16	result	O
17	in	O
18	truncated	O
19	proteins	O
20	lacking	O
21	HLH	O
22	-	O
23	Zip	O
24	or	O
25	Zip	O
26	structure	O
27	.	O

1	Here	O
2	,	O
3	a	O
4	case	O
5	of	O
6	Sjogren	O
7	'	O
8	s	O
9	syndrome	O
10	is	O
11	presented	O
12	that	O
13	was	O
14	initially	O
15	diagnosed	O
16	because	O
17	of	O
18	dental	O
19	complaints	O
20	,	O
21	and	O
22	long	O
23	-	O
24	term	O
25	treatment	O
26	of	O
27	Sjogren	O
28	'	O
29	s	O
30	patients	O
31	is	O
32	discussed	O
33	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	bacteriophage	B
10	-	I
11	type	I
12	RNA	I
13	polymerase	I
14	from	O
15	the	O
16	higher	O
17	plant	O
18	Chenopodium	O
19	album	O
20	.	O

1	Similarly	O
2	,	O
3	overexpression	O
4	of	O
5	increasing	O
6	concentration	O
7	of	O
8	COUP	B
9	-	I
10	TFI	I
11	,	O
12	but	O
13	not	O
14	COUP	B
15	-	I
16	TFI	I
17	delta35	I
18	,	O
19	can	O
20	squelch	O
21	the	O
22	silencing	O
23	activity	O
24	of	O
25	the	O
26	unliganded	O
27	TRbeta	B
28	.	O

1	These	O
2	six	O
3	amino	O
4	acids	O
5	are	O
6	part	O
7	of	O
8	an	O
9	amphipathic	O
10	helix	O
11	that	O
12	is	O
13	highly	O
14	conserved	O
15	among	O
16	nuclear	B
17	hormone	I
18	receptors	I
19	and	O
20	contains	O
21	the	O
22	core	O
23	domain	O
24	of	O
25	the	O
26	ligand	O
27	-	O
28	dependent	O
29	transactivation	O
30	function	O
31	,	O
32	AF	O
33	-	O
34	2	O
35	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	RXR	B
5	-	O
6	specific	O
7	ligand	O
8	9	O
9	-	O
10	cis	O
11	-	O
12	retinoic	O
13	acid	O
14	induced	O
15	binding	O
16	of	O
17	SRC	B
18	-	I
19	1	I
20	to	O
21	the	O
22	RXR	B
23	component	I
24	of	O
25	the	O
26	TRE	O
27	-	O
28	bound	O
29	heterodimer	O
30	.	O

1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O

1	Based	O
2	on	O
3	the	O
4	occurrence	O
5	of	O
6	several	O
7	transcription	O
8	signals	O
9	in	O
10	the	O
11	Thermus	B
12	pyr	I
13	promoter	I
14	region	I
15	and	O
16	strong	O
17	amino	O
18	acid	O
19	sequence	O
20	identities	O
21	(	O
22	about	O
23	60	O
24	%)	O
25	between	O
26	Thermus	B
27	PyrR	I
28	and	O
29	the	O
30	PyrR	B
31	attenuation	I
32	proteins	I
33	of	O
34	two	O
35	Bacillus	O
36	sp	O
37	.,	O
38	we	O
39	propose	O
40	a	O
41	regulatory	O
42	mechanism	O
43	involving	O
44	transcriptional	O
45	attenuation	O
46	to	O
47	control	O
48	pyr	B
49	gene	I
50	expression	O
51	in	O
52	Thermus	O
53	.	O

1	Diver	O
2	respiratory	O
3	responses	O
4	to	O
5	a	O
6	tunable	O
7	closed	O
8	-	O
9	circuit	O
10	breathing	O
11	apparatus	O
12	.	O

1	Measurement	O
2	of	O
3	the	O
4	time	O
5	constant	O
6	of	O
7	VO2	O
8	and	O
9	oxygen	O
10	pulse	O
11	during	O
12	constant	O
13	work	O
14	rate	O
15	exercise	O
16	are	O
17	useful	O
18	for	O
19	the	O
20	objective	O
21	evaluation	O
22	of	O
23	the	O
24	training	O
25	effect	O
26	of	O
27	patients	O
28	with	O
29	COPD	O
30	.	O

1	Characterization	O
2	of	O
3	CR1	B
4	repeat	O
5	random	O
6	PCR	O
7	markers	O
8	for	O
9	mapping	O
10	the	O
11	chicken	O
12	genome	O
13	.	O

1	A	O
2	reversed	O
3	-	O
4	phase	O
5	high	O
6	-	O
7	performance	O
8	liquid	O
9	chromatographic	O
10	(	O
11	HPLC	O
12	)	O
13	method	O
14	for	O
15	the	O
16	determination	O
17	of	O
18	cocaine	O
19	metabolites	O
20	produced	O
21	in	O
22	vitro	O
23	by	O
24	serum	B
25	and	I
26	liver	I
27	esterases	I
28	is	O
29	described	O
30	.	O

1	Mutational	O
2	studies	O
3	provide	O
4	evidence	O
5	to	O
6	this	O
7	end	O
8	and	O
9	indicate	O
10	that	O
11	the	O
12	side	O
13	chains	O
14	of	O
15	subdomain	O
16	4	O
17	.	O
18	2	O
19	make	O
20	specific	O
21	contacts	O
22	with	O
23	the	O
24	nucleotides	O
25	at	O
26	-	O
27	35	O
28	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	fludarabine	O
6	is	O
7	a	O
8	highly	O
9	useful	O
10	agent	O
11	in	O
12	CLL	O
13	.	O

1	Three	O
2	different	O
3	techniques	O
4	of	O
5	EA	O
6	analysis	O
7	were	O
8	used	O
9	in	O
10	the	O
11	study	O
12	:	O
13	1	O
14	)	O
15	fast	O
16	Fourier	O
17	transformation	O
18	(	O
19	FFT	O
20	)	O
21	of	O
22	EA	O
23	in	O
24	a	O
25	broad	O
26	band	O
27	,	O
28	2	O
29	)	O
30	developed	O
31	by	O
32	us	O
33	alternative	O
34	method	O
35	of	O
36	non	O
37	-	O
38	harmonic	O
39	expansion	O
40	of	O
41	the	O
42	EEG	O
43	curves	O
44	taking	O
45	into	O
46	account	O
47	their	O
48	shape	O
49	,	O
50	3	O
51	)	O
52	factor	O
53	analysis	O
54	of	O
55	the	O
56	EA	O
57	spectral	O
58	densities	O
59	.	O

1	Concomitantly	O
2	,	O
3	p34CDC2	B
4	histone	I
5	H1	I
6	kinase	O
7	activity	O
8	increases	O
9	in	O
10	the	O
11	former	O
12	,	O
13	but	O
14	not	O
15	in	O
16	the	O
17	latter	O
18	cell	O
19	lines	O
20	,	O
21	hence	O
22	suggesting	O
23	a	O
24	role	O
25	for	O
26	this	O
27	protein	O
28	in	O
29	radiation	O
30	-	O
31	induced	O
32	cell	O
33	death	O
34	.	O

1	Using	O
2	PRL	B
3	-	I
4	R	I
5	tagged	O
6	both	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	or	O
13	C	O
14	-	O
15	terminal	O
16	regions	O
17	of	O
18	the	O
19	mature	O
20	receptor	O
21	excludes	O
22	the	O
23	possibility	O
24	of	O
25	a	O
26	cleaved	O
27	fragment	O
28	which	O
29	could	O
30	have	O
31	been	O
32	subsequently	O
33	imported	O
34	into	O
35	the	O
36	nucleus	O
37	.	O

1	Thus	O
2	,	O
3	the	O
4	B	O
5	-	O
6	S	O
7	mutant	O
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	B
14	GAPDHs	I
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	B
58	GAPDH	I
59	.	O

1	Transcription	O
2	of	O
3	these	O
4	genes	O
5	was	O
6	also	O
7	elevated	O
8	in	O
9	gut	O
10	and	O
11	lung	O
12	during	O
13	freezing	O
14	,	O
15	but	O
16	mRNA	O
17	levels	O
18	in	O
19	these	O
20	tissues	O
21	were	O
22	lower	O
23	than	O
24	in	O
25	liver	O
26	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	A	O
2	similar	O
3	chimera	O
4	was	O
5	assembled	O
6	from	O
7	the	O
8	two	O
9	halves	O
10	of	O
11	the	O
12	molecule	O
13	expressed	O
14	separately	O
15	in	O
16	different	O
17	bacteria	O
18	and	O
19	refolded	O
20	together	O
21	.	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	All	O
2	six	O
3	genes	O
4	were	O
5	cloned	O
6	and	O
7	characterised	O
8	.	O

1	We	O
2	analysed	O
3	two	O
4	regions	O
5	involved	O
6	in	O
7	preS2	B
8	/	O
9	S	B
10	gene	I
11	transcription	O
12	of	O
13	the	O
14	HBV	O
15	adw	O
16	subtype	O
17	:	O
18	the	O
19	diverged	O
20	TATA	O
21	box	O
22	and	O
23	a	O
24	putative	O
25	initiator	O
26	element	O
27	.	O

1	Indeed	O
2	the	O
3	predicted	O
4	folding	O
5	of	O
6	the	O
7	5	O
8	'	O
9	and	O
10	3	O
11	'-	O
12	untranslated	O
13	regions	O
14	revealed	O
15	patterns	O
16	of	O
17	stem	O
18	and	O
19	loop	O
20	structures	O
21	conserved	O
22	for	O
23	all	O
24	tick	O
25	-	O
26	borne	O
27	flaviviruses	O
28	suggesting	O
29	a	O
30	purifying	O
31	selection	O
32	for	O
33	preservation	O
34	of	O
35	essential	O
36	RNA	O
37	secondary	O
38	structures	O
39	which	O
40	could	O
41	be	O
42	involved	O
43	in	O
44	translational	O
45	control	O
46	and	O
47	replication	O
48	.	O

1	EGF	B
2	acts	O
3	primarily	O
4	by	O
5	means	O
6	of	O
7	transactivation	O
8	domain	O
9	AF	O
10	-	O
11	1	O
12	,	O
13	whereas	O
14	cAMP	O
15	acts	O
16	via	O
17	transactivation	O
18	domain	O
19	AF	O
20	-	O
21	2	O
22	of	O
23	the	O
24	ER	B
25	.	O

1	To	O
2	determine	O
3	which	O
4	region	O
5	of	O
6	SulA	B
7	is	O
8	essential	O
9	for	O
10	the	O
11	inhibition	O
12	of	O
13	cell	O
14	division	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	series	O
20	of	O
21	N	O
22	-	O
23	terminal	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	deletions	O
29	of	O
30	SulA	B
31	and	O
32	a	O
33	series	O
34	of	O
35	alanine	O
36	substitution	O
37	mutants	O
38	.	O

1	We	O
2	have	O
3	inactivated	O
4	Krox	B
5	-	I
6	20	I
7	by	O
8	homologous	O
9	recombination	O
10	in	O
11	ES	O
12	cells	O
13	and	O
14	demonstrated	O
15	that	O
16	the	O
17	mutation	O
18	leads	O
19	to	O
20	the	O
21	deletion	O
22	of	O
23	r3	O
24	and	O
25	r5	O
26	.	O

1	Recently	O
2	we	O
3	have	O
4	performed	O
5	a	O
6	detailed	O
7	analysis	O
8	of	O
9	specific	O
10	neuronal	O
11	populations	O
12	affected	O
13	by	O
14	the	O
15	mutation	O
16	which	O
17	shed	O
18	new	O
19	light	O
20	on	O
21	the	O
22	role	O
23	of	O
24	Krox	B
25	-	I
26	20	I
27	in	O
28	the	O
29	segmentation	O
30	and	O
31	on	O
32	the	O
33	physiological	O
34	consequences	O
35	of	O
36	its	O
37	inactivation	O
38	.	O

1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	Cyclosporin	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	immunosuppressive	O
16	drug	O
17	.	O

1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	B
10	-	I
11	AP	I
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	B
23	-	I
24	4	I
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O

1	SPP	B
2	also	O
3	induced	O
4	transient	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	focal	B
9	adhesion	I
10	kinase	I
11	(	O
12	p125	B
13	(	O
14	FAK	B
15	)),	O
16	a	O
17	cytosolic	B
18	tyrosine	I
19	kinase	I
20	that	O
21	localizes	O
22	in	O
23	focal	O
24	adhesions	O
25	,	O
26	and	O
27	of	O
28	the	O
29	cytoskeleton	B
30	-	I
31	associated	I
32	protein	I
33	paxillin	I
34	.	O

1	Using	O
2	a	O
3	conditional	O
4	-	O
5	lethal	O
6	mutant	O
7	allele	O
8	of	O
9	SUP45	B
10	(	O
11	sup45	B
12	-	I
13	2	I
14	)	O
15	and	O
16	a	O
17	combination	O
18	of	O
19	in	O
20	vivo	O
21	and	O
22	in	O
23	vitro	O
24	approaches	O
25	,	O
26	we	O
27	demonstrate	O
28	that	O
29	the	O
30	product	O
31	of	O
32	the	O
33	SUP45	B
34	gene	I
35	(	O
36	Sup45p	B
37	or	O
38	eRF1	B
39	)	O
40	is	O
41	a	O
42	factor	O
43	required	O
44	for	O
45	translation	O
46	termination	O
47	in	O
48	yeast	O
49	.	O

1	Evaluation	O
2	of	O
3	myocardial	O
4	perfusion	O
5	by	O
6	99mTc	O
7	-	O
8	tetrofosmin	O
9	SPECT	O
10	before	O
11	and	O
12	after	O
13	emergent	O
14	percutaneous	O
15	transluminal	O
16	coronary	O
17	angioplasty	O
18	for	O
19	acute	O
20	myocardial	O
21	infarction	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	B
8	-	I
9	3a	I
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	She	O
2	was	O
3	able	O
4	to	O
5	stand	O
6	unaided	O
7	by	O
8	3	O
9	years	O
10	of	O
11	age	O
12	with	O
13	then	O
14	progressive	O
15	worsening	O
16	of	O
17	motor	O
18	abilities	O
19	.	O

1	Merosin	B
2	positive	O
3	congenital	O
4	muscular	O
5	dystrophy	O
6	with	O
7	mental	O
8	deficiency	O
9	,	O
10	epilepsy	O
11	and	O
12	MRI	O
13	changes	O
14	in	O
15	the	O
16	cerebral	O
17	white	O
18	matter	O
19	.	O

1	Most	O
2	eukaryotic	O
3	mRNAs	O
4	are	O
5	translated	O
6	by	O
7	a	O
8	"	O
9	scanning	O
10	ribosome	O
11	"	O
12	mechanism	O
13	.	O

1	Comparison	O
2	of	O
3	Tc	O
4	-	O
5	99m	O
6	sestamibi	O
7	perfusion	O
8	imaging	O
9	and	O
10	echocardiography	O
11	using	O
12	an	O
13	arbutamine	O
14	infusion	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	coronary	O
20	artery	O
21	disease	O
22	.	O

1	Also	O
2	,	O
3	transient	O
4	overexpression	O
5	of	O
6	this	O
7	protein	O
8	in	O
9	C2C12	O
10	cells	O
11	reduced	O
12	the	O
13	transcription	O
14	of	O
15	a	O
16	CAT	B
17	-	O
18	reporter	O
19	regulated	O
20	by	O
21	an	O
22	E12	B
23	/	O
24	MyoD	B
25	driven	O
26	enhancer	O
27	.	O

1	Five	O
2	of	O
3	these	O
4	have	O
5	ocular	O
6	or	O
7	oculocutaneous	O
8	albinism	O
9	.	O

1	Comprising	O
2	a	O
3	126	O
4	-	O
5	nucleotide	O
6	5	O
7	'	O
8	untranscribed	O
9	genomic	O
10	sequence	O
11	and	O
12	a	O
13	466	O
14	-	O
15	nucleotide	O
16	5	O
17	'	O
18	noncoding	O
19	cDNA	O
20	sequence	O
21	,	O
22	the	O
23	592	O
24	-	O
25	nucleotide	O
26	5	O
27	'	O
28	CpG	O
29	island	O
30	lacked	O
31	TATA	O
32	and	O
33	CAAT	O
34	boxes	O
35	but	O
36	displayed	O
37	a	O
38	high	O
39	G	O
40	+	O
41	C	O
42	content	O
43	,	O
44	was	O
45	enriched	O
46	for	O
47	CpG	O
48	dinucleotides	O
49	,	O
50	and	O
51	contained	O
52	a	O
53	potential	O
54	Sp1	B
55	-	I
56	binding	I
57	site	I
58	,	O
59	i	O
60	.	O
61	e	O
62	.,	O
63	features	O
64	compatible	O
65	with	O
66	a	O
67	housekeeping	O
68	gene	O
69	.	O

1	SSeCKS	B
2	(	O
3	pronounced	O
4	essex	O
5	)	O
6	encodes	O
7	a	O
8	major	O
9	protein	B
10	kinase	I
11	C	I
12	substrate	O
13	,	O
14	the	O
15	expression	O
16	of	O
17	which	O
18	is	O
19	down	O
20	-	O
21	regulated	O
22	in	O
23	src	B
24	-	O
25	and	O
26	ras	B
27	-	O
28	transformed	O
29	rodent	O
30	fibroblasts	O
31	but	O
32	not	O
33	in	O
34	raf	O
35	-	O
36	transformed	O
37	rodent	O
38	fibroblasts	O
39	(	O
40	X	O
41	.	O

1	Type	O
2	I	O
3	position	O
4	-	O
5	vestibular	O
6	-	O
7	pause	O
8	(	O
9	PVP	O
10	I	O
11	)	O
12	and	O
13	vestibular	O
14	-	O
15	only	O
16	(	O
17	V	O
18	I	O
19	)	O
20	neurons	O
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	smaller	O
27	number	O
28	of	O
29	other	O
30	type	O
31	I	O
32	and	O
33	type	O
34	II	O
35	eye	O
36	-	O
37	plus	O
38	-	O
39	vestibular	O
40	neurons	O
41	were	O
42	studied	O
43	.	O

1	The	O
2	1	O
3	.	O
4	1	O
5	-	O
6	and	O
7	1	O
8	.	O
9	3	O
10	-	O
11	kb	O
12	mRNA	O
13	species	O
14	were	O
15	found	O
16	only	O
17	in	O
18	the	O
19	heart	O
20	,	O
21	and	O
22	the	O
23	2	O
24	.	O
25	6	O
26	-	O
27	kb	O
28	species	O
29	was	O
30	found	O
31	in	O
32	the	O
33	heart	O
34	,	O
35	kidney	O
36	and	O
37	brain	O
38	,	O
39	but	O
40	not	O
41	in	O
42	skeletal	O
43	muscle	O
44	or	O
45	liver	O
46	.	O

1	Taurine	O
2	deficiency	O
3	significantly	O
4	depressed	O
5	the	O
6	amplitude	O
7	of	O
8	OP1	O
9	and	O
10	OP4	O
11	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	mcs4	B
6	-	O
7	cells	O
8	are	O
9	defective	O
10	at	O
11	activation	O
12	of	O
13	Spc1	B
14	in	O
15	response	O
16	to	O
17	various	O
18	forms	O
19	of	O
20	stress	O
21	.	O

1	The	O
2	extended	O
3	rat	B
4	SP	I
5	-	I
6	A	I
7	isoforms	I
8	were	O
9	enriched	O
10	in	O
11	the	O
12	more	O
13	fully	O
14	glycosylated	O
15	and	O
16	multimeric	O
17	SP	B
18	-	I
19	A	I
20	species	O
21	separated	O
22	on	O
23	SDS	O
24	-	O
25	PAGE	O
26	gels	O
27	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	CDC25B	B
5	may	O
6	therefore	O
7	contribute	O
8	to	O
9	the	O
10	control	O
11	of	O
12	cell	O
13	proliferation	O
14	.	O

1	This	O
2	investigation	O
3	was	O
4	undertaken	O
5	to	O
6	determine	O
7	whether	O
8	consuming	O
9	several	O
10	small	O
11	feedings	O
12	of	O
13	preexercise	O
14	carbohydrate	O
15	(	O
16	CHO	O
17	),	O
18	rather	O
19	than	O
20	a	O
21	single	O
22	bolus	O
23	,	O
24	would	O
25	affect	O
26	blood	O
27	glucose	O
28	and	O
29	insulin	B
30	responses	O
31	during	O
32	rest	O
33	and	O
34	exercise	O
35	.	O

1	The	O
2	findings	O
3	suggest	O
4	that	O
5	ERP	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	instructions	O
18	.	O

1	This	O
2	coat	B
3	protein	I
4	consists	O
5	of	O
6	Sar1p	B
7	,	O
8	the	O
9	Sec23p	B
10	protein	I
11	complex	I
12	containing	O
13	Sec23p	B
14	and	O
15	Sec24p	B
16	,	O
17	and	O
18	the	O
19	Sec13p	B
20	protein	I
21	complex	I
22	containing	O
23	Sec13p	B
24	and	O
25	a	O
26	novel	O
27	150	B
28	-	I
29	kDa	I
30	protein	I
31	,	I
32	p150	I
33	.	O

1	The	O
2	second	O
3	primary	O
4	mutant	O
5	contained	O
6	a	O
7	proline	O
8	-	O
9	to	O
10	-	O
11	leucine	O
12	change	O
13	at	O
14	position	O
15	243	O
16	(	O
17	P243L	O
18	).	O

1	Induction	O
2	of	O
3	correctly	O
4	spliced	O
5	germline	O
6	transcripts	O
7	is	O
8	necessary	O
9	to	O
10	target	O
11	a	O
12	switch	O
13	region	O
14	for	O
15	recombination	O
16	and	O
17	switching	O
18	.	O

1	Thus	O
2	,	O
3	the	O
4	PCE	B
5	binds	O
6	a	O
7	Pbx	B
8	dimer	I
9	partner	I
10	that	O
11	behaves	O
12	unlike	O
13	Class	B
14	I	I
15	Hox	I
16	proteins	I
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	NH2	O
5	-	O
6	terminal	O
7	portion	O
8	of	O
9	the	O
10	homologue	O
11	was	O
12	not	O
13	translocated	O
14	into	O
15	the	O
16	outer	O
17	membrane	O
18	without	O
19	its	O
20	COOH	O
21	-	O
22	terminal	O
23	part	O
24	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	cDNA	O
8	,	O
9	CHEMR1	B
10	,	O
11	encoding	O
12	a	O
13	chemokine	O
14	receptor	O
15	with	O
16	a	O
17	homology	O
18	to	O
19	the	O
20	human	B
21	C	I
22	-	I
23	C	I
24	chemokine	I
25	receptor	I
26	,	O
27	CCR	B
28	-	I
29	4	I
30	.	O

1	Organization	O
2	of	O
3	the	O
4	human	B
5	LU	I
6	gene	I
7	and	O
8	molecular	O
9	basis	O
10	of	O
11	the	O
12	Lu	O
13	(	O
14	a	O
15	)/	O
16	Lu	B
17	(	I
18	b	I
19	)	I
20	blood	O
21	group	O
22	polymorphism	O
23	.	O

1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	hybrids	O
7	and	O
8	FISH	O
9	analysis	O
10	,	O
11	the	O
12	PE	B
13	-	I
14	2	I
15	gene	I
16	is	O
17	localized	O
18	to	O
19	human	O
20	chromosome	O
21	19q13	O
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	translocations	O
30	and	O
31	deletions	O
32	in	O
33	leukemias	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	B
44	factor	I
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	carcinogenesis	O
51	.	O

1	Whereas	O
2	the	O
3	mutant	O
4	enzymes	O
5	terminate	O
6	normally	O
7	at	O
8	the	O
9	late	O
10	terminator	O
11	in	O
12	T7	O
13	DNA	O
14	(	O
15	T	O
16	(	O
17	phi	O
18	))	O
19	and	O
20	rrnB	B
21	T2	O
22	,	O
23	they	O
24	fail	O
25	to	O
26	terminate	O
27	at	O
28	one	O
29	of	O
30	the	O
31	termination	O
32	sites	O
33	of	O
34	rrnB	B
35	T1	O
36	,	O
37	and	O
38	also	O
39	fail	O
40	to	O
41	recognize	O
42	the	O
43	PTH	B
44	and	O
45	CJ	O
46	signals	O
47	.	O

1	Cytological	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	transgenes	O
7	associate	O
8	with	O
9	a	O
10	nucleolus	O
11	.	O

1	Light	B
2	regulatory	I
3	unit	I
4	1	I
5	(	O
6	LRU1	B
7	)	O
8	is	O
9	necessary	O
10	for	O
11	and	O
12	sufficient	O
13	to	O
14	mediate	O
15	light	O
16	-	O
17	dependent	O
18	activation	O
19	of	O
20	the	O
21	chalcone	B
22	synthase	I
23	(	I
24	CHS	I
25	)	I
26	minimal	I
27	promoter	I
28	in	O
29	Petroselinum	O
30	crispum	O
31	.	O

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	The	O
2	active	O
3	state	O
4	is	O
5	terminated	O
6	by	O
7	hydrolysis	O
8	of	O
9	bound	O
10	GTP	O
11	,	O
12	producing	O
13	inactive	O
14	ARF	B
15	-	I
16	GDP	I
17	.	O

1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O

1	The	O
2	immunophilin	B
3	,	O
4	which	O
5	can	O
6	be	O
7	of	O
8	the	O
9	FK506	O
10	-	O
11	or	O
12	cyclosporin	O
13	A	O
14	-	O
15	binding	O
16	class	O
17	,	O
18	binds	O
19	to	O
20	hsp90	B
21	via	O
22	its	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	different	O
32	receptor	O
33	heterocomplexes	O
34	exist	O
35	depending	O
36	upon	O
37	which	O
38	immunophilin	B
39	occupies	O
40	the	O
41	TPR	O
42	-	O
43	binding	O
44	region	O
45	of	O
46	hsp90	B
47	.	O

1	In	O
2	adherent	O
3	macrophages	O
4	,	O
5	absence	O
6	of	O
7	CD45	B
8	led	O
9	to	O
10	the	O
11	hyperphosphorylation	O
12	and	O
13	hyperactivation	O
14	of	O
15	p56	B
16	/	I
17	59	I
18	(	O
19	hck	B
20	)	O
21	and	O
22	p53	B
23	/	I
24	56	I
25	(	O
26	lyn	B
27	),	O
28	but	O
29	not	O
30	of	O
31	p58	B
32	(	O
33	c	B
34	-	I
35	fgr	I
36	).	O

1	Secretion	O
2	in	O
3	milk	O
4	and	O
5	transplacental	O
6	transfer	O
7	of	O
8	two	O
9	iodized	O
10	oils	O
11	,	O
12	Lipiodol	O
13	UF	O
14	and	O
15	Oriodol	O
16	,	O
17	in	O
18	rabbits	O
19	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	B
5	gene	I
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	O
16	-	O
17	terminal	O
18	GAL4	B
19	-	O
20	like	O
21	Zn	O
22	(	O
23	II	O
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	O
29	zinc	O
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	O
40	like	O
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	O
48	-	O
49	terminal	O
50	acidic	O
51	alpha	O
52	-	O
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O

1	Overexpression	O
2	of	O
3	Sed5p	B
4	allowed	O
5	growth	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	Vti1p	B
11	.	O

1	The	O
2	coding	O
3	region	O
4	of	O
5	mkh1	B
6	is	O
7	contained	O
8	within	O
9	a	O
10	single	O
11	exon	O
12	encoding	O
13	a	O
14	1	O
15	,	O
16	116	O
17	-	O
18	amino	O
19	-	O
20	acid	O
21	protein	O
22	.	O

1	Strikingly	O
2	,	O
3	stoichiometric	O
4	association	O
5	of	O
6	p107	B
7	or	O
8	p130	B
9	with	O
10	either	O
11	cyclin	B
12	E	I
13	-	O
14	cdk2	B
15	or	O
16	cyclin	B
17	A	I
18	-	O
19	cdk2	B
20	negated	O
21	the	O
22	activities	O
23	of	O
24	these	O
25	kinases	O
26	.	O

1	Furthermore	O
2	,	O
3	p150	B
4	suppresses	O
5	actin	B
6	gelation	O
7	,	O
8	which	O
9	is	O
10	induced	O
11	by	O
12	smooth	B
13	muscle	I
14	alpha	I
15	-	I
16	actinin	I
17	.	O

1	Denaturation	O
2	of	O
3	the	O
4	simian	O
5	virus	O
6	40	O
7	origin	O
8	of	O
9	replication	O
10	mediated	O
11	by	O
12	human	B
13	replication	I
14	protein	I
15	A	I
16	.	O

1	This	O
2	effect	O
3	was	O
4	abolished	O
5	once	O
6	the	O
7	EM	O
8	motif	O
9	in	O
10	the	O
11	promoter	O
12	-	O
13	reporter	O
14	construct	O
15	was	O
16	mutated	O
17	,	O
18	thus	O
19	suggesting	O
20	that	O
21	the	O
22	synergistic	O
23	transactivation	O
24	function	O
25	of	O
26	the	O
27	TEF	B
28	-	I
29	1	I
30	-	O
31	Max	B
32	heterotypic	O
33	complex	O
34	is	O
35	mediated	O
36	through	O
37	binding	O
38	of	O
39	the	O
40	complex	O
41	to	O
42	the	O
43	EM	O
44	motif	O
45	.	O

1	Interdigitated	O
2	residues	O
3	within	O
4	a	O
5	small	O
6	region	O
7	of	O
8	VP16	B
9	interact	O
10	with	O
11	Oct	B
12	-	I
13	1	I
14	,	O
15	HCF	B
16	,	O
17	and	O
18	DNA	O
19	.	O

1	With	O
2	a	O
3	view	O
4	to	O
5	identifying	O
6	other	O
7	important	O
8	U14	B
9	interactions	O
10	,	O
11	a	O
12	stem	O
13	-	O
14	loop	O
15	domain	O
16	required	O
17	for	O
18	activity	O
19	of	O
20	Saccharomyces	B
21	cerevisiae	I
22	U14	I
23	RNAs	I
24	(	O
25	the	O
26	Y	O
27	domain	O
28	)	O
29	was	O
30	first	O
31	subjected	O
32	to	O
33	detailed	O
34	mutational	O
35	analysis	O
36	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	and	O
6	because	O
7	Cdc68	B
8	has	O
9	been	O
10	implicated	O
11	as	O
12	a	O
13	regulator	O
14	of	O
15	chromatin	O
16	structure	O
17	,	O
18	we	O
19	postulate	O
20	that	O
21	polymerase	B
22	alpha	I
23	may	O
24	interact	O
25	with	O
26	these	O
27	proteins	O
28	to	O
29	gain	O
30	access	O
31	to	O
32	its	O
33	template	O
34	or	O
35	to	O
36	origins	O
37	of	O
38	replication	O
39	in	O
40	vivo	O
41	.	O

1	Even	O
2	when	O
3	the	O
4	inoculum	O
5	size	O
6	was	O
7	reduced	O
8	sixfold	O
9	(	O
10	i	O
11	.	O
12	e	O
13	.,	O
14	6	O
15	x	O
16	10	O
17	(	O
18	6	O
19	)	O
20	CFU	O
21	/	O
22	mouse	O
23	),	O
24	50	O
25	%	O
26	of	O
27	the	O
28	RB6	B
29	-	I
30	8C5	I
31	-	O
32	treated	O
33	animals	O
34	died	O
35	within	O
36	6	O
37	days	O
38	.	O

1	In	O
2	12	O
3	cases	O
4	(	O
5	3	O
6	.	O
7	1	O
8	%),	O
9	a	O
10	change	O
11	in	O
12	stage	O
13	resulted	O
14	.	O

1	Promoter	O
2	recognition	O
3	algorithms	O
4	identified	O
5	divergent	O
6	promoter	O
7	elements	O
8	within	O
9	the	O
10	CpG	O
11	island	O
12	,	O
13	which	O
14	lies	O
15	between	O
16	the	O
17	ATM	B
18	and	O
19	E14	B
20	/	O
21	NPAT	B
22	genes	O
23	,	O
24	and	O
25	provide	O
26	evidence	O
27	for	O
28	a	O
29	putative	O
30	second	O
31	ATM	B
32	promoter	I
33	located	O
34	within	O
35	intron	O
36	3	O
37	,	O
38	immediately	O
39	upstream	O
40	of	O
41	the	O
42	first	O
43	coding	O
44	exon	O
45	.	O

1	Recombinant	B
2	soluble	I
3	pMCP	I
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	B
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	B
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	B
32	.	O

1	Clinical	O
2	and	O
3	haematological	O
4	signs	O
5	are	O
6	not	O
7	specific	O
8	in	O
9	this	O
10	setting	O
11	,	O
12	and	O
13	the	O
14	diagnosis	O
15	relies	O
16	on	O
17	histological	O
18	features	O
19	,	O
20	mainly	O
21	bone	O
22	marrow	O
23	examination	O
24	.	O

1	Spatial	O
2	zones	O
3	for	O
4	muscle	O
5	coactivation	O
6	and	O
7	the	O
8	control	O
9	of	O
10	postural	O
11	stability	O
12	.	O

1	Liquid	O
2	chromatographic	O
3	separation	O
4	was	O
5	achieved	O
6	on	O
7	a	O
8	Zorbax	O
9	RX	O
10	C8	O
11	analytical	O
12	column	O
13	using	O
14	gradient	O
15	elution	O
16	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pDHL1	O
5	from	O
6	Debaryomyces	O
7	hansenii	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	pGKL1	B
16	-	I
17	plasmid	I
18	DNA	I
19	polymerase	I
20	.	O

1	The	O
2	RNA	O
3	-	O
4	binding	O
5	and	O
6	RNA	B
7	-	I
8	DNA	I
9	helicase	I
10	activities	O
11	of	O
12	the	O
13	Escherichia	B
14	coli	I
15	transcription	I
16	termination	I
17	factor	I
18	rho	I
19	have	O
20	been	O
21	investigated	O
22	using	O
23	natural	O
24	RNA	O
25	molecules	O
26	that	O
27	are	O
28	255	O
29	and	O
30	391	O
31	nucleotide	O
32	residues	O
33	in	O
34	length	O
35	and	O
36	that	O
37	contain	O
38	the	O
39	trp	B
40	t	I
41	'	I
42	rho	I
43	-	I
44	dependent	I
45	termination	I
46	sequence	I
47	of	O
48	E	O
49	.	O
50	coli	O
51	.	O

1	The	O
2	p20	B
3	-	I
4	CGGBP	I
5	gene	I
6	is	O
7	conserved	O
8	among	O
9	mammals	O
10	but	O
11	shows	O
12	no	O
13	homology	O
14	to	O
15	non	O
16	-	O
17	vertebrate	O
18	species	O
19	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	like	O
6	in	O
7	yeast	O
8	,	O
9	in	O
10	plants	O
11	a	O
12	certain	O
13	subfamily	O
14	of	O
15	UBC	B
16	is	O
17	specifically	O
18	involved	O
19	in	O
20	the	O
21	proteolytic	O
22	degradation	O
23	of	O
24	abnormal	O
25	proteins	O
26	as	O
27	result	O
28	of	O
29	stress	O
30	.	O

1	The	O
2	pWP	B
3	-	I
4	19	I
5	also	O
6	encodes	O
7	the	O
8	AAV	O
9	inverted	O
10	terminal	O
11	repeats	O
12	for	O
13	integration	O
14	and	O
15	replication	O
16	and	O
17	the	O
18	herpes	O
19	virus	O
20	thymidine	B
21	kinase	I
22	promoter	O
23	-	O
24	driven	O
25	gene	O
26	for	O
27	neomycin	O
28	resistance	O
29	(	O
30	neoR	B
31	).	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	rAAV	O
6	-	O
7	mediated	O
8	gene	O
9	transfer	O
10	system	O
11	for	O
12	the	O
13	rat	B
14	preproinsulin	I
15	II	I
16	gene	I
17	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	beta	B
6	-	I
7	human	I
8	chorionic	I
9	gonadotropin	I
10	(	O
11	HCG	B
12	)	O
13	and	O
14	placental	B
15	alkaline	I
16	phosphatase	I
17	(	O
18	PLAP	B
19	)	O
20	were	O
21	not	O
22	elevated	O
23	.	O

1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	I
21	cassette	I
22	.	O

1	This	O
2	indicates	O
3	that	O
4	recruitment	O
5	of	O
6	large	B
7	T	I
8	antigen	I
9	to	O
10	the	O
11	rRNA	O
12	promoter	O
13	by	O
14	SL1	B
15	constitutes	O
16	a	O
17	crucial	O
18	step	O
19	in	O
20	the	O
21	activation	O
22	process	O
23	.	O

1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O

1	Functional	O
2	and	O
3	regulatory	O
4	analysis	O
5	of	O
6	the	O
7	two	O
8	copies	O
9	of	O
10	the	O
11	fixNOQP	B
12	operon	I
13	of	O
14	Rhizobium	O
15	leguminosarum	O
16	strain	O
17	VF39	O
18	.	O

1	This	O
2	study	O
3	describes	O
4	a	O
5	new	O
6	MADS	B
7	box	I
8	gene	I
9	,	O
10	nmhC5	B
11	,	O
12	which	O
13	along	O
14	with	O
15	nmh7	B
16	(	O
17	J	O
18	.	O

1	Thus	O
2	E14	O
3	.	O
4	1TG3B1	O
5	is	O
6	a	O
7	useful	O
8	ES	O
9	cell	O
10	line	O
11	for	O
12	modifying	O
13	the	O
14	mouse	O
15	genome	O
16	using	O
17	the	O
18	HPRT	B
19	gene	I
20	as	O
21	a	O
22	selection	O
23	marker	O
24	and	O
25	for	O
26	transmission	O
27	at	O
28	a	O
29	high	O
30	frequency	O
31	into	O
32	the	O
33	mouse	O
34	germ	O
35	line	O
36	.	O

1	Lung	O
2	and	O
3	multi	O
4	-	O
5	system	O
6	damage	O
7	were	O
8	early	O
9	indicators	O
10	of	O
11	poor	O
12	outcome	O
13	in	O
14	severe	O
15	non	O
16	-	O
17	fatal	O
18	disease	O
19	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	bulbospinal	O
7	micturition	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	dopa	O
17	involves	O
18	a	O
19	descending	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	B
28	alpha	I
29	1	I
30	-	I
31	adrenoceptors	I
32	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	analyze	O
9	the	O
10	common	O
11	cause	O
12	of	O
13	asthenopia	O
14	,	O
15	mixed	O
16	astigmatism	O
17	.	O

1	Disturbance	O
2	of	O
3	regeneration	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	tunica	O
15	propria	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	homeostasis	O
27	.	O

1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O

1	Identification	O
2	of	O
3	five	O
4	new	O
5	genes	O
6	,	O
7	closely	O
8	related	O
9	to	O
10	the	O
11	interleukin	B
12	-	I
13	1beta	I
14	converting	I
15	enzyme	I
16	gene	I
17	,	O
18	that	O
19	do	O
20	not	O
21	encode	O
22	functional	O
23	proteases	O
24	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	B
13	carboxypeptidases	I
14	.	O

1	One	O
2	RNA	O
3	construct	O
4	which	O
5	consisted	O
6	of	O
7	112	O
8	nucleotides	O
9	(	O
10	nt	O
11	)	O
12	from	O
13	nt	O
14	639	O
15	to	O
16	nt	O
17	750	O
18	formed	O
19	a	O
20	heterodimeric	O
21	complex	O
22	with	O
23	the	O
24	RNA	O
25	which	O
26	consisted	O
27	of	O
28	200	O
29	nucleotides	O
30	from	O
31	nt	O
32	551	O
33	to	O
34	nt	O
35	750	O
36	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	AML1a	B
6	,	O
7	which	O
8	solely	O
9	has	O
10	no	O
11	effects	O
12	as	O
13	a	O
14	transcriptional	O
15	regulator	O
16	,	O
17	dominantly	O
18	suppresses	O
19	transcriptional	O
20	activation	O
21	by	O
22	AML1b	B
23	,	O
24	and	O
25	that	O
26	AML1a	B
27	exhibits	O
28	the	O
29	higher	O
30	affinity	O
31	for	O
32	DNA	O
33	-	O
34	binding	O
35	than	O
36	AML1b	B
37	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	B
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	O
16	GTPase	B
17	-	I
18	activating	I
19	proteins	I
20	in	O
21	the	O
22	c	B
23	-	I
24	cbl	I
25	gene	I
26	.	O

1	However	O
2	,	O
3	using	O
4	ATL	O
5	-	O
6	16T	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	that	O
13	GATA	B
14	-	I
15	4	I
16	is	O
17	the	O
18	only	O
19	GATA	B
20	-	I
21	binding	I
22	protein	I
23	that	O
24	forms	O
25	specific	O
26	DNA	O
27	-	O
28	protein	O
29	complex	O
30	with	O
31	the	O
32	-	O
33	70	O
34	GATA	O
35	site	O
36	.	O

1	The	O
2	impact	O
3	of	O
4	social	O
5	support	O
6	on	O
7	the	O
8	relationships	O
9	of	O
10	gay	O
11	male	O
12	couples	O
13	is	O
14	examined	O
15	.	O

1	The	O
2	ubiquitously	O
3	expressed	O
4	hypoxia	B
5	-	I
6	inducible	I
7	factor	I
8	-	I
9	1	I
10	(	O
11	HIF	B
12	-	I
13	1	I
14	)	O
15	is	O
16	involved	O
17	in	O
18	expression	O
19	of	O
20	a	O
21	large	O
22	number	O
23	of	O
24	oxygen	O
25	-	O
26	regulated	O
27	genes	O
28	.	O

1	Stromelysin	B
2	-	I
3	1	I
4	,	O
5	matrix	B
6	metalloproteinase	I
7	-	I
8	3	I
9	(	O
10	MMP	B
11	-	I
12	3	I
13	),	O
14	is	O
15	an	O
16	important	O
17	endopeptidase	O
18	selectively	O
19	expressed	O
20	by	O
21	somatic	O
22	cells	O
23	in	O
24	organ	O
25	tissues	O
26	.	O

1	Tendon	O
2	also	O
3	shows	O
4	a	O
5	degree	O
6	of	O
7	extensibility	O
8	.	O

1	Surveillance	O
2	for	O
3	preeclampsia	O
4	was	O
5	conducted	O
6	by	O
7	personnel	O
8	unaware	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	assignments	O
14	,	O
15	using	O
16	standardized	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	uniformly	O
27	scheduled	O
28	prenatal	O
29	visits	O
30	,	O
31	protocols	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	hospitalization	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	reviews	O
44	of	O
45	medical	O
46	records	O
47	of	O
48	unscheduled	O
49	outpatient	O
50	visits	O
51	and	O
52	all	O
53	hospitalizations	O
54	.	O

1	Aryl	B
2	hydrocarbon	I
3	receptor	I
4	nuclear	I
5	translocator	I
6	(	O
7	ARNT	B
8	)	O
9	is	O
10	a	O
11	component	O
12	of	O
13	the	O
14	transcription	O
15	factors	O
16	,	O
17	aryl	B
18	hydrocarbon	I
19	receptor	I
20	(	O
21	AhR	B
22	)	O
23	and	O
24	hypoxia	B
25	-	I
26	inducible	I
27	factor	I
28	1	I
29	,	O
30	which	O
31	transactivate	O
32	their	O
33	target	O
34	genes	O
35	,	O
36	such	O
37	as	O
38	CYP1A1	B
39	and	O
40	erythropoietin	B
41	,	O
42	in	O
43	response	O
44	to	O
45	xenobiotic	O
46	aromatic	O
47	hydrocarbons	O
48	and	O
49	to	O
50	low	O
51	O2	O
52	concentration	O
53	,	O
54	respectively	O
55	.	O

1	DNase	B
2	I	I
3	footprint	O
4	analysis	O
5	identified	O
6	a	O
7	protected	O
8	region	O
9	from	O
10	-	O
11	37	O
12	to	O
13	-	O
14	53	O
15	.	O

1	We	O
2	also	O
3	provide	O
4	evidence	O
5	that	O
6	gar2	B
7	is	O
8	phosphorylated	O
9	in	O
10	vitro	O
11	by	O
12	a	O
13	p13	B
14	(	O
15	suc1	B
16	)-	O
17	Sepharose	O
18	-	O
19	bound	O
20	kinase	O
21	from	O
22	Schizosaccharomyces	O
23	pombe	O
24	extracts	O
25	that	O
26	displays	O
27	cell	O
28	cycle	O
29	-	O
30	regulated	O
31	activity	O
32	similar	O
33	to	O
34	that	O
35	of	O
36	the	O
37	p34	B
38	(	O
39	cdc2	B
40	(	O
41	kinase	O
42	.	O

1	However	O
2	,	O
3	by	O
4	immobilized	O
5	metal	O
6	affinity	O
7	chromatography	O
8	assay	O
9	,	O
10	self	O
11	-	O
12	association	O
13	of	O
14	PR	B
15	-	I
16	A	I
17	was	O
18	3	O
19	.	O
20	5	O
21	-	O
22	fold	O
23	more	O
24	efficient	O
25	than	O
26	that	O
27	of	O
28	either	O
29	the	O
30	DhLBD	O
31	or	O
32	hLBD	O
33	constructs	O
34	.	O

1	The	O
2	overall	O
3	results	O
4	of	O
5	this	O
6	paper	O
7	are	O
8	consistent	O
9	with	O
10	the	O
11	conclusion	O
12	that	O
13	the	O
14	carboxyl	O
15	-	O
16	terminal	O
17	LBD	O
18	is	O
19	not	O
20	sufficient	O
21	for	O
22	mediating	O
23	PR	B
24	dimerization	O
25	and	O
26	that	O
27	multiple	O
28	regions	O
29	,	O
30	including	O
31	the	O
32	hinge	O
33	and	O
34	amino	O
35	-	O
36	terminal	O
37	sequences	O
38	,	O
39	contribute	O
40	either	O
41	directly	O
42	or	O
43	indirectly	O
44	to	O
45	homodimerization	O
46	of	O
47	PR	B
48	.	O

1	We	O
2	isolated	O
3	several	O
4	overlapping	O
5	A	O
6	-	O
7	phage	O
8	and	O
9	cosmid	O
10	clones	O
11	that	O
12	cover	O
13	more	O
14	than	O
15	100	O
16	kb	O
17	of	O
18	human	O
19	DNA	O
20	and	O
21	contained	O
22	the	O
23	entire	O
24	VDR	B
25	gene	I
26	.	O

1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O

1	Here	O
2	,	O
3	we	O
4	correlate	O
5	Dox	O
6	effects	O
7	on	O
8	cell	O
9	cycle	O
10	with	O
11	changes	O
12	of	O
13	E2F	B
14	/	O
15	DP	B
16	complexes	O
17	and	O
18	activity	O
19	in	O
20	differentiating	O
21	C2C12	O
22	myocytes	O
23	.	O

1	The	O
2	products	O
3	of	O
4	the	O
5	Saccharomyces	B
6	cerevisiae	I
7	CIN1	I
8	,	O
9	CIN2	B
10	and	O
11	CIN4	B
12	genes	I
13	participate	O
14	in	O
15	a	O
16	nonessential	O
17	pathway	O
18	required	O
19	for	O
20	normal	O
21	microtubule	O
22	function	O
23	.	O

1	Vitrectomy	O
2	was	O
3	still	O
4	a	O
5	significant	O
6	risk	O
7	factor	O
8	when	O
9	macular	O
10	holes	O
11	were	O
12	excluded	O
13	.	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	B
13	levels	O
14	in	O
15	humans	O
16	".	O

1	Both	O
2	promoters	O
3	lack	O
4	a	O
5	TATA	O
6	box	O
7	,	O
8	and	O
9	Pint	B
10	belongs	O
11	to	O
12	the	O
13	MED	B
14	-	I
15	1	I
16	class	O
17	of	O
18	promoters	O
19	,	O
20	which	O
21	initiate	O
22	transcription	O
23	at	O
24	multiple	O
25	sites	O
26	.	O

1	Serum	B
2	response	I
3	factor	I
4	(	O
5	SRF	B
6	),	O
7	a	O
8	member	O
9	of	O
10	an	O
11	ancient	O
12	family	O
13	of	O
14	DNA	O
15	-	O
16	binding	O
17	proteins	O
18	,	O
19	is	O
20	generally	O
21	assumed	O
22	to	O
23	be	O
24	a	O
25	ubiquitous	O
26	transcription	O
27	factor	O
28	involved	O
29	in	O
30	regulating	O
31	growth	O
32	factor	O
33	-	O
34	responsive	O
35	genes	O
36	.	O

1	We	O
2	have	O
3	initiated	O
4	studies	O
5	to	O
6	identify	O
7	candidate	O
8	signal	O
9	transducers	O
10	that	O
11	associate	O
12	with	O
13	the	O
14	cytosolic	O
15	domain	O
16	(	O
17	cd	O
18	)	O
19	of	O
20	the	O
21	IL	B
22	-	I
23	1R	I
24	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	sought	O
7	to	O
8	identify	O
9	mechanisms	O
10	that	O
11	could	O
12	account	O
13	for	O
14	the	O
15	antimitogenic	O
16	effects	O
17	of	O
18	IL	B
19	-	I
20	4	I
21	.	O

1	Pseudomonas	O
2	aeruginosa	O
3	strains	O
4	infecting	O
5	patients	O
6	with	O
7	cystic	O
8	fibrosis	O
9	(	O
10	CF	O
11	)	O
12	acquire	O
13	a	O
14	mucoid	O
15	phenotype	O
16	due	O
17	to	O
18	overproduction	O
19	of	O
20	alginate	O
21	.	O

1	Activity	O
2	of	O
3	palgD	B
4	in	O
5	the	O
6	cysB	B
7	mutant	I
8	,	O
9	in	O
10	CHA	O
11	and	O
12	in	O
13	the	O
14	non	O
15	-	O
16	mucoid	O
17	strain	O
18	PAO	O
19	was	O
20	assessed	O
21	by	O
22	the	O
23	use	O
24	of	O
25	a	O
26	transcriptional	O
27	algD	B
28	-	O
29	xylE	B
30	fusion	O
31	.	O

1	The	O
2	Man9	B
3	-	I
4	mannosidase	I
5	specificity	O
6	of	O
7	the	O
8	cDNA	O
9	construct	O
10	was	O
11	verified	O
12	by	O
13	the	O
14	observation	O
15	that	O
16	all	O
17	peptide	O
18	sequences	O
19	derived	O
20	from	O
21	a	O
22	previously	O
23	purified	O
24	,	O
25	catalytically	O
26	active	O
27	49	O
28	-	O
29	kDa	O
30	fragment	O
31	were	O
32	found	O
33	within	O
34	the	O
35	coding	O
36	region	O
37	.	O

1	A	O
2	soluble	O
3	62	O
4	-	O
5	kDa	O
6	protein	O
7	was	O
8	produced	O
9	without	O
10	the	O
11	proteolytic	O
12	processing	O
13	by	O
14	inserting	O
15	the	O
16	coding	O
17	sequence	O
18	of	O
19	amino	O
20	acids	O
21	112	O
22	to	O
23	660	O
24	of	O
25	ORF	O
26	-	O
27	2	O
28	in	O
29	a	O
30	baculovirus	O
31	expression	O
32	vector	O
33	and	O
34	using	O
35	the	O
36	corresponding	O
37	virus	O
38	to	O
39	infect	O
40	Sf9	O
41	cells	O
42	.	O

1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	O
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	B
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O

1	Serum	O
2	and	O
3	peritoneal	O
4	dialysis	O
5	fluid	O
6	(	O
7	PDF	O
8	)	O
9	were	O
10	collected	O
11	for	O
12	assay	O
13	throughout	O
14	the	O
15	course	O
16	of	O
17	the	O
18	study	O
19	and	O
20	for	O
21	5	O
22	days	O
23	thereafter	O
24	.	O

1	Results	O
2	support	O
3	the	O
4	hypothesis	O
5	that	O
6	endogenous	B
7	corticotropin	I
8	-	I
9	releasing	I
10	factor	I
11	,	O
12	perhaps	O
13	acting	O
14	at	O
15	a	O
16	peripheral	O
17	binding	O
18	site	O
19	,	O
20	suppresses	O
21	the	O
22	active	O
23	behavioral	O
24	response	O
25	characteristic	O
26	of	O
27	pups	O
28	during	O
29	the	O
30	early	O
31	phase	O
32	of	O
33	isolation	O
34	in	O
35	novel	O
36	surroundings	O
37	.	O

1	Liver	O
2	regional	O
3	blood	O
4	volume	O
5	(	O
6	LRBV	O
7	)	O
8	is	O
9	altered	O
10	by	O
11	several	O
12	disease	O
13	states	O
14	and	O
15	various	O
16	drugs	O
17	.	O

1	The	O
2	gray	O
3	matter	O
4	NAA	O
5	/	O
6	mI	O
7	ratio	O
8	clearly	O
9	separated	O
10	the	O
11	two	O
12	groups	O
13	.	O

1	As	O
2	with	O
3	the	O
4	murine	B
5	and	I
6	human	I
7	mb	I
8	-	I
9	1	I
10	genes	I
11	,	O
12	the	O
13	5	O
14	'	O
15	region	O
16	of	O
17	the	O
18	bovine	B
19	mb	I
20	-	I
21	1	I
22	gene	I
23	lacked	O
24	a	O
25	TATA	O
26	box	O
27	.	O

1	Chloramphenicol	B
2	acetyltransferase	I
3	assays	O
4	examining	O
5	the	O
6	ability	O
7	of	O
8	IE86	B
9	to	O
10	repress	O
11	activity	O
12	from	O
13	the	O
14	HCMV	O
15	major	O
16	IE	B
17	promoter	I
18	or	O
19	activate	O
20	the	O
21	HCMV	B
22	early	I
23	promoter	I
24	for	O
25	the	O
26	2	O
27	.	O
28	2	O
29	-	O
30	kb	O
31	class	O
32	of	O
33	RNAs	O
34	demonstrated	O
35	the	O
36	functional	O
37	integrity	O
38	of	O
39	the	O
40	IE86	B
41	protein	I
42	.	O

1	ORF	O
2	M1	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	poxvirus	O
8	serpins	B
9	,	O
10	while	O
11	ORF	O
12	M11	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	I
20	2	I
21	-	I
22	like	I
23	molecules	I
24	encoded	O
25	by	O
26	other	O
27	gammaherpesviruses	O
28	(	O
29	gene	B
30	16	I
31	of	O
32	HVS	O
33	and	O
34	KSHV	O
35	and	O
36	the	O
37	BHRF1	B
38	gene	I
39	of	O
40	EBV	O
41	).	O

1	Transcription	O
2	factor	O
3	binding	O
4	sites	O
5	downstream	O
6	of	O
7	the	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	transcription	O
14	start	O
15	site	O
16	are	O
17	important	O
18	for	O
19	virus	O
20	infectivity	O
21	.	O

1	Crystal	O
2	structure	O
3	of	O
4	an	O
5	oligomer	O
6	of	O
7	proteolytic	O
8	zymogens	O
9	:	O
10	detailed	O
11	conformational	O
12	analysis	O
13	of	O
14	the	O
15	bovine	O
16	ternary	O
17	complex	O
18	and	O
19	implications	O
20	for	O
21	their	O
22	activation	O
23	.	O

1	Through	O
2	transient	O
3	transfection	O
4	of	O
5	NIH3T3	O
6	fibroblast	O
7	cells	O
8	and	O
9	gel	O
10	mobility	O
11	shift	O
12	assays	O
13	,	O
14	the	O
15	functional	O
16	binding	O
17	site	O
18	was	O
19	localized	O
20	to	O
21	a	O
22	short	O
23	region	O
24	(-	O
25	318	O
26	to	O
27	-	O
28	303	O
29	bp	O
30	from	O
31	the	O
32	transcription	O
33	start	O
34	site	O
35	)	O
36	which	O
37	has	O
38	a	O
39	CTCCC	O
40	sequence	O
41	.	O

1	We	O
2	suppose	O
3	that	O
4	this	O
5	injection	O
6	speed	O
7	(	O
8	0	O
9	.	O
10	1	O
11	-	O
12	0	O
13	.	O
14	2	O
15	ml	O
16	.	O
17	s	O
18	-	O
19	1	O
20	)	O
21	is	O
22	suitable	O
23	for	O
24	spinal	O
25	anesthesia	O
26	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	ClC	B
5	-	I
6	6	I
7	(	O
8	a	O
9	member	O
10	of	O
11	the	O
12	CIC	B
13	chloride	I
14	-	I
15	channel	I
16	family	I
17	)	O
18	transcripts	O
19	generates	O
20	three	O
21	truncated	O
22	isoforms	O
23	one	O
24	of	O
25	which	O
26	,	O
27	ClC	B
28	-	I
29	6c	I
30	,	O
31	is	O
32	kidney	O
33	-	O
34	specific	O
35	.	O

1	The	O
2	current	O
3	study	O
4	demonstrates	O
5	that	O
6	T3	O
7	-	O
8	activated	O
9	transcription	O
10	of	O
11	the	O
12	NADPH	B
13	:	I
14	cytochrome	I
15	P450	I
16	oxidoreductase	I
17	(	O
18	P450R	B
19	)	O
20	gene	O
21	is	O
22	dependent	O
23	on	O
24	the	O
25	thyroid	O
26	hormonal	O
27	status	O
28	of	O
29	the	O
30	animal	O
31	,	O
32	with	O
33	both	O
34	transcriptional	O
35	and	O
36	post	O
37	-	O
38	transcriptional	O
39	pathways	O
40	being	O
41	important	O
42	in	O
43	regulating	O
44	the	O
45	cellular	O
46	P450R	B
47	mRNA	O
48	level	O
49	.	O

1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	O
8	(	O
9	PTFE	O
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O

1	The	O
2	control	O
3	group	O
4	revealed	O
5	significantly	O
6	higher	O
7	levels	O
8	of	O
9	coagulation	B
10	factors	I
11	II	I
12	,	I
13	V	I
14	and	I
15	VIII	I
16	,	O
17	compared	O
18	to	O
19	the	O
20	index	O
21	group	O
22	.	O

1	The	O
2	frequency	O
3	of	O
4	positive	O
5	anti	B
6	-	I
7	GM1	I
8	antibody	I
9	titers	O
10	in	O
11	the	O
12	Guillain	O
13	-	O
14	Barre	O
15	syndrome	O
16	patients	O
17	with	O
18	PEN	O
19	19	O
20	isolates	O
21	was	O
22	higher	O
23	than	O
24	that	O
25	in	O
26	the	O
27	Guillain	O
28	-	O
29	Barre	O
30	syndrome	O
31	and	O
32	Fisher	O
33	'	O
34	s	O
35	syndrome	O
36	patients	O
37	without	O
38	PEN	O
39	19	O
40	isolates	O
41	.	O

1	Stereotactic	O
2	radiofrequency	O
3	lesioning	O
4	of	O
5	the	O
6	hamartoma	O
7	resulted	O
8	in	O
9	seizure	O
10	remission	O
11	without	O
12	complications	O
13	20	O
14	months	O
15	after	O
16	surgery	O
17	.	O

1	NF	B
2	-	I
3	kappa	I
4	B	I
5	/	O
6	Rel	B
7	transcription	O
8	factors	O
9	participate	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	numerous	O
15	genes	O
16	involved	O
17	in	O
18	immune	O
19	regulation	O
20	/	O
21	inflammation	O
22	including	O
23	cytokines	O
24	,	O
25	cell	O
26	surface	O
27	receptors	O
28	,	O
29	adhesion	O
30	molecules	O
31	,	O
32	and	O
33	acute	O
34	phase	O
35	proteins	O
36	.	O

1	If	O
2	E	O
3	.	O
4	coli	O
5	is	O
6	present	O
7	in	O
8	any	O
9	source	O
10	water	O
11	sample	O
12	,	O
13	the	O
14	borehole	O
15	and	O
16	any	O
17	directly	O
18	connected	O
19	borehole	O
20	should	O
21	be	O
22	embargoed	O
23	.	O

1	However	O
2	,	O
3	mean	O
4	food	O
5	intake	O
6	in	O
7	the	O
8	40	O
9	%	O
10	group	O
11	was	O
12	half	O
13	that	O
14	of	O
15	the	O
16	ACT	O
17	group	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	001	O
24	)	O
25	and	O
26	significantly	O
27	less	O
28	(	O
29	p	O
30	<	O
31	0	O
32	.	O
33	01	O
34	)	O
35	than	O
36	the	O
37	SEP	O
38	group	O
39	,	O
40	which	O
41	consumed	O
42	amounts	O
43	equivalent	O
44	to	O
45	65	O
46	%	O
47	of	O
48	daily	O
49	requirement	O
50	.	O

1	The	O
2	following	O
3	technique	O
4	describes	O
5	a	O
6	modification	O
7	to	O
8	a	O
9	bar	O
10	superstructure	O
11	that	O
12	provided	O
13	the	O
14	advantages	O
15	of	O
16	convenience	O
17	,	O
18	security	O
19	,	O
20	and	O
21	consistent	O
22	positioning	O
23	even	O
24	though	O
25	one	O
26	implant	O
27	was	O
28	lost	O
29	and	O
30	the	O
31	angulation	O
32	of	O
33	implants	O
34	limited	O
35	accuracy	O
36	.	O

1	In	O
2	summary	O
3	,	O
4	DDC	O
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O

1	Its	O
2	potential	O
3	as	O
4	a	O
5	diagnostic	O
6	tool	O
7	for	O
8	epidemiological	O
9	surveillance	O
10	was	O
11	assessed	O
12	in	O
13	comparison	O
14	with	O
15	three	O
16	other	O
17	diagnostic	O
18	tests	O
19	:	O
20	stool	O
21	examination	O
22	,	O
23	ELISA	O
24	with	O
25	soluble	B
26	egg	I
27	antigen	I
28	(	O
29	SEA	B
30	)	O
31	and	O
32	the	O
33	circumoval	O
34	precipitin	B
35	test	O
36	(	O
37	COPT	O
38	).	O

1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	B
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O

1	These	O
2	analyses	O
3	demonstrate	O
4	that	O
5	the	O
6	dUTPase	B
7	isoforms	O
8	are	O
9	encoded	O
10	by	O
11	the	O
12	same	O
13	gene	O
14	with	O
15	isoform	O
16	-	O
17	specific	O
18	transcripts	O
19	arising	O
20	through	O
21	the	O
22	use	O
23	of	O
24	alternative	O
25	5	O
26	'	O
27	exons	O
28	.	O

1	The	O
2	selective	O
3	5	B
4	-	I
5	HT3	I
6	receptor	I
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	O
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	B
28	-	I
29	HT4	I
30	receptor	I
31	agonist	O
32	/	O
33	5	B
34	-	I
35	HT3	I
36	receptor	I
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O

1	Re	O
2	-	O
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	specimen	O
8	from	O
9	the	O
10	right	O
11	hip	O
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	O
18	initial	O
19	operation	O
20	showed	O
21	areas	O
22	of	O
23	chondrosarcoma	O
24	arising	O
25	in	O
26	the	O
27	background	O
28	of	O
29	synovial	O
30	chondromatosis	O
31	.	O

1	All	O
2	corneal	O
3	buttons	O
4	were	O
5	processed	O
6	for	O
7	histopathologic	O
8	and	O
9	electron	O
10	microscopic	O
11	studies	O
12	.	O

1	3600	O
2	-	O
3	fold	O
4	to	O
5	apparent	O
6	homogeneity	O
7	with	O
8	a	O
9	41	O
10	%	O
11	yield	O
12	by	O
13	affinity	O
14	chromatography	O
15	utilizing	O
16	DNA	O
17	-	O
18	cellulose	O
19	;	O
20	the	O
21	purity	O
22	of	O
23	the	O
24	final	O
25	preparation	O
26	was	O
27	assessed	O
28	by	O
29	SDS	O
30	/	O
31	PAGE	O
32	,	O
33	lack	O
34	of	O
35	contamination	O
36	by	O
37	other	O
38	nucleases	O
39	and	O
40	production	O
41	of	O
42	a	O
43	monospecific	O
44	antibody	O
45	against	O
46	the	O
47	enzyme	O
48	.	O

1	Human	B
2	thymine	I
3	-	I
4	DNA	I
5	glycosylase	I
6	maps	O
7	at	O
8	chromosome	O
9	12q22	O
10	-	O
11	q24	O
12	.	O
13	1	O
14	:	O
15	a	O
16	region	O
17	of	O
18	high	O
19	loss	O
20	of	O
21	heterozygosity	O
22	in	O
23	gastric	O
24	cancer	O
25	.	O

1	FOG	B
2	is	O
3	coexpressed	O
4	with	O
5	GATA	B
6	-	I
7	1	I
8	during	O
9	embryonic	O
10	development	O
11	and	O
12	in	O
13	erythroid	O
14	and	O
15	megakaryocytic	O
16	cells	O
17	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	Though	O
2	the	O
3	BACTEC	O
4	9000	O
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O

1	We	O
2	further	O
3	found	O
4	that	O
5	KmMig1p	B
6	is	O
7	fully	O
8	functional	O
9	when	O
10	expressed	O
11	in	O
12	S	O
13	.	O
14	cerevisiae	O
15	.	O

1	A	O
2	pre	O
3	-	O
4	boutonniere	O
5	deformity	O
6	was	O
7	simulated	O
8	by	O
9	dividing	O
10	the	O
11	central	O
12	slip	O
13	.	O

1	Autoimmune	O
2	neutropenia	O
3	(	O
4	AIN	O
5	)	O
6	is	O
7	a	O
8	frequent	O
9	cause	O
10	of	O
11	chronic	O
12	neutropenia	O
13	especially	O
14	in	O
15	youngest	O
16	children	O
17	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	characteristic	O
6	expression	O
7	pattern	O
8	of	O
9	DJ	B
10	protein	I
11	and	O
12	its	O
13	conspicuous	O
14	repeat	O
15	units	O
16	possible	O
17	functional	O
18	roles	O
19	are	O
20	discussed	O
21	.	O

1	Future	O
2	analysis	O
3	of	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	measures	O
9	of	O
10	performance	O
11	with	O
12	the	O
13	implant	O
14	will	O
15	confirm	O
16	or	O
17	dispute	O
18	the	O
19	benefit	O
20	of	O
21	ear	O
22	selection	O
23	using	O
24	the	O
25	Prom	O
26	-	O
27	EABR	O
28	.	O

1	This	O
2	protein	O
3	,	O
4	designated	O
5	p532	B
6	based	O
7	on	O
8	its	O
9	predicted	O
10	molecular	O
11	weight	O
12	(	O
13	EMBO	O
14	J	O
15	15	O
16	:	O
17	5738	O
18	,	O
19	1996	O
20	),	O
21	contains	O
22	multiple	O
23	structural	O
24	domains	O
25	including	O
26	two	O
27	regions	O
28	of	O
29	seven	O
30	internal	O
31	repeats	O
32	highly	O
33	related	O
34	to	O
35	the	O
36	cell	O
37	cycle	O
38	regulator	O
39	RCC1	B
40	,	O
41	a	O
42	guanine	B
43	nucleotide	I
44	exchange	I
45	factor	I
46	for	O
47	the	O
48	small	B
49	GTP	I
50	-	I
51	binding	I
52	protein	I
53	Ran	I
54	,	O
55	seven	O
56	beta	O
57	-	O
58	repeat	O
59	domains	O
60	characteristic	O
61	of	O
62	the	O
63	beta	O
64	subunit	O
65	of	O
66	heterotrimeric	B
67	G	I
68	proteins	I
69	,	O
70	three	O
71	putative	O
72	SH3	B
73	binding	I
74	sites	I
75	,	O
76	a	O
77	putative	O
78	leucine	O
79	-	O
80	zipper	O
81	and	O
82	a	O
83	carboxy	B
84	-	I
85	terminal	I
86	HECT	I
87	domain	I
88	characteristic	O
89	of	O
90	E3	B
91	ubiquitin	I
92	-	I
93	protein	I
94	ligases	I
95	.	O

1	Thus	O
2	,	O
3	the	O
4	L45	O
5	sequence	O
6	between	O
7	kinase	O
8	subdomains	O
9	IV	O
10	and	O
11	V	O
12	specifies	O
13	TGF	B
14	-	I
15	beta	I
16	responsiveness	O
17	of	O
18	the	O
19	type	B
20	I	I
21	receptor	I
22	.	O

1	The	O
2	two	O
3	mouse	O
4	lines	O
5	carrying	O
6	the	O
7	unfragmented	O
8	Hnf3g	B
9	-	O
10	lacZ	B
11	YAC	O
12	showed	O
13	tissue	O
14	-	O
15	specific	O
16	,	O
17	copy	O
18	number	O
19	-	O
20	dependent	O
21	and	O
22	position	O
23	-	O
24	independent	O
25	expression	O
26	,	O
27	proving	O
28	that	O
29	170	O
30	kb	O
31	of	O
32	the	O
33	Hnf3g	B
34	locus	O
35	contain	O
36	all	O
37	elements	O
38	important	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	Hnf3g	B
44	.	O

1	Second	O
2	,	O
3	plasmid	O
4	-	O
5	derived	O
6	transgenes	O
7	and	O
8	gene	O
9	targeting	O
10	of	O
11	the	O
12	endogenous	B
13	Hnf3g	I
14	gene	I
15	locus	I
16	were	O
17	used	O
18	to	O
19	demonstrate	O
20	that	O
21	the	O
22	3	O
23	'-	O
24	flanking	O
25	region	O
26	of	O
27	the	O
28	gene	O
29	is	O
30	necessary	O
31	and	O
32	sufficient	O
33	to	O
34	direct	O
35	reporter	O
36	gene	O
37	expression	O
38	in	O
39	liver	O
40	,	O
41	pancreas	O
42	,	O
43	stomach	O
44	and	O
45	small	O
46	intestine	O
47	.	O

1	This	O
2	regulation	O
3	requires	O
4	two	O
5	HMG	B
6	-	I
7	box	I
8	proteins	I
9	:	O
10	the	O
11	ubiquitous	O
12	Ste11	B
13	transcription	I
14	factor	I
15	and	O
16	the	O
17	M	O
18	cell	O
19	-	O
20	controlling	O
21	protein	O
22	Mat1	B
23	-	I
24	Mc	I
25	.	O

1	Here	O
2	we	O
3	have	O
4	tested	O
5	the	O
6	hypothesis	O
7	that	O
8	the	O
9	short	O
10	transcripts	O
11	,	O
12	or	O
13	proteins	O
14	translated	O
15	from	O
16	the	O
17	short	O
18	transcripts	O
19	,	O
20	are	O
21	also	O
22	required	O
23	for	O
24	respiration	O
25	.	O

1	Upstream	O
2	activating	O
3	sequences	O
4	(	O
5	UASs	O
6	)	O
7	derived	O
8	from	O
9	known	O
10	Ste12p	B
11	-	O
12	dependent	O
13	genes	O
14	have	O
15	previously	O
16	been	O
17	characterized	O
18	to	O
19	require	O
20	either	O
21	multiple	O
22	PREs	O
23	or	O
24	a	O
25	single	O
26	PRE	O
27	coupled	O
28	to	O
29	a	O
30	binding	O
31	site	O
32	for	O
33	a	O
34	second	O
35	protein	O
36	.	O

1	Prominent	O
2	protein	O
3	kinase	O
4	cascades	O
5	are	O
6	those	O
7	that	O
8	activate	O
9	mitogen	B
10	-	I
11	activated	I
12	protein	I
13	(	I
14	MAP	I
15	)	I
16	kinases	I
17	.	O

1	JNK	B
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	O
7	Ras	B
8	-	O
9	related	O
10	G	B
11	proteins	I
12	Rac	I
13	and	O
14	Cdc42	B
15	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	tested	O
7	this	O
8	notion	O
9	by	O
10	using	O
11	ligation	O
12	-	O
13	mediated	O
14	PCR	O
15	to	O
16	assess	O
17	the	O
18	formation	O
19	of	O
20	recombination	B
21	-	I
22	activating	I
23	gene	I
24	(	O
25	RAG	B
26	)-	O
27	dependent	O
28	double	O
29	-	O
30	strand	O
31	breaks	O
32	(	O
33	DSBs	O
34	)	O
35	at	O
36	RSSs	O
37	3	O
38	'	O
39	of	O
40	Ddelta3	B
41	and	O
42	5	O
43	'	O
44	of	O
45	Jdelta1	B
46	.	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	Cbl	B
7	,	O
8	the	O
9	120	O
10	-	O
11	kDa	O
12	protein	O
13	product	O
14	of	O
15	the	O
16	c	B
17	-	I
18	cbl	I
19	proto	I
20	-	I
21	oncogene	I
22	,	O
23	serves	O
24	as	O
25	a	O
26	substrate	O
27	of	O
28	a	O
29	number	O
30	of	O
31	receptor	B
32	-	I
33	coupled	I
34	tyrosine	I
35	kinases	I
36	and	O
37	forms	O
38	complexes	O
39	with	O
40	SH3	B
41	and	O
42	SH2	B
43	domain	O
44	-	O
45	containing	O
46	proteins	O
47	,	O
48	pointing	O
49	to	O
50	its	O
51	role	O
52	in	O
53	signal	O
54	transduction	O
55	.	O

1	Although	O
2	neither	O
3	constitutively	O
4	activated	O
5	MEK	B
6	(	O
7	MEK	B
8	-	I
9	2E	I
10	)	O
11	nor	O
12	v	B
13	-	I
14	Src	I
15	was	O
16	sufficient	O
17	individually	O
18	to	O
19	differentiate	O
20	the	O
21	H19	O
22	-	O
23	7	O
24	cells	O
25	,	O
26	coexpression	O
27	of	O
28	constitutively	O
29	activated	O
30	MEK	B
31	and	O
32	v	B
33	-	I
34	Src	I
35	induced	O
36	neurite	O
37	outgrowth	O
38	.	O

1	This	O
2	mechanism	O
3	is	O
4	in	O
5	contrast	O
6	to	O
7	other	O
8	cases	O
9	of	O
10	splicing	O
11	regulation	O
12	by	O
13	PTB	B
14	,	O
15	in	O
16	which	O
17	the	O
18	protein	O
19	represses	O
20	the	O
21	splice	O
22	site	O
23	to	O
24	which	O
25	it	O
26	binds	O
27	.	O

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O

1	Gal4	B
2	-	O
3	Eed	B
4	fusion	O
5	protein	O
6	represses	O
7	transcription	O
8	of	O
9	a	O
10	reporter	O
11	gene	O
12	driven	O
13	by	O
14	a	O
15	promoter	O
16	that	O
17	contains	O
18	Gal4	B
19	-	I
20	binding	I
21	DNA	I
22	elements	I
23	.	O

1	In	O
2	situ	O
3	hybridization	O
4	analysis	O
5	in	O
6	adult	O
7	rat	O
8	tissue	O
9	reveals	O
10	good	O
11	correlation	O
12	with	O
13	this	O
14	pattern	O
15	and	O
16	indicates	O
17	that	O
18	drm	B
19	mRNA	I
20	is	O
21	most	O
22	highly	O
23	expressed	O
24	in	O
25	nondividing	O
26	and	O
27	terminally	O
28	differentiated	O
29	cells	O
30	,	O
31	such	O
32	as	O
33	neurons	O
34	,	O
35	type	O
36	1	O
37	lung	O
38	cells	O
39	,	O
40	and	O
41	goblet	O
42	cells	O
43	.	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	B
39	-	I
40	complex	I
41	.	O

1	A	O
2	2	O
3	years	O
4	and	O
5	9	O
6	months	O
7	old	O
8	female	O
9	patient	O
10	,	O
11	with	O
12	the	O
13	diagnosis	O
14	of	O
15	Weaver	O
16	syndrome	O
17	is	O
18	reported	O
19	.	O

1	Confirming	O
2	measures	O
3	made	O
4	by	O
5	nurses	O
6	and	O
7	additionally	O
8	,	O
9	ABPM	O
10	for	O
11	women	O
12	,	O
13	seem	O
14	to	O
15	lessen	O
16	this	O
17	effect	O
18	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O

1	(	O
2	1996a	O
3	)	O
4	Biochemistry	O
5	35	O
6	,	O
7	1589	O
8	-	O
9	1598	O
10	].	O

1	Second	O
2	,	O
3	the	O
4	membrane	O
5	expression	O
6	of	O
7	alpha	O
8	and	O
9	beta	O
10	subunits	O
11	was	O
12	mimicked	O
13	by	O
14	cholesterol	O
15	and	O
16	17	O
17	-	O
18	ketocholesterol	O
19	,	O
20	both	O
21	of	O
22	which	O
23	inhibit	O
24	HMG	B
25	-	I
26	CoA	I
27	reductase	I
28	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Lrp	B
6	binds	O
7	a	O
8	central	O
9	palindromic	O
10	site	O
11	,	O
12	interacting	O
13	predominantly	O
14	with	O
15	the	O
16	major	O
17	groove	O
18	of	O
19	its	O
20	DNA	O
21	target	O
22	,	O
23	and	O
24	that	O
25	additional	O
26	dimers	O
27	bind	O
28	to	O
29	flanking	O
30	sites	O
31	to	O
32	form	O
33	a	O
34	nucleoprotein	O
35	activation	O
36	complex	O
37	.	O

1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O

1	The	O
2	remaining	O
3	80	O
4	patients	O
5	underwent	O
6	recordings	O
7	of	O
8	ECG	O
9	,	O
10	beat	O
11	-	O
12	to	O
13	-	O
14	beat	O
15	arterial	O
16	oxygen	O
17	saturation	O
18	(	O
19	SaO2	O
20	),	O
21	and	O
22	respiration	O
23	during	O
24	both	O
25	spontaneous	O
26	and	O
27	controlled	O
28	breathing	O
29	.	O

1	The	O
2	mean	O
3	total	O
4	white	O
5	cell	O
6	count	O
7	increased	O
8	from	O
9	a	O
10	baseline	O
11	of	O
12	11	O
13	.	O
14	3	O
15	x	O
16	10	O
17	(	O
18	9	O
19	)/	O
20	L	O
21	(	O
22	SD	O
23	2	O
24	.	O
25	3	O
26	)	O
27	to	O
28	16	O
29	.	O
30	2	O
31	x	O
32	10	O
33	(	O
34	9	O
35	)/	O
36	L	O
37	(	O
38	SD	O
39	4	O
40	.	O
41	6	O
42	)	O
43	on	O
44	day	O
45	1	O
46	,	O
47	normalising	O
48	thereafter	O
49	.	O

1	A	O
2	prospective	O
3	observational	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	identify	O
9	early	O
10	indicators	O
11	of	O
12	acute	O
13	dengue	O
14	virus	O
15	infection	O
16	.	O

1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	never	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	iris	O
23	.	O

1	These	O
2	lesions	O
3	may	O
4	be	O
5	treated	O
6	by	O
7	propranolol	O
8	or	O
9	phentolamine	O
10	.	O

1	Furthermore	O
2	,	O
3	ICER	B
4	negatively	O
5	autoregulates	O
6	the	O
7	alternative	O
8	promoter	O
9	,	O
10	thus	O
11	generating	O
12	a	O
13	feedback	O
14	loop	O
15	.	O

1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O

1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	B
30	tau	I
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O

1	These	O
2	cells	O
3	fail	O
4	to	O
5	generate	O
6	the	O
7	signals	O
8	to	O
9	phosphorylate	O
10	CREB	B
11	and	O
12	produce	O
13	significantly	O
14	less	O
15	of	O
16	the	O
17	cytokine	O
18	Interleukin	B
19	-	I
20	2	I
21	(	O
22	IL	B
23	-	I
24	2	I
25	)	O
26	in	O
27	response	O
28	to	O
29	agents	O
30	that	O
31	either	O
32	increase	O
33	intracellular	O
34	Ca2	O
35	+	O
36	and	O
37	/	O
38	or	O
39	activate	O
40	protein	B
41	kinase	I
42	C	I
43	.	O

1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	B
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	B
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O

1	CONCLUSIONS	O
2	:	O
3	Valproate	O
4	appears	O
5	to	O
6	inhibit	O
7	the	O
8	glucuronidation	O
9	of	O
10	carbamazepine	O
11	-	O
12	10	O
13	,	O
14	11	O
15	-	O
16	trans	O
17	-	O
18	diol	O
19	,	O
20	and	O
21	probably	O
22	also	O
23	inhibits	O
24	the	O
25	conversion	O
26	of	O
27	carbamazepine	O
28	-	O
29	10	O
30	,	O
31	11	O
32	-	O
33	epoxide	O
34	to	O
35	this	O
36	trans	O
37	-	O
38	diol	O
39	derivative	O
40	,	O
41	rather	O
42	than	O
43	simply	O
44	inhibiting	O
45	the	O
46	latter	O
47	reaction	O
48	only	O
49	.	O

1	The	O
2	Ogg1	B
3	protein	I
4	efficiently	O
5	cleaves	O
6	a	O
7	DNA	O
8	duplex	O
9	where	O
10	a	O
11	preformed	O
12	AP	B
13	site	I
14	is	O
15	placed	O
16	opposite	O
17	a	O
18	cytosine	O
19	(	O
20	AP	O
21	/	O
22	C	O
23	).	O

1	A	O
2	consensus	O
3	sequence	O
4	indicates	O
5	a	O
6	highly	O
7	conserved	O
8	lysine	O
9	residue	O
10	,	O
11	K120	O
12	of	O
13	endonuclease	B
14	III	I
15	or	O
16	K241	O
17	of	O
18	Ogg1	B
19	,	O
20	respectively	O
21	.	O

1	Overall	O
2	,	O
3	these	O
4	findings	O
5	demonstrate	O
6	that	O
7	mutations	O
8	E768D	O
9	and	O
10	V804L	O
11	are	O
12	gain	O
13	-	O
14	of	O
15	-	O
16	function	O
17	mutations	O
18	that	O
19	confer	O
20	to	O
21	the	O
22	long	B
23	RET	I
24	isoform	I
25	the	O
26	capacity	O
27	to	O
28	exert	O
29	a	O
30	biological	O
31	effect	O
32	,	O
33	although	O
34	these	O
35	mutations	O
36	are	O
37	more	O
38	weakly	O
39	activating	O
40	than	O
41	the	O
42	MEN2A	B
43	and	O
44	MEN2B	B
45	mutations	O
46	.	O

1	Volunteers	O
2	were	O
3	irradiated	O
4	on	O
5	their	O
6	backs	O
7	with	O
8	suberythemal	O
9	UV	O
10	daily	O
11	for	O
12	5	O
13	d	O
14	after	O
15	application	O
16	of	O
17	the	O
18	sunscreens	O
19	and	O
20	their	O
21	base	O
22	lotion	O
23	to	O
24	different	O
25	sites	O
26	.	O

1	E2F	B
2	is	O
3	a	O
4	heterodimeric	O
5	complex	O
6	consisting	O
7	of	O
8	E2F	B
9	family	I
10	members	I
11	(	I
12	1	I
13	-	I
14	5	I
15	)	I
16	and	O
17	DP	O
18	proteins	O
19	(	O
20	1	O
21	-	O
22	3	O
23	).	O

1	EBER1	B
2	mRNA	I
3	,	O
4	a	O
5	consistent	O
6	marker	O
7	of	O
8	viral	O
9	latency	O
10	,	O
11	was	O
12	positive	O
13	in	O
14	all	O
15	PEL	O
16	cases	O
17	,	O
18	although	O
19	at	O
20	lower	O
21	levels	O
22	than	O
23	in	O
24	the	O
25	non	O
26	-	O
27	PEL	O
28	controls	O
29	due	O
30	to	O
31	EBER1	B
32	expression	O
33	by	O
34	only	O
35	a	O
36	variable	O
37	subset	O
38	of	O
39	lymphoma	O
40	cells	O
41	.	O

1	METHODS	O
2	:	O
3	Four	O
4	hundred	O
5	fifty	O
6	patients	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	squamous	O
12	cell	O
13	carcinoma	O
14	of	O
15	the	O
16	oral	O
17	cavity	O
18	received	O
19	their	O
20	primary	O
21	treatment	O
22	at	O
23	Roswell	O
24	Park	O
25	Cancer	O
26	Center	O
27	(	O
28	RPCI	O
29	)	O
30	from	O
31	1971	O
32	to	O
33	1991	O
34	.	O

1	Therefore	O
2	,	O
3	use	O
4	of	O
5	presaturation	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	cine	O
14	PC	O
15	velocity	O
16	data	O
17	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	MADS	B
17	domains	I
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	MADS	B
48	domain	O
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O

1	PURPOSE	O
2	/	O
3	OBJECTIVES	O
4	:	O
5	To	O
6	examine	O
7	the	O
8	question	O
9	of	O
10	whether	O
11	an	O
12	early	O
13	first	O
14	full	O
15	-	O
16	term	O
17	pregnancy	O
18	(	O
19	FFTP	O
20	)	O
21	protects	O
22	against	O
23	breast	O
24	cancer	O
25	and	O
26	whether	O
27	interruption	O
28	of	O
29	the	O
30	pregnancy	O
31	with	O
32	an	O
33	induced	O
34	abortion	O
35	increases	O
36	breast	O
37	cancer	O
38	risk	O
39	.	O

1	Two	O
2	related	O
3	studies	O
4	conducted	O
5	over	O
6	a	O
7	five	O
8	week	O
9	period	O
10	measured	O
11	and	O
12	typed	O
13	HLA	B
14	-	I
15	DQA1	I
16	from	O
17	accumulated	O
18	DNA	O
19	on	O
20	autopsy	O
21	room	O
22	and	O
23	Forensic	O
24	DNA	O
25	Laboratory	O
26	structures	O
27	.	O

1	Thirty	O
2	-	O
3	two	O
4	rats	O
5	were	O
6	divided	O
7	into	O
8	four	O
9	groups	O
10	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	pecT	B
5	regulatory	O
6	region	O
7	revealed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	sites	O
13	in	O
14	which	O
15	insertions	O
16	reproduced	O
17	the	O
18	pec	B
19	-	I
20	1	I
21	phenotype	O
22	.	O

1	BRCA1	B
2	,	O
3	a	O
4	familial	O
5	breast	O
6	and	O
7	ovarian	O
8	cancer	O
9	susceptibility	O
10	gene	O
11	encodes	O
12	nuclear	O
13	phosphoproteins	O
14	that	O
15	function	O
16	as	O
17	tumor	O
18	suppressors	O
19	in	O
20	human	O
21	breast	O
22	cancer	O
23	cells	O
24	.	O

1	The	O
2	alternative	O
3	splice	O
4	sites	O
5	for	O
6	the	O
7	smallest	O
8	adducin	B
9	isoform	O
10	,	O
11	beta	B
12	-	I
13	3	I
14	,	O
15	are	O
16	alternative	O
17	donor	O
18	and	O
19	acceptor	O
20	sites	O
21	within	O
22	exons	O
23	7	O
24	and	O
25	12	O
26	.	O

1	Proteinuria	O
2	in	O
3	a	O
4	young	O
5	man	O
6	.	O

1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O

1	Two	O
2	new	O
3	temperature	O
4	-	O
5	sensitive	O
6	alleles	O
7	of	O
8	SEC3	B
9	,	O
10	1	O
11	of	O
12	10	O
13	late	O
14	-	O
15	acting	O
16	SEC	B
17	genes	I
18	required	O
19	for	O
20	targeting	O
21	or	O
22	fusion	O
23	of	O
24	post	O
25	-	O
26	Golgi	O
27	secretory	O
28	vesicles	O
29	to	O
30	the	O
31	plasma	O
32	membrane	O
33	in	O
34	Saccharomyces	O
35	cerevisiae	O
36	,	O
37	were	O
38	isolated	O
39	in	O
40	a	O
41	screen	O
42	for	O
43	temperature	O
44	-	O
45	sensitive	O
46	secretory	O
47	mutants	O
48	that	O
49	are	O
50	synthetically	O
51	lethal	O
52	with	O
53	sec4	B
54	-	I
55	8	I
56	.	O

1	Five	O
2	cell	O
3	strains	O
4	of	O
5	human	O
6	dermal	O
7	fibroblasts	O
8	were	O
9	each	O
10	treated	O
11	with	O
12	three	O
13	samples	O
14	of	O
15	burn	O
16	blister	O
17	fluid	O
18	and	O
19	the	O
20	effect	O
21	compared	O
22	with	O
23	the	O
24	rate	O
25	of	O
26	contraction	O
27	of	O
28	free	O
29	floating	O
30	fibroblast	O
31	populated	O
32	collagen	B
33	lattices	O
34	(	O
35	FPCL	O
36	).	O

1	It	O
2	is	O
3	thus	O
4	one	O
5	of	O
6	the	O
7	key	O
8	enzymes	O
9	involved	O
10	in	O
11	the	O
12	triiodothyronine	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	growth	O
18	,	O
19	differentiation	O
20	and	O
21	basal	O
22	metabolism	O
23	in	O
24	vertebrates	O
25	.	O

1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O

1	Twenty	O
2	-	O
3	one	O
4	ELISA	O
5	-	O
6	positive	O
7	sera	O
8	were	O
9	tested	O
10	and	O
11	confirmed	O
12	positive	O
13	by	O
14	plaque	O
15	reduction	O
16	neutralization	O
17	testing	O
18	.	O

1	Patients	O
2	received	O
3	either	O
4	diltiazem	O
5	CD	O
6	180	O
7	mg	O
8	or	O
9	placebo	O
10	once	O
11	/	O
12	day	O
13	in	O
14	combination	O
15	with	O
16	existing	O
17	antianginal	O
18	therapy	O
19	.	O

1	Reactive	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O

1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	O
12	nucleotide	O
13	resolution	O
14	along	O
15	the	O
16	human	B
17	JUN	I
18	gene	I
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	O
25	efficient	O
26	repair	O
27	of	O
28	sequences	O
29	near	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O

1	Tyrosine	O
2	1356	O
3	forms	O
4	a	O
5	multisubstrate	O
6	binding	O
7	site	O
8	for	O
9	the	O
10	Grb2	B
11	and	O
12	Shc	B
13	adaptor	I
14	proteins	I
15	,	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'-	I
23	kinase	I
24	,	O
25	phospholipase	B
26	Cgamma	I
27	,	O
28	and	O
29	a	O
30	phosphatase	O
31	,	O
32	SHP2	B
33	.	O

1	Then	O
2	we	O
3	correlated	O
4	HRCT	O
5	findings	O
6	with	O
7	the	O
8	clinical	O
9	features	O
10	,	O
11	pulmonary	O
12	functions	O
13	and	O
14	methacholine	O
15	PC20	O
16	(	O
17	PC20M	O
18	)	O
19	and	O
20	studied	O
21	their	O
22	clinical	O
23	significance	O
24	.	O

1	Gtx	B
2	mRNA	I
3	accumulates	O
4	in	O
5	parallel	O
6	with	O
7	the	O
8	RNAs	O
9	encoding	O
10	the	O
11	major	O
12	structural	O
13	proteins	O
14	of	O
15	myelin	O
16	,	O
17	myelin	B
18	basic	I
19	protein	I
20	(	O
21	MBP	B
22	),	O
23	and	O
24	proteolipid	B
25	protein	I
26	(	O
27	PLP	B
28	)	O
29	during	O
30	postnatal	O
31	brain	O
32	development	O
33	;	O
34	Gtx	B
35	mRNA	I
36	decreases	O
37	in	O
38	parallel	O
39	with	O
40	MBP	B
41	and	O
42	PLP	B
43	mRNAs	I
44	in	O
45	the	O
46	brains	O
47	of	O
48	myelin	O
49	-	O
50	deficient	O
51	rats	O
52	,	O
53	which	O
54	have	O
55	a	O
56	point	O
57	mutation	O
58	in	O
59	the	O
60	PLP	B
61	gene	I
62	.	O

1	Contacts	O
2	between	O
3	Bacillus	O
4	subtilis	O
5	catabolite	O
6	regulatory	O
7	protein	O
8	CcpA	B
9	and	O
10	amyO	B
11	target	O
12	site	O
13	.	O

1	They	O
2	also	O
3	interact	O
4	with	O
5	GTPase	B
6	activating	I
7	proteins	I
8	encoded	O
9	by	O
10	IRA1	B
11	and	O
12	IRA2	B
13	.	O

1	For	O
2	E2	O
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	itraconazole	O
25	/	O
26	kg	O
27	(	O
28	capsules	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O

1	RESULTS	O
2	:	O
3	For	O
4	E1	O
5	,	O
6	itraconazole	O
7	plasma	O
8	drug	O
9	concentration	O
10	extrapolated	O
11	to	O
12	time	O
13	zero	O
14	(	O
15	IV	O
16	dose	O
17	)	O
18	was	O
19	5	O
20	.	O
21	2	O
22	+/-	O
23	1	O
24	.	O
25	4	O
26	micrograms	O
27	/	O
28	ml	O
29	,	O
30	and	O
31	mean	O
32	residence	O
33	time	O
34	(	O
35	MRT	O
36	)	O
37	was	O
38	37	O
39	+/-	O
40	16	O
41	hours	O
42	.	O

1	The	O
2	human	O
3	U4	B
4	/	O
5	U6	B
6	snRNP	O
7	contains	O
8	60	O
9	and	O
10	90kD	O
11	proteins	O
12	that	O
13	are	O
14	structurally	O
15	homologous	O
16	to	O
17	the	O
18	yeast	O
19	splicing	O
20	factors	O
21	Prp4p	B
22	and	O
23	Prp3p	B
24	.	O

1	G	B
2	-	I
3	CSF	I
4	was	O
5	started	O
6	on	O
7	day	O
8	3	O
9	of	O
10	each	O
11	cycle	O
12	(	O
13	5	O
14	microg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	was	O
22	stopped	O
23	the	O
24	day	O
25	before	O
26	the	O
27	last	O
28	apheresis	O
29	or	O
30	when	O
31	absolute	O
32	neutrophil	O
33	count	O
34	was	O
35	above	O
36	0	O
37	.	O
38	5	O
39	x	O
40	10	O
41	(	O
42	9	O
43	)/	O
44	l	O
45	.	O

1	The	O
2	used	O
3	expression	O
4	system	O
5	could	O
6	allow	O
7	to	O
8	produce	O
9	mutated	O
10	forms	O
11	of	O
12	SsEF	B
13	-	I
14	2	I
15	obtained	O
16	by	O
17	mutagenesis	O
18	of	O
19	the	O
20	corresponding	O
21	gene	O
22	.	O

1	Crosstalk	O
2	among	O
3	the	O
4	pathways	O
5	may	O
6	explain	O
7	how	O
8	some	O
9	forms	O
10	of	O
11	stress	O
12	can	O
13	contribute	O
14	to	O
15	the	O
16	development	O
17	of	O
18	a	O
19	malignancy	O
20	.	O

1	Supershift	O
2	assays	O
3	,	O
4	using	O
5	Jun	B
6	and	I
7	Fos	I
8	family	I
9	member	I
10	-	I
11	specific	I
12	antibodies	I
13	,	O
14	showed	O
15	that	O
16	protein	O
17	complexes	O
18	formed	O
19	by	O
20	AtT	O
21	-	O
22	20	O
23	cell	O
24	nuclear	O
25	extracts	O
26	bound	O
27	to	O
28	the	O
29	c	B
30	-	I
31	jun	I
32	AP	I
33	-	I
34	1	I
35	site	I
36	were	O
37	comprised	O
38	of	O
39	Jun	B
40	family	O
41	members	O
42	,	O
43	JunD	B
44	,	O
45	JunB	B
46	,	O
47	and	O
48	cJun	B
49	.	O

1	The	O
2	majority	O
3	of	O
4	PI	B
5	kinase	I
6	activity	O
7	appeared	O
8	to	O
9	be	O
10	cbl	B
11	-	O
12	associated	O
13	after	O
14	PRL	B
15	stimulation	O
16	.	O

1	Mutation	O
2	of	O
3	Enh4	B
4	,	O
5	an	O
6	essential	O
7	GT	B
8	-	I
9	IIC	I
10	-	I
11	like	I
12	enhanson	I
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	B
28	-	I
29	IIC	I
30	enhansons	I
31	mimic	O
32	the	O
33	intact	O
34	CSEn	B
35	enhancer	I
36	/	I
37	silencer	I
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O

1	Using	O
2	lectin	B
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	discordance	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	SSBP	B
17	and	O
18	DSBP	B
19	was	O
20	demonstrated	O
21	.	O

1	Deletion	O
2	mapping	O
3	experiments	O
4	determined	O
5	that	O
6	the	O
7	sequences	O
8	required	O
9	for	O
10	full	O
11	activity	O
12	in	O
13	MSC	O
14	-	O
15	1	O
16	cells	O
17	were	O
18	included	O
19	within	O
20	619	O
21	bp	O
22	of	O
23	the	O
24	start	O
25	site	O
26	and	O
27	identified	O
28	several	O
29	regions	O
30	that	O
31	demonstrated	O
32	increased	O
33	luciferase	B
34	activity	O
35	:	O
36	the	O
37	-	O
38	583	O
39	bp	O
40	to	O
41	-	O
42	564	O
43	bp	O
44	,	O
45	-	O
46	503	O
47	bp	O
48	to	O
49	-	O
50	484	O
51	bp	O
52	,	O
53	and	O
54	-	O
55	114	O
56	bp	O
57	to	O
58	-	O
59	65	O
60	regions	O
61	.	O

1	Furthermore	O
2	,	O
3	the	O
4	PH	B
5	and	O
6	PTB	O
7	domains	O
8	are	O
9	highly	O
10	homologous	O
11	(	O
12	at	O
13	least	O
14	40	O
15	%	O
16	identical	O
17	)	O
18	to	O
19	those	O
20	found	O
21	in	O
22	insulin	B
23	receptor	I
24	substrates	I
25	1	I
26	,	I
27	2	I
28	,	I
29	and	I
30	3	I
31	(	O
32	IRS	B
33	-	I
34	1	I
35	,	O
36	IRS	B
37	-	I
38	2	I
39	,	O
40	and	O
41	IRS	B
42	-	I
43	3	I
44	).	O

1	The	O
2	mouse	O
3	extracellular	B
4	signal	I
5	-	I
6	regulated	I
7	kinase	I
8	2	I
9	gene	I
10	.	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	B
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	B
27	-	I
28	Y	I
29	.	O

1	MR	O
2	imaging	O
3	of	O
4	traumatic	O
5	head	O
6	injuries	O
7	using	O
8	FLAIR	O
9	technique	O

1	Gag	B
2	protein	O
3	sequence	O
4	motifs	O
5	of	O
6	the	O
7	NC	B
8	domain	I
9	of	O
10	primate	O
11	foamy	O
12	viruses	O
13	assumed	O
14	to	O
15	be	O
16	involved	O
17	in	O
18	genome	O
19	encapsidation	O
20	are	O
21	not	O
22	conserved	O
23	in	O
24	FeFV	O
25	.	O

1	Induction	O
2	of	O
3	B	O
4	cell	O
5	apoptosis	O
6	by	O
7	co	O
8	-	O
9	cross	O
10	-	O
11	linking	O
12	CD23	B
13	and	O
14	sIg	B
15	involves	O
16	aberrant	O
17	regulation	O
18	of	O
19	c	B
20	-	I
21	myc	I
22	and	O
23	is	O
24	inhibited	O
25	by	O
26	bcl	B
27	-	I
28	2	I
29	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	theoretical	O
6	models	O
7	for	O
8	the	O
9	Gla	O
10	and	O
11	EGF	B
12	-	I
13	1	I
14	modules	I
15	of	O
16	human	B
17	PS	I
18	constructed	O
19	using	O
20	prothrombin	B
21	and	O
22	factor	B
23	X	I
24	experimental	O
25	structures	O
26	.	O

1	The	O
2	Cut9	B
3	subunit	I
4	is	O
5	likely	O
6	to	O
7	be	O
8	a	O
9	target	O
10	for	O
11	regulating	O
12	APC	B
13	/	I
14	cyclosome	I
15	function	O
16	through	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	and	O
22	phosphorylation	O
23	.	O

1	The	O
2	dose	O
3	was	O
4	50	O
5	Gy	O
6	/	O
7	20	O
8	fractions	O
9	/	O
10	5	O
11	weeks	O
12	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	B
30	mutants	I
31	.	O

1	All	O
2	the	O
3	women	O
4	received	O
5	13	O
6	.	O
7	5	O
8	mg	O
9	plain	O
10	bupivacaine	O
11	via	O
12	subarachnoid	O
13	injection	O
14	at	O
15	the	O
16	L2	O
17	-	O
18	3	O
19	interspace	O
20	.	O

1	Far	O
2	from	O
3	this	O
4	being	O
5	the	O
6	case	O
7	,	O
8	however	O
9	,	O
10	the	O
11	measurement	O
12	of	O
13	apo	B
14	B	I
15	has	O
16	met	O
17	every	O
18	reasonable	O
19	standard	O
20	of	O
21	laboratory	O
22	precision	O
23	and	O
24	reliability	O
25	to	O
26	allow	O
27	its	O
28	widespread	O
29	introduction	O
30	in	O
31	clinical	O
32	laboratories	O
33	.	O

1	Two	O
2	soybean	O
3	cDNA	O
4	clones	O
5	,	O
6	SPK	B
7	-	I
8	3	I
9	and	O
10	SPK	B
11	-	I
12	4	I
13	,	O
14	encoding	O
15	putative	O
16	protein	O
17	kinases	O
18	were	O
19	isolated	O
20	and	O
21	characterized	O
22	.	O

1	Genes	O
2	belonging	O
3	to	O
4	the	O
5	ras	B
6	superfamily	I
7	encode	O
8	low	B
9	-	I
10	molecular	I
11	-	I
12	weight	I
13	GTP	I
14	/	I
15	GDP	I
16	-	I
17	binding	I
18	proteins	I
19	that	O
20	are	O
21	highly	O
22	conserved	O
23	in	O
24	wide	O
25	variety	O
26	of	O
27	organisms	O
28	.	O

1	Naltrexone	O
2	has	O
3	been	O
4	recently	O
5	approved	O
6	by	O
7	the	O
8	Food	O
9	and	O
10	Drug	O
11	Administration	O
12	for	O
13	the	O
14	treatment	O
15	of	O
16	alcohol	O
17	dependence	O
18	.	O

1	Ent	B
2	-	I
3	kaurene	I
4	synthase	I
5	from	I
6	the	I
7	fungus	I
8	Phaeosphaeria	I
9	sp	O
10	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	B
12	functional	I
13	domains	I
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	B
20	polymerase	I
21	II	I
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O

1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	B
10	up	I
11	-	I
12	regulated	I
13	during	I
14	death	I
15	(	I
16	mud	I
17	)-	I
18	1	I
19	-	I
20	8	I
21	.	O

1	The	O
2	position	O
3	,	O
4	transcription	O
5	orientation	O
6	,	O
7	and	O
8	imprinted	O
9	status	O
10	of	O
11	the	O
12	genes	O
13	immediately	O
14	flanking	O
15	Igf2r	B
16	have	O
17	been	O
18	assessed	O
19	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	directional	O
6	chromosome	O
7	walking	O
8	studies	O
9	starting	O
10	from	O
11	D8S260	B
12	as	O
13	well	O
14	as	O
15	D8S285	B
16	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	B
6	finger	I
7	protein	I
8	,	O
9	dsRBP	B
10	-	I
11	ZFa	I
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	retroplasmid	O
7	reverse	B
8	transcriptase	I
9	is	O
10	uniquely	O
11	adapted	O
12	to	O
13	initiate	O
14	cDNA	O
15	synthesis	O
16	by	O
17	recognizing	O
18	a	O
19	3	O
20	'	O
21	CCA	O
22	sequence	O
23	.	O

1	Nasal	O
2	absorption	O
3	was	O
4	rapid	O
5	,	O
6	nasal	O
7	bioavailability	O
8	was	O
9	43	O
10	%,	O
11	and	O
12	the	O
13	iv	O
14	and	O
15	nasal	O
16	elimination	O
17	profiles	O
18	were	O
19	similar	O
20	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	ATF3	B
19	/	O
20	c	B
21	-	I
22	Jun	I
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	JunD	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	support	O
6	a	O
7	model	O
8	in	O
9	which	O
10	Tax	B
11	anchors	O
12	CBP	B
13	to	O
14	the	O
15	HTLV	B
16	-	I
17	1	I
18	promoter	I
19	,	O
20	with	O
21	strong	O
22	transcriptional	O
23	activation	O
24	resulting	O
25	from	O
26	the	O
27	CBP	B
28	-	O
29	associated	O
30	activities	O
31	of	O
32	nucleosome	O
33	remodeling	O
34	and	O
35	recruitment	O
36	of	O
37	the	O
38	general	O
39	transcription	O
40	machinery	O
41	.	O

1	DNase	B
2	I	I
3	and	O
4	1	O
5	,	O
6	10	O
7	-	O
8	phenanthroline	O
9	-	O
10	copper	O
11	footprinting	O
12	of	O
13	MURA	B
14	-	O
15	Mu1	B
16	TIR	O
17	complexes	O
18	indicate	O
19	that	O
20	MURA	B
21	binds	O
22	to	O
23	a	O
24	conserved	O
25	approximately	O
26	32	O
27	-	O
28	bp	O
29	region	O
30	in	O
31	the	O
32	TIR	O
33	of	O
34	Mu1	B
35	.	O

1	Consistent	O
2	with	O
3	this	O
4	model	O
5	,	O
6	a	O
7	synthetic	O
8	construct	O
9	containing	O
10	three	O
11	tandem	O
12	copies	O
13	of	O
14	the	O
15	native	O
16	LDL	B
17	receptor	I
18	SREBP	I
19	site	O
20	linked	O
21	to	O
22	a	O
23	single	O
24	Sp1	B
25	site	I
26	was	O
27	also	O
28	significantly	O
29	activated	O
30	in	O
31	a	O
32	buttonhead	B
33	-	O
34	independent	O
35	fashion	O
36	.	O

1	Various	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	reproduces	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	E2F2	B
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O

1	In	O
2	the	O
3	adult	O
4	mouse	O
5	,	O
6	ERR	B
7	alpha	I
8	is	O
9	most	O
10	highly	O
11	expressed	O
12	in	O
13	kidney	O
14	,	O
15	heart	O
16	,	O
17	and	O
18	brown	O
19	adipocytes	O
20	,	O
21	tissues	O
22	which	O
23	preferentially	O
24	metabolize	O
25	fatty	O
26	acids	O
27	.	O

1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	B
18	alpha	I
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	The	O
2	complete	O
3	response	O
4	(	O
5	CR	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	CODE	O
14	with	O
15	rhG	B
16	-	I
17	CSF	I
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	CODE	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	004	O
48	).	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	A1	I
5	binds	O
6	to	O
7	the	O
8	transcription	O
9	-	O
10	regulatory	O
11	region	O
12	of	O
13	mouse	O
14	hepatitis	O
15	virus	O
16	RNA	O
17	.	O

1	The	O
2	m7GpppN	O
3	cap	O
4	structure	O
5	of	O
6	eukaryotic	O
7	mRNA	O
8	is	O
9	formed	O
10	cotranscriptionally	O
11	by	O
12	the	O
13	sequential	O
14	action	O
15	of	O
16	three	O
17	enzymes	O
18	:	O
19	RNA	B
20	triphosphatase	I
21	,	O
22	RNA	B
23	guanylyltransferase	I
24	,	O
25	and	O
26	RNA	B
27	(	I
28	guanine	I
29	-	I
30	7	I
31	)-	I
32	methyltransferase	I
33	.	O

1	In	O
2	the	O
3	first	O
4	part	O
5	of	O
6	our	O
7	study	O
8	,	O
9	the	O
10	highest	O
11	mutagenicity	O
12	was	O
13	revealed	O
14	by	O
15	TA98	O
16	strain	O
17	without	O
18	enzymatic	O
19	activation	O
20	,	O
21	suggesting	O
22	a	O
23	direct	O
24	-	O
25	acting	O
26	mutagenicity	O
27	prevalence	O
28	in	O
29	diesel	O
30	particulate	O
31	.	O

1	The	O
2	addition	O
3	of	O
4	culture	O
5	to	O
6	the	O
7	CC	O
8	and	O
9	CC	O
10	:	O
11	SW	O
12	by	O
13	-	O
14	products	O
15	resulted	O
16	in	O
17	pH	O
18	values	O
19	lower	O
20	(	O
21	P	O
22	<	O
23	0	O
24	.	O
25	05	O
26	)	O
27	than	O
28	those	O
29	without	O
30	culture	O
31	on	O
32	Day	O
33	21	O
34	,	O
35	and	O
36	the	O
37	15	O
38	%	O
39	carbohydrate	O
40	treatment	O
41	significantly	O
42	reduced	O
43	pH	O
44	beyond	O
45	the	O
46	5	O
47	%	O
48	carbohydrate	O
49	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	Two	O
2	experiments	O
3	(	O
4	N	O
5	=	O
6	20	O
7	each	O
8	)	O
9	were	O
10	carried	O
11	out	O
12	to	O
13	explore	O
14	the	O
15	nature	O
16	of	O
17	ERP	O
18	negativities	O
19	in	O
20	a	O
21	visuospatial	O
22	memory	O
23	task	O
24	and	O
25	in	O
26	an	O
27	auditory	O
28	spatial	O
29	memory	O
30	task	O
31	,	O
32	respectively	O
33	.	O

1	Biol	O
2	.	O

1	The	O
2	pattern	O
3	and	O
4	timing	O
5	of	O
6	CARP	B
7	mRNA	I
8	expression	O
9	,	O
10	including	O
11	transient	O
12	expression	O
13	in	O
14	the	O
15	tongue	O
16	at	O
17	14	O
18	.	O
19	5	O
20	days	O
21	p	O
22	.	O
23	c	O
24	.,	O
25	coincides	O
26	with	O
27	that	O
28	of	O
29	Nkx2	B
30	.	I
31	5	I
32	/	O
33	Csx	B
34	(	O
35	a	O
36	putative	O
37	homolog	O
38	of	O
39	tinman	B
40	,	O
41	the	O
42	Drosophila	O
43	melanogaster	O
44	gene	O
45	responsible	O
46	for	O
47	cardiac	O
48	development	O
49	).	O

1	Overexpression	O
2	of	O
3	CARP	B
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	B
8	troponin	I
9	C	I
10	and	O
11	atrial	B
12	natriuretic	I
13	factor	I
14	transcription	O
15	.	O

1	Substrate	O
2	specificity	O
3	of	O
4	the	O
5	RNase	B
6	activity	O
7	of	O
8	yeast	B
9	RNA	I
10	polymerase	I
11	III	I
12	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	I
18	.	O

1	Examination	O
2	of	O
3	the	O
4	MMP	B
5	-	I
6	2	I
7	RE1	I
8	sequence	I
9	revealed	O
10	an	O
11	incomplete	O
12	Y	O
13	-	O
14	box	O
15	sequence	O
16	(	O
17	CTGCTGGGCAAG	O
18	),	O
19	which	O
20	specifically	O
21	interacted	O
22	with	O
23	recombinant	B
24	YB	I
25	-	I
26	1	I
27	on	O
28	DMS	O
29	protection	O
30	footprinting	O
31	analysis	O
32	.	O

1	Hence	O
2	,	O
3	scs32	B
4	only	O
5	partially	O
6	suppressed	O
7	the	O
8	ts	O
9	phenotype	O
10	and	O
11	was	O
12	unable	O
13	to	O
14	suppress	O
15	the	O
16	Ino	O
17	-	O
18	phenotype	O
19	of	O
20	rpo26	B
21	-	I
22	31	I
23	.	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	Sp1	B
6	and	O
7	ETS	B
8	proteins	I
9	are	O
10	required	O
11	to	O
12	bring	O
13	about	O
14	full	O
15	promoter	O
16	activity	O
17	in	O
18	the	O
19	Surf	B
20	-	I
21	1	I
22	direction	O
23	.	O

1	CONCLUSION	O
2	:	O
3	Patients	O
4	wit	O
5	clinically	O
6	palpable	O
7	neck	O
8	disease	O
9	(	O
10	N1	O
11	-	O
12	3	O
13	),	O
14	histological	O
15	evidence	O
16	of	O
17	metastatic	O
18	nodal	O
19	disease	O
20	,	O
21	extracapsular	O
22	spread	O
23	,	O
24	and	O
25	three	O
26	or	O
27	more	O
28	positive	O
29	lymph	O
30	nodes	O
31	are	O
32	at	O
33	greater	O
34	risk	O
35	of	O
36	developing	O
37	failure	O
38	at	O
39	distant	O
40	sites	O
41	.	O

1	We	O
2	have	O
3	subcloned	O
4	into	O
5	pBR322	O
6	deoxyribonucleic	O
7	acid	O
8	(	O
9	DNA	O
10	)	O
11	sequences	O
12	mapping	O
13	either	O
14	in	O
15	the	O
16	coding	O
17	region	O
18	,	O
19	the	O
20	5	O
21	'	O
22	spacer	O
23	,	O
24	or	O
25	the	O
26	3	O
27	'	O
28	spacer	O
29	of	O
30	the	O
31	H2B	B
32	histone	I
33	gene	I
34	.	O

1	4	O
2	.	O

1	Area	O
2	under	O
3	the	O
4	drug	O
5	concentration	O
6	-	O
7	time	O
8	curves	O
9	(	O
10	AUC0	O
11	-	O
12	24	O
13	hr	O
14	)	O
15	for	O
16	MTX	O
17	were	O
18	2379	O
19	and	O
20	3534	O
21	ng	O
22	*	O
23	hr	O
24	/	O
25	ml	O
26	from	O
27	PG	O
28	-	O
29	2	O
30	.	O
31	5	O
32	%	O
33	Azone	O
34	and	O
35	PG	O
36	-	O
37	7	O
38	.	O
39	5	O
40	%	O
41	Azone	O
42	systems	O
43	respectively	O
44	.	O

1	The	O
2	combination	O
3	of	O
4	hydralazine	O
5	hydrochloride	O
6	and	O
7	isosorbide	O
8	dinitrate	O
9	also	O
10	improves	O
11	survival	O
12	,	O
13	but	O
14	direct	O
15	comparison	O
16	of	O
17	both	O
18	regimens	O
19	provided	O
20	evidence	O
21	for	O
22	a	O
23	less	O
24	favourable	O
25	effect	O
26	than	O
27	that	O
28	of	O
29	the	O
30	ACE	B
31	inhibitors	O
32	.	O

1	To	O
2	address	O
3	mechanisms	O
4	that	O
5	define	O
6	interactions	O
7	of	O
8	Site	B
9	II	I
10	regulatory	I
11	factors	I
12	with	O
13	this	O
14	cell	O
15	cycle	O
16	control	O
17	element	O
18	,	O
19	we	O
20	have	O
21	investigated	O
22	these	O
23	determinants	O
24	of	O
25	transcriptional	O
26	regulation	O
27	at	O
28	the	O
29	G1	O
30	/	O
31	S	O
32	phase	O
33	transition	O
34	in	O
35	FDC	O
36	-	O
37	P1	O
38	hematopoietic	O
39	progenitor	O
40	cells	O
41	.	O

1	The	O
2	goal	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	identify	O
9	neuronal	O
10	cell	O
11	cultures	O
12	that	O
13	express	O
14	RC3	B
15	/	O
16	neurogranin	B
17	,	O
18	to	O
19	check	O
20	whether	O
21	they	O
22	are	O
23	sensitive	O
24	to	O
25	T3	O
26	,	O
27	and	O
28	to	O
29	examine	O
30	the	O
31	mechanism	O
32	of	O
33	regulation	O
34	.	O

1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	Their	O
2	circadian	O
3	responses	O
4	to	O
5	both	O
6	photic	O
7	and	O
8	non	O
9	-	O
10	photic	O
11	cues	O
12	were	O
13	then	O
14	tested	O
15	.	O

1	Although	O
2	previous	O
3	data	O
4	have	O
5	suggested	O
6	that	O
7	Rev	B
8	uses	O
9	the	O
10	same	O
11	export	O
12	pathway	O
13	as	O
14	uracil	O
15	-	O
16	rich	O
17	small	O
18	nuclear	O
19	RNAs	O
20	and	O
21	5S	B
22	ribosomal	I
23	RNA	I
24	,	O
25	the	O
26	CTE	O
27	seems	O
28	to	O
29	interact	O
30	with	O
31	evolutionarily	O
32	conserved	O
33	factors	O
34	that	O
35	are	O
36	essential	O
37	for	O
38	cellular	O
39	mRNA	O
40	export	O
41	.	O

1	Human	B
2	Duo	I
3	contains	O
4	a	O
5	guanine	B
6	nucleotide	I
7	exchange	I
8	factor	I
9	(	O
10	GEF	B
11	)	O
12	domain	O
13	that	O
14	is	O
15	likely	O
16	to	O
17	be	O
18	rac1	B
19	-	O
20	specific	O
21	,	O
22	a	O
23	pleckstrin	B
24	homology	I
25	(	O
26	PH	B
27	)	O
28	domain	O
29	and	O
30	spectrin	B
31	-	I
32	like	I
33	repeat	I
34	units	I
35	.	O

1	S2F	B
2	,	O
3	a	O
4	leaf	O
5	-	O
6	specific	O
7	trans	O
8	-	O
9	acting	O
10	factor	O
11	,	O
12	binds	O
13	to	O
14	a	O
15	novel	O
16	cis	O
17	-	O
18	acting	O
19	element	O
20	and	O
21	differentially	O
22	activates	O
23	the	O
24	RPL21	B
25	gene	I
26	.	O

1	ArgR	B
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O

1	Plasma	B
2	leptin	I
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O

1	Consistent	O
2	with	O
3	effects	O
4	on	O
5	STAT	B
6	activation	O
7	,	O
8	altered	O
9	SHP	B
10	-	I
11	1	I
12	expression	O
13	also	O
14	affected	O
15	EGF	B
16	-	O
17	induced	O
18	activation	O
19	of	O
20	the	O
21	mitogen	B
22	-	I
23	activated	I
24	protein	I
25	kinase	I
26	pathway	O
27	;	O
28	expression	O
29	of	O
30	SHP	B
31	-	I
32	1	I
33	-(	I
34	Cys	I
35	-->	I
36	Ser	I
37	)	I
38	inhibited	O
39	activity	O
40	of	O
41	MEK	B
42	by	O
43	approximately	O
44	25	O
45	%,	O
46	whereas	O
47	expression	O
48	of	O
49	SHP	B
50	-	I
51	1	I
52	resulted	O
53	in	O
54	a	O
55	approximately	O
56	25	O
57	%	O
58	increase	O
59	.	O

1	This	O
2	interaction	O
3	involved	O
4	the	O
5	SH3	B
6	region	I
7	of	O
8	p50	B
9	(	O
10	csk	B
11	)	O
12	and	O
13	a	O
14	proline	O
15	-	O
16	rich	O
17	region	O
18	(	O
19	PPPLPERTPESFVLADM	O
20	)	O
21	outside	O
22	the	O
23	catalytic	O
24	region	O
25	of	O
26	PTP	B
27	-	O
28	PEST	O
29	.	O

1	Following	O
2	2	O
3	.	O
4	5	O
5	Gy	O
6	,	O
7	HbO2	B
8	changes	O
9	were	O
10	minimal	O
11	.	O

1	Polarised	O
2	expression	O
3	of	O
4	human	O
5	intestinal	O
6	N	B
7	-	I
8	benzoyl	I
9	-	I
10	L	I
11	-	I
12	tyrosyl	I
13	-	I
14	p	I
15	-	I
16	aminobenzoic	I
17	acid	I
18	hydrolase	I
19	(	O
20	human	B
21	meprin	I
22	)	O
23	alpha	O
24	and	O
25	beta	O
26	subunits	O
27	in	O
28	Madin	O
29	-	O
30	Darby	O
31	canine	O
32	kidney	O
33	cells	O
34	.	O

1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	B
8	mating	I
9	type	I
10	loci	I
11	.	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	O
11	VTs	O
12	)	O
13	was	O
14	380	O
15	+/-	O
16	41	O
17	msec	O
18	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	We	O
2	established	O
3	that	O
4	the	O
5	2	O
6	.	O
7	6	O
8	kb	O
9	mRNA	O
10	V	O
11	-	O
12	1	O
13	and	O
14	the	O
15	2	O
16	.	O
17	3	O
18	kb	O
19	GGT	B
20	mRNA	O
21	V	O
22	-	O
23	2	O
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	B
42	GGT	I
43	gene	I
44	.	O

1	A	O
2	specific	O
3	distal	O
4	promoter	O
5	controls	O
6	gamma	B
7	-	I
8	glutamyl	I
9	transpeptidase	I
10	gene	I
11	expression	O
12	in	O
13	undifferentiated	O
14	rat	O
15	transformed	O
16	liver	O
17	cells	O
18	.	O

1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	B
13	tract	I
14	binding	I
15	protein	I
16	(	O
17	PTB	B
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	crosslinking	O
28	/	O
29	competition	O
30	assays	O
31	.	O

1	For	O
2	higher	O
3	expression	O
4	of	O
5	lipA	B
6	in	O
7	S	O
8	.	O
9	lividans	O
10	,	O
11	the	O
12	gene	O
13	was	O
14	cloned	O
15	next	O
16	to	O
17	the	O
18	strong	O
19	aphII	B
20	promoter	I
21	.	O

1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	wild	O
6	-	O
7	type	O
8	protein	O
9	,	O
10	expression	O
11	of	O
12	p45	B
13	NF	I
14	-	I
15	E2	I
16	lacking	O
17	this	O
18	activation	O
19	domain	O
20	in	O
21	an	O
22	NF	B
23	-	I
24	E2	I
25	null	O
26	cell	O
27	line	O
28	fails	O
29	to	O
30	support	O
31	enhancer	O
32	-	O
33	dependent	O
34	transcription	O
35	in	O
36	transient	O
37	assays	O
38	.	O

1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	B
17	loci	I
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O

1	The	O
2	promoter	O
3	region	O
4	showed	O
5	no	O
6	consensus	O
7	TATA	O
8	box	O
9	but	O
10	it	O
11	contains	O
12	CCAAT	O
13	and	O
14	CreA	B
15	boxes	O
16	known	O
17	to	O
18	be	O
19	involved	O
20	in	O
21	both	O
22	stress	O
23	and	O
24	carbon	O
25	-	O
26	catabolite	O
27	regulation	O
28	of	O
29	fungal	O
30	promoters	O
31	.	O

1	The	O
2	two	O
3	cysteine	O
4	residues	O
5	located	O
6	in	O
7	this	O
8	additional	O
9	region	O
10	may	O
11	be	O
12	involved	O
13	in	O
14	the	O
15	formation	O
16	of	O
17	a	O
18	disulfide	O
19	bridge	O
20	associated	O
21	with	O
22	the	O
23	activation	O
24	process	O
25	of	O
26	the	O
27	catalytic	O
28	activity	O
29	.	O

1	The	O
2	por	B
3	gene	I
4	has	O
5	been	O
6	expressed	O
7	,	O
8	for	O
9	the	O
10	first	O
11	time	O
12	,	O
13	in	O
14	anaerobically	O
15	grown	O
16	Escherichia	O
17	coli	O
18	behind	O
19	the	O
20	isopropyl	O
21	-	O
22	beta	O
23	-	O
24	D	O
25	-	O
26	thiogalactopyranoside	O
27	-	O
28	inducible	O
29	tac	B
30	promoter	I
31	,	O
32	resulting	O
33	in	O
34	the	O
35	production	O
36	of	O
37	POR	B
38	in	O
39	its	O
40	active	O
41	form	O
42	.	O

1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O

1	The	O
2	ORF3	O
3	mutant	O
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	tabtoxin	B
9	,	O
10	indicating	O
11	that	O
12	ORF3	O
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	B
19	beta	I
20	L	I
21	biosynthesis	O
22	.	O

1	Refined	O
2	Cox	O
3	models	O
4	using	O
5	a	O
6	CD4	B
7	count	O
8	of	O
9	150	O
10	/	O
11	microL	O
12	rather	O
13	than	O
14	200	O
15	/	O
16	microL	O
17	to	O
18	distinguish	O
19	I0	O
20	and	O
21	I1	O
22	yielded	O
23	a	O
24	simplified	O
25	model	O
26	with	O
27	better	O
28	fit	O
29	to	O
30	the	O
31	observed	O
32	data	O
33	.	O

1	However	O
2	,	O
3	the	O
4	published	O
5	reports	O
6	consist	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	and	O
14	limited	O
15	data	O
16	.	O

1	These	O
2	transcripts	O
3	contain	O
4	the	O
5	5	O
6	'	O
7	ends	O
8	of	O
9	mature	O
10	UbCRBP	B
11	mRNAs	I
12	;	O
13	extend	O
14	through	O
15	UbCRBP	B
16	,	O
17	across	O
18	the	O
19	intergenic	O
20	region	O
21	,	O
22	and	O
23	a	O
24	significant	O
25	distance	O
26	3	O
27	'	O
28	into	O
29	the	O
30	enolase	B
31	gene	I
32	.	O

1	The	O
2	distribution	O
3	of	O
4	cryptosporidia	O
5	in	O
6	the	O
7	intestine	O
8	and	O
9	number	O
10	of	O
11	cryptosporidia	O
12	per	O
13	ileal	O
14	villus	O
15	on	O
16	different	O
17	DPI	O
18	were	O
19	also	O
20	estimated	O
21	for	O
22	detailed	O
23	characterization	O
24	of	O
25	the	O
26	infection	O
27	in	O
28	kids	O
29	as	O
30	a	O
31	model	O
32	for	O
33	experimental	O
34	cryptosporidiosis	O
35	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	the	O
6	subendocardial	O
7	/	O
8	subepicardial	O
9	blood	O
10	flow	O
11	ratio	O
12	(	O
13	ENDO	O
14	/	O
15	EPI	O
16	)	O
17	increased	O
18	from	O
19	0	O
20	.	O
21	44	O
22	+/-	O
23	0	O
24	.	O
25	09	O
26	during	O
27	control	O
28	stenosis	O
29	to	O
30	0	O
31	.	O
32	85	O
33	+/-	O
34	0	O
35	.	O
36	13	O
37	after	O
38	ITF	O
39	1129	O
40	(	O
41	10	O
42	micrograms	O
43	/	O
44	kg	O
45	/	O
46	min	O
47	i	O
48	.	O
49	v	O
50	.)	O
51	and	O
52	to	O
53	0	O
54	.	O
55	81	O
56	+/-	O
57	0	O
58	.	O
59	12	O
60	after	O
61	NTG	O
62	.	O

1	Proteasomes	O
2	are	O
3	the	O
4	multisubunit	O
5	protease	O
6	involved	O
7	in	O
8	the	O
9	generation	O
10	of	O
11	peptides	O
12	presented	O
13	by	O
14	MHC	B
15	class	I
16	I	I
17	molecules	I
18	.	O

1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	B
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O

1	Takahashi	O
2	,	O
3	H	O
4	.	O

1	For	O
2	sputum	B
3	interleukin	I
4	-	I
5	8	I
6	there	O
7	was	O
8	an	O
9	estimated	O
10	true	O
11	treatment	O
12	median	O
13	difference	O
14	of	O
15	142	O
16	pg	O
17	/	O
18	ml	O
19	(	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	(	O
25	CI	O
26	)	O
27	8	O
28	to	O
29	2866	O
30	pg	O
31	/	O
32	ml	O
33	)	O
34	in	O
35	favour	O
36	of	O
37	placebo	O
38	;	O
39	while	O
40	for	O
41	maximal	O
42	expiratory	O
43	flow	O
44	at	O
45	25	O
46	%	O
47	(	O
48	MEF25	O
49	%)	O
50	remaining	O
51	forced	O
52	vital	O
53	capacity	O
54	predicted	O
55	for	O
56	sex	O
57	and	O
58	height	O
59	there	O
60	was	O
61	a	O
62	15	O
63	percentage	O
64	points	O
65	(	O
66	pp	O
67	)	O
68	(	O
69	95	O
70	%	O
71	CI	O
72	4	O
73	to	O
74	26	O
75	pp	O
76	)	O
77	mean	O
78	treatment	O
79	difference	O
80	in	O
81	favour	O
82	of	O
83	placebo	O
84	.	O

1	However	O
2	,	O
3	although	O
4	deletion	O
5	of	O
6	Fp1	B
7	in	O
8	the	O
9	hCRBP1	B
10	gene	I
11	yielded	O
12	increased	O
13	CAT	B
14	activity	O
15	,	O
16	pointing	O
17	toward	O
18	a	O
19	negative	O
20	regulatory	O
21	function	O
22	exerted	O
23	by	O
24	this	O
25	element	O
26	,	O
27	its	O
28	insertion	O
29	upstream	O
30	of	O
31	the	O
32	p12	B
33	basal	I
34	promoter	I
35	results	O
36	in	O
37	an	O
38	impressive	O
39	positive	O
40	stimulation	O
41	of	O
42	CAT	B
43	gene	I
44	expression	O
45	.	O

1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	I
17	glucocerebrosidase	I
18	enzyme	I
19	.	O

1	These	O
2	discoloration	O
3	'	O
4	s	O
5	can	O
6	be	O
7	treated	O
8	in	O
9	several	O
10	ways	O
11	but	O
12	up	O
13	to	O
14	lately	O
15	tooth	O
16	structure	O
17	had	O
18	to	O
19	be	O
20	removed	O
21	in	O
22	an	O
23	irreversible	O
24	manner	O
25	in	O
26	order	O
27	to	O
28	provide	O
29	sufficient	O
30	bulk	O
31	for	O
32	the	O
33	new	O
34	restorative	O
35	material	O
36	.	O

1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	O
16	abl	B
17	gene	O
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	B
25	/	O
26	abl	B
27	.	O

1	Overexpression	O
2	of	O
3	BAG	B
4	-	I
5	1	I
6	also	O
7	protected	O
8	certain	O
9	cell	O
10	lines	O
11	from	O
12	heat	O
13	shock	O
14	-	O
15	induced	O
16	cell	O
17	death	O
18	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	contains	O
7	potential	O
8	binding	O
9	sites	O
10	for	O
11	TATA	B
12	-	I
13	binding	I
14	protein	I
15	,	O
16	Sp1	B
17	,	O
18	nuclear	B
19	factor	I
20	1	I
21	(	O
22	NF1	B
23	),	O
24	CAAT	B
25	-	I
26	box	I
27	binding	I
28	protein	I
29	(	O
30	C	B
31	/	I
32	EBP	I
33	),	O
34	hepatocyte	B
35	nuclear	I
36	factors	I
37	1	I
38	and	I
39	5	I
40	(	O
41	HNF1	B
42	,	O
43	HNF5	B
44	)	O
45	and	O
46	activator	B
47	proteins	I
48	1	I
49	and	I
50	2	I
51	(	O
52	AP1	B
53	,	O
54	AP2	B
55	).	O

1	The	O
2	recognition	O
3	specificity	O
4	of	O
5	the	O
6	p55	B
7	PDZ	I
8	domain	I
9	appears	O
10	to	O
11	be	O
12	unique	O
13	,	O
14	since	O
15	the	O
16	three	O
17	PDZ	B
18	domains	I
19	of	O
20	hDlg	B
21	(	O
22	human	O
23	lymphocyte	O
24	homologue	O
25	of	O
26	the	O
27	Drosophila	B
28	discs	I
29	large	I
30	tumor	I
31	suppressor	I
32	)	O
33	do	O
34	not	O
35	bind	O
36	the	O
37	cytoplasmic	O
38	domain	O
39	of	O
40	glycophorin	B
41	C	I
42	.	O

1	By	O
2	analyzing	O
3	the	O
4	RanGAP	B
5	activity	O
6	of	O
7	a	O
8	series	O
9	of	O
10	recombinantly	O
11	expressed	O
12	rna1p	B
13	mutant	I
14	derivatives	O
15	,	O
16	we	O
17	show	O
18	that	O
19	the	O
20	highly	O
21	acidic	O
22	sequence	O
23	in	O
24	the	O
25	C	O
26	-	O
27	terminal	O
28	domain	O
29	of	O
30	both	O
31	yeast	O
32	proteins	O
33	is	O
34	indispensable	O
35	for	O
36	activating	O
37	Ran	B
38	-	O
39	mediated	O
40	GTP	O
41	hydrolysis	O
42	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	MHC	B
6	class	I
7	II	I
8	,	O
9	purified	B
10	soluble	I
11	D10	I
12	TCR	I
13	bound	O
14	to	O
15	Staphylococcus	B
16	aureus	I
17	enterotoxin	I
18	C2	I
19	with	O
20	an	O
21	association	O
22	rate	O
23	of	O
24	1	O
25	.	O
26	69	O
27	+/-	O
28	0	O
29	.	O
30	12	O
31	x	O
32	10	O
33	(	O
34	4	O
35	)	O
36	M	O
37	(-	O
38	1	O
39	)	O
40	sec	O
41	(-	O
42	1	O
43	)	O
44	and	O
45	a	O
46	dissociation	O
47	rate	O
48	of	O
49	1	O
50	.	O
51	9	O
52	+/-	O
53	0	O
54	.	O
55	47	O
56	x	O
57	10	O
58	(-	O
59	2	O
60	)	O
61	sec	O
62	(-	O
63	1	O
64	),	O
65	giving	O
66	a	O
67	dissociation	O
68	constant	O
69	of	O
70	1	O
71	.	O
72	1	O
73	microM	O
74	.	O

1	Evidence	O
2	for	O
3	such	O
4	peak	O
5	shifts	O
6	has	O
7	been	O
8	found	O
9	in	O
10	the	O
11	responses	O
12	of	O
13	auditory	O
14	nerve	O
15	fibers	O
16	,	O
17	cochlear	O
18	microphonics	O
19	,	O
20	and	O
21	the	O
22	responses	O
23	of	O
24	outer	O
25	hair	O
26	cells	O
27	and	O
28	supporting	O
29	cells	O
30	in	O
31	the	O
32	cochlea	O
33	,	O
34	as	O
35	well	O
36	as	O
37	in	O
38	basilar	O
39	membrane	O
40	vibration	O
41	measurements	O
42	,	O
43	and	O
44	indirectly	O
45	,	O
46	in	O
47	psychophysical	O
48	data	O
49	.	O

1	Mnt	B
2	:	O
3	Max	B
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	In	O
2	the	O
3	United	O
4	States	O
5	high	O
6	-	O
7	MW	O
8	HES	O
9	480	O
10	which	O
11	is	O
12	difficult	O
13	to	O
14	degrade	O
15	is	O
16	most	O
17	frequently	O
18	used	O
19	and	O
20	results	O
21	in	O
22	a	O
23	larger	O
24	in	O
25	vivo	O
26	MW	O
27	and	O
28	subsequent	O
29	decrease	O
30	in	O
31	factor	B
32	VIII	I
33	/	O
34	von	B
35	Willebrand	I
36	factor	I
37	levels	O
38	.	O

1	Assays	O
2	of	O
3	total	O
4	cholesterol	O
5	as	O
6	well	O
7	as	O
8	the	O
9	HDL	B
10	,	O
11	HDL2	B
12	,	O
13	LDL	B
14	,	O
15	triglycerides	O
16	,	O
17	endothelin	B
18	-	I
19	1	I
20	,	O
21	lipoprotein	O
22	(	O
23	a	O
24	),	O
25	estradiol	O
26	and	O
27	FSH	B
28	were	O
29	also	O
30	obtained	O
31	at	O
32	baseline	O
33	before	O
34	receiving	O
35	ERT	O
36	and	O
37	after	O
38	3	O
39	months	O
40	of	O
41	ERT	O
42	.	O

1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	B
7	element	I
8	linked	O
9	to	O
10	the	O
11	SV40	B
12	promoter	I
13	responded	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O

1	The	O
2	distributed	O
3	current	O
4	density	O
5	J	O
6	is	O
7	calculated	O
8	within	O
9	the	O
10	volume	O
11	defined	O
12	by	O
13	the	O
14	motor	O
15	unit	O
16	.	O

1	The	O
2	cleavage	O
3	dipeptides	O
4	of	O
5	C1YVV	B
6	NIa	I
7	protease	I
8	are	O
9	Q	O
10	(	O
11	E	O
12	)/	O
13	S	O
14	(	O
15	A	O
16	,	O
17	G	O
18	).	O

1	In	O
2	our	O
3	previous	O
4	studies	O
5	,	O
6	transcriptional	O
7	activation	O
8	was	O
9	shown	O
10	to	O
11	correlate	O
12	with	O
13	IEP86	B
14	binding	O
15	to	O
16	both	O
17	the	O
18	TATA	B
19	-	I
20	box	I
21	binding	I
22	protein	I
23	(	O
24	TBP	B
25	)	O
26	and	O
27	the	O
28	transcription	O
29	factor	O
30	bound	O
31	upstream	O
32	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	B
10	molecule	O
11	.	O

1	(	O
2	iv	O
3	)	O
4	The	O
5	accumulation	O
6	of	O
7	cyclin	B
8	D3	I
9	protein	I
10	in	O
11	Vero	O
12	cells	O
13	infected	O
14	with	O
15	an	O
16	alpha0	B
17	deletion	I
18	mutant	I
19	was	O
20	reduced	O
21	relative	O
22	to	O
23	that	O
24	of	O
25	cells	O
26	infected	O
27	with	O
28	wild	O
29	-	O
30	type	O
31	virus	O
32	or	O
33	a	O
34	recombinant	O
35	virus	O
36	in	O
37	which	O
38	the	O
39	deleted	O
40	alpha0	B
41	sequences	I
42	were	O
43	restored	O
44	.	O

1	We	O
2	report	O
3	the	O
4	preliminary	O
5	biochemical	O
6	characterization	O
7	of	O
8	the	O
9	T	B
10	antigens	I
11	encoded	O
12	by	O
13	three	O
14	SV40	O
15	mutants	O
16	,	O
17	5030	O
18	,	O
19	5031	O
20	,	O
21	and	O
22	5061	O
23	,	O
24	each	O
25	of	O
26	which	O
27	have	O
28	altered	O
29	residues	O
30	within	O
31	or	O
32	near	O
33	the	O
34	ATP	O
35	binding	O
36	pocket	O
37	.	O

1	These	O
2	effects	O
3	were	O
4	abrogated	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	B
11	-	I
12	deficient	I
13	PKC	I
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	p85alpha	I
23	-	O
24	p110	B
25	by	O
26	wortmannin	O
27	,	O
28	LY294002	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	p85alpha	B
37	.	O

1	Protein	B
2	phosphatase	I
3	2A	I
4	is	O
5	a	O
6	critical	O
7	regulator	O
8	of	O
9	protein	B
10	kinase	I
11	C	I
12	zeta	I
13	signaling	O
14	targeted	O
15	by	O
16	SV40	B
17	small	I
18	t	I
19	to	O
20	promote	O
21	cell	O
22	growth	O
23	and	O
24	NF	B
25	-	I
26	kappaB	I
27	activation	O
28	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RXRalphaF318A	B
5	constitutive	O
6	activity	O
7	generated	O
8	within	O
9	heterodimers	O
10	in	O
11	the	O
12	presence	O
13	of	O
14	BMS614	O
15	requires	O
16	the	O
17	integrity	O
18	of	O
19	both	O
20	RXR	B
21	and	O
22	RAR	B
23	AF	O
24	-	O
25	2	O
26	domains	O
27	.	O

1	These	O
2	introns	O
3	contain	O
4	only	O
5	single	O
6	snoRNA	B
7	genes	I
8	and	O
9	their	O
10	processing	O
11	involves	O
12	exonucleolytic	O
13	release	O
14	of	O
15	the	O
16	snoRNA	O
17	from	O
18	debranched	O
19	intron	O
20	lariats	O
21	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	Src	B
8	homology	I
9	-	I
10	2	I
11	(	O
12	SH2	B
13	)	O
14	domain	O
15	-	O
16	containing	O
17	protein	B
18	-	I
19	tyrosine	I
20	phosphatase	I
21	,	O
22	SHP	B
23	-	I
24	2	I
25	,	O
26	associates	O
27	with	O
28	the	O
29	cytoplasmic	O
30	domain	O
31	of	O
32	PECAM	B
33	-	I
34	1	I
35	as	O
36	it	O
37	becomes	O
38	tyrosine	O
39	-	O
40	phosphorylated	O
41	during	O
42	platelet	O
43	aggregation	O
44	:	O
45	a	O
46	process	O
47	that	O
48	can	O
49	be	O
50	mimicked	O
51	in	O
52	part	O
53	by	O
54	small	O
55	synthetic	O
56	phosphopeptides	O
57	corresponding	O
58	to	O
59	the	O
60	cytoplasmic	O
61	domain	O
62	of	O
63	PECAM	B
64	-	I
65	1	I
66	encompassing	O
67	tyrosine	O
68	residues	O
69	Tyr	O
70	-	O
71	663	O
72	or	O
73	Tyr	O
74	-	O
75	686	O
76	.	O

1	Underlying	O
2	the	O
3	clustering	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O

1	Supplementation	O
2	was	O
3	stopped	O
4	when	O
5	pl	B
6	-	I
7	ALB	I
8	reached	O
9	2	O
10	.	O
11	0	O
12	g	O
13	/	O
14	dL	O
15	.	O

1	Detection	O
2	of	O
3	airborne	O
4	Mycobacterium	O
5	tuberculosis	O
6	by	O
7	air	O
8	filtration	O
9	and	O
10	polymerase	O
11	chain	O
12	reaction	O
13	.	O

1	These	O
2	findings	O
3	show	O
4	that	O
5	EBP50	B
6	is	O
7	a	O
8	physiologically	O
9	relevant	O
10	ezrin	B
11	binding	I
12	protein	I
13	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	that	O
6	scanthrough	O
7	translation	O
8	,	O
9	where	O
10	the	O
11	initiating	O
12	AUG	O
13	of	O
14	a	O
15	primary	O
16	open	O
17	reading	O
18	frame	O
19	is	O
20	bypassed	O
21	,	O
22	is	O
23	most	O
24	likely	O
25	to	O
26	account	O
27	for	O
28	the	O
29	presentation	O
30	of	O
31	cryptic	O
32	epitopes	O
33	from	O
34	alternative	O
35	reading	O
36	frames	O
37	within	O
38	the	O
39	influenza	B
40	A	I
41	PR	I
42	/	I
43	8	I
44	/	I
45	34	I
46	nucleoprotein	I
47	gene	I
48	.	O

1	This	O
2	family	O
3	of	O
4	proteins	O
5	binds	O
6	GC	O
7	-	O
8	rich	O
9	motifs	O
10	widely	O
11	distributed	O
12	in	O
13	gene	O
14	promoters	O
15	,	O
16	resulting	O
17	in	O
18	distinct	O
19	activation	O
20	or	O
21	repression	O
22	of	O
23	transcriptional	O
24	activities	O
25	.	O

1	Deletion	O
2	of	O
3	the	O
4	POR2	B
5	gene	I
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	yeasts	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	POR1	B
20	and	O
21	POR2	B
22	genes	I
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	grow	O
29	on	O
30	glycerol	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	albeit	O
37	more	O
38	slowly	O
39	than	O
40	delta	B
41	por1	I
42	single	I
43	mutants	I
44	.	O

1	Furthermore	O
2	,	O
3	our	O
4	novel	O
5	observation	O
6	that	O
7	expression	O
8	of	O
9	a	O
10	highly	O
11	activated	O
12	FGFR3	B
13	kinase	I
14	domain	I
15	is	O
16	able	O
17	to	O
18	morphologically	O
19	transform	O
20	fibroblasts	O
21	suggests	O
22	that	O
23	dysregulation	O
24	of	O
25	FGFR3	B
26	has	O
27	the	O
28	potential	O
29	to	O
30	play	O
31	a	O
32	role	O
33	in	O
34	human	O
35	neoplasia	O
36	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	interferon	B
15	regulatory	I
16	factors	I
17	(	O
18	IRFs	B
19	).	O

1	Involvement	O
2	of	O
3	AP	B
4	-	I
5	2	I
6	in	O
7	regulation	O
8	of	O
9	the	O
10	R	B
11	-	I
12	FABP	I
13	gene	I
14	in	O
15	the	O
16	developing	O
17	chick	O
18	retina	O
19	.	O

1	However	O
2	,	O
3	Cbf5p	B
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	B
16	nucleolar	I
17	protein	I
18	NAP57	I
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	B
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O

1	This	O
2	newly	O
3	described	O
4	organism	O
5	was	O
6	difficult	O
7	to	O
8	identify	O
9	due	O
10	to	O
11	discrepancies	O
12	between	O
13	the	O
14	Vitek	O
15	and	O
16	API	O
17	20E	O
18	identification	O
19	systems	O
20	.	O

1	Ig	B
2	heavy	I
3	chain	I
4	class	O
5	switching	O
6	is	O
7	directed	O
8	by	O
9	cytokines	O
10	inducing	O
11	transcription	O
12	from	O
13	unrearranged	O
14	CH	B
15	genes	I
16	.	O

1	The	O
2	available	O
3	data	O
4	suggest	O
5	that	O
6	the	O
7	NF	B
8	kappa	I
9	B2	I
10	nucleoprotein	I
11	complex	I
12	may	O
13	cooperate	O
14	with	O
15	DNA	O
16	-	O
17	bound	O
18	STAT6	B
19	to	O
20	achieve	O
21	IL	B
22	-	I
23	4	I
24	-	O
25	dependent	O
26	activation	O
27	of	O
28	the	O
29	human	B
30	IgE	I
31	germline	I
32	gene	I
33	.	O

1	EXERCISE	O
2	IN	O
3	THE	O
4	TERRESTRIAL	O
5	CHRISTMAS	O
6	ISLAND	O
7	RED	O
8	CRAB	O
9	GECARCOIDEA	O
10	NATALIS	O
11	-	O
12	ENERGETICS	O
13	OF	O
14	LOCOMOTION	O

1	THE	O
2	SCALING	O
3	OF	O
4	SONG	O
5	FREQUENCY	O
6	IN	O
7	CICADAS	O

1	The	O
2	pheromone	O
3	response	O
4	pathway	O
5	activates	O
6	transcription	O
7	of	O
8	Ty5	B
9	retrotransposons	I
10	located	O
11	within	O
12	silent	O
13	chromatin	O
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	introduced	O
7	mutations	O
8	into	O
9	the	O
10	corresponding	O
11	elements	O
12	of	O
13	two	O
14	cox3	B
15	promoters	I
16	and	O
17	show	O
18	that	O
19	while	O
20	the	O
21	core	O
22	element	O
23	is	O
24	essential	O
25	for	O
26	cox3	B
27	promoter	I
28	activity	O
29	,	O
30	upstream	O
31	element	O
32	mutations	O
33	have	O
34	little	O
35	or	O
36	no	O
37	effect	O
38	.	O

1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O

1	The	O
2	histidine	O
3	-	O
4	tagged	O
5	gene	O
6	,	O
7	rpoCHIS	B
8	,	O
9	was	O
10	used	O
11	to	O
12	replace	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	allele	O
18	in	O
19	the	O
20	chromosome	O
21	of	O
22	S	O
23	.	O
24	coelicolor	O
25	and	O
26	S	O
27	.	O
28	lividans	O
29	.	O

1	Because	O
2	the	O
3	deletion	O
4	included	O
5	the	O
6	TK	B
7	gene	I
8	,	O
9	selection	O
10	with	O
11	gancyclovir	O
12	against	O
13	cells	O
14	not	O
15	having	O
16	undergone	O
17	recombination	O
18	was	O
19	possible	O
20	.	O

1	The	O
2	malate	B
3	synthase	I
4	gene	I
5	,	O
6	MLS1	B
7	,	O
8	of	O
9	the	O
10	yeast	O
11	Saccharomyces	O
12	cerevisiae	O
13	is	O
14	transcriptionally	O
15	regulated	O
16	by	O
17	the	O
18	carbon	O
19	source	O
20	in	O
21	the	O
22	growth	O
23	medium	O
24	.	O

1	By	O
2	deletion	O
3	analysis	O
4	of	O
5	the	O
6	MLS1	B
7	control	O
8	region	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	sites	O
14	,	O
15	UAS1	O
16	and	O
17	UAS2	O
18	,	O
19	as	O
20	important	O
21	for	O
22	efficient	O
23	derepression	O
24	of	O
25	the	O
26	gene	O
27	.	O

1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	Prior	O
2	to	O
3	meals	O
4	2	O
5	to	O
6	3	O
7	times	O
8	daily	O
9	,	O
10	1	O
11	-	O
12	2	O
13	tablespoons	O
14	of	O
15	Alzoon	O
16	are	O
17	recommended	O
18	.	O

1	Widening	O
2	of	O
3	the	O
4	abdominal	O
5	aortic	O
6	wall	O
7	on	O
8	an	O
9	ultrasound	O
10	examination	O
11	was	O
12	the	O
13	key	O
14	to	O
15	the	O
16	incidental	O
17	diagnosis	O
18	of	O
19	a	O
20	clinically	O
21	unsuspected	O
22	type	O
23	B	O
24	dissection	O
25	.	O

1	Fermentation	O
2	process	O
3	after	O
4	supplementation	O
5	of	O
6	nitrate	O
7	,	O
8	nitrite	O
9	,	O
10	lactic	O
11	acid	O
12	bacteria	O
13	and	O
14	formic	O
15	acid	O

1	Substrates	O
2	include	O
3	the	O
4	p21	B
5	(	O
6	ras	B
7	)	O
8	proteins	O
9	,	O
10	nuclear	B
11	lamins	I
12	,	O
13	and	O
14	a	O
15	series	O
16	of	O
17	retinal	O
18	proteins	O
19	.	O

1	Ovaries	O
2	of	O
3	10	O
4	animals	O
5	per	O
6	group	O
7	from	O
8	16	O
9	studies	O
10	in	O
11	CD	O
12	-	O
13	1	O
14	mice	O
15	and	O
16	1	O
17	study	O
18	each	O
19	in	O
20	C3H	O
21	and	O
22	C57BL	O
23	/	O
24	6	O
25	mice	O
26	were	O
27	sectioned	O
28	serially	O
29	at	O
30	6	O
31	microm	O
32	.	O

1	The	O
2	Trx	B
3	-	O
4	CT	B
5	fusion	O
6	protein	O
7	was	O
8	produced	O
9	less	O
10	efficiently	O
11	(	O
12	20	O
13	%	O
14	of	O
15	total	O
16	soluble	O
17	cellular	O
18	protein	O
19	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	UBP41	B
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	recycling	O
14	of	O
15	ubiquitin	B
16	by	O
17	hydrolysis	O
18	of	O
19	branched	B
20	poly	I
21	-	I
22	ubiquitin	I
23	chains	I
24	generated	O
25	by	O
26	the	O
27	action	O
28	of	O
29	26	B
30	S	I
31	proteasome	I
32	on	O
33	poly	O
34	-	O
35	ubiquitinated	O
36	protein	O
37	substrates	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	production	O
45	of	O
46	free	O
47	ubiquitin	B
48	from	O
49	linear	B
50	poly	I
51	-	I
52	ubiquitin	I
53	chains	I
54	and	O
55	of	O
56	certain	O
57	ribosomal	O
58	proteins	O
59	from	O
60	ubiquitin	B
61	fusion	I
62	proteins	I
63	.	O

1	A	O
2	data	O
3	base	O
4	homology	O
5	search	O
6	revealed	O
7	that	O
8	the	O
9	predicted	O
10	ER1	B
11	amino	O
12	acid	O
13	sequence	O
14	contains	O
15	three	O
16	regions	O
17	of	O
18	similarity	O
19	to	O
20	the	O
21	rat	O
22	and	O
23	human	O
24	proteins	O
25	encoded	O
26	by	O
27	the	O
28	metastasis	O
29	-	O
30	associated	O
31	gene	O
32	,	O
33	mta1	B
34	,	O
35	and	O
36	two	O
37	regions	O
38	of	O
39	similarity	O
40	to	O
41	the	O
42	Caenorhabditis	O
43	elegans	O
44	sequence	O
45	that	O
46	is	O
47	similar	O
48	to	O
49	mta1	B
50	.	O

1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	80	O
12	%	O
13	identical	O
14	to	O
15	human	B
16	progelatinase	I
17	B	I
18	.	O

1	The	O
2	inhibition	O
3	by	O
4	cytosolic	O
5	Ca2	O
6	+	O
7	was	O
8	caused	O
9	by	O
10	a	O
11	decrease	O
12	in	O
13	cooperativity	O
14	and	O
15	by	O
16	a	O
17	shift	O
18	in	O
19	EC50	O
20	toward	O
21	higher	O
22	InsP3	O
23	concentrations	O
24	.	O

1	RESULTS	O
2	:	O
3	The	O
4	standardised	O
5	mortality	O
6	ratio	O
7	(	O
8	SMR	O
9	)	O
10	for	O
11	all	O
12	malignant	O
13	neoplasms	O
14	was	O
15	94	O
16	(	O
17	95	O
18	%	O
19	CI	O
20	74	O
21	to	O
22	118	O
23	).	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O

1	Using	O
2	5	O
3	'	O
4	RACE	O
5	and	O
6	reverse	O
7	transcription	O
8	-	O
9	PCR	O
10	(	O
11	RT	O
12	-	O
13	PCR	O
14	)	O
15	methodologies	O
16	,	O
17	we	O
18	cloned	O
19	these	O
20	sequences	O
21	from	O
22	brain	O
23	and	O
24	placenta	O
25	and	O
26	found	O
27	this	O
28	material	O
29	to	O
30	be	O
31	composed	O
32	of	O
33	alternatively	O
34	spliced	O
35	exons	O
36	using	O
37	a	O
38	previously	O
39	reported	O
40	noncoding	O
41	exon	O
42	(	O
43	1A	O
44	)	O
45	and	O
46	a	O
47	novel	O
48	97	O
49	-	O
50	bp	O
51	noncoding	O
52	exon	O
53	(	O
54	1B	O
55	).	O

1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	B
17	and	O
18	EXT2	B
19	genes	I
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O

1	The	O
2	regurgitation	O
3	of	O
4	large	O
5	vitreous	O
6	injections	O
7	.	O

1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	B
7	transporters	I
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O

1	Attenuation	O
2	from	O
3	the	O
4	vit	B
5	A2	I
6	consensus	O
7	ERE	O
8	is	O
9	not	O
10	necessarily	O
11	dependent	O
12	on	O
13	DNA	O
14	binding	O
15	as	O
16	the	O
17	TR	B
18	alpha	I
19	DNA	O
20	binding	O
21	mutant	O
22	was	O
23	still	O
24	able	O
25	to	O
26	inhibit	O
27	E	O
28	-	O
29	dependent	O
30	transactivation	O
31	.	O

1	Expression	O
2	from	O
3	this	O
4	element	O
5	is	O
6	regulated	O
7	by	O
8	a	O
9	heteromeric	O
10	protein	O
11	complex	O
12	containing	O
13	ubiquitous	O
14	(	O
15	i	O
16	.	O
17	e	O
18	.	O
19	the	O
20	E2A	B
21	-	O
22	and	O
23	HEB	B
24	-	I
25	encoded	I
26	proteins	I
27	)	O
28	and	O
29	islet	O
30	-	O
31	enriched	O
32	members	O
33	of	O
34	the	O
35	bHLH	B
36	family	I
37	.	O

1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	B
20	-	I
21	subunit	I
22	gene	I
23	to	O
24	trophoblasts	O
25	.	O

1	U4	B
2	/	O
3	U6	B
4	snRNP	O
5	is	O
6	one	O
7	of	O
8	four	O
9	essential	O
10	small	O
11	nuclear	O
12	ribonucleoprotein	O
13	(	O
14	snRNP	O
15	)	O
16	particles	O
17	(	O
18	U1	B
19	,	O
20	U2	B
21	,	O
22	U5	B
23	and	O
24	U4	B
25	/	O
26	U6	B
27	)	O
28	present	O
29	in	O
30	the	O
31	spliceosome	O
32	.	O

1	Hprp3p	B
2	is	O
3	a	O
4	77	O
5	kDa	O
6	protein	O
7	,	O
8	which	O
9	is	O
10	homologous	O
11	to	O
12	the	O
13	Saccharomyces	B
14	cerevisiae	I
15	splicing	I
16	factor	I
17	Prp3p	I
18	.	O

1	The	O
2	growth	O
3	-	O
4	promoting	O
5	properties	O
6	of	O
7	the	O
8	retroviral	B
9	v	I
10	-	I
11	erbA	I
12	oncogene	I
13	,	O
14	a	O
15	highly	O
16	mutated	O
17	version	O
18	of	O
19	the	O
20	chicken	B
21	thyroid	I
22	hormone	I
23	receptor	I
24	(	I
25	TR	I
26	)	I
27	alpha	I
28	,	O
29	have	O
30	so	O
31	far	O
32	exclusively	O
33	been	O
34	linked	O
35	to	O
36	dominant	O
37	repression	O
38	of	O
39	the	O
40	antimitogenic	O
41	roles	O
42	of	O
43	TR	B
44	and	O
45	retinoic	B
46	acid	I
47	receptors	I
48	.	O

1	We	O
2	cloned	O
3	a	O
4	complete	O
5	cDNA	O
6	(	O
7	2	O
8	.	O
9	9	O
10	kb	O
11	)	O
12	for	O
13	HET	B
14	from	O
15	an	O
16	MCF	O
17	-	O
18	7	O
19	cDNA	O
20	library	O
21	.	O

1	The	O
2	most	O
3	common	O
4	grade	O
5	3	O
6	toxicity	O
7	was	O
8	neutropenia	O
9	,	O
10	thrombocytopenia	O
11	,	O
12	and	O
13	parasthesias	O
14	(	O
15	observed	O
16	in	O
17	<	O
18	10	O
19	%	O
20	of	O
21	cycles	O
22	).	O

1	Serum	O
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	TBOH	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	140	O
37	in	O
38	finishing	O
39	heifers	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	MGA	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	heifer	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	Revalor	O
63	-	O
64	H	O
65	(	O
66	140	O
67	mg	O
68	TBA	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	Revalor	O
77	-	O
78	H	O
79	+	O
80	MGA	O
81	;	O
82	5	O
83	)	O
84	Finaplix	O
85	-	O
86	H	O
87	(	O
88	200	O
89	mg	O
90	TBA	O
91	);	O
92	and	O
93	6	O
94	)	O
95	Finaplix	O
96	-	O
97	H	O
98	+	O
99	MGA	O
100	.	O

1	Serum	O
2	E2	O
3	concentrations	O
4	increased	O
5	numerically	O
6	two	O
7	-	O
8	to	O
9	threefold	O
10	from	O
11	d	O
12	56	O
13	to	O
14	140	O
15	in	O
16	controls	O
17	fed	O
18	MGA	O
19	,	O
20	compared	O
21	with	O
22	controls	O
23	not	O
24	fed	O
25	MGA	O
26	.	O

1	Interferon	B
2	Regulatory	I
3	Factor	I
4	(	I
5	IRF	I
6	)-	I
7	1	I
8	has	O
9	been	O
10	characterized	O
11	as	O
12	an	O
13	important	O
14	growth	O
15	regulatory	O
16	and	O
17	immunomodulatory	O
18	transcription	O
19	factor	O
20	.	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	brk	B
6	consists	O
7	of	O
8	8	O
9	exons	O
10	,	O
11	whose	O
12	boundaries	O
13	are	O
14	distinct	O
15	from	O
16	other	O
17	non	O
18	-	O
19	receptor	O
20	PTK	B
21	family	I
22	members	O
23	,	O
24	again	O
25	indicating	O
26	a	O
27	structural	O
28	and	O
29	functional	O
30	divergence	O
31	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	expression	O
7	of	O
8	a	O
9	tumour	O
10	derived	O
11	brk	B
12	cDNA	I
13	in	O
14	mouse	O
15	embryonic	O
16	fibroblasts	O
17	and	O
18	human	O
19	mammary	O
20	epithelial	O
21	cells	O
22	supports	O
23	anchorage	O
24	independent	O
25	growth	O
26	,	O
27	and	O
28	in	O
29	the	O
30	latter	O
31	potentiates	O
32	the	O
33	mitogenic	O
34	response	O
35	to	O
36	epidermal	B
37	growth	I
38	factor	I
39	.	O

1	Anti	B
2	-	I
3	hepatitis	I
4	A	I
5	virus	O
6	(	O
7	HAV	O
8	)	O
9	titer	O
10	after	O
11	vaccination	O
12	was	O
13	measured	O
14	in	O
15	83	O
16	HIV	O
17	-	O
18	positive	O
19	and	O
20	39	O
21	HIV	O
22	-	O
23	negative	O
24	men	O
25	.	O

1	One	O
2	skull	O
3	does	O
4	not	O
5	a	O
6	species	O
7	make	O
8	.	O

1	Surprisingly	O
2	,	O
3	calf	B
4	thymus	I
5	CstF	I
6	contained	O
7	an	O
8	additional	O
9	,	O
10	novel	O
11	form	O
12	of	O
13	the	O
14	64	O
15	-	O
16	kDa	O
17	subunit	O
18	with	O
19	a	O
20	molecular	O
21	mass	O
22	of	O
23	70	O
24	kDa	O
25	.	O

1	Null	O
2	mutations	O
3	in	O
4	daf	B
5	-	I
6	3	I
7	suppress	O
8	mutations	O
9	in	O
10	genes	O
11	encoding	O
12	this	O
13	TGF	B
14	-	I
15	beta	I
16	signal	O
17	,	O
18	its	O
19	receptors	O
20	,	O
21	and	O
22	associated	O
23	Smad	B
24	signal	I
25	transduction	I
26	proteins	I
27	.	O
28	daf	B
29	-	I
30	3	I
31	encodes	O
32	a	O
33	Smad	B
34	protein	I
35	that	O
36	is	O
37	most	O
38	closely	O
39	related	O
40	to	O
41	mammalian	B
42	DPC4	I
43	,	O
44	and	O
45	is	O
46	expressed	O
47	throughout	O
48	development	O
49	in	O
50	many	O
51	of	O
52	the	O
53	tissues	O
54	that	O
55	are	O
56	remodeled	O
57	during	O
58	dauer	O
59	development	O
60	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	B
9	EGF	I
10	receptor	I
11	DER	I
12	/	O
13	Egfr	B
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	B
25	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	B
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O

1	It	O
2	has	O
3	been	O
4	proposed	O
5	that	O
6	the	O
7	parCBA	B
8	operon	I
9	encodes	O
10	a	O
11	plasmid	O
12	partitioning	O
13	system	O
14	(	O
15	M	O
16	.	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	B
8	cer	I
9	site	I
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	O
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	B
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	O
51	.	O

1	To	O
2	examine	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	apparent	O
8	differences	O
9	in	O
10	postsegregational	O
11	killing	O
12	between	O
13	the	O
14	two	O
15	E	O
16	.	O
17	coli	O
18	strains	O
19	,	O
20	transformation	O
21	assays	O
22	were	O
23	carried	O
24	out	O
25	to	O
26	determine	O
27	the	O
28	relative	O
29	sensitivities	O
30	of	O
31	the	O
32	strains	O
33	to	O
34	the	O
35	ParE	B
36	toxin	I
37	protein	I
38	.	O

1	Splice	O
2	-	O
3	junction	O
4	elements	O
5	and	O
6	intronic	O
7	sequences	O
8	regulate	O
9	alternative	O
10	splicing	O
11	of	O
12	the	O
13	Drosophila	O
14	myosin	B
15	heavy	I
16	chain	I
17	gene	I
18	transcript	O
19	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	B
40	mitochondrial	I
41	gene	I
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	B
59	gene	I
60	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	B
16	and	O
17	RNR3	B
18	genes	I
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O

1	Cloning	O
2	of	O
3	a	O
4	human	B
5	phosphoinositide	I
6	3	I
7	-	I
8	kinase	I
9	with	O
10	a	O
11	C2	B
12	domain	O
13	that	O
14	displays	O
15	reduced	O
16	sensitivity	O
17	to	O
18	the	O
19	inhibitor	O
20	wortmannin	O
21	.	O

1	Ea	O
2	value	O
3	was	O
4	calculated	O
5	as	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	end	O
14	-	O
15	systolic	O
16	aortic	O
17	pressure	O
18	(	O
19	ESAP	O
20	)	O
21	to	O
22	stroke	O
23	volume	O
24	(	O
25	thermodilution	O
26	).	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	cyclin	B
14	D2	I
15	suggested	O
16	that	O
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	B
28	/	I
29	EBP	I
30	,	O
31	PEA3	B
32	,	O
33	AP2	B
34	,	O
35	NF	B
36	-	I
37	Y	I
38	,	O
39	c	B
40	-	I
41	Myc	I
42	,	O
43	and	O
44	Sp1	B
45	may	O
46	have	O
47	a	O
48	major	O
49	positive	O
50	regulatory	O
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	Effect	O
2	of	O
3	alcohol	O
4	on	O
5	minimal	O
6	effective	O
7	nCPAP	O
8	pressure	O

1	In	O
2	contrast	O
3	,	O
4	resensitization	O
5	of	O
6	a	O
7	sequestration	O
8	-	O
9	impaired	O
10	beta2AR	B
11	mutant	O
12	(	O
13	Y326A	O
14	)	O
15	was	O
16	reestablished	O
17	following	O
18	the	O
19	overexpression	O
20	of	O
21	either	O
22	GRK2	B
23	or	O
24	beta	B
25	-	I
26	arrestin	I
27	1	I
28	.	O

1	The	O
2	medium	O
3	chains	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	mu1	B
9	and	O
10	mu2	B
11	,	O
12	have	O
13	been	O
14	implicated	O
15	in	O
16	two	O
17	types	O
18	of	O
19	interaction	O
20	:	O
21	assembly	O
22	with	O
23	the	O
24	beta1	B
25	and	I
26	beta2	I
27	chains	I
28	of	O
29	the	O
30	corresponding	O
31	complexes	O
32	and	O
33	recognition	O
34	of	O
35	tyrosine	O
36	-	O
37	based	O
38	sorting	O
39	signals	O
40	.	O

1	We	O
2	have	O
3	overexpressed	O
4	,	O
5	purified	O
6	,	O
7	characterized	O
8	,	O
9	and	O
10	crystallized	O
11	the	O
12	BTB	B
13	/	O
14	POZ	O
15	domain	O
16	from	O
17	PLZF	B
18	(	O
19	PLZF	B
20	-	O
21	BTB	B
22	/	O
23	POZ	O
24	).	O

1	Osmotic	O
2	shock	O
3	stimulates	O
4	GLUT4	B
5	translocation	O
6	in	O
7	3T3L1	O
8	adipocytes	O
9	by	O
10	a	O
11	novel	O
12	tyrosine	B
13	kinase	I
14	pathway	O
15	.	O

1	We	O
2	also	O
3	identified	O
4	Sp1	B
5	,	O
6	Sp3	B
7	,	O
8	and	O
9	NGFI	B
10	-	I
11	A	I
12	/	O
13	Egr	B
14	-	I
15	1	I
16	as	O
17	the	O
18	primary	O
19	nuclear	O
20	transcription	O
21	factors	O
22	binding	O
23	to	O
24	TRE1	B
25	which	O
26	mediate	O
27	Tax	B
28	responsiveness	O
29	.	O

1	Interestingly	O
2	,	O
3	segment	O
4	nesting	O
5	differentially	O
6	increases	O
7	the	O
8	copy	O
9	number	O
10	of	O
11	genes	O
12	encoded	O
13	by	O
14	segment	O
15	W	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	unusual	O
21	genomic	O
22	organization	O
23	of	O
24	PDVs	O
25	may	O
26	be	O
27	directly	O
28	linked	O
29	to	O
30	the	O
31	unique	O
32	functions	O
33	of	O
34	this	O
35	virus	O
36	in	O
37	its	O
38	obligate	O
39	mutualistic	O
40	association	O
41	with	O
42	parasitic	O
43	wasps	O
44	.	O

1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	B
10	-	I
11	1	I
12	promoter	I
13	performed	O
14	with	O
15	chloramphenicol	B
16	acetyltransferase	I
17	constructs	I
18	revealed	O
19	that	O
20	Tax	B
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	B
26	-	I
27	1	I
28	promoter	I
29	via	O
30	two	O
31	NF	B
32	-	I
33	kappaB	I
34	sites	I
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	B
46	-	I
47	1	I
48	gene	I
49	promoter	I
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	B
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O

1	The	O
2	AGM	B
3	and	I
4	NIH	I
5	/	I
6	Swiss	I
7	mouse	I
8	CCR5	I
9	proteins	I
10	are	O
11	97	O
12	.	O
13	7	O
14	to	O
15	98	O
16	.	O
17	3	O
18	%	O
19	and	O
20	79	O
21	.	O
22	8	O
23	%	O
24	identical	O
25	to	O
26	the	O
27	human	O
28	protein	O
29	,	O
30	respectively	O
31	.	O

1	Processivity	O
2	of	O
3	DNA	O
4	synthesis	O
5	by	O
6	the	O
7	mutant	O
8	holoenzyme	O
9	containing	O
10	pcna	B
11	-	I
12	79	I
13	was	O
14	unaffected	O
15	on	O
16	poly	O
17	(	O
18	dA	O
19	)	O
20	x	O
21	oligo	O
22	(	O
23	dT	O
24	)	O
25	but	O
26	was	O
27	dramatically	O
28	reduced	O
29	on	O
30	a	O
31	natural	O
32	template	O
33	with	O
34	secondary	O
35	structure	O
36	.	O

1	Alanine	O
2	substitution	O
3	mutations	O
4	in	O
5	the	O
6	Zta	B
7	activation	I
8	domain	I
9	which	O
10	eliminate	O
11	the	O
12	ability	O
13	of	O
14	Zta	B
15	to	O
16	stimulate	O
17	the	O
18	D	B
19	-	I
20	A	I
21	complex	I
22	were	O
23	examined	O
24	.	O

1	The	O
2	Scm	B
3	and	O
4	ph	B
5	proteins	O
6	share	O
7	a	O
8	homology	O
9	domain	O
10	with	O
11	38	O
12	%	O
13	identity	O
14	over	O
15	a	O
16	length	O
17	of	O
18	65	O
19	amino	O
20	acids	O
21	,	O
22	termed	O
23	the	O
24	SPM	O
25	domain	O
26	,	O
27	that	O
28	is	O
29	located	O
30	at	O
31	their	O
32	respective	O
33	C	O
34	termini	O
35	.	O

1	It	O
2	has	O
3	been	O
4	previously	O
5	shown	O
6	that	O
7	genes	O
8	transcribed	O
9	by	O
10	RNA	B
11	polymerase	I
12	II	I
13	(	O
14	RNAP	B
15	II	I
16	)	O
17	are	O
18	subject	O
19	to	O
20	position	O
21	effect	O
22	variegation	O
23	when	O
24	located	O
25	near	O
26	yeast	O
27	telomeres	O
28	.	O

1	Likewise	O
2	,	O
3	rad6	B
4	-	I
5	delta	I
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	B
11	-	I
12	located	I
13	RNAP	I
14	II	I
15	-	I
16	transcribed	I
17	genes	I
18	URA3	I
19	and	O
20	ADE2	B
21	.	O

1	The	O
2	amplitude	O
3	of	O
4	detrusor	O
5	contractions	O
6	at	O
7	6	O
8	,	O
9	12	O
10	,	O
11	and	O
12	24	O
13	hours	O
14	showed	O
15	no	O
16	significant	O
17	difference	O
18	from	O
19	that	O
20	in	O
21	the	O
22	controls	O
23	.	O

1	In	O
2	the	O
3	predicted	O
4	transmembrane	O
5	domain	O
6	,	O
7	Casr	B
8	-	I
9	rs2	I
10	and	O
11	Casr	B
12	-	I
13	rs3	I
14	are	O
15	95	O
16	%	O
17	identical	O
18	to	O
19	Casr	B
20	-	I
21	rs1	I
22	.	O

1	Recently	O
2	,	O
3	roles	O
4	also	O
5	have	O
6	been	O
7	suggested	O
8	for	O
9	the	O
10	nuclear	O
11	trans	O
12	-	O
13	factor	O
14	GATA	B
15	-	I
16	1	I
17	in	O
18	regulating	O
19	progenitor	O
20	cell	O
21	proliferation	O
22	.	O

1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O

1	F	B
2	-	I
3	box	I
4	proteins	I
5	are	O
6	receptors	O
7	that	O
8	recruit	O
9	phosphorylated	O
10	substrates	O
11	to	O
12	the	O
13	SCF	B
14	ubiquitin	I
15	-	O
16	ligase	B
17	complex	O
18	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	liver	O
6	allograft	O
7	shortage	O
8	,	O
9	our	O
10	results	O
11	suggest	O
12	that	O
13	an	O
14	ELT	O
15	should	O
16	not	O
17	be	O
18	performed	O
19	in	O
20	patients	O
21	with	O
22	cardiac	O
23	failure	O
24	,	O
25	more	O
26	than	O
27	two	O
28	OSF	O
29	,	O
30	or	O
31	an	O
32	APACHE	O
33	II	O
34	score	O
35	higher	O
36	than	O
37	30	O
38	.	O

1	The	O
2	SH3	B
3	domains	I
4	of	O
5	Grb2	B
6	bound	O
7	in	O
8	vitro	O
9	to	O
10	specific	O
11	proline	O
12	-	O
13	rich	O
14	motifs	O
15	in	O
16	the	O
17	HPK1	B
18	tail	O
19	and	O
20	functioned	O
21	synergistically	O
22	to	O
23	direct	O
24	the	O
25	stable	O
26	binding	O
27	of	O
28	Grb2	B
29	to	O
30	HPK1	B
31	in	O
32	transfected	O
33	Cos1	O
34	cells	O
35	.	O

1	By	O
2	far	O
3	-	O
4	Western	O
5	analysis	O
6	and	O
7	coimmunoprecipitation	O
8	studies	O
9	,	O
10	we	O
11	demonstrate	O
12	that	O
13	ZNF74	B
14	interacts	O
15	,	O
16	via	O
17	its	O
18	zinc	O
19	finger	O
20	domain	O
21	,	O
22	with	O
23	the	O
24	hyperphosphorylated	O
25	largest	O
26	subunit	O
27	of	O
28	RNA	B
29	polymerase	I
30	II	I
31	(	O
32	pol	B
33	IIo	I
34	)	O
35	but	O
36	not	O
37	with	O
38	the	O
39	hypophosphorylated	O
40	form	O
41	.	O

1	Thus	O
2	,	O
3	ZNF74	B
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	I
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	Ki	B
2	-	I
3	ras4BVal	I
4	-	I
5	12	I
6	transfectant	O
7	cells	O
8	expressed	O
9	2	O
10	-	O
11	fold	O
12	elevated	O
13	protein	O
14	levels	O
15	of	O
16	the	O
17	lysosomal	B
18	cysteine	I
19	protease	I
20	cathepsin	I
21	B	I
22	but	O
23	did	O
24	not	O
25	up	O
26	-	O
27	regulate	O
28	cathepsin	B
29	B	I
30	mRNA	I
31	expression	O
32	.	O

1	The	O
2	cellular	O
3	rate	O
4	of	O
5	anticoagulant	B
6	heparan	I
7	sulfate	I
8	proteoglycan	I
9	(	O
10	HSPGact	B
11	)	O
12	generation	O
13	is	O
14	determined	O
15	by	O
16	the	O
17	level	O
18	of	O
19	a	O
20	kinetically	O
21	limiting	O
22	microsomal	O
23	activity	O
24	,	O
25	HSact	O
26	conversion	O
27	activity	O
28	,	O
29	which	O
30	is	O
31	predominantly	O
32	composed	O
33	of	O
34	the	O
35	long	O
36	sought	O
37	heparan	B
38	sulfate	I
39	D	I
40	-	I
41	glucosaminyl	I
42	3	I
43	-	I
44	O	I
45	-	I
46	sulfotransferase	I
47	(	O
48	3	B
49	-	I
50	OST	I
51	)	O
52	(	O
53	Shworak	O
54	,	O
55	N	O
56	.	O

1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	I
15	cbl	I
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	I
22	II	I
23	.	O

1	An	O
2	end	O
3	to	O
4	the	O
5	lottery	O
6	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	B
14	MLL	I
15	products	I
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	MLL	B
22	-	I
23	LTG9	I
24	and	O
25	MLL	B
26	-	I
27	LTG19	I
28	,	O
29	localizes	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	leukemogenesis	O
46	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	pattern	O
7	of	O
8	blood	O
9	supply	O
10	is	O
11	relevant	O
12	to	O
13	the	O
14	structural	O
15	organisation	O
16	of	O
17	mature	O
18	lamellar	O
19	bone	O
20	around	O
21	the	O
22	implant	O
23	.	O

1	Induction	O
2	of	O
3	AtP5CS1	B
4	mRNA	I
5	accumulation	O
6	in	O
7	salt	O
8	-	O
9	treated	O
10	seedlings	O
11	involves	O
12	an	O
13	immediate	O
14	early	O
15	transcriptional	O
16	response	O
17	regulated	O
18	by	O
19	ABA	O
20	signalling	O
21	that	O
22	is	O
23	not	O
24	inhibited	O
25	by	O
26	cycloheximide	O
27	,	O
28	but	O
29	abolished	O
30	by	O
31	the	O
32	deficiency	O
33	of	O
34	ABA	O
35	biosynthesis	O
36	in	O
37	the	O
38	aba1	B
39	Arabidopsis	I
40	mutant	I
41	.	O

1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O

1	(	O
2	ii	O
3	)	O
4	An	O
5	AF	O
6	G	B
7	-	I
8	CSF	I
9	level	O
10	>	O
11	2000	O
12	pg	O
13	/	O
14	ml	O
15	is	O
16	a	O
17	strong	O
18	positive	O
19	predictor	O
20	of	O
21	CAM	O
22	.	O

1	A	O
2	positive	O
3	correlation	O
4	between	O
5	serum	B
6	myoglobin	I
7	and	O
8	CA	B
9	III	I
10	concentrations	O
11	(	O
12	rs	O
13	=	O
14	0	O
15	.	O
16	933	O
17	,	O
18	P	O
19	<	O
20	0	O
21	.	O
22	001	O
23	)	O
24	was	O
25	observed	O
26	in	O
27	hemodialyzed	O
28	patients	O
29	with	O
30	chronic	O
31	renal	O
32	failure	O
33	.	O

1	Furthermore	O
2	,	O
3	the	O
4	over	O
5	-	O
6	replication	O
7	phenotype	O
8	produced	O
9	by	O
10	this	O
11	mutant	B
12	p65cdc18	I
13	is	O
14	resistant	O
15	to	O
16	increased	O
17	mitotic	O
18	cyclin	B
19	/	O
20	CDK	B
21	activity	O
22	,	O
23	a	O
24	known	O
25	inhibitor	O
26	of	O
27	over	O
28	-	O
29	replication	O
30	.	O

1	Rip1p	B
2	is	O
3	inessential	O
4	,	O
5	associated	O
6	with	O
7	nuclear	O
8	pore	O
9	complexes	O
10	,	O
11	and	O
12	structurally	O
13	related	O
14	to	O
15	the	O
16	FG	B
17	-	I
18	nucleoporin	I
19	family	I
20	of	O
21	pore	O
22	proteins	O
23	.	O

1	The	O
2	CNXA	O
3	domain	O
4	is	O
5	similar	O
6	at	O
7	the	O
8	amino	O
9	acid	O
10	level	O
11	to	O
12	the	O
13	Escherichia	B
14	coli	I
15	moaA	I
16	gene	I
17	product	I
18	,	O
19	while	O
20	CNXC	O
21	is	O
22	similar	O
23	to	O
24	the	O
25	E	B
26	.	I
27	coli	I
28	moaC	I
29	product	I
30	,	O
31	with	O
32	both	O
33	E	O
34	.	O
35	coli	O
36	products	O
37	encoded	O
38	by	O
39	different	O
40	cistrons	O
41	.	O

1	Deletions	O
2	in	O
3	each	O
4	of	O
5	these	O
6	regions	O
7	abolish	O
8	membrane	O
9	localization	O
10	of	O
11	Tiam1	B
12	and	O
13	membrane	O
14	ruffling	O
15	,	O
16	suggesting	O
17	that	O
18	they	O
19	function	O
20	cooperatively	O
21	.	O

1	However	O
2	,	O
3	besides	O
4	the	O
5	kinase	O
6	catalytic	O
7	domain	O
8	and	O
9	double	O
10	leucine	O
11	/	O
12	isoleucine	O
13	zippers	O
14	,	O
15	there	O
16	was	O
17	no	O
18	significant	O
19	homology	O
20	with	O
21	known	O
22	proteins	O
23	.	O

1	RNA	B
2	polymerase	I
3	II	I
4	inhibition	O
5	increased	O
6	the	O
7	binding	O
8	of	O
9	ARE	O
10	(	O
11	AUBP	O
12	activity	O
13	)	O
14	and	O
15	poly	O
16	(	O
17	U	O
18	)-	O
19	Sepharose	O
20	by	O
21	cytoplasmic	B
22	hnRNP	I
23	A1	I
24	,	O
25	while	O
26	nuclear	B
27	hnRNP	I
28	A1	I
29	binding	O
30	was	O
31	unaffected	O
32	.	O

1	Modulation	O
2	of	O
3	AUUUA	O
4	response	O
5	element	O
6	binding	O
7	by	O
8	heterogeneous	B
9	nuclear	I
10	ribonucleoprotein	I
11	A1	I
12	in	O
13	human	O
14	T	O
15	lymphocytes	O
16	.	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	O
29	-	O
30	Starry	O
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	Their	O
2	biosynthesis	O
3	proceeds	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	branched	O
10	by	O
11	beta1	B
12	,	I
13	6	I
14	-	I
15	GlcNAc	I
16	transferases	I
17	(	O
18	IGnT6	O
19	,	O
20	GlcNAc	O
21	to	O
22	Gal	O
23	).	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	the	O
6	t	O
7	(	O
8	4	O
9	;	O
10	14	O
11	)(	O
12	p16	O
13	.	O
14	3	O
15	;	O
16	q32	O
17	)	O
18	represents	O
19	a	O
20	novel	O
21	,	O
22	recurrent	O
23	chromosomal	O
24	translocation	O
25	in	O
26	MM	O
27	,	O
28	and	O
29	suggest	O
30	that	O
31	the	O
32	FGFR3	B
33	gene	I
34	may	O
35	be	O
36	the	O
37	target	O
38	of	O
39	this	O
40	abnormality	O
41	and	O
42	thus	O
43	contribute	O
44	to	O
45	tumorigenesis	O
46	in	O
47	MM	O
48	.	O

1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	I
9	also	O
10	significantly	O
11	reduced	O
12	promoter	O
13	activity	O
14	.	O

1	Amino	O
2	acid	O
3	residues	O
4	of	O
5	beta	O
6	1	O
7	',	O
8	alpha	O
9	A	O
10	',	O
11	alpha	O
12	B	O
13	',	O
14	and	O
15	the	O
16	loop	O
17	containing	O
18	His539	O
19	of	O
20	the	O
21	RNase	B
22	H	I
23	domain	I
24	interact	O
25	with	O
26	the	O
27	primer	O
28	strand	O
29	of	O
30	the	O
31	dsDNA	O
32	.	O

1	Moreover	O
2	,	O
3	in	O
4	one	O
5	patient	O
6	with	O
7	a	O
8	sarcoma	O
9	who	O
10	underwent	O
11	a	O
12	leg	O
13	-	O
14	sparing	O
15	procedure	O
16	,	O
17	no	O
18	sciatic	O
19	nerve	O
20	enlargement	O
21	was	O
22	seen	O
23	postoperatively	O
24	.	O

1	The	O
2	full	O
3	length	O
4	cDNA	O
5	sequence	O
6	of	O
7	a	O
8	Type	B
9	I	I
10	transforming	I
11	growth	I
12	factor	I
13	-	I
14	beta	I
15	(	I
16	TGF	I
17	-	I
18	beta	I
19	)	I
20	receptor	I
21	has	O
22	been	O
23	isolated	O
24	from	O
25	the	O
26	filarial	O
27	parasitic	O
28	nematode	O
29	Brugia	O
30	pahangi	O
31	.	O

1	This	O
2	sequence	O
3	possessed	O
4	homology	O
5	with	O
6	a	O
7	methylation	O
8	-	O
9	sensitive	O
10	promoter	O
11	element	O
12	,	O
13	Enh2	O
14	,	O
15	present	O
16	in	O
17	the	O
18	LTR	O
19	of	O
20	mouse	O
21	intractisternal	O
22	A	O
23	-	O
24	particles	O
25	.	O

1	Codon	O
2	optimization	O
3	for	O
4	high	O
5	-	O
6	level	O
7	expression	O
8	of	O
9	human	B
10	erythropoietin	I
11	(	O
12	EPO	B
13	)	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	Parodoxical	O
2	rise	O
3	in	O
4	urinary	B
5	albumin	I
6	levels	O
7	after	O
8	treatment	O
9	of	O
10	essential	O
11	hypertension	O
12	.	O

1	20	O
2	%	O
3	of	O
4	total	O
5	HSL	B
6	transcripts	I
7	in	O
8	human	O
9	subcutaneous	O
10	adipocytes	O
11	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Rat7p	B
9	/	O
10	Nup159p	B
11	is	O
12	anchored	O
13	within	O
14	the	O
15	NPC	O
16	through	O
17	its	O
18	coiled	O
19	-	O
20	coil	O
21	region	O
22	and	O
23	adjacent	O
24	sequences	O
25	.	O

1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	B
19	(	O
20	TM	B
21	),	O
22	betathromboglobulin	B
23	(	O
24	beta	B
25	-	I
26	TG	I
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	B
36	activator	I
37	-	I
38	inhibitor	I
39	(	O
40	pAI	B
41	-	I
42	1	I
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O

1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	O
11	helix	O
12	3	O
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	O
18	COOH	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	O
35	PTH	B
36	-	I
37	1	I
38	receptor	I
39	,	O
40	respectively	O
41	.	O

1	We	O
2	have	O
3	now	O
4	shown	O
5	that	O
6	in	O
7	vivo	O
8	phosphorylation	O
9	of	O
10	14	B
11	-	I
12	3	I
13	-	I
14	3	I
15	zeta	I
16	at	O
17	the	O
18	CKIalpha	B
19	site	I
20	(	I
21	Thr	I
22	-	I
23	233	I
24	)	I
25	negatively	O
26	regulates	O
27	its	O
28	binding	O
29	to	O
30	c	B
31	-	I
32	Raf	I
33	,	O
34	and	O
35	may	O
36	be	O
37	important	O
38	in	O
39	Raf	B
40	-	O
41	mediated	O
42	signal	O
43	transduction	O
44	.	O

1	Mouse	B
2	mast	I
3	cell	I
4	protease	I
5	9	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	B
17	proteases	I
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O

1	A	O
2	DNase	B
3	I	I
4	-	I
5	hypersensitive	I
6	site	I
7	has	O
8	also	O
9	been	O
10	mapped	O
11	in	O
12	the	O
13	258	O
14	-	O
15	base	O
16	pair	O
17	enhancer	O
18	region	O
19	.	O

1	[	O
2	Pulmonary	O
3	vascular	O
4	resistance	O
5	(	O
6	PVR	O
7	)	O
8	during	O
9	10	O
10	%	O
11	O2	O
12	-	O
13	PVR	O
14	during	O
15	21	O
16	%	O
17	O2	O
18	/	O
19	PVR	O
20	during	O
21	21	O
22	%	O
23	O2	O
24	]	O
25	x	O
26	100	O
27	was	O
28	termed	O
29	as	O
30	hypoxic	O
31	pulmonary	O
32	vasoconstriction	O
33	(	O
34	HPV	O
35	).	O

1	Together	O
2	,	O
3	our	O
4	results	O
5	show	O
6	that	O
7	tinman	B
8	is	O
9	controlled	O
10	by	O
11	an	O
12	array	O
13	of	O
14	discrete	O
15	enhancer	O
16	elements	O
17	that	O
18	are	O
19	activated	O
20	successively	O
21	by	O
22	differential	O
23	genetic	O
24	inputs	O
25	,	O
26	as	O
27	well	O
28	as	O
29	by	O
30	closely	O
31	linked	O
32	activator	O
33	and	O
34	repressor	O
35	binding	O
36	sites	O
37	within	O
38	an	O
39	early	O
40	-	O
41	acting	O
42	enhancer	O
43	,	O
44	which	O
45	restrict	O
46	twist	B
47	activity	O
48	to	O
49	specific	O
50	areas	O
51	within	O
52	the	O
53	twist	B
54	expression	I
55	domain	I
56	.	O

1	An	O
2	unusual	O
3	cysteine	O
4	triplet	O
5	conserved	O
6	in	O
7	the	O
8	sequences	O
9	of	O
10	TB	B
11	domains	I
12	is	O
13	localized	O
14	to	O
15	the	O
16	hydrophobic	O
17	core	O
18	,	O
19	at	O
20	the	O
21	C	O
22	-	O
23	terminus	O
24	of	O
25	an	O
26	alpha	O
27	-	O
28	helix	O
29	.	O

1	The	O
2	Fis	B
3	protein	I
4	regulates	O
5	site	O
6	-	O
7	specific	O
8	DNA	O
9	inversion	O
10	catalyzed	O
11	by	O
12	a	O
13	family	O
14	of	O
15	DNA	B
16	invertases	I
17	when	O
18	bound	O
19	to	O
20	a	O
21	cis	O
22	-	O
23	acting	O
24	recombinational	O
25	enhancer	O
26	.	O

1	Protein	O
2	phosphatases	O
3	play	O
4	a	O
5	critical	O
6	role	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	eukaryotic	O
13	cell	O
14	cycle	O
15	and	O
16	signal	O
17	transduction	O
18	.	O

1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	O
7	factor	O
8	E2F	B
9	is	O
10	also	O
11	known	O
12	to	O
13	bend	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O

1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	O
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	SUP35	B
5	and	O
6	SUP45	B
7	in	I
8	Saccharomyces	I
9	cerevisiae	I
10	.	O

1	These	O
2	studies	O
3	serve	O
4	as	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	further	O
10	characterization	O
11	of	O
12	the	O
13	regulatory	O
14	mechanism	O
15	of	O
16	aromatase	B
17	expression	O
18	in	O
19	human	O
20	breast	O
21	cancer	O
22	and	O
23	ASCs	O
24	.	O

1	Xenopus	B
2	Ran	I
3	-	I
4	binding	I
5	protein	I
6	1	I
7	:	O
8	molecular	O
9	interactions	O
10	and	O
11	effects	O
12	on	O
13	nuclear	O
14	assembly	O
15	in	O
16	Xenopus	O
17	egg	O
18	extracts	O
19	.	O

1	She	O
2	improved	O
3	with	O
4	a	O
5	combination	O
6	of	O
7	benzodiazepines	O
8	and	O
9	the	O
10	acetylcholinesterase	B
11	inhibitor	O
12	physostigmine	O
13	.	O

1	METHODS	O
2	:	O
3	Total	O
4	muscle	O
5	paralysis	O
6	was	O
7	induced	O
8	under	O
9	general	O
10	anesthesia	O
11	in	O
12	a	O
13	group	O
14	of	O
15	obese	O
16	persons	O
17	(	O
18	n	O
19	=	O
20	9	O
21	;	O
22	body	O
23	mass	O
24	index	O
25	,	O
26	32	O
27	+/-	O
28	3	O
29	kg	O
30	[-	O
31	2	O
32	])	O
33	and	O
34	in	O
35	a	O
36	group	O
37	of	O
38	nonobese	O
39	persons	O
40	(	O
41	n	O
42	=	O
43	9	O
44	;	O
45	body	O
46	mas	O
47	index	O
48	,	O
49	21	O
50	+/-	O
51	2	O
52	kg	O
53	[-	O
54	2	O
55	]).	O

1	PKA	B
2	phosphorylated	O
3	WT1	B
4	at	O
5	Ser	O
6	-	O
7	365	O
8	and	O
9	Ser	O
10	-	O
11	393	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	WT1	B
33	in	O
34	vitro	O
35	.	O

1	Our	O
2	findings	O
3	provide	O
4	the	O
5	first	O
6	evidence	O
7	that	O
8	the	O
9	function	O
10	of	O
11	WT1	B
12	can	O
13	be	O
14	modulated	O
15	by	O
16	its	O
17	phosphorylation	O
18	in	O
19	vivo	O
20	.	O

1	Re	O
2	:	O
3	"	O
4	Assessing	O
5	the	O
6	direction	O
7	of	O
8	causality	O
9	in	O
10	cross	O
11	-	O
12	sectional	O
13	studies	O
14	".	O

1	A	O
2	second	O
3	aim	O
4	was	O
5	to	O
6	determine	O
7	whether	O
8	the	O
9	decrease	O
10	in	O
11	muscle	O
12	-	O
13	tendon	O
14	unit	O
15	rest	O
16	length	O
17	produced	O
18	by	O
19	prolonged	O
20	immobilisation	O
21	in	O
22	a	O
23	shortened	O
24	position	O
25	is	O
26	mediated	O
27	primarily	O
28	by	O
29	adaptations	O
30	of	O
31	the	O
32	muscle	O
33	or	O
34	tendon	O
35	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	B
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	B
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	B
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O

1	We	O
2	argue	O
3	that	O
4	the	O
5	primary	O
6	role	O
7	of	O
8	hh	B
9	in	O
10	controlling	O
11	polarity	O
12	is	O
13	to	O
14	cause	O
15	anterior	O
16	compartment	O
17	cells	O
18	to	O
19	reverse	O
20	their	O
21	interpretation	O
22	of	O
23	an	O
24	underlying	O
25	symmetric	O
26	polarization	O
27	.	O

1	Restriction	O
2	enzyme	O
3	mapping	O
4	,	O
5	subcloning	O
6	,	O
7	and	O
8	DNA	O
9	sequencing	O
10	analysis	O
11	of	O
12	recombinant	O
13	phage	O
14	lambda	O
15	and	O
16	P1	O
17	clones	O
18	revealed	O
19	that	O
20	exons	O
21	encoding	O
22	the	O
23	1	O
24	.	O
25	9	O
26	-	O
27	kb	O
28	mouse	B
29	TS	I
30	mRNA	I
31	are	O
32	dispersed	O
33	over	O
34	>	O
35	150	O
36	kb	O
37	genomic	O
38	DNA	O
39	.	O

1	Transfection	O
2	analyses	O
3	indicated	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Tbxas1	B
9	is	O
10	controlled	O
11	by	O
12	a	O
13	short	O
14	(	O
15	70	O
16	-	O
17	bp	O
18	)	O
19	positive	O
20	regulatory	O
21	sequence	O
22	and	O
23	several	O
24	upstream	O
25	repressive	O
26	elements	O
27	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O

1	The	O
2	lysozyme	B
3	FEF	I
4	site	O
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O

1	Osteocalcin	B
2	(	O
3	OC	B
4	)	O
5	is	O
6	a	O
7	matrix	B
8	calcium	I
9	-	I
10	binding	I
11	protein	I
12	expressed	O
13	in	O
14	osteoblasts	O
15	and	O
16	odontoblasts	O
17	undergoing	O
18	mineralization	O
19	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	examine	O
7	the	O
8	effects	O
9	of	O
10	Msx2	B
11	expression	O
12	on	O
13	OC	B
14	promoter	I
15	activation	O
16	(	O
17	luciferase	B
18	reporter	I
19	)	O
20	by	O
21	FGF2	B
22	/	O
23	FSK	B
24	and	O
25	calcitriol	O
26	in	O
27	MC3T3	O
28	-	O
29	E1	O
30	osteoblasts	O
31	.	O

1	Thus	O
2	,	O
3	unlike	O
4	other	O
5	proteins	O
6	reported	O
7	to	O
8	inhibit	O
9	SRF	B
10	activity	O
11	,	O
12	the	O
13	repressor	O
14	activity	O
15	associated	O
16	with	O
17	the	O
18	GC	O
19	-	O
20	rich	O
21	element	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	function	O
27	through	O
28	direct	O
29	inhibition	O
30	of	O
31	SRF	B
32	binding	O
33	.	O

1	However	O
2	,	O
3	one	O
4	CAK	B
5	-	O
6	phosphorylated	O
7	phosphopeptide	O
8	comigrates	O
9	with	O
10	a	O
11	Cdc2	B
12	-	O
13	phosphorylated	O
14	phosphopeptide	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	B
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O

1	The	O
2	pen	O
3	can	O
4	heal	O
5	.	O

1	The	O
2	mHIF	B
3	-	I
4	1	I
5	alpha	I
6	structural	I
7	gene	I
8	is	O
9	composed	O
10	of	O
11	15	O
12	exons	O
13	.	O

1	However	O
2	,	O
3	when	O
4	a	O
5	second	O
6	,	O
7	upstream	B
8	IRE	I
9	-	I
10	like	I
11	sequence	I
12	was	O
13	evaluated	O
14	by	O
15	EMSA	O
16	,	O
17	a	O
18	DNA	O
19	binding	O
20	pattern	O
21	distinct	O
22	from	O
23	that	O
24	seen	O
25	following	O
26	exposure	O
27	to	O
28	IFN	B
29	-	I
30	gamma	I
31	alone	O
32	was	O
33	observed	O
34	after	O
35	prolonged	O
36	stimulation	O
37	with	O
38	both	O
39	IFN	B
40	-	I
41	alpha	I
42	and	O
43	IFN	B
44	-	I
45	gamma	I
46	.	O

1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	O
9	-	O
10	responsive	O
11	gene	O
12	,	O
13	rd22	B
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	MYC	B
6	-	I
7	related	I
8	DNA	I
9	binding	I
10	protein	I
11	was	O
12	isolated	O
13	by	O
14	DNA	O
15	-	O
16	ligand	O
17	binding	O
18	screening	O
19	,	O
20	using	O
21	the	O
22	67	O
23	-	O
24	bp	O
25	region	O
26	as	O
27	a	O
28	probe	O
29	,	O
30	and	O
31	designated	O
32	rd22BP1	B
33	.	O

1	Human	B
2	PDK1	I
3	is	O
4	homologous	O
5	to	O
6	the	O
7	Drosophila	B
8	protein	I
9	kinase	I
10	DSTPK61	I
11	,	O
12	which	O
13	has	O
14	been	O
15	implicated	O
16	in	O
17	the	O
18	regulation	O
19	of	O
20	sex	O
21	differentiation	O
22	,	O
23	oogenesis	O
24	and	O
25	spermatogenesis	O
26	.	O

1	Thus	O
2	,	O
3	the	O
4	synergistic	O
5	effects	O
6	of	O
7	HNF	B
8	-	I
9	1beta	I
10	and	O
11	the	O
12	GR	B
13	on	O
14	dexamethasone	O
15	-	O
16	stimulated	O
17	promoter	O
18	activity	O
19	require	O
20	that	O
21	they	O
22	are	O
23	bound	O
24	to	O
25	the	O
26	HNF	B
27	-	I
28	1	I
29	site	I
30	and	O
31	the	O
32	GRE	O
33	,	O
34	respectively	O
35	,	O
36	and	O
37	may	O
38	involve	O
39	protein	O
40	-	O
41	protein	O
42	interactions	O
43	between	O
44	the	O
45	transcription	O
46	factors	O
47	,	O
48	or	O
49	between	O
50	them	O
51	and	O
52	the	O
53	basal	O
54	transcription	O
55	machinery	O
56	or	O
57	a	O
58	steroid	B
59	receptor	I
60	coactivator	I
61	.	O

1	Mutational	O
2	analysis	O
3	shows	O
4	that	O
5	both	O
6	an	O
7	AP	B
8	-	I
9	1	I
10	like	I
11	sequence	I
12	(-	O
13	294	O
14	/-	O
15	285	O
16	,	O
17	TGAATCATCA	O
18	)	O
19	and	O
20	an	O
21	A	O
22	/	O
23	T	O
24	-	O
25	rich	O
26	myocyte	B
27	enhancer	I
28	factor	I
29	(	I
30	MEF	I
31	)-	I
32	2	I
33	like	I
34	sequence	I
35	(-	O
36	310	O
37	/-	O
38	298	O
39	,	O
40	TTAAAAATAAAAA	O
41	)	O
42	in	O
43	the	O
44	33	O
45	-	O
46	bp	O
47	region	O
48	are	O
49	necessary	O
50	for	O
51	the	O
52	OP	B
53	-	I
54	1	I
55	effect	O
56	.	O

1	Unlike	O
2	most	O
3	other	O
4	members	O
5	of	O
6	the	O
7	Bcl	B
8	-	I
9	2	I
10	family	I
11	,	O
12	BAD	B
13	(	O
14	Bcl	B
15	-	I
16	xL	I
17	/	I
18	Bcl	I
19	-	I
20	2	I
21	associated	I
22	death	I
23	promoter	I
24	),	O
25	a	O
26	death	B
27	enhancer	I
28	,	O
29	has	O
30	no	O
31	C	O
32	-	O
33	terminal	O
34	transmembrane	O
35	domain	O
36	for	O
37	targeting	O
38	to	O
39	the	O
40	outer	O
41	mitochondrial	O
42	membrane	O
43	and	O
44	nuclear	O
45	envelope	O
46	.	O

1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	B
9	,	O
10	but	O
11	not	O
12	HNF4	B
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	I
23	expression	O
24	.	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	of	O
6	2862	O
7	bp	O
8	encoding	O
9	a	O
10	954	O
11	amino	O
12	acid	O
13	protein	O
14	was	O
15	identified	O
16	.	O

1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	AACA	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	seed	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	barley	O
29	gibberellin	O
30	responsive	O
31	element	O
32	recognized	O
33	by	O
34	MYB	B
35	-	I
36	like	I
37	DNA	I
38	binding	I
39	proteins	I
40	.	O

1	Strain	O
2	CFN037	O
3	is	O
4	an	O
5	R	O
6	.	O
7	etli	O
8	mutant	O
9	induced	O
10	by	O
11	a	O
12	single	O
13	Tn5mob	B
14	insertion	O
15	in	O
16	the	O
17	promoter	O
18	region	O
19	of	O
20	the	O
21	thiCOGE	B
22	gene	I
23	cluster	I
24	.	O

1	Expression	O
2	of	O
3	thiamin	O
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	B
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	I
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	I
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	uncharacterized	O
18	metalloprotease	B
19	of	I
20	Vibrio	I
21	cholerae	I
22	O1	I
23	.	O

1	Furthermore	O
2	,	O
3	the	O
4	amount	O
5	of	O
6	tRNA	B
7	(	I
8	3Lys	I
9	)	I
10	that	O
11	was	O
12	placed	O
13	onto	O
14	viral	O
15	RNA	O
16	in	O
17	mutated	O
18	viruses	O
19	was	O
20	significantly	O
21	less	O
22	than	O
23	that	O
24	placed	O
25	in	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	virus	O
31	.	O

1	This	O
2	protein	O
3	is	O
4	present	O
5	in	O
6	both	O
7	HeLa	O
8	nuclear	O
9	extracts	O
10	and	O
11	S100	B
12	extracts	O
13	but	O
14	absent	O
15	from	O
16	SR	B
17	protein	I
18	preparations	O
19	,	O
20	suggesting	O
21	that	O
22	it	O
23	is	O
24	not	O
25	a	O
26	classical	O
27	SR	B
28	protein	I
29	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	B
6	-	I
7	C	I
8	and	O
9	pregenomic	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	B
21	receptor	I
22	superfamily	I
23	.	O

1	Acad	O
2	.	O

1	Chimeras	O
2	containing	O
3	IE1	B
4	peptides	I
5	dramatically	O
6	activated	O
7	transcription	O
8	of	O
9	the	O
10	basal	O
11	promoter	O
12	only	O
13	when	O
14	lac	B
15	operator	I
16	sequences	I
17	were	O
18	present	O
19	.	O

1	The	O
2	results	O
3	of	O
4	replicase	B
5	assays	O
6	performed	O
7	with	O
8	mutant	B
9	VP2	I
10	containing	O
11	a	O
12	deletion	O
13	in	O
14	its	O
15	RNA	O
16	-	O
17	binding	O
18	domain	O
19	suggests	O
20	that	O
21	the	O
22	essential	O
23	role	O
24	for	O
25	VP2	B
26	in	O
27	replication	O
28	is	O
29	linked	O
30	to	O
31	the	O
32	protein	O
33	'	O
34	s	O
35	ability	O
36	to	O
37	bind	O
38	the	O
39	mRNA	O
40	template	O
41	for	O
42	minus	O
43	-	O
44	strand	O
45	synthesis	O
46	.	O

1	We	O
2	previously	O
3	described	O
4	two	O
5	alanine	O
6	cluster	O
7	mutations	O
8	,	O
9	R77	O
10	to	O
11	A	O
12	(	O
13	R77A	O
14	)-	O
15	K79A	O
16	and	O
17	E192A	O
18	-	O
19	E194A	O
20	,	O
21	which	O
22	selectively	O
23	inactivated	O
24	the	O
25	triphosphatase	O
26	component	O
27	.	O

1	Transfection	O
2	of	O
3	HepG2	O
4	and	O
5	SK	O
6	-	O
7	N	O
8	-	O
9	MC	O
10	cells	O
11	with	O
12	constructs	O
13	deleted	O
14	of	O
15	additional	O
16	5	O
17	'-	O
18	flanking	O
19	fragments	O
20	permitted	O
21	the	O
22	definition	O
23	of	O
24	a	O
25	minimal	O
26	200	O
27	bp	O
28	promoter	O
29	fragment	O
30	containing	O
31	the	O
32	pseudo	O
33	-	O
34	TATA	O
35	box	O
36	and	O
37	two	O
38	putative	O
39	SP1	B
40	-	I
41	binding	I
42	sites	I
43	.	O

1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	I
11	2alpha	I
12	kinases	I
13	.	O

1	Three	O
2	monopolar	O
3	electrodes	O
4	were	O
5	inserted	O
6	into	O
7	the	O
8	left	O
9	and	O
10	right	O
11	lateral	O
12	vestibulospinal	O
13	tract	O
14	(	O
15	LVST	O
16	)	O
17	and	O
18	medial	O
19	vestibulospinal	O
20	tract	O
21	(	O
22	MVST	O
23	)	O
24	of	O
25	the	O
26	C1	O
27	segment	O
28	,	O
29	to	O
30	determine	O
31	the	O
32	pathway	O
33	of	O
34	axons	O
35	.	O

1	Epitopes	O
2	of	O
3	adhesion	O
4	-	O
5	perturbing	O
6	monoclonal	O
7	antibodies	O
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	I
20	1	I
21	subunit	I
22	.	O

1	Polyhomeotic	B
2	and	I
3	Posterior	I
4	Sex	I
5	Combs	I
6	may	O
7	participate	O
8	in	O
9	a	O
10	more	O
11	general	O
12	transcriptional	O
13	mechanism	O
14	that	O
15	causes	O
16	modulated	O
17	gene	O
18	repression	O
19	,	O
20	whereas	O
21	the	O
22	inclusion	O
23	of	O
24	Polycomb	B
25	protein	I
26	in	O
27	the	O
28	complex	O
29	at	O
30	PREs	B
31	leads	O
32	to	O
33	stable	O
34	silencing	O
35	.	O

1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	B
5	proteins	I
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	B
22	proteins	I
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	B
32	.	O

1	The	O
2	yeast	O
3	silent	B
4	information	I
5	regulator	I
6	Sir4p	I
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	These	O
2	results	O
3	implicate	O
4	a	O
5	precursor	O
6	-	O
7	specific	O
8	base	O
9	-	O
10	paired	O
11	structure	O
12	involving	O
13	sequences	O
14	on	O
15	both	O
16	sides	O
17	of	O
18	the	O
19	mature	O
20	cleavage	O
21	site	O
22	in	O
23	the	O
24	3	O
25	'	O
26	processing	O
27	of	O
28	human	B
29	U2	I
30	RNA	I
31	.	O

1	Polysome	O
2	analyses	O
3	in	O
4	a	O
5	temperature	O
6	-	O
7	sensitive	O
8	fal1	B
9	-	I
10	1	I
11	mutant	I
12	and	O
13	a	O
14	Fal1p	B
15	-	O
16	depleted	O
17	strain	O
18	reveal	O
19	a	O
20	decrease	O
21	in	O
22	the	O
23	number	O
24	of	O
25	40S	B
26	ribosomal	I
27	subunits	I
28	.	O

1	Sequence	O
2	analysis	O
3	identified	O
4	some	O
5	of	O
6	these	O
7	cDNA	O
8	clones	O
9	as	O
10	Dlc	B
11	-	I
12	1	I
13	,	O
14	a	O
15	sequence	O
16	encoding	O
17	a	O
18	small	O
19	,	O
20	9	B
21	-	I
22	kDa	I
23	human	I
24	homolog	I
25	of	I
26	the	I
27	outer	I
28	-	I
29	arm	I
30	dynein	I
31	light	I
32	-	I
33	chain	I
34	protein	O
35	.	O

1	Importantly	O
2	,	O
3	in	O
4	HeLa	O
5	and	O
6	293	O
7	cells	O
8	,	O
9	endogenous	O
10	and	O
11	transfected	O
12	I	B
13	kappaB	I
14	alpha	I
15	coimmunoprecipitated	O
16	with	O
17	Myc	B
18	-	O
19	tagged	O
20	or	O
21	endogenous	O
22	Dlc	B
23	-	I
24	1	I
25	.	O

1	The	O
2	mouse	B
3	M	I
4	-	I
5	lysozyme	I
6	downstream	I
7	enhancer	I
8	has	O
9	been	O
10	previously	O
11	characterized	O
12	on	O
13	several	O
14	levels	O
15	of	O
16	gene	O
17	regulation	O
18	.	O

1	Identification	O
2	of	O
3	dynein	B
4	heavy	I
5	chain	I
6	genes	I
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	B
19	dynein	I
20	gene	I
21	.	O

1	Bitter	O
2	cassava	O
3	contains	O
4	cyanogenic	O
5	glycosides	O
6	;	O
7	processing	O
8	breaks	O
9	them	O
10	down	O
11	to	O
12	acetone	O
13	cyanohydrin	O
14	and	O
15	hydrogen	O
16	cyanide	O
17	.	O

1	The	O
2	proposed	O
3	mechanism	O
4	of	O
5	effect	O
6	states	O
7	that	O
8	mono	O
9	(	O
10	2	O
11	-	O
12	ethylhexyl	O
13	)	O
14	phthalate	O
15	(	O
16	MEHP	O
17	),	O
18	the	O
19	primary	O
20	hydrolysis	O
21	product	O
22	of	O
23	DEHP	O
24	,	O
25	mimics	O
26	the	O
27	inducing	O
28	prostaglandins	O
29	(	O
30	PG	O
31	)	O
32	PGD	O
33	(	O
34	2	O
35	),	O
36	9alpha	O
37	,	O
38	11betaPGF2	O
39	,	O
40	and	O
41	PGF2alpha	O
42	,	O
43	and	O
44	thromboxanes	O
45	in	O
46	the	O
47	lungs	O
48	,	O
49	thereby	O
50	increasing	O
51	the	O
52	risk	O
53	of	O
54	inducing	O
55	inflammation	O
56	in	O
57	the	O
58	airways	O
59	,	O
60	which	O
61	is	O
62	a	O
63	characteristic	O
64	of	O
65	asthma	O
66	.	O

1	We	O
2	found	O
3	14	O
4	protein	O
5	binding	O
6	sites	O
7	that	O
8	were	O
9	occupied	O
10	in	O
11	vivo	O
12	.	O

1	Constitutive	O
2	protection	O
3	of	O
4	E2F	B
5	recognition	I
6	sequences	I
7	in	O
8	the	O
9	human	B
10	thymidine	I
11	kinase	I
12	promoter	I
13	during	O
14	cell	O
15	cycle	O
16	progression	O
17	.	O

1	Comparison	O
2	of	O
3	genomic	O
4	sequence	O
5	shows	O
6	that	O
7	the	O
8	ph	B
9	locus	I
10	has	O
11	been	O
12	duplicated	O
13	,	O
14	and	O
15	that	O
16	it	O
17	contains	O
18	proximal	O
19	and	O
20	distal	O
21	transcription	O
22	units	O
23	.	O

1	Radiation	O
2	decreased	O
3	the	O
4	levels	O
5	of	O
6	T4	O
7	and	O
8	T3	O
9	6	O
10	h	O
11	and	O
12	72	O
13	h	O
14	in	O
15	group	O
16	C	O
17	,	O
18	in	O
19	group	O
20	A	O
21	at	O
22	72	O
23	h	O
24	,	O
25	in	O
26	group	O
27	B	O
28	at	O
29	24	O
30	h	O
31	postexposure	O
32	.	O

1	We	O
2	have	O
3	reviewed	O
4	the	O
5	experience	O
6	of	O
7	a	O
8	major	O
9	MMT	O
10	general	O
11	practice	O
12	with	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	infection	O
20	from	O
21	1991	O
22	to	O
23	1995	O
24	.	O

1	The	O
2	author	O
3	analyzes	O
4	extensive	O
5	own	O
6	data	O
7	based	O
8	on	O
9	study	O
10	into	O
11	particular	O
12	features	O
13	of	O
14	cardiovascular	O
15	disorders	O
16	in	O
17	chronic	O
18	renal	O
19	impairement	O
20	with	O
21	making	O
22	use	O
23	of	O
24	modern	O
25	diagnostic	O
26	tools	O
27	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	characterization	O
6	is	O
7	given	O
8	of	O
9	clinical	O
10	and	O
11	biochemical	O
12	features	O
13	of	O
14	VH	O
15	B	O
16	course	O
17	against	O
18	the	O
19	background	O
20	of	O
21	narcomania	O
22	.	O

1	447	O
2	microns	O
3	for	O
4	A	O
5	.	O
6	microcephalum	O
7	and	O
8	350	O
9	microns	O
10	for	O
11	A	O
12	.	O
13	wedli	O
14	),	O
15	and	O
16	fewer	O
17	testes	O
18	per	O
19	proglottis	O
20	(	O
21	44	O
22	-	O
23	73	O
24	vs	O
25	.	O

1	The	O
2	ZnF20	B
3	cDNA	I
4	hybridized	O
5	to	O
6	multiple	O
7	transcripts	O
8	in	O
9	a	O
10	thyroid	O
11	cancer	O
12	cell	O
13	line	O
14	(	O
15	8	O
16	.	O
17	0	O
18	,	O
19	4	O
20	.	O
21	5	O
22	and	O
23	2	O
24	kb	O
25	)	O
26	that	O
27	increased	O
28	after	O
29	cycloheximide	O
30	treatment	O
31	and	O
32	decayed	O
33	<	O
34	2	O
35	h	O
36	after	O
37	addition	O
38	of	O
39	actinomycin	O
40	D	O
41	.	O

1	Glutathione	B
2	S	I
3	-	I
4	transferase	I
5	(	O
6	GST	B
7	)-	O
8	E2F	B
9	and	O
10	GST	B
11	-	O
12	DP	B
13	fusion	O
14	proteins	O
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	B
25	sites	I
26	in	O
27	the	O
28	DNA	B
29	polymerase	I
30	alpha	I
31	gene	I
32	promoter	I
33	in	O
34	vitro	O
35	.	O

1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	B
14	gene	I
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	B
20	density	I
21	lipoprotein	I
22	free	O
23	cholesterol	O
24	.	O

1	Furthermore	O
2	,	O
3	DNA	O
4	-	O
5	bound	O
6	LAZ3	B
7	/	O
8	BCL6	B
9	recruits	O
10	SMRT	B
11	in	O
12	vivo	O
13	,	O
14	and	O
15	both	O
16	overexpressed	O
17	proteins	O
18	completely	O
19	colocalize	O
20	in	O
21	nuclear	O
22	dots	O
23	.	O

1	CONCLUSIONS	O
2	:	O
3	We	O
4	obtained	O
5	normal	O
6	EPO	B
7	levels	O
8	for	O
9	mothers	O
10	and	O
11	newborns	O
12	for	O
13	our	O
14	area	O
15	,	O
16	similarly	O
17	to	O
18	the	O
19	previously	O
20	described	O
21	ones	O
22	.	O

1	Ischaemia	O
2	was	O
3	induced	O
4	by	O
5	a	O
6	low	O
7	flow	O
8	rate	O
9	of	O
10	0	O
11	.	O
12	8	O
13	mL	O
14	min	O
15	-	O
16	1	O
17	for	O
18	30	O
19	min	O
20	,	O
21	and	O
22	was	O
23	followed	O
24	by	O
25	a	O
26	40	O
27	-	O
28	minute	O
29	reperfusion	O
30	.	O

1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O

1	BACKGROUND	O
2	:	O
3	Checkpoint	O
4	pathways	O
5	prevent	O
6	cell	O
7	-	O
8	cycle	O
9	progression	O
10	in	O
11	the	O
12	event	O
13	of	O
14	DNA	O
15	lesions	O
16	.	O

1	Direct	O
2	proof	O
3	that	O
4	the	O
5	heightened	O
6	renal	O
7	cellular	O
8	apoptosis	O
9	in	O
10	PKD	O
11	is	O
12	not	O
13	occurring	O
14	through	O
15	p53	B
16	was	O
17	obtained	O
18	by	O
19	successive	O
20	matings	O
21	between	O
22	SBM	O
23	and	O
24	p53	B
25	(-/-)	O
26	mice	O
27	.	O

1	Accumulated	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	O
9	interferon	B
10	-	I
11	gamma	I
12	(	O
13	IFN	B
14	-	I
15	gamma	I
16	),	O
17	three	O
18	beta	O
19	-	O
20	type	O
21	subunits	O
22	,	O
23	designated	O
24	LMP2	B
25	,	O
26	LMP7	B
27	,	O
28	and	O
29	PSMB10	B
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	20S	B
36	proteasome	I
37	by	O
38	displacing	O
39	the	O
40	housekeeping	O
41	beta	O
42	-	O
43	type	O
44	subunits	O
45	designated	O
46	PSMB6	B
47	,	O
48	PSMB5	B
49	,	O
50	and	O
51	PSMB7	B
52	,	O
53	respectively	O
54	.	O

1	The	O
2	major	O
3	RNase	B
4	E	I
5	cleavage	O
6	product	O
7	(	O
8	denoted	O
9	pSok	B
10	-	I
11	6	I
12	)	O
13	is	O
14	rapidly	O
15	degraded	O
16	by	O
17	polynucleotide	B
18	phosphorylase	I
19	(	O
20	PNPase	B
21	).	O

1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	match	O
9	to	O
10	the	O
11	ARG	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	B
17	(	I
18	rocD	I
19	)	I
20	site	I
21	.	O

1	Ask	O
2	AONE	O
3	'	O
4	s	O
5	experts	O
6	...	O
7	about	O
8	productivity	O
9	indicators	O
10	.	O

1	All	O
2	pigs	O
3	had	O
4	significant	O
5	regional	O
6	LV	O
7	dysfunction	O
8	and	O
9	reduced	O
10	LV	O
11	ejection	O
12	fraction	O
13	(	O
14	41	O
15	+/-	O
16	11	O
17	%).	O

1	The	O
2	progress	O
3	of	O
4	morphological	O
5	research	O
6	on	O
7	the	O
8	parabrachial	O
9	nucleus	O

1	The	O
2	amplitudes	O
3	of	O
4	DPOAE	O
5	also	O
6	recovered	O
7	to	O
8	a	O
9	greater	O
10	extent	O
11	and	O
12	outer	O
13	hair	O
14	cell	O
15	losses	O
16	were	O
17	less	O
18	severe	O
19	in	O
20	the	O
21	R	O
22	-	O
23	PIA	O
24	-	O
25	treated	O
26	ears	O
27	.	O

1	The	O
2	data	O
3	provide	O
4	evidence	O
5	both	O
6	for	O
7	a	O
8	signal	O
9	transduction	O
10	pathway	O
11	independent	O
12	of	O
13	JNK	B
14	,	O
15	ERK	B
16	,	O
17	and	O
18	p38	B
19	MAP	I
20	kinase	I
21	to	O
22	be	O
23	involved	O
24	in	O
25	the	O
26	induction	O
27	of	O
28	rhoB	B
29	by	O
30	genotoxic	O
31	stress	O
32	,	O
33	and	O
34	furthermore	O
35	,	O
36	indicate	O
37	autoregulation	O
38	of	O
39	rhoB	B
40	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	B
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	B
35	were	O
36	constructed	O
37	.	O

1	Inhibition	O
2	appears	O
3	to	O
4	result	O
5	from	O
6	titration	O
7	of	O
8	general	O
9	transcription	O
10	factors	O
11	because	O
12	MDM2	B
13	overexpression	O
14	inhibits	O
15	c	B
16	-	I
17	fos	I
18	as	O
19	well	O
20	as	O
21	other	O
22	promoters	O
23	in	O
24	vivo	O
25	and	O
26	basal	O
27	transcription	O
28	in	O
29	vitro	O
30	.	O

1	4	O
2	)	O
3	PU	B
4	and	O
5	PD	B
6	lacked	O
7	the	O
8	canonical	O
9	TATA	O
10	or	O
11	CAAT	O
12	motifs	O
13	,	O
14	and	O
15	are	O
16	AT	O
17	-	O
18	rich	O
19	.	O

1	We	O
2	also	O
3	show	O
4	by	O
5	immunogold	O
6	electron	O
7	microscopy	O
8	immunocytochemistry	O
9	that	O
10	amphiphysin	B
11	I	I
12	is	O
13	localized	O
14	in	O
15	the	O
16	nerve	O
17	terminal	O
18	cytomatrix	O
19	and	O
20	is	O
21	partially	O
22	associated	O
23	with	O
24	endocytic	O
25	intermediates	O
26	.	O

1	The	O
2	mobility	O
3	shift	O
4	of	O
5	both	O
6	of	O
7	these	O
8	proteins	O
9	is	O
10	abolished	O
11	by	O
12	treatment	O
13	with	O
14	inhibitors	O
15	of	O
16	PKC	B
17	or	O
18	mitogen	B
19	-	I
20	activated	I
21	protein	I
22	kinase	I
23	/	O
24	extracellular	B
25	signal	I
26	-	I
27	related	I
28	kinase	I
29	kinase	I
30	.	O

1	The	O
2	prescription	O
3	for	O
4	apoplexy	O
5	includes	O
6	C1	O
7	-	O
8	7	O
9	,	O
10	T1	O
11	-	O
12	9	O
13	and	O
14	L2	O
15	-	O
16	4	O
17	.	O

1	During	O
2	the	O
3	aftermath	O
4	of	O
5	excitation	O
6	of	O
7	the	O
8	skin	O
9	sympathetic	O
10	nerve	O
11	by	O
12	mental	O
13	arithmetics	O
14	,	O
15	3	O
16	/	O
17	12	O
18	A	O
19	delta	O
20	units	O
21	were	O
22	turned	O
23	to	O
24	the	O
25	active	O
26	state	O
27	with	O
28	decreased	O
29	mechanical	O
30	threshold	O
31	.	O

1	In	O
2	a	O
3	similar	O
4	fashion	O
5	to	O
6	adipose	O
7	stromal	O
8	cells	O
9	,	O
10	serum	O
11	potentiated	O
12	the	O
13	response	O
14	to	O
15	dexamethasone	O
16	but	O
17	had	O
18	no	O
19	effect	O
20	on	O
21	phorbol	O
22	ester	O
23	-	O
24	stimulated	O
25	activity	O
26	.	O

1	Thus	O
2	,	O
3	Hex	B
4	expression	O
5	marks	O
6	the	O
7	earliest	O
8	unequivocal	O
9	molecular	O
10	anteroposterior	O
11	asymmetry	O
12	in	O
13	the	O
14	mouse	O
15	embryo	O
16	and	O
17	indicates	O
18	that	O
19	the	O
20	anteroposterior	O
21	axis	O
22	of	O
23	the	O
24	embryo	O
25	develops	O
26	from	O
27	conversion	O
28	of	O
29	a	O
30	proximodistal	O
31	asymmetry	O
32	established	O
33	in	O
34	the	O
35	primitive	O
36	endoderm	O
37	lineage	O
38	.	O

1	Thus	O
2	,	O
3	dpp	B
4	and	O
5	omb	B
6	promote	O
7	both	O
8	dorsal	O
9	leg	O
10	cell	O
11	fate	O
12	as	O
13	well	O
14	as	O
15	transdetermination	O
16	-	O
17	competent	O
18	leg	O
19	disc	O
20	cells	O
21	.	O

1	CONCLUSIONS	O
2	:	O
3	While	O
4	INR	O
5	correction	O
6	may	O
7	be	O
8	achieved	O
9	by	O
10	all	O
11	the	O
12	above	O
13	methods	O
14	,	O
15	that	O
16	relating	O
17	log	O
18	reference	O
19	INR	O
20	to	O
21	log	O
22	local	O
23	prothrombin	B
24	time	O
25	by	O
26	linear	O
27	regression	O
28	analysis	O
29	is	O
30	the	O
31	simplest	O
32	to	O
33	perform	O
34	.	O

1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	FNF	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	successive	O
34	quarters	O
35	in	O
36	1992	O
37	.	O

1	Western	O
2	blot	O
3	analysis	O
4	of	O
5	various	O
6	bovine	O
7	tissues	O
8	with	O
9	human	O
10	NMT	B
11	peptide	I
12	antibody	I
13	indicated	O
14	a	O
15	common	O
16	prominent	O
17	immunoreactive	O
18	band	O
19	with	O
20	an	O
21	apparent	O
22	molecular	O
23	mass	O
24	of	O
25	48	O
26	.	O
27	5	O
28	-	O
29	50	O
30	kDa	O
31	in	O
32	all	O
33	tissues	O
34	.	O

1	Transcription	O
2	start	O
3	sites	O
4	of	O
5	the	O
6	plastid	O
7	ACCase	B
8	genes	I
9	were	O
10	estimated	O
11	from	O
12	the	O
13	longest	O
14	cDNA	O
15	clones	O
16	obtained	O
17	by	O
18	5	O
19	'-	O
20	RACE	O
21	(	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	).	O

1	AIDS	O
2	-	O
3	related	O
4	disseminated	O
5	histoplasmosis	O
6	in	O
7	San	O
8	Francisco	O
9	,	O
10	California	O
11	.	O

1	Thus	O
2	,	O
3	Fis	B
4	acts	O
5	as	O
6	an	O
7	accessory	O
8	transcriptional	O
9	activator	O
10	at	O
11	the	O
12	mar	B
13	promoter	I
14	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	O
13	tRNA	O
14	can	O
15	confer	O
16	a	O
17	mutator	O
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	B
29	and	O
30	mutC	B
31	cells	O
32	.	O

1	TNF	B
2	-	I
3	alpha	I
4	exposure	O
5	markedly	O
6	increased	O
7	activity	O
8	of	O
9	several	O
10	RNA	O
11	-	O
12	binding	O
13	proteins	O
14	,	O
15	especially	O
16	a	O
17	novel	O
18	Mr	O
19	50	O
20	,	O
21	000	O
22	-	O
23	55	O
24	,	O
25	000	O
26	RNA	O
27	-	O
28	binding	O
29	protein	O
30	.	O

1	We	O
2	speculate	O
3	that	O
4	the	O
5	human	O
6	papillomavirus	O
7	late	O
8	mRNAs	O
9	,	O
10	produced	O
11	from	O
12	several	O
13	hundred	O
14	copies	O
15	of	O
16	the	O
17	virus	O
18	genome	O
19	present	O
20	in	O
21	infected	O
22	cells	O
23	,	O
24	compete	O
25	with	O
26	the	O
27	c	B
28	-	I
29	fos	I
30	mRNAs	I
31	for	O
32	destabilizing	O
33	cellular	O
34	factors	O
35	and	O
36	that	O
37	this	O
38	may	O
39	lead	O
40	to	O
41	elevated	O
42	Fos	B
43	protein	I
44	levels	O
45	in	O
46	human	O
47	papillomavirus	O
48	infected	O
49	cells	O
50	.	O

1	Two	O
2	closely	O
3	related	O
4	IgH	B
5	constant	O
6	region	O
7	genes	O
8	,	O
9	CHA	B
10	and	O
11	CHB	B
12	,	O
13	have	O
14	been	O
15	sequenced	O
16	completely	O
17	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	find	O
9	out	O
10	whether	O
11	it	O
12	was	O
13	possible	O
14	to	O
15	detect	O
16	normal	O
17	lymph	O
18	nodes	O
19	by	O
20	high	O
21	-	O
22	resolution	O
23	mediastinal	O
24	US	O
25	.	O

1	To	O
2	study	O
3	the	O
4	role	O
5	of	O
6	heavy	O
7	chain	O
8	motifs	O
9	in	O
10	substrate	O
11	recognition	O
12	,	O
13	secreted	O
14	variants	O
15	of	O
16	recombinant	B
17	bovine	I
18	proenteropeptidase	I
19	were	O
20	constructed	O
21	by	O
22	replacing	O
23	the	O
24	transmembrane	O
25	domain	O
26	with	O
27	a	O
28	signal	O
29	peptide	O
30	.	O

1	CKbeta4GT	B
2	-	I
3	II	I
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	B
10	II	I
11	transmembrane	I
12	glycoprotein	I
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O

1	We	O
2	now	O
3	demonstrate	O
4	that	O
5	CCAAT	B
6	/	I
7	enhancer	I
8	-	I
9	binding	I
10	protein	I
11	(	I
12	C	I
13	/	I
14	EBP	I
15	)	I
16	delta	I
17	is	O
18	a	O
19	major	O
20	component	O
21	of	O
22	a	O
23	PGE2	O
24	-	O
25	stimulated	O
26	DNA	O
27	-	O
28	protein	O
29	complex	O
30	involving	O
31	HS3D	B
32	and	O
33	find	O
34	that	O
35	C	B
36	/	I
37	EBPdelta	I
38	transactivates	O
39	IGF	B
40	-	I
41	I	I
42	promoter	I
43	1	I
44	through	O
45	this	O
46	site	O
47	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Semen	O
6	analyses	O
7	were	O
8	performed	O
9	on	O
10	58	O
11	patients	O
12	with	O
13	stages	O
14	I	O
15	-	O
16	III	O
17	HD	O
18	before	O
19	,	O
20	during	O
21	,	O
22	and	O
23	after	O
24	chemotherapy	O
25	and	O
26	after	O
27	the	O
28	sperm	O
29	count	O
30	recovered	O
31	from	O
32	the	O
33	effects	O
34	of	O
35	abdominal	O
36	radiotherapy	O
37	that	O
38	was	O
39	given	O
40	after	O
41	chemotherapy	O
42	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	With	O
2	a	O
3	BMI	O
4	cutoff	O
5	of	O
6	27	O
7	,	O
8	mean	O
9	cardiac	O
10	NE	O
11	spillover	O
12	was	O
13	46	O
14	%	O
15	lower	O
16	in	O
17	the	O
18	obese	O
19	subjects	O
20	when	O
21	compared	O
22	with	O
23	the	O
24	lean	O
25	subjects	O
26	(	O
27	P	O
28	=.	O
29	017	O
30	).	O

1	The	O
2	gene	O
3	(	O
4	ApxII	B
5	)	O
6	encoding	O
7	both	O
8	chloroplastic	B
9	ascorbate	I
10	peroxidase	I
11	isoenzymes	I
12	was	O
13	isolated	O
14	and	O
15	the	O
16	organization	O
17	of	O
18	the	O
19	gene	O
20	was	O
21	determined	O
22	.	O

1	This	O
2	emphasizes	O
3	the	O
4	conclusion	O
5	that	O
6	CDF	B
7	-	I
8	1	I
9	is	O
10	not	O
11	an	O
12	E2F	B
13	family	I
14	member	I
15	and	O
16	points	O
17	to	O
18	profound	O
19	differences	O
20	in	O
21	the	O
22	cell	O
23	cycle	O
24	regulation	O
25	of	O
26	CDF	B
27	-	I
28	1	I
29	and	O
30	E2F	B
31	.	O

1	The	O
2	proofreading	O
3	domain	O
4	of	O
5	Escherichia	B
6	coli	I
7	DNA	I
8	polymerase	I
9	I	I
10	and	O
11	other	O
12	DNA	B
13	and	I
14	/	I
15	or	I
16	RNA	I
17	exonuclease	I
18	domains	I
19	.	O

1	Interleukin	B
2	-	I
3	1	I
4	levels	O
5	remained	O
6	low	O
7	throughout	O
8	the	O
9	course	O
10	.	O

1	Responsibility	O
2	matters	O
3	--	O
4	this	O
5	is	O
6	a	O
7	scientific	O
8	council	O

1	Southern	O
2	blot	O
3	analysis	O
4	of	O
5	endonuclease	O
6	-	O
7	digested	O
8	genomic	O
9	DNA	O
10	from	O
11	primary	O
12	chick	O
13	embryo	O
14	fibroblasts	O
15	(	O
16	CEF	O
17	)	O
18	suggested	O
19	that	O
20	MEK2	B
21	is	O
22	a	O
23	single	O
24	-	O
25	copy	O
26	gene	O
27	in	O
28	this	O
29	vertebrate	O
30	species	O
31	.	O

1	Sequences	O
2	required	O
3	for	O
4	interaction	O
5	of	O
6	mu2	B
7	and	O
8	CTLA	B
9	-	I
10	4	I
11	were	O
12	localized	O
13	to	O
14	residues	O
15	,	O
16	161TTGVY	O
17	in	O
18	CTLA	B
19	-	I
20	4	I
21	;	O
22	this	O
23	sequence	O
24	is	O
25	N	O
26	-	O
27	terminal	O
28	to	O
29	,	O
30	but	O
31	overlaps	O
32	with	O
33	,	O
34	a	O
35	previously	O
36	identified	O
37	SH2	B
38	binding	I
39	motif	I
40	,	O
41	165YVKM	O
42	,	O
43	involved	O
44	in	O
45	CTLA	B
46	-	I
47	4	I
48	signaling	O
49	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	a	O
7	transfected	O
8	Chinese	O
9	hamster	O
10	ovary	O
11	(	O
12	CHO	O
13	)	O
14	cell	O
15	line	O
16	expressing	O
17	a	O
18	murine	B
19	CD4	I
20	fragment	I
21	containing	O
22	the	O
23	first	O
24	two	O
25	N	O
26	-	O
27	terminal	O
28	domains	O
29	secretes	O
30	both	O
31	monomeric	O
32	molecules	O
33	and	O
34	disulfide	O
35	-	O
36	linked	O
37	multimers	O
38	.	O

1	SCID	O
2	V	B
3	(	O
4	D	B
5	)	O
6	J	B
7	recombination	O
8	can	O
9	be	O
10	partly	O
11	rescued	O
12	in	O
13	T	O
14	-	O
15	lymphocytes	O
16	by	O
17	either	O
18	DNA	O
19	-	O
20	damaging	O
21	agents	O
22	(	O
23	gamma	O
24	-	O
25	irradiation	O
26	and	O
27	bieomycin	O
28	)	O
29	or	O
30	a	O
31	null	O
32	mutation	O
33	of	O
34	the	O
35	p53	B
36	gene	I
37	,	O
38	possibly	O
39	because	O
40	of	O
41	transiently	O
42	elevated	O
43	DNA	O
44	repair	O
45	activity	O
46	in	O
47	response	O
48	to	O
49	DNA	O
50	damage	O
51	or	O
52	to	O
53	delayed	O
54	apoptosis	O
55	in	O
56	the	O
57	absence	O
58	of	O
59	p53	B
60	.	O

1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O

1	Using	O
2	GST	B
3	-	O
4	PKR	B
5	fusion	O
6	chromatography	O
7	,	O
8	direct	O
9	physical	O
10	interaction	O
11	between	O
12	the	O
13	mouse	O
14	and	O
15	human	B
16	PKR	I
17	homologs	I
18	was	O
19	established	O
20	.	O

1	An	O
2	even	O
3	greater	O
4	inflammatory	O
5	response	O
6	was	O
7	observed	O
8	after	O
9	intratracheal	O
10	instillation	O
11	of	O
12	ufCB	O
13	,	O
14	but	O
15	not	O
16	after	O
17	CB	O
18	instillation	O
19	.	O

1	Interestingly	O
2	,	O
3	the	O
4	avirulent	O
5	strain	O
6	H37Ra	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	avirulent	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	opposed	O
36	to	O
37	those	O
38	in	O
39	the	O
40	virulent	O
41	strain	O
42	H37Rv	O
43	.	O

1	These	O
2	defects	O
3	no	O
4	doubt	O
5	impair	O
6	the	O
7	folding	O
8	and	O
9	configuration	O
10	necessary	O
11	for	O
12	normal	O
13	processing	O
14	of	O
15	the	O
16	AVP	B
17	gene	I
18	precursor	I
19	.	O

1	Similarities	O
2	between	O
3	the	O
4	hIGFBP	B
5	-	I
6	1	I
7	and	O
8	phosphoenolpyruvate	B
9	kinase	I
10	(	O
11	PEPCK	B
12	)	O
13	promoters	O
14	,	O
15	including	O
16	regions	O
17	conferring	O
18	insulin	B
19	,	O
20	glucocorticoid	O
21	,	O
22	and	O
23	cyclic	O
24	adenosine	O
25	-	O
26	monophosphate	O
27	responses	O
28	,	O
29	are	O
30	consistent	O
31	with	O
32	our	O
33	previous	O
34	hypothesis	O
35	that	O
36	IGFBP	B
37	-	I
38	1	I
39	is	O
40	involved	O
41	in	O
42	regulation	O
43	of	O
44	glucose	O
45	metabolism	O
46	.	O

1	This	O
2	binary	O
3	repeat	O
4	contains	O
5	repetitive	O
6	DNA	O
7	elements	O
8	that	O
9	include	O
10	LINES	O
11	,	O
12	SINES	O
13	,	O
14	medium	O
15	reiteration	O
16	frequency	O
17	repeats	O
18	,	O
19	and	O
20	a	O
21	transposon	O
22	-	O
23	like	O
24	element	O
25	.	O

1	At	O
2	60	O
3	days	O
4	the	O
5	amount	O
6	of	O
7	gangliosides	O
8	was	O
9	on	O
10	average	O
11	lower	O
12	in	O
13	females	O
14	than	O
15	in	O
16	males	O
17	,	O
18	even	O
19	if	O
20	with	O
21	some	O
22	exception	O
23	.	O

1	Large	O
2	genomic	O
3	constructs	O
4	integrate	O
5	at	O
6	the	O
7	endogenous	O
8	locus	O
9	by	O
10	homologous	O
11	recombination	O
12	,	O
13	but	O
14	cDNA	O
15	-	O
16	derived	O
17	sequences	O
18	lacking	O
19	long	O
20	stretches	O
21	of	O
22	contiguous	O
23	genomic	O
24	DNA	O
25	(	O
26	due	O
27	to	O
28	intron	O
29	excision	O
30	)	O
31	typically	O
32	integrate	O
33	into	O
34	chromosomal	O
35	DNA	O
36	by	O
37	nonhomologous	O
38	recombination	O
39	.	O

1	The	O
2	existence	O
3	of	O
4	these	O
5	two	O
6	categories	O
7	of	O
8	strains	O
9	offers	O
10	a	O
11	new	O
12	genetic	O
13	system	O
14	in	O
15	which	O
16	the	O
17	properties	O
18	of	O
19	a	O
20	potential	O
21	invertebrate	O
22	retrovirus	O
23	can	O
24	be	O
25	tested	O
26	.	O

1	During	O
2	the	O
3	conditioning	O
4	procedure	O
5	,	O
6	the	O
7	C	O
8	-	O
9	fiber	O
10	reflex	O
11	was	O
12	facilitated	O
13	(	O
14	wind	O
15	-	O
16	up	O
17	)	O
18	in	O
19	a	O
20	stimulus	O
21	-	O
22	dependent	O
23	fashion	O
24	in	O
25	intact	O
26	,	O
27	anesthetized	O
28	animals	O
29	during	O
30	the	O
31	application	O
32	of	O
33	the	O
34	first	O
35	seven	O
36	conditioning	O
37	stimuli	O
38	;	O
39	thereafter	O
40	,	O
41	the	O
42	magnitude	O
43	of	O
44	the	O
45	responses	O
46	reached	O
47	a	O
48	plateau	O
49	and	O
50	then	O
51	decreased	O
52	.	O

1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	O
7	binding	O
8	transcription	O
9	factor	O
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	O
35	(	O
36	A	O
37	/	O
38	T	O
39	)(	O
40	T	O
41	/	O
42	A	O
43	)	O
44	GPyPyPy	O
45	-	O
46	3	O
47	'.	O

1	TSA	O
2	treatment	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	detectably	O
9	alter	O
10	enhancer	O
11	factor	O
12	binding	O
13	or	O
14	the	O
15	positioning	O
16	of	O
17	nuc	B
18	-	I
19	1	I
20	on	O
21	the	O
22	majority	O
23	of	O
24	the	O
25	chromatin	O
26	templates	O
27	indicating	O
28	that	O
29	protein	O
30	acetylation	O
31	and	O
32	chromatin	O
33	remodeling	O
34	may	O
35	be	O
36	limiting	O
37	steps	O
38	that	O
39	occur	O
40	only	O
41	on	O
42	transcriptionally	O
43	competent	O
44	templates	O
45	,	O
46	or	O
47	that	O
48	remodeling	O
49	of	O
50	nuc	B
51	-	I
52	1	I
53	requires	O
54	additional	O
55	factors	O
56	.	O

1	Upon	O
2	UV	O
3	damage	O
4	,	O
5	Crb2	B
6	is	O
7	transiently	O
8	modified	O
9	,	O
10	probably	O
11	phosphorylated	O
12	,	O
13	with	O
14	a	O
15	similar	O
16	timing	O
17	of	O
18	phosphorylation	O
19	in	O
20	Chk1	B
21	kinase	I
22	,	O
23	which	O
24	is	O
25	reported	O
26	to	O
27	restrain	O
28	Cdc2	B
29	activation	O
30	.	O

1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	B
12	and	O
13	crb2	B
14	mutants	I
15	.	O

1	Tcn1p	B
2	/	O
3	Crz1p	B
4	,	O
5	a	O
6	calcineurin	O
7	-	O
8	dependent	O
9	transcription	O
10	factor	O
11	that	O
12	differentially	O
13	regulates	O
14	gene	O
15	expression	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

1	Structure	O
2	and	O
3	localization	O
4	of	O
5	the	O
6	human	O
7	gene	O
8	encoding	O
9	SR	B
10	-	I
11	BI	I
12	/	O
13	CLA	B
14	-	I
15	1	I
16	.	O

1	We	O
2	introduced	O
3	the	O
4	gel	O
5	technique	O
6	as	O
7	a	O
8	routine	O
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O

1	Multiple	O
2	regression	O
3	analyses	O
4	revealed	O
5	that	O
6	WAIS	O
7	-	O
8	R	O
9	factor	O
10	scores	O
11	Verbal	O
12	Comprehension	O
13	and	O
14	Freedom	O
15	from	O
16	Distractibility	O
17	accounted	O
18	for	O
19	up	O
20	to	O
21	42	O
22	%	O
23	of	O
24	the	O
25	variance	O
26	in	O
27	WMS	O
28	-	O
29	R	O
30	and	O
31	CVLT	O
32	indices	O
33	.	O

1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	O
19	-	O
20	2	O
21	64B	O
22	EME	O
23	).	O

1	At	O
2	the	O
3	genomic	O
4	level	O
5	,	O
6	the	O
7	sequences	O
8	of	O
9	two	O
10	members	O
11	of	O
12	this	O
13	family	O
14	are	O
15	known	O
16	in	O
17	the	O
18	rat	O
19	Rattus	O
20	norvegicus	O
21	:	O
22	the	O
23	VCSA1	B
24	gene	I
25	,	O
26	encoding	O
27	the	O
28	prohormone	B
29	-	I
30	like	I
31	polypeptide	I
32	SMR1	I
33	,	O
34	and	O
35	the	O
36	VCSB1	B
37	gene	I
38	,	O
39	encoding	O
40	a	O
41	salivary	O
42	Pro	O
43	-	O
44	rich	O
45	polypeptide	O
46	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	RAD30	I
5	gene	I
6	,	O
7	a	O
8	homologue	B
9	of	I
10	Escherichia	I
11	coli	I
12	dinB	I
13	and	O
14	umuC	B
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	new	O
6	experiment	O
7	in	O
8	which	O
9	the	O
10	deletion	O
11	task	O
12	was	O
13	presented	O
14	as	O
15	a	O
16	puppet	O
17	game	O
18	,	O
19	and	O
20	with	O
21	pretraining	O
22	and	O
23	selection	O
24	on	O
25	vowel	O
26	deletion	O
27	,	O
28	a	O
29	significantly	O
30	higher	O
31	level	O
32	of	O
33	success	O
34	was	O
35	achieved	O
36	by	O
37	the	O
38	children	O
39	working	O
40	with	O
41	the	O
42	CVCC	O
43	material	O
44	.	O

1	Diet	O
2	therapy	O
3	with	O
4	soy	O
5	proteins	O
6	for	O
7	chronic	O
8	stomach	O
9	ulcers	O

1	In	O
2	ICU	O
3	patients	O
4	,	O
5	the	O
6	LIS	O
7	related	O
8	to	O
9	the	O
10	postoperative	O
11	rise	O
12	in	O
13	IL	B
14	-	I
15	6	I
16	level	O
17	only	O
18	,	O
19	even	O
20	though	O
21	the	O
22	rise	O
23	in	O
24	plasma	O
25	concentrations	O
26	of	O
27	cytokines	O
28	interrelated	O
29	.	O

1	Resistance	O
2	training	O
3	shifts	O
4	the	O
5	power	O
6	curve	O
7	in	O
8	a	O
9	positive	O
10	direction	O
11	when	O
12	the	O
13	measurements	O
14	are	O
15	determined	O
16	with	O
17	absolute	O
18	loads	O
19	,	O
20	but	O
21	the	O
22	increased	O
23	power	O
24	may	O
25	not	O
26	be	O
27	transferred	O
28	to	O
29	an	O
30	absolute	O
31	performance	O
32	task	O
33	like	O
34	the	O
35	SSP	O
36	.	O

1	Gel	O
2	-	O
3	shift	O
4	assays	O
5	identified	O
6	two	O
7	Sp1	B
8	binding	I
9	sites	I
10	within	O
11	this	O
12	element	O
13	.	O

1	Y15170	B
2	(	O
3	Surf	B
4	-	I
5	2	I
6	,	O
7	Surf	B
8	-	I
9	4	I
10	),	O
11	Y15171	B
12	(	O
13	Surf	B
14	-	I
15	3	I
16	,	O
17	Surf	B
18	-	I
19	1	I
20	,	O
21	Surf	B
22	-	I
23	6	I
24	),	O
25	and	O
26	Y15172	B
27	(	O
28	Surf	B
29	-	I
30	5	I
31	.)]	O

1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	super	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	DDT1MF	O
19	-	O
20	2	O
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	B
29	1B	I
30	-	I
31	AR	I
32	gene	I
33	bound	O
34	CRE	B
35	binding	I
36	protein	I
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	this	O
8	experimental	O
9	model	O
10	,	O
11	ACE	B
12	inhibitors	O
13	limit	O
14	the	O
15	arrhythmias	O
16	following	O
17	ischemia	O
18	-	O
19	reperfusion	O
20	and	O
21	free	O
22	radical	O
23	scavenging	O
24	action	O
25	of	O
26	these	O
27	drugs	O
28	does	O
29	not	O
30	have	O
31	a	O
32	major	O
33	contributory	O
34	role	O
35	in	O
36	their	O
37	protective	O
38	effect	O
39	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	ARVD	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O

1	However	O
2	,	O
3	the	O
4	signaling	O
5	cascade	O
6	utilized	O
7	by	O
8	the	O
9	urokinase	B
10	receptor	I
11	is	O
12	only	O
13	incompletely	O
14	understood	O
15	.	O

1	The	O
2	murine	O
3	Htf9	B
4	-	I
5	a	I
6	/	O
7	RanBP1	B
8	and	O
9	Htf9	B
10	-	I
11	c	I
12	genes	I
13	are	O
14	divergently	O
15	transcribed	O
16	from	O
17	a	O
18	shared	O
19	TATA	O
20	-	O
21	less	O
22	promoter	O
23	.	O

1	In	O
2	accordance	O
3	with	O
4	clinical	O
5	improvement	O
6	we	O
7	found	O
8	a	O
9	decrease	O
10	of	O
11	laboratory	O
12	indicators	O
13	of	O
14	inflammation	O
15	(	O
16	C	B
17	-	I
18	reactive	I
19	protein	I
20	,	O
21	alpha	B
22	2	I
23	-	I
24	globuline	I
25	,	O
26	prostaglandin	O
27	E2	O
28	).	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	B
9	kinase	I
10	C	I
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	Two	O
2	disulphide	O
3	bridges	O
4	,	O
5	which	O
6	are	O
7	conserved	O
8	in	O
9	all	O
10	spermadhesin	O
11	molecules	O
12	and	O
13	many	O
14	CUB	O
15	domains	O
16	,	O
17	crosslink	O
18	loop	O
19	LA	O
20	and	O
21	strand	O
22	beta	O
23	4	O
24	and	O
25	loops	O
26	LE	O
27	and	O
28	LG	O
29	,	O
30	respectively	O
31	,	O
32	at	O
33	opposite	O
34	edges	O
35	of	O
36	the	O
37	same	O
38	face	O
39	of	O
40	the	O
41	domain	O
42	.	O

1	Mg	B
2	-	I
3	chelatase	I
4	of	O
5	tobacco	O
6	:	O
7	identification	O
8	of	O
9	a	O
10	Chl	B
11	D	I
12	cDNA	I
13	sequence	I
14	encoding	O
15	a	O
16	third	O
17	subunit	O
18	,	O
19	analysis	O
20	of	O
21	the	O
22	interaction	O
23	of	O
24	the	O
25	three	O
26	subunits	O
27	with	O
28	the	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	system	O
34	,	O
35	and	O
36	reconstitution	O
37	of	O
38	the	O
39	enzyme	O
40	activity	O
41	by	O
42	co	O
43	-	O
44	expression	O
45	of	O
46	recombinant	B
47	CHL	I
48	D	I
49	,	O
50	CHL	B
51	H	I
52	and	O
53	CHL	B
54	I	I
55	.	O

1	One	O
2	R	O
3	-	O
4	EST	O
5	and	O
6	one	O
7	Pto	B
8	-	I
9	like	I
10	sequence	I
11	each	O
12	mapped	O
13	to	O
14	two	O
15	locations	O
16	.	O

1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	B
18	-	I
19	chimaerin	I
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O

1	The	O
2	interaction	O
3	between	O
4	DDB	B
5	and	O
6	E2F1	B
7	can	O
8	also	O
9	be	O
10	detected	O
11	by	O
12	coimmunoprecipitation	O
13	experiments	O
14	.	O

1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O

1	Nevertheless	O
2	,	O
3	antibodies	O
4	directed	O
5	against	O
6	an	O
7	epitope	O
8	-	O
9	tagged	O
10	version	O
11	of	O
12	Prp42p	B
13	specifically	O
14	precipitate	O
15	U1	B
16	snRNA	I
17	from	O
18	yeast	O
19	extracts	O
20	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	in	O
6	addition	O
7	to	O
8	Grb2	B
9	-	O
10	mediated	O
11	activation	O
12	of	O
13	Ras	B
14	,	O
15	PLC	B
16	-	I
17	gamma1	I
18	-	O
19	mediated	O
20	DAG	O
21	production	O
22	is	O
23	required	O
24	for	O
25	EGF	B
26	-	O
27	and	O
28	PDGF	B
29	-	O
30	induced	O
31	S	O
32	-	O
33	phase	O
34	entry	O
35	and	O
36	gene	O
37	expression	O
38	,	O
39	possibly	O
40	through	O
41	activation	O
42	of	O
43	PKC	B
44	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	STAT	B
8	activation	O
9	in	O
10	a	O
11	panel	O
12	of	O
13	rodent	O
14	fibroblast	O
15	cell	O
16	lines	O
17	stably	O
18	transformed	O
19	by	O
20	diverse	O
21	viral	O
22	oncoproteins	O
23	.	O

1	In	O
2	serum	O
3	-	O
4	stimulated	O
5	cells	O
6	,	O
7	the	O
8	binding	O
9	of	O
10	NF	B
11	-	I
12	Y	I
13	/	O
14	CBF	B
15	to	O
16	TKC1	B
17	increased	O
18	gradually	O
19	,	O
20	reaching	O
21	a	O
22	plateau	O
23	at	O
24	the	O
25	S	O
26	phase	O
27	.	O

1	CONCLUSION	O
2	:	O
3	In	O
4	our	O
5	animal	O
6	model	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	disruption	O
13	was	O
14	a	O
15	reproducible	O
16	,	O
17	integral	O
18	finding	O
19	of	O
20	single	O
21	-	O
22	fraction	O
23	,	O
24	high	O
25	-	O
26	dose	O
27	irradiation	O
28	injury	O
29	.	O

1	To	O
2	facilitate	O
3	the	O
4	investigation	O
5	of	O
6	parameters	O
7	that	O
8	govern	O
9	selective	O
10	export	O
11	in	O
12	adenovirus	O
13	-	O
14	infected	O
15	cells	O
16	,	O
17	we	O
18	constructed	O
19	a	O
20	marked	O
21	human	O
22	beta	B
23	-	I
24	actin	I
25	minigene	I
26	under	O
27	the	O
28	control	O
29	of	O
30	the	O
31	glucocorticoid	B
32	-	I
33	inducible	I
34	enhancer	I
35	-	I
36	promoter	I
37	of	O
38	mouse	O
39	mammary	O
40	tumor	O
41	virus	O
42	and	O
43	introduced	O
44	it	O
45	into	O
46	the	O
47	left	O
48	end	O
49	of	O
50	the	O
51	adenovirus	O
52	type	O
53	5	O
54	(	O
55	Ad5	O
56	)	O
57	genome	O
58	.	O

1	Cell	O
2	factor	O
3	-	O
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	B
17	major	I
18	immediate	I
19	-	I
20	early	I
21	(	I
22	IE	I
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O

1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O

1	The	O
2	critical	O
3	mutations	O
4	were	O
5	likely	O
6	to	O
7	have	O
8	been	O
9	multiple	O
10	and	O
11	dispersed	O
12	,	O
13	including	O
14	elongation	O
15	of	O
16	the	O
17	TM	O
18	and	O
19	Nef	B
20	coding	I
21	sequences	I
22	;	O
23	changes	O
24	in	O
25	RNA	O
26	splice	O
27	donor	O
28	and	O
29	acceptor	O
30	sites	O
31	,	O
32	TATA	O
33	box	O
34	sites	O
35	,	O
36	and	O
37	Sp1	B
38	sites	I
39	;	O
40	multiple	O
41	changes	O
42	in	O
43	the	O
44	V2	B
45	region	O
46	of	O
47	SU	B
48	,	O
49	including	O
50	a	O
51	consensus	O
52	neutralization	O
53	epitope	O
54	;	O
55	and	O
56	five	O
57	new	O
58	N	O
59	-	O
60	linked	O
61	glycosylation	O
62	sites	O
63	in	O
64	SU	B
65	.	O

1	C	O
2	.	O

1	These	O
2	are	O
3	the	O
4	long	O
5	terminal	O
6	repeat	O
7	(	O
8	LTR	O
9	)	O
10	promoter	O
11	,	O
12	which	O
13	regulates	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	structural	O
19	proteins	O
20	,	O
21	and	O
22	a	O
23	second	O
24	internal	O
25	promoter	O
26	,	O
27	located	O
28	towards	O
29	the	O
30	3	O
31	'	O
32	end	O
33	of	O
34	the	O
35	env	B
36	gene	I
37	,	O
38	that	O
39	directs	O
40	expression	O
41	of	O
42	the	O
43	viral	O
44	auxiliary	O
45	proteins	O
46	.	O

1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	genomic	O
8	RNA	O
9	of	O
10	rubella	O
11	virus	O
12	(	O
13	RUB	O
14	)	O
15	contains	O
16	a	O
17	14	O
18	-	O
19	nucleotide	O
20	(	O
21	nt	O
22	)	O
23	single	O
24	-	O
25	stranded	O
26	leader	O
27	(	O
28	ss	O
29	-	O
30	leader	O
31	)	O
32	followed	O
33	by	O
34	a	O
35	stem	O
36	-	O
37	and	O
38	-	O
39	loop	O
40	structure	O
41	[	O
42	5	O
43	'(+)	O
44	SL	O
45	]	O
46	(	O
47	nt	O
48	15	O
49	to	O
50	65	O
51	),	O
52	the	O
53	complement	O
54	of	O
55	which	O
56	at	O
57	the	O
58	3	O
59	'	O
60	end	O
61	of	O
62	the	O
63	minus	O
64	-	O
65	strand	O
66	RNA	O
67	[	O
68	3	O
69	'(-)	O
70	SL	O
71	]	O
72	has	O
73	been	O
74	proposed	O
75	to	O
76	function	O
77	as	O
78	a	O
79	promoter	O
80	for	O
81	synthesis	O
82	of	O
83	genomic	O
84	plus	O
85	strands	O
86	.	O

1	To	O
2	investigate	O
3	the	O
4	requirements	O
5	for	O
6	CBF2	B
7	binding	O
8	,	O
9	we	O
10	synthesized	O
11	a	O
12	series	O
13	of	O
14	oligonucleotides	O
15	carrying	O
16	double	O
17	transversion	O
18	mutations	O
19	spanning	O
20	both	O
21	the	O
22	conserved	O
23	core	O
24	sequence	O
25	and	O
26	outside	O
27	flanking	O
28	sequences	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	B
8	for	O
9	binding	O
10	to	O
11	the	O
12	LMP	B
13	-	I
14	1	I
15	,	O
16	LMP	B
17	-	I
18	2	I
19	,	O
20	and	O
21	CD23	B
22	promoters	I
23	were	O
24	also	O
25	measured	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	myocardial	O
5	uptake	O
6	of	O
7	99mTc	O
8	sestamibi	O
9	in	O
10	normal	O
11	subjects	O
12	and	O
13	patients	O
14	with	O
15	coronary	O
16	artery	O
17	disease	O
18	is	O
19	comparable	O
20	after	O
21	exercise	O
22	,	O
23	dipyridamole	O
24	,	O
25	and	O
26	adenosine	O
27	stress	O
28	.	O

1	The	O
2	SR	B
3	protein	I
4	family	I
5	is	O
6	involved	O
7	in	O
8	constitutive	O
9	and	O
10	regulated	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	and	O
16	has	O
17	been	O
18	found	O
19	to	O
20	be	O
21	evolutionarily	O
22	conserved	O
23	in	O
24	metazoan	O
25	organisms	O
26	.	O

1	To	O
2	investigate	O
3	the	O
4	activity	O
5	of	O
6	TCF11	B
7	through	O
8	this	O
9	selected	O
10	site	O
11	,	O
12	both	O
13	alone	O
14	and	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	MafG	B
20	,	O
21	we	O
22	have	O
23	used	O
24	a	O
25	transient	O
26	transfection	O
27	assay	O
28	.	O

1	These	O
2	and	O
3	other	O
4	comparisons	O
5	suggest	O
6	that	O
7	,	O
8	during	O
9	evolution	O
10	,	O
11	both	O
12	the	O
13	RNA	B
14	-	I
15	polymerase	I
16	specificity	O
17	of	O
18	telomerase	B
19	RNA	I
20	-	I
21	gene	I
22	promoters	I
23	and	O
24	,	O
25	more	O
26	recently	O
27	,	O
28	the	O
29	position	O
30	of	O
31	the	O
32	template	O
33	sequence	O
34	in	O
35	the	O
36	telomerase	B
37	RNA	I
38	changed	O
39	.	O

1	Deadenylation	O
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	I
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	Holliday	B
2	junction	I
3	resolvase	I
4	in	O
5	Schizosaccharomyces	O
6	pombe	O
7	has	O
8	identical	O
9	endonuclease	O
10	activity	O
11	to	O
12	the	O
13	CCE1	B
14	homologue	O
15	YDC2	B
16	.	O

1	Ca2	B
2	+/	I
3	calmodulin	I
4	-	I
5	dependent	I
6	protein	I
7	kinase	I
8	II	I
9	(	O
10	CaMK	B
11	II	I
12	)	O
13	is	O
14	a	O
15	multifunctional	O
16	serine	B
17	/	I
18	threonine	I
19	protein	I
20	kinase	I
21	that	O
22	regulates	O
23	ion	O
24	channels	O
25	,	O
26	metabolic	O
27	enzymes	O
28	,	O
29	cytoskeletal	O
30	proteins	O
31	,	O
32	and	O
33	possibly	O
34	transcription	O
35	factors	O
36	.	O

1	A	O
2	cAMP	O
3	-	O
4	responsive	O
5	element	O
6	-	O
7	like	O
8	(	O
9	CRE	O
10	-	O
11	like	O
12	,	O
13	TGACGTGA	O
14	)	O
15	promoter	O
16	sequence	O
17	and	O
18	a	O
19	protein	B
20	kinase	I
21	A	I
22	signaling	O
23	pathway	O
24	are	O
25	involved	O
26	in	O
27	this	O
28	induction	O
29	,	O
30	and	O
31	activation	O
32	of	O
33	both	O
34	CRE	B
35	binding	I
36	protein	I
37	(	O
38	CREB	B
39	)	O
40	and	O
41	activating	B
42	transcription	I
43	factor	I
44	-	I
45	2	I
46	(	O
47	ATF	B
48	-	I
49	2	I
50	)	O
51	is	O
52	required	O
53	in	O
54	the	O
55	above	O
56	process	O
57	.	O

1	IVOX	O
2	was	O
3	named	O
4	as	O
5	an	O
6	acronym	O
7	for	O
8	intravascular	O
9	oxygenator	O
10	.	O

1	Histopathologically	O
2	,	O
3	a	O
4	cystic	O
5	lymphangioma	O
6	was	O
7	diagnosed	O
8	because	O
9	of	O
10	the	O
11	morphological	O
12	features	O
13	and	O
14	the	O
15	immunohistochemical	O
16	stainings	O
17	of	O
18	CD34	B
19	and	O
20	Factor	B
21	VIII	I
22	related	I
23	antigen	I
24	which	O
25	were	O
26	observed	O
27	positive	O
28	reactions	O
29	in	O
30	endothelial	O
31	cells	O
32	of	O
33	the	O
34	cysts	O
35	.	O

1	Protease	O
2	activities	O
3	in	O
4	cultures	O
5	of	O
6	the	O
7	streptococcal	O
8	strains	O
9	were	O
10	associated	O
11	with	O
12	species	O
13	of	O
14	different	O
15	molecular	O
16	masses	O
17	ranging	O
18	from	O
19	130	O
20	to	O
21	200	O
22	kDa	O
23	,	O
24	suggesting	O
25	posttranslational	O
26	processing	O
27	possibly	O
28	as	O
29	a	O
30	result	O
31	of	O
32	autoproteolysis	O
33	at	O
34	post	O
35	-	O
36	proline	O
37	peptide	O
38	bonds	O
39	in	O
40	the	O
41	N	O
42	-	O
43	terminal	O
44	parts	O
45	of	O
46	the	O
47	molecules	O
48	.	O

1	The	O
2	mechanism	O
3	underlying	O
4	such	O
5	analgesia	O
6	has	O
7	been	O
8	suggested	O
9	to	O
10	involve	O
11	the	O
12	interaction	O
13	between	O
14	the	O
15	two	O
16	separate	O
17	but	O
18	interconnected	O
19	motivational	O
20	systems	O
21	"	O
22	defense	O
23	"	O
24	and	O
25	"	O
26	pain	O
27	."	O
28	To	O
29	determine	O
30	the	O
31	developmental	O
32	course	O
33	of	O
34	defense	O
35	and	O
36	nociception	O
37	,	O
38	these	O
39	processes	O
40	were	O
41	analyzed	O
42	during	O
43	early	O
44	ontogeny	O
45	in	O
46	rats	O
47	.	O

1	Three	O
2	large	O
3	field	O
4	placement	O
5	errors	O
6	(	O
7	two	O
8	patients	O
9	with	O
10	11	O
11	.	O
12	5	O
13	and	O
14	16	O
15	.	O
16	0	O
17	mm	O
18	distances	O
19	of	O
20	the	O
21	planned	O
22	versus	O
23	simulated	O
24	isocenter	O
25	,	O
26	respectively	O
27	and	O
28	one	O
29	patient	O
30	with	O
31	a	O
32	7	O
33	degree	O
34	rotational	O
35	error	O
36	)	O
37	were	O
38	detected	O
39	and	O
40	,	O
41	as	O
42	with	O
43	the	O
44	smaller	O
45	errors	O
46	,	O
47	were	O
48	immediately	O
49	corrected	O
50	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	catalytically	O
6	inactive	O
7	version	O
8	of	O
9	the	O
10	Src	B
11	family	I
12	member	O
13	,	O
14	Lck	B
15	(	O
16	lymphoid	B
17	cell	I
18	kinase	I
19	),	O
20	was	O
21	expressed	O
22	,	O
23	purified	O
24	,	O
25	and	O
26	evaluated	O
27	as	O
28	a	O
29	Csk	B
30	substrate	O
31	.	O

1	A	O
2	.,	O
3	Swift	O
4	,	O
5	A	O
6	.	O

1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	/	O
6	TGF	B
7	-	I
8	alpha	I
9	HCCs	O
10	were	O
11	also	O
12	characterized	O
13	by	O
14	a	O
15	particularly	O
16	strong	O
17	expression	O
18	of	O
19	TGF	B
20	-	I
21	alpha	I
22	and	O
23	very	O
24	low	O
25	apoptotic	O
26	index	O
27	in	O
28	contrast	O
29	to	O
30	high	O
31	levels	O
32	of	O
33	apoptosis	O
34	in	O
35	peritumorous	O
36	tissues	O
37	and	O
38	c	B
39	-	I
40	myc	I
41	HCCs	O
42	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	the	O
9	antagonistic	O
10	effects	O
11	of	O
12	CRP	B
13	and	O
14	KdgR	B
15	on	O
16	the	O
17	expression	O
18	of	O
19	the	O
20	pectinolysis	B
21	genes	I
22	occur	O
23	by	O
24	different	O
25	mechanisms	O
26	,	O
27	including	O
28	direct	O
29	competition	O
30	between	O
31	the	O
32	two	O
33	regulators	O
34	or	O
35	between	O
36	the	O
37	repressor	O
38	and	O
39	RNA	B
40	polymerase	I
41	for	O
42	the	O
43	occupation	O
44	of	O
45	a	O
46	common	O
47	DNA	O
48	region	O
49	on	O
50	the	O
51	target	O
52	genes	O
53	.	O

1	The	O
2	well	O
3	-	O
4	known	O
5	Rel	B
6	/	O
7	NF	B
8	-	I
9	kappaB	I
10	family	O
11	of	O
12	vertebrate	O
13	transcription	O
14	factors	O
15	comprises	O
16	a	O
17	number	O
18	of	O
19	structurally	O
20	related	O
21	,	O
22	interacting	O
23	proteins	O
24	that	O
25	bind	O
26	DNA	O
27	as	O
28	dimers	O
29	and	O
30	whose	O
31	activity	O
32	is	O
33	regulated	O
34	by	O
35	subcellular	O
36	location	O
37	.	O

1	The	O
2	cglIM	B
3	gene	I
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O

1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	O
6	saccharopine	B
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	investigation	O
6	was	O
7	to	O
8	describe	O
9	a	O
10	new	O
11	formulation	O
12	of	O
13	silver	O
14	sulfadiazine	O
15	in	O
16	a	O
17	water	O
18	soluble	O
19	gel	O
20	,	O
21	poloxamer	O
22	188	O
23	.	O

1	The	O
2	study	O
3	goals	O
4	were	O
5	to	O
6	isolate	O
7	a	O
8	full	O
9	-	O
10	length	O
11	clone	O
12	encoding	O
13	CO	B
14	-	I
15	Ag	I
16	from	O
17	a	O
18	bovine	O
19	corneal	O
20	cDNA	O
21	library	O
22	and	O
23	to	O
24	express	O
25	this	O
26	clone	O
27	in	O
28	Escherichia	O
29	coli	O
30	(	O
31	E	O
32	.	O
33	coli	O
34	).	O

1	The	O
2	pel	B
3	gene	I
4	from	O
5	an	O
6	Amycolata	O
7	sp	O
8	.	O
9	encoding	O
10	a	O
11	pectate	B
12	lyase	I
13	(	O
14	EC	B
15	4	I
16	.	I
17	2	I
18	.	I
19	2	I
20	.	I
21	2	I
22	)	O
23	was	O
24	isolated	O
25	by	O
26	activity	O
27	screening	O
28	a	O
29	genomic	O
30	DNA	O
31	library	O
32	in	O
33	Streptomyces	O
34	lividans	O
35	TK24	O
36	.	O

1	The	O
2	gene	O
3	contains	O
4	six	O
5	exons	O
6	separated	O
7	by	O
8	1	O
9	.	O
10	1	O
11	-	O
12	5	O
13	.	O
14	8	O
15	kb	O
16	introns	O
17	and	O
18	has	O
19	been	O
20	localized	O
21	to	O
22	the	O
23	murine	O
24	chromosome	O
25	2	O
26	by	O
27	linkage	O
28	analysis	O
29	.	O

1	In	O
2	Xenopus	O
3	embryos	O
4	,	O
5	the	O
6	engineered	B
7	PDGF	I
8	receptor	I
9	protein	I
10	induced	O
11	the	O
12	formation	O
13	of	O
14	mesoderm	O
15	from	O
16	animal	O
17	-	O
18	pole	O
19	explants	O
20	in	O
21	an	O
22	FK1012	O
23	-	O
24	dependent	O
25	manner	O
26	.	O

1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	B
18	(	O
19	S6k	B
20	)	O
21	or	O
22	MAP	B
23	kinase	I
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O

1	Small	O
2	-	O
3	molecule	O
4	control	O
5	of	O
6	insulin	B
7	and	O
8	PDGF	B
9	receptor	I
10	signaling	O
11	and	O
12	the	O
13	role	O
14	of	O
15	membrane	O
16	attachment	O
17	.	O

1	Conversely	O
2	,	O
3	the	O
4	inactive	O
5	dAK	B
6	subunit	I
7	is	O
8	progressively	O
9	activated	O
10	by	O
11	1	O
12	)	O
13	association	O
14	with	O
15	a	O
16	dGK	B
17	or	O
18	dCK	B
19	subunit	I
20	and	O
21	2	O
22	)	O
23	the	O
24	conformationally	O
25	driven	O
26	heterotropic	O
27	affect	O
28	of	O
29	dGuo	B
30	or	O
31	dCyd	B
32	bound	O
33	to	O
34	the	O
35	opposing	O
36	subunit	O
37	.	O

1	CONCLUSIONS	O
2	:	O
3	A	O
4	50	O
5	-	O
6	mg	O
7	daily	O
8	dose	O
9	of	O
10	bicalutamide	O
11	is	O
12	sufficient	O
13	when	O
14	given	O
15	in	O
16	combination	O
17	with	O
18	an	O
19	agent	O
20	,	O
21	such	O
22	as	O
23	a	O
24	LHRH	B
25	-	O
26	A	O
27	,	O
28	that	O
29	lowers	O
30	serum	O
31	testosterone	O
32	,	O
33	but	O
34	higher	O
35	doses	O
36	of	O
37	bicalutamide	O
38	may	O
39	be	O
40	needed	O
41	when	O
42	the	O
43	drug	O
44	is	O
45	given	O
46	as	O
47	monotherapy	O
48	.	O

1	A	O
2	genomic	O
3	clone	O
4	was	O
5	isolated	O
6	that	O
7	contained	O
8	12	O
9	.	O
10	5	O
11	kb	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	flanking	O
17	region	O
18	and	O
19	the	O
20	first	O
21	exon	O
22	of	O
23	the	O
24	p69	B
25	/	I
26	71	I
27	2	I
28	-	I
29	5A	I
30	synthetase	I
31	gene	I
32	.	O

1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	P450scc	B
30	.	O

1	RESULTS	O
2	:	O
3	Looking	O
4	at	O
5	the	O
6	question	O
7	of	O
8	its	O
9	benefits	O
10	,	O
11	we	O
12	were	O
13	unable	O
14	to	O
15	find	O
16	any	O
17	methodologically	O
18	sound	O
19	studies	O
20	that	O
21	have	O
22	shown	O
23	efficacy	O
24	for	O
25	EMDR	O
26	in	O
27	eating	O
28	disorders	O
29	,	O
30	or	O
31	,	O
32	indeed	O
33	,	O
34	any	O
35	psychiatric	O
36	disorder	O
37	.	O

1	In	O
2	the	O
3	clinical	O
4	study	O
5	,	O
6	the	O
7	defect	O
8	size	O
9	shown	O
10	by	O
11	BMIPP	O
12	imaging	O
13	was	O
14	greater	O
15	in	O
16	anterior	O
17	than	O
18	in	O
19	inferior	O
20	infarcts	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	001	O
27	)	O
28	and	O
29	correlated	O
30	well	O
31	with	O
32	the	O
33	risk	O
34	area	O
35	revealed	O
36	by	O
37	contrast	O
38	ventriculography	O
39	(	O
40	r	O
41	=	O
42	0	O
43	.	O
44	80	O
45	,	O
46	p	O
47	<	O
48	0	O
49	.	O
50	0001	O
51	)	O
52	CONCLUSION	O
53	:	O
54	The	O
55	above	O
56	preliminary	O
57	data	O
58	,	O
59	admittedly	O
60	from	O
61	a	O
62	small	O
63	group	O
64	of	O
65	patients	O
66	,	O
67	suggest	O
68	that	O
69	tomographic	O
70	BMIPP	O
71	imaging	O
72	provides	O
73	an	O
74	accurate	O
75	quantification	O
76	of	O
77	defect	O
78	size	O
79	by	O
80	means	O
81	of	O
82	a	O
83	simple	O
84	threshold	O
85	technique	O
86	and	O
87	,	O
88	in	O
89	the	O
90	subacute	O
91	phase	O
92	,	O
93	permits	O
94	determination	O
95	of	O
96	the	O
97	amount	O
98	of	O
99	myocardium	O
100	at	O
101	risk	O
102	after	O
103	acute	O
104	myocardial	O
105	infarction	O
106	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	mutant	B
5	EphB1	I
6	receptors	I
7	(	O
8	Y594F	O
9	)	O
10	blocked	O
11	Nck	B
12	recruitment	O
13	to	O
14	EphB1	B
15	,	O
16	attenuated	O
17	downstream	O
18	JNK	B
19	activation	O
20	,	O
21	and	O
22	blocked	O
23	cell	O
24	attachment	O
25	responses	O
26	.	O

1	The	O
2	promoter	O
3	for	O
4	HMG	B
5	-	I
6	CoA	I
7	synthase	I
8	contains	O
9	two	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	sterol	B
15	regulatory	I
16	element	I
17	-	I
18	binding	I
19	proteins	I
20	(	O
21	SREBPs	B
22	).	O

1	S	O
2	.,	O
3	and	O
4	Walter	O
5	,	O
6	P	O
7	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	Hh	B
6	and	O
7	Patched	B
8	(	O
9	Ptc	B
10	)	O
11	act	O
12	through	O
13	those	O
14	Ci	B
15	binding	O
16	sites	O
17	to	O
18	modulate	O
19	the	O
20	level	O
21	of	O
22	Ci	B
23	-	O
24	dependent	O
25	transcriptional	O
26	activation	O
27	in	O
28	S2	O
29	cells	O
30	.	O

1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O

1	Patients	O
2	and	O
3	their	O
4	relatives	O
5	must	O
6	be	O
7	informed	O
8	about	O
9	the	O
10	available	O
11	effective	O
12	treatment	O
13	possibilities	O
14	and	O
15	about	O
16	the	O
17	right	O
18	moment	O
19	for	O
20	their	O
21	application	O
22	in	O
23	an	O
24	individual	O
25	patient	O
26	.	O

1	Several	O
2	PTPases	B
3	were	O
4	expressed	O
5	abundantly	O
6	in	O
7	the	O
8	5	O
9	-	O
10	FU	O
11	-	O
12	treated	O
13	bone	O
14	marrow	O
15	stem	O
16	cells	O
17	.	O

1	Expression	O
2	of	O
3	PTPRO	B
4	was	O
5	also	O
6	observed	O
7	in	O
8	human	B
9	CD34	I
10	+	I
11	bone	O
12	marrow	O
13	cells	O
14	and	O
15	5	O
16	-	O
17	FU	O
18	-	O
19	treated	O
20	murine	O
21	primitive	O
22	stem	O
23	cells	O
24	.	O

1	The	O
2	organization	O
3	of	O
4	SPP1	B
5	genes	I
6	involved	O
7	in	O
8	the	O
9	replication	O
10	,	O
11	DNA	O
12	packaging	O
13	and	O
14	phage	O
15	assembly	O
16	proteins	O
17	resembles	O
18	the	O
19	organization	O
20	of	O
21	genes	O
22	of	O
23	equivalent	O
24	regions	O
25	of	O
26	different	O
27	E	O
28	.	O
29	coli	O
30	double	O
31	-	O
32	stranded	O
33	DNA	O
34	phages	O
35	.	O

1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O

1	The	O
2	functional	O
3	mature	O
4	domain	O
5	of	O
6	pediocin	B
7	AcH	I
8	(	I
9	Lys	I
10	+	I
11	1	I
12	to	I
13	Cys	I
14	+	I
15	44	I
16	)	I
17	is	O
18	targeted	O
19	into	O
20	the	O
21	E	O
22	.	O
23	coli	O
24	sec	O
25	machinery	O
26	and	O
27	secreted	O
28	to	O
29	the	O
30	periplasm	O
31	in	O
32	active	O
33	form	O
34	when	O
35	fused	O
36	in	O
37	frame	O
38	to	O
39	the	O
40	COOH	O
41	terminus	O
42	of	O
43	the	O
44	secretory	B
45	protein	I
46	maltose	I
47	-	I
48	binding	I
49	protein	I
50	(	O
51	MBP	B
52	).	O

1	Isomers	O
2	were	O
3	differentiated	O
4	based	O
5	on	O
6	the	O
7	MS	O
8	-	O
9	MS	O
10	data	O
11	of	O
12	the	O
13	trofluoroacetyl	O
14	-	O
15	biphenylol	O
16	derivatives	O
17	.	O

1	Although	O
2	RAD17	B
3	,	O
4	RAD24	B
5	and	O
6	MEC3	B
7	are	O
8	not	O
9	required	O
10	for	O
11	cell	O
12	cycle	O
13	arrest	O
14	when	O
15	S	O
16	phase	O
17	is	O
18	inhibited	O
19	by	O
20	hydroxyurea	O
21	(	O
22	HU	O
23	),	O
24	they	O
25	do	O
26	contribute	O
27	to	O
28	the	O
29	viability	O
30	of	O
31	yeast	O
32	cells	O
33	grown	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	HU	O
39	,	O
40	possibly	O
41	because	O
42	they	O
43	are	O
44	required	O
45	for	O
46	the	O
47	repair	O
48	of	O
49	HU	O
50	-	O
51	induced	O
52	DNA	O
53	damage	O
54	.	O

1	Clinical	O
2	value	O
3	of	O
4	the	O
5	estimation	O
6	of	O
7	growth	O
8	kinetics	O
9	of	O
10	primary	O
11	ovarian	O
12	cancer	O
13	recurrences	O
14	by	O
15	CA125	B
16	doubling	O
17	time	O

1	This	O
2	review	O
3	seeks	O
4	to	O
5	summarize	O
6	the	O
7	disease	O
8	,	O
9	to	O
10	propose	O
11	pathways	O
12	of	O
13	carcinogenesis	O
14	and	O
15	to	O
16	suggest	O
17	ways	O
18	in	O
19	which	O
20	the	O
21	"	O
22	traditional	O
23	"	O
24	risk	O
25	factors	O
26	may	O
27	be	O
28	interpreted	O
29	on	O
30	the	O
31	basis	O
32	of	O
33	evolving	O
34	knowledge	O
35	.	O

1	The	O
2	patient	O
3	underwent	O
4	two	O
5	intracytoplasmic	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	thawed	O
11	epididymal	O
12	spermatozoa	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	pharmacist	O
21	'	O
22	s	O
23	mistake	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	gonadotrophin	B
38	-	I
39	releasing	I
40	hormone	I
41	agonist	O
42	(	O
43	leuprolide	O
44	depot	O
45	)	O
46	and	O
47	gonadotrophins	B
48	.	O

1	Protein	B
2	C	I
3	deficiency	O
4	or	O
5	protein	B
6	S	I
7	deficiency	O
8	was	O
9	the	O
10	only	O
11	identified	O
12	risk	O
13	factor	O
14	for	O
15	5	O
16	.	O
17	4	O
18	%	O
19	(	O
20	2	O
21	patients	O
22	)	O
23	and	O
24	13	O
25	.	O
26	5	O
27	%	O
28	(	O
29	5	O
30	patients	O
31	),	O
32	respectively	O
33	,	O
34	of	O
35	these	O
36	37	O
37	children	O
38	.	O

1	Perhaps	O
2	in	O
3	addition	O
4	to	O
5	,	O
6	or	O
7	as	O
8	part	O
9	of	O
10	,	O
11	its	O
12	essential	O
13	function	O
14	in	O
15	late	O
16	mitosis	O
17	,	O
18	MOB1	B
19	is	O
20	required	O
21	for	O
22	a	O
23	cell	O
24	cycle	O
25	reset	O
26	function	O
27	necessary	O
28	for	O
29	the	O
30	initiation	O
31	of	O
32	the	O
33	spindle	O
34	pole	O
35	body	O
36	duplication	O
37	.	O

1	In	O
2	contrast	O
3	,	O
4	overproduction	O
5	of	O
6	Der3p	B
7	is	O
8	lethal	O
9	in	O
10	a	O
11	sec61	B
12	-	I
13	2	I
14	strain	O
15	at	O
16	the	O
17	permissive	O
18	temperature	O
19	of	O
20	25	O
21	degrees	O
22	C	O
23	.	O

1	Normal	O
2	baseline	O
3	(	O
4	day	O
5	-	O
6	8	O
7	)	O
8	PC	O
9	levels	O
10	(	O
11	86	O
12	and	O
13	89	O
14	%)	O
15	were	O
16	markedly	O
17	reduced	O
18	in	O
19	both	O
20	patients	O
21	at	O
22	the	O
23	time	O
24	of	O
25	VOD	O
26	manifestation	O
27	on	O
28	day	O
29	20	O
30	and	O
31	40	O
32	,	O
33	respectively	O
34	(	O
35	26	O
36	and	O
37	31	O
38	%).	O

1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O

1	An	O
2	evolutionary	O
3	conserved	O
4	element	O
5	is	O
6	essential	O
7	for	O
8	somite	O
9	and	O
10	adjacent	O
11	mesenchymal	O
12	expression	O
13	of	O
14	the	O
15	Hoxa1	B
16	gene	I
17	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bovine	O
5	cDNA	O
6	insert	O
7	sequence	O
8	was	O
9	273	O
10	nucleotides	O
11	in	O
12	length	O
13	for	O
14	the	O
15	entire	O
16	mRNA	O
17	coding	O
18	region	O
19	,	O
20	212	O
21	nucleotides	O
22	in	O
23	the	O
24	5	O
25	'	O
26	untranslated	O
27	region	O
28	,	O
29	83	O
30	nucleotides	O
31	in	O
32	the	O
33	3	O
34	'	O
35	untranslated	O
36	region	O
37	and	O
38	a	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	tail	O
44	.	O

1	Altogether	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	a	O
6	liver	O
7	-	O
8	enriched	O
9	transcription	O
10	factor	O
11	,	O
12	HNF	B
13	-	I
14	6	I
15	,	O
16	which	O
17	is	O
18	required	O
19	for	O
20	HNF	B
21	-	I
22	3	I
23	beta	I
24	promoter	I
25	activity	O
26	and	O
27	also	O
28	recognizes	O
29	the	O
30	regulatory	O
31	region	O
32	of	O
33	numerous	O
34	hepatocyte	O
35	-	O
36	specific	O
37	genes	O
38	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	identified	O
6	encoding	O
7	a	O
8	second	O
9	GHS	B
10	-	I
11	R	I
12	-	I
13	related	I
14	gene	I
15	(	O
16	GPR39	B
17	).	O

1	(	O
2	1997	O
3	)	O
4	Science	O
5	275	O
6	,	O
7	1927	O
8	-	O
9	1930	O
10	).	O

1	P	O
2	.,	O
3	Peyron	O
4	,	O
5	J	O
6	.	O

1	A	O
2	hybridoma	O
3	clone	O
4	(	O
5	7H1	O
6	)	O
7	resulting	O
8	from	O
9	the	O
10	fusion	O
11	between	O
12	CEMLAI	O
13	/	O
14	NP	O
15	and	O
16	human	O
17	embryonic	O
18	fibroblasts	O
19	MRC5	O
20	cells	O
21	produced	O
22	very	O
23	large	O
24	amounts	O
25	of	O
26	P47	B
27	that	O
28	was	O
29	purified	O
30	using	O
31	Jacalin	B
32	lectin	I
33	(	O
34	specific	O
35	for	O
36	O	O
37	-	O
38	glycans	O
39	)	O
40	and	O
41	microsequenced	O
42	.	O

1	This	O
2	information	O
3	,	O
4	together	O
5	with	O
6	estimation	O
7	of	O
8	the	O
9	size	O
10	of	O
11	the	O
12	deglycosylated	O
13	A	O
14	subunit	O
15	relative	O
16	to	O
17	a	O
18	series	O
19	of	O
20	C	B
21	-	I
22	terminal	I
23	truncated	I
24	TSHR	I
25	ectodomain	I
26	variants	I
27	,	O
28	places	O
29	cleavage	O
30	Site	O
31	1	O
32	in	O
33	the	O
34	vicinity	O
35	of	O
36	,	O
37	or	O
38	closely	O
39	upstream	O
40	to	O
41	,	O
42	residue	O
43	317	O
44	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	O
19	Hepa	O
20	1	O
21	-	O
22	6	O
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	footprint	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	B
44	fVII	I
45	gene	I
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O

1	A	O
2	reciprocal	O
3	binding	O
4	assay	O
5	using	O
6	IM	O
7	-	O
8	9	O
9	cells	O
10	as	O
11	a	O
12	source	O
13	of	O
14	SHP	B
15	-	I
16	1	I
17	and	O
18	SHP	B
19	-	I
20	2	I
21	revealed	O
22	specific	O
23	association	O
24	of	O
25	SHP	B
26	-	I
27	2	I
28	(	O
29	but	O
30	not	O
31	SHP	B
32	-	I
33	1	I
34	)	O
35	with	O
36	a	O
37	glutathione	B
38	S	I
39	-	I
40	transferase	I
41	fusion	I
42	incorporating	O
43	GHR	B
44	cytoplasmic	I
45	domain	I
46	residues	I
47	485	I
48	-	I
49	620	I
50	,	O
51	but	O
52	only	O
53	if	O
54	the	O
55	fusion	O
56	was	O
57	first	O
58	rendered	O
59	tyrosine	O
60	-	O
61	phosphorylated	O
62	.	O

1	Both	O
2	increasing	O
3	basal	O
4	FSH	B
5	and	O
6	age	O
7	were	O
8	associated	O
9	significantly	O
10	with	O
11	increased	O
12	total	O
13	gonadotrophin	B
14	dose	O
15	,	O
16	and	O
17	reduced	O
18	number	O
19	of	O
20	oocytes	O
21	collected	O
22	and	O
23	pregnancy	O
24	rate	O
25	.	O

1	A	O
2	comparative	O
3	study	O
4	was	O
5	undertaken	O
6	between	O
7	an	O
8	enzymatic	O
9	immunohistochemical	O
10	technique	O
11	(	O
12	EIT	O
13	)	O
14	developed	O
15	for	O
16	the	O
17	diagnosis	O
18	of	O
19	human	O
20	trichinellosis	O
21	and	O
22	the	O
23	indirect	O
24	immunofluorescence	O
25	test	O
26	(	O
27	IIF	O
28	),	O
29	analysing	O
30	sera	O
31	from	O
32	outbreaks	O
33	of	O
34	human	O
35	trichinellosis	O
36	in	O
37	Argentina	O
38	.	O

1	Our	O
2	results	O
3	establish	O
4	GKLF	B
5	as	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcription	O
11	factor	O
12	likely	O
13	involved	O
14	in	O
15	regulation	O
16	of	O
17	expression	O
18	of	O
19	endogenous	O
20	genes	O
21	.	O

1	CES4	B
2	on	O
3	a	O
4	multicopy	O
5	plasmid	O
6	was	O
7	unable	O
8	to	O
9	suppress	O
10	tif1	B
11	-	I
12	A79V	I
13	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	in	O
6	cultured	O
7	cells	O
8	from	O
9	Drosophila	O
10	melanogaster	O
11	human	B
12	Sp1	I
13	efficiently	O
14	activates	O
15	transcription	O
16	from	O
17	synthetic	O
18	promoters	O
19	containing	O
20	TATA	O
21	boxes	O
22	,	O
23	but	O
24	not	O
25	from	O
26	promoters	O
27	that	O
28	contain	O
29	an	O
30	initiator	O
31	instead	O
32	of	O
33	a	O
34	TATA	O
35	box	O
36	.	O

1	No	O
2	apparent	O
3	clinical	O
4	signs	O
5	indicative	O
6	of	O
7	systemic	O
8	toxicity	O
9	were	O
10	observed	O
11	in	O
12	the	O
13	F0	O
14	and	O
15	F1	O
16	animals	O
17	of	O
18	either	O
19	sex	O
20	.	O

1	We	O
2	have	O
3	used	O
4	mutation	O
5	-	O
6	directed	O
7	chemical	O
8	cross	O
9	-	O
10	linking	O
11	with	O
12	bis	O
13	(	O
14	sulfosuccinimidyl	O
15	)	O
16	suberate	O
17	(	O
18	BS3	O
19	)	O
20	to	O
21	investigate	O
22	the	O
23	architecture	O
24	of	O
25	the	O
26	gp41	B
27	oligomer	I
28	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	identify	O
6	the	O
7	USH1C	B
8	disease	I
9	gene	I
10	we	O
11	have	O
12	isolated	O
13	the	O
14	region	O
15	between	O
16	these	O
17	markers	O
18	in	O
19	yeast	O
20	artificial	O
21	chromosomes	O
22	(	O
23	YACs	O
24	)	O
25	using	O
26	a	O
27	combination	O
28	of	O
29	STS	O
30	content	O
31	mapping	O
32	and	O
33	Alu	B
34	-	O
35	PCR	O
36	hybridization	O
37	.	O

1	PowerBLAST	O
2	analysis	O
3	identified	O
4	six	O
5	clusters	O
6	of	O
7	expressed	O
8	sequence	O
9	tags	O
10	(	O
11	ESTs	O
12	),	O
13	two	O
14	known	O
15	genes	O
16	(	O
17	BIR	B
18	,	O
19	SUR1	B
20	)	O
21	mapped	O
22	previously	O
23	to	O
24	this	O
25	region	O
26	,	O
27	and	O
28	a	O
29	previously	O
30	characterized	O
31	but	O
32	unmapped	O
33	gene	B
34	NEFA	I
35	(	O
36	DNA	B
37	binding	I
38	/	I
39	EF	I
40	hand	I
41	/	I
42	acidic	I
43	amino	I
44	-	I
45	acid	I
46	-	I
47	rich	I
48	).	O

1	A	O
2	fusion	O
3	protein	O
4	composed	O
5	of	O
6	beta	B
7	-	I
8	galactosidase	I
9	and	O
10	full	B
11	-	I
12	length	I
13	Ahr	I
14	translocates	O
15	from	O
16	the	O
17	cytoplasm	O
18	to	O
19	the	O
20	nucleus	O
21	in	O
22	a	O
23	ligand	O
24	-	O
25	dependent	O
26	manner	O
27	.	O

1	Reconstitution	O
2	of	O
3	Raf	B
4	-	I
5	1	I
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	O
12	active	O
13	Jak1	B
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O

1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O

1	The	O
2	hypothesis	O
3	of	O
4	Geisler	O
5	(	O
6	Brain	O
7	Res	O
8	.	O

1	The	O
2	second	O
3	transcript	O
4	,	O
5	rhis4l	B
6	,	O
7	is	O
8	bicistronic	O
9	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	a	O
7	mutant	O
8	form	O
9	of	O
10	XRN1	B
11	,	O
12	which	O
13	encodes	O
14	a	O
15	5	O
16	'-	O
17	3	O
18	'	O
19	exonuclease	O
20	,	O
21	was	O
22	identified	O
23	as	O
24	an	O
25	extragenic	O
26	suppressor	O
27	that	O
28	increases	O
29	the	O
30	half	O
31	-	O
32	life	O
33	of	O
34	rhis4	B
35	mRNA	I
36	,	O
37	leading	O
38	to	O
39	a	O
40	10	O
41	-	O
42	fold	O
43	increase	O
44	in	O
45	steady	O
46	-	O
47	state	O
48	mRNA	O
49	levels	O
50	compared	O
51	to	O
52	the	O
53	wild	B
54	-	I
55	type	I
56	HIS4	I
57	mRNA	I
58	level	O
59	.	O

1	Sip1	B
2	was	O
3	initially	O
4	identified	O
5	by	O
6	virtue	O
7	of	O
8	its	O
9	interaction	O
10	with	O
11	SC35	B
12	,	O
13	a	O
14	splicing	O
15	factor	O
16	of	O
17	the	O
18	SR	B
19	family	I
20	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	B
13	(	O
14	MyrSos1	B
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	B
28	C	I
29	terminus	I
30	(	O
31	MyrSos1	B
32	-	I
33	deltaC	I
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	Such	O
2	mutations	O
3	are	O
4	thought	O
5	to	O
6	exert	O
7	their	O
8	dominant	O
9	phenotype	O
10	by	O
11	sequestration	O
12	of	O
13	the	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	(	O
19	GNEF	B
20	).	O

1	Several	O
2	studies	O
3	have	O
4	characterized	O
5	the	O
6	upstream	O
7	regulatory	O
8	region	O
9	of	O
10	c	B
11	-	I
12	fos	I
13	,	O
14	and	O
15	identified	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	termed	O
21	the	O
22	cyclic	O
23	AMP	O
24	(	O
25	cAMP	O
26	)	O
27	response	O
28	elements	O
29	(	O
30	CREs	O
31	)	O
32	that	O
33	are	O
34	critical	O
35	for	O
36	c	B
37	-	I
38	fos	I
39	transcription	O
40	in	O
41	response	O
42	to	O
43	a	O
44	variety	O
45	of	O
46	extracellular	O
47	stimuli	O
48	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	kinase	O
6	,	O
7	Nlk	B
8	,	O
9	that	O
10	is	O
11	a	O
12	murine	B
13	homolog	I
14	of	I
15	the	I
16	Drosophila	I
17	nemo	I
18	(	O
19	nmo	B
20	)	O
21	gene	O
22	.	O

1	Our	O
2	findings	O
3	suggest	O
4	that	O
5	striatal	O
6	FDG	O
7	and	O
8	particularly	O
9	RACLO	O
10	are	O
11	sensitive	O
12	and	O
13	effective	O
14	measures	O
15	of	O
16	striatal	O
17	function	O
18	and	O
19	may	O
20	help	O
21	characterizing	O
22	patients	O
23	with	O
24	multiple	O
25	system	O
26	atrophy	O
27	.	O

1	Childhood	O
2	misbehavior	O
3	and	O
4	the	O
5	risk	O
6	of	O
7	injecting	O
8	drug	O
9	use	O
10	.	O

1	Genetic	O
2	analysis	O
3	has	O
4	subsequently	O
5	identified	O
6	subpathways	O
7	of	O
8	the	O
9	DNA	O
10	structure	O
11	checkpoints	O
12	,	O
13	including	O
14	the	O
15	reversible	O
16	arrest	O
17	of	O
18	DNA	O
19	synthesis	O
20	.	O

1	Thus	O
2	,	O
3	Esigma54	B
4	promoters	I
5	are	O
6	responsive	O
7	to	O
8	CRP	B
9	,	O
10	a	O
11	protein	O
12	unrelated	O
13	to	O
14	sigma54	B
15	activators	I
16	,	O
17	and	O
18	the	O
19	repression	O
20	exerted	O
21	is	O
22	the	O
23	direct	O
24	result	O
25	of	O
26	an	O
27	interaction	O
28	between	O
29	Esigma54	B
30	and	O
31	the	O
32	CRP	B
33	-	I
34	cAMP	I
35	complex	I
36	.	O

1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O

1	Demonstration	O
2	of	O
3	tissue	O
4	lesions	O
5	after	O
6	intramuscular	O
7	injection	O
8	by	O
9	determination	O
10	of	O
11	creatine	B
12	kinase	I
13	in	O
14	blood	O

1	Antibodies	O
2	raised	O
3	against	O
4	GST	B
5	mSH2	I
6	-	I
7	B	I
8	identified	O
9	a	O
10	cellular	O
11	protein	O
12	of	O
13	92	O
14	kDa	O
15	that	O
16	was	O
17	not	O
18	found	O
19	to	O
20	be	O
21	phosphorylated	O
22	on	O
23	Tyr	O
24	.	O

1	Interleukin	B
2	-	I
3	6	I
4	(	O
5	IL	B
6	-	I
7	6	I
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	B
14	IL	I
15	-	I
16	6	I
17	gene	I
18	promoter	I
19	coupled	O
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	O
32	.	O

1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	B
24	.	O

1	Our	O
2	purpose	O
3	was	O
4	to	O
5	determine	O
6	if	O
7	intact	O
8	perianal	O
9	(	O
10	S4	O
11	-	O
12	5	O
13	)	O
14	pin	O
15	sensation	O
16	(	O
17	PPS	O
18	)	O
19	and	O
20	bulbocavernosus	O
21	(	O
22	S2	O
23	-	O
24	4	O
25	)	O
26	reflex	O
27	(	O
28	BCR	O
29	)	O
30	shortly	O
31	after	O
32	spinal	O
33	cord	O
34	injury	O
35	(	O
36	SCI	O
37	)	O
38	are	O
39	predictive	O
40	of	O
41	bladder	O
42	function	O
43	recovery	O
44	.	O

1	The	O
2	correct	O
3	termination	O
4	of	O
5	retroviral	O
6	transcripts	O
7	at	O
8	the	O
9	3	O
10	'	O
11	LTR	O
12	R	O
13	/	O
14	U5	O
15	junction	O
16	is	O
17	primarily	O
18	dependent	O
19	on	O
20	the	O
21	canonical	O
22	AAUAAA	O
23	polyadenylation	O
24	signal	O
25	,	O
26	so	O
27	we	O
28	have	O
29	analyzed	O
30	the	O
31	effect	O
32	of	O
33	mutating	O
34	the	O
35	polyadenylation	O
36	signal	O
37	sequences	O
38	on	O
39	the	O
40	properties	O
41	of	O
42	a	O
43	selectable	O
44	murine	O
45	retroviral	O
46	vector	O
47	.	O

1	Levels	O
2	of	O
3	the	O
4	MEK	B
5	inhibitor	O
6	PD98059	O
7	that	O
8	block	O
9	EGF	B
10	-	O
11	induced	O
12	mitogenesis	O
13	and	O
14	MAP	B
15	kinase	I
16	phosphorylation	O
17	also	O
18	abrogate	O
19	EGF	B
20	-	O
21	induced	O
22	focal	O
23	adhesion	O
24	disassembly	O
25	and	O
26	cell	O
27	motility	O
28	.	O

1	ALT	B
2	levels	O
3	in	O
4	responders	O
5	were	O
6	lowered	O
7	by	O
8	46	O
9	%	O
10	and	O
11	AST	B
12	levels	O
13	were	O
14	lowered	O
15	by	O
16	35	O
17	%	O
18	after	O
19	12	O
20	weeks	O
21	of	O
22	vitamin	O
23	E	O
24	treatment	O
25	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	COOH	O
5	-	O
6	terminal	O
7	domain	O
8	of	O
9	RanGAP1	B
10	was	O
11	also	O
12	found	O
13	to	O
14	harbor	O
15	a	O
16	nuclear	O
17	localization	O
18	signal	O
19	.	O

1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	O
20	respectively	O
21	.	O

1	Our	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	investigate	O
7	the	O
8	effect	O
9	of	O
10	MMF	O
11	on	O
12	in	O
13	vivo	O
14	bone	O
15	mineral	O
16	metabolism	O
17	.	O

1	Pao2	O
2	increased	O
3	from	O
4	15	O
5	.	O
6	5	O
7	+/-	O
8	5	O
9	.	O
10	6	O
11	kPa	O
12	(	O
13	116	O
14	+/-	O
15	42	O
16	mm	O
17	Hg	O
18	)	O
19	to	O
20	17	O
21	.	O
22	3	O
23	+/-	O
24	6	O
25	.	O
26	3	O
27	kPa	O
28	(	O
29	130	O
30	+/-	O
31	47	O
32	mm	O
33	Hg	O
34	)	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	05	O
41	).	O

1	Typical	O
2	configurations	O
3	of	O
4	psychosocial	O
5	stress	O
6	factors	O
7	of	O
8	psychiatrically	O
9	conspicuous	O
10	children	O
11	and	O
12	adolescents	O

1	Nine	O
2	cats	O
3	received	O
4	PMEA	O
5	at	O
6	a	O
7	dosage	O
8	of	O
9	10	O
10	mg	O
11	/	O
12	kg	O
13	body	O
14	weight	O
15	,	O
16	nine	O
17	cats	O
18	received	O
19	FPMPA	O
20	at	O
21	a	O
22	dosage	O
23	of	O
24	25	O
25	mg	O
26	/	O
27	kg	O
28	body	O
29	weight	O
30	.	O

1	Resistance	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	neurodevelopmental	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	disruptors	O
17	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	exposure	O
8	of	O
9	DT40	O
10	lymphoma	O
11	B	O
12	cells	O
13	to	O
14	low	O
15	energy	O
16	electromagnetic	O
17	field	O
18	(	O
19	EMF	O
20	)	O
21	results	O
22	in	O
23	a	O
24	tyrosine	B
25	kinase	I
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	phospholipase	B
31	Cgamma2	I
32	(	O
33	PLC	B
34	-	I
35	gamma2	I
36	)	O
37	leading	O
38	to	O
39	increased	O
40	inositol	O
41	phospholipid	O
42	turnover	O
43	.	O

1	We	O
2	present	O
3	the	O
4	preliminary	O
5	results	O
6	obtained	O
7	on	O
8	36	O
9	patients	O
10	which	O
11	were	O
12	followed	O
13	for	O
14	a	O
15	mean	O
16	period	O
17	of	O
18	12	O
19	months	O
20	.	O

1	Moreover	O
2	,	O
3	xTAK1KN	B
4	could	O
5	block	O
6	the	O
7	expression	O
8	of	O
9	ventral	O
10	mesoderm	O
11	marker	O
12	genes	O
13	induced	O
14	by	O
15	Smad1	B
16	or	I
17	5	I
18	.	O

1	PATIENTS	O
2	AND	O
3	METHOD	O
4	:	O
5	Since	O
6	1986	O
7	,	O
8	62	O
9	patients	O
10	were	O
11	irradiated	O
12	stereotactically	O
13	.	O

1	The	O
2	assay	O
3	exhibits	O
4	a	O
5	dynamic	O
6	range	O
7	of	O
8	0	O
9	.	O
10	1	O
11	-	O
12	100	O
13	micrograms	O
14	l	O
15	-	O
16	1	O
17	using	O
18	a	O
19	monoclonal	O
20	antibody	O
21	or	O
22	alternatively	O
23	10	O
24	micrograms	O
25	l	O
26	-	O
27	1	O
28	to	O
29	10	O
30	mg	O
31	l	O
32	-	O
33	1	O
34	using	O
35	commercially	O
36	available	O
37	antiserum	O
38	.	O

1	Training	O
2	for	O
3	audit	O
4	.	O

1	A	O
2	canonical	O
3	TATA	O
4	box	O
5	was	O
6	not	O
7	detected	O
8	.	O

1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	I
10	and	O
11	Fv	B
12	fragments	I
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O

1	A	O
2	putative	O
3	inhibitor	O
4	(	O
5	s	O
6	)	O
7	appears	O
8	to	O
9	co	O
10	-	O
11	elute	O
12	in	O
13	the	O
14	inactive	O
15	fraction	O
16	that	O
17	blocked	O
18	the	O
19	L	B
20	(	I
21	alpha	I
22	)	I
23	activity	O
24	.	O

1	Platelet	O
2	aggregation	O
3	in	O
4	response	O
5	to	O
6	10	O
7	micrograms	O
8	collagen	B
9	/	O
10	ml	O
11	was	O
12	decreased	O
13	in	O
14	parallel	O
15	after	O
16	treatment	O
17	with	O
18	ASA	O
19	.	O

1	Using	O
2	himA	B
3	mutants	I
4	,	O
5	we	O
6	confirmed	O
7	that	O
8	IHF	B
9	plays	O
10	a	O
11	role	O
12	in	O
13	the	O
14	molybdate	O
15	-	O
16	dependent	O
17	regulation	O
18	of	O
19	dmsA	B
20	-	O
21	lacZ	B
22	expression	O
23	in	O
24	vivo	O
25	.	O

1	Cross	O
2	-	O
3	talking	O
4	among	O
5	Drosophila	O
6	nuclear	O
7	receptors	O
8	at	O
9	the	O
10	promiscuous	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	B
16	-	I
17	1	I
18	and	O
19	ng	B
20	-	I
21	2	I
22	intermolt	I
23	genes	I
24	.	O

1	The	O
2	ipsilateral	O
3	breast	O
4	tumor	O
5	relapse	O
6	rate	O
7	was	O
8	similar	O
9	between	O
10	the	O
11	PALP	O
12	and	O
13	MGDET	O
14	groups	O
15	.	O

1	Sibling	O
2	aggregation	O
3	of	O
4	low	B
5	-	I
6	and	I
7	high	I
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	O
13	apolipoproteins	B
14	B	I
15	and	I
16	A	I
17	-	I
18	I	I
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O

1	The	O
2	CAPLC1	B
3	protein	I
4	also	O
5	exhibited	O
6	several	O
7	unique	O
8	features	O
9	,	O
10	including	O
11	a	O
12	novel	O
13	stretch	O
14	of	O
15	18	O
16	-	O
17	19	O
18	amino	O
19	acid	O
20	residues	O
21	within	O
22	the	O
23	X	O
24	domain	O
25	and	O
26	an	O
27	unusually	O
28	long	O
29	N	O
30	-	O
31	terminus	O
32	which	O
33	did	O
34	not	O
35	contain	O
36	a	O
37	recognizable	O
38	EF	O
39	-	O
40	hand	O
41	Ca	O
42	(	O
43	2	O
44	+)-	O
45	binding	O
46	domain	O
47	.	O

1	This	O
2	hypothesis	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	PEA3	B
10	binding	I
11	sites	I
12	in	O
13	the	O
14	PEA3	B
15	promoter	I
16	and	O
17	with	O
18	the	O
19	ability	O
20	of	O
21	PEA3	B
22	to	O
23	transactivate	O
24	this	O
25	promoter	O
26	.	O

1	Pet	B
2	-	I
3	1	I
4	can	O
5	bind	O
6	specifically	O
7	to	O
8	a	O
9	PEA3	B
10	ETS	I
11	DNA	O
12	-	O
13	binding	O
14	motif	O
15	and	O
16	can	O
17	modulate	O
18	transcription	O
19	of	O
20	synthetic	O
21	promoter	O
22	constructs	O
23	in	O
24	a	O
25	sequence	O
26	-	O
27	specific	O
28	manner	O
29	.	O

1	The	O
2	protein	O
3	expressed	O
4	by	O
5	F2771	B
6	cDNA	I
7	in	O
8	transfected	O
9	COS	O
10	cells	O
11	is	O
12	localized	O
13	in	O
14	the	O
15	cytoplasm	O
16	.	O

1	Northern	O
2	analysis	O
3	indicated	O
4	differential	O
5	expression	O
6	by	O
7	tissue	O
8	with	O
9	highest	O
10	expression	O
11	in	O
12	the	O
13	heart	O
14	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	I
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	B
45	2m	I
46	.	O

1	The	O
2	mRNAs	O
3	of	O
4	these	O
5	genes	O
6	contain	O
7	respectively	O
8	one	O
9	(	O
10	YAP1	B
11	uORF	I
12	)	O
13	and	O
14	two	O
15	(	O
16	YAP2	B
17	uORF1	I
18	and	O
19	uORF2	O
20	)	O
21	upstream	O
22	open	O
23	reading	O
24	frames	O
25	.	O
26	uORF	O
27	-	O
28	mediated	O
29	modulation	O
30	of	O
31	post	O
32	-	O
33	termination	O
34	events	O
35	on	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	5	O
43	'-	O
44	UTR	O
45	)	O
46	directs	O
47	differential	O
48	control	O
49	not	O
50	only	O
51	of	O
52	translation	O
53	but	O
54	also	O
55	of	O
56	mRNA	O
57	decay	O
58	.	O

1	To	O
2	further	O
3	investigate	O
4	the	O
5	nature	O
6	of	O
7	the	O
8	site	O
9	specificity	O
10	a	O
11	set	O
12	of	O
13	deletion	O
14	mutants	O
15	of	O
16	the	O
17	160	O
18	bp	O
19	sequence	O
20	were	O
21	analysed	O
22	.	O

1	In	O
2	the	O
3	tissues	O
4	tested	O
5	,	O
6	except	O
7	brain	O
8	,	O
9	the	O
10	message	O
11	for	O
12	CLIP	B
13	-	I
14	170	I
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	B
22	.	O

1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O

1	Cytoskeletal	O
2	polarization	O
3	of	O
4	T	O
5	cells	O
6	is	O
7	regulated	O
8	by	O
9	an	O
10	immunoreceptor	O
11	tyrosine	O
12	-	O
13	based	O
14	activation	O
15	motif	O
16	-	O
17	dependent	O
18	mechanism	O
19	.	O

1	Here	O
2	we	O
3	have	O
4	examined	O
5	the	O
6	ability	O
7	of	O
8	the	O
9	cellular	O
10	protein	O
11	YB	B
12	-	I
13	1	I
14	to	O
15	modulate	O
16	transcription	O
17	of	O
18	the	O
19	HIV	B
20	-	I
21	1	I
22	promoter	I
23	in	O
24	a	O
25	human	O
26	astrocytic	O
27	cell	O
28	line	O
29	(	O
30	U	O
31	-	O
32	87MG	O
33	),	O
34	a	O
35	neuronal	O
36	cell	O
37	line	O
38	(	O
39	SK	O
40	-	O
41	N	O
42	-	O
43	MC	O
44	)	O
45	and	O
46	lymphoid	O
47	cells	O
48	(	O
49	Jurkat	O
50	)	O
51	by	O
52	transfection	O
53	assay	O
54	.	O

1	Also	O
2	,	O
3	the	O
4	deduced	O
5	amino	O
6	acids	O
7	of	O
8	the	O
9	antigenic	B
10	regions	I
11	A	I
12	,	I
13	B	I
14	and	I
15	C	I
16	of	I
17	VP7	I
18	were	O
19	nearly	O
20	conserved	O
21	within	O
22	the	O
23	phylogenetic	O
24	lineages	O
25	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	It	O
2	may	O
3	also	O
4	be	O
5	suggested	O
6	that	O
7	particular	O
8	care	O
9	should	O
10	be	O
11	taken	O
12	when	O
13	such	O
14	a	O
15	trans	O
16	-	O
17	dominant	O
18	Rev	B
19	mutant	I
20	is	O
21	considered	O
22	to	O
23	be	O
24	used	O
25	as	O
26	a	O
27	genetic	O
28	therapy	O
29	against	O
30	HIV	O
31	-	O
32	I	O
33	infection	O
34	,	O
35	in	O
36	individuals	O
37	infected	O
38	with	O
39	both	O
40	HIV	O
41	-	O
42	I	O
43	and	O
44	HTLV	O
45	-	O
46	1	O
47	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Between	O
6	January	O
7	1992	O
8	and	O
9	June	O
10	1994	O
11	at	O
12	St	O
13	.	O

1	The	O
2	frequency	O
3	of	O
4	SPs	O
5	for	O
6	both	O
7	the	O
8	moderate	O
9	and	O
10	severe	O
11	groups	O
12	was	O
13	significantly	O
14	higher	O
15	than	O
16	that	O
17	in	O
18	patients	O
19	with	O
20	a	O
21	normal	O
22	MMFCV	O
23	(	O
24	p	O
25	<	O
26	.	O
27	01	O
28	);	O
29	of	O
30	154	O
31	arms	O
32	with	O
33	a	O
34	normal	O
35	MMFCV	O
36	,	O
37	only	O
38	9	O
39	(	O
40	6	O
41	%)	O
42	had	O
43	an	O
44	SP	O
45	.	O

1	We	O
2	analyzed	O
3	the	O
4	P	O
5	-	O
6	SAECG	O
7	in	O
8	the	O
9	time	O
10	and	O
11	frequency	O
12	domain	O
13	in	O
14	23	O
15	patients	O
16	with	O
17	Paf	O
18	and	O
19	19	O
20	controls	O
21	.	O

1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	B
14	-	I
15	1alpha	I
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O

1	TOR2	B
2	is	O
3	part	O
4	of	O
5	two	O
6	related	O
7	signaling	O
8	pathways	O
9	coordinating	O
10	cell	O
11	growth	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	Transcervical	O
2	amnioinfusion	O
3	.	O

1	SETTING	O
2	:	O
3	A	O
4	division	O
5	of	O
6	a	O
7	large	O
8	tea	O
9	plantation	O
10	in	O
11	Kandy	O
12	.	O

1	Simple	O
2	models	O
3	of	O
4	bimolecular	O
5	interaction	O
6	did	O
7	not	O
8	fully	O
9	account	O
10	for	O
11	the	O
12	kinetic	O
13	profiles	O
14	obtained	O
15	with	O
16	the	O
17	parental	O
18	antibodies	O
19	and	O
20	the	O
21	hybrids	O
22	,	O
23	and	O
24	this	O
25	complexity	O
26	suggested	O
27	the	O
28	existence	O
29	of	O
30	a	O
31	conformational	O
32	heterogeneity	O
33	in	O
34	these	O
35	molecules	O
36	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	O
22	,	O
23	the	O
24	leucine	O
25	zipper	O
26	transcription	O
27	factor	O
28	MafB	B
29	/	O
30	Kr	B
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	Substrates	O
2	for	O
3	p210	B
4	(	O
5	bcr	B
6	-	O
7	abl	B
8	)	O
9	are	O
10	likely	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	the	O
16	pathogenesis	O
17	of	O
18	CML	O
19	.	O

1	Reporter	O
2	constructs	O
3	function	O
4	in	O
5	a	O
6	parallel	O
7	manner	O
8	,	O
9	demonstrating	O
10	the	O
11	key	O
12	role	O
13	of	O
14	the	O
15	AhR	B
16	in	O
17	constitutive	O
18	as	O
19	well	O
20	as	O
21	TCDD	O
22	-	O
23	induced	O
24	expression	O
25	of	O
26	Cyp1B1	B
27	in	O
28	mouse	O
29	embryo	O
30	fibroblasts	O
31	.	O

1	Transfection	O
2	studies	O
3	also	O
4	showed	O
5	that	O
6	3	O
7	'-	O
8	deletion	O
9	of	O
10	sequences	O
11	downstream	O
12	of	O
13	the	O
14	transcriptional	O
15	start	O
16	site	O
17	(+	O
18	1	O
19	/+	O
20	47	O
21	)	O
22	markedly	O
23	reduced	O
24	OSM	B
25	-	O
26	fold	O
27	induction	O
28	.	O

1	Oncostatin	B
2	M	I
3	stimulates	O
4	c	B
5	-	I
6	Fos	I
7	to	O
8	bind	O
9	a	O
10	transcriptionally	O
11	responsive	O
12	AP	B
13	-	I
14	1	I
15	element	I
16	within	O
17	the	O
18	tissue	B
19	inhibitor	I
20	of	I
21	metalloproteinase	I
22	-	I
23	1	I
24	promoter	I
25	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	O
6	human	B
7	RING	I
8	-	I
9	finger	I
10	gene	I
11	(	O
12	RNF4	B
13	)	O
14	that	O
15	encodes	O
16	a	O
17	190	O
18	-	O
19	amino	O
20	-	O
21	acid	O
22	protein	O
23	.	O

1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	B
21	gene	I
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O

1	The	O
2	COOH	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	the	O
8	transcripts	O
9	contained	O
10	fifteen	O
11	triplet	O
12	repeats	O
13	(	O
14	GCT	O
15	;	O
16	alanine	O
17	)	O
18	at	O
19	nucleotide	O
20	465	O
21	to	O
22	509	O
23	,	O
24	which	O
25	is	O
26	significantly	O
27	expanded	O
28	compared	O
29	to	O
30	the	O
31	rat	B
32	RL14	I
33	.	O

1	Soluble	O
2	FasR	B
3	ligand	O
4	-	O
5	binding	O
6	domain	O
7	:	O
8	high	O
9	-	O
10	yield	O
11	production	O
12	of	O
13	active	O
14	fusion	O
15	and	O
16	non	O
17	-	O
18	fusion	O
19	recombinant	O
20	proteins	O
21	using	O
22	the	O
23	baculovirus	O
24	/	O
25	insect	O
26	cell	O
27	system	O
28	.	O

1	Control	O
2	of	O
3	fatty	O
4	liver	O
5	syndrome	O
6	in	O
7	a	O
8	Jersey	O
9	herd	O
10	by	O
11	a	O
12	change	O
13	of	O
14	diet	O
15	and	O
16	the	O
17	use	O
18	of	O
19	recombinant	O
20	bovine	O
21	somatotrophin	B
22	.	O

1	The	O
2	inhibition	O
3	of	O
4	focus	O
5	formation	O
6	observed	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	C3G	B
12	was	O
13	not	O
14	due	O
15	to	O
16	toxic	O
17	effects	O
18	on	O
19	cell	O
20	viability	O
21	,	O
22	since	O
23	transfected	O
24	C3G	B
25	cells	O
26	exhibited	O
27	the	O
28	same	O
29	survival	O
30	and	O
31	growth	O
32	rates	O
33	as	O
34	untransfected	O
35	NIH3T3	O
36	cells	O
37	or	O
38	cells	O
39	transfected	O
40	with	O
41	plasmid	O
42	vector	O
43	alone	O
44	.	O

1	C	O
2	.	O
3	D2	O
4	-	O
5	Chr	O
6	4	O
7	congenic	O
8	strains	O
9	harboring	O
10	DBA	O
11	/	O
12	2	O
13	alleles	O
14	associated	O
15	with	O
16	the	O
17	Pctr1	B
18	locus	I
19	contained	O
20	DBA	O
21	/	O
22	2	O
23	"	O
24	resistant	O
25	"	O
26	alleles	O
27	of	O
28	the	O
29	CDK4	B
30	/	O
31	CDK6	B
32	inhibitors	O
33	p16	B
34	and	O
35	p15	B
36	.	O

1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	B
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	O
21	-	O
22	specific	O
23	variants	O
24	of	O
25	p16	B
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	CDK4	B
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	B
72	(	O
73	INK4a	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O

1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	O
13	minute	O
14	with	O
15	25	O
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	O
24	and	O
25	27	O
26	excellent	O
27	/	O
28	3	O
29	good	O
30	in	O
31	the	O
32	rocuronium	O
33	group	O
34	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	two	O
6	genes	O
7	encoding	O
8	auxin	B
9	-	I
10	binding	I
11	proteins	I
12	from	O
13	tobacco	O
14	.	O

1	Furthermore	O
2	,	O
3	direct	O
4	association	O
5	with	O
6	D3	O
7	phosphatidylinositides	O
8	seems	O
9	to	O
10	be	O
11	essential	O
12	for	O
13	activation	O
14	of	O
15	PKB	B
16	/	O
17	Akt	B
18	.	O

1	The	O
2	FMN	O
3	moiety	O
4	but	O
5	not	O
6	the	O
7	[	O
8	3Fe	O
9	-	O
10	4S	O
11	]	O
12	cluster	O
13	of	O
14	the	O
15	subunit	O
16	appears	O
17	to	O
18	participate	O
19	in	O
20	this	O
21	reaction	O
22	.	O

1	Alison	O
2	Bell	O
3	Memorial	O
4	Award	O
5	.	O

1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O

1	During	O
2	organogenesis	O
3	,	O
4	HFH	B
5	-	I
6	8	I
7	expression	O
8	is	O
9	found	O
10	in	O
11	the	O
12	splanchnic	O
13	mesoderm	O
14	in	O
15	close	O
16	apposition	O
17	of	O
18	the	O
19	gut	O
20	endoderm	O
21	,	O
22	suggesting	O
23	a	O
24	role	O
25	in	O
26	mesenchymal	O
27	-	O
28	epithelial	O
29	induction	O
30	of	O
31	lung	O
32	and	O
33	gut	O
34	morphogenesis	O
35	.	O

1	However	O
2	,	O
3	laparoscopy	O
4	failed	O
5	to	O
6	establish	O
7	inoperability	O
8	in	O
9	any	O
10	cases	O
11	of	O
12	carcinoma	O
13	spread	O
14	to	O
15	areas	O
16	not	O
17	accessible	O
18	to	O
19	laparoscopic	O
20	visualization	O
21	.	O

1	No	O
2	difference	O
3	in	O
4	telomere	O
5	length	O
6	was	O
7	seen	O
8	in	O
9	mutants	O
10	affected	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	Cdc2	B
16	,	O
17	whereas	O
18	some	O
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	O
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O

1	The	O
2	mean	O
3	duration	O
4	of	O
5	pain	O
6	relief	O
7	was	O
8	4	O
9	-	O
10	6	O
11	weeks	O
12	.	O

1	The	O
2	ESEM	O
3	differs	O
4	from	O
5	conventional	O
6	SEM	O
7	in	O
8	that	O
9	no	O
10	sample	O
11	preparation	O
12	is	O
13	needed	O
14	,	O
15	eliminating	O
16	artifactual	O
17	changes	O
18	.	O

1	Sp1	B
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	B
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	O
12	P	B
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	O
21	p50	B
22	homodimers	I
23	replace	O
24	Sp1	B
25	from	O
26	the	O
27	P	B
28	-	I
29	selectin	I
30	promoter	I
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	B
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	B
50	-	I
51	3	I
52	,	O
53	stimulate	O
54	expression	O
55	.	O

1	The	O
2	3	O
3	'	O
4	fragment	O
5	was	O
6	shown	O
7	to	O
8	accumulate	O
9	as	O
10	full	O
11	-	O
12	length	O
13	mRNA	O
14	disappeared	O
15	in	O
16	actinomycin	O
17	D	O
18	-	O
19	treated	O
20	cells	O
21	,	O
22	indicating	O
23	a	O
24	precursor	O
25	-	O
26	product	O
27	relationship	O
28	.	O

1	The	O
2	TATA	B
3	box	I
4	-	I
5	binding	I
6	protein	I
7	(	O
8	TBP	B
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	O
20	nuclear	B
21	RNA	I
22	polymerases	I
23	,	O
24	polymerases	B
25	(	I
26	Pol	I
27	)	I
28	I	I
29	,	I
30	II	I
31	,	I
32	and	I
33	III	I
34	.	O

1	A	O
2	triple	B
3	-	I
4	mutant	I
5	TBP	I
6	(	O
7	R231E	O
8	+	O
9	R235E	O
10	+	O
11	R239S	O
12	)	O
13	had	O
14	greatly	O
15	reduced	O
16	activity	O
17	for	O
18	yeast	B
19	U6	I
20	snRNA	I
21	gene	I
22	transcription	O
23	while	O
24	remaining	O
25	active	O
26	for	O
27	Pol	B
28	II	I
29	basal	O
30	transcription	O
31	.	O

1	E2F	B
2	activity	O
3	is	O
4	regulated	O
5	in	O
6	part	O
7	by	O
8	the	O
9	retinoblastoma	B
10	family	I
11	of	I
12	tumor	I
13	suppressor	I
14	proteins	I
15	.	O

1	This	O
2	resulted	O
3	in	O
4	a	O
5	complete	O
6	inhibition	O
7	of	O
8	Site	O
9	-	O
10	1	O
11	cleavage	O
12	that	O
13	was	O
14	restored	O
15	by	O
16	concomitant	O
17	overexpression	O
18	of	O
19	full	O
20	-	O
21	length	O
22	SCAP	B
23	.	O

1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	the	O
5	50	O
6	-	O
7	and	O
8	57	O
9	-	O
10	kDa	O
11	subunits	O
12	of	O
13	the	O
14	bovine	B
15	vacuolar	I
16	proton	I
17	pump	I
18	.	O

1	In	O
2	C	O
3	.	O
4	albicans	O
5	,	O
6	HST6	B
7	is	O
8	expressed	O
9	constitutively	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	the	O
15	different	O
16	cell	O
17	types	O
18	analysed	O
19	(	O
20	yeast	O
21	,	O
22	hyphae	O
23	,	O
24	white	O
25	and	O
26	opaque	O
27	),	O
28	demonstrating	O
29	that	O
30	HST6	B
31	transcription	O
32	is	O
33	not	O
34	repressed	O
35	in	O
36	this	O
37	diploid	O
38	yeast	O
39	,	O
40	unlike	O
41	in	O
42	diploid	O
43	S	O
44	.	O
45	cerevisiae	O
46	,	O
47	and	O
48	suggesting	O
49	a	O
50	basic	O
51	biological	O
52	function	O
53	for	O
54	the	O
55	Hst6p	B
56	transporter	O
57	in	O
58	C	O
59	.	O
60	albicans	O
61	.	O

1	Furthermore	O
2	,	O
3	binding	O
4	of	O
5	recombinant	B
6	Myb	I
7	and	O
8	Ets	B
9	-	I
10	2	I
11	protein	I
12	to	O
13	these	O
14	fragments	O
15	could	O
16	be	O
17	competed	O
18	with	O
19	an	O
20	excess	O
21	of	O
22	double	O
23	stranded	O
24	oligodeoxynucleotides	O
25	containing	O
26	canonical	O
27	,	O
28	but	O
29	not	O
30	mutated	O
31	,	O
32	Myb	B
33	-	O
34	or	O
35	Ets	B
36	-	I
37	binding	I
38	sites	I
39	.	O

1	This	O
2	structure	O
3	interconnects	O
4	specific	O
5	triplets	O
6	of	O
7	the	O
8	basal	O
9	bodies	O
10	with	O
11	the	O
12	microtubular	O
13	bundles	O
14	that	O
15	emerge	O
16	from	O
17	the	O
18	basal	O
19	apparatus	O
20	.	O

1	To	O
2	understand	O
3	the	O
4	regulatory	O
5	mechanism	O
6	controlling	O
7	its	O
8	expression	O
9	at	O
10	low	O
11	temperature	O
12	,	O
13	the	O
14	promoter	O
15	region	O
16	has	O
17	been	O
18	characterized	O
19	.	O

1	In	O
2	the	O
3	current	O
4	study	O
5	,	O
6	the	O
7	roles	O
8	of	O
9	two	O
10	putative	O
11	cis	O
12	-	O
13	acting	O
14	elements	O
15	within	O
16	the	O
17	-	O
18	73	O
19	to	O
20	+	O
21	44	O
22	region	O
23	in	O
24	basal	O
25	exon	O
26	2	O
27	promoter	O
28	activity	O
29	were	O
30	evaluated	O
31	using	O
32	mutagenesis	O
33	and	O
34	nuclear	O
35	protein	O
36	-	O
37	DNA	O
38	binding	O
39	assays	O
40	.	O

1	For	O
2	the	O
3	5HT5A	B
4	receptor	I
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O

1	We	O
2	have	O
3	examined	O
4	reporter	O
5	gene	O
6	(	O
7	beta	B
8	-	I
9	gal	I
10	)	O
11	expression	O
12	directed	O
13	by	O
14	human	B
15	heat	I
16	shock	I
17	transcription	I
18	factors	I
19	1	I
20	and	I
21	2	I
22	(	O
23	HSF1	B
24	and	O
25	HSF2	B
26	)	O
27	in	O
28	HeLa	O
29	cells	O
30	and	O
31	in	O
32	yeast	O
33	(	O
34	Saccharomyces	O
35	cerevisiae	O
36	).	O

1	Localized	O
2	fluorescence	O
3	was	O
4	detectable	O
5	only	O
6	in	O
7	cells	O
8	containing	O
9	a	O
10	visible	O
11	midcell	O
12	constriction	O
13	,	O
14	suggesting	O
15	that	O
16	FtsK	B
17	targeting	O
18	normally	O
19	occurs	O
20	only	O
21	at	O
22	a	O
23	late	O
24	stage	O
25	of	O
26	septation	O
27	.	O

1	No	O
2	TATA	O
3	box	O
4	was	O
5	found	O
6	in	O
7	the	O
8	putative	O
9	promoter	O
10	region	O
11	,	O
12	but	O
13	multiple	O
14	GC	O
15	boxes	O
16	were	O
17	found	O
18	around	O
19	the	O
20	cap	O
21	sites	O
22	,	O
23	supporting	O
24	the	O
25	previously	O
26	inferred	O
27	housekeeping	O
28	nature	O
29	of	O
30	CYP51	B
31	gene	I
32	and	O
33	the	O
34	existence	O
35	of	O
36	the	O
37	multiple	O
38	transcription	O
39	initiation	O
40	sites	O
41	.	O

1	Structural	O
2	and	O
3	evolutionary	O
4	studies	O
5	on	O
6	sterol	B
7	14	I
8	-	I
9	demethylase	I
10	P450	I
11	(	O
12	CYP51	B
13	),	O
14	the	O
15	most	O
16	conserved	O
17	P450	B
18	monooxygenase	I
19	:	O
20	I	O
21	.	O

1	Its	O
2	expression	O
3	pattern	O
4	is	O
5	representative	O
6	of	O
7	many	O
8	B	O
9	cell	O
10	-	O
11	specific	O
12	proteins	O
13	,	O
14	which	O
15	are	O
16	essential	O
17	for	O
18	B	O
19	cell	O
20	development	O
21	and	O
22	activation	O
23	but	O
24	are	O
25	down	O
26	-	O
27	regulated	O
28	after	O
29	B	O
30	cells	O
31	become	O
32	terminally	O
33	differentiated	O
34	plasma	O
35	cells	O
36	.	O

1	The	O
2	intercistronic	O
3	gene	O
4	junctions	O
5	of	O
6	vesicular	O
7	stomatitis	O
8	virus	O
9	(	O
10	VSV	O
11	)	O
12	contain	O
13	conserved	O
14	sequence	O
15	elements	O
16	that	O
17	are	O
18	important	O
19	for	O
20	polyadenylation	O
21	and	O
22	transcription	O
23	termination	O
24	of	O
25	upstream	O
26	transcript	O
27	as	O
28	well	O
29	as	O
30	reinitiation	O
31	of	O
32	transcription	O
33	of	O
34	downstream	O
35	transcript	O
36	.	O

1	Infectious	O
2	mutant	O
3	virus	O
4	progeny	O
5	was	O
6	obtained	O
7	only	O
8	on	O
9	complementing	O
10	gK	B
11	-	O
12	expressing	O
13	cells	O
14	,	O
15	suggesting	O
16	that	O
17	gK	B
18	has	O
19	an	O
20	important	O
21	function	O
22	in	O
23	the	O
24	replication	O
25	cycle	O
26	.	O

1	Cleavage	O
2	and	O
3	DNA	O
4	joining	O
5	reactions	O
6	,	O
7	carried	O
8	out	O
9	by	O
10	human	B
11	immunodeficiency	I
12	virus	I
13	type	I
14	1	I
15	(	I
16	HIV	I
17	-	I
18	1	I
19	)	I
20	integrase	I
21	,	O
22	are	O
23	necessary	O
24	to	O
25	effect	O
26	the	O
27	covalent	O
28	insertion	O
29	of	O
30	HIV	O
31	-	O
32	1	O
33	DNA	O
34	into	O
35	the	O
36	host	O
37	genome	O
38	.	O

1	The	O
2	DSF	O
3	regimen	O
4	appears	O
5	to	O
6	have	O
7	significant	O
8	activity	O
9	in	O
10	patients	O
11	who	O
12	have	O
13	metastatic	O
14	pancreatic	O
15	islet	O
16	-	O
17	cell	O
18	carcinoma	O
19	,	O
20	and	O
21	patient	O
22	tolerance	O
23	of	O
24	the	O
25	regimen	O
26	is	O
27	excellent	O
28	,	O
29	thus	O
30	warranting	O
31	further	O
32	investigation	O
33	.	O

1	Activation	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	is	O
12	a	O
13	primary	O
14	consequence	O
15	of	O
16	Ras	B
17	activation	O
18	and	O
19	plays	O
20	a	O
21	key	O
22	role	O
23	in	O
24	mediating	O
25	Ras	B
26	signal	O
27	transduction	O
28	.	O

1	Histone	B
2	acetylation	O
3	levels	O
4	in	O
5	cells	O
6	result	O
7	from	O
8	a	O
9	dynamic	O
10	equilibrium	O
11	between	O
12	competing	O
13	histone	B
14	acetylases	I
15	and	I
16	deacetylases	I
17	.	O

1	CONCLUSIONS	O
2	:	O
3	XCoe2	B
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	B
24	-	O
25	Notch	B
26	signalling	O
27	,	O
28	XCoe2	B
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	B
41	-	I
42	ngnr	I
43	-	I
44	1	I
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	B
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	CyIIa	B
2	transcription	O
3	follows	O
4	,	O
5	and	O
6	is	O
7	therefore	O
8	downstream	O
9	of	O
10	,	O
11	the	O
12	initial	O
13	specification	O
14	of	O
15	these	O
16	embryonic	O
17	domains	O
18	.	O

1	Cis	O
2	-	O
3	regulation	O
4	downstream	O
5	of	O
6	cell	O
7	type	O
8	specification	O
9	:	O
10	a	O
11	single	O
12	compact	O
13	element	O
14	controls	O
15	the	O
16	complex	O
17	expression	O
18	of	O
19	the	O
20	CyIIa	B
21	gene	I
22	in	O
23	sea	O
24	urchin	O
25	embryos	O
26	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	that	O
6	human	B
7	HYAL1	I
8	is	O
9	identical	O
10	to	O
11	an	O
12	uncharacterized	O
13	gene	O
14	positionally	O
15	cloned	O
16	by	O
17	others	O
18	from	O
19	chromosome	O
20	3p21	O
21	.	O
22	3	O
23	that	O
24	is	O
25	homozygously	O
26	deleted	O
27	in	O
28	several	O
29	small	O
30	-	O
31	cell	O
32	lung	O
33	carcinoma	O
34	cell	O
35	lines	O
36	.	O

1	In	O
2	patients	O
3	with	O
4	myalgia	O
5	,	O
6	Raynaud	O
7	'	O
8	s	O
9	syndrome	O
10	,	O
11	skin	O
12	vasculitis	O
13	and	O
14	vascular	O
15	diseases	O
16	WFAg	B
17	concentrations	O
18	were	O
19	higher	O
20	than	O
21	in	O
22	patients	O
23	without	O
24	them	O
25	.	O

1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	O
52	-	O
53	4T	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	B
72	-	I
73	thrombin	I
74	.	O

1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	O
26	10	O
27	trial	O
28	.	O

1	Therapeutic	O
2	use	O
3	of	O
4	cannabis	O
5	.	O

1	Analysis	O
2	of	O
3	intragenic	O
4	revertants	O
5	shows	O
6	that	O
7	this	O
8	function	O
9	depends	O
10	on	O
11	the	O
12	amino	O
13	acid	O
14	preceding	O
15	the	O
16	first	O
17	cysteine	O
18	residue	O
19	of	O
20	the	O
21	DNA	O
22	-	O
23	binding	O
24	domain	O
25	of	O
26	Hap1p	B
27	.	O

1	Peripheral	O
2	visual	O
3	stimuli	O
4	and	O
5	monoaural	O
6	auditory	O
7	stimuli	O
8	were	O
9	used	O
10	as	O
11	targets	O
12	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	PKC	B
2	-	I
3	gamma	I
4	,	O
5	which	O
6	is	O
7	not	O
8	present	O
9	in	O
10	keratinocytes	O
11	,	O
12	also	O
13	induces	O
14	involucrin	B
15	gene	I
16	expression	O
17	in	O
18	a	O
19	TPA	O
20	-	O
21	independent	O
22	manner	O
23	,	O
24	when	O
25	introduced	O
26	into	O
27	SVHK	O
28	cells	O
29	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	specific	O
6	DNA	O
7	-	O
8	binding	O
9	complexes	O
10	containing	O
11	members	O
12	of	O
13	the	O
14	Myc	B
15	/	O
16	Max	B
17	/	O
18	Mad	B
19	network	O
20	of	O
21	transcriptional	O
22	regulators	O
23	.	O

1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	B
9	II	I
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	B
19	.	O

1	Primers	O
2	for	O
3	subsequent	O
4	rounds	O
5	of	O
6	RACE	O
7	were	O
8	designed	O
9	from	O
10	the	O
11	5	O
12	'-	O
13	ends	O
14	of	O
15	amplified	O
16	RACE	O
17	products	O
18	.	O

1	Human	O
2	ZFM1	B
3	protein	I
4	is	O
5	a	O
6	transcriptional	O
7	repressor	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	transcription	B
13	activation	I
14	domain	I
15	of	I
16	stage	I
17	-	I
18	specific	I
19	activator	I
20	protein	I
21	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	B
5	/	O
6	IRDelta960	B
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	B
13	/	O
14	IR	B
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	special	O
5	clinical	O
6	presentation	O
7	of	O
8	our	O
9	case	O
10	of	O
11	possible	O
12	Gardner	O
13	'	O
14	s	O
15	syndrome	O
16	is	O
17	discussed	O
18	.	O

1	These	O
2	results	O
3	would	O
4	suggest	O
5	that	O
6	a	O
7	high	O
8	UV	O
9	sensitivity	O
10	is	O
11	associated	O
12	with	O
13	high	O
14	phaeomelanin	O
15	and	O
16	low	O
17	eumelanin	O
18	levels	O
19	,	O
20	and	O
21	point	O
22	to	O
23	the	O
24	eumelanin	O
25	/	O
26	phaeomelanin	O
27	ratio	O
28	as	O
29	a	O
30	novel	O
31	chemical	O
32	parameter	O
33	that	O
34	could	O
35	be	O
36	used	O
37	for	O
38	predicting	O
39	individuals	O
40	at	O
41	high	O
42	risk	O
43	for	O
44	skin	O
45	cancer	O
46	and	O
47	melanoma	O
48	.	O

1	In	O
2	ferrets	O
3	naturally	O
4	infected	O
5	with	O
6	H	O
7	.	O
8	mustelae	O
9	,	O
10	a	O
11	single	O
12	dose	O
13	(	O
14	50	O
15	mg	O
16	/	O
17	kg	O
18	,	O
19	per	O
20	os	O
21	)	O
22	of	O
23	fluorofamide	O
24	completely	O
25	inhibited	O
26	bacterial	B
27	urease	I
28	.	O

1	The	O
2	cAMP	O
3	-	O
4	dependent	O
5	mitogenic	O
6	pathway	O
7	is	O
8	unique	O
9	as	O
10	it	O
11	is	O
12	independent	O
13	of	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	and	O
21	differs	O
22	from	O
23	growth	O
24	factor	O
25	-	O
26	dependent	O
27	pathways	O
28	at	O
29	the	O
30	level	O
31	of	O
32	the	O
33	expression	O
34	of	O
35	several	O
36	protooncogenes	O
37	/	O
38	transcription	O
39	factors	O
40	.	O

1	CONCLUSIONS	O
2	:	O
3	Use	O
4	of	O
5	the	O
6	first	O
7	method	O
8	was	O
9	associated	O
10	with	O
11	a	O
12	reduction	O
13	in	O
14	the	O
15	time	O
16	patients	O
17	remained	O
18	in	O
19	the	O
20	ICU	O
21	before	O
22	transfer	O
23	to	O
24	another	O
25	unit	O
26	and	O
27	savings	O
28	in	O
29	nursing	O
30	time	O
31	,	O
32	but	O
33	the	O
34	two	O
35	methods	O
36	did	O
37	not	O
38	differ	O
39	according	O
40	to	O
41	clinical	O
42	outcomes	O
43	.	O

1	We	O
2	have	O
3	elucidated	O
4	the	O
5	exon	O
6	-	O
7	intron	O
8	organization	O
9	of	O
10	the	O
11	entire	O
12	human	O
13	CD58	B
14	gene	I
15	,	O
16	including	O
17	approximately	O
18	2	O
19	.	O
20	5	O
21	kilobases	O
22	(	O
23	kb	O
24	)	O
25	of	O
26	5	O
27	'-	O
28	flanking	O
29	DNA	O
30	.	O

1	The	O
2	risk	O
3	factors	O
4	for	O
5	hematuria	O
6	in	O
7	patients	O
8	with	O
9	renal	O
10	hypouricemia	O
11	are	O
12	the	O
13	elevation	O
14	of	O
15	urinary	O
16	urate	O
17	concentration	O
18	and	O
19	the	O
20	subtypes	O
21	of	O
22	Post	O
23	and	O
24	Secretion	O
25	.	O

1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O

1	If	O
2	the	O
3	haemoglobin	B
4	concentration	O
5	(	O
6	Hb	B
7	)	O
8	was	O
9	less	O
10	than	O
11	12	O
12	g	O
13	dL	O
14	-	O
15	1	O
16	they	O
17	were	O
18	given	O
19	a	O
20	four	O
21	week	O
22	course	O
23	of	O
24	ferrous	O
25	sulphate	O
26	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	B
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	Based	O
2	on	O
3	restriction	O
4	enzyme	O
5	analysis	O
6	,	O
7	Southern	O
8	blots	O
9	,	O
10	polymerase	O
11	chain	O
12	reaction	O
13	analysis	O
14	and	O
15	DNA	O
16	sequencing	O
17	,	O
18	it	O
19	was	O
20	confirmed	O
21	that	O
22	the	O
23	three	O
24	overlapping	O
25	clones	O
26	isolated	O
27	cover	O
28	the	O
29	entire	O
30	cHO	B
31	-	I
32	1	I
33	gene	I
34	,	O
35	as	O
36	well	O
37	as	O
38	approximately	O
39	10	O
40	kb	O
41	of	O
42	the	O
43	flanking	O
44	regions	O
45	on	O
46	both	O
47	ends	O
48	.	O

1	RESULTS	O
2	:	O
3	Using	O
4	information	O
5	in	O
6	the	O
7	dbEST	O
8	database	O
9	of	O
10	expressed	O
11	sequence	O
12	tags	O
13	,	O
14	we	O
15	isolated	O
16	an	O
17	Arabidopsis	O
18	thaliana	O
19	gene	O
20	(	O
21	GCR1	B
22	)	O
23	that	O
24	encodes	O
25	a	O
26	protein	O
27	with	O
28	seven	O
29	predicted	O
30	membrane	O
31	-	O
32	spanning	O
33	domains	O
34	and	O
35	other	O
36	features	O
37	characteristic	O
38	of	O
39	7TM	B
40	receptors	I
41	.	O

1	E1A	B
2	represses	O
3	apolipoprotein	B
4	AI	I
5	enhancer	I
6	activity	O
7	in	O
8	liver	O
9	cells	O
10	through	O
11	a	O
12	pRb	B
13	-	O
14	and	O
15	CBP	B
16	-	O
17	independent	O
18	pathway	O
19	.	O

1	Position	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	O
8	nerve	B
9	growth	I
10	factor	I
11	-	O
12	luciferase	B
13	reporter	O
14	gene	O
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O

1	Calcitriol	O
2	therapy	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	decrease	O
8	in	O
9	serum	O
10	iPTH	B
11	levels	O
12	(	O
13	701	O
14	+/-	O
15	103	O
16	.	O
17	9	O
18	vs	O
19	.	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	Most	O
2	pituitary	O
3	hormone	O
4	-	O
5	coding	O
6	gene	O
7	promoters	O
8	are	O
9	activated	O
10	by	O
11	Ptx1	B
12	.	O

1	One	O
2	of	O
3	these	O
4	small	B
5	inteins	I
6	might	O
7	be	O
8	inactive	O
9	or	O
10	a	O
11	"	B
12	pseudo	I
13	intein	I
14	."	I
15	The	O
16	results	O
17	suggest	O
18	a	O
19	modular	O
20	architecture	O
21	for	O
22	inteins	B
23	,	O
24	clarify	O
25	their	O
26	origin	O
27	and	O
28	relationship	O
29	to	O
30	other	O
31	protein	O
32	families	O
33	,	O
34	and	O
35	extend	O
36	recent	O
37	experimental	O
38	findings	O
39	on	O
40	the	O
41	functional	O
42	roles	O
43	of	O
44	intein	B
45	N	I
46	,	I
47	C	I
48	,	I
49	and	I
50	EN	I
51	motifs	I
52	.	O

1	Purification	O
2	of	O
3	MvaT	B
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	B
20	and	O
21	P16	B
22	.	O

1	M	B
2	-	I
3	66	I
4	identified	O
5	the	O
6	14	O
7	-	O
8	kDa	O
9	protein	O
10	in	O
11	another	O
12	MMTV	O
13	bearing	O
14	T	O
15	-	O
16	cell	O
17	lymphoma	O
18	,	O
19	EL	O
20	-	O
21	4	O
22	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	TGF	B
6	-	I
7	betaf	I
8	potentiates	O
9	the	O
10	c	B
11	-	I
12	fos	I
13	SRE	O
14	activated	O
15	by	O
16	PKC	B
17	through	O
18	the	O
19	SRF	B
20	binding	I
21	site	I
22	.	O

1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O

1	Ganciclovir	O
2	and	O
3	foscarnet	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	polyradiculopathy	O
11	.	O

1	BACKGROUND	O
2	:	O
3	Defensins	B
4	,	O
5	also	O
6	known	O
7	as	O
8	human	B
9	neutrophil	I
10	peptides	I
11	,	O
12	are	O
13	antimicrobial	O
14	peptides	O
15	present	O
16	in	O
17	the	O
18	azurophil	O
19	granules	O
20	of	O
21	neutrophils	O
22	.	O

1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	B
6	gene	I
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	B
16	operon	I
17	.	O

1	From	O
2	250	O
3	g	O
4	of	O
5	cells	O
6	,	O
7	we	O
8	isolated	O
9	1	O
10	mg	O
11	of	O
12	PDH	B
13	complex	I
14	with	O
15	a	O
16	specific	O
17	activity	O
18	of	O
19	12	O
20	.	O
21	6	O
22	U	O
23	/	O
24	mg	O
25	of	O
26	protein	O
27	.	O

1	The	O
2	PDH	B
3	complex	I
4	-	I
5	encoding	I
6	genes	I
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	O
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	O
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	mobilis	O
27	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	functional	O
6	elements	O
7	,	O
8	both	O
9	located	O
10	downstream	O
11	from	O
12	the	O
13	TATA	O
14	motif	O
15	,	O
16	that	O
17	control	O
18	Id4	B
19	promoter	I
20	activity	O
21	.	O

1	Azithromycin	O
2	is	O
3	a	O
4	new	O
5	generation	O
6	macrolide	O
7	antibiotic	O
8	with	O
9	unusual	O
10	and	O
11	favorable	O
12	pharmacokinetics	O
13	,	O
14	and	O
15	seems	O
16	to	O
17	be	O
18	a	O
19	very	O
20	promising	O
21	agent	O
22	for	O
23	innovative	O
24	anti	O
25	-	O
26	H	O
27	.	O
28	pylori	O
29	regimens	O
30	.	O

1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O

1	BACKGROUND	O
2	AND	O
3	OBJECTIVES	O
4	:	O
5	The	O
6	sexually	O
7	transmitted	O
8	diseases	O
9	(	O
10	STD	O
11	)	O
12	control	O
13	program	O
14	for	O
15	female	O
16	sex	O
17	workers	O
18	(	O
19	FSW	O
20	)	O
21	in	O
22	Lima	O
23	,	O
24	Peru	O
25	,	O
26	provided	O
27	periodic	O
28	serological	O
29	tests	O
30	for	O
31	syphilis	O
32	and	O
33	cervical	O
34	smears	O
35	for	O
36	gonococci	O
37	,	O
38	but	O
39	not	O
40	medication	O
41	for	O
42	STD	O
43	or	O
44	condoms	O
45	.	O

1	National	O
2	certification	O
3	:	O
4	a	O
5	vital	O
6	component	O
7	of	O
8	quality	O
9	assurance	O
10	.	O

1	Two	O
2	rare	O
3	novel	O
4	mutations	O
5	,	O
6	D811N	O
7	in	O
8	exon	O
9	20	O
10	and	O
11	R835C	O
12	in	O
13	exon	O
14	21	O
15	,	O
16	were	O
17	identified	O
18	in	O
19	the	O
20	first	O
21	nucleotide	O
22	-	O
23	binding	O
24	fold	O
25	(	O
26	NBF	O
27	),	O
28	a	O
29	functionally	O
30	important	O
31	region	O
32	of	O
33	SUR1	B
34	,	O
35	in	O
36	one	O
37	patient	O
38	each	O
39	,	O
40	both	O
41	heterozygotes	O
42	.	O

1	Chimaeric	O
2	VP16	B
3	-	O
4	E2	B
5	molecules	O
6	suggest	O
7	that	O
8	the	O
9	epithelial	O
10	specific	O
11	transcriptional	O
12	activation	O
13	of	O
14	the	O
15	BPV	B
16	-	I
17	4	I
18	LCR	I
19	promoter	I
20	is	O
21	mediated	O
22	by	O
23	the	O
24	E2	B
25	transactivation	I
26	domain	I
27	.	O

1	In	O
2	order	O
3	to	O
4	examine	O
5	the	O
6	potential	O
7	role	O
8	of	O
9	transcriptional	O
10	silencing	O
11	during	O
12	productive	O
13	HSV	O
14	-	O
15	1	O
16	infection	O
17	,	O
18	recombinant	O
19	viruses	O
20	were	O
21	generated	O
22	in	O
23	which	O
24	wild	B
25	-	I
26	type	I
27	or	I
28	mutant	I
29	ICP34	I
30	.	I
31	5	I
32	promoters	I
33	controlling	O
34	the	O
35	expression	O
36	of	O
37	a	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	gene	I
42	were	O
43	inserted	O
44	into	O
45	the	O
46	thymidine	B
47	kinase	I
48	gene	I
49	of	O
50	the	O
51	viral	O
52	genome	O
53	.	O

1	These	O
2	changes	O
3	correlate	O
4	directly	O
5	with	O
6	an	O
7	increase	O
8	in	O
9	the	O
10	acetylation	O
11	levels	O
12	of	O
13	all	O
14	four	O
15	core	B
16	histones	I
17	in	O
18	vivo	O
19	.	O

1	Drosophila	B
2	orthodenticle	I
3	(	O
4	otd	B
5	)	O
6	and	O
7	murine	B
8	Otx	I
9	genes	I
10	exemplify	O
11	this	O
12	,	O
13	both	O
14	in	O
15	terms	O
16	of	O
17	expression	O
18	patterns	O
19	and	O
20	mutant	O
21	phenotypes	O
22	.	O

1	APETALA3	B
2	transcripts	I
3	are	O
4	first	O
5	detected	O
6	in	O
7	a	O
8	meristematic	O
9	region	O
10	that	O
11	will	O
12	give	O
13	rise	O
14	to	O
15	the	O
16	petal	O
17	and	O
18	stamen	O
19	primordia	O
20	,	O
21	and	O
22	expression	O
23	is	O
24	maintained	O
25	in	O
26	this	O
27	region	O
28	during	O
29	subsequent	O
30	development	O
31	of	O
32	these	O
33	organs	O
34	.	O

1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	60A	B
8	gene	I
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	I
14	beta	I
15	-	I
16	related	I
17	factor	I
18	in	O
19	Drosophila	O
20	.	O

1	Cell	O
2	lines	O
3	are	O
4	checked	O
5	to	O
6	find	O
7	out	O
8	whether	O
9	they	O
10	develop	O
11	tumors	O
12	in	O
13	nude	O
14	mice	O
15	followed	O
16	by	O
17	an	O
18	analysis	O
19	of	O
20	the	O
21	karyotype	O
22	.	O

1	Cervicovaginal	O
2	foetal	B
3	fibronectin	I
4	in	O
5	the	O
6	prediction	O
7	of	O
8	preterm	O
9	labour	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	IgM	B
5	can	O
6	be	O
7	absent	O
8	in	O
9	children	O
10	with	O
11	congenital	O
12	toxoplasmosis	O
13	or	O
14	subjects	O
15	with	O
16	secondary	O
17	reactivation	O
18	.	O

1	Both	O
2	variants	O
3	display	O
4	the	O
5	seven	O
6	-	O
7	transmembrane	O
8	topology	O
9	that	O
10	is	O
11	typical	O
12	for	O
13	G	B
14	protein	I
15	-	I
16	coupled	I
17	receptors	I
18	.	O

1	A	O
2	constitutive	O
3	allele	O
4	of	O
5	GPA2	B
6	could	O
7	stimulate	O
8	growth	O
9	of	O
10	a	O
11	strain	O
12	lacking	O
13	both	O
14	RAS	B
15	genes	I
16	.	O

1	The	O
2	COOH	O
3	-	O
4	terminus	O
5	of	O
6	this	O
7	new	O
8	isoform	O
9	,	O
10	which	O
11	we	O
12	designate	O
13	beta	B
14	4	I
15	,	O
16	lacks	O
17	a	O
18	22	O
19	amino	O
20	acid	O
21	lysine	O
22	-	O
23	rich	O
24	sequence	O
25	common	O
26	to	O
27	both	O
28	the	O
29	human	B
30	red	I
31	cell	I
32	alpha	I
33	-	I
34	and	I
35	beta	I
36	-	I
37	adducin	I
38	subunits	I
39	and	O
40	homologous	O
41	to	O
42	a	O
43	highly	O
44	conserved	O
45	region	O
46	in	O
47	MARCKS	B
48	,	O
49	a	O
50	filamentous	O
51	actin	B
52	-	O
53	cross	O
54	linking	O
55	protein	O
56	regulated	O
57	by	O
58	protein	B
59	kinase	I
60	C	I
61	and	O
62	calcium	O
63	/	O
64	calmodulin	B
65	.	O
66	beta	B
67	4	I
68	-	I
69	adducin	I
70	preserves	O
71	a	O
72	previously	O
73	identified	O
74	calmodulin	B
75	binding	I
76	domain	I
77	.	O

1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	B
8	-	I
9	adducin	I
10	isoform	I
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	NT	O
24	-	O
25	2	O
26	(	O
27	neuroepithelial	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O

1	The	O
2	gene	B
3	lac	I
4	-	I
5	1	I
6	,	O
7	encoding	O
8	the	O
9	enzyme	O
10	laccase	B
11	,	O
12	is	O
13	the	O
14	best	O
15	characterized	O
16	of	O
17	a	O
18	number	O
19	of	O
20	genes	O
21	in	O
22	the	O
23	chestnut	O
24	blight	O
25	fungus	O
26	,	O
27	Cryphonectria	O
28	parasitica	O
29	,	O
30	that	O
31	are	O
32	repressed	O
33	by	O
34	hypoviruses	O
35	,	O
36	a	O
37	group	O
38	of	O
39	virulence	O
40	-	O
41	attenuating	O
42	mycoviruses	O
43	.	O
44	lac	B
45	-	I
46	1	I
47	has	O
48	also	O
49	been	O
50	shown	O
51	to	O
52	be	O
53	transcriptionally	O
54	activated	O
55	by	O
56	low	O
57	concentrations	O
58	of	O
59	the	O
60	translational	O
61	inhibitor	O
62	cycloheximide	O
63	(	O
64	CHX	O
65	)	O
66	and	O
67	by	O
68	the	O
69	immunosuppressant	O
70	cyclosporin	O
71	A	O
72	.	O

1	Both	O
2	TRE	O
3	-	O
4	like	O
5	elements	O
6	were	O
7	capable	O
8	of	O
9	binding	O
10	AP1	B
11	.	O

1	The	O
2	hp55	B
3	gamma	I
4	protein	I
5	interacts	O
6	strongly	O
7	with	O
8	the	O
9	activated	O
10	IGFIR	B
11	but	O
12	not	O
13	with	O
14	the	O
15	kinase	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	O
20	.	O
21	hp55	B
22	gamma	I
23	also	O
24	interacts	O
25	with	O
26	the	O
27	insulin	B
28	receptor	I
29	(	O
30	IR	B
31	)	O
32	in	O
33	the	O
34	yeast	O
35	two	O
36	-	O
37	hybrid	O
38	system	O
39	.	O

1	The	O
2	plant	O
3	protein	O
4	maintains	O
5	all	O
6	the	O
7	functional	O
8	domains	O
9	found	O
10	in	O
11	the	O
12	other	O
13	proteins	O
14	,	O
15	including	O
16	nuclear	O
17	localization	O
18	signal	O
19	,	O
20	DNA	O
21	-	O
22	binding	O
23	domain	O
24	and	O
25	helicase	B
26	motifs	I
27	,	O
28	suggesting	O
29	that	O
30	it	O
31	might	O
32	also	O
33	act	O
34	as	O
35	part	O
36	of	O
37	the	O
38	RNA	O
39	transcription	O
40	apparatus	O
41	,	O
42	as	O
43	well	O
44	as	O
45	nucleotide	O
46	excision	O
47	repair	O
48	in	O
49	plant	O
50	cells	O
51	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	genomic	O
6	organization	O
7	of	O
8	mouse	O
9	gC1qBP	B
10	and	O
11	the	O
12	characterization	O
13	of	O
14	its	O
15	5	O
16	'	O
17	flanking	O
18	region	O
19	.	O

1	LysR	B
2	proteins	I
3	have	O
4	been	O
5	shown	O
6	to	O
7	regulate	O
8	urease	B
9	in	I
10	Klebsiella	I
11	aerogenes	I
12	(	O
13	NAC	B
14	),	O
15	and	O
16	catalase	B
17	in	I
18	Escherichia	I
19	coli	I
20	(	O
21	OxyR	B
22	),	O
23	which	O
24	offers	O
25	the	O
26	intracellular	O
27	bacterium	O
28	protection	O
29	from	O
30	phagolysosome	O
31	damage	O
32	.	O

1	Also	O
2	,	O
3	the	O
4	anti	O
5	-	O
6	inflammatory	O
7	activities	O
8	of	O
9	an	O
10	aqueous	O
11	extract	O
12	of	O
13	Buddleia	O
14	cordata	O
15	and	O
16	its	O
17	principal	O
18	glycoside	O
19	linarin	O
20	were	O
21	evaluated	O
22	.	O

1	Regulation	O
2	of	O
3	the	O
4	Raf	B
5	kinase	I
6	in	O
7	T	O
8	cells	O
9	differs	O
10	from	O
11	findings	O
12	with	O
13	a	O
14	variety	O
15	of	O
16	cell	O
17	lines	O
18	that	O
19	the	O
20	catalytic	B
21	domain	I
22	of	I
23	Raf	I
24	(	O
25	Raf	B
26	(	O
27	delta26	O
28	-	O
29	303	O
30	))	O
31	shows	O
32	no	O
33	activity	O
34	.	O

1	Full	B
2	-	I
3	length	I
4	FLAP	I
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O

1	Members	O
2	of	O
3	the	O
4	meis1	B
5	and	O
6	pbx	B
7	homeodomain	I
8	protein	I
9	families	I
10	cooperatively	O
11	bind	O
12	a	O
13	cAMP	O
14	-	O
15	responsive	O
16	sequence	O
17	(	O
18	CRS1	O
19	)	O
20	from	O
21	bovine	B
22	CYP17	I
23	.	O

1	We	O
2	have	O
3	visualized	O
4	DNA	O
5	-	O
6	protein	O
7	complexes	O
8	by	O
9	electron	O
10	microscopy	O
11	and	O
12	a	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	site	O
18	of	O
19	WDV	B
20	Rep	I
21	protein	I
22	within	O
23	the	O
24	core	O
25	element	O
26	has	O
27	been	O
28	mapped	O
29	to	O
30	approximately	O
31	144	O
32	+/-	O
33	18	O
34	bp	O
35	upstream	O
36	from	O
37	the	O
38	initiation	O
39	site	O
40	,	O
41	between	O
42	the	O
43	start	O
44	site	O
45	for	O
46	complementary	O
47	-	O
48	sense	O
49	transcription	O
50	and	O
51	the	O
52	TATA	O
53	box	O
54	.	O

1	Rex	B
2	-	I
3	1	I
4	,	O
5	a	O
6	gene	O
7	encoding	O
8	a	O
9	transcription	O
10	factor	O
11	expressed	O
12	in	O
13	the	O
14	early	O
15	embryo	O
16	,	O
17	is	O
18	regulated	O
19	via	O
20	Oct	B
21	-	I
22	3	I
23	/	I
24	4	I
25	and	O
26	Oct	B
27	-	I
28	6	I
29	binding	O
30	to	O
31	an	O
32	octamer	O
33	site	O
34	and	O
35	a	O
36	novel	O
37	protein	O
38	,	O
39	Rox	B
40	-	I
41	1	I
42	,	O
43	binding	O
44	to	O
45	an	O
46	adjacent	O
47	site	O
48	.	O

1	However	O
2	,	O
3	inhibition	O
4	of	O
5	both	O
6	the	O
7	ERK	B
8	/	O
9	RSK	B
10	and	O
11	the	O
12	p38	B
13	/	O
14	MAPKAP	B
15	kinase	I
16	2	I
17	pathways	O
18	completely	O
19	abolished	O
20	NGF	B
21	-	O
22	induced	O
23	CREB	B
24	Ser	O
25	-	O
26	133	O
27	phosphorylation	O
28	.	O

1	Cells	O
2	respond	O
3	to	O
4	the	O
5	accumulation	O
6	of	O
7	unfolded	O
8	proteins	O
9	in	O
10	the	O
11	endoplasmic	O
12	reticulum	O
13	(	O
14	ER	O
15	)	O
16	by	O
17	increasing	O
18	the	O
19	transcription	O
20	of	O
21	the	O
22	genes	O
23	encoding	O
24	ER	B
25	-	I
26	resident	I
27	chaperone	I
28	proteins	I
29	.	O

1	The	O
2	RAS	B
3	-	O
4	cyclic	B
5	AMP	I
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	cAPK	I
11	pathway	O
12	prevents	O
13	the	O
14	UAS	O
15	activity	O
16	of	O
17	IREu	B
18	in	O
19	the	O
20	presence	O
21	of	O
22	glucose	O
23	as	O
24	the	O
25	sole	O
26	carbon	O
27	source	O
28	,	O
29	while	O
30	the	O
31	transcriptional	O
32	activators	O
33	Msn2p	B
34	and	O
35	Msn4p	B
36	promote	O
37	the	O
38	UAS	O
39	activity	O
40	of	O
41	this	O
42	repeat	O
43	in	O
44	the	O
45	presence	O
46	of	O
47	acetate	O
48	.	O

1	The	O
2	mei4	B
3	+	I
4	gene	I
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	fibroblast	B
5	growth	I
6	factor	I
7	receptor	I
8	2	I
9	(	O
10	FGF	B
11	-	I
12	R2	I
13	)	O
14	is	O
15	an	O
16	example	O
17	of	O
18	highly	O
19	regulated	O
20	alternative	O
21	splicing	O
22	in	O
23	which	O
24	exons	O
25	IIIb	O
26	and	O
27	IIIc	O
28	are	O
29	utilized	O
30	in	O
31	a	O
32	mutually	O
33	exclusive	O
34	manner	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	In	O
2	some	O
3	cases	O
4	,	O
5	the	O
6	aberrant	O
7	methylation	O
8	of	O
9	CpGs	O
10	within	O
11	5	O
12	'	O
13	regulatory	O
14	regions	O
15	has	O
16	led	O
17	to	O
18	suppression	O
19	of	O
20	gene	O
21	activity	O
22	.	O

1	The	O
2	genomic	O
3	fragments	O
4	were	O
5	fused	O
6	upstream	O
7	of	O
8	the	O
9	luciferase	B
10	reporter	I
11	gene	I
12	.	O

1	Cotransfection	O
2	analyses	O
3	of	O
4	the	O
5	T	B
6	/	I
7	EBP	I
8	promoter	I
9	-	I
10	reporter	I
11	constructs	I
12	with	O
13	a	O
14	T	B
15	/	I
16	EBP	I
17	expression	O
18	vector	O
19	into	O
20	human	O
21	HepG2	O
22	cells	O
23	,	O
24	which	O
25	do	O
26	not	O
27	express	O
28	T	B
29	/	I
30	EBP	I
31	,	O
32	suggested	O
33	that	O
34	autoregulation	O
35	may	O
36	be	O
37	involved	O
38	in	O
39	controlling	O
40	both	O
41	rat	O
42	and	O
43	human	B
44	T	I
45	/	I
46	EBP	I
47	gene	I
48	expression	O
49	.	O

1	Deletion	O
2	of	O
3	the	O
4	last	O
5	two	O
6	Ser	O
7	residues	O
8	,	O
9	including	O
10	one	O
11	PKC	B
12	consensus	O
13	site	O
14	in	O
15	the	O
16	receptor	O
17	tail	O
18	,	O
19	prevented	O
20	only	O
21	phorbol	O
22	12	O
23	-	O
24	myristate	O
25	13	O
26	-	O
27	acetate	O
28	-	O
29	induced	O
30	desensitization	O
31	by	O
32	30	O
33	%.	O

1	Flap	O
2	survival	O
3	depends	O
4	on	O
5	the	O
6	development	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	vascular	O
13	connections	O
14	between	O
15	vessels	O
16	arising	O
17	from	O
18	the	O
19	pedicle	O
20	and	O
21	preexisting	O
22	dermal	O
23	vessels	O
24	.	O

1	Jean	O
2	Klig	O
3	reviews	O
4	recent	O
5	literature	O
6	about	O
7	lower	O
8	respiratory	O
9	tract	O
10	infection	O
11	in	O
12	children	O
13	.	O

1	Potential	O
2	indicators	O
3	were	O
4	assessed	O
5	for	O
6	the	O
7	two	O
8	classifications	O
9	of	O
10	protein	O
11	-	O
12	energy	O
13	malnutrition	O
14	in	O
15	the	O
16	guidelines	O
17	for	O
18	integrated	O
19	management	O
20	of	O
21	childhood	O
22	illness	O
23	:	O
24	severe	O
25	malnutrition	O
26	,	O
27	which	O
28	requires	O
29	immediate	O
30	referral	O
31	to	O
32	hospital	O
33	,	O
34	and	O
35	very	O
36	low	O
37	weight	O
38	,	O
39	which	O
40	calls	O
41	for	O
42	feeding	O
43	assessment	O
44	,	O
45	nutritional	O
46	counselling	O
47	and	O
48	follow	O
49	-	O
50	up	O
51	.	O

1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O

1	Despite	O
2	its	O
3	requirement	O
4	for	O
5	enhancer	O
6	-	O
7	dependent	O
8	splicing	O
9	activity	O
10	in	O
11	vitro	O
12	,	O
13	the	O
14	dU2AF38	B
15	RS	I
16	domain	I
17	was	O
18	also	O
19	inessential	O
20	in	O
21	vivo	O
22	.	O

1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	yAP180A	B
18	for	O
19	Pan1p	B
20	and	O
21	clathrin	B
22	.	O
23	yAP180	B
24	proteins	I
25	and	O
26	Pan1p	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	localize	O
32	to	O
33	peripheral	O
34	patches	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O

1	In	O
2	vitro	O
3	affinity	O
4	analyses	O
5	demonstrated	O
6	that	O
7	recombinant	O
8	130	O
9	-	O
10	kD	O
11	protein	O
12	directly	O
13	interacts	O
14	with	O
15	ZO	B
16	-	I
17	1	I
18	and	O
19	the	O
20	cytoplasmic	O
21	domain	O
22	of	O
23	occludin	B
24	,	O
25	but	O
26	not	O
27	with	O
28	ZO	B
29	-	I
30	2	I
31	.	O

1	Cytochrome	B
2	b	I
3	in	O
4	human	B
5	complex	I
6	II	I
7	(	O
8	succinate	B
9	-	I
10	ubiquinone	I
11	oxidoreductase	I
12	):	O
13	cDNA	O
14	cloning	O
15	of	O
16	the	O
17	components	O
18	in	O
19	liver	O
20	mitochondria	O
21	and	O
22	chromosome	O
23	assignment	O
24	of	O
25	the	O
26	genes	O
27	for	O
28	the	O
29	large	O
30	(	O
31	SDHC	B
32	)	O
33	and	O
34	small	O
35	(	O
36	SDHD	B
37	)	O
38	subunits	O
39	to	O
40	1q21	O
41	and	O
42	11q23	O
43	.	O

1	A	O
2	possible	O
3	decrease	O
4	in	O
5	theophylline	O
6	'	O
7	s	O
8	volume	O
9	of	O
10	distribution	O
11	at	O
12	4	O
13	days	O
14	,	O
15	but	O
16	not	O
17	immediately	O
18	,	O
19	after	O
20	administration	O
21	of	O
22	chloroquine	O
23	was	O
24	suggested	O
25	,	O
26	although	O
27	this	O
28	just	O
29	failed	O
30	to	O
31	achieve	O
32	statistical	O
33	significance	O
34	(	O
35	p	O
36	=	O
37	0	O
38	.	O
39	055	O
40	).	O

1	The	O
2	addition	O
3	of	O
4	a	O
5	Paf	B
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	hly	B
20	target	I
21	sequences	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	PrfA	B
27	but	O
28	converts	O
29	the	O
30	complex	O
31	(	O
32	CIII	O
33	)	O
34	consisting	O
35	of	O
36	PrfA	B
37	and	O
38	the	O
39	109	B
40	bp	I
41	hly	I
42	DNA	I
43	fragment	I
44	to	O
45	a	O
46	slower	O
47	migrating	O
48	PrfA	B
49	-	O
50	Paf	B
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O

1	Moreover	O
2	,	O
3	it	O
4	is	O
5	the	O
6	assumptions	O
7	behind	O
8	steady	O
9	-	O
10	state	O
11	O2	O
12	uptake	O
13	that	O
14	do	O
15	not	O
16	permit	O
17	proper	O
18	interpretation	O
19	of	O
20	energy	O
21	expenditure	O
22	during	O
23	EPOC	O
24	;	O
25	1	O
26	l	O
27	O2	O
28	not	O
29	=	O
30	20	O
31	.	O
32	9	O
33	kJ	O
34	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	m	B
8	-	I
9	Staf	I
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	that	O
15	of	O
16	Staf	B
17	,	O
18	another	O
19	selenocysteine	B
20	tRNA	I
21	gene	I
22	transcription	I
23	activating	I
24	factor	I
25	of	O
26	Xenopus	O
27	laevis	O
28	.	O

1	ROCK	B
2	-	I
3	I	I
4	,	O
5	Kinectin	B
6	,	O
7	and	O
8	mDia2	B
9	can	O
10	bind	O
11	the	O
12	wild	O
13	type	O
14	forms	O
15	of	O
16	both	O
17	RhoA	B
18	and	O
19	Cdc42	B
20	in	O
21	a	O
22	GTP	O
23	-	O
24	dependent	O
25	manner	O
26	in	O
27	vitro	O
28	.	O

1	Among	O
2	three	O
3	isoforms	O
4	,	O
5	the	O
6	beta	O
7	isoform	O
8	has	O
9	the	O
10	greatest	O
11	Vmax	O
12	value	O
13	for	O
14	the	O
15	PtdIns	B
16	(	I
17	4	I
18	)	I
19	P	I
20	kinase	I
21	activity	O
22	and	O
23	the	O
24	gamma	O
25	isoform	O
26	is	O
27	most	O
28	markedly	O
29	stimulated	O
30	by	O
31	phosphatidic	O
32	acid	O
33	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	heterotrimeric	B
7	G	I
8	proteins	I
9	that	O
10	transduce	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	repeating	O
32	units	O
33	called	O
34	WD	O
35	(	O
36	Trp	O
37	-	O
38	Asp	O
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	140	O
46	different	O
47	proteins	O
48	.	O

1	Two	O
2	differentially	O
3	expressed	O
4	LNX	B
5	messages	I
6	encode	O
7	overlapping	O
8	proteins	O
9	with	O
10	predicted	O
11	molecular	O
12	masses	O
13	of	O
14	80	B
15	kDa	I
16	(	I
17	LNX	I
18	)	I
19	and	O
20	70	O
21	kDa	O
22	(	O
23	LNX	O
24	-	O
25	b	O
26	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	B
15	product	O
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	Recent	O
2	studies	O
3	have	O
4	revealed	O
5	unconventional	O
6	myosin	B
7	V	I
8	to	O
9	be	O
10	an	O
11	important	O
12	actin	B
13	-	O
14	based	O
15	molecular	O
16	motor	O
17	involved	O
18	in	O
19	vesicular	O
20	movement	O
21	.	O

1	On	O
2	a	O
3	separate	O
4	occasion	O
5	the	O
6	T1	O
7	weighted	O
8	and	O
9	T2	O
10	weighted	O
11	sagittal	O
12	and	O
13	T2	O
14	weighted	O
15	axial	O
16	sequences	O
17	were	O
18	reported	O
19	blind	O
20	in	O
21	relation	O
22	to	O
23	the	O
24	initial	O
25	assessment	O
26	.	O

1	Furthermore	O
2	,	O
3	a	O
4	minor	O
5	start	O
6	site	O
7	was	O
8	localized	O
9	179	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	major	O
15	site	O
16	using	O
17	reverse	B
18	transcriptase	I
19	-	O
20	polymerase	O
21	chain	O
22	reaction	O
23	with	O
24	various	O
25	P1	O
26	primers	O
27	(	O
28	primer	O
29	walking	O
30	),	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	cDNA	O
36	cloning	O
37	.	O

1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	B
16	-	I
17	binding	I
18	protein	I
19	gene	O
20	.	O

1	The	O
2	iron	O
3	dependence	O
4	of	O
5	transcription	O
6	and	O
7	expression	O
8	of	O
9	cvaA	B
10	,	O
11	which	O
12	encodes	O
13	a	O
14	transporter	O
15	accessory	O
16	protein	O
17	,	O
18	and	O
19	cvi	B
20	,	O
21	encoding	O
22	the	O
23	colicin	B
24	V	I
25	immunity	I
26	protein	I
27	,	O
28	was	O
29	assessed	O
30	under	O
31	conditions	O
32	of	O
33	iron	O
34	excess	O
35	or	O
36	depletion	O
37	.	O

1	In	O
2	a	O
3	gntR	B
4	deletion	I
5	mutant	I
6	,	O
7	the	O
8	expression	O
9	of	O
10	a	O
11	chromosomal	O
12	gntT	B
13	::	O
14	lacZ	B
15	fusion	O
16	is	O
17	both	O
18	high	O
19	and	O
20	constitutive	O
21	,	O
22	confirming	O
23	that	O
24	GntR	B
25	is	O
26	the	O
27	negative	O
28	regulator	O
29	of	O
30	gntT	B
31	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	B
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	B
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	Of	O
2	these	O
3	sites	O
4	,	O
5	PEA3	B
6	and	O
7	STAT	B
8	contributed	O
9	specifically	O
10	to	O
11	induction	O
12	by	O
13	v	B
14	-	I
15	src	I
16	,	O
17	whereas	O
18	the	O
19	remaining	O
20	elements	O
21	were	O
22	also	O
23	involved	O
24	in	O
25	induction	O
26	by	O
27	the	O
28	phorbol	O
29	ester	O
30	phorbol	O
31	myristate	O
32	acetate	O
33	(	O
34	PMA	O
35	).	O

1	BRCA1	B
2	protein	I
3	contains	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	zinc	O
9	finger	O
10	motif	O
11	and	O
12	a	O
13	carboxy	O
14	-	O
15	terminal	O
16	acidic	O
17	region	O
18	.	O

1	The	O
2	mitochondrial	B
3	regulatory	I
4	region	I
5	(	O
6	mrr	B
7	)	O
8	located	O
9	between	O
10	the	O
11	tRNAPhe	B
12	and	O
13	tRNAPro	B
14	genes	I
15	of	O
16	mitochondrial	O
17	DNA	O
18	(	O
19	mtDNA	O
20	)	O
21	is	O
22	essential	O
23	for	O
24	regulation	O
25	of	O
26	replication	O
27	and	O
28	transcription	O
29	of	O
30	the	O
31	mitochondrial	O
32	genome	O
33	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	investigate	O
7	the	O
8	mechanism	O
9	underlying	O
10	Ras	B
11	activation	O
12	upon	O
13	stimulation	O
14	of	O
15	these	O
16	two	O
17	types	O
18	of	O
19	receptors	O
20	in	O
21	hematopoietic	O
22	cells	O
23	.	O

1	Thus	O
2	,	O
3	Sir	B
4	proteins	I
5	from	O
6	K	O
7	.	O
8	lactis	O
9	have	O
10	roles	O
11	in	O
12	both	O
13	silencing	O
14	and	O
15	telomere	O
16	length	O
17	maintenance	O
18	,	O
19	reflecting	O
20	conserved	O
21	functional	O
22	themes	O
23	.	O

1	Therefore	O
2	,	O
3	we	O
4	conclude	O
5	that	O
6	DnaA	B
7	may	O
8	contact	O
9	the	O
10	beta	O
11	subunit	O
12	of	O
13	RNA	B
14	polymerase	I
15	during	O
16	activation	O
17	of	O
18	the	O
19	pR	B
20	promoter	I
21	.	O

1	Expression	O
2	of	O
3	Bcl	B
4	-	I
5	XL	I
6	inhibited	O
7	the	O
8	association	O
9	of	O
10	Apaf	B
11	-	I
12	1	I
13	with	O
14	caspase	B
15	-	I
16	9	I
17	in	O
18	mammalian	O
19	cells	O
20	.	O

1	Whole	O
2	-	O
3	mount	O
4	in	O
5	situ	O
6	hybridization	O
7	to	O
8	early	O
9	mouse	O
10	embryos	O
11	of	O
12	9	O
13	.	O
14	5	O
15	-	O
16	10	O
17	.	O
18	5	O
19	days	O
20	indicated	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	Arp1	B
26	expression	O
27	spatially	O
28	overlapping	O
29	with	O
30	the	O
31	expression	O
32	of	O
33	All1	B
34	.	O

1	These	O
2	mutants	O
3	were	O
4	tested	O
5	for	O
6	ability	O
7	to	O
8	bind	O
9	each	O
10	of	O
11	the	O
12	Site	B
13	II	I
14	cognate	I
15	proteins	I
16	,	O
17	and	O
18	subsequently	O
19	evaluated	O
20	for	O
21	ability	O
22	to	O
23	confer	O
24	H4	B
25	transcriptional	O
26	activity	O
27	using	O
28	chimeric	O
29	H4	B
30	promoter	O
31	/	O
32	CAT	B
33	fusion	O
34	constructs	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	Increased	O
2	plasma	O
3	IgE	B
4	was	O
5	also	O
6	confirmed	O
7	in	O
8	the	O
9	NC	O
10	mice	O
11	,	O
12	and	O
13	treatment	O
14	with	O
15	FK506	O
16	ointment	O
17	reduced	O
18	the	O
19	plasma	O
20	IgE	B
21	level	O
22	.	O

1	Creatine	B
2	kinase	I
3	release	O
4	after	O
5	hepatic	O
6	artery	O
7	embolization	O
8	in	O
9	patients	O
10	with	O
11	carcinoid	O
12	tumors	O
13	.	O

1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	B
8	II	I
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O

1	Group	O
2	A	O
3	(	O
4	68	O
5	.	O
6	7	O
7	+/-	O
8	2	O
9	.	O
10	7	O
11	years	O
12	)	O
13	consisted	O
14	of	O
15	patients	O
16	with	O
17	0	O
18	or	O
19	1	O
20	risk	O
21	factors	O
22	;	O
23	B	O
24	(	O
25	68	O
26	.	O
27	3	O
28	+/-	O
29	4	O
30	.	O
31	2	O
32	years	O
33	)	O
34	those	O
35	with	O
36	2	O
37	risk	O
38	factors	O
39	;	O
40	and	O
41	C	O
42	(	O
43	69	O
44	.	O
45	2	O
46	+/-	O
47	3	O
48	.	O
49	6	O
50	years	O
51	)	O
52	those	O
53	with	O
54	3	O
55	or	O
56	more	O
57	risk	O
58	factors	O
59	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	RU486	O
6	-	O
7	PR	B
8	-	I
9	B	I
10	interacts	O
11	physically	O
12	with	O
13	NCoR	B
14	in	O
15	vitro	O
16	.	O

1	PRL	B
2	receptor	I
3	also	O
4	activates	O
5	SHP	B
6	-	I
7	2	I
8	,	O
9	a	O
10	cytosolic	B
11	tyrosine	I
12	phosphatase	I
13	.	O

1	The	O
2	dominant	O
3	negative	O
4	mutant	O
5	of	O
6	SHP	B
7	-	I
8	2	I
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	the	O
14	induction	O
15	of	O
16	tyrosine	O
17	phosphorylation	O
18	and	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	m	B
25	-	I
26	Stat5a	I
27	,	O
28	m	B
29	-	I
30	Stat5b	I
31	,	O
32	and	O
33	the	O
34	carboxyl	O
35	-	O
36	terminal	O
37	deletion	O
38	variant	O
39	m	B
40	-	I
41	Stat5adelta749	I
42	,	O
43	as	O
44	well	O
45	as	O
46	the	O
47	transactivation	O
48	potential	O
49	of	O
50	m	B
51	-	I
52	Stat5a	I
53	and	O
54	m	B
55	-	I
56	Stat5b	I
57	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O

1	Sites	O
2	1	O
3	and	O
4	4	O
5	in	O
6	lumican	B
7	and	O
8	keratocan	B
9	are	O
10	in	O
11	a	O
12	homologous	O
13	location	O
14	.	O

1	Our	O
2	observations	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	HMG	B
9	-	I
10	I	I
11	family	I
12	play	O
13	an	O
14	important	O
15	role	O
16	in	O
17	SRF	B
18	-	O
19	dependent	O
20	transcription	O
21	and	O
22	that	O
23	their	O
24	effect	O
25	is	O
26	mediated	O
27	primarily	O
28	by	O
29	a	O
30	protein	O
31	-	O
32	protein	O
33	interaction	O
34	.	O

1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	B
18	-	O
19	MSH6	B
20	and	O
21	MLH1	B
22	-	O
23	PMS1	B
24	protein	O
25	complexes	O
26	.	O

1	Mutation	O
2	of	O
3	the	O
4	central	O
5	Tyr497	O
6	to	O
7	Phe	O
8	blocks	O
9	the	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	insulin	B
15	receptor	I
16	substrate	I
17	1	I
18	(	O
19	IRS1	B
20	)	O
21	and	O
22	diminishes	O
23	proliferation	O
24	in	O
25	response	O
26	to	O
27	IL	B
28	-	I
29	4	I
30	.	O

1	Instead	O
2	,	O
3	it	O
4	contained	O
5	two	O
6	tandem	O
7	kappaB	B
8	elements	I
9	and	O
10	a	O
11	variant	O
12	activating	B
13	transcription	I
14	factor	I
15	/	I
16	cAMP	I
17	response	I
18	element	I
19	site	O
20	,	O
21	which	O
22	closely	O
23	resembled	O
24	sites	O
25	in	O
26	the	O
27	E	B
28	-	I
29	selectin	I
30	gene	I
31	that	O
32	are	O
33	required	O
34	for	O
35	TNF	B
36	-	I
37	alpha	I
38	-	O
39	or	O
40	LPS	O
41	-	O
42	inducible	O
43	expression	O
44	.	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O

1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O

1	The	O
2	possible	O
3	roles	O
4	of	O
5	HRMT1L1	B
6	and	O
7	HRMT1L2	B
8	in	O
9	human	O
10	disease	O
11	are	O
12	currently	O
13	unknown	O
14	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	two	O
6	putative	O
7	human	B
8	arginine	I
9	methyltransferases	I
10	(	O
11	HRMT1L1	B
12	and	O
13	HRMT1L2	B
14	).	O

1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	I
7	-	I
8	receptor	I
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	I
16	.	O

1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	B
8	E	I
9	-	I
10	cadherin	I
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	I
20	domain	I
21	and	O
22	the	O
23	desmoglein	B
24	1	I
25	intracellular	I
26	domain	I
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	I
41	domains	I
42	.	O

1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O

1	In	O
2	addition	O
3	to	O
4	a	O
5	previously	O
6	characterized	O
7	promoter	O
8	(	O
9	P1	O
10	),	O
11	we	O
12	now	O
13	show	O
14	the	O
15	existence	O
16	of	O
17	a	O
18	second	O
19	promoter	O
20	for	O
21	the	O
22	human	B
23	IL	I
24	-	I
25	5Ralpha	I
26	gene	I
27	.	O

1	Serum	O
2	levels	O
3	of	O
4	testosterone	O
5	also	O
6	showed	O
7	no	O
8	significant	O
9	changes	O
10	by	O
11	exposure	O
12	to	O
13	p	O
14	,	O
15	p	O
16	'-	O
17	DDE	O
18	under	O
19	the	O
20	conditions	O
21	of	O
22	this	O
23	study	O
24	.	O

1	Overall	O
2	agreement	O
3	between	O
4	rest	O
5	/	O
6	postnitroglycerin	O
7	technetium	O
8	-	O
9	99m	O
10	tetrofosmin	O
11	SPET	O
12	studies	O
13	and	O
14	rest	O
15	/	O
16	redistribution	O
17	or	O
18	rest	O
19	/	O
20	reinjection	O
21	thallium	O
22	-	O
23	201	O
24	SPET	O
25	studies	O
26	,	O
27	regarding	O
28	the	O
29	presence	O
30	of	O
31	myocardial	O
32	viability	O
33	,	O
34	was	O
35	87	O
36	%	O
37	and	O
38	90	O
39	%,	O
40	respectively	O
41	.	O

1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	predictability	O
20	of	O
21	ALT	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O

1	One	O
2	hundred	O
3	replicate	O
4	data	O
5	sets	O
6	of	O
7	100	O
8	subjects	O
9	each	O
10	were	O
11	simulated	O
12	for	O
13	each	O
14	missing	O
15	data	O
16	scenario	O
17	.	O

1	Spatial	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	guided	O
10	saccades	O
11	in	O
12	schizophrenic	O
13	patients	O
14	.	O

1	Successful	O
2	treatment	O
3	with	O
4	nasal	O
5	continuous	O
6	positive	O
7	airway	O
8	pressure	O
9	(	O
10	8	O
11	.	O
12	3	O
13	+/-	O
14	1	O
15	.	O
16	5	O
17	cmH2O	O
18	)	O
19	for	O
20	3	O
21	days	O
22	caused	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	mean	O
28	blood	O
29	pressure	O
30	in	O
31	OSAS	O
32	.	O

1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	cumulative	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	PSVT	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O

1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O

1	To	O
2	study	O
3	retinoid	O
4	signalling	O
5	in	O
6	zebrafish	O
7	embryos	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	novel	O
13	method	O
14	to	O
15	detect	O
16	endogenous	O
17	retinoids	O
18	in	O
19	situ	O
20	in	O
21	embryos	O
22	,	O
23	using	O
24	a	O
25	fusion	O
26	protein	O
27	of	O
28	the	O
29	ligand	O
30	inducible	O
31	transactivation	O
32	domain	O
33	of	O
34	a	O
35	retinoic	B
36	acid	I
37	receptor	I
38	and	O
39	a	O
40	heterologous	O
41	DNA	O
42	binding	O
43	domain	O
44	.	O

1	To	O
2	identify	O
3	nuclear	O
4	regulatory	O
5	factors	O
6	,	O
7	we	O
8	have	O
9	located	O
10	and	O
11	functionally	O
12	characterized	O
13	the	O
14	CCR5	B
15	gene	I
16	promoter	I
17	.	O

1	Fluorescence	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	metaphase	O
7	spreads	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	706	O
17	-	O
18	B6	O
19	clone	O
20	17	O
21	(	O
22	CL	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	c101F1	O
29	,	O
30	placed	O
31	the	O
32	9804	B
33	gene	I
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	8q24	O
40	.	O
41	3	O
42	.	O

1	The	O
2	interaction	O
3	between	O
4	piroxicam	O
5	and	O
6	poloxamer	O
7	was	O
8	studied	O
9	by	O
10	x	O
11	-	O
12	ray	O
13	diffractometry	O
14	(	O
15	XRD	O
16	),	O
17	infrared	O
18	(	O
19	IR	O
20	)	O
21	spectroscopy	O
22	and	O
23	differential	O
24	thermal	O
25	analysis	O
26	(	O
27	DTA	O
28	)	O
29	with	O
30	a	O
31	solid	O
32	dispersion	O
33	,	O
34	coprecipitate	O
35	,	O
36	or	O
37	physical	O
38	mixture	O
39	.	O

1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	B
27	.	O

1	The	O
2	N	O
3	-	O
4	syndecan	O
5	-	O
6	dependent	O
7	neurite	O
8	outgrowth	O
9	is	O
10	inhibited	O
11	by	O
12	the	O
13	tyrosine	B
14	kinase	I
15	inhibitors	O
16	herbimycin	O
17	A	O
18	and	O
19	PP1	B
20	.	O

1	An	O
2	in	O
3	vivo	O
4	ZAP	B
5	-	I
6	70	I
7	substrate	O
8	,	O
9	SLP	B
10	-	I
11	76	I
12	,	O
13	implicated	O
14	in	O
15	Erk	B
16	activation	O
17	,	O
18	also	O
19	became	O
20	rapidly	O
21	tyrosine	O
22	-	O
23	phosphorylated	O
24	in	O
25	Jurkat	O
26	cells	O
27	,	O
28	but	O
29	not	O
30	in	O
31	P116	O
32	cells	O
33	,	O
34	upon	O
35	treatment	O
36	with	O
37	H2O2	O
38	.	O

1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	"	O
62	patch	O
63	7D	O
64	").	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	Conversely	O
2	,	O
3	the	O
4	central	O
5	regions	O
6	are	O
7	highly	O
8	variable	O
9	.	O

1	Among	O
2	the	O
3	H	B
4	/	I
5	ACA	I
6	snoRNAs	I
7	associated	O
8	with	O
9	Gar1p	B
10	,	O
11	one	O
12	can	O
13	distinguish	O
14	a	O
15	large	O
16	group	O
17	of	O
18	snoRNAs	O
19	that	O
20	are	O
21	not	O
22	essential	O
23	in	O
24	yeast	O
25	and	O
26	serve	O
27	as	O
28	guides	O
29	for	O
30	pseudouridine	O
31	synthesis	O
32	onto	O
33	the	O
34	pre	O
35	-	O
36	rRNA	O
37	molecule	O
38	.	O

1	It	O
2	bound	O
3	to	O
4	vitamin	B
5	D	I
6	receptor	I
7	(	O
8	VDR	B
9	)	O
10	but	O
11	not	O
12	retinoic	B
13	acid	I
14	Xalpha	I
15	receptor	I
16	(	O
17	RXRalpha	B
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O

1	Further	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	PPARalpha	B
7	ligand	O
8	8	O
9	(	O
10	S	O
11	)-	O
12	hydroxyeicosatetraenoic	O
13	acid	O
14	strongly	O
15	promotes	O
16	the	O
17	interaction	O
18	of	O
19	PPARalpha	B
20	with	O
21	the	O
22	co	O
23	-	O
24	activator	O
25	RIP	B
26	-	I
27	140	I
28	but	O
29	decreases	O
30	the	O
31	interaction	O
32	of	O
33	PPARalpha	B
34	with	O
35	the	O
36	co	O
37	-	O
38	repressor	O
39	SMRT	B
40	.	O

1	Based	O
2	on	O
3	the	O
4	current	O
5	literature	O
6	,	O
7	the	O
8	mechanisms	O
9	involved	O
10	in	O
11	the	O
12	toxicity	O
13	of	O
14	OA	B
15	indicate	O
16	three	O
17	major	O
18	effects	O
19	:	O
20	(	O
21	1	O
22	)	O
23	inhibition	O
24	of	O
25	mitochondrial	O
26	respiration	O
27	correlated	O
28	with	O
29	a	O
30	depletion	O
31	of	O
32	ATP	O
33	;	O
34	(	O
35	2	O
36	)	O
37	inhibition	O
38	of	O
39	tRNA	B
40	-	I
41	synthetase	I
42	accompanied	O
43	by	O
44	a	O
45	reduced	O
46	protein	O
47	synthesis	O
48	;	O
49	and	O
50	(	O
51	3	O
52	)	O
53	enhanced	O
54	lipid	O
55	peroxidation	O
56	.	O

1	We	O
2	previously	O
3	demonstrated	O
4	that	O
5	acute	O
6	expression	O
7	of	O
8	the	O
9	bovine	O
10	papillomavirus	O
11	type	O
12	1	O
13	(	O
14	BPV1	O
15	)	O
16	E2	B
17	protein	I
18	in	O
19	HeLa	O
20	and	O
21	HT	O
22	-	O
23	3	O
24	cervical	O
25	carcinoma	O
26	cell	O
27	lines	O
28	greatly	O
29	reduced	O
30	cellular	O
31	proliferation	O
32	by	O
33	imposing	O
34	a	O
35	specific	O
36	G1	O
37	/	O
38	S	O
39	phase	O
40	growth	O
41	arrest	O
42	.	O

1	Four	O
2	possible	O
3	isoforms	O
4	(	O
5	hGli2	B
6	alpha	I
7	,	I
8	beta	I
9	,	I
10	gamma	I
11	,	I
12	and	I
13	delta	I
14	)	O
15	are	O
16	formed	O
17	by	O
18	combinations	O
19	of	O
20	two	O
21	independent	O
22	alternative	O
23	splicings	O
24	,	O
25	and	O
26	all	O
27	the	O
28	isoforms	O
29	could	O
30	bind	O
31	to	O
32	a	O
33	DNA	O
34	motif	O
35	,	O
36	TRE2S	O
37	,	O
38	in	O
39	the	O
40	LTR	O
41	.	O

1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	O
34	.	O

1	Their	O
2	mean	O
3	IOP	O
4	was	O
5	15	O
6	.	O
7	3	O
8	(	O
9	SD	O
10	3	O
11	.	O
12	7	O
13	)	O
14	mmHg	O
15	prior	O
16	to	O
17	induction	O
18	of	O
19	anesthesia	O
20	,	O
21	13	O
22	.	O
23	5	O
24	(	O
25	SD	O
26	3	O
27	.	O
28	5	O
29	)	O
30	mmHg	O
31	after	O
32	loss	O
33	of	O
34	eyelash	O
35	reflex	O
36	following	O
37	injection	O
38	of	O
39	methohexitone	O
40	,	O
41	16	O
42	.	O
43	1	O
44	(	O
45	SD	O
46	2	O
47	.	O
48	4	O
49	)	O
50	mmHg	O
51	after	O
52	cessation	O
53	of	O
54	muscle	O
55	fasciculations	O
56	induced	O
57	by	O
58	suxamethonium	O
59	,	O
60	19	O
61	.	O
62	2	O
63	(	O
64	SD	O
65	5	O
66	.	O
67	6	O
68	)	O
69	mmHg	O
70	after	O
71	cessation	O
72	of	O
73	convulsion	O
74	and	O
75	15	O
76	.	O
77	5	O
78	(	O
79	SD	O
80	4	O
81	.	O
82	4	O
83	)	O
84	mmHg	O
85	following	O
86	resumption	O
87	of	O
88	regular	O
89	spontaneous	O
90	respiration	O
91	.	O

1	A	O
2	cDNA	O
3	,	O
4	cak1At	B
5	,	O
6	was	O
7	isolated	O
8	that	O
9	suppressed	O
10	the	O
11	CAK	B
12	mutation	I
13	in	O
14	budding	O
15	yeast	O
16	,	O
17	and	O
18	it	O
19	also	O
20	complemented	O
21	a	O
22	fission	B
23	yeast	I
24	CAK	I
25	mutant	I
26	.	O
27	cak1At	B
28	encodes	O
29	a	O
30	protein	O
31	related	O
32	to	O
33	animal	B
34	CAKs	I
35	.	O

1	Post	O
2	-	O
3	translational	O
4	modifications	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	O
11	be	O
12	excluded	O
13	as	O
14	potential	O
15	explanations	O
16	for	O
17	the	O
18	protein	O
19	heterogeneity	O
20	.	O

1	In	O
2	addition	O
3	to	O
4	restoring	O
5	checkpoint	O
6	control	O
7	,	O
8	overexpression	O
9	of	O
10	sum1	B
11	+	I
12	inhibits	O
13	the	O
14	normal	O
15	cell	O
16	cycle	O
17	response	O
18	to	O
19	osmotic	O
20	stress	O
21	.	O

1	Ime1	B
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Rhesus	O
2	macaques	O
3	and	O
4	BALB	O
5	/	O
6	c	O
7	mice	O
8	inoculated	O
9	with	O
10	the	O
11	Mengo	O
12	virus	O
13	SIV	O
14	recombinants	O
15	failed	O
16	to	O
17	develop	O
18	CTL	O
19	responses	O
20	against	O
21	the	O
22	SIV	O
23	gene	O
24	products	O
25	,	O
26	while	O
27	one	O
28	of	O
29	the	O
30	HIV	B
31	-	I
32	Nef	I
33	recombinants	I
34	induced	O
35	a	O
36	weak	O
37	CTL	O
38	response	O
39	in	O
40	mice	O
41	directed	O
42	to	O
43	an	O
44	HIV1	B
45	Nef	I
46	peptide	I
47	spanning	O
48	positions	O
49	182	O
50	-	O
51	198	O
52	.	O

1	Deltamethrin	O
2	was	O
3	most	O
4	effective	O
5	on	O
6	the	O
7	thatched	O
8	surface	O
9	and	O
10	produced	O
11	100	O
12	%	O
13	mortality	O
14	of	O
15	An	O
16	.	O
17	culicifacies	O
18	adults	O
19	up	O
20	to	O
21	12	O
22	weeks	O
23	,	O
24	even	O
25	when	O
26	exposed	O
27	at	O
28	the	O
29	lowest	O
30	dose	O
31	/	O
32	12	O
33	.	O
34	5	O
35	mg	O
36	/	O
37	m2	O
38	.	O

1	Trichloroethylene	O
2	,	O
3	in	O
4	turn	O
5	,	O
6	increased	O
7	the	O
8	AUC	O
9	5	O
10	.	O
11	0	O
12	(	O
13	1	O
14	.	O
15	9	O
16	-	O
17	13	O
18	.	O
19	4	O
20	),	O
21	25	O
22	.	O
23	8	O
24	(	O
25	8	O
26	.	O
27	2	O
28	-	O
29	80	O
30	.	O
31	8	O
32	)	O
33	and	O
34	2	O
35	.	O
36	9	O
37	(	O
38	1	O
39	.	O
40	6	O
41	-	O
42	5	O
43	.	O
44	4	O
45	),	O
46	respectively	O
47	,	O
48	whereas	O
49	the	O
50	corresponding	O
51	values	O
52	for	O
53	n	O
54	-	O
55	hexane	O
56	were	O
57	1	O
58	.	O
59	9	O
60	(	O
61	0	O
62	.	O
63	7	O
64	-	O
65	5	O
66	.	O
67	1	O
68	),	O
69	1	O
70	.	O
71	5	O
72	(	O
73	0	O
74	.	O
75	5	O
76	-	O
77	4	O
78	.	O
79	6	O
80	),	O
81	and	O
82	3	O
83	.	O
84	2	O
85	(	O
86	1	O
87	.	O
88	8	O
89	-	O
90	5	O
91	.	O
92	9	O
93	).	O

1	Solution	O
2	structure	O
3	of	O
4	the	O
5	IRF	B
6	-	I
7	2	I
8	DNA	I
9	-	I
10	binding	I
11	domain	I
12	:	O
13	a	O
14	novel	O
15	subgroup	O
16	of	O
17	the	O
18	winged	B
19	helix	I
20	-	I
21	turn	I
22	-	I
23	helix	I
24	family	I
25	.	O

1	In	O
2	contrast	O
3	,	O
4	receptor	B
5	/	I
6	G	I
7	protein	I
8	coupling	O
9	appeared	O
10	unaffected	O
11	by	O
12	expression	O
13	of	O
14	loop	O
15	3i	O
16	domains	O
17	derived	O
18	from	O
19	two	O
20	receptors	O
21	coupled	O
22	to	O
23	G	B
24	(	I
25	i	I
26	/	I
27	o	I
28	)	I
29	proteins	I
30	(	O
31	M2Ach	B
32	-	I
33	muscarinic	I
34	and	I
35	alpha2A	I
36	-	I
37	adrenergic	I
38	receptors	I
39	).	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	third	O
7	intracellular	O
8	loop	O
9	of	O
10	the	O
11	rat	B
12	GnRH	I
13	-	I
14	R	I
15	is	O
16	involved	O
17	in	O
18	receptor	B
19	G	I
20	(	I
21	q	I
22	/	I
23	11	I
24	)	I
25	protein	I
26	coupling	O
27	and	O
28	/	O
29	or	O
30	selectivity	O
31	,	O
32	and	O
33	in	O
34	the	O
35	GGH	O
36	(	O
37	3	O
38	)	O
39	1	O
40	'	O
41	cell	O
42	line	O
43	,	O
44	this	O
45	loop	O
46	is	O
47	also	O
48	involved	O
49	in	O
50	signal	O
51	transduction	O
52	mediated	O
53	through	O
54	the	O
55	Gs	B
56	protein	O
57	pathway	O
58	.	O

1	Decreased	O
2	levels	O
3	of	O
4	alpha2	B
5	-	I
6	antiplasmin	I
7	were	O
8	also	O
9	observed	O
10	in	O
11	the	O
12	mediastinum	O
13	(	O
14	0	O
15	.	O
16	50	O
17	versus	O
18	0	O
19	.	O
20	61	O
21	U	O
22	/	O
23	mL	O
24	;	O
25	p	O
26	<	O
27	0	O
28	.	O
29	05	O
30	).	O

1	A	O
2	catalytic	O
3	domain	O
4	of	O
5	eukaryotic	B
6	DNA	I
7	topoisomerase	I
8	I	I
9	.	O

1	A	O
2	cluster	O
3	of	O
4	basic	O
5	amino	O
6	acids	O
7	,	O
8	KKKR	O
9	,	O
10	generated	O
11	by	O
12	joining	O
13	of	O
14	the	O
15	sequences	O
16	encoded	O
17	by	O
18	the	O
19	constitutive	O
20	exon	O
21	13	O
22	and	O
23	the	O
24	alternative	O
25	exon	O
26	16	O
27	,	O
28	is	O
29	necessary	O
30	for	O
31	the	O
32	nuclear	O
33	targeting	O
34	of	O
35	4	B
36	.	I
37	1H	I
38	,	O
39	as	O
40	demonstrated	O
41	by	O
42	site	O
43	-	O
44	directed	O
45	mutagenesis	O
46	analysis	O
47	.	O

1	Another	O
2	stem	O
3	-	O
4	loop	O
5	called	O
6	structure	O
7	III	O
8	near	O
9	the	O
10	3	O
11	'-	O
12	end	O
13	of	O
14	repY	B
15	sequesters	O
16	both	O
17	the	O
18	5	O
19	'-	O
20	rCGCC	O
21	-	O
22	3	O
23	'	O
24	sequence	O
25	and	O
26	the	O
27	repZ	B
28	ribosome	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	All	O
2	three	O
3	genes	O
4	have	O
5	been	O
6	mapped	O
7	precisely	O
8	to	O
9	a	O
10	small	O
11	region	O
12	on	O
13	human	O
14	chromosome	O
15	16p12	O
16	.	O
17	1	O
18	-	O
19	p11	O
20	.	O
21	2	O
22	(	O
23	homologous	O
24	to	O
25	mouse	O
26	chromosome	O
27	7	O
28	),	O
29	using	O
30	somatic	O
31	cell	O
32	hybrids	O
33	and	O
34	cosmid	O
35	clones	O
36	.	O

1	In	O
2	fus3	B
3	mutants	I
4	,	O
5	the	O
6	levels	O
7	of	O
8	Ty1	B
9	RNA	I
10	,	O
11	protein	O
12	synthesis	O
13	,	O
14	and	O
15	proteolytic	O
16	processing	O
17	were	O
18	not	O
19	altered	O
20	relative	O
21	to	O
22	those	O
23	in	O
24	FUS3	B
25	strains	O
26	but	O
27	steady	O
28	-	O
29	state	O
30	levels	O
31	of	O
32	TyA	B
33	,	O
34	integrase	B
35	,	O
36	and	O
37	reverse	B
38	transcriptase	I
39	proteins	O
40	and	O
41	Ty1	B
42	cDNA	I
43	were	O
44	all	O
45	increased	O
46	.	O

1	Posttranslational	O
2	regulation	O
3	of	O
4	Ty1	B
5	retrotransposition	O
6	by	O
7	mitogen	B
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	Fus3	I
13	.	O

1	The	O
2	general	O
3	transcription	B
4	factor	I
5	IIA	I
6	(	O
7	TFIIA	B
8	)	O
9	interacts	O
10	with	O
11	the	O
12	TATA	B
13	binding	I
14	protein	I
15	(	O
16	TBP	B
17	)	O
18	and	O
19	promoter	O
20	DNA	O
21	to	O
22	mediate	O
23	transcription	O
24	activation	O
25	in	O
26	vitro	O
27	.	O

1	Their	O
2	function	O
3	is	O
4	not	O
5	only	O
6	to	O
7	recruit	O
8	Pho2	B
9	to	O
10	the	O
11	promoter	O
12	but	O
13	to	O
14	allow	O
15	cooperative	O
16	binding	O
17	of	O
18	Pho4	B
19	together	O
20	with	O
21	Pho2	B
22	.	O

1	Substitution	O
2	of	O
3	the	O
4	Ser	O
5	-	O
6	Thr	O
7	sites	O
8	with	O
9	the	O
10	phosphomimetic	O
11	Asp	O
12	generated	O
13	a	O
14	constitutively	O
15	active	O
16	form	O
17	of	O
18	IRF	B
19	-	I
20	3	I
21	that	O
22	functioned	O
23	as	O
24	a	O
25	very	O
26	strong	O
27	activator	O
28	of	O
29	promoters	O
30	containing	O
31	PRDI	B
32	-	O
33	PRDIII	B
34	or	O
35	ISRE	B
36	regulatory	I
37	elements	I
38	.	O

1	New	O
2	-	O
3	onset	O
4	angina	O
5	preceding	O
6	acute	O
7	myocardial	O
8	infarction	O
9	is	O
10	associated	O
11	with	O
12	improved	O
13	contractile	O
14	recovery	O
15	after	O
16	thrombolysis	O
17	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	effect	O
7	of	O
8	acute	O
9	administration	O
10	of	O
11	various	O
12	doses	O
13	of	O
14	malathion	O
15	via	O
16	oral	O
17	and	O
18	dermal	O
19	routes	O
20	to	O
21	mice	O
22	and	O
23	rats	O
24	on	O
25	serum	O
26	levels	O
27	of	O
28	histamine	O
29	was	O
30	evaluated	O
31	.	O

1	Fetal	O
2	growth	O
3	retardation	O
4	as	O
5	a	O
6	cause	O
7	of	O
8	impaired	O
9	ovarian	O
10	development	O
11	.	O

1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O

1	In	O
2	addition	O
3	to	O
4	DNA	O
5	-	O
6	protein	O
7	interactions	O
8	,	O
9	protein	O
10	-	O
11	protein	O
12	interactions	O
13	with	O
14	partner	O
15	proteins	O
16	often	O
17	play	O
18	major	O
19	roles	O
20	in	O
21	targeting	O
22	ETS	B
23	-	I
24	domain	I
25	proteins	I
26	to	O
27	specific	O
28	promoters	O
29	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	B
17	resistance	I
18	gene	I
19	region	I
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	organization	O
7	of	O
8	the	O
9	murine	O
10	gene	O
11	encoding	O
12	M	B
13	-	I
14	protein	I
15	,	O
16	a	O
17	structural	O
18	protein	O
19	of	O
20	sarcomeric	O
21	myofibrils	O
22	,	O
23	was	O
24	determined	O
25	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	introduce	O
5	an	O
6	image	O
7	analysis	O
8	of	O
9	the	O
10	cornea	O
11	in	O
12	photorefractive	O
13	keratectomy	O
14	(	O
15	PRK	O
16	)	O
17	for	O
18	preoperative	O
19	and	O
20	early	O
21	postoperative	O
22	determination	O
23	of	O
24	changes	O
25	in	O
26	the	O
27	condition	O
28	of	O
29	the	O
30	cornea	O
31	.	O

1	Mean	O
2	+/-	O
3	SD	O
4	serum	B
5	VEGF	I
6	concentrations	O
7	were	O
8	significantly	O
9	higher	O
10	(	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	)	O
17	in	O
18	women	O
19	with	O
20	PCO	O
21	and	O
22	PCOS	O
23	(	O
24	3	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	7	O
31	and	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	0	O
37	.	O
38	66	O
39	ng	O
40	/	O
41	ml	O
42	respectively	O
43	)	O
44	compared	O
45	with	O
46	women	O
47	with	O
48	normal	O
49	ovaries	O
50	(	O
51	2	O
52	.	O
53	3	O
54	+/-	O
55	0	O
56	.	O
57	5	O
58	ng	O
59	/	O
60	ml	O
61	).	O

1	Strikingly	O
2	,	O
3	these	O
4	cells	O
5	contain	O
6	a	O
7	missense	O
8	mutation	O
9	of	O
10	the	O
11	p53	B
12	gene	I
13	at	O
14	codon	O
15	242	O
16	(	O
17	p53	B
18	(	O
19	242	O
20	)),	O
21	which	O
22	substitutes	O
23	alanine	O
24	for	O
25	glycine	O
26	.	O

1	The	O
2	new	O
3	algorithm	O
4	,	O
5	called	O
6	RBI	O
7	-	O
8	MAP	O
9	,	O
10	is	O
11	based	O
12	on	O
13	the	O
14	rescaled	O
15	block	O
16	iterative	O
17	EM	O
18	(	O
19	RBI	O
20	-	O
21	EM	O
22	)	O
23	algorithm	O
24	.	O

1	A	O
2	third	O
3	ORF	O
4	,	O
5	ORF5	O
6	,	O
7	shows	O
8	homology	O
9	with	O
10	gene	B
11	agrB	I
12	from	O
13	Staphylococcus	O
14	aureus	O
15	,	O
16	which	O
17	is	O
18	involved	O
19	in	O
20	the	O
21	mechanism	O
22	of	O
23	regulation	O
24	of	O
25	the	O
26	virulence	O
27	phenotype	O
28	in	O
29	this	O
30	species	O
31	.	O

1	An	O
2	association	O
3	between	O
4	hSIE	B
5	and	O
6	Stat	B
7	-	I
8	3	I
9	after	O
10	MHC	B
11	-	I
12	I	I
13	ligation	O
14	was	O
15	directly	O
16	demonstrated	O
17	by	O
18	precipitating	O
19	Stat	B
20	-	I
21	3	I
22	from	O
23	nuclear	O
24	extracts	O
25	with	O
26	biotinylated	O
27	hSIE	B
28	probe	O
29	and	O
30	avidin	B
31	-	O
32	coupled	O
33	agarose	O
34	.	O

1	Transcriptional	O
2	repression	O
3	mediated	O
4	by	O
5	LysR	B
6	-	I
7	type	I
8	regulator	I
9	CatR	I
10	bound	O
11	at	O
12	multiple	O
13	binding	O
14	sites	O
15	.	O

1	Two	O
2	of	O
3	these	O
4	resulted	O
5	in	O
6	increased	O
7	levels	O
8	of	O
9	the	O
10	alpha	O
11	subunit	O
12	,	O
13	and	O
14	one	O
15	caused	O
16	a	O
17	substitution	O
18	of	O
19	glycine	O
20	for	O
21	the	O
22	aspartic	O
23	acid	O
24	residue	O
25	at	O
26	position	O
27	171	O
28	,	O
29	in	O
30	the	O
31	N	O
32	-	O
33	terminal	O
34	domain	O
35	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	Using	O
2	Southern	O
3	blot	O
4	analysis	O
5	and	O
6	restriction	O
7	mapping	O
8	of	O
9	genomic	O
10	YAC	O
11	(	O
12	yeast	O
13	artificial	O
14	chromosome	O
15	)	O
16	and	O
17	cosmid	O
18	clones	O
19	,	O
20	we	O
21	located	O
22	the	O
23	human	B
24	RIL	I
25	gene	I
26	240	O
27	-	O
28	260	O
29	kb	O
30	telomeric	O
31	to	O
32	the	O
33	IRF1	B
34	gene	I
35	and	O
36	characterized	O
37	its	O
38	genomic	O
39	structure	O
40	.	O

1	U73	B
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	O
14	N	O
15	-	O
16	Pog	O
17	)	O
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O

1	Echinostomiasis	O
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	O
22	lack	O
23	of	O
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O

1	Finally	O
2	,	O
3	a	O
4	role	O
5	for	O
6	NF	B
7	-	I
8	kappaB	I
9	in	O
10	preventing	O
11	apoptosis	O
12	induced	O
13	by	O
14	ER	O
15	calcium	O
16	release	O
17	was	O
18	demonstrated	O
19	by	O
20	data	O
21	showing	O
22	that	O
23	sAPPalpha	B
24	prevents	O
25	thapsigargin	O
26	-	O
27	induced	O
28	apoptosis	O
29	,	O
30	an	O
31	effect	O
32	blocked	O
33	by	O
34	kappaB	B
35	decoy	O
36	DNA	O
37	.	O

1	Many	O
2	cytokine	O
3	receptors	O
4	employ	O
5	Janus	B
6	protein	I
7	tyrosine	I
8	kinases	I
9	(	O
10	Jaks	B
11	)	O
12	and	O
13	signal	B
14	transducers	I
15	and	I
16	activators	I
17	of	I
18	transcription	I
19	(	O
20	Stats	B
21	)	O
22	for	O
23	nuclear	O
24	signaling	O
25	.	O

1	A	O
2	site	O
3	-	O
4	directed	O
5	R618K	O
6	mutation	O
7	in	O
8	the	O
9	Stat5	B
10	SH2	I
11	domain	I
12	abolished	O
13	the	O
14	phosphorylation	O
15	by	O
16	Jak2	B
17	,	O
18	while	O
19	deletion	O
20	of	O
21	the	O
22	C	O
23	terminus	O
24	led	O
25	to	O
26	Stat5	B
27	hyperphosphorylation	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	nitric	B
5	oxide	I
6	synthase	I
7	inhibitor	O
8	on	O
9	reperfusion	O
10	injury	O
11	of	O
12	the	O
13	brain	O
14	under	O
15	hypothermic	O
16	circulatory	O
17	arrest	O
18	.	O

1	Specifically	O
2	,	O
3	recombination	O
4	at	O
5	HMR	B
6	was	O
7	used	O
8	to	O
9	produce	O
10	rings	O
11	that	O
12	lacked	O
13	the	O
14	E	O
15	and	O
16	I	O
17	silencers	O
18	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O

1	We	O
2	studied	O
3	the	O
4	human	O
5	vestibulo	O
6	-	O
7	ocular	O
8	reflex	O
9	(	O
10	VOR	O
11	)	O
12	in	O
13	response	O
14	to	O
15	head	O
16	'	O
17	impulses	O
18	':	O
19	brief	O
20	,	O
21	unpredictable	O
22	,	O
23	passive	O
24	,	O
25	high	O
26	-	O
27	acceleration	O
28	(	O
29	up	O
30	to	O
31	4000	O
32	degrees	O
33	/	O
34	s2	O
35	),	O
36	low	O
37	-	O
38	amplitude	O
39	(	O
40	20	O
41	-	O
42	30	O
43	degrees	O
44	)	O
45	head	O
46	rotations	O
47	.	O

1	To	O
2	clarify	O
3	whether	O
4	seizure	O
5	-	O
6	offset	O
7	patterns	O
8	are	O
9	reliable	O
10	in	O
11	predicting	O
12	seizure	O
13	outcome	O
14	,	O
15	we	O
16	studied	O
17	SEEG	O
18	/	O
19	ECoG	O
20	in	O
21	a	O
22	similar	O
23	group	O
24	of	O
25	patients	O
26	with	O
27	temporal	O
28	lobe	O
29	epilepsy	O
30	(	O
31	TLE	O
32	).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	to	O
6	characterize	O
7	the	O
8	gene	O
9	for	O
10	protein	B
11	Z	I
12	,	O
13	its	O
14	organization	O
15	and	O
16	structure	O
17	were	O
18	determined	O
19	by	O
20	a	O
21	combination	O
22	of	O
23	PCR	O
24	amplification	O
25	of	O
26	leukocyte	O
27	DNA	O
28	and	O
29	isolation	O
30	of	O
31	phage	O
32	clones	O
33	from	O
34	a	O
35	human	O
36	genomic	O
37	library	O
38	.	O

1	These	O
2	modifications	O
3	may	O
4	improve	O
5	the	O
6	interlaboratory	O
7	reproducibility	O
8	of	O
9	CD34	B
10	determinations	O
11	due	O
12	to	O
13	the	O
14	reduction	O
15	in	O
16	sample	O
17	handling	O
18	and	O
19	calculation	O
20	of	O
21	results	O
22	.	O

1	The	O
2	present	O
3	results	O
4	demonstrate	O
5	that	O
6	rats	O
7	with	O
8	relatively	O
9	small	O
10	remnants	O
11	of	O
12	one	O
13	olfactory	O
14	bulb	O
15	can	O
16	perform	O
17	a	O
18	variety	O
19	of	O
20	odor	O
21	detection	O
22	and	O
23	discrimination	O
24	tasks	O
25	as	O
26	well	O
27	or	O
28	nearly	O
29	as	O
30	well	O
31	as	O
32	controls	O
33	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	O
5	alpha	B
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	I
16	2	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	B
24	II	I
25	;	O
26	EC	B
27	2	I
28	.	I
29	4	I
30	.	I
31	1	I
32	.	I
33	143	I
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	These	O
2	patients	O
3	failed	O
4	to	O
5	respond	O
6	to	O
7	intravenous	O
8	cyclophosphamide	O
9	and	O
10	steroids	O
11	and	O
12	were	O
13	then	O
14	changed	O
15	to	O
16	receive	O
17	oral	O
18	cyclosporine	O
19	A	O
20	,	O
21	at	O
22	a	O
23	dose	O
24	of	O
25	5	O
26	mg	O
27	/	O
28	kg	O
29	/	O
30	day	O
31	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	is	O
7	78	O
8	.	O
9	0	O
10	%	O
11	identical	O
12	to	O
13	the	O
14	cytoplasmic	B
15	dynein	I
16	heavy	I
17	chain	I
18	of	I
19	Neurospora	I
20	crassa	I
21	,	O
22	70	O
23	.	O
24	2	O
25	%	O
26	identical	O
27	to	O
28	that	O
29	of	O
30	Aspergillus	O
31	nidulans	O
32	and	O
33	24	O
34	.	O
35	8	O
36	%	O
37	identical	O
38	to	O
39	that	O
40	of	O
41	Saccharomyces	O
42	cerevisiae	O
43	.	O

1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	CIRs	O
16	(	O
17	CIR3	O
18	-	O
19	CIR6	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	I
31	footprinting	O
32	.	O

1	Molecular	O
2	modelling	O
3	suggested	O
4	that	O
5	the	O
6	tetramerization	O
7	domain	O
8	was	O
9	a	O
10	four	O
11	-	O
12	helix	O
13	bundle	O
14	,	O
15	stabilized	O
16	by	O
17	interactions	O
18	of	O
19	seven	O
20	conserved	O
21	aromatic	O
22	amino	O
23	acids	O
24	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	sought	O
8	to	O
9	investigate	O
10	whether	O
11	constitutive	O
12	NF	B
13	-	I
14	kappaB	I
15	activity	O
16	in	O
17	chronically	O
18	HIV	O
19	-	O
20	1	O
21	-	O
22	infected	O
23	promonocytic	O
24	U937	O
25	(	O
26	U9	O
27	-	O
28	IIIB	O
29	)	O
30	and	O
31	myeloblastic	O
32	PLB	O
33	-	O
34	985	O
35	(	O
36	PLB	O
37	-	O
38	IIIB	O
39	)	O
40	cells	O
41	affects	O
42	apoptotic	O
43	signaling	O
44	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	silymarin	O
9	may	O
10	exert	O
11	a	O
12	strong	O
13	anticarcinogenic	O
14	effect	O
15	against	O
16	PCA	O
17	and	O
18	that	O
19	this	O
20	effect	O
21	is	O
22	likely	O
23	to	O
24	involve	O
25	impairment	O
26	of	O
27	erbB1	B
28	-	O
29	SHC	B
30	-	O
31	mediated	O
32	signaling	O
33	pathway	O
34	,	O
35	induction	O
36	of	O
37	CDKIs	B
38	,	O
39	and	O
40	a	O
41	resultant	O
42	G1	O
43	arrest	O
44	.	O

1	In	O
2	connective	O
3	tissue	O
4	,	O
5	cell	O
6	structure	O
7	contributes	O
8	to	O
9	type	B
10	I	I
11	collagen	I
12	expression	O
13	.	O

1	To	O
2	explore	O
3	the	O
4	function	O
5	of	O
6	human	O
7	SINA	B
8	-	I
9	homologous	I
10	(	I
11	Siah	I
12	)	I
13	proteins	I
14	,	O
15	expression	O
16	plasmids	O
17	encoding	O
18	Siah	B
19	-	I
20	1A	I
21	were	O
22	transiently	O
23	transfected	O
24	into	O
25	293	O
26	epithelial	O
27	cells	O
28	and	O
29	GM701	O
30	fibroblast	O
31	cells	O
32	,	O
33	resulting	O
34	in	O
35	growth	O
36	arrest	O
37	without	O
38	induction	O
39	of	O
40	apoptosis	O
41	.	O

1	A	O
2	point	O
3	mutation	O
4	in	O
5	Galphao	B
6	and	O
7	Galphai1	B
8	blocks	O
9	interaction	O
10	with	O
11	regulator	O
12	of	O
13	G	B
14	protein	I
15	signaling	O
16	proteins	O
17	.	O

1	Indeed	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	it	O
8	mediates	O
9	the	O
10	formation	O
11	of	O
12	disulfide	O
13	-	O
14	linked	O
15	homodimers	O
16	and	O
17	that	O
18	the	O
19	formation	O
20	of	O
21	homo	O
22	-	O
23	and	O
24	heterodimers	O
25	are	O
26	mutually	O
27	excluded	O
28	.	O

1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	B
12	GnRH	I
13	receptor	I
14	cDNA	I
15	(	O
16	GGH3	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	O
36	rat	B
37	LHbeta	I
38	gene	I
39	5	I
40	'-	I
41	flanking	I
42	sequence	I
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	I
60	(-	I
61	797	I
62	/+	I
63	5LHbetaLUC	I
64	)	I
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O

1	The	O
2	5	O
3	'-	O
4	flanking	O
5	region	O
6	,	O
7	from	O
8	nucleotide	O
9	-	O
10	837	O
11	to	O
12	-	O
13	336	O
14	,	O
15	contains	O
16	TATA	O
17	and	O
18	inverted	O
19	CAAT	O
20	boxes	O
21	as	O
22	well	O
23	as	O
24	GATA	B
25	-	I
26	1	I
27	/	O
28	SP1	B
29	erythroid	O
30	-	O
31	specific	O
32	cis	O
33	-	O
34	acting	O
35	regulatory	O
36	elements	O
37	.	O

1	We	O
2	established	O
3	the	O
4	radiosensitive	O
5	cell	O
6	line	O
7	SX9	O
8	from	O
9	mammary	O
10	carcinoma	O
11	cell	O
12	line	O
13	FM3A	O
14	.	O

1	In	O
2	patients	O
3	with	O
4	type	O
5	IA	O
6	maple	O
7	syrup	O
8	urine	O
9	disease	O
10	,	O
11	the	O
12	E1alpha	B
13	subunit	I
14	is	O
15	affected	O
16	,	O
17	resulting	O
18	in	O
19	the	O
20	loss	O
21	of	O
22	E1	B
23	and	O
24	branched	B
25	-	I
26	chain	I
27	ketoacid	I
28	dehydrogenase	I
29	catalytic	O
30	activities	O
31	.	O

1	Results	O
2	showed	O
3	that	O
4	the	O
5	mean	O
6	bond	O
7	strength	O
8	of	O
9	H	O
10	.	O
11	T	O
12	.	O
13	V	O
14	.	O
15	specimens	O
16	ranged	O
17	from	O
18	9	O
19	.	O
20	6	O
21	to	O
22	13	O
23	.	O
24	12	O
25	kg	O
26	/	O
27	cm2	O
28	,	O
29	while	O
30	the	O
31	mean	O
32	bond	O
33	strength	O
34	of	O
35	R	O
36	.	O
37	T	O
38	.	O
39	V	O
40	.	O
41	specimens	O
42	ranged	O
43	from	O
44	0	O
45	.	O
46	36	O
47	to	O
48	1	O
49	.	O
50	75	O
51	kg	O
52	/	O
53	cm2	O
54	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	B
6	factor	I
7	VIII	I
8	:	I
9	coagulant	I
10	(	O
11	F	B
12	.	I
13	VIII	I
14	:	I
15	C	I
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	I
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	B
37	factors	I
38	VII	I
39	(	O
40	F	B
41	.	I
42	VII	I
43	),	O
44	IX	O
45	(	O
46	F	B
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	B
54	.	I
55	X	I
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O

1	RESULTS	O
2	:	O
3	Horses	O
4	with	O
5	colic	O
6	had	O
7	significantly	O
8	higher	O
9	fibrinogen	B
10	concentration	O
11	,	O
12	greater	O
13	alpha	B
14	2AP	I
15	and	O
16	protein	B
17	C	I
18	activities	O
19	,	O
20	and	O
21	longer	O
22	PT	O
23	and	O
24	APTT	O
25	than	O
26	did	O
27	healthy	O
28	horses	O
29	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	B
6	,	O
7	alpha	B
8	2AP	I
9	,	O
10	and	O
11	C1	B
12	-	I
13	INH	I
14	,	O
15	should	O
16	be	O
17	considered	O
18	equine	O
19	acute	O
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	None	O
2	of	O
3	the	O
4	patients	O
5	was	O
6	obese	O
7	.	O

1	Marked	O
2	elevation	O
3	of	O
4	creatine	B
5	kinase	I
6	was	O
7	observed	O
8	while	O
9	serum	O
10	albumin	B
11	,	O
12	immunoglobulin	B
13	,	O
14	and	O
15	complement	O
16	were	O
17	decreased	O
18	.	O

1	DESIGN	O
2	AND	O
3	METHODS	O
4	:	O
5	Case	O
6	study	O
7	.	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	RACK1	B
2	,	O
3	a	O
4	receptor	O
5	for	O
6	activated	B
7	C	I
8	kinase	I
9	and	O
10	a	O
11	homolog	O
12	of	O
13	the	O
14	beta	O
15	subunit	O
16	of	O
17	G	B
18	proteins	I
19	,	O
20	inhibits	O
21	activity	O
22	of	O
23	src	B
24	tyrosine	I
25	kinases	I
26	and	O
27	growth	O
28	of	O
29	NIH	O
30	3T3	O
31	cells	O
32	.	O

1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	B
6	finger	I
7	protein	I
8	Ttk	I
9	and	O
10	the	O
11	transcription	B
12	factor	I
13	Adf	I
14	-	I
15	1	I
16	were	O
17	obtained	O
18	.	O

1	The	O
2	same	O
3	IL	B
4	-	I
5	4	I
6	-	O
7	inducible	O
8	reporter	O
9	gene	O
10	is	O
11	also	O
12	synergistically	O
13	activated	O
14	by	O
15	the	O
16	endogenous	B
17	Stat6	I
18	and	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	in	O
24	IL	B
25	-	I
26	4	I
27	-	O
28	stimulated	O
29	I	O
30	.	O
31	29mu	O
32	B	O
33	lymphoma	O
34	cells	O
35	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	B
6	),	O
7	and	O
8	Efs	B
9	/	O
10	Sin	B
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	B
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	B
24	/	I
25	M	I
26	spindle	I
27	-	I
28	regulatory	I
29	protein	I
30	Dim1p	I
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	B
40	encompassed	O
41	in	O
42	p55	B
43	(	O
44	HEF1	B
45	).	O

1	Our	O
2	data	O
3	showed	O
4	that	O
5	activation	O
6	of	O
7	the	O
8	raf	B
9	-	O
10	ERK	B
11	pathway	O
12	led	O
13	to	O
14	activation	O
15	of	O
16	TF	B
17	expression	O
18	in	O
19	breast	O
20	carcinoma	O
21	cells	O
22	and	O
23	suggested	O
24	that	O
25	constitutive	O
26	activation	O
27	of	O
28	this	O
29	pathway	O
30	leads	O
31	to	O
32	high	O
33	TF	B
34	expression	O
35	in	O
36	MDA	O
37	-	O
38	MB	O
39	-	O
40	231	O
41	cells	O
42	.	O

1	However	O
2	,	O
3	a	O
4	zinc	O
5	-	O
6	depleted	O
7	enzyme	O
8	was	O
9	obtained	O
10	after	O
11	prolonged	O
12	dialysis	O
13	against	O
14	the	O
15	specific	O
16	chelating	O
17	agent	O
18	1	O
19	,	O
20	10	O
21	-	O
22	phenanthroline	O
23	.	O

1	All	O
2	patients	O
3	diagnosed	O
4	of	O
5	H	O
6	.	O
7	influenza	O
8	type	O
9	b	O
10	meningitis	O
11	were	O
12	less	O
13	than	O
14	3	O
15	years	O
16	old	O
17	.	O

1	The	O
2	lines	O
3	also	O
4	differed	O
5	in	O
6	postsynaptic	O
7	,	O
8	but	O
9	not	O
10	presynaptic	O
11	,	O
12	5	B
13	-	I
14	HT1A	I
15	receptors	I
16	.	O

1	Convulsive	O
2	seizure	O
3	during	O
4	a	O
5	treatment	O
6	with	O
7	interferon	B
8	alpha	I
9	for	O
10	chronic	O
11	viral	O
12	hepatitis	O
13	C	O

1	Immunohistochemically	O
2	,	O
3	anticytokeratin	B
4	19	I
5	antibody	I
6	revealed	O
7	strong	O
8	staining	O
9	in	O
10	both	O
11	epithelial	O
12	and	O
13	sarcomatous	O
14	MPM	O
15	tissues	O
16	.	O

1	Genetic	O
2	studies	O
3	in	O
4	Drosophila	O
5	have	O
6	led	O
7	to	O
8	the	O
9	identification	O
10	of	O
11	several	O
12	components	O
13	of	O
14	the	O
15	Notch	B
16	pathway	O
17	.	O

1	The	O
2	bZP2	O
3	cDNA	O
4	(	O
5	115	O
6	-	O
7	1914	O
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	B
36	-	O
37	Sal1	B
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	O
47	promoter	O
48	under	O
49	the	O
50	lac	B
51	operator	I
52	control	O
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O

1	Control	O
2	subjects	O
3	'	O
4	evoked	O
5	potentials	O
6	(	O
7	EPs	O
8	)	O
9	were	O
10	characterized	O
11	by	O
12	an	O
13	initial	O
14	positivity	O
15	in	O
16	the	O
17	90	O
18	-	O
19	140	O
20	ms	O
21	range	O
22	(	O
23	P1	O
24	)	O
25	at	O
26	the	O
27	temporo	O
28	-	O
29	occipital	O
30	site	O
31	.	O

1	Class	B
2	I	I
3	alpha1	I
4	,	I
5	2	I
6	-	I
7	mannosidases	I
8	play	O
9	an	O
10	essential	O
11	role	O
12	in	O
13	the	O
14	elaboration	O
15	of	O
16	complex	O
17	and	O
18	hybrid	O
19	N	O
20	-	O
21	glycans	O
22	in	O
23	mammalian	O
24	cells	O
25	.	O

1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	M98	O
11	-	O
12	F219	O
13	)	O
14	of	O
15	human	B
16	nucleotide	I
17	excision	I
18	repair	I
19	protein	I
20	XPA	I
21	.	O

1	Amongst	O
2	other	O
3	qualities	O
4	,	O
5	the	O
6	book	O
7	'	O
8	s	O
9	importance	O
10	lies	O
11	in	O
12	the	O
13	fact	O
14	that	O
15	it	O
16	associates	O
17	an	O
18	elaborate	O
19	theoretical	O
20	construction	O
21	with	O
22	the	O
23	empirical	O
24	data	O
25	,	O
26	working	O
27	within	O
28	the	O
29	possibilities	O
30	provided	O
31	by	O
32	late	O
33	19th	O
34	-	O
35	century	O
36	moral	O
37	statistics	O
38	.	O

1	The	O
2	results	O
3	point	O
4	to	O
5	the	O
6	effectiveness	O
7	of	O
8	the	O
9	educational	O
10	intervention	O
11	.	O

1	The	O
2	mechanistic	O
3	implications	O
4	of	O
5	aromatic	O
6	non	O
7	-	O
8	responsiveness	O
9	of	O
10	autonomously	O
11	expressed	O
12	A	O
13	-	O
14	domain	O
15	,	O
16	despite	O
17	its	O
18	demonstrated	O
19	ability	O
20	to	O
21	bind	O
22	phenol	O
23	,	O
24	are	O
25	discussed	O
26	.	O

1	RESULTS	O
2	:	O
3	Acetabular	O
4	index	O
5	returned	O
6	to	O
7	normal	O
8	gradually	O
9	as	O
10	the	O
11	time	O
12	went	O
13	by	O
14	and	O
15	significantly	O
16	within	O
17	one	O
18	year	O
19	after	O
20	the	O
21	reduction	O
22	of	O
23	developmental	O
24	dislocation	O
25	of	O
26	the	O
27	hip	O
28	.	O

1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	endothelin	B
8	-	I
9	1	I
10	(	O
11	ET	B
12	-	I
13	1	I
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	pericardial	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O

1	Consequently	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	how	O
8	knee	O
9	loading	O
10	changes	O
11	following	O
12	ACL	O
13	transection	O
14	,	O
15	and	O
16	how	O
17	it	O
18	contributes	O
19	to	O
20	cartilage	O
21	degeneration	O
22	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	surfaces	O
6	of	O
7	tracheal	O
8	cartilage	O
9	matrix	O
10	are	O
11	collagen	B
12	-	O
13	rich	O
14	and	O
15	surround	O
16	a	O
17	proteoglycan	O
18	-	O
19	rich	O
20	core	O
21	.	O

1	Comparative	O
2	mapping	O
3	of	O
4	the	O
5	Brassica	B
6	S	I
7	locus	I
8	region	I
9	and	O
10	its	O
11	homeolog	O
12	in	O
13	Arabidopsis	O
14	.	O

1	Roles	O
2	of	O
3	the	O
4	Candida	B
5	albicans	I
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	I
12	,	O
13	Cek1p	B
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O

1	Neither	O
2	the	O
3	reaction	O
4	of	O
5	monosaccharides	O
6	nor	O
7	the	O
8	disaccharides	O
9	with	O
10	beta	O
11	-	O
12	alanine	O
13	resulted	O
14	in	O
15	the	O
16	formation	O
17	of	O
18	maltol	O
19	.	O

1	In	O
2	most	O
3	subjects	O
4	,	O
5	markers	O
6	of	O
7	bone	O
8	formation	O
9	and	O
10	resorption	O
11	were	O
12	normal	O
13	.	O

1	Analysis	O
2	of	O
3	a	O
4	Mac1p	B
5	mutant	I
6	,	O
7	refractile	O
8	for	O
9	copper	O
10	-	O
11	dependent	O
12	repression	O
13	of	O
14	the	O
15	Cu	B
16	(	I
17	I	I
18	)	I
19	transport	I
20	genes	I
21	,	O
22	showed	O
23	an	O
24	aberrant	O
25	pattern	O
26	of	O
27	CUP1	B
28	expression	O
29	and	O
30	copper	O
31	sensitivity	O
32	.	O

1	The	O
2	DNA	O
3	sequencing	O
4	of	O
5	the	O
6	recombinant	O
7	clones	O
8	revealed	O
9	the	O
10	expression	O
11	of	O
12	RXR	B
13	alpha	I
14	and	O
15	RXR	B
16	beta	I
17	.	O

1	A	O
2	stratified	O
3	random	O
4	sample	O
5	of	O
6	20	O
7	active	O
8	employees	O
9	from	O
10	a	O
11	cohort	O
12	of	O
13	phenoxy	O
14	herbicide	O
15	workers	O
16	was	O
17	selected	O
18	in	O
19	1995	O
20	for	O
21	determining	O
22	PCDD	O
23	and	O
24	PCDF	O
25	congeners	O
26	in	O
27	blood	O
28	lipids	O
29	to	O
30	assess	O
31	the	O
32	extent	O
33	of	O
34	past	O
35	PCDD	O
36	and	O
37	PCDF	O
38	exposure	O
39	in	O
40	this	O
41	cohort	O
42	and	O
43	whether	O
44	that	O
45	exposure	O
46	might	O
47	explain	O
48	site	O
49	-	O
50	specific	O
51	cancer	O
52	findings	O
53	in	O
54	the	O
55	total	O
56	cohort	O
57	.	O

1	The	O
2	clinical	O
3	and	O
4	laboratory	O
5	features	O
6	of	O
7	72	O
8	children	O
9	with	O
10	Henoch	O
11	-	O
12	Schonlein	O
13	purpura	O
14	(	O
15	HSP	O
16	)	O
17	were	O
18	examined	O
19	to	O
20	determine	O
21	if	O
22	there	O
23	were	O
24	associations	O
25	between	O
26	the	O
27	laboratory	O
28	indices	O
29	--	O
30	including	O
31	white	O
32	blood	O
33	cell	O
34	(	O
35	WBC	O
36	)	O
37	counts	O
38	,	O
39	serum	B
40	C	I
41	-	I
42	reactive	I
43	protein	I
44	(	O
45	CRP	B
46	)	O
47	levels	O
48	,	O
49	platelet	O
50	(	O
51	PLT	O
52	)	O
53	counts	O
54	--	O
55	and	O
56	the	O
57	clinical	O
58	manifestations	O
59	of	O
60	acute	O
61	HSP	O
62	.	O

1	We	O
2	provide	O
3	community	O
4	metabolic	O
5	data	O
6	that	O
7	indicate	O
8	that	O
9	large	O
10	changes	O
11	in	O
12	CO2	O
13	concentration	O
14	can	O
15	occur	O
16	in	O
17	coral	O
18	reef	O
19	waters	O
20	via	O
21	biogeochemical	O
22	processes	O
23	not	O
24	directly	O
25	associated	O
26	with	O
27	photosynthesis	O
28	,	O
29	respiration	O
30	,	O
31	calcification	O
32	,	O
33	and	O
34	CaCO3	O
35	dissolution	O
36	.	O

1	In	O
2	contrast	O
3	to	O
4	other	O
5	known	O
6	retroviruses	O
7	,	O
8	the	O
9	FV	B
10	pol	I
11	genes	I
12	are	O
13	expressed	O
14	via	O
15	spliced	O
16	transcripts	O
17	.	O

1	Substitution	O
2	of	O
3	bulky	O
4	hydrophobic	O
5	residues	O
6	with	O
7	charged	O
8	residues	O
9	within	O
10	PEP1	B
11	affects	O
12	the	O
13	fusion	O
14	activity	O
15	of	O
16	the	O
17	S	B
18	protein	I
19	without	O
20	affecting	O
21	processing	O
22	and	O
23	surface	O
24	expression	O
25	.	O

1	Tributyltin	O
2	and	O
3	its	O
4	breakdown	O
5	products	O
6	,	O
7	mono	O
8	-	O
9	and	O
10	di	O
11	-	O
12	butyltin	O
13	,	O
14	were	O
15	determined	O
16	in	O
17	water	O
18	birds	O
19	collected	O
20	from	O
21	Lake	O
22	Huron	O
23	(	O
24	the	O
25	Great	O
26	Lakes	O
27	),	O
28	marine	O
29	coastal	O
30	United	O
31	States	O
32	,	O
33	and	O
34	the	O
35	west	O
36	coast	O
37	of	O
38	British	O
39	Columbia	O
40	,	O
41	Canada	O
42	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	CD1	B
9	gene	I
10	contained	O
11	the	O
12	binding	O
13	motifs	O
14	for	O
15	two	O
16	cytokine	O
17	-	O
18	inducible	O
19	transcription	O
20	factors	O
21	,	O
22	NF	B
23	-	I
24	IL2	I
25	-	I
26	A	I
27	and	O
28	NF	B
29	-	I
30	IL6	I
31	.	O

1	Fregnac	O
2	,	O
3	M	O
4	.	O

1	GLRaV	O
2	-	O
3	2	O
4	is	O
5	the	O
6	only	O
7	closterovirus	O
8	,	O
9	so	O
10	far	O
11	,	O
12	that	O
13	matches	O
14	the	O
15	genome	O
16	organization	O
17	of	O
18	the	O
19	type	O
20	member	O
21	of	O
22	the	O
23	group	O
24	,	O
25	BYV	O
26	,	O
27	and	O
28	thus	O
29	can	O
30	be	O
31	unambiguously	O
32	classified	O
33	as	O
34	a	O
35	definitive	O
36	member	O
37	of	O
38	the	O
39	genus	O
40	Closterovirus	O
41	.	O

1	Demographic	O
2	and	O
3	clinical	O
4	data	O
5	were	O
6	compared	O
7	with	O
8	a	O
9	control	O
10	group	O
11	of	O
12	339	O
13	healthy	O
14	age	O
15	-	O
16	matched	O
17	women	O
18	and	O
19	with	O
20	a	O
21	sample	O
22	of	O
23	224	O
24	women	O
25	with	O
26	wrist	O
27	fracture	O
28	.	O

1	Combined	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	and	O
8	p65	B
9	induced	O
10	vigorous	O
11	transcription	O
12	of	O
13	IL	B
14	-	I
15	2	I
16	promoter	O
17	-	O
18	and	O
19	CD28RE	B
20	-	I
21	driven	I
22	reporter	I
23	constructs	I
24	in	O
25	both	O
26	LFA	B
27	-	I
28	3	I
29	-	O
30	and	O
31	B7	B
32	-	I
33	1	I
34	-	O
35	costimulated	O
36	Jurkat	O
37	cells	O
38	.	O

1	Identical	O
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	B
22	gene	I
23	is	O
24	expressed	O
25	.	O

1	This	O
2	E	O
3	box	O
4	sequence	O
5	(	O
6	CACGTG	O
7	)	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	binding	O
13	element	O
14	for	O
15	USF	B
16	(	O
17	upstream	B
18	stimulatory	I
19	factor	I
20	),	O
21	a	O
22	member	O
23	of	O
24	the	O
25	helix	B
26	-	I
27	loop	I
28	-	I
29	helix	I
30	family	I
31	of	I
32	transcription	I
33	factors	I
34	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	Liquid	O
2	chromatographic	O
3	method	O
4	for	O
5	analysis	O
6	of	O
7	all	O
8	-	O
9	rac	O
10	-	O
11	alpha	O
12	-	O
13	tocopheryl	O
14	acetate	O
15	and	O
16	retinyl	O
17	palmitate	O
18	in	O
19	milk	O
20	-	O
21	based	O
22	infant	O
23	formula	O
24	using	O
25	matrix	O
26	solid	O
27	-	O
28	phase	O
29	dispersion	O
30	.	O

1	We	O
2	specially	O
3	devised	O
4	3	O
5	types	O
6	of	O
7	turbo	O
8	pumps	O
9	,	O
10	a	O
11	centrifugal	O
12	pump	O
13	(	O
14	CFP	O
15	),	O
16	a	O
17	mixed	O
18	flow	O
19	pump	O
20	(	O
21	MFP	O
22	),	O
23	and	O
24	an	O
25	axial	O
26	flow	O
27	pump	O
28	(	O
29	AFP	O
30	),	O
31	and	O
32	analyzed	O
33	their	O
34	in	O
35	vitro	O
36	performance	O
37	.	O

1	Examination	O
2	of	O
3	the	O
4	mitochondrial	B
5	bc1	I
6	complex	I
7	crystal	I
8	structure	I
9	[	O
10	Zhang	O
11	,	O
12	Z	O
13	.,	O
14	Huang	O
15	,	O
16	L	O
17	.,	O
18	Shulmeister	O
19	,	O
20	V	O
21	.	O

1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O

1	The	O
2	side	O
3	-	O
4	to	O
5	-	O
6	side	O
7	difference	O
8	was	O
9	statistically	O
10	significant	O
11	at	O
12	EXT	O
13	30	O
14	degrees	O
15	/	O
16	s	O
17	and	O
18	60	O
19	degrees	O
20	/	O
21	s	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	CONCLUSION	O
2	:	O
3	In	O
4	women	O
5	who	O
6	want	O
7	or	O
8	require	O
9	conservative	O
10	management	O
11	of	O
12	grade	O
13	4	O
14	prolapse	O
15	and	O
16	are	O
17	unable	O
18	to	O
19	retain	O
20	a	O
21	single	O
22	pessary	O
23	,	O
24	the	O
25	placement	O
26	of	O
27	two	O
28	pessaries	O
29	often	O
30	will	O
31	be	O
32	successful	O
33	.	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	B
8	in	O
9	nmt1	B
10	-	O
11	451Dino2	B
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O

1	Rev	B
2	-	O
3	erbAalpha	B
4	/	I
5	beta	I
6	),	O
7	Mxi	B
8	-	I
9	1	I
10	and	O
11	Mad	B
12	bHLH	O
13	-	O
14	zip	O
15	proteins	O
16	and	O
17	the	O
18	oncoproteins	O
19	PLZF	B
20	and	O
21	LAZ3	B
22	/	O
23	BCL6	B
24	is	O
25	mediated	O
26	by	O
27	the	O
28	corepressors	O
29	N	B
30	-	I
31	CoR	I
32	and	O
33	SMRT	B
34	.	O

1	The	O
2	identified	O
3	isolates	O
4	of	O
5	CSF	O
6	(	O
7	20	O
8	of	O
9	29	O
10	)	O
11	were	O
12	:	O
13	ECHO	O
14	30	O
15	(	O
16	9	O
17	),	O
18	ECHO	O
19	11	O
20	(	O
21	7	O
22	),	O
23	ECHO	O
24	9	O
25	(	O
26	3	O
27	)	O
28	and	O
29	ECHO	O
30	7	O
31	(	O
32	1	O
33	).	O

1	There	O
2	was	O
3	no	O
4	evidence	O
5	of	O
6	any	O
7	persistent	O
8	oscillation	O
9	within	O
10	the	O
11	ULF	O
12	band	O
13	.	O

1	The	O
2	ParaSight	O
3	-	O
4	F	O
5	test	O
6	alone	O
7	was	O
8	used	O
9	to	O
10	monitor	O
11	serum	O
12	antigen	O
13	levels	O
14	after	O
15	treatment	O
16	in	O
17	24	O
18	patients	O
19	.	O

1	The	O
2	purified	O
3	recombinant	O
4	protein	O
5	was	O
6	assayed	O
7	for	O
8	its	O
9	enzyme	O
10	activity	O
11	by	O
12	monitoring	O
13	transfer	O
14	of	O
15	[	O
16	3H	O
17	]	O
18	methyl	O
19	groups	O
20	from	O
21	the	O
22	substrate	O
23	DNA	O
24	to	O
25	the	O
26	MGMT	B
27	protein	I
28	;	O
29	the	O
30	activity	O
31	was	O
32	found	O
33	to	O
34	be	O
35	stable	O
36	at	O
37	90	O
38	degrees	O
39	C	O
40	for	O
41	at	O
42	least	O
43	30	O
44	min	O
45	.	O

1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O

1	Elimination	O
2	of	O
3	the	O
4	inducible	O
5	response	O
6	requires	O
7	simultaneous	O
8	mutation	O
9	of	O
10	both	O
11	sequences	O
12	,	O
13	however	O
14	,	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	an	O
20	intact	O
21	EpRE	O
22	the	O
23	upstream	O
24	AP	B
25	-	I
26	1	I
27	site	I
28	is	O
29	irrelevant	O
30	to	O
31	induction	O
32	.	O

1	Three	O
2	high	B
3	mobility	I
4	group	I
5	-	I
6	like	I
7	sequences	I
8	within	O
9	a	O
10	48	O
11	-	O
12	base	O
13	pair	O
14	enhancer	O
15	of	O
16	the	O
17	Col2a1	B
18	gene	I
19	are	O
20	required	O
21	for	O
22	cartilage	O
23	-	O
24	specific	O
25	expression	O
26	in	O
27	vivo	O
28	.	O

1	The	O
2	sequence	O
3	contains	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1744	O
10	nt	O
11	in	O
12	the	O
13	virus	O
14	-	O
15	sense	O
16	strand	O
17	,	O
18	a	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	1360	O
25	nt	O
26	and	O
27	a	O
28	3	O
29	'	O
30	poly	O
31	(	O
32	A	O
33	)	O
34	tail	O
35	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	of	O
5	the	O
6	reverse	B
7	transcriptase	I
8	domain	I
9	confirms	O
10	our	O
11	differential	O
12	genetic	O
13	assessment	O
14	that	O
15	Cyclops	B
16	from	O
17	pea	O
18	is	O
19	a	O
20	novel	O
21	element	O
22	with	O
23	no	O
24	specific	O
25	relationship	O
26	to	O
27	the	O
28	previously	O
29	described	O
30	Gypsy	B
31	-	I
32	like	I
33	elements	I
34	from	O
35	plants	O
36	.	O

1	At	O
2	physiological	O
3	doses	O
4	,	O
5	either	O
6	insulin	B
7	-	I
8	like	I
9	growth	I
10	factor	I
11	I	I
12	(	O
13	IGF	B
14	-	I
15	I	I
16	)	O
17	or	O
18	insulin	B
19	turned	O
20	out	O
21	to	O
22	be	O
23	as	O
24	potent	O
25	as	O
26	dibutyryl	O
27	cAMP	O
28	(	O
29	dbcAMP	O
30	)	O
31	in	O
32	increasing	O
33	UCP1	B
34	gene	I
35	transcription	O
36	rate	O
37	(	O
38	1	O
39	h	O
40	)	O
41	and	O
42	also	O
43	UCP1	B
44	mRNA	I
45	accumulation	O
46	(	O
47	3	O
48	h	O
49	),	O
50	their	O
51	maximal	O
52	effect	O
53	(	O
54	15	O
55	-	O
56	fold	O
57	increase	O
58	)	O
59	reached	O
60	upon	O
61	treatment	O
62	for	O
63	24	O
64	h	O
65	.	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	Essentially	O
2	,	O
3	2	O
4	'-	O
5	O	O
6	-	O
7	methyl	O
8	oligoribonucleotides	O
9	(	O
10	2	O
11	'	O
12	OMeRNA	O
13	)	O
14	were	O
15	delivered	O
16	to	O
17	the	O
18	nuclei	O
19	of	O
20	primary	O
21	mdx	O
22	myoblasts	O
23	in	O
24	culture	O
25	.	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	B
7	-	I
8	binding	I
9	motif	I
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	B
23	.	O

1	Regulation	O
2	of	O
3	the	O
4	human	O
5	p21	B
6	/	O
7	WAF1	B
8	/	O
9	Cip1	B
10	promoter	O
11	in	O
12	hepatic	O
13	cells	O
14	by	O
15	functional	O
16	interactions	O
17	between	O
18	Sp1	B
19	and	O
20	Smad	B
21	family	I
22	members	I
23	.	O

1	RESULTS	O
2	:	O
3	We	O
4	isolated	O
5	a	O
6	C	O
7	.	O
8	elegans	O
9	cDNA	O
10	that	O
11	encoded	O
12	a	O
13	protein	O
14	which	O
15	was	O
16	similar	O
17	to	O
18	,	O
19	but	O
20	not	O
21	exactly	O
22	homologous	O
23	with	O
24	mammalian	O
25	p120	B
26	Ras	I
27	-	O
28	GAP	B
29	.	O

1	The	O
2	weak	O
3	base	O
4	ketoconazole	O
5	showed	O
6	complete	O
7	dissolution	O
8	from	O
9	a	O
10	tablet	O
11	formulation	O
12	in	O
13	Simulated	O
14	Gastric	O
15	Fluid	O
16	without	O
17	pepsin	B
18	(	O
19	SGFsp	O
20	)	O
21	within	O
22	30	O
23	minutes	O
24	,	O
25	70	O
26	%	O
27	dissolution	O
28	in	O
29	2	O
30	hours	O
31	under	O
32	fed	O
33	state	O
34	simulated	O
35	upper	O
36	jejunal	O
37	conditions	O
38	but	O
39	only	O
40	6	O
41	%	O
42	dissolution	O
43	in	O
44	2	O
45	hours	O
46	under	O
47	fasted	O
48	state	O
49	conditions	O
50	.	O

1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	B
6	protein	I
7	interacts	O
8	specifically	O
9	with	O
10	D	B
11	-	I
12	type	I
13	cyclins	I
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	B
23	transcription	I
24	factors	I
25	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	signals	O
6	obtained	O
7	by	O
8	ligation	O
9	of	O
10	the	O
11	TCR	B
12	,	O
13	T	O
14	cells	O
15	need	O
16	additional	O
17	,	O
18	co	O
19	-	O
20	stimulatory	O
21	signals	O
22	to	O
23	be	O
24	activated	O
25	.	O

1	Moreover	O
2	,	O
3	the	O
4	observation	O
5	of	O
6	enhanced	O
7	luteal	B
8	HSP	I
9	-	I
10	27	I
11	phosphorylation	O
12	in	O
13	vivo	O
14	,	O
15	in	O
16	late	O
17	pregnancy	O
18	,	O
19	when	O
20	PKC	B
21	-	I
22	delta	I
23	is	O
24	abundant	O
25	and	O
26	active	O
27	,	O
28	suggests	O
29	that	O
30	select	O
31	PKC	B
32	family	I
33	members	I
34	contribute	O
35	to	O
36	sHSP	B
37	phosphorylation	O
38	events	O
39	in	O
40	vivo	O
41	.	O

1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	.	O

1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	system	O
30	.	O

1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O

1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	moderate	O
7	cooling	O
8	increases	O
9	the	O
10	responsiveness	O
11	of	O
12	vascular	B
13	alpha2	I
14	-	I
15	adrenoceptors	I
16	.	O

1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	B
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	I
16	Cbl	I
17	and	O
18	Cbl	B
19	-	I
20	b	I
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	B
29	-	I
30	1	I
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	B
38	-	I
39	Cbl	I
40	).	O

1	Anti	B
2	-	I
3	PTB	I
4	antibodies	I
5	did	O
6	not	O
7	inhibit	O
8	the	O
9	binding	O
10	of	O
11	PTB	B
12	to	O
13	RNA	O
14	because	O
15	they	O
16	were	O
17	able	O
18	to	O
19	supershift	O
20	RNA	B
21	-	I
22	PTB	I
23	complexes	I
24	.	O

1	The	O
2	use	O
3	of	O
4	antibodies	O
5	to	O
6	the	O
7	polypyrimidine	B
8	tract	I
9	binding	I
10	protein	I
11	(	O
12	PTB	B
13	)	O
14	to	O
15	analyze	O
16	the	O
17	protein	O
18	components	O
19	that	O
20	assemble	O
21	on	O
22	alternatively	O
23	spliced	O
24	pre	O
25	-	O
26	mRNAs	O
27	that	O
28	use	O
29	distant	O
30	branch	O
31	points	O
32	.	O

1	The	O
2	therapeutic	O
3	use	O
4	of	O
5	botulinum	B
6	toxin	I
7	(	O
8	Botox	B
9	)	O
10	is	O
11	increasing	O
12	in	O
13	popularity	O
14	.	O

1	The	O
2	viral	B
3	oncoprotein	I
4	E1A	I
5	inhibits	O
6	NFAT	B
7	-	O
8	dependent	O
9	transactivation	O
10	in	O
11	a	O
12	p300	B
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	Similar	O
2	experiments	O
3	with	O
4	TR	B
5	support	O
6	the	O
7	high	O
8	affinity	O
9	of	O
10	RIP140	B
11	to	O
12	the	O
13	RXR	B
14	subunit	I
15	and	O
16	also	O
17	suggest	O
18	that	O
19	either	O
20	partner	O
21	in	O
22	the	O
23	TR	B
24	/	O
25	RXR	B
26	heterodimer	O
27	can	O
28	independently	O
29	respond	O
30	to	O
31	ligand	O
32	.	O

1	SETTING	O
2	:	O
3	University	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	tertiary	O
9	care	O
10	infertility	O
11	center	O
12	.	O

1	RESULT	O
2	(	O
3	S	O
4	):	O
5	In	O
6	patients	O
7	with	O
8	elevated	O
9	FSH	B
10	levels	O
11	on	O
12	cycle	O
13	day	O
14	3	O
15	,	O
16	a	O
17	low	O
18	oocyte	O
19	yield	O
20	was	O
21	achieved	O
22	(	O
23	7	O
24	versus	O
25	11	O
26	)	O
27	and	O
28	a	O
29	high	O
30	number	O
31	of	O
32	ampules	O
33	of	O
34	hMG	B
35	was	O
36	necessary	O
37	(	O
38	56	O
39	versus	O
40	33	O
41	).	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O

1	In	O
2	the	O
3	ePTFE	O
4	specimens	O
5	,	O
6	tissue	O
7	coverage	O
8	had	O
9	increased	O
10	.	O

1	As	O
2	predicted	O
3	by	O
4	the	O
5	Wing	O
6	and	O
7	Kristofferson	O
8	model	O
9	,	O
10	the	O
11	durations	O
12	of	O
13	successive	O
14	ISIs	O
15	tended	O
16	to	O
17	be	O
18	negatively	O
19	correlated	O
20	.	O

1	Thus	O
2	,	O
3	included	O
4	in	O
5	the	O
6	KG1a	O
7	EST	O
8	dataset	O
9	are	O
10	candidates	O
11	for	O
12	new	O
13	human	O
14	genes	O
15	that	O
16	may	O
17	play	O
18	roles	O
19	in	O
20	hematopoietic	O
21	differentiative	O
22	progression	O
23	and	O
24	lineage	O
25	commitment	O
26	.	O

1	We	O
2	found	O
3	the	O
4	following	O
5	:	O
6	Specific	O
7	mutations	O
8	affected	O
9	the	O
10	precise	O
11	carbohydrate	O
12	structure	O
13	and	O
14	folding	O
15	of	O
16	the	O
17	HA	B
18	trimer	I
19	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	ROS	O
6	production	O
7	by	O
8	viable	O
9	spermatozoa	O
10	is	O
11	highly	O
12	correlated	O
13	with	O
14	the	O
15	concentration	O
16	of	O
17	PMN	B
18	elastase	I
19	and	O
20	the	O
21	number	O
22	of	O
23	both	O
24	peroxidase	B
25	-	O
26	positive	O
27	and	O
28	round	O
29	cells	O
30	.	O

1	Yeast	B
2	U1	I
3	snRNP	I
4	is	O
5	considerably	O
6	more	O
7	complex	O
8	than	O
9	its	O
10	metazoan	O
11	counterpart	O
12	,	O
13	which	O
14	suggests	O
15	possible	O
16	differences	O
17	between	O
18	yeast	O
19	and	O
20	metazoa	O
21	in	O
22	early	O
23	splicing	O
24	events	O
25	.	O

1	Yeast	B
2	U1	I
3	snRNP	I
4	therefore	O
5	contains	O
6	16	O
7	different	O
8	proteins	O
9	,	O
10	including	O
11	seven	O
12	snRNP	B
13	core	I
14	proteins	I
15	,	O
16	three	O
17	homologues	O
18	of	O
19	the	O
20	metazoan	B
21	U1	I
22	snRNP	I
23	-	I
24	specific	I
25	proteins	I
26	,	O
27	and	O
28	six	O
29	yeast	B
30	-	I
31	specific	I
32	U1	I
33	snRNP	I
34	proteins	I
35	.	O

1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O

1	The	O
2	opioid	O
3	antagonist	O
4	naltrexone	O
5	(	O
6	0	O
7	.	O
8	01	O
9	-	O
10	1	O
11	.	O
12	0	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	antagonized	O
18	the	O
19	discriminative	O
20	stimulus	O
21	effects	O
22	of	O
23	heroin	O
24	,	O
25	but	O
26	naltrexone	O
27	at	O
28	doses	O
29	up	O
30	to	O
31	10	O
32	mg	O
33	/	O
34	kg	O
35	had	O
36	no	O
37	effect	O
38	on	O
39	the	O
40	discriminative	O
41	stimulus	O
42	effects	O
43	of	O
44	cocaine	O
45	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	B
12	/	O
13	IGFIIR	B
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	B
19	/	O
20	IGFIIR	B
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O

1	One	O
2	cDNA	O
3	clone	O
4	designated	O
5	NCoA	O
6	-	O
7	62	O
8	,	O
9	encoded	O
10	a	O
11	62	O
12	,	O
13	000	O
14	-	O
15	Da	O
16	protein	O
17	that	O
18	is	O
19	highly	O
20	related	O
21	to	O
22	BX42	B
23	,	O
24	a	O
25	Drosophila	O
26	melanogaster	O
27	nuclear	O
28	protein	O
29	involved	O
30	in	O
31	ecdysone	O
32	-	O
33	stimulated	O
34	gene	O
35	expression	O
36	.	O

1	These	O
2	widely	O
3	expressed	O
4	proteins	O
5	share	O
6	a	O
7	C	O
8	-	O
9	terminal	O
10	region	O
11	that	O
12	bears	O
13	significant	O
14	sequence	O
15	homology	O
16	to	O
17	a	O
18	group	O
19	of	O
20	GDP	B
21	/	I
22	GTP	I
23	exchange	I
24	proteins	I
25	for	O
26	the	O
27	Rab3	B
28	family	I
29	of	O
30	small	B
31	GTP	I
32	binding	I
33	proteins	I
34	.	O

1	Whereas	O
2	p82	B
3	expression	O
4	had	O
5	no	O
6	effect	O
7	on	O
8	ERK2	B
9	activation	O
10	by	O
11	p126	B
12	,	O
13	p70	B
14	completely	O
15	abrogated	O
16	this	O
17	activity	O
18	.	O

1	The	O
2	pre	O
3	-	O
4	mRNA	O
5	splicing	O
6	factor	O
7	U2AF	B
8	(	O
9	U2	B
10	small	I
11	nuclear	I
12	ribonucleoprotein	I
13	particle	I
14	[	I
15	snRNP	I
16	]	I
17	auxiliary	I
18	factor	I
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O

1	The	O
2	brackets	O
3	were	O
4	bonded	O
5	to	O
6	100	O
7	freshly	O
8	extracted	O
9	bovine	O
10	incisors	O
11	,	O
12	and	O
13	,	O
14	after	O
15	storage	O
16	in	O
17	tap	O
18	water	O
19	at	O
20	room	O
21	temperature	O
22	for	O
23	24	O
24	hours	O
25	,	O
26	they	O
27	were	O
28	subsequently	O
29	tested	O
30	in	O
31	a	O
32	shear	O
33	mode	O
34	using	O
35	a	O
36	universal	O
37	testing	O
38	machine	O
39	.	O

1	Exercise	O
2	training	O
3	has	O
4	become	O
5	increasingly	O
6	important	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	heart	O
12	failure	O
13	patients	O
14	.	O

1	The	O
2	growth	O
3	of	O
4	Aer	O
5	.	O
6	hydrophila	O
7	in	O
8	filter	O
9	-	O
10	sterilized	O
11	lettuce	O
12	extract	O
13	was	O
14	completely	O
15	inhibited	O
16	by	O
17	0	O
18	.	O
19	1	O
20	%	O
21	(	O
22	v	O
23	/	O
24	v	O
25	)	O
26	BMC	O
27	whereas	O
28	that	O
29	of	O
30	Ps	O
31	.	O
32	fluorescens	O
33	was	O
34	not	O
35	significantly	O
36	affected	O
37	by	O
38	1	O
39	%	O
40	(	O
41	v	O
42	/	O
43	v	O
44	)	O
45	BMC	O
46	.	O

1	Despite	O
2	continuous	O
3	compliance	O
4	,	O
5	unexplained	O
6	resurgence	O
7	of	O
8	serum	O
9	ferritin	B
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	veteran	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O

1	Hematocrit	O
2	and	O
3	PaO2	O
4	did	O
5	not	O
6	change	O
7	.	O

1	Regulation	O
2	of	O
3	myosin	B
4	phosphatase	I
5	activity	O
6	involves	O
7	changes	O
8	in	O
9	subunit	O
10	interactions	O
11	,	O
12	although	O
13	molecular	O
14	mechanisms	O
15	are	O
16	not	O
17	defined	O
18	.	O

1	Commutative	O
2	saccadic	O
3	generator	O
4	is	O
5	sufficient	O
6	to	O
7	control	O
8	a	O
9	3	O
10	-	O
11	D	O
12	ocular	O
13	plant	O
14	with	O
15	pulleys	O
16	.	O

1	The	O
2	virus	O
3	-	O
4	associated	O
5	VAI	B
6	RNA	O
7	of	O
8	adenovirus	O
9	is	O
10	a	O
11	small	O
12	highly	O
13	structured	O
14	RNA	O
15	that	O
16	is	O
17	required	O
18	for	O
19	the	O
20	efficient	O
21	translation	O
22	of	O
23	cellular	O
24	and	O
25	viral	O
26	mRNAs	O
27	at	O
28	late	O
29	times	O
30	after	O
31	infection	O
32	.	O

1	Structure	O
2	of	O
3	the	O
4	gene	O
5	encoding	O
6	the	O
7	human	O
8	cyclin	B
9	-	I
10	dependent	I
11	kinase	I
12	inhibitor	O
13	p18	B
14	and	O
15	mutational	O
16	analysis	O
17	in	O
18	breast	O
19	cancer	O
20	.	O

1	The	O
2	YccA	B
3	protein	I
4	was	O
5	found	O
6	to	O
7	be	O
8	degraded	O
9	in	O
10	an	O
11	FtsH	B
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	vivo	O
17	and	O
18	in	O
19	vitro	O
20	,	O
21	whereas	O
22	the	O
23	YccA11	B
24	mutant	I
25	protein	I
26	,	O
27	lacking	O
28	eight	O
29	amino	O
30	acid	O
31	residues	O
32	within	O
33	the	O
34	amino	O
35	-	O
36	terminal	O
37	cytoplasmic	O
38	domain	O
39	,	O
40	was	O
41	refractory	O
42	to	O
43	the	O
44	degradation	O
45	.	O

1	The	O
2	major	O
3	type	O
4	involves	O
5	activator	O
6	proteins	O
7	that	O
8	bind	O
9	to	O
10	DNA	O
11	adjacent	O
12	to	O
13	where	O
14	the	O
15	RNA	B
16	polymerase	I
17	(	O
18	RNAP	B
19	)	O
20	holoenzyme	O
21	binds	O
22	,	O
23	usually	O
24	assisting	O
25	in	O
26	recruitment	O
27	of	O
28	the	O
29	RNAP	B
30	to	O
31	the	O
32	promoter	O
33	.	O

1	A	O
2	conserved	O
3	role	O
4	for	O
5	L1	B
6	as	O
7	a	O
8	transmembrane	O
9	link	O
10	between	O
11	neuronal	O
12	adhesion	O
13	and	O
14	membrane	O
15	cytoskeleton	O
16	assembly	O
17	.	O

1	Atmospheric	O
2	benzene	O
3	,	O
4	urinary	O
5	muconic	O
6	acid	O
7	(	O
8	tt	O
9	-	O
10	MA	O
11	)	O
12	and	O
13	leukocyte	B
14	alkaline	I
15	phosphatase	I
16	activity	O
17	(	O
18	LAPA	O
19	)	O
20	were	O
21	evaluated	O
22	among	O
23	66	O
24	car	O
25	mechanics	O
26	,	O
27	34	O
28	road	O
29	tanker	O
30	drivers	O
31	,	O
32	and	O
33	28	O
34	nonexposed	O
35	workers	O
36	.	O

1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	O
30	(	O
31	r	O
32	)	O
33	160	O
34	kDa	O
35	RNA	O
36	-	O
37	dependent	O
38	RNA	O
39	polymerase	O
40	(	O
41	ORF1	O
42	),	O
43	26	O
44	kDa	O
45	movement	O
46	protein	O
47	1	O
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	O
68	kDa	O
69	coat	O
70	protein	O
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O

1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O

1	Sp1	B
2	and	O
3	two	O
4	Sp3	B
5	isoforms	I
6	were	O
7	detected	O
8	as	O
9	the	O
10	primary	O
11	cellular	O
12	constituents	O
13	of	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	formed	O
19	with	O
20	the	O
21	NF	B
22	-	I
23	kappaB	I
24	-	I
25	proximal	I
26	site	I
27	.	O

1	These	O
2	genes	O
3	may	O
4	represent	O
5	interesting	O
6	targets	O
7	for	O
8	new	O
9	therapeutic	O
10	strategies	O
11	.	O

1	It	O
2	could	O
3	also	O
4	inhibit	O
5	C1q	B
6	-	O
7	dependent	O
8	haemolysis	O
9	of	O
10	both	O
11	IgG	B
12	-	O
13	and	O
14	IgM	B
15	-	O
16	sensitized	O
17	erythrocytes	O
18	.	O

1	3	O
2	)	O
3	and	O
4	one	O
5	distal	O
6	(-	O
7	11	O
8	.	O
9	8	O
10	/-	O
11	10	O
12	.	O
13	9	O
14	),	O
15	presented	O
16	an	O
17	enhancer	O
18	activity	O
19	in	O
20	pituitary	O
21	cells	O
22	when	O
23	placed	O
24	upstream	O
25	of	O
26	the	O
27	SV40	B
28	promoter	I
29	.	O

1	The	O
2	second	O
3	patient	O
4	had	O
5	received	O
6	pituitary	B
7	-	I
8	derived	I
9	growth	I
10	hormone	I
11	for	O
12	treatment	O
13	of	O
14	growth	B
15	hormone	I
16	deficiency	O
17	,	O
18	secondary	O
19	to	O
20	a	O
21	third	O
22	ventricle	O
23	teratoma	O
24	,	O
25	exised	O
26	13	O
27	yr	O
28	earlier	O
29	.	O

1	3	O
2	--	O
3	It	O
4	is	O
5	necessary	O
6	to	O
7	think	O
8	about	O
9	cosmetic	O
10	consequences	O
11	of	O
12	the	O
13	chinese	O
14	flap	O
15	and	O
16	consider	O
17	other	O
18	possibilities	O
19	of	O
20	the	O
21	flap	O
22	choice	O
23	.	O

1	CONCLUSION	O
2	:	O
3	TNF	B
4	alpha	I
5	,	O
6	TGF	B
7	beta	I
8	,	O
9	PDGF	B
10	and	O
11	IL	B
12	-	I
13	1beta	I
14	increased	O
15	LDLr	B
16	gene	I
17	expression	O
18	by	O
19	increasing	O
20	sterol	O
21	-	O
22	independent	O
23	and	O
24	mitogenesis	O
25	-	O
26	independent	O
27	gene	O
28	transcription	O
29	.	O

1	Binding	O
2	affinities	O
3	of	O
4	different	O
5	nucleotide	O
6	mono	O
7	-,	O
8	di	O
9	-	O
10	and	O
11	triphosphates	O
12	and	O
13	non	O
14	-	O
15	hydrolyzable	O
16	analogs	O
17	indicate	O
18	that	O
19	the	O
20	beta	O
21	-	O
22	phosphate	O
23	moiety	O
24	is	O
25	required	O
26	for	O
27	substrate	O
28	binding	O
29	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	only	O
6	one	O
7	-	O
8	half	O
9	and	O
10	one	O
11	-	O
12	third	O
13	the	O
14	size	O
15	of	O
16	the	O
17	proteolipids	O
18	from	O
19	M	O
20	.	O
21	thermoautotrophicum	O
22	and	O
23	M	O
24	.	O
25	jannaschii	O
26	,	O
27	respectively	O
28	.	O
29	ahaK	B
30	is	O
31	expressed	O
32	in	O
33	Escherichia	O
34	coli	O
35	,	O
36	and	O
37	it	O
38	is	O
39	incorporated	O
40	into	O
41	the	O
42	cytoplasmic	O
43	membrane	O
44	despite	O
45	the	O
46	different	O
47	chemical	O
48	natures	O
49	of	O
50	lipids	O
51	from	O
52	archaea	O
53	and	O
54	bacteria	O
55	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	studied	O
6	the	O
7	role	O
8	of	O
9	protein	B
10	-	I
11	tyrosine	I
12	phosphatase	I
13	SHP	I
14	-	I
15	2	I
16	in	O
17	ErbB	B
18	-	O
19	mediated	O
20	activation	O
21	of	O
22	mitogen	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	(	O
28	MAPK	B
29	)	O
30	by	O
31	overexpressing	O
32	SHP	B
33	-	I
34	2	I
35	mutants	I
36	in	O
37	COS	O
38	-	O
39	7	O
40	cells	O
41	.	O

1	Osteoadherin	B
2	is	O
3	a	O
4	recently	O
5	described	O
6	bone	O
7	proteoglycan	O
8	containing	O
9	keratan	O
10	sulfate	O
11	.	O

1	Intron	O
2	8	O
3	harbored	O
4	a	O
5	strong	O
6	erythroid	O
7	-	O
8	specific	O
9	enhancer	O
10	activity	O
11	which	O
12	was	O
13	orientation	O
14	-	O
15	dependent	O
16	.	O

1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	B
11	-	I
12	1	I
13	together	O
14	with	O
15	Sp1	B
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	B
31	protein	I
32	or	O
33	of	O
34	another	O
35	unidentified	O
36	erythroid	O
37	factor	O
38	.	O

1	The	O
2	cleavage	O
3	of	O
4	Fak	B
5	by	O
6	caspases	B
7	may	O
8	thus	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	the	O
15	execution	O
16	of	O
17	the	O
18	suicide	O
19	program	O
20	by	O
21	disabling	O
22	the	O
23	anti	O
24	-	O
25	apoptotic	O
26	function	O
27	of	O
28	Fak	B
29	.	O

1	Moreover	O
2	,	O
3	the	O
4	mass	O
5	estimated	O
6	with	O
7	the	O
8	QCM	O
9	response	O
10	through	O
11	the	O
12	Sauerbrey	O
13	equation	O
14	and	O
15	the	O
16	mass	O
17	which	O
18	can	O
19	be	O
20	measured	O
21	thanks	O
22	to	O
23	other	O
24	analytical	O
25	techniques	O
26	,	O
27	in	O
28	our	O
29	case	O
30	an	O
31	enzymatic	O
32	assay	O
33	,	O
34	are	O
35	different	O
36	:	O
37	the	O
38	deposited	O
39	mass	O
40	is	O
41	generally	O
42	overestimated	O
43	by	O
44	the	O
45	QCM	O
46	.	O

1	[	O
2	Treatment	O
3	of	O
4	early	O
5	T1	O
6	small	O
7	T2N	O
8	breast	O
9	cancers	O
10	.	O

1	Transcription	O
2	initiation	O
3	occurred	O
4	predominantly	O
5	at	O
6	the	O
7	putative	O
8	sigmaA	B
9	-	I
10	dependent	I
11	promoter	I
12	in	O
13	exponentially	O
14	growing	O
15	cells	O
16	and	O
17	was	O
18	induced	O
19	under	O
20	stress	O
21	conditions	O
22	.	O

1	The	O
2	genes	O
3	encoding	O
4	(	B
5	2Fe	I
6	-	I
7	2S	I
8	)	I
9	plant	I
10	-	I
11	like	I
12	ferredoxins	I
13	were	O
14	studied	O
15	in	O
16	the	O
17	widely	O
18	used	O
19	cyanobacterium	O
20	Synechocystis	O
21	PCC6803	O
22	.	O

1	RNA	O
2	of	O
3	GBV	O
4	-	O
5	C	O
6	was	O
7	detected	O
8	in	O
9	14	O
10	(	O
11	18	O
12	%)	O
13	patients	O
14	before	O
15	BMT	O
16	.	O

1	A	O
2	major	O
3	pool	O
4	of	O
5	Dsg	B
6	-	O
7	plakoglobin	B
8	complexes	O
9	sedimented	O
10	at	O
11	8S	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	stoichiometry	O
19	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	CBF	B
9	/	O
10	NF	B
11	-	I
12	Y	I
13	to	O
14	the	O
15	inverted	O
16	CCAAT	O
17	box	O
18	is	O
19	responsible	O
20	for	O
21	transcriptional	O
22	activation	O
23	of	O
24	the	O
25	nTPH	B
26	gene	I
27	.	O

1	In	O
2	macrophages	O
3	,	O
4	LPS	O
5	-	O
6	inducible	O
7	HIV	O
8	-	O
9	1	O
10	gene	O
11	expression	O
12	is	O
13	mediated	O
14	in	O
15	part	O
16	by	O
17	binding	O
18	of	O
19	NF	B
20	-	I
21	kappa	I
22	B	I
23	to	O
24	identical	O
25	tandem	O
26	binding	O
27	sites	O
28	located	O
29	within	O
30	the	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	LTR	O
36	).	O

1	The	O
2	influence	O
3	of	O
4	p53	B
5	on	O
6	cytokine	O
7	-	O
8	triggered	O
9	Janus	B
10	kinase	I
11	-	O
12	STAT	B
13	signaling	O
14	was	O
15	investigated	O
16	in	O
17	human	O
18	hepatoma	O
19	Hep3B	O
20	cell	O
21	lines	O
22	engineered	O
23	to	O
24	constitutively	O
25	express	O
26	the	O
27	temperature	O
28	-	O
29	sensitive	O
30	Val135	B
31	mutant	I
32	of	I
33	p53	I
34	.	O

1	It	O
2	can	O
3	also	O
4	be	O
5	used	O
6	to	O
7	examine	O
8	various	O
9	laryngeal	O
10	parameters	O
11	obtained	O
12	from	O
13	videotaped	O
14	endoscopic	O
15	and	O
16	stroboscopic	O
17	examinations	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	Two	O
4	consecutive	O
5	sets	O
6	of	O
7	transrectal	O
8	ultrasound	O
9	guided	O
10	sextant	O
11	biopsies	O
12	of	O
13	the	O
14	prostate	O
15	performed	O
16	in	O
17	a	O
18	single	O
19	office	O
20	visit	O
21	represent	O
22	a	O
23	cost	O
24	-	O
25	effective	O
26	biopsy	O
27	strategy	O
28	for	O
29	men	O
30	presenting	O
31	with	O
32	an	O
33	abnormal	O
34	digital	O
35	rectal	O
36	examination	O
37	and	O
38	/	O
39	or	O
40	elevated	O
41	serum	B
42	PSA	I
43	.	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	B
15	-	I
16	terminally	I
17	truncated	I
18	MIP	I
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	Interestingly	O
2	,	O
3	PKA	B
4	activity	O
5	is	O
6	dispensable	O
7	in	O
8	a	O
9	strain	O
10	lacking	O
11	Msn2p	B
12	and	O
13	Msn4p	B
14	activity	O
15	.	O

1	They	O
2	also	O
3	indicate	O
4	that	O
5	direct	O
6	interactions	O
7	between	O
8	C	B
9	/	I
10	EBPs	I
11	and	O
12	specific	O
13	Ets	B
14	family	O
15	members	O
16	,	O
17	together	O
18	with	O
19	GATA	B
20	-	I
21	1	I
22	,	O
23	are	O
24	important	O
25	for	O
26	eosinophil	O
27	lineage	O
28	determination	O
29	.	O

1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	B
42	-	I
43	TEFb	I
44	.	O

1	We	O
2	have	O
3	used	O
4	the	O
5	hydrophobic	O
6	repeats	O
7	of	O
8	the	O
9	HSF1	B
10	trimerization	I
11	domain	I
12	in	O
13	the	O
14	yeast	O
15	two	O
16	-	O
17	hybrid	O
18	protein	O
19	interaction	O
20	assay	O
21	to	O
22	identify	O
23	heat	B
24	shock	I
25	factor	I
26	binding	I
27	protein	I
28	1	I
29	(	O
30	HSBP1	B
31	),	O
32	a	O
33	novel	O
34	,	O
35	conserved	O
36	,	O
37	76	O
38	-	O
39	amino	O
40	-	O
41	acid	O
42	protein	O
43	that	O
44	contains	O
45	two	O
46	extended	O
47	arrays	O
48	of	O
49	hydrophobic	O
50	repeats	O
51	that	O
52	interact	O
53	with	O
54	the	O
55	HSF1	B
56	heptad	I
57	repeats	I
58	.	O

1	Genomic	O
2	and	O
3	cDNA	O
4	clones	O
5	homologous	O
6	to	O
7	the	O
8	yeast	O
9	GCN2	B
10	eIF	I
11	-	I
12	2alpha	I
13	kinase	O
14	(	O
15	yGCN2	O
16	)	O
17	were	O
18	isolated	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	.	O

1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	Strengthening	O
2	the	O
3	biological	O
4	weapons	O
5	convention	O
6	and	O
7	implications	O
8	on	O
9	the	O
10	pharmaceutical	O
11	and	O
12	biotechnology	O
13	industry	O
14	.	O

1	VirD2	B
2	is	O
3	one	O
4	of	O
5	the	O
6	key	O
7	Agrobacterium	O
8	tumefaciens	O
9	proteins	O
10	involved	O
11	in	O
12	T	O
13	-	O
14	DNA	O
15	processing	O
16	and	O
17	transfer	O
18	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	data	O
6	indicate	O
7	that	O
8	the	O
9	VirD2	B
10	omega	I
11	domain	I
12	is	O
13	important	O
14	for	O
15	efficient	O
16	T	O
17	-	O
18	DNA	O
19	integration	O
20	.	O

1	The	O
2	DHEAS	O
3	levels	O
4	in	O
5	all	O
6	stages	O
7	of	O
8	decreased	O
9	BMD	O
10	were	O
11	significantly	O
12	lower	O
13	than	O
14	those	O
15	in	O
16	the	O
17	group	O
18	with	O
19	normal	O
20	BMD	O
21	.	O

1	Orientation	O
2	of	O
3	the	O
4	nuclear	O
5	spin	O
6	system	O
7	by	O
8	optical	O
9	pumping	O
10	causes	O
11	an	O
12	Overhauser	O
13	shift	O
14	of	O
15	the	O
16	excitonic	O
17	energy	O
18	levels	O
19	proportional	O
20	to	O
21	the	O
22	degree	O
23	of	O
24	nuclear	O
25	orientation	O
26	.	O

1	Cystatin	B
2	A	I
3	,	O
4	a	O
5	cysteine	B
6	proteinase	I
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	cornified	B
17	cell	I
18	envelope	I
19	of	O
20	keratinocytes	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	keratinocyte	O
30	differentiation	O
31	.	O

1	A	O
2	role	O
3	for	O
4	RalGDS	B
5	and	O
6	a	O
7	novel	O
8	Ras	B
9	effector	O
10	in	O
11	the	O
12	Ras	B
13	-	O
14	mediated	O
15	inhibition	O
16	of	O
17	skeletal	O
18	myogenesis	O
19	.	O

1	GTPase	B
2	activating	O
3	specificity	O
4	of	O
5	RGS12	B
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	O
12	spliced	O
13	PDZ	B
14	(	O
15	PSD	B
16	-	I
17	95	I
18	/	O
19	Dlg	B
20	/	O
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	However	O
2	,	O
3	mutations	O
4	in	O
5	the	O
6	HNF	B
7	-	I
8	4	I
9	binding	I
10	site	I
11	on	O
12	element	B
13	CIIB	I
14	and	O
15	inhibition	O
16	of	O
17	HNF	B
18	-	I
19	4	I
20	synthesis	O
21	in	O
22	HepG2	O
23	cells	O
24	by	O
25	antisense	O
26	HNF	B
27	-	I
28	4	I
29	constructs	I
30	decreased	O
31	the	O
32	apoCII	B
33	promoter	I
34	activity	O
35	to	O
36	25	O
37	-	O
38	40	O
39	%	O
40	of	O
41	the	O
42	control	O
43	,	O
44	indicating	O
45	that	O
46	HNF	B
47	-	I
48	4	I
49	is	O
50	a	O
51	positive	O
52	regulator	O
53	of	O
54	the	O
55	apoCII	B
56	gene	I
57	.	O

1	272	O
2	,	O
3	19107	O
4	-	O
5	19110	O
6	).	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	find	O
6	that	O
7	E2F	B
8	-	I
9	1	I
10	can	O
11	cause	O
12	apoptosis	O
13	in	O
14	p53	B
15	-/-	I
16	tumour	O
17	cells	O
18	and	O
19	further	O
20	p300	B
21	,	O
22	which	O
23	also	O
24	functions	O
25	as	O
26	a	O
27	co	O
28	-	O
29	activator	O
30	for	O
31	the	O
32	E2F	B
33	/	O
34	DP	B
35	heterodimer	O
36	,	O
37	enhances	O
38	the	O
39	apoptotic	O
40	activity	O
41	of	O
42	E2F	B
43	-	I
44	1	I
45	.	O

1	Blocked	O
2	shift	O
3	/	O
4	supershift	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	I
10	member	O
11	proteins	O
12	especially	O
13	Fra	B
14	-	I
15	1	I
16	and	O
17	Fra	B
18	-	I
19	2	I
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	I
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	I
42	1	I
43	/	I
44	DNA	I
45	binding	I
46	complex	I
47	.	O

1	Initially	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	unmutated	O
7	p53	B
8	is	O
9	strongly	O
10	expressed	O
11	in	O
12	premalignant	O
13	mammary	O
14	glands	O
15	and	O
16	in	O
17	mammary	O
18	tumors	O
19	derived	O
20	from	O
21	the	O
22	MMTV	O
23	-	O
24	c	B
25	-	I
26	myc	I
27	strain	O
28	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	heterologous	O
6	virus	O
7	RNAs	O
8	(	O
9	BSMV	O
10	)	O
11	can	O
12	serve	O
13	as	O
14	primer	O
15	donors	O
16	for	O
17	MStV	O
18	mRNA	O
19	capped	O
20	RNA	O
21	-	O
22	primed	O
23	transcription	O
24	in	O
25	doubly	O
26	infected	O
27	plants	O
28	.	O

1	Human	O
2	isoforms	O
3	,	O
4	designated	O
5	1	O
6	to	O
7	4	O
8	,	O
9	differ	O
10	from	O
11	each	O
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	O
17	used	O
18	.	O

1	Comparison	O
2	of	O
3	cDNA	O
4	and	O
5	genomic	O
6	sequences	O
7	shows	O
8	that	O
9	the	O
10	ZNF189	B
11	gene	I
12	spans	O
13	approximately	O
14	11	O
15	kb	O
16	and	O
17	is	O
18	organized	O
19	into	O
20	at	O
21	least	O
22	four	O
23	exons	O
24	,	O
25	the	O
26	large	O
27	3	O
28	'-	O
29	end	O
30	exon	O
31	coding	O
32	for	O
33	the	O
34	complete	O
35	zinc	O
36	finger	O
37	domain	O
38	and	O
39	the	O
40	3	O
41	'	O
42	untranslated	O
43	region	O
44	.	O

1	Malaria	O
2	had	O
3	diminished	O
4	significantly	O
5	by	O
6	the	O
7	early	O
8	1940s	O
9	,	O
10	and	O
11	this	O
12	paper	O
13	queries	O
14	whether	O
15	that	O
16	reduction	O
17	was	O
18	due	O
19	to	O
20	the	O
21	control	O
22	projects	O
23	of	O
24	the	O
25	thirties	O
26	,	O
27	and	O
28	,	O
29	if	O
30	so	O
31	,	O
32	whether	O
33	such	O
34	projects	O
35	should	O
36	be	O
37	a	O
38	model	O
39	for	O
40	the	O
41	current	O
42	developing	O
43	world	O
44	,	O
45	where	O
46	malaria	O
47	is	O
48	a	O
49	growing	O
50	problem	O
51	today	O
52	.	O

1	The	O
2	gp330	B
3	/	O
4	Megalin	B
5	/	O
6	LRP	B
7	-	I
8	2	I
9	protein	O
10	belongs	O
11	to	O
12	the	O
13	low	B
14	-	I
15	density	I
16	lipoprotein	I
17	receptor	I
18	gene	I
19	family	I
20	and	O
21	is	O
22	believed	O
23	to	O
24	function	O
25	as	O
26	an	O
27	endocytic	O
28	receptor	O
29	for	O
30	the	O
31	uptake	O
32	of	O
33	lipoproteins	O
34	and	O
35	many	O
36	other	O
37	ligands	O
38	.	O

1	In	O
2	the	O
3	DNA	O
4	recognition	O
5	helix	O
6	of	O
7	finger	O
8	II	O
9	,	O
10	the	O
11	conserved	O
12	Arg	O
13	at	O
14	position	O
15	62	O
16	(	O
17	N	O
18	-	O
19	terminal	O
20	side	O
21	of	O
22	the	O
23	first	O
24	zinc	O
25	-	O
26	coordinating	O
27	histidine	O
28	)	O
29	was	O
30	changed	O
31	to	O
32	a	O
33	Leu	O
34	or	O
35	Gln	O
36	.	O

1	Dosage	O
2	in	O
3	both	O
4	cases	O
5	was	O
6	0	O
7	.	O
8	2	O
9	g	O
10	/	O
11	m2	O
12	.	O

1	Five	O
2	additional	O
3	copies	O
4	of	O
5	Lian	B
6	elements	I
7	were	O
8	isolated	O
9	,	O
10	mapped	O
11	by	O
12	restriction	O
13	digestion	O
14	,	O
15	and	O
16	partially	O
17	sequenced	O
18	.	O

1	Evolutionary	O
2	relationships	O
3	among	O
4	putative	O
5	RNA	B
6	-	I
7	dependent	I
8	RNA	I
9	polymerases	I
10	encoded	O
11	by	O
12	a	O
13	mitochondrial	O
14	virus	O
15	-	O
16	like	O
17	RNA	O
18	in	O
19	the	O
20	Dutch	O
21	elm	O
22	disease	O
23	fungus	O
24	,	O
25	Ophiostoma	O
26	novo	O
27	-	O
28	ulmi	O
29	,	O
30	by	O
31	other	O
32	viruses	O
33	and	O
34	virus	O
35	-	O
36	like	O
37	RNAs	O
38	and	O
39	by	O
40	the	O
41	Arabidopsis	O
42	mitochondrial	O
43	genome	O
44	.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	O
7	core	O
8	region	O
9	and	O
10	transcription	B
11	factor	I
12	YY1	I
13	in	O
14	Rous	B
15	sarcoma	I
16	virus	I
17	long	I
18	terminal	I
19	repeat	I
20	promoter	I
21	activity	O
22	.	O

1	Fowlpox	O
2	virus	O
3	encodes	O
4	nonessential	O
5	homologs	O
6	of	O
7	cellular	B
8	alpha	I
9	-	I
10	SNAP	I
11	,	O
12	PC	B
13	-	I
14	1	I
15	,	O
16	and	O
17	an	O
18	orphan	O
19	human	O
20	homolog	O
21	of	O
22	a	O
23	secreted	O
24	nematode	O
25	protein	O
26	.	O

1	Addition	O
2	of	O
3	Rap	O
4	or	O
5	KN62	O
6	after	O
7	exposure	O
8	of	O
9	cells	O
10	to	O
11	progesterone	O
12	agonist	O
13	Org	O
14	2058	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	induction	O
20	of	O
21	CAT	B
22	activity	O
23	.	O

1	The	O
2	Dax	B
3	-	I
4	1	I
5	gene	I
6	encodes	O
7	a	O
8	protein	O
9	that	O
10	is	O
11	structurally	O
12	related	O
13	to	O
14	members	O
15	of	O
16	the	O
17	orphan	B
18	nuclear	I
19	receptor	I
20	superfamily	I
21	.	O

1	He	O
2	was	O
3	administered	O
4	recombinant	B
5	IFN	I
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O

1	Further	O
2	,	O
3	Ser	O
4	/	O
5	Thr	O
6	phosphorylation	O
7	of	O
8	downstream	O
9	molecules	O
10	Akt	B
11	and	O
12	p70	B
13	S6	I
14	kinase	I
15	was	O
16	inhibited	O
17	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	kinetics	O
8	of	O
9	MEK	B
10	inhibition	O
11	by	O
12	these	O
13	compounds	O
14	reveals	O
15	that	O
16	U0126	O
17	has	O
18	approximately	O
19	100	O
20	-	O
21	fold	O
22	higher	O
23	affinity	O
24	for	O
25	deltaN3	B
26	-	I
27	S218E	I
28	/	I
29	S222D	I
30	MEK	I
31	than	O
32	does	O
33	PD098059	O
34	.	O

1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	O
16	cascades	O
17	that	O
18	repress	O
19	HSF1	B
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	303	O
26	,	O
27	307	O
28	,	O
29	and	O
30	363	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	suppressing	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O

1	Clinical	O
2	implication	O
3	of	O
4	protein	O
5	levels	O
6	of	O
7	IL	B
8	-	I
9	5	I
10	in	O
11	induced	O
12	sputum	O
13	in	O
14	asthmatic	O
15	patients	O
16	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	ras	B
6	-	O
7	induced	O
8	transition	O
9	is	O
10	accompanied	O
11	by	O
12	a	O
13	strong	O
14	induction	O
15	of	O
16	AP	B
17	-	I
18	1	I
19	-	O
20	binding	O
21	activity	O
22	along	O
23	with	O
24	increased	O
25	expression	O
26	of	O
27	CD44	B
28	mRNA	I
29	and	O
30	protein	O
31	.	O

1	However	O
2	,	O
3	little	O
4	is	O
5	known	O
6	regarding	O
7	the	O
8	genomic	O
9	organization	O
10	and	O
11	developmental	O
12	expression	O
13	of	O
14	the	O
15	caveolin	B
16	gene	I
17	family	I
18	.	O

1	Tensile	O
2	bond	O
3	strengths	O
4	between	O
5	resin	O
6	composite	O
7	and	O
8	bovine	O
9	dentin	O
10	using	O
11	dentin	O
12	adhesive	O
13	systems	O
14	(	O
15	Clearfil	O
16	Liner	O
17	Bond	O
18	II	O
19	:	O
20	LB	O
21	II	O
22	;	O
23	Scotchbond	O
24	Multi	O
25	-	O
26	Purpose	O
27	:	O
28	MP	O
29	)	O
30	bonding	O
31	systems	O
32	showed	O
33	a	O
34	large	O
35	scatter	O
36	among	O
37	students	O
38	and	O
39	dentists	O
40	.	O

1	This	O
2	distribution	O
3	implies	O
4	that	O
5	the	O
6	polycistronic	O
7	precursor	O
8	is	O
9	imported	O
10	into	O
11	the	O
12	nucleolus	O
13	for	O
14	processing	O
15	to	O
16	the	O
17	mature	O
18	snoRNAs	O
19	,	O
20	and	O
21	that	O
22	the	O
23	import	O
24	or	O
25	processing	O
26	pathway	O
27	involves	O
28	coiled	O
29	bodies	O
30	.	O

1	Suppressive	O
2	therapy	O
3	for	O
4	thyroid	O
5	nodules	O
6	.	O

1	Fourteen	O
2	healthy	O
3	male	O
4	volunteers	O
5	completed	O
6	the	O
7	study	O
8	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	Mg2	O
6	+,	O
7	a	O
8	hydrophobic	O
9	exonuclease	O
10	site	O
11	dominates	O
12	over	O
13	the	O
14	polymerase	O
15	site	O
16	for	O
17	possession	O
18	of	O
19	the	O
20	primer	O
21	terminus	O
22	.	O

1	As	O
2	the	O
3	high	O
4	-	O
5	affinity	O
6	Mg2	O
7	+	O
8	binding	O
9	sites	O
10	are	O
11	filled	O
12	,	O
13	the	O
14	primer	O
15	terminus	O
16	migrates	O
17	from	O
18	the	O
19	exonuclease	O
20	site	O
21	to	O
22	a	O
23	highly	O
24	based	O
25	stacked	O
26	polymerase	O
27	active	O
28	site	O
29	.	O

1	One	O
2	missense	O
3	allele	O
4	(	O
5	P236S	O
6	)	O
7	with	O
8	complete	O
9	loss	O
10	of	O
11	function	O
12	at	O
13	30	O
14	degreesC	O
15	and	O
16	four	O
17	missense	O
18	alleles	O
19	(	O
20	L173F	O
21	,	O
22	E225K	O
23	,	O
24	S269L	O
25	and	O
26	E274K	O
27	)	O
28	that	O
29	conferred	O
30	a	O
31	temperature	O
32	sensitive	O
33	phenotype	O
34	were	O
35	identified	O
36	.	O

1	Structural	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	regulatory	O
8	region	O
9	reveals	O
10	that	O
11	the	O
12	c	B
13	-	I
14	met	I
15	promoter	I
16	lacks	O
17	TATA	O
18	or	O
19	CAAT	O
20	elements	O
21	but	O
22	has	O
23	an	O
24	extremely	O
25	high	O
26	G	O
27	-	O
28	C	O
29	content	O
30	and	O
31	multiple	O
32	Sp1	B
33	binding	I
34	sites	I
35	.	O

1	The	O
2	report	O
3	highlights	O
4	the	O
5	possible	O
6	contribution	O
7	of	O
8	stress	O
9	factors	O
10	in	O
11	the	O
12	context	O
13	of	O
14	therapy	O
15	resistant	O
16	periodontal	O
17	disease	O
18	,	O
19	and	O
20	the	O
21	results	O
22	seem	O
23	to	O
24	be	O
25	understandable	O
26	within	O
27	the	O
28	context	O
29	of	O
30	a	O
31	stress	O
32	system	O
33	disorder	O
34	perspective	O
35	.	O

1	Acute	O
2	pancreatitis	O
3	is	O
4	a	O
5	rather	O
6	common	O
7	abdominal	O
8	disorder	O
9	.	O

1	To	O
2	better	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	Ets	B
8	proteins	I
9	in	O
10	Ras	B
11	transformation	O
12	,	O
13	we	O
14	have	O
15	now	O
16	analyzed	O
17	the	O
18	effects	O
19	of	O
20	stably	O
21	expressing	O
22	a	O
23	variety	O
24	of	O
25	Ets2	B
26	constructs	I
27	in	O
28	Ras	B
29	-	O
30	transformed	O
31	NIH3T3	O
32	(	O
33	DT	O
34	)	O
35	cells	O
36	.	O

1	Each	O
2	binding	O
3	site	O
4	,	O
5	however	O
6	,	O
7	was	O
8	different	O
9	in	O
10	its	O
11	preference	O
12	for	O
13	binding	O
14	partners	O
15	.	O

1	We	O
2	isolated	O
3	the	O
4	human	B
5	FGF	I
6	-	I
7	BP	I
8	promoter	I
9	and	O
10	determined	O
11	by	O
12	deletion	O
13	analysis	O
14	that	O
15	TPA	O
16	regulatory	O
17	elements	O
18	were	O
19	all	O
20	contained	O
21	in	O
22	the	O
23	first	O
24	118	O
25	base	O
26	pairs	O
27	upstream	O
28	of	O
29	the	O
30	transcription	O
31	start	O
32	site	O
33	.	O

1	Manipulation	O
2	of	O
3	the	O
4	checkpoint	O
5	regulators	O
6	involved	O
7	in	O
8	cell	O
9	cycle	O
10	arrest	O
11	and	O
12	apoptosis	O
13	may	O
14	thus	O
15	provide	O
16	a	O
17	novel	O
18	strategy	O
19	to	O
20	cancer	O
21	therapy	O
22	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	demonstrated	O
6	specific	O
7	nuclear	O
8	protein	O
9	binding	O
10	to	O
11	-	O
12	85	O
13	/-	O
14	64	O
15	,	O
16	and	O
17	single	O
18	point	O
19	mutations	O
20	suggested	O
21	important	O
22	binding	O
23	nucleotides	O
24	between	O
25	-	O
26	79	O
27	/-	O
28	68	O
29	with	O
30	five	O
31	critical	O
32	bases	O
33	between	O
34	-	O
35	74	O
36	/-	O
37	70	O
38	(	O
39	5	O
40	'-	O
41	CTCCT	O
42	-	O
43	3	O
44	').	O

1	The	O
2	diagnostic	O
3	accuracy	O
4	of	O
5	serum	O
6	PE	B
7	-	I
8	1	I
9	was	O
10	0	O
11	.	O
12	80	O
13	,	O
14	and	O
15	that	O
16	of	O
17	amylase	B
18	0	O
19	.	O
20	97	O
21	.	O

1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	B
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	B
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	B
17	.	O

1	"	O
2	Complex	O
3	partial	O
4	"	O
5	seizures	O
6	.	O

1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	O
8	mediated	O
9	formation	O
10	of	O
11	a	O
12	SHP	B
13	-	I
14	2	I
15	-	O
16	pp120	B
17	complex	O
18	and	O
19	its	O
20	inhibition	O
21	by	O
22	Fc	B
23	gamma	I
24	RIIB1	I
25	-	O
26	BCR	B
27	coligation	O
28	.	O

1	Chem	O
2	.,	O
3	270	O
4	:	O
5	7117	O
6	-	O
7	7124	O
8	,	O
9	1995	O
10	;	O
11	and	O
12	MT	O
13	Hartsough	O
14	et	O
15	al	O
16	.,	O
17	J	O
18	.	O

1	Deleting	O
2	SNF1	B
3	repressed	O
4	meiosis	O
5	at	O
6	the	O
7	same	O
8	three	O
9	steps	O
10	that	O
11	were	O
12	inhibited	O
13	by	O
14	glucose	O
15	,	O
16	suggesting	O
17	that	O
18	glucose	O
19	blocks	O
20	meiosis	O
21	by	O
22	inhibiting	O
23	Snf1	B
24	.	O

1	Here	O
2	we	O
3	investigate	O
4	the	O
5	role	O
6	of	O
7	c	B
8	-	I
9	Cbl	I
10	in	O
11	development	O
12	and	O
13	homeostasis	O
14	in	O
15	mice	O
16	by	O
17	targeted	O
18	disruption	O
19	of	O
20	the	O
21	c	B
22	-	I
23	Cbl	I
24	locus	I
25	.	O
26	c	B
27	-	I
28	Cbl	I
29	-	O
30	deficient	O
31	mice	O
32	were	O
33	viable	O
34	,	O
35	fertile	O
36	,	O
37	and	O
38	outwardly	O
39	normal	O
40	in	O
41	appearance	O
42	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	We	O
2	propose	O
3	that	O
4	noi	B
5	/	O
6	pax2	B
7	.	I
8	1	I
9	participates	O
10	in	O
11	sequential	O
12	signaling	O
13	processes	O
14	as	O
15	a	O
16	key	O
17	integrator	O
18	of	O
19	midbrain	O
20	-	O
21	hindbrain	O
22	boundary	O
23	development	O
24	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	O
6	platelet	B
7	-	I
8	derived	I
9	growth	I
10	factor	I
11	receptor	I
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	METHODS	O
2	:	O
3	Fibrotic	O
4	changes	O
5	involving	O
6	bone	O
7	marrow	O
8	were	O
9	evaluated	O
10	histologically	O
11	semiquantitatively	O
12	using	O
13	reticulin	B
14	fiber	O
15	impregnation	O
16	(	O
17	method	O
18	of	O
19	Gomori	O
20	).	O

1	In	O
2	canrenoate	O
3	-	O
4	treated	O
5	rats	O
6	,	O
7	ANP	B
8	infusion	O
9	caused	O
10	greater	O
11	increases	O
12	in	O
13	sodium	O
14	excretion	O
15	(	O
16	FENA	O
17	from	O
18	3	O
19	.	O
20	05	O
21	+/-	O
22	0	O
23	.	O
24	71	O
25	to	O
26	7	O
27	.	O
28	21	O
29	+/-	O
30	0	O
31	.	O
32	45	O
33	%;	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	;	O
40	n	O
41	=	O
42	8	O
43	)	O
44	than	O
45	saline	O
46	infusion	O
47	(	O
48	FENA	O
49	from	O
50	4	O
51	.	O
52	16	O
53	+/-	O
54	1	O
55	.	O
56	11	O
57	to	O
58	5	O
59	.	O
60	47	O
61	+/-	O
62	0	O
63	.	O
64	66	O
65	%;	O
66	n	O
67	=	O
68	6	O
69	),	O
70	despite	O
71	the	O
72	hypocapnia	O
73	.	O

1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O

1	Removal	O
2	of	O
3	the	O
4	carboxyl	O
5	region	O
6	severely	O
7	reduced	O
8	transcriptional	O
9	activation	O
10	.	O

1	A	O
2	"	O
3	Level	O
4	A	O
5	"	O
6	in	O
7	vitro	O
8	/	O
9	in	O
10	vivo	O
11	correlation	O
12	was	O
13	established	O
14	for	O
15	a	O
16	sustained	O
17	release	O
18	theophylline	O
19	(	O
20	CAS	O
21	58	O
22	-	O
23	55	O
24	-	O
25	9	O
26	)	O
27	preparation	O
28	(	O
29	Bronchoretard	O
30	)	O
31	under	O
32	investigation	O
33	.	O

1	METHOD	O
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	O
42	serum	B
43	immunoglobulin	I
44	E	I
45	(	O
46	IgE	B
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	O
53	serum	B
54	IgE	I
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O

1	The	O
2	PDE4A	B
3	-	I
4	subfamily	I
5	-	I
6	specific	I
7	linker	I
8	region	I
9	LR1	O
10	,	O
11	which	O
12	joins	O
13	UCR1	O
14	and	O
15	UCR2	O
16	,	O
17	is	O
18	encoded	O
19	by	O
20	two	O
21	exons	O
22	,	O
23	whereas	O
24	LR2	O
25	,	O
26	which	O
27	joins	O
28	UCR2	O
29	to	O
30	the	O
31	catalytic	O
32	unit	O
33	,	O
34	is	O
35	encoded	O
36	by	O
37	a	O
38	single	O
39	exon	O
40	.	O

1	Pol32Delta	B
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	B
22	core	I
23	promoter	I
24	through	O
25	liver	B
26	-	I
27	specific	I
28	enhancer	I
29	II	I
30	and	O
31	HBx	B
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O

1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	expression	O
7	of	O
8	the	O
9	AtCP1	B
10	gene	I
11	,	O
12	northern	O
13	blot	O
14	analysis	O
15	was	O
16	carried	O
17	out	O
18	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	These	O
2	results	O
3	provide	O
4	the	O
5	first	O
6	demonstration	O
7	that	O
8	an	O
9	SR	B
10	protein	I
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	potential	O
6	for	O
7	prostate	O
8	cancer	O
9	chemoprevention	O
10	using	O
11	nonsteroidal	O
12	anti	O
13	-	O
14	inflammatory	O
15	drugs	O
16	(	O
17	cyclo	B
18	-	I
19	oxygenase	I
20	inhibitors	O
21	;	O
22	NSAIDs	O
23	)	O
24	has	O
25	received	O
26	little	O
27	attention	O
28	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	P	O
9	.	O
10	hybrida	O
11	gene	O
12	,	O
13	jaf13	B
14	,	O
15	encoding	O
16	a	O
17	basic	B
18	helix	I
19	-	I
20	loop	I
21	-	I
22	helix	I
23	protein	I
24	that	O
25	,	O
26	on	O
27	the	O
28	basis	O
29	of	O
30	sequence	O
31	homology	O
32	and	O
33	intron	O
34	/	O
35	exon	O
36	structure	O
37	,	O
38	represents	O
39	the	O
40	P	O
41	.	O
42	hybrida	O
43	orthologue	O
44	of	O
45	the	O
46	Z	B
47	.	I
48	mays	I
49	r	I
50	genes	I
51	.	O

1	Identical	O
2	c	B
3	-	I
4	erbB3	I
5	transcripts	I
6	are	O
7	expressed	O
8	in	O
9	normal	O
10	human	O
11	placental	O
12	tissues	O
13	.	O

1	During	O
2	the	O
3	past	O
4	4	O
5	years	O
6	,	O
7	a	O
8	purposeful	O
9	search	O
10	was	O
11	made	O
12	for	O
13	electrocardiograms	O
14	with	O
15	documented	O
16	reversible	O
17	QRS	O
18	changes	O
19	associated	O
20	with	O
21	all	O
22	acute	O
23	injury	O
24	pattern	O
25	.	O

1	Mutating	O
2	a	O
3	potential	O
4	cleavage	O
5	site	O
6	located	O
7	N	O
8	-	O
9	terminal	O
10	to	O
11	the	O
12	protease	O
13	domain	O
14	,	O
15	Gln2526	O
16	-	O
17	Asp2527	O
18	,	O
19	diminished	O
20	processing	O
21	.	O

1	METHODS	O
2	:	O
3	Millipore	O
4	ultrafiltration	O
5	membranes	O
6	of	O
7	three	O
8	different	O
9	pore	O
10	sizes	O
11	were	O
12	used	O
13	as	O
14	model	O
15	lenticule	O
16	materials	O
17	.	O
18	The	O
19	nominal	O
20	membrane	O
21	pore	O
22	sizes	O
23	were	O
24	0	O
25	.	O
26	1	O
27	microm	O
28	,	O
29	0	O
30	.	O
31	45	O
32	microm	O
33	,	O
34	and	O
35	3	O
36	microm	O
37	;	O
38	the	O
39	surface	O
40	roughness	O
41	increased	O
42	in	O
43	the	O
44	same	O
45	order	O
46	The	O
47	membranes	O
48	were	O
49	coated	O
50	with	O
51	a	O
52	thin	O
53	layer	O
54	of	O
55	collagen	B
56	I	I
57	and	O
58	implanted	O
59	in	O
60	a	O
61	circular	O
62	pocket	O
63	of	O
64	the	O
65	anterior	O
66	cornea	O
67	of	O
68	adult	O
69	cats	O
70	,	O
71	and	O
72	were	O
73	clinically	O
74	evaluated	O
75	for	O
76	the	O
77	extent	O
78	of	O
79	epithelialization	O
80	and	O
81	the	O
82	persistence	O
83	of	O
84	epithelial	O
85	attachment	O
86	.	O

1	The	O
2	role	O
3	of	O
4	calcitonin	B
5	,	O
6	and	O
7	other	O
8	agonists	O
9	which	O
10	activate	O
11	the	O
12	cAMP	O
13	pathway	O
14	,	O
15	in	O
16	regulating	O
17	transcription	O
18	of	O
19	the	O
20	human	B
21	parathyroid	I
22	hormone	I
23	-	I
24	related	I
25	protein	I
26	(	O
27	PTHrP	B
28	)	O
29	gene	O
30	was	O
31	investigated	O
32	in	O
33	a	O
34	human	O
35	lung	O
36	cancer	O
37	cell	O
38	line	O
39	(	O
40	BEN	O
41	).	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	B
5	and	O
6	another	O
7	homeodomain	B
8	protein	I
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	B
24	promoter	I
25	in	O
26	transfection	O
27	assays	O
28	.	O

1	The	O
2	biochemical	O
3	and	O
4	molecular	O
5	spectrum	O
6	of	O
7	ornithine	B
8	transcarbamylase	I
9	deficiency	O
10	.	O

1	To	O
2	further	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	cis	O
8	-	O
9	acting	O
10	elements	O
11	in	O
12	these	O
13	regulatory	O
14	mechanisms	O
15	,	O
16	we	O
17	have	O
18	characterized	O
19	a	O
20	transcriptional	O
21	promoter	O
22	that	O
23	drives	O
24	germline	O
25	expression	O
26	of	O
27	TCR	B
28	beta	I
29	gene	I
30	segments	I
31	in	O
32	vivo	O
33	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	B
13	-	I
14	erbA	I
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	B
24	-	I
25	ErbA	I
26	/	O
27	TRalpha	B
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O

1	Downregulation	O
2	of	O
3	FUS	B
4	expression	O
5	in	O
6	BCR	B
7	/	O
8	ABL	B
9	-	O
10	expressing	O
11	32Dcl3	O
12	cells	O
13	was	O
14	associated	O
15	with	O
16	suppression	O
17	of	O
18	growth	O
19	factor	O
20	-	O
21	independent	O
22	colony	O
23	formation	O
24	,	O
25	restoration	O
26	of	O
27	G	B
28	-	I
29	CSF	I
30	-	O
31	induced	O
32	granulocytic	O
33	differentiation	O
34	and	O
35	reduced	O
36	tumorigenic	O
37	potential	O
38	in	O
39	vivo	O
40	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	describe	O
7	a	O
8	mammalian	O
9	cell	O
10	-	O
11	free	O
12	transcription	O
13	system	O
14	reconstituted	O
15	with	O
16	only	O
17	recombinant	O
18	proteins	O
19	and	O
20	epitope	O
21	-	O
22	tagged	O
23	multiprotein	O
24	complexes	O
25	.	O

1	This	O
2	repressor	O
3	is	O
4	however	O
5	unlikely	O
6	to	O
7	mediate	O
8	spi	B
9	2	I
10	.	I
11	3	I
12	3	I
13	'	I
14	UTR	I
15	silencer	I
16	action	O
17	since	O
18	it	O
19	was	O
20	not	O
21	detected	O
22	in	O
23	rat	O
24	hepatocytes	O
25	.	O

1	A	O
2	prerequisite	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	sialylated	O
8	glycoconjugates	O
9	is	O
10	the	O
11	activated	O
12	sugar	O
13	-	O
14	nucleotide	O
15	cytidine	O
16	5	O
17	'-	O
18	monophosphate	O
19	N	O
20	-	O
21	acetylneuraminic	O
22	acid	O
23	(	O
24	CMP	O
25	-	O
26	Neu5Ac	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	B
34	sialyltransferases	I
35	.	O

1	Thus	O
2	,	O
3	the	O
4	bovine	B
5	PEDF	I
6	cDNA	I
7	isolated	O
8	here	O
9	codes	O
10	for	O
11	a	O
12	functional	O
13	soluble	O
14	secreted	B
15	PEDF	I
16	glycoprotein	I
17	.	O

1	We	O
2	propose	O
3	a	O
4	model	O
5	in	O
6	which	O
7	Sro7	B
8	function	O
9	is	O
10	involved	O
11	in	O
12	the	O
13	targeting	O
14	of	O
15	the	O
16	myosin	B
17	proteins	I
18	to	O
19	their	O
20	intrinsic	O
21	pathways	O
22	.	O

1	We	O
2	found	O
3	sequences	O
4	related	O
5	to	O
6	this	O
7	insertion	O
8	in	O
9	wild	O
10	-	O
11	type	O
12	strains	O
13	of	O
14	N	O
15	.	O
16	crassa	O
17	and	O
18	other	O
19	Neurospora	O
20	species	O
21	.	O

1	When	O
2	cysteine	O
3	is	O
4	scanned	O
5	through	O
6	the	O
7	helices	O
8	,	O
9	characteristic	O
10	repeating	O
11	patterns	O
12	of	O
13	solvent	O
14	exposure	O
15	and	O
16	burial	O
17	are	O
18	observed	O
19	.	O

1	Human	B
2	ULK1	I
3	,	O
4	a	O
5	novel	O
6	serine	B
7	/	I
8	threonine	I
9	kinase	I
10	related	O
11	to	O
12	UNC	B
13	-	I
14	51	I
15	kinase	I
16	of	O
17	Caenorhabditis	O
18	elegans	O
19	:	O
20	cDNA	O
21	cloning	O
22	,	O
23	expression	O
24	,	O
25	and	O
26	chromosomal	O
27	assignment	O
28	.	O

1	Specifically	O
2	,	O
3	I	O
4	use	O
5	molecular	O
6	markers	O
7	that	O
8	identify	O
9	particular	O
10	neuroectodermal	O
11	domains	O
12	,	O
13	all	O
14	neuroblasts	O
15	or	O
16	individual	O
17	neuroblasts	O
18	,	O
19	to	O
20	show	O
21	that	O
22	in	O
23	DER	B
24	mutant	I
25	embryos	O
26	(	O
27	1	O
28	)	O
29	intermediate	O
30	column	O
31	neuroblasts	O
32	do	O
33	not	O
34	form	O
35	,	O
36	(	O
37	2	O
38	)	O
39	medial	O
40	column	O
41	neuroblasts	O
42	often	O
43	acquire	O
44	identities	O
45	inappropriate	O
46	for	O
47	their	O
48	position	O
49	,	O
50	while	O
51	(	O
52	3	O
53	)	O
54	lateral	O
55	neuroblasts	O
56	develop	O
57	normally	O
58	.	O

1	Cochlear	O
2	microphonic	O
3	potentials	O
4	in	O
5	patients	O
6	with	O
7	vestibular	O
8	schwannomas	O
9	.	O

1	These	O
2	results	O
3	with	O
4	clozapine	O
5	illustrate	O
6	that	O
7	LI	O
8	is	O
9	sensitive	O
10	to	O
11	antipsychotics	O
12	which	O
13	differ	O
14	in	O
15	their	O
16	mode	O
17	of	O
18	action	O
19	and	O
20	furthermore	O
21	emphasize	O
22	the	O
23	value	O
24	of	O
25	LI	O
26	as	O
27	a	O
28	test	O
29	model	O
30	for	O
31	detecting	O
32	the	O
33	antipsychotic	O
34	potential	O
35	of	O
36	novel	O
37	drugs	O
38	.	O

1	The	O
2	complement	B
3	C3a	I
4	anaphylatoxin	I
5	receptor	I
6	(	O
7	C3aR	B
8	)	O
9	is	O
10	a	O
11	seven	B
12	-	I
13	transmembrane	I
14	G	I
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	B
25	peptide	I
26	ligand	I
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	were	O
6	performed	O
7	using	O
8	the	O
9	LPS	B
10	-	I
11	and	I
12	IL	I
13	-	I
14	1	I
15	-	I
16	responsive	I
17	element	I
18	(	O
19	LILRE	B
20	)	O
21	oligonucleotide	O
22	,	O
23	a	O
24	gamma	B
25	interferon	I
26	activation	I
27	site	I
28	-	I
29	like	I
30	site	I
31	that	O
32	is	O
33	present	O
34	in	O
35	the	O
36	human	B
37	IL	I
38	-	I
39	1beta	I
40	promoter	I
41	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	contains	O
7	the	O
8	PTP	B
9	-	I
10	like	I
11	domain	I
12	,	O
13	whereas	O
14	the	O
15	N	O
16	-	O
17	terminal	O
18	region	O
19	shows	O
20	no	O
21	homology	O
22	to	O
23	any	O
24	known	O
25	mammalian	O
26	protein	O
27	.	O

1	In	O
2	addition	O
3	,	O
4	and	O
5	in	O
6	support	O
7	of	O
8	a	O
9	mediating	O
10	role	O
11	of	O
12	STATs	B
13	in	O
14	the	O
15	activation	O
16	of	O
17	the	O
18	p21	B
19	promoter	I
20	,	O
21	overexpression	O
22	of	O
23	Stat3	B
24	potentiated	O
25	the	O
26	cytokine	O
27	effect	O
28	on	O
29	the	O
30	p21	B
31	promoter	I
32	;	O
33	whereas	O
34	a	O
35	dominant	B
36	negative	I
37	Stat3	I
38	,	O
39	or	O
40	a	O
41	mutation	O
42	of	O
43	the	O
44	STAT	B
45	response	I
46	element	I
47	on	O
48	the	O
49	promoter	O
50	,	O
51	significantly	O
52	reduced	O
53	the	O
54	cytokine	O
55	effect	O
56	.	O

1	The	O
2	heterogeneous	O
3	nuclear	B
4	ribonucleoprotein	I
5	C	I
6	protein	I
7	tetramer	I
8	binds	O
9	U1	B
10	,	O
11	U2	B
12	,	O
13	and	O
14	U6	B
15	snRNAs	I
16	through	O
17	its	O
18	high	O
19	affinity	O
20	RNA	O
21	binding	O
22	domain	O
23	(	O
24	the	O
25	bZIP	O
26	-	O
27	like	O
28	motif	O
29	).	O

1	On	O
2	the	O
3	comparison	O
4	of	O
5	correlated	O
6	proportions	O
7	for	O
8	clustered	O
9	data	O
10	.	O

1	A	O
2	safe	O
3	and	O
4	simple	O
5	system	O
6	for	O
7	the	O
8	detection	O
9	of	O
10	sudden	O
11	infant	O
12	death	O
13	syndrome	O
14	(	O
15	SIDS	O
16	)	O
17	is	O
18	proposed	O
19	.	O

1	The	O
2	resulting	O
3	mutants	O
4	were	O
5	coexpressed	O
6	with	O
7	gE	B
8	in	O
9	the	O
10	vaccinia	O
11	virus	O
12	-	O
13	based	O
14	vTF7	O
15	-	O
16	3	O
17	system	O
18	,	O
19	and	O
20	the	O
21	formation	O
22	and	O
23	endoplasmic	O
24	reticulum	O
25	(	O
26	ER	O
27	)-	O
28	to	O
29	-	O
30	Golgi	O
31	transport	O
32	of	O
33	the	O
34	hetero	O
35	-	O
36	oligomeric	O
37	complex	O
38	were	O
39	monitored	O
40	.	O

1	Homozygous	O
2	mutant	O
3	mice	O
4	,	O
5	designated	O
6	Cux	B
7	/	O
8	CDPDeltaCR1	B
9	,	O
10	display	O
11	a	O
12	phenotype	O
13	characterized	O
14	by	O
15	curly	O
16	vibrissae	O
17	and	O
18	wavy	O
19	hair	O
20	.	O

1	The	O
2	mutant	O
3	protein	O
4	is	O
5	present	O
6	at	O
7	levels	O
8	slightly	O
9	greater	O
10	than	O
11	wild	O
12	-	O
13	type	O
14	,	O
15	but	O
16	exhibits	O
17	the	O
18	same	O
19	tissue	O
20	distribution	O
21	as	O
22	wild	O
23	-	O
24	type	O
25	protein	O
26	,	O
27	and	O
28	has	O
29	approximately	O
30	normal	O
31	affinity	O
32	for	O
33	known	O
34	target	O
35	sequences	O
36	(	O
37	though	O
38	no	O
39	DNA	O
40	targets	O
41	identified	O
42	to	O
43	date	O
44	require	O
45	the	O
46	first	O
47	cut	O
48	repeat	O
49	for	O
50	binding	O
51	).	O

1	METHODS	O
2	:	O
3	We	O
4	retrospectively	O
5	reviewed	O
6	242	O
7	adult	O
8	cadaveric	O
9	renal	O
10	transplant	O
11	recipients	O
12	treated	O
13	between	O
14	11	O
15	/	O
16	91	O
17	and	O
18	5	O
19	/	O
20	97	O
21	.	O

1	The	O
2	spectrum	O
3	of	O
4	age	O
5	-	O
6	associated	O
7	brain	O
8	abnormalities	O
9	:	O
10	their	O
11	measurement	O
12	and	O
13	histopathological	O
14	correlates	O
15	.	O

1	Our	O
2	laboratory	O
3	has	O
4	recently	O
5	identified	O
6	two	O
7	phosducin	B
8	-	I
9	like	I
10	orphan	I
11	proteins	I
12	(	O
13	PhLOP1	B
14	and	O
15	PhLOP2	B
16	)	O
17	that	O
18	lack	O
19	the	O
20	ability	O
21	to	O
22	interact	O
23	with	O
24	Gbetagamma	B
25	.	O

1	Reverse	B
2	transcriptase	I
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	B
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	In	O
2	contrast	O
3	,	O
4	transcription	O
5	initiating	O
6	from	O
7	opuE	B
8	P	I
9	-	I
10	1	I
11	(	O
12	sigma	B
13	A	I
14	)	O
15	rose	O
16	in	O
17	proportion	O
18	to	O
19	the	O
20	external	O
21	osmolarity	O
22	and	O
23	was	O
24	maintained	O
25	at	O
26	high	O
27	levels	O
28	.	O

1	Randomly	O
2	selected	O
3	300	O
4	children	O
5	aged	O
6	3	O
7	months	O
8	-	O
9	3	O
10	yr	O
11	were	O
12	analysed	O
13	over	O
14	a	O
15	period	O
16	of	O
17	one	O
18	year	O
19	for	O
20	estimating	O
21	prevalence	O
22	of	O
23	nutritional	O
24	anaemia	O
25	.	O

1	In	O
2	insects	O
3	,	O
4	arylalkylamine	B
5	N	I
6	-	I
7	acetyltransferases	I
8	(	O
9	AANATs	B
10	)	O
11	have	O
12	been	O
13	implicated	O
14	in	O
15	several	O
16	physiological	O
17	processes	O
18	,	O
19	including	O
20	sclerotization	O
21	,	O
22	inactivation	O
23	of	O
24	certain	O
25	neurotransmitters	O
26	,	O
27	and	O
28	,	O
29	similar	O
30	to	O
31	the	O
32	function	O
33	in	O
34	vertebrates	O
35	,	O
36	catalysis	O
37	of	O
38	the	O
39	rate	O
40	-	O
41	limiting	O
42	step	O
43	in	O
44	melatonin	O
45	biosynthesis	O
46	.	O

1	In	O
2	experiments	O
3	with	O
4	the	O
5	D1	O
6	antagonist	O
7	SCH	O
8	23390	O
9	,	O
10	buprenorphine	O
11	-	O
12	induced	O
13	depression	O
14	was	O
15	consistently	O
16	blocked	O
17	,	O
18	but	O
19	facilitation	O
20	was	O
21	unaffected	O
22	.	O

1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O

1	IA	O
2	-	O
3	CT	O
4	with	O
5	cisplatin	O
6	50	O
7	mg	O
8	and	O
9	doxorubicin	O
10	30	O
11	mg	O
12	was	O
13	administered	O
14	by	O
15	one	O
16	shot	O
17	method	O
18	in	O
19	bilateral	O
20	internal	O
21	iliac	O
22	arteries	O
23	.	O

1	Arnt3	B
2	mRNA	I
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	P19	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O

1	Acute	O
2	idiopathic	O
3	thrombocytopenic	O
4	purpura	O
5	presenting	O
6	a	O
7	high	O
8	serum	O
9	level	O
10	of	O
11	immunoglobulin	B
12	E	I
13	and	O
14	eosinophilia	O
15	in	O
16	an	O
17	elderly	O
18	patient	O
19	.	O

1	The	O
2	genomic	O
3	structure	O
4	and	O
5	chromosomal	O
6	location	O
7	of	O
8	the	O
9	human	B
10	TR2	I
11	orphan	I
12	receptor	I
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	steroid	B
19	receptor	I
20	superfamily	I
21	.	O

1	Correlation	O
2	of	O
3	skin	O
4	disorders	O
5	with	O
6	CD4	B
7	lymphocyte	O
8	counts	O
9	in	O
10	patients	O
11	with	O
12	HIV	O
13	/	O
14	AIDS	O
15	.	O

1	E2F	B
2	-	I
3	6	I
4	shares	O
5	significant	O
6	homology	O
7	with	O
8	E2Fs	B
9	1	I
10	-	I
11	5	I
12	,	O
13	especially	O
14	within	O
15	the	O
16	DNA	O
17	binding	O
18	,	O
19	heterodimerization	O
20	and	O
21	marked	O
22	box	O
23	domains	O
24	.	O

1	The	O
2	IE13	O
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	I
31	gene	I
32	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	analyses	O
9	revealed	O
10	two	O
11	hepatocyte	B
12	nuclear	I
13	factor	I
14	-	I
15	1	I
16	(	O
17	HNF1	B
18	),	O
19	three	O
20	CCAAT	B
21	/	I
22	enhancer	I
23	-	I
24	binding	I
25	protein	I
26	(	O
27	C	B
28	/	I
29	EBP	I
30	),	O
31	and	O
32	one	O
33	consensus	O
34	palindromic	O
35	thyroid	O
36	hormone	O
37	response	O
38	elements	O
39	within	O
40	the	O
41	first	O
42	215	O
43	base	O
44	pairs	O
45	(	O
46	bp	O
47	)	O
48	of	O
49	the	O
50	promoter	O
51	sequence	O
52	of	O
53	rat	B
54	Std	I
55	.	O

1	Thus	O
2	,	O
3	these	O
4	studies	O
5	on	O
6	rat	B
7	Std	I
8	promoter	I
9	function	O
10	indicate	O
11	that	O
12	(	O
13	i	O
14	)	O
15	HNF1	B
16	and	O
17	C	B
18	/	I
19	EBP	I
20	are	O
21	responsible	O
22	for	O
23	liver	O
24	specificity	O
25	of	O
26	the	O
27	rat	B
28	Std	I
29	gene	I
30	;	O
31	(	O
32	ii	O
33	)	O
34	androgenic	O
35	repression	O
36	of	O
37	the	O
38	gene	O
39	requires	O
40	the	O
41	presence	O
42	of	O
43	all	O
44	of	O
45	the	O
46	OCT	B
47	-	I
48	1	I
49	and	O
50	C	B
51	/	I
52	EBP	I
53	elements	I
54	between	O
55	positions	O
56	-	O
57	231	O
58	and	O
59	-	O
60	292	O
61	;	O
62	and	O
63	(	O
64	iii	O
65	)	O
66	AR	B
67	may	O
68	exert	O
69	its	O
70	negative	O
71	regulatory	O
72	effect	O
73	indirectly	O
74	through	O
75	transcriptional	O
76	interference	O
77	of	O
78	OCT	B
79	-	I
80	1	I
81	and	O
82	C	B
83	/	I
84	EBP	I
85	rather	O
86	than	O
87	through	O
88	a	O
89	direct	O
90	DNA	B
91	-	I
92	AR	I
93	interaction	O
94	.	O

1	Purified	O
2	Hsk1	B
3	phosphorylates	O
4	the	O
5	Cdc19	B
6	(	O
7	Mcm2	B
8	)	O
9	subunit	O
10	of	O
11	the	O
12	six	B
13	-	I
14	member	I
15	minichromosome	I
16	maintenance	I
17	protein	I
18	complex	I
19	purified	O
20	from	O
21	fission	O
22	yeast	O
23	.	O

1	The	O
2	yeast	B
3	MMS2	I
4	gene	I
5	was	O
6	cloned	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	the	O
13	methyl	O
14	methanesulfonate	O
15	sensitivity	O
16	of	O
17	the	O
18	mms2	B
19	-	I
20	1	I
21	mutant	I
22	and	O
23	was	O
24	later	O
25	shown	O
26	to	O
27	be	O
28	involved	O
29	in	O
30	DNA	O
31	post	O
32	-	O
33	replication	O
34	repair	O
35	.	O

1	Expression	O
2	of	O
3	the	O
4	human	B
5	papillomavirus	I
6	type	I
7	11	I
8	E5A	I
9	protein	I
10	from	O
11	the	O
12	E1E4	B
13	,	I
14	E5	I
15	transcript	I
16	.	O

1	Anesthesia	O
2	with	O
3	M	O
4	/	O
5	K	O
6	was	O
7	reversed	O
8	after	O
9	41	O
10	.	O
11	6	O
12	min	O
13	of	O
14	immobilization	O
15	with	O
16	atipamezole	O
17	.	O

1	There	O
2	was	O
3	no	O
4	evident	O
5	inciting	O
6	agent	O
7	of	O
8	the	O
9	disease	O
10	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	distribution	O
6	of	O
7	endocytic	O
8	markers	O
9	is	O
10	not	O
11	affected	O
12	.	O

1	Toxicity	O
2	during	O
3	the	O
4	therapeutic	O
5	period	O
6	was	O
7	not	O
8	significant	O
9	in	O
10	the	O
11	study	O
12	group	O
13	compared	O
14	with	O
15	the	O
16	historical	O
17	control	O
18	,	O
19	treated	O
20	with	O
21	the	O
22	same	O
23	regimen	O
24	without	O
25	G	B
26	-	I
27	CSF	I
28	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	article	O
6	is	O
7	to	O
8	discuss	O
9	the	O
10	factors	O
11	involved	O
12	in	O
13	the	O
14	selection	O
15	of	O
16	antibodies	O
17	,	O
18	radionuclides	O
19	and	O
20	labeling	O
21	methods	O
22	in	O
23	the	O
24	development	O
25	of	O
26	radioimmunotherapy	O
27	(	O
28	RIT	O
29	)	O
30	for	O
31	non	O
32	-	O
33	Hodgkin	O
34	'	O
35	s	O
36	lymphoma	O
37	(	O
38	NHL	O
39	)	O
40	from	O
41	a	O
42	single	O
43	clinical	O
44	study	O
45	site	O
46	through	O
47	multicenter	O
48	trials	O
49	and	O
50	commercialization	O
51	.	O

1	Both	O
2	methods	O
3	were	O
4	employed	O
5	for	O
6	various	O
7	focal	O
8	-	O
9	film	O
10	distances	O
11	,	O
12	image	O
13	intensifier	O
14	tube	O
15	modes	O
16	and	O
17	laser	O
18	printer	O
19	formats	O
20	.	O

1	The	O
2	effect	O
3	of	O
4	Rho	B
5	on	O
6	AP	B
7	-	I
8	1	I
9	is	O
10	independent	O
11	of	O
12	the	O
13	mitogen	B
14	-	I
15	activated	I
16	protein	I
17	kinase	I
18	pathway	O
19	,	O
20	as	O
21	a	O
22	dominant	B
23	-	I
24	negative	I
25	MEK	I
26	and	O
27	a	O
28	MEK	B
29	inhibitor	O
30	(	O
31	PD98059	O
32	)	O
33	did	O
34	not	O
35	affect	O
36	Rho	B
37	-	O
38	induced	O
39	AP	B
40	-	I
41	1	I
42	activity	O
43	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	residues	O
7	in	O
8	this	O
9	domain	O
10	(	O
11	R82A	O
12	,	O
13	K85A	O
14	,	O
15	K88A	O
16	,	O
17	and	O
18	V89A	O
19	)	O
20	resulted	O
21	in	O
22	proteins	O
23	which	O
24	failed	O
25	to	O
26	transactivate	O
27	from	O
28	the	O
29	HTLV	B
30	-	I
31	1	I
32	LTR	I
33	in	O
34	vivo	O
35	.	O

1	Mutations	O
2	within	O
3	the	O
4	C	O
5	terminus	O
6	of	O
7	c	B
8	-	I
9	fos	I
10	at	O
11	serine	O
12	residues	O
13	that	O
14	are	O
15	phosphorylation	O
16	targets	O
17	for	O
18	growth	O
19	factors	O
20	and	O
21	MAP	B
22	kinase	I
23	completely	O
24	abrogate	O
25	transactivation	O
26	and	O
27	block	O
28	potentiation	O
29	by	O
30	MAP	B
31	kinase	I
32	.	O

1	In	O
2	the	O
3	former	O
4	cells	O
5	,	O
6	ets	B
7	-	I
8	2	I
9	was	O
10	a	O
11	CSF	B
12	-	I
13	1	I
14	immediate	O
15	-	O
16	early	O
17	response	O
18	gene	O
19	,	O
20	and	O
21	phosphorylated	O
22	ets	B
23	-	I
24	2	I
25	was	O
26	detected	O
27	after	O
28	2	O
29	to	O
30	4	O
31	h	O
32	,	O
33	coincident	O
34	with	O
35	expression	O
36	of	O
37	ets	B
38	-	I
39	2	I
40	protein	I
41	.	O

1	Persistent	O
2	activation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	kinases	I
9	p42	I
10	and	O
11	p44	B
12	and	O
13	ets	B
14	-	I
15	2	I
16	phosphorylation	O
17	in	O
18	response	O
19	to	O
20	colony	B
21	-	I
22	stimulating	I
23	factor	I
24	1	I
25	/	O
26	c	B
27	-	I
28	fms	I
29	signaling	O
30	.	O

1	Identification	O
2	of	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	sequence	O
8	in	O
9	the	O
10	CD2	B
11	cytoplasmic	I
12	domain	I
13	critical	O
14	for	O
15	regulation	O
16	of	O
17	integrin	B
18	-	O
19	mediated	O
20	adhesion	O
21	and	O
22	activation	O
23	of	O
24	phosphoinositide	B
25	3	I
26	-	I
27	kinase	I
28	.	O

1	Vam7p	B
2	,	O
3	a	O
4	SNAP	B
5	-	I
6	25	I
7	-	I
8	like	I
9	molecule	I
10	,	O
11	and	O
12	Vam3p	B
13	,	O
14	a	O
15	syntaxin	B
16	homolog	I
17	,	O
18	function	O
19	together	O
20	in	O
21	yeast	O
22	vacuolar	O
23	protein	O
24	trafficking	O
25	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	possibility	O
6	by	O
7	constructing	O
8	a	O
9	consecutive	O
10	series	O
11	of	O
12	cysteine	O
13	substitutions	O
14	in	O
15	the	O
16	Neu	B
17	juxtamembrane	I
18	domain	I
19	in	O
20	order	O
21	to	O
22	force	O
23	dimerization	O
24	along	O
25	a	O
26	series	O
27	of	O
28	interreceptor	O
29	faces	O
30	.	O

1	It	O
2	has	O
3	been	O
4	demonstrated	O
5	previously	O
6	that	O
7	Pax	B
8	-	I
9	6	I
10	,	O
11	a	O
12	paired	B
13	domain	I
14	(	O
15	PD	B
16	)/	O
17	homeodomain	B
18	(	O
19	HD	B
20	)	O
21	transcription	O
22	factor	O
23	critical	O
24	for	O
25	eye	O
26	development	O
27	,	O
28	contributes	O
29	to	O
30	the	O
31	activation	O
32	of	O
33	the	O
34	alphaB	B
35	-,	I
36	alphaA	I
37	-,	I
38	delta1	I
39	-,	I
40	and	I
41	zeta	I
42	-	I
43	crystallin	I
44	genes	O
45	in	O
46	the	O
47	lens	O
48	.	O

1	Tctex	B
2	-	I
3	1	I
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	O

1	The	O
2	prothrombin	B
3	gene	I
4	G20210A	I
5	mutation	I
6	is	O
7	not	O
8	found	O
9	among	O
10	Japanese	O
11	patients	O
12	with	O
13	deep	O
14	vein	O
15	thrombosis	O
16	and	O
17	healthy	O
18	individuals	O
19	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	GluR2	B
6	gene	I
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O

1	The	O
2	binding	O
3	of	O
4	NF	B
5	-	I
6	ATp	I
7	,	O
8	although	O
9	not	O
10	NF	B
11	-	I
12	AT4	I
13	,	O
14	to	O
15	this	O
16	enhancer	O
17	also	O
18	occurs	O
19	along	O
20	with	O
21	HTLV	O
22	-	O
23	I	O
24	-	O
25	mediated	O
26	infection	O
27	of	O
28	human	O
29	peripheral	O
30	blood	O
31	T	O
32	-	O
33	cells	O
34	.	O

1	Thus	O
2	,	O
3	TRAF2	B
4	initiates	O
5	SAPK	B
6	and	O
7	p38	B
8	activation	O
9	by	O
10	binding	O
11	two	O
12	proximal	O
13	protein	O
14	kinases	O
15	:	O
16	GCK	B
17	and	O
18	RIP	B
19	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	signaling	O
5	to	O
6	stress	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	(	O
12	SAPK	B
13	)/	O
14	Jun	B
15	NH2	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	)	O
22	and	O
23	p38	B
24	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	Sp3	B
25	,	O
26	and	O
27	NF	B
28	-	I
29	Y	I
30	.	O

1	In	O
2	the	O
3	studies	O
4	described	O
5	in	O
6	this	O
7	report	O
8	,	O
9	we	O
10	have	O
11	investigated	O
12	the	O
13	signaling	O
14	pathway	O
15	(	O
16	s	O
17	)	O
18	that	O
19	are	O
20	responsible	O
21	for	O
22	CREB	B
23	activation	O
24	in	O
25	normal	O
26	T	O
27	cells	O
28	.	O

1	Respondents	O
2	who	O
3	lived	O
4	with	O
5	a	O
6	spouse	O
7	/	O
8	partner	O
9	only	O
10	were	O
11	less	O
12	likely	O
13	to	O
14	have	O
15	an	O
16	unfavorable	O
17	BMI	O
18	status	O
19	than	O
20	people	O
21	in	O
22	the	O
23	other	O
24	two	O
25	groups	O
26	.	O

1	Isolation	O
2	of	O
3	a	O
4	novel	O
5	TP53	B
6	target	I
7	gene	I
8	from	O
9	a	O
10	colon	O
11	cancer	O
12	cell	O
13	line	O
14	carrying	O
15	a	O
16	highly	O
17	regulated	O
18	wild	B
19	-	I
20	type	I
21	TP53	I
22	expression	O
23	system	O
24	.	O

1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	Cytogenetic	O
2	and	O
3	molecular	O
4	characterization	O
5	of	O
6	random	O
7	chromosomal	O
8	rearrangements	O
9	activating	O
10	the	O
11	drug	O
12	resistance	O
13	gene	O
14	,	O
15	MDR1	B
16	/	O
17	P	B
18	-	I
19	glycoprotein	I
20	,	O
21	in	O
22	drug	O
23	-	O
24	selected	O
25	cell	O
26	lines	O
27	and	O
28	patients	O
29	with	O
30	drug	O
31	refractory	O
32	ALL	O
33	.	O

1	BACKGROUND	O
2	:	O
3	It	O
4	is	O
5	generally	O
6	accepted	O
7	that	O
8	smoking	O
9	increases	O
10	blood	O
11	pressure	O
12	and	O
13	inhibits	O
14	muscle	O
15	sympathetic	O
16	nerve	O
17	activity	O
18	(	O
19	SNA	O
20	).	O

1	When	O
2	the	O
3	blood	O
4	pressure	O
5	increase	O
6	in	O
7	response	O
8	to	O
9	smoking	O
10	was	O
11	blunted	O
12	by	O
13	nitroprusside	O
14	infusion	O
15	,	O
16	there	O
17	was	O
18	a	O
19	striking	O
20	increase	O
21	in	O
22	muscle	O
23	SNA	O
24	.	O

1	After	O
2	that	O
3	report	O
4	,	O
5	carboxypeptidase	B
6	D	I
7	(	O
8	CPD	B
9	)	O
10	was	O
11	subsequently	O
12	purified	O
13	from	O
14	bovine	O
15	pituitary	O
16	and	O
17	characterized	O
18	as	O
19	a	O
20	novel	O
21	carboxypeptidase	B
22	E	I
23	(	O
24	CPE	B
25	)-	O
26	like	O
27	enzyme	O
28	,	O
29	with	O
30	many	O
31	characteristics	O
32	in	O
33	common	O
34	with	O
35	duck	O
36	gp180	B
37	(	O
38	Song	O
39	,	O
40	L	O
41	.,	O
42	Fricker	O
43	,	O
44	L	O
45	.	O
46	D	O
47	.,	O
48	1995	O
49	.	O

1	RA	O
2	-	O
3	treatment	O
4	of	O
5	these	O
6	transfectants	O
7	induced	O
8	morphologic	O
9	and	O
10	immunophenotypic	O
11	maturation	O
12	,	O
13	changes	O
14	in	O
15	RA	O
16	-	O
17	regulated	O
18	genes	O
19	,	O
20	and	O
21	a	O
22	G1	O
23	cell	O
24	cycle	O
25	arrest	O
26	in	O
27	a	O
28	manner	O
29	similar	O
30	to	O
31	parental	O
32	NT2	O
33	/	O
34	D1	O
35	cells	O
36	.	O

1	The	O
2	histopathology	O
3	and	O
4	neovascularization	O
5	did	O
6	not	O
7	appreciably	O
8	differ	O
9	between	O
10	xenograft	O
11	tumors	O
12	derived	O
13	from	O
14	FGF4	B
15	over	O
16	-	O
17	expressing	O
18	versus	O
19	control	O
20	transfectants	O
21	.	O

1	For	O
2	smaller	O
3	vessels	O
4	up	O
5	to	O
6	a	O
7	diameter	O
8	of	O
9	0	O
10	.	O
11	5	O
12	mm	O
13	,	O
14	treatments	O
15	at	O
16	16	O
17	and	O
18	18	O
19	J	O
20	/	O
21	cm2	O
22	showed	O
23	good	O
24	results	O
25	in	O
26	60	O
27	and	O
28	82	O
29	%	O
30	respectively	O
31	;	O
32	for	O
33	vessels	O
34	up	O
35	to	O
36	1	O
37	mm	O
38	in	O
39	27	O
40	and	O
41	33	O
42	%.	O

1	Pressure	O
2	ulcers	O
3	.	O

1	RXR	B
2	-	I
3	gamma	I
4	expression	O
5	produced	O
6	significant	O
7	reduction	O
8	in	O
9	levels	O
10	of	O
11	RA	O
12	-	O
13	responsive	O
14	genes	O
15	including	O
16	the	O
17	cyclin	B
18	-	I
19	dependent	I
20	kinase	I
21	inhibitors	O
22	p21Cip1	B
23	/	O
24	WAF1	B
25	and	O
26	p27Kip1	B
27	,	O
28	resulting	O
29	in	O
30	increased	O
31	cdc2	B
32	and	O
33	cdk2	B
34	kinase	I
35	activity	O
36	and	O
37	RB	B
38	phosphorylation	O
39	.	O

1	TBP	B
2	can	O
3	be	O
4	phosphorylated	O
5	in	O
6	vitro	O
7	by	O
8	extracts	O
9	of	O
10	U937	O
11	cells	O
12	or	O
13	by	O
14	bacterially	O
15	expressed	O
16	activated	O
17	ERK2	B
18	;	O
19	the	O
20	phosphorylation	O
21	sites	O
22	were	O
23	mapped	O
24	to	O
25	ERK	B
26	kinase	I
27	consensus	I
28	sites	I
29	in	O
30	the	O
31	TBP	B
32	amino	I
33	-	I
34	terminal	I
35	domain	I
36	.	O

1	During	O
2	the	O
3	CR	O
4	/	O
5	PP	O
6	diet	O
7	only	O
8	the	O
9	HS	O
10	subjects	O
11	did	O
12	not	O
13	show	O
14	the	O
15	stress	O
16	-	O
17	induced	O
18	rise	O
19	in	O
20	depression	O
21	,	O
22	decline	O
23	in	O
24	vigour	O
25	and	O
26	cortisol	O
27	elevation	O
28	that	O
29	they	O
30	showed	O
31	after	O
32	the	O
33	PR	O
34	/	O
35	CP	O
36	diet	O
37	.	O

1	Generally	O
2	ILC	O
3	and	O
4	ILVF	O
5	values	O
6	decreased	O
7	with	O
8	increasing	O
9	exposure	O
10	time	O
11	with	O
12	rate	O
13	constants	O
14	ranging	O
15	from	O
16	0	O
17	.	O
18	03	O
19	to	O
20	0	O
21	.	O
22	33	O
23	day	O
24	-	O
25	1	O
26	(	O
27	wet	O
28	and	O
29	lipid	O
30	weight	O
31	)	O
32	for	O
33	ILC	O
34	and	O
35	0	O
36	.	O
37	03	O
38	to	O
39	0	O
40	.	O
41	31	O
42	day	O
43	-	O
44	1	O
45	for	O
46	ILVF	O
47	.	O

1	These	O
2	sequence	O
3	analyses	O
4	suggest	O
5	that	O
6	xIRS	B
7	-	I
8	u	I
9	is	O
10	a	O
11	novel	O
12	member	O
13	of	O
14	the	O
15	IRS	B
16	family	I
17	rather	O
18	than	O
19	a	O
20	Xenopus	O
21	homolog	O
22	of	O
23	an	O
24	existing	O
25	member	O
26	.	O

1	The	O
2	present	O
3	study	O
4	sought	O
5	to	O
6	develop	O
7	an	O
8	equation	O
9	to	O
10	estimate	O
11	VO2peak	O
12	in	O
13	peripheral	O
14	arterial	O
15	occlusive	O
16	disease	O
17	(	O
18	PAOD	O
19	)	O
20	patients	O
21	with	O
22	intermittent	O
23	claudication	O
24	and	O
25	to	O
26	determine	O
27	independent	O
28	predictors	O
29	of	O
30	VO2peak	O
31	in	O
32	this	O
33	population	O
34	.	O

1	Evidence	O
2	for	O
3	a	O
4	novel	O
5	MAPKKK	B
6	-	O
7	independent	O
8	pathway	O
9	controlling	O
10	the	O
11	stress	O
12	activated	O
13	Sty1	B
14	/	O
15	Spc1	B
16	MAP	O
17	kinase	O
18	in	O
19	fission	O
20	yeast	O
21	.	O

1	The	O
2	Abbreviated	O
3	Injury	O
4	Scale	O
5	(	O
6	AIS	O
7	),	O
8	Injury	O
9	Severity	O
10	Scale	O
11	and	O
12	TRISS	O
13	methodology	O
14	comprise	O
15	a	O
16	mathematically	O
17	sound	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	injured	O
26	patients	O
27	.	O

1	This	O
2	hypothesis	O
3	was	O
4	tested	O
5	by	O
6	introducing	O
7	mutations	O
8	at	O
9	each	O
10	of	O
11	the	O
12	three	O
13	histidine	O
14	pairs	O
15	,	O
16	the	O
17	H382	O
18	-	O
19	X2	O
20	-	O
21	H385	O
22	pair	O
23	,	O
24	the	O
25	H411	O
26	-	O
27	X2	O
28	-	O
29	H414	O
30	pair	O
31	and	O
32	the	O
33	H430	O
34	-	O
35	X5	O
36	-	O
37	H436	O
38	pair	O
39	,	O
40	which	O
41	constitute	O
42	the	O
43	histidine	O
44	-	O
45	rich	O
46	region	O
47	near	O
48	the	O
49	C	O
50	terminus	O
51	of	O
52	gp17	B
53	.	O

1	Using	O
2	backcross	O
3	analysis	O
4	,	O
5	both	O
6	exons	O
7	1	O
8	and	O
9	4	O
10	mapped	O
11	to	O
12	a	O
13	proximal	O
14	region	O
15	of	O
16	murine	O
17	Chromosome	O
18	4	O
19	indistinguishable	O
20	from	O
21	the	O
22	vacillans	B
23	gene	I
24	.	O

1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O

1	However	O
2	,	O
3	both	O
4	TPN	O
5	groups	O
6	showed	O
7	a	O
8	marked	O
9	increase	O
10	in	O
11	activities	O
12	of	O
13	liver	O
14	lysosomal	B
15	enzymes	I
16	.	O

1	Regulation	O
2	of	O
3	embryonic	O
4	growth	O
5	and	O
6	lysosomal	O
7	targeting	O
8	by	O
9	the	O
10	imprinted	O
11	Igf2	B
12	/	O
13	Mpr	B
14	gene	O
15	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	Galpha11	B
7	Q209L	I
8	stimulated	O
9	Src	B
10	family	I
11	kinase	O
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	HEK	O
22	-	O
23	293	O
24	cells	O
25	.	O

1	The	O
2	micturition	O
3	pressure	O
4	was	O
5	significantly	O
6	decreased	O
7	only	O
8	after	O
9	injection	O
10	with	O
11	BUP	O
12	-	O
13	4	O
14	in	O
15	both	O
16	normal	O
17	and	O
18	obstructed	O
19	rats	O
20	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPAR	B
8	)	O
9	modulate	O
10	transcription	O
11	by	O
12	binding	O
13	to	O
14	specific	O
15	peroxisome	O
16	proliferator	O
17	-	O
18	response	O
19	elements	O
20	(	O
21	PPRE	O
22	)	O
23	through	O
24	heterodimerization	O
25	with	O
26	the	O
27	9	B
28	-	I
29	cis	I
30	retinoic	I
31	acid	I
32	receptor	I
33	(	O
34	RXR	B
35	).	O

1	Furthermore	O
2	,	O
3	early	O
4	-	O
5	and	O
6	late	O
7	-	O
8	firing	O
9	origins	O
10	differ	O
11	not	O
12	in	O
13	the	O
14	timing	O
15	of	O
16	their	O
17	recruitment	O
18	of	O
19	an	O
20	Mcm	B
21	protein	I
22	,	O
23	but	O
24	in	O
25	the	O
26	timing	O
27	of	O
28	RPA	B
29	'	I
30	s	I
31	recruitment	O
32	.	O

1	Thus	O
2	,	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	active	B
8	S	I
9	-	I
10	CDKs	I
11	and	O
12	Dbf4	B
13	/	O
14	Cdc7	B
15	,	O
16	Mcms	B
17	may	O
18	open	O
19	origins	O
20	and	O
21	thereby	O
22	facilitate	O
23	the	O
24	loading	O
25	of	O
26	RPA	B
27	.	O

1	Tyrosine	O
2	phosphorylated	O
3	STATs	B
4	dimerize	O
5	and	O
6	translocate	O
7	into	O
8	the	O
9	nucleus	O
10	to	O
11	activate	O
12	specific	O
13	genes	O
14	.	O

1	Nonsynonymous	O
2	substitution	O
3	in	O
4	abalone	O
5	sperm	O
6	fertilization	O
7	genes	O
8	exceeds	O
9	substitution	O
10	in	O
11	introns	O
12	and	O
13	mitochondrial	O
14	DNA	O
15	.	O

1	Gel	O
2	retardation	O
3	assays	O
4	detected	O
5	ZiaR	B
6	-	O
7	dependent	O
8	complexes	O
9	forming	O
10	with	O
11	the	O
12	zia	B
13	operator	I
14	-	I
15	promoter	I
16	and	O
17	ZiaR	B
18	-	O
19	DNA	O
20	binding	O
21	was	O
22	enhanced	O
23	by	O
24	treatment	O
25	with	O
26	a	O
27	metal	O
28	-	O
29	chelator	O
30	in	O
31	vitro	O
32	.	O

1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O

1	The	O
2	PC	O
3	-	O
4	based	O
5	RTPS	O
6	is	O
7	designed	O
8	to	O
9	run	O
10	in	O
11	the	O
12	Microsoft	O
13	Windows	O
14	3	O
15	.	O
16	11	O
17	environment	O
18	(	O
19	and	O
20	later	O
21	versions	O
22	),	O
23	for	O
24	computers	O
25	equipped	O
26	with	O
27	486	O
28	or	O
29	Pentium	O
30	processors	O
31	.	O

1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	I
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	B
35	and	O
36	urf209	B
37	processing	O
38	activities	O
39	.	O

1	JCAHO	O
2	revised	O
3	interpretation	O

1	Molecular	O
2	cloning	O
3	and	O
4	functional	O
5	characterization	O
6	of	O
7	murine	B
8	sphingosine	I
9	kinase	I
10	.	O

1	A	O
2	human	O
3	SPT3	B
4	-	O
5	TAFII31	B
6	-	O
7	GCN5	B
8	-	O
9	L	B
10	acetylase	I
11	complex	O
12	distinct	O
13	from	O
14	transcription	B
15	factor	I
16	IID	I
17	.	O

1	Oleate	O
2	induced	O
3	steady	O
4	-	O
5	state	O
6	levels	O
7	of	O
8	M	B
9	-	I
10	CPT	I
11	I	I
12	mRNA	I
13	4	O
14	.	O
15	5	O
16	-	O
17	fold	O
18	.	O

1	Mapping	O
2	of	O
3	the	O
4	DNA	O
5	binding	O
6	domain	O
7	of	O
8	the	O
9	copper	O
10	-	O
11	responsive	O
12	transcription	O
13	factor	O
14	Mac1	B
15	from	I
16	Saccharomyces	I
17	cerevisiae	I
18	.	O

1	A	O
2	further	O
3	mechanism	O
4	increasing	O
5	specific	O
6	activation	O
7	was	O
8	cooperation	O
9	of	O
10	receptors	O
11	at	O
12	multiple	O
13	and	O
14	weak	O
15	HREs	O
16	,	O
17	which	O
18	was	O
19	accentuated	O
20	in	O
21	the	O
22	presence	O
23	of	O
24	both	O
25	the	O
26	AR	B
27	N	O
28	terminus	O
29	and	O
30	ligand	O
31	binding	O
32	domain	O
33	.	O

1	Previously	O
2	,	O
3	we	O
4	characterized	O
5	a	O
6	DNA	O
7	-	O
8	binding	O
9	protein	O
10	,	O
11	HS2NF5	B
12	,	O
13	that	O
14	bound	O
15	tightly	O
16	to	O
17	a	O
18	conserved	O
19	region	O
20	within	O
21	hypersensitive	O
22	site	O
23	2	O
24	(	O
25	HS2	O
26	)	O
27	of	O
28	the	O
29	human	B
30	beta	I
31	-	I
32	globin	I
33	locus	I
34	control	I
35	region	I
36	(	O
37	LCR	O
38	)	O
39	(	O
40	Lam	O
41	,	O
42	L	O
43	.	O

1	The	O
2	CBF1	B
3	site	I
4	within	O
5	HS2	O
6	resides	O
7	near	O
8	sites	O
9	for	O
10	hematopoietic	O
11	regulators	O
12	such	O
13	as	O
14	GATA	B
15	-	I
16	1	I
17	,	O
18	NF	B
19	-	I
20	E2	I
21	,	O
22	and	O
23	TAL1	B
24	.	O

1	The	O
2	rat	B
3	branched	I
4	-	I
5	chain	I
6	-	I
7	2	I
8	-	I
9	oxo	I
10	-	I
11	acid	I
12	dehydrogenase	I
13	(	I
14	BCOD	I
15	)	I
16	kinase	I
17	mRNA	I
18	is	O
19	transcribed	O
20	from	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	that	O
27	has	O
28	GC	O
29	-	O
30	rich	O
31	sequences	O
32	and	O
33	two	O
34	putative	O
35	Sp1	B
36	binding	I
37	sites	I
38	near	O
39	the	O
40	transcription	O
41	start	O
42	site	O
43	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	the	O
6	Sp1	B
7	expression	O
8	plasmid	O
9	and	O
10	the	O
11	-	O
12	58	O
13	promoter	O
14	construct	O
15	into	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	revealed	O
20	that	O
21	Sp1	B
22	contributed	O
23	to	O
24	the	O
25	kinase	O
26	basal	O
27	promoter	O
28	activity	O
29	by	O
30	binding	O
31	to	O
32	the	O
33	non	O
34	-	O
35	consensus	O
36	site	O
37	in	O
38	the	O
39	-	O
40	58	O
41	region	O
42	.	O

1	Until	O
2	such	O
3	investigations	O
4	are	O
5	performed	O
6	,	O
7	we	O
8	conclude	O
9	that	O
10	the	O
11	role	O
12	for	O
13	adjuvant	O
14	treatment	O
15	is	O
16	questionable	O
17	and	O
18	that	O
19	TME	O
20	surgery	O
21	is	O
22	preferred	O
23	as	O
24	the	O
25	treatment	O
26	option	O
27	for	O
28	Stage	O
29	T1	O
30	-	O
31	T3	O
32	rectal	O
33	cancers	O
34	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	B
12	factors	I
13	NF	I
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	B
31	-	I
32	I	I
33	Tax	I
34	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	cooperative	O
6	effects	O
7	of	O
8	a	O
9	human	O
10	estrogen	B
11	receptor	I
12	-	I
13	alpha	I
14	(	O
15	ERalpha	B
16	)	O
17	isoform	O
18	on	O
19	estrogen	O
20	(	O
21	E2	O
22	)-	O
23	mediated	O
24	gene	O
25	activation	O
26	in	O
27	U2	O
28	-	O
29	OS	O
30	osteosarcoma	O
31	cells	O
32	.	O

1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	B
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	B
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	O
20	-	O
21	stimulated	O
22	ERELuc	B
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	Studies	O
2	using	O
3	the	O
4	yeast	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	also	O
10	did	O
11	not	O
12	provide	O
13	evidence	O
14	for	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	VDR	B
20	-	O
21	TR	B
22	protein	O
23	-	O
24	protein	O
25	interaction	O
26	.	O

1	Our	O
2	results	O
3	show	O
4	that	O
5	,	O
6	from	O
7	a	O
8	thermodynamical	O
9	standpoint	O
10	,	O
11	melatonin	O
12	may	O
13	directly	O
14	scavenge	O
15	hydroxyl	O
16	radicals	O
17	both	O
18	in	O
19	vacuum	O
20	and	O
21	in	O
22	aqueous	O
23	solution	O
24	.	O

1	This	O
2	sequence	O
3	,	O
4	Thr	O
5	-	O
6	Gly	O
7	-	O
8	X	O
9	-	O
10	X	O
11	-	O
12	Gly	O
13	-	O
14	Asp	O
15	-	O
16	Gly	O
17	-	O
18	Lys	O
19	-	O
20	Ile	O
21	-	O
22	Phe	O
23	,	O
24	forms	O
25	part	O
26	of	O
27	the	O
28	B	O
29	-	O
30	loop	O
31	and	O
32	is	O
33	conserved	O
34	in	O
35	a	O
36	wide	O
37	variety	O
38	of	O
39	organisms	O
40	that	O
41	include	O
42	bacteria	O
43	,	O
44	algae	O
45	and	O
46	archeabacteria	O
47	.	O

1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	I
22	,	O
23	Bax	B
24	,	O
25	and	O
26	Bad	B
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	B
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O

1	Tyrosine	O
2	112	O
3	of	O
4	latent	B
5	membrane	I
6	protein	I
7	2A	I
8	is	O
9	essential	O
10	for	O
11	protein	B
12	tyrosine	I
13	kinase	I
14	loading	O
15	and	O
16	regulation	O
17	of	O
18	Epstein	O
19	-	O
20	Barr	O
21	virus	O
22	latency	O
23	.	O

1	The	O
2	only	O
3	abundant	O
4	viral	O
5	transcript	O
6	expressed	O
7	during	O
8	latency	O
9	is	O
10	the	O
11	latency	B
12	-	I
13	related	I
14	(	O
15	LR	B
16	)	O
17	RNA	O
18	.	O

1	To	O
2	improve	O
3	test	O
4	efficiency	O
5	,	O
6	we	O
7	modified	O
8	our	O
9	previously	O
10	introduced	O
11	contrast	O
12	/	O
13	color	O
14	card	O
15	test	O
16	by	O
17	including	O
18	a	O
19	patterned	O
20	test	O
21	stimulus	O
22	and	O
23	reducing	O
24	the	O
25	number	O
26	of	O
27	stimuli	O
28	in	O
29	both	O
30	experimental	O
31	phases	O
32	.	O

1	The	O
2	defect	O
3	in	O
4	these	O
5	proteins	O
6	was	O
7	also	O
8	uniformly	O
9	suppressed	O
10	by	O
11	either	O
12	Mn2	O
13	+,	O
14	or	O
15	the	O
16	Mu	B
17	B	I
18	protein	I
19	in	O
20	the	O
21	presence	O
22	of	O
23	ATP	O
24	and	O
25	target	O
26	DNA	O
27	.	O

1	Using	O
2	homology	O
3	cloning	O
4	techniques	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	mouse	O
10	homologue	O
11	of	O
12	E	O
13	(	O
14	Pc	O
15	),	O
16	termed	O
17	Epc1	B
18	,	O
19	a	O
20	yeast	O
21	protein	O
22	that	O
23	we	O
24	name	O
25	EPL1	B
26	,	O
27	and	O
28	as	O
29	well	O
30	as	O
31	additional	O
32	ESTs	O
33	from	O
34	Caenorhabditis	O
35	elegans	O
36	,	O
37	mice	O
38	and	O
39	humans	O
40	.	O

1	Second	O
2	,	O
3	the	O
4	wild	B
5	-	I
6	type	I
7	m8	I
8	3	I
9	'	I
10	UTR	I
11	strongly	O
12	reduces	O
13	accumulation	O
14	of	O
15	heterologous	O
16	transcripts	O
17	in	O
18	vivo	O
19	,	O
20	an	O
21	activity	O
22	that	O
23	requires	O
24	its	O
25	K	O
26	box	O
27	sequences	O
28	.	O

1	In	O
2	particular	O
3	,	O
4	unc	B
5	-	I
6	86	I
7	encodes	O
8	a	O
9	POU	B
10	-	I
11	type	I
12	homeodomain	I
13	protein	I
14	needed	O
15	for	O
16	the	O
17	production	O
18	of	O
19	the	O
20	touch	O
21	cells	O
22	,	O
23	while	O
24	mec	B
25	-	I
26	3	I
27	encodes	O
28	a	O
29	LIM	B
30	-	I
31	type	I
32	homeodomain	I
33	protein	I
34	needed	O
35	for	O
36	the	O
37	differentiation	O
38	of	O
39	the	O
40	touch	O
41	cells	O
42	.	O

1	During	O
2	the	O
3	2h	O
4	resuscitation	O
5	period	O
6	,	O
7	extracellular	O
8	aspartate	O
9	and	O
10	glutamate	O
11	concentrations	O
12	in	O
13	the	O
14	cerebral	O
15	striatum	O
16	were	O
17	higher	O
18	during	O
19	hypoxaemic	O
20	resuscitation	O
21	(	O
22	p	O
23	=	O
24	0	O
25	.	O
26	044	O
27	and	O
28	p	O
29	=	O
30	0	O
31	.	O
32	055	O
33	,	O
34	respectively	O
35	)	O
36	than	O
37	during	O
38	resuscitation	O
39	with	O
40	21	O
41	%	O
42	O2	O
43	or	O
44	100	O
45	%	O
46	O2	O
47	,	O
48	suggesting	O
49	an	O
50	unfavourable	O
51	accumulation	O
52	of	O
53	potent	O
54	excitotoxins	O
55	during	O
56	hypoxaemic	O
57	resuscitation	O
58	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	B
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	MEKs	B
2	and	O
3	ERKs	B
4	inhibited	O
5	IL	B
6	-	I
7	6	I
8	activation	O
9	of	O
10	Stat3	B
11	harboring	O
12	a	O
13	mutation	O
14	at	O
15	serine	O
16	-	O
17	727	O
18	,	O
19	the	O
20	major	O
21	site	O
22	for	O
23	serine	O
24	phosphorylation	O
25	,	O
26	similar	O
27	to	O
28	inhibition	O
29	of	O
30	wild	B
31	-	I
32	type	I
33	Stat3	I
34	,	O
35	and	O
36	inhibited	O
37	Janus	B
38	kinases	I
39	Jak1	I
40	and	O
41	Jak2	B
42	upstream	O
43	of	O
44	Stat3	B
45	in	O
46	the	O
47	Jak	B
48	-	O
49	STAT	B
50	-	O
51	signaling	O
52	pathway	O
53	.	O

1	Furthermore	O
2	,	O
3	phosphatidylinositol	O
4	(	O
5	3	O
6	,	O
7	4	O
8	,	O
9	5	O
10	)	O
11	trisphosphate	O
12	specifically	O
13	stimulates	O
14	the	O
15	activity	O
16	of	O
17	ILK	B
18	in	O
19	vitro	O
20	,	O
21	and	O
22	in	O
23	addition	O
24	,	O
25	membrane	O
26	targetted	O
27	constitutively	O
28	active	O
29	Pi	B
30	(	I
31	3	I
32	)	I
33	K	I
34	activates	O
35	ILK	B
36	in	O
37	vivo	O
38	.	O

1	Transfection	O
2	and	O
3	in	O
4	vitro	O
5	binding	O
6	studies	O
7	identified	O
8	within	O
9	HEFT1	B
10	a	I
11	promoter	I
12	whose	O
13	basal	O
14	activity	O
15	required	O
16	a	O
17	GC	O
18	box	O
19	activated	O
20	by	O
21	Sp1	B
22	or	O
23	Sp3	B
24	.	O

1	Plasma	O
2	was	O
3	tested	O
4	before	O
5	and	O
6	after	O
7	(	O
8	14	O
9	+/-	O
10	7	O
11	.	O
12	5	O
13	[	O
14	SD	O
15	]	O
16	days	O
17	)	O
18	surgery	O
19	for	O
20	IgG	B
21	antibodies	I
22	to	O
23	the	O
24	complex	O
25	of	O
26	heparin	B
27	/	I
28	platelet	I
29	factor	I
30	4	I
31	,	O
32	using	O
33	a	O
34	standardized	O
35	,	O
36	validated	O
37	enzyme	O
38	-	O
39	linked	O
40	immunosorbent	O
41	assay	O
42	(	O
43	ELISA	O
44	).	O

1	Genome	O
2	plasticity	O
3	in	O
4	the	O
5	distal	O
6	tail	O
7	fiber	O
8	locus	O
9	of	O
10	the	O
11	T	O
12	-	O
13	even	O
14	bacteriophage	O
15	:	O
16	recombination	O
17	between	O
18	conserved	O
19	motifs	O
20	swaps	O
21	adhesin	B
22	specificity	O
23	.	O

1	The	O
2	FAS	B
3	promoter	I
4	was	O
5	up	O
6	-	O
7	regulated	O
8	by	O
9	insulin	B
10	through	O
11	the	O
12	proximal	O
13	insulin	B
14	response	I
15	sequence	I
16	containing	O
17	an	O
18	E	O
19	-	O
20	box	O
21	motif	O
22	at	O
23	the	O
24	-	O
25	65	O
26	-	O
27	base	O
28	pair	O
29	position	O
30	.	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	Effects	O
2	of	O
3	rhG	B
4	-	I
5	CSF	I
6	on	O
7	neutrophil	O
8	functions	O
9	and	O
10	survival	O
11	in	O
12	sepsis	O
13	induced	O
14	diabetic	O
15	rats	O
16	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	purpose	O
5	of	O
6	this	O
7	article	O
8	is	O
9	to	O
10	review	O
11	balance	O
12	instruments	O
13	developed	O
14	within	O
15	the	O
16	past	O
17	10	O
18	years	O
19	that	O
20	can	O
21	be	O
22	used	O
23	in	O
24	the	O
25	clinic	O
26	or	O
27	home	O
28	environment	O
29	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	We	O
5	observed	O
6	a	O
7	congenital	O
8	skin	O
9	defect	O
10	located	O
11	exclusively	O
12	on	O
13	the	O
14	trunk	O
15	.	O

1	Whereas	O
2	,	O
3	in	O
4	the	O
5	single	O
6	-	O
7	chambered	O
8	body	O
9	box	O
10	,	O
11	PenH	O
12	units	O
13	(	O
14	Enhanced	O
15	Pause	O
16	)	O
17	reflect	O
18	"	O
19	effort	O
20	of	O
21	breathing	O
22	."	O
23	This	O
24	is	O
25	measured	O
26	as	O
27	the	O
28	pause	O
29	between	O
30	inspiration	O
31	and	O
32	expiration	O
33	.	O

1	Anastrozole	O
2	is	O
3	the	O
4	first	O
5	aromatase	B
6	inhibitor	O
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O

1	W	O
2	.	O

1	Moritta	O
2	)	O
3	and	O
4	contains	O
5	Bis	O
6	-	O
7	GMA	O
8	.	O

1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	or	O
9	the	O
10	ets	B
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O

1	ANIMALS	O
2	:	O
3	Fifty	O
4	dogs	O
5	with	O
6	naturally	O
7	developing	O
8	DM	O
9	.	O

1	Surprisingly	O
2	,	O
3	double	O
4	mutants	O
5	of	O
6	the	O
7	shy2	B
8	-	I
9	1D	I
10	mutant	I
11	with	O
12	the	O
13	phytochrome	B
14	-	O
15	deficient	O
16	mutants	O
17	hy2	B
18	,	O
19	hy3	B
20	(	O
21	phyB	B
22	-	I
23	1	I
24	)	O
25	and	O
26	fre1	B
27	-	I
28	1	I
29	(	O
30	phyA	B
31	-	I
32	201	I
33	)	O
34	showed	O
35	reduced	O
36	photomorphogenic	O
37	response	O
38	in	O
39	darkness	O
40	with	O
41	a	O
42	longer	O
43	hypocotyl	O
44	,	O
45	a	O
46	longer	O
47	inflorescence	O
48	stem	O
49	,	O
50	and	O
51	a	O
52	lower	O
53	level	O
54	expression	O
55	of	O
56	the	O
57	CAB	B
58	gene	I
59	than	O
60	the	O
61	shy2	B
62	-	I
63	1D	I
64	single	I
65	mutant	I
66	.	O

1	This	O
2	suggests	O
3	that	O
4	while	O
5	underpredictions	O
6	of	O
7	pain	O
8	do	O
9	not	O
10	hurt	O
11	more	O
12	,	O
13	disruption	O
14	on	O
15	primary	O
16	tasks	O
17	and	O
18	physiological	O
19	impact	O
20	are	O
21	higher	O
22	.	O

1	Laser	O
2	ablation	O
3	has	O
4	been	O
5	employed	O
6	as	O
7	a	O
8	therapeutic	O
9	measure	O
10	for	O
11	chronic	O
12	pulmonary	O
13	emphysema	O
14	.	O

1	The	O
2	SH2	O
3	-	O
4	containing	O
5	adapter	O
6	protein	O
7	GRB10	B
8	interacts	O
9	with	O
10	BCR	B
11	-	O
12	ABL	B
13	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	four	O
5	known	O
6	acyl	B
7	-	I
8	CoA	I
9	synthetases	I
10	(	O
11	fatty	B
12	acid	I
13	activation	I
14	proteins	I
15	,	O
16	Faaps	B
17	).	O

1	We	O
2	recently	O
3	reported	O
4	a	O
5	placenta	O
6	-	O
7	specific	O
8	enhancer	O
9	in	O
10	the	O
11	human	B
12	leukemia	I
13	inhibitory	I
14	factor	I
15	receptor	I
16	(	O
17	LIFR	B
18	)	O
19	gene	O
20	and	O
21	now	O
22	show	O
23	detailed	O
24	characterization	O
25	of	O
26	the	O
27	226	O
28	-	O
29	base	O
30	pair	O
31	enhancer	O
32	(-	O
33	4625	O
34	/-	O
35	4400	O
36	nucleotides	O
37	).	O

1	Copyright	O
2	1998	O
3	Elsevier	O
4	Science	O
5	B	O
6	.	O
7	V	O
8	.	O

1	It	O
2	may	O
3	be	O
4	time	O
5	to	O
6	reevaluate	O
7	the	O
8	dichotomy	O
9	between	O
10	AD	O
11	and	O
12	VaD	O
13	.	O

1	Clone	O
2	39	O
3	was	O
4	a	O
5	homolog	O
6	of	O
7	CONSTANS	B
8	,	O
9	which	O
10	is	O
11	a	O
12	gene	O
13	involved	O
14	in	O
15	controlling	O
16	the	O
17	flowering	O
18	time	O
19	in	O
20	Arabidopsis	O
21	.	O

1	Badcock	O
2	and	O
3	Westheimer	O
4	(	O
5	Spatial	O
6	Vision	O
7	1	O
8	(	O
9	1	O
10	),	O
11	3	O
12	-	O
13	11	O
14	,	O
15	1985	O
16	)	O
17	showed	O
18	that	O
19	a	O
20	thin	O
21	vertical	O
22	line	O
23	induces	O
24	nearby	O
25	zones	O
26	of	O
27	attraction	O
28	and	O
29	repulsion	O
30	;	O
31	this	O
32	study	O
33	extends	O
34	those	O
35	results	O
36	by	O
37	more	O
38	closely	O
39	examining	O
40	the	O
41	horizontal	O
42	and	O
43	vertical	O
44	extents	O
45	of	O
46	the	O
47	repulsion	O
48	zone	O
49	and	O
50	by	O
51	using	O
52	an	O
53	illusory	O
54	contour	O
55	to	O
56	induce	O
57	repulsion	O
58	.	O

1	The	O
2	effects	O
3	of	O
4	high	O
5	intensity	O
6	light	O
7	emissions	O
8	,	O
9	produced	O
10	by	O
11	a	O
12	novel	O
13	pulsed	O
14	power	O
15	energization	O
16	technique	O
17	(	O
18	PPET	O
19	),	O
20	on	O
21	the	O
22	survival	O
23	of	O
24	bacterial	O
25	populations	O
26	of	O
27	verocytotoxigenic	O
28	Escherichia	O
29	coli	O
30	(	O
31	serotype	O
32	0157	O
33	:	O
34	H7	O
35	)	O
36	and	O
37	Listeria	O
38	monocytogenes	O
39	(	O
40	serotype	O
41	4b	O
42	)	O
43	were	O
44	investigated	O
45	.	O

1	Multiple	O
2	chemical	O
3	sensitivity	O
4	(	O
5	MCS	O
6	)	O
7	is	O
8	a	O
9	syndrome	O
10	in	O
11	which	O
12	multiple	O
13	symptoms	O
14	reportedly	O
15	occur	O
16	with	O
17	low	O
18	-	O
19	level	O
20	chemical	O
21	exposure	O
22	.	O

1	POU	B
2	-	I
3	domain	I
4	proteins	I
5	,	O
6	such	O
7	as	O
8	the	O
9	pituitary	B
10	-	I
11	specific	I
12	factor	I
13	Pit	I
14	-	I
15	1	I
16	,	O
17	are	O
18	members	O
19	of	O
20	the	O
21	homeodomain	B
22	family	I
23	of	O
24	proteins	O
25	which	O
26	are	O
27	important	O
28	in	O
29	development	O
30	and	O
31	homeostasis	O
32	,	O
33	acting	O
34	constitutively	O
35	or	O
36	in	O
37	response	O
38	to	O
39	signal	O
40	-	O
41	transduction	O
42	pathways	O
43	to	O
44	either	O
45	repress	O
46	or	O
47	activate	O
48	the	O
49	expression	O
50	of	O
51	specific	O
52	genes	O
53	.	O

1	Wild	O
2	-	O
3	type	O
4	and	O
5	mutant	O
6	MyoD	B
7	were	O
8	introduced	O
9	into	O
10	cells	O
11	using	O
12	an	O
13	E1	B
14	,	O
15	E3	B
16	-	O
17	deleted	O
18	adenoviral	O
19	vector	O
20	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	This	O
2	and	O
3	previous	O
4	results	O
5	suggest	O
6	that	O
7	the	O
8	CRE	O
9	and	O
10	Sp1	B
11	site	I
12	may	O
13	synergistically	O
14	activate	O
15	TH	B
16	transcription	O
17	in	O
18	a	O
19	promoter	O
20	context	O
21	-	O
22	dependent	O
23	manner	O
24	.	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	Endoscopic	O
2	examinations	O
3	,	O
4	peripheral	O
5	white	O
6	blood	O
7	cell	O
8	(	O
9	WBC	O
10	)	O
11	counts	O
12	,	O
13	and	O
14	assays	O
15	of	O
16	myeloperoxidase	B
17	activity	O
18	(	O
19	MPO	B
20	)	O
21	in	O
22	homogenates	O
23	of	O
24	colon	O
25	mucosa	O
26	were	O
27	performed	O
28	after	O
29	one	O
30	week	O
31	(	O
32	4	O
33	%	O
34	DSS	O
35	model	O
36	)	O
37	and	O
38	eight	O
39	weeks	O
40	(	O
41	1	O
42	%	O
43	DSS	O
44	model	O
45	).	O

1	T7	O
2	transcription	O
3	could	O
4	be	O
5	manipulated	O
6	to	O
7	achieve	O
8	different	O
9	levels	O
10	of	O
11	constitutive	O
12	expression	O
13	,	O
14	through	O
15	the	O
16	use	O
17	of	O
18	promoter	O
19	mutations	O
20	.	O

1	The	O
2	primers	O
3	were	O
4	degenerate	O
5	sets	O
6	of	O
7	oligonucleotides	O
8	derived	O
9	from	O
10	known	O
11	amino	O
12	acid	O
13	sequences	O
14	of	O
15	the	O
16	PBAN	B
17	precursor	I
18	.	O

1	Plants	O
2	transformed	O
3	with	O
4	the	O
5	35S	B
6	-	O
7	1	B
8	-	I
9	sst	I
10	construct	O
11	accumulated	O
12	the	O
13	oligofructans	O
14	1	O
15	-	O
16	kestose	O
17	(	O
18	GF2	O
19	),	O
20	1	O
21	,	O
22	1	O
23	-	O
24	nystose	O
25	(	O
26	GF3	O
27	)	O
28	and	O
29	1	O
30	,	O
31	1	O
32	,	O
33	1	O
34	-	O
35	fructosylnystose	O
36	(	O
37	GF4	O
38	).	O

1	Based	O
2	on	O
3	the	O
4	comparison	O
5	of	O
6	the	O
7	predicted	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	1	B
13	-	I
14	sst	I
15	and	O
16	1	B
17	-	I
18	fft	I
19	with	O
20	those	O
21	of	O
22	other	O
23	plant	O
24	fructosyl	B
25	transferase	I
26	genes	I
27	,	O
28	we	O
29	postulate	O
30	that	O
31	both	O
32	plant	O
33	fructan	B
34	genes	I
35	have	O
36	evolved	O
37	from	O
38	plant	O
39	invertase	B
40	genes	O
41	.	O

1	However	O
2	,	O
3	ICK1	B
4	was	O
5	induced	O
6	by	O
7	ABA	O
8	,	O
9	and	O
10	along	O
11	with	O
12	ICK1	B
13	induction	O
14	there	O
15	was	O
16	a	O
17	decrease	O
18	in	O
19	Cdc2	B
20	-	I
21	like	I
22	histone	I
23	H1	I
24	kinase	I
25	activity	O
26	.	O

1	A	O
2	5	O
3	.	O
4	0	O
5	-	O
6	kb	O
7	transcript	O
8	detected	O
9	by	O
10	the	O
11	differential	O
12	display	O
13	amplicon	O
14	3G1	O
15	was	O
16	found	O
17	to	O
18	correlate	O
19	strongly	O
20	with	O
21	RAG1	B
22	mRNA	I
23	expression	O
24	in	O
25	various	O
26	human	O
27	cell	O
28	lines	O
29	.	O

1	The	O
2	hBRAG	B
3	gene	I
4	was	O
5	localized	O
6	to	O
7	the	O
8	long	O
9	arm	O
10	of	O
11	chromosome	O
12	10	O
13	(	O
14	10q26	O
15	).	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	swa5	B
7	-	I
8	1	I
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	I
20	chain	I
21	gene	I
22	(	O
23	chc1	B
24	-	I
25	5	I
26	),	O
27	which	O
28	carries	O
29	a	O
30	frameshift	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	CHC1	B
40	open	O
41	reading	O
42	frame	O
43	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	Scm	B
10	mutant	I
11	alleles	I
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O

1	Intriguingly	O
2	,	O
3	three	O
4	hypomorphic	O
5	Scm	B
6	mutations	O
7	,	O
8	which	O
9	map	O
10	within	O
11	an	O
12	mbt	B
13	repeat	I
14	,	O
15	interact	O
16	with	O
17	PcG	B
18	mutations	I
19	more	O
20	strongly	O
21	than	O
22	do	O
23	Scm	B
24	null	O
25	alleles	O
26	.	O

1	Northern	O
2	analysis	O
3	revealed	O
4	no	O
5	detectable	O
6	expression	O
7	of	O
8	the	O
9	transcript	O
10	in	O
11	diapause	O
12	-	O
13	or	O
14	nondiapause	O
15	-	O
16	programmed	O
17	wandering	O
18	larvae	O
19	,	O
20	and	O
21	only	O
22	trace	O
23	expression	O
24	in	O
25	nondiapausing	O
26	pupae	O
27	.	O

1	Besides	O
2	the	O
3	characterization	O
4	and	O
5	discussion	O
6	of	O
7	the	O
8	experimental	O
9	setup	O
10	used	O
11	,	O
12	the	O
13	rate	O
14	constants	O
15	obtained	O
16	are	O
17	discussed	O
18	and	O
19	compared	O
20	with	O
21	estimated	O
22	values	O
23	.	O

1	Genomic	O
2	locus	O
3	of	O
4	chCTCF	B
5	contains	O
6	a	O
7	GC	O
8	-	O
9	rich	O
10	untranslated	O
11	exon	O
12	separated	O
13	from	O
14	seven	O
15	coding	O
16	exons	O
17	by	O
18	a	O
19	long	O
20	intron	O
21	.	O

1	The	O
2	presence	O
3	of	O
4	PDZ	B
5	and	O
6	SAM	O
7	domains	O
8	in	O
9	the	O
10	KS5	B
11	protein	I
12	suggests	O
13	that	O
14	it	O
15	may	O
16	act	O
17	as	O
18	a	O
19	molecular	O
20	adaptor	O
21	,	O
22	promoting	O
23	and	O
24	relaying	O
25	information	O
26	in	O
27	a	O
28	signal	O
29	transduction	O
30	pathway	O
31	.	O

1	BACKGROUND	O
2	:	O
3	Fluoroquinolones	O
4	(	O
5	FQ	O
6	)	O
7	are	O
8	contraindicated	O
9	in	O
10	children	O
11	because	O
12	of	O
13	the	O
14	risk	O
15	of	O
16	cartilage	O
17	damage	O
18	.	O

1	In	O
2	analyses	O
3	with	O
4	control	O
5	for	O
6	multiple	O
7	variables	O
8	,	O
9	relative	O
10	risk	O
11	for	O
12	microalbuminuria	O
13	(	O
14	urinary	O
15	albumin	B
16	excretion	O
17	,	O
18	20	O
19	-	O
20	199	O
21	microg	O
22	/	O
23	min	O
24	)	O
25	in	O
26	men	O
27	and	O
28	women	O
29	was	O
30	2	O
31	.	O
32	51	O
33	and	O
34	1	O
35	.	O
36	62	O
37	,	O
38	respectively	O
39	,	O
40	with	O
41	18	O
42	mm	O
43	Hg	O
44	higher	O
45	(	O
46	1	O
47	SD	O
48	)	O
49	systolic	O
50	blood	O
51	pressure	O
52	;	O
53	2	O
54	.	O
55	25	O
56	and	O
57	2	O
58	.	O
59	10	O
60	,	O
61	respectively	O
62	,	O
63	with	O
64	1	O
65	.	O
66	0	O
67	-	O
68	mmol	O
69	/	O
70	L	O
71	(	O
72	40	O
73	mg	O
74	/	O
75	dL	O
76	)	O
77	higher	O
78	plasma	O
79	cholesterol	O
80	level	O
81	;	O
82	1	O
83	.	O
84	99	O
85	and	O
86	1	O
87	.	O
88	91	O
89	,	O
90	respectively	O
91	,	O
92	for	O
93	smokers	O
94	vs	O
95	nonsmokers	O
96	;	O
97	and	O
98	1	O
99	.	O
100	83	O
101	and	O
102	1	O
103	.	O
104	33	O
105	,	O
106	respectively	O
107	,	O
108	with	O
109	4	O
110	kg	O
111	/	O
112	m2	O
113	higher	O
114	body	O
115	mass	O
116	index	O
117	.	O

1	However	O
2	,	O
3	while	O
4	IL	B
5	-	I
6	1beta	I
7	and	O
8	TNF	B
9	-	I
10	alpha	I
11	both	O
12	induced	O
13	nuclear	O
14	binding	O
15	of	O
16	the	O
17	Rel	B
18	proteins	I
19	p50	I
20	and	O
21	p65	B
22	to	O
23	an	O
24	NF	B
25	-	I
26	kappaB	I
27	consensus	I
28	oligonucleotide	I
29	in	O
30	gel	O
31	shift	O
32	assays	O
33	and	O
34	caused	O
35	transient	O
36	degradation	O
37	of	O
38	inhibitor	B
39	of	I
40	NF	I
41	-	I
42	kappaB	I
43	-	I
44	alpha	I
45	(	O
46	IkappaB	B
47	-	I
48	alpha	I
49	)	O
50	in	O
51	the	O
52	cytoplasm	O
53	of	O
54	myofibroblasts	O
55	,	O
56	only	O
57	IL	B
58	-	I
59	1beta	I
60	upregulated	O
61	PDGF	B
62	-	I
63	Ralpha	I
64	.	O

1	Cotransfections	O
2	with	O
3	ATF	B
4	-	I
5	2	I
6	and	O
7	HNF	B
8	-	I
9	4	I
10	expression	O
11	plasmids	O
12	resulted	O
13	in	O
14	additive	O
15	transactivation	O
16	of	O
17	the	O
18	apoCIII	B
19	promoter	I
20	.	O

1	Phosphocreatine	O
2	hydrolysis	O
3	during	O
4	submaximal	O
5	exercise	O
6	:	O
7	the	O
8	effect	O
9	of	O
10	FIO2	O
11	.	O

1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O

1	GETS	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	many	O
8	tissues	O
9	,	O
10	but	O
11	is	O
12	enriched	O
13	in	O
14	retina	O
15	and	O
16	brain	O
17	.	O

1	The	O
2	interaction	O
3	of	O
4	U1	B
5	-	I
6	70K	I
7	with	O
8	the	O
9	SRZ	B
10	proteins	I
11	is	O
12	confirmed	O
13	further	O
14	in	O
15	vitro	O
16	using	O
17	a	O
18	blot	O
19	overlay	O
20	assay	O
21	.	O

1	The	O
2	major	O
3	phenotypes	O
4	resulting	O
5	from	O
6	Fab1p	B
7	kinase	I
8	inactivation	O
9	include	O
10	temperature	O
11	-	O
12	sensitive	O
13	growth	O
14	,	O
15	vacuolar	O
16	acidification	O
17	defects	O
18	,	O
19	and	O
20	dramatic	O
21	increases	O
22	in	O
23	vacuolar	O
24	size	O
25	.	O

1	Small	B
2	GTPases	I
3	of	O
4	the	O
5	Ypt	B
6	/	O
7	Rab	B
8	family	O
9	are	O
10	involved	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	vesicular	O
16	transport	O
17	.	O

1	The	O
2	GEF	B
3	and	O
4	GAP	B
5	activities	O
6	for	O
7	Ypt1p	B
8	localize	O
9	to	O
10	particulate	O
11	cellular	O
12	fractions	O
13	.	O

1	Dopamine	B
2	beta	I
3	-	I
4	hydroxylase	I
5	(	O
6	DBH	B
7	)	O
8	catalyzes	O
9	the	O
10	conversion	O
11	of	O
12	dopamine	O
13	to	O
14	noradrenaline	O
15	and	O
16	is	O
17	selectively	O
18	expressed	O
19	in	O
20	noradrenergic	O
21	and	O
22	adrenergic	O
23	neurons	O
24	and	O
25	neuroendocrine	O
26	cells	O
27	.	O

1	Collectively	O
2	,	O
3	this	O
4	study	O
5	emphasizes	O
6	a	O
7	critical	O
8	role	O
9	of	O
10	Phox2a	B
11	as	O
12	well	O
13	as	O
14	its	O
15	functional	O
16	synergism	O
17	with	O
18	other	O
19	transcription	O
20	factors	O
21	(	O
22	e	O
23	.	O
24	g	O
25	.,	O
26	CREB	B
27	,	O
28	AP2	B
29	,	O
30	and	O
31	Sp1	B
32	)	O
33	in	O
34	transcriptional	O
35	activation	O
36	of	O
37	the	O
38	DBH	B
39	gene	I
40	.	O

1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	B
7	-	I
8	SMase	I
9	can	O
10	abrogate	O
11	Ox	B
12	-	I
13	LDL	I
14	-	O
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	O
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O

1	We	O
2	found	O
3	that	O
4	virulent	O
5	Ngo	O
6	strains	O
7	induce	O
8	phosphorylation	O
9	and	O
10	activation	O
11	of	O
12	JNK	B
13	but	O
14	not	O
15	of	O
16	p38	B
17	kinase	O
18	.	O

1	Focused	O
2	beams	O
3	of	O
4	classical	O
5	light	O
6	ablate	O
7	elements	O
8	of	O
9	the	O
10	cell	O
11	division	O
12	machinery	O
13	and	O
14	switch	O
15	the	O
16	beating	O
17	of	O
18	hearts	O
19	on	O
20	a	O
21	cellular	O
22	basis	O
23	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	B
25	-	I
26	domain	I
27	/	I
28	leucine	I
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	B
48	Tax	I
49	-	I
50	responsive	I
51	element	I
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O

1	This	O
2	sequence	O
3	is	O
4	very	O
5	similar	O
6	to	O
7	the	O
8	insulin	B
9	response	I
10	sequence	I
11	found	O
12	in	O
13	the	O
14	regulatory	O
15	region	O
16	of	O
17	other	O
18	genes	O
19	negatively	O
20	regulated	O
21	by	O
22	insulin	B
23	such	O
24	as	O
25	those	O
26	encoding	O
27	phosphoenolpyruvate	B
28	carboxykinase	I
29	,	O
30	tyrosine	B
31	aminotransferase	I
32	,	O
33	and	O
34	insulin	B
35	-	I
36	like	I
37	growth	I
38	factor	I
39	-	I
40	binding	I
41	protein	I
42	1	I
43	.	O

1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O

1	However	O
2	,	O
3	changing	O
4	the	O
5	half	O
6	-	O
7	site	O
8	to	O
9	the	O
10	consensus	O
11	sequence	O
12	AGGTCA	O
13	(	O
14	IRper	O
15	-	O
16	1	O
17	)	O
18	increased	O
19	binding	O
20	of	O
21	AaEcR	B
22	.	I
23	AaUSP	I
24	10	O
25	-	O
26	fold	O
27	over	O
28	IRhsp	O
29	-	O
30	1	O
31	and	O
32	,	O
33	at	O
34	the	O
35	same	O
36	time	O
37	,	O
38	reduced	O
39	the	O
40	stringency	O
41	of	O
42	the	O
43	spacer	O
44	length	O
45	requirement	O
46	,	O
47	with	O
48	IRper	O
49	-	O
50	0	O
51	to	O
52	IRper	O
53	-	O
54	5	O
55	showing	O
56	detectable	O
57	binding	O
58	.	O

1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	respective	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	IRper	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	IRhsp	O
26	-	O
27	1	O
28	).	O

1	The	O
2	high	O
3	density	O
4	of	O
5	tegumental	O
6	spines	O
7	on	O
8	posterior	O
9	half	O
10	of	O
11	the	O
12	body	O
13	and	O
14	the	O
15	distribution	O
16	of	O
17	type	O
18	II	O
19	papillae	O
20	on	O
21	dorsal	O
22	surface	O
23	are	O
24	considered	O
25	to	O
26	be	O
27	characteristic	O
28	of	O
29	C	O
30	.	O
31	armatus	O
32	.	O

1	Inactivation	O
2	of	O
3	p53	B
4	but	O
5	not	O
6	p73	B
7	by	O
8	adenovirus	B
9	type	I
10	5	I
11	E1B	I
12	55	I
13	-	I
14	kilodalton	I
15	and	I
16	E4	I
17	34	I
18	-	I
19	kilodalton	I
20	oncoproteins	I
21	.	O

1	The	O
2	Epstein	B
3	-	I
4	Barr	I
5	virus	I
6	transactivator	I
7	Zta	I
8	triggers	O
9	lytic	O
10	gene	O
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	O
23	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	helicase	B
5	-	O
6	primase	B
7	proteins	O
8	,	O
9	one	O
10	of	O
11	which	O
12	was	O
13	fused	O
14	to	O
15	a	O
16	heterologous	O
17	activation	O
18	domain	O
19	,	O
20	led	O
21	to	O
22	Zta	B
23	-	O
24	dependent	O
25	superactivation	O
26	of	O
27	CAT	B
28	expression	O
29	.	O

1	Sequence	O
2	comparisons	O
3	strongly	O
4	suggest	O
5	that	O
6	the	O
7	S27a	B
8	and	O
9	the	O
10	ubiquitin	B
11	coding	O
12	sequences	O
13	found	O
14	in	O
15	the	O
16	genome	O
17	of	O
18	CP	O
19	Rit	O
20	were	O
21	both	O
22	derived	O
23	from	O
24	a	O
25	bovine	O
26	mRNA	O
27	encoding	O
28	a	O
29	hybrid	O
30	protein	O
31	with	O
32	the	O
33	structure	O
34	NH2	O
35	-	O
36	ubiquitin	B
37	-	O
38	S27a	B
39	-	O
40	COOH	O
41	.	O

1	J	O
2	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	in	O
6	all	O
7	studies	O
8	favouring	O
9	PVI	O
10	.	O

1	A	O
2	single	O
3	rectal	O
4	dose	O
5	of	O
6	25	O
7	mg	O
8	/	O
9	kg	O
10	will	O
11	obtain	O
12	this	O
13	lower	O
14	concentration	O
15	within	O
16	1	O
17	h	O
18	of	O
19	administration	O
20	and	O
21	maintain	O
22	it	O
23	for	O
24	up	O
25	to	O
26	6	O
27	h	O
28	.	O

1	This	O
2	domain	O
3	,	O
4	although	O
5	adjacent	O
6	to	O
7	the	O
8	5	O
9	'	O
10	edge	O
11	of	O
12	the	O
13	SD	O
14	sequence	O
15	,	O
16	does	O
17	not	O
18	inhibit	O
19	ribosome	O
20	binding	O
21	as	O
22	long	O
23	as	O
24	the	O
25	single	O
26	-	O
27	stranded	O
28	region	O
29	of	O
30	domain	O
31	3	O
32	is	O
33	present	O
34	.	O

1	Although	O
2	YopH	B
3	is	O
4	a	O
5	highly	O
6	active	O
7	PTP	B
8	,	O
9	it	O
10	preferentially	O
11	targets	O
12	a	O
13	subset	O
14	of	O
15	tyrosine	O
16	-	O
17	phosphorylated	O
18	proteins	O
19	in	O
20	host	O
21	cells	O
22	,	O
23	including	O
24	p130Cas	B
25	.	O

1	Phylogenetic	O
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	B
14	rDNA	I
15	and	O
16	rbcL	B
17	sequences	I
18	.	O

1	Previous	O
2	genetic	O
3	studies	O
4	led	O
5	to	O
6	the	O
7	conclusion	O
8	that	O
9	nitrate	O
10	and	O
11	nitrite	O
12	induction	O
13	of	O
14	nasF	B
15	operon	I
16	expression	O
17	is	O
18	determined	O
19	by	O
20	a	O
21	transcriptional	O
22	antitermination	O
23	mechanism	O
24	.	O

1	The	O
2	activation	O
3	and	O
4	injury	O
5	of	O
6	endothelial	O
7	cells	O
8	induced	O
9	by	O
10	TNF	B
11	and	O
12	other	O
13	proinflammatory	O
14	cytokines	O
15	may	O
16	underlie	O
17	the	O
18	local	O
19	effects	O
20	of	O
21	these	O
22	mediators	O
23	in	O
24	vivo	O
25	.	O

1	A	O
2	technique	O
3	for	O
4	thermal	O
5	imaging	O
6	of	O
7	the	O
8	animal	O
9	and	O
10	human	O
11	brain	O
12	cortex	O
13	using	O
14	an	O
15	infrared	O
16	optical	O
17	system	O
18	is	O
19	described	O
20	.	O

1	EGFR	B
2	levels	O
3	were	O
4	found	O
5	to	O
6	be	O
7	elevated	O
8	5	O
9	-,	O
10	3	O
11	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	THOV	B
6	NP	I
7	contains	O
8	a	O
9	motif	O
10	(	O
11	KRxxxxxxxxxKTKK	O
12	)	O
13	at	O
14	amino	O
15	acid	O
16	positions	O
17	179	O
18	-	O
19	193	O
20	that	O
21	represents	O
22	a	O
23	classical	O
24	bipartite	O
25	nuclear	O
26	localization	O
27	signal	O
28	(	O
29	NLS	O
30	).	O

1	As	O
2	PP2A	B
3	exerts	O
4	a	O
5	range	O
6	of	O
7	cellular	O
8	functions	O
9	including	O
10	cell	O
11	cycle	O
12	regulation	O
13	and	O
14	cell	O
15	fate	O
16	determination	O
17	,	O
18	we	O
19	were	O
20	surprised	O
21	to	O
22	find	O
23	that	O
24	these	O
25	embryos	O
26	develop	O
27	normally	O
28	until	O
29	postimplantation	O
30	,	O
31	around	O
32	embryonic	O
33	day	O
34	5	O
35	.	O
36	5	O
37	/	O
38	6	O
39	.	O
40	0	O
41	.	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	anthraquinone	O
6	sennoside	O
7	B	O
8	and	O
9	rhein	O
10	are	O
11	weakly	O
12	genotoxic	O
13	.	O

1	Furthermore	O
2	,	O
3	LB1	B
4	gene	I
5	mapped	O
6	to	O
7	chromosome	O
8	13q14	O
9	,	O
10	a	O
11	region	O
12	that	O
13	has	O
14	been	O
15	involved	O
16	as	O
17	a	O
18	chromosomal	O
19	breakpoint	O
20	in	O
21	DLBL	O
22	.	O

1	16	O
2	subjects	O
3	were	O
4	repatch	O
5	tested	O
6	to	O
7	ethylmercury	O
8	chloride	O
9	(	O
10	EtHgCl	O
11	)	O
12	and	O
13	to	O
14	solutions	O
15	containing	O
16	EtHgCl	O
17	mixed	O
18	with	O
19	L	O
20	-	O
21	cysteine	O
22	and	O
23	glutathione	O
24	,	O
25	respectively	O
26	.	O

1	Wild	B
2	-	I
3	type	I
4	AT1A	I
5	receptors	I
6	,	O
7	expressed	O
8	in	O
9	Chinese	O
10	hamster	O
11	ovary	O
12	cells	O
13	,	O
14	rapidly	O
15	internalized	O
16	after	O
17	Ang	B
18	II	I
19	stimulation	O
20	[	O
21	t1	O
22	/	O
23	2	O
24	2	O
25	.	O
26	3	O
27	min	O
28	;	O
29	maximal	O
30	level	O
31	of	O
32	internalization	O
33	(	O
34	Ymax	O
35	)	O
36	78	O
37	.	O
38	2	O
39	%],	O
40	as	O
41	did	O
42	mutant	O
43	receptors	O
44	carrying	O
45	single	O
46	acidic	O
47	substitutions	O
48	(	O
49	T332E	O
50	,	O
51	t1	O
52	/	O
53	2	O
54	2	O
55	.	O
56	7	O
57	min	O
58	,	O
59	Ymax	O
60	76	O
61	.	O
62	3	O
63	%;	O
64	S335D	O
65	,	O
66	t1	O
67	/	O
68	2	O
69	2	O
70	.	O
71	4	O
72	min	O
73	,	O
74	Ymax	O
75	76	O
76	.	O
77	7	O
78	%;	O
79	T336E	O
80	,	O
81	t1	O
82	/	O
83	2	O
84	2	O
85	.	O
86	5	O
87	min	O
88	,	O
89	Ymax	O
90	78	O
91	.	O
92	2	O
93	%;	O
94	S338D	O
95	,	O
96	t1	O
97	/	O
98	2	O
99	2	O
100	.	O
101	6	O
102	min	O
103	,	O
104	Ymax	O
105	78	O
106	.	O
107	4	O
108	%).	O

1	The	O
2	activated	O
3	glucocorticoid	B
4	receptor	I
5	forms	O
6	a	O
7	complex	O
8	with	O
9	Stat5	B
10	and	O
11	enhances	O
12	Stat5	B
13	-	O
14	mediated	O
15	transcriptional	O
16	induction	O
17	.	O

1	T	O
2	.,	O
3	Mahasneh	O
4	,	O
5	A	O
6	.,	O
7	and	O
8	Cote	O
9	,	O
10	G	O
11	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	portion	O
6	of	O
7	UKLF	B
8	contains	O
9	three	O
10	zinc	O
11	fingers	O
12	of	O
13	the	O
14	Cys2	O
15	-	O
16	His2	O
17	type	O
18	and	O
19	binds	O
20	in	O
21	vitro	O
22	to	O
23	the	O
24	CACCC	O
25	motif	O
26	of	O
27	the	O
28	beta	B
29	-	I
30	globin	I
31	promoter	I
32	and	O
33	to	O
34	the	O
35	Sp1	B
36	recognition	I
37	sequence	I
38	.	O

1	We	O
2	have	O
3	recently	O
4	identified	O
5	a	O
6	mouse	O
7	enzyme	O
8	termed	O
9	gamma	B
10	-	I
11	glutamyl	I
12	leukotrienase	I
13	(	O
14	GGL	B
15	)	O
16	that	O
17	converts	O
18	leukotriene	O
19	C4	O
20	(	O
21	LTC4	O
22	)	O
23	to	O
24	leukotriene	O
25	D4	O
26	(	O
27	LTD4	O
28	).	O

1	UGA	O
2	codon	O
3	position	O
4	affects	O
5	the	O
6	efficiency	O
7	of	O
8	selenocysteine	O
9	incorporation	O
10	into	O
11	glutathione	B
12	peroxidase	I
13	-	I
14	1	I
15	.	O

1	Forskolin	O
2	significantly	O
3	enhanced	O
4	heregulin	B
5	-	O
6	stimulated	O
7	expression	O
8	of	O
9	cyclin	B
10	D	I
11	and	O
12	phosphorylation	O
13	of	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	.	O

1	The	O
2	ARF	B
3	promoter	I
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	B
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	HMPAO	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O

1	CM	O
2	reduced	O
3	the	O
4	nuclear	O
5	binding	O
6	activity	O
7	of	O
8	transcription	B
9	factor	I
10	AP	I
11	-	I
12	1	I
13	.	O

1	NF	B
2	-	I
3	kappaB	I
4	,	O
5	which	O
6	is	O
7	probably	O
8	important	O
9	for	O
10	basal	O
11	activity	O
12	of	O
13	the	O
14	human	B
15	NOS	I
16	II	I
17	promoter	I
18	,	O
19	is	O
20	unlikely	O
21	to	O
22	function	O
23	as	O
24	a	O
25	major	O
26	effector	O
27	of	O
28	CM	O
29	in	O
30	DLD	O
31	-	O
32	1	O
33	cells	O
34	.	O

1	Observers	O
2	with	O
3	brain	O
4	injury	O
5	and	O
6	control	O
7	participants	O
8	performed	O
9	a	O
10	vigilance	O
11	task	O
12	during	O
13	which	O
14	they	O
15	received	O
16	periodic	O
17	whiffs	O
18	of	O
19	unscented	O
20	air	O
21	or	O
22	air	O
23	scented	O
24	with	O
25	peppermint	O
26	.	O

1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	polarized	O
18	photometric	O
19	detector	O
20	was	O
21	established	O
22	.	O

1	RESULTS	O
2	:	O
3	The	O
4	cardiac	O
5	index	O
6	significantly	O
7	changed	O
8	with	O
9	varying	O
10	PaCO2	O
11	levels	O
12	(	O
13	hypocapnia	O
14	,	O
15	-	O
16	9	O
17	%;	O
18	hypercapnia	O
19	,	O
20	13	O
21	%).	O

1	After	O
2	measuring	O
3	baseline	O
4	Vmca	O
5	at	O
6	a	O
7	partial	O
8	pressure	O
9	of	O
10	carbon	O
11	dioxide	O
12	in	O
13	arterial	O
14	blood	O
15	(	O
16	PaCO2	O
17	)	O
18	of	O
19	37	O
20	.	O
21	7	O
22	+/-	O
23	4	O
24	.	O
25	5	O
26	mmHg	O
27	(	O
28	mean	O
29	+/-	O
30	SD	O
31	),	O
32	measurements	O
33	were	O
34	repeated	O
35	at	O
36	a	O
37	PaCO	O
38	of	O
39	44	O
40	.	O
41	2	O
42	+/-	O
43	3	O
44	.	O
45	8	O
46	mmHg	O
47	,	O
48	and	O
49	the	O
50	carbon	O
51	dioxide	O
52	reactivity	O
53	(	O
54	absolute	O
55	value	O
56	:	O
57	cm	O
58	x	O
59	s	O
60	(-	O
61	1	O
62	)	O
63	x	O
64	mmHg	O
65	(-	O
66	1	O
67	);	O
68	relative	O
69	value	O
70	:	O
71	percentage	O
72	of	O
73	baseline	O
74	Vmca	O
75	/	O
76	mmHg	O
77	)	O
78	was	O
79	calculated	O
80	.	O

1	Multivariate	O
2	Cox	O
3	survival	O
4	analysis	O
5	identified	O
6	baseline	O
7	EF	O
8	<	O
9	or	O
10	=	O
11	30	O
12	%,	O
13	presence	O
14	of	O
15	significant	O
16	mitral	O
17	regurgitation	O
18	(>	O
19	2	O
20	+)	O
21	before	O
22	ablation	O
23	,	O
24	and	O
25	failure	O
26	to	O
27	exhibit	O
28	improved	O
29	cardiac	O
30	performance	O
31	by	O
32	1	O
33	month	O
34	after	O
35	ablation	O
36	as	O
37	the	O
38	only	O
39	independent	O
40	predictors	O
41	of	O
42	death	O
43	.	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	new	O
6	method	O
7	for	O
8	estimation	O
9	of	O
10	regional	O
11	CBF	O
12	(	O
13	rCBF	O
14	)	O
15	and	O
16	cerebrovascular	O
17	reserve	O
18	capacity	O
19	on	O
20	a	O
21	pixel	O
22	-	O
23	by	O
24	-	O
25	pixel	O
26	basis	O
27	by	O
28	means	O
29	of	O
30	dynamic	O
31	magnetic	O
32	resonance	O
33	imaging	O
34	(	O
35	MRI	O
36	).	O

1	Cost	O
2	-	O
3	effectiveness	O
4	analysis	O
5	provides	O
6	a	O
7	rational	O
8	means	O
9	of	O
10	allocating	O
11	limited	O
12	health	O
13	care	O
14	resources	O
15	by	O
16	allowing	O
17	the	O
18	comparison	O
19	of	O
20	the	O
21	costs	O
22	of	O
23	lipid	O
24	-	O
25	lowering	O
26	therapy	O
27	,	O
28	in	O
29	particular	O
30	,	O
31	therapy	O
32	with	O
33	beta	B
34	-	I
35	hydroxy	I
36	-	I
37	beta	I
38	-	I
39	methylglutaryl	I
40	-	I
41	CoA	I
42	(	I
43	coenzyme	I
44	A	I
45	)	I
46	reductase	I
47	inhibitors	O
48	(	O
49	statins	O
50	),	O
51	with	O
52	the	O
53	costs	O
54	of	O
55	atherosclerosis	O
56	that	O
57	could	O
58	be	O
59	prevented	O
60	by	O
61	lowering	O
62	cholesterol	O
63	.	O

1	Although	O
2	E2FBP1	B
3	lacks	O
4	the	O
5	transactivation	O
6	domain	O
7	,	O
8	it	O
9	stimulates	O
10	E2F	B
11	site	O
12	-	O
13	dependent	O
14	transcription	O
15	in	O
16	cooperation	O
17	with	O
18	E2F	B
19	-	I
20	1	I
21	.	O

1	Sequencing	O
2	of	O
3	a	O
4	40	O
5	-	O
6	kb	O
7	DNA	O
8	segment	O
9	of	O
10	the	O
11	FK506	O
12	gene	O
13	cluster	O
14	from	O
15	Streptomyces	O
16	sp	O
17	.	O

1	The	O
2	predicted	O
3	domain	O
4	structures	O
5	of	O
6	FkbB	B
7	and	O
8	FkbC	B
9	are	O
10	analogous	O
11	to	O
12	that	O
13	of	O
14	FkbA	B
15	and	O
16	comprise	O
17	30	O
18	fatty	B
19	-	I
20	acid	I
21	-	I
22	synthase	I
23	(	O
24	FAS	B
25	)-	O
26	like	O
27	domains	O
28	arranged	O
29	in	O
30	6	O
31	modules	O
32	.	O

1	Analysis	O
2	of	O
3	Msy2	B
4	mRNA	I
5	expression	O
6	in	O
7	prepubertal	O
8	and	O
9	adult	O
10	mouse	O
11	testes	O
12	,	O
13	and	O
14	in	O
15	isolated	O
16	populations	O
17	of	O
18	germ	O
19	cells	O
20	,	O
21	reveals	O
22	maximal	O
23	expression	O
24	in	O
25	postmeiotic	O
26	round	O
27	spermatids	O
28	,	O
29	a	O
30	cell	O
31	type	O
32	with	O
33	abundant	O
34	amounts	O
35	of	O
36	stored	O
37	messenger	O
38	ribonucleoproteins	O
39	.	O

1	1	O
2	in	O
3	Ho	O
4	Chi	O
5	Minh	O
6	City	O
7	was	O
8	studied	O
9	by	O
10	culture	O
11	and	O
12	latex	O
13	agglutination	O
14	of	O
15	blood	O
16	,	O
17	cerebrospinal	O
18	fluid	O
19	,	O
20	urine	O
21	and	O
22	pleural	O
23	fluid	O
24	.	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	B
21	in	I
22	Escherichia	I
23	coli	I
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	B
40	(	O
41	Ecc	B
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	B
54	in	I
55	Erwinia	I
56	carotovora	I
57	.	O

1	The	O
2	cwg2	B
3	-	I
4	1	I
5	mutation	I
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	604	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	originating	O
23	the	O
24	change	O
25	A202T	O
26	in	O
27	the	O
28	cwg2p	B
29	.	O

1	Deletion	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	essential	O
7	domain	O
8	of	O
9	this	O
10	promoter	O
11	,	O
12	termed	O
13	the	O
14	ORF5	B
15	/	I
16	deltaX	I
17	transcript	I
18	promoter	I
19	,	O
20	mapped	O
21	to	O
22	nucleotides	O
23	1525	O
24	-	O
25	1625	O
26	.	O

1	Some	O
2	of	O
3	the	O
4	peptide	B
5	:	I
6	MBP	I
7	fusions	I
8	were	O
9	also	O
10	analyzed	O
11	using	O
12	surface	O
13	plasmon	O
14	resonance	O
15	.	O

1	Cardiac	B
2	myosin	I
3	-	I
4	binding	I
5	protein	I
6	C	I
7	(	O
8	MyBP	B
9	-	I
10	C	I
11	):	O
12	identification	O
13	of	O
14	protein	B
15	kinase	I
16	A	I
17	and	O
18	protein	B
19	kinase	I
20	C	I
21	phosphorylation	O
22	sites	O
23	.	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	csrR	B
20	and	O
21	csrS	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O

1	633	O
2	+/-	O
3	258	O
4	aggregates	O
5	/	O
6	ml	O
7	at	O
8	0	O
9	rpm	O
10	;	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	).	O

1	We	O
2	previously	O
3	delineated	O
4	a	O
5	region	O
6	in	O
7	the	O
8	fatty	B
9	-	I
10	acid	I
11	synthase	I
12	promoter	I
13	,	O
14	which	O
15	was	O
16	responsible	O
17	for	O
18	obesity	O
19	-	O
20	related	O
21	overexpression	O
22	of	O
23	the	O
24	fatty	B
25	-	I
26	acid	I
27	synthase	I
28	(	O
29	FAS	B
30	)	O
31	gene	O
32	,	O
33	by	O
34	negatively	O
35	regulating	O
36	the	O
37	activity	O
38	of	O
39	the	O
40	downstream	O
41	promoter	O
42	in	O
43	lean	O
44	but	O
45	not	O
46	obese	O
47	rat	O
48	fat	O
49	cells	O
50	.	O

1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	B
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	B
18	/	O
19	SREBP1	B
20	binding	O
21	from	O
22	the	O
23	sterol	O
24	regulatory	O
25	element	O
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O

1	Thus	O
2	,	O
3	IRF	B
4	-	I
5	7	I
6	exhibits	O
7	functional	O
8	similarity	O
9	to	O
10	IRF	B
11	-	I
12	3	I
13	;	O
14	however	O
15	,	O
16	the	O
17	preferential	O
18	expression	O
19	of	O
20	IRF	B
21	-	I
22	7	I
23	in	O
24	lymphoid	O
25	cells	O
26	(	O
27	the	O
28	cell	O
29	type	O
30	that	O
31	expresses	O
32	IFNA	B
33	)	O
34	suggests	O
35	that	O
36	IRF	B
37	-	I
38	7	I
39	may	O
40	play	O
41	a	O
42	critical	O
43	role	O
44	in	O
45	regulating	O
46	the	O
47	IFNA	B
48	gene	I
49	expression	O
50	.	O

1	J	O
2	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	role	O
5	interleukin	B
6	-	I
7	6	I
8	(	O
9	IL	B
10	-	I
11	6	I
12	)	O
13	in	O
14	the	O
15	treatment	O
16	of	O
17	congenital	O
18	thrombocytopenias	O
19	is	O
20	unknown	O
21	.	O

1	CKII	B
2	as	O
3	a	O
4	CD44	B
5	-	I
6	associated	I
7	serine	I
8	kinase	I
9	therefore	O
10	may	O
11	serve	O
12	as	O
13	an	O
14	important	O
15	molecule	O
16	in	O
17	a	O
18	signaling	O
19	cascade	O
20	that	O
21	produces	O
22	a	O
23	variety	O
24	of	O
25	cellular	O
26	responses	O
27	in	O
28	MDA231	O
29	breast	O
30	cancer	O
31	cells	O
32	.	O

1	Galphaq	B
2	,	O
3	Galpha12	B
4	,	O
5	and	O
6	Galpha13	B
7	,	O
8	but	O
9	not	O
10	Galphai	B
11	,	O
12	activate	O
13	SRF	B
14	through	O
15	RhoA	B
16	.	O

1	Additionally	O
2	in	O
3	seven	O
4	subjects	O
5	adrenaline	O
6	(	O
7	A	O
8	)	O
9	and	O
10	noradrenaline	O
11	(	O
12	NA	O
13	)	O
14	concentrations	O
15	were	O
16	determined	O
17	.	O

1	Northern	O
2	blot	O
3	analyses	O
4	show	O
5	that	O
6	the	O
7	hBub1	B
8	mRNA	I
9	level	O
10	is	O
11	abundantly	O
12	expressed	O
13	in	O
14	tissues	O
15	or	O
16	cells	O
17	with	O
18	a	O
19	high	O
20	mitotic	O
21	index	O
22	.	O

1	We	O
2	mapped	O
3	two	O
4	overlapping	O
5	expressed	O
6	sequence	O
7	tag	O
8	clones	O
9	within	O
10	a	O
11	genomic	O
12	contig	O
13	on	O
14	human	O
15	chromosome	O
16	5	O
17	,	O
18	band	O
19	q31	O
20	.	O

1	Htra2	B
2	-	I
3	beta3	I
4	is	O
5	developmentally	O
6	regulated	O
7	and	O
8	expressed	O
9	predominantly	O
10	in	O
11	brain	O
12	,	O
13	liver	O
14	testis	O
15	,	O
16	and	O
17	weakly	O
18	in	O
19	kidney	O
20	.	O

1	Gng3lg	B
2	transcripts	I
3	are	O
4	expressed	O
5	in	O
6	a	O
7	variety	O
8	of	O
9	tissues	O
10	including	O
11	both	O
12	brain	O
13	and	O
14	testes	O
15	.	O

1	Using	O
2	an	O
3	interspecific	O
4	backcross	O
5	panel	O
6	,	O
7	we	O
8	localized	O
9	both	O
10	Gng3	B
11	and	O
12	Gng3lg	B
13	to	O
14	the	O
15	same	O
16	locus	O
17	on	O
18	chromosome	O
19	19	O
20	.	O

1	We	O
2	also	O
3	raised	O
4	a	O
5	polyclonal	O
6	antibody	O
7	against	O
8	the	O
9	glutathione	B
10	S	I
11	-	I
12	transferase	I
13	fusion	I
14	protein	I
15	containing	O
16	the	O
17	NH2	O
18	-	O
19	terminal	O
20	86	O
21	amino	O
22	acids	O
23	of	O
24	human	B
25	NRAMP2	I
26	.	O

1	Inhibition	O
2	of	O
3	the	O
4	apolipoprotein	B
5	B	I
6	mRNA	I
7	editing	O
8	enzyme	O
9	-	O
10	complex	O
11	by	O
12	hnRNP	B
13	C1	I
14	protein	I
15	and	O
16	40S	B
17	hnRNP	I
18	complexes	I
19	.	O

1	SRC	B
2	-	I
3	1	I
4	can	O
5	relieve	O
6	the	O
7	NF	B
8	-	I
9	kappaB	I
10	-	O
11	mediated	O
12	repression	O
13	of	O
14	GR	B
15	activity	O
16	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	total	O
7	number	O
8	of	O
9	subunit	O
10	c	O
11	in	O
12	F0	B
13	should	O
14	be	O
15	a	O
16	multiple	O
17	of	O
18	2	O
19	and	O
20	3	O
21	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	-	O
6	negative	O
7	mutant	O
8	of	O
9	JNK1	B
10	also	O
11	suppressed	O
12	glucose	O
13	deprivation	O
14	-	O
15	induced	O
16	JNK1	B
17	activation	O
18	as	O
19	well	O
20	as	O
21	HSP70	B
22	gene	I
23	expression	O
24	.	O

1	The	O
2	interaction	O
3	of	O
4	AF	O
5	-	O
6	1	O
7	with	O
8	proteins	O
9	that	O
10	regulate	O
11	distinct	O
12	steps	O
13	of	O
14	transcription	O
15	may	O
16	provide	O
17	a	O
18	mechanism	O
19	for	O
20	synergistic	O
21	activation	O
22	of	O
23	gene	O
24	expression	O
25	by	O
26	AF	O
27	-	O
28	1	O
29	.	O

1	The	O
2	role	O
3	of	O
4	protein	B
5	kinase	I
6	C	I
7	signaling	O
8	in	O
9	activated	O
10	DRA	B
11	transcription	O
12	.	O

1	Ligand	O
2	binding	O
3	to	O
4	the	O
5	receptor	O
6	complex	O
7	leads	O
8	to	O
9	tyrosine	O
10	phosphorylation	O
11	and	O
12	activation	O
13	of	O
14	Janus	B
15	kinases	I
16	(	O
17	Jak	B
18	),	O
19	phosphorylation	O
20	of	O
21	the	O
22	signal	B
23	transducing	I
24	subunit	I
25	gp130	I
26	,	O
27	followed	O
28	by	O
29	recruitment	O
30	and	O
31	phosphorylation	O
32	of	O
33	the	O
34	signal	B
35	transducer	I
36	and	I
37	activator	I
38	of	I
39	transcription	I
40	factors	I
41	STAT3	I
42	and	O
43	STAT1	B
44	and	O
45	the	O
46	src	B
47	homology	I
48	domain	I
49	(	O
50	SH2	B
51	)-	O
52	containing	O
53	protein	B
54	tyrosine	I
55	phosphatase	I
56	(	O
57	SHP2	B
58	).	O

1	Interestingly	O
2	,	O
3	an	O
4	increase	O
5	of	O
6	distance	O
7	per	O
8	se	O
9	did	O
10	not	O
11	have	O
12	a	O
13	deleterious	O
14	effect	O
15	on	O
16	translation	O
17	efficiency	O
18	.	O

1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	O
21	.	O
22	5kb	O
23	transcript	O
24	size	O
25	.	O

1	RBP56	B
2	protein	I
3	turned	O
4	out	O
5	to	O
6	be	O
7	hTAFII68	B
8	which	O
9	was	O
10	isolated	O
11	as	O
12	a	O
13	TATA	B
14	-	I
15	binding	I
16	protein	I
17	associated	I
18	factor	I
19	(	O
20	TAF	B
21	)	O
22	from	O
23	a	O
24	sub	O
25	-	O
26	population	O
27	of	O
28	TFIID	B
29	complexes	I
30	(	O
31	Bertolotti	O
32	A	O
33	.,	O
34	Lutz	O
35	,	O
36	Y	O
37	.,	O
38	Heard	O
39	,	O
40	D	O
41	.	O
42	J	O
43	.,	O
44	Chambon	O
45	,	O
46	P	O
47	.,	O
48	Tora	O
49	,	O
50	L	O
51	.,	O
52	1996	O
53	.	O
54	hTAFII68	B
55	,	O
56	a	O
57	novel	O
58	RNA	O
59	/	O
60	ssDNA	O
61	-	O
62	binding	O
63	protein	O
64	with	O
65	homology	O
66	to	O
67	the	O
68	proto	O
69	-	O
70	oncoproteins	O
71	TLS	B
72	/	O
73	FUS	B
74	and	O
75	EWS	B
76	is	O
77	associated	O
78	with	O
79	both	O
80	TFIID	B
81	and	O
82	RNA	B
83	polymerase	I
84	II	I
85	.	O

1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	O
14	TR2	B
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O

1	Gel	O
2	-	O
3	mobility	O
4	shift	O
5	analysis	O
6	was	O
7	also	O
8	performed	O
9	for	O
10	the	O
11	CCAAT	O
12	motif	O
13	at	O
14	-	O
15	67	O
16	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	c	B
5	-	I
6	myc	I
7	proto	I
8	-	I
9	oncogene	I
10	has	O
11	been	O
12	suggested	O
13	to	O
14	play	O
15	key	O
16	roles	O
17	in	O
18	cell	O
19	proliferation	O
20	,	O
21	differentiation	O
22	,	O
23	transformation	O
24	and	O
25	apoptosis	O
26	.	O

1	AMY	B
2	-	I
3	1	I
4	was	O
5	localized	O
6	in	O
7	the	O
8	cytoplasm	O
9	in	O
10	cells	O
11	expressing	O
12	c	B
13	-	I
14	myc	I
15	at	O
16	low	O
17	levels	O
18	,	O
19	but	O
20	in	O
21	the	O
22	nucleus	O
23	in	O
24	the	O
25	cells	O
26	of	O
27	a	O
28	high	O
29	c	B
30	-	I
31	myc	I
32	expression	O
33	in	O
34	transiently	O
35	transfected	O
36	cells	O
37	.	O

1	RESULTS	O
2	:	O
3	We	O
4	identified	O
5	a	O
6	full	O
7	-	O
8	length	O
9	cDNA	O
10	with	O
11	an	O
12	open	O
13	reading	O
14	frame	O
15	of	O
16	2883	O
17	bp	O
18	corresponding	O
19	to	O
20	a	O
21	predicted	O
22	protein	O
23	of	O
24	961	O
25	amino	O
26	acids	O
27	that	O
28	shares	O
29	greater	O
30	than	O
31	95	O
32	%	O
33	homology	O
34	with	O
35	the	O
36	rat	B
37	gamma	I
38	-	I
39	aminobutyric	I
40	acid	I
41	B	I
42	(	I
43	GABAB	I
44	)	I
45	receptor	I
46	.	O

1	On	O
2	Day	O
3	8	O
4	,	O
5	the	O
6	CIDR	O
7	-	O
8	B	O
9	was	O
10	removed	O
11	and	O
12	500	O
13	micrograms	O
14	cloprostenol	O
15	injected	O
16	,	O
17	IM	O
18	.	O

1	Antidepressant	O
2	-	O
3	like	O
4	properties	O
5	of	O
6	some	O
7	serotonin	B
8	receptor	I
9	ligands	O
10	and	O
11	calcium	O
12	channel	O
13	antagonists	O
14	measured	O
15	with	O
16	the	O
17	forced	O
18	swimming	O
19	test	O
20	in	O
21	mice	O
22	.	O

1	Another	O
2	tentative	O
3	hotspot	O
4	mutation	O
5	in	O
6	the	O
7	third	O
8	patient	O
9	,	O
10	a	O
11	frame	O
12	shift	O
13	caused	O
14	by	O
15	a	O
16	G	O
17	nucleotide	O
18	insertion	O
19	in	O
20	a	O
21	monotonous	O
22	repeat	O
23	of	O
24	six	O
25	Gs	O
26	in	O
27	HPRT	B
28	exon	I
29	3	I
30	,	O
31	has	O
32	been	O
33	reported	O
34	previously	O
35	in	O
36	three	O
37	other	O
38	LN	O
39	patients	O
40	.	O

1	SRF	B
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	Srf	B
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O

1	These	O
2	characteristic	O
3	structural	O
4	features	O
5	were	O
6	used	O
7	to	O
8	create	O
9	the	O
10	abbreviation	O
11	AZF1	B
12	(	O
13	Asparagine	B
14	-	I
15	rich	I
16	Zinc	I
17	Finger	I
18	protein	I
19	).	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	Azf1p	B
6	in	O
7	the	O
8	yeast	O
9	cell	O
10	does	O
11	not	O
12	influence	O
13	the	O
14	expression	O
15	level	O
16	of	O
17	the	O
18	mitochondrial	B
19	transcription	I
20	factor	I
21	Mtf1p	I
22	,	O
23	indicating	O
24	that	O
25	the	O
26	influence	O
27	of	O
28	Azf1p	B
29	on	O
30	the	O
31	suppression	O
32	of	O
33	the	O
34	special	O
35	mitochondrial	B
36	RNA	I
37	polymerase	I
38	mutant	I
39	is	O
40	an	O
41	indirect	O
42	one	O
43	.	O

1	We	O
2	have	O
3	generated	O
4	a	O
5	computer	O
6	model	O
7	of	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	domain	O
13	of	O
14	the	O
15	434	O
16	repressor	O
17	based	O
18	on	O
19	the	O
20	crystal	O
21	structure	O
22	of	O
23	the	O
24	homologous	B
25	UmuD	I
26	'	I
27	protein	I
28	.	O

1	Large	O
2	-	O
3	scale	O
4	sequencing	O
5	of	O
6	two	O
7	regions	O
8	in	O
9	human	O
10	chromosome	O
11	7q22	O
12	:	O
13	analysis	O
14	of	O
15	650	O
16	kb	O
17	of	O
18	genomic	O
19	sequence	O
20	around	O
21	the	O
22	EPO	B
23	and	O
24	CUTL1	B
25	loci	I
26	reveals	O
27	17	O
28	genes	O
29	.	O

1	Because	O
2	Trp53	B
3	(	O
4	the	O
5	mouse	B
6	homolog	I
7	of	I
8	human	I
9	TP53	I
10	)	O
11	is	O
12	located	O
13	with	O
14	Tk1	B
15	on	O
16	chromosome	O
17	11	O
18	and	O
19	is	O
20	critical	O
21	in	O
22	regulating	O
23	cellular	O
24	responses	O
25	following	O
26	exposure	O
27	to	O
28	DNA	O
29	damaging	O
30	agents	O
31	,	O
32	we	O
33	wanted	O
34	to	O
35	determine	O
36	if	O
37	these	O
38	mouse	O
39	lymphoma	O
40	cells	O
41	harbor	O
42	mutations	O
43	in	O
44	Trp53	B
45	.	O

1	One	O
2	of	O
3	these	O
4	fragments	O
5	shows	O
6	the	O
7	highest	O
8	amino	O
9	acid	O
10	sequence	O
11	homology	O
12	to	O
13	the	O
14	insect	O
15	ecdysone	O
16	inducible	O
17	gene	B
18	E75	I
19	.	O

1	The	O
2	full	O
3	-	O
4	length	O
5	N	B
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	O
24	-	O
25	8	O
26	.	O

1	Based	O
2	on	O
3	sequence	O
4	homology	O
5	,	O
6	the	O
7	genes	O
8	were	O
9	identified	O
10	as	O
11	TEF	B
12	,	O
13	encoding	O
14	translation	B
15	elongation	I
16	factor	I
17	-	I
18	1	I
19	alpha	I
20	and	O
21	RPS7	B
22	,	O
23	encoding	O
24	ribosomal	O
25	protein	O
26	S7	B
27	.	O

1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	ARNO	B
7	localizes	O
8	to	O
9	the	O
10	plasma	O
11	membrane	O
12	in	O
13	vivo	O
14	and	O
15	efficiently	O
16	catalyzes	O
17	ARF6	B
18	nucleotide	O
19	exchange	O
20	in	O
21	vitro	O
22	.	O

1	Renal	O
2	pathology	O
3	and	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	in	O
9	childhood	O
10	SLE	O
11	.	O

1	Transcription	O
2	factors	O
3	of	O
4	the	O
5	Stat	B
6	family	I
7	are	O
8	controlled	O
9	by	O
10	protein	O
11	kinases	O
12	.	O

1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	Stat5	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	PD98059	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	PD98059	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	Stat5a	B
35	.	O

1	An	O
2	approximately	O
3	37	O
4	-	O
5	kDa	O
6	cytoplasmic	O
7	protein	O
8	is	O
9	rapidly	O
10	tyrosine	O
11	-	O
12	phosphorylated	O
13	in	O
14	the	O
15	response	O
16	of	O
17	mouse	O
18	BAC1	O
19	.	O
20	2F5	O
21	macrophages	O
22	to	O
23	colony	B
24	stimulating	I
25	factor	I
26	-	I
27	1	I
28	(	O
29	CSF	B
30	-	I
31	1	I
32	).	O
33	pp37	B
34	was	O
35	purified	O
36	from	O
37	the	O
38	cytosolic	O
39	fraction	O
40	by	O
41	anti	B
42	-	I
43	Tyr	I
44	(	I
45	P	I
46	)	I
47	affinity	O
48	chromatography	O
49	,	O
50	size	O
51	exclusion	O
52	chromatography	O
53	,	O
54	and	O
55	C4	O
56	reverse	O
57	phase	O
58	high	O
59	pressure	O
60	liquid	O
61	chromatography	O
62	.	O

1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O

1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	"	O
14	sperm	O
15	fall	O
16	"	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O

1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	Its	O
2	interaction	O
3	with	O
4	RFX5	B
5	and	O
6	RFXAP	B
7	is	O
8	essential	O
9	for	O
10	binding	O
11	of	O
12	the	O
13	RFX	B
14	complex	I
15	to	O
16	MHC	B
17	-	I
18	II	I
19	promoters	I
20	.	O

1	We	O
2	have	O
3	previously	O
4	mapped	O
5	the	O
6	defect	O
7	in	O
8	RIIIS	O
9	/	O
10	J	O
11	to	O
12	distal	O
13	mouse	O
14	Chr	O
15	11	O
16	,	O
17	distinct	O
18	from	O
19	the	O
20	Vwf	B
21	locus	I
22	on	O
23	Chr	O
24	6	O
25	.	O

1	These	O
2	data	O
3	may	O
4	also	O
5	aid	O
6	in	O
7	the	O
8	localization	O
9	of	O
10	other	O
11	disease	O
12	loci	O
13	mapped	O
14	to	O
15	this	O
16	region	O
17	,	O
18	including	O
19	the	O
20	gene	O
21	for	O
22	tricho	O
23	-	O
24	dento	O
25	-	O
26	osseous	O
27	syndrome	O
28	and	O
29	a	O
30	murine	O
31	locus	O
32	for	O
33	susceptibility	O
34	to	O
35	ozone	O
36	-	O
37	induced	O
38	acute	O
39	lung	O
40	injury	O
41	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	invertases	B
14	and	O
15	resolvases	B
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	Pac25I	B
23	R	I
24	-	I
25	M	I
26	operon	I
27	.	O

1	Identification	O
2	of	O
3	a	O
4	new	O
5	gene	O
6	in	O
7	the	O
8	streptococcal	O
9	plasmid	O
10	pLS1	O
11	:	O
12	the	O
13	rnaI	B
14	gene	I
15	.	O

1	Rather	O
2	,	O
3	usp	B
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O

1	An	O
2	intact	O
3	neurovascular	O
4	supply	O
5	is	O
6	essential	O
7	for	O
8	the	O
9	viability	O
10	of	O
11	a	O
12	muscle	O
13	flap	O
14	.	O

1	Examination	O
2	of	O
3	DNA	O
4	:	O
5	protein	O
6	binding	O
7	complexes	O
8	by	O
9	gel	O
10	-	O
11	shift	O
12	analysis	O
13	indicated	O
14	that	O
15	nuclear	O
16	factors	O
17	from	O
18	both	O
19	proliferative	O
20	and	O
21	growth	O
22	-	O
23	arrested	O
24	cells	O
25	bound	O
26	to	O
27	the	O
28	DNA	O
29	fragment	O
30	spanning	O
31	-	O
32	949	O
33	-	O
34	-	O
35	722	O
36	bp	O
37	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	Fatal	O
2	apneusis	O
3	was	O
4	observed	O
5	under	O
6	following	O
7	conditions	O
8	:	O
9	(	O
10	1	O
11	)	O
12	Persistent	O
13	apnea	O
14	was	O
15	produced	O
16	after	O
17	a	O
18	single	O
19	KA	O
20	microinjection	O
21	in	O
22	one	O
23	side	O
24	of	O
25	the	O
26	VRG	O
27	-	O
28	Apa	O
29	(	O
30	5	O
31	animals	O
32	).	O

1	A	O
2	comparative	O
3	analysis	O
4	of	O
5	the	O
6	reported	O
7	MOCT	O
8	-	O
9	associated	O
10	malignant	O
11	melanomas	O
12	emphasizes	O
13	the	O
14	singularity	O
15	of	O
16	our	O
17	case	O
18	in	O
19	the	O
20	amelanotic	O
21	character	O
22	of	O
23	the	O
24	melanoma	O
25	,	O
26	its	O
27	lymphotropism	O
28	and	O
29	the	O
30	coexistence	O
31	of	O
32	invasive	O
33	squamous	O
34	cell	O
35	carcinoma	O
36	.	O

1	RESULTS	O
2	:	O
3	An	O
4	herpetic	O
5	seroconversion	O
6	is	O
7	observed	O
8	with	O
9	presence	O
10	of	O
11	type	O
12	I	O
13	herpes	O
14	simplex	O
15	virus	O
16	(	O
17	HSV	O
18	I	O
19	)	O
20	nucleic	O
21	acids	O
22	in	O
23	the	O
24	recipient	O
25	'	O
26	s	O
27	aqueous	O
28	humor	O
29	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	O
6	-	O
7	1	O
8	Gag	B
9	sequences	I
10	can	O
11	influence	O
12	the	O
13	viral	B
14	PR	I
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	O
21	TM	B
22	Env	I
23	protein	I
24	p15	O
25	(	O
26	E	O
27	).	O

1	These	O
2	results	O
3	demonstrate	O
4	a	O
5	specific	O
6	association	O
7	of	O
8	SIV	O
9	and	O
10	HIV	B
11	-	I
12	2	I
13	nef	I
14	,	O
15	but	O
16	not	O
17	HIV	B
18	-	I
19	1	I
20	nef	I
21	,	O
22	with	O
23	TCRzeta	B
24	.	O

1	Competition	O
2	EMSA	O
3	established	O
4	that	O
5	constitutively	O
6	expressed	O
7	nuclear	O
8	proteins	O
9	bound	O
10	the	O
11	KCS	B
12	element	I
13	selectively	O
14	;	O
15	KCS	B
16	protein	I
17	binding	O
18	activity	O
19	correlated	O
20	with	O
21	promoter	O
22	activity	O
23	in	O
24	the	O
25	transient	O
26	transfection	O
27	reporter	O
28	assay	O
29	.	O

1	Mechanism	O
2	of	O
3	interferon	B
4	action	O
5	:	O
6	identification	O
7	of	O
8	essential	O
9	positions	O
10	within	O
11	the	O
12	novel	O
13	15	B
14	-	I
15	base	I
16	-	I
17	pair	I
18	KCS	I
19	element	I
20	required	O
21	for	O
22	transcriptional	O
23	activation	O
24	of	O
25	the	O
26	RNA	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	pkr	I
32	gene	I
33	.	O

1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O

1	Expression	O
2	of	O
3	a	O
4	novel	O
5	murine	B
6	phospholipase	I
7	D	I
8	homolog	I
9	coincides	O
10	with	O
11	late	O
12	neuronal	O
13	development	O
14	in	O
15	the	O
16	forebrain	O
17	.	O

1	We	O
2	detected	O
3	no	O
4	effect	O
5	of	O
6	deleting	O
7	YCL024W	B
8	,	O
9	either	O
10	alone	O
11	or	O
12	in	O
13	combination	O
14	with	O
15	deletion	O
16	of	O
17	GIN4	B
18	.	O

1	Paralemmin	B
2	is	O
3	also	O
4	phosphorylated	O
5	,	O
6	and	O
7	its	O
8	mRNA	O
9	is	O
10	differentially	O
11	spliced	O
12	in	O
13	a	O
14	tissue	O
15	-	O
16	specific	O
17	and	O
18	developmentally	O
19	regulated	O
20	manner	O
21	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	CBP90	B
8	had	O
9	no	O
10	significant	O
11	similarity	O
12	to	O
13	any	O
14	other	O
15	protein	O
16	,	O
17	but	O
18	it	O
19	had	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	domain	O
25	at	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	-	O
6	profile	O
7	serine	O
8	substitutions	O
9	in	O
10	the	O
11	V3	B
12	loop	O
13	of	O
14	HIV	O
15	-	O
16	1	O
17	gp120	B
18	IIIB	I
19	/	O
20	LAI	B
21	on	O
22	the	O
23	immunogenicity	O
24	of	O
25	the	O
26	envelope	B
27	protein	O
28	.	O

1	Transcription	O
2	start	O
3	site	O
4	mapping	O
5	identified	O
6	the	O
7	presence	O
8	of	O
9	an	O
10	aphidicolin	O
11	-	O
12	sensitive	O
13	late	O
14	transcript	O
15	arising	O
16	from	O
17	a	O
18	TAAG	O
19	motif	O
20	located	O
21	at	O
22	-	O
23	352	O
24	nucleotides	O
25	and	O
26	an	O
27	aphidicolin	O
28	-	O
29	insensitive	O
30	early	O
31	transcript	O
32	originating	O
33	from	O
34	a	O
35	TTGT	O
36	motif	O
37	located	O
38	35	O
39	nucleotides	O
40	downstream	O
41	to	O
42	a	O
43	TATA	O
44	box	O
45	at	O
46	-	O
47	312	O
48	nucleotides	O
49	,	O
50	with	O
51	respect	O
52	to	O
53	the	O
54	+	O
55	1	O
56	ATG	O
57	of	O
58	lef2	B
59	.	O

1	The	O
2	human	B
3	2	I
4	',	I
5	5	I
6	'-	I
7	oligoadenylate	I
8	(	I
9	2	I
10	-	I
11	5A	I
12	)	I
13	synthetases	I
14	are	O
15	members	O
16	of	O
17	a	O
18	family	O
19	interferon	B
20	(	O
21	IFN	B
22	)-	O
23	inducible	O
24	anti	B
25	-	I
26	viral	I
27	proteins	I
28	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O

1	Low	O
2	PbrO2	O
3	readings	O
4	,	O
5	however	O
6	,	O
7	could	O
8	be	O
9	caused	O
10	by	O
11	local	O
12	microhemorrhages	O
13	,	O
14	undetectable	O
15	on	O
16	CT	O
17	or	O
18	MRI	O
19	.	O

1	The	O
2	consequences	O
3	of	O
4	intensive	O
5	swine	O
6	production	O
7	on	O
8	the	O
9	environment	O
10	and	O
11	possible	O
12	solutions	O
13	by	O
14	means	O
15	of	O
16	nutrition	O
17	are	O
18	outlined	O
19	.	O

1	This	O
2	study	O
3	demonstrates	O
4	that	O
5	alteration	O
6	of	O
7	CDKN2	B
8	is	O
9	one	O
10	of	O
11	the	O
12	most	O
13	frequent	O
14	genetic	O
15	abnormalities	O
16	in	O
17	prostate	O
18	cancer	O
19	and	O
20	may	O
21	contribute	O
22	to	O
23	prostate	O
24	carcinogenesis	O
25	.	O

1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	helped	O
6	predict	O
7	these	O
8	toxicities	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	O
7	-	O
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	However	O
2	,	O
3	the	O
4	use	O
5	of	O
6	cyclosporin	O
7	A	O
8	is	O
9	associated	O
10	with	O
11	an	O
12	increased	O
13	prevalence	O
14	of	O
15	hypertension	O
16	in	O
17	kidney	O
18	transplant	O
19	recipients	O
20	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	effects	O
7	of	O
8	hypercholesterolemia	O
9	and	O
10	atherosclerosis	O
11	-	O
12	induced	O
13	chronic	O
14	cavernosal	O
15	arterial	O
16	insufficiency	O
17	on	O
18	cavernosal	O
19	smooth	O
20	muscle	O
21	tone	O
22	,	O
23	nitric	B
24	oxide	I
25	synthase	I
26	(	O
27	NOS	B
28	)	O
29	activity	O
30	and	O
31	cavernosal	O
32	tissue	O
33	synthesis	O
34	of	O
35	constrictor	O
36	eicosanoids	O
37	.	O

1	Characterization	O
2	of	O
3	the	O
4	regulatory	O
5	regions	O
6	of	O
7	the	O
8	human	B
9	aromatase	I
10	(	O
11	P450arom	B
12	)	O
13	gene	O
14	involved	O
15	in	O
16	placenta	O
17	-	O
18	specific	O
19	expression	O
20	.	O

1	Recombinant	B
2	FVIIa	I
3	was	O
4	stable	O
5	in	O
6	the	O
7	infusion	O
8	pump	O
9	for	O
10	several	O
11	days	O
12	at	O
13	room	O
14	temperature	O
15	and	O
16	for	O
17	24	O
18	h	O
19	at	O
20	body	O
21	temperature	O
22	.	O

1	CD4	B
2	lymphocyte	O
3	and	O
4	viral	O
5	load	O
6	levels	O
7	suggested	O
8	an	O
9	optimal	O
10	response	O
11	to	O
12	ARV	O
13	therapy	O
14	at	O
15	the	O
16	time	O
17	LD	O
18	developed	O
19	.	O

1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O

1	Levels	O
2	of	O
3	serum	O
4	IgE	B
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O

1	A	O
2	mutation	O
3	in	O
4	the	O
5	5	O
6	'	O
7	C2U4	O
8	repeat	O
9	causes	O
10	underaccumulation	O
11	of	O
12	snR13F	B
13	,	O
14	whereas	O
15	mutations	O
16	in	O
17	the	O
18	3	O
19	'	O
20	C2U4	O
21	repeat	O
22	cause	O
23	the	O
24	accumulation	O
25	of	O
26	two	O
27	novel	O
28	RNAs	O
29	that	O
30	migrate	O
31	in	O
32	the	O
33	500	O
34	-	O
35	nt	O
36	range	O
37	.	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	B
7	and	O
8	tyrosine	B
9	kinases	I
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	B
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	By	O
2	DNase	B
3	I	I
4	footprint	O
5	analysis	O
6	of	O
7	the	O
8	PNR	O
9	element	O
10	,	O
11	a	O
12	palindrome	O
13	of	O
14	two	O
15	high	O
16	-	O
17	affinity	O
18	Ets	B
19	-	I
20	binding	I
21	sites	I
22	(	O
23	CTTCCCTGGAAG	O
24	)	O
25	was	O
26	identified	O
27	.	O

1	These	O
2	sorting	B
3	nexins	I
4	also	O
5	associated	O
6	with	O
7	the	O
8	long	O
9	isoform	O
10	of	O
11	the	O
12	leptin	B
13	receptor	I
14	but	O
15	not	O
16	with	O
17	the	O
18	short	O
19	and	O
20	medium	O
21	isoforms	O
22	.	O

1	Cyclophilins	B
2	are	O
3	cis	B
4	-	I
5	trans	I
6	-	I
7	peptidyl	I
8	-	I
9	prolyl	I
10	isomerases	I
11	that	O
12	bind	O
13	to	O
14	and	O
15	are	O
16	inhibited	O
17	by	O
18	the	O
19	immunosuppressant	O
20	cyclosporin	O
21	A	O
22	(	O
23	CsA	O
24	).	O

1	In	O
2	vitro	O
3	protein	O
4	retention	O
5	experiments	O
6	in	O
7	which	O
8	Hsp90	B
9	heterocomplexes	I
10	were	O
11	precipitated	O
12	resulted	O
13	in	O
14	coprecipitation	O
15	of	O
16	Cns1	B
17	.	O

1	The	O
2	Ras	B
3	-	I
4	related	I
5	GTPases	I
6	are	O
7	small	O
8	,	O
9	20	O
10	-	O
11	to	O
12	25	O
13	-	O
14	kDa	O
15	proteins	O
16	which	O
17	cycle	O
18	between	O
19	an	O
20	inactive	O
21	GDP	O
22	-	O
23	bound	O
24	form	O
25	and	O
26	an	O
27	active	O
28	GTP	O
29	-	O
30	bound	O
31	state	O
32	.	O

1	To	O
2	modulate	O
3	transcription	O
4	,	O
5	regulatory	O
6	factors	O
7	communicate	O
8	with	O
9	basal	O
10	transcription	O
11	factors	O
12	and	O
13	/	O
14	or	O
15	RNA	B
16	polymerases	I
17	in	O
18	a	O
19	variety	O
20	of	O
21	ways	O
22	.	O

1	Endogenous	O
2	RMP	B
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	B
10	in	O
11	RNA	B
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	rabbits	O
6	were	O
7	used	O
8	to	O
9	evaluate	O
10	the	O
11	sutured	O
12	wound	O
13	reaction	O
14	with	O
15	Dexon	O
16	or	O
17	nylon	O
18	in	O
19	the	O
20	conjunctival	O
21	flap	O
22	1	O
23	,	O
24	4	O
25	,	O
26	7	O
27	,	O
28	14	O
29	and	O
30	28	O
31	days	O
32	after	O
33	trabeculectomy	O
34	surgery	O
35	with	O
36	or	O
37	without	O
38	the	O
39	use	O
40	of	O
41	mitomycin	O
42	-	O
43	C	O
44	.	O

1	The	O
2	mapping	O
3	was	O
4	completed	O
5	with	O
6	Southern	O
7	blotting	O
8	and	O
9	restriction	O
10	analysis	O
11	.	O

1	The	O
2	zona	O
3	pellucida	O
4	(	O
5	ZP	O
6	),	O
7	the	O
8	extracellular	O
9	glycocalyx	O
10	that	O
11	surrounds	O
12	the	O
13	oocyte	O
14	,	O
15	is	O
16	well	O
17	known	O
18	to	O
19	mediate	O
20	homologous	O
21	gamete	O
22	interaction	O
23	.	O

1	Therapeutic	O
2	use	O
3	of	O
4	continuous	O
5	subcutaneous	O
6	infusion	O
7	of	O
8	recombinant	B
9	human	I
10	erythropoietin	I
11	in	O
12	malnourished	O
13	predialysis	O
14	anemic	O
15	patients	O
16	with	O
17	diabetic	O
18	nephropathy	O
19	.	O

1	Although	O
2	pathological	O
3	thyroid	O
4	function	O
5	is	O
6	related	O
7	to	O
8	changes	O
9	in	O
10	energy	O
11	expenditure	O
12	and	O
13	body	O
14	composition	O
15	,	O
16	its	O
17	possible	O
18	influence	O
19	on	O
20	leptin	B
21	levels	O
22	remains	O
23	to	O
24	be	O
25	determined	O
26	.	O

1	These	O
2	cognitive	O
3	deficits	O
4	were	O
5	prevented	O
6	in	O
7	animals	O
8	treated	O
9	with	O
10	MK	O
11	-	O
12	801	O
13	during	O
14	SE	O
15	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	HIF	B
11	-	I
12	1alpha	I
13	is	O
14	a	O
15	multi	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	O
26	and	O
27	activation	O
28	(	O
29	derepression	O
30	)	O
31	of	O
32	the	O
33	transactivation	O
34	domain	O
35	,	O
36	resulting	O
37	in	O
38	recruitment	O
39	of	O
40	the	O
41	CREB	B
42	-	I
43	binding	I
44	protein	I
45	(	O
46	CBP	B
47	)/	O
48	p300	B
49	coactivator	I
50	.	O

1	Thus	O
2	,	O
3	hypoxia	O
4	-	O
5	inducible	O
6	nuclear	O
7	import	O
8	and	O
9	transactivation	O
10	by	O
11	recruitment	O
12	of	O
13	CBP	B
14	can	O
15	be	O
16	functionally	O
17	separated	O
18	from	O
19	one	O
20	another	O
21	and	O
22	play	O
23	critical	O
24	roles	O
25	in	O
26	signal	O
27	transduction	O
28	by	O
29	HIF	B
30	-	I
31	1alpha	I
32	.	O

1	The	O
2	rat	B
3	aldolase	I
4	C	I
5	gene	I
6	encodes	O
7	a	O
8	glycolytic	O
9	enzyme	O
10	strongly	O
11	expressed	O
12	in	O
13	adult	O
14	brain	O
15	.	O

1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	B
6	promoter	I
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O

1	Quinone	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	O
12	binding	O
13	.	O

1	Western	O
2	analyses	O
3	with	O
4	antisera	O
5	raised	O
6	against	O
7	Lu	B
8	-	I
9	ECAM	I
10	-	I
11	1	I
12	peptides	I
13	show	O
14	that	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	predicted	O
23	open	O
24	reading	O
25	frame	O
26	is	O
27	present	O
28	only	O
29	in	O
30	the	O
31	larger	O
32	size	O
33	proteins	O
34	(	O
35	i	O
36	.	O
37	e	O
38	.	O

1	Mammalian	O
2	sperm	O
3	motility	O
4	is	O
5	regulated	O
6	by	O
7	a	O
8	cascade	O
9	of	O
10	cAMP	O
11	-	O
12	dependent	O
13	protein	O
14	phosphorylation	O
15	events	O
16	mediated	O
17	by	O
18	protein	B
19	kinase	I
20	A	I
21	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	BAP2	B
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	BAP3	B
17	gene	I
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	branched	O
29	-	O
30	chain	O
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O

1	Effect	O
2	of	O
3	enteral	O
4	nutritional	O
5	products	O
6	differing	O
7	in	O
8	carbohydrate	O
9	and	O
10	fat	O
11	on	O
12	indices	O
13	of	O
14	carbohydrate	O
15	and	O
16	lipid	O
17	metabolism	O
18	in	O
19	patients	O
20	with	O
21	NIDDM	O
22	.	O

1	Low	O
2	-	O
3	grade	O
4	gastric	O
5	MALT	O
6	lymphoma	O
7	and	O
8	helicobacter	O
9	heilmannii	O
10	(	O
11	Gastrospirillum	O
12	hominis	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	B
8	I	I
9	(	I
10	Y	I
11	)	I
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	B
18	-	I
19	DRA	I
20	gene	I
21	activation	O
22	by	O
23	Oct	B
24	-	I
25	2A	I
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	In	O
2	contrast	O
3	to	O
4	hemodynamic	O
5	and	O
6	histopathological	O
7	predictors	O
8	of	O
9	survival	O
10	,	O
11	vWF	B
12	:	O
13	Ag	O
14	does	O
15	not	O
16	require	O
17	invasive	O
18	techniques	O
19	to	O
20	be	O
21	determined	O
22	.	O

1	CONCLUSION	O
2	:	O
3	We	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	features	O
9	of	O
10	disease	O
11	likely	O
12	to	O
13	be	O
14	associated	O
15	with	O
16	a	O
17	clinically	O
18	useful	O
19	response	O
20	to	O
21	inhaled	O
22	NO	O
23	therapy	O
24	using	O
25	the	O
26	parameters	O
27	studied	O
28	.	O

1	We	O
2	find	O
3	that	O
4	BCL	B
5	-	I
6	6	I
7	POZ	O
8	domain	O
9	mutations	O
10	that	O
11	disrupt	O
12	the	O
13	interaction	O
14	with	O
15	N	B
16	-	I
17	CoR	I
18	and	O
19	SMRT	B
20	no	O
21	longer	O
22	repress	O
23	transcription	O
24	.	O

1	Partial	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	B
8	platelet	I
9	cAMP	I
10	phosphodiesterase	I
11	,	O
12	PDE3A	B
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O

1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	O
23	BPV	O
24	-	O
25	1	O
26	pre	O
27	-	O
28	mRNAs	O
29	.	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	myoD	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	alleviated	O
21	repression	O
22	by	O
23	COUP	B
24	-	I
25	TF	I
26	II	I
27	.	O

1	Familial	O
2	autoimmune	O
3	hepatitis	O
4	and	O
5	C4	B
6	deficiency	O

1	No	O
2	mutations	O
3	were	O
4	found	O
5	in	O
6	follicular	O
7	adenomas	O
8	.	O

1	Since	O
2	glutathione	B
3	peroxidase	I
4	(	O
5	GPX	B
6	)	O
7	and	O
8	superoxide	B
9	dismutase	I
10	(	O
11	SOD	B
12	)	O
13	play	O
14	a	O
15	significant	O
16	role	O
17	in	O
18	erythrocyte	O
19	antioxidative	O
20	defence	O
21	,	O
22	it	O
23	is	O
24	very	O
25	important	O
26	to	O
27	determine	O
28	their	O
29	activity	O
30	in	O
31	occupationally	O
32	exposed	O
33	workers	O
34	.	O

1	Retroviral	B
2	nucleocapsid	I
3	proteins	I
4	(	O
5	NCPs	B
6	)	O
7	are	O
8	CCHC	B
9	-	I
10	type	I
11	zinc	I
12	finger	I
13	proteins	I
14	that	O
15	mediate	O
16	virion	O
17	RNA	O
18	binding	O
19	activities	O
20	associated	O
21	with	O
22	retrovirus	O
23	assembly	O
24	and	O
25	genomic	O
26	RNA	O
27	encapsidation	O
28	.	O

1	The	O
2	Schizosaccharomyces	B
3	pombe	I
4	rad1	I
5	+	I
6	cell	I
7	cycle	I
8	checkpoint	I
9	control	I
10	gene	I
11	is	O
12	required	O
13	for	O
14	S	O
15	-	O
16	phase	O
17	and	O
18	G2	O
19	/	O
20	M	O
21	arrest	O
22	in	O
23	response	O
24	to	O
25	both	O
26	DNA	O
27	damage	O
28	and	O
29	incomplete	O
30	DNA	O
31	replication	O
32	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	I
23	dependent	I
24	kinases	I
25	(	O
26	CDKs	B
27	).	O

1	Positive	O
2	genetic	O
3	selections	O
4	for	O
5	inhibition	O
6	of	O
7	cyclin	B
8	/	O
9	CDK	B
10	function	O
11	were	O
12	characterized	O
13	using	O
14	the	O
15	E	B
16	.	I
17	coli	I
18	neo	I
19	and	O
20	yeast	B
21	LEU2	I
22	genes	I
23	.	O

1	The	O
2	hematopoietic	B
3	colony	I
4	-	I
5	stimulating	I
6	factors	I
7	(	O
8	CSF	B
9	)	O
10	have	O
11	been	O
12	introduced	O
13	into	O
14	clinical	O
15	practice	O
16	as	O
17	additional	O
18	supportive	O
19	measures	O
20	that	O
21	can	O
22	reduce	O
23	the	O
24	incidence	O
25	of	O
26	infectious	O
27	complications	O
28	in	O
29	patients	O
30	with	O
31	cancer	O
32	and	O
33	neutropenia	O
34	.	O

1	All	O
2	injections	O
3	of	O
4	CSF	B
5	were	O
6	given	O
7	after	O
8	the	O
9	initiation	O
10	of	O
11	neutropenia	O
12	and	O
13	continued	O
14	until	O
15	the	O
16	occurrence	O
17	of	O
18	an	O
19	absolute	O
20	neutrophil	O
21	recovery	O
22	.	O
23	rHu	B
24	GM	I
25	-	I
26	CSF	I
27	and	O
28	rHu	B
29	G	I
30	-	I
31	CSF	I
32	,	O
33	administered	O
34	once	O
35	daily	O
36	at	O
37	the	O
38	250	O
39	microg	O
40	m	O
41	(-	O
42	2	O
43	)	O
44	day	O
45	(-	O
46	1	O
47	)	O
48	and	O
49	5	O
50	microg	O
51	kg	O
52	(-	O
53	1	O
54	)	O
55	day	O
56	(-	O
57	1	O
58	)	O
59	level	O
60	,	O
61	were	O
62	effective	O
63	in	O
64	increasing	O
65	the	O
66	absolute	O
67	neutrophil	O
68	count	O
69	and	O
70	neutrophil	O
71	function	O
72	,	O
73	as	O
74	measured	O
75	by	O
76	an	O
77	automated	O
78	chemiluminescence	O
79	system	O
80	.	O

1	Expression	O
2	of	O
3	lacZ	B
4	from	O
5	the	O
6	promoter	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	spc	I
12	operon	I
13	cloned	O
14	into	O
15	vectors	O
16	carrying	O
17	the	O
18	W205	O
19	trp	B
20	-	O
21	lac	B
22	fusion	O
23	.	O

1	We	O
2	evaluated	O
3	regional	O
4	right	O
5	ventricular	O
6	wall	O
7	motion	O
8	during	O
9	systole	O
10	in	O
11	patients	O
12	with	O
13	surgically	O
14	repaired	O
15	tetralogy	O
16	of	O
17	Fallot	O
18	(	O
19	TOF	O
20	)	O
21	using	O
22	color	O
23	kinesis	O
24	imaging	O
25	.	O

1	RT	O
2	-	O
3	PCR	O
4	analysis	O
5	showed	O
6	that	O
7	PLP	B
8	-	I
9	H	I
10	as	O
11	well	O
12	as	O
13	PLP	B
14	-	I
15	C	I
16	and	O
17	PLP	B
18	-	I
19	D	I
20	are	O
21	expressed	O
22	in	O
23	all	O
24	rat	O
25	strains	O
26	examined	O
27	,	O
28	confirming	O
29	that	O
30	PLP	B
31	diversity	O
32	is	O
33	not	O
34	due	O
35	to	O
36	strain	O
37	differences	O
38	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	rat	B
12	placental	I
13	prolactin	I
14	(	O
15	PRL	B
16	)	O
17	family	O
18	,	O
19	PRL	B
20	-	O
21	like	O
22	protein	B
23	H	I
24	.	O

1	Interestingly	O
2	,	O
3	we	O
4	find	O
5	that	O
6	the	O
7	interaction	O
8	between	O
9	Tat	B
10	and	O
11	hCycT1	B
12	requires	O
13	zinc	O
14	as	O
15	well	O
16	as	O
17	essential	O
18	cysteine	O
19	residues	O
20	in	O
21	both	O
22	proteins	O
23	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	an	O
7	activation	O
8	target	O
9	of	O
10	a	O
11	human	O
12	activator	O
13	,	O
14	Oct	B
15	-	I
16	1	I
17	,	O
18	within	O
19	its	O
20	cognate	O
21	basal	O
22	transcription	O
23	complex	O
24	.	O

1	During	O
2	early	O
3	neurogenesis	O
4	,	O
5	Vnd	B
6	protein	I
7	is	O
8	restricted	O
9	to	O
10	ventral	O
11	column	O
12	neuroectoderm	O
13	and	O
14	neuroblasts	O
15	;	O
16	later	O
17	it	O
18	is	O
19	detected	O
20	in	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	neurons	O
26	.	O

1	The	O
2	repression	O
3	domain	O
4	,	O
5	and	O
6	indeed	O
7	the	O
8	entire	O
9	Cdc68	B
10	protein	I
11	,	O
12	is	O
13	highly	O
14	conserved	O
15	,	O
16	as	O
17	shown	O
18	by	O
19	the	O
20	sequence	O
21	of	O
22	the	O
23	Cdc68	B
24	functional	I
25	homolog	I
26	from	O
27	the	O
28	yeast	O
29	Kluyveromyces	O
30	lactis	O
31	and	O
32	by	O
33	database	O
34	searches	O
35	.	O

1	The	O
2	exodomain	O
3	alone	O
4	has	O
5	the	O
6	high	O
7	affinity	O
8	hormone	O
9	binding	O
10	site	O
11	but	O
12	is	O
13	not	O
14	capable	O
15	of	O
16	generating	O
17	hormonal	O
18	signal	O
19	.	O

1	Pyrrolidine	O
2	dithiocarbamate	O
3	,	O
4	a	O
5	potent	O
6	transcriptional	O
7	inhibitor	O
8	of	O
9	the	O
10	viral	B
11	LTR	I
12	,	O
13	abrogated	O
14	the	O
15	cytokine	O
16	responses	O
17	in	O
18	both	O
19	U1	O
20	and	O
21	ACH	O
22	-	O
23	2	O
24	cells	O
25	,	O
26	suggesting	O
27	a	O
28	common	O
29	TNF	B
30	-	I
31	alpha	I
32	-	O
33	mediated	O
34	transcriptional	O
35	mechanism	O
36	in	O
37	these	O
38	cell	O
39	types	O
40	despite	O
41	their	O
42	different	O
43	modes	O
44	of	O
45	provirus	O
46	latency	O
47	.	O

1	Furthermore	O
2	,	O
3	synergistic	O
4	activation	O
5	of	O
6	ERK2	B
7	occurred	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	changes	O
13	in	O
14	intracellular	O
15	Ca2	O
16	+,	O
17	and	O
18	was	O
19	not	O
20	blocked	O
21	by	O
22	inhibition	O
23	of	O
24	protein	B
25	kinase	I
26	C	I
27	activity	O
28	and	O
29	represents	O
30	a	O
31	separate	O
32	pathway	O
33	by	O
34	which	O
35	CD19	B
36	regulates	O
37	B	O
38	cell	O
39	function	O
40	.	O

1	The	O
2	retrovesical	O
3	hydatid	O
4	cyst	O
5	is	O
6	a	O
7	very	O
8	rare	O
9	site	O
10	.	O

1	Biochemical	O
2	analysis	O
3	reveals	O
4	that	O
5	KS1	B
6	is	O
7	a	O
8	nuclear	O
9	protein	O
10	containing	O
11	two	O
12	transcriptional	O
13	repressor	O
14	domains	O
15	,	O
16	R1	O
17	and	O
18	R2	O
19	.	O

1	However	O
2	,	O
3	the	O
4	BCH	O
5	group	O
6	showed	O
7	inferior	O
8	gross	O
9	motor	O
10	performance	O
11	on	O
12	the	O
13	Bruininks	O
14	-	O
15	Oseretsky	O
16	Test	O
17	of	O
18	Motor	O
19	Proficiency	O
20	(	O
21	Bruininks	O
22	1978	O
23	).	O

1	The	O
2	results	O
3	raise	O
4	the	O
5	possibility	O
6	that	O
7	pH	O
8	induced	O
9	post	O
10	-	O
11	translational	O
12	modifications	O
13	of	O
14	DdRPA	B
15	are	O
16	involved	O
17	in	O
18	events	O
19	that	O
20	halt	O
21	cell	O
22	proliferation	O
23	and	O
24	induce	O
25	differentiation	O
26	in	O
27	Dictyostelium	O
28	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	B
39	virus	I
40	(	I
41	MLV	I
42	)	I
43	SL3	I
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O

1	We	O
2	identified	O
3	telSMN	B
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	SMA	O
11	-	O
12	like	O
13	individuals	O
14	who	O
15	carry	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	telSMN	B
21	:	O
22	these	O
23	include	O
24	two	O
25	frameshift	O
26	mutations	O
27	(	O
28	800ins11	O
29	and	O
30	542delGT	O
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	A2G	O
38	,	O
39	S262I	O
40	,	O
41	and	O
42	T274I	O
43	).	O

1	The	O
2	decrease	O
3	of	O
4	TNF	B
5	receptors	I
6	by	O
7	IL	B
8	-	I
9	4	I
10	was	O
11	accompanied	O
12	by	O
13	down	O
14	-	O
15	regulation	O
16	of	O
17	TNF	B
18	-	O
19	induced	O
20	activities	O
21	,	O
22	including	O
23	cytotoxicity	O
24	,	O
25	caspase	B
26	-	I
27	3	I
28	activation	O
29	,	O
30	NF	B
31	-	I
32	kappaB	I
33	and	O
34	AP	B
35	-	I
36	1	I
37	activation	O
38	,	O
39	and	O
40	c	B
41	-	I
42	Jun	I
43	N	I
44	-	I
45	terminal	I
46	kinase	I
47	induction	O
48	.	O

1	Type	B
2	2	I
3	deiodinase	I
4	(	O
5	D2	B
6	)	O
7	catalyzes	O
8	the	O
9	5	O
10	'-	O
11	deiodination	O
12	of	O
13	thyroxine	O
14	to	O
15	form	O
16	3	O
17	,	O
18	5	O
19	,	O
20	3	O
21	'-	O
22	triiodothyronine	O
23	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	B
26	D2	I
27	(	O
28	hD2	B
29	)	O
30	cDNA	O
31	.	O

1	Biol	O
2	.	O

1	Here	O
2	we	O
3	have	O
4	investigated	O
5	the	O
6	structural	O
7	requirements	O
8	and	O
9	consequences	O
10	of	O
11	regulatory	O
12	phosphorylation	O
13	for	O
14	the	O
15	interaction	O
16	between	O
17	c	B
18	-	I
19	Jun	I
20	and	O
21	JNK	B
22	in	O
23	vivo	O
24	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	I
19	monooxygenase	I
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	B
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	B
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	Resultant	O
2	activation	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	N	I
8	-	I
9	terminal	I
10	kinase	I
11	/	O
12	stress	B
13	-	I
14	activated	I
15	protein	I
16	kinase	I
17	(	O
18	JNK	B
19	/	O
20	SAPK	B
21	).	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	full	O
6	-	O
7	length	O
8	coding	O
9	cDNA	O
10	sequence	O
11	of	O
12	the	O
13	mouse	B
14	homologue	I
15	of	I
16	MPP3	I
17	.	O

1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O

1	Consistent	O
2	with	O
3	this	O
4	,	O
5	purified	O
6	Dlk	B
7	phosphorylated	O
8	core	O
9	histones	B
10	H3	I
11	,	O
12	H2A	B
13	and	O
14	H4	B
15	as	O
16	exogenous	O
17	substrates	O
18	and	O
19	endogenous	O
20	histone	B
21	H3	I
22	in	O
23	kinase	O
24	assays	O
25	with	O
26	nuclear	O
27	extracts	O
28	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O

1	Neither	O
2	Ha	B
3	-	I
4	Ras	I
5	(	O
6	G12V	O
7	,	O
8	T35S	O
9	)	O
10	(	O
11	Ha	B
12	-	I
13	RasV12S35	I
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	B
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	B
24	-	I
25	Ras	I
26	(	I
27	G12V	I
28	,	I
29	E37G	I
30	)	I
31	(	O
32	Ha	B
33	-	I
34	RasV12G37	I
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	B
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O

1	Initial	O
2	experience	O
3	with	O
4	the	O
5	new	O
6	technology	O
7	indicates	O
8	that	O
9	SieScape	O
10	is	O
11	an	O
12	alternative	O
13	to	O
14	other	O
15	methods	O
16	such	O
17	as	O
18	CT	O
19	and	O
20	MRI	O
21	.	O

1	The	O
2	dopamine	B
3	D4	I
4	receptor	I
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	B
11	receptors	I
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	I
17	domains	I
18	.	O

1	The	O
2	highly	O
3	amyloidogenic	O
4	42	O
5	-	O
6	residue	O
7	form	O
8	of	O
9	Abeta	B
10	(	O
11	Abeta42	B
12	)	O
13	is	O
14	the	O
15	first	O
16	species	O
17	to	O
18	be	O
19	deposited	O
20	in	O
21	both	O
22	sporadic	O
23	and	O
24	familial	O
25	AD	O
26	.	O

1	This	O
2	model	O
3	is	O
4	supported	O
5	by	O
6	experiments	O
7	showing	O
8	that	O
9	Cdr2	B
10	associates	O
11	with	O
12	the	O
13	N	B
14	-	I
15	terminal	I
16	regulatory	I
17	domain	I
18	of	I
19	Wee1	I
20	in	O
21	cell	O
22	lysates	O
23	and	O
24	phosphorylates	O
25	Wee1	B
26	in	O
27	vitro	O
28	.	O

1	Schizosaccharomyces	O
2	pombe	O
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	O
9	altering	O
10	G2	O
11	/	O
12	M	O
13	cell	O
14	size	O
15	control	O
16	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	O
19	farther	O
20	upstream	O
21	,	O
22	similar	O
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	Pyk2	B
2	phosphorylation	O
3	increased	O
4	upon	O
5	adherence	O
6	of	O
7	FLG	O
8	29	O
9	.	O
10	1	O
11	cells	O
12	to	O
13	fibronectin	B
14	and	O
15	to	O
16	ST2	O
17	stromal	O
18	cells	O
19	.	O

1	Raf	B
2	is	O
3	a	O
4	key	O
5	serine	B
6	-	I
7	threonine	I
8	protein	I
9	kinase	I
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	O
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O

1	The	O
2	US	O
3	National	O
4	Institute	O
5	on	O
6	Alcohol	O
7	Abuse	O
8	and	O
9	Alcoholism	O
10	(	O
11	NIAAA	O
12	)	O
13	recognizes	O
14	two	O
15	forms	O
16	of	O
17	problematic	O
18	drinking	O
19	:	O
20	'	O
21	willful	O
22	alcohol	O
23	abuse	O
24	',	O
25	a	O
26	behavioural	O
27	problem	O
28	,	O
29	and	O
30	'	O
31	alcohol	O
32	dependence	O
33	',	O
34	a	O
35	true	O
36	medical	O
37	disorder	O
38	,	O
39	which	O
40	includes	O
41	a	O
42	genetic	O
43	component	O
44	,	O
45	that	O
46	can	O
47	be	O
48	scientifically	O
49	understood	O
50	and	O
51	medically	O
52	treated	O
53	.	O

1	Collagen	B
2	was	O
3	extracted	O
4	from	O
5	the	O
6	skin	O
7	,	O
8	and	O
9	the	O
10	lack	O
11	of	O
12	type	B
13	III	I
14	collagen	I
15	was	O
16	determined	O
17	by	O
18	means	O
19	of	O
20	sodium	O
21	dodecyl	O
22	sulfate	O
23	-	O
24	polyacrylamide	O
25	gel	O
26	electrophoresis	O
27	(	O
28	SDS	O
29	-	O
30	PAGE	O
31	).	O

1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O

1	RESULTS	O
2	:	O
3	Significant	O
4	changes	O
5	from	O
6	pretreatment	O
7	to	O
8	posttreatment	O
9	were	O
10	observed	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	001	O
17	).	O

1	In	O
2	turn	O
3	,	O
4	assembly	O
5	of	O
6	this	O
7	complex	O
8	mediates	O
9	the	O
10	enzymatic	O
11	activation	O
12	of	O
13	the	O
14	p21	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	1	I
20	and	O
21	facilitates	O
22	actin	B
23	polymerization	O
24	.	O

1	The	O
2	tip	O
3	of	O
4	the	O
5	button	O
6	caused	O
7	a	O
8	perforation	O
9	of	O
10	the	O
11	posterior	O
12	stomach	O
13	wall	O
14	,	O
15	leading	O
16	to	O
17	death	O
18	.	O

1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	residues	O
7	are	O
8	conserved	O
9	among	O
10	all	O
11	three	O
12	sequences	O
13	,	O
14	yet	O
15	all	O
16	three	O
17	viruses	O
18	have	O
19	retained	O
20	response	O
21	elements	O
22	for	O
23	glucocorticoids	O
24	,	O
25	two	O
26	positionally	O
27	conserved	O
28	CCAAT	O
29	boxes	O
30	,	O
31	and	O
32	positionally	O
33	conserved	O
34	TATA	O
35	boxes	O
36	.	O

1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	During	O
2	presentation	O
3	of	O
4	happy	O
5	facial	O
6	expressions	O
7	,	O
8	we	O
9	detected	O
10	a	O
11	signal	O
12	increase	O
13	predominantly	O
14	in	O
15	the	O
16	left	O
17	anterior	O
18	cingulate	O
19	gyrus	O
20	,	O
21	bilateral	O
22	posterior	O
23	cingulate	O
24	gyri	O
25	,	O
26	medial	O
27	frontal	O
28	cortex	O
29	and	O
30	right	O
31	supramarginal	O
32	gyrus	O
33	,	O
34	brain	O
35	regions	O
36	previously	O
37	implicated	O
38	in	O
39	visuospatial	O
40	and	O
41	emotion	O
42	processing	O
43	tasks	O
44	.	O

1	Down	O
2	-	O
3	regulation	O
4	of	O
5	IRS	B
6	-	I
7	1	I
8	is	O
9	linked	O
10	to	O
11	its	O
12	serine	O
13	phosphorylation	O
14	dependent	O
15	on	O
16	PI	B
17	3	I
18	-	I
19	kinase	I
20	activity	O
21	and	O
22	appears	O
23	required	O
24	for	O
25	differentiation	O
26	to	O
27	occur	O
28	,	O
29	as	O
30	IRS	B
31	-	I
32	1	I
33	is	O
34	not	O
35	modified	O
36	and	O
37	continues	O
38	to	O
39	accumulate	O
40	in	O
41	a	O
42	nondifferentiating	O
43	myoblast	O
44	cell	O
45	line	O
46	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	B
21	progesterone	I
22	receptor	I
23	(	O
24	hPR	B
25	).	O

1	One	O
2	of	O
3	its	O
4	unique	O
5	features	O
6	appears	O
7	to	O
8	be	O
9	the	O
10	unusually	O
11	short	O
12	5	O
13	'-	O
14	untranslated	O
15	regions	O
16	(	O
17	UTR	O
18	)	O
19	(	O
20	1	O
21	-	O
22	6	O
23	nucleotides	O
24	(	O
25	nts	O
26	))	O
27	and	O
28	the	O
29	apparent	O
30	absence	O
31	of	O
32	5	O
33	'-	O
34	cap	O
35	structures	O
36	from	O
37	its	O
38	mRNAs	O
39	.	O

1	The	O
2	gene	B
3	encoding	I
4	human	I
5	tissue	I
6	-	I
7	type	I
8	plasminogen	I
9	activator	I
10	(	O
11	t	B
12	-	I
13	PA	I
14	)	O
15	is	O
16	regulated	O
17	in	O
18	a	O
19	cell	O
20	-	O
21	type	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	Both	O
2	the	O
3	presence	O
4	of	O
5	arginine	O
6	and	O
7	anaerobiosis	O
8	are	O
9	needed	O
10	to	O
11	trigger	O
12	induction	O
13	of	O
14	the	O
15	pathway	O
16	.	O

1	Competition	O
2	with	O
3	a	O
4	putative	O
5	MADS	B
6	box	I
7	consensus	O
8	binding	O
9	site	O
10	from	O
11	the	O
12	promoter	O
13	of	O
14	the	O
15	coordinately	O
16	regulated	O
17	opaque	B
18	-	I
19	phase	I
20	-	I
21	specific	I
22	gene	I
23	PEP1	I
24	(	O
25	SAP1	B
26	)	O
27	and	O
28	the	O
29	human	B
30	MADS	I
31	box	I
32	consensus	I
33	binding	I
34	site	I
35	for	O
36	serum	B
37	response	I
38	factor	I
39	demonstrated	O
40	that	O
41	one	O
42	of	O
43	the	O
44	three	O
45	complexes	O
46	formed	O
47	was	O
48	specific	O
49	to	O
50	the	O
51	OP4	B
52	sequence	I
53	.	O

1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	We	O
2	have	O
3	introduced	O
4	a	O
5	mutation	O
6	(	O
7	Ser36	O
8	-->	O
9	Asn	O
10	)	O
11	into	O
12	this	O
13	domain	O
14	of	O
15	p190	B
16	that	O
17	decreased	O
18	its	O
19	ability	O
20	to	O
21	bind	O
22	guanine	O
23	nucleotide	O
24	when	O
25	expressed	O
26	as	O
27	a	O
28	hemagglutinin	B
29	(	O
30	HA	B
31	)-	O
32	tagged	O
33	protein	O
34	in	O
35	COS	O
36	cells	O
37	.	O

1	Wild	O
2	type	O
3	HA	B
4	-	O
5	p190	B
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	We	O
2	emphasize	O
3	that	O
4	ANCA	B
5	-	O
6	associated	O
7	vasculitis	O
8	is	O
9	another	O
10	important	O
11	complication	O
12	of	O
13	RA	O
14	.	O

1	The	O
2	downstream	O
3	,	O
4	TATA	O
5	-	O
6	less	O
7	promoter	O
8	has	O
9	high	O
10	G	O
11	+	O
12	C	O
13	content	O
14	,	O
15	and	O
16	exon	O
17	1b	O
18	predominates	O
19	among	O
20	abundantly	O
21	expressed	O
22	mRNA	O
23	species	O
24	.	O

1	Although	O
2	we	O
3	predicted	O
4	that	O
5	overexpression	O
6	of	O
7	the	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	,	O
13	which	O
14	were	O
15	thought	O
16	to	O
17	be	O
18	involved	O
19	in	O
20	the	O
21	regulation	O
22	of	O
23	SREBP	B
24	processing	O
25	,	O
26	would	O
27	result	O
28	in	O
29	disruption	O
30	of	O
31	the	O
32	SREBP	B
33	-	O
34	dependent	O
35	transcriptional	O
36	regulation	O
37	of	O
38	several	O
39	genes	O
40	,	O
41	the	O
42	mRNA	O
43	levels	O
44	for	O
45	3	B
46	-	I
47	hydroxy	I
48	-	I
49	3	I
50	-	I
51	methylglutaryl	I
52	coenzyme	I
53	A	I
54	(	I
55	HMG	I
56	CoA	I
57	)	I
58	synthase	I
59	in	O
60	these	O
61	two	O
62	cell	O
63	lines	O
64	were	O
65	regulated	O
66	in	O
67	a	O
68	sterol	O
69	-	O
70	dependent	O
71	manner	O
72	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	However	O
2	,	O
3	no	O
4	studies	O
5	have	O
6	been	O
7	conducted	O
8	to	O
9	further	O
10	investigate	O
11	this	O
12	potentially	O
13	hazardous	O
14	effect	O
15	of	O
16	lidocaine	O
17	.	O

1	E	O
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O

1	Yap1p	B
2	is	O
3	constitutively	O
4	nuclear	O
5	in	O
6	a	O
7	crm1	B
8	mutant	I
9	,	O
10	and	O
11	Crm1p	B
12	binds	O
13	to	O
14	a	O
15	nuclear	O
16	export	O
17	sequence	O
18	(	O
19	NES	O
20	)-	O
21	like	O
22	sequence	O
23	in	O
24	Yap1p	B
25	in	O
26	the	O
27	presence	O
28	of	O
29	RanGTP	B
30	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	Also	O
2	,	O
3	the	O
4	amplitude	O
5	of	O
6	the	O
7	oscillatory	O
8	potentials	O
9	(	O
10	O1	O
11	+	O
12	O2	O
13	+	O
14	O3	O
15	+	O
16	O4	O
17	)	O
18	was	O
19	significantly	O
20	reduced	O
21	in	O
22	the	O
23	early	O
24	postoperative	O
25	period	O
26	.	O

1	Furthermore	O
2	,	O
3	RING1	B
4	overexpression	O
5	results	O
6	in	O
7	enhanced	O
8	expression	O
9	of	O
10	the	O
11	proto	O
12	-	O
13	oncogenes	O
14	c	B
15	-	I
16	jun	I
17	and	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	The	O
2	yeast	B
3	RER2	I
4	gene	I
5	,	O
6	identified	O
7	by	O
8	endoplasmic	O
9	reticulum	O
10	protein	O
11	localization	O
12	mutations	O
13	,	O
14	encodes	O
15	cis	B
16	-	I
17	prenyltransferase	I
18	,	O
19	a	O
20	key	O
21	enzyme	O
22	in	O
23	dolichol	O
24	synthesis	O
25	.	O

1	The	O
2	yeast	O
3	retrotransposon	B
4	Ty5	I
5	preferentially	O
6	integrates	O
7	into	O
8	regions	O
9	of	O
10	silent	O
11	chromatin	O
12	.	O

1	The	O
2	loss	O
3	of	O
4	SKO1	B
5	completely	O
6	restored	O
7	ENA1	B
8	expression	O
9	in	O
10	a	O
11	hog1	B
12	mutant	I
13	and	O
14	partially	O
15	suppressed	O
16	the	O
17	osmotic	O
18	stress	O
19	sensitivity	O
20	,	O
21	qualifying	O
22	Sko1p	B
23	as	O
24	a	O
25	downstream	O
26	effector	O
27	of	O
28	the	O
29	HOG	B
30	pathway	O
31	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	O
9	SPP381	B
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	O
25	)	O
26	mutant	B
27	prp38	I
28	-	I
29	1	I
30	.	O

1	The	O
2	slower	O
3	-	O
4	electrophoretic	O
5	-	O
6	mobility	O
7	form	O
8	of	O
9	p68	B
10	was	O
11	absent	O
12	in	O
13	human	O
14	cells	O
15	in	O
16	G1	O
17	/	O
18	S	O
19	and	O
20	appeared	O
21	as	O
22	the	O
23	cells	O
24	entered	O
25	G2	O
26	/	O
27	M	O
28	.	O

1	We	O
2	have	O
3	identified	O
4	amino	O
5	acid	O
6	sequences	O
7	in	O
8	mammalian	O
9	and	O
10	Xenopus	O
11	NeuroD1	B
12	/	O
13	BETA2	B
14	that	O
15	are	O
16	necessary	O
17	for	O
18	insulin	B
19	gene	I
20	expression	O
21	and	O
22	ectopic	O
23	neurogenesis	O
24	.	O

1	Both	O
2	NUP98	B
3	-	O
4	HOXA9	B
5	chimeras	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	HOXA9	B
17	domains	I
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	PBX	B
23	interaction	O
24	.	O

1	Recent	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	Y319	O
7	also	O
8	positively	O
9	regulate	O
10	ZAP	B
11	-	I
12	70	I
13	function	O
14	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	data	O
5	indicate	O
6	that	O
7	wild	B
8	-	I
9	type	I
10	Pan	I
11	and	O
12	CiD	B
13	compete	O
14	for	O
15	binding	O
16	to	O
17	Arm	B
18	,	O
19	leading	O
20	to	O
21	a	O
22	compromised	O
23	transduction	O
24	of	O
25	the	O
26	Wg	B
27	signal	O
28	in	O
29	heterozygous	O
30	ciD	B
31	/+	I
32	animals	O
33	and	O
34	to	O
35	a	O
36	dramatic	O
37	enhancement	O
38	of	O
39	the	O
40	gain	O
41	-	O
42	of	O
43	-	O
44	function	O
45	activity	O
46	of	O
47	CiD	B
48	in	O
49	homozygous	O
50	mutants	O
51	.	O

1	Another	O
2	ORF	O
3	,	O
4	dda	B
5	.	I
6	2	I
7	located	O
8	between	O
9	modA	B
10	and	O
11	dda	B
12	,	O
13	shares	O
14	sequence	O
15	similarity	O
16	with	O
17	sigma70	B
18	,	O
19	and	O
20	we	O
21	call	O
22	it	O
23	srd	B
24	.	O

1	The	O
2	location	O
3	of	O
4	the	O
5	IBS	O
6	within	O
7	the	O
8	catB	B
9	structural	I
10	gene	I
11	,	O
12	the	O
13	cooperativity	O
14	observed	O
15	in	O
16	footprinting	O
17	studies	O
18	and	O
19	phasing	O
20	studies	O
21	suggest	O
22	that	O
23	the	O
24	IBS	O
25	participates	O
26	in	O
27	the	O
28	interaction	O
29	of	O
30	CatR	B
31	with	O
32	the	O
33	upstream	O
34	binding	O
35	sites	O
36	by	O
37	looping	O
38	out	O
39	the	O
40	intervening	O
41	DNA	O
42	.	O

1	In	O
2	vitro	O
3	transcription	O
4	assays	O
5	demonstrate	O
6	that	O
7	the	O
8	TCA	O
9	-	O
10	cycle	O
11	intermediate	O
12	,	O
13	fumarate	O
14	,	O
15	directly	O
16	and	O
17	specifically	O
18	inhibits	O
19	the	O
20	formation	O
21	of	O
22	the	O
23	clcA	B
24	transcript	I
25	.	O

1	BIAcore	O
2	analysis	O
3	gave	O
4	a	O
5	Kaff	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	B
23	-	I
24	A3	I
25	to	O
26	T84	B
27	.	I
28	1	I
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	B
46	-	I
47	A3	I
48	to	O
49	T84	B
50	.	I
51	66	I
52	.	O

1	Expression	O
2	of	O
3	p130	B
4	(	O
5	Cas	B
6	)	O
7	(	O
8	Cas	B
9	),	O
10	a	O
11	major	O
12	binding	O
13	protein	O
14	for	O
15	the	O
16	Crk	B
17	SH2	I
18	-	I
19	domain	I
20	,	O
21	also	O
22	induced	O
23	JNK	B
24	activation	O
25	,	O
26	which	O
27	was	O
28	blocked	O
29	by	O
30	the	O
31	SH2	B
32	-	I
33	mutant	I
34	of	O
35	Crk	B
36	.	O

1	Positive	O
2	correlations	O
3	were	O
4	seen	O
5	between	O
6	the	O
7	measurements	O
8	for	O
9	protein	O
10	intake	O
11	(	O
12	r	O
13	=.	O
14	58	O
15	,	O
16	P	O
17	=.	O
18	0026	O
19	)	O
20	energy	O
21	intake	O
22	(	O
23	r	O
24	=.	O
25	78	O
26	,	O
27	P	O
28	<.	O
29	00001	O
30	),	O
31	with	O
32	mean	O
33	differences	O
34	of	O
35	.	O
36	066	O
37	g	O
38	/	O
39	kg	O
40	/	O
41	d	O
42	(	O
43	SD	O
44	.	O
45	38	O
46	)	O
47	2	O
48	.	O
49	04	O
50	kcal	O
51	/	O
52	kg	O
53	/	O
54	day	O
55	(	O
56	SD	O
57	6	O
58	.	O
59	67	O
60	),	O
61	respectively	O
62	.	O

1	The	O
2	Og4C3	B
3	enzyme	O
4	-	O
5	linked	O
6	immunosorbent	O
7	assay	O
8	(	O
9	ELISA	O
10	)	O
11	to	O
12	detect	O
13	circulating	O
14	Wuchereria	B
15	bancrofti	I
16	antigen	I
17	uses	O
18	50	O
19	microL	O
20	of	O
21	serum	O
22	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	gp200	B
6	-	O
7	MR6	B
8	ligation	O
9	can	O
10	also	O
11	mimic	O
12	IL	B
13	-	I
14	4	I
15	and	O
16	have	O
17	an	O
18	anti	O
19	-	O
20	proliferative	O
21	pro	O
22	-	O
23	maturational	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O

1	The	O
2	Mig1	B
3	repressor	I
4	is	O
5	a	O
6	zinc	B
7	finger	I
8	protein	I
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O

1	Ethylene	O
2	is	O
3	involved	O
4	in	O
5	endosperm	O
6	rupture	O
7	and	O
8	high	O
9	-	O
10	level	O
11	betaGLU	B
12	I	I
13	expression	O
14	;	O
15	but	O
16	,	O
17	it	O
18	does	O
19	not	O
20	affect	O
21	the	O
22	spatial	O
23	and	O
24	temporal	O
25	pattern	O
26	of	O
27	betaGLU	B
28	I	I
29	expression	O
30	.	O

1	The	O
2	divergence	O
3	in	O
4	primary	O
5	structure	O
6	between	O
7	the	O
8	sheep	O
9	CRF1	B
10	and	O
11	the	O
12	other	O
13	mammalian	B
14	CRF1s	I
15	is	O
16	primarily	O
17	localized	O
18	to	O
19	the	O
20	extracellular	O
21	amino	O
22	terminal	O
23	domain	O
24	of	O
25	the	O
26	receptor	O
27	(	O
28	18	O
29	of	O
30	22	O
31	divergent	O
32	residues	O
33	,	O
34	ovine	O
35	vs	O
36	human	B
37	CRF1	I
38	).	O

1	Agonist	O
2	-	O
3	induced	O
4	receptor	O
5	internalization	O
6	,	O
7	determined	O
8	as	O
9	the	O
10	percent	O
11	of	O
12	total	O
13	[	O
14	125I	O
15	]	O
16	Tyr0	B
17	-	I
18	oCRF	I
19	bound	O
20	located	O
21	in	O
22	the	O
23	acid	O
24	-	O
25	resistant	O
26	fraction	O
27	of	O
28	transfected	O
29	Cos	O
30	7	O
31	cells	O
32	,	O
33	increased	O
34	with	O
35	time	O
36	(	O
37	0	O
38	-	O
39	60	O
40	min	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	)	O
46	for	O
47	both	O
48	wild	O
49	-	O
50	type	O
51	and	O
52	variant	O
53	oCRF1	B
54	.	O

1	Recurrent	O
2	arterial	O
3	thrombotic	O
4	disease	O
5	on	O
6	young	O
7	onset	O
8	and	O
9	protein	B
10	S	I
11	deficiency	O
12	.	O

1	We	O
2	showed	O
3	that	O
4	Stat3	B
5	and	O
6	Stat3beta	B
7	were	O
8	affinity	O
9	purified	O
10	using	O
11	phosphopeptides	O
12	containing	O
13	Y704	O
14	and	O
15	Y744	O
16	but	O
17	not	O
18	by	O
19	nonphosphorylated	O
20	peptide	O
21	analogues	O
22	or	O
23	by	O
24	phosphopeptides	O
25	containing	O
26	Y729	O
27	and	O
28	Y764	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	B
10	gene	I
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	B
43	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	O
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	evaluate	O
7	how	O
8	couplers	O
9	and	O
10	their	O
11	placement	O
12	affect	O
13	the	O
14	ALGO2	O
15	click	O
16	spectral	O
17	properties	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	This	O
2	c	B
3	-	I
4	Jun	I
5	activity	O
6	is	O
7	inhibited	O
8	by	O
9	c	B
10	-	I
11	Fos	I
12	,	O
13	another	O
14	protooncoprotein	O
15	that	O
16	can	O
17	dimerize	O
18	with	O
19	c	B
20	-	I
21	Jun	I
22	to	O
23	form	O
24	the	O
25	transcription	O
26	factor	O
27	AP	B
28	-	I
29	1	I
30	.	O

1	Dorsal	O
2	root	O
3	ganglia	O
4	neuron	O
5	-	O
6	specific	O
7	promoter	O
8	activity	O
9	of	O
10	the	O
11	rabbit	B
12	beta	I
13	-	I
14	galactoside	I
15	alpha1	I
16	,	I
17	2	I
18	-	I
19	fucosyltransferase	I
20	gene	I
21	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	BMD	O
13	and	O
14	femoral	O
15	neck	O
16	BMD	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	exercises	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	swimming	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	BMD	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	swimming	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	building	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	shoulder	O
65	,	O
66	back	O
67	,	O
68	and	O
69	grip	O
70	muscle	O
71	strength	O
72	.	O

1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O

1	CAL	O
2	gain	O
3	amounted	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	CAL	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O

1	Comparisons	O
2	with	O
3	other	O
4	known	O
5	germins	B
6	and	O
7	germin	B
8	-	I
9	like	I
10	proteins	I
11	indicate	O
12	that	O
13	these	O
14	Arabidopsis	O
15	GLP	B
16	subfamilies	O
17	are	O
18	unique	O
19	from	O
20	wheat	O
21	germin	B
22	.	O

1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O

1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O

1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	B
8	-	O
9	inducible	O
10	CBF	O
11	/	O
12	cdc2	B
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	B
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	B
25	shock	I
26	protein	I
27	70	I
28	promoter	I
29	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	O
19	interleukin	B
20	-	I
21	6	I
22	(	O
23	IL	B
24	-	I
25	6	I
26	),	O
27	IL	B
28	-	I
29	8	I
30	,	O
31	IL	B
32	-	I
33	12	I
34	,	O
35	tumor	B
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	O
41	TNF	B
42	-	I
43	alpha	I
44	),	O
45	and	O
46	interferon	B
47	gamma	I
48	(	O
49	IFN	B
50	-	I
51	gamma	I
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	Phosphorylation	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	O
7	ERK	B
8	-	I
9	1	I
10	/	I
11	2	I
12	decreased	O
13	okadaic	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	JunD	B
20	and	O
21	FosB	B
22	.	O

1	Two	O
2	-	O
3	way	O
4	analysis	O
5	of	O
6	variance	O
7	was	O
8	used	O
9	to	O
10	determine	O
11	whether	O
12	composite	O
13	knowledge	O
14	score	O
15	differed	O
16	among	O
17	patient	O
18	groups	O
19	.	O

1	The	O
2	human	O
3	pathogenic	O
4	bacterium	O
5	group	O
6	A	O
7	Streptococcus	O
8	produces	O
9	an	O
10	extracellular	O
11	cysteine	B
12	protease	I
13	[	O
14	streptococcal	B
15	pyrogenic	I
16	exotoxin	I
17	B	I
18	(	O
19	SpeB	B
20	)]	O
21	that	O
22	is	O
23	a	O
24	critical	O
25	virulence	O
26	factor	O
27	for	O
28	invasive	O
29	disease	O
30	episodes	O
31	.	O

1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O

1	Improving	O
2	the	O
3	evidence	O
4	base	O
5	for	O
6	anaesthesia	O
7	.	O

1	Plasma	O
2	CCK	B
3	levels	O
4	were	O
5	determined	O
6	at	O
7	regular	O
8	intervals	O
9	.	O

1	The	O
2	peroxisome	O
3	biogenesis	O
4	disorders	O
5	(	O
6	PBDs	O
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	peroxisomal	O
18	metabolic	O
19	deficiencies	O
20	,	O
21	multisystem	O
22	abnormalities	O
23	,	O
24	mental	O
25	retardation	O
26	,	O
27	and	O
28	premature	O
29	death	O
30	.	O

1	The	O
2	active	O
3	site	O
4	includes	O
5	the	O
6	acidic	O
7	triad	O
8	Asp53	O
9	(	O
10	the	O
11	site	O
12	of	O
13	phosphorylation	O
14	),	O
15	Asp10	O
16	and	O
17	Glu9	O
18	.	O

1	Consistent	O
2	with	O
3	these	O
4	findings	O
5	,	O
6	relatively	O
7	weak	O
8	transcriptional	O
9	silencing	O
10	by	O
11	the	O
12	native	O
13	VDR	B
14	was	O
15	observed	O
16	using	O
17	the	O
18	osteopontin	B
19	VDRE	O
20	.	O

1	In	O
2	PAV	O
3	-	O
4	3	O
5	,	O
6	the	O
7	E1A	B
8	region	I
9	is	O
10	located	O
11	between	O
12	1	O
13	.	O
14	5	O
15	and	O
16	3	O
17	.	O
18	8	O
19	map	O
20	units	O
21	.	O

1	Six	O
2	putative	O
3	MDV	O
4	genome	O
5	products	O
6	,	O
7	including	O
8	one	O
9	Rep	B
10	and	O
11	five	O
12	non	O
13	-	O
14	Rep	B
15	proteins	O
16	,	O
17	show	O
18	high	O
19	(	O
20	70	O
21	.	O
22	4	O
23	-	O
24	90	O
25	.	O
26	9	O
27	%)	O
28	amino	O
29	acid	O
30	identity	O
31	to	O
32	the	O
33	corresponding	O
34	six	O
35	FBNYV	B
36	proteins	I
37	,	O
38	whereas	O
39	two	O
40	other	O
41	Rep	B
42	proteins	I
43	encoded	O
44	by	O
45	MDV	B
46	-	I
47	C2	I
48	and	O
49	C3	B
50	are	O
51	82	O
52	.	O
53	3	O
54	%	O
55	and	O
56	73	O
57	.	O
58	0	O
59	%	O
60	identical	O
61	to	O
62	those	O
63	encoded	O
64	by	O
65	SCSV	B
66	-	I
67	C2	I
68	and	O
69	C6	B
70	,	O
71	respectively	O
72	.	O

1	MPO	B
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O

1	It	O
2	is	O
3	related	O
4	to	O
5	a	O
6	variety	O
7	of	O
8	mammalian	O
9	Golgi	O
10	-	O
11	associated	O
12	proteins	O
13	and	O
14	to	O
15	the	O
16	yeast	O
17	Uso1p	B
18	,	O
19	an	O
20	essential	O
21	protein	O
22	involved	O
23	in	O
24	docking	O
25	of	O
26	endoplasmic	O
27	reticulum	O
28	-	O
29	derived	O
30	vesicles	O
31	to	O
32	the	O
33	cis	O
34	-	O
35	Golgi	O
36	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	Bmp2	B
6	is	O
7	directly	O
8	regulated	O
9	by	O
10	retinoic	O
11	acid	O
12	-	O
13	bound	O
14	receptors	O
15	and	O
16	Sp1	B
17	.	O

1	Both	O
2	proteins	O
3	were	O
4	shown	O
5	to	O
6	be	O
7	constitutively	O
8	associated	O
9	with	O
10	tubulin	B
11	.	O

1	HEED	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	to	O
7	MA	B
8	protein	I
9	in	O
10	vitro	O
11	,	O
12	as	O
13	efficiently	O
14	as	O
15	in	O
16	vivo	O
17	in	O
18	yeast	O
19	cells	O
20	.	O

1	Fas	B
2	-	O
3	resistant	O
4	DT	O
5	-	O
6	40	O
7	lymphoma	O
8	B	O
9	-	O
10	cells	O
11	rendered	O
12	BTK	B
13	-	O
14	deficient	O
15	through	O
16	targeted	O
17	disruption	O
18	of	O
19	the	O
20	btk	B
21	gene	I
22	by	O
23	homologous	O
24	recombination	O
25	knockout	O
26	underwent	O
27	apoptosis	O
28	after	O
29	Fas	B
30	ligation	O
31	,	O
32	but	O
33	wild	O
34	-	O
35	type	O
36	DT	O
37	-	O
38	40	O
39	cells	O
40	or	O
41	BTK	B
42	-	O
43	deficient	O
44	DT	O
45	-	O
46	40	O
47	cells	O
48	reconstituted	O
49	with	O
50	wild	B
51	-	I
52	type	I
53	human	I
54	btk	I
55	gene	I
56	did	O
57	not	O
58	.	O

1	A	O
2	motif	O
3	(	O
4	TGATGTCA	O
5	)	O
6	which	O
7	matches	O
8	a	O
9	CREB	B
10	site	I
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	is	O
21	embedded	O
22	within	O
23	ER2	B
24	.	O

1	Conventionally	O
2	,	O
3	four	O
4	nominal	O
5	allotypic	O
6	variants	O
7	,	O
8	b4	O
9	,	O
10	b5	O
11	,	O
12	b6	O
13	and	O
14	b9	O
15	have	O
16	been	O
17	shown	O
18	to	O
19	be	O
20	co	O
21	-	O
22	dominantly	O
23	expressed	O
24	at	O
25	the	O
26	Ckappa1	B
27	gene	I
28	locus	I
29	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	TRAF2	B
2	is	O
3	known	O
4	to	O
5	associate	O
6	with	O
7	TRADD	B
8	,	O
9	and	O
10	expression	O
11	of	O
12	a	O
13	dominant	O
14	-	O
15	negative	O
16	N	O
17	-	O
18	terminal	O
19	deletion	O
20	TRAF2	B
21	mutant	I
22	was	O
23	found	O
24	to	O
25	partially	O
26	inhibit	O
27	LMP1	B
28	-	O
29	induced	O
30	JNK	B
31	activation	O
32	in	O
33	293	O
34	cells	O
35	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	B
9	and	O
10	TRAF2	B
11	in	O
12	JNK	B
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	B
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	B
25	receptor	I
26	/	O
27	CD40	B
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	-	I
6	encoded	I
7	latent	I
8	membrane	I
9	protein	I
10	1	I
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	extreme	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	TRADD	B
25	and	O
26	TRAF2	B
27	.	O

1	In	O
2	contrast	O
3	,	O
4	transiently	O
5	transfected	O
6	cells	O
7	expressing	O
8	EBNA	B
9	-	I
10	3	I
11	revealed	O
12	a	O
13	sixfold	O
14	increase	O
15	in	O
16	EBNA	B
17	-	I
18	3	I
19	protein	I
20	expression	O
21	from	O
22	the	O
23	genomic	O
24	EBNA	B
25	-	I
26	3	I
27	gene	I
28	compared	O
29	to	O
30	EBNA	B
31	-	I
32	3	I
33	cDNA	I
34	.	O

1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O

1	Varicella	B
2	-	I
3	zoster	I
4	virus	I
5	(	I
6	VZV	I
7	)	I
8	glycoprotein	I
9	gI	I
10	is	O
11	a	O
12	type	B
13	1	I
14	transmembrane	I
15	glycoprotein	I
16	which	O
17	is	O
18	one	O
19	component	O
20	of	O
21	the	O
22	heterodimeric	O
23	gE	B
24	:	O
25	gI	B
26	Fc	I
27	receptor	I
28	complex	O
29	.	O

1	To	O
2	this	O
3	end	O
4	,	O
5	we	O
6	analyzed	O
7	the	O
8	phosphorylation	O
9	status	O
10	of	O
11	a	O
12	universal	O
13	tyrosine	B
14	kinase	I
15	substrate	O
16	,	O
17	the	O
18	transforming	O
19	Shc	B
20	adapter	I
21	protein	I
22	,	O
23	in	O
24	fibroblasts	O
25	expressing	O
26	the	O
27	viral	O
28	oncogene	O
29	.	O

1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	B
14	ferrochelatase	I
15	gene	I
16	(	O
17	HEM15	B
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	B
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O

1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	B
22	.	O

1	In	O
2	the	O
3	second	O
4	experiment	O
5	,	O
6	a	O
7	stable	O
8	nickel	O
9	isotope	O
10	,	O
11	61Ni	O
12	,	O
13	was	O
14	given	O
15	in	O
16	drinking	O
17	water	O
18	to	O
19	20	O
20	nickel	O
21	-	O
22	sensitized	O
23	women	O
24	and	O
25	20	O
26	age	O
27	-	O
28	matched	O
29	controls	O
30	,	O
31	both	O
32	groups	O
33	having	O
34	vesicular	O
35	hand	O
36	eczema	O
37	of	O
38	the	O
39	pompholyx	O
40	type	O
41	.	O

1	Folded	O
2	tissue	O
3	and	O
4	crimped	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	tunica	O
10	albuginea	O
11	permit	O
12	its	O
13	expansion	O
14	during	O
15	erection	O
16	.	O

1	Number	O
2	of	O
3	patients	O
4	infected	O
5	with	O
6	nontuberculous	O
7	mycobacteria	O
8	(	O
9	NTM	O
10	)	O
11	is	O
12	increasing	O
13	world	O
14	-	O
15	wide	O
16	in	O
17	recent	O
18	years	O
19	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	B
7	,	O
8	attB	B
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	B
15	and	O
16	attR	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	treatment	O
5	of	O
6	posttransplant	O
7	lymphoproliferative	O
8	disorder	O
9	in	O
10	recipients	O
11	of	O
12	solid	O
13	organ	O
14	transplants	O
15	.	O

1	Immunological	O
2	testing	O
3	was	O
4	performed	O
5	on	O
6	all	O
7	brewery	O
8	workers	O
9	and	O
10	some	O
11	control	O
12	volunteers	O
13	using	O
14	skin	O
15	prick	O
16	testing	O
17	with	O
18	hops	O
19	,	O
20	barley	O
21	,	O
22	and	O
23	yeast	O
24	antigens	O
25	as	O
26	well	O
27	as	O
28	other	O
29	nonoccupational	O
30	allergens	O
31	,	O
32	and	O
33	by	O
34	determining	O
35	total	O
36	serum	B
37	IgE	I
38	levels	O
39	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	accuracy	O
7	of	O
8	working	O
9	casts	O
10	for	O
11	crown	O
12	and	O
13	bridge	O
14	restorations	O
15	made	O
16	from	O
17	twin	O
18	mix	O
19	putty	O
20	/	O
21	wash	O
22	silicone	O
23	elastomeric	O
24	impression	O
25	materials	O
26	using	O
27	different	O
28	types	O
29	of	O
30	stock	O
31	tray	O
32	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	assess	O
5	the	O
6	ability	O
7	of	O
8	pretreatment	O
9	and	O
10	post	O
11	-	O
12	treatment	O
13	prostate	B
14	-	I
15	specific	I
16	antigen	I
17	(	O
18	PSA	B
19	)	O
20	measurements	O
21	,	O
22	clinical	O
23	tumor	O
24	stage	O
25	,	O
26	tumor	O
27	grade	O
28	,	O
29	Gleason	O
30	sum	O
31	,	O
32	race	O
33	,	O
34	age	O
35	,	O
36	and	O
37	radiation	O
38	dose	O
39	to	O
40	predict	O
41	the	O
42	recurrence	O
43	of	O
44	prostate	O
45	cancer	O
46	following	O
47	external	O
48	beam	O
49	radiation	O
50	therapy	O
51	(	O
52	XRT	O
53	)	O
54	since	O
55	the	O
56	introduction	O
57	of	O
58	PSA	B
59	as	O
60	a	O
61	tumor	O
62	marker	O
63	at	O
64	one	O
65	tertiary	O
66	care	O
67	center	O
68	.	O

1	To	O
2	evaluate	O
3	whether	O
4	the	O
5	human	O
6	gene	O
7	is	O
8	also	O
9	a	O
10	target	O
11	of	O
12	thyroid	O
13	hormone	O
14	we	O
15	have	O
16	searched	O
17	for	O
18	T3	O
19	-	O
20	responsive	O
21	elements	O
22	in	O
23	NRGN	B
24	cloned	O
25	genomic	O
26	fragments	O
27	spanning	O
28	the	O
29	whole	O
30	gene	O
31	.	O

1	The	O
2	transcriptional	O
3	activity	O
4	of	O
5	PPARgamma	B
6	is	O
7	positively	O
8	modulated	O
9	by	O
10	ligand	O
11	binding	O
12	and	O
13	negatively	O
14	regulated	O
15	by	O
16	phosphorylation	O
17	mediated	O
18	by	O
19	the	O
20	MEK	B
21	/	O
22	ERK	B
23	signaling	O
24	pathway	O
25	.	O

1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O

1	Bioplastique	O
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	This	O
2	Tbx6	B
3	-	I
4	subfamily	I
5	gene	I
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O

1	Structure	O
2	-	O
3	function	O
4	analysis	O
5	of	O
6	the	O
7	Z	O
8	-	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	Zalpha	O
14	of	O
15	dsRNA	B
16	adenosine	I
17	deaminase	I
18	type	I
19	I	I
20	reveals	O
21	similarity	O
22	to	O
23	the	O
24	(	B
25	alpha	I
26	+	I
27	beta	I
28	)	I
29	family	I
30	of	O
31	helix	B
32	-	I
33	turn	I
34	-	I
35	helix	I
36	proteins	I
37	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	regulation	O
6	of	O
7	Glvr	B
8	-	I
9	1	I
10	gene	I
11	expression	O
12	also	O
13	has	O
14	potential	O
15	applications	O
16	to	O
17	gene	O
18	therapy	O
19	,	O
20	since	O
21	retroviral	O
22	vectors	O
23	carrying	O
24	gibbon	B
25	ape	I
26	leukemia	I
27	virus	I
28	envelope	I
29	proteins	I
30	are	O
31	used	O
32	for	O
33	gene	O
34	delivery	O
35	into	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O

1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O

1	We	O
2	isolated	O
3	a	O
4	ribosomal	B
5	protein	I
6	L18	I
7	by	O
8	interaction	O
9	with	O
10	PKR	B
11	.	O

1	Processing	O
2	of	O
3	the	O
4	polycistronic	O
5	precursor	O
6	requires	O
7	nucleases	O
8	also	O
9	involved	O
10	in	O
11	rRNA	O
12	processing	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.,	O
18	Rnt1p	B
19	and	O
20	Rat1p	B
21	.	O

1	To	O
2	search	O
3	for	O
4	transcriptional	O
5	regulators	O
6	,	O
7	we	O
8	used	O
9	a	O
10	fragment	O
11	of	O
12	the	O
13	SpHE	B
14	promoter	I
15	containing	O
16	several	O
17	individual	O
18	elements	O
19	instead	O
20	of	O
21	the	O
22	conventional	O
23	bait	O
24	that	O
25	contains	O
26	a	O
27	multimerized	O
28	cis	O
29	element	O
30	.	O

1	As	O
2	expected	O
3	for	O
4	a	O
5	positive	O
6	SpHE	B
7	transcriptional	I
8	regulator	I
9	,	O
10	the	O
11	timing	O
12	of	O
13	SpEts4	B
14	gene	I
15	expression	O
16	precedes	O
17	the	O
18	transient	O
19	expression	O
20	of	O
21	SpHE	B
22	in	O
23	the	O
24	very	O
25	early	O
26	sea	O
27	urchin	O
28	blastula	O
29	.	O

1	Furthermore	O
2	,	O
3	rhoA	B
4	-	O
5	mediated	O
6	SRE	O
7	activation	O
8	was	O
9	blocked	O
10	by	O
11	dominant	O
12	negative	O
13	mutants	O
14	of	O
15	PKC	B
16	-	I
17	alpha	I
18	or	O
19	PKC	B
20	-	I
21	epsilon	I
22	.	O

1	Nip7p	B
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	B
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	B
20	precursors	I
21	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	Sm	B
6	-	I
7	binding	I
8	site	I
9	and	O
10	stem	O
11	-	O
12	loop	O
13	III	O
14	structures	O
15	are	O
16	necessary	O
17	for	O
18	correct	O
19	3	O
20	'-	O
21	end	O
22	formation	O
23	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	Further	O
2	experiments	O
3	will	O
4	be	O
5	required	O
6	to	O
7	highlight	O
8	the	O
9	in	O
10	vivo	O
11	role	O
12	of	O
13	ELE1	B
14	in	O
15	nuclear	O
16	receptor	O
17	functioning	O
18	.	O

1	Overexpression	O
2	of	O
3	PTTG	B
4	in	O
5	transfected	O
6	NIH	O
7	3T3	O
8	cells	O
9	also	O
10	stimulated	O
11	expression	O
12	and	O
13	secretion	O
14	of	O
15	basic	B
16	fibroblast	I
17	growth	I
18	factor	I
19	,	O
20	a	O
21	human	B
22	pituitary	I
23	tumor	I
24	growth	I
25	-	I
26	regulating	I
27	factor	I
28	.	O

1	The	O
2	perifascicular	O
3	connective	O
4	tissue	O
5	sheath	O
6	is	O
7	important	O
8	in	O
9	organising	O
10	the	O
11	contraction	O
12	of	O
13	the	O
14	myocardium	O
15	by	O
16	preventing	O
17	lateral	O
18	spread	O
19	of	O
20	conduction	O
21	and	O
22	by	O
23	permitting	O
24	transmission	O
25	of	O
26	the	O
27	impulse	O
28	only	O
29	at	O
30	the	O
31	termination	O
32	of	O
33	the	O
34	purkinje	O
35	fibre	O
36	.	O

1	E1	B
2	,	O
3	a	O
4	DNA	B
5	helicase	I
6	,	O
7	collaborates	O
8	with	O
9	the	O
10	HPV	B
11	E2	I
12	protein	I
13	in	O
14	ori	O
15	-	O
16	dependent	O
17	replication	O
18	.	O

1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	B
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	adenylyl	B
24	cyclase	I
25	.	O

1	A	O
2	gapped	O
3	search	O
4	with	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	of	O
11	CDED	B
12	/	O
13	LIOR	B
14	revealed	O
15	a	O
16	36	O
17	-	O
18	41	O
19	%	O
20	similarity	O
21	to	O
22	several	O
23	proteins	O
24	related	O
25	to	O
26	signal	O
27	transduction	O
28	and	O
29	cell	O
30	replication	O
31	,	O
32	such	O
33	as	O
34	ORC1	B
35	and	O
36	KSR	B
37	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O

1	Additionally	O
2	,	O
3	a	O
4	variety	O
5	of	O
6	regulatory	O
7	schemes	O
8	contribute	O
9	temporal	O
10	and	O
11	/	O
12	or	O
13	spatial	O
14	restriction	O
15	to	O
16	TGF	B
17	-	I
18	beta	I
19	responses	O
20	.	O

1	Induction	O
2	of	O
3	anaesthesia	O
4	was	O
5	standardised	O
6	:	O
7	fentanyl	O
8	(	O
9	3	O
10	micrograms	O
11	/	O
12	kg	O
13	),	O
14	thiopentone	O
15	(	O
16	5	O
17	mg	O
18	/	O
19	kg	O
20	),	O
21	atracurium	O
22	(	O
23	0	O
24	.	O
25	4	O
26	mg	O
27	/	O
28	kg	O
29	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	Conserved	O
2	and	O
3	distinct	O
4	roles	O
5	of	O
6	kreisler	B
7	in	O
8	regulation	O
9	of	O
10	the	O
11	paralogous	O
12	Hoxa3	B
13	and	O
14	Hoxb3	B
15	genes	I
16	.	O

1	Magnetically	O
2	induced	O
3	optical	O
4	self	O
5	-	O
6	pulsing	O
7	in	O
8	a	O
9	nonlinear	O
10	resonator	O
11	.	O

1	Wave	O
2	cybernetics	O
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	Autoionization	O
2	rates	O
3	and	O
4	energy	O
5	levels	O
6	of	O
7	triplet	O
8	nf	O
9	,	O
10	v	O
11	=	O
12	1	O
13	Rydberg	O
14	states	O
15	of	O
16	H2	O
17	.	O

1	Unitary	O
2	-	O
3	group	O
4	approach	O
5	to	O
6	spin	O
7	-	O
8	dependent	O
9	operators	O
10	.	O

1	Nonlocal	O
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	B
17	-	I
18	C	I
19	promoter	I
20	constructs	I
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	O
29	collagen	B
30	-	I
31	dependent	I
32	promoter	I
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O

1	Nuclear	B
2	factor	I
3	kappa	I
4	B	I
5	(	O
6	NF	B
7	-	I
8	kappaB	I
9	)	O
10	is	O
11	an	O
12	important	O
13	transcription	O
14	factor	O
15	for	O
16	the	O
17	genes	O
18	of	O
19	many	O
20	pro	O
21	-	O
22	inflammatory	O
23	proteins	O
24	and	O
25	is	O
26	strongly	O
27	activated	O
28	by	O
29	the	O
30	cytokines	O
31	interleukin	B
32	-	I
33	1	I
34	and	O
35	tumor	B
36	necrosis	I
37	factor	I
38	(	I
39	TNF	I
40	)	I
41	alpha	I
42	under	O
43	various	O
44	pathological	O
45	conditions	O
46	.	O

1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	O
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O

1	Recombinant	B
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	B
7	/	O
8	mdr1b	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	B
25	genes	I
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O

1	Sp1	B
2	'	O
3	s	O
4	role	O
5	in	O
6	transactivation	O
7	of	O
8	the	O
9	pgp2	B
10	/	O
11	mdr1b	B
12	promoter	O
13	was	O
14	tested	O
15	in	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	.	O

1	Measurements	O
2	included	O
3	bone	O
4	mineral	O
5	density	O
6	of	O
7	the	O
8	lumbar	O
9	spine	O
10	and	O
11	proximal	O
12	femur	O
13	(	O
14	by	O
15	dual	O
16	-	O
17	energy	O
18	X	O
19	-	O
20	ray	O
21	absorptiometry	O
22	)	O
23	and	O
24	biochemical	O
25	markers	O
26	of	O
27	bone	O
28	remodeling	O
29	(	O
30	serum	O
31	bone	O
32	-	O
33	specific	O
34	alkaline	B
35	phosphatase	I
36	by	O
37	immunoassay	O
38	and	O
39	urine	O
40	deoxypyridinoline	O
41	by	O
42	high	O
43	-	O
44	pressure	O
45	liquid	O
46	chromatography	O
47	).	O

1	Human	B
2	MGP	I
3	is	O
4	a	O
5	10	B
6	-	I
7	kD	I
8	skeletal	I
9	extracellular	I
10	matrix	I
11	(	I
12	ECM	I
13	)	I
14	protein	I
15	that	O
16	consists	O
17	of	O
18	an	O
19	84	O
20	-	O
21	aa	O
22	mature	O
23	protein	O
24	and	O
25	a	O
26	19	O
27	-	O
28	aa	O
29	transmembrane	O
30	signal	O
31	peptide	O
32	.	O

1	Dual	O
2	roles	O
3	of	O
4	p82	B
5	,	O
6	the	O
7	clam	O
8	CPEB	B
9	homolog	I
10	,	O
11	in	O
12	cytoplasmic	O
13	polyadenylation	O
14	and	O
15	translational	O
16	masking	O
17	.	O

1	The	O
2	RNA	B
3	polymerase	I
4	III	I
5	-	I
6	recruiting	I
7	factor	I
8	TFIIIB	I
9	induces	O
10	a	O
11	DNA	O
12	bend	O
13	between	O
14	the	O
15	TATA	O
16	box	O
17	and	O
18	the	O
19	transcriptional	O
20	start	O
21	site	O
22	.	O

1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	B
9	RNA	I
10	differed	O
11	from	O
12	FinP	B
13	,	O
14	and	O
15	GST	B
16	-	O
17	FinO	B
18	did	O
19	not	O
20	protect	O
21	finP305	B
22	RNA	I
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O

1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	In	O
2	the	O
3	second	O
4	case	O
5	,	O
6	an	O
7	epidermal	O
8	cyst	O
9	was	O
10	diagnosed	O
11	.	O

1	MotA	B
2	also	O
3	binds	O
4	a	O
5	DNA	O
6	sequence	O
7	(	O
8	a	O
9	MotA	B
10	box	I
11	),	O
12	centered	O
13	at	O
14	position	O
15	-	O
16	30	O
17	.	O

1	We	O
2	suggest	O
3	that	O
4	MotA	B
5	and	O
6	AsiA	B
7	may	O
8	function	O
9	like	O
10	certain	O
11	eukaryotic	B
12	TAFs	I
13	(	O
14	TATA	B
15	binding	I
16	protein	I
17	(	I
18	TBP	I
19	)	I
20	associated	I
21	factors	I
22	)	O
23	whose	O
24	binding	O
25	to	O
26	TBP	B
27	results	O
28	in	O
29	transcription	O
30	from	O
31	new	O
32	core	O
33	promoter	O
34	sequences	O
35	.	O

1	The	O
2	S229A	O
3	variant	O
4	can	O
5	better	O
6	flip	O
7	modified	O
8	bases	O
9	but	O
10	does	O
11	not	O
12	tightly	O
13	lock	O
14	the	O
15	flipped	O
16	base	O
17	into	O
18	the	O
19	adenine	O
20	-	O
21	binding	O
22	pocket	O
23	,	O
24	suggesting	O
25	that	O
26	Ser229	O
27	could	O
28	form	O
29	a	O
30	contact	O
31	to	O
32	the	O
33	flipped	O
34	adenine	O
35	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	O
16	of	O
17	proteins	O
18	required	O
19	for	O
20	the	O
21	initiation	O
22	of	O
23	RNA	O
24	replication	O
25	.	O

1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	I
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	B
21	stimulation	O
22	.	O

1	The	O
2	sequence	O
3	up	O
4	to	O
5	-	O
6	267	O
7	bp	O
8	relative	O
9	to	O
10	the	O
11	transcription	O
12	start	O
13	site	O
14	was	O
15	sufficient	O
16	to	O
17	enhance	O
18	reporter	O
19	gene	O
20	expression	O
21	depending	O
22	on	O
23	the	O
24	mesodermal	O
25	differentiation	O
26	of	O
27	P19	O
28	cells	O
29	.	O

1	Chem	O
2	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	O
9	type	O
10	peptides	O
11	were	O
12	observed	O
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	c	B
7	-	I
8	met	I
9	gene	I
10	is	O
11	also	O
12	a	O
13	target	O
14	of	O
15	p53	B
16	gene	I
17	regulation	O
18	.	O

1	C3	B
2	toxin	I
3	completely	O
4	inhibited	O
5	RhoA	B
6	function	O
7	,	O
8	partially	O
9	inhibited	O
10	SRE	O
11	:	O
12	Luc	B
13	activity	O
14	,	O
15	but	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	LPA	O
21	-	O
22	stimulated	O
23	c	B
24	-	I
25	Fos	I
26	expression	O
27	.	O

1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	B
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	B
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	O
45	-	O
46	31	O
47	-	O
48	8220	O
49	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	O
35	ID	O
36	ANA	O
37	II	O
38	panel	O
39	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	demonstrate	O
7	that	O
8	CAP1	B
9	is	O
10	involved	O
11	in	O
12	multidrug	O
13	resistance	O
14	and	O
15	oxidative	O
16	stress	O
17	response	O
18	in	O
19	C	O
20	.	O
21	albicans	O
22	.	O

1	Trinipatch	O
2	is	O
3	a	O
4	small	O
5	,	O
6	transparent	O
7	,	O
8	matricial	O
9	,	O
10	monolayer	O
11	patch	O
12	with	O
13	an	O
14	absorption	O
15	promoter	O
16	,	O
17	marketed	O
18	in	O
19	two	O
20	dose	O
21	-	O
22	strengths	O
23	(	O
24	5	O
25	mg	O
26	/	O
27	24	O
28	h	O
29	and	O
30	10	O
31	mg	O
32	/	O
33	24	O
34	h	O
35	)	O
36	by	O
37	Laboratoires	O
38	Synthelabo	O
39	.	O

1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O

1	The	O
2	starting	O
3	point	O
4	is	O
5	the	O
6	consideration	O
7	that	O
8	the	O
9	conceptions	O
10	underlying	O
11	the	O
12	ICIDH	O
13	are	O
14	not	O
15	suitable	O
16	to	O
17	serve	O
18	as	O
19	a	O
20	mainstay	O
21	of	O
22	a	O
23	model	O
24	for	O
25	diagnostics	O
26	in	O
27	rehabilitation	O
28	because	O
29	they	O
30	do	O
31	not	O
32	reflect	O
33	essential	O
34	characteristics	O
35	of	O
36	the	O
37	diagnostic	O
38	process	O
39	which	O
40	is	O
41	the	O
42	basis	O
43	for	O
44	intervention	O
45	.	O

1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	B
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	B
15	-	I
16	glycosidase	I
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O

1	Among	O
2	these	O
3	360	O
4	ZFPs	B
5	,	O
6	a	O
7	novel	O
8	ZFP	B
9	cDNA	I
10	named	O
11	HFHZ	B
12	(	O
13	human	B
14	fetal	I
15	heart	I
16	ZFP	I
17	)	O
18	with	O
19	sequence	O
20	homology	O
21	to	O
22	a	O
23	Kruppel	B
24	-	I
25	associated	I
26	box	I
27	(	O
28	KRAB	B
29	)	O
30	was	O
31	identified	O
32	.	O

1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	B
21	mRNA	I
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O

1	When	O
2	the	O
3	high	O
4	affinity	O
5	hnRNP	B
6	A1	I
7	binding	I
8	site	I
9	was	O
10	inserted	O
11	into	O
12	the	O
13	beta	B
14	-	I
15	globin	I
16	reporter	I
17	,	O
18	Rev	B
19	was	O
20	able	O
21	to	O
22	increase	O
23	the	O
24	cytoplasmic	O
25	levels	O
26	of	O
27	unspliced	O
28	mRNAs	O
29	to	O
30	14	O
31	%.	O

1	To	O
2	date	O
3	,	O
4	two	O
5	such	O
6	proteins	O
7	,	O
8	PLZF	B
9	and	O
10	LAZ	B
11	-	I
12	3	I
13	/	O
14	BCL	B
15	-	I
16	6	I
17	,	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	oncogenesis	O
23	.	O

1	Overexpression	O
2	of	O
3	POG1	B
4	inhibits	O
5	alpha	B
6	-	I
7	factor	I
8	-	O
9	induced	O
10	G1	O
11	arrest	O
12	and	O
13	transcriptional	O
14	repression	O
15	of	O
16	the	O
17	CLN1	B
18	and	O
19	CLN2	B
20	genes	I
21	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	B
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	B
18	E1B	I
19	55	O
20	kDa	O
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	B
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	O
33	3	O
34	E1A	B
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	O
43	kDa	O
44	and	O
45	55	O
46	kDa	O
47	proteins	O
48	).	O

1	Competitionsupershift	O
2	EMSA	O
3	assays	O
4	revealed	O
5	that	O
6	multiple	O
7	proteins	O
8	were	O
9	involved	O
10	in	O
11	bandshift	O
12	complex	O
13	formation	O
14	with	O
15	KCS	B
16	,	O
17	one	O
18	of	O
19	which	O
20	was	O
21	identified	O
22	as	O
23	factor	O
24	Sp1	O
25	.	O

1	Similarity	O
2	of	O
3	DNA	O
4	binding	O
5	and	O
6	transcriptional	O
7	regulation	O
8	by	O
9	Caenorhabditis	B
10	elegans	I
11	MAB	I
12	-	I
13	3	I
14	and	O
15	Drosophila	B
16	melanogaster	I
17	DSX	I
18	suggests	O
19	conservation	O
20	of	O
21	sex	O
22	determining	O
23	mechanisms	O
24	.	O

1	CONTEXT	O
2	:	O
3	ThinPrep	O
4	,	O
5	AutoPap	O
6	,	O
7	and	O
8	Papnet	O
9	are	O
10	3	O
11	new	O
12	technologies	O
13	that	O
14	increase	O
15	the	O
16	sensitivity	O
17	and	O
18	cost	O
19	of	O
20	cervical	O
21	cancer	O
22	screening	O
23	.	O

1	Experiments	O
2	on	O
3	narcotized	O
4	cats	O
5	demonstrated	O
6	that	O
7	the	O
8	derivatives	O
9	of	O
10	2	O
11	-	O
12	mercaptobenzimidazole	O
13	possessing	O
14	the	O
15	properties	O
16	of	O
17	specific	O
18	bradycardic	O
19	agents	O
20	and	O
21	coded	O
22	as	O
23	CM	O
24	-	O
25	251	O
26	,	O
27	CM	O
28	-	O
29	266	O
30	,	O
31	and	O
32	CM	O
33	-	O
34	345	O
35	,	O
36	reduce	O
37	the	O
38	mean	O
39	rise	O
40	of	O
41	segment	O
42	ST	O
43	on	O
44	numerous	O
45	leads	O
46	of	O
47	the	O
48	epicardial	O
49	electrogram	O
50	during	O
51	5	O
52	-	O
53	min	O
54	occlusion	O
55	of	O
56	the	O
57	anterior	O
58	descending	O
59	branch	O
60	of	O
61	the	O
62	left	O
63	coronary	O
64	artery	O
65	.	O

1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	O
10	and	O
11	Ecc	O
12	arm	O
13	curls	O
14	to	O
15	fatigue	O
16	,	O
17	followed	O
18	by	O
19	postexercise	O
20	muscle	O
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O

1	Airflow	O
2	was	O
3	measured	O
4	with	O
5	a	O
6	custom	O
7	-	O
8	designed	O
9	turbine	O
10	and	O
11	a	O
12	45	O
13	-	O
14	ft	O
15	.-	O
16	long	O
17	cable	O
18	to	O
19	reach	O
20	the	O
21	volume	O
22	-	O
23	measuring	O
24	module	O
25	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	B
23	protein	I
24	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	Although	O
2	both	O
3	transcripts	O
4	share	O
5	the	O
6	first	O
7	nine	O
8	exons	O
9	,	O
10	exon	O
11	10	O
12	of	O
13	ZIS	B
14	-	I
15	2	I
16	is	O
17	lacking	O
18	in	O
19	ZIS	B
20	-	I
21	1	I
22	,	O
23	and	O
24	instead	O
25	,	O
26	exon	O
27	11	O
28	(	O
29	10th	O
30	exon	O
31	)	O
32	of	O
33	ZIS	B
34	-	I
35	1	I
36	is	O
37	larger	O
38	in	O
39	size	O
40	,	O
41	leading	O
42	to	O
43	the	O
44	longer	O
45	3	O
46	'-	O
47	UTR	O
48	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	B
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	IFN	B
2	-	I
3	gamma	I
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O

1	The	O
2	missing	O
3	5	O
4	'	O
5	sequences	O
6	were	O
7	obtained	O
8	by	O
9	5	O
10	'-	O
11	rapid	O
12	amplification	O
13	of	O
14	cDNA	O
15	ends	O
16	and	O
17	by	O
18	analysis	O
19	of	O
20	an	O
21	NHE5	B
22	genomic	I
23	clone	I
24	,	O
25	and	O
26	the	O
27	missing	O
28	3	O
29	'	O
30	sequences	O
31	were	O
32	obtained	O
33	by	O
34	3	O
35	'-	O
36	rapid	O
37	amplification	O
38	of	O
39	cDNA	O
40	ends	O
41	.	O

1	If	O
2	no	O
3	alloantibodies	O
4	are	O
5	detected	O
6	,	O
7	further	O
8	analysis	O
9	to	O
10	define	O
11	a	O
12	role	O
13	of	O
14	drug	O
15	-	O
16	related	O
17	or	O
18	autoantibodies	O
19	is	O
20	required	O
21	.	O

1	This	O
2	dependence	O
3	,	O
4	however	O
5	,	O
6	can	O
7	be	O
8	overcome	O
9	to	O
10	a	O
11	large	O
12	extent	O
13	by	O
14	dividing	O
15	min	O
16	LVdP	O
17	/	O
18	dt	O
19	by	O
20	mean	O
21	aortic	O
22	pressure	O
23	.	O

1	Genoa	O
2	,	O
3	Italy	O
4	,	O
5	24	O
6	-	O
7	28	O
8	August	O
9	1997	O
10	.	O

1	Electronic	O
2	structure	O
3	of	O
4	delta	O
5	-	O
6	plutonium	O
7	and	O
8	of	O
9	single	O
10	Al	O
11	,	O
12	Ga	O
13	,	O
14	and	O
15	Sc	O
16	impurities	O
17	in	O
18	delta	O
19	-	O
20	plutonium	O
21	.	O

1	Bound	O
2	-	O
3	exciton	O
4	transfer	O
5	and	O
6	photoluminescence	O
7	undulation	O
8	spectra	O
9	for	O
10	acceptors	O
11	in	O
12	ZnTe	O
13	.	O

1	Unified	O
2	theory	O
3	of	O
4	segregated	O
5	-	O
6	stack	O
7	organic	O
8	charge	O
9	-	O
10	transfer	O
11	solids	O
12	:	O
13	Magnetic	O
14	properties	O
15	.	O

1	Internal	O
2	modes	O
3	of	O
4	a	O
5	soliton	O
6	.	O

1	II	O
2	.	O

1	Envelope	O
2	-	O
3	function	O
4	matching	O
5	conditions	O
6	for	O
7	GaAs	O
8	/(	O
9	Al	O
10	,	O
11	Ga	O
12	)	O
13	As	O
14	heterojunctions	O
15	.	O

1	Neutron	O
2	scattering	O
3	measurements	O
4	of	O
5	critical	O
6	exponents	O
7	in	O
8	CsMnBr3	O
9	:	O
10	A	O
11	Z2	O
12	&	O
13	gt	O
14	;=	O
15	1	O
16	antiferromagnet	O
17	.	O

1	(	O
2	2	O
3	)	O
4	Erythroid	O
5	32D	O
6	Epo1	B
7	cells	O
8	showed	O
9	a	O
10	lower	O
11	level	O
12	of	O
13	bulk	O
14	PKC	B
15	catalytic	O
16	activity	O
17	,	O
18	lacked	O
19	the	O
20	expression	O
21	of	O
22	epsilon	B
23	and	I
24	eta	I
25	PKC	I
26	isoforms	I
27	,	O
28	and	O
29	showed	O
30	a	O
31	weak	O
32	or	O
33	absent	O
34	upregulation	O
35	of	O
36	the	O
37	remaining	O
38	isoforms	O
39	,	O
40	except	O
41	betaI	B
42	,	O
43	upon	O
44	readdition	O
45	of	O
46	Epo	B
47	to	O
48	growth	O
49	factor	O
50	-	O
51	starved	O
52	cells	O
53	.	O

1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	I
9	6	I
10	(	O
11	IL	B
12	-	I
13	6	I
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	1A9	O
32	-	O
33	M	O
34	.	O

1	Airflow	O
2	through	O
3	the	O
4	dust	O
5	trap	O
6	was	O
7	controlled	O
8	with	O
9	a	O
10	vacuum	O
11	pump	O
12	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	B
11	and	O
12	TbetaRII	B
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	B
28	.	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	The	O
2	odds	O
3	ratio	O
4	for	O
5	CHD	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	confidence	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	serostatus	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	O
32	after	O
33	adjustment	O
34	for	O
35	covariates	O
36	.	O

1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O

1	The	O
2	case	O
3	for	O
4	neutrinos	O
5	from	O
6	SN	O
7	1987A	O
8	.	O

1	Scaling	O
2	of	O
3	fluctuations	O
4	in	O
5	one	O
6	-	O
7	dimensional	O
8	interface	O
9	and	O
10	hopping	O
11	models	O
12	.	O

1	Model	O
2	of	O
3	spatiotemporal	O
4	dynamics	O
5	of	O
6	stick	O
7	-	O
8	slip	O
9	motion	O
10	.	O

1	NMR	O
2	of	O
3	diffusing	O
4	atoms	O
5	in	O
6	a	O
7	periodic	O
8	porous	O
9	medium	O
10	in	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	nonuniform	O
16	magnetic	O
17	field	O
18	.	O

1	Microstructure	O
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O

1	Anisotropic	O
2	heat	O
3	transport	O
4	in	O
5	the	O
6	octylcyanobiphenyl	O
7	(	O
8	8CB	O
9	)	O
10	liquid	O
11	crystal	O
12	.	O

1	Direct	O
2	approach	O
3	to	O
4	the	O
5	study	O
6	of	O
7	soliton	O
8	perturbations	O
9	.	O

1	Mutations	O
2	affecting	O
3	only	O
4	CD4	B
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	Nef	B
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	W57	O
24	and	O
25	L58	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	B
33	-	I
34	recruiting	I
35	dileucine	I
36	motif	I
37	and	O
38	to	O
39	an	O
40	acidic	O
41	dipeptide	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O

1	Several	O
2	mutations	O
3	disrupted	O
4	the	O
5	endonuclease	O
6	and	O
7	helicase	B
8	activities	O
9	;	O
10	however	O
11	,	O
12	only	O
13	one	O
14	amino	B
15	-	I
16	terminal	I
17	-	I
18	charge	I
19	cluster	I
20	mutant	I
21	protein	I
22	(	O
23	D40A	O
24	-	O
25	D42A	O
26	-	O
27	D44A	O
28	)	O
29	completely	O
30	lost	O
31	AAV	O
32	hairpin	O
33	DNA	O
34	binding	O
35	activity	O
36	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	O
15	murine	O
16	gammaHV68	O
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	O
57	v	B
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	I
63	,	O
64	v	B
65	-	I
66	GCR	I
67	gene	I
68	,	O
69	and	O
70	gene	B
71	73	I
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	O
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	B
9	in	O
10	NRS	B
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	This	O
2	suggests	O
3	that	O
4	the	O
5	DcuS	B
6	-	O
7	DcuR	B
8	system	O
9	responds	O
10	to	O
11	external	O
12	substrates	O
13	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	identification	O
6	and	O
7	characterization	O
8	of	O
9	several	O
10	Sp100	B
11	splice	I
12	variant	I
13	proteins	I
14	and	O
15	support	O
16	their	O
17	existence	O
18	by	O
19	elucidation	O
20	of	O
21	the	O
22	3	O
23	'-	O
24	end	O
25	of	O
26	the	O
27	Sp100	B
28	gene	I
29	.	O

1	Crossover	O
2	in	O
3	the	O
4	specific	O
5	heat	O
6	of	O
7	dilute	O
8	magnets	O
9	induced	O
10	by	O
11	critical	O
12	spin	O
13	-	O
14	wave	O
15	dynamics	O
16	.	O

1	Erratum	O
2	:	O
3	Absence	O
4	of	O
5	precursor	O
6	effects	O
7	above	O
8	the	O
9	martensitic	O
10	transformation	O
11	in	O
12	a	O
13	virgin	O
14	crystal	O
15	of	O
16	Li	O
17	metal	O

1	Interplane	O
2	coupling	O
3	in	O
4	the	O
5	superconductor	O
6	Y2Ba4Cu7O15	O
7	as	O
8	revealed	O
9	by	O
10	NQR	O
11	spin	O
12	-	O
13	echo	O
14	double	O
15	resonance	O
16	.	O

1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O

1	Raman	O
2	investigation	O
3	of	O
4	YBa2	O
5	-	O
6	xLaxCu3O7	O
7	ceramics	O
8	.	O

1	Effects	O
2	of	O
3	point	O
4	defects	O
5	on	O
6	lattice	O
7	parameters	O
8	of	O
9	semiconductors	O
10	.	O

1	Chaotic	O
2	electron	O
3	dynamics	O
4	around	O
5	a	O
6	single	O
7	elliptically	O
8	shaped	O
9	antidot	O
10	.	O

1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O

1	Sixty	O
2	months	O
3	after	O
4	the	O
5	initial	O
6	vaccination	O
7	,	O
8	all	O
9	vaccinees	O
10	who	O
11	received	O
12	annual	O
13	follow	O
14	-	O
15	up	O
16	still	O
17	had	O
18	protective	O
19	levels	O
20	of	O
21	anti	B
22	-	I
23	HAV	I
24	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	Its	O
2	early	O
3	lesions	O
4	were	O
5	characterized	O
6	by	O
7	angiomatosis	O
8	,	O
9	vasculopathy	O
10	,	O
11	and	O
12	proliferation	O
13	of	O
14	synoviocytes	O
15	and	O
16	fibroblasts	O
17	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	novel	O
9	beta1	B
10	,	I
11	6	I
12	-	I
13	N	I
14	-	I
15	acetylglucosaminyltransferase	I
16	forming	O
17	core	O
18	2	O
19	and	O
20	core	O
21	4	O
22	.	O

1	Interspecific	O
2	mouse	O
3	back	O
4	-	O
5	cross	O
6	analysis	O
7	identified	O
8	the	O
9	loci	O
10	for	O
11	mouse	B
12	3Ost	I
13	genes	I
14	and	O
15	syntenic	O
16	assignments	O
17	of	O
18	corresponding	O
19	human	O
20	isologs	O
21	were	O
22	confirmed	O
23	by	O
24	the	O
25	identification	O
26	of	O
27	mapped	O
28	sequence	O
29	-	O
30	tagged	O
31	site	O
32	markers	O
33	.	O

1	The	O
2	Scales	O
3	of	O
4	Cognitive	O
5	Impairment	O
6	Rated	O
7	From	O
8	Institutional	O
9	Records	O
10	(	O
11	SCIRFIR	O
12	),	O
13	a	O
14	battery	O
15	based	O
16	on	O
17	commonly	O
18	used	O
19	dementia	O
20	rating	O
21	instruments	O
22	,	O
23	was	O
24	tested	O
25	on	O
26	the	O
27	records	O
28	of	O
29	26	O
30	chronically	O
31	institutionalized	O
32	,	O
33	elderly	O
34	schizophrenia	O
35	patients	O
36	,	O
37	for	O
38	the	O
39	purpose	O
40	of	O
41	retrospectively	O
42	evaluating	O
43	the	O
44	long	O
45	-	O
46	term	O
47	course	O
48	of	O
49	cognitive	O
50	change	O
51	in	O
52	schizophrenia	O
53	and	O
54	relating	O
55	it	O
56	to	O
57	available	O
58	autopsy	O
59	materials	O
60	.	O

1	It	O
2	was	O
3	demonstrated	O
4	that	O
5	the	O
6	processing	O
7	signals	O
8	in	O
9	the	O
10	transcript	O
11	,	O
12	i	O
13	.	O
14	e	O
15	.	O
16	both	O
17	donor	O
18	splice	O
19	sites	O
20	and	O
21	the	O
22	polyadenylation	O
23	site	O
24	located	O
25	in	O
26	the	O
27	muscle	O
28	-	O
29	specific	O
30	intron	O
31	,	O
32	have	O
33	to	O
34	be	O
35	weak	O
36	.	O

1	Most	O
2	recently	O
3	,	O
4	the	O
5	use	O
6	of	O
7	the	O
8	product	O
9	of	O
10	brain	O
11	weight	O
12	and	O
13	clearance	O
14	has	O
15	been	O
16	proposed	O
17	.	O

1	Recombination	O
2	and	O
3	transcription	O
4	of	O
5	the	O
6	endogenous	B
7	Ig	I
8	heavy	I
9	chain	I
10	locus	I
11	is	O
12	effected	O
13	by	O
14	the	O
15	Ig	B
16	heavy	I
17	chain	I
18	intronic	I
19	enhancer	I
20	core	I
21	region	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	the	O
27	matrix	O
28	attachment	O
29	regions	O
30	.	O

1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	O
22	IL	B
23	-	I
24	2	I
25	enhancer	I
26	and	O
27	the	O
28	CD18	B
29	promoter	I
30	.	O

1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	O
6	CREB	B
7	binding	I
8	protein	I
9	/	O
10	p300	B
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	B
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	B
21	and	I
22	-	I
23	beta	I
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	I
35	16	I
36	promoter	I
37	in	O
38	T	O
39	cells	O
40	.	O

1	TPO	B
2	by	O
3	itself	O
4	did	O
5	not	O
6	activate	O
7	ERK1	B
8	,	O
9	ERK2	B
10	and	O
11	protein	B
12	kinase	I
13	C	I
14	(	O
15	PKC	B
16	),	O
17	whereas	O
18	TPO	B
19	directly	O
20	enhanced	O
21	the	O
22	PKC	B
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	ERKs	B
28	induced	O
29	by	O
30	other	O
31	agonists	O
32	including	O
33	thrombin	B
34	and	O
35	phorbol	O
36	esters	O
37	,	O
38	without	O
39	affecting	O
40	the	O
41	PKC	B
42	activation	O
43	by	O
44	those	O
45	agonists	O
46	.	O

1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	B
6	-	O
7	dependent	O
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	B
13	ligase	I
14	(	O
15	E3	B
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	Fission	B
4	yeast	I
5	SCF	I
6	is	O
7	composed	O
8	of	O
9	Pop1	B
10	and	O
11	Pop2	B
12	,	O
13	two	O
14	structurally	O
15	related	O
16	but	O
17	functionally	O
18	independent	O
19	F	B
20	-	I
21	box	I
22	/	I
23	WD	I
24	-	I
25	repeat	I
26	proteins	I
27	.	O

1	19F	O
2	NMR	O
3	studies	O
4	in	O
5	ABF4	O
6	-	O
7	type	O
8	layered	O
9	antiferromagnets	O
10	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	Observation	O
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O

1	Quantum	O
2	-	O
3	statistical	O
4	theory	O
5	of	O
6	high	O
7	-	O
8	field	O
9	transport	O
10	phenomena	O
11	.	O

1	NH3	O
2	and	O
3	NO	O
4	interaction	O
5	with	O
6	Si	O
7	(	O
8	100	O
9	)-(	O
10	2	O
11	x	O
12	1	O
13	)	O
14	surfaces	O
15	.	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	Echo	O
2	modulation	O
3	in	O
4	Pr3	O
5	+:	O
6	YAlO3	O
7	.	O

1	Mechanisms	O
2	of	O
3	visible	O
4	-	O
5	light	O
6	emission	O
7	from	O
8	electro	O
9	-	O
10	oxidized	O
11	porous	O
12	silicon	O
13	.	O

1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	O
9	chains	O
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	O
15	YBa2Cu3O7	O
16	-	O
17	delta	O
18	crystal	O
19	.	O

1	Surface	O
2	spin	O
3	waves	O
4	in	O
5	a	O
6	Heisenberg	O
7	ferrimagnet	O
8	with	O
9	a	O
10	single	O
11	-	O
12	ion	O
13	anisotropy	O
14	(	O
15	uniaxial	O
16	and	O
17	nonuniaxial	O
18	).	O

1	Optically	O
2	detected	O
3	librons	O
4	and	O
5	phonons	O
6	in	O
7	crystalline	O
8	C60	O
9	.	O

1	Multilayer	O
2	-	O
3	relaxation	O
4	geometry	O
5	and	O
6	electronic	O
7	structure	O
8	of	O
9	a	O
10	W	O
11	(	O
12	111	O
13	)	O
14	surface	O
15	.	O

1	Temperature	O
2	dependence	O
3	of	O
4	the	O
5	sublattice	O
6	spontaneous	O
7	magnetization	O
8	of	O
9	YBa2Cu3O6	O
10	.	O

1	GW	O
2	Gamma	O
3	approximation	O
4	for	O
5	electron	O
6	self	O
7	-	O
8	energies	O
9	in	O
10	semiconductors	O
11	and	O
12	insulators	O
13	.	O

1	Precision	O
2	measurement	O
3	of	O
4	the	O
5	pion	O
6	mass	O
7	difference	O
8	m	O
9	pi	O
10	--	O
11	m	O
12	pi	O
13	0	O
14	.	O

1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O

1	Genetic	O
2	experiments	O
3	using	O
4	mutants	O
5	defective	O
6	in	O
7	apontic	B
8	and	O
9	bruno	B
10	reveal	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	these	O
16	genes	O
17	.	O

1	In	O
2	the	O
3	current	O
4	model	O
5	,	O
6	Wingless	B
7	/	O
8	Wnt	B
9	signal	O
10	stabilizes	O
11	Armadillo	B
12	/	O
13	beta	B
14	-	I
15	catenin	I
16	,	O
17	which	O
18	then	O
19	accumulates	O
20	in	O
21	nuclei	O
22	and	O
23	binds	O
24	TCF	B
25	/	O
26	LEF	B
27	family	O
28	proteins	O
29	,	O
30	forming	O
31	bipartite	O
32	transcription	O
33	factors	O
34	which	O
35	activate	O
36	transcription	O
37	of	O
38	Wingless	B
39	/	O
40	Wnt	B
41	responsive	O
42	genes	O
43	.	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	O
18	beta	B
19	-	I
20	adrenergic	I
21	receptor	I
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	Factors	O
2	influencing	O
3	direct	O
4	-	O
5	immersion	O
6	(	O
7	DI	O
8	)-	O
9	SPME	O
10	process	O
11	were	O
12	also	O
13	checked	O
14	and	O
15	chosen	O
16	experimentally	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	O
12	/	O
13	H1	O
14	domain	O
15	was	O
16	sufficient	O
17	for	O
18	coactivation	O
19	of	O
20	Zta	B
21	transcription	O
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	B
17	-	I
18	kDa	I
19	SR	I
20	protein	I
21	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	other	O
6	Ras	B
7	effectors	I
8	can	O
9	collaborate	O
10	with	O
11	PI	B
12	3	I
13	-	I
14	kinase	I
15	and	O
16	with	O
17	each	O
18	other	O
19	to	O
20	activate	O
21	Pak	B
22	.	O

1	Mammalian	O
2	Ras	B
3	GTPase	I
4	-	I
5	activating	I
6	protein	I
7	(	O
8	GAP	B
9	),	O
10	p120	B
11	Ras	I
12	-	O
13	GAP	B
14	,	O
15	has	O
16	been	O
17	implicated	O
18	as	O
19	both	O
20	a	O
21	downregulator	O
22	and	O
23	effector	O
24	of	O
25	Ras	B
26	proteins	I
27	,	O
28	but	O
29	its	O
30	precise	O
31	role	O
32	in	O
33	Ras	B
34	-	O
35	mediated	O
36	signal	O
37	transduction	O
38	pathways	O
39	is	O
40	unclear	O
41	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	B
6	gene	I
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	B
12	(+)	I
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	B
17	/	O
18	twy	B
19	)	O
20	in	O
21	vivo	O
22	.	O

1	Electrophoretic	O
2	mobility	O
3	-	O
4	shift	O
5	assays	O
6	performed	O
7	with	O
8	the	O
9	HNF	B
10	-	I
11	3	I
12	X	O
13	and	O
14	Y	O
15	sites	O
16	demonstrated	O
17	that	O
18	both	O
19	sites	O
20	are	O
21	capable	O
22	of	O
23	binding	O
24	HNF	B
25	-	I
26	3alpha	I
27	and	O
28	HNF	B
29	-	I
30	3beta	I
31	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	show	O
7	that	O
8	cdk7	B
9	may	O
10	phosphorylate	O
11	the	O
12	carboxy	O
13	-	O
14	terminal	O
15	domain	O
16	(	O
17	CTD	O
18	)	O
19	of	O
20	RNA	B
21	pol	I
22	II	I
23	in	O
24	the	O
25	absence	O
26	of	O
27	promoter	O
28	opening	O
29	.	O

1	The	O
2	therapy	O
3	with	O
4	a	O
5	H2	B
6	-	I
7	receptor	I
8	antagonist	O
9	is	O
10	less	O
11	effective	O
12	than	O
13	the	O
14	triple	O
15	therapies	O
16	with	O
17	omeprazole	O
18	or	O
19	lansoprazole	O
20	.	O

1	In	O
2	humans	O
3	,	O
4	three	O
5	tissue	B
6	-	I
7	specific	I
8	plastin	I
9	isoforms	I
10	have	O
11	been	O
12	identified	O
13	.	O

1	No	O
2	TATA	O
3	or	O
4	Inr	O
5	sequence	O
6	was	O
7	found	O
8	.	O

1	The	O
2	inhibition	O
3	by	O
4	the	O
5	RIalpha	B
6	subunit	I
7	is	O
8	reversed	O
9	by	O
10	addition	O
11	of	O
12	nanomolar	O
13	concentrations	O
14	of	O
15	cAMP	O
16	(	O
17	Ka	O
18	=	O
19	40	O
20	nM	O
21	),	O
22	thus	O
23	demonstrating	O
24	that	O
25	PrKX	B
26	is	O
27	a	O
28	novel	O
29	,	O
30	type	B
31	I	I
32	cAMP	I
33	-	I
34	dependent	I
35	protein	I
36	kinase	I
37	that	O
38	is	O
39	activated	O
40	at	O
41	lower	O
42	cAMP	O
43	concentrations	O
44	than	O
45	the	O
46	holoenzyme	O
47	with	O
48	the	O
49	Calpha	B
50	subunit	I
51	of	O
52	cAMP	B
53	-	I
54	dependent	I
55	protein	I
56	kinase	I
57	.	O

1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O

1	This	O
2	construct	O
3	,	O
4	termed	O
5	pDeltaCREC	B
6	/	O
7	EBP	B
8	,	O
9	binds	O
10	C	B
11	/	I
12	EBPalpha	I
13	and	I
14	beta	I
15	but	O
16	not	O
17	CREB	B
18	,	O
19	yet	O
20	it	O
21	confers	O
22	a	O
23	nearly	O
24	complete	O
25	glucocorticoid	O
26	response	O
27	when	O
28	transiently	O
29	transfected	O
30	into	O
31	H4IIE	O
32	rat	O
33	hepatoma	O
34	cells	O
35	.	O

1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	B
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O

1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O

1	Here	O
2	,	O
3	we	O
4	evidence	O
5	that	O
6	the	O
7	developmental	O
8	functions	O
9	of	O
10	the	O
11	family	O
12	of	O
13	transcription	O
14	factors	O
15	characterized	O
16	by	O
17	the	O
18	POU	B
19	DNA	I
20	binding	I
21	motif	I
22	exerts	O
23	roles	O
24	in	O
25	mammalian	O
26	development	O
27	.	O

1	High	O
2	-	O
3	affinity	O
4	site	O
5	-	O
6	specific	O
7	DNA	O
8	binding	O
9	by	O
10	POU	B
11	domain	I
12	transcription	I
13	factors	I
14	requires	O
15	both	O
16	the	O
17	POU	B
18	-	I
19	specific	I
20	and	O
21	the	O
22	POU	B
23	-	I
24	homeodomain	I
25	.	O

1	In	O
2	the	O
3	Oct	B
4	-	I
5	1	I
6	crystal	O
7	,	O
8	the	O
9	POU	B
10	-	I
11	specific	I
12	domain	I
13	recognizes	O
14	a	O
15	GCAT	O
16	half	O
17	-	O
18	site	O
19	,	O
20	while	O
21	the	O
22	corresponding	O
23	sequence	O
24	recognized	O
25	by	O
26	the	O
27	Pit	B
28	-	I
29	1	I
30	POU	I
31	-	O
32	specific	O
33	domain	O
34	,	O
35	GTAT	O
36	,	O
37	is	O
38	on	O
39	the	O
40	opposing	O
41	strand	O
42	.	O

1	Systematic	O
2	functional	O
3	analysis	O
4	of	O
5	V1a	B
6	/	I
7	V2	I
8	hybrid	I
9	receptors	I
10	showed	O
11	that	O
12	the	O
13	second	O
14	intracellular	O
15	loop	O
16	of	O
17	the	O
18	V1a	B
19	receptor	I
20	is	O
21	required	O
22	and	O
23	sufficient	O
24	for	O
25	efficient	O
26	coupling	O
27	to	O
28	Gq	B
29	/	I
30	11	I
31	,	O
32	whereas	O
33	the	O
34	third	O
35	intracellular	O
36	loop	O
37	of	O
38	the	O
39	V2	B
40	receptor	I
41	is	O
42	required	O
43	and	O
44	sufficient	O
45	for	O
46	coupling	O
47	to	O
48	Gs	B
49	.	O

1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O

1	The	O
2	other	O
3	is	O
4	located	O
5	at	O
6	-	O
7	1335	O
8	,	O
9	outside	O
10	this	O
11	highly	O
12	conserved	O
13	region	O
14	.	O

1	The	O
2	fatigue	O
3	exercise	O
4	showed	O
5	relatively	O
6	high	O
7	blood	O
8	lactate	O
9	concentration	O
10	[	O
11	12	O
12	.	O
13	5	O
14	(	O
15	SD	O
16	2	O
17	.	O
18	6	O
19	)	O
20	mmol	O
21	x	O
22	l	O
23	(-	O
24	1	O
25	)]	O
26	and	O
27	an	O
28	increase	O
29	of	O
30	serum	B
31	creatine	I
32	kinase	I
33	(	O
34	CK	B
35	)	O
36	activity	O
37	delayed	O
38	by	O
39	2	O
40	days	O
41	[	O
42	540	O
43	(	O
44	SD	O
45	407	O
46	)	O
47	U	O
48	x	O
49	l	O
50	(-	O
51	1	O
52	)].	O

1	Those	O
2	radiological	O
3	aspects	O
4	were	O
5	distributed	O
6	in	O
7	two	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	type	O
13	I	O
14	-	O
15	presenting	O
16	variable	O
17	sinusoidal	O
18	filling	O
19	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	New	O
2	Langevin	O
3	equations	O
4	for	O
5	a	O
6	translating	O
7	and	O
8	simultaneously	O
9	rotating	O
10	asymmetric	O
11	top	O
12	.	O

1	Radiative	O
2	corrections	O
3	to	O
4	beta	O
5	decay	O
6	and	O
7	the	O
8	possibility	O
9	of	O
10	a	O
11	fourth	O
12	generation	O
13	.	O

1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	Oscillatory	O
2	exchange	O
3	of	O
4	atoms	O
5	between	O
6	traps	O
7	containing	O
8	Bose	O
9	condensates	O
10	.	O

1	Structure	O
2	determination	O
3	of	O
4	an	O
5	adsorbate	O
6	-	O
7	induced	O
8	multilayer	O
9	reconstruction	O
10	:	O
11	(	O
12	1	O
13	x	O
14	2	O
15	)-	O
16	H	O
17	/	O
18	Ni	O
19	(	O
20	110	O
21	).	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	Northern	O
2	blot	O
3	and	O
4	in	O
5	situ	O
6	hybridization	O
7	analyses	O
8	revealed	O
9	GPR34	B
10	mRNA	I
11	transcripts	I
12	in	O
13	several	O
14	human	O
15	and	O
16	rat	O
17	brain	O
18	regions	O
19	.	O

1	The	O
2	microphthalmia	B
3	-	I
4	TFE	I
5	(	O
6	MiT	B
7	)	O
8	subfamily	O
9	of	O
10	basic	B
11	helix	I
12	-	I
13	loop	I
14	-	I
15	helix	I
16	leucine	I
17	zipper	I
18	(	I
19	bHLH	I
20	-	I
21	ZIP	I
22	)	I
23	transcription	I
24	factors	I
25	,	O
26	including	O
27	TFE3	B
28	,	O
29	TFEB	B
30	,	O
31	TFEC	B
32	,	O
33	and	O
34	Mitf	B
35	,	O
36	has	O
37	been	O
38	implicated	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	tissue	O
44	-	O
45	specific	O
46	gene	O
47	expression	O
48	in	O
49	several	O
50	cell	O
51	lineages	O
52	.	O

1	Fifty	O
2	-	O
3	seven	O
4	patients	O
5	aged	O
6	<	O
7	55	O
8	years	O
9	with	O
10	acute	O
11	lymphoblastic	O
12	leukemia	O
13	(	O
14	ALL	O
15	)	O
16	in	O
17	second	O
18	or	O
19	third	O
20	bone	O
21	marrow	O
22	(	O
23	BM	O
24	)	O
25	relapse	O
26	or	O
27	refractory	O
28	to	O
29	first	O
30	-	O
31	line	O
32	therapy	O
33	were	O
34	enrolled	O
35	in	O
36	an	O
37	Italian	O
38	cooperative	O
39	study	O
40	.	O

1	The	O
2	dorsal	O
3	nerves	O
4	of	O
5	the	O
6	penis	O
7	were	O
8	anesthetized	O
9	bilaterally	O
10	with	O
11	lidocaine	O
12	.	O

1	In	O
2	the	O
3	brain	O
4	,	O
5	muscarinic	B
6	receptors	I
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	O
12	by	O
13	interaction	O
14	with	O
15	their	O
16	ligand	O
17	acetylcholine	O
18	.	O

1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O

1	Successful	O
2	interaction	O
3	of	O
4	ARF	B
5	and	O
6	PKC	B
7	-	I
8	alpha	I
9	with	O
10	PLD1	B
11	was	O
12	not	O
13	achieved	O
14	,	O
15	but	O
16	a	O
17	C	O
18	-	O
19	terminal	O
20	fragment	O
21	of	O
22	human	B
23	PLD1	I
24	(	O
25	denoted	O
26	"	O
27	D4	O
28	")	O
29	interacted	O
30	with	O
31	the	O
32	active	O
33	mutant	O
34	of	O
35	RhoA	B
36	,	O
37	RhoAVal	B
38	-	I
39	14	I
40	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	signal	O
9	transduction	O
10	pathways	O
11	that	O
12	are	O
13	involved	O
14	in	O
15	OM	B
16	-	O
17	induced	O
18	LDLR	B
19	transcription	O
20	.	O

1	Vacuum	O
2	Rabi	O
3	splitting	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	dispersion	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O

1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O

1	Drag	O
2	reduction	O
3	in	O
4	turbulent	O
5	flows	O
6	by	O
7	polymers	O
8	.	O

1	Large	O
2	scale	O
3	electronic	O
4	structure	O
5	calculations	O
6	.	O

1	Current	O
2	world	O
3	literature	O
4	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	Ski	B
6	is	O
7	a	O
8	component	O
9	of	O
10	the	O
11	HDAC	B
12	complex	I
13	and	O
14	that	O
15	Ski	B
16	is	O
17	required	O
18	for	O
19	the	O
20	transcriptional	O
21	repression	O
22	mediated	O
23	by	O
24	this	O
25	complex	O
26	.	O

1	Recombinant	O
2	unr	B
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	B
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	rhinovirus	O
15	IRES	O
16	.	O

1	Analysis	O
2	of	O
3	the	O
4	consensus	O
5	binding	O
6	sequence	O
7	and	O
8	the	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	of	O
14	ZF5	B
15	.	O

1	Mapping	O
2	of	O
3	the	O
4	human	B
5	Voltage	I
6	-	I
7	Dependent	I
8	Anion	I
9	Channel	I
10	isoforms	I
11	1	I
12	and	I
13	2	I
14	reconsidered	O
15	.	O

1	Identification	O
2	of	O
3	RNase	B
4	T	I
5	as	O
6	a	O
7	high	O
8	-	O
9	copy	O
10	suppressor	O
11	of	O
12	the	O
13	UV	O
14	sensitivity	O
15	associated	O
16	with	O
17	single	B
18	-	I
19	strand	I
20	DNA	I
21	exonuclease	I
22	deficiency	O
23	in	O
24	Escherichia	O
25	coli	O
26	.	O

1	Inhibition	O
2	of	O
3	phosphatidylinositol	B
4	-	I
5	3	I
6	kinase	I
7	did	O
8	not	O
9	have	O
10	a	O
11	significant	O
12	effect	O
13	on	O
14	p53	B
15	conformation	O
16	but	O
17	did	O
18	have	O
19	a	O
20	weak	O
21	but	O
22	significant	O
23	effect	O
24	on	O
25	Tpo	B
26	-	O
27	enhanced	O
28	viability	O
29	.	O

1	No	O
2	difference	O
3	in	O
4	percentage	O
5	of	O
6	males	O
7	in	O
8	semen	O
9	production	O
10	was	O
11	noted	O
12	between	O
13	strains	O
14	,	O
15	CP	O
16	levels	O
17	,	O
18	or	O
19	feeding	O
20	regimens	O
21	.	O

1	The	O
2	Lp	B
3	mouse	I
4	mutant	I
5	provides	O
6	a	O
7	model	O
8	for	O
9	the	O
10	severe	O
11	human	O
12	neural	O
13	tube	O
14	defect	O
15	(	O
16	NTD	O
17	),	O
18	cranio	O
19	-	O
20	rachischisis	O
21	.	O

1	Further	O
2	analysis	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	DNA	O
8	binding	O
9	activities	O
10	in	O
11	7	O
12	-	O
13	to	O
14	14	O
15	-	O
16	day	O
17	culture	O
18	activated	O
19	HSCs	O
20	led	O
21	to	O
22	the	O
23	discovery	O
24	of	O
25	high	B
26	mobility	I
27	AP	I
28	-	I
29	1	I
30	complexes	I
31	(	O
32	HMAP	B
33	-	I
34	1	I
35	).	O

1	Mutations	O
2	of	O
3	the	O
4	AP	B
5	-	I
6	1	I
7	site	I
8	of	O
9	the	O
10	TIMP	B
11	-	I
12	1	I
13	promoter	I
14	that	O
15	prevented	O
16	formation	O
17	of	O
18	HMAP	B
19	-	I
20	1	I
21	caused	O
22	a	O
23	70	O
24	%	O
25	loss	O
26	of	O
27	activity	O
28	in	O
29	transfected	O
30	activated	O
31	HSCs	O
32	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Salivary	B
5	immunoglobulin	I
6	A	I
7	levels	O
8	of	O
9	each	O
10	of	O
11	20	O
12	subjects	O
13	were	O
14	determined	O
15	on	O
16	3	O
17	occasions	O
18	:	O
19	first	O
20	,	O
21	while	O
22	the	O
23	subject	O
24	was	O
25	still	O
26	smoking	O
27	;	O
28	second	O
29	,	O
30	7	O
31	days	O
32	after	O
33	cessation	O
34	of	O
35	smoking	O
36	;	O
37	third	O
38	,	O
39	on	O
40	the	O
41	14th	O
42	day	O
43	after	O
44	cessation	O
45	.	O

1	Therefore	O
2	,	O
3	high	O
4	set	O
5	-	O
6	up	O
7	accuracy	O
8	and	O
9	reproducibility	O
10	are	O
11	mandatory	O
12	.	O

1	Role	O
2	of	O
3	g2	O
4	in	O
5	relating	O
6	the	O
7	Schwinger	O
8	and	O
9	Gerasimov	O
10	-	O
11	Drell	O
12	-	O
13	Hearn	O
14	sum	O
15	rules	O
16	.	O

1	Spectroscopy	O
2	of	O
3	negative	O
4	ions	O
5	utilizing	O
6	multiphoton	O
7	detachment	O
8	in	O
9	a	O
10	Raman	O
11	coupling	O
12	regime	O
13	.	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O

1	Two	O
2	-	O
3	Channel	O
4	Kondo	O
5	Lattice	O
6	:	O
7	An	O
8	Incoherent	O
9	Metal	O
10	.	O

1	Basal	O
2	midexpiratory	O
3	lower	O
4	esophageal	O
5	sphincter	O
6	pressure	O
7	was	O
8	similar	O
9	in	O
10	the	O
11	study	O
12	group	O
13	(	O
14	mean	O
15	[	O
16	SD	O
17	]	O
18	20	O
19	.	O
20	1	O
21	[	O
22	9	O
23	.	O
24	1	O
25	]	O
26	mmHg	O
27	)	O
28	and	O
29	controls	O
30	(	O
31	17	O
32	.	O
33	6	O
34	[	O
35	6	O
36	.	O
37	0	O
38	]	O
39	mmHg	O
40	);	O
41	the	O
42	pressure	O
43	did	O
44	not	O
45	change	O
46	following	O
47	EVS	O
48	or	O
49	EVL	O
50	.	O

1	CPDs	O
2	at	O
3	these	O
4	three	O
5	sites	O
6	may	O
7	partially	O
8	displace	O
9	TFIIIA	B
10	,	O
11	thereby	O
12	enabling	O
13	rapid	O
14	repair	O
15	.	O

1	There	O
2	was	O
3	no	O
4	difference	O
5	in	O
6	the	O
7	hormone	O
8	receptor	O
9	status	O
10	between	O
11	the	O
12	cases	O
13	without	O
14	lymph	O
15	node	O
16	metastases	O
17	and	O
18	with	O
19	lymph	O
20	node	O
21	metastases	O
22	,	O
23	'	O
24	clandestine	O
25	'	O
26	or	O
27	macrometastases	O
28	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	subjects	O
7	with	O
8	air	O
9	trapping	O
10	(	O
11	residual	O
12	volume	O
13	(	O
14	RV	O
15	)/	O
16	total	O
17	lung	O
18	capacity	O
19	(	O
20	TLC	O
21	)	O
22	>	O
23	37	O
24	%)	O
25	disclosed	O
26	not	O
27	only	O
28	a	O
29	higher	O
30	n	O
31	(	O
32	mit	O
33	)	O
34	(	O
35	0	O
36	.	O
37	63	O
38	+/-	O
39	0	O
40	.	O
41	17	O
42	versus	O
43	0	O
44	.	O
45	43	O
46	+/-	O
47	0	O
48	.	O
49	07	O
50	mt	O
51	x	O
52	microm	O
53	(-	O
54	2	O
55	),	O
56	p	O
57	<	O
58	0	O
59	.	O
60	05	O
61	)	O
62	but	O
63	shorter	O
64	sarcomeres	O
65	(	O
66	L	O
67	(	O
68	sar	O
69	))	O
70	than	O
71	subjects	O
72	without	O
73	this	O
74	functional	O
75	abnormality	O
76	(	O
77	2	O
78	.	O
79	08	O
80	+/-	O
81	0	O
82	.	O
83	16	O
84	to	O
85	2	O
86	.	O
87	27	O
88	+/-	O
89	0	O
90	.	O
91	15	O
92	microm	O
93	,	O
94	p	O
95	<	O
96	0	O
97	.	O
98	05	O
99	).	O

1	Gel	O
2	filtration	O
3	,	O
4	sedimentation	O
5	velocity	O
6	,	O
7	and	O
8	immunoprecipitation	O
9	experiments	O
10	revealed	O
11	that	O
12	beta4	O
13	is	O
14	a	O
15	component	O
16	of	O
17	a	O
18	multisubunit	O
19	complex	O
20	(	O
21	AP	B
22	-	I
23	4	I
24	)	O
25	that	O
26	also	O
27	contains	O
28	the	O
29	sigma4	O
30	polypeptide	O
31	and	O
32	two	O
33	additional	O
34	adaptor	O
35	subunit	O
36	homologs	O
37	named	O
38	mu4	O
39	(	O
40	mu	O
41	-	O
42	ARP2	O
43	)	O
44	and	O
45	epsilon	O
46	.	O

1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	B
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O

1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	O
11	SHIP	B
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	O
18	phosphoinositide	B
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	B
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	B
29	cell	I
30	receptor	I
31	signaling	O
32	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	mouse	O
6	genome	O
7	contains	O
8	four	O
9	copies	O
10	of	O
11	the	O
12	ubc	B
13	-	I
14	9	I
15	gene	I
16	.	O

1	An	O
2	increase	O
3	in	O
4	bone	O
5	mineral	O
6	density	O
7	at	O
8	the	O
9	spine	O
10	,	O
11	total	O
12	hip	O
13	,	O
14	and	O
15	total	O
16	body	O
17	has	O
18	been	O
19	reported	O
20	with	O
21	raloxifene	O
22	but	O
23	seems	O
24	to	O
25	be	O
26	less	O
27	than	O
28	that	O
29	seen	O
30	with	O
31	estrogen	O
32	or	O
33	alendronate	O
34	therapy	O
35	.	O

1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	B
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	O
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	B
31	was	O
32	not	O
33	observed	O
34	.	O

1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	B
10	RNA	I
11	,	O
12	Lyp2	B
13	.	O

1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O

1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Each	O
2	of	O
3	these	O
4	genes	O
5	contains	O
6	a	O
7	putative	O
8	upstream	O
9	ORF	O
10	,	O
11	while	O
12	STA2	B
13	has	O
14	two	O
15	additional	O
16	in	O
17	-	O
18	frame	O
19	AUG	O
20	codons	O
21	5	O
22	'	O
23	to	O
24	the	O
25	major	O
26	cistron	O
27	.	O

1	Nipponbare	O
2	as	O
3	well	O
4	as	O
5	O	O
6	.	O
7	australiensis	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	O
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O

1	RT	O
2	-	O
3	PCR	O
4	was	O
5	performed	O
6	using	O
7	previously	O
8	reported	O
9	degenerate	O
10	oligonucleotide	O
11	primers	O
12	to	O
13	the	O
14	ligand	O
15	binding	O
16	domain	O
17	(	O
18	LBD	O
19	)	O
20	of	O
21	known	O
22	beta	B
23	integrin	I
24	subunits	I
25	and	O
26	Bge	B
27	cDNA	I
28	.	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	d	B
5	-	I
6	axin	I
7	inhibited	O
8	Wingless	B
9	signaling	O
10	.	O

1	The	O
2	corresponding	O
3	differences	O
4	in	O
5	FVIIa	B
6	and	O
7	PAI	B
8	-	I
9	1	I
10	were	O
11	not	O
12	statistically	O
13	significant	O
14	.	O

1	Primary	O
2	and	O
3	secondary	O
4	structural	O
5	elements	O
6	required	O
7	for	O
8	synthesis	O
9	of	O
10	barley	O
11	yellow	O
12	dwarf	O
13	virus	O
14	subgenomic	O
15	RNA1	O
16	.	O

1	On	O
2	the	O
3	other	O
4	side	O
5	,	O
6	when	O
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	O
21	)	O
22	or	O
23	methylene	O
24	blue	O
25	(	O
26	soluble	O
27	cGMPase	B
28	inhibitor	O
29	),	O
30	the	O
31	changes	O
32	could	O
33	be	O
34	attenuated	O
35	.	O

1	Nevertheless	O
2	,	O
3	inactivation	O
4	of	O
5	the	O
6	cyclin	B
7	E	I
8	-	O
9	Cdk2	B
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	O
27	p27	B
28	gene	I
29	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	IS2404	B
6	and	O
7	IS2606	B
8	:	O
9	two	O
10	distinct	O
11	repeated	O
12	sequences	O
13	for	O
14	detection	O
15	of	O
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	are	O
7	consistent	O
8	with	O
9	the	O
10	possibility	O
11	that	O
12	p202	B
13	protein	I
14	contributes	O
15	to	O
16	the	O
17	cell	O
18	growth	O
19	retardation	O
20	activity	O
21	of	O
22	the	O
23	IFNs	B
24	,	O
25	at	O
26	least	O
27	in	O
28	part	O
29	,	O
30	by	O
31	modulating	O
32	p21	B
33	protein	I
34	levels	O
35	.	O

1	Similar	O
2	results	O
3	were	O
4	also	O
5	obtained	O
6	with	O
7	a	O
8	HepG2	O
9	hepatoblastoma	O
10	cell	O
11	line	O
12	carrying	O
13	wt	B
14	p53	I
15	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	B
9	-	I
10	Pto	I
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	B
16	/	I
17	AB	I
18	genes	I
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	The	O
2	MSY2	B
3	associated	O
4	kinase	O
5	is	O
6	not	O
7	casein	B
8	kinase	I
9	2	I
10	,	O
11	the	O
12	kinase	O
13	believed	O
14	to	O
15	phosphorylate	O
16	mRNP3	B
17	+	I
18	4	I
19	in	O
20	oocytes	O
21	,	O
22	but	O
23	a	O
24	yet	O
25	unidentified	O
26	kinase	O
27	.	O

1	This	O
2	suggests	O
3	that	O
4	helicase	B
5	-	I
6	like	I
7	genes	I
8	may	O
9	be	O
10	involved	O
11	in	O
12	the	O
13	biosynthesis	O
14	of	O
15	nucleic	O
16	acids	O
17	and	O
18	proteins	O
19	,	O
20	and	O
21	that	O
22	the	O
23	genes	O
24	can	O
25	be	O
26	transcriptionally	O
27	activated	O
28	by	O
29	heat	O
30	shock	O
31	to	O
32	compensate	O
33	for	O
34	the	O
35	repressed	O
36	synthesis	O
37	of	O
38	mRNA	O
39	and	O
40	protein	O
41	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	B
14	and	O
15	the	O
16	MUL	B
17	genes	I
18	.	O

1	The	O
2	H	O
3	-	O
4	reflex	O
5	recovery	O
6	curve	O
7	was	O
8	obtained	O
9	after	O
10	stimulation	O
11	of	O
12	the	O
13	median	O
14	nerve	O
15	at	O
16	the	O
17	elbow	O
18	and	O
19	recording	O
20	from	O
21	the	O
22	flexor	O
23	carpi	O
24	radialis	O
25	.	O

1	The	O
2	origins	O
3	of	O
4	reflected	O
5	light	O
6	changes	O
7	associated	O
8	with	O
9	neuronal	O
10	activity	O
11	(	O
12	optical	O
13	signals	O
14	)	O
15	were	O
16	investigated	O
17	in	O
18	rat	O
19	somatosensory	O
20	cortex	O
21	with	O
22	optical	O
23	imaging	O
24	,	O
25	microspectrophotometry	O
26	,	O
27	and	O
28	laser	O
29	-	O
30	Doppler	O
31	flowmetry	O
32	,	O
33	and	O
34	dynamic	O
35	changes	O
36	in	O
37	local	O
38	hemoglobin	B
39	concentration	O
40	and	O
41	oxygenation	O
42	were	O
43	focused	O
44	on	O
45	.	O

1	Human	B
2	neuronal	I
3	Elav	I
4	-	I
5	like	I
6	proteins	I
7	contain	O
8	three	O
9	RNP	O
10	-	O
11	type	O
12	RNA	O
13	recognition	O
14	motifs	O
15	(	O
16	RRMs	O
17	).	O

1	Comparison	O
2	of	O
3	frequencies	O
4	of	O
5	atrial	O
6	fibrillation	O
7	after	O
8	coronary	O
9	artery	O
10	bypass	O
11	grafting	O
12	with	O
13	and	O
14	without	O
15	the	O
16	use	O
17	of	O
18	cardiopulmonary	O
19	bypass	O
20	.	O

1	The	O
2	results	O
3	of	O
4	supershift	O
5	analysis	O
6	using	O
7	specific	O
8	antibodies	O
9	against	O
10	transcription	O
11	factors	O
12	suggested	O
13	that	O
14	both	O
15	binding	O
16	complexes	O
17	contained	O
18	the	O
19	NF	B
20	-	I
21	kappaB	I
22	components	O
23	p50	B
24	and	O
25	p65	B
26	,	O
27	and	O
28	did	O
29	not	O
30	contain	O
31	other	O
32	NF	B
33	-	I
34	kappaB	I
35	proteins	I
36	(	O
37	p52	B
38	,	O
39	c	B
40	-	I
41	Rel	I
42	,	O
43	Rel	B
44	B	I
45	),	O
46	AP	B
47	-	I
48	1	I
49	proteins	I
50	(	O
51	c	B
52	-	I
53	Fos	I
54	,	O
55	C	B
56	-	I
57	Jun	I
58	),	O
59	CREB	B
60	or	O
61	C	B
62	/	I
63	EBPbeta	I
64	(	O
65	NF	B
66	-	I
67	IL6	I
68	).	O

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	B
23	protein	I
24	L9	I
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	IFN	B
6	-	I
7	gamma	I
8	stimulated	O
9	the	O
10	rapid	O
11	accumulation	O
12	of	O
13	interferon	B
14	regulated	I
15	factor	I
16	(	I
17	IRF	I
18	)-	I
19	1	I
20	mRNA	I
21	,	O
22	followed	O
23	by	O
24	a	O
25	delayed	O
26	and	O
27	dose	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	alpha1	B
33	(	I
34	I	I
35	)	I
36	procollagen	I
37	mRNA	I
38	expression	O
39	in	O
40	skin	O
41	fibroblasts	O
42	from	O
43	several	O
44	different	O
45	donors	O
46	.	O

1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	promoter	I
8	binding	I
9	protein	I
10	1	I
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	named	O
6	this	O
7	gene	O
8	UBP43	B
9	.	O

1	These	O
2	results	O
3	continue	O
4	to	O
5	support	O
6	the	O
7	hypothesis	O
8	that	O
9	HS2	O
10	,	O
11	HS3	O
12	,	O
13	and	O
14	HS4	O
15	act	O
16	as	O
17	a	O
18	single	O
19	,	O
20	integral	O
21	unit	O
22	to	O
23	regulate	O
24	human	B
25	globin	I
26	gene	I
27	transcription	O
28	as	O
29	a	O
30	holocomplex	O
31	,	O
32	but	O
33	they	O
34	can	O
35	also	O
36	be	O
37	interpreted	O
38	to	O
39	say	O
40	that	O
41	formation	O
42	of	O
43	a	O
44	DNase	B
45	I	I
46	hypersensitive	O
47	holocomplex	O
48	alone	O
49	is	O
50	not	O
51	sufficient	O
52	for	O
53	mediating	O
54	high	O
55	-	O
56	level	O
57	globin	B
58	gene	I
59	transcription	O
60	.	O

1	To	O
2	identify	O
3	additional	O
4	non	O
5	-	O
6	Sir	B
7	factors	I
8	that	O
9	affect	O
10	rDNA	O
11	silencing	O
12	,	O
13	we	O
14	performed	O
15	a	O
16	genetic	O
17	screen	O
18	designed	O
19	to	O
20	isolate	O
21	mutations	O
22	which	O
23	alter	O
24	the	O
25	expression	O
26	of	O
27	reporter	O
28	genes	O
29	integrated	O
30	within	O
31	the	O
32	rDNA	O
33	.	O

1	Because	O
2	there	O
3	is	O
4	great	O
5	need	O
6	for	O
7	iron	O
8	in	O
9	the	O
10	EPO	B
11	-	O
12	stimulated	O
13	erythroid	O
14	progenitors	O
15	,	O
16	it	O
17	is	O
18	essential	O
19	that	O
20	serum	B
21	ferritin	I
22	and	O
23	transferrin	B
24	saturation	O
25	levels	O
26	should	O
27	be	O
28	maintained	O
29	over	O
30	300	O
31	microg	O
32	/	O
33	liter	O
34	and	O
35	30	O
36	%,	O
37	respectively	O
38	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	p33	B
7	subunit	I
8	of	O
9	eIF3	B
10	plays	O
11	an	O
12	important	O
13	role	O
14	in	O
15	the	O
16	initiation	O
17	phase	O
18	of	O
19	protein	O
20	synthesis	O
21	and	O
22	that	O
23	its	O
24	RNA	O
25	-	O
26	binding	O
27	domain	O
28	is	O
29	required	O
30	for	O
31	optimal	O
32	activity	O
33	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	elucidate	O
7	signaling	O
8	pathways	O
9	induced	O
10	by	O
11	photodynamic	O
12	therapy	O
13	(	O
14	PDT	O
15	)	O
16	with	O
17	hypericin	O
18	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	I
7	2	I
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	I
15	beta	I
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	Smad	B
27	and	O
28	TAK1	B
29	pathways	O
30	.	O

1	KEY	O
2	WORDS	O
3	:	O
4	Melaleuca	O
5	;	O
6	Lake	O
7	Okeechobee	O
8	;	O
9	Littoral	O
10	zone	O
11	;	O
12	Water	O
13	level	O
14	;	O
15	Regulation	O
16	schedule	O

1	The	O
2	systolic	O
3	peak	O
4	of	O
5	pulmonary	O
6	vein	O
7	was	O
8	higher	O
9	than	O
10	the	O
11	diastolic	O
12	peak	O
13	in	O
14	45	O
15	out	O
16	of	O
17	56	O
18	cases	O
19	.	O

1	Specimens	O
2	were	O
3	assayed	O
4	for	O
5	alpha	B
6	-	I
7	fetoprotein	I
8	,	O
9	unconjugated	O
10	estriol	O
11	,	O
12	free	O
13	alpha	B
14	hCG	I
15	,	O
16	and	O
17	total	O
18	hCG	B
19	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	arrival	O
8	in	O
9	the	O
10	intensive	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	CPB	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	B
60	elastase	I
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	echocardiographic	O
66	factors	O
67	shortening	O
68	fraction	O
69	and	O
70	preejection	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	cumulative	O
81	doses	O
82	of	O
83	catecholamines	O
84	(	O
85	epinephrine	O
86	),	O
87	enoximone	O
88	,	O
89	and	O
90	furosemide	O
91	.	O

1	MDS1	B
2	/	O
3	EVI1	B
4	,	O
5	located	O
6	on	O
7	chromosome	O
8	3	O
9	band	O
10	q26	O
11	,	O
12	encodes	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	DNA	I
18	-	I
19	binding	I
20	transcription	I
21	activator	I
22	not	O
23	detected	O
24	in	O
25	normal	O
26	hematopoietic	O
27	cells	O
28	but	O
29	expressed	O
30	in	O
31	several	O
32	normal	O
33	tissues	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	B
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	B
16	.	I
17	pylori	I
18	plasmid	I
19	replication	I
20	proteins	I
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	B
31	.	I
32	pylori	I
33	plasmid	I
34	proteins	I
35	.	O

1	The	O
2	JTc	O
3	delta	O
4	among	O
5	the	O
6	three	O
7	groups	O
8	did	O
9	not	O
10	differ	O
11	as	O
12	well	O
13	:	O
14	JTc	O
15	delta	O
16	of	O
17	the	O
18	VT	O
19	group	O
20	was	O
21	70	O
22	ms	O
23	+/-	O
24	30	O
25	ms	O
26	,	O
27	the	O
28	JTc	O
29	delta	O
30	of	O
31	the	O
32	PVC	O
33	group	O
34	was	O
35	60	O
36	msec	O
37	+/-	O
38	25	O
39	msec	O
40	,	O
41	and	O
42	the	O
43	JTc	O
44	delta	O
45	of	O
46	the	O
47	control	O
48	group	O
49	was	O
50	70	O
51	ms	O
52	+/-	O
53	30	O
54	ms	O
55	.	O

1	In	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	the	O
7	upstream	O
8	portion	O
9	of	O
10	the	O
11	delta	O
12	promoter	O
13	led	O
14	to	O
15	a	O
16	10	O
17	fold	O
18	decrease	O
19	in	O
20	expression	O
21	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	B
11	proteins	I
12	BP1	I
13	and	O
14	BP2	B
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	I
23	gene	I
24	flanking	I
25	region	I
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O

1	However	O
2	,	O
3	with	O
4	the	O
5	alpha1	O
6	antagonist	O
7	prazosin	O
8	(	O
9	5	O
10	x	O
11	10	O
12	(-	O
13	8	O
14	)-	O
15	5	O
16	x	O
17	10	O
18	(-	O
19	7	O
20	)	O
21	M	O
22	),	O
23	no	O
24	relaxation	O
25	occurred	O
26	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	I
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	The	O
2	algorithm	O
3	also	O
4	limited	O
5	TG	O
6	to	O
7	20	O
8	and	O
9	64	O
10	%,	O
11	apoB	B
12	to	O
13	6	O
14	and	O
15	20	O
16	%,	O
17	and	O
18	Lp	B
19	(	I
20	a	I
21	)	I
22	to	O
23	15	O
24	and	O
25	56	O
26	%,	O
27	of	O
28	low	O
29	-	O
30	and	O
31	high	O
32	-	O
33	risk	O
34	groups	O
35	,	O
36	respectively	O
37	.	O

1	The	O
2	mean	O
3	value	O
4	of	O
5	the	O
6	CD79b	B
7	to	O
8	the	O
9	CD79b	B
10	internally	O
11	deleted	O
12	ratio	O
13	was	O
14	0	O
15	.	O
16	64	O
17	+/-	O
18	0	O
19	.	O
20	20	O
21	SD	O
22	in	O
23	normal	O
24	donors	O
25	and	O
26	0	O
27	.	O
28	44	O
29	+/-	O
30	0	O
31	.	O
32	27	O
33	SD	O
34	in	O
35	B	O
36	-	O
37	CLL	O
38	(	O
39	P	O
40	=.	O
41	01	O
42	).	O

1	As	O
2	normal	O
3	B	O
4	cells	O
5	also	O
6	present	O
7	this	O
8	variant	O
9	,	O
10	the	O
11	mechanism	O
12	of	O
13	CD79b	B
14	posttranscriptional	O
15	regulation	O
16	might	O
17	reflect	O
18	the	O
19	activation	O
20	stage	O
21	of	O
22	the	O
23	normal	O
24	B	O
25	cell	O
26	from	O
27	which	O
28	B	O
29	-	O
30	CLL	O
31	derives	O
32	.	O

1	Conformational	O
2	studies	O
3	combining	O
4	secondary	O
5	structure	O
6	predictions	O
7	,	O
8	CD	O
9	and	O
10	NMR	O
11	spectroscopy	O
12	together	O
13	with	O
14	ELISA	O
15	assays	O
16	,	O
17	showed	O
18	that	O
19	the	O
20	greater	O
21	is	O
22	the	O
23	propensity	O
24	of	O
25	the	O
26	epitope	O
27	for	O
28	helix	O
29	formation	O
30	the	O
31	higher	O
32	is	O
33	the	O
34	recognition	O
35	by	O
36	anti	B
37	-	I
38	K159	I
39	.	O

1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	"	O
9	off	O
10	"	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	"	O
21	on	O
22	"	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O

1	High	O
2	-	O
3	level	O
4	gains	O
5	(	O
6	HLGs	O
7	)	O
8	indicative	O
9	of	O
10	gene	O
11	amplifications	O
12	were	O
13	identified	O
14	at	O
15	11q13	O
16	in	O
17	two	O
18	cases	O
19	,	O
20	and	O
21	in	O
22	one	O
23	case	O
24	each	O
25	at	O
26	2q33	O
27	-	O
28	34	O
29	,	O
30	3q25	O
31	-	O
32	29	O
33	,	O
34	5p15	O
35	.	O
36	1	O
37	-	O
38	15	O
39	.	O
40	2	O
41	,	O
42	7q21	O
43	-	O
44	22	O
45	,	O
46	11p11	O
47	.	O
48	2	O
49	,	O
50	12p11	O
51	.	O
52	2	O
53	-	O
54	12	O
55	,	O
56	and	O
57	13q34	O
58	.	O

1	With	O
2	respect	O
3	to	O
4	the	O
5	distribution	O
6	of	O
7	active	O
8	MREs	O
9	over	O
10	the	O
11	promoter	O
12	region	O
13	,	O
14	the	O
15	hMT	B
16	-	I
17	IIA	I
18	gene	I
19	is	O
20	largely	O
21	different	O
22	from	O
23	the	O
24	mouse	O
25	metallothionein	B
26	-	I
27	I	I
28	gene	I
29	,	O
30	suggesting	O
31	that	O
32	MRE	O
33	arrangement	O
34	is	O
35	not	O
36	an	O
37	important	O
38	factor	O
39	for	O
40	metal	O
41	regulation	O
42	.	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	B
14	triose	I
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	B
11	knuckle	I
12	9G8	I
13	variant	I
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	B
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	B
30	and	O
31	SRp20	B
32	are	O
33	similar	O
34	.	O

1	Topoisomerase	B
2	II	I
3	is	O
4	a	O
5	major	O
6	target	O
7	of	O
8	the	O
9	protein	B
10	kinase	I
11	casein	I
12	kinase	I
13	2	I
14	(	O
15	PK	B
16	CK2	I
17	)	O
18	in	O
19	vivo	O
20	.	O

1	Recent	O
2	work	O
3	in	O
4	this	O
5	laboratory	O
6	has	O
7	shown	O
8	that	O
9	the	O
10	gene	O
11	coding	O
12	for	O
13	acetate	B
14	kinase	I
15	(	O
16	ackA	B
17	)	O
18	in	O
19	Sinorhizobium	O
20	meliloti	O
21	is	O
22	up	O
23	-	O
24	regulated	O
25	in	O
26	response	O
27	to	O
28	phosphate	O
29	limitation	O
30	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	HIV	O
13	-	O
14	1	O
15	transcript	O
16	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	MEMA	B
7	protein	I
8	is	O
9	identical	O
10	with	O
11	a	O
12	160	B
13	kDa	I
14	nuclear	I
15	'	I
16	domain	I
17	rich	I
18	in	I
19	serines	I
20	'	I
21	(	I
22	DRS	I
23	)	I
24	protein	I
25	occurring	O
26	free	O
27	in	O
28	the	O
29	nucleoplasm	O
30	and	O
31	in	O
32	U2	B
33	-	I
34	ribonucleoprotein	I
35	structures	I
36	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	complete	O
7	structure	O
8	of	O
9	the	O
10	human	B
11	topoisomerase	I
12	IIalpha	I
13	gene	I
14	,	O
15	which	O
16	consists	O
17	of	O
18	35	O
19	exons	O
20	spanning	O
21	27	O
22	.	O
23	5	O
24	kb	O
25	.	O

1	Dopaminergic	O
2	modulation	O
3	of	O
4	transcallosal	O
5	activity	O
6	of	O
7	cat	O
8	motor	O
9	cortical	O
10	neurons	O
11	.	O

1	Previous	O
2	studies	O
3	characterized	O
4	a	O
5	cytokine	O
6	-	O
7	inducible	O
8	,	O
9	functional	O
10	nuclear	B
11	factor	I
12	(	I
13	NF	I
14	)-	I
15	kappaB	I
16	consensus	I
17	element	I
18	in	O
19	the	O
20	immediate	O
21	5	O
22	'	O
23	regulatory	O
24	region	O
25	of	O
26	the	O
27	MGSA	B
28	/	O
29	GRO	B
30	-	I
31	alpha	I
32	gene	O
33	at	O
34	-	O
35	78	O
36	bp	O
37	.	O

1	An	O
2	exon	O
3	that	O
4	prevents	O
5	transport	O
6	of	O
7	a	O
8	mature	O
9	mRNA	O
10	.	O

1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	-	O
6	84	O
7	/-	O
8	55	O
9	DNA	O
10	showed	O
11	that	O
12	JEG	O
13	-	O
14	3	O
15	nuclear	O
16	proteins	O
17	bound	O
18	to	O
19	a	O
20	site	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	identical	O
26	to	O
27	,	O
28	the	O
29	SF	B
30	-	I
31	1	I
32	sequence	I
33	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	A	O
2	high	O
3	reactor	O
4	pH	O
5	(+/-	O
6	8	O
7	),	O
8	a	O
9	short	O
10	solid	O
11	retention	O
12	time	O
13	(<	O
14	150	O
15	days	O
16	),	O
17	and	O
18	the	O
19	presence	O
20	of	O
21	a	O
22	substantial	O
23	SRB	O
24	population	O
25	in	O
26	the	O
27	inoculum	O
28	may	O
29	considerably	O
30	reduce	O
31	the	O
32	time	O
33	required	O
34	for	O
35	acetate	O
36	-	O
37	utilising	O
38	SRB	O
39	to	O
40	outcompete	O
41	MB	O
42	.	O

1	In	O
2	throttling	O
3	valves	O
4	,	O
5	the	O
6	aim	O
7	is	O
8	to	O
9	correlate	O
10	the	O
11	effect	O
12	of	O
13	shear	O
14	to	O
15	a	O
16	parameter	O
17	related	O
18	to	O
19	the	O
20	inner	O
21	geometry	O
22	of	O
23	the	O
24	valve	O
25	and	O
26	to	O
27	operating	O
28	conditions	O
29	.	O

1	The	O
2	induced	O
3	respiratory	O
4	burst	O
5	was	O
6	investigated	O
7	by	O
8	the	O
9	intracellular	O
10	oxidative	O
11	transformation	O
12	of	O
13	dihydrorhodamine	O
14	123	O
15	to	O
16	the	O
17	fluorescent	O
18	dye	O
19	rhodamine	O
20	123	O
21	via	O
22	flow	O
23	cytometry	O
24	.	O

1	A	O
2	mutation	O
3	linked	O
4	to	O
5	the	O
6	SOC1	B
7	gene	I
8	,	O
9	previously	O
10	defined	O
11	by	O
12	recessive	O
13	mutations	O
14	that	O
15	suppress	O
16	cbp1	B
17	ts	I
18	alleles	I
19	and	O
20	stabilize	O
21	many	O
22	mitochondrial	O
23	mRNAs	O
24	,	O
25	was	O
26	also	O
27	isolated	O
28	.	O

1	A	O
2	deletion	O
3	mutation	O
4	analysis	O
5	of	O
6	the	O
7	recombinant	O
8	protein	O
9	has	O
10	shown	O
11	that	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	region	O
17	and	O
18	the	O
19	two	O
20	leucine	O
21	zippers	O
22	are	O
23	necessary	O
24	for	O
25	the	O
26	binding	O
27	.	O

1	A	O
2	database	O
3	search	O
4	has	O
5	revealed	O
6	as	O
7	the	O
8	most	O
9	significative	O
10	homology	O
11	a	O
12	match	O
13	with	O
14	the	O
15	human	B
16	mitochondrial	I
17	transcription	I
18	termination	I
19	factor	I
20	(	O
21	mTERF	B
22	),	O
23	a	O
24	protein	O
25	that	O
26	also	O
27	binds	O
28	DNA	O
29	as	O
30	a	O
31	monomer	O
32	and	O
33	contains	O
34	three	O
35	leucine	O
36	zippers	O
37	forming	O
38	intramolecular	O
39	interactions	O
40	.	O

1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O

1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O

1	We	O
2	found	O
3	that	O
4	total	O
5	PSA	B
6	can	O
7	be	O
8	detected	O
9	in	O
10	all	O
11	cyst	O
12	fluids	O
13	and	O
14	in	O
15	about	O
16	75	O
17	%	O
18	of	O
19	female	O
20	sera	O
21	.	O

1	Type	O
2	I	O
3	cysts	O
4	(	O
5	with	O
6	a	O
7	high	O
8	K	O
9	+/	O
10	Na	O
11	+	O
12	ratio	O
13	)	O
14	tend	O
15	to	O
16	have	O
17	higher	O
18	total	O
19	PSA	B
20	than	O
21	Type	O
22	II	O
23	cysts	O
24	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	A	O
2	single	O
3	N	O
4	-	O
5	glycosylation	O
6	site	O
7	present	O
8	in	O
9	chicken	B
10	gp42	I
11	is	O
12	conserved	O
13	among	O
14	all	O
15	five	O
16	of	O
17	these	O
18	proteins	O
19	:	O
20	carbohydrate	O
21	analysis	O
22	of	O
23	gp42	B
24	revealed	O
25	the	O
26	presence	O
27	of	O
28	a	O
29	complex	O
30	type	O
31	glycan	O
32	chain	O
33	at	O
34	this	O
35	site	O
36	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	optimization	O
6	and	O
7	characterization	O
8	of	O
9	a	O
10	140	O
11	-	O
12	residue	O
13	fragment	O
14	,	O
15	containing	O
16	the	O
17	Runt	B
18	domain	I
19	of	O
20	AML1	B
21	,	O
22	which	O
23	is	O
24	suitable	O
25	for	O
26	structural	O
27	studies	O
28	.	O

1	Judge	O
2	OKs	O
3	docs	O
4	'	O
5	bid	O
6	for	O
7	Chicago	O
8	hospital	O
9	.	O

1	HANYS	O
2	criticizes	O
3	laparoscopic	O
4	gall	O
5	bladder	O
6	guidelines	O
7	.	O

1	Groups	O
2	dicker	O
3	for	O
4	price	O
5	breaks	O
6	as	O
7	anesthetic	O
8	gas	O
9	goes	O
10	multi	O
11	-	O
12	source	O
13	.	O

1	Troubled	O
2	CareNetwork	O
3	gets	O
4	pact	O
5	from	O
6	largest	O
7	teacher	O
8	union	O
9	in	O
10	Wis	O
11	.	O

1	JCAHO	O
2	asks	O
3	for	O
4	hospitals	O
5	'	O
6	patience	O
7	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Because	O
2	of	O
3	concerns	O
4	regarding	O
5	blood	O
6	transfusion	O
7	-	O
8	related	O
9	communicable	O
10	disease	O
11	(	O
12	eg	O
13	,	O
14	acquired	O
15	immune	O
16	deficiency	O
17	syndrome	O
18	and	O
19	non	O
20	-	O
21	A	O
22	,	O
23	non	O
24	-	O
25	B	O
26	hepatitis	O
27	),	O
28	there	O
29	has	O
30	been	O
31	increasing	O
32	research	O
33	effort	O
34	into	O
35	postoperative	O
36	hemorrhage	O
37	related	O
38	to	O
39	cardiopulmonary	O
40	bypass	O
41	with	O
42	extracorporeal	O
43	circulation	O
44	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	Holger	O
2	v	O
3	.	O

1	Hospital	O
2	hit	O
3	for	O
4	hiring	O
5	AHERF	O
6	physicians	O
7	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	B
5	-	I
6	1	I
7	or	O
8	sentrin	B
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	B
13	-	O
14	sensitive	O
15	L929	O
16	fibroblast	O
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	B
24	-	O
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	to	O
6	PPARgamma2	B
7	,	O
8	which	O
9	was	O
10	previously	O
11	shown	O
12	to	O
13	be	O
14	phosphorylated	O
15	at	O
16	a	O
17	single	O
18	site	O
19	in	O
20	a	O
21	motif	O
22	that	O
23	is	O
24	not	O
25	homologous	O
26	to	O
27	the	O
28	sites	O
29	now	O
30	described	O
31	in	O
32	PPARalpha	B
33	.	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	B
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	I
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O

1	Spatiotemporal	O
2	expression	O
3	of	O
4	the	O
5	PAX3	B
6	gene	I
7	is	O
8	tightly	O
9	regulated	O
10	during	O
11	development	O
12	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	A	O
2	list	O
3	of	O
4	12	O
5	names	O
6	for	O
7	the	O
8	disease	O
9	and	O
10	37	O
11	diagnostic	O
12	criteria	O
13	were	O
14	proposed	O
15	to	O
16	a	O
17	Consensus	O
18	Panel	O
19	of	O
20	12	O
21	Italian	O
22	experts	O
23	who	O
24	ranked	O
25	them	O
26	in	O
27	order	O
28	so	O
29	as	O
30	to	O
31	identify	O
32	a	O
33	core	O
34	set	O
35	of	O
36	criteria	O
37	.	O

1	Methanesulfonyl	O
2	fluoride	O
3	(	O
4	MSF	O
5	):	O
6	a	O
7	double	O
8	-	O
9	blind	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	of	O
16	safety	O
17	and	O
18	efficacy	O
19	in	O
20	the	O
21	treatment	O
22	of	O
23	senile	O
24	dementia	O
25	of	O
26	the	O
27	Alzheimer	O
28	type	O
29	.	O

1	METHODS	O
2	:	O
3	Between	O
4	August	O
5	1991	O
6	and	O
7	June	O
8	1994	O
9	,	O
10	198	O
11	men	O
12	with	O
13	clinical	O
14	T2	O
15	or	O
16	T3	O
17	classified	O
18	(	O
19	TNM	O
20	)	O
21	prostate	O
22	carcinoma	O
23	(	O
24	bone	O
25	scan	O
26	negative	O
27	)	O
28	who	O
29	were	O
30	at	O
31	high	O
32	risk	O
33	of	O
34	lymph	O
35	node	O
36	involvement	O
37	underwent	O
38	a	O
39	111In	O
40	-	O
41	capromab	O
42	pendetide	O
43	scan	O
44	prior	O
45	to	O
46	staging	O
47	lymphadenectomy	O
48	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	Immediately	O
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	Because	O
2	of	O
3	the	O
4	probable	O
5	causal	O
6	relationship	O
7	between	O
8	constitutive	O
9	p210	B
10	(	O
11	bcr	B
12	/	O
13	abl	B
14	)	O
15	protein	B
16	tyrosine	I
17	kinase	I
18	activity	O
19	and	O
20	manifestations	O
21	of	O
22	chronic	O
23	-	O
24	phase	O
25	chronic	O
26	myelogenous	O
27	leukemia	O
28	(	O
29	CML	O
30	;	O
31	myeloid	O
32	expansion	O
33	),	O
34	a	O
35	key	O
36	goal	O
37	is	O
38	to	O
39	identify	O
40	relevant	O
41	p210	B
42	substrates	O
43	in	O
44	primary	O
45	chronic	O
46	-	O
47	phase	O
48	CML	O
49	hematopoietic	O
50	progenitor	O
51	cells	O
52	.	O

1	In	O
2	vitro	O
3	precipitation	O
4	with	O
5	a	O
6	glutathione	B
7	-	I
8	S	I
9	-	I
10	transferase	I
11	-	I
12	fusion	I
13	protein	I
14	containing	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	transactivation	O
20	domain	O
21	of	O
22	STAT5a	B
23	showed	O
24	GH	B
25	-	O
26	regulated	O
27	association	O
28	of	O
29	ERK1	B
30	/	I
31	2	I
32	with	O
33	the	O
34	fusion	O
35	protein	O
36	,	O
37	while	O
38	this	O
39	was	O
40	not	O
41	seen	O
42	when	O
43	serine	O
44	780	O
45	in	O
46	STAT5a	B
47	was	O
48	changed	O
49	to	O
50	alanine	O
51	.	O

1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	O
14	pituitary	O
15	cDNA	O
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	B
21	-	I
22	amino	I
23	acid	I
24	WD	I
25	protein	I
26	,	O
27	designated	O
28	PREB	B
29	(	I
30	PRL	I
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O

1	Characterization	O
2	of	O
3	the	O
4	transcription	B
5	factor	I
6	MTF	I
7	-	I
8	1	I
9	from	O
10	the	O
11	Japanese	O
12	pufferfish	O
13	(	O
14	Fugu	O
15	rubripes	O
16	)	O
17	reveals	O
18	evolutionary	O
19	conservation	O
20	of	O
21	heavy	O
22	metal	O
23	stress	O
24	response	O
25	.	O

1	The	O
2	peroxisome	B
3	proliferator	I
4	-	I
5	activated	I
6	receptors	I
7	(	O
8	PPARs	B
9	)	O
10	are	O
11	members	O
12	of	O
13	the	O
14	nuclear	B
15	hormone	I
16	receptor	I
17	superfamily	I
18	.	O

1	However	O
2	,	O
3	F	B
4	-	I
5	SRC	I
6	-	I
7	1	I
8	mutant	I
9	lacking	O
10	CBP	B
11	-	I
12	interacting	I
13	domain	I
14	still	O
15	preserved	O
16	enhancing	O
17	activity	O
18	.	O

1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	O
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O

1	The	O
2	complete	O
3	circular	O
4	TTV	O
5	genome	O
6	contained	O
7	a	O
8	novel	O
9	sequence	O
10	of	O
11	113	O
12	nt	O
13	(	O
14	nt	O
15	3740	O
16	to	O
17	3852	O
18	[=	O
19	0	O
20	])	O
21	in	O
22	between	O
23	the	O
24	known	O
25	3	O
26	'-	O
27	and	O
28	5	O
29	'-	O
30	end	O
31	arms	O
32	,	O
33	forming	O
34	a	O
35	117	O
36	-	O
37	nt	O
38	GC	O
39	-	O
40	rich	O
41	stretch	O
42	(	O
43	GC	O
44	content	O
45	,	O
46	90	O
47	.	O
48	6	O
49	%	O
50	at	O
51	nt	O
52	3736	O
53	to	O
54	3852	O
55	).	O

1	The	O
2	Asian	O
3	mouse	O
4	Mus	O
5	castaneus	O
6	is	O
7	resistant	O
8	to	O
9	infection	O
10	by	O
11	the	O
12	polytropic	O
13	mink	O
14	cell	O
15	focus	O
16	-	O
17	inducing	O
18	(	O
19	MCF	O
20	)	O
21	subgroup	O
22	of	O
23	murine	O
24	leukemia	O
25	viruses	O
26	(	O
27	MuLVs	O
28	).	O

1	To	O
2	determine	O
3	the	O
4	function	O
5	of	O
6	VZV	B
7	gK	I
8	in	O
9	virus	O
10	growth	O
11	,	O
12	a	O
13	series	O
14	of	O
15	gK	B
16	deletion	I
17	mutants	I
18	were	O
19	constructed	O
20	with	O
21	VZV	O
22	cosmid	O
23	DNA	O
24	derived	O
25	from	O
26	the	O
27	Oka	O
28	strain	O
29	.	O

1	CCAAT	B
2	displacement	I
3	protein	I
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	B
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	O
20	.	O

1	As	O
2	such	O
3	the	O
4	findings	O
5	support	O
6	existing	O
7	studies	O
8	that	O
9	have	O
10	identified	O
11	given	O
12	social	O
13	characteristics	O
14	of	O
15	drink	O
16	drivers	O
17	.	O

1	Three	O
2	different	O
3	site	O
4	-	O
5	directed	O
6	mutations	O
7	of	O
8	the	O
9	cyclic	O
10	AMP	O
11	response	O
12	element	O
13	each	O
14	reduced	O
15	the	O
16	nerve	B
17	growth	I
18	factor	I
19	effect	O
20	by	O
21	>	O
22	90	O
23	%.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	protection	O
6	assay	O
7	and	O
8	specific	O
9	blocking	O
10	oligonucleotides	O
11	,	O
12	we	O
13	find	O
14	that	O
15	recognition	O
16	of	O
17	the	O
18	5	O
19	'	O
20	splice	O
21	-	O
22	site	O
23	(	O
24	5	O
25	'	O
26	ss	O
27	)	O
28	and	O
29	branchpoint	O
30	sequence	O
31	(	O
32	BPS	O
33	)	O
34	elements	O
35	by	O
36	U11	B
37	and	O
38	U12	B
39	snRNPs	I
40	,	O
41	respectively	O
42	,	O
43	displays	O
44	strong	O
45	cooperativity	O
46	,	O
47	requiring	O
48	both	O
49	sites	O
50	in	O
51	the	O
52	pre	O
53	-	O
54	mRNA	O
55	substrate	O
56	for	O
57	efficient	O
58	complex	O
59	formation	O
60	.	O

1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	I
5	fusions	I
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O

1	Many	O
2	eukaryotic	O
3	cell	O
4	surface	O
5	proteins	O
6	are	O
7	anchored	O
8	in	O
9	the	O
10	lipid	O
11	bilayer	O
12	through	O
13	glycosylphosphatidylinositol	O
14	(	O
15	GPI	O
16	).	O

1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	An	O
2	endogenous	O
3	mammalian	O
4	regulator	O
5	of	O
6	this	O
7	process	O
8	,	O
9	named	O
10	Usurpin	B
11	,	O
12	has	O
13	been	O
14	identified	O
15	(	O
16	aliases	O
17	for	O
18	Usurpin	B
19	include	O
20	CASH	B
21	,	O
22	Casper	B
23	,	O
24	CLARP	B
25	,	O
26	FLAME	B
27	-	I
28	1	I
29	,	O
30	FLIP	B
31	,	O
32	I	B
33	-	I
34	FLICE	I
35	and	O
36	MRIT	B
37	).	O

1	Plasma	O
2	glucose	O
3	,	O
4	immunoreactive	B
5	insulin	I
6	(	O
7	IRI	B
8	),	O
9	C	B
10	-	I
11	peptide	I
12	,	O
13	glucagon	B
14	,	O
15	and	O
16	GLP	B
17	-	I
18	1	I
19	levels	O
20	at	O
21	each	O
22	time	O
23	point	O
24	during	O
25	OGTT	O
26	were	O
27	measured	O
28	.	O

1	Each	O
2	recombinant	O
3	product	O
4	was	O
5	a	O
6	fusion	O
7	protein	O
8	with	O
9	a	O
10	B	O
11	domain	O
12	of	O
13	Staphylococcal	B
14	protein	I
15	A	I
16	(	O
17	SPA	B
18	).	O

1	Polypyrimidine	O
2	and	O
3	ssDNA	O
4	binding	O
5	by	O
6	the	O
7	isolated	O
8	VH	B
9	domain	I
10	of	O
11	immunization	O
12	-	O
13	induced	O
14	anti	O
15	-	O
16	Z	O
17	-	O
18	DNA	O
19	Ab	O
20	resembles	O
21	the	O
22	activity	O
23	of	O
24	natural	O
25	autoantibodies	O
26	and	O
27	suggests	O
28	that	O
29	VH	B
30	-	O
31	dependent	O
32	binding	O
33	to	O
34	a	O
35	ligand	O
36	mimicked	O
37	by	O
38	polypyrimidines	O
39	may	O
40	play	O
41	a	O
42	role	O
43	in	O
44	B	O
45	cell	O
46	selection	O
47	before	O
48	immunization	O
49	with	O
50	Z	O
51	-	O
52	DNA	O
53	.	O

1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O

1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O

1	Nuclear	O
2	receptors	O
3	(	O
4	NRs	O
5	)	O
6	can	O
7	function	O
8	as	O
9	ligandinducible	O
10	transregulators	O
11	in	O
12	both	O
13	mammalian	O
14	and	O
15	yeast	O
16	cells	O
17	,	O
18	indicating	O
19	that	O
20	important	O
21	features	O
22	of	O
23	transcriptional	O
24	control	O
25	have	O
26	been	O
27	conserved	O
28	throughout	O
29	evolution	O
30	.	O

1	When	O
2	tethered	O
3	to	O
4	a	O
5	heterologous	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	,	O
11	PSU1	B
12	can	O
13	activate	O
14	transcription	O
15	on	O
16	its	O
17	own	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	follow	O
5	-	O
6	up	O
7	prospectively	O
8	patients	O
9	with	O
10	arthritis	O
11	after	O
12	infection	O
13	with	O
14	beta	O
15	-	O
16	haemolytic	O
17	streptococci	O
18	of	O
19	Lancefield	O
20	group	O
21	A	O
22	(	O
23	beta	O
24	HSA	O
25	),	O
26	with	O
27	emphasis	O
28	on	O
29	clinical	O
30	characteristics	O
31	and	O
32	serological	O
33	features	O
34	.	O

1	Bacteria	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	protein	O
9	was	O
10	maximum	O
11	in	O
12	mitosis	O
13	and	O
14	minimum	O
15	in	O
16	G1	O
17	,	O
18	which	O
19	correlated	O
20	with	O
21	the	O
22	expression	O
23	of	O
24	its	O
25	messenger	O
26	RNA	O
27	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	signature	O
6	-	O
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	Pathol	O
2	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	The	O
2	GAC1	B
3	gene	I
4	encodes	O
5	the	O
6	regulatory	O
7	subunit	O
8	for	O
9	a	O
10	type	B
11	1	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	phosphatase	I
17	,	O
18	Glc7	B
19	.	O

1	The	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	Glc7	B
7	phosphatase	I
8	and	O
9	its	O
10	Gac1	B
11	regulatory	O
12	subunit	O
13	play	O
14	positive	O
15	roles	O
16	in	O
17	HSF	B
18	activation	O
19	of	O
20	CUP1	B
21	transcription	O
22	.	O

1	MEF	B
2	and	O
3	AML1B	B
4	synergistically	O
5	transactivated	O
6	an	O
7	interleukin	B
8	3	I
9	promoter	I
10	reporter	I
11	gene	I
12	construct	I
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	B
20	was	O
21	abolished	O
22	when	O
23	MEF	B
24	was	O
25	coexpressed	O
26	with	O
27	AML1	B
28	/	O
29	ETO	B
30	.	O

1	Mechanistically	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	GRR	O
8	appears	O
9	to	O
10	stop	O
11	further	O
12	degradation	O
13	of	O
14	p50	B
15	and	O
16	to	O
17	stabilize	O
18	the	O
19	molecule	O
20	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	O
9	-	O
10	ended	O
11	double	O
12	-	O
13	stranded	O
14	DNA	O
15	-	O
16	activated	O
17	protein	O
18	kinase	O
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O

1	Moreover	O
2	,	O
3	when	O
4	added	O
5	to	O
6	the	O
7	osteoclast	O
8	cultures	O
9	,	O
10	mrIhh	B
11	-	I
12	N	I
13	markedly	O
14	stimulated	O
15	the	O
16	formation	O
17	of	O
18	resorption	O
19	pits	O
20	on	O
21	dentine	O
22	slices	O
23	.	O

1	Overall	O
2	,	O
3	our	O
4	results	O
5	suggest	O
6	that	O
7	resistant	O
8	genotypes	O
9	exist	O
10	among	O
11	the	O
12	WAD	O
13	goat	O
14	population	O
15	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	by	O
5	which	O
6	Gle2p	B
7	and	O
8	the	O
9	Gle2p	B
10	-	O
11	Nup116p	B
12	interaction	O
13	function	O
14	in	O
15	mRNA	O
16	export	O
17	is	O
18	unknown	O
19	.	O

1	The	O
2	Fyn	B
3	NH2	I
4	terminus	I
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	I
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	I
35	phosphotyrosines	O
36	.	O

1	In	O
2	budding	O
3	yeast	O
4	,	O
5	the	O
6	protein	O
7	Skp1p	B
8	,	O
9	the	O
10	cullin	B
11	-	I
12	family	I
13	member	I
14	Cdc53p	I
15	,	O
16	and	O
17	the	O
18	F	O
19	-	O
20	box	O
21	/	O
22	WD	O
23	-	O
24	repeat	O
25	protein	O
26	Cdc4p	B
27	form	O
28	the	O
29	SCFCdc4p	B
30	ubiquitin	I
31	ligase	I
32	complex	O
33	,	O
34	which	O
35	targets	O
36	the	O
37	cyclin	B
38	-	I
39	dependent	I
40	kinase	I
41	(	O
42	Cdk	B
43	)	O
44	inhibitor	O
45	Sic1p	B
46	for	O
47	proteolysis	O
48	[	O
49	3	O
50	]	O
51	[	O
52	4	O
53	]	O
54	[	O
55	5	O
56	]	O
57	[	O
58	6	O
59	]	O
60	[	O
61	7	O
62	]	O
63	[	O
64	8	O
65	].	O

1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O

1	Antithrombin	B
2	III	I
3	prevents	O
4	60	O
5	min	O
6	warm	O
7	intestinal	O
8	ischemia	O
9	reperfusion	O
10	injury	O
11	in	O
12	rats	O
13	.	O

1	In	O
2	retrospect	O
3	,	O
4	the	O
5	diagnoses	O
6	were	O
7	reconsidered	O
8	applying	O
9	strict	O
10	criteria	O
11	.	O

1	These	O
2	observations	O
3	of	O
4	elevated	O
5	serum	B
6	lipase	I
7	and	O
8	serum	O
9	CA	B
10	19	I
11	-	I
12	9	I
13	in	O
14	Sjogren	O
15	'	O
16	s	O
17	syndrome	O
18	without	O
19	evidence	O
20	of	O
21	malignancy	O
22	may	O
23	reflect	O
24	pancreatic	O
25	involvement	O
26	in	O
27	this	O
28	disorder	O
29	.	O

1	Acute	O
2	pancreatitis	O
3	as	O
4	a	O
5	complication	O
6	of	O
7	polyarteritis	O
8	nodosa	O
9	.	O

1	Significantly	O
2	greater	O
3	improvement	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	05	O
10	)	O
11	in	O
12	the	O
13	sertraline	O
14	group	O
15	first	O
16	became	O
17	apparent	O
18	by	O
19	the	O
20	end	O
21	of	O
22	week	O
23	3	O
24	on	O
25	the	O
26	Y	O
27	-	O
28	BOCS	O
29	and	O
30	the	O
31	CGI	O
32	Improvement	O
33	scale	O
34	,	O
35	and	O
36	by	O
37	the	O
38	end	O
39	of	O
40	weeks	O
41	6	O
42	and	O
43	8	O
44	,	O
45	respectively	O
46	,	O
47	on	O
48	the	O
49	NIMH	O
50	and	O
51	CGI	O
52	Severity	O
53	scale	O
54	.	O

1	Stress	B
2	-	I
3	inducible	I
4	protein	I
5	kinases	I
6	capable	O
7	of	O
8	activating	O
9	c	B
10	-	I
11	jun	I
12	expression	O
13	include	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	/	O
20	c	B
21	-	I
22	Jun	I
23	N	I
24	-	I
25	terminal	I
26	protein	I
27	kinase	I
28	(	O
29	SAPK	B
30	/	O
31	JNK	B
32	)	O
33	and	O
34	p38	B
35	members	O
36	of	O
37	the	O
38	mitogen	B
39	-	I
40	activated	I
41	protein	I
42	kinase	I
43	(	O
44	MAPK	B
45	)	O
46	superfamily	O
47	of	O
48	signaling	O
49	molecules	O
50	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O

1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O

1	Group	O
2	psychometric	O
3	functions	O
4	for	O
5	listeners	O
6	with	O
7	hearing	O
8	loss	O
9	do	O
10	not	O
11	show	O
12	a	O
13	decrease	O
14	in	O
15	performance	O
16	at	O
17	the	O
18	largest	O
19	values	O
20	of	O
21	delta	O
22	f	O
23	included	O
24	in	O
25	this	O
26	study	O
27	.	O

1	Uroflowmetry	O
2	can	O
3	detect	O
4	dysuria	O
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	Marked	O
2	racial	O
3	variation	O
4	in	O
5	birthweight	O
6	percentiles	O
7	by	O
8	gestational	O
9	age	O
10	was	O
11	evident	O
12	.	O

1	Significant	O
2	correlations	O
3	between	O
4	mental	O
5	status	O
6	as	O
7	measured	O
8	by	O
9	the	O
10	Mini	O
11	-	O
12	Mental	O
13	State	O
14	Examination	O
15	and	O
16	NA	O
17	/	O
18	mI	O
19	,	O
20	mI	O
21	/	O
22	Cr	O
23	and	O
24	NA	O
25	were	O
26	found	O
27	.	O

1	Glucagon	B
2	also	O
3	induced	O
4	LUC	B
5	activity	O
6	very	O
7	strongly	O
8	when	O
9	the	O
10	CRE1	O
11	and	O
12	CRE2	O
13	sites	O
14	were	O
15	combined	O
16	;	O
17	induction	O
18	of	O
19	the	O
20	(	O
21	CRE1	O
22	)	O
23	3	O
24	(	O
25	CRE2	O
26	)	O
27	2SV40	O
28	-	O
29	LUC	B
30	constructs	O
31	was	O
32	positively	O
33	modulated	O
34	by	O
35	the	O
36	pO2	O
37	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	B
15	GSTA3	I
16	(	O
17	rGST	B
18	Yc1	I
19	)	O
20	subunit	O
21	gene	O
22	.	O

1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O

1	Initial	O
2	control	O
3	of	O
4	bleeding	O
5	is	O
6	similar	O
7	,	O
8	but	O
9	eradication	O
10	is	O
11	achieved	O
12	in	O
13	fewer	O
14	sessions	O
15	with	O
16	EVL	O
17	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	B
11	TrxR2	I
12	gene	I
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	The	O
2	aims	O
3	of	O
4	this	O
5	study	O
6	were	O
7	to	O
8	determine	O
9	and	O
10	rank	O
11	the	O
12	frequency	O
13	of	O
14	self	O
15	reported	O
16	visual	O
17	disability	O
18	in	O
19	daily	O
20	tasks	O
21	performed	O
22	by	O
23	glaucoma	O
24	patients	O
25	;	O
26	to	O
27	examine	O
28	the	O
29	interrelation	O
30	between	O
31	disabilities	O
32	using	O
33	factor	O
34	analysis	O
35	;	O
36	to	O
37	study	O
38	the	O
39	relation	O
40	between	O
41	perceived	O
42	visual	O
43	difficulty	O
44	and	O
45	a	O
46	measure	O
47	of	O
48	the	O
49	severity	O
50	of	O
51	visual	O
52	field	O
53	loss	O
54	;	O
55	to	O
56	develop	O
57	a	O
58	glaucoma	O
59	specific	O
60	subgroup	O
61	of	O
62	questions	O
63	;	O
64	and	O
65	examine	O
66	the	O
67	validity	O
68	and	O
69	reliability	O
70	of	O
71	this	O
72	subgroup	O
73	of	O
74	questions	O
75	.	O

1	Furthermore	O
2	,	O
3	the	O
4	validity	O
5	of	O
6	this	O
7	new	O
8	subset	O
9	of	O
10	questions	O
11	was	O
12	shown	O
13	to	O
14	be	O
15	significant	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	037	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	for	O
30	the	O
31	correlation	O
32	between	O
33	a	O
34	measure	O
35	of	O
36	the	O
37	severity	O
38	of	O
39	binocular	O
40	visual	O
41	field	O
42	loss	O
43	and	O
44	the	O
45	mean	O
46	score	O
47	of	O
48	the	O
49	variables	O
50	used	O
51	in	O
52	the	O
53	glaucoma	O
54	specific	O
55	subgroup	O
56	of	O
57	questions	O
58	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	B
5	bd	I
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	B
28	.	I
29	coli	I
30	bd	I
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	Canalith	O
2	repositioning	O
3	is	O
4	the	O
5	mainstay	O
6	of	O
7	treatment	O
8	.	O

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	B
8	pyrophosphohydrolase	I
9	.	O

1	In	O
2	11	O
3	eyes	O
4	that	O
5	had	O
6	been	O
7	selected	O
8	at	O
9	random	O
10	10	O
11	micrograms	O
12	of	O
13	recombinant	B
14	tissue	I
15	plasminogen	I
16	activator	I
17	were	O
18	injected	O
19	midvitreally	O
20	24	O
21	hrs	O
22	later	O
23	.	O

1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	Brandt	O
6	'	O
7	s	O
8	double	O
9	cuff	O
10	-	O
11	tubes	O
12	(	O
13	G2	O
14	)	O
15	succeed	O
16	in	O
17	avoiding	O
18	uncontrolled	O
19	increase	O
20	of	O
21	cuff	O
22	-	O
23	pressure	O
24	during	O
25	anaesthesia	O
26	with	O
27	N2O	O
28	.	O

1	Accordingly	O
2	,	O
3	we	O
4	designated	O
5	this	O
6	gene	B
7	CTL1	I
8	(	O
9	capping	B
10	enzyme	I
11	RNAtriphosphatase	I
12	-	I
13	like	I
14	1	I
15	).	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O

1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O

1	Constrictive	O
2	pericarditis	O
3	and	O
4	pleuropulmonary	O
5	disease	O
6	linked	O
7	to	O
8	ergot	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	cabergoline	O
14	)	O
15	for	O
16	Parkinson	O
17	'	O
18	s	O
19	disease	O
20	.	O

1	An	O
2	undilated	O
3	type	O
4	of	O
5	APBD	O
6	is	O
7	frequently	O
8	associated	O
9	with	O
10	AMT	O
11	and	O
12	we	O
13	believe	O
14	,	O
15	therefore	O
16	,	O
17	that	O
18	clinicians	O
19	should	O
20	be	O
21	aware	O
22	of	O
23	a	O
24	possible	O
25	coexistence	O
26	of	O
27	APBD	O
28	and	O
29	AMT	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	constructed	O
7	and	O
8	expressed	O
9	chimeric	O
10	fusion	O
11	protein	O
12	that	O
13	contains	O
14	HIV	B
15	-	I
16	2	I
17	gag	I
18	with	O
19	V3	B
20	domains	O
21	of	O
22	HIV	O
23	-	O
24	1IIIB	O
25	,	O
26	HIV	O
27	-	O
28	1MN	O
29	,	O
30	HIV	O
31	-	O
32	1SF2	O
33	and	O
34	HIV	O
35	-	O
36	1RF	O
37	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	V3	B
6	peptides	O
7	from	O
8	all	O
9	major	O
10	clades	O
11	of	O
12	HIV	O
13	-	O
14	1	O
15	carried	O
16	by	O
17	HIV	B
18	-	I
19	2	I
20	gag	I
21	can	O
22	be	O
23	used	O
24	as	O
25	a	O
26	potential	O
27	HIV	O
28	/	O
29	AIDS	O
30	vaccine	O
31	.	O

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	O
35	Function	O
36	(	O
37	IIEF	O
38	).	O

1	Evidence	O
2	for	O
3	the	O
4	involvement	O
5	of	O
6	the	O
7	Glc7	B
8	-	O
9	Reg1	B
10	phosphatase	O
11	and	O
12	the	O
13	Snf1	B
14	-	O
15	Snf4	B
16	kinase	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	INO1	B
22	transcription	O
23	in	O
24	Saccharomyces	O
25	cerevisiae	O
26	.	O

1	In	O
2	XO	O
3	males	O
4	,	O
5	two	O
6	her	B
7	-	I
8	1	I
9	mRNAs	I
10	,	O
11	her	B
12	-	I
13	1a	I
14	and	O
15	her	B
16	-	I
17	1b	I
18	,	O
19	are	O
20	transcribed	O
21	from	O
22	two	O
23	separate	O
24	promoters	O
25	:	O
26	P1	O
27	,	O
28	located	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	flanking	O
34	region	O
35	,	O
36	and	O
37	P2	O
38	,	O
39	located	O
40	in	O
41	the	O
42	large	O
43	second	O
44	intron	O
45	.	O

1	Induction	O
2	of	O
3	Fas	B
4	ligand	I
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	B
13	with	O
14	the	O
15	T	B
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	O

1	Receptor	B
2	protein	I
3	tyrosine	I
4	phosphatases	I
5	(	O
6	RPTPs	B
7	)	O
8	comprise	O
9	a	O
10	family	O
11	of	O
12	proteins	O
13	that	O
14	feature	O
15	intracellular	O
16	phosphatase	O
17	domains	O
18	and	O
19	an	O
20	ectodomain	O
21	with	O
22	putative	O
23	ligand	O
24	-	O
25	binding	O
26	motifs	O
27	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	Commonly	O
2	used	O
3	stressors	O
4	are	O
5	mental	O
6	arithmetics	O
7	,	O
8	speech	O
9	tasks	O
10	,	O
11	the	O
12	Stroop	O
13	test	O
14	,	O
15	videogame	O
16	playing	O
17	,	O
18	films	O
19	or	O
20	videotapes	O
21	and	O
22	interviews	O
23	.	O

1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	pregnancies	O
14	.	O

1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	MDV2	B
10	UL54	I
11	and	O
12	UL55	B
13	genes	I
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	B
19	ORF	I
20	(	I
21	ORF	I
22	-	I
23	1	I
24	)	I
25	of	I
26	equine	I
27	herpesvirus	I
28	type	I
29	1	I
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	pseudorabies	O
36	virus	O
37	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	loss	O
6	of	O
7	MAD2	B
8	staining	O
9	in	O
10	meiosis	O
11	was	O
12	not	O
13	correlated	O
14	with	O
15	initial	O
16	microtubule	O
17	attachment	O
18	but	O
19	was	O
20	correlated	O
21	with	O
22	a	O
23	measure	O
24	of	O
25	tension	O
26	:	O
27	the	O
28	distance	O
29	between	O
30	homologous	O
31	or	O
32	sister	O
33	kinetochores	O
34	(	O
35	in	O
36	meiosis	O
37	I	O
38	and	O
39	II	O
40	,	O
41	respectively	O
42	).	O

1	In	O
2	epithelial	O
3	cells	O
4	,	O
5	the	O
6	PH	B
7	domain	I
8	of	O
9	Akt	B
10	/	O
11	PKB	B
12	localised	O
13	to	O
14	sites	O
15	of	O
16	cell	O
17	-	O
18	cell	O
19	and	O
20	cell	O
21	-	O
22	matrix	O
23	contact	O
24	,	O
25	distinct	O
26	from	O
27	focal	O
28	contacts	O
29	,	O
30	even	O
31	in	O
32	the	O
33	absence	O
34	of	O
35	serum	O
36	.	O

1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O

1	The	O
2	motility	O
3	of	O
4	sperm	O
5	,	O
6	except	O
7	for	O
8	those	O
9	adjacent	O
10	to	O
11	both	O
12	electrodes	O
13	,	O
14	did	O
15	not	O
16	change	O
17	after	O
18	stimulation	O
19	for	O
20	60s	O
21	,	O
22	despite	O
23	a	O
24	high	O
25	electrical	O
26	energy	O
27	.	O

1	Induction	O
2	of	O
3	the	O
4	CINC	B
5	promoter	I
6	by	O
7	IL	B
8	-	I
9	17	I
10	in	O
11	IEC	O
12	-	O
13	6	O
14	cells	O
15	was	O
16	TNF	B
17	receptor	I
18	-	I
19	associated	I
20	factor	I
21	-	I
22	6	I
23	(	O
24	TRAF6	B
25	),	O
26	but	O
27	not	O
28	TRAF2	B
29	,	O
30	dependent	O
31	.	O

1	SCFFWD1	B
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	A	O
2	Bub2p	B
3	-	O
4	dependent	O
5	spindle	O
6	checkpoint	O
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	B
11	kinase	I
12	in	I
13	budding	I
14	yeast	I
15	.	O

1	We	O
2	analyzed	O
3	the	O
4	modular	O
5	organization	O
6	of	O
7	DNA	B
8	polymerase	I
9	beta	I
10	and	O
11	found	O
12	that	O
13	residues	O
14	making	O
15	contact	O
16	with	O
17	DNA	O
18	phosphates	O
19	were	O
20	localized	O
21	to	O
22	five	O
23	modules	O
24	.	O

1	RESULTS	O
2	:	O
3	Cholinergic	O
4	nerves	O
5	are	O
6	mainly	O
7	involved	O
8	in	O
9	the	O
10	regulation	O
11	of	O
12	enteric	O
13	nerve	O
14	responses	O
15	to	O
16	EFS	O
17	in	O
18	the	O
19	normal	O
20	IAS	O
21	.	O

1	Two	O
2	-	O
3	dimensional	O
4	gel	O
5	electrophoresis	O
6	of	O
7	anti	B
8	-	I
9	p59fyn	I
10	immunoprecipitates	O
11	obtained	O
12	from	O
13	non	O
14	-	O
15	transformed	O
16	resting	O
17	human	O
18	T	O
19	lymphocytes	O
20	resulted	O
21	in	O
22	the	O
23	identification	O
24	of	O
25	an	O
26	oligomeric	O
27	protein	O
28	complex	O
29	which	O
30	is	O
31	constitutively	O
32	formed	O
33	between	O
34	Fyn	B
35	and	O
36	several	O
37	additional	O
38	phosphoproteins	O
39	(	O
40	pp43	B
41	,	O
42	pp72	B
43	,	O
44	pp85	B
45	,	O
46	the	O
47	protein	B
48	tyrosine	I
49	kinase	I
50	Pyk2	I
51	,	O
52	as	O
53	well	O
54	as	O
55	the	O
56	two	O
57	recently	O
58	cloned	O
59	adaptor	O
60	proteins	O
61	,	O
62	SKAP55	B
63	and	O
64	SLAP	B
65	-	I
66	130	I
67	).	O

1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	B
6	mutants	I
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O

1	A	O
2	cdc33	B
3	-	I
4	1	I
5	strain	O
6	expressing	O
7	either	O
8	stable	O
9	Cln3p	B
10	(	O
11	Cln3	B
12	-	I
13	1p	I
14	)	O
15	or	O
16	a	O
17	hybrid	O
18	UBI4	B
19	5	I
20	'-	I
21	CLN3	I
22	mRNA	O
23	,	O
24	whose	O
25	translation	O
26	displays	O
27	decreased	O
28	dependence	O
29	on	O
30	eIF4E	B
31	,	O
32	arrested	O
33	randomly	O
34	in	O
35	the	O
36	cell	O
37	cycle	O
38	.	O

1	Regulatory	O
2	motifs	O
3	for	O
4	gene	O
5	expression	O
6	such	O
7	as	O
8	nuclear	B
9	-	I
10	factor	I
11	-	I
12	kappaB	I
13	-	I
14	binding	I
15	-	I
16	site	I
17	-	I
18	like	I
19	sequence	I
20	(	O
21	kappaB	B
22	site	I
23	)	O
24	and	O
25	nuclear	B
26	-	I
27	factor	I
28	-	I
29	interleukin	I
30	-	I
31	6	I
32	-	I
33	binding	I
34	-	I
35	site	I
36	-	I
37	like	I
38	sequence	I
39	(	O
40	NF	B
41	-	I
42	IL	I
43	-	I
44	6	I
45	site	I
46	)	O
47	were	O
48	found	O
49	in	O
50	the	O
51	5	O
52	'-	O
53	upstream	O
54	regulatory	O
55	region	O
56	.	O

1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	B
6	spans	O
7	15	O
8	.	O
9	2	O
10	kb	O
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O

1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	B
45	phosphatase	I
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O

1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	B
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	B
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	B
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O

1	Cranio	O
2	-	O
3	caudal	O
4	differences	O
5	in	O
6	granulation	O
7	tissue	O
8	formation	O
9	:	O
10	an	O
11	experimental	O
12	study	O
13	in	O
14	the	O
15	rat	O
16	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	B
10	sites	I
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O

1	Breast	O
2	-	O
3	fed	O
4	newborn	O
5	infants	O
6	synthesize	O
7	n	O
8	-	O
9	6	O
10	long	O
11	-	O
12	chain	O
13	polyunsaturated	O
14	fatty	O
15	acids	O
16	already	O
17	during	O
18	the	O
19	first	O
20	week	O
21	of	O
22	life	O
23	,	O
24	but	O
25	the	O
26	contribution	O
27	of	O
28	endogenous	O
29	synthesis	O
30	to	O
31	the	O
32	total	O
33	plasma	O
34	long	O
35	-	O
36	chain	O
37	polyunsaturated	O
38	pool	O
39	is	O
40	small	O
41	.	O

1	Ischemia	O
2	and	O
3	reperfusion	O
4	markedly	O
5	increased	O
6	the	O
7	release	O
8	of	O
9	6	O
10	-	O
11	keto	O
12	-	O
13	PGF1	O
14	alpha	O
15	and	O
16	TXB2	O
17	.	O

1	Prostate	B
2	-	I
3	specific	I
4	antigen	I
5	(	O
6	PSA	B
7	)	O
8	promoter	O
9	-	O
10	driven	O
11	androgen	O
12	-	O
13	inducible	O
14	expression	O
15	of	O
16	sodium	B
17	iodide	I
18	symporter	I
19	in	O
20	prostate	O
21	cancer	O
22	cell	O
23	lines	O
24	.	O

1	It	O
2	is	O
3	clear	O
4	that	O
5	subclinical	O
6	and	O
7	silent	O
8	CD	O
9	exist	O
10	in	O
11	a	O
12	large	O
13	subgroup	O
14	of	O
15	the	O
16	celiac	O
17	population	O
18	.	O

1	Ras2p	B
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	B
16	(	O
17	Cdc42p	B
18	/	O
19	Ste20p	B
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	B
33	/	O
34	cAMP	O
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	Consistent	O
2	with	O
3	this	O
4	prediction	O
5	,	O
6	transfections	O
7	into	O
8	the	O
9	hematopoietic	O
10	cell	O
11	line	O
12	Jurkat	O
13	showed	O
14	a	O
15	9	O
16	.	O
17	0	O
18	-	O
19	and	O
20	2	O
21	.	O
22	5	O
23	-	O
24	fold	O
25	activation	O
26	of	O
27	the	O
28	mim	B
29	-	I
30	1	I
31	promoter	I
32	by	O
33	the	O
34	p32	B
35	and	O
36	p30	B
37	isoforms	I
38	,	O
39	respectively	O
40	.	O

1	Previous	O
2	work	O
3	has	O
4	shown	O
5	that	O
6	spleen	B
7	necrosis	I
8	virus	I
9	(	I
10	SNV	I
11	)	I
12	long	I
13	terminal	I
14	repeats	I
15	(	O
16	LTRs	O
17	)	O
18	are	O
19	associated	O
20	with	O
21	Rex	B
22	/	O
23	Rex	B
24	-	O
25	responsive	O
26	element	O
27	-	O
28	independent	O
29	expression	O
30	of	O
31	bovine	O
32	leukemia	O
33	virus	O
34	RNA	O
35	and	O
36	supports	O
37	the	O
38	hypothesis	O
39	that	O
40	SNV	O
41	RNA	O
42	contains	O
43	a	O
44	cis	O
45	-	O
46	acting	O
47	element	O
48	that	O
49	interacts	O
50	with	O
51	cellular	B
52	Rex	I
53	-	I
54	like	I
55	proteins	I
56	.	O

1	Despite	O
2	the	O
3	reported	O
4	detrimental	O
5	effects	O
6	on	O
7	CNS	O
8	development	O
9	,	O
10	a	O
11	number	O
12	of	O
13	animal	O
14	studies	O
15	have	O
16	shown	O
17	that	O
18	pretreatment	O
19	with	O
20	corticosteroids	O
21	nevertheless	O
22	protect	O
23	the	O
24	brain	O
25	from	O
26	hypoxia	O
27	-	O
28	ischemic	O
29	injury	O
30	;	O
31	however	O
32	,	O
33	clinically	O
34	such	O
35	treatment	O
36	is	O
37	no	O
38	longer	O
39	favored	O
40	.	O

1	In	O
2	one	O
3	mechanism	O
4	,	O
5	a	O
6	specialized	O
7	ubiquitin	B
8	-	O
9	dependent	O
10	proteolytic	O
11	system	O
12	(	O
13	called	O
14	the	O
15	APC	O
16	-	O
17	dependent	O
18	proteolysis	O
19	machinery	O
20	)	O
21	degrades	O
22	the	O
23	mitotic	O
24	(	O
25	Clb	B
26	)	O
27	cyclin	B
28	subunit	I
29	.	O

1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O

1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	16	O
6	full	O
7	-	O
8	scale	O
9	fire	O
10	tests	O
11	,	O
12	investigators	O
13	at	O
14	the	O
15	IIT	O
16	Research	O
17	Institute	O
18	have	O
19	concluded	O
20	that	O
21	automatic	O
22	door	O
23	control	O
24	in	O
25	the	O
26	room	O
27	of	O
28	fire	O
29	origin	O
30	can	O
31	significantly	O
32	reduce	O
33	the	O
34	spread	O
35	of	O
36	toxic	O
37	smoke	O
38	and	O
39	gases	O
40	.	O

1	Online	O
2	LATCH	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	interactive	O
18	resource	O
19	center	O
20	.	O

1	Reporting	O
2	of	O
3	adverse	O
4	events	O
5	occurring	O
6	during	O
7	clinical	O
8	trials	O
9	of	O
10	investigational	O
11	drugs	O
12	is	O
13	a	O
14	complex	O
15	and	O
16	controversial	O
17	issue	O
18	.	O

1	Medicare	O
2	SNF	O
3	benefits	O
4	revised	O
5	--	O
6	again	O
7	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	the	O
6	current	O
7	status	O
8	of	O
9	the	O
10	understanding	O
11	of	O
12	the	O
13	interaction	O
14	mechanisms	O
15	of	O
16	ultrasound	O
17	with	O
18	biological	O
19	media	O
20	and	O
21	the	O
22	factors	O
23	that	O
24	govern	O
25	different	O
26	biological	O
27	effects	O
28	are	O
29	surveyed	O
30	.	O

1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	O
27	c	B
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	investigated	O
9	the	O
10	functional	O
11	role	O
12	of	O
13	the	O
14	other	O
15	MAP	B
16	kinases	I
17	in	O
18	PDGF	B
19	-	O
20	mediated	O
21	cellular	O
22	responses	O
23	.	O

1	Analyses	O
2	of	O
3	tyrosine	O
4	residue	O
5	-	O
6	mutated	O
7	PDGF	B
8	receptors	I
9	show	O
10	that	O
11	Src	B
12	homology	I
13	2	I
14	domain	I
15	-	I
16	containing	I
17	proteins	I
18	including	O
19	Src	B
20	family	I
21	kinases	I
22	,	O
23	phosphatidylinositol	B
24	3	I
25	-	I
26	kinase	I
27	,	O
28	the	O
29	GTPase	B
30	-	I
31	activating	I
32	protein	I
33	of	O
34	Ras	B
35	,	O
36	the	O
37	Src	B
38	homology	I
39	2	I
40	domain	I
41	-	I
42	containing	I
43	phosphatase	I
44	SHP	I
45	-	I
46	2	I
47	,	O
48	phospholipase	B
49	C	I
50	-	I
51	gamma	I
52	,	O
53	and	O
54	Crk	B
55	do	O
56	not	O
57	play	O
58	a	O
59	major	O
60	role	O
61	in	O
62	mediating	O
63	the	O
64	PDGF	B
65	-	O
66	induced	O
67	activation	O
68	of	O
69	p38	B
70	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	B
6	inhibits	O
7	tyrosine	B
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	O

1	Three	O
2	-	O
3	dimensional	O
4	structural	O
5	studies	O
6	using	O
7	electron	O
8	cryomicroscopy	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	one	O
15	Fab	B
16	(	O
17	8H2	O
18	/	O
19	G5	O
20	)	O
21	does	O
22	not	O
23	affect	O
24	the	O
25	conformation	O
26	of	O
27	the	O
28	capsid	O
29	,	O
30	and	O
31	the	O
32	efficiency	O
33	of	O
34	mRNA	O
35	production	O
36	is	O
37	similar	O
38	to	O
39	that	O
40	of	O
41	the	O
42	native	O
43	subviral	O
44	particle	O
45	.	O

1	Further	O
2	,	O
3	mutational	O
4	analysis	O
5	of	O
6	NS5A	B
7	assigned	O
8	the	O
9	SH3	B
10	-	I
11	binding	I
12	region	I
13	to	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	motif	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	among	O
24	HCV	O
25	genotypes	O
26	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	B
9	hPRL	I
10	inhibits	O
11	the	O
12	VEGF	B
13	-	O
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	Analysis	O
2	of	O
3	SRE	O
4	oligonucleotide	O
5	gel	O
6	mobility	O
7	shift	O
8	assays	O
9	with	O
10	nuclear	O
11	extracts	O
12	from	O
13	Sertoli	O
14	cells	O
15	demonstrated	O
16	the	O
17	presence	O
18	of	O
19	both	O
20	the	O
21	SRF	B
22	and	O
23	the	O
24	ubiquitously	O
25	expressed	O
26	bHLH	O
27	protein	O
28	E12	B
29	/	O
30	E47	B
31	.	O

1	We	O
2	calculated	O
3	differences	O
4	in	O
5	late	O
6	occlusion	O
7	rates	O
8	by	O
9	the	O
10	chi2	O
11	(	O
12	chi	O
13	-	O
14	square	O
15	)	O
16	test	O
17	,	O
18	and	O
19	found	O
20	these	O
21	differences	O
22	were	O
23	significant	O
24	(	O
25	P	O
26	=.	O
27	04	O
28	).	O

1	Baseline	O
2	electrocorticography	O
3	over	O
4	the	O
5	surface	O
6	of	O
7	the	O
8	temporal	O
9	lobe	O
10	and	O
11	depth	O
12	electrode	O
13	recordings	O
14	in	O
15	the	O
16	amygdala	O
17	and	O
18	hippocampus	O
19	were	O
20	obtained	O
21	,	O
22	followed	O
23	by	O
24	10	O
25	min	O
26	of	O
27	recording	O
28	before	O
29	and	O
30	after	O
31	the	O
32	i	O
33	.	O
34	v	O
35	.	O
36	administration	O
37	of	O
38	both	O
39	alfentanil	O
40	50	O
41	microg	O
42	/	O
43	kg	O
44	and	O
45	fentanyl	O
46	10	O
47	microg	O
48	/	O
49	kg	O
50	.	O

1	We	O
2	describe	O
3	a	O
4	genetic	O
5	system	O
6	for	O
7	further	O
8	characterizing	O
9	the	O
10	role	O
11	of	O
12	the	O
13	extreme	O
14	C	O
15	-	O
16	terminus	O
17	of	O
18	the	O
19	beta	O
20	subunit	O
21	of	O
22	E	B
23	.	I
24	coli	I
25	RNA	I
26	polymerase	I
27	.	O

1	We	O
2	suggest	O
3	that	O
4	FlgN	B
5	and	O
6	FliT	B
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	flagellar	O
12	chaperones	O
13	that	O
14	prevent	O
15	oligomerization	O
16	of	O
17	the	O
18	HAPs	B
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O

1	Post	O
2	and	O
3	core	O
4	fabrication	O
5	for	O
6	divergent	O
7	canals	O
8	with	O
9	a	O
10	cast	O
11	post	O
12	and	O
13	core	O
14	and	O
15	a	O
16	prefabricated	O
17	dowel	O
18	.	O

1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	O
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	O
40	replicon	O
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	O
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	and	O
7	characterization	O
8	of	O
9	Xenopus	B
10	Pax	I
11	-	I
12	5	I
13	and	O
14	Pax	B
15	-	I
16	8	I
17	,	O
18	two	O
19	orthologues	O
20	of	O
21	the	O
22	Pax	B
23	-	I
24	2	I
25	/	I
26	5	I
27	/	I
28	8	I
29	gene	I
30	family	I
31	.	O

1	Km	O
2	values	O
3	for	O
4	ammonium	O
5	,	O
6	2	O
7	-	O
8	oxoglutarate	O
9	,	O
10	NADH	O
11	,	O
12	glutamate	O
13	and	O
14	NAD	O
15	+	O
16	were	O
17	6	O
18	.	O
19	5	O
20	,	O
21	3	O
22	.	O
23	5	O
24	,	O
25	0	O
26	.	O
27	06	O
28	,	O
29	37	O
30	.	O
31	1	O
32	and	O
33	0	O
34	.	O
35	046	O
36	mM	O
37	,	O
38	respectively	O
39	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	I
12	telomerase	I
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	The	O
2	enhanced	O
3	binding	O
4	of	O
5	c	B
6	-	I
7	Abl	I
8	to	O
9	DNA	O
10	containing	O
11	5	O
12	-	O
13	methylcytosine	O
14	residues	O
15	may	O
16	result	O
17	from	O
18	an	O
19	increased	O
20	propensity	O
21	of	O
22	the	O
23	double	O
24	helix	O
25	to	O
26	denature	O
27	locally	O
28	coupled	O
29	with	O
30	a	O
31	protein	O
32	-	O
33	induced	O
34	reduction	O
35	in	O
36	the	O
37	base	O
38	stacking	O
39	interaction	O
40	.	O

1	Homozygous	O
2	mutation	O
3	in	O
4	two	O
5	children	O
6	led	O
7	to	O
8	amputation	O
9	of	O
10	legs	O
11	due	O
12	to	O
13	purpura	O
14	fulminans	O
15	.	O

1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	the	O
6	Stress	B
7	-	I
8	Activated	I
9	-	I
10	Protein	I
11	-	I
12	Kinase	I
13	(	O
14	SAPK	B
15	)	O
16	target	O
17	sites	O
18	of	O
19	ATF2	B
20	,	O
21	Thr69	O
22	and	O
23	Thr71	O
24	are	O
25	not	O
26	required	O
27	for	O
28	the	O
29	formation	O
30	of	O
31	the	O
32	p300	B
33	/	O
34	CBP	B
35	-	O
36	ATF2	B
37	multiprotein	O
38	complex	O
39	.	O

1	Blood	O
2	samples	O
3	were	O
4	obtained	O
5	daily	O
6	during	O
7	this	O
8	supplementation	O
9	period	O
10	and	O
11	5	O
12	d	O
13	thereafter	O
14	(	O
15	d	O
16	11	O
17	to	O
18	15	O
19	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	O
6	the	O
7	genome	O
8	can	O
9	be	O
10	folded	O
11	into	O
12	a	O
13	tRNA	O
14	-	O
15	like	O
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	O
26	-	O
27	like	O
28	structure	O
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	O
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	O	B
2	.	I
3	novo	I
4	-	I
5	ulmi	I
6	RNA	I
7	-	I
8	7	I
9	,	O
10	previously	O
11	believed	O
12	to	O
13	be	O
14	a	O
15	satellite	O
16	-	O
17	like	O
18	RNA	O
19	,	O
20	is	O
21	shown	O
22	to	O
23	be	O
24	a	O
25	defective	O
26	RNA	O
27	,	O
28	derived	O
29	from	O
30	OnuMV4	B
31	-	I
32	Ld	I
33	RNA	I
34	by	O
35	multiple	O
36	internal	O
37	deletions	O
38	.	O

1	Only	O
2	one	O
3	gene	O
4	,	O
5	fibronectin	B
6	(	O
7	FN	B
8	),	O
9	was	O
10	highly	O
11	overexpressed	O
12	(>	O
13	60	O
14	-	O
15	fold	O
16	)	O
17	in	O
18	LNCaP	O
19	-	O
20	r	O
21	cells	O
22	,	O
23	consistent	O
24	with	O
25	previously	O
26	reported	O
27	overexpression	O
28	of	O
29	FN	B
30	in	O
31	prostate	O
32	cancer	O
33	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	B
8	(-)	O
9	CD8	B
10	(-)	O
11	CD3	B
12	(-)	O
13	cells	O
14	with	O
15	rearranged	B
16	TCR	I
17	genes	I
18	developed	O
19	from	O
20	Id3	B
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	O
28	transduced	O
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O

1	As	O
2	determined	O
3	in	O
4	a	O
5	modified	O
6	yeast	O
7	two	O
8	-	O
9	hybrid	O
10	system	O
11	,	O
12	mIRS3	B
13	bound	O
14	strongly	O
15	to	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	-	I
23	kinase	I
24	.	O

1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O

1	The	O
2	mRNA	O
3	expression	O
4	of	O
5	RFX1	B
6	,	O
7	RFX2	B
8	,	O
9	and	O
10	RFX3	B
11	was	O
12	detected	O
13	ubiquitously	O
14	,	O
15	but	O
16	in	O
17	transient	O
18	-	O
19	transfection	O
20	assays	O
21	,	O
22	multimerized	B
23	RFX	I
24	binding	I
25	sites	I
26	in	O
27	front	O
28	of	O
29	a	O
30	basal	O
31	promoter	O
32	efficiently	O
33	functioned	O
34	in	O
35	a	O
36	tissue	O
37	-	O
38	and	O
39	lineage	O
40	-	O
41	specific	O
42	manner	O
43	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	B
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	AUF1	B
17	-	I
18	binding	I
19	sequences	I
20	,	O
21	since	O
22	luciferase	B
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O

1	Thus	O
2	,	O
3	VDR	B
4	acts	O
5	selectively	O
6	on	O
7	the	O
8	two	O
9	components	O
10	required	O
11	for	O
12	activation	O
13	of	O
14	this	O
15	promoter	O
16	/	O
17	enhancer	O
18	:	O
19	it	O
20	competes	O
21	with	O
22	NFAT1	B
23	for	O
24	binding	O
25	to	O
26	the	O
27	composite	O
28	site	O
29	,	O
30	positioning	O
31	itself	O
32	adjacent	O
33	to	O
34	Jun	B
35	-	O
36	Fos	B
37	on	O
38	the	O
39	DNA	O
40	.	O

1	Two	O
2	evolutionarily	O
3	conserved	O
4	kinases	O
5	,	O
6	the	O
7	cyclin	B
8	B	I
9	(	O
10	Clb	B
11	)/	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	(	O
17	Cdk	B
18	/	O
19	Cdc28p	B
20	)	O
21	and	O
22	Cdc7p	B
23	along	O
24	with	O
25	its	O
26	interacting	O
27	factor	O
28	Dbf4p	B
29	,	O
30	are	O
31	required	O
32	late	O
33	in	O
34	G1	O
35	to	O
36	initiate	O
37	DNA	O
38	replication	O
39	.	O

1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	B
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	B
29	/	O
30	Nup214	B
31	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	deduced	O
6	amino	O
7	acid	O
8	sequence	O
9	of	O
10	a	O
11	second	O
12	family	O
13	(	O
14	ART5	B
15	)	O
16	of	O
17	transferases	O
18	,	O
19	cloned	O
20	from	O
21	murine	O
22	lymphoma	O
23	cells	O
24	and	O
25	expressed	O
26	in	O
27	high	O
28	abundance	O
29	in	O
30	testis	O
31	,	O
32	displays	O
33	a	O
34	hydrophobic	O
35	amino	O
36	terminus	O
37	,	O
38	consistent	O
39	with	O
40	a	O
41	signal	O
42	sequence	O
43	,	O
44	but	O
45	lacks	O
46	a	O
47	hydrophobic	O
48	signal	O
49	sequence	O
50	at	O
51	its	O
52	carboxyl	O
53	terminus	O
54	,	O
55	suggesting	O
56	that	O
57	the	O
58	protein	O
59	is	O
60	destined	O
61	for	O
62	export	O
63	.	O

1	RESULTS	O
2	:	O
3	Each	O
4	year	O
5	,	O
6	on	O
7	average	O
8	39	O
9	%	O
10	of	O
11	cases	O
12	seen	O
13	in	O
14	Sardinia	O
15	are	O
16	notified	O
17	;	O
18	646	O
19	(	O
20	40	O
21	%)	O
22	of	O
23	the	O
24	1591	O
25	patients	O
26	notified	O
27	during	O
28	the	O
29	study	O
30	period	O
31	were	O
32	never	O
33	seen	O
34	by	O
35	regional	O
36	medical	O
37	centres	O
38	.	O

1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	B
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O

1	The	O
2	paramyxovirus	B
3	fusion	I
4	(	I
5	F	I
6	)	I
7	protein	I
8	mediates	O
9	membrane	O
10	fusion	O
11	.	O

1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	B
8	promoter	O
9	-	O
10	PLAP	B
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O

1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O

1	Both	O
2	betaAPP	B
3	mRNA	I
4	and	O
5	Abeta	B
6	levels	O
7	are	O
8	increased	O
9	in	O
10	trisomy	O
11	21	O
12	.	O

1	In	O
2	reperfusion	O
3	B	O
4	,	O
5	only	O
6	the	O
7	diabetic	O
8	group	O
9	demonstrated	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	IL	B
15	-	I
16	8	I
17	concentrations	O
18	at	O
19	1	O
20	and	O
21	15	O
22	min	O
23	compared	O
24	to	O
25	nondiabetics	O
26	.	O

1	This	O
2	repression	O
3	was	O
4	reversed	O
5	agonists	O
6	of	O
7	either	O
8	receptor	O
9	demonstrating	O
10	a	O
11	functional	O
12	interaction	O
13	between	O
14	NCoR	B
15	and	O
16	PPARalpha	B
17	.	O
18	RXRalpha	B
19	heterodimeric	O
20	complexes	O
21	in	O
22	mammalian	O
23	cells	O
24	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	B
10	/	I
11	300	I
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	O
18	rich	O
19	ESE	B
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	B
33	doublesex	I
34	gene	I
35	.	O

1	Spc42p	B
2	also	O
3	was	O
4	identified	O
5	as	O
6	a	O
7	component	O
8	of	O
9	a	O
10	cytoplasmic	O
11	SPB	O
12	subcomplex	O
13	containing	O
14	Spc94p	B
15	/	O
16	Nud1p	B
17	,	O
18	Cnm67p	B
19	,	O
20	and	O
21	Spc42p	B
22	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	The	O
2	5	O
3	-	O
4	year	O
5	OS	O
6	for	O
7	stage	O
8	IIIB	O
9	was	O
10	30	O
11	.	O
12	9	O
13	%,	O
14	compared	O
15	to	O
16	7	O
17	.	O
18	8	O
19	%	O
20	for	O
21	stage	O
22	IV	O
23	.	O

1	Furthermore	O
2	,	O
3	heparin	B
4	lyase	I
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	B
12	YD	I
13	-	I
14	repeat	I
15	protein	I
16	releases	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	aggregates	O
24	.	O

1	The	O
2	coefficient	O
3	of	O
4	determination	O
5	,	O
6	r2	O
7	,	O
8	of	O
9	the	O
10	other	O
11	scores	O
12	ranged	O
13	from	O
14	0	O
15	.	O
16	56	O
17	to	O
18	0	O
19	.	O
20	61	O
21	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	B
43	/	I
44	pork	I
45	collagen	I
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	O
7	GnRHR	B
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	O
18	human	B
19	GnRHR	I
20	(	O
21	hGnRHR	B
22	)	O
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	Competitive	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	either	O
7	alphaT3	O
8	-	O
9	1	O
10	nuclear	O
11	extract	O
12	or	O
13	recombinant	B
14	SF	I
15	-	I
16	1	I
17	protein	I
18	clearly	O
19	indicated	O
20	that	O
21	SF	B
22	-	I
23	1	I
24	is	O
25	able	O
26	to	O
27	interact	O
28	specifically	O
29	with	O
30	this	O
31	GSE	B
32	element	I
33	positioned	O
34	at	O
35	-	O
36	134	O
37	.	O

1	Grade	O
2	3	O
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	CDK4	B
2	kinase	I
3	activities	O
4	were	O
5	unaffected	O
6	,	O
7	as	O
8	were	O
9	the	O
10	levels	O
11	of	O
12	the	O
13	CDK	B
14	inhibitor	O
15	p21Cip1	B
16	present	O
17	in	O
18	cyclin	B
19	E	I
20	immunocomplexes	I
21	.	O

1	The	O
2	recombinant	O
3	purified	O
4	protein	O
5	expressed	O
6	in	O
7	the	O
8	baculovirus	O
9	system	O
10	had	O
11	an	O
12	approximate	O
13	molecular	O
14	size	O
15	20	O
16	kDa	O
17	with	O
18	amino	O
19	-	O
20	terminal	O
21	sequence	O
22	of	O
23	AVQGP	O
24	.	O

1	Induction	O
2	of	O
3	the	O
4	urokinase	B
5	promoter	I
6	by	O
7	HGF	B
8	/	O
9	SF	B
10	via	O
11	the	O
12	Met	B
13	receptor	I
14	was	O
15	blocked	O
16	by	O
17	co	O
18	-	O
19	expression	O
20	of	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	Grb2	B
26	and	O
27	Sos1	B
28	expression	O
29	construct	O
30	.	O

1	Serine	O
2	phosphorylation	O
3	of	O
4	STAT3	B
5	was	O
6	only	O
7	apparent	O
8	after	O
9	somatostatin	B
10	treatment	O
11	and	O
12	was	O
13	abolished	O
14	by	O
15	pertussis	B
16	toxin	I
17	or	O
18	PD	O
19	98059	O
20	,	O
21	together	O
22	with	O
23	the	O
24	associated	O
25	increases	O
26	in	O
27	proliferation	O
28	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	I
56	121	I
57	-	I
58	476	I
59	)	I
60	p	I
61	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	Although	O
2	it	O
3	has	O
4	two	O
5	potential	O
6	binding	O
7	sites	O
8	,	O
9	the	O
10	purified	O
11	MerR	B
12	homodimer	I
13	binds	O
14	only	O
15	one	O
16	Hg	O
17	(	O
18	II	O
19	)	O
20	ion	O
21	,	O
22	employing	O
23	Cys82	O
24	from	O
25	one	O
26	monomer	O
27	and	O
28	Cys117	O
29	and	O
30	Cys126	O
31	from	O
32	the	O
33	other	O
34	.	O

1	The	O
2	influence	O
3	of	O
4	Epstein	O
5	-	O
6	Barr	O
7	virus	O
8	seropositivity	O
9	on	O
10	the	O
11	efficacy	O
12	of	O
13	intravenous	O
14	immune	B
15	globulin	I
16	in	O
17	children	O
18	with	O
19	immune	O
20	thrombocytopenic	O
21	purpura	O
22	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	lab	O
6	and	O
7	field	O
8	tests	O
9	yielded	O
10	high	O
11	levels	O
12	of	O
13	infestation	O
14	in	O
15	larvae	O
16	with	O
17	values	O
18	ranging	O
19	from	O
20	90	O
21	to	O
22	100	O
23	%	O
24	and	O
25	from	O
26	85	O
27	to	O
28	95	O
29	%,	O
30	respectively	O
31	.	O

1	Amisulpride	O
2	400	O
3	mg	O
4	had	O
5	several	O
6	adverse	O
7	effects	O
8	on	O
9	psychomotor	O
10	and	O
11	,	O
12	although	O
13	less	O
14	severe	O
15	,	O
16	on	O
17	cognitive	O
18	performance	O
19	on	O
20	the	O
21	fifth	O
22	day	O
23	only	O
24	.	O

1	MutY	B
2	is	O
3	an	O
4	adenine	B
5	-	I
6	DNA	I
7	glycosylase	I
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O

1	The	O
2	kinetics	O
3	of	O
4	kinase	O
5	activity	O
6	within	O
7	these	O
8	complexes	O
9	compared	O
10	to	O
11	CheA	B
12	alone	O
13	indicate	O
14	approximately	O
15	a	O
16	50	O
17	%	O
18	decrease	O
19	in	O
20	the	O
21	KM	O
22	for	O
23	ATP	O
24	and	O
25	a	O
26	100	O
27	-	O
28	fold	O
29	increase	O
30	in	O
31	the	O
32	Vmax	O
33	.	O

1	Latexin	B
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	During	O
2	1985	O
3	,	O
4	1990	O
5	,	O
6	and	O
7	1995	O
8	,	O
9	respectively	O
10	,	O
11	11	O
12	.	O
13	7	O
14	,	O
15	11	O
16	.	O
17	3	O
18	,	O
19	and	O
20	11	O
21	.	O
22	4	O
23	infants	O
24	per	O
25	100	O
26	,	O
27	000	O
28	live	O
29	births	O
30	had	O
31	a	O
32	diagnosis	O
33	of	O
34	HSV	O
35	(	O
36	P	O
37	=.	O
38	98	O
39	).	O

1	Subsets	O
2	of	O
3	patients	O
4	were	O
5	performed	O
6	according	O
7	to	O
8	the	O
9	severity	O
10	of	O
11	trauma	O
12	(	O
13	ISS	O
14	<	O
15	9	O
16	;	O
17	9	O
18	-	O
19	17	O
20	;	O
21	18	O
22	-	O
23	31	O
24	;	O
25	>	O
26	32	O
27	),	O
28	based	O
29	on	O
30	the	O
31	different	O
32	injury	O
33	pattern	O
34	,	O
35	and	O
36	survivors	O
37	versus	O
38	nonsurvivors	O
39	as	O
40	well	O
41	.	O

1	The	O
2	median	O
3	age	O
4	was	O
5	33	O
6	years	O
7	(	O
8	range	O
9	17	O
10	-	O
11	56	O
12	years	O
13	).	O

1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	of	O
6	infected	O
7	children	O
8	,	O
9	an	O
10	age	O
11	-	O
12	specific	O
13	z	O
14	score	O
15	<	O
16	-	O
17	2	O
18	for	O
19	weight	O
20	and	O
21	for	O
22	FFM	O
23	was	O
24	significantly	O
25	associated	O
26	with	O
27	an	O
28	increased	O
29	risk	O
30	of	O
31	death	O
32	[	O
33	relative	O
34	risk	O
35	(	O
36	95	O
37	%	O
38	CI	O
39	)	O
40	=	O
41	11	O
42	.	O
43	4	O
44	(	O
45	3	O
46	.	O
47	1	O
48	,	O
49	41	O
50	.	O
51	0	O
52	)	O
53	and	O
54	5	O
55	.	O
56	1	O
57	(	O
58	1	O
59	.	O
60	5	O
61	,	O
62	18	O
63	.	O
64	2	O
65	),	O
66	respectively	O
67	];	O
68	when	O
69	only	O
70	children	O
71	with	O
72	more	O
73	severe	O
74	disease	O
75	were	O
76	considered	O
77	,	O
78	only	O
79	z	O
80	score	O
81	for	O
82	weight	O
83	was	O
84	significantly	O
85	associated	O
86	with	O
87	an	O
88	increased	O
89	risk	O
90	[	O
91	4	O
92	.	O
93	6	O
94	(	O
95	1	O
96	.	O
97	4	O
98	,	O
99	14	O
100	.	O
101	9	O
102	)].	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	O
8	,	O
9	two	O
10	,	O
11	or	O
12	multiple	O
13	nuclei	O
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	O
24	and	O
25	also	O
26	a	O
27	defect	O
28	in	O
29	cytokinesis	O
30	and	O
31	/	O
32	or	O
33	cell	O
34	separation	O
35	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	However	O
2	,	O
3	neu	B
4	differentiation	O
5	factor	O
6	-	O
7	induced	O
8	heterodimers	O
9	of	O
10	ErbB2	B
11	and	O
12	ErbB4	B
13	activated	O
14	Stat5	B
15	.	O

1	Although	O
2	linker	O
3	regions	O
4	in	O
5	transcription	O
6	factors	O
7	are	O
8	known	O
9	to	O
10	modulate	O
11	DNA	O
12	binding	O
13	specificity	O
14	,	O
15	our	O
16	studies	O
17	suggest	O
18	that	O
19	the	O
20	human	B
21	HSF1	I
22	linker	O
23	plays	O
24	no	O
25	role	O
26	in	O
27	determining	O
28	HSF1	B
29	binding	O
30	preferences	O
31	in	O
32	vivo	O
33	but	O
34	is	O
35	a	O
36	critical	O
37	determinant	O
38	in	O
39	regulating	O
40	the	O
41	HSF1	B
42	monomer	I
43	-	I
44	trimer	I
45	equilibrium	O
46	.	O

1	Modulation	O
2	of	O
3	human	B
4	heat	I
5	shock	I
6	factor	I
7	trimerization	O
8	by	O
9	the	O
10	linker	O
11	domain	O
12	.	O

1	Both	O
2	functional	O
3	analyses	O
4	in	O
5	undifferentiated	O
6	and	O
7	differentiated	O
8	F9	O
9	cells	O
10	and	O
11	characterization	O
12	of	O
13	DNA	O
14	-	O
15	protein	O
16	complexes	O
17	in	O
18	vitro	O
19	have	O
20	identified	O
21	the	O
22	sequence	O
23	motifs	O
24	GTGACT	O
25	(	O
26	C	O
27	),	O
28	ATTGT	O
29	,	O
30	and	O
31	GATA	O
32	as	O
33	the	O
34	key	O
35	transcription	O
36	factor	O
37	binding	O
38	sites	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	O
12	perturbed	O
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	B
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	B
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	We	O
2	also	O
3	localized	O
4	the	O
5	Fra	B
6	-	I
7	2	I
8	phosphorylation	I
9	sites	I
10	by	O
11	MAPK	B
12	to	O
13	three	O
14	threonine	O
15	and	O
16	three	O
17	serine	O
18	residues	O
19	in	O
20	the	O
21	COOH	O
22	-	O
23	terminal	O
24	region	O
25	by	O
26	means	O
27	of	O
28	site	O
29	-	O
30	directed	O
31	mutagenesis	O
32	and	O
33	showed	O
34	that	O
35	the	O
36	threonine	O
37	residues	O
38	were	O
39	more	O
40	susceptible	O
41	to	O
42	MAPK	B
43	.	O

1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	B
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O

1	Vac1p	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	the	O
7	Sec1p	B
8	homologue	I
9	Vps45p	I
10	.	O

1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	B
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	B
19	virus	I
20	40	I
21	(	I
22	SV40	I
23	)	I
24	promoter	I
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	B
45	-	O
46	SV40	O
47	-	O
48	CAT	B
49	transactivation	O
50	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	O
8	phosphorylated	O
9	MARCKS	B
10	was	O
11	digested	O
12	with	O
13	lysyl	B
14	endoprotease	I
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O

1	The	O
2	yeast	B
3	LPD1	I
4	gene	I
5	encoding	O
6	lipoamide	B
7	dehydrogenase	I
8	is	O
9	subject	O
10	to	O
11	the	O
12	general	O
13	control	O
14	of	O
15	amino	O
16	acid	O
17	biosynthesis	O
18	mediated	O
19	by	O
20	the	O
21	GCN4	B
22	transcription	I
23	factor	I
24	.	O

1	The	O
2	relatively	O
3	mild	O
4	defects	O
5	observed	O
6	in	O
7	Rpd3	B
8	mutants	I
9	suggest	O
10	that	O
11	the	O
12	recently	O
13	identified	O
14	Groucho	B
15	and	O
16	dCtBP	B
17	corepressor	I
18	proteins	I
19	do	O
20	not	O
21	function	O
22	solely	O
23	through	O
24	the	O
25	recruitment	O
26	of	O
27	histone	B
28	deacetylases	I
29	.	O

1	However	O
2	,	O
3	the	O
4	serum	B
5	TNF	I
6	-	I
7	a	I
8	concentration	O
9	decreased	O
10	significantly	O
11	in	O
12	patients	O
13	receiving	O
14	pentoxifylline	O
15	(	O
16	basal	O
17	623	O
18	+/-	O
19	366	O
20	pg	O
21	/	O
22	ml	O
23	;	O
24	6th	O
25	month	O
26	562	O
27	+/-	O
28	358	O
29	pg	O
30	/	O
31	ml	O
32	,	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	),	O
39	but	O
40	not	O
41	in	O
42	the	O
43	control	O
44	group	O
45	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	show	O
6	that	O
7	the	O
8	expression	O
9	of	O
10	individual	O
11	members	O
12	of	O
13	one	O
14	subfamily	O
15	of	O
16	KRAB	B
17	zinc	I
18	finger	I
19	genes	I
20	is	O
21	restricted	O
22	to	O
23	specific	O
24	hematopoietic	O
25	cell	O
26	lineages	O
27	.	O

1	Employing	O
2	fluorescence	O
3	spectroscopy	O
4	and	O
5	circular	O
6	dichroism	O
7	,	O
8	we	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	Ca2	O
15	+	O
16	to	O
17	ALG	B
18	-	I
19	2	I
20	induced	O
21	significant	O
22	conformational	O
23	changes	O
24	in	O
25	both	O
26	the	O
27	N	O
28	-	O
29	terminal	O
30	and	O
31	C	O
32	-	O
33	terminal	O
34	domains	O
35	of	O
36	the	O
37	protein	O
38	.	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	Both	O
2	carbachol	O
3	(	O
4	100	O
5	microM	O
6	)	O
7	and	O
8	EGF	B
9	(	O
10	10	O
11	nM	O
12	)	O
13	induced	O
14	Ras	B
15	activation	O
16	.	O

1	Dominant	O
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	O
12	ERK2	B
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	such	O
6	lesions	O
7	in	O
8	two	O
9	cases	O
10	were	O
11	evaluated	O
12	by	O
13	ultrasonography	O
14	.	O

1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	B
16	-	I
17	1	I
18	with	O
19	different	O
20	affinities	O
21	.	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	O
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	Hrs	B
2	has	O
3	a	O
4	FYVE	O
5	double	O
6	zinc	O
7	finger	O
8	domain	O
9	,	O
10	which	O
11	specifically	O
12	binds	O
13	phosphatidylinositol	O
14	(	O
15	3	O
16	)-	O
17	phosphate	O
18	and	O
19	is	O
20	conserved	O
21	in	O
22	several	O
23	proteins	O
24	involved	O
25	in	O
26	vesicular	O
27	traffic	O
28	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	B
14	leukemia	I
15	factor	I
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	O
28	DBP	B
29	fusion	O
30	proteins	O
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	NS2	B
18	gene	I
19	.	O

1	Cp	B
2	is	O
3	normally	O
4	the	O
5	main	O
6	promoter	O
7	for	O
8	EBNA	B
9	mRNA	I
10	initiation	O
11	,	O
12	so	O
13	it	O
14	appears	O
15	that	O
16	EBNA3C	B
17	contributes	O
18	to	O
19	a	O
20	negative	O
21	autoregulatory	O
22	control	O
23	loop	O
24	.	O

1	These	O
2	indications	O
3	of	O
4	deregulated	O
5	signalling	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	tyrosine	O
11	118	O
12	were	O
13	substantiated	O
14	by	O
15	sustained	O
16	activation	O
17	of	O
18	STAT3	B
19	.	O

1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O

1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	B
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O

1	The	O
2	most	O
3	common	O
4	characteristics	O
5	of	O
6	VRE	O
7	patients	O
8	were	O
9	recent	O
10	prior	O
11	vancomycin	O
12	use	O
13	,	O
14	recent	O
15	prior	O
16	susceptible	O
17	enterococcal	O
18	infection	O
19	,	O
20	coinfection	O
21	with	O
22	other	O
23	microbial	O
24	pathogens	O
25	,	O
26	and	O
27	concurrent	O
28	fungal	O
29	infection	O
30	.	O

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	B
21	LRR	I
22	.	O

1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	B
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	B
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	B
39	protein	I
40	and	O
41	terminase	B
42	interaction	I
43	sites	I
44	.	O

1	Although	O
2	the	O
3	terminase	B
4	apparently	O
5	interacts	O
6	with	O
7	this	O
8	gp20	B
9	portal	I
10	peptide	I
11	,	O
12	polyclonal	O
13	antibody	O
14	against	O
15	the	O
16	portal	O
17	peptide	O
18	appears	O
19	unable	O
20	to	O
21	access	O
22	it	O
23	in	O
24	the	O
25	native	O
26	structure	O
27	,	O
28	suggesting	O
29	intimate	O
30	association	O
31	of	O
32	gp20	B
33	and	O
34	gp17	B
35	possibly	O
36	internalizes	O
37	terminase	B
38	regions	I
39	within	O
40	the	O
41	portal	O
42	in	O
43	the	O
44	packasome	O
45	complex	O
46	.	O

1	The	O
2	hybrid	O
3	viruses	O
4	were	O
5	found	O
6	to	O
7	accumulate	O
8	to	O
9	high	O
10	levels	O
11	in	O
12	infected	O
13	plants	O
14	,	O
15	to	O
16	form	O
17	stable	O
18	virions	O
19	,	O
20	and	O
21	to	O
22	be	O
23	mechanically	O
24	transmissible	O
25	.	O

1	cDNA	O
2	and	O
3	structural	O
4	organization	O
5	of	O
6	the	O
7	gene	B
8	Pole1	I
9	for	O
10	the	O
11	mouse	B
12	DNA	I
13	polymerase	I
14	epsilon	I
15	catalytic	I
16	subunit	I
17	.	O

1	Nevertheless	O
2	cryopreservation	O
3	of	O
4	spermatozoa	O
5	in	O
6	a	O
7	medium	O
8	containing	O
9	neither	O
10	SP	O
11	nor	O
12	biological	O
13	substances	O
14	could	O
15	offer	O
16	an	O
17	acceptable	O
18	cryoprotection	O
19	of	O
20	spermatozoa	O
21	to	O
22	be	O
23	used	O
24	in	O
25	assisted	O
26	fertilization	O
27	procedures	O
28	,	O
29	especially	O
30	for	O
31	intracytoplasmic	O
32	sperm	O
33	injection	O
34	.	O

1	A	O
2	liquid	O
3	chromatographic	O
4	method	O
5	is	O
6	described	O
7	for	O
8	analysis	O
9	of	O
10	beta	O
11	-	O
12	carotene	O
13	in	O
14	medical	O
15	food	O
16	.	O

1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O

1	Severe	O
2	hemolysis	O
3	resulted	O
4	in	O
5	statistically	O
6	significant	O
7	changes	O
8	in	O
9	the	O
10	mean	O
11	values	O
12	of	O
13	the	O
14	above	O
15	analytes	O
16	in	O
17	addition	O
18	to	O
19	the	O
20	following	O
21	increases	O
22	:	O
23	alanine	B
24	aminotransferase	I
25	,	O
26	calcium	O
27	,	O
28	and	O
29	serum	B
30	globulins	I
31	(	O
32	P	O
33	<	O
34	0	O
35	.	O
36	001	O
37	)	O
38	and	O
39	albumin	B
40	and	O
41	total	O
42	protein	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	01	O
49	).	O

1	EMSA	O
2	with	O
3	crude	O
4	nuclear	O
5	extracts	O
6	demonstrated	O
7	that	O
8	stimulation	O
9	with	O
10	CD40L	B
11	results	O
12	in	O
13	the	O
14	induction	O
15	of	O
16	NF	B
17	-	I
18	kappaB	I
19	complexes	I
20	that	O
21	bind	O
22	to	O
23	each	O
24	of	O
25	the	O
26	three	O
27	NF	B
28	-	I
29	kappaB	I
30	sites	I
31	and	O
32	are	O
33	composed	O
34	mainly	O
35	of	O
36	p50	B
37	and	O
38	RelB	B
39	,	O
40	but	O
41	also	O
42	include	O
43	c	B
44	-	I
45	Rel	I
46	and	O
47	p65	B
48	.	O

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	B
16	and	O
17	AhrC	B
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	B
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	O
23	GR	B
24	.	O

1	The	O
2	exon	O
3	:	O
4	intron	O
5	structure	O
6	of	O
7	chicken	B
8	IL8	I
9	corresponds	O
10	almost	O
11	exactly	O
12	to	O
13	that	O
14	of	O
15	human	B
16	IL8	I
17	and	O
18	differs	O
19	from	O
20	those	O
21	of	O
22	other	O
23	known	O
24	mammalian	B
25	CXC	I
26	chemokine	I
27	genes	I
28	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	CONCLUSIONS	O
2	:	O
3	Turbutest	O
4	is	O
5	a	O
6	valuable	O
7	tool	O
8	in	O
9	asthmatic	O
10	patients	O
11	'	O
12	training	O
13	,	O
14	allowing	O
15	identification	O
16	and	O
17	improvement	O
18	of	O
19	an	O
20	inadequate	O
21	inhalation	O
22	technique	O
23	with	O
24	Turbuhaler	O
25	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	The	O
2	femoral	O
3	artery	O
4	/	O
5	vein	O
6	and	O
7	the	O
8	soleus	O
9	and	O
10	gastrocnemius	O
11	muscles	O
12	were	O
13	examined	O
14	in	O
15	healthy	O
16	human	O
17	male	O
18	volunteers	O
19	.	O

1	SRFDelta5	B
2	acts	O
3	as	O
4	a	O
5	naturally	O
6	occurring	O
7	dominant	O
8	negative	O
9	regulatory	O
10	mutant	O
11	that	O
12	blocks	O
13	SRF	B
14	-	O
15	dependent	O
16	skeletal	B
17	alpha	I
18	-	I
19	actin	I
20	,	O
21	cardiac	B
22	alpha	I
23	-	I
24	actin	I
25	,	O
26	smooth	B
27	alpha	I
28	-	I
29	actin	I
30	,	O
31	SM22alpha	B
32	,	O
33	and	O
34	SRF	B
35	promoter	O
36	-	O
37	luciferase	B
38	reporter	O
39	activities	O
40	.	O

1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	B
8	accelerated	O
9	E1A	B
10	-	O
11	induced	O
12	apoptosis	O
13	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	O
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	O
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	CONCLUSION	O
2	:	O
3	NBP	O
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O

1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O

1	Mutations	O
2	within	O
3	human	O
4	UTR1	O
5	modulate	O
6	NRF	B
7	-	I
8	1	I
9	expression	O
10	by	O
11	interfering	O
12	with	O
13	mRNA	O
14	translational	O
15	efficiency	O
16	in	O
17	transfected	O
18	cells	O
19	and	O
20	in	O
21	an	O
22	in	O
23	vitro	O
24	translation	O
25	system	O
26	.	O

1	As	O
2	is	O
3	deduced	O
4	from	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	the	O
10	cDNA	O
11	,	O
12	CBS	B
13	-	I
14	1	I
15	contains	O
16	an	O
17	open	O
18	reading	O
19	frame	O
20	consisting	O
21	of	O
22	182	O
23	amino	O
24	acids	O
25	,	O
26	with	O
27	a	O
28	molecular	O
29	weight	O
30	of	O
31	19	O
32	.	O
33	5kDa	O
34	.	O

1	Corticostriatal	O
2	and	O
3	corticosubthalamic	O
4	input	O
5	zones	O
6	from	O
7	the	O
8	presupplementary	O
9	motor	O
10	area	O
11	in	O
12	the	O
13	macaque	O
14	monkey	O
15	:	O
16	comparison	O
17	with	O
18	the	O
19	input	O
20	zones	O
21	from	O
22	the	O
23	supplementary	O
24	motor	O
25	area	O
26	.	O

1	Basic	B
2	fibroblast	I
3	growth	I
4	factor	I
5	(	O
6	bFGF	B
7	)	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	induce	O
13	angiogenesis	O
14	in	O
15	various	O
16	animal	O
17	models	O
18	,	O
19	but	O
20	the	O
21	methods	O
22	of	O
23	administration	O
24	used	O
25	experimentally	O
26	are	O
27	not	O
28	clinically	O
29	feasible	O
30	.	O

1	Both	O
2	filters	O
3	equally	O
4	contributed	O
5	to	O
6	elevation	O
7	of	O
8	iliac	O
9	venous	O
10	pressure	O
11	(	O
12	median	O
13	,	O
14	9	O
15	.	O
16	3	O
17	and	O
18	7	O
19	.	O
20	2	O
21	mm	O
22	Hg	O
23	[	O
24	n	O
25	=	O
26	9	O
27	]	O
28	with	O
29	the	O
30	spring	O
31	filter	O
32	and	O
33	RF02	O
34	filter	O
35	,	O
36	respectively	O
37	).	O

1	12	O
2	healthy	O
3	women	O
4	(	O
5	age	O
6	18	O
7	-	O
8	38	O
9	years	O
10	)	O
11	were	O
12	examined	O
13	using	O
14	the	O
15	2	O
16	-	O
17	hour	O
18	'	O
19	s	O
20	method	O
21	of	O
22	passive	O
23	leg	O
24	rising	O
25	(	O
26	PLR	O
27	)	O
28	in	O
29	follicular	O
30	(	O
31	FP	O
32	)	O
33	and	O
34	luteal	O
35	(	O
36	LP	O
37	)	O
38	phases	O
39	of	O
40	normal	O
41	ovulatory	O
42	cycle	O
43	.	O

1	Thus	O
2	,	O
3	sgRNA2	B
4	has	O
5	the	O
6	3	O
7	'	O
8	TE	O
9	in	O
10	its	O
11	5	O
12	'	O
13	UTR	O
14	.	O

1	These	O
2	single	O
3	mutational	O
4	defects	O
5	in	O
6	the	O
7	eRF1	B
8	-	O
9	eRF3	B
10	interaction	O
11	became	O
12	evident	O
13	when	O
14	either	O
15	truncated	O
16	protein	O
17	eRF3C	B
18	or	O
19	C	O
20	-	O
21	terminally	O
22	altered	O
23	eRF1	B
24	proteins	O
25	were	O
26	used	O
27	for	O
28	the	O
29	authentic	O
30	protein	O
31	,	O
32	providing	O
33	further	O
34	support	O
35	for	O
36	the	O
37	presence	O
38	of	O
39	a	O
40	C	O
41	-	O
42	terminal	O
43	interaction	O
44	.	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	B
20	.	I
21	8Ss	I
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	Green	O
2	fluorescent	O
3	protein	O
4	-	O
5	tagged	O
6	UNC	B
7	-	I
8	49B	I
9	and	O
10	UNC	B
11	-	I
12	49C	I
13	subunits	I
14	are	O
15	coexpressed	O
16	in	O
17	muscle	O
18	cells	O
19	and	O
20	are	O
21	colocalized	O
22	to	O
23	synaptic	O
24	regions	O
25	.	O

1	We	O
2	show	O
3	that	O
4	a	O
5	protein	O
6	,	O
7	UBC9	B
8	,	O
9	interacts	O
10	specifically	O
11	with	O
12	TEL	B
13	in	O
14	vitro	O
15	and	O
16	in	O
17	vivo	O
18	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O

1	Molecules	O
2	of	O
3	NH3	O
4	are	O
5	capable	O
6	of	O
7	emitting	O
8	stimulated	O
9	radiation	O
10	(	O
11	MASER	O
12	).	O

1	The	O
2	major	O
3	findings	O
4	of	O
5	our	O
6	studies	O
7	are	O
8	as	O
9	follows	O
10	:	O
11	1	O
12	)	O
13	There	O
14	are	O
15	no	O
16	detectable	O
17	signals	O
18	around	O
19	GDF	B
20	-	I
21	9	I
22	-	O
23	deficient	O
24	follicles	O
25	for	O
26	several	O
27	theca	O
28	cell	O
29	layer	O
30	markers	O
31	[	O
32	i	O
33	.	O
34	e	O
35	.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	O
17	MDV2	B
18	UL10	I
19	protein	I
20	.	O

1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	B
7	'	I
8	s	I
9	disease	I
10	virus	I
11	serotype	I
12	2	I
13	glycoprotein	I
14	M	I
15	gene	I
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	B
20	M	I
21	genes	I
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	perform	O
5	a	O
6	cost	O
7	-	O
8	effectiveness	O
9	analysis	O
10	(	O
11	CEA	O
12	)	O
13	between	O
14	a	O
15	standard	O
16	antiemetic	O
17	regimen	O
18	-	O
19	chlorpromazine	O
20	+	O
21	dexamethasone	O
22	(	O
23	CPM	O
24	-	O
25	DEX	O
26	)-	O
27	and	O
28	a	O
29	5	B
30	-	I
31	HT3	I
32	receptor	I
33	antagonist	O
34	-	O
35	tropisetron	O
36	(	O
37	TROP	O
38	)--	O
39	in	O
40	the	O
41	control	O
42	of	O
43	acute	O
44	emesis	O
45	induced	O
46	by	O
47	highly	O
48	emetogenic	O
49	chemotherapy	O
50	in	O
51	children	O
52	,	O
53	considering	O
54	two	O
55	analytic	O
56	perspectives	O
57	:	O
58	hospital	O
59	and	O
60	patients	O
61	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	and	O
7	deduced	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	the	O
13	core	O
14	regions	O
15	of	O
16	the	O
17	RNA	B
18	-	I
19	dependent	I
20	RNA	I
21	polymerase	I
22	domains	I
23	found	O
24	in	O
25	these	O
26	three	O
27	dsRNAs	O
28	suggested	O
29	that	O
30	these	O
31	dsRNAs	O
32	probably	O
33	evolved	O
34	independently	O
35	within	O
36	each	O
37	host	O
38	plant	O
39	from	O
40	a	O
41	common	O
42	ancestor	O
43	.	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	B
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	Forty	O
2	-	O
3	eight	O
4	sequences	O
5	,	O
6	30	O
7	not	O
8	previously	O
9	identified	O
10	as	O
11	IR	O
12	-	O
13	responsive	O
14	,	O
15	were	O
16	significantly	O
17	regulated	O
18	by	O
19	IR	O
20	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	B
7	1	I
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	rat	B
5	SH2	I
6	-	I
7	containing	I
8	inositol	I
9	phosphatase	I
10	2	I
11	(	O
12	SHIP2	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O

1	Slp1	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	B
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	B
12	dimers	I
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O

1	The	O
2	penicillin	B
3	binding	I
4	proteins	I
5	(	O
6	PBPs	B
7	)	O
8	synthesize	O
9	and	O
10	remodel	O
11	peptidoglycan	O
12	,	O
13	the	O
14	structural	O
15	component	O
16	of	O
17	the	O
18	bacterial	O
19	cell	O
20	wall	O
21	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	B
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	O
19	+,	O
20	CD8	O
21	+,	O
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	Similar	O
2	results	O
3	were	O
4	obtained	O
5	with	O
6	xylitol	O
7	,	O
8	an	O
9	activator	O
10	of	O
11	the	O
12	pentose	O
13	phosphate	O
14	pathway	O
15	.	O

1	The	O
2	high	B
3	density	I
4	lipoprotein	I
5	(	I
6	HDL	I
7	)	I
8	receptor	I
9	mediates	O
10	the	O
11	uptake	O
12	of	O
13	cholesterol	O
14	and	O
15	cholesteryl	O
16	esters	O
17	,	O
18	substrates	O
19	for	O
20	steroidogenesis	O
21	,	O
22	from	O
23	an	O
24	HDL	B
25	particle	O
26	in	O
27	the	O
28	adrenal	O
29	gland	O
30	and	O
31	gonads	O
32	.	O

1	D3S1261	B
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	B
10	locus	I
11	,	O
12	while	O
13	D3S2465	B
14	and	O
15	D3S1766	B
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	site	O
6	that	O
7	suppressed	O
8	Pit	B
9	-	I
10	1	I
11	binding	O
12	in	O
13	vitro	O
14	restored	O
15	full	O
16	tiGH	B
17	promoter	I
18	activity	O
19	.	O

1	A	O
2	human	B
3	Raf	I
4	-	I
5	responsive	I
6	zinc	I
7	-	I
8	finger	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	divergent	O
14	sequences	O
15	.	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	Furthermore	O
2	,	O
3	MOM	B
4	-	I
5	4	I
6	and	O
7	TAK1	B
8	bind	O
9	related	O
10	proteins	O
11	that	O
12	promote	O
13	their	O
14	kinase	O
15	activities	O
16	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	O
5	-	O
6	III	O
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	Gab2	B
2	,	O
3	a	O
4	new	O
5	pleckstrin	B
6	homology	O
7	domain	O
8	-	O
9	containing	O
10	adapter	O
11	protein	O
12	,	O
13	acts	O
14	to	O
15	uncouple	O
16	signaling	O
17	from	O
18	ERK	B
19	kinase	I
20	to	O
21	Elk	B
22	-	I
23	1	I
24	.	O

1	The	O
2	presence	O
3	of	O
4	cutaneous	O
5	xanthomas	O
6	with	O
7	normal	O
8	serum	O
9	lipid	O
10	levels	O
11	is	O
12	due	O
13	to	O
14	the	O
15	antibetalipoproteic	O
16	activity	O
17	of	O
18	the	O
19	monoclonal	B
20	immunoglobulin	I
21	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	reduce	O
6	the	O
7	incidence	O
8	of	O
9	NSAID	O
10	-	O
11	induced	O
12	gastrointestinal	O
13	lesions	O
14	,	O
15	the	O
16	following	O
17	approaches	O
18	have	O
19	been	O
20	proposed	O
21	:	O
22	(	O
23	i	O
24	)	O
25	use	O
26	of	O
27	the	O
28	prostaglandin	O
29	analogue	O
30	misoprostol	O
31	,	O
32	which	O
33	is	O
34	an	O
35	antiulcer	O
36	drug	O
37	which	O
38	has	O
39	been	O
40	proven	O
41	to	O
42	be	O
43	as	O
44	effective	O
45	in	O
46	the	O
47	prevention	O
48	of	O
49	NSAID	O
50	-	O
51	induced	O
52	gastric	O
53	and	O
54	duodenal	O
55	ulcers	O
56	as	O
57	in	O
58	the	O
59	reduction	O
60	of	O
61	serious	O
62	upper	O
63	gastrointestinal	O
64	complications	O
65	;	O
66	(	O
67	ii	O
68	)	O
69	histamine	B
70	H2	I
71	receptor	I
72	antagonists	O
73	(	O
74	H2	O
75	antagonists	O
76	),	O
77	e	O
78	.	O
79	g	O
80	.	O
81	ranitidine	O
82	,	O
83	cimetidine	O
84	and	O
85	famotidine	O
86	,	O
87	which	O
88	are	O
89	useful	O
90	in	O
91	the	O
92	prevention	O
93	of	O
94	NSAID	O
95	-	O
96	induced	O
97	duodenal	O
98	ulcers	O
99	during	O
100	long	O
101	term	O
102	treatment	O
103	,	O
104	but	O
105	not	O
106	in	O
107	the	O
108	prevention	O
109	of	O
110	NSAID	O
111	-	O
112	induced	O
113	gastric	O
114	ulcers	O
115	;	O
116	(	O
117	iii	O
118	)	O
119	proton	O
120	pump	O
121	inhibitors	O
122	,	O
123	e	O
124	.	O
125	g	O
126	omeprazole	O
127	,	O
128	and	O
129	pantoprazole	O
130	,	O
131	whose	O
132	efficacy	O
133	in	O
134	preventing	O
135	NSAID	O
136	-	O
137	associated	O
138	ulcers	O
139	has	O
140	been	O
141	recently	O
142	demonstrated	O
143	;	O
144	and	O
145	(	O
146	iv	O
147	)	O
148	barrier	O
149	agents	O
150	,	O
151	e	O
152	.	O
153	g	O
154	.	O
155	sucralfate	O
156	,	O
157	which	O
158	cannot	O
159	be	O
160	recommended	O
161	as	O
162	prophylactic	O
163	agents	O
164	to	O
165	prevent	O
166	NSAID	O
167	-	O
168	induced	O
169	gastropathy	O
170	.	O

1	Lung	O
2	mesenchyme	O
3	serves	O
4	as	O
5	a	O
6	'	O
7	compleat	O
8	'	O
9	inducer	O
10	of	O
11	lung	O
12	morphogenesis	O
13	by	O
14	secreting	O
15	soluble	O
16	peptide	O
17	growth	O
18	factors	O
19	.	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	The	O
2	bovine	B
3	papillomavirus	I
4	E2	I
5	protein	I
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	O
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O

1	E2	B
2	point	O
3	mutants	O
4	unable	O
5	to	O
6	inhibit	O
7	cell	O
8	growth	O
9	did	O
10	not	O
11	repress	O
12	cdc25A	B
13	and	O
14	cdc25B	B
15	expression	O
16	,	O
17	nor	O
18	did	O
19	the	O
20	cell	O
21	cycle	O
22	inhibitors	O
23	hydroxyurea	O
24	and	O
25	mimosine	O
26	.	O

1	BACKGROUND	O
2	/	O
3	PURPOSE	O
4	:	O
5	Anomalous	O
6	arrangement	O
7	of	O
8	the	O
9	pancreaticobiliary	O
10	duct	O
11	(	O
12	AAPBD	O
13	)	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	congenital	O
19	biliary	O
20	dilatation	O
21	and	O
22	frequently	O
23	associated	O
24	with	O
25	biliary	O
26	tract	O
27	malignancy	O
28	.	O

1	Neurospora	O
2	crassa	O
3	CYT	B
4	-	I
5	18	I
6	,	O
7	can	O
8	rescue	O
9	the	O
10	exonic	O
11	trap	O
12	and	O
13	intron	O
14	mutants	O
15	which	O
16	cause	O
17	a	O
18	structural	O
19	defect	O
20	.	O

1	DDP1	B
2	also	O
3	localizes	O
4	to	O
5	heterochromatin	O
6	in	O
7	interphase	O
8	nuclei	O
9	of	O
10	larval	O
11	neuroblasts	O
12	.	O

1	In	O
2	a	O
3	reconstituted	O
4	human	O
5	DNA	O
6	repair	O
7	system	O
8	containing	O
9	DNA	B
10	polymerase	I
11	beta	I
12	and	O
13	DNA	B
14	ligase	I
15	III	I
16	-	O
17	XRCC1	B
18	,	O
19	accurate	O
20	rejoining	O
21	of	O
22	a	O
23	3	O
24	'	O
25	mismatched	O
26	base	O
27	residue	O
28	at	O
29	a	O
30	single	O
31	-	O
32	strand	O
33	break	O
34	is	O
35	dependent	O
36	on	O
37	addition	O
38	of	O
39	the	O
40	exonuclease	O
41	.	O

1	The	O
2	PAC	O
3	clone	O
4	with	O
5	an	O
6	insert	O
7	size	O
8	of	O
9	120kb	O
10	was	O
11	isolated	O
12	and	O
13	mapped	O
14	by	O
15	restriction	O
16	analysis	O
17	.	O

1	Sequence	O
2	of	O
3	10q24	B
4	locus	I
5	surrounding	O
6	the	O
7	HOX11	B
8	oncogene	I
9	reveals	O
10	a	O
11	new	O
12	gene	O
13	HUG1	B
14	expressed	O
15	in	O
16	a	O
17	T	O
18	-	O
19	ALL	O
20	cell	O
21	line	O
22	.	O

1	About	O
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	B
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	O
18	LAMB2	B
19	-	I
20	like	I
21	pseudogene	I
22	(	O
23	LAMB2L	B
24	).	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	B
8	protein	I
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	The	O
2	infected	B
3	cell	I
4	protein	I
5	no	I
6	.	I
7	0	I
8	(	O
9	ICP0	B
10	)	O
11	of	O
12	herpes	O
13	simplex	O
14	virus	O
15	1	O
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	Wrist	O
2	measurement	O
3	of	O
4	blood	O
5	pressure	O
6	:	O
7	some	O
8	critical	O
9	remarks	O
10	to	O
11	oscillometry	O
12	.	O

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	B
25	promoter	I
26	.	O

1	Another	O
2	element	O
3	necessary	O
4	for	O
5	augmenting	O
6	the	O
7	amplitude	O
8	of	O
9	the	O
10	oscillation	O
11	lies	O
12	between	O
13	-	O
14	178	O
15	and	O
16	-	O
17	264	O
18	.	O

1	This	O
2	scFv	O
3	was	O
4	therefore	O
5	used	O
6	as	O
7	control	O
8	in	O
9	experiments	O
10	where	O
11	another	O
12	anti	B
13	-	I
14	Ras	I
15	scFv	I
16	(	O
17	Y259	B
18	scFv	I
19	,	O
20	derived	O
21	from	O
22	the	O
23	neutralizing	O
24	anti	B
25	-	I
26	Ras	I
27	mAb	I
28	Y13	I
29	-	I
30	259	I
31	)	O
32	blocked	O
33	the	O
34	Ras	B
35	pathway	O
36	in	O
37	vitro	O
38	and	O
39	led	O
40	to	O
41	tumor	O
42	regression	O
43	in	O
44	a	O
45	nude	O
46	mouse	O
47	model	O
48	[	O
49	Cochet	O
50	,	O
51	O	O
52	.,	O
53	Kenigsberg	O
54	,	O
55	M	O
56	.,	O
57	Delumeau	O
58	,	O
59	I	O
60	.,	O
61	Virone	O
62	-	O
63	Oddos	O
64	,	O
65	A	O
66	.,	O
67	Multon	O
68	,	O
69	M	O
70	.	O
71	C	O
72	.,	O
73	Fridman	O
74	,	O
75	W	O
76	.	O
77	H	O
78	.,	O
79	Schweighoffer	O
80	,	O
81	F	O
82	.,	O
83	Teillaud	O
84	,	O
85	J	O
86	.	O
87	L	O
88	.,	O
89	Tocque	O
90	,	O
91	B	O
92	.,	O
93	1998	O
94	.	O

1	There	O
2	was	O
3	no	O
4	competition	O
5	between	O
6	activin	B
7	A	I
8	and	O
9	OP	B
10	-	I
11	1	I
12	for	O
13	availability	O
14	of	O
15	Smad4	B
16	,	O
17	indicating	O
18	that	O
19	the	O
20	concentration	O
21	of	O
22	this	O
23	common	O
24	signal	O
25	transducer	O
26	is	O
27	not	O
28	limiting	O
29	for	O
30	generating	O
31	the	O
32	observed	O
33	biological	O
34	responses	O
35	.	O

1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	B
13	envelope	I
14	glycoprotein	I
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O

1	However	O
2	,	O
3	the	O
4	favored	O
5	,	O
6	parallel	O
7	beta	O
8	helix	O
9	model	O
10	is	O
11	a	O
12	compact	O
13	coil	O
14	of	O
15	ten	O
16	helically	O
17	arranged	O
18	beta	O
19	strands	O
20	forming	O
21	two	O
22	parallel	O
23	beta	O
24	sheet	O
25	faces	O
26	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O

1	Characterisation	O
2	of	O
3	the	O
4	chicken	B
5	apolipoprotein	I
6	A	I
7	-	I
8	I	I
9	gene	I
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	ATF	B
9	family	I
10	are	O
11	involved	O
12	in	O
13	mediating	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	the	O
19	KGF	B
20	gene	I
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	via	O
27	a	O
28	novel	O
29	CRE	O
30	regulatory	O
31	element	O
32	.	O

1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O

1	A	O
2	multi	O
3	-	O
4	centre	O
5	evaluation	O
6	of	O
7	the	O
8	card	O
9	indirect	O
10	agglutination	O
11	test	O
12	for	O
13	trypanosomiasis	O
14	(	O
15	TrypTect	O
16	CIATT	O
17	).	O

1	Results	O
2	for	O
3	men	O
4	who	O
5	drank	O
6	up	O
7	to	O
8	two	O
9	drinks	O
10	per	O
11	day	O
12	suggest	O
13	that	O
14	if	O
15	the	O
16	dependence	O
17	criteria	O
18	were	O
19	invalid	O
20	,	O
21	reductions	O
22	in	O
23	the	O
24	prevalence	O
25	of	O
26	specific	O
27	indicators	O
28	of	O
29	alcohol	O
30	dependence	O
31	would	O
32	range	O
33	from	O
34	0	O
35	.	O
36	3	O
37	%	O
38	to	O
39	5	O
40	.	O
41	2	O
42	%.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	CDE	O
5	/	O
6	CHR	O
7	elements	O
8	and	O
9	Sp1	B
10	sites	I
11	in	O
12	this	O
13	region	O
14	,	O
15	alone	O
16	or	O
17	in	O
18	combination	O
19	,	O
20	reduced	O
21	transcriptional	O
22	activity	O
23	by	O
24	40	O
25	-	O
26	60	O
27	%	O
28	in	O
29	asynchronously	O
30	growing	O
31	cells	O
32	and	O
33	abolished	O
34	cell	O
35	cycle	O
36	periodicity	O
37	in	O
38	G2	O
39	-	O
40	M	O
41	-	O
42	synchronized	O
43	cells	O
44	.	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O

1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	I
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O

1	Ozagrel	O
2	,	O
3	ifenprodil	O
4	,	O
5	cinnarizine	O
6	and	O
7	dilazep	O
8	were	O
9	more	O
10	effective	O
11	than	O
12	pentoxifylline	O
13	in	O
14	increasing	O
15	rCBF	O
16	at	O
17	the	O
18	HPC	O
19	.	O

1	The	O
2	latter	O
3	method	O
4	adds	O
5	clamping	O
6	of	O
7	the	O
8	inferior	O
9	vena	O
10	cava	O
11	,	O
12	which	O
13	results	O
14	in	O
15	hypotension	O
16	,	O
17	requiring	O
18	invasive	O
19	anesthetic	O
20	management	O
21	.	O

1	By	O
2	contrast	O
3	,	O
4	PvirE	B
5	or	O
6	Plac	B
7	promoter	I
8	constructs	I
9	yielded	O
10	functional	O
11	VirE2	B
12	only	O
13	if	O
14	virE1	B
15	was	O
16	coexpressed	O
17	with	O
18	virE2	B
19	.	O

1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O

1	To	O
2	investigate	O
3	the	O
4	functions	O
5	of	O
6	GE	O
7	,	O
8	IG	O
9	,	O
10	and	O
11	GS	O
12	sequences	O
13	in	O
14	transcription	O
15	,	O
16	we	O
17	constructed	O
18	plasmids	O
19	containing	O
20	cDNAs	O
21	of	O
22	the	O
23	full	O
24	-	O
25	length	O
26	SV5	O
27	genome	O
28	in	O
29	which	O
30	the	O
31	gene	O
32	junction	O
33	sequences	O
34	(	O
35	GE	O
36	,	O
37	IG	O
38	,	O
39	and	O
40	GS	O
41	sequences	O
42	)	O
43	located	O
44	between	O
45	the	O
46	hemagglutinin	B
47	-	I
48	neuraminidase	I
49	(	O
50	HN	B
51	)	O
52	and	O
53	the	O
54	polymerase	B
55	(	I
56	L	I
57	)	I
58	genes	I
59	were	O
60	replaced	O
61	with	O
62	the	O
63	counterpart	O
64	sequences	O
65	from	O
66	other	O
67	gene	O
68	junctions	O
69	.	O

1	CXCR4	B
2	is	O
3	a	O
4	chemokine	O
5	receptor	O
6	and	O
7	a	O
8	coreceptor	O
9	for	O
10	T	O
11	-	O
12	cell	O
13	-	O
14	line	O
15	-	O
16	tropic	O
17	(	O
18	X4	O
19	)	O
20	and	O
21	dual	O
22	-	O
23	tropic	O
24	(	O
25	R5X4	O
26	)	O
27	human	O
28	immunodeficiency	O
29	virus	O
30	type	O
31	1	O
32	(	O
33	HIV	O
34	-	O
35	1	O
36	)	O
37	isolates	O
38	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	B
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	B
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	B
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	O
16	-	O
17	A961	O
18	,	O
19	E1071	O
20	-	O
21	S1072	O
22	,	O
23	E1345	O
24	-	O
25	T1346	O
26	,	O
27	and	O
28	E1419	O
29	-	O
30	G1420	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O

1	y	O
2	.	O

1	SM	B
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	B
16	1	I
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	B
23	GTPase	I
24	Ran	I
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	B
29	/	O
30	Nup214	B
31	.	O

1	Identification	O
2	of	O
3	a	O
4	spliced	O
5	gene	O
6	from	O
7	Kaposi	O
8	'	O
9	s	O
10	sarcoma	O
11	-	O
12	associated	O
13	herpesvirus	O
14	encoding	O
15	a	O
16	protein	O
17	with	O
18	similarities	O
19	to	O
20	latent	B
21	membrane	I
22	proteins	I
23	1	I
24	and	I
25	2A	I
26	of	I
27	Epstein	I
28	-	I
29	Barr	I
30	virus	I
31	.	O

1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O

1	Myosin	B
2	light	I
3	chain	I
4	kinase	I
5	functions	O
6	downstream	O
7	of	O
8	Ras	B
9	/	O
10	ERK	B
11	to	O
12	promote	O
13	migration	O
14	of	O
15	urokinase	B
16	-	I
17	type	I
18	plasminogen	I
19	activator	I
20	-	O
21	stimulated	O
22	cells	O
23	in	O
24	an	O
25	integrin	B
26	-	O
27	selective	O
28	manner	O
29	.	O

1	The	O
2	inhibition	O
3	of	O
4	StAR	B
5	gene	I
6	transcription	O
7	by	O
8	DAX	B
9	-	I
10	1	I
11	was	O
12	dose	O
13	-	O
14	dependent	O
15	reducing	O
16	transcription	O
17	to	O
18	6	O
19	%	O
20	of	O
21	control	O
22	levels	O
23	.	O

1	In	O
2	a	O
3	prospective	O
4	randomized	O
5	study	O
6	,	O
7	287	O
8	patients	O
9	with	O
10	advanced	O
11	non	O
12	-	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	(	O
18	NSCLC	O
19	)	O
20	stage	O
21	IIIb	O
22	or	O
23	IV	O
24	with	O
25	ECOG	O
26	performance	O
27	status	O
28	(	O
29	PS	O
30	)	O
31	0	O
32	-	O
33	1	O
34	or	O
35	2	O
36	were	O
37	randomly	O
38	assigned	O
39	to	O
40	receive	O
41	either	O
42	best	O
43	supportive	O
44	care	O
45	(	O
46	BSC	O
47	)	O
48	or	O
49	supportive	O
50	care	O
51	plus	O
52	combination	O
53	chemotherapy	O
54	(	O
55	IEP	O
56	regimen	O
57	:	O
58	ifosfamide	O
59	3	O
60	gm	O
61	/	O
62	m2	O
63	IV	O
64	with	O
65	mesna	O
66	uroprotection	O
67	,	O
68	epirubicin	O
69	60	O
70	mg	O
71	/	O
72	m2	O
73	IV	O
74	on	O
75	day	O
76	1	O
77	and	O
78	cisplatin	O
79	60	O
80	mg	O
81	/	O
82	m2	O
83	IV	O
84	on	O
85	day	O
86	2	O
87	;	O
88	or	O
89	MVP	O
90	regimen	O
91	:	O
92	mitomycin	O
93	-	O
94	C	O
95	8	O
96	mg	O
97	/	O
98	m2	O
99	,	O
100	cisplatin	O
101	100	O
102	mg	O
103	/	O
104	m2	O
105	IV	O
106	on	O
107	day	O
108	1	O
109	,	O
110	vinblastine	O
111	4	O
112	mg	O
113	/	O
114	m2	O
115	IV	O
116	on	O
117	days	O
118	1	O
119	and	O
120	15	O
121	).	O

1	Using	O
2	sequence	O
3	information	O
4	from	O
5	human	B
6	BMAL1	I
7	(	O
8	hBMAL1	B
9	)	O
10	cDNAs	O
11	previously	O
12	reported	O
13	by	O
14	our	O
15	laboratory	O
16	,	O
17	we	O
18	have	O
19	isolated	O
20	and	O
21	characterized	O
22	cDNAs	O
23	encoding	O
24	three	O
25	splice	O
26	variants	O
27	of	O
28	the	O
29	mouse	B
30	BMAL1	I
31	(	O
32	mBMAL1	B
33	)	O
34	gene	O
35	.	O

1	Comparison	O
2	with	O
3	the	O
4	bHLH	B
5	/	O
6	PAS	B
7	family	O
8	genes	O
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	B
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	B
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	B
31	and	O
32	Ahr	B
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	O
46	gene	O
47	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	We	O
2	were	O
3	able	O
4	to	O
5	detect	O
6	significant	O
7	differences	O
8	in	O
9	functional	O
10	residual	O
11	capacity	O
12	adjusted	O
13	for	O
14	weight	O
15	or	O
16	height	O
17	,	O
18	and	O
19	compliance	O
20	of	O
21	the	O
22	respiratory	O
23	system	O
24	adjusted	O
25	for	O
26	weight	O
27	or	O
28	lung	O
29	volume	O
30	in	O
31	the	O
32	ILD	O
33	infants	O
34	compared	O
35	to	O
36	the	O
37	healthy	O
38	controls	O
39	or	O
40	infants	O
41	who	O
42	had	O
43	PPHN	O
44	,	O
45	indicating	O
46	that	O
47	these	O
48	PFTs	O
49	were	O
50	sensitive	O
51	enough	O
52	to	O
53	determine	O
54	abnormal	O
55	lung	O
56	function	O
57	in	O
58	this	O
59	age	O
60	group	O
61	.	O

1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	B
16	retrotransposon	I
17	Tto1	I
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	describe	O
6	that	O
7	platelet	B
8	-	I
9	derived	I
10	growth	I
11	factor	I
12	(	O
13	PDGF	B
14	),	O
15	12	O
16	-	O
17	O	O
18	-	O
19	tetradecanoyl	O
20	-	O
21	phorbol	O
22	-	O
23	acetate	O
24	(	O
25	TPA	O
26	),	O
27	and	O
28	forskolin	O
29	induced	O
30	CREB	B
31	(	O
32	cAMP	B
33	-	I
34	responsive	I
35	element	I
36	-	I
37	binding	I
38	protein	I
39	)	O
40	Ser	O
41	-	O
42	133	O
43	phosphorylation	O
44	with	O
45	comparable	O
46	magnitude	O
47	and	O
48	kinetics	O
49	in	O
50	NIH	O
51	3T3	O
52	cells	O
53	.	O

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	O
10	SRC	B
11	-	I
12	1	I
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	B
20	/	O
21	RXRalpha	B
22	.	O

1	By	O
2	contrast	O
3	,	O
4	mTRAP100	B
5	coprecipitates	O
6	in	O
7	vivo	O
8	with	O
9	another	O
10	component	O
11	of	O
12	the	O
13	TRAP	B
14	complex	I
15	(	O
16	TRAP220	B
17	),	O
18	which	O
19	directly	O
20	contacts	O
21	TR	B
22	and	O
23	the	O
24	vitamin	B
25	D	I
26	receptor	I
27	in	O
28	a	O
29	ligand	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O

1	Classical	O
2	ligand	O
3	-	O
4	activated	O
5	nuclear	O
6	receptors	O
7	(	O
8	e	O
9	.	O
10	g	O
11	.	O
12	thyroid	B
13	hormone	I
14	receptor	I
15	,	O
16	retinoic	B
17	acid	I
18	receptor	I
19	),	O
20	orphan	B
21	nuclear	I
22	receptors	I
23	(	O
24	e	O
25	.	O
26	g	O
27	.	O

1	Expression	O
2	of	O
3	GlcNAc	B
4	-	I
5	TI	I
6	mRNA	I
7	in	O
8	tobacco	O
9	leaves	O
10	was	O
11	detected	O
12	using	O
13	RT	O
14	-	O
15	PCR	O
16	.	O

1	Chemical	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	H219	O
13	and	O
14	D63	O
15	of	O
16	RegS	B
17	and	O
18	RegR	B
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O

1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O

1	For	O
2	functional	O
3	studies	O
4	,	O
5	two	O
6	promoter	O
7	regions	O
8	were	O
9	cloned	O
10	upstream	O
11	of	O
12	the	O
13	reporter	O
14	gene	O
15	,	O
16	chloramphenicol	B
17	acetyl	I
18	transferase	I
19	(	O
20	CAT	B
21	):	O
22	(	O
23	i	O
24	)	O
25	phbetaE	O
26	-	O
27	B	O
28	-	O
29	the	O
30	plasmid	O
31	that	O
32	contains	O
33	the	O
34	human	O
35	(	O
36	h	O
37	)	O
38	promoter	O
39	region	O
40	(-	O
41	2832	O
42	to	O
43	+	O
44	101	O
45	)	O
46	including	O
47	URE	O
48	,	O
49	and	O
50	(	O
51	ii	O
52	)	O
53	prhbetaE	O
54	-	O
55	B	O
56	-	O
57	the	O
58	plasmid	O
59	that	O
60	contains	O
61	the	O
62	rhesus	O
63	(	O
64	rh	O
65	)	O
66	promoter	O
67	region	O
68	excluding	O
69	URE	O
70	as	O
71	it	O
72	lacks	O
73	a	O
74	270	O
75	bp	O
76	region	O
77	of	O
78	the	O
79	hbetaAPP	B
80	promoter	I
81	(-	O
82	2435	O
83	to	O
84	-	O
85	2165	O
86	).	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	G	B
2	-	I
3	CSF	I
4	(	O
5	480	O
6	micrograms	O
7	subcutaneously	O
8	(	O
9	s	O
10	.	O
11	c	O
12	.))	O
13	were	O
14	used	O
15	in	O
16	55	O
17	and	O
18	GM	B
19	-	I
20	CSF	I
21	(	O
22	400	O
23	micrograms	O
24	s	O
25	.	O
26	c	O
27	.)	O
28	in	O
29	28	O
30	chemotherapeutic	O
31	cycles	O
32	.	O

1	Overexpression	O
2	of	O
3	H411	B
4	cDNA	I
5	in	O
6	the	O
7	RAW	O
8	264	O
9	.	O
10	7	O
11	macrophage	O
12	cell	O
13	line	O
14	promoted	O
15	an	O
16	increased	O
17	growth	O
18	rate	O
19	,	O
20	suggesting	O
21	that	O
22	expression	O
23	of	O
24	H411	B
25	is	O
26	part	O
27	of	O
28	the	O
29	proliferative	O
30	cell	O
31	response	O
32	to	O
33	LPS	O
34	.	O

1	Human	O
2	expressed	O
3	sequence	O
4	tag	O
5	clones	O
6	were	O
7	identified	O
8	by	O
9	sequence	O
10	similarity	O
11	to	O
12	mammalian	B
13	and	I
14	yeast	I
15	oligosaccharide	I
16	-	I
17	processing	I
18	mannosidases	I
19	,	O
20	and	O
21	the	O
22	full	O
23	-	O
24	length	O
25	coding	O
26	region	O
27	of	O
28	the	O
29	putative	O
30	mannosidase	B
31	homolog	I
32	was	O
33	isolated	O
34	by	O
35	a	O
36	combination	O
37	of	O
38	5	O
39	'-	O
40	rapid	O
41	amplification	O
42	of	O
43	cDNA	O
44	ends	O
45	and	O
46	direct	O
47	polymerase	O
48	chain	O
49	reaction	O
50	from	O
51	human	O
52	placental	O
53	cDNA	O
54	.	O

1	Activation	O
2	of	O
3	ERK1	B
4	/	I
5	2	I
6	is	O
7	correlated	O
8	with	O
9	induction	O
10	of	O
11	the	O
12	immediate	B
13	-	I
14	early	I
15	response	I
16	genes	I
17	.	O

1	The	O
2	transcription	O
3	of	O
4	most	O
5	RP	B
6	genes	I
7	is	O
8	activated	O
9	by	O
10	two	O
11	Rap1p	B
12	binding	I
13	sites	I
14	,	O
15	250	O
16	to	O
17	400	O
18	bp	O
19	upstream	O
20	from	O
21	the	O
22	initiation	O
23	of	O
24	transcription	O
25	.	O

1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	B
11	-	I
12	10	I
13	,	O
14	cdc4	B
15	-	I
16	11	I
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	B
31	-	I
32	1	I
33	cells	O
34	.	O

1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O

1	In	O
2	summary	O
3	,	O
4	Ca	O
5	(	O
6	2	O
7	+)-	O
8	dependent	O
9	activation	O
10	of	O
11	NO	O
12	production	O
13	mediates	O
14	apoptosis	O
15	after	O
16	TG	B
17	exposure	O
18	in	O
19	JT	O
20	/	O
21	Neo	O
22	cells	O
23	.	O

1	Accumulation	O
2	of	O
3	the	O
4	U4	B
5	/	O
6	U6	B
7	duplex	O
8	was	O
9	relieved	O
10	by	O
11	overexpression	O
12	of	O
13	wild	B
14	-	I
15	type	I
16	Prp44p	I
17	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	B
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	O
25	U6	B
26	helix	O
27	.	O

1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	I
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O

1	The	O
2	mysteries	O
3	of	O
4	geographic	O
5	variability	O
6	in	O
7	nonmelanoma	O
8	skin	O
9	cancer	O
10	incidence	O
11	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	in	O
7	contrast	O
8	to	O
9	other	O
10	extracellular	O
11	matrix	O
12	molecules	O
13	pepsin	B
14	-	O
15	solubilized	O
16	collagen	B
17	VI	I
18	(	O
19	CVI	B
20	)	O
21	can	O
22	stimulate	O
23	DNA	O
24	synthesis	O
25	of	O
26	various	O
27	mesenchymal	O
28	cell	O
29	types	O
30	,	O
31	apparently	O
32	independent	O
33	of	O
34	integrin	B
35	-	O
36	mediated	O
37	signal	O
38	transduction	O
39	.	O

1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	O
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O

1	FAK	B
2	localizes	O
3	to	O
4	sites	O
5	of	O
6	transmembrane	B
7	integrin	I
8	receptor	I
9	clustering	O
10	and	O
11	facilitates	O
12	intracellular	O
13	signaling	O
14	events	O
15	.	O

1	Expression	O
2	of	O
3	various	O
4	FAK	B
5	mutants	I
6	in	O
7	the	O
8	FAK	B
9	-	O
10	cells	O
11	showed	O
12	that	O
13	FAK	B
14	kinase	I
15	activity	O
16	,	O
17	the	O
18	Tyr	B
19	-	I
20	397	I
21	/	I
22	SH2	I
23	domain	I
24	binding	I
25	site	I
26	,	O
27	and	O
28	the	O
29	first	O
30	proline	O
31	-	O
32	rich	O
33	SH3	B
34	binding	I
35	region	I
36	in	O
37	the	O
38	FAK	B
39	C	I
40	-	I
41	terminal	I
42	domain	I
43	were	O
44	individually	O
45	needed	O
46	to	O
47	promote	O
48	full	O
49	FAK	B
50	-	O
51	mediated	O
52	FAK	B
53	-	O
54	cell	O
55	migration	O
56	to	O
57	FN	B
58	whereas	O
59	direct	O
60	paxillin	B
61	binding	O
62	to	O
63	FAK	B
64	was	O
65	not	O
66	required	O
67	.	O

1	This	O
2	dominant	O
3	-	O
4	negative	O
5	effect	O
6	of	O
7	FRNK	B
8	was	O
9	reversed	O
10	by	O
11	a	O
12	point	O
13	mutation	O
14	(	O
15	Leu	O
16	-	O
17	1034	O
18	to	O
19	Ser	O
20	)	O
21	which	O
22	prevented	O
23	FRNK	B
24	localization	O
25	to	O
26	focal	O
27	contact	O
28	sites	O
29	.	O

1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	O
9	yr	O
10	)	O
11	with	O
12	doppler	O
13	-	O
14	proven	O
15	DVT	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	B
25	protein	I
26	C	I
27	(	O
28	APC	B
29	-	I
30	R	I
31	),	O
32	lupus	O
33	anticoagulant	O
34	(	O
35	LA	O
36	),	O
37	anticardiolipin	B
38	antibodies	I
39	and	O
40	deficiencies	O
41	of	O
42	protein	B
43	C	I
44	,	O
45	protein	B
46	S	I
47	,	O
48	ATIII	B
49	activities	O
50	.	O

1	DESIGN	O
2	:	O
3	Comparison	O
4	of	O
5	number	O
6	of	O
7	women	O
8	with	O
9	PKU	O
10	aged	O
11	15	O
12	-	O
13	44	O
14	years	O
15	on	O
16	the	O
17	NSW	O
18	PKU	O
19	database	O
20	(	O
21	observed	O
22	number	O
23	)	O
24	with	O
25	expected	O
26	number	O
27	derived	O
28	from	O
29	population	O
30	data	O
31	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	purposes	O
5	of	O
6	the	O
7	present	O
8	study	O
9	were	O
10	to	O
11	assess	O
12	the	O
13	effects	O
14	of	O
15	a	O
16	12	O
17	-	O
18	wk	O
19	laboratory	O
20	based	O
21	aerobic	O
22	exercise	O
23	program	O
24	on	O
25	cardiopulmonary	O
26	function	O
27	,	O
28	CD4	B
29	cell	O
30	count	O
31	,	O
32	and	O
33	physician	O
34	-	O
35	assessed	O
36	health	O
37	status	O
38	among	O
39	symptomatic	O
40	pre	O
41	-	O
42	AIDS	O
43	HIV	O
44	-	O
45	infected	O
46	individuals	O
47	(	O
48	N	O
49	=	O
50	28	O
51	)	O
52	and	O
53	to	O
54	assess	O
55	the	O
56	degree	O
57	to	O
58	which	O
59	ill	O
60	health	O
61	was	O
62	associated	O
63	with	O
64	exercise	O
65	relapse	O
66	.	O

1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	demonstrate	O
7	that	O
8	the	O
9	RP	B
10	,	O
11	like	O
12	the	O
13	20S	B
14	proteasome	I
15	,	O
16	is	O
17	functionally	O
18	and	O
19	structurally	O
20	conserved	O
21	among	O
22	eukaryotes	O
23	and	O
24	indicate	O
25	that	O
26	the	O
27	plant	B
28	RPT	I
29	subunits	I
30	,	O
31	like	O
32	their	O
33	yeast	O
34	counterparts	O
35	,	O
36	have	O
37	non	O
38	-	O
39	redundant	O
40	functions	O
41	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	elongation	O
6	activity	O
7	,	O
8	ELL	B
9	contains	O
10	a	O
11	novel	O
12	type	O
13	of	O
14	RNA	B
15	polymerase	I
16	II	I
17	interaction	I
18	domain	I
19	that	O
20	is	O
21	capable	O
22	of	O
23	repressing	O
24	polymerase	O
25	activity	O
26	in	O
27	promoter	O
28	-	O
29	specific	O
30	transcription	O
31	.	O

1	A	O
2	diagnosis	O
3	of	O
4	IgA	B
5	lambda	I
6	multiple	O
7	myeloma	O
8	with	O
9	peritoneal	O
10	involvement	O
11	was	O
12	made	O
13	.	O

1	The	O
2	radiation	O
3	burden	O
4	associated	O
5	with	O
6	the	O
7	majority	O
8	of	O
9	examinations	O
10	in	O
11	nuclear	O
12	medicine	O
13	expressed	O
14	as	O
15	the	O
16	effective	O
17	dose	O
18	is	O
19	comparable	O
20	with	O
21	the	O
22	radiation	O
23	burden	O
24	of	O
25	radiodiagnostic	O
26	examinations	O
27	,	O
28	only	O
29	after	O
30	administration	O
31	of	O
32	preparations	O
33	with	O
34	131I	O
35	,	O
36	201Tl	O
37	,	O
38	67Ga	O
39	and	O
40	111In	O
41	it	O
42	is	O
43	markedly	O
44	higher	O
45	.	O

1	Although	O
2	the	O
3	risk	O
4	of	O
5	malformation	O
6	in	O
7	children	O
8	born	O
9	after	O
10	ICSI	O
11	is	O
12	not	O
13	increased	O
14	there	O
15	is	O
16	an	O
17	increased	O
18	risk	O
19	to	O
20	transmit	O
21	genetic	O
22	abnormalities	O
23	in	O
24	case	O
25	of	O
26	NOA	O
27	(	O
28	such	O
29	as	O
30	the	O
31	rate	O
32	of	O
33	sex	O
34	chromosome	O
35	,	O
36	or	O
37	microdeletions	O
38	of	O
39	the	O
40	Y	O
41	chromosome	O
42	)	O
43	and	O
44	in	O
45	case	O
46	of	O
47	congenital	O
48	OA	O
49	(	O
50	mutations	O
51	of	O
52	the	O
53	cystic	B
54	fibrosis	I
55	gene	I
56	).	O

1	TaV	O
2	particles	O
3	have	O
4	a	O
5	buoyant	O
6	density	O
7	of	O
8	1	O
9	.	O
10	296	O
11	g	O
12	/	O
13	cm3	O
14	in	O
15	CsCl	O
16	and	O
17	consist	O
18	of	O
19	two	O
20	capsid	B
21	proteins	I
22	of	O
23	56	O
24	and	O
25	6	O
26	kDa	O
27	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	results	O
5	suggest	O
6	that	O
7	vibration	O
8	-	O
9	induced	O
10	neural	O
11	involvement	O
12	can	O
13	be	O
14	considered	O
15	neither	O
16	pure	O
17	digital	O
18	neuropathy	O
19	,	O
20	nor	O
21	definite	O
22	CTS	O
23	,	O
24	as	O
25	previously	O
26	described	O
27	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	B
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	B
7	growth	I
8	hormone	I
9	receptor	I
10	/	O
11	growth	B
12	hormone	I
13	binding	I
14	protein	I
15	gene	I
16	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	This	O
2	report	O
3	presents	O
4	state	O
5	-	O
6	specific	O
7	MMRs	O
8	for	O
9	1987	O
10	-	O
11	1996	O
12	,	O
13	focusing	O
14	on	O
15	persistent	O
16	disparities	O
17	in	O
18	maternal	O
19	mortality	O
20	between	O
21	black	O
22	and	O
23	white	O
24	women	O
25	.	O

1	Preheparin	O
2	LPL	B
3	mass	O
4	level	O
5	did	O
6	not	O
7	significantly	O
8	differ	O
9	in	O
10	individuals	O
11	from	O
12	19	O
13	to	O
14	70	O
15	years	O
16	old	O
17	,	O
18	for	O
19	both	O
20	men	O
21	and	O
22	women	O
23	.	O

1	A	O
2	decrease	O
3	in	O
4	insulin	B
5	-	O
6	induced	O
7	receptor	O
8	kinase	O
9	activity	O
10	was	O
11	observed	O
12	for	O
13	solubilized	O
14	chimeric	O
15	receptors	O
16	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	B
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	B
32	-	O
33	GAP	B
34	activity	O
35	.	O

1	Cat	B
2	proteins	I
3	are	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	when	O
8	co	O
9	-	O
10	expressed	O
11	in	O
12	cells	O
13	with	O
14	the	O
15	focal	B
16	adhesion	I
17	kinase	I
18	Fak	I
19	and	O
20	Src	B
21	.	O

1	Immunoprecipitation	O
2	experiments	O
3	using	O
4	DokR	B
5	-	I
6	specific	I
7	antibodies	I
8	revealed	O
9	an	O
10	interaction	O
11	between	O
12	endogenous	B
13	DokR	I
14	and	O
15	a	O
16	150	O
17	-	O
18	kDa	O
19	protein	O
20	that	O
21	is	O
22	tyrosine	O
23	-	O
24	phosphorylated	O
25	in	O
26	EGF	B
27	-	O
28	stimulated	O
29	BaF	O
30	/	O
31	3	O
32	cells	O
33	.	O

1	Expansins	B
2	are	O
3	a	O
4	family	O
5	of	O
6	proteins	O
7	that	O
8	catalyse	O
9	long	O
10	-	O
11	term	O
12	extension	O
13	of	O
14	isolated	O
15	plant	O
16	cell	O
17	walls	O
18	due	O
19	to	O
20	an	O
21	as	O
22	yet	O
23	unknown	O
24	biochemical	O
25	mechanism	O
26	.	O

1	This	O
2	review	O
3	summarizes	O
4	the	O
5	clinical	O
6	evidence	O
7	to	O
8	support	O
9	current	O
10	therapies	O
11	in	O
12	irritable	O
13	bowel	O
14	syndrome	O
15	(	O
16	IBS	O
17	).	O

1	The	O
2	responsive	O
3	region	O
4	of	O
5	the	O
6	alpha	B
7	2	I
8	(	I
9	V	I
10	)	I
11	collagen	I
12	gene	I
13	was	O
14	localized	O
15	to	O
16	a	O
17	fragment	O
18	including	O
19	100	O
20	bp	O
21	of	O
22	basal	O
23	promoter	O
24	and	O
25	150	O
26	bp	O
27	of	O
28	exon	O
29	1	O
30	sequences	O
31	,	O
32	which	O
33	contained	O
34	two	O
35	CRE	O
36	-	O
37	like	O
38	elements	O
39	.	O

1	Furthermore	O
2	,	O
3	addition	O
4	of	O
5	B	B
6	-	I
7	Myb	I
8	-	O
9	glutathionine	B
10	S	I
11	-	I
12	transferase	I
13	fusion	O
14	protein	O
15	inhibited	O
16	complex	O
17	formation	O
18	.	O

1	APOE	B
2	-	O
3	epsilon4	O
4	count	O
5	predicts	O
6	age	O
7	when	O
8	prevalence	O
9	of	O
10	AD	O
11	increases	O
12	,	O
13	then	O
14	declines	O
15	:	O
16	the	O
17	Cache	O
18	County	O
19	Study	O
20	.	O

1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	A	O
2	new	O
3	DNA	B
4	repair	I
5	gene	I
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	RecA	B
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O

1	Among	O
2	mucus	O
3	-	O
4	secreting	O
5	cells	O
6	,	O
7	the	O
8	gastric	O
9	gland	O
10	mucous	O
11	cells	O
12	,	O
13	Brunner	O
14	'	O
15	s	O
16	glands	O
17	,	O
18	accessory	O
19	glands	O
20	of	O
21	pancreaticobiliary	O
22	tract	O
23	,	O
24	and	O
25	pancreatic	O
26	ducts	O
27	exhibiting	O
28	gastric	O
29	metaplasia	O
30	are	O
31	unique	O
32	in	O
33	that	O
34	they	O
35	express	O
36	class	B
37	III	I
38	mucin	I
39	identified	O
40	by	O
41	paradoxical	O
42	Con	B
43	A	I
44	staining	O
45	composed	O
46	of	O
47	periodate	O
48	oxidation	O
49	,	O
50	sodium	O
51	borohydride	O
52	reduction	O
53	,	O
54	Con	B
55	A	I
56	,	O
57	and	O
58	horseradish	B
59	peroxidase	I
60	reaction	O
61	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O

1	Thus	O
2	,	O
3	elongin	B
4	C	I
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	The	O
2	data	O
3	imply	O
4	that	O
5	JAK	B
6	/	O
7	STAT	B
8	signaling	O
9	has	O
10	a	O
11	role	O
12	in	O
13	EBV	O
14	-	O
15	associated	O
16	malignancies	O
17	.	O

1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O

1	A	O
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O

1	Spfkh1	B
2	is	O
3	transcribed	O
4	in	O
5	one	O
6	open	O
7	reading	O
8	frame	O
9	that	O
10	contains	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	,	O
16	nuclear	O
17	localization	O
18	signal	O
19	and	O
20	transactivation	O
21	domain	O
22	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	Gel	O
2	filtration	O
3	and	O
4	co	O
5	-	O
6	immunoprecipitation	O
7	analyses	O
8	reveal	O
9	that	O
10	Mad2p	B
11	tightly	O
12	associates	O
13	with	O
14	another	O
15	spindle	O
16	checkpoint	O
17	component	O
18	,	O
19	Mad1p	B
20	.	O

1	METHODS	O
2	:	O
3	109	O
4	suspected	O
5	cases	O
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	-	I
7	1	I
8	(	I
9	HIV	I
10	-	I
11	1	I
12	)	I
13	Tat	I
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	O
22	.	O

1	One	O
2	of	O
3	these	O
4	SEBPs	B
5	,	O
6	SEBP2	B
7	,	O
8	was	O
9	shown	O
10	to	O
11	be	O
12	the	O
13	product	O
14	of	O
15	the	O
16	homeotic	B
17	gene	I
18	fork	I
19	head	I
20	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	B
27	(	I
28	Asp	I
29	)	I
30	and	O
31	tRNA	B
32	(	I
33	Phe	I
34	)	I
35	from	O
36	yeast	O
37	.	O

1	In	O
2	insulin	B
3	-	O
4	responsive	O
5	cells	O
6	,	O
7	Akt	B
8	phosphorylates	O
9	and	O
10	inactivates	O
11	the	O
12	serine	B
13	/	I
14	threonine	I
15	kinase	I
16	glycogen	I
17	synthase	I
18	kinase	I
19	-	I
20	3	I
21	(	O
22	GSK	B
23	-	I
24	3	I
25	).	O

1	The	O
2	B	B
3	cell	I
4	antigen	I
5	receptor	I
6	activates	O
7	the	O
8	Akt	B
9	(	O
10	protein	B
11	kinase	I
12	B	I
13	)/	O
14	glycogen	B
15	synthase	I
16	kinase	I
17	-	I
18	3	I
19	signaling	O
20	pathway	O
21	via	O
22	phosphatidylinositol	B
23	3	I
24	-	I
25	kinase	I
26	.	O

1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	B
8	-	I
9	34	I
10	transcript	I
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	To	O
2	determine	O
3	what	O
4	role	O
5	eIF4E	B
6	might	O
7	play	O
8	in	O
9	c	B
10	-	I
11	myc	I
12	expression	O
13	,	O
14	the	O
15	c	B
16	-	I
17	myc	I
18	5	I
19	'	I
20	untranslated	I
21	region	I
22	(	I
23	UTR	I
24	)	I
25	was	O
26	fused	O
27	in	O
28	-	O
29	frame	O
30	to	O
31	CAT	B
32	reporters	I
33	,	O
34	and	O
35	several	O
36	more	O
37	derivative	O
38	constructs	O
39	were	O
40	made	O
41	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	RESULTS	O
2	:	O
3	Circulating	O
4	leptin	B
5	concentrations	O
6	in	O
7	AN	O
8	were	O
9	3	O
10	.	O
11	5	O
12	+/-	O
13	0	O
14	.	O
15	5	O
16	versus	O
17	7	O
18	.	O
19	6	O
20	+/-	O
21	1	O
22	.	O
23	2	O
24	ng	O
25	/	O
26	ml	O
27	in	O
28	control	O
29	subjects	O
30	.	O

1	Copyright	O
2	1999	O
3	Academic	O
4	Press	O
5	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	PKNbeta	B
2	had	O
3	high	O
4	sequence	O
5	homology	O
6	with	O
7	PKNalpha	B
8	,	O
9	originally	O
10	isolated	O
11	PKN	B
12	,	O
13	especially	O
14	in	O
15	the	O
16	repeats	O
17	of	O
18	charged	O
19	amino	O
20	acid	O
21	-	O
22	rich	O
23	region	O
24	with	O
25	leucine	O
26	-	O
27	zipper	O
28	like	O
29	sequences	O
30	(	O
31	CZ	O
32	region	O
33	/	O
34	HR1	O
35	),	O
36	in	O
37	the	O
38	carboxyl	O
39	-	O
40	terminal	O
41	catalytic	O
42	domain	O
43	,	O
44	and	O
45	in	O
46	approximately	O
47	130	O
48	amino	O
49	acid	O
50	stretch	O
51	(	O
52	D	O
53	region	O
54	/	O
55	HR2	O
56	),	O
57	located	O
58	between	O
59	CZ	O
60	region	O
61	/	O
62	HR1	O
63	and	O
64	the	O
65	catalytic	O
66	domain	O
67	.	O

1	At	O
2	baseline	O
3	,	O
4	serum	O
5	levels	O
6	of	O
7	lycopene	O
8	and	O
9	FLOP	O
10	were	O
11	abnormally	O
12	high	O
13	and	O
14	serum	O
15	FLOP	O
16	was	O
17	correlated	O
18	significantly	O
19	with	O
20	plasma	O
21	cyclosporine	O
22	levels	O
23	(	O
24	r	O
25	=	O
26	0	O
27	.	O
28	646	O
29	,	O
30	p	O
31	=	O
32	0	O
33	.	O
34	016	O
35	).	O

1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O

1	Interestingly	O
2	,	O
3	following	O
4	induction	O
5	of	O
6	stress	O
7	by	O
8	heat	O
9	shock	O
10	,	O
11	high	O
12	salt	O
13	,	O
14	or	O
15	ethanol	O
16	,	O
17	conditions	O
18	under	O
19	which	O
20	most	O
21	mRNA	O
22	export	O
23	is	O
24	blocked	O
25	,	O
26	Npl3p	B
27	is	O
28	still	O
29	exported	O
30	from	O
31	the	O
32	nucleus	O
33	.	O

1	For	O
2	symptomatic	O
3	relief	O
4	and	O
5	inhibition	O
6	of	O
7	the	O
8	growth	O
9	of	O
10	the	O
11	metastases	O
12	interferon	B
13	-	I
14	a	I
15	and	O
16	somatostatin	B
17	analogues	O
18	can	O
19	be	O
20	employed	O
21	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O

1	Some	O
2	of	O
3	them	O
4	produce	O
5	gigantic	O
6	sperm	O
7	several	O
8	times	O
9	the	O
10	total	O
11	male	O
12	body	O
13	length	O
14	.	O

1	John	O
2	leonard	O
3	dawson	O

1	PDGF	B
2	A	I
3	-	I
4	chain	I
5	levels	O
6	increase	O
7	in	O
8	cultured	O
9	vascular	O
10	smooth	O
11	muscle	O
12	cells	O
13	(	O
14	SMCs	O
15	)	O
16	exposed	O
17	to	O
18	ATII	B
19	.	O

1	M	B
2	-	I
3	Ras	I
4	interacted	O
5	poorly	O
6	in	O
7	a	O
8	yeast	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	with	O
14	multiple	O
15	Ras	B
16	effectors	O
17	,	O
18	including	O
19	c	B
20	-	I
21	Raf	I
22	-	I
23	1	I
24	,	O
25	A	B
26	-	I
27	Raf	I
28	,	O
29	B	B
30	-	I
31	Raf	I
32	,	O
33	phosphoinositol	B
34	-	I
35	3	I
36	kinase	I
37	delta	I
38	,	O
39	RalGDS	B
40	,	O
41	and	O
42	Rin1	B
43	.	O

1	Deletion	O
2	mapping	O
3	of	O
4	the	O
5	human	B
6	presenilin	I
7	-	I
8	1	I
9	(	O
10	PS1	B
11	)	O
12	promoter	O
13	delineated	O
14	the	O
15	most	O
16	active	O
17	fragment	O
18	from	O
19	-	O
20	118	O
21	to	O
22	+	O
23	178	O
24	in	O
25	relation	O
26	to	O
27	the	O
28	transcription	O
29	start	O
30	site	O
31	mapped	O
32	in	O
33	this	O
34	study	O
35	,	O
36	in	O
37	both	O
38	human	O
39	neuroblastoma	O
40	SK	O
41	-	O
42	N	O
43	-	O
44	SH	O
45	and	O
46	hepatoma	O
47	HepG2	O
48	cells	O
49	.	O

1	Microcirculatory	O
2	oxygenation	O
3	and	O
4	shunting	O
5	in	O
6	sepsis	O
7	and	O
8	shock	O
9	.	O

1	Analysis	O
2	of	O
3	the	O
4	E2F1	B
5	gene	I
6	promoter	I
7	showed	O
8	that	O
9	the	O
10	-	O
11	146	O
12	to	O
13	-	O
14	54	O
15	region	O
16	was	O
17	required	O
18	for	O
19	E2	B
20	-	O
21	responsiveness	O
22	in	O
23	transient	O
24	transfection	O
25	assays	O
26	,	O
27	and	O
28	subsequent	O
29	deletion	O
30	/	O
31	mutation	O
32	analysis	O
33	showed	O
34	that	O
35	a	O
36	single	O
37	upstream	O
38	GC	O
39	-	O
40	rich	O
41	and	O
42	two	O
43	downstream	O
44	CCAAT	O
45	-	O
46	binding	O
47	sites	O
48	were	O
49	required	O
50	for	O
51	transactivation	O
52	by	O
53	E2	B
54	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	investigating	O
6	the	O
7	mechanisms	O
8	by	O
9	which	O
10	OF5	B
11	and	O
12	OF3	B
13	regulated	O
14	CYP11A1	B
15	transcription	O
16	,	O
17	we	O
18	found	O
19	that	O
20	OF5	B
21	and	O
22	OF3	B
23	bound	O
24	Sp1	B
25	and	O
26	Sp3	B
27	in	O
28	JEG	O
29	-	O
30	3	O
31	cells	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	differentiation	O
6	of	O
7	neoplastically	O
8	transformed	O
9	cells	O
10	does	O
11	not	O
12	repress	O
13	mitogenic	O
14	responsiveness	O
15	or	O
16	junB	B
17	or	O
18	c	B
19	-	I
20	fos	I
21	inducibility	O
22	.	O

1	Adipocyte	O
2	differentiation	O
3	of	O
4	nontransformed	O
5	cells	O
6	also	O
7	markedly	O
8	represses	O
9	the	O
10	ability	O
11	of	O
12	SRF	B
13	to	O
14	bind	O
15	to	O
16	the	O
17	junB	B
18	SRE	O
19	,	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	SRE	O
25	,	O
26	and	O
27	other	O
28	SREs	O
29	,	O
30	as	O
31	determined	O
32	by	O
33	mobility	O
34	shift	O
35	and	O
36	gel	O
37	supershift	O
38	assays	O
39	,	O
40	without	O
41	affecting	O
42	the	O
43	DNA	O
44	binding	O
45	characteristics	O
46	of	O
47	the	O
48	nuclear	O
49	protein	O
50	SP	O
51	-	O
52	1	O
53	.	O

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	B
9	response	I
10	factor	I
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	The	O
2	core	B
3	enzyme	I
4	is	O
5	homologous	O
6	to	O
7	those	O
8	of	O
9	bacteriophages	O
10	T3	O
11	,	O
12	T7	O
13	and	O
14	SP6	O
15	whereas	O
16	the	O
17	specificity	O
18	factor	O
19	shows	O
20	similarities	O
21	with	O
22	bacterial	B
23	sigma	I
24	factors	I
25	.	O

1	The	O
2	Cr	B
3	.	I
4	psbA	I
5	-	I
6	4	I
7	ORF	I
8	contains	O
9	an	O
10	H	O
11	-	O
12	N	O
13	-	O
14	H	O
15	motif	O
16	,	O
17	and	O
18	possibly	O
19	a	O
20	GIY	O
21	-	O
22	YIG	O
23	motif	O
24	.	O

1	The	O
2	interaction	O
3	of	O
4	zf4	B
5	-	I
6	6	I
7	with	O
8	full	B
9	-	I
10	length	I
11	5	I
12	S	I
13	RNA	I
14	was	O
15	far	O
16	more	O
17	sensitive	O
18	to	O
19	non	O
20	-	O
21	specific	O
22	competitor	O
23	concentration	O
24	than	O
25	was	O
26	the	O
27	zf4	B
28	-	I
29	7	I
30	:	O
31	5	B
32	S	I
33	RNA	I
34	interaction	O
35	,	O
36	suggesting	O
37	that	O
38	finger	O
39	seven	O
40	contributes	O
41	to	O
42	both	O
43	affinity	O
44	and	O
45	specificity	O
46	in	O
47	this	O
48	protein	O
49	:	O
50	RNA	O
51	interaction	O
52	.	O

1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	The	O
2	role	O
3	of	O
4	'	O
5	scientific	O
6	psychiatry	O
7	'	O
8	in	O
9	understanding	O
10	patients	O
11	with	O
12	chronic	O
13	schizophrenia	O
14	or	O
15	severe	O
16	personality	O
17	disorder	O
18	.	O

1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	B
6	,	O
7	glutathione	B
8	peroxidase	I
9	and	O
10	superoxide	B
11	dismutase	I
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O

1	The	O
2	second	O
3	goal	O
4	was	O
5	to	O
6	ascertain	O
7	the	O
8	somatotopic	O
9	arrangement	O
10	of	O
11	the	O
12	GPi	O
13	in	O
14	PD	O
15	.	O

1	These	O
2	overall	O
3	results	O
4	indicate	O
5	that	O
6	there	O
7	is	O
8	generally	O
9	one	O
10	PERV	O
11	copy	O
12	per	O
13	integration	O
14	site	O
15	.	O

1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O

1	Patients	O
2	were	O
3	assessed	O
4	for	O
5	cardiac	O
6	MIBG	O
7	uptake	O
8	,	O
9	circulating	O
10	norepinephrine	O
11	concentration	O
12	,	O
13	LVEF	O
14	,	O
15	peak	O
16	Vo2	O
17	,	O
18	x	O
19	-	O
20	ray	O
21	cardiothoracic	O
22	ratio	O
23	,	O
24	M	O
25	-	O
26	mode	O
27	echographic	O
28	end	O
29	-	O
30	diastolic	O
31	diameter	O
32	and	O
33	right	O
34	-	O
35	sided	O
36	heart	O
37	catheterization	O
38	parameters	O
39	.	O

1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O

1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O

1	Sequencing	O
2	of	O
3	zebrafish	O
4	(	O
5	Danio	O
6	rerio	O
7	)	O
8	bacterial	O
9	artificial	O
10	chromosome	O
11	and	O
12	P1	O
13	artificial	O
14	chromosome	O
15	genomic	O
16	clone	O
17	fragments	O
18	and	O
19	of	O
20	cDNA	O
21	clones	O
22	has	O
23	led	O
24	to	O
25	the	O
26	identification	O
27	of	O
28	five	O
29	new	O
30	loci	O
31	coding	O
32	for	O
33	beta	O
34	subunits	O
35	of	O
36	proteasomes	O
37	(	O
38	PSMB	B
39	).	O

1	In	O
2	addition	O
3	to	O
4	homologues	O
5	of	O
6	the	O
7	human	B
8	genes	I
9	PSMB5	I
10	through	O
11	PSMB9	B
12	,	O
13	two	O
14	new	O
15	genes	O
16	,	O
17	PSMB11	B
18	and	O
19	PSMB12	B
20	,	O
21	have	O
22	been	O
23	found	O
24	for	O
25	which	O
26	there	O
27	are	O
28	no	O
29	known	O
30	corresponding	O
31	genes	O
32	in	O
33	humans	O
34	.	O

1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O

1	Weight	O
2	and	O
3	height	O
4	z	O
5	-	O
6	scores	O
7	were	O
8	significantly	O
9	associated	O
10	with	O
11	BMD	O
12	z	O
13	-	O
14	scores	O
15	.	O

1	A	O
2	limited	O
3	sampling	O
4	strategy	O
5	was	O
6	used	O
7	based	O
8	on	O
9	a	O
10	bayesian	O
11	parameter	O
12	estimation	O
13	algorithm	O
14	that	O
15	is	O
16	part	O
17	of	O
18	the	O
19	ADAPT	O
20	II	O
21	software	O
22	package	O
23	.	O

1	Interaction	O
2	of	O
3	HRI	B
4	with	O
5	Hsc70	B
6	was	O
7	required	O
8	for	O
9	the	O
10	transformation	O
11	of	O
12	HRI	B
13	,	O
14	as	O
15	the	O
16	Hsc70	B
17	antagonist	O
18	clofibric	O
19	acid	O
20	inhibited	O
21	the	O
22	folding	O
23	of	O
24	HRI	B
25	into	O
26	a	O
27	mature	O
28	-	O
29	competent	O
30	conformation	O
31	.	O

1	The	O
2	amino	O
3	acid	O
4	changes	O
5	D206A	O
6	and	O
7	D208A	O
8	abolish	O
9	singly	O
10	or	O
11	in	O
12	combination	O
13	the	O
14	exonuclease	O
15	activity	O
16	in	O
17	vivo	O
18	.	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	B
8	might	O
9	target	O
10	Glc7	B
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	I
19	complex	I
20	.	O

1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	replicators	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	O
36	HML	B
37	locus	I
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	for	O
7	the	O
8	HML	B
9	ARS	O
10	cluster	O
11	(	O
12	ARS303	B
13	,	O
14	ARS320	B
15	,	O
16	and	O
17	ARS302	B
18	),	O
19	inactivity	O
20	of	O
21	origins	O
22	is	O
23	independent	O
24	of	O
25	local	O
26	transcriptional	O
27	silencing	O
28	,	O
29	even	O
30	though	O
31	origins	O
32	and	O
33	silencers	O
34	share	O
35	key	O
36	cis	O
37	-	O
38	and	O
39	trans	O
40	-	O
41	acting	O
42	components	O
43	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	expression	O
10	of	O
11	TD	B
12	-	I
13	IkappaBalpha	I
14	blocked	O
15	phorbol	O
16	myristate	O
17	acetate	B
18	-	I
19	phytohemagglutinin	I
20	or	O
21	tumor	B
22	necrosis	I
23	factor	I
24	alpha	I
25	-	O
26	induced	O
27	IkappaBalpha	B
28	gene	I
29	transcription	O
30	and	O
31	abolished	O
32	NF	B
33	-	I
34	kappaB	I
35	DNA	O
36	binding	O
37	activity	O
38	,	O
39	due	O
40	to	O
41	the	O
42	continued	O
43	cytoplasmic	O
44	sequestration	O
45	of	O
46	RelA	B
47	(	O
48	p65	B
49	)	O
50	by	O
51	TD	B
52	-	I
53	IkappaBalpha	I
54	.	O

1	(	O
2	i	O
3	)	O
4	Complete	O
5	Grb10	B
6	expression	O
7	from	O
8	cDNA	O
9	with	O
10	an	O
11	ecdysone	O
12	-	O
13	regulated	O
14	transient	O
15	expression	O
16	system	O
17	stimulated	O
18	PDGF	B
19	-	I
20	BB	I
21	-,	O
22	IGF	B
23	-	I
24	I	I
25	,	O
26	and	O
27	insulin	B
28	-	O
29	but	O
30	not	O
31	epidermal	B
32	growth	I
33	factor	I
34	(	O
35	EGF	B
36	)-	O
37	induced	O
38	DNA	O
39	synthesis	O
40	in	O
41	an	O
42	ecdysone	O
43	dose	O
44	-	O
45	responsive	O
46	fashion	O
47	.	O

1	The	O
2	analysis	O
3	of	O
4	two	O
5	distinct	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	pathways	O
12	shows	O
13	that	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	-	O
20	Jun	B
21	N	I
22	-	I
23	terminal	I
24	kinase	I
25	activation	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	phosphorylation	O
31	of	O
32	ATF	B
33	-	I
34	2	I
35	,	O
36	c	B
37	-	I
38	Jun	I
39	,	O
40	and	O
41	JunD	B
42	,	O
43	is	O
44	required	O
45	not	O
46	only	O
47	for	O
48	the	O
49	IL	B
50	-	I
51	1	I
52	-	O
53	but	O
54	also	O
55	for	O
56	the	O
57	TPA	O
58	-	O
59	dependent	O
60	induction	O
61	,	O
62	while	O
63	the	O
64	extracellular	B
65	signal	I
66	-	I
67	related	I
68	kinase	I
69	1	I
70	(	O
71	ERK	B
72	-	I
73	1	I
74	)	O
75	and	O
76	ERK	B
77	-	I
78	2	I
79	activation	O
80	is	O
81	involved	O
82	in	O
83	the	O
84	TPA	O
85	-	O
86	but	O
87	not	O
88	in	O
89	the	O
90	IL	B
91	-	I
92	1	I
93	-	O
94	dependent	O
95	stimulation	O
96	of	O
97	the	O
98	uPA	B
99	enhancer	I
100	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	healthy	O
5	individuals	O
6	,	O
7	whole	O
8	body	O
9	insulin	B
10	sensitivity	O
11	is	O
12	related	O
13	,	O
14	or	O
15	"	O
16	coupled	O
17	,	O
18	"	O
19	to	O
20	the	O
21	anaerobic	O
22	threshold	O
23	.	O

1	Interdomain	O
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	B
12	glucocorticoid	I
13	receptor	I
14	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	xtRNA	B
6	(	O
7	Sec	B
8	)	O
9	gene	O
10	needs	O
11	the	O
12	binding	O
13	of	O
14	the	O
15	seven	O
16	Staf	B
17	zinc	I
18	fingers	I
19	,	O
20	but	O
21	not	O
22	Oct	B
23	-	I
24	1	I
25	,	O
26	for	O
27	optimal	O
28	transcriptional	O
29	capacity	O
30	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	show	O
6	that	O
7	the	O
8	differential	O
9	utilization	O
10	of	O
11	Staf	B
12	zinc	I
13	finger	I
14	1	I
15	represents	O
16	a	O
17	new	O
18	,	O
19	critical	O
20	determinant	O
21	of	O
22	the	O
23	transcriptional	O
24	activation	O
25	mechanism	O
26	for	O
27	the	O
28	Xenopus	B
29	tRNA	I
30	(	O
31	Sec	B
32	)	O
33	and	O
34	human	B
35	U6	I
36	snRNA	I
37	genes	I
38	.	O

1	In	O
2	B	O
3	cells	O
4	,	O
5	HEF1	B
6	is	O
7	phosphorylated	O
8	by	O
9	a	O
10	cytoskeleton	O
11	-	O
12	dependent	O
13	mechanism	O
14	that	O
15	is	O
16	triggered	O
17	by	O
18	integrin	B
19	ligation	O
20	.	O

1	The	O
2	calcitonin	B
3	-	O
4	induced	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	HEF1	B
9	increased	O
10	in	O
11	a	O
12	time	O
13	-	O
14	and	O
15	dose	O
16	-	O
17	dependent	O
18	manner	O
19	.	O

1	Independent	O
2	protrudor	O
3	muscle	O
4	stimulation	O
5	increased	O
6	VI	O
7	,	O
8	max	O
9	(	O
10	peak	O
11	increase	O
12	61	O
13	%,	O
14	P	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	did	O
21	not	O
22	change	O
23	Pcrit	O
24	,	O
25	and	O
26	decreased	O
27	Rn	O
28	(	O
29	peak	O
30	decrease	O
31	of	O
32	41	O
33	%,	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O

1	We	O
2	report	O
3	the	O
4	construction	O
5	of	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	7	O
11	-	O
12	Mb	O
13	sequence	O
14	-	O
15	ready	O
16	YAC	O
17	/	O
18	BAC	O
19	clone	O
20	contig	O
21	of	O
22	8p22	O
23	-	O
24	p23	O
25	.	O

1	The	O
2	human	B
3	RAD30B	I
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	Analysis	O
2	of	O
3	the	O
4	mouse	B
5	STAP	I
6	gene	I
7	isolated	O
8	from	O
9	the	O
10	genomic	O
11	library	O
12	revealed	O
13	that	O
14	the	O
15	STAP	B
16	gene	I
17	spans	O
18	a	O
19	region	O
20	of	O
21	over	O
22	11	O
23	kb	O
24	and	O
25	comprises	O
26	eight	O
27	exons	O
28	.	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	O
9	were	O
10	observed	O
11	as	O
12	the	O
13	biofilm	O
14	aged	O
15	.	O

1	After	O
2	10	O
3	months	O
4	of	O
5	treatment	O
6	with	O
7	the	O
8	conjugated	O
9	estrogen	O
10	,	O
11	both	O
12	his	O
13	height	O
14	and	O
15	weight	O
16	showed	O
17	improvement	O
18	,	O
19	while	O
20	his	O
21	bone	O
22	mineral	O
23	density	O
24	and	O
25	bone	O
26	age	O
27	were	O
28	increased	O
29	.	O

1	Viscosity	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	O
7	kinase	O
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	phosphoryl	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O

1	Velocity	O
2	sedimentation	O
3	,	O
4	cross	O
5	-	O
6	linking	O
7	,	O
8	and	O
9	immunoprecipitation	O
10	analyses	O
11	of	O
12	detergent	O
13	-	O
14	solubilized	O
15	rat	O
16	brain	O
17	revealed	O
18	that	O
19	the	O
20	32	O
21	and	O
22	34	O
23	kDa	O
24	polypeptides	O
25	reside	O
26	within	O
27	heterotetramers	O
28	.	O

1	In	O
2	vitro	O
3	expression	O
4	levels	O
5	of	O
6	the	O
7	different	O
8	plasmids	O
9	differed	O
10	by	O
11	as	O
12	much	O
13	as	O
14	tenfold	O
15	.	O

1	In	O
2	EEG	O
3	only	O
4	single	O
5	slow	O
6	waves	O
7	above	O
8	left	O
9	temporal	O
10	region	O
11	were	O
12	revealed	O
13	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	type	O
5	-	O
6	specific	O
7	capsular	O
8	polysaccharide	O
9	biosynthesis	O
10	genes	O
11	of	O
12	Streptococcus	O
13	agalactiae	O
14	type	O
15	Ia	O
16	.	O

1	(	O
2	1998	O
3	)	O
4	FASEB	O
5	J	O
6	.	O

1	IL	B
2	-	I
3	1beta	I
4	(	O
5	10	O
6	ng	O
7	/	O
8	ml	O
9	)	O
10	drastically	O
11	increased	O
12	both	O
13	PDGFalphaR	B
14	and	O
15	CCAAT	B
16	/	I
17	enhancer	I
18	-	I
19	binding	I
20	protein	I
21	delta	I
22	(	O
23	C	B
24	/	I
25	EBPdelta	I
26	)	O
27	mRNA	O
28	levels	O
29	in	O
30	a	O
31	time	O
32	dependent	O
33	manner	O
34	.	O

1	The	O
2	recruitment	O
3	of	O
4	constitutively	O
5	phosphorylated	O
6	p185	B
7	(	O
8	neu	B
9	)	O
10	and	O
11	the	O
12	activated	O
13	mitogenic	O
14	pathway	O
15	proteins	O
16	to	O
17	this	O
18	membrane	O
19	-	O
20	microfilament	O
21	interaction	O
22	site	O
23	provides	O
24	a	O
25	physical	O
26	model	O
27	for	O
28	integrating	O
29	the	O
30	assembly	O
31	of	O
32	the	O
33	mitogenic	O
34	pathway	O
35	with	O
36	the	O
37	transmission	O
38	of	O
39	growth	O
40	factor	O
41	signal	O
42	to	O
43	the	O
44	cytoskeleton	O
45	.	O

1	Transient	O
2	tyrosine	O
3	phosphorylation	O
4	of	O
5	Crk	B
6	in	O
7	fibroblast	B
8	growth	I
9	factor	I
10	-	I
11	2	I
12	-	O
13	stimulated	O
14	endothelial	O
15	cells	O
16	was	O
17	dependent	O
18	on	O
19	the	O
20	juxtamembrane	O
21	tyrosine	O
22	residue	O
23	463	O
24	in	O
25	FGFR	B
26	-	I
27	1	I
28	,	O
29	and	O
30	a	O
31	Crk	B
32	SH2	I
33	domain	I
34	precipitated	O
35	FGFR	B
36	-	I
37	1	I
38	via	O
39	phosphorylated	O
40	Tyr	O
41	-	O
42	463	O
43	,	O
44	indicating	O
45	direct	O
46	complex	O
47	formation	O
48	between	O
49	Crk	B
50	and	O
51	FGFR	B
52	-	I
53	1	I
54	.	O

1	ECG	O
2	-	O
3	gated	O
4	myocardial	O
5	Technetium	O
6	-	O
7	99m	O
8	sestamibi	O
9	SPECT	O
10	is	O
11	a	O
12	useful	O
13	technique	O
14	to	O
15	measure	O
16	myocardial	O
17	perfusion	O
18	and	O
19	function	O
20	simultaneously	O
21	.	O

1	Role	O
2	of	O
3	the	O
4	3	O
5	'	O
6	untranslated	O
7	region	O
8	of	O
9	baculovirus	B
10	p10	I
11	mRNA	I
12	in	O
13	high	O
14	-	O
15	level	O
16	expression	O
17	of	O
18	foreign	O
19	genes	O
20	.	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	The	O
2	intron	O
3	is	O
4	capable	O
5	of	O
6	splicing	O
7	despite	O
8	the	O
9	fact	O
10	that	O
11	both	O
12	the	O
13	EBS1	B
14	/	O
15	IBS1	B
16	and	O
17	the	O
18	EBS2	B
19	/	O
20	IBS2	B
21	sequence	O
22	motifs	O
23	,	O
24	thought	O
25	to	O
26	be	O
27	necessary	O
28	for	O
29	correct	O
30	splicing	O
31	,	O
32	extend	O
33	over	O
34	5	O
35	instead	O
36	of	O
37	6	O
38	bp	O
39	.	O

1	The	O
2	Trk	B
3	/	I
4	Nerve	I
5	Growth	I
6	Factor	I
7	receptor	I
8	mediates	O
9	the	O
10	rapid	O
11	activation	O
12	of	O
13	a	O
14	number	O
15	of	O
16	intracellular	O
17	signaling	O
18	proteins	O
19	,	O
20	including	O
21	phosphatidylinositol	B
22	3	I
23	-	I
24	kinase	I
25	(	O
26	PI	B
27	3	I
28	-	I
29	kinase	I
30	).	O

1	The	O
2	controversy	O
3	of	O
4	significance	O
5	testing	O
6	:	O
7	misconceptions	O
8	and	O
9	alternatives	O
10	.	O

1	Chemical	O
2	uptake	O
3	into	O
4	human	O
5	stratum	O
6	corneum	O
7	in	O
8	vivo	O
9	from	O
10	volatile	O
11	and	O
12	non	O
13	-	O
14	volatile	O
15	solvents	O
16	.	O

1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O

1	We	O
2	have	O
3	tested	O
4	the	O
5	function	O
6	of	O
7	two	O
8	potential	O
9	NF	B
10	-	I
11	kappaB	I
12	-	I
13	like	I
14	sites	I
15	present	O
16	in	O
17	the	O
18	PAI	B
19	-	I
20	2	I
21	proximal	I
22	promoter	I
23	for	O
24	responsiveness	O
25	to	O
26	TNFalpha	B
27	using	O
28	chloramphenicol	B
29	acetyl	I
30	transferase	I
31	reporter	I
32	gene	I
33	deletion	O
34	and	O
35	mutation	O
36	analyses	O
37	.	O

1	N	O
2	-	O
3	terminal	O
4	sequence	O
5	analysis	O
6	and	O
7	NMR	O
8	measurements	O
9	revealed	O
10	that	O
11	this	O
12	fragment	O
13	originates	O
14	from	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	80	O
20	residues	O
21	of	O
22	MBF1	B
23	and	O
24	form	O
25	a	O
26	well	O
27	structured	O
28	C	O
29	-	O
30	terminal	O
31	domain	O
32	of	O
33	MBF1	B
34	,	O
35	MBF1CTD	B
36	.	O

1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	I
9	gene	I
10	induction	O
11	is	O
12	mediated	O
13	via	O
14	alternative	O
15	MAP	B
16	kinase	I
17	cascades	I
18	:	O
19	MSK1	B
20	as	O
21	a	O
22	potential	O
23	histone	B
24	H3	I
25	/	O
26	HMG	B
27	-	I
28	14	I
29	kinase	O
30	.	O

1	The	O
2	arrangement	O
3	of	O
4	these	O
5	cutoff	O
6	-	O
7	levels	O
8	leads	O
9	to	O
10	a	O
11	sensitivity	O
12	of	O
13	85	O
14	%	O
15	at	O
16	a	O
17	specificity	O
18	of	O
19	55	O
20	%	O
21	for	O
22	Protein	B
23	S100	I
24	when	O
25	measured	O
26	by	O
27	RIA	O
28	,	O
29	and	O
30	to	O
31	a	O
32	sensitivity	O
33	of	O
34	77	O
35	%	O
36	at	O
37	a	O
38	specificity	O
39	of	O
40	61	O
41	%	O
42	when	O
43	measured	O
44	by	O
45	LIA	O
46	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Using	O
2	16	O
3	strains	O
4	of	O
5	C	O
6	.	O
7	trachomatis	O
8	in	O
9	triplicate	O
10	assays	O
11	,	O
12	we	O
13	found	O
14	the	O
15	RT	O
16	-	O
17	PCR	O
18	method	O
19	consistently	O
20	more	O
21	sensitive	O
22	than	O
23	the	O
24	conventional	O
25	technique	O
26	for	O
27	all	O
28	eight	O
29	antimicrobials	O
30	tested	O
31	,	O
32	with	O
33	resultant	O
34	MICs	O
35	determined	O
36	by	O
37	RT	O
38	-	O
39	PCR	O
40	ranging	O
41	from	O
42	1	O
43	.	O
44	6	O
45	-	O
46	fold	O
47	higher	O
48	(	O
49	erythromycin	O
50	)	O
51	to	O
52	>/=	O
53	195	O
54	-	O
55	fold	O
56	higher	O
57	(	O
58	amoxicillin	O
59	).	O

1	Null	O
2	alleles	O
3	of	O
4	SAS4	B
5	and	O
6	SAS5	B
7	bypassed	O
8	the	O
9	role	O
10	of	O
11	the	O
12	Abf1p	B
13	binding	I
14	site	I
15	of	O
16	the	O
17	HMR	B
18	-	I
19	E	I
20	silencer	I
21	but	O
22	not	O
23	the	O
24	role	O
25	of	O
26	the	O
27	ACS	B
28	or	O
29	Rap1p	B
30	binding	I
31	site	I
32	.	O

1	Recent	O
2	molecular	O
3	analysis	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	S	B
9	locus	I
10	is	O
11	highly	O
12	polymorphic	O
13	and	O
14	contains	O
15	several	O
16	genes	O
17	,	O
18	i	O
19	.	O
20	e	O
21	.,	O
22	SLG	B
23	,	O
24	SRK	B
25	,	O
26	the	O
27	as	O
28	-	O
29	yet	O
30	-	O
31	unidentified	O
32	pollen	O
33	S	O
34	gene	O
35	(	O
36	s	O
37	),	O
38	and	O
39	other	O
40	linked	O
41	genes	O
42	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	putative	O
6	RNA	B
7	and	I
8	/	I
9	or	I
10	DNA	I
11	helicase	I
12	has	O
13	been	O
14	isolated	O
15	from	O
16	Arabidopsis	O
17	thaliana	O
18	cDNA	O
19	libraries	O
20	.	O

1	In	O
2	vivo	O
3	,	O
4	MyoD	B
5	requires	O
6	this	O
7	tryptophan	O
8	motif	O
9	to	O
10	evoke	O
11	chromatin	O
12	remodeling	O
13	in	O
14	the	O
15	Myogenin	B
16	promoter	I
17	and	O
18	to	O
19	activate	O
20	Myogenin	B
21	transcription	O
22	.	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	Feed	O
2	intake	O
3	and	O
4	BW	O
5	gains	O
6	were	O
7	decreased	O
8	(	O
9	P	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	by	O
16	dietary	O
17	treatments	O
18	containing	O
19	M	O
20	.	O

1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	B
16	domain	I
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O

1	Skn	B
2	-	I
3	1a	I
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	O
13	activin	B
14	induces	O
15	the	O
16	gene	B
17	Mix	I
18	.	I
19	2	I
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	O
34	ARF	B
35	).	O

1	To	O
2	further	O
3	characterize	O
4	the	O
5	structure	O
6	and	O
7	evolutionary	O
8	synthesis	O
9	of	O
10	the	O
11	CMT1A	O
12	-	O
13	REP	O
14	repeat	O
15	,	O
16	fluorescent	O
17	in	O
18	situ	O
19	hybridization	O
20	(	O
21	FISH	O
22	)	O
23	analysis	O
24	and	O
25	heterologous	O
26	PCR	O
27	-	O
28	based	O
29	assays	O
30	were	O
31	carried	O
32	out	O
33	for	O
34	a	O
35	series	O
36	of	O
37	primates	O
38	.	O

1	Natl	O
2	.	O

1	In	O
2	the	O
3	face	O
4	of	O
5	the	O
6	outbreak	O
7	,	O
8	there	O
9	was	O
10	a	O
11	delay	O
12	before	O
13	vaccination	O
14	was	O
15	able	O
16	to	O
17	stop	O
18	deaths	O
19	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	a	O
6	novel	O
7	isoform	O
8	of	O
9	Rapl	B
10	GTPase	I
11	-	I
12	activating	I
13	protein	I
14	,	O
15	called	O
16	rap1GAPII	B
17	,	O
18	binds	O
19	specifically	O
20	to	O
21	the	O
22	alpha	O
23	-	O
24	subunits	O
25	of	O
26	the	O
27	G	B
28	(	I
29	i	I
30	)	I
31	family	I
32	of	O
33	heterotrimeric	B
34	G	I
35	-	I
36	proteins	I
37	.	O

1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	B
10	chemokine	I
11	receptor	I
12	5	I
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O

1	An	O
2	activation	O
3	-	O
4	responsive	O
5	element	O
6	in	O
7	single	B
8	C	I
9	motif	I
10	-	I
11	1	I
12	/	O
13	lymphotactin	B
14	promoter	O
15	is	O
16	a	O
17	site	O
18	of	O
19	constitutive	O
20	and	O
21	inducible	O
22	DNA	O
23	-	O
24	protein	O
25	interactions	O
26	involving	O
27	nuclear	O
28	factor	O
29	of	O
30	activated	O
31	T	O
32	cell	O
33	.	O

1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	O
9	binding	O
10	activity	O
11	,	O
12	RelA	B
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	O
21	,	O
22	I	B
23	kappa	I
24	B	I
25	serine	O
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	B
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O

1	A	O
2	portion	O
3	of	O
4	p193	B
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	B
6	-	I
7	binding	I
8	protein	I
9	relieved	O
10	the	O
11	transcriptional	O
12	repression	O
13	of	O
14	PPARalphawt	B
15	by	O
16	PPARalphatr	B
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	B
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O

1	SF	B
2	-	I
3	1	I
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	To	O
2	estimate	O
3	the	O
4	locations	O
5	of	O
6	sources	O
7	with	O
8	the	O
9	TF	O
10	-	O
11	MUSIC	O
12	algorithm	O
13	,	O
14	we	O
15	first	O
16	set	O
17	the	O
18	target	O
19	region	O
20	on	O
21	the	O
22	spectrogram	O
23	of	O
24	the	O
25	somatosensory	O
26	responses	O
27	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	in	O
6	terms	O
7	of	O
8	the	O
9	influence	O
10	that	O
11	time	O
12	and	O
13	nutritional	O
14	constraints	O
15	have	O
16	on	O
17	odonate	O
18	development	O
19	patterns	O
20	and	O
21	fitness	O
22	.	O

1	OBJECTIVE	O
2	:	O
3	1998	O
4	Surveillance	O
5	,	O
6	Epidemiology	O
7	,	O
8	and	O
9	End	O
10	Results	O
11	(	O
12	SEER	O
13	)	O
14	data	O
15	estimate	O
16	an	O
17	83	O
18	.	O
19	1	O
20	%	O
21	5	O
22	-	O
23	year	O
24	survival	O
25	rate	O
26	for	O
27	corpus	O
28	uteri	O
29	adenocarcinoma	O
30	FIGO	O
31	stage	O
32	II	O
33	.	O

1	A	O
2	novel	O
3	Drosophila	B
4	A	I
5	kinase	I
6	anchor	I
7	protein	I
8	,	O
9	Drosophila	B
10	A	I
11	kinase	I
12	anchor	I
13	protein	I
14	200	I
15	(	O
16	DAKAP200	B
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	A	O
2	5	O
3	'	O
4	RNA	O
5	stem	O
6	-	O
7	loop	O
8	participates	O
9	in	O
10	the	O
11	transcription	O
12	attenuation	O
13	mechanism	O
14	that	O
15	controls	O
16	expression	O
17	of	O
18	the	O
19	Bacillus	B
20	subtilis	I
21	trpEDCFBA	I
22	operon	I
23	.	O

1	Single	O
2	-	O
3	alanine	O
4	-	O
5	substitution	O
6	mutations	O
7	had	O
8	minimal	O
9	,	O
10	if	O
11	any	O
12	,	O
13	effects	O
14	on	O
15	S	O
16	-	O
17	induced	O
18	cell	O
19	-	O
20	to	O
21	-	O
22	cell	O
23	fusion	O
24	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	MMTV	B
10	5	I
11	'	I
12	LTR	I
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	Stat5a	B
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	MMTV	B
38	LTR	I
39	.	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	B
10	/	O
11	CIC2B9	B
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	B
21	/	O
22	Ds	B
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	B
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	O
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O

1	Activated	O
2	areas	O
3	have	O
4	been	O
5	identified	O
6	by	O
7	means	O
8	of	O
9	cross	O
10	-	O
11	correlation	O
12	analysis	O
13	.	O

1	Natural	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	capsular	O
7	polysaccharide	O
8	antibodies	O
9	in	O
10	412	O
11	infants	O
12	and	O
13	children	O
14	from	O
15	West	O
16	Africa	O
17	(	O
18	Burkina	O
19	-	O
20	Faso	O
21	)	O
22	and	O
23	France	O
24	:	O
25	a	O
26	cross	O
27	-	O
28	sectional	O
29	serosurvey	O
30	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	O
22	WAF1	B
23	/	O
24	Cip1	B
25	promoter	O
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	O
11	neurohormones	O
12	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	B
5	-	I
6	1	I
7	and	O
8	p53	B
9	antibodies	I
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O

1	The	O
2	C2C	B
3	-	O
4	Prx	B
5	is	O
6	encoded	O
7	as	O
8	a	O
9	preprotein	O
10	of	O
11	273	O
12	amino	O
13	acids	O
14	containing	O
15	a	O
16	putative	O
17	chloroplast	O
18	-	O
19	targeting	O
20	signal	O
21	of	O
22	65	O
23	amino	O
24	acids	O
25	at	O
26	its	O
27	N	O
28	-	O
29	terminus	O
30	.	O

1	Immediately	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	hydrocortisone	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	O
19	order	O
20	.	O

1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	B
10	integrin	I
11	cytoplasmic	I
12	domain	I
13	mediates	O
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	B
5	protein	I
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	Using	O
2	transgenic	O
3	Xenopus	O
4	embryos	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	the	O
10	integrity	O
11	of	O
12	these	O
13	two	O
14	sequences	O
15	is	O
16	necessary	O
17	for	O
18	correct	O
19	spatial	O
20	expression	O
21	of	O
22	a	O
23	Xbra2	B
24	promoter	I
25	-	I
26	driven	I
27	reporter	I
28	gene	I
29	.	O

1	In	O
2	order	O
3	to	O
4	screen	O
5	for	O
6	such	O
7	cofactors	O
8	,	O
9	we	O
10	have	O
11	used	O
12	a	O
13	transcriptionally	O
14	inactive	O
15	mutant	O
16	of	O
17	Xenopus	B
18	MEF2D	I
19	in	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	screen	O
26	.	O

1	NuA4	B
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	ATF1	B
2	transcription	O
3	is	O
4	negatively	O
5	regulated	O
6	by	O
7	unsaturated	O
8	fatty	O
9	acids	O
10	and	O
11	oxygen	O
12	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O

1	Mutation	O
2	of	O
3	TTF	B
4	-	I
5	1	I
6	-	I
7	binding	I
8	sites	I
9	(	I
10	TBE	I
11	)	I
12	1	I
13	,	I
14	3	I
15	,	I
16	and	I
17	4	I
18	in	O
19	combination	O
20	markedly	O
21	decreased	O
22	transcriptional	O
23	activity	O
24	of	O
25	SP	B
26	-	I
27	A	I
28	promoter	O
29	-	O
30	chloramphenicol	B
31	acetyltransferase	I
32	constructs	O
33	containing	O
34	SP	B
35	-	I
36	A	I
37	gene	I
38	sequences	O
39	from	O
40	-	O
41	256	O
42	to	O
43	+	O
44	45	O
45	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	I	I
8	induces	O
9	bcl	B
10	-	I
11	2	I
12	promoter	I
13	through	O
14	the	O
15	transcription	O
16	factor	O
17	cAMP	B
18	-	I
19	response	I
20	element	I
21	-	I
22	binding	I
23	protein	I
24	.	O

1	Synthesis	O
2	of	O
3	antisense	O
4	RNA	O
5	and	O
6	S	O
7	phase	O
8	-	O
9	dependent	O
10	binding	O
11	of	O
12	E2F	B
13	complexes	I
14	in	O
15	intron	O
16	1	O
17	.	O

1	Identification	O
2	of	O
3	eotaxin	B
4	-	I
5	3	I
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	B
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	NF	B
2	-	I
3	kappaB	I
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	O
12	-	O
13	1	O
14	gene	O
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	switch	O
31	from	O
32	latent	O
33	to	O
34	productive	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O

1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	B
6	acts	O
7	by	O
8	stimulating	O
9	AP	B
10	-	I
11	1	I
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	O
20	AP	B
21	-	I
22	1	I
23	with	O
24	NF	B
25	-	I
26	kappaB	I
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	transactivates	O
35	the	O
36	HIV	B
37	-	I
38	1	I
39	LTR	I
40	.	O

1	ERK	B
2	MAP	I
3	kinase	I
4	links	O
5	cytokine	O
6	signals	O
7	to	O
8	activation	O
9	of	O
10	latent	O
11	HIV	O
12	-	O
13	1	O
14	infection	O
15	by	O
16	stimulating	O
17	a	O
18	cooperative	O
19	interaction	O
20	of	O
21	AP	B
22	-	I
23	1	I
24	and	O
25	NF	B
26	-	I
27	kappaB	I
28	.	O

1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	chaperone	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	bZIP	B
19	proteins	I
20	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	Montelukast	O
2	reduces	O
3	airway	O
4	eosinophilic	O
5	inflammation	O
6	in	O
7	asthma	O
8	:	O
9	a	O
10	randomized	O
11	,	O
12	controlled	O
13	trial	O
14	.	O

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	Here	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	kinase	O
7	-	O
8	dead	O
9	but	O
10	not	O
11	wild	O
12	-	O
13	type	O
14	forms	O
15	of	O
16	Fyn	B
17	,	O
18	Lck	B
19	,	O
20	and	O
21	ZAP	B
22	-	I
23	70	I
24	block	O
25	70Z	O
26	Cbl	B
27	-	O
28	mediated	O
29	NFAT	B
30	activation	O
31	.	O

1	Substitutions	O
2	of	O
3	region	O
4	I	O
5	with	O
6	synthetic	O
7	sequences	O
8	showed	O
9	that	O
10	no	O
11	specific	O
12	sequence	O
13	but	O
14	rather	O
15	repeats	O
16	of	O
17	three	O
18	or	O
19	more	O
20	consecutive	O
21	adenines	O
22	or	O
23	thymines	O
24	,	O
25	without	O
26	interruption	O
27	by	O
28	guanine	O
29	or	O
30	cytosine	O
31	,	O
32	are	O
33	required	O
34	for	O
35	the	O
36	ARS	O
37	activity	O
38	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	PHO85	B
6	encodes	O
7	a	O
8	cyclin	B
9	-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	Cdk	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	specified	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	partners	O
32	(	O
33	Pcls	B
34	).	O

1	Mutants	O
2	with	O
3	mild	O
4	lace	B
5	alleles	I
6	grow	O
7	to	O
8	become	O
9	adults	O
10	with	O
11	multiple	O
12	aberrant	O
13	morphologies	O
14	in	O
15	the	O
16	appendages	O
17	,	O
18	compound	O
19	eye	O
20	,	O
21	and	O
22	bristles	O
23	.	O

1	In	O
2	fact	O
3	,	O
4	SPT	B
5	activity	O
6	in	O
7	the	O
8	fly	O
9	expressing	O
10	epitope	O
11	-	O
12	tagged	O
13	Lace	B
14	was	O
15	absorbed	O
16	by	O
17	epitope	O
18	-	O
19	specific	O
20	antibody	O
21	.	O

1	Mutations	O
2	of	O
3	the	O
4	RET	B
5	gene	I
6	,	O
7	encoding	O
8	a	O
9	receptor	B
10	tyrosine	I
11	kinase	I
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	B
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O

1	EB	B
2	-	I
3	1	I
4	,	O
5	a	O
6	tyrosine	B
7	kinase	I
8	signal	I
9	transduction	I
10	gene	I
11	,	O
12	is	O
13	transcriptionally	O
14	activated	O
15	in	O
16	the	O
17	t	O
18	(	O
19	1	O
20	;	O
21	19	O
22	)	O
23	subset	O
24	of	O
25	pre	O
26	-	O
27	B	O
28	ALL	O
29	,	O
30	which	O
31	express	O
32	oncoprotein	O
33	E2a	B
34	-	O
35	Pbx1	B
36	.	O

1	Protein	B
2	kinase	I
3	A	I
4	-	I
5	Ialpha	I
6	subunit	O
7	-	O
8	directed	O
9	antisense	O
10	inhibition	O
11	of	O
12	ovarian	O
13	cancer	O
14	cell	O
15	growth	O
16	:	O
17	crosstalk	O
18	with	O
19	tyrosine	B
20	kinase	I
21	signaling	O
22	pathway	O
23	.	O

1	BCL6	B
2	encodes	O
3	a	O
4	POZ	B
5	/	I
6	Zn	I
7	finger	I
8	protein	I
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O

1	Beta	B
2	1	I
3	integrin	I
4	-	O
5	and	O
6	proteoglycan	O
7	-	O
8	mediated	O
9	stimulation	O
10	of	O
11	T	O
12	lymphoma	O
13	cell	O
14	adhesion	O
15	and	O
16	mitogen	B
17	-	I
18	activated	I
19	protein	I
20	kinase	I
21	signaling	O
22	by	O
23	thrombospondin	B
24	-	I
25	1	I
26	and	O
27	thrombospondin	B
28	-	I
29	1	I
30	peptides	I
31	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	I
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	The	O
2	phosphotransferase	O
3	system	O
4	(	O
5	PTS	O
6	)	O
7	of	O
8	Streptomyces	O
9	coelicolor	O
10	identification	O
11	and	O
12	biochemical	O
13	analysis	O
14	of	O
15	a	O
16	histidine	B
17	phosphocarrier	I
18	protein	I
19	HPr	I
20	encoded	O
21	by	O
22	the	O
23	gene	O
24	ptsH	B
25	.	O

1	Serum	O
2	concentrations	O
3	of	O
4	bone	B
5	specific	I
6	alkaline	I
7	phosphatase	I
8	(	O
9	BALP	B
10	)	O
11	and	O
12	osteocalcin	B
13	(	O
14	bone	B
15	Gla	I
16	protein	I
17	,	O
18	BGP	B
19	),	O
20	urinary	O
21	levels	O
22	of	O
23	pyridinoline	O
24	(	O
25	Pyr	O
26	)	O
27	and	O
28	deoxypyridinoline	O
29	(	O
30	Dpyr	O
31	)	O
32	and	O
33	computed	O
34	tomography	O
35	(	O
36	CT	O
37	)	O
38	measurements	O
39	of	O
40	the	O
41	cross	O
42	-	O
43	sectional	O
44	areas	O
45	of	O
46	the	O
47	vertebrae	O
48	and	O
49	the	O
50	femurs	O
51	,	O
52	the	O
53	apparent	O
54	density	O
55	of	O
56	cancellous	O
57	bone	O
58	in	O
59	the	O
60	vertebrae	O
61	,	O
62	and	O
63	the	O
64	volume	O
65	and	O
66	the	O
67	material	O
68	density	O
69	of	O
70	cortical	O
71	bone	O
72	in	O
73	the	O
74	femurs	O
75	were	O
76	determined	O
77	in	O
78	126	O
79	boys	O
80	and	O
81	143	O
82	girls	O
83	,	O
84	ages	O
85	7	O
86	-	O
87	18	O
88	years	O
89	.	O

1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	B
13	-	I
14	A	I
15	receptor	I
16	antagonist	O
17	,	O
18	at	O
19	a	O
20	dose	O
21	of	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	/	O
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O

1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	B
14	-	I
15	associated	I
16	plasma	I
17	protein	I
18	-	I
19	A	I
20	(	O
21	PAPP	B
22	-	I
23	A	I
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	B
33	-	I
34	YD1	I
35	).	O

1	Prognostic	O
2	value	O
3	of	O
4	a	O
5	treadmill	O
6	exercise	O
7	score	O
8	in	O
9	symptomatic	O
10	patients	O
11	with	O
12	nonspecific	O
13	ST	O
14	-	O
15	T	O
16	abnormalities	O
17	on	O
18	resting	O
19	ECG	O
20	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	O
15	beta	B
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	O
27	-	O
28	terminal	O
29	regulatory	O
30	domain	O
31	of	O
32	p53	B
33	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O

1	The	O
2	solution	O
3	structure	O
4	of	O
5	the	O
6	adduct	O
7	derived	O
8	from	O
9	the	O
10	covalent	O
11	bonding	O
12	of	O
13	the	O
14	fjord	O
15	region	O
16	(+)-(	O
17	11S	O
18	,	O
19	12R	O
20	,	O
21	13R	O
22	,	O
23	14S	O
24	)	O
25	stereoisomer	O
26	of	O
27	anti	O
28	-	O
29	11	O
30	,	O
31	12	O
32	-	O
33	dihydroxy	O
34	-	O
35	13	O
36	,	O
37	14	O
38	-	O
39	epoxy	O
40	-	O
41	11	O
42	,	O
43	12	O
44	,	O
45	13	O
46	,	O
47	14	O
48	-	O
49	tetrahydrobenzo	O
50	[	O
51	g	O
52	]	O
53	chrysene	O
54	,	O
55	(+)-	O
56	anti	O
57	-	O
58	B	O
59	[	O
60	g	O
61	]	O
62	CDE	O
63	,	O
64	to	O
65	the	O
66	exocyclic	O
67	N	O
68	(	O
69	6	O
70	)	O
71	amino	O
72	group	O
73	of	O
74	the	O
75	adenine	O
76	residue	O
77	dA6	O
78	,	O
79	(	O
80	designated	O
81	(+)-	O
82	trans	O
83	-	O
84	anti	O
85	-(	O
86	B	O
87	[	O
88	g	O
89	]	O
90	C	O
91	)	O
92	dA6	O
93	),	O
94	positioned	O
95	opposite	O
96	a	O
97	thymine	O
98	residue	O
99	dT17	O
100	in	O
101	the	O
102	DNA	O
103	sequence	O
104	context	O
105	d	O
106	(	O
107	C1	O
108	-	O
109	T2	O
110	-	O
111	C3	O
112	-	O
113	T4	O
114	-	O
115	C5	O
116	-(	O
117	B	O
118	[	O
119	g	O
120	]	O
121	C	O
122	)	O
123	A6	O
124	-	O
125	C7	O
126	-	O
127	T8	O
128	-	O
129	T9	O
130	-	O
131	C10	O
132	-	O
133	C11	O
134	).	O
135	d	O
136	(	O
137	G12	O
138	-	O
139	G13	O
140	-	O
141	A14	O
142	-	O
143	A15	O
144	-	O
145	G16	O
146	-	O
147	T17	O
148	-	O
149	G18	O
150	-	O
151	A19	O
152	-	O
153	G20	O
154	++	O
155	+-	O
156	A21	O
157	-	O
158	G22	O
159	)	O
160	(	O
161	designated	O
162	(	O
163	B	O
164	[	O
165	g	O
166	]	O
167	C	O
168	)	O
169	dA	O
170	.	O
171	dT	O
172	11	O
173	-	O
174	mer	O
175	duplex	O
176	),	O
177	has	O
178	been	O
179	studied	O
180	using	O
181	structural	O
182	information	O
183	derived	O
184	from	O
185	NMR	O
186	data	O
187	in	O
188	combination	O
189	with	O
190	molecular	O
191	dynamics	O
192	(	O
193	MD	O
194	)	O
195	calculations	O
196	.	O

1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O

1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	WPI	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	WPI	O
27	.	O

1	During	O
2	both	O
3	encephalopathy	O
4	episodes	O
5	,	O
6	CSF	O
7	protein	O
8	and	O
9	immunoglobulin	B
10	G	I
11	(	O
12	IgG	B
13	)	O
14	levels	O
15	were	O
16	elevated	O
17	without	O
18	an	O
19	increased	O
20	IgG	B
21	index	O
22	or	O
23	IgG	B
24	synthesis	O
25	rate	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	results	O
5	show	O
6	that	O
7	once	O
8	daily	O
9	oral	O
10	valganciclovir	O
11	can	O
12	produce	O
13	exposures	O
14	of	O
15	ganciclovir	O
16	(	O
17	AUC24	O
18	)	O
19	exceeding	O
20	those	O
21	attained	O
22	using	O
23	intravenous	O
24	ganciclovir	O
25	10	O
26	mg	O
27	/	O
28	kg	O
29	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	The	O
2	healing	O
3	rate	O
4	in	O
5	HIV	O
6	-	O
7	positive	O
8	patients	O
9	was	O
10	66	O
11	percent	O
12	after	O
13	14	O
14	weeks	O
15	and	O
16	100	O
17	percent	O
18	after	O
19	32	O
20	weeks	O
21	;	O
22	the	O
23	corresponding	O
24	figures	O
25	for	O
26	patients	O
27	with	O
28	acquired	O
29	immunodeficiency	O
30	syndrome	O
31	were	O
32	0	O
33	and	O
34	50	O
35	percent	O
36	.	O

1	The	O
2	P	B
3	mRNA	I
4	also	O
5	contains	O
6	a	O
7	third	O
8	ORF	O
9	for	O
10	the	O
11	V	B
12	protein	I
13	,	O
14	although	O
15	it	O
16	is	O
17	unclear	O
18	how	O
19	or	O
20	whether	O
21	this	O
22	ORF	O
23	is	O
24	accessed	O
25	.	O

1	A	O
2	genetic	O
3	screen	O
4	in	O
5	yeast	O
6	has	O
7	allowed	O
8	us	O
9	to	O
10	identify	O
11	a	O
12	novel	O
13	transcriptional	O
14	factor	O
15	binding	O
16	to	O
17	the	O
18	GlRE	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	chicken	B
26	ovalbumin	I
27	upstream	I
28	promoter	I
29	-	I
30	transcription	I
31	factor	I
32	II	I
33	(	O
34	COUP	B
35	-	I
36	TFII	I
37	).	O

1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	B
12	-	I
13	spliceosomal	I
14	U5	I
15	snRNA	I
16	from	O
17	the	O
18	trypanosomatid	O
19	species	O
20	Leptomonas	O
21	seymouri	O
22	,	O
23	using	O
24	U5	B
25	RNA	I
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	O
10	1992	O
11	),	O
12	like	O
13	the	O
14	older	O
15	MMPI	O
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	phosphatidyl	O
7	inositol	O
8	4	O
9	,	O
10	5	O
11	bisphosphate	O
12	(	O
13	PIP2	O
14	)	O
15	hydrolysis	O
16	requires	O
17	direct	O
18	phosphorylation	O
19	at	O
20	tyrosine	O
21	residue	O
22	of	O
23	the	O
24	PLC	B
25	-	I
26	gamma1	I
27	isozyme	I
28	.	O

1	A	O
2	G22V	B
3	mutant	I
4	of	O
5	M	B
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	O
20	IL	B
21	-	I
22	3	I
23	)-	O
24	dependent	O
25	mast	O
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Mammalian	B
2	M	I
3	-	I
4	Ras	I
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	O
34	p21	B
35	Ras	I
36	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	PecS	B
9	attenuates	O
10	pelD	B
11	and	O
12	pelE	B
13	expression	O
14	rather	O
15	than	O
16	acting	O
17	as	O
18	a	O
19	true	O
20	repressor	O
21	like	O
22	KdgR	B
23	.	O

1	These	O
2	observations	O
3	establish	O
4	that	O
5	RsmC	B
6	negatively	O
7	regulates	O
8	rsmB	B
9	transcription	O
10	but	O
11	positively	O
12	affects	O
13	RsmA	B
14	production	O
15	.	O

1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O

1	SCOB	O
2	testing	O
3	of	O
4	food	O
5	-	O
6	restricted	O
7	animals	O
8	,	O
9	using	O
10	a	O
11	multiple	O
12	fixed	O
13	ratio	O
14	(	O
15	FR	O
16	)/	O
17	fixed	O
18	interval	O
19	(	O
20	FI	O
21	)	O
22	schedule	O
23	(	O
24	FR20	O
25	:	O
26	FI120	O
27	),	O
28	was	O
29	conducted	O
30	prior	O
31	to	O
32	each	O
33	exposure	O
34	to	O
35	maintain	O
36	the	O
37	operant	O
38	behavior	O
39	;	O
40	the	O
41	data	O
42	from	O
43	Weeks	O
44	-	O
45	1	O
46	,	O
47	4	O
48	,	O
49	8	O
50	,	O
51	and	O
52	13	O
53	were	O
54	evaluated	O
55	for	O
56	evidence	O
57	of	O
58	neurotoxicity	O
59	.	O

1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	B
7	and	O
8	hmg2	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	O
15	-	O
16	and	O
17	spatially	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O

1	Differential	O
2	expression	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blot	O
8	analysis	O
9	employing	O
10	multiple	O
11	normal	O
12	and	O
13	tumor	O
14	cell	O
15	lines	O
16	.	O

1	Inactivation	O
2	of	O
3	the	O
4	Neurospora	B
5	crassa	I
6	mitochondrial	I
7	outer	I
8	membrane	I
9	protein	I
10	TOM70	I
11	by	O
12	repeat	O
13	-	O
14	induced	O
15	point	O
16	mutation	O
17	(	O
18	RIP	O
19	)	O
20	causes	O
21	defects	O
22	in	O
23	mitochondrial	O
24	protein	O
25	import	O
26	and	O
27	morphology	O
28	.	O

1	Several	O
2	genes	O
3	or	O
4	transcriptional	O
5	units	O
6	were	O
7	identified	O
8	,	O
9	including	O
10	the	O
11	3	O
12	'	O
13	end	O
14	of	O
15	ribosomal	B
16	s6	I
17	kinase	I
18	(	O
19	Rsk3	B
20	);	O
21	two	O
22	apparently	O
23	intronless	O
24	and	O
25	ORF	O
26	-	O
27	less	O
28	genes	O
29	;	O
30	and	O
31	Gpr31	B
32	,	O
33	an	O
34	intronless	O
35	,	O
36	putative	O
37	G	B
38	-	I
39	protein	I
40	coupled	I
41	receptor	I
42	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	GATA	B
6	-	I
7	5	I
8	may	O
9	have	O
10	specific	O
11	downstream	O
12	targets	O
13	and	O
14	that	O
15	GATA	B
16	-	I
17	4	I
18	,	I
19	-	I
20	5	I
21	,	I
22	and	I
23	-	I
24	6	I
25	can	O
26	only	O
27	partially	O
28	substitute	O
29	for	O
30	each	O
31	other	O
32	in	O
33	cardiogenesis	O
34	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	compare	O
7	the	O
8	efficacy	O
9	of	O
10	efegatran	O
11	plus	O
12	streptokinase	B
13	versus	O
14	heparin	O
15	plus	O
16	accelerated	O
17	tissue	B
18	plasminogen	I
19	activator	I
20	(	O
21	TPA	B
22	)	O
23	in	O
24	coronary	O
25	reperfusion	O
26	in	O
27	acute	O
28	MI	O
29	.	O

1	Recently	O
2	,	O
3	cell	O
4	-	O
5	surface	O
6	TRAIL	B
7	has	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	expressed	O
13	by	O
14	activated	O
15	human	O
16	and	O
17	mouse	O
18	T	O
19	lymphocytes	O
20	,	O
21	raising	O
22	the	O
23	possibility	O
24	that	O
25	TRAIL	B
26	might	O
27	be	O
28	involved	O
29	in	O
30	T	O
31	cell	O
32	-	O
33	mediated	O
34	cytotoxicity	O
35	and	O
36	/	O
37	or	O
38	immune	O
39	regulation	O
40	.	O

1	A	O
2	panel	O
3	of	O
4	pharmacologic	O
5	inhibitors	O
6	was	O
7	used	O
8	to	O
9	investigate	O
10	the	O
11	signal	O
12	transduction	O
13	pathways	O
14	involved	O
15	in	O
16	TRAIL	B
17	gene	I
18	induction	O
19	following	O
20	T	O
21	lymphocyte	O
22	activation	O
23	.	O

1	From	O
2	February	O
3	1991	O
4	to	O
5	August	O
6	1997	O
7	,	O
8	124	O
9	patients	O
10	with	O
11	endometrial	O
12	carcinoma	O
13	were	O
14	treated	O
15	postoperatively	O
16	with	O
17	high	O
18	-	O
19	dose	O
20	-	O
21	rate	O
22	vaginal	O
23	vault	O
24	brachytherapy	O
25	as	O
26	the	O
27	only	O
28	adjuvant	O
29	treatment	O
30	.	O

1	Twelve	O
2	patients	O
3	had	O
4	stage	O
5	IBG3	O
6	,	O
7	14	O
8	had	O
9	ICG1	O
10	,	O
11	9	O
12	had	O
13	ICG2	O
14	,	O
15	and	O
16	3	O
17	had	O
18	ICG3	O
19	disease	O
20	.	O

1	Defective	O
2	provirus	O
3	genomes	O
4	of	O
5	human	O
6	T	O
7	-	O
8	cell	O
9	leukemia	O
10	virus	O
11	type	O
12	I	O
13	are	O
14	frequently	O
15	detected	O
16	in	O
17	lymphocytes	O
18	from	O
19	infected	O
20	individuals	O
21	and	O
22	in	O
23	infected	O
24	cell	O
25	lines	O
26	.	O

1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O

1	A	O
2	population	O
3	pharmacokinetic	O
4	study	O
5	of	O
6	cyclosporin	O
7	in	O
8	organ	O
9	transplant	O
10	patients	O
11	,	O
12	including	O
13	elderly	O
14	allograft	O
15	recipients	O
16	up	O
17	to	O
18	75	O
19	years	O
20	of	O
21	age	O
22	,	O
23	did	O
24	not	O
25	identify	O
26	age	O
27	as	O
28	a	O
29	covariable	O
30	influencing	O
31	cyclosporin	O
32	pharmacokinetics	O
33	.	O

1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	O
10	receptor	O
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	B
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	O
33	-	O
34	type	O
35	receptor	O
36	,	O
37	RAP	B
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	O
44	markers	O
45	.	O

1	Interleukin	B
2	-	I
3	12	I
4	(	O
5	IL	B
6	-	I
7	12	I
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	O
23	interferon	B
24	-	I
25	gamma	I
26	(	O
27	IFN	B
28	-	I
29	gamma	I
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	IL	B
2	-	I
3	12	I
4	production	O
5	was	O
6	correlated	O
7	with	O
8	C3a	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	outlet	O
14	of	O
15	hemodialyzer	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	the	O
6	JNKK2	B
7	-	O
8	JNK1	B
9	fusion	O
10	protein	O
11	showed	O
12	significant	O
13	JNK	B
14	activity	O
15	,	O
16	which	O
17	was	O
18	comparable	O
19	with	O
20	that	O
21	of	O
22	JNK1	B
23	activated	O
24	by	O
25	many	O
26	stimuli	O
27	and	O
28	activators	O
29	,	O
30	including	O
31	EGF	B
32	,	O
33	TNF	B
34	-	I
35	alpha	I
36	,	O
37	anisomycin	O
38	,	O
39	UV	O
40	irradiation	O
41	,	O
42	MEKK1	B
43	,	O
44	and	O
45	small	B
46	GTP	I
47	binding	I
48	proteins	I
49	Rac1	I
50	and	O
51	Cdc42Hs	B
52	.	O

1	J	O
2	.	O

1	Our	O
2	results	O
3	implicate	O
4	TGF	B
5	-	I
6	beta	I
7	RII	I
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	EWS	B
14	-	O
15	FLI1	B
16	.	O

1	The	O
2	reduction	O
3	in	O
4	saturated	O
5	fatty	O
6	acids	O
7	intake	O
8	led	O
9	to	O
10	modest	O
11	(	O
12	but	O
13	in	O
14	group	O
15	1	O
16	significant	O
17	)	O
18	0	O
19	.	O
20	15	O
21	mmol	O
22	/	O
23	l	O
24	(	O
25	2	O
26	.	O
27	5	O
28	%)	O
29	reduction	O
30	in	O
31	total	O
32	serum	O
33	cholesterol	O
34	level	O
35	.	O

1	Secondly	O
2	,	O
3	an	O
4	ethanol	O
5	repression	O
6	autoregulation	O
7	(	O
8	ERA	O
9	)/	O
10	twelve	O
11	-	O
12	fold	O
13	TA	O
14	repeat	O
15	(	O
16	TAB	O
17	)	O
18	repressor	O
19	element	O
20	was	O
21	identified	O
22	within	O
23	the	O
24	promoter	O
25	region	O
26	of	O
27	the	O
28	GLK1	B
29	gene	I
30	.	O

1	A	O
2	crucial	O
3	transcription	O
4	factor	O
5	in	O
6	this	O
7	process	O
8	is	O
9	STAT6	B
10	,	O
11	which	O
12	binds	O
13	to	O
14	a	O
15	specific	O
16	DNA	O
17	element	O
18	upon	O
19	cytokine	O
20	activation	O
21	.	O

1	CONCLUSIONS	O
2	:	O
3	Congenital	O
4	horizontal	O
5	tarsal	O
6	kink	O
7	is	O
8	rare	O
9	and	O
10	its	O
11	cause	O
12	is	O
13	unknown	O
14	.	O

1	A	O
2	local	O
3	,	O
4	high	O
5	-	O
6	density	O
7	,	O
8	single	O
9	-	O
10	nucleotide	O
11	polymorphism	O
12	map	O
13	used	O
14	to	O
15	clone	O
16	Caenorhabditis	B
17	elegans	I
18	cdf	I
19	-	I
20	1	I
21	.	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	B
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	selenocysteine	O
10	-	O
11	containing	O
12	rat	B
13	thioredoxin	I
14	reductase	I
15	utilizing	O
16	gene	O
17	fusions	O
18	with	O
19	engineered	O
20	bacterial	O
21	-	O
22	type	O
23	SECIS	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	selA	B
32	,	O
33	selB	B
34	and	O
35	selC	B
36	genes	I
37	.	O

1	In	O
2	Wnt	B
3	signaling	O
4	,	O
5	beta	B
6	-	I
7	catenin	I
8	and	O
9	plakoglobin	B
10	transduce	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	O
18	TCF	B
19	-	I
20	type	I
21	transcription	I
22	factors	I
23	.	O

1	Assembly	O
2	of	O
3	a	O
4	complex	O
5	between	O
6	FAK	B
7	and	O
8	Src	B
9	kinases	I
10	may	O
11	serve	O
12	to	O
13	regulate	O
14	the	O
15	subcellular	O
16	localization	O
17	and	O
18	the	O
19	enzymatic	O
20	activity	O
21	of	O
22	members	O
23	of	O
24	the	O
25	Src	B
26	family	I
27	of	O
28	kinases	O
29	.	O

1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Our	O
2	study	O
3	also	O
4	demonstrated	O
5	significant	O
6	increases	O
7	in	O
8	the	O
9	number	O
10	of	O
11	larger	O
12	myelinated	O
13	fibers	O
14	crossing	O
15	the	O
16	repair	O
17	site	O
18	in	O
19	comparison	O
20	with	O
21	the	O
22	neonatal	O
23	and	O
24	adult	O
25	groups	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	04	O
32	).	O

1	Me	O
2	(	O
3	2	O
4	)	O
5	SO	O
6	-	O
7	induced	O
8	neuronal	O
9	differentiation	O
10	of	O
11	N1E	O
12	-	O
13	115	O
14	neuroblastoma	O
15	cells	O
16	increased	O
17	both	O
18	the	O
19	expression	O
20	of	O
21	the	O
22	endogenous	B
23	Ntr	I
24	-	I
25	1	I
26	gene	I
27	and	O
28	reporter	O
29	genes	O
30	driven	O
31	by	O
32	NTR	B
33	-	I
34	1	I
35	promoter	I
36	sequences	I
37	by	O
38	3	O
39	-	O
40	4	O
41	-	O
42	fold	O
43	.	O

1	Cortical	O
2	dysplasias	O
3	,	O
4	genetics	O
5	,	O
6	and	O
7	epileptogenesis	O
8	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	O
15	and	O
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	O
22	two	O
23	sets	O
24	of	O
25	pAP	B
26	phosphorylation	O
27	sites	O
28	.	O

1	Both	O
2	HERV	O
3	-	O
4	K	O
5	type	O
6	1	O
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	Duch	O
2	,	O
3	and	O
4	F	O
5	.	O

1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	(>/=	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	irbesartan	O
15	/	O
16	HCTZ	O
17	alone	O
18	.	O

1	Modification	O
2	of	O
3	dopamine	B
4	D2	I
5	receptor	I
6	activity	O
7	by	O
8	pergolide	O
9	in	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	:	O
15	an	O
16	in	O
17	vivo	O
18	study	O
19	by	O
20	PET	O
21	.	O

1	High	O
2	-	O
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	I
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O

1	When	O
2	the	O
3	73	O
4	-	O
5	bp	O
6	fragment	O
7	was	O
8	fused	O
9	to	O
10	an	O
11	alpha1	B
12	-	I
13	globin	I
14	promoter	O
15	-	O
16	CAT	B
17	construct	O
18	and	O
19	cotransfected	O
20	with	O
21	CCAAT	B
22	transcription	I
23	factor	I
24	1	I
25	(	O
26	CTF1	B
27	)/	O
28	NF1	B
29	into	O
30	Drosophila	O
31	Schneider	O
32	SL2	O
33	insect	O
34	cells	O
35	(	O
36	which	O
37	lack	O
38	NF1	B
39	-	I
40	like	I
41	proteins	I
42	)	O
43	trans	O
44	-	O
45	activation	O
46	of	O
47	CAT	B
48	activity	O
49	was	O
50	observed	O
51	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	B
11	/	O
12	CIP1	B
13	protein	O
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	B
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	Aggregation	O
2	of	O
3	vHnf1	B
4	-	O
5	deficient	O
6	embryonic	O
7	stem	O
8	cells	O
9	with	O
10	wild	O
11	-	O
12	type	O
13	tetraploid	O
14	embryos	O
15	,	O
16	which	O
17	contribute	O
18	exclusively	O
19	to	O
20	extraembryonic	O
21	tissues	O
22	,	O
23	rescues	O
24	periimplantation	O
25	lethality	O
26	and	O
27	allows	O
28	development	O
29	to	O
30	progress	O
31	to	O
32	early	O
33	organogenesis	O
34	.	O

1	nos	B
2	-	I
3	1	I
4	and	O
5	nos	B
6	-	I
7	2	I
8	,	O
9	two	O
10	genes	O
11	related	O
12	to	O
13	Drosophila	B
14	nanos	I
15	,	O
16	regulate	O
17	primordial	O
18	germ	O
19	cell	O
20	development	O
21	and	O
22	survival	O
23	in	O
24	Caenorhabditis	O
25	elegans	O
26	.	O

1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	Tec	B
6	family	I
7	kinases	I
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	effectors	O
20	of	O
21	these	O
22	enzymes	O
23	.	O

1	Efficient	O
2	phosphorylation	O
3	of	O
4	BRDG1	B
5	by	O
6	Tec	B
7	required	O
8	the	O
9	PH	B
10	and	O
11	SH2	B
12	domains	I
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	findings	O
5	imply	O
6	that	O
7	eotaxin	O
8	either	O
9	is	O
10	mechanistically	O
11	involved	O
12	in	O
13	acute	O
14	asthma	O
15	or	O
16	serves	O
17	as	O
18	a	O
19	biomarker	O
20	for	O
21	activity	O
22	of	O
23	the	O
24	CCR3	B
25	receptor	I
26	ligand	I
27	system	O
28	,	O
29	which	O
30	is	O
31	functionally	O
32	linked	O
33	to	O
34	asthma	O
35	.	O

1	The	O
2	expression	O
3	analysis	O
4	of	O
5	the	O
6	KlHIS4	B
7	gene	I
8	under	O
9	phosphate	O
10	starvation	O
11	or	O
12	high	O
13	adenine	O
14	supply	O
15	shows	O
16	that	O
17	factors	O
18	,	O
19	such	O
20	as	O
21	Bas1	B
22	or	O
23	Bas2	B
24	,	O
25	involved	O
26	in	O
27	the	O
28	basal	O
29	control	O
30	may	O
31	also	O
32	operate	O
33	in	O
34	a	O
35	different	O
36	way	O
37	in	O
38	K	O
39	.	O
40	lactis	O
41	.	O

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	B
35	deiodinase	I
36	system	O
37	.	O

1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	O
22	and	O
23	after	O
24	septal	O
25	reduction	O
26	using	O
27	echocardiography	O
28	and	O
29	electrocardiogram	O
30	(	O
31	ECG	O
32	).	O

1	Paleoceanographic	O
2	data	O
3	from	O
4	the	O
5	Laurentian	O
6	Fan	O
7	,	O
8	used	O
9	as	O
10	a	O
11	proxy	O
12	for	O
13	sea	O
14	surface	O
15	temperature	O
16	,	O
17	reveal	O
18	that	O
19	surface	O
20	slope	O
21	waters	O
22	north	O
23	of	O
24	the	O
25	Gulf	O
26	Stream	O
27	experienced	O
28	warming	O
29	during	O
30	the	O
31	Little	O
32	Ice	O
33	Age	O
34	of	O
35	the	O
36	16th	O
37	to	O
38	19th	O
39	centuries	O
40	and	O
41	support	O
42	the	O
43	notion	O
44	of	O
45	an	O
46	NAO	O
47	-	O
48	driven	O
49	coupled	O
50	system	O
51	.	O

1	This	O
2	effect	O
3	required	O
4	(	O
5	i	O
6	)	O
7	IR	B
8	activation	O
9	since	O
10	it	O
11	was	O
12	abrogated	O
13	by	O
14	IR	B
15	mutation	O
16	at	O
17	tyrosines	O
18	1162	O
19	and	O
20	1163	O
21	and	O
22	(	O
23	ii	O
24	)	O
25	NF	B
26	-	I
27	kappaB	I
28	activation	O
29	since	O
30	it	O
31	was	O
32	abolished	O
33	by	O
34	overexpression	O
35	of	O
36	dominant	B
37	-	I
38	negative	I
39	IkappaB	I
40	-	I
41	alpha	I
42	(	I
43	A32	I
44	/	I
45	36	I
46	)	I
47	and	O
48	mimicked	O
49	by	O
50	overexpression	O
51	of	O
52	the	O
53	NF	B
54	-	I
55	kappaB	I
56	c	I
57	-	I
58	Rel	I
59	subunit	I
60	.	O

1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	centered	O
9	on	O
10	the	O
11	sequence	O
12	TGTGGT	O
13	,	O
14	a	O
15	core	O
16	motif	O
17	recognized	O
18	by	O
19	members	O
20	of	O
21	the	O
22	AML	B
23	/	I
24	CBFalpha	I
25	transcription	I
26	factor	I
27	family	I
28	.	O

1	Furthermore	O
2	,	O
3	overexpression	O
4	of	O
5	AML3	B
6	/	O
7	CBFalpha1	B
8	could	O
9	rescue	O
10	the	O
11	AML1	B
12	-	O
13	ETO	B
14	repression	O
15	.	O

1	We	O
2	examined	O
3	Akt	B
4	activation	O
5	in	O
6	Lyn	B
7	-,	O
8	Syk	B
9	-	O
10	and	O
11	Btk	B
12	-	O
13	deficient	O
14	DT40	O
15	cells	O
16	and	O
17	B	O
18	cells	O
19	from	O
20	Lyn	B
21	(-/-)	I
22	mice	O
23	.	O

1	Regulators	O
2	of	O
3	G	B
4	protein	I
5	signaling	I
6	(	I
7	RGS	I
8	)	I
9	proteins	I
10	that	O
11	contain	O
12	DEP	B
13	(	O
14	disheveled	B
15	,	O
16	EGL	B
17	-	I
18	10	I
19	,	O
20	pleckstrin	B
21	)	O
22	and	O
23	GGL	B
24	(	O
25	G	B
26	protein	I
27	gamma	I
28	subunit	I
29	-	I
30	like	I
31	)	O
32	domains	O
33	form	O
34	a	O
35	subfamily	O
36	that	O
37	includes	O
38	the	O
39	mammalian	B
40	RGS	I
41	proteins	I
42	RGS6	I
43	,	O
44	RGS7	B
45	,	O
46	RGS9	B
47	,	O
48	and	O
49	RGS11	B
50	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	B
8	alpha	I
9	1	I
10	,	I
11	2	I
12	-	I
13	mannosidase	I
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	Dbp5p	B
6	and	O
7	Rat7p	B
8	interact	O
9	through	O
10	their	O
11	Nterminal	O
12	domains	O
13	.	O

1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	B
10	of	I
11	Hh	I
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O

1	A	O
2	subset	O
3	of	O
4	mutations	O
5	in	O
6	the	O
7	Psi	B
8	synthase	I
9	domain	I
10	impairs	O
11	association	O
12	of	O
13	the	O
14	altered	O
15	Cbf5p	B
16	proteins	I
17	with	O
18	selected	O
19	box	O
20	H	B
21	/	I
22	ACA	I
23	snoRNAs	I
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	functional	O
29	catalytic	O
30	domain	O
31	is	O
32	essential	O
33	for	O
34	that	O
35	interaction	O
36	.	O

1	Although	O
2	the	O
3	Src	B
4	tyrosine	I
5	kinase	I
6	induces	O
7	constitutive	O
8	Stat3	B
9	phosphorylation	O
10	on	O
11	tyrosine	O
12	,	O
13	activation	O
14	of	O
15	Stat3	B
16	-	O
17	mediated	O
18	gene	O
19	regulation	O
20	requires	O
21	both	O
22	tyrosine	O
23	and	O
24	serine	O
25	phosphorylation	O
26	of	O
27	Stat3	B
28	.	O

1	The	O
2	transcription	B
3	factor	I
4	CHOP	I
5	(	O
6	C	B
7	/	I
8	EBP	I
9	homologous	I
10	protein	I
11	10	I
12	)	O
13	is	O
14	a	O
15	bZIP	B
16	protein	I
17	induced	O
18	by	O
19	a	O
20	variety	O
21	of	O
22	stimuli	O
23	that	O
24	evoke	O
25	cellular	O
26	stress	O
27	responses	O
28	and	O
29	has	O
30	been	O
31	shown	O
32	to	O
33	arrest	O
34	cell	O
35	growth	O
36	and	O
37	to	O
38	promote	O
39	programmed	O
40	cell	O
41	death	O
42	.	O

1	Thus	O
2	,	O
3	CHOP	B
4	not	O
5	only	O
6	is	O
7	a	O
8	negative	O
9	or	O
10	a	O
11	positive	O
12	regulator	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	target	O
18	genes	O
19	but	O
20	also	O
21	,	O
22	when	O
23	tethered	O
24	to	O
25	AP	B
26	-	I
27	1	I
28	factors	I
29	,	O
30	can	O
31	activate	O
32	AP	B
33	-	I
34	1	I
35	target	O
36	genes	O
37	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	RNase	B
2	MRP	I
3	is	O
4	a	O
5	ribonucleoprotein	O
6	endoribonuclease	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	B
21	5	I
22	.	I
23	8S	I
24	rRNA	I
25	processing	O
26	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	regulation	O
6	of	O
7	the	O
8	FGFR	B
9	-	I
10	1	I
11	gene	I
12	(	O
13	cek	B
14	-	I
15	1	I
16	)	O
17	in	O
18	avian	O
19	myogenic	O
20	cultures	O
21	by	O
22	immunocytochemistry	O
23	and	O
24	Northern	O
25	blot	O
26	analysis	O
27	.	O

1	Regulation	O
2	of	O
3	avian	B
4	fibroblast	I
5	growth	I
6	factor	I
7	receptor	I
8	1	I
9	(	O
10	FGFR	B
11	-	I
12	1	I
13	)	O
14	gene	O
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	The	O
2	backbone	O
3	dynamics	O
4	of	O
5	residues	O
6	located	O
7	in	O
8	the	O
9	folded	O
10	part	O
11	of	O
12	CRP2	B
13	(	O
14	LIM2	B
15	)	O
16	R122A	B
17	have	O
18	been	O
19	characterized	O
20	by	O
21	proton	O
22	-	O
23	detected	O
24	(	O
25	15	O
26	)	O
27	N	O
28	NMR	O
29	spectroscopy	O
30	.	O

1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	O
8	F	B
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	O
20	4	O
21	,	O
22	5	O
23	bisphosphate	O
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O

1	However	O
2	,	O
3	a	O
4	specific	O
5	ICE	B
6	/	O
7	caspase	B
8	-	I
9	1	I
10	inhibitor	O
11	called	O
12	N1445	O
13	completely	O
14	abolished	O
15	the	O
16	CK	B
17	-	O
18	induced	O
19	apoptosis	O
20	by	O
21	reactivating	O
22	PKB	B
23	,	O
24	but	O
25	without	O
26	affecting	O
27	the	O
28	CK	B
29	-	O
30	induced	O
31	suppression	O
32	of	O
33	Ras	B
34	transformation	O
35	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	The	O
2	AL	O
3	-	O
4	R8	O
5	SI	O
6	:	O
7	the	O
8	next	O
9	generation	O
10	staging	O
11	container	O
12	for	O
13	plutonium	O
14	pits	O
15	at	O
16	the	O
17	USDOE	O
18	Pantex	O
19	Plant	O
20	.	O

1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<.	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	Cox	O
20	multivariate	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	hazard	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	confidence	O
39	interval	O
40	[	O
41	CI	O
42	],	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	Karnofsky	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	adjuvant	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	adjuvant	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	metastases	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	O
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	approaches	O
193	significance	O
194	])	O
195	vs	O
196	soft	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	incomplete	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O

1	One	O
2	form	O
3	of	O
4	the	O
5	SBEI	B
6	gene	I
7	transcript	I
8	in	O
9	12	O
10	-	O
11	day	O
12	old	O
13	kernels	O
14	contained	O
15	the	O
16	exon	O
17	I	O
18	+	O
19	II	O
20	+	O
21	III	O
22	combination	O
23	at	O
24	the	O
25	5	O
26	'	O
27	end	O
28	,	O
29	whereas	O
30	other	O
31	forms	O
32	differed	O
33	by	O
34	inclusion	O
35	of	O
36	intron	O
37	1	O
38	or	O
39	exclusion	O
40	of	O
41	exon	O
42	II	O
43	sequences	O
44	.	O

1	In	O
2	PC	O
3	,	O
4	rare	O
5	MNGCs	O
6	had	O
7	intranuclear	O
8	inclusions	O
9	and	O
10	grooves	O
11	.	O

1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	B
15	alanine	I
16	aminotransferase	I
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O

1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	O
16	p140	B
17	(	O
18	ras	B
19	-	O
20	GRF	B
21	)	O
22	and	O
23	Sos	B
24	.	O

1	356	O
2	,	O
3	93	O
4	-	O
5	98	O
6	].	O

1	The	O
2	proteasome	O
3	is	O
4	a	O
5	large	O
6	complex	O
7	consisting	O
8	of	O
9	two	O
10	multisubunit	O
11	structures	O
12	,	O
13	the	O
14	20S	B
15	and	O
16	19S	B
17	(	O
18	PA700	B
19	)	O
20	or	O
21	P28	B
22	complexes	I
23	,	O
24	that	O
25	combine	O
26	to	O
27	form	O
28	the	O
29	26S	B
30	particles	I
31	.	O

1	In	O
2	assays	O
3	with	O
4	purified	O
5	enzymes	O
6	,	O
7	wild	O
8	-	O
9	type	O
10	but	O
11	not	O
12	PTPS	B
13	-	O
14	S19A	B
15	was	O
16	a	O
17	specific	O
18	substrate	O
19	for	O
20	the	O
21	cGMP	B
22	-	I
23	dependent	I
24	protein	I
25	kinase	I
26	(	I
27	cGK	I
28	)	I
29	type	I
30	I	I
31	and	I
32	II	I
33	.	O

1	R	O
2	.,	O
3	Fleischmann	O
4	,	O
5	R	O
6	.,	O
7	Venter	O
8	,	O
9	J	O
10	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	B
27	/	O
28	gp46	B
29	complex	O
30	.	O

1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	B
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O

1	Most	O
2	important	O
3	,	O
4	infection	O
5	of	O
6	the	O
7	cells	O
8	with	O
9	an	O
10	adenoviral	O
11	construct	O
12	expressing	O
13	this	O
14	mutant	O
15	inhibited	O
16	the	O
17	induction	O
18	of	O
19	VEGF	B
20	mRNA	I
21	under	O
22	conditions	O
23	that	O
24	mimic	O
25	hypoxia	O
26	.	O

1	Neuregulin	B
2	stimulates	O
3	ErbB2	B
4	,	O
5	ErbB3	B
6	,	O
7	and	O
8	ErbB4	B
9	,	O
10	members	O
11	of	O
12	the	O
13	ErbB	B
14	family	I
15	of	O
16	receptor	B
17	tyrosine	I
18	kinases	I
19	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Anu2p	B
6	is	O
7	the	O
8	yeast	B
9	homologue	I
10	of	I
11	mammalian	I
12	epsilon	I
13	-	I
14	COP	I
15	and	O
16	the	O
17	abrupt	O
18	accumulation	O
19	of	O
20	the	O
21	ER	O
22	membrane	O
23	caused	O
24	by	O
25	a	O
26	blockage	O
27	of	O
28	the	O
29	early	O
30	protein	O
31	transport	O
32	pathway	O
33	leads	O
34	to	O
35	alteration	O
36	of	O
37	nuclear	O
38	morphology	O
39	of	O
40	the	O
41	budding	O
42	yeast	O
43	cells	O
44	.	O

1	In	O
2	PC12	O
3	cells	O
4	,	O
5	nerve	B
6	growth	I
7	factor	I
8	induces	O
9	neuronal	O
10	differentiation	O
11	and	O
12	repressed	O
13	expression	O
14	of	O
15	nrg	B
16	-	I
17	1	I
18	.	O

1	In	O
2	a	O
3	PC12	O
4	cell	O
5	mutant	O
6	that	O
7	is	O
8	deficient	O
9	in	O
10	protein	B
11	kinase	I
12	A	I
13	activity	O
14	(	O
15	AB	O
16	.	O
17	11	O
18	),	O
19	all	O
20	three	O
21	differentiating	O
22	agents	O
23	were	O
24	unable	O
25	to	O
26	down	O
27	-	O
28	regulate	O
29	nrg	B
30	-	I
31	1	I
32	mRNA	I
33	.	O

1	TSC1	B
2	mutations	I
3	include	O
4	two	O
5	nonsense	O
6	mutations	O
7	,	O
8	four	O
9	insertions	O
10	,	O
11	and	O
12	three	O
13	splice	O
14	mutations	O
15	.	O

1	Twelve	O
2	patients	O
3	without	O
4	abnormalities	O
5	in	O
6	the	O
7	PTT	O
8	are	O
9	assumed	O
10	to	O
11	harbor	O
12	missense	O
13	mutations	O
14	,	O
15	probably	O
16	in	O
17	TSC2	B
18	.	O

1	The	O
2	first	O
3	algorithm	O
4	,	O
5	FOREPROJ	O
6	,	O
7	is	O
8	a	O
9	fast	O
10	-	O
11	forward	O
12	projection	O
13	algorithm	O
14	that	O
15	allows	O
16	calculation	O
17	of	O
18	the	O
19	3	O
20	-	O
21	D	O
22	attenuation	O
23	correction	O
24	factors	O
25	(	O
26	ACF	O
27	'	O
28	s	O
29	)	O
30	directly	O
31	from	O
32	a	O
33	two	O
34	-	O
35	dimensional	O
36	(	O
37	2	O
38	-	O
39	D	O
40	)	O
41	transmission	O
42	scan	O
43	,	O
44	without	O
45	first	O
46	reconstructing	O
47	the	O
48	attenuation	O
49	map	O
50	and	O
51	then	O
52	performing	O
53	a	O
54	3	O
55	-	O
56	D	O
57	forward	O
58	projection	O
59	.	O

1	We	O
2	have	O
3	cloned	O
4	cDNA	O
5	and	O
6	genomic	O
7	DNA	O
8	for	O
9	a	O
10	mouse	O
11	gene	O
12	encoding	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	sequence	O
18	similarity	O
19	to	O
20	conserved	O
21	domains	O
22	found	O
23	in	O
24	proteins	O
25	of	O
26	the	O
27	Spo11p	B
28	family	I
29	.	O

1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	O
18	that	O
19	Spo11	B
20	expression	O
21	begins	O
22	in	O
23	early	O
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O

1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O

1	The	O
2	RMR	O
3	was	O
4	measured	O
5	twice	O
6	in	O
7	each	O
8	phase	O
9	and	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	(	O
15	F	O
16	(	O
17	1	O
18	,	O
19	18	O
20	)	O
21	=	O
22	0	O
23	.	O
24	863	O
25	)	O
26	across	O
27	the	O
28	follicular	O
29	(	O
30	5018	O
31	kJ	O
32	/	O
33	24	O
34	h	O
35	)	O
36	and	O
37	the	O
38	luteal	O
39	(	O
40	5098	O
41	kJ	O
42	/	O
43	24	O
44	h	O
45	)	O
46	phases	O
47	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	B
24	neuraminidases	I
25	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	we	O
8	found	O
9	no	O
10	evidence	O
11	for	O
12	VDR	B
13	-	O
14	TR	B
15	heterodimer	O
16	interaction	O
17	with	O
18	any	O
19	tested	O
20	element	O
21	.	O

1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O

1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O

1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	B
7	virulence	I
8	genes	I
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	B
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	B
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O

1	Tracheal	O
2	transsection	O
3	combined	O
4	with	O
5	hilar	O
6	ligation	O
7	(	O
8	TL	O
9	&	O
10	PL	O
11	)	O
12	effected	O
13	a	O
14	reduction	O
15	of	O
16	19	O
17	.	O
18	9	O
19	%	O
20	(	O
21	n	O
22	.	O
23	s	O
24	.).	O

1	Kinase	O
2	-	O
3	deficient	O
4	erbB	B
5	proteins	I
6	reduced	O
7	epidermal	B
8	growth	I
9	factor	I
10	(	O
11	EGF	B
12	)-	O
13	induced	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	endogenous	O
18	Shc	B
19	proteins	I
20	and	O
21	also	O
22	reduced	O
23	immediate	O
24	and	O
25	sustained	O
26	EGF	B
27	-	I
28	induced	I
29	ERK	I
30	MAPK	I
31	activities	O
32	in	O
33	human	O
34	glioblastoma	O
35	cells	O
36	,	O
37	although	O
38	basal	O
39	ERK	B
40	MAPK	I
41	activities	O
42	were	O
43	unaffected	O
44	.	O

1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	B
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	B
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	B
9	and	O
10	CDKN2B	B
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	aortic	O
7	explants	O
8	isolated	O
9	from	O
10	PPARalpha	B
11	-	O
12	null	O
13	mice	O
14	display	O
15	an	O
16	exacerbated	O
17	response	O
18	to	O
19	inflammatory	O
20	stimuli	O
21	,	O
22	such	O
23	as	O
24	lipopolysaccharide	O
25	(	O
26	LPS	O
27	),	O
28	as	O
29	demonstrated	O
30	by	O
31	increased	O
32	IL	B
33	-	I
34	6	I
35	secretion	O
36	.	O

1	Albumin	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	O
31	C	B
32	/	I
33	EBPbeta	I
34	.	O

1	The	O
2	requirement	O
3	for	O
4	proteolytic	O
5	activity	O
6	of	O
7	both	O
8	FVIIa	B
9	and	O
10	FXa	B
11	suggests	O
12	that	O
13	protease	O
14	-	O
15	activated	O
16	receptors	O
17	may	O
18	be	O
19	involved	O
20	.	O

1	Amyloid	B
2	beta	I
3	-	I
4	protein	I
5	(	O
6	Abeta	B
7	)	O
8	is	O
9	the	O
10	main	O
11	constituent	O
12	of	O
13	amyloid	O
14	fibrils	O
15	found	O
16	in	O
17	senile	O
18	plaques	O
19	and	O
20	cerebral	O
21	vessels	O
22	in	O
23	Alzheimer	O
24	'	O
25	s	O
26	disease	O
27	(	O
28	AD	O
29	)	O
30	and	O
31	is	O
32	derived	O
33	by	O
34	proteolysis	O
35	from	O
36	the	O
37	beta	B
38	-	I
39	amyloid	I
40	precursor	I
41	protein	I
42	(	O
43	APP	B
44	).	O

1	We	O
2	also	O
3	show	O
4	that	O
5	activation	O
6	of	O
7	protein	B
8	kinase	I
9	A	I
10	(	O
11	PKA	B
12	)	O
13	signaling	O
14	is	O
15	sufficient	O
16	to	O
17	down	O
18	-	O
19	regulate	O
20	caveolin	B
21	-	I
22	1	I
23	protein	I
24	expression	O
25	and	O
26	promoter	O
27	activity	O
28	.	O

1	The	O
2	importin	B
3	alpha	I
4	.	I
5	beta	I
6	heterodimer	I
7	mediates	O
8	nuclear	O
9	import	O
10	of	O
11	proteins	O
12	containing	O
13	classical	O
14	nuclear	O
15	localization	O
16	signals	O
17	.	O

1	The	O
2	expressed	O
3	G1	B
4	-	O
5	G2	B
6	bound	O
7	to	O
8	both	O
9	hyaluronan	O
10	and	O
11	link	B
12	protein	I
13	indicating	O
14	that	O
15	the	O
16	immunoglobulin	B
17	-	I
18	fold	I
19	motif	I
20	and	O
21	proteoglycan	O
22	tandem	O
23	repeat	O
24	loops	O
25	of	O
26	the	O
27	G1	B
28	domain	I
29	were	O
30	correctly	O
31	folded	O
32	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	per	O
10	se	O
11	of	O
12	keratan	O
13	sulfate	O
14	on	O
15	native	O
16	G1	O
17	-	O
18	G2	O
19	does	O
20	not	O
21	affect	O
22	the	O
23	activity	O
24	of	O
25	atrolysin	O
26	C	O
27	toward	O
28	the	O
29	two	O
30	sites	O
31	.	O

1	Despite	O
2	i	O
3	.	O
4	v	O
5	.	O
6	steroid	O
7	therapy	O
8	,	O
9	[	O
10	NOexh	O
11	]	O
12	remained	O
13	elevated	O
14	throughout	O
15	recovery	O
16	(	O
17	37	O
18	.	O
19	9	O
20	+/-	O
21	4	O
22	.	O
23	8	O
24	ppb	O
25	,	O
26	p	O
27	<	O
28	0	O
29	.	O
30	001	O
31	)	O
32	until	O
33	discharge	O
34	(	O
35	40	O
36	.	O
37	9	O
38	+/-	O
39	4	O
40	.	O
41	3	O
42	ppb	O
43	,	O
44	p	O
45	<	O
46	0	O
47	.	O
48	001	O
49	).	O

1	It	O
2	contains	O
3	binding	O
4	sites	O
5	for	O
6	several	O
7	transcription	O
8	factors	O
9	,	O
10	for	O
11	example	O
12	:	O
13	(	O
14	i	O
15	)	O
16	a	O
17	well	O
18	-	O
19	characterized	O
20	binding	O
21	site	O
22	for	O
23	rel	B
24	/	O
25	NF	B
26	-	I
27	kappaB	I
28	transcription	O
29	factors	O
30	in	O
31	its	O
32	3	O
33	'-	O
34	end	O
35	(	O
36	the	O
37	H2TF1	B
38	or	O
39	kappaB1	B
40	element	I
41	),	O
42	(	O
43	ii	O
44	)	O
45	a	O
46	second	O
47	kappaB	B
48	site	I
49	(	O
50	the	O
51	kappaB2	B
52	element	I
53	),	O
54	which	O
55	is	O
56	located	O
57	immediately	O
58	adjacent	O
59	5	O
60	'	O
61	to	O
62	the	O
63	H2TF1	B
64	element	I
65	and	O
66	which	O
67	is	O
68	recognized	O
69	by	O
70	p65	B
71	/	O
72	relA	B
73	in	O
74	the	O
75	human	B
76	HLA	I
77	system	O
78	,	O
79	and	O
80	(	O
81	iii	O
82	)	O
83	an	O
84	AP	B
85	-	I
86	1	I
87	/	O
88	ATF	B
89	recognition	O
90	sequence	O
91	in	O
92	the	O
93	5	O
94	'	O
95	end	O
96	(	O
97	EnA	B
98	-	I
99	TRE	I
100	).	O

1	The	O
2	tumorigenic	O
3	E1A	B
4	+	O
5	cHa	B
6	-	I
7	ras	I
8	cells	O
9	are	O
10	characterized	O
11	by	O
12	high	O
13	and	O
14	constitutive	O
15	DNA	O
16	binding	O
17	activities	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	,	O
23	in	O
24	contrast	O
25	to	O
26	nontransformed	O
27	cells	O
28	and	O
29	the	O
30	E1A	B
31	cells	O
32	.	O

1	The	O
2	yeast	O
3	C	B
4	-	I
5	type	I
6	cyclin	I
7	Ume3p	I
8	/	O
9	Srb11p	B
10	and	O
11	its	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	(	O
17	Cdk	B
18	)	O
19	Ume5p	B
20	are	O
21	required	O
22	for	O
23	the	O
24	full	O
25	repression	O
26	of	O
27	genes	O
28	involved	O
29	in	O
30	the	O
31	stress	O
32	response	O
33	or	O
34	meiosis	O
35	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	S1	B
6	'	I
7	specificity	I
8	site	I
9	is	O
10	a	O
11	deep	O
12	and	O
13	highly	O
14	hydrophobic	O
15	cavity	O
16	.	O

1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	O
6	reporter	O
7	construct	O
8	,	O
9	(	O
10	PRDII	O
11	)(	O
12	4	O
13	)-	O
14	CAT	B
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	O
27	by	O
28	Tat	B
29	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	B
8	(	I
9	2	I
10	)	I
11	sgRNAs	I
12	of	O
13	TMV	B
14	U1	I
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	B
30	(	I
31	MP	I
32	,	I
33	75	I
34	)	I
35	(	I
36	HIRES	I
37	(	I
38	MP	I
39	),	I
40	(	I
41	75	I
42	)(	I
43	CR	I
44	)-	I
45	MP	I
46	-	I
47	CP	I
48	-	I
49	3	I
50	'	I
51	UTR	I
52	;	O
53	HIRES	B
54	(	I
55	MP	I
56	,	I
57	75	I
58	)(	I
59	U1	I
60	)-	I
61	MP	I
62	-	I
63	CP	I
64	-	I
65	3	I
66	'	I
67	UTR	I
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	B
75	gene	I
76	in	O
77	vitro	O
78	.	O

1	EIAV	B
2	LTR	I
3	sequence	I
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O

1	Phosphatidylinositol	B
2	3	I
3	-	I
4	kinase	I
5	requirement	O
6	in	O
7	activation	O
8	of	O
9	the	O
10	ras	B
11	/	O
12	C	B
13	-	I
14	raf	I
15	-	I
16	1	I
17	/	O
18	MEK	B
19	/	O
20	ERK	B
21	and	O
22	p70	B
23	(	O
24	s6k	B
25	)	O
26	signaling	O
27	cascade	O
28	by	O
29	the	O
30	insulinomimetic	O
31	agent	O
32	vanadyl	O
33	sulfate	O
34	.	O

1	The	O
2	core	O
3	of	O
4	this	O
5	enhancer	O
6	contains	O
7	two	O
8	evolutionarily	O
9	conserved	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	homeodomain	B
15	protein	I
16	Tinman	I
17	(	O
18	Tin	B
19	),	O
20	expressed	O
21	in	O
22	developing	O
23	cardiac	O
24	,	O
25	somatic	O
26	,	O
27	and	O
28	visceral	O
29	muscle	O
30	lineages	O
31	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	O
17	region	O
18	significantly	O
19	decreased	O
20	bop	B
21	gene	I
22	mRNA	I
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	Furthermore	O
2	,	O
3	the	O
4	striking	O
5	ability	O
6	of	O
7	polyoma	B
8	middle	I
9	T	I
10	antigens	I
11	to	O
12	promote	O
13	retinoic	O
14	acid	O
15	-	O
16	induced	O
17	differentiation	O
18	appears	O
19	to	O
20	utilize	O
21	ERK	B
22	,	O
23	but	O
24	not	O
25	JNK	B
26	/	O
27	SPK	B
28	or	O
29	p38	B
30	signaling	O
31	.	O

1	We	O
2	recommend	O
3	that	O
4	paracervical	O
5	block	O
6	with	O
7	lignocaine	O
8	should	O
9	be	O
10	used	O
11	in	O
12	conjunction	O
13	with	O
14	i	O
15	.	O
16	v	O
17	.	O
18	sedation	O
19	/	O
20	analgesia	O
21	during	O
22	egg	O
23	collection	O
24	performed	O
25	through	O
26	the	O
27	transvaginal	O
28	route	O
29	under	O
30	ultrasound	O
31	guidance	O
32	(	O
33	TUGOR	O
34	)	O
35	to	O
36	reduce	O
37	the	O
38	pain	O
39	of	O
40	the	O
41	procedure	O
42	.	O

1	All	O
2	loci	O
3	have	O
4	a	O
5	similar	O
6	organization	O
7	,	O
8	except	O
9	for	O
10	H1	B
11	.	I
12	8	I
13	that	O
14	harbors	O
15	two	O
16	TcP2beta	B
17	genes	I
18	arranged	O
19	in	O
20	tandem	O
21	and	O
22	separated	O
23	by	O
24	a	O
25	short	O
26	repetitive	O
27	sequence	O
28	,	O
29	named	O
30	SIRE	O
31	(	O
32	short	O
33	interspersed	O
34	repetitive	O
35	element	O
36	),	O
37	which	O
38	is	O
39	also	O
40	found	O
41	upstream	O
42	of	O
43	the	O
44	first	O
45	gene	O
46	of	O
47	the	O
48	tandem	O
49	and	O
50	downstream	O
51	of	O
52	the	O
53	second	O
54	.	O

1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	O
20	beta	B
21	-	I
22	catenin	I
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	O
53	Conductin	B
54	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	B
8	target	I
9	gene	I
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O

1	This	O
2	report	O
3	describes	O
4	a	O
5	patient	O
6	with	O
7	a	O
8	previous	O
9	inferior	O
10	acute	O
11	myocardial	O
12	infarction	O
13	who	O
14	developed	O
15	right	O
16	ventricular	O
17	infarction	O
18	with	O
19	significant	O
20	anterior	O
21	lead	O
22	ST	O
23	segment	O
24	elevation	O
25	(	O
26	V1	O
27	-	O
28	V4	O
29	)	O
30	caused	O
31	by	O
32	the	O
33	loss	O
34	of	O
35	two	O
36	large	O
37	right	O
38	ventricular	O
39	branches	O
40	during	O
41	a	O
42	coronary	O
43	angioplasty	O
44	of	O
45	the	O
46	right	O
47	coronary	O
48	artery	O
49	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Immediately	O
6	before	O
7	radical	O
8	prostatectomy	O
9	,	O
10	bone	O
11	marrow	O
12	aspirates	O
13	from	O
14	both	O
15	sides	O
16	of	O
17	the	O
18	iliac	O
19	crest	O
20	were	O
21	taken	O
22	from	O
23	287	O
24	patients	O
25	.	O

1	PURPOSE	O
2	:	O
3	Previous	O
4	WR	O
5	-	O
6	2721	O
7	human	O
8	pharmacokinetic	O
9	studies	O
10	were	O
11	limited	O
12	to	O
13	plasma	O
14	levels	O
15	in	O
16	patients	O
17	receiving	O
18	platinum	O
19	-	O
20	based	O
21	compounds	O
22	,	O
23	and	O
24	none	O
25	includes	O
26	the	O
27	effects	O
28	of	O
29	WR	O
30	-	O
31	2721	O
32	on	O
33	endogenous	O
34	thiols	O
35	.	O

1	With	O
2	regard	O
3	to	O
4	nonhematologic	O
5	toxicities	O
6	,	O
7	diarrhea	O
8	,	O
9	infection	O
10	and	O
11	elevated	O
12	serum	B
13	alkaline	I
14	phosphatase	I
15	of	O
16	grade	O
17	3	O
18	or	O
19	over	O
20	were	O
21	observed	O
22	in	O
23	2	O
24	%	O
25	of	O
26	cycles	O
27	,	O
28	but	O
29	were	O
30	tolerable	O
31	and	O
32	reversible	O
33	.	O

1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O

1	Regulation	O
2	of	O
3	HIV	O
4	-	O
5	1	O
6	transcription	O
7	.	O

1	Human	B
2	LTBP	I
3	-	I
4	1	I
5	is	O
6	known	O
7	to	O
8	exist	O
9	in	O
10	different	O
11	forms	O
12	.	O

1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	Cyclic	B
2	AMP	I
3	-	I
4	dependent	I
5	protein	I
6	kinase	I
7	binding	O
8	to	O
9	A	B
10	-	I
11	kinase	I
12	anchoring	O
13	proteins	O
14	in	O
15	living	O
16	cells	O
17	by	O
18	fluorescence	O
19	resonance	O
20	energy	O
21	transfer	O
22	of	O
23	green	B
24	fluorescent	I
25	protein	I
26	fusion	O
27	proteins	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	addition	O
5	to	O
6	the	O
7	superiority	O
8	of	O
9	octafluoropropane	O
10	-	O
11	filled	O
12	microspheres	O
13	to	O
14	air	O
15	-	O
16	filled	O
17	microspheres	O
18	for	O
19	LV	O
20	opacification	O
21	,	O
22	the	O
23	efficacy	O
24	of	O
25	OCTA	O
26	is	O
27	relatively	O
28	unaffected	O
29	by	O
30	impaired	O
31	LV	O
32	function	O
33	and	O
34	is	O
35	less	O
36	susceptible	O
37	to	O
38	the	O
39	effects	O
40	of	O
41	poor	O
42	echogenicity	O
43	than	O
44	AIR	O
45	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	The	O
2	Ishasha	O
3	samples	O
4	show	O
5	a	O
6	range	O
7	encompassing	O
8	three	O
9	trophic	O
10	levels	O
11	.	O

1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O

1	Ti	O
2	exhibited	O
3	a	O
4	feather	O
5	-	O
6	like	O
7	morphology	O
8	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	B
13	-	O
14	FUT5	B
15	-	O
16	FUT6	B
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O

1	S	O
2	.,	O
3	Kim	O
4	,	O
5	S	O
6	.	O

1	The	O
2	cop	B
3	region	I
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	B
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	B
23	promoter	I
24	,	O
25	Prep	B
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	B
33	binding	I
34	sites	I
35	,	O
36	BD	O
37	-	O
38	1	O
39	and	O
40	BD	O
41	-	O
42	2	O
43	.	O

1	WA	O
2	constructs	O
3	afforded	O
4	relaxed	O
5	and	O
6	positive	O
7	topoisomers	O
8	,	O
9	and	O
10	cyclization	O
11	kinetics	O
12	indicated	O
13	slow	O
14	interconversion	O
15	of	O
16	precursors	O
17	to	O
18	the	O
19	two	O
20	topoisomers	O
21	.	O

1	The	O
2	RFX	B
3	protein	I
4	family	I
5	includes	O
6	members	O
7	from	O
8	yeast	O
9	to	O
10	humans	O
11	,	O
12	which	O
13	function	O
14	in	O
15	various	O
16	biological	O
17	systems	O
18	,	O
19	and	O
20	share	O
21	a	O
22	DNA	O
23	-	O
24	binding	O
25	domain	O
26	and	O
27	a	O
28	conserved	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	B
19	modules	I
20	.	O

1	Here	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	an	O
7	antagonistic	O
8	,	O
9	BMP	B
10	/	O
11	ALK2	B
12	/	O
13	Smad	B
14	-	O
15	mediated	O
16	signaling	O
17	pathway	O
18	is	O
19	active	O
20	on	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	Xenopus	O
27	embryo	O
28	.	O

1	These	O
2	kinases	O
3	belong	O
4	to	O
5	a	O
6	new	O
7	subfamily	O
8	related	O
9	to	O
10	the	O
11	Trk	B
12	subfamily	I
13	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	etr	B
6	-	I
7	1	I
8	is	O
9	essential	O
10	for	O
11	muscle	O
12	development	O
13	in	O
14	C	O
15	.	O
16	elegans	O
17	,	O
18	perhaps	O
19	by	O
20	playing	O
21	a	O
22	role	O
23	in	O
24	post	O
25	-	O
26	transcriptional	O
27	processing	O
28	of	O
29	some	O
30	muscle	O
31	component	O
32	,	O
33	and	O
34	thus	O
35	suggesting	O
36	a	O
37	possible	O
38	conservation	O
39	of	O
40	gene	O
41	function	O
42	with	O
43	human	B
44	CUG	I
45	-	I
46	bp	I
47	.	O

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	An	O
2	analysis	O
3	of	O
4	sequence	O
5	of	O
6	the	O
7	mutant	B
8	recN	I
9	gene	I
10	revealed	O
11	a	O
12	G	O
13	:	O
14	C	O
15	to	O
16	T	O
17	:	O
18	A	O
19	transversion	O
20	near	O
21	the	O
22	3	O
23	'	O
24	end	O
25	of	O
26	the	O
27	coding	O
28	region	O
29	.	O

1	Nevertheless	O
2	,	O
3	in	O
4	view	O
5	of	O
6	the	O
7	potential	O
8	transmission	O
9	rates	O
10	of	O
11	HGV	O
12	and	O
13	the	O
14	lack	O
15	of	O
16	effective	O
17	immunization	O
18	,	O
19	HGV	O
20	should	O
21	be	O
22	regarded	O
23	as	O
24	a	O
25	potential	O
26	occupational	O
27	hazard	O
28	for	O
29	medical	O
30	and	O
31	dental	O
32	staff	O
33	.	O

1	Detection	O
2	of	O
3	poisoning	O
4	by	O
5	Impila	O
6	(	O
7	Callilepis	O
8	laureola	O
9	)	O
10	in	O
11	a	O
12	mother	O
13	and	O
14	child	O
15	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	B
6	and	I
7	human	I
8	cDNAs	I
9	encoding	I
10	UNC	I
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	B
18	).	O

1	ULKs	B
2	and	O
3	UNC	B
4	-	I
5	51	I
6	share	O
7	a	O
8	typical	O
9	domain	O
10	structure	O
11	of	O
12	an	O
13	amino	O
14	-	O
15	terminal	O
16	kinase	O
17	domain	O
18	,	O
19	a	O
20	central	O
21	proline	O
22	/	O
23	serine	O
24	rich	O
25	(	O
26	PS	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	a	O
32	carboxy	O
33	-	O
34	terminal	O
35	(	O
36	C	O
37	)	O
38	domain	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	ULK2	B
6	is	O
7	involved	O
8	in	O
9	a	O
10	previously	O
11	uncharacterized	O
12	signaling	O
13	pathway	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	Connector	B
2	enhancer	I
3	of	I
4	KSR	I
5	(	O
6	CNK	B
7	)	O
8	is	O
9	a	O
10	multidomain	O
11	protein	O
12	required	O
13	for	O
14	RAS	B
15	signaling	O
16	.	O

1	In	O
2	simpler	O
3	organisms	O
4	,	O
5	the	O
6	ATP	B
7	sulfurylase	I
8	and	O
9	APS	B
10	kinase	I
11	reactions	O
12	are	O
13	catalyzed	O
14	by	O
15	separate	O
16	enzymes	O
17	encoded	O
18	by	O
19	two	O
20	or	O
21	three	O
22	genes	O
23	,	O
24	suggesting	O
25	that	O
26	a	O
27	fusion	O
28	of	O
29	separate	O
30	genes	O
31	during	O
32	the	O
33	course	O
34	of	O
35	evolution	O
36	generated	O
37	the	O
38	bifunctional	O
39	enzyme	O
40	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	(	I
6	EBV	I
7	)	I
8	latent	I
9	membrane	I
10	protein	I
11	1	I
12	(	O
13	LMP1	B
14	)	O
15	is	O
16	essential	O
17	for	O
18	EBV	O
19	-	O
20	mediated	O
21	transformation	O
22	of	O
23	primary	O
24	B	O
25	lymphocytes	O
26	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	Moreover	O
2	,	O
3	a	O
4	recombinant	O
5	Ad	O
6	expressing	O
7	Ad5	B
8	E4orf6	I
9	/	I
10	7	I
11	induced	O
12	apoptosis	O
13	in	O
14	rat	O
15	cells	O
16	when	O
17	coinfected	O
18	with	O
19	wild	O
20	-	O
21	type	O
22	p53	B
23	-	O
24	expressing	O
25	Ad	O
26	.	O

1	In	O
2	HCMV	O
3	(	O
4	Towne	O
5	)-	O
6	infected	O
7	HF	O
8	cells	O
9	at	O
10	24	O
11	to	O
12	48	O
13	h	O
14	,	O
15	IE2	B
16	also	O
17	accumulated	O
18	in	O
19	newly	O
20	formed	O
21	viral	O
22	DNA	O
23	replication	O
24	compartments	O
25	containing	O
26	the	O
27	polymerase	B
28	processivity	I
29	factor	I
30	(	O
31	UL44	B
32	),	O
33	the	O
34	single	B
35	-	I
36	stranded	I
37	DNA	I
38	binding	I
39	protein	I
40	(	O
41	SSB	B
42	;	O
43	UL57	B
44	),	O
45	the	O
46	UL112	B
47	-	I
48	113	I
49	accessory	I
50	protein	I
51	,	O
52	and	O
53	newly	O
54	incorporated	O
55	bromodeoxyuridine	O
56	(	O
57	BrdU	O
58	).	O

1	Macroscopic	O
2	researches	O
3	on	O
4	heart	O
5	vascularization	O
6	have	O
7	indicated	O
8	that	O
9	the	O
10	angioarchitecture	O
11	of	O
12	the	O
13	conducting	O
14	system	O
15	differs	O
16	from	O
17	that	O
18	of	O
19	the	O
20	normal	O
21	myocardium	O
22	.	O

1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	Measuring	O
6	urinary	O
7	LH	B
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	ovulation	O
16	.	O

1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	disease	O
7	-	O
8	free	O
9	survival	O
10	(	O
11	DFS	O
12	)	O
13	and	O
14	overall	O
15	survival	O
16	(	O
17	OS	O
18	),	O
19	prognostic	O
20	factors	O
21	,	O
22	and	O
23	treatment	O
24	-	O
25	related	O
26	mortality	O
27	of	O
28	women	O
29	with	O
30	stage	O
31	IIIB	O
32	inflammatory	O
33	breast	O
34	cancer	O
35	(	O
36	IBC	O
37	)	O
38	treated	O
39	with	O
40	combined	O
41	modality	O
42	therapy	O
43	(	O
44	CMT	O
45	)	O
46	and	O
47	high	O
48	-	O
49	dose	O
50	chemotherapy	O
51	(	O
52	HDCT	O
53	)	O
54	with	O
55	autologous	O
56	stem	O
57	-	O
58	cell	O
59	transplantation	O
60	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	100	O
7	-	O
8	kDa	O
9	mammalian	O
10	protein	O
11	,	O
12	which	O
13	was	O
14	recognized	O
15	by	O
16	an	O
17	anti	O
18	-	O
19	peptide	O
20	antibody	O
21	against	O
22	an	O
23	epitope	O
24	-	O
25	containing	O
26	nuclear	O
27	localization	O
28	signal	O
29	of	O
30	NF	B
31	-	I
32	kappaB	I
33	p65	I
34	subunit	I
35	.	O

1	Insulin	B
2	-	O
3	regulated	O
4	events	O
5	,	O
6	however	O
7	,	O
8	occur	O
9	in	O
10	all	O
11	cells	O
12	.	O

1	Regulatory	O
2	regions	O
3	in	O
4	the	O
5	promoter	O
6	and	O
7	third	O
8	intron	O
9	of	O
10	the	O
11	growth	B
12	hormone	I
13	gene	I
14	in	I
15	rainbow	I
16	trout	I
17	,	O
18	Oncorhynchus	O
19	mykiss	O
20	walbaum	O
21	.	O

1	Although	O
2	most	O
3	SFV	O
4	genes	O
5	have	O
6	homologs	O
7	encoded	O
8	by	O
9	other	O
10	Chordopoxvirinae	O
11	,	O
12	the	O
13	SFV	O
14	genome	O
15	lacks	O
16	a	O
17	key	O
18	gene	O
19	required	O
20	for	O
21	the	O
22	production	O
23	of	O
24	extracellular	O
25	enveloped	O
26	virus	O
27	.	O

1	They	O
2	self	O
3	-	O
4	completed	O
5	the	O
6	SF	O
7	-	O
8	36	O
9	questionnaire	O
10	and	O
11	their	O
12	QoL	O
13	was	O
14	described	O
15	and	O
16	retrospectively	O
17	compared	O
18	to	O
19	that	O
20	of	O
21	historical	O
22	controls	O
23	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	toward	O
6	an	O
7	association	O
8	between	O
9	IENF	O
10	and	O
11	sural	O
12	nerve	O
13	unmyelinated	O
14	fiber	O
15	densities	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	32	O
22	,	O
23	p	O
24	=	O
25	0	O
26	.	O
27	054	O
28	).	O

1	In	O
2	addition	O
3	,	O
4	media	O
5	containing	O
6	F	B
7	beta	I
8	alpha	I
9	/	O
10	CG	B
11	beta	I
12	displayed	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	to	O
18	both	O
19	CG	B
20	and	I
21	FSH	I
22	receptors	I
23	.	O

1	In	O
2	contrast	O
3	,	O
4	AP	B
5	-	I
6	2	I
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	T47D	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	blots	O
19	confirmed	O
20	increased	O
21	AP	B
22	-	I
23	2	I
24	protein	I
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O

1	N	O
2	.	O
3	van	O
4	Hoek	O
5	,	O
6	and	O
7	M	O
8	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	B
24	transcriptosomal	I
25	component	I
26	scaffold	I
27	attachment	I
28	factor	I
29	B	I
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	These	O
2	mutants	O
3	all	O
4	failed	O
5	to	O
6	interact	O
7	with	O
8	the	O
9	TraR	B
10	fusion	I
11	in	O
12	the	O
13	two	O
14	-	O
15	hybrid	O
16	system	O
17	.	O

1	PhoP	B
2	-	O
3	PhoQ	B
4	homologues	O
5	in	O
6	Pseudomonas	O
7	aeruginosa	O
8	regulate	O
9	expression	O
10	of	O
11	the	O
12	outer	B
13	-	I
14	membrane	I
15	protein	I
16	OprH	I
17	and	O
18	polymyxin	O
19	B	O
20	resistance	O
21	.	O

1	Deletion	O
2	of	O
3	fdsR	B
4	revealed	O
5	a	O
6	dual	O
7	regulatory	O
8	effect	O
9	of	O
10	FdsR	B
11	on	O
12	the	O
13	fds	B
14	operon	I
15	by	O
16	acting	O
17	as	O
18	transcriptional	O
19	activator	O
20	in	O
21	the	O
22	presence	O
23	of	O
24	formate	O
25	or	O
26	as	O
27	repressor	O
28	in	O
29	the	O
30	absence	O
31	of	O
32	formate	O
33	.	O

1	With	O
2	constructs	O
3	containing	O
4	the	O
5	binding	O
6	site	O
7	of	O
8	one	O
9	gene	O
10	fused	O
11	to	O
12	the	O
13	promoter	O
14	of	O
15	the	O
16	other	O
17	,	O
18	we	O
19	demonstrated	O
20	that	O
21	the	O
22	positional	O
23	requirements	O
24	are	O
25	a	O
26	function	O
27	of	O
28	the	O
29	specific	O
30	binding	O
31	site	O
32	,	O
33	not	O
34	the	O
35	promoter	O
36	.	O

1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	Opa	B
7	proteins	I
8	of	O
9	C751	O
10	bind	O
11	equally	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	carcinoembryonic	B
22	antigen	I
23	[	O
24	CEA	B
25	(	O
26	CD66e	B
27	)]	O
28	subgroup	O
29	of	O
30	the	O
31	CD66	B
32	family	I
33	,	O
34	but	O
35	show	O
36	distinct	O
37	tropism	O
38	for	O
39	CGM1	B
40	-	O
41	(	O
42	CD66d	B
43	)	O
44	and	O
45	NCA	B
46	(	O
47	CD66c	B
48	)-	O
49	expressing	O
50	cells	O
51	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	O
27	-	O
28	M1	O
29	-	O
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	The	O
2	MXR	B
3	gene	I
4	encodes	O
5	a	O
6	half	O
7	-	O
8	transporter	O
9	and	O
10	the	O
11	absence	O
12	of	O
13	cytogenetic	O
14	evidence	O
15	of	O
16	coamplification	O
17	of	O
18	other	O
19	regions	O
20	suggests	O
21	that	O
22	a	O
23	partner	O
24	may	O
25	not	O
26	be	O
27	overexpressed	O
28	,	O
29	and	O
30	instead	O
31	the	O
32	MXR	B
33	half	I
34	-	I
35	transporter	I
36	homodimerizes	O
37	to	O
38	mediate	O
39	drug	O
40	transport	O
41	.	O

1	The	O
2	effect	O
3	of	O
4	smoking	O
5	was	O
6	not	O
7	examined	O
8	in	O
9	this	O
10	study	O
11	,	O
12	as	O
13	such	O
14	data	O
15	were	O
16	not	O
17	available	O
18	.	O

1	Serum	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	I	I
8	(	O
9	IGF	B
10	-	I
11	I	I
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O

1	BACKGROUND	O
2	:	O
3	Measurement	O
4	of	O
5	stereoacuity	O
6	at	O
7	varying	O
8	distances	O
9	,	O
10	by	O
11	real	O
12	or	O
13	simulated	O
14	depth	O
15	stereoacuity	O
16	tests	O
17	,	O
18	is	O
19	helpful	O
20	in	O
21	the	O
22	evaluation	O
23	of	O
24	patients	O
25	with	O
26	binocular	O
27	imbalance	O
28	or	O
29	strabismus	O
30	.	O

1	Additional	O
2	studies	O
3	revealed	O
4	that	O
5	bovine	B
6	brain	I
7	Galpha	I
8	(	I
9	q	I
10	/	I
11	11	I
12	)	I
13	could	O
14	also	O
15	bind	O
16	to	O
17	an	O
18	N	O
19	-	O
20	terminal	O
21	construct	O
22	of	O
23	GRK2	B
24	,	O
25	while	O
26	no	O
27	binding	O
28	of	O
29	Galpha	O
30	(	O
31	q	O
32	/	O
33	11	O
34	),	O
35	Galpha	O
36	(	O
37	s	O
38	),	O
39	Galpha	O
40	(	O
41	i	O
42	),	O
43	or	O
44	Galpha	B
45	(	I
46	12	I
47	/	I
48	13	I
49	)	I
50	to	O
51	comparable	O
52	constructs	O
53	of	O
54	GRK5	B
55	or	O
56	GRK6	B
57	was	O
58	observed	O
59	.	O

1	The	O
2	elm1	B
3	kinase	I
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O

1	Reverse	O
2	transcription	O
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	B
22	kinases	I
23	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	O
6	activity	O
7	of	O
8	p300	B
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	O
15	the	O
16	broadly	O
17	essential	O
18	activation	O
19	function	O
20	of	O
21	the	O
22	CH3	B
23	domain	I
24	/	O
25	E1A	B
26	-	O
27	binding	O
28	region	O
29	.	O

1	The	O
2	proliferation	O
3	-	O
4	specific	O
5	HNF	B
6	-	I
7	3	I
8	/	O
9	fork	B
10	head	I
11	homolog	I
12	-	I
13	11B	I
14	protein	O
15	(	O
16	HFH	B
17	-	I
18	11B	I
19	;	O
20	also	O
21	known	O
22	as	O
23	Trident	B
24	and	O
25	Win	B
26	)	O
27	is	O
28	a	O
29	family	O
30	member	O
31	of	O
32	the	O
33	winged	B
34	helix	I
35	/	O
36	fork	B
37	head	I
38	transcription	O
39	factors	O
40	and	O
41	in	O
42	regenerating	O
43	liver	O
44	its	O
45	expression	O
46	is	O
47	reactivated	O
48	prior	O
49	to	O
50	hepatocyte	O
51	entry	O
52	into	O
53	DNA	O
54	replication	O
55	(	O
56	S	O
57	phase	O
58	).	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	B
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	B
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	The	O
2	multiple	O
3	functions	O
4	of	O
5	Pmt3p	B
6	described	O
7	here	O
8	suggest	O
9	that	O
10	several	O
11	nuclear	O
12	proteins	O
13	are	O
14	regulated	O
15	by	O
16	Pmt3p	B
17	conjugation	O
18	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	We	O
2	determined	O
3	whether	O
4	a	O
5	single	O
6	injection	O
7	of	O
8	slow	O
9	-	O
10	release	O
11	estradiol	O
12	-	O
13	17beta	O
14	(	O
15	SRE2	O
16	)	O
17	would	O
18	induce	O
19	pseudopregnancy	O
20	in	O
21	gilts	O
22	and	O
23	whether	O
24	PGF2alpha	O
25	would	O
26	regress	O
27	the	O
28	corpora	O
29	lutea	O
30	(	O
31	CL	O
32	)	O
33	of	O
34	pseudopregnancy	O
35	.	O

1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	Activation	O
2	of	O
3	T	O
4	cells	O
5	via	O
6	the	O
7	TCR	B
8	and	O
9	other	O
10	costimulatory	O
11	receptors	O
12	triggers	O
13	a	O
14	number	O
15	of	O
16	signaling	O
17	cascades	O
18	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	with	O
5	the	O
6	TK	B
7	domains	I
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	scavenger	B
19	RTK	I
20	(	O
21	all	O
22	domains	O
23	comprise	O
24	the	O
25	signature	O
26	for	O
27	the	O
28	TK	B
29	class	I
30	II	I
31	receptors	I
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	distantly	O
38	related	O
39	to	O
40	the	O
41	insulin	B
42	and	O
43	insulin	B
44	-	I
45	like	I
46	receptors	I
47	.	O

1	Several	O
2	7SL	B
3	RNA	I
4	-	I
5	encoding	I
6	sequences	I
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	B
17	fragments	I
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	B
10	anemia	I
11	group	I
12	C	I
13	protein	I
14	(	O
15	FANCC	B
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	both	O
6	transcription	O
7	activators	O
8	depend	O
9	on	O
10	or	O
11	interact	O
12	with	O
13	different	O
14	subunits	O
15	of	O
16	RNA	B
17	polymerase	I
18	,	O
19	although	O
20	their	O
21	role	O
22	in	O
23	formation	O
24	of	O
25	proper	O
26	DNA	O
27	geometry	O
28	may	O
29	also	O
30	be	O
31	crucial	O
32	.	O

1	Klebsiella	O
2	oxytoca	O
3	can	O
4	assimilate	O
5	nitrate	O
6	and	O
7	nitrite	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	nasFEDCBA	B
15	operon	I
16	.	O

1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	B
17	aminotransferase	I
18	.	O

1	Studies	O
2	have	O
3	substantiated	O
4	the	O
5	involvement	O
6	of	O
7	numerous	O
8	loci	O
9	on	O
10	certain	O
11	chromosomes	O
12	;	O
13	in	O
14	excess	O
15	of	O
16	10	O
17	chromosomes	O
18	are	O
19	thought	O
20	to	O
21	be	O
22	involved	O
23	.	O

1	By	O
2	negatively	O
3	regulating	O
4	GRK	B
5	-	O
6	mediated	O
7	receptor	O
8	phosphorylation	O
9	,	O
10	beta	B
11	-	I
12	arrestin	I
13	-	O
14	mediated	O
15	processes	O
16	such	O
17	as	O
18	Src	B
19	recruitment	O
20	and	O
21	clathrin	B
22	-	O
23	mediated	O
24	internalization	O
25	,	O
26	which	O
27	are	O
28	required	O
29	for	O
30	GPCR	B
31	-	O
32	mediated	O
33	ERK	B
34	activation	O
35	,	O
36	are	O
37	inhibited	O
38	,	O
39	thus	O
40	dampening	O
41	further	O
42	ERK	B
43	activation	O
44	.	O

1	Based	O
2	on	O
3	subcellular	O
4	fractionation	O
5	,	O
6	the	O
7	47	B
8	-	I
9	kDa	I
10	P	I
11	-	I
12	CIP2	I
13	protein	I
14	is	O
15	mostly	O
16	cytosolic	O
17	.	O

1	Supershift	O
2	EMSAs	O
3	identified	O
4	that	O
5	upstream	B
6	stimulatory	I
7	factor	I
8	-	I
9	1	I
10	and	I
11	-	I
12	2	I
13	(	O
14	USF	B
15	-	I
16	1	I
17	and	I
18	-	I
19	2	I
20	)	O
21	were	O
22	part	O
23	of	O
24	these	O
25	complexes	O
26	.	O

1	Conversely	O
2	,	O
3	E1A	B
4	binding	O
5	to	O
6	only	O
7	p300	B
8	/	O
9	CBP	B
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	B
16	enzyme	I
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	B
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O

1	Analysis	O
2	of	O
3	its	O
4	genomic	O
5	region	O
6	revealed	O
7	that	O
8	the	O
9	13	O
10	-	O
11	kb	O
12	Cdc6	B
13	gene	I
14	is	O
15	divided	O
16	into	O
17	12	O
18	exons	O
19	by	O
20	11	O
21	introns	O
22	.	O

1	These	O
2	include	O
3	the	O
4	CACCC	O
5	and	O
6	CAAT	O
7	motifs	O
8	.	O

1	Skin	O
2	pH	O
3	changes	O
4	associated	O
5	with	O
6	iontophoresis	O
7	.	O

1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O

1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	cassettes	O
8	harboring	O
9	the	O
10	murine	B
11	D1A	I
12	gene	I
13	promoter	I
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	transgenes	O
24	in	O
25	vivo	O
26	.	O

1	It	O
2	may	O
3	be	O
4	dependent	O
5	on	O
6	location	O
7	of	O
8	a	O
9	focus	O
10	(	O
11	according	O
12	to	O
13	EEG	O
14	)	O
15	as	O
16	well	O
17	as	O
18	on	O
19	the	O
20	character	O
21	and	O
22	manifestation	O
23	of	O
24	the	O
25	accompanying	O
26	neuropsychologic	O
27	symptomatology	O
28	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	demonstrate	O
7	that	O
8	the	O
9	rat	O
10	HDL	O
11	receptor	O
12	SR	B
13	-	I
14	BI	I
15	promoter	O
16	contains	O
17	two	O
18	sterol	O
19	response	O
20	elements	O
21	(	O
22	pSRE	O
23	and	O
24	dSRE	O
25	)	O
26	through	O
27	which	O
28	SREBP	B
29	-	I
30	1a	I
31	can	O
32	bind	O
33	and	O
34	activate	O
35	transcription	O
36	of	O
37	this	O
38	gene	O
39	.	O

1	Phosphorylation	O
2	of	O
3	myosin	B
4	-	I
5	binding	I
6	subunit	I
7	(	O
8	MBS	B
9	)	O
10	of	O
11	myosin	B
12	phosphatase	I
13	by	O
14	Rho	B
15	-	I
16	kinase	I
17	in	O
18	vivo	O
19	.	O

1	Of	O
2	these	O
3	patients	O
4	,	O
5	46	O
6	,	O
7	164	O
8	were	O
9	placed	O
10	on	O
11	a	O
12	waiting	O
13	list	O
14	for	O
15	transplantation	O
16	,	O
17	23	O
18	,	O
19	275	O
20	of	O
21	whom	O
22	received	O
23	a	O
24	first	O
25	cadaveric	O
26	transplant	O
27	between	O
28	1991	O
29	and	O
30	1997	O
31	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	(	O
7	EMSA	O
8	),	O
9	this	O
10	GLUT4	B
11	repressor	I
12	element	I
13	(	O
14	G4RE	B
15	)	O
16	generated	O
17	specific	O
18	bands	O
19	with	O
20	nuclear	O
21	extracts	O
22	from	O
23	preadipocytes	O
24	,	O
25	but	O
26	not	O
27	from	O
28	adipocytes	O
29	.	O

1	Syndromes	O
2	of	O
3	abnormal	O
4	fat	O
5	redistribution	O
6	and	O
7	metabolic	O
8	complications	O
9	in	O
10	HIV	O
11	-	O
12	infected	O
13	patients	O
14	.	O

1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O

1	Immunohistochemical	O
2	staining	O
3	was	O
4	positive	O
5	for	O
6	S	B
7	-	I
8	100	I
9	in	O
10	all	O
11	9	O
12	cases	O
13	stained	O
14	,	O
15	positive	O
16	for	O
17	HMB	B
18	-	I
19	45	I
20	in	O
21	9	O
22	(	O
23	90	O
24	%)	O
25	of	O
26	10	O
27	,	O
28	and	O
29	negative	O
30	for	O
31	cytokeratin	B
32	in	O
33	all	O
34	9	O
35	cases	O
36	in	O
37	which	O
38	myxoid	O
39	melanoma	O
40	remained	O
41	in	O
42	the	O
43	block	O
44	after	O
45	previous	O
46	sections	O
47	.	O

1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O

1	Residual	O
2	urinary	O
3	abnormalities	O
4	were	O
5	significantly	O
6	more	O
7	frequent	O
8	in	O
9	patients	O
10	with	O
11	type	O
12	III	O
13	than	O
14	type	O
15	I	O
16	MPGN	O
17	.	O

1	Taken	O
2	together	O
3	,	O
4	differences	O
5	in	O
6	signaling	O
7	and	O
8	tissue	O
9	expression	O
10	suggest	O
11	that	O
12	the	O
13	human	B
14	intermediate	I
15	PRLr	I
16	differs	O
17	from	O
18	the	O
19	long	B
20	PRLr	I
21	in	O
22	physiological	O
23	function	O
24	.	O

1	We	O
2	describe	O
3	here	O
4	a	O
5	Drosophila	B
6	melanogaster	I
7	FAK	I
8	homologue	I
9	,	O
10	DFak56	B
11	,	O
12	which	O
13	maps	O
14	to	O
15	band	O
16	56D	O
17	on	O
18	the	O
19	right	O
20	arm	O
21	of	O
22	the	O
23	second	O
24	chromosome	O
25	.	O

1	Because	O
2	the	O
3	Pit	B
4	-	I
5	1	I
6	sites	I
7	in	O
8	the	O
9	hGH	B
10	-	I
11	N	I
12	gene	I
13	promoter	I
14	are	O
15	insufficient	O
16	for	O
17	such	O
18	gene	O
19	activation	O
20	in	O
21	vivo	O
22	,	O
23	these	O
24	data	O
25	suggested	O
26	a	O
27	unique	O
28	chromatin	O
29	-	O
30	mediated	O
31	developmental	O
32	role	O
33	for	O
34	Pit	B
35	-	I
36	1	I
37	in	O
38	the	O
39	hGH	B
40	LCR	I
41	.	O

1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	third	O
7	SH3	B
8	domain	I
9	binds	O
10	to	O
11	Sos	B
12	,	O
13	a	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	for	O
19	Ras	B
20	and	O
21	Rac	B
22	,	O
23	both	O
24	in	O
25	vitro	O
26	and	O
27	in	O
28	vivo	O
29	.	O

1	Point	O
2	mutations	O
3	in	O
4	the	O
5	third	O
6	SH3	B
7	domain	I
8	abolished	O
9	the	O
10	vinexin	B
11	-	O
12	Sos	B
13	interaction	O
14	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	B
12	to	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	AtpC	I
18	promoter	I
19	sequence	I
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	AtpC	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	etiolated	O
40	and	O
41	photobleached	O
42	seedlings	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	AtpC	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	O
72	seedlings	O
73	treated	O
74	with	O
75	cytokinin	B
76	.	O

1	Mycoplasma	O
2	hominis	O
3	infections	O
4	are	O
5	easily	O
6	missed	O
7	because	O
8	conventional	O
9	methods	O
10	for	O
11	bacterial	O
12	detection	O
13	may	O
14	fail	O
15	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	we	O
6	used	O
7	a	O
8	series	O
9	of	O
10	plasmid	O
11	constructs	O
12	encoding	O
13	different	O
14	forms	O
15	of	O
16	the	O
17	envelope	B
18	glycoprotein	I
19	E	I
20	of	I
21	the	I
22	flavivirus	I
23	tick	I
24	-	I
25	borne	I
26	encephalitis	I
27	virus	I
28	.	O

1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	B
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O

1	To	O
2	define	O
3	the	O
4	minimal	O
5	VDRE	O
6	binding	O
7	domain	O
8	for	O
9	human	B
10	VDR	I
11	(	O
12	hVDR	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	O
18	-	O
19	terminally	O
20	truncated	O
21	hVDR	B
22	mutants	I
23	(	O
24	Delta134	O
25	,	O
26	Delta113	O
27	,	O
28	Delta102	O
29	,	O
30	Delta90	O
31	,	O
32	Delta84	O
33	,	O
34	Delta80	O
35	,	O
36	and	O
37	Delta60	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O

1	By	O
2	an	O
3	induced	O
4	-	O
5	fit	O
6	mechanism	O
7	,	O
8	contacts	O
9	with	O
10	the	O
11	anticodon	O
12	can	O
13	activate	O
14	formation	O
15	of	O
16	a	O
17	robust	O
18	transition	O
19	state	O
20	at	O
21	a	O
22	site	O
23	over	O
24	70	O
25	A	O
26	away	O
27	.	O

1	These	O
2	REPs	O
3	,	O
4	or	O
5	clusters	O
6	of	O
7	paralogous	O
8	loci	O
9	,	O
10	are	O
11	15	O
12	-	O
13	100	O
14	kb	O
15	and	O
16	harbor	O
17	at	O
18	least	O
19	four	O
20	ESTs	O
21	and	O
22	an	O
23	expressed	O
24	SH3GL	B
25	pseudogene	I
26	.	O

1	This	O
2	revealed	O
3	a	O
4	minimum	O
5	of	O
6	six	O
7	novel	O
8	OSBP	B
9	-	I
10	related	I
11	proteins	I
12	,	O
13	designated	O
14	ORP	B
15	-	I
16	1	I
17	to	O
18	ORP	B
19	-	I
20	6	I
21	.	O

1	In	O
2	part	O
3	as	O
4	a	O
5	result	O
6	of	O
7	its	O
8	inability	O
9	to	O
10	sustain	O
11	radiative	O
12	loses	O
13	,	O
14	the	O
15	BB	O
16	resonator	O
17	has	O
18	extremely	O
19	low	O
20	RF	O
21	power	O
22	requirements	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	narZ	B
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O

1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	O
8	gene	O
9	expression	O
10	in	O
11	the	O
12	CNS	O
13	are	O
14	poorly	O
15	understood	O
16	.	O

1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O

1	A	O
2	key	O
3	event	O
4	in	O
5	this	O
6	process	O
7	is	O
8	the	O
9	selective	O
10	recognition	O
11	of	O
12	the	O
13	target	O
14	membrane	O
15	by	O
16	the	O
17	vesicle	O
18	and	O
19	the	O
20	current	O
21	view	O
22	is	O
23	that	O
24	SNARE	B
25	protein	I
26	interactions	O
27	likely	O
28	play	O
29	a	O
30	central	O
31	role	O
32	in	O
33	vesicle	O
34	-	O
35	target	O
36	recognition	O
37	and	O
38	or	O
39	membrane	O
40	fusion	O
41	.	O

1	Scapulae	O
2	with	O
3	a	O
4	Type	O
5	I	O
6	configuration	O
7	were	O
8	found	O
9	to	O
10	have	O
11	low	O
12	values	O
13	for	O
14	the	O
15	coraco	O
16	-	O
17	glenoid	O
18	angle	O
19	and	O
20	coracoid	O
21	overlap	O
22	,	O
23	which	O
24	are	O
25	known	O
26	to	O
27	be	O
28	associated	O
29	with	O
30	a	O
31	short	O
32	coraco	O
33	-	O
34	humeral	O
35	distance	O
36	.	O

1	Measurements	O
2	in	O
3	the	O
4	LWS	O
5	p	O
6	.	O
7	a	O
8	.	O
9	,	O
10	LWS	O
11	lat	O
12	.	O
13	and	O
14	at	O
15	Ward	O
16	'	O
17	s	O
18	triangle	O
19	were	O
20	made	O
21	in	O
22	a	O
23	total	O
24	of	O
25	100	O
26	patients	O
27	.	O

1	A	O
2	group	O
3	of	O
4	66	O
5	DSM	O
6	-	O
7	IV	O
8	paranoid	O
9	schizophrenic	O
10	in	O
11	-	O
12	patients	O
13	were	O
14	assessed	O
15	three	O
16	times	O
17	using	O
18	the	O
19	SAPS	O
20	,	O
21	SANS	O
22	,	O
23	BPRS	O
24	and	O
25	PAS	O
26	.	O

1	In	O
2	conclusion	O
3	:	O
4	(	O
5	i	O
6	)	O
7	TECRA	O
8	kit	O
9	is	O
10	suggested	O
11	to	O
12	be	O
13	used	O
14	for	O
15	screening	O
16	SE	O
17	producing	O
18	strains	O
19	;	O
20	(	O
21	ii	O
22	)	O
23	SET	O
24	-	O
25	RPLA	O
26	and	O
27	RIDASCREEN	O
28	kits	O
29	are	O
30	suitable	O
31	for	O
32	epidemiological	O
33	investigation	O
34	of	O
35	SE	O
36	types	O
37	,	O
38	but	O
39	the	O
40	lack	O
41	of	O
42	ability	O
43	for	O
44	detecting	O
45	SEE	O
46	,	O
47	long	O
48	time	O
49	required	O
50	for	O
51	testing	O
52	with	O
53	SET	O
54	-	O
55	RPLA	O
56	kit	O
57	and	O
58	high	O
59	background	O
60	when	O
61	using	O
62	RIDASCREEN	O
63	kit	O
64	must	O
65	be	O
66	overcome	O
67	;	O
68	and	O
69	(	O
70	iii	O
71	)	O
72	because	O
73	of	O
74	the	O
75	complicated	O
76	test	O
77	procedures	O
78	and	O
79	the	O
80	lack	O
81	of	O
82	ability	O
83	for	O
84	detecting	O
85	SEE	O
86	,	O
87	the	O
88	practicality	O
89	of	O
90	SET	O
91	-	O
92	EIA	O
93	kit	O
94	in	O
95	screening	O
96	and	O
97	epidemiological	O
98	research	O
99	purposes	O
100	is	O
101	low	O
102	.	O

1	Comparison	O
2	of	O
3	immunoassay	O
4	kits	O
5	for	O
6	detection	O
7	of	O
8	staphylococcal	B
9	enterotoxins	I
10	produced	O
11	by	O
12	Staphylococcus	O
13	aureus	O

1	Despite	O
2	the	O
3	high	O
4	frequency	O
5	of	O
6	natural	O
7	infection	O
8	,	O
9	the	O
10	seropositive	O
11	rates	O
12	of	O
13	JEV	O
14	antibody	O
15	still	O
16	correlated	O
17	well	O
18	with	O
19	the	O
20	dose	O
21	of	O
22	vaccine	O
23	received	O
24	,	O
25	i	O
26	.	O
27	e	O
28	.,	O
29	67	O
30	%	O
31	(	O
32	1122	O
33	/	O
34	1664	O
35	),	O
36	66	O
37	%	O
38	(	O
39	65	O
40	/	O
41	97	O
42	),	O
43	33	O
44	%	O
45	(	O
46	4	O
47	/	O
48	12	O
49	)	O
50	and	O
51	40	O
52	%	O
53	(	O
54	19	O
55	/	O
56	47	O
57	)	O
58	for	O
59	children	O
60	receiving	O
61	3	O
62	,	O
63	2	O
64	,	O
65	1	O
66	,	O
67	and	O
68	0	O
69	dose	O
70	of	O
71	JE	O
72	vaccines	O
73	,	O
74	respectively	O
75	(	O
76	P	O
77	<	O
78	0	O
79	.	O
80	0001	O
81	Chi	O
82	-	O
83	square	O
84	for	O
85	trend	O
86	test	O
87	).	O

1	Furthermore	O
2	,	O
3	in	O
4	vivo	O
5	and	O
6	in	O
7	vitro	O
8	protein	O
9	-	O
10	protein	O
11	interaction	O
12	experiments	O
13	have	O
14	shown	O
15	that	O
16	SR33	B
17	protein	I
18	interacts	O
19	with	O
20	itself	O
21	and	O
22	with	O
23	SR45	B
24	protein	I
25	but	O
26	not	O
27	with	O
28	two	O
29	other	O
30	members	O
31	(	O
32	SRZ21	B
33	and	O
34	SRZ22	B
35	)	O
36	of	O
37	the	O
38	SR	B
39	family	I
40	that	O
41	are	O
42	known	O
43	to	O
44	interact	O
45	with	O
46	the	O
47	Arabidopsis	O
48	full	O
49	-	O
50	length	O
51	U	B
52	-	I
53	70K	I
54	only	O
55	.	O

1	In	O
2	summary	O
3	,	O
4	WT1	B
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	B
17	,	O
18	the	O
19	U5	B
20	small	I
21	nuclear	I
22	RNP	I
23	-	I
24	associated	I
25	protein	I
26	p116	I
27	and	O
28	hnRNP	O
29	A1	B
30	.	O

1	Six	O
2	out	O
3	of	O
4	ten	O
5	hearts	O
6	from	O
7	macerated	O
8	stillborn	O
9	infants	O
10	showed	O
11	varying	O
12	degrees	O
13	of	O
14	positive	O
15	staining	O
16	.	O

1	Tih1	B
2	maps	O
3	to	O
4	distal	O
5	mouse	O
6	Chr	O
7	1	O
8	and	O
9	human	O
10	Chr	O
11	1q31	O
12	,	O
13	chromosomal	O
14	regions	O
15	that	O
16	have	O
17	not	O
18	shown	O
19	evidence	O
20	for	O
21	imprinting	O
22	and	O
23	,	O
24	in	O
25	contrast	O
26	to	O
27	Ipl	B
28	,	O
29	Tih1	B
30	is	O
31	expressed	O
32	equally	O
33	from	O
34	both	O
35	parental	O
36	alleles	O
37	.	O

1	A	O
2	novel	O
3	pleckstrin	B
4	homology	I
5	-	I
6	related	I
7	gene	I
8	family	I
9	defined	O
10	by	O
11	Ipl	B
12	/	O
13	Tssc3	B
14	,	O
15	TDAG51	B
16	,	O
17	and	O
18	Tih1	B
19	:	O
20	tissue	O
21	-	O
22	specific	O
23	expression	O
24	,	O
25	chromosomal	O
26	location	O
27	,	O
28	and	O
29	parental	O
30	imprinting	O
31	.	O

1	The	O
2	potential	O
3	for	O
4	highly	O
5	reactive	O
6	nanoparticles	O
7	(	O
8	RNP	O
9	)	O
10	to	O
11	absorb	O
12	destructively	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.	O
18	to	O
19	neutralize	O
20	highly	O
21	toxic	O
22	substances	O
23	such	O
24	as	O
25	the	O
26	warfare	O
27	agents	O
28	GA	O
29	,	O
30	GB	O
31	,	O
32	HD	O
33	and	O
34	VX	O
35	,	O
36	has	O
37	been	O
38	demonstrated	O
39	in	O
40	the	O
41	laboratory	O
42	.	O

1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O

1	Twelve	O
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	troponin	B
10	I	I
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	Axsym	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	Immuno	O
41	1	O
42	.	O

1	Therefore	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	p27	B
7	represents	O
8	a	O
9	crucial	O
10	molecule	O
11	in	O
12	HMBA	O
13	signaling	O
14	that	O
15	cannot	O
16	be	O
17	replaced	O
18	by	O
19	p21	B
20	.	O

1	Transient	O
2	,	O
3	high	O
4	-	O
5	level	O
6	Ras	B
7	-	O
8	expression	O
9	induces	O
10	transcriptional	O
11	activation	O
12	of	O
13	p21	B
14	mediated	O
15	by	O
16	a	O
17	GC	O
18	-	O
19	rich	O
20	region	O
21	in	O
22	p21	B
23	promoter	I
24	-	O
25	83	O
26	-	O
27	54	O
28	bp	O
29	relative	O
30	to	O
31	the	O
32	transcription	O
33	initiation	O
34	site	O
35	containing	O
36	binding	O
37	sites	O
38	for	O
39	Sp1	B
40	-	I
41	family	I
42	transcription	I
43	factors	I
44	.	O

1	The	O
2	RET	B
3	/	O
4	PTC3	B
5	rearrangement	O
6	is	O
7	formed	O
8	by	O
9	fusion	O
10	of	O
11	the	O
12	ELE1	B
13	and	O
14	RET	B
15	genes	I
16	,	O
17	and	O
18	is	O
19	highly	O
20	prevalent	O
21	in	O
22	radiation	O
23	-	O
24	induced	O
25	post	O
26	-	O
27	Chernobyl	O
28	papillary	O
29	thyroid	O
30	carcinomas	O
31	.	O

1	Apoptosis	O
2	of	O
3	small	O
4	cells	O
5	is	O
6	still	O
7	observed	O
8	after	O
9	co	O
10	-	O
11	transfection	O
12	of	O
13	JBD	B
14	and	O
15	LMP1	B
16	but	O
17	in	O
18	addition	O
19	a	O
20	few	O
21	apoptotic	O
22	HD	O
23	-	O
24	MyZ	O
25	cells	O
26	with	O
27	large	O
28	fused	O
29	nuclear	O
30	masses	O
31	are	O
32	identified	O
33	suggesting	O
34	that	O
35	specific	O
36	inhibition	O
37	of	O
38	JNK	B
39	leads	O
40	also	O
41	to	O
42	apoptosis	O
43	of	O
44	LMP1	B
45	induced	O
46	RS	O
47	cells	O
48	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	bZIP	B
6	protein	I
7	Opaque2	I
8	(	O
9	O2	B
10	),	O
11	there	O
12	are	O
13	other	O
14	maize	O
15	endosperm	O
16	nuclear	O
17	proteins	O
18	that	O
19	recognize	O
20	the	O
21	O2	B
22	box	I
23	in	O
24	22	O
25	kDa	O
26	zein	B
27	gene	O
28	promoters	O
29	.	O

1	The	O
2	mEmBP	B
3	-	I
4	1	I
5	protein	I
6	can	O
7	activate	O
8	transcription	O
9	from	O
10	a	O
11	truncated	O
12	promoter	O
13	containing	O
14	a	O
15	pentamer	O
16	of	O
17	the	O
18	O2	B
19	site	I
20	in	O
21	yeast	O
22	cells	O
23	;	O
24	however	O
25	,	O
26	it	O
27	inhibited	O
28	regulated	O
29	transcription	O
30	of	O
31	a	O
32	22	B
33	kDa	I
34	zein	I
35	promoter	I
36	in	O
37	a	O
38	transient	O
39	expression	O
40	assay	O
41	using	O
42	cultured	O
43	maize	O
44	endosperm	O
45	cells	O
46	.	O

1	GHB	O
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O

1	There	O
2	were	O
3	15	O
4	deaths	O
5	,	O
6	seven	O
7	of	O
8	which	O
9	were	O
10	felt	O
11	to	O
12	be	O
13	avoidable	O
14	.	O

1	With	O
2	this	O
3	GH	B
4	and	O
5	estrogen	O
6	treatment	O
7	regimen	O
8	,	O
9	most	O
10	girls	O
11	with	O
12	TS	O
13	can	O
14	grow	O
15	and	O
16	develop	O
17	much	O
18	more	O
19	in	O
20	conformity	O
21	with	O
22	their	O
23	healthy	O
24	peers	O
25	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	reduced	O
6	responsiveness	O
7	of	O
8	CYP3A2	B
9	is	O
10	the	O
11	result	O
12	of	O
13	preferential	O
14	binding	O
15	of	O
16	COUP	B
17	-	I
18	TF	I
19	at	O
20	the	O
21	CYP3A2	B
22	DexRE	I
23	-	I
24	1	I
25	site	I
26	.	O

1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	B
17	promoter	I
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O

1	To	O
2	understand	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	increased	O
8	cell	O
9	surface	O
10	stability	O
11	compared	O
12	with	O
13	wild	O
14	-	O
15	type	O
16	peptide	O
17	and	O
18	to	O
19	understand	O
20	the	O
21	differences	O
22	in	O
23	T	O
24	cell	O
25	recognition	O
26	between	O
27	I1Y	B
28	and	O
29	I1F	B
30	,	O
31	we	O
32	determined	O
33	the	O
34	x	O
35	-	O
36	ray	O
37	crystal	O
38	structures	O
39	of	O
40	the	O
41	two	O
42	class	B
43	I	I
44	MHC	I
45	-	I
46	peptide	I
47	complexes	I
48	.	O

1	Redistribution	O
2	of	O
3	mannosidase	B
4	I	I
5	was	O
6	also	O
7	observed	O
8	in	O
9	cells	O
10	incubated	O
11	at	O
12	15	O
13	degrees	O
14	C	O
15	.	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	O
11	like	O
12	GTPases	B
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	B
21	,	O
22	beta1D	B
23	,	O
24	or	O
25	IL2R	B
26	-	O
27	beta1A	B
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	O

1	In	O
2	conclusion	O
3	,	O
4	our	O
5	data	O
6	do	O
7	not	O
8	support	O
9	a	O
10	role	O
11	for	O
12	IVIg	B
13	in	O
14	the	O
15	remyelination	O
16	of	O
17	stable	O
18	multiple	O
19	sclerosis	O
20	lesions	O
21	as	O
22	measured	O
23	by	O
24	central	O
25	conduction	O
26	time	O
27	.	O

1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O

1	Relative	O
2	to	O
3	coherent	O
4	control	O
5	words	O
6	(	O
7	e	O
8	.	O
9	g	O
10	.,	O
11	quick	O
12	),	O
13	these	O
14	discourse	O
15	-	O
16	dependent	O
17	semantic	O
18	anomalies	O
19	elicited	O
20	a	O
21	large	O
22	N400	O
23	effect	O
24	that	O
25	began	O
26	at	O
27	about	O
28	200	O
29	to	O
30	250	O
31	msec	O
32	after	O
33	word	O
34	onset	O
35	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	Like	O
2	the	O
3	Tob	B
4	protein	I
5	,	O
6	Tob2	B
7	inhibited	O
8	cell	O
9	cycle	O
10	progression	O
11	from	O
12	the	O
13	G0	O
14	/	O
15	G1	O
16	to	O
17	S	O
18	phases	O
19	.	O

1	The	O
2	coordinate	O
3	increase	O
4	in	O
5	cyclin	B
6	D1	I
7	and	O
8	p21	B
9	had	O
10	the	O
11	effect	O
12	of	O
13	decreasing	O
14	the	O
15	specific	O
16	but	O
17	not	O
18	absolute	O
19	activity	O
20	of	O
21	cyclin	B
22	D1	I
23	/	O
24	cdk4	B
25	.	O
26	p53	B
27	was	O
28	not	O
29	involved	O
30	since	O
31	CSF	B
32	-	I
33	1	I
34	induction	O
35	of	O
36	p21	B
37	was	O
38	unaffected	O
39	by	O
40	dominant	B
41	-	I
42	negative	I
43	p53	I
44	expression	O
45	.	O

1	In	O
2	addition	O
3	,	O
4	SLK	B
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	B
10	and	I
11	nuclear	I
12	associated	I
13	protein	I
14	(	O
15	M	B
16	-	I
17	NAP	I
18	)	O
19	and	O
20	AT1	B
21	-	I
22	46	I
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O

1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	B
5	and	O
6	Sonic	B
7	hedgehog	I
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	B
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	B
32	expression	I
33	domain	I
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	O
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O

1	Albumin	B
2	dialysis	O
3	:	O
4	effective	O
5	removal	O
6	of	O
7	copper	O
8	in	O
9	a	O
10	patient	O
11	with	O
12	fulminant	O
13	Wilson	O
14	disease	O
15	and	O
16	successful	O
17	bridging	O
18	to	O
19	liver	O
20	transplantation	O
21	:	O
22	a	O
23	new	O
24	possibility	O
25	for	O
26	the	O
27	elimination	O
28	of	O
29	protein	O
30	-	O
31	bound	O
32	toxins	O
33	.	O

1	Some	O
2	artificial	O
3	promoter	O
4	constructs	O
5	containing	O
6	multiple	O
7	Sp1	B
8	sites	I
9	were	O
10	highly	O
11	responsive	O
12	to	O
13	ethanol	O
14	,	O
15	but	O
16	others	O
17	were	O
18	not	O
19	,	O
20	suggesting	O
21	that	O
22	the	O
23	organization	O
24	of	O
25	the	O
26	proximal	O
27	promoter	O
28	region	O
29	was	O
30	an	O
31	additional	O
32	factor	O
33	that	O
34	affected	O
35	the	O
36	ethanol	O
37	response	O
38	.	O

1	Overexpression	O
2	of	O
3	CDP	B
4	/	O
5	cut	B
6	in	O
7	ROS	O
8	17	O
9	/	O
10	2	O
11	.	O
12	8	O
13	osteosarcoma	O
14	cells	O
15	results	O
16	in	O
17	repression	O
18	of	O
19	OC	B
20	promoter	I
21	activity	O
22	;	O
23	this	O
24	repression	O
25	is	O
26	abrogated	O
27	by	O
28	mutating	O
29	OC	B
30	box	I
31	I	I
32	.	O

1	Injection	O
2	of	O
3	double	O
4	-	O
5	stranded	O
6	RNA	O
7	into	O
8	C	O
9	.	O
10	elegans	O
11	results	O
12	in	O
13	embryonic	O
14	lethality	O
15	;	O
16	thus	O
17	,	O
18	the	O
19	SF1	B
20	gene	I
21	is	O
22	essential	O
23	not	O
24	only	O
25	in	O
26	yeast	O
27	but	O
28	also	O
29	in	O
30	at	O
31	least	O
32	one	O
33	metazoan	O
34	.	O

1	Both	O
2	domains	O
3	were	O
4	required	O
5	for	O
6	specific	O
7	DNA	O
8	binding	O
9	to	O
10	the	O
11	beta	B
12	-	I
13	retinoic	I
14	acid	I
15	receptor	I
16	element	I
17	,	O
18	producing	O
19	a	O
20	DNase	B
21	I	I
22	footprint	O
23	covering	O
24	predominantly	O
25	one	O
26	strand	O
27	.	O

1	Snail	B
2	family	I
3	proteins	I
4	are	O
5	zinc	O
6	finger	O
7	transcriptional	O
8	regulators	O
9	first	O
10	identified	O
11	in	O
12	Drosophila	O
13	which	O
14	play	O
15	critical	O
16	roles	O
17	in	O
18	cell	O
19	fate	O
20	determination	O
21	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	O
45	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	showed	O
8	no	O
9	TATA	O
10	box	O
11	but	O
12	identified	O
13	consensus	O
14	binding	O
15	motifs	O
16	for	O
17	Sp1	B
18	,	O
19	CREB	B
20	,	O
21	and	O
22	half	O
23	sites	O
24	of	O
25	the	O
26	estrogen	B
27	receptor	I
28	binding	I
29	site	I
30	.	O

1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	O
19	human	B
20	AC	I
21	gene	I
22	from	O
23	FD	O
24	patients	O
25	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	interaction	O
7	of	O
8	eIF4A	B
9	with	O
10	the	O
11	middle	O
12	region	O
13	of	O
14	eIF4GI	B
15	is	O
16	necessary	O
17	for	O
18	translation	O
19	,	O
20	whereas	O
21	the	O
22	interaction	O
23	of	O
24	eIF4A	B
25	with	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	plays	O
32	a	O
33	modulatory	O
34	role	O
35	.	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	12	O
2	:	O
3	2684	O
4	-	O
5	2697	O
6	,	O
7	1998	O
8	):	O
9	a	O
10	key	O
11	step	O
12	of	O
13	this	O
14	model	O
15	is	O
16	the	O
17	activation	O
18	of	O
19	the	O
20	MAPK	B
21	Fus3p	I
22	through	O
23	the	O
24	G	O
25	(	O
26	betagamma	O
27	)-	O
28	dependent	O
29	relocalization	O
30	of	O
31	the	O
32	Ste5p	B
33	-	O
34	MAPK	B
35	cascade	O
36	to	O
37	the	O
38	plasma	O
39	membrane	O
40	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	SAGA	I
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	B
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	B
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	a	O
5	genetically	O
6	and	O
7	biochemically	O
8	proven	O
9	CAK	B
10	gene	I
11	,	O
12	CAK1	B
13	,	O
14	that	O
15	encodes	O
16	a	O
17	monomeric	O
18	44	B
19	-	I
20	kDa	I
21	Cak1p	I
22	protein	I
23	unrelated	O
24	to	O
25	Cdk7	B
26	.	O

1	Northern	O
2	blot	O
3	and	O
4	reverse	O
5	transcription	O
6	-	O
7	PCR	O
8	analyses	O
9	of	O
10	human	O
11	mRNA	O
12	samples	O
13	demonstrate	O
14	that	O
15	RNR	B
16	is	O
17	expressed	O
18	exclusively	O
19	in	O
20	the	O
21	retina	O
22	,	O
23	with	O
24	transcripts	O
25	of	O
26	approximately	O
27	7	O
28	.	O
29	5	O
30	kb	O
31	,	O
32	approximately	O
33	3	O
34	.	O
35	0	O
36	kb	O
37	,	O
38	and	O
39	approximately	O
40	2	O
41	.	O
42	3	O
43	kb	O
44	by	O
45	Northern	O
46	blot	O
47	analysis	O
48	.	O

1	Particularly	O
2	striking	O
3	was	O
4	the	O
5	conservation	O
6	of	O
7	an	O
8	AP	B
9	-	I
10	4	I
11	binding	I
12	site	I
13	within	O
14	100	O
15	nucleotides	O
16	upstream	O
17	of	O
18	the	O
19	transcription	O
20	initiation	O
21	site	O
22	in	O
23	both	O
24	Aal	B
25	-	O
26	rpL34	B
27	and	O
28	Aal	B
29	-	O
30	rpL8	B
31	genes	O
32	.	O

1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	O
4	levels	O
5	of	O
6	S	B
7	-	I
8	100beta	I
9	are	O
10	reliable	O
11	markers	O
12	for	O
13	adverse	O
14	neurologic	O
15	outcomes	O
16	after	O
17	cardiac	O
18	surgery	O
19	.	O

1	However	O
2	,	O
3	no	O
4	genetic	O
5	alteration	O
6	was	O
7	detected	O
8	in	O
9	any	O
10	of	O
11	the	O
12	cancers	O
13	examined	O
14	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	Statins	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	The	O
2	VirR	B
3	response	I
4	regulator	I
5	from	O
6	Clostridium	O
7	perfringens	O
8	binds	O
9	independently	O
10	to	O
11	two	O
12	imperfect	O
13	direct	O
14	repeats	O
15	located	O
16	upstream	O
17	of	O
18	the	O
19	pfoA	B
20	promoter	I
21	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	upstream	O
7	region	O
8	of	O
9	pepX	B
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	O
24	were	O
25	shown	O
26	to	O
27	be	O
28	able	O
29	to	O
30	encode	O
31	proteins	O
32	with	O
33	high	O
34	homology	O
35	to	O
36	GlnR	B
37	and	O
38	GlnA	B
39	proteins	I
40	,	O
41	respectively	O
42	.	O

1	Objective	O
2	:	O
3	To	O
4	evaluate	O
5	endometrial	O
6	thickness	O
7	and	O
8	the	O
9	incidence	O
10	of	O
11	uterine	O
12	bleeding	O
13	in	O
14	postmenopausal	O
15	women	O
16	using	O
17	either	O
18	tibolone	O
19	2	O
20	.	O
21	5	O
22	mg	O
23	or	O
24	continuous	O
25	combined	O
26	2	O
27	mg	O
28	estradiol	O
29	and	O
30	1	O
31	mg	O
32	norethisterone	O
33	acetate	O
34	(	O
35	E	O
36	+	O
37	NETA	O
38	)	O
39	daily	O
40	as	O
41	hormone	O
42	replacement	O
43	therapy	O
44	.	O

1	Leukocyte	O
2	cultures	O
3	,	O
4	prepared	O
5	from	O
6	blood	O
7	drawn	O
8	from	O
9	these	O
10	18	O
11	children	O
12	at	O
13	6	O
14	months	O
15	of	O
16	age	O
17	,	O
18	produced	O
19	lower	O
20	yields	O
21	of	O
22	IFN	B
23	than	O
24	those	O
25	of	O
26	the	O
27	remaining	O
28	53	O
29	children	O
30	,	O
31	when	O
32	stimulated	O
33	with	O
34	adenovirus	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	coronavirus	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	001	O
49	)	O
50	or	O
51	rhinovirus	O
52	(	O
53	P	O
54	=	O
55	0	O
56	.	O
57	002	O
58	).	O

1	In	O
2	the	O
3	BF	O
4	ECT	O
5	group	O
6	the	O
7	-	O
8	age	O
9	based	O
10	dose	O
11	would	O
12	have	O
13	been	O
14	similarly	O
15	dependent	O
16	on	O
17	the	O
18	initial	O
19	seizure	O
20	threshold	O
21	level	O
22	.	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	The	O
2	extents	O
3	of	O
4	phosphorylation	O
5	of	O
6	Ser44	O
7	and	O
8	Ser64	O
9	were	O
10	1	O
11	:	O
12	1	O
13	,	O
14	whereas	O
15	those	O
16	of	O
17	the	O
18	four	O
19	minor	O
20	sites	O
21	all	O
22	together	O
23	were	O
24	<	O
25	30	O
26	%	O
27	of	O
28	the	O
29	major	O
30	one	O
31	.	O

1	Serum	O
2	HBV	O
3	-	O
4	DNA	O
5	,	O
6	viral	O
7	serology	O
8	,	O
9	and	O
10	liver	O
11	enzymes	O
12	were	O
13	measured	O
14	sequentially	O
15	;	O
16	liver	O
17	histology	O
18	was	O
19	taken	O
20	before	O
21	and	O
22	during	O
23	treatment	O
24	in	O
25	12	O
26	patients	O
27	.	O

1	Chem	O
2	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Haycocknema	O
2	perplexum	O
3	n	O
4	.	O
5	g	O
6	.,	O
7	n	O
8	.	O
9	sp	O
10	.	O

1	Rams	O
2	were	O
3	weighed	O
4	and	O
5	testis	O
6	size	O
7	was	O
8	estimated	O
9	by	O
10	orchimetry	O
11	at	O
12	each	O
13	time	O
14	period	O
15	.	O

1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	Role	O
2	of	O
3	estrogen	B
4	receptor	I
5	ligand	O
6	and	O
7	estrogen	O
8	response	O
9	element	O
10	sequence	O
11	on	O
12	interaction	O
13	with	O
14	chicken	B
15	ovalbumin	I
16	upstream	I
17	promoter	I
18	transcription	I
19	factor	I
20	(	O
21	COUP	B
22	-	I
23	TF	I
24	).	O

1	CONCLUSION	O
2	:	O
3	In	O
4	Cdks	B
5	functioning	O
6	throughout	O
7	the	O
8	cell	O
9	cycle	O
10	,	O
11	tyrosine	O
12	phosphorylation	O
13	is	O
14	inhibitory	O
15	to	O
16	the	O
17	activation	O
18	of	O
19	kinase	O
20	,	O
21	whereas	O
22	the	O
23	phosphorylation	O
24	of	O
25	threonine	O
26	in	O
27	the	O
28	T	O
29	-	O
30	loop	O
31	is	O
32	essential	O
33	for	O
34	activation	O
35	.	O

1	We	O
2	also	O
3	report	O
4	that	O
5	AHR	B
6	interacts	O
7	with	O
8	COUP	B
9	-	I
10	TF	I
11	in	O
12	transfected	O
13	CV	O
14	-	O
15	1	O
16	cells	O
17	.	O

1	AB004534	B
2	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	is	O
12	relatively	O
13	low	O
14	in	O
15	childhood	O
16	,	O
17	with	O
18	anti	B
19	-	I
20	HCV	I
21	prevalence	O
22	rates	O
23	of	O
24	0	O
25	.	O
26	1	O
27	-	O
28	0	O
29	.	O
30	4	O
31	%	O
32	in	O
33	the	O
34	Western	O
35	world	O
36	.	O

1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	As	O
2	an	O
3	alternative	O
4	approach	O
5	to	O
6	this	O
7	question	O
8	,	O
9	we	O
10	have	O
11	studied	O
12	the	O
13	effects	O
14	of	O
15	ectopically	O
16	expressed	O
17	SHIP	B
18	,	O
19	SHP	B
20	-	I
21	1	I
22	,	O
23	or	O
24	SHP	B
25	-	I
26	2	I
27	SH2	O
28	-	O
29	containing	O
30	decoy	O
31	proteins	O
32	on	O
33	Fc	B
34	gamma	I
35	RIIB1	I
36	signaling	O
37	.	O

1	Compared	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	DM	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	waist	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O

1	In	O
2	all	O
3	tissues	O
4	examined	O
5	only	O
6	transcripts	O
7	positive	O
8	for	O
9	insert	O
10	3	O
11	,	O
12	an	O
13	18	O
14	bp	O
15	insertion	O
16	in	O
17	repeat	O
18	21	O
19	,	O
20	were	O
21	amplified	O
22	,	O
23	even	O
24	under	O
25	conditions	O
26	in	O
27	which	O
28	a	O
29	30	O
30	%	O
31	level	O
32	of	O
33	insert	O
34	3	O
35	negative	O
36	transcript	O
37	could	O
38	be	O
39	easily	O
40	detected	O
41	in	O
42	artificially	O
43	prepared	O
44	control	O
45	samples	O
46	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	CAAT	O
7	-	O
8	region	O
9	is	O
10	involved	O
11	in	O
12	upregulating	O
13	the	O
14	MDR1	B
15	promoter	I
16	in	O
17	HL60	O
18	/	O
19	VCR	O
20	cells	O
21	.	O

1	Both	O
2	receptors	O
3	utilize	O
4	protein	B
5	tyrosine	I
6	kinases	I
7	(	O
8	PTKs	B
9	)	O
10	for	O
11	the	O
12	phosphorylation	O
13	of	O
14	various	O
15	signaling	O
16	molecules	O
17	,	O
18	a	O
19	process	O
20	that	O
21	is	O
22	critical	O
23	for	O
24	the	O
25	function	O
26	of	O
27	both	O
28	receptors	O
29	.	O

1	Hypothermia	O
2	After	O
3	Cardiac	O
4	Arrest	O
5	(	O
6	HACA	O
7	)	O
8	Study	O
9	Group	O
10	.	O

1	The	O
2	synergistic	O
3	effect	O
4	due	O
5	to	O
6	the	O
7	5	O
8	'-	O
9	3	O
10	'	O
11	cooperation	O
12	was	O
13	at	O
14	least	O
15	fourfold	O
16	greater	O
17	than	O
18	the	O
19	sum	O
20	of	O
21	the	O
22	contributions	O
23	of	O
24	the	O
25	individual	O
26	UTRs	O
27	.	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	B
6	and	O
7	Z	B
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	B
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	I
18	)	I
19	kinases	I
20	,	O
21	p38	B
22	and	O
23	JNK	B
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	B
35	transcription	I
36	factor	I
37	ATF2	I
38	.	O

1	Two	O
2	US	O
3	commercial	O
4	cultivars	O
5	(	O
6	Tehama	O
7	and	O
8	Vina	O
9	),	O
10	three	O
11	European	O
12	commercial	O
13	cultivars	O
14	(	O
15	Esterhazy	O
16	,	O
17	139	O
18	,	O
19	G120	O
20	)	O
21	and	O
22	five	O
23	New	O
24	Zealand	O
25	selections	O
26	(	O
27	Rex	O
28	,	O
29	Dublin	O
30	'	O
31	s	O
32	Glory	O
33	,	O
34	Meyric	O
35	,	O
36	McKinster	O
37	,	O
38	Stanley	O
39	)	O
40	were	O
41	evaluated	O
42	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	However	O
2	,	O
3	activation	O
4	of	O
5	the	O
6	cAMP	O
7	pathway	O
8	,	O
9	which	O
10	is	O
11	known	O
12	to	O
13	regulate	O
14	inhibin	B
15	alpha	I
16	expression	O
17	,	O
18	greatly	O
19	enhanced	O
20	the	O
21	actions	O
22	of	O
23	SF	B
24	-	I
25	1	I
26	.	O

1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	B
11	-	I
12	1	I
13	regulatory	I
14	element	I
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	O
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	114	O
41	).	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	O
31	NF	B
32	-	I
33	kappaB	I
34	)	O
35	complex	O
36	Rel	B
37	A	I
38	x	O
39	NF	B
40	-	I
41	kappaB1	I
42	.	O

1	Angiotensin	B
2	II	I
3	induces	O
4	nuclear	B
5	factor	I
6	(	I
7	NF	I
8	)-	I
9	kappaB1	I
10	isoforms	I
11	to	O
12	bind	O
13	the	O
14	angiotensinogen	B
15	gene	I
16	acute	O
17	-	O
18	phase	O
19	response	O
20	element	O
21	:	O
22	a	O
23	stimulus	O
24	-	O
25	specific	O
26	pathway	O
27	for	O
28	NF	B
29	-	I
30	kappaB	I
31	activation	O
32	.	O

1	Synthetic	O
2	ligands	O
3	have	O
4	been	O
5	identified	O
6	that	O
7	reset	O
8	and	O
9	amplify	O
10	the	O
11	cycle	O
12	of	O
13	pulsatile	O
14	GH	B
15	secretion	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	orphan	B
21	GH	I
22	-	I
23	secretagogue	I
24	receptor	I
25	(	O
26	GHS	B
27	-	I
28	R	I
29	).	O

1	The	O
2	collection	O
3	of	O
4	mutants	O
5	displaying	O
6	TGN	O
7	sorting	O
8	defects	O
9	includes	O
10	members	O
11	with	O
12	mutations	O
13	in	O
14	previously	O
15	identified	O
16	vacuolar	B
17	protein	I
18	sorting	I
19	genes	I
20	(	O
21	VPS	B
22	),	O
23	including	O
24	the	O
25	dynamin	B
26	family	O
27	member	O
28	VPS1	B
29	.	O

1	Also	O
2	in	O
3	the	O
4	spectrum	O
5	of	O
6	mutants	O
7	with	O
8	TGN	O
9	sorting	O
10	defects	O
11	are	O
12	isolates	O
13	with	O
14	mutations	O
15	in	O
16	the	O
17	following	O
18	:	O
19	RIC1	B
20	,	O
21	encoding	O
22	a	O
23	product	O
24	originally	O
25	proposed	O
26	to	O
27	participate	O
28	in	O
29	ribosome	O
30	biogenesis	O
31	;	O
32	LUV1	B
33	,	O
34	encoding	O
35	a	O
36	product	O
37	potentially	O
38	involved	O
39	in	O
40	vacuole	O
41	and	O
42	microtubule	O
43	organization	O
44	;	O
45	and	O
46	INP53	B
47	,	O
48	encoding	O
49	a	O
50	synaptojanin	B
51	-	I
52	like	I
53	inositol	I
54	polyphosphate	I
55	5	I
56	-	I
57	phosphatase	I
58	.	O

1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	O
13	-	O
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	B
26	,	O
27	suggesting	O
28	that	O
29	cdc17	B
30	/	O
31	pol1	B
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O

1	Furthermore	O
2	,	O
3	the	O
4	wide	O
5	distribution	O
6	of	O
7	the	O
8	GFP	B
9	-	O
10	POLO	B
11	protein	O
12	to	O
13	all	O
14	compartments	O
15	of	O
16	the	O
17	mitotic	O
18	apparatus	O
19	provides	O
20	a	O
21	valuable	O
22	tool	O
23	for	O
24	future	O
25	studies	O
26	on	O
27	cell	O
28	cycle	O
29	during	O
30	development	O
31	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	However	O
2	,	O
3	calphostin	O
4	C	O
5	,	O
6	a	O
7	specific	O
8	inhibitor	O
9	of	O
10	PKC	B
11	,	O
12	abolished	O
13	the	O
14	TPA	O
15	-	O
16	induced	O
17	increase	O
18	in	O
19	CFI	B
20	mRNA	I
21	levels	O
22	.	O

1	Preimmune	B
2	IgG	I
3	,	O
4	anti	B
5	-	I
6	GalT	I
7	Fab	I
8	fragments	I
9	,	O
10	irrelevant	O
11	polymers	O
12	and	O
13	monomeric	O
14	N	O
15	-	O
16	acetylglucosamine	O
17	had	O
18	no	O
19	effect	O
20	.	O

1	Arhythmacanthus	O
2	Yamaguti	O
3	,	O
4	1935	O
5	is	O
6	maintained	O
7	as	O
8	a	O
9	synonym	O
10	of	O
11	Heterosentis	O
12	because	O
13	the	O
14	distinction	O
15	between	O
16	two	O
17	and	O
18	three	O
19	hook	O
20	types	O
21	is	O
22	made	O
23	equivocal	O
24	when	O
25	the	O
26	transition	O
27	between	O
28	the	O
29	apical	O
30	and	O
31	subapical	O
32	hooks	O
33	is	O
34	gradual	O
35	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	O
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O

1	Following	O
2	conditioning	O
3	,	O
4	a	O
5	single	O
6	coat	O
7	of	O
8	adhesive	O
9	was	O
10	applied	O
11	and	O
12	light	O
13	-	O
14	cured	O
15	.	O

1	Downstream	O
2	of	O
3	the	O
4	G	O
5	-	O
6	A	O
7	anastomosis	O
8	,	O
9	the	O
10	RD	O
11	,	O
12	CC	O
13	,	O
14	E	O
15	(	O
16	p	O
17	)	O
18	and	O
19	loop	O
20	areas	O
21	were	O
22	significantly	O
23	different	O
24	from	O
25	REF	O
26	,	O
27	but	O
28	significantly	O
29	different	O
30	from	O
31	A	O
32	-	O
33	A	O
34	.	O

1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	B
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	B
23	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	We	O
2	determined	O
3	how	O
4	DNA	O
5	repair	O
6	is	O
7	affected	O
8	by	O
9	TFA1	B
10	conditional	O
11	mutations	O
12	.	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	O
27	3	O
28	N0	O
29	-	O
30	1	O
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	NDRF	B
2	/	O
3	NeuroD2	B
4	was	O
5	co	O
6	-	O
7	precipitated	O
8	with	O
9	PKN	B
10	from	O
11	the	O
12	lysate	O
13	of	O
14	COS	O
15	-	O
16	7	O
17	cells	O
18	transfected	O
19	with	O
20	both	O
21	expression	O
22	constructs	O
23	for	O
24	NDRF	B
25	/	O
26	NeuroD2	B
27	and	O
28	PKN	B
29	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	B
12	/	O
13	NeuroD2	B
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	B
20	insulin	I
21	promoter	I
22	element	I
23	3	I
24	(	O
25	RIPE3	B
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	B
45	,	O
46	but	O
47	not	O
48	kinase	O
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	B
61	/	O
62	NeuroD2	B
63	-	O
64	mediated	O
65	transcription	O
66	.	O

1	Two	O
2	Pax2	B
3	/	I
4	5	I
5	/	I
6	8	I
7	-	I
8	binding	I
9	sites	I
10	in	O
11	Engrailed2	B
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	Upon	O
2	tyrosine	O
3	phosphorylation	O
4	at	O
5	the	O
6	ITIMs	O
7	,	O
8	these	O
9	molecules	O
10	recruit	O
11	SH2	B
12	domain	O
13	-	O
14	containing	O
15	phosphatases	O
16	such	O
17	as	O
18	SH2	B
19	-	O
20	containing	O
21	tyrosine	B
22	phosphatase	I
23	-	I
24	1	I
25	and	O
26	negatively	O
27	regulate	O
28	cell	O
29	activity	O
30	.	O

1	AF154055	B
2	.	O

1	Alignment	O
2	of	O
3	the	O
4	cervical	O
5	spine	O
6	,	O
7	vertebral	O
8	abnormalities	O
9	,	O
10	and	O
11	disc	O
12	changes	O
13	also	O
14	were	O
15	evaluated	O
16	.	O

1	The	O
2	concomitant	O
3	interaction	O
4	of	O
5	mSTI1	B
6	with	O
7	hsp70	B
8	and	O
9	hsp90	B
10	at	O
11	its	O
12	N	O
13	-	O
14	and	O
15	C	O
16	-	O
17	termini	O
18	respectively	O
19	is	O
20	mediated	O
21	by	O
22	the	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	motifs	O
29	in	O
30	these	O
31	regions	O
32	.	O

1	Competition	O
2	experiments	O
3	demonstrate	O
4	a	O
5	negative	O
6	allosteric	O
7	relationship	O
8	between	O
9	these	O
10	RGD	O
11	recognition	O
12	sites	O
13	.	O

1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	acetazolamide	O
11	and	O
12	disinfection	O
13	of	O
14	the	O
15	conjunctiva	O
16	,	O
17	50	O
18	micrograms	O
19	rt	B
20	-	I
21	PA	I
22	in	O
23	0	O
24	.	O
25	1	O
26	ml	O
27	(	O
28	BSS	O
29	)	O
30	and	O
31	0	O
32	.	O
33	5	O
34	ml	O
35	SF6	O
36	were	O
37	injected	O
38	intravitreally	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	VP1	B
6	was	O
7	efficiently	O
8	transported	O
9	to	O
10	the	O
11	nucleus	O
12	and	O
13	localized	O
14	in	O
15	the	O
16	discrete	O
17	subnuclear	O
18	regions	O
19	,	O
20	possibly	O
21	with	O
22	VP2	B
23	and	O
24	VP3	B
25	.	O

1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	The	O
2	differentiation	O
3	and	O
4	maintenance	O
5	of	O
6	a	O
7	neurotransmitter	O
8	phenotype	O
9	is	O
10	guided	O
11	by	O
12	the	O
13	interaction	O
14	of	O
15	exogenous	O
16	cues	O
17	with	O
18	intrinsic	O
19	genetic	O
20	machinery	O
21	.	O

1	Analysis	O
2	of	O
3	functional	O
4	domains	O
5	of	O
6	Arix	B
7	reveals	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	activation	O
13	domain	O
14	and	O
15	a	O
16	C	O
17	-	O
18	terminal	O
19	repression	O
20	domain	O
21	.	O

1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O

1	Multivariate	O
2	predictors	O
3	were	O
4	concentric	O
5	remodeling	O
6	(	O
7	P	O
8	<	O
9	0	O
10	.	O
11	0001	O
12	;	O
13	odds	O
14	ratio	O
15	,	O
16	13	O
17	.	O
18	5	O
19	),	O
20	left	O
21	ventricular	O
22	ejection	O
23	fraction	O
24	>	O
25	2	O
26	SD	O
27	above	O
28	normal	O
29	(	O
30	P	O
31	<	O
32	0	O
33	.	O
34	0001	O
35	),	O
36	and	O
37	single	O
38	-	O
39	vessel	O
40	left	O
41	circumflex	O
42	disease	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	0007	O
49	;	O
50	odds	O
51	ratio	O
52	,	O
53	7	O
54	.	O
55	6	O
56	).	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O

1	The	O
2	RNA	O
3	aptamer	O
4	contains	O
5	three	O
6	stems	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	bulges	O
16	,	O
17	and	O
18	adopts	O
19	an	O
20	unanticipated	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	junctional	O
26	sites	O
27	are	O
28	anchored	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	Isolation	O
2	of	O
3	cDNAs	B
4	encoding	I
5	gibbon	I
6	and	I
7	monkey	I
8	platelet	I
9	and	I
10	T	I
11	cell	I
12	activation	I
13	antigen	I
14	1	I
15	(	O
16	PTA1	B
17	).	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	METHODS	O
2	:	O
3	Von	B
4	Willebrand	I
5	factor	I
6	(	O
7	vWF	B
8	)	O
9	and	O
10	the	O
11	fibrinolytic	O
12	factors	O
13	tissue	B
14	plasminogen	I
15	activator	I
16	(	O
17	tPA	B
18	),	O
19	measured	O
20	as	O
21	tPA	B
22	capacity	O
23	,	O
24	and	O
25	plasminogen	B
26	activator	I
27	inhibitor	I
28	1	I
29	(	O
30	PAI	B
31	-	I
32	1	I
33	),	O
34	platelets	O
35	,	O
36	fibrinogen	B
37	,	O
38	and	O
39	inflammatory	O
40	markers	O
41	were	O
42	measured	O
43	in	O
44	74	O
45	patients	O
46	with	O
47	active	O
48	seropositive	O
49	RA	O
50	.	O

1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O

1	Treatment	O
2	also	O
3	led	O
4	to	O
5	a	O
6	significant	O
7	dose	O
8	dependent	O
9	reduction	O
10	in	O
11	the	O
12	sum	O
13	of	O
14	ST	O
15	segment	O
16	depression	O
17	at	O
18	both	O
19	trough	O
20	and	O
21	peak	O
22	concentrations	O
23	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	B
9	-	I
10	binding	I
11	protein	I
12	(	O
13	TBP	B
14	)-	O
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	B
26	tRNA	I
27	(	I
28	C	I
29	)(	I
30	Ala	I
31	)	I
32	gene	I
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	B
52	gland	I
53	-	I
54	specific	I
55	tRNA	I
56	(	I
57	SG	I
58	)(	I
59	Ala	I
60	)	I
61	gene	I
62	.	O

1	The	O
2	sequences	O
3	showed	O
4	extensive	O
5	homologies	O
6	with	O
7	squalene	B
8	synthase	I
9	genes	I
10	and	O
11	enzymes	O
12	from	O
13	a	O
14	number	O
15	of	O
16	other	O
17	organisms	O
18	and	O
19	extreme	O
20	amino	O
21	acid	O
22	conservation	O
23	within	O
24	the	O
25	binding	O
26	and	O
27	catalytic	O
28	domains	O
29	.	O

1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	deposited	O
9	in	O
10	the	O
11	EUROFAN	O
12	genetic	O
13	stock	O
14	centre	O
15	(	O
16	EUROSCARF	O
17	,	O
18	Frankfurt	O
19	).	O

1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O

1	Copyright	O
2	2000	O
3	The	O
4	Royal	O
5	College	O
6	of	O
7	Radiologists	O
8	.	O

1	Two	O
2	estrogen	B
3	receptor	I
4	(	O
5	ER	B
6	)	O
7	isoforms	O
8	with	O
9	different	O
10	estrogen	O
11	dependencies	O
12	are	O
13	generated	O
14	from	O
15	the	O
16	trout	B
17	ER	I
18	gene	I
19	.	O

1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	B
8	-	I
9	Fos	I
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O

1	In	O
2	myometrial	O
3	SMC	O
4	,	O
5	both	O
6	isoforms	O
7	of	O
8	the	O
9	progesterone	B
10	receptor	I
11	,	O
12	PR	B
13	-	I
14	B	I
15	and	O
16	PR	B
17	-	I
18	A	I
19	,	O
20	caused	O
21	a	O
22	ligand	O
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	PGDH	B
28	-	I
29	2368	I
30	/	O
31	luc3	B
32	.	O

1	Element	O
2	B	O
3	(-	O
4	249	O
5	/-	O
6	229	O
7	)	O
8	shows	O
9	more	O
10	than	O
11	80	O
12	%	O
13	homology	O
14	to	O
15	a	O
16	consensus	B
17	c	I
18	-	I
19	myb	I
20	element	I
21	,	O
22	but	O
23	formed	O
24	two	O
25	specific	O
26	complexes	O
27	that	O
28	differed	O
29	from	O
30	that	O
31	of	O
32	c	B
33	-	I
34	myb	I
35	in	O
36	the	O
37	electrophoretic	O
38	mobility	O
39	shift	O
40	assay	O
41	.	O

1	High	O
2	resolution	O
3	computed	O
4	tomography	O
5	of	O
6	the	O
7	lungs	O
8	in	O
9	patients	O
10	with	O
11	rheumatoid	O
12	arthritis	O
13	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	truncated	O
6	reduced	B
7	folate	I
8	carrier	I
9	cDNA	I
10	into	O
11	mouse	O
12	L1210	O
13	leukemia	O
14	cells	O
15	:	O
16	increased	O
17	folate	O
18	accumulation	O
19	,	O
20	decreased	O
21	their	O
22	leucovorin	O
23	and	O
24	folic	O
25	acid	O
26	growth	O
27	requirements	O
28	,	O
29	and	O
30	increased	O
31	their	O
32	sensitivity	O
33	to	O
34	methotrexate	O
35	.	O

1	Characterization	O
2	of	O
3	a	O
4	human	B
5	alternatively	I
6	spliced	I
7	truncated	I
8	reduced	I
9	folate	I
10	carrier	I
11	increasing	O
12	folate	O
13	accumulation	O
14	in	O
15	parental	O
16	leukemia	O
17	cells	O
18	.	O

1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	B
8	-	I
9	type	I
10	Fus3	I
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	Consistently	O
2	,	O
3	activation	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	N	I
9	-	I
10	terminal	I
11	kinase	I
12	downstream	O
13	of	O
14	Rho	B
15	family	I
16	GTP	I
17	-	I
18	binding	I
19	proteins	I
20	was	O
21	also	O
22	enhanced	O
23	when	O
24	Dbl	B
25	was	O
26	tyrosine	O
27	-	O
28	phosphorylated	O
29	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	collagen	B
7	binding	O
8	has	O
9	not	O
10	been	O
11	shown	O
12	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	carboxyl	O
9	terminus	O
10	of	O
11	CFTR	B
12	contains	O
13	a	O
14	tyrosine	O
15	-	O
16	based	O
17	internalization	O
18	signal	O
19	that	O
20	interacts	O
21	with	O
22	the	O
23	endocytic	O
24	adaptor	O
25	complex	O
26	AP	B
27	-	I
28	2	I
29	to	O
30	facilitate	O
31	efficient	O
32	entry	O
33	of	O
34	CFTR	B
35	into	O
36	clathrin	B
37	-	O
38	coated	O
39	vesicles	O
40	.	O

1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O

1	Scmh1	B
2	maps	O
3	to	O
4	4D1	O
5	-	O
6	D2	O
7	.	O
8	1	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	applicability	O
3	of	O
4	laparoscopic	O
5	donor	O
6	nephrectomy	O
7	(	O
8	LDN	O
9	)	O
10	has	O
11	not	O
12	been	O
13	assessed	O
14	in	O
15	the	O
16	obese	O
17	donor	O
18	.	O

1	Hyaluronan	O
2	treatment	O
3	stimulated	O
4	collagen	B
5	remodeling	O
6	in	O
7	the	O
8	peripheral	O
9	region	O
10	and	O
11	inhibited	O
12	swelling	O
13	of	O
14	the	O
15	meniscus	O
16	repaired	O
17	in	O
18	the	O
19	inner	O
20	region	O
21	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	The	O
2	RING	O
3	finger	O
4	,	O
5	B2	O
6	box	O
7	,	O
8	and	O
9	coiled	O
10	-	O
11	coil	O
12	region	O
13	are	O
14	required	O
15	for	O
16	oligomerization	O
17	of	O
18	KAP	B
19	-	I
20	1	I
21	-	O
22	RBCC	B
23	and	O
24	KRAB	B
25	binding	O
26	,	O
27	as	O
28	mutations	O
29	in	O
30	these	O
31	domains	O
32	concomitantly	O
33	abolished	O
34	these	O
35	functions	O
36	.	O

1	Actins	B
2	show	O
3	two	O
4	different	O
5	forms	O
6	of	O
7	N	O
8	-	O
9	terminal	O
10	processing	O
11	dependent	O
12	on	O
13	their	O
14	N	O
15	-	O
16	terminal	O
17	sequence	O
18	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O

1	Like	O
2	their	O
3	yeast	O
4	counterpart	O
5	,	O
6	the	O
7	mouse	O
8	GCN2	B
9	isoforms	O
10	contain	O
11	HisRS	B
12	-	I
13	related	I
14	sequences	I
15	juxtaposed	O
16	to	O
17	the	O
18	kinase	O
19	catalytic	O
20	domain	O
21	.	O

1	Five	O
2	women	O
3	(	O
4	15	O
5	.	O
6	6	O
7	%)	O
8	met	O
9	criteria	O
10	for	O
11	PMS	O
12	.	O

1	MBI	O
2	and	O
3	MMBI	O
4	showed	O
5	similar	O
6	Cmax	O
7	values	O
8	,	O
9	but	O
10	the	O
11	former	O
12	disappeared	O
13	slower	O
14	in	O
15	the	O
16	serum	O
17	than	O
18	the	O
19	latter	O
20	and	O
21	resulted	O
22	in	O
23	its	O
24	larger	O
25	AUC	O
26	values	O
27	.	O

1	Another	O
2	long	O
3	insertion	O
4	in	O
5	the	O
6	cathepsin	B
7	X	I
8	amino	I
9	acid	I
10	sequence	I
11	forms	O
12	a	O
13	beta	O
14	-	O
15	hairpin	O
16	pointing	O
17	away	O
18	from	O
19	the	O
20	active	O
21	site	O
22	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	Further	O
2	studies	O
3	in	O
4	T	O
5	-	O
6	24	O
7	cells	O
8	demonstrated	O
9	that	O
10	HA	O
11	fragments	O
12	also	O
13	induced	O
14	I	B
15	kappa	I
16	B	I
17	alpha	I
18	phosphorylation	O
19	and	O
20	degradation	O
21	,	O
22	kappa	B
23	B	I
24	-	I
25	linked	I
26	reporter	I
27	gene	I
28	expression	O
29	,	O
30	and	O
31	ICAM	B
32	-	I
33	1	I
34	promoter	I
35	activity	O
36	in	O
37	an	O
38	NF	B
39	-	I
40	kappa	I
41	B	I
42	-	O
43	dependent	O
44	manner	O
45	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	or	O
5	mouse	O
6	skin	O
7	with	O
8	antisense	O
9	oligonucleotides	O
10	of	O
11	PKCzeta	B
12	impaired	O
13	UV	O
14	-	O
15	induced	O
16	activation	O
17	of	O
18	AP	B
19	-	I
20	1	I
21	in	O
22	JB6	O
23	cells	O
24	as	O
25	well	O
26	as	O
27	in	O
28	AP	B
29	-	I
30	1	I
31	-	O
32	luciferase	B
33	transgenic	O
34	mice	O
35	.	O

1	The	O
2	level	O
3	of	O
4	subclinical	O
5	infection	O
6	was	O
7	75	O
8	%	O
9	among	O
10	seropositive	O
11	dogs	O
12	.	O

1	METHODS	O
2	:	O
3	The	O
4	former	O
5	group	O
6	included	O
7	patients	O
8	who	O
9	had	O
10	been	O
11	treated	O
12	with	O
13	at	O
14	least	O
15	four	O
16	PGE1	O
17	alpha	O
18	-	O
19	ciclodestrina	O
20	,	O
21	short	O
22	-	O
23	term	O
24	treatment	O
25	cycles	O
26	per	O
27	year	O
28	while	O
29	the	O
30	latter	O
31	was	O
32	a	O
33	historical	O
34	reference	O
35	group	O
36	managed	O
37	without	O
38	prostaglandins	O
39	.	O

1	Desmethylferrochloroquine	O
2	1a	O
3	and	O
4	didesmethylferrochloroquine	O
5	2	O
6	would	O
7	be	O
8	more	O
9	potent	O
10	against	O
11	schizontocides	O
12	than	O
13	CQ	O
14	in	O
15	vitro	O
16	against	O
17	two	O
18	strains	O
19	(	O
20	HB3	O
21	and	O
22	Dd2	O
23	)	O
24	of	O
25	Plasmodium	O
26	falciparum	O
27	.	O

1	The	O
2	rrd1	B
3	,	I
4	2delta	I
5	mutant	I
6	was	O
7	partially	O
8	rescued	O
9	by	O
10	inactivation	O
11	of	O
12	HOG1	B
13	or	O
14	PBS2	B
15	,	O
16	suggesting	O
17	an	O
18	interaction	O
19	between	O
20	the	O
21	RRD	B
22	genes	I
23	and	O
24	the	O
25	Hog1p	B
26	signal	I
27	transduction	I
28	pathway	I
29	.	O

1	Members	O
2	of	O
3	the	O
4	JAK	B
5	/	O
6	Tyk	B
7	family	O
8	of	O
9	tyrosine	B
10	kinases	I
11	mediate	O
12	phosphorylation	O
13	of	O
14	STAT3	B
15	at	O
16	Tyr705	O
17	during	O
18	CNTF	B
19	signaling	O
20	;	O
21	however	O
22	,	O
23	the	O
24	kinase	O
25	responsible	O
26	for	O
27	phosphorylation	O
28	at	O
29	STAT3	B
30	Tyr727	O
31	appears	O
32	to	O
33	depend	O
34	on	O
35	both	O
36	the	O
37	extracellular	O
38	stimulus	O
39	and	O
40	the	O
41	cellular	O
42	context	O
43	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	B
5	/	O
6	RXRalpha	B
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	B
12	-	O
13	PPRE	O
14	luciferase	B
15	reporter	I
16	construct	I
17	.	O

1	Zebrafish	O
2	cyclops	B
3	(	O
4	cyc	B
5	)	O
6	encodes	O
7	a	O
8	Transforming	B
9	Growth	I
10	Factor	I
11	beta	I
12	(	O
13	TGFbeta	B
14	)	O
15	signaling	O
16	factor	O
17	closely	O
18	related	O
19	to	O
20	mouse	O
21	Nodal	B
22	.	O

1	Thus	O
2	,	O
3	SOX8	B
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O

1	The	O
2	genome	O
3	organization	O
4	of	O
5	the	O
6	mite	O
7	-	O
8	transmitted	O
9	wheat	O
10	streak	O
11	mosaic	O
12	virus	O
13	(	O
14	WSMV	O
15	)	O
16	appears	O
17	to	O
18	parallel	O
19	that	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Potyviridae	O
25	with	O
26	monopartite	O
27	genomes	O
28	,	O
29	but	O
30	there	O
31	are	O
32	substantial	O
33	amino	O
34	acid	O
35	dissimilarities	O
36	with	O
37	other	O
38	potyviral	O
39	polyproteins	O
40	.	O

1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	B
16	,	O
17	HC	B
18	-	I
19	Pro	I
20	,	O
21	P1	B
22	,	O
23	P3	B
24	,	O
25	and	O
26	CP	B
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O

1	Diverse	O
2	endogenous	O
3	light	O
4	chains	O
5	contribute	O
6	to	O
7	basement	O
8	membrane	O
9	reactivity	O
10	in	O
11	nonautoimmune	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	B
17	-	I
18	laminin	I
19	Ig	I
20	heavy	I
21	chain	I
22	.	O

1	Patch	O
2	test	O
3	results	O
4	obtained	O
5	with	O
6	corticosteroid	O
7	allergic	O
8	patients	O
9	tested	O
10	with	O
11	a	O
12	large	O
13	corticosteroid	O
14	series	O
15	validated	O
16	the	O
17	earlier	O
18	classification	O
19	of	O
20	corticosteroid	O
21	molecules	O
22	in	O
23	four	O
24	groups	O
25	of	O
26	cross	O
27	-	O
28	reacting	O
29	molecules	O
30	:	O
31	i	O
32	.	O
33	e	O
34	.,	O
35	group	O
36	A	O
37	(	O
38	hydrocortisone	O
39	type	O
40	),	O
41	group	O
42	B	O
43	(	O
44	acetonides	O
45	),	O
46	group	O
47	C	O
48	(	O
49	betamethasone	O
50	type	O
51	-	O
52	non	O
53	esterified	O
54	)	O
55	and	O
56	group	O
57	D	O
58	(	O
59	esters	O
60	).	O

1	Mechanisms	O
2	of	O
3	tachyphylaxis	O
4	in	O
5	regional	O
6	anesthesia	O
7	of	O
8	long	O
9	duration	O

1	An	O
2	increase	O
3	in	O
4	the	O
5	level	O
6	of	O
7	serum	O
8	enzymes	O
9	,	O
10	such	O
11	as	O
12	aspartate	B
13	transaminase	I
14	,	O
15	alkaline	B
16	phosphatase	I
17	,	O
18	creatine	B
19	phosphokinase	I
20	,	O
21	lactate	B
22	dehydrogenase	I
23	after	O
24	D	O
25	.	O
26	russelli	O
27	venom	O
28	injection	O
29	in	O
30	albino	O
31	rats	O
32	is	O
33	indicative	O
34	of	O
35	cell	O
36	or	O
37	tissue	O
38	damage	O
39	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Surprisingly	O
2	,	O
3	3	O
4	full	B
5	-	I
6	length	I
7	murine	I
8	survivin	I
9	cDNA	I
10	clones	O
11	were	O
12	isolated	O
13	,	O
14	predicting	O
15	the	O
16	existence	O
17	of	O
18	3	O
19	distinct	O
20	survivin	B
21	proteins	I
22	.	O

1	Thus	O
2	,	O
3	the	O
4	induction	O
5	of	O
6	E2F	B
7	binding	O
8	to	O
9	the	O
10	E2F	B
11	-	I
12	1	I
13	promoter	I
14	by	O
15	the	O
16	E4	B
17	-	I
18	6	I
19	/	I
20	7	I
21	protein	I
22	observed	O
23	in	O
24	vitro	O
25	correlates	O
26	with	O
27	transactivation	O
28	of	O
29	E2F	B
30	-	I
31	1	I
32	promoter	I
33	activity	O
34	in	O
35	vivo	O
36	.	O

1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O

1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O

1	ZK7	B
2	and	O
3	HZF16	B
4	genes	I
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O

1	CONCLUSION	O
2	:	O
3	Presence	O
4	of	O
5	APOE	B
6	epsilon4	I
7	/*	I
8	seems	O
9	to	O
10	increase	O
11	the	O
12	risk	O
13	for	O
14	dementia	O
15	and	O
16	AD	O
17	independently	O
18	of	O
19	its	O
20	effect	O
21	on	O
22	dyslipidemia	O
23	and	O
24	atherogenesis	O
25	.	O

1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O

1	Two	O
2	distinct	O
3	Salmonella	B
4	fimbrins	I
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	B
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	B
6	,	O
7	none	O
8	of	O
9	the	O
10	chimeric	B
11	SefA	I
12	proteins	I
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	B
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	B
42	-	O
43	modified	O
44	RecBCD	B
45	nuclease	I
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	molecular	O
9	mechanisms	O
10	underlying	O
11	the	O
12	inducible	O
13	expression	O
14	of	O
15	the	O
16	flt	B
17	-	I
18	1	I
19	gene	I
20	during	O
21	the	O
22	activation	O
23	of	O
24	THP	O
25	-	O
26	1	O
27	cells	O
28	.	O

1	There	O
2	was	O
3	a	O
4	2	O
5	.	O
6	4	O
7	-	O
8	fold	O
9	difference	O
10	in	O
11	CAT	B
12	produced	O
13	from	O
14	these	O
15	transcripts	O
16	in	O
17	HeLa	O
18	cells	O
19	,	O
20	which	O
21	contain	O
22	a	O
23	greater	O
24	natural	O
25	abundance	O
26	of	O
27	PTB	B
28	.	O

1	Multiple	O
2	mitogen	B
3	-	I
4	activated	I
5	protein	I
6	kinase	I
7	signaling	O
8	pathways	O
9	connect	O
10	the	O
11	cot	B
12	oncoprotein	I
13	to	O
14	the	O
15	c	B
16	-	I
17	jun	I
18	promoter	I
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O

1	Dermatology	O
2	is	O
3	no	O
4	exception	O
5	.	O

1	4	O
2	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	B
13	expression	O
14	.	O

1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	B
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	B
23	module	I
24	,	O
25	with	O
26	inner	O
27	nuclear	O
28	membrane	O
29	proteins	O
30	lamina	B
31	-	I
32	associated	I
33	polypeptide	I
34	2	I
35	and	O
36	emerin	B
37	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	B
7	I	I
8	-	I
9	mfa	I
10	domain	I
11	-	I
12	containing	I
13	protein	I
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O

1	The	O
2	encoded	O
3	amino	O
4	acid	O
5	sequences	O
6	in	O
7	the	O
8	full	O
9	-	O
10	length	O
11	bovine	O
12	and	O
13	porcine	O
14	cDNAs	O
15	were	O
16	identical	O
17	,	O
18	consisting	O
19	of	O
20	209	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	and	O
26	were	O
27	nearly	O
28	the	O
29	same	O
30	as	O
31	the	O
32	published	O
33	sequence	O
34	determined	O
35	by	O
36	Edman	O
37	degradation	O
38	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	For	O
2	each	O
3	night	O
4	,	O
5	the	O
6	diary	O
7	allowed	O
8	the	O
9	subjective	O
10	measurement	O
11	of	O
12	bedtime	O
13	,	O
14	wake	O
15	time	O
16	,	O
17	time	O
18	in	O
19	bed	O
20	(	O
21	TIB	O
22	),	O
23	sleep	O
24	efficiency	O
25	,	O
26	number	O
27	of	O
28	minutes	O
29	of	O
30	wake	O
31	after	O
32	sleep	O
33	onset	O
34	(	O
35	WASO	O
36	),	O
37	alertness	O
38	on	O
39	awakening	O
40	,	O
41	and	O
42	percentage	O
43	of	O
44	morning	O
45	needing	O
46	an	O
47	alarm	O
48	(	O
49	or	O
50	a	O
51	person	O
52	functioning	O
53	as	O
54	one	O
55	).	O

1	Acad	O
2	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	central	O
3	(	O
4	R	O
5	)	O
6	domain	O
7	is	O
8	responsible	O
9	for	O
10	receptor	O
11	-	O
12	binding	O
13	activity	O
14	whereas	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	(	O
20	T	O
21	)	O
22	domain	O
23	mediates	O
24	translocation	O
25	,	O
26	the	O
27	process	O
28	by	O
29	which	O
30	the	O
31	C	O
32	-	O
33	terminal	O
34	cytotoxic	O
35	domain	O
36	is	O
37	transported	O
38	from	O
39	the	O
40	receptor	O
41	to	O
42	the	O
43	site	O
44	of	O
45	its	O
46	cytotoxicity	O
47	.	O

1	We	O
2	have	O
3	previously	O
4	demonstrated	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	gene	O
10	for	O
11	the	O
12	reproductive	O
13	neuropeptide	O
14	,	O
15	GnRH	B
16	,	O
17	is	O
18	repressed	O
19	by	O
20	the	O
21	glutamate	O
22	/	O
23	NO	O
24	/	O
25	cyclic	O
26	GMP	O
27	(	O
28	cGMP	O
29	)	O
30	signal	O
31	transduction	O
32	pathway	O
33	through	O
34	cGMP	B
35	-	I
36	dependent	I
37	protein	I
38	kinase	I
39	in	O
40	the	O
41	hypothalamic	O
42	GnRH	B
43	-	O
44	secreting	O
45	neuronal	O
46	cell	O
47	line	O
48	GT1	O
49	-	O
50	7	O
51	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	Extreme	O
2	potency	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	B
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	B
27	or	O
28	Stat3	B
29	.	O

1	MSSPs	B
2	are	O
3	believed	O
4	to	O
5	regulate	O
6	DNA	O
7	replication	O
8	,	O
9	transcription	O
10	,	O
11	apopotosis	O
12	and	O
13	cell	O
14	cycle	O
15	progression	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	C	B
21	-	I
22	MYC	I
23	protein	I
24	.	O

1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	O
7	damaged	O
8	E44D	O
9	mutant	O
10	detected	O
11	in	O
12	(	O
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	O
31	I	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	O
40	the	O
41	active	O
42	site	O
43	region	O
44	.	O

1	In	O
2	vitro	O
3	expression	O
4	of	O
5	four	O
6	different	O
7	naturally	O
8	occurring	O
9	nonsense	O
10	and	O
11	missense	O
12	mutations	O
13	revealed	O
14	a	O
15	dramatically	O
16	altered	O
17	subcellular	O
18	location	O
19	of	O
20	the	O
21	protein	O
22	in	O
23	cultured	O
24	cells	O
25	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	Immunity	O
2	acquired	O
3	by	O
4	mice	O
5	during	O
6	I	O
7	.	O
8	scapularis	O
9	nymphal	O
10	activity	O
11	in	O
12	early	O
13	summer	O
14	may	O
15	exclude	O
16	a	O
17	large	O
18	proportion	O
19	of	O
20	the	O
21	mouse	O
22	population	O
23	from	O
24	maintaining	O
25	E	O
26	.	O
27	phagocytophila	O
28	during	O
29	the	O
30	period	O
31	of	O
32	larval	O
33	activity	O
34	later	O
35	in	O
36	the	O
37	season	O
38	.	O

1	The	O
2	emerging	O
3	view	O
4	based	O
5	on	O
6	studies	O
7	in	O
8	yeast	O
9	is	O
10	that	O
11	each	O
12	class	O
13	of	O
14	snoRNPs	O
15	is	O
16	composed	O
17	of	O
18	a	O
19	unique	O
20	set	O
21	of	O
22	proteins	O
23	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	O
11	activated	O
12	protein	B
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	O
30	activated	O
31	protein	B
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	Activation	O
2	of	O
3	a	O
4	CRE	O
5	-	O
6	dependent	O
7	junB	B
8	promoter	I
9	/	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	by	O
18	the	O
19	BCR	B
20	was	O
21	also	O
22	blocked	O
23	by	O
24	SB203580	O
25	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O

1	METHODS	O
2	:	O
3	TBN	O
4	measurements	O
5	were	O
6	performed	O
7	in	O
8	31	O
9	female	O
10	outpatients	O
11	with	O
12	breast	O
13	carcinoma	O
14	who	O
15	were	O
16	undergoing	O
17	standard	O
18	cyclophosphamide	O
19	,	O
20	methotrexate	O
21	,	O
22	and	O
23	5	O
24	-	O
25	fluorouracil	O
26	(	O
27	CMF	O
28	)-	O
29	based	O
30	chemotherapy	O
31	(	O
32	median	O
33	age	O
34	,	O
35	48	O
36	years	O
37	;	O
38	range	O
39	,	O
40	26	O
41	-	O
42	77	O
43	years	O
44	).	O

1	A	O
2	385	O
3	bp	O
4	Glucocorticoid	O
5	Response	O
6	Unit	O
7	(	O
8	GRU	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	dibutyryl	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O

1	No	O
2	somatic	O
3	mutations	O
4	were	O
5	found	O
6	in	O
7	any	O
8	of	O
9	the	O
10	samples	O
11	,	O
12	suggesting	O
13	that	O
14	ING1	B
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O

1	Ras	B
2	-	O
3	GRF1	B
4	transiently	O
5	expressed	O
6	with	O
7	v	B
8	-	I
9	Src	I
10	was	O
11	tyrosine	O
12	-	O
13	phosphorylated	O
14	and	O
15	showed	O
16	significant	O
17	GEF	B
18	activity	O
19	toward	O
20	Rac	B
21	,	O
22	but	O
23	not	O
24	Rho	B
25	and	O
26	Cdc42	B
27	,	O
28	which	O
29	was	O
30	comparable	O
31	with	O
32	that	O
33	induced	O
34	by	O
35	Gbetagamma	B
36	.	O

1	As	O
2	no	O
3	complete	O
4	PPARgamma	B
5	antagonists	O
6	have	O
7	been	O
8	described	O
9	hitherto	O
10	,	O
11	we	O
12	have	O
13	constructed	O
14	a	O
15	dominant	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	O
20	to	O
21	inhibit	O
22	wild	O
23	-	O
24	type	O
25	PPARgamma	B
26	action	O
27	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	LPO	O
2	and	O
3	SOD	B
4	levels	O
5	were	O
6	measured	O
7	at	O
8	five	O
9	points	O
10	before	O
11	and	O
12	during	O
13	the	O
14	operation	O
15	.	O

1	Sustained	O
2	ventricular	O
3	tachycardia	O
4	and	O
5	its	O
6	successful	O
7	prophylaxis	O
8	during	O
9	high	O
10	-	O
11	dose	O
12	bolus	O
13	interleukin	B
14	-	I
15	2	I
16	therapy	O
17	for	O
18	metastatic	O
19	renal	O
20	cell	O
21	carcinoma	O
22	.	O

1	Second	O
2	,	O
3	when	O
4	the	O
5	NBF1	B
6	+	I
7	R	I
8	protein	I
9	,	O
10	the	O
11	NBF2	B
12	protein	I
13	,	O
14	and	O
15	a	O
16	mixture	O
17	of	O
18	the	O
19	two	O
20	proteins	O
21	were	O
22	folded	O
23	separately	O
24	and	O
25	analyzed	O
26	by	O
27	molecular	O
28	sieve	O
29	chomatography	O
30	,	O
31	the	O
32	mixture	O
33	was	O
34	found	O
35	to	O
36	elute	O
37	prior	O
38	to	O
39	either	O
40	NBF1	B
41	+	I
42	R	I
43	or	O
44	NBF2	B
45	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O

1	After	O
2	nitric	O
3	oxide	O
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	MIP	O
6	,	O
7	MMIF	O
8	,	O
9	FIC	O
10	,	O
11	Wimax	O
12	,	O
13	P0	O
14	.	O
15	1	O
16	and	O
17	minute	O
18	ventilation	O
19	(	O
20	Vr	O
21	)	O
22	were	O
23	significantly	O
24	increased	O
25	after	O
26	administration	O
27	of	O
28	methylphenidatum	O
29	and	O
30	aminophylline	O
31	.	O

1	Forty	O
2	4	O
3	-	O
4	month	O
5	old	O
6	SD	O
7	female	O
8	rats	O
9	were	O
10	randomly	O
11	divided	O
12	into	O
13	four	O
14	groups	O
15	,	O
16	namely	O
17	sham	O
18	operation	O
19	,	O
20	bilateral	O
21	ovariectomy	O
22	,	O
23	ovariectomy	O
24	plus	O
25	supplementary	O
26	ethinyl	O
27	estradiol	O
28	(	O
29	0	O
30	.	O
31	2	O
32	microgram	O
33	/	O
34	100	O
35	g	O
36	B	O
37	.	O

1	It	O
2	has	O
3	also	O
4	been	O
5	shown	O
6	that	O
7	a	O
8	variety	O
9	of	O
10	extracellular	O
11	factors	O
12	stimulate	O
13	a	O
14	pair	O
15	of	O
16	MAPK	O
17	p44	B
18	and	O
19	MAPK	O
20	p42	B
21	of	O
22	MAPK	B
23	family	I
24	members	I
25	.	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	B
8	-	O
9	p86	B
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	B
26	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	Protamine	B
2	and	O
3	heparin	O
4	doses	O
5	,	O
6	their	O
7	sum	O
8	(	O
9	Sigma	O
10	-	O
11	dose	O
12	)	O
13	and	O
14	differential	O
15	(	O
16	Delta	O
17	-	O
18	dose	O
19	)	O
20	doses	O
21	,	O
22	and	O
23	activated	O
24	clotting	O
25	times	O
26	were	O
27	tabulated	O
28	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	a	O
6	common	O
7	mechanism	O
8	has	O
9	been	O
10	identified	O
11	to	O
12	coordinate	O
13	the	O
14	growth	O
15	-	O
16	and	O
17	FC	O
18	-	O
19	dependent	O
20	expression	O
21	of	O
22	caveolin	B
23	.	O

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	O
6	tRNA	O
7	3	O
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	O
19	activities	O
20	are	O
21	different	O
22	enzymes	O
23	.	O

1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O

1	NKX2	B
2	.	I
3	1	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	NK2	B
10	family	I
11	of	O
12	homeodomain	B
13	-	I
14	containing	I
15	transcription	I
16	factors	I
17	whose	O
18	targeted	O
19	disruption	O
20	in	O
21	mouse	O
22	results	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	thyroid	O
28	tissue	O
29	and	O
30	a	O
31	severely	O
32	abnormal	O
33	lung	O
34	phenotype	O
35	.	O

1	National	O
2	abortion	O
3	laws	O
4	usually	O
5	do	O
6	not	O
7	allow	O
8	abortion	O
9	when	O
10	a	O
11	foetus	O
12	is	O
13	independently	O
14	viable	O
15	,	O
16	i	O
17	.	O
18	e	O
19	.	O
20	from	O
21	a	O
22	gestational	O
23	age	O
24	of	O
25	about	O
26	24	O
27	weeks	O
28	.	O

1	Expression	O
2	in	O
3	early	O
4	postnatal	O
5	pituitary	O
6	and	O
7	in	O
8	pre	O
9	-	O
10	somatotrophic	O
11	cells	O
12	suggests	O
13	that	O
14	Zn	B
15	-	I
16	16	I
17	could	O
18	play	O
19	a	O
20	role	O
21	in	O
22	pituitary	O
23	development	O
24	prior	O
25	to	O
26	somatotroph	O
27	differentiation	O
28	.	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	I
8	16	I
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	B
23	Zn	I
24	-	I
25	15	I
26	.	O

1	The	O
2	CCAAT	O
3	core	O
4	sequence	O
5	mutants	O
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	Deglutition	O
2	is	O
3	considered	O
4	to	O
5	be	O
6	immature	O
7	in	O
8	infants	O
9	and	O
10	to	O
11	mature	O
12	postnatally	O
13	.	O

1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	I
9	1	I
10	transactivation	O
11	or	O
12	PEST	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O

1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	O
25	growth	B
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O

1	Interestingly	O
2	,	O
3	addition	O
4	of	O
5	purified	O
6	CBP	B
7	to	O
8	the	O
9	nuclear	O
10	extracts	O
11	of	O
12	T47D	O
13	cells	O
14	markedly	O
15	stimulated	O
16	progesterone	O
17	-	O
18	and	O
19	PR	B
20	-	O
21	dependent	O
22	transcription	O
23	from	O
24	a	O
25	nucleosome	O
26	-	O
27	free	O
28	,	O
29	progesterone	O
30	response	O
31	element	O
32	(	O
33	PRE	O
34	)-	O
35	linked	O
36	reporter	O
37	DNA	O
38	template	O
39	.	O

1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	B
7	/	O
8	NRSF	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	lethality	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O

1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	B
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	B
17	histone	I
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O

1	Finally	O
2	,	O
3	the	O
4	mechanism	O
5	of	O
6	ASK1	B
7	activation	O
8	involves	O
9	,	O
10	in	O
11	part	O
12	,	O
13	homo	O
14	-	O
15	oligomerization	O
16	.	O

1	OUTCOME	O
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O

1	Two	O
2	other	O
3	patients	O
4	underwent	O
5	PRFR	O
6	.	O

1	The	O
2	variations	O
3	were	O
4	caused	O
5	by	O
6	opposite	O
7	shifts	O
8	in	O
9	TSH	B
10	frequency	O
11	distribution	O
12	in	O
13	mothers	O
14	and	O
15	neonates	O
16	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	B
11	multidrug	I
12	resistance	I
13	protein	I
14	2	I
15	(	O
16	MRP2	B
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	B
26	resistance	I
27	protein	I
28	3	I
29	(	O
30	MRP3	B
31	)	O
32	gene	O
33	.	O

1	However	O
2	,	O
3	such	O
4	a	O
5	mechanism	O
6	was	O
7	not	O
8	detected	O
9	in	O
10	preliminary	O
11	observations	O
12	on	O
13	M	O
14	.	O
15	synoviae	O
16	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	jannaschii	O
9	as	O
10	well	O
11	as	O
12	related	O
13	archaeal	B
14	20S	I
15	proteasomes	I
16	require	O
17	a	O
18	nucleotidase	O
19	complex	O
20	such	O
21	as	O
22	PAN	B
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	folded	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	PAN	B
47	are	O
48	not	O
49	absolutely	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O

1	The	O
2	transcription	O
3	factor	O
4	E2F	B
5	plays	O
6	an	O
7	important	O
8	role	O
9	in	O
10	G	O
11	(	O
12	1	O
13	)	O
14	to	O
15	S	O
16	phase	O
17	transition	O
18	in	O
19	the	O
20	higher	O
21	eukaryotic	O
22	cell	O
23	cycle	O
24	.	O

1	In	O
2	two	O
3	-	O
4	field	O
5	nodal	O
6	dissection	O
7	,	O
8	two	O
9	components	O
10	are	O
11	included	O
12	with	O
13	(	O
14	modern	O
15	two	O
16	-	O
17	field	O
18	)	O
19	or	O
20	without	O
21	(	O
22	traditional	O
23	two	O
24	-	O
25	field	O
26	)	O
27	nodal	O
28	dissection	O
29	around	O
30	both	O
31	recurrent	O
32	laryngeal	O
33	nerve	O
34	chains	O
35	in	O
36	the	O
37	upper	O
38	mediastinum	O
39	.	O

1	Of	O
2	the	O
3	153	O
4	patients	O
5	studied	O
6	,	O
7	CK	B
8	-	I
9	MB	I
10	results	O
11	were	O
12	positive	O
13	in	O
14	91	O
15	(	O
16	59	O
17	%)	O
18	patients	O
19	;	O
20	ECG	O
21	revealed	O
22	AMI	O
23	in	O
24	72	O
25	(	O
26	47	O
27	%)	O
28	patients	O
29	.	O

1	The	O
2	effect	O
3	of	O
4	MIB	O
5	on	O
6	the	O
7	dose	O
8	-	O
9	response	O
10	curve	O
11	of	O
12	externally	O
13	applied	O
14	noradrenaline	O
15	was	O
16	also	O
17	studied	O
18	.	O

1	The	O
2	regional	O
3	blockade	O
4	of	O
5	H1R	B
6	was	O
7	observed	O
8	mainly	O
9	in	O
10	the	O
11	frontal	O
12	,	O
13	temporal	O
14	and	O
15	anterior	O
16	cingulate	O
17	cortices	O
18	,	O
19	and	O
20	the	O
21	intravenous	O
22	administration	O
23	of	O
24	d	O
25	-	O
26	chlorpheniramine	O
27	as	O
28	a	O
29	therapeutic	O
30	dose	O
31	(	O
32	2	O
33	mg	O
34	)	O
35	blocked	O
36	over	O
37	60	O
38	%	O
39	of	O
40	H1R	B
41	in	O
42	the	O
43	frontal	O
44	cortices	O
45	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	yam8	B
6	(+)	I
7	cDNA	I
8	in	O
9	the	O
10	mid1	B
11	mutant	I
12	cells	O
13	partially	O
14	remediated	O
15	the	O
16	mid	O
17	phenotype	O
18	and	O
19	resulted	O
20	in	O
21	a	O
22	slight	O
23	increase	O
24	in	O
25	Ca	O
26	(	O
27	2	O
28	+)	O
29	uptake	O
30	activity	O
31	.	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	Static	O
2	and	O
3	dynamic	O
4	compliance	O
5	was	O
6	measured	O
7	after	O
8	induction	O
9	of	O
10	anesthesia	O
11	,	O
12	before	O
13	and	O
14	immediately	O
15	after	O
16	filtration	O
17	in	O
18	the	O
19	operating	O
20	theater	O
21	,	O
22	1	O
23	hour	O
24	after	O
25	return	O
26	to	O
27	the	O
28	pediatric	O
29	intensive	O
30	care	O
31	unit	O
32	,	O
33	and	O
34	24	O
35	hours	O
36	after	O
37	the	O
38	operation	O
39	.	O

1	Antipyretic	O
2	therapy	O
3	:	O
4	physiologic	O
5	rationale	O
6	,	O
7	diagnostic	O
8	implications	O
9	,	O
10	and	O
11	clinical	O
12	consequences	O
13	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	KFC	B
2	,	O
3	a	O
4	Ste20	B
5	-	I
6	like	I
7	kinase	I
8	with	O
9	mitogenic	O
10	potential	O
11	and	O
12	capability	O
13	to	O
14	activate	O
15	the	O
16	SAPK	B
17	/	O
18	JNK	B
19	pathway	O
20	.	O

1	TIP30	B
2	has	O
3	an	O
4	intrinsic	O
5	kinase	O
6	activity	O
7	required	O
8	for	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	a	O
14	subset	O
15	of	O
16	apoptotic	O
17	genes	O
18	.	O

1	We	O
2	have	O
3	mapped	O
4	the	O
5	human	B
6	STAG3	I
7	gene	I
8	to	O
9	the	O
10	7q22	O
11	region	O
12	of	O
13	chromosome	O
14	7	O
15	;	O
16	six	O
17	human	B
18	STAG3	I
19	-	I
20	related	I
21	genes	I
22	have	O
23	also	O
24	been	O
25	mapped	O
26	:	O
27	two	O
28	at	O
29	7q22	O
30	near	O
31	the	O
32	functional	O
33	gene	O
34	,	O
35	one	O
36	at	O
37	7q11	O
38	.	O
39	22	O
40	,	O
41	and	O
42	three	O
43	at	O
44	7q11	O
45	.	O
46	23	O
47	,	O
48	two	O
49	of	O
50	them	O
51	flanking	O
52	the	O
53	breakpoints	O
54	commonly	O
55	associated	O
56	with	O
57	the	O
58	Williams	B
59	-	I
60	Beuren	I
61	syndrome	I
62	(	I
63	WBS	I
64	)	I
65	deletion	I
66	.	O

1	Reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O

1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	access	O
9	to	O
10	two	O
11	bottles	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	tap	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	sucrose	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O

1	Furthermore	O
2	,	O
3	Zelen	O
4	'	O
5	s	O
6	method	O
7	is	O
8	used	O
9	to	O
10	balance	O
11	the	O
12	number	O
13	of	O
14	patients	O
15	allocated	O
16	to	O
17	the	O
18	two	O
19	groups	O
20	within	O
21	each	O
22	institution	O
23	(	O
24	M	O
25	.	O

1	RESULTS	O
2	:	O
3	In	O
4	this	O
5	group	O
6	of	O
7	patients	O
8	,	O
9	male	O
10	gender	O
11	(	O
12	P	O
13	=	O
14	0	O
15	.	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	During	O
2	the	O
3	cloning	O
4	by	O
5	reverse	B
6	transcriptase	I
7	-	O
8	polymerase	O
9	chain	O
10	reaction	O
11	of	O
12	the	O
13	human	B
14	HIF	I
15	-	I
16	1alpha	I
17	subunit	I
18	,	O
19	we	O
20	isolated	O
21	two	O
22	cDNA	O
23	clones	O
24	which	O
25	corresponded	O
26	to	O
27	alternative	O
28	splicing	O
29	of	O
30	the	O
31	HIF	B
32	-	I
33	1alpha	I
34	gene	I
35	.	O

1	To	O
2	assess	O
3	the	O
4	relationship	O
5	between	O
6	G	O
7	(	O
8	q	O
9	)/	O
10	G	B
11	(	I
12	11	I
13	)	I
14	function	O
15	with	O
16	the	O
17	phosphatidylinositol	B
18	3	I
19	-	I
20	kinase	I
21	dependent	O
22	pathway	O
23	,	O
24	expression	O
25	of	O
26	a	O
27	dominant	O
28	-	O
29	interfering	O
30	p85	B
31	regulatory	I
32	subunit	I
33	,	O
34	as	O
35	well	O
36	as	O
37	wortmannin	O
38	treatment	O
39	inhibited	O
40	insulin	B
41	-	O
42	stimulated	O
43	but	O
44	not	O
45	G	B
46	(	I
47	q	I
48	)/	I
49	Q209L	I
50	-	O
51	stimulated	O
52	GLUT4	B
53	-	O
54	EGFP	B
55	translocation	O
56	.	O

1	In	O
2	endemic	O
3	BL	O
4	,	O
5	the	O
6	RB2	B
7	/	O
8	p130	B
9	gene	O
10	is	O
11	mutated	O
12	in	O
13	most	O
14	of	O
15	the	O
16	cases	O
17	,	O
18	and	O
19	the	O
20	protein	O
21	is	O
22	restricted	O
23	to	O
24	the	O
25	cytoplasm	O
26	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	B
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	B
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	Strontium	O
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O

1	The	O
2	pCMBS	O
3	-	O
4	reactive	O
5	sulfhydryl	O
6	groups	O
7	were	O
8	located	O
9	exclusively	O
10	in	O
11	the	O
12	exofacial	O
13	half	O
14	of	O
15	the	O
16	plasma	O
17	membrane	O
18	and	O
19	,	O
20	when	O
21	presented	O
22	in	O
23	a	O
24	helical	O
25	model	O
26	,	O
27	lie	O
28	along	O
29	one	O
30	side	O
31	of	O
32	the	O
33	helices	O
34	.	O

1	Analysis	O
2	of	O
3	1	O
4	Mb	O
5	of	O
6	published	O
7	sequence	O
8	from	O
9	the	O
10	region	O
11	of	O
12	conserved	O
13	synteny	O
14	on	O
15	human	O
16	chromosome	O
17	5q31	O
18	-	O
19	q33	O
20	identified	O
21	45	O
22	gene	O
23	candidates	O
24	,	O
25	including	O
26	35	O
27	expressed	O
28	genes	O
29	in	O
30	the	O
31	human	B
32	IL	I
33	-	I
34	4	I
35	cytokine	I
36	gene	I
37	cluster	I
38	.	O

1	Human	B
2	AP	I
3	-	I
4	2rep	I
5	repressed	O
6	both	O
7	reporter	O
8	expression	O
9	from	O
10	a	O
11	transiently	O
12	transfected	O
13	AP	B
14	-	I
15	2alpha	I
16	promoter	I
17	and	O
18	the	O
19	endogenous	O
20	AP	B
21	-	I
22	2alpha	I
23	gene	I
24	and	O
25	inversely	O
26	was	O
27	negatively	O
28	regulated	O
29	by	O
30	AP	B
31	-	I
32	2alpha	I
33	.	O

1	In	O
2	order	O
3	to	O
4	gain	O
5	deeper	O
6	insight	O
7	into	O
8	the	O
9	role	O
10	of	O
11	the	O
12	amino	O
13	-	O
14	terminal	O
15	domain	O
16	of	O
17	the	O
18	p24	B
19	(	O
20	CA	B
21	)	O
22	protein	O
23	during	O
24	viral	O
25	replication	O
26	,	O
27	eight	O
28	highly	O
29	conserved	O
30	proline	O
31	residues	O
32	known	O
33	to	O
34	promote	O
35	turns	O
36	and	O
37	to	O
38	terminate	O
39	alpha	O
40	-	O
41	helices	O
42	within	O
43	the	O
44	p24	B
45	tertiary	O
46	structure	O
47	were	O
48	replaced	O
49	by	O
50	a	O
51	leucine	O
52	residue	O
53	(	O
54	P	O
55	-	O
56	position	O
57	-	O
58	L	O
59	).	O

1	Clb	B
2	/	O
3	Cdc28	B
4	kinases	O
5	promote	O
6	nuclear	O
7	export	O
8	of	O
9	the	O
10	replication	B
11	initiator	I
12	proteins	I
13	Mcm2	I
14	-	I
15	7	I
16	.	O

1	Alternatively	O
2	,	O
3	PC12	O
4	-	O
5	E2	O
6	cells	O
7	were	O
8	submitted	O
9	to	O
10	treatment	O
11	with	O
12	antibodies	O
13	to	O
14	the	O
15	fibroblast	B
16	growth	I
17	factor	I
18	(	I
19	FGF	I
20	)	I
21	receptor	I
22	,	O
23	inhibitors	O
24	of	O
25	the	O
26	nonreceptor	B
27	tyrosine	I
28	kinase	I
29	p59	I
30	(	O
31	fyn	B
32	),	O
33	PLC	B
34	,	O
35	PKC	B
36	and	O
37	MEK	B
38	and	O
39	an	O
40	activator	O
41	of	O
42	PKC	B
43	,	O
44	phorbol	O
45	-	O
46	12	O
47	-	O
48	myristate	O
49	-	O
50	13	O
51	-	O
52	acetate	O
53	(	O
54	PMA	O
55	).	O

1	Cooperative	O
2	roles	O
3	of	O
4	Bozozok	B
5	/	O
6	Dharma	B
7	and	O
8	Nodal	B
9	-	I
10	related	I
11	proteins	I
12	in	O
13	the	O
14	formation	O
15	of	O
16	the	O
17	dorsal	O
18	organizer	O
19	in	O
20	zebrafish	O
21	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	O
21	-	O
22	5	O
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	zygotically	O
6	activated	O
7	Xretpos	O
8	transcripts	O
9	are	O
10	restricted	O
11	to	O
12	ventro	O
13	-	O
14	posterior	O
15	specific	O
16	regions	O
17	and	O
18	induced	O
19	by	O
20	UV	O
21	-	O
22	irradiation	O
23	and	O
24	BMP	B
25	-	I
26	4	I
27	overexpression	O
28	in	O
29	cycloheximide	O
30	-	O
31	dependent	O
32	way	O
33	.	O
34	genesis	O
35	26	O
36	:	O
37	198	O
38	-	O
39	207	O
40	,	O
41	2000	O
42	.	O

1	In	O
2	all	O
3	other	O
4	cases	O
5	,	O
6	vestibular	O
7	neurectomy	O
8	or	O
9	chemical	O
10	vestibular	O
11	labyrinthectomy	O
12	,	O
13	by	O
14	means	O
15	of	O
16	intratympanic	O
17	low	O
18	concentration	O
19	gentamicin	O
20	(	O
21	20	O
22	mg	O
23	/	O
24	mL	O
25	),	O
26	are	O
27	indicated	O
28	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O

1	It	O
2	has	O
3	a	O
4	grave	O
5	prognosis	O
6	with	O
7	>	O
8	70	O
9	%	O
10	mortality	O
11	in	O
12	3	O
13	months	O
14	,	O
15	despite	O
16	mechanical	O
17	ventilation	O
18	.	O

1	We	O
2	found	O
3	that	O
4	TCR	B
5	signaling	O
6	induces	O
7	AP	B
8	-	I
9	1	I
10	binding	O
11	to	O
12	this	O
13	site	O
14	and	O
15	regulates	O
16	the	O
17	fasl	B
18	promoter	I
19	function	O
20	in	O
21	a	O
22	fashion	O
23	dependent	O
24	on	O
25	NF	B
26	-	I
27	kappaB	I
28	binding	O
29	.	O

1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	B
12	Ag	I
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	B
19	+	I
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	I
27	A	I
28	*	I
29	0201	I
30	-	O
31	restricted	O
32	,	O
33	gp100	B
34	-	O
35	derived	O
36	epitopes	O
37	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	B
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	B
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	Following	O
2	the	O
3	observation	O
4	that	O
5	non	O
6	-	O
7	organ	O
8	-	O
9	specific	O
10	antibodies	O
11	are	O
12	related	O
13	with	O
14	pregnancy	O
15	loss	O
16	and	O
17	preeclampsia	O
18	,	O
19	the	O
20	role	O
21	of	O
22	organ	O
23	-	O
24	specific	O
25	antibodies	O
26	is	O
27	currently	O
28	being	O
29	extensively	O
30	investigated	O
31	.	O

1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	B
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	The	O
2	Mif1	B
3	5	I
4	'	I
5	flanking	I
6	region	I
7	contains	O
8	a	O
9	functional	O
10	ER	O
11	stress	O
12	-	O
13	responsive	O
14	element	O
15	which	O
16	is	O
17	sufficient	O
18	for	O
19	induction	O
20	by	O
21	tunicamycin	O
22	.	O

1	Rigid	O
2	point	O
3	feature	O
4	registration	O
5	using	O
6	mutual	O
7	information	O
8	.	O

1	Methysergide	O
2	is	O
3	a	O
4	serotonin	O
5	antagonist	O
6	and	O
7	has	O
8	been	O
9	demonstrated	O
10	to	O
11	reduce	O
12	wound	O
13	blood	O
14	flow	O
15	and	O
16	edema	O
17	formation	O
18	.	O

1	Serum	O
2	leptin	B
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	B
8	stimulation	O
9	cycles	O
10	.	O

1	Valuing	O
2	families	O
3	:	O
4	social	O
5	work	O
6	practice	O
7	with	O
8	families	O
9	from	O
10	a	O
11	strengths	O
12	perspective	O
13	.	O

1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	O
9	family	O
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O

1	Ste18p	B
2	was	O
3	targeted	O
4	to	O
5	the	O
6	plasma	O
7	membrane	O
8	even	O
9	in	O
10	the	O
11	absence	O
12	of	O
13	prenylation	O
14	or	O
15	thioacylation	O
16	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	I
8	1	I
9	is	O
10	degraded	O
11	via	O
12	the	O
13	ubiquitin	B
14	-	O
15	proteasome	O
16	pathway	O
17	.	O

1	An	O
2	amino	O
3	-	O
4	acid	O
5	sequence	O
6	comparison	O
7	revealed	O
8	that	O
9	Bacillus	B
10	YM55	I
11	-	I
12	1	I
13	aspartase	I
14	shared	O
15	71	O
16	%	O
17	homology	O
18	with	O
19	Bacillus	B
20	subtilis	I
21	aspartase	I
22	and	O
23	49	O
24	%	O
25	with	O
26	Escherichia	O
27	coli	O
28	and	O
29	Pseudomonas	B
30	fluorescens	I
31	aspartases	I
32	.	O

1	Unique	O
2	to	O
3	this	O
4	system	O
5	,	O
6	the	O
7	activity	O
8	of	O
9	TraR	B
10	is	O
11	negatively	O
12	modulated	O
13	by	O
14	an	O
15	antiactivator	O
16	called	O
17	TraM	B
18	.	O

1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	O
10	-	O
11	dependent	O
12	DNA	O
13	binding	O
14	,	O
15	TraM	B
16	inhibited	O
17	TraR	B
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O

1	Inactivation	O
2	of	O
3	Ulp2	B
4	also	O
5	suppresses	O
6	several	O
7	ulp1	B
8	(	I
9	ts	I
10	)	I
11	defects	O
12	,	O
13	and	O
14	the	O
15	double	O
16	mutant	O
17	accumulates	O
18	far	O
19	fewer	O
20	Smt3	B
21	-	I
22	protein	I
23	conjugates	O
24	than	O
25	either	O
26	single	O
27	mutant	O
28	.	O

1	Collectively	O
2	,	O
3	the	O
4	results	O
5	suggest	O
6	that	O
7	ARF	B
8	binding	O
9	to	O
10	Mdm2	B
11	induces	O
12	a	O
13	conformational	O
14	change	O
15	that	O
16	facilitates	O
17	nucleolar	O
18	import	O
19	of	O
20	the	O
21	ARF	B
22	-	O
23	Mdm2	B
24	complex	O
25	and	O
26	p53	B
27	-	O
28	dependent	O
29	cell	O
30	cycle	O
31	arrest	O
32	.	O

1	Cyclin	B
2	A	I
3	expression	O
4	is	O
5	repressed	O
6	in	O
7	quiescent	O
8	cells	O
9	by	O
10	E2F	B
11	acting	O
12	in	O
13	conjunction	O
14	with	O
15	its	O
16	pocket	O
17	protein	O
18	partners	O
19	Rb	B
20	,	O
21	p107	B
22	,	O
23	and	O
24	p130	B
25	;	O
26	however	O
27	,	O
28	v	B
29	-	I
30	Jun	I
31	overrides	O
32	this	O
33	control	O
34	,	O
35	causing	O
36	phosphorylated	O
37	Rb	B
38	and	O
39	proliferation	O
40	-	O
41	specific	O
42	E2F	B
43	-	O
44	p107	B
45	complexes	O
46	to	O
47	persist	O
48	after	O
49	mitogen	O
50	withdrawal	O
51	.	O

1	D	B
2	-	I
3	cyclin	I
4	-	O
5	cdk	B
6	activity	O
7	is	O
8	required	O
9	for	O
10	Rb	B
11	phosphorylation	O
12	in	O
13	v	B
14	-	I
15	Jun	I
16	-	O
17	transformed	O
18	cells	O
19	,	O
20	since	O
21	ectopic	O
22	expression	O
23	of	O
24	the	O
25	cdk4	B
26	-	O
27	and	O
28	cdk6	B
29	-	O
30	specific	O
31	inhibitor	O
32	p16	B
33	(	O
34	INK4A	B
35	)	O
36	inhibits	O
37	both	O
38	DNA	O
39	synthesis	O
40	and	O
41	cell	O
42	proliferation	O
43	.	O

1	CONCLUSION	O
2	:	O
3	A	O
4	valve	O
5	-	O
6	like	O
7	mechanism	O
8	formed	O
9	by	O
10	the	O
11	capsulorhexis	O
12	rim	O
13	partially	O
14	adhered	O
15	to	O
16	the	O
17	IOL	O
18	optic	O
19	can	O
20	occur	O
21	postoperatively	O
22	.	O

1	The	O
2	protein	O
3	first	O
4	identified	O
5	by	O
6	the	O
7	monoclonal	B
8	antibody	I
9	Q18	I
10	is	O
11	encoded	O
12	by	O
13	a	O
14	gene	O
15	located	O
16	in	O
17	57A	O
18	on	O
19	polytene	O
20	chromosomes	O
21	and	O
22	has	O
23	been	O
24	consequently	O
25	named	O
26	Hrb57A	B
27	.	O

1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	O
28	trp	B
29	leader	O
30	RNA	O
31	association	O
32	.	O

1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O

1	The	O
2	AtERF	B
3	genes	I
4	were	O
5	differentially	O
6	regulated	O
7	by	O
8	ethylene	O
9	and	O
10	by	O
11	abiotic	O
12	stress	O
13	conditions	O
14	,	O
15	such	O
16	as	O
17	wounding	O
18	,	O
19	cold	O
20	,	O
21	high	O
22	salinity	O
23	,	O
24	or	O
25	drought	O
26	,	O
27	via	O
28	ETHYLENE	B
29	-	I
30	INSENSITIVE2	I
31	(	O
32	EIN2	B
33	)-	O
34	dependent	O
35	or	O
36	-	O
37	independent	O
38	pathways	O
39	.	O

1	Animals	O
2	received	O
3	a	O
4	dose	O
5	of	O
6	dexamethasone	O
7	(	O
8	10	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	p	O
15	.)	O
16	prior	O
17	to	O
18	the	O
19	protein	O
20	-	O
21	free	O
22	surfactant	O
23	preparation	O
24	Exosurf	O
25	(	O
26	pure	O
27	phospholipids	O
28	containing	O
29	surfactant	O
30	,	O
31	Wellcome	O
32	GmbH	O
33	,	O
34	Burgwedel	O
35	,	O
36	Germany	O
37	)	O
38	and	O
39	a	O
40	rSP	O
41	-	O
42	C	O
43	based	O
44	surfactant	O
45	,	O
46	respectively	O
47	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	O
28	GM	B
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	O
39	IL	B
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O

1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	B
21	B1	I
22	mRNA	I
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	expansion	O
6	of	O
7	the	O
8	dodecamer	O
9	repeat	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	of	O
16	CSTB	B
17	severely	O
18	disrupts	O
19	the	O
20	function	O
21	of	O
22	the	O
23	promoter	O
24	and	O
25	thereby	O
26	reduces	O
27	transcription	O
28	of	O
29	CSTB	B
30	.	O

1	Thus	O
2	,	O
3	while	O
4	the	O
5	genomic	O
6	organization	O
7	of	O
8	mHuA	B
9	is	O
10	similar	O
11	to	O
12	the	O
13	neural	O
14	-	O
15	restricted	O
16	members	O
17	of	O
18	the	O
19	Elav	B
20	family	I
21	,	O
22	the	O
23	promoter	O
24	element	O
25	differs	O
26	substantially	O
27	both	O
28	by	O
29	sequence	O
30	analysis	O
31	and	O
32	transcriptional	O
33	activity	O
34	in	O
35	non	O
36	-	O
37	neural	O
38	cell	O
39	types	O
40	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	mouse	B
10	Elavl1	I
11	(	O
12	mHuA	B
13	)	O
14	gene	O
15	reveals	O
16	a	O
17	transcriptional	O
18	regulatory	O
19	element	O
20	and	O
21	evidence	O
22	for	O
23	conserved	O
24	genomic	O
25	organization	O
26	.	O
27	mHuA	B
28	(	O
29	Elavl1	B
30	)	O
31	belongs	O
32	to	O
33	a	O
34	highly	O
35	conserved	O
36	family	O
37	of	O
38	genes	O
39	encoding	O
40	RNA	O
41	-	O
42	binding	O
43	proteins	O
44	and	O
45	has	O
46	been	O
47	linked	O
48	to	O
49	cell	O
50	growth	O
51	and	O
52	proliferation	O
53	through	O
54	its	O
55	regulation	O
56	of	O
57	mRNA	O
58	stability	O
59	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	revealed	O
6	that	O
7	Sp1	B
8	binds	O
9	to	O
10	two	O
11	different	O
12	regions	O
13	in	O
14	the	O
15	proximal	O
16	promoter	O
17	,	O
18	a	O
19	typical	O
20	Sp1	B
21	site	I
22	located	O
23	at	O
24	(-	O
25	38	O
26	;	O
27	-	O
28	33	O
29	)	O
30	and	O
31	a	O
32	G	O
33	/	O
34	C	O
35	-	O
36	rich	O
37	region	O
38	between	O
39	(-	O
40	67	O
41	;	O
42	-	O
43	62	O
44	).	O

1	Fgd3	B
2	and	O
3	FGD1	B
4	share	O
5	a	O
6	high	O
7	degree	O
8	of	O
9	sequence	O
10	identity	O
11	that	O
12	spans	O
13	>	O
14	560	O
15	contiguous	O
16	amino	O
17	acid	O
18	residues	O
19	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	thioredoxin	I
6	reductases	I
7	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	O
30	/	O
31	v	O
32	)	O
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	Eight	O
2	patients	O
3	received	O
4	1	O
5	.	O
6	5	O
7	mg	O
8	of	O
9	adefovir	O
10	dipivoxil	O
11	per	O
12	kg	O
13	of	O
14	body	O
15	weight	O
16	,	O
17	and	O
18	six	O
19	patients	O
20	received	O
21	3	O
22	.	O
23	0	O
24	mg	O
25	of	O
26	adefovir	O
27	dipivoxil	O
28	per	O
29	kg	O
30	.	O

1	CYC2	B
2	encodes	O
3	a	O
4	24	O
5	-	O
6	kDa	O
7	protein	O
8	that	O
9	has	O
10	sequence	O
11	identity	O
12	to	O
13	the	O
14	Neurospora	B
15	crassa	I
16	PREG1	I
17	and	O
18	the	O
19	S	B
20	.	I
21	cerevisiae	I
22	PHO80	I
23	cyclin	I
24	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	These	O
2	findings	O
3	indicate	O
4	the	O
5	involvement	O
6	of	O
7	Sp1	B
8	and	O
9	an	O
10	Inr	O
11	in	O
12	non	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	regulation	O
18	and	O
19	a	O
20	Kruppel	B
21	-	I
22	like	I
23	transcription	I
24	factor	I
25	and	O
26	Sp1	B
27	in	O
28	the	O
29	cell	O
30	-	O
31	specific	O
32	regulation	O
33	of	O
34	the	O
35	LTC	B
36	(	I
37	4	I
38	)	I
39	S	I
40	gene	I
41	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	Additionally	O
2	,	O
3	the	O
4	mouse	O
5	promoter	O
6	contains	O
7	22	O
8	copies	O
9	of	O
10	a	O
11	CT	O
12	dinucleotide	O
13	repeat	O
14	sequence	O
15	located	O
16	approximately	O
17	155	O
18	bp	O
19	5	O
20	'	O
21	to	O
22	exon	O
23	1	O
24	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	Therefore	O
2	,	O
3	the	O
4	positive	O
5	cAMP	O
6	control	O
7	of	O
8	the	O
9	hypoxic	O
10	SRP1	B
11	and	O
12	HEM13	B
13	genes	I
14	was	O
15	uncoupled	O
16	from	O
17	the	O
18	HOG	B
19	pathway	O
20	.	O

1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	transposable	O
11	elements	O
12	.	O

1	This	O
2	paper	O
3	reviews	O
4	the	O
5	middleware	O
6	-	O
7	based	O
8	approach	O
9	adopted	O
10	by	O
11	CEN	O
12	ENV	O
13	12967	O
14	-	O
15	1	O
16	and	O
17	the	O
18	specialisation	O
19	necessary	O
20	for	O
21	the	O
22	healthcare	O
23	record	O
24	based	O
25	on	O
26	CEN	O
27	ENV	O
28	12265	O
29	'	O
30	Electronic	O
31	Healthcare	O
32	Record	O
33	Architecture	O
34	'.	O

1	Sequence	O
2	analyses	O
3	of	O
4	sos2	B
5	mutant	I
6	alleles	I
7	reveal	O
8	that	O
9	both	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	catalytic	O
15	domain	O
16	and	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	regulatory	O
22	domain	O
23	of	O
24	SOS2	B
25	are	O
26	functionally	O
27	essential	O
28	.	O

1	A	O
2	mutation	O
3	which	O
4	abrogates	O
5	the	O
6	binding	O
7	of	O
8	these	O
9	factors	O
10	reduces	O
11	Wp	B
12	reporter	I
13	activity	O
14	specifically	O
15	in	O
16	B	O
17	cell	O
18	lines	O
19	,	O
20	whereas	O
21	a	O
22	mutation	O
23	which	O
24	converts	O
25	the	O
26	site	O
27	to	O
28	a	O
29	consensus	O
30	CREB	B
31	-	I
32	binding	I
33	sequence	I
34	maintains	O
35	wild	O
36	-	O
37	type	O
38	promoter	O
39	function	O
40	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O

1	Therefore	O
2	the	O
3	binding	O
4	sites	O
5	for	O
6	liver	O
7	-	O
8	enriched	O
9	factors	O
10	,	O
11	present	O
12	in	O
13	the	O
14	hamster	B
15	CYP7A1	I
16	proximal	I
17	promoter	I
18	in	O
19	close	O
20	vicinity	O
21	and	O
22	conserved	O
23	between	O
24	species	O
25	,	O
26	constitute	O
27	a	O
28	regulatory	O
29	unit	O
30	important	O
31	for	O
32	basal	O
33	hepatic	O
34	expression	O
35	and	O
36	tissue	O
37	restriction	O
38	of	O
39	the	O
40	action	O
41	of	O
42	hormones	O
43	such	O
44	as	O
45	insulin	B
46	.	O

1	The	O
2	kinase	O
3	activity	O
4	of	O
5	PfPK6	B
6	is	O
7	sensitive	O
8	to	O
9	CDK	B
10	inhibitors	O
11	such	O
12	as	O
13	olomoucine	O
14	and	O
15	roscovitine	O
16	.	O

1	Although	O
2	MAP	B
3	(	I
4	mitogen	I
5	-	I
6	activated	I
7	protein	I
8	)	I
9	kinases	I
10	are	O
11	implicated	O
12	in	O
13	cell	O
14	proliferation	O
15	and	O
16	differentiation	O
17	in	O
18	many	O
19	cell	O
20	types	O
21	,	O
22	the	O
23	role	O
24	of	O
25	MAP	B
26	kinases	I
27	in	O
28	cardiac	O
29	hypertrophy	O
30	remains	O
31	unclear	O
32	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	B
11	-	I
12	1	I
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	O
24	AP1	B
25	(	O
26	activator	B
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	O
48	protein	O
49	kinase	O
50	C	O
51	pathways	O
52	.	O

1	Regulation	O
2	of	O
3	urokinase	B
4	plasminogen	I
5	activator	I
6	gene	I
7	transcription	O
8	in	O
9	the	O
10	RAW264	O
11	murine	O
12	macrophage	O
13	cell	O
14	line	O
15	by	O
16	macrophage	B
17	colony	I
18	-	I
19	stimulating	I
20	factor	I
21	(	O
22	CSF	B
23	-	I
24	1	I
25	)	O
26	is	O
27	dependent	O
28	upon	O
29	the	O
30	level	O
31	of	O
32	cell	O
33	-	O
34	surface	O
35	receptor	O
36	.	O

1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	B
15	-	I
16	1	I
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O

1	Coactivation	O
2	of	O
3	endogenous	O
4	or	O
5	exogenous	O
6	G	B
7	(	I
8	q	I
9	)-	I
10	coupled	I
11	receptors	I
12	with	O
13	the	O
14	delta	B
15	-	I
16	opioid	I
17	receptor	I
18	produced	O
19	strong	O
20	stimulations	O
21	of	O
22	PLCbeta	B
23	and	O
24	such	O
25	responses	O
26	could	O
27	be	O
28	partially	O
29	blocked	O
30	by	O
31	pertussis	B
32	toxin	I
33	.	O

1	Patients	O
2	enrolled	O
3	in	O
4	the	O
5	Integrilin	O
6	to	O
7	Minimize	O
8	Platelet	O
9	Aggregation	O
10	and	O
11	Coronary	O
12	Thrombosis	O
13	-	O
14	II	O
15	(	O
16	IMPACT	O
17	-	O
18	II	O
19	)	O
20	trial	O
21	were	O
22	analyzed	O
23	.	O

1	The	O
2	Wnt	B
3	signaling	O
4	pathway	O
5	functions	O
6	reiteratively	O
7	during	O
8	animal	O
9	development	O
10	to	O
11	control	O
12	cell	O
13	fate	O
14	decisions	O
15	.	O

1	This	O
2	mutation	O
3	no	O
4	longer	O
5	repressed	O
6	the	O
7	HPV	O
8	-	O
9	11	O
10	upstream	O
11	regulatory	O
12	region	O
13	-	O
14	controlled	O
15	reporter	O
16	expression	O
17	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	O
16	beta	O
17	-	O
18	strand	O
19	I	O
20	(	O
21	betaI	O
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	The	O
2	two	O
3	contiguous	O
4	IGF2	B
5	(	O
6	human	B
7	insulin	I
8	-	I
9	like	I
10	growth	I
11	factor	I
12	II	I
13	)	O
14	and	O
15	H19	B
16	genes	I
17	are	O
18	reciprocally	O
19	imprinted	O
20	in	O
21	both	O
22	human	O
23	and	O
24	mouse	O
25	.	O

1	The	O
2	asymmetric	O
3	methylation	O
4	was	O
5	associated	O
6	with	O
7	tissue	O
8	-	O
9	specific	O
10	disruption	O
11	of	O
12	H19	B
13	genomic	O
14	imprinting	O
15	in	O
16	fetal	O
17	brain	O
18	.	O

1	The	O
2	comparison	O
3	of	O
4	the	O
5	expression	O
6	patterns	O
7	of	O
8	the	O
9	known	O
10	Kv4	B
11	family	I
12	members	I
13	shows	O
14	subtype	O
15	specificity	O
16	with	O
17	significant	O
18	overlaps	O
19	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	Preliminary	O
2	use	O
3	of	O
4	the	O
5	Nottingham	O
6	Eczema	O
7	Severity	O
8	Score	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	tool	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O

1	The	O
2	consensus	O
3	highlights	O
4	the	O
5	importance	O
6	of	O
7	residues	O
8	other	O
9	than	O
10	the	O
11	eight	O
12	motifs	O
13	that	O
14	are	O
15	often	O
16	associated	O
17	with	O
18	DEAD	B
19	-	I
20	box	I
21	RNA	I
22	helicases	I
23	,	O
24	as	O
25	well	O
26	as	O
27	de	O
28	-	O
29	emphasising	O
30	the	O
31	importance	O
32	of	O
33	the	O
34	"	O
35	A	O
36	"	O
37	residue	O
38	within	O
39	the	O
40	"	O
41	DEAD	O
42	"	O
43	motif	O
44	.	O

1	Advanced	O
2	adenoma	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	adenoma	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	adenoma	O
15	of	O
16	any	O
17	size	O
18	with	O
19	villous	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	dysplasia	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O

1	In	O
2	transient	O
3	assays	O
4	,	O
5	using	O
6	rice	O
7	suspension	O
8	-	O
9	cultured	O
10	cells	O
11	transformed	O
12	by	O
13	particle	O
14	bombardment	O
15	,	O
16	we	O
17	showed	O
18	previously	O
19	that	O
20	Oshox1	B
21	can	O
22	transcriptionally	O
23	repress	O
24	the	O
25	activity	O
26	of	O
27	reporter	O
28	gene	O
29	constructs	O
30	with	O
31	upstream	O
32	HD	B
33	-	I
34	Zip	I
35	binding	O
36	sites	O
37	.	O

1	Results	O
2	of	O
3	two	O
4	-	O
5	hybrid	O
6	assays	O
7	and	O
8	electrophoretic	O
9	mobility	O
10	shift	O
11	assays	O
12	strongly	O
13	suggest	O
14	that	O
15	all	O
16	HD	B
17	-	I
18	Zip	I
19	proteins	I
20	of	O
21	families	O
22	I	O
23	and	O
24	II	O
25	can	O
26	form	O
27	homodimers	O
28	and	O
29	also	O
30	heterodimers	O
31	with	O
32	all	O
33	HD	B
34	-	I
35	Zip	I
36	proteins	I
37	of	O
38	the	O
39	same	O
40	family	O
41	.	O

1	Among	O
2	mammalian	B
3	HSFs	I
4	,	O
5	HSF1	B
6	has	O
7	been	O
8	shown	O
9	to	O
10	be	O
11	important	O
12	for	O
13	regulation	O
14	of	O
15	the	O
16	heat	O
17	-	O
18	induced	O
19	stress	O
20	gene	O
21	expression	O
22	,	O
23	whereas	O
24	the	O
25	function	O
26	of	O
27	HSF2	B
28	in	O
29	stress	O
30	response	O
31	is	O
32	unclear	O
33	.	O

1	Importantly	O
2	,	O
3	concomitant	O
4	expression	O
5	of	O
6	constitutive	O
7	activated	O
8	Raf	B
9	and	O
10	V12N38	B
11	Ras	I
12	results	O
13	in	O
14	almost	O
15	complete	O
16	loss	O
17	of	O
18	TTF	B
19	-	I
20	1	I
21	activity	O
22	.	O

1	They	O
2	share	O
3	many	O
4	downstream	O
5	targets	O
6	,	O
7	including	O
8	remodeling	O
9	of	O
10	the	O
11	actin	B
12	cytoskeleton	O
13	,	O
14	activation	O
15	of	O
16	p70	B
17	(	I
18	S6	I
19	)	I
20	kinase	I
21	and	O
22	c	B
23	-	I
24	jun	I
25	N	I
26	-	I
27	terminal	I
28	kinase	I
29	(	O
30	JNK	B
31	),	O
32	and	O
33	regulation	O
34	of	O
35	transcription	O
36	and	O
37	cell	O
38	proliferation	O
39	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	B
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	B
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	I
21	containing	O
22	the	O
23	Ras	B
24	membrane	I
25	localization	I
26	motif	I
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	Southern	O
2	blotting	O
3	and	O
4	single	O
5	strand	O
6	conformation	O
7	polymorphism	O
8	analyses	O
9	did	O
10	not	O
11	show	O
12	tumor	O
13	-	O
14	specific	O
15	alterations	O
16	of	O
17	this	O
18	gene	O
19	in	O
20	gliomas	O
21	and	O
22	RT	O
23	-	O
24	PCR	O
25	studies	O
26	showed	O
27	expression	O
28	in	O
29	glioma	O
30	cell	O
31	lines	O
32	,	O
33	suggesting	O
34	that	O
35	ANOVA	B
36	is	O
37	not	O
38	the	O
39	chromosome	O
40	19q	O
41	glioma	O
42	tumor	O
43	suppressor	O
44	gene	O
45	.	O

1	RegA	B
2	is	O
3	a	O
4	positive	O
5	yet	O
6	nonessential	O
7	regulator	O
8	of	O
9	tol	B
10	-	O
11	oprL	B
12	expression	O
13	.	O

1	Enzyme	B
2	I	I
3	of	O
4	the	O
5	phosphoenolpyruvate	B
6	:	I
7	sugar	I
8	phosphotransferase	I
9	system	O
10	.	O

1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	B
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	B
17	promoter	I
18	in	O
19	prgQ	B
20	,	O
21	and	O
22	PrgX	B
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O

1	Family	O
2	environment	O
3	was	O
4	an	O
5	important	O
6	influence	O
7	on	O
8	interpersonal	O
9	relationships	O
10	,	O
11	substance	O
12	use	O
13	,	O
14	and	O
15	social	O
16	support	O
17	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	I
22	pause	I
23	region	I
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	O
65	IRFs	B
66	)	O
67	nuclear	O
68	proteins	O
69	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Fine	O
5	needle	O
6	aspiration	O
7	cytologic	O
8	smears	O
9	from	O
10	21	O
11	cases	O
12	of	O
13	invasive	O
14	lobular	O
15	carcinoma	O
16	(	O
17	ILC	O
18	)	O
19	of	O
20	breast	O
21	were	O
22	subjected	O
23	to	O
24	detailed	O
25	cytomorphologic	O
26	analysis	O
27	.	O

1	Electrophile	O
2	Response	O
3	Elements	O
4	(	O
5	EpREs	O
6	),	O
7	located	O
8	in	O
9	5	O
10	'-	O
11	flanking	O
12	sequences	O
13	of	O
14	both	O
15	the	O
16	GCSh	B
17	and	O
18	GCSl	B
19	subunit	I
20	genes	I
21	,	O
22	are	O
23	hypothesized	O
24	to	O
25	at	O
26	least	O
27	partially	O
28	mediate	O
29	gene	O
30	induction	O
31	following	O
32	xenobiotic	O
33	exposure	O
34	.	O

1	A	O
2	new	O
3	technique	O
4	to	O
5	create	O
6	an	O
7	artificial	O
8	stenosis	O
9	in	O
10	the	O
11	native	O
12	LAD	O
13	using	O
14	a	O
15	hemoclip	O
16	.	O

1	Dll3	B
2	is	O
3	mutated	O
4	in	O
5	the	O
6	X	O
7	-	O
8	ray	O
9	-	O
10	induced	O
11	mouse	B
12	mutant	I
13	pudgy	I
14	(	O
15	pu	B
16	),	O
17	causing	O
18	a	O
19	variety	O
20	of	O
21	vertebrocostal	O
22	defects	O
23	similar	O
24	to	O
25	SD	O
26	phenotypes	O
27	.	O

1	Schlegel	O
2	,	O
3	J	O
4	.	O

1	TbRAB31	B
2	behaviour	O
3	was	O
4	also	O
5	studied	O
6	during	O
7	the	O
8	cell	O
9	cycle	O
10	;	O
11	TbRAB31	B
12	always	O
13	localised	O
14	to	O
15	a	O
16	discrete	O
17	structure	O
18	that	O
19	duplicated	O
20	very	O
21	early	O
22	in	O
23	mitosis	O
24	and	O
25	relocated	O
26	to	O
27	daughter	O
28	cells	O
29	in	O
30	a	O
31	coordinate	O
32	manner	O
33	with	O
34	the	O
35	basal	O
36	body	O
37	and	O
38	kinetoplast	O
39	,	O
40	suggesting	O
41	the	O
42	involvement	O
43	of	O
44	microtubules	O
45	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	Invertases	B
2	are	O
3	responsible	O
4	for	O
5	the	O
6	breakdown	O
7	of	O
8	sucrose	O
9	to	O
10	fructose	O
11	and	O
12	glucose	O
13	.	O

1	To	O
2	investigate	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	this	O
8	Tax	B
9	-	O
10	mediated	O
11	inhibition	O
12	,	O
13	we	O
14	analyzed	O
15	its	O
16	effect	O
17	on	O
18	the	O
19	transcriptional	O
20	activity	O
21	of	O
22	the	O
23	myogenic	O
24	MyoD	B
25	protein	I
26	,	O
27	which	O
28	was	O
29	used	O
30	as	O
31	a	O
32	paradigm	O
33	of	O
34	bHLH	B
35	factors	I
36	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	leukemia	I
6	/	I
7	lymphotropic	I
8	virus	I
9	type	I
10	1	I
11	Tax	I
12	protein	I
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	B
26	domain	I
27	of	O
28	p300	B
29	.	O

1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	B
10	mitotic	I
11	regulatory	I
12	protein	I
13	kinase	I
14	in	I
15	budding	I
16	yeast	I
17	.	O

1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	O
33	-	O
34	endothelium	O
35	.	O

1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	B
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	I
23	II	I
24	)	I
25	s	I
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	B
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	B
43	and	O
44	MBF	B
45	.	O

1	Extracellular	B
2	-	I
3	regulated	I
4	kinase	I
5	(	O
6	ERK	B
7	)	O
8	activation	O
9	and	O
10	molecular	O
11	coupling	O
12	of	O
13	the	O
14	adaptor	O
15	proteins	O
16	p130	B
17	Crk	I
18	-	I
19	associated	I
20	substrate	I
21	(	O
22	CAS	B
23	)	O
24	and	O
25	c	B
26	-	I
27	CrkII	I
28	(	O
29	Crk	B
30	)	O
31	represent	O
32	two	O
33	distinct	O
34	pathways	O
35	that	O
36	induce	O
37	cell	O
38	invasion	O
39	and	O
40	protect	O
41	cells	O
42	from	O
43	apoptosis	O
44	in	O
45	a	O
46	three	O
47	-	O
48	dimensional	O
49	collagen	B
50	matrix	O
51	.	O

1	Proteolysis	O
2	of	O
3	Mbp1	B
4	and	O
5	Swi4	B
6	DNA	I
7	-	I
8	protein	I
9	complexes	I
10	has	O
11	revealed	O
12	the	O
13	extent	O
14	of	O
15	these	O
16	sequences	O
17	,	O
18	and	O
19	C	O
20	-	O
21	terminally	O
22	extended	O
23	molecules	O
24	with	O
25	substantially	O
26	enhanced	O
27	DNA	O
28	binding	O
29	activity	O
30	compared	O
31	to	O
32	the	O
33	core	O
34	domains	O
35	alone	O
36	have	O
37	been	O
38	produced	O
39	.	O

1	The	O
2	evolution	O
3	of	O
4	the	O
5	CCR5	B
6	cis	I
7	-	I
8	regulatory	I
9	region	I
10	versus	O
11	the	O
12	open	O
13	reading	O
14	frame	O
15	as	O
16	well	O
17	as	O
18	among	O
19	different	O
20	domains	O
21	of	O
22	the	O
23	open	O
24	reading	O
25	frame	O
26	differed	O
27	from	O
28	one	O
29	another	O
30	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	We	O
2	now	O
3	describe	O
4	a	O
5	second	O
6	RIM	B
7	protein	I
8	,	O
9	called	O
10	RIM2	B
11	,	O
12	that	O
13	is	O
14	highly	O
15	homologous	O
16	to	O
17	RIM1	B
18	and	O
19	also	O
20	expressed	O
21	primarily	O
22	in	O
23	brain	O
24	.	O

1	Inhibitor	B
2	-	I
3	1	I
4	(	O
5	I	B
6	-	I
7	1	I
8	)	O
9	and	O
10	inhibitor	B
11	-	I
12	2	I
13	(	O
14	I	B
15	-	I
16	2	I
17	)	O
18	selectively	O
19	inhibit	O
20	type	B
21	1	I
22	protein	I
23	serine	I
24	/	I
25	threonine	I
26	phosphatases	I
27	(	O
28	PP1	B
29	).	O

1	Scanning	O
2	mutations	O
3	throughout	O
4	the	O
5	AC	O
6	element	O
7	interfered	O
8	with	O
9	induction	O
10	but	O
11	allowed	O
12	us	O
13	to	O
14	define	O
15	five	O
16	overlapping	O
17	sites	O
18	for	O
19	regulatory	O
20	factors	O
21	in	O
22	AC	O
23	and	O
24	to	O
25	design	O
26	probes	O
27	binding	O
28	just	O
29	one	O
30	or	O
31	two	O
32	factors	O
33	.	O

1	The	O
2	substrates	O
3	for	O
4	glycan	O
5	synthesis	O
6	in	O
7	the	O
8	lumen	O
9	of	O
10	the	O
11	Golgi	O
12	are	O
13	nucleotide	O
14	sugars	O
15	that	O
16	must	O
17	be	O
18	transported	O
19	from	O
20	the	O
21	cytosol	O
22	by	O
23	specific	O
24	membrane	O
25	-	O
26	bound	O
27	transporters	O
28	.	O

1	Synaptic	O
2	targeting	O
3	of	O
4	the	O
5	postsynaptic	B
6	density	I
7	protein	I
8	PSD	I
9	-	I
10	95	I
11	mediated	O
12	by	O
13	a	O
14	tyrosine	O
15	-	O
16	based	O
17	trafficking	O
18	signal	O
19	.	O

1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O

1	Bites	O
2	by	O
3	two	O
4	species	O
5	of	O
6	adders	O
7	(	O
8	Vipera	O
9	aspis	O
10	and	O
11	Vipera	O
12	berus	O
13	)	O
14	can	O
15	lead	O
16	to	O
17	extensive	O
18	swelling	O
19	with	O
20	multiorgan	O
21	failure	O
22	.	O

1	Both	O
2	normal	O
3	and	O
4	transforming	O
5	PCPH	B
6	proteins	I
7	have	O
8	guanosine	B
9	diphosphatase	I
10	activity	O
11	but	O
12	only	O
13	the	O
14	oncoprotein	O
15	cooperates	O
16	with	O
17	Ras	B
18	in	O
19	activating	O
20	extracellular	B
21	signal	I
22	-	I
23	regulated	I
24	kinase	I
25	ERK1	I
26	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	virulence	O
6	-	O
7	associated	O
8	genes	O
9	and	O
10	their	O
11	overall	O
12	chromosomal	O
13	arrangement	O
14	are	O
15	relatively	O
16	well	O
17	conserved	O
18	between	O
19	B	O
20	.	O
21	henselae	O
22	and	O
23	other	O
24	gram	O
25	-	O
26	negative	O
27	bacteria	O
28	such	O
29	as	O
30	A	O
31	.	O
32	tumefaciens	O
33	.	O

1	An	O
2	important	O
3	mechanism	O
4	by	O
5	which	O
6	the	O
7	tumor	O
8	suppressor	O
9	p53	B
10	maintains	O
11	genomic	O
12	stability	O
13	is	O
14	to	O
15	induce	O
16	cell	O
17	cycle	O
18	arrest	O
19	through	O
20	activation	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	O
28	p21	B
29	(	O
30	WAF1	B
31	/	O
32	Cip1	B
33	)	O
34	gene	O
35	.	O

1	Paxillin	B
2	acts	O
3	as	O
4	an	O
5	adaptor	O
6	molecule	O
7	in	O
8	integrin	B
9	signaling	O
10	.	O

1	Thus	O
2	,	O
3	growth	O
4	factor	O
5	activation	O
6	of	O
7	ER	B
8	can	O
9	mediate	O
10	transactivation	O
11	vs	O
12	ER	B
13	/	O
14	Sp1	B
15	binding	O
16	to	O
17	GC	O
18	-	O
19	rich	O
20	sites	O
21	and	O
22	represents	O
23	a	O
24	novel	O
25	pathway	O
26	for	O
27	ligand	O
28	-	O
29	independent	O
30	ER	B
31	action	O
32	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	deletion	O
6	promoter	O
7	-	O
8	reporter	O
9	constructs	O
10	found	O
11	that	O
12	the	O
13	basal	O
14	activity	O
15	of	O
16	P2	O
17	resided	O
18	in	O
19	the	O
20	proximal	O
21	region	O
22	of	O
23	P2	O
24	.	O

1	RESULTS	O
2	:	O
3	Auditory	O
4	thresholds	O
5	collected	O
6	during	O
7	audiometric	O
8	tests	O
9	increased	O
10	gradually	O
11	in	O
12	proportion	O
13	with	O
14	age	O
15	,	O
16	especially	O
17	in	O
18	the	O
19	hypertensive	O
20	group	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O

1	A	O
2	variety	O
3	of	O
4	professional	O
5	and	O
6	self	O
7	-	O
8	applied	O
9	fluoride	O
10	products	O
11	are	O
12	available	O
13	and	O
14	new	O
15	fluoride	O
16	delivery	O
17	systems	O
18	have	O
19	recently	O
20	entered	O
21	the	O
22	market	O
23	.	O

1	These	O
2	studies	O
3	identify	O
4	several	O
5	of	O
6	the	O
7	signal	O
8	-	O
9	transduction	O
10	events	O
11	involved	O
12	in	O
13	the	O
14	apoptosis	O
15	of	O
16	malignant	O
17	B	O
18	cells	O
19	that	O
20	transpire	O
21	following	O
22	ligation	O
23	of	O
24	CD20	B
25	by	O
26	anti	B
27	-	I
28	CD20	I
29	antibodies	I
30	in	O
31	the	O
32	presence	O
33	of	O
34	Fc	B
35	-	I
36	receptor	I
37	-	O
38	expressing	O
39	cells	O
40	or	O
41	secondary	O
42	goat	O
43	anti	B
44	-(	I
45	mouse	I
46	Ig	I
47	)	I
48	antibodies	I
49	and	O
50	which	O
51	may	O
52	contribute	O
53	to	O
54	the	O
55	tumor	O
56	regressions	O
57	observed	O
58	in	O
59	mouse	O
60	models	O
61	and	O
62	clinical	O
63	trials	O
64	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	solubility	O
3	of	O
4	all	O
5	the	O
6	mutated	O
7	proteins	O
8	was	O
9	remarkably	O
10	reduced	O
11	.	O

1	Recently	O
2	,	O
3	identical	O
4	RBE	B
5	sequences	I
6	have	O
7	been	O
8	identified	O
9	at	O
10	other	O
11	locations	O
12	in	O
13	the	O
14	human	O
15	genome	O
16	.	O

1	EM	O
2	analysis	O
3	demonstrated	O
4	that	O
5	only	O
6	one	O
7	Rep	B
8	-	I
9	DNA	I
10	complex	I
11	was	O
12	formed	O
13	on	O
14	ch	O
15	-	O
16	19	O
17	target	O
18	DNA	O
19	.	O

1	The	O
2	protein	O
3	was	O
4	associated	O
5	with	O
6	purified	O
7	vaccinia	O
8	virus	O
9	particles	O
10	and	O
11	with	O
12	membranes	O
13	of	O
14	immature	O
15	and	O
16	mature	O
17	virions	O
18	that	O
19	were	O
20	visualized	O
21	by	O
22	electron	O
23	microscopy	O
24	of	O
25	infected	O
26	cells	O
27	.	O

1	In	O
2	vivo	O
3	dimethyl	O
4	sulfate	O
5	footprinting	O
6	of	O
7	the	O
8	cyclin	B
9	E	I
10	promoter	I
11	revealed	O
12	several	O
13	regions	O
14	of	O
15	protection	O
16	and	O
17	hypersensitivity	O
18	that	O
19	were	O
20	unique	O
21	to	O
22	infected	O
23	cells	O
24	.	O

1	A	O
2	total	O
3	of	O
4	194	O
5	STSs	O
6	map	O
7	to	O
8	this	O
9	interval	O
10	of	O
11	3	O
12	Mb	O
13	,	O
14	giving	O
15	an	O
16	average	O
17	marker	O
18	resolution	O
19	of	O
20	approximately	O
21	one	O
22	per	O
23	15	O
24	kb	O
25	.	O

1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	B
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O

1	CONCLUSION	O
2	:	O
3	More	O
4	than	O
5	50	O
6	%	O
7	of	O
8	patients	O
9	with	O
10	perennial	O
11	rhinitis	O
12	and	O
13	CRS	O
14	do	O
15	not	O
16	improve	O
17	after	O
18	surgery	O
19	,	O
20	a	O
21	response	O
22	that	O
23	may	O
24	be	O
25	predicted	O
26	by	O
27	more	O
28	cells	O
29	expressing	O
30	IL	B
31	-	I
32	5	I
33	mRNA	I
34	in	O
35	the	O
36	ethmoid	O
37	sinuses	O
38	.	O

1	Biol	O
2	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	size	O
6	,	O
7	the	O
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	B
22	finger	I
23	protein	I
24	,	O
25	Adx	B
26	factor	I
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	B
33	-	I
34	like	I
35	zinc	I
36	finger	I
37	protein	I
38	(	O
39	a	O
40	mouse	B
41	ZBP	I
42	-	I
43	89	I
44	homologue	I
45	).	O

1	METHODS	O
2	:	O
3	The	O
4	most	O
5	distal	O
6	muscle	O
7	fibres	O
8	from	O
9	the	O
10	deep	O
11	and	O
12	superficial	O
13	finger	O
14	flexors	O
15	were	O
16	measured	O
17	relative	O
18	to	O
19	the	O
20	pisiform	O
21	bone	O
22	in	O
23	18	O
24	cadaveric	O
25	specimens	O
26	.	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	B
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	B
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	I
25	Arabidopsis	I
26	,	O
27	Cdc2bAt	B
28	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	METHODS	O
2	:	O
3	We	O
4	determined	O
5	an	O
6	odds	O
7	ratio	O
8	(	O
9	OR	O
10	),	O
11	as	O
12	a	O
13	measure	O
14	of	O
15	the	O
16	relative	O
17	risk	O
18	of	O
19	being	O
20	exposed	O
21	to	O
22	a	O
23	potential	O
24	interaction	O
25	,	O
26	comparing	O
27	the	O
28	use	O
29	of	O
30	the	O
31	H2	B
32	-	I
33	receptor	I
34	antagonist	O
35	,	O
36	cimetidine	O
37	,	O
38	with	O
39	that	O
40	of	O
41	the	O
42	noninteracting	O
43	agents	O
44	ranitidine	O
45	,	O
46	famotidine	O
47	and	O
48	nizatidine	O
49	in	O
50	users	O
51	and	O
52	nonusers	O
53	of	O
54	warfarin	O
55	,	O
56	phenytoin	O
57	and	O
58	theophylline	O
59	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	O
42	plasma	B
43	IGF	I
44	-	I
45	1	I
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	B
54	hemoglobin	I
55	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	Ypt	B
18	protein	I
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O

1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	B
7	sites	I
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O

1	A	O
2	distinct	O
3	staining	O
4	pattern	O
5	for	O
6	the	O
7	N	B
8	-	I
9	utrophin	I
10	was	O
11	not	O
12	detectable	O
13	,	O
14	although	O
15	it	O
16	was	O
17	expected	O
18	to	O
19	localise	O
20	at	O
21	the	O
22	actin	B
23	stress	O
24	fibers	O
25	.	O

1	The	O
2	'	O
3	Newcastle	O
4	'	O
5	model	O
6	,	O
7	which	O
8	is	O
9	based	O
10	on	O
11	Hotelling	O
12	'	O
13	s	O
14	T2	O
15	statistic	O
16	,	O
17	proved	O
18	to	O
19	be	O
20	more	O
21	sensitive	O
22	and	O
23	diagnosed	O
24	a	O
25	systematic	O
26	displacement	O
27	for	O
28	three	O
29	prostate	O
30	patients	O
31	.	O

1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Overexpression	O
2	of	O
3	mcl	B
4	-	I
5	1	I
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	B
18	-	I
19	1	I
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	Thus	O
2	,	O
3	although	O
4	multiple	O
5	senescence	O
6	pathways	O
7	are	O
8	activated	O
9	in	O
10	response	O
11	to	O
12	a	O
13	ras	B
14	oncogene	I
15	,	O
16	inactivation	O
17	of	O
18	TGFbeta1	B
19	secretion	O
20	or	O
21	response	O
22	is	O
23	sufficient	O
24	to	O
25	block	O
26	the	O
27	senescence	O
28	program	O
29	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	abilities	O
7	of	O
8	constitutive	O
9	and	O
10	conditional	O
11	forms	O
12	of	O
13	the	O
14	three	O
15	Raf	B
16	kinases	I
17	to	O
18	abrogate	O
19	the	O
20	cytokine	O
21	dependency	O
22	of	O
23	FDC	O
24	-	O
25	P1	O
26	cells	O
27	were	O
28	examined	O
29	.	O

1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O

1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O

1	Transactivation	O
2	of	O
3	naturally	O
4	occurring	O
5	HIV	B
6	-	I
7	1	I
8	long	I
9	terminal	I
10	repeats	I
11	by	O
12	the	O
13	JNK	B
14	signaling	O
15	pathway	O
16	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	O
7	-	O
8	helix	O
9	domain	O
10	of	O
11	p57	B
12	(	O
13	Kip2	B
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	Cip	B
21	/	O
22	Kip	B
23	proteins	O
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	confers	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	Cdk	B
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	p57	B
51	(	O
52	Kip2	B
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O

1	The	O
2	mode	O
3	of	O
4	resistance	O
5	to	O
6	quinupristin	O
7	/	O
8	dalfopristin	O
9	was	O
10	not	O
11	evident	O
12	(	O
13	sat	O
14	A	O
15	-	O
16	negative	O
17	by	O
18	PCR	O
19	);	O
20	and	O
21	these	O
22	cases	O
23	illustrate	O
24	the	O
25	existence	O
26	of	O
27	streptogramin	O
28	-	O
29	resistant	O
30	isolates	O
31	before	O
32	the	O
33	introduction	O
34	of	O
35	this	O
36	antimicrobial	O
37	class	O
38	into	O
39	human	O
40	clinical	O
41	practice	O
42	.	O

1	This	O
2	study	O
3	was	O
4	carried	O
5	out	O
6	to	O
7	analyze	O
8	PRL	B
9	secretion	O
10	in	O
11	metastatic	O
12	prostate	O
13	cancer	O
14	patients	O
15	both	O
16	at	O
17	basal	O
18	conditions	O
19	and	O
20	in	O
21	response	O
22	to	O
23	L	O
24	-	O
25	Dopa	O
26	and	O
27	metoclopramide	O
28	,	O
29	which	O
30	represents	O
31	the	O
32	most	O
33	classical	O
34	inhibitory	O
35	and	O
36	stimulatory	O
37	tests	O
38	for	O
39	PRL	B
40	secretion	O
41	,	O
42	respectively	O
43	.	O

1	Integrin	B
2	adhesion	I
3	receptors	I
4	transduce	O
5	signals	O
6	that	O
7	control	O
8	complex	O
9	cell	O
10	functions	O
11	which	O
12	require	O
13	the	O
14	regulation	O
15	of	O
16	gene	O
17	expression	O
18	,	O
19	such	O
20	as	O
21	proliferation	O
22	,	O
23	differentiation	O
24	and	O
25	survival	O
26	.	O

1	Recombination	O
2	,	O
3	replication	O
4	,	O
5	repair	O
6	:	O
7	from	O
8	complexity	O
9	to	O
10	harmony	O
11	.	O

1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O

1	Intra	O
2	-	O
3	operative	O
4	ultrasound	O
5	(	O
6	IOUS	O
7	)	O
8	has	O
9	been	O
10	widely	O
11	used	O
12	in	O
13	an	O
14	attempt	O
15	to	O
16	overcome	O
17	these	O
18	difficulties	O
19	,	O
20	but	O
21	is	O
22	limited	O
23	by	O
24	its	O
25	two	O
26	-	O
27	dimensional	O
28	nature	O
29	,	O
30	inter	O
31	-	O
32	user	O
33	variability	O
34	,	O
35	and	O
36	image	O
37	obliteration	O
38	with	O
39	ablative	O
40	or	O
41	resectional	O
42	techniques	O
43	.	O

1	CONCLUSIONS	O
2	:	O
3	This	O
4	randomized	O
5	study	O
6	shows	O
7	that	O
8	Vivostat	O
9	fibrin	B
10	sealant	O
11	is	O
12	effective	O
13	in	O
14	preventing	O
15	air	O
16	leakage	O
17	after	O
18	small	O
19	lung	O
20	resections	O
21	in	O
22	pigs	O
23	,	O
24	even	O
25	at	O
26	high	O
27	inspiratory	O
28	pressures	O
29	.	O

1	Hailey	O
2	-	O
3	Hailey	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	ATP2C1	B
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	pump	O
19	.	O

1	Hex	B
2	is	O
3	expressed	O
4	in	O
5	the	O
6	developing	O
7	liver	O
8	coincident	O
9	with	O
10	the	O
11	forkhead	B
12	/	O
13	winged	B
14	helix	I
15	transcription	O
16	factor	O
17	,	O
18	Hepatocyte	B
19	Nuclear	I
20	Factor	I
21	3beta	I
22	(	O
23	HNF3beta	B
24	).	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	B
17	Pkr	I
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	B
28	Pkr	I
29	promoter	I
30	region	I
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	Kidney	O
2	length	O
3	did	O
4	not	O
5	significantly	O
6	differ	O
7	between	O
8	right	O
9	and	O
10	left	O
11	,	O
12	however	O
13	,	O
14	kidney	O
15	width	O
16	,	O
17	cortical	O
18	thickness	O
19	and	O
20	size	O
21	did	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	Benztropine	O
2	for	O
3	venlafaxine	O
4	-	O
5	induced	O
6	night	O
7	sweats	O
8	.	O

1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	B
7	phosphatase	I
8	in	O
9	children	O

1	The	O
2	physicians	O
3	in	O
4	charge	O
5	of	O
6	all	O
7	patients	O
8	with	O
9	evidence	O
10	of	O
11	acute	O
12	Q	O
13	fever	O
14	(	O
15	seroconversion	O
16	and	O
17	/	O
18	or	O
19	presence	O
20	of	O
21	IgM	B
22	)	O
23	or	O
24	chronic	O
25	Q	O
26	fever	O
27	(	O
28	prolonged	O
29	disease	O
30	and	O
31	/	O
32	or	O
33	IgG	B
34	antibody	I
35	titer	O
36	to	O
37	phase	O
38	I	O
39	of	O
40	Coxiella	O
41	burnetii	O
42	>	O
43	or	O
44	=	O
45	800	O
46	)	O
47	were	O
48	asked	O
49	to	O
50	complete	O
51	a	O
52	questionnaire	O
53	,	O
54	which	O
55	was	O
56	computerized	O
57	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O

1	Induction	O
2	of	O
3	CD86	B
4	expression	O
5	by	O
6	stimulation	O
7	of	O
8	U937	O
9	cells	O
10	with	O
11	IFN	B
12	-	I
13	gamma	I
14	revealed	O
15	the	O
16	presence	O
17	of	O
18	two	O
19	functional	O
20	GAS	B
21	(	O
22	gamma	B
23	-	I
24	interferon	I
25	activation	I
26	site	I
27	)	O
28	elements	O
29	.	O

1	Significantly	O
2	,	O
3	two	O
4	proximal	O
5	GATA	B
6	-	I
7	1	I
8	-	I
9	binding	I
10	sites	I
11	(-	O
12	118	O
13	/-	O
14	113	O
15	and	O
16	-	O
17	98	O
18	/-	O
19	93	O
20	)	O
21	and	O
22	a	O
23	region	O
24	located	O
25	within	O
26	-	O
27	518	O
28	to	O
29	-	O
30	315bp	O
31	of	O
32	the	O
33	mouse	B
34	ALAS2	I
35	promoter	I
36	were	O
37	essential	O
38	for	O
39	transcriptional	O
40	activation	O
41	during	O
42	chemically	O
43	induced	O
44	differentiation	O
45	of	O
46	MEL	O
47	cells	O
48	,	O
49	implying	O
50	their	O
51	importance	O
52	in	O
53	conferring	O
54	erythroid	O
55	specificity	O
56	to	O
57	the	O
58	ALAS2	B
59	transcriptional	O
60	activation	O
61	.	O

1	SNAP	B
2	-	I
3	23	I
4	plays	O
5	an	O
6	important	O
7	role	O
8	in	O
9	the	O
10	regulation	O
11	of	O
12	vesicle	O
13	trafficking	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	B
7	proteins	I
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	B
15	NHP6A	I
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	understand	O
6	Wee1	B
7	regulation	O
8	during	O
9	cell	O
10	cycle	O
11	,	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screening	O
17	was	O
18	used	O
19	to	O
20	identify	O
21	Wee1	O
22	-	O
23	binding	O
24	protein	O
25	(	O
26	s	O
27	).	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	Ab	O
2	-	O
3	MLV	O
4	strains	O
5	expressing	O
6	P70	B
7	/	O
8	S2	B
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	O
30	dependent	O
31	mitogen	B
32	-	I
33	activated	I
34	protein	I
35	(	I
36	MAP	I
37	)	I
38	kinase	I
39	pathway	O
40	.	O

1	The	O
2	codon	O
3	usage	O
4	is	O
5	particularly	O
6	marked	O
7	for	O
8	the	O
9	gag	B
10	,	O
11	pol	B
12	,	O
13	and	O
14	env	B
15	genes	I
16	.	O

1	The	O
2	p53	B
3	-	I
4	homolog	I
5	p73beta	I
6	also	O
7	activated	O
8	the	O
9	PIG3	B
10	promoter	I
11	,	O
12	but	O
13	in	O
14	contrast	O
15	to	O
16	p53	B
17	,	O
18	the	O
19	proline	O
20	-	O
21	rich	O
22	domain	O
23	of	O
24	p73beta	B
25	(	I
26	residues	I
27	81	I
28	-	I
29	113	I
30	)	I
31	was	O
32	dispensable	O
33	to	O
34	induce	O
35	the	O
36	PIG3	B
37	promoter	I
38	.	O

1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	O
15	phytochromes	B
16	A	I
17	and	I
18	B	I
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O

1	Co	O
2	-	O
3	immunoprecipitation	O
4	and	O
5	DNA	O
6	affinity	O
7	chromatography	O
8	prove	O
9	that	O
10	Sp1	B
11	heterodimerizes	O
12	with	O
13	ZBP	B
14	-	I
15	89	I
16	when	O
17	bound	O
18	to	O
19	the	O
20	silencer	O
21	element	O
22	to	O
23	yield	O
24	a	O
25	DNA	O
26	-	O
27	protein	O
28	complex	O
29	whose	O
30	mobility	O
31	is	O
32	indistinguishable	O
33	from	O
34	that	O
35	displayed	O
36	by	O
37	HeLa	O
38	nuclear	O
39	extract	O
40	in	O
41	band	O
42	shift	O
43	assays	O
44	.	O

1	The	O
2	ZNF274	B
3	gene	I
4	is	O
5	mapped	O
6	distal	O
7	to	O
8	marker	O
9	RP	O
10	S28	O
11	1	O
12	in	O
13	the	O
14	human	O
15	chromosome	O
16	19qter	O
17	region	O
18	,	O
19	by	O
20	RH	O
21	mapping	O
22	.	O

1	The	O
2	C	B
3	-	I
4	terminal	I
5	Cdk2	I
6	truncations	O
7	,	O
8	however	O
9	,	O
10	were	O
11	non	O
12	-	O
13	functional	O
14	in	O
15	these	O
16	strains	O
17	and	O
18	thus	O
19	dependent	O
20	for	O
21	activity	O
22	on	O
23	the	O
24	pho85	B
25	coding	I
26	region	I
27	which	O
28	remained	O
29	in	O
30	the	O
31	mutant	B
32	pho85	I
33	::	O
34	HIS3	B
35	chromosomal	I
36	locus	I
37	.	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	B
16	-	I
17	89	I
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	B
26	(	O
27	Mn1	B
28	)	O
29	seed	O
30	locus	O
31	that	O
32	encodes	O
33	a	O
34	seed	B
35	-	I
36	specific	I
37	cell	I
38	wall	I
39	invertase	I
40	,	O
41	INCW2	B
42	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	O
22	evoked	O
23	GIRK	B
24	channels	I
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	B
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	I
38	2	I
39	)	I
40	AR	I
41	.	O

1	Slap	B
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	O
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	B
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	O
21	ERRalpha1	B
22	fusion	O
23	protein	O
24	.	O

1	Overexpressing	O
2	the	O
3	coactivator	O
4	,	O
5	SRC1a	B
6	or	O
7	GRIP1	B
8	,	O
9	further	O
10	enhances	O
11	ERRalpha1	B
12	-	O
13	induced	O
14	transcriptional	O
15	activity	O
16	.	O

1	Estrogen	B
2	receptor	I
3	-	I
4	related	I
5	receptor	I
6	alpha	I
7	1	I
8	interacts	O
9	with	O
10	coactivator	O
11	and	O
12	constitutively	O
13	activates	O
14	the	O
15	estrogen	O
16	response	O
17	elements	O
18	of	O
19	the	O
20	human	B
21	lactoferrin	I
22	gene	I
23	.	O

1	We	O
2	examine	O
3	current	O
4	models	O
5	of	O
6	the	O
7	effects	O
8	of	O
9	aging	O
10	on	O
11	mean	O
12	response	O
13	time	O
14	and	O
15	show	O
16	how	O
17	they	O
18	might	O
19	be	O
20	reinterpreted	O
21	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	The	O
2	median	O
3	levels	O
4	of	O
5	particles	O
6	with	O
7	50	O
8	%	O
9	cut	O
10	-	O
11	off	O
12	aerodynamic	O
13	diameters	O
14	of	O
15	10	O
16	(	O
17	PM10	O
18	)	O
19	and	O
20	2	O
21	.	O
22	5	O
23	microm	O
24	(	O
25	PM2	O
26	.	O
27	5	O
28	)	O
29	were	O
30	170	O
31	(	O
32	range	O
33	103	O
34	-	O
35	613	O
36	)	O
37	and	O
38	95	O
39	(	O
40	range	O
41	61	O
42	-	O
43	218	O
44	)	O
45	micro	O
46	x	O
47	m	O
48	-	O
49	3	O
50	,	O
51	respectively	O
52	.	O

1	Kaposi	O
2	'	O
3	s	O
4	sarcoma	O
5	-	O
6	associated	O
7	herpesvirus	O
8	viral	B
9	interferon	I
10	regulatory	I
11	factor	I
12	confers	O
13	resistance	O
14	to	O
15	the	O
16	antiproliferative	O
17	effect	O
18	of	O
19	interferon	B
20	-	I
21	alpha	I
22	.	O

1	Specific	O
2	and	O
3	heritable	O
4	genetic	O
5	interference	O
6	by	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	in	O
12	Arabidopsis	O
13	thaliana	O
14	.	O

1	Comparison	O
2	of	O
3	sequences	O
4	from	O
5	-	O
6	215	O
7	to	O
8	+	O
9	1	O
10	bp	O
11	identified	O
12	consensus	O
13	binding	O
14	sites	O
15	for	O
16	the	O
17	homeodomain	B
18	transcription	I
19	factor	I
20	thyroid	I
21	transcription	I
22	factor	I
23	-	I
24	1	I
25	(	O
26	TTF	B
27	-	I
28	1	I
29	).	O

1	Two	O
2	additional	O
3	cis	O
4	-	O
5	acting	O
6	sequences	O
7	,	O
8	conserved	O
9	in	O
10	both	O
11	the	O
12	region	O
13	1	O
14	and	O
15	3	O
16	promoters	O
17	,	O
18	were	O
19	identified	O
20	,	O
21	suggesting	O
22	a	O
23	role	O
24	for	O
25	these	O
26	sequences	O
27	in	O
28	the	O
29	coordinate	O
30	regulation	O
31	of	O
32	transcription	O
33	from	O
34	these	O
35	promoters	O
36	.	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	O
9	CTD	O
10	sequence	O
11	that	O
12	is	O
13	sufficient	O
14	to	O
15	bind	O
16	to	O
17	the	O
18	second	O
19	Rsp5	B
20	WW	I
21	domain	I
22	(	O
23	Rsp5	B
24	WW2	I
25	)	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	yeast	O
31	two	O
32	-	O
33	hybrid	O
34	assays	O
35	.	O

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	B
10	-	O
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	T1	O
2	-	O
3	weighted	O
4	MRI	O
5	on	O
6	the	O
7	49th	O
8	postoperative	O
9	day	O
10	demonstrated	O
11	bilateral	O
12	and	O
13	symmetrical	O
14	hyperintense	O
15	lesions	O
16	in	O
17	the	O
18	globus	O
19	pallidus	O
20	.	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	METHOD	O
2	:	O
3	The	O
4	sample	O
5	of	O
6	subjects	O
7	was	O
8	drawn	O
9	from	O
10	the	O
11	Suffolk	O
12	County	O
13	Mental	O
14	Health	O
15	Project	O
16	,	O
17	a	O
18	longitudinal	O
19	epidemiologic	O
20	study	O
21	of	O
22	first	O
23	-	O
24	hospitalized	O
25	subjects	O
26	with	O
27	psychotic	O
28	disorders	O
29	;	O
30	the	O
31	present	O
32	study	O
33	focused	O
34	on	O
35	patients	O
36	with	O
37	schizophrenic	O
38	disorders	O
39	.	O

1	Marrow	O
2	dysplasia	O
3	is	O
4	a	O
5	major	O
6	characteristic	O
7	of	O
8	patients	O
9	with	O
10	myelodysplastic	O
11	syndrome	O
12	(	O
13	MDS	O
14	),	O
15	along	O
16	with	O
17	marrow	O
18	blastosis	O
19	,	O
20	cytopenia	O
21	and	O
22	cytogenetic	O
23	anomalies	O
24	.	O

1	Eight	O
2	of	O
3	the	O
4	non	O
5	-	O
6	acceptable	O
7	inlays	O
8	/	O
9	onlays	O
10	and	O
11	five	O
12	of	O
13	the	O
14	direct	O
15	restorations	O
16	were	O
17	replaced	O
18	,	O
19	while	O
20	the	O
21	other	O
22	ones	O
23	were	O
24	repaired	O
25	with	O
26	resin	O
27	composite	O
28	.	O

1	How	O
2	plants	O
3	respond	O
4	to	O
5	attack	O
6	by	O
7	the	O
8	range	O
9	of	O
10	herbivores	O
11	and	O
12	pathogens	O
13	that	O
14	confront	O
15	them	O
16	in	O
17	the	O
18	field	O
19	is	O
20	the	O
21	subject	O
22	of	O
23	considerable	O
24	research	O
25	by	O
26	both	O
27	molecular	O
28	biologists	O
29	and	O
30	ecologists	O
31	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	probability	O
5	of	O
6	cardiopulmonary	O
7	complications	O
8	increases	O
9	significantly	O
10	when	O
11	patients	O
12	develop	O
13	class	O
14	1	O
15	HELLP	O
16	syndrome	O
17	.	O

1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	telomerase	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	B
26	telomerase	I
27	reverse	I
28	transcriptase	I
29	(	O
30	hTERT	B
31	)	O
32	gene	O
33	.	O

1	In	O
2	the	O
3	control	O
4	group	O
5	,	O
6	platelet	O
7	markers	O
8	increased	O
9	1	O
10	h	O
11	after	O
12	surgery	O
13	.	O

1	However	O
2	,	O
3	the	O
4	element	O
5	proximal	O
6	to	O
7	the	O
8	transcription	O
9	start	O
10	site	O
11	is	O
12	dependent	O
13	on	O
14	the	O
15	SRE	O
16	-	O
17	1	O
18	.	O

1	AMDA	O
2	white	O
3	paper	O
4	identifies	O
5	ways	O
6	to	O
7	improve	O
8	pharmaceutical	O
9	care	O
10	in	O
11	SNFs	O
12	.	O

1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	O
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	B
32	and	O
33	U4	B
34	/	O
35	U6	B
36	snRNPs	O
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	C	O
6	-	O
7	terminal	O
8	portion	O
9	of	O
10	Sec31A	B
11	co	O
12	-	O
13	precipitate	O
14	Sec13	B
15	and	O
16	inhibit	O
17	ER	O
18	-	O
19	Golgi	O
20	transport	O
21	of	O
22	temperature	O
23	-	O
24	arrested	O
25	vesicular	O
26	stomatitis	B
27	G	I
28	protein	I
29	in	O
30	a	O
31	semi	O
32	-	O
33	intact	O
34	cell	O
35	assay	O
36	.	O

1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O

1	They	O
2	are	O
3	present	O
4	in	O
5	many	O
6	kinds	O
7	of	O
8	living	O
9	things	O
10	,	O
11	but	O
12	their	O
13	functions	O
14	,	O
15	especially	O
16	those	O
17	in	O
18	humans	O
19	,	O
20	are	O
21	unclear	O
22	.	O

1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O

1	Transduction	O
2	of	O
3	the	O
4	human	O
5	leukemic	O
6	cell	O
7	line	O
8	K562	O
9	showed	O
10	that	O
11	viral	O
12	MRP1	B
13	-	O
14	PG13	O
15	supernatants	O
16	routinely	O
17	transfer	O
18	the	O
19	MRP1	B
20	gene	I
21	to	O
22	approximately	O
23	35	O
24	%	O
25	of	O
26	target	O
27	K562	O
28	cells	O
29	,	O
30	of	O
31	which	O
32	at	O
33	least	O
34	one	O
35	third	O
36	are	O
37	capable	O
38	of	O
39	proliferating	O
40	in	O
41	the	O
42	presence	O
43	of	O
44	otherwise	O
45	toxic	O
46	concentrations	O
47	of	O
48	etoposide	O
49	.	O

1	Regulation	O
2	of	O
3	pituitary	O
4	vasopressin	B
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	B
5	homologue	I
6	(	O
7	BarX	B
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Given	O
2	its	O
3	relative	O
4	longevity	O
5	on	O
6	the	O
7	Web	O
8	,	O
9	TIE	O
10	researchers	O
11	have	O
12	been	O
13	in	O
14	a	O
15	unique	O
16	position	O
17	to	O
18	observe	O
19	trends	O
20	in	O
21	telemedicine	O
22	.	O

1	The	O
2	structural	O
3	study	O
4	of	O
5	peptides	O
6	belonging	O
7	to	O
8	the	O
9	terminal	O
10	domains	O
11	of	O
12	histone	B
13	H1	I
14	can	O
15	be	O
16	considered	O
17	as	O
18	a	O
19	step	O
20	toward	O
21	the	O
22	understanding	O
23	of	O
24	the	O
25	function	O
26	of	O
27	H1	B
28	in	O
29	chromatin	O
30	.	O

1	The	O
2	recovery	O
3	rates	O
4	for	O
5	the	O
6	MB	O
7	/	O
8	BacT	O
9	,	O
10	MGIT	O
11	960	O
12	,	O
13	and	O
14	solid	O
15	media	O
16	were	O
17	91	O
18	.	O
19	6	O
20	,	O
21	87	O
22	.	O
23	4	O
24	,	O
25	and	O
26	54	O
27	.	O
28	7	O
29	%,	O
30	respectively	O
31	,	O
32	for	O
33	all	O
34	mycobacteria	O
35	;	O
36	the	O
37	recovery	O
38	rates	O
39	were	O
40	93	O
41	.	O
42	6	O
43	,	O
44	88	O
45	.	O
46	9	O
47	,	O
48	and	O
49	63	O
50	.	O
51	4	O
52	%,	O
53	respectively	O
54	,	O
55	for	O
56	M	O
57	.	O
58	tuberculosis	O
59	complex	O
60	alone	O
61	,	O
62	and	O
63	87	O
64	.	O
65	5	O
66	,	O
67	84	O
68	.	O
69	4	O
70	,	O
71	and	O
72	37	O
73	.	O
74	5	O
75	%,	O
76	respectively	O
77	,	O
78	for	O
79	all	O
80	nontuberculous	O
81	mycobacteria	O
82	.	O

1	Cerebral	O
2	vasculitis	O
3	secondary	O
4	to	O
5	Crohn	O
6	'	O
7	s	O
8	disease	O
9	seems	O
10	to	O
11	be	O
12	a	O
13	very	O
14	rare	O
15	phenomenon	O
16	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	and	O
6	possibly	O
7	randomised	O
8	trials	O
9	using	O
10	acupuncture	O
11	to	O
12	treat	O
13	asthma	O
14	and	O
15	asthma	O
16	-	O
17	like	O
18	symptoms	O
19	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	These	O
2	studies	O
3	suggest	O
4	an	O
5	additional	O
6	component	O
7	or	O
8	cellular	O
9	environment	O
10	is	O
11	required	O
12	for	O
13	SPRK	B
14	activation	O
15	by	O
16	Cdc42	B
17	.	O

1	M	O
2	.	O

1	Jkappa	B
2	DNA	I
3	-	I
4	binding	I
5	sites	I
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	B
16	EBNA	I
17	-	I
18	3C	I
19	protein	I
20	unable	O
21	to	O
22	bind	O
23	Jkappa	B
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	B
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	I
35	,	O
36	indicating	O
37	that	O
38	EBNA	B
39	-	I
40	3C	I
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	B
52	.	O

1	Thus	O
2	,	O
3	both	O
4	YY1	B
5	and	O
6	CDP	B
7	appear	O
8	to	O
9	be	O
10	negative	O
11	regulators	O
12	of	O
13	the	O
14	differentiation	O
15	-	O
16	induced	O
17	HPV	B
18	-	I
19	6	I
20	E1	I
21	promoter	I
22	and	O
23	thereby	O
24	the	O
25	HPV	O
26	life	O
27	cycle	O
28	.	O

1	Sequential	O
2	cleavage	O
3	by	O
4	metallopeptidases	B
5	and	O
6	proteasomes	O
7	is	O
8	involved	O
9	in	O
10	processing	O
11	HIV	B
12	-	I
13	1	I
14	ENV	I
15	epitope	I
16	for	O
17	endogenous	O
18	MHC	B
19	class	I
20	I	I
21	antigen	I
22	presentation	O
23	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	human	B
6	Lnk	I
7	,	O
8	an	O
9	adaptor	O
10	protein	O
11	with	O
12	pleckstrin	B
13	homology	O
14	and	O
15	Src	B
16	homology	I
17	2	I
18	domains	I
19	that	O
20	can	O
21	inhibit	O
22	T	O
23	cell	O
24	activation	O
25	.	O

1	Vancomycin	O
2	data	O
3	were	O
4	analyzed	O
5	according	O
6	to	O
7	a	O
8	one	O
9	-	O
10	compartment	O
11	open	O
12	model	O
13	with	O
14	use	O
15	of	O
16	NONMEM	O
17	population	O
18	pharmacokinetic	O
19	software	O
20	.	O

1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	p65	B
6	binds	O
7	to	O
8	these	O
9	targets	O
10	with	O
11	almost	O
12	equal	O
13	affinity	O
14	and	O
15	that	O
16	different	O
17	residues	O
18	have	O
19	variable	O
20	roles	O
21	in	O
22	binding	O
23	different	O
24	kappaB	B
25	targets	I
26	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	B
6	PHO8	I
7	promoter	I
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	B
14	promoter	I
15	.	O

1	The	O
2	Siglecs	B
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	B
8	-	I
9	type	I
10	lectins	I
11	(	O
12	immunoglobulin	B
13	superfamily	I
14	proteins	I
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O

1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	Update	O
2	on	O
3	maternal	O
4	-	O
5	fetal	O
6	infections	O
7	by	O
8	hepatitis	O
9	C	O
10	,	O
11	HIV	O
12	and	O
13	cytomegalovirus	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	In	O
2	the	O
3	study	O
4	on	O
5	PCI	B
6	mRNA	I
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	B
17	PCI	I
18	cDNA	I
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	B
29	mRNA	I
30	expression	O
31	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	The	O
2	stoichiometry	O
3	of	O
4	the	O
5	complexes	O
6	formed	O
7	with	O
8	the	O
9	dodeca	O
10	-	O
11	satellite	O
12	C	O
13	strand	O
14	suggests	O
15	that	O
16	,	O
17	in	O
18	DDP1	B
19	,	O
20	the	O
21	15	O
22	consecutive	O
23	KH	O
24	domains	O
25	are	O
26	organized	O
27	such	O
28	that	O
29	they	O
30	define	O
31	two	O
32	nucleic	O
33	acid	O
34	binding	O
35	surfaces	O
36	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	B
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O

1	Much	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	O
26	responsive	O
27	genes	O
28	,	O
29	(	O
30	ii	O
31	)	O
32	enforced	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	Gal4	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	reporters	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	p38alpha	B
77	(-/-)	I
78	embryos	O
79	.	O

1	This	O
2	activity	O
3	is	O
4	stimulated	O
5	by	O
6	complex	O
7	formation	O
8	with	O
9	the	O
10	other	O
11	eIF2B	B
12	subunits	I
13	.	O

1	Our	O
2	analysis	O
3	of	O
4	nonsense	O
5	mutations	O
6	indicates	O
7	that	O
8	the	O
9	C	O
10	terminus	O
11	of	O
12	eIF2Bepsilon	B
13	(	I
14	residues	I
15	518	I
16	to	I
17	712	I
18	)	I
19	is	O
20	required	O
21	for	O
22	both	O
23	catalytic	O
24	activity	O
25	and	O
26	interaction	O
27	with	O
28	eIF2	B
29	.	O

1	In	O
2	contrast	O
3	,	O
4	mutations	O
5	affecting	O
6	the	O
7	other	O
8	two	O
9	Nim1p	B
10	-	I
11	related	I
12	kinases	I
13	in	O
14	S	O
15	.	O
16	cerevisiae	O
17	,	O
18	Hsl1p	B
19	and	O
20	Kcc4p	B
21	,	O
22	produce	O
23	no	O
24	detectable	O
25	effect	O
26	on	O
27	septin	B
28	organization	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	Physiologic	O
4	pacing	O
5	provides	O
6	little	O
7	benefit	O
8	over	O
9	ventricular	O
10	pacing	O
11	for	O
12	the	O
13	prevention	O
14	of	O
15	stroke	O
16	or	O
17	death	O
18	due	O
19	to	O
20	cardiovascular	O
21	causes	O
22	.	O

1	Among	O
2	non	O
3	-	O
4	cirrhotics	O
5	,	O
6	lack	O
7	of	O
8	portal	O
9	vein	O
10	visualisation	O
11	had	O
12	a	O
13	90	O
14	%	O
15	sensitivity	O
16	,	O
17	88	O
18	%	O
19	specificity	O
20	,	O
21	94	O
22	%	O
23	negative	O
24	predictive	O
25	value	O
26	,	O
27	and	O
28	83	O
29	%	O
30	positive	O
31	predictive	O
32	value	O
33	in	O
34	the	O
35	diagnosis	O
36	of	O
37	pre	O
38	-	O
39	sinusoidal	O
40	portal	O
41	hypertension	O
42	.	O

1	D5	B
2	/	I
3	D1	I
4	(	I
5	CT	I
6	)	I
7	or	O
8	D5	B
9	/	I
10	D1D	I
11	(	I
12	CT	I
13	)	I
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	B
29	-	I
30	type	I
31	(	I
32	wt	I
33	)	I
34	D1	I
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	O
56	D1	B
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	O
26	,	O
27	and	O
28	H11	O
29	.	O

1	The	O
2	serine	B
3	-	I
4	threonine	I
5	kinase	I
6	gene	I
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	nonfunctional	O
19	.	O

1	Stat	B
2	activation	O
3	in	O
4	response	O
5	to	O
6	GH	B
7	and	O
8	IL	B
9	-	I
10	6	I
11	was	O
12	determined	O
13	by	O
14	reporter	O
15	gene	O
16	induction	O
17	.	O

1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O

1	Mitogen	B
2	-	I
3	activated	I
4	protein	I
5	(	I
6	MAP	I
7	)	I
8	kinase	I
9	phosphatase	I
10	-	I
11	3	I
12	(	O
13	MKP	B
14	-	I
15	3	I
16	)	O
17	is	O
18	a	O
19	dual	O
20	specificity	O
21	phosphatase	O
22	that	O
23	inactivates	O
24	extracellular	B
25	signal	I
26	-	I
27	regulated	I
28	kinase	I
29	(	O
30	ERK	B
31	)	O
32	MAP	B
33	kinases	I
34	.	O

1	Consistent	O
2	with	O
3	this	O
4	,	O
5	we	O
6	show	O
7	that	O
8	peptides	O
9	representing	O
10	docking	O
11	sites	O
12	within	O
13	the	O
14	target	O
15	substrates	O
16	Elk	B
17	-	I
18	1	I
19	and	O
20	p90	B
21	(	O
22	rsk	B
23	)	O
24	inhibit	O
25	ERK	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	MKP	B
31	-	I
32	3	I
33	.	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	When	O
2	the	O
3	entire	O
4	diet	O
5	consisted	O
6	of	O
7	SBF	O
8	,	O
9	voluntary	O
10	feed	O
11	intake	O
12	was	O
13	reduced	O
14	,	O
15	indicating	O
16	that	O
17	SBF	O
18	should	O
19	not	O
20	be	O
21	fed	O
22	to	O
23	ponies	O
24	as	O
25	the	O
26	sole	O
27	dietary	O
28	ingredient	O
29	.	O

1	Hepatitis	O
2	C	O
3	virus	O
4	infection	O
5	and	O
6	lymphoproliferative	O
7	diseases	O
8	in	O
9	France	O
10	:	O
11	a	O
12	national	O
13	study	O
14	.	O

1	The	O
2	immune	O
3	system	O
4	is	O
5	closely	O
6	integrated	O
7	with	O
8	the	O
9	neuroendocrine	O
10	system	O
11	,	O
12	and	O
13	infection	O
14	-	O
15	induced	O
16	increases	O
17	in	O
18	cytokines	O
19	such	O
20	as	O
21	IL	B
22	-	I
23	1	I
24	,	O
25	IL	B
26	-	I
27	6	I
28	and	O
29	TNF	B
30	have	O
31	numerous	O
32	effects	O
33	on	O
34	the	O
35	central	O
36	nervous	O
37	system	O
38	.	O

1	Interestingly	O
2	,	O
3	a	O
4	decreased	O
5	transcription	O
6	from	O
7	the	O
8	endogenous	O
9	c	B
10	-	I
11	Myb	I
12	promoter	I
13	was	O
14	observed	O
15	in	O
16	several	O
17	HTLV	O
18	-	O
19	I	O
20	transformed	O
21	T	O
22	-	O
23	cell	O
24	lines	O
25	.	O

1	H19	B
2	and	O
3	Igf2	B
4	monoallelic	O
5	expression	O
6	is	O
7	regulated	O
8	in	O
9	two	O
10	distinct	O
11	ways	O
12	by	O
13	a	O
14	shared	O
15	cis	O
16	acting	O
17	regulatory	O
18	region	O
19	upstream	O
20	of	O
21	H19	B
22	.	O

1	C	O
2	.	O
3	elegans	O
4	KLP	B
5	-	I
6	11	I
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	O
12	KAP	B
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	B
20	urchin	I
21	kinesin	I
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	B
28	/	O
29	KIFB	B
30	/	O
31	KAP3	B
32	kinesin	I
33	complexes	O
34	.	O

1	Flavonoids	O
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	These	O
2	natural	O
3	antisense	O
4	S	B
5	transcripts	I
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	B
15	transcripts	I
16	.	O

1	Nor	O
2	is	O
3	such	O
4	adjustment	O
5	possible	O
6	unless	O
7	one	O
8	posits	O
9	a	O
10	model	O
11	that	O
12	relates	O
13	the	O
14	missing	O
15	observations	O
16	to	O
17	other	O
18	observed	O
19	information	O
20	for	O
21	each	O
22	subject	O
23	-	O
24	models	O
25	that	O
26	are	O
27	inherently	O
28	untestable	O
29	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	B
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	The	O
2	C	O
3	terminus	O
4	of	O
5	TRBP	B
6	binds	O
7	to	O
8	CBP	B
9	/	O
10	p300	B
11	and	O
12	DRIP130	B
13	,	O
14	a	O
15	component	O
16	of	O
17	the	O
18	DRIP	B
19	/	O
20	TRAP	B
21	/	O
22	ARC	B
23	complex	O
24	,	O
25	which	O
26	suggests	O
27	that	O
28	TRBP	B
29	may	O
30	activate	O
31	transcription	O
32	by	O
33	means	O
34	of	O
35	such	O
36	interactions	O
37	.	O

1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O

1	Increased	O
2	dietary	O
3	energy	O
4	decreased	O
5	PAB	O
6	and	O
7	the	O
8	use	O
9	of	O
10	added	O
11	dietary	O
12	CO	O
13	rather	O
14	than	O
15	PF	O
16	decreased	O
17	PSHL	O
18	in	O
19	broiler	O
20	breeders	O
21	between	O
22	26	O
23	and	O
24	47	O
25	wk	O
26	of	O
27	age	O
28	.	O

1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	O
7	et	O
8	al	O
9	.	O

1	Hierarchy	O
2	of	O
3	protein	B
4	tyrosine	I
5	kinases	I
6	in	O
7	interleukin	B
8	-	I
9	2	I
10	(	O
11	IL	B
12	-	I
13	2	I
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	syk	B
20	depends	O
21	on	O
22	Jak3	B
23	;	O
24	however	O
25	,	O
26	neither	O
27	Syk	B
28	nor	O
29	Lck	B
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	I
35	2	I
36	-	O
37	mediated	O
38	STAT	B
39	activation	O
40	.	O

1	Immobilized	O
2	dimers	O
3	of	O
4	N	B
5	-	I
6	cadherin	I
7	-	O
8	Fc	B
9	chimera	O
10	mimic	O
11	cadherin	O
12	-	O
13	mediated	O
14	cell	O
15	contact	O
16	formation	O
17	:	O
18	contribution	O
19	of	O
20	both	O
21	outside	O
22	-	O
23	in	O
24	and	O
25	inside	O
26	-	O
27	out	O
28	signals	O
29	.	O

1	Although	O
2	the	O
3	OC	B
4	promoter	I
5	is	O
6	activated	O
7	in	O
8	a	O
9	C	O
10	terminus	O
11	dependent	O
12	manner	O
13	,	O
14	the	O
15	MDR	B
16	,	O
17	LTR	O
18	and	O
19	BSP	B
20	promoters	I
21	are	O
22	repressed	O
23	by	O
24	three	O
25	distinct	O
26	mechanisms	O
27	,	O
28	either	O
29	independent	O
30	of	O
31	or	O
32	involving	O
33	the	O
34	AML	B
35	C	I
36	terminus	I
37	,	O
38	or	O
39	requiring	O
40	only	O
41	the	O
42	conserved	O
43	C	O
44	-	O
45	terminal	O
46	pentapeptide	O
47	VWRPY	O
48	.	O

1	The	O
2	monoclonal	O
3	immunoglobulin	B
4	products	O
5	of	O
6	plasma	O
7	cell	O
8	neoplasm	O
9	can	O
10	give	O
11	rise	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	manifestations	O
17	including	O
18	hyperviscosity	O
19	,	O
20	amyloidosis	O
21	,	O
22	cryoglobulinemia	O
23	,	O
24	neuropathy	O
25	,	O
26	and	O
27	renal	O
28	failure	O
29	.	O

1	Investigation	O
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	O
10	human	B
11	Igs	I
12	and	O
13	gp120	B
14	shows	O
15	that	O
16	the	O
17	viral	B
18	gp120	I
19	SAg	I
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	O
27	human	B
28	V	I
29	(	I
30	H	I
31	)	I
32	3	I
33	+	I
34	Igs	I
35	.	O

1	Double	O
2	-	O
3	blind	O
4	,	O
5	placebo	O
6	-	O
7	controlled	O
8	trial	O
9	.	O

1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	B
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	B
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	O
26	histone	B
27	H4	I
28	peptides	I
29	.	O

1	Endostatin	O
2	treatment	O
3	for	O
4	10	O
5	minutes	O
6	or	O
7	24	O
8	hours	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	Shb	B
14	and	O
15	formation	O
16	of	O
17	multiprotein	O
18	complexes	O
19	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	O
24	D11S1765	B
25	and	O
26	uteroglobin	B
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O

1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O

1	Iodine	O
2	deficiency	O
3	disorders	O
4	in	O
5	Bangladesh	O
6	.	O

1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	B
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	B
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	O
8	-	O
9	1	O
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	B
21	length	I
22	UGT2B7	I
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	Age	O
2	>/=	O
3	50	O
4	years	O
5	(	O
6	odds	O
7	ratio	O
8	[	O
9	OR	O
10	],	O
11	14	O
12	.	O
13	1	O
14	),	O
15	BMI	O
16	>/=	O
17	28	O
18	kg	O
19	/	O
20	m	O
21	(	O
22	2	O
23	)	O
24	(	O
25	OR	O
26	,	O
27	5	O
28	.	O
29	7	O
30	),	O
31	triglycerides	O
32	>/=	O
33	1	O
34	.	O
35	7	O
36	mmol	O
37	/	O
38	L	O
39	(	O
40	OR	O
41	,	O
42	5	O
43	),	O
44	and	O
45	alanine	B
46	aminotransferase	I
47	(	O
48	ALT	B
49	)	O
50	>/=	O
51	2N	O
52	(	O
53	OR	O
54	,	O
55	4	O
56	.	O
57	6	O
58	)	O
59	were	O
60	independently	O
61	associated	O
62	with	O
63	septal	O
64	fibrosis	O
65	.	O

1	Biologically	O
2	significant	O
3	amounts	O
4	of	O
5	platelet	B
6	activating	I
7	factor	I
8	were	O
9	eluted	O
10	from	O
11	the	O
12	sorbent	O
13	during	O
14	the	O
15	entire	O
16	treatment	O
17	time	O
18	.	O

1	However	O
2	,	O
3	the	O
4	elderly	O
5	group	O
6	showed	O
7	significantly	O
8	longer	O
9	mean	O
10	residence	O
11	times	O
12	(	O
13	MRTs	O
14	)	O
15	and	O
16	lower	O
17	plasma	O
18	clearance	O
19	of	O
20	lidocaine	O
21	during	O
22	the	O
23	period	O
24	compared	O
25	with	O
26	the	O
27	adult	O
28	group	O
29	(	O
30	P	O
31	<	O
32	.	O
33	05	O
34	).	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	I
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	B
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	B
31	.	O

1	The	O
2	so	O
3	-	O
4	called	O
5	"	B
6	SH3	I
7	"	I
8	segment	I
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O

1	No	O
2	differences	O
3	in	O
4	total	O
5	cholesterol	O
6	levels	O
7	were	O
8	observed	O
9	between	O
10	mapuches	O
11	and	O
12	aymaras	O
13	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	O
13	function	O
14	and	O
15	substrate	O
16	specificity	O
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	O
29	RNase	B
30	MRP	I
31	RNA	I
32	and	O
33	RNase	B
34	P	I
35	RNA	I
36	of	I
37	S	I
38	.	I
39	cerevisiae	I
40	.	O

1	Among	O
2	genes	O
3	induced	O
4	by	O
5	added	O
6	pMesogenin1	B
7	is	O
8	Xwnt	B
9	-	I
10	8	I
11	,	O
12	a	O
13	signaling	O
14	factor	O
15	that	O
16	induces	O
17	a	O
18	similar	O
19	repertoire	O
20	of	O
21	marker	O
22	genes	O
23	and	O
24	a	O
25	similar	O
26	cellular	O
27	phenotype	O
28	.	O

1	Accordingly	O
2	,	O
3	no	O
4	Ha	B
5	-	I
6	ras	I
7	codon	I
8	12	I
9	mutations	O
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	False	O
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	Tumor	O
2	stages	O
3	were	O
4	IIB	O
5	(	O
6	T3	O
7	N0	O
8	)	O
9	in	O
10	52	O
11	%,	O
12	IIIA	O
13	in	O
14	15	O
15	%,	O
16	and	O
17	IIIB	O
18	in	O
19	27	O
20	%	O
21	of	O
22	patients	O
23	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	B
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O

1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O

1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O

1	Paper	O
2	alert	O
3	.	O

1	The	O
2	tryptase	B
3	locus	I
4	also	O
5	contains	O
6	at	O
7	least	O
8	four	O
9	tryptase	B
10	-	I
11	like	I
12	pseudogenes	I
13	,	O
14	including	O
15	mastin	B
16	,	O
17	a	O
18	gene	O
19	expressed	O
20	in	O
21	dogs	O
22	but	O
23	not	O
24	in	O
25	humans	O
26	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O

1	Mutational	O
2	analyses	O
3	showed	O
4	that	O
5	in	O
6	-	O
7	frame	O
8	stop	O
9	codons	O
10	introduced	O
11	into	O
12	five	O
13	of	O
14	seven	O
15	RNA	B
16	2	I
17	ORFs	I
18	did	O
19	not	O
20	affect	O
21	accumulation	O
22	of	O
23	progeny	O
24	LIYV	B
25	RNA	I
26	1	I
27	or	O
28	RNA	B
29	2	I
30	,	O
31	confirming	O
32	that	O
33	RNA	B
34	2	I
35	does	O
36	not	O
37	encode	O
38	proteins	O
39	necessary	O
40	for	O
41	LIYV	O
42	RNA	O
43	replication	O
44	.	O

1	Role	O
2	of	O
3	NH	O
4	(	O
5	2	O
6	)-	O
7	and	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	of	O
13	the	O
14	P	B
15	protein	I
16	of	O
17	human	O
18	parainfluenza	O
19	virus	O
20	type	O
21	3	O
22	in	O
23	transcription	O
24	and	O
25	replication	O
26	.	O

1	Phosphorylation	O
2	of	O
3	tyrosine	O
4	residues	O
5	in	O
6	the	O
7	kinase	O
8	domain	O
9	and	O
10	juxtamembrane	O
11	region	O
12	regulates	O
13	the	O
14	biological	O
15	and	O
16	catalytic	O
17	activities	O
18	of	O
19	Eph	B
20	receptors	I
21	.	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	B
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	B
46	).	O

1	IL	B
2	-	I
3	2	I
4	is	O
5	accepted	O
6	as	O
7	a	O
8	standard	O
9	treatment	O
10	used	O
11	alone	O
12	,	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	chemotherapy	O
18	or	O
19	biotherapy	O
20	in	O
21	the	O
22	management	O
23	of	O
24	metastatic	O
25	melanoma	O
26	and	O
27	metastatic	O
28	renal	O
29	cell	O
30	carcinoma	O
31	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	antisense	B
6	Ha	I
7	-	I
8	Ras	I
9	or	O
10	dominant	B
11	negative	I
12	Raf	I
13	-	I
14	1	I
15	abrogated	O
16	the	O
17	mitogenic	O
18	effect	O
19	of	O
20	TGF	B
21	-	I
22	beta1	I
23	in	O
24	TSU	O
25	-	O
26	Pr1	O
27	,	O
28	and	O
29	the	O
30	TGF	B
31	-	I
32	beta1	I
33	inhibition	O
34	of	O
35	DU145	O
36	was	O
37	switched	O
38	to	O
39	stimulation	O
40	by	O
41	V12Ha	B
42	-	I
43	Ras	I
44	transfection	O
45	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	O
12	Ras	B
13	/	O
14	MAPK	B
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	O
25	TGF	B
26	-	I
27	beta1	I
28	production	O
29	.	O

1	Vbeta	B
2	segments	O
3	are	O
4	appended	O
5	to	O
6	DJbeta	B
7	rearrangements	O
8	,	O
9	with	O
10	little	O
11	or	O
12	no	O
13	direct	O
14	Vbeta	B
15	to	O
16	Jbeta	B
17	joining	O
18	,	O
19	despite	O
20	12	O
21	/	O
22	23	O
23	compatibility	O
24	of	O
25	Vbeta	B
26	23	I
27	-	I
28	RSSs	I
29	and	O
30	Jbeta12	B
31	-	I
32	RSSs	I
33	.	O

1	For	O
2	oral	O
3	administration	O
4	,	O
5	AUC0	O
6	-	O
7	infinity	O
8	was	O
9	58	O
10	.	O
11	47	O
12	+/-	O
13	16	O
14	.	O
15	37	O
16	microg	O
17	x	O
18	h	O
19	/	O
20	ml	O
21	,	O
22	t1	O
23	/	O
24	2beta	O
25	was	O
26	18	O
27	.	O
28	39	O
29	+/-	O
30	0	O
31	.	O
32	06	O
33	hours	O
34	,	O
35	maximum	O
36	concentration	O
37	(	O
38	Cmax	O
39	)	O
40	was	O
41	2	O
42	.	O
43	12	O
44	+/-	O
45	00	O
46	.	O
47	51	O
48	microg	O
49	/	O
50	ml	O
51	,	O
52	time	O
53	to	O
54	Cmax	O
55	was	O
56	2	O
57	.	O
58	20	O
59	+/-	O
60	2	O
61	.	O
62	17	O
63	hours	O
64	,	O
65	mean	O
66	absorption	O
67	time	O
68	was	O
69	2	O
70	.	O
71	09	O
72	+/-	O
73	0	O
74	.	O
75	51	O
76	hours	O
77	,	O
78	and	O
79	bioavailability	O
80	was	O
81	42	O
82	+/-	O
83	0	O
84	.	O
85	42	O
86	%.	O

1	In	O
2	experiment	O
3	2	O
4	,	O
5	no	O
6	difference	O
7	in	O
8	gastric	O
9	emptying	O
10	of	O
11	40	O
12	%	O
13	peptone	O
14	or	O
15	25	O
16	%	O
17	glucose	O
18	was	O
19	found	O
20	between	O
21	rats	O
22	receiving	O
23	TPN	O
24	and	O
25	those	O
26	receiving	O
27	intragastric	O
28	nutrition	O
29	for	O
30	10	O
31	to	O
32	12	O
33	days	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	H	B
5	-	I
6	NS	I
7	negative	O
8	regulation	O
9	operated	O
10	only	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	Fur	B
16	.	O

1	Thus	O
2	,	O
3	SAG	B
4	appears	O
5	to	O
6	control	O
7	cell	O
8	cycle	O
9	progression	O
10	in	O
11	yeast	O
12	by	O
13	promoting	O
14	ubiquitination	O
15	and	O
16	degradation	O
17	of	O
18	cell	O
19	cycle	O
20	regulatory	O
21	proteins	O
22	.	O

1	E2F	B
2	-	I
3	1	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	that	O
9	regulates	O
10	cell	O
11	cycle	O
12	progression	O
13	into	O
14	S	O
15	-	O
16	phase	O
17	.	O

1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	O
9	and	O
10	impaired	O
11	health	O
12	,	O
13	sleep	O
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O

1	This	O
2	demonstrates	O
3	that	O
4	treatment	O
5	of	O
6	the	O
7	graft	O
8	recipient	O
9	for	O
10	a	O
11	relatively	O
12	short	O
13	period	O
14	during	O
15	and	O
16	after	O
17	surgery	O
18	has	O
19	a	O
20	favorable	O
21	effect	O
22	on	O
23	the	O
24	survival	O
25	of	O
26	grafted	O
27	dopaminergic	O
28	neurons	O
29	.	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	O
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	Chinese	O
2	Spring	O
3	(	O
4	CS	O
5	)	O
6	carrying	O
7	the	O
8	Q	B
9	gene	I
10	to	O
11	those	O
12	of	O
13	a	O
14	chromosome	O
15	deletion	O
16	line	O
17	of	O
18	CS	O
19	,	O
20	namely	O
21	,	O
22	q5	O
23	,	O
24	which	O
25	lacks	O
26	15	O
27	%	O
28	of	O
29	5AL	O
30	including	O
31	the	O
32	Q	B
33	gene	I
34	.	O

1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O

1	Karger	O
2	AG	O
3	,	O
4	Basel	O

1	During	O
2	surgery	O
3	bone	O
4	cysts	O
5	were	O
6	excised	O
7	and	O
8	filled	O
9	by	O
10	bone	O
11	grafts	O
12	.	O

1	Urinary	O
2	LTE4	O
3	increased	O
4	after	O
5	both	O
6	challenges	O
7	the	O
8	rise	O
9	being	O
10	higher	O
11	following	O
12	oral	O
13	as	O
14	compared	O
15	to	O
16	inhalation	O
17	provocation	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0001	O
24	).	O

1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O

1	Three	O
2	FGF	B
3	-	I
4	AS	I
5	cDNAs	I
6	were	O
7	isolated	O
8	;	O
9	the	O
10	full	B
11	-	I
12	length	I
13	FGF	I
14	-	I
15	AS	I
16	mRNA	I
17	and	O
18	two	O
19	alternative	O
20	splice	O
21	variants	O
22	lacking	O
23	exon	O
24	2	O
25	or	O
26	exons	O
27	2	O
28	and	O
29	3	O
30	of	O
31	the	O
32	FGF	B
33	-	I
34	AS	I
35	sequence	I
36	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	indicate	O
7	that	O
8	MAP	B
9	kinase	I
10	stimulates	O
11	the	O
12	hPL	B
13	-	I
14	B	I
15	enhancer	I
16	by	O
17	an	O
18	NF	B
19	-	I
20	IL	I
21	-	I
22	6	I
23	-	O
24	dependent	O
25	pathway	O
26	.	O

1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O

1	Finally	O
2	,	O
3	in	O
4	situ	O
5	RNA	O
6	hybridization	O
7	studies	O
8	revealed	O
9	a	O
10	very	O
11	specific	O
12	pattern	O
13	of	O
14	EphA8	B
15	gene	I
16	expression	O
17	restricted	O
18	to	O
19	the	O
20	rostral	O
21	region	O
22	of	O
23	midbrain	O
24	tectum	O
25	during	O
26	embryonic	O
27	development	O
28	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	B
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	SETTING	O
2	:	O
3	University	O
4	of	O
5	Paris	O
6	VII	O
7	hospital	O
8	.	O
9	Patient	O
10	(	O
11	s	O
12	):	O
13	Nine	O
14	women	O
15	had	O
16	embolization	O
17	for	O
18	symptomatic	O
19	myoma	O
20	,	O
21	with	O
22	12	O
23	pregnancies	O
24	observed	O
25	.	O

1	Improving	O
2	fissure	O
3	sealant	O
4	quality	O
5	:	O
6	mechanical	O
7	preparation	O
8	and	O
9	filling	O
10	level	O
11	.	O

1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O

1	The	O
2	MRS	O
3	II	O
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	the	O
6	fruA	B
7	transcript	I
8	is	O
9	well	O
10	conserved	O
11	with	O
12	the	O
13	D	B
14	.	I
15	melanogaster	I
16	type	I
17	A	I
18	protein	I
19	,	O
20	particularly	O
21	the	O
22	BTB	B
23	protein	I
24	-	O
25	protein	O
26	-	O
27	binding	O
28	domain	O
29	,	O
30	which	O
31	is	O
32	encoded	O
33	by	O
34	exons	O
35	I	O
36	and	O
37	II	O
38	and	O
39	is	O
40	100	O
41	%	O
42	conserved	O
43	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	B
9	/	O
10	Smarcal1	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	Sparfloxacin	O
2	and	O
3	clinafloxacin	O
4	were	O
5	evaluated	O
6	against	O
7	Enterococcus	O
8	faecium	O
9	SF2149	O
10	and	O
11	Enterococcus	O
12	faecalis	O
13	WH245	O
14	,	O
15	respectively	O
16	.	O

1	ECP	B
2	and	O
3	tryptase	B
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O

1	Tolterodine	O
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	For	O
2	an	O
3	unsupervised	O
4	program	O
5	,	O
6	the	O
7	costs	O
8	were	O
9	estimated	O
10	at	O
11	$	O
12	311	O
13	for	O
14	the	O
15	first	O
16	year	O
17	and	O
18	$	O
19	73	O
20	for	O
21	all	O
22	additional	O
23	years	O
24	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	Deletion	O
2	and	O
3	mutational	O
4	analyses	O
5	revealed	O
6	two	O
7	positive	O
8	cis	O
9	-	O
10	regulatory	O
11	elements	O
12	in	O
13	this	O
14	region	O
15	that	O
16	are	O
17	essential	O
18	for	O
19	CSX1	B
20	expression	O
21	in	O
22	cardiomyocytes	O
23	.	O

1	Functional	O
2	studies	O
3	which	O
4	introduced	O
5	a	O
6	mutation	O
7	in	O
8	the	O
9	AP2	B
10	core	I
11	binding	I
12	region	I
13	as	O
14	well	O
15	as	O
16	cotransfection	O
17	experiments	O
18	using	O
19	an	O
20	AP2	B
21	expression	O
22	vector	O
23	revealed	O
24	that	O
25	AP2	B
26	exerts	O
27	a	O
28	repressive	O
29	role	O
30	on	O
31	the	O
32	HGF	B
33	gene	I
34	promoter	I
35	activity	O
36	.	O

1	Using	O
2	adenoviral	O
3	transfer	O
4	of	O
5	IkappaBalpha	B
6	(	O
7	IkappaBalpha	B
8	overexpression	O
9	),	O
10	the	O
11	production	O
12	of	O
13	TNF	B
14	-	I
15	alpha	I
16	induced	O
17	by	O
18	whole	O
19	GBS	O
20	was	O
21	inhibited	O
22	by	O
23	only	O
24	20	O
25	%.	O

1	In	O
2	reconstitution	O
3	experiments	O
4	,	O
5	we	O
6	first	O
7	showed	O
8	that	O
9	expression	O
10	in	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	cell	O
17	line	O
18	of	O
19	C	B
20	-	I
21	terminal	I
22	Src	I
23	kinase	I
24	(	O
25	Csk	B
26	)	O
27	inhibited	O
28	and	O
29	that	O
30	of	O
31	a	O
32	membrane	O
33	-	O
34	anchored	O
35	,	O
36	gain	O
37	-	O
38	of	O
39	-	O
40	function	O
41	Csk	B
42	abolished	O
43	the	O
44	Fc	B
45	gamma	I
46	R	I
47	-	O
48	mediated	O
49	signaling	O
50	that	O
51	leads	O
52	to	O
53	phagocytosis	O
54	in	O
55	a	O
56	kinase	O
57	-	O
58	dependent	O
59	manner	O
60	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	-	I
8	derived	I
9	construct	I
10	(	O
11	a	B
12	-	I
13	Src	I
14	),	O
15	that	O
16	was	O
17	excluded	O
18	from	O
19	detergent	O
20	-	O
21	resistant	O
22	membranes	O
23	,	O
24	could	O
25	not	O
26	restore	O
27	the	O
28	series	O
29	of	O
30	phagocytosis	O
31	signaling	O
32	.	O

1	The	O
2	delta	B
3	srb10	I
4	mutation	I
5	also	O
6	influenced	O
7	on	O
8	the	O
9	transcript	O
10	levels	O
11	of	O
12	meiosis	O
13	-	O
14	inducing	O
15	genes	O
16	called	O
17	IME1	B
18	and	O
19	IME2	B
20	:	O
21	the	O
22	mutation	O
23	elevated	O
24	the	O
25	transcript	O
26	level	O
27	of	O
28	IME1	B
29	but	O
30	reduced	O
31	that	O
32	of	O
33	IME2	B
34	,	O
35	resulting	O
36	in	O
37	partial	O
38	defects	O
39	in	O
40	premeiotic	O
41	DNA	O
42	synthesis	O
43	and	O
44	meiosis	O
45	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	environmental	O
6	conditions	O
7	for	O
8	meiosis	O
9	finely	O
10	regulate	O
11	the	O
12	transcript	O
13	levels	O
14	of	O
15	KIN28	B
16	and	O
17	CCL1	B
18	,	O
19	such	O
20	that	O
21	nitrogen	O
22	starvation	O
23	first	O
24	elevates	O
25	them	O
26	but	O
27	subsequent	O
28	alkalization	O
29	of	O
30	medium	O
31	decreases	O
32	them	O
33	.	O

1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	B
19	2	I
20	gene	I
21	,	O
22	which	O
23	complements	O
24	S	B
25	.	I
26	pombe	I
27	leu1	I
28	-	I
29	gene	I
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	B
35	+	I
36	and	O
37	his3	B
38	+	I
39	genes	I
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	B
49	promoter	I
50	(	O
51	3X	O
52	,	O
53	41X	O
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	O
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	I
25	bodies	I
26	to	O
27	A60	B
28	antigen	I
29	.	O

1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O

1	Franz	O
2	Schubert	O
3	--	O
4	his	O
5	life	O
6	,	O
7	music	O
8	and	O
9	diseases	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	role	O
7	of	O
8	S	O
9	.	O
10	argyrostoma	O
11	in	O
12	the	O
13	dissemination	O
14	of	O
15	Trichinella	O
16	larvae	O
17	in	O
18	nature	O
19	is	O
20	limited	O
21	in	O
22	comparison	O
23	to	O
24	the	O
25	role	O
26	played	O
27	by	O
28	mammals	O
29	with	O
30	scavenger	O
31	and	O
32	cannibalistic	O
33	behavior	O
34	.	O

1	The	O
2	equilibrium	O
3	dissociation	O
4	binding	O
5	constant	O
6	for	O
7	the	O
8	interaction	O
9	of	O
10	TnrA	B
11	with	O
12	the	O
13	nrgAB	B
14	promoter	I
15	fragment	I
16	was	O
17	7	O
18	.	O
19	7	O
20	nM	O
21	under	O
22	the	O
23	conditions	O
24	used	O
25	here	O
26	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	N	O
6	-	O
7	glycans	O
8	flanking	O
9	the	O
10	receptor	O
11	-	O
12	binding	O
13	site	O
14	of	O
15	the	O
16	HA	B
17	molecule	I
18	are	O
19	potent	O
20	regulators	O
21	of	O
22	influenza	O
23	virus	O
24	growth	O
25	,	O
26	with	O
27	the	O
28	glycan	O
29	at	O
30	Asn149	O
31	being	O
32	dominant	O
33	and	O
34	that	O
35	at	O
36	Asn123	O
37	being	O
38	less	O
39	effective	O
40	.	O

1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O

1	All	O
2	were	O
3	tested	O
4	for	O
5	serum	O
6	ferritin	B
7	(	O
8	SF	B
9	),	O
10	hemoglobin	B
11	(	O
12	Hb	B
13	)	O
14	level	O
15	and	O
16	asked	O
17	for	O
18	detailed	O
19	histories	O
20	of	O
21	donations	O
22	and	O
23	iron	O
24	supplementation	O
25	.	O

1	Vascular	B
2	endothelial	I
3	growth	I
4	factor	I
5	(	O
6	VEGF	B
7	),	O
8	a	O
9	potent	O
10	agonist	O
11	secreted	O
12	by	O
13	virtually	O
14	all	O
15	cells	O
16	,	O
17	controls	O
18	migration	O
19	and	O
20	division	O
21	of	O
22	vascular	O
23	endothelial	O
24	cells	O
25	.	O

1	The	O
2	antioxidant	O
3	agent	O
4	pyrrolidine	O
5	dithiocarbamate	O
6	(	O
7	PDTC	O
8	)	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	protect	O
14	endothelial	O
15	cells	O
16	(	O
17	EC	O
18	)	O
19	from	O
20	pro	O
21	-	O
22	inflammatory	O
23	-	O
24	induced	O
25	and	O
26	pro	O
27	-	O
28	oxidant	O
29	-	O
30	induced	O
31	NF	B
32	-	I
33	kappaB	I
34	activation	O
35	.	O

1	We	O
2	further	O
3	studied	O
4	the	O
5	effects	O
6	of	O
7	SIE	B
8	-	I
9	1	I
10	hypermethylation	O
11	on	O
12	p21WAF1	B
13	induction	O
14	by	O
15	STAT	B
16	activation	O
17	.	O

1	Phd	B
2	antibody	O
3	-	O
4	immunoreactive	O
5	peptides	O
6	are	O
7	seen	O
8	in	O
9	light	O
10	-	O
11	adapted	O
12	mouse	O
13	retinal	O
14	cytosolic	O
15	and	O
16	nuclear	O
17	extracts	O
18	.	O

1	In	O
2	the	O
3	pRb	B
4	(-)	I
5	SAOS	O
6	-	O
7	2	O
8	cell	O
9	line	O
10	transiently	O
11	transfected	O
12	with	O
13	a	O
14	reporter	O
15	plasmid	O
16	containing	O
17	six	O
18	tal	B
19	-	I
20	1	I
21	binding	I
22	site	I
23	,	O
24	pRb	B
25	enhances	O
26	the	O
27	transcriptional	O
28	activity	O
29	of	O
30	tal	B
31	-	I
32	1	I
33	-	O
34	E12	B
35	-	O
36	Lmo2	B
37	and	O
38	tal	B
39	-	I
40	1	I
41	-	O
42	E12	B
43	-	O
44	Lmo2	B
45	-	O
46	Ldb1	B
47	complexes	O
48	but	O
49	not	O
50	that	O
51	of	O
52	a	O
53	tal	B
54	-	I
55	1	I
56	-	O
57	E12	B
58	heterodimer	O
59	.	O

1	This	O
2	effect	O
3	was	O
4	not	O
5	seen	O
6	in	O
7	conjunction	O
8	with	O
9	oxycodone	O
10	,	O
11	a	O
12	morphine	B
13	-	I
14	like	I
15	mu	I
16	-	I
17	receptor	I
18	agonist	O
19	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	morphological	O
6	criteria	O
7	,	O
8	the	O
9	few	O
10	data	O
11	available	O
12	from	O
13	recent	O
14	studies	O
15	at	O
16	the	O
17	genetic	O
18	level	O
19	have	O
20	suggested	O
21	that	O
22	EPVs	O
23	infecting	O
24	different	O
25	insect	O
26	orders	O
27	are	O
28	phylogenetically	O
29	distant	O
30	.	O

1	Neurofibromatosis	O
2	of	O
3	the	O
4	breast	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	Morbus	O
10	von	O
11	Recklinghausen	O

1	In	O
2	the	O
3	premating	O
4	period	O
5	male	O
6	rate	O
7	of	O
8	aggression	O
9	was	O
10	not	O
11	significantly	O
12	correlated	O
13	with	O
14	testosterone	O
15	level	O
16	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	B
16	blocks	O
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	B
24	and	O
25	rut	B
26	sites	I
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	In	O
2	situ	O
3	hybridization	O
4	with	O
5	the	O
6	antisense	O
7	RNA	O
8	probes	O
9	further	O
10	supported	O
11	the	O
12	expression	O
13	changes	O
14	of	O
15	these	O
16	six	O
17	clones	O
18	and	O
19	localized	O
20	the	O
21	changes	O
22	in	O
23	multiple	O
24	germ	O
25	cell	O
26	stages	O
27	as	O
28	well	O
29	as	O
30	other	O
31	cell	O
32	types	O
33	(	O
34	Sertoli	O
35	,	O
36	interstitial	O
37	and	O
38	peritubular	O
39	cells	O
40	).	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	Prevention	O
2	,	O
3	differential	O
4	diagnosis	O
5	and	O
6	therapy	O
7	of	O
8	travel	O
9	diarrhea	O

1	This	O
2	study	O
3	shows	O
4	that	O
5	C	B
6	/	I
7	EBPbeta	I
8	is	O
9	the	O
10	predominant	O
11	C	B
12	/	I
13	EBP	I
14	isoform	I
15	found	O
16	in	O
17	activated	O
18	stellate	O
19	cells	O
20	and	O
21	that	O
22	increased	O
23	C	B
24	/	I
25	EBPbeta	I
26	protein	I
27	and	O
28	C	B
29	/	I
30	EBPbeta	I
31	binding	O
32	to	O
33	a	O
34	proximal	O
35	C	B
36	/	I
37	EBP	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	promoter	O
43	mediates	O
44	the	O
45	activating	O
46	effect	O
47	of	O
48	acetaldehyde	O
49	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O

1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O

1	After	O
2	two	O
3	successive	O
4	rounds	O
5	of	O
6	selection	O
7	by	O
8	focus	O
9	formation	O
10	assay	O
11	,	O
12	a	O
13	transforming	O
14	ribozyme	O
15	(	O
16	Rz007	B
17	)	O
18	was	O
19	identified	O
20	.	O

1	G	O
2	.,	O
3	and	O
4	Hyde	O
5	,	O
6	C	O
7	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	proteasome	O
6	inhibition	O
7	leads	O
8	to	O
9	upregulation	O
10	of	O
11	specific	O
12	members	O
13	of	O
14	transcription	O
15	factor	O
16	families	O
17	controlling	O
18	cellular	O
19	stress	O
20	response	O
21	and	O
22	proliferation	O
23	.	O

1	The	O
2	ATR	O
3	-	O
4	X	O
5	syndrome	O
6	results	O
7	from	O
8	mutations	O
9	of	O
10	the	O
11	XH2	B
12	gene	I
13	,	O
14	located	O
15	on	O
16	the	O
17	X	O
18	chromosome	O
19	(	O
20	Xq13	O
21	.	O
22	3	O
23	)	O
24	and	O
25	coding	O
26	for	O
27	a	O
28	transacting	O
29	factor	O
30	which	O
31	regulates	O
32	gene	O
33	expression	O
34	.	O

1	AIMS	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	role	O
7	of	O
8	environmental	O
9	intra	O
10	-	O
11	uterine	O
12	factors	O
13	in	O
14	determining	O
15	the	O
16	birthweights	O
17	of	O
18	twins	O
19	with	O
20	increased	O
21	susceptibility	O
22	to	O
23	diabetes	O
24	and	O
25	discordant	O
26	for	O
27	abnormal	O
28	responses	O
29	to	O
30	the	O
31	oral	O
32	glucose	O
33	tolerance	O
34	test	O
35	(	O
36	OGTT	O
37	)	O
38	and	O
39	verify	O
40	the	O
41	possible	O
42	association	O
43	of	O
44	within	O
45	-	O
46	pair	O
47	birthweight	O
48	differences	O
49	and	O
50	metabolic	O
51	abnormalities	O
52	in	O
53	adult	O
54	life	O
55	.	O

1	In	O
2	NASCIS	O
3	III	O
4	,	O
5	a	O
6	randomization	O
7	imbalance	O
8	occurred	O
9	that	O
10	allocated	O
11	a	O
12	disproportionate	O
13	number	O
14	of	O
15	patients	O
16	with	O
17	no	O
18	motor	O
19	deficit	O
20	(	O
21	and	O
22	therefore	O
23	no	O
24	chance	O
25	for	O
26	recovery	O
27	)	O
28	to	O
29	the	O
30	lower	O
31	dose	O
32	control	O
33	group	O
34	.	O

1	Penicillin	B
2	acylase	I
3	(	O
4	PA	B
5	)	O
6	from	O
7	Escherichia	O
8	coli	O
9	ATCC11105	O
10	is	O
11	a	O
12	periplasmic	O
13	heterodimer	O
14	consisting	O
15	of	O
16	a	O
17	24	O
18	kDa	O
19	small	O
20	subunit	O
21	and	O
22	a	O
23	65	O
24	kDa	O
25	large	O
26	subunit	O
27	.	O

1	A	O
2	murine	O
3	expressed	O
4	sequence	O
5	tag	O
6	(	O
7	EST	O
8	)	O
9	showing	O
10	homology	O
11	with	O
12	erythropoietin	B
13	receptor	I
14	(	O
15	EPOR	B
16	)	O
17	was	O
18	identified	O
19	in	O
20	the	O
21	EST	O
22	database	O
23	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	GAP	O
2	JUNCTIONS	O
3	IN	O
4	THE	O
5	BRAIN	O
6	:	O
7	PREFACE	O
8	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	functionally	O
6	characterized	O
7	the	O
8	mouse	O
9	gene	O
10	for	O
11	the	O
12	C2	O
13	subunit	O
14	of	O
15	the	O
16	20S	B
17	proteasome	I
18	.	O

1	Furthermore	O
2	,	O
3	as	O
4	in	O
5	the	O
6	human	O
7	gene	O
8	,	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	the	O
15	Cacna1f	B
16	gene	I
17	maps	O
18	within	O
19	5	O
20	kb	O
21	of	O
22	the	O
23	5	O
24	'	O
25	end	O
26	of	O
27	the	O
28	mouse	B
29	synaptophysin	I
30	gene	I
31	in	O
32	a	O
33	region	O
34	orthologous	O
35	to	O
36	Xp11	O
37	.	O
38	23	O
39	.	O

1	With	O
2	the	O
3	human	B
4	Rhotekin	I
5	cDNA	I
6	as	O
7	a	O
8	probe	O
9	,	O
10	Northern	O
11	hybridization	O
12	revealed	O
13	that	O
14	a	O
15	4	O
16	.	O
17	0	O
18	-	O
19	kb	O
20	transcript	O
21	was	O
22	expressed	O
23	at	O
24	a	O
25	high	O
26	level	O
27	in	O
28	prostate	O
29	and	O
30	at	O
31	a	O
32	middle	O
33	level	O
34	in	O
35	13	O
36	of	O
37	16	O
38	tissues	O
39	examined	O
40	,	O
41	but	O
42	it	O
43	cannot	O
44	be	O
45	detected	O
46	in	O
47	liver	O
48	and	O
49	lung	O
50	tissues	O
51	.	O

1	Similarly	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	a	O
8	dominant	O
9	-	O
10	negative	O
11	mutant	O
12	of	O
13	p38alpha	B
14	,	O
15	but	O
16	not	O
17	of	O
18	ERK1	B
19	,	O
20	ERK2	B
21	,	O
22	JNK1	B
23	,	O
24	or	O
25	JNK2	B
26	,	O
27	reduces	O
28	basal	O
29	and	O
30	cadmium	O
31	-	O
32	induced	O
33	pE1	B
34	-	I
35	luc	I
36	activity	O
37	.	O

1	BACKGROUND	O
2	:	O
3	Gamma	O
4	knife	O
5	radiosurgery	O
6	(	O
7	GKR	O
8	)	O
9	is	O
10	a	O
11	safe	O
12	and	O
13	effective	O
14	alternative	O
15	to	O
16	surgery	O
17	for	O
18	intracranial	O
19	lesions	O
20	.	O

1	In	O
2	hemodialyzed	O
3	patients	O
4	(	O
5	Epo	B
6	and	O
7	Non	O
8	-	O
9	Epo	B
10	group	O
11	)	O
12	leptin	B
13	levels	O
14	were	O
15	significantly	O
16	higher	O
17	when	O
18	compared	O
19	to	O
20	CAPD	O
21	patients	O
22	(	O
23	Epo	B
24	and	O
25	Non	O
26	-	O
27	Epo	B
28	group	O
29	,	O
30	respectively	O
31	).	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	O
5	-	O
6	adrenergic	O
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O

1	ID	O
2	-	O
3	PaGIA	O
4	diphtheria	B
5	toxin	I
6	polymer	O
7	particle	O
8	diagnostic	O
9	agent	O
10	manufactured	O
11	by	O
12	DiaMed	O
13	AG	O
14	,	O
15	Switzerland	O
16	,	O
17	was	O
18	tried	O
19	at	O
20	bacteriological	O
21	laboratory	O
22	of	O
23	Institute	O
24	of	O
25	Childhood	O
26	Infections	O
27	in	O
28	St	O
29	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	Therefore	O
2	,	O
3	the	O
4	results	O
5	indicate	O
6	that	O
7	repeated	O
8	exposure	O
9	to	O
10	amphetamine	O
11	or	O
12	apomorphine	O
13	overcomes	O
14	the	O
15	context	O
16	-	O
17	dependent	O
18	component	O
19	of	O
20	sensitization	O
21	of	O
22	amphetamine	O
23	-	O
24	or	O
25	apomorphine	O
26	-	O
27	induced	O
28	stereotyped	O
29	behavior	O
30	.	O

1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	B
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	Topics	O
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	The	O
2	science	O
3	of	O
4	tissue	O
5	engineering	O
6	.	O

1	Endonuclease	B
2	III	I
3	(	O
4	Nth	B
5	)	O
6	of	O
7	Escherichia	O
8	coli	O
9	is	O
10	a	O
11	DNA	B
12	glycosylase	I
13	essential	O
14	for	O
15	the	O
16	removal	O
17	of	O
18	oxidised	O
19	pyrimidine	O
20	base	O
21	residues	O
22	from	O
23	DNA	O
24	.	O

1	The	O
2	duration	O
3	of	O
4	reactive	O
5	hyperemia	O
6	decreased	O
7	with	O
8	aging	O
9	,	O
10	but	O
11	the	O
12	difference	O
13	between	O
14	males	O
15	and	O
16	females	O
17	was	O
18	not	O
19	significant	O
20	at	O
21	any	O
22	age	O
23	.	O

1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O

1	However	O
2	,	O
3	little	O
4	was	O
5	understood	O
6	about	O
7	the	O
8	normal	O
9	function	O
10	of	O
11	CREB	B
12	-	I
13	2	I
14	in	O
15	mammalian	O
16	development	O
17	or	O
18	organ	O
19	physiology	O
20	.	O

1	The	O
2	outer	O
3	diameter	O
4	and	O
5	the	O
6	thickness	O
7	of	O
8	the	O
9	rotor	O
10	are	O
11	60	O
12	mm	O
13	and	O
14	8	O
15	mm	O
16	,	O
17	respectively	O
18	.	O

1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O

1	CONCLUSIONS	O
2	:	O
3	There	O
4	is	O
5	a	O
6	relation	O
7	in	O
8	the	O
9	topography	O
10	of	O
11	some	O
12	visual	O
13	field	O
14	areas	O
15	assessed	O
16	by	O
17	SWAP	O
18	and	O
19	the	O
20	inferotemporal	O
21	neuroretinal	O
22	rim	O
23	area	O
24	,	O
25	which	O
26	may	O
27	play	O
28	a	O
29	role	O
30	in	O
31	the	O
32	diagnosis	O
33	and	O
34	follow	O
35	-	O
36	up	O
37	of	O
38	suspected	O
39	glaucoma	O
40	.	O

1	The	O
2	total	O
3	alkaloids	O
4	contained	O
5	in	O
6	the	O
7	peel	O
8	of	O
9	Atzimba	O
10	,	O
11	Lopez	O
12	,	O
13	Marciana	O
14	,	O
15	Montsama	O
16	,	O
17	Murca	O
18	,	O
19	and	O
20	Puebla	O
21	was	O
22	lower	O
23	than	O
24	the	O
25	limits	O
26	recommended	O
27	for	O
28	food	O
29	safety	O
30	.	O

1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O

1	Herein	O
2	,	O
3	we	O
4	show	O
5	that	O
6	Smad3	B
7	physically	O
8	interacts	O
9	with	O
10	the	O
11	HMG	B
12	box	O
13	domain	O
14	of	O
15	LEF1	B
16	and	O
17	that	O
18	TGFbeta	B
19	and	O
20	Wnt	B
21	pathways	O
22	synergize	O
23	to	O
24	activate	O
25	transcription	O
26	of	O
27	the	O
28	Xenopus	O
29	homeobox	O
30	gene	O
31	twin	B
32	(	O
33	Xtwn	B
34	).	O

1	The	O
2	transmembrane	O
3	topology	O
4	of	O
5	Na	O
6	(+)/	O
7	H	O
8	(+)	O
9	exchanger	O
10	NHE3	B
11	has	O
12	been	O
13	studied	O
14	using	O
15	in	O
16	vitro	O
17	transcription	O
18	/	O
19	translation	O
20	of	O
21	two	O
22	types	O
23	of	O
24	fusion	O
25	vectors	O
26	designed	O
27	to	O
28	test	O
29	membrane	O
30	insertion	O
31	properties	O
32	of	O
33	cDNA	O
34	sequences	O
35	encoding	O
36	putative	O
37	NHE3	B
38	membrane	O
39	spanning	O
40	domains	O
41	(	O
42	msds	O
43	).	O

1	ACE	B
2	-	I
3	2	I
4	has	O
5	a	O
6	hydrophobic	O
7	C	O
8	terminus	O
9	of	O
10	H	O
11	type	O
12	.	O

1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	O
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	O
22	myosin	B
23	cytoskeleton	O
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O

1	We	O
2	concluded	O
3	that	O
4	activation	O
5	of	O
6	c	B
7	-	I
8	fosER	I
9	mediated	O
10	transcriptional	O
11	inhibition	O
12	of	O
13	p21	B
14	(	O
15	Cip1	B
16	/	O
17	WAF1	B
18	)	O
19	through	O
20	a	O
21	previously	O
22	uncharacterized	O
23	AP	B
24	-	I
25	1	I
26	site	I
27	,	O
28	revealing	O
29	an	O
30	important	O
31	role	O
32	for	O
33	c	B
34	-	I
35	fos	I
36	in	O
37	negative	O
38	control	O
39	of	O
40	cell	O
41	cycle	O
42	regulatory	O
43	genes	O
44	.	O

1	Furthermore	O
2	,	O
3	a	O
4	pTyr317	B
5	Shc	I
6	phosphopeptide	I
7	selectively	O
8	recognized	O
9	Grb2	B
10	,	O
11	Sos1	B
12	,	O
13	SHIP	B
14	,	O
15	and	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'	I
23	kinase	I
24	from	O
25	mast	O
26	cells	O
27	,	O
28	as	O
29	characterized	O
30	by	O
31	mass	O
32	spectrometry	O
33	.	O

1	Although	O
2	increased	O
3	expression	O
4	of	O
5	the	O
6	HMG	B
7	-	I
8	I	I
9	/	I
10	Y	I
11	proteins	I
12	is	O
13	associated	O
14	with	O
15	cellular	O
16	proliferation	O
17	,	O
18	neoplastic	O
19	transformation	O
20	,	O
21	and	O
22	several	O
23	human	O
24	cancers	O
25	,	O
26	the	O
27	role	O
28	of	O
29	these	O
30	proteins	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	malignancy	O
36	remains	O
37	unclear	O
38	.	O

1	The	O
2	naltrexone	O
3	/	O
4	lofexidine	O
5	combination	O
6	was	O
7	associated	O
8	with	O
9	a	O
10	more	O
11	rapid	O
12	resolution	O
13	of	O
14	the	O
15	opiate	O
16	withdrawal	O
17	syndrome	O
18	than	O
19	a	O
20	7	O
21	-	O
22	day	O
23	lofexidine	O
24	-	O
25	only	O
26	treatment	O
27	schedule	O
28	,	O
29	without	O
30	substantial	O
31	increases	O
32	in	O
33	withdrawal	O
34	symptoms	O
35	or	O
36	hypotensive	O
37	side	O
38	-	O
39	effects	O
40	.	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	Screening	O
2	,	O
3	counseling	O
4	,	O
5	and	O
6	treatment	O
7	for	O
8	alcohol	O
9	and	O
10	illicit	O
11	drug	O
12	use	O
13	should	O
14	be	O
15	essential	O
16	components	O
17	in	O
18	comprehensive	O
19	HBP	O
20	care	O
21	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	mouse	B
6	cytosolic	I
7	chaperonin	I
8	subunit	I
9	gene	I
10	Ccta	I
11	/	I
12	t	I
13	-	I
14	complex	I
15	polypeptide	I
16	1	I
17	by	O
18	selenocysteine	B
19	tRNA	I
20	gene	I
21	transcription	I
22	activating	I
23	factor	I
24	family	I
25	zinc	I
26	finger	I
27	proteins	I
28	.	O

1	The	O
2	unfolded	O
3	protein	O
4	response	O
5	regulates	O
6	multiple	O
7	aspects	O
8	of	O
9	secretory	O
10	and	O
11	membrane	O
12	protein	O
13	biogenesis	O
14	and	O
15	endoplasmic	O
16	reticulum	O
17	quality	O
18	control	O
19	.	O

1	PNRC	B
2	:	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	nuclear	O
8	receptor	O
9	coregulatory	O
10	protein	O
11	that	O
12	modulates	O
13	transcriptional	O
14	activation	O
15	of	O
16	multiple	O
17	nuclear	O
18	receptors	O
19	including	O
20	orphan	O
21	receptors	O
22	SF1	B
23	(	O
24	steroidogenic	B
25	factor	I
26	1	I
27	)	O
28	and	O
29	ERRalpha1	B
30	(	O
31	estrogen	B
32	related	I
33	receptor	I
34	alpha	I
35	-	I
36	1	I
37	).	O

1	Studies	O
2	using	O
3	a	O
4	reporter	O
5	plasmid	O
6	with	O
7	a	O
8	functionally	O
9	disrupted	O
10	sterol	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	SRE	O
16	)-	O
17	1	O
18	revealed	O
19	a	O
20	reduced	O
21	stimulatory	O
22	response	O
23	to	O
24	IL	B
25	-	I
26	6	I
27	.	O

1	However	O
2	,	O
3	there	O
4	is	O
5	still	O
6	a	O
7	subset	O
8	of	O
9	tumors	O
10	that	O
11	displayed	O
12	no	O
13	changes	O
14	in	O
15	these	O
16	genes	O
17	.	O

1	We	O
2	have	O
3	shown	O
4	that	O
5	the	O
6	epidural	O
7	(	O
8	EPI	O
9	)	O
10	delivery	O
11	of	O
12	morphine	O
13	encapsulated	O
14	in	O
15	multivesicular	O
16	liposomes	O
17	(	O
18	DepoFoam	O
19	drug	O
20	delivery	O
21	system	O
22	)	O
23	produces	O
24	a	O
25	sustained	O
26	clearance	O
27	of	O
28	morphine	O
29	and	O
30	a	O
31	prolonged	O
32	analgesia	O
33	.	O

1	Following	O
2	EPI	O
3	-	O
4	C0401	O
5	,	O
6	but	O
7	not	O
8	saline	O
9	or	O
10	DepoFoam	O
11	vehicle	O
12	,	O
13	there	O
14	were	O
15	transient	O
16	(<	O
17	72	O
18	hr	O
19	)	O
20	decreases	O
21	in	O
22	food	O
23	consumption	O
24	,	O
25	arousal	O
26	,	O
27	hindlimb	O
28	muscle	O
29	tone	O
30	,	O
31	and	O
32	body	O
33	temperature	O
34	.	O

1	Bailey	O
2	Instruments	O
3	and	O
4	Owen	O
5	Mumford	O
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	PARTICIPANTS	O
2	:	O
3	Convenience	O
4	sample	O
5	of	O
6	ambulatory	O
7	outpatients	O
8	with	O
9	hereditary	O
10	motor	O
11	and	O
12	sensory	O
13	neuropathy	O
14	,	O
15	type	O
16	I	O
17	(	O
18	n	O
19	=	O
20	9	O
21	),	O
22	myotonic	O
23	muscular	O
24	dystrophy	O
25	(	O
26	n	O
27	=	O
28	10	O
29	),	O
30	and	O
31	able	O
32	-	O
33	bodied	O
34	controls	O
35	(	O
36	n	O
37	=	O
38	11	O
39	).	O

1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	CONCLUSION	O
2	:	O
3	Rheumatic	O
4	fever	O
5	in	O
6	the	O
7	Nazareth	O
8	area	O
9	is	O
10	still	O
11	manifest	O
12	.	O

1	Antithrombin	B
2	III	I
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	O
10	?	O
11	Thrombosis	O
12	ABC	O
13	,	O
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I

1	Specific	O
2	class	B
3	I	I
4	and	I
5	II	I
6	histone	I
7	deacetylases	I
8	(	O
9	HDACs	B
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	B
16	,	O
17	suggesting	O
18	that	O
19	BCoR	B
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	B
28	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	example	O
6	of	O
7	a	O
8	eukaryotic	O
9	transcription	O
10	factor	O
11	complex	O
12	containing	O
13	both	O
14	a	O
15	MADS	B
16	-	I
17	box	I
18	and	O
19	a	O
20	forkhead	B
21	protein	I
22	,	O
23	and	O
24	it	O
25	has	O
26	important	O
27	implications	O
28	for	O
29	the	O
30	regulation	O
31	of	O
32	mammalian	O
33	gene	O
34	expression	O
35	.	O

1	After	O
2	screening	O
3	the	O
4	Berkeley	O
5	Drosophila	O
6	Genome	O
7	Project	O
8	database	O
9	with	O
10	sequences	O
11	from	O
12	a	O
13	recently	O
14	characterized	O
15	Leu	B
16	-	I
17	rich	I
18	repeats	I
19	-	I
20	containing	I
21	G	I
22	protein	I
23	-	I
24	coupled	I
25	receptor	I
26	(	O
27	LGR	B
28	)	O
29	from	O
30	Drosophila	O
31	(	O
32	DLGR	B
33	-	I
34	1	I
35	),	O
36	we	O
37	identified	O
38	a	O
39	second	O
40	gene	O
41	for	O
42	a	O
43	different	O
44	LGR	B
45	(	O
46	DLGR	B
47	-	I
48	2	I
49	)	O
50	and	O
51	cloned	O
52	its	O
53	cDNA	O
54	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	B
11	sequences	I
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O

1	Resistance	O
2	ratios	O
3	for	O
4	the	O
5	other	O
6	field	O
7	strains	O
8	obtained	O
9	by	O
10	comparison	O
11	with	O
12	the	O
13	R5	O
14	strain	O
15	ranged	O
16	from	O
17	24	O
18	.	O
19	5	O
20	to	O
21	239	O
22	for	O
23	topical	O
24	application	O
25	and	O
26	from	O
27	1	O
28	.	O
29	2	O
30	to	O
31	9	O
32	.	O
33	8	O
34	for	O
35	the	O
36	glass	O
37	jar	O
38	method	O
39	.	O

1	Only	O
2	transcripts	O
3	specific	O
4	for	O
5	TSGF	B
6	-	I
7	2	I
8	are	O
9	detected	O
10	in	O
11	ovary	O
12	and	O
13	testes	O
14	tissues	O
15	of	O
16	adults	O
17	as	O
18	well	O
19	as	O
20	in	O
21	puparia	O
22	,	O
23	while	O
24	neither	O
25	gene	O
26	is	O
27	expressed	O
28	during	O
29	the	O
30	larval	O
31	developmental	O
32	stages	O
33	.	O

1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	Coimmunoprecipitation	O
2	experiments	O
3	performed	O
4	in	O
5	transfected	O
6	cells	O
7	showed	O
8	that	O
9	BCMA	B
10	associates	O
11	with	O
12	TNFR	B
13	-	I
14	associated	I
15	factor	I
16	(	I
17	TRAF	I
18	)	I
19	1	I
20	,	O
21	TRAF2	B
22	,	O
23	and	O
24	TRAF3	B
25	adaptor	I
26	proteins	I
27	.	O

1	Since	O
2	the	O
3	RINX	B
4	gene	I
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	B
12	Vsx1	I
13	gene	I
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	B
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O

1	The	O
2	chromosomal	O
3	localization	O
4	on	O
5	distal	O
6	chromosome	O
7	7	O
8	places	O
9	it	O
10	in	O
11	a	O
12	cluster	O
13	of	O
14	imprinted	O
15	genes	O
16	,	O
17	flanked	O
18	by	O
19	the	O
20	previously	O
21	described	O
22	Tapa1	B
23	and	O
24	Kcnq1	B
25	genes	I
26	.	O

1	Activation	O
2	of	O
3	PKA	B
4	by	O
5	8	O
6	-	O
7	bromo	O
8	-	O
9	cyclic	O
10	AMP	O
11	or	O
12	forskolin	O
13	,	O
14	and	O
15	inhibition	O
16	of	O
17	PKC	B
18	by	O
19	calphostin	O
20	C	O
21	,	O
22	resulted	O
23	in	O
24	a	O
25	significant	O
26	decrease	O
27	in	O
28	3TP	B
29	activity	O
30	as	O
31	well	O
32	as	O
33	in	O
34	vitro	O
35	ERK	B
36	kinase	I
37	activity	O
38	in	O
39	CRAC	O
40	.	O

1	The	O
2	present	O
3	study	O
4	was	O
5	designed	O
6	to	O
7	evaluate	O
8	the	O
9	sensitivity	O
10	and	O
11	specificity	O
12	of	O
13	AMP	O
14	CT	O
15	(	O
16	Gen	O
17	-	O
18	Probe	O
19	Incorporated	O
20	,	O
21	San	O
22	Diego	O
23	,	O
24	CA	O
25	,	O
26	USA	O
27	)	O
28	on	O
29	urogenital	O
30	specimens	O
31	taken	O
32	from	O
33	symptomatic	O
34	patients	O
35	and	O
36	on	O
37	first	O
38	void	O
39	urine	O
40	(	O
41	FVU	O
42	)	O
43	specimens	O
44	from	O
45	asymptomatic	O
46	patients	O
47	.	O

1	Mus81p	B
2	also	O
3	shares	O
4	homology	O
5	with	O
6	motifs	O
7	found	O
8	in	O
9	the	O
10	XPF	B
11	endonuclease	I
12	superfamily	I
13	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	B
28	protein	I
29	(	O
30	TP	B
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	The	O
2	repetitive	O
3	ETn	B
4	(	O
5	early	B
6	transposon	I
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O

1	The	O
2	measurement	O
3	of	O
4	NO	O
5	in	O
6	biological	O
7	systems	O
8	using	O
9	chemiluminescence	O
10	.	O

1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	B
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O

1	Atorvastatin	O
2	was	O
3	the	O
4	most	O
5	cost	O
6	-	O
7	effective	O
8	HMG	B
9	-	I
10	CoA	I
11	reductase	I
12	inhibitor	O
13	.	O

1	Pharmacoeconomic	O
2	assessment	O
3	of	O
4	HMG	B
5	-	I
6	CoA	I
7	reductase	I
8	inhibitor	O
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O

1	Interestingly	O
2	,	O
3	although	O
4	E	O
5	domains	O
6	of	O
7	these	O
8	two	O
9	receptors	O
10	are	O
11	much	O
12	less	O
13	conserved	O
14	,	O
15	replacement	O
16	of	O
17	this	O
18	domain	O
19	in	O
20	rtER	B
21	by	O
22	its	O
23	human	O
24	counterpart	O
25	resulted	O
26	in	O
27	higher	O
28	estradiol	O
29	sensitivity	O
30	but	O
31	no	O
32	increase	O
33	in	O
34	the	O
35	magnitude	O
36	of	O
37	transactivation	O
38	.	O

1	G	O
2	-	O
3	DNA	O
4	is	O
5	a	O
6	four	O
7	-	O
8	stranded	O
9	DNA	O
10	structure	O
11	with	O
12	diverse	O
13	putative	O
14	biological	O
15	roles	O
16	.	O

1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	All	O
5	controlled	O
6	trials	O
7	where	O
8	adults	O
9	with	O
10	schizophrenia	O
11	or	O
12	similar	O
13	illnesses	O
14	were	O
15	randomised	O
16	to	O
17	quetiapine	O
18	,	O
19	placebo	O
20	or	O
21	other	O
22	neuroleptic	O
23	drugs	O
24	and	O
25	where	O
26	clinically	O
27	relevant	O
28	outcomes	O
29	were	O
30	reported	O
31	.	O

1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	O
10	3	O
11	-	O
12	44	O
13	.	O
14	3	O
15	%).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	action	O
6	of	O
7	GLP	B
8	-	I
9	1	I
10	at	O
11	the	O
12	CRE	O
13	was	O
14	not	O
15	blocked	O
16	by	O
17	cotransfection	O
18	with	O
19	M1	B
20	-	I
21	CREB	I
22	,	O
23	an	O
24	isoform	O
25	that	O
26	lacks	O
27	a	O
28	consensus	O
29	serine	O
30	residue	O
31	serving	O
32	as	O
33	substrate	O
34	for	O
35	PKA	B
36	-	O
37	mediated	O
38	phosphorylation	O
39	.	O

1	Because	O
2	all	O
3	PDGFbetaR	B
4	fusions	I
5	described	O
6	thus	O
7	far	O
8	result	O
9	in	O
10	splicing	O
11	to	O
12	a	O
13	common	O
14	exon	O
15	of	O
16	this	O
17	gene	O
18	,	O
19	we	O
20	performed	O
21	5	O
22	'-	O
23	rapid	O
24	amplification	O
25	of	O
26	cDNA	O
27	ends	O
28	PCR	O
29	on	O
30	patient	O
31	RNA	O
32	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	essential	O
5	hypertension	O
6	an	O
7	acute	O
8	protein	O
9	load	O
10	induces	O
11	a	O
12	decrease	O
13	in	O
14	GFR	O
15	that	O
16	may	O
17	normalize	O
18	under	O
19	antihypertensive	O
20	treatment	O
21	.	O

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	B
7	-	O
8	Akt	B
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	B
20	.	O

1	Nine	O
2	DNA	O
3	fragments	O
4	that	O
5	were	O
6	specifically	O
7	recognized	O
8	and	O
9	bound	O
10	by	O
11	histidine	O
12	-	O
13	tagged	O
14	AdpA	B
15	were	O
16	isolated	O
17	by	O
18	cycles	O
19	of	O
20	a	O
21	gel	O
22	mobility	O
23	shift	O
24	-	O
25	PCR	O
26	method	O
27	.	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	NTP	O
6	-	O
7	binding	O
8	motif	O
9	is	O
10	important	O
11	for	O
12	Rad24	B
13	function	O
14	,	O
15	we	O
16	mutated	O
17	the	O
18	conserved	O
19	lysine	O
20	(	O
21	115	O
22	)	O
23	residue	O
24	in	O
25	this	O
26	motif	O
27	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	B
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	I
20	gamma1	I
21	SH3	I
22	domain	I
23	.	O

1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	I
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	B
24	in	O
25	vivo	O
26	.	O

1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	B
9	,	O
10	Fli1	B
11	,	O
12	GABPalpha	B
13	,	O
14	SAP1	B
15	,	O
16	Elk1	B
17	,	O
18	and	O
19	PE1	B
20	.	O

1	A	O
2	2	O
3	kb	O
4	transcript	O
5	was	O
6	isolated	O
7	from	O
8	brain	O
9	that	O
10	encodes	O
11	a	O
12	approximately	O
13	57	O
14	kDa	O
15	protein	O
16	;	O
17	the	O
18	predicted	O
19	protein	O
20	contains	O
21	the	O
22	known	O
23	N	B
24	-	I
25	terminal	I
26	Ets	I
27	domain	I
28	of	O
29	PE1	B
30	and	O
31	a	O
32	novel	O
33	C	O
34	-	O
35	terminal	O
36	domain	O
37	with	O
38	signficant	O
39	homology	O
40	to	O
41	murine	B
42	ERF	I
43	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O

1	Wnt	B
2	-	I
3	1	I
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	B
18	-	I
19	1	I
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	B
30	activity	O
31	and	O
32	cyclin	B
33	D1	I
34	levels	O
35	.	O

1	Intravenous	O
2	versus	O
3	oral	O
4	administration	O
5	of	O
6	amitriptyline	O
7	in	O
8	patients	O
9	with	O
10	major	O
11	depression	O
12	.	O

1	Deletion	O
2	of	O
3	the	O
4	RVH	B
5	domain	I
6	resulted	O
7	in	O
8	loss	O
9	of	O
10	Ca	O
11	(	O
12	2	O
13	+)-	O
14	dependent	O
15	activation	O
16	.	O

1	Logistic	O
2	regression	O
3	analysis	O
4	revealed	O
5	that	O
6	physicians	O
7	were	O
8	3	O
9	.	O
10	6	O
11	times	O
12	more	O
13	likely	O
14	to	O
15	detect	O
16	thin	O
17	lesions	O
18	(</=	O
19	0	O
20	.	O
21	75	O
22	mm	O
23	)	O
24	compared	O
25	with	O
26	nonphysician	O
27	detectors	O
28	(	O
29	95	O
30	%	O
31	confidence	O
32	interval	O
33	[	O
34	95	O
35	%	O
36	CI	O
37	],	O
38	2	O
39	.	O
40	1	O
41	,	O
42	6	O
43	.	O
44	5	O
45	;	O
46	P	O
47	=	O
48	0	O
49	.	O
50	0001	O
51	).	O

1	Erythema	O
2	exsudativum	O
3	multiforme	O
4	induced	O
5	by	O
6	granulocyte	B
7	colony	I
8	-	I
9	stimulating	I
10	factor	I
11	in	O
12	an	O
13	allogeneic	O
14	peripheral	O
15	blood	O
16	stem	O
17	cell	O
18	donor	O
19	.	O

1	VaI	O
2	and	O
3	VaII	O
4	co	O
5	-	O
6	immunoprecipitated	O
7	with	O
8	ErbB2	B
9	,	O
10	but	O
11	not	O
12	with	O
13	ErbB1	B
14	,	O
15	ErbB3	B
16	,	O
17	or	O
18	ErbB4	B
19	.	O

1	While	O
2	interactions	O
3	of	O
4	WT	O
5	and	O
6	variant	O
7	TGF	B
8	-	I
9	alpha	I
10	with	O
11	the	O
12	ErbBs	B
13	all	O
14	result	O
15	in	O
16	ErbB2	B
17	activation	O
18	,	O
19	they	O
20	produce	O
21	different	O
22	biological	O
23	consequences	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	various	O
29	TGF	B
30	-	I
31	alpha	I
32	precursors	I
33	differentially	O
34	modulate	O
35	ErbB	B
36	signaling	O
37	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	I
11	terminus	I
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	In	O
2	contrast	O
3	to	O
4	full	B
5	-	I
6	length	I
7	E2F	I
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	I
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	The	O
2	transcription	O
3	factor	O
4	Jun	B
5	(	O
6	c	B
7	-	I
8	Jun	I
9	)	O
10	functions	O
11	as	O
12	a	O
13	recipient	O
14	of	O
15	extracellular	O
16	growth	O
17	signals	O
18	and	O
19	converts	O
20	them	O
21	into	O
22	patterns	O
23	of	O
24	gene	O
25	expression	O
26	.	O

1	Developmental	O
2	toxicity	O
3	of	O
4	the	O
5	class	O
6	III	O
7	antiarrhythmic	O
8	agent	O
9	almokalant	O
10	in	O
11	mice	O
12	.	O

1	This	O
2	compound	O
3	is	O
4	the	O
5	main	O
6	bioactive	O
7	metabolite	O
8	of	O
9	trimebutine	O
10	II	O
11	(	O
12	Debridat	O
13	,	O
14	CAS	O
15	39133	O
16	-	O
17	31	O
18	-	O
19	8	O
20	),	O
21	an	O
22	antispasmodic	O
23	widely	O
24	used	O
25	for	O
26	intestinal	O
27	diseases	O
28	since	O
29	1969	O
30	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	This	O
2	enabled	O
3	the	O
4	formation	O
5	of	O
6	stem	O
7	-	O
8	loop	O
9	templates	O
10	with	O
11	the	O
12	fusion	O
13	point	O
14	of	O
15	the	O
16	chimeric	O
17	transcript	O
18	in	O
19	the	O
20	loop	O
21	and	O
22	the	O
23	use	O
24	of	O
25	MLL	B
26	primers	O
27	in	O
28	two	O
29	-	O
30	sided	O
31	PCR	O
32	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O

1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	Whereas	O
2	MARTA1	B
3	is	O
4	clearly	O
5	detectable	O
6	in	O
7	crude	O
8	lysates	O
9	,	O
10	cytosolic	O
11	and	O
12	ribosomal	O
13	salt	O
14	-	O
15	wash	O
16	fractions	O
17	,	O
18	and	O
19	in	O
20	nuclear	O
21	extracts	O
22	,	O
23	MARTA2	B
24	is	O
25	preferentially	O
26	found	O
27	in	O
28	the	O
29	ribosomal	O
30	salt	O
31	-	O
32	wash	O
33	preparation	O
34	.	O

1	It	O
2	contains	O
3	25	O
4	exons	O
5	coding	O
6	for	O
7	a	O
8	4	O
9	.	O
10	7kb	O
11	transcript	O
12	including	O
13	large	O
14	5	O
15	'-	O
16	and	O
17	3	O
18	'-	O
19	(	O
20	1218bp	O
21	and	O
22	701bp	O
23	,	O
24	respectively	O
25	)	O
26	untranslated	O
27	regions	O
28	(	O
29	UTRs	O
30	).	O

1	Five	O
2	of	O
3	the	O
4	PDP1	B
5	isoforms	I
6	differ	O
7	by	O
8	the	O
9	substitution	O
10	or	O
11	insertion	O
12	of	O
13	amino	O
14	acids	O
15	at	O
16	or	O
17	near	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	of	O
23	the	O
24	protein	O
25	.	O

1	The	O
2	optimum	O
3	technique	O
4	for	O
5	the	O
6	pathological	O
7	examination	O
8	of	O
9	sentinel	O
10	lymph	O
11	nodes	O
12	(	O
13	SLNs	O
14	)	O
15	is	O
16	still	O
17	under	O
18	debate	O
19	.	O

1	Partial	O
2	correction	O
3	of	O
4	anemia	O
5	with	O
6	recombinant	B
7	human	I
8	erythropoietin	I
9	likely	O
10	reduces	O
11	left	O
12	ventricular	O
13	mass	O
14	and	O
15	volume	O
16	.	O

1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	PFA	O
7	-	O
8	100	O
9	analyzer	O
10	can	O
11	accurately	O
12	assess	O
13	vWF	B
14	-	O
15	dependent	O
16	platelet	O
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	shear	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	B
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	B
15	-	I
16	binding	I
17	sequence	I
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O

1	Using	O
2	an	O
3	oligomer	O
4	duplex	O
5	5	O
6	'-	O
7	A	O
8	(	O
9	GGGTTA	O
10	)(	O
11	5	O
12	)-	O
13	3	O
14	'/	O
15	5	O
16	'-(	O
17	TAACCC	O
18	)(	O
19	5	O
20	)	O
21	T	O
22	-	O
23	3	O
24	'	O
25	as	O
26	a	O
27	template	O
28	-	O
29	primer	O
30	,	O
31	we	O
32	show	O
33	that	O
34	both	O
35	the	O
36	Klenow	B
37	fragment	I
38	of	I
39	Escherichia	I
40	coli	I
41	DNA	I
42	polymerase	I
43	I	I
44	and	O
45	HIV	B
46	reverse	I
47	transcriptase	I
48	could	O
49	expand	O
50	telomere	O
51	DNA	O
52	sequences	O
53	as	O
54	well	O
55	,	O
56	giving	O
57	products	O
58	greater	O
59	than	O
60	the	O
61	size	O
62	of	O
63	the	O
64	template	O
65	DNA	O
66	.	O

1	Cdk2	B
2	and	O
3	MAPK	B
4	precipitates	O
5	from	O
6	untreated	O
7	tumor	O
8	lysates	O
9	phosphorylated	O
10	recombinant	B
11	wild	I
12	-	I
13	type	I
14	p27	I
15	but	O
16	not	O
17	the	O
18	T187A	O
19	mutant	O
20	in	O
21	vitro	O
22	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O

1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O

1	The	O
2	effectiveness	O
3	of	O
4	the	O
5	haemodialysate	O
6	Solcoseryl	O
7	for	O
8	second	O
9	-	O
10	intention	O
11	wound	O
12	healing	O
13	in	O
14	horses	O
15	and	O
16	ponies	O
17	.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	These	O
2	findings	O
3	were	O
4	reinforced	O
5	by	O
6	an	O
7	analysis	O
8	that	O
9	was	O
10	restricted	O
11	to	O
12	living	O
13	donor	O
14	transplants	O
15	without	O
16	acute	O
17	rejection	O
18	.	O

1	These	O
2	results	O
3	further	O
4	support	O
5	an	O
6	important	O
7	role	O
8	for	O
9	CBF2	B
10	in	O
11	mediating	O
12	EBNA2	B
13	transactivation	O
14	;	O
15	they	O
16	identify	O
17	the	O
18	hnRNP	B
19	protein	I
20	AUF1	I
21	as	O
22	a	O
23	major	O
24	component	O
25	of	O
26	CBF2	B
27	and	O
28	are	O
29	also	O
30	the	O
31	first	O
32	evidence	O
33	of	O
34	a	O
35	cis	O
36	-	O
37	acting	O
38	sequence	O
39	other	O
40	than	O
41	a	O
42	CBF1	B
43	binding	I
44	element	I
45	that	O
46	is	O
47	able	O
48	to	O
49	confer	O
50	responsiveness	O
51	to	O
52	EBNA2	B
53	.	O

1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	HHV	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	I
36	factor	I
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O

1	Despite	O
2	these	O
3	limitations	O
4	the	O
5	CHIME	O
6	monitor	O
7	provides	O
8	an	O
9	opportunity	O
10	to	O
11	record	O
12	physiological	O
13	data	O
14	previously	O
15	unavailable	O
16	in	O
17	the	O
18	home	O
19	.	O

1	DATA	O
2	SYNTHESIS	O
3	:	O
4	Intracoronary	O
5	ultrasound	O
6	has	O
7	been	O
8	shown	O
9	to	O
10	improve	O
11	upon	O
12	demonstrated	O
13	weaknesses	O
14	of	O
15	coronary	O
16	angiography	O
17	.	O

1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	O
41	BMC	O
42	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	Troglitazone	O
2	also	O
3	induced	O
4	an	O
5	endogenous	B
6	PPARgamma	I
7	target	I
8	gene	I
9	in	O
10	T24	O
11	cells	O
12	,	O
13	adipocyte	B
14	-	I
15	type	I
16	fatty	I
17	acid	I
18	binding	I
19	protein	I
20	(	O
21	A	B
22	-	I
23	FABP	I
24	),	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	correlates	O
30	with	O
31	bladder	O
32	cancer	O
33	differentiation	O
34	.	O

1	Viruses	O
2	were	O
3	isolated	O
4	from	O
5	9	O
6	lungs	O
7	:	O
8	7	O
9	with	O
10	PI	O
11	-	O
12	3V	O
13	,	O
14	1	O
15	with	O
16	NCP	O
17	BVDV	O
18	type	O
19	1	O
20	,	O
21	and	O
22	1	O
23	with	O
24	both	O
25	BVHV	O
26	-	O
27	1	O
28	and	O
29	BVDV	O
30	.	O

1	The	O
2	RS447	B
3	human	I
4	megasatellite	I
5	tandem	I
6	repetitive	I
7	sequence	I
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	Previous	O
2	experience	O
3	and	O
4	contextual	O
5	cues	O
6	are	O
7	essential	O
8	elements	O
9	in	O
10	the	O
11	generation	O
12	of	O
13	a	O
14	subjective	O
15	prediction	O
16	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	B
12	influenza	I
13	virus	I
14	protein	I
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	Collectively	O
2	,	O
3	these	O
4	and	O
5	previously	O
6	published	O
7	data	O
8	suggest	O
9	a	O
10	model	O
11	where	O
12	NS1	B
13	recruits	O
14	eIF4GI	B
15	specifically	O
16	to	O
17	the	O
18	5	O
19	'	O
20	untranslated	O
21	region	O
22	(	O
23	5	O
24	'	O
25	UTR	O
26	)	O
27	of	O
28	the	O
29	viral	O
30	mRNA	O
31	,	O
32	allowing	O
33	for	O
34	the	O
35	preferential	O
36	translation	O
37	of	O
38	the	O
39	influenza	O
40	virus	O
41	messengers	O
42	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	B
5	-	I
6	SAM	I
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	B
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	I
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	B
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	whether	O
8	the	O
9	recently	O
10	identified	O
11	isoforms	O
12	Vav2	B
13	and	O
14	Vav3	B
15	,	O
16	which	O
17	are	O
18	broadly	O
19	expressed	O
20	,	O
21	can	O
22	couple	O
23	with	O
24	similar	O
25	classes	O
26	of	O
27	receptors	O
28	,	O
29	nor	O
30	is	O
31	it	O
32	known	O
33	whether	O
34	all	O
35	Vav	B
36	isoforms	I
37	possess	O
38	identical	O
39	functional	O
40	activities	O
41	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	fbp1	B
5	promoter	I
6	constructs	I
7	containing	O
8	only	O
9	UAS1	O
10	or	O
11	UAS2	O
12	confirms	O
13	that	O
14	the	O
15	PKA	B
16	and	O
17	MAPK	B
18	regulation	O
19	is	O
20	targeted	O
21	to	O
22	both	O
23	sites	O
24	.	O

1	X	O
2	-	O
3	ray	O
4	crystallographic	O
5	data	O
6	show	O
7	that	O
8	the	O
9	PLZF	B
10	BTB	I
11	/	O
12	POZ	O
13	domain	O
14	forms	O
15	an	O
16	obligate	O
17	homodimer	O
18	via	O
19	an	O
20	extensive	O
21	interface	O
22	.	O

1	The	O
2	ability	O
3	of	O
4	SMRT	B
5	to	O
6	associate	O
7	with	O
8	these	O
9	transcription	O
10	factors	O
11	and	O
12	thereby	O
13	to	O
14	mediate	O
15	repression	O
16	is	O
17	strongly	O
18	inhibited	O
19	by	O
20	activation	O
21	of	O
22	tyrosine	B
23	kinase	I
24	signaling	O
25	pathways	O
26	,	O
27	such	O
28	as	O
29	that	O
30	represented	O
31	by	O
32	the	O
33	epidermal	B
34	growth	I
35	factor	I
36	receptor	I
37	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	ketamine	O
6	-	O
7	treated	O
8	rats	O
9	had	O
10	more	O
11	neurons	O
12	and	O
13	glial	O
14	cells	O
15	surrounding	O
16	the	O
17	ventricles	O
18	.	O

1	The	O
2	differences	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	for	O
8	overall	O
9	response	O
10	rate	O
11	p	O
12	=	O
13	0	O
14	.	O
15	004	O
16	;	O
17	power	O
18	(	O
19	for	O
20	p	O
21	=	O
22	0	O
23	.	O
24	05	O
25	)	O
26	85	O
27	%;	O
28	for	O
29	survival	O
30	p	O
31	=	O
32	0	O
33	.	O
34	09	O
35	;	O
36	for	O
37	grade	O
38	IV	O
39	granulocytopenia	O
40	p	O
41	=	O
42	0	O
43	.	O
44	3	O
45	;	O
46	and	O
47	for	O
48	febrile	O
49	neutropenia	O
50	p	O
51	=	O
52	0	O
53	.	O
54	61	O
55	.	O

1	Patients	O
2	were	O
3	randomly	O
4	assigned	O
5	to	O
6	treatment	O
7	with	O
8	the	O
9	ACE	B
10	inhibitor	O
11	perindopril	O
12	(	O
13	and	O
14	the	O
15	diuretic	O
16	indapamide	O
17	for	O
18	those	O
19	with	O
20	no	O
21	definite	O
22	indication	O
23	for	O
24	or	O
25	contraindication	O
26	to	O
27	treatment	O
28	with	O
29	a	O
30	diuretic	O
31	)	O
32	or	O
33	matching	O
34	placebo	O
35	(	O
36	s	O
37	).	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	open	O
7	-	O
8	section	O
9	effect	O
10	decreases	O
11	the	O
12	torsional	O
13	stiffness	O
14	and	O
15	stress	O
16	concentration	O
17	effects	O
18	decrease	O
19	the	O
20	torsional	O
21	strength	O
22	of	O
23	a	O
24	long	O
25	bone	O
26	with	O
27	a	O
28	longitudinal	O
29	defect	O
30	.	O

1	These	O
2	regions	O
3	may	O
4	be	O
5	differentially	O
6	involved	O
7	in	O
8	tissue	O
9	-	O
10	specificity	O
11	,	O
12	and	O
13	/	O
14	or	O
15	circadian	O
16	regulation	O
17	,	O
18	of	O
19	the	O
20	human	B
21	hPer1	I
22	gene	I
23	transcription	O
24	.	O

1	Additionally	O
2	,	O
3	putative	O
4	CF1	B
5	/	O
6	USP	B
7	and	O
8	Broad	B
9	Complex	I
10	Z2	I
11	transcription	O
12	factor	O
13	elements	O
14	were	O
15	found	O
16	in	O
17	the	O
18	upstream	O
19	regions	O
20	of	O
21	MIH	B
22	and	O
23	MO	B
24	-	I
25	IH	I
26	genes	O
27	respectively	O
28	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	B
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O

1	Genomic	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	oas	B
8	gene	I
9	family	I
10	encoding	O
11	O	B
12	-	I
13	acetylserine	I
14	(	I
15	thiol	I
16	)	I
17	lyases	I
18	,	O
19	enzymes	O
20	catalyzing	O
21	the	O
22	final	O
23	step	O
24	in	O
25	cysteine	O
26	biosynthesis	O
27	in	O
28	Arabidopsis	O
29	thaliana	O
30	.	O

1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	B
18	and	O
19	D4Mit147	B
20	in	O
21	both	O
22	progenies	O
23	.	O

1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	B
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	O
19	E6	B
20	/	O
21	E7	B
22	genes	O
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	B
32	protein	I
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	B
42	immunoprecipitated	O
43	with	O
44	anti	B
45	-	I
46	E7	I
47	antibodies	I
48	were	O
49	observed	O
50	.	O

1	Further	O
2	characterization	O
3	of	O
4	these	O
5	putative	O
6	Hoxa	B
7	-	I
8	1	I
9	target	I
10	genes	I
11	will	O
12	aid	O
13	in	O
14	delineating	O
15	the	O
16	functions	O
17	of	O
18	the	O
19	Hoxa	B
20	-	I
21	1	I
22	protein	I
23	in	O
24	the	O
25	differentiation	O
26	processes	O
27	which	O
28	occur	O
29	during	O
30	embryogenesis	O
31	.	O

1	The	O
2	ability	O
3	of	O
4	U6	B
5	-	O
6	U57	B
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	fidelity	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	spliceosome	O
41	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	O
11	non	O
12	-	O
13	O1	O
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O

1	TNF	B
2	-	I
3	alpha	I
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	B
15	-	I
16	2	I
17	(	O
18	COX	B
19	-	I
20	2	I
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	O
30	H292	O
31	epithelial	O
32	cells	O
33	.	O

1	The	O
2	therapy	O
3	time	O
4	to	O
5	deliver	O
6	the	O
7	NCS	O
8	therapeutic	O
9	dose	O
10	of	O
11	10000	O
12	RBE	O
13	-	O
14	cGy	O
15	,	O
16	is	O
17	27	O
18	times	O
19	longer	O
20	when	O
21	157Gd	O
22	is	O
23	used	O
24	instead	O
25	of	O
26	10B	O
27	.	O

1	Mis3	B
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	Losartan	O
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	CONCLUSION	O
2	:	O
3	Vitrectomy	O
4	for	O
5	vitreous	O
6	hemorrhage	O
7	in	O
8	Terson	O
9	syndrome	O
10	is	O
11	a	O
12	safe	O
13	and	O
14	effective	O
15	procedure	O
16	,	O
17	offering	O
18	a	O
19	rapid	O
20	and	O
21	prolonged	O
22	improvement	O
23	in	O
24	vision	O
25	.	O

1	RNA	O
2	in	O
3	situ	O
4	hybridization	O
5	on	O
6	brain	O
7	sections	O
8	of	O
9	normal	O
10	human	O
11	embryos	O
12	revealed	O
13	a	O
14	strong	O
15	labeling	O
16	in	O
17	restricted	O
18	areas	O
19	of	O
20	the	O
21	cerebral	O
22	cortex	O
23	.	O

1	To	O
2	facilitate	O
3	manipulation	O
4	of	O
5	large	O
6	genomic	O
7	sequences	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	method	O
13	of	O
14	converting	O
15	Escherichia	O
16	coli	O
17	P1	O
18	artificial	O
19	chromosomes	O
20	(	O
21	PACs	O
22	)	O
23	into	O
24	yeast	O
25	artificial	O
26	chromosomes	O
27	(	O
28	YACs	O
29	).	O

1	After	O
2	gamma	O
3	-	O
4	irradiation	O
5	,	O
6	the	O
7	majority	O
8	of	O
9	F9	O
10	cells	O
11	undergo	O
12	apoptosis	O
13	implying	O
14	that	O
15	wt	B
16	-	I
17	p53	I
18	likely	O
19	triggers	O
20	pro	O
21	-	O
22	apoptotic	O
23	gene	O
24	expression	O
25	in	O
26	DNA	O
27	damaged	O
28	cells	O
29	.	O

1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	A	O
2	degenerate	O
3	DNA	O
4	transposon	O
5	,	O
6	Pat	B
7	,	O
8	was	O
9	identified	O
10	in	O
11	the	O
12	genomes	O
13	of	O
14	various	O
15	wild	O
16	-	O
17	type	O
18	strains	O
19	of	O
20	the	O
21	filamentous	O
22	fungus	O
23	Podospora	O
24	anserina	O
25	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	Tax	B
7	I	I
8	increased	O
9	the	O
10	extent	O
11	and	O
12	altered	O
13	the	O
14	profile	O
15	of	O
16	proteins	O
17	binding	O
18	TRE	B
19	-	I
20	2	I
21	in	O
22	vivo	O
23	.	O

1	We	O
2	have	O
3	also	O
4	identified	O
5	a	O
6	functional	O
7	domain	O
8	in	O
9	the	O
10	ORF	O
11	50	O
12	protein	O
13	,	O
14	an	O
15	immediate	B
16	-	I
17	early	I
18	gene	I
19	product	I
20	that	O
21	is	O
22	mainly	O
23	encoded	O
24	by	O
25	ORF	O
26	50	O
27	.	O

1	A	O
2	2	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	full	O
8	-	O
9	length	O
10	cDNA	O
11	clone	O
12	of	O
13	an	O
14	Atlantic	B
15	halibut	I
16	Mx	I
17	gene	I
18	was	O
19	isolated	O
20	from	O
21	a	O
22	liver	O
23	cDNA	O
24	library	O
25	.	O

1	PLUS	O
2	-	O
3	3	O
4	is	O
5	a	O
6	new	O
7	Swedish	O
8	protocol	O
9	of	O
10	natural	O
11	speech	O
12	in	O
13	3	O
14	-	O
15	year	O
16	-	O
17	old	O
18	children	O
19	.	O

1	Once	O
2	HIT	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	heparins	O
16	)	O
17	should	O
18	be	O
19	stopped	O
20	immediately	O
21	.	O

1	The	O
2	reduced	O
3	efficiency	O
4	in	O
5	the	O
6	glycosylase	B
7	activity	O
8	is	O
9	also	O
10	reflected	O
11	in	O
12	a	O
13	reduced	O
14	ability	O
15	of	O
16	S120K	B
17	MutY	I
18	to	O
19	prevent	O
20	DNA	O
21	mutations	O
22	in	O
23	vivo	O
24	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	We	O
6	prospectively	O
7	compared	O
8	the	O
9	automated	O
10	measurements	O
11	of	O
12	left	O
13	ventricular	O
14	ejection	O
15	fraction	O
16	(	O
17	LVEF	O
18	)	O
19	and	O
20	volumes	O
21	from	O
22	rest	O
23	-	O
24	injected	O
25	gated	O
26	Technetium	O
27	99m	O
28	(	O
29	Tc99m	O
30	)	O
31	perfusion	O
32	SPECT	O
33	with	O
34	equilibrium	O
35	radionuclide	O
36	angiocardiography	O
37	(	O
38	ERNA	O
39	)	O
40	in	O
41	62	O
42	patients	O
43	and	O
44	the	O
45	assessment	O
46	of	O
47	regional	O
48	function	O
49	with	O
50	echocardiography	O
51	in	O
52	22	O
53	patients	O
54	.	O

1	The	O
2	2	O
3	cDNAs	O
4	differed	O
5	in	O
6	the	O
7	length	O
8	of	O
9	their	O
10	respective	O
11	3	O
12	'	O
13	untranslated	O
14	regions	O
15	,	O
16	of	O
17	577	O
18	bp	O
19	in	O
20	Cp	B
21	.	I
22	F6	I
23	and	O
24	72	O
25	bp	O
26	in	O
27	Cp	B
28	.	I
29	F10	I
30	,	O
31	in	O
32	both	O
33	of	O
34	which	O
35	a	O
36	putative	O
37	polyadenylation	O
38	signal	O
39	was	O
40	identified	O
41	.	O

1	This	O
2	intracellular	O
3	signaling	O
4	,	O
5	known	O
6	as	O
7	the	O
8	unfolded	O
9	protein	O
10	response	O
11	(	O
12	UPR	O
13	),	O
14	is	O
15	mediated	O
16	by	O
17	the	O
18	cis	O
19	-	O
20	acting	O
21	ER	O
22	stress	O
23	response	O
24	element	O
25	(	O
26	ERSE	O
27	)	O
28	in	O
29	mammals	O
30	.	O

1	A	O
2	Y	B
3	.	I
4	lipolytica	I
5	Kar2p	I
6	mutant	I
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	Sls1p	B
15	mutant	I
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	Sls1p	B
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O

1	We	O
2	have	O
3	carried	O
4	out	O
5	a	O
6	comprehensive	O
7	and	O
8	systematic	O
9	mutagenesis	O
10	of	O
11	the	O
12	Cse4p	B
13	N	I
14	terminus	I
15	to	O
16	analyze	O
17	its	O
18	function	O
19	.	O

1	The	O
2	spacing	O
3	of	O
4	the	O
5	essential	O
6	N	O
7	-	O
8	terminal	O
9	domain	O
10	(	O
11	END	O
12	)	O
13	relative	O
14	to	O
15	the	O
16	HFD	B
17	can	O
18	be	O
19	changed	O
20	significantly	O
21	without	O
22	an	O
23	apparent	O
24	effect	O
25	on	O
26	Cse4p	B
27	function	O
28	.	O

1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O

1	In	O
2	invertebrates	O
3	,	O
4	Fhit	B
5	is	O
6	encoded	O
7	as	O
8	a	O
9	fusion	O
10	protein	O
11	with	O
12	Nit	B
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	nitrilase	B
19	superfamily	I
20	.	O

1	Platelet	O
2	counts	O
3	and	O
4	function	O
5	as	O
6	well	O
7	as	O
8	fibrinogen	B
9	and	O
10	von	B
11	Willebrand	I
12	factor	I
13	(	O
14	vWF	B
15	)	O
16	levels	O
17	were	O
18	determined	O
19	in	O
20	each	O
21	sample	O
22	.	O

1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O

1	A	O
2	beta2	B
3	RARE	I
4	reporter	I
5	construct	I
6	in	O
7	which	O
8	the	O
9	methylation	O
10	-	O
11	susceptible	O
12	cytosines	O
13	in	O
14	the	O
15	sense	O
16	strand	O
17	were	O
18	replaced	O
19	by	O
20	thymine	O
21	displayed	O
22	marked	O
23	loss	O
24	of	O
25	activity	O
26	in	O
27	a	O
28	replicated	O
29	chromatin	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Non	O
2	-	O
3	poliomyelitis	O
4	AFP	O
5	rate	O
6	had	O
7	increased	O
8	from	O
9	0	O
10	.	O
11	9	O
12	in	O
13	1997	O
14	to	O
15	2	O
16	.	O
17	8	O
18	in	O
19	1998	O
20	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	Multiparity	O
2	had	O
3	a	O
4	protective	O
5	effect	O
6	with	O
7	0	O
8	.	O
9	66	O
10	less	O
11	risk	O
12	(	O
13	95	O
14	%	O
15	CI	O
16	0	O
17	.	O
18	44	O
19	-	O
20	0	O
21	.	O
22	99	O
23	).	O

1	Picture	O
2	the	O
3	smell	O
4	.	O

1	The	O
2	aim	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	level	O
11	of	O
12	oxidative	O
13	stress	O
14	in	O
15	healthy	O
16	controls	O
17	(	O
18	CTL	O
19	)	O
20	compared	O
21	with	O
22	CRF	O
23	and	O
24	HD	O
25	patients	O
26	before	O
27	(	O
28	pre	O
29	-	O
30	HD	O
31	)	O
32	and	O
33	after	O
34	(	O
35	post	O
36	-	O
37	HD	O
38	)	O
39	the	O
40	dialysis	O
41	session	O
42	,	O
43	carried	O
44	out	O
45	on	O
46	a	O
47	high	O
48	biocompatible	O
49	polyacrylonitrile	O
50	membrane	O
51	AN69	O
52	.	O

1	Indirect	O
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O

1	Only	O
2	two	O
3	of	O
4	27	O
5	participants	O
6	(	O
7	7	O
8	.	O
9	4	O
10	%)	O
11	with	O
12	definite	O
13	POAG	O
14	had	O
15	been	O
16	previously	O
17	diagnosed	O
18	and	O
19	treated	O
20	,	O
21	and	O
22	66	O
23	.	O
24	7	O
25	%	O
26	of	O
27	the	O
28	previously	O
29	undiagnosed	O
30	had	O
31	IOP	O
32	less	O
33	than	O
34	22	O
35	mmHg	O
36	.	O

1	Taken	O
2	together	O
3	,	O
4	they	O
5	uphold	O
6	the	O
7	emerging	O
8	concern	O
9	that	O
10	women	O
11	with	O
12	ER	B
13	(+)	I
14	cancers	O
15	may	O
16	not	O
17	benefit	O
18	significantly	O
19	from	O
20	endocrine	O
21	treatment	O
22	if	O
23	the	O
24	tumors	O
25	also	O
26	overexpress	O
27	HER	B
28	-	I
29	2	I
30	.	O

1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	mos	B
15	oncogenes	I
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	MKK	B
38	)	O
39	inhibitor	O
40	PD98059	O
41	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Cktsf1b1	B
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	B
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	INTERVENTIONS	O
2	:	O
3	Subcutaneous	O
4	tissue	O
5	PO2	O
6	and	O
7	PCO2	O
8	tensions	O
9	were	O
10	measured	O
11	directly	O
12	in	O
13	patients	O
14	with	O
15	necrotising	O
16	fasciitis	O
17	and	O
18	in	O
19	healthy	O
20	volunteers	O
21	during	O
22	normobaric	O
23	and	O
24	hyperbaric	O
25	conditions	O
26	.	O

1	Because	O
2	GH	B
3	-	O
4	induced	O
5	Akt	B
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	LY294002	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	wortmannin	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	IRS	B
31	-	I
32	1	I
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	B
39	-	O
40	induced	O
41	MAP	B
42	kinase	I
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	wortmannin	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	PI3K	B
61	in	O
62	mediation	O
63	of	O
64	GH	B
65	-	O
66	induced	O
67	MAP	B
68	kinase	I
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O

1	Insulin	B
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	B
11	hormone	I
12	-	O
13	induced	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	.	O

1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	O
21	invasive	O
22	feature	O
23	and	O
24	good	O
25	spatial	O
26	resolution	O
27	.	O

1	After	O
2	declamping	O
3	of	O
4	the	O
5	aorta	O
6	,	O
7	there	O
8	were	O
9	also	O
10	severe	O
11	edema	O
12	,	O
13	local	O
14	fibre	O
15	necrosis	O
16	,	O
17	and	O
18	adhesion	O
19	of	O
20	leucocytes	O
21	,	O
22	whereas	O
23	muscle	O
24	fibre	O
25	areas	O
26	became	O
27	3	O
28	,	O
29	935	O
30	.	O
31	18	O
32	micro	O
33	531	O
34	microm	O
35	(	O
36	2	O
37	)	O
38	for	O
39	type	O
40	I	O
41	and	O
42	5	O
43	,	O
44	804	O
45	+/-	O
46	1	O
47	,	O
48	075	O
49	microm	O
50	(	O
51	2	O
52	)	O
53	for	O
54	type	O
55	II	O
56	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O

1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O

1	Genomic	O
2	libraries	O
3	were	O
4	stored	O
5	as	O
6	frozen	O
7	cultures	O
8	in	O
9	a	O
10	96	O
11	-	O
12	well	O
13	format	O
14	,	O
15	each	O
16	well	O
17	containing	O
18	approximately	O
19	300	O
20	-	O
21	600	O
22	colonies	O
23	(	O
24	12	O
25	plates	O
26	for	O
27	small	O
28	library	O
29	,	O
30	four	O
31	for	O
32	medium	O
33	-	O
34	size	O
35	library	O
36	and	O
37	four	O
38	for	O
39	large	O
40	library	O
41	).	O

1	In	O
2	several	O
3	cell	O
4	lines	O
5	,	O
6	mTOR	B
7	or	O
8	its	O
9	downstream	O
10	targets	O
11	can	O
12	be	O
13	regulated	O
14	by	O
15	phosphatidylinositol	B
16	(	I
17	PI	I
18	)	I
19	3	I
20	-	I
21	kinase	I
22	;	O
23	protein	B
24	kinases	I
25	A	I
26	,	I
27	B	I
28	,	I
29	and	I
30	C	I
31	;	O
32	heterotrimeric	B
33	G	I
34	-	I
35	proteins	I
36	;	O
37	a	O
38	PD98059	O
39	-	O
40	sensitive	O
41	kinase	O
42	or	O
43	calcium	O
44	;	O
45	as	O
46	well	O
47	as	O
48	by	O
49	amino	O
50	acids	O
51	.	O

1	The	O
2	tumor	B
3	-	I
4	suppressor	I
5	protein	I
6	p53	I
7	is	O
8	involved	O
9	in	O
10	maintaining	O
11	genomic	O
12	stability	O
13	.	O

1	Abrogation	O
2	of	O
3	p53	B
4	function	O
5	by	O
6	E6	B
7	resulted	O
8	in	O
9	an	O
10	increase	O
11	in	O
12	the	O
13	spontaneous	O
14	mutation	O
15	frequencies	O
16	at	O
17	the	O
18	heterozygous	O
19	thymidine	B
20	kinase	I
21	(	O
22	TK	B
23	)	O
24	locus	O
25	but	O
26	not	O
27	at	O
28	the	O
29	hemizygous	O
30	hypoxanthine	B
31	phosphoribosyl	I
32	transferase	I
33	(	O
34	HPRT	B
35	)	O
36	locus	O
37	.	O

1	Cytogenetic	O
2	analysis	O
3	of	O
4	LOH	O
5	mutants	O
6	by	O
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	O
18	,	O
19	in	O
20	which	O
21	partial	O
22	chromosome	O
23	deletions	O
24	,	O
25	amplifications	O
26	,	O
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	O
33	a	O
34	single	O
35	mutant	O
36	.	O

1	These	O
2	results	O
3	support	O
4	a	O
5	model	O
6	in	O
7	which	O
8	p53	B
9	protein	I
10	contributes	O
11	to	O
12	the	O
13	maintenance	O
14	of	O
15	genomic	O
16	integrity	O
17	through	O
18	recombinational	O
19	repair	O
20	.	O

1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	schistosomiasis	O
10	in	O
11	the	O
12	State	O
13	of	O
14	Pernambuco	O
15	relies	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	drastic	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O

1	In	O
2	patients	O
3	with	O
4	type	O
5	II	O
6	tumors	O
7	,	O
8	the	O
9	pattern	O
10	of	O
11	lymphatic	O
12	spread	O
13	was	O
14	primarily	O
15	directed	O
16	toward	O
17	the	O
18	paracardial	O
19	,	O
20	lesser	O
21	curvature	O
22	,	O
23	and	O
24	left	O
25	gastric	O
26	artery	O
27	nodes	O
28	;	O
29	esophagectomy	O
30	offered	O
31	no	O
32	survival	O
33	benefit	O
34	over	O
35	extended	O
36	gastrectomy	O
37	in	O
38	these	O
39	patients	O
40	.	O

1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O

1	We	O
2	screened	O
3	a	O
4	K562	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	MZF1B	B
13	and	O
14	MZF1C	B
15	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	O
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	B
33	domains	I
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	B
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O

1	Parathyroid	B
2	hormone	I
3	regulation	O
4	of	O
5	bone	B
6	sialoprotein	I
7	(	O
8	BSP	B
9	)	O
10	gene	O
11	transcription	O
12	is	O
13	mediated	O
14	through	O
15	a	O
16	pituitary	B
17	-	I
18	specific	I
19	transcription	I
20	factor	I
21	-	I
22	1	I
23	(	O
24	Pit	B
25	-	I
26	1	I
27	)	O
28	motif	O
29	in	O
30	the	O
31	rat	B
32	BSP	I
33	gene	I
34	promoter	I
35	.	O

1	Recent	O
2	target	O
3	BP	O
4	goals	O
5	promulgated	O
6	by	O
7	the	O
8	Sixth	O
9	Report	O
10	from	O
11	the	O
12	Joint	O
13	National	O
14	Committee	O
15	(	O
16	JNC	O
17	VI	O
18	)	O
19	are	O
20	based	O
21	on	O
22	the	O
23	premise	O
24	that	O
25	the	O
26	intensity	O
27	of	O
28	treatment	O
29	directly	O
30	corresponds	O
31	to	O
32	the	O
33	magnitude	O
34	of	O
35	pretreatment	O
36	risk	O
37	.	O

1	Linking	O
2	continuous	O
3	community	O
4	-	O
5	based	O
6	morbidity	O
7	recording	O
8	of	O
9	influenza	O
10	-	O
11	like	O
12	illness	O
13	(	O
14	ILI	O
15	)	O
16	with	O
17	virological	O
18	sampling	O
19	has	O
20	consistently	O
21	proved	O
22	its	O
23	value	O
24	as	O
25	one	O
26	of	O
27	the	O
28	earliest	O
29	indicators	O
30	of	O
31	circulating	O
32	influenza	O
33	activity	O
34	.	O

1	The	O
2	muskox	O
3	is	O
4	a	O
5	new	O
6	host	O
7	record	O
8	for	O
9	T	O
10	.	O
11	gondii	O
12	.	O

1	These	O
2	include	O
3	NPF	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	heptad	O
9	repeat	O
10	enriched	O
11	in	O
12	charged	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	I
22	like	I
23	and	O
24	/	O
25	or	O
26	WW	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	amphiphilic	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	this	O
6	difference	O
7	is	O
8	due	O
9	to	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	Mot3	B
15	binding	I
16	site	I
17	in	O
18	OpA	B
19	.	O

1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O

1	Mucosal	O
2	application	O
3	of	O
4	NCX	O
5	-	O
6	4016	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O

1	Functional	O
2	recognition	O
3	of	O
4	5	O
5	'	O
6	splice	O
7	site	O
8	by	O
9	U4	B
10	/	O
11	U6	B
12	.	O
13	U5	B
14	tri	O
15	-	O
16	snRNP	O
17	defines	O
18	a	O
19	novel	O
20	ATP	O
21	-	O
22	dependent	O
23	step	O
24	in	O
25	early	O
26	spliceosome	O
27	assembly	O
28	.	O

1	As	O
2	control	O
3	,	O
4	the	O
5	cells	O
6	were	O
7	transfected	O
8	with	O
9	DNA	O
10	mixtures	O
11	containing	O
12	vector	O
13	mU6	O
14	-	O
15	C1	O
16	or	O
17	mU6	O
18	-	O
19	C2	O
20	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	matrilysin	B
7	-	I
8	2	I
9	also	O
10	contains	O
11	a	O
12	threonine	O
13	residue	O
14	adjacent	O
15	to	O
16	the	O
17	Zn	O
18	-	O
19	binding	O
20	site	O
21	that	O
22	has	O
23	been	O
24	defined	O
25	as	O
26	a	O
27	specific	O
28	feature	O
29	of	O
30	matrilysin	B
31	.	O

1	In	O
2	this	O
3	regard	O
4	,	O
5	we	O
6	have	O
7	recently	O
8	observed	O
9	that	O
10	a	O
11	constitutively	O
12	active	O
13	G	B
14	protein	I
15	-	I
16	coupled	I
17	receptor	I
18	(	O
19	GPCR	B
20	)	O
21	encoded	O
22	by	O
23	the	O
24	Kaposi	O
25	'	O
26	s	O
27	sarcoma	O
28	-	O
29	associated	O
30	herpes	O
31	virus	O
32	(	O
33	KSHV	O
34	)/	O
35	human	O
36	herpes	O
37	virus	O
38	8	O
39	is	O
40	oncogenic	O
41	and	O
42	stimulates	O
43	angiogenesis	O
44	by	O
45	increasing	O
46	the	O
47	secretion	O
48	of	O
49	vascular	B
50	endothelial	I
51	growth	I
52	factor	I
53	(	O
54	VEGF	B
55	),	O
56	which	O
57	is	O
58	a	O
59	key	O
60	angiogenic	O
61	stimulator	O
62	and	O
63	a	O
64	critical	O
65	mitogen	O
66	for	O
67	the	O
68	development	O
69	of	O
70	Kaposi	O
71	'	O
72	s	O
73	sarcoma	O
74	.	O

1	No	O
2	specific	O
3	subgroup	O
4	of	O
5	clients	O
6	benefited	O
7	more	O
8	from	O
9	URD	O
10	,	O
11	although	O
12	a	O
13	prospective	O
14	study	O
15	employing	O
16	random	O
17	assignment	O
18	might	O
19	be	O
20	more	O
21	successful	O
22	in	O
23	identifying	O
24	such	O
25	a	O
26	group	O
27	.	O

1	In	O
2	the	O
3	lattice	O
4	,	O
5	23	O
6	%	O
7	of	O
8	the	O
9	sites	O
10	are	O
11	occupied	O
12	,	O
13	95	O
14	%	O
15	of	O
16	the	O
17	atoms	O
18	are	O
19	in	O
20	the	O
21	lowest	O
22	energy	O
23	magnetic	O
24	sublevel	O
25	,	O
26	and	O
27	37	O
28	%	O
29	are	O
30	in	O
31	the	O
32	lowest	O
33	3D	O
34	vibrational	O
35	state	O
36	.	O

1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O

1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	B
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O

1	Regarding	O
2	"	O
3	the	O
4	relation	O
5	between	O
6	sexual	O
7	orientation	O
8	and	O
9	penile	O
10	size	O
11	,"	O
12	by	O
13	A	O
14	.	O

1	This	O
2	slope	O
3	was	O
4	further	O
5	significantly	O
6	decreased	O
7	at	O
8	5	O
9	min	O
10	ischemia	O
11	(-	O
12	26	O
13	.	O
14	5	O
15	+/-	O
16	8	O
17	.	O
18	8	O
19	microm	O
20	/	O
21	mmHg	O
22	)	O
23	but	O
24	returned	O
25	toward	O
26	control	O
27	values	O
28	in	O
29	short	O
30	-	O
31	term	O
32	hibernating	O
33	myocardium	O
34	at	O
35	90	O
36	min	O
37	ischemia	O
38	(-	O
39	17	O
40	.	O
41	2	O
42	+/-	O
43	6	O
44	.	O
45	6	O
46	microm	O
47	/	O
48	mmHg	O
49	).	O

1	Whereas	O
2	both	O
3	MAP	O
4	and	O
5	MSNA	O
6	increase	O
7	during	O
8	SHG	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	SHG	O
14	to	O
15	PHI	O
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	O
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	MSNA	O
29	,	O
30	facilitating	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O

1	Analysis	O
2	of	O
3	Standard	O
4	Reference	O
5	Material	O
6	1846	O
7	,	O
8	Infant	O
9	Formula	O
10	,	O
11	gave	O
12	a	O
13	mean	O
14	value	O
15	of	O
16	0	O
17	.	O
18	95	O
19	+/-	O
20	0	O
21	.	O
22	088	O
23	mg	O
24	vitamin	O
25	K	O
26	/	O
27	kg	O
28	(	O
29	K	O
30	or	O
31	K1	O
32	?)	O
33	(	O
34	n	O
35	=	O
36	31	O
37	)	O
38	with	O
39	a	O
40	coefficient	O
41	of	O
42	variation	O
43	of	O
44	9	O
45	.	O
46	26	O
47	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	the	O
7	STORP	B
8	gene	I
9	has	O
10	a	O
11	ubiquitous	O
12	pattern	O
13	of	O
14	expression	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	PML	B
21	gene	I
22	.	O

1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O

1	The	O
2	Spo0F	B
3	residues	I
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	O
33	pairs	O
34	.	O

1	The	O
2	psychologic	O
3	factors	O
4	associated	O
5	wth	O
6	serious	O
7	illness	O
8	,	O
9	terminal	O
10	prognoses	O
11	,	O
12	and	O
13	dying	O
14	complicate	O
15	the	O
16	scenario	O
17	even	O
18	more	O
19	as	O
20	compared	O
21	with	O
22	that	O
23	of	O
24	nonmalignant	O
25	pain	O
26	.	O

1	However	O
2	,	O
3	if	O
4	the	O
5	spatial	O
6	resolution	O
7	is	O
8	not	O
9	critical	O
10	and	O
11	interest	O
12	is	O
13	to	O
14	compare	O
15	a	O
16	pathologic	O
17	area	O
18	with	O
19	a	O
20	contralateral	O
21	VOI	O
22	,	O
23	then	O
24	the	O
25	acquisition	O
26	of	O
27	two	O
28	single	O
29	-	O
30	voxel	O
31	spectra	O
32	may	O
33	be	O
34	preferred	O
35	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	cortical	O
9	evoked	O
10	potentials	O
11	(	O
12	amplitude	O
13	of	O
14	the	O
15	N2	O
16	/	O
17	P2	O
18	peak	O
19	)	O
20	increased	O
21	from	O
22	5	O
23	.	O
24	1	O
25	+/-	O
26	0	O
27	.	O
28	7	O
29	microV	O
30	at	O
31	5	O
32	mA	O
33	to	O
34	16	O
35	.	O
36	3	O
37	+/-	O
38	1	O
39	.	O
40	1	O
41	microV	O
42	at	O
43	20	O
44	mA	O
45	.	O

1	While	O
2	mutations	O
3	in	O
4	K	B
5	-	I
6	Rev	I
7	that	O
8	inactivate	O
9	any	O
10	one	O
11	of	O
12	these	O
13	properties	O
14	also	O
15	blocked	O
16	K	B
17	-	I
18	Rev	I
19	-	O
20	dependent	O
21	nuclear	O
22	RNA	O
23	export	O
24	,	O
25	several	O
26	K	B
27	-	I
28	Rev	I
29	mutants	I
30	were	O
31	comparable	O
32	to	O
33	wild	O
34	type	O
35	when	O
36	assayed	O
37	for	O
38	any	O
39	of	O
40	these	O
41	individual	O
42	activities	O
43	yet	O
44	nevertheless	O
45	defective	O
46	for	O
47	RNA	O
48	export	O
49	.	O

1	LMP	B
2	-	I
3	1	I
4	is	O
5	targeted	O
6	to	O
7	the	O
8	plasma	O
9	membrane	O
10	,	O
11	where	O
12	it	O
13	binds	O
14	TRAF	B
15	,	O
16	TRADD	B
17	,	O
18	and	O
19	JAK	B
20	molecules	I
21	to	O
22	activate	O
23	NF	B
24	-	I
25	kappaB	I
26	-,	O
27	AP	B
28	-	I
29	1	I
30	-,	O
31	and	O
32	STAT	B
33	-	O
34	dependent	O
35	pathways	O
36	as	O
37	does	O
38	CD40	B
39	.	O

1	Identification	O
2	of	O
3	an	O
4	enhancer	O
5	and	O
6	an	O
7	alternative	O
8	promoter	O
9	in	O
10	the	O
11	first	O
12	intron	O
13	of	O
14	the	O
15	alpha	B
16	-	I
17	fetoprotein	I
18	gene	I
19	.	O

1	Studying	O
2	intracellular	O
3	signaling	O
4	pathways	O
5	,	O
6	which	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	malignant	O
12	transformation	O
13	of	O
14	Ret	B
15	-	I
16	9bp	I
17	expressing	O
18	NIH3T3	O
19	cells	O
20	,	O
21	we	O
22	could	O
23	demonstrate	O
24	Ret	B
25	-	I
26	9bp	I
27	dependent	O
28	phosphorylation	O
29	of	O
30	insulin	B
31	receptor	I
32	substrate	I
33	-	I
34	2	I
35	(	O
36	IRS	B
37	-	I
38	2	I
39	)	O
40	with	O
41	consecutive	O
42	activation	O
43	of	O
44	phosphatidylinositol	B
45	3	I
46	-	I
47	kinase	I
48	(	O
49	PI	B
50	3	I
51	-	I
52	kinase	I
53	)	O
54	and	O
55	protein	B
56	kinase	I
57	B	I
58	(	O
59	PKB	B
60	/	O
61	AKT	B
62	).	O

1	METHODS	O
2	:	O
3	In	O
4	the	O
5	current	O
6	study	O
7	the	O
8	authors	O
9	reported	O
10	on	O
11	PPB	O
12	cases	O
13	from	O
14	a	O
15	national	O
16	retrospective	O
17	search	O
18	performed	O
19	in	O
20	18	O
21	Italian	O
22	Associations	O
23	for	O
24	Pediatric	O
25	Hematology	O
26	and	O
27	Oncology	O
28	centers	O
29	.	O

1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O

1	Mutating	O
2	the	O
3	Fcp1p	B
4	-	O
5	binding	O
6	motif	O
7	KEFGK	O
8	in	O
9	the	O
10	RAP74	B
11	(	O
12	Tfg1p	B
13	)	O
14	subunit	O
15	of	O
16	TFIIF	B
17	to	O
18	EEFGE	O
19	led	O
20	to	O
21	both	O
22	synthetic	O
23	phenotypes	O
24	in	O
25	certain	O
26	fcp1	B
27	tfg1	I
28	double	O
29	mutants	O
30	and	O
31	a	O
32	reduced	O
33	ability	O
34	of	O
35	Fcp1p	B
36	to	O
37	activate	O
38	transcription	O
39	when	O
40	it	O
41	is	O
42	artificially	O
43	tethered	O
44	to	O
45	a	O
46	promoter	O
47	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Cdc42p	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	pheromone	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	PAK	B
19	Ste20p	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O

1	Deletion	O
2	of	O
3	an	O
4	intergenic	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	B
15	beta	I
16	-	I
17	globin	I
18	locus	I
19	construct	I
20	results	O
21	in	O
22	delayed	O
23	human	B
24	gamma	I
25	-	I
26	to	I
27	beta	I
28	-	I
29	globin	I
30	switching	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	PYR	B
39	complex	I
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	switch	O
45	.	O

1	The	O
2	product	O
3	of	O
4	rat	B
5	gene	I
6	33	I
7	was	O
8	identified	O
9	as	O
10	an	O
11	ErbB	B
12	-	I
13	2	I
14	-	I
15	interacting	I
16	protein	I
17	in	O
18	a	O
19	two	O
20	-	O
21	hybrid	O
22	screen	O
23	employing	O
24	the	O
25	ErbB	B
26	-	I
27	2	I
28	juxtamembrane	I
29	and	I
30	kinase	I
31	domains	I
32	as	O
33	bait	O
34	.	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	B
24	endothelial	I
25	growth	I
26	factor	I
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	These	O
2	results	O
3	demonstrate	O
4	Ras	B
5	-	O
6	and	O
7	Raf	B
8	-	O
9	independent	O
10	ERK	B
11	MAPK	O
12	activation	O
13	maintains	O
14	cell	O
15	viability	O
16	following	O
17	heat	O
18	shock	O
19	.	O

1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	B
5	leucine	I
6	zipper	I
7	(	I
8	bZIP	I
9	)-	I
10	type	I
11	ABRE	I
12	-	I
13	binding	I
14	proteins	I
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	B
29	,	O
30	AREB2	B
31	,	O
32	and	O
33	AREB3	B
34	(	O
35	ABA	B
36	-	I
37	responsive	I
38	element	I
39	binding	I
40	protein	I
41	).	O

1	Recombinant	O
2	AROM	B
3	-	O
4	p64	B
5	displayed	O
6	high	O
7	binding	O
8	to	O
9	single	O
10	-	O
11	stranded	O
12	DNA	O
13	and	O
14	poly	O
15	(	O
16	A	O
17	)	O
18	homopolymers	O
19	suggesting	O
20	that	O
21	this	O
22	protein	O
23	could	O
24	play	O
25	a	O
26	role	O
27	in	O
28	mRNA	O
29	maturation	O
30	/	O
31	metabolism	O
32	.	O

1	The	O
2	protein	B
3	-	I
4	tyrosine	I
5	kinase	I
6	fer	I
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	B
13	receptor	I
14	substrate	I
15	-	I
16	1	I
17	and	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	.	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	In	O
2	the	O
3	PMR	O
4	target	O
5	area	O
6	but	O
7	not	O
8	in	O
9	the	O
10	nontreated	O
11	area	O
12	an	O
13	improvement	O
14	in	O
15	regional	O
16	myocardial	O
17	flow	O
18	reserve	O
19	occurs	O
20	in	O
21	wall	O
22	segments	O
23	with	O
24	initially	O
25	severely	O
26	or	O
27	moderately	O
28	reduced	O
29	stress	O
30	perfusion	O
31	.	O

1	Analysis	O
2	of	O
3	intron	O
4	/	O
5	exon	O
6	boundaries	O
7	of	O
8	the	O
9	genomic	O
10	BAC	O
11	clones	O
12	demonstrate	O
13	that	O
14	junctin	B
15	,	O
16	junctate	B
17	,	O
18	and	O
19	aspartyl	B
20	beta	I
21	-	I
22	hydroxylase	I
23	result	O
24	from	O
25	alternative	O
26	splicing	O
27	of	O
28	the	O
29	same	O
30	gene	O
31	.	O

1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	B
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	O
15	all	O
16	forms	O
17	of	O
18	solid	O
19	tumors	O
20	.	O

1	We	O
2	have	O
3	demonstrated	O
4	that	O
5	the	O
6	activity	O
7	of	O
8	ILK	B
9	is	O
10	constitutively	O
11	elevated	O
12	in	O
13	PTEN	B
14	mutant	I
15	cells	O
16	.	O

1	The	O
2	growth	B
3	factor	I
4	receptor	I
5	-	I
6	bound	I
7	protein	I
8	2	I
9	(	O
10	Grb2	B
11	)	O
12	adaptor	O
13	when	O
14	complexed	O
15	with	O
16	Sos	B
17	(	O
18	Son	B
19	of	I
20	sevenless	I
21	),	O
22	the	O
23	exchange	O
24	factor	O
25	of	O
26	Ras	B
27	,	O
28	conveys	O
29	the	O
30	signal	O
31	induced	O
32	by	O
33	tyrosine	B
34	kinase	I
35	-	I
36	activated	I
37	receptor	I
38	to	O
39	Ras	B
40	by	O
41	recruiting	O
42	Sos	B
43	to	O
44	the	O
45	membrane	O
46	,	O
47	allowing	O
48	activation	O
49	of	O
50	Ras	B
51	.	O

1	Mutations	O
2	in	O
3	genes	O
4	encoding	O
5	PR65	B
6	/	I
7	A	I
8	subunits	I
9	have	O
10	been	O
11	identified	O
12	in	O
13	several	O
14	different	O
15	human	O
16	cancers	O
17	and	O
18	the	O
19	PP2A	B
20	inhibitor	O
21	,	O
22	termed	O
23	fostriecin	O
24	,	O
25	is	O
26	being	O
27	tested	O
28	as	O
29	an	O
30	anticancer	O
31	drug	O
32	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	segment	O
7	of	O
8	dxr	B
9	was	O
10	amplified	O
11	from	O
12	Synechococcus	O
13	leopoliensis	O
14	SAUG	O
15	1402	O
16	-	O
17	1	O
18	DNA	O
19	via	O
20	PCR	O
21	using	O
22	oligonucleotides	O
23	for	O
24	conserved	O
25	regions	O
26	.	O

1	Perceptual	O
2	learning	O
3	for	O
4	a	O
5	pattern	O
6	discrimination	O
7	task	O
8	.	O

1	The	O
2	detector	O
3	has	O
4	the	O
5	advantage	O
6	of	O
7	finding	O
8	both	O
9	ST	O
10	segment	O
11	deviations	O
12	and	O
13	entire	O
14	ST	O
15	-	O
16	T	O
17	complex	O
18	changes	O
19	thereby	O
20	providing	O
21	a	O
22	wider	O
23	characterization	O
24	of	O
25	the	O
26	potential	O
27	ischemic	O
28	events	O
29	.	O

1	While	O
2	this	O
3	Saccharomyces	O
4	cerevisiae	O
5	SIN4	B
6	gene	I
7	product	I
8	is	O
9	a	O
10	component	O
11	of	O
12	a	O
13	mediator	O
14	complex	O
15	associated	O
16	with	O
17	RNA	B
18	polymerase	I
19	II	I
20	,	O
21	various	O
22	studies	O
23	suggest	O
24	the	O
25	involvement	O
26	of	O
27	Sin4	B
28	in	O
29	the	O
30	alteration	O
31	of	O
32	higher	O
33	-	O
34	order	O
35	chromatin	O
36	structure	O
37	.	O

1	Primary	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	drive	O
7	in	O
8	obesity	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	noncanonical	O
6	C	B
7	/	I
8	EBP	I
9	-	I
10	binding	I
11	site	I
12	within	O
13	the	O
14	Gadd45gamma	B
15	promoter	I
16	where	O
17	C	B
18	/	I
19	EBPbeta	I
20	and	O
21	C	B
22	/	I
23	EBPdelta	I
24	could	O
25	bind	O
26	,	O
27	was	O
28	identified	O
29	by	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assay	O
34	(	O
35	EMSA	O
36	)	O
37	and	O
38	reporter	O
39	gene	O
40	analysis	O
41	.	O

1	Src	B
2	activation	O
3	induced	O
4	by	O
5	FGF1	B
6	was	O
7	blocked	O
8	by	O
9	the	O
10	SH2	B
11	domain	I
12	of	O
13	Src	B
14	and	O
15	PP2	B
16	,	O
17	a	O
18	specific	O
19	inhibitor	O
20	of	O
21	Src	B
22	.	O

1	The	O
2	use	O
3	of	O
4	the	O
5	PLCgamma	B
6	inhibitory	I
7	peptide	I
8	,	O
9	neomycin	O
10	and	O
11	the	O
12	calcium	O
13	chelator	O
14	BAPTA	O
15	-	O
16	AM	O
17	on	O
18	oocytes	O
19	expressing	O
20	FGFR1	B
21	or	O
22	the	O
23	stimulation	O
24	by	O
25	PDGF	B
26	-	I
27	BB	I
28	of	O
29	oocytes	O
30	expressing	O
31	PDGFR	B
32	-	O
33	FGFR1	B
34	mutated	O
35	on	O
36	the	O
37	PLCgamma	B
38	binding	I
39	site	I
40	,	O
41	prevented	O
42	GVBD	O
43	and	O
44	ERK2	B
45	phosphorylation	O
46	.	O

1	Multiple	O
2	transcription	O
3	start	O
4	sites	O
5	were	O
6	revealed	O
7	by	O
8	primer	O
9	extension	O
10	analysis	O
11	of	O
12	the	O
13	mouse	O
14	gene	O
15	,	O
16	and	O
17	transfection	O
18	constructs	O
19	containing	O
20	the	O
21	prospective	O
22	promoter	O
23	generated	O
24	transcriptional	O
25	activity	O
26	comparable	O
27	to	O
28	that	O
29	of	O
30	the	O
31	SV40	B
32	promoter	I
33	.	O

1	From	O
2	two	O
3	inhibitor	O
4	scaffolds	O
5	,	O
6	we	O
7	have	O
8	identified	O
9	potent	O
10	and	O
11	selective	O
12	inhibitors	O
13	for	O
14	sensitized	O
15	kinases	O
16	from	O
17	five	O
18	distinct	O
19	subfamilies	O
20	.	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	I
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	B
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	O
58	responsive	O
59	CAT	B
60	reporter	I
61	gene	I
62	.	O

1	By	O
2	progressive	O
3	5	O
4	'-	O
5	deletion	O
6	studies	O
7	,	O
8	we	O
9	have	O
10	identified	O
11	a	O
12	248	O
13	-	O
14	bp	O
15	DNA	O
16	fragment	O
17	(-	O
18	1018	O
19	to	O
20	-	O
21	771	O
22	,	O
23	relative	O
24	to	O
25	the	O
26	translation	O
27	start	O
28	site	O
29	)	O
30	at	O
31	the	O
32	5	O
33	'-	O
34	flanking	O
35	region	O
36	of	O
37	the	O
38	human	B
39	GnRHR	I
40	gene	I
41	that	O
42	is	O
43	responsible	O
44	for	O
45	the	O
46	GnRHa	O
47	-	O
48	mediated	O
49	down	O
50	-	O
51	regulation	O
52	of	O
53	human	B
54	GnRHR	I
55	promoter	I
56	activity	O
57	.	O

1	The	O
2	mean	O
3	day	O
4	of	O
5	diagnosis	O
6	of	O
7	periventricular	O
8	echodensities	O
9	was	O
10	3	O
11	+/-	O
12	2	O
13	days	O
14	(	O
15	range	O
16	1	O
17	-	O
18	11	O
19	days	O
20	),	O
21	and	O
22	of	O
23	cystic	O
24	PVL	O
25	21	O
26	+/-	O
27	8	O
28	days	O
29	(	O
30	range	O
31	2	O
32	-	O
33	47	O
34	days	O
35	).	O

1	The	O
2	LAMMER	B
3	protein	O
4	kinase	O
5	encoded	O
6	by	O
7	the	O
8	Doa	B
9	locus	I
10	of	O
11	Drosophila	O
12	is	O
13	required	O
14	in	O
15	both	O
16	somatic	O
17	and	O
18	germline	O
19	cells	O
20	and	O
21	is	O
22	expressed	O
23	as	O
24	both	O
25	nuclear	O
26	and	O
27	cytoplasmic	O
28	isoforms	O
29	throughout	O
30	development	O
31	.	O

1	We	O
2	have	O
3	mutated	O
4	to	O
5	cysteine	O
6	,	O
7	one	O
8	at	O
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	O
15	in	O
16	the	O
17	fourth	O
18	TMS	O
19	(	O
20	TM4	O
21	).	O

1	(	O
2	1995	O
3	)	O
4	J	O
5	.	O

1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	I
19	lipoproteins	I
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O

1	In	O
2	group	O
3	B	O
4	37	O
5	MBq	O
6	in	O
7	150	O
8	microL	O
9	of	O
10	99mTc	O
11	-	O
12	HSA	O
13	nanocolloid	O
14	was	O
15	additionally	O
16	injected	O
17	intradermally	O
18	18	O
19	h	O
20	before	O
21	surgery	O
22	(	O
23	3	O
24	-	O
25	6	O
26	aliquots	O
27	injected	O
28	perilesionally	O
29	).	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	We	O
2	cloned	O
3	a	O
4	DNA	O
5	fragment	O
6	encoding	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	part	O
12	of	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	similarity	O
18	to	O
19	members	O
20	of	O
21	the	O
22	LysR	B
23	family	I
24	of	I
25	transcriptional	I
26	regulators	I
27	(	O
28	LTTRs	B
29	).	O

1	AGO1	B
2	is	O
3	similar	O
4	to	O
5	QDE	B
6	-	I
7	2	I
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	B
13	-	I
14	1	I
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	B
7	-	I
8	3	I
9	/	O
10	EGFP	B
11	fusion	O
12	protein	O
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	B
22	-	I
23	3	I
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	B
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	B
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O

1	Reporter	O
2	gene	O
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	B
9	promoters	I
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	We	O
2	find	O
3	that	O
4	3T1	O
5	-	O
6	3T2	O
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	O
37	of	O
38	nontetrahedral	O
39	distortions	O
40	.	O

1	A	O
2	total	O
3	of	O
4	576	O
5	1	O
6	-	O
7	day	O
8	-	O
9	old	O
10	Ross	O
11	broiler	O
12	chicks	O
13	were	O
14	housed	O
15	in	O
16	six	O
17	treatment	O
18	groups	O
19	[	O
20	six	O
21	replicates	O
22	of	O
23	16	O
24	each	O
25	;	O
26	control	O
27	,	O
28	CLI	O
29	(	O
30	15	O
31	g	O
32	kg	O
33	(-	O
34	1	O
35	)	O
36	diet	O
37	),	O
38	50	O
39	parts	O
40	per	O
41	billion	O
42	(	O
43	ppb	O
44	)	O
45	AF	B
46	,	O
47	50	O
48	ppb	O
49	AF	B
50	plus	O
51	CLI	O
52	,	O
53	100	O
54	ppb	O
55	AF	B
56	,	O
57	100	O
58	ppb	O
59	AF	B
60	plus	O
61	CLI	O
62	]	O
63	for	O
64	42	O
65	days	O
66	.	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	O
13	and	O
14	PACE2	O
15	.	O

1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	B
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	B
17	-	I
18	PLC	I
19	and	O
20	PLD	B
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	O
28	mitogen	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	O
34	MAP	B
35	kinase	I
36	)	O
37	and	O
38	NF	B
39	-	I
40	kappaB	I
41	signalling	O
42	respectively	O
43	.	O

1	Concurrently	O
2	,	O
3	we	O
4	monitored	O
5	weather	O
6	conditions	O
7	and	O
8	used	O
9	time	O
10	-	O
11	activity	O
12	budget	O
13	data	O
14	of	O
15	free	O
16	-	O
17	living	O
18	birds	O
19	and	O
20	laboratory	O
21	data	O
22	on	O
23	resting	O
24	metabolic	O
25	rate	O
26	to	O
27	construct	O
28	time	O
29	-	O
30	activity	O
31	laboratory	O
32	(	O
33	TAL	O
34	)	O
35	estimates	O
36	of	O
37	daily	O
38	energy	O
39	expenditure	O
40	(	O
41	DEE	O
42	)	O
43	and	O
44	to	O
45	partition	O
46	the	O
47	verdins	O
48	'	O
49	energy	O
50	budget	O
51	into	O
52	thermoregulatory	O
53	,	O
54	activity	O
55	and	O
56	basal	O
57	components	O
58	.	O

1	L	O
2	/	O
3	H	O
4	>	O
5	0	O
6	.	O
7	61	O
8	(	O
9	chi	O
10	(	O
11	2	O
12	)=	O
13	10	O
14	.	O
15	8	O
16	;	O
17	P	O
18	:<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	and	O
24	a	O
25	restrictive	O
26	filling	O
27	pattern	O
28	(	O
29	chi	O
30	(	O
31	2	O
32	)=	O
33	3	O
34	.	O
35	6	O
36	;	O
37	P	O
38	:<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	were	O
44	independent	O
45	predictors	O
46	of	O
47	events	O
48	.	O

1	The	O
2	high	O
3	selectivity	O
4	of	O
5	arrestins	B
6	for	O
7	this	O
8	particular	O
9	functional	O
10	form	O
11	of	O
12	receptor	O
13	ensures	O
14	their	O
15	timely	O
16	binding	O
17	and	O
18	dissociation	O
19	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	negative	I
6	Smad2	I
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	Normal	O
2	alpha1	B
3	(	I
4	I	I
5	)	I
6	collagen	I
7	mRNA	I
8	showed	O
9	no	O
10	significant	O
11	reduction	O
12	when	O
13	AR	O
14	or	O
15	IR	O
16	was	O
17	expressed	O
18	from	O
19	the	O
20	pHbetaAPr	O
21	-	O
22	1	O
23	-	O
24	neo	O
25	vector	O
26	and	O
27	a	O
28	small	O
29	(	O
30	10	O
31	-	O
32	20	O
33	%)	O
34	but	O
35	significant	O
36	reduction	O
37	when	O
38	either	O
39	ribozyme	O
40	was	O
41	expressed	O
42	from	O
43	the	O
44	pCI	O
45	.	O
46	neo	O
47	vector	O
48	.	O

1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	B
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	B
45	-	I
46	1	I
47	mRNA	I
48	.	O

1	Abnormalities	O
2	of	O
3	plasma	B
4	cholecystokinin	I
5	were	O
6	observed	O
7	only	O
8	in	O
9	patients	O
10	with	O
11	delayed	O
12	gastric	O
13	emptying	O
14	.	O

1	5	O
2	(	O
3	Sunset	O
4	Yellow	O
5	FCF	O
6	)	O
7	were	O
8	determined	O
9	using	O
10	liquid	O
11	chromatography	O
12	/	O
13	mass	O
14	spectrometry	O
15	(	O
16	LC	O
17	/	O
18	MS	O
19	)	O
20	with	O
21	electrospray	O
22	ionization	O
23	.	O

1	Polysome	O
2	and	O
3	40S	B
4	ribosome	I
5	fractions	O
6	were	O
7	severely	O
8	decreased	O
9	in	O
10	the	O
11	krr1	B
12	mutant	I
13	and	O
14	Kri1p	B
15	-	O
16	depleted	O
17	cells	O
18	.	O

1	They	O
2	also	O
3	negatively	O
4	modulate	O
5	the	O
6	PI	B
7	3	I
8	-	I
9	kinase	I
10	catalytic	O
11	activity	O
12	but	O
13	to	O
14	different	O
15	extents	O
16	,	O
17	dependent	O
18	on	O
19	the	O
20	unique	O
21	N	O
22	-	O
23	terminal	O
24	structure	O
25	of	O
26	each	O
27	isoform	O
28	.	O

1	Cam	B
2	kinase	I
3	II	I
4	induces	O
5	in	O
6	vivo	O
7	phosphorylation	O
8	of	O
9	Smad2	B
10	and	O
11	Smad4	B
12	and	O
13	,	O
14	to	O
15	a	O
16	lesser	O
17	extent	O
18	,	O
19	Smad3	B
20	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	suppressor	I
5	of	I
6	sable	I
7	gene	I
8	,	O
9	su	O
10	(	O
11	s	O
12	),	O
13	encodes	O
14	a	O
15	novel	O
16	,	O
17	150	O
18	-	O
19	kDa	O
20	nuclear	O
21	RNA	O
22	binding	O
23	protein	O
24	,	O
25	SU	O
26	(	O
27	S	O
28	),	O
29	that	O
30	negatively	O
31	regulates	O
32	RNA	O
33	accumulation	O
34	from	O
35	mutant	O
36	alleles	O
37	of	O
38	other	O
39	genes	O
40	that	O
41	have	O
42	transposon	O
43	insertions	O
44	in	O
45	the	O
46	5	O
47	'	O
48	transcribed	O
49	region	O
50	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	ARM1	O
15	and	O
16	ARM2	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	SU	O
26	(	O
27	S	O
28	).	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	B
6	acetyltransferase	I
7	activity	O
8	of	O
9	p300	B
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	B
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	Recombinant	B
2	BRI1	I
3	-	I
4	KD	I
5	autophosphorylated	O
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	Flow	O
2	cytomery	O
3	was	O
4	used	O
5	for	O
6	cell	O
7	cycle	O
8	analysis	O
9	.	O

1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	B
23	beta	I
24	-	I
25	1b	I
26	in	O
27	RRMS	O
28	.	O

1	Cost	O
2	-	O
3	effectiveness	O
4	of	O
5	interferon	B
6	beta	I
7	-	I
8	1b	I
9	in	O
10	slowing	O
11	multiple	O
12	sclerosis	O
13	disability	O
14	progression	O
15	.	O

1	Both	O
2	the	O
3	Cmax	O
4	and	O
5	AUC	O
6	values	O
7	were	O
8	almost	O
9	doubled	O
10	with	O
11	doubling	O
12	the	O
13	dose	O
14	.	O

1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	O
5	fission	O
6	yeast	O
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O

1	Diary	O
2	.	O

1	Cells	O
2	differentiate	O
3	in	O
4	response	O
5	to	O
6	various	O
7	extracellular	O
8	stimuli	O
9	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	O
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O

1	Vasoactive	B
2	intestinal	I
3	peptide	I
4	and	O
5	pituitary	B
6	adenylate	I
7	cyclase	I
8	-	I
9	activating	I
10	polypeptide	I
11	inhibit	O
12	nuclear	B
13	factor	I
14	-	I
15	kappa	I
16	B	I
17	-	I
18	dependent	I
19	gene	I
20	activation	O
21	at	O
22	multiple	O
23	levels	O
24	in	O
25	the	O
26	human	O
27	monocytic	O
28	cell	O
29	line	O
30	THP	O
31	-	O
32	1	O
33	.	O

1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O

1	While	O
2	Pt	B
3	;	I
4	cycH	I
5	;	I
6	1	I
7	and	O
8	Os	B
9	;	I
10	cycH	I
11	;	I
12	1	I
13	were	O
14	expressed	O
15	in	O
16	all	O
17	tissues	O
18	examined	O
19	,	O
20	the	O
21	transcripts	O
22	accumulated	O
23	abundantly	O
24	in	O
25	dividing	O
26	cells	O
27	.	O

1	Moreover	O
2	,	O
3	an	O
4	in	O
5	vitro	O
6	pull	O
7	-	O
8	down	O
9	assay	O
10	showed	O
11	that	O
12	Os	B
13	;	I
14	CycH	I
15	;	I
16	1	I
17	specifically	O
18	bound	O
19	to	O
20	R2	B
21	but	O
22	not	O
23	to	O
24	other	O
25	rice	B
26	CDKs	I
27	.	O

1	In	O
2	transient	O
3	analysis	O
4	using	O
5	particle	O
6	bombardment	O
7	of	O
8	tobacco	O
9	leaf	O
10	sections	O
11	,	O
12	a	O
13	tetramer	O
14	of	O
15	the	O
16	distB	O
17	ABRE	O
18	(	O
19	abscisic	O
20	acid	O
21	-	O
22	responsive	O
23	element	O
24	)	O
25	mediated	O
26	transactivation	O
27	by	O
28	ABI3	B
29	and	O
30	ABI3	B
31	-	O
32	dependent	O
33	response	O
34	to	O
35	ABA	O
36	,	O
37	whereas	O
38	a	O
39	tetramer	O
40	of	O
41	the	O
42	composite	O
43	RY	O
44	/	O
45	G	O
46	complex	O
47	,	O
48	containing	O
49	RY	O
50	repeats	O
51	and	O
52	a	O
53	G	O
54	-	O
55	box	O
56	,	O
57	mediated	O
58	only	O
59	ABA	O
60	-	O
61	independent	O
62	transactivation	O
63	by	O
64	ABI3	B
65	.	O

1	The	O
2	major	O
3	neurological	O
4	manifestations	O
5	of	O
6	brain	O
7	injury	O
8	in	O
9	these	O
10	babies	O
11	are	O
12	spastic	O
13	motor	O
14	deficits	O
15	.	O

1	Spores	O
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O

1	Overexpression	O
2	of	O
3	Trdpm1	B
4	in	O
5	a	O
6	dpm1	O
7	(+)::	O
8	his7	B
9	/	I
10	dpm1	I
11	(+)	I
12	S	O
13	.	O
14	pombe	O
15	diploid	O
16	resulted	O
17	in	O
18	a	O
19	4	O
20	-	O
21	fold	O
22	increase	O
23	in	O
24	specific	O
25	DPM	B
26	synthase	I
27	activity	O
28	.	O

1	The	O
2	LMW	B
3	FGF	I
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	B
24	isoform	I
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	Helicobacter	O
2	pylori	O
3	and	O
4	stomach	O
5	diseases	O
6	:	O
7	from	O
8	clinical	O
9	point	O
10	of	O
11	view	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	the	O
6	writhing	O
7	test	O
8	,	O
9	capsaicin	O
10	and	O
11	formalin	O
12	induced	O
13	-	O
14	pain	O
15	in	O
16	mice	O
17	were	O
18	used	O
19	.	O

1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	B
25	-	I
26	3K	I
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	In	O
2	vitro	O
3	,	O
4	Arix	B
5	and	O
6	NBPhox	B
7	form	O
8	DNA	O
9	-	O
10	independent	O
11	multimers	O
12	and	O
13	exhibit	O
14	cooperative	O
15	binding	O
16	to	O
17	the	O
18	DB1	B
19	regulatory	I
20	element	I
21	,	O
22	which	O
23	contains	O
24	two	O
25	homeodomain	B
26	recognition	I
27	sites	I
28	.	O

1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	B
8	and	O
9	NBPhox	B
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	B
20	promoter	I
21	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	Studies	O
6	were	O
7	undertaken	O
8	in	O
9	9	O
10	isolated	O
11	guinea	O
12	pig	O
13	hearts	O
14	,	O
15	which	O
16	demonstrated	O
17	reverse	O
18	use	O
19	-	O
20	dependent	O
21	prolongation	O
22	of	O
23	cardiac	O
24	repolarization	O
25	by	O
26	100	O
27	nmol	O
28	/	O
29	L	O
30	domperidone	O
31	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	small	O
6	segment	O
7	of	O
8	yeast	B
9	TAF145	I
10	(	O
11	yTAF145	B
12	)	O
13	binds	O
14	to	O
15	TBP	B
16	and	O
17	thereby	O
18	inhibits	O
19	TBP	B
20	function	O
21	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	overall	O
7	performance	O
8	of	O
9	a	O
10	new	O
11	oscillometric	O
12	wrist	O
13	blood	O
14	pressure	O
15	monitor	O
16	(	O
17	Braun	O
18	PrecisionSensor	O
19	,	O
20	Braun	O
21	GmbH	O
22	,	O
23	Kronberg	O
24	,	O
25	Germany	O
26	)	O
27	as	O
28	defined	O
29	by	O
30	the	O
31	ANSI	O
32	/	O
33	AAMI	O
34	SP10	O
35	-	O
36	1992	O
37	guidelines	O
38	,	O
39	and	O
40	to	O
41	analyze	O
42	the	O
43	data	O
44	for	O
45	the	O
46	optimized	O
47	selection	O
48	of	O
49	the	O
50	algorithm	O
51	that	O
52	derives	O
53	the	O
54	blood	O
55	pressure	O
56	values	O
57	from	O
58	the	O
59	oscillometric	O
60	blood	O
61	pressure	O
62	curves	O
63	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	O
13	Drinking	O
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	An	O
2	increase	O
3	in	O
4	hypothalamic	O
5	expression	O
6	of	O
7	at	O
8	least	O
9	two	O
10	of	O
11	the	O
12	erbB	B
13	receptors	I
14	is	O
15	initiated	O
16	before	O
17	the	O
18	pubertal	O
19	augmentation	O
20	of	O
21	gonadal	O
22	steroid	O
23	secretion	O
24	and	O
25	is	O
26	completed	O
27	on	O
28	the	O
29	day	O
30	of	O
31	the	O
32	first	O
33	preovulatory	O
34	surge	O
35	of	O
36	gonadotropins	B
37	.	O

1	Dsh	B
2	is	O
3	required	O
4	for	O
5	two	O
6	different	O
7	pathways	O
8	,	O
9	the	O
10	Wnt	B
11	pathway	O
12	and	O
13	planar	O
14	polarity	O
15	pathway	O
16	in	O
17	Drosophila	O
18	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	and	O
6	craniofacial	O
7	dimensions	O
8	following	O
9	administration	O
10	of	O
11	the	O
12	antineoplastic	O
13	agent	O
14	vincristine	O
15	to	O
16	young	O
17	rats	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	LSCC	O
4	malformation	O
5	,	O
6	like	O
7	other	O
8	inner	O
9	ear	O
10	malformations	O
11	such	O
12	as	O
13	large	O
14	vestibular	O
15	aqueduct	O
16	and	O
17	X	O
18	-	O
19	linked	O
20	mixed	O
21	deafness	O
22	with	O
23	perilymph	O
24	gusher	O
25	,	O
26	can	O
27	be	O
28	associated	O
29	with	O
30	CHL	O
31	,	O
32	SNHL	O
33	,	O
34	or	O
35	normal	O
36	hearing	O
37	.	O

1	Escalation	O
2	to	O
3	180	O
4	mg	O
5	/	O
6	m2	O
7	was	O
8	to	O
9	be	O
10	carried	O
11	out	O
12	if	O
13	white	O
14	blood	O
15	cell	O
16	nadir	O
17	count	O
18	was	O
19	>	O
20	2	O
21	.	O
22	0	O
23	x	O
24	10	O
25	(	O
26	9	O
27	)/	O
28	l	O
29	and	O
30	platelet	O
31	nadir	O
32	count	O
33	was	O
34	>	O
35	75	O
36	x	O
37	10	O
38	(	O
39	9	O
40	)/	O
41	l	O
42	.	O

1	Methyl	O
2	formate	O
3	was	O
4	used	O
5	as	O
6	the	O
7	solvent	O
8	of	O
9	biodegradable	O
10	oligoesters	O
11	for	O
12	the	O
13	fabrication	O
14	of	O
15	microspheres	O
16	with	O
17	encapsulated	O
18	bovine	B
19	serum	I
20	albumin	I
21	(	O
22	BSA	B
23	).	O

1	The	O
2	small	B
3	monomeric	I
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	of	O
9	the	O
10	RAB	B
11	subfamily	I
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	B
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	I
13	and	I
14	dimeric	I
15	complexes	I
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	analyze	O
9	the	O
10	temporal	O
11	characteristics	O
12	and	O
13	the	O
14	spatial	O
15	mapping	O
16	of	O
17	the	O
18	independent	O
19	components	O
20	identified	O
21	by	O
22	ICA	O
23	when	O
24	the	O
25	subject	O
26	performs	O
27	a	O
28	finger	O
29	-	O
30	tapping	O
31	task	O
32	.	O

1	The	O
2	authors	O
3	present	O
4	the	O
5	only	O
6	two	O
7	studies	O
8	that	O
9	have	O
10	proved	O
11	successful	O
12	in	O
13	treating	O
14	animal	O
15	models	O
16	of	O
17	osteoarthritis	O
18	using	O
19	gene	O
20	therapy	O
21	,	O
22	and	O
23	propose	O
24	an	O
25	overview	O
26	of	O
27	several	O
28	strategies	O
29	for	O
30	the	O
31	development	O
32	of	O
33	gene	O
34	therapy	O
35	in	O
36	osteoarthritis	O
37	treatment	O
38	in	O
39	the	O
40	future	O
41	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O

1	Binding	O
2	of	O
3	NusA	B
4	to	O
5	RNA	O
6	in	O
7	the	O
8	presence	O
9	of	O
10	alpha	O
11	or	O
12	N	O
13	involves	O
14	an	O
15	amino	B
16	-	I
17	terminal	I
18	S1	I
19	homology	I
20	region	I
21	that	O
22	is	O
23	otherwise	O
24	inactive	O
25	in	O
26	full	B
27	-	I
28	length	I
29	NusA	I
30	.	O

1	The	O
2	subjects	O
3	were	O
4	diagnosed	O
5	on	O
6	the	O
7	basis	O
8	of	O
9	DSM	O
10	-	O
11	IV	O
12	pathological	O
13	gambling	O
14	criteria	O
15	and	O
16	completed	O
17	the	O
18	Turkish	O
19	Version	O
20	of	O
21	South	O
22	Oaks	O
23	Gambling	O
24	Screen	O
25	(	O
26	SOGS	O
27	).	O

1	Lys	O
2	(	O
3	193	O
4	)	O
5	and	O
6	Arg	O
7	(	O
8	194	O
9	),	O
10	located	O
11	at	O
12	the	O
13	COOH	O
14	-	O
15	terminal	O
16	end	O
17	of	O
18	HD	B
19	,	O
20	are	O
21	essential	O
22	for	O
23	dimerization	O
24	.	O

1	Elevation	O
2	of	O
3	intracellular	O
4	Ca	O
5	(	O
6	2	O
7	+)	O
8	levels	O
9	are	O
10	also	O
11	involved	O
12	because	O
13	treatment	O
14	with	O
15	receptor	O
16	-	O
17	associated	O
18	protein	O
19	,	O
20	nifedipine	O
21	,	O
22	MK801	O
23	,	O
24	removal	O
25	of	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	from	O
31	the	O
32	medium	O
33	and	O
34	dantrolene	O
35	all	O
36	served	O
37	to	O
38	inhibit	O
39	calcium	O
40	elevation	O
41	and	O
42	attenuate	O
43	the	O
44	activation	O
45	of	O
46	CREB	B
47	.	O

1	The	O
2	present	O
3	study	O
4	shows	O
5	that	O
6	phosphatidylinositol	B
7	3	I
8	-	I
9	kinase	I
10	-	O
11	dependent	O
12	p38	B
13	kinase	I
14	activation	O
15	regulates	O
16	Akt	B
17	phosphorylation	O
18	and	O
19	activity	O
20	in	O
21	human	O
22	neutrophils	O
23	.	O

1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O

1	These	O
2	probable	O
3	border	O
4	sequences	O
5	are	O
6	closely	O
7	related	O
8	to	O
9	those	O
10	of	O
11	other	O
12	known	O
13	T	O
14	-	O
15	regions	O
16	and	O
17	define	O
18	a	O
19	second	O
20	T	O
21	-	O
22	region	O
23	of	O
24	pTiChry5	O
25	,	O
26	called	O
27	T	O
28	-	O
29	right	O
30	(	O
31	TR	O
32	),	O
33	that	O
34	confers	O
35	production	O
36	of	O
37	the	O
38	Amadoriopines	O
39	.	O

1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	O
21	binding	O
22	sites	O
23	.	O

1	High	B
2	-	I
3	mobility	I
4	-	I
5	group	I
6	protein	I
7	I	I
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	I
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	O
8	splicing	O
9	suppressor	O
10	1	O
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	5	O
2	'-	O
3	RACE	O
4	analysis	O
5	suggested	O
6	a	O
7	single	O
8	transcription	O
9	initiation	O
10	site	O
11	187	O
12	bp	O
13	upstream	O
14	from	O
15	the	O
16	translational	O
17	start	O
18	site	O
19	.	O

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	O
11	binding	O
12	of	O
13	NFI	B
14	proteins	I
15	,	O
16	and	O
17	the	O
18	addition	O
19	of	O
20	higher	O
21	concentrations	O
22	of	O
23	dithiothreitol	O
24	to	O
25	nuclear	O
26	extracts	O
27	from	O
28	TG	B
29	-	O
30	treated	O
31	cells	O
32	restores	O
33	NFI	B
34	-	I
35	DNA	I
36	binding	O
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	O
44	.	O

1	LMP2A	B
2	enhances	O
3	Lyn	B
4	and	O
5	Syk	B
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	B
28	tyrosine	I
29	kinase	I
30	.	O

1	Further	O
2	,	O
3	Tax	B
4	-	O
5	mediated	O
6	apoptosis	O
7	was	O
8	effectively	O
9	prevented	O
10	by	O
11	ectopic	O
12	expression	O
13	of	O
14	the	O
15	p300	B
16	coactivator	I
17	.	O

1	Our	O
2	results	O
3	,	O
4	however	O
5	,	O
6	were	O
7	obtained	O
8	for	O
9	Z	O
10	itself	O
11	and	O
12	not	O
13	for	O
14	[	O
15	Z	O
16	].	O

1	Fisher	O
2	'	O
3	s	O
4	exact	O
5	test	O
6	or	O
7	Pearson	O
8	'	O
9	s	O
10	chi2	O
11	test	O
12	were	O
13	used	O
14	for	O
15	statistical	O
16	analysis	O
17	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	pregnant	O
6	group	O
7	,	O
8	serum	O
9	PP14	B
10	concentrations	O
11	were	O
12	markedly	O
13	increased	O
14	after	O
15	ET	O
16	,	O
17	and	O
18	a	O
19	significant	O
20	difference	O
21	between	O
22	the	O
23	pregnant	O
24	group	O
25	and	O
26	the	O
27	nonpregnant	O
28	group	O
29	was	O
30	observed	O
31	8	O
32	days	O
33	following	O
34	ET	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Thromboelastography	O
2	is	O
3	a	O
4	test	O
5	that	O
6	could	O
7	potentially	O
8	correlate	O
9	with	O
10	the	O
11	degree	O
12	of	O
13	anticoagulation	O
14	produced	O
15	by	O
16	low	O
17	molecular	O
18	weight	O
19	heparin	O
20	.	O

1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	O
22	RNA	O
23	-	O
24	binding	O
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	RESULTS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	(	O
7	26	O
8	%)	O
9	patients	O
10	had	O
11	PHG	O
12	before	O
13	(	O
14	group	O
15	A	O
16	)	O
17	and	O
18	64	O
19	(	O
20	74	O
21	%)	O
22	developed	O
23	PHG	O
24	after	O
25	variceal	O
26	eradication	O
27	(	O
28	group	O
29	B	O
30	).	O

1	Response	O
2	was	O
3	extremely	O
4	poor	O
5	in	O
6	African	O
7	Americans	O
8	and	O
9	those	O
10	with	O
11	HCV	O
12	genotype	O
13	1	O
14	.	O

1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	B
9	mucosal	I
10	cyclooxygenase	I
11	(	O
12	COX	B
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O

1	A	O
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O

1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	B
15	fused	O
16	to	O
17	glutathione	B
18	S	I
19	-	I
20	transferase	I
21	(	O
22	GST	B
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	B
28	signaling	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	surgical	O
5	or	O
6	multimodality	O
7	treatment	O
8	of	O
9	MSGT	O
10	has	O
11	provided	O
12	a	O
13	good	O
14	locoregional	O
15	control	O
16	(	O
17	78	O
18	%)	O
19	and	O
20	68	O
21	%	O
22	10	O
23	-	O
24	year	O
25	survival	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	treated	O
32	at	O
33	the	O
34	oncology	O
35	department	O
36	of	O
37	a	O
38	general	O
39	hospital	O
40	in	O
41	Quito	O
42	,	O
43	Ecuador	O
44	.	O

1	RESULTS	O
2	:	O
3	Glaucoma	O
4	suspects	O
5	were	O
6	divided	O
7	into	O
8	two	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	SWAP	O
14	results	O
15	:	O
16	high	O
17	risk	O
18	(	O
19	with	O
20	SWAP	O
21	abnormalities	O
22	)	O
23	and	O
24	low	O
25	risk	O
26	(	O
27	with	O
28	normal	O
29	SWAP	O
30	result	O
31	).	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	Like	O
2	the	O
3	p190	B
4	-	I
5	B	I
6	exon	O
7	,	O
8	the	O
9	first	O
10	exon	O
11	of	O
12	p190	B
13	-	I
14	A	I
15	is	O
16	extremely	O
17	large	O
18	(	O
19	3	O
20	.	O
21	7	O
22	kb	O
23	in	O
24	length	O
25	),	O
26	encoding	O
27	both	O
28	the	O
29	GTPase	B
30	and	O
31	middle	O
32	domains	O
33	(	O
34	residues	O
35	1	O
36	-	O
37	1228	O
38	),	O
39	but	O
40	not	O
41	the	O
42	remaining	O
43	GAP	B
44	domain	I
45	,	O
46	suggesting	O
47	a	O
48	high	O
49	conservation	O
50	of	O
51	genomic	O
52	structure	O
53	between	O
54	two	O
55	p190	B
56	genes	I
57	.	O

1	The	O
2	entire	O
3	human	B
4	teneurin	I
5	-	I
6	1	I
7	(	O
8	TEN1	B
9	)	O
10	gene	O
11	is	O
12	contained	O
13	in	O
14	eight	O
15	PAC	O
16	clones	O
17	representing	O
18	part	O
19	of	O
20	the	O
21	chromosomal	O
22	locus	O
23	Xq25	O
24	.	O

1	The	O
2	plexiform	O
3	neurofibroma	O
4	and	O
5	multiple	O
6	localized	O
7	neurofibromas	O
8	are	O
9	characteristic	O
10	of	O
11	NF1	B
12	.	O

1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	B
31	(	O
32	Suvar3	B
33	-	I
34	9	I
35	,	O
36	Enhancer	B
37	-	I
38	of	I
39	-	I
40	zeste	I
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	B
51	.	O

1	MED1	B
2	has	O
3	a	O
4	weak	O
5	glycosylase	B
6	activity	O
7	on	O
8	the	O
9	mutagenic	O
10	adduct	O
11	3	O
12	,	O
13	N	O
14	(	O
15	4	O
16	)-	O
17	ethenocytosine	O
18	,	O
19	a	O
20	metabolite	O
21	of	O
22	vinyl	O
23	chloride	O
24	and	O
25	ethyl	O
26	carbamate	O
27	.	O

1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	XAB1	B
6	is	O
7	a	O
8	novel	O
9	cytoplasmic	B
10	GTPase	I
11	involved	O
12	in	O
13	nuclear	O
14	localization	O
15	of	O
16	XPA	B
17	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	IRF	B
7	-	I
8	2	I
9	,	O
10	was	O
11	initially	O
12	cloned	O
13	as	O
14	an	O
15	antagonistic	O
16	counterpart	O
17	to	O
18	IRF	B
19	-	I
20	1	I
21	with	O
22	oncogenic	O
23	potential	O
24	.	O

1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Bacteriol	O
2	.	O

1	Terminal	B
2	deoxynucleotidyl	I
3	transferase	I
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	B
17	repressors	I
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	I
32	L	I
33	)	I
34	expression	O
35	.	O

1	VEGF	B
2	promoter	I
3	activity	O
4	in	O
5	transient	O
6	transfections	O
7	was	O
8	decreased	O
9	by	O
10	either	O
11	pharmacological	O
12	or	O
13	genetic	O
14	inhibition	O
15	of	O
16	EGFR	B
17	,	O
18	Ras	B
19	,	O
20	or	O
21	phosphatidylinositol	B
22	3	I
23	'-	I
24	kinase	I
25	[	O
26	PI	O
27	(	O
28	3	O
29	)	O
30	kinase	O
31	].	O

1	Epidermal	B
2	growth	I
3	factor	I
4	receptor	I
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	B
10	endothelial	I
11	growth	I
12	factor	I
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	B
23	3	I
24	'-	I
25	kinase	I
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O

1	Thus	O
2	,	O
3	IHHNV	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	densoviruses	O
9	of	O
10	the	O
11	genus	O
12	Brevidensovirus	O
13	in	O
14	the	O
15	family	O
16	Parvoviridae	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	rename	O
24	this	O
25	virus	O
26	Penaeus	O
27	stylirostris	O
28	densovirus	O
29	(	O
30	PstDNV	O
31	).	O

1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O

1	Catalytic	O
2	activation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	(	I
9	MAP	I
10	)	I
11	kinase	I
12	phosphatase	I
13	-	I
14	1	I
15	by	O
16	binding	O
17	to	O
18	p38	B
19	MAP	I
20	kinase	I
21	:	O
22	critical	O
23	role	O
24	of	O
25	the	O
26	p38	B
27	C	I
28	-	I
29	terminal	I
30	domain	I
31	in	O
32	its	O
33	negative	O
34	regulation	O
35	.	O

1	Thus	O
2	,	O
3	the	O
4	class	B
5	C	I
6	-	O
7	Vps	B
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	Signal	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O

1	Botulinum	B
2	toxin	I
3	A	I
4	in	O
5	the	O
6	treatment	O
7	of	O
8	hemiplegic	O
9	spastic	O
10	foot	O
11	drop	O
12	--	O
13	clinical	O
14	and	O
15	functional	O
16	outcomes	O
17	.	O

1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	B
13	translation	I
14	start	I
15	site	I
16	.	O

1	NF	B
2	-	I
3	kappaB	I
4	is	O
5	a	O
6	redox	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	O
14	activated	O
15	by	O
16	oxidative	O
17	stress	O
18	as	O
19	well	O
20	as	O
21	chemical	O
22	and	O
23	biological	O
24	reductants	O
25	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	and	O
5	antihypertensive	O
6	treatment	O
7	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	EBCT	O
4	technology	O
5	allows	O
6	minimally	O
7	invasive	O
8	evaluation	O
9	of	O
10	intramyocardial	O
11	microcirculatory	O
12	function	O
13	and	O
14	permits	O
15	assessment	O
16	of	O
17	microvascular	O
18	BV	O
19	distribution	O
20	in	O
21	different	O
22	functional	O
23	components	O
24	.	O

1	These	O
2	two	O
3	mAbs	O
4	used	O
5	the	O
6	same	O
7	V	O
8	(	O
9	H	O
10	)	O
11	and	O
12	J	O
13	(	O
14	H	O
15	)	O
16	gene	O
17	segments	O
18	,	O
19	but	O
20	different	O
21	D	O
22	,	O
23	Vkappa	O
24	,	O
25	and	O
26	Jkappa	O
27	genes	O
28	.	O

1	SSF	O
2	experiments	O
3	were	O
4	carried	O
5	out	O
6	in	O
7	bench	O
8	-	O
9	scale	O
10	bioreactors	O
11	(	O
12	equipped	O
13	with	O
14	CO2	O
15	and	O
16	volatile	O
17	organic	O
18	traps	O
19	)	O
20	containing	O
21	a	O
22	mixture	O
23	of	O
24	lignocellulosic	O
25	materials	O
26	and	O
27	a	O
28	radiolabeled	O
29	pesticide	O
30	.	O

1	Characterization	O
2	of	O
3	a	O
4	Xenopus	B
5	laevis	I
6	CXC	I
7	chemokine	I
8	receptor	I
9	4	I
10	:	O
11	implications	O
12	for	O
13	hematopoietic	O
14	cell	O
15	development	O
16	in	O
17	the	O
18	vertebrate	O
19	embryo	O
20	.	O

1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O

1	Inhibition	O
2	of	O
3	RNA2	B
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	B
20	-	O
21	encoded	O
22	replication	B
23	factor	I
24	1a	I
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	B
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	B
37	function	O
38	in	O
39	translation	O
40	.	O

1	Abbreviations	O
2	:	O
3	CAS	B
4	,	O
5	CRK	B
6	-	I
7	associated	I
8	substrate	I
9	;	O
10	CH	B
11	,	O
12	calponin	B
13	-	I
14	homology	I
15	domain	I
16	;	O
17	CSK	B
18	,	O
19	C	B
20	-	I
21	terminal	I
22	SRC	I
23	kinase	I
24	;	O
25	E6	B
26	,	O
27	Papillomavirus	B
28	E6	I
29	protein	I
30	;	O
31	FAK	B
32	,	O
33	focal	B
34	adhesion	I
35	kinase	I
36	;	O
37	GIT	B
38	,	O
39	GRK	B
40	interacter	I
41	;	O
42	GPCR	B
43	,	O
44	heterotrimeric	B
45	-	I
46	G	I
47	-	I
48	protein	I
49	-	I
50	coupled	I
51	receptor	I
52	;	O
53	GRK	B
54	,	O
55	G	B
56	-	I
57	protein	I
58	-	I
59	coupled	I
60	-	I
61	receptor	I
62	kinase	I
63	;	O
64	MAPK	B
65	,	O
66	mitogen	B
67	-	I
68	activated	I
69	protein	I
70	kinase	I
71	(	O
72	ERK	B
73	,	O
74	p38	B
75	,	O
76	JNK	B
77	);	O
78	PAK	B
79	,	O
80	p21	B
81	-	I
82	activated	I
83	kinase	I
84	;	O
85	PBS	B
86	,	O
87	paxillin	B
88	-	I
89	binding	I
90	subdomain	I
91	;	O
92	PIX	B
93	,	O
94	PAK	B
95	-	I
96	interacting	I
97	exchange	I
98	factor	I
99	;	O
100	PKL	B
101	,	O
102	paxillin	B
103	kinase	I
104	linker	I
105	;	O
106	POR1	B
107	,	O
108	partner	B
109	of	I
110	Rac	I
111	;	O
112	PS	O
113	,	O
114	phosphoserine	O
115	;	O
116	PT	O
117	,	O
118	phosphothreonine	O
119	;	O
120	PY	O
121	,	O
122	phosphotyrosine	O
123	;	O
124	RTK	B
125	,	O
126	growth	B
127	factor	I
128	receptor	I
129	tyrosine	I
130	kinase	I
131	;	O
132	SH	B
133	,	O
134	SRC	B
135	-	I
136	homology	I
137	domain	I
138	.	O

1	In	O
2	15	O
3	ventilator	O
4	-	O
5	dependent	O
6	,	O
7	SB	O
8	,	O
9	and	O
10	actively	O
11	expiring	O
12	patients	O
13	,	O
14	we	O
15	found	O
16	that	O
17	the	O
18	difference	O
19	PEEP	O
20	(	O
21	i	O
22	),	O
23	dyn	O
24	-	O
25	Pga	O
26	,	O
27	total	O
28	decay	O
29	(	O
30	mean	O
31	+/-	O
32	SD	O
33	,	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	9	O
41	cm	O
42	H	O
43	(	O
44	2	O
45	)	O
46	O	O
47	)	O
48	was	O
49	quite	O
50	similar	O
51	to	O
52	PEEP	O
53	(	O
54	i	O
55	),	O
56	dyn	O
57	ref	O
58	(	O
59	5	O
60	.	O
61	3	O
62	+/-	O
63	1	O
64	.	O
65	9	O
66	cm	O
67	H	O
68	(	O
69	2	O
70	)	O
71	O	O
72	).	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	There	O
2	were	O
3	122	O
4	cases	O
5	of	O
6	tuberculosis	O
7	over	O
8	an	O
9	average	O
10	10	O
11	.	O
12	3	O
13	yr	O
14	of	O
15	follow	O
16	-	O
17	up	O
18	(	O
19	crude	O
20	annual	O
21	incidence	O
22	,	O
23	76	O
24	.	O
25	2	O
26	/	O
27	100	O
28	,	O
29	000	O
30	).	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	BACH1t	B
6	recruits	O
7	BACH1	B
8	to	O
9	the	O
10	nucleus	O
11	through	O
12	BTB	B
13	domain	O
14	-	O
15	mediated	O
16	interaction	O
17	.	O

1	The	O
2	U17	B
3	/	O
4	U16	B
5	and	O
6	the	O
7	U16	B
8	+	I
9	gene	I
10	products	I
11	transactivated	O
12	the	O
13	HIV	B
14	LTR	I
15	.	O

1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O

1	The	O
2	Cili	B
3	-	I
4	2	I
5	sequences	I
6	possess	O
7	similarity	O
8	to	O
9	the	O
10	RNaseH	B
11	domain	I
12	of	O
13	Lian	B
14	-	O
15	Aa1	B
16	,	O
17	a	O
18	mosquito	B
19	non	I
20	-	I
21	LTR	I
22	retrotransposon	I
23	.	O

1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	O
12	suppressor	O
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	B
24	E6	I
25	and	O
26	E7	B
27	mobilizes	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	orderly	O
33	fashion	O
34	to	O
35	deliver	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	B
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	Is	O
2	more	O
3	better	O
4	?	O
5	About	O
6	dose	O
7	levels	O
8	of	O
9	ACE	B
10	inhibitors	O
11	in	O
12	chronic	O
13	heart	O
14	failure	O
15	.	O

1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	SOCS	B
7	-	I
8	3	I
9	also	O
10	binds	O
11	to	O
12	the	O
13	IGFIR	B
14	,	O
15	we	O
16	cloned	O
17	human	B
18	SOCS	I
19	-	I
20	3	I
21	by	O
22	reverse	O
23	transcription	O
24	-	O
25	polymerase	O
26	chain	O
27	reaction	O
28	from	O
29	human	O
30	skeletal	O
31	muscle	O
32	mRNA	O
33	.	O

1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	RING	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	RING	O
23	finger	O
24	domains	O
25	of	O
26	SLI	B
27	-	I
28	1	I
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	Tightly	O
2	ordered	O
3	proteasomal	O
4	degradation	O
5	of	O
6	proteins	O
7	critical	O
8	for	O
9	cell	O
10	cycle	O
11	control	O
12	implies	O
13	a	O
14	role	O
15	of	O
16	the	O
17	proteasome	O
18	in	O
19	maintaining	O
20	cell	O
21	proliferation	O
22	and	O
23	cell	O
24	survival	O
25	.	O

1	The	O
2	sixth	O
3	nucleotide	O
4	was	O
5	bulged	O
6	out	O
7	to	O
8	allow	O
9	stacking	O
10	of	O
11	this	O
12	U	O
13	.	O
14	G	O
15	pair	O
16	on	O
17	the	O
18	adjacent	O
19	helical	O
20	region	O
21	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	B
6	desmin	I
7	in	O
8	SW13	O
9	(	O
10	vim	B
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	B
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	In	O
2	addition	O
3	,	O
4	26	O
5	amino	O
6	acid	O
7	residues	O
8	,	O
9	K69	O
10	,	O
11	D88	O
12	,	O
13	E94	O
14	,	O
15	D134	O
16	,	O
17	R154	O
18	,	O
19	K169	O
20	,	O
21	H197	O
22	,	O
23	D233	O
24	,	O
25	G235	O
26	,	O
27	G236	O
28	,	O
29	G237	O
30	,	O
31	F238	O
32	,	O
33	E274	O
34	,	O
35	G276	O
36	,	O
37	R277	O
38	,	O
39	Y278	O
40	,	O
41	K294	O
42	,	O
43	Y323	O
44	,	O
45	Y331	O
46	,	O
47	D332	O
48	,	O
49	C360	O
50	,	O
51	D361	O
52	,	O
53	D364	O
54	,	O
55	G387	O
56	,	O
57	Y389	O
58	,	O
59	and	O
60	F397	O
61	(	O
62	mouse	O
63	ODC	B
64	numbering	O
65	),	O
66	all	O
67	of	O
68	which	O
69	are	O
70	implicated	O
71	in	O
72	the	O
73	formation	O
74	of	O
75	the	O
76	pyridoxal	O
77	phosphate	O
78	-	O
79	binding	O
80	domain	O
81	and	O
82	the	O
83	substrate	O
84	-	O
85	binding	O
86	domain	O
87	and	O
88	in	O
89	dimer	O
90	stabilization	O
91	with	O
92	the	O
93	eukaryotic	O
94	ODCs	B
95	,	O
96	were	O
97	also	O
98	conserved	O
99	in	O
100	S	O
101	.	O
102	ruminantium	O
103	LDC	B
104	.	O

1	The	O
2	Psc2	B
3	cDNA	I
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	Shh	B
6	can	O
7	drive	O
8	continued	O
9	cycling	O
10	in	O
11	immature	O
12	,	O
13	proliferating	O
14	CGNPs	O
15	.	O

1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O

1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	B
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	B
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	npm3	B
5	,	O
6	which	O
7	is	O
8	usually	O
9	coactivated	O
10	with	O
11	fgf8	B
12	by	O
13	MMTV	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	androgens	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O

1	Experiments	O
2	with	O
3	epitope	O
4	-	O
5	tagged	O
6	proteins	O
7	show	O
8	that	O
9	UEV1A	B
10	is	O
11	a	O
12	nuclear	O
13	protein	O
14	,	O
15	whereas	O
16	both	O
17	Kua	B
18	and	O
19	Kua	B
20	-	O
21	UEV	B
22	localize	O
23	to	O
24	cytoplasmic	O
25	structures	O
26	,	O
27	indicating	O
28	that	O
29	the	O
30	Kua	B
31	domain	I
32	determines	O
33	the	O
34	cytoplasmic	O
35	localization	O
36	of	O
37	Kua	B
38	-	O
39	UEV	B
40	.	O

1	Stoichiometric	O
2	phosphorylation	O
3	of	O
4	human	B
5	p53	I
6	at	O
7	Ser315	O
8	stimulates	O
9	p53	B
10	-	O
11	dependent	O
12	transcription	O
13	.	O
14	p53	B
15	protein	I
16	activity	O
17	as	O
18	a	O
19	transcription	O
20	factor	O
21	can	O
22	be	O
23	activated	O
24	in	O
25	vivo	O
26	by	O
27	antibodies	O
28	that	O
29	target	O
30	its	O
31	C	O
32	-	O
33	terminal	O
34	negative	O
35	regulatory	O
36	domain	O
37	suggesting	O
38	that	O
39	cellular	O
40	enzymes	O
41	that	O
42	target	O
43	this	O
44	domain	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	stimulating	O
51	p53	B
52	-	O
53	dependent	O
54	gene	O
55	expression	O
56	.	O

1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	B
16	.	O

1	The	O
2	Tax	B
3	/	O
4	IKKgamma	B
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	B
13	catalytic	I
14	subunits	I
15	,	O
16	IKKalpha	B
17	and	O
18	IKKbeta	B
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	B
37	.	O

1	An	O
2	anchored	O
3	AFLP	O
4	-	O
5	and	O
6	retrotransposon	O
7	-	O
8	based	O
9	map	O
10	of	O
11	diploid	O
12	Avena	O
13	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O

1	Effects	O
2	of	O
3	spatial	O
4	and	O
5	temporal	O
6	smoothing	O
7	on	O
8	stimulated	O
9	brillouin	O
10	scattering	O
11	in	O
12	the	O
13	independent	O
14	-	O
15	hot	O
16	-	O
17	spot	O
18	model	O
19	limit	O
20	The	O
21	influence	O
22	of	O
23	laser	O
24	beam	O
25	smoothing	O
26	on	O
27	stimulated	O
28	Brillouin	O
29	backscattering	O
30	(	O
31	SBBS	O
32	)	O
33	is	O
34	studied	O
35	analytically	O
36	in	O
37	the	O
38	limit	O
39	of	O
40	the	O
41	independent	O
42	hot	O
43	spot	O
44	model	O
45	.	O

1	Simultaneous	O
2	determination	O
3	of	O
4	theophylline	O
5	and	O
6	its	O
7	metabolites	O
8	by	O
9	HPLC	O
10	]	O
11	A	O
12	high	O
13	performance	O
14	liquid	O
15	chromatography	O
16	(	O
17	HPLC	O
18	)	O
19	method	O
20	has	O
21	been	O
22	developed	O
23	for	O
24	the	O
25	simultaneous	O
26	determination	O
27	of	O
28	theophylline	O
29	and	O
30	its	O
31	metabolites	O
32	,	O
33	with	O
34	caffeine	O
35	and	O
36	its	O
37	metabolites	O
38	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	CONCLUSION	O
2	:	O
3	SPT	O
4	is	O
5	more	O
6	useful	O
7	than	O
8	WST	O
9	in	O
10	differentiating	O
11	patients	O
12	predisposed	O
13	to	O
14	aspiration	O
15	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	O
17	FK	O
18	-	O
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	O
28	FK	O
29	-	O
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O

1	DNA	O
2	binding	O
3	and	O
4	glutathione	B
5	S	I
6	-	I
7	transferase	I
8	pull	O
9	-	O
10	down	O
11	assays	O
12	demonstrate	O
13	that	O
14	binding	O
15	requires	O
16	Elk	B
17	-	I
18	1	I
19	(	I
20	1	I
21	-	I
22	212	I
23	)	I
24	but	O
25	not	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	transactivation	O
31	domain	O
32	.	O

1	Unexpectedly	O
2	,	O
3	ALK7	B
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O

1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	I
43	.	O

1	Association	O
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O

1	In	O
2	slightly	O
3	older	O
4	embryos	O
5	,	O
6	the	O
7	expression	O
8	was	O
9	skewed	O
10	to	O
11	one	O
12	side	O
13	of	O
14	the	O
15	embryo	O
16	and	O
17	by	O
18	E6	O
19	.	O
20	5	O
21	,	O
22	at	O
23	the	O
24	onset	O
25	of	O
26	gastrulation	O
27	,	O
28	expression	O
29	was	O
30	seen	O
31	in	O
32	the	O
33	epiblast	O
34	,	O
35	visceral	O
36	endoderm	O
37	,	O
38	nascent	O
39	mesoderm	O
40	,	O
41	and	O
42	the	O
43	primitive	O
44	streak	O
45	.	O

1	Transformation	O
2	of	O
3	the	O
4	sconC3	B
5	mutant	I
6	with	O
7	sconB	B
8	+	I
9	restores	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	phenotype	O
15	.	O

1	The	O
2	authors	O
3	proposed	O
4	that	O
5	the	O
6	highly	O
7	convergent	O
8	inputs	O
9	to	O
10	the	O
11	entorhinal	O
12	cortex	O
13	indicate	O
14	this	O
15	region	O
16	may	O
17	be	O
18	particularly	O
19	important	O
20	for	O
21	selecting	O
22	or	O
23	compressing	O
24	information	O
25	.	O

1	Influence	O
2	of	O
3	oil	O
4	emulsions	O
5	and	O
6	diphenyl	O
7	on	O
8	post	O
9	-	O
10	harvest	O
11	physiconutritional	O
12	changes	O
13	in	O
14	Kagzi	O
15	limes	O
16	(	O
17	Citrus	O
18	aurantifolia	O
19	)	O
20	was	O
21	studied	O
22	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	B
5	,	I
6	3GT	I
7	transcripts	I
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	O
23	UTR	O
24	)	O
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	A	O
2	thermal	O
3	Kubo	O
4	-	O
5	Martin	O
6	-	O
7	Schwinger	O
8	condition	O
9	arises	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	periodic	O
21	source	O
22	,	O
23	namely	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O

1	The	O
2	non	O
3	-	O
4	homologous	O
5	sequences	O
6	in	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	regions	O
12	might	O
13	be	O
14	acquired	O
15	at	O
16	or	O
17	after	O
18	transcription	O
19	during	O
20	retrotransposition	O
21	of	O
22	the	O
23	ATLN	O
24	elements	O
25	.	O

1	The	O
2	time	O
3	course	O
4	of	O
5	RNA1	B
6	replication	O
7	and	O
8	RNA3	B
9	synthesis	O
10	in	O
11	induced	O
12	yeast	O
13	paralleled	O
14	that	O
15	in	O
16	yeast	O
17	transfected	O
18	with	O
19	natural	O
20	FHV	O
21	virion	O
22	RNA	O
23	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	B
8	ORL1	I
9	and	O
10	GAIP	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	RESULTS	O
2	:	O
3	The	O
4	main	O
5	effect	O
6	of	O
7	muscle	O
8	pain	O
9	,	O
10	compared	O
11	to	O
12	non	O
13	-	O
14	painful	O
15	stimulation	O
16	,	O
17	was	O
18	a	O
19	significant	O
20	and	O
21	long	O
22	-	O
23	lasting	O
24	increase	O
25	of	O
26	delta	O
27	(	O
28	1	O
29	-	O
30	3	O
31	Hz	O
32	)	O
33	power	O
34	and	O
35	an	O
36	alpha	O
37	-	O
38	1	O
39	(	O
40	9	O
41	-	O
42	11	O
43	Hz	O
44	)	O
45	power	O
46	increase	O
47	over	O
48	the	O
49	contralateral	O
50	parietal	O
51	locus	O
52	.	O

1	The	O
2	extraction	O
3	was	O
4	subsequently	O
5	rated	O
6	as	O
7	'	O
8	easy	O
9	'	O
10	or	O
11	'	O
12	difficult	O
13	'.	O
14	Taking	O
15	Pell	O
16	-	O
17	Gregory	O
18	class	O
19	C	O
20	as	O
21	a	O
22	predictor	O
23	of	O
24	a	O
25	'	O
26	difficult	O
27	'	O
28	extraction	O
29	,	O
30	specificity	O
31	was	O
32	88	O
33	%	O
34	but	O
35	sensitivity	O
36	was	O
37	low	O
38	at	O
39	15	O
40	%.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	B
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O

1	Based	O
2	on	O
3	16S	B
4	rRNA	I
5	gene	I
6	sequence	I
7	analysis	O
8	,	O
9	the	O
10	11	O
11	species	O
12	having	O
13	two	O
14	tuf	B
15	genes	I
16	all	O
17	have	O
18	a	O
19	common	O
20	ancestor	O
21	,	O
22	while	O
23	the	O
24	six	O
25	species	O
26	having	O
27	only	O
28	one	O
29	copy	O
30	diverged	O
31	from	O
32	the	O
33	enterococcal	O
34	lineage	O
35	before	O
36	that	O
37	common	O
38	ancestor	O
39	.	O

1	Nevertheless	O
2	,	O
3	protein	B
4	kinase	I
5	A	I
6	stimulation	O
7	induces	O
8	CREMalpha	B
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	O
15	in	O
16	the	O
17	phosphoenolpyruvate	B
18	carboxykinase	I
19	(	O
20	PEPCK	B
21	)	O
22	gene	O
23	.	O

1	Another	O
2	putative	O
3	HNF3	B
4	site	I
5	in	O
6	close	O
7	apposition	O
8	to	O
9	a	O
10	NF1	B
11	/	O
12	CTF	B
13	site	O
14	was	O
15	localized	O
16	upstream	O
17	of	O
18	the	O
19	silencer	O
20	-	O
21	like	O
22	element	O
23	.	O

1	This	O
2	transcriptional	O
3	regulation	O
4	occurs	O
5	through	O
6	modulation	O
7	of	O
8	the	O
9	forkhead	B
10	transcription	I
11	factor	I
12	FKHR	I
13	-	I
14	L1	I
15	,	O
16	and	O
17	IL	B
18	-	I
19	3	I
20	inhibited	O
21	FKHR	B
22	-	I
23	L1	I
24	activity	O
25	in	O
26	a	O
27	PI3K	B
28	-	O
29	dependent	O
30	manner	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	inhibition	O
9	of	O
10	p27	B
11	(	O
12	KIP1	B
13	)	O
14	transcription	O
15	through	O
16	PI3K	B
17	-	O
18	induced	O
19	FKHR	B
20	-	I
21	L1	I
22	phosphorylation	O
23	provides	O
24	a	O
25	novel	O
26	mechanism	O
27	of	O
28	regulating	O
29	cytokine	O
30	-	O
31	mediated	O
32	survival	O
33	and	O
34	proliferation	O
35	.	O

1	DNase	B
2	I	I
3	genomic	O
4	footprinting	O
5	revealed	O
6	that	O
7	the	O
8	c	B
9	-	I
10	Myb	I
11	site	I
12	is	O
13	occupied	O
14	in	O
15	a	O
16	tissue	O
17	-	O
18	specific	O
19	fashion	O
20	in	O
21	vivo	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Myb	I
7	regulates	O
8	the	O
9	RAG	B
10	-	I
11	2	I
12	promoter	I
13	in	O
14	T	O
15	cells	O
16	by	O
17	binding	O
18	to	O
19	this	O
20	consensus	B
21	c	I
22	-	I
23	Myb	I
24	binding	I
25	site	I
26	.	O

1	A	O
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	B
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	O
24	RPTK	B
25	)	O
26	interacting	O
27	protein	O
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O

1	Subsequently	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	reexpression	O
8	of	O
9	the	O
10	r	B
11	-	I
12	PTPeta	I
13	gene	I
14	in	O
15	highly	O
16	malignant	O
17	rat	O
18	thyroid	O
19	cells	O
20	transformed	O
21	by	O
22	retroviruses	O
23	carrying	O
24	the	O
25	v	B
26	-	I
27	mos	I
28	and	O
29	v	B
30	-	I
31	ras	I
32	-	I
33	Ki	I
34	oncogenes	I
35	suppresses	O
36	their	O
37	malignant	O
38	phenotype	O
39	.	O

1	Induced	O
2	expression	O
3	of	O
4	Rnd3	B
5	is	O
6	associated	O
7	with	O
8	transformation	O
9	of	O
10	polarized	O
11	epithelial	O
12	cells	O
13	by	O
14	the	O
15	Raf	B
16	-	O
17	MEK	B
18	-	O
19	extracellular	O
20	signal	O
21	-	O
22	regulated	O
23	kinase	O
24	pathway	O
25	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	transcription	B
6	factor	I
7	CREB	I
8	is	O
9	regulated	O
10	by	O
11	extracellular	O
12	stimuli	O
13	that	O
14	result	O
15	in	O
16	its	O
17	phosphorylation	O
18	at	O
19	a	O
20	critical	O
21	serine	O
22	residue	O
23	,	O
24	Ser133	O
25	.	O

1	RESULTS	O
2	:	O
3	Average	O
4	age	O
5	at	O
6	symptom	O
7	onset	O
8	was	O
9	41	O
10	.	O
11	2	O
12	years	O
13	.	O

1	When	O
2	10	O
3	fields	O
4	were	O
5	analysed	O
6	,	O
7	a	O
8	strong	O
9	relationship	O
10	was	O
11	found	O
12	between	O
13	the	O
14	presence	O
15	of	O
16	bacteria	O
17	on	O
18	Gram	O
19	staining	O
20	and	O
21	the	O
22	final	O
23	diagnosis	O
24	of	O
25	VAP	O
26	(	O
27	for	O
28	PSB	O
29	and	O
30	PTC	O
31	respectively	O
32	:	O
33	sensitivity	O
34	74	O
35	and	O
36	81	O
37	%,	O
38	specificity	O
39	94	O
40	and	O
41	100	O
42	%,	O
43	positive	O
44	predictive	O
45	value	O
46	91	O
47	and	O
48	100	O
49	%,	O
50	negative	O
51	predictive	O
52	value	O
53	82	O
54	and	O
55	88	O
56	%).	O

1	Unlike	O
2	the	O
3	mammalian	O
4	proteins	O
5	,	O
6	XFGF3	B
7	is	O
8	efficiently	O
9	secreted	O
10	as	O
11	a	O
12	Mr	O
13	31	O
14	,	O
15	000	O
16	glycoprotein	O
17	,	O
18	gp31	B
19	,	O
20	which	O
21	undergoes	O
22	proteolytic	O
23	cleavage	O
24	to	O
25	produce	O
26	an	O
27	NH2	O
28	-	O
29	terminally	O
30	truncated	O
31	product	O
32	,	O
33	gp27	B
34	.	O

1	NH2	O
2	-	O
3	terminal	O
4	trimming	O
5	of	O
6	Xenopus	O
7	and	O
8	mammalian	B
9	FGF3s	I
10	may	O
11	therefore	O
12	be	O
13	a	O
14	prerequisite	O
15	of	O
16	optimal	O
17	biological	O
18	activity	O
19	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	O
26	deletions	O
27	.	O

1	Tranilast	O
2	in	O
3	the	O
4	Therapy	O
5	of	O
6	Coronary	O
7	Artery	O
8	Disease	O
9	.	O

1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O

1	This	O
2	study	O
3	is	O
4	a	O
5	further	O
6	and	O
7	more	O
8	extensive	O
9	validation	O
10	of	O
11	the	O
12	clinician	O
13	rated	O
14	NIMH	O
15	-	O
16	LCM	O
17	-	O
18	p	O
19	.	O

1	The	O
2	Aie1	B
3	locus	I
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	O
10	-	O
11	A3	O
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	Psychiatric	O
2	disorders	O
3	in	O
4	children	O
5	and	O
6	adolescents	O
7	carry	O
8	considerable	O
9	morbidity	O
10	,	O
11	impede	O
12	development	O
13	,	O
14	and	O
15	carry	O
16	a	O
17	significant	O
18	mortality	O
19	by	O
20	suicide	O
21	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	human	B
7	UDP	I
8	-	I
9	d	I
10	-	I
11	Xylose	I
12	:	I
13	proteoglycan	I
14	core	I
15	protein	I
16	beta	I
17	-	I
18	d	I
19	-	I
20	xylosyltransferase	I
21	and	O
22	its	O
23	first	O
24	isoform	B
25	XT	I
26	-	I
27	II	I
28	.	O

1	Thyrotoxicosis	O
2	due	O
3	to	O
4	amiodarone	O
5	is	O
6	difficult	O
7	to	O
8	treat	O
9	and	O
10	is	O
11	further	O
12	complicated	O
13	by	O
14	the	O
15	pro	O
16	-	O
17	arrhythmic	O
18	potential	O
19	of	O
20	thyrotoxicosis	O
21	and	O
22	the	O
23	fading	O
24	antiarrhythmic	O
25	effect	O
26	after	O
27	amiodarone	O
28	withdrawal	O
29	.	O

1	Chaperones	O
2	/	O
3	HSPs	B
4	thus	O
5	play	O
6	important	O
7	roles	O
8	within	O
9	cell	O
10	cycle	O
11	processes	O
12	.	O

1	Oncogenic	O
2	signalling	O
3	by	O
4	E2F1	B
5	has	O
6	recently	O
7	been	O
8	linked	O
9	to	O
10	stabilization	O
11	and	O
12	activation	O
13	of	O
14	the	O
15	tumour	O
16	suppressor	O
17	p53	B
18	(	O
19	refs	O
20	1	O
21	,	O
22	3	O
23	,	O
24	4	O
25	).	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	We	O
2	describe	O
3	the	O
4	identification	O
5	and	O
6	initial	O
7	characterization	O
8	of	O
9	neurobeachin	B
10	,	O
11	a	O
12	neuron	O
13	-	O
14	specific	O
15	multidomain	O
16	protein	O
17	of	O
18	327	O
19	kDa	O
20	with	O
21	a	O
22	high	O
23	-	O
24	affinity	O
25	binding	O
26	site	O
27	(	O
28	K	O
29	(	O
30	d	O
31	),	O
32	10	O
33	nm	O
34	)	O
35	for	O
36	the	O
37	type	B
38	II	I
39	regulatory	I
40	subunit	I
41	of	I
42	protein	I
43	kinase	I
44	A	I
45	(	O
46	PKA	B
47	RII	I
48	).	O

1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O

1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	Overexpression	O
2	of	O
3	c	B
4	-	I
5	Myc	I
6	in	O
7	serum	O
8	-	O
9	starved	O
10	human	O
11	or	O
12	mouse	O
13	embryonic	O
14	cells	O
15	leads	O
16	to	O
17	apoptosis	O
18	which	O
19	is	O
20	significantly	O
21	reduced	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	growth	O
27	factor	O
28	-	O
29	containing	O
30	serum	O
31	.	O
32	c	B
33	-	I
34	Myc	I
35	-	O
36	induced	O
37	apoptosis	O
38	appears	O
39	to	O
40	be	O
41	deficient	O
42	in	O
43	bax	B
44	-	O
45	null	O
46	as	O
47	compared	O
48	with	O
49	bax	B
50	-	O
51	wild	O
52	-	O
53	type	O
54	mouse	O
55	embryonic	O
56	fibroblasts	O
57	.	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O

1	METHODS	O
2	:	O
3	T2	O
4	*-	O
5	weighted	O
6	,	O
7	three	O
8	-	O
9	dimensional	O
10	gradient	O
11	-	O
12	echo	O
13	images	O
14	were	O
15	acquired	O
16	by	O
17	exploiting	O
18	the	O
19	magnetic	O
20	susceptibility	O
21	difference	O
22	between	O
23	oxygenated	O
24	and	O
25	deoxygenated	O
26	hemoglobin	B
27	in	O
28	the	O
29	vasculature	O
30	and	O
31	microvasculature	O
32	.	O

1	In	O
2	the	O
3	COPD	O
4	patients	O
5	,	O
6	the	O
7	variability	O
8	of	O
9	Delta	O
10	-	O
11	inst	O
12	Rrs	O
13	(	O
14	30	O
15	%)	O
16	was	O
17	greater	O
18	than	O
19	that	O
20	of	O
21	FOT	O
22	Rrs	O
23	(	O
24	21	O
25	%).	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	I
23	amino	I
24	acids	I
25	)	I
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	Thus	O
2	,	O
3	Pet111p	B
4	could	O
5	play	O
6	dual	O
7	roles	O
8	in	O
9	both	O
10	membrane	O
11	localization	O
12	and	O
13	regulation	O
14	of	O
15	Cox2p	B
16	synthesis	O
17	within	O
18	mitochondria	O
19	.	O

1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	O
11	domain	O
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	B
23	domain	O
24	of	O
25	c	B
26	-	I
27	IAP1	I
28	and	O
29	induced	O
30	apoptosis	O
31	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	B
28	negative	I
29	EGF	I
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	Acoust	O
2	.	O

1	Video	O
2	images	O
3	of	O
4	the	O
5	nostrils	O
6	were	O
7	captured	O
8	and	O
9	then	O
10	analyzed	O
11	for	O
12	area	O
13	,	O
14	perimeter	O
15	,	O
16	centroid	O
17	,	O
18	principal	O
19	axis	O
20	,	O
21	moments	O
22	about	O
23	the	O
24	major	O
25	and	O
26	minor	O
27	axes	O
28	(	O
29	I11	O
30	,	O
31	I22	O
32	),	O
33	anisometry	O
34	,	O
35	bulkiness	O
36	,	O
37	lateral	O
38	offset	O
39	,	O
40	internostril	O
41	angle	O
42	,	O
43	and	O
44	rotational	O
45	angle	O
46	.	O

1	MS	O
2	characteristics	O
3	of	O
4	coumarins	O
5	,	O
6	psoralens	O
7	and	O
8	polymethoxylated	O
9	flavones	O
10	with	O
11	different	O
12	substitution	O
13	patterns	O
14	were	O
15	determined	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	the	O
21	response	O
22	obtained	O
23	with	O
24	the	O
25	APcI	O
26	interface	O
27	.	O

1	Young	O
2	fish	O
3	(	O
4	Oreochromis	O
5	mossambicus	O
6	)	O
7	were	O
8	exposed	O
9	to	O
10	microgravity	O
11	(	O
12	micro	O
13	g	O
14	)	O
15	for	O
16	9	O
17	to	O
18	10	O
19	days	O
20	during	O
21	space	O
22	missions	O
23	STS	O
24	-	O
25	55	O
26	and	O
27	STS	O
28	-	O
29	84	O
30	,	O
31	or	O
32	to	O
33	hypergravity	O
34	(	O
35	hg	O
36	)	O
37	for	O
38	9	O
39	days	O
40	.	O

1	S6K2	B
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	B
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	B
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	B
48	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	T	O
2	cells	O
3	express	O
4	two	O
5	isoforms	O
6	of	O
7	S6k1	B
8	:	O
9	a	O
10	70	O
11	kDa	O
12	cytoplasmic	O
13	kinase	O
14	and	O
15	an	O
16	85	O
17	kDa	O
18	isoform	O
19	that	O
20	has	O
21	a	O
22	classic	O
23	nuclear	O
24	localisation	O
25	.	O

1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	It	O
2	was	O
3	subsequently	O
4	shown	O
5	that	O
6	Tip60	B
7	had	O
8	histone	B
9	acetyltransferase	I
10	(	O
11	HAT	B
12	)	O
13	activity	O
14	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Plectin	B
2	and	O
3	desmoplakin	B
4	have	O
5	GSR	O
6	-	O
7	containing	O
8	domains	O
9	at	O
10	their	O
11	C	O
12	-	O
13	termini	O
14	and	O
15	we	O
16	further	O
17	demonstrate	O
18	that	O
19	the	O
20	GSR	O
21	-	O
22	containing	O
23	domain	O
24	of	O
25	plectin	B
26	,	O
27	but	O
28	not	O
29	desmoplakin	B
30	,	O
31	can	O
32	bind	O
33	to	O
34	MTs	O
35	in	O
36	vivo	O
37	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	B
22	associated	I
23	proteins	I
24	.	O

1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	B
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	B
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	O
21	region	O
22	of	O
23	SRC1	B
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	Since	O
2	MEK	B
3	acts	O
4	as	O
5	a	O
6	cytoplasmic	O
7	anchor	O
8	for	O
9	the	O
10	ERKs	B
11	,	O
12	the	O
13	lack	O
14	of	O
15	a	O
16	MEK	B
17	interaction	O
18	resulted	O
19	in	O
20	the	O
21	aberrant	O
22	nuclear	O
23	localization	O
24	of	O
25	ERK2	B
26	-	O
27	Delta19	B
28	-	I
29	25	I
30	mutants	O
31	in	O
32	serum	O
33	-	O
34	starved	O
35	cells	O
36	.	O

1	Pmt2	B
2	is	O
3	a	O
4	member	O
5	of	O
6	a	O
7	six	O
8	-	O
9	protein	O
10	family	O
11	in	O
12	yeast	O
13	that	O
14	catalyzes	O
15	the	O
16	first	O
17	step	O
18	in	O
19	O	O
20	mannosylation	O
21	of	O
22	target	O
23	proteins	O
24	.	O

1	Fecal	O
2	samples	O
3	were	O
4	collected	O
5	at	O
6	the	O
7	beginning	O
8	and	O
9	end	O
10	of	O
11	each	O
12	trial	O
13	period	O
14	and	O
15	were	O
16	analyzed	O
17	for	O
18	gastrointestinal	O
19	nematode	O
20	eggs	O
21	and	O
22	Giardia	O
23	cyst	O
24	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	O
7	the	O
8	controls	O
9	,	O
10	17	O
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	O
17	pathoses	O
18	.	O

1	Four	O
2	cases	O
3	of	O
4	synovial	O
5	chondromatosis	O
6	are	O
7	presented	O
8	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	pro	O
8	-	O
9	inflammatory	O
10	cytokines	O
11	tumor	B
12	necrosis	I
13	factor	I
14	alpha	I
15	and	O
16	interferon	B
17	gamma	I
18	reduce	O
19	the	O
20	expression	O
21	of	O
22	the	O
23	cystic	B
24	fibrosis	I
25	transmembrane	I
26	conductance	I
27	regulator	I
28	(	O
29	CFTR	B
30	)	O
31	gene	O
32	(	O
33	CFTR	B
34	)	O
35	in	O
36	HT	O
37	-	O
38	29	O
39	and	O
40	T84	O
41	cells	O
42	by	O
43	acting	O
44	post	O
45	-	O
46	transcriptionally	O
47	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	Here	O
2	we	O
3	show	O
4	in	O
5	mouse	O
6	fibroblasts	O
7	stably	O
8	transformed	O
9	by	O
10	v	B
11	-	I
12	Src	I
13	that	O
14	mRNA	O
15	and	O
16	protein	O
17	levels	O
18	of	O
19	p21	B
20	(	O
21	WAF1	B
22	/	O
23	CIP1	B
24	),	O
25	cyclin	B
26	D1	I
27	,	O
28	and	O
29	cyclin	B
30	E	I
31	are	O
32	elevated	O
33	.	O

1	ORFA	O
2	and	O
3	ccdA	B
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Mouse	B
2	Impact	I
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O

1	These	O
2	cells	O
3	produced	O
4	P2Y	B
5	(	I
6	11	I
7	)	I
8	mRNA	I
9	during	O
10	culture	O
11	.	O

1	Coexpression	O
2	studies	O
3	indicate	O
4	that	O
5	insulin	B
6	and	O
7	PKB	B
8	suppress	O
9	transactivation	O
10	by	O
11	C	B
12	/	I
13	EBPbeta	I
14	,	O
15	but	O
16	not	O
17	C	B
18	/	I
19	EBPalpha	I
20	,	O
21	and	O
22	that	O
23	N	O
24	-	O
25	terminal	O
26	transactivation	O
27	domains	O
28	in	O
29	C	B
30	/	I
31	EBPbeta	I
32	are	O
33	required	O
34	.	O

1	Among	O
2	eight	O
3	graminaceous	O
4	species	O
5	tested	O
6	,	O
7	Ids3	B
8	expression	O
9	was	O
10	observed	O
11	only	O
12	in	O
13	Fe	O
14	-	O
15	deficient	O
16	roots	O
17	of	O
18	H	O
19	.	O
20	vulgare	O
21	and	O
22	Secale	O
23	cereale	O
24	.	O
25	which	O
26	not	O
27	only	O
28	secrete	O
29	2	O
30	'-	O
31	deoxymugineic	O
32	acid	O
33	(	O
34	DMA	O
35	),	O
36	but	O
37	also	O
38	mugineic	O
39	acid	O
40	(	O
41	MA	O
42	)	O
43	and	O
44	3	O
45	-	O
46	epihydroxymugineic	O
47	acid	O
48	(	O
49	epiHMA	O
50	,	O
51	H	O
52	.	O
53	vulgare	O
54	),	O
55	and	O
56	3	O
57	-	O
58	hydroxymugineic	O
59	acid	O
60	(	O
61	HMA	O
62	,	O
63	S	O
64	.	O
65	cereale	O
66	).	O

1	In	O
2	contrast	O
3	,	O
4	high	O
5	COUP	B
6	-	I
7	TFI	I
8	expression	O
9	impeded	O
10	the	O
11	neuronal	O
12	differentiation	O
13	of	O
14	P19	O
15	cells	O
16	induced	O
17	with	O
18	RA	O
19	,	O
20	resulting	O
21	in	O
22	cell	O
23	cultures	O
24	lacking	O
25	neurons	O
26	.	O

1	Because	O
2	PET	O
3	is	O
4	also	O
5	useful	O
6	for	O
7	the	O
8	pretreatment	O
9	and	O
10	follow	O
11	-	O
12	up	O
13	evaluation	O
14	,	O
15	the	O
16	use	O
17	of	O
18	stereotactic	O
19	PET	O
20	in	O
21	these	O
22	patients	O
23	can	O
24	enable	O
25	an	O
26	accurate	O
27	comparison	O
28	of	O
29	PET	O
30	-	O
31	based	O
32	metabolic	O
33	data	O
34	with	O
35	MR	O
36	-	O
37	based	O
38	anatomical	O
39	data	O
40	.	O

1	Therefore	O
2	,	O
3	in	O
4	our	O
5	in	O
6	vitro	O
7	model	O
8	,	O
9	the	O
10	localization	O
11	of	O
12	the	O
13	mutation	O
14	in	O
15	the	O
16	K	B
17	-	I
18	ras	I
19	gene	I
20	predisposes	O
21	to	O
22	a	O
23	different	O
24	level	O
25	of	O
26	aggressiveness	O
27	in	O
28	the	O
29	transforming	O
30	phenotype	O
31	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	MdPin1	B
9	,	O
10	a	O
11	Pin1	B
12	homologue	O
13	from	O
14	the	O
15	plant	O
16	species	O
17	apple	O
18	(	O
19	Malus	O
20	domestica	O
21	)	O
22	and	O
23	show	O
24	that	O
25	it	O
26	has	O
27	the	O
28	same	O
29	phosphorylation	O
30	-	O
31	specific	O
32	substrate	O
33	specificity	O
34	and	O
35	can	O
36	be	O
37	inhibited	O
38	by	O
39	juglone	O
40	in	O
41	vitro	O
42	,	O
43	as	O
44	is	O
45	the	O
46	case	O
47	for	O
48	Pin1	B
49	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	B
12	suppressor	I
13	ING1	I
14	with	O
15	the	O
16	mSin3	B
17	/	O
18	HDAC1	B
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	These	O
2	and	O
3	other	O
4	data	O
5	presented	O
6	suggest	O
7	that	O
8	TAg	B
9	'	O
10	re	O
11	-	O
12	models	O
13	'	O
14	host	O
15	cell	O
16	transcription	O
17	factors	O
18	that	O
19	are	O
20	used	O
21	early	O
22	in	O
23	viral	O
24	infection	O
25	,	O
26	and	O
27	thereby	O
28	mimics	O
29	an	O
30	event	O
31	that	O
32	naturally	O
33	occurs	O
34	during	O
35	transformation	O
36	.	O

1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	O
52	larger	O
53	adult	O
54	herd	O
55	size	O
56	(>	O
57	5	O
58	).	O

1	ORFK10	B
2	.	I
3	5	I
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	B
9	-	I
10	associated	I
11	nuclear	I
12	antigen	I
13	2	I
14	(	O
15	LANA2	B
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	In	O
2	Xenopus	O
3	,	O
4	BMPs	B
5	act	O
6	as	O
7	epidermal	O
8	inducers	O
9	and	O
10	also	O
11	as	O
12	negative	O
13	regulators	O
14	of	O
15	neurogenesis	O
16	.	O

1	Presently	O
2	four	O
3	unique	O
4	variants	O
5	carrying	O
6	distinct	O
7	GAF	B
8	sequences	I
9	in	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	region	O
15	have	O
16	been	O
17	identified	O
18	.	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	O
6	phosphodiesterase	B
7	PDE11A	I
8	gene	I
9	.	O

1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	B
8	-	I
9	2	I
10	protein	I
11	was	O
12	a	O
13	unique	O
14	alpha1	B
15	,	I
16	4	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	O
30	sulfate	O
31	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	B
5	/	O
6	Erk	B
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	B
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	The	O
2	transcription	O
3	factor	O
4	CHOP	B
5	/	O
6	GADD153	B
7	gene	O
8	is	O
9	induced	O
10	by	O
11	cellular	O
12	stress	O
13	and	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	apoptosis	O
19	.	O

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	B
26	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	O
24	sleep	O
25	)	O
26	and	O
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	O
39	an	O
40	AHI	O
41	>	O
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	O
56	weight	O
57	.	O

1	Paraneoplastic	O
2	rheumatic	O
3	syndromes	O
4	.	O

1	This	O
2	article	O
3	reviews	O
4	recent	O
5	information	O
6	on	O
7	the	O
8	frequency	O
9	,	O
10	characteristics	O
11	,	O
12	and	O
13	possible	O
14	pathogenic	O
15	mechanisms	O
16	of	O
17	the	O
18	vasculitides	O
19	occurring	O
20	in	O
21	patients	O
22	with	O
23	the	O
24	main	O
25	connective	O
26	tissue	O
27	diseases	O
28	.	O

1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O

1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	O
20	activities	O
21	of	O
22	promoters	O
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	B
30	).	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Nucleotide	O
2	sequence	O
3	,	O
4	genome	O
5	organization	O
6	and	O
7	phylogenetic	O
8	analysis	O
9	of	O
10	pineapple	O
11	mealybug	O
12	wilt	O
13	-	O
14	associated	O
15	virus	O
16	-	O
17	2	O
18	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	laparoscopy	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	vanished	O
17	and	O
18	2	O
19	peeping	O
20	testes	O
21	,	O
22	and	O
23	1	O
24	atrophic	O
25	testis	O
26	in	O
27	the	O
28	inguinal	O
29	canal	O
30	.	O

1	This	O
2	philosophy	O
3	was	O
4	instituted	O
5	for	O
6	the	O
7	compound	O
8	RP	O
9	73401	O
10	,	O
11	a	O
12	specific	O
13	phosphodiesterase	B
14	IV	I
15	inhibitor	O
16	,	O
17	that	O
18	was	O
19	being	O
20	developed	O
21	simultaneously	O
22	for	O
23	delivery	O
24	by	O
25	both	O
26	oral	O
27	and	O
28	pulmonary	O
29	routes	O
30	of	O
31	administration	O
32	.	O

1	Increased	O
2	levels	O
3	of	O
4	anticardiolipin	B
5	immunoglobulin	I
6	G	I
7	may	O
8	also	O
9	cause	O
10	bleeding	O
11	.	O

1	RESULTS	O
2	:	O
3	Prevalence	O
4	of	O
5	obesity	O
6	(	O
7	BMI	O
8	SDS	O
9	>	O
10	2	O
11	.	O
12	0	O
13	)	O
14	was	O
15	<	O
16	2	O
17	%	O
18	at	O
19	diagnosis	O
20	,	O
21	but	O
22	increased	O
23	to	O
24	16	O
25	%	O
26	at	O
27	3y	O
28	.	O

1	One	O
2	of	O
3	the	O
4	sequelae	O
5	of	O
6	the	O
7	antiphospholipid	O
8	-	O
9	antibodies	O
10	is	O
11	an	O
12	impaired	O
13	uteroplacental	O
14	circulation	O
15	.	O

1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	B
8	-	I
9	1	I
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	B
26	-	I
27	1	I
28	transcription	I
29	factors	I
30	mediated	O
31	TGF	B
32	-	I
33	beta1	I
34	-	O
35	and	O
36	BMP	B
37	-	I
38	2	I
39	-	O
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	B
45	alpha1	I
46	)	I
47	collagen	I
48	I	I
49	gene	I
50	as	O
51	well	O
52	as	O
53	TGF	B
54	-	I
55	beta1	I
56	-	O
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	B
62	hormone	I
63	(	O
64	PTH	B
65	)/	O
66	PTH	B
67	-	I
68	related	I
69	peptide	I
70	(	I
71	PTHrP	I
72	)	I
73	receptor	I
74	.	O

1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	O
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O

1	Adjuvant	O
2	therapy	O
3	for	O
4	colon	O
5	cancer	O
6	]	O
7	Surgery	O
8	alone	O
9	may	O
10	fail	O
11	to	O
12	cure	O
13	a	O
14	considerable	O
15	number	O
16	of	O
17	locally	O
18	advanced	O
19	colon	O
20	cancers	O
21	.	O

1	There	O
2	were	O
3	significant	O
4	differences	O
5	(	O
6	p	O
7	<	O
8	0	O
9	.	O
10	05	O
11	)	O
12	between	O
13	the	O
14	fracture	O
15	and	O
16	nonfracture	O
17	groups	O
18	in	O
19	the	O
20	total	O
21	femur	O
22	BMD	O
23	(	O
24	13	O
25	%),	O
26	trabecular	O
27	BMD	O
28	in	O
29	the	O
30	distal	O
31	radius	O
32	(	O
33	4	O
34	%),	O
35	and	O
36	the	O
37	fractal	O
38	dimension	O
39	in	O
40	the	O
41	radiographs	O
42	(	O
43	FD2	O
44	)	O
45	(	O
46	3	O
47	%).	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	multicentre	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	Vitex	O
12	agnus	O
13	castus	O
14	L	O
15	extract	O
16	Ze	O
17	440	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	menstrual	O
27	syndrome	O
28	(	O
29	PMS	O
30	).	O

1	Studies	O
2	are	O
3	necessary	O
4	to	O
5	assess	O
6	the	O
7	source	O
8	of	O
9	contamination	O
10	and	O
11	potential	O
12	role	O
13	of	O
14	MRSA	O
15	-	O
16	contaminated	O
17	milk	O
18	in	O
19	the	O
20	transmission	O
21	of	O
22	MRSA	O
23	to	O
24	neonates	O
25	.	O

1	Effects	O
2	of	O
3	Trypanosoma	O
4	vivax	O
5	on	O
6	pregnancy	O
7	of	O
8	Yankasa	O
9	sheep	O
10	and	O
11	the	O
12	results	O
13	of	O
14	homidum	O
15	chloride	O
16	chemotherapy	O
17	.	O

1	NF	B
2	kappa	I
3	B	I
4	was	O
5	activated	O
6	to	O
7	a	O
8	much	O
9	greater	O
10	extent	O
11	by	O
12	roscovitine	O
13	in	O
14	the	O
15	WT	O
16	cells	O
17	than	O
18	in	O
19	Y8	O
20	cells	O
21	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	The	O
2	presence	O
3	of	O
4	locus	O
5	-	O
6	specific	O
7	residues	O
8	throughout	O
9	the	O
10	entire	O
11	promoter	O
12	region	O
13	strongly	O
14	suggests	O
15	that	O
16	the	O
17	various	O
18	HLA	B
19	class	I
20	I	I
21	loci	I
22	are	O
23	differentially	O
24	regulated	O
25	.	O

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	The	O
2	standard	O
3	method	O
4	for	O
5	calculating	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	O
12	-	O
13	B	O
14	IV	O
15	excludes	O
16	subtests	O
17	with	O
18	a	O
19	raw	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	overestimates	O
26	cognitive	O
27	functioning	O
28	in	O
29	young	O
30	biologically	O
31	high	O
32	risk	O
33	children	O
34	.	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	O
6	MCP	B
7	-	I
8	1	I
9	synthesis	O
10	required	O
11	activation	O
12	of	O
13	NF	B
14	-	I
15	kappaB	I
16	since	O
17	mutation	O
18	of	O
19	NF	B
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	I
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	Engagement	O
2	of	O
3	human	B
4	CD2	I
5	by	O
6	mitogenic	O
7	pairs	O
8	of	O
9	anti	B
10	-	I
11	CD2	I
12	mAb	I
13	induces	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	a	O
18	number	O
19	of	O
20	intracellular	O
21	proteins	O
22	including	O
23	a	O
24	120	O
25	kDa	O
26	phosphoprotein	O
27	that	O
28	we	O
29	identify	O
30	as	O
31	the	O
32	proto	B
33	-	I
34	oncogene	I
35	c	I
36	-	I
37	Cbl	I
38	.	O

1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	B
13	.	I
14	1	I
15	and	O
16	PU	B
17	.	I
18	1	I
19	interaction	I
20	partner	I
21	(	O
22	PIP	B
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	B
38	'-	I
39	enhancer	I
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	The	O
2	murine	B
3	int	I
4	-	I
5	6	I
6	locus	I
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	B
23	-	I
24	kDa	I
25	eIF3e	I
26	subunit	I
27	of	I
28	translation	I
29	initiation	I
30	factor	I
31	eIF3	I
32	.	O

1	An	O
2	int6	B
3	deletion	I
4	(	O
5	int6Delta	B
6	)	O
7	mutant	O
8	was	O
9	viable	O
10	but	O
11	grew	O
12	slowly	O
13	in	O
14	minimal	O
15	medium	O
16	.	O

1	Additionally	O
2	,	O
3	MIP	B
4	-	I
5	2A	I
6	antagonizes	O
7	cell	O
8	growth	O
9	regulatory	O
10	role	O
11	of	O
12	MBP	B
13	-	I
14	1	I
15	.	O

1	We	O
2	produced	O
3	transgenic	O
4	plants	O
5	expressing	O
6	the	O
7	antisense	B
8	Arabidopsis	I
9	HD	I
10	(	O
11	AtHD1	B
12	)	O
13	gene	O
14	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	Four	O
2	transcription	O
3	initiation	O
4	sites	O
5	have	O
6	been	O
7	identified	O
8	by	O
9	full	O
10	-	O
11	length	O
12	RNA	B
13	ligase	I
14	-	O
15	mediated	O
16	rapid	O
17	amplification	O
18	of	O
19	cDNA	O
20	ends	O
21	(	O
22	RLM	O
23	-	O
24	RACE	O
25	)	O
26	between	O
27	-	O
28	61	O
29	and	O
30	-	O
31	32	O
32	bp	O
33	from	O
34	the	O
35	translation	O
36	initiation	O
37	codon	O
38	.	O
39	Reverse	O
40	transcription	O
41	-	O
42	PCR	O
43	analysis	O
44	revealed	O
45	that	O
46	PFK	B
47	-	I
48	A	I
49	,	O
50	PFK	B
51	-	I
52	B	I
53	and	O
54	PFK	B
55	-	I
56	C	I
57	genes	I
58	were	O
59	expressed	O
60	,	O
61	in	O
62	all	O
63	mouse	O
64	tissues	O
65	tested	O
66	,	O
67	at	O
68	varying	O
69	levels	O
70	.	O

1	PFK	B
2	-	I
3	A	I
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	B
16	-	I
17	B	I
18	and	O
19	PFK	B
20	-	I
21	C	I
22	genes	I
23	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	In	O
2	whole	O
3	sardine	O
4	,	O
5	domoic	O
6	acid	O
7	was	O
8	detected	O
9	in	O
10	levels	O
11	exceeding	O
12	sometimes	O
13	the	O
14	regulatory	O
15	limit	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	two	O
7	mutations	O
8	,	O
9	Delta	O
10	M1281	O
11	and	O
12	IVS51	O
13	+	O
14	5G	O
15	-->	O
16	A	O
17	,	O
18	in	O
19	a	O
20	German	O
21	USH1	B
22	patient	O
23	.	O

1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	[	O
2	18F	O
3	](+)-	O
4	4	O
5	-	O
6	fluorobenzyltrozamicol	O
7	(	O
8	FBT	O
9	),	O
10	which	O
11	selectively	O
12	binds	O
13	to	O
14	the	O
15	vesicular	O
16	acetylcholine	B
17	transporter	I
18	in	O
19	the	O
20	presynaptic	O
21	cholinergic	O
22	neuron	O
23	,	O
24	has	O
25	previously	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	a	O
31	useful	O
32	ligand	O
33	for	O
34	the	O
35	study	O
36	of	O
37	cholinergic	O
38	terminal	O
39	density	O
40	in	O
41	the	O
42	basal	O
43	ganglia	O
44	with	O
45	PET	O
46	.	O

1	We	O
2	demonstrate	O
3	that	O
4	the	O
5	protein	O
6	is	O
7	a	O
8	murine	B
9	homologue	I
10	of	I
11	SAF	I
12	-	I
13	A	I
14	which	O
15	has	O
16	been	O
17	shown	O
18	to	O
19	bind	O
20	selectively	O
21	to	O
22	MARs	O
23	and	O
24	is	O
25	responsible	O
26	for	O
27	the	O
28	satMa	B
29	-	O
30	binding	O
31	activity	O
32	in	O
33	the	O
34	chromatographic	O
35	fractions	O
36	.	O

1	The	O
2	molecular	O
3	associations	O
4	dictating	O
5	INCENP	B
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O

1	Ang	B
2	II	I
3	significantly	O
4	induced	O
5	Ang2	B
6	mRNA	I
7	accumulations	O
8	without	O
9	affecting	O
10	Ang1	B
11	or	O
12	Tie2	B
13	expression	O
14	,	O
15	which	O
16	was	O
17	inhibited	O
18	by	O
19	protein	B
20	kinase	I
21	C	I
22	inhibitors	O
23	and	O
24	by	O
25	intracellular	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	chelating	O
31	agents	O
32	.	O

1	Promoter	O
2	analysis	O
3	demonstrated	O
4	that	O
5	the	O
6	sequence	O
7	identical	O
8	to	O
9	consensus	O
10	cAMP	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	CRE	O
16	)	O
17	located	O
18	at	O
19	-	O
20	481	O
21	of	O
22	the	O
23	SMemb	B
24	promoter	I
25	was	O
26	critical	O
27	for	O
28	Hex	B
29	responsiveness	O
30	.	O

1	LH	B
2	/	I
3	CG	I
4	receptor	I
5	activation	O
6	of	O
7	ARNO	B
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	B
15	3	I
16	-	I
17	kinase	I
18	(	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	)	O
24	or	O
25	by	O
26	G	B
27	protein	I
28	beta	I
29	gamma	I
30	subunits	I
31	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	-	O
7	321	O
8	/+	O
9	41	O
10	sequence	O
11	was	O
12	sufficient	O
13	for	O
14	both	O
15	the	O
16	constitutive	O
17	promoter	O
18	activity	O
19	and	O
20	auto	O
21	-	O
22	activation	O
23	and	O
24	electrophoretic	O
25	mobility	O
26	shift	O
27	assays	O
28	identified	O
29	the	O
30	interaction	O
31	of	O
32	C	B
33	/	I
34	EBPs	I
35	and	O
36	Sp1	B
37	to	O
38	this	O
39	region	O
40	.	O

1	Termination	O
2	of	O
3	induced	O
4	VT	O
5	on	O
6	the	O
7	first	O
8	attempt	O
9	was	O
10	comparable	O
11	with	O
12	BV	O
13	pacing	O
14	(	O
15	87	O
16	.	O
17	4	O
18	%)	O
19	versus	O
20	RV	O
21	pacing	O
22	(	O
23	89	O
24	.	O
25	6	O
26	%).	O

1	We	O
2	compare	O
3	the	O
4	results	O
5	of	O
6	this	O
7	algorithm	O
8	with	O
9	the	O
10	results	O
11	obtained	O
12	with	O
13	two	O
14	other	O
15	algorithms	O
16	,	O
17	the	O
18	optimal	O
19	algorithm	O
20	for	O
21	monochannel	O
22	nonoverlapping	O
23	noise	O
24	and	O
25	the	O
26	optimal	O
27	algorithm	O
28	for	O
29	multichannel	O
30	additive	O
31	noise	O
32	,	O
33	and	O
34	we	O
35	show	O
36	that	O
37	in	O
38	both	O
39	cases	O
40	improvement	O
41	can	O
42	be	O
43	obtained	O
44	.	O

1	Changes	O
2	in	O
3	stimulation	O
4	levels	O
5	over	O
6	time	O
7	in	O
8	nucleus	O
9	22	O
10	cochlear	O
11	implant	O
12	users	O
13	.	O

1	Nuclease	O
2	probing	O
3	and	O
4	structure	O
5	-	O
6	directed	O
7	mutagenesis	O
8	revealed	O
9	that	O
10	the	O
11	105	O
12	-	O
13	nt	O
14	TE	O
15	(	O
16	TE105	O
17	)	O
18	forms	O
19	a	O
20	cruciform	O
21	secondary	O
22	structure	O
23	containing	O
24	four	O
25	helices	O
26	connected	O
27	by	O
28	single	O
29	-	O
30	stranded	O
31	regions	O
32	.	O

1	Tele	O
2	-	O
3	Talk	O
4	has	O
5	the	O
6	extra	O
7	capability	O
8	of	O
9	operating	O
10	in	O
11	live	O
12	conference	O
13	situations	O
14	using	O
15	microphone	O
16	input	O
17	.	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	B
7	1	I
8	insulin	I
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	The	O
2	P69	O
3	cell	O
4	line	O
5	was	O
6	derived	O
7	by	O
8	immortalization	O
9	of	O
10	human	O
11	primary	O
12	prostate	O
13	epithelial	O
14	cells	O
15	with	O
16	simian	B
17	virus	I
18	-	I
19	40	I
20	T	I
21	antigen	I
22	and	O
23	is	O
24	rarely	O
25	tumorigenic	O
26	.	O

1	We	O
2	determined	O
3	whether	O
4	the	O
5	human	B
6	StAR	I
7	promoter	I
8	is	O
9	responsive	O
10	to	O
11	sterol	B
12	regulatory	I
13	element	I
14	-	I
15	binding	I
16	proteins	I
17	(	O
18	SREBPs	B
19	).	O

1	Expression	O
2	of	O
3	SREBP	B
4	-	I
5	1a	I
6	stimulated	O
7	StAR	B
8	promoter	I
9	activity	O
10	in	O
11	the	O
12	context	O
13	of	O
14	COS	O
15	-	O
16	1	O
17	cells	O
18	and	O
19	human	O
20	granulosa	O
21	-	O
22	lutein	O
23	cells	O
24	.	O

1	Because	O
2	the	O
3	high	B
4	-	I
5	density	I
6	lipoprotein	I
7	receptor	I
8	(	O
9	HDL	B
10	-	I
11	R	I
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	O
21	a	O
22	potential	O
23	therapeutic	O
24	target	O
25	for	O
26	hypercholesterolemic	O
27	drugs	O
28	,	O
29	an	O
30	understanding	O
31	of	O
32	HDL	B
33	-	I
34	R	I
35	regulation	O
36	is	O
37	essential	O
38	.	O

1	IFN	B
2	-	I
3	stimulated	I
4	gene	I
5	factor	I
6	-	I
7	3	I
8	and	O
9	STAT1	B
10	homodimers	I
11	formed	O
12	and	O
13	bound	O
14	an	O
15	IFN	B
16	-	I
17	stimulated	I
18	response	I
19	element	I
20	(	O
21	ISRE	B
22	)	O
23	and	O
24	gamma	B
25	-	I
26	activated	I
27	sequence	I
28	(	O
29	GAS	B
30	)	O
31	element	O
32	,	O
33	respectively	O
34	.	O

1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	B
10	-	I
11	beta1	I
12	action	O
13	on	O
14	thyroglobulin	B
15	(	O
16	TG	B
17	)	O
18	gene	O
19	expression	O
20	by	O
21	focusing	O
22	our	O
23	attention	O
24	on	O
25	TGF	B
26	-	I
27	beta1	I
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	To	O
2	understand	O
3	the	O
4	molecular	O
5	regulation	O
6	of	O
7	these	O
8	genes	O
9	in	O
10	thyroid	O
11	cells	O
12	,	O
13	the	O
14	effect	O
15	of	O
16	thyroid	B
17	transcription	I
18	factor	I
19	1	I
20	(	O
21	TTF	B
22	-	I
23	1	I
24	)	O
25	and	O
26	the	O
27	paired	B
28	domain	I
29	-	I
30	containing	I
31	protein	I
32	8	I
33	(	O
34	Pax	B
35	-	I
36	8	I
37	)	O
38	on	O
39	the	O
40	transcriptional	O
41	activity	O
42	of	O
43	the	O
44	deiodinase	B
45	promoters	I
46	were	O
47	studied	O
48	.	O
